SAMPLE_ID	washed_SMILES	mean_pAC50	Class	PRIMARY_MOA	range_pAC50	count_IDs	SAMPLE_NAME	PUBCHEM_SID	LIBRARY	ASSAY_NAME	CURVE_CLASS2	EFFICACY	SMILES	ALL-SMILES
NCGC00093656-03	Br/C=C/C=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1		Inactive	Reverse Transcriptase Inhibitor		1	Brivudine	90341813.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Br/C=C/C=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1	Br/C=C/C=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1
NCGC00262958-01	Br/C=C\C=1C(=O)NC(=O)N([C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=1		Inactive			1	Bravavir	170466041.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Br/C=C\C=1C(=O)NC(=O)N([C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=1	Br/C=C\C=1C(=O)NC(=O)N([C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=1
NCGC00160445-02	BrC(C(=O)NC(=O)N)C(C)C		Inactive			1	Bromisovalum	170465828.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	BrC(C(=O)NC(=O)N)C(C)C	BrC(C(=O)NC(=O)N)C(C)C
NCGC00090868-06	BrC(Cl)C(F)(F)F		Inactive	GABA-A receptor; anion channel Positive Allosteric Modulator		1	HALOTHANE	405558947.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	BrC(Cl)C(F)(F)F	BrC(Cl)C(F)(F)F
NCGC00166217-02	BrC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F		Inactive			1	1-Bromoheptadecafluorooctane	170465144.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	BrC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	BrC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F
NCGC00164057-03	BrC([N+](=O)[O-])(CO)CO		Inactive	reactive oxygen species biosynthetic process Activator		1	2-Bromo-2-nitro-1,3-propanediol	225144251.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	BrC([N+](=O)[O-])(CO)CO	BrC([N+](=O)[O-])(CO)CO
NCGC00387868-06&NCGC00387868-07	BrC1=C(N)n2ncc(-c3cn(C)nc3)c2N=C1[C@@H]1CNCCC1		Inactive			2	SCH900776 (S-isomer)&(S)-SCH900776		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		BrC1=C(N)n2ncc(-c3cn(C)nc3)c2N=C1[C@@H]1CNCCC1	BrC1=C(N)n2ncc(-c3cn(C)nc3)c2N=C1[C@@H]1CNCCC1
NCGC00346449-02	BrC1=C(NCc2cnccc2)C(OCCCc2ccc(Cl)cc2)=NNC1=O		Inactive	Phosphodiesterase III/Va (PDE) Inhibitor		1	Parogrelil	363677409.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.814147016	BrC1=C(NCc2cnccc2)C(OCCCc2ccc(Cl)cc2)=NNC1=O	BrC1=C(NCc2cnccc2)C(OCCCc2ccc(Cl)cc2)=NNC1=O
NCGC00346500-08	BrC1=Cn2c(/C=N/N(S(=O)(=O)c3c(C)ccc([N+](=O)[O-])c3)C)cnc2C=C1		Inactive	PI3K Inhibitor		1	PIK-75	384568805.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		BrC1=Cn2c(/C=N/N(S(=O)(=O)c3c(C)ccc([N+](=O)[O-])c3)C)cnc2C=C1	BrC1=Cn2c(/C=N/N(S(=O)(=O)c3c(C)ccc([N+](=O)[O-])c3)C)cnc2C=C1
NCGC00092358-02	BrC1C(Br)C(Br)C(Br)C(Br)C1Br		Inactive			1	1,2,3,4,5,6-Hexabromocyclohexane	377020502.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	BrC1C(Br)C(Br)C(Br)C(Br)C1Br	BrC1C(Br)C(Br)C(Br)C(Br)C1Br
NCGC00378753-01	BrC=1C(=O)C2(C=1N[C@H](C(=O)O)Cc1ccc(Nc3nccc4c3cncc4)cc1)CCCCC2		Inactive	Acyl coenzyme A:cholesterol acyltransferase Substrate		1	Zaurategrast	363678181.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	BrC=1C(=O)C2(C=1N[C@H](C(=O)O)Cc1ccc(Nc3nccc4c3cncc4)cc1)CCCCC2	BrC=1C(=O)C2(C=1N[C@H](C(=O)O)Cc1ccc(Nc3nccc4c3cncc4)cc1)CCCCC2
NCGC00263165-02	BrC=1C(=O)N(c2c(C)ccc(C(=O)NC)c2)C(C)=CC=1OCc1c(F)cc(F)cc1		Inactive	p38 MAPK Inhibitor		1	PH-797804	363677239.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	BrC=1C(=O)N(c2c(C)ccc(C(=O)NC)c2)C(C)=CC=1OCc1c(F)cc(F)cc1	BrC=1C(=O)N(c2c(C)ccc(C(=O)NC)c2)C(C)=CC=1OCc1c(F)cc(F)cc1
NCGC00273564-01	BrC=1C(=O)N=C(N)NC=1c1ccccc1		Inactive	Toll-like receptor 7 Agonist		1	Bropirimine	170465913.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	BrC=1C(=O)N=C(N)NC=1c1ccccc1	BrC=1C(=O)N=C(N)NC=1c1ccccc1
NCGC00090770-09	BrC=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1		Inactive	base conversion or substitution editing Activator		1	5-Bromo-2'-deoxyuridine	170465870.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	BrC=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1	BrC=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1
NCGC00386412-04	BrC=1c2nc(NC3CCN(C)CC3)nc(Nc3ccc(Oc4ccccc4)cc3)c2C(=O)NC=1		Inactive	Receptor-type tyrosine-protein kinase FLT3 Inhibitor		1	G749	363680265.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	BrC=1c2nc(NC3CCN(C)CC3)nc(Nc3ccc(Oc4ccccc4)cc3)c2C(=O)NC=1	BrC=1c2nc(NC3CCN(C)CC3)nc(Nc3ccc(Oc4ccccc4)cc3)c2C(=O)NC=1
NCGC00346824-01	BrCC(=O)C(=O)OCC		Inactive	Hexokinase 2 Inhibitor		1	3-Bromopyruvate	174007400.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	BrCC(=O)C(=O)OCC	BrCC(=O)C(=O)OCC
NCGC00510494-01	BrCC(=O)N1CC([N+](=O)[O-])([N+](=O)[O-])C1		Inactive	Radiosensitizers		1	RRx-001	384569456.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	BrCC(=O)N1CC([N+](=O)[O-])([N+](=O)[O-])C1	BrCC(=O)N1CC([N+](=O)[O-])([N+](=O)[O-])C1
NCGC00095048-06	BrCCC(=O)N1CCN(C(=O)CCBr)CC1		Inactive	DNA Crosslinking Agent		1	Pipobroman	170465158.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	BrCCC(=O)N1CCN(C(=O)CCBr)CC1	BrCCC(=O)N1CCN(C(=O)CCBr)CC1
NCGC00390633-02	BrCCNP(=O)(OCc1n(C)c([N+](=O)[O-])nc1)NCCBr		Inactive	DNA Alkylating Drugs		1	Evofosfamide	384569202.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	BrCCNP(=O)(OCc1n(C)c([N+](=O)[O-])nc1)NCCBr	BrCCNP(=O)(OCc1n(C)c([N+](=O)[O-])nc1)NCCBr
NCGC00091099-01	BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr		Inactive	DNA Crosslinking Agent		1	Dibromomannitol	17389938.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr	BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr
NCGC00485518-01	Br[C@@H]1C(=O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](C[C@H](O)CC4)CC3)CC2)C1		Inactive			1	16Î²-Bromoandrosterone	363681360.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Br[C@@H]1C(=O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](C[C@H](O)CC4)CC3)CC2)C1	Br[C@@H]1C(=O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](C[C@H](O)CC4)CC3)CC2)C1
NCGC00167564-03	Brc1[nH]c2N(C)C(=O)N(C)C(=O)c2n1		Inactive			1	8-Bromotheophylline	170465479.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Brc1[nH]c2N(C)C(=O)N(C)C(=O)c2n1	Brc1[nH]c2N(C)C(=O)N(C)C(=O)c2n1
NCGC00024584-17	Brc1[nH]c2c3c(ccc2)C=2[C@H](N(C)C[C@H](C(=O)N[C@@]4(C(C)C)C(=O)N5[C@@H](CC(C)C)C(=O)N6[C@H]([C@]5(O)O4)CCC6)C=2)Cc13		Inactive			1	BROMOCRIPTINE		2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	12.388473348&0.0	Brc1[nH]c2c3c(ccc2)C=2[C@H](N(C)C[C@H](C(=O)N[C@@]4(C(C)C)C(=O)N5[C@@H](CC(C)C)C(=O)N6[C@H]([C@]5(O)O4)CCC6)C=2)Cc13	Brc1[nH]c2c3c(ccc2)C=2[C@H](N(C)C[C@H](C(=O)N[C@@]4(C(C)C)C(=O)N5[C@@H](CC(C)C)C(=O)N6[C@H]([C@]5(O)O4)CCC6)C=2)Cc13
NCGC00159391-03	Brc1c(Br)c(Br)c2C(c3cc(S(=O)(=O)[O-])c(O)cc3)(c3cc(S(=O)(=O)[O-])c(O)cc3)OC(=O)c2c1Br		Inactive	Solute carrier organic anion transporter family member 1B1 Substrate		1	Sulfobromophthalein	170465816.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Brc1c(Br)c(Br)c2C(c3cc(S(=O)(=O)[O-])c(O)cc3)(c3cc(S(=O)(=O)[O-])c(O)cc3)OC(=O)c2c1Br.[Na+].[Na+]	Brc1c(Br)c(Br)c2C(c3cc(S(=O)(=O)[O-])c(O)cc3)(c3cc(S(=O)(=O)[O-])c(O)cc3)OC(=O)c2c1Br.[Na+].[Na+]
NCGC00093787-06	Brc1c(Br)c(Br)c2nc(N(C)C)[nH]c2c1Br		Inactive			1	DMAT	377020460.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(Br)c(Br)c2nc(N(C)C)[nH]c2c1Br	Brc1c(Br)c(Br)c2nc(N(C)C)[nH]c2c1Br
NCGC00387111-01	Brc1c(Br)c(Br)c2nc(N(C)C)n(CC(=O)O)c2c1Br		Inactive			1	TMCB	434146938.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(Br)c(Br)c2nc(N(C)C)n(CC(=O)O)c2c1Br	Brc1c(Br)c(Br)c2nc(N(C)C)n(CC(=O)O)c2c1Br
NCGC00092352-04	Brc1c(Br)c(Br)c2nn[nH]c2c1Br		Inactive			1	TBB	90341691.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(Br)c(Br)c2nn[nH]c2c1Br	Brc1c(Br)c(Br)c2nn[nH]c2c1Br
NCGC00371123-06	Brc1c(C(=O)Nc2cc(NC(=O)CCC)ccc2)cccc1		Inactive	Proteinase-activated receptor 1 Antagonist		1	ML161	363678039.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(C(=O)Nc2cc(NC(=O)CCC)ccc2)cccc1	Brc1c(C(=O)Nc2cc(NC(=O)CCC)ccc2)cccc1
NCGC00386616-01	Brc1c(C)c(CNCCCNC=2Nc3c(C(=O)C=2)cccc3)sc1C(F)=C		Inactive	Methionyl-tRNA synthetase  Inhibitor		1	REP 8839	363680357.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(C)c(CNCCCNC=2Nc3c(C(=O)C=2)cccc3)sc1C(F)=C	Brc1c(C)c(CNCCCNC=2Nc3c(C(=O)C=2)cccc3)sc1C(F)=C
NCGC00181297-01	Brc1c(C)c(NC(=O)CN(CC(=O)O)CC(=O)O)c(C)cc1C		Inactive			1	Mebrofenin	144206328.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(C)c(NC(=O)CN(CC(=O)O)CC(=O)O)c(C)cc1C	Brc1c(C)c(NC(=O)CN(CC(=O)O)CC(=O)O)c(C)cc1C
NCGC00343768-05	Brc1c(C)cc(OC[C@H]2OCCNC2)c(NC(=O)Nc2ncc(C)nc2)c1	4.9000001	Active	Chk1 Inhibitor	0.0	1	Rabusertib	384568714.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	37.0461644479	Brc1c(C)cc(OC[C@H]2OCCNC2)c(NC(=O)Nc2ncc(C)nc2)c1	Brc1c(C)cc(OC[C@H]2OCCNC2)c(NC(=O)Nc2ncc(C)nc2)c1
NCGC00522629-01	Brc1c(C)ccc(Nc2nnc(Cc3ccncc3)c3c2cccc3)c1		Inactive	VEGFR-2 Inhibitor		1	ACC-789	384569532.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	23.9679532279	Brc1c(C)ccc(Nc2nnc(Cc3ccncc3)c3c2cccc3)c1	Brc1c(C)ccc(Nc2nnc(Cc3ccncc3)c3c2cccc3)c1
NCGC00181118-01	Brc1c(C)nc(NS(=O)(=O)c2ccc(N)cc2)nc1C		Inactive			1	Sulfabromomethazine	144206282.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(C)nc(NS(=O)(=O)c2ccc(N)cc2)nc1C	Brc1c(C)nc(NS(=O)(=O)c2ccc(N)cc2)nc1C
NCGC00402272-02	Brc1c(C2=NCc3c(C(=O)N)ncn3-c3c2cc(F)cc3)cccc1		Inactive	GABA-A receptor; anion channel Positive Allosteric Modulator		1	Imidazenil	363681011.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(C2=NCc3c(C(=O)N)ncn3-c3c2cc(F)cc3)cccc1	Brc1c(C2=NCc3c(C(=O)N)ncn3-c3c2cc(F)cc3)cccc1
NCGC00189071-01	Brc1c(C2N=C(Nc3oc4c(n3)cccc4)NC3=C2C(=O)CCC3)cccc1		Inactive			1	NCGC00189071-01	99431312.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(C2N=C(Nc3oc4c(n3)cccc4)NC3=C2C(=O)CCC3)cccc1	Brc1c(C2N=C(Nc3oc4c(n3)cccc4)NC3=C2C(=O)CCC3)cccc1
NCGC00229722-01	Brc1c(C2N=C(Nc3oc4c(n3)cccc4)NC3=C2C(=O)CCC3)ccnc1		Inactive			1	NCGC00229722-01	99431330.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(C2N=C(Nc3oc4c(n3)cccc4)NC3=C2C(=O)CCC3)ccnc1	Brc1c(C2N=C(Nc3oc4c(n3)cccc4)NC3=C2C(=O)CCC3)ccnc1
NCGC00189284-01	Brc1c(C2N=C(Nc3oc4c(n3)cccc4)NC3=C2C(=O)CCC3)nccc1		Inactive			1	NCGC00189284-01	99431317.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(C2N=C(Nc3oc4c(n3)cccc4)NC3=C2C(=O)CCC3)nccc1	Brc1c(C2N=C(Nc3oc4c(n3)cccc4)NC3=C2C(=O)CCC3)nccc1
NCGC00378890-01	Brc1c(CN(CC#C)c2ccc(C(=O)NCc3cnccc3)cc2)cc2C(=O)NC(C)=Nc2c1		Inactive	Nicotinamide phosphoribosyltransferase Inhibitor		1	CB30865	363678259.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(CN(CC#C)c2ccc(C(=O)NCc3cnccc3)cc2)cc2C(=O)NC(C)=Nc2c1	Brc1c(CN(CC#C)c2ccc(C(=O)NCc3cnccc3)cc2)cc2C(=O)NC(C)=Nc2c1
NCGC00168463-06	Brc1c(C[N+](CC)(C)C)cccc1		Inactive	norepinephrine secretion Inhibitor		1	Bretylium tosylate	405558464.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(C[N+](CC)(C)C)cccc1	Brc1c(C[N+](CC)(C)C)cccc1
NCGC00388506-02	Brc1c(C[N+]2(CCOCCC3[C@H]4C(C)(C)[C@H](C4)CC3)CCOCC2)cc(OC)c(OC)c1		Inactive			1	Pinaverium bromide	405559006.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(C[N+]2(CCOCCC3[C@H]4C(C)(C)[C@H](C4)CC3)CCOCC2)cc(OC)c(OC)c1	Brc1c(C[N+]2(CCOCCC3[C@H]4C(C)(C)[C@H](C4)CC3)CCOCC2)cc(OC)c(OC)c1
NCGC00386831-01	Brc1c(Cl)cc(NC(=O)c2ccc(C(C)(C)C)cc2)c(C(=O)O)c1	4.9000001	Active		0.0	1	NCGC00386831-01	363680455.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	3.0	86.537159376	Brc1c(Cl)cc(NC(=O)c2ccc(C(C)(C)C)cc2)c(C(=O)O)c1	Brc1c(Cl)cc(NC(=O)c2ccc(C(C)(C)C)cc2)c(C(=O)O)c1
NCGC00181132-01	Brc1c(Cl)cc2C(=O)N(CC(=O)C[C@H]3[C@H](O)CCCN3)C=Nc2c1		Inactive			1	Halofuginone hydrochloride	144206292.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(Cl)cc2C(=O)N(CC(=O)C[C@H]3[C@H](O)CCCN3)C=Nc2c1.Cl	Brc1c(Cl)cc2C(=O)N(CC(=O)C[C@H]3[C@H](O)CCCN3)C=Nc2c1.Cl
NCGC00387194-02	Brc1c(F)c(Br)cc2N(C=O)C(C)CCc12		Inactive			1	CE3F4		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(F)c(Br)cc2N(C=O)C(C)CCc12	Brc1c(F)c(Br)cc2N(C=O)C(C)CCc12
NCGC00402358-02	Brc1c(F)ccc(N/C(=N\O)/c2c(NCCNS(=O)(=O)N)non2)c1		Inactive	IDO Inhibitor		1	Epacadostat	384569216.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(F)ccc(N/C(=N\O)/c2c(NCCNS(=O)(=O)N)non2)c1	Brc1c(F)ccc(N/C(=N\O)/c2c(NCCNS(=O)(=O)N)non2)c1
NCGC00263232-01	Brc1c(N(C)C)ccc(C2Nc3c(c4c(cc3)cccc4)C3=C2C(=O)CC(C)(C)C3)c1	4.9499998	Active	Glutaminase Inhibitor	0.0	1	GLS-968	137276076.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	113.1150721216	Brc1c(N(C)C)ccc(C2Nc3c(c4c(cc3)cccc4)C3=C2C(=O)CC(C)(C)C3)c1	Brc1c(N(C)C)ccc(C2Nc3c(c4c(cc3)cccc4)C3=C2C(=O)CC(C)(C)C3)c1
NCGC00016781-08	Brc1c(N)c(CNC2CCC(O)CC2)cc(Br)c1		Inactive	surfactant homeostasis Modulator		1	Ambroxol hydrochloride	225144182.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(N)c(CNC2CCC(O)CC2)cc(Br)c1	Brc1c(N)c(CNC2CCC(O)CC2)cc(Br)c1
NCGC00346676-04	Brc1c(N2CCN(Cc3noc(C)c3)CC2)c2nc(-c3ccc(N4CCN(C)CC4)cc3)[nH]c2nc1		Inactive	Aurora-A/B/C Kinase Inhibitor		1	CCT-137690	384568902.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(N2CCN(Cc3noc(C)c3)CC2)c2nc(-c3ccc(N4CCN(C)CC4)cc3)[nH]c2nc1	Brc1c(N2CCN(Cc3noc(C)c3)CC2)c2nc(-c3ccc(N4CCN(C)CC4)cc3)[nH]c2nc1
NCGC00025100-17	Brc1c(NC(=O)/C(/C#N)=C(\O)/C)cc(Br)cc1		Inactive	BTK Inhibitor		1	LFM-A13	384568049.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(NC(=O)/C(/C#N)=C(\O)/C)cc(Br)cc1	Brc1c(NC(=O)/C(/C#N)=C(\O)/C)cc(Br)cc1
NCGC00387088-01	Brc1c(NC(=O)NCCN(CC)c2cc(C)ccc2)cccc1		Inactive	Vanilloid receptor Antagonist		1	SB 452533	363680539.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(NC(=O)NCCN(CC)c2cc(C)ccc2)cccc1	Brc1c(NC(=O)NCCN(CC)c2cc(C)ccc2)cccc1
NCGC00379105-01	Brc1c(NC(=O)N[C@@H]2[C@H](c3ccccc3)OC(C)(C)OC2)ccc(Br)c1		Inactive	Orexin receptor 2 Antagonist		1	JNJ 10397049	363678355.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(NC(=O)N[C@@H]2[C@H](c3ccccc3)OC(C)(C)OC2)ccc(Br)c1	Brc1c(NC(=O)N[C@@H]2[C@H](c3ccccc3)OC(C)(C)OC2)ccc(Br)c1
NCGC00346690-04	Brc1c(NC(=O)N[C@H]2CN(c3ncc(C(F)(F)F)cc3)CC2)cccc1		Inactive	TRPV1 (Vanilloid VR1 Receptor) Agonist		1	SB-705498	384568912.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	10.9199182999	Brc1c(NC(=O)N[C@H]2CN(c3ncc(C(F)(F)F)cc3)CC2)cccc1	Brc1c(NC(=O)N[C@H]2CN(c3ncc(C(F)(F)F)cc3)CC2)cccc1
NCGC00242491-03	Brc1c(NC(=O)Nc2c3nn[nH]c3c(C#N)cc2)cccc1		Inactive	CXCR2 Antagonist		1	SB-265610	384568497.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(NC(=O)Nc2c3nn[nH]c3c(C#N)cc2)cccc1	Brc1c(NC(=O)Nc2c3nn[nH]c3c(C#N)cc2)cccc1
NCGC00532499-01	Brc1c(NC2=NCCN2)c(F)ccc1		Inactive	Alpha-2B adrenergic receptor Agonist		1	ROMIFIDINE	405559124.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(NC2=NCCN2)c(F)ccc1	Brc1c(NC2=NCCN2)c(F)ccc1
NCGC00016069-13	Brc1c(NC2=NCCN2)ccc2nccnc12		Inactive	Alpha-2C adrenergic receptor Agonist		1	Brimonidine	170464941.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Brc1c(NC2=NCCN2)ccc2nccnc12	Brc1c(NC2=NCCN2)ccc2nccnc12
NCGC00346687-10	Brc1c(NCCc2[nH]cnc2)nc(Nc2cc(NC(=O)N3CCCC3)ccc2)nc1		Inactive	Phosphoinositide Dependent Kinase Inhibitor		1	BX-912	384568911.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(NCCc2[nH]cnc2)nc(Nc2cc(NC(=O)N3CCCC3)ccc2)nc1	Brc1c(NCCc2[nH]cnc2)nc(Nc2cc(NC(=O)N3CCCC3)ccc2)nc1
NCGC00378862-01	Brc1c(Nc2c(S(=O)(=O)NC)cccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1		Inactive	ALK tyrosine kinase receptor Inhibitor		1	ALK inhibitor 1	363678242.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(Nc2c(S(=O)(=O)NC)cccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1	Brc1c(Nc2c(S(=O)(=O)NC)cccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1
NCGC00350943-01	Brc1c(Nc2ncnc3c2c2sc(C(OC)=N)nc2cc3)ccc(F)c1		Inactive			1	NCGC00350943-01	377020530.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(Nc2ncnc3c2c2sc(C(OC)=N)nc2cc3)ccc(F)c1	Brc1c(Nc2ncnc3c2c2sc(C(OC)=N)nc2cc3)ccc(F)c1
NCGC00371138-10	Brc1c(Nc2scc(-c3c(C)nc4n3C=CC=N4)n2)c(Br)cc(OC)c1		Inactive	Polycomb complex protein BMI-1 Inhibitor		1	PTC-209 	363678053.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	30.5	Brc1c(Nc2scc(-c3c(C)nc4n3C=CC=N4)n2)c(Br)cc(OC)c1	Brc1c(Nc2scc(-c3c(C)nc4n3C=CC=N4)n2)c(Br)cc(OC)c1
NCGC00386303-01	Brc1c(O)c(Br)cc(-c2nc(C(=O)NCc3ccc(Oc4ccccc4)cc3)on2)c1		Inactive	Cystic fibrosis transmembrane conductance regulator Inhibitor		1	IOWH032	363680196.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(O)c(Br)cc(-c2nc(C(=O)NCc3ccc(Oc4ccccc4)cc3)on2)c1	Brc1c(O)c(Br)cc(-c2nc(C(=O)NCc3ccc(Oc4ccccc4)cc3)on2)c1
NCGC00013895-08	Brc1c(O)c(Br)cc(C(=O)c2c(CC)oc3c2cccc3)c1		Inactive	Xanthine dehydrogenase Inhibitor		1	Benzbromarone	170465792.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Brc1c(O)c(Br)cc(C(=O)c2c(CC)oc3c2cccc3)c1	Brc1c(O)c(Br)cc(C(=O)c2c(CC)oc3c2cccc3)c1
NCGC00346942-01	Brc1c(O)c(Br)cc(Nc2ncnc3c2cc(OC)c(OC)c3)c1		Inactive	EGFR Inhibitor		1	WHI-P97	174006541.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(O)c(Br)cc(Nc2ncnc3c2cc(OC)c(OC)c3)c1	Brc1c(O)c(Br)cc(Nc2ncnc3c2cc(OC)c(OC)c3)c1
NCGC00246387-06&NCGC00246387-08	Brc1c(O)c(CN(C)C)c2c(C(=O)OCC)c(CSc3ccccc3)n(C)c2c1	4.96249985	Active	antiinfluenza drug	0.025000100000000636	2	Arbidol	434146926.0&384568511.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General&SARS-CoV-2 cytopathic effect (CPE)	3.0&1.1&3.0	100.7029216829&86.3519163732&117.9254943572	Brc1c(O)c(CN(C)C)c2c(C(=O)OCC)c(CSc3ccccc3)n(C)c2c1	Brc1c(O)c(CN(C)C)c2c(C(=O)OCC)c(CSc3ccccc3)n(C)c2c1
NCGC00538143-01	Brc1c(O)c(CNC2CCC(O)CC2)cc(Br)c1		Inactive	surfactant homeostasis Activator		1	NCGC00538143-01	405558668.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(O)c(CNC2CCC(O)CC2)cc(Br)c1	Brc1c(O)c(CNC2CCC(O)CC2)cc(Br)c1
NCGC00386728-01	Brc1c(O)c(O)cc(/C=C/C(=S)NCc2cc(O)c(O)c(O)c2)c1		Inactive			1	NT 157	377020482.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	21.657142856	Brc1c(O)c(O)cc(/C=C/C(=S)NCc2cc(O)c(O)c(O)c2)c1	Brc1c(O)c(O)cc(/C=C/C(=S)NCc2cc(O)c(O)c(O)c2)c1
NCGC00351598-04	Brc1c(O)ccc(Nc2ncnc3c2cc(OC)c(OC)c3)c1		Inactive	EGFR Inhibitor		1	WHI-P154	384569016.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(O)ccc(Nc2ncnc3c2cc(OC)c(OC)c3)c1	Brc1c(O)ccc(Nc2ncnc3c2cc(OC)c(OC)c3)c1
NCGC00346680-05	Brc1c(OC2CCN(c3noc(-c4nn(CC(=O)O)nn4)c3)CC2)cc(F)cc1		Inactive	Stearoyl-CoA Desaturase Inhibitor		1	MK-8245	363677514.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(OC2CCN(c3noc(-c4nn(CC(=O)O)nn4)c3)CC2)cc(F)cc1	Brc1c(OC2CCN(c3noc(-c4nn(CC(=O)O)nn4)c3)CC2)cc(F)cc1
NCGC00370710-02	Brc1c(OCC(=O)Nc2cnccc2)ccc2c1cccc2		Inactive	HERG Agonist		1	VU0405601	363677817.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(OCC(=O)Nc2cnccc2)ccc2c1cccc2	Brc1c(OCC(=O)Nc2cnccc2)ccc2c1cccc2
NCGC00189076-01	Brc1c(OCCCOc2c(Br)cc(C(=N)N)cc2)ccc(C(=N)N)c1		Inactive			1	Dibromopropamidine dihydrochloride	144207153.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c(OCCCOc2c(Br)cc(C(=N)N)cc2)ccc(C(=N)N)c1.Cl.Cl	Brc1c(OCCCOc2c(Br)cc(C(=N)N)cc2)ccc(C(=N)N)c1.Cl.Cl
NCGC00387262-03	Brc1c(OCCSc2ncccn2)ccc(C)c1		Inactive			1	ZLN024		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(OCCSc2ncccn2)ccc(C)c1	Brc1c(OCCSc2ncccn2)ccc(C)c1
NCGC00481542-04	Brc1c(Oc2c(C(=O)NC)cccc2)nc(Nc2cc(OC)c(OC)c(OC)c2)nc1		Inactive			1	NCGC00481542-04		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(Oc2c(C(=O)NC)cccc2)nc(Nc2cc(OC)c(OC)c(OC)c2)nc1	Brc1c(Oc2c(C(=O)NC)cccc2)nc(Nc2cc(OC)c(OC)c(OC)c2)nc1
NCGC00345885-02&NCGC00345885-04	Brc1c(Oc2c(C)cc(C#N)cc2C)nc(Nc2ccc(C#N)cc2)nc1N		Inactive	P-glycoprotein 1 Inhibitor		2	Etravirine (TMC125)&Etravirine	434147085.0&405558520.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Brc1c(Oc2c(C)cc(C#N)cc2C)nc(Nc2ccc(C#N)cc2)nc1N	Brc1c(Oc2c(C)cc(C#N)cc2C)nc(Nc2ccc(C#N)cc2)nc1N
NCGC00378683-01	Brc1c(Oc2ccc(NC(=O)C[C@H](N)C(=O)O)cc2)cc(F)c(F)c1		Inactive	Excitatory amino acid transporter 3 Inhibitor		1	WAY 213613	363678148.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(Oc2ccc(NC(=O)C[C@H](N)C(=O)O)cc2)cc(F)c(F)c1	Brc1c(Oc2ccc(NC(=O)C[C@H](N)C(=O)O)cc2)cc(F)c(F)c1
NCGC00379177-01	Brc1c(S(=O)(=O)Nc2cc(O[C@H]3CN(C)CC3)c(C(F)(F)F)cc2)cc(OC)c(OC)c1		Inactive	Urotensin II receptor Antagonist		1	SB 706375	363678399.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(S(=O)(=O)Nc2cc(O[C@H]3CN(C)CC3)c(C(F)(F)F)cc2)cc(OC)c(OC)c1	Brc1c(S(=O)(=O)Nc2cc(O[C@H]3CN(C)CC3)c(C(F)(F)F)cc2)cc(OC)c(OC)c1
NCGC00370845-01	Brc1c(S(=O)(=O)Nc2cc(O[C@H]3CN(C)CC3)c(Cl)cc2)cc(OC)c(OC)c1		Inactive	Urotensin II receptor Antagonist		1	SB 657510	363677881.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c(S(=O)(=O)Nc2cc(O[C@H]3CN(C)CC3)c(Cl)cc2)cc(OC)c(OC)c1	Brc1c(S(=O)(=O)Nc2cc(O[C@H]3CN(C)CC3)c(Cl)cc2)cc(OC)c(OC)c1
NCGC00386617-01	Brc1c2OCC[C@@H](NCCCNC=3Nc4c(C(=O)C=3)scc4)c2cc(Br)c1		Inactive	Streptococcus pyogenes Inhibitor		1	REP 3123 dihydrochloride	363680358.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c2OCC[C@@H](NCCCNC=3Nc4c(C(=O)C=3)scc4)c2cc(Br)c1	Brc1c2OCC[C@@H](NCCCNC=3Nc4c(C(=O)C=3)scc4)c2cc(Br)c1
NCGC00346707-05	Brc1c2[C@@H](C3CCN(C(=O)CC4CCN(C(=O)N)CC4)CC3)c3ncc(Br)cc3CCc2cc(Cl)c1		Inactive	Farnesyltransferase Inhibitor		1	Lonafarnib	384568925.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1c2[C@@H](C3CCN(C(=O)CC4CCN(C(=O)N)CC4)CC3)c3ncc(Br)cc3CCc2cc(Cl)c1	Brc1c2[C@@H](C3CCN(C(=O)CC4CCN(C(=O)N)CC4)CC3)c3ncc(Br)cc3CCc2cc(Cl)c1
NCGC00344622-15	Brc1c2c(N)ncnc2n([C@H]2[C@H](O)[C@H](O)[C@@H](CN(C(C)C)CCCNC(=O)Nc3ccc(C(C)(C)C)cc3)O2)c1		Inactive	DOT1L Inhibitor		1	SGC-0946	384568725.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-12.686571392	Brc1c2c(N)ncnc2n([C@H]2[C@H](O)[C@H](O)[C@@H](CN(C(C)C)CCCNC(=O)Nc3ccc(C(C)(C)C)cc3)O2)c1	Brc1c2c(N)ncnc2n([C@H]2[C@H](O)[C@H](O)[C@@H](CN(C(C)C)CCCNC(=O)Nc3ccc(C(C)(C)C)cc3)O2)c1
NCGC00485018-01	Brc1c2c(c(S(=O)(=O)NCc3ncccc3)cc1)cccc2		Inactive			1	Pyrabactin	363681188.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c2c(c(S(=O)(=O)NCc3ncccc3)cc1)cccc2	Brc1c2c(c(S(=O)(=O)NCc3ncccc3)cc1)cccc2
NCGC00485277-01	Brc1c2c(c3NC(=O)CC(c4cc(OC)c(OC)c(OC)c4)c3c1)cccc2		Inactive			1	6-B345TTQ	363681275.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1c2c(c3NC(=O)CC(c4cc(OC)c(OC)c(OC)c4)c3c1)cccc2	Brc1c2c(c3NC(=O)CC(c4cc(OC)c(OC)c(OC)c4)c3c1)cccc2
NCGC00379133-01	Brc1cc(-c2[nH]nnn2)c(NC(=O)Nc2cc(C(F)(F)F)ccc2)cc1		Inactive	HERG Activator		1	NS 3623	363678376.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cc(-c2[nH]nnn2)c(NC(=O)Nc2cc(C(F)(F)F)ccc2)cc1	Brc1cc(-c2[nH]nnn2)c(NC(=O)Nc2cc(C(F)(F)F)ccc2)cc1
NCGC00092381-04	Brc1cc(-c2c3c(N)ncnc3nc(-c3cnc(N4CCOCC4)cc3)c2)ccc1		Inactive	Adenosine Kinase Inhibitor		1	ABT-702	384568109.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1cc(-c2c3c(N)ncnc3nc(-c3cnc(N4CCOCC4)cc3)c2)ccc1	Brc1cc(-c2c3c(N)ncnc3nc(-c3cnc(N4CCOCC4)cc3)c2)ccc1
NCGC00370887-06	Brc1cc(/C(=N/NC(=O)C(NC(=O)c2ccccc2)C2=NNC(=O)c3c2cccc3)/C)ccc1		Inactive			1	AC-55541	434146897.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	25.5101123639	Brc1cc(/C(=N/NC(=O)C(NC(=O)c2ccccc2)C2=NNC(=O)c3c2cccc3)/C)ccc1	Brc1cc(/C(=N/NC(=O)C(NC(=O)c2ccccc2)C2=NNC(=O)c3c2cccc3)/C)ccc1
NCGC00481428-01	Brc1cc(C#N)c(NC(=O)c2ccc(CP(=O)(OCC)OCC)cc2)cc1		Inactive			1	NCGC00481428-01	363681120.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cc(C#N)c(NC(=O)c2ccc(CP(=O)(OCC)OCC)cc2)cc1	Brc1cc(C#N)c(NC(=O)c2ccc(CP(=O)(OCC)OCC)cc2)cc1
NCGC00379146-01	Brc1cc(C(=O)N2CCC(N3CCCC3)CC2)ccc1		Inactive			1	UNC 926 hydrochloride		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cc(C(=O)N2CCC(N3CCCC3)CC2)ccc1	Brc1cc(C(=O)N2CCC(N3CCCC3)CC2)ccc1
NCGC00347957-09	Brc1cc(C(=O)N2CCC(N3CCCC3)CC2)cnc1		Inactive	L3MBTL3 methyllysine (Kme) reader domain Inhibitor		1	UNC-669	363677733.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1cc(C(=O)N2CCC(N3CCCC3)CC2)cnc1	Brc1cc(C(=O)N2CCC(N3CCCC3)CC2)cnc1
NCGC00402308-03	Brc1cc(C(=O)NCCCNC(C)(C)C)ccc1		Inactive	Tumor suppressor p53-binding protein 1 Inhibitor		1	UNC2170 Maleate	363681023.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cc(C(=O)NCCCNC(C)(C)C)ccc1	Brc1cc(C(=O)NCCCNC(C)(C)C)ccc1
NCGC00386932-01	Brc1cc(C(=O)OC)c(N2CC(O)C(NC3CCCCC3)CC2)nc1		Inactive			1	NCGC00386932-01	363680516.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cc(C(=O)OC)c(N2CC(O)C(NC3CCCCC3)CC2)nc1	Brc1cc(C(=O)OC)c(N2CC(O)C(NC3CCCCC3)CC2)nc1
NCGC00370894-01	Brc1cc(C2=NCC(=O)Nc3c4c(oc23)cccc4)ccc1		Inactive	P2X purinoceptor 4 Antagonist		1	5-BDBD	363677915.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cc(C2=NCC(=O)Nc3c4c(oc23)cccc4)ccc1	Brc1cc(C2=NCC(=O)Nc3c4c(oc23)cccc4)ccc1
NCGC00389085-04	Brc1cc(CCN(S(=O)(=O)c2c(C)cc(C)cc2C)Cc2ccc(-c3cc(S(=O)(=O)C)ccc3)cc2)ccc1		Inactive	Liver-X-receptor (LXR) inverse Agonist that induces LXR-corepressor interaction		1	SR-9243	384569171.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1cc(CCN(S(=O)(=O)c2c(C)cc(C)cc2C)Cc2ccc(-c3cc(S(=O)(=O)C)ccc3)cc2)ccc1	Brc1cc(CCN(S(=O)(=O)c2c(C)cc(C)cc2C)Cc2ccc(-c3cc(S(=O)(=O)C)ccc3)cc2)ccc1
NCGC00345496-08	Brc1cc(COc2nc(N)nc3nc[nH]c23)sc1		Inactive	MGMT Inhibitor		1	Lomeguatrib	363677349.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1cc(COc2nc(N)nc3nc[nH]c23)sc1	Brc1cc(COc2nc(N)nc3nc[nH]c23)sc1
NCGC00189073-04	Brc1cc(Cl)c(Nc2c(F)c3ncn(C)c3cc2C(=O)NOCCO)cc1		Inactive	Mek1/2 inibitor		1	Selumetinib	384568456.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Brc1cc(Cl)c(Nc2c(F)c3ncn(C)c3cc2C(=O)NOCCO)cc1	Brc1cc(Cl)c(Nc2c(F)c3ncn(C)c3cc2C(=O)NOCCO)cc1
NCGC00371139-12	Brc1cc(Cl)c(OCC(=O)NC(=S)Nc2ccc(S(=O)(=O)Nc3nc(C)cc(C)n3)cc2)cc1		Inactive			1	ZCl278	363678054.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cc(Cl)c(OCC(=O)NC(=S)Nc2ccc(S(=O)(=O)Nc3nc(C)cc(C)n3)cc2)cc1	Brc1cc(Cl)c(OCC(=O)NC(=S)Nc2ccc(S(=O)(=O)Nc3nc(C)cc(C)n3)cc2)cc1
NCGC00484081-01	Brc1cc(F)c(CN2C(=O)[C@@]3(C(=O)NC(=O)C3)n3c(C2=O)ccc3)cc1		Inactive	Aldose reductase Inhibitor		1	Ranirestat	363681172.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cc(F)c(CN2C(=O)[C@@]3(C(=O)NC(=O)C3)n3c(C2=O)ccc3)cc1	Brc1cc(F)c(CN2C(=O)[C@@]3(C(=O)NC(=O)C3)n3c(C2=O)ccc3)cc1
NCGC00263100-02	Brc1cc(F)c(COc2c(C(=O)N)c(NC(=O)NCCCCN3CCCC3)sn2)c(F)c1	4.9000001	Active	VEGFR-2 Inhibitor	0.0	1	OSI-632	363677201.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	42.2704434419	Brc1cc(F)c(COc2c(C(=O)N)c(NC(=O)NCCCCN3CCCC3)sn2)c(F)c1	Brc1cc(F)c(COc2c(C(=O)N)c(NC(=O)NCCCCN3CCCC3)sn2)c(F)c1
NCGC00345804-10	Brc1cc(F)c(Nc2c(F)c3ncn(C)c3cc2C(=O)NOCCO)cc1		Inactive	Mek 1/2 Inhibitor		1	ARRY-162	363677367.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1cc(F)c(Nc2c(F)c3ncn(C)c3cc2C(=O)NOCCO)cc1	Brc1cc(F)c(Nc2c(F)c3ncn(C)c3cc2C(=O)NOCCO)cc1
NCGC00167513-04&NCGC00167513-13	Brc1cc(F)c(Nc2ncnc3c2cc(OC)c(OCC2CCN(C)CC2)c3)cc1		Inactive	EGFR Inhibitor		2	Vandetanib	170465617.0&384568321.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Brc1cc(F)c(Nc2ncnc3c2cc(OC)c(OCC2CCN(C)CC2)c3)cc1	Brc1cc(F)c(Nc2ncnc3c2cc(OC)c(OCC2CCN(C)CC2)c3)cc1
NCGC00346804-01	Brc1cc(N)c(Nc2cc(Cl)c(C(=O)c3c(C)cccc3)cc2)cc1		Inactive	p38 MAPK Inhibitor		1	EO-1428	174007089.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Brc1cc(N)c(Nc2cc(Cl)c(C(=O)c3c(C)cccc3)cc2)cc1	Brc1cc(N)c(Nc2cc(Cl)c(C(=O)c3c(C)cccc3)cc2)cc1
NCGC00347936-06	Brc1cc(NC(=O)c2cc(S(=O)(=O)N3CCCCCC3)ccc2)ccc1		Inactive	Histone Deacetylase SIRT2 Inhibitor		1	Ak-7	363677722.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	13.8329283159	Brc1cc(NC(=O)c2cc(S(=O)(=O)N3CCCCCC3)ccc2)ccc1	Brc1cc(NC(=O)c2cc(S(=O)(=O)N3CCCCCC3)ccc2)ccc1
NCGC00229552-01	Brc1cc(Nc2nc(C3=C(C)N(C)C(=O)S3)ccn2)cc(C(F)(F)F)c1		Inactive			1	NCGC00229552-01	124939209.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cc(Nc2nc(C3=C(C)N(C)C(=O)S3)ccn2)cc(C(F)(F)F)c1	Brc1cc(Nc2nc(C3=C(C)N(C)C(=O)S3)ccn2)cc(C(F)(F)F)c1
NCGC00386260-02	Brc1cc(Nc2ncnc3c2cc(NC(=O)C=C)cc3)ccc1		Inactive	EGFR Inhibitor		1	PD-168393	363680172.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1cc(Nc2ncnc3c2cc(NC(=O)C=C)cc3)ccc1	Brc1cc(Nc2ncnc3c2cc(NC(=O)C=C)cc3)ccc1
NCGC00167795-06	Brc1cc(Nc2ncnc3c2cc(NC)nc3)ccc1		Inactive			1	PD158780	377020383.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	16.4190968919	Brc1cc(Nc2ncnc3c2cc(NC)nc3)ccc1	Brc1cc(Nc2ncnc3c2cc(NC)nc3)ccc1
NCGC00024956-17	Brc1cc(Nc2ncnc3c2cc(OC)c(OC)c3)ccc1		Inactive	EGFR Inhibitor		1	PD-153035	384568037.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1cc(Nc2ncnc3c2cc(OC)c(OC)c3)ccc1	Brc1cc(Nc2ncnc3c2cc(OC)c(OC)c3)ccc1
NCGC00390566-03	Brc1cc([C@@H](NC(=O)CNC(=O)c2cc(O)cc(NC3=NCC(O)CN3)c2)CC(=O)O)cc(C(C)(C)C)c1		Inactive	Integrin alpha-V/beta-6 Inhibitor		1	CWHM-12	363680906.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cc([C@@H](NC(=O)CNC(=O)c2cc(O)cc(NC3=NCC(O)CN3)c2)CC(=O)O)cc(C(C)(C)C)c1	Brc1cc([C@@H](NC(=O)CNC(=O)c2cc(O)cc(NC3=NCC(O)CN3)c2)CC(=O)O)cc(C(C)(C)C)c1
NCGC00351594-01	Brc1cc2/C(=C/3\C(=O)N(C(C(=O)O)CC(=O)O)C(=S)S\3)/C(=O)Nc2cc1		Inactive	Bcl-6 Inhibitor		1	BCL6 Inhibitor	384569013.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1cc2/C(=C/3\C(=O)N(C(C(=O)O)CC(=O)O)C(=S)S\3)/C(=O)Nc2cc1	Brc1cc2/C(=C/3\C(=O)N(C(C(=O)O)CC(=O)O)C(=S)S\3)/C(=O)Nc2cc1
NCGC00387981-01	Brc1cc2/C(=N/Nc3ccc(S(=O)(=O)N)cc3)/C(=O)Nc2cc1		Inactive			1	Cdk2 Inhibitor II	377020170.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cc2/C(=N/Nc3ccc(S(=O)(=O)N)cc3)/C(=O)Nc2cc1	Brc1cc2/C(=N/Nc3ccc(S(=O)(=O)N)cc3)/C(=O)Nc2cc1
NCGC00025207-15	Brc1cc2C(C(C(=O)OCC)C#N)C(C(=O)OCC)=C(N)Oc2cc1		Inactive	Bcl-2 Inhibitor		1	HA-14-1	363676538.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1cc2C(C(C(=O)OCC)C#N)C(C(=O)OCC)=C(N)Oc2cc1	Brc1cc2C(C(C(=O)OCC)C#N)C(C(=O)OCC)=C(N)Oc2cc1
NCGC00390271-01	Brc1cc2C(c3c(Cl)cccc3)=NCC(=O)Nc2cc1		Inactive	GABA-A receptor; agonist GABA site Agonist		1	Phenazepam	363680871.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cc2C(c3c(Cl)cccc3)=NCC(=O)Nc2cc1	Brc1cc2C(c3c(Cl)cccc3)=NCC(=O)Nc2cc1
NCGC00346883-02	Brc1cc2NC(=O)/C(=C/3\C(=N\OC(=O)C)\c4c(N\3)cccc4)/c2cc1		Inactive	GSK-3 Inhibitor		1	6-Bromoindirubin-3'-acetoxime	384568960.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Brc1cc2NC(=O)/C(=C/3\C(=N\OC(=O)C)\c4c(N\3)cccc4)/c2cc1	Brc1cc2NC(=O)/C(=C/3\C(=N\OC(=O)C)\c4c(N\3)cccc4)/c2cc1
NCGC00094112-11	Brc1cc2NC(=O)/C(=C\3/C(=N/O)/c4c(N/3)cccc4)/c2cc1		Inactive	GSK-3 Inhibitor		1	BIO	384568126.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1cc2NC(=O)/C(=C\3/C(=N/O)/c4c(N/3)cccc4)/c2cc1	Brc1cc2NC(=O)/C(=C\3/C(=N/O)/c4c(N/3)cccc4)/c2cc1
NCGC00379117-01	Brc1cc2NC(=O)CC(c3cc(C#N)ncc3)=Nc2cc1		Inactive	Metabotropic glutamate receptor 2 Negative Allosteric Modulator		1	MNI 137	363678366.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cc2NC(=O)CC(c3cc(C#N)ncc3)=Nc2cc1	Brc1cc2NC(=O)CC(c3cc(C#N)ncc3)=Nc2cc1
NCGC00386841-04	Brc1cc2NC(=O)N(C3CCN(C[C@@H](NC(=O)[C@H]4[C@H](c5ccccc5)C4)C)CC3)c2cc1		Inactive	Phospholipase D2 Negative Allosteric Modulator		1	VU0359595	363680461.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cc2NC(=O)N(C3CCN(C[C@@H](NC(=O)[C@H]4[C@H](c5ccccc5)C4)C)CC3)c2cc1	Brc1cc2NC(=O)N(C3CCN(C[C@@H](NC(=O)[C@H]4[C@H](c5ccccc5)C4)C)CC3)c2cc1
NCGC00079175-02	Brc1cc2c(NCC=C)ncnc2cc1		Inactive			1	SMER28	90340720.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cc2c(NCC=C)ncnc2cc1	Brc1cc2c(NCC=C)ncnc2cc1
NCGC00015582-11	Brc1cc2c([nH]c3-c4c(NC(=O)Cc23)cccc4)cc1		Inactive			1	Kenpaullone	404904656.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	16.6749472719	Brc1cc2c([nH]c3-c4c(NC(=O)Cc23)cccc4)cc1	Brc1cc2c([nH]c3-c4c(NC(=O)Cc23)cccc4)cc1
NCGC00386322-01	Brc1cc2c([nH]c3-c4ncccc4NC(=O)Cc23)cc1		Inactive	Glycogen synthase kinase-3 beta Inhibitor		1	1-Azakenpaullone	363680209.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cc2c([nH]c3-c4ncccc4NC(=O)Cc23)cc1	Brc1cc2c([nH]c3-c4ncccc4NC(=O)Cc23)cc1
NCGC00370834-01	Brc1cc2c(n(CC(F)CN3CCNCC3)c3c2cc(Br)cc3)cc1		Inactive	Apoptosis regulator BAX Inhibitor		1	iMAC2	363677875.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	-25.6617460302	Brc1cc2c(n(CC(F)CN3CCNCC3)c3c2cc(Br)cc3)cc1	Brc1cc2c(n(CC(F)CN3CCNCC3)c3c2cc(Br)cc3)cc1
NCGC00390267-02	Brc1cc2c(n(CC(F)CNc3cc(OC)ccc3)c3c2cc(Br)cc3)cc1		Inactive			1	P7C3-A20	363680870.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cc2c(n(CC(F)CNc3cc(OC)ccc3)c3c2cc(Br)cc3)cc1	Brc1cc2c(n(CC(F)CNc3cc(OC)ccc3)c3c2cc(Br)cc3)cc1
NCGC00408808-01	Brc1cc2c(n(C[C@H](O)CNc3cc(OC)ccc3)c3c2cc(Br)cc3)cc1	4.9000001	Active		0.0	1	(R)-P7C3-Ome	363681054.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	67.2929771648	Brc1cc2c(n(C[C@H](O)CNc3cc(OC)ccc3)c3c2cc(Br)cc3)cc1	Brc1cc2c(n(C[C@H](O)CNc3cc(OC)ccc3)c3c2cc(Br)cc3)cc1
NCGC00348215-03	Brc1cc2c(nc(OC)c([C@H]([C@@](O)(CCN(C)C)c3c4c(ccc3)cccc4)c3ccccc3)c2)cc1		Inactive	ATP synthase subunit c Inhibitor		1	Bedaquiline (TMC-207)	405558612.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1cc2c(nc(OC)c([C@H]([C@@](O)(CCN(C)C)c3c4c(ccc3)cccc4)c3ccccc3)c2)cc1	Brc1cc2c(nc(OC)c([C@H]([C@@](O)(CCN(C)C)c3c4c(ccc3)cccc4)c3ccccc3)c2)cc1
NCGC00370767-01	Brc1cc2nc(c(CN3CCC(N4CCCCC4)CC3)c(C(=O)NC3(c4ccccc4)CC3)c2cc1)-c1cc(C(F)(F)F)ccc1		Inactive	Transient receptor potential cation channel subfamily V member 4 Blocker		1	GSK 2193874	363677842.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	-11.910814304	Brc1cc2nc(c(CN3CCC(N4CCCCC4)CC3)c(C(=O)NC3(c4ccccc4)CC3)c2cc1)-c1cc(C(F)(F)F)ccc1	Brc1cc2nc(c(CN3CCC(N4CCCCC4)CC3)c(C(=O)NC3(c4ccccc4)CC3)c2cc1)-c1cc(C(F)(F)F)ccc1
NCGC00262959-01	Brc1ccc(-c2ccc(C3CC(C=4C(=O)Sc5c(C=4O)cccc5)c4c(cccc4)C3)cc2)cc1		Inactive			1	Difethialone	170465892.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Brc1ccc(-c2ccc(C3CC(C=4C(=O)Sc5c(C=4O)cccc5)c4c(cccc4)C3)cc2)cc1	Brc1ccc(-c2ccc(C3CC(C=4C(=O)Sc5c(C=4O)cccc5)c4c(cccc4)C3)cc2)cc1
NCGC00263127-03	Brc1ccc(-c2ccc(S(=O)(=O)C[C@H](C(=O)O)C(C)C)cc2)cc1		Inactive	MMP13 Inhibitor		1	PD-166793	363677215.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1ccc(-c2ccc(S(=O)(=O)C[C@H](C(=O)O)C(C)C)cc2)cc1	Brc1ccc(-c2ccc(S(=O)(=O)C[C@H](C(=O)O)C(C)C)cc2)cc1
NCGC00387244-01	Brc1ccc(/C=C/C(=O)N2CCN(C(=O)c3ccc(OC)cc3)CC2)cc1		Inactive	G-Protein Coupled Receptor 183 (GPR183; EBI2) Modulators		1	NIBR-189	384569155.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1ccc(/C=C/C(=O)N2CCN(C(=O)c3ccc(OC)cc3)CC2)cc1	Brc1ccc(/C=C/C(=O)N2CCN(C(=O)c3ccc(OC)cc3)CC2)cc1
NCGC00371087-01	Brc1ccc(/C=C/C(=O)Nc2c(F)cc(-c3oc4c(n3)cc(CC(=O)O)cc4)cc2)cc1		Inactive	Heparanase Inhibitor		1	OGT 2115	363678023.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1ccc(/C=C/C(=O)Nc2c(F)cc(-c3oc4c(n3)cc(CC(=O)O)cc4)cc2)cc1	Brc1ccc(/C=C/C(=O)Nc2c(F)cc(-c3oc4c(n3)cc(CC(=O)O)cc4)cc2)cc1
NCGC00162073-12	Brc1ccc(/C=C/CNCCNS(=O)(=O)c2c3c(cncc3)ccc2)cc1	4.9250002	Active	AKT Inhibitor	0.0	1	H-89	384568218.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	41.3094767984&39.507518792	Brc1ccc(/C=C/CNCCNS(=O)(=O)c2c3c(cncc3)ccc2)cc1	Brc1ccc(/C=C/CNCCNS(=O)(=O)c2c3c(cncc3)ccc2)cc1
NCGC00386857-03	Brc1ccc(C(=O)N[C@H](CN2CCC3(N(c4cc(F)ccc4)CNC3=O)CC2)C)cc1	4.9000001	Active	Phospholipase D2 Inhibitor	0.0	1	ML299	363680467.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	39.017142857	Brc1ccc(C(=O)N[C@H](CN2CCC3(N(c4cc(F)ccc4)CNC3=O)CC2)C)cc1	Brc1ccc(C(=O)N[C@H](CN2CCC3(N(c4cc(F)ccc4)CNC3=O)CC2)C)cc1
NCGC00387771-01	Brc1ccc(C(=O)Nc2c(C#N)c3c(s2)CC(C(CC)(C)C)CC3)cc1		Inactive			1	Glucagon receptor antagonist, inactive control	363680658.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1ccc(C(=O)Nc2c(C#N)c3c(s2)CC(C(CC)(C)C)CC3)cc1	Brc1ccc(C(=O)Nc2c(C#N)c3c(s2)CC(C(CC)(C)C)CC3)cc1
NCGC00164552-06	Brc1ccc(C(=O)c2c(N)c(CC(=O)O)ccc2)cc1		Inactive			1	Bromfenac Na		2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Brc1ccc(C(=O)c2c(N)c(CC(=O)[O-])ccc2)cc1	Brc1ccc(C(=O)c2c(N)c(CC(=O)[O-])ccc2)cc1
NCGC00015146-17	Brc1ccc(C(CCN(C)C)c2ncccc2)cc1		Inactive	Histamine H1 receptor Antagonist		1	Brompheniramine (maleate)	405559063.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1ccc(C(CCN(C)C)c2ncccc2)cc1	Brc1ccc(C(CCN(C)C)c2ncccc2)cc1
NCGC00249891-01	Brc1ccc(C(OCCN(C)C)c2ccccc2)cc1	4.9000001	Active	Histamine H1 receptor Antagonist	0.0	1	Bromodiphenhydramine	170465292.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	82.3326131799	Brc1ccc(C(OCCN(C)C)c2ccccc2)cc1	Brc1ccc(C(OCCN(C)C)c2ccccc2)cc1
NCGC00016692-05	Brc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1		Inactive	Dopamine D2 receptor Antagonist		1	Bromperidol	170465873.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	11.4754813719&12.8073220121	Brc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1	Brc1ccc(C2(O)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1
NCGC00379140-01	Brc1ccc(C2N(C(=O)CCC(=O)O)N=C(C=3C(=O)Nc4c(C=3c3ccccc3)cc(C)cc4)C2)cc1		Inactive	Glutamate [NMDA] receptor subunit epsilon 4 Antagonist		1	DQP 1105	363678382.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1ccc(C2N(C(=O)CCC(=O)O)N=C(C=3C(=O)Nc4c(C=3c3ccccc3)cc(C)cc4)C2)cc1	Brc1ccc(C2N(C(=O)CCC(=O)O)N=C(C=3C(=O)Nc4c(C=3c3ccccc3)cc(C)cc4)C2)cc1
NCGC00387089-01	Brc1ccc(CN(n2cnnc2)c2ccc(C#N)cc2)cc1		Inactive	Aromatase Inhibitor		1	YM-511	384569152.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1ccc(CN(n2cnnc2)c2ccc(C#N)cc2)cc1	Brc1ccc(CN(n2cnnc2)c2ccc(C#N)cc2)cc1
NCGC00387192-01	Brc1ccc(C[C@@]2(C)N(C)C(=O)N(c3cc(Cl)cc(Cl)c3)C2=O)cc1		Inactive	Intercellular adhesion molecule (ICAM-1), Integrin alpha-L/beta-2 Inhibitor		1	BIRT 377	363680565.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	17.238596492	Brc1ccc(C[C@@]2(C)N(C)C(=O)N(c3cc(Cl)cc(Cl)c3)C2=O)cc1	Brc1ccc(C[C@@]2(C)N(C)C(=O)N(c3cc(Cl)cc(Cl)c3)C2=O)cc1
NCGC00386703-01	Brc1ccc(Cc2nc([C@H](NS(=O)(=O)CCCN(CC)CC)CCc3ccccc3)on2)cc1	4.9499998	Active	Ghrelin receptor Antagonist	0.0	1	CpdD hydrochloride	363680406.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	110.4145182398	Brc1ccc(Cc2nc([C@H](NS(=O)(=O)CCCN(CC)CC)CCc3ccccc3)on2)cc1	Brc1ccc(Cc2nc([C@H](NS(=O)(=O)CCCN(CC)CC)CCc3ccccc3)on2)cc1
NCGC00370772-05	Brc1ccc(Cn2c(Cn3cc(C(=O)N4CCOCC4)c(-c4c5c(ccc4)cccc5)c3)cnc2)cc1		Inactive	Protein farnesyltransferase Inhibitor		1	LB42708	363677845.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1ccc(Cn2c(Cn3cc(C(=O)N4CCOCC4)c(-c4c5c(ccc4)cccc5)c3)cnc2)cc1	Brc1ccc(Cn2c(Cn3cc(C(=O)N4CCOCC4)c(-c4c5c(ccc4)cccc5)c3)cnc2)cc1
NCGC00347940-04	Brc1ccc(N2C(=O)/C(=C/c3oc(-c4cc5C(=O)NC(=O)c5cc4)cc3)/SC2=N)cc1		Inactive	TRAIL Receptor DR5 Agonist		1	Bioymifi	384568992.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1ccc(N2C(=O)/C(=C/c3oc(-c4cc5C(=O)NC(=O)c5cc4)cc3)/SC2=N)cc1	Brc1ccc(N2C(=O)/C(=C/c3oc(-c4cc5C(=O)NC(=O)c5cc4)cc3)/SC2=N)cc1
NCGC00390686-01	Brc1ccc(NC(=O)C(=O)NC2CC(C)(C)NC(C)(C)C2)cc1		Inactive	Envelope glycoprotein gp160 Binding Agent		1	NBD-557	363680970.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1ccc(NC(=O)C(=O)NC2CC(C)(C)NC(C)(C)C2)cc1	Brc1ccc(NC(=O)C(=O)NC2CC(C)(C)NC(C)(C)C2)cc1
NCGC00402235-03	Brc1ccc(NC(=O)CCN2C[C@H](C)C[C@H](C)C2)cc1	4.9000001	Active	Hedgehog Signaling Pathway Antagonist	0.0	1	SMANT hydrochloride	363680992.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	53.4896949144	Brc1ccc(NC(=O)CCN2C[C@H](C)C[C@H](C)C2)cc1	Brc1ccc(NC(=O)CCN2C[C@H](C)C[C@H](C)C2)cc1
NCGC00386409-01	Brc1ccc(S(=O)(=O)Nc2c3c(c(O)c(SCC(=O)O)c2)cccc3)cc1		Inactive	Induced myeloid leukemia cell differentiation protein Mcl-1 Inhibitor		1	UMI-77	363680262.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1ccc(S(=O)(=O)Nc2c3c(c(O)c(SCC(=O)O)c2)cccc3)cc1	Brc1ccc(S(=O)(=O)Nc2c3c(c(O)c(SCC(=O)O)c2)cccc3)cc1
NCGC00485422-01	Brc1ccc([C@@H](NC(P(=O)(O)O)c2c3NC(=O)C(=O)Nc3ccc2)C)cc1		Inactive	Glutamate NMDA receptor; GRIN1/GRIN2A Antagonist		1	PEAQX tetrasodium hydrate	363681332.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1ccc([C@@H](NC(P(=O)(O)O)c2c3NC(=O)C(=O)Nc3ccc2)C)cc1	Brc1ccc([C@@H](NC(P(=O)(O)O)c2c3NC(=O)C(=O)Nc3ccc2)C)cc1
NCGC00162046-04	Brc1ccc([C@@H]2N=C3SCCN3C2)cc1		Inactive	Alkaline phosphatase, tissue-nonspecific isozyme Inhibitor		1	(-)-p-Bromotetramisole Oxalate	363676608.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1ccc([C@@H]2N=C3SCCN3C2)cc1	Brc1ccc([C@@H]2N=C3SCCN3C2)cc1
NCGC00370988-01	Brc1cnc(N2C[C@@H](NCc3c(Cl)cc(Cl)cc3)CC2)nc1		Inactive	Metabotropic glutamate receptor 3 Negative Allosteric Modulator		1	LY 2389575 hydrochloride	363677979.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cnc(N2C[C@@H](NCc3c(Cl)cc(Cl)cc3)CC2)nc1	Brc1cnc(N2C[C@@H](NCc3c(Cl)cc(Cl)cc3)CC2)nc1
NCGC00522539-01	Brc1cnc(NC(=S)NCCc2ncccc2)cc1		Inactive			1	Trovirdine	434147238.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1cnc(NC(=S)NCCc2ncccc2)cc1	Brc1cnc(NC(=S)NCCc2ncccc2)cc1
NCGC00402232-02	Brc1cnc(NC[C@H]2N(C(=O)c3c(OC)c(F)ccc3)C[C@@H](C)CC2)cc1		Inactive	Orexin receptor type 1 Antagonist		1	GSK1059865	363680990.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cnc(NC[C@H]2N(C(=O)c3c(OC)c(F)ccc3)C[C@@H](C)CC2)cc1	Brc1cnc(NC[C@H]2N(C(=O)c3c(OC)c(F)ccc3)C[C@@H](C)CC2)cc1
NCGC00485960-01	Brc1cnc(OCCOc2c(c(NS(=O)(=O)CCCC)ncn2)-c2ccc(Br)cc2)nc1		Inactive	Endothelin receptor ET-A Antagonist		1	Macitentan (n-butyl analogue)	363681444.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cnc(OCCOc2c(c(NS(=O)(=O)CCCC)ncn2)-c2ccc(Br)cc2)nc1	Brc1cnc(OCCOc2c(c(NS(=O)(=O)CCCC)ncn2)-c2ccc(Br)cc2)nc1
NCGC00378592-01	Brc1cnc(OCCOc2c(c(NS(=O)(=O)N)ncn2)-c2ccc(Br)cc2)nc1		Inactive	Endothelin receptor ET-B Antagonist		1	ACT-132577	363678108.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1cnc(OCCOc2c(c(NS(=O)(=O)N)ncn2)-c2ccc(Br)cc2)nc1	Brc1cnc(OCCOc2c(c(NS(=O)(=O)N)ncn2)-c2ccc(Br)cc2)nc1
NCGC00346456-05&NCGC00346456-07	Brc1cnc(OCCOc2c(c(NS(=O)(=O)NCCC)ncn2)-c2ccc(Br)cc2)nc1		Inactive	Endothelin ETA/ETB Receptor Antagonist		2	Macitentan	405558977.0&384568781.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Brc1cnc(OCCOc2c(c(NS(=O)(=O)NCCC)ncn2)-c2ccc(Br)cc2)nc1	Brc1cnc(OCCOc2c(c(NS(=O)(=O)NCCC)ncn2)-c2ccc(Br)cc2)nc1
NCGC00077915-02	Brc1cnc2n3C(=O)/C(=C/c4oc(-c5c(C(=O)O)cccc5)cc4)/Sc3nc2c1		Inactive	Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitor		1	ML-119	384568074.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	25.2030075241	Brc1cnc2n3C(=O)/C(=C/c4oc(-c5c(C(=O)O)cccc5)cc4)/Sc3nc2c1	Brc1cnc2n3C(=O)/C(=C/c4oc(-c5c(C(=O)O)cccc5)cc4)/Sc3nc2c1
NCGC00390351-01	Brc1n(C2C(O)C(O)C(CN(C(C)C)CCCNC(=O)Nc3ccc(C(C)(C)C)cc3)O2)c2ncnc(N)c2c1		Inactive			1	SGC0946	363680878.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1n(C2C(O)C(O)C(CN(C(C)C)CCCNC(=O)Nc3ccc(C(C)(C)C)cc3)O2)c2ncnc(N)c2c1	Brc1n(C2C(O)C(O)C(CN(C(C)C)CCCNC(=O)Nc3ccc(C(C)(C)C)cc3)O2)c2ncnc(N)c2c1
NCGC00485363-01	Brc1n([C@H]2[C@H](O)[C@@H]3OP(=O)([O-])OC[C@H]3O2)c2N=C(N)NC(=O)c2n1		Inactive	cGMP-gated cation channel alpha-1 Agonist		1	8-Bromoguanosine 3â€²,5â€²-cyclic monophosphate sodium salt	363681299.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1n([C@H]2[C@H](O)[C@@H]3OP(=O)([O-])OC[C@H]3O2)c2N=C(N)NC(=O)c2n1	Brc1n([C@H]2[C@H](O)[C@@H]3OP(=O)([O-])OC[C@H]3O2)c2N=C(N)NC(=O)c2n1
NCGC00390657-02	Brc1n(c(SCC(=O)O)nn1)-c1c2c(c(C3CC3)cc1)cccc2		Inactive	Solute carrier family 22 member 12 Inhibitor		1	Lesinurad (sodium)	405558615.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1n(c(SCC(O[Na])=O)nn1)-c1c2c(c(C3CC3)cc1)cccc2	Brc1n(c(SCC(O[Na])=O)nn1)-c1c2c(c(C3CC3)cc1)cccc2
NCGC00386658-01	Brc1n[nH]c2ncnc(N3CCN(c4c(OC)cccc4)CC3)c12		Inactive	Ribosomal protein S6 kinase 1 Inhibitor		1	DG2	363680377.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1n[nH]c2ncnc(N3CCN(c4c(OC)cccc4)CC3)c12	Brc1n[nH]c2ncnc(N3CCN(c4c(OC)cccc4)CC3)c12
NCGC00262642-10	Brc1nc(/C=C(\C#N)/C(=O)N[C@@H](C)c2ccccc2)ccc1		Inactive	STAT-3/5 Inhibitor		1	WP-1066	384568577.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-17.1159309559	Brc1nc(/C=C(\C#N)/C(=O)N[C@@H](C)c2ccccc2)ccc1	Brc1nc(/C=C(\C#N)/C(=O)N[C@@H](C)c2ccccc2)ccc1
NCGC00485938-01	Brc1nn(-c2c(Cl)cccn2)c(C(=O)Nc2c(C(=O)NC)cc(C#N)cc2C)c1		Inactive			1	Cyantraniliprole	363681430.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1nn(-c2c(Cl)cccn2)c(C(=O)Nc2c(C(=O)NC)cc(C#N)cc2C)c1	Brc1nn(-c2c(Cl)cccn2)c(C(=O)Nc2c(C(=O)NC)cc(C#N)cc2C)c1
NCGC00386305-05	Brc1sc(S(=O)(=O)NC(=O)c2c(Cl)cc(Cl)cc2)cc1		Inactive			1	LY573636	363680198.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Brc1sc(S(=O)(=O)NC(=O)c2c(Cl)cc(Cl)cc2)cc1	Brc1sc(S(=O)(=O)NC(=O)c2c(Cl)cc(Cl)cc2)cc1
NCGC00183872-01	Brc1sc2-n3c(C)nnc3CN=C(c3c(Cl)cccc3)c2c1		Inactive			1	Brotizolam	144207150.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Brc1sc2-n3c(C)nnc3CN=C(c3c(Cl)cccc3)c2c1	Brc1sc2-n3c(C)nnc3CN=C(c3c(Cl)cccc3)c2c1
NCGC00371051-01	C(#Cc1cc(CN2CCOCC2)ccc1)CCN1CCCCC1		Inactive	Histamine H3 receptor Antagonist		1	JNJ 10181457 dihydrochloride	363678008.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	C(#Cc1cc(CN2CCOCC2)ccc1)CCN1CCCCC1	C(#Cc1cc(CN2CCOCC2)ccc1)CCN1CCCCC1
NCGC00163742-05	C(=C)(C)C1CC=C(C)CC1		Inactive	response to oxidative stress Modulator		1	d-LIMONENE	405558745.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(=C)(C)C1CC=C(C)CC1	C(=C)(C)C1CC=C(C)CC1
NCGC00091056-05	C(=C)c1ccccc1		Inactive			1	Styrene	225144204.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(=C)c1ccccc1	C(=C)c1ccccc1
NCGC00178575-05	C(=C/C=1N(C)CCCN=1)\c1c(C)ccs1		Inactive	Neuronal acetylcholine receptor; alpha3/beta2 Agonist		1	Morantel tartrate	170465696.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H](O)[C@@H](O)C(=O)O.C(=C/C=1N(C)CCCN=1)\c1c(C)ccs1	O=C(O)[C@@H](O)[C@@H](O)C(=O)O.C(=C/C=1N(C)CCCN=1)\c1c(C)ccs1
NCGC00174007-04&NCGC00174007-13	C(=C/C=1N(C)CCCN=1)\c1sccc1		Inactive	Antiparasitic Agent		2	Pyrantel tartrate&PYRANTEL PAMOATE	170465676.0&384568350.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@H](O)[C@@H](O)C(=O)O.C(=C/C=1N(C)CCCN=1)\c1sccc1	O=C(O)[C@H](O)[C@@H](O)C(=O)O.C(=C/C=1N(C)CCCN=1)\c1sccc1&C(=C/C=1N(C)CCCN=1)\c1sccc1
NCGC00166291-03&NCGC00166291-04	C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C=C(/CCC=C(C)C)\C)\C)\C)/C)(\C=C\C=C(\CCC=C(C)C)/C)/C		Inactive	response to oxidative stress Modulator		2	Lycopene	405558667.0&434146925.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C=C(/CCC=C(C)C)\C)\C)\C)/C)(\C=C\C=C(\CCC=C(C)C)/C)/C	C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C=C(/CCC=C(C)C)\C)\C)\C)/C)(\C=C\C=C(\CCC=C(C)C)/C)/C
NCGC00096081-04&NCGC00096081-05	C(=C/C=C/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C)(\C=C\C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)/C		Inactive	Vitamin/Supplement		2	beta-Carotene	225144219.0&384568160.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	C(=C/C=C/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C)(\C=C\C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)/C	C(=C/C=C/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C)(\C=C\C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)/C
NCGC00181323-02	C(=C/CC/C(=C/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)/C)(\CCC=C(C)C)/C		Inactive	Steroid biosynthesis Modulator		1	Squalene	225144321.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(=C/CC/C(=C/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)/C)(\CCC=C(C)C)/C	C(=C/CC/C(=C/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)/C)(\CCC=C(C)C)/C
NCGC00024714-11	C(=C/CN1CCCC1)(\c1ncccc1)/c1ccc(C)cc1		Inactive	Histamine H1 receptor Antagonist		1	Triprolidine	170464931.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	C(=C/CN1CCCC1)(\c1ncccc1)/c1ccc(C)cc1	C(=C/CN1CCCC1)(\c1ncccc1)/c1ccc(C)cc1
NCGC00018187-09	C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1		Inactive	Voltage-gated calcium channel Blocker		1	Cinnarizine	170465920.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1	C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1
NCGC00485927-01	C(=C/c1ccccc1)\c1c(-c2cc(C)c(-c3cnccc3)nc2)ncc(-c2cnccc2)c1		Inactive	Induced myeloid leukemia cell differentiation protein Mcl-1 Inhibitor		1	Pyridoclax	363681422.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	C(=C/c1ccccc1)\c1c(-c2cc(C)c(-c3cnccc3)nc2)ncc(-c2cnccc2)c1	C(=C/c1ccccc1)\c1c(-c2cc(C)c(-c3cnccc3)nc2)ncc(-c2cnccc2)c1
NCGC00160181-03	C(=CCCC1(C)Oc2c(C)cc3c([nH]c4c3cccc4)c2C=C1)(C)C		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00160181-03	363676599.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	C(=CCCC1(C)Oc2c(C)cc3c([nH]c4c3cccc4)c2C=C1)(C)C	C(=CCCC1(C)Oc2c(C)cc3c([nH]c4c3cccc4)c2C=C1)(C)C
NCGC00160603-02	C(=Cc1ccccc1)c1ccncc1		Inactive			1	4-Styrylpyridine	144205483.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(=Cc1ccccc1)c1ccncc1	C(=Cc1ccccc1)c1ccncc1
NCGC00165889-13	C(C)(C)(C)c1[nH]c(c(-c2cc3OCOc3cc2)n1)-c1nc(C)ccc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	SB-505124	384568295.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(C)(C)(C)c1[nH]c(c(-c2cc3OCOc3cc2)n1)-c1nc(C)ccc1	C(C)(C)(C)c1[nH]c(c(-c2cc3OCOc3cc2)n1)-c1nc(C)ccc1
NCGC00186024-12	C(C)(C)(C)c1[nH]c(c(-c2cc3nccnc3cc2)n1)-c1nc(C)ccc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	SB-525334	384568435.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(C)(C)(C)c1[nH]c(c(-c2cc3nccnc3cc2)n1)-c1nc(C)ccc1	C(C)(C)(C)c1[nH]c(c(-c2cc3nccnc3cc2)n1)-c1nc(C)ccc1
NCGC00370941-01	C(C)(C)(C)c1ccc(-c2[nH]c3c(N4CCN(Cc5cc6nccnc6cc5)CC4)cccc3n2)cc1		Inactive	Neurokinin 2 receptor Modulator		1	WAY 207024 dihydrochloride	363677947.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	C(C)(C)(C)c1ccc(-c2[nH]c3c(N4CCN(Cc5cc6nccnc6cc5)CC4)cccc3n2)cc1	C(C)(C)(C)c1ccc(-c2[nH]c3c(N4CCN(Cc5cc6nccnc6cc5)CC4)cccc3n2)cc1
NCGC00371152-01	C(C)(C)(C)c1ccc(-c2[nH]c3c(n2)cccc3)cc1		Inactive	Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Modulator		1	ZLN005	363678066.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	8.618701664	C(C)(C)(C)c1ccc(-c2[nH]c3c(n2)cccc3)cc1	C(C)(C)(C)c1ccc(-c2[nH]c3c(n2)cccc3)cc1
NCGC00095836-05	C(C)(C)c1cc-2c(C)ccc-2c(C)cc1		Inactive	lipid oxidation Inhibitor		1	Guaiazulene	170465862.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	C(C)(C)c1cc-2c(C)ccc-2c(C)cc1	C(C)(C)c1cc-2c(C)ccc-2c(C)cc1
NCGC00387477-01	C(C)(C)c1n(c(-c2cnc(-c3ccccc3)cc2)nn1)-c1c2nonc2ccc1		Inactive	Glycine transporter 1 Inhibitor		1	ASP 2535	363680633.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	C(C)(C)c1n(c(-c2cnc(-c3ccccc3)cc2)nn1)-c1c2nonc2ccc1	C(C)(C)c1n(c(-c2cnc(-c3ccccc3)cc2)nn1)-c1c2nonc2ccc1
NCGC00386410-02	C(C)(C)c1sc2ncnc(N3CCN(C=4SC(C)(C)CN=4)CC3)c2c1		Inactive	Menin/Histone-lysine N-methyltransferase MLL Inhibitor		1	MI-3	363680263.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	C(C)(C)c1sc2ncnc(N3CCN(C=4SC(C)(C)CN=4)CC3)c2c1	C(C)(C)c1sc2ncnc(N3CCN(C=4SC(C)(C)CN=4)CC3)c2c1
NCGC00408838-01	C(C)N1C(C)C(=C2c3c(cccc3)CCc3c2cccc3)CC1		Inactive	Muscarinic acetylcholine receptor Antagonist		1	Piroheptine Hydrochloride	405558780.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(C)N1C(C)C(=C2c3c(cccc3)CCc3c2cccc3)CC1	C(C)N1C(C)C(=C2c3c(cccc3)CCc3c2cccc3)CC1
NCGC00273481-01	C(C1c2c(Sc3c1cccc3)cccc2)C1CN(C)CCC1	4.9499998	Active	Muscarinic acetylcholine receptor Antagonist	0.0	1	Metixene hydrochloride	170465287.0	2019_NPC-3.2	SARS-CoV-2_CPE_SRI	2.1	109.7477888023	C(C1c2c(Sc3c1cccc3)cccc2)C1CN(C)CCC1.Cl	C(C1c2c(Sc3c1cccc3)cccc2)C1CN(C)CCC1.Cl
NCGC00167524-02	C(CC)(C)(C)c1ccc(CC(CN2C[C@@H](C)O[C@@H](C)C2)C)cc1		Inactive	Antifungal Agent		1	Amorolfine hydrochloride	170466078.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	C(CC)(C)(C)c1ccc(CC(CN2C[C@@H](C)O[C@@H](C)C2)C)cc1	C(CC)(C)(C)c1ccc(CC(CN2C[C@@H](C)O[C@@H](C)C2)C)cc1
NCGC00344012-02	C(CC)CC1CCC(c2onc(-c3ccncc3)n2)CC1		Inactive	Glucose-dependent insulinotropic receptor Agonist		1	PSN 375963 hydrochloride	363677320.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	C(CC)CC1CCC(c2onc(-c3ccncc3)n2)CC1	C(CC)CC1CCC(c2onc(-c3ccncc3)n2)CC1
NCGC00509991-01	C(CC1CCNCC1)c1c2c(nc(-c3ccccc3)c1)cccc2	4.9000001	Active	GABA(A) Receptor Agonist	0.0	1	Pipequaline	384569399.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	63.5645310099	C(CC1CCNCC1)c1c2c(nc(-c3ccccc3)c1)cccc2	C(CC1CCNCC1)c1c2c(nc(-c3ccccc3)c1)cccc2
NCGC00181040-02	C(CC1NCCCC1)C		Inactive	Nicotinic acetylcholine receptor alpha1/beta1/gamma/delta Agonist		1	dl-Coniine	170465693.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(CC1NCCCC1)C	C(CC1NCCCC1)C
NCGC00165976-02	C(CCCC(CCCCC(CCCC(CCCC(C)C)C)C)C)(CCCC(C)C)C		Inactive			1	Squalane	170465658.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(CCCC(CCCCC(CCCC(CCCC(C)C)C)C)C)(CCCC(C)C)C	C(CCCC(CCCCC(CCCC(CCCC(C)C)C)C)C)(CCCC(C)C)C
NCGC00181122-01	C(CCCCCC)CCCCC[n+]1cc2c(cc1)cccc2		Inactive			1	2-Dodecylisoquinolinium tosylate	144206285.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])c1ccc(C)cc1.C(CCCCCC)CCCCC[n+]1cc2c(cc1)cccc2	S(=O)(=O)([O-])c1ccc(C)cc1.C(CCCCCC)CCCCC[n+]1cc2c(cc1)cccc2
NCGC00181085-01	C(CCCCCCC)CCCCCC[n+]1ccc(C)cc1		Inactive			1	Miripirium chloride	144206257.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(CCCCCCC)CCCCCC[n+]1ccc(C)cc1.[Cl-]	C(CCCCCCC)CCCCCC[n+]1ccc(C)cc1.[Cl-]
NCGC00165841-02	C(CCCCCCCC)CCCCCCC[n+]1c(C)n(Cc2ccccc2)cc1		Inactive			1	NH125	434147032.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(CCCCCCCC)CCCCCCC[n+]1c(C)n(Cc2ccccc2)cc1	C(CCCCCCCC)CCCCCCC[n+]1c(C)n(Cc2ccccc2)cc1
NCGC00091023-06&NCGC00091023-07	C(CCCCCCCC)CCCCCCC[n+]1ccccc1		Inactive			2	Cetylpyridinium bromide&CETYLPYRIDINIUM CHLORIDE	170465500.0&434146985.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	C(CCCCCCCC)CCCCCCC[n+]1ccccc1.[Br-]	C(CCCCCCCC)CCCCCCC[n+]1ccccc1.[Br-]&C(CCCCCCCC)CCCCCCC[n+]1ccccc1
NCGC00094207-05	C(CC[N+]1(C)CCCC1)CC[N+]1(C)CCCC1		Inactive			1	Pentolinium bitartrate	405559046.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(CC[N+]1(C)CCCC1)CC[N+]1(C)CCCC1	C(CC[N+]1(C)CCCC1)CC[N+]1(C)CCCC1
NCGC00370706-02	C(CCc1n[nH]nn1)CN1CCC(=C2c3c(cccc3)C=Cc3c2cccc3)CC1		Inactive	Prostaglandin-H2 D-isomerase Inhibitor		1	AT-56	363677814.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	C(CCc1n[nH]nn1)CN1CCC(=C2c3c(cccc3)C=Cc3c2cccc3)CC1	C(CCc1n[nH]nn1)CN1CCC(=C2c3c(cccc3)C=Cc3c2cccc3)CC1
NCGC00378668-01	C(CN1CC(c2onc(-c3ccc(C)cc3)c2)=CCC1)C		Inactive	Sigma opioid receptor Antagonist		1	PD 144418 oxalate	363678143.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(CN1CC(c2onc(-c3ccc(C)cc3)c2)=CCC1)C	C(CN1CC(c2onc(-c3ccc(C)cc3)c2)=CCC1)C
NCGC00159492-03	C(CN1c2c(Sc3c1cccc3)cccc2)CN1CCN(C)CC1		Inactive	Cytochrome P450 1A2 Inhibitor		1	Perazine	29215457.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(CN1c2c(Sc3c1cccc3)cccc2)CN1CCN(C)CC1	C(CN1c2c(Sc3c1cccc3)cccc2)CN1CCN(C)CC1
NCGC00182554-04	C(Cc1cnc(C)cc1)n1c2c(c3c1CCN(C)C3)cc(C)cc2		Inactive	NMDA Antagonist		1	Latrepirdine	363677092.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	20.634541252	C(Cc1cnc(C)cc1)n1c2c(c3c1CCN(C)C3)cc(C)cc2	C(Cc1cnc(C)cc1)n1c2c(c3c1CCN(C)C3)cc(C)cc2
NCGC00188443-01	C(Cc1n2c(nn1)CCCC2)N1CCN(c2c(C)cccc2)CC1		Inactive	Adrenergic Receptor Alpha-1 Antagonist		1	Dapiprazole hydrochloride	144206586.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(Cc1n2c(nn1)CCCC2)N1CCN(c2c(C)cccc2)CC1.Cl	C(Cc1n2c(nn1)CCCC2)N1CCN(c2c(C)cccc2)CC1.Cl
NCGC00408903-01	C(Cc1n[nH]nn1)N1CCN(c2ccccc2)CC1		Inactive	Alpha-1D adrenergic receptor Antagonist		1	Zolertine Hydrochloride	363681078.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	C(Cc1n[nH]nn1)N1CCN(c2ccccc2)CC1	C(Cc1n[nH]nn1)N1CCN(c2ccccc2)CC1
NCGC00112827-02	C(Cc1nn2C(N3CCN(c4c(C)c(C)ccc4)CC3)=Nc3c(-c2n1)cccc3)n1c(C)cc(C)n1		Inactive			1	NCGC00112827-02		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	C(Cc1nn2C(N3CCN(c4c(C)c(C)ccc4)CC3)=Nc3c(-c2n1)cccc3)n1c(C)cc(C)n1	C(Cc1nn2C(N3CCN(c4c(C)c(C)ccc4)CC3)=Nc3c(-c2n1)cccc3)n1c(C)cc(C)n1
NCGC00016421-07	C(N1CCN(C)CC1)(c1ccccc1)c1ccccc1		Inactive	Histamine H1 receptor Antagonist		1	Cyclizine hydrochloride	170465270.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&24.5221238919	C(N1CCN(C)CC1)(c1ccccc1)c1ccccc1.Cl.Cl	C(N1CCN(C)CC1)(c1ccccc1)c1ccccc1.Cl.Cl
NCGC00370818-01	C(N1CCN(c2ncccn2)CC1)c1[nH]c(-c2ccccc2)nc1		Inactive	Dopamine D4 receptor Antagonist		1	NGD 94-1	363677868.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	C(N1CCN(c2ncccn2)CC1)c1[nH]c(-c2ccccc2)nc1	C(N1CCN(c2ncccn2)CC1)c1[nH]c(-c2ccccc2)nc1
NCGC00346474-01	C(N1CCNCC1)c1c2c(ccc1)cccc2		Inactive	Bacterial Efflux Pump Inhibitor		1	NMP	174006243.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(N1CCNCC1)c1c2c(ccc1)cccc2	C(N1CCNCC1)c1c2c(ccc1)cccc2
NCGC00165722-03&NCGC00165722-19	C(N1CCNCCCNCCNCCC1)c1ccc(CN2CCNCCCNCCNCCC2)cc1		Inactive	Chemokine CXCR4 (SDF-1 Receptor) Antagonist		2	Plerixafor hydrochloride	405558840.0&384568275.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	C(N1CCNCCCNCCNCCC1)c1ccc(CN2CCNCCCNCCNCCC2)cc1	C(N1CCNCCCNCCNCCC1)c1ccc(CN2CCNCCCNCCNCCC2)cc1
NCGC00183046-03	C(N1c2c(Sc3c1cccc3)cccc2)C1C2CCN(C1)CC2		Inactive	Histamine H1 receptor Antagonist		1	Mequitazine	170465794.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.4211695039	C(N1c2c(Sc3c1cccc3)cccc2)C1C2CCN(C1)CC2	C(N1c2c(Sc3c1cccc3)cccc2)C1C2CCN(C1)CC2
NCGC00014482-03	C(N1c2c(Sc3c1cccc3)cccc2)[C@@H]1CN(C)CC1	5.1500001	Active	ion channel	0.0	1	Methdilazine hydrochloride	124878446.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	2.2	75.9371778316	C(N1c2c(Sc3c1cccc3)cccc2)[C@@H]1CN(C)CC1	C(N1c2c(Sc3c1cccc3)cccc2)[C@@H]1CN(C)CC1
NCGC00181356-02	C([N+]1(C)CCCCC1)C1OC(c2ccccc2)(C2CCCCC2)OC1		Inactive			1	Oxapium iodide	170465824.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C([N+]1(C)CCCCC1)C1OC(c2ccccc2)(C2CCCCC2)OC1.[I-]	C([N+]1(C)CCCCC1)C1OC(c2ccccc2)(C2CCCCC2)OC1.[I-]
NCGC00182994-01	C([N+]1(C)CCCCC1)C1OC(c2ccccc2)(c2ccccc2)OC1		Inactive			1	Anacolin	144206808.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&0.0	C([N+]1(C)CCCCC1)C1OC(c2ccccc2)(c2ccccc2)OC1.[I-]	C([N+]1(C)CCCCC1)C1OC(c2ccccc2)(c2ccccc2)OC1.[I-]
NCGC00181104-04	C(\C=C\c1[n+](CC)c2c(s1)cccc2)=C/C=C\1/N(CC)c2c(S/1)cccc2		Inactive			1	Dithiazanine chloride	124893646.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(\C=C\c1[n+](CC)c2c(s1)cccc2)=C/C=C\1/N(CC)c2c(S/1)cccc2	C(\C=C\c1[n+](CC)c2c(s1)cccc2)=C/C=C\1/N(CC)c2c(S/1)cccc2
NCGC00183859-01	C(\c1ccccc1)(/c1ccccc1)=C\1/C(C)[N+](CC)(CC)CC/1		Inactive	Muscarinic acetylcholine receptor Antagonist		1	Prifinium bromide	144206846.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(\c1ccccc1)(/c1ccccc1)=C\1/C(C)[N+](CC)(CC)CC/1.[Br-]	C(\c1ccccc1)(/c1ccccc1)=C\1/C(C)[N+](CC)(CC)CC/1.[Br-]
NCGC00167984-01	C(\c1sccc1)(/c1sccc1)=C\1/C[N@+]2(C)[C@@H](CC/1)CCCC2		Inactive			1	Tiquizium bromide	144206157.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(\c1sccc1)(/c1sccc1)=C\1/C[N@+]2(C)[C@@H](CC/1)CCCC2.[Br-]	C(\c1sccc1)(/c1sccc1)=C\1/C[N@+]2(C)[C@@H](CC/1)CCCC2.[Br-]
NCGC00182057-03	C(c1c(C)c(C)ccc1)c1[nH]cnc1		Inactive	Alpha-2 adrenergic receptor Agonist		1	Detomidine hydrochloride	170465639.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(c1c(C)c(C)ccc1)c1[nH]cnc1.Cl	C(c1c(C)c(C)ccc1)c1[nH]cnc1.Cl
NCGC00095348-11	C(c1c2c([nH]c1)cccc2)c1c2c([nH]c1)cccc2		Inactive	Androgen Receptor Antagonist		1	Diindolylmethane	384568156.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(c1c2c([nH]c1)cccc2)c1c2c([nH]c1)cccc2	C(c1c2c([nH]c1)cccc2)c1c2c([nH]c1)cccc2
NCGC00016506-07	C(c1cc2c(cc1)cccc2)C1=NCCN1		Inactive	Alpha-1b adrenergic receptor Agonist		1	Naphazoline hydrochloride	170464797.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(c1cc2c(cc1)cccc2)C1=NCCN1.Cl	C(c1cc2c(cc1)cccc2)C1=NCCN1.Cl
NCGC00016283-04	C(c1ccccc1)(c1ccccc1)=C1CC[N+](C)(C)CC1		Inactive	antimitotic		1	Diphemanil methylsulfate	170464876.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(OC)[O-].C(c1ccccc1)(c1ccccc1)=C1CC[N+](C)(C)CC1	S(=O)(=O)(OC)[O-].C(c1ccccc1)(c1ccccc1)=C1CC[N+](C)(C)CC1
NCGC00016271-05	C(c1ccccc1)C1=NCCN1		Inactive	Adrenergic receptor alpha-1 Antagonist		1	Tolazoline hydrochloride	170465219.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	C(c1ccccc1)C1=NCCN1.Cl	C(c1ccccc1)C1=NCCN1.Cl
NCGC00346689-06	C(c1n2N=C(c3cn(C)nc3)C=Cc2nc1)c1cc2c(nccc2)cc1		Inactive	HGFR Inhibitor		1	NVP-BVU-972	363677518.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(c1n2N=C(c3cn(C)nc3)C=Cc2nc1)c1cc2c(nccc2)cc1	C(c1n2N=C(c3cn(C)nc3)C=Cc2nc1)c1cc2c(nccc2)cc1
NCGC00485021-01	C(c1nc2c(cn1)CCNCC2)c1ccccc1		Inactive	Serotonin 2c (5-HT2c) receptor Agonist		1	PF-03246799 hydrochloride	363681190.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	C(c1nc2c(cn1)CCNCC2)c1ccccc1	C(c1nc2c(cn1)CCNCC2)c1ccccc1
NCGC00085849-02	C(n1c2c(c3c1CCN(C)C3)cccc2)c1ccccc1		Inactive	Histamine H1 receptor Antagonist		1	MEBHYDROLIN	405558588.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C(n1c2c(c3c1CCN(C)C3)cccc2)c1ccccc1	C(n1c2c(c3c1CCN(C)C3)cccc2)c1ccccc1
NCGC00016018-11	C1(C2c3c(cccc3)CCC2)=NCCN1		Inactive	Adrenergic receptor alpha Agonist		1	Tetrahydrozoline HCl	405559075.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C1(C2c3c(cccc3)CCC2)=NCCN1	C1(C2c3c(cccc3)CCC2)=NCCN1
NCGC00482591-01	C=C1[C@H]2[C@@](C)(Cc3occ(C)c3C2)CCC1		Inactive			1	Atractylon		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C=C1[C@H]2[C@@](C)(Cc3occ(C)c3C2)CCC1	C=C1[C@H]2[C@@](C)(Cc3occ(C)c3C2)CCC1
NCGC00091666-04	CC1(C)OC2(C)CCC1CC2		Inactive	tumor necrosis factor production Inhibitor		1	1,8-Cineol	170465483.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	CC1(C)OC2(C)CCC1CC2	CC1(C)OC2(C)CCC1CC2
NCGC00346896-03	CC1(N2CCC(n3c([C@H]4CNCCC4)nc4c3cccc4)CC2)CCCCCCC1	5.9000001	Active	ORL1 (OP4, NOP) Agonist	0.0	1	MCOPPB	384568966.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	1.4	80.609605298	CC1(N2CCC(n3c([C@H]4CNCCC4)nc4c3cccc4)CC2)CCCCCCC1	CC1(N2CCC(n3c([C@H]4CNCCC4)nc4c3cccc4)CC2)CCCCCCC1
NCGC00163169-05	CN1CC/C(=C\2/c3c(scc3)CCc3c/2cccc3)/CC1	4.9250002	Active	Antimigraine drugs	0.0	1	Pizotifen	170466311.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	117.0868011018&107.9334796318	CN1CC/C(=C\2/c3c(scc3)CCc3c/2cccc3)/CC1	CN1CC/C(=C\2/c3c(scc3)CCc3c/2cccc3)/CC1
NCGC00182705-02	CN1CC/C(=C\2/c3ncccc3CCc3c/2cccc3)/CC1		Inactive	Histamine H1 receptor Antagonist		1	Azatadine	170464865.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	CN1CC/C(=C\2/c3ncccc3CCc3c/2cccc3)/CC1	CN1CC/C(=C\2/c3ncccc3CCc3c/2cccc3)/CC1
NCGC00015656-12	CN1CC2N(c3c(cccc3)Cc3c2cccc3)CC1		Inactive	5-HT2A Antagonists?		1	Mianserin	170465596.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	CN1CC2N(c3c(cccc3)Cc3c2cccc3)CC1	CN1CC2N(c3c(cccc3)Cc3c2cccc3)CC1
NCGC00025346-08&NCGC00025346-15	CN1CC2N(c3ncccc3Cc3c2cccc3)CC1		Inactive	5-HT2A/3 Antagonist		2	Mirtazapine	405558918.0&384568069.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	CN1CC2N(c3ncccc3Cc3c2cccc3)CC1	CN1CC2N(c3ncccc3Cc3c2cccc3)CC1
NCGC00532494-01	CN1CC=2C(c3ccccc3)c3c(cccc3)C=2CC1		Inactive	Histamine H1 receptor Antagonist		1	PHENINDAMINE	405558785.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	CN1CC=2C(c3ccccc3)c3c(cccc3)C=2CC1	CN1CC=2C(c3ccccc3)c3c(cccc3)C=2CC1
NCGC00378937-01	CN1CC=2c3c(cccc3)Cc3c(cccc3)C=2CC1		Inactive	serotonin receptor signaling pathway Modulator		1	Setiptiline	405559104.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	CN1CC=2c3c(cccc3)Cc3c(cccc3)C=2CC1	CN1CC=2c3c(cccc3)Cc3c(cccc3)C=2CC1
NCGC00485141-01	CN1CC=C(c2c(C)cccc2)CC1		Inactive	Monoamine oxidase Substrate		1	1-Methyl-4-(2â€²-methylphenyl)-1,2,3,6-tetrahydropyridine hydrochloride	363681240.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	CN1CC=C(c2c(C)cccc2)CC1	CN1CC=C(c2c(C)cccc2)CC1
NCGC00015252-12&NCGC00015252-17	CN1CCC(=C2c3c(cccc3)C=Cc3c2cccc3)CC1	5.1500001	Active	Histamine H1 Receptor Antagonist	0.5	2	Cyproheptadine hydrochloride	170465127.0&384567832.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	79.3065744949&107.2590979694	CN1CCC(=C2c3c(cccc3)C=Cc3c2cccc3)CC1	CN1CCC(=C2c3c(cccc3)C=Cc3c2cccc3)CC1
NCGC00096077-06&NCGC00096077-20	CN1CCN(C2=Nc3c(Nc4sc(C)cc24)cccc3)CC1		Inactive	Dopamine D2 Antagonist		2	Olanzapine&Olanzapine (LY170053)	170465009.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	CN1CCN(C2=Nc3c(Nc4sc(C)cc24)cccc3)CC1	CN1CCN(C2=Nc3c(Nc4sc(C)cc24)cccc3)CC1
NCGC00182979-02	CN1CCN(C2=Nc3c(cccc3)Cc3c2cccc3)CC1		Inactive	Histamine H1 receptor Inverse Agonist		1	Perlapine	405558916.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	CN1CCN(C2=Nc3c(cccc3)Cc3c2cccc3)CC1	CN1CCN(C2=Nc3c(cccc3)Cc3c2cccc3)CC1
NCGC00370937-01	CN1C[C@H]2[C@@H](C1)CN(c1nnc(-c3ccccc3)cc1)C2		Inactive	Neuronal acetylcholine receptor protein alpha-7 subunit Agonist		1	A 582941	363677945.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	CN1C[C@H]2[C@@H](C1)CN(c1nnc(-c3ccccc3)cc1)C2	CN1C[C@H]2[C@@H](C1)CN(c1nnc(-c3ccccc3)cc1)C2
NCGC00094906-06	CN1Cc2c(C(c3ccccc3)OCC1)cccc2		Inactive	Serotonin transporter Inhibitor		1	Nefopam hydrochloride	170465579.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	CN1Cc2c(C(c3ccccc3)OCC1)cccc2.Cl	CN1Cc2c(C(c3ccccc3)OCC1)cccc2.Cl
NCGC00378999-05	CN1Cc2cc(Nc3nc(-c4cc(OCC/C=C/C1)ccc4)ccn3)ccc2		Inactive	CDK Inhibitor		1	SB-1317	377020528.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-38.7829592789	CN1Cc2cc(Nc3nc(-c4cc(OCC/C=C/C1)ccc4)ccn3)ccc2	CN1Cc2cc(Nc3nc(-c4cc(OCC/C=C/C1)ccc4)ccn3)ccc2
NCGC00090693-11	CN1[C@@H](c2cnccc2)CCC1		Inactive	Neuronal acetylcholine receptor; alpha4/beta2 Agonist		1	D-Nicotine	170464932.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&-5.8520859719	CN1[C@@H](c2cnccc2)CCC1	CN1[C@@H](c2cnccc2)CCC1
NCGC00182065-02	CN1[C@@H]2[C@@H]3[C@@](c4c(ccc(C)c4)C2)(CC1)CCCC3		Inactive			1	Dimemorfan phosphate	144206689.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(O)(O)O.CN1[C@@H]2[C@@H]3[C@@](c4c(ccc(C)c4)C2)(CC1)CCCC3	P(=O)(O)(O)O.CN1[C@@H]2[C@@H]3[C@@](c4c(ccc(C)c4)C2)(CC1)CCCC3
NCGC00371104-01	C[C@@H]1SC[C@]2(O1)C1CCN(C2)CC1		Inactive			1	Cevimeline hydrochloride	405558818.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	C[C@@H]1SC[C@]2(O1)C1CCN(C2)CC1	C[C@@H]1SC[C@]2(O1)C1CCN(C2)CC1
NCGC00015959-09	C[n+]1c2c3c(cc4OCOc4c3)ccc2c2c(c3OCOc3cc2)c1		Inactive	Serine/threonine-protein phosphatase PP1-alpha catalytic subunit Inhibitor		1	Sanguinarine	170466353.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		C[n+]1c2c3c(cc4OCOc4c3)ccc2c2c(c3OCOc3cc2)c1	C[n+]1c2c3c(cc4OCOc4c3)ccc2c2c(c3OCOc3cc2)c1
NCGC00163373-02	Cc1c(C)cc2ncc(-c3ccccc3)nc2c1		Inactive			1	TyrphostinAG1295	377020322.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Cc1c(C)cc2ncc(-c3ccccc3)nc2c1	Cc1c(C)cc2ncc(-c3ccccc3)nc2c1
NCGC00167540-03	Cc1c2c([nH]c1)cccc2		Inactive	Aryl hydrocarbon receptor Partial Agonist		1	3-Methylindole	170465747.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Cc1c2c([nH]c1)cccc2	Cc1c2c([nH]c1)cccc2
NCGC00379188-02	Cc1c2c(nc(N3CCCCC3)c1)cccc2		Inactive			1	ML 204	363678407.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Cc1c2c(nc(N3CCCCC3)c1)cccc2	Cc1c2c(nc(N3CCCCC3)c1)cccc2
NCGC00385934-01	Cc1c2c(oc1)CC1(C)OC1CCC1(C)OC1C2		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Smyrnium | Family: Umbelliferae | Species: olusatrum		1	NCGC00385934-01	363680016.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Cc1c2c(oc1)CC1(C)OC1CCC1(C)OC1C2	Cc1c2c(oc1)CC1(C)OC1CCC1(C)OC1C2
NCGC00015646-03&NCGC00015646-05	Cc1c[nH]nc1		Inactive	Alcohol Dehydrogenase Inhibitor		2	Fomepizole	90341211.0&170465026.0	Annotated/Bioactive Compound Collection&2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Cc1c[nH]nc1	Cc1c[nH]nc1&Cc1c[nH]nc1.Cl
NCGC00370942-04	Cc1ccc(-c2nc3SC4=C(n3c2)CCCC4)cc1		Inactive	Cellular tumor antigen p53 Inhibitor		1	Pifithrin-? (hydrobromide)	363677948.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Cc1ccc(-c2nc3SC4=C(n3c2)CCCC4)cc1	Cc1ccc(-c2nc3SC4=C(n3c2)CCCC4)cc1
NCGC00510442-01	Cc1cnc(-c2ncc(C)cc2)cc1		Inactive	MMP-9 (Gelatinase B) Inhibitor		1	Abametapir	384569434.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	27.7189866&0.0	Cc1cnc(-c2ncc(C)cc2)cc1	Cc1cnc(-c2ncc(C)cc2)cc1
NCGC00249661-03	Cc1n(c(C)cc1-c1n2c(nn1)CCCCC2)-c1ccc(C)cc1		Inactive	HPGD Inhibitor		1	NCGC00249661	384568531.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Cc1n(c(C)cc1-c1n2c(nn1)CCCCC2)-c1ccc(C)cc1	Cc1n(c(C)cc1-c1n2c(nn1)CCCCC2)-c1ccc(C)cc1
NCGC00242054-15	Cc1nc(-c2c(-c3nc4c(nccc4)cc3)c[nH]n2)ccc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	SJN-2511	384568483.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Cc1nc(-c2c(-c3nc4c(nccc4)cc3)c[nH]n2)ccc1	Cc1nc(-c2c(-c3nc4c(nccc4)cc3)c[nH]n2)ccc1
NCGC00016893-04&NCGC00182084-01	Cl/C(/Cl)=C(/Cl)\c1c(S(=O)(=O)N)cc(S(=O)(=O)N)c(N)c1		Inactive	antiparasitic agent		2	Clorsulon	170466229.0&124893809.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Cl/C(/Cl)=C(/Cl)\c1c(S(=O)(=O)N)cc(S(=O)(=O)N)c(N)c1	Cl/C(/Cl)=C(/Cl)\c1c(S(=O)(=O)N)cc(S(=O)(=O)N)c(N)c1
NCGC00090997-11	Cl/C(/Cl)=C\OP(=O)(OC)OC		Inactive	Butyrylcholinesterase Inhibitor		1	Dichlorvos	170466226.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Cl/C(/Cl)=C\OP(=O)(OC)OC	Cl/C(/Cl)=C\OP(=O)(OC)OC
NCGC00016511-08	Cl/C(=C(/c1ccc(OC)cc1)\c1ccc(OC)cc1)/c1ccc(OC)cc1		Inactive	Estrogen receptor Modulator		1	Chlorotrianisene	170465394.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.06321112	Cl/C(=C(/c1ccc(OC)cc1)\c1ccc(OC)cc1)/c1ccc(OC)cc1	Cl/C(=C(/c1ccc(OC)cc1)\c1ccc(OC)cc1)/c1ccc(OC)cc1
NCGC00164385-06	Cl/C(=C(\c1ccc(OCCN(CC)CC)cc1)/c1ccccc1)/c1ccccc1		Inactive	Selective Estrogen Receptor Modulators (SERM)		1	Clomifene citrate	363676631.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-9.394014436	Cl/C(=C(\c1ccc(OCCN(CC)CC)cc1)/c1ccccc1)/c1ccccc1	Cl/C(=C(\c1ccc(OCCN(CC)CC)cc1)/c1ccccc1)/c1ccccc1
NCGC00253575-01	Cl/C(=N\OC[C@H](O)CN1CCCCC1)/c1c[n+]([O-])ccc1		Inactive	Heat shock 70 kDa protein 1 Activator		1	Arimoclomol	170465602.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Cl/C(=N\OC[C@H](O)CN1CCCCC1)/c1c[n+]([O-])ccc1	Cl/C(=N\OC[C@H](O)CN1CCCCC1)/c1c[n+]([O-])ccc1
NCGC00253596-01	Cl/C=C\C(O)(C#C)CC		Inactive	GABA-A receptor; anion channel Positive Allosteric Modulator		1	Ethchlorvynol	170464750.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Cl/C=C\C(O)(C#C)CC	Cl/C=C\C(O)(C#C)CC
NCGC00344521-01	Cl/C=C\[CH-][N+]12CN3CN(C1)CN(C2)C3		Inactive			1	1-(cis-3-Chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride	225144377.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Cl/C=C\[CH-][N+]12CN3CN(C1)CN(C2)C3	Cl/C=C\[CH-][N+]12CN3CN(C1)CN(C2)C3
NCGC00164385-05	ClC(=C(c1ccc(OCCN(CC)CC)cc1)c1ccccc1)c1ccccc1		Inactive	Selective Estrogen Receptor Modulators (SERM)		1	Clomifene citrate	170464951.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	ClC(=C(c1ccc(OCCN(CC)CC)cc1)c1ccccc1)c1ccccc1	ClC(=C(c1ccc(OCCN(CC)CC)cc1)c1ccccc1)c1ccccc1
NCGC00386194-01	ClC(C(NC(=O)C1N(C)CC(CCC)C1)C1C(O)C(O)C(OC(=O)CCCCCCCCCCCCCCC)C(SC)O1)C		Inactive	Antibacterial		1	Clindamycin palmitate HCl	405558990.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC(C(NC(=O)C1N(C)CC(CCC)C1)C1C(O)C(O)C(OC(=O)CCCCCCCCCCCCCCC)C(SC)O1)C	ClC(C(NC(=O)C1N(C)CC(CCC)C1)C1C(O)C(O)C(OC(=O)CCCCCCCCCCCCCCC)C(SC)O1)C
NCGC00389304-01	ClC(C(NC(=O)C1N(C)CC(CCC)C1)C1C(O)C(O)C(OP(=O)(O)O)C(SC)O1)C		Inactive	Bacterial 70S ribosome Inhibitor		1	Clindamycin Phosphate	405559083.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC(C(NC(=O)C1N(C)CC(CCC)C1)C1C(O)C(O)C(OP(=O)(O)O)C(SC)O1)C	ClC(C(NC(=O)C1N(C)CC(CCC)C1)C1C(O)C(O)C(OP(=O)(O)O)C(SC)O1)C
NCGC00091021-01	ClC(Cl)(Cl)C(=O)O		Inactive			1	Trichloroacetic acid	17388684.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC(Cl)(Cl)C(=O)O	ClC(Cl)(Cl)C(=O)O
NCGC00159554-09	ClC(Cl)(Cl)C(NC(=S)Nc1c2ncccc2ccc1)NC(=O)/C=C/c1ccccc1	4.9000001	Active		0.0	1	Salubrinal	406861841.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	3.0	76.8690173719	ClC(Cl)(Cl)C(NC(=S)Nc1c2ncccc2ccc1)NC(=O)/C=C/c1ccccc1	ClC(Cl)(Cl)C(NC(=S)Nc1c2ncccc2ccc1)NC(=O)/C=C/c1ccccc1
NCGC00159392-05	ClC(Cl)(Cl)C(O)(C)C		Inactive			1	1,1,1-Trichloro-2-methyl-2-propanol	170465458.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	ClC(Cl)(Cl)C(O)(C)C	ClC(Cl)(Cl)C(O)(C)C
NCGC00018237-09	ClC(Cl)(Cl)C(P(=O)(OC)OC)O		Inactive	Butyrylcholinesterase Inhibitor		1	Trichlorfon	170465707.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC(Cl)(Cl)C(P(=O)(OC)OC)O	ClC(Cl)(Cl)C(P(=O)(OC)OC)O
NCGC00160570-01	ClC(Cl)(Cl)C(P(=O)(OC)OC)OC(=O)CCC		Inactive			1	Butonate	144205461.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC(Cl)(Cl)C(P(=O)(OC)OC)OC(=O)CCC	ClC(Cl)(Cl)C(P(=O)(OC)OC)OC(=O)CCC
NCGC00091071-08	ClC(Cl)(Cl)C(c1ccc(Cl)cc1)c1ccc(Cl)cc1		Inactive			1	p,p'-DDT	170465529.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&14.522973156	ClC(Cl)(Cl)C(c1ccc(Cl)cc1)c1ccc(Cl)cc1	ClC(Cl)(Cl)C(c1ccc(Cl)cc1)c1ccc(Cl)cc1
NCGC00091034-10	ClC(Cl)(Cl)SN1C(=O)C2C(C1=O)CC=CC2		Inactive			1	Captan	225144202.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC(Cl)(Cl)SN1C(=O)C2C(C1=O)CC=CC2	ClC(Cl)(Cl)SN1C(=O)C2C(C1=O)CC=CC2
NCGC00162143-03	ClC(Cl)(P(=O)(O)[O-])P(=O)(O)[O-]		Inactive	ADP/ATP translocase 3 Inhibitor		1	Clodronate	225144247.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	ClC(Cl)(P(=O)(O)[O-])P(=O)(O)[O-]	ClC(Cl)(P(=O)(O)[O-])P(=O)(O)[O-]
NCGC00480787-02	ClC(Cl)(P(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3nc(SCCC(F)(F)F)nc(NCCSC)c3nc2)O1)O)(=O)O)P(=O)(O)O		Inactive			1	Cangrelor (AR-C69931)	405559017.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC(Cl)(P(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3nc(SCCC(F)(F)F)nc(NCCSC)c3nc2)O1)O)(=O)O)P(=O)(O)O	ClC(Cl)(P(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3nc(SCCC(F)(F)F)nc(NCCSC)c3nc2)O1)O)(=O)O)P(=O)(O)O
NCGC00370970-01	ClC(Cl)=C(Cl)C(=O)Nc1ccc(-n2c(C(F)(F)F)c(C(=O)OCC)cn2)cc1		Inactive	Potassium channel subfamily K member 2 Inhibitor		1	Pyr3	363677966.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC(Cl)=C(Cl)C(=O)Nc1ccc(-n2c(C(F)(F)F)c(C(=O)OCC)cn2)cc1	ClC(Cl)=C(Cl)C(=O)Nc1ccc(-n2c(C(F)(F)F)c(C(=O)OCC)cn2)cc1
NCGC00159390-14	ClC(Cl)=CC1C(C)(C)C1C(=O)OCc1cc(Oc2ccccc2)ccc1		Inactive	Voltage-sensitive sodium channel Inhibitor		1	PERMETHRIN	405558899.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC(Cl)=CC1C(C)(C)C1C(=O)OCc1cc(Oc2ccccc2)ccc1	ClC(Cl)=CC1C(C)(C)C1C(=O)OCc1cc(Oc2ccccc2)ccc1
NCGC00344542-01	ClC(Cl)=C[C@@H]1[C@@H](C(=O)OCc2c(F)c(F)cc(F)c2F)C1(C)C		Inactive	Cytochrome P450 3A2 Activator		1	Transfluthrin	225144388.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	ClC(Cl)=C[C@@H]1[C@@H](C(=O)OCc2c(F)c(F)cc(F)c2F)C1(C)C	ClC(Cl)=C[C@@H]1[C@@H](C(=O)OCc2c(F)c(F)cc(F)c2F)C1(C)C
NCGC00016637-10	ClC(Cl)C(=O)N(C)c1ccc(OC(=O)c2occc2)cc1		Inactive			1	Diloxanide furoate	170466783.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	ClC(Cl)C(=O)N(C)c1ccc(OC(=O)c2occc2)cc1	ClC(Cl)C(=O)N(C)c1ccc(OC(=O)c2occc2)cc1
NCGC00387188-01	ClC(Cl)C(=O)NCCCCCCCCNC(=O)C(Cl)Cl		Inactive	Retinal dehydrogenase 2 Inhibitor		1	WIN 18446	363680563.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC(Cl)C(=O)NCCCCCCCCNC(=O)C(Cl)Cl	ClC(Cl)C(=O)NCCCCCCCCNC(=O)C(Cl)Cl
NCGC00179366-03	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc(S(=O)(=O)C)cc1)CF		Inactive			1	Florfenicol	170465648.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc(S(=O)(=O)C)cc1)CF	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc(S(=O)(=O)C)cc1)CF
NCGC00178319-06	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc(S(=O)(=O)C)cc1)CO		Inactive	Antibiotic		1	Thiamphenicol	170465845.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc(S(=O)(=O)C)cc1)CO	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc(S(=O)(=O)C)cc1)CO
NCGC00167498-02	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc(S(=O)(=O)C)cc1)COC(=O)CN		Inactive			1	Thiamphenicol glycinate	405558635.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc(S(=O)(=O)C)cc1)COC(=O)CN	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc(S(=O)(=O)C)cc1)COC(=O)CN
NCGC00091011-08&NCGC00091011-20	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)CO		Inactive	Antibiotic		2	Chloramphenicol&CHLORAMPHENICOL	225144201.0&434147244.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)CO	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)CO
NCGC00094619-06	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)COC(=O)CCC(=O)[O-]		Inactive	Bacterial 70S ribosome Inhibitor		1	Chloramphenicol sodium succinate	170465429.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)COC(=O)CCC(=O)[O-].[Na+]	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)COC(=O)CCC(=O)[O-].[Na+]
NCGC00348371-01	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)COC(=O)CCCCCCCCCCCCCCC		Inactive	Antibiotic		1	Chloramphenicol palmitate	405558999.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)COC(=O)CCCCCCCCCCCCCCC	ClC(Cl)C(=O)N[C@@H]([C@H](O)c1ccc([N+](=O)[O-])cc1)COC(=O)CCCCCCCCCCCCCCC
NCGC00255419-01	ClC(Cl)C(=O)O		Inactive			1	Sodium dichloroacetate	144211711.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC(Cl)C(=O)[O-].[Na+]	ClC(Cl)C(=O)[O-].[Na+]
NCGC00168747-01	ClC(Cl)C(F)(F)OC		Inactive	synaptic transmission Inhibitor		1	Methoxyflurane	144206179.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC(Cl)C(F)(F)OC	ClC(Cl)C(F)(F)OC
NCGC00015226-12&NCGC00015226-17	ClC(Cl)C(c1c(Cl)cccc1)c1ccc(Cl)cc1		Inactive	Antineoplastic Agent		2	Mitotane	170464927.0&384567827.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&9.7720598439&0.0	ClC(Cl)C(c1c(Cl)cccc1)c1ccc(Cl)cc1	ClC(Cl)C(c1c(Cl)cccc1)c1ccc(Cl)cc1
NCGC00018302-07&NCGC00018302-12	ClC(Cl)C1NS(=O)(=O)c2c(N1)cc(Cl)c(S(=O)(=O)N)c2		Inactive	Diuretic		2	Trichlormethiazide	170464812.0&384568004.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	ClC(Cl)C1NS(=O)(=O)c2c(N1)cc(Cl)c(S(=O)(=O)N)c2	ClC(Cl)C1NS(=O)(=O)c2c(N1)cc(Cl)c(S(=O)(=O)N)c2
NCGC00379046-01	ClC(F)(F)C=1n2nc(C(=O)NCc3sccc3)cc2N=C(c2occc2)C=1		Inactive			1	Anguizole	363678327.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC(F)(F)C=1n2nc(C(=O)NCc3sccc3)cc2N=C(c2occc2)C=1	ClC(F)(F)C=1n2nc(C(=O)NCc3sccc3)cc2N=C(c2occc2)C=1
NCGC00402295-03	ClC(F)(F)C=1n2nc(C(=O)Nc3n(-c4ccccc4)ncc3C(=O)OCC)cc2N=C(c2occc2)C=1		Inactive	c-Myc/Max Inhibitor		1	Mycro3	363681018.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC(F)(F)C=1n2nc(C(=O)Nc3n(-c4ccccc4)ncc3C(=O)OCC)cc2N=C(c2occc2)C=1	ClC(F)(F)C=1n2nc(C(=O)Nc3n(-c4ccccc4)ncc3C(=O)OCC)cc2N=C(c2occc2)C=1
NCGC00509944-01	ClC(F)(F)Oc1ccc(NC(=O)c2cc(c(N3C[C@H](O)CC3)nc2)-c2[nH]ncc2)cc1		Inactive	Bcr-Abl Inhibitor		1	Asciminib	384569392.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.594739004	ClC(F)(F)Oc1ccc(NC(=O)c2cc(c(N3C[C@H](O)CC3)nc2)-c2[nH]ncc2)cc1	ClC(F)(F)Oc1ccc(NC(=O)c2cc(c(N3C[C@H](O)CC3)nc2)-c2[nH]ncc2)cc1
NCGC00167422-01	ClC(F)C(F)(F)OC(F)F		Inactive	Glycine receptor Positive Allosteric Modulator		1	Enflurane	144205979.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC(F)C(F)(F)OC(F)F	ClC(F)C(F)(F)OC(F)F
NCGC00181037-03	ClC(OC(F)F)C(F)(F)F		Inactive	Glycine receptor Positive Allosteric Modulator		1	Isoflurane	405558879.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC(OC(F)F)C(F)(F)F	ClC(OC(F)F)C(F)(F)F
NCGC00015202-08&NCGC00015202-21	ClC1(Cl)C(c2ccc(OC(C(=O)O)(C)C)cc2)C1		Inactive	PPARalpha Agonist		2	Ciprofibrate&NCGC00015202-21	170466356.0&434147248.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	ClC1(Cl)C(c2ccc(OC(C(=O)O)(C)C)cc2)C1	ClC1(Cl)C(c2ccc(OC(C(=O)O)(C)C)cc2)C1
NCGC00510749-15	ClC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2CC1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	Loracarbef	405558434.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2CC1	ClC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2CC1
NCGC00015260-22	ClC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1		Inactive			1	CEFACLOR	405559149.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1	ClC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1
NCGC00371100-01	ClC1=C(N)n2c(C(C(=O)NCC3CCN(CC(C)C)CC3)=C1)nc(C)c2		Inactive	Serotonin 4 (5-HT4) receptor Partial Agonist		1	CJ 033466	363678031.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	11.7893217879	ClC1=C(N)n2c(C(C(=O)NCC3CCN(CC(C)C)CC3)=C1)nc(C)c2	ClC1=C(N)n2c(C(C(=O)NCC3CCN(CC(C)C)CC3)=C1)nc(C)c2
NCGC00379237-02	ClC1=C(Oc2ccc(OC)cc2)C(=O)N(C2c3c(-c4c2cccc4)cccc3)N=C1		Inactive			1	CYM 50769	363678439.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC1=C(Oc2ccc(OC)cc2)C(=O)N(C2c3c(-c4c2cccc4)cccc3)N=C1	ClC1=C(Oc2ccc(OC)cc2)C(=O)N(C2c3c(-c4c2cccc4)cccc3)N=C1
NCGC00386912-01	ClC1=C(Oc2ccc(OC)cc2)C(=O)N(c2cc(C)cc(C)c2)N=C1		Inactive			1	NCGC00386912-01	363680499.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC1=C(Oc2ccc(OC)cc2)C(=O)N(c2cc(C)cc(C)c2)N=C1	ClC1=C(Oc2ccc(OC)cc2)C(=O)N(c2cc(C)cc(C)c2)N=C1
NCGC00249350-02	ClC1=Cn2c(-c3nc(NC4CCNCC4)ccc3)cnc2C=C1		Inactive			1	NCGC00249350-02	377020363.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC1=Cn2c(-c3nc(NC4CCNCC4)ccc3)cnc2C=C1	ClC1=Cn2c(-c3nc(NC4CCNCC4)ccc3)cnc2C=C1
NCGC00241410-02	ClC1=Cn2c(-c3nc(NC4CNC4)ccc3)cnc2C=C1		Inactive	IRAK Inhibitor		1	NCGC00241410	363677139.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC1=Cn2c(-c3nc(NC4CNC4)ccc3)cnc2C=C1	ClC1=Cn2c(-c3nc(NC4CNC4)ccc3)cnc2C=C1
NCGC00249372-02	ClC1=Cn2c(-c3nc(NC4CNCC4)ccc3)cnc2C=C1		Inactive			1	NCGC00249372-02	377020183.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC1=Cn2c(-c3nc(NC4CNCC4)ccc3)cnc2C=C1	ClC1=Cn2c(-c3nc(NC4CNCC4)ccc3)cnc2C=C1
NCGC00476209-02	ClC1=Nn2c(c(C)nc2C(NCCNC(=O)C)=C1)-c1cc(S(=O)(=O)N(C)C)ccc1		Inactive			1	MI 14	377020495.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	21.0652563639	ClC1=Nn2c(c(C)nc2C(NCCNC(=O)C)=C1)-c1cc(S(=O)(=O)N(C)C)ccc1	ClC1=Nn2c(c(C)nc2C(NCCNC(=O)C)=C1)-c1cc(S(=O)(=O)N(C)C)ccc1
NCGC00348372-01	ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl		Inactive	GABA-A receptor Binding Agent		1	LINDANE	405558821.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl	ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl
NCGC00385589-01	ClC1C(Cl)CN2C(=O)C(C(O)C)NC(=O)CC(c3ccccc3)NC(=O)C(CO)NC(=O)C(CC)NC(=O)C12		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385589-01	363679824.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC1C(Cl)CN2C(=O)C(C(O)C)NC(=O)CC(c3ccccc3)NC(=O)C(CO)NC(=O)C(CC)NC(=O)C12	ClC1C(Cl)CN2C(=O)C(C(O)C)NC(=O)CC(c3ccccc3)NC(=O)C(CO)NC(=O)C(CC)NC(=O)C12
NCGC00384857-01	ClC1C(Cl)CN2C(=O)C(CC)NC(=O)CC(c3ccccc3)NC(=O)C(CO)NC(=O)C(CC)NC(=O)C12		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384857-01	363679400.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC1C(Cl)CN2C(=O)C(CC)NC(=O)CC(c3ccccc3)NC(=O)C(CO)NC(=O)C(CC)NC(=O)C12	ClC1C(Cl)CN2C(=O)C(CC)NC(=O)CC(c3ccccc3)NC(=O)C(CO)NC(=O)C(CC)NC(=O)C12
NCGC00381300-01	ClC1C(O)C(OC(=O)c2ccccc2)C(O)C(COC(=O)c2ccccc2)=C1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381300-01	363679075.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC1C(O)C(OC(=O)c2ccccc2)C(O)C(COC(=O)c2ccccc2)=C1	ClC1C(O)C(OC(=O)c2ccccc2)C(O)C(COC(=O)c2ccccc2)=C1
NCGC00481577-01	ClC=1/C(=N\c2c(S(=O)(=O)N(C)C)cccc2)/NC(Nc2ccc(CN3CCN(C)CC3)cc2)=NC=1		Inactive	AXL Kinase Inhibitor		1	TP-0903	377020308.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	18.155567436	ClC=1/C(=N\c2c(S(=O)(=O)N(C)C)cccc2)/NC(Nc2ccc(CN3CCN(C)CC3)cc2)=NC=1	ClC=1/C(=N\c2c(S(=O)(=O)N(C)C)cccc2)/NC(Nc2ccc(CN3CCN(C)CC3)cc2)=NC=1
NCGC00380773-01	ClC=1C(=O)C(O)(C)C(=O)C2(O)C(OC)OC(/C=C/C(=C/C(CC)C)/C)=CC=12		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380773-01	363678775.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC=1C(=O)C(O)(C)C(=O)C2(O)C(OC)OC(/C=C/C(=C/C(CC)C)/C)=CC=12	ClC=1C(=O)C(O)(C)C(=O)C2(O)C(OC)OC(/C=C/C(=C/C(CC)C)/C)=CC=12
NCGC00380774-01	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C2(O)C(OC)OC(/C=C/C(=C/C(CC)C)/C)=CC=12		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380774-01	363678776.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C2(O)C(OC)OC(/C=C/C(=C/C(CC)C)/C)=CC=12	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C2(O)C(OC)OC(/C=C/C(=C/C(CC)C)/C)=CC=12
NCGC00385711-01	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(C(C(=O)O)CC(=O)O)C=2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385711-01	363679891.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(C(C(=O)O)CC(=O)O)C=2	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(C(C(=O)O)CC(=O)O)C=2
NCGC00380203-01	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(C(C(=O)O)CCC(=O)O)C=2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380203-01	363678496.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(C(C(=O)O)CCC(=O)O)C=2	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(C(C(=O)O)CCC(=O)O)C=2
NCGC00380205-01	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(C(C(=O)O)CCCNC(=N)N)C=2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380205-01	363678498.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(C(C(=O)O)CCCNC(=N)N)C=2	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(C(C(=O)O)CCCNC(=N)N)C=2
NCGC00385710-01	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(C1C(=O)N(C(C(=O)O)CCC(=O)N)CCCC1)C=2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385710-01	363679890.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(C1C(=O)N(C(C(=O)O)CCC(=O)N)CCCC1)C=2	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(C1C(=O)N(C(C(=O)O)CCC(=O)N)CCCC1)C=2
NCGC00169389-03	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(CCCC(=O)O)C=2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169389-03	363676810.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(CCCC(=O)O)C=2	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(CCCC(=O)O)C=2
NCGC00381154-01	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(CCCCC(N)C(=O)O)C=2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381154-01	363678997.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(CCCCC(N)C(=O)O)C=2	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)N(CCCCC(N)C(=O)O)C=2
NCGC00380768-01	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)NC=2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380768-01	363678771.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)NC=2	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)NC=2
NCGC00168901-04	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)OC=2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00168901-04	363676717.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)OC=2	ClC=1C(=O)C(OC(=O)C)(C)C(=O)C=2C=1C=C(/C=C/C(=C/C(CC)C)/C)OC=2
NCGC00485897-01	ClC=1C(=O)N(CCCC)C=CC=1N1CCC(c2ccccc2)CC1		Inactive	Metabotropic glutamate receptor 2 Positive Allosteric Modulator		1	JNJ-40411813	363681400.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC=1C(=O)N(CCCC)C=CC=1N1CCC(c2ccccc2)CC1	ClC=1C(=O)N(CCCC)C=CC=1N1CCC(c2ccccc2)CC1
NCGC00074967-03	ClC=1C(=O)N(c2c(OC)ccc(OC)c2)C(=O)C=1N1CCCCC1		Inactive			1	NCGC00074967-03		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC=1C(=O)N(c2c(OC)ccc(OC)c2)C(=O)C=1N1CCCCC1	ClC=1C(=O)N(c2c(OC)ccc(OC)c2)C(=O)C=1N1CCCCC1
NCGC00389632-02&NCGC00389632-06	ClC=1C(=O)NC(=O)NC=1CN1C(=N)CCC1		Inactive	Thymidine Phosphorylase Inhibitor		2	Tipiracil	405558450.0&384569178.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	ClC=1C(=O)NC(=O)NC=1CN1C(=N)CCC1	ClC=1C(=O)NC(=O)NC=1CN1C(=N)CCC1
NCGC00094516-08	ClC=1C(=O)Oc2c(C=1C)ccc(OP(=S)(OCC)OCC)c2		Inactive			1	Coumaphos	170466302.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	ClC=1C(=O)Oc2c(C=1C)ccc(OP(=S)(OCC)OCC)c2	ClC=1C(=O)Oc2c(C=1C)ccc(OP(=S)(OCC)OCC)c2
NCGC00380255-01	ClC=1C(=O)[C@@](O)(C)[C@H](OC(=O)C)[C@@H]2C=1C=C(/C=C/C(=C/[C@H](CC)C)/C)OC2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380255-01	363678516.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClC=1C(=O)[C@@](O)(C)[C@H](OC(=O)C)[C@@H]2C=1C=C(/C=C/C(=C/[C@H](CC)C)/C)OC2	ClC=1C(=O)[C@@](O)(C)[C@H](OC(=O)C)[C@@H]2C=1C=C(/C=C/C(=C/[C@H](CC)C)/C)OC2
NCGC00181011-02	ClC=1C(O)=CC(=O)NC=1		Inactive	Dihydropyrimidine Dehydrogenase Inhibitor		1	Gimeracil	170466048.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	ClC=1C(O)=CC(=O)NC=1	ClC=1C(O)=CC(=O)NC=1
NCGC00480898-01	ClC=1C(c2c(F)cc(OCCCNC)cc2F)=C(N[C@H](C(F)(F)F)C)n2ncnc2N=1		Inactive	Microtubule-Stabilizing Agents		1	Cevipabulin	384569249.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC=1C(c2c(F)cc(OCCCNC)cc2F)=C(N[C@H](C(F)(F)F)C)n2ncnc2N=1	ClC=1C(c2c(F)cc(OCCCNC)cc2F)=C(N[C@H](C(F)(F)F)C)n2ncnc2N=1
NCGC00022680-05	ClC=1C=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@](OC(=O)C)(C(=O)C)CC4)CC3)C=1)CCC(=O)C=2	4.9000001	Active	Androgen receptor Antagonist	0.0	1	Chlormadinone acetate	170465776.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	43.1838038448	ClC=1C=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@](OC(=O)C)(C(=O)C)CC4)CC3)C=1)CCC(=O)C=2	ClC=1C=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@](OC(=O)C)(C(=O)C)CC4)CC3)C=1)CCC(=O)C=2
NCGC00091032-09&NCGC00262575-02	ClC=1C=2[C@](C)([C@@H]3[C@H](C(=O)C=2)C3)[C@@H]2[C@H]([C@H]3[C@@](C)([C@@](OC(=O)C)(C(=O)C)CC3)CC2)C=1		Inactive	Androgen Receptor Antagonist		2	Cyproterone acetate	363676548.0&170465682.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&28.870179948	ClC=1C=2[C@](C)([C@@H]3[C@H](C(=O)C=2)C3)[C@@H]2[C@H]([C@H]3[C@@](C)([C@@](OC(=O)C)(C(=O)C)CC3)CC2)C=1	ClC=1C=2[C@](C)([C@@H]3[C@H](C(=O)C=2)C3)[C@@H]2[C@H]([C@H]3[C@@](C)([C@@](OC(=O)C)(C(=O)C)CC3)CC2)C=1
NCGC00181041-01	ClC=1SN(C)C(=O)C=1		Inactive	aerobic respiration Inhibitor		1	5-Chloro-2-methyl-3(2H)-isothiazolone	144206242.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC=1SN(C)C(=O)C=1	ClC=1SN(C)C(=O)C=1
NCGC00343773-03	ClCC(=N)NCCC[C@H](NC(=O)c1cc2c(cc(N(C)C)cc2)cc1)C(=O)NCc1ccccc1		Inactive	Peptidylarginine Deiminase (PAD) Inhibitor		1	YW3-56	384568715.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClCC(=N)NCCC[C@H](NC(=O)c1cc2c(cc(N(C)C)cc2)cc1)C(=O)NCc1ccccc1	ClCC(=N)NCCC[C@H](NC(=O)c1cc2c(cc(N(C)C)cc2)cc1)C(=O)NCc1ccccc1
NCGC00485266-01	ClCC(=O)N1C(C(=O)OC)(C)c2[nH]c3c(c2CC1)cccc3		Inactive	Protein disulfide-isomerase Inhibitor		1	PDI inhibitor 16F16	363681272.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	28.200571432	ClCC(=O)N1C(C(=O)OC)(C)c2[nH]c3c(c2CC1)cccc3	ClCC(=O)N1C(C(=O)OC)(C)c2[nH]c3c(c2CC1)cccc3
NCGC00507863-01	ClCC(=O)N1[C@@H](c2ccc(C(=O)OC)cc2)c2[nH]c3c(c2C[C@@H]1C(=O)OC)cccc3		Inactive	GPX4 Inhibitor		1	RSL3	384569338.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClCC(=O)N1[C@@H](c2ccc(C(=O)OC)cc2)c2[nH]c3c(c2C[C@@H]1C(=O)OC)cccc3	ClCC(=O)N1[C@@H](c2ccc(C(=O)OC)cc2)c2[nH]c3c(c2C[C@@H]1C(=O)OC)cccc3
NCGC00384179-01	ClCC(=O)Nc1cc(NC2=NS(=O)(=O)c3c2cccc3)ccc1		Inactive	p97 ATPase Inhibitor		1	NMS-859	363679177.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClCC(=O)Nc1cc(NC2=NS(=O)(=O)c3c2cccc3)ccc1	ClCC(=O)Nc1cc(NC2=NS(=O)(=O)c3c2cccc3)ccc1
NCGC00347285-06	ClCC(=O)Nc1ccc(-n2c(-c3cc(Cl)c(Cl)cc3)nc(OCCOC)n2)cc1		Inactive	mucosa associated lymphoid tissue lymphoma translocation 1 (MALT1) Inhibitor		1	MI-2	363677575.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClCC(=O)Nc1ccc(-n2c(-c3cc(Cl)c(Cl)cc3)nc(OCCOC)n2)cc1	ClCC(=O)Nc1ccc(-n2c(-c3cc(Cl)c(Cl)cc3)nc(OCCOC)n2)cc1
NCGC00370996-03	ClCC(=O)Nc1ccc(S(=O)(=O)c2ccc(NC(=O)CCl)cc2)cc1		Inactive			1	NSC-30176 (TC-E5003)		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	19.365142852	ClCC(=O)Nc1ccc(S(=O)(=O)c2ccc(NC(=O)CCl)cc2)cc1	ClCC(=O)Nc1ccc(S(=O)(=O)c2ccc(NC(=O)CCl)cc2)cc1
NCGC00485375-01	ClCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)OCc1ccccc1)CC(C)C)Cc1ccccc1	5.5500002	Active	Granzyme B Inhibitor	0.0	1	Z-Gly-Leu-Phe-chloromethyl ketone	363681304.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	82.5883617752	ClCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)OCc1ccccc1)CC(C)C)Cc1ccccc1	ClCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)OCc1ccccc1)CC(C)C)Cc1ccccc1
NCGC00094419-03	ClCC(=O)[C@@H](NS(=O)(=O)c1ccc(C)cc1)Cc1ccccc1		Inactive	Cysteine Protease Inhibitor		1	TPCK	26753659.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClCC(=O)[C@@H](NS(=O)(=O)c1ccc(C)cc1)Cc1ccccc1	ClCC(=O)[C@@H](NS(=O)(=O)c1ccc(C)cc1)Cc1ccccc1
NCGC00023373-03&NCGC00023373-10	ClCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21		Inactive	Corticosteroid		2	Clobetasol propionate	170465385.0&384568017.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&11.625204952	ClCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21	ClCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21
NCGC00167451-04	ClCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)C[C@@H]21)=CC(=O)C=C3		Inactive			1	Halobetasol Propionate		Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)C[C@@H]21)=CC(=O)C=C3	ClCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)C[C@@H]21)=CC(=O)C=C3
NCGC00022019-03	ClCC(=O)[C@@]1(OC(=O)CCC)[C@@H](C)C[C@@H]2[C@]1(C)CC(=O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21		Inactive	corticosteroid		1	Clobetasone butyrate	170465575.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	ClCC(=O)[C@@]1(OC(=O)CCC)[C@@H](C)C[C@@H]2[C@]1(C)CC(=O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21	ClCC(=O)[C@@]1(OC(=O)CCC)[C@@H](C)C[C@@H]2[C@]1(C)CC(=O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21
NCGC00179578-03&NCGC00179578-11	ClCC(=O)[C@@]1(OC(=O)c2occc2)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(Cl)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21	4.92499995	Active	Corticosteroid	0.04999969999999987	2	Mometasone furoate	170464666.0&384568377.0	2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	34.9459724919&59.4683452356	ClCC(=O)[C@@]1(OC(=O)c2occc2)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(Cl)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21	ClCC(=O)[C@@]1(OC(=O)c2occc2)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(Cl)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21
NCGC00179475-03	ClCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@](F)([C@@H](O)C3)[C@]3(C)C(=CC(=O)CC3)CC4)C[C@H]1OC(C)(C)O2		Inactive			1	Halcinonide	170465389.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	ClCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@](F)([C@@H](O)C3)[C@]3(C)C(=CC(=O)CC3)CC4)C[C@H]1OC(C)(C)O2	ClCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@](F)([C@@H](O)C3)[C@]3(C)C(=CC(=O)CC3)CC4)C[C@H]1OC(C)(C)O2
NCGC00485901-01	ClCC(=O)c1n(CCCO)c2ncnc(N)c2c1-c1ccc(C)cc1	4.9000001	Active	Tyrosine-protein kinase FYN Inhibitor	0.0	1	CMK	363681403.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	3.0	73.3381699464	ClCC(=O)c1n(CCCO)c2ncnc(N)c2c1-c1ccc(C)cc1	ClCC(=O)c1n(CCCO)c2ncnc(N)c2c1-c1ccc(C)cc1
NCGC00508824-01	ClCC(O)COc1ccc(C(C)(C)c2ccc(OCC(O)CO)cc2)cc1		Inactive	Androgen Receptor Antagonist		1	Ralaniten (EPI-001)	384569361.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClCC(O)COc1ccc(C(C)(C)c2ccc(OCC(O)CO)cc2)cc1	ClCC(O)COc1ccc(C(C)(C)c2ccc(OCC(O)CO)cc2)cc1
NCGC00380703-01	ClCC(O)C[C@@H]1C(=O)N2[C@H](C(=O)N[C@@H]([C@@H](CC)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N(C)[C@@H](C)C(=O)NCCC(=O)O1)CCC2		Inactive	<MOA Unknown> | Class: depsipeptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380703-01	363678720.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClCC(O)C[C@@H]1C(=O)N2[C@H](C(=O)N[C@@H]([C@@H](CC)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N(C)[C@@H](C)C(=O)NCCC(=O)O1)CCC2	ClCC(O)C[C@@H]1C(=O)N2[C@H](C(=O)N[C@@H]([C@@H](CC)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N(C)[C@@H](C)C(=O)NCCC(=O)O1)CCC2
NCGC00160530-12&NCGC00160530-13	ClCC/C(=C(/c1ccc(OCCN(C)C)cc1)\c1ccccc1)/c1ccccc1		Inactive	Selective Estrogen Receptor Modulators (SERM)		2	Toremifene citrate	384568200.0&405558853.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	ClCC/C(=C(/c1ccc(OCCN(C)C)cc1)\c1ccccc1)/c1ccccc1	ClCC/C(=C(/c1ccc(OCCN(C)C)cc1)\c1ccccc1)/c1ccccc1
NCGC00386347-01&NCGC00386347-02	ClCC/C(=C(/c1ccc(OCCO)cc1)\c1ccccc1)/c1ccccc1	4.9000001	Active	Selective Estrogen Receptor Modulators (SERM)	0.0	2	Ospemifene	405558829.0&384569127.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	2.4&3.0	32.0655930839&90.2100325769	ClCC/C(=C(/c1ccc(OCCO)cc1)\c1ccccc1)/c1ccccc1	ClCC/C(=C(/c1ccc(OCCO)cc1)\c1ccccc1)/c1ccccc1
NCGC00167446-02	ClCC1N(C)S(=O)(=O)c2c(N1)cc(Cl)c(S(=O)(=O)N)c2		Inactive	Sodium-(potassium)-chloride cotransporter 2 Inhibitor		1	Methyclothiazide	170465243.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	ClCC1N(C)S(=O)(=O)c2c(N1)cc(Cl)c(S(=O)(=O)N)c2	ClCC1N(C)S(=O)(=O)c2c(N1)cc(Cl)c(S(=O)(=O)N)c2
NCGC00249908-01	ClCCCNC(Cc1ccccc1)C		Inactive			1	Mefenorex	170465601.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClCCCNC(Cc1ccccc1)C	ClCCCNC(Cc1ccccc1)C
NCGC00164581-02	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)CCCl		Inactive	Estrogen receptor beta Modulator		1	Estramustine	170466403.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	25.756257004&11.5	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)CCCl	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)CCCl
NCGC00484900-01	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](OP(=O)(O)O)CC4)CC3)CC2)cc1)CCCl		Inactive	Dna Alkylating Agent		1	Estramustine Phosphate·Na	405558512.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](OP(=O)(O)O)CC4)CC3)CC2)cc1)CCCl	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](OP(=O)(O)O)CC4)CC3)CC2)cc1)CCCl
NCGC00185756-04	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](OP(=O)([O-])[O-])CC4)CC3)CC2)cc1)CCCl	5.0	Active	DNA Alkylating Agent	0.0	1	Estramustine	384568425.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.4	31.972833404	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](OP(=O)([O-])[O-])CC4)CC3)CC2)cc1)CCCl	ClCCN(C(=O)Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](OP(=O)([O-])[O-])CC4)CC3)CC2)cc1)CCCl
NCGC00015121-17&NCGC00015121-25	ClCCN(C(COc1ccccc1)C)Cc1ccccc1		Inactive	Adrenergenic Receptor Antagonist		2	Phenoxybenzamine hydrochloride	170465147.0&384567812.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	ClCCN(C(COc1ccccc1)C)Cc1ccccc1	ClCCN(C(COc1ccccc1)C)Cc1ccccc1
NCGC00091835-10&NCGC00091835-15	ClCCN(CCCl)C		Inactive	DNA Alkylating Agent		2	Chlormethine	170465017.0&384568099.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		ClCCN(CCCl)C.Cl	ClCCN(CCCl)C.Cl&ClCCN(CCCl)C
NCGC00160575-01	ClCCN(CCCl)C=1C(=O)NC(=O)NC=1		Inactive	DNA Interacts		1	Uracil mustard	144205464.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClCCN(CCCl)C=1C(=O)NC(=O)NC=1	ClCCN(CCCl)C=1C(=O)NC(=O)NC=1
NCGC00015209-11&NCGC00015209-16	ClCCN(CCCl)P1(=O)OCCCN1		Inactive	Bcl-2 Expression Inhibitor		2	Cyclophosphamide	170464624.0&384567825.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	ClCCN(CCCl)P1(=O)OCCCN1.O	ClCCN(CCCl)P1(=O)OCCCN1.O&ClCCN(CCCl)P1(=O)OCCCN1
NCGC00485834-01	ClCCN(CCCl)[C@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CC2)CC3)C4)CC1		Inactive	Mu-type opioid receptor Antagonist		1	Î²-Chlornaltrexamine dihydrochloride	363681377.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	ClCCN(CCCl)[C@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CC2)CC3)C4)CC1	ClCCN(CCCl)[C@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CC2)CC3)C4)CC1
NCGC00181170-02&NCGC00181170-09	ClCCN(CCCl)c1cc2nc(CCCC(=O)O)n(C)c2cc1		Inactive	DNA Alkylating Drugs		2	Bendamustine	170465340.0&384568394.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		ClCCN(CCCl)c1cc2nc(CCCC(=O)O)n(C)c2cc1	ClCCN(CCCl)c1cc2nc(CCCC(=O)O)n(C)c2cc1
NCGC00510486-01	ClCCN(CCCl)c1cc2nc(CCCCCCC(=O)NO)n(C)c2cc1		Inactive	DNA Alkylating Drugs		1	Tinostamustine	384569448.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClCCN(CCCl)c1cc2nc(CCCCCCC(=O)NO)n(C)c2cc1	ClCCN(CCCl)c1cc2nc(CCCCCCC(=O)NO)n(C)c2cc1
NCGC00015199-20&NCGC00015199-24	ClCCN(CCCl)c1ccc(CCCC(=O)O)cc1		Inactive	DNA Alkylating Agent		2	Chlorambucil	170464770.0&384567821.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	ClCCN(CCCl)c1ccc(CCCC(=O)O)cc1	ClCCN(CCCl)c1ccc(CCCC(=O)O)cc1
NCGC00090757-06&NCGC00090757-12	ClCCN(CCCl)c1ccc(C[C@H](N)C(=O)O)cc1		Inactive	DNA Alkylating Agent		2	Melphalan	170464727.0&384568082.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		ClCCN(CCCl)c1ccc(C[C@H](N)C(=O)O)cc1	ClCCN(CCCl)c1ccc(C[C@H](N)C(=O)O)cc1
NCGC00346829-02&NCGC00346829-03	ClCCN(N=O)C(=O)NC(P(=O)(OCC)OCC)C		Inactive	DNA Alkylating Agent		2	Fotemustine	384568945.0&405558771.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	ClCCN(N=O)C(=O)NC(P(=O)(OCC)OCC)C	ClCCN(N=O)C(=O)NC(P(=O)(OCC)OCC)C
NCGC00167466-02&NCGC00167466-04	ClCCN(N=O)C(=O)NC1CCCCC1		Inactive	DNA Alkylating Agent		2	Lomustine	170464967.0&384568316.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	5.333524248&0.0&0.0	ClCCN(N=O)C(=O)NC1CCCCC1	ClCCN(N=O)C(=O)NC1CCCCC1
NCGC00015204-09	ClCCN(N=O)C(=O)NCCCl		Inactive	DNA Alkylating Agent		1	Carmustine	170464880.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	ClCCN(N=O)C(=O)NCCCl	ClCCN(N=O)C(=O)NCCCl
NCGC00015755-10	ClCCN(N=O)C(=O)NCc1c(N)nc(C)nc1		Inactive	DNA Crosslinking Agent		1	Nimustine	170466029.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	ClCCN(N=O)C(=O)NCc1c(N)nc(C)nc1	ClCCN(N=O)C(=O)NCc1c(N)nc(C)nc1
NCGC00179435-05&NCGC00179435-06	ClCCNP1(=O)N(CCCl)CCCO1		Inactive	DNA Alkylating Agent		2	Ifomide	384568373.0&170464854.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	ClCCNP1(=O)N(CCCl)CCCO1	ClCCNP1(=O)N(CCCl)CCCO1
NCGC00160546-02	ClCCOP(=O)(OCCCl)Oc1cc2OC(=O)C(Cl)=C(C)c2cc1		Inactive	Acetylcholinesterase Inhibitor		1	Haloxon	170466328.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClCCOP(=O)(OCCCl)Oc1cc2OC(=O)C(Cl)=C(C)c2cc1	ClCCOP(=O)(OCCCl)Oc1cc2OC(=O)C(Cl)=C(C)c2cc1
NCGC00344630-02	ClCC[C@@H]1[C@@]2(C)[C@]([C@@H](O)[C@@H]3C=CCCC3)(C(=O)O2)NC1=O		Inactive	Proteasome Inhibitor		1	Marizomib	384568728.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	15.445908464	ClCC[C@@H]1[C@@]2(C)[C@]([C@@H](O)[C@@H]3C=CCCC3)(C(=O)O2)NC1=O	ClCC[C@@H]1[C@@]2(C)[C@]([C@@H](O)[C@@H]3C=CCCC3)(C(=O)O2)NC1=O
NCGC00249933-01	ClCC[N+]([O-])(CCCl)C		Inactive			1	Nitrogen mustard N-oxide	170465894.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	ClCC[N+]([O-])(CCCl)C	ClCC[N+]([O-])(CCCl)C
NCGC00384198-02	ClCC[N+]([O-])(CCCl)c1ccc(C[C@H](N)C(=O)O)cc1		Inactive	HIF-1alpha Inhibitor		1	PX-478	384569105.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClCC[N+]([O-])(CCCl)c1ccc(C[C@H](N)C(=O)O)cc1	ClCC[N+]([O-])(CCCl)c1ccc(C[C@H](N)C(=O)O)cc1
NCGC00024842-05	ClCCc1c(C)ncs1		Inactive			1	Clomethiazole	170466516.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	ClCCc1c(C)ncs1	ClCCc1c(C)ncs1
NCGC00164594-02&NCGC00164594-08	ClCOC(=O)[C@]1(OC(=O)OCC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1		Inactive	Corticosteroid		2	Loteprednol etabonate	170465195.0&384568262.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	ClCOC(=O)[C@]1(OC(=O)OCC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1	ClCOC(=O)[C@]1(OC(=O)OCC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1
NCGC00249110-03	ClC[C@@H]1[C@@H](O)[C@H](O)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@@H](Cl)[C@@H](CO)O2)(CCl)O1		Inactive			1	Sucralose	170466823.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClC[C@@H]1[C@@H](O)[C@H](O)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@@H](Cl)[C@@H](CO)O2)(CCl)O1	ClC[C@@H]1[C@@H](O)[C@H](O)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@@H](Cl)[C@@H](CO)O2)(CCl)O1
NCGC00164344-04	ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O		Inactive			1	Symclosene	170465634.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O	ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O
NCGC00650297-01	ClS(=O)(=O)c1ccc(-c2ccccc2)cc1		Inactive			1	Biphenyl-4-sulfonyl chloride	434147203.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ClS(=O)(=O)c1ccc(-c2ccccc2)cc1	ClS(=O)(=O)c1ccc(-c2ccccc2)cc1
NCGC00380871-01	Cl[C@@H]1[C@@H](OC(=O)c2cc(O)c(O)cc2)[C@H]2[C@H]3[C@]1(O)CO[C@H](OC3O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Veronica | Family: Scrophulariaceae | Species: anagallis-aquatica		1	NCGC00380871-01	363678825.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Cl[C@@H]1[C@@H](OC(=O)c2cc(O)c(O)cc2)[C@H]2[C@H]3[C@]1(O)CO[C@H](OC3O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C2	Cl[C@@H]1[C@@H](OC(=O)c2cc(O)c(O)cc2)[C@H]2[C@H]3[C@]1(O)CO[C@H](OC3O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C2
NCGC00167506-04	Cl[C@@H]1[C@H](OC)C[C@H](/C=C(\C)/[C@@H]2[C@H](C)[C@@H](O)CC(=O)[C@H](CC)/C=C(\C)/C[C@H](C)C[C@H](OC)[C@@H]3[C@@H](OC)C[C@@H](C)[C@](O)(C(=O)C(=O)N4[C@H](C(=O)O2)CCCC4)O3)CC1		Inactive	Macrolide Antibiotic		1	Pimecrolimus	405558652.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Cl[C@@H]1[C@H](OC)C[C@H](/C=C(\C)/[C@@H]2[C@H](C)[C@@H](O)CC(=O)[C@H](CC)/C=C(\C)/C[C@H](C)C[C@H](OC)[C@@H]3[C@@H](OC)C[C@@H](C)[C@](O)(C(=O)C(=O)N4[C@H](C(=O)O2)CCCC4)O3)CC1	Cl[C@@H]1[C@H](OC)C[C@H](/C=C(\C)/[C@@H]2[C@H](C)[C@@H](O)CC(=O)[C@H](CC)/C=C(\C)/C[C@H](C)C[C@H](OC)[C@@H]3[C@@H](OC)C[C@@H](C)[C@](O)(C(=O)C(=O)N4[C@H](C(=O)O2)CCCC4)O3)CC1
NCGC00179636-04	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)C1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C		Inactive	Antibacterial		1	Clindamycin hydrochloride	405558965.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)C1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)C1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C
NCGC00263950-13	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C		Inactive	Bacterial 70S ribosome Inhibitor		1	Clindamycin HCl	384568701.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C
NCGC00185773-02	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](SC)O1)C		Inactive	Antibacterial		1	Clindamycin palmitate	124896661.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](SC)O1)C.Cl	Cl[C@H]([C@@H](NC(=O)[C@H]1N(C)C[C@H](CCC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](OC(=O)CCCCCCCCCCCCCCC)[C@@H](SC)O1)C.Cl
NCGC00522015-01	Cl[C@H]([C@@H](NC(=O)[C@H]1NCC[C@@H](CC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C		Inactive	Bacterial 70S ribosome Inhibitor		1	Pirlimycin Hydrochloride	405558973.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Cl[C@H]([C@@H](NC(=O)[C@H]1NCC[C@@H](CC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C	Cl[C@H]([C@@H](NC(=O)[C@H]1NCC[C@@H](CC)C1)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1)C
NCGC00390090-01	Cl[C@H]1[C@@H]2[C@H]([C@@H](O)C[C@]3(C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@H](C)C[C@@H]23)[C@]2(C)C(=CC(=O)C=C2)C1		Inactive	Glucocorticoid receptor Agonist		1	Alclometasone dipropionate	405559007.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Cl[C@H]1[C@@H]2[C@H]([C@@H](O)C[C@]3(C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@H](C)C[C@@H]23)[C@]2(C)C(=CC(=O)C=C2)C1	Cl[C@H]1[C@@H]2[C@H]([C@@H](O)C[C@]3(C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@H](C)C[C@@H]23)[C@]2(C)C(=CC(=O)C=C2)C1
NCGC00179239-05	Cl[C@]12[C@@H](O)C[C@]3(C)[C@@H](C(=O)COC(=O)C(C)(C)C)[C@H](C)C[C@H]3[C@@H]1C[C@H](F)C=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Clocortolone pivalate	405559113.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Cl[C@]12[C@@H](O)C[C@]3(C)[C@@H](C(=O)COC(=O)C(C)(C)C)[C@H](C)C[C@H]3[C@@H]1C[C@H](F)C=1[C@]2(C)C=CC(=O)C=1	Cl[C@]12[C@@H](O)C[C@]3(C)[C@@H](C(=O)COC(=O)C(C)(C)C)[C@H](C)C[C@H]3[C@@H]1C[C@H](F)C=1[C@]2(C)C=CC(=O)C=1
NCGC00179392-03	Cl[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Beclomethasone	170464981.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Cl[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	Cl[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00178241-04	Cl[Pt]1(Cl)NCCN1		Inactive	DNA Alkylating Agent		1	Dichloro(ethylenediamine)platinum(II)	170466890.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Cl[Pt]1(Cl)NCCN1	Cl[Pt]1(Cl)NCCN1
NCGC00390666-01	Clc1[n+]([O-])c(C)c(Cl)c(C)c1-c1nc(-c2cc(O)c(O)c([N+](=O)[O-])c2)on1		Inactive	Catechol O-methyltransferase Inhibitor		1	Opicapone	405559022.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1[n+]([O-])c(C)c(Cl)c(C)c1-c1nc(-c2cc(O)c(O)c([N+](=O)[O-])c2)on1	Clc1[n+]([O-])c(C)c(Cl)c(C)c1-c1nc(-c2cc(O)c(O)c([N+](=O)[O-])c2)on1
NCGC00378698-01	Clc1c(-c2[nH]c3c(n2)ccc(N(C)C)c3)cc(NC(=O)c2cc(OC)cc(OC)c2)cc1		Inactive	Smoothened homolog Antagonist		1	HhAntag	363678155.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	16.7680909759	Clc1c(-c2[nH]c3c(n2)ccc(N(C)C)c3)cc(NC(=O)c2cc(OC)cc(OC)c2)cc1	Clc1c(-c2[nH]c3c(n2)ccc(N(C)C)c3)cc(NC(=O)c2cc(OC)cc(OC)c2)cc1
NCGC00263210-04	Clc1c(-c2[nH]c3c(n2)cccc3)cc(NC(=O)c2cc(OCC)c(OCC)c(OCC)c2)cc1		Inactive	Smoothened (Smo) Receptor Antagonist		1	SANT-2	363677267.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	9.480477724	Clc1c(-c2[nH]c3c(n2)cccc3)cc(NC(=O)c2cc(OCC)c(OCC)c(OCC)c2)cc1	Clc1c(-c2[nH]c3c(n2)cccc3)cc(NC(=O)c2cc(OCC)c(OCC)c(OCC)c2)cc1
NCGC00250379-21	Clc1c(-c2c(-c3[nH]cc(C)n3)cnc(NCCNc3ncc(C#N)cc3)n2)ccc(Cl)c1		Inactive	GSK-3 Inhibitor		1	CT-99021	377020168.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.5	Clc1c(-c2c(-c3[nH]cc(C)n3)cnc(NCCNc3ncc(C#N)cc3)n2)ccc(Cl)c1	Clc1c(-c2c(-c3[nH]cc(C)n3)cnc(NCCNc3ncc(C#N)cc3)n2)ccc(Cl)c1
NCGC00485051-01	Clc1c(-c2c(-c3ccc(Cl)cc3)c3n(C(N4CC(NCC)(C(=O)N)C4)=NC(C)=N3)n2)cccc1		Inactive	Cannabinoid CB1 receptor Antagonist		1	CE-178253 benzenesulfonate salt	363681207.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(-c2c(-c3ccc(Cl)cc3)c3n(C(N4CC(NCC)(C(=O)N)C4)=NC(C)=N3)n2)cccc1	Clc1c(-c2c(-c3ccc(Cl)cc3)c3n(C(N4CC(NCC)(C(=O)N)C4)=NC(C)=N3)n2)cccc1
NCGC00346677-02	Clc1c(-c2c(-n3cncc3)cnc(NCCNc3nc(N)c([N+](=O)[O-])cc3)n2)ccc(Cl)c1		Inactive	GSK-3 Inhibitor		1	CT-98014	384568903.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.0	Clc1c(-c2c(-n3cncc3)cnc(NCCNc3nc(N)c([N+](=O)[O-])cc3)n2)ccc(Cl)c1	Clc1c(-c2c(-n3cncc3)cnc(NCCNc3nc(N)c([N+](=O)[O-])cc3)n2)ccc(Cl)c1
NCGC00371150-04	Clc1c(-c2c(C(=O)N(C)c3ccc(Cl)cc3)c(C)on2)cccc1		Inactive			1	CCDC	363678064.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(-c2c(C(=O)N(C)c3ccc(Cl)cc3)c(C)on2)cccc1	Clc1c(-c2c(C(=O)N(C)c3ccc(Cl)cc3)c(C)on2)cccc1
NCGC00178782-04	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@@H](C(=O)O)C(C)(C)S[C@H]34)c(C)on2)c(Cl)ccc1		Inactive	peptidoglycan biosynthetic process Inhibitor		1	Dicloxacillin sodium salt monohydrate	170465296.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@@H](C(=O)[O-])C(C)(C)S[C@H]34)c(C)on2)c(Cl)ccc1.[Na+].O	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@@H](C(=O)[O-])C(C)(C)S[C@H]34)c(C)on2)c(Cl)ccc1.[Na+].O
NCGC00178840-05&NCGC00178840-12	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@@H](C(=O)O)C(C)(C)S[C@H]34)c(C)on2)cccc1		Inactive	beta-lactam antibiotic		2	Cloxacillin sodium	170465404.0&363676936.0	Approved Drugs Collection (NPC)&2020_NPACT-1_CPE	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@@H](C(=O)[O-])C(C)(C)S[C@H]34)c(C)on2)cccc1.[Na+]	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@@H](C(=O)[O-])C(C)(C)S[C@H]34)c(C)on2)cccc1.[Na+]&Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@@H](C(=O)[O-])C(C)(C)S[C@H]34)c(C)on2)cccc1
NCGC00262578-03	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@H](C(=O)O)C(C)(C)S[C@H]34)c(C)on2)c(F)ccc1		Inactive	Penicillin-binding protein Inhibitor		1	Flucloxacillin sodium	405558889.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@H](C(=O)[O-])C(C)(C)S[C@H]34)c(C)on2)c(F)ccc1	Clc1c(-c2c(C(=O)N[C@@H]3C(=O)N4[C@H](C(=O)[O-])C(C)(C)S[C@H]34)c(C)on2)c(F)ccc1
NCGC00346696-07	Clc1c(-c2c(C)cc(C)cn2)cc(N2CCN(C(=O)CCS(=O)(=O)C)CC2)nc1		Inactive	Smoothened (Smo) receptor Agonist		1	PF-5274857	384568916.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(-c2c(C)cc(C)cn2)cc(N2CCN(C(=O)CCS(=O)(=O)C)CC2)nc1	Clc1c(-c2c(C)cc(C)cn2)cc(N2CCN(C(=O)CCS(=O)(=O)C)CC2)nc1
NCGC00386642-01	Clc1c(-c2c(C)sc(N([C@@H](CC3CC3)c3cc(F)c(C)cc3)CC#C)n2)cc(C)c(OC)c1		Inactive	Corticotropin releasing factor receptor 1 Antagonist		1	SSR 125543A	363680369.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(-c2c(C)sc(N([C@@H](CC3CC3)c3cc(F)c(C)cc3)CC#C)n2)cc(C)c(OC)c1	Clc1c(-c2c(C)sc(N([C@@H](CC3CC3)c3cc(F)c(C)cc3)CC#C)n2)cc(C)c(OC)c1
NCGC00386641-01	Clc1c(-c2c(CC(=O)NCc3cnc(OCC(F)(F)F)cc3)c(C)on2)c(Cl)ccc1		Inactive	Sodium channel protein type IX alpha subunit Inhibitor		1	Nav1.7 blocker 24	363680368.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(-c2c(CC(=O)NCc3cnc(OCC(F)(F)F)cc3)c(C)on2)c(Cl)ccc1	Clc1c(-c2c(CC(=O)NCc3cnc(OCC(F)(F)F)cc3)c(C)on2)c(Cl)ccc1
NCGC00390630-01	Clc1c(-c2c(Cl)ccc(Cl)c2)cc(C(=O)N2CCN(C(=O)C=C)CC2)c(OC)c1		Inactive	GTPase KRas Inhibitor		1	K-Ras G12C-IN-3	363680938.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	15.0	Clc1c(-c2c(Cl)ccc(Cl)c2)cc(C(=O)N2CCN(C(=O)C=C)CC2)c(OC)c1	Clc1c(-c2c(Cl)ccc(Cl)c2)cc(C(=O)N2CCN(C(=O)C=C)CC2)c(OC)c1
NCGC00390636-01	Clc1c(-c2c(Cl)cccc2)cc(NCC(=O)N2CCN(C(=O)C=C)CC2)c(OC)c1		Inactive	GTPase KRas Inhibitor		1	K-Ras G12C-IN-1	363680941.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(-c2c(Cl)cccc2)cc(NCC(=O)N2CCN(C(=O)C=C)CC2)c(OC)c1	Clc1c(-c2c(Cl)cccc2)cc(NCC(=O)N2CCN(C(=O)C=C)CC2)c(OC)c1
NCGC00181136-01	Clc1c(-c2c([N+](=O)[O-])c(Cl)ccc2)c[nH]c1		Inactive	respiratory electron transport chain Inhibitor		1	Pyrrolnitrin	144206296.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(-c2c([N+](=O)[O-])c(Cl)ccc2)c[nH]c1	Clc1c(-c2c([N+](=O)[O-])c(Cl)ccc2)c[nH]c1
NCGC00510167-01	Clc1c(-c2c3c([nH]c2)cccc3)nc(N[C@H]2CN(C(=O)c3ccc(NC(=O)/C=C/CN(C)C)cc3)CCC2)nc1		Inactive	CDK12/CDK13		1	THZ531	384569412.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	19.4445250199	Clc1c(-c2c3c([nH]c2)cccc3)nc(N[C@H]2CN(C(=O)c3ccc(NC(=O)/C=C/CN(C)C)cc3)CCC2)nc1	Clc1c(-c2c3c([nH]c2)cccc3)nc(N[C@H]2CN(C(=O)c3ccc(NC(=O)/C=C/CN(C)C)cc3)CCC2)nc1
NCGC00351596-02	Clc1c(-c2c3c([nH]c2)cccc3)nc(Nc2c(OC)cc(N3CCC(N)CC3)cc2)nc1		Inactive	ALK Inhibitor		1	AZD-3463	384569014.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(-c2c3c([nH]c2)cccc3)nc(Nc2c(OC)cc(N3CCC(N)CC3)cc2)nc1	Clc1c(-c2c3c([nH]c2)cccc3)nc(Nc2c(OC)cc(N3CCC(N)CC3)cc2)nc1
NCGC00485484-02	Clc1c(-c2c3c([nH]c2)cccc3)nc(Nc2cc(NC(=O)c3cc(NC(=O)/C=C/CN(C)C)ccc3)ccc2)nc1		Inactive	CDK 7 Inhibitor		1	THZ-2	384569276.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	19.682008372	Clc1c(-c2c3c([nH]c2)cccc3)nc(Nc2cc(NC(=O)c3cc(NC(=O)/C=C/CN(C)C)ccc3)ccc2)nc1	Clc1c(-c2c3c([nH]c2)cccc3)nc(Nc2cc(NC(=O)c3cc(NC(=O)/C=C/CN(C)C)ccc3)ccc2)nc1
NCGC00389590-05	Clc1c(-c2c3c([nH]c2)cccc3)nc(Nc2cc(NC(=O)c3ccc(NC(=O)/C=C/CN(C)C)cc3)ccc2)nc1		Inactive	CDK 7 Inhibitor		1	THZ1	363680811.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	16.52794904	Clc1c(-c2c3c([nH]c2)cccc3)nc(Nc2cc(NC(=O)c3ccc(NC(=O)/C=C/CN(C)C)cc3)ccc2)nc1	Clc1c(-c2c3c([nH]c2)cccc3)nc(Nc2cc(NC(=O)c3ccc(NC(=O)/C=C/CN(C)C)cc3)ccc2)nc1
NCGC00380969-01	Clc1c(-c2c3c([nH]c2)cccc3)ocn1		Inactive	<MOA Unknown> | Class: AS | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380969-01	363678893.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(-c2c3c([nH]c2)cccc3)ocn1	Clc1c(-c2c3c([nH]c2)cccc3)ocn1
NCGC00378692-06	Clc1c(-c2cc(C(=O)N[C@H](CO)c3cc(Cl)ccc3)[nH]c2)cc(NC(C)C)nc1		Inactive	ERK1/2 Inhibitor		1	Ulixertinib	384569063.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(-c2cc(C(=O)N[C@H](CO)c3cc(Cl)ccc3)[nH]c2)cc(NC(C)C)nc1	Clc1c(-c2cc(C(=O)N[C@H](CO)c3cc(Cl)ccc3)[nH]c2)cc(NC(C)C)nc1
NCGC00378840-01	Clc1c(-c2cc(C)c3nc(Nc4ccc(OCCN5CCCC5)cc4)nnc3c2)cc(OC(=O)c2ccccc2)cc1		Inactive	Src Kinase Inhibitor		1	TG-100801	363678229.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(-c2cc(C)c3nc(Nc4ccc(OCCN5CCCC5)cc4)nnc3c2)cc(OC(=O)c2ccccc2)cc1	Clc1c(-c2cc(C)c3nc(Nc4ccc(OCCN5CCCC5)cc4)nnc3c2)cc(OC(=O)c2ccccc2)cc1
NCGC00387228-01	Clc1c(-c2cc(O)ccc2)cc2c(OCCCN)c(-c3cc(C)cc(C)c3)cnc2c1	4.9000001	Active	Somatostatin receptor 2 Agonist	0.0	1	TC-G 1003	363680582.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	108.8403428627	Clc1c(-c2cc(O)ccc2)cc2c(OCCCN)c(-c3cc(C)cc(C)c3)cnc2c1	Clc1c(-c2cc(O)ccc2)cc2c(OCCCN)c(-c3cc(C)cc(C)c3)cnc2c1
NCGC00386681-01	Clc1c(-c2ccc(Cl)cc2)cc2oc(N3CCC(C(=O)N[C@@H]4C[C@@H](CO)CCC4)CC3)nc2c1		Inactive	Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) Inhibitor		1	PF-4693627	363680394.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(-c2ccc(Cl)cc2)cc2oc(N3CCC(C(=O)N[C@@H]4C[C@@H](CO)CCC4)CC3)nc2c1	Clc1c(-c2ccc(Cl)cc2)cc2oc(N3CCC(C(=O)N[C@@H]4C[C@@H](CO)CCC4)CC3)nc2c1
NCGC00351601-07	Clc1c(-c2n(-c3ccc(Cl)cc3)c3ncnc(N4CCC(NCC)(C(=O)N)CC4)c3n2)cccc1		Inactive	Cannabinoid CB1 Antagonist		1	Otenabant	363677769.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	20.059492564	Clc1c(-c2n(-c3ccc(Cl)cc3)c3ncnc(N4CCC(NCC)(C(=O)N)CC4)c3n2)cccc1	Clc1c(-c2n(-c3ccc(Cl)cc3)c3ncnc(N4CCC(NCC)(C(=O)N)CC4)c3n2)cccc1
NCGC00387870-04	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)NC(CN)Cc2cc(F)c(F)cc2)o1		Inactive	Serine/threonine-protein kinase AKT3 Inhibitor		1	GSK2141795	384569165.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)NC(CN)Cc2cc(F)c(F)cc2)o1	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)NC(CN)Cc2cc(F)c(F)cc2)o1
NCGC00390611-02	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)N[C@H](CN)Cc2cc(F)c(F)cc2)s1		Inactive			1	GSK2110183 (hydrochloride)	384569200.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)N[C@H](CN)Cc2cc(F)c(F)cc2)s1	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)N[C@H](CN)Cc2cc(F)c(F)cc2)s1
NCGC00387879-02	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)N[C@H](CN)Cc2cc(F)ccc2)s1		Inactive	AKT Inhibitor		1	Afuresertib (GSK2110183)	384569168.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)N[C@H](CN)Cc2cc(F)ccc2)s1	Clc1c(-c2n(C)ncc2Cl)cc(C(=O)N[C@H](CN)Cc2cc(F)ccc2)s1
NCGC00015205-10	Clc1c(-c2nc(C(=O)N(C(CC)C)C)cc3c2cccc3)cccc1		Inactive			1	PK 11195	384567822.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(-c2nc(C(=O)N(C(CC)C)C)cc3c2cccc3)cccc1	Clc1c(-c2nc(C(=O)N(C(CC)C)C)cc3c2cccc3)cccc1
NCGC00378912-01	Clc1c(-c2nc(COc3cc(C)c(OCC(=O)O)cc3)sc2)cccc1		Inactive	Free fatty acid receptor 4 Modulator		1	GPR120 modulator 1	363678272.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(-c2nc(COc3cc(C)c(OCC(=O)O)cc3)sc2)cccc1	Clc1c(-c2nc(COc3cc(C)c(OCC(=O)O)cc3)sc2)cccc1
NCGC00160397-04&NCGC00160397-13	Clc1c(-c2nc(N)nc(N)n2)cc(Cl)cc1		Inactive	M1 Muscarinic acetylcholine receptor Antagonist		2	Irsogladine maleate	170465947.0&384568192.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1c(-c2nc(N)nc(N)n2)cc(Cl)cc1.O=C(O)/C=C\C(=O)O	Clc1c(-c2nc(N)nc(N)n2)cc(Cl)cc1.O=C(O)/C=C\C(=O)O&Clc1c(-c2nc(N)nc(N)n2)cc(Cl)cc1
NCGC00378918-01	Clc1c(-c2nc(NCc3cc(F)ccc3)ccc2)cc(NC2CCC(N)CC2)nc1		Inactive	CDK9/cyclin T1 Inhibitor		1	CDK9-IN-2	363678275.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(-c2nc(NCc3cc(F)ccc3)ccc2)cc(NC2CCC(N)CC2)nc1	Clc1c(-c2nc(NCc3cc(F)ccc3)ccc2)cc(NC2CCC(N)CC2)nc1
NCGC00386331-01	Clc1c(-c2nc(SCCCC(=O)N)nc(N)n2)c2c3c(c1)COCc3ccc2		Inactive	Heat shock protein HSP 90-alpha Inhibitor		1	CH5138303	363680216.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(-c2nc(SCCCC(=O)N)nc(N)n2)c2c3c(c1)COCc3ccc2	Clc1c(-c2nc(SCCCC(=O)N)nc(N)n2)c2c3c(c1)COCc3ccc2
NCGC00379182-01	Clc1c(-c2oc(C(=O)Nc3c(C)cc(CN)cc3C)cc2)cc(Cl)cc1	5.0	Active	Sphingosine 1-phosphate receptor Edg-6 Antagonist	0.0	1	CYM 50358 hydrochloride	363678403.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	78.3246445536	Clc1c(-c2oc(C(=O)Nc3c(C)cc(CN)cc3C)cc2)cc(Cl)cc1	Clc1c(-c2oc(C(=O)Nc3c(C)cc(CN)cc3C)cc2)cc(Cl)cc1
NCGC00141101-01	Clc1c(-c2oc3c(n2)cc(NC(=O)c2ccc(OC)cc2)cc3)ccc(F)c1		Inactive			1	NCGC00141101-01	24416484.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(-c2oc3c(n2)cc(NC(=O)c2ccc(OC)cc2)cc3)ccc(F)c1	Clc1c(-c2oc3c(n2)cc(NC(=O)c2ccc(OC)cc2)cc3)ccc(F)c1
NCGC00481567-03	Clc1c(-c2sc3c(c(C(=O)NC4CC4)ccc3)c2)nc(NCCCN2CCN(C)CC2)nc1		Inactive	IKK beta Inhibitor		1	LY-2409881	377020225.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(-c2sc3c(c(C(=O)NC4CC4)ccc3)c2)nc(NCCCN2CCN(C)CC2)nc1	Clc1c(-c2sc3c(c(C(=O)NC4CC4)ccc3)c2)nc(NCCCN2CCN(C)CC2)nc1
NCGC00370822-01	Clc1c(-n2c(-c3ccc(Cl)cc3)c3OCCN(CC(F)(F)C)C(=O)c3n2)cccc1		Inactive	Cannabinoid CB1 receptor Antagonist		1	PF 514273	363677870.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(-n2c(-c3ccc(Cl)cc3)c3OCCN(CC(F)(F)C)C(=O)c3n2)cccc1	Clc1c(-n2c(-c3ccc(Cl)cc3)c3OCCN(CC(F)(F)C)C(=O)c3n2)cccc1
NCGC00263197-03	Clc1c(-n2c(-c3sc(NC(=O)C(C)C)nc3)cc(C(F)F)n2)c(Cl)ccc1		Inactive	LIMK1/LIMK2 Inhibitor		1	BMS-5	363677258.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(-n2c(-c3sc(NC(=O)C(C)C)nc3)cc(C(F)F)n2)c(Cl)ccc1	Clc1c(-n2c(-c3sc(NC(=O)C(C)C)nc3)cc(C(F)F)n2)c(Cl)ccc1
NCGC00345825-02	Clc1c(-n2c(-c3sc(NC(=O)C4CC4)nc3)cc(C(F)F)n2)c(Cl)ccc1		Inactive	LIMK Inhibitor		1	BMS-3	363677372.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Clc1c(-n2c(-c3sc(NC(=O)C4CC4)nc3)cc(C(F)F)n2)c(Cl)ccc1	Clc1c(-n2c(-c3sc(NC(=O)C4CC4)nc3)cc(C(F)F)n2)c(Cl)ccc1
NCGC00390587-01&NCGC00390587-03	Clc1c(-n2c(/C=C/c3oc(-c4ccc(C#N)cc4)nn3)nnc2-c2ncc(S(=O)(=O)C)cc2)cccc1		Inactive	Tachykinin NK1 Antagonist		2	G-007-LK	363680917.0&434147143.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(-n2c(/C=C/c3oc(-c4ccc(C#N)cc4)nn3)nnc2-c2ncc(S(=O)(=O)C)cc2)cccc1	Clc1c(-n2c(/C=C/c3oc(-c4ccc(C#N)cc4)nn3)nnc2-c2ncc(S(=O)(=O)C)cc2)cccc1
NCGC00094574-15	Clc1c(-n2c(N)c([SH0](=O)C(F)(F)F)c(C#N)n2)c(Cl)cc(C(F)(F)F)c1		Inactive			1	Fipronil	170465992.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(-n2c(N)c([SH0](=O)C(F)(F)F)c(C#N)n2)c(Cl)cc(C(F)(F)F)c1	Clc1c(-n2c(N)c([SH0](=O)C(F)(F)F)c(C#N)n2)c(Cl)cc(C(F)(F)F)c1
NCGC00371029-01	Clc1c(-n2c(c(C)c(C(=O)NCc3cnccc3)n2)-c2ccc(Cl)cc2)ccc(Cl)c1		Inactive	Cannabinoid receptor Antagonist		1	MJ 15	363677999.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(-n2c(c(C)c(C(=O)NCc3cnccc3)n2)-c2ccc(Cl)cc2)ccc(Cl)c1	Clc1c(-n2c(c(C)c(C(=O)NCc3cnccc3)n2)-c2ccc(Cl)cc2)ccc(Cl)c1
NCGC00164572-02&NCGC00164572-14	Clc1c(-n2c(c(C)c(C(=O)NN3CCCCC3)n2)-c2ccc(Cl)cc2)ccc(Cl)c1		Inactive	Cannabinoid CB1 Antagonist		2	Rimonabant	170465599.0&384568257.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1c(-n2c(c(C)c(C(=O)NN3CCCCC3)n2)-c2ccc(Cl)cc2)ccc(Cl)c1	Clc1c(-n2c(c(C)c(C(=O)NN3CCCCC3)n2)-c2ccc(Cl)cc2)ccc(Cl)c1
NCGC00370913-02	Clc1c(-n2c(c(C)c(C(=O)NN3CCCCC3)n2)-c2ccc(OC)cc2)ccc(Cl)c1		Inactive	Cannabinoid CB1 receptor Antagonist		1	NIDA-41020	363677929.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(-n2c(c(C)c(C(=O)NN3CCCCC3)n2)-c2ccc(OC)cc2)ccc(Cl)c1	Clc1c(-n2c(c(C)c(C(=O)NN3CCCCC3)n2)-c2ccc(OC)cc2)ccc(Cl)c1
NCGC00485482-01	Clc1c(-n2c(c(CNS(=O)(=O)N3CCCC3)c(C(=O)NN3CCCCC3)n2)-c2sc(C#Cc3ccc(C(F)(F)F)cc3)cc2)ccc(Cl)c1		Inactive	Cannabinoid receptor 1 Inverse Agonist		1	CB1-IN-1	363681351.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(-n2c(c(CNS(=O)(=O)N3CCCC3)c(C(=O)NN3CCCCC3)n2)-c2sc(C#Cc3ccc(C(F)(F)F)cc3)cc2)ccc(Cl)c1	Clc1c(-n2c(c(CNS(=O)(=O)N3CCCC3)c(C(=O)NN3CCCCC3)n2)-c2sc(C#Cc3ccc(C(F)(F)F)cc3)cc2)ccc(Cl)c1
NCGC00345809-03	Clc1c(-n2nc(C(C)C)c3C(=O)NC(Cc4ccc(OCCO)cc4)=Nc23)c(Cl)ccc1		Inactive	CDK1/2/3/7/9 Inhibitor		1	RGB-286147	384568754.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Clc1c(-n2nc(C(C)C)c3C(=O)NC(Cc4ccc(OCCO)cc4)=Nc23)c(Cl)ccc1	Clc1c(-n2nc(C(C)C)c3C(=O)NC(Cc4ccc(OCCO)cc4)=Nc23)c(Cl)ccc1
NCGC00249921-01	Clc1c(/C(/OCCOc2ccc(Cl)cc2)=C(\C)/n2cncc2)ccc(Cl)c1	4.8499999	Active		0.0	1	Omoconazole	170465847.0	2019_NPC-3.2	SARS-CoV-2_CPE_SRI	2.4	34.5390362399	Clc1c(/C(/OCCOc2ccc(Cl)cc2)=C(\C)/n2cncc2)ccc(Cl)c1	Clc1c(/C(/OCCOc2ccc(Cl)cc2)=C(\C)/n2cncc2)ccc(Cl)c1
NCGC00509938-02	Clc1c(/C(=C(/c2cc3c([nH]nc3)cc2)\c2ccc(/C=C/C(=O)O)cc2)/CC)ccc(F)c1		Inactive	Selective Estrogen Receptor Destabilizers (SERD)		1	Brilanestrant	384569387.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.621508168	Clc1c(/C(=C(/c2cc3c([nH]nc3)cc2)\c2ccc(/C=C/C(=O)O)cc2)/CC)ccc(F)c1	Clc1c(/C(=C(/c2cc3c([nH]nc3)cc2)\c2ccc(/C=C/C(=O)O)cc2)/CC)ccc(F)c1
NCGC00177980-03	Clc1c(/C(=N/OCc2c(Cl)cc(Cl)cc2)/Cn2cncc2)ccc(Cl)c1		Inactive	Steroid biosynthesis Inhibitor		1	Oxiconazole nitrate	170465226.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(/C(=N/OCc2c(Cl)cc(Cl)cc2)/Cn2cncc2)ccc(Cl)c1.O=[N+](O)[O-]	Clc1c(/C(=N/OCc2c(Cl)cc(Cl)cc2)/Cn2cncc2)ccc(Cl)c1.O=[N+](O)[O-]
NCGC00522464-01	Clc1c(/C=C(/C(=O)O)\C)c(Cl)cc(C(=O)Nc2scc(-c3c(OC)c([C@@H](OCCCCCC)C)ccc3)n2)c1		Inactive	Thrombopoietin receptor Agonist		1	Lusutrombopag	405558628.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	15.360887096	Clc1c(/C=C(/C(=O)O)\C)c(Cl)cc(C(=O)Nc2scc(-c3c(OC)c([C@@H](OCCCCCC)C)ccc3)n2)c1	Clc1c(/C=C(/C(=O)O)\C)c(Cl)cc(C(=O)Nc2scc(-c3c(OC)c([C@@H](OCCCCCC)C)ccc3)n2)c1
NCGC00167739-08	Clc1c(/C=C/c2cc(C(=O)O)ccc2)ccc(OCc2c(C(C)C)onc2-c2c(Cl)cccc2Cl)c1	4.9499998	Active	Farnesoid X Receptor Agonist	0.0	1	GW-4064X	384568331.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	66.5264584547	Clc1c(/C=C/c2cc(C(=O)O)ccc2)ccc(OCc2c(C(C)C)onc2-c2c(Cl)cccc2Cl)c1	Clc1c(/C=C/c2cc(C(=O)O)ccc2)ccc(OCc2c(C(C)C)onc2-c2c(Cl)cccc2Cl)c1
NCGC00024846-08	Clc1c(/C=N/NC(=N)N)c(Cl)ccc1		Inactive	Adrenergic receptor alpha-2 Agonist		1	Guanabenz	170465364.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(/C=N/NC(=N)N)c(Cl)ccc1	Clc1c(/C=N/NC(=N)N)c(Cl)ccc1
NCGC00421818-01	Clc1c(/C=N/NC(=N)N)cccc1		Inactive	Protein phosphatase 1 regulatory subunit 15A Inhibitor		1	Sephin 1	363681093.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(/C=N/NC(=N)N)cccc1	Clc1c(/C=N/NC(=N)N)cccc1
NCGC00179680-05	Clc1c(/N=C/2\NCCN\2)c(Cl)ccc1		Inactive	alpha1-Adrenoceptor Agonists		1	Clonidine	170464900.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(/N=C/2\NCCN\2)c(Cl)ccc1	Clc1c(/N=C/2\NCCN\2)c(Cl)ccc1
NCGC00344510-06	Clc1c(C#N)c(OC[C@H](O)CNC(Cc2cc3c(cc2)cccc3)(C)C)ccc1		Inactive	Calcium-Sensing Receptor (CaSR) Antagonist		1	NPS-2143	384568720.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-15.743030984	Clc1c(C#N)c(OC[C@H](O)CNC(Cc2cc3c(cc2)cccc3)(C)C)ccc1	Clc1c(C#N)c(OC[C@H](O)CNC(Cc2cc3c(cc2)cccc3)(C)C)ccc1
NCGC00263230-01	Clc1c(C#N)cc2C(O)=C(c3cc(-c4c(OC)cccc4)ccc3)C(=O)Nc2c1		Inactive	Fatty Acid Synthase (FAS) Inhibitor		1	FASN MRK	137276074.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	27.3716461159	Clc1c(C#N)cc2C(O)=C(c3cc(-c4c(OC)cccc4)ccc3)C(=O)Nc2c1	Clc1c(C#N)cc2C(O)=C(c3cc(-c4c(OC)cccc4)ccc3)C(=O)Nc2c1
NCGC00485475-01	Clc1c(C#N)ccc(-c2nn(C[C@@H](NC(=O)c3n[nH]c(C(=O)C)c3)C)cc2)c1		Inactive	Androgen Receptor Antagonist		1	ORM-15341	363681344.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C#N)ccc(-c2nn(C[C@@H](NC(=O)c3n[nH]c(C(=O)C)c3)C)cc2)c1	Clc1c(C#N)ccc(-c2nn(C[C@@H](NC(=O)c3n[nH]c(C(=O)C)c3)C)cc2)c1
NCGC00484078-02	Clc1c(C#N)ccc(-c2nn(C[C@@H](NC(=O)c3n[nH]c(C(O)C)c3)C)cc2)c1		Inactive	Androgen Receptor Antagonist		1	Darolutamide (ODM-201)	384569270.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C#N)ccc(-c2nn(C[C@@H](NC(=O)c3n[nH]c(C(O)C)c3)C)cc2)c1	Clc1c(C#N)ccc(-c2nn(C[C@@H](NC(=O)c3n[nH]c(C(O)C)c3)C)cc2)c1
NCGC00485023-01	Clc1c(C#N)ccc(N2[C@@H](C3CCCC3)[C@@H]3C(=N2)c2c(cc(C(=O)O)cc2)CC3)c1		Inactive	Mineralocorticoid receptor Antagonist		1	PF-03882845	363681191.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C#N)ccc(N2[C@@H](C3CCCC3)[C@@H]3C(=N2)c2c(cc(C(=O)O)cc2)CC3)c1	Clc1c(C#N)ccc(N2[C@@H](C3CCCC3)[C@@H]3C(=N2)c2c(cc(C(=O)O)cc2)CC3)c1
NCGC00263084-02	Clc1c(C(=O)N(Cc2cc(-c3ccncc3)ccc2)C2CCC(NC)CC2)sc2c(F)ccc(F)c12		Inactive	Smoothened (Smo) receptor Agonist		1	Hh-Ag1.5	174006719.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-13.175109664	Clc1c(C(=O)N(Cc2cc(-c3ccncc3)ccc2)C2CCC(NC)CC2)sc2c(F)ccc(F)c12	Clc1c(C(=O)N(Cc2cc(-c3ccncc3)ccc2)C2CCC(NC)CC2)sc2c(F)ccc(F)c12
NCGC00384168-11	Clc1c(C(=O)N(Cc2cc(-c3ccncc3)ccc2)C2CCC(NC)CC2)sc2c1cccc2		Inactive			1	SAG		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Clc1c(C(=O)N(Cc2cc(-c3ccncc3)ccc2)C2CCC(NC)CC2)sc2c1cccc2	Clc1c(C(=O)N(Cc2cc(-c3ccncc3)ccc2)C2CCC(NC)CC2)sc2c1cccc2
NCGC00094557-06	Clc1c(C(=O)N)ccc([N+](=O)[O-])c1		Inactive			1	2-Chloro-4-nitrobenzamide	170466191.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C(=O)N)ccc([N+](=O)[O-])c1	Clc1c(C(=O)N)ccc([N+](=O)[O-])c1
NCGC00263140-03	Clc1c(C(=O)N2[C@H](C)CN(Cc3ccc(F)cc3)[C@@H](C)C2)cc2c(C(=O)C(=O)N(C)C)cn(C)c2c1		Inactive	p38 MAPK Inhibitor		1	Talmapimod	363677225.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	20.8113818841	Clc1c(C(=O)N2[C@H](C)CN(Cc3ccc(F)cc3)[C@@H](C)C2)cc2c(C(=O)C(=O)N(C)C)cn(C)c2c1	Clc1c(C(=O)N2[C@H](C)CN(Cc3ccc(F)cc3)[C@@H](C)C2)cc2c(C(=O)C(=O)N(C)C)cn(C)c2c1
NCGC00485402-01	Clc1c(C(=O)N2c3c(cccc3)Cn3c(ccc3)C2)ccc(NC(=O)c2c(C)ccc(F)c2)c1		Inactive	Cytochrome P450 3A4 Substrate		1	Lixivaptan	363681315.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C(=O)N2c3c(cccc3)Cn3c(ccc3)C2)ccc(NC(=O)c2c(C)ccc(F)c2)c1	Clc1c(C(=O)N2c3c(cccc3)Cn3c(ccc3)C2)ccc(NC(=O)c2c(C)ccc(F)c2)c1
NCGC00387762-01	Clc1c(C(=O)NC(=O)Nc2c(OC)ccc(NC(=O)NC)c2)cc(F)c(F)c1		Inactive	Liver glycogen phosphorylase Inhibitor		1	Glycogen phosphorylase inhibitor	363680653.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C(=O)NC(=O)Nc2c(OC)ccc(NC(=O)NC)c2)cc(F)c(F)c1	Clc1c(C(=O)NC(=O)Nc2c(OC)ccc(NC(=O)NC)c2)cc(F)c(F)c1
NCGC00510488-01	Clc1c(C(=O)NC2C[C@@H]3N(S(=O)(=O)CC4CCN(CCCC(F)(F)F)CC4)[C@H](C2)CC3)cc2c(NC(=O)C2)c1		Inactive	SMYD3 Inhibitor		1	EPZ-031686	384569450.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C(=O)NC2C[C@@H]3N(S(=O)(=O)CC4CCN(CCCC(F)(F)F)CC4)[C@H](C2)CC3)cc2c(NC(=O)C2)c1	Clc1c(C(=O)NC2C[C@@H]3N(S(=O)(=O)CC4CCN(CCCC(F)(F)F)CC4)[C@H](C2)CC3)cc2c(NC(=O)C2)c1
NCGC00249611-04&NCGC00249611-05	Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B(O)O)cc(Cl)cc1		Inactive	Proteasome Inhibitor		2	Ixazomib	405558551.0&384568528.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B(O)O)cc(Cl)cc1	Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B(O)O)cc(Cl)cc1
NCGC00522453-01&NCGC00522453-02	Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B2OC(=O)C(CC(=O)O)(CC(=O)O)O2)cc(Cl)cc1		Inactive	Proteasome subunit beta type-5 Inhibitor		2	MLN9708&IXAZOMIB CITRATE	405559125.0&434146871.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B2OC(=O)C(CC(=O)O)(CC(=O)O)O2)cc(Cl)cc1	Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B2OC(=O)C(CC(=O)O)(CC(=O)O)O2)cc(Cl)cc1
NCGC00249612-02	Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B2OC(=O)CC(C(=O)O)(CC(=O)O)O2)cc(Cl)cc1		Inactive	Proteasome Inhibitor		1	Ixazomib citrate	384568529.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B2OC(=O)CC(C(=O)O)(CC(=O)O)O2)cc(Cl)cc1	Clc1c(C(=O)NCC(=O)N[C@@H](CC(C)C)B2OC(=O)CC(C(=O)O)(CC(=O)O)O2)cc(Cl)cc1
NCGC00244254-01	Clc1c(C(=O)NCCCNc2nc(-c3ccc(N)cc3)ccn2)c(Cl)ccc1		Inactive			1	NCGC00244254-01	377020386.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C(=O)NCCCNc2nc(-c3ccc(N)cc3)ccn2)c(Cl)ccc1	Clc1c(C(=O)NCCCNc2nc(-c3ccc(N)cc3)ccn2)c(Cl)ccc1
NCGC00390682-01	Clc1c(C(=O)NCc2ccc(Oc3ccc(C)cc3)cc2)n(C)nc1CC		Inactive	Haemonchus contortus Inhibitor		1	Tolfenpyrad	363680969.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C(=O)NCc2ccc(Oc3ccc(C)cc3)cc2)n(C)nc1CC	Clc1c(C(=O)NCc2ccc(Oc3ccc(C)cc3)cc2)n(C)nc1CC
NCGC00379226-01	Clc1c(C(=O)N[C@@H](C(=O)O)Cc2ccccc2)sc2c1ccc(F)c2		Inactive	Toll-like receptor 3 Antagonist		1	CU CPT 4a	363678432.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C(=O)N[C@@H](C(=O)O)Cc2ccccc2)sc2c1ccc(F)c2	Clc1c(C(=O)N[C@@H](C(=O)O)Cc2ccccc2)sc2c1ccc(F)c2
NCGC00390619-01	Clc1c(C(=O)N[C@H](C(=O)O)Cc2ccc(-c3c(OC)cccc3OC)cc2)c(Cl)ccc1		Inactive	Integrin alpha-4/beta-7 Antagonist		1	TR-14035	363680933.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C(=O)N[C@H](C(=O)O)Cc2ccc(-c3c(OC)cccc3OC)cc2)c(Cl)ccc1	Clc1c(C(=O)N[C@H](C(=O)O)Cc2ccc(-c3c(OC)cccc3OC)cc2)c(Cl)ccc1
NCGC00379060-01	Clc1c(C(=O)Nc2c(C(=O)NC3CCN(S(=O)(=O)C)CC3)[nH]nc2)c(Cl)ccc1	5.0	Active	CDK1/2 Inhibitor	0.0	1	NVP-LCQ195	363678333.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	44.2338096015	Clc1c(C(=O)Nc2c(C(=O)NC3CCN(S(=O)(=O)C)CC3)[nH]nc2)c(Cl)ccc1	Clc1c(C(=O)Nc2c(C(=O)NC3CCN(S(=O)(=O)C)CC3)[nH]nc2)c(Cl)ccc1
NCGC00263091-15	Clc1c(C(=O)Nc2c(C(=O)NC3CCNCC3)n[nH]c2)c(Cl)ccc1		Inactive	CDK1/2/9 Inhibitor		1	AT-7519	377020489.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Clc1c(C(=O)Nc2c(C(=O)NC3CCNCC3)n[nH]c2)c(Cl)ccc1	Clc1c(C(=O)Nc2c(C(=O)NC3CCNCC3)n[nH]c2)c(Cl)ccc1
NCGC00345858-03	Clc1c(C(=O)Nc2c(F)ccc(Oc3nc4sc(NC(=O)C5CC5)nc4cc3)c2)cccc1C1(C#N)CC1		Inactive	VEGFR-2 Inhibitor		1	Takeda-6d	384568772.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C(=O)Nc2c(F)ccc(Oc3nc4sc(NC(=O)C5CC5)nc4cc3)c2)cccc1C1(C#N)CC1	Clc1c(C(=O)Nc2c(F)ccc(Oc3nc4sc(NC(=O)C5CC5)nc4cc3)c2)cccc1C1(C#N)CC1
NCGC00386883-01	Clc1c(C(=O)Nc2cc(C#N)c(Sc3ccc(OC)cc3)cc2)cccc1		Inactive			1	NCGC00386883-01	363680479.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C(=O)Nc2cc(C#N)c(Sc3ccc(OC)cc3)cc2)cccc1	Clc1c(C(=O)Nc2cc(C#N)c(Sc3ccc(OC)cc3)cc2)cccc1
NCGC00387038-01	Clc1c(C(=O)Nc2cc(NC(=O)C3CC3)ncc2)c(Cl)ccc1		Inactive	Tyk 2 Inhibitor		1	GDC-046	363680531.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	21.005956932	Clc1c(C(=O)Nc2cc(NC(=O)C3CC3)ncc2)c(Cl)ccc1	Clc1c(C(=O)Nc2cc(NC(=O)C3CC3)ncc2)c(Cl)ccc1
NCGC00263200-02	Clc1c(C(=O)Nc2cc(Nc3nc(N)nc(C)c3)ncc2)c(Cl)ccc1		Inactive	Tyk 2 Inhibitor		1	RO495	377020413.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Clc1c(C(=O)Nc2cc(Nc3nc(N)nc(C)c3)ncc2)c(Cl)ccc1	Clc1c(C(=O)Nc2cc(Nc3nc(N)nc(C)c3)ncc2)c(Cl)ccc1
NCGC00242497-12&NCGC00242497-14	Clc1c(C(=O)Nc2cc(c(Cl)cc2)-c2ncccc2)ccc(S(=O)(=O)C)c1		Inactive	Hedgehog Antagonist		2	Vismodegib	405558608.0&384568500.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(C(=O)Nc2cc(c(Cl)cc2)-c2ncccc2)ccc(S(=O)(=O)C)c1	Clc1c(C(=O)Nc2cc(c(Cl)cc2)-c2ncccc2)ccc(S(=O)(=O)C)c1
NCGC00250384-02	Clc1c(C(=O)Nc2cc3-c4n(-c5ccc(F)cc5)nc(C(=O)N)c4CCc3cc2)cc(N2CCN(C)CC2)nc1	5.1999998	Active	IKK-beta Inhibitor	0.0	1	PHA-408	377020291.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.2	55.2439499738	Clc1c(C(=O)Nc2cc3-c4n(-c5ccc(F)cc5)nc(C(=O)N)c4CCc3cc2)cc(N2CCN(C)CC2)nc1	Clc1c(C(=O)Nc2cc3-c4n(-c5ccc(F)cc5)nc(C(=O)N)c4CCc3cc2)cc(N2CCN(C)CC2)nc1
NCGC00686697-01	Clc1c(C(=O)O)cc(-c2oc(/C=C\3/C(=O)N(Cc4ccccc4)C(=S)S/3)cc2)cc1		Inactive			1	4E2RCat	434147184.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	10.732584272	Clc1c(C(=O)O)cc(-c2oc(/C=C\3/C(=O)N(Cc4ccccc4)C(=S)S/3)cc2)cc1	Clc1c(C(=O)O)cc(-c2oc(/C=C\3/C(=O)N(Cc4ccccc4)C(=S)S/3)cc2)cc1
NCGC00387134-03	Clc1c(C(=O)O)cc(/N=C/2\S/C(=C\c3oc(-c4c([N+](=O)[O-])cc(C)c(C)c4)cc3)/C(=O)N\2)cc1		Inactive			1	PT1	377020318.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C(=O)O)cc(/N=C/2\S/C(=C\c3oc(-c4c([N+](=O)[O-])cc(C)c(C)c4)cc3)/C(=O)N\2)cc1	Clc1c(C(=O)O)cc(/N=C/2\S/C(=C\c3oc(-c4c([N+](=O)[O-])cc(C)c(C)c4)cc3)/C(=O)N\2)cc1
NCGC00025220-11	Clc1c(C(=O)O)ccc(Nc2nc(N[C@H](C(C)C)CO)nc3n(C(C)C)cnc23)c1		Inactive	CDK1/2/3/4/5 Inhibitor		1	Purvalanol B	384568058.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C(=O)O)ccc(Nc2nc(N[C@H](C(C)C)CO)nc3n(C(C)C)cnc23)c1	Clc1c(C(=O)O)ccc(Nc2nc(N[C@H](C(C)C)CO)nc3n(C(C)C)cnc23)c1
NCGC00183273-04	Clc1c(C(=O)OCCN(CC)CC)ccc(N)c1		Inactive	Sodium Channel Alpha Subunits; Brain (types I, Ii, Iii) Inhibitor		1	Chloroprocaine HCl	405558437.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C(=O)OCCN(CC)CC)ccc(N)c1	Clc1c(C(=O)OCCN(CC)CC)ccc(N)c1
NCGC00183104-02	Clc1c(C(=O)c2c(-n3c(CN(CC)CC)ncc3)ccc([N+](=O)[O-])c2)cccc1		Inactive			1	Nizofenone	170466022.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C(=O)c2c(-n3c(CN(CC)CC)ncc3)ccc([N+](=O)[O-])c2)cccc1	Clc1c(C(=O)c2c(-n3c(CN(CC)CC)ncc3)ccc([N+](=O)[O-])c2)cccc1
NCGC00263118-02	Clc1c(C(=O)c2c(NC(=O)N)c3c(o2)cc(OS(=O)(=O)C)cc3)ccc(Cl)c1		Inactive	Phosphodiesterase IIII (PDE4) Inhibitor		1	Lirimilast	384568602.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C(=O)c2c(NC(=O)N)c3c(o2)cc(OS(=O)(=O)C)cc3)ccc(Cl)c1	Clc1c(C(=O)c2c(NC(=O)N)c3c(o2)cc(OS(=O)(=O)C)cc3)ccc(Cl)c1
NCGC00510266-01	Clc1c(C(F)(F)F)cc(C(Nc2ncnc3c(C(=O)N)cccc23)CN2CCC2)cc1		Inactive	AKT Inhibitor		1	M2698	384569423.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C(F)(F)F)cc(C(Nc2ncnc3c(C(=O)N)cccc23)CN2CCC2)cc1	Clc1c(C(F)(F)F)cc(C(Nc2ncnc3c(C(=O)N)cccc23)CN2CCC2)cc1
NCGC00165865-03	Clc1c(C(F)(F)F)cc(C2(O)CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1		Inactive	Dopamine receptor Blocker		1	Penfluridol	363676646.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	-23.669538992	Clc1c(C(F)(F)F)cc(C2(O)CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1	Clc1c(C(F)(F)F)cc(C2(O)CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
NCGC00485097-01	Clc1c(C(F)(F)F)cc(NC(=O)CC(=O)C)cc1		Inactive	Glucose transporter Inhibitor		1	Fasentin	363681220.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C(F)(F)F)cc(NC(=O)CC(=O)C)cc1	Clc1c(C(F)(F)F)cc(NC(=O)CC(=O)C)cc1
NCGC00388375-02	Clc1c(C(F)(F)F)cc(NC(=O)NCC=2N(c3ccc(F)cc3)C(=O)c3c(N=2)cccc3)cc1		Inactive	Sonic hedgehog protein Antagonist		1	HhSignalingPathwayAntagonist	363680729.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C(F)(F)F)cc(NC(=O)NCC=2N(c3ccc(F)cc3)C(=O)c3c(N=2)cccc3)cc1	Clc1c(C(F)(F)F)cc(NC(=O)NCC=2N(c3ccc(F)cc3)C(=O)c3c(N=2)cccc3)cc1
NCGC00185743-02	Clc1c(C(F)(F)F)cc(NC(=O)Nc2ccc(Cl)cc2)cc1		Inactive			1	Cloflucarban	170465550.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C(F)(F)F)cc(NC(=O)Nc2ccc(Cl)cc2)cc1	Clc1c(C(F)(F)F)cc(NC(=O)Nc2ccc(Cl)cc2)cc1
NCGC00167488-08	Clc1c(C(F)(F)F)cc(NC(=O)Nc2ccc(Oc3cc(C(=O)NC)ncc3)cc2)cc1	5.5	Active	VEGFR-1/2/3 Inhibitor	0.0	1	Sorafenib	170465175.0	2019_NPC-3.2	SARS-CoV-2_CPE_SRI	3.0	42.9608090972	Clc1c(C(F)(F)F)cc(NC(=O)Nc2ccc(Oc3cc(C(=O)NC)ncc3)cc2)cc1.S(=O)(=O)(O)c1ccc(C)cc1	Clc1c(C(F)(F)F)cc(NC(=O)Nc2ccc(Oc3cc(C(=O)NC)ncc3)cc2)cc1.S(=O)(=O)(O)c1ccc(C)cc1
NCGC00384205-02	Clc1c(C(F)(F)F)cc(S(=O)(=O)N2CCN(C(=O)c3ccc(-n4c(C)ccn4)cc3)CC2)cc1		Inactive	E3 ubiquitin-protein ligase SMURF1 Inhibitor		1	A01	363679196.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C(F)(F)F)cc(S(=O)(=O)N2CCN(C(=O)c3ccc(-n4c(C)ccn4)cc3)CC2)cc1	Clc1c(C(F)(F)F)cc(S(=O)(=O)N2CCN(C(=O)c3ccc(-n4c(C)ccn4)cc3)CC2)cc1
NCGC00370871-01	Clc1c(C(F)(F)F)ccc(N2CCNCC2)n1		Inactive	Serotonin 2c (5-HT2c) receptor Agonist		1	Org 12962 hydrochloride	363677899.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	13.152134008	Clc1c(C(F)(F)F)ccc(N2CCNCC2)n1	Clc1c(C(F)(F)F)ccc(N2CCNCC2)n1
NCGC00247954-03	Clc1c(C(F)(F)F)cccc1C(=O)N[C@H]([C@H]1NCCCC1)c1ccccc1	4.9000001	Active	Glycine Transporter 1 (GlyT-1) Inhibitor	0.0	1	SSR-504734	384568521.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	69.0550724718	Clc1c(C(F)(F)F)cccc1C(=O)N[C@H]([C@H]1NCCCC1)c1ccccc1	Clc1c(C(F)(F)F)cccc1C(=O)N[C@H]([C@H]1NCCCC1)c1ccccc1
NCGC00161825-08	Clc1c(C(F)(F)F)cccc1CN(CC(c1ccccc1)c1ccccc1)CCCOc1cc(CC(=O)O)ccc1		Inactive	ABCA1 Expression Enhancer		1	GSK-3965	384568215.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	20.069375968	Clc1c(C(F)(F)F)cccc1CN(CC(c1ccccc1)c1ccccc1)CCCOc1cc(CC(=O)O)ccc1	Clc1c(C(F)(F)F)cccc1CN(CC(c1ccccc1)c1ccccc1)CCCOc1cc(CC(=O)O)ccc1
NCGC00421877-04	Clc1c(C(N(C(=O)[C@H]2N(c3nccc(C#N)c3)C(=O)CC2)c2cc(F)cnc2)C(=O)NC2CC(F)(F)C2)cccc1		Inactive			1	AG-120	384569229.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C(N(C(=O)[C@H]2N(c3nccc(C#N)c3)C(=O)CC2)c2cc(F)cnc2)C(=O)NC2CC(F)(F)C2)cccc1	Clc1c(C(N(C(=O)[C@H]2N(c3nccc(C#N)c3)C(=O)CC2)c2cc(F)cnc2)C(=O)NC2CC(F)(F)C2)cccc1
NCGC00137340-01	Clc1c(C(N2CCN(C)CC2)C2=C(O)n3nc(-c4occc4)nc3S2)ccc(Cl)c1		Inactive			1	NCGC00137340-01	24412723.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C(N2CCN(C)CC2)C2=C(O)n3nc(-c4occc4)nc3S2)ccc(Cl)c1	Clc1c(C(N2CCN(C)CC2)C2=C(O)n3nc(-c4occc4)nc3S2)ccc(Cl)c1
NCGC00137344-01	Clc1c(C(N2CCN(CCO)CC2)C2=C(O)n3nc(-c4occc4)nc3S2)ccc(Cl)c1		Inactive			1	NCGC00137344-01	24412727.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C(N2CCN(CCO)CC2)C2=C(O)n3nc(-c4occc4)nc3S2)ccc(Cl)c1	Clc1c(C(N2CCN(CCO)CC2)C2=C(O)n3nc(-c4occc4)nc3S2)ccc(Cl)c1
NCGC00181096-01	Clc1c(C(O)(CCN(C)C)c2ccccc2)cccc1		Inactive			1	Chlophedianol	144206265.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C(O)(CCN(C)C)c2ccccc2)cccc1	Clc1c(C(O)(CCN(C)C)c2ccccc2)cccc1
NCGC00016034-05	Clc1c(C(O)CNC(C)(C)C)cccc1		Inactive	Beta-2 adrenergic receptor Agonist		1	Tulobuterol hydrochloride	170465781.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1c(C(O)CNC(C)(C)C)cccc1.Cl	Clc1c(C(O)CNC(C)(C)C)cccc1.Cl
NCGC00167538-02	Clc1c(C(O)CNC(C)C)cccc1		Inactive	Beta-2 adrenergic receptor Agonist		1	Clorprenaline hydrochloride	170466032.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(C(O)CNC(C)C)cccc1.Cl	Clc1c(C(O)CNC(C)C)cccc1.Cl
NCGC00165816-04	Clc1c(C(OC(=O)Nc2c(-c3ccc(CSCCC(=O)O)cc3)onc2C)C)cccc1		Inactive	Lysophospholipid edg2 (LPA1)/edg7 (LPA3) Receptor Antagonist		1	KI-16425	384568287.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C(OC(=O)Nc2c(-c3ccc(CSCCC(=O)O)cc3)onc2C)C)cccc1	Clc1c(C(OC(=O)Nc2c(-c3ccc(CSCCC(=O)O)cc3)onc2C)C)cccc1
NCGC00386223-02	Clc1c(C(OC(=O)Nc2c(-c3ccc(CSCCC(=O)OC)cc3)onc2C)C)cccc1		Inactive	Lysophosphatidic acid receptor Edg-7 Antagonist		1	Ki16198	363680157.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C(OC(=O)Nc2c(-c3ccc(CSCCC(=O)OC)cc3)onc2C)C)cccc1	Clc1c(C(OC(=O)Nc2c(-c3ccc(CSCCC(=O)OC)cc3)onc2C)C)cccc1
NCGC00163778-09	Clc1c(C(OCC=C)Cn2cncc2)ccc(Cl)c1		Inactive	O75469|||Q9UJ26 REC20 - 20% relative effective concentration; the concentration of the test compound showing 20% of the agonistic activity of 1 _ 10_5 M rifampicin via hPXR		1	Imazalil sulfate	170466809.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(C(OCC=C)Cn2cncc2)ccc(Cl)c1.S(=O)(=O)(O)O	Clc1c(C(OCC=C)Cn2cncc2)ccc(Cl)c1.S(=O)(=O)(O)O
NCGC00381656-01	Clc1c(C(OCCC)c2[nH]c3c(C(=O)O)ccnc3c2)cccc1		Inactive			1	NCGC00381656-01	363679158.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C(OCCC)c2[nH]c3c(C(=O)O)ccnc3c2)cccc1	Clc1c(C(OCCC)c2[nH]c3c(C(=O)O)ccnc3c2)cccc1
NCGC00421826-01	Clc1c(C(OCCC2N(C)CCC2)c2[nH]c3c(C(=O)O)ccnc3c2)cccc1		Inactive			1	NCGC00421826-01	363681094.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C(OCCC2N(C)CCC2)c2[nH]c3c(C(=O)O)ccnc3c2)cccc1	Clc1c(C(OCCC2N(C)CCC2)c2[nH]c3c(C(=O)O)ccnc3c2)cccc1
NCGC00421948-01	Clc1c(C(OCCCN2CCCCC2)c2[nH]c3c(C(=O)O)ccnc3c2)cccc1		Inactive			1	NCGC00421948-01		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C(OCCCN2CCCCC2)c2[nH]c3c(C(=O)O)ccnc3c2)cccc1	Clc1c(C(OCCCN2CCCCC2)c2[nH]c3c(C(=O)O)ccnc3c2)cccc1
NCGC00414992-02	Clc1c(C(OCCN2CCC(F)(F)CC2)c2[nH]c3c(C(=O)O)ccnc3c2)cccc1		Inactive			1	NCGC00414992-02		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C(OCCN2CCC(F)(F)CC2)c2[nH]c3c(C(=O)O)ccnc3c2)cccc1	Clc1c(C(OCCN2CCC(F)(F)CC2)c2[nH]c3c(C(=O)O)ccnc3c2)cccc1
NCGC00479257-01&NCGC00479258-01	Clc1c(C(OCCN2CCCCC2)c2[nH]c3c(C(=O)O)ccnc3c2)cccc1		Inactive			2	NCGC00479257-01&NCGC00479258-01	434146920.0&434147151.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(C(OCCN2CCCCC2)c2[nH]c3c(C(=O)O)ccnc3c2)cccc1	Clc1c(C(OCCN2CCCCC2)c2[nH]c3c(C(=O)O)ccnc3c2)cccc1
NCGC00015233-07	Clc1c(C(OCc2c(Cl)cc(Cl)cc2)Cn2c[n+](C(c3ccc(Cl)cc3)c3ccc(Cl)cc3)cc2)ccc(Cl)c1		Inactive	CaMK-II Inhibitor		1	Calmidazolium chloride	384567828.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C(OCc2c(Cl)cc(Cl)cc2)Cn2c[n+](C(c3ccc(Cl)cc3)c3ccc(Cl)cc3)cc2)ccc(Cl)c1	Clc1c(C(OCc2c(Cl)cc(Cl)cc2)Cn2c[n+](C(c3ccc(Cl)cc3)c3ccc(Cl)cc3)cc2)ccc(Cl)c1
NCGC00018294-13	Clc1c(C(OCc2c(Cl)cc(Cl)cc2)Cn2cncc2)ccc(Cl)c1		Inactive	Aromatase Inhibitor		1	Miconazole nitrate	384568002.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	15.4083215759	Clc1c(C(OCc2c(Cl)cc(Cl)cc2)Cn2cncc2)ccc(Cl)c1	Clc1c(C(OCc2c(Cl)cc(Cl)cc2)Cn2cncc2)ccc(Cl)c1
NCGC00179642-03&NCGC00179642-05	Clc1c(C(OCc2c(Cl)cccc2Cl)Cn2cncc2)ccc(Cl)c1		Inactive	Antifungal Agent		2	Isoconazole nitrate	170466012.0&363676952.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(C(OCc2c(Cl)cccc2Cl)Cn2cncc2)ccc(Cl)c1	Clc1c(C(OCc2c(Cl)cccc2Cl)Cn2cncc2)ccc(Cl)c1
NCGC00018258-10&NCGC00018258-12	Clc1c(C(OCc2ccc(Cl)cc2)Cn2cncc2)ccc(Cl)c1		Inactive	Antifungal Agent		2	Econazole nitrate	170465422.0&384568000.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	16.9120602999&0.0	Clc1c(C(OCc2ccc(Cl)cc2)Cn2cncc2)ccc(Cl)c1.O=[N+](O)[O-]	Clc1c(C(OCc2ccc(Cl)cc2)Cn2cncc2)ccc(Cl)c1.O=[N+](O)[O-]&Clc1c(C(OCc2ccc(Cl)cc2)Cn2cncc2)ccc(Cl)c1
NCGC00253713-01	Clc1c(C(OCc2ccc(Sc3ccccc3)cc2)Cn2cncc2)ccc(Cl)c1		Inactive	Antifungal Agent		1	Fenticonazole nitrate	170466486.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	19.10902256	Clc1c(C(OCc2ccc(Sc3ccccc3)cc2)Cn2cncc2)ccc(Cl)c1	Clc1c(C(OCc2ccc(Sc3ccccc3)cc2)Cn2cncc2)ccc(Cl)c1
NCGC00018250-06	Clc1c(C(SCc2ccc(Cl)cc2)Cn2cncc2)ccc(Cl)c1		Inactive	Lanosterol 14-alpha demethylase Inhibitor		1	Sulconazole nitrate	170465344.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&11.996350364	Clc1c(C(SCc2ccc(Cl)cc2)Cn2cncc2)ccc(Cl)c1.O=[N+](O)[O-]	Clc1c(C(SCc2ccc(Cl)cc2)Cn2cncc2)ccc(Cl)c1.O=[N+](O)[O-]
NCGC00015251-13	Clc1c(C(n2cncc2)(c2ccccc2)c2ccccc2)cccc1		Inactive	Lanosterol 14alpha-demethylase Inhibitor		1	Clotrimazole	170464807.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	24.9120603&27.3368382919	Clc1c(C(n2cncc2)(c2ccccc2)c2ccccc2)cccc1	Clc1c(C(n2cncc2)(c2ccccc2)c2ccccc2)cccc1
NCGC00165909-10	Clc1c(C(n2nccc2)(c2ccccc2)c2ccccc2)cccc1		Inactive	Intermediate Conductance Channel Blocker		1	TRAM-34	384568298.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C(n2nccc2)(c2ccccc2)c2ccccc2)cccc1	Clc1c(C(n2nccc2)(c2ccccc2)c2ccccc2)cccc1
NCGC00505919-02	Clc1c(C)c(-c2c(-c3oc(F)cc3)sc3ncnc(O[C@H](C(=O)O)Cc4c(OCc5n(CC(F)(F)F)ncc5)cccc4)c23)ccc1OCCN1CCN(C)CC1		Inactive	Mcl-1 Inhibitor		1	S63845	384569318.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C)c(-c2c(-c3oc(F)cc3)sc3ncnc(O[C@H](C(=O)O)Cc4c(OCc5n(CC(F)(F)F)ncc5)cccc4)c23)ccc1OCCN1CCN(C)CC1	Clc1c(C)c(-c2c(-c3oc(F)cc3)sc3ncnc(O[C@H](C(=O)O)Cc4c(OCc5n(CC(F)(F)F)ncc5)cccc4)c23)ccc1OCCN1CCN(C)CC1
NCGC00384172-01	Clc1c(C)c(F)ccc1C(=O)Nc1c(N2CCN(C)CC2)ccc([N+](=O)[O-])c1		Inactive	Inhibitor of WDR5-MLL interaction. Not the mest WDR5-MLL Inhibitor available but this one offers a different chemotype.		1	WDR5-C47	363679175.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C)c(F)ccc1C(=O)Nc1c(N2CCN(C)CC2)ccc([N+](=O)[O-])c1	Clc1c(C)c(F)ccc1C(=O)Nc1c(N2CCN(C)CC2)ccc([N+](=O)[O-])c1
NCGC00378909-01	Clc1c(C)c(N2C(=O)N3[C@@H]([C@H](O)CC3)C2=O)ccc1C#N		Inactive	Androgen Receptor Agonist		1	BMS-564929	363678271.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C)c(N2C(=O)N3[C@@H]([C@H](O)CC3)C2=O)ccc1C#N	Clc1c(C)c(N2C(=O)N3[C@@H]([C@H](O)CC3)C2=O)ccc1C#N
NCGC00485476-01	Clc1c(C)c(N[C@H]([C@@H](O)C)c2oc(-c3ccc(C#N)cc3)nn2)ccc1C#N		Inactive	Androgen Receptor Modulator		1	RAD140	363681345.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C)c(N[C@H]([C@@H](O)C)c2oc(-c3ccc(C#N)cc3)nn2)ccc1C#N	Clc1c(C)c(N[C@H]([C@@H](O)C)c2oc(-c3ccc(C#N)cc3)nn2)ccc1C#N
NCGC00511352-01	Clc1c(C)c(S(=O)(=O)Nc2scc(CC(=O)N(CC)CC)n2)ccc1		Inactive	11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitor		1	BVT-14225	384569497.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C)c(S(=O)(=O)Nc2scc(CC(=O)N(CC)CC)n2)ccc1	Clc1c(C)c(S(=O)(=O)Nc2scc(CC(=O)N(CC)CC)n2)ccc1
NCGC00386635-01	Clc1c(C)c(S(=O)(=O)Nc2scc(CC(=O)N3CCN(C)CC3)n2)ccc1		Inactive	11-beta-hydroxysteroid dehydrogenase 1 Inhibitor		1	BVT 2733 hydrochloride	363680364.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C)c(S(=O)(=O)Nc2scc(CC(=O)N3CCN(C)CC3)n2)ccc1	Clc1c(C)c(S(=O)(=O)Nc2scc(CC(=O)N3CCN(C)CC3)n2)ccc1
NCGC00522639-01	Clc1c(C)c(S(=O)(=O)Nc2scc(CCN3C(=O)COCC3)n2)ccc1		Inactive	11-beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitor		1	BVT-3498	384569535.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C)c(S(=O)(=O)Nc2scc(CCN3C(=O)COCC3)n2)ccc1	Clc1c(C)c(S(=O)(=O)Nc2scc(CCN3C(=O)COCC3)n2)ccc1
NCGC00386662-01	Clc1c(C)cc(-c2n(Cc3ccc(C)cc3)nc(C(=O)N[C@@H]3C(C)(C)[C@H]4C[C@]3(C)CC4)c2)cc1		Inactive	Cannabinoid CB1 receptor Inverse Agonist		1	SR 144528	363680380.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C)cc(-c2n(Cc3ccc(C)cc3)nc(C(=O)N[C@@H]3C(C)(C)[C@H]4C[C@]3(C)CC4)c2)cc1	Clc1c(C)cc(-c2n(Cc3ccc(C)cc3)nc(C(=O)N[C@@H]3C(C)(C)[C@H]4C[C@]3(C)CC4)c2)cc1
NCGC00160431-02	Clc1c(C)cc(Nc2c(C(=O)O)cccc2)cc1		Inactive			1	2-[(4-Chloro-3-methylphenyl)amino]benzoic acid	405558671.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C)cc(Nc2c(C(=O)O)cccc2)cc1	Clc1c(C)cc(Nc2c(C(=O)O)cccc2)cc1
NCGC00159384-04	Clc1c(C)cc(O)c(C(C)C)c1		Inactive	Estrogen receptor Binding Agent		1	6-Chlorothymol	170465546.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(C)cc(O)c(C(C)C)c1	Clc1c(C)cc(O)c(C(C)C)c1
NCGC00091338-06	Clc1c(C)cc(O)cc1		Inactive			1	4-Chloro-3-methylphenol	170466134.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(C)cc(O)cc1	Clc1c(C)cc(O)cc1
NCGC00094614-06&NCGC00094614-07	Clc1c(C)cc(O)cc1C		Inactive			2	4-Chloro-3,5-dimethylphenol&CHLOROXYLENOL	170465503.0&434147232.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1c(C)cc(O)cc1C	Clc1c(C)cc(O)cc1C
MLS000051624-02	Clc1c(C)cc(OCC)c(S(=O)(=O)n2c3c(nc2)cccc3)c1		Inactive			1	MLS000051624-02	363676421.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C)cc(OCC)c(S(=O)(=O)n2c3c(nc2)cccc3)c1	Clc1c(C)cc(OCC)c(S(=O)(=O)n2c3c(nc2)cccc3)c1
NCGC00489906-01	Clc1c(C)cc(OCCCc2c3c(c(-c4c(C)n(C)nc4C)c(Cl)cc3)n3[C@H](C)CN(c4c5c(n(C)c4)ccc(C(=O)O)c5)C(=O)c23)cc1C		Inactive	Mcl-1 Inhibitor		1	VU0661013	384569286.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-11.36885246	Clc1c(C)cc(OCCCc2c3c(c(-c4c(C)n(C)nc4C)c(Cl)cc3)n3[C@H](C)CN(c4c5c(n(C)c4)ccc(C(=O)O)c5)C(=O)c23)cc1C	Clc1c(C)cc(OCCCc2c3c(c(-c4c(C)n(C)nc4C)c(Cl)cc3)n3[C@H](C)CN(c4c5c(n(C)c4)ccc(C(=O)O)c5)C(=O)c23)cc1C
NCGC00402261-03	Clc1c(C)ccc(C(=O)N2CCN(c3ccc([N+](=O)[O-])cc3)CC2)c1	4.9000001	Active		0.0	1	Filastatin	363681003.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	36.0	Clc1c(C)ccc(C(=O)N2CCN(c3ccc([N+](=O)[O-])cc3)CC2)c1	Clc1c(C)ccc(C(=O)N2CCN(c3ccc([N+](=O)[O-])cc3)CC2)c1
NCGC00522444-01	Clc1c(C)ccc(N(C(=O)C2CCN(C(=O)C)CC2)CCCN2CCC(Cc3ccc(C(=O)N)cc3)CC2)c1		Inactive			1	TAK-220	434147173.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C)ccc(N(C(=O)C2CCN(C(=O)C)CC2)CCCN2CCC(Cc3ccc(C(=O)N)cc3)CC2)c1	Clc1c(C)ccc(N(C(=O)C2CCN(C(=O)C)CC2)CCCN2CCC(Cc3ccc(C(=O)N)cc3)CC2)c1
NCGC00510347-01	Clc1c(C)ccc(NC(=O)NCc2cc3c(C(=O)N(C4C(=O)NC(=O)CC4)C3)cc2)c1		Inactive			1	CC-885	384569427.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C)ccc(NC(=O)NCc2cc3c(C(=O)N(C4C(=O)NC(=O)CC4)C3)cc2)c1	Clc1c(C)ccc(NC(=O)NCc2cc3c(C(=O)N(C4C(=O)NC(=O)CC4)C3)cc2)c1
NCGC00188476-02	Clc1c(C)ccc(NS(=O)(=O)c2c(Cl)cc3c(NC(=O)CC3)c2)c1		Inactive			1	NCGC00188476-02	99431212.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C)ccc(NS(=O)(=O)c2c(Cl)cc3c(NC(=O)CC3)c2)c1	Clc1c(C)ccc(NS(=O)(=O)c2c(Cl)cc3c(NC(=O)CC3)c2)c1
NCGC00188481-04	Clc1c(C)ccc(NS(=O)(=O)c2c(F)cc3NC(=O)CCc3c2)c1		Inactive			1	NCGC00188481-04	377020496.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C)ccc(NS(=O)(=O)c2c(F)cc3NC(=O)CCc3c2)c1	Clc1c(C)ccc(NS(=O)(=O)c2c(F)cc3NC(=O)CCc3c2)c1
NCGC00189368-03	Clc1c(C)ccc(NS(=O)(=O)c2c(N[C@H](CO)C)cc3NC(=O)CCc3c2)c1		Inactive			1	NCGC00189368-03	377020436.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C)ccc(NS(=O)(=O)c2c(N[C@H](CO)C)cc3NC(=O)CCc3c2)c1	Clc1c(C)ccc(NS(=O)(=O)c2c(N[C@H](CO)C)cc3NC(=O)CCc3c2)c1
NCGC00103791-01	Clc1c(C)ccc(Nc2ncc(C(=O)N3CCN(c4ccc(F)cc4)CC3)c3c2cccc3)c1		Inactive			1	NCGC00103791-01	24267136.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C)ccc(Nc2ncc(C(=O)N3CCN(c4ccc(F)cc4)CC3)c3c2cccc3)c1	Clc1c(C)ccc(Nc2ncc(C(=O)N3CCN(c4ccc(F)cc4)CC3)c3c2cccc3)c1
NCGC00386930-01	Clc1c(C)nc2sc(C(=O)NCc3ccncc3)c(N)c2c1C		Inactive			1	NCGC00386930-01	363680514.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C)nc2sc(C(=O)NCc3ccncc3)c(N)c2c1C	Clc1c(C)nc2sc(C(=O)NCc3ccncc3)c(N)c2c1C
NCGC00492447-02	Clc1c(C2(C)CC2)cc(NCC(=O)N2CCN(C3CN(C(=O)C=C)C3)CC2)c(O)c1		Inactive	KRAS (G12C) Inhibitor		1	ARS-853	384569288.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C2(C)CC2)cc(NCC(=O)N2CCN(C3CN(C(=O)C=C)C3)CC2)c(O)c1	Clc1c(C2(C)CC2)cc(NCC(=O)N2CCN(C3CN(C(=O)C=C)C3)CC2)c(O)c1
NCGC00485971-01	Clc1c(C2(Cn3ncnc3)OC(COc3ccc(N4CCN(c5ccc(N6C(=O)N(C(C(O)C)C)N=C6)cc5)CC4)cc3)CO2)ccc(Cl)c1	5.5	Active	P-glycoprotein 1 Inhibitor	0.0	1	Itraconazole metabolite Hydroxy Itraconazole	363681452.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	2.2	38.418236734	Clc1c(C2(Cn3ncnc3)OC(COc3ccc(N4CCN(c5ccc(N6C(=O)N(C(C(O)C)C)N=C6)cc5)CC4)cc3)CO2)ccc(Cl)c1	Clc1c(C2(Cn3ncnc3)OC(COc3ccc(N4CCN(c5ccc(N6C(=O)N(C(C(O)C)C)N=C6)cc5)CC4)cc3)CO2)ccc(Cl)c1
NCGC00018268-05&NCGC00018268-08	Clc1c(C2(Cn3ncnc3)OC(COc3ccc(N4CCN(c5ccc(N6C(=O)N(C(CC)C)N=C6)cc5)CC4)cc3)CO2)ccc(Cl)c1		Inactive	cytochrome inhibitor		2	Itraconazole	434146971.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&18.3232890364&15.0	Clc1c(C2(Cn3ncnc3)OC(COc3ccc(N4CCN(c5ccc(N6C(=O)N(C(CC)C)N=C6)cc5)CC4)cc3)CO2)ccc(Cl)c1	Clc1c(C2(Cn3ncnc3)OC(COc3ccc(N4CCN(c5ccc(N6C(=O)N(C(CC)C)N=C6)cc5)CC4)cc3)CO2)ccc(Cl)c1
NCGC00379110-01	Clc1c(C2(c3ccc(F)cc3)Oc3c(O2)cc(C(=O)N2CCOCC2)c(F)c3)ccc(Cl)c1	4.9000001	Active	Cannabinoid CB1 receptor Inverse Agonist	0.0	1	TC-C 14G	363678360.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	41.4192158592	Clc1c(C2(c3ccc(F)cc3)Oc3c(O2)cc(C(=O)N2CCOCC2)c(F)c3)ccc(Cl)c1	Clc1c(C2(c3ccc(F)cc3)Oc3c(O2)cc(C(=O)N2CCOCC2)c(F)c3)ccc(Cl)c1
NCGC00253606-01	Clc1c(C23OCC(C)N2CC(=O)Nc2c3cc(Cl)cc2)cccc1		Inactive			1	Mexazolam	170465840.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(C23OCC(C)N2CC(=O)Nc2c3cc(Cl)cc2)cccc1	Clc1c(C23OCC(C)N2CC(=O)Nc2c3cc(Cl)cc2)cccc1
NCGC00249917-01	Clc1c(C23OCCN2CC(=O)Nc2c3cc(Cl)cc2)cccc1		Inactive	GABA-A receptor; benzodiazepine site Agonist		1	Cloxazolam	170465787.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C23OCCN2CC(=O)Nc2c3cc(Cl)cc2)cccc1	Clc1c(C23OCCN2CC(=O)Nc2c3cc(Cl)cc2)cccc1
NCGC00015949-07	Clc1c(C2=C(c3c4c(n(C)c3)cccc4)C(=O)NC2=O)ccc(Cl)c1		Inactive			1	SB216763		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C2=C(c3c4c(n(C)c3)cccc4)C(=O)NC2=O)ccc(Cl)c1	Clc1c(C2=C(c3c4c(n(C)c3)cccc4)C(=O)NC2=O)ccc(Cl)c1
NCGC00183008-01	Clc1c(C2=NC(C)c3n(c(C)nn3)-c3sc(CCc4ccc(CC(C)C)cc4)cc23)cccc1		Inactive	Interleukin-5 Inhibitor		1	Israpafant	144206851.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(C2=NC(C)c3n(c(C)nn3)-c3sc(CCc4ccc(CC(C)C)cc4)cc23)cccc1	Clc1c(C2=NC(C)c3n(c(C)nn3)-c3sc(CCc4ccc(CC(C)C)cc4)cc23)cccc1
NCGC00390699-04	Clc1c(C2=NC3=C(C)NNC3=Nc3c2cc(F)c(OC)c3)cccc1		Inactive	VEGFR-3 Inhibitor		1	R-1530	377020209.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C2=NC3=C(C)NNC3=Nc3c2cc(F)c(OC)c3)cccc1	Clc1c(C2=NC3=C(C)NNC3=Nc3c2cc(F)c(OC)c3)cccc1
NCGC00371636-03	Clc1c(C2=NCC(=O)N(C)c3c2cc(Cl)cc3)cccc1		Inactive			1	Diclazepam	363678074.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C2=NCC(=O)N(C)c3c2cc(Cl)cc3)cccc1	Clc1c(C2=NCC(=O)N(C)c3c2cc(Cl)cc3)cccc1
NCGC00182031-05	Clc1c(C2=NCc3n(c(C)nn3)-c3sc(CC)cc23)cccc1		Inactive	GABA-A receptor Agonist		1	Etizolam	405558675.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C2=NCc3n(c(C)nn3)-c3sc(CC)cc23)cccc1	Clc1c(C2=NCc3n(c(C)nn3)-c3sc(CC)cc23)cccc1
NCGC00092377-04	Clc1c(C2=NCc3n(c(C)nn3)-c3sc(CCC(=O)N4CCOCC4)cc23)cccc1		Inactive	Platelet activating factor receptor Inhibitor		1	Apafant	170466052.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C2=NCc3n(c(C)nn3)-c3sc(CCC(=O)N4CCOCC4)cc23)cccc1	Clc1c(C2=NCc3n(c(C)nn3)-c3sc(CCC(=O)N4CCOCC4)cc23)cccc1
NCGC00485016-01	Clc1c(C2=NCc3n(c(CO)nn3)-c3c2cc(Cl)cc3)cccc1		Inactive	GABA-A receptor; anion channel Agonist		1	Î±-Hydroxytriazolam	363681187.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C2=NCc3n(c(CO)nn3)-c3c2cc(Cl)cc3)cccc1	Clc1c(C2=NCc3n(c(CO)nn3)-c3c2cc(Cl)cc3)cccc1
NCGC00165957-07	Clc1c(C2C(C(=O)OCC)=C(COCCN)NC(C)=C2C(=O)OC)cccc1	4.9000001	Active		0.0	1	Amlodipine	225144262.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	102.3418226992	Clc1c(C2C(C(=O)OCC)=C(COCCN)NC(C)=C2C(=O)OC)cccc1	Clc1c(C2C(C(=O)OCC)=C(COCCN)NC(C)=C2C(=O)OC)cccc1
NCGC00390661-01	Clc1c(C2CC2)cc(NCC(=O)N2CCN(C3CN(C(=O)C=C)C3)CC2)c(O)c1		Inactive	GTPase KRas Inhibitor		1	K-Ras G12C-IN-2	363680962.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C2CC2)cc(NCC(=O)N2CCN(C3CN(C(=O)C=C)C3)CC2)c(O)c1	Clc1c(C2CC2)cc(NCC(=O)N2CCN(C3CN(C(=O)C=C)C3)CC2)c(O)c1
NCGC00538320-01	Clc1c(C2CCCCC2)cc2c(C(C(=O)O)CC2)c1		Inactive	Prostamide/prostaglandin F synthase Inhibitor		1	NCGC00538320-01	405558505.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C2CCCCC2)cc2c(C(C(=O)O)CC2)c1	Clc1c(C2CCCCC2)cc2c(C(C(=O)O)CC2)c1
NCGC00379183-01	Clc1c(C2CCCCC2)ccc(-c2n(-c3cc(OC)ccc3)nc(C(=O)O)c2)c1		Inactive	Lysophosphatidic acid receptor 5 Antagonist		1	TC LPA5 4	363678404.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C2CCCCC2)ccc(-c2n(-c3cc(OC)ccc3)nc(C(=O)O)c2)c1	Clc1c(C2CCCCC2)ccc(-c2n(-c3cc(OC)ccc3)nc(C(=O)O)c2)c1
NCGC00402352-02	Clc1c(C2N(C(=O)CCCC)c3c(NC4=C2C(=O)CCC4)cccc3)cccc1		Inactive	Transcription factor p65 Inhibitor		1	RBC10	363681036.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(C2N(C(=O)CCCC)c3c(NC4=C2C(=O)CCC4)cccc3)cccc1	Clc1c(C2N(C(=O)CCCC)c3c(NC4=C2C(=O)CCC4)cccc3)cccc1
NCGC00238624-07	Clc1c(C2NC(Nc3oc4c(n3)cccc4)=NC3=C2C(=O)CCC3)n[nH]c1		Inactive	GALK Inhibitor		1	NCGC00238624	163827054.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C2NC(Nc3oc4c(n3)cccc4)=NC3=C2C(=O)CCC3)n[nH]c1	Clc1c(C2NC(Nc3oc4c(n3)cccc4)=NC3=C2C(=O)CCC3)n[nH]c1
NCGC00164544-02	Clc1c(C2S/C(=C(/C#N)\n3cncc3)/SC2)cccc1		Inactive	Lanosterol 14-alpha demethylase Inhibitor		1	Lanoconazole	170465886.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(C2S/C(=C(/C#N)\n3cncc3)/SC2)cccc1	Clc1c(C2S/C(=C(/C#N)\n3cncc3)/SC2)cccc1
NCGC00507861-01	Clc1c(C=2C(=O)N(CC)c3nc(NCCC4CCN(C)CC4)ncc3C=2)ccc(-c2nc(C)cnc2)c1		Inactive	p21-Activated Kinase 1/2 (PAK1/2) Inhibitor		1	FRAX-1036	384569337.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.7512690319	Clc1c(C=2C(=O)N(CC)c3nc(NCCC4CCN(C)CC4)ncc3C=2)ccc(-c2nc(C)cnc2)c1	Clc1c(C=2C(=O)N(CC)c3nc(NCCC4CCN(C)CC4)ncc3C=2)ccc(-c2nc(C)cnc2)c1
NCGC00379255-03	Clc1c(C=2C(=O)N(CC)c3nc(Nc4cc(F)c(N5CCNCC5)cc4)ncc3C=2)ccc(Cl)c1		Inactive	p21-Activated Kinase 1 (PAK1) Inhibitor		1	FRAX-486	384569097.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	20.777574308	Clc1c(C=2C(=O)N(CC)c3nc(Nc4cc(F)c(N5CCNCC5)cc4)ncc3C=2)ccc(Cl)c1	Clc1c(C=2C(=O)N(CC)c3nc(Nc4cc(F)c(N5CCNCC5)cc4)ncc3C=2)ccc(Cl)c1
NCGC00389582-02	Clc1c(C=2C(=O)N(CC)c3nc(Nc4ccc(N5CCN(C)CC5)cc4)ncc3C=2)ccc(-c2scnc2)c1		Inactive	p21-Activated Kinase 1/2 (PAK1/2) Inhibitor		1	FRAX-597	363680807.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(C=2C(=O)N(CC)c3nc(Nc4ccc(N5CCN(C)CC5)cc4)ncc3C=2)ccc(-c2scnc2)c1	Clc1c(C=2C(=O)N(CC)c3nc(Nc4ccc(N5CCN(C)CC5)cc4)ncc3C=2)ccc(-c2scnc2)c1
NCGC00250401-11	Clc1c(C=2Oc3c([C@H]4[C@@H](O)CN(C)CC4)c(O)cc(O)c3C(=O)C=2)cccc1		Inactive	CDK1/2/4/6/7/9 Inhibitor		1	Flavopiridol	384568550.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		Clc1c(C=2Oc3c([C@H]4[C@@H](O)CN(C)CC4)c(O)cc(O)c3C(=O)C=2)cccc1	Clc1c(C=2Oc3c([C@H]4[C@@H](O)CN(C)CC4)c(O)cc(O)c3C(=O)C=2)cccc1
NCGC00387877-01	Clc1c(C=2Oc3c([C@H]4[C@H](CO)N(C)CC4)c(O)cc(O)c3C(=O)C=2)ccc(C(F)(F)F)c1	5.0	Active	CDK1/2/4/9 Inhibitor	0.0	1	Voruciclib	363680717.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	79.8215097736	Clc1c(C=2Oc3c([C@H]4[C@H](CO)N(C)CC4)c(O)cc(O)c3C(=O)C=2)ccc(C(F)(F)F)c1	Clc1c(C=2Oc3c([C@H]4[C@H](CO)N(C)CC4)c(O)cc(O)c3C(=O)C=2)ccc(C(F)(F)F)c1
NCGC00389231-01	Clc1c(C=2Oc3c(c(O)cc(O)c3C(=O)C=2)C2C(CO)N(C)CC2)cccc1		Inactive	CDK1/4/9 Inhibitor		1	Riviciclib (P276-00)	377020350.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.606548616	Clc1c(C=2Oc3c(c(O)cc(O)c3C(=O)C=2)C2C(CO)N(C)CC2)cccc1	Clc1c(C=2Oc3c(c(O)cc(O)c3C(=O)C=2)C2C(CO)N(C)CC2)cccc1
NCGC00015469-09	Clc1c(CC(=O)NC(=N)N)c(Cl)ccc1		Inactive	Alpha-2a adrenergic receptor Agonist		1	Guanfacine hydrochloride	170465381.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(CC(=O)NC(=N)N)c(Cl)ccc1.Cl	Clc1c(CC(=O)NC(=N)N)c(Cl)ccc1.Cl
NCGC00345801-04	Clc1c(CC(=O)O)c(N(C)C)nc(Cc2ccc(NC(=O)c3cc4c(cc3)cccc4)cc2)n1		Inactive	prostaglandin D2 CRTH2 inhibitor		1	AP-768	363677364.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(CC(=O)O)c(N(C)C)nc(Cc2ccc(NC(=O)c3cc4c(cc3)cccc4)cc2)n1	Clc1c(CC(=O)O)c(N(C)C)nc(Cc2ccc(NC(=O)c3cc4c(cc3)cccc4)cc2)n1
NCGC00250388-04	Clc1c(CCC(N)(CO)CO)ccc(Sc2cc(OCc3ccccc3)ccc2)c1		Inactive	S1P1/3/4 Agonist		1	KRP-203	384568541.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.37188336	Clc1c(CCC(N)(CO)CO)ccc(Sc2cc(OCc3ccccc3)ccc2)c1	Clc1c(CCC(N)(CO)CO)ccc(Sc2cc(OCc3ccccc3)ccc2)c1
NCGC00344508-02	Clc1c(CCCN[C@H](C)c2cc(OC)ccc2)cccc1	4.9000001	Active	Calcium-Sensing Receptor (CaSR) Agonist	0.0	1	NPS-R568	384568718.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	99.4333425644	Clc1c(CCCN[C@H](C)c2cc(OC)ccc2)cccc1	Clc1c(CCCN[C@H](C)c2cc(OC)ccc2)cccc1
NCGC00263539-01	Clc1c(CCN2CCN(c3nsc4c3cccc4)CC2)cc2c(NC(=O)C2)c1		Inactive	5-HT2A Antagonists?		1	Ziprasidone	170465342.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(CCN2CCN(c3nsc4c3cccc4)CC2)cc2c(NC(=O)C2)c1	Clc1c(CCN2CCN(c3nsc4c3cccc4)CC2)cc2c(NC(=O)C2)c1
NCGC00386643-01	Clc1c(CCNC(=O)c2cc(NC(=O)c3cc(Cl)ccc3)c(N3CCN(C(=O)NCC)CCC3)cc2)ccc(Cl)c1		Inactive	C-X-C chemokine receptor type 3 Antagonist		1	CXCR3 Antagonist 6c	363680370.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(CCNC(=O)c2cc(NC(=O)c3cc(Cl)ccc3)c(N3CCN(C(=O)NCC)CCC3)cc2)ccc(Cl)c1	Clc1c(CCNC(=O)c2cc(NC(=O)c3cc(Cl)ccc3)c(N3CCN(C(=O)NCC)CCC3)cc2)ccc(Cl)c1
NCGC00378821-01	Clc1c(CN(CC#C)c2ccc(C(=O)NCc3cnccc3)cc2)cc2C(=O)N(C)C(CN3CCN(C)CC3)=Nc2c1		Inactive	Nicotinamide phosphoribosyltransferase Inhibitor		1	CB 300919	363678220.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(CN(CC#C)c2ccc(C(=O)NCc3cnccc3)cc2)cc2C(=O)N(C)C(CN3CCN(C)CC3)=Nc2c1	Clc1c(CN(CC#C)c2ccc(C(=O)NCc3cnccc3)cc2)cc2C(=O)N(C)C(CN3CCN(C)CC3)=Nc2c1
NCGC00182980-01	Clc1c(CN(CC(=O)N2CCOCC2)C)c(NC(=O)c2ccccc2)ccc1		Inactive			1	Fominoben hydrochloride	144206774.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(CN(CC(=O)N2CCOCC2)C)c(NC(=O)c2ccccc2)ccc1.Cl	Clc1c(CN(CC(=O)N2CCOCC2)C)c(NC(=O)c2ccccc2)ccc1.Cl
NCGC00247668-03	Clc1c(CN2C(=O)/C(=N\OC(=O)C)/c3c2ccc(Cl)c3)cc(Cl)cc1	5.0500002	Active	Reversible, competitive Inhibitor of UCH-L1 deubiquitinase	0.0	1	LDN-57444	384568515.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&2.3	109.4476375082&103.2256150493	Clc1c(CN2C(=O)/C(=N\OC(=O)C)/c3c2ccc(Cl)c3)cc(Cl)cc1	Clc1c(CN2C(=O)/C(=N\OC(=O)C)/c3c2ccc(Cl)c3)cc(Cl)cc1
NCGC00480888-01	Clc1c(CN2C(=O)CSc3c2cc(C(=O)NCc2occc2)cc3)c(F)ccc1		Inactive			1	STING agonist G10	434146932.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(CN2C(=O)CSc3c2cc(C(=O)NCc2occc2)cc3)c(F)ccc1	Clc1c(CN2C(=O)CSc3c2cc(C(=O)NCc2occc2)cc3)c(F)ccc1
NCGC00485397-01	Clc1c(CN2CC3(C2)CCN(C(=O)Cc2nc4SC(C)=Cn4c2)CC3)ccc(-n2nccn2)c1		Inactive	Ghrelin receptor Inverse Agonist		1	PF-04628935	363681311.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(CN2CC3(C2)CCN(C(=O)Cc2nc4SC(C)=Cn4c2)CC3)ccc(-n2nccn2)c1	Clc1c(CN2CC3(C2)CCN(C(=O)Cc2nc4SC(C)=Cn4c2)CC3)ccc(-n2nccn2)c1
NCGC00016872-12&NCGC00016872-19	Clc1c(CN2Cc3c(scc3)CC2)cccc1		Inactive	P2Y12 (P2T) Antagonist		2	Ticlopidine hydrochloride	170464698.0&384567964.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	Clc1c(CN2Cc3c(scc3)CC2)cccc1	Clc1c(CN2Cc3c(scc3)CC2)cccc1
NCGC00387235-01	Clc1c(CNC(=O)c2cc3ncn(-c4c(C)ccc(C)c4)c3cc2)cccc1		Inactive	endosomal transport Activator		1	NAB 2	363680587.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(CNC(=O)c2cc3ncn(-c4c(C)ccc(C)c4)c3cc2)cccc1	Clc1c(CNC(=O)c2cc3ncn(-c4c(C)ccc(C)c4)c3cc2)cccc1
NCGC00160424-02	Clc1c(CNC(Cc2ccccc2)C)cccc1		Inactive			1	Clobenzorex hydrochloride	170465619.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(CNC(Cc2ccccc2)C)cccc1.Cl	Clc1c(CNC(Cc2ccccc2)C)cccc1.Cl
NCGC00378548-01	Clc1c(CNCC2CCC(CNCc3c(Cl)cccc3)CC2)cccc1	4.9499998	Active	7-dehydrocholesterol reductase Inhibitor	0.0	1	AY 9944 dihydrochloride	363678086.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	96.1166719175	Clc1c(CNCC2CCC(CNCc3c(Cl)cccc3)CC2)cccc1	Clc1c(CNCC2CCC(CNCc3c(Cl)cccc3)CC2)cccc1
NCGC00384191-01	Clc1c(CNc2nc(NC)nc(-c3ncccc3)c2)ccc(NS(=O)(=O)C)c1		Inactive	G-protein coupled receptor 39 Agonist		1	GPR39-C3	363679183.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(CNc2nc(NC)nc(-c3ncccc3)c2)ccc(NS(=O)(=O)C)c1	Clc1c(CNc2nc(NC)nc(-c3ncccc3)c2)ccc(NS(=O)(=O)C)c1
NCGC00181337-01&NCGC00181337-03	Clc1c(CO)ccc(Cl)c1		Inactive			2	2,4-Dichlorobenzyl alcohol	144206349.0&170465574.0	Anti-infectives&Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&0.0	Clc1c(CO)ccc(Cl)c1	Clc1c(CO)ccc(Cl)c1
NCGC00095125-15	Clc1c(CO)n(Cc2ccc(-c3c(-c4[nH]nnn4)cccc3)cc2)c(CCCC)n1		Inactive	Angiotensin II receptor Antagonist		1	Losartan potassium	434146997.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(CO)n(Cc2ccc(-c3c(-c4[nH]nnn4)cccc3)cc2)c(CCCC)n1	Clc1c(CO)n(Cc2ccc(-c3c(-c4[nH]nnn4)cccc3)cc2)c(CCCC)n1
NCGC00095125-05	Clc1c(CO)n(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c(CCCC)n1		Inactive	Angiotensin II receptor Antagonist		1	Losartan	170465135.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(CO)n(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c(CCCC)n1	Clc1c(CO)n(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c(CCCC)n1
NCGC00167430-04	Clc1c(COC(Cn2cncc2)c2c(Cl)cc(Cl)cc2)ccs1		Inactive	Antifungal Agent		1	Tioconazole	170465343.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	18.963730572&16.8556701	Clc1c(COC(Cn2cncc2)c2c(Cl)cc(Cl)cc2)ccs1	Clc1c(COC(Cn2cncc2)c2c(Cl)cc(Cl)cc2)ccs1
NCGC00386767-01	Clc1c(COC)c2c([C@H](c3[nH]ccn3)CC2)cc1		Inactive	Alpha-1a adrenergic receptor Partial Agonist		1	PF 3774076	363680441.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(COC)c2c([C@H](c3[nH]ccn3)CC2)cc1	Clc1c(COC)c2c([C@H](c3[nH]ccn3)CC2)cc1
NCGC00506875-01	Clc1c(COCCOCCCCCCNCC(O)c2cc(CO)c(O)cc2)c(Cl)ccc1		Inactive	adrenoceptor beta 2, surface Agonist		1	Vilanterol (GW642444; GW 642444X)	405558572.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(COCCOCCCCCCNCC(O)c2cc(CO)c(O)cc2)c(Cl)ccc1	Clc1c(COCCOCCCCCCNCC(O)c2cc(CO)c(O)cc2)c(Cl)ccc1
NCGC00346642-04	Clc1c(CS(=O)(=O)c2cc3/C(=C/c4c(C)c(C(=O)N5[C@@H](CN6CCCC6)CCC5)c(C)[nH]4)/C(=O)Nc3cc2)c(Cl)ccc1		Inactive	HGFR Inhibitor		1	PHA-665752	384568875.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-8.0554352519	Clc1c(CS(=O)(=O)c2cc3/C(=C/c4c(C)c(C(=O)N5[C@@H](CN6CCCC6)CCC5)c(C)[nH]4)/C(=O)Nc3cc2)c(Cl)ccc1	Clc1c(CS(=O)(=O)c2cc3/C(=C/c4c(C)c(C(=O)N5[C@@H](CN6CCCC6)CCC5)c(C)[nH]4)/C(=O)Nc3cc2)c(Cl)ccc1
NCGC00024567-03	Clc1c(C[N+](CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc2c(Cl)cccc2)(CC)CC)cccc1		Inactive	Acetylcholinesterase Inhibitor		1	Ambenonium chloride	170465386.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(C[N+](CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc2c(Cl)cccc2)(CC)CC)cccc1.[Cl-].[Cl-]	Clc1c(C[N+](CCNC(=O)C(=O)NCC[N+](CC)(CC)Cc2c(Cl)cccc2)(CC)CC)cccc1.[Cl-].[Cl-]
NCGC00389663-01	Clc1c(Cc2ccc(OC3COCC3)cc2)cc(C2C(O)C(O)C(O)C(CO)O2)cc1		Inactive	Sodium/glucose cotransporter 2 Antagonist		1	Empagliflozin (BI 10773)	405558611.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cc2ccc(OC3COCC3)cc2)cc(C2C(O)C(O)C(O)C(CO)O2)cc1	Clc1c(Cc2ccc(OC3COCC3)cc2)cc(C2C(O)C(O)C(O)C(CO)O2)cc1
NCGC00250402-05&NCGC00250402-09	Clc1c(Cc2ccc(OCC)cc2)cc([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1		Inactive	SGLT-2 Inhibitor		2	Dapagliflozin	384568551.0&405558733.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(Cc2ccc(OCC)cc2)cc([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1	Clc1c(Cc2ccc(OCC)cc2)cc([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1
NCGC00378889-01	Clc1c(Cc2ccc(OCC)cc2)cc([C@]23[C@H](O)[C@@H](O)[C@H](O)[C@](CO)(O2)CO3)cc1		Inactive	Sodium/glucose cotransporter 2 Inhibitor		1	PF-04971729	405558956.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cc2ccc(OCC)cc2)cc([C@]23[C@H](O)[C@@H](O)[C@H](O)[C@](CO)(O2)CO3)cc1	Clc1c(Cc2ccc(OCC)cc2)cc([C@]23[C@H](O)[C@@H](O)[C@H](O)[C@](CO)(O2)CO3)cc1
NCGC00016260-13	Clc1c(Cl)c(C(=O)C(=C)CC)ccc1OCC(=O)O		Inactive	Sodium/potassium-transporting ATPase subunit alpha-1 Inhibitor		1	Ethacrynic acid	170465426.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(Cl)c(C(=O)C(=C)CC)ccc1OCC(=O)O	Clc1c(Cl)c(C(=O)C(=C)CC)ccc1OCC(=O)O
NCGC00386265-04	Clc1c(Cl)c(Cl)c2C(=O)CC(=O)c2c1Cl		Inactive			1	TCID	434147128.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cl)c(Cl)c2C(=O)CC(=O)c2c1Cl	Clc1c(Cl)c(Cl)c2C(=O)CC(=O)c2c1Cl
NCGC00485900-01	Clc1c(Cl)c2C(=O)[C@@](C)(C3CCCC3)Cc2cc1OCC(=O)O		Inactive	Chloride intracellular channel protein 5 Inhibitor		1	R(+)-IAA-94	363681402.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Cl)c2C(=O)[C@@](C)(C3CCCC3)Cc2cc1OCC(=O)O	Clc1c(Cl)c2C(=O)[C@@](C)(C3CCCC3)Cc2cc1OCC(=O)O
NCGC00346885-02	Clc1c(Cl)cc(Cl)cc1-c1c(N)nc(N2CCN(C)CC2)nc1		Inactive	Nav1.2 (Brain Type II) Sodium Channel Blocker		1	Sipatrigine	384568962.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	31.59476162	Clc1c(Cl)cc(Cl)cc1-c1c(N)nc(N2CCN(C)CC2)nc1	Clc1c(Cl)cc(Cl)cc1-c1c(N)nc(N2CCN(C)CC2)nc1
NCGC00390222-01	Clc1c(Cl)cc(Nc2ncnc3c2cc(OC)c(OCC2CCCN(C)CCC2)c3)cc1F		Inactive			1	XL647	363680863.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	-8.505714284	Clc1c(Cl)cc(Nc2ncnc3c2cc(OC)c(OCC2CCCN(C)CCC2)c3)cc1F	Clc1c(Cl)cc(Nc2ncnc3c2cc(OC)c(OCC2CCCN(C)CCC2)c3)cc1F
NCGC00163886-05	Clc1c(Cl)cc(OP(=S)(OC)OC)c(Cl)c1		Inactive	Cholinesterases; ACHE & BCHE Inhibitor		1	Fenchlorphos	170466415.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cl)cc(OP(=S)(OC)OC)c(Cl)c1	Clc1c(Cl)cc(OP(=S)(OC)OC)c(Cl)c1
NCGC00016371-06&NCGC00016371-08	Clc1c(Cl)cc(S(=O)(=O)N)cc1S(=O)(=O)N		Inactive	Carbonic Anhydrase Inhibitor		2	Diclofenamide	363676482.0&405558546.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(Cl)cc(S(=O)(=O)N)cc1S(=O)(=O)N	Clc1c(Cl)cc(S(=O)(=O)N)cc1S(=O)(=O)N
NCGC00371000-01	Clc1c(Cl)cc2OCC(=O)N(CC(=O)N([C@@H](CN3CCCC3)c3ccc(-c4cc(C(=O)N)ccc4)cc3)C)c2c1		Inactive	Urotensin-2 receptor Antagonist		1	GSK 1562590 hydrochloride	363677986.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Cl)cc2OCC(=O)N(CC(=O)N([C@@H](CN3CCCC3)c3ccc(-c4cc(C(=O)N)ccc4)cc3)C)c2c1	Clc1c(Cl)cc2OCC(=O)N(CC(=O)N([C@@H](CN3CCCC3)c3ccc(-c4cc(C(=O)N)ccc4)cc3)C)c2c1
NCGC00387310-02	Clc1c(Cl)cc2c(-c3ccncc3)nnc(NC3CCCC3)c2c1	4.9000001	Active	Inhibitor of SUV420H1 and SUV420H2	0.0	1	A-196	384569158.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	43.9497926579	Clc1c(Cl)cc2c(-c3ccncc3)nnc(NC3CCCC3)c2c1	Clc1c(Cl)cc2c(-c3ccncc3)nnc(NC3CCCC3)c2c1
NCGC00386659-01	Clc1c(Cl)cc2nc(NC(C)(C)C)c(S(=O)(=O)C)nc2c1		Inactive	Glucagon-like peptide 1 receptor Agonist		1	GLP-1R agonist DMB	363680378.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	25.493714284	Clc1c(Cl)cc2nc(NC(C)(C)C)c(S(=O)(=O)C)nc2c1	Clc1c(Cl)cc2nc(NC(C)(C)C)c(S(=O)(=O)C)nc2c1
NCGC00378559-03	Clc1c(Cl)cc2nc(NC(C)C)n([C@@H]3[C@@H](O)[C@@H](O)[C@H](CO)O3)c2c1		Inactive	Serine/threonine protein kinase UL97 Inhibitor		1	Maribavir	434147105.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cl)cc2nc(NC(C)C)n([C@@H]3[C@@H](O)[C@@H](O)[C@H](CO)O3)c2c1	Clc1c(Cl)cc2nc(NC(C)C)n([C@@H]3[C@@H](O)[C@@H](O)[C@H](CO)O3)c2c1
NCGC00263128-02	Clc1c(Cl)cc2nc(c(NCCCCN(CC)CC)nc2c1)-c1sc(-c2sccc2)cc1	4.9000001	Active	CXCR1/CXCR2 Receptor Antagonist	0.0	1	PD-0220245	384568609.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	68.856499913	Clc1c(Cl)cc2nc(c(NCCCCN(CC)CC)nc2c1)-c1sc(-c2sccc2)cc1	Clc1c(Cl)cc2nc(c(NCCCCN(CC)CC)nc2c1)-c1sc(-c2sccc2)cc1
NCGC00092379-02	Clc1c(Cl)ccc(-c2c(-c3ccncc3)sc(N)n2)c1		Inactive			1	CGH 2466 dihydrochloride	377020164.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Cl)ccc(-c2c(-c3ccncc3)sc(N)n2)c1	Clc1c(Cl)ccc(-c2c(-c3ccncc3)sc(N)n2)c1
NCGC00408905-01	Clc1c(Cl)ccc(-c2c(F)cc(C3(C(=O)O)CC3)cc2)c1		Inactive	Gamma-secretase Modulator		1	CHF 5074	363681079.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Cl)ccc(-c2c(F)cc(C3(C(=O)O)CC3)cc2)c1	Clc1c(Cl)ccc(-c2c(F)cc(C3(C(=O)O)CC3)cc2)c1
NCGC00402263-03	Clc1c(Cl)ccc(-c2ccc(NC(=O)C3=C(O)c4c(S(=O)(=O)N3)cccc4)cc2)c1		Inactive	Prostaglandin E synthase Inhibitor		1	PF-9184	363681004.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Cl)ccc(-c2ccc(NC(=O)C3=C(O)c4c(S(=O)(=O)N3)cccc4)cc2)c1	Clc1c(Cl)ccc(-c2ccc(NC(=O)C3=C(O)c4c(S(=O)(=O)N3)cccc4)cc2)c1
NCGC00408862-01	Clc1c(Cl)ccc(-c2oc(C(=S)N3CCCCC3)cc2)c1		Inactive	root development Inhibitor		1	DFPM	363681068.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	11.0	Clc1c(Cl)ccc(-c2oc(C(=S)N3CCCCC3)cc2)c1	Clc1c(Cl)ccc(-c2oc(C(=S)N3CCCCC3)cc2)c1
NCGC00274083-01	Clc1c(Cl)ccc(C(=O)NC(C(=O)N(CCCOC)CCCCC)CCC(=O)O)c1		Inactive	Cholecystokinin A receptor Antagonist		1	Loxiglumide	170465971.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cl)ccc(C(=O)NC(C(=O)N(CCCOC)CCCCC)CCC(=O)O)c1	Clc1c(Cl)ccc(C(=O)NC(C(=O)N(CCCOC)CCCCC)CCC(=O)O)c1
NCGC00386282-01	Clc1c(Cl)ccc(C(=O)NC(CCC)C)c1		Inactive			1	NSC 405020	434147200.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cl)ccc(C(=O)NC(CCC)C)c1	Clc1c(Cl)ccc(C(=O)NC(CCC)C)c1
NCGC00387309-01	Clc1c(Cl)ccc(C=2[C@@H](N(C(=O)CO)CC)CN(/C(=N\C#N)/Nc3cc(OC(F)F)ccc3)N=2)c1	4.9000001	Active		0.0	1	NCGC00387309-01		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	45.8053316564	Clc1c(Cl)ccc(C=2[C@@H](N(C(=O)CO)CC)CN(/C(=N\C#N)/Nc3cc(OC(F)F)ccc3)N=2)c1	Clc1c(Cl)ccc(C=2[C@@H](N(C(=O)CO)CC)CN(/C(=N\C#N)/Nc3cc(OC(F)F)ccc3)N=2)c1
NCGC00386515-01	Clc1c(Cl)ccc(CC(=O)N(C)[C@@H]2[C@H](N3CCCC3)CCCC2)c1		Inactive	Kappa opioid receptor Agonist		1	U 50488 hydrochloride	363680314.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	33.126817848	Clc1c(Cl)ccc(CC(=O)N(C)[C@@H]2[C@H](N3CCCC3)CCCC2)c1	Clc1c(Cl)ccc(CC(=O)N(C)[C@@H]2[C@H](N3CCCC3)CCCC2)c1
NCGC00015465-10	Clc1c(Cl)ccc(CC(=O)N2C(CN3CCCC3)CN(C(=O)OC)CC2)c1		Inactive			1	GR 89696 fumarate		2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Cl)ccc(CC(=O)N2C(CN3CCCC3)CN(C(=O)OC)CC2)c1	Clc1c(Cl)ccc(CC(=O)N2C(CN3CCCC3)CN(C(=O)OC)CC2)c1
NCGC00024901-04	Clc1c(Cl)ccc(CCN(CCN(C)C)C)c1		Inactive	sigma Receptor Antagonist		1	BD-1047	384568035.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	22.793219576	Clc1c(Cl)ccc(CCN(CCN(C)C)C)c1	Clc1c(Cl)ccc(CCN(CCN(C)C)C)c1
NCGC00378958-02	Clc1c(Cl)ccc(CCNCCC(=O)N(CCNCCc2c3OCC(=O)Nc3c(O)cc2)C2CCCCC2)c1		Inactive			1	AZ505 (ditrifluoroacetate)		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Cl)ccc(CCNCCC(=O)N(CCNCCc2c3OCC(=O)Nc3c(O)cc2)C2CCCCC2)c1	Clc1c(Cl)ccc(CCNCCC(=O)N(CCNCCc2c3OCC(=O)Nc3c(O)cc2)C2CCCCC2)c1
NCGC00510481-01	Clc1c(Cl)ccc(CN2C(=O)OC3(C2)CCN(C(=O)/C=C/c2ccc(Cl)cc2)CC3)c1	4.9499998	Active	EBI2/GPR183 Agonist	0.0	1	GSK-682753A	384569444.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	79.2729558915	Clc1c(Cl)ccc(CN2C(=O)OC3(C2)CCN(C(=O)/C=C/c2ccc(Cl)cc2)CC3)c1	Clc1c(Cl)ccc(CN2C(=O)OC3(C2)CCN(C(=O)/C=C/c2ccc(Cl)cc2)CC3)c1
NCGC00538147-01	Clc1c(Cl)ccc(CNC(NC(=N)NCCCCCCCC)=N)c1		Inactive			1	NCGC00538147-01	405558439.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cl)ccc(CNC(NC(=N)NCCCCCCCC)=N)c1	Clc1c(Cl)ccc(CNC(NC(=N)NCCCCCCCC)=N)c1
NCGC00263143-07	Clc1c(Cl)ccc(CNc2n([C@H]3[C@H](O)[C@H](O)[C@@H](COCc4ccc(C#N)cc4)O3)c3ncnc(N)c3n2)c1		Inactive	Heat Shock Protein 70 (hsp70) Inhibitor		1	VER-155008	384568618.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cl)ccc(CNc2n([C@H]3[C@H](O)[C@H](O)[C@@H](COCc4ccc(C#N)cc4)O3)c3ncnc(N)c3n2)c1	Clc1c(Cl)ccc(CNc2n([C@H]3[C@H](O)[C@H](O)[C@@H](COCc4ccc(C#N)cc4)O3)c3ncnc(N)c3n2)c1
NCGC00163107-07	Clc1c(Cl)ccc(CO/N=C/c2c(-c3ccc(Cl)cc3)nc3SC=Cn23)c1		Inactive	Constitutive androstane receptor Agonist		1	CITCO	384568229.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cl)ccc(CO/N=C/c2c(-c3ccc(Cl)cc3)nc3SC=Cn23)c1	Clc1c(Cl)ccc(CO/N=C/c2c(-c3ccc(Cl)cc3)nc3SC=Cn23)c1
NCGC00371132-01	Clc1c(Cl)ccc(N2C(=O)C(Cl)=C(N3CCOCC3)C2=O)c1		Inactive	DNA repair protein RAD51 homolog 1 Inhibitor		1	RI-1	363678048.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Cl)ccc(N2C(=O)C(Cl)=C(N3CCOCC3)C2=O)c1	Clc1c(Cl)ccc(N2C(=O)C(Cl)=C(N3CCOCC3)C2=O)c1
NCGC00164034-05	Clc1c(Cl)ccc(NC(=O)Nc2ccc(Cl)cc2)c1		Inactive			1	Triclocarban	170465481.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	16.333581528&16.5	Clc1c(Cl)ccc(NC(=O)Nc2ccc(Cl)cc2)c1	Clc1c(Cl)ccc(NC(=O)Nc2ccc(Cl)cc2)c1
NCGC00378900-01	Clc1c(Cl)ccc(Nc2nc3c(c4nc(C5CCCCC5)[nH]c24)cccc3)c1		Inactive	Adenosine A3 receptor Positive Allosteric Modulator		1	LUF6000	363678266.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	27.7666666719	Clc1c(Cl)ccc(Nc2nc3c(c4nc(C5CCCCC5)[nH]c24)cccc3)c1	Clc1c(Cl)ccc(Nc2nc3c(c4nc(C5CCCCC5)[nH]c24)cccc3)c1
NCGC00408857-02	Clc1c(Cl)ccc(OCC2=NCCN2)c1		Inactive	Adrenergic receptor alpha-2 Antagonist		1	Fenmetozole	363681067.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Cl)ccc(OCC2=NCCN2)c1	Clc1c(Cl)ccc(OCC2=NCCN2)c1
NCGC00390601-01	Clc1c(Cl)ccc(S(=O)(=O)N2CCN(C[C@@H](Nc3ncnc4c(C)csc34)C)CC2)c1	4.9000001	Active	Lysophosphatidic acid receptor Edg-4 Antagonist	0.0	1	LPA2 antagonist 1	363680922.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	35.5	Clc1c(Cl)ccc(S(=O)(=O)N2CCN(C[C@@H](Nc3ncnc4c(C)csc34)C)CC2)c1	Clc1c(Cl)ccc(S(=O)(=O)N2CCN(C[C@@H](Nc3ncnc4c(C)csc34)C)CC2)c1
NCGC00485407-01	Clc1c(Cl)ccc([C@@H](NC([C@@H](O)C)c2cc(C[PH](=O)O)ccc2)C)c1		Inactive	GABA-B receptor Antagonist		1	CGP 55845 hydrochloride	363681320.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Cl)ccc([C@@H](NC([C@@H](O)C)c2cc(C[PH](=O)O)ccc2)C)c1	Clc1c(Cl)ccc([C@@H](NC([C@@H](O)C)c2cc(C[PH](=O)O)ccc2)C)c1
NCGC00092386-13&NCGC00092386-26	Clc1c(Cl)ccc([C@H]2c3c([C@@H](NC)CC2)cccc3)c1		Inactive	Selective Seratonin Reuptake Inhibitor (SSRI)		2	Sertraline hydrochloride	170465121.0&384568111.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	15.844788092&0.0&14.4409015919	Clc1c(Cl)ccc([C@H]2c3c([C@@H](NC)CC2)cccc3)c1.Cl	Clc1c(Cl)ccc([C@H]2c3c([C@@H](NC)CC2)cccc3)c1.Cl&Clc1c(Cl)ccc([C@H]2c3c([C@@H](NC)CC2)cccc3)c1
NCGC00263110-02	Clc1c(Cl)ccc([C@]2(CCCN3CCC(N(C(=O)C)C)(c4ccccc4)CC3)CN(C(=O)c3ccccc3)CCC2)c1		Inactive	Tachykinin NK3 Antagonist		1	Osanetant	363677208.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	-8.576092828	Clc1c(Cl)ccc([C@]2(CCCN3CCC(N(C(=O)C)C)(c4ccccc4)CC3)CN(C(=O)c3ccccc3)CCC2)c1	Clc1c(Cl)ccc([C@]2(CCCN3CCC(N(C(=O)C)C)(c4ccccc4)CC3)CN(C(=O)c3ccccc3)CCC2)c1
NCGC00370814-01	Clc1c(Cl)ccc([C@]2(CCCN3CCC(NC(=O)N(C)C)(c4ccccc4)CC3)CN(C(=O)c3ccccc3)CCC2)c1	4.9000001	Active		0.0	1	SSR 146977 hydrochloride	363677865.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	75.0847034519	Clc1c(Cl)ccc([C@]2(CCCN3CCC(NC(=O)N(C)C)(c4ccccc4)CC3)CN(C(=O)c3ccccc3)CCC2)c1	Clc1c(Cl)ccc([C@]2(CCCN3CCC(NC(=O)N(C)C)(c4ccccc4)CC3)CN(C(=O)c3ccccc3)CCC2)c1
NCGC00485472-01	Clc1c(Cl)ccc([C@]23[C@H](C2)CNC3)c1		Inactive			1	Amitifadine (hydrochloride)	363681341.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Cl)ccc([C@]23[C@H](C2)CNC3)c1	Clc1c(Cl)ccc([C@]23[C@H](C2)CNC3)c1
NCGC00161408-07	Clc1c(Cl)ccc2NC3=NC(=O)CN3Cc12		Inactive	Phosphodiesterase III (PDE3) Inhibitor		1	Anagrelide	384568206.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cl)ccc2NC3=NC(=O)CN3Cc12	Clc1c(Cl)ccc2NC3=NC(=O)CN3Cc12
NCGC00247665-04	Clc1c(Cl)ccc2Nc3n(cc(O)n3)Cc12		Inactive	Phosphodiesterase III (PDE3) inhibitor		1	Anagrelide hydrochloride	170465269.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cl)ccc2Nc3n(cc(O)n3)Cc12.Cl	Clc1c(Cl)ccc2Nc3n(cc(O)n3)Cc12.Cl
NCGC00345739-02	Clc1c(Cl)ccc2c(/C(/C#N)=C\N)c(C(=O)OCC)n(C)c12		Inactive	Clk1, Clk4 Inhibitor		1	KH-CB19	174007137.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cl)ccc2c(/C(/C#N)=C\N)c(C(=O)OCC)n(C)c12	Clc1c(Cl)ccc2c(/C(/C#N)=C\N)c(C(=O)OCC)n(C)c12
NCGC00015605-09&NCGC00015605-13	Clc1c(Cl)cccc1-c1c(N)nc(N)nn1		Inactive	Sodium Channel Blocker		2	Lamotrigine	170465024.0&384567872.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(Cl)cccc1-c1c(N)nc(N)nn1	Clc1c(Cl)cccc1-c1c(N)nc(N)nn1
NCGC00498442-01	Clc1c(Cl)cccc1-c1c(N)nc(N2CCC(N)(C)CC2)cn1		Inactive	Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitor		1	SHP-099	384569303.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cl)cccc1-c1c(N)nc(N2CCC(N)(C)CC2)cn1	Clc1c(Cl)cccc1-c1c(N)nc(N2CCC(N)(C)CC2)cn1
NCGC00347906-04	Clc1c(Cl)cccc1-c1n(Cc2cnccc2)nnn1		Inactive	P2X7 Receptor Antagonist		1	A 438079	363677718.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Cl)cccc1-c1n(Cc2cnccc2)nnn1	Clc1c(Cl)cccc1-c1n(Cc2cnccc2)nnn1
NCGC00384192-02	Clc1c(Cl)cccc1-c1nc(N)nc(NC2CC2)c1		Inactive	Tubulin alpha-4A chain Inhibitor		1	TH588	363679184.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Cl)cccc1-c1nc(N)nc(NC2CC2)c1	Clc1c(Cl)cccc1-c1nc(N)nc(NC2CC2)c1
NCGC00347909-06	Clc1c(Cl)cccc1-n1c(NCc2c(Oc3ncccc3)cccc2)nnn1		Inactive	P2X7 Receptor Antagonist		1	A-839977	363677719.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cl)cccc1-n1c(NCc2c(Oc3ncccc3)cccc2)nnn1	Clc1c(Cl)cccc1-n1c(NCc2c(Oc3ncccc3)cccc2)nnn1
NCGC00183830-01	Clc1c(Cl)cccc1C1C(C(=O)OC(C)C)=C(COC(=O)N)NC(C)=C1C(=O)OC	4.9000001	Active	Voltage-gated calcium channel Blocker	0.0	1	Lemildipine	144206840.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	46.9011356419	Clc1c(Cl)cccc1C1C(C(=O)OC(C)C)=C(COC(=O)N)NC(C)=C1C(=O)OC	Clc1c(Cl)cccc1C1C(C(=O)OC(C)C)=C(COC(=O)N)NC(C)=C1C(=O)OC
NCGC00015455-10	Clc1c(Cl)cccc1C1C(C(=O)OCC)=C(C)NC(C)=C1C(=O)OC		Inactive	Voltage-gated calcium channel alpha2/delta subunit 1 Inhibitor		1	Felodipine	170464849.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&20.658573028	Clc1c(Cl)cccc1C1C(C(=O)OCC)=C(C)NC(C)=C1C(=O)OC	Clc1c(Cl)cccc1C1C(C(=O)OCC)=C(C)NC(C)=C1C(=O)OC
NCGC00262928-01	Clc1c(Cl)cccc1C1C(C(=O)OCOC(=O)CCC)=C(C)NC(C)=C1C(=O)OC		Inactive	Voltage-gated L-type calcium channel Blocker		1	Clevidipine	170466066.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cl)cccc1C1C(C(=O)OCOC(=O)CCC)=C(C)NC(C)=C1C(=O)OC	Clc1c(Cl)cccc1C1C(C(=O)OCOC(=O)CCC)=C(C)NC(C)=C1C(=O)OC
NCGC00370952-01	Clc1c(Cl)cccc1N1CCN(C/C=C/CNC(=O)c2ccc(-c3ncccc3)cc2)CC1	4.9000001	Active	Dopamine D3 receptor Antagonist	0.0	1	PG 01037 dihydrochloride	363677953.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	52.773961595	Clc1c(Cl)cccc1N1CCN(C/C=C/CNC(=O)c2ccc(-c3ncccc3)cc2)CC1	Clc1c(Cl)cccc1N1CCN(C/C=C/CNC(=O)c2ccc(-c3ncccc3)cc2)CC1
NCGC00379014-01	Clc1c(Cl)cccc1N1CCN(CCC2CCC(NC(=O)N(C)C)CC2)CC1		Inactive	Serotonin 1a (5-HT1a) receptor Partial Agonist		1	Cariprazine	405558596.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cl)cccc1N1CCN(CCC2CCC(NC(=O)N(C)C)CC2)CC1	Clc1c(Cl)cccc1N1CCN(CCC2CCC(NC(=O)N(C)C)CC2)CC1
NCGC00370702-02	Clc1c(Cl)cccc1N1CCN(CCCCNC(=O)c2sc3c(c2)cccc3)CC1	4.9000001	Active	Dopamine D3 receptor Antagonist	0.0	1	FAUC-365	363677812.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	3.0	102.7692419497	Clc1c(Cl)cccc1N1CCN(CCCCNC(=O)c2sc3c(c2)cccc3)CC1	Clc1c(Cl)cccc1N1CCN(CCCCNC(=O)c2sc3c(c2)cccc3)CC1
NCGC00532501-01	Clc1c(Cl)cccc1N1CCN(CCCCOc2cc3N(COC(=O)CCCCCCCCCCC)C(=O)CCc3cc2)CC1		Inactive	Serotonin 1a (5-HT1a) receptor Partial Agonist		1	ARIPIPRAZOLE LAUROXIL	405558833.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cl)cccc1N1CCN(CCCCOc2cc3N(COC(=O)CCCCCCCCCCC)C(=O)CCc3cc2)CC1	Clc1c(Cl)cccc1N1CCN(CCCCOc2cc3N(COC(=O)CCCCCCCCCCC)C(=O)CCc3cc2)CC1
NCGC00164610-08	Clc1c(Cl)cccc1Oc1c(Cl)cc2nc(SC)[nH]c2c1		Inactive	Trichinella spiralis Inhibitor		1	Triclabendazole		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Cl)cccc1Oc1c(Cl)cc2nc(SC)[nH]c2c1	Clc1c(Cl)cccc1Oc1c(Cl)cc2nc(SC)[nH]c2c1
NCGC00379189-01	Clc1c(Cl)cccc1Sc1c([N+](=O)[O-])cc(C(=O)C)s1		Inactive			1	P005091	434147115.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	16.0194104919	Clc1c(Cl)cccc1Sc1c([N+](=O)[O-])cc(C(=O)C)s1	Clc1c(Cl)cccc1Sc1c([N+](=O)[O-])cc(C(=O)C)s1
NCGC00378927-02	Clc1c(Cn2c(-c3ccc(F)cc3)c3c(c(C(F)(F)F)ccc3)n2)ccc(F)c1		Inactive	Oxysterols receptor LXR-beta Agonist		1	LXR 623	363678282.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Cn2c(-c3ccc(F)cc3)c3c(c(C(F)(F)F)ccc3)n2)ccc(F)c1	Clc1c(Cn2c(-c3ccc(F)cc3)c3c(c(C(F)(F)F)ccc3)n2)ccc(F)c1
NCGC00263015-01	Clc1c(Cn2c(C)c(CN(CC(O)COc3ccc(Cl)cc3)C)c(C)n2)cccc1	4.9000001	Active	TLR4 (LPS) Inhibitor	0.0	1	NCGC00263015	137275919.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	38.020048604	Clc1c(Cn2c(C)c(CN(CC(O)COc3ccc(Cl)cc3)C)c(C)n2)cccc1	Clc1c(Cn2c(C)c(CN(CC(O)COc3ccc(Cl)cc3)C)c(C)n2)cccc1
NCGC00484074-01	Clc1c(Cn2nc(C(=O)NN)c3c2cccc3)ccc(Cl)c1		Inactive	germ cell development Inhibitor		1	Adjudin	363681166.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Cn2nc(C(=O)NN)c3c2cccc3)ccc(Cl)c1	Clc1c(Cn2nc(C(=O)NN)c3c2cccc3)ccc(Cl)c1
NCGC00015609-15	Clc1c(Cn2nc(C(=O)O)c3c2cccc3)ccc(Cl)c1		Inactive	Phosphotransferase (HK) (Trypanosoma brucei) Inhibitor		1	Lonidamine	384567874.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Cn2nc(C(=O)O)c3c2cccc3)ccc(Cl)c1	Clc1c(Cn2nc(C(=O)O)c3c2cccc3)ccc(Cl)c1
NCGC00386362-01	Clc1c(F)c(C(=O)N([C@H](CC#C)C=2N(Nc3ccccc3)C(=O)c3c(N=2)cc(Cl)cc3)CCCN)ccc1		Inactive	Kinesin-Like Spindle Protein Inhibitor		1	ARQ-621	363680233.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(F)c(C(=O)N([C@H](CC#C)C=2N(Nc3ccccc3)C(=O)c3c(N=2)cc(Cl)cc3)CCCN)ccc1	Clc1c(F)c(C(=O)N([C@H](CC#C)C=2N(Nc3ccccc3)C(=O)c3c(N=2)cc(Cl)cc3)CCCN)ccc1
NCGC00386315-02	Clc1c(F)c(C(=O)N2CCN(Cc3nc(Nc4sccn4)ccc3)CC2)ccc1		Inactive	Aurora kinase A Inhibitor		1	MK-8745	363680206.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(F)c(C(=O)N2CCN(Cc3nc(Nc4sccn4)ccc3)CC2)ccc1	Clc1c(F)c(C(=O)N2CCN(Cc3nc(Nc4sccn4)ccc3)CC2)ccc1
NCGC00346565-04&NCGC00346565-07&NCGC00346565-08	Clc1c(F)c(Cc2c(OC)cc3N([C@@H](C(C)C)CO)C=C(C(=O)O)C(=O)c3c2)ccc1		Inactive	HIV Integrase Inhibitor		3	Elvitegravir	405558598.0&384568842.0&434147209.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1c(F)c(Cc2c(OC)cc3N([C@@H](C(C)C)CO)C=C(C(=O)O)C(=O)c3c2)ccc1	Clc1c(F)c(Cc2c(OC)cc3N([C@@H](C(C)C)CO)C=C(C(=O)O)C(=O)c3c2)ccc1
NCGC00483922-01	Clc1c(F)c(Nc2ncnc3c2cc(OC(=O)N2[C@H](C)CN(C)CC2)c(OC)c3)ccc1		Inactive	EGFR Inhibitor		1	AZD-3759	363681141.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(F)c(Nc2ncnc3c2cc(OC(=O)N2[C@H](C)CN(C)CC2)c(OC)c3)ccc1	Clc1c(F)c(Nc2ncnc3c2cc(OC(=O)N2[C@H](C)CN(C)CC2)c(OC)c3)ccc1
NCGC00347284-02&NCGC00347284-03	Clc1c(F)c(Nc2ncnc3c2cc(OC)c(OCC2C[C@@H]4[C@@H](CN(C)C4)C2)c3)ccc1Cl		Inactive			2	XL647&XL-647	384568985.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	15.522147552&12.879334252	Clc1c(F)c(Nc2ncnc3c2cc(OC)c(OCC2C[C@@H]4[C@@H](CN(C)C4)C2)c3)ccc1Cl	Clc1c(F)c(Nc2ncnc3c2cc(OC)c(OCC2C[C@@H]4[C@@H](CN(C)C4)C2)c3)ccc1Cl
NCGC00386427-01	Clc1c(F)c(Nc2ncnc3c2cc(OC2CCN(C(=O)C=C)CC2)c(OC)c3)ccc1Cl		Inactive	EGFR Inhibitor		1	Poziotinib	363680279.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.2387998319	Clc1c(F)c(Nc2ncnc3c2cc(OC2CCN(C(=O)C=C)CC2)c(OC)c3)ccc1Cl	Clc1c(F)c(Nc2ncnc3c2cc(OC2CCN(C(=O)C=C)CC2)c(OC)c3)ccc1Cl
NCGC00346573-02	Clc1c(F)c(Nc2ncnc3c2cc(OC2CCN(CC(=O)NC)CC2)c(OC)c3)ccc1		Inactive	HER2/3 Inhibitor		1	Sapitinib	384568846.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(F)c(Nc2ncnc3c2cc(OC2CCN(CC(=O)NC)CC2)c(OC)c3)ccc1	Clc1c(F)c(Nc2ncnc3c2cc(OC2CCN(CC(=O)NC)CC2)c(OC)c3)ccc1
NCGC00346657-02	Clc1c(F)c(OC2CCC(C(=O)O)(Cc3nc(Nc4sccn4)ccc3)CC2)ccc1		Inactive	Aurora A Inhibitor		1	MK-5108	384568888.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(F)c(OC2CCC(C(=O)O)(Cc3nc(Nc4sccn4)ccc3)CC2)ccc1	Clc1c(F)c(OC2CCC(C(=O)O)(Cc3nc(Nc4sccn4)ccc3)CC2)ccc1
NCGC00378611-03	Clc1c(F)c([C@H]2[C@H](C(=O)NC3CCC(O)CC3)N[C@H](CC(C)(C)C)[C@@]32C(=O)Nc2c3ccc(Cl)c2)ccc1		Inactive	p53-binding protein Mdm-2 Inhibitor		1	MI-773 (SAR405838)	384569055.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(F)c([C@H]2[C@H](C(=O)NC3CCC(O)CC3)N[C@H](CC(C)(C)C)[C@@]32C(=O)Nc2c3ccc(Cl)c2)ccc1	Clc1c(F)c([C@H]2[C@H](C(=O)NC3CCC(O)CC3)N[C@H](CC(C)(C)C)[C@@]32C(=O)Nc2c3ccc(Cl)c2)ccc1
NCGC00521942-01	Clc1c(F)c([C@H]2[C@H](C(=O)N[C@H]3CO[C@H](C(=O)N)CC3)NC3([C@]42C(=O)Nc2c4ccc(Cl)c2)CCC(C)(C)CC3)ccn1		Inactive	MDM2 (hdm2) Inhibitor		1	Milademetan	384569507.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(F)c([C@H]2[C@H](C(=O)N[C@H]3CO[C@H](C(=O)N)CC3)NC3([C@]42C(=O)Nc2c4ccc(Cl)c2)CCC(C)(C)CC3)ccn1	Clc1c(F)c([C@H]2[C@H](C(=O)N[C@H]3CO[C@H](C(=O)N)CC3)NC3([C@]42C(=O)Nc2c4ccc(Cl)c2)CCC(C)(C)CC3)ccn1
NCGC00511386-01	Clc1c(F)c([C@H]2[C@H](C(=O)Nc3c(OC)cc(C(=O)N)cc3)N[C@@H](CC(C)(C)C)[C@]32C(=O)Nc2c3ccc(Cl)c2)ccc1		Inactive	MDM2 (hdm2) Inhibitor		1	RO8994	384569501.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(F)c([C@H]2[C@H](C(=O)Nc3c(OC)cc(C(=O)N)cc3)N[C@@H](CC(C)(C)C)[C@]32C(=O)Nc2c3ccc(Cl)c2)ccc1	Clc1c(F)c([C@H]2[C@H](C(=O)Nc3c(OC)cc(C(=O)N)cc3)N[C@@H](CC(C)(C)C)[C@]32C(=O)Nc2c3ccc(Cl)c2)ccc1
NCGC00378976-03	Clc1c(F)c([C@H]2[C@H](C(=O)Nc3c(OC)cc(C(=O)O)cc3)N[C@@H](CC(C)(C)C)[C@]2(C#N)c2c(F)cc(Cl)cc2)ccc1		Inactive	MDM2 (hdm2) Inhibitor		1	Idasanutlin	384569081.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	15.7076782159	Clc1c(F)c([C@H]2[C@H](C(=O)Nc3c(OC)cc(C(=O)O)cc3)N[C@@H](CC(C)(C)C)[C@]2(C#N)c2c(F)cc(Cl)cc2)ccc1	Clc1c(F)c([C@H]2[C@H](C(=O)Nc3c(OC)cc(C(=O)O)cc3)N[C@@H](CC(C)(C)C)[C@]2(C#N)c2c(F)cc(Cl)cc2)ccc1
NCGC00386401-01	Clc1c(F)cc([C@@H](CO)N2C(=O)C=C(c3nc(Nc4n(C)ncc4)ncc3)C=C2)cc1		Inactive	ERK1 Inhibitor		1	Ravoxertinib	384569132.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(F)cc([C@@H](CO)N2C(=O)C=C(c3nc(Nc4n(C)ncc4)ncc3)C=C2)cc1	Clc1c(F)cc([C@@H](CO)N2C(=O)C=C(c3nc(Nc4n(C)ncc4)ncc3)C=C2)cc1
NCGC00379030-01	Clc1c(F)ccc(C(=O)N[C@@H]2[C@H](O)C(C)(C)Oc3c2cc(C(=O)C)cc3)c1		Inactive	Gap junction Inhibitor		1	Tonabersat	363678322.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(F)ccc(C(=O)N[C@@H]2[C@H](O)C(C)(C)Oc3c2cc(C(=O)C)cc3)c1	Clc1c(F)ccc(C(=O)N[C@@H]2[C@H](O)C(C)(C)Oc3c2cc(C(=O)C)cc3)c1
NCGC00346694-03	Clc1c(F)ccc(CN2C(=O)c3c(O)c4C(=O)N(CC)C[C@H](C)n4c3C(C(=O)NC)=N2)c1		Inactive	HIV Integrase Inhibitors		1	MK-2048	434147095.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(F)ccc(CN2C(=O)c3c(O)c4C(=O)N(CC)C[C@H](C)n4c3C(C(=O)NC)=N2)c1	Clc1c(F)ccc(CN2C(=O)c3c(O)c4C(=O)N(CC)C[C@H](C)n4c3C(C(=O)NC)=N2)c1
NCGC00386366-01	Clc1c(F)ccc(N/C(=N/O)/c2c(N)non2)c1		Inactive	Indoleamine 2,3-dioxygenase Inhibitor		1	INCB024360	363680235.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(F)ccc(N/C(=N/O)/c2c(N)non2)c1	Clc1c(F)ccc(N/C(=N/O)/c2c(N)non2)c1
NCGC00188799-03	Clc1c(F)ccc(NS(=O)(=O)c2c(F)cc3NC(=O)CCc3c2)c1		Inactive			1	NCGC00188799-03		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(F)ccc(NS(=O)(=O)c2c(F)cc3NC(=O)CCc3c2)c1	Clc1c(F)ccc(NS(=O)(=O)c2c(F)cc3NC(=O)CCc3c2)c1
NCGC00273985-04	Clc1c(F)ccc(Nc2c(C#N)cnc3c(Cl)cc(NCc4nnn(C5CCN(CC)CC5)c4)cc23)c1		Inactive	Tpl-2/Cot (MAP3K8) Kinase Inhibitor		1	Wyeth Cot Inhibitor 2	363677309.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(F)ccc(Nc2c(C#N)cnc3c(Cl)cc(NCc4nnn(C5CCN(CC)CC5)c4)cc23)c1	Clc1c(F)ccc(Nc2c(C#N)cnc3c(Cl)cc(NCc4nnn(C5CCN(CC)CC5)c4)cc23)c1
NCGC00263103-02&NCGC00263103-09	Clc1c(F)ccc(Nc2c(C#N)cnc3c2cc(NC(=O)/C=C/CN(C)C)c(OCC)c3)c1		Inactive	EGFR Inhibitor		2	Pelitinib	384568592.0&434147073.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(F)ccc(Nc2c(C#N)cnc3c2cc(NC(=O)/C=C/CN(C)C)c(OCC)c3)c1	Clc1c(F)ccc(Nc2c(C#N)cnc3c2cc(NC(=O)/C=C/CN(C)C)c(OCC)c3)c1
NCGC00185000-18&NCGC00185000-22	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)/C=C/CN(C)C)c(O[C@@H]2COCC2)c3)c1		Inactive	EGFR Inhibitor		2	Afatinib&Afatinib (BIBW2992)	384568423.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)/C=C/CN(C)C)c(O[C@@H]2COCC2)c3)c1	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)/C=C/CN(C)C)c(O[C@@H]2COCC2)c3)c1
NCGC00263185-09	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)/C=C/CN2CCCCC2)c(OC)c3)c1		Inactive	EGFR Inhibitor		1	Dacomitinib	363677251.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)/C=C/CN2CCCCC2)c(OC)c3)c1	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)/C=C/CN2CCCCC2)c(OC)c3)c1
NCGC00263195-04	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)C=C)c(C#CC(C)(C)N2CCN(C)CC2)c3)c1		Inactive	EGFR Inhibitor		1	AV-412	377020296.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)C=C)c(C#CC(C)(C)N2CCN(C)CC2)c3)c1	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)C=C)c(C#CC(C)(C)N2CCN(C)CC2)c3)c1
NCGC00182713-18	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)C=C)c(OCCCN2CCOCC2)c3)c1		Inactive	EGFR Inhibitor		1	Canertinib	377020273.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)C=C)c(OCCCN2CCOCC2)c3)c1	Clc1c(F)ccc(Nc2ncnc3c2cc(NC(=O)C=C)c(OCCCN2CCOCC2)c3)c1
NCGC00485886-01	Clc1c(F)ccc(Nc2ncnc3c2cc(O)c(OC)c3)c1		Inactive			1	FAAH-IN-2	363681394.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(F)ccc(Nc2ncnc3c2cc(O)c(OC)c3)c1	Clc1c(F)ccc(Nc2ncnc3c2cc(O)c(OC)c3)c1
NCGC00159455-09&NCGC00159455-27	Clc1c(F)ccc(Nc2ncnc3c2cc(OCCCN2CCOCC2)c(OC)c3)c1		Inactive	EGFR Inhibitor		2	Gefitinib	170464828.0&384568178.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1c(F)ccc(Nc2ncnc3c2cc(OCCCN2CCOCC2)c(OC)c3)c1	Clc1c(F)ccc(Nc2ncnc3c2cc(OCCCN2CCOCC2)c(OC)c3)c1
NCGC00159563-02	Clc1c(F)ccc(Nc2ncnc3c2nc(N2CCC(CN(CC)CC)CC2)nc3)c1	4.9000001	Active		0.0	1	BIBU 1361 dihydrochloride	377020276.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	63.1658845381	Clc1c(F)ccc(Nc2ncnc3c2nc(N2CCC(CN(CC)CC)CC2)nc3)c1	Clc1c(F)ccc(Nc2ncnc3c2nc(N2CCC(CN(CC)CC)CC2)nc3)c1
NCGC00161422-09	Clc1c(F)ccc(Nc2ncnc3c2nc(NC2CCN(C)CC2)nc3)c1		Inactive	Epidermal growth factor receptor Inhibitor		1	BIBX 1382	377020239.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	19.2925284879	Clc1c(F)ccc(Nc2ncnc3c2nc(NC2CCN(C)CC2)nc3)c1	Clc1c(F)ccc(Nc2ncnc3c2nc(NC2CCN(C)CC2)nc3)c1
NCGC00485087-01	Clc1c(N(Cc2cc(F)ccc2)C2=NCCN2)c(Cl)ccc1		Inactive	Sulfonylurea receptors; K-ATP channels Inhibitor		1	IMID-4F hydrochloride	363681217.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(N(Cc2cc(F)ccc2)C2=NCCN2)c(Cl)ccc1	Clc1c(N(Cc2cc(F)ccc2)C2=NCCN2)c(Cl)ccc1
NCGC00386817-01	Clc1c(N(S(=O)(=O)C)CC(=O)NCC2CC2)cc(C(F)(F)F)cc1		Inactive			1	NCGC00386817-01	363680446.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(N(S(=O)(=O)C)CC(=O)NCC2CC2)cc(C(F)(F)F)cc1	Clc1c(N(S(=O)(=O)C)CC(=O)NCC2CC2)cc(C(F)(F)F)cc1
NCGC00387486-01	Clc1c(N(S(=O)(=O)c2ccc(C(=O)O)cc2)Cc2ccc(OC(F)(F)F)cc2)ncc(C(F)(F)F)c1		Inactive	Transient receptor potential cation channel subfamily M member 8 Antagonist		1	RQ 00203078	363680638.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	19.821707204	Clc1c(N(S(=O)(=O)c2ccc(C(=O)O)cc2)Cc2ccc(OC(F)(F)F)cc2)ncc(C(F)(F)F)c1	Clc1c(N(S(=O)(=O)c2ccc(C(=O)O)cc2)Cc2ccc(OC(F)(F)F)cc2)ncc(C(F)(F)F)c1
NCGC00481588-01	Clc1c(N(c2ncc(C(=O)NCCCCCCC(=O)NO)cn2)c2ccccc2)cccc1		Inactive			1	ACY-241	384569257.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(N(c2ncc(C(=O)NCCCCCCC(=O)NO)cn2)c2ccccc2)cccc1	Clc1c(N(c2ncc(C(=O)NCCCCCCC(=O)NO)cn2)c2ccccc2)cccc1
NCGC00181010-02	Clc1c(N)c(C(F)(F)F)cc(C(O)CNC(C)(C)C)c1		Inactive	Beta-2 adrenergic receptor Agonist		1	Mabuterol hydrochloride	170465921.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(N)c(C(F)(F)F)cc(C(O)CNC(C)(C)C)c1.Cl	Clc1c(N)c(C(F)(F)F)cc(C(O)CNC(C)(C)C)c1.Cl
NCGC00163150-07	Clc1c(N)c(Cl)cc(C(O)CNC(C)(C)C)c1		Inactive	Beta-2 adrenergic receptor Agonist		1	Clenbuterol	170465955.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(N)c(Cl)cc(C(O)CNC(C)(C)C)c1	Clc1c(N)c(Cl)cc(C(O)CNC(C)(C)C)c1
NCGC00253867-02&NCGC00253867-11	Clc1c(N)c2c(c(C(=O)NC3CCN(CCCOC)CC3)c1)OCC2		Inactive	5-HT4 Agonist		2	Prucalopride	170466188.0&384568568.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1c(N)c2c(c(C(=O)NC3CCN(CCCOC)CC3)c1)OCC2	Clc1c(N)c2c(c(C(=O)NC3CCN(CCCOC)CC3)c1)OCC2
NCGC00025262-02	Clc1c(N)cc(OC)c(C(=O)NC2C(OC)CN(CCCOc3ccc(F)cc3)CC2)c1		Inactive			1	Cisapride	170465200.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(N)cc(OC)c(C(=O)NC2C(OC)CN(CCCOc3ccc(F)cc3)CC2)c1	Clc1c(N)cc(OC)c(C(=O)NC2C(OC)CN(CCCOc3ccc(F)cc3)CC2)c1
NCGC00016951-05	Clc1c(N)cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)CC2)c1		Inactive	Dopamine D2 receptor Antagonist		1	Clebopride maleate	170465853.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(N)cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)CC2)c1.O=C(O)/C=C\C(=O)O	Clc1c(N)cc(OC)c(C(=O)NC2CCN(Cc3ccccc3)CC2)c1.O=C(O)/C=C\C(=O)O
NCGC00015643-11	Clc1c(N)cc(OC)c(C(=O)NCCN(CC)CC)c1		Inactive	Muscarinic acetylcholine receptor M3 Antagonist		1	Metoclopramide	170464848.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(N)cc(OC)c(C(=O)NCCN(CC)CC)c1	Clc1c(N)cc(OC)c(C(=O)NCCN(CC)CC)c1
NCGC00408826-01	Clc1c(N)cc(OC)c(C(=O)NC[C@H]2[C@H]3N(CC2)CCC3)c1		Inactive	5-hydroxytryptamine receptor 4 Agonist		1	SC-53116 Hydrochloride	363681059.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(N)cc(OC)c(C(=O)NC[C@H]2[C@H]3N(CC2)CCC3)c1	Clc1c(N)cc(OC)c(C(=O)NC[C@H]2[C@H]3N(CC2)CCC3)c1
NCGC00160527-03&NCGC00160527-12	Clc1c(N)cc(OCC)c(C(=O)NCC2OCCN(Cc3ccc(F)cc3)C2)c1		Inactive	5-HT4 Antagonist		2	Mosapride citrate	170466008.0&384568198.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&12.141123496	Clc1c(N)cc(OCC)c(C(=O)NCC2OCCN(Cc3ccc(F)cc3)C2)c1.O=C(O)C(O)(CC(=O)O)CC(=O)O	Clc1c(N)cc(OCC)c(C(=O)NCC2OCCN(Cc3ccc(F)cc3)C2)c1.O=C(O)C(O)(CC(=O)O)CC(=O)O&Clc1c(N)cc(OCC)c(C(=O)NCC2OCCN(Cc3ccc(F)cc3)C2)c1
NCGC00183682-13&NCGC00183682-14	Clc1c(N)ccc(C(=O)N[C@@H](C(C)(C)C)C(=O)N2[C@H](C(=O)N[C@@H]3[C@H](OCC)OC(=O)C3)CCC2)c1		Inactive	Caspase-1 Inhibitor		2	VX-765	434147195.0&384568419.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(N)ccc(C(=O)N[C@@H](C(C)(C)C)C(=O)N2[C@H](C(=O)N[C@@H]3[C@H](OCC)OC(=O)C3)CCC2)c1	Clc1c(N)ccc(C(=O)N[C@@H](C(C)(C)C)C(=O)N2[C@H](C(=O)N[C@@H]3[C@H](OCC)OC(=O)C3)CCC2)c1
NCGC00183434-06	Clc1c(N)ccc(C(=O)N[C@@H](C(C)(C)C)C(=O)N2[C@H](C(=O)N[C@H](C#N)CC(=O)O)CCC2)c1		Inactive	Caspase 1 Inhibitors		1	NCGC00183434-01	363677094.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(N)ccc(C(=O)N[C@@H](C(C)(C)C)C(=O)N2[C@H](C(=O)N[C@H](C#N)CC(=O)O)CCC2)c1	Clc1c(N)ccc(C(=O)N[C@@H](C(C)(C)C)C(=O)N2[C@H](C(=O)N[C@H](C#N)CC(=O)O)CCC2)c1
NCGC00015147-04	Clc1c(N)nc(N)c(C(=O)/N=C(/NCc2ccccc2)\N)n1		Inactive	Epithelial Sodium Channels (ENaC) Blocker		1	Benzamil	124879400.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(N)nc(N)c(C(=O)/N=C(/NCc2ccccc2)\N)n1	Clc1c(N)nc(N)c(C(=O)/N=C(/NCc2ccccc2)\N)n1
NCGC00015089-14&NCGC00015089-17	Clc1c(N)nc(N)c(C(=O)NC(=N)N)n1		Inactive	Epithelial Sodium Channels (ENaC) Blocker		2	Amiloride hydrochloride	124879266.0&170465124.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&0.0	Clc1c(N)nc(N)c(C(=O)NC(=N)N)n1	Clc1c(N)nc(N)c(C(=O)NC(=N)N)n1
NCGC00263176-03	Clc1c(N)nccc1Oc1c(F)cc(NC(=O)C=2C(=O)C(c3ccc(F)cc3)=CNC=2)cc1		Inactive	VEGFR-2 Inhibitor		1	BMS-794833	363677245.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	15.0	Clc1c(N)nccc1Oc1c(F)cc(NC(=O)C=2C(=O)C(c3ccc(F)cc3)=CNC=2)cc1	Clc1c(N)nccc1Oc1c(F)cc(NC(=O)C=2C(=O)C(c3ccc(F)cc3)=CNC=2)cc1
NCGC00263157-02	Clc1c(N)nccc1Oc1c(F)cc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C=CC=2OCC)cc1		Inactive	HGFR Inhibitor		1	BMS-777607	384568631.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(N)nccc1Oc1c(F)cc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C=CC=2OCC)cc1	Clc1c(N)nccc1Oc1c(F)cc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C=CC=2OCC)cc1
NCGC00346458-02	Clc1c(N)ncnc1C(=O)N[C@H](C)c1sc(C(=O)Nc2ncc(Cl)c(C(F)(F)F)c2)cn1		Inactive			1	MLN 2480	363677413.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(N)ncnc1C(=O)N[C@H](C)c1sc(C(=O)Nc2ncc(Cl)c(C(F)(F)F)c2)cn1	Clc1c(N)ncnc1C(=O)N[C@H](C)c1sc(C(=O)Nc2ncc(Cl)c(C(F)(F)F)c2)cn1
NCGC00371073-01	Clc1c(N2C(/C=C/c3nc(CN(CC)CC)ccc3)=Nc3c(C2=O)cc(F)cc3)cccc1	5.0500002	Active	Glutamate receptor ionotropic AMPA Antagonist	0.0	1	CP 465022 hydrochloride	363678017.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	3.0	97.4772975985	Clc1c(N2C(/C=C/c3nc(CN(CC)CC)ccc3)=Nc3c(C2=O)cc(F)cc3)cccc1	Clc1c(N2C(/C=C/c3nc(CN(CC)CC)ccc3)=Nc3c(C2=O)cc(F)cc3)cccc1
NCGC00378460-08	Clc1c(N2C(=O)C3=C(N(C)C(=O)C=C3N2)c2cc(N(C)C)ccc2)cccc1		Inactive	NOX 1/4 Inhibitor		1	GKT-137831	363678082.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(N2C(=O)C3=C(N(C)C(=O)C=C3N2)c2cc(N(C)C)ccc2)cccc1	Clc1c(N2C(=O)C3=C(N(C)C(=O)C=C3N2)c2cc(N(C)C)ccc2)cccc1
NCGC00378818-01	Clc1c(N2C(=O)N(Cc3cc(NC(=O)C=C)ccc3)c3nc(NCCCCN(CC)CC)ncc3C2)c(Cl)c(OC)cc1OC	4.9000001	Active	Vascular endothelial growth factor receptor 3 Inhibitor	0.0	1	FIIN 1 hydrochloride	363678218.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	117.0985786271	Clc1c(N2C(=O)N(Cc3cc(NC(=O)C=C)ccc3)c3nc(NCCCCN(CC)CC)ncc3C2)c(Cl)c(OC)cc1OC	Clc1c(N2C(=O)N(Cc3cc(NC(=O)C=C)ccc3)c3nc(NCCCCN(CC)CC)ncc3C2)c(Cl)c(OC)cc1OC
NCGC00510480-01	Clc1c(N2C(=O)N(c3ncc(OC)cc3)c3nc(Nc4c(OC)cc(C5CCN(C)CC5)cc4)ncc3C2)c(C)ccc1		Inactive	Salt-inducible Kinase (SIK) Inhibitor		1	YKL-05-099	384569443.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(N2C(=O)N(c3ncc(OC)cc3)c3nc(Nc4c(OC)cc(C5CCN(C)CC5)cc4)ncc3C2)c(C)ccc1	Clc1c(N2C(=O)N(c3ncc(OC)cc3)c3nc(Nc4c(OC)cc(C5CCN(C)CC5)cc4)ncc3C2)c(C)ccc1
NCGC00386910-01	Clc1c(N2C(=O)[C@H]3[C@@H](C2=O)[C@H]2C=C[C@@H]3C2)ccc(NC(=O)c2ncccc2)c1		Inactive			1	NCGC00386910-01	363680498.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(N2C(=O)[C@H]3[C@@H](C2=O)[C@H]2C=C[C@@H]3C2)ccc(NC(=O)c2ncccc2)c1	Clc1c(N2C(=O)[C@H]3[C@@H](C2=O)[C@H]2C=C[C@@H]3C2)ccc(NC(=O)c2ncccc2)c1
NCGC00390187-02	Clc1c(N2CC(O)C2)c(F)cc2C(=O)C(C(=O)O)=CN(c3c(F)cc(F)c(N)n3)c12		Inactive	Staphylococcus Aureus Inhibitor		1	Delafloxacin (meglumine)	405558581.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(N2CC(O)C2)c(F)cc2C(=O)C(C(=O)O)=CN(c3c(F)cc(F)c(N)n3)c12	Clc1c(N2CC(O)C2)c(F)cc2C(=O)C(C(=O)O)=CN(c3c(F)cc(F)c(N)n3)c12
NCGC00489873-03	Clc1c(N2CCC3(C(=O)NCC3)CC2)c(-c2cc3c(n(C)nc3)cc2)cnc1N	5.0500002	Active	CDK 8/19 Inhibitor	0.0	1	CCT-251921	384569285.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.4	58.7855993652	Clc1c(N2CCC3(C(=O)NCC3)CC2)c(-c2cc3c(n(C)nc3)cc2)cnc1N	Clc1c(N2CCC3(C(=O)NCC3)CC2)c(-c2cc3c(n(C)nc3)cc2)cnc1N
NCGC00509936-02	Clc1c(N2CCC3(C(=O)NCC3)CC2)c(-c2ccc(-c3cn(C)nc3)cc2)cnc1	5.0	Active	CDK 8/19 Inhibitor	0.0	1	CCT-251545	384569385.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.2	96.1759691728	Clc1c(N2CCC3(C(=O)NCC3)CC2)c(-c2ccc(-c3cn(C)nc3)cc2)cnc1	Clc1c(N2CCC3(C(=O)NCC3)CC2)c(-c2ccc(-c3cn(C)nc3)cc2)cnc1
NCGC00370959-01	Clc1c(N2CCN(C(=O)Nc3ccc(C(C)(C)C)cc3)CC2)nccc1		Inactive	Vanilloid receptor Antagonist		1	BCTC	363677957.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(N2CCN(C(=O)Nc3ccc(C(C)(C)C)cc3)CC2)nccc1	Clc1c(N2CCN(C(=O)Nc3ccc(C(C)(C)C)cc3)CC2)nccc1
NCGC00378806-01	Clc1c(N2CCN(C(=O)c3c(C)onc3-c3ccccc3)CC2)ccc([N+](=O)[O-])c1		Inactive			1	Nucleozin	363678210.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(N2CCN(C(=O)c3c(C)onc3-c3ccccc3)CC2)ccc([N+](=O)[O-])c1	Clc1c(N2CCN(C(=O)c3c(C)onc3-c3ccccc3)CC2)ccc([N+](=O)[O-])c1
NCGC00379152-02	Clc1c(N2CCN(C)CC2)nc2c(n1)cccc2		Inactive	Serotonin 3a (5-HT3a) receptor Antagonist		1	VUF 10166	363678386.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(N2CCN(C)CC2)nc2c(n1)cccc2	Clc1c(N2CCN(C)CC2)nc2c(n1)cccc2
NCGC00346539-05	Clc1c(N2CCN(CC(=O)Nc3sccn3)CC2)c2nc(-c3ccc(N(C)C)cc3)[nH]c2nc1		Inactive	Aurora Kinase Inhibitor		1	CCT-129202	363677446.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(N2CCN(CC(=O)Nc3sccn3)CC2)c2nc(-c3ccc(N(C)C)cc3)[nH]c2nc1	Clc1c(N2CCN(CC(=O)Nc3sccn3)CC2)c2nc(-c3ccc(N(C)C)cc3)[nH]c2nc1
NCGC00183844-04	Clc1c(N2C[C@@H](N)C3(C2)CC3)c(F)cc2C(=O)C(C(=O)O)=CN([C@H]3[C@@H](F)C3)c12		Inactive	DNA Topoisomerase IV Inhibitor		1	Sitafloxacin hydrate	384568421.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(N2C[C@@H](N)C3(C2)CC3)c(F)cc2C(=O)C(C(=O)O)=CN([C@H]3[C@@H](F)C3)c12	Clc1c(N2C[C@@H](N)C3(C2)CC3)c(F)cc2C(=O)C(C(=O)O)=CN([C@H]3[C@@H](F)C3)c12
NCGC00387040-01	Clc1c(N2C[C@@H]([C@](O)(C(C)C)C)NCC2)nc(-c2n[nH]c3ncccc23)c(F)c1		Inactive	Protein kinase C theta Inhibitor		1	VTX-27	363680533.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(N2C[C@@H]([C@](O)(C(C)C)C)NCC2)nc(-c2n[nH]c3ncccc23)c(F)c1	Clc1c(N2C[C@@H]([C@](O)(C(C)C)C)NCC2)nc(-c2n[nH]c3ncccc23)c(F)c1
NCGC00378618-01	Clc1c(N2C[C@H](CC)N(C3CCN(Cc4ccc(Cl)cc4)CC3)CC2)nc(N)c(C(=O)N)n1		Inactive			1	SCH 546738	363678124.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(N2C[C@H](CC)N(C3CCN(Cc4ccc(Cl)cc4)CC3)CC2)nc(N)c(C(=O)N)n1	Clc1c(N2C[C@H](CC)N(C3CCN(Cc4ccc(Cl)cc4)CC3)CC2)nc(N)c(C(=O)N)n1
NCGC00183844-01	Clc1c(N2C[C@H](N)C3(C2)CC3)c(F)cc2C(=O)C(C(=O)O)=CN(C3[C@H](F)C3)c12		Inactive	DNA Topoisomerase IV Inhibitor		1	Sitafloxacin hydrate	124894559.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(N2C[C@H](N)C3(C2)CC3)c(F)cc2C(=O)C(C(=O)O)=CN(C3[C@H](F)C3)c12	Clc1c(N2C[C@H](N)C3(C2)CC3)c(F)cc2C(=O)C(C(=O)O)=CN(C3[C@H](F)C3)c12
NCGC00386381-04	Clc1c(N2C[C@H](N)CCCC2)c(F)cc2C(=O)C(C(=O)O)=CN(C3CC3)c12		Inactive	Topoisomerase IV Inhibitor		1	Besifloxacin Hydrochloride	405558885.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(N2C[C@H](N)CCCC2)c(F)cc2C(=O)C(C(=O)O)=CN(C3CC3)c12	Clc1c(N2C[C@H](N)CCCC2)c(F)cc2C(=O)C(C(=O)O)=CN(C3CC3)c12
NCGC00346747-02	Clc1c(N2c3c(ccc(C#CC(O)(C)c4sccn4)c3)CC2)nc(N)nc1	4.9499998	Active	NFkappaB-inducing kinase Inhibitor	0.0	1	NCGC00346747	174007018.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	52.8780574046	Clc1c(N2c3c(ccc(C#CC(O)(C)c4sccn4)c3)CC2)nc(N)nc1	Clc1c(N2c3c(ccc(C#CC(O)(C)c4sccn4)c3)CC2)nc(N)nc1
NCGC00015033-03	Clc1c(N=C2NCCN2)c(Cl)cc(N)c1		Inactive	Alpha-2A adrenergic receptor Agonist		1	p-Aminoclonidine hydrochloride	90341674.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(N=C2NCCN2)c(Cl)cc(N)c1	Clc1c(N=C2NCCN2)c(Cl)cc(N)c1
NCGC00249893-01	Clc1c(NC(=O)C(=O)O)cc(C#N)cc1NC(=O)C(=O)O		Inactive	type I hypersensitivity Inhibitor		1	Lodoxamide	170465346.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(NC(=O)C(=O)O)cc(C#N)cc1NC(=O)C(=O)O	Clc1c(NC(=O)C(=O)O)cc(C#N)cc1NC(=O)C(=O)O
NCGC00402353-02	Clc1c(NC(=O)C2=C(C)NC3=C(C(=O)CCC3)C2c2occc2)cc(Cl)cc1		Inactive	Free fatty acid receptor 3 Agonist		1	AR420626	363681037.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(NC(=O)C2=C(C)NC3=C(C(=O)CCC3)C2c2occc2)cc(Cl)cc1	Clc1c(NC(=O)C2=C(C)NC3=C(C(=O)CCC3)C2c2occc2)cc(Cl)cc1
NCGC00182988-01	Clc1c(NC(=O)COC(=O)C)cc(C#N)cc1NC(=O)COC(=O)C		Inactive			1	Acreozast	144206850.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(NC(=O)COC(=O)C)cc(C#N)cc1NC(=O)COC(=O)C	Clc1c(NC(=O)COC(=O)C)cc(C#N)cc1NC(=O)COC(=O)C
NCGC00510235-01	Clc1c(NC(=O)N(C)c2ncnc(Nc3c(NC(=O)C=C)cc(N4CCN(CC)CC4)cc3)c2)c(Cl)c(OC)cc1OC		Inactive			1	H3B-6527	384569420.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(NC(=O)N(C)c2ncnc(Nc3c(NC(=O)C=C)cc(N4CCN(CC)CC4)cc3)c2)c(Cl)c(OC)cc1OC	Clc1c(NC(=O)N(C)c2ncnc(Nc3c(NC(=O)C=C)cc(N4CCN(CC)CC4)cc3)c2)c(Cl)c(OC)cc1OC
NCGC00274030-16	Clc1c(NC(=O)N(C)c2ncnc(Nc3ccc(N4CCN(CC)CC4)cc3)c2)c(Cl)c(OC)cc1OC		Inactive	FGFR3 Inhibitor		1	Infigratinib	384568707.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(NC(=O)N(C)c2ncnc(Nc3ccc(N4CCN(CC)CC4)cc3)c2)c(Cl)c(OC)cc1OC	Clc1c(NC(=O)N(C)c2ncnc(Nc3ccc(N4CCN(CC)CC4)cc3)c2)c(Cl)c(OC)cc1OC
NCGC00522488-01	Clc1c(NC(=O)N2CCN(Cc3cc4OC(F)(F)Oc4cc3)CC2)cncc1		Inactive	Fatty Acid Amide Hydrolase (FAAH) Inhibitor		1	JNJ-42165279	384569520.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(NC(=O)N2CCN(Cc3cc4OC(F)(F)Oc4cc3)CC2)cncc1	Clc1c(NC(=O)N2CCN(Cc3cc4OC(F)(F)Oc4cc3)CC2)cncc1
NCGC00263198-04&NCGC00263198-07	Clc1c(NC(=O)NC2CC2)ccc(Oc2c3c(ncc2)cc(OC)c(C(=O)N)c3)c1		Inactive	VEGFR-1/2/3 Inhibitor		2	Lenvatinib	405559112.0&363677259.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(NC(=O)NC2CC2)ccc(Oc2c3c(ncc2)cc(OC)c(C(=O)N)c3)c1	Clc1c(NC(=O)NC2CC2)ccc(Oc2c3c(ncc2)cc(OC)c(C(=O)N)c3)c1
NCGC00345847-02	Clc1c(NC(=O)NCC)ccc(Oc2c(/C=N/OC)c(N)ncn2)c1		Inactive	VEGFR-2 Inhibitor		1	JNJ-38158471	377020179.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(NC(=O)NCC)ccc(Oc2c(/C=N/OC)c(N)ncn2)c1	Clc1c(NC(=O)NCC)ccc(Oc2c(/C=N/OC)c(N)ncn2)c1
NCGC00346548-07	Clc1c(NC(=O)NCCC)ccc(Oc2ncnc3c2cc(OC)c(OC)c3)c1		Inactive	VEGFR-2 Inhibitor		1	KRN-633	363677450.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(NC(=O)NCCC)ccc(Oc2ncnc3c2cc(OC)c(OC)c3)c1	Clc1c(NC(=O)NCCC)ccc(Oc2ncnc3c2cc(OC)c(OC)c3)c1
NCGC00249390-02	Clc1c(NC(=O)Nc2noc(C)c2)ccc(Oc2c3c(ncc2)cc(OC)c(OC)c3)c1		Inactive			1	Tivozanib (AV-951)	384568525.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	18.0138696279	Clc1c(NC(=O)Nc2noc(C)c2)ccc(Oc2c3c(ncc2)cc(OC)c(OC)c3)c1	Clc1c(NC(=O)Nc2noc(C)c2)ccc(Oc2c3c(ncc2)cc(OC)c(OC)c3)c1
NCGC00250391-05	Clc1c(NC(=O)[C@@](O)(C(F)(F)F)C)ccc(S(=O)(=O)c2ccc(C(=O)N(C)C)cc2)c1		Inactive	Pyruvate Dehydrogenase Kinase 2 Inhibitor		1	AZD-7545	384568544.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(NC(=O)[C@@](O)(C(F)(F)F)C)ccc(S(=O)(=O)c2ccc(C(=O)N(C)C)cc2)c1	Clc1c(NC(=O)[C@@](O)(C(F)(F)F)C)ccc(S(=O)(=O)c2ccc(C(=O)N(C)C)cc2)c1
NCGC00015735-18&NCGC00015735-22	Clc1c(NC(=O)c2c(O)ccc(Cl)c2)ccc([N+](=O)[O-])c1		Inactive	STAT-3 Inhibitor		2	Niclosamide	384567886.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0&4.0		Clc1c(NC(=O)c2c(O)ccc(Cl)c2)ccc([N+](=O)[O-])c1	Clc1c(NC(=O)c2c(O)ccc(Cl)c2)ccc([N+](=O)[O-])c1
NCGC00379066-01	Clc1c(NC(=O)c2c3c(c(OC(F)F)cc2)oc2c3cc(NS(=O)(=O)C)cc2)c(Cl)cnc1		Inactive	Phosphodiesterase 4D Inhibitor		1	Oglemilast	363678335.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(NC(=O)c2c3c(c(OC(F)F)cc2)oc2c3cc(NS(=O)(=O)C)cc2)c(Cl)cnc1	Clc1c(NC(=O)c2c3c(c(OC(F)F)cc2)oc2c3cc(NS(=O)(=O)C)cc2)c(Cl)cnc1
NCGC00371037-01	Clc1c(NC(=O)c2cc(OC3CCCC3)c(OC)cc2)c(Cl)cnc1		Inactive	Cytochrome P450 2B6 Substrate		1	Piclamilast	363678002.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(NC(=O)c2cc(OC3CCCC3)c(OC)cc2)c(Cl)cnc1	Clc1c(NC(=O)c2cc(OC3CCCC3)c(OC)cc2)c(Cl)cnc1
NCGC00346566-09&NCGC00346566-10	Clc1c(NC(=O)c2cc(OCC3CC3)c(OC(F)F)cc2)c(Cl)cnc1		Inactive	Phosphodiesterase IIII (PDE4) Inhibitor		2	Roflumilast	405558995.0&384568843.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1c(NC(=O)c2cc(OCC3CC3)c(OC(F)F)cc2)c(Cl)cnc1	Clc1c(NC(=O)c2cc(OCC3CC3)c(OC(F)F)cc2)c(Cl)cnc1
NCGC00103278-01	Clc1c(NC(=O)c2cc3OCCOc3cc2)cc(-c2oc3c(n2)ccc(C)c3)cc1		Inactive			1	NCGC00103278-01	24266975.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	-16.3232711359	Clc1c(NC(=O)c2cc3OCCOc3cc2)cc(-c2oc3c(n2)ccc(C)c3)cc1	Clc1c(NC(=O)c2cc3OCCOc3cc2)cc(-c2oc3c(n2)ccc(C)c3)cc1
NCGC00346525-03	Clc1c(NC(=O)c2ccc(Nc3c(F)cnc(Nc4ccc(CC(=O)N5CCN(CC)CC5)cc4)n3)cc2)cccc1		Inactive	Aurora A Inhibitor		1	Aurora A Inhibitor I	384568819.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(NC(=O)c2ccc(Nc3c(F)cnc(Nc4ccc(CC(=O)N5CCN(CC)CC5)cc4)n3)cc2)cccc1	Clc1c(NC(=O)c2ccc(Nc3c(F)cnc(Nc4ccc(CC(=O)N5CCN(CC)CC5)cc4)n3)cc2)cccc1
NCGC00402290-03	Clc1c(NC(=O)c2n3c(nc2)C=CC(C2CCNCC2)=C3)cccc1		Inactive	Ephrin type-B receptor 3 Inhibitor		1	LDN-211904 Oxalate	363681014.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(NC(=O)c2n3c(nc2)C=CC(C2CCNCC2)=C3)cccc1	Clc1c(NC(=O)c2n3c(nc2)C=CC(C2CCNCC2)=C3)cccc1
NCGC00181129-08&NCGC00181129-14&NCGC00181129-22	Clc1c(NC(=O)c2sc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)nc2)c(C)ccc1		Inactive	Bcr-Abl Inhibitor		3	Dasatinib	384568391.0&405558859.0&434146874.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1c(NC(=O)c2sc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)nc2)c(C)ccc1	Clc1c(NC(=O)c2sc(Nc3nc(C)nc(N4CCN(CCO)CC4)c3)nc2)c(C)ccc1
NCGC00371107-01	Clc1c(NC)cc(OC)c(C(=O)N[C@H]2[C@@H](C)N(Cc3ccccc3)CC2)c1		Inactive			1	Nemonapride	363678034.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	19.5	Clc1c(NC)cc(OC)c(C(=O)N[C@H]2[C@@H](C)N(Cc3ccccc3)CC2)c1	Clc1c(NC)cc(OC)c(C(=O)N[C@H]2[C@@H](C)N(Cc3ccccc3)CC2)c1
NCGC00347944-06	Clc1c(NC)nc(Nc2c(OC)cc(C(=O)N3CCOCC3)cc2)nc1		Inactive	LRRK2 Inhibitor		1	Hg-10-102-01	363677725.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(NC)nc(Nc2c(OC)cc(C(=O)N3CCOCC3)cc2)nc1	Clc1c(NC)nc(Nc2c(OC)cc(C(=O)N3CCOCC3)cc2)nc1
NCGC00015649-08	Clc1c(NC2=NCCN2)c(OC)nc(C)n1		Inactive	Imidazoline I1 Receptor Agonist		1	Moxonidine hydrochloride hydrate	170466534.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&12.769069692	Clc1c(NC2=NCCN2)c(OC)nc(C)n1	Clc1c(NC2=NCCN2)c(OC)nc(C)n1
NCGC00160529-06&NCGC00160529-08	Clc1c(NC2=NCCN2)c2nsnc2cc1		Inactive	alpha2-Adrenoceptor Agonist		2	Tizanidine hydrochloride	170465419.0&384568199.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(NC2=NCCN2)c2nsnc2cc1	Clc1c(NC2=NCCN2)c2nsnc2cc1
NCGC00522603-01	Clc1c(NS(=O)(=O)C2C(C(=O)OCC)=CCCC2)ccc(F)c1		Inactive			1	TAK-242	384569531.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.55690942	Clc1c(NS(=O)(=O)C2C(C(=O)OCC)=CCCC2)ccc(F)c1	Clc1c(NS(=O)(=O)C2C(C(=O)OCC)=CCCC2)ccc(F)c1
NCGC00253587-01&NCGC00253587-02	Clc1c(NS(=O)(=O)c2c(C(=O)Cc3c(C)cc4OCOc4c3)scc2)onc1C		Inactive	Endothelin ETA Receptor Antagonist		2	Sitaxentan	170465720.0&384568564.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1c(NS(=O)(=O)c2c(C(=O)Cc3c(C)cc4OCOc4c3)scc2)onc1C	Clc1c(NS(=O)(=O)c2c(C(=O)Cc3c(C)cc4OCOc4c3)scc2)onc1C
NCGC00387821-04	Clc1c(N[C@H]2[C@@H](C(=O)N)[C@@H]3C=C[C@H]2C3)nc(Nc2c(OC)c3c(cc2)CC[C@H](N2CCOCC2)CC3)nc1		Inactive			1	CEP28122		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.7964763119	Clc1c(N[C@H]2[C@@H](C(=O)N)[C@@H]3C=C[C@H]2C3)nc(Nc2c(OC)c3c(cc2)CC[C@H](N2CCOCC2)CC3)nc1	Clc1c(N[C@H]2[C@@H](C(=O)N)[C@@H]3C=C[C@H]2C3)nc(Nc2c(OC)c3c(cc2)CC[C@H](N2CCOCC2)CC3)nc1
NCGC00378557-07	Clc1c(Nc2c(C(=O)NC)cccc2)nc(Nc2c(OC)c3c(cc2)C[C@@H](N2CCN(CCO)CC2)CCC3)nc1		Inactive			1	CEP-37440		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Nc2c(C(=O)NC)cccc2)nc(Nc2c(OC)c3c(cc2)C[C@@H](N2CCN(CCO)CC2)CCC3)nc1	Clc1c(Nc2c(C(=O)NC)cccc2)nc(Nc2c(OC)c3c(cc2)C[C@@H](N2CCN(CCO)CC2)CCC3)nc1
NCGC00346931-02	Clc1c(Nc2c(C(=O)NC)cccc2)nc(Nc2c(OC)cc(N3CCOCC3)cc2)nc1		Inactive	Focal Adhesion Kinase (FAK) Inhibitor		1	NVP-TAE226	384568967.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Nc2c(C(=O)NC)cccc2)nc(Nc2c(OC)cc(N3CCOCC3)cc2)nc1	Clc1c(Nc2c(C(=O)NC)cccc2)nc(Nc2c(OC)cc(N3CCOCC3)cc2)nc1
NCGC00390644-02	Clc1c(Nc2c(C(=O)NC)cccc2)nc(Nc2ccc(N3CCNCC3)cc2)nc1		Inactive	Casein kinase I Inhibitor		1	CTX0294885	363680949.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Nc2c(C(=O)NC)cccc2)nc(Nc2ccc(N3CCNCC3)cc2)nc1	Clc1c(Nc2c(C(=O)NC)cccc2)nc(Nc2ccc(N3CCNCC3)cc2)nc1
NCGC00482799-01	Clc1c(Nc2c(C(=O)NOC)cccc2)cc(Nc2n(C(C)C)nc(C)c2)nc1		Inactive	Focal Adhesion Kinase (FAK) Inhibitor		1	GSK-2256098	384569260.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Nc2c(C(=O)NOC)cccc2)cc(Nc2n(C(C)C)nc(C)c2)nc1	Clc1c(Nc2c(C(=O)NOC)cccc2)cc(Nc2n(C(C)C)nc(C)c2)nc1
NCGC00023217-08	Clc1c(Nc2c(C(=O)O)cccc2)c(Cl)ccc1C		Inactive	Cyclooxygenase Inhibitor		1	Meclofenamate sodium	170464886.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(Nc2c(C(=O)[O-])cccc2)c(Cl)ccc1C.[Na+].O	Clc1c(Nc2c(C(=O)[O-])cccc2)c(Cl)ccc1C.[Na+].O
NCGC00181795-02	Clc1c(Nc2c(CC(=O)O)cc(C)cc2)c(F)ccc1		Inactive	Solute carrier family 22 member 8 Inhibitor		1	Lumiracoxib	170465597.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(Nc2c(CC(=O)O)cc(C)cc2)c(F)ccc1	Clc1c(Nc2c(CC(=O)O)cc(C)cc2)c(F)ccc1
NCGC00021125-03&NCGC00021336-14	Clc1c(Nc2c(CC(=O)O)cccc2)c(Cl)ccc1		Inactive	Cyclooxygenase-1/2/3 Inhibitor		2	Diclofenac sodium	170464642.0&384568007.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1c(Nc2c(CC(=O)[O-])cccc2)c(Cl)ccc1.[Na+]	Clc1c(Nc2c(CC(=O)[O-])cccc2)c(Cl)ccc1.[Na+]&Clc1c(Nc2c(CC(=O)[O-])cccc2)c(Cl)ccc1
NCGC00016957-05	Clc1c(Nc2c(CC(=O)OCC(=O)O)cccc2)c(Cl)ccc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Aceclofenac	170465979.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Nc2c(CC(=O)OCC(=O)O)cccc2)c(Cl)ccc1	Clc1c(Nc2c(CC(=O)OCC(=O)O)cccc2)c(Cl)ccc1
NCGC00378973-06	Clc1c(Nc2c(NS(=O)(=O)c3cc(NC(=O)C(N)(C)C)ccc3)nc3c(n2)cccc3)cc(OC)cc1		Inactive	PI3Kalpha Inhibitor		1	Pilaralisib	384569080.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.042713192	Clc1c(Nc2c(NS(=O)(=O)c3cc(NC(=O)C(N)(C)C)ccc3)nc3c(n2)cccc3)cc(OC)cc1	Clc1c(Nc2c(NS(=O)(=O)c3cc(NC(=O)C(N)(C)C)ccc3)nc3c(n2)cccc3)cc(OC)cc1
NCGC00379254-06	Clc1c(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc1		Inactive	ALK Inhibitor		1	KRCA-0008	384569096.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc1	Clc1c(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc1
NCGC00351602-09	Clc1c(Nc2c(P(=O)(C)C)cccc2)nc(Nc2c(OC)cc(N3CCC(N(C)C)CC3)cc2)nc1		Inactive	ALK Inhibitor		1	AP-26113	363677771.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Nc2c(P(=O)(C)C)cccc2)nc(Nc2c(OC)cc(N3CCC(N(C)C)CC3)cc2)nc1	Clc1c(Nc2c(P(=O)(C)C)cccc2)nc(Nc2c(OC)cc(N3CCC(N(C)C)CC3)cc2)nc1
NCGC00483924-02	Clc1c(Nc2c(P(=O)(C)C)cccc2)nc(Nc2c(OC)cc(N3CCC(N4CCN(C)CC4)CC3)cc2)nc1		Inactive	IGF-1R Inhibitor		1	Brigatinib	384569265.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(Nc2c(P(=O)(C)C)cccc2)nc(Nc2c(OC)cc(N3CCC(N4CCN(C)CC4)CC3)cc2)nc1	Clc1c(Nc2c(P(=O)(C)C)cccc2)nc(Nc2c(OC)cc(N3CCC(N4CCN(C)CC4)CC3)cc2)nc1
NCGC00238453-16	Clc1c(Nc2c(S(=O)(=O)C(C)C)cccc2)nc(Nc2c(OC)cc(N3CCC(N4CCN(C)CC4)CC3)cc2)nc1		Inactive	ALK Inhibitor		1	TAE-684	384568466.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Nc2c(S(=O)(=O)C(C)C)cccc2)nc(Nc2c(OC)cc(N3CCC(N4CCN(C)CC4)CC3)cc2)nc1	Clc1c(Nc2c(S(=O)(=O)C(C)C)cccc2)nc(Nc2c(OC)cc(N3CCC(N4CCN(C)CC4)CC3)cc2)nc1
NCGC00378875-01	Clc1c(Nc2c(S(=O)(=O)NC)cccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1		Inactive	ALK tyrosine kinase receptor Inhibitor		1	ALK inhibitor 2	363678251.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Nc2c(S(=O)(=O)NC)cccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1	Clc1c(Nc2c(S(=O)(=O)NC)cccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1
NCGC00242486-04	Clc1c(Nc2n[nH]c(C)c2)nc(N[C@@H](C)c2ncc(F)cn2)nc1		Inactive	Jak1/2 Inhibitor		1	AZD-1480	384568494.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Nc2n[nH]c(C)c2)nc(N[C@@H](C)c2ncc(F)cn2)nc1	Clc1c(Nc2n[nH]c(C)c2)nc(N[C@@H](C)c2ncc(F)cn2)nc1
NCGC00250381-02	Clc1c(Nc2n[nH]c(OC(C)C)c2)nc(N[C@@H](C)c2ncc(F)cc2)nc1		Inactive	Trk Inhibitor		1	AZ-23	174006473.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Nc2n[nH]c(OC(C)C)c2)nc(N[C@@H](C)c2ncc(F)cc2)nc1	Clc1c(Nc2n[nH]c(OC(C)C)c2)nc(N[C@@H](C)c2ncc(F)cc2)nc1
NCGC00346697-02	Clc1c(Nc2nc(C(F)(F)F)c(C(=O)NCC3CCOCC3)cn2)ccc(Cl)c1		Inactive	Cannabinoid CB2 Agonist		1	842166X	384568917.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Nc2nc(C(F)(F)F)c(C(=O)NCC3CCOCC3)cn2)ccc(Cl)c1	Clc1c(Nc2nc(C(F)(F)F)c(C(=O)NCC3CCOCC3)cn2)ccc(Cl)c1
NCGC00387872-01	Clc1c(Nc2nc(c(C)cn2)-c2cc(C(=O)NC(CO)c3cc(Cl)ccc3)[nH]c2)ccc(F)c1		Inactive	ERK2 Inhibitor		1	VS-4718	363680714.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Nc2nc(c(C)cn2)-c2cc(C(=O)NC(CO)c3cc(Cl)ccc3)[nH]c2)ccc(F)c1	Clc1c(Nc2nc(c(C)cn2)-c2cc(C(=O)NC(CO)c3cc(Cl)ccc3)[nH]c2)ccc(F)c1
NCGC00242487-08	Clc1c(Nc2nc(c(C)cn2)-c2cc(C(=O)N[C@H](CO)c3cc(Cl)ccc3)[nH]c2)ccc(F)c1		Inactive	ERK Inhibitor		1	NCGC00242487	384568495.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Nc2nc(c(C)cn2)-c2cc(C(=O)N[C@H](CO)c3cc(Cl)ccc3)[nH]c2)ccc(F)c1	Clc1c(Nc2nc(c(C)cn2)-c2cc(C(=O)N[C@H](CO)c3cc(Cl)ccc3)[nH]c2)ccc(F)c1
NCGC00241099-04	Clc1c(Nc2ncnc3c2c(OC2CCOCC2)cc(OCCN2CCN(C)CC2)c3)c2OCOc2cc1		Inactive	cSRC Inhibitor		1	Saracatinib	384568470.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(Nc2ncnc3c2c(OC2CCOCC2)cc(OCCN2CCN(C)CC2)c3)c2OCOc2cc1	Clc1c(Nc2ncnc3c2c(OC2CCOCC2)cc(OCCN2CCN(C)CC2)c3)c2OCOc2cc1
NCGC00484800-01	Clc1c(Nc2ncnc3c2c2sc(C(OCC)=N)nc2cc3)cc(F)c(F)c1		Inactive	DYRK Inhibitor		1	FX-9847	384569272.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Nc2ncnc3c2c2sc(C(OCC)=N)nc2cc3)cc(F)c(F)c1	Clc1c(Nc2ncnc3c2c2sc(C(OCC)=N)nc2cc3)cc(F)c(F)c1
NCGC00370984-01	Clc1c(Nc2ncnc3c2cc(OC)c(OCC2CCN(C)CC2)c3)cc(OC)cc1		Inactive	Src Kinase Inhibitor		1	M-475271	363677978.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Nc2ncnc3c2cc(OC)c(OCC2CCN(C)CC2)c3)cc(OC)cc1	Clc1c(Nc2ncnc3c2cc(OC)c(OCC2CCN(C)CC2)c3)cc(OC)cc1
NCGC00380324-01	Clc1c(O)c(C/C=C(/CC/C=C(\C)/[C@@H]2OC(C)(C)C(=O)C2)\C)c(O)c(C=O)c1C		Inactive	<MOA Unknown> | Class: polyketide/sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380324-01	363678542.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(O)c(C/C=C(/CC/C=C(\C)/[C@@H]2OC(C)(C)C(=O)C2)\C)c(O)c(C=O)c1C	Clc1c(O)c(C/C=C(/CC/C=C(\C)/[C@@H]2OC(C)(C)C(=O)C2)\C)c(O)c(C=O)c1C
NCGC00402340-02	Clc1c(O)c(C2C(C#N)=C(N)Oc3[nH]nc(CCC)c23)cc(Cl)c1		Inactive	Transcription factor p65 Inhibitor		1	RBC6	363681029.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(O)c(C2C(C#N)=C(N)Oc3[nH]nc(CCC)c23)cc(Cl)c1	Clc1c(O)c(C2C(C#N)=C(N)Oc3[nH]nc(CCC)c23)cc(Cl)c1
NCGC00095166-04	Clc1c(O)c(Cl)c(C)nc1C		Inactive			1	Clopidol	170465668.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(O)c(Cl)c(C)nc1C	Clc1c(O)c(Cl)c(C)nc1C
NCGC00386281-05	Clc1c(O)c(Cl)c(CC)c(C(=O)O[C@H]2[C@H](O)[C@H](OC)[C@H](OC/C=3/C(=O)O[C@H]([C@H](O)C)C/C=C(\C)/C=C(\C)/[C@H](O[C@H]4[C@@H](O)[C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O4)[C@@H](CC)/C=C(/C)\[C@@H](O)C/C=C/C=3)O[C@@H]2C)c1O		Inactive			1	Fidaxomicin	405558974.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(O)c(Cl)c(CC)c(C(=O)O[C@H]2[C@H](O)[C@H](OC)[C@H](OC/C=3/C(=O)O[C@H]([C@H](O)C)C/C=C(\C)/C=C(\C)/[C@H](O[C@H]4[C@@H](O)[C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O4)[C@@H](CC)/C=C(/C)\[C@@H](O)C/C=C/C=3)O[C@@H]2C)c1O	Clc1c(O)c(Cl)c(CC)c(C(=O)O[C@H]2[C@H](O)[C@H](OC)[C@H](OC/C=3/C(=O)O[C@H]([C@H](O)C)C/C=C(\C)/C=C(\C)/[C@H](O[C@H]4[C@@H](O)[C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O4)[C@@H](CC)/C=C(/C)\[C@@H](O)C/C=C/C=3)O[C@@H]2C)c1O
NCGC00386398-03	Clc1c(O)c(Cl)cc(-c2nc3c(NC4CCC(CN(C)C)CC4)c(C(=O)C)cnc3cc2)c1		Inactive	MELK Inhibitor		1	OTS-167	363680254.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	21.0	Clc1c(O)c(Cl)cc(-c2nc3c(NC4CCC(CN(C)C)CC4)c(C(=O)C)cnc3cc2)c1	Clc1c(O)c(Cl)cc(-c2nc3c(NC4CCC(CN(C)C)CC4)c(C(=O)C)cnc3cc2)c1
NCGC00015444-07&NCGC00015444-10	Clc1c(O)c(O)cc2C(c3ccc(O)cc3)CNCCc12		Inactive	Dopamine D1 Receptor (DRD1) Agonist		2	Fenoldopam	170465321.0&384567848.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1c(O)c(O)cc2C(c3ccc(O)cc3)CNCCc12	Clc1c(O)c(O)cc2C(c3ccc(O)cc3)CNCCc12
NCGC00371135-01	Clc1c(O)c(S(=O)(=O)Nc2c(OC)ccc(-c3ccccc3)c2)cc(Cl)c1		Inactive	ATP-citrate synthase Inhibitor		1	BMS303141	363678051.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(O)c(S(=O)(=O)Nc2c(OC)ccc(-c3ccccc3)c2)cc(Cl)c1	Clc1c(O)c(S(=O)(=O)Nc2c(OC)ccc(-c3ccccc3)c2)cc(Cl)c1
NCGC00095795-06	Clc1c(O)c2nc(C)ccc2c(Cl)c1		Inactive	Botulinum neurotoxin type A Inhibitor		1	5,7-Dichloro-8-hydroxy-2-methylquinoline	170465701.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(O)c2nc(C)ccc2c(Cl)c1	Clc1c(O)c2nc(C)ccc2c(Cl)c1
NCGC00346304-02	Clc1c(O)cc(-c2c(-c3ccncc3)[nH]c(-c3ccccc3)n2)cc1		Inactive	Raf kinase C Inhibitor		1	L-779450	174006393.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	8.0	Clc1c(O)cc(-c2c(-c3ccncc3)[nH]c(-c3ccccc3)n2)cc1	Clc1c(O)cc(-c2c(-c3ccncc3)[nH]c(-c3ccccc3)n2)cc1
NCGC00378612-02	Clc1c(O)cc(O)c(-c2c(c(C(=O)NCC)no2)-c2ccc(OC)cc2)c1		Inactive	Heat shock protein HSP 90-beta Inhibitor		1	VER-50589	363678121.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	28.0	Clc1c(O)cc(O)c(-c2c(c(C(=O)NCC)no2)-c2ccc(OC)cc2)c1	Clc1c(O)cc(O)c(-c2c(c(C(=O)NCC)no2)-c2ccc(OC)cc2)c1
NCGC00381414-01	Clc1c(O)cc(O)c2C(=O)OC(C)CC(O)/C=C/C(O)C(O)CC(=O)Cc12		Inactive	<MOA Unknown> | Class: macrolide | Genus: Fusarium | Family: N/A | Species: N/A		1	NCGC00381414-01	363679132.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(O)cc(O)c2C(=O)OC(C)CC(O)/C=C/C(O)C(O)CC(=O)Cc12	Clc1c(O)cc(O)c2C(=O)OC(C)CC(O)/C=C/C(O)C(O)CC(=O)Cc12
NCGC00420878-02	Clc1c(O)cc2Oc3c(O)ccc([C@@H](NC)C(=O)N[C@H]4C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@H]6C(=O)N[C@@H]([C@H](O)c7cc(Cl)c(Oc8c(O[C@H]9[C@H](NC(=O)CCCCCCCCC(C)C)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O9)c(Oc9ccc(cc9)C4)cc5c8)cc7)C(=O)N[C@H](C(=O)NCCCN(C)C)c4c(c(O[C@@H]5[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)cc(O)c4)-c4c(O)ccc6c4)c1c2)c3		Inactive			1	Dalbavancin	405558602.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(O)cc2Oc3c(O)ccc([C@@H](NC)C(=O)N[C@H]4C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@H]6C(=O)N[C@@H]([C@H](O)c7cc(Cl)c(Oc8c(O[C@H]9[C@H](NC(=O)CCCCCCCCC(C)C)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O9)c(Oc9ccc(cc9)C4)cc5c8)cc7)C(=O)N[C@H](C(=O)NCCCN(C)C)c4c(c(O[C@@H]5[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)cc(O)c4)-c4c(O)ccc6c4)c1c2)c3	Clc1c(O)cc2Oc3c(O)ccc([C@@H](NC)C(=O)N[C@H]4C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@H]6C(=O)N[C@@H]([C@H](O)c7cc(Cl)c(Oc8c(O[C@H]9[C@H](NC(=O)CCCCCCCCC(C)C)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O9)c(Oc9ccc(cc9)C4)cc5c8)cc7)C(=O)N[C@H](C(=O)NCCCN(C)C)c4c(c(O[C@@H]5[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)cc(O)c4)-c4c(O)ccc6c4)c1c2)c3
NCGC00386542-01	Clc1c(O)cc2[C@@H](c3c4OCCc4ccc3)CN(C)CCc2c1		Inactive	Dopamine D1 receptor Antagonist		1	NNC 756	363680321.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(O)cc2[C@@H](c3c4OCCc4ccc3)CN(C)CCc2c1	Clc1c(O)cc2[C@@H](c3c4OCCc4ccc3)CN(C)CCc2c1
NCGC00386673-01	Clc1c(O)ccc(CCNc2nc(NCc3ccccc3)c(C(=O)N)cn2)c1		Inactive	Signal transducer and activator of transcription 6 Inhibitor		1	AS 1517499	363680388.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(O)ccc(CCNc2nc(NCc3ccccc3)c(C(=O)N)cn2)c1	Clc1c(O)ccc(CCNc2nc(NCc3ccccc3)c(C(=O)N)cn2)c1
NCGC00386827-01	Clc1c(O)ccc(CN2CCC(C(=O)OCC)(CCOc3ccccc3)CC2)c1		Inactive			1	NCGC00386827-01	363680452.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	31.2621011161	Clc1c(O)ccc(CN2CCC(C(=O)OCC)(CCOc3ccccc3)CC2)c1	Clc1c(O)ccc(CN2CCC(C(=O)OCC)(CCOc3ccccc3)CC2)c1
NCGC00015950-05&NCGC00015950-14	Clc1c(O)ccc(NC2=C(c3c([N+](=O)[O-])cccc3)C(=O)NC2=O)c1		Inactive	GSK-3 beta Inhibitor		2	SB-415286	124881443.0&434147196.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(O)ccc(NC2=C(c3c([N+](=O)[O-])cccc3)C(=O)NC2=O)c1	Clc1c(O)ccc(NC2=C(c3c([N+](=O)[O-])cccc3)C(=O)NC2=O)c1
NCGC00271513-02	Clc1c(OC(C)C2=NCCN2)c(Cl)ccc1		Inactive	Adrenergic receptor alpha-2 Agonist		1	Lofexidine	170466275.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(OC(C)C2=NCCN2)c(Cl)ccc1	Clc1c(OC(C)C2=NCCN2)c(Cl)ccc1
NCGC00095978-06	Clc1c(OC(F)(F)C(F)C(F)(F)F)cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)c1	4.9499998	Active		0.0	1	Lufenuron	170465736.0	2019_NPC-3.2	SARS-CoV-2_CPE_SRI	3.0	38.0884086441	Clc1c(OC(F)(F)C(F)C(F)(F)F)cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)c1	Clc1c(OC(F)(F)C(F)C(F)(F)F)cc(Cl)c(NC(=O)NC(=O)c2c(F)cccc2F)c1
NCGC00484069-01	Clc1c(OC(F)(F)F)cc2[nH]c(-n3ncc(C(=O)O)c3)nc2c1		Inactive	HIF Prolyl Hydroxylase Inhibitor		1	JNJ-42041935	363681161.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(OC(F)(F)F)cc2[nH]c(-n3ncc(C(=O)O)c3)nc2c1	Clc1c(OC(F)(F)F)cc2[nH]c(-n3ncc(C(=O)O)c3)nc2c1
NCGC00263021-04	Clc1c(OC)c(NC(=O)c2c(C)nccc2)c2[nH]c3c(c2c1)ccnc3		Inactive	IKK beta Inhibitor		1	MLN-120B	363677194.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(OC)c(NC(=O)c2c(C)nccc2)c2[nH]c3c(c2c1)ccnc3	Clc1c(OC)c(NC(=O)c2c(C)nccc2)c2[nH]c3c(c2c1)ccnc3
NCGC00378790-01	Clc1c(OC)c(NS(=O)(=O)c2cc(N3CCNCC3)c(OC)cc2)cc(Cl)c1		Inactive	Serotonin 6 (5-HT6) receptor Antagonist		1	SB 399885 hydrochloride	363678203.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	11.7118525399	Clc1c(OC)c(NS(=O)(=O)c2cc(N3CCNCC3)c(OC)cc2)cc(Cl)c1	Clc1c(OC)c(NS(=O)(=O)c2cc(N3CCNCC3)c(OC)cc2)cc(Cl)c1
NCGC00386217-04	Clc1c(OC)cc(NC(=O)c2ncccc2)cc1		Inactive	Metabotropic glutamate receptor 8 Positive Allosteric Modulator		1	VU 0361737	363680154.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(OC)cc(NC(=O)c2ncccc2)cc1	Clc1c(OC)cc(NC(=O)c2ncccc2)cc1
NCGC00402332-02	Clc1c(OC)cc(NC(=O)c2noc(C3CC3)c2)c(OC)c1		Inactive	Signal transducer and activator of transcription 3 Activator		1	ML115	363681027.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(OC)cc(NC(=O)c2noc(C3CC3)c2)c(OC)c1	Clc1c(OC)cc(NC(=O)c2noc(C3CC3)c2)c(OC)c1
NCGC00241107-02&NCGC00241107-12	Clc1c(OC)cc(Nc2c(C#N)cnc3c2cc(OC)c(OCCCN2CCN(C)CC2)c3)c(Cl)c1		Inactive	Bcr-Abl Inhibitor		2	Bosutinib	170466788.0&384568475.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(OC)cc(Nc2c(C#N)cnc3c2cc(OC)c(OCCCN2CCN(C)CC2)c3)c(Cl)c1.OC	Clc1c(OC)cc(Nc2c(C#N)cnc3c2cc(OC)c(OCCCN2CCN(C)CC2)c3)c(Cl)c1.OC&Clc1c(OC)cc(Nc2c(C#N)cnc3c2cc(OC)c(OCCCN2CCN(C)CC2)c3)c(Cl)c1
NCGC00390366-01	Clc1c(OC)cc(Nc2c3c(nc(C#N)c2)cc(OCCCN2CCN(C)CC2)c(OC)c3)c(Cl)c1		Inactive			1	Bosutinib(SKI-606)	363680881.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(OC)cc(Nc2c3c(nc(C#N)c2)cc(OCCCN2CCN(C)CC2)c(OC)c3)c(Cl)c1	Clc1c(OC)cc(Nc2c3c(nc(C#N)c2)cc(OCCCN2CCN(C)CC2)c(OC)c3)c(Cl)c1
NCGC00385961-01	Clc1c(OC)cc(O)c2C(=O)OC(C)Cc12		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385961-01	363680030.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(OC)cc(O)c2C(=O)OC(C)Cc12	Clc1c(OC)cc(O)c2C(=O)OC(C)Cc12
NCGC00167746-09	Clc1c(OC)cc(OC)c(NC(=O)Nc2noc(C)c2)c1		Inactive	Nicotinic alpha7 Positive Allosteric Modulators		1	PNU-120596	384568333.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	9.5	Clc1c(OC)cc(OC)c(NC(=O)Nc2noc(C)c2)c1	Clc1c(OC)cc(OC)c(NC(=O)Nc2noc(C)c2)c1
NCGC00380818-01	Clc1c(OC)cc(OC)c2C(=O)C3(C(OC)=CC(=O)C=C3C)Oc12		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380818-01	363678799.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(OC)cc(OC)c2C(=O)C3(C(OC)=CC(=O)C=C3C)Oc12	Clc1c(OC)cc(OC)c2C(=O)C3(C(OC)=CC(=O)C=C3C)Oc12
NCGC00091120-13	Clc1c(OC)cc(OC)c2C(=O)[C@@]3([C@H](C)CC(=O)C=C3OC)Oc12		Inactive	Tubulin beta chain Inhibitor		1	Griseofulvin	170465739.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(OC)cc(OC)c2C(=O)[C@@]3([C@H](C)CC(=O)C=C3OC)Oc12	Clc1c(OC)cc(OC)c2C(=O)[C@@]3([C@H](C)CC(=O)C=C3OC)Oc12
NCGC00014650-04	Clc1c(OC)cc2cc1N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]1(C)O[C@@H]1[C@H](C)[C@H]1OC(=O)N[C@@](O)([C@H](OC)/C=C/C=C(\C)/C2)C1		Inactive	Tubulin polymerization Inhibitor		1	Ansamitocin P3	384567792.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(OC)cc2cc1N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]1(C)O[C@@H]1[C@H](C)[C@H]1OC(=O)N[C@@](O)([C@H](OC)/C=C/C=C(\C)/C2)C1	Clc1c(OC)cc2cc1N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]1(C)O[C@@H]1[C@H](C)[C@H]1OC(=O)N[C@@](O)([C@H](OC)/C=C/C=C(\C)/C2)C1
NCGC00386241-01	Clc1c(OC)ccc(CNc2c(C(=O)NCc3ncccn3)cnc(N3[C@H](CO)CCC3)n2)c1		Inactive	Phosphodiesterase 5A Inhibitor		1	Avanafil	405558527.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(OC)ccc(CNc2c(C(=O)NCc3ncccn3)cnc(N3[C@H](CO)CCC3)n2)c1	Clc1c(OC)ccc(CNc2c(C(=O)NCc3ncccn3)cnc(N3[C@H](CO)CCC3)n2)c1
NCGC00485302-01	Clc1c(OC)nc2sc(C(=O)NC3CC3)c(N)c2c1C		Inactive	Muscarinic acetylcholine receptor M4 Positive Allosteric Modulator		1	LY2033298	363681282.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(OC)nc2sc(C(=O)NC3CC3)c(N)c2c1C	Clc1c(OC)nc2sc(C(=O)NC3CC3)c(N)c2c1C
NCGC00386411-02	Clc1c(OCC(=O)N2CCN(C)CC2)nc2sc(C(=O)NC3CC3)c(N)c2c1C		Inactive	Muscarinic acetylcholine receptor M4 Positive Allosteric Modulator		1	LY2119620	363680264.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(OCC(=O)N2CCN(C)CC2)nc2sc(C(=O)NC3CC3)c(N)c2c1C	Clc1c(OCC(=O)N2CCN(C)CC2)nc2sc(C(=O)NC3CC3)c(N)c2c1C
NCGC00378919-01	Clc1c(OCC(=O)Nc2ccc(CC(=O)N3[C@]4(C(=O)N5[C@@H](C(=O)N)CCS[C@@H]5C4)CCC3)cc2)ccc(Cl)c1		Inactive	Myd88 Dimerization Inhibitor		1	ST-2825	363678276.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(OCC(=O)Nc2ccc(CC(=O)N3[C@]4(C(=O)N5[C@@H](C(=O)N)CCS[C@@H]5C4)CCC3)cc2)ccc(Cl)c1	Clc1c(OCC(=O)Nc2ccc(CC(=O)N3[C@]4(C(=O)N5[C@@H](C(=O)N)CCS[C@@H]5C4)CCC3)cc2)ccc(Cl)c1
NCGC00263212-05	Clc1c(OCC(=O)OC)c(OCC)cc(/C=C\2/C(=O)N(c3ccccc3)N=C/2C)c1		Inactive	MDM4 (MDMX) Inhibitor		1	SJ-172550	384568669.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(OCC(=O)OC)c(OCC)cc(/C=C\2/C(=O)N(c3ccccc3)N=C/2C)c1	Clc1c(OCC(=O)OC)c(OCC)cc(/C=C\2/C(=O)N(c3ccccc3)N=C/2C)c1
NCGC00249915-01	Clc1c(OCC(O)CNC(C)(C)C)cc(C)cc1		Inactive	Beta-3 adrenergic receptor Antagonist		1	Bupranolol	170465802.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(OCC(O)CNC(C)(C)C)cc(C)cc1	Clc1c(OCC(O)CNC(C)(C)C)cc(C)cc1
NCGC00159507-02	Clc1c(OCC=C)ccc(CC(=O)O)c1		Inactive	Cyclooxygenase-2 Inhibitor		1	Alclofenac	144205279.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(OCC=C)ccc(CC(=O)O)c1	Clc1c(OCC=C)ccc(CC(=O)O)c1
NCGC00370930-01	Clc1c(OCCCC)ccc(-c2cc(C(=O)NCc3c(N4CCOCC4)nccc3)cnc2)c1		Inactive	Sodium channel protein type X alpha subunit Blocker		1	A 887826	363677942.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(OCCCC)ccc(-c2cc(C(=O)NCc3c(N4CCOCC4)nccc3)cnc2)c1	Clc1c(OCCCC)ccc(-c2cc(C(=O)NCc3c(N4CCOCC4)nccc3)cnc2)c1
NCGC00247879-05	Clc1c(OCCN2CCCC2)cc(-c2nc(N)nc3sc(C(=O)NCC)cc23)c(Cl)c1		Inactive	Heat Shock Protein 90 (hsp90) Inhibitor		1	VER-82576	384568520.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.0	Clc1c(OCCN2CCCC2)cc(-c2nc(N)nc3sc(C(=O)NCC)cc23)c(Cl)c1	Clc1c(OCCN2CCCC2)cc(-c2nc(N)nc3sc(C(=O)NCC)cc23)c(Cl)c1
NCGC00510750-02	Clc1c(OCc2c3oc(-c4ccccc4)nc3cc(N)c2)c(Cl)cc(C[C@H](N)C(=O)O)c1		Inactive	LAT1 Inhibitor		1	JPH203	384569490.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(OCc2c3oc(-c4ccccc4)nc3cc(N)c2)c(Cl)cc(C[C@H](N)C(=O)O)c1	Clc1c(OCc2c3oc(-c4ccccc4)nc3cc(N)c2)c(Cl)cc(C[C@H](N)C(=O)O)c1
NCGC00092346-08	Clc1c(OCc2cc(F)ccc2)ccc(Nc2ncnc3c2cc(-c2nc(CNCCS(=O)(=O)C)sc2)cc3)c1		Inactive			1	GW583340  dihydrochloride	377020202.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(OCc2cc(F)ccc2)ccc(Nc2ncnc3c2cc(-c2nc(CNCCS(=O)(=O)C)sc2)cc3)c1	Clc1c(OCc2cc(F)ccc2)ccc(Nc2ncnc3c2cc(-c2nc(CNCCS(=O)(=O)C)sc2)cc3)c1
NCGC00346478-06	Clc1c(OCc2cc(F)ccc2)ccc(Nc2ncnc3c2cc(NC(=O)C=C)cc3)c1		Inactive	HER2/4 Inhibitor		1	AST-1306	384568792.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(OCc2cc(F)ccc2)ccc(Nc2ncnc3c2cc(NC(=O)C=C)cc3)c1	Clc1c(OCc2cc(F)ccc2)ccc(Nc2ncnc3c2cc(NC(=O)C=C)cc3)c1
NCGC00386829-01	Clc1c(OCc2ccc(Cl)cc2)c(OCC)cc(CNC2CCCC2)c1		Inactive			1	NCGC00386829-01	363680454.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(OCc2ccc(Cl)cc2)c(OCC)cc(CNC2CCCC2)c1	Clc1c(OCc2ccc(Cl)cc2)c(OCC)cc(CNC2CCCC2)c1
NCGC00370832-01	Clc1c(OCc2ccccc2)ccc(Nc2c(/C=N/OCCN3CCOCC3)c(N)ncn2)c1		Inactive	EGFR Inhibitor		1	JNJ-28871063 hydrochloride	377020311.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	24.0233498	Clc1c(OCc2ccccc2)ccc(Nc2c(/C=N/OCCN3CCOCC3)c(N)ncn2)c1	Clc1c(OCc2ccccc2)ccc(Nc2c(/C=N/OCCN3CCOCC3)c(N)ncn2)c1
NCGC00241101-09&NCGC00241101-10	Clc1c(OCc2ncccc2)ccc(Nc2c(C#N)cnc3c2cc(NC(=O)/C=C/CN(C)C)c(OCC)c3)c1		Inactive	EGFR Inhibitor		2	Neratinib	405558751.0&384568471.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(OCc2ncccc2)ccc(Nc2c(C#N)cnc3c2cc(NC(=O)/C=C/CN(C)C)c(OCC)c3)c1	Clc1c(OCc2ncccc2)ccc(Nc2c(C#N)cnc3c2cc(NC(=O)/C=C/CN(C)C)c(OCC)c3)c1
NCGC00346724-02	Clc1c(OCc2sccn2)ccc(Nc2ncnc3c2cc(NC=2OC[C@@H](C)N=2)cc3)c1		Inactive	EGFR Inhibitor		1	Varlitinib tosylate	363677537.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	20.3849372439	Clc1c(OCc2sccn2)ccc(Nc2ncnc3c2cc(NC=2OC[C@@H](C)N=2)cc3)c1	Clc1c(OCc2sccn2)ccc(Nc2ncnc3c2cc(NC=2OC[C@@H](C)N=2)cc3)c1
NCGC00183855-01	Clc1c(Oc2c(CC(=O)O)cccc2)ccc(Cl)c1		Inactive	Cyclooxygenase Inhibitor		1	Fenclofenac	144206863.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Oc2c(CC(=O)O)cccc2)ccc(Cl)c1	Clc1c(Oc2c(CC(=O)O)cccc2)ccc(Cl)c1
NCGC00159417-05	Clc1c(Oc2c(O)cc(Cl)cc2)ccc(Cl)c1		Inactive	Bacterial enoyl-[acyl-carrier-protein] reductase Binding Agent		1	Triclosan	170464936.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(Oc2c(O)cc(Cl)cc2)ccc(Cl)c1	Clc1c(Oc2c(O)cc(Cl)cc2)ccc(Cl)c1
NCGC00346699-02	Clc1c(Oc2cc(C(F)(F)F)ccc2)ccc(Nc2ncnc3c2n(CCNC(=O)CC(O)(C)C)cc3)c1		Inactive	EGFR Inhibitor		1	TAK-285	384568919.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Oc2cc(C(F)(F)F)ccc2)ccc(Nc2ncnc3c2n(CCNC(=O)CC(O)(C)C)cc3)c1	Clc1c(Oc2cc(C(F)(F)F)ccc2)ccc(Nc2ncnc3c2n(CCNC(=O)CC(O)(C)C)cc3)c1
NCGC00402237-03	Clc1c(Oc2cc(N3CCNCC3)ccc2)sc(S(=O)(=O)NCc2c3c(ccc2)cccc3)c1		Inactive			1	B355252	363680993.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(Oc2cc(N3CCNCC3)ccc2)sc(S(=O)(=O)NCc2c3c(ccc2)cccc3)c1	Clc1c(Oc2cc(N3CCNCC3)ccc2)sc(S(=O)(=O)NCc2c3c(ccc2)cccc3)c1
NCGC00263144-09	Clc1c(Oc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1		Inactive	EGFR Inhibitor		1	WZ-4002	384568619.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Oc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1	Clc1c(Oc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1
NCGC00346496-05	Clc1c(Oc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(N3CCN(C)CC3)cc2)nc1		Inactive	EGFR Inhibitor		1	WZ-3146	384568802.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.878493968	Clc1c(Oc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(N3CCN(C)CC3)cc2)nc1	Clc1c(Oc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(N3CCN(C)CC3)cc2)nc1
NCGC00386309-03	Clc1c(Oc2cc(NC(=O)CC)ccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1		Inactive	NUAK kinase Inhibitor		1	WZ-4003	384569122.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	16.3432563839	Clc1c(Oc2cc(NC(=O)CC)ccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1	Clc1c(Oc2cc(NC(=O)CC)ccc2)nc(Nc2c(OC)cc(N3CCN(C)CC3)cc2)nc1
NCGC00386680-01	Clc1c(Oc2cnc3c(c2)cccc3)c(Cl)cc(NS(=O)(=O)c2c(Cl)cc(Cl)cc2)c1		Inactive	Peroxisome proliferator-activated receptor gamma Partial Agonist		1	INT 131	363680393.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	12.5	Clc1c(Oc2cnc3c(c2)cccc3)c(Cl)cc(NS(=O)(=O)c2c(Cl)cc(Cl)cc2)c1	Clc1c(Oc2cnc3c(c2)cccc3)c(Cl)cc(NS(=O)(=O)c2c(Cl)cc(Cl)cc2)c1
NCGC00257498-01	Clc1c(S(=O)(=O)C)ccc([C@H](C(=O)Nc2nccnc2)CC2CCCC2)c1		Inactive			1	PharmaGSID_48506	144213669.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(S(=O)(=O)C)ccc([C@H](C(=O)Nc2nccnc2)CC2CCCC2)c1	Clc1c(S(=O)(=O)C)ccc([C@H](C(=O)Nc2nccnc2)CC2CCCC2)c1
NCGC00257426-01	Clc1c(S(=O)(=O)C)ccc([C@H](C(=O)Nc2nccnc2)C[C@@H]2CC(=O)CC2)c1		Inactive			1	Piragliatin	144213898.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(S(=O)(=O)C)ccc([C@H](C(=O)Nc2nccnc2)C[C@@H]2CC(=O)CC2)c1	Clc1c(S(=O)(=O)C)ccc([C@H](C(=O)Nc2nccnc2)C[C@@H]2CC(=O)CC2)c1
NCGC00181340-02	Clc1c(S(=O)(=O)N)cc(-c2n[nH]nn2)c(NCc2sccc2)c1		Inactive			1	Azosemide	170465933.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(S(=O)(=O)N)cc(-c2n[nH]nn2)c(NCc2sccc2)c1	Clc1c(S(=O)(=O)N)cc(-c2n[nH]nn2)c(NCc2sccc2)c1
NCGC00018172-09&NCGC00018172-18	Clc1c(S(=O)(=O)N)cc(C(=O)NN2C(C)Cc3c2cccc3)cc1		Inactive	Carbonic Anhydrase Type VII Inhibitor		2	Indapamide	170465366.0&384567994.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1c(S(=O)(=O)N)cc(C(=O)NN2C(C)Cc3c2cccc3)cc1	Clc1c(S(=O)(=O)N)cc(C(=O)NN2C(C)Cc3c2cccc3)cc1
NCGC00274275-01	Clc1c(S(=O)(=O)N)cc(C(=O)NN2C[C@@H]3[C@@H](C4C[C@@H]3CC4)C2)cc1		Inactive	Solute carrier family 12 member 2 Inhibitor		1	Tripamide	170466047.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(S(=O)(=O)N)cc(C(=O)NN2C[C@@H]3[C@@H](C4C[C@@H]3CC4)C2)cc1	Clc1c(S(=O)(=O)N)cc(C(=O)NN2C[C@@H]3[C@@H](C4C[C@@H]3CC4)C2)cc1
NCGC00016527-06	Clc1c(S(=O)(=O)N)cc(C(=O)NN2[C@@H](C)CCC[C@H]2C)cc1		Inactive			1	Clopamine	405559024.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(S(=O)(=O)N)cc(C(=O)NN2[C@@H](C)CCC[C@H]2C)cc1	Clc1c(S(=O)(=O)N)cc(C(=O)NN2[C@@H](C)CCC[C@H]2C)cc1
NCGC00182543-02	Clc1c(S(=O)(=O)N)cc(C(=O)Nc2c(C)cccc2C)c(O)c1		Inactive	renal sodium excretion Activator		1	Xipamide	170466623.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(S(=O)(=O)N)cc(C(=O)Nc2c(C)cccc2C)c(O)c1	Clc1c(S(=O)(=O)N)cc(C(=O)Nc2c(C)cccc2C)c(O)c1
NCGC00016241-10	Clc1c(S(=O)(=O)N)cc(C(=O)O)c(NCc2occc2)c1		Inactive	Loop Diuretics		1	Furosemide	170464879.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(S(=O)(=O)N)cc(C(=O)O)c(NCc2occc2)c1	Clc1c(S(=O)(=O)N)cc(C(=O)O)c(NCc2occc2)c1
NCGC00094616-07	Clc1c(S(=O)(=O)N)cc(C2(O)NC(=O)c3c2cccc3)cc1		Inactive	renal sodium excretion Activator		1	Chlorthalidone	170464745.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(S(=O)(=O)N)cc(C2(O)NC(=O)c3c2cccc3)cc1	Clc1c(S(=O)(=O)N)cc(C2(O)NC(=O)c3c2cccc3)cc1
NCGC00183860-01	Clc1c(S(=O)(=O)N)cc(S(=O)(=O)N(CC2(C)OCCC2)C)cc1		Inactive	Carbonic anhydrase Inhibitor		1	Mefruside	144206878.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(S(=O)(=O)N)cc(S(=O)(=O)N(CC2(C)OCCC2)C)cc1	Clc1c(S(=O)(=O)N)cc(S(=O)(=O)N(CC2(C)OCCC2)C)cc1
NCGC00160444-02	Clc1c(S(=O)(=O)N)cc(S(=O)(=O)N)cc1		Inactive	Carbonic anhydrase Inhibitor		1	Clofenamide	170466058.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(S(=O)(=O)N)cc(S(=O)(=O)N)cc1	Clc1c(S(=O)(=O)N)cc(S(=O)(=O)N)cc1
NCGC00253608-01	Clc1c(S(=O)(=O)N)cc2C(=O)N(C3CCCCC3)Cc2c1		Inactive			1	Chlorexolone	170466039.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(S(=O)(=O)N)cc2C(=O)N(C3CCCCC3)Cc2c1	Clc1c(S(=O)(=O)N)cc2C(=O)N(C3CCCCC3)Cc2c1
NCGC00093985-11&NCGC00093985-19	Clc1c(S(=O)(=O)N)cc2C(=O)N(c3c(C)cccc3)C(C)Nc2c1		Inactive	Carbonic Anhydrase Type VII Inhibitor		2	Metolazone	170464665.0&384568122.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1c(S(=O)(=O)N)cc2C(=O)N(c3c(C)cccc3)C(C)Nc2c1	Clc1c(S(=O)(=O)N)cc2C(=O)N(c3c(C)cccc3)C(C)Nc2c1
NCGC00179351-03	Clc1c(S(=O)(=O)N)cc2C(=O)NC(CC)Nc2c1		Inactive	Thiazide-sensitive sodium-chloride cotransporter Inhibitor		1	Quinethazone	170465167.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(S(=O)(=O)N)cc2C(=O)NC(CC)Nc2c1	Clc1c(S(=O)(=O)N)cc2C(=O)NC(CC)Nc2c1
NCGC00182076-03	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)N(C)C(CSCC(F)(F)F)Nc2c1		Inactive	Thiazide-sensitive sodium-chloride cotransporter Inhibitor		1	Polythiazide	170465068.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)N(C)C(CSCC(F)(F)F)Nc2c1	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)N(C)C(CSCC(F)(F)F)Nc2c1
NCGC00015288-09	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(C3C4C=CC(C3)C4)Nc2c1		Inactive	renal sodium ion absorption Inhibitor		1	Cyclothiazide	170465274.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(C3C4C=CC(C3)C4)Nc2c1	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(C3C4C=CC(C3)C4)Nc2c1
NCGC00160540-03	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CC)Nc2c1		Inactive			1	Ethiazide	170465925.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CC)Nc2c1	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CC)Nc2c1
NCGC00179312-03	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CC3CCCC3)Nc2c1		Inactive	Solute carrier family 12 member 3 Inhibitor		1	Cyclopenthiazide	170466046.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CC3CCCC3)Nc2c1	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CC3CCCC3)Nc2c1
NCGC00016347-07	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CSCc3ccccc3)=Nc2c1		Inactive	Thiazide-sensitive sodium-chloride cotransporter Inhibitor		1	Benzthiazide	170465246.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CSCc3ccccc3)=Nc2c1	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(CSCc3ccccc3)=Nc2c1
NCGC00014617-01	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(Cc3ccccc3)Nc2c1		Inactive			1	Benzylhydrochlorothiazide	144203604.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(Cc3ccccc3)Nc2c1	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC(Cc3ccccc3)Nc2c1
NCGC00015242-13&NCGC00015242-16	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC=Nc2c1		Inactive	Hypertension treatment		2	Chlorothiazide	170465303.0&384567829.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC=Nc2c1	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NC=Nc2c1
NCGC00015508-16&NCGC00015508-23	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NCNc2c1		Inactive	Hypertension treatment		2	Hydrochlorothiazide	170465005.0&384567858.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NCNc2c1	Clc1c(S(=O)(=O)N)cc2S(=O)(=O)NCNc2c1
NCGC00346536-05&NCGC00346536-06	Clc1c(S(=O)(=O)NCCO)cc(-c2c(C)nc(NC(=O)C)s2)cc1		Inactive	PI3K Inhibitor		2	PIK-93	363677444.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	-8.516129032&0.0	Clc1c(S(=O)(=O)NCCO)cc(-c2c(C)nc(NC(=O)C)s2)cc1	Clc1c(S(=O)(=O)NCCO)cc(-c2c(C)nc(NC(=O)C)s2)cc1
NCGC00250409-02	Clc1c(S(=O)(=O)N[C@H](C(=O)N2CCN(C(=O)[C@@H](NC(=O)c3sc4c(c3)cccc4)CC(C)C)CC2)CO)ccc(Cl)c1		Inactive	TRPV4 Agonist		1	GSK-1016790A	384568557.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	25.1779123839	Clc1c(S(=O)(=O)N[C@H](C(=O)N2CCN(C(=O)[C@@H](NC(=O)c3sc4c(c3)cccc4)CC(C)C)CC2)CO)ccc(Cl)c1	Clc1c(S(=O)(=O)N[C@H](C(=O)N2CCN(C(=O)[C@@H](NC(=O)c3sc4c(c3)cccc4)CC(C)C)CC2)CO)ccc(Cl)c1
NCGC00371141-08	Clc1c(S(=O)(=O)Nc2c(Cl)cccc2)ccc(NC(=O)c2ncccc2)c1		Inactive	Metabotropic glutamate receptor 4 Positive Allosteric Modulator		1	VU0364439	363678055.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(S(=O)(=O)Nc2c(Cl)cccc2)ccc(NC(=O)c2ncccc2)c1	Clc1c(S(=O)(=O)Nc2c(Cl)cccc2)ccc(NC(=O)c2ncccc2)c1
NCGC00141596-01	Clc1c(S(=O)(=O)Nc2cc(-c3nnc(N4CCOCC4)cc3)ccc2)cc(C(F)(F)F)cc1		Inactive			1	NCGC00141596-01	24416979.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(S(=O)(=O)Nc2cc(-c3nnc(N4CCOCC4)cc3)ccc2)cc(C(F)(F)F)cc1	Clc1c(S(=O)(=O)Nc2cc(-c3nnc(N4CCOCC4)cc3)ccc2)cc(C(F)(F)F)cc1
NCGC00379178-01	Clc1c(S(=O)(=O)Nc2cc(OCCN(C)C)c(Cl)cc2)c(Cl)cc(C(F)(F)F)c1		Inactive	Urotensin II receptor Antagonist		1	SB 611812	363678400.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(S(=O)(=O)Nc2cc(OCCN(C)C)c(Cl)cc2)c(Cl)cc(C(F)(F)F)c1	Clc1c(S(=O)(=O)Nc2cc(OCCN(C)C)c(Cl)cc2)c(Cl)cc(C(F)(F)F)c1
NCGC00508855-01	Clc1c(S(=O)(=O)[C@@H]2CNCCC2)c(O)c(NC(=O)Nc2c(C)c(F)ccc2)cc1		Inactive	Chemokine CXCR2 (IL-8 beta Receptor) Antagonist		1	Danirixin	384569363.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(S(=O)(=O)[C@@H]2CNCCC2)c(O)c(NC(=O)Nc2c(C)c(F)ccc2)cc1	Clc1c(S(=O)(=O)[C@@H]2CNCCC2)c(O)c(NC(=O)Nc2c(C)c(F)ccc2)cc1
NCGC00179596-03&NCGC00179596-11	Clc1c(SC(CCc2ccc(Cl)cc2)Cn2cncc2)c(Cl)ccc1		Inactive	Antifungal Agent		2	Butoconazole nitrate	170464901.0&384568378.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0	Clc1c(SC(CCc2ccc(Cl)cc2)Cn2cncc2)c(Cl)ccc1.O=[N+](O)[O-]	Clc1c(SC(CCc2ccc(Cl)cc2)Cn2cncc2)c(Cl)ccc1.O=[N+](O)[O-]&Clc1c(SC(CCc2ccc(Cl)cc2)Cn2cncc2)c(Cl)ccc1
NCGC00346497-03	Clc1c(Sc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(N3CCN(C)CC3)cc2)nc1		Inactive	EGFR Inhibitor		1	WZ-8040	384568803.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(Sc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(N3CCN(C)CC3)cc2)nc1	Clc1c(Sc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(N3CCN(C)CC3)cc2)nc1
NCGC00484086-01	Clc1c([C@@H](C(=O)OC)N2CC3=CC(=O)SC3CC2)cccc1		Inactive	Cytochrome P450 2C19 Inhibitor		1	Clopidogrel thiolactone	363681177.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c([C@@H](C(=O)OC)N2CC3=CC(=O)SC3CC2)cccc1	Clc1c([C@@H](C(=O)OC)N2CC3=CC(=O)SC3CC2)cccc1
NCGC00163329-03&NCGC00163329-11	Clc1c([C@@H](C(=O)OC)N2Cc3c(scc3)CC2)cccc1		Inactive	P2Y12 (P2T) Antagonist		2	Clopidogrel bisulfate	170465231.0&384568233.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c([C@@H](C(=O)OC)N2Cc3c(scc3)CC2)cccc1.S(=O)(=O)(O)O	Clc1c([C@@H](C(=O)OC)N2Cc3c(scc3)CC2)cccc1.S(=O)(=O)(O)O&Clc1c([C@@H](C(=O)OC)N2Cc3c(scc3)CC2)cccc1
NCGC00183842-01	Clc1c([C@@H](O)CNC(C)(C)C)ccc(O)c1		Inactive	Beta-2 adrenergic receptor Agonist		1	Meluadrine	144206838.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c([C@@H](O)CNC(C)(C)C)ccc(O)c1	Clc1c([C@@H](O)CNC(C)(C)C)ccc(O)c1
NCGC00384190-03	Clc1c([C@@H](Oc2c(N)ncc(-c3cn(C4CCNCC4)nc3)c2)C)c(Cl)ccc1F		Inactive	HGFR (MET; c-Met) Inhibitor		1	(S)-Crizotinib	405558812.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c([C@@H](Oc2c(N)ncc(-c3cn(C4CCNCC4)nc3)c2)C)c(Cl)ccc1F	Clc1c([C@@H](Oc2c(N)ncc(-c3cn(C4CCNCC4)nc3)c2)C)c(Cl)ccc1F
NCGC00509996-01	Clc1c([C@@H]2C(C(=O)OC)=C(C)N=C(c3c(F)cc(F)cn3)N2)ccc(F)c1		Inactive	HIF Prolyl Hydroxylase Inhibitor		1	Vadadustat	384569403.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c([C@@H]2C(C(=O)OC)=C(C)N=C(c3c(F)cc(F)cn3)N2)ccc(F)c1	Clc1c([C@@H]2C(C(=O)OC)=C(C)N=C(c3c(F)cc(F)cn3)N2)ccc(F)c1
NCGC00016912-06	Clc1c([C@@]2(Cn3ncnc3)O[C@H](COc3ccc(N4CCN(C(C)C)CC4)cc3)CO2)ccc(Cl)c1		Inactive			1	Terconazole	405558493.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c([C@@]2(Cn3ncnc3)O[C@H](COc3ccc(N4CCN(C(C)C)CC4)cc3)CO2)ccc(Cl)c1	Clc1c([C@@]2(Cn3ncnc3)O[C@H](COc3ccc(N4CCN(C(C)C)CC4)cc3)CO2)ccc(Cl)c1
NCGC00476170-03	Clc1c([C@H](N(C(=O)[C@H]2N(c3nccc(C#N)c3)C(=O)CC2)c2cc(F)cnc2)C(=O)NC2CC(F)(F)C2)cccc1		Inactive	IDH1 Inhibitor		1	Ivosidenib	384569240.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c([C@H](N(C(=O)[C@H]2N(c3nccc(C#N)c3)C(=O)CC2)c2cc(F)cnc2)C(=O)NC2CC(F)(F)C2)cccc1	Clc1c([C@H](N(C(=O)[C@H]2N(c3nccc(C#N)c3)C(=O)CC2)c2cc(F)cnc2)C(=O)NC2CC(F)(F)C2)cccc1
NCGC00378914-01	Clc1c([C@H](OC(=O)Nc2c(-c3ccc(-c4ccc(CC(=O)O)cc4)cc3)onc2C)C)cccc1		Inactive	Lysophosphatidic acid receptor Edg-2 Antagonist		1	AM966	363678274.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c([C@H](OC(=O)Nc2c(-c3ccc(-c4ccc(CC(=O)O)cc4)cc3)onc2C)C)cccc1	Clc1c([C@H](OC(=O)Nc2c(-c3ccc(-c4ccc(CC(=O)O)cc4)cc3)onc2C)C)cccc1
NCGC00510267-01	Clc1c([C@H](OC)C2COC2)cc(Cl)c2c1C(=O)N(CC=1C(=O)NC(C)=CC=1OC)CC2		Inactive	EZH2 Inhibitor		1	PF-06821497	384569424.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c([C@H](OC)C2COC2)cc(Cl)c2c1C(=O)N(CC=1C(=O)NC(C)=CC=1OC)CC2	Clc1c([C@H](OC)C2COC2)cc(Cl)c2c1C(=O)N(CC=1C(=O)NC(C)=CC=1OC)CC2
NCGC00250400-05	Clc1c([C@H](Oc2c(N)ncc(-c3cn(C4CCNCC4)nc3)c2)C)c(Cl)ccc1F		Inactive	HGFR Inhibitor		1	Crizotinib	384568549.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c([C@H](Oc2c(N)ncc(-c3cn(C4CCNCC4)nc3)c2)C)c(Cl)ccc1F	Clc1c([C@H](Oc2c(N)ncc(-c3cn(C4CCNCC4)nc3)c2)C)c(Cl)ccc1F
NCGC00510479-01	Clc1c([C@H](Oc2c(N)nnc(C(=O)Nc3ccc(C(=O)N4CCN(C)CC4)cc3)c2)C)c(Cl)ccc1F		Inactive	ALK Inhibitor		1	Ensartinib	384569442.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.6081904519	Clc1c([C@H](Oc2c(N)nnc(C(=O)Nc3ccc(C(=O)N4CCN(C)CC4)cc3)c2)C)c(Cl)ccc1F	Clc1c([C@H](Oc2c(N)nnc(C(=O)Nc3ccc(C(=O)N4CCN(C)CC4)cc3)c2)C)c(Cl)ccc1F
NCGC00510002-01	Clc1c([C@H]2C(C(=O)OC)=C(C)N=C(c3c(F)cc(F)cn3)N2)ccc(F)c1		Inactive	Integrin Receptor Antagonist		1	GLPG0187	384569406.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c([C@H]2C(C(=O)OC)=C(C)N=C(c3c(F)cc(F)cn3)N2)ccc(F)c1	Clc1c([C@H]2C(C(=O)OC)=C(C)N=C(c3c(F)cc(F)cn3)N2)ccc(F)c1
NCGC00485358-01	Clc1c([C@H]2O[C@H]([C@@H](C/C=C\CCC(=O)O)CO2)c2c(O)cccc2)cccc1		Inactive	Thromboxane A2 receptor Antagonist		1	ICI 192605	363681297.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c([C@H]2O[C@H]([C@@H](C/C=C\CCC(=O)O)CO2)c2c(O)cccc2)cccc1	Clc1c([C@H]2O[C@H]([C@@H](C/C=C\CCC(=O)O)CO2)c2c(O)cccc2)cccc1
NCGC00182704-02	Clc1c([C@H]2S/C(=C(\C#N)/n3cncc3)/SC2)ccc(Cl)c1		Inactive	Lanosterol 14-alpha demethylase Inhibitor		1	Luliconazole	144206804.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c([C@H]2S/C(=C(\C#N)/n3cncc3)/SC2)ccc(Cl)c1	Clc1c([C@H]2S/C(=C(\C#N)/n3cncc3)/SC2)ccc(Cl)c1
NCGC00025000-14&NCGC00025000-22	Clc1c([C@]2(Cn3cncc3)O[C@@H](COc3ccc(N4CCN(C(=O)C)CC4)cc3)CO2)ccc(Cl)c1		Inactive	Aromatase Inhibitor		2	Ketoconazole	405559066.0&384568041.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&13.155853316	Clc1c([C@]2(Cn3cncc3)O[C@@H](COc3ccc(N4CCN(C(=O)C)CC4)cc3)CO2)ccc(Cl)c1	Clc1c([C@]2(Cn3cncc3)O[C@@H](COc3ccc(N4CCN(C(=O)C)CC4)cc3)CO2)ccc(Cl)c1
NCGC00386768-04	Clc1c([N+](=O)[O-])cc(C(=O)N2CCN(c3c(F)cccc3)CC2)cc1		Inactive	SEC14 cytosolic factor Inhibitor		1	SMI481	363680442.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c([N+](=O)[O-])cc(C(=O)N2CCN(c3c(F)cccc3)CC2)cc1	Clc1c([N+](=O)[O-])cc(C(=O)N2CCN(c3c(F)cccc3)CC2)cc1
NCGC00402305-04	Clc1c([N+](=O)[O-])cc(S(=O)(=O)Nc2c3c(c(O)cc2)cccc3)cc1		Inactive			1	SW155246		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	15.5365722479	Clc1c([N+](=O)[O-])cc(S(=O)(=O)Nc2c3c(c(O)cc2)cccc3)cc1	Clc1c([N+](=O)[O-])cc(S(=O)(=O)Nc2c3c(c(O)cc2)cccc3)cc1
NCGC00509912-01	Clc1c(c(Cl)c(OC)cc1OC)-c1cc2c(nc(N[C@H]3[C@@H](NC(=O)C=C)CCOC3)nc2)cc1	4.9000001	Active	FGFR4 Inhibitor	0.0	1	BLU-554	384569378.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	63.8418010088	Clc1c(c(Cl)c(OC)cc1OC)-c1cc2c(nc(N[C@H]3[C@@H](NC(=O)C=C)CCOC3)nc2)cc1	Clc1c(c(Cl)c(OC)cc1OC)-c1cc2c(nc(N[C@H]3[C@@H](NC(=O)C=C)CCOC3)nc2)cc1
NCGC00480785-05	Clc1c(c(Cl)c(OC)cc1OC)-c1cc2c(nc(Nc3c(NC(=O)C=C)cccc3C)nc2)cc1	4.9000001	Active	FGFR 4 Inhibitor	0.0	1	BLU-9931	377020469.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	46.2958424751	Clc1c(c(Cl)c(OC)cc1OC)-c1cc2c(nc(Nc3c(NC(=O)C=C)cccc3C)nc2)cc1	Clc1c(c(Cl)c(OC)cc1OC)-c1cc2c(nc(Nc3c(NC(=O)C=C)cccc3C)nc2)cc1
NCGC00386348-01	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)C2N=C(Nc3cc(SC)ccc3)N=CC2C=1		Inactive	Tyrosine-protein kinase SRC Inhibitor		1	PD173955	363680227.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)C2N=C(Nc3cc(SC)ccc3)N=CC2C=1	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)C2N=C(Nc3cc(SC)ccc3)N=CC2C=1
NCGC00345830-02	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3cc(C(=O)O)ccc3)ncc2C=1		Inactive	cSRC Inhibitor		1	PD-173955 Analogue 1	363677374.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3cc(C(=O)O)ccc3)ncc2C=1	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3cc(C(=O)O)ccc3)ncc2C=1
NCGC00345829-03	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3cc(SC)ccc3)ncc2C=1		Inactive	cSRC Inhibitor		1	PD-173955	377020285.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3cc(SC)ccc3)ncc2C=1	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3cc(SC)ccc3)ncc2C=1
NCGC00242490-05	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3ccc(OCCN(CC)CC)cc3)ncc2C=1	5.8499999	Active	cSRC Inhibitor	0.0	1	PD-166285	384568496.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	44.593500435	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3ccc(OCCN(CC)CC)cc3)ncc2C=1	Clc1c(c(Cl)ccc1)C=1C(=O)N(C)c2nc(Nc3ccc(OCCN(CC)CC)cc3)ncc2C=1
NCGC00241111-12	Clc1c(c(Cl)ccc1)C=1C(=O)N=CN2N=C(Sc3c(F)cc(F)cc3)C=CC=12		Inactive	p38 MAPK Inhibitor		1	VX-745	377020233.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(c(Cl)ccc1)C=1C(=O)N=CN2N=C(Sc3c(F)cc(F)cc3)C=CC=12	Clc1c(c(Cl)ccc1)C=1C(=O)N=CN2N=C(Sc3c(F)cc(F)cc3)C=CC=12
NCGC00531794-01	Clc1c(n(-c2ccc(S(=O)(=O)N)cc2)cn1)-c1cc(F)c(OC)cc1		Inactive			1	Cimicoxib	405559129.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c(n(-c2ccc(S(=O)(=O)N)cc2)cn1)-c1cc(F)c(OC)cc1	Clc1c(n(-c2ccc(S(=O)(=O)N)cc2)cn1)-c1cc(F)c(OC)cc1
NCGC00017134-08	Clc1c2C(=C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(=O)N)C(=O)[C@]4(O)C(O)=C3C(=O)c2c(O)cc1		Inactive			1	Meclocycline sulfosalicylate	405559138.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c2C(=C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(=O)N)C(=O)[C@]4(O)C(O)=C3C(=O)c2c(O)cc1.S(=O)(=O)(O)c1cc(C(=O)O)c(O)cc1	Clc1c2C(=C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(=O)N)C(=O)[C@]4(O)C(O)=C3C(=O)c2c(O)cc1.S(=O)(=O)(O)c1cc(C(=O)O)c(O)cc1
NCGC00485481-02	Clc1c2C(=O)N(c3cc(C(=O)N4CCC5(CC4)CCN(c4ccncc4)CC5)ccc3)Cc2ccc1		Inactive	Bradykinin B1 Receptor Antagonist		1	ELN-441958	384569275.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c2C(=O)N(c3cc(C(=O)N4CCC5(CC4)CCN(c4ccncc4)CC5)ccc3)Cc2ccc1	Clc1c2C(=O)N(c3cc(C(=O)N4CCC5(CC4)CCN(c4ccncc4)CC5)ccc3)Cc2ccc1
NCGC00351482-09&NCGC00351482-12	Clc1c2C(=O)N(c3ccccc3)C([C@@H](Nc3ncnc4[nH]cnc34)C)=Cc2ccc1		Inactive	PI3Kd/g Inhibitor		2	Duvelisib&IPI-145	384569009.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c2C(=O)N(c3ccccc3)C([C@@H](Nc3ncnc4[nH]cnc34)C)=Cc2ccc1	Clc1c2C(=O)N(c3ccccc3)C([C@@H](Nc3ncnc4[nH]cnc34)C)=Cc2ccc1
NCGC00510263-01	Clc1c2C(=O)N(c3cnccc3)C([C@@H](Nc3c(C#N)c(N)nc(N)n3)C3CC3)=Nc2c(F)cc1		Inactive	PI3Kdelta Inhibitor		1	GS-9901	384569421.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c2C(=O)N(c3cnccc3)C([C@@H](Nc3c(C#N)c(N)nc(N)n3)C3CC3)=Nc2c(F)cc1	Clc1c2C(=O)N(c3cnccc3)C([C@@H](Nc3c(C#N)c(N)nc(N)n3)C3CC3)=Nc2c(F)cc1
NCGC00389453-01	Clc1c2C(O)(C)C3C(C(=O)C4(O)C(O)=C(C(=O)N)C(=O)C(N(C)C)C4C3)=C(O)c2c(O)cc1		Inactive	translation Inhibitor		1	Chlortetracycline HCl	405558866.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c2C(O)(C)C3C(C(=O)C4(O)C(O)=C(C(=O)N)C(=O)C(N(C)C)C4C3)=C(O)c2c(O)cc1	Clc1c2C(O)(C)C3C(C(=O)C4(O)C(O)=C(C(=O)N)C(=O)C(N(C)C)C4C3)=C(O)c2c(O)cc1
NCGC00346886-09	Clc1c2C(O)(CC(=O)c3ccc(OC)cc3)C(=O)Nc2c(Cl)cc1		Inactive	EWS-FLI1 Inhibitor		1	YK-4-279	363677551.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c2C(O)(CC(=O)c3ccc(OC)cc3)C(=O)Nc2c(Cl)cc1	Clc1c2C(O)(CC(=O)c3ccc(OC)cc3)C(=O)Nc2c(Cl)cc1
NCGC00346701-07&NCGC00346701-09	Clc1c2C(O)=C(C(=O)N(CC)c3ccccc3)C(=O)N(C)c2ccc1		Inactive	Immunomodulators		2	Laquinimod	405558743.0&384568921.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c2C(O)=C(C(=O)N(CC)c3ccccc3)C(=O)N(C)c2ccc1	Clc1c2C(O)=C(C(=O)N(CC)c3ccccc3)C(=O)N(C)c2ccc1
NCGC00484083-01	Clc1c2Oc3c(O[C@H]4[C@H](O[C@@H]5O[C@@H](C)[C@@H](O)[C@](N)(C)C5)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc([C@@H](O)[C@H]6C(=O)N[C@H](C(=O)O)c7c(c(O)cc(O)c7)-c7c(O)ccc([C@H](C(=O)N6)NC(=O)[C@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](N)CC(C)C)[C@H](O)c(c1)cc2)c(c3)c4)c7)cc5		Inactive	Peptidoglycan biosynthesis Inhibitor		1	Norvancomycin (hydrochloride)	363681174.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c2Oc3c(O[C@H]4[C@H](O[C@@H]5O[C@@H](C)[C@@H](O)[C@](N)(C)C5)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc([C@@H](O)[C@H]6C(=O)N[C@H](C(=O)O)c7c(c(O)cc(O)c7)-c7c(O)ccc([C@H](C(=O)N6)NC(=O)[C@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](N)CC(C)C)[C@H](O)c(c1)cc2)c(c3)c4)c7)cc5	Clc1c2Oc3c(O[C@H]4[C@H](O[C@@H]5O[C@@H](C)[C@@H](O)[C@](N)(C)C5)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc([C@@H](O)[C@H]6C(=O)N[C@H](C(=O)O)c7c(c(O)cc(O)c7)-c7c(O)ccc([C@H](C(=O)N6)NC(=O)[C@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](N)CC(C)C)[C@H](O)c(c1)cc2)c(c3)c4)c7)cc5
NCGC00485990-01	Clc1c2Oc3c(O[C@H]4[C@H](O[C@@H]5O[C@@H](C)[C@@H](O)[C@](N)(C)C5)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc([C@@H](O)[C@H]6C(=O)N[C@H](C(=O)O)c7c(c(O)cc(O)c7)-c7c(O)ccc([C@H](C(=O)N6)NC(=O)[C@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](NC)C(C)(C)C)[C@H](O)c(c1)cc2)c(c3)c4)c7)cc5		Inactive			1	Vancomycin (hydrochloride)	363681467.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c2Oc3c(O[C@H]4[C@H](O[C@@H]5O[C@@H](C)[C@@H](O)[C@](N)(C)C5)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc([C@@H](O)[C@H]6C(=O)N[C@H](C(=O)O)c7c(c(O)cc(O)c7)-c7c(O)ccc([C@H](C(=O)N6)NC(=O)[C@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](NC)C(C)(C)C)[C@H](O)c(c1)cc2)c(c3)c4)c7)cc5	Clc1c2Oc3c(O[C@H]4[C@H](O[C@@H]5O[C@@H](C)[C@@H](O)[C@](N)(C)C5)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc([C@@H](O)[C@H]6C(=O)N[C@H](C(=O)O)c7c(c(O)cc(O)c7)-c7c(O)ccc([C@H](C(=O)N6)NC(=O)[C@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](NC)C(C)(C)C)[C@H](O)c(c1)cc2)c(c3)c4)c7)cc5
NCGC00162383-04&NCGC00162383-05	Clc1c2Oc3c(O[C@H]4[C@H](O[C@@H]5O[C@@H](C)[C@@H](O)[C@](N)(C)C5)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc([C@@H](O)[C@H]6C(=O)N[C@H](C(=O)O)c7c(c(O)cc(O)c7)-c7c(O)ccc([C@H](C(=O)N6)NC(=O)[C@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](NC)CC(C)C)[C@H](O)c(c1)cc2)c(c3)c4)c7)cc5		Inactive	glycopeptide antibiotic		2	Vancomycin hydrochloride	405558582.0&384568223.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c2Oc3c(O[C@H]4[C@H](O[C@@H]5O[C@@H](C)[C@@H](O)[C@](N)(C)C5)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc([C@@H](O)[C@H]6C(=O)N[C@H](C(=O)O)c7c(c(O)cc(O)c7)-c7c(O)ccc([C@H](C(=O)N6)NC(=O)[C@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](NC)CC(C)C)[C@H](O)c(c1)cc2)c(c3)c4)c7)cc5	Clc1c2Oc3c(O[C@H]4[C@H](O[C@@H]5O[C@@H](C)[C@@H](O)[C@](N)(C)C5)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc([C@@H](O)[C@H]6C(=O)N[C@H](C(=O)O)c7c(c(O)cc(O)c7)-c7c(O)ccc([C@H](C(=O)N6)NC(=O)[C@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](NC)CC(C)C)[C@H](O)c(c1)cc2)c(c3)c4)c7)cc5
NCGC00485478-02	Clc1c2Oc3c(O[C@H]4[C@H](O[C@@H]5O[C@@H](C)[C@H](O)[C@](NCc6ccc(-c7ccc(Cl)cc7)cc6)(C)C5)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc([C@@H](O[C@@H]6O[C@@H](C)[C@H](O)[C@](N)(C)C6)[C@H]6C(=O)N[C@H](C(=O)O)c7c(c(O)cc(O)c7)-c7c(O)ccc([C@H](C(=O)N6)NC(=O)[C@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](NC)CC(C)C)[C@H](O)c(c1)cc2)c(c3)c4)c7)cc5		Inactive			1	Oritavancin (diphosphate)	434147160.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0	0.0&0.0	Clc1c2Oc3c(O[C@H]4[C@H](O[C@@H]5O[C@@H](C)[C@H](O)[C@](NCc6ccc(-c7ccc(Cl)cc7)cc6)(C)C5)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc([C@@H](O[C@@H]6O[C@@H](C)[C@H](O)[C@](N)(C)C6)[C@H]6C(=O)N[C@H](C(=O)O)c7c(c(O)cc(O)c7)-c7c(O)ccc([C@H](C(=O)N6)NC(=O)[C@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](NC)CC(C)C)[C@H](O)c(c1)cc2)c(c3)c4)c7)cc5	Clc1c2Oc3c(O[C@H]4[C@H](O[C@@H]5O[C@@H](C)[C@H](O)[C@](NCc6ccc(-c7ccc(Cl)cc7)cc6)(C)C5)[C@@H](O)[C@H](O)[C@@H](CO)O4)c4Oc5c(Cl)cc([C@@H](O[C@@H]6O[C@@H](C)[C@H](O)[C@](N)(C)C6)[C@H]6C(=O)N[C@H](C(=O)O)c7c(c(O)cc(O)c7)-c7c(O)ccc([C@H](C(=O)N6)NC(=O)[C@H](NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](NC(=O)[C@H](NC)CC(C)C)[C@H](O)c(c1)cc2)c(c3)c4)c7)cc5
NCGC00162149-07	Clc1c2[C@@H](O)[C@@H]3C(C(=O)c2c(O)cc1)=C(O)[C@]1(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]1C3		Inactive	Bacterial 70S ribosome Inhibitor		1	Demeclocycline hydrochloride	170465205.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1c2[C@@H](O)[C@@H]3C(C(=O)c2c(O)cc1)=C(O)[C@]1(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]1C3.Cl	Clc1c2[C@@H](O)[C@@H]3C(C(=O)c2c(O)cc1)=C(O)[C@]1(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]1C3.Cl
NCGC00370731-05	Clc1c2[nH]c(-c3nc(C4CCC(C(=O)O)CC4)n4c3C(N)=NC=C4)cc2ccc1		Inactive	Serine/threonine-protein kinase mTOR Inhibitor		1	OXA-01	384569035.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c2[nH]c(-c3nc(C4CCC(C(=O)O)CC4)n4c3C(N)=NC=C4)cc2ccc1	Clc1c2[nH]c(-c3nc(C4CCC(C(=O)O)CC4)n4c3C(N)=NC=C4)cc2ccc1
NCGC00378970-01	Clc1c2[nH]cc(C[C@@H]3C(=O)N(C)C(=O)N3)c2ccc1		Inactive			1	Necrostatin 2	384569079.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c2[nH]cc(C[C@@H]3C(=O)N(C)C(=O)N3)c2ccc1	Clc1c2[nH]cc(C[C@@H]3C(=O)N(C)C(=O)N3)c2ccc1
NCGC00390744-01	Clc1c2[nH]cc(C[C@H]3C(=O)N(C)C(=O)N3)c2ccc1		Inactive	RIP1 Kinase Inhibitor		1	Necrostatin 2	363680980.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c2[nH]cc(C[C@H]3C(=O)N(C)C(=O)N3)c2ccc1	Clc1c2[nH]cc(C[C@H]3C(=O)N(C)C(=O)N3)c2ccc1
NCGC00263106-03	Clc1c2c(/C=C/C(=O)Nc3ccccc3)c(C(=O)O)[nH]c2cc(Cl)c1		Inactive	NMDA Glycine-Site Antagonist		1	Gavestinel	363677206.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c2c(/C=C/C(=O)Nc3ccccc3)c(C(=O)[O-])[nH]c2cc(Cl)c1	Clc1c2c(/C=C/C(=O)Nc3ccccc3)c(C(=O)[O-])[nH]c2cc(Cl)c1
NCGC00163269-02	Clc1c2c(CCC(=O)O)c(C(=O)O)[nH]c2cc(Cl)c1		Inactive	Fructose-1,6-bisphosphatase Inhibitor		1	MDL29951	363676614.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c2c(CCC(=O)O)c(C(=O)O)[nH]c2cc(Cl)c1	Clc1c2c(CCC(=O)O)c(C(=O)O)[nH]c2cc(Cl)c1
NCGC00254535-01	Clc1c2c(N=C3N(C2)CCCCC3)cc(Cl)c1		Inactive			1	PharmaGSID_47259	144210745.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c2c(N=C3N(C2)CCCCC3)cc(Cl)c1.Cl	Clc1c2c(N=C3N(C2)CCCCC3)cc(Cl)c1.Cl
NCGC00507893-01	Clc1c2c(c(NC(=N)N)nc1)cc(S(=O)(=O)NC(C(=O)O)(C)C)cc2		Inactive	Urokinase (u-PA) Inhibitor		1	UK-371804	384569356.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c2c(c(NC(=N)N)nc1)cc(S(=O)(=O)NC(C(=O)O)(C)C)cc2	Clc1c2c(c(NC(=N)N)nc1)cc(S(=O)(=O)NC(C(=O)O)(C)C)cc2
NCGC00390261-01	Clc1c2c(c(NS(=O)(=O)c3ccc(S(=O)(=O)N)cc3)ccc2)[nH]c1		Inactive	Carbonic Anhydrase Type I/II/IV/VB/IX Inhibitor		1	Indisulam (E7070)	384569182.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c2c(c(NS(=O)(=O)c3ccc(S(=O)(=O)N)cc3)ccc2)[nH]c1	Clc1c2c(c(NS(=O)(=O)c3ccc(S(=O)(=O)N)cc3)ccc2)[nH]c1
NCGC00162403-05	Clc1c2c(c(O)c(C(=O)N[C@H](C(=O)O)Cc3ccccc3)c1)C(=O)O[C@H](C)C2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	Ochratoxin A	363676611.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c2c(c(O)c(C(=O)N[C@H](C(=O)O)Cc3ccccc3)c1)C(=O)O[C@H](C)C2	Clc1c2c(c(O)c(C(=O)N[C@H](C(=O)O)Cc3ccccc3)c1)C(=O)O[C@H](C)C2
NCGC00095303-04	Clc1c2c(c(O)cc1)nccc2		Inactive	Mycobacterium tuberculosis Inhibitor		1	Cloxyquin	170465523.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1c2c(c(O)cc1)nccc2	Clc1c2c(c(O)cc1)nccc2
NCGC00015214-07	Clc1c2c(c(S(=O)(=O)N3CCNCCC3)ccc2)ccc1	4.9000001	Active	cAMP-dependent protein kinase (PKA) Inhibitor	0.0	1	ML-9	90340625.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	3.0	68.316100054	Clc1c2c(c(S(=O)(=O)N3CCNCCC3)ccc2)ccc1	Clc1c2c(c(S(=O)(=O)N3CCNCCC3)ccc2)ccc1
NCGC00179250-03	Clc1c2c(c3c(c(C(O)CCN(CCCC)CCCC)c2)ccc(C(F)(F)F)c3)cc(Cl)c1	4.9499998	Active	antimalarial agents	0.0	1	Halofantrine	170465140.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	103.60639383&116.7285289989	Clc1c2c(c3c(c(C(O)CCN(CCCC)CCCC)c2)ccc(C(F)(F)F)c3)cc(Cl)c1.Cl	Clc1c2c(c3c(c(C(O)CCN(CCCC)CCCC)c2)ccc(C(F)(F)F)c3)cc(Cl)c1.Cl
NCGC00387035-02	Clc1c2c(cc(Nc3nc(O[C@@H](CN(C)C)C)c(C#N)nc3)nc2)ccc1		Inactive	Chk1 Inhibitor		1	SAR-020106	384569149.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.3378985159	Clc1c2c(cc(Nc3nc(O[C@@H](CN(C)C)C)c(C#N)nc3)nc2)ccc1	Clc1c2c(cc(Nc3nc(O[C@@H](CN(C)C)C)c(C#N)nc3)nc2)ccc1
NCGC00378705-01	Clc1c2c(nc3c1CCCC3)ccc(C(=O)NCCCN(Cc1ccccc1)C)c2	4.9000001	Active	Ubiquitin carboxyl-terminal hydrolase 7 Inhibitor	0.0	1	HBX 19818	363678159.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	110.1870476145	Clc1c2c(nc3c1CCCC3)ccc(C(=O)NCCCN(Cc1ccccc1)C)c2	Clc1c2c(nc3c1CCCC3)ccc(C(=O)NCCCN(Cc1ccccc1)C)c2
NCGC00380694-01	Clc1c2c3[C@]4(O)[C@@H](C(C)(C)O[C@@H]5c6c3c([nH]c6[C@]3(C)[C@]6(C)[C@](O)([C@@]78O[C@@H]7[C@H]7OC(C)(C)[C@H]7O[C@H]8CC6)CCC53)c1)C[C@@H]4C(=C)C2	5.4499998	Active	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00380694-01	363678713.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	3.0	78.7218543072	Clc1c2c3[C@]4(O)[C@@H](C(C)(C)O[C@@H]5c6c3c([nH]c6[C@]3(C)[C@]6(C)[C@](O)([C@@]78O[C@@H]7[C@H]7OC(C)(C)[C@H]7O[C@H]8CC6)CCC53)c1)C[C@@H]4C(=C)C2	Clc1c2c3[C@]4(O)[C@@H](C(C)(C)O[C@@H]5c6c3c([nH]c6[C@]3(C)[C@]6(C)[C@](O)([C@@]78O[C@@H]7[C@H]7OC(C)(C)[C@H]7O[C@H]8CC6)CCC53)c1)C[C@@H]4C(=C)C2
NCGC00163403-03	Clc1c2c3[C@]4(O)[C@@H](C(C)(C)O[C@H]5[C@H]6[C@@](C)([C@]7(C)[C@](O)([C@@]89O[C@@H]8[C@@H](O)[C@@H](C(=C)C)O[C@H]9CC7)CC6)c6[nH]c(c3c56)c1)C[C@@H]4C(=C)C2		Inactive	<MOA Unknown> | Class: alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	PENITREM A	363676617.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1c2c3[C@]4(O)[C@@H](C(C)(C)O[C@H]5[C@H]6[C@@](C)([C@]7(C)[C@](O)([C@@]89O[C@@H]8[C@@H](O)[C@@H](C(=C)C)O[C@H]9CC7)CC6)c6[nH]c(c3c56)c1)C[C@@H]4C(=C)C2	Clc1c2c3[C@]4(O)[C@@H](C(C)(C)O[C@H]5[C@H]6[C@@](C)([C@]7(C)[C@](O)([C@@]89O[C@@H]8[C@@H](O)[C@@H](C(=C)C)O[C@H]9CC7)CC6)c6[nH]c(c3c56)c1)C[C@@H]4C(=C)C2
NCGC00346471-03	Clc1c2n([C@@H]3[C@@H](O)[C@H](O)[C@@H](OC)[C@H](CO)O3)c3c4[nH]c5c(Cl)cccc5c4c4C(=O)NC(=O)c4c3c2ccc1		Inactive	DNA Topoisomerase I Inhibitor		1	Rebeccamycin	384568789.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Clc1c2n([C@@H]3[C@@H](O)[C@H](O)[C@@H](OC)[C@H](CO)O3)c3c4[nH]c5c(Cl)cccc5c4c4C(=O)NC(=O)c4c3c2ccc1	Clc1c2n([C@@H]3[C@@H](O)[C@H](O)[C@@H](OC)[C@H](CO)O3)c3c4[nH]c5c(Cl)cccc5c4c4C(=O)NC(=O)c4c3c2ccc1
NCGC00481602-01	Clc1c2n(c(NC(=O)c3cc(C)ncc3)nc2ccc1)C1CN(C(=O)/C=C/CN(C)C)CCCC1	4.9499998	Active		0.0	1	EGF816	377020292.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	38.2	Clc1c2n(c(NC(=O)c3cc(C)ncc3)nc2ccc1)C1CN(C(=O)/C=C/CN(C)C)CCCC1	Clc1c2n(c(NC(=O)c3cc(C)ncc3)nc2ccc1)C1CN(C(=O)/C=C/CN(C)C)CCCC1
NCGC00509999-02	Clc1c2nc(c([C@@H](Nc3ncnc4c3nccc4)C(F)(F)F)cc2ccc1)-c1c[n+]([O-])ccc1		Inactive	PI3K delta Inhibitor		1	Seletalisib	384569405.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1c2nc(c([C@@H](Nc3ncnc4c3nccc4)C(F)(F)F)cc2ccc1)-c1c[n+]([O-])ccc1	Clc1c2nc(c([C@@H](Nc3ncnc4c3nccc4)C(F)(F)F)cc2ccc1)-c1c[n+]([O-])ccc1
NCGC00378871-01	Clc1c2sc(C(=O)N[C@@H]3C4CCN(C3)CC4)cc2ccc1		Inactive	Neuronal acetylcholine receptor protein alpha-7 subunit Partial Agonist		1	EVP-6124 hydrochloride	363678249.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	32.1333333279	Clc1c2sc(C(=O)N[C@@H]3C4CCN(C3)CC4)cc2ccc1	Clc1c2sc(C(=O)N[C@@H]3C4CCN(C3)CC4)cc2ccc1
NCGC00345018-01	Clc1cc(-c2c(OC)ccc(Cc3ccc(NC(=O)N)cc3)c2)ccc1		Inactive	Phosphodiesterase IIII D (PDE4D) Inhibitor		1	D-159687	174006279.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.68410042	Clc1cc(-c2c(OC)ccc(Cc3ccc(NC(=O)N)cc3)c2)ccc1	Clc1cc(-c2c(OC)ccc(Cc3ccc(NC(=O)N)cc3)c2)ccc1
NCGC00510490-01	Clc1cc(-c2cc(C(=O)NCc3nc(OC)c(OC)cc3)c(-c3ncccc3)nc2)cnc1		Inactive	Orexin OX-2 Receptor Antagonist		1	MK-1064	384569452.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(-c2cc(C(=O)NCc3nc(OC)c(OC)cc3)c(-c3ncccc3)nc2)cnc1	Clc1cc(-c2cc(C(=O)NCc3nc(OC)c(OC)cc3)c(-c3ncccc3)nc2)cnc1
NCGC00509994-02	Clc1cc(-c2cc(O)c(C(=O)NCC(=O)O)nc2)ccc1		Inactive			1	Vadadustat	384569401.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(-c2cc(O)c(C(=O)NCC(=O)O)nc2)ccc1	Clc1cc(-c2cc(O)c(C(=O)NCC(=O)O)nc2)ccc1
NCGC00350511-01	Clc1cc(-c2ccc(-c3oc(CCCc4nc5ncccc5cc4)nn3)cc2)ccc1		Inactive	GPR91 Inhibitor		1	PRP003-073	384569004.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(-c2ccc(-c3oc(CCCc4nc5ncccc5cc4)nn3)cc2)ccc1	Clc1cc(-c2ccc(-c3oc(CCCc4nc5ncccc5cc4)nn3)cc2)ccc1
NCGC00165898-11	Clc1cc(-c2nc(Nc3ccncc3)c3nccnc3n2)c(F)cc1	4.9499998	Active	TGF-bR1 (ALK5) Inhibitor	0.0	1	SD-208	384568296.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.4	34.2218922359	Clc1cc(-c2nc(Nc3ccncc3)c3nccnc3n2)c(F)cc1	Clc1cc(-c2nc(Nc3ccncc3)c3nccnc3n2)c(F)cc1
NCGC00344091-03	Clc1cc(-c2oc(-c3[nH]c(c(-c4ccc(OC)cc4)n3)-c3ccc(OC)cc3)cc2)ccc1		Inactive	neurogenesis Activator		1	Neurodazine	363677327.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(-c2oc(-c3[nH]c(c(-c4ccc(OC)cc4)n3)-c3ccc(OC)cc3)cc2)ccc1	Clc1cc(-c2oc(-c3[nH]c(c(-c4ccc(OC)cc4)n3)-c3ccc(OC)cc3)cc2)ccc1
NCGC00370746-10	Clc1cc(-c2oc(C(=O)Nc3ccc(CN4CCOCC4)cc3)cc2)ccc1		Inactive	Protein kinase C mu Inhibitor		1	CID-2011756	363677833.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	35.23955774	Clc1cc(-c2oc(C(=O)Nc3ccc(CN4CCOCC4)cc3)cc2)ccc1	Clc1cc(-c2oc(C(=O)Nc3ccc(CN4CCOCC4)cc3)cc2)ccc1
NCGC00485953-01	Clc1cc(-n2nc(C)cc2)c([C@@H](Oc2nc(N)nc(-c3ccc(C[C@H](N)C(=O)O)cc3)c2)C(F)(F)F)cc1		Inactive			1	Telotristat	363681440.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(-n2nc(C)cc2)c([C@@H](Oc2nc(N)nc(-c3ccc(C[C@H](N)C(=O)O)cc3)c2)C(F)(F)F)cc1	Clc1cc(-n2nc(C)cc2)c([C@@H](Oc2nc(N)nc(-c3ccc(C[C@H](N)C(=O)O)cc3)c2)C(F)(F)F)cc1
NCGC00390241-07&NCGC00390241-09	Clc1cc(-n2nc(C)cc2)c([C@@H](Oc2nc(N)nc(-c3ccc(C[C@H](N)C(=O)OCC)cc3)c2)C(F)(F)F)cc1		Inactive	5-HT Release Inhibitor		2	LX1606 (Hippurate)&Telotristat Etiprate (LX 1606 Hippurate)	405559103.0&384569180.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	22.1744730681&24.2445319359	Clc1cc(-n2nc(C)cc2)c([C@@H](Oc2nc(N)nc(-c3ccc(C[C@H](N)C(=O)OCC)cc3)c2)C(F)(F)F)cc1	Clc1cc(-n2nc(C)cc2)c([C@@H](Oc2nc(N)nc(-c3ccc(C[C@H](N)C(=O)OCC)cc3)c2)C(F)(F)F)cc1
NCGC00487352-01	Clc1cc(-n2ncc3C(=O)NC(SC(C(=O)N)C)=Nc23)ccc1		Inactive			1	HS38	377020191.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(-n2ncc3C(=O)NC(SC(C(=O)N)C)=Nc23)ccc1	Clc1cc(-n2ncc3C(=O)NC(SC(C(=O)N)C)=Nc23)ccc1
NCGC00384181-05	Clc1cc(/C(=N/NC(=O)c2cc(S(=O)(=O)N3CCOCC3)ccc2)/C)c(O)cc1		Inactive			1	SP2509	384569103.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	26.4970284453	Clc1cc(/C(=N/NC(=O)c2cc(S(=O)(=O)N3CCOCC3)ccc2)/C)c(O)cc1	Clc1cc(/C(=N/NC(=O)c2cc(S(=O)(=O)N3CCOCC3)ccc2)/C)c(O)cc1
NCGC00386882-01	Clc1cc(/C=C/C(=O)NCC(=O)N(C)C2CCS(=O)(=O)CC2)ccc1		Inactive	In vivo Inhibitor of KLF5 and EGR1 expression		1	ML264	384569147.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	29.6298389539	Clc1cc(/C=C/C(=O)NCC(=O)N(C)C2CCS(=O)(=O)CC2)ccc1	Clc1cc(/C=C/C(=O)NCC(=O)N(C)C2CCS(=O)(=O)CC2)ccc1
NCGC00485217-01	Clc1cc(/C=C/c2n(C)c3N(C)C(=O)N(C)C(=O)c3n2)ccc1		Inactive	Monoamine oxidase B Inhibitor		1	8-(3-Chlorostyryl)caffeine	363681256.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(/C=C/c2n(C)c3N(C)C(=O)N(C)C(=O)c3n2)ccc1	Clc1cc(/C=C/c2n(C)c3N(C)C(=O)N(C)C(=O)c3n2)ccc1
NCGC00015122-11&NCGC00015122-14	Clc1cc(C(=O)C(NC(C)(C)C)C)ccc1		Inactive	Dopamine Transporter (DAT) Inhibitor		2	Bupropion hydrochloride	170464747.0&363676440.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1cc(C(=O)C(NC(C)(C)C)C)ccc1.Cl	Clc1cc(C(=O)C(NC(C)(C)C)C)ccc1.Cl&Clc1cc(C(=O)C(NC(C)(C)C)C)ccc1
NCGC00522116-02	Clc1cc(C(=O)N2[C@H](c3nn4c(N=C(N5C[C@@H](N)CC5)C(C)=C4)c3)CCCC2)c(NS(=O)(=O)C)cc1		Inactive			1	Presatovir	434147170.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(C(=O)N2[C@H](c3nn4c(N=C(N5C[C@@H](N)CC5)C(C)=C4)c3)CCCC2)c(NS(=O)(=O)C)cc1	Clc1cc(C(=O)N2[C@H](c3nn4c(N=C(N5C[C@@H](N)CC5)C(C)=C4)c3)CCCC2)c(NS(=O)(=O)C)cc1
NCGC00024563-11	Clc1cc(C(=O)NC2C3CCN(C2)CC3)c2OCC(=O)N(C)c2c1		Inactive	5-HT3 Receptor Antagonist		1	Azasetron hydrochloride	384568029.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(C(=O)NC2C3CCN(C2)CC3)c2OCC(=O)N(C)c2c1	Clc1cc(C(=O)NC2C3CCN(C2)CC3)c2OCC(=O)N(C)c2c1
NCGC00386636-01	Clc1cc(C(=O)NCCc2cc(S(=O)(=O)NC(=S)NC)c(OC)cc2)c(OC)cc1		Inactive	Sulfonylurea receptor 1, Kir6.2 Antagonist		1	HMR 1098	363680365.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(C(=O)NCCc2cc(S(=O)(=O)NC(=S)NC)c(OC)cc2)c(OC)cc1	Clc1cc(C(=O)NCCc2cc(S(=O)(=O)NC(=S)NC)c(OC)cc2)c(OC)cc1
NCGC00253706-02	Clc1cc(C(=O)NCCc2ccc(S(=O)(=O)N)cc2)c(OC)cc1		Inactive			1	N-(2-(4-sulfamoyl)phenyl)ethyl-5-chloro-2-methoxybenzamide	363677186.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(C(=O)NCCc2ccc(S(=O)(=O)N)cc2)c(OC)cc1	Clc1cc(C(=O)NCCc2ccc(S(=O)(=O)N)cc2)c(OC)cc1
NCGC00015467-20	Clc1cc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)c(OC)cc1		Inactive	Sulfonylurea receptor 2 Modulator		1	Glybenclamide	170464964.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1cc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)c(OC)cc1	Clc1cc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)c(OC)cc1
NCGC00165811-08	Clc1cc(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c(O)cc1		Inactive	IKK beta Inhibitor		1	IMD-0354	384568285.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Clc1cc(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c(O)cc1	Clc1cc(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c(O)cc1
NCGC00189231-01	Clc1cc(C(=O)O)c(NC(=O)C(SC)Cc2ccc(Cl)cc2)cc1		Inactive			1	NCGC00189231-01	104224372.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(C(=O)O)c(NC(=O)C(SC)Cc2ccc(Cl)cc2)cc1	Clc1cc(C(=O)O)c(NC(=O)C(SC)Cc2ccc(Cl)cc2)cc1
NCGC00486932-01	Clc1cc(C(=O)O)c(NC(=O)COCC(=O)N2CCN(C(c3ccccc3)c3ccccc3)CC2)cc1		Inactive	PAI Inhibitor		1	TM-5275	384569281.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(C(=O)O)c(NC(=O)COCC(=O)N2CCN(C(c3ccccc3)c3ccccc3)CC2)cc1	Clc1cc(C(=O)O)c(NC(=O)COCC(=O)N2CCN(C(c3ccccc3)c3ccccc3)CC2)cc1
NCGC00249937-01	Clc1cc(C(=O)OC)c(NS(=O)(=O)C(F)(F)F)cc1		Inactive			1	Amidoflumet	170465981.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(C(=O)OC)c(NS(=O)(=O)C(F)(F)F)cc1	Clc1cc(C(=O)OC)c(NS(=O)(=O)C(F)(F)F)cc1
NCGC00485483-01	Clc1cc(C(=O)c2cc[n+]([O-])cc2)c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)cc1		Inactive	C-C chemokine receptor type 9 Antagonist		1	Vercirnon	363681352.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(C(=O)c2cc[n+]([O-])cc2)c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)cc1	Clc1cc(C(=O)c2cc[n+]([O-])cc2)c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)cc1
NCGC00167490-03	Clc1cc(C(O)CN(CCCC)CCCC)c-2c(/C(=C\c3ccc(Cl)cc3)/c3c-2ccc(Cl)c3)c1		Inactive	antimalarial agents		1	Lumefantrine	170465388.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&32.354768156	Clc1cc(C(O)CN(CCCC)CCCC)c-2c(/C(=C\c3ccc(Cl)cc3)/c3c-2ccc(Cl)c3)c1	Clc1cc(C(O)CN(CCCC)CCCC)c-2c(/C(=C\c3ccc(Cl)cc3)/c3c-2ccc(Cl)c3)c1
NCGC00181034-03&NCGC00181034-04	Clc1cc(C(n2cncc2)c2cc3[nH]cnc3cc2)ccc1		Inactive	Cytochrome P450 CYP17A1 Inhibitor		2	Liarozole	170465610.0&384568388.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1cc(C(n2cncc2)c2cc3[nH]cnc3cc2)ccc1.Cl	Clc1cc(C(n2cncc2)c2cc3[nH]cnc3cc2)ccc1.Cl&Clc1cc(C(n2cncc2)c2cc3[nH]cnc3cc2)ccc1
NCGC00087387-05	Clc1cc(C)c(OCCCC(=O)NO)cc1		Inactive	HDAC Inhibitor		1	Droxinostat	384568077.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1cc(C)c(OCCCC(=O)NO)cc1	Clc1cc(C)c(OCCCC(=O)NO)cc1
NCGC00389510-02	Clc1cc(C=2c3c(N(C)C(=O)C=2)ccc(C(N)(c2n(C)cnc2)c2ccc(Cl)cc2)c3)ccc1		Inactive	Farnesyltransferase Inhibitor		1	Tipifarnib,Freebase	363680793.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(C=2c3c(N(C)C(=O)C=2)ccc(C(N)(c2n(C)cnc2)c2ccc(Cl)cc2)c3)ccc1	Clc1cc(C=2c3c(N(C)C(=O)C=2)ccc(C(N)(c2n(C)cnc2)c2ccc(Cl)cc2)c3)ccc1
NCGC00386609-01	Clc1cc(CC2=C(C)n3nc(C(=O)NCc4ncccc4)cc3N=C2C)ccc1		Inactive			1	Unknown	363680353.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(CC2=C(C)n3nc(C(=O)NCc4ncccc4)cc3N=C2C)ccc1	Clc1cc(CC2=C(C)n3nc(C(=O)NCc4ncccc4)cc3N=C2C)ccc1
NCGC00508901-01	Clc1cc(CN(C(=O)[C@]2(C)N(C(=O)c3c4c(sc3)cccc4)CC2)CCCC(=O)O)ccc1		Inactive	Free Fatty Acid Receptor 2 (FFAR2; GPR43) Antagonist		1	GLPG-0974	384569372.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(CN(C(=O)[C@]2(C)N(C(=O)c3c4c(sc3)cccc4)CC2)CCCC(=O)O)ccc1	Clc1cc(CN(C(=O)[C@]2(C)N(C(=O)c3c4c(sc3)cccc4)CC2)CCCC(=O)O)ccc1
NCGC00386899-01	Clc1cc(CN2CCC(CNC(=O)[C@H]3CN(c4ncnc5n6c(nc45)CCCC6)CCC3)CC2)ccc1		Inactive			1	NCGC00386899-01	363680491.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(CN2CCC(CNC(=O)[C@H]3CN(c4ncnc5n6c(nc45)CCCC6)CCC3)CC2)ccc1	Clc1cc(CN2CCC(CNC(=O)[C@H]3CN(c4ncnc5n6c(nc45)CCCC6)CCC3)CC2)ccc1
NCGC00381477-05	Clc1cc(CN2[C@H](C(F)(F)F)CCN3C(=O)C=C(N4[C@H](C)COCC4)N=C23)cnc1		Inactive	VPS34 Inhibitor		1	SAR-405	384569098.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	30.876894804	Clc1cc(CN2[C@H](C(F)(F)F)CCN3C(=O)C=C(N4[C@H](C)COCC4)N=C23)cnc1	Clc1cc(CN2[C@H](C(F)(F)F)CCN3C(=O)C=C(N4[C@H](C)COCC4)N=C23)cnc1
NCGC00370813-01	Clc1cc(CNCCc2ccc(NC(=N)c3sccc3)cc2)ccc1	4.9499998	Active	Nitric oxide synthase, brain Inhibitor	0.0	1	ARL 17477 dihydrochloride	363677864.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	104.7673478052	Clc1cc(CNCCc2ccc(NC(=N)c3sccc3)cc2)ccc1	Clc1cc(CNCCc2ccc(NC(=N)c3sccc3)cc2)ccc1
NCGC00371074-02	Clc1cc(COc2nc(N3CCNCC3)cnc2)ccc1	4.9000001	Active	Serotonin 2c (5-HT2c) receptor Agonist	0.0	1	CP-809101 (hydrochloride)	363678018.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	35.803317536	Clc1cc(COc2nc(N3CCNCC3)cnc2)ccc1	Clc1cc(COc2nc(N3CCNCC3)cnc2)ccc1
NCGC00386232-01	Clc1cc(C[C@H](NC(=O)c2n(C)nc(C(C)(C)C)c2)C(=O)NCC#N)ccc1	6.5500002	Active		0.0	1	Cathepsin Inhibitor 1	363680160.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	1.3	82.1162527344	Clc1cc(C[C@H](NC(=O)c2n(C)nc(C(C)(C)C)c2)C(=O)NCC#N)ccc1	Clc1cc(C[C@H](NC(=O)c2n(C)nc(C(C)(C)C)c2)C(=O)NCC#N)ccc1
NCGC00091325-09	Clc1cc(Cc2c(O)ccc(Cl)c2)c(O)cc1		Inactive	Indoleamine 2,3-dioxygenase Inhibitor		1	Dichlorophen	170465475.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	26.875250428&20.3326439719	Clc1cc(Cc2c(O)ccc(Cl)c2)c(O)cc1	Clc1cc(Cc2c(O)ccc(Cl)c2)c(O)cc1
NCGC00091532-06	Clc1cc(Cc2ccccc2)c(O)cc1		Inactive			1	Clorophene	170465725.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(Cc2ccccc2)c(O)cc1	Clc1cc(Cc2ccccc2)c(O)cc1
NCGC00390731-01	Clc1cc(Cl)cc(-c2oc3c(n2)ccc(C(=O)O)c3)c1		Inactive	Transthyretin Modulator		1	Tafamidis	405558810.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(Cl)cc(-c2oc3c(n2)ccc(C(=O)O)c3)c1	Clc1cc(Cl)cc(-c2oc3c(n2)ccc(C(=O)O)c3)c1
NCGC00386915-01	Clc1cc(Cl)cc(C(=O)NCC2[C@H]3[C@@H]2CN(CCC(C)(C)C)C3)c1		Inactive			1	NCGC00386915-01	363680502.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	23.338395372	Clc1cc(Cl)cc(C(=O)NCC2[C@H]3[C@@H]2CN(CCC(C)(C)C)C3)c1	Clc1cc(Cl)cc(C(=O)NCC2[C@H]3[C@@H]2CN(CCC(C)(C)C)C3)c1
NCGC00509862-02	Clc1cc(Cl)cc(C2(C(F)(F)F)ON=C(c3cc(C)c(C(=O)NCC(=O)NCC(F)(F)F)cc3)C2)c1	4.9499998	Active		0.0	1	Fluralaner	405558651.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	39.0737704919	Clc1cc(Cl)cc(C2(C(F)(F)F)ON=C(c3cc(C)c(C(=O)NCC(=O)NCC(F)(F)F)cc3)C2)c1	Clc1cc(Cl)cc(C2(C(F)(F)F)ON=C(c3cc(C)c(C(=O)NCC(=O)NCC(F)(F)F)cc3)C2)c1
NCGC00263194-02	Clc1cc(Cl)cc(C2=C(c3c4c(n(C)c3)cccc4)C(=O)NC2=O)c1		Inactive	GSK-3 Inhibitor		1	SB-216763	384568658.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(Cl)cc(C2=C(c3c4c(n(C)c3)cccc4)C(=O)NC2=O)c1	Clc1cc(Cl)cc(C2=C(c3c4c(n(C)c3)cccc4)C(=O)NC2=O)c1
NCGC00241342-03	Clc1cc(Cl)cc(CNc2c(-c3cc4OCOc4cc3)cncn2)c1		Inactive	Clk Inhibitor		1	KUC107550N	377020353.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(Cl)cc(CNc2c(-c3cc4OCOc4cc3)cncn2)c1	Clc1cc(Cl)cc(CNc2c(-c3cc4OCOc4cc3)cncn2)c1
NCGC00346939-07	Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3cc4OC(=O)Nc4cc3)CC2)c1		Inactive	Phosphodiesterase II (ENPP2; Autotaxin) Inhibitor		1	PF-8380	384568973.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3cc4OC(=O)Nc4cc3)CC2)c1	Clc1cc(Cl)cc(COC(=O)N2CCN(CCC(=O)c3cc4OC(=O)Nc4cc3)CC2)c1
NCGC00244248-01	Clc1cc(Cl)cc(Cn2c(C[C@H](N[C@H](C(=O)O)CC(C)C)C(=O)O)cnc2)c1		Inactive			1	NCGC00244248-01		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0	0.0&0.0	Clc1cc(Cl)cc(Cn2c(C[C@H](N[C@H](C(=O)O)CC(C)C)C(=O)O)cnc2)c1	Clc1cc(Cl)cc(Cn2c(C[C@H](N[C@H](C(=O)O)CC(C)C)C(=O)O)cnc2)c1
NCGC00521067-01	Clc1cc(Cl)cc(N2C(=O)N(C)[C@]3([C@H](c4ccc(C#N)cc4)CN(Cc4scc(C(=O)O)c4)C3)C2=O)c1		Inactive	ICAM-1 Inhibitor		1	BMS-587101	384569504.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(Cl)cc(N2C(=O)N(C)[C@]3([C@H](c4ccc(C#N)cc4)CN(Cc4scc(C(=O)O)c4)C3)C2=O)c1	Clc1cc(Cl)cc(N2C(=O)N(C)[C@]3([C@H](c4ccc(C#N)cc4)CN(Cc4scc(C(=O)O)c4)C3)C2=O)c1
NCGC00370997-01	Clc1cc(Cl)cc(S(=O)(=O)N2[C@H](C(=O)N[C@H](C(=O)O)CCNC(=O)[C@@H](N(C(=O)Cc3ccc(NC(=O)Nc4c(C)cccc4)cc3)C)CC(C)C)CCC2)c1		Inactive	Integrin alpha-4/beta-1 Antagonist		1	BIO 5192	363677984.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(Cl)cc(S(=O)(=O)N2[C@H](C(=O)N[C@H](C(=O)O)CCNC(=O)[C@@H](N(C(=O)Cc3ccc(NC(=O)Nc4c(C)cccc4)cc3)C)CC(C)C)CCC2)c1	Clc1cc(Cl)cc(S(=O)(=O)N2[C@H](C(=O)N[C@H](C(=O)O)CCNC(=O)[C@@H](N(C(=O)Cc3ccc(NC(=O)Nc4c(C)cccc4)cc3)C)CC(C)C)CCC2)c1
NCGC00420895-01	Clc1cc(Cl)cc(Sc2n(CCCNC(C)C)c3ncnc(N)c3n2)c1		Inactive	Heat Shock Protein 90 (hsp90) Inhibitor		1	PU-WS-13	384569227.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	19.397451708	Clc1cc(Cl)cc(Sc2n(CCCNC(C)C)c3ncnc(N)c3n2)c1	Clc1cc(Cl)cc(Sc2n(CCCNC(C)C)c3ncnc(N)c3n2)c1
NCGC00345461-06	Clc1cc(F)c(Cc2c(C)nc3C(CN4CCOCC4)=CC(Nc4[nH]nc(C)c4)=Nn23)cc1		Inactive	Jak2 Inhibitor		1	Gandotinib	384568735.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(F)c(Cc2c(C)nc3C(CN4CCOCC4)=CC(Nc4[nH]nc(C)c4)=Nn23)cc1	Clc1cc(F)c(Cc2c(C)nc3C(CN4CCOCC4)=CC(Nc4[nH]nc(C)c4)=Nn23)cc1
NCGC00402296-03	Clc1cc(F)c(NC(=O)c2c(O)cccc2)cc1		Inactive	Dipeptidyl peptidase IV Inhibitor		1	NDMC101	363681019.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(F)c(NC(=O)c2c(O)cccc2)cc1	Clc1cc(F)c(NC(=O)c2c(O)cccc2)cc1
NCGC00384175-04	Clc1cc(N(S(=O)(=O)C)CC(=O)Nc2c(F)cccc2F)c(C)cc1		Inactive			1	FPH1	363679176.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(N(S(=O)(=O)C)CC(=O)Nc2c(F)cccc2F)c(C)cc1	Clc1cc(N(S(=O)(=O)C)CC(=O)Nc2c(F)cccc2F)c(C)cc1
NCGC00165902-08	Clc1cc(N(S(=O)(=O)c2cc3/C(=C/c4c(C)c(C(=O)N5CCN(C)CC5)c(C)[nH]4)/C(=O)Nc3cc2)C)ccc1	4.9000001	Active	HGFR Inhibitor	0.0	1	SU-MI-2	384568297.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	87.935679022	Clc1cc(N(S(=O)(=O)c2cc3/C(=C/c4c(C)c(C(=O)N5CCN(C)CC5)c(C)[nH]4)/C(=O)Nc3cc2)C)ccc1	Clc1cc(N(S(=O)(=O)c2cc3/C(=C/c4c(C)c(C(=O)N5CCN(C)CC5)c(C)[nH]4)/C(=O)Nc3cc2)C)ccc1
NCGC00350413-05	Clc1cc(N/N=C(\C#N)/C(=O)c2noc(C(C)(C)C)c2)ccc1		Inactive			1	ESI-09	434147260.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	19.0955056159	Clc1cc(N/N=C(\C#N)/C(=O)c2noc(C(C)(C)C)c2)ccc1	Clc1cc(N/N=C(\C#N)/C(=O)c2noc(C(C)(C)C)c2)ccc1
NCGC00508850-01	Clc1cc(N2C(=O)CN(Cc3n(Cc4ccc(C#N)cc4)cnc3)CC2)ccc1		Inactive	Farnesyltransferase Inhibitor		1	L-778123	384569362.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(N2C(=O)CN(Cc3n(Cc4ccc(C#N)cc4)cnc3)CC2)ccc1	Clc1cc(N2C(=O)CN(Cc3n(Cc4ccc(C#N)cc4)cnc3)CC2)ccc1
NCGC00346805-02	Clc1cc(N2CCN(C(=O)c3n(-c4ccccc4)nc(C)c3)CC2)ccc1		Inactive	Tubulin polymerization Inhibitor		1	XRP-44X	363677543.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(N2CCN(C(=O)c3n(-c4ccccc4)nc(C)c3)CC2)ccc1	Clc1cc(N2CCN(C(=O)c3n(-c4ccccc4)nc(C)c3)CC2)ccc1
NCGC00112793-01	Clc1cc(N2CCN(C=3n4nc(-c5cnccc5)nc4-c4c(N=3)cccc4)CC2)ccc1		Inactive			1	NCGC00112793-01	24387372.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(N2CCN(C=3n4nc(-c5cnccc5)nc4-c4c(N=3)cccc4)CC2)ccc1	Clc1cc(N2CCN(C=3n4nc(-c5cnccc5)nc4-c4c(N=3)cccc4)CC2)ccc1
NCGC00015173-08	Clc1cc(N2CCN(CC(O)C(c3ccccc3)c3ccccc3)CC2)ccc1		Inactive	5-HT1D Receptor Antagonist		1	BRL-15572	363676443.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(N2CCN(CC(O)C(c3ccccc3)c3ccccc3)CC2)ccc1	Clc1cc(N2CCN(CC(O)C(c3ccccc3)c3ccccc3)CC2)ccc1
NCGC00165846-04	Clc1cc(N2CCN(CCCN3C(=O)N(CCOc4ccccc4)C(CC)=N3)CC2)ccc1		Inactive	Serotonin transporter Antagonist		1	Nefazodone hydrochloride	170465078.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(N2CCN(CCCN3C(=O)N(CCOc4ccccc4)C(CC)=N3)CC2)ccc1.Cl	Clc1cc(N2CCN(CCCN3C(=O)N(CCOc4ccccc4)C(CC)=N3)CC2)ccc1.Cl
NCGC00016035-13	Clc1cc(N2CCN(CCCN3C(=O)N4C(=N3)C=CC=C4)CC2)ccc1		Inactive	alpha2-Adrenoceptor Antagonists		1	Trazodone hydrochloride	170465234.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1cc(N2CCN(CCCN3C(=O)N4C(=N3)C=CC=C4)CC2)ccc1.Cl	Clc1cc(N2CCN(CCCN3C(=O)N4C(=N3)C=CC=C4)CC2)ccc1.Cl
NCGC00485404-01	Clc1cc(NC(=O)/C=C/c2ccc(CCCCC)cc2)c(C(=O)O)cc1		Inactive	Calcium-independent phospholipase A2 Inhibitor		1	ONO-RS-082	363681317.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(NC(=O)/C=C/c2ccc(CCCCC)cc2)c(C(=O)O)cc1	Clc1cc(NC(=O)/C=C/c2ccc(CCCCC)cc2)c(C(=O)O)cc1
NCGC00370909-03	Clc1cc(NC(=O)N)c(OCC(=O)N2[C@H](C)CN(Cc3ccc(F)cc3)CC2)cc1		Inactive	Chemokine CCR1 Receptor Antagonist		1	BX-471	363677927.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(NC(=O)N)c(OCC(=O)N2[C@H](C)CN(Cc3ccc(F)cc3)CC2)cc1	Clc1cc(NC(=O)N)c(OCC(=O)N2[C@H](C)CN(Cc3ccc(F)cc3)CC2)cc1
NCGC00092384-05	Clc1cc(NC(=O)NC=2N(C)CC(=O)N=2)ccc1		Inactive	mgluR5 Antagonist		1	Fenobam	384568110.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(NC(=O)NC=2N(C)CC(=O)N=2)ccc1	Clc1cc(NC(=O)NC=2N(C)CC(=O)N=2)ccc1
NCGC00162341-09	Clc1cc(NC(=O)Nc2c3c(nc(C)c2)cccc3)c(OC)cc1		Inactive	Insulin-like growth factor 1 receptor Inhibitor		1	PQ401	377020157.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	14.7	Clc1cc(NC(=O)Nc2c3c(nc(C)c2)cccc3)c(OC)cc1	Clc1cc(NC(=O)Nc2c3c(nc(C)c2)cccc3)c(OC)cc1
NCGC00242482-11	Clc1cc(NC(=O)Nc2sc(CCNc3ncnc4c3scc4)cn2)ccc1		Inactive	Aurora-A/B/C Kinase Inhibitor		1	SNS-314	377020426.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.266998344	Clc1cc(NC(=O)Nc2sc(CCNc3ncnc4c3scc4)cn2)ccc1	Clc1cc(NC(=O)Nc2sc(CCNc3ncnc4c3scc4)cn2)ccc1
NCGC00244259-01	Clc1cc(NC(=O)c2c(C(=O)Nc3[nH]c4c(n3)cccc4)[nH]cn2)c(C)cc1		Inactive			1	NCGC00244259-01	377020325.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(NC(=O)c2c(C(=O)Nc3[nH]c4c(n3)cccc4)[nH]cn2)c(C)cc1	Clc1cc(NC(=O)c2c(C(=O)Nc3[nH]c4c(n3)cccc4)[nH]cn2)c(C)cc1
NCGC00165873-03	Clc1cc(NC(=O)c2cnccc2)c2[nH]c3c(c2c1)ccnc3		Inactive	IKK beta Inhibitor		1	PS-1145	384568293.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(NC(=O)c2cnccc2)c2[nH]c3c(c2c1)ccnc3	Clc1cc(NC(=O)c2cnccc2)c2[nH]c3c(c2c1)ccnc3
NCGC00386341-01	Clc1cc(NC(=S)Nc2c(C(=O)N)nn(CC)c2)c(OC)cc1		Inactive			1	FPH2 (BRD-9424)	363680223.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(NC(=S)Nc2c(C(=O)N)nn(CC)c2)c(OC)cc1	Clc1cc(NC(=S)Nc2c(C(=O)N)nn(CC)c2)c(OC)cc1
NCGC00387841-01	Clc1cc(NCc2sc(C(=O)NC(C(=O)NC3CC3)CC3CCCC3)cc2)c(C)nc1		Inactive	Protein phosphatase 1D (PP-2Cdelta; WIP1) Allosteric Inhibitor		1	GSK-2830371	363680692.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(NCc2sc(C(=O)NC(C(=O)NC3CC3)CC3CCCC3)cc2)c(C)nc1	Clc1cc(NCc2sc(C(=O)NC(C(=O)NC3CC3)CC3CCCC3)cc2)c(C)nc1
NCGC00378599-01	Clc1cc(NS(=O)(=O)C)c(F)c(-c2c(-c3nc(NC[C@@H](NC(=O)OC)C)ncc3)cn(C(C)C)n2)c1		Inactive	Raf Kinase Inhibitor B (V600E Mutant)		1	Encorafenib	384569054.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(NS(=O)(=O)C)c(F)c(-c2c(-c3nc(NC[C@@H](NC(=O)OC)C)ncc3)cn(C(C)C)n2)c1	Clc1cc(NS(=O)(=O)C)c(F)c(-c2c(-c3nc(NC[C@@H](NC(=O)OC)C)ncc3)cn(C(C)C)n2)c1
NCGC00186544-01	Clc1cc(NS(=O)(=O)c2cc3c(NC(=O)CC3)cc2)ccc1		Inactive			1	NCGC00186544-01	87915628.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(NS(=O)(=O)c2cc3c(NC(=O)CC3)cc2)ccc1	Clc1cc(NS(=O)(=O)c2cc3c(NC(=O)CC3)cc2)ccc1
NCGC00181760-01	Clc1cc(Nc2c(C(=O)O)cccc2)c(C(=O)O)cc1		Inactive	response to oxidative stress Modulator		1	Lobenzarit sodium	144206494.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(Nc2c(C(=O)[O-])cccc2)c(C(=O)[O-])cc1.[Na+].[Na+]	Clc1cc(Nc2c(C(=O)[O-])cccc2)c(C(=O)[O-])cc1.[Na+].[Na+]
NCGC00346940-03	Clc1cc(Nc2nc(-c3cc(NCCCO)ncc3)ccn2)ccc1	4.9499998	Active	CDK1/2 Inhibitor	0.0	1	CGP-60474	384568974.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.4	73.1144757271	Clc1cc(Nc2nc(-c3cc(NCCCO)ncc3)ccn2)ccc1	Clc1cc(Nc2nc(-c3cc(NCCCO)ncc3)ccn2)ccc1
NCGC00390411-01	Clc1cc(Nc2nc(NC(C(C)C)CO)nc3n(C(C)C)cnc23)cc(N)c1		Inactive	Cyclin-dependent kinase 1/cyclin B Inhibitor		1	AminopurvalanolA	363680891.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(Nc2nc(NC(C(C)C)CO)nc3n(C(C)C)cnc23)cc(N)c1	Clc1cc(Nc2nc(NC(C(C)C)CO)nc3n(C(C)C)cnc23)cc(N)c1
NCGC00378928-02	Clc1cc(Nc2nc(NCCO)nc3n(C(C)C)cnc23)ccc1		Inactive	Glycogen synthase kinase-3 beta Inhibitor		1	NG-52	363678283.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(Nc2nc(NCCO)nc3n(C(C)C)cnc23)ccc1	Clc1cc(Nc2nc(NCCO)nc3n(C(C)C)cnc23)ccc1
NCGC00025219-10	Clc1cc(Nc2nc(N[C@H](C(C)C)CO)nc3n(C(C)C)cnc23)ccc1		Inactive	CDK1/2/3/4/5 Inhibitor		1	Purvalanol A	377020478.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.5951953239	Clc1cc(Nc2nc(N[C@H](C(C)C)CO)nc3n(C(C)C)cnc23)ccc1	Clc1cc(Nc2nc(N[C@H](C(C)C)CO)nc3n(C(C)C)cnc23)ccc1
NCGC00263192-04	Clc1cc(Nc2nc3c(c4c2ccnc4)ccc(C(=O)O)c3)ccc1		Inactive	Casein Kinase 2 Inhibitor		1	Silmitasertib	384568656.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1cc(Nc2nc3c(c4c2ccnc4)ccc(C(=O)O)c3)ccc1	Clc1cc(Nc2nc3c(c4c2ccnc4)ccc(C(=O)O)c3)ccc1
NCGC00016017-20	Clc1cc(Nc2ncnc3c2cc(OC)c(OC)c3)ccc1		Inactive	EGFR Inhibitor		1	AG-1478	363676471.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(Nc2ncnc3c2cc(OC)c(OC)c3)ccc1	Clc1cc(Nc2ncnc3c2cc(OC)c(OC)c3)ccc1
NCGC00508866-01	Clc1cc(OC=2C(=O)N(CC=3N(C)C(=O)NN=3)C=CC=2C(F)(F)F)cc(C#N)c1		Inactive			1	MK-1439	434147221.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(OC=2C(=O)N(CC=3N(C)C(=O)NN=3)C=CC=2C(F)(F)F)cc(C#N)c1	Clc1cc(OC=2C(=O)N(CC=3N(C)C(=O)NN=3)C=CC=2C(F)(F)F)cc(C#N)c1
NCGC00249416-01	Clc1cc(OCC(O)CNC(CNc2ccc(C=3C(C)CC(=O)NN=3)cc2)(C)C)c(C#N)cc1		Inactive	Adrenergic receptor beta Antagonist		1	Oberadilol	144206753.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(OCC(O)CNC(CNc2ccc(C=3C(C)CC(=O)NN=3)cc2)(C)C)c(C#N)cc1	Clc1cc(OCC(O)CNC(CNc2ccc(C=3C(C)CC(=O)NN=3)cc2)(C)C)c(C#N)cc1
NCGC00181914-01	Clc1cc(OCC=C)c(C(=O)NCCN(CC)CC)cc1		Inactive			1	Alloclamide	144206889.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1cc(OCC=C)c(C(=O)NCCN(CC)CC)cc1	Clc1cc(OCC=C)c(C(=O)NCCN(CC)CC)cc1
NCGC00165774-05	Clc1cc(OC[C@H](O)/C=C/[C@@H]2[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]2O)ccc1		Inactive			1	Cloprostenol (sodium salt)	405558813.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(OC[C@H](O)/C=C/[C@@H]2[C@@H](C/C=C\CCCC(=O)[O-])[C@@H](O)C[C@H]2O)ccc1	Clc1cc(OC[C@H](O)/C=C/[C@@H]2[C@@H](C/C=C\CCCC(=O)[O-])[C@@H](O)C[C@H]2O)ccc1
NCGC00370925-02	Clc1cc(OCc2nn(C3CCOCC3)c3ncnc(N)c23)ccc1		Inactive	Casein Kinase 1 Inhibitor		1	PF-4800567	363677938.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(OCc2nn(C3CCOCC3)c3ncnc(N)c23)ccc1	Clc1cc(OCc2nn(C3CCOCC3)c3ncnc(N)c23)ccc1
NCGC00386893-01	Clc1cc(OCc2oc(C(=O)Nc3scc(C)n3)cc2)ccc1		Inactive			1	NCGC00386893-01	363680488.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(OCc2oc(C(=O)Nc3scc(C)n3)cc2)ccc1	Clc1cc(OCc2oc(C(=O)Nc3scc(C)n3)cc2)ccc1
NCGC00371013-01	Clc1cc([C@@H](O)CN[C@@H]2Cc3c(ccc(OCC(=O)OCC)c3)CC2)ccc1		Inactive	Beta-3 adrenergic receptor Agonist		1	SR 58611A hydrochloride	363677993.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc([C@@H](O)CN[C@@H]2Cc3c(ccc(OCC(=O)OCC)c3)CC2)ccc1	Clc1cc([C@@H](O)CN[C@@H]2Cc3c(ccc(OCC(=O)OCC)c3)CC2)ccc1
NCGC00387801-02	Clc1cc([C@@H]2[C@H](N([C@@H](C(C)C)CS(=O)(=O)C(C)C)C(=O)[C@](CC(=O)O)(C)C2)c2ccc(Cl)cc2)ccc1		Inactive	MDM2 (hdm2) Inhibitor		1	AMG-232	384569162.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc([C@@H]2[C@H](N([C@@H](C(C)C)CS(=O)(=O)C(C)C)C(=O)[C@](CC(=O)O)(C)C2)c2ccc(Cl)cc2)ccc1	Clc1cc([C@@H]2[C@H](N([C@@H](C(C)C)CS(=O)(=O)C(C)C)C(=O)[C@](CC(=O)O)(C)C2)c2ccc(Cl)cc2)ccc1
NCGC00346460-05	Clc1cc([C@H](O)CNC2=C(c3[nH]c4c(c(C)cc(N5CCOCC5)c4)n3)C(=O)NC=C2)ccc1		Inactive	IGF-1R Inhibitor		1	BMS-536924	363677414.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc([C@H](O)CNC2=C(c3[nH]c4c(c(C)cc(N5CCOCC5)c4)n3)C(=O)NC=C2)ccc1	Clc1cc([C@H](O)CNC2=C(c3[nH]c4c(c(C)cc(N5CCOCC5)c4)n3)C(=O)NC=C2)ccc1
NCGC00378838-02	Clc1cc([C@H](OCCNC(=O)OC)[C@H]2CN(C(=O)NC[C@@H](NC)C[C@@H]3COCCC3)CCC2)ccc1		Inactive	Renin Inhibitor		1	VTP-27999 (2,2,2-trifluoroacetate)	363678228.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc([C@H](OCCNC(=O)OC)[C@H]2CN(C(=O)NC[C@@H](NC)C[C@@H]3COCCC3)CCC2)ccc1	Clc1cc([C@H](OCCNC(=O)OC)[C@H]2CN(C(=O)NC[C@@H](NC)C[C@@H]3COCCC3)CCC2)ccc1
NCGC00370824-01	Clc1cc([N+](=O)[O-])c(S(=O)(=O)N2CCN(Cc3ccccc3)CC2)cc1		Inactive	Transient receptor potential cation channel subfamily M member 8 Antagonist		1	RN 1747	363677871.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc([N+](=O)[O-])c(S(=O)(=O)N2CCN(Cc3ccccc3)CC2)cc1	Clc1cc([N+](=O)[O-])c(S(=O)(=O)N2CCN(Cc3ccccc3)CC2)cc1
NCGC00164578-02&NCGC00164578-06	Clc1cc(c(-c2cnc(C)cc2)nc1)-c1ccc(S(=O)(=O)C)cc1		Inactive	Cyclooxygenase Inhibitor		2	Etoricoxib	170465621.0&384568258.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1cc(c(-c2cnc(C)cc2)nc1)-c1ccc(S(=O)(=O)C)cc1	Clc1cc(c(-c2cnc(C)cc2)nc1)-c1ccc(S(=O)(=O)C)cc1
NCGC00485488-01	Clc1cc(c(O)cc1)C1=NC(=O)C(C#N)C(c2cc(OCc3ccccc3)cc(OCc3ccccc3)c2)=C1		Inactive	Baculoviral IAP repeat-containing protein 5 Binding Agent		1	LLP-3	363681357.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc(c(O)cc1)C1=NC(=O)C(C#N)C(c2cc(OCc3ccccc3)cc(OCc3ccccc3)c2)=C1	Clc1cc(c(O)cc1)C1=NC(=O)C(C#N)C(c2cc(OCc3ccccc3)cc(OCc3ccccc3)c2)=C1
NCGC00521070-01	Clc1cc(c(OC)cc1)C=1N(CC(=O)N)C(=S)NC(=O)C=1		Inactive	myeloperoxidase Inhibitor		1	PF-06282999	384569505.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc(c(OC)cc1)C=1N(CC(=O)N)C(=S)NC(=O)C=1	Clc1cc(c(OC)cc1)C=1N(CC(=O)N)C(=S)NC(=O)C=1
NCGC00386524-01	Clc1cc(c(OC)cc1)[C@@]1(F)C(=O)Nc2c1ccc(C(F)(F)F)c2	4.9000001	Active	Voltage-gated potassium channel subunit Kv7.5 Opener	0.0	1	(R)-(-)-BMS 204352	363680316.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	38.6717572788	Clc1cc(c(OC)cc1)[C@@]1(F)C(=O)Nc2c1ccc(C(F)(F)F)c2	Clc1cc(c(OC)cc1)[C@@]1(F)C(=O)Nc2c1ccc(C(F)(F)F)c2
NCGC00387493-01	Clc1cc2-n3c(C(F)(F)F)nnc3C(Sc3ccccc3)=Nc2cc1		Inactive	TNF alpha Signaling Pathway Inhibitor		1	R 7050	363680643.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2-n3c(C(F)(F)F)nnc3C(Sc3ccccc3)=Nc2cc1	Clc1cc2-n3c(C(F)(F)F)nnc3C(Sc3ccccc3)=Nc2cc1
NCGC00013683-06	Clc1cc2/C(=C/CCN(C)C)/c3c(Sc2cc1)cccc3	5.0500002	Active	Serotonin (5-HT) receptor Antagonist	0.0	1	Chlorprothixene	170465069.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	50.3197062278	Clc1cc2/C(=C/CCN(C)C)/c3c(Sc2cc1)cccc3	Clc1cc2/C(=C/CCN(C)C)/c3c(Sc2cc1)cccc3
NCGC00484848-01	Clc1cc2/C(=C/c3c(C)c(C(=O)NCCN(CC)CC)c(C)[nH]3)/C(=O)Nc2cc1		Inactive			1	SU11652	377020437.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2/C(=C/c3c(C)c(C(=O)NCCN(CC)CC)c(C)[nH]3)/C(=O)Nc2cc1	Clc1cc2/C(=C/c3c(C)c(C(=O)NCCN(CC)CC)c(C)[nH]3)/C(=O)Nc2cc1
NCGC00480782-01	Clc1cc2/C(=C/c3c(C)cc(C)[nH]3)/C(=O)Nc2cc1		Inactive			1	SU5614	377020294.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2/C(=C/c3c(C)cc(C)[nH]3)/C(=O)Nc2cc1	Clc1cc2/C(=C/c3c(C)cc(C)[nH]3)/C(=O)Nc2cc1
NCGC00179306-04	Clc1cc2/C(=C\CCN3CCN(CCO)CC3)/c3c(Sc2cc1)cccc3		Inactive	Serotonin 2 (5-HT2) receptor Antagonist		1	Zuclopenthixol (-)-10-Camphorsulfonic Acid Salt	405558792.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2/C(=C\CCN3CCN(CCO)CC3)/c3c(Sc2cc1)cccc3	Clc1cc2/C(=C\CCN3CCN(CCO)CC3)/c3c(Sc2cc1)cccc3
NCGC00522029-01	Clc1cc2/C(=C\CCN3CCN(CCOC(=O)CCCCCCCCC)CC3)/c3c(Sc2cc1)cccc3		Inactive			1	Zuclopenthixol Decanoate	405558666.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2/C(=C\CCN3CCN(CCOC(=O)CCCCCCCCC)CC3)/c3c(Sc2cc1)cccc3	Clc1cc2/C(=C\CCN3CCN(CCOC(=O)CCCCCCCCC)CC3)/c3c(Sc2cc1)cccc3
NCGC00346935-09	Clc1cc2/C(=C\c3oc(-c4cc(C(=O)N5CCN(C)CCC5)ccc4)cc3)/C(=O)Nc2cc1		Inactive	Pim 1/2/3 Kinase Inhibitor		1	CX-6258	384568970.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.7498872	Clc1cc2/C(=C\c3oc(-c4cc(C(=O)N5CCN(C)CCC5)ccc4)cc3)/C(=O)Nc2cc1	Clc1cc2/C(=C\c3oc(-c4cc(C(=O)N5CCN(C)CCC5)ccc4)cc3)/C(=O)Nc2cc1
NCGC00378716-01	Clc1cc2C(C(=O)NC3CC[N+](CC)(CC4=CCCCCCC4)CC3)c3c(Oc2cc1)ccc(Cl)c3		Inactive	C-C chemokine receptor type 5 Antagonist		1	UCB 35625	363678168.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2C(C(=O)NC3CC[N+](CC)(CC4=CCCCCCC4)CC3)c3c(Oc2cc1)ccc(Cl)c3	Clc1cc2C(C(=O)NC3CC[N+](CC)(CC4=CCCCCCC4)CC3)c3c(Oc2cc1)ccc(Cl)c3
NCGC00387181-02	Clc1cc2C(C(C(=O)OCC)C#N)C(C(=O)OCC)=C(N)Oc2cc1		Inactive	Serine/threonine-protein kinase AKT Activator		1	SC-79	363680558.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2C(C(C(=O)OCC)C#N)C(C(=O)OCC)=C(N)Oc2cc1	Clc1cc2C(C(C(=O)OCC)C#N)C(C(=O)OCC)=C(N)Oc2cc1
NCGC00386501-01	Clc1cc2C(N3CCN(C)CC3)=Nc3c(Nc2cc1)cccc3		Inactive	Serotonin 2c (5-HT2c) receptor Antagonist		1	Isoclozapine	363680307.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2C(N3CCN(C)CC3)=Nc3c(Nc2cc1)cccc3	Clc1cc2C(N3CCN(C)CC3)=Nc3c(Nc2cc1)cccc3
NCGC00021145-11	Clc1cc2C(N3CCN(C)CC3)=Nc3c(Oc2cc1)cccc3	5.0	Active	Muscarinic acetylcholine receptor M1 Antagonist	0.0	1	Loxapine succinate	170465094.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	48.1377540847	Clc1cc2C(N3CCN(C)CC3)=Nc3c(Oc2cc1)cccc3.O=C(O)CCC(=O)O	Clc1cc2C(N3CCN(C)CC3)=Nc3c(Oc2cc1)cccc3.O=C(O)CCC(=O)O
NCGC00160387-04	Clc1cc2C(N3CCN(C)CC3)=Nc3c(Sc2cc1)cccc3		Inactive	GABA-A receptor; benzodiazepine site Antagonist		1	Clothiapine	170465938.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	10.837160748&0.0	Clc1cc2C(N3CCN(C)CC3)=Nc3c(Sc2cc1)cccc3	Clc1cc2C(N3CCN(C)CC3)=Nc3c(Sc2cc1)cccc3
NCGC00015004-13	Clc1cc2C(N3CCNCC3)=Nc3c(Oc2cc1)cccc3	5.0500002	Active	5-HT2A Antagonists?	0.0	1	Amoxapine	170465376.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	69.739904985	Clc1cc2C(N3CCNCC3)=Nc3c(Oc2cc1)cccc3	Clc1cc2C(N3CCNCC3)=Nc3c(Oc2cc1)cccc3
NCGC00486944-01	Clc1cc2C(N[C@@H]3CN(C(=O)NC(C)C)CC3)=Nc3c(N(CC(F)F)c2cc1)ccc(F)c3		Inactive	p21-Activated Kinase 1 (PAK1) Inhibitor		1	NVS-PAK1-1	363681470.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2C(N[C@@H]3CN(C(=O)NC(C)C)CC3)=Nc3c(N(CC(F)F)c2cc1)ccc(F)c3	Clc1cc2C(N[C@@H]3CN(C(=O)NC(C)C)CC3)=Nc3c(N(CC(F)F)c2cc1)ccc(F)c3
NCGC00346626-05	Clc1cc2C(N[C@H]3C4CCN(C3)CC4)=C(c3[nH]c4c(n3)cccc4)C(=O)Nc2cc1		Inactive	Chk1 Inhibitor		1	CHIR-124	384568866.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Clc1cc2C(N[C@H]3C4CCN(C3)CC4)=C(c3[nH]c4c(n3)cccc4)C(=O)Nc2cc1	Clc1cc2C(N[C@H]3C4CCN(C3)CC4)=C(c3[nH]c4c(n3)cccc4)C(=O)Nc2cc1
NCGC00183001-01	Clc1cc2C(O)CCCN(C(=O)c3c(C)cc(NC(=O)c4c(C)cccc4)cc3)c2cc1		Inactive	Vasopressin (AVP) V2 Antagonist		1	Tolvaptan	124894207.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1cc2C(O)CCCN(C(=O)c3c(C)cc(NC(=O)c4c(C)cccc4)cc3)c2cc1	Clc1cc2C(O)CCCN(C(=O)c3c(C)cc(NC(=O)c4c(C)cccc4)cc3)c2cc1
NCGC00182081-04	Clc1cc2C(OCCN(C)C)=Cc3c(Sc2cc1)cccc3	4.9000001	Active	Histamine H1 receptor Antagonist	0.0	1	Zotepine	170465934.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	46.7270091463	Clc1cc2C(OCCN(C)C)=Cc3c(Sc2cc1)cccc3	Clc1cc2C(OCCN(C)C)=Cc3c(Sc2cc1)cccc3
NCGC00346488-03	Clc1cc2C(c3c(F)cccc3F)=NCc3c(nc(Nc4ccc(C(=O)O)cc4)nc3)-c2cc1		Inactive	Aurora-A Inhibitor		1	MLN-8054	384568797.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2C(c3c(F)cccc3F)=NCc3c(nc(Nc4ccc(C(=O)O)cc4)nc3)-c2cc1	Clc1cc2C(c3c(F)cccc3F)=NCc3c(nc(Nc4ccc(C(=O)O)cc4)nc3)-c2cc1
NCGC00263271-04	Clc1cc2C(c3c(F)cccc3OC)=NCc3c(nc(Nc4cc(OC)c(C(=O)O)cc4)nc3)-c2cc1		Inactive	Aurora-A Inhibitor		1	Alisertib	384568683.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2C(c3c(F)cccc3OC)=NCc3c(nc(Nc4cc(OC)c(C(=O)O)cc4)nc3)-c2cc1	Clc1cc2C(c3c(F)cccc3OC)=NCc3c(nc(Nc4cc(OC)c(C(=O)O)cc4)nc3)-c2cc1
NCGC00371089-01	Clc1cc2C(c3ccc(N)cc3)=Nn3c(nc(C)c3)Cc2cc1		Inactive	Glutamate receptor ionotropic kainate Antagonist		1	GYKI 47261 dihydrochloride	363678025.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2C(c3ccc(N)cc3)=Nn3c(nc(C)c3)Cc2cc1	Clc1cc2C(c3ccc(N)cc3)=Nn3c(nc(C)c3)Cc2cc1
NCGC00402356-02	Clc1cc2C(c3ccccc3)=C(C(=O)/C=C/c3[nH]c4c(n3)cccc4)C(=O)Nc2cc1		Inactive			1	BI-69A11	377020231.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2C(c3ccccc3)=C(C(=O)/C=C/c3[nH]c4c(n3)cccc4)C(=O)Nc2cc1	Clc1cc2C(c3ccccc3)=C(C(=O)/C=C/c3[nH]c4c(n3)cccc4)C(=O)Nc2cc1
NCGC00386715-01	Clc1cc2C3(CN(C(=O)c4c(F)cccc4F)c2cc1)CCN(CCC=C)CC3		Inactive	Proto-oncogene Mas Inverse Agonist		1	AR 244555	363680413.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2C3(CN(C(=O)c4c(F)cccc4F)c2cc1)CCN(CCC=C)CC3	Clc1cc2C3(CN(C(=O)c4c(F)cccc4F)c2cc1)CCN(CCC=C)CC3
NCGC00183004-01	Clc1cc2N(C(=O)c3c(C)cccc3)CC/C(=N\OS(=O)(=O)[O-])/c2cc1		Inactive	renal sodium ion transport Inhibitor		1	Alilusem potassium	144206835.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&2020_NPACT-1_CPE	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&0.0	Clc1cc2N(C(=O)c3c(C)cccc3)CC/C(=N\OS(=O)(=O)[O-])/c2cc1.[K+]	Clc1cc2N(C(=O)c3c(C)cccc3)CC/C(=N\OS(=O)(=O)[O-])/c2cc1.[K+]
NCGC00182978-01	Clc1cc2N(CC(=O)N3CCN(CCO)CC3)C(=O)Sc2cc1		Inactive			1	Tiaramide hydrochloride	144206772.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2N(CC(=O)N3CCN(CCO)CC3)C(=O)Sc2cc1.Cl	Clc1cc2N(CC(=O)N3CCN(CCO)CC3)C(=O)Sc2cc1.Cl
NCGC00015273-15&NCGC00015273-19	Clc1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3	5.0	Active	Histamine H1 receptor Antagonist	0.10000040000000077	2	Chlorpromazine hydrochloride&Chlorpromazine	124879758.0&170465371.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	59.8589457697&68.753399053	Clc1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3	Clc1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3
NCGC00015264-13&NCGC00015264-24	Clc1cc2N(CCCN(C)C)c3c(cccc3)CCc2cc1	4.9625001	Active	Serotonin Transporter (SERT) Inhibitor	0.07499979999999962	2	Clomipramine hydrochloride	170464702.0&384567835.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	3.0&3.0&1.1	81.2308286143&107.4539361255&92.987938891	Clc1cc2N(CCCN(C)C)c3c(cccc3)CCc2cc1	Clc1cc2N(CCCN(C)C)c3c(cccc3)CCc2cc1
NCGC00253595-01	Clc1cc2N(CCCN3CCC(C(=O)N)(N4CCCCC4)CC3)c3c(cccc3)CCc2cc1		Inactive	Serotonin 2a (5-HT2a) receptor Antagonist		1	Clocapramine	170465785.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2N(CCCN3CCC(C(=O)N)(N4CCCCC4)CC3)c3c(cccc3)CCc2cc1	Clc1cc2N(CCCN3CCC(C(=O)N)(N4CCCCC4)CC3)c3c(cccc3)CCc2cc1
NCGC00183853-01	Clc1cc2N(CCCN3CCC4(C(=O)NC5N4CCCC5)CC3)c3c(cccc3)CCc2cc1		Inactive	Dopamine D4 receptor Antagonist		1	Mosapramine	144206880.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	-8.4285714319&0.0	Clc1cc2N(CCCN3CCC4(C(=O)NC5N4CCCC5)CC3)c3c(cccc3)CCc2cc1	Clc1cc2N(CCCN3CCC4(C(=O)NC5N4CCCC5)CC3)c3c(cccc3)CCc2cc1
NCGC00014648-04	Clc1cc2N(CCCN3CCC4(SCC(=O)N4)CC3)c3c(Sc2cc1)cccc3	4.9000001	Active	Adrenergic receptor Antagonist	0.0	1	Spiclomazine hydrochloride	405558575.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	38.9353695191	Clc1cc2N(CCCN3CCC4(SCC(=O)N4)CC3)c3c(Sc2cc1)cccc3	Clc1cc2N(CCCN3CCC4(SCC(=O)N4)CC3)c3c(Sc2cc1)cccc3
NCGC00015856-10	Clc1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3	5.0500002	Active	Dopamine D2 Antagonist	0.0	1	Prochlorperazine dimaleate	170464761.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	129.3326258642	Clc1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O	Clc1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3.O=C(O)/C=C\C(=O)O.O=C(O)/C=C\C(=O)O
NCGC00015826-13	Clc1cc2N(CCCN3CCN(CCO)CC3)c3c(Sc2cc1)cccc3	4.9000001	Active	Muscarinic acetylcholine receptor M1 Antagonist	0.0	1	Perphenazine	170464834.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	120.5381646602	Clc1cc2N(CCCN3CCN(CCO)CC3)c3c(Sc2cc1)cccc3	Clc1cc2N(CCCN3CCN(CCO)CC3)c3c(Sc2cc1)cccc3
NCGC00024936-06	Clc1cc2N=C(N3CCNCC3)c3c(Nc2cc1)cccc3	5.0500002	Active		0.0	1	N-Desmethylclozapine	406861836.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	3.0	87.5218686688	Clc1cc2N=C(N3CCNCC3)c3c(Nc2cc1)cccc3	Clc1cc2N=C(N3CCNCC3)c3c(Nc2cc1)cccc3
NCGC00263174-02	Clc1cc2N=C([C@H](N(C(=O)c3ccc(C)cc3)CCCN)C(C)C)N(Cc3ccccc3)C(=O)c2cc1		Inactive	Kinesin-Like Spindle Protein Inhibitor		1	Ispinesib	384568644.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Clc1cc2N=C([C@H](N(C(=O)c3ccc(C)cc3)CCCN)C(C)C)N(Cc3ccccc3)C(=O)c2cc1	Clc1cc2N=C([C@H](N(C(=O)c3ccc(C)cc3)CCCN)C(C)C)N(Cc3ccccc3)C(=O)c2cc1
NCGC00390658-01	Clc1cc2N=CN(CC3(O)CCN(C(=O)CCc4ccccc4)CC3)C(=O)c2cc1		Inactive	Ubiquitin carboxyl-terminal hydrolase 7 Inhibitor		1	USP7-IN-1	363680959.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2N=CN(CC3(O)CCN(C(=O)CCc4ccccc4)CC3)C(=O)c2cc1	Clc1cc2N=CN(CC3(O)CCN(C(=O)CCc4ccccc4)CC3)C(=O)c2cc1
NCGC00014670-17&NCGC00014670-26	Clc1cc2NC(=O)N(C3CCN(CCCN4C(=O)Nc5c4cccc5)CC3)c2cc1		Inactive	Dopamine Receptor Antagonist		2	Domperidone	170465594.0&384567793.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	28.4102401999&0.0	Clc1cc2NC(=O)N(C3CCN(CCCN4C(=O)Nc5c4cccc5)CC3)c2cc1	Clc1cc2NC(=O)N(C3CCN(CCCN4C(=O)Nc5c4cccc5)CC3)c2cc1
NCGC00370881-01	Clc1cc2NC(=O)N(C3CCN(C[C@@H](NC(=O)c4cc5c(cc4)cccc5)C)CC3)c2cc1		Inactive	Phospholipase D2 Inhibitor		1	VU 0155069	363677907.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2NC(=O)N(C3CCN(C[C@@H](NC(=O)c4cc5c(cc4)cccc5)C)CC3)c2cc1	Clc1cc2NC(=O)N(C3CCN(C[C@@H](NC(=O)c4cc5c(cc4)cccc5)C)CC3)c2cc1
NCGC00015238-13	Clc1cc2NC(=O)Oc2cc1		Inactive	Intermediate conductance calcium-activated potassium channel protein 4 Activator		1	Chlorzoxazone	170464957.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1cc2NC(=O)Oc2cc1	Clc1cc2NC(=O)Oc2cc1
NCGC00246187-03&NCGC00246187-06	Clc1cc2NC=3C(=C(N=C4C=C(CN5CCCC5)C(=O)C(CN5CCCC5)=C4)c2cc1)NC(OC)=CC=3		Inactive			2	PYRONARIDINE TETRAPHOSPHATE&Pyronaridine Tetraphosphate	384568510.0&434147065.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	23.0&-16.852659112	Clc1cc2NC=3C(=C(N=C4C=C(CN5CCCC5)C(=O)C(CN5CCCC5)=C4)c2cc1)NC(OC)=CC=3	Clc1cc2NC=3C(=C(N=C4C=C(CN5CCCC5)C(=O)C(CN5CCCC5)=C4)c2cc1)NC(OC)=CC=3
NCGC00386738-02	Clc1cc2NC=3C(=O)NN(c4c(C)cc(OC)cc4)C(=O)C=3C(=O)c2cc1		Inactive	Glutamate [NMDA] receptor Antagonist		1	ZD 9379	363680426.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2NC=3C(=O)NN(c4c(C)cc(OC)cc4)C(=O)C=3C(=O)c2cc1	Clc1cc2NC=3C(=O)NN(c4c(C)cc(OC)cc4)C(=O)C=3C(=O)c2cc1
NCGC00346571-07	Clc1cc2OC([C@H](N(C(=O)c3ccc(C)cc3)CCCN)C(C)C)=C(Cc3ccccc3)C(=O)c2cc1		Inactive	Kinesin-Like Spindle Protein Inhibitor		1	SB-743921	384568845.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2OC([C@H](N(C(=O)c3ccc(C)cc3)CCCN)C(C)C)=C(Cc3ccccc3)C(=O)c2cc1	Clc1cc2OC([C@H](N(C(=O)c3ccc(C)cc3)CCCN)C(C)C)=C(Cc3ccccc3)C(=O)c2cc1
NCGC00347937-02	Clc1cc2OCC(c3ccc(C)cc3)=Nc2cc1		Inactive	RARalpha Antagonist		1	AR-7	384568989.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2OCC(c3ccc(C)cc3)=Nc2cc1	Clc1cc2OCC(c3ccc(C)cc3)=Nc2cc1
NCGC00022882-03	Clc1cc2S(=O)(=O)NC(C)=Nc2cc1		Inactive	Sulfonylurea receptor 1, Kir6.2 Opener		1	Diazoxide	170465328.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2S(=O)(=O)NC(C)=Nc2cc1	Clc1cc2S(=O)(=O)NC(C)=Nc2cc1
NCGC00188689-09	Clc1cc2[C@@H]3[C@@H](c4c(Oc2cc1)cccc4)CN(C)C3	5.0	Active	Dopamine D1/D2 Antagonist	0.0	1	Asenapine maleate	384568450.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.1	112.6961171959	Clc1cc2[C@@H]3[C@@H](c4c(Oc2cc1)cccc4)CN(C)C3	Clc1cc2[C@@H]3[C@@H](c4c(Oc2cc1)cccc4)CN(C)C3
NCGC00263540-04	Clc1cc2[C@H]3[C@H](c4c(Oc2cc1)cccc4)CN(C)C3		Inactive	Dopamine D1/D2 Antagonist		1	Asenapine	405558453.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2[C@H]3[C@H](c4c(Oc2cc1)cccc4)CN(C)C3	Clc1cc2[C@H]3[C@H](c4c(Oc2cc1)cccc4)CN(C)C3
NCGC00159337-04&NCGC00159337-12	Clc1cc2[C@](C(F)(F)F)(C#CC3CC3)OC(=O)Nc2cc1	4.91666675	Active	Reverse Transcriptase Inhibitor	0.033333300000000676	2	Efavirenz	170464810.0&406861840.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0&3.0&3.0	100.1675187595&101.7667516447&82.9083709432&122.4462997115	Clc1cc2[C@](C(F)(F)F)(C#CC3CC3)OC(=O)Nc2cc1	Clc1cc2[C@](C(F)(F)F)(C#CC3CC3)OC(=O)Nc2cc1
NCGC00378706-01	Clc1cc2c(-n3c(c(-c4nc(C5CC5)on4)nc3)N3C2=NCC3)cc1		Inactive	GABA-A receptor; alpha-1/beta-2/gamma-2 Agonist		1	U 90042	363678160.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2c(-n3c(c(-c4nc(C5CC5)on4)nc3)N3C2=NCC3)cc1	Clc1cc2c(-n3c(c(-c4nc(C5CC5)on4)nc3)N3C2=NCC3)cc1
NCGC00015619-13	Clc1cc2c(/C(=C/3\CCN(C(=O)OCC)CC\3)/c3ncccc3CC2)cc1	4.9749999	Active	Histamine H1 Receptor Antagonists	0.0	1	Loratadine	170464867.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	42.7176470624&40.1809244016	Clc1cc2c(/C(=C/3\CCN(C(=O)OCC)CC\3)/c3ncccc3CC2)cc1	Clc1cc2c(/C(=C/3\CCN(C(=O)OCC)CC\3)/c3ncccc3CC2)cc1
NCGC00159325-05	Clc1cc2c(/C(=C/3\CCNCC\3)/c3ncccc3CC2)cc1	4.9499998	Active	Histamine H1 receptor Antagonist	0.0	1	Desloratadine	170464781.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	105.7789144095	Clc1cc2c(/C(=C/3\CCNCC\3)/c3ncccc3CC2)cc1	Clc1cc2c(/C(=C/3\CCNCC\3)/c3ncccc3CC2)cc1
NCGC00386213-04	Clc1cc2c(C(=C3CCN(Cc4cc(C)cnc4)CC3)c3ncccc3CC2)cc1	4.9000001	Active	Platelet activating factor receptor Antagonist	0.0	1	Rupatadine (Fumarate)	405558713.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	2.4	35.2956298239	Clc1cc2c(C(=C3CCN(Cc4cc(C)cnc4)CC3)c3ncccc3CC2)cc1	Clc1cc2c(C(=C3CCN(Cc4cc(C)cnc4)CC3)c3ncccc3CC2)cc1
NCGC00386219-06	Clc1cc2c(C)c(S(=O)(=O)Nc3cc(N4CCNCC4)c(OC)cc3)sc2cc1	4.9000001	Active	Serotonin 6 (5-HT6) receptor Antagonist	0.0	1	SB 271046 hydrochloride	363680155.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	59.8228571389	Clc1cc2c(C)c(S(=O)(=O)Nc3cc(N4CCNCC4)c(OC)cc3)sc2cc1	Clc1cc2c(C)c(S(=O)(=O)Nc3cc(N4CCNCC4)c(OC)cc3)sc2cc1
NCGC00181782-03	Clc1cc2c(C3CCN(CCN4C(=O)NCC4)CC3)cn(-c3ccc(F)cc3)c2cc1		Inactive	Serotonin 2c (5-HT2c) receptor Antagonist		1	Sertindole	170465613.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0		Clc1cc2c(C3CCN(CCN4C(=O)NCC4)CC3)cn(-c3ccc(F)cc3)c2cc1	Clc1cc2c(C3CCN(CCN4C(=O)NCC4)CC3)cn(-c3ccc(F)cc3)c2cc1
NCGC00379109-01	Clc1cc2c(CCN(C)C)c(C)[nH]c2cc1		Inactive	Serotonin 6 (5-HT6) receptor Agonist		1	ST 1936 oxalate	363678359.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2c(CCN(C)C)c(C)[nH]c2cc1	Clc1cc2c(CCN(C)C)c(C)[nH]c2cc1
NCGC00250389-02	Clc1cc2c(CCOc3ccc(C(=O)O)cc3)c(C)n(C(c3ccccc3)c3ccccc3)c2cc1	4.9000001	Active	Phospholipase C Inhibitor	0.0	1	CDIBA	384568542.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	75.2789782949	Clc1cc2c(CCOc3ccc(C(=O)O)cc3)c(C)n(C(c3ccccc3)c3ccccc3)c2cc1	Clc1cc2c(CCOc3ccc(C(=O)O)cc3)c(C)n(C(c3ccccc3)c3ccccc3)c2cc1
NCGC00378691-02&NCGC00378691-05	Clc1cc2c(O[C@H]3CN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)[C@H](C(=O)N[C@@]4(C(=O)NS(=O)(=O)C5CC5)[C@H](C=C)C4)C3)ncc(OC)c2cc1		Inactive	Solute carrier organic anion transporter family member 2B1 Inhibitor		2	Asunaprevir (BMS-650032)&Asunaprevir (Prop INN; USAN) BMS-650032   Sunvepra  	405558863.0&434146884.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1cc2c(O[C@H]3CN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)[C@H](C(=O)N[C@@]4(C(=O)NS(=O)(=O)C5CC5)[C@H](C=C)C4)C3)ncc(OC)c2cc1	Clc1cc2c(O[C@H]3CN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)[C@H](C(=O)N[C@@]4(C(=O)NS(=O)(=O)C5CC5)[C@H](C=C)C4)C3)ncc(OC)c2cc1
NCGC00165814-04	Clc1cc2c([nH]c(C(=O)N3CCN(C)CC3)c2)cc1		Inactive	Histamine H4 receptor Antagonist		1	JNJ-7777120	363676643.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2c([nH]c(C(=O)N3CCN(C)CC3)c2)cc1	Clc1cc2c([nH]c(C(=O)N3CCN(C)CC3)c2)cc1
NCGC00346646-02	Clc1cc2c([nH]c(C(=O)N[C@H]([C@@H](O)C(=O)N(C)C)Cc3ccccc3)c2)cc1		Inactive	Glycogen Phosphorylase a Inhibitor		1	CP-91149	363677494.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2c([nH]c(C(=O)N[C@H]([C@@H](O)C(=O)N(C)C)Cc3ccccc3)c2)cc1	Clc1cc2c([nH]c(C(=O)N[C@H]([C@@H](O)C(=O)N(C)C)Cc3ccccc3)c2)cc1
NCGC00370853-02	Clc1cc2c([nH]c(C(=O)N[C@H]([C@@H](O)C(=O)N(OC)C)Cc3ccccc3)c2)cc1		Inactive	Muscle glycogen phosphorylase Inhibitor		1	CP 316819	363677887.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2c([nH]c(C(=O)N[C@H]([C@@H](O)C(=O)N(OC)C)Cc3ccccc3)c2)cc1	Clc1cc2c([nH]c(C(=O)N[C@H]([C@@H](O)C(=O)N(OC)C)Cc3ccccc3)c2)cc1
NCGC00242458-15	Clc1cc2c([nH]c3C(C(=O)N)CCCc23)cc1		Inactive	Histone Deacetylase SIRT1 Inhibitor		1	Selisistat	384568488.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2c([nH]c3C(C(=O)N)CCCc23)cc1	Clc1cc2c([nH]c3C(C(=O)N)CCCc23)cc1
NCGC00485645-01	Clc1cc2c([nH]c3[C@@H](C(=O)N)CCCCc23)cc1		Inactive	NAD-dependent deacetylase sirtuin 1 Inhibitor		1	CHIC-35	363681371.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2c([nH]c3[C@@H](C(=O)N)CCCCc23)cc1	Clc1cc2c([nH]c3[C@@H](C(=O)N)CCCCc23)cc1
NCGC00094937-04	Clc1cc2c([nH]c3c2ccc(C(C(=O)O)C)c3)cc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Carprofen	170464799.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1cc2c([nH]c3c2ccc(C(C(=O)O)C)c3)cc1	Clc1cc2c([nH]c3c2ccc(C(C(=O)O)C)c3)cc1
NCGC00378998-01	Clc1cc2c(c(C(C(=O)O)CCC)c(C)nc2cc1)-c1ccccc1		Inactive	Human immunodeficiency virus type 1 integrase Negative Allosteric Modulator		1	HIV-1 integrase inhibitor 2	363678307.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2c(c(C(C(=O)O)CCC)c(C)nc2cc1)-c1ccccc1	Clc1cc2c(c(C(C(=O)O)CCC)c(C)nc2cc1)-c1ccccc1
NCGC00485909-01	Clc1cc2c(c3[nH]c(-c4c(C#N)cccc4C#N)nc3c3c2cccc3)cc1		Inactive	Microsomal prostaglandin E synthase-1 Inhibitor		1	MF63	363681408.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2c(c3[nH]c(-c4c(C#N)cccc4C#N)nc3c3c2cccc3)cc1	Clc1cc2c(c3[nH]c(-c4c(C#N)cccc4C#N)nc3c3c2cccc3)cc1
NCGC00485104-01	Clc1cc2c(n(CC(O)CNC(CO)(CO)CO)c3c2cc(Cl)cc3)cc1	4.9000001	Active	regulation of membrane potential Modulator	0.0	1	DCAP	363681223.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	3.0	79.7958446377	Clc1cc2c(n(CC(O)CNC(CO)(CO)CO)c3c2cc(Cl)cc3)cc1	Clc1cc2c(n(CC(O)CNC(CO)(CO)CO)c3c2cc(Cl)cc3)cc1
NCGC00378617-04	Clc1cc2c(oc3C(=O)NC([C@H]4NCCC4)=Nc23)cc1		Inactive	Serine/threonine-protein kinase PIM1  Inhibitor		1	XL 413 hydrochloride	384569057.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1cc2c(oc3C(=O)NC([C@H]4NCCC4)=Nc23)cc1	Clc1cc2c(oc3C(=O)NC([C@H]4NCCC4)=Nc23)cc1
NCGC00386771-01	Clc1cc2nc(-c3ccc(OC(C(=O)O)(C)C)cc3)sc2cc1		Inactive	Tyrosinase Inhibitor		1	MHY 908	363680443.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2nc(-c3ccc(OC(C(=O)O)(C)C)cc3)sc2cc1	Clc1cc2nc(-c3ccc(OC(C(=O)O)(C)C)cc3)sc2cc1
NCGC00164568-04	Clc1cc2nc(/C=C/c3cc([C@H](SCC4(CC(=O)O)CC4)CCc4c(C(O)(C)C)cccc4)ccc3)ccc2cc1		Inactive	Cysteinyl leukotriene receptor 1 Antagonist		1	Montelukast sodium	170465230.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	-7.245810056&0.0	Clc1cc2nc(/C=C/c3cc([C@H](SCC4(CC(=O)[O-])CC4)CCc4c(C(O)(C)C)cccc4)ccc3)ccc2cc1.[Na+]	Clc1cc2nc(/C=C/c3cc([C@H](SCC4(CC(=O)[O-])CC4)CCc4c(C(O)(C)C)cccc4)ccc3)ccc2cc1.[Na+]
NCGC00016280-11	Clc1cc2nc(N)oc2cc1		Inactive			1	Zoxazolamine	434146953.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2nc(N)oc2cc1	Clc1cc2nc(N)oc2cc1
NCGC00386302-04	Clc1cc2nc(N3CCN(C(=O)c4c(-n5nccn5)ccc(C)c4)[C@H](C)CC3)oc2cc1		Inactive			1	MK-4305		2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2nc(N3CCN(C(=O)c4c(-n5nccn5)ccc(C)c4)[C@H](C)CC3)oc2cc1	Clc1cc2nc(N3CCN(C(=O)c4c(-n5nccn5)ccc(C)c4)[C@H](C)CC3)oc2cc1
NCGC00242503-02	Clc1cc2nccc(-n3c(-c4c(OC)cccc4OC)cc(C(=O)NC4(C(=O)O)C5CC6CC4CC(C5)C6)n3)c2cc1		Inactive	Carboxypeptidase A Inhibitor		1	Meclinertant	384568503.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2nccc(-n3c(-c4c(OC)cccc4OC)cc(C(=O)NC4(C(=O)O)C5CC6CC4CC(C5)C6)n3)c2cc1	Clc1cc2nccc(-n3c(-c4c(OC)cccc4OC)cc(C(=O)NC4(C(=O)O)C5CC6CC4CC(C5)C6)n3)c2cc1
NCGC00387458-01	Clc1cc2nccc(-n3c(-c4c(OC)cccc4OC)cc(C(=O)N[C@H](C(=O)O)CC(C)C)n3)c2cc1		Inactive	Neurotensin receptor type 1 Agonist		1	TC NTR1 17	363680619.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2nccc(-n3c(-c4c(OC)cccc4OC)cc(C(=O)N[C@H](C(=O)O)CC(C)C)n3)c2cc1	Clc1cc2nccc(-n3c(-c4c(OC)cccc4OC)cc(C(=O)N[C@H](C(=O)O)CC(C)C)n3)c2cc1
NCGC00386838-01	Clc1cc2nccc(-n3c(-c4c(OC)cccc4OC)nc(C(=O)N[C@H](C(=O)O)CC(C)C)c3)c2cc1		Inactive			1	NCGC00386838-01	363680458.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2nccc(-n3c(-c4c(OC)cccc4OC)nc(C(=O)N[C@H](C(=O)O)CC(C)C)c3)c2cc1	Clc1cc2nccc(-n3c(-c4c(OC)cccc4OC)nc(C(=O)N[C@H](C(=O)O)CC(C)C)c3)c2cc1
NCGC00386822-01	Clc1cc2nccc(N3CCN(C(=O)c4ccc(Cl)cc4)CC3)c2cc1	4.9000001	Active		0.0	1	NCGC00386822-01	363680449.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	54.9351105558	Clc1cc2nccc(N3CCN(C(=O)c4ccc(Cl)cc4)CC3)c2cc1	Clc1cc2nccc(N3CCN(C(=O)c4ccc(Cl)cc4)CC3)c2cc1
NCGC00344515-02	Clc1cc2nccc(N3CCN(CCCN4CCN(c5c6c(ncc5)cc(Cl)cc6)CC4)CC3)c2cc1		Inactive	antimalarial agents		1	Piperaquine	174006179.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2nccc(N3CCN(CCCN4CCN(c5c6c(ncc5)cc(Cl)cc6)CC4)CC3)c2cc1	Clc1cc2nccc(N3CCN(CCCN4CCN(c5c6c(ncc5)cc(Cl)cc6)CC4)CC3)c2cc1
NCGC00482878-01	Clc1cc2nccc(N3CCN(S(=O)(=O)c4c([N+](=O)[O-])cc([N+](=O)[O-])cc4)CC3)c2cc1		Inactive			1	VR23	434147217.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2nccc(N3CCN(S(=O)(=O)c4c([N+](=O)[O-])cc([N+](=O)[O-])cc4)CC3)c2cc1	Clc1cc2nccc(N3CCN(S(=O)(=O)c4c([N+](=O)[O-])cc([N+](=O)[O-])cc4)CC3)c2cc1
NCGC00378786-01	Clc1cc2nccc(N3CCN(S(=O)(=O)c4ccc(Cl)cc4)CC3)c2cc1		Inactive	Cystic fibrosis transmembrane conductance regulator Modulator		1	KM 11060	363678199.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	26.7742460759	Clc1cc2nccc(N3CCN(S(=O)(=O)c4ccc(Cl)cc4)CC3)c2cc1	Clc1cc2nccc(N3CCN(S(=O)(=O)c4ccc(Cl)cc4)CC3)c2cc1
NCGC00159483-04&NCGC00159483-06	Clc1cc2nccc(NC(CCCN(CCO)CC)C)c2cc1		Inactive	Autophagy Inhibitor		2	Hydroxychloroquine sulfate	170464696.0&363676594.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0&4.0	0.0&0.0&-11.480211084&19.678470976&0.0	Clc1cc2nccc(NC(CCCN(CCO)CC)C)c2cc1.S(=O)(=O)(O)O	Clc1cc2nccc(NC(CCCN(CCO)CC)C)c2cc1.S(=O)(=O)(O)O&Clc1cc2nccc(NC(CCCN(CCO)CC)C)c2cc1
NCGC00094881-07	Clc1cc2nccc(Nc3c(C(=O)OCC(O)CO)cccc3)c2cc1		Inactive			1	Glafenine hydrochloride	170465943.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&18.67883212	Clc1cc2nccc(Nc3c(C(=O)OCC(O)CO)cccc3)c2cc1.Cl	Clc1cc2nccc(Nc3c(C(=O)OCC(O)CO)cccc3)c2cc1.Cl
NCGC00378822-01	Clc1cc2nccc(Nc3c4c(c(O)c(CNC(C)(C)C)c3)CCCC4)c2cc1		Inactive			1	Naphthoquine phosphate	363678221.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cc2nccc(Nc3c4c(c(O)c(CNC(C)(C)C)c3)CCCC4)c2cc1	Clc1cc2nccc(Nc3c4c(c(O)c(CNC(C)(C)C)c3)CCCC4)c2cc1
NCGC00017063-07&NCGC00017063-13	Clc1cc2nccc(Nc3cc(CN(CC)CC)c(O)cc3)c2cc1	5.4250002	Active	Antimalarial; Histamine N-methyl Transferase Inhibitor	0.75	2	Amodiaquin dihydrochloride dihydrate&Amodiaquine	405558845.0&434146962.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	1.3&2.1	87.3953906497&109.7081952953	Clc1cc2nccc(Nc3cc(CN(CC)CC)c(O)cc3)c2cc1	Clc1cc2nccc(Nc3cc(CN(CC)CC)c(O)cc3)c2cc1
NCGC00347949-11	Clc1cc2sc(NC(=O)CCc3cc(OC)c(OC)cc3)nc2cc1		Inactive	Wnt Signaling Inhibitor		1	KY-02111	363677729.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cc2sc(NC(=O)CCc3cc(OC)c(OC)cc3)nc2cc1	Clc1cc2sc(NC(=O)CCc3cc(OC)c(OC)cc3)nc2cc1
NCGC00250374-02	Clc1ccc(-c2c(CC(=O)O)n3c(c2-c2ccccc2)CC(C)(C)C3)cc1		Inactive	5-Lipoxygenase Inhibitor		1	Licofelone	363677173.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(-c2c(CC(=O)O)n3c(c2-c2ccccc2)CC(C)(C)C3)cc1	Clc1ccc(-c2c(CC(=O)O)n3c(c2-c2ccccc2)CC(C)(C)C3)cc1
NCGC00183868-02	Clc1ccc(-c2c(CC(=O)O)sc(-c3ccccc3)n2)cc1		Inactive			1	Fentiazac	170466003.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(-c2c(CC(=O)O)sc(-c3ccccc3)n2)cc1	Clc1ccc(-c2c(CC(=O)O)sc(-c3ccccc3)n2)cc1
NCGC00253562-10	Clc1ccc(-c2c(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5cc([N+](=O)[O-])c(N[C@@H](CSc6ccccc6)CCN(C)C)cc5)cc4)CC3)cccc2)cc1		Inactive	Bcl-xL Inhibitor		1	ABT-737	384568563.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	31.2985156719	Clc1ccc(-c2c(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5cc([N+](=O)[O-])c(N[C@@H](CSc6ccccc6)CCN(C)C)cc5)cc4)CC3)cccc2)cc1	Clc1ccc(-c2c(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5cc([N+](=O)[O-])c(N[C@@H](CSc6ccccc6)CCN(C)C)cc5)cc4)CC3)cccc2)cc1
NCGC00480754-01	Clc1ccc(-c2c(N)ncc(-c3cnc(N)cc3)c2)cc1	5.4000001	Active		0.0	1	PF 06260933 dihydrochloride	377020362.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	2.4	32.228571428	Clc1ccc(-c2c(N)ncc(-c3cnc(N)cc3)c2)cc1	Clc1ccc(-c2c(N)ncc(-c3cnc(N)cc3)c2)cc1
NCGC00386821-01	Clc1ccc(-c2c(c(C)on2)-c2nn(S(=O)(=O)c3ccc(C)cc3)cc2)cc1		Inactive			1	NCGC00386821-01	363680448.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(-c2c(c(C)on2)-c2nn(S(=O)(=O)c3ccc(C)cc3)cc2)cc1	Clc1ccc(-c2c(c(C)on2)-c2nn(S(=O)(=O)c3ccc(C)cc3)cc2)cc1
NCGC00345832-03	Clc1ccc(-c2c(c(C3CCN(C(=O)CO)CC3)n[nH]2)-c2ncncc2)cc1		Inactive	p38 MAPK Inhibitor		1	SD-06	384568759.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(-c2c(c(C3CCN(C(=O)CO)CC3)n[nH]2)-c2ncncc2)cc1	Clc1ccc(-c2c(c(C3CCN(C(=O)CO)CC3)n[nH]2)-c2ncncc2)cc1
NCGC00250399-02&NCGC00250399-08	Clc1ccc(-c2cnc3[nH]cc(C(=O)c4c(F)c(NS(=O)(=O)CCC)ccc4F)c3c2)cc1		Inactive	Raf kinase B Inhibitor		2	Vemurafenib	384568548.0&405559058.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	23.5&0.0	Clc1ccc(-c2cnc3[nH]cc(C(=O)c4c(F)c(NS(=O)(=O)CCC)ccc4F)c3c2)cc1	Clc1ccc(-c2cnc3[nH]cc(C(=O)c4c(F)c(NS(=O)(=O)CCC)ccc4F)c3c2)cc1
NCGC00253573-01	Clc1ccc(-c2n(-c3ccc(OC)cc3)nc(CCC(=O)N(O)C)c2)cc1		Inactive	platelet aggregation Inhibitor		1	Tepoxalin	170466265.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	17.5212211519&16.7045169439	Clc1ccc(-c2n(-c3ccc(OC)cc3)nc(CCC(=O)N(O)C)c2)cc1	Clc1ccc(-c2n(-c3ccc(OC)cc3)nc(CCC(=O)N(O)C)c2)cc1
NCGC00370982-02	Clc1ccc(-c2n(-c3ccc(S(=O)(=O)N)cc3)nc(C(F)(F)F)c2)cc1		Inactive	Transcription factor AP-1 Inhibitor		1	SC 236	363677976.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(-c2n(-c3ccc(S(=O)(=O)N)cc3)nc(C(F)(F)F)c2)cc1	Clc1ccc(-c2n(-c3ccc(S(=O)(=O)N)cc3)nc(C(F)(F)F)c2)cc1
NCGC00371047-02	Clc1ccc(-c2n(c(C)c(C(=O)CC)c2)-c2ccc(S(=O)(=O)N)cc2)cc1	5.0	Active	Neuronal acetylcholine receptor protein alpha-7 subunit Positive Allosteric Modulator	0.0	1	A-867744	363678007.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	93.4819483087	Clc1ccc(-c2n(c(C)c(C(=O)CC)c2)-c2ccc(S(=O)(=O)N)cc2)cc1	Clc1ccc(-c2n(c(C)c(C(=O)CC)c2)-c2ccc(S(=O)(=O)N)cc2)cc1
NCGC00263646-02	Clc1ccc(-c2nc(NN=C3CCCC3)sc2)cc1		Inactive			1	CPTH2 (hydrochloride)		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(-c2nc(NN=C3CCCC3)sc2)cc1	Clc1ccc(-c2nc(NN=C3CCCC3)sc2)cc1
NCGC00092309-06	Clc1ccc(-c2nc(Nc3ccc(O)cc3)sc2)cc1		Inactive	Sphingosine Kinase Inhibitor		1	SKI-II	363676558.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(-c2nc(Nc3ccc(O)cc3)sc2)cc1	Clc1ccc(-c2nc(Nc3ccc(O)cc3)sc2)cc1
NCGC00165112-01	Clc1ccc(-c2nc3-c4c(OCc3c(C=3C(=O)c5c(OC=3)cccc5)c2)ccc(C)c4)cc1		Inactive			1	NCGC00165112-01	29216866.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(-c2nc3-c4c(OCc3c(C=3C(=O)c5c(OC=3)cccc5)c2)ccc(C)c4)cc1	Clc1ccc(-c2nc3-c4c(OCc3c(C=3C(=O)c5c(OC=3)cccc5)c2)ccc(C)c4)cc1
NCGC00163385-14	Clc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1		Inactive			1	PP2	377020216.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1	Clc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1
NCGC00388282-01	Clc1ccc(-c2oc(C(=O)N(Cc3ncccc3)c3ccc(N4CCNCC4)cc3)cc2)cc1	4.9000001	Active		0.0	1	MK2 Inhibitor IV	377020527.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	103.5468715743	Clc1ccc(-c2oc(C(=O)N(Cc3ncccc3)c3ccc(N4CCNCC4)cc3)cc2)cc1	Clc1ccc(-c2oc(C(=O)N(Cc3ncccc3)c3ccc(N4CCNCC4)cc3)cc2)cc1
NCGC00346700-13	Clc1ccc(-c2oc(C(=O)Nc3cc(OC)cc(OC)c3)cc2)cc1	4.9000001	Active	Nav1.8 (SNS/PN3) Sodium Channel Blocker	0.0	1	A-803467	384568920.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	36.639976441	Clc1ccc(-c2oc(C(=O)Nc3cc(OC)cc(OC)c3)cc2)cc1	Clc1ccc(-c2oc(C(=O)Nc3cc(OC)cc(OC)c3)cc2)cc1
NCGC00510190-02	Clc1ccc(-c2oc(C)c(COc3cc(CN(C(=O)OC)CC(=O)O)ccc3)n2)cc1		Inactive	PPARalpha Agonist		1	BMS-687453	384569413.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(-c2oc(C)c(COc3cc(CN(C(=O)OC)CC(=O)O)ccc3)n2)cc1	Clc1ccc(-c2oc(C)c(COc3cc(CN(C(=O)OC)CC(=O)O)ccc3)n2)cc1
NCGC00242499-02	Clc1ccc(-c2onc3c2cc(-c2nc(N)ncc2)cc3)cc1		Inactive	Pim-1 Kinase Inhibitor		1	Pim 1 Inhibitor 2	384568502.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(-c2onc3c2cc(-c2nc(N)ncc2)cc3)cc1	Clc1ccc(-c2onc3c2cc(-c2nc(N)ncc2)cc3)cc1
NCGC00370950-02	Clc1ccc(-c2sc3C(=O)N(c4cc(OC)c(OCCN5CCCC5)cc4)C=Nc3c2)cc1	5.1500001	Active	Melanin-concentrating hormone receptor 1 Antagonist	0.0	1	GW 803430	363677951.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	2.3	101.3738857189	Clc1ccc(-c2sc3C(=O)N(c4cc(OC)c(OCCN5CCCC5)cc4)C=Nc3c2)cc1	Clc1ccc(-c2sc3C(=O)N(c4cc(OC)c(OCCN5CCCC5)cc4)C=Nc3c2)cc1
NCGC00484058-01	Clc1ccc(-c2scc(CCNC(=O)CCC)n2)cc1		Inactive	response to unfolded protein Modulator		1	Azoramide	363681151.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	18.0	Clc1ccc(-c2scc(CCNC(=O)CCC)n2)cc1	Clc1ccc(-c2scc(CCNC(=O)CCC)n2)cc1
NCGC00386694-01	Clc1ccc(-n2c(NC(=O)c3ccc(CCCC)cc3)cc(-c3ccc(Cl)cc3)n2)cc1		Inactive	Heat shock factor protein 1 Activator		1	HSF1B	363680400.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(-n2c(NC(=O)c3ccc(CCCC)cc3)cc(-c3ccc(Cl)cc3)n2)cc1	Clc1ccc(-n2c(NC(=O)c3ccc(CCCC)cc3)cc(-c3ccc(Cl)cc3)n2)cc1
NCGC00408879-01	Clc1ccc(-n2c(SCC(=O)N3[C@H]4[C@@H](c5c3ccc(C)c5)CN(C)CC4)nnn2)cc1		Inactive	Membrane-associated progesterone receptor component 1 Inhibitor		1	AG-205	363681070.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(-n2c(SCC(=O)N3[C@H]4[C@@H](c5c3ccc(C)c5)CN(C)CC4)nnn2)cc1	Clc1ccc(-n2c(SCC(=O)N3[C@H]4[C@@H](c5c3ccc(C)c5)CN(C)CC4)nnn2)cc1
NCGC00181026-02	Clc1ccc(/C=N/NC(N/N=C\c2ccc(Cl)cc2)=N)cc1		Inactive	Eimeria tenella Inhibitor		1	Robenidine	170465629.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(/C=N/NC(N/N=C\c2ccc(Cl)cc2)=N)cc1	Clc1ccc(/C=N/NC(N/N=C\c2ccc(Cl)cc2)=N)cc1
NCGC00166397-04	Clc1ccc(C(=O)CN(CCCN2c3c(cccc3)CCc3c2cccc3)C)cc1		Inactive	norepinephrine uptake Inhibitor		1	Lofepramine hydrochloride	170465926.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(C(=O)CN(CCCN2c3c(cccc3)CCc3c2cccc3)C)cc1.Cl	Clc1ccc(C(=O)CN(CCCN2c3c(cccc3)CCc3c2cccc3)C)cc1.Cl
NCGC00095161-05&NCGC00095161-10	Clc1ccc(C(=O)NC(C(=O)O)CC=2c3c(NC(=O)C=2)cccc3)cc1		Inactive	Free Radical Scavenger		2	Rebamipide	170465891.0&384568152.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1ccc(C(=O)NC(C(=O)O)CC=2c3c(NC(=O)C=2)cccc3)cc1	Clc1ccc(C(=O)NC(C(=O)O)CC=2c3c(NC(=O)C=2)cccc3)cc1
NCGC00027930-07	Clc1ccc(C(=O)NCCN2CCOCC2)cc1		Inactive	Monoamine oxidase A Inhibitor		1	Moclobemide	170465663.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(C(=O)NCCN2CCOCC2)cc1	Clc1ccc(C(=O)NCCN2CCOCC2)cc1
NCGC00263111-11	Clc1ccc(C(=O)NCCS(=O)(=O)c2ncc(C(F)(F)F)cc2)cc1		Inactive	PPARdelta Antagonist		1	GSK-3787	384568597.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(C(=O)NCCS(=O)(=O)c2ncc(C(F)(F)F)cc2)cc1	Clc1ccc(C(=O)NCCS(=O)(=O)c2ncc(C(F)(F)F)cc2)cc1
NCGC00016850-15	Clc1ccc(C(=O)NCCc2ccc(OC(C(=O)O)(C)C)cc2)cc1		Inactive	Peroxisome proliferator-activated receptor gamma Agonist		1	Bezafibrate	170465743.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(C(=O)NCCc2ccc(OC(C(=O)O)(C)C)cc2)cc1	Clc1ccc(C(=O)NCCc2ccc(OC(C(=O)O)(C)C)cc2)cc1
NCGC00092364-11	Clc1ccc(C(=O)N[C@@H]2C3CCN(C2)CC3)cc1		Inactive	Nicotinic alpha7 Agonist		1	PNU-282987	384568107.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(C(=O)N[C@@H]2C3CCN(C2)CC3)cc1	Clc1ccc(C(=O)N[C@@H]2C3CCN(C2)CC3)cc1
NCGC00344507-02	Clc1ccc(C(=O)N[C@@H]2[C@@H](NC(C)c3c4c(ccc3)cccc4)CCCC2)cc1		Inactive	Calcium-Sensing Receptor (CaSR) Agonist		1	Calhex-231	174006263.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(C(=O)N[C@@H]2[C@@H](NC(C)c3c4c(ccc3)cccc4)CCCC2)cc1	Clc1ccc(C(=O)N[C@@H]2[C@@H](NC(C)c3c4c(ccc3)cccc4)CCCC2)cc1
NCGC00370916-01	Clc1ccc(C(=O)Nc2c(-c3sccc3)nc3n2C=CC=C3)cc1		Inactive	GABA receptor delta subunit Positive Allosteric Modulator		1	DS2	363677932.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(C(=O)Nc2c(-c3sccc3)nc3n2C=CC=C3)cc1	Clc1ccc(C(=O)Nc2c(-c3sccc3)nc3n2C=CC=C3)cc1
NCGC00183863-01	Clc1ccc(C(=O)c2c(C)n(CC(=O)O)c3c2ccc(OC)c3)cc1		Inactive	Prostaglandin-H2 D-isomerase Inhibitor		1	Clometacine	144206860.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(C(=O)c2c(C)n(CC(=O)O)c3c2ccc(OC)c3)cc1	Clc1ccc(C(=O)c2c(C)n(CC(=O)O)c3c2ccc(OC)c3)cc1
NCGC00015437-17&NCGC00015437-22	Clc1ccc(C(=O)c2ccc(OC(C(=O)OC(C)C)(C)C)cc2)cc1		Inactive	PPARalpha Agonist		2	Fenofibrate	170464718.0&384567844.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1ccc(C(=O)c2ccc(OC(C(=O)OC(C)C)(C)C)cc2)cc1	Clc1ccc(C(=O)c2ccc(OC(C(=O)OC(C)C)(C)C)cc2)cc1
NCGC00015562-25&NCGC00015562-39	Clc1ccc(C(=O)n2c(C)c(CC(=O)O)c3c2ccc(OC)c3)cc1		Inactive	Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitor		2	Indomethacin	170464705.0&384567865.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0&0.0	Clc1ccc(C(=O)n2c(C)c(CC(=O)O)c3c2ccc(OC)c3)cc1	Clc1ccc(C(=O)n2c(C)c(CC(=O)O)c3c2ccc(OC)c3)cc1
NCGC00253581-01	Clc1ccc(C(=O)n2c(C)c(CC(=O)OC/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C)c3c2ccc(OC)c3)cc1		Inactive			1	Indomethacin farnesil	170466014.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1ccc(C(=O)n2c(C)c(CC(=O)OC/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C)c3c2ccc(OC)c3)cc1	Clc1ccc(C(=O)n2c(C)c(CC(=O)OC/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C)c3c2ccc(OC)c3)cc1
NCGC00016868-12	Clc1ccc(C(=O)n2c(C)c(CC(=O)OCC(=O)O)c3c2ccc(OC)c3)cc1		Inactive	Cyclooxygenase-1/2/3 Inhibitor		1	Acemetacin	170466043.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	11.94160584&0.0	Clc1ccc(C(=O)n2c(C)c(CC(=O)OCC(=O)O)c3c2ccc(OC)c3)cc1	Clc1ccc(C(=O)n2c(C)c(CC(=O)OCC(=O)O)c3c2ccc(OC)c3)cc1
NCGC00183024-01	Clc1ccc(C(=O)n2c(C)c(CC(=O)OCCN3CCN(CCCOC(=O)CCC(NC(=O)c4ccccc4)C(=O)N(CCC)CCC)CC3)c3c2ccc(OC)c3)cc1	4.9000001	Active	Cyclooxygenase-2 Inhibitor	0.0	1	Proglumetacin	144206876.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	120.095250761	Clc1ccc(C(=O)n2c(C)c(CC(=O)OCCN3CCN(CCCOC(=O)CCC(NC(=O)c4ccccc4)C(=O)N(CCC)CCC)CC3)c3c2ccc(OC)c3)cc1	Clc1ccc(C(=O)n2c(C)c(CC(=O)OCCN3CCN(CCCOC(=O)CCC(NC(=O)c4ccccc4)C(=O)N(CCC)CCC)CC3)c3c2ccc(OC)c3)cc1
NCGC00015156-15&NCGC00015156-28	Clc1ccc(C(CN)CC(=O)O)cc1		Inactive	GABA-B receptor Agonist		2	Baclofen	170465099.0&434146942.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1ccc(C(CN)CC(=O)O)cc1	Clc1ccc(C(CN)CC(=O)O)cc1
NCGC00386679-01	Clc1ccc(C(N2CCN(C(=O)c3c([N+](=O)[O-])c(C)on3)CC2)c2ccc(Cl)cc2)cc1		Inactive			1	ML 210	363680392.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(C(N2CCN(C(=O)c3c([N+](=O)[O-])c(C)on3)CC2)c2ccc(Cl)cc2)cc1	Clc1ccc(C(N2CCN(C(=O)c3c([N+](=O)[O-])c(C)on3)CC2)c2ccc(Cl)cc2)cc1
NCGC00179384-10	Clc1ccc(C(N2CCN(C)CC2)c2ccccc2)cc1	4.9000001	Active	Hepatitis C virus Inhibitor	0.0	1	Chlorcyclizine	405558456.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	75.7372153727	Clc1ccc(C(N2CCN(C)CC2)c2ccccc2)cc1	Clc1ccc(C(N2CCN(C)CC2)c2ccccc2)cc1
NCGC00018271-07	Clc1ccc(C(N2CCN(C)CCC2)c2ccccc2)cc1	5.3000002	Active		0.0	1	Homochlorcyclizine	170465786.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	97.2051275539	Clc1ccc(C(N2CCN(C)CCC2)c2ccccc2)cc1	Clc1ccc(C(N2CCN(C)CCC2)c2ccccc2)cc1
NCGC00351414-01	Clc1ccc(C(N2CCN(CC)CC2)c2ccc(Cl)cc2)cc1		Inactive			1	NCGC00351414-01	440681478.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(C(N2CCN(CC)CC2)c2ccc(Cl)cc2)cc1	Clc1ccc(C(N2CCN(CC)CC2)c2ccc(Cl)cc2)cc1
NCGC00167781-12	Clc1ccc(C(N2CCN(CCOCC(=O)O)CC2)c2ccccc2)cc1		Inactive	Histamine H1 Receptor Antagonists		1	CETIRIZINE HYDROCHLORIDE	405558424.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(C(N2CCN(CCOCC(=O)O)CC2)c2ccccc2)cc1	Clc1ccc(C(N2CCN(CCOCC(=O)O)CC2)c2ccccc2)cc1
NCGC00021152-06	Clc1ccc(C(N2CCN(CCOCCO)CC2)c2ccccc2)cc1		Inactive	antiparasitic agent		1	Hydroxyzine	170464958.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(C(N2CCN(CCOCCO)CC2)c2ccccc2)cc1	Clc1ccc(C(N2CCN(CCOCCO)CC2)c2ccccc2)cc1
NCGC00018296-07&NCGC00018296-15	Clc1ccc(C(N2CCN(Cc3cc(C)ccc3)CC2)c2ccccc2)cc1		Inactive	Constitutive Androstane Receptor Agonist		2	Meclizine hydrochloride	170464899.0&384568003.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&24.90700412	Clc1ccc(C(N2CCN(Cc3cc(C)ccc3)CC2)c2ccccc2)cc1.Cl.Cl	Clc1ccc(C(N2CCN(Cc3cc(C)ccc3)CC2)c2ccccc2)cc1.Cl.Cl&Clc1ccc(C(N2CCN(Cc3cc(C)ccc3)CC2)c2ccccc2)cc1
NCGC00386387-01	Clc1ccc(C(N2CCN(Cc3ccc(C(C)(C)C)cc3)CC2)c2ccccc2)cc1	4.9000001	Active	Histamine H1 receptor Antagonist	0.0	1	Buclizine HCl	405558507.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	71.0949282979	Clc1ccc(C(N2CCN(Cc3ccc(C(C)(C)C)cc3)CC2)c2ccccc2)cc1	Clc1ccc(C(N2CCN(Cc3ccc(C(C)(C)C)cc3)CC2)c2ccccc2)cc1
NCGC00386733-02	Clc1ccc(C(N2CCN(Cc3nc(NCCCN(C)C)c4c(n3)cccc4)CC2)c2ccc(Cl)cc2)cc1		Inactive	Cellular tumor antigen p53 Chaperone		1	SCH 529074	363680423.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(C(N2CCN(Cc3nc(NCCCN(C)C)c4c(n3)cccc4)CC2)c2ccc(Cl)cc2)cc1	Clc1ccc(C(N2CCN(Cc3nc(NCCCN(C)C)c4c(n3)cccc4)CC2)c2ccc(Cl)cc2)cc1
NCGC00386490-01	Clc1ccc(C(O)CN2CCN(Cc3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)CC2)cc1		Inactive			1	AM 36 dihydrochloride	363680302.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(C(O)CN2CCN(Cc3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)CC2)cc1	Clc1ccc(C(O)CN2CCN(Cc3cc(C(C)(C)C)c(O)c(C(C)(C)C)c3)CC2)cc1
NCGC00484055-01	Clc1ccc(C(OCCN(C)C)(C)c2ccccc2)cc1	5.0	Active	Histamine H1 receptor Antagonist	0.0	1	Chlorphenoxamine	363681149.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	3.0	108.1809611876	Clc1ccc(C(OCCN(C)C)(C)c2ccccc2)cc1	Clc1ccc(C(OCCN(C)C)(C)c2ccccc2)cc1
NCGC00166141-06	Clc1ccc(C(OCCN(C)C)c2ncccc2)cc1		Inactive	Histamine H1 receptor Antagonist		1	Carbinoxamine maleate	170465237.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(C(OCCN(C)C)c2ncccc2)cc1.O=C(O)/C=C\C(=O)O	Clc1ccc(C(OCCN(C)C)c2ncccc2)cc1.O=C(O)/C=C\C(=O)O
NCGC00178069-05	Clc1ccc(C(OCCN2CCCCC2)c2ccccc2)cc1	5.5	Active		0.0	1	Cloperastine hydrochloride	170465832.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	33.5876826719	Clc1ccc(C(OCCN2CCCCC2)c2ccccc2)cc1.Cl	Clc1ccc(C(OCCN2CCCCC2)c2ccccc2)cc1.Cl
NCGC00092357-04	Clc1ccc(C2(C(N(C)C)CC(C)C)CCC2)cc1		Inactive	5-HT Reuptake Inhibitor		1	Sibutramine hydrochloride	174007250.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(C2(C(N(C)C)CC(C)C)CCC2)cc1	Clc1ccc(C2(C(N(C)C)CC(C)C)CCC2)cc1
NCGC00389745-01	Clc1ccc(C2(C)N(C(=O)N3CCN(CCCS(=O)(=O)C)CC3)C(c3c(OCC)cc(C(C)(C)C)cc3)=NC2(C)c2ccc(Cl)cc2)cc1		Inactive	p53-binding protein Mdm-2 Binding Agent		1	RG7112	363680847.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(C2(C)N(C(=O)N3CCN(CCCS(=O)(=O)C)CC3)C(c3c(OCC)cc(C(C)(C)C)cc3)=NC2(C)c2ccc(Cl)cc2)cc1	Clc1ccc(C2(C)N(C(=O)N3CCN(CCCS(=O)(=O)C)CC3)C(c3c(OCC)cc(C(C)(C)C)cc3)=NC2(C)c2ccc(Cl)cc2)cc1
NCGC00015608-11&NCGC00015608-22	Clc1ccc(C2(O)CCN(CCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CC2)cc1	5.07500005	Active	mu-Opioid Antagonist	0.34999990000000025	2	Loperamide hydrochloride	170464852.0&384567873.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0&3.0	103.1170135449&110.1459363173&109.5223432906	Clc1ccc(C2(O)CCN(CCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CC2)cc1	Clc1ccc(C2(O)CCN(CCC(C(=O)N(C)C)(c3ccccc3)c3ccccc3)CC2)cc1
NCGC00378719-01	Clc1ccc(C2(O)CCN(CCCC(C#N)(c3ccccc3)c3ccccc3)CC2)cc1		Inactive	Human herpesvirus 5 chemokine receptor Inverse Agonist		1	BX 513 hydrochloride	363678170.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	-11.738474792	Clc1ccc(C2(O)CCN(CCCC(C#N)(c3ccccc3)c3ccccc3)CC2)cc1	Clc1ccc(C2(O)CCN(CCCC(C#N)(c3ccccc3)c3ccccc3)CC2)cc1
NCGC00378886-01	Clc1ccc(C2(O)N3C(=NCC3)c3c2cccc3)cc1		Inactive			1	Mazindol	363678258.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(C2(O)N3C(=NCC3)c3c2cccc3)cc1	Clc1ccc(C2(O)N3C(=NCC3)c3c2cccc3)cc1
NCGC00508704-02	Clc1ccc(C2(OC(=O)CCCCCCCCC)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1		Inactive	Dopamine D4 receptor Inverse Agonist		1	HALOPERIDOL DECANOATE	405558790.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	16.5	Clc1ccc(C2(OC(=O)CCCCCCCCC)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1	Clc1ccc(C2(OC(=O)CCCCCCCCC)CCN(CCCC(=O)c3ccc(F)cc3)CC2)cc1
NCGC00346549-08	Clc1ccc(C2(c3ccc(-c4c[nH]nc4)cc3)CCNCC2)cc1		Inactive	AKT Inhibitor		1	AT-7867	384568834.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(C2(c3ccc(-c4c[nH]nc4)cc3)CCNCC2)cc1	Clc1ccc(C2(c3ccc(-c4c[nH]nc4)cc3)CCNCC2)cc1
NCGC00346441-01	Clc1ccc(C23CC4(C(=O)NCc5ccncc5)C[C@H](C2)C[C@@H](C4)C3)cc1		Inactive	Sphingosine Kinase 1 (SphK1) Inhibitor		1	ABC-294640	174006706.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(C23CC4(C(=O)NCc5ccncc5)C[C@H](C2)C[C@@H](C4)C3)cc1	Clc1ccc(C23CC4(C(=O)NCc5ccncc5)C[C@H](C2)C[C@@H](C4)C3)cc1
NCGC00345789-05&NCGC00345789-16	Clc1ccc(C2=C(CN3CCN(c4cc(Oc5cnc6[nH]ccc6c5)c(C(=O)NS(=O)(=O)c5cc([N+](=O)[O-])c(NCC6CCOCC6)cc5)cc4)CC3)CCC(C)(C)C2)cc1		Inactive	Bcl-2 Inhibitor		2	Venetoclax (ABT-199)	405558742.0&384568742.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&15.5221948199	Clc1ccc(C2=C(CN3CCN(c4cc(Oc5cnc6[nH]ccc6c5)c(C(=O)NS(=O)(=O)c5cc([N+](=O)[O-])c(NCC6CCOCC6)cc5)cc4)CC3)CCC(C)(C)C2)cc1	Clc1ccc(C2=C(CN3CCN(c4cc(Oc5cnc6[nH]ccc6c5)c(C(=O)NS(=O)(=O)c5cc([N+](=O)[O-])c(NCC6CCOCC6)cc5)cc4)CC3)CCC(C)(C)C2)cc1
NCGC00188344-07	Clc1ccc(C2=C(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5cc(S(=O)(=O)C(F)(F)F)c(N[C@@H](CSc6ccccc6)CCN6CCOCC6)cc5)cc4)CC3)CC(C)(C)CC2)cc1		Inactive	Bcl-xL Inhibitor		1	Navitoclax (ABT-263)	384568447.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	28.85355648	Clc1ccc(C2=C(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5cc(S(=O)(=O)C(F)(F)F)c(N[C@@H](CSc6ccccc6)CCN6CCOCC6)cc5)cc4)CC3)CC(C)(C)CC2)cc1	Clc1ccc(C2=C(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5cc(S(=O)(=O)C(F)(F)F)c(N[C@@H](CSc6ccccc6)CCN6CCOCC6)cc5)cc4)CC3)CC(C)(C)CC2)cc1
NCGC00356071-11&NCGC00356071-12	Clc1ccc(C2=N[C@@H](CC(=O)N)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1		Inactive	Bromodomain-containing protein 4 Inhibitor		2	CPI-203	384569026.0&404904718.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1ccc(C2=N[C@@H](CC(=O)N)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1	Clc1ccc(C2=N[C@@H](CC(=O)N)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1
NCGC00483135-03	Clc1ccc(C2=N[C@@H](CC(=O)N)c3onc(C)c3-c3c2cccc3)cc1		Inactive	Bromodomain-containing protein 4 Inhibitor		1	CPI-0610	384569263.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1ccc(C2=N[C@@H](CC(=O)N)c3onc(C)c3-c3c2cccc3)cc1	Clc1ccc(C2=N[C@@H](CC(=O)N)c3onc(C)c3-c3c2cccc3)cc1
NCGC00263621-06&NCGC00263621-12	Clc1ccc(C2=N[C@@H](CC(=O)NCC)c3n(c(C)nn3)-c3c2cc(OC)cc3)cc1		Inactive	Brd4 Inhibitor		2	I-BET762	434147078.0&384568695.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&-7.535966148	Clc1ccc(C2=N[C@@H](CC(=O)NCC)c3n(c(C)nn3)-c3c2cc(OC)cc3)cc1	Clc1ccc(C2=N[C@@H](CC(=O)NCC)c3n(c(C)nn3)-c3c2cc(OC)cc3)cc1
NCGC00510478-01	Clc1ccc(C2=N[C@@H](CC(=O)NCCOCCCOCC(=O)N[C@@H](C(C)(C)C)C(=O)N3[C@H](C(=O)N[C@@H](C)c4ccc(-c5c(C)ncs5)cc4)C[C@@H](O)C3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1		Inactive	Brd4 Inhibitor		1	ARV-771	384569441.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(C2=N[C@@H](CC(=O)NCCOCCCOCC(=O)N[C@@H](C(C)(C)C)C(=O)N3[C@H](C(=O)N[C@@H](C)c4ccc(-c5c(C)ncs5)cc4)C[C@@H](O)C3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1	Clc1ccc(C2=N[C@@H](CC(=O)NCCOCCCOCC(=O)N[C@@H](C(C)(C)C)C(=O)N3[C@H](C(=O)N[C@@H](C)c4ccc(-c5c(C)ncs5)cc4)C[C@@H](O)C3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1
NCGC00356067-11&NCGC00356067-12	Clc1ccc(C2=N[C@@H](CC(=O)Nc3ccc(O)cc3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1		Inactive			2	OTX -015&OTX-015	434147098.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1ccc(C2=N[C@@H](CC(=O)Nc3ccc(O)cc3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1	Clc1ccc(C2=N[C@@H](CC(=O)Nc3ccc(O)cc3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1
NCGC00483927-02	Clc1ccc(C2=N[C@@H](CC(=O)Nc3ccc(OCCOCCOCCOCCNc4c5C(=O)N(C(=O)c5ccc4)C4C(=O)NC(=O)CC4)cc3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1		Inactive	Brd4 Inhibitor		1	ARV-825	384569267.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-12.5089418719	Clc1ccc(C2=N[C@@H](CC(=O)Nc3ccc(OCCOCCOCCOCCNc4c5C(=O)N(C(=O)c5ccc4)C4C(=O)NC(=O)CC4)cc3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1	Clc1ccc(C2=N[C@@H](CC(=O)Nc3ccc(OCCOCCOCCOCCNc4c5C(=O)N(C(=O)c5ccc4)C4C(=O)NC(=O)CC4)cc3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1
NCGC00250412-08&NCGC00250412-15&NCGC00250412-21	Clc1ccc(C2=N[C@@H](CC(=O)OC(C)(C)C)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1		Inactive	Brd4 Inhibitor		3	JQ1	384568560.0&434146892.0&440681379.0	Annotated/Bioactive Compound Collection&Anti-infectives&2020_NPACT-12_CPE	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	Clc1ccc(C2=N[C@@H](CC(=O)OC(C)(C)C)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1	Clc1ccc(C2=N[C@@H](CC(=O)OC(C)(C)C)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1
NCGC00345173-01	Clc1ccc(C2=N[C@H](CC(=O)NCC)c3n(c(C)nn3)-c3c2cc(OC)cc3)cc1		Inactive	Brd4 Inhibitor		1	GSK-525768	174006338.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(C2=N[C@H](CC(=O)NCC)c3n(c(C)nn3)-c3c2cc(OC)cc3)cc1	Clc1ccc(C2=N[C@H](CC(=O)NCC)c3n(c(C)nn3)-c3c2cc(OC)cc3)cc1
NCGC00483928-01	Clc1ccc(C2=N[C@H](CC(=O)NCCCCNC(=O)COc3c4C(=O)N([C@@H]5C(=O)NC(=O)CC5)C(=O)c4ccc3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1		Inactive	Bromodomain-containing protein 4 Binding Agent		1	dBET1	363681147.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(C2=N[C@H](CC(=O)NCCCCNC(=O)COc3c4C(=O)N([C@@H]5C(=O)NC(=O)CC5)C(=O)c4ccc3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1	Clc1ccc(C2=N[C@H](CC(=O)NCCCCNC(=O)COc3c4C(=O)N([C@@H]5C(=O)NC(=O)CC5)C(=O)c4ccc3)c3n(c(C)nn3)-c3sc(C)c(C)c23)cc1
NCGC00016961-06&NCGC00016961-11	Clc1ccc(C2CCC(C3=C(O)C(=O)c4c(C3=O)cccc4)CC2)cc1		Inactive	Synergistic with proguanil, mitochondrial sensitizer (cytochrome bc1 complex)		2	Atovaquone&ATOVAQUONE	170464681.0&434146960.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	20.7477876119&0.0&0.0	Clc1ccc(C2CCC(C3=C(O)C(=O)c4c(C3=O)cccc4)CC2)cc1	Clc1ccc(C2CCC(C3=C(O)C(=O)c4c(C3=O)cccc4)CC2)cc1
NCGC00015191-13&NCGC00015191-21	Clc1ccc(C2S(=O)(=O)CCC(=O)N2C)cc1		Inactive	GABA Modulators		2	Chlormezanone	170465161.0&384567820.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1ccc(C2S(=O)(=O)CCC(=O)N2C)cc1	Clc1ccc(C2S(=O)(=O)CCC(=O)N2C)cc1
NCGC00390670-01	Clc1ccc(C=2c3c(-n4c(C)nnc4[C@H](Cc4oc(C)nn4)C=2)cccc3)cc1		Inactive	Brd4 Inhibitor		1	BAY-356	363680965.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(C=2c3c(-n4c(C)nnc4[C@H](Cc4oc(C)nn4)C=2)cccc3)cc1	Clc1ccc(C=2c3c(-n4c(C)nnc4[C@H](Cc4oc(C)nn4)C=2)cccc3)cc1
NCGC00124342-01	Clc1ccc(CC(=O)Nc2cc3c(C)cc(Nc4cc(C(F)(F)F)ccc4)nc3cc2)cc1		Inactive			1	NCGC00124342-01	24399725.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(CC(=O)Nc2cc3c(C)cc(Nc4cc(C(F)(F)F)ccc4)nc3cc2)cc1	Clc1ccc(CC(=O)Nc2cc3c(C)cc(Nc4cc(C(F)(F)F)ccc4)nc3cc2)cc1
NCGC00408854-01	Clc1ccc(CC(C(O)(C)c2ccccc2)n2ncnc2)cc1		Inactive	Cytochrome P450 Inhibitor		1	Brassinazole	363681065.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(CC(C(O)(C)c2ccccc2)n2ncnc2)cc1	Clc1ccc(CC(C(O)(C)c2ccccc2)n2ncnc2)cc1
NCGC00183835-01	Clc1ccc(CC(NC(=O)OCC)(C)C)cc1		Inactive			1	Cloforex	144206822.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(CC(NC(=O)OCC)(C)C)cc1	Clc1ccc(CC(NC(=O)OCC)(C)C)cc1
NCGC00159437-03	Clc1ccc(CC(O)(C(CN(C)C)C)C)cc1		Inactive	HERG Inhibitor		1	Clobutinol hydrochloride	170466051.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(CC(O)(C(CN(C)C)C)C)cc1.Cl	Clc1ccc(CC(O)(C(CN(C)C)C)C)cc1.Cl
NCGC00346621-05	Clc1ccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1		Inactive	AKT Inhibitor		1	CCT-128930	363677482.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1	Clc1ccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1
NCGC00177979-05	Clc1ccc(CC2=NN(C(=O)c3c2cccc3)C2CCN(C)CCC2)cc1	4.9499998	Active	Histamine H1 Receptor Antagonists	0.0	1	Azelastine hydrochloride	170465172.0	2019_NPC-3.2	SARS-CoV-2_CPE_SRI	3.0	83.8655213059	Clc1ccc(CC2=NN(C(=O)c3c2cccc3)C2CCN(C)CCC2)cc1.Cl	Clc1ccc(CC2=NN(C(=O)c3c2cccc3)C2CCN(C)CCC2)cc1.Cl
NCGC00379194-01	Clc1ccc(CCC2CCN(C(=O)OCC(=O)NC)CC2)cc1		Inactive	Monoglyceride lipase Inhibitor		1	SA 57	363678410.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(CCC2CCN(C(=O)OCC(=O)NC)CC2)cc1	Clc1ccc(CCC2CCN(C(=O)OCC(=O)NC)CC2)cc1
NCGC00370823-03	Clc1ccc(CCCOCCCN2CCCCC2)cc1	4.8499999	Active	Histamine H3 receptor Inverse Agonist	0.0	1	Pitolisant (hydrochloride)	405558641.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	38.0	Clc1ccc(CCCOCCCN2CCCCC2)cc1	Clc1ccc(CCCOCCCN2CCCCC2)cc1
NCGC00242476-03	Clc1ccc(CN(CC(=O)OC(C)(C)C)Cc2sc([N+](=O)[O-])cc2)cc1		Inactive	Rev-erb alpha Agonist		1	GSK-4112	384568489.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(CN(CC(=O)OC(C)(C)C)Cc2sc([N+](=O)[O-])cc2)cc1	Clc1ccc(CN(CC(=O)OC(C)(C)C)Cc2sc([N+](=O)[O-])cc2)cc1
NCGC00016672-07	Clc1ccc(CN(CCN(C)C)c2ncccc2)cc1		Inactive	Histamine H1 Receptor Antagonists		1	Chloropyramine hydrochloride	434146958.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(CN(CCN(C)C)c2ncccc2)cc1	Clc1ccc(CN(CCN(C)C)c2ncccc2)cc1
NCGC00537955-01	Clc1ccc(CN(C[C@H](O)[C@@]23C(=C(C(C)C)C(=O)C2)[C@@H]2[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](OC(=O)CC(C(=O)O)(C)C)CC5)CC4)CC2)CC3)CCN(C)C)cc1		Inactive			1	GSK2838232	434147177.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(CN(C[C@H](O)[C@@]23C(=C(C(C)C)C(=O)C2)[C@@H]2[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](OC(=O)CC(C(=O)O)(C)C)CC5)CC4)CC2)CC3)CCN(C)C)cc1	Clc1ccc(CN(C[C@H](O)[C@@]23C(=C(C(C)C)C(=O)C2)[C@@H]2[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](OC(=O)CC(C(=O)O)(C)C)CC5)CC4)CC2)CC3)CCN(C)C)cc1
NCGC00347956-02	Clc1ccc(CN(Cc2sc([N+](=O)[O-])cc2)CC2CN(C(=O)NCCCCC)CC2)cc1		Inactive	Rev-erb alpha Agonist		1	SR-9011	384569000.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(CN(Cc2sc([N+](=O)[O-])cc2)CC2CN(C(=O)NCCCCC)CC2)cc1	Clc1ccc(CN(Cc2sc([N+](=O)[O-])cc2)CC2CN(C(=O)NCCCCC)CC2)cc1
NCGC00384202-01	Clc1ccc(CN(Cc2sc([N+](=O)[O-])cc2)CC2CN(C(=O)OCC)CC2)cc1		Inactive	Nuclear receptor subfamily 1 group D member 2 Agonist		1	SR9009	363679193.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(CN(Cc2sc([N+](=O)[O-])cc2)CC2CN(C(=O)OCC)CC2)cc1	Clc1ccc(CN(Cc2sc([N+](=O)[O-])cc2)CC2CN(C(=O)OCC)CC2)cc1
NCGC00390377-01	Clc1ccc(CN2C(=O)c3c(-n4c(CCC(=O)NCCC5=CCCCC5)nnc24)cccc3)cc1		Inactive	Hedgehog Signaling Pathway Inhibitor		1	SmoAntagonist,SA9	363680883.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(CN2C(=O)c3c(-n4c(CCC(=O)NCCC5=CCCCC5)nnc24)cccc3)cc1	Clc1ccc(CN2C(=O)c3c(-n4c(CCC(=O)NCCC5=CCCCC5)nnc24)cccc3)cc1
NCGC00386531-01	Clc1ccc(CN2CCc3sc(N)nc3CC2)cc1		Inactive	Adrenergic receptor alpha-2 Partial Agonist		1	B-HT 958 dihydrochloride	363680317.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(CN2CCc3sc(N)nc3CC2)cc1	Clc1ccc(CN2CCc3sc(N)nc3CC2)cc1
NCGC00370812-01	Clc1ccc(CN2C[C@H](NC(=O)CNC(=O)c3cc(C(F)(F)F)ccc3)CC2)cc1		Inactive	C-C chemokine receptor type 2 Antagonist		1	Teijin compound 1	363677863.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(CN2C[C@H](NC(=O)CNC(=O)c3cc(C(F)(F)F)ccc3)CC2)cc1	Clc1ccc(CN2C[C@H](NC(=O)CNC(=O)c3cc(C(F)(F)F)ccc3)CC2)cc1
NCGC00112645-01	Clc1ccc(CNC(=O)CN2C(=O)Oc3c2ccc(S(=O)(=O)N2CCCCC2)c3)cc1		Inactive			1	NCGC00112645-01	24387224.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(CNC(=O)CN2C(=O)Oc3c2ccc(S(=O)(=O)N2CCCCC2)c3)cc1	Clc1ccc(CNC(=O)CN2C(=O)Oc3c2ccc(S(=O)(=O)N2CCCCC2)c3)cc1
NCGC00345084-02	Clc1ccc(CNC(=O)C[C@H]2C(=O)NC[C@@H](c3ccccc3)OC(=O)CC/C=C\C2)cc1		Inactive	Hedgehog Antagonist		1	Robotnikinin	384568732.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(CNC(=O)C[C@H]2C(=O)NC[C@@H](c3ccccc3)OC(=O)CC/C=C\C2)cc1	Clc1ccc(CNC(=O)C[C@H]2C(=O)NC[C@@H](c3ccccc3)OC(=O)CC/C=C\C2)cc1
NCGC00378784-01	Clc1ccc(CNC(=O)c2c(N)c3c(C)cc(C)nc3s2)cc1		Inactive	Muscarinic acetylcholine receptor M4 Positive Allosteric Modulator		1	VU 10010	363678197.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(CNC(=O)c2c(N)c3c(C)cc(C)nc3s2)cc1	Clc1ccc(CNC(=O)c2c(N)c3c(C)cc(C)nc3s2)cc1
NCGC00386666-01	Clc1ccc(CNC(=O)c2sc3C(=O)N(c4nc(OC)c(OC)cc4)C(=O)Nc3c2)cc1		Inactive			1	HIF Phd Inhibitor 4	363680382.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(CNC(=O)c2sc3C(=O)N(c4nc(OC)c(OC)cc4)C(=O)Nc3c2)cc1	Clc1ccc(CNC(=O)c2sc3C(=O)N(c4nc(OC)c(OC)cc4)C(=O)Nc3c2)cc1
NCGC00379239-01	Clc1ccc(CNCC[C@H](N)C(=O)N2CCCCC2)cc1		Inactive	Dipeptidyl peptidase VIII Inhibitor		1	UAMC 00039 dihydrochloride	363678440.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(CNCC[C@H](N)C(=O)N2CCCCC2)cc1	Clc1ccc(CNCC[C@H](N)C(=O)N2CCCCC2)cc1
NCGC00346882-02	Clc1ccc(COc2c(C(=O)N[C@@H](C)c3ccccc3)scc2)cc1		Inactive	SH2 containing inositol phosphatase (SHIP) Inhibitor		1	AS-1949490	384568959.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(COc2c(C(=O)N[C@@H](C)c3ccccc3)scc2)cc1	Clc1ccc(COc2c(C(=O)N[C@@H](C)c3ccccc3)scc2)cc1
NCGC00484076-01	Clc1ccc(COc2cc(NC(=O)Cc3c(F)cccc3F)ncc2)cc1		Inactive	Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase 2 Inhibitor		1	CPDA	363681168.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(COc2cc(NC(=O)Cc3c(F)cccc3F)ncc2)cc1	Clc1ccc(COc2cc(NC(=O)Cc3c(F)cccc3F)ncc2)cc1
NCGC00481544-01	Clc1ccc(C[C@@H](/N=C(\O)/[C@H](/N=C(\O)/C)Cc2cc3c(cc2)cccc3)/C(/O)=N/[C@@H](/C(/O)=N/[C@H](/C(/O)=N/[C@H](/C(/O)=N/[C@@H](/C(/O)=N/[C@H](/C(/O)=N/[C@H](C(=O)N2[C@H](/C(/O)=N/[C@@H](C(O)=N)C)CCC2)CCCNC(=N)N)CC(C)C)CCCNC(O)=N)Cc2ccc(O)cc2)CO)Cc2cnccc2)cc1		Inactive	Gonadotropin-releasing hormone receptor Antagonist		1	Cetrorelix	405558930.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(C[C@@H](/N=C(\O)/[C@H](/N=C(\O)/C)Cc2cc3c(cc2)cccc3)/C(/O)=N/[C@@H](/C(/O)=N/[C@H](/C(/O)=N/[C@H](/C(/O)=N/[C@@H](/C(/O)=N/[C@H](/C(/O)=N/[C@H](C(=O)N2[C@H](/C(/O)=N/[C@@H](C(O)=N)C)CCC2)CCCNC(=N)N)CC(C)C)CCCNC(O)=N)Cc2ccc(O)cc2)CO)Cc2cnccc2)cc1	Clc1ccc(C[C@@H](/N=C(\O)/[C@H](/N=C(\O)/C)Cc2cc3c(cc2)cccc3)/C(/O)=N/[C@@H](/C(/O)=N/[C@H](/C(/O)=N/[C@H](/C(/O)=N/[C@@H](/C(/O)=N/[C@H](/C(/O)=N/[C@H](C(=O)N2[C@H](/C(/O)=N/[C@@H](C(O)=N)C)CCC2)CCCNC(=N)N)CC(C)C)CCCNC(O)=N)Cc2ccc(O)cc2)CO)Cc2cnccc2)cc1
NCGC00482546-01	Clc1ccc(C[C@H](NC(=O)C(NC(=O)C)Cc2cc3c(cc2)cccc3)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2C(C(=O)N[C@@H](C(=O)N)C)CCC2)CCCCN=C(NCC)NCC)CC(C)C)CCCCN=C(NCC)NCC)Cc2ccc(O)cc2)CO)Cc2cnccc2)cc1		Inactive			1	Ganirelix	405558835.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(C[C@H](NC(=O)C(NC(=O)C)Cc2cc3c(cc2)cccc3)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2C(C(=O)N[C@@H](C(=O)N)C)CCC2)CCCCN=C(NCC)NCC)CC(C)C)CCCCN=C(NCC)NCC)Cc2ccc(O)cc2)CO)Cc2cnccc2)cc1	Clc1ccc(C[C@H](NC(=O)C(NC(=O)C)Cc2cc3c(cc2)cccc3)C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2C(C(=O)N[C@@H](C(=O)N)C)CCC2)CCCCN=C(NCC)NCC)CC(C)C)CCCCN=C(NCC)NCC)Cc2ccc(O)cc2)CO)Cc2cnccc2)cc1
NCGC00378803-02	Clc1ccc(C[C@H]([C@@H](NC(=O)C(Oc2ncc(C(F)(F)F)cc2)(C)C)C)c2cc(C#N)ccc2)cc1		Inactive	Cannabinoid CB1 receptor Inverse Agonist		1	MK 0364	363678207.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(C[C@H]([C@@H](NC(=O)C(Oc2ncc(C(F)(F)F)cc2)(C)C)C)c2cc(C#N)ccc2)cc1	Clc1ccc(C[C@H]([C@@H](NC(=O)C(Oc2ncc(C(F)(F)F)cc2)(C)C)C)c2cc(C#N)ccc2)cc1
NCGC00378898-01	Clc1ccc(C[C@H]2N(C(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)CC[C@H](NC(=O)c3c4c(ncc3)cccc4)C2)cc1		Inactive	Neurokinin 1 receptor Antagonist		1	NKP608	363678264.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	27.7823592641	Clc1ccc(C[C@H]2N(C(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)CC[C@H](NC(=O)c3c4c(ncc3)cccc4)C2)cc1	Clc1ccc(C[C@H]2N(C(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)CC[C@H](NC(=O)c3c4c(ncc3)cccc4)C2)cc1
NCGC00162249-09	Clc1ccc(Cn2c(CC(C(=O)O)(C)C)c(SC(C)(C)C)c3c2ccc(C(C)C)c3)cc1	5.0	Active	5-lipoxygenase-activating (FLAP) Inhibitor	0.0	1	MK-886	384568221.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	42.0938230834	Clc1ccc(Cn2c(CC(C(=O)[O-])(C)C)c(SC(C)(C)C)c3c2ccc(C(C)C)c3)cc1	Clc1ccc(Cn2c(CC(C(=O)[O-])(C)C)c(SC(C)(C)C)c3c2ccc(C(C)C)c3)cc1
NCGC00379068-03	Clc1ccc(Cn2c(CC(C(=O)O)(C)C)c(SC(C)(C)C)c3c2ccc(OCc2nc4c(cc2)cccc4)c3)cc1		Inactive	5-lipoxygenase activating protein Inhibitor		1	MK591	384569092.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	18.052301256	Clc1ccc(Cn2c(CC(C(=O)O)(C)C)c(SC(C)(C)C)c3c2ccc(OCc2nc4c(cc2)cccc4)c3)cc1	Clc1ccc(Cn2c(CC(C(=O)O)(C)C)c(SC(C)(C)C)c3c2ccc(OCc2nc4c(cc2)cccc4)c3)cc1
NCGC00015243-10&NCGC00015243-14&NCGC00015243-17	Clc1ccc(Cn2c(CN3CCCC3)nc3c2cccc3)cc1		Inactive	Histamine H1 Receptor Antagonist		3	Clemizole hydrochloride&Clemizole (hydrochloride)	170465924.0&384567830.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&10.715607404&0.0&0.0	Clc1ccc(Cn2c(CN3CCCC3)nc3c2cccc3)cc1.Cl	Clc1ccc(Cn2c(CN3CCCC3)nc3c2cccc3)cc1.Cl&Clc1ccc(Cn2c(CN3CCCC3)nc3c2cccc3)cc1
NCGC00379195-02	Clc1ccc(Cn2c(Cc3ccccc3)nc3c2cccc3)cc1		Inactive	Proteinase-activated receptor 1 Antagonist		1	Q94 hydrochloride	363678411.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(Cn2c(Cc3ccccc3)nc3c2cccc3)cc1	Clc1ccc(Cn2c(Cc3ccccc3)nc3c2cccc3)cc1
NCGC00345790-03	Clc1ccc(Cn2c3c(S(=O)(=O)C)cc(F)cc3c3c2[C@@H](CC(=O)O)CC3)cc1		Inactive	prostaglandin D2 DP1 Inhibitor		1	Laropiprant	384568743.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(Cn2c3c(S(=O)(=O)C)cc(F)cc3c3c2[C@@H](CC(=O)O)CC3)cc1	Clc1ccc(Cn2c3c(S(=O)(=O)C)cc(F)cc3c3c2[C@@H](CC(=O)O)CC3)cc1
NCGC00160428-03	Clc1ccc(Cn2c3c(c(C(=O)C(=O)Nc4ccncc4)c2)cccc3)cc1		Inactive	Tubulin polymerization Inhibitor		1	Indibulin	384568195.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Clc1ccc(Cn2c3c(c(C(=O)C(=O)Nc4ccncc4)c2)cccc3)cc1	Clc1ccc(Cn2c3c(c(C(=O)C(=O)Nc4ccncc4)c2)cccc3)cc1
NCGC00356154-01	Clc1ccc(N(C(=O)C=2N=Cc3n(c(-c4ccc(C(=O)NC)cc4)cn3)C=2)C)cc1		Inactive			1	NCGC00356154-01	377020249.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(N(C(=O)C=2N=Cc3n(c(-c4ccc(C(=O)NC)cc4)cn3)C=2)C)cc1	Clc1ccc(N(C(=O)C=2N=Cc3n(c(-c4ccc(C(=O)NC)cc4)cn3)C=2)C)cc1
NCGC00371144-02	Clc1ccc(N2C(=O)N=C(N3CCOCC3)C2)cc1		Inactive			1	AWD 131-138	405558706.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(N2C(=O)N=C(N3CCOCC3)C2)cc1	Clc1ccc(N2C(=O)N=C(N3CCOCC3)C2)cc1
NCGC00390454-01	Clc1ccc(N2CCN(C(=O)N3CCOCC3)CC2)cc1		Inactive	Aldo-keto-reductase family 1 member C3 Inhibitor		1	AKR1C3InhibitorIII	363680898.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(N2CCN(C(=O)N3CCOCC3)CC2)cc1	Clc1ccc(N2CCN(C(=O)N3CCOCC3)CC2)cc1
NCGC00378746-04	Clc1ccc(NC(=O)C(=O)NC2CC(C)(C)NC(C)(C)C2)cc1		Inactive	Envelope glycoprotein gp160 Binding Agent		1	NBD 556	434147107.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(NC(=O)C(=O)NC2CC(C)(C)NC(C)(C)C2)cc1	Clc1ccc(NC(=O)C(=O)NC2CC(C)(C)NC(C)(C)C2)cc1
NCGC00387259-04	Clc1ccc(NC(=O)C2CN(C(=O)c3cc(-c4occc4)ccc3)CCC2)cc1		Inactive	MKL/myocardin-like protein 1 Binding Agent		1	CCG-203971	363680600.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(NC(=O)C2CN(C(=O)c3cc(-c4occc4)ccc3)CCC2)cc1	Clc1ccc(NC(=O)C2CN(C(=O)c3cc(-c4occc4)ccc3)CCC2)cc1
NCGC00346884-02	Clc1ccc(NC(=O)N(O)C2N(c3ccc(Cl)cc3)C(=O)N(CC(=O)N/N=C/C=C/c3oc([N+](=O)[O-])cc3)C2(C)C)cc1		Inactive	Inhibitor of endoplasmic reticulum associated protein degradation		1	Eeyarestatin I	384568961.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(NC(=O)N(O)C2N(c3ccc(Cl)cc3)C(=O)N(CC(=O)N/N=C/C=C/c3oc([N+](=O)[O-])cc3)C2(C)C)cc1	Clc1ccc(NC(=O)N(O)C2N(c3ccc(Cl)cc3)C(=O)N(CC(=O)N/N=C/C=C/c3oc([N+](=O)[O-])cc3)C2(C)C)cc1
NCGC00387180-01	Clc1ccc(NC(=O)NC=2C(=O)N(N(C)C=2C(C)C)c2ccccc2)cc1		Inactive	Lipoxin A4 receptor Agonist		1	TC-FPR 43	363680557.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(NC(=O)NC=2C(=O)N(N(C)C=2C(C)C)c2ccccc2)cc1	Clc1ccc(NC(=O)NC=2C(=O)N(N(C)C=2C(C)C)c2ccccc2)cc1
NCGC00386583-02	Clc1ccc(NC(=O)Nc2cc(-c3nc(N4CCCC4)ccc3)ccc2)cc1		Inactive	Cannabinoid CB1 receptor Negative Allosteric Modulator		1	PSNCBAM-1	363680339.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(NC(=O)Nc2cc(-c3nc(N4CCCC4)ccc3)ccc2)cc1	Clc1ccc(NC(=O)Nc2cc(-c3nc(N4CCCC4)ccc3)ccc2)cc1
NCGC00510233-01	Clc1ccc(NC(=O)[C@H](C)C2CCC(c3c4c(ncc3)ccc(F)c4)CC2)cc1	4.9000001	Active	IDO Inhibitor	0.0	1	BMS-986205	384569418.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	69.1826484713	Clc1ccc(NC(=O)[C@H](C)C2CCC(c3c4c(ncc3)ccc(F)c4)CC2)cc1	Clc1ccc(NC(=O)[C@H](C)C2CCC(c3c4c(ncc3)ccc(F)c4)CC2)cc1
NCGC00016528-05	Clc1ccc(NC(NC(=N)NC(C)C)=N)cc1		Inactive	DHFR inhibitor		1	Proguanil hydrochloride	170464800.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1ccc(NC(NC(=N)NC(C)C)=N)cc1.Cl	Clc1ccc(NC(NC(=N)NC(C)C)=N)cc1.Cl
NCGC00016246-09&NCGC00016246-10&NCGC00016246-21	Clc1ccc(NC(NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)=N)cc1		Inactive	N-Acetyltransferase Eis (Mycobacterium tuberculosis) Inhibitor		3	Chlorhexidine&Chlorhexidine HCl	170464748.0&384567925.0&434146896.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	Clc1ccc(NC(NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)=N)cc1	Clc1ccc(NC(NC(=N)NCCCCCCNC(=N)NC(=N)Nc2ccc(Cl)cc2)=N)cc1
NCGC00016600-08	Clc1ccc(NC=2/C(=N/C(C)C)/C=C3N(c4ccc(Cl)cc4)c4c(N=C3C=2)cccc4)cc1	5.4499998	Active	DNA Binding Agent	0.0	1	Clofazimine	387065713.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	2.4	31.4527844999	Clc1ccc(NC=2/C(=N/C(C)C)/C=C3N(c4ccc(Cl)cc4)c4c(N=C3C=2)cccc4)cc1	Clc1ccc(NC=2/C(=N/C(C)C)/C=C3N(c4ccc(Cl)cc4)c4c(N=C3C=2)cccc4)cc1
NCGC00356069-03&NCGC00356069-06	Clc1ccc(N[C@H]2c3c(N(C(=O)C)[C@@H](C)C2)ccc(-c2ccc(C(=O)O)cc2)c3)cc1		Inactive	Bromodomain-containing protein 4 Inhibitor		2	GSK1324726A (I-BET726)&GSK1324726A	384569025.0&434146895.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1ccc(N[C@H]2c3c(N(C(=O)C)[C@@H](C)C2)ccc(-c2ccc(C(=O)O)cc2)c3)cc1	Clc1ccc(N[C@H]2c3c(N(C(=O)C)[C@@H](C)C2)ccc(-c2ccc(C(=O)O)cc2)c3)cc1
NCGC00181350-14	Clc1ccc(Nc2nnc(Cc3ccncc3)c3c2cccc3)cc1		Inactive	VEGFR-2 Inhibitor		1	Vatalanib	384568397.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	18.0	Clc1ccc(Nc2nnc(Cc3ccncc3)c3c2cccc3)cc1	Clc1ccc(Nc2nnc(Cc3ccncc3)c3c2cccc3)cc1
NCGC00249392-05	Clc1ccc(Nc2nnc(OCc3cc(C(=O)NC)ncc3)c3occc23)cc1		Inactive	VEGFR-2,3 Inhibitor		1	Telatinib	377020517.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	19.5	Clc1ccc(Nc2nnc(OCc3cc(C(=O)NC)ncc3)c3occc23)cc1	Clc1ccc(Nc2nnc(OCc3cc(C(=O)NC)ncc3)c3occc23)cc1
NCGC00484070-01	Clc1ccc(Nc2scc(C(=O)OCC)n2)cc1		Inactive	POU domain, class 5, transcription factor 1 Activator		1	O4I2	363681162.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(Nc2scc(C(=O)OCC)n2)cc1	Clc1ccc(Nc2scc(C(=O)OCC)n2)cc1
NCGC00090814-07	Clc1ccc(O)cc1		Inactive	macrophage activation involved in immune response Inhibitor		1	4-Chlorophenol	170465673.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1ccc(O)cc1	Clc1ccc(O)cc1
NCGC00166153-02	Clc1ccc(OC(C(=O)C(C)(C)C)n2cncc2)cc1		Inactive			1	Climbazole	170465557.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1ccc(OC(C(=O)C(C)(C)C)n2cncc2)cc1	Clc1ccc(OC(C(=O)C(C)(C)C)n2cncc2)cc1
NCGC00015257-14&NCGC00015257-18	Clc1ccc(OC(C(=O)OCC)(C)C)cc1		Inactive	PPARalpha Agonist		2	Clofibrate	170465329.0&384567834.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Clc1ccc(OC(C(=O)OCC)(C)C)cc1	Clc1ccc(OC(C(=O)OCC)(C)C)cc1
NCGC00249923-01	Clc1ccc(OC(C(=O)OCCCOC(=O)C(Oc2ccc(Cl)cc2)(C)C)(C)C)cc1		Inactive	Triglyceride Biosynthesis Inhibitor		1	Cholesolvin	170466018.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(OC(C(=O)OCCCOC(=O)C(Oc2ccc(Cl)cc2)(C)C)(C)C)cc1	Clc1ccc(OC(C(=O)OCCCOC(=O)C(Oc2ccc(Cl)cc2)(C)C)(C)C)cc1
NCGC00351608-02	Clc1ccc(OCC(=O)N2CCN(C(C)C=3N(c4c(OCC)cccc4)C(=O)c4c(N=3)cccc4)CC2)cc1	4.9000001	Active	Ferroptosis Activator	0.0	1	Erastin	384569022.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	47.3283779808	Clc1ccc(OCC(=O)N2CCN(C(C)C=3N(c4c(OCC)cccc4)C(=O)c4c(N=3)cccc4)CC2)cc1	Clc1ccc(OCC(=O)N2CCN(C(C)C=3N(c4c(OCC)cccc4)C(=O)c4c(N=3)cccc4)CC2)cc1
NCGC00384174-13	Clc1ccc(OCC(=O)NC2CCC(NC(=O)COc3ccc(Cl)cc3)CC2)cc1		Inactive			1	ISRIB (trans-isomer)		2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(OCC(=O)NC2CCC(NC(=O)COc3ccc(Cl)cc3)CC2)cc1	Clc1ccc(OCC(=O)NC2CCC(NC(=O)COc3ccc(Cl)cc3)CC2)cc1
NCGC00015279-08	Clc1ccc(OCC(=O)OCCN(C)C)cc1		Inactive			1	Meclofenoxate hydrochloride	170465815.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(OCC(=O)OCCN(C)C)cc1.Cl	Clc1ccc(OCC(=O)OCCN(C)C)cc1.Cl
NCGC00160584-01	Clc1ccc(OCC(O)CO)cc1		Inactive			1	Chlorphenesin	144207103.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(OCC(O)CO)cc1	Clc1ccc(OCC(O)CO)cc1
NCGC00179607-03	Clc1ccc(OCC(O)COC(=O)N)cc1		Inactive			1	Chlorphensin carbamate	225144309.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(OCC(O)COC(=O)N)cc1	Clc1ccc(OCC(O)COC(=O)N)cc1
NCGC00345782-02	Clc1ccc(OCCCCCCN/C(=N\C#N)/Nc2ccncc2)cc1		Inactive	IKK beta Inhibitor		1	GMX-1778	384568738.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(OCCCCCCN/C(=N\C#N)/Nc2ccncc2)cc1	Clc1ccc(OCCCCCCN/C(=N\C#N)/Nc2ccncc2)cc1
NCGC00378789-02	Clc1ccc(OCCCCCC[C@@]2(C(=O)OCC)OC2)cc1		Inactive	CPT-1 Inhibitor		1	Etomoxir	384569068.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.609137052	Clc1ccc(OCCCCCC[C@@]2(C(=O)OCC)OC2)cc1	Clc1ccc(OCCCCCC[C@@]2(C(=O)OCC)OC2)cc1
NCGC00499786-01	Clc1ccc(Oc2c(F)cc(S(=O)(=O)N3C(C(=O)NO)CN(C(=O)OCCOC)CC3)cc2F)cc1		Inactive	ADAM10 Inhibitor		1	XL-784	384569310.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	13.7998673199	Clc1ccc(Oc2c(F)cc(S(=O)(=O)N3C(C(=O)NO)CN(C(=O)OCCOC)CC3)cc2F)cc1	Clc1ccc(Oc2c(F)cc(S(=O)(=O)N3C(C(=O)NO)CN(C(=O)OCCOC)CC3)cc2F)cc1
NCGC00165768-05	Clc1ccc(Oc2ccc(-c3[nH]c4c(n3)cc(C(=O)N)cc4)cc2)cc1	5.0	Active	Chk2 Inhibitor	0.0	1	BML-277	363676640.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	66.4982057365	Clc1ccc(Oc2ccc(-c3[nH]c4c(n3)cc(C(=O)N)cc4)cc2)cc1	Clc1ccc(Oc2ccc(-c3[nH]c4c(n3)cc(C(=O)N)cc4)cc2)cc1
NCGC00378723-01	Clc1ccc(Oc2ccc(S(=O)(=O)CC3(C(=O)NO)CCOCC3)cc2)cc1		Inactive	MMP-12 (Macrophage Elastase) Inhibitor		1	CTS-1027	384569065.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.171078356	Clc1ccc(Oc2ccc(S(=O)(=O)CC3(C(=O)NO)CCOCC3)cc2)cc1	Clc1ccc(Oc2ccc(S(=O)(=O)CC3(C(=O)NO)CCOCC3)cc2)cc1
NCGC00386621-02	Clc1ccc(S(=O)(=O)/N=C(/NC)\N2N=C([C@@H](c3ccccc3)C2)c2ccc(Cl)cc2)cc1		Inactive	Cannabinoid CB2 receptor Inhibitor		1	(R)-(+)-SLV 319	363680361.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	14.2960687919	Clc1ccc(S(=O)(=O)/N=C(/NC)\N2N=C([C@@H](c3ccccc3)C2)c2ccc(Cl)cc2)cc1	Clc1ccc(S(=O)(=O)/N=C(/NC)\N2N=C([C@@H](c3ccccc3)C2)c2ccc(Cl)cc2)cc1
NCGC00263184-03&NCGC00263184-06	Clc1ccc(S(=O)(=O)C2(c3c(F)ccc(F)c3)CCC(CCC(=O)O)CC2)cc1		Inactive	g-Secretase Inhibitor		2	MK-0752	434147245.0&384568652.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1ccc(S(=O)(=O)C2(c3c(F)ccc(F)c3)CCC(CCC(=O)O)CC2)cc1	Clc1ccc(S(=O)(=O)C2(c3c(F)ccc(F)c3)CCC(CCC(=O)O)CC2)cc1
NCGC00371101-01	Clc1ccc(S(=O)(=O)C2(c3c(F)ccc(F)c3)CCC(NS(=O)(=O)C(F)(F)F)CC2)cc1		Inactive	Gamma-secretase Inhibitor		1	MRK 560	363678032.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(S(=O)(=O)C2(c3c(F)ccc(F)c3)CCC(NS(=O)(=O)C(F)(F)F)CC2)cc1	Clc1ccc(S(=O)(=O)C2(c3c(F)ccc(F)c3)CCC(NS(=O)(=O)C(F)(F)F)CC2)cc1
NCGC00346504-07	Clc1ccc(S(=O)(=O)N([C@@H](C(=O)N)CCC(F)(F)F)Cc2c(F)cc(-c3nocn3)cc2)cc1		Inactive	g-Secretase Inhibitor		1	Avagacestat	384568808.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1ccc(S(=O)(=O)N([C@@H](C(=O)N)CCC(F)(F)F)Cc2c(F)cc(-c3nocn3)cc2)cc1	Clc1ccc(S(=O)(=O)N([C@@H](C(=O)N)CCC(F)(F)F)Cc2c(F)cc(-c3nocn3)cc2)cc1
NCGC00346875-02	Clc1ccc(S(=O)(=O)N([C@H](C)c2c(CCCC(=O)O)cc(F)cc2)c2c(F)ccc(F)c2)cc1		Inactive	g-Secretase Inhibitor		1	BMS-299897	384568953.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(S(=O)(=O)N([C@H](C)c2c(CCCC(=O)O)cc(F)cc2)c2c(F)ccc(F)c2)cc1	Clc1ccc(S(=O)(=O)N([C@H](C)c2c(CCCC(=O)O)cc(F)cc2)c2c(F)ccc(F)c2)cc1
NCGC00015216-17	Clc1ccc(S(=O)(=O)NC(=O)NCCC)cc1		Inactive	Sulfonylurea receptor 1, Kir6.2 Inhibitor		1	Chlorpropamide	170464898.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1ccc(S(=O)(=O)NC(=O)NCCC)cc1	Clc1ccc(S(=O)(=O)NC(=O)NCCC)cc1
NCGC00182989-01	Clc1ccc(S(=O)(=O)NC(=O)NN2CCCC2)cc1		Inactive			1	Glyclopyramide	144206854.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1ccc(S(=O)(=O)NC(=O)NN2CCCC2)cc1	Clc1ccc(S(=O)(=O)NC(=O)NN2CCCC2)cc1
NCGC00485899-01	Clc1ccc(S(=O)(=O)NC(=O)Nc2ccc(N(C)C)cc2)cc1		Inactive			1	Glyparamide	363681401.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(S(=O)(=O)NC(=O)Nc2ccc(N(C)C)cc2)cc1	Clc1ccc(S(=O)(=O)NC(=O)Nc2ccc(N(C)C)cc2)cc1
NCGC00386891-01	Clc1ccc(S(=O)(=O)N[C@@H]2[C@@H](N3CCOCC3)CCCC2)cc1		Inactive			1	NCGC00386891-01	363680487.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(S(=O)(=O)N[C@@H]2[C@@H](N3CCOCC3)CCCC2)cc1	Clc1ccc(S(=O)(=O)N[C@@H]2[C@@H](N3CCOCC3)CCCC2)cc1
NCGC00386585-01	Clc1ccc(S(=O)(=O)c2c3c(n(C)c2)c(N2CCNCC2)ccc3)cc1	4.9000001	Active		0.0	1	5-HT6 antagonist 29	363680341.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	120.1666358547	Clc1ccc(S(=O)(=O)c2c3c(n(C)c2)c(N2CCNCC2)ccc3)cc1	Clc1ccc(S(=O)(=O)c2c3c(n(C)c2)c(N2CCNCC2)ccc3)cc1
NCGC00182026-02	Clc1ccc(SC(P(=O)(O)[O-])P(=O)(O)[O-])cc1		Inactive	Osteoclasts Inhibitor		1	Tiludronate disodium salt hydrate	225144329.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc(SC(P(=O)(O)[O-])P(=O)(O)[O-])cc1	Clc1ccc(SC(P(=O)(O)[O-])P(=O)(O)[O-])cc1
NCGC00485218-01	Clc1ccc(SC=2N([C@H]3[C@H](O)[C@@H]4OP(=O)([O-])OC[C@H]4O3)C3=NC(=[NH2+])NC(=O)C3N=2)cc1		Inactive	cGMP-gated cation channel alpha-1 Agonist		1	8-(4-Chlorophenylthio)-guanosine 3â€²,5â€²-cyclic monophosphate sodium salt	363681257.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(Sc2n([C@H]3[C@H](O)[C@@H]4OP(=O)([O-])OC[C@H]4O3)c3N=C(N)NC(=O)c3n2)cc1	Clc1ccc(Sc2n([C@H]3[C@H](O)[C@@H]4OP(=O)([O-])OC[C@H]4O3)c3N=C(N)NC(=O)c3n2)cc1
NCGC00386290-04	Clc1ccc(Sc2c(C)n(CC(=O)O)c3c2c(NC(=O)C)ccc3)cc1		Inactive	G protein-coupled receptor 44 Antagonist		1	AZD1981	363680190.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ccc(Sc2c(C)n(CC(=O)O)c3c2c(NC(=O)C)ccc3)cc1	Clc1ccc(Sc2c(C)n(CC(=O)O)c3c2c(NC(=O)C)ccc3)cc1
NCGC00345795-04	Clc1ccc([C@@H](NC(=O)C2(N)CCN(c3ncnc4[nH]ccc34)CC2)CCO)cc1		Inactive	AKT Inhibitor		1	AZD-5363	363677359.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc([C@@H](NC(=O)C2(N)CCN(c3ncnc4[nH]ccc34)CC2)CCO)cc1	Clc1ccc([C@@H](NC(=O)C2(N)CCN(c3ncnc4[nH]ccc34)CC2)CCO)cc1
NCGC00263124-09	Clc1ccc([C@@H]2N(C(=O)N3CC(=O)NCC3)C(c3c(OC(C)C)cc(OC)cc3)=N[C@@H]2c2ccc(Cl)cc2)cc1		Inactive	HDM2/HDMX Inhibitor		1	Nutlin-3	384568607.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc([C@@H]2N(C(=O)N3CC(=O)NCC3)C(c3c(OC(C)C)cc(OC)cc3)=N[C@@H]2c2ccc(Cl)cc2)cc1	Clc1ccc([C@@H]2N(C(=O)N3CC(=O)NCC3)C(c3c(OC(C)C)cc(OC)cc3)=N[C@@H]2c2ccc(Cl)cc2)cc1
NCGC00390552-02	Clc1ccc([C@@H]2N(c3ccc(N(CC4CCC(N5CC(=O)N(C)CC5)CC4)C)cc3)C(=O)Cc3c2cc(OC(C)C)c(OC)c3)cc1		Inactive	MDM2 (hdm2) Inhibitor		1	CGM-097	384569191.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.2084523959	Clc1ccc([C@@H]2N(c3ccc(N(CC4CCC(N5CC(=O)N(C)CC5)CC4)C)cc3)C(=O)Cc3c2cc(OC(C)C)c(OC)c3)cc1	Clc1ccc([C@@H]2N(c3ccc(N(CC4CCC(N5CC(=O)N(C)CC5)CC4)C)cc3)C(=O)Cc3c2cc(OC(C)C)c(OC)c3)cc1
NCGC00016710-05	Clc1ccc([C@@](OCC[C@@H]2N(C)CCC2)(C)c2ccccc2)cc1	4.9499998	Active	Histamine H1 Receptor Antagonists	0.0	1	Clemastine fumarate	170465318.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	104.2022058803	Clc1ccc([C@@](OCC[C@@H]2N(C)CCC2)(C)c2ccccc2)cc1.O=C(O)/C=C/C(=O)O	Clc1ccc([C@@](OCC[C@@H]2N(C)CCC2)(C)c2ccccc2)cc1.O=C(O)/C=C/C(=O)O
NCGC00378588-02	Clc1ccc([C@@]2(C)N(C(=O)N3CCN(CC(=O)N4CCOCC4)CC3)C(c3c(OCC)cc(C(C)(C)C)cc3)=N[C@@]2(C)c2ccc(Cl)cc2)cc1		Inactive	p53-MDM2 interaction Inhibitor		1	NCGC00378588	363678105.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc([C@@]2(C)N(C(=O)N3CCN(CC(=O)N4CCOCC4)CC3)C(c3c(OCC)cc(C(C)(C)C)cc3)=N[C@@]2(C)c2ccc(Cl)cc2)cc1	Clc1ccc([C@@]2(C)N(C(=O)N3CCN(CC(=O)N4CCOCC4)CC3)C(c3c(OCC)cc(C(C)(C)C)cc3)=N[C@@]2(C)c2ccc(Cl)cc2)cc1
NCGC00346714-02	Clc1ccc([C@H](C(=O)N2CCN(c3ncnc4[C@H](O)C[C@@H](C)c34)CC2)CNC(C)C)cc1		Inactive	AKT Inhibitor		1	Ipatasertib	384568928.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc([C@H](C(=O)N2CCN(c3ncnc4[C@H](O)C[C@@H](C)c34)CC2)CNC(C)C)cc1	Clc1ccc([C@H](C(=O)N2CCN(c3ncnc4[C@H](O)C[C@@H](C)c34)CC2)CNC(C)C)cc1
NCGC00015227-08	Clc1ccc([C@H](CCN(C)C)c2ncccc2)cc1		Inactive	Histamine H1 Receptor Antagonists; SNRI		1	Dexchlorpheniramine hydrochloride	170466889.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1ccc([C@H](CCN(C)C)c2ncccc2)cc1.Cl	Clc1ccc([C@H](CCN(C)C)c2ncccc2)cc1.Cl
NCGC00386356-02&NCGC00386356-05	Clc1ccc([C@H](OC2CCN(CCCC(=O)O)CC2)c2ncccc2)cc1		Inactive	Histamine H1 receptor Antagonist		2	Bepotastine (Beslilate)	405558923.0&434147129.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1ccc([C@H](OC2CCN(CCCC(=O)O)CC2)c2ncccc2)cc1	Clc1ccc([C@H](OC2CCN(CCCC(=O)O)CC2)c2ncccc2)cc1
NCGC00510162-01	Clc1ccc([C@H]2N(C(=O)c3cnc4[nH]nc(C)c4c3)CCC2)cc1		Inactive	CDK8 Inhibitor		1	MSC2530818	384569411.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.64853556	Clc1ccc([C@H]2N(C(=O)c3cnc4[nH]nc(C)c4c3)CCC2)cc1	Clc1ccc([C@H]2N(C(=O)c3cnc4[nH]nc(C)c4c3)CCC2)cc1
NCGC00386423-05	Clc1ccc([C@](O)(CN)c2ccc(-c3c[nH]nc3)cc2)cc1		Inactive	AKT Inhibitor		1	AT-13148	384569136.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1ccc([C@](O)(CN)c2ccc(-c3c[nH]nc3)cc2)cc1	Clc1ccc([C@](O)(CN)c2ccc(-c3c[nH]nc3)cc2)cc1
NCGC00485074-01	Clc1cn(C2(c3[nH]c4nc(N5C[C@H](C(=O)N6CCCC6)CCC5)ccc4n3)CC2)nc1		Inactive	Diacylglycerol O-acyltransferase 2 Inhibitor		1	PF-06424439	363681210.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1cn(C2(c3[nH]c4nc(N5C[C@H](C(=O)N6CCCC6)CCC5)ccc4n3)CC2)nc1	Clc1cn(C2(c3[nH]c4nc(N5C[C@H](C(=O)N6CCCC6)CCC5)ccc4n3)CC2)nc1
NCGC00167737-02	Clc1cnc(C(=O)NCCN)cc1		Inactive	Monoamine oxidase B Inhibitor		1	Lazabemide hydrochloride	170466038.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1cnc(C(=O)NCCN)cc1.Cl	Clc1cnc(C(=O)NCCN)cc1.Cl
NCGC00506868-01	Clc1cnc(CC(=O)Nc2cc(C(=O)c3c4c(n(C(CO)(C)C)c3)nc(N)nc4)cnc2)cc1		Inactive	Trk A/B/C Inhibitor		1	PF-06273340	384569320.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cnc(CC(=O)Nc2cc(C(=O)c3c4c(n(C(CO)(C)C)c3)nc(N)nc4)cnc2)cc1	Clc1cnc(CC(=O)Nc2cc(C(=O)c3c4c(n(C(CO)(C)C)c3)nc(N)nc4)cnc2)cc1
NCGC00510689-01	Clc1cnc(CCNC(=O)c2ccc(CNS(=O)(=O)c3ccc(OC)cc3)cc2)cc1		Inactive	homology-dependent DNA repair Inhibitor		1	YU-238259	384569479.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cnc(CCNC(=O)c2ccc(CNS(=O)(=O)c3ccc(OC)cc3)cc2)cc1	Clc1cnc(CCNC(=O)c2ccc(CNS(=O)(=O)c3ccc(OC)cc3)cc2)cc1
NCGC00159515-03	Clc1cnc(N2[C@@H](OC(=O)N3CCN(C)CC3)c3nccnc3C2=O)cc1		Inactive	GABAA Receptor Modulator		1	Eszopiclone	170465445.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cnc(N2[C@@H](OC(=O)N3CCN(C)CC3)c3nccnc3C2=O)cc1	Clc1cnc(N2[C@@H](OC(=O)N3CCN(C)CC3)c3nccnc3C2=O)cc1
NCGC00378907-01&NCGC00378907-02	Clc1cnc(NC(=O)C(=O)N[C@@H]2[C@H](NC(=O)c3sc4c(n3)CCN(C)C4)C[C@@H](C(=O)N(C)C)CC2)cc1		Inactive	Coagulation Factor X Inhibitor&Coagulation factor X Inhibitor		2	Edoxaban tosylate monohydrate&Edoxaban 	405559062.0&434147216.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&-19.052808984	Clc1cnc(NC(=O)C(=O)N[C@@H]2[C@H](NC(=O)c3sc4c(n3)CCN(C)C4)C[C@@H](C(=O)N(C)C)CC2)cc1	Clc1cnc(NC(=O)C(=O)N[C@@H]2[C@H](NC(=O)c3sc4c(n3)CCN(C)C4)C[C@@H](C(=O)N(C)C)CC2)cc1
NCGC00371122-02&NCGC00371122-04	Clc1cnc(NC(=O)c2c(NC(=O)c3ccc(C(N(C)C)=N)cc3)ccc(OC)c2)cc1		Inactive	Coagulation factor X Inhibitor		2	Betrixaban	363678038.0&405558517.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1cnc(NC(=O)c2c(NC(=O)c3ccc(C(N(C)C)=N)cc3)ccc(OC)c2)cc1	Clc1cnc(NC(=O)c2c(NC(=O)c3ccc(C(N(C)C)=N)cc3)ccc(OC)c2)cc1
NCGC00187911-06	Clc1cnc2[nH]cc(C(=O)c3c(F)c(NS(=O)(=O)CCC)ccc3F)c2c1		Inactive	Raf kinase B Inhibitor		1	PLX-4720	363677115.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cnc2[nH]cc(C(=O)c3c(F)c(NS(=O)(=O)CCC)ccc3F)c2c1	Clc1cnc2[nH]cc(C(=O)c3c(F)c(NS(=O)(=O)CCC)ccc3F)c2c1
NCGC00480774-04	Clc1cnc2[nH]cc(Cc3cnc(NCc4cnc(C(F)(F)F)cc4)cc3)c2c1		Inactive	CSF1R (c-FMS) Inhibitor		1	Pexidartinib	384569242.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1cnc2[nH]cc(Cc3cnc(NCc4cnc(C(F)(F)F)cc4)cc3)c2c1	Clc1cnc2[nH]cc(Cc3cnc(NCc4cnc(C(F)(F)F)cc4)cc3)c2c1
NCGC00490687-03	Clc1n(-c2ccc(-c3c(O)c(OC)ccc3)cc2)c2C(=O)N(c3cc(OC)ccc3)C(=O)Nc2c1	5.0	Active		0.0	1	GSK621		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	96.8614552307	Clc1n(-c2ccc(-c3c(O)c(OC)ccc3)cc2)c2C(=O)N(c3cc(OC)ccc3)C(=O)Nc2c1	Clc1n(-c2ccc(-c3c(O)c(OC)ccc3)cc2)c2C(=O)N(c3cc(OC)ccc3)C(=O)Nc2c1
NCGC00485288-01	Clc1n(C2C(O)C3OP(=O)(O)OCC3O2)c2ncnc(N)c2n1		Inactive	cAMP-dependent protein kinase (PKA) Agonist		1	8-Chloroadenosine 3â€²,5â€²-cyclic-monophosphate	363681278.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1n(C2C(O)C3OP(=O)(O)OCC3O2)c2ncnc(N)c2n1	Clc1n(C2C(O)C3OP(=O)(O)OCC3O2)c2ncnc(N)c2n1
NCGC00386367-02	Clc1n([C@@H]2[C@@H](F)CN(C3COC3)CC2)ncc1Nc1nc(NC)c(C(F)(F)F)cn1		Inactive	LRRK2 Inhibitor		1	GNE-9605	363680236.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1n([C@@H]2[C@@H](F)CN(C3COC3)CC2)ncc1Nc1nc(NC)c(C(F)(F)F)cn1	Clc1n([C@@H]2[C@@H](F)CN(C3COC3)CC2)ncc1Nc1nc(NC)c(C(F)(F)F)cn1
NCGC00096095-02	Clc1n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)c2ncnc(N)c2n1		Inactive	Telomerase Inhibitor		1	8-Cl-Ado	26753806.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)c2ncnc(N)c2n1	Clc1n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)c2ncnc(N)c2n1
NCGC00509935-01	Clc1nc(-c2nc(N[C@@H](C(F)(F)F)C)nc(N[C@H](C(F)(F)F)C)n2)ccc1		Inactive	Mutant IDH1 Inhibitor		1	AG-881	384569384.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1nc(-c2nc(N[C@@H](C(F)(F)F)C)nc(N[C@H](C(F)(F)F)C)n2)ccc1	Clc1nc(-c2nc(N[C@@H](C(F)(F)F)C)nc(N[C@H](C(F)(F)F)C)n2)ccc1
NCGC00480817-01	Clc1nc(C(=O)NCC(=O)O)c(O)c2c1cccc2		Inactive	alpha-Ketoglutarate-Dependent Dioxygenase FTO Inhibitor		1	FG-2216	384569247.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1nc(C(=O)NCC(=O)O)c(O)c2c1cccc2	Clc1nc(C(=O)NCC(=O)O)c(O)c2c1cccc2
NCGC00387265-01	Clc1nc(C(F)(F)F)c(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cn1		Inactive	Proto-oncogene c-JUN Inhibitor		1	SP 100030	363680604.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1nc(C(F)(F)F)c(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cn1	Clc1nc(C(F)(F)F)c(C(=O)Nc2cc(C(F)(F)F)cc(C(F)(F)F)c2)cn1
NCGC00386491-01	Clc1nc(C)nc2n(-c3c(C)cc(C)cc3C)cc(C)c12		Inactive			1	4-chloro-2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine	363680303.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1nc(C)nc2n(-c3c(C)cc(C)cc3C)cc(C)c12	Clc1nc(C)nc2n(-c3c(C)cc(C)cc3C)cc(C)c12
NCGC00105281-01	Clc1nc(C=2C(=O)Oc3c(cccc3)C=2)nc2sc3c(c12)CCC(C)C3		Inactive			1	NCGC00105281-01	24268626.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1nc(C=2C(=O)Oc3c(cccc3)C=2)nc2sc3c(c12)CCC(C)C3	Clc1nc(C=2C(=O)Oc3c(cccc3)C=2)nc2sc3c(c12)CCC(C)C3
NCGC00018167-05	Clc1nc(N)c2ncn(C3OC(CO)C(O)C3)c2n1		Inactive	Adenosine Deaminase Inhibitor		1	Cladribine	405558565.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1nc(N)c2ncn(C3OC(CO)C(O)C3)c2n1	Clc1nc(N)c2ncn(C3OC(CO)C(O)C3)c2n1
NCGC00022567-15	Clc1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)C3)c2n1		Inactive	Adenosine Deaminase Inhibitor		1	Cladribine	384568011.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)C3)c2n1	Clc1nc(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)C3)c2n1
NCGC00164553-02&NCGC00164553-07	Clc1nc(N)c2ncn([C@H]3[C@@H](F)[C@H](O)[C@@H](CO)O3)c2n1		Inactive	DNA Polymerase Inhibitor		2	Clofarabine	170465145.0&384568252.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		Clc1nc(N)c2ncn([C@H]3[C@@H](F)[C@H](O)[C@@H](CO)O3)c2n1	Clc1nc(N)c2ncn([C@H]3[C@@H](F)[C@H](O)[C@@H](CO)O3)c2n1
NCGC00387184-01	Clc1nc(N)nc2n(Cc3c(C)c(OC)c(C)cn3)cc(C#CCC(O)(C)C)c12		Inactive	Endoplasmin Inhibitor		1	EC 144	363680560.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1nc(N)nc2n(Cc3c(C)c(OC)c(C)cn3)cc(C#CCC(O)(C)C)c12	Clc1nc(N)nc2n(Cc3c(C)c(OC)c(C)cn3)cc(C#CCC(O)(C)C)c12
NCGC00247877-09	Clc1nc(N)nc2n(Cc3c(C)c(OC)c(C)cn3)cnc12	5.0999999	Active	Heat Shock Protein 90 (hsp90) Inhibitor	0.0	1	CNF-2024	384568518.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.2	62.3467958291	Clc1nc(N)nc2n(Cc3c(C)c(OC)c(C)cn3)cnc12	Clc1nc(N)nc2n(Cc3c(C)c(OC)c(C)cn3)cnc12
NCGC00014702-17	Clc1nc(SCC(=O)O)nc(Nc2c(C)c(C)ccc2)c1		Inactive	Peroxisome proliferator-activated receptor gamma Agonist		1	WY-14643 (Pirinixic Acid)	363676434.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1nc(SCC(=O)O)nc(Nc2c(C)c(C)ccc2)c1	Clc1nc(SCC(=O)O)nc(Nc2c(C)c(C)ccc2)c1
NCGC00387230-01	Clc1nc(c(N)c2C(=O)NNC(=O)c12)-c1ccccc1		Inactive			1	L 012 sodium salt	363680584.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1nc(c(N)c2C(=O)NN=C(O[Na])c12)-c1ccccc1	Clc1nc(c(N)c2C(=O)NN=C(O[Na])c12)-c1ccccc1
NCGC00386587-01	Clc1nc2nc(N3C(=O)c4c(C3CC(=O)CCC(C)C)cccc4)ccc2cc1		Inactive	GABA-A receptor; anion channel Partial Agonist		1	(+)-Pagoclone	363680343.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1nc2nc(N3C(=O)c4c(C3CC(=O)CCC(C)C)cccc4)ccc2cc1	Clc1nc2nc(N3C(=O)c4c(C3CC(=O)CCC(C)C)cccc4)ccc2cc1
NCGC00163736-04	Clc1ncc(CN2/C(=N/[N+](=O)[O-])/NCC2)cc1		Inactive			1	Imidacloprid	170465741.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1ncc(CN2/C(=N/[N+](=O)[O-])/NCC2)cc1	Clc1ncc(CN2/C(=N/[N+](=O)[O-])/NCC2)cc1
NCGC00386430-01	Clc1ncc(COc2c(OC)cc(CNCCc3cc(OC)c(OC)cc3)cc2)cc1		Inactive			1	SBE 13 HCl		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ncc(COc2c(OC)cc(CNCCc3cc(OC)c(OC)cc3)cc2)cc1	Clc1ncc(COc2c(OC)cc(CNCCc3cc(OC)c(OC)cc3)cc2)cc1
NCGC00387162-01	Clc1ncc(NC(=O)c2cc(F)c(F)cc2)cn1		Inactive	Voltage-gated potassium channel, KQT; KCNQ2(Kv7.2)/KCNQ3(Kv7.3) Activator		1	ICA 069673	363680553.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1ncc(NC(=O)c2cc(F)c(F)cc2)cn1	Clc1ncc(NC(=O)c2cc(F)c(F)cc2)cn1
NCGC00390716-02	Clc1nccc(C#Cc2c(C)n(c(C)n2)-c2ccc(F)cc2)c1		Inactive	Metabotropic glutamate receptor 5 Negative Allosteric Modulator		1	RG7090 (CTEP Derive)	363680975.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	14.5	Clc1nccc(C#Cc2c(C)n(c(C)n2)-c2ccc(F)cc2)c1	Clc1nccc(C#Cc2c(C)n(c(C)n2)-c2ccc(F)cc2)c1
NCGC00386156-06	Clc1nccc(C#Cc2c(C)n(c(C)n2)-c2ccc(OC(F)(F)F)cc2)c1		Inactive	Metabotropic glutamate receptor 5 Negative Allosteric Modulator		1	CTEP (RO4956371)	363680126.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	29.0	Clc1nccc(C#Cc2c(C)n(c(C)n2)-c2ccc(OC(F)(F)F)cc2)c1	Clc1nccc(C#Cc2c(C)n(c(C)n2)-c2ccc(OC(F)(F)F)cc2)c1
NCGC00345842-03	Clc1nccc(C2=NC(c3c(F)cc(Cl)cc3)C(C(=O)Nc3c(F)cc4[nH]ncc4c3)=C(C)N2)c1		Inactive	ROCK Inhibitor		1	GSK-25	384568764.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.0364870599	Clc1nccc(C2=NC(c3c(F)cc(Cl)cc3)C(C(=O)Nc3c(F)cc4[nH]ncc4c3)=C(C)N2)c1	Clc1nccc(C2=NC(c3c(F)cc(Cl)cc3)C(C(=O)Nc3c(F)cc4[nH]ncc4c3)=C(C)N2)c1
NCGC00387732-02	Clc1nccc(Nc2nc(-c3c(CC4CC4)nc(NCC(O)(C)C)nc3)ccn2)c1	6.5	Active		0.0	1	VPS34-IN1		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	1.3	113.5671169229	Clc1nccc(Nc2nc(-c3c(CC4CC4)nc(NCC(O)(C)C)nc3)ccn2)c1	Clc1nccc(Nc2nc(-c3c(CC4CC4)nc(NCC(O)(C)C)nc3)ccn2)c1
NCGC00485128-01	Clc1nnc(N2C[C@@H]3N[C@H](C2)CC3)cc1		Inactive	Neuronal acetylcholine receptor; alpha4/beta2 Agonist		1	DBO-83	363681235.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1nnc(N2C[C@@H]3N[C@H](C2)CC3)cc1	Clc1nnc(N2C[C@@H]3N[C@H](C2)CC3)cc1
NCGC00016323-09	Clc1nnc(NS(=O)(=O)c2ccc(N)cc2)cc1		Inactive	Salmonella Inhibitor		1	Sulfachloropyridazine	170466574.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Clc1nnc(NS(=O)(=O)c2ccc(N)cc2)cc1	Clc1nnc(NS(=O)(=O)c2ccc(N)cc2)cc1
NCGC00262945-01	Clc1sc(C(=O)NCC2OC(=O)N(c3ccc(N4C(=O)COCC4)cc3)C2)cc1		Inactive	Coagulation Factor Xa Inhibitor		1	Rivaroxaban	170466121.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Clc1sc(C(=O)NCC2OC(=O)N(c3ccc(N4C(=O)COCC4)cc3)C2)cc1	Clc1sc(C(=O)NCC2OC(=O)N(c3ccc(N4C(=O)COCC4)cc3)C2)cc1
NCGC00262945-03&NCGC00262945-10	Clc1sc(C(=O)NC[C@@H]2OC(=O)N(c3ccc(N4C(=O)COCC4)cc3)C2)cc1		Inactive			2	Rivaroxaban	363677193.0&434147205.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1sc(C(=O)NC[C@@H]2OC(=O)N(c3ccc(N4C(=O)COCC4)cc3)C2)cc1	Clc1sc(C(=O)NC[C@@H]2OC(=O)N(c3ccc(N4C(=O)COCC4)cc3)C2)cc1
NCGC00387478-01	Clc1sc(S(=O)(=O)NC(=O)Nc2ccc(N3C(=O)Nc4c(C3=O)cc(F)c(NC)c4)cc2)cc1		Inactive	Purinergic receptor P2Y12 Antagonist		1	Elinogrel	363680634.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1sc(S(=O)(=O)NC(=O)Nc2ccc(N3C(=O)Nc4c(C3=O)cc(F)c(NC)c4)cc2)cc1	Clc1sc(S(=O)(=O)NC(=O)Nc2ccc(N3C(=O)Nc4c(C3=O)cc(F)c(NC)c4)cc2)cc1
NCGC00249417-03	Clc1sc(S(=O)(=O)Nc2c(C(=O)Nc3ccc(S(=O)(=O)N4CCOCC4)cc3)cc(Cl)cc2)cc1	4.9000001	Active	Soluble Guanylate Cyclase (sGC) Activator	0.0	1	Ataciguat	384568527.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	52.7499525808	Clc1sc(S(=O)(=O)Nc2c(C(=O)Nc3ccc(S(=O)(=O)N4CCOCC4)cc3)cc(Cl)cc2)cc1	Clc1sc(S(=O)(=O)Nc2c(C(=O)Nc3ccc(S(=O)(=O)N4CCOCC4)cc3)cc(Cl)cc2)cc1
NCGC00356114-04	Clc1sc(S(=O)(=O)Nc2c(N3CCCCC3)cccc2)cc1		Inactive	MCOLN3 protein Activator		1	SF-22	363677798.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1sc(S(=O)(=O)Nc2c(N3CCCCC3)cccc2)cc1	Clc1sc(S(=O)(=O)Nc2c(N3CCCCC3)cccc2)cc1
NCGC00346667-02&NCGC00346667-07	Clc1sc2C(O)=C(C(=O)Nc3ncccc3)N(C)S(=O)(=O)c2c1		Inactive	non-steroidal antiinflammatory		2	Lornoxicam	405558606.0&384568894.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Clc1sc2C(O)=C(C(=O)Nc3ncccc3)N(C)S(=O)(=O)c2c1	Clc1sc2C(O)=C(C(=O)Nc3ncccc3)N(C)S(=O)(=O)c2c1
NCGC00370755-01	Clc1sc2[nH]c(C(=O)NC3C(=O)N(C[C@@H](O)CO)c4c(cccc4)C3)cc2c1		Inactive	Glycogen phosphorylase, liver form Inhibitor		1	GPi 688	363677837.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1sc2[nH]c(C(=O)NC3C(=O)N(C[C@@H](O)CO)c4c(cccc4)C3)cc2c1	Clc1sc2[nH]c(C(=O)NC3C(=O)N(C[C@@H](O)CO)c4c(cccc4)C3)cc2c1
NCGC00386867-04	Clc1sc2c(n(C)c(C(=O)NCCc3cc(OCC)c(OCC)cc3)c2)c1		Inactive			1	ML261	363680474.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1sc2c(n(C)c(C(=O)NCCc3cc(OCC)c(OCC)cc3)c2)c1	Clc1sc2c(n(C)c(C(=O)NCCc3cc(OCC)c(OCC)cc3)c2)c1
NCGC00386238-02	Clc1sc2ncnc(NC3CCN(Cc4cc(C#N)c(F)cc4)CC3)c2c1		Inactive	Serotonin 2b (5-HT2b) receptor Antagonist		1	PRX-08066 Maleic acid	363680163.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Clc1sc2ncnc(NC3CCN(Cc4cc(C#N)c(F)cc4)CC3)c2c1	Clc1sc2ncnc(NC3CCN(Cc4cc(C#N)c(F)cc4)CC3)c2c1
NCGC00510268-01	Cn1c(-c2c3c(c(-c4[nH]ncc4)ncc3)nc(N3[C@H](C)COCC3)c2)ccn1		Inactive	ATR Kinase Inhibitor		1	BAY-1895344	384569425.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Cn1c(-c2c3c(c(-c4[nH]ncc4)ncc3)nc(N3[C@H](C)COCC3)c2)ccn1	Cn1c(-c2c3c(c(-c4[nH]ncc4)ncc3)nc(N3[C@H](C)COCC3)c2)ccn1
NCGC00378707-01	Cn1c(C)cc2c(N3CCCC3)nc(N3CCCC3)nc12		Inactive			1	U 89843A	363678161.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Cn1c(C)cc2c(N3CCCC3)nc(N3CCCC3)nc12	Cn1c(C)cc2c(N3CCCC3)nc(N3CCCC3)nc12
NCGC00389601-01	Cn1c(c(-c2nn(C)c3ncnc(N4CC(N5CCCCC5)CC4)c23)cn1)-c1ccc(C)cc1		Inactive			1	PF-4981517	363680815.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Cn1c(c(-c2nn(C)c3ncnc(N4CC(N5CCCCC5)CC4)c23)cn1)-c1ccc(C)cc1	Cn1c(c(-c2nn(C)c3ncnc(N4CC(N5CCCCC5)CC4)c23)cn1)-c1ccc(C)cc1
NCGC00379101-02	Cn1c(c(-c2nn(C)c3ncnc(N4C[C@@H](N5CCCCC5)CC4)c23)cn1)-c1ccc(C)cc1		Inactive			1	PF-4981517	363678351.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Cn1c(c(-c2nn(C)c3ncnc(N4C[C@@H](N5CCCCC5)CC4)c23)cn1)-c1ccc(C)cc1	Cn1c(c(-c2nn(C)c3ncnc(N4C[C@@H](N5CCCCC5)CC4)c23)cn1)-c1ccc(C)cc1
NCGC00485024-02	Cn1ncc(-c2c3c(N4CCOCC4)ncnc3[nH]c2)c1		Inactive	LRRK2 Inhibitor		1	PF-06454589	384569274.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Cn1ncc(-c2c3c(N4CCOCC4)ncnc3[nH]c2)c1	Cn1ncc(-c2c3c(N4CCOCC4)ncnc3[nH]c2)c1
NCGC00481319-01	FC(CN1[C@H](c2c(F)cc(/C=C/C(=O)O)cc2F)c2[nH]c3c(c2C[C@H]1C)cccc3)(C)C		Inactive	Selective Estrogen Receptor Destabilizers (SERD)		1	AZD-9496 maleate	384569254.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(CN1[C@H](c2c(F)cc(/C=C/C(=O)O)cc2F)c2[nH]c3c(c2C[C@H]1C)cccc3)(C)C	FC(CN1[C@H](c2c(F)cc(/C=C/C(=O)O)cc2F)c2[nH]c3c(c2C[C@H]1C)cccc3)(C)C
NCGC00390577-02	FC(F)(C(=O)N[C@]12[C@H]([C@H]3C(=O)C=C4[C@]5(C)[C@H](C(C)(C)C(=O)C(C#N)=C5)CC[C@@]4(C)[C@]3(C)CC1)CC(C)(C)CC2)C		Inactive	Nuclear Factor Erythroid 2-Related Factor 2 (NFE2-Related Factor 2; NFE2L2; NRF2) Activator		1	Omaveloxolone	384569196.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-15.175109664	FC(F)(C(=O)N[C@]12[C@H]([C@H]3C(=O)C=C4[C@]5(C)[C@H](C(C)(C)C(=O)C(C#N)=C5)CC[C@@]4(C)[C@]3(C)CC1)CC(C)(C)CC2)C	FC(F)(C(=O)N[C@]12[C@H]([C@H]3C(=O)C=C4[C@]5(C)[C@H](C(C)(C)C(=O)C(C#N)=C5)CC[C@@]4(C)[C@]3(C)CC1)CC(C)(C)CC2)C
NCGC00378842-04	FC(F)(C(F)F)COc1cc(CNCCc2c3c([nH]c2)cc(F)cc3)ccc1	4.9499998	Active	Serotonin 6 (5-HT6) receptor Antagonist	0.0	1	Lu AE58054 (Hydrochloride)	363678230.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	3.0	74.2553203112	FC(F)(C(F)F)COc1cc(CNCCc2c3c([nH]c2)cc(F)cc3)ccc1	FC(F)(C(F)F)COc1cc(CNCCc2c3c([nH]c2)cc(F)cc3)ccc1
NCGC00346580-02&NCGC00346580-04&NCGC00346580-05	FC(F)(C)[C@H]1CN2C[C@H](C1)C[C@](C(=O)OC)(c1c(OC)cc3N(C)[C@H]4[C@@](O)(C(=O)OC)[C@H](OC(=O)C)[C@@]5(CC)[C@@H]6N(CC=C5)CC[C@]46c3c1)c1[nH]c3c(c1C2)cccc3		Inactive	Tubulin polymerization Inhibitor		3	Vinflunine&Vinflunine (Tartrate)	363677462.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	FC(F)(C)[C@H]1CN2C[C@H](C1)C[C@](C(=O)OC)(c1c(OC)cc3N(C)[C@H]4[C@@](O)(C(=O)OC)[C@H](OC(=O)C)[C@@]5(CC)[C@@H]6N(CC=C5)CC[C@]46c3c1)c1[nH]c3c(c1C2)cccc3	FC(F)(C)[C@H]1CN2C[C@H](C1)C[C@](C(=O)OC)(c1c(OC)cc3N(C)[C@H]4[C@@](O)(C(=O)OC)[C@H](OC(=O)C)[C@@]5(CC)[C@@H]6N(CC=C5)CC[C@]46c3c1)c1[nH]c3c(c1C2)cccc3
NCGC00389309-01	FC(F)(CCCC)C1(O)OC2C(C(CCCCCCC(=O)O)C(=O)C2)CC1		Inactive	ClC-2 Channel Activators		1	Lubiprostone	405559047.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(CCCC)C1(O)OC2C(C(CCCCCCC(=O)O)C(=O)C2)CC1	FC(F)(CCCC)C1(O)OC2C(C(CCCCCCC(=O)O)C(=O)C2)CC1
NCGC00183105-01	FC(F)(CCCC)[C@]1(O)O[C@H]2[C@@H]([C@@H](CCCCCCC(=O)O)C(=O)C2)CC1		Inactive	ClC-2 Channel Activator		1	Lubiprostone	124894305.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(CCCC)[C@]1(O)O[C@H]2[C@@H]([C@@H](CCCCCCC(=O)O)C(=O)C2)CC1	FC(F)(CCCC)[C@]1(O)O[C@H]2[C@@H]([C@@H](CCCCCCC(=O)O)C(=O)C2)CC1
NCGC00402329-01	FC(F)(F)C(=O)CCCCc1cc2c(cc1)cccc2		Inactive	Calcium-independent phospholipase A2 Inhibitor		1	FKGK18	363681026.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)C(=O)CCCCc1cc2c(cc1)cccc2	FC(F)(F)C(=O)CCCCc1cc2c(cc1)cccc2
NCGC00390545-01&NCGC00390545-02	FC(F)(F)C(=O)N[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2c3c(O)c4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C[C@@](O)(C(=O)COC(=O)CCCC)C2)C1		Inactive	DNA Topoisomerase II Inhibitor		2	Valrubicin	405558480.0&384569188.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	FC(F)(F)C(=O)N[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2c3c(O)c4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C[C@@](O)(C(=O)COC(=O)CCCC)C2)C1	FC(F)(F)C(=O)N[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2c3c(O)c4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C[C@@](O)(C(=O)COC(=O)CCCC)C2)C1
NCGC00346717-02&NCGC00346717-12	FC(F)(F)C(C)(C)c1nccc(-c2c(C)nc(NC(=O)N3[C@H](C(=O)N)CCC3)s2)c1		Inactive	PI3K alpha Inhibitor		2	Alpelisib&BYL-719	384568930.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	FC(F)(F)C(C)(C)c1nccc(-c2c(C)nc(NC(=O)N3[C@H](C(=O)N)CCC3)s2)c1	FC(F)(F)C(C)(C)c1nccc(-c2c(C)nc(NC(=O)N3[C@H](C(=O)N)CCC3)s2)c1
NCGC00386234-03	FC(F)(F)C(C)(C)c1onc(NC(=O)Nc2cc(Oc3ncnc4c3cc(OC)c(OC)c4)ccc2)c1		Inactive	EGFR Inhibitor		1	CEP-32496	363680161.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)C(C)(C)c1onc(NC(=O)Nc2cc(Oc3ncnc4c3cc(OC)c(OC)c4)ccc2)c1	FC(F)(F)C(C)(C)c1onc(NC(=O)Nc2cc(Oc3ncnc4c3cc(OC)c(OC)c4)ccc2)c1
NCGC00166122-01	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F		Inactive			1	Perflexane	144205881.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F
NCGC00167420-01	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F		Inactive			1	Perflenapent	144205977.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F	FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F
NCGC00263162-08	FC(F)(F)C(F)(F)CNC(=O)C(C(=O)N[C@@H]1C(=O)Nc2c(-c3c1cccc3)cccc2)(C)C		Inactive	g-Secretase Inhibitor		1	RO-4929097	384568633.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)C(F)(F)CNC(=O)C(C(=O)N[C@@H]1C(=O)Nc2c(-c3c1cccc3)cccc2)(C)C	FC(F)(F)C(F)(F)CNC(=O)C(C(=O)N[C@@H]1C(=O)Nc2c(-c3c1cccc3)cccc2)(C)C
NCGC00378688-01	FC(F)(F)C(F)(F)c1cc2N=C(N)CC(C(=O)OCC)=Cc2cc1		Inactive	Toll-like receptor 8 Modulator		1	Toll-like receptor modulator	363678150.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)C(F)(F)c1cc2N=C(N)CC(C(=O)OCC)=Cc2cc1	FC(F)(F)C(F)(F)c1cc2N=C(N)CC(C(=O)OCC)=Cc2cc1
NCGC00496795-01	FC(F)(F)C(N(C(=O)CN1C(=O)C2(NC1=O)c1c(C(F)C2)cc(-c2cn(CC(=O)NC)nc2)cc1)Cc1ccc(F)cc1)C		Inactive			1	WO2016044770	384569291.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)C(N(C(=O)CN1C(=O)C2(NC1=O)c1c(C(F)C2)cc(-c2cn(CC(=O)NC)nc2)cc1)Cc1ccc(F)cc1)C	FC(F)(F)C(N(C(=O)CN1C(=O)C2(NC1=O)c1c(C(F)C2)cc(-c2cn(CC(=O)NC)nc2)cc1)Cc1ccc(F)cc1)C
NCGC00386729-01	FC(F)(F)C(O)(C(=O)Nc1cc2C(C)=NOC(=O)c2cc1)CC(C)(C)c1c2OCCc2ccc1		Inactive	Progesterone receptor Antagonist		1	(+)-ZK 216348	363680421.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)C(O)(C(=O)Nc1cc2C(C)=NOC(=O)c2cc1)CC(C)(C)c1c2OCCc2ccc1	FC(F)(F)C(O)(C(=O)Nc1cc2C(C)=NOC(=O)c2cc1)CC(C)(C)c1c2OCCc2ccc1
NCGC00378920-01	FC(F)(F)C(O)(C(F)(F)F)CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1		Inactive			1	Falecalcitriol	405558573.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)C(O)(C(F)(F)F)CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1	FC(F)(F)C(O)(C(F)(F)F)CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1
NCGC00379220-07	FC(F)(F)C(O)(C(F)(F)F)c1cc(F)c(-c2ccc(CN3CCN(Cc4ccncc4)CC3)cc2)cc1		Inactive	ROR-gamma Inverse Agonist		1	SR-2211	384569095.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)C(O)(C(F)(F)F)c1cc(F)c(-c2ccc(CN3CCN(Cc4ccncc4)CC3)cc2)cc1	FC(F)(F)C(O)(C(F)(F)F)c1cc(F)c(-c2ccc(CN3CCN(Cc4ccncc4)CC3)cc2)cc1
NCGC00379222-02	FC(F)(F)C(O)(C(F)(F)F)c1ccc(NC(=O)c2ccc(C(F)(F)F)cc2)cc1		Inactive	Nuclear receptor ROR-gamma Agonist		1	SR1078	363678428.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	29.0	FC(F)(F)C(O)(C(F)(F)F)c1ccc(NC(=O)c2ccc(C(F)(F)F)cc2)cc1	FC(F)(F)C(O)(C(F)(F)F)c1ccc(NC(=O)c2ccc(C(F)(F)F)cc2)cc1
NCGC00379230-01	FC(F)(F)C(OC(=O)N1CCN(Cc2cc(Oc3ccccc3)ccc2)CC1)C(F)(F)F		Inactive	Monoglyceride lipase Inhibitor		1	JW 642	363678435.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)C(OC(=O)N1CCN(Cc2cc(Oc3ccccc3)ccc2)CC1)C(F)(F)F	FC(F)(F)C(OC(=O)N1CCN(Cc2cc(Oc3ccccc3)ccc2)CC1)C(F)(F)F
NCGC00167421-02	FC(F)(F)C(OCF)C(F)(F)F		Inactive	GABA-B receptor Modulator		1	Sevoflurane	225144283.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)C(OCF)C(F)(F)F	FC(F)(F)C(OCF)C(F)(F)F
NCGC00482953-01	FC(F)(F)C(Oc1nc(N)nc(-c2ccc(C[C@@H](N)C(=O)O)cc2)c1)c1ccc(-c2cc(F)ccc2)cc1	4.9000001	Active	Tryptophan Hydroxylase 2 (TPH2) Inhibitor	0.0	1	LP-533401	384569262.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	42.253926697	FC(F)(F)C(Oc1nc(N)nc(-c2ccc(C[C@@H](N)C(=O)O)cc2)c1)c1ccc(-c2cc(F)ccc2)cc1	FC(F)(F)C(Oc1nc(N)nc(-c2ccc(C[C@@H](N)C(=O)O)cc2)c1)c1ccc(-c2cc(F)ccc2)cc1
NCGC00480794-01	FC(F)(F)C(Oc1nc(N)nc(-c2ccc(C[C@H](N)C(=O)O)cc2)c1)c1ccc(-c2cc(F)ccc2)cc1	4.9499998	Active	Tryptophan Hydroxylase 2 (TPH2) Inhibitor	0.0	1	LP-533401	384569246.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	90.9269833943	FC(F)(F)C(Oc1nc(N)nc(-c2ccc(C[C@H](N)C(=O)O)cc2)c1)c1ccc(-c2cc(F)ccc2)cc1	FC(F)(F)C(Oc1nc(N)nc(-c2ccc(C[C@H](N)C(=O)O)cc2)c1)c1ccc(-c2cc(F)ccc2)cc1
NCGC00370908-01	FC(F)(F)C1(O)C(=O)Oc2c(C(C)(C)C)cc(C(C)(C)C)cc12		Inactive	GABA-B receptor Positive Allosteric Modulator		1	rac BHFF	363677926.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)C1(O)C(=O)Oc2c(C(C)(C)C)cc(C(C)(C)C)cc12	FC(F)(F)C1(O)C(=O)Oc2c(C(C)(C)C)cc(C(C)(C)C)cc12
NCGC00166323-02&NCGC00166323-05&NCGC00166323-16	FC(F)(F)C=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1		Inactive	thymidylate synthase Inhibitor		3	Trifluridine&Trifluorothymidine	170464911.0&384568306.0&434147224.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	FC(F)(F)C=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1	FC(F)(F)C=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1
NCGC00371263-02	FC(F)(F)C=1C(C(=O)Nc2c(N3CCN(C)CC3)ccc(-c3cc(CN4CCOCC4)ccc3)c2)=CNC(=O)C=1		Inactive	Inhibitor of WDR5-MLL interaction.		1	OICR-9429	363678072.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)C=1C(C(=O)Nc2c(N3CCN(C)CC3)ccc(-c3cc(CN4CCOCC4)ccc3)c2)=CNC(=O)C=1	FC(F)(F)C=1C(C(=O)Nc2c(N3CCN(C)CC3)ccc(-c3cc(CN4CCOCC4)ccc3)c2)=CNC(=O)C=1
NCGC00345841-02	FC(F)(F)C=1C=C(NC(C)C)n2nc(NC(=O)c3cnccc3)nc2C=1		Inactive	ASK1 Inhibitor		1	S-99	363677384.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)C=1C=C(NC(C)C)n2nc(NC(=O)c3cnccc3)nc2C=1	FC(F)(F)C=1C=C(NC(C)C)n2nc(NC(=O)c3cnccc3)nc2C=1
NCGC00479218-01	FC(F)(F)C=1C=C(NC2CC2)n2nc(NC(=O)c3cnccc3)nc2C=1		Inactive	Mitogen-activated protein kinase kinase kinase 5 Inhibitor		1	MSC 2032964A	363681105.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)C=1C=C(NC2CC2)n2nc(NC(=O)c3cnccc3)nc2C=1	FC(F)(F)C=1C=C(NC2CC2)n2nc(NC(=O)c3cnccc3)nc2C=1
NCGC00485341-01	FC(F)(F)C=1c2c(OC(=O)C=1)cc(NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)CC(C)C)CCC(=O)O)CCC(=O)O)CC(=O)O)cc2		Inactive	Caspase-13 Substrate		1	N-Acetyl-Leu-Glu-Glu-Asp-7-amido-4-trifluoromethylcoumarin	363681292.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)C=1c2c(OC(=O)C=1)cc(NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)CC(C)C)CCC(=O)O)CCC(=O)O)CC(=O)O)cc2	FC(F)(F)C=1c2c(OC(=O)C=1)cc(NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)CC(C)C)CCC(=O)O)CCC(=O)O)CC(=O)O)cc2
NCGC00485377-01	FC(F)(F)C=1c2c(OC(=O)C=1)cc(NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)Cc1c3c([nH]c1)cccc3)CCC(=O)O)Cc1nc[nH]c1)CC(=O)O)cc2		Inactive	Caspase-14 Substrate		1	N-Acetyl-Trp-Glu-His-Asp-7-amido-4-trifluoromethylcoumarin trifluoroacetate salt	363681305.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)C=1c2c(OC(=O)C=1)cc(NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)Cc1c3c([nH]c1)cccc3)CCC(=O)O)Cc1nc[nH]c1)CC(=O)O)cc2	FC(F)(F)C=1c2c(OC(=O)C=1)cc(NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)Cc1c3c([nH]c1)cccc3)CCC(=O)O)Cc1nc[nH]c1)CC(=O)O)cc2
NCGC00507841-02	FC(F)(F)CCC(=O)N[C@H](C(=O)N[C@@H]1C(=O)N(CCO)c2ncccc2-c2c1cccc2)C		Inactive	Notch Signaling Inhibitor		1	Crenigacestat	384569323.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)CCC(=O)N[C@H](C(=O)N[C@@H]1C(=O)N(CCO)c2ncccc2-c2c1cccc2)C	FC(F)(F)CCC(=O)N[C@H](C(=O)N[C@@H]1C(=O)N(CCO)c2ncccc2-c2c1cccc2)C
NCGC00507871-01	FC(F)(F)CCNC=1c2n(c(-c3cc(C)c(C(=O)NC4CC4)cc3)cn2)N=C(Oc2c(F)c(F)c(OC)cc2)C=1		Inactive	MPS1 Inhibitor		1	BAY-1217389	384569344.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)CCNC=1c2n(c(-c3cc(C)c(C(=O)NC4CC4)cc3)cn2)N=C(Oc2c(F)c(F)c(OC)cc2)C=1	FC(F)(F)CCNC=1c2n(c(-c3cc(C)c(C(=O)NC4CC4)cc3)cn2)N=C(Oc2c(F)c(F)c(OC)cc2)C=1
NCGC00510498-01	FC(F)(F)CC[C@H](Oc1cc(C)c(c(C)c1)-c1ccc(C(C)(C)C)cc1)c1ccc(C(=O)NCCC(=O)O)cc1	5.6500001	Active	Glucagon Receptor (GCGR) Antagonist	0.0	1	Adomeglivant	384569460.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	58.1600538435	FC(F)(F)CC[C@H](Oc1cc(C)c(c(C)c1)-c1ccc(C(C)(C)C)cc1)c1ccc(C(=O)NCCC(=O)O)cc1	FC(F)(F)CC[C@H](Oc1cc(C)c(c(C)c1)-c1ccc(C(C)(C)C)cc1)c1ccc(C(=O)NCCC(=O)O)cc1
NCGC00390592-01	FC(F)(F)CC[C@H]([C@@H](C(=O)N)CC1CC1)C(=O)N[C@@H]1C(=O)Nc2c(F)cccc2C(c2ccccc2)=N1		Inactive	Notch Signaling Inhibitor		1	BMS-983970	363680919.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)CC[C@H]([C@@H](C(=O)N)CC1CC1)C(=O)N[C@@H]1C(=O)Nc2c(F)cccc2C(c2ccccc2)=N1	FC(F)(F)CC[C@H]([C@@H](C(=O)N)CC1CC1)C(=O)N[C@@H]1C(=O)Nc2c(F)cccc2C(c2ccccc2)=N1
NCGC00475729-01	FC(F)(F)CC[C@H]([C@@H](C(=O)N)CCC(F)(F)F)C(=O)N[C@@H]1C(=O)N(C)c2c(C(c3ccccc3)=N1)cccc2		Inactive	Notch Signaling Inhibitor		1	BMS-906024	384569232.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)CC[C@H]([C@@H](C(=O)N)CCC(F)(F)F)C(=O)N[C@@H]1C(=O)N(C)c2c(C(c3ccccc3)=N1)cccc2	FC(F)(F)CC[C@H]([C@@H](C(=O)N)CCC(F)(F)F)C(=O)N[C@@H]1C(=O)N(C)c2c(C(c3ccccc3)=N1)cccc2
NCGC00378720-01	FC(F)(F)CN1C(=O)C(n2nnc(-c3cc(OC)c(-n4cc(C)nc4)cc3)c2)CCc2c(F)cccc12		Inactive	Gamma-secretase Modulator		1	gamma-secretase modulator 2	363678171.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)CN1C(=O)C(n2nnc(-c3cc(OC)c(-n4cc(C)nc4)cc3)c2)CCc2c(F)cccc12	FC(F)(F)CN1C(=O)C(n2nnc(-c3cc(OC)c(-n4cc(C)nc4)cc3)c2)CCc2c(F)cccc12
NCGC00386438-01	FC(F)(F)CN1C(=O)[C@H](CC(=O)O)Cc2c(cc(OCCc3nc(NC)ccc3)cc2)C1		Inactive	Integrin alpha-V/beta-3 Antagonist		1	SB273005	363680290.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)CN1C(=O)[C@H](CC(=O)O)Cc2c(cc(OCCc3nc(NC)ccc3)cc2)C1	FC(F)(F)CN1C(=O)[C@H](CC(=O)O)Cc2c(cc(OCCc3nc(NC)ccc3)cc2)C1
NCGC00378827-01	FC(F)(F)CN1C(=O)[C@H](NC(=O)N2CCC(N3C(=O)Nc4ncccc34)CC2)CC[C@@H](c2c(F)c(F)ccc2)C1		Inactive	Calcitonin gene-related peptide type 1 receptor Antagonist		1	MK-0974	363678224.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)CN1C(=O)[C@H](NC(=O)N2CCC(N3C(=O)Nc4ncccc34)CC2)CC[C@@H](c2c(F)c(F)ccc2)C1	FC(F)(F)CN1C(=O)[C@H](NC(=O)N2CCC(N3C(=O)Nc4ncccc34)CC2)CC[C@@H](c2c(F)c(F)ccc2)C1
NCGC00371128-04	FC(F)(F)CN1CCC(NC(=O)c2cnc(-c3cc(F)ccc3)cc2)CC1		Inactive	Hematopoietic prostaglandin D synthase Inhibitor		1	HPGDS-inhibitor-1	363678044.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)CN1CCC(NC(=O)c2cnc(-c3cc(F)ccc3)cc2)CC1	FC(F)(F)CN1CCC(NC(=O)c2cnc(-c3cc(F)ccc3)cc2)CC1
NCGC00507883-01	FC(F)(F)CN1CCC([C@@H](C)n2c(C)c(C(=O)NCC=3C(=O)NC(C)=CC=3OC)c3c2cccc3)CC1		Inactive	EZH2 Inhibitor		1	CPI-1205	384569348.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)CN1CCC([C@@H](C)n2c(C)c(C(=O)NCC=3C(=O)NC(C)=CC=3OC)c3c2cccc3)CC1	FC(F)(F)CN1CCC([C@@H](C)n2c(C)c(C(=O)NCC=3C(=O)NC(C)=CC=3OC)c3c2cccc3)CC1
NCGC00386364-01	FC(F)(F)CNC(=O)C1(CCCCN2CCC(NC(=O)c3c(-c4ccc(C(F)(F)F)cc4)cccc3)CC2)c2c(-c3c1cccc3)cccc2		Inactive	Microsomal triglyceride transfer protein large subunit Inhibitor		1	Lomitapide	405558897.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	19.22100314	FC(F)(F)CNC(=O)C1(CCCCN2CCC(NC(=O)c3c(-c4ccc(C(F)(F)F)cc4)cccc3)CC2)c2c(-c3c1cccc3)cccc2	FC(F)(F)CNC(=O)C1(CCCCN2CCC(NC(=O)c3c(-c4ccc(C(F)(F)F)cc4)cccc3)CC2)c2c(-c3c1cccc3)cccc2
NCGC00402345-02	FC(F)(F)CNC(=O)[C@](Nc1nc(-c2c3c([nH]c2)nccc3)ncc1)(CC)C		Inactive	Jak2/3 Inhibitor		1	Decernotinib	363681031.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)CNC(=O)[C@](Nc1nc(-c2c3c([nH]c2)nccc3)ncc1)(CC)C	FC(F)(F)CNC(=O)[C@](Nc1nc(-c2c3c([nH]c2)nccc3)ncc1)(CC)C
NCGC00475741-01	FC(F)(F)COc1c(C(=O)NC2CCN(C(=O)CO)CC2)n(C)c2c1C(=O)N(CC(=O)c1ccccc1)C(CC)=C2		Inactive	Hedgehog Antagonist		1	TAK-441	384569236.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	26.0460664079	FC(F)(F)COc1c(C(=O)NC2CCN(C(=O)CO)CC2)n(C)c2c1C(=O)N(CC(=O)c1ccccc1)C(CC)=C2	FC(F)(F)COc1c(C(=O)NC2CCN(C(=O)CO)CC2)n(C)c2c1C(=O)N(CC(=O)c1ccccc1)C(CC)=C2
NCGC00015443-17&NCGC00015443-22	FC(F)(F)COc1c(C(=O)NCC2NCCCC2)cc(OCC(F)(F)F)cc1		Inactive	Sodium Channel Protein Type 5 Subunit alpha (Nav1.5) Channel Blocker		2	Flecainide acetate	170464874.0&384567847.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	FC(F)(F)COc1c(C(=O)NCC2NCCCC2)cc(OCC(F)(F)F)cc1	FC(F)(F)COc1c(C(=O)NCC2NCCCC2)cc(OCC(F)(F)F)cc1
NCGC00345882-03	FC(F)(F)COc1c(OCCN[C@@H](Cc2cc(C(=O)N)c3N(CCCO)CCc3c2)C)cccc1		Inactive	alpha1-Adrenoceptor Antagonists		1	Silodosin	405558750.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)COc1c(OCCN[C@@H](Cc2cc(C(=O)N)c3N(CCCO)CCc3c2)C)cccc1	FC(F)(F)COc1c(OCCN[C@@H](Cc2cc(C(=O)N)c3N(CCCO)CCc3c2)C)cccc1
NCGC00507854-01	FC(F)(F)Cc1sc2ncnc(NC3CCN(Cc4c(C)c5c(n(Cc6c[nH]nc6)c(C#N)c5)cc4)CC3)c2c1		Inactive	Histone methyl transferase Inhibitor		1	MI-503	384569332.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	31.360203652	FC(F)(F)Cc1sc2ncnc(NC3CCN(Cc4c(C)c5c(n(Cc6c[nH]nc6)c(C#N)c5)cc4)CC3)c2c1	FC(F)(F)Cc1sc2ncnc(NC3CCN(Cc4c(C)c5c(n(Cc6c[nH]nc6)c(C#N)c5)cc4)CC3)c2c1
NCGC00510519-01	FC(F)(F)Cc1sc2ncnc(NC3CCN(Cc4c(O)cc5n(Cc6c[nH]nc6)c(C#N)cc5c4)CC3)c2c1		Inactive	In vivo active Menin-MLL Inhibitor		1	MI-538	384569472.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)Cc1sc2ncnc(NC3CCN(Cc4c(O)cc5n(Cc6c[nH]nc6)c(C#N)cc5c4)CC3)c2c1	FC(F)(F)Cc1sc2ncnc(NC3CCN(Cc4c(O)cc5n(Cc6c[nH]nc6)c(C#N)cc5c4)CC3)c2c1
NCGC00263223-02	FC(F)(F)Cn1c2nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N(CCN(C)C)C)cc4)cc3)nc(N3CCOCC3)c2cc1		Inactive	PI3Kalpha Inhibitor		1	CAY-10626	384568677.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		FC(F)(F)Cn1c2nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N(CCN(C)C)C)cc4)cc3)nc(N3CCOCC3)c2cc1	FC(F)(F)Cn1c2nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N(CCN(C)C)C)cc4)cc3)nc(N3CCOCC3)c2cc1
NCGC00390557-01	FC(F)(F)Oc1c(-c2cc3c(Nc4n(C5CCC(O)CC5)c5c(n4)cc(C(=O)NCCC(C)C)cc5)n[nH]c3cc2)cccc1		Inactive	Interleukin-1 receptor-associated kinase 4 Inhibitor		1	IRAK inhibitor 4 (trans)	363680902.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	25.5	FC(F)(F)Oc1c(-c2cc3c(Nc4n(C5CCC(O)CC5)c5c(n4)cc(C(=O)NCCC(C)C)cc5)n[nH]c3cc2)cccc1	FC(F)(F)Oc1c(-c2cc3c(Nc4n(C5CCC(O)CC5)c5c(n4)cc(C(=O)NCCC(C)C)cc5)n[nH]c3cc2)cccc1
NCGC00390549-01	FC(F)(F)Oc1c(Nc2nc3-c4n(C)nc(C(=O)Nc5c(CC)cccc5CC)c4CCc3cn2)ccc(C(=O)NC2CCN(C)CC2)c1		Inactive	Dual specificity protein kinase TTK Inhibitor		1	NMS-P715	363680900.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	19.3497363839	FC(F)(F)Oc1c(Nc2nc3-c4n(C)nc(C(=O)Nc5c(CC)cccc5CC)c4CCc3cn2)ccc(C(=O)NC2CCN(C)CC2)c1	FC(F)(F)Oc1c(Nc2nc3-c4n(C)nc(C(=O)Nc5c(CC)cccc5CC)c4CCc3cn2)ccc(C(=O)NC2CCN(C)CC2)c1
NCGC00386361-02	FC(F)(F)Oc1c(Nc2nc3-c4n(CCO)nc(C(=O)N)c4CCc3cn2)cc(N2CCN(C)CC2)cc1		Inactive	Polo-like Kinase-1 (Plk-1) Inhibitor		1	NMS-P937	384569128.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)Oc1c(Nc2nc3-c4n(CCO)nc(C(=O)N)c4CCc3cn2)cc(N2CCN(C)CC2)cc1	FC(F)(F)Oc1c(Nc2nc3-c4n(CCO)nc(C(=O)N)c4CCc3cn2)cc(N2CCN(C)CC2)cc1
NCGC00263186-04	FC(F)(F)Oc1cc(-c2n3N=C(NCC4CCN(C)CC4)C=Cc3nc2)ccc1		Inactive	Pim-1/Flt3 Inhibitor		1	SGI-1776	384568653.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)Oc1cc(-c2n3N=C(NCC4CCN(C)CC4)C=Cc3nc2)ccc1	FC(F)(F)Oc1cc(-c2n3N=C(NCC4CCN(C)CC4)C=Cc3nc2)ccc1
NCGC00402372-02	FC(F)(F)Oc1cc(-c2ncc(C[C@@H](NC(=O)c3sc(C)c(CCC)c3)C(=O)N[C@H]3CNCC3)cc2)ccc1		Inactive	Kinesin-Like Spindle Protein Inhibitor		1	AZ-82	384569218.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)Oc1cc(-c2ncc(C[C@@H](NC(=O)c3sc(C)c(CCC)c3)C(=O)N[C@H]3CNCC3)cc2)ccc1	FC(F)(F)Oc1cc(-c2ncc(C[C@@H](NC(=O)c3sc(C)c(CCC)c3)C(=O)N[C@H]3CNCC3)cc2)ccc1
NCGC00356145-10	FC(F)(F)Oc1cc(CC(=O)Nc2nnc(CCCCc3sc(NC(=O)Cc4ncccc4)nn3)cc2)ccc1		Inactive	Glutaminase Inhibitor		1	CB-839	384569029.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	FC(F)(F)Oc1cc(CC(=O)Nc2nnc(CCCCc3sc(NC(=O)Cc4ncccc4)nn3)cc2)ccc1	FC(F)(F)Oc1cc(CC(=O)Nc2nnc(CCCCc3sc(NC(=O)Cc4ncccc4)nn3)cc2)ccc1
NCGC00379104-01	FC(F)(F)Oc1cc(OC)c(-c2c(C)nc(NC(CC)CC)c(OC)n2)cc1		Inactive	Corticotropin releasing factor receptor 1 Antagonist		1	NGD 98-2 hydrochloride	363678354.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)Oc1cc(OC)c(-c2c(C)nc(NC(CC)CC)c(OC)n2)cc1	FC(F)(F)Oc1cc(OC)c(-c2c(C)nc(NC(CC)CC)c(OC)n2)cc1
NCGC00390369-01	FC(F)(F)Oc1cc2c(Cc3cc(O[C@H](C(=O)O)C)ccc3)c(C)n(C(=O)c3ccc(OC)cc3)c2cc1		Inactive	Peroxisome proliferator-activated receptor gamma Partial Agonist		1	MRL-24	363680882.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)Oc1cc2c(Cc3cc(O[C@H](C(=O)O)C)ccc3)c(C)n(C(=O)c3ccc(OC)cc3)c2cc1	FC(F)(F)Oc1cc2c(Cc3cc(O[C@H](C(=O)O)C)ccc3)c(C)n(C(=O)c3ccc(OC)cc3)c2cc1
NCGC00015882-15	FC(F)(F)Oc1cc2sc(N)nc2cc1		Inactive	Glutamate Release Inhibitor		1	Riluzole	170464928.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	FC(F)(F)Oc1cc2sc(N)nc2cc1	FC(F)(F)Oc1cc2sc(N)nc2cc1
NCGC00250382-06&NCGC00250382-07	FC(F)(F)Oc1ccc(-c2c(C)c(C(=O)Nc3cnc(N4C[C@@H](C)O[C@@H](C)C4)cc3)ccc2)cc1		Inactive	Smo Receptor Antagonist		2	Sonidegib	384568538.0&405558711.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	FC(F)(F)Oc1ccc(-c2c(C)c(C(=O)Nc3cnc(N4C[C@@H](C)O[C@@H](C)C4)cc3)ccc2)cc1	FC(F)(F)Oc1ccc(-c2c(C)c(C(=O)Nc3cnc(N4C[C@@H](C)O[C@@H](C)C4)cc3)ccc2)cc1
NCGC00263142-04	FC(F)(F)Oc1ccc(-c2cc3c(C(=O)C(=O)O)cn(Cc4ccccc4)c3cc2)cc1	4.9000001	Active	PAI Inhibitor	0.0	1	Tiplasinin	363677226.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	58.0842604039	FC(F)(F)Oc1ccc(-c2cc3c(C(=O)C(=O)O)cn(Cc4ccccc4)c3cc2)cc1	FC(F)(F)Oc1ccc(-c2cc3c(C(=O)C(=O)O)cn(Cc4ccccc4)c3cc2)cc1
NCGC00379232-01	FC(F)(F)Oc1ccc(-c2nc(C(N)(C)C)[nH]c2)cc1		Inactive	Sodium channel protein type X alpha subunit Inhibitor		1	PF 04885614	363678436.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)Oc1ccc(-c2nc(C(N)(C)C)[nH]c2)cc1	FC(F)(F)Oc1ccc(-c2nc(C(N)(C)C)[nH]c2)cc1
NCGC00390647-01	FC(F)(F)Oc1ccc(-c2ncc(CO[C@@H]3COc4n(cc([N+](=O)[O-])n4)C3)cc2)cc1		Inactive	Mycobacterium tuberculosis H37Rv Inhibitor		1	TBA-354	363680952.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)Oc1ccc(-c2ncc(CO[C@@H]3COc4n(cc([N+](=O)[O-])n4)C3)cc2)cc1	FC(F)(F)Oc1ccc(-c2ncc(CO[C@@H]3COc4n(cc([N+](=O)[O-])n4)C3)cc2)cc1
NCGC00507887-01	FC(F)(F)Oc1ccc(C(=O)NCCC(=O)N[C@H]2c3c(cccc3)CCC2)cc1		Inactive	DHODH Inhibitor		1	ML-390	384569351.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)Oc1ccc(C(=O)NCCC(=O)N[C@H]2c3c(cccc3)CCC2)cc1	FC(F)(F)Oc1ccc(C(=O)NCCC(=O)N[C@H]2c3c(cccc3)CCC2)cc1
NCGC00408812-01	FC(F)(F)Oc1ccc(C2=Cn3c(C(F)(F)F)nnc3C=C2)cc1		Inactive	Sodium channel protein type 5 subunit alpha Blocker		1	GS967	363681055.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)Oc1ccc(C2=Cn3c(C(F)(F)F)nnc3C=C2)cc1	FC(F)(F)Oc1ccc(C2=Cn3c(C(F)(F)F)nnc3C=C2)cc1
NCGC00378587-01	FC(F)(F)Oc1ccc(CC(=O)N([C@H](C)C=2N(c3ccc(OCC)cc3)C(=O)c3c(nccc3)N=2)Cc2cnccc2)cc1		Inactive	C-X-C chemokine receptor type 3 Antagonist		1	AMG 487	363678104.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)Oc1ccc(CC(=O)N([C@H](C)C=2N(c3ccc(OCC)cc3)C(=O)c3c(nccc3)N=2)Cc2cnccc2)cc1	FC(F)(F)Oc1ccc(CC(=O)N([C@H](C)C=2N(c3ccc(OCC)cc3)C(=O)c3c(nccc3)N=2)Cc2cnccc2)cc1
NCGC00387182-01	FC(F)(F)Oc1ccc(CNC(=O)C2N(C(=O)c3c2cccc3)C2CCOCC2)cc1		Inactive	Sodium channel protein type IX alpha subunit Inhibitor		1	NAV 26	363680559.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)Oc1ccc(CNC(=O)C2N(C(=O)c3c2cccc3)C2CCOCC2)cc1	FC(F)(F)Oc1ccc(CNC(=O)C2N(C(=O)c3c2cccc3)C2CCOCC2)cc1
NCGC00379083-01	FC(F)(F)Oc1ccc(CNC(=O)C2N(CCc3ncccc3)C(=O)c3c2c(F)ccc3)cc1		Inactive	Sodium channel protein type IX alpha subunit Inhibitor		1	Sodium Channel inhibitor 1	363678345.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)Oc1ccc(CNC(=O)C2N(CCc3ncccc3)C(=O)c3c2c(F)ccc3)cc1	FC(F)(F)Oc1ccc(CNC(=O)C2N(CCc3ncccc3)C(=O)c3c2c(F)ccc3)cc1
NCGC00390579-01	FC(F)(F)Oc1ccc(CNC(=O)c2nc3n(c2)C=C(c2ccc(C4CCC(CC(=O)O)CC4)cc2)C=C3)cc1		Inactive	Diacylglycerol O-acyltransferase 1 Inhibitor		1	DGAT1-IN-1	363680912.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)Oc1ccc(CNC(=O)c2nc3n(c2)C=C(c2ccc(C4CCC(CC(=O)O)CC4)cc2)C=C3)cc1	FC(F)(F)Oc1ccc(CNC(=O)c2nc3n(c2)C=C(c2ccc(C4CCC(CC(=O)O)CC4)cc2)C=C3)cc1
NCGC00379126-02	FC(F)(F)Oc1ccc(COC2CCN(c3nc(Nc4c(C)c(NC(=O)C)ccc4)ncn3)CC2)cc1		Inactive	Sodium channel protein type IX alpha subunit Inhibitor		1	Nav1.7 blocker 52	363678372.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)Oc1ccc(COC2CCN(c3nc(Nc4c(C)c(NC(=O)C)ccc4)ncn3)CC2)cc1	FC(F)(F)Oc1ccc(COC2CCN(c3nc(Nc4c(C)c(NC(=O)C)ccc4)ncn3)CC2)cc1
NCGC00346682-08	FC(F)(F)Oc1ccc(CO[C@@H]2COc3n(cc([N+](=O)[O-])n3)C2)cc1		Inactive	Nitric Oxide (NO) Donors		1	PA-824	384568906.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)Oc1ccc(CO[C@@H]2COc3n(cc([N+](=O)[O-])n3)C2)cc1	FC(F)(F)Oc1ccc(CO[C@@H]2COc3n(cc([N+](=O)[O-])n3)C2)cc1
NCGC00263159-10	FC(F)(F)Oc1ccc(NC(=O)c2c(NCc3c4c(ncc3)cccc4)ccs2)cc1		Inactive	PDGFR beta Inhibitor		1	OSI-930	363677236.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)Oc1ccc(NC(=O)c2c(NCc3c4c(ncc3)cccc4)ccs2)cc1	FC(F)(F)Oc1ccc(NC(=O)c2c(NCc3c4c(ncc3)cccc4)ccs2)cc1
NCGC00488771-02	FC(F)(F)Oc1ccc(Nc2n([C@@H]3C[C@H](C)CC(C)(C)C3)c3c(n2)cc(CCC(=O)O)cc3)cc1		Inactive	IDH1 Inhibitor		1	BAY-1436032	384569284.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)Oc1ccc(Nc2n([C@@H]3C[C@H](C)CC(C)(C)C3)c3c(n2)cc(CCC(=O)O)cc3)cc1	FC(F)(F)Oc1ccc(Nc2n([C@@H]3C[C@H](C)CC(C)(C)C3)c3c(n2)cc(CCC(=O)O)cc3)cc1
NCGC00346808-03	FC(F)(F)Oc1ccc(Nc2ncnc(-c3cc(C(=O)N)ccc3)c2)cc1	4.9499998	Active	Bcr-Abl Inhibitor	0.0	1	GNF-2	384568942.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	72.1287347128	FC(F)(F)Oc1ccc(Nc2ncnc(-c3cc(C(=O)N)ccc3)c2)cc1	FC(F)(F)Oc1ccc(Nc2ncnc(-c3cc(C(=O)N)ccc3)c2)cc1
NCGC00390365-01	FC(F)(F)Oc1ccc(OC2CCN(c3ccc(OCC4(C)Oc5n(cc([N+](=O)[O-])n5)C4)cc3)CC2)cc1		Inactive			1	Delamanid	405558727.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)Oc1ccc(OC2CCN(c3ccc(OCC4(C)Oc5n(cc([N+](=O)[O-])n5)C4)cc3)CC2)cc1	FC(F)(F)Oc1ccc(OC2CCN(c3ccc(OCC4(C)Oc5n(cc([N+](=O)[O-])n5)C4)cc3)CC2)cc1
NCGC00505117-01&NCGC00505118-01	FC(F)(F)[C@@H](N(C(=O)CN1C(=O)C2(NC1=O)c1c(C(F)C2)cc(-c2cn(CC(=O)NC)nc2)cc1)Cc1ccc(F)cc1)C		Inactive	CBP/p300 Inhibitor		2	NCGC00505117&NCGC00505118	384569316.0&384569317.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	FC(F)(F)[C@@H](N(C(=O)CN1C(=O)C2(NC1=O)c1c(C(F)C2)cc(-c2cn(CC(=O)NC)nc2)cc1)Cc1ccc(F)cc1)C	FC(F)(F)[C@@H](N(C(=O)CN1C(=O)C2(NC1=O)c1c(C(F)C2)cc(-c2cn(CC(=O)NC)nc2)cc1)Cc1ccc(F)cc1)C
NCGC00378773-01	FC(F)(F)[C@@](O)(CC(C)(C)c1c(O)ccc(F)c1)Cc1[nH]c2c(c1)ccnc2	4.9000001	Active	Glucocorticoid receptor Agonist	0.0	1	Glucocorticoid receptor agonist	363678190.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	122.7085663171	FC(F)(F)[C@@](O)(CC(C)(C)c1c(O)ccc(F)c1)Cc1[nH]c2c(c1)ccnc2	FC(F)(F)[C@@](O)(CC(C)(C)c1c(O)ccc(F)c1)Cc1[nH]c2c(c1)ccnc2
NCGC00378785-01	FC(F)(F)[C@H](Oc1nc(N)nc(-c2ccc(C[C@H](N)C(=O)O)cc2)c1)c1ccc(-c2cc(OC)ccc2)cc1		Inactive	Tryptophan 5-hydroxylase 1 Inhibitor		1	LX-1031	363678198.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)[C@H](Oc1nc(N)nc(-c2ccc(C[C@H](N)C(=O)O)cc2)c1)c1ccc(-c2cc(OC)ccc2)cc1	FC(F)(F)[C@H](Oc1nc(N)nc(-c2ccc(C[C@H](N)C(=O)O)cc2)c1)c1ccc(-c2cc(OC)ccc2)cc1
NCGC00484084-01	FC(F)(F)[C@](O)(Cc1[nH]cc(CC2(C(F)(F)F)CC2)n1)c1ccc(-n2nccc2)cc1		Inactive	Bombesin receptor subtype-3 Agonist		1	MK-5046	363681175.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)[C@](O)(Cc1[nH]cc(CC2(C(F)(F)F)CC2)n1)c1ccc(-n2nccc2)cc1	FC(F)(F)[C@](O)(Cc1[nH]cc(CC2(C(F)(F)F)CC2)n1)c1ccc(-n2nccc2)cc1
NCGC00346577-02	FC(F)(F)c1[nH]c(-c2nccc(Oc3cc4nc(Nc5ccc(C(F)(F)F)cc5)[nH]c4cc3)c2)nc1		Inactive	Raf kinase B/C Inhibitor		1	RAF-265 derivative	363677460.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1[nH]c(-c2nccc(Oc3cc4nc(Nc5ccc(C(F)(F)F)cc5)[nH]c4cc3)c2)nc1	FC(F)(F)c1[nH]c(-c2nccc(Oc3cc4nc(Nc5ccc(C(F)(F)F)cc5)[nH]c4cc3)c2)nc1
NCGC00387489-01	FC(F)(F)c1c(-c2cc(C(F)(F)F)c3[nH]c(C4=NOC5(C4)CCCCC5)nc3c2)cccc1		Inactive	Transient receptor potential cation channel subfamily M member 8 Antagonist		1	TC-I 2014	363680641.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1c(-c2cc(C(F)(F)F)c3[nH]c(C4=NOC5(C4)CCCCC5)nc3c2)cccc1	FC(F)(F)c1c(-c2cc(C(F)(F)F)c3[nH]c(C4=NOC5(C4)CCCCC5)nc3c2)cccc1
NCGC00379192-01	FC(F)(F)c1c(-c2ccccc2)ccc(NC(=O)NC(=O)c2c(OC)ccnc2)c1		Inactive	Sphingosine 1-phosphate receptor 1 Agonist		1	TC-G 1006	363678408.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1c(-c2ccccc2)ccc(NC(=O)NC(=O)c2c(OC)ccnc2)c1	FC(F)(F)c1c(-c2ccccc2)ccc(NC(=O)NC(=O)c2c(OC)ccnc2)c1
NCGC00496841-01	FC(F)(F)c1c(-c2n(C)c(C34CCC(c5nc(C6CC(F)(F)C6)on5)(CC3)CC4)nn2)cccc1		Inactive	Smo Inhibitor		1	MK-4101	384569295.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(-c2n(C)c(C34CCC(c5nc(C6CC(F)(F)C6)on5)(CC3)CC4)nn2)cccc1	FC(F)(F)c1c(-c2n(C)c(C34CCC(c5nc(C6CC(F)(F)C6)on5)(CC3)CC4)nn2)cccc1
NCGC00510232-02	FC(F)(F)c1c(-c2nc(C(=O)Nc3c(N4CCC(N)(C)CC4)cccn3)c(N)nc2)nccc1		Inactive	PKC-alpha, PKC-theta Inhibitor		1	LXS-196	384569417.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(-c2nc(C(=O)Nc3c(N4CCC(N)(C)CC4)cccn3)c(N)nc2)nccc1	FC(F)(F)c1c(-c2nc(C(=O)Nc3c(N4CCC(N)(C)CC4)cccn3)c(N)nc2)nccc1
NCGC00262604-18	FC(F)(F)c1c(-c2nc(N3CCOCC3)nc(N3CCOCC3)c2)cnc(N)c1		Inactive	PI3Kalpha Inhibitor		1	BKM-120	384568575.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		FC(F)(F)c1c(-c2nc(N3CCOCC3)nc(N3CCOCC3)c2)cnc(N)c1	FC(F)(F)c1c(-c2nc(N3CCOCC3)nc(N3CCOCC3)c2)cnc(N)c1
NCGC00510199-01	FC(F)(F)c1c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cnc(N)c1		Inactive	PI3K Inhibitor		1	Bimiralisib	384569414.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cnc(N)c1	FC(F)(F)c1c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cnc(N)c1
NCGC00390655-01	FC(F)(F)c1c(-c2nc(Nc3ccc(C(F)(F)F)cc3)sc2)n2c(n1)C=CC=C2		Inactive	Polycomb Complex Protein BMI-1 Inhibitor		1	PTC-691	363680957.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(-c2nc(Nc3ccc(C(F)(F)F)cc3)sc2)n2c(n1)C=CC=C2	FC(F)(F)c1c(-c2nc(Nc3ccc(C(F)(F)F)cc3)sc2)n2c(n1)C=CC=C2
NCGC00378881-01	FC(F)(F)c1c(-c2nnc(Cn3cc-4nc(-c5c(F)cccc5)nc-4cc3)cc2)ccc(C(F)(F)F)c1		Inactive			1	Tegobuvir	363678254.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(-c2nnc(Cn3cc-4nc(-c5c(F)cccc5)nc-4cc3)cc2)ccc(C(F)(F)F)c1	FC(F)(F)c1c(-c2nnc(Cn3cc-4nc(-c5c(F)cccc5)nc-4cc3)cc2)ccc(C(F)(F)F)c1
NCGC00485913-01	FC(F)(F)c1c(C#N)ccc(N2C(=O)N(C)[C@@](CO)(c3ccccc3)C2=O)c1		Inactive	Androgen Receptor Modulator		1	GLPG0492 (R enantiomer)	363681409.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1c(C#N)ccc(N2C(=O)N(C)[C@@](CO)(c3ccccc3)C2=O)c1	FC(F)(F)c1c(C#N)ccc(N2C(=O)N(C)[C@@](CO)(c3ccccc3)C2=O)c1
NCGC00485914-01	FC(F)(F)c1c(C#N)ccc(N2C(=O)N(C)[C@](CO)(c3ccccc3)C2=O)c1		Inactive	Androgen Receptor Modulator		1	GLPG0492	363681410.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1c(C#N)ccc(N2C(=O)N(C)[C@](CO)(c3ccccc3)C2=O)c1	FC(F)(F)c1c(C#N)ccc(N2C(=O)N(C)[C@](CO)(c3ccccc3)C2=O)c1
NCGC00378632-02	FC(F)(F)c1c(C#N)ccc(N2C(=O)N(CCCCO)C(C)(C)C2=O)c1		Inactive	Androgen Receptor Antagonist		1	RU 58841	363678132.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1c(C#N)ccc(N2C(=O)N(CCCCO)C(C)(C)C2=O)c1	FC(F)(F)c1c(C#N)ccc(N2C(=O)N(CCCCO)C(C)(C)C2=O)c1
NCGC00346499-02	FC(F)(F)c1c(C#N)ccc(NC(=O)[C@@](O)(COc2ccc(C#N)cc2)C)c1		Inactive	Selective Androgen Receptor Modulators (SARM)		1	Ostarine	384568804.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(C#N)ccc(NC(=O)[C@@](O)(COc2ccc(C#N)cc2)C)c1	FC(F)(F)c1c(C#N)ccc(NC(=O)[C@@](O)(COc2ccc(C#N)cc2)C)c1
NCGC00386816-01	FC(F)(F)c1c(C#N)ccc(Nc2scc(-c3c(O)cc(O)cc3)n2)c1		Inactive			1	NCGC00386816-01	363680445.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1c(C#N)ccc(Nc2scc(-c3c(O)cc(O)cc3)n2)c1	FC(F)(F)c1c(C#N)ccc(Nc2scc(-c3c(O)cc(O)cc3)n2)c1
NCGC00370969-01	FC(F)(F)c1c(C#N)ccc([C@@H]2[C@H](O)CCCC2)c1		Inactive	Androgen Receptor Antagonist		1	PF 998425	363677965.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1c(C#N)ccc([C@@H]2[C@H](O)CCCC2)c1	FC(F)(F)c1c(C#N)ccc([C@@H]2[C@H](O)CCCC2)c1
NCGC00263170-02	FC(F)(F)c1c(C(=O)N(C)C2CCN(c3nnc(-c4n(C)ncc4)c4c3cccc4)CC2)ccc(F)c1		Inactive	Smoothened (Smo) Receptor Antagonist		1	Taladegib	384568640.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(C(=O)N(C)C2CCN(c3nnc(-c4n(C)ncc4)c4c3cccc4)CC2)ccc(F)c1	FC(F)(F)c1c(C(=O)N(C)C2CCN(c3nnc(-c4n(C)ncc4)c4c3cccc4)CC2)ccc(F)c1
NCGC00345796-09	FC(F)(F)c1c(C)c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc23)ccc1		Inactive	PI3Kbeta Inhibitor		1	GSK-2636771	384568746.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(C)c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc23)ccc1	FC(F)(F)c1c(C)c(Cn2c(C)nc3c(C(=O)O)cc(N4CCOCC4)cc23)ccc1
NCGC00180889-03	FC(F)(F)c1c(C)c(Nc2c(C(=O)O)cccn2)ccc1		Inactive	Prostaglandin G/H synthase 2 Inhibitor		1	Flunixin meglumine	170466598.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&10.540656604	FC(F)(F)c1c(C)c(Nc2c(C(=O)O)cccn2)ccc1.O[C@H]([C@H](O)[C@@H](O)CNC)[C@H](O)CO	FC(F)(F)c1c(C)c(Nc2c(C(=O)O)cccn2)ccc1.O[C@H]([C@H](O)[C@@H](O)CNC)[C@H](O)CO
NCGC00509987-01	FC(F)(F)c1c(C)ccc(NC(=O)[C@@H]2[C@@H](N(C(=O)c3c(F)cccc3C)CCC2)c2ccc(NC3CCCC3)cc2)c1		Inactive	C5a Anaphylatoxin Chemotactic Receptor 1 Antagonist		1	Avacopan	384569396.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(C)ccc(NC(=O)[C@@H]2[C@@H](N(C(=O)c3c(F)cccc3C)CCC2)c2ccc(NC3CCCC3)cc2)c1	FC(F)(F)c1c(C)ccc(NC(=O)[C@@H]2[C@@H](N(C(=O)c3c(F)cccc3C)CCC2)c2ccc(NC3CCCC3)cc2)c1
NCGC00522578-01	FC(F)(F)c1c(C2CCCC2)ccc(COc2cc3c([nH]c4[C@@H](CC(=O)O)CCc34)cc2)c1		Inactive	Lysophospholipid edg8 (S1P5) Receptor Agonist		1	Etrasimod	384569527.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.2366530441	FC(F)(F)c1c(C2CCCC2)ccc(COc2cc3c([nH]c4[C@@H](CC(=O)O)CCc34)cc2)c1	FC(F)(F)c1c(C2CCCC2)ccc(COc2cc3c([nH]c4[C@@H](CC(=O)O)CCc34)cc2)c1
NCGC00347938-05	FC(F)(F)c1c(C2CCCCC2)ccc(CO/N=C(\C)/c2cc(CC)c(CN3CC(C(=O)O)C3)cc2)c1		Inactive	Lysophospholipid edg8 (S1P5) Receptor Ligands; Lysophospholipid edg1 (S1P1) Receptor Agonist		1	BAF-312	384568990.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	19.538688288	FC(F)(F)c1c(C2CCCCC2)ccc(CO/N=C(\C)/c2cc(CC)c(CN3CC(C(=O)O)C3)cc2)c1	FC(F)(F)c1c(C2CCCCC2)ccc(CO/N=C(\C)/c2cc(CC)c(CN3CC(C(=O)O)C3)cc2)c1
NCGC00370977-01	FC(F)(F)c1c(C2CCN(C(=O)Nc3c(C(=O)O)cccc3)CC2)cccc1		Inactive	Plasma retinol-binding protein Antagonist		1	A 1120	363677971.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1c(C2CCN(C(=O)Nc3c(C(=O)O)cccc3)CC2)cccc1	FC(F)(F)c1c(C2CCN(C(=O)Nc3c(C(=O)O)cccc3)CC2)cccc1
NCGC00522303-02&NCGC00522303-03	FC(F)(F)c1c(CN2C(=O)N(C[C@H](NCCCC(=O)O)c3ccccc3)C(=O)C(c3c(F)c(OC)ccc3)=C2C)c(F)ccc1		Inactive	GnRH (LHRH) Receptor Antagonist		2	Elagolix	384569515.0&384569516.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	FC(F)(F)c1c(CN2C(=O)N(C[C@H](NCCCC(=O)O)c3ccccc3)C(=O)C(c3c(F)c(OC)ccc3)=C2C)c(F)ccc1	FC(F)(F)c1c(CN2C(=O)N(C[C@H](NCCCC(=O)O)c3ccccc3)C(=O)C(c3c(F)c(OC)ccc3)=C2C)c(F)ccc1
NCGC00378614-02	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(C(=O)Nc2cc(Nc3nc(-c4cnccc4)ccn3)c(C)nc2)c1	5.0999999	Active	Bcr-Abl Inhibitor	0.0	1	Flumatinib mesylate	384569056.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.3	110.4938629406	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(C(=O)Nc2cc(Nc3nc(-c4cnccc4)ccn3)c(C)nc2)c1	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(C(=O)Nc2cc(Nc3nc(-c4cnccc4)ccn3)c(C)nc2)c1
NCGC00384169-08	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)Cc2ccc(Oc3ncnc(NC(=O)C4CC4)c3)cc2)c1		Inactive	Proliferation-associated protein 2G4 Binding Agent		1	WS6	363679173.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	9.5	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)Cc2ccc(Oc3ncnc(NC(=O)C4CC4)c3)cc2)c1	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)Cc2ccc(Oc3ncnc(NC(=O)C4CC4)c3)cc2)c1
NCGC00347958-03	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)Nc2ccc(Oc3ncnc(NC(=O)C4CC4)c3)cc2)c1		Inactive	beta Cell Proliferation Inducer		1	WS-3	384569001.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)Nc2ccc(Oc3ncnc(NC(=O)C4CC4)c3)cc2)c1	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)Nc2ccc(Oc3ncnc(NC(=O)C4CC4)c3)cc2)c1
NCGC00351607-02	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)c2cc(C#Cc3cnc4[nH]ncc4c3)c(C)cc2)c1		Inactive	Bcr-Abl Inhibitor		1	GZD-824	384569021.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)c2cc(C#Cc3cnc4[nH]ncc4c3)c(C)cc2)c1	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)c2cc(C#Cc3cnc4[nH]ncc4c3)c(C)cc2)c1
NCGC00263152-05&NCGC00263152-12	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)c2cc(C#Cc3n4N=CC=Cc4nc3)c(C)cc2)c1		Inactive	FGFR Inhibitor		2	Ponatinib	405558658.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	-19.2124463479&0.0	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)c2cc(C#Cc3n4N=CC=Cc4nc3)c(C)cc2)c1	FC(F)(F)c1c(CN2CCN(C)CC2)ccc(NC(=O)c2cc(C#Cc3n4N=CC=Cc4nc3)c(C)cc2)c1
NCGC00354729-02	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)Nc2ccc(Oc3ncnc(NC)c3)cc2)c1		Inactive	Flt3 Inhibitor		1	AST-487	384569023.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)Nc2ccc(Oc3ncnc(NC)c3)cc2)c1	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)Nc2ccc(Oc3ncnc(NC)c3)cc2)c1
NCGC00390570-02	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)c2cc(/C=C/c3c(OC)c4c([nH]cc4)nc3)c(C)cc2)c1		Inactive	Raf kinase B Inhibitor		1	HG-6-64-1	384569194.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)c2cc(/C=C/c3c(OC)c4c([nH]cc4)nc3)c(C)cc2)c1	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)c2cc(/C=C/c3c(OC)c4c([nH]cc4)nc3)c(C)cc2)c1
NCGC00390558-02	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)c2cc(NC(=O)c3cc(-c4sccc4)cnc3)c(C)cc2)c1		Inactive	RET Inhibitor		1	ALW-II-41-27	384569192.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)c2cc(NC(=O)c3cc(-c4sccc4)cnc3)c(C)cc2)c1	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)c2cc(NC(=O)c3cc(-c4sccc4)cnc3)c(C)cc2)c1
NCGC00378847-01	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)c2cc(Oc3ncnc4[nH]c(C)cc34)c(C)cc2)c1		Inactive	Serine/threonine-protein kinase B-raf Inhibitor		1	B-Raf inhibitor	363678233.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	-14.8027522959	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)c2cc(Oc3ncnc4[nH]c(C)cc34)c(C)cc2)c1	FC(F)(F)c1c(CN2CCN(CC)CC2)ccc(NC(=O)c2cc(Oc3ncnc4[nH]c(C)cc34)c(C)cc2)c1
NCGC00346514-04&NCGC00346514-07	FC(F)(F)c1c(CN2C[C@@H](N(C)C)CC2)ccc(C(=O)Nc2cc(Nc3ncc(-c4cncnc4)cn3)c(C)cc2)c1	5.04999995	Active	Bcr-Abl Inhibitor	0.29999969999999987	2	Bafetinib	384568814.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	81.9947731617&61.068554397	FC(F)(F)c1c(CN2C[C@@H](N(C)C)CC2)ccc(C(=O)Nc2cc(Nc3ncc(-c4cncnc4)cn3)c(C)cc2)c1	FC(F)(F)c1c(CN2C[C@@H](N(C)C)CC2)ccc(C(=O)Nc2cc(Nc3ncc(-c4cncnc4)cn3)c(C)cc2)c1
NCGC00386723-01	FC(F)(F)c1c(CNC(=O)[C@H]2C[C@@H](Nc3nc(NC)nc(C)n3)CCC2)ccc(C#N)c1		Inactive	Soluble Epoxide Hydrolase Inhibitor		1	GSK-2256294A	363680418.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(CNC(=O)[C@H]2C[C@@H](Nc3nc(NC)nc(C)n3)CCC2)ccc(C#N)c1	FC(F)(F)c1c(CNC(=O)[C@H]2C[C@@H](Nc3nc(NC)nc(C)n3)CCC2)ccc(C#N)c1
NCGC00480744-01	FC(F)(F)c1c(CNC(=O)c2cc(NCc3n(C)c(-c4ccncc4)nn3)ccc2)cccc1		Inactive			1	CMPD101		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1c(CNC(=O)c2cc(NCc3n(C)c(-c4ccncc4)nn3)ccc2)cccc1	FC(F)(F)c1c(CNC(=O)c2cc(NCc3n(C)c(-c4ccncc4)nn3)ccc2)cccc1
NCGC00242217-09	FC(F)(F)c1c(COc2c(C(=O)N)sc(-n3c4c(nc3)cc(OC)c(OC)c4)c2)cccc1		Inactive	Polo-like Kinase-1 (Plk-1) Inhibitor		1	GW-843682X	384568486.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(COc2c(C(=O)N)sc(-n3c4c(nc3)cc(OC)c(OC)c4)c2)cccc1	FC(F)(F)c1c(COc2c(C(=O)N)sc(-n3c4c(nc3)cc(OC)c(OC)c4)c2)cccc1
NCGC00415059-02	FC(F)(F)c1c(Cc2c(C(=O)N3OC[C@](O)(C)C3)c3C(=O)N(C)C(=O)N(C(C)C)c3s2)c(C)[nH]n1		Inactive	MCT2 Inhibitor		1	AZD-3965	384569222.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(Cc2c(C(=O)N3OC[C@](O)(C)C3)c3C(=O)N(C)C(=O)N(C(C)C)c3s2)c(C)[nH]n1	FC(F)(F)c1c(Cc2c(C(=O)N3OC[C@](O)(C)C3)c3C(=O)N(C)C(=O)N(C(C)C)c3s2)c(C)[nH]n1
NCGC00485916-01	FC(F)(F)c1c(Cn2nc(NC(=O)c3c(F)cccc3F)cc2)c(F)ccc1		Inactive	Calcium release-activated calcium channel protein 1 Inhibitor		1	GSK-5498A	363681412.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1c(Cn2nc(NC(=O)c3c(F)cccc3F)cc2)c(F)ccc1	FC(F)(F)c1c(Cn2nc(NC(=O)c3c(F)cccc3F)cc2)c(F)ccc1
NCGC00402346-02	FC(F)(F)c1c(Cn2nc(NC(=O)c3c(F)cccc3F)cc2)ccc(O)c1		Inactive	Calcium release-activated calcium channel protein 1 Inhibitor		1	GSK-7975A	363681032.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1c(Cn2nc(NC(=O)c3c(F)cccc3F)cc2)ccc(O)c1	FC(F)(F)c1c(Cn2nc(NC(=O)c3c(F)cccc3F)cc2)ccc(O)c1
NCGC00511388-01	FC(F)(F)c1c(F)c(C(=O)N2CCC(N3CC(CC#N)(n4ncc(-c5ncnc6[nH]ccc56)c4)C3)CC2)ccn1		Inactive	Jak1 Inhibitor		1	Itacitinib	384569502.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(F)c(C(=O)N2CCC(N3CC(CC#N)(n4ncc(-c5ncnc6[nH]ccc56)c4)C3)CC2)ccn1	FC(F)(F)c1c(F)c(C(=O)N2CCC(N3CC(CC#N)(n4ncc(-c5ncnc6[nH]ccc56)c4)C3)CC2)ccn1
NCGC00386428-07	FC(F)(F)c1c(F)ccc(-c2nc(n(C)c2)C2CCN(c3ncnc4[nH]ncc34)CC2)c1		Inactive	Ribosomal Protein S6 Kinase beta (p70S6K) Inhibitor		1	LY-2584702	384569138.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(F)ccc(-c2nc(n(C)c2)C2CCN(c3ncnc4[nH]ncc34)CC2)c1	FC(F)(F)c1c(F)ccc(-c2nc(n(C)c2)C2CCN(c3ncnc4[nH]ncc34)CC2)c1
NCGC00350264-01	FC(F)(F)c1c(F)ccc(-c2noc(CNC(=O)CCCc3nc4ncccc4cc3)c2)c1		Inactive	GPR91 Inhibitor		1	PRP003-062	384569003.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(F)ccc(-c2noc(CNC(=O)CCCc3nc4ncccc4cc3)c2)c1	FC(F)(F)c1c(F)ccc(-c2noc(CNC(=O)CCCc3nc4ncccc4cc3)c2)c1
NCGC00378793-02	FC(F)(F)c1c(F)ccc(CC(=O)N([C@H](C)C=2N(c3ccc(OCC)cc3)C(=O)c3c(nccc3)N=2)Cc2cnccc2)c1		Inactive	Chemokine CXCR3 Receptor Antagonist		1	NBI-74330	384569069.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(F)ccc(CC(=O)N([C@H](C)C=2N(c3ccc(OCC)cc3)C(=O)c3c(nccc3)N=2)Cc2cnccc2)c1	FC(F)(F)c1c(F)ccc(CC(=O)N([C@H](C)C=2N(c3ccc(OCC)cc3)C(=O)c3c(nccc3)N=2)Cc2cnccc2)c1
NCGC00189393-09	FC(F)(F)c1c(F)ccc(NC(=O)Nc2sc(-c3ccncc3)nn2)c1	5.9499998	Active	BLM Inhibitor	0.0	1	NCGC00189393	363677130.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	1.4	43.5167796268	FC(F)(F)c1c(F)ccc(NC(=O)Nc2sc(-c3ccncc3)nn2)c1	FC(F)(F)c1c(F)ccc(NC(=O)Nc2sc(-c3ccncc3)nn2)c1
NCGC00387175-01	FC(F)(F)c1c(N2CCCC2)ccc(C(=O)Nc2cc(OCC)ccc2)c1		Inactive	Trace amine-associated receptor 1 Antagonist		1	EPPTB	363680556.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1c(N2CCCC2)ccc(C(=O)Nc2cc(OCC)ccc2)c1	FC(F)(F)c1c(N2CCCC2)ccc(C(=O)Nc2cc(OCC)ccc2)c1
NCGC00263215-04	FC(F)(F)c1c(N2CCN(C(=O)CC)CC2)ccc(N2C(=O)C=Cc3c2c2c(nc3)ccc(-c3cnc4c(c3)cccc4)c2)c1		Inactive	mTOR Inhibitor		1	Torin-1	384568670.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		FC(F)(F)c1c(N2CCN(C(=O)CC)CC2)ccc(N2C(=O)C=Cc3c2c2c(nc3)ccc(-c3cnc4c(c3)cccc4)c2)c1	FC(F)(F)c1c(N2CCN(C(=O)CC)CC2)ccc(N2C(=O)C=Cc3c2c2c(nc3)ccc(-c3cnc4c(c3)cccc4)c2)c1
NCGC00370883-04	FC(F)(F)c1c(N2CCN(C(=O)Nc3ncc(C(F)(F)F)cc3)CC2)nccc1		Inactive	Vanilloid receptor Antagonist		1	JNJ-17203212	363677909.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1c(N2CCN(C(=O)Nc3ncc(C(F)(F)F)cc3)CC2)nccc1	FC(F)(F)c1c(N2CCN(C(=O)Nc3ncc(C(F)(F)F)cc3)CC2)nccc1
NCGC00242047-05	FC(F)(F)c1c(N2CCN(C)CC2)ccc(Nc2nc(-c3c4n(nc3)N=CC=C4)ccn2)c1		Inactive			1	GW779439X	377020488.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	-19.331943048	FC(F)(F)c1c(N2CCN(C)CC2)ccc(Nc2nc(-c3c4n(nc3)N=CC=C4)ccn2)c1	FC(F)(F)c1c(N2CCN(C)CC2)ccc(Nc2nc(-c3c4n(nc3)N=CC=C4)ccn2)c1
NCGC00346681-07&NCGC00346681-13	FC(F)(F)c1c(N2CCNCC2)ccc(N2C(=O)N(C)c3c2c2c(nc3)ccc(-c3cnc(OC)cc3)c2)c1		Inactive	PI3K Inhibitor		2	NVP-BGT226	384568905.0	Annotated/Bioactive Compound Collection&2020_NPACT-10_CPE	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0		FC(F)(F)c1c(N2CCNCC2)ccc(N2C(=O)N(C)c3c2c2c(nc3)ccc(-c3cnc(OC)cc3)c2)c1	FC(F)(F)c1c(N2CCNCC2)ccc(N2C(=O)N(C)c3c2c2c(nc3)ccc(-c3cnc(OC)cc3)c2)c1
NCGC00164571-04&NCGC00164571-14	FC(F)(F)c1c(NC(=O)[C@@H]2[C@]3(C)[C@H]([C@H]4C([C@]5(C)[C@H](NC(=O)C=C5)CC4)CC3)CC2)cc(C(F)(F)F)cc1		Inactive	Steroid 5alpha-Reductase Inhibitors		2	Dutasteride	384568256.0	Anti-infectives&Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	FC(F)(F)c1c(NC(=O)[C@@H]2[C@]3(C)[C@H]([C@H]4C([C@]5(C)[C@H](NC(=O)C=C5)CC4)CC3)CC2)cc(C(F)(F)F)cc1	FC(F)(F)c1c(NC(=O)[C@@H]2[C@]3(C)[C@H]([C@H]4C([C@]5(C)[C@H](NC(=O)C=C5)CC4)CC3)CC2)cc(C(F)(F)F)cc1
NCGC00488701-03	FC(F)(F)c1c(NC(=O)c2c3c(nc(C(=O)N)c2)cc(F)cc3)c(C)n(Cc2ccc(C#N)cc2)n1		Inactive	Solute Carrier Family 2, Facilitated Glucose Transporter Member 1 (GLUT-1; SLC2A1) Inhibitor		1	BAY-876	384569283.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(NC(=O)c2c3c(nc(C(=O)N)c2)cc(F)cc3)c(C)n(Cc2ccc(C#N)cc2)n1	FC(F)(F)c1c(NC(=O)c2c3c(nc(C(=O)N)c2)cc(F)cc3)c(C)n(Cc2ccc(C#N)cc2)n1
NCGC00510779-01	FC(F)(F)c1c(NC(=O)c2c3c(nc(C(=O)N)c2)cc(F)cc3)c(C)n(Cc2ccc(C(C)(C)C)cc2)n1		Inactive	Orally bioavailable GLUT1 Inhibitor for oncology		1	BAY-876	384569491.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(NC(=O)c2c3c(nc(C(=O)N)c2)cc(F)cc3)c(C)n(Cc2ccc(C(C)(C)C)cc2)n1	FC(F)(F)c1c(NC(=O)c2c3c(nc(C(=O)N)c2)cc(F)cc3)c(C)n(Cc2ccc(C(C)(C)C)cc2)n1
NCGC00386334-01	FC(F)(F)c1c(NC)nc(Nc2c(C)nn(C(C#N)(C)C)c2)nc1		Inactive	Leucine-rich repeat serine/threonine-protein kinase 2 Inhibitor		1	GNE-0877		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1c(NC)nc(Nc2c(C)nn(C(C#N)(C)C)c2)nc1	FC(F)(F)c1c(NC)nc(Nc2c(C)nn(C(C#N)(C)C)c2)nc1
NCGC00346652-08	FC(F)(F)c1c(NC2CCC2)nc(Nc2cc3[C@@H]4N(C(=O)CNC(=O)C)[C@H](c3cc2)CC4)nc1		Inactive	Aurora Kinase Inhibitor		1	PF-03814735	384568883.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	31.709991024	FC(F)(F)c1c(NC2CCC2)nc(Nc2cc3[C@@H]4N(C(=O)CNC(=O)C)[C@H](c3cc2)CC4)nc1	FC(F)(F)c1c(NC2CCC2)nc(Nc2cc3[C@@H]4N(C(=O)CNC(=O)C)[C@H](c3cc2)CC4)nc1
NCGC00386346-05	FC(F)(F)c1c(NCC)nc(Nc2c(OC)cc(C(=O)N3CCOCC3)c(F)c2)nc1		Inactive	Leucine-rich repeat serine/threonine-protein kinase 2 Inhibitor		1	GNE7915	363680226.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1c(NCC)nc(Nc2c(OC)cc(C(=O)N3CCOCC3)c(F)c2)nc1	FC(F)(F)c1c(NCC)nc(Nc2c(OC)cc(C(=O)N3CCOCC3)c(F)c2)nc1
NCGC00378620-04	FC(F)(F)c1c(Nc2c(C(=O)NC)cccc2)cc(Nc2c(OC)cc(N3CCOCC3)cc2)nc1		Inactive	Focal adhesion kinase 1 Inhibitor		1	PND-1186	363678126.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1c(Nc2c(C(=O)NC)cccc2)cc(Nc2c(OC)cc(N3CCOCC3)cc2)nc1	FC(F)(F)c1c(Nc2c(C(=O)NC)cccc2)cc(Nc2c(OC)cc(N3CCOCC3)cc2)nc1
NCGC00386293-01	FC(F)(F)c1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc1		Inactive	EGFR (Thr790Met Mutant) Inhibitor		1	Rociletinib	384569121.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc1	FC(F)(F)c1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(N3CCN(C(=O)C)CC3)cc2)nc1
NCGC00386271-02	FC(F)(F)c1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(NC3CN(CCF)C3)cc2)nc1		Inactive	EGFR Inhibitor		1	CNX-2006	384569119.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(NC3CN(CCF)C3)cc2)nc1	FC(F)(F)c1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2c(OC)cc(NC3CN(CCF)C3)cc2)nc1
NCGC00510495-01	FC(F)(F)c1c(OCCCCCCC)ccc(CCC(N)(CO)CO)c1		Inactive	Lysophospholipid edg1 (S1P1) Receptor Ligands		1	Amiselimod hydrochloride	384569457.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-8.836027712	FC(F)(F)c1c(OCCCCCCC)ccc(CCC(N)(CO)CO)c1	FC(F)(F)c1c(OCCCCCCC)ccc(CCC(N)(CO)CO)c1
NCGC00263112-02	FC(F)(F)c1c([C@H](Oc2c(C(=O)N)sc(-n3c4c(nc3)ccc(CN3CCN(C)CC3)c4)c2)C)cccc1		Inactive	Polo-like Kinase-1 (Plk-1) Inhibitor		1	GSK-461364A	384568598.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		FC(F)(F)c1c([C@H](Oc2c(C(=O)N)sc(-n3c4c(nc3)ccc(CN3CCN(C)CC3)c4)c2)C)cccc1	FC(F)(F)c1c([C@H](Oc2c(C(=O)N)sc(-n3c4c(nc3)ccc(CN3CCN(C)CC3)c4)c2)C)cccc1
NCGC00015754-16&NCGC00015754-17	FC(F)(F)c1c([N+](=O)[O-])ccc(N2C(=O)C(C)(C)NC2=O)c1		Inactive	Androgen Receptor Antagonist		2	Nilutamide	170465021.0&384567887.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	FC(F)(F)c1c([N+](=O)[O-])ccc(N2C(=O)C(C)(C)NC2=O)c1	FC(F)(F)c1c([N+](=O)[O-])ccc(N2C(=O)C(C)(C)NC2=O)c1
NCGC00015452-20&NCGC00015452-23	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)C(C)C)c1		Inactive	Androgen Receptor Antagonist		2	Flutamide	170464921.0&384567851.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)C(C)C)c1	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)C(C)C)c1
NCGC00091014-06	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)C(O)(C)C)c1		Inactive	Androgen Receptor Antagonist		1	Hydroxyflutamide	174007324.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)C(O)(C)C)c1	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)C(O)(C)C)c1
NCGC00263150-04	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)[C@@](O)(COc2ccc(NC(=O)C)cc2)C)c1		Inactive	Selective Androgen Receptor Modulators (SARM)		1	Andarine	363677230.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)[C@@](O)(COc2ccc(NC(=O)C)cc2)C)c1	FC(F)(F)c1c([N+](=O)[O-])ccc(NC(=O)[C@@](O)(COc2ccc(NC(=O)C)cc2)C)c1
NCGC00099374-07	FC(F)(F)c1c2c(N)c(C(=O)Nc3ccc(F)cc3)sc2nc(-c2sccc2)c1		Inactive			1	FDI 6		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1c2c(N)c(C(=O)Nc3ccc(F)cc3)sc2nc(-c2sccc2)c1	FC(F)(F)c1c2c(N)c(C(=O)Nc3ccc(F)cc3)sc2nc(-c2sccc2)c1
NCGC00250383-02	FC(F)(F)c1c2c(N)c(C(=O)Nc3scc(C)n3)sc2nc2c1CCC2		Inactive	IRE1alpha/XBP-1 Inhibitor		1	Irestatin 9389	363677177.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1c2c(N)c(C(=O)Nc3scc(C)n3)sc2nc2c1CCC2	FC(F)(F)c1c2c(N)c(C(=O)Nc3scc(C)n3)sc2nc2c1CCC2
NCGC00387483-01	FC(F)(F)c1c2c(n(O)c(C(=O)OC)c2)cc(-c2ccccc2)c1	4.9499998	Active	L-lactate dehydrogenase A chain Inhibitor	0.0	1	NHI 2	363680637.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	48.3478305439	FC(F)(F)c1c2c(n(O)c(C(=O)OC)c2)cc(-c2ccccc2)c1	FC(F)(F)c1c2c(n(O)c(C(=O)OC)c2)cc(-c2ccccc2)c1
NCGC00249912-01	FC(F)(F)c1c2nccc(Nc3c(C(=O)OCC(O)CO)cccc3)c2ccc1		Inactive	Prostaglandin G/H synthase 2 Inhibitor		1	Floctafenine	170465681.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	FC(F)(F)c1c2nccc(Nc3c(C(=O)OCC(O)CO)cccc3)c2ccc1	FC(F)(F)c1c2nccc(Nc3c(C(=O)OCC(O)CO)cccc3)c2ccc1
NCGC00511354-01	FC(F)(F)c1cc(-c2n3N=C(NC4CCC(C(O)(C)C)CC4)C=Cc3nc2)ccc1	6.0	Active	Pim-1/3 kinase Inhibitor	0.0	1	TP-3654	384569498.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	1.4	32.2926033319	FC(F)(F)c1cc(-c2n3N=C(NC4CCC(C(O)(C)C)CC4)C=Cc3nc2)ccc1	FC(F)(F)c1cc(-c2n3N=C(NC4CCC(C(O)(C)C)CC4)C=Cc3nc2)ccc1
NCGC00370932-01	FC(F)(F)c1cc(-c2nc(-n3c(C)c(C(=O)NCCCO)cn3)sc2)ccc1		Inactive	natural killer cell mediated cytotoxicity Inhibitor		1	RWJ 50271	363677943.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(-c2nc(-n3c(C)c(C(=O)NCCCO)cn3)sc2)ccc1	FC(F)(F)c1cc(-c2nc(-n3c(C)c(C(=O)NCCCO)cn3)sc2)ccc1
NCGC00386701-02	FC(F)(F)c1cc(-n2c3c(c(CN(CCN(CC=4C(=O)c5c(OC=4)cc(C)c(C)c5)C)C)c2)cccc3)ccc1	5.5999999	Active	TNF-alpha Binding Agent	0.0	1	SPD304	363680404.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	48.3408345442	FC(F)(F)c1cc(-n2c3c(c(CN(CCN(CC=4C(=O)c5c(OC=4)cc(C)c(C)c5)C)C)c2)cccc3)ccc1	FC(F)(F)c1cc(-n2c3c(c(CN(CCN(CC=4C(=O)c5c(OC=4)cc(C)c(C)c5)C)C)c2)cccc3)ccc1
NCGC00345836-13	FC(F)(F)c1cc(/C=C\2/C(=O)NC(=O)S/2)ccc1	4.9000001	Active	Pim-1 Kinase Inhibitor	0.0	1	SMI-4a	384568760.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	70.219546066	FC(F)(F)c1cc(/C=C\2/C(=O)NC(=O)S/2)ccc1	FC(F)(F)c1cc(/C=C\2/C(=O)NC(=O)S/2)ccc1
NCGC00480775-01	FC(F)(F)c1cc(C(=O)NCC(=O)N2C[C@@H](NC3CCC(O)(c4ncc(-c5ncccn5)cc4)CC3)CC2)ccc1		Inactive	Chemokine CCR2 (MCP-1 Receptor) Antagonist		1	INCB8761 (PF-4136309)	384569243.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(C(=O)NCC(=O)N2C[C@@H](NC3CCC(O)(c4ncc(-c5ncccn5)cc4)CC3)CC2)ccc1	FC(F)(F)c1cc(C(=O)NCC(=O)N2C[C@@H](NC3CCC(O)(c4ncc(-c5ncccn5)cc4)CC3)CC2)ccc1
NCGC00378837-01	FC(F)(F)c1cc(C(=O)NCC(=O)N[C@@H]2[C@@H](OCC)CN(C3CCC(O)(c4cc5OCOc5cc4)CC3)C2)ccc1		Inactive			1	INCB3344	363678227.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(C(=O)NCC(=O)N[C@@H]2[C@@H](OCC)CN(C3CCC(O)(c4cc5OCOc5cc4)CC3)C2)ccc1	FC(F)(F)c1cc(C(=O)NCC(=O)N[C@@H]2[C@@H](OCC)CN(C3CCC(O)(c4cc5OCOc5cc4)CC3)C2)ccc1
NCGC00370911-01	FC(F)(F)c1cc(C(=O)NCC(=O)N[C@H]2CN(C3CCC(O)(c4cnc(OC)cc4)CC3)CC2)ccc1		Inactive	C-C chemokine receptor type 2 Antagonist		1	INCB 3284 dimesylate	363677928.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(C(=O)NCC(=O)N[C@H]2CN(C3CCC(O)(c4cnc(OC)cc4)CC3)CC2)ccc1	FC(F)(F)c1cc(C(=O)NCC(=O)N[C@H]2CN(C3CCC(O)(c4cnc(OC)cc4)CC3)CC2)ccc1
NCGC00370760-01	FC(F)(F)c1cc(C(=O)N[C@H]2Cc3c(ccc(OC4=C5C(=NC(=O)CC5)NC=C4)c3)CC2)cc(C(N)(C)C)c1		Inactive			1	ML 786 dihydrochloride	377020284.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(C(=O)N[C@H]2Cc3c(ccc(OC4=C5C(=NC(=O)CC5)NC=C4)c3)CC2)cc(C(N)(C)C)c1	FC(F)(F)c1cc(C(=O)N[C@H]2Cc3c(ccc(OC4=C5C(=NC(=O)CC5)NC=C4)c3)CC2)cc(C(N)(C)C)c1
NCGC00390594-01	FC(F)(F)c1cc(C(=O)Nc2cc(C=3n4ncc(-c5ccc(CN(C)C)cc5)c4N=CC=3)ccc2)ccc1		Inactive	Serine/threonine-protein kinase RAF Inhibitor		1	B-Raf IN 1	363680920.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(C(=O)Nc2cc(C=3n4ncc(-c5ccc(CN(C)C)cc5)c4N=CC=3)ccc2)ccc1	FC(F)(F)c1cc(C(=O)Nc2cc(C=3n4ncc(-c5ccc(CN(C)C)cc5)c4N=CC=3)ccc2)ccc1
NCGC00476210-01	FC(F)(F)c1cc(C(=O)Nc2cc(N3C(=O)N(C)c4nc(Nc5cnc(C)cc5)ncc4C3)c(C)cc2)ccc1		Inactive	Bcr-Abl Inhibitor		1	GNF-7	377020190.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(C(=O)Nc2cc(N3C(=O)N(C)c4nc(Nc5cnc(C)cc5)ncc4C3)c(C)cc2)ccc1	FC(F)(F)c1cc(C(=O)Nc2cc(N3C(=O)N(C)c4nc(Nc5cnc(C)cc5)ncc4C3)c(C)cc2)ccc1
NCGC00485887-01	FC(F)(F)c1cc(C(=O)O)c(C(=O)Nc2nc(C)ccc2)cc1		Inactive	Neurotensin receptor 3 Inhibitor		1	AF38469	363681395.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(C(=O)O)c(C(=O)Nc2nc(C)ccc2)cc1	FC(F)(F)c1cc(C(=O)O)c(C(=O)Nc2nc(C)ccc2)cc1
NCGC00371158-09	FC(F)(F)c1cc(C(=O)O)c(N2C[C@@H](OCc3ncccc3)CC2)cc1		Inactive	Endothelial lipase Inhibitor		1	XEN 445	434147103.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(C(=O)O)c(N2C[C@@H](OCc3ncccc3)CC2)cc1	FC(F)(F)c1cc(C(=O)O)c(N2C[C@@H](OCc3ncccc3)CC2)cc1
NCGC00386734-01	FC(F)(F)c1cc(C(F)(F)F)cc(-c2n(Cc3ccc(C(=O)N)cc3)c(c(-c3ccc(OC)cc3)n2)-c2ccc(OC)cc2)c1		Inactive	Heat shock cognate 71 kDa protein Inhibitor		1	Apoptozole	363680424.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	25.7666360719	FC(F)(F)c1cc(C(F)(F)F)cc(-c2n(Cc3ccc(C(=O)N)cc3)c(c(-c3ccc(OC)cc3)n2)-c2ccc(OC)cc2)c1	FC(F)(F)c1cc(C(F)(F)F)cc(-c2n(Cc3ccc(C(=O)N)cc3)c(c(-c3ccc(OC)cc3)n2)-c2ccc(OC)cc2)c1
NCGC00508985-02	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C(/C(=O)N)\c3cncnc3)cn2)c1		Inactive	Exportin-1 Antagonist		1	Eltanexor	384569373.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C(/C(=O)N)\c3cncnc3)cn2)c1	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C(/C(=O)N)\c3cncnc3)cn2)c1
NCGC00386295-01	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C\C(=O)N3CC(F)(F)C3)cn2)c1		Inactive	Exportin-1 Antagonist		1	KPT-276	363680194.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C\C(=O)N3CC(F)(F)C3)cn2)c1	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C\C(=O)N3CC(F)(F)C3)cn2)c1
NCGC00386421-05&NCGC00386421-08	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C\C(=O)NNc3ncccc3)cn2)c1		Inactive	Exportin-1 Antagonist		2	Verdinexor	384569135.0&434146891.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C\C(=O)NNc3ncccc3)cn2)c1	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C\C(=O)NNc3ncccc3)cn2)c1
NCGC00386310-01&NCGC00386310-03	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C\C(=O)NNc3nccnc3)cn2)c1		Inactive	Exportin-1 Antagonist		2	Selinexor	434146875.0&363680201.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C\C(=O)NNc3nccnc3)cn2)c1	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C\C(=O)NNc3nccnc3)cn2)c1
NCGC00351777-01	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C\c3ocnn3)cn2)c1		Inactive	Exportin-1 Inhibitor		1	KPT-251	363677784.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C\c3ocnn3)cn2)c1	FC(F)(F)c1cc(C(F)(F)F)cc(-c2nn(/C=C\c3ocnn3)cn2)c1
NCGC00390569-01	FC(F)(F)c1cc(C(F)(F)F)cc(C(C(=O)N(C)c2c(-c3c(C)cccc3)cc(N3CCN(C)CC3)nc2)(C)C)c1		Inactive			1	Netupitant	363680908.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(C(F)(F)F)cc(C(C(=O)N(C)c2c(-c3c(C)cccc3)cc(N3CCN(C)CC3)nc2)(C)C)c1	FC(F)(F)c1cc(C(F)(F)F)cc(C(C(=O)N(C)c2c(-c3c(C)cccc3)cc(N3CCN(C)CC3)nc2)(C)C)c1
NCGC00346703-08	FC(F)(F)c1cc(C(F)(F)F)cc(CN(C(=O)OC)[C@@H]2c3c(N(C(=O)OCC)[C@H](CC)C2)ccc(C(F)(F)F)c3)c1		Inactive	Cholesteryl Ester Transfer Protein (CETP) Inhibitor		1	Torcetrapib	384568922.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(C(F)(F)F)cc(CN(C(=O)OC)[C@@H]2c3c(N(C(=O)OCC)[C@H](CC)C2)ccc(C(F)(F)F)c3)c1	FC(F)(F)c1cc(C(F)(F)F)cc(CN(C(=O)OC)[C@@H]2c3c(N(C(=O)OCC)[C@H](CC)C2)ccc(C(F)(F)F)c3)c1
NCGC00408924-01	FC(F)(F)c1cc(C(F)(F)F)cc(CN(Cc2c([C@H](C(C)C)N3CCC(C(=O)O)CC3)ccc(C(F)(F)F)c2)c2nn(C)nn2)c1		Inactive	Cholesteryl ester transfer protein Inhibitor		1	PF-0445597	363681087.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	17.326067004	FC(F)(F)c1cc(C(F)(F)F)cc(CN(Cc2c([C@H](C(C)C)N3CCC(C(=O)O)CC3)ccc(C(F)(F)F)c2)c2nn(C)nn2)c1	FC(F)(F)c1cc(C(F)(F)F)cc(CN(Cc2c([C@H](C(C)C)N3CCC(C(=O)O)CC3)ccc(C(F)(F)F)c2)c2nn(C)nn2)c1
NCGC00386231-04	FC(F)(F)c1cc(C(F)(F)F)cc(CN([C@@H]2c3c(N(CC4CCC(C(=O)O)CC4)CCC2)c(C)cc(C)c3)c2nn(C)nn2)c1		Inactive	Cholesteryl Ester Transfer Protein (CETP) Inhibitor		1	Evacetrapib (LY2484595)	384569117.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(C(F)(F)F)cc(CN([C@@H]2c3c(N(CC4CCC(C(=O)O)CC4)CCC2)c(C)cc(C)c3)c2nn(C)nn2)c1	FC(F)(F)c1cc(C(F)(F)F)cc(CN([C@@H]2c3c(N(CC4CCC(C(=O)O)CC4)CCC2)c(C)cc(C)c3)c2nn(C)nn2)c1
NCGC00379136-01	FC(F)(F)c1cc(C(F)(F)F)cc(CN2C(=O)COc3nccc(-c4c(F)cccc4)c3C2)c1		Inactive	G-protein coupled bile acid receptor 1 Agonist		1	GPBAR-A	363678378.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(C(F)(F)F)cc(CN2C(=O)COc3nccc(-c4c(F)cccc4)c3C2)c1	FC(F)(F)c1cc(C(F)(F)F)cc(CN2C(=O)COc3nccc(-c4c(F)cccc4)c3C2)c1
NCGC00387054-01	FC(F)(F)c1cc(C(F)(F)F)cc(COC(=O)[C@H](NC(=O)C)Cc2c3c([nH]c2)cccc3)c1		Inactive	Neurokinin 1 receptor Antagonist		1	L-732,138	363680536.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(C(F)(F)F)cc(COC(=O)[C@H](NC(=O)C)Cc2c3c([nH]c2)cccc3)c1	FC(F)(F)c1cc(C(F)(F)F)cc(COC(=O)[C@H](NC(=O)C)Cc2c3c([nH]c2)cccc3)c1
NCGC00346671-06	FC(F)(F)c1cc(C(F)(F)F)cc([C@@H]2[C@H](C)N(Cc3c(-c4c(OC)cc(F)c(C(C)C)c4)ccc(C(F)(F)F)c3)C(=O)O2)c1		Inactive	Cholesteryl Ester Transfer Protein (CETP) Inhibitor		1	Anacetrapib	384568897.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(C(F)(F)F)cc([C@@H]2[C@H](C)N(Cc3c(-c4c(OC)cc(F)c(C(C)C)c4)ccc(C(F)(F)F)c3)C(=O)O2)c1	FC(F)(F)c1cc(C(F)(F)F)cc([C@@H]2[C@H](C)N(Cc3c(-c4c(OC)cc(F)c(C(C)C)c4)ccc(C(F)(F)F)c3)C(=O)O2)c1
NCGC00167574-03	FC(F)(F)c1cc(C2=CCN(CCc3cc4c(cc3)cccc4)CC2)ccc1		Inactive	Serotonin 1a (5-HT1a) receptor Agonist		1	Xaliproden hydrochloride	170465603.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(C2=CCN(CCc3cc4c(cc3)cccc4)CC2)ccc1.Cl	FC(F)(F)c1cc(C2=CCN(CCc3cc4c(cc3)cccc4)CC2)ccc1.Cl
NCGC00485180-01	FC(F)(F)c1cc(C2C(C#N)=C(N)Oc3c2ccc(N(C)C)c3)ccc1		Inactive	Peroxisomal multifunctional enzyme type 2 Binding Agent		1	Chromeceptin	363681249.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	24.7214411281	FC(F)(F)c1cc(C2C(C#N)=C(N)Oc3c2ccc(N(C)C)c3)ccc1	FC(F)(F)c1cc(C2C(C#N)=C(N)Oc3c2ccc(N(C)C)c3)ccc1
NCGC00263019-01	FC(F)(F)c1cc(C2CCN(C(=O)[C@@]([C@H](c3c(OC)cccc3)c3c4c(ccc3)cccc4)(C#N)C)CC2)ccc1		Inactive	NF-kappaB Activation Inhibitor		1	WAY-204688	137275923.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(C2CCN(C(=O)[C@@]([C@H](c3c(OC)cccc3)c3c4c(ccc3)cccc4)(C#N)C)CC2)ccc1	FC(F)(F)c1cc(C2CCN(C(=O)[C@@]([C@H](c3c(OC)cccc3)c3c4c(ccc3)cccc4)(C#N)C)CC2)ccc1
NCGC00387308-01	FC(F)(F)c1cc(C=2c3sc(C(=N)NC4CCS(=O)(=O)CC4)cc3C(=O)N(CC)C=2)ccc1		Inactive			1	GSK602		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(C=2c3sc(C(=N)NC4CCS(=O)(=O)CC4)cc3C(=O)N(CC)C=2)ccc1	FC(F)(F)c1cc(C=2c3sc(C(=N)NC4CCS(=O)(=O)CC4)cc3C(=O)N(CC)C=2)ccc1
NCGC00346070-02	FC(F)(F)c1cc(CC(=O)N2c3c(cc(-c4c5c(N)ncnc5n(C)c4)cc3)CC2)ccc1		Inactive	PERK Inhibitor		1	GSK-2606414	384568773.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(CC(=O)N2c3c(cc(-c4c5c(N)ncnc5n(C)c4)cc3)CC2)ccc1	FC(F)(F)c1cc(CC(=O)N2c3c(cc(-c4c5c(N)ncnc5n(C)c4)cc3)CC2)ccc1
NCGC00181002-04&NCGC00181002-10	FC(F)(F)c1cc(CCCN[C@H](C)c2c3c(ccc2)cccc3)ccc1		Inactive	Calcium-Sensing Receptor (CaSR) Agonist		2	Cinacalcet hydrochloride	170465336.0&384568386.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	-7.860335196&0.0&-8.4468822119	FC(F)(F)c1cc(CCCN[C@H](C)c2c3c(ccc2)cccc3)ccc1.Cl	FC(F)(F)c1cc(CCCN[C@H](C)c2c3c(ccc2)cccc3)ccc1.Cl&FC(F)(F)c1cc(CCCN[C@H](C)c2c3c(ccc2)cccc3)ccc1
NCGC00379216-03	FC(F)(F)c1cc(CN2C(=O)CSc3c2cccc3)ccc1		Inactive	Intermediate conductance calcium-activated potassium channel protein 4 Blocker		1	NS6180	363678424.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(CN2C(=O)CSc3c2cccc3)ccc1	FC(F)(F)c1cc(CN2C(=O)CSc3c2cccc3)ccc1
NCGC00378815-01	FC(F)(F)c1cc(CNc2nc(NCc3ccc([N+](=O)[O-])cc3)c3nc[nH]c3n2)ccc1		Inactive	Inositol-trisphosphate 3-kinase A Inhibitor		1	TNP	363678215.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(CNc2nc(NCc3ccc([N+](=O)[O-])cc3)c3nc[nH]c3n2)ccc1	FC(F)(F)c1cc(CNc2nc(NCc3ccc([N+](=O)[O-])cc3)c3nc[nH]c3n2)ccc1
NCGC00487170-01	FC(F)(F)c1cc(CNc2ncnc3n(C(C)C)cnc23)ccc1		Inactive			1	Longdaysin	377020297.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(CNc2ncnc3n(C(C)C)cnc23)ccc1	FC(F)(F)c1cc(CNc2ncnc3n(C(C)C)cnc23)ccc1
NCGC00345800-03	FC(F)(F)c1cc(Cn2ncc(-c3[nH]c4C(=O)N(CCC)C(=O)N(CC)c4n3)c2)ccc1		Inactive	Adenosine A2B Antagonist		1	CVT-6883	384568749.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(Cn2ncc(-c3[nH]c4C(=O)N(CCC)C(=O)N(CC)c4n3)c2)ccc1	FC(F)(F)c1cc(Cn2ncc(-c3[nH]c4C(=O)N(CCC)C(=O)N(CC)c4n3)c2)ccc1
NCGC00263216-02	FC(F)(F)c1cc(N2C(=O)C=Cc3c2c2c(nc3)ccc(-c3cnc(N)cc3)c2)ccc1		Inactive	mTOR Inhibitor		1	Torin-2	174006464.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		FC(F)(F)c1cc(N2C(=O)C=Cc3c2c2c(nc3)ccc(-c3cnc(N)cc3)c2)ccc1	FC(F)(F)c1cc(N2C(=O)C=Cc3c2c2c(nc3)ccc(-c3cnc(N)cc3)c2)ccc1
NCGC00370713-04	FC(F)(F)c1cc(N2CCN(C=3NC(=O)N(C(=O)C=3)C3CCCCC3)CC2)ccc1		Inactive	Orphan nuclear receptor LRH-1 Inverse Agonist		1	ML179	363677820.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(N2CCN(C=3NC(=O)N(C(=O)C=3)C3CCCCC3)CC2)ccc1	FC(F)(F)c1cc(N2CCN(C=3NC(=O)N(C(=O)C=3)C3CCCCC3)CC2)ccc1
NCGC00386567-02	FC(F)(F)c1cc(N2CCN(CCN3C(=O)Nc4c3cccc4)CC2)ccc1		Inactive	Serotonin 2a (5-HT2a) receptor Antagonist		1	FLIBANSERIN	405558804.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(N2CCN(CCN3C(=O)Nc4c3cccc4)CC2)ccc1	FC(F)(F)c1cc(N2CCN(CCN3C(=O)Nc4c3cccc4)CC2)ccc1
NCGC00499575-01	FC(F)(F)c1cc(N2[C@H]3CN(c4ncc(C(=O)NO)cn4)[C@@H](C2)C3)ncc1		Inactive	HDAC Inhibitor		1	HDACi-02	384569307.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(N2[C@H]3CN(c4ncc(C(=O)NO)cn4)[C@@H](C2)C3)ncc1	FC(F)(F)c1cc(N2[C@H]3CN(c4ncc(C(=O)NO)cn4)[C@@H](C2)C3)ncc1
NCGC00125924-01	FC(F)(F)c1cc(NC(=O)CN2C(=O)C(CNc3ccc(C)cc3)=Cc3c2cc(OC)cc3)ccc1		Inactive			1	NCGC00125924-01	24401307.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(NC(=O)CN2C(=O)C(CNc3ccc(C)cc3)=Cc3c2cc(OC)cc3)ccc1	FC(F)(F)c1cc(NC(=O)CN2C(=O)C(CNc3ccc(C)cc3)=Cc3c2cc(OC)cc3)ccc1
NCGC00481611-02	FC(F)(F)c1cc(NC(=O)Nc2c(F)cc(-c3c(COC)c(CN4CCOCC4)n4N=CN=C(N)c34)cc2)c(F)cc1		Inactive	FGFR Inhibitor		1	ACTB-1003	377020235.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	22.0623969199	FC(F)(F)c1cc(NC(=O)Nc2c(F)cc(-c3c(COC)c(CN4CCOCC4)n4N=CN=C(N)c34)cc2)c(F)cc1	FC(F)(F)c1cc(NC(=O)Nc2c(F)cc(-c3c(COC)c(CN4CCOCC4)n4N=CN=C(N)c34)cc2)c(F)cc1
NCGC00384185-01	FC(F)(F)c1cc(NC(=O)Nc2c3c(c(-c4nc(C(C)C)n5c4C(N)=NC=C5)cc2)cccc3)ccc1		Inactive	Serine/threonine-protein kinase/endoribonuclease IRE1 Inhibitor		1	IRE-3	363679179.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(NC(=O)Nc2c3c(c(-c4nc(C(C)C)n5c4C(N)=NC=C5)cc2)cccc3)ccc1	FC(F)(F)c1cc(NC(=O)Nc2c3c(c(-c4nc(C(C)C)n5c4C(N)=NC=C5)cc2)cccc3)ccc1
NCGC00346936-13	FC(F)(F)c1cc(NC(=O)Nc2cc(Nc3cc4NC(=O)/C(=C\c5[nH]ccc5)/c4cc3)c(C)cc2)c(F)cc1	5.5500002	Active	Trk A/B/C Inhibitor	0.0	1	GNF-5837	384568971.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	100.6226516272	FC(F)(F)c1cc(NC(=O)Nc2cc(Nc3cc4NC(=O)/C(=C\c5[nH]ccc5)/c4cc3)c(C)cc2)c(F)cc1	FC(F)(F)c1cc(NC(=O)Nc2cc(Nc3cc4NC(=O)/C(=C\c5[nH]ccc5)/c4cc3)c(C)cc2)c(F)cc1
NCGC00242057-03	FC(F)(F)c1cc(NC(=O)Nc2ccc(-c3c(-c4ccc(OC)cc4)oc4ncnc(N)c34)cc2)c(F)cc1	4.9499998	Active	Tie-2 kinase Inhibitor	0.0	1	GW-768505A	384568485.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	46.490850379	FC(F)(F)c1cc(NC(=O)Nc2ccc(-c3c(-c4ccc(OC)cc4)oc4ncnc(N)c34)cc2)c(F)cc1	FC(F)(F)c1cc(NC(=O)Nc2ccc(-c3c(-c4ccc(OC)cc4)oc4ncnc(N)c34)cc2)c(F)cc1
NCGC00387999-01	FC(F)(F)c1cc(NC(=O)Nc2ccc(-c3nn(C(C)C)c4ncnc(N)c34)cc2)ccc1		Inactive			1	AD57 (hydrochloride)	377020207.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(NC(=O)Nc2ccc(-c3nn(C(C)C)c4ncnc(N)c34)cc2)ccc1	FC(F)(F)c1cc(NC(=O)Nc2ccc(-c3nn(C(C)C)c4ncnc(N)c34)cc2)ccc1
NCGC00263214-02	FC(F)(F)c1cc(NC(=O)c2c(C)n(CCCN3CCOCC3)c(-c3ccccc3)c2)ccc1	4.9000001	Active	TRPV4 Antagonist	0.0	1	HC-067047	363677270.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	69.8273541509	FC(F)(F)c1cc(NC(=O)c2c(C)n(CCCN3CCOCC3)c(-c3ccccc3)c2)ccc1	FC(F)(F)c1cc(NC(=O)c2c(C)n(CCCN3CCOCC3)c(-c3ccccc3)c2)ccc1
NCGC00507846-01	FC(F)(F)c1cc(NC(=O)c2c3c(cc(Oc4ncnc(CO)c4)cc3)ccc2)ccc1		Inactive	VEGFR-2 Inhibitor		1	BFH-772	384569327.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(NC(=O)c2c3c(cc(Oc4ncnc(CO)c4)cc3)ccc2)ccc1	FC(F)(F)c1cc(NC(=O)c2c3c(cc(Oc4ncnc(CO)c4)cc3)ccc2)ccc1
NCGC00347217-03	FC(F)(F)c1cc(NC(=O)c2cc(C#CC3=Cn4nccc4N=C3)c(CC)cc2)cc(CN2CCN(C)CC2)c1		Inactive	DDR1 Inhibitor		1	PRP003-013	377020175.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-11.0111773519	FC(F)(F)c1cc(NC(=O)c2cc(C#CC3=Cn4nccc4N=C3)c(CC)cc2)cc(CN2CCN(C)CC2)c1	FC(F)(F)c1cc(NC(=O)c2cc(C#CC3=Cn4nccc4N=C3)c(CC)cc2)cc(CN2CCN(C)CC2)c1
NCGC00387256-02	FC(F)(F)c1cc(NC(=O)c2cc(NC(=O)c3onc(C)c3)ccc2)ccc1		Inactive	LIM domain kinase 2 Inhibitor		1	T-5601640 (T56-LIMKi)	363680597.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(NC(=O)c2cc(NC(=O)c3onc(C)c3)ccc2)ccc1	FC(F)(F)c1cc(NC(=O)c2cc(NC(=O)c3onc(C)c3)ccc2)ccc1
NCGC00183285-06&NCGC00183285-15	FC(F)(F)c1cc(NC(=O)c2cc(Nc3nc(-c4cnccc4)ccn3)c(C)cc2)cc(-n2cc(C)nc2)c1		Inactive	Bcr-Abl Inhibitor		2	Nilotinib	384568418.0&405558616.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	14.5&0.0	FC(F)(F)c1cc(NC(=O)c2cc(Nc3nc(-c4cnccc4)ccn3)c(C)cc2)cc(-n2cc(C)nc2)c1	FC(F)(F)c1cc(NC(=O)c2cc(Nc3nc(-c4cnccc4)ccn3)c(C)cc2)cc(-n2cc(C)nc2)c1
NCGC00249391-11	FC(F)(F)c1cc(NC(=O)c2cc(Nc3nc(-c4cnccc4)nc4n(C)ncc34)c(C)cc2)ccc1	5.9000001	Active	Raf kinase B/C Inhibitor	0.0	1	NVP-BHG712	384568526.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.3	128.9819257104	FC(F)(F)c1cc(NC(=O)c2cc(Nc3nc(-c4cnccc4)nc4n(C)ncc34)c(C)cc2)ccc1	FC(F)(F)c1cc(NC(=O)c2cc(Nc3nc(-c4cnccc4)nc4n(C)ncc34)c(C)cc2)ccc1
NCGC00263199-04	FC(F)(F)c1cc(NC(=O)c2cc(Oc3c(-c4nc(NC)ncc4)cccn3)c(C)cc2)ccc1		Inactive	Tie-2 kinase Inhibitor		1	AMG-Tie2-1	384568659.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(NC(=O)c2cc(Oc3c(-c4nc(NC)ncc4)cccn3)c(C)cc2)ccc1	FC(F)(F)c1cc(NC(=O)c2cc(Oc3c(-c4nc(NC)ncc4)cccn3)c(C)cc2)ccc1
NCGC00263206-04	FC(F)(F)c1cc(NC(=O)c2cc(c(C)cc2)-c2cc3c(nc(NCCN4CCOCC4)nc3)cc2)ccc1		Inactive	Lck Kinase Inhibitor		1	AMG-47a	384568665.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(NC(=O)c2cc(c(C)cc2)-c2cc3c(nc(NCCN4CCOCC4)nc3)cc2)ccc1	FC(F)(F)c1cc(NC(=O)c2cc(c(C)cc2)-c2cc3c(nc(NCCN4CCOCC4)nc3)cc2)ccc1
NCGC00370995-10	FC(F)(F)c1cc(NC(=O)c2ccncc2)c(N2CCCCC2)cc1		Inactive	Serine/threonine-protein kinase SRPK1 Inhibitor		1	SRPIN340	363677983.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(NC(=O)c2ccncc2)c(N2CCCCC2)cc1	FC(F)(F)c1cc(NC(=O)c2ccncc2)c(N2CCCCC2)cc1
NCGC00016490-12	FC(F)(F)c1cc(Nc2c(C(=O)O)cccc2)ccc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Flufenamic acid	170465857.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	9.299607068&0.0	FC(F)(F)c1cc(Nc2c(C(=O)O)cccc2)ccc1	FC(F)(F)c1cc(Nc2c(C(=O)O)cccc2)ccc1
NCGC00016804-03	FC(F)(F)c1cc(Nc2c(C(=O)OCCOCCO)cccc2)ccc1		Inactive	lipoxygenase pathway Inhibitor		1	Etofenamate	363676491.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(Nc2c(C(=O)OCCOCCO)cccc2)ccc1	FC(F)(F)c1cc(Nc2c(C(=O)OCCOCCO)cccc2)ccc1
NCGC00167956-01	FC(F)(F)c1cc(Nc2nc(Nc3cc(NC(=O)C4CC4)ccc3)ncc2)ccc1		Inactive			1	NCGC00167956-01	50112994.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(Nc2nc(Nc3cc(NC(=O)C4CC4)ccc3)ncc2)ccc1	FC(F)(F)c1cc(Nc2nc(Nc3cc(NC(=O)C4CC4)ccc3)ncc2)ccc1
NCGC00124368-01	FC(F)(F)c1cc(Nc2nc3c(c(C)c2)cc(NC(=O)C2=CNC(=O)C=C2)cc3)ccc1		Inactive			1	NCGC00124368-01	24399751.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(Nc2nc3c(c(C)c2)cc(NC(=O)C2=CNC(=O)C=C2)cc3)ccc1	FC(F)(F)c1cc(Nc2nc3c(c(C)c2)cc(NC(=O)C2=CNC(=O)C=C2)cc3)ccc1
NCGC00124338-01	FC(F)(F)c1cc(Nc2nc3c(c(C)c2)cc(NC(=O)c2cc(OC)cc(OC)c2)cc3)ccc1		Inactive			1	NCGC00124338-01	24399721.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(Nc2nc3c(c(C)c2)cc(NC(=O)c2cc(OC)cc(OC)c2)cc3)ccc1	FC(F)(F)c1cc(Nc2nc3c(c(C)c2)cc(NC(=O)c2cc(OC)cc(OC)c2)cc3)ccc1
NCGC00167954-03	FC(F)(F)c1cc(Nc2ncnc(Nc3cc(NC(=O)C4CC4)ccc3)c2)ccc1		Inactive			1	EGFR Inhibitor	377020501.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	10.7714285759	FC(F)(F)c1cc(Nc2ncnc(Nc3cc(NC(=O)C4CC4)ccc3)c2)ccc1	FC(F)(F)c1cc(Nc2ncnc(Nc3cc(NC(=O)C4CC4)ccc3)c2)ccc1
NCGC00386294-01	FC(F)(F)c1cc(OC)cc(-c2nn(/C=C\C(=O)OC(C)C)cn2)c1		Inactive	Exportin-1 Inhibitor		1	KPT-185	363680193.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc(OC)cc(-c2nn(/C=C\C(=O)OC(C)C)cn2)c1	FC(F)(F)c1cc(OC)cc(-c2nn(/C=C\C(=O)OC(C)C)cn2)c1
NCGC00346741-02	FC(F)(F)c1cc(OC[C@H](O)/C=C/[C@@H]2[C@@H](C/C=C\CCCC(=O)OC(C)C)[C@@H](O)C[C@H]2O)ccc1		Inactive	Prostanoid TP Agonist		1	Travoprost	405558495.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc(OC[C@H](O)/C=C/[C@@H]2[C@@H](C/C=C\CCCC(=O)OC(C)C)[C@@H](O)C[C@H]2O)ccc1	FC(F)(F)c1cc(OC[C@H](O)/C=C/[C@@H]2[C@@H](C/C=C\CCCC(=O)OC(C)C)[C@@H](O)C[C@H]2O)ccc1
NCGC00386657-01	FC(F)(F)c1cc([C@H](N(C(=O)N2[C@@H](c3c(C)cc(F)cc3)C[C@@H](N3CCN(C(=O)C)CC3)CC2)C)C)cc(C(F)(F)F)c1		Inactive	Cytochrome P450 3A4 Inhibitor		1	Casopitant mesylate	363680376.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc([C@H](N(C(=O)N2[C@@H](c3c(C)cc(F)cc3)C[C@@H](N3CCN(C(=O)C)CC3)CC2)C)C)cc(C(F)(F)F)c1	FC(F)(F)c1cc([C@H](N(C(=O)N2[C@@H](c3c(C)cc(F)cc3)C[C@@H](N3CCN(C(=O)C)CC3)CC2)C)C)cc(C(F)(F)F)c1
NCGC00386593-01	FC(F)(F)c1cc([C@H](N(C(=O)N2[C@@H](c3c(C)cc(F)cc3)C[C@@H](N3C[C@H]4N(C(=O)CC4)CC3)CC2)C)C)cc(C(F)(F)F)c1		Inactive	Sigma opioid receptor Modulator		1	Orvepitant maleate	363680348.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	11.1666666639	FC(F)(F)c1cc([C@H](N(C(=O)N2[C@@H](c3c(C)cc(F)cc3)C[C@@H](N3C[C@H]4N(C(=O)CC4)CC3)CC2)C)C)cc(C(F)(F)F)c1	FC(F)(F)c1cc([C@H](N(C(=O)N2[C@@H](c3c(C)cc(F)cc3)C[C@@H](N3C[C@H]4N(C(=O)CC4)CC3)CC2)C)C)cc(C(F)(F)F)c1
NCGC00480777-01	FC(F)(F)c1cc([C@H](OC[C@]2(c3ccccc3)NC[C@]3(NC(=O)CC3)CC2)C)cc(C(F)(F)F)c1		Inactive	Tachykinin NK1 Antagonist		1	Rolapitant	384569244.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc([C@H](OC[C@]2(c3ccccc3)NC[C@]3(NC(=O)CC3)CC2)C)cc(C(F)(F)F)c1	FC(F)(F)c1cc([C@H](OC[C@]2(c3ccccc3)NC[C@]3(NC(=O)CC3)CC2)C)cc(C(F)(F)F)c1
NCGC00181785-01	FC(F)(F)c1cc([C@H](O[C@@H]2[C@@H](N(CC3=NC(=O)N=N3)CCO2)C2CCC(F)CC2)C)cc(C(F)(F)F)c1		Inactive	Tachykinin NK1 Antagonist		1	Aprepitant	50126334.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc([C@H](O[C@@H]2[C@@H](N(CC3=NC(=O)N=N3)CCO2)C2CCC(F)CC2)C)cc(C(F)(F)F)c1	FC(F)(F)c1cc([C@H](O[C@@H]2[C@@H](N(CC3=NC(=O)N=N3)CCO2)C2CCC(F)CC2)C)cc(C(F)(F)F)c1
NCGC00181785-03&NCGC00181785-11	FC(F)(F)c1cc([C@H](O[C@@H]2[C@@H](N(CC3=NC(=O)NN3)CCO2)c2ccc(F)cc2)C)cc(C(F)(F)F)c1		Inactive			2	Aprepitant	434146917.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	FC(F)(F)c1cc([C@H](O[C@@H]2[C@@H](N(CC3=NC(=O)NN3)CCO2)c2ccc(F)cc2)C)cc(C(F)(F)F)c1	FC(F)(F)c1cc([C@H](O[C@@H]2[C@@H](N(CC3=NC(=O)NN3)CCO2)c2ccc(F)cc2)C)cc(C(F)(F)F)c1
NCGC00185778-04&NCGC00185778-06	FC(F)(F)c1cc([N+](=O)[O-])c(C(=O)C2C(=O)CCCC2=O)cc1		Inactive	4-Hydroxyphenylpyruvate Dioxygenase (4HPPD) Inhibitor		2	Nitisinone	405558957.0&384568427.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	FC(F)(F)c1cc([N+](=O)[O-])c(C(=O)C2C(=O)CCCC2=O)cc1	FC(F)(F)c1cc([N+](=O)[O-])c(C(=O)C2C(=O)CCCC2=O)cc1
NCGC00346489-03	FC(F)(F)c1cc([N+](=O)[O-])c2SC(N3CCC4(OC(C)CO4)CC3)=NC(=O)c2c1		Inactive	tuberculosis pathway Inhibitor		1	BTZ-10526043	363677423.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc([N+](=O)[O-])c2SC(N3CCC4(OC(C)CO4)CC3)=NC(=O)c2c1	FC(F)(F)c1cc([N+](=O)[O-])c2SC(N3CCC4(OC(C)CO4)CC3)=NC(=O)c2c1
NCGC00532514-01	FC(F)(F)c1cc2/C(=C/CCN3CCN(CCOC(=O)CCCCCCCCC)CC3)/c3c(Sc2cc1)cccc3		Inactive	Serotonin 2 (5-HT2) receptor Antagonist		1	FLUPENTIXOL DECANOATE	405558676.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc2/C(=C/CCN3CCN(CCOC(=O)CCCCCCCCC)CC3)/c3c(Sc2cc1)cccc3	FC(F)(F)c1cc2/C(=C/CCN3CCN(CCOC(=O)CCCCCCCCC)CC3)/c3c(Sc2cc1)cccc3
NCGC00162179-08	FC(F)(F)c1cc2/C(=C\CCN3CCN(CCO)CC3)/c3c(Sc2cc1)cccc3		Inactive			1	cis-Flupentixol	170465964.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	FC(F)(F)c1cc2/C(=C\CCN3CCN(CCO)CC3)/c3c(Sc2cc1)cccc3	FC(F)(F)c1cc2/C(=C\CCN3CCN(CCO)CC3)/c3c(Sc2cc1)cccc3
NCGC00181168-01	FC(F)(F)c1cc2N(CC(CN(C)C)C)c3c(Sc2cc1)cccc3	5.0	Active		0.0	1	Trifluomeprazine 2-butenedioate	144206322.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	92.7925320277	FC(F)(F)c1cc2N(CC(CN(C)C)C)c3c(Sc2cc1)cccc3.O=C(O)C=CC(=O)O	FC(F)(F)c1cc2N(CC(CN(C)C)C)c3c(Sc2cc1)cccc3.O=C(O)C=CC(=O)O
NCGC00016012-08&NCGC00016012-12	FC(F)(F)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3	5.0250001	Active	Muscarinic acetylcholine receptor M2 Antagonist	0.25	2	Triflupromazine hydrochloride	124881619.0&170465325.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	2.4&3.0	75.2518244978&63.1093304009	FC(F)(F)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3	FC(F)(F)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3&FC(F)(F)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3.Cl
NCGC00015436-09&NCGC00015436-11&NCGC00015436-14	FC(F)(F)c1cc2N(CCCN3CCN(CCO)CC3)c3c(Sc2cc1)cccc3		Inactive	Nicotinic alpha7 Receptor Ligands		3	Fluphenazine hydrochloride	124880096.0&170465375.0&384567843.0	Anti-infectives&Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0		FC(F)(F)c1cc2N(CCCN3CCN(CCO)CC3)c3c(Sc2cc1)cccc3	FC(F)(F)c1cc2N(CCCN3CCN(CCO)CC3)c3c(Sc2cc1)cccc3
NCGC00386699-01	FC(F)(F)c1cc2N(CCCN3CCN(CCOC(=O)CCCCCCCCC)CC3)c3c(Sc2cc1)cccc3	4.9000001	Active		0.0	1	Fluphenazine decanoate dihydrochloride	405558673.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	83.0065191295	FC(F)(F)c1cc2N(CCCN3CCN(CCOC(=O)CCCCCCCCC)CC3)c3c(Sc2cc1)cccc3	FC(F)(F)c1cc2N(CCCN3CCN(CCOC(=O)CCCCCCCCC)CC3)c3c(Sc2cc1)cccc3
NCGC00522550-01	FC(F)(F)c1cc2[C@H]3O[C@@H](CNC(=O)NCCN(C)C)CC[C@H]3[C@H](c3ccccc3)Nc2cc1		Inactive	Kinesin-like Spindle Protein KIF11 (KSP; Eg5) Inhibitor		1	EMD-534085	384569525.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	23.5300410959	FC(F)(F)c1cc2[C@H]3O[C@@H](CNC(=O)NCCN(C)C)CC[C@H]3[C@H](c3ccccc3)Nc2cc1	FC(F)(F)c1cc2[C@H]3O[C@@H](CNC(=O)NCCN(C)C)CC[C@H]3[C@H](c3ccccc3)Nc2cc1
NCGC00522492-01	FC(F)(F)c1cc2nc(/C=C/C(=O)c3ccncc3)ccc2cc1		Inactive	PFKFB3 Inhibitor		1	PFK-158	384569521.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc2nc(/C=C/C(=O)c3ccncc3)ccc2cc1	FC(F)(F)c1cc2nc(/C=C/C(=O)c3ccncc3)ccc2cc1
NCGC00484072-01	FC(F)(F)c1cc2nc(CN3C(=O)c4nccnc4C(CC(=O)O)=N3)sc2cc1		Inactive	Aldose reductase Inhibitor		1	Aldose reductase-IN-1	363681164.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1cc2nc(CN3C(=O)c4nccnc4C(CC(=O)O)=N3)sc2cc1	FC(F)(F)c1cc2nc(CN3C(=O)c4nccnc4C(CC(=O)O)=N3)sc2cc1
NCGC00263134-08	FC(F)(F)c1cc2nc(CN3CCN(c4c(CC)cncn4)CC3)[nH]c2cc1		Inactive	p70 ribosomal S6 kinase (S6K1) Inhibitor		1	PF-4708671	363677221.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cc2nc(CN3CCN(c4c(CC)cncn4)CC3)[nH]c2cc1	FC(F)(F)c1cc2nc(CN3CCN(c4c(CC)cncn4)CC3)[nH]c2cc1
NCGC00386720-01	FC(F)(F)c1ccc(-c2c(C(=O)Nc3cc4c(cc3)CN(Cc3[nH]ncn3)CC4)cccc2)cc1		Inactive	ApoB Secretion Inhibitor		1	CP-346086	363680415.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1ccc(-c2c(C(=O)Nc3cc4c(cc3)CN(Cc3[nH]ncn3)CC4)cccc2)cc1	FC(F)(F)c1ccc(-c2c(C(=O)Nc3cc4c(cc3)CN(Cc3[nH]ncn3)CC4)cccc2)cc1
NCGC00538141-01	FC(F)(F)c1ccc(-c2c(C(=O)Nc3cc4c(n(C)c(C(=O)N[C@@H](C(=O)N(Cc5ccccc5)C)c5ccccc5)c4)cc3)cccc2)cc1		Inactive	Microsomal triglyceride transfer protein Inhibitor		1	NCGC00538141-01	405558747.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1ccc(-c2c(C(=O)Nc3cc4c(n(C)c(C(=O)N[C@@H](C(=O)N(Cc5ccccc5)C)c5ccccc5)c4)cc3)cccc2)cc1	FC(F)(F)c1ccc(-c2c(C(=O)Nc3cc4c(n(C)c(C(=O)N[C@@H](C(=O)N(Cc5ccccc5)C)c5ccccc5)c4)cc3)cccc2)cc1
NCGC00370782-01	FC(F)(F)c1ccc(-c2c(C(N3CCC(C)CC3)c3ccc(F)cc3)ccc(C(C(=O)O)C)c2)cc1	4.9499998	Active	Gamma-secretase Modulator	0.0	1	TC-E 5006	363677853.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	61.9812374599	FC(F)(F)c1ccc(-c2c(C(N3CCC(C)CC3)c3ccc(F)cc3)ccc(C(C(=O)O)C)c2)cc1	FC(F)(F)c1ccc(-c2c(C(N3CCC(C)CC3)c3ccc(F)cc3)ccc(C(C(=O)O)C)c2)cc1
NCGC00386948-01	FC(F)(F)c1ccc(-c2cc(COc3ccc([C@@H](C#CC)CC(=O)O)cc3)ccc2)cc1	4.9499998	Active	Free Fatty Acid Receptor 1 (FFAR1; GPR40) Agonist	0.0	1	AMG-837	363680520.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	103.7041030028	FC(F)(F)c1ccc(-c2cc(COc3ccc([C@@H](C#CC)CC(=O)O)cc3)ccc2)cc1	FC(F)(F)c1ccc(-c2cc(COc3ccc([C@@H](C#CC)CC(=O)O)cc3)ccc2)cc1
NCGC00370685-02	FC(F)(F)c1ccc(-c2cc([C@@H](C(=O)O)CC(C)C)cc(-c3ccc(C(F)(F)F)cc3)c2)cc1		Inactive	Gamma-secretase Inhibitor		1	JNJ-40418677	363677808.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1ccc(-c2cc([C@@H](C(=O)O)CC(C)C)cc(-c3ccc(C(F)(F)F)cc3)c2)cc1	FC(F)(F)c1ccc(-c2cc([C@@H](C(=O)O)CC(C)C)cc(-c3ccc(C(F)(F)F)cc3)c2)cc1
NCGC00386667-01	FC(F)(F)c1ccc(-c2cc3c(c(-c4ccc(C5CCNCC5)cc4)cc(C(=O)OCC(=O)N(C)C)c3)cc2)cc1		Inactive	Purinergic receptor P2Y14 Antagonist		1	P2Y14 Antagonist Prodrug 7j hydrochloride	363680383.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1ccc(-c2cc3c(c(-c4ccc(C5CCNCC5)cc4)cc(C(=O)OCC(=O)N(C)C)c3)cc2)cc1	FC(F)(F)c1ccc(-c2cc3c(c(-c4ccc(C5CCNCC5)cc4)cc(C(=O)OCC(=O)N(C)C)c3)cc2)cc1
NCGC00522470-01	FC(F)(F)c1ccc(-c2ccc(-c3n(-c4ccc(N5CCNCC5)cc4)nc(CCC(=O)NC)c3)cc2)cc1		Inactive	ILK Inhibitor		1	OSU-T315	384569519.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1ccc(-c2ccc(-c3n(-c4ccc(N5CCNCC5)cc4)nc(CCC(=O)NC)c3)cc2)cc1	FC(F)(F)c1ccc(-c2ccc(-c3n(-c4ccc(N5CCNCC5)cc4)nc(CCC(=O)NC)c3)cc2)cc1
NCGC00356149-01	FC(F)(F)c1ccc(-c2n3c(nc2)C=NC(C(=O)N(C)c2ccc(C#N)cc2)=C3)cc1		Inactive			1	NCGC00356149-01	377020242.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1ccc(-c2n3c(nc2)C=NC(C(=O)N(C)c2ccc(C#N)cc2)=C3)cc1	FC(F)(F)c1ccc(-c2n3c(nc2)C=NC(C(=O)N(C)c2ccc(C#N)cc2)=C3)cc1
NCGC00384350-01	FC(F)(F)c1ccc(-c2nc(C=3C(=O)N(c4c(CC)cccc4CC)C(C=C(C)C)=C(C(=O)N4CCNCC4)C=3)sc2)cc1	5.25	Active		0.0	1	NCGC00384350-01	363679203.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	3.0	120.0313620895	FC(F)(F)c1ccc(-c2nc(C=3C(=O)N(c4c(CC)cccc4CC)C(C=C(C)C)=C(C(=O)N4CCNCC4)C=3)sc2)cc1	FC(F)(F)c1ccc(-c2nc(C=3C(=O)N(c4c(CC)cccc4CC)C(C=C(C)C)=C(C(=O)N4CCNCC4)C=3)sc2)cc1
NCGC00250397-04	FC(F)(F)c1ccc(-c2nc(O)c3c(n2)CCSC3)cc1		Inactive	TNKS1/TNKS2 Inhibitor		1	NVP-XAV-939	384568546.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1ccc(-c2nc(O)c3c(n2)CCSC3)cc1	FC(F)(F)c1ccc(-c2nc(O)c3c(n2)CCSC3)cc1
NCGC00387491-01	FC(F)(F)c1ccc(-c2ncn(-c3c(NC)ccc([N+](=O)[O-])c3)c2)cc1		Inactive	Toll-like receptor 2 Agonist		1	CU-T12-9	363680642.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1ccc(-c2ncn(-c3c(NC)ccc([N+](=O)[O-])c3)c2)cc1	FC(F)(F)c1ccc(-c2ncn(-c3c(NC)ccc([N+](=O)[O-])c3)c2)cc1
NCGC00386259-04	FC(F)(F)c1ccc(-c2ncnc(Oc3c4nc(NC(=O)C)sc4ccc3)c2)cc1		Inactive	Vanilloid receptor Antagonist		1	AMG517	363680171.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1ccc(-c2ncnc(Oc3c4nc(NC(=O)C)sc4ccc3)c2)cc1	FC(F)(F)c1ccc(-c2ncnc(Oc3c4nc(NC(=O)C)sc4ccc3)c2)cc1
NCGC00018193-11	FC(F)(F)c1ccc(/C(=N/OCCN)/CCCCOC)cc1		Inactive	5-HT Reuptake Inhibitor		1	Fluvoxamine	170464809.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	18.7127243879&29.439524832	FC(F)(F)c1ccc(/C(=N/OCCN)/CCCCOC)cc1	FC(F)(F)c1ccc(/C(=N/OCCN)/CCCCOC)cc1
NCGC00346582-03	FC(F)(F)c1ccc(/C=C/c2occ(COc3ccc(CCCCn4nncc4)cc3)n2)cc1		Inactive	HER2 Inhibitor		1	Mubritinib	384568851.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1ccc(/C=C/c2occ(COc3ccc(CCCCn4nncc4)cc3)n2)cc1	FC(F)(F)c1ccc(/C=C/c2occ(COc3ccc(CCCCn4nncc4)cc3)n2)cc1
NCGC00165799-03	FC(F)(F)c1ccc(C(=O)/C=C(\N[C@H](CNC(=O)CC)Cc2ccc(OCCc3c(C)oc(-c4ccccc4)n3)cc2)/C)cc1		Inactive	PPARalpha Antagonist		1	GW-6471	384568284.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1ccc(C(=O)/C=C(\N[C@H](CNC(=O)CC)Cc2ccc(OCCc3c(C)oc(-c4ccccc4)n3)cc2)/C)cc1	FC(F)(F)c1ccc(C(=O)/C=C(\N[C@H](CNC(=O)CC)Cc2ccc(OCCc3c(C)oc(-c4ccccc4)n3)cc2)/C)cc1
NCGC00345797-02	FC(F)(F)c1ccc(C(=O)Nc2ccc(Cc3nc(N(C)C)c(CC(=O)O)c(N(C)C)n3)cc2)cc1		Inactive	prostaglandin D2 CRTH2 inhibitor		1	AP-761	363677361.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1ccc(C(=O)Nc2ccc(Cc3nc(N(C)C)c(CC(=O)O)c(N(C)C)n3)cc2)cc1	FC(F)(F)c1ccc(C(=O)Nc2ccc(Cc3nc(N(C)C)c(CC(=O)O)c(N(C)C)n3)cc2)cc1
NCGC00183000-01	FC(F)(F)c1ccc(C(=O)[C@@H](CN2CCCC2)C)cc1		Inactive	Sodium channel alpha subunit Binding Agent		1	Lanperisone hydrochloride	144206892.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	FC(F)(F)c1ccc(C(=O)[C@@H](CN2CCCC2)C)cc1	FC(F)(F)c1ccc(C(=O)[C@@H](CN2CCCC2)C)cc1
NCGC00025099-02	FC(F)(F)c1ccc(C(OCCN2CC(C(=O)O)=CCC2)c2ccc(C(F)(F)F)cc2)cc1		Inactive	GAT-1 Inhibitor		1	CI-966	384568048.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1ccc(C(OCCN2CC(C(=O)O)=CCC2)c2ccc(C(F)(F)F)cc2)cc1	FC(F)(F)c1ccc(C(OCCN2CC(C(=O)O)=CCC2)c2ccc(C(F)(F)F)cc2)cc1
NCGC00481596-01	FC(F)(F)c1ccc(C/N=C\2/NC=C(Cc3c4c([nH]c3)nccc4)C=C/2)cc1		Inactive	cKit Inhibitor		1	PLX-647	377020230.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1ccc(C/N=C\2/NC=C(Cc3c4c([nH]c3)nccc4)C=C/2)cc1	FC(F)(F)c1ccc(C/N=C\2/NC=C(Cc3c4c([nH]c3)nccc4)C=C/2)cc1
NCGC00371145-02	FC(F)(F)c1ccc(C2=NN(C)C3=NC(=O)N(C)C(=O)C3=N2)cc1	5.0	Active	Transcriptional regulatory protein YycF Inhibitor	0.0	1	Walrycin B	363678059.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	45.8685660134	FC(F)(F)c1ccc(C2=NN(C)C3=NC(=O)N(C)C(=O)C3=N2)cc1	FC(F)(F)c1ccc(C2=NN(C)C3=NC(=O)N(C)C(=O)C3=N2)cc1
NCGC00378431-08	FC(F)(F)c1ccc(C2C(C#N)=C(N)Oc3n(C)nc(C)c23)cc1		Inactive	Ral GTPase Inhibitor		1	BQU-57	363678080.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1ccc(C2C(C#N)=C(N)Oc3n(C)nc(C)c23)cc1	FC(F)(F)c1ccc(C2C(C#N)=C(N)Oc3n(C)nc(C)c23)cc1
NCGC00346096-02	FC(F)(F)c1ccc(C2C(C(=O)Nc3c(F)cc4[nH]ncc4c3)=C(C)NC(=O)C2)cc1		Inactive	ROCK 1, ROCK 2 Inhibitor		1	GSK-429286A	174006479.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1ccc(C2C(C(=O)Nc3c(F)cc4[nH]ncc4c3)=C(C)NC(=O)C2)cc1	FC(F)(F)c1ccc(C2C(C(=O)Nc3c(F)cc4[nH]ncc4c3)=C(C)NC(=O)C2)cc1
NCGC00379172-01	FC(F)(F)c1ccc(C2N(C(=O)Nc3ccc(F)cc3)CCc3c2cccc3)cc1		Inactive	Transient receptor potential cation channel subfamily M member 8 Blocker		1	TC-I 2000	363678397.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1ccc(C2N(C(=O)Nc3ccc(F)cc3)CCc3c2cccc3)cc1	FC(F)(F)c1ccc(C2N(C(=O)Nc3ccc(F)cc3)CCc3c2cccc3)cc1
NCGC00378603-03	FC(F)(F)c1ccc(CC[C@@H]2N([C@@H](C(=O)NC)c3ccccc3)CCc3c2cc(OC)c(OC)c3)cc1		Inactive	Orexin receptor Antagonist		1	Almorexant HCl	363678118.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1ccc(CC[C@@H]2N([C@@H](C(=O)NC)c3ccccc3)CCc3c2cc(OC)c(OC)c3)cc1	FC(F)(F)c1ccc(CC[C@@H]2N([C@@H](C(=O)NC)c3ccccc3)CCc3c2cc(OC)c(OC)c3)cc1
NCGC00263123-02	FC(F)(F)c1ccc(CNC(=O)c2c(OC)ccc(CC3C(=O)NC(=O)S3)c2)cc1		Inactive	PPARalpha/gamma Agonist		1	MK-767	384568606.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	10.0167363959	FC(F)(F)c1ccc(CNC(=O)c2c(OC)ccc(CC3C(=O)NC(=O)S3)c2)cc1	FC(F)(F)c1ccc(CNC(=O)c2c(OC)ccc(CC3C(=O)NC(=O)S3)c2)cc1
NCGC00379051-02	FC(F)(F)c1ccc(Cc2c(C(=O)NC3(c4ccc(C(=O)O)cc4)CC3)c(C)sc2C)cc1		Inactive	Prostanoid EP4 receptor Antagonist		1	MK-2894	363678329.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1ccc(Cc2c(C(=O)NC3(c4ccc(C(=O)O)cc4)CC3)c(C)sc2C)cc1	FC(F)(F)c1ccc(Cc2c(C(=O)NC3(c4ccc(C(=O)O)cc4)CC3)c(C)sc2C)cc1
NCGC00379032-06	FC(F)(F)c1ccc(N(C(=O)C=2C(=O)N(C)c3c(c(OC)ccc3)C=2O)C)cc1		Inactive	S100A9 Inhibitor		1	Tasquinimod	384569088.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	FC(F)(F)c1ccc(N(C(=O)C=2C(=O)N(C)c3c(c(OC)ccc3)C=2O)C)cc1	FC(F)(F)c1ccc(N(C(=O)C=2C(=O)N(C)c3c(c(OC)ccc3)C=2O)C)cc1
NCGC00263218-07&NCGC00263218-08	FC(F)(F)c1ccc(NC(=O)/C(/C#N)=C(\O)/C)cc1		Inactive	DHODH Inhibitor		2	Teriflunomide	405558506.0&384568672.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	FC(F)(F)c1ccc(NC(=O)/C(/C#N)=C(\O)/C)cc1	FC(F)(F)c1ccc(NC(=O)/C(/C#N)=C(\O)/C)cc1
NCGC00015610-17&NCGC00015610-29	FC(F)(F)c1ccc(NC(=O)c2c(C)onc2)cc1		Inactive	DHODH Inhibitor		2	Leflunomide	170464823.0&384567875.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	FC(F)(F)c1ccc(NC(=O)c2c(C)onc2)cc1	FC(F)(F)c1ccc(NC(=O)c2c(C)onc2)cc1
NCGC00015428-15	FC(F)(F)c1ccc(OC(CCNC)c2ccccc2)cc1	5.3499999	Active	Serotonin transporter Inhibitor	0.0	1	(+/-) -Fluoxetine	170465374.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	96.2234766766	FC(F)(F)c1ccc(OC(CCNC)c2ccccc2)cc1	FC(F)(F)c1ccc(OC(CCNC)c2ccccc2)cc1
NCGC00182549-04	FC(F)(F)c1ccc([C@H](COC)N2[C@@H](C)CN(C3(C)CCN(C(=O)c4c(C)ncnc4C)CC3)CC2)cc1		Inactive	Chemokine CCR5 Antagonist		1	Vicriviroc (SCH-417690)	384568410.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	9.0227140319&0.0	FC(F)(F)c1ccc([C@H](COC)N2[C@@H](C)CN(C3(C)CCN(C(=O)c4c(C)ncnc4C)CC3)CC2)cc1	FC(F)(F)c1ccc([C@H](COC)N2[C@@H](C)CN(C3(C)CCN(C(=O)c4c(C)ncnc4C)CC3)CC2)cc1
NCGC00378983-02	FC(F)(F)c1cnc(Oc2cc(C=C3CCN(C(=O)Nc4nnccc4)CC3)ccc2)cc1		Inactive	Fatty Acid Amide Hydrolase (FAAH) Inhibitor		1	PF-04457845	384569083.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cnc(Oc2cc(C=C3CCN(C(=O)Nc4nnccc4)CC3)ccc2)cc1	FC(F)(F)c1cnc(Oc2cc(C=C3CCN(C(=O)Nc4nnccc4)CC3)ccc2)cc1
NCGC00263131-05	FC(F)(F)c1cnc(Oc2cc(CC3CCN(C(=O)Nc4cnccc4)CC3)ccc2)cc1		Inactive	Fatty Acid Amide Hydrolase (FAAH) Inhibitor		1	PF-3845	384568611.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cnc(Oc2cc(CC3CCN(C(=O)Nc4cnccc4)CC3)ccc2)cc1	FC(F)(F)c1cnc(Oc2cc(CC3CCN(C(=O)Nc4cnccc4)CC3)ccc2)cc1
NCGC00378765-02	FC(F)(F)c1cnc2c(c1)CN(C(=O)[C@]1(C(C)C)C[C@H](N[C@@H]3[C@H](OC)COCC3)CC1)CC2		Inactive	Chemokine CCR2 (MCP-1 Receptor) Antagonist		1	MK-0812	363678186.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1cnc2c(c1)CN(C(=O)[C@]1(C(C)C)C[C@H](N[C@@H]3[C@H](OC)COCC3)CC1)CC2	FC(F)(F)c1cnc2c(c1)CN(C(=O)[C@]1(C(C)C)C[C@H](N[C@@H]3[C@H](OC)COCC3)CC1)CC2
NCGC00485880-01	FC(F)(F)c1n(-c2ccc(N)cc2)nc(C(F)(F)F)c1		Inactive			1	CRAC intermediate 2	363681389.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1n(-c2ccc(N)cc2)nc(C(F)(F)F)c1	FC(F)(F)c1n(-c2ccc(N)cc2)nc(C(F)(F)F)c1
NCGC00390662-01	FC(F)(F)c1n(-c2ccc(NC(=O)c3c(F)cncc3)cc2)nc(C(F)(F)F)c1		Inactive	Short transient receptor potential channel 3 Inhibitor		1	Pyr6	363680963.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	27.0	FC(F)(F)c1n(-c2ccc(NC(=O)c3c(F)cncc3)cc2)nc(C(F)(F)F)c1	FC(F)(F)c1n(-c2ccc(NC(=O)c3c(F)cncc3)cc2)nc(C(F)(F)F)c1
NCGC00484068-01	FC(F)(F)c1n(CCNC(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)c2c(c1)cccc2		Inactive	Prostaglandin E2 receptor EP2 subtype Antagonist		1	TG6-10-1	363681160.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1n(CCNC(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)c2c(c1)cccc2	FC(F)(F)c1n(CCNC(=O)/C=C/c2cc(OC)c(OC)c(OC)c2)c2c(c1)cccc2
NCGC00386284-05	FC(F)(F)c1n2N=C(N3CCC(c4ccc(OCCN5CCN(C(=O)C)CC5)cc4)CC3)CCc2nn1		Inactive	Drugs Acting on Androgen Receptor		1	AZD-3514	363680185.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1n2N=C(N3CCC(c4ccc(OCCN5CCN(C(=O)C)CC5)cc4)CC3)CCc2nn1	FC(F)(F)c1n2N=C(N3CCC(c4ccc(OCCN5CCN(C(=O)C)CC5)cc4)CC3)CCc2nn1
NCGC00178734-06&NCGC00178734-10&NCGC00178734-13	FC(F)(F)c1n2c(nn1)CN(C(=O)C[C@H](N)Cc1c(F)cc(F)c(F)c1)CC2		Inactive	DPP-IV Inhibitor		3	Sitagliptin	405558639.0&384568363.0&434147051.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	FC(F)(F)c1n2c(nn1)CN(C(=O)C[C@H](N)Cc1c(F)cc(F)c(F)c1)CC2	FC(F)(F)c1n2c(nn1)CN(C(=O)C[C@H](N)Cc1c(F)cc(F)c(F)c1)CC2
NCGC00370781-01	FC(F)(F)c1n2c(nn1)CN(C(=O)C[C@H](N)Cc1n[nH]c3c(F)c(F)ccc13)CC2		Inactive	Dipeptidyl peptidase 4 Inhibitor		1	PK 44 phosphate	363677852.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1n2c(nn1)CN(C(=O)C[C@H](N)Cc1n[nH]c3c(F)c(F)ccc13)CC2	FC(F)(F)c1n2c(nn1)CN(C(=O)C[C@H](N)Cc1n[nH]c3c(F)c(F)ccc13)CC2
NCGC00250407-05	FC(F)(F)c1nc(-c2nccc(Oc3cc4nc(Nc5ccc(C(F)(F)F)cc5)n(C)c4cc3)c2)[nH]c1	5.8000002	Active	Raf kinase B/C Inhibitor	0.0	1	CHIR-265	384568555.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	65.689064874	FC(F)(F)c1nc(-c2nccc(Oc3cc4nc(Nc5ccc(C(F)(F)F)cc5)n(C)c4cc3)c2)[nH]c1	FC(F)(F)c1nc(-c2nccc(Oc3cc4nc(Nc5ccc(C(F)(F)F)cc5)n(C)c4cc3)c2)[nH]c1
NCGC00408901-01	FC(F)(F)c1nc2-n3c(nc(-c4ocnn4)c3)C=Cc2c(C(F)(F)F)c1		Inactive	Interferon alpha/beta receptor 2 Agonist		1	RO8191	363681077.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	14.5	FC(F)(F)c1nc2-n3c(nc(-c4ocnn4)c3)C=Cc2c(C(F)(F)F)c1	FC(F)(F)c1nc2-n3c(nc(-c4ocnn4)c3)C=Cc2c(C(F)(F)F)c1
NCGC00094994-10	FC(F)(F)c1nc2c(C(F)(F)F)cccc2c(C(O)C2NCCCC2)c1	4.9499998	Active		0.0	1	MEFLOQUINE	384568139.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	72.4867642812	FC(F)(F)c1nc2c(C(F)(F)F)cccc2c(C(O)C2NCCCC2)c1	FC(F)(F)c1nc2c(C(F)(F)F)cccc2c(C(O)C2NCCCC2)c1
NCGC00378933-01	FC(F)(F)c1ncc(Nc2cnc(-c3ccc(C4CCC(CC(=O)O)CC4)cc3)cc2)cc1		Inactive	Diacylglycerol Acyltransferase Type 1 (DGAT-1) Inhibitor		1	Pradigastat	363678285.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.9007212559	FC(F)(F)c1ncc(Nc2cnc(-c3ccc(C4CCC(CC(=O)O)CC4)cc3)cc2)cc1	FC(F)(F)c1ncc(Nc2cnc(-c3ccc(C4CCC(CC(=O)O)CC4)cc3)cc2)cc1
NCGC00479249-03	FC(F)(F)c1nccc(Nc2nc(NCC(O)(C)C)nc(-c3nc(C(F)(F)F)ccc3)n2)c1		Inactive	IDH1 Inhibitor		1	Enasidenib	363681106.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	21.421370972&23.0&14.5909732	FC(F)(F)c1nccc(Nc2nc(NCC(O)(C)C)nc(-c3nc(C(F)(F)F)ccc3)n2)c1	FC(F)(F)c1nccc(Nc2nc(NCC(O)(C)C)nc(-c3nc(C(F)(F)F)ccc3)n2)c1
NCGC00346633-03	FC(F)(F)c1nn(-c2cc(NC3CCC(O)CC3)c(C(=O)N)cc2)c2c1C(=O)CC(C)(C)C2		Inactive	Heat Shock Protein 90 (hsp90) Inhibitor		1	SNX-2112		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	31.1370142138	FC(F)(F)c1nn(-c2cc(NC3CCC(O)CC3)c(C(=O)N)cc2)c2c1C(=O)CC(C)(C)C2	FC(F)(F)c1nn(-c2cc(NC3CCC(O)CC3)c(C(=O)N)cc2)c2c1C(=O)CC(C)(C)C2
NCGC00346490-06	FC(F)(F)c1nn(c(-c2cc3c(c4c(cc3)cccc4)cc2)c1)-c1ccc(NC(=O)CN)cc1		Inactive	Phosphoinositide Dependent Kinase Inhibitor		1	OSU-03012	384568798.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		FC(F)(F)c1nn(c(-c2cc3c(c4c(cc3)cccc4)cc2)c1)-c1ccc(NC(=O)CN)cc1	FC(F)(F)c1nn(c(-c2cc3c(c4c(cc3)cccc4)cc2)c1)-c1ccc(NC(=O)CN)cc1
NCGC00386644-01	FC(F)(F)c1nnc(NC2CCN(Cc3cc(F)c(F)cc3)CC2)cc1		Inactive	Dopamine D2 receptor Antagonist		1	JNJ 37822681 dihydrochloride	363680371.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)(F)c1nnc(NC2CCN(Cc3cc(F)c(F)cc3)CC2)cc1	FC(F)(F)c1nnc(NC2CCN(Cc3cc(F)c(F)cc3)CC2)cc1
NCGC00507884-01	FC(F)(F)c1oc(-c2cnc(N3CCC(n4c(C(=O)NC(C)(C)C)cnc4)CC3)cc2)nn1		Inactive	WNK kinase Inhibitor		1	WNK-463	384569349.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1oc(-c2cnc(N3CCC(n4c(C(=O)NC(C)(C)C)cnc4)CC3)cc2)nn1	FC(F)(F)c1oc(-c2cnc(N3CCC(n4c(C(=O)NC(C)(C)C)cnc4)CC3)cc2)nn1
NCGC00378626-06	FC(F)(F)c1onc(-c2cc(C(=O)NCC3(c4scc(-c5ccccc5)n4)CCOCC3)ccc2)n1		Inactive	Histone deacetylase 9 Inhibitor		1	TMP269	363678130.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1onc(-c2cc(C(=O)NCC3(c4scc(-c5ccccc5)n4)CCOCC3)ccc2)n1	FC(F)(F)c1onc(-c2cc(C(=O)NCC3(c4scc(-c5ccccc5)n4)CCOCC3)ccc2)n1
NCGC00253627-01	FC(F)(F)c1onc(-c2cc(C)c(OCCCc3onc(C)c3)c(C)c2)n1		Inactive	Human rhinovirus A protease Inhibitor		1	Pleconaril	170466405.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1onc(-c2cc(C)c(OCCCc3onc(C)c3)c(C)c2)n1	FC(F)(F)c1onc(-c2cc(C)c(OCCCc3onc(C)c3)c(C)c2)n1
NCGC00165952-05	FC(F)(F)c1sc(NC(=O)/C(/C#N)=C/c2cc(OC)c(OCc3c(C(F)(F)F)cc(C(F)(F)F)cc3)cc2)nn1		Inactive	Estrogen-Related Receptor alpha (ERRalpha, ERR1) Inverse Agonist		1	XCT-790	384568300.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(F)c1sc(NC(=O)/C(/C#N)=C/c2cc(OC)c(OCc3c(C(F)(F)F)cc(C(F)(F)F)cc3)cc2)nn1	FC(F)(F)c1sc(NC(=O)/C(/C#N)=C/c2cc(OC)c(OCc3c(C(F)(F)F)cc(C(F)(F)F)cc3)cc2)nn1
NCGC00263189-06	FC(F)(c1n2N=C(c3cn(C)nc3)C=Cc2nn1)c1cc2c(nccc2)cc1		Inactive	HGFR Inhibitor		1	JNJ-38877605	363677254.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)(c1n2N=C(c3cn(C)nc3)C=Cc2nn1)c1cc2c(nccc2)cc1	FC(F)(c1n2N=C(c3cn(C)nc3)C=Cc2nn1)c1cc2c(nccc2)cc1
NCGC00015316-05&NCGC00015316-08	FC(F)C(N)(C(=O)O)CCCN		Inactive	Ornithine Decarboxylase Inhibitor		2	Eflornithine Hydrochloride	170465007.0&384567837.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	FC(F)C(N)(C(=O)O)CCCN.Cl	FC(F)C(N)(C(=O)O)CCCN.Cl&FC(F)C(N)(C(=O)O)CCCN
NCGC00181770-02	FC(F)Oc1c(-c2cc3c([C@@H](C)NC3)cc2)ccc2C(=O)C(C(=O)O)=CN(C3CC3)c12		Inactive	Topoisomerase IV Inhibitor		1	Garenoxacin mesylate hydrate	170465937.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)C.FC(F)Oc1c(-c2cc3c([C@@H](C)NC3)cc2)ccc2C(=O)C(C(=O)O)=CN(C3CC3)c12.O	S(=O)(=O)(O)C.FC(F)Oc1c(-c2cc3c([C@@H](C)NC3)cc2)ccc2C(=O)C(C(=O)O)=CN(C3CC3)c12.O
NCGC00402239-03	FC(F)Oc1c(C#Cc2ncccc2)cc(C(=O)N2Cc3ncccc3C2)cc1		Inactive	Metabotropic glutamate receptor 5 Negative Allosteric Modulator		1	GRN-529	363680995.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC(F)Oc1c(C#Cc2ncccc2)cc(C(=O)N2Cc3ncccc3C2)cc1	FC(F)Oc1c(C#Cc2ncccc2)cc(C(=O)N2Cc3ncccc3C2)cc1
NCGC00390672-01	FC(F)Oc1c(OC(F)F)cc2c(c1)cc([C@@](O)(C(C)C)c1nn[nH]c1)cc2	4.9499998	Active	Cytochrome P450 CYP17A1 Inhibitor	0.0	1	Seviteronel	363680966.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	55.7889196114	FC(F)Oc1c(OC(F)F)cc2c(c1)cc([C@@](O)(C(C)C)c1nn[nH]c1)cc2	FC(F)Oc1c(OC(F)F)cc2c(c1)cc([C@@](O)(C(C)C)c1nn[nH]c1)cc2
NCGC00249759-02	FC(F)Oc1cc(-c2c3ncccc3cc(COc3ccc(CCC(O)(C)C)cc3)c2)ccc1		Inactive	Phosphodiesterase IIII (PDE4) Inhibitor		1	NCGC00249759	174006307.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	15.330690996	FC(F)Oc1cc(-c2c3ncccc3cc(COc3ccc(CCC(O)(C)C)cc3)c2)ccc1	FC(F)Oc1cc(-c2c3ncccc3cc(COc3ccc(CCC(O)(C)C)cc3)c2)ccc1
NCGC00346484-04	FC(F)c1n(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)c2c(n1)cccc2		Inactive	PI3K Inhibitor		1	ZSTK-474	384568794.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		FC(F)c1n(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)c2c(n1)cccc2	FC(F)c1n(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)c2c(n1)cccc2
NCGC00481568-01	FC(F)c1nccc([C@]2(c3cc(-c4cncnc4)ccc3)NC(=N)c3c(F)cccc23)c1		Inactive			1	AZD3839	434147261.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC(F)c1nccc([C@]2(c3cc(-c4cncnc4)ccc3)NC(=N)c3c(F)cccc23)c1	FC(F)c1nccc([C@]2(c3cc(-c4cncnc4)ccc3)NC(=N)c3c(F)cccc23)c1
NCGC00386371-04	FC1(F)C(=O)N(C)c2c(N(C3CCCC3)C1)nc(Nc1c(OC)cc(C(=O)NC3CCN(C)CC3)cc1)nc2		Inactive	Serine/threonine-protein kinase PLK1 Inhibitor		1	Ro3280	363680242.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	25.839727496	FC1(F)C(=O)N(C)c2c(N(C3CCCC3)C1)nc(Nc1c(OC)cc(C(=O)NC3CCN(C)CC3)cc1)nc2	FC1(F)C(=O)N(C)c2c(N(C3CCCC3)C1)nc(Nc1c(OC)cc(C(=O)NC3CCN(C)CC3)cc1)nc2
NCGC00183109-05&NCGC00183109-08&NCGC00183109-10	FC1(F)CCC(C(=O)N[C@@H](CCN2C3CC(n4c(C(C)C)nnc4C)CC2CC3)c2ccccc2)CC1		Inactive			3	Maraviroc	384568416.0	Anti-infectives&Annotated/Bioactive Compound Collection&Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	FC1(F)CCC(C(=O)N[C@@H](CCN2C3CC(n4c(C(C)C)nnc4C)CC2CC3)c2ccccc2)CC1	FC1(F)CCC(C(=O)N[C@@H](CCN2C3CC(n4c(C(C)C)nnc4C)CC2CC3)c2ccccc2)CC1
NCGC00384250-02	FC1(F)CN(c2nc(Nc3nccc(C#N)c3)cc(C3CCN(C4COC4)CC3)c2)CC1		Inactive	DLK Inhibitor		1	GNE-3511	384569109.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	21.403205916	FC1(F)CN(c2nc(Nc3nccc(C#N)c3)cc(C3CCN(C4COC4)CC3)c2)CC1	FC1(F)CN(c2nc(Nc3nccc(C#N)c3)cc(C3CCN(C4COC4)CC3)c2)CC1
NCGC00186009-04	FC1(F)Oc2c(O1)ccc(/C=C\1/C(=O)NC(=O)S/1)c2	4.9000001	Active	PI3K gamma Inhibitor	0.0	1	AS-604850	363677107.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	67.0483750846	FC1(F)Oc2c(O1)ccc(/C=C\1/C(=O)NC(=O)S/1)c2	FC1(F)Oc2c(O1)ccc(/C=C\1/C(=O)NC(=O)S/1)c2
NCGC00346550-02&NCGC00346550-03	FC1(F)Oc2c(O1)ccc(C1(C(=O)Nc3nc(c(C)cc3)-c3cc(C(=O)O)ccc3)CC1)c2		Inactive	CFTR Channel Modulator		2	Lumacaftor	405559081.0&384568835.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	FC1(F)Oc2c(O1)ccc(C1(C(=O)Nc3nc(c(C)cc3)-c3cc(C(=O)O)ccc3)CC1)c2	FC1(F)Oc2c(O1)ccc(C1(C(=O)Nc3nc(c(C)cc3)-c3cc(C(=O)O)ccc3)CC1)c2
NCGC00168784-03&NCGC00168784-10&NCGC00168784-12	FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1		Inactive	Ribonucleotide reductase Inhibitor		3	Gemcitabine	170465129.0&384568348.0&434147042.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1.Cl	FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1.Cl&FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1
NCGC00378563-01	FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(NC(=O)C(CCC)CCC)C=C1		Inactive	Ribonucleotide reductase Inhibitor		1	LY-2334737	363678091.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(NC(=O)C(CCC)CCC)C=C1	FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(NC(=O)C(CCC)CCC)C=C1
NCGC00274062-01	FC1(F)[C@H]2[C@@H]1c1c(C(N3CCN(C[C@@H](O)COc4c5c(nccc5)ccc4)CC3)c3c2cccc3)cccc1		Inactive	P-Glycoprotein (MDR-1) Inhibitor		1	Zosuquidar trihydrochloride	174006281.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&8.9786708599	FC1(F)[C@H]2[C@@H]1c1c(C(N3CCN(C[C@@H](O)COc4c5c(nccc5)ccc4)CC3)c3c2cccc3)cccc1.Cl.Cl.Cl	FC1(F)[C@H]2[C@@H]1c1c(C(N3CCN(C[C@@H](O)COc4c5c(nccc5)ccc4)CC3)c3c2cccc3)cccc1.Cl.Cl.Cl
NCGC00378990-02&NCGC00378990-05&NCGC00378990-07	FC1(F)c2c(-c3c1cc(-c1cc4[nH]c([C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)[C@H]6C[C@@H]5CC6)nc4cc1)cc3)ccc(-c1[nH]c([C@H]3N(C(=O)[C@@H](NC(=O)OC)C(C)C)CC4(C3)CC4)nc1)c2		Inactive	Nonstructural protein 5A Inhibitor		3	Ledipasvir (GS 5885)&Ledipasvir (D-tartrate)&Ledipasvir (GS5885)	405559115.0&434147111.0	Approved Drugs Collection (NPC)&Anti-infectives&2020_NPACT-2_CPE	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	FC1(F)c2c(-c3c1cc(-c1cc4[nH]c([C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)[C@H]6C[C@@H]5CC6)nc4cc1)cc3)ccc(-c1[nH]c([C@H]3N(C(=O)[C@@H](NC(=O)OC)C(C)C)CC4(C3)CC4)nc1)c2	FC1(F)c2c(-c3c1cc(-c1cc4[nH]c([C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)[C@H]6C[C@@H]5CC6)nc4cc1)cc3)ccc(-c1[nH]c([C@H]3N(C(=O)[C@@H](NC(=O)OC)C(C)C)CC4(C3)CC4)nc1)c2
NCGC00159360-03	FC12C3(C)C(=CC(=O)C=C3)CCC1C1C(C)(C(OC(=O)CC)(C(=O)COC(=O)CC)C(C)C1)CC2O		Inactive	Glucocorticoid steroid		1	Betamethasone dipropionate	384568172.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC12C3(C)C(=CC(=O)C=C3)CCC1C1C(C)(C(OC(=O)CC)(C(=O)COC(=O)CC)C(C)C1)CC2O	FC12C3(C)C(=CC(=O)C=C3)CCC1C1C(C)(C(OC(=O)CC)(C(=O)COC(=O)CC)C(C)C1)CC2O
MLS002608668-02	FC12C3(C)C(=CC(=O)C=C3)CCC1C1C(C)(C3(C(=O)C)OC(C)(C)OC3C1)CC2O		Inactive			1	MLS002608668-02	363676427.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC12C3(C)C(=CC(=O)C=C3)CCC1C1C(C)(C3(C(=O)C)OC(C)(C)OC3C1)CC2O	FC12C3(C)C(=CC(=O)C=C3)CCC1C1C(C)(C3(C(=O)C)OC(C)(C)OC3C1)CC2O
NCGC00183865-01	FC12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)C)CC[C@H]3[C@@H]1CCC=1[C@]2(C)CCC(=O)C=1		Inactive			1	Flugestone	144206781.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)C)CC[C@H]3[C@@H]1CCC=1[C@]2(C)CCC(=O)C=1	FC12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)C)CC[C@H]3[C@@H]1CCC=1[C@]2(C)CCC(=O)C=1
NCGC00253576-01	FC12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CC)(C(=O)COC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Amelometasone	170465753.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	FC12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CC)(C(=O)COC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	FC12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CC)(C(=O)COC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00351745-02	FC1=Cn2c(nc(CCC#Cc3ncccc3)c2)C=C1		Inactive	Metabotropic glutamate receptor 5 Negative Allosteric Modulator		1	Dipraglurant	363677781.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC1=Cn2c(nc(CCC#Cc3ncccc3)c2)C=C1	FC1=Cn2c(nc(CCC#Cc3ncccc3)c2)C=C1
MLS002702049-02	FC=1C(=N)N=C2OC3C(O)C(CO)OC3N2C=1		Inactive			1	MLS002702049-02	363676429.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FC=1C(=N)N=C2OC3C(O)C(CO)OC3N2C=1	FC=1C(=N)N=C2OC3C(O)C(CO)OC3N2C=1
NCGC00095165-07&NCGC00095165-08	FC=1C(=O)NC(=O)N(C(=O)NCCCCCC)C=1		Inactive	Pyrimidine Antagonist		2	Carmofur	170465833.0&384568154.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&-18.81668318	FC=1C(=O)NC(=O)N(C(=O)NCCCCCC)C=1	FC=1C(=O)NC(=O)N(C(=O)NCCCCCC)C=1
NCGC00159418-05&NCGC00159418-07	FC=1C(=O)NC(=O)N(C2OCCC2)C=1		Inactive	Pyrimidine Antagonist		2	Tegafur	170465809.0&384568175.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	FC=1C(=O)NC(=O)N(C2OCCC2)C=1	FC=1C(=O)NC(=O)N(C2OCCC2)C=1
NCGC00023722-08&NCGC00023722-16	FC=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1		Inactive	Pyrimidine Antagonist		2	Floxuridine	170465247.0&384568020.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		FC=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1	FC=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1
NCGC00093926-05&NCGC00093926-10	FC=1C(=O)NC(=O)N([C@H]2[C@H](O)[C@H](O)[C@@H](C)O2)C=1		Inactive	thymidylate synthase Inhibitor		2	Doxifluridine	170465861.0&384568120.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	FC=1C(=O)NC(=O)N([C@H]2[C@H](O)[C@H](O)[C@@H](C)O2)C=1	FC=1C(=O)NC(=O)N([C@H]2[C@H](O)[C@H](O)[C@@H](C)O2)C=1
NCGC00015442-15&NCGC00015442-19&NCGC00015442-24	FC=1C(=O)NC(=O)NC=1		Inactive	Pyrimidine Antagonist		3	Fluorouracil	170464762.0&384567846.0&434146877.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	FC=1C(=O)NC(=O)NC=1	FC=1C(=O)NC(=O)NC=1
NCGC00346830-03	FC=1C(N)=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1		Inactive	DNA Methyltransferase (DNMT) Inhibitor		1	NSC-48006	384568946.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC=1C(N)=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1	FC=1C(N)=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1
NCGC00164564-06&NCGC00164564-09	FC=1C(N)=NC(=O)N([C@H]2O[C@@H](CO)SC2)C=1		Inactive	Reverse Transcriptase Inhibitor		2	Emtricitabine	405558951.0&434147026.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	FC=1C(N)=NC(=O)N([C@H]2O[C@@H](CO)SC2)C=1	FC=1C(N)=NC(=O)N([C@H]2O[C@@H](CO)SC2)C=1
NCGC00016599-04&NCGC00016599-10	FC=1C(N)=NC(=O)NC=1		Inactive	Pyrimidine Antagonist		2	Flucytosine	170465407.0&384567951.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	FC=1C(N)=NC(=O)NC=1	FC=1C(N)=NC(=O)NC=1
NCGC00164569-02&NCGC00164569-08	FC=1C(NC(=O)OCCCCC)=NC(=O)N([C@H]2[C@H](O)[C@H](O)[C@@H](C)O2)C=1		Inactive	Pyrimidine Antagonist		2	Capecitabine	170464779.0&384568255.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	FC=1C(NC(=O)OCCCCC)=NC(=O)N([C@H]2[C@H](O)[C@H](O)[C@@H](C)O2)C=1	FC=1C(NC(=O)OCCCCC)=NC(=O)N([C@H]2[C@H](O)[C@H](O)[C@@H](C)O2)C=1
NCGC00485875-01	FC=1[C@@H](N2C(=O)N=C(N)C=C2)[C@H](O)[C@H](O)C=1CO		Inactive	CDK Inhibitor		1	Fluorocyclopentenylcytosine	363681386.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC=1[C@@H](N2C(=O)N=C(N)C=C2)[C@H](O)[C@H](O)C=1CO	FC=1[C@@H](N2C(=O)N=C(N)C=C2)[C@H](O)[C@H](O)C=1CO
NCGC00483923-01	FC=1c2n(c([C@@H](C)N3C(=O)c4c(ncc(OCCOC)c4)C=C3)nn2)C=C(c2cn(C)nc2)C=1		Inactive	HGFR Inhibitor		1	AMG-337	363681142.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FC=1c2n(c([C@@H](C)N3C(=O)c4c(ncc(OCCOC)c4)C=C3)nn2)C=C(c2cn(C)nc2)C=1	FC=1c2n(c([C@@H](C)N3C(=O)c4c(ncc(OCCOC)c4)C=C3)nn2)C=C(c2cn(C)nc2)C=1
NCGC00386330-03	FCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)OCc1ccccc1)Cc1ccccc1)C	6.5	Active		0.0	1	Z-FA-FMK	406861859.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	1.1	85.5599458208	FCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)OCc1ccccc1)Cc1ccccc1)C	FCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)OCc1ccccc1)Cc1ccccc1)C
NCGC00388311-01	FCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C)C)CC(=O)O		Inactive			1	Z-VAD(OH)-FMK	434147135.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C)C)CC(=O)O	FCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)OCc1ccccc1)C(C)C)C)CC(=O)O
NCGC00485589-01	FCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)OCc1ccccc1)CC(C)C)CCC(=O)OC)Cc1nc[nH]c1)CC(=O)OC		Inactive	Caspase-9 Inhibitor		1	Z-Leu-Glu(O-Me)-His-Asp(O-Me) fluoromethyl ketone trifluoroacetate salt hydrate	363681367.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)OCc1ccccc1)CC(C)C)CCC(=O)OC)Cc1nc[nH]c1)CC(=O)OC	FCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)OCc1ccccc1)CC(C)C)CCC(=O)OC)Cc1nc[nH]c1)CC(=O)OC
NCGC00386403-01	FCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)[C@@H](NC(=O)OCc1ccccc1)CC(=O)OC)CCC(=O)OC)C(C)C)CC(=O)OC		Inactive	Caspase-3 Inhibitor		1	Z-DEVD-FMK	363680258.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)[C@@H](NC(=O)OCc1ccccc1)CC(=O)OC)CCC(=O)OC)C(C)C)CC(=O)OC	FCC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)[C@@H](NC(=O)OCc1ccccc1)CC(=O)OC)CCC(=O)OC)C(C)C)CC(=O)OC
NCGC00263239-03	FCC(=O)c1n(CCCNCCOC)c2ncnc(N)c2c1-c1ccc(C)cc1		Inactive	RSK Inhibitor		1	FMK	384568682.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FCC(=O)c1n(CCCNCCOC)c2ncnc(N)c2c1-c1ccc(C)cc1	FCC(=O)c1n(CCCNCCOC)c2ncnc(N)c2c1-c1ccc(C)cc1
NCGC00386649-02	FCC(=O)c1n(CCCO)c2ncnc(N)c2c1-c1ccc(C)cc1		Inactive	Ribosomal protein S6 kinase alpha 2 Inhibitor		1	FMK	363680373.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	FCC(=O)c1n(CCCO)c2ncnc(N)c2c1-c1ccc(C)cc1	FCC(=O)c1n(CCCO)c2ncnc(N)c2c1-c1ccc(C)cc1
NCGC00167443-02	FCC=1N(c2c(C)cccc2)C(=O)c2c(N=1)ccc(N)c2		Inactive			1	Afloqualone	405558862.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FCC=1N(c2c(C)cccc2)C(=O)c2c(N=1)ccc(N)c2	FCC=1N(c2c(C)cccc2)C(=O)c2c(N=1)ccc(N)c2
NCGC00167558-02	FCCN1c2c(F)c(N3CCN(C)CC3)c(F)cc2C(=O)C(C(=O)O)=C1		Inactive	Quinoline Antibiotic		1	Fleroxacin	170466056.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FCCN1c2c(F)c(N3CCN(C)CC3)c(F)cc2C(=O)C(C(=O)O)=C1	FCCN1c2c(F)c(N3CCN(C)CC3)c(F)cc2C(=O)C(C(=O)O)=C1
NCGC00182548-02	FCC[N+]1(C)[C@H]2CC(OC(=O)C(O)(c3ccccc3)c3ccccc3)C[C@@H]1CC2		Inactive	Muscarinic acetylcholine receptor Antagonist		1	Flutropium bromide	170465904.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	FCC[N+]1(C)[C@H]2CC(OC(=O)C(O)(c3ccccc3)c3ccccc3)C[C@@H]1CC2.[Br-].[Br-]	FCC[N+]1(C)[C@H]2CC(OC(=O)C(O)(c3ccccc3)c3ccccc3)C[C@@H]1CC2.[Br-].[Br-]
NCGC00263574-01	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@H](C(=O)COC(=O)CCCC)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive	Annexin A1 Activator		1	Diflucortolone valerate	170465700.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@H](C(=O)COC(=O)CCCC)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@H](C(=O)COC(=O)CCCC)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00021761-05	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)CO)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive	Glucocorticoid receptor Agonist		1	Flumethasone	170465750.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)CO)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)CO)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00022408-04	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C(C)(C)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive			1	Flumethasone pivalate	405559110.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C(C)(C)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C(C)(C)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00507799-01	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive			1	Flumethasone acetate	405558593.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00022003-06	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](OC(=O)C)(C(=O)COC(=O)C)[C@@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive			1	Diflorasone diacetate	170465294.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	10.5741952719&0.0	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](OC(=O)C)(C(=O)COC(=O)C)[C@@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](OC(=O)C)(C(=O)COC(=O)C)[C@@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00386547-01	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](OC(=O)CCC)(C(=O)COC(=O)C)CC[C@H]4C3C1)C=CC(=O)C=2		Inactive	Glucocorticoid receptor Agonist		1	Difluprednate	405558562.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](OC(=O)CCC)(C(=O)COC(=O)C)CC[C@H]4C3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@@](OC(=O)CCC)(C(=O)COC(=O)C)CC[C@H]4C3C1)C=CC(=O)C=2
NCGC00021301-06&NCGC00021301-09	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive	Glucocorticoid steroid		2	Fluocinolone acetonide	170464630.0&384568006.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00022398-05&NCGC00022398-13	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@]5(C(=O)COC(=O)C)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive	Glucocorticoid steroid		2	Fluocinonide	170464717.0&384568010.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@]5(C(=O)COC(=O)C)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@@]3(F)[C@@H](O)C[C@]4(C)[C@]5(C(=O)COC(=O)C)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00159474-03	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)CO)CC[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive	Glucocorticoid receptor Agonist		1	Fluprednisolone	170465086.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)CO)CC[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)CO)CC[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00185748-01	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive	Glucocorticoid receptor Interacts		1	Paramethasone acetate	144206683.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00179492-03&NCGC00179492-08	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2		Inactive	Corticosteroid		2	Flunisolide&FLUNISOLIDE	170465331.0&384568374.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)C=CC(=O)C=2
NCGC00023234-05	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)CCC(=O)C=2		Inactive			1	Flurandrenolide	170465298.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)CCC(=O)C=2	F[C@@H]1C=2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@]5(C(=O)CO)OC(C)(C)O[C@@H]5C[C@H]4[C@@H]3C1)CCC(=O)C=2
NCGC00485889-01	F[C@@H]1CN(C(=O)CNC(CC(=O)N2CCCC2)(C)C)[C@H](C#N)C1		Inactive	Dipeptidyl peptidase IV Inhibitor		1	DBPR108	363681396.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	F[C@@H]1CN(C(=O)CNC(CC(=O)N2CCCC2)(C)C)[C@H](C#N)C1	F[C@@H]1CN(C(=O)CNC(CC(=O)N2CCCC2)(C)C)[C@H](C#N)C1
NCGC00485373-01	F[C@@H]1CN(C(=O)CNC2[C@H]3[C@@H]2CN(C(=O)c2ccc(F)cc2)C3)[C@H](C#N)C1		Inactive	Prolyl endopeptidase Inhibitor		1	RBx-0597	363681302.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	F[C@@H]1CN(C(=O)CNC2[C@H]3[C@@H]2CN(C(=O)c2ccc(F)cc2)C3)[C@H](C#N)C1	F[C@@H]1CN(C(=O)CNC2[C@H]3[C@@H]2CN(C(=O)c2ccc(F)cc2)C3)[C@H](C#N)C1
NCGC00509941-01	F[C@@H]1[C@@H](NC(=O)C=C)CN(c2nc(Nc3c(OC)nn(C)c3)c3ncn(C)c3n2)C1		Inactive	EGFR (Thr790Met Mutant) Inhibitor		1	PF-06747775	384569389.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@@H]1[C@@H](NC(=O)C=C)CN(c2nc(Nc3c(OC)nn(C)c3)c3ncn(C)c3n2)C1	F[C@@H]1[C@@H](NC(=O)C=C)CN(c2nc(Nc3c(OC)nn(C)c3)c3ncn(C)c3n2)C1
NCGC00371259-05	F[C@@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C(C)=C1		Inactive	Reverse Transcriptase Inhibitor		1	Clevudine	434147104.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	10.9123595479	F[C@@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C(C)=C1	F[C@@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C(C)=C1
NCGC00386561-01	F[C@@H]1[C@H](CNc2ncccn2)CCN(C(=O)OCc2ccc(C)cc2)C1		Inactive			1	MK 0657 - cis-(+)-isomer	363680327.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	F[C@@H]1[C@H](CNc2ncccn2)CCN(C(=O)OCc2ccc(C)cc2)C1	F[C@@H]1[C@H](CNc2ncccn2)CCN(C(=O)OCc2ccc(C)cc2)C1
NCGC00370855-01	F[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1		Inactive			1	Gemcitabine hydrochloride	377020344.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	F[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1	F[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1
NCGC00510500-01	F[C@H]1[C@@H](CC)[C@@H](COc2nccc3c2cc(OC)c(C(=O)N)c3)NC1=O		Inactive	Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4) Inhibitor		1	PF-06650833	384569461.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@H]1[C@@H](CC)[C@@H](COc2nccc3c2cc(OC)c(C(=O)N)c3)NC1=O	F[C@H]1[C@@H](CC)[C@@H](COc2nccc3c2cc(OC)c(C(=O)N)c3)NC1=O
NCGC00522572-01	F[C@H]1[C@H](N)CCN(c2n(C)ncc2NC(=O)c2c(N)sc(-c3c(F)cccc3F)n2)CC1		Inactive	Pim-1/2/3 Kinase Inhibitor		1	GDC-0339	384569526.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@H]1[C@H](N)CCN(c2n(C)ncc2NC(=O)c2c(N)sc(-c3c(F)cccc3F)n2)CC1	F[C@H]1[C@H](N)CCN(c2n(C)ncc2NC(=O)c2c(N)sc(-c3c(F)cccc3F)n2)CC1
NCGC00345781-01	F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1		Inactive	DNA-Intercalating Drugs		1	NSC-678515	174006953.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1	F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1
NCGC00483076-02	F[C@]1(C)C(=O)[C@H](C)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@](OC)(C)C[C@@H](C)C(=O)[C@@H](C)[C@H]2N(CCCCn3nnc(-c4cc(N)ccc4)c3)C(=O)O[C@]2(C)[C@@H](CC)OC1=O		Inactive	Streptococcus pneumoniae Inhibitor		1	Solithromycin	363681133.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	29.4857142881	F[C@]1(C)C(=O)[C@H](C)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@](OC)(C)C[C@@H](C)C(=O)[C@@H](C)[C@H]2N(CCCCn3nnc(-c4cc(N)ccc4)c3)C(=O)O[C@]2(C)[C@@H](CC)OC1=O	F[C@]1(C)C(=O)[C@H](C)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@](OC)(C)C[C@@H](C)C(=O)[C@@H](C)[C@H]2N(CCCCn3nnc(-c4cc(N)ccc4)c3)C(=O)O[C@]2(C)[C@@H](CC)OC1=O
NCGC00379028-01	F[C@]1(C)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1		Inactive	Hepatitis C virus NS5B RNA-dependent RNA polymerase Inhibitor		1	PSI-6130		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@]1(C)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1	F[C@]1(C)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1
NCGC00379006-04	F[C@]1(C)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1		Inactive			1	PSI-6206	434147112.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@]1(C)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1	F[C@]1(C)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1
NCGC00379064-01	F[C@]1(C)[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@H]1N1C(=O)N=C(N)C=C1		Inactive			1	R-7128	377020456.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0	0.0&0.0	F[C@]1(C)[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@H]1N1C(=O)N=C(N)C=C1	F[C@]1(C)[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@H]1N1C(=O)N=C(N)C=C1
NCGC00023648-04	F[C@]12[C@@H](O)C[C@]3(C)[C@@H](C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive	Glucocorticoid receptor Agonist		1	Desoximetasone	170464795.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@H](C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@H](C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00021575-05	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)C)CC[C@H]3[C@@H]1C[C@H](C)C=1[C@]2(C)C=CC(=O)C=1		Inactive	Glucocorticoid receptor Agonist		1	Fluorometholone	170464629.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)C)CC[C@H]3[C@@H]1C[C@H](C)C=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)C)CC[C@H]3[C@@H]1C[C@H](C)C=1[C@]2(C)C=CC(=O)C=1
NCGC00274078-01	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)CC[C@H]3[C@@H]1CCC=1[C@]2(C)CCC(=O)C=1		Inactive			1	Fludrocortisone	170464959.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)CC[C@H]3[C@@H]1CCC=1[C@]2(C)CCC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)CC[C@H]3[C@@H]1CCC=1[C@]2(C)CCC(=O)C=1
NCGC00093684-06	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@@H](C)CC3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	BETAMETHASONE	384568117.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@@H](C)CC3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@@H](C)CC3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00091019-19&NCGC00091019-23	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive	Antiinflammatory agent		2	Dexamethasone	384568091.0&405559016.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00178404-03	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@H](O)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Triamcinolone	170465188.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@H](O)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)CO)[C@H](O)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00182066-02	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)C(=C)CC3C1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Fluprednidene acetate	144206681.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)C(=C)CC3C1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)C(=C)CC3C1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00179685-03	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)CC[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Isoflupredone acetate	170465628.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)CC[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)CC[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00022662-05	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive	Mineralocorticoid receptor Agonist		1	Dexamethasone acetate	170466872.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00159320-04	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)[C@H](OC(=O)C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Triamcinolone diacetate	170464837.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)[C@H](OC(=O)C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)C)[C@H](OC(=O)C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00522021-01	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)CCCCCCCCCCCCCCC)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive	Glucocorticoid receptor Agonist		1	Dexamethasone 21-Palmitate	405558516.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)CCCCCCCCCCCCCCC)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)CCCCCCCCCCCCCCC)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00249903-01	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)c4ccncc4)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Dexamethasone isonicotinate	170466851.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)c4ccncc4)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](O)(C(=O)COC(=O)c4ccncc4)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00373228-02	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)C)(C(=O)C)CC[C@H]3[C@@H]1C[C@H](C)C=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Fluorometholone Acetate	363678077.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)C)(C(=O)C)CC[C@H]3[C@@H]1C[C@H](C)C=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)C)(C(=O)C)CC[C@H]3[C@@H]1C[C@H](C)C=1[C@]2(C)C=CC(=O)C=1
NCGC00159443-05	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive	Glucocorticoid steroid		1	BETAMETHASONE 17,21-DIPROPIONATE	405558654.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00183597-01	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCC)(C(=O)COC(=O)CC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Betamethasone butyrate propionate	144206581.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCC)(C(=O)COC(=O)CC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCC)(C(=O)COC(=O)CC)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00274064-02	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCCC)(C(=O)CO)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive	Glucocorticoid steroid		1	Betamethasone valerate	384568710.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.196495716	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCCC)(C(=O)CO)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCCC)(C(=O)CO)[C@@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00274064-01	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCCC)(C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive	Glucocorticoid steroid		1	Betamethasone valerate	174007479.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCCC)(C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)CCCC)(C(=O)CO)[C@H](C)C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00183040-01	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)c4ccccc4)(C(=O)CO)[C@@H](C)C[C@H]3[C@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	NCGC00183040-01	124894246.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	16.5	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)c4ccccc4)(C(=O)CO)[C@@H](C)C[C@H]3[C@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@@](OC(=O)c4ccccc4)(C(=O)CO)[C@@H](C)C[C@H]3[C@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00023193-06&NCGC00023193-11	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)CO)OC(C)(C)O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive	Glucocorticoid steroid		2	Triamcinolone acetonide	170464660.0&384568016.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)CO)OC(C)(C)O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)CO)OC(C)(C)O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00021193-03	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)COC(=O)C)OC5(O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1)CCCC5		Inactive			1	AMCINONIDE	405559147.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)COC(=O)C)OC5(O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1)CCCC5	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)COC(=O)C)OC5(O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1)CCCC5
NCGC00182544-01	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)COC(=O)CC(C)(C)C)OC(C)(C)O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1		Inactive			1	Triamcinolone hexacetonide	144206532.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)COC(=O)CC(C)(C)C)OC(C)(C)O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1	F[C@]12[C@@H](O)C[C@]3(C)[C@]4(C(=O)COC(=O)CC(C)(C)C)OC(C)(C)O[C@@H]4C[C@H]3[C@@H]1CCC=1[C@]2(C)C=CC(=O)C=1
NCGC00387272-01	Fc1c(-c2[nH]c(c(-c3ccc(F)cc3)n2)-c2ccncc2)c(F)ccc1	5.4499998	Active	MAP kinase p38 alpha Inhibitor	0.0	1	TA 01	363680606.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	2.4	41.5	Fc1c(-c2[nH]c(c(-c3ccc(F)cc3)n2)-c2ccncc2)c(F)ccc1	Fc1c(-c2[nH]c(c(-c3ccc(F)cc3)n2)-c2ccncc2)c(F)ccc1
NCGC00387273-01	Fc1c(-c2[nH]c(c(-c3ccc(F)cc3)n2)-c2ccncc2)cccc1	4.9499998	Active	p38 MAPK Inhibitor	0.0	1	TA02	363680607.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	42.360276913	Fc1c(-c2[nH]c(c(-c3ccc(F)cc3)n2)-c2ccncc2)cccc1	Fc1c(-c2[nH]c(c(-c3ccc(F)cc3)n2)-c2ccncc2)cccc1
NCGC00345451-03&NCGC00345451-04	Fc1c(-c2[nH]c3c(c(C(=O)N)ccc3)n2)ccc([C@H]2NCCC2)c1		Inactive	PARP-1 Inhibitor		2	A-966492	434147082.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&15.5	Fc1c(-c2[nH]c3c(c(C(=O)N)ccc3)n2)ccc([C@H]2NCCC2)c1	Fc1c(-c2[nH]c3c(c(C(=O)N)ccc3)n2)ccc([C@H]2NCCC2)c1
NCGC00402309-03	Fc1c(-c2[nH]nc(-c3c(O)cccc3)c2)cccc1		Inactive			1	VU0420373	363681024.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(-c2[nH]nc(-c3c(O)cccc3)c2)cccc1	Fc1c(-c2[nH]nc(-c3c(O)cccc3)c2)cccc1
NCGC00475739-01	Fc1c(-c2c(C#N)c(N3CCOCC3)sc2-c2[nH]cnn2)ccc(C#N)c1		Inactive	PI3Kalpha Inhibitor		1	PF-4989216	384569235.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	36.407451752	Fc1c(-c2c(C#N)c(N3CCOCC3)sc2-c2[nH]cnn2)ccc(C#N)c1	Fc1c(-c2c(C#N)c(N3CCOCC3)sc2-c2[nH]cnn2)ccc(C#N)c1
NCGC00379121-02	Fc1c(-c2c(C#N)cc(F)cc2)cc(-c2n3c(C(F)=C(C(O)(C)C)C=C3)nc2)cc1		Inactive	Gamma-aminobutyric acid receptor subunit alpha-5 Agonist		1	TP 003	363678369.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(-c2c(C#N)cc(F)cc2)cc(-c2n3c(C(F)=C(C(O)(C)C)C=C3)nc2)cc1	Fc1c(-c2c(C#N)cc(F)cc2)cc(-c2n3c(C(F)=C(C(O)(C)C)C=C3)nc2)cc1
NCGC00249684-04	Fc1c(-c2c(C(=O)N)ccc(N(C(=O)N)c3c(F)cccc3F)n2)ccc(F)c1		Inactive	p38 MAPK Inhibitor		1	VX-702	384568532.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(-c2c(C(=O)N)ccc(N(C(=O)N)c3c(F)cccc3F)n2)ccc(F)c1	Fc1c(-c2c(C(=O)N)ccc(N(C(=O)N)c3c(F)cccc3F)n2)ccc(F)c1
NCGC00379073-05	Fc1c(-c2c(C(=O)N3[C@H](Cc4oc(-c5ccccc5)nn4)CCC3)nc(C)s2)cccc1		Inactive	Orexin receptor 1 Antagonist		1	SB-674042	363678341.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(-c2c(C(=O)N3[C@H](Cc4oc(-c5ccccc5)nn4)CCC3)nc(C)s2)cccc1	Fc1c(-c2c(C(=O)N3[C@H](Cc4oc(-c5ccccc5)nn4)CCC3)nc(C)s2)cccc1
NCGC00510688-01	Fc1c(-c2c(F)ccc(C(=O)Nc3c([C@H]4C[C@@H](N)C[C@@H](C)C4)ccnc3)n2)c(F)ccc1	5.0500002	Active	Pim-1 Kinase Inhibitor	0.0	1	LGH-447	384569478.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	90.3988575516	Fc1c(-c2c(F)ccc(C(=O)Nc3c([C@H]4C[C@@H](N)C[C@@H](C)C4)ccnc3)n2)c(F)ccc1	Fc1c(-c2c(F)ccc(C(=O)Nc3c([C@H]4C[C@@H](N)C[C@@H](C)C4)ccnc3)n2)c(F)ccc1
NCGC00386314-03	Fc1c(-c2c3c(N)ncnc3n(C)c2)ccc2N(C(=O)Cc3nc(C)ccc3)CCc12		Inactive	PERK Inhibitor		1	GSK-2656157	363680205.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	10.732414796	Fc1c(-c2c3c(N)ncnc3n(C)c2)ccc2N(C(=O)Cc3nc(C)ccc3)CCc12	Fc1c(-c2c3c(N)ncnc3n(C)c2)ccc2N(C(=O)Cc3nc(C)ccc3)CCc12
NCGC00016765-09	Fc1c(-c2cc(C(=O)O)c(O)cc2)ccc(F)c1		Inactive	Cyclooxygenase-2 Inhibitor		1	Diflunisal	170464956.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(-c2cc(C(=O)O)c(O)cc2)ccc(F)c1	Fc1c(-c2cc(C(=O)O)c(O)cc2)ccc(F)c1
NCGC00351599-02	Fc1c(-c2cc(F)c3nc(C)n(C(C)C)c3c2)nc(Nc2ncc(CN3CCN(CC)CC3)cc2)nc1	5.0999999	Active	CDK4/6 Inhibitor	0.0	1	Abemaciclib	405558877.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	2.2	59.4401166243	Fc1c(-c2cc(F)c3nc(C)n(C(C)C)c3c2)nc(Nc2ncc(CN3CCN(CC)CC3)cc2)nc1	Fc1c(-c2cc(F)c3nc(C)n(C(C)C)c3c2)nc(Nc2ncc(CN3CCN(CC)CC3)cc2)nc1
NCGC00480786-02&NCGC00480786-05	Fc1c(-c2ccc(-c3c(C)c(C(=O)O)c4c(n3)ccc(F)c4)cc2)cccc1		Inactive	DHODH Inhibitor		2	Brequinar&Brequinar sodium	384569245.0&434147153.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c(-c2ccc(-c3c(C)c(C(=O)O)c4c(n3)ccc(F)c4)cc2)cccc1	Fc1c(-c2ccc(-c3c(C)c(C(=O)O)c4c(n3)ccc(F)c4)cc2)cccc1
NCGC00389744-01	Fc1c(-c2ccc(CNCc3n[nH]nc3)cc2)ccc(N2C(=O)OC(CNC(=O)C)C2)c1		Inactive	Bacterial 70S ribosome Inhibitor		1	Radezolid	363680846.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(-c2ccc(CNCc3n[nH]nc3)cc2)ccc(N2C(=O)OC(CNC(=O)C)C2)c1	Fc1c(-c2ccc(CNCc3n[nH]nc3)cc2)ccc(N2C(=O)OC(CNC(=O)C)C2)c1
NCGC00018157-13&NCGC00018157-21	Fc1c(-c2ccccc2)ccc(C(C(=O)O)C)c1		Inactive	non-steroidal antiinflammatory		2	Flurbiprofen	405559106.0&384567993.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Fc1c(-c2ccccc2)ccc(C(C(=O)O)C)c1	Fc1c(-c2ccccc2)ccc(C(C(=O)O)C)c1
NCGC00182710-02	Fc1c(-c2ccccc2)ccc(C(C(=O)OC(OC(=O)C)C)C)c1		Inactive			1	Flurbiprofen axetil	144206486.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(-c2ccccc2)ccc(C(C(=O)OC(OC(=O)C)C)C)c1	Fc1c(-c2ccccc2)ccc(C(C(=O)OC(OC(=O)C)C)C)c1
NCGC00387472-01	Fc1c(-c2cn(CCO)nc2)cc(-c2c(-c3nc(C)ccc3)n[nH]c2)cc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	R-268712	363680628.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(-c2cn(CCO)nc2)cc(-c2c(-c3nc(C)ccc3)n[nH]c2)cc1	Fc1c(-c2cn(CCO)nc2)cc(-c2c(-c3nc(C)ccc3)n[nH]c2)cc1
NCGC00378911-02	Fc1c(-c2cnc(-c3nn(C)nn3)cc2)ccc(N2C(=O)O[C@H](CO)C2)c1		Inactive	Bacterial 70S ribosome Inhibitor		1	(S)-Tedizolid	405558814.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(-c2cnc(-c3nn(C)nn3)cc2)ccc(N2C(=O)O[C@H](CO)C2)c1	Fc1c(-c2cnc(-c3nn(C)nn3)cc2)ccc(N2C(=O)O[C@H](CO)C2)c1
NCGC00346719-03	Fc1c(-c2cncnc2)cc(c(F)c1)[C@@]1(C)N=C(N)SCC1		Inactive	beta-Secretase Inhibitor		1	LY-2811376	384568932.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c(-c2cncnc2)cc(c(F)c1)[C@@]1(C)N=C(N)SCC1	Fc1c(-c2cncnc2)cc(c(F)c1)[C@@]1(C)N=C(N)SCC1
NCGC00481606-01	Fc1c(-c2n(C(C)C)c(C)nc2)nc(Nc2ccc(C(=O)N3C[C@@H](NC)CC3)cc2)nc1		Inactive			1	AZD-5597	377020334.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(-c2n(C(C)C)c(C)nc2)nc(Nc2ccc(C(=O)N3C[C@@H](NC)CC3)cc2)nc1	Fc1c(-c2n(C(C)C)c(C)nc2)nc(Nc2ccc(C(=O)N3C[C@@H](NC)CC3)cc2)nc1
NCGC00370896-02	Fc1c(-c2n3N=C(OCc4n(C)ncn4)C(C(C)(C)C)=Cc3nn2)cc(F)cc1		Inactive	GABA-A receptor; alpha-5/beta-3/gamma-2 Partial Agonist		1	L 838417	363677917.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(-c2n3N=C(OCc4n(C)ncn4)C(C(C)(C)C)=Cc3nn2)cc(F)cc1	Fc1c(-c2n3N=C(OCc4n(C)ncn4)C(C(C)(C)C)=Cc3nn2)cc(F)cc1
NCGC00379122-01	Fc1c(-c2n3N=C(OCc4n(C)ncn4)C(C4CCC4)=Cc3nn2)c(F)ccc1		Inactive	GABA receptor alpha-2 subunit Inhibitor		1	MK 0343	363678370.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(-c2n3N=C(OCc4n(C)ncn4)C(C4CCC4)=Cc3nn2)c(F)ccc1	Fc1c(-c2n3N=C(OCc4n(C)ncn4)C(C4CCC4)=Cc3nn2)c(F)ccc1
NCGC00386429-04	Fc1c(-c2nc(N3CCOCC3)c3sc(CN4CCN(CC5CC5)CC4)cc3n2)c2c([nH]cc2)cc1	4.9000001	Active	PI3K alpha Inhibitor	0.0	1	PI-3065	384569139.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	69.4768358499	Fc1c(-c2nc(N3CCOCC3)c3sc(CN4CCN(CC5CC5)CC4)cc3n2)c2c([nH]cc2)cc1	Fc1c(-c2nc(N3CCOCC3)c3sc(CN4CCN(CC5CC5)CC4)cc3n2)c2c([nH]cc2)cc1
NCGC00499577-01	Fc1c(-c2ncnc3[nH]cc(C(=O)OCC)c23)cc(NC(=O)C=C)cc1		Inactive	Jak3		1	JAK3i	384569309.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(-c2ncnc3[nH]cc(C(=O)OCC)c23)cc(NC(=O)C=C)cc1	Fc1c(-c2ncnc3[nH]cc(C(=O)OCC)c23)cc(NC(=O)C=C)cc1
NCGC00168759-05&NCGC00168759-10	Fc1c(-c2onc(-c3cc(C(=O)O)ccc3)n2)cccc1		Inactive	CFTR-G542X nonsense allele Inhibitor		2	PTC-124	170466862.0&363676681.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Fc1c(-c2onc(-c3cc(C(=O)O)ccc3)n2)cccc1	Fc1c(-c2onc(-c3cc(C(=O)O)ccc3)n2)cccc1
NCGC00379113-01	Fc1c(-c2sc3c(n2)cc(Cc2c(F)cccc2)cc3)ccc(CN2CC(C(=O)O)C2)c1		Inactive	Sphingosine 1-phosphate receptor 3 Agonist		1	TC-SP 14	363678363.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(-c2sc3c(n2)cc(Cc2c(F)cccc2)cc3)ccc(CN2CC(C(=O)O)C2)c1	Fc1c(-c2sc3c(n2)cc(Cc2c(F)cccc2)cc3)ccc(CN2CC(C(=O)O)C2)c1
NCGC00387221-01	Fc1c(-n2c(C)c(C3=CCN(C(=O)N(C(C)C)C)CC3)nn2)cccn1		Inactive	Metabotropic glutamate receptor 5 Antagonist		1	FTIDC	363680576.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(-n2c(C)c(C3=CCN(C(=O)N(C(C)C)C)CC3)nn2)cccn1	Fc1c(-n2c(C)c(C3=CCN(C(=O)N(C(C)C)C)CC3)nn2)cccn1
NCGC00370849-01	Fc1c(-n2c(NC(=O)c3ccc([N+](=O)[O-])cc3)cc(-c3ccccc3)n2)cccc1		Inactive	Metabotropic glutamate receptor 5 Positive Allosteric Modulator		1	VU 1545	363677884.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	29.333333332	Fc1c(-n2c(NC(=O)c3ccc([N+](=O)[O-])cc3)cc(-c3ccccc3)n2)cccc1	Fc1c(-n2c(NC(=O)c3ccc([N+](=O)[O-])cc3)cc(-c3ccccc3)n2)cccc1
NCGC00509989-01	Fc1c(-n2nc(NC(=O)C3CCC4(OC(=O)c5c4cncc5)CC3)cc2)cccc1		Inactive	Neuropeptide Y5 (NPY Y5) Receptor Antagonist		1	MK-0557	384569397.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(-n2nc(NC(=O)C3CCC4(OC(=O)c5c4cncc5)CC3)cc2)cccc1	Fc1c(-n2nc(NC(=O)C3CCC4(OC(=O)c5c4cncc5)CC3)cc2)cccc1
NCGC00386914-01	Fc1c(-n2ncc3[C@H](NC(=O)c4ncccc4)CCCc23)ccc(F)c1		Inactive			1	NCGC00386914-01	363680501.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(-n2ncc3[C@H](NC(=O)c4ncccc4)CCCc23)ccc(F)c1	Fc1c(-n2ncc3[C@H](NC(=O)c4ncccc4)CCCc23)ccc(F)c1
NCGC00386839-01	Fc1c(/C=C\2/C(=O)Nc3c(S/2)ccc(C(=O)NC[C@@H]2N(CC)CCC2)c3)cccc1		Inactive			1	NCGC00386839-01	363680459.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(/C=C\2/C(=O)Nc3c(S/2)ccc(C(=O)NC[C@@H]2N(CC)CCC2)c3)cccc1	Fc1c(/C=C\2/C(=O)Nc3c(S/2)ccc(C(=O)NC[C@@H]2N(CC)CCC2)c3)cccc1
NCGC00381558-03&NCGC00381558-06	Fc1c(C(=O)N2CCC(OC)CC2)cc(CC2=NNC(=O)c3c2cccc3)cc1		Inactive	PARP Inhibitor		2	AZD-2461	434147236.0&363679154.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&-16.0	Fc1c(C(=O)N2CCC(OC)CC2)cc(CC2=NNC(=O)c3c2cccc3)cc1	Fc1c(C(=O)N2CCC(OC)CC2)cc(CC2=NNC(=O)c3c2cccc3)cc1
NCGC00485403-01	Fc1c(C(=O)N2CCC2)ccc(Oc2c3c(OC(C)(C)C3)cc(C(=O)Nc3nn(C)cc3)c2)c1		Inactive			1	PF-04279405	363681316.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(C(=O)N2CCC2)ccc(Oc2c3c(OC(C)(C)C3)cc(C(=O)Nc3nn(C)cc3)c2)c1	Fc1c(C(=O)N2CCC2)ccc(Oc2c3c(OC(C)(C)C3)cc(C(=O)Nc3nn(C)cc3)c2)c1
NCGC00238451-08&NCGC00238451-09&NCGC00238451-11	Fc1c(C(=O)N2CCN(C(=O)C3CC3)CC2)cc(CC2=NNC(=O)c3c2cccc3)cc1		Inactive	PARP Inhibitor		3	Olaparib	434147062.0&363677132.0&405559119.0	Anti-infectives&Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	10.5&0.0&0.0	Fc1c(C(=O)N2CCN(C(=O)C3CC3)CC2)cc(CC2=NNC(=O)c3c2cccc3)cc1	Fc1c(C(=O)N2CCN(C(=O)C3CC3)CC2)cc(CC2=NNC(=O)c3c2cccc3)cc1
NCGC00386677-01	Fc1c(C(=O)N2CCNCCC2)cc(CC2=NNC(=O)c3c2cccc3)cc1		Inactive	Poly [ADP-ribose] polymerase-1 Inhibitor		1	KU 0058948 hydrochloride	363680390.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(C(=O)N2CCNCCC2)cc(CC2=NNC(=O)c3c2cccc3)cc1	Fc1c(C(=O)N2CCNCCC2)cc(CC2=NNC(=O)c3c2cccc3)cc1
NCGC00379242-02	Fc1c(C(=O)N2C[C@H](O)CCC2)ccc(C#Cc2ccc(OC)cc2)c1		Inactive			1	ML 337	363678442.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(C(=O)N2C[C@H](O)CCC2)ccc(C#Cc2ccc(OC)cc2)c1	Fc1c(C(=O)N2C[C@H](O)CCC2)ccc(C#Cc2ccc(OC)cc2)c1
NCGC00346647-03	Fc1c(C(=O)NC)c(Nc2nc(Nc3c(OC)cc4c(N(C(=O)CN(C)C)CC4)c3)nc3[nH]ccc23)ccc1		Inactive	IGF-1R Inhibitor		1	GSK-1838705A	384568878.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-10.3323397919	Fc1c(C(=O)NC)c(Nc2nc(Nc3c(OC)cc4c(N(C(=O)CN(C)C)CC4)c3)nc3[nH]ccc23)ccc1	Fc1c(C(=O)NC)c(Nc2nc(Nc3c(OC)cc4c(N(C(=O)CN(C)C)CC4)c3)nc3[nH]ccc23)ccc1
NCGC00346702-05	Fc1c(C(=O)NC)ccc(C2=Nn3c(Cc4cc5c(nccc5)cc4)cnc3N=C2)c1		Inactive	HGFR Inhibitor		1	Capmatinib	363677527.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.3749312799	Fc1c(C(=O)NC)ccc(C2=Nn3c(Cc4cc5c(nccc5)cc4)cnc3N=C2)c1	Fc1c(C(=O)NC)ccc(C2=Nn3c(Cc4cc5c(nccc5)cc4)cnc3N=C2)c1
NCGC00387488-03	Fc1c(C(=O)NC2CCN(C)CC2)cc(OC)c(Nc2nc3N(C4CCCC4)CC(F)(F)C(=O)N(C)c3cn2)c1		Inactive	Polo-like Kinase-1 (Plk-1) Inhibitor		1	TAK-960	363680640.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(C(=O)NC2CCN(C)CC2)cc(OC)c(Nc2nc3N(C4CCCC4)CC(F)(F)C(=O)N(C)c3cn2)c1	Fc1c(C(=O)NC2CCN(C)CC2)cc(OC)c(Nc2nc3N(C4CCCC4)CC(F)(F)C(=O)N(C)c3cn2)c1
NCGC00370920-01	Fc1c(C(=O)NCCc2c(C)[nH]c3c2cccc3)cccc1		Inactive	Actin-related protein 2 Inhibitor		1	CK 666	363677935.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(C(=O)NCCc2c(C)[nH]c3c2cccc3)cccc1	Fc1c(C(=O)NCCc2c(C)[nH]c3c2cccc3)cccc1
NCGC00485473-01	Fc1c(C(=O)NC[C@]2(N)CN(c3ncnc4[nH]cc(CC)c34)CC2)ccc(F)c1		Inactive	Serine/threonine-protein kinase AKT Inhibitor		1	AKT inhibitor	363681342.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(C(=O)NC[C@]2(N)CN(c3ncnc4[nH]cc(CC)c34)CC2)ccc(F)c1	Fc1c(C(=O)NC[C@]2(N)CN(c3ncnc4[nH]cc(CC)c34)CC2)ccc(F)c1
NCGC00390603-01	Fc1c(C(=O)N[C@H](C(=O)O)Cc2ccc(-c3c(OC)cc(COCC)cc3OC)cc2)c(F)ccc1		Inactive			1	Firategrast	363680923.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(C(=O)N[C@H](C(=O)O)Cc2ccc(-c3c(OC)cc(COCC)cc3OC)cc2)c(F)ccc1	Fc1c(C(=O)N[C@H](C(=O)O)Cc2ccc(-c3c(OC)cc(COCC)cc3OC)cc2)c(F)ccc1
NCGC00386875-01	Fc1c(C(=O)Nc2c(C(=O)O)sc(-c3ccc(OCC)cc3)c2)c(F)ccc1		Inactive			1	NCGC00386875-01	363680478.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(C(=O)Nc2c(C(=O)O)sc(-c3ccc(OCC)cc3)c2)c(F)ccc1	Fc1c(C(=O)Nc2c(C(=O)O)sc(-c3ccc(OCC)cc3)c2)c(F)ccc1
NCGC00402338-02	Fc1c(C(=O)Nc2ccc(-c3c(OC)ccc(OC)c3)cc2)ccnc1		Inactive			1	Synta66	363681028.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(C(=O)Nc2ccc(-c3c(OC)ccc(OC)c3)cc2)ccnc1	Fc1c(C(=O)Nc2ccc(-c3c(OC)ccc(OC)c3)cc2)ccnc1
NCGC00386652-01	Fc1c(C(=O)Nc2ccc(C3=C(C)CCN(c4sccn4)C3)cc2)c(F)ccc1		Inactive	ORAI 1/2/3 Inhibitor		1	CRAC inhibitor 44	363680374.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(C(=O)Nc2ccc(C3=C(C)CCN(c4sccn4)C3)cc2)c(F)ccc1	Fc1c(C(=O)Nc2ccc(C3=C(C)CCN(c4sccn4)C3)cc2)c(F)ccc1
NCGC00485873-01	Fc1c(C(=O)Nc2n[nH]cc2)c(F)ccc1		Inactive			1	CRAC intermediate 1	363681385.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(C(=O)Nc2n[nH]cc2)c(F)ccc1	Fc1c(C(=O)Nc2n[nH]cc2)c(F)ccc1
NCGC00479176-02	Fc1c(C(=O)Nc2nc(-c3n(C(C)C)cnn3)ccc2)cc(-n2cc(C3CC3)nc2)c(C)c1		Inactive	ASK1 Inhibitor		1	Selonsertib	363681104.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(C(=O)Nc2nc(-c3n(C(C)C)cnn3)ccc2)cc(-n2cc(C3CC3)nc2)c(C)c1	Fc1c(C(=O)Nc2nc(-c3n(C(C)C)cnn3)ccc2)cc(-n2cc(C3CC3)nc2)c(C)c1
NCGC00242477-02	Fc1c(C(=O)O)ccc(-c2sc(C)c(OCCOCCCC)n2)c1		Inactive	RARbeta2 Agonist		1	AC-261066	384568490.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(C(=O)O)ccc(-c2sc(C)c(OCCOCCCC)n2)c1	Fc1c(C(=O)O)ccc(-c2sc(C)c(OCCOCCCC)n2)c1
NCGC00346693-02	Fc1c(C(=O)c2c(OCCCC)c3c([nH]nc3)nc2)c(F)cc(C)c1		Inactive	CDK1/2 Inhibitor		1	BMS-265246	384568915.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.68410042	Fc1c(C(=O)c2c(OCCCC)c3c([nH]nc3)nc2)c(F)cc(C)c1	Fc1c(C(=O)c2c(OCCCC)c3c([nH]nc3)nc2)c(F)cc(C)c1
NCGC00244250-02	Fc1c(C(=O)n2c(N)nc(Nc3ccc(N(C)C)cc3)n2)c(F)ccc1		Inactive	Tyk 2 Inhibitor		1	NCGC00244250	174006689.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.0	Fc1c(C(=O)n2c(N)nc(Nc3ccc(N(C)C)cc3)n2)c(F)ccc1	Fc1c(C(=O)n2c(N)nc(Nc3ccc(N(C)C)cc3)n2)c(F)ccc1
NCGC00188690-02&NCGC00188690-09	Fc1c(C(C(=O)C2CC2)N2Cc3c(sc(OC(=O)C)c3)CC2)cccc1		Inactive	P2Y12 (P2T) Antagonist		2	Prasugrel	174006898.0&384568451.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c(C(C(=O)C2CC2)N2Cc3c(sc(OC(=O)C)c3)CC2)cccc1.Cl	Fc1c(C(C(=O)C2CC2)N2Cc3c(sc(OC(=O)C)c3)CC2)cccc1.Cl&Fc1c(C(C(=O)C2CC2)N2Cc3c(sc(OC(=O)C)c3)CC2)cccc1
NCGC00095089-10&NCGC00095089-21	Fc1c(C(O)(Cn2ncnc2)Cn2ncnc2)ccc(F)c1		Inactive	Antifungal Agent		2	Fluconazole	170464782.0&384568143.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Fc1c(C(O)(Cn2ncnc2)Cn2ncnc2)ccc(F)c1	Fc1c(C(O)(Cn2ncnc2)Cn2ncnc2)ccc(F)c1
NCGC00386332-03	Fc1c(C)c(-c2ncc(C(=O)NCC(C)(C)C)cc2)cc(C(=O)NC2CC2)c1		Inactive	MAP kinase p38 beta Inhibitor		1	Losmapimod	363680217.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	16.215549004	Fc1c(C)c(-c2ncc(C(=O)NCC(C)(C)C)cc2)cc(C(=O)NC2CC2)c1	Fc1c(C)c(-c2ncc(C(=O)NCC(C)(C)C)cc2)cc(C(=O)NC2CC2)c1
NCGC00387189-01	Fc1c(C)c(C2=C(F)c3n(c(C(C)(C)C)nn3)C=C2F)cc(C(=O)NC2CC2)c1		Inactive	p38 MAPK Inhibitor		1	AL-8697	363680564.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.982662968	Fc1c(C)c(C2=C(F)c3n(c(C(C)(C)C)nn3)C=C2F)cc(C(=O)NC2CC2)c1	Fc1c(C)c(C2=C(F)c3n(c(C(C)(C)C)nn3)C=C2F)cc(C(=O)NC2CC2)c1
NCGC00167527-03	Fc1c(C)c2C(=O)C(C(=O)O)=CN(C3CC3)c2cc1N1CC(C)NCC1		Inactive	Topoisomerase IV Inhibitor		1	Grepafloxacin hydrochloride	170466148.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(C)c2C(=O)C(C(=O)O)=CN(C3CC3)c2cc1N1CC(C)NCC1.Cl	Fc1c(C)c2C(=O)C(C(=O)O)=CN(C3CC3)c2cc1N1CC(C)NCC1.Cl
NCGC00249910-01	Fc1c(C)c2c3N(C(C)CC2)C=C(C(=O)O)C(=O)c3c1		Inactive	Bacterial DNA gyrase Inhibitor		1	Ibafloxacine	170466478.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Fc1c(C)c2c3N(C(C)CC2)C=C(C(=O)O)C(=O)c3c1	Fc1c(C)c2c3N(C(C)CC2)C=C(C(=O)O)C(=O)c3c1
NCGC00390584-01	Fc1c(C)c2c3c(nc4c(c3[C@@H](N)CC2)CN2C(=O)C3=C([C@@](O)(CC)C(=O)OC3)C=C42)c1		Inactive	DNA Topoisomerase I Inhibitor		1	Exatecan	384569198.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c(C)c2c3c(nc4c(c3[C@@H](N)CC2)CN2C(=O)C3=C([C@@](O)(CC)C(=O)OC3)C=C42)c1	Fc1c(C)c2c3c(nc4c(c3[C@@H](N)CC2)CN2C(=O)C3=C([C@@](O)(CC)C(=O)OC3)C=C42)c1
NCGC00351982-01	Fc1c(C)cc(-c2occ(CN3CCC(C(=O)NCCCN4C[C@H](C)C[C@H](C)C4)CC3)n2)cc1	5.3499999	Active		0.0	1	NCGC00351982-01	440681235.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	2.2	54.4379587142	Fc1c(C)cc(-c2occ(CN3CCC(C(=O)NCCCN4C[C@H](C)C[C@H](C)C4)CC3)n2)cc1	Fc1c(C)cc(-c2occ(CN3CCC(C(=O)NCCCN4C[C@H](C)C[C@H](C)C4)CC3)n2)cc1
NCGC00387774-01	Fc1c(C)cc(CNC(=O)c2ncnc(C(=O)NCc3cc(C)c(F)cc3)c2)cc1		Inactive	Matrix metalloproteinase 13 Inhibitor		1	MMP-13 inhibitor	363680661.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(C)cc(CNC(=O)c2ncnc(C(=O)NCc3cc(C)c(F)cc3)c2)cc1	Fc1c(C)cc(CNC(=O)c2ncnc(C(=O)NCc3cc(C)c(F)cc3)c2)cc1
NCGC00510463-03	Fc1c(C)cc(N2C(=O)C=Cc3c2c2c([nH]cc2)nc3)cc1		Inactive	STK16 kinase Inhibitor		1	STK16-IN-1	384569437.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(C)cc(N2C(=O)C=Cc3c2c2c([nH]cc2)nc3)cc1	Fc1c(C)cc(N2C(=O)C=Cc3c2c2c([nH]cc2)nc3)cc1
NCGC00167534-02	Fc1c(C2(N)CC2)c2OC[C@H](C)N3c2c(C(=O)C(C(=O)O)=C3)c1		Inactive	Topoisomerase IV Inhibitor		1	Pazufloxacin	170465985.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(C2(N)CC2)c2OC[C@H](C)N3c2c(C(=O)C(C(=O)O)=C3)c1	Fc1c(C2(N)CC2)c2OC[C@H](C)N3c2c(C(=O)C(C(=O)O)=C3)c1
NCGC00522014-01	Fc1c(C2=NCC(=O)N(C)c3n(C)nc(C)c23)cccc1		Inactive			1	Zolazepam Hydrochloride	405558721.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(C2=NCC(=O)N(C)c3n(C)nc(C)c23)cccc1	Fc1c(C2=NCC(=O)N(C)c3n(C)nc(C)c23)cccc1
NCGC00379118-01	Fc1c(C2=NOC(CC(=O)N3CCOCC3)C2)ccc(F)c1		Inactive	Macrophage migration inhibitory factor Antagonist		1	(?)-CPSI 1306	363678367.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(C2=NOC(CC(=O)N3CCOCC3)C2)ccc(F)c1	Fc1c(C2=NOC(CC(=O)N3CCOCC3)C2)ccc(F)c1
NCGC00378686-01	Fc1c(C2=N[C@H](Cc3c4c([nH]c3)cccc4)C(=O)N(C)c3c2cccc3)cccc1		Inactive	Voltage-gated potassium channel subunit Kv7.1 Activator		1	L-364,373	363678149.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(C2=N[C@H](Cc3c4c([nH]c3)cccc4)C(=O)N(C)c3c2cccc3)cccc1	Fc1c(C2=N[C@H](Cc3c4c([nH]c3)cccc4)C(=O)N(C)c3c2cccc3)cccc1
NCGC00183009-01	Fc1c(C2=N[C@H](NC(=O)c3[nH]c4c(c3)cccc4)C(=O)N3c4c2cccc4CC3)cccc1		Inactive	Cholecystokinin A receptor Antagonist		1	Pranazepide	144206813.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	14.6807942&25.0168482441	Fc1c(C2=N[C@H](NC(=O)c3[nH]c4c(c3)cccc4)C(=O)N3c4c2cccc4CC3)cccc1	Fc1c(C2=N[C@H](NC(=O)c3[nH]c4c(c3)cccc4)C(=O)N3c4c2cccc4CC3)cccc1
NCGC00381751-04	Fc1c(C=2S[C@](CCCN)(N(C(=O)N(OC)C)N=2)c2ccccc2)cc(F)cc1	4.9000001	Active	Kinesin-Like Spindle Protein Inhibitor	0.0	1	Filanesib	363679167.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	39.5895728039	Fc1c(C=2S[C@](CCCN)(N(C(=O)N(OC)C)N=2)c2ccccc2)cc(F)cc1	Fc1c(C=2S[C@](CCCN)(N(C(=O)N(OC)C)N=2)c2ccccc2)cc(F)cc1
NCGC00379098-01	Fc1c(CC2CCN(Cc3[nH]c4c(n3)ccc(O)c4)CC2)cccc1		Inactive	Glutamate receptor ionotropic, NMDA 2B Antagonist		1	TCN 237 dihydrochloride	363678349.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(CC2CCN(Cc3[nH]c4c(n3)ccc(O)c4)CC2)cccc1	Fc1c(CC2CCN(Cc3[nH]c4c(n3)ccc(O)c4)CC2)cccc1
NCGC00370998-03	Fc1c(CCC(=O)O)ccc(NCc2c3c(N(CCOc4ccccc4)CCC3)ccc2)c1		Inactive	Free fatty acid receptor 1 Agonist		1	AS2034178	363677985.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	13.0	Fc1c(CCC(=O)O)ccc(NCc2c3c(N(CCOc4ccccc4)CCC3)ccc2)c1	Fc1c(CCC(=O)O)ccc(NCc2c3c(N(CCOc4ccccc4)CCC3)ccc2)c1
NCGC00476166-01	Fc1c(CCNCC(=O)N(CC(=O)N(CC(=O)N)CCCN2C(=O)CCC2)CC(C)C)cccc1		Inactive			1	NCGC00476166-01	377020474.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(CCNCC(=O)N(CC(=O)N(CC(=O)N)CCCN2C(=O)CCC2)CC(C)C)cccc1	Fc1c(CCNCC(=O)N(CC(=O)N(CC(=O)N)CCCN2C(=O)CCC2)CC(C)C)cccc1
NCGC00263130-02	Fc1c(CN2C(=O)N(CCCC)c3[nH]c(Cc4ccc(NC(=O)C)cc4)nc3C2=O)cccc1		Inactive	cPEPCK Inhibitor		1	cPEPCK Inhibitor	363677217.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(CN2C(=O)N(CCCC)c3[nH]c(Cc4ccc(NC(=O)C)cc4)nc3C2=O)cccc1	Fc1c(CN2C(=O)N(CCCC)c3[nH]c(Cc4ccc(NC(=O)C)cc4)nc3C2=O)cccc1
NCGC00509985-02	Fc1c(CN2C(=O)N(c3ccccc3)C(=O)c3c(CN(Cc4ccccc4)C)c(-c4ccc(NC(=O)NOC)cc4)sc23)c(F)ccc1	4.9000001	Active	GnRH (LHRH) Receptor Antagonist	0.0	1	Sufugolix	384569395.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	77.689447548	Fc1c(CN2C(=O)N(c3ccccc3)C(=O)c3c(CN(Cc4ccccc4)C)c(-c4ccc(NC(=O)NOC)cc4)sc23)c(F)ccc1	Fc1c(CN2C(=O)N(c3ccccc3)C(=O)c3c(CN(Cc4ccccc4)C)c(-c4ccc(NC(=O)NOC)cc4)sc23)c(F)ccc1
NCGC00522107-03	Fc1c(CN2C(=O)N(c3nnc(OC)cc3)C(=O)c3c(CN(C)C)c(-c4ccc(NC(=O)NOC)cc4)sc23)c(F)ccc1		Inactive	GnRH (LHRH) Receptor Antagonist		1	Relugolix	384569513.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(CN2C(=O)N(c3nnc(OC)cc3)C(=O)c3c(CN(C)C)c(-c4ccc(NC(=O)NOC)cc4)sc23)c(F)ccc1	Fc1c(CN2C(=O)N(c3nnc(OC)cc3)C(=O)c3c(CN(C)C)c(-c4ccc(NC(=O)NOC)cc4)sc23)c(F)ccc1
NCGC00386988-01	Fc1c(CN2CCCC2)ccc(C2(F)CC(C(=O)NCC)C2)c1		Inactive	Histamine H3 receptor Antagonist		1	PF 3654746	363680521.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(CN2CCCC2)ccc(C2(F)CC(C(=O)NCC)C2)c1	Fc1c(CN2CCCC2)ccc(C2(F)CC(C(=O)NCC)C2)c1
NCGC00263202-06	Fc1c(CN2CCOCC2)c(F)cc(-c2c3nc(-c4cn(C5CCNCC5)nc4)cnc3ccc2)c1		Inactive	Jak2 Inhibitor		1	NVP-BSK805	384568661.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(CN2CCOCC2)c(F)cc(-c2c3nc(-c4cn(C5CCNCC5)nc4)cnc3ccc2)c1	Fc1c(CN2CCOCC2)c(F)cc(-c2c3nc(-c4cn(C5CCNCC5)nc4)cnc3ccc2)c1
NCGC00601813-01	Fc1c(CNC(=O)C=2C(=O)C(O)=C3C(=O)N4C(OC5CC4CC5)CN3C=2)c(F)cc(F)c1		Inactive			1	Bictegravir	434147180.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(CNC(=O)C=2C(=O)C(O)=C3C(=O)N4C(OC5CC4CC5)CN3C=2)c(F)cc(F)c1	Fc1c(CNC(=O)C=2C(=O)C(O)=C3C(=O)N4C(OC5CC4CC5)CN3C=2)c(F)cc(F)c1
NCGC00386434-02	Fc1c(CNC(=O)C=2C(=O)C(O)=C3C(=O)N4[C@@H](C)CO[C@@H]4CN3C=2)ccc(F)c1		Inactive	Solute carrier family 22 member 8 Inhibitor		1	GSK744 (S/GSK1265744)	363680286.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(CNC(=O)C=2C(=O)C(O)=C3C(=O)N4[C@@H](C)CO[C@@H]4CN3C=2)ccc(F)c1	Fc1c(CNC(=O)C=2C(=O)C(O)=C3C(=O)N4[C@@H](C)CO[C@@H]4CN3C=2)ccc(F)c1
NCGC00346629-02&NCGC00346629-09	Fc1c(CNC(=O)C=2C(=O)C(O)=C3C(=O)N4[C@H](C)CCO[C@H]4CN3C=2)ccc(F)c1		Inactive	HIV Integrase Inhibitors		2	Dolutegravir (GSK1349572)&GSK1349572	405558481.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c(CNC(=O)C=2C(=O)C(O)=C3C(=O)N4[C@H](C)CCO[C@H]4CN3C=2)ccc(F)c1	Fc1c(CNC(=O)C=2C(=O)C(O)=C3C(=O)N4[C@H](C)CCO[C@H]4CN3C=2)ccc(F)c1
NCGC00370789-01	Fc1c(COc2ccc(CN[C@H](C(=O)N)C)cc2)cccc1		Inactive	Monoamine oxidase B Inhibitor		1	Ralfinamide mesylate	363677857.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(COc2ccc(CN[C@H](C(=O)N)C)cc2)cccc1	Fc1c(COc2ccc(CN[C@H](C(=O)N)C)cc2)cccc1
NCGC00378867-01	Fc1c(COc2ccc(Oc3c(N)cc(OCC)cc3)cc2)cc(F)cc1		Inactive	Sodium/calcium exchanger 1 Blocker		1	SEA0400	363678247.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(COc2ccc(Oc3c(N)cc(OCC)cc3)cc2)cc(F)cc1	Fc1c(COc2ccc(Oc3c(N)cc(OCC)cc3)cc2)cc(F)cc1
NCGC00386656-01	Fc1c(COc2ccc([C@@H]3N[C@H](C(=O)N)CC3)cc2)cccc1		Inactive	Sodium channel protein type IX alpha subunit Blocker		1	GSK2	363680375.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(COc2ccc([C@@H]3N[C@H](C(=O)N)CC3)cc2)cccc1	Fc1c(COc2ccc([C@@H]3N[C@H](C(=O)N)CC3)cc2)cccc1
NCGC00378606-02	Fc1c(Cc2sc3c(c2)cccc3)cc([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1		Inactive	Sodium/glucose cotransporter 2 Inhibitor		1	Ipragliflozin	405558762.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Cc2sc3c(c2)cccc3)cc([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1	Fc1c(Cc2sc3c(c2)cccc3)cc([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1
NCGC00165759-02	Fc1c(Cn2nc(-c3nc(N)c(C4CC4)cn3)c3c2nccc3)cccc1		Inactive	Soluble Guanylate Cyclase (sGC) Activator		1	BAY-41-2272	384568278.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Cn2nc(-c3nc(N)c(C4CC4)cn3)c3c2nccc3)cccc1	Fc1c(Cn2nc(-c3nc(N)c(C4CC4)cn3)c3c2nccc3)cccc1
NCGC00379065-03&NCGC00379065-05	Fc1c(Cn2nc(-c3nc(N)c(N(C(=O)OC)C)c(N)n3)c3c2nccc3)cccc1		Inactive	Soluble Guanylate Cyclase (sGC) Activator		2	Riociguat	363678334.0&405558591.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c(Cn2nc(-c3nc(N)c(N(C(=O)OC)C)c(N)n3)c3c2nccc3)cccc1	Fc1c(Cn2nc(-c3nc(N)c(N(C(=O)OC)C)c(N)n3)c3c2nccc3)cccc1
NCGC00263227-02	Fc1c(Cn2nc(-c3nc(N)c(N4CCOCC4)c(N)n3)c3c2nccc3)cccc1		Inactive	Soluble Guanylate Cyclase (sGC) Activator		1	BAY-41-8543	384568679.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Cn2nc(-c3nc(N)c(N4CCOCC4)c(N)n3)c3c2nccc3)cccc1	Fc1c(Cn2nc(-c3nc(N)c(N4CCOCC4)c(N)n3)c3c2nccc3)cccc1
NCGC00165883-04	Fc1c(Cn2nnc(C(=O)N)c2)c(F)ccc1		Inactive	Sodium channel protein type IX alpha subunit Modulator		1	Rufinamide	170465202.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Cn2nnc(C(=O)N)c2)c(F)ccc1	Fc1c(Cn2nnc(C(=O)N)c2)c(F)ccc1
NCGC00319021-01	Fc1c(F)c(COC)c(F)c(F)c1COC(=O)C1C(C)(C)C1/C=C/C		Inactive	DNA synthesis involved in DNA replication Activator		1	NCGC00319021-01	225144375.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(F)c(COC)c(F)c(F)c1COC(=O)C1C(C)(C)C1/C=C/C	Fc1c(F)c(COC)c(F)c(F)c1COC(=O)C1C(C)(C)C1/C=C/C
NCGC00402366-02	Fc1c(F)cc(F)cc1C#CCN1C[C@H](C(=O)O)[C@H](CCC(=O)c2c3c(ncc2)ccc(OC)c3)CC1		Inactive	HERG Activator		1	RPR-260243	363681044.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(F)cc(F)cc1C#CCN1C[C@H](C(=O)O)[C@H](CCC(=O)c2c3c(ncc2)ccc(OC)c3)CC1	Fc1c(F)cc(F)cc1C#CCN1C[C@H](C(=O)O)[C@H](CCC(=O)c2c3c(ncc2)ccc(OC)c3)CC1
NCGC00485942-01	Fc1c(F)cc([C@H]2N3C(=O)/C(=C/c4cc(OC)c(-n5cc(C)nc5)cc4)/CC[C@H]3COC2)cc1F		Inactive	Gamma-secretase Modulator		1	gamma-Secretase Modulators	363681433.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(F)cc([C@H]2N3C(=O)/C(=C/c4cc(OC)c(-n5cc(C)nc5)cc4)/CC[C@H]3COC2)cc1F	Fc1c(F)cc([C@H]2N3C(=O)/C(=C/c4cc(OC)c(-n5cc(C)nc5)cc4)/CC[C@H]3COC2)cc1F
NCGC00387246-01	Fc1c(F)ccc(-c2nc(N3CCN(C(=O)Nc4nnccc4)CC3)ncc2)c1		Inactive	Anandamide amidohydrolase Inhibitor		1	TAK 21d	363680591.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(F)ccc(-c2nc(N3CCN(C(=O)Nc4nnccc4)CC3)ncc2)c1	Fc1c(F)ccc(-c2nc(N3CCN(C(=O)Nc4nnccc4)CC3)ncc2)c1
NCGC00263105-06	Fc1c(F)ccc(C(=O)N2C=C(C(=O)OC(C)C)c3[nH]c4c(c3C(C)(C)C2)cccc4)c1		Inactive	Farnesoid X Receptor Agonist		1	Turofexorate isopropyl	363677205.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(F)ccc(C(=O)N2C=C(C(=O)OC(C)C)c3[nH]c4c(c3C(C)(C)C2)cccc4)c1	Fc1c(F)ccc(C(=O)N2C=C(C(=O)OC(C)C)c3[nH]c4c(c3C(C)(C)C2)cccc4)c1
NCGC00370847-01	Fc1c(F)ccc(C(=O)NC2CCC(Nc3nc(N(C)C)c4c(n3)cccc4)CC2)c1		Inactive	Serotonin 1a (5-HT1a) receptor Partial Agonist		1	ATC 0175 hydrochloride	363677883.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(F)ccc(C(=O)NC2CCC(Nc3nc(N(C)C)c4c(n3)cccc4)CC2)c1	Fc1c(F)ccc(C(=O)NC2CCC(Nc3nc(N(C)C)c4c(n3)cccc4)CC2)c1
NCGC00379229-03	Fc1c(F)ccc(C(=O)NCCN2CCC3(N(c4cc(F)ccc4)CNC3=O)CC2)c1		Inactive	Phospholipase D2 Inhibitor		1	ML298	363678434.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(F)ccc(C(=O)NCCN2CCC3(N(c4cc(F)ccc4)CNC3=O)CC2)c1	Fc1c(F)ccc(C(=O)NCCN2CCC3(N(c4cc(F)ccc4)CNC3=O)CC2)c1
NCGC00346947-02	Fc1c(F)ccc(CN2C(=O)C(C(=O)N[C@@H](COc3cc4NC(=O)Nc4cc3)c3ccccc3)=CC=C2)c1		Inactive	Phosphoinositide Dependent Kinase Inhibitor		1	PDPK1 Inhibitor	363677565.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	29.228088544	Fc1c(F)ccc(CN2C(=O)C(C(=O)N[C@@H](COc3cc4NC(=O)Nc4cc3)c3ccccc3)=CC=C2)c1	Fc1c(F)ccc(CN2C(=O)C(C(=O)N[C@@H](COc3cc4NC(=O)Nc4cc3)c3ccccc3)=CC=C2)c1
NCGC00386853-05	Fc1c(F)ccc(NC(=O)Nc2n(-c3ccccc3)nc(C)c2)c1		Inactive	Kir3.1/Kir3.2 Activator		1	ML297	363680466.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(F)ccc(NC(=O)Nc2n(-c3ccccc3)nc(C)c2)c1	Fc1c(F)ccc(NC(=O)Nc2n(-c3ccccc3)nc(C)c2)c1
NCGC00346721-04	Fc1c(F)ccc(NCC(=O)Nc2c(C)ccc(CN3CCNCC3)c2)c1		Inactive	P2X7 Receptor Antagonist		1	GW-791343	363677536.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(F)ccc(NCC(=O)Nc2c(C)ccc(CN3CCNCC3)c2)c1	Fc1c(F)ccc(NCC(=O)Nc2c(C)ccc(CN3CCNCC3)c2)c1
NCGC00387203-01	Fc1c(F)ccc(Nc2oc(C(=O)Nc3ccc(C4CCC(CC(=O)O)CC4)cc3)nn2)c1		Inactive	Diacylglycerol O-acyltransferase 1 Inhibitor		1	AZD 3988	363680566.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(F)ccc(Nc2oc(C(=O)Nc3ccc(C4CCC(CC(=O)O)CC4)cc3)nn2)c1	Fc1c(F)ccc(Nc2oc(C(=O)Nc3ccc(C4CCC(CC(=O)O)CC4)cc3)nn2)c1
NCGC00370900-01	Fc1c(F)ccc(Oc2ccc(CN3CCC(c4c(C)ccc(NC(=O)C(C)C)c4)CC3)cc2)c1	4.9000001	Active	Melanin-concentrating hormone receptor 1 Antagonist	0.0	1	SNAP 94847 hydrochloride	363677920.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	102.2604050036	Fc1c(F)ccc(Oc2ccc(CN3CCC(c4c(C)ccc(NC(=O)C(C)C)c4)CC3)cc2)c1	Fc1c(F)ccc(Oc2ccc(CN3CCC(c4c(C)ccc(NC(=O)C(C)C)c4)CC3)cc2)c1
NCGC00510078-03	Fc1c(F)ccc2nc(CNc3nc(N4CCOCC4)nc4n(-c5cc(F)ccc5)cnc34)[nH]c12		Inactive	CDK6 Inhibitor		1	SR-3029	384569408.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-23.25081364	Fc1c(F)ccc2nc(CNc3nc(N4CCOCC4)nc4n(-c5cc(F)ccc5)cnc34)[nH]c12	Fc1c(F)ccc2nc(CNc3nc(N4CCOCC4)nc4n(-c5cc(F)ccc5)cnc34)[nH]c12
NCGC00378677-01	Fc1c(F)cccc1[C@H]1[C@H](N)c2c([C@H](OC(=O)N3CCC(N4C(=O)Nc5ncccc45)CC3)CC1)nccc2		Inactive			1	BMS-927711	363678145.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(F)cccc1[C@H]1[C@H](N)c2c([C@H](OC(=O)N3CCC(N4C(=O)Nc5ncccc45)CC3)CC1)nccc2	Fc1c(F)cccc1[C@H]1[C@H](N)c2c([C@H](OC(=O)N3CCC(N4C(=O)Nc5ncccc45)CC3)CC1)nccc2
NCGC00481604-01	Fc1c(N/C(/O)=N/CCC(C)(C)C)cc(c(C)c1)-c1c(C)nc2N/C(=N/C)/N=Cc2c1		Inactive	Raf Kinase Inhibitor		1	LY-3009120	377020508.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(N/C(/O)=N/CCC(C)(C)C)cc(c(C)c1)-c1c(C)nc2N/C(=N/C)/N=Cc2c1	Fc1c(N/C(/O)=N/CCC(C)(C)C)cc(c(C)c1)-c1c(C)nc2N/C(=N/C)/N=Cc2c1
NCGC00178711-03	Fc1c(N2C/C(=N\OC)/C(CN)C2)nc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1		Inactive	Topoisomerase IV subunit A  Inhibitor		1	Gemifloxacin mesylate	170465333.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)C.Fc1c(N2C/C(=N\OC)/C(CN)C2)nc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1	S(=O)(=O)(O)C.Fc1c(N2C/C(=N\OC)/C(CN)C2)nc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1
NCGC00015603-08&NCGC00015603-14	Fc1c(N2CC(C)NCC2)c(F)cc2C(=O)C(C(=O)O)=CN(CC)c12		Inactive	Quinoline Antibiotic		2	Lomefloxacin hydrochloride	170465262.0&384567871.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Fc1c(N2CC(C)NCC2)c(F)cc2C(=O)C(C(=O)O)=CN(CC)c12.Cl	Fc1c(N2CC(C)NCC2)c(F)cc2C(=O)C(C(=O)O)=CN(CC)c12.Cl&Fc1c(N2CC(C)NCC2)c(F)cc2C(=O)C(C(=O)O)=CN(CC)c12
NCGC00068236-07&NCGC00068236-11	Fc1c(N2CC(C)NCC2)c(OC)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1		Inactive	DNA Topoisomerase IV Inhibitor		2	Gatifloxacin	170465592.0&384568072.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Fc1c(N2CC(C)NCC2)c(OC)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1	Fc1c(N2CC(C)NCC2)c(OC)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1
NCGC00167532-02&NCGC00167532-05	Fc1c(N2CC(NC)CCC2)c(OC)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1		Inactive	Antibacterial		2	Balofloxacin	170465911.0&384568327.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c(N2CC(NC)CCC2)c(OC)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1	Fc1c(N2CC(NC)CCC2)c(OC)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1
NCGC00164620-02	Fc1c(N2CCC(O)CC2)c2c3N(C(C)CC2)C=C(C(=O)O)C(=O)c3c1		Inactive	DNA gyrase Inhibitor		1	Nadifloxacin	170465882.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c(N2CCC(O)CC2)c2c3N(C(C)CC2)C=C(C(=O)O)C(=O)c3c1	Fc1c(N2CCC(O)CC2)c2c3N(C(C)CC2)C=C(C(=O)O)C(=O)c3c1
NCGC00378601-01	Fc1c(N2CCN(C(=O)CO)CC2)ccc(N2C(=O)O[C@@H](CNC(=O)C)C2)c1		Inactive	Bacterial 70S ribosome Binding Agent		1	Eperezolid	363678117.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(N2CCN(C(=O)CO)CC2)ccc(N2C(=O)O[C@@H](CNC(=O)C)C2)c1	Fc1c(N2CCN(C(=O)CO)CC2)ccc(N2C(=O)O[C@@H](CNC(=O)C)C2)c1
NCGC00390574-01	Fc1c(N2CCN(C(C(=O)N(CC)CC)c3ccccc3)CC2)ccc(NC(=O)c2c(-c3cnccc3)cccc2)c1		Inactive	Neuropeptide Y receptor type 2 Antagonist		1	JNJ-31020028	363680911.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(N2CCN(C(C(=O)N(CC)CC)c3ccccc3)CC2)ccc(NC(=O)c2c(-c3cnccc3)cccc2)c1	Fc1c(N2CCN(C(C(=O)N(CC)CC)c3ccccc3)CC2)ccc(NC(=O)c2c(-c3cnccc3)cccc2)c1
NCGC00015772-20	Fc1c(N2CCN(C)CC2)c2OCC(C)N3c2c(C(=O)C(C(=O)O)=C3)c1		Inactive	Antibiotic		1	Ofloxacin	384567889.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(N2CCN(C)CC2)c2OCC(C)N3c2c(C(=O)C(C(=O)O)=C3)c1	Fc1c(N2CCN(C)CC2)c2OCC(C)N3c2c(C(=O)C(C(=O)O)=C3)c1
NCGC00166310-02	Fc1c(N2CCN(C)CC2)c2OCN(C)N3c2c(C(=O)C(C(=O)O)=C3)c1		Inactive	Antibiotic		1	Marbofloxacin	170465732.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Fc1c(N2CCN(C)CC2)c2OCN(C)N3c2c(C(=O)C(C(=O)O)=C3)c1	Fc1c(N2CCN(C)CC2)c2OCN(C)N3c2c(C(=O)C(C(=O)O)=C3)c1
NCGC00178529-06&NCGC00178529-07	Fc1c(N2CCN(C)CC2)c2OC[C@H](C)N3c2c(C(=O)C(C(=O)O)=C3)c1		Inactive	DNA Topoisomerase IV Inhibitor		2	Levofloxacin	405559032.0&384568358.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c(N2CCN(C)CC2)c2OC[C@H](C)N3c2c(C(=O)C(C(=O)O)=C3)c1	Fc1c(N2CCN(C)CC2)c2OC[C@H](C)N3c2c(C(=O)C(C(=O)O)=C3)c1
NCGC00177986-12	Fc1c(N2CCN(C)CC2)cc2N(CC)C=C(C(=O)O)C(=O)c2c1		Inactive	Antibacterial		1	Pefloxacin	384568351.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(N2CCN(C)CC2)cc2N(CC)C=C(C(=O)O)C(=O)c2c1	Fc1c(N2CCN(C)CC2)cc2N(CC)C=C(C(=O)O)C(=O)c2c1
NCGC00166308-02	Fc1c(N2CCN(C)CC2)cc2N(c3ccc(F)cc3)C=C(C(=O)O)C(=O)c2c1		Inactive	Bacterial DNA gyrase Inhibitor		1	Difloxacin hydrochloride	170465623.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(N2CCN(C)CC2)cc2N(c3ccc(F)cc3)C=C(C(=O)O)C(=O)c2c1.Cl	Fc1c(N2CCN(C)CC2)cc2N(c3ccc(F)cc3)C=C(C(=O)O)C(=O)c2c1.Cl
NCGC00507855-03	Fc1c(N2CCN(C)CC2)ccc(Nc2nc(-c3cc(CC#N)ccc3)c3c(C)c[nH]c3n2)c1		Inactive	AXL Kinase Inhibitor		1	SGI-7079	384569333.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(N2CCN(C)CC2)ccc(Nc2nc(-c3cc(CC#N)ccc3)c3c(C)c[nH]c3n2)c1	Fc1c(N2CCN(C)CC2)ccc(Nc2nc(-c3cc(CC#N)ccc3)c3c(C)c[nH]c3n2)c1
NCGC00510234-01	Fc1c(N2CCN(C)CC2)ccc(Nc2nc(Oc3cc(NC(=O)C=C)ccc3)c3c([nH]cc3)n2)c1		Inactive	EGFR Inhibitor		1	Avitinib	384569419.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(N2CCN(C)CC2)ccc(Nc2nc(Oc3cc(NC(=O)C=C)ccc3)c3c([nH]cc3)n2)c1	Fc1c(N2CCN(C)CC2)ccc(Nc2nc(Oc3cc(NC(=O)C=C)ccc3)c3c([nH]cc3)n2)c1
NCGC00018143-05	Fc1c(N2CCN(CC)CC2)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1		Inactive	Topoisomerase IV Inhibitor		1	Enrofloxacin	170465572.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(N2CCN(CC)CC2)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1	Fc1c(N2CCN(CC)CC2)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1
NCGC00164615-02&NCGC00164615-05	Fc1c(N2CCN(CC3=C(C)OC(=O)O3)CC2)cc2N3C(C)SC3=C(C(=O)O)C(=O)c2c1		Inactive	Antibacterial		2	Prulifloxacin	170465849.0&384568265.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	Fc1c(N2CCN(CC3=C(C)OC(=O)O3)CC2)cc2N3C(C)SC3=C(C(=O)O)C(=O)c2c1	Fc1c(N2CCN(CC3=C(C)OC(=O)O3)CC2)cc2N3C(C)SC3=C(C(=O)O)C(=O)c2c1
NCGC00378816-01	Fc1c(N2CCN(Cc3c(OC)ccc([C@@H]4N[C@H](C(=O)O)Cc5c6c([nH]c45)cccc6)c3)CC2)cccc1		Inactive			1	cis-Ned 19	363678216.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	16.0	Fc1c(N2CCN(Cc3c(OC)ccc([C@@H]4N[C@H](C(=O)O)Cc5c6c([nH]c45)cccc6)c3)CC2)cccc1	Fc1c(N2CCN(Cc3c(OC)ccc([C@@H]4N[C@H](C(=O)O)Cc5c6c([nH]c45)cccc6)c3)CC2)cccc1
NCGC00016959-06&NCGC00016959-17	Fc1c(N2CCNCC2)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1		Inactive	DNA Topoisomerase IV Inhibitor		2	Ciprofloxacin	170464757.0&384567969.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Fc1c(N2CCNCC2)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1.Cl	Fc1c(N2CCNCC2)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1.Cl&Fc1c(N2CCNCC2)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1
NCGC00016916-11&NCGC00016916-15	Fc1c(N2CCNCC2)cc2N(CC)C=C(C(=O)O)C(=O)c2c1		Inactive	DNA Topoisomerase IV Inhibitor		2	Norfloxacin	170464769.0&384567967.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Fc1c(N2CCNCC2)cc2N(CC)C=C(C(=O)O)C(=O)c2c1	Fc1c(N2CCNCC2)cc2N(CC)C=C(C(=O)O)C(=O)c2c1
NCGC00177995-02&NCGC00177995-10	Fc1c(N2CCNCC2)cc2N(c3ccc(F)cc3)C=C(C(=O)O)C(=O)c2c1		Inactive	Antibacterial		2	Sarafloxacin hydrochloride	170466185.0&384568352.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c(N2CCNCC2)cc2N(c3ccc(F)cc3)C=C(C(=O)O)C(=O)c2c1.Cl	Fc1c(N2CCNCC2)cc2N(c3ccc(F)cc3)C=C(C(=O)O)C(=O)c2c1.Cl&Fc1c(N2CCNCC2)cc2N(c3ccc(F)cc3)C=C(C(=O)O)C(=O)c2c1
NCGC00016927-11	Fc1c(N2CCNCC2)nc2N(CC)C=C(C(=O)O)C(=O)c2c1		Inactive	Quinoline Antibiotic		1	Enoxacin	170465263.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(N2CCNCC2)nc2N(CC)C=C(C(=O)O)C(=O)c2c1	Fc1c(N2CCNCC2)nc2N(CC)C=C(C(=O)O)C(=O)c2c1
NCGC00263531-05&NCGC00263531-10	Fc1c(N2CCOCC2)ccc(N2C(=O)O[C@@H](CNC(=O)C)C2)c1		Inactive	50S Ribosomal Protein Inhibitor		2	Linezolid	405558678.0&363677279.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Fc1c(N2CCOCC2)ccc(N2C(=O)O[C@@H](CNC(=O)C)C2)c1	Fc1c(N2CCOCC2)ccc(N2C(=O)O[C@@H](CNC(=O)C)C2)c1
NCGC00348189-02	Fc1c(N2CCSCC2)ccc(N2C(=O)O[C@@H](CNC(=O)C)C2)c1		Inactive			1	PNU 100480	363677737.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(N2CCSCC2)ccc(N2C(=O)O[C@@H](CNC(=O)C)C2)c1	Fc1c(N2CCSCC2)ccc(N2C(=O)O[C@@H](CNC(=O)C)C2)c1
NCGC00160518-03	Fc1c(N2C[C@@H](C)N[C@@H](C)C2)c(F)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1F		Inactive	DNA gyrase Binding Agent		1	Orbifloxacin	170465644.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c(N2C[C@@H](C)N[C@@H](C)C2)c(F)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1F	Fc1c(N2C[C@@H](C)N[C@@H](C)C2)c(F)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1F
NCGC00166294-03&NCGC00166294-08	Fc1c(N2C[C@@H](C)N[C@@H](C)C2)c(F)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1N		Inactive	DNA Topoisomerase IV Inhibitor		2	Sparfloxacin	170465370.0&384568305.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c(N2C[C@@H](C)N[C@@H](C)C2)c(F)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1N	Fc1c(N2C[C@@H](C)N[C@@H](C)C2)c(F)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1N
NCGC00510315-02	Fc1c(N2C[C@@H]3OCCN[C@H]3C2)c(C#N)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1		Inactive			1	Finafloxacin	405558895.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(N2C[C@@H]3OCCN[C@H]3C2)c(C#N)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1	Fc1c(N2C[C@@H]3OCCN[C@H]3C2)c(C#N)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1
NCGC00183881-01&NCGC00183881-09	Fc1c(N2C[C@H]3NCCC[C@H]3C2)c(OC)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1		Inactive	DNA Topoisomerase IV Inhibitor		2	Moxifloxacin hydrochloride	124894598.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c(N2C[C@H]3NCCC[C@H]3C2)c(OC)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1.Cl.O	Fc1c(N2C[C@H]3NCCC[C@H]3C2)c(OC)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1.Cl.O&Fc1c(N2C[C@H]3NCCC[C@H]3C2)c(OC)c2N(C3CC3)C=C(C(=O)O)C(=O)c2c1
NCGC00390654-01	Fc1c(N2N=C(c3n(-c4ccccc4)ncc3)C(=O)C(OC)=C2)ccc(-n2nccc2)c1		Inactive	Phosphodiesterase 10A Inhibitor		1	TAK-063	363680956.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(N2N=C(c3n(-c4ccccc4)ncc3)C(=O)C(OC)=C2)ccc(-n2nccc2)c1	Fc1c(N2N=C(c3n(-c4ccccc4)ncc3)C(=O)C(OC)=C2)ccc(-n2nccc2)c1
NCGC00164548-02	Fc1c(N2[C@@H]3CN(C)[C@H](C2)C3)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1		Inactive	Bacterial DNA gyrase Inhibitor		1	Danofloxacin	170466637.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(N2[C@@H]3CN(C)[C@H](C2)C3)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1	Fc1c(N2[C@@H]3CN(C)[C@H](C2)C3)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1
NCGC00485406-01	Fc1c(N2[C@@H]3CN[C@H](C2)C3)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1		Inactive	Bacterial DNA gyrase Inhibitor		1	CP-74416 methanesulfonate hydrate	363681319.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(N2[C@@H]3CN[C@H](C2)C3)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1	Fc1c(N2[C@@H]3CN[C@H](C2)C3)cc2N(C3CC3)C=C(C(=O)O)C(=O)c2c1
NCGC00183857-01	Fc1c(N2c3c(C(=O)C(C(=O)O)=C2)cc(F)c(N2CC(C)NCC2)c3)ccc(F)c1		Inactive	Bacterial DNA gyrase Inhibitor		1	Temafloxacin	144206857.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(N2c3c(C(=O)C(C(=O)O)=C2)cc(F)c(N2CC(C)NCC2)c3)ccc(F)c1	Fc1c(N2c3c(C(=O)C(C(=O)O)=C2)cc(F)c(N2CC(C)NCC2)c3)ccc(F)c1
NCGC00167536-03	Fc1c(N2c3nc(N4CC(N)CC4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1		Inactive	Topoisomerase IV Inhibitor		1	Tosufloxacin toluenesulfonic acid	170466053.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)c1ccc(C)cc1.Fc1c(N2c3nc(N4CC(N)CC4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1	S(=O)(=O)(O)c1ccc(C)cc1.Fc1c(N2c3nc(N4CC(N)CC4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1
NCGC00263538-01	Fc1c(N2c3nc(N4C[C@H]5C(N)[C@H]5C4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1		Inactive	Streptococcus pneumoniae Inhibitor		1	Trovafloxacin mesylate	170465074.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)C.Fc1c(N2c3nc(N4C[C@H]5C(N)[C@H]5C4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1	S(=O)(=O)(O)C.Fc1c(N2c3nc(N4C[C@H]5C(N)[C@H]5C4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1
NCGC00261969-01	Fc1c(N2c3nc(N4C[C@H]5C(NC(=O)[C@@H](NC(=O)[C@@H](N)C)C)(C)[C@H]5C4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1		Inactive			1	Alatrofloxacin mesylate	170465095.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)C.Fc1c(N2c3nc(N4C[C@H]5C(NC(=O)[C@@H](NC(=O)[C@@H](N)C)C)(C)[C@H]5C4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1	S(=O)(=O)(O)C.Fc1c(N2c3nc(N4C[C@H]5C(NC(=O)[C@@H](NC(=O)[C@@H](N)C)C)(C)[C@H]5C4)c(F)cc3C(=O)C(C(=O)O)=C2)ccc(F)c1
NCGC00386210-03	Fc1c(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)ccc(Oc2cc(NC(=O)N3CCC(N4CCN(C)CC4)CC3)ncc2)c1		Inactive	VEGFR-2 Inhibitor		1	Golvatinib	384569115.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)ccc(Oc2cc(NC(=O)N3CCC(N4CCN(C)CC4)CC3)ncc2)c1	Fc1c(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)ccc(Oc2cc(NC(=O)N3CCC(N4CCN(C)CC4)CC3)ncc2)c1
NCGC00389346-01	Fc1c(NC(=O)C2(c3cc4OC(F)(F)Oc4cc3)CC2)cc2c(n(CC(O)CO)c(C(CO)(C)C)c2)c1		Inactive	Cystic fibrosis transmembrane conductance regulator Modulator		1	VX-661	363680774.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(NC(=O)C2(c3cc4OC(F)(F)Oc4cc3)CC2)cc2c(n(CC(O)CO)c(C(CO)(C)C)c2)c1	Fc1c(NC(=O)C2(c3cc4OC(F)(F)Oc4cc3)CC2)cc2c(n(CC(O)CO)c(C(CO)(C)C)c2)c1
NCGC00345056-07	Fc1c(NC(=O)C2=C(C(=O)O)CCC2)ccc(-c2cc(OC)ccc2)c1		Inactive	DHODH Inhibitor		1	Vidofludimus	384568731.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Fc1c(NC(=O)C2=C(C(=O)O)CCC2)ccc(-c2cc(OC)ccc2)c1	Fc1c(NC(=O)C2=C(C(=O)O)CCC2)ccc(-c2cc(OC)ccc2)c1
NCGC00510789-01	Fc1c(NC(=O)N[C@@H]2C(=O)Nc3c(C(c4ccccc4)=N2)cccc3)cccc1		Inactive			1	RSV604	434147167.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(NC(=O)N[C@@H]2C(=O)Nc3c(C(c4ccccc4)=N2)cccc3)cccc1	Fc1c(NC(=O)N[C@@H]2C(=O)Nc3c(C(c4ccccc4)=N2)cccc3)cccc1
NCGC00522593-01	Fc1c(NC(=O)N[C@H]2C(=O)Nc3c(C(c4ccccc4)=N2)cccc3)cccc1		Inactive			1	RSV604 (R enantiomer)	434147176.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(NC(=O)N[C@H]2C(=O)Nc3c(C(c4ccccc4)=N2)cccc3)cccc1	Fc1c(NC(=O)N[C@H]2C(=O)Nc3c(C(c4ccccc4)=N2)cccc3)cccc1
NCGC00167768-11	Fc1c(NC(=O)Nc2c(F)cc(Oc3c4c(ncc3)cc(OC)c(OC)c4)cc2)ccc(F)c1		Inactive	VEGFR-2 Inhibitor		1	KI-8751	377020487.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(NC(=O)Nc2c(F)cc(Oc3c4c(ncc3)cc(OC)c(OC)c4)cc2)ccc(F)c1	Fc1c(NC(=O)Nc2c(F)cc(Oc3c4c(ncc3)cc(OC)c(OC)c4)cc2)ccc(F)c1
NCGC00250403-11	Fc1c(NC(=O)Nc2ccc(-c3c4c(N)n[nH]c4ccc3)cc2)cc(C)cc1	4.9499998	Active	VEGFR-2 Inhibitor	0.0	1	Linifanib	377020321.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.4	30.8410041799	Fc1c(NC(=O)Nc2ccc(-c3c4c(N)n[nH]c4ccc3)cc2)cc(C)cc1	Fc1c(NC(=O)Nc2ccc(-c3c4c(N)n[nH]c4ccc3)cc2)cc(C)cc1
NCGC00346618-07	Fc1c(NC(=O)Nc2cnc(C)cc2)cccc1CN1CCN(C(=O)OC)CC1		Inactive	Cardiac Myosin Activator		1	Omecamtiv mecarbil	363677479.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(NC(=O)Nc2cnc(C)cc2)cccc1CN1CCN(C(=O)OC)CC1	Fc1c(NC(=O)Nc2cnc(C)cc2)cccc1CN1CCN(C(=O)OC)CC1
NCGC00386510-01	Fc1c(NC(=O)[C@H](O)c2cc3C(C)(C)CCC(C)(C)c3cc2)ccc(C(=O)O)c1		Inactive	Retinoic acid receptor gamma Agonist		1	BMS 270394	363680310.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	15.3297458159	Fc1c(NC(=O)[C@H](O)c2cc3C(C)(C)CCC(C)(C)c3cc2)ccc(C(=O)O)c1	Fc1c(NC(=O)[C@H](O)c2cc3C(C)(C)CCC(C)(C)c3cc2)ccc(C(=O)O)c1
NCGC00346706-07	Fc1c(NC(=O)c2ccc(OCCCC)cc2)ccc(F)c1		Inactive	mgluR5 allosteric modulator		1	VU0357121	363677528.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(NC(=O)c2ccc(OCCCC)cc2)ccc(F)c1	Fc1c(NC(=O)c2ccc(OCCCC)cc2)ccc(F)c1
NCGC00387023-02	Fc1c(NC(=O)c2n(C)nc(C)c2)cc(Nc2cc3n[nH]c(/C=C/c4ncccc4)c3cc2)cc1		Inactive	VEGFR-2 Inhibitor		1	AG-13958	384569148.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	21.5	Fc1c(NC(=O)c2n(C)nc(C)c2)cc(Nc2cc3n[nH]c(/C=C/c4ncccc4)c3cc2)cc1	Fc1c(NC(=O)c2n(C)nc(C)c2)cc(Nc2cc3n[nH]c(/C=C/c4ncccc4)c3cc2)cc1
NCGC00345844-02	Fc1c(NC(CO)(C)C)nc(Nc2cc(NC(=O)NC(C)(C)C)ccc2)nc1		Inactive	Tyk 2 Inhibitor		1	Bayer-18	363677387.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(NC(CO)(C)C)nc(Nc2cc(NC(=O)NC(C)(C)C)ccc2)nc1	Fc1c(NC(CO)(C)C)nc(Nc2cc(NC(=O)NC(C)(C)C)ccc2)nc1
NCGC00263018-01	Fc1c(NC2=NC(C)=Cn3c(-c4c[nH]nc4)cnc23)ccc(C(=O)N2CCNCC2)c1		Inactive	Brk/PTK6 inhibitor		1	NCGC00263018-01	137275922.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(NC2=NC(C)=Cn3c(-c4c[nH]nc4)cnc23)ccc(C(=O)N2CCNCC2)c1	Fc1c(NC2=NC(C)=Cn3c(-c4c[nH]nc4)cnc23)ccc(C(=O)N2CCNCC2)c1
NCGC00510464-01	Fc1c(NC2=NC(C3CC3)=Cn3c(-c4c[nH]nc4)cnc23)ccc(C(=O)N2CCOCC2)c1		Inactive	BRK/PTK6 Inhibitor		1	P21d hydrochloride	384569438.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(NC2=NC(C3CC3)=Cn3c(-c4c[nH]nc4)cnc23)ccc(C(=O)N2CCOCC2)c1	Fc1c(NC2=NC(C3CC3)=Cn3c(-c4c[nH]nc4)cnc23)ccc(C(=O)N2CCOCC2)c1
NCGC00387206-01	Fc1c(NC=2S/C(=C\c3ccc(C(=O)O)cc3)/C(=O)N=2)cccc1		Inactive	G-protein coupled receptor 35 Agonist		1	TC-G 1001	363680567.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(NC=2S/C(=C\c3ccc(C(=O)O)cc3)/C(=O)N=2)cccc1	Fc1c(NC=2S/C(=C\c3ccc(C(=O)O)cc3)/C(=O)N=2)cccc1
NCGC00386413-01	Fc1c(NCc2[nH]c(c(C3=Cn4ncnc4C=C3)n2)-c2nc(C)ccc2)cccc1		Inactive	ALK5 Inhibitor		1	Vactosertib	363680266.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	16.1153009439	Fc1c(NCc2[nH]c(c(C3=Cn4ncnc4C=C3)n2)-c2nc(C)ccc2)cccc1	Fc1c(NCc2[nH]c(c(C3=Cn4ncnc4C=C3)n2)-c2nc(C)ccc2)cccc1
NCGC00510523-01	Fc1c(N[C@@H]2[C@@H](C(=O)O)C3CCC2CC3)nc(-c2c3c([nH]c2)ncc(F)c3)nc1		Inactive			1	Pimodivir	434147187.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(N[C@@H]2[C@@H](C(=O)O)C3CCC2CC3)nc(-c2c3c([nH]c2)ncc(F)c3)nc1	Fc1c(N[C@@H]2[C@@H](C(=O)O)C3CCC2CC3)nc(-c2c3c([nH]c2)ncc(F)c3)nc1
NCGC00510693-01	Fc1c(N[C@H]2[C@@H](N)CCCC2)nc(-c2cn(C)nc2)c2C(=O)NCc12		Inactive	Syk Kinase Inhibitor		1	TAK-659	384569483.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(N[C@H]2[C@@H](N)CCCC2)nc(-c2cn(C)nc2)c2C(=O)NCc12	Fc1c(N[C@H]2[C@@H](N)CCCC2)nc(-c2cn(C)nc2)c2C(=O)NCc12
NCGC00532515-01	Fc1c(Nc2c(CC(=O)O)cc(CC)cc2)c(F)c(F)cc1F		Inactive	Cyclooxygenase-2 Inhibitor		1	ROBENACOXIB	405558760.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Nc2c(CC(=O)O)cc(CC)cc2)c(F)c(F)cc1F	Fc1c(Nc2c(CC(=O)O)cc(CC)cc2)c(F)c(F)cc1F
NCGC00386306-06	Fc1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(OCCOC)cc2)nc1		Inactive	BTK Inhibitor		1	Spebrutinib (AVL-292)	363680199.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(OCCOC)cc2)nc1	Fc1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(OCCOC)cc2)nc1
NCGC00386312-01	Fc1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(Oc3cc(C(=O)NC)ncc3)cc2)nc1		Inactive	BTK Inhibitor		1	CNX-774	384569123.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	10.194735268	Fc1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(Oc3cc(C(=O)NC)ncc3)cc2)nc1	Fc1c(Nc2cc(NC(=O)C=C)ccc2)nc(Nc2ccc(Oc3cc(C(=O)NC)ncc3)cc2)nc1
NCGC00387026-01	Fc1c(Nc2ccccc2)nc(Nc2ccc(CN)cc2)nc1		Inactive			1	Dianilinopyrimidine_01	363680526.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(Nc2ccccc2)nc(Nc2ccc(CN)cc2)nc1	Fc1c(Nc2ccccc2)nc(Nc2ccc(CN)cc2)nc1
NCGC00510526-01	Fc1c(Nc2n(C)c3c(c(C)c(Oc4cc(NC(=O)C)ncc4)cc3)n2)ccc(F)c1		Inactive	Jak2 Inhibitor		1	CHZ868	384569473.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Nc2n(C)c3c(c(C)c(Oc4cc(NC(=O)C)ncc4)cc3)n2)ccc(F)c1	Fc1c(Nc2n(C)c3c(c(C)c(Oc4cc(NC(=O)C)ncc4)cc3)n2)ccc(F)c1
NCGC00346960-01	Fc1c(Nc2n([C@H]3COCC3)c3nc(NC4CCC(O)CC4)ncc3n2)c(F)cc(F)c1		Inactive	JNK Inhibitor		1	HMSL10058	174006727.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Nc2n([C@H]3COCC3)c3nc(NC4CCC(O)CC4)ncc3n2)c(F)cc(F)c1	Fc1c(Nc2n([C@H]3COCC3)c3nc(NC4CCC(O)CC4)ncc3n2)c(F)cc(F)c1
NCGC00346581-05&NCGC00346581-06	Fc1c(Nc2n[nH]c(C)c2)nc(N[C@@H](C)c2ccc(F)cc2)c(C#N)c1		Inactive	Jak2/3 Inhibitor		2	AZ-960	384568850.0&434147092.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c(Nc2n[nH]c(C)c2)nc(N[C@@H](C)c2ccc(F)cc2)c(C#N)c1	Fc1c(Nc2n[nH]c(C)c2)nc(N[C@@H](C)c2ccc(F)cc2)c(C#N)c1
NCGC00182051-05	Fc1c(Nc2nc3NC(=O)C(C)(C)Oc3cc2)nc(Nc2cc(OC)c(OC)c(OC)c2)nc1		Inactive	Syk Kinase Inhibitor		1	R-406	384568406.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Nc2nc3NC(=O)C(C)(C)Oc3cc2)nc(Nc2cc(OC)c(OC)c(OC)c2)nc1	Fc1c(Nc2nc3NC(=O)C(C)(C)Oc3cc2)nc(Nc2cc(OC)c(OC)c(OC)c2)nc1
NCGC00161416-02	Fc1c(Nc2ncnc3c2ccc(OCc2ccccc2)c3)cc(O)c(C)c1		Inactive			1	ZM 323881 HCl		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(Nc2ncnc3c2ccc(OCc2ccccc2)c3)cc(O)c(C)c1	Fc1c(Nc2ncnc3c2ccc(OCc2ccccc2)c3)cc(O)c(C)c1
NCGC00263086-08	Fc1c(O)c(F)cc(Nc2nc3N(CCC(C)C)C(C)C(=N)N(C)c3cn2)c1		Inactive	RSK Inhibitor		1	BI-D1870	363677195.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(O)c(F)cc(Nc2nc3N(CCC(C)C)C(C)C(=N)N(C)c3cn2)c1	Fc1c(O)c(F)cc(Nc2nc3N(CCC(C)C)C(C)C(=N)N(C)c3cn2)c1
NCGC00370919-02	Fc1c(O)ccc(-c2oc3c(C=C)cc(O)cc3n2)c1		Inactive	Selective Estrogen Receptor beta Agonist		1	Prinaberel	363677934.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(O)ccc(-c2oc3c(C=C)cc(O)cc3n2)c1	Fc1c(O)ccc(-c2oc3c(C=C)cc(O)cc3n2)c1
NCGC00485115-01	Fc1c(O)ccc(-c2oc3c(n2)cc(O)c(C=C)c3)c1		Inactive			1	ERB-041	363681228.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(O)ccc(-c2oc3c(n2)cc(O)c(C=C)c3)c1	Fc1c(O)ccc(-c2oc3c(n2)cc(O)c(C=C)c3)c1
NCGC00509910-02	Fc1c(OC(C)C)ccc(-c2nn([C@@H](C)C3=C(c4cc(F)ccc4)C(=O)c4c(O3)ccc(F)c4)c3ncnc(N)c23)c1		Inactive	Casein Kinase 1 Inhibitor		1	Umbralisib	384569377.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	21.8594168239	Fc1c(OC(C)C)ccc(-c2nn([C@@H](C)C3=C(c4cc(F)ccc4)C(=O)c4c(O3)ccc(F)c4)c3ncnc(N)c23)c1	Fc1c(OC(C)C)ccc(-c2nn([C@@H](C)C3=C(c4cc(F)ccc4)C(=O)c4c(O3)ccc(F)c4)c3ncnc(N)c23)c1
NCGC00263160-06	Fc1c(OC2=NC=Nn3c2c(C)c(OC[C@H](O)C)c3)ccc2[nH]c(C)cc12		Inactive	VEGFR-2,3/FGFR1,2,3 Inhibitor		1	Brivanib	384568632.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Fc1c(OC2=NC=Nn3c2c(C)c(OC[C@H](O)C)c3)ccc2[nH]c(C)cc12	Fc1c(OC2=NC=Nn3c2c(C)c(OC[C@H](O)C)c3)ccc2[nH]c(C)cc12
NCGC00386131-05	Fc1c(OC2=NC=Nn3c2c(C)c(OC[C@H](OC(=O)[C@@H](N)C)C)c3)ccc2[nH]c(C)cc12		Inactive			1	Brivanib Alaninate (BMS-582664)		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.878894028	Fc1c(OC2=NC=Nn3c2c(C)c(OC[C@H](OC(=O)[C@@H](N)C)C)c3)ccc2[nH]c(C)cc12	Fc1c(OC2=NC=Nn3c2c(C)c(OC[C@H](OC(=O)[C@@H](N)C)C)c3)ccc2[nH]c(C)cc12
NCGC00262195-03	Fc1c(OC=2C(=O)N(C)c3nc(NC4CCOCC4)ncc3C=2)ccc(F)c1		Inactive	p38 MAPK Inhibitor		1	R-1487	377020177.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(OC=2C(=O)N(C)c3nc(NC4CCOCC4)ncc3C=2)ccc(F)c1	Fc1c(OC=2C(=O)N(C)c3nc(NC4CCOCC4)ncc3C=2)ccc(F)c1
NCGC00389721-01	Fc1c(OCC(=O)C(NC(=O)C(NC(=O)c2nc3c(cc2)cccc3)C(C)C)CC(=O)O)c(F)ccc1		Inactive	Irreversible pan-Caspase inhibitor		1	Q-VD-OPh hydrate	363680840.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	15.5	Fc1c(OCC(=O)C(NC(=O)C(NC(=O)c2nc3c(cc2)cccc3)C(C)C)CC(=O)O)c(F)ccc1	Fc1c(OCC(=O)C(NC(=O)C(NC(=O)c2nc3c(cc2)cccc3)C(C)C)CC(=O)O)c(F)ccc1
NCGC00346938-02	Fc1c(OCC)c(OCC)cc2c1C(=N)N(CC(=O)c1cc(C(C)(C)C)c(OC)c(N3CCOCC3)c1)C2		Inactive	Thrombin Inhibitor		1	E5555	384568972.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.3264554119	Fc1c(OCC)c(OCC)cc2c1C(=N)N(CC(=O)c1cc(C(C)(C)C)c(OC)c(N3CCOCC3)c1)C2	Fc1c(OCC)c(OCC)cc2c1C(=N)N(CC(=O)c1cc(C(C)(C)C)c(OC)c(N3CCOCC3)c1)C2
NCGC00348110-01	Fc1c(OCCN2CCCC2)ccc(Nc2nc3n(CCC(OC)(C)C)nc(Nc4c(C)cccc4C)c3cn2)c1		Inactive	ACK1 Inhibitor		1	PRP003-032	384569002.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.254532264	Fc1c(OCCN2CCCC2)ccc(Nc2nc3n(CCC(OC)(C)C)nc(Nc4c(C)cccc4C)c3cn2)c1	Fc1c(OCCN2CCCC2)ccc(Nc2nc3n(CCC(OC)(C)C)nc(Nc4c(C)cccc4C)c3cn2)c1
NCGC00386589-01	Fc1c(OCCNCCC)ccc(NC(=O)c2c3C(=O)CCCc3[nH]c2)c1		Inactive	GABA-A receptor; benzodiazepine site Partial Agonist		1	CP 615003 mesylate	363680344.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c(OCCNCCC)ccc(NC(=O)c2c3C(=O)CCCc3[nH]c2)c1	Fc1c(OCCNCCC)ccc(NC(=O)c2c3C(=O)CCCc3[nH]c2)c1
NCGC00378921-05	Fc1c(Oc2c(-c3c[nH]nc3)cc3n(C)ncc3c2)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C(C)=CC=2)c1		Inactive	MET Inhibitor		1	Merestinib	384569075.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Oc2c(-c3c[nH]nc3)cc3n(C)ncc3c2)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C(C)=CC=2)c1	Fc1c(Oc2c(-c3c[nH]nc3)cc3n(C)ncc3c2)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C(C)=CC=2)c1
NCGC00481564-01	Fc1c(Oc2c3c(-c4ccccc4)c[nH]c3ncc2)ccc(NC(=O)C=2C(=O)N(N(C)C=2C)c2ccc(F)cc2)c1		Inactive	HGFR Inhibitor		1	NPS-1034	377020339.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Oc2c3c(-c4ccccc4)c[nH]c3ncc2)ccc(NC(=O)C=2C(=O)N(N(C)C=2C)c2ccc(F)cc2)c1	Fc1c(Oc2c3c(-c4ccccc4)c[nH]c3ncc2)ccc(NC(=O)C=2C(=O)N(N(C)C=2C)c2ccc(F)cc2)c1
NCGC00345824-02	Fc1c(Oc2c3c([nH]cc3)ncc2)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C=CC=2)c1		Inactive	HGFR Inhibitor		1	BMS-2	363677371.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Oc2c3c([nH]cc3)ncc2)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C=CC=2)c1	Fc1c(Oc2c3c([nH]cc3)ncc2)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C=CC=2)c1
NCGC00509945-01	Fc1c(Oc2c3c(ncc2)cc(OC)c(OC)c3)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C(=O)N(C(C)C)C=2)c1		Inactive	TYRO3 Inhibitor		1	CEP-40783	384569393.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Oc2c3c(ncc2)cc(OC)c(OC)c3)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C(=O)N(C(C)C)C=2)c1	Fc1c(Oc2c3c(ncc2)cc(OC)c(OC)c3)ccc(NC(=O)C=2C(=O)N(c3ccc(F)cc3)C(=O)N(C(C)C)C=2)c1
NCGC00345848-02	Fc1c(Oc2c3c(ncc2)cc(OC)cc3)ccc(NC(=O)C=2C(=O)N(N(CC(O)(C)C)C=2C)c2ccccc2)c1	5.0	Active	HGFR Inhibitor	0.0	1	AMG-1	363677390.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	64.420904204	Fc1c(Oc2c3c(ncc2)cc(OC)cc3)ccc(NC(=O)C=2C(=O)N(N(CC(O)(C)C)C=2C)c2ccccc2)c1	Fc1c(Oc2c3c(ncc2)cc(OC)cc3)ccc(NC(=O)C=2C(=O)N(N(CC(O)(C)C)C=2C)c2ccccc2)c1
NCGC00510492-02	Fc1c(Oc2c3c(ncc2)cc(OCC2(N)CC2)c(OC)c3)ccc2[nH]c(C)cc12		Inactive	VEGFR-3 Inhibitor		1	Anlotinib	384569454.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	15.677695896	Fc1c(Oc2c3c(ncc2)cc(OCC2(N)CC2)c(OC)c3)ccc2[nH]c(C)cc12	Fc1c(Oc2c3c(ncc2)cc(OCC2(N)CC2)c(OC)c3)ccc2[nH]c(C)cc12
NCGC00263201-04	Fc1c(Oc2c3c(ncc2)cc(OCCCN2CCOCC2)c(OC)c3)ccc(C=2C(=O)N(C)C(Nc3ccc(F)cc3)=NC=2)c1		Inactive	HGFR Inhibitor		1	AMG-51	384568660.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Oc2c3c(ncc2)cc(OCCCN2CCOCC2)c(OC)c3)ccc(C=2C(=O)N(C)C(Nc3ccc(F)cc3)=NC=2)c1	Fc1c(Oc2c3c(ncc2)cc(OCCCN2CCOCC2)c(OC)c3)ccc(C=2C(=O)N(C)C(Nc3ccc(F)cc3)=NC=2)c1
NCGC00263104-06	Fc1c(Oc2c3c(ncc2)cc(OCCCN2CCOCC2)c(OC)c3)ccc(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)c1		Inactive	VEGFR-2 Inhibitor		1	Foretinib	384568593.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Oc2c3c(ncc2)cc(OCCCN2CCOCC2)c(OC)c3)ccc(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)c1	Fc1c(Oc2c3c(ncc2)cc(OCCCN2CCOCC2)c(OC)c3)ccc(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)c1
NCGC00378974-02	Fc1c(Oc2cc(-c3cn(C)nc3)ncc2)cc(F)c(NC(=O)C2(C(=O)Nc3ccccc3)CC2)c1	4.9000001	Active	PDGFR alpha Inhibitor	0.0	1	DCC-2618	377020266.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	62.9001490329	Fc1c(Oc2cc(-c3cn(C)nc3)ncc2)cc(F)c(NC(=O)C2(C(=O)Nc3ccccc3)CC2)c1	Fc1c(Oc2cc(-c3cn(C)nc3)ncc2)cc(F)c(NC(=O)C2(C(=O)Nc3ccccc3)CC2)c1
NCGC00480913-01	Fc1c(Oc2cc(NC(=O)C3CC3)ncc2)cc(F)c(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)c1		Inactive	HGFR Inhibitor		1	Altiratinib	384569250.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Oc2cc(NC(=O)C3CC3)ncc2)cc(F)c(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)c1	Fc1c(Oc2cc(NC(=O)C3CC3)ncc2)cc(F)c(NC(=O)C2(C(=O)Nc3ccc(F)cc3)CC2)c1
NCGC00485430-01	Fc1c(Oc2ccc(-c3c(C(=O)N)c(N)n([C@H]4CN(C#N)CCC4)n3)cc2)ccc(F)c1		Inactive	BTK Inhibitor		1	PF-06250112	363681335.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Oc2ccc(-c3c(C(=O)N)c(N)n([C@H]4CN(C#N)CCC4)n3)cc2)ccc(F)c1	Fc1c(Oc2ccc(-c3c(C(=O)N)c(N)n([C@H]4CN(C#N)CCC4)n3)cc2)ccc(F)c1
NCGC00263097-03	Fc1c(Oc2ncnc3c2cc(OC)c(OCCCN2CCCC2)c3)ccc2[nH]c(C)cc12		Inactive	VEGFR-1/2/3 Inhibitor		1	Cediranib	384568588.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c(Oc2ncnc3c2cc(OC)c(OCCCN2CCCC2)c3)ccc2[nH]c(C)cc12	Fc1c(Oc2ncnc3c2cc(OC)c(OCCCN2CCCC2)c3)ccc2[nH]c(C)cc12
NCGC00507859-01	Fc1c([C@@H]2N(C3=Nc4c(NC(=O)N5C[C@@H](O)CC5)cnn4C=C3)CCC2)cc(F)cc1		Inactive	TRK B Inhibitor		1	Larotrectinib	384569335.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c([C@@H]2N(C3=Nc4c(NC(=O)N5C[C@@H](O)CC5)cnn4C=C3)CCC2)cc(F)cc1	Fc1c([C@@H]2N(C3=Nc4c(NC(=O)N5C[C@@H](O)CC5)cnn4C=C3)CCC2)cc(F)cc1
NCGC00522475-03	Fc1c([C@@]2(C)N=C(N)N(C)S(=O)(=O)C2)cc(NC(=O)c2ncc(F)cc2)cc1		Inactive			1	Verubecestat (MK-8931)	434146934.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c([C@@]2(C)N=C(N)N(C)S(=O)(=O)C2)cc(NC(=O)c2ncc(F)cc2)cc1	Fc1c([C@@]2(C)N=C(N)N(C)S(=O)(=O)C2)cc(NC(=O)c2ncc(F)cc2)cc1
NCGC00346506-05	Fc1c([C@@]23N=C(N)SC[C@@H]2COC3)cc(NC(=O)c2ncc(F)cc2)cc1		Inactive	beta-Secretase 1/2 (BACE1/2) Inhibitor		1	LY-2886721	384568809.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c([C@@]23N=C(N)SC[C@@H]2COC3)cc(NC(=O)c2ncc(F)cc2)cc1	Fc1c([C@@]23N=C(N)SC[C@@H]2COC3)cc(NC(=O)c2ncc(F)cc2)cc1
NCGC00509932-01	Fc1c([C@H]2c3c(-c4nc(Nc5cc(CCNCCOC)ccc5)ncc4C2)cccc3)cccc1		Inactive	FGFR Inhibitor		1	Derazantinib	384569382.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c([C@H]2c3c(-c4nc(Nc5cc(CCNCCOC)ccc5)ncc4C2)cccc3)cccc1	Fc1c([C@H]2c3c(-c4nc(Nc5cc(CCNCCOC)ccc5)ncc4C2)cccc3)cccc1
NCGC00390702-02	Fc1c([C@](O)([C@@H](C)N2CCC(=C)CC2)Cn2ncnc2)ccc(F)c1		Inactive	Lanosterol 14-alpha demethylase Inhibitor		1	Efinaconazole	405558761.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c([C@](O)([C@@H](C)N2CCC(=C)CC2)Cn2ncnc2)ccc(F)c1	Fc1c([C@](O)([C@@H](C)N2CCC(=C)CC2)Cn2ncnc2)ccc(F)c1
NCGC00164622-02&NCGC00164622-16	Fc1c([C@](O)([C@@H](C)c2c(F)cncn2)Cn2ncnc2)ccc(F)c1		Inactive	Lanosterol 14alpha-demethylase Inhibitor		2	Voriconazole	170464890.0&384568268.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c([C@](O)([C@@H](C)c2c(F)cncn2)Cn2ncnc2)ccc(F)c1	Fc1c([C@](O)([C@@H](C)c2c(F)cncn2)Cn2ncnc2)ccc(F)c1
NCGC00532509-01	Fc1c([C@](O)([C@@H](C)c2scc(-c3ccc(C#N)cc3)n2)Cn2nc[n+](C(OC(=O)N(C)c3c(COC(=O)CNC)cccn3)C)c2)cc(F)cc1		Inactive	Lanosterol 14-alpha demethylase Inhibitor		1	ISAVUCONAZONIUM SULFATE	405558653.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c([C@](O)([C@@H](C)c2scc(-c3ccc(C#N)cc3)n2)Cn2nc[n+](C(OC(=O)N(C)c3c(COC(=O)CNC)cccn3)C)c2)cc(F)cc1	Fc1c([C@](O)([C@@H](C)c2scc(-c3ccc(C#N)cc3)n2)Cn2nc[n+](C(OC(=O)N(C)c3c(COC(=O)CNC)cccn3)C)c2)cc(F)cc1
NCGC00390646-02	Fc1c([C@](O)([C@@H](C)c2scc(-c3ccc(C#N)cc3)n2)Cn2ncnc2)cc(F)cc1		Inactive			1	Isavuconazole	405558433.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.1124121719	Fc1c([C@](O)([C@@H](C)c2scc(-c3ccc(C#N)cc3)n2)Cn2ncnc2)cc(F)cc1	Fc1c([C@](O)([C@@H](C)c2scc(-c3ccc(C#N)cc3)n2)Cn2ncnc2)cc(F)cc1
NCGC00498439-01	Fc1c([C@]2(C)NC(=O)c3c2ccc(-c2c[nH]nc2)c3)ncnc1		Inactive	CDK 7 Inhibitor		1	LY-3177833	384569302.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c([C@]2(C)NC(=O)c3c2ccc(-c2c[nH]nc2)c3)ncnc1	Fc1c([C@]2(C)NC(=O)c3c2ccc(-c2c[nH]nc2)c3)ncnc1
NCGC00274060-01	Fc1c([C@]2(Cn3ncnc3)OCC(COc3ccc(N4CCN(c5ccc(N6C(=O)N([C@H]([C@@H](O)C)CC)N=C6)cc5)CC4)cc3)C2)ccc(F)c1	5.6500001	Active	Lanosterol 14alpha-demethylase Inhibitors	0.0	1	Posaconazole	170464963.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	39.4159387288	Fc1c([C@]2(Cn3ncnc3)OCC(COc3ccc(N4CCN(c5ccc(N6C(=O)N([C@H]([C@@H](O)C)CC)N=C6)cc5)CC4)cc3)C2)ccc(F)c1	Fc1c([C@]2(Cn3ncnc3)OCC(COc3ccc(N4CCN(c5ccc(N6C(=O)N([C@H]([C@@H](O)C)CC)N=C6)cc5)CC4)cc3)C2)ccc(F)c1
NCGC00274060-07	Fc1c([C@]2(Cn3ncnc3)OC[C@@H](COc3ccc(N4CCN(c5ccc(N6C(=O)N([C@H]([C@@H](O)C)CC)N=C6)cc5)CC4)cc3)C2)ccc(F)c1		Inactive			1	Posaconazole	434147080.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0		Fc1c([C@]2(Cn3ncnc3)OC[C@@H](COc3ccc(N4CCN(c5ccc(N6C(=O)N([C@H]([C@@H](O)C)CC)N=C6)cc5)CC4)cc3)C2)ccc(F)c1	Fc1c([C@]2(Cn3ncnc3)OC[C@@H](COc3ccc(N4CCN(c5ccc(N6C(=O)N([C@H]([C@@H](O)C)CC)N=C6)cc5)CC4)cc3)C2)ccc(F)c1
NCGC00510496-01	Fc1c([N+](=O)[O-])cc(/C=C\2/C(=O)/C(=C/c3cc([N+](=O)[O-])c(F)cc3)/CCN(C(=O)C=C)C/2)cc1		Inactive	Ubiquitin C-terminal Hydrolase L5 (UCH-L5) Inhibitor		1	VLX-1570	384569458.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c([N+](=O)[O-])cc(/C=C\2/C(=O)/C(=C/c3cc([N+](=O)[O-])c(F)cc3)/CCN(C(=O)C=C)C/2)cc1	Fc1c([N+](=O)[O-])cc(/C=C\2/C(=O)/C(=C/c3cc([N+](=O)[O-])c(F)cc3)/CCN(C(=O)C=C)C/2)cc1
NCGC00262603-04&NCGC00262603-12	Fc1c2C(=O)N(c3ccccc3)C([C@@H](Nc3ncnc4[nH]cnc34)CC)=Nc2ccc1		Inactive	PI3Kdelta Inhibitor		2	Idelalisib	405558681.0&384568574.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1c2C(=O)N(c3ccccc3)C([C@@H](Nc3ncnc4[nH]cnc34)CC)=Nc2ccc1	Fc1c2C(=O)N(c3ccccc3)C([C@@H](Nc3ncnc4[nH]cnc34)CC)=Nc2ccc1
NCGC00249685-09	Fc1c2C(N)=C(c3[nH]c4c(n3)cc(N3CCN(C)CC3)cc4)C(=O)Nc2ccc1		Inactive	FGFR Inhibitor		1	Dovitinib	384568533.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c2C(N)=C(c3[nH]c4c(n3)cc(N3CCN(C)CC3)cc4)C(=O)Nc2ccc1	Fc1c2C(N)=C(c3[nH]c4c(n3)cc(N3CCN(C)CC3)cc4)C(=O)Nc2ccc1
NCGC00371031-01	Fc1c2C(N)=NC3(Nc2c(F)cc1)CCN(C(=O)c1cnc(C#N)cc1)CC3		Inactive	Nitric oxide synthase, inducible Inhibitor		1	AR-C 102222	363678000.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c2C(N)=NC3(Nc2c(F)cc1)CCN(C(=O)c1cnc(C#N)cc1)CC3	Fc1c2C(N)=NC3(Nc2c(F)cc1)CCN(C(=O)c1cnc(C#N)cc1)CC3
NCGC00370899-04	Fc1c2NC(c3cnccc3)[C@H]3[C@@H](c2cc(F)c1)C=CC3		Inactive			1	Golgicide A	434147101.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	-7.950643776	Fc1c2NC(c3cnccc3)[C@H]3[C@@H](c2cc(F)c1)C=CC3	Fc1c2NC(c3cnccc3)[C@H]3[C@@H](c2cc(F)c1)C=CC3
NCGC00370859-01	Fc1c2OC[C@H](N(C3CCC3)C3CCC3)Cc2c(C(=O)N)cc1		Inactive	Serotonin 1a (5-HT1a) receptor Antagonist		1	NAD 299 hydrochloride	363677891.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c2OC[C@H](N(C3CCC3)C3CCC3)Cc2c(C(=O)N)cc1	Fc1c2OC[C@H](N(C3CCC3)C3CCC3)Cc2c(C(=O)N)cc1
NCGC00510487-01	Fc1c2[C@H](C[C@@H](O)C3CCC(O)CC3)n3c(-c2ccc1)cnc3		Inactive	IDO Inhibitor		1	Navoximod	384569449.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c2[C@H](C[C@@H](O)C3CCC(O)CC3)n3c(-c2ccc1)cnc3	Fc1c2[C@H](C[C@@H](O)C3CCC(O)CC3)n3c(-c2ccc1)cnc3
NCGC00386190-05	Fc1c2c(c(-c3nc(N)nc(C(C)C)c3)cc1)cccc2		Inactive	Serotonin 2b (5-HT2b) receptor Antagonist		1	RS 127445	363680143.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c2c(c(-c3nc(N)nc(C(C)C)c3)cc1)cccc2	Fc1c2c(c(-c3nc(N)nc(C(C)C)c3)cc1)cccc2
NCGC00378671-02	Fc1c2c(c(C(C(=O)Nc3c(CCCC(=O)O)ccc(C#N)c3)C)cc1)cccc2		Inactive	Prostanoid EP4 receptor Antagonist		1	ONO AE3 208	363678144.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1c2c(c(C(C(=O)Nc3c(CCCC(=O)O)ccc(C#N)c3)C)cc1)cccc2	Fc1c2c(c(C(C(=O)Nc3c(CCCC(=O)O)ccc(C#N)c3)C)cc1)cccc2
NCGC00378713-01&NCGC00378713-03	Fc1c2c(cc(F)c1)CC[C@H](N[C@H](C(=O)Nc1ncn(C(CNCC(C)(C)C)(C)C)c1)CCC)C2	4.9000001	Active	g-Secretase Inhibitor	0.0	2	Nirogacestat	363678166.0&384569064.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	38.8721047449&49.5302172929	Fc1c2c(cc(F)c1)CC[C@H](N[C@H](C(=O)Nc1ncn(C(CNCC(C)(C)C)(C)C)c1)CCC)C2	Fc1c2c(cc(F)c1)CC[C@H](N[C@H](C(=O)Nc1ncn(C(CNCC(C)(C)C)(C)C)c1)CCC)C2
NCGC00025330-09	Fc1c2nc(C)cc(NC(=O)Nc3ccc(N(C)C)cc3)c2cc(F)c1		Inactive	Orexin OX-1 Antagonist		1	SB-408124	384568068.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1c2nc(C)cc(NC(=O)Nc3ccc(N(C)C)cc3)c2cc(F)c1	Fc1c2nc(C)cc(NC(=O)Nc3ccc(N(C)C)cc3)c2cc(F)c1
NCGC00263108-02	Fc1cc(-c2cnc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@H]4[C@H]3CC[C@@H](NC(=O)OCC)C4)cc2)ccc1	5.0	Active	PAR1 Antagonist	0.0	1	Vorapaxar	384568595.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	54.193638736	Fc1cc(-c2cnc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@H]4[C@H]3CC[C@@H](NC(=O)OCC)C4)cc2)ccc1	Fc1cc(-c2cnc(/C=C/[C@@H]3[C@@H]4[C@@H](C)OC(=O)[C@@H]4C[C@H]4[C@H]3CC[C@@H](NC(=O)OCC)C4)cc2)ccc1
NCGC00482976-01	Fc1cc(-c2cnc(/C=C/[C@H]3[C@H]4[C@@H](C[C@H](NC(=O)OCC)CC4)C[C@H]4C(=O)O[C@H](C)C34)cc2)ccc1	5.0500002	Active	Proteinase-activated receptor 1 Antagonist	0.0	1	Vorapaxar Sulfate	405558904.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	2.2	75.1932802894	Fc1cc(-c2cnc(/C=C/[C@H]3[C@H]4[C@@H](C[C@H](NC(=O)OCC)CC4)C[C@H]4C(=O)O[C@H](C)C34)cc2)ccc1	Fc1cc(-c2cnc(/C=C/[C@H]3[C@H]4[C@@H](C[C@H](NC(=O)OCC)CC4)C[C@H]4C(=O)O[C@H](C)C34)cc2)ccc1
NCGC00346436-04	Fc1cc(-c2nc(N[C@H]3[C@H](C(O)(C)C)CNC3)c3c(n2)cc(OC)c(OC)c3)c(O)cc1		Inactive	Chk2 Inhibitor		1	CCT-241533	384568776.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Fc1cc(-c2nc(N[C@H]3[C@H](C(O)(C)C)CNC3)c3c(n2)cc(OC)c(OC)c3)c(O)cc1	Fc1cc(-c2nc(N[C@H]3[C@H](C(O)(C)C)CNC3)c3c(n2)cc(OC)c(OC)c3)c(O)cc1
NCGC00522520-01	Fc1cc(-c2nc3c(N)ncc(C(=O)NC4CN(C(=O)C5CC5)C4)c3cc2)ccc1		Inactive	MAP4K4 Inhibitor		1	GNE-495	384569524.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	26.8925126319	Fc1cc(-c2nc3c(N)ncc(C(=O)NC4CN(C(=O)C5CC5)C4)c3cc2)ccc1	Fc1cc(-c2nc3c(N)ncc(C(=O)NC4CN(C(=O)C5CC5)C4)c3cc2)ccc1
NCGC00242481-05	Fc1cc(-c2sc(C(=O)N[C@@H]3CNCCC3)c(NC(=O)N)c2)ccc1		Inactive	Chk1/2 Inhibitor		1	AZD-7762	384568493.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Fc1cc(-c2sc(C(=O)N[C@@H]3CNCCC3)c(NC(=O)N)c2)ccc1	Fc1cc(-c2sc(C(=O)N[C@@H]3CNCCC3)c(NC(=O)N)c2)ccc1
NCGC00386906-01	Fc1cc(C#Cc2cnc(C(=O)N3CC4C(C3)C4)cc2)ccc1		Inactive			1	NCGC00386906-01	363680494.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc(C#Cc2cnc(C(=O)N3CC4C(C3)C4)cc2)ccc1	Fc1cc(C#Cc2cnc(C(=O)N3CC4C(C3)C4)cc2)ccc1
NCGC00370719-04	Fc1cc(C#Cc2cnc(C(=O)NC3(C)COC3)cc2)ccc1		Inactive	Metabotropic glutamate receptor 5 Positive Allosteric Modulator		1	ML254	363677822.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc(C#Cc2cnc(C(=O)NC3(C)COC3)cc2)ccc1	Fc1cc(C#Cc2cnc(C(=O)NC3(C)COC3)cc2)ccc1
NCGC00386861-01	Fc1cc(C#Cc2cnc(C(=O)N[C@@H](C(O)(C)C)C)cc2)ccc1		Inactive			1	NCGC00386861-01	363680470.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc(C#Cc2cnc(C(=O)N[C@@H](C(O)(C)C)C)cc2)ccc1	Fc1cc(C#Cc2cnc(C(=O)N[C@@H](C(O)(C)C)C)cc2)ccc1
NCGC00379106-01	Fc1cc(C#Cc2ncc(C(=O)NC3CCC3)cc2)ccc1		Inactive	Metabotropic glutamate receptor 5 Positive Allosteric Modulator		1	VU 0360172 hydrochloride	363678356.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc(C#Cc2ncc(C(=O)NC3CCC3)cc2)ccc1	Fc1cc(C#Cc2ncc(C(=O)NC3CCC3)cc2)ccc1
NCGC00370983-02	Fc1cc(C#N)cc(-c2cc3nc(C)sc3cc2)c1		Inactive	Metabotropic glutamate receptor 5 Negative Allosteric Modulator		1	VU 0360223	363677977.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc(C#N)cc(-c2cc3nc(C)sc3cc2)c1	Fc1cc(C#N)cc(-c2cc3nc(C)sc3cc2)c1
NCGC00379115-01	Fc1cc(C#N)cc(-c2onc(-c3ncccc3)n2)c1		Inactive	Metabotropic glutamate receptor 5 Negative Allosteric Modulator		1	VU 0285683	363678365.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc(C#N)cc(-c2onc(-c3ncccc3)n2)c1	Fc1cc(C#N)cc(-c2onc(-c3ncccc3)n2)c1
NCGC00379127-01	Fc1cc(C#N)cc(C#Cc2nc(C)ccc2)c1		Inactive	Metabotropic glutamate receptor 5 Antagonist		1	MFZ 10-7	363678373.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc(C#N)cc(C#Cc2nc(C)ccc2)c1	Fc1cc(C#N)cc(C#Cc2nc(C)ccc2)c1
NCGC00346534-03&NCGC00346534-07	Fc1cc(C(=O)/C=C/c2cn(C)c(/C=C/C(=O)NO)c2)ccc1		Inactive	HDAC Inhibitor		2	MC-1568	384568824.0&434147252.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1cc(C(=O)/C=C/c2cn(C)c(/C=C/C(=O)NO)c2)ccc1	Fc1cc(C(=O)/C=C/c2cn(C)c(/C=C/C(=O)NO)c2)ccc1
NCGC00475777-02	Fc1cc(C(=O)/C=C/c2n(C)c(/C=C/C(=O)NO)cc2)ccc1		Inactive			1	MC-1568		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc(C(=O)/C=C/c2n(C)c(/C=C/C(=O)NO)cc2)ccc1	Fc1cc(C(=O)/C=C/c2n(C)c(/C=C/C(=O)NO)cc2)ccc1
NCGC00509914-01&NCGC00509914-02	Fc1cc(C(=O)N)c2C(=O)N(C3CCN(C4CCC(F)(F)CC4)CC3)Cc2c1		Inactive	PARP Inhibitor		2	NMS-P118	384569380.0&434147166.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1cc(C(=O)N)c2C(=O)N(C3CCN(C4CCC(F)(F)CC4)CC3)Cc2c1	Fc1cc(C(=O)N)c2C(=O)N(C3CCN(C4CCC(F)(F)CC4)CC3)Cc2c1
NCGC00507873-02	Fc1cc(C(C(=O)Nc2sccn2)N2C(=O)c3c(cccc3)C2)c(O)cc1		Inactive	Allosteric EGFR Inhibitor (L858R/T790M-specific)		1	EAI045	384569345.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc(C(C(=O)Nc2sccn2)N2C(=O)c3c(cccc3)C2)c(O)cc1	Fc1cc(C(C(=O)Nc2sccn2)N2C(=O)c3c(cccc3)C2)c(O)cc1
NCGC00651745-01	Fc1cc(C)c(Oc2c(C=3c4c(C(=O)N(C)C=3)[nH]c(C(=O)NCC)c4)cc(C(O)(C)C)cc2)c(C)c1		Inactive			1	ABBV-744	434147256.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc(C)c(Oc2c(C=3c4c(C(=O)N(C)C=3)[nH]c(C(=O)NCC)c4)cc(C(O)(C)C)cc2)c(C)c1	Fc1cc(C)c(Oc2c(C=3c4c(C(=O)N(C)C=3)[nH]c(C(=O)NCC)c4)cc(C(O)(C)C)cc2)c(C)c1
NCGC00481573-01	Fc1cc(C/N=C(\O)/Nc2n(-c3ccc(C)cc3)nc(C(C)(C)C)c2)c(Oc2cc3c(n(CCO)nc3)cc2)cc1		Inactive	p38 MAPK Inhibitor		1	Pexmetinib	377020380.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	20.604487868	Fc1cc(C/N=C(\O)/Nc2n(-c3ccc(C)cc3)nc(C(C)(C)C)c2)c(Oc2cc3c(n(CCO)nc3)cc2)cc1	Fc1cc(C/N=C(\O)/Nc2n(-c3ccc(C)cc3)nc(C(C)(C)C)c2)c(Oc2cc3c(n(CCO)nc3)cc2)cc1
NCGC00531749-01	Fc1cc(C2(Nc3ncc(C(=O)NO)cn3)CCCCC2)ccc1		Inactive	HDAC Inhibitor		1	ACY-775	384569536.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc(C2(Nc3ncc(C(=O)NO)cn3)CCCCC2)ccc1	Fc1cc(C2(Nc3ncc(C(=O)NO)cn3)CCCCC2)ccc1
NCGC00509995-02	Fc1cc(C2=C([C@@H](Nc3ncnc4nc[nH]c34)CC)Oc3c(C2=O)cccc3)ccc1		Inactive	PI3Kdelta/gamma Inhibitor		1	Tenalisib	384569402.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc(C2=C([C@@H](Nc3ncnc4nc[nH]c34)CC)Oc3c(C2=O)cccc3)ccc1	Fc1cc(C2=C([C@@H](Nc3ncnc4nc[nH]c34)CC)Oc3c(C2=O)cccc3)ccc1
NCGC00389507-02	Fc1cc(CN2C(=O)N(C)C(=O)C=C2N2CC(N)CCC2)c(C#N)cc1		Inactive	Dipeptidyl peptidase IV Inhibitor		1	Trelagliptinsuccinate	363680791.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc(CN2C(=O)N(C)C(=O)C=C2N2CC(N)CCC2)c(C#N)cc1	Fc1cc(CN2C(=O)N(C)C(=O)C=C2N2CC(N)CCC2)c(C#N)cc1
NCGC00378845-01&NCGC00378845-08	Fc1cc(CN2C(=O)N(C)C(=O)C=C2N2C[C@H](N)CCC2)c(C#N)cc1		Inactive			2	Trelagliptin succinate&Trelagliptin (succinate)	405558763.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1cc(CN2C(=O)N(C)C(=O)C=C2N2C[C@H](N)CCC2)c(C#N)cc1	Fc1cc(CN2C(=O)N(C)C(=O)C=C2N2C[C@H](N)CCC2)c(C#N)cc1
NCGC00346529-03	Fc1cc(COc2ccc(CN[C@H](C(=O)N)C)cc2)ccc1		Inactive	Sodium channel inhibitor		1	Safinamide	405558801.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1cc(COc2ccc(CN[C@H](C(=O)N)C)cc2)ccc1	Fc1cc(COc2ccc(CN[C@H](C(=O)N)C)cc2)ccc1
NCGC00379156-01	Fc1cc(COc2ccc(Oc3ncc(C(=O)NCc4cc(N)ccc4)cc3)cc2)ccc1		Inactive	Sodium/calcium exchanger 3 Inhibitor		1	YM 244769	363678390.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc(COc2ccc(Oc3ncc(C(=O)NCc4cc(N)ccc4)cc3)cc2)ccc1	Fc1cc(COc2ccc(Oc3ncc(C(=O)NCc4cc(N)ccc4)cc3)cc2)ccc1
NCGC00346483-02&NCGC00346483-11	Fc1cc(Cn2ncc3c2ccc(NC2=NC=Nn4c2c(C)c(NC(=O)OC[C@H]2NCCOC2)c4)c3)ccc1	4.9000001	Active	EGFR Inhibitor	0.0	2	AC-480&AC480 (BMS-599626)	384568793.0&406861852.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	113.02236985&73.60489788	Fc1cc(Cn2ncc3c2ccc(NC2=NC=Nn4c2c(C)c(NC(=O)OC[C@H]2NCCOC2)c4)c3)ccc1	Fc1cc(Cn2ncc3c2ccc(NC2=NC=Nn4c2c(C)c(NC(=O)OC[C@H]2NCCOC2)c4)c3)ccc1
NCGC00263188-03&NCGC00263188-15	Fc1cc(F)cc(CC(=O)N[C@H](C(=O)N[C@@H]2C(=O)N(C)c3c(-c4c2cccc4)cccc3)C)c1		Inactive	g-Secretase Inhibitor		2	YO-01027&DBZ	363677253.0	Annotated/Bioactive Compound Collection&2020_NPACT-1_CPE	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Fc1cc(F)cc(CC(=O)N[C@H](C(=O)N[C@@H]2C(=O)N(C)c3c(-c4c2cccc4)cccc3)C)c1	Fc1cc(F)cc(CC(=O)N[C@H](C(=O)N[C@@H]2C(=O)N(C)c3c(-c4c2cccc4)cccc3)C)c1
NCGC00167803-13	Fc1cc(F)cc(CC(=O)N[C@H](C(=O)N[C@H](C(=O)OC(C)(C)C)c2ccccc2)C)c1		Inactive	g-Secretase Inhibitor		1	GSI-IX	384568339.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1cc(F)cc(CC(=O)N[C@H](C(=O)N[C@H](C(=O)OC(C)(C)C)c2ccccc2)C)c1	Fc1cc(F)cc(CC(=O)N[C@H](C(=O)N[C@H](C(=O)OC(C)(C)C)c2ccccc2)C)c1
NCGC00386563-01	Fc1cc(F)cc(CC(=O)N[C@H](C(=O)N[C@H]2C(=O)N(C)c3c(C(c4ccccc4)=N2)cccc3)C)c1		Inactive	Gamma-secretase Inhibitor		1	?-Secretase Inhibitor BZ	363680328.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc(F)cc(CC(=O)N[C@H](C(=O)N[C@H]2C(=O)N(C)c3c(C(c4ccccc4)=N2)cccc3)C)c1	Fc1cc(F)cc(CC(=O)N[C@H](C(=O)N[C@H]2C(=O)N(C)c3c(C(c4ccccc4)=N2)cccc3)C)c1
NCGC00475728-01	Fc1cc(F)cc(N[C@H](C)c2c3OC(N4CCOCC4)=CC(=O)c3cc(C(=O)N(C)C)c2)c1		Inactive			1	AZD-8186	384569231.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc(F)cc(N[C@H](C)c2c3OC(N4CCOCC4)=CC(=O)c3cc(C(=O)N(C)C)c2)c1	Fc1cc(F)cc(N[C@H](C)c2c3OC(N4CCOCC4)=CC(=O)c3cc(C(=O)N(C)C)c2)c1
NCGC00390695-02	Fc1cc(F)cc([C@H](O)C(=O)NNC(=O)c2c(CC)c(C)c(O)cc2)c1		Inactive	SGK1 Inhibitor		1	EMD-638683	377020505.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc(F)cc([C@H](O)C(=O)NNC(=O)c2c(CC)c(C)c(O)cc2)c1	Fc1cc(F)cc([C@H](O)C(=O)NNC(=O)c2c(CC)c(C)c(O)cc2)c1
NCGC00346841-07	Fc1cc(F)cc([C@H](O)C(=O)N[C@H](C(=O)N[C@@H]2C(=O)N(C)c3c(-c4c2cccc4)cccc3)C)c1		Inactive	g-Secretase Inhibitor		1	LY-411575	384568950.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1cc(F)cc([C@H](O)C(=O)N[C@H](C(=O)N[C@@H]2C(=O)N(C)c3c(-c4c2cccc4)cccc3)C)c1	Fc1cc(F)cc([C@H](O)C(=O)N[C@H](C(=O)N[C@@H]2C(=O)N(C)c3c(-c4c2cccc4)cccc3)C)c1
NCGC00346546-04	Fc1cc(F)cc([C@H]2N(CC(=O)Nc3cc4c(cc3)C[C@@]3(C(=O)Nc5ncccc35)C4)C(=O)C3(NC2)CCCC3)c1		Inactive	Calcitonin Gene-Related Peptides (CGRP) Antagonist		1	MK-3207	384568832.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc(F)cc([C@H]2N(CC(=O)Nc3cc4c(cc3)C[C@@]3(C(=O)Nc5ncccc35)C4)C(=O)C3(NC2)CCCC3)c1	Fc1cc(F)cc([C@H]2N(CC(=O)Nc3cc4c(cc3)C[C@@]3(C(=O)Nc5ncccc35)C4)C(=O)C3(NC2)CCCC3)c1
NCGC00347946-02	Fc1cc(N(C(=O)CNc2ccc(C#N)cc2)C(C(=O)NC2CCCCC2)c2c(C)cccc2)ccc1		Inactive	IDH1 Inhibitor		1	IDH-C227	363677726.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc(N(C(=O)CNc2ccc(C#N)cc2)C(C(=O)NC2CCCCC2)c2c(C)cccc2)ccc1	Fc1cc(N(C(=O)CNc2ccc(C#N)cc2)C(C(=O)NC2CCCCC2)c2c(C)cccc2)ccc1
NCGC00347934-09	Fc1cc(N(C(=O)Cn2c(C)ncc2)C(C(=O)NC2CCCCC2)c2c(C)cccc2)ccc1		Inactive	Mutant IDH1 Inhibitor		1	AGI-5198	363677720.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc(N(C(=O)Cn2c(C)ncc2)C(C(=O)NC2CCCCC2)c2c(C)cccc2)ccc1	Fc1cc(N(C(=O)Cn2c(C)ncc2)C(C(=O)NC2CCCCC2)c2c(C)cccc2)ccc1
NCGC00390604-01	Fc1cc(N(C(=O)Cn2c3c(nc2)cccc3)C(C(=O)NC2CCCCC2)c2c(C)cccc2)ccc1		Inactive	Isocitrate dehydrogenase [NADP] cytoplasmic Inhibitor		1	Mutant IDH1-IN-1	363680924.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc(N(C(=O)Cn2c3c(nc2)cccc3)C(C(=O)NC2CCCCC2)c2c(C)cccc2)ccc1	Fc1cc(N(C(=O)Cn2c3c(nc2)cccc3)C(C(=O)NC2CCCCC2)c2c(C)cccc2)ccc1
NCGC00381560-10	Fc1cc(N)c(NC(=O)/C=C/c2cn(C/C=C/c3ccccc3)nc2)cc1		Inactive			1	RGFP966	434147118.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc(N)c(NC(=O)/C=C/c2cn(C/C=C/c3ccccc3)nc2)cc1	Fc1cc(N)c(NC(=O)/C=C/c2cn(C/C=C/c3ccccc3)nc2)cc1
NCGC00370779-02	Fc1cc(N2C3(C(=O)NC2)CCN(CCNC(=O)c2cc4c(cc2)cccc4)CC3)ccc1		Inactive			1	VU 0364739 hydrochloride	363677851.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc(N2C3(C(=O)NC2)CCN(CCNC(=O)c2cc4c(cc2)cccc4)CC3)ccc1	Fc1cc(N2C3(C(=O)NC2)CCN(CCNC(=O)c2cc4c(cc2)cccc4)CC3)ccc1
NCGC00263089-07	Fc1cc(NC(=O)Cc2[nH]nc(Nc3ncnc4c3ccc(OCCCN(CCO)CC)c4)c2)ccc1		Inactive	Aurora-B/C Inhibitor		1	Barasertib	363677197.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc(NC(=O)Cc2[nH]nc(Nc3ncnc4c3ccc(OCCCN(CCO)CC)c4)c2)ccc1	Fc1cc(NC(=O)Cc2[nH]nc(Nc3ncnc4c3ccc(OCCCN(CCO)CC)c4)c2)ccc1
NCGC00263598-06&NCGC00263598-10	Fc1cc(NC(=O)c2ccc(CNC(=O)/C=C/c3cnccc3)cc2)c(N)cc1		Inactive	Histone deacetylase 8 Inhibitor		2	Chidamide	384568691.0&434147077.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	-7.788453372&0.0	Fc1cc(NC(=O)c2ccc(CNC(=O)/C=C/c3cnccc3)cc2)c(N)cc1	Fc1cc(NC(=O)c2ccc(CNC(=O)/C=C/c3cnccc3)cc2)c(N)cc1
NCGC00378581-01	Fc1cc(NC2CCN(C(=O)Cc3ccc(CN4C[C@H](C)NCC4)cc3)CC2)ccc1		Inactive	Motilin receptor Agonist		1	GSK962040	363678098.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc(NC2CCN(C(=O)Cc3ccc(CN4C[C@H](C)NCC4)cc3)CC2)ccc1	Fc1cc(NC2CCN(C(=O)Cc3ccc(CN4C[C@H](C)NCC4)cc3)CC2)ccc1
NCGC00343986-02	Fc1cc(Nc2n[nH]c3-c4c(cc(OC)c(OC)c4)Cc23)ccc1		Inactive	Platelet-derived growth factor receptor beta Inhibitor		1	PDGF receptor tyrosine kinase inhibitor IV	363677319.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	15.7709958719	Fc1cc(Nc2n[nH]c3-c4c(cc(OC)c(OC)c4)Cc23)ccc1	Fc1cc(Nc2n[nH]c3-c4c(cc(OC)c(OC)c4)Cc23)ccc1
NCGC00378733-02	Fc1cc(O)c(-c2c([C@H](O)C)c(C(C)C)nc(C(C)C)c2CCC)cc1		Inactive	Glucagon receptor Antagonist		1	glucagon receptor antagonists-2	363678174.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc(O)c(-c2c([C@H](O)C)c(C(C)C)nc(C(C)C)c2CCC)cc1	Fc1cc(O)c(-c2c([C@H](O)C)c(C(C)C)nc(C(C)C)c2CCC)cc1
NCGC00185997-11	Fc1cc(O)c(-c2oc(/C=C\3/C(=O)NC(=O)S/3)cc2)cc1		Inactive	PI3K gamma Inhibitor		1	AS-252424	384568433.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.5167363959	Fc1cc(O)c(-c2oc(/C=C\3/C(=O)NC(=O)S/3)cc2)cc1	Fc1cc(O)c(-c2oc(/C=C\3/C(=O)NC(=O)S/3)cc2)cc1
NCGC00488783-01	Fc1cc([C@@]2(COc3c(C)nc(C)nc3)[C@H](C(=O)Nc3ncc(F)cc3)C2)ccc1		Inactive	Orexin OX-1/2 Antagonist		1	Lemborexant	363681476.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc([C@@]2(COc3c(C)nc(C)nc3)[C@H](C(=O)Nc3ncc(F)cc3)C2)ccc1	Fc1cc([C@@]2(COc3c(C)nc(C)nc3)[C@H](C(=O)Nc3ncc(F)cc3)C2)ccc1
NCGC00485046-01	Fc1cc([C@H](Oc2c(N)ncc(-c3c(C)nc([C@](O)(CO)C)s3)c2)C)c(-n2nccn2)cc1		Inactive	ALK Inhibitor		1	PF-06439015	363681205.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.848536272	Fc1cc([C@H](Oc2c(N)ncc(-c3c(C)nc([C@](O)(CO)C)s3)c2)C)c(-n2nccn2)cc1	Fc1cc([C@H](Oc2c(N)ncc(-c3c(C)nc([C@](O)(CO)C)s3)c2)C)c(-n2nccn2)cc1
NCGC00164912-01	Fc1cc2-c3nc(-c4ccc(F)cc4)cc(C=4C(=O)c5c(OC=4)ccc(C)c5)c3COc2cc1		Inactive			1	NCGC00164912-01	29216666.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc2-c3nc(-c4ccc(F)cc4)cc(C=4C(=O)c5c(OC=4)ccc(C)c5)c3COc2cc1	Fc1cc2-c3nc(-c4ccc(F)cc4)cc(C=4C(=O)c5c(OC=4)ccc(C)c5)c3COc2cc1
NCGC00387133-01	Fc1cc2/C(/C(=O)Nc2cc1)=C\1/C(=N\O)/c2c(N/1)cccc2		Inactive			1	5 -Fluoroindirubinoxime	377020459.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	17.962385748	Fc1cc2/C(/C(=O)Nc2cc1)=C\1/C(=N\O)/c2c(N/1)cccc2	Fc1cc2/C(/C(=O)Nc2cc1)=C\1/C(=N\O)/c2c(N/1)cccc2
NCGC00164631-05	Fc1cc2/C(=C/C3=C(C)C(C(=O)NCCN(CC)CC)C(C)=N3)/C(=O)Nc2cc1		Inactive	VEGFR-1/2/3 Inhibitor		1	Sunitinib malate	170465289.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1cc2/C(=C/C3=C(C)C(C(=O)NCCN(CC)CC)C(C)=N3)/C(=O)Nc2cc1.O=C(O)C(O)CC(=O)O	Fc1cc2/C(=C/C3=C(C)C(C(=O)NCCN(CC)CC)C(C)=N3)/C(=O)Nc2cc1.O=C(O)C(O)CC(=O)O
NCGC00164631-19	Fc1cc2/C(=C/c3c(C)c(C(=O)NCCN(CC)CC)c(C)[nH]3)/C(=O)Nc2cc1		Inactive	VEGFR-1/2/3 Inhibitor		1	Sunitinib malate	384568270.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc2/C(=C/c3c(C)c(C(=O)NCCN(CC)CC)c(C)[nH]3)/C(=O)Nc2cc1	Fc1cc2/C(=C/c3c(C)c(C(=O)NCCN(CC)CC)c(C)[nH]3)/C(=O)Nc2cc1
NCGC00378902-02&NCGC00378902-03	Fc1cc2/C(=C/c3c(C)c(C(=O)NCCN4CCCC4)c(C)[nH]3)/C(=O)Nc2cc1		Inactive	VEGFR Inhibitor		2	Toceranib	384569074.0&405558487.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1cc2/C(=C/c3c(C)c(C(=O)NCCN4CCCC4)c(C)[nH]3)/C(=O)Nc2cc1	Fc1cc2/C(=C/c3c(C)c(C(=O)NCCN4CCCC4)c(C)[nH]3)/C(=O)Nc2cc1
NCGC00379021-02	Fc1cc2/C(=C/c3c(C)c(C(=O)NC[C@H](O)CN4CCOCC4)c(C)[nH]3)/C(=O)Nc2cc1		Inactive	VEGFR-2 Inhibitor		1	SU-014813	384569086.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc2/C(=C/c3c(C)c(C(=O)NC[C@H](O)CN4CCOCC4)c(C)[nH]3)/C(=O)Nc2cc1	Fc1cc2/C(=C/c3c(C)c(C(=O)NC[C@H](O)CN4CCOCC4)c(C)[nH]3)/C(=O)Nc2cc1
NCGC00015439-11&NCGC00015439-20	Fc1cc2C(=O)N(C)Cc3c(C(=O)OCC)ncn3-c2cc1		Inactive	GABA(A) BZ Site Receptor Antagonist		2	Flumazenil	170464960.0&384567845.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Fc1cc2C(=O)N(C)Cc3c(C(=O)OCC)ncn3-c2cc1	Fc1cc2C(=O)N(C)Cc3c(C(=O)OCC)ncn3-c2cc1
NCGC00408915-01	Fc1cc2C(=O)N(c3ccccc3)C([C@@H](Nc3ncnc4nc[nH]c34)C)=Nc2cc1		Inactive	PI3Kdelta Inhibitor		1	Acalisib	363681083.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc2C(=O)N(c3ccccc3)C([C@@H](Nc3ncnc4nc[nH]c34)C)=Nc2cc1	Fc1cc2C(=O)N(c3ccccc3)C([C@@H](Nc3ncnc4nc[nH]c34)C)=Nc2cc1
NCGC00351600-04	Fc1cc2C(=O)NN=C3[C@@H]([C@@H](c4ccc(F)cc4)Nc(c23)c1)c1n(C)ncn1		Inactive	PARP Inhibitor		1	BMN-673	384569018.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-19.449661464	Fc1cc2C(=O)NN=C3[C@@H]([C@@H](c4ccc(F)cc4)Nc(c23)c1)c1n(C)ncn1	Fc1cc2C(=O)NN=C3[C@@H]([C@@H](c4ccc(F)cc4)Nc(c23)c1)c1n(C)ncn1
NCGC00386287-06	Fc1cc2N=C(NNC(=O)c3nccnc3)c3n(-c2cc1)ccc3		Inactive	Interleukin-6 receptor subunit beta Antagonist		1	SC-114 HCl	363680187.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	17.5	Fc1cc2N=C(NNC(=O)c3nccnc3)c3n(-c2cc1)ccc3	Fc1cc2N=C(NNC(=O)c3nccnc3)c3n(-c2cc1)ccc3
NCGC00510692-02	Fc1cc2[C@@H](C)NC3=Nc4n(ncc4C(=O)NC[C@H](C)Oc2cc1)C=C3		Inactive	ALK Inhibitor		1	TPX-0005	384569482.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc2[C@@H](C)NC3=Nc4n(ncc4C(=O)NC[C@H](C)Oc2cc1)C=C3	Fc1cc2[C@@H](C)NC3=Nc4n(ncc4C(=O)NC[C@H](C)Oc2cc1)C=C3
NCGC00386417-06&NCGC00386417-15	Fc1cc2[C@@H](C)Oc3c(N)ncc(-c4c(C#N)n(C)nc4CN(C)C(=O)c2cc1)c3		Inactive	ROS1/ALK Inhibitor		2	Lorlatinib&PF-06463922	384569134.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	9.824907524&0.0	Fc1cc2[C@@H](C)Oc3c(N)ncc(-c4c(C#N)n(C)nc4CN(C)C(=O)c2cc1)c3	Fc1cc2[C@@H](C)Oc3c(N)ncc(-c4c(C#N)n(C)nc4CN(C)C(=O)c2cc1)c3
NCGC00167477-01	Fc1cc2[C@]3(C(=O)NC(=O)N3)C[C@@H](C(=O)N)Oc2cc1		Inactive	Aldose reductase Inhibitor		1	Fidarestat	144206034.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc2[C@]3(C(=O)NC(=O)N3)C[C@@H](C(=O)N)Oc2cc1	Fc1cc2[C@]3(C(=O)NC(=O)N3)C[C@@H](C(=O)N)Oc2cc1
NCGC00346475-02	Fc1cc2[nH]c(-c3c(C[C@H]4N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)CC)C[C@@H](O)C4)c4c([nH]3)cc(F)cc4)c(C[C@H]3N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)CC)C[C@@H](O)C3)c2cc1		Inactive	IAP Inhibitor		1	Birinapant	384568790.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&-11.1261646559	Fc1cc2[nH]c(-c3c(C[C@H]4N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)CC)C[C@@H](O)C4)c4c([nH]3)cc(F)cc4)c(C[C@H]3N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)CC)C[C@@H](O)C3)c2cc1	Fc1cc2[nH]c(-c3c(C[C@H]4N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)CC)C[C@@H](O)C4)c4c([nH]3)cc(F)cc4)c(C[C@H]3N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)CC)C[C@@H](O)C3)c2cc1
NCGC00263173-05&NCGC00263173-09	Fc1cc2[nH]c(-c3ccc(CNC)cc3)c3c2c(C(=O)NCC3)c1		Inactive	PARP Inhibitor		2	Rucaparib	384568643.0&405558795.0	Anti-infectives&Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Fc1cc2[nH]c(-c3ccc(CNC)cc3)c3c2c(C(=O)NCC3)c1	Fc1cc2[nH]c(-c3ccc(CNC)cc3)c3c2c(C(=O)NCC3)c1
NCGC00510231-01	Fc1cc2[nH]c3[C@]4(C)N(CC5=NNC(=O)c(c2c35)c1)CCC4		Inactive	PARP inhibitor		1	GDC-0077	384569416.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	-12.0&0.0	Fc1cc2[nH]c3[C@]4(C)N(CC5=NNC(=O)c(c2c35)c1)CCC4	Fc1cc2[nH]c3[C@]4(C)N(CC5=NNC(=O)c(c2c35)c1)CCC4
NCGC00264110-02	Fc1cc2c(B(O)OC2)cc1		Inactive			1	AN-2690	405558827.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc2c(B(O)OC2)cc1	Fc1cc2c(B(O)OC2)cc1
NCGC00490685-01	Fc1cc2c(C(=O)NCCN3CCCC3)cc(-c3ccc(CN4CCOCC4)cc3)nc2cc1		Inactive			1	DDD107498	363681479.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc2c(C(=O)NCCN3CCCC3)cc(-c3ccc(CN4CCOCC4)cc3)nc2cc1	Fc1cc2c(C(=O)NCCN3CCCC3)cc(-c3ccc(CN4CCOCC4)cc3)nc2cc1
NCGC00119183-01	Fc1cc2c(C)c(C(=O)Nc3cc(-c4sc5c(n4)cccc5)ccc3)oc2cc1		Inactive			1	NCGC00119183-01	24393762.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc2c(C)c(C(=O)Nc3cc(-c4sc5c(n4)cccc5)ccc3)oc2cc1	Fc1cc2c(C)c(C(=O)Nc3cc(-c4sc5c(n4)cccc5)ccc3)oc2cc1
NCGC00378942-03	Fc1cc2c(C3=C(c4n5c(nc4)C=CC=C5)C(=O)NC3=O)cn3c2c(c1)CN(C(=O)N1CCCCC1)CC3	4.9000001	Active	GSK-3 beta Inhibitor	0.0	1	LY-2090314	384569077.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	42.4996558181	Fc1cc2c(C3=C(c4n5c(nc4)C=CC=C5)C(=O)NC3=O)cn3c2c(c1)CN(C(=O)N1CCCCC1)CC3	Fc1cc2c(C3=C(c4n5c(nc4)C=CC=C5)C(=O)NC3=O)cn3c2c(c1)CN(C(=O)N1CCCCC1)CC3
NCGC00509942-01	Fc1cc2c(C3C(=O)NC(=O)C3)c[nH]c2cc1		Inactive	IDO Inhibitor		1	EOS-200271	384569390.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc2c(C3C(=O)NC(=O)C3)c[nH]c2cc1	Fc1cc2c(C3C(=O)NC(=O)C3)c[nH]c2cc1
NCGC00386286-04	Fc1cc2c(Cc3nc4c(cc3)cccc4)c(C)n(CC(=O)O)c2cc1		Inactive	G protein-coupled receptor 44 Antagonist		1	OC000459	363680186.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc2c(Cc3nc4c(cc3)cccc4)c(C)n(CC(=O)O)c2cc1	Fc1cc2c(Cc3nc4c(cc3)cccc4)c(C)n(CC(=O)O)c2cc1
NCGC00263555-02&NCGC00263555-05	Fc1cc2c(NCc3ccc(F)cc3)ncnc2cc1		Inactive	Ubiquitin Specific Peptidase (USP10/13) Inhibitor		2	Spautin-1	174006174.0&363677285.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1cc2c(NCc3ccc(F)cc3)ncnc2cc1	Fc1cc2c(NCc3ccc(F)cc3)ncnc2cc1
NCGC00263579-01	Fc1cc2c(O[C@H]([C@@H](O)CNC[C@H](O)[C@@H]3Oc4c(cc(F)cc4)CC3)CC2)cc1		Inactive	beta1-Adrenoceptor Antagonists		1	rac Nebivolol hydrochloride	170465208.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0		Fc1cc2c(O[C@H]([C@@H](O)CNC[C@H](O)[C@@H]3Oc4c(cc(F)cc4)CC3)CC2)cc1.Cl	Fc1cc2c(O[C@H]([C@@H](O)CNC[C@H](O)[C@@H]3Oc4c(cc(F)cc4)CC3)CC2)cc1.Cl
NCGC00370807-05	Fc1cc2c([nH]c(C(=O)NCCN3CCC(N4C(=O)Nc5c4cccc5)CC3)c2)cc1		Inactive	Phospholipase D2 Inhibitor		1	FIPI hydrochloride	363677860.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc2c([nH]c(C(=O)NCCN3CCC(N4C(=O)Nc5c4cccc5)CC3)c2)cc1	Fc1cc2c([nH]c(C(=O)NCCN3CCC(N4C(=O)Nc5c4cccc5)CC3)c2)cc1
NCGC00371148-03	Fc1cc2c([nH]c(C(=O)NCc3cc(O)ccc3)c2)cc1		Inactive	Tyrosine-protein kinase SRC Inhibitor		1	KX1-004	363678062.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc2c([nH]c(C(=O)NCc3cc(O)ccc3)c2)cc1	Fc1cc2c([nH]c(C(=O)NCc3cc(O)ccc3)c2)cc1
NCGC00386574-01	Fc1cc2c([nH]c(CN3CCN(c4ncccc4)CC3)c2)cc1		Inactive	Dopamine D4 receptor Agonist		1	CP 226269	363680335.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc2c([nH]c(CN3CCN(c4ncccc4)CC3)c2)cc1	Fc1cc2c([nH]c(CN3CCN(c4ncccc4)CC3)c2)cc1
NCGC00378895-01	Fc1cc2c([nH]c3C4(OCCc23)CCC(N(C)C)(c2ccccc2)CC4)cc1		Inactive	Nociceptin Receptor (OPRL1; KOR3; ORL1) Agonist		1	Cebranopadol	363678262.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc2c([nH]c3C4(OCCc23)CCC(N(C)C)(c2ccccc2)CC4)cc1	Fc1cc2c([nH]c3C4(OCCc23)CCC(N(C)C)(c2ccccc2)CC4)cc1
NCGC00345828-07	Fc1cc2c(c3[nH]c(C(C)(C)C)nc3c3c2C(=O)NC=C3)cc1		Inactive	Jak Inhibitor		1	Pyridone 6	377020265.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc2c(c3[nH]c(C(C)(C)C)nc3c3c2C(=O)NC=C3)cc1	Fc1cc2c(c3[nH]c(C(C)(C)C)nc3c3c2C(=O)NC=C3)cc1
NCGC00386514-01	Fc1cc2c(n(C)c3C(=O)N(c4ccccc4)C=C(C(=O)N4CCCC4)c23)cc1		Inactive			1	SL 651498	363680313.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cc2c(n(C)c3C(=O)N(c4ccccc4)C=C(C(=O)N4CCCC4)c23)cc1	Fc1cc2c(n(C)c3C(=O)N(c4ccccc4)C=C(C(=O)N4CCCC4)c23)cc1
NCGC00379246-01	Fc1cc2nc(-c3cc(C)c(NC(=O)[C@@H](N)CCCCN)cc3)sc2cc1	4.9000001	Active	Aryl Hydrocarbon Receptor (AhR) Agonist	0.0	1	Phortress (NSC-710305)	363678445.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	55.487807077	Fc1cc2nc(-c3cc(C)c(NC(=O)[C@@H](N)CCCCN)cc3)sc2cc1	Fc1cc2nc(-c3cc(C)c(NC(=O)[C@@H](N)CCCCN)cc3)sc2cc1
NCGC00498438-01	Fc1cc2nc(NC(=O)N3CCN(c4cc(OC)cc(OC)c4)CC3)c(OC)nc2cc1		Inactive	p68 RNA Helicase Inhibitor		1	RX-5902 (SUPINOXIN)	384569301.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc2nc(NC(=O)N3CCN(c4cc(OC)cc(OC)c4)CC3)c(OC)nc2cc1	Fc1cc2nc(NC(=O)N3CCN(c4cc(OC)cc(OC)c4)CC3)c(OC)nc2cc1
NCGC00481653-02	Fc1cc2nc(c([C@@H](Nc3ncnc4[nH]cnc34)C)cc2cc1)-c1ncccc1		Inactive	PI3Kdelta Inhibitor		1	AMG-319	363681127.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc2nc(c([C@@H](Nc3ncnc4[nH]cnc34)C)cc2cc1)-c1ncccc1	Fc1cc2nc(c([C@@H](Nc3ncnc4[nH]cnc34)C)cc2cc1)-c1ncccc1
NCGC00015883-11	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C(=NC=4C)CCCC5)CC3)c2cc1		Inactive	Dopamine D2 Antagonist		1	Risperidone	170464925.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C(=NC=4C)CCCC5)CC3)c2cc1	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C(=NC=4C)CCCC5)CC3)c2cc1
NCGC00522023-01	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C(C(OC(=O)CCCCCCCCCCCCCCC)CCC5)=NC=4C)CC3)c2cc1		Inactive			1	Paliperidone Palmitate	405558884.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C(C(OC(=O)CCCCCCCCCCCCCCC)CCC5)=NC=4C)CC3)c2cc1	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C(C(OC(=O)CCCCCCCCCCCCCCC)CCC5)=NC=4C)CC3)c2cc1
NCGC00186014-02	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C([C@H](O)CCC5)=NC=4C)CC3)c2cc1		Inactive	Serotonin 2a (5-HT2a) receptor Antagonist		1	Paliperidone	170464996.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C([C@H](O)CCC5)=NC=4C)CC3)c2cc1	Fc1cc2onc(C3CCN(CCC=4C(=O)N5C([C@H](O)CCC5)=NC=4C)CC3)c2cc1
NCGC00188864-02	Fc1cc2onc(C3CCN(CCCOc4c(OC)cc(C(=O)C)cc4)CC3)c2cc1	4.9000001	Active	Dopamine D2 Antagonist	0.0	1	Iloperidone	170465198.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	95.8793441059	Fc1cc2onc(C3CCN(CCCOc4c(OC)cc(C(=O)C)cc4)CC3)c2cc1	Fc1cc2onc(C3CCN(CCCOc4c(OC)cc(C(=O)C)cc4)CC3)c2cc1
NCGC00093828-12	Fc1ccc(-c2c(-c3ccncc3)[nH]c(-c3ccc([N+](=O)[O-])cc3)n2)cc1		Inactive	p38 MAPK Inhibitor		1	PD-169316	384568119.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(-c2c(-c3ccncc3)[nH]c(-c3ccc([N+](=O)[O-])cc3)n2)cc1	Fc1ccc(-c2c(-c3ccncc3)[nH]c(-c3ccc([N+](=O)[O-])cc3)n2)cc1
NCGC00092295-07	Fc1ccc(-c2c(-c3ccncc3)n3c(SCC3)n2)cc1		Inactive			1	SKF-86002		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(-c2c(-c3ccncc3)n3c(SCC3)n2)cc1	Fc1ccc(-c2c(-c3ccncc3)n3c(SCC3)n2)cc1
NCGC00015962-25	Fc1ccc(-c2c(-c3ccncc3)nc(-c3ccc(O)cc3)[nH]2)cc1	4.9499998	Active	SAPK1 (JNK) Inhibitor	0.0	1	SB-202190	384567911.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	117.7283672566	Fc1ccc(-c2c(-c3ccncc3)nc(-c3ccc(O)cc3)[nH]2)cc1	Fc1ccc(-c2c(-c3ccncc3)nc(-c3ccc(O)cc3)[nH]2)cc1
NCGC00346537-04	Fc1ccc(-c2c(-c3nc4n(CC(C)(C)C)c(N)nc4cc3)[nH]c(C(C)(C)C)n2)cc1	5.8499999	Active	p38 MAPK Inhibitor	0.0	1	LY-2228820	384568826.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	93.8288282908	Fc1ccc(-c2c(-c3nc4n(CC(C)(C)C)c(N)nc4cc3)[nH]c(C(C)(C)C)n2)cc1	Fc1ccc(-c2c(-c3nc4n(CC(C)(C)C)c(N)nc4cc3)[nH]c(C(C)(C)C)n2)cc1
NCGC00402300-03	Fc1ccc(-c2c(-n3cccc3)nn(CCN(C)C)c2)cc1		Inactive	Cellular tumor antigen p53 Binding Agent		1	PK7242 maleate	363681021.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(-c2c(-n3cccc3)nn(CCN(C)C)c2)cc1	Fc1ccc(-c2c(-n3cccc3)nn(CCN(C)C)c2)cc1
NCGC00164625-04	Fc1ccc(-c2c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(C(C)C)nc(C(C)C)c2COC)cc1		Inactive	HMG-CoA reductase Inhibitor		1	Cerivastatin sodium	170465109.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	15.0&-13.264873288	Fc1ccc(-c2c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])c(C(C)C)nc(C(C)C)c2COC)cc1.[Na+]	Fc1ccc(-c2c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])c(C(C)C)nc(C(C)C)c2COC)cc1.[Na+]
NCGC00164566-07&NCGC00164566-08&NCGC00164566-09	Fc1ccc(-c2c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c(C3CC3)nc3c2cccc3)cc1		Inactive	HMG-CoA Reductase Inhibitor		3	Pitavastatin calcium&Pitavastatin Calcium	384568254.0&434147027.0	Annotated/Bioactive Compound Collection&Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	16.5&24.3876324039&22.1299765839	Fc1ccc(-c2c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])c(C3CC3)nc3c2cccc3)cc1	Fc1ccc(-c2c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])c(C3CC3)nc3c2cccc3)cc1
NCGC00164604-06&NCGC00164604-10	Fc1ccc(-c2c(/C=C/[C@H](O)C[C@H](O)CC(=O)O)n(C(C)C)c3c2cccc3)cc1		Inactive	HMG-CoA Reductase Inhibitor		2	Fluvastatin&Fluvastatin Na	384568263.0&405559141.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	11.5473128159&21.5238393999&20.940919792	Fc1ccc(-c2c(/C=C/[C@H](O)C[C@H](O)CC(=O)O)n(C(C)C)c3c2cccc3)cc1	Fc1ccc(-c2c(/C=C/[C@H](O)C[C@H](O)CC(=O)O)n(C(C)C)c3c2cccc3)cc1
NCGC00402250-03	Fc1ccc(-c2c(C3=NN(c4c(C)cccc4)C(=O)C=C3)c3n(n2)C[C@H](CO)CN3)cc1		Inactive	p38 MAPK Inhibitor		1	AS-1940477	363680999.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(-c2c(C3=NN(c4c(C)cccc4)C(=O)C=C3)c3n(n2)C[C@H](CO)CN3)cc1	Fc1ccc(-c2c(C3=NN(c4c(C)cccc4)C(=O)C=C3)c3n(n2)C[C@H](CO)CN3)cc1
NCGC00020328-05	Fc1ccc(-c2c(C3C(=O)NC(=O)N3)cn(-c3ccccc3)n2)cc1		Inactive			1	DPH	363676508.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(-c2c(C3C(=O)NC(=O)N3)cn(-c3ccccc3)n2)cc1	Fc1ccc(-c2c(C3C(=O)NC(=O)N3)cn(-c3ccccc3)n2)cc1
NCGC00494684-01	Fc1ccc(-c2c(COc3ncc(C(=O)N4CCS(=O)(=O)CC4)cc3)c(C)on2)cc1		Inactive	GABA(A) Receptor Subunit alpha-5 (GABRA5) Inverse Agonist		1	Basmisanil	384569290.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(-c2c(COc3ncc(C(=O)N4CCS(=O)(=O)CC4)cc3)c(C)on2)cc1	Fc1ccc(-c2c(COc3ncc(C(=O)N4CCS(=O)(=O)CC4)cc3)c(C)on2)cc1
NCGC00025329-02	Fc1ccc(-c2c(n(C3CCC(O)CC3)cn2)-c2nc(OC)ncc2)cc1		Inactive	p38 MAPK Inhibitor		1	SB-239063	174007082.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(-c2c(n(C3CCC(O)CC3)cn2)-c2nc(OC)ncc2)cc1	Fc1ccc(-c2c(n(C3CCC(O)CC3)cn2)-c2nc(OC)ncc2)cc1
NCGC00370842-02	Fc1ccc(-c2c(n(C3CCCCC3)cn2)-c2nc(N)ncc2)cc1		Inactive	Casein Kinase 1 Inhibitor		1	PF-670462	384569037.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(-c2c(n(C3CCCCC3)cn2)-c2nc(N)ncc2)cc1	Fc1ccc(-c2c(n(C3CCCCC3)cn2)-c2nc(N)ncc2)cc1
NCGC00522007-01	Fc1ccc(-c2c(n(C3CCN(Cc4nocc4)CC3)cn2)-c2nc(N)ncc2)cc1		Inactive	Casein Kinase 1 delta/epsilon Inhibitor		1	PF-5006739	384569509.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(-c2c(n(C3CCN(Cc4nocc4)CC3)cn2)-c2nc(N)ncc2)cc1	Fc1ccc(-c2c(n(C3CCN(Cc4nocc4)CC3)cn2)-c2nc(N)ncc2)cc1
NCGC00345831-03	Fc1ccc(-c2c(n(C3CCNCC3)cn2)-c2nc(OC)ncc2)cc1		Inactive	p38 MAPK Inhibitor		1	SB-242235	363677375.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(-c2c(n(C3CCNCC3)cn2)-c2nc(OC)ncc2)cc1	Fc1ccc(-c2c(n(C3CCNCC3)cn2)-c2nc(OC)ncc2)cc1
NCGC00241112-04	Fc1ccc(-c2c(n(CCCc3ccccc3)c(C#CCCO)n2)-c2ccncc2)cc1	5.0	Active	p38 MAPK Inhibitor	0.0	1	RWJ-67657	384568477.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	53.9887397106	Fc1ccc(-c2c(n(CCCc3ccccc3)c(C#CCCO)n2)-c2ccncc2)cc1	Fc1ccc(-c2c(n(CCCc3ccccc3)c(C#CCCO)n2)-c2ccncc2)cc1
NCGC00408930-02	Fc1ccc(-c2c3c(NCc4cc5OCOc5cc4)ncnc3sc2)cc1		Inactive	NRF2 Inhibitor		1	NCGC00408930	384569221.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	27.563082328	Fc1ccc(-c2c3c(NCc4cc5OCOc5cc4)ncnc3sc2)cc1	Fc1ccc(-c2c3c(NCc4cc5OCOc5cc4)ncnc3sc2)cc1
NCGC00183858-01	Fc1ccc(-c2c3c(nc(N4CCN(CC)CC4)c2)CCCCCC3)cc1	5.25	Active	Serotonin 2a (5-HT2a) receptor Antagonist	0.0	1	Blonanserin	144206818.0	2019_NPC-2.2	SARS-CoV-2_CPE_SRI	3.0	49.344556051	Fc1ccc(-c2c3c(nc(N4CCN(CC)CC4)c2)CCCCCC3)cc1	Fc1ccc(-c2c3c(nc(N4CCN(CC)CC4)c2)CCCCCC3)cc1
NCGC00484085-01	Fc1ccc(-c2c3oc(CNC(=O)/C=C/c4cnc(N)cc4)cc3cc(-c3ccc(C(=O)N4CCC(F)(F)CC4)cc3)c2)cc1		Inactive	PAK4/NAMPT		1	KPT-9274	363681176.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(-c2c3oc(CNC(=O)/C=C/c4cnc(N)cc4)cc3cc(-c3ccc(C(=O)N4CCC(F)(F)CC4)cc3)c2)cc1	Fc1ccc(-c2c3oc(CNC(=O)/C=C/c4cnc(N)cc4)cc3cc(-c3ccc(C(=O)N4CCC(F)(F)CC4)cc3)c2)cc1
NCGC00378989-01	Fc1ccc(-c2cc(CN3CCN(c4c5OCCOc5ccc4)CC3)cnc2)cc1		Inactive	Dopamine receptors; D2 & D3 Antagonist		1	Adoprazine	363678304.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(-c2cc(CN3CCN(c4c5OCCOc5ccc4)CC3)cnc2)cc1	Fc1ccc(-c2cc(CN3CCN(c4c5OCCOc5ccc4)CC3)cnc2)cc1
NCGC00159458-05&NCGC00159458-11	Fc1ccc(-c2n(CC[C@@H](O)C[C@@H](O)CC(=O)O)c(C(C)C)c(C(=O)Nc3ccccc3)c2-c2ccccc2)cc1		Inactive	HMG-CoA Reductase Inhibitor		2	Atorvastatin calcium	170465113.0&384568180.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&14.439632548	Fc1ccc(-c2n(CC[C@@H](O)C[C@@H](O)CC(=O)[O-])c(C(C)C)c(C(=O)Nc3ccccc3)c2-c2ccccc2)cc1.Fc1ccc(-c2n(CC[C@@H](O)C[C@@H](O)CC(=O)[O-])c(C(C)C)c(C(=O)Nc3ccccc3)c2-c2ccccc2)cc1.[Ca+2]	Fc1ccc(-c2n(CC[C@@H](O)C[C@@H](O)CC(=O)[O-])c(C(C)C)c(C(=O)Nc3ccccc3)c2-c2ccccc2)cc1.Fc1ccc(-c2n(CC[C@@H](O)C[C@@H](O)CC(=O)[O-])c(C(C)C)c(C(=O)Nc3ccccc3)c2-c2ccccc2)cc1.[Ca+2]&Fc1ccc(-c2n(CC[C@@H](O)C[C@@H](O)CC(=O)O)c(C(C)C)c(C(=O)Nc3ccccc3)c2-c2ccccc2)cc1
NCGC00346625-03	Fc1ccc(-c2oc(/C=C/3\C(=O)NC(=O)S\3)cc2)cc1	5.1999998	Active	PI3K gamma Inhibitor	0.0	1	CAY10505	384568865.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.2	62.1355386047	Fc1ccc(-c2oc(/C=C/3\C(=O)NC(=O)S\3)cc2)cc1	Fc1ccc(-c2oc(/C=C/3\C(=O)NC(=O)S\3)cc2)cc1
NCGC00346691-02&NCGC00346691-07	Fc1ccc(-c2sc(Cc3c(C)ccc([C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c3)cc2)cc1		Inactive	SGLT-2 Inhibitor		2	Canagliflozin	405558992.0&384568913.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1ccc(-c2sc(Cc3c(C)ccc([C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c3)cc2)cc1	Fc1ccc(-c2sc(Cc3c(C)ccc([C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c3)cc2)cc1
NCGC00167773-13	Fc1ccc(-c2sc(NC(=O)N)c(C(=O)N)c2)cc1		Inactive	IKK beta Inhibitor		1	TPCA-1	384568335.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	10.425544432	Fc1ccc(-c2sc(NC(=O)N)c(C(=O)N)c2)cc1	Fc1ccc(-c2sc(NC(=O)N)c(C(=O)N)c2)cc1
NCGC00509993-01	Fc1ccc(-c2scc(C(NC(=O)O[C@H]3C4CCN(C3)CC4)(C)C)n2)cc1		Inactive	Ceramide Glucosyltransferase Inhibitor		1	Ibiglustat	384569400.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(-c2scc(C(NC(=O)O[C@H]3C4CCN(C3)CC4)(C)C)n2)cc1	Fc1ccc(-c2scc(C(NC(=O)O[C@H]3C4CCN(C3)CC4)(C)C)n2)cc1
NCGC00249377-04	Fc1ccc(-n2c(C)c(C(=O)CN3CCCC3)cc2C)cc1		Inactive	Ubiquitin carboxyl-terminal hydrolase 14 Inhibitor		1	IU1	363677167.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(-n2c(C)c(C(=O)CN3CCCC3)cc2C)cc1	Fc1ccc(-n2c(C)c(C(=O)CN3CCCC3)cc2C)cc1
NCGC00370727-06	Fc1ccc(-n2c3c(c(CCCCN4CCC5(OCc6c5cccc6)CC4)c2)cccc3)cc1		Inactive	Sigma 2 receptor Agonist		1	Siramesine Fumarate Salt	363677826.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	20.0	Fc1ccc(-n2c3c(c(CCCCN4CCC5(OCc6c5cccc6)CC4)c2)cccc3)cc1	Fc1ccc(-n2c3c(c(CCCCN4CCC5(OCc6c5cccc6)CC4)c2)cccc3)cc1
NCGC00379138-01	Fc1ccc(C(=O)C2CCN(CCN3C(=O)N=C4N(C3=O)CCCC4)CC2)cc1		Inactive	Serotonin 2a (5-HT2a) receptor Antagonist		1	DV 7028 hydrochloride	363678380.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(C(=O)C2CCN(CCN3C(=O)N=C4N(C3=O)CCCC4)CC2)cc1	Fc1ccc(C(=O)C2CCN(CCN3C(=O)N=C4N(C3=O)CCCC4)CC2)cc1
NCGC00021146-09	Fc1ccc(C(=O)C2CCN(CCN3C(=O)Nc4c(C3=O)cccc4)CC2)cc1	4.9000001	Active	5-HT2A Antagonists?	0.0	1	Ketanserin	170466645.0	2019_NPC-2.2	SARS-CoV-2_CPE_SRI	2.4	30.386597936	Fc1ccc(C(=O)C2CCN(CCN3C(=O)Nc4c(C3=O)cccc4)CC2)cc1	Fc1ccc(C(=O)C2CCN(CCN3C(=O)Nc4c(C3=O)cccc4)CC2)cc1
NCGC00016504-09	Fc1ccc(C(=O)CCCN2CC=C(N3C(=O)Nc4c3cccc4)CC2)cc1		Inactive	HERG Inhibitor		1	Droperidol	170464722.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Fc1ccc(C(=O)CCCN2CC=C(N3C(=O)Nc4c3cccc4)CC2)cc1	Fc1ccc(C(=O)CCCN2CC=C(N3C(=O)Nc4c3cccc4)CC2)cc1
NCGC00165864-04	Fc1ccc(C(=O)CCCN2CCC(C(=O)N)(N3CCCCC3)CC2)cc1		Inactive	Serotonin 2c (5-HT2c) receptor Antagonist		1	Pipamperone dihydrochloride	170465949.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Fc1ccc(C(=O)CCCN2CCC(C(=O)N)(N3CCCCC3)CC2)cc1.Cl.Cl	Fc1ccc(C(=O)CCCN2CCC(C(=O)N)(N3CCCCC3)CC2)cc1.Cl.Cl
NCGC00160383-02	Fc1ccc(C(=O)CCCN2CCC(C(=O)c3ccc(F)cc3)CC2)cc1		Inactive	Serotonin 2 (5-HT2) receptor Antagonist		1	Lenperone Hydrochloride	405558683.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(C(=O)CCCN2CCC(C(=O)c3ccc(F)cc3)CC2)cc1	Fc1ccc(C(=O)CCCN2CCC(C(=O)c3ccc(F)cc3)CC2)cc1
NCGC00167744-02	Fc1ccc(C(=O)CCCN2CCC(C)CC2)cc1		Inactive			1	Methylperone	170466288.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(C(=O)CCCN2CCC(C)CC2)cc1	Fc1ccc(C(=O)CCCN2CCC(C)CC2)cc1
NCGC00016602-04	Fc1ccc(C(=O)CCCN2CCC(N3C(=O)Nc4c3cccc4)CC2)cc1		Inactive	Dopamine D2 receptor Antagonist		1	Benperidol	170466409.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Fc1ccc(C(=O)CCCN2CCC(N3C(=O)Nc4c3cccc4)CC2)cc1	Fc1ccc(C(=O)CCCN2CCC(N3C(=O)Nc4c3cccc4)CC2)cc1
NCGC00188430-01	Fc1ccc(C(=O)CCCN2CCC(O)(c3ccc(C)cc3)CC2)cc1		Inactive	Serotonin 2a (5-HT2a) receptor Inverse Agonist		1	Moperone	144207164.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)O.Fc1ccc(C(=O)CCCN2CCC(O)(c3ccc(C)cc3)CC2)cc1	S(=O)(=O)(O)O.Fc1ccc(C(=O)CCCN2CCC(O)(c3ccc(C)cc3)CC2)cc1
NCGC00485045-01	Fc1ccc(C(=O)CCCN2CCC3(N(c4ccccc4)CN(C)C3=O)CC2)cc1	5.1999998	Active	Serotonin 2 (5-HT2) receptor Antagonist	0.0	1	N-Methylspiperone hydrochloride	363681204.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	2.3	91.7469342915	Fc1ccc(C(=O)CCCN2CCC3(N(c4ccccc4)CN(C)C3=O)CC2)cc1	Fc1ccc(C(=O)CCCN2CCC3(N(c4ccccc4)CN(C)C3=O)CC2)cc1
NCGC00015964-17	Fc1ccc(C(=O)CCCN2CCC3(N(c4ccccc4)CNC3=O)CC2)cc1	4.9000001	Active	Dopamine D4 receptor Antagonist	0.0	1	Spiperone	170465856.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	107.0104070262	Fc1ccc(C(=O)CCCN2CCC3(N(c4ccccc4)CNC3=O)CC2)cc1	Fc1ccc(C(=O)CCCN2CCC3(N(c4ccccc4)CNC3=O)CC2)cc1
NCGC00016590-06	Fc1ccc(C(=O)CCCN2CCN(c3ncccc3)CC2)cc1		Inactive			1	Azaperone	170465697.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Fc1ccc(C(=O)CCCN2CCN(c3ncccc3)CC2)cc1	Fc1ccc(C(=O)CCCN2CCN(c3ncccc3)CC2)cc1
NCGC00371019-02	Fc1ccc(C(=O)N2CC(C(=O)O)(COc3cc4c(cc(OC)cc4)cc3)C2)cc1		Inactive	Prostaglandin EP2 receptor Antagonist		1	PF-04418948	363677996.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(C(=O)N2CC(C(=O)O)(COc3cc4c(cc(OC)cc4)cc3)C2)cc1	Fc1ccc(C(=O)N2CC(C(=O)O)(COc3cc4c(cc(OC)cc4)cc3)C2)cc1
NCGC00346722-06	Fc1ccc(C(=O)N2C[C@@H](c3onc(-c4ccc(F)cc4)n3)CCC2)cc1		Inactive	mgluR5 Antagonist		1	ADX-47273	384568933.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(C(=O)N2C[C@@H](c3onc(-c4ccc(F)cc4)n3)CCC2)cc1	Fc1ccc(C(=O)N2C[C@@H](c3onc(-c4ccc(F)cc4)n3)CCC2)cc1
NCGC00386743-01	Fc1ccc(C(=O)NCCN2CCN(c3c4OCCOc4ccc3)CC2)cc1		Inactive	Serotonin 1a (5-HT1a) receptor Agonist		1	1,4-Benzodioxin, benzamide deriv.	363680428.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(C(=O)NCCN2CCN(c3c4OCCOc4ccc3)CC2)cc1	Fc1ccc(C(=O)NCCN2CCN(c3c4OCCOc4ccc3)CC2)cc1
NCGC00386481-01	Fc1ccc(C(=O)NCCN2CCN(c3c4c(ccc(O)c4)ccc3)CC2)cc1		Inactive			1	desmethyl-S 14506	363680299.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(C(=O)NCCN2CCN(c3c4c(ccc(O)c4)ccc3)CC2)cc1	Fc1ccc(C(=O)NCCN2CCN(c3c4c(ccc(O)c4)ccc3)CC2)cc1
NCGC00386591-01	Fc1ccc(C(=O)NN2CCN(C(=O)C)CC2)cc1		Inactive	synaptic transmission, glutamatergic Modulator		1	FK 960	363680346.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(C(=O)NN2CCN(C(=O)C)CC2)cc1	Fc1ccc(C(=O)NN2CCN(C(=O)C)CC2)cc1
NCGC00378866-01	Fc1ccc(C(=O)N[C@@H]2[C@@H](OC(=O)NC)COc3c2cc(N2CCN(C4COC4)CC2)cc3)cc1		Inactive	Cathepsin S Inhibitor		1	Cathepsin S inhibitor	363678246.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(C(=O)N[C@@H]2[C@@H](OC(=O)NC)COc3c2cc(N2CCN(C4COC4)CC2)cc3)cc1	Fc1ccc(C(=O)N[C@@H]2[C@@H](OC(=O)NC)COc3c2cc(N2CCN(C4COC4)CC2)cc3)cc1
NCGC00378776-02	Fc1ccc(C(=O)Nc2cc3c(C4CCN(C)CC4)c[nH]c3cc2)cc1		Inactive	Serotonin 1f (5-HT1f) receptor Agonist		1	LY 334370 hydrochloride	363678192.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(C(=O)Nc2cc3c(C4CCN(C)CC4)c[nH]c3cc2)cc1	Fc1ccc(C(=O)Nc2cc3c(C4CCN(C)CC4)c[nH]c3cc2)cc1
NCGC00370709-05	Fc1ccc(C(=O)Nc2cc3c([nH]c4c3C[C@H](N(C)C)CC4)cc2)cc1		Inactive	5-hydroxytryptamine receptor 1F Agonist		1	LY344864	363677816.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	24.7960687919	Fc1ccc(C(=O)Nc2cc3c([nH]c4c3C[C@H](N(C)C)CC4)cc2)cc1	Fc1ccc(C(=O)Nc2cc3c([nH]c4c3C[C@H](N(C)C)CC4)cc2)cc1
NCGC00510695-01	Fc1ccc(C(=O)Nc2n(C3CCC(C(=O)NC(C)C)CC3)c3c(n2)ccc(CN2CCC(C(O)(C)C)CC2)c3)cc1		Inactive	ALK Inhibitor		1	Belizatinib	384569484.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(C(=O)Nc2n(C3CCC(C(=O)NC(C)C)CC3)c3c(n2)ccc(CN2CCC(C(O)(C)C)CC2)c3)cc1	Fc1ccc(C(=O)Nc2n(C3CCC(C(=O)NC(C)C)CC3)c3c(n2)ccc(CN2CCC(C(O)(C)C)CC2)c3)cc1
NCGC00246966-11	Fc1ccc(C(=O)c2cc3nc(NC(=O)OC)[nH]c3cc2)cc1		Inactive	antiparasitic agent		1	Flubendazole	384568513.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(C(=O)c2cc3nc(NC(=O)OC)[nH]c3cc2)cc1	Fc1ccc(C(=O)c2cc3nc(NC(=O)OC)[nH]c3cc2)cc1
NCGC00378579-06	Fc1ccc(C(=O)c2nc([C@H]3N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)C4CCCCC4)CCC3)sc2)cc1	4.9000001	Active	IAP Inhibitor	0.0	1	LCL-161	384569051.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	46.8823071749	Fc1ccc(C(=O)c2nc([C@H]3N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)C4CCCCC4)CCC3)sc2)cc1	Fc1ccc(C(=O)c2nc([C@H]3N(C(=O)[C@@H](NC(=O)[C@@H](NC)C)C4CCCCC4)CCC3)sc2)cc1
NCGC00015802-18	Fc1ccc(C(CCCN2CCC(N3C(=O)Nc4c3cccc4)CC2)c2ccc(F)cc2)cc1		Inactive	HERG Inhibitor		1	Pimozide	170464864.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Fc1ccc(C(CCCN2CCC(N3C(=O)Nc4c3cccc4)CC2)c2ccc(F)cc2)cc1	Fc1ccc(C(CCCN2CCC(N3C(=O)Nc4c3cccc4)CC2)c2ccc(F)cc2)cc1
NCGC00386631-01	Fc1ccc(C(CCOc2c(OCCN3CCCCC3)c(C(=O)C)c(C)c3nc(C)oc23)C)cc1	4.9000001	Active	Voltage-gated potassium channel subunit Kv1.3 Blocker	0.0	1	Kv1.3 Channel blocker 42	363680363.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	101.3002857095	Fc1ccc(C(CCOc2c(OCCN3CCCCC3)c(C(=O)C)c(C)c3nc(C)oc23)C)cc1	Fc1ccc(C(CCOc2c(OCCN3CCCCC3)c(C(=O)C)c(C)c3nc(C)oc23)C)cc1
NCGC00137220-01	Fc1ccc(C(N2CCN(C)CC2)C2=C(O)n3nc(-c4occc4)nc3S2)cc1		Inactive			1	NCGC00137220-01	24412603.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(C(N2CCN(C)CC2)C2=C(O)n3nc(-c4occc4)nc3S2)cc1	Fc1ccc(C(N2CCN(C)CC2)C2=C(O)n3nc(-c4occc4)nc3S2)cc1
NCGC00018102-12	Fc1ccc(C(N2CCN(C/C=C/c3ccccc3)CC2)c2ccc(F)cc2)cc1	4.9499998	Active	Calcium Channel Blocker	0.0	1	Flunarizine	170466037.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	92.8882720404	Fc1ccc(C(N2CCN(C/C=C/c3ccccc3)CC2)c2ccc(F)cc2)cc1	Fc1ccc(C(N2CCN(C/C=C/c3ccccc3)CC2)c2ccc(F)cc2)cc1
NCGC00384249-01	Fc1ccc(C(N2CCN(Cc3c(C)nc(C)c(C)n3)CC2)c2ccc(F)cc2)cc1	4.9499998	Active	NOX Inhibitor	0.0	1	CXC-195	384569108.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	64.3731253159	Fc1ccc(C(N2CCN(Cc3c(C)nc(C)c(C)n3)CC2)c2ccc(F)cc2)cc1	Fc1ccc(C(N2CCN(Cc3c(C)nc(C)c(C)n3)CC2)c2ccc(F)cc2)cc1
NCGC00164543-02	Fc1ccc(C(N2CCN(Cc3c(OC)c(OC)c(OC)cc3)CC2)c2ccc(F)cc2)cc1	4.9499998	Active	Ca channel blocker - benzhydryl class	0.0	1	Lomerizine dihydrochloride	170466010.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	2.4	35.611350388	Fc1ccc(C(N2CCN(Cc3c(OC)c(OC)c(OC)cc3)CC2)c2ccc(F)cc2)cc1.Cl.Cl	Fc1ccc(C(N2CCN(Cc3c(OC)c(OC)c(OC)cc3)CC2)c2ccc(F)cc2)cc1.Cl.Cl
NCGC00253707-01	Fc1ccc(C(N2CCNCC2)c2ccc(F)cc2)cc1		Inactive			1	1-(Bis(4-fluorophenyl)methyl)piperazine	170466736.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(C(N2CCNCC2)c2ccc(F)cc2)cc1	Fc1ccc(C(N2CCNCC2)c2ccc(F)cc2)cc1
NCGC00370917-01	Fc1ccc(C(OC2C[C@@H]3N(CCCC)[C@H](C2)CC3)c2ccc(F)cc2)cc1	5.0	Active	Dopamine transporter Antagonist	0.0	1	JHW 007 hydrochloride	363677933.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	94.882715824	Fc1ccc(C(OC2C[C@@H]3N(CCCC)[C@H](C2)CC3)c2ccc(F)cc2)cc1	Fc1ccc(C(OC2C[C@@H]3N(CCCC)[C@H](C2)CC3)c2ccc(F)cc2)cc1
NCGC00015300-11	Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1		Inactive	Dopamine Reuptake Inhibitor		1	Vanoxeamine	384567836.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	19.776150628	Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1	Fc1ccc(C(OCCN2CCN(CCCc3ccccc3)CC2)c2ccc(F)cc2)cc1
NCGC00179240-04	Fc1ccc(C2(C#N)CCC(N3C[C@@H](C)[C@@](C(=O)O)(c4ccccc4)CC3)CC2)cc1		Inactive	Neurotensin receptor type 2 Inverse Agonist		1	Levocabastine hydrochloride	170465061.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(C2(C#N)CCC(N3C[C@@H](C)[C@@](C(=O)O)(c4ccccc4)CC3)CC2)cc1.Cl	Fc1ccc(C2(C#N)CCC(N3C[C@@H](C)[C@@](C(=O)O)(c4ccccc4)CC3)CC2)cc1.Cl
NCGC00015267-11	Fc1ccc(C2(CCCN(C)C)OCc3c2ccc(C#N)c3)cc1		Inactive	5-HT Reuptake Inhibitor		1	Citalopram hydrobromide	405558908.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(C2(CCCN(C)C)OCc3c2ccc(C#N)c3)cc1	Fc1ccc(C2(CCCN(C)C)OCc3c2ccc(C#N)c3)cc1
NCGC00510356-01	Fc1ccc(C2=C(CN3CCCC3)COc3c2cc(OC)cc3)cc1		Inactive	T Cell Receptor (TCR)/Cytoplasmic Protein NCK1 Interaction Inhibitor		1	AX-024	384569431.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(C2=C(CN3CCCC3)COc3c2cc(OC)cc3)cc1	Fc1ccc(C2=C(CN3CCCC3)COc3c2cc(OC)cc3)cc1
NCGC00387684-01	Fc1ccc(C2C([N+](=O)[O-])=Cc3c(c(OCC)ccc3)O2)cc1	4.9000001	Active		0.0	1	S14161	377020355.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	3.0	37.4602329919	Fc1ccc(C2C([N+](=O)[O-])=Cc3c(c(OCC)ccc3)O2)cc1	Fc1ccc(C2C([N+](=O)[O-])=Cc3c(c(OCC)ccc3)O2)cc1
NCGC00378929-01	Fc1ccc(C2c3nc(Nc4cc(OC)c(-n5cc(C)nc5)cc4)sc3CCC2)cc1	4.9499998	Active	Gamma-secretase Modulator	0.0	1	gamma-secretase modulator 3	363678284.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	54.9317104669	Fc1ccc(C2c3nc(Nc4cc(OC)c(-n5cc(C)nc5)cc4)sc3CCC2)cc1	Fc1ccc(C2c3nc(Nc4cc(OC)c(-n5cc(C)nc5)cc4)sc3CCC2)cc1
NCGC00402234-02	Fc1ccc(C=2n3nc(C(C)(C)C)cc3N=C(C(=O)N(CCN(C)C)Cc3ccccc3)C=2)cc1	4.9000001	Active	Beta amyloid A4 protein Binding Agent	0.0	1	RU-505	363680991.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	116.1235809544	Fc1ccc(C=2n3nc(C(C)(C)C)cc3N=C(C(=O)N(CCN(C)C)Cc3ccccc3)C=2)cc1	Fc1ccc(C=2n3nc(C(C)(C)C)cc3N=C(C(=O)N(CCN(C)C)Cc3ccccc3)C=2)cc1
NCGC00386549-01	Fc1ccc(CC2CCN(C(=O)C(=O)Nc3cc4OC(=O)Nc4cc3)CC2)cc1		Inactive	Glutamate [NMDA] receptor subunit epsilon 2 Antagonist		1	RGH 896	363680323.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(CC2CCN(C(=O)C(=O)Nc3cc4OC(=O)Nc4cc3)CC2)cc1	Fc1ccc(CC2CCN(C(=O)C(=O)Nc3cc4OC(=O)Nc4cc3)CC2)cc1
NCGC00370956-01	Fc1ccc(CCN2CCN(C(=O)c3c4[nH]cc(C#N)c4ccc3)CC2)cc1		Inactive	Serotonin 2a (5-HT2a) receptor Antagonist		1	EMD 281014 hydrochloride	363677954.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(CCN2CCN(C(=O)c3c4[nH]cc(C#N)c4ccc3)CC2)cc1	Fc1ccc(CCN2CCN(C(=O)c3c4[nH]cc(C#N)c4ccc3)CC2)cc1
NCGC00387775-03	Fc1ccc(CCOc2ccc(CCCc3oc(C(=O)O)cc3)cc2)cc1	4.9000001	Active	AMPK Activator	0.0	1	D-942	363680662.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	59.0519630871	Fc1ccc(CCOc2ccc(CCCc3oc(C(=O)O)cc3)cc2)cc1	Fc1ccc(CCOc2ccc(CCCc3oc(C(=O)O)cc3)cc2)cc1
NCGC00390656-02	Fc1ccc(CN(C(=O)NCc2ccc(OCC(C)C)cc2)C2CCN(C)CC2)cc1		Inactive			1	Pimavanserin	405558435.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(CN(C(=O)NCc2ccc(OCC(C)C)cc2)C2CCN(C)CC2)cc1	Fc1ccc(CN(C(=O)NCc2ccc(OCC(C)C)cc2)C2CCN(C)CC2)cc1
NCGC00387145-01	Fc1ccc(CN2C(=O)/C(=C/c3ccc(OCc4cc(B(O)O)ccc4)cc3)/SC2=O)cc1		Inactive	ENPP2 (Autotaxin) Inhibitor		1	HA-130	384569153.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-10.885049364	Fc1ccc(CN2C(=O)/C(=C/c3ccc(OCc4cc(B(O)O)ccc4)cc3)/SC2=O)cc1	Fc1ccc(CN2C(=O)/C(=C/c3ccc(OCc4cc(B(O)O)ccc4)cc3)/SC2=O)cc1
NCGC00370973-01	Fc1ccc(CNC(=O)C(=O)c2c3c([nH]c2)cccc3)cc1		Inactive	GABA-A receptor; alpha-1/beta-2/gamma-2 Antagonist		1	TCS 1105	363677968.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(CNC(=O)C(=O)c2c3c([nH]c2)cccc3)cc1	Fc1ccc(CNC(=O)C(=O)c2c3c([nH]c2)cccc3)cc1
NCGC00346512-02	Fc1ccc(CNC(=O)C2=C(O)C(=O)N(C)C(N3S(=O)(=O)CCCC3)=N2)cc1		Inactive	HIV Integrase Inhibitors		1	BMS-707035	363677435.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(CNC(=O)C2=C(O)C(=O)N(C)C(N3S(=O)(=O)CCCC3)=N2)cc1	Fc1ccc(CNC(=O)C2=C(O)C(=O)N(C)C(N3S(=O)(=O)CCCC3)=N2)cc1
NCGC00167356-07&NCGC00167356-11&NCGC00167356-14	Fc1ccc(CNC(=O)C2C(=O)C(=O)N(C)C(C(NC(=O)c3oc(C)nn3)(C)C)=N2)cc1		Inactive	Human immunodeficiency virus type 1 integrase Inhibitor		3	Raltegravir&Raltegravir Potassium	405559137.0&384568309.0&434147039.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	Fc1ccc(CNC(=O)C2=C([O-])C(=O)N(C)C(C(NC(=O)c3oc(C)nn3)(C)C)=N2)cc1	Fc1ccc(CNC(=O)C2=C([O-])C(=O)N(C)C(C(NC(=O)c3oc(C)nn3)(C)C)=N2)cc1
NCGC00346739-06	Fc1ccc(CNc2cc(N)c(NC(=O)OCC)cc2)cc1		Inactive	Voltage-Gated K(V) 7 (KCNQ) Channel Activator		1	Retigabine	363677539.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(CNc2cc(N)c(NC(=O)OCC)cc2)cc1	Fc1ccc(CNc2cc(N)c(NC(=O)OCC)cc2)cc1
NCGC00015451-11	Fc1ccc(CNc2nc(N)c(NC(=O)OCC)cc2)cc1		Inactive	Voltage-Gated K(V) 7 (KCNQ) Channel Activator		1	Flupirtine maleate	384567850.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(CNc2nc(N)c(NC(=O)OCC)cc2)cc1	Fc1ccc(CNc2nc(N)c(NC(=O)OCC)cc2)cc1
NCGC00371157-01	Fc1ccc(CNc2nc(NCC3CCCCC3)nc(Nc3ccc(CC(=O)NCCOCCOCCN)cc3)n2)cc1		Inactive	Alpha enolase Inhibitor		1	AP-III-a4	363678070.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(CNc2nc(NCC3CCCCC3)nc(Nc3ccc(CC(=O)NCCOCCOCCN)cc3)n2)cc1	Fc1ccc(CNc2nc(NCC3CCCCC3)nc(Nc3ccc(CC(=O)NCCOCCOCCN)cc3)n2)cc1
NCGC00379114-01	Fc1ccc(COC2=CC(=O)N(c3ccc(OCCN4CCCC4)cc3)C=C2)cc1		Inactive	Melanin-concentrating hormone receptor 1 Antagonist		1	TC-MCH 7c	363678364.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(COC2=CC(=O)N(c3ccc(OCCN4CCCC4)cc3)C=C2)cc1	Fc1ccc(COC2=CC(=O)N(c3ccc(OCCN4CCCC4)cc3)C=C2)cc1
NCGC00346443-01	Fc1ccc(C[C@@H](C(=O)N[C@H](/C=C/C(=O)OCC)C[C@H]2C(=O)NCC2)CC(=O)[C@@H](NC(=O)c2noc(C)c2)C(C)C)cc1		Inactive	HRV 3C Protease Inhibitor		1	Rupintrivir	174007383.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	11.035585904&0.0	Fc1ccc(C[C@@H](C(=O)N[C@H](/C=C/C(=O)OCC)C[C@H]2C(=O)NCC2)CC(=O)[C@@H](NC(=O)c2noc(C)c2)C(C)C)cc1	Fc1ccc(C[C@@H](C(=O)N[C@H](/C=C/C(=O)OCC)C[C@H]2C(=O)NCC2)CC(=O)[C@@H](NC(=O)c2noc(C)c2)C(C)C)cc1
NCGC00420704-02	Fc1ccc(Cc2cnc3C(C)(C)CN(C(=O)CN4[C@@H](CN5[C@H](C)COCC5)CN[C@H](C)C4)c3c2)cc1	4.9499998	Active	IAP Inhibitor	0.0	1	AT-IAP	384569224.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	99.2832535923	Fc1ccc(Cc2cnc3C(C)(C)CN(C(=O)CN4[C@@H](CN5[C@H](C)COCC5)CN[C@H](C)C4)c3c2)cc1	Fc1ccc(Cc2cnc3C(C)(C)CN(C(=O)CN4[C@@H](CN5[C@H](C)COCC5)CN[C@H](C)C4)c3c2)cc1
NCGC00344565-01	Fc1ccc(Cn2c(N3CCC(N(C)C4=NC=CC(=O)N4)CC3)nc3c2cccc3)cc1		Inactive	Histamine H1 Receptor Antagonists		1	Mizolastine	170465604.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(Cn2c(N3CCC(N(C)C4=NC=CC(=O)N4)CC3)nc3c2cccc3)cc1	Fc1ccc(Cn2c(N3CCC(N(C)C4=NC=CC(=O)N4)CC3)nc3c2cccc3)cc1
NCGC00016913-14	Fc1ccc(Cn2c(NC3CCN(CCc4ccc(OC)cc4)CC3)nc3c2cccc3)cc1		Inactive	Histamine H1 receptor Antagonist		1	Astemizole	170465888.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&10.952462776	Fc1ccc(Cn2c(NC3CCN(CCc4ccc(OC)cc4)CC3)nc3c2cccc3)cc1	Fc1ccc(Cn2c(NC3CCN(CCc4ccc(OC)cc4)CC3)nc3c2cccc3)cc1
NCGC00390276-01	Fc1ccc(Cn2nc(C(=O)N[C@H](C(=O)N)C(C)C)c3c2cccc3)cc1		Inactive	Cannabinoid CB1 receptor Agonist		1	AB-FUBINACA	363680872.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(Cn2nc(C(=O)N[C@H](C(=O)N)C(C)C)c3c2cccc3)cc1	Fc1ccc(Cn2nc(C(=O)N[C@H](C(=O)N)C(C)C)c3c2cccc3)cc1
NCGC00480972-03	Fc1ccc(Cn2nc(C(=O)Nc3cc(C)c(OC)c(C)c3)c3c2[C@](C(=O)N)(C)CN(C(=O)c2[nH]ccc2)C3)cc1		Inactive	IDH1 Inhibitor		1	GSK-864	363681115.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ccc(Cn2nc(C(=O)Nc3cc(C)c(OC)c(C)c3)c3c2[C@](C(=O)N)(C)CN(C(=O)c2[nH]ccc2)C3)cc1	Fc1ccc(Cn2nc(C(=O)Nc3cc(C)c(OC)c(C)c3)c3c2[C@](C(=O)N)(C)CN(C(=O)c2[nH]ccc2)C3)cc1
NCGC00112757-01	Fc1ccc(N2CCN(C=3n4nc(-c5ccccc5)nc4-c4c(N=3)cccc4)CC2)cc1		Inactive			1	NCGC00112757-01	24387336.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(N2CCN(C=3n4nc(-c5ccccc5)nc4-c4c(N=3)cccc4)CC2)cc1	Fc1ccc(N2CCN(C=3n4nc(-c5ccccc5)nc4-c4c(N=3)cccc4)CC2)cc1
NCGC00112791-01	Fc1ccc(N2CCN(C=3n4nc(-c5cnccc5)nc4-c4c(N=3)cccc4)CC2)cc1		Inactive			1	NCGC00112791-01	24387370.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(N2CCN(C=3n4nc(-c5cnccc5)nc4-c4c(N=3)cccc4)CC2)cc1	Fc1ccc(N2CCN(C=3n4nc(-c5cnccc5)nc4-c4c(N=3)cccc4)CC2)cc1
NCGC00378709-01	Fc1ccc(N2CCN(CCC3OCCc4c3cccc4)CC2)cc1		Inactive	D(4) dopamine receptor Antagonist		1	PNU 96415E	363678163.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(N2CCN(CCC3OCCc4c3cccc4)CC2)cc1	Fc1ccc(N2CCN(CCC3OCCc4c3cccc4)CC2)cc1
NCGC00183837-01	Fc1ccc(N2CCN(CCCC(=O)NC3c4c(SCc5c3cccc5)cccc4)CC2)cc1	4.9000001	Active	Calcium Channel Blocker	0.0	1	Monatepil	124894552.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	103.5671282691	Fc1ccc(N2CCN(CCCC(=O)NC3c4c(SCc5c3cccc5)cccc4)CC2)cc1	Fc1ccc(N2CCN(CCCC(=O)NC3c4c(SCc5c3cccc5)cccc4)CC2)cc1
NCGC00390567-01	Fc1ccc(NC(=O)C2(C(=O)Nc3ccc(Oc4c5c([nH]c(C(=O)NCCN6CCOCC6)c5)ncc4)cc3)CC2)cc1		Inactive	Hepatocyte growth factor receptor Inhibitor		1	Tyrosine kinase inhibitor	363680907.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1ccc(NC(=O)C2(C(=O)Nc3ccc(Oc4c5c([nH]c(C(=O)NCCN6CCOCC6)c5)ncc4)cc3)CC2)cc1	Fc1ccc(NC(=O)C2(C(=O)Nc3ccc(Oc4c5c([nH]c(C(=O)NCCN6CCOCC6)c5)ncc4)cc3)CC2)cc1
NCGC00263164-07&NCGC00263164-17	Fc1ccc(NC(=O)C2(C(=O)Nc3ccc(Oc4c5c(ncc4)cc(OC)c(OC)c5)cc3)CC2)cc1		Inactive	VEGFR-2 Inhibitor		2	Cabozantinib	384568635.0&405558578.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Fc1ccc(NC(=O)C2(C(=O)Nc3ccc(Oc4c5c(ncc4)cc(OC)c(OC)c5)cc3)CC2)cc1	Fc1ccc(NC(=O)C2(C(=O)Nc3ccc(Oc4c5c(ncc4)cc(OC)c(OC)c5)cc3)CC2)cc1
NCGC00159569-02	Fc1ccc(Nc2c(Nc3ccc(F)cc3)cc3C(=O)NC(=O)c3c2)cc1	5.0	Active		0.0	1	CGP 53353	29215546.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	78.6198682785	Fc1ccc(Nc2c(Nc3ccc(F)cc3)cc3C(=O)NC(=O)c3c2)cc1	Fc1ccc(Nc2c(Nc3ccc(F)cc3)cc3C(=O)NC(=O)c3c2)cc1
NCGC00408843-01	Fc1ccc(Nc2nc(C)c(C)c(N3C(C)c4c(cccc4)CC3)n2)cc1	4.9000001	Active	Sodium/potassium-transporting ATPase subunit alpha-1 Antagonist	0.0	1	Revaprazan HCl	363681062.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	113.3546857095	Fc1ccc(Nc2nc(C)c(C)c(N3C(C)c4c(cccc4)CC3)n2)cc1	Fc1ccc(Nc2nc(C)c(C)c(N3C(C)c4c(cccc4)CC3)n2)cc1
NCGC00370967-01	Fc1ccc(Oc2cc3C(=O)N(C[C@@H]4CN(C(C)C)CCC4)C(C)=Nc3cc2)cc1	4.9499998	Active	Growth hormone secretagogue receptor type 1 Antagonist	0.0	1	YIL 781	363677963.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	100.9902620816	Fc1ccc(Oc2cc3C(=O)N(C[C@@H]4CN(C(C)C)CCC4)C(C)=Nc3cc2)cc1	Fc1ccc(Oc2cc3C(=O)N(C[C@@H]4CN(C(C)C)CCC4)C(C)=Nc3cc2)cc1
NCGC00263575-01&NCGC00263575-10	Fc1ccc([C@@H](O)CC[C@@H]2[C@H](N(c3ccc(F)cc3)C2=O)c2ccc(O)cc2)cc1		Inactive	NPC1L1 Inhibitor		2	Ezetimibe	170465013.0&384568690.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&30.3226002479	Fc1ccc([C@@H](O)CC[C@@H]2[C@H](N(c3ccc(F)cc3)C2=O)c2ccc(O)cc2)cc1	Fc1ccc([C@@H](O)CC[C@@H]2[C@H](N(c3ccc(F)cc3)C2=O)c2ccc(O)cc2)cc1
NCGC00378817-01	Fc1ccc([C@H](C)N2C(=O)/C(=C/c3cc(OC)c(-n4cc(C)nc4)cc3)/CCC2)cc1		Inactive	Gamma-secretase Modulator		1	E 2012	363678217.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	17.0944047279	Fc1ccc([C@H](C)N2C(=O)/C(=C/c3cc(OC)c(-n4cc(C)nc4)cc3)/CCC2)cc1	Fc1ccc([C@H](C)N2C(=O)/C(=C/c3cc(OC)c(-n4cc(C)nc4)cc3)/CCC2)cc1
NCGC00025355-12	Fc1ccc([C@H]2[C@H](COc3cc4OCOc4cc3)CNCC2)cc1		Inactive	5-HT Reuptake Inhibitor		1	Paroxetine	170465075.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.2495802999	Fc1ccc([C@H]2[C@H](COc3cc4OCOc4cc3)CNCC2)cc1	Fc1ccc([C@H]2[C@H](COc3cc4OCOc4cc3)CNCC2)cc1
NCGC00484077-01	Fc1cnc(OC[C@H]2CN(C(=O)c3c(-c4ncccn4)ccc(C)c3)[C@H](C)CC2)cc1		Inactive	Orexin receptor 2 Antagonist		1	MK-6096	363681169.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Fc1cnc(OC[C@H]2CN(C(=O)c3c(-c4ncccn4)ccc(C)c3)[C@H](C)CC2)cc1	Fc1cnc(OC[C@H]2CN(C(=O)c3c(-c4ncccn4)ccc(C)c3)[C@H](C)CC2)cc1
NCGC00373041-01&NCGC00373041-02&NCGC00373041-03	Fc1nc(C(=O)N)c(O)nc1		Inactive	RNA-dependant RNA polymeriase		3	Favipiravir	384569046.0&405558604.0	Anti-infectives&Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	Fc1nc(C(=O)N)c(O)nc1	Fc1nc(C(=O)N)c(O)nc1
NCGC00181336-01&NCGC00182047-03	Fc1nc(N)c2ncn([C@H]3[C@@H](O)[C@H](O)[C@@H](CO)O3)c2n1		Inactive	Purine-Nucleoside Phosphorylase Inhibitor&Purine Antagonist		2	2-Fluoroadenosine&Fludarabine phosphate	144206348.0&170464764.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0		Fc1nc(N)c2ncn([C@H]3[C@@H](O)[C@H](O)[C@@H](CO)O3)c2n1	Fc1nc(N)c2ncn([C@H]3[C@@H](O)[C@H](O)[C@@H](CO)O3)c2n1
NCGC00346453-03	Fc1ncc(NC(=O)[C@@]2(C)N(C=3N=C(Nc4n[nH]c(C5CC5)c4)c4n(N=3)ccc4)CCC2)cc1		Inactive	IGF-1R Inhibitor		1	BMS-754807	363677410.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1ncc(NC(=O)[C@@]2(C)N(C=3N=C(Nc4n[nH]c(C5CC5)c4)c4n(N=3)ccc4)CCC2)cc1	Fc1ncc(NC(=O)[C@@]2(C)N(C=3N=C(Nc4n[nH]c(C5CC5)c4)c4n(N=3)ccc4)CCC2)cc1
NCGC00522465-01	Fc1nccc(-c2c(C)cc(CC(=O)Nc3ncc(N4CCN(C(=O)C)CC4)cc3)cn2)c1		Inactive	Wnt Signaling Inhibitor		1	GNF-6231	384569518.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1nccc(-c2c(C)cc(CC(=O)Nc3ncc(N4CCN(C(=O)C)CC4)cc3)cn2)c1	Fc1nccc(-c2c(C)cc(CC(=O)Nc3ncc(N4CCN(C(=O)C)CC4)cc3)cn2)c1
NCGC00370783-06	Fc1nccc(-c2cc(C(=O)Nc3cnccc3)c(OCc3ccccc3)cc2)c1		Inactive	LRRK2 Inhibitor		1	GSK-2578215A	363677854.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1nccc(-c2cc(C(=O)Nc3cnccc3)c(OCc3ccccc3)cc2)c1	Fc1nccc(-c2cc(C(=O)Nc3cnccc3)c(OCc3ccccc3)cc2)c1
NCGC00475723-01	Fc1nccc2c1n(C1CCCC1)c1nc(Nc3ncc(N4CCC(N(CCO)C)CC4)cc3)ncc21		Inactive	CDK4 Inhibitor		1	AM-5992	377020299.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Fc1nccc2c1n(C1CCCC1)c1nc(Nc3ncc(N4CCC(N(CCO)C)CC4)cc3)ncc21	Fc1nccc2c1n(C1CCCC1)c1nc(Nc3ncc(N4CCC(N(CCO)C)CC4)cc3)ncc21
NCGC00183856-01	IC#CCCCCCCCCC(=O)Oc1ccccc1		Inactive			1	Phenyl 11-iodo-10-undecynoate	144206805.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&17.4059040599	IC#CCCCCCCCCC(=O)Oc1ccccc1	IC#CCCCCCCCCC(=O)Oc1ccccc1
NCGC00181134-04	IC#CCOc1c(Cl)cc(Cl)c(Cl)c1		Inactive			1	Haloprogin	405558522.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	20.308483292	IC#CCOc1c(Cl)cc(Cl)c(Cl)c1	IC#CCOc1c(Cl)cc(Cl)c(Cl)c1
NCGC00159397-03	IC=1C(=O)N(N(C)C=1C)c1ccccc1		Inactive			1	Iodoantipyrine	170465556.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	IC=1C(=O)N(N(C)C=1C)c1ccccc1	IC=1C(=O)N(N(C)C=1C)c1ccccc1
NCGC00179673-03&NCGC00179673-05&NCGC00179673-09	IC=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1		Inactive	Anti-Herpes Simplex Virus Drug		3	Idoxuridine	170465014.0&434147053.0&384568382.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	IC=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1	IC=1C(=O)NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=1
NCGC00262963-03	IC=1C(N)=NC(=O)N([C@H]2[C@@H](F)[C@H](O)[C@@H](CO)O2)C=1		Inactive			1	Fiacitabine	434147072.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	IC=1C(N)=NC(=O)N([C@H]2[C@@H](F)[C@H](O)[C@@H](CO)O2)C=1	IC=1C(N)=NC(=O)N([C@H]2[C@@H](F)[C@H](O)[C@@H](CO)O2)C=1
NCGC00485527-01	IC[C@@]12[C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC=C1C[C@@H](OC(=O)C)CC2		Inactive			1	19-Iodo-5-androstene-3Î²-ol-17-one 3-acetate	363681361.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	IC[C@@]12[C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC=C1C[C@@H](OC(=O)C)CC2	IC[C@@]12[C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC=C1C[C@@H](OC(=O)C)CC2
NCGC00485509-01	IC[C@@]12[C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC=C1C[C@@H](OC(=O)C)CC2		Inactive			1	19-Iodocholesterol 3-acetate	363681359.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	IC[C@@]12[C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC=C1C[C@@H](OC(=O)C)CC2	IC[C@@]12[C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC=C1C[C@@H](OC(=O)C)CC2
NCGC00159504-04	IOc1c(C(C)C)cc(c(C)c1)-c1c(C)cc(OI)c(C(C)C)c1		Inactive			1	Thymol iodide	170465466.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	IOc1c(C(C)C)cc(c(C)c1)-c1c(C)cc(OI)c(C(C)C)c1	IOc1c(C(C)C)cc(c(C)c1)-c1c(C)cc(OI)c(C(C)C)c1
NCGC00181092-01	Ic1c(/N=C/N(C)C)c(I)cc(I)c1CCC(=O)O		Inactive			1	Ipodate sodium	144206261.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(/N=C/N(C)C)c(I)cc(I)c1CCC(=O)[O-].[Na+]	Ic1c(/N=C/N(C)C)c(I)cc(I)c1CCC(=O)[O-].[Na+]
NCGC00160456-03	Ic1c(C(=O)NCC(=O)O)cccc1		Inactive	renal filtration Interacts		1	2-Iodohippuric acid	170465302.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(C(=O)NCC(=O)O)cccc1	Ic1c(C(=O)NCC(=O)O)cccc1
NCGC00165726-04	Ic1c(C(=O)c2c3c(n(CC4N(C)CCCC4)c2)cccc3)cc([N+](=O)[O-])cc1	4.9000001	Active	Cannabinoid CB2 receptor Agonist	0.0	1	AM1241	363676639.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	106.0981655413	Ic1c(C(=O)c2c3c(n(CC4N(C)CCCC4)c2)cccc3)cc([N+](=O)[O-])cc1	Ic1c(C(=O)c2c3c(n(CC4N(C)CCCC4)c2)cccc3)cc([N+](=O)[O-])cc1
NCGC00189287-01	Ic1c(C2N=C(Nc3oc4c(n3)cccc4)NC3=C2C(=O)CCC3)cccc1		Inactive			1	NCGC00189287-01	99431320.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Ic1c(C2N=C(Nc3oc4c(n3)cccc4)NC3=C2C(=O)CCC3)cccc1	Ic1c(C2N=C(Nc3oc4c(n3)cccc4)NC3=C2C(=O)CCC3)cccc1
NCGC00386405-01	Ic1c(Cl)cc(O)c(NCC(=O)N2CCN(C(=O)C=C)CC2)c1		Inactive	GTPase KRas Inhibitor		1	K-Ras(G12C) inhibitor 12	363680260.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	24.0	Ic1c(Cl)cc(O)c(NCC(=O)N2CCN(C(=O)C=C)CC2)c1	Ic1c(Cl)cc(O)c(NCC(=O)N2CCN(C(=O)C=C)CC2)c1
NCGC00384194-02	Ic1c(Cl)cc(OC)c(NCC(=O)N2CCC(NS(=O)(=O)C=C)CC2)c1		Inactive	GTPase KRas Inhibitor		1	K-Ras(G12C) inhibitor 9	363679186.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	31.0	Ic1c(Cl)cc(OC)c(NCC(=O)N2CCC(NS(=O)(=O)C=C)CC2)c1	Ic1c(Cl)cc(OC)c(NCC(=O)N2CCC(NS(=O)(=O)C=C)CC2)c1
NCGC00016886-04	Ic1c(N(C(=O)C)C)c(I)c(C(=O)NC)c(I)c1C(=O)NCC(=O)Nc1c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c1I		Inactive	Thrombin Inhibitor		1	Ioxaglic Acid	405558537.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(N(C(=O)C)C)c(I)c(C(=O)NC)c(I)c1C(=O)NCC(=O)Nc1c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c1I	Ic1c(N(C(=O)C)C)c(I)c(C(=O)NC)c(I)c1C(=O)NCC(=O)Nc1c(I)c(C(=O)O)c(I)c(C(=O)NCCO)c1I
NCGC00179520-04	Ic1c(N(C(=O)C)C)c(I)c(C(=O)N[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)OC2O)c(I)c1NC(=O)C		Inactive			1	Metrizamide	405559101.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(N(C(=O)C)C)c(I)c(C(=O)N[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)OC2O)c(I)c1NC(=O)C	Ic1c(N(C(=O)C)C)c(I)c(C(=O)N[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)OC2O)c(I)c1NC(=O)C
NCGC00181093-01	Ic1c(N(C(=O)C)C)c(I)c(C(=O)O)c(I)c1NC(=O)C		Inactive			1	Metrizoate sodium	144206262.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(N(C(=O)C)C)c(I)c(C(=O)[O-])c(I)c1NC(=O)C.[Na+]	Ic1c(N(C(=O)C)C)c(I)c(C(=O)[O-])c(I)c1NC(=O)C.[Na+]
NCGC00179430-04	Ic1c(N(C(=O)C)CC(C(=O)O)C)c(I)cc(I)c1N		Inactive			1	Iocetamic acid	405559045.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(N(C(=O)C)CC(C(=O)O)C)c(I)cc(I)c1N	Ic1c(N(C(=O)C)CC(C(=O)O)C)c(I)cc(I)c1N
NCGC00179408-03	Ic1c(N(C(=O)C)CC(O)CN(C(=O)C)c2c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c2I)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO		Inactive			1	Iodixanol	170464924.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(N(C(=O)C)CC(O)CN(C(=O)C)c2c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c2I)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO	Ic1c(N(C(=O)C)CC(O)CN(C(=O)C)c2c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c2I)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO
NCGC00166000-04	Ic1c(N(C(=O)C)CC(O)CO)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO		Inactive			1	Iohexol	170464962.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(N(C(=O)C)CC(O)CO)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO	Ic1c(N(C(=O)C)CC(O)CO)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO
NCGC00182070-03	Ic1c(N(C(=O)C)CC(O)CO)c(I)c(C(=O)NCCO)c(I)c1C(=O)NCC(O)CO		Inactive			1	Ioxilan	170465160.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(N(C(=O)C)CC(O)CO)c(I)c(C(=O)NCCO)c(I)c1C(=O)NCC(O)CO	Ic1c(N(C(=O)C)CC(O)CO)c(I)c(C(=O)NCCO)c(I)c1C(=O)NCC(O)CO
NCGC00183283-01	Ic1c(N(C(=O)CO)C)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO		Inactive			1	Iomeprol	144207160.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(N(C(=O)CO)C)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO	Ic1c(N(C(=O)CO)C)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO
NCGC00179364-03	Ic1c(N(C(=O)CO)CCO)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO		Inactive			1	Ioversol	170464725.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(N(C(=O)CO)CCO)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO	Ic1c(N(C(=O)CO)CCO)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)NCC(O)CO
NCGC00274272-01	Ic1c(N)c(I)cc(I)c1C(=O)N(CCC(=O)O)c1ccccc1		Inactive			1	Iobenzamic acid	170465948.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Ic1c(N)c(I)cc(I)c1C(=O)N(CCC(=O)O)c1ccccc1	Ic1c(N)c(I)cc(I)c1C(=O)N(CCC(=O)O)c1ccccc1
NCGC00095082-06	Ic1c(N)c(I)cc(I)c1CC(C(=O)O)CC		Inactive			1	Iopanoic acid	170465056.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Ic1c(N)c(I)cc(I)c1CC(C(=O)O)CC	Ic1c(N)c(I)cc(I)c1CC(C(=O)O)CC
NCGC00485570-01	Ic1c(N)ccc(CNc2ncnc3n([C@H]4[C@H](O)[C@H](O)[C@@H](C(=O)NC)O4)cnc23)c1		Inactive	Adenosine A3 receptor Agonist		1	I-AB-MECA	363681364.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Ic1c(N)ccc(CNc2ncnc3n([C@H]4[C@H](O)[C@H](O)[C@@H](C(=O)NC)O4)cnc23)c1	Ic1c(N)ccc(CNc2ncnc3n([C@H]4[C@H](O)[C@H](O)[C@@H](C(=O)NC)O4)cnc23)c1
NCGC00532516-01	Ic1c(NC(=O)C(CO)CO)c(I)c(C(=O)N(CC(O)CO)C)c(I)c1C(=O)N(CC(O)CO)C		Inactive			1	IOBITRIDOL	405559008.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(NC(=O)C(CO)CO)c(I)c(C(=O)N(CC(O)CO)C)c(I)c1C(=O)N(CC(O)CO)C	Ic1c(NC(=O)C(CO)CO)c(I)c(C(=O)N(CC(O)CO)C)c(I)c1C(=O)N(CC(O)CO)C
NCGC00253600-01	Ic1c(NC(=O)C)c(I)c(C(=O)NC)c(I)c1C(=O)O		Inactive			1	Iothalamate sodium	170465058.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Ic1c(NC(=O)C)c(I)c(C(=O)NC)c(I)c1C(=O)[O-].[Na+]	Ic1c(NC(=O)C)c(I)c(C(=O)NC)c(I)c1C(=O)[O-].[Na+]
NCGC00021123-03	Ic1c(NC(=O)C)c(I)c(C(=O)O)c(I)c1NC(=O)C		Inactive			1	Diatrizoic acid dihydrate	170464638.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Ic1c(NC(=O)C)c(I)c(C(=O)O)c(I)c1NC(=O)C.O.O	Ic1c(NC(=O)C)c(I)c(C(=O)O)c(I)c1NC(=O)C.O.O
NCGC00094851-05	Ic1c(NC(=O)C)c(I)c(CNC(=O)C)c(I)c1C(=O)O		Inactive			1	Iodamide	170465213.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(NC(=O)C)c(I)c(CNC(=O)C)c(I)c1C(=O)O	Ic1c(NC(=O)C)c(I)c(CNC(=O)C)c(I)c1C(=O)O
NCGC00095105-05	Ic1c(NC(=O)C)c(I)cc(I)c1C(=O)O		Inactive	Solute carrier organic anion transporter family member 1B1 Activator		1	Acetrizoic acid	170465154.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(NC(=O)C)c(I)cc(I)c1C(=O)O	Ic1c(NC(=O)C)c(I)cc(I)c1C(=O)O
NCGC00181094-01	Ic1c(NC(=O)CCC)c(I)cc(I)c1CC(C(=O)O)CC		Inactive			1	Sodium tyropanoate	144206263.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(NC(=O)CCC)c(I)cc(I)c1CC(C(=O)[O-])CC.[Na+]	Ic1c(NC(=O)CCC)c(I)cc(I)c1CC(C(=O)[O-])CC.[Na+]
NCGC00249936-01	Ic1c(NC(=O)CCCCC(=O)Nc2c(I)c(C(=O)O)c(I)c(C(=O)NC)c2I)c(I)c(C(=O)NC)c(I)c1C(=O)O		Inactive			1	Iocarmic acid	170465965.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(NC(=O)CCCCC(=O)Nc2c(I)c(C(=O)O)c(I)c(C(=O)NC)c2I)c(I)c(C(=O)NC)c(I)c1C(=O)O	Ic1c(NC(=O)CCCCC(=O)Nc2c(I)c(C(=O)O)c(I)c(C(=O)NC)c2I)c(I)c(C(=O)NC)c(I)c1C(=O)O
NCGC00016523-05	Ic1c(NC(=O)CCCCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O		Inactive	Complement factor B Inhibitor		1	Iodipamide	170464888.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Ic1c(NC(=O)CCCCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O	Ic1c(NC(=O)CCCCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O
NCGC00262940-01	Ic1c(NC(=O)CCOCCOCCOCCOCCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O		Inactive			1	Iodoxamic Acid	170465432.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Ic1c(NC(=O)CCOCCOCCOCCOCCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O	Ic1c(NC(=O)CCOCCOCCOCCOCCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O
NCGC00179367-03	Ic1c(NC(=O)COC)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)N(CC(O)CO)C		Inactive			1	Iopromide	170465023.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(NC(=O)COC)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)N(CC(O)CO)C	Ic1c(NC(=O)COC)c(I)c(C(=O)NCC(O)CO)c(I)c1C(=O)N(CC(O)CO)C
NCGC00183025-01	Ic1c(NC(=O)COCCOCCOCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O		Inactive			1	Biliscopin	144206809.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Ic1c(NC(=O)COCCOCCOCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O	Ic1c(NC(=O)COCCOCCOCC(=O)Nc2c(I)c(C(=O)O)c(I)cc2I)c(I)cc(I)c1C(=O)O
NCGC00016892-04	Ic1c(NC(=O)[C@@H](O)C)c(I)c(C(=O)NC(CO)CO)c(I)c1C(=O)NC(CO)CO		Inactive			1	Iopamidol	170464646.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Ic1c(NC(=O)[C@@H](O)C)c(I)c(C(=O)NC(CO)CO)c(I)c1C(=O)NC(CO)CO	Ic1c(NC(=O)[C@@H](O)C)c(I)c(C(=O)NC(CO)CO)c(I)c1C(=O)NC(CO)CO
NCGC00371149-01	Ic1c(NCC(C(=O)c2sccc2)CN)nc(Nc2cc(NC(=O)N3CCCC3)ccc2)nc1		Inactive	Serine/threonine-protein kinase TBK1 Inhibitor		1	BX795	363678063.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Ic1c(NCC(C(=O)c2sccc2)CN)nc(Nc2cc(NC(=O)N3CCCC3)ccc2)nc1	Ic1c(NCC(C(=O)c2sccc2)CN)nc(Nc2cc(NC(=O)N3CCCC3)ccc2)nc1
NCGC00250386-10	Ic1c(NCCCNC(=O)c2sccc2)nc(Nc2cc(NC(=O)N3CCCC3)ccc2)nc1		Inactive	IKK-epsilon Inhibitor		1	BX-795	384568539.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(NCCCNC(=O)c2sccc2)nc(Nc2cc(NC(=O)N3CCCC3)ccc2)nc1	Ic1c(NCCCNC(=O)c2sccc2)nc(Nc2cc(NC(=O)N3CCCC3)ccc2)nc1
NCGC00160408-06	Ic1c(O)c(I)cc(C(=O)c2c(CC)oc3c2cccc3)c1		Inactive			1	Benziodarone	405558418.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(O)c(I)cc(C(=O)c2c(CC)oc3c2cccc3)c1	Ic1c(O)c(I)cc(C(=O)c2c(CC)oc3c2cccc3)c1
NCGC00166241-02	Ic1c(O)c(I)cc([N+](=O)[O-])c1	4.9000001	Active		0.0	1	2,6-DIIODO-4-NITROPHENOL	225144276.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	55.5703942456	Ic1c(O)c(I)cc([N+](=O)[O-])c1	Ic1c(O)c(I)cc([N+](=O)[O-])c1
NCGC00166249-03	Ic1c(O)c(I)cc2C3(OC(=O)c4c3cccc4)c3c(c(I)c(O)c(I)c3)Oc12		Inactive			1	Erythrosin B	170465719.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(O)c(I)cc2C3(OC(=O)c4c3cccc4)c3c(c(I)c(O)c(I)c3)Oc12	Ic1c(O)c(I)cc2C3(OC(=O)c4c3cccc4)c3c(c(I)c(O)c(I)c3)Oc12
NCGC00016391-13	Ic1c(O)c2ncccc2c(Cl)c1	5.0	Active		0.0	1	Clioquinol	170465019.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	66.5491381248	Ic1c(O)c2ncccc2c(Cl)c1	Ic1c(O)c2ncccc2c(Cl)c1
NCGC00484064-01	Ic1c(OC)cc(C(C)C)c(Oc2c(N)nc(N)nc2)c1		Inactive	P2X purinoceptor 3 Antagonist		1	AF-353	363681156.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Ic1c(OC)cc(C(C)C)c(Oc2c(N)nc(N)nc2)c1	Ic1c(OC)cc(C(C)C)c(Oc2c(N)nc(N)nc2)c1
NCGC00347903-02	Ic1c(OC)cc(C(C)C)c(Oc2c(N)nc(NC(CO)CO)nc2)c1		Inactive	P2X3/P2X2 Receptor Antagonist		1	Ro-51	384568987.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(OC)cc(C(C)C)c(Oc2c(N)nc(NC(CO)CO)nc2)c1	Ic1c(OC)cc(C(C)C)c(Oc2c(N)nc(NC(CO)CO)nc2)c1
NCGC00015096-17&NCGC00015096-27	Ic1c(OCCN(CC)CC)c(I)cc(C(=O)c2c(CCCC)oc3c2cccc3)c1	5.0	Active	Muscarinic M3 Receptor Ligands	0.10000040000000077	2	Amiodarone hydrochloride	170464920.0&384567808.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	93.8476860096&105.6264744792	Ic1c(OCCN(CC)CC)c(I)cc(C(=O)c2c(CCCC)oc3c2cccc3)c1	Ic1c(OCCN(CC)CC)c(I)cc(C(=O)c2c(CCCC)oc3c2cccc3)c1
NCGC00094852-04	Ic1c(Oc2cc(I)c(O)c(I)c2)c(I)cc(CC(N)C(=O)O)c1		Inactive	synthetic hormone		1	L-Thyroxine	405558662.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(Oc2cc(I)c(O)c(I)c2)c(I)cc(CC(N)C(=O)O)c1	Ic1c(Oc2cc(I)c(O)c(I)c2)c(I)cc(CC(N)C(=O)O)c1
NCGC00164336-05	Ic1c(Oc2cc(I)c(O)c(I)c2)c(I)cc(C[C@H](N)C(=O)O)c1		Inactive	synthetic hormone		1	L-Thyroxine	174006930.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(Oc2cc(I)c(O)c(I)c2)c(I)cc(C[C@H](N)C(=O)O)c1	Ic1c(Oc2cc(I)c(O)c(I)c2)c(I)cc(C[C@H](N)C(=O)O)c1
NCGC00016227-08	Ic1c(Oc2cc(I)c(O)cc2)c(I)cc(CC(=O)O)c1		Inactive	Thyroid hormone receptor beta-1 Agonist		1	Tiratricol	363676478.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Ic1c(Oc2cc(I)c(O)cc2)c(I)cc(CC(=O)O)c1	Ic1c(Oc2cc(I)c(O)cc2)c(I)cc(CC(=O)O)c1
NCGC00013556-15	Ic1c(Oc2cc(I)c(O)cc2)c(I)cc(C[C@H](N)C(=O)O)c1		Inactive	Thyroid hormone receptor beta-1 Agonist		1	Liothyronine Sodium	405559084.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1c(Oc2cc(I)c(O)cc2)c(I)cc(C[C@H](N)C(=O)O)c1	Ic1c(Oc2cc(I)c(O)cc2)c(I)cc(C[C@H](N)C(=O)O)c1
NCGC00371072-06	Ic1c(Sc2n(CCCNC(C)C)c3ncnc(N)c3n2)cc2OCOc2c1		Inactive	Heat shock protein HSP90 Inhibitor		1	PU-H71	363678016.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	21.5	Ic1c(Sc2n(CCCNC(C)C)c3ncnc(N)c3n2)cc2OCOc2c1	Ic1c(Sc2n(CCCNC(C)C)c3ncnc(N)c3n2)cc2OCOc2c1
NCGC00263096-16	Ic1c([N+](=O)[O-])cc(C(=O)N)cc1		Inactive	PARP Inhibitor		1	Iniparib	384568587.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Ic1c([N+](=O)[O-])cc(C(=O)N)cc1	Ic1c([N+](=O)[O-])cc(C(=O)N)cc1
NCGC00159508-04&NCGC00159508-05	Ic1c([O-])c(I)cc2C(c3c(Cl)c(Cl)c(Cl)c(Cl)c3C(=O)[O-])=C3C(=C(I)C(=O)C(I)=C3)Oc12		Inactive	Free Radical Stimulator		2	Rose Bengal disodium	225144230.0&174006187.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Ic1c([O-])c(I)cc2C(c3c(Cl)c(Cl)c(Cl)c(Cl)c3C(=O)[O-])=C3C(=C(I)C(=O)C(I)=C3)Oc12	Ic1c([O-])c(I)cc2C(c3c(Cl)c(Cl)c(Cl)c(Cl)c3C(=O)[O-])=C3C(=C(I)C(=O)C(I)=C3)Oc12
NCGC00181912-01	Ic1c2C(=O)N(C)Cc3c(C(=O)OCC)ncn3-c2ccc1		Inactive	GABAergic synapse Modulator		1	Iomazenil	144206800.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Ic1c2C(=O)N(C)Cc3c(C(=O)OCC)ncn3-c2ccc1	Ic1c2C(=O)N(C)Cc3c(C(=O)OCC)ncn3-c2ccc1
NCGC00096117-01	Ic1c2c(N)ncnc2n([C@H]2C(O)[C@@H](O)[C@@H](CO)O2)c1		Inactive			1	5-Iodotubercidin	26753828.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Ic1c2c(N)ncnc2n([C@H]2C(O)[C@@H](O)[C@@H](CO)O2)c1	Ic1c2c(N)ncnc2n([C@H]2C(O)[C@@H](O)[C@@H](CO)O2)c1
NCGC00015554-13	Ic1c2c(c(S(=O)(=O)N3CCNCCC3)ccc2)ccc1	4.9499998	Active	MLCK Inhibitor	0.0	1	ML-7	384567863.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	80.2651477632	Ic1c2c(c(S(=O)(=O)N3CCNCCC3)ccc2)ccc1	Ic1c2c(c(S(=O)(=O)N3CCNCCC3)ccc2)ccc1
NCGC00371127-01	Ic1cc(C(=O)O)c(NC(=O)[C@@H](NCc2ccccc2)Cc2ccccc2)cc1		Inactive	Kinesin-like protein KIFC1 Inhibitor		1	CW069	363678043.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Ic1cc(C(=O)O)c(NC(=O)[C@@H](NCc2ccccc2)Cc2ccccc2)cc1	Ic1cc(C(=O)O)c(NC(=O)[C@@H](NCc2ccccc2)Cc2ccccc2)cc1
NCGC00167793-02	Ic1cc(C)c(Nc2c(F)c(F)c(F)cc2C(=O)NOCC2CC2)cc1		Inactive	ERK1/2 Inhibitor		1	PD-198306	377020440.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	16.5238860799	Ic1cc(C)c(Nc2c(F)c(F)c(F)cc2C(=O)NOCC2CC2)cc1	Ic1cc(C)c(Nc2c(F)c(F)c(F)cc2C(=O)NOCC2CC2)cc1
NCGC00015572-06	Ic1cc(CNC(=N)N)ccc1		Inactive			1	MIBG	405558858.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1cc(CNC(=N)N)ccc1	Ic1cc(CNC(=N)N)ccc1
NCGC00025001-03	Ic1cc(CNc2nc(Cl)nc3n([C@H]4[C@H](O)[C@H](O)[C@@H](C(=O)NC)O4)cnc23)ccc1		Inactive	Adenosine A3 Agonist		1	Namodenoson	384568042.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1cc(CNc2nc(Cl)nc3n([C@H]4[C@H](O)[C@H](O)[C@@H](C(=O)NC)O4)cnc23)ccc1	Ic1cc(CNc2nc(Cl)nc3n([C@H]4[C@H](O)[C@H](O)[C@@H](C(=O)NC)O4)cnc23)ccc1
NCGC00189074-12	Ic1cc(Cl)c(Nc2c(F)c(F)ccc2C(=O)NOCC2CC2)cc1		Inactive	MEK Inhibitor		1	PD-184352	384568457.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1cc(Cl)c(Nc2c(F)c(F)ccc2C(=O)NOCC2CC2)cc1	Ic1cc(Cl)c(Nc2c(F)c(F)ccc2C(=O)NOCC2CC2)cc1
NCGC00351593-05	Ic1cc(F)c(NC2=C(C(=O)NOCCO)C=Cc3n2cnc3)cc1		Inactive	MEK Inhibitor		1	GDC-0623	377020510.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1cc(F)c(NC2=C(C(=O)NOCCO)C=Cc3n2cnc3)cc1	Ic1cc(F)c(NC2=C(C(=O)NOCCO)C=Cc3n2cnc3)cc1
NCGC00263187-07	Ic1cc(F)c(NC2=C(F)C(=O)N(C)C=3N=CN(C[C@@H](O)CO)C(=O)C2=3)cc1		Inactive	MEK Inhibitor		1	TAK-733	384568654.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1cc(F)c(NC2=C(F)C(=O)N(C)C=3N=CN(C[C@@H](O)CO)C(=O)C2=3)cc1	Ic1cc(F)c(NC2=C(F)C(=O)N(C)C=3N=CN(C[C@@H](O)CO)C(=O)C2=3)cc1
NCGC00263180-08&NCGC00263180-14	Ic1cc(F)c(NC=2N(C)C(=O)C(C)=C3N(c4cc(NC(=O)C)ccc4)C(=O)N(C(=O)C=23)C2CC2)cc1		Inactive	Mek 1/2 Inhibitor		2	Trametinib	384568648.0&405558802.0	Anti-infectives&Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Ic1cc(F)c(NC=2N(C)C(=O)C(C)=C3N(c4cc(NC(=O)C)ccc4)C(=O)N(C(=O)C=23)C2CC2)cc1	Ic1cc(F)c(NC=2N(C)C(=O)C(C)=C3N(c4cc(NC(=O)C)ccc4)C(=O)N(C(=O)C=23)C2CC2)cc1
NCGC00346567-12	Ic1cc(F)c(NC=2N(C)C(=O)C(C)=CC=2C(=O)NOCCO)cc1		Inactive	MEK Inhibitor		1	AZD-8330	377020162.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1cc(F)c(NC=2N(C)C(=O)C(C)=CC=2C(=O)NOCCO)cc1	Ic1cc(F)c(NC=2N(C)C(=O)C(C)=CC=2C(=O)NOCCO)cc1
NCGC00346530-09	Ic1cc(F)c(Nc2c(C(=O)NC[C@H](O)CO)ccnc2)cc1		Inactive	Mek 1/2 Inhibitor		1	Pimasertib	384568822.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1cc(F)c(Nc2c(C(=O)NC[C@H](O)CO)ccnc2)cc1	Ic1cc(F)c(Nc2c(C(=O)NC[C@H](O)CO)ccnc2)cc1
NCGC00346552-08	Ic1cc(F)c(Nc2c(F)c(F)c(Br)cc2C(=O)NOCC(O)CO)cc1		Inactive	Mek 1/2 Inhibitor		1	PD-318088	384568837.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1cc(F)c(Nc2c(F)c(F)c(Br)cc2C(=O)NOCC(O)CO)cc1	Ic1cc(F)c(Nc2c(F)c(F)c(Br)cc2C(=O)NOCC(O)CO)cc1
NCGC00378595-03	Ic1cc(F)c(Nc2c(F)c(F)c(CN3C(=O)CCCO3)cc2C(=O)NOCCO)cc1		Inactive	MEK Inhibitor		1	RO-4987655	377020160.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1cc(F)c(Nc2c(F)c(F)c(CN3C(=O)CCCO3)cc2C(=O)NOCCO)cc1	Ic1cc(F)c(Nc2c(F)c(F)c(CN3C(=O)CCCO3)cc2C(=O)NOCCO)cc1
NCGC00188380-05	Ic1cc(F)c(Nc2c(F)c(F)cc(OC)c2NS(=O)(=O)C2(C[C@H](O)CO)CC2)cc1	4.9499998	Active	Mek 1/2 Inhibitor	0.0	1	Refametinib	384568448.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	52.0770030847	Ic1cc(F)c(Nc2c(F)c(F)cc(OC)c2NS(=O)(=O)C2(C[C@H](O)CO)CC2)cc1	Ic1cc(F)c(Nc2c(F)c(F)cc(OC)c2NS(=O)(=O)C2(C[C@H](O)CO)CC2)cc1
NCGC00379208-01	Ic1cc(F)c(Nc2c(F)c(F)ccc2-c2oc(NCCN3CCOCC3)nn2)cc1		Inactive	Dual specificity mitogen-activated protein kinase kinase 1 Inhibitor		1	PD 334581	363678418.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Ic1cc(F)c(Nc2c(F)c(F)ccc2-c2oc(NCCN3CCOCC3)nn2)cc1	Ic1cc(F)c(Nc2c(F)c(F)ccc2-c2oc(NCCN3CCOCC3)nn2)cc1
NCGC00346455-02&NCGC00346455-05	Ic1cc(F)c(Nc2c(F)c(F)ccc2C(=O)N2CC(O)([C@H]3NCCCC3)C2)cc1		Inactive	Mek Inhibitor		2	Cobimetinib	384568780.0&405558491.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Ic1cc(F)c(Nc2c(F)c(F)ccc2C(=O)N2CC(O)([C@H]3NCCCC3)C2)cc1	Ic1cc(F)c(Nc2c(F)c(F)ccc2C(=O)N2CC(O)([C@H]3NCCCC3)C2)cc1
NCGC00189075-02	Ic1cc(F)c(Nc2c(F)c(F)ccc2C(=O)NOCC(O)CO)cc1		Inactive	MEK Inhibitor		1	PD-0325901	363677126.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1cc(F)c(Nc2c(F)c(F)ccc2C(=O)NOCC(O)CO)cc1	Ic1cc(F)c(Nc2c(F)c(F)ccc2C(=O)NOCC(O)CO)cc1
NCGC00015478-17	Ic1cc2/C(=C/c3cc(Br)c(O)c(Br)c3)/C(=O)Nc2cc1	5.1500001	Active	Raf Kinase C Inhibitor	0.0	1	GW-5074	384567854.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.2	72.5995676168	Ic1cc2/C(=C/c3cc(Br)c(O)c(Br)c3)/C(=O)Nc2cc1	Ic1cc2/C(=C/c3cc(Br)c(O)c(Br)c3)/C(=O)Nc2cc1
NCGC00025012-06	Ic1cc2n(CCN3CCOCC3)c(C)c(C(=O)c3ccc(OC)cc3)c2cc1		Inactive	cannabinoid CB2 Antagonist		1	AM-630	384568043.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1cc2n(CCN3CCOCC3)c(C)c(C(=O)c3ccc(OC)cc3)c2cc1	Ic1cc2n(CCN3CCOCC3)c(C)c(C(=O)c3ccc(OC)cc3)c2cc1
NCGC00388136-02	Ic1ccc(-[n+]2n(-c3ccc([N+](=O)[O-])cc3)nc(-c3ccccc3)n2)cc1		Inactive	Succinate-ubiquinone oxidoreductase Substrate		1	INT	363680723.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Ic1ccc(-[n+]2n(-c3ccc([N+](=O)[O-])cc3)nc(-c3ccccc3)n2)cc1	Ic1ccc(-[n+]2n(-c3ccc([N+](=O)[O-])cc3)nc(-c3ccccc3)n2)cc1
NCGC00346821-04	Ic1ccc(/C=C(\S)/C(=O)O)cc1		Inactive	Calpain Inhibitor		1	PD-150606	384568943.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1ccc(/C=C(\S)/C(=O)O)cc1	Ic1ccc(/C=C(\S)/C(=O)O)cc1
NCGC00094048-01	Ic1ccc(CC(NC(C)C)C)cc1		Inactive			1	Iofetamine hydrochloride	144204790.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Ic1ccc(CC(NC(C)C)C)cc1.Cl	Ic1ccc(CC(NC(C)C)C)cc1.Cl
NCGC00390609-01	Ic1ccc(CN2CCC(C3(c4ccccc4)C(=O)NC(=O)CC3)CC2)cc1		Inactive	Muscarinic acetylcholine receptor M4 Antagonist		1	mAChR-IN-1	363680929.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	19.98424684	Ic1ccc(CN2CCC(C3(c4ccccc4)C(=O)NC(=O)CC3)CC2)cc1	Ic1ccc(CN2CCC(C3(c4ccccc4)C(=O)NC(=O)CC3)CC2)cc1
NCGC00319175-03&NCGC00319175-08	N#C/C=C/c1cc(C)c(Nc2nc(Nc3ccc(C#N)cc3)ncc2)c(C)c1		Inactive			2	Rilpivirine	405558769.0&434147081.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	N#C/C=C/c1cc(C)c(Nc2nc(Nc3ccc(C#N)cc3)ncc2)c(C)c1	N#C/C=C/c1cc(C)c(Nc2nc(Nc3ccc(C#N)cc3)ncc2)c(C)c1
NCGC00015787-09	N#C/N=C(/NC(C(C)(C)C)C)\Nc1ccncc1		Inactive	Sulfonylurea receptor 2, Kir6.2 Opener		1	PINACIDIL	405558656.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N#C/N=C(/NC(C(C)(C)C)C)\Nc1ccncc1	N#C/N=C(/NC(C(C)(C)C)C)\Nc1ccncc1
NCGC00253611-01	N#CC(C(C)C)(CC(N(C)C)C)c1ccccc1		Inactive			1	Isoaminile	170465846.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	N#CC(C(C)C)(CC(N(C)C)C)c1ccccc1	N#CC(C(C)C)(CC(N(C)C)C)c1ccccc1
NCGC00164619-02&NCGC00164619-06	N#CC(C)(C)c1cc(C(C#N)(C)C)cc(Cn2ncnc2)c1		Inactive	Aromatase Inhibitor		2	Anastrozole	170464923.0&384568267.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	N#CC(C)(C)c1cc(C(C#N)(C)C)cc(Cn2ncnc2)c1	N#CC(C)(C)c1cc(C(C#N)(C)C)cc(Cn2ncnc2)c1
NCGC00386695-02	N#CC(CCCN1CCN(/N=C/c2cnccc2)CC1)(c1ccccc1)c1ccccc1		Inactive	Fatty acid desaturase 2 Inhibitor		1	SC 26196	363680401.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N#CC(CCCN1CCN(/N=C/c2cnccc2)CC1)(c1ccccc1)c1ccccc1	N#CC(CCCN1CCN(/N=C/c2cnccc2)CC1)(c1ccccc1)c1ccccc1
NCGC00346953-01	N#CC(c1sc2c(n1)cccc2)c1nc(NCCc2cnccc2)ncc1		Inactive	JNK Inhibitor		1	JNK Inhibitor V	174006712.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	30.0795502759	N#CC(c1sc2c(n1)cccc2)c1nc(NCCc2cnccc2)ncc1	N#CC(c1sc2c(n1)cccc2)c1nc(NCCc2cnccc2)ncc1
NCGC00244253-12&NCGC00244253-18&NCGC00244253-21	N#CC[C@@H](n1ncc(-c2ncnc3[nH]ccc23)c1)C1CCCC1		Inactive	Jak1/2 Inhibitor		3	Ruxolitinib&INCB018424	405558887.0&384568508.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	N#CC[C@@H](n1ncc(-c2ncnc3[nH]ccc23)c1)C1CCCC1	N#CC[C@@H](n1ncc(-c2ncnc3[nH]ccc23)c1)C1CCCC1
NCGC00402268-01	N#CNC(N([C@@H](C)c1ccccc1)c1c2c(nccc2)ccc1)=N		Inactive	P2X purinoceptor 7 Antagonist		1	A-804598	363681008.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N#CNC(N([C@@H](C)c1ccccc1)c1c2c(nccc2)ccc1)=N	N#CNC(N([C@@H](C)c1ccccc1)c1c2c(nccc2)ccc1)=N
NCGC00386520-01	N#Cc1[nH]c2c(c3c(cc2)CC[C@@H](N(CCC)CCC)C3)c1		Inactive	Dopamine D2 receptor Antagonist		1	U 92016A	363680315.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N#Cc1[nH]c2c(c3c(cc2)CC[C@@H](N(CCC)CCC)C3)c1	N#Cc1[nH]c2c(c3c(cc2)CC[C@@H](N(CCC)CCC)C3)c1
NCGC00390733-04	N#Cc1cc(-c2c3c(N4CCOCC4)ncnc3[nH]c2)ccc1		Inactive	LRRK2 Inhibitor		1	PF-06447475	384569210.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N#Cc1cc(-c2c3c(N4CCOCC4)ncnc3[nH]c2)ccc1	N#Cc1cc(-c2c3c(N4CCOCC4)ncnc3[nH]c2)ccc1
NCGC00387232-01	N#Cc1cc(-c2onc(-c3cnccc3)n2)ccc1		Inactive	Neuronal acetylcholine receptor; alpha4/beta2 Positive Allosteric Modulator		1	NS 9283	363680586.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N#Cc1cc(-c2onc(-c3cnccc3)n2)ccc1	N#Cc1cc(-c2onc(-c3cnccc3)n2)ccc1
NCGC00386570-01	N#Cc1ccc(-c2cc3c(oc(CCN4[C@H](C)CCC4)c3)cc2)cc1	4.9000001	Active	Histamine H3 receptor Antagonist	0.0	1	ABT 239 tartrate	363680333.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	3.0	49.594264923	N#Cc1ccc(-c2cc3c(oc(CCN4[C@H](C)CCC4)c3)cc2)cc1	N#Cc1ccc(-c2cc3c(oc(CCN4[C@H](C)CCC4)c3)cc2)cc1
NCGC00384186-05	N#Cc1ccc(-c2nc(NN=C3CCCC3)sc2)cc1		Inactive			1	Remodelin (hydrobromide)		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N#Cc1ccc(-c2nc(NN=C3CCCC3)sc2)cc1	N#Cc1ccc(-c2nc(NN=C3CCCC3)sc2)cc1
NCGC00016973-06&NCGC00016973-08	N#Cc1ccc(C(n2ncnc2)c2ccc(C#N)cc2)cc1		Inactive	Aromatase Inhibitor		2	Letrozole	225144183.0&384567970.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	N#Cc1ccc(C(n2ncnc2)c2ccc(C#N)cc2)cc1	N#Cc1ccc(C(n2ncnc2)c2ccc(C#N)cc2)cc1
NCGC00390223-01	N#Cc1ccc(C2n3c(cnc3)CCC2)cc1		Inactive	Aromatase Inhibitor		1	Fadrozole	363680864.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N#Cc1ccc(C2n3c(cnc3)CCC2)cc1	N#Cc1ccc(C2n3c(cnc3)CCC2)cc1
NCGC00371120-06	N#Cc1ccc(Nc2nc(Nc3c(C)cc(C)cc3C)ccn2)cc1		Inactive	Human immunodeficiency virus type 1 reverse transcriptase Inhibitor		1	Dapivirine?TMC-120	363678036.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.223678264	N#Cc1ccc(Nc2nc(Nc3c(C)cc(C)cc3C)ccn2)cc1	N#Cc1ccc(Nc2nc(Nc3c(C)cc(C)cc3C)ccn2)cc1
NCGC00442629-01	N#Cc1n(C)cc(CN2CCN(C(c3ccccc3)c3ccccc3)CC2)c1		Inactive			1	NCGC00442629-01	375883140.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N#Cc1n(C)cc(CN2CCN(C(c3ccccc3)c3ccccc3)CC2)c1	N#Cc1n(C)cc(CN2CCN(C(c3ccccc3)c3ccccc3)CC2)c1
NCGC00378610-02	N#Cc1nccc(-c2nc(-c3ccncc3)[nH]n2)c1		Inactive	Xanthine dehydrogenase Inhibitor		1	Topiroxostat	405558772.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N#Cc1nccc(-c2nc(-c3ccncc3)[nH]n2)c1	N#Cc1nccc(-c2nc(-c3ccncc3)[nH]n2)c1
NCGC00185023-02	N#Cc1ncccn1		Inactive			1	2-cyano-Pyrimidine		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N#Cc1ncccn1	N#Cc1ncccn1
NCGC00094572-12	N(/C=N/c1c(C)cc(C)cc1)(/C=N/c1c(C)cc(C)cc1)C		Inactive			1	Amitraz	170465703.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(/C=N/c1c(C)cc(C)cc1)(/C=N/c1c(C)cc(C)cc1)C	N(/C=N/c1c(C)cc(C)cc1)(/C=N/c1c(C)cc(C)cc1)C
NCGC00183050-01	N(=C(/NCc1ccccc1)\NC)\C		Inactive	adrenergic receptor signaling pathway involved in heart process Inhibitor		1	Bethanidine sulfate (2:1)	144206760.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)O.N(=C(/NCc1ccccc1)\NC)\C.N(=C(/NCc1ccccc1)\NC)\C	S(=O)(=O)(O)O.N(=C(/NCc1ccccc1)\NC)\C.N(=C(/NCc1ccccc1)\NC)\C
NCGC00092291-03	N(=C/c1c(C)n(-c2ccccc2)nc1C)\N1CCN(Cc2ccccc2)CC1		Inactive	Smoothened homolog Antagonist		1	SANT-1	363676557.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(=C/c1c(C)n(-c2ccccc2)nc1C)\N1CCN(Cc2ccccc2)CC1	N(=C/c1c(C)n(-c2ccccc2)nc1C)\N1CCN(Cc2ccccc2)CC1
NCGC00018130-08&NCGC00018130-09	N(=N/c1ccccc1)\c1c(N)nc(N)cc1		Inactive			2	PHENAZOPYRIDINE HYDROCHLORIDE&Phenazopyridine hydrochloride	434147257.0&170465267.0	Anti-infectives&Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&13.969843632	N(=N/c1ccccc1)\c1c(N)nc(N)cc1	N(=N/c1ccccc1)\c1c(N)nc(N)cc1&N(=N/c1ccccc1)\c1c(N)nc(N)cc1.Cl
NCGC00016564-06&NCGC00016564-17	N(C(=N)NC(=N)N)(C)C		Inactive	AMPK Activator		2	Metformin	170464804.0&384567949.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	N(C(=N)NC(=N)N)(C)C.Cl	N(C(=N)NC(=N)N)(C)C.Cl&N(C(=N)NC(=N)N)(C)C
NCGC00183030-02	N(C(C)(C)C)C(CC(c1ccccc1)c1ccccc1)C		Inactive	HERG Inhibitor		1	Terodiline hydrochloride	405558600.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	27.4289049679	N(C(C)(C)C)C(CC(c1ccccc1)c1ccccc1)C	N(C(C)(C)C)C(CC(c1ccccc1)c1ccccc1)C
NCGC00091070-02	N(C(C)C)C(C)C		Inactive	Pyruvate dehydrogenase kinase isoform 4 Inhibitor		1	Diisopropylamine	170466002.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	N(C(C)C)C(C)C	N(C(C)C)C(C)C
NCGC00384187-01	N(C(C)C)c1nc(Nc2ccccc2)nc(-c2ccccc2)n1		Inactive	Isocitrate dehydrogenase [NADP], mitochondrial Inhibitor		1	IDH2-C100	363679180.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(C(C)C)c1nc(Nc2ccccc2)nc(-c2ccccc2)n1	N(C(C)C)c1nc(Nc2ccccc2)nc(-c2ccccc2)n1
NCGC00347951-03	N(C(C)c1cc2OCCOc2cc1)[C@@H]1[C@@H](c2ccccc2)C1		Inactive	Lysine Specific Demethylase 1 (LSD1) Inhibitor		1	LSD1-C76	384568996.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(C(C)c1cc2OCCOc2cc1)[C@@H]1[C@@H](c2ccccc2)C1	N(C(C)c1cc2OCCOc2cc1)[C@@H]1[C@@H](c2ccccc2)C1
NCGC00015884-15	N(C(C1CC1)C1CC1)C=1OCCN=1		Inactive	Imidazoline I1 Receptor Agonist		1	Rilmenidine	384567900.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(C(C1CC1)C1CC1)C=1OCCN=1	N(C(C1CC1)C1CC1)C=1OCCN=1
NCGC00510944-01	N(C(CC1CCCC1)C)C		Inactive			1	Cyclopentamine hydrochloride	405558489.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(C(CC1CCCC1)C)C	N(C(CC1CCCC1)C)C
NCGC00182042-04	N(C(CC1CCCCC1)C)C		Inactive	Trace amine-associated receptor 1 Agonist		1	Propylhexedrine (hydrochloride)	405558687.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(C(CC1CCCCC1)C)C	N(C(CC1CCCCC1)C)C
NCGC00160594-03	N(C(CCCC(C)C)C)C(C)C		Inactive	Histamine H1 receptor Antagonist		1	IPROHEPTINE	405558890.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(C(CCCC(C)C)C)C(C)C	N(C(CCCC(C)C)C)C(C)C
NCGC00015817-14&NCGC00015817-17	N(C(CN1c2c(Sc3c1cccc3)cccc2)C)(C)C	4.97500015	Active		0.15000010000000064	2	Promethazine&Promethazine HCl	170465107.0&434146948.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	107.2107867374&100.814507794	N(C(CN1c2c(Sc3c1cccc3)cccc2)C)(C)C	N(C(CN1c2c(Sc3c1cccc3)cccc2)C)(C)C
NCGC00178860-06	N(C(CN1c2c(Sc3c1cccc3)cccc2)C)(CC)CC	4.9000001	Active	Butyrylcholinesterase Inhibitor	0.0	1	Ethopropazine hydrochloride	170465065.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	35.5	N(C(CN1c2c(Sc3c1cccc3)cccc2)C)(CC)CC.Cl	N(C(CN1c2c(Sc3c1cccc3)cccc2)C)(CC)CC.Cl
NCGC00181101-01	N(C(CN1c2ncccc2Sc2c1cccc2)C)(C)C		Inactive	Histamine H1 receptor Antagonist		1	Isothipendyl hydrochloride	144206270.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(C(CN1c2ncccc2Sc2c1cccc2)C)(C)C.Cl	N(C(CN1c2ncccc2Sc2c1cccc2)C)(C)C.Cl
NCGC00016570-06	N(C(Cc1ccccc1)(C)C)C		Inactive			1	Mephentermine hemisulfate	170465271.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)O.N(C(Cc1ccccc1)(C)C)C.N(C(Cc1ccccc1)(C)C)C	S(=O)(=O)(O)O.N(C(Cc1ccccc1)(C)C)C.N(C(Cc1ccccc1)(C)C)C
NCGC00378621-01	N(C)(C)C1=N[C@H](C)N=C(N)N1		Inactive	AMPK Activator		1	Imeglimin	384569058.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(C)(C)C1=N[C@H](C)N=C(N)N1	N(C)(C)C1=N[C@H](C)N=C(N)N1
NCGC00092388-15	N(C)(C)[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@]5([C@@H]([C@H](C)N(C)C5)CC4)CC3)CC=2)CC1		Inactive			1	Conessine	434147228.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(C)(C)[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@]5([C@@H]([C@H](C)N(C)C5)CC4)CC3)CC=2)CC1	N(C)(C)[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@]5([C@@H]([C@H](C)N(C)C5)CC4)CC3)CC=2)CC1
NCGC00014352-10	N(C)(C)c1c(CN2C(N(Cc3c(N(C)C)cccc3)CCC2)c2ccncc2)cccc1	5.3000002	Active	Hedgehog pathway Inhibitor	0.0	1	GANT-61	384567791.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.4	31.222987672	N(C)(C)c1c(CN2C(N(Cc3c(N(C)C)cccc3)CCC2)c2ccncc2)cccc1	N(C)(C)c1c(CN2C(N(Cc3c(N(C)C)cccc3)CCC2)c2ccncc2)cccc1
NCGC00390626-01	N(C)(C)c1cc(C)c(-c2[nH]c3c(n2)cc(-c2[nH]c4c(n2)cc(N2CCN(C)CC2)cc4)cc3)cc1		Inactive	DNA Binding Agent		1	Methylproamine	363680936.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(C)(C)c1cc(C)c(-c2[nH]c3c(n2)cc(-c2[nH]c4c(n2)cc(N2CCN(C)CC2)cc4)cc3)cc1	N(C)(C)c1cc(C)c(-c2[nH]c3c(n2)cc(-c2[nH]c4c(n2)cc(N2CCN(C)CC2)cc4)cc3)cc1
NCGC00181775-02	N(C)(C)c1cc2[s+]c3c(nc2cc1)cc(C)c(N)c3		Inactive			1	Toluidine blue	170466390.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	15.3916236121	N(C)(C)c1cc2[s+]c3c(nc2cc1)cc(C)c(N)c3.[Cl-]	N(C)(C)c1cc2[s+]c3c(nc2cc1)cc(C)c(N)c3.[Cl-]
NCGC00167496-03	N(C)(C)c1cc2[s+]c3c(nc2cc1)ccc(N(C)C)c3		Inactive	antimalarial agents		1	Methylene blue	170465461.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(C)(C)c1cc2[s+]c3c(nc2cc1)ccc(N(C)C)c3.[Cl-]	N(C)(C)c1cc2[s+]c3c(nc2cc1)ccc(N(C)C)c3.[Cl-]
NCGC00094772-04	N(C)(C)c1cc2c([n+](C)c(/C=C/c3c(C)n(c(C)c3)-c3ccccc3)cc2)cc1		Inactive	Cryptosporidium parvum Inhibitor		1	PYRVINIUM PAMOATE	405558483.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1c(O)c(Cc2c(O)c(C(=O)[O-])cc3c2cccc3)c2c(c1)cccc2.N(C)(C)c1cc2c([n+](C)c(/C=C/c3c(C)n(c(C)c3)-c3ccccc3)cc2)cc1	O=C(O)c1c(O)c(Cc2c(O)c(C(=O)[O-])cc3c2cccc3)c2c(c1)cccc2.N(C)(C)c1cc2c([n+](C)c(/C=C/c3c(C)n(c(C)c3)-c3ccccc3)cc2)cc1
NCGC00180911-03	N(C)(C)c1cc2c([n+](C)c(/C=C\c3c(C)n(c(C)c3)-c3ccccc3)cc2)cc1		Inactive			1	Pyrvinium pamoate	434146893.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])c1c(O)c(Cc2c(O)c(C(=O)[O-])cc3c2cccc3)c2c(c1)cccc2.N(C)(C)c1cc2c([n+](C)c(/C=C\c3c(C)n(c(C)c3)-c3ccccc3)cc2)cc1	O=C([O-])c1c(O)c(Cc2c(O)c(C(=O)[O-])cc3c2cccc3)c2c(c1)cccc2.N(C)(C)c1cc2c([n+](C)c(/C=C\c3c(C)n(c(C)c3)-c3ccccc3)cc2)cc1
NCGC00370693-02	N(C)(C)c1ccc(C2O[C@@H](c3ccccc3)C[C@H](c3ccccc3)O2)cc1		Inactive	Nuclear receptor subfamily 1 group I member 3 Activator		1	transpDMA	363677810.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(C)(C)c1ccc(C2O[C@@H](c3ccccc3)C[C@H](c3ccccc3)O2)cc1	N(C)(C)c1ccc(C2O[C@@H](c3ccccc3)C[C@H](c3ccccc3)O2)cc1
NCGC00015100-15&NCGC00015100-16	N(C)(C)c1nc(N(C)C)nc(N(C)C)n1		Inactive	DNA Alkylating Drugs		2	Altretamine	170464714.0&384567809.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	N(C)(C)c1nc(N(C)C)nc(N(C)C)n1	N(C)(C)c1nc(N(C)C)nc(N(C)C)n1
NCGC00015703-06	N(C)C1(C)C(C)(C)C2CC1CC2		Inactive	Neuronal acetylcholine receptor; alpha4/beta2 Antagonist		1	Mecamylamine	170465225.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	N(C)C1(C)C(C)(C)C2CC1CC2	N(C)C1(C)C(C)(C)C2CC1CC2
NCGC00485118-01	N(C)C12C[C@]3(C)C[C@](C)(C1)CC(C2)C3		Inactive	Glutamate [NMDA] receptor Binding Agent		1	1-N-Methylamino-3,5-dimethyladamantane hydrochloride	363681229.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(C)C12C[C@]3(C)C[C@](C)(C1)CC(C2)C3	N(C)C12C[C@]3(C)C[C@](C)(C1)CC(C2)C3
NCGC00485020-01	N(C)c1nc(Cc2ccccc2)nc2[C@@H](C)CNCCc12		Inactive	Serotonin 2c (5-HT2c) receptor Agonist		1	PF-04479745	363681189.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(C)c1nc(Cc2ccccc2)nc2[C@@H](C)CNCCc12	N(C)c1nc(Cc2ccccc2)nc2[C@@H](C)CNCCc12
NCGC00159346-04	N(C/C=C/C#CC(C)(C)C)(Cc1c2c(ccc1)cccc2)C		Inactive	Fungal Squalene Monooxygenase Inhibitor		1	Terbinafine	170465174.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	N(C/C=C/C#CC(C)(C)C)(Cc1c2c(ccc1)cccc2)C	N(C/C=C/C#CC(C)(C)C)(Cc1c2c(ccc1)cccc2)C
NCGC00179332-03	N(C/C=C/c1ccccc1)(Cc1c2c(ccc1)cccc2)C		Inactive	Squalene monooxygenase Inhibitor		1	Naftifine hydrochloride	170464903.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(C/C=C/c1ccccc1)(Cc1c2c(ccc1)cccc2)C.Cl	N(C/C=C/c1ccccc1)(Cc1c2c(ccc1)cccc2)C.Cl
NCGC00090955-06	N(C1CCCCC1)C1CCCCC1		Inactive	spermidine biosynthetic process Inhibitor		1	Dicyclohexylamine	170466864.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	N(C1CCCCC1)C1CCCCC1	N(C1CCCCC1)C1CCCCC1
NCGC00346431-02	N(CC#C)(CC=1c2c(Oc3c(cccc3)C=1)cccc2)C		Inactive	Glyceraldehyde 3-phosphate Dehydrogenase (GAPDH) Inhibitor		1	Omigapil	384568774.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(CC#C)(CC=1c2c(Oc3c(cccc3)C=1)cccc2)C	N(CC#C)(CC=1c2c(Oc3c(cccc3)C=1)cccc2)C
NCGC00015841-11	N(CC#C)(Cc1ccccc1)C		Inactive	Monoamine oxidase B Inhibitor		1	Pargyline hydrochloride	170465066.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	N(CC#C)(Cc1ccccc1)C.Cl	N(CC#C)(Cc1ccccc1)C.Cl
NCGC00168774-02&NCGC00168774-04	N(CC#C)[C@H]1c2c(cccc2)CC1		Inactive	MAO-B Inhibitor		2	Rasagiline mesylate	170465410.0&384568347.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(O)C.N(CC#C)[C@H]1c2c(cccc2)CC1	S(=O)(=O)(O)C.N(CC#C)[C@H]1c2c(cccc2)CC1&N(CC#C)[C@H]1c2c(cccc2)CC1
NCGC00016013-06	N(CC(CN1c2c(cccc2)CCc2c1cccc2)C)(C)C	5.0	Active	Serotonin 2 (5-HT2) receptor Antagonist	0.0	1	Trimipramine maleate	170465260.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	123.4066955573	O=C(O)/C=C\C(=O)O.N(CC(CN1c2c(cccc2)CCc2c1cccc2)C)(C)C	O=C(O)/C=C\C(=O)O.N(CC(CN1c2c(cccc2)CCc2c1cccc2)C)(C)C
NCGC00345822-02	N(CC(CNC=1C(C2CCC2)=Cc2n(c(-c3ccccc3)nn2)N=1)(C)C)(C)C		Inactive	AKT Inhibitor		1	Akt-I-1	363677369.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(CC(CNC=1C(C2CCC2)=Cc2n(c(-c3ccccc3)nn2)N=1)(C)C)(C)C	N(CC(CNC=1C(C2CCC2)=Cc2n(c(-c3ccccc3)nn2)N=1)(C)C)(C)C
NCGC00016715-04	N(CC)(CC)C=1n2ncnc2N=C(C)C=1		Inactive	C-C motif chemokine 2 Inhibitor		1	Trapidil	170465770.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(CC)(CC)C=1n2ncnc2N=C(C)C=1	N(CC)(CC)C=1n2ncnc2N=C(C)C=1
NCGC00024929-02	N(CC)(c1nc(C)[n+](C)c(NC)c1)c1ccccc1		Inactive	HCN [I(h)] Blocker		1	ICI-D7288	384568036.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(CC)(c1nc(C)[n+](C)c(NC)c1)c1ccccc1	N(CC)(c1nc(C)[n+](C)c(NC)c1)c1ccccc1
NCGC00181088-01	N(CC/C=C/1\c2c(C(C)(C)c3c\1cccc3)cccc2)(C)C	4.9499998	Active		0.0	1	Melitracen hydrochloride	144206258.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	123.075644694	N(CC/C=C/1\c2c(C(C)(C)c3c\1cccc3)cccc2)(C)C.Cl	N(CC/C=C/1\c2c(C(C)(C)c3c\1cccc3)cccc2)(C)C.Cl
NCGC00013841-09	N(CC/C=C/1\c2c(cccc2)C=Cc2c\1cccc2)(C)C	4.9000001	Active	5-HT2A Receptor Ligands	0.0	1	Cyclobenzaprine hydrochloride	170464953.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	108.1660893984	N(CC/C=C/1\c2c(cccc2)C=Cc2c\1cccc2)(C)C.Cl	N(CC/C=C/1\c2c(cccc2)C=Cc2c\1cccc2)(C)C.Cl
NCGC00015095-15	N(CC/C=C/1\c2c(cccc2)CCc2c\1cccc2)(C)C	4.9000001	Active	Sodium-dependent serotonin transporter Inhibitor	0.0	1	Amitriptyline hydrochloride	170464758.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	116.8801732227	N(CC/C=C/1\c2c(cccc2)CCc2c\1cccc2)(C)C.Cl	N(CC/C=C/1\c2c(cccc2)CCc2c\1cccc2)(C)C.Cl
NCGC00015344-16	N(CC/C=C\1/c2c(OCc3c/1cccc3)cccc2)(C)C		Inactive			1	NCGC00015344-16		2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&16.4289333719	N(CC/C=C\1/c2c(OCc3c/1cccc3)cccc2)(C)C	N(CC/C=C\1/c2c(OCc3c/1cccc3)cccc2)(C)C
NCGC00016549-05	N(CC/C=C\1/c2c(SCc3c/1cccc3)cccc2)(C)C	4.9000001	Active	Serotonin transporter Inhibitor	0.0	1	Dosulepin hydrochloride	405558989.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	91.438375273	N(CC/C=C\1/c2c(SCc3c/1cccc3)cccc2)(C)C	N(CC/C=C\1/c2c(SCc3c/1cccc3)cccc2)(C)C
NCGC00387227-01	N(CC1C(c2ccccc2)(c2ccccc2)OCC1)(C)C		Inactive	Sodium channel alpha subunit Modulator		1	ANAVEX 2-73	363680581.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(CC1C(c2ccccc2)(c2ccccc2)OCC1)(C)C	N(CC1C(c2ccccc2)(c2ccccc2)OCC1)(C)C
NCGC00229610-04	N(CC1COCC1)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2		Inactive			1	NCGC00229610-04	377020358.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(CC1COCC1)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2	N(CC1COCC1)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2
NCGC00370724-05	N(CCC)C1=Nn2c(-c3cc4c([nH]nc4)cc3)cnc2C=C1		Inactive	Serine/threonine-protein kinase haspin Inhibitor		1	CHR-6494 TFA Salt	363677825.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	27.0	N(CCC)C1=Nn2c(-c3cc4c([nH]nc4)cc3)cnc2C=C1	N(CCC)C1=Nn2c(-c3cc4c([nH]nc4)cc3)cnc2C=C1
NCGC00167441-02&NCGC00167441-07	N(CCC)[C@@H]1Cc2sc(N)nc2CC1		Inactive	Dopamine D3 Antagonist		2	Pramipexole hydrochloride	170465264.0&384568313.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	N(CCC)[C@@H]1Cc2sc(N)nc2CC1	N(CCC)[C@@H]1Cc2sc(N)nc2CC1
NCGC00025158-02	N(CCC1=C([C@H](C)c2ncccc2)c2c(cccc2)C1)(C)C		Inactive	Histamine H1 receptor Antagonist		1	(S)-(+)-Dimethindene maleate	170465880.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	10.5&0.0	O=C(O)/C=C\C(=O)O.N(CCC1=C([C@H](C)c2ncccc2)c2c(cccc2)C1)(C)C	O=C(O)/C=C\C(=O)O.N(CCC1=C([C@H](C)c2ncccc2)c2c(cccc2)C1)(C)C
NCGC00013841-13	N(CCC=C1c2c(cccc2)C=Cc2c1cccc2)(C)C	5.0	Active	5-HT2A Receptor Ligands	0.0	1	Cyclobenzaprine hydrochloride	384567790.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	80.9093015742	N(CCC=C1c2c(cccc2)C=Cc2c1cccc2)(C)C	N(CCC=C1c2c(cccc2)C=Cc2c1cccc2)(C)C
NCGC00014483-16	N(CCC=C1c2c(cccc2)CCc2c1cccc2)C	4.9000001	Active	Norepinephrine transporter Inhibitor	0.0	1	Pamelor	405559064.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	122.1980268385	N(CCC=C1c2c(cccc2)CCc2c1cccc2)C	N(CCC=C1c2c(cccc2)CCc2c1cccc2)C
NCGC00092318-12	N(CCCC(Nc1nc(Nc2cc3c(N)cc(C)nc3cc2)cc(C)n1)C)(CC)CC		Inactive	Rac1-GEF Inhibitor		1	NSC-23766	384568105.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-10.259203124	N(CCCC(Nc1nc(Nc2cc3c(N)cc(C)nc3cc2)cc(C)n1)C)(CC)CC	N(CCCC(Nc1nc(Nc2cc3c(N)cc(C)nc3cc2)cc(C)n1)C)(CC)CC
NCGC00378725-02	N(CCCC)(CC)c1nc(C)nc2n(-c3c(C)cc(C)cc3C)cc(C)c12		Inactive	Corticotropin releasing factor receptor 2 Antagonist		1	CP 154526 hydrochloride	363678172.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	10.9342798239	N(CCCC)(CC)c1nc(C)nc2n(-c3c(C)cc(C)cc3C)cc(C)c12	N(CCCC)(CC)c1nc(C)nc2n(-c3c(C)cc(C)cc3C)cc(C)c12
NCGC00371094-01	N(CCCC1(c2ccccc2)OC(C)(C)c2c1cccc2)C		Inactive	Norepinephrine transporter Inhibitor		1	Talopram hydrochloride	363678027.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(CCCC1(c2ccccc2)OC(C)(C)c2c1cccc2)C	N(CCCC1(c2ccccc2)OC(C)(C)c2c1cccc2)C
NCGC00015708-15&NCGC00015708-19	N(CCCC12c3c(cccc3)C(c3c1cccc3)CC2)C	4.9000001	Active	Noradrenaline Reuptake Inhibitor	0.0	2	Maprotiline hydrochloride	170464778.0&363676460.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	120.4360874139&106.2489885799	N(CCCC12c3c(cccc3)C(c3c1cccc3)CC2)C	N(CCCC12c3c(cccc3)C(c3c1cccc3)CC2)C
NCGC00015851-10	N(CCCC1c2c(cccc2)C=Cc2c1cccc2)C	4.9000001	Active	Norepinephrine transporter Inhibitor	0.0	1	Protriptyline hydrochloride	170465077.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	118.0639172875	N(CCCC1c2c(cccc2)C=Cc2c1cccc2)C.Cl	N(CCCC1c2c(cccc2)C=Cc2c1cccc2)C.Cl
NCGC00387146-01	N(CCCCCN)C1(c2ccccc2)CCCCC1	4.9000001	Active	Glutamate receptor ionotropic, AMPA Antagonist	0.0	1	IEM 1925 dihydrobromide	363680548.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	45.777142861	N(CCCCCN)C1(c2ccccc2)CCCCC1	N(CCCCCN)C1(c2ccccc2)CCCCC1
NCGC00378947-03	N(CCCCN)(Cc1[nH]c2c(n1)cccc2)[C@@H]1c2ncccc2CCC1		Inactive	Human immunodeficiency virus 1 Inhibitor		1	AMD-070 (hydrochloride)	434147108.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(CCCCN)(Cc1[nH]c2c(n1)cccc2)[C@@H]1c2ncccc2CCC1	N(CCCCN)(Cc1[nH]c2c(n1)cccc2)[C@@H]1c2ncccc2CCC1
NCGC00167576-02	N(CCCN(c1ccccc1)C1Cc2c(cccc2)C1)(CC)CC	5.0500002	Active	Calmodulin Inhibitor	0.0	1	Aprindine hydrochloride	170465842.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	50.5921669784	N(CCCN(c1ccccc1)C1Cc2c(cccc2)C1)(CC)CC.Cl	N(CCCN(c1ccccc1)C1Cc2c(cccc2)C1)(CC)CC.Cl
NCGC00015937-04	N(CCCN)CCCCN		Inactive	NOS Inhibitor		1	Spermidine	124881420.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(CCCN)CCCCN	N(CCCN)CCCCN
NCGC00485903-01	N(CCCN)c1ccc(Nc2nc(Nc3n[nH]c(C4CC4)c3)ccn2)cc1		Inactive			1	2,4-Pyrimidinediamine with linker	363681405.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(CCCN)c1ccc(Nc2nc(Nc3n[nH]c(C4CC4)c3)ccn2)cc1	N(CCCN)c1ccc(Nc2nc(Nc3n[nH]c(C4CC4)c3)ccn2)cc1
NCGC00379163-01	N(CCCN1CC2(CC1)CCC(CCC)(CCC)CC2)(CC)CC	5.5500002	Active	IL-6 Production Inhibitor	0.0	1	Atiprimod	363678393.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	149.6460957478	N(CCCN1CC2(CC1)CCC(CCC)(CCC)CC2)(CC)CC	N(CCCN1CC2(CC1)CCC(CCC)(CCC)CC2)(CC)CC
NCGC00370728-03	N(CCCN1CCOCC1)c1nc(Nc2cc3c(n(CC)c4c3cccc4)cc2)ccn1		Inactive			1	EHop 016	363677827.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(CCCN1CCOCC1)c1nc(Nc2cc3c(n(CC)c4c3cccc4)cc2)ccn1	N(CCCN1CCOCC1)c1nc(Nc2cc3c(n(CC)c4c3cccc4)cc2)ccn1
NCGC00015563-13	N(CCCN1c2c(cccc2)CCc2c1cccc2)(C)C	5.0500002	Active	Serum paraoxonase/arylesterase 1 Inhibitor	0.0	1	Imipramine	170464777.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	114.5890840457	N(CCCN1c2c(cccc2)CCc2c1cccc2)(C)C	N(CCCN1c2c(cccc2)CCc2c1cccc2)(C)C
NCGC00015340-14&NCGC00261043-01	N(CCCN1c2c(cccc2)CCc2c1cccc2)C	5.0	Active	Serotonin transporter Inhibitor	0.10000040000000077	2	Desipramine hydrochloride	170465424.0&312344483.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	105.9692424286&38.6968819487	N(CCCN1c2c(cccc2)CCc2c1cccc2)C.Cl	N(CCCN1c2c(cccc2)CCc2c1cccc2)C.Cl
NCGC00487123-01	N(CCCNc1c2[nH]c3c(c2nc2c1cccc2)cccc3)(C)C		Inactive			1	SYUIQ-5	377020345.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(CCCNc1c2[nH]c3c(c2nc2c1cccc2)cccc3)(C)C	N(CCCNc1c2[nH]c3c(c2nc2c1cccc2)cccc3)(C)C
NCGC00021122-08	N(CCCc1ccccc1)(CCCc1ccccc1)CC	5.3000002	Active		0.0	1	Alverine citrate	170466248.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	43.4155953599	O=C(O)C(O)(CC(=O)O)CC(=O)O.N(CCCc1ccccc1)(CCCc1ccccc1)CC	O=C(O)C(O)(CC(=O)O)CC(=O)O.N(CCCc1ccccc1)(CCCc1ccccc1)CC
NCGC00018125-05	N(CCN(Cc1ccccc1)c1ncccc1)(C)C		Inactive	Histamine H1 receptor Antagonist		1	Tripelennamine citrate	170465118.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)C(O)(CC(=O)O)CC(=O)O.N(CCN(Cc1ccccc1)c1ncccc1)(C)C	O=C(O)C(O)(CC(=O)O)CC(=O)O.N(CCN(Cc1ccccc1)c1ncccc1)(C)C
NCGC00253602-01	N(CCN(Cc1cscc1)c1ncccc1)(C)C		Inactive			1	Thenyldiamine	170465520.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(CCN(Cc1cscc1)c1ncccc1)(C)C	N(CCN(Cc1cscc1)c1ncccc1)(C)C
NCGC00015704-09	N(CCN(Cc1sccc1)c1ncccc1)(C)C		Inactive			1	Methapyrilene hydrochloride	170465531.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	N(CCN(Cc1sccc1)c1ncccc1)(C)C.Cl	N(CCN(Cc1sccc1)c1ncccc1)(C)C.Cl
NCGC00165761-07	N(CCN)C1=Nc2c(-n3c(C)cnc13)cc(C)cc2		Inactive	IKK beta Inhibitor		1	BMS-345541	384568279.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	18.5630823281	N(CCN)C1=Nc2c(-n3c(C)cnc13)cc(C)cc2	N(CCN)C1=Nc2c(-n3c(C)cnc13)cc(C)cc2
NCGC00091695-03	N(CCNCCN)CCN		Inactive	Copper Chelating Agent		1	Triethylenetetramine	170465257.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	N(CCNCCN)CCN	N(CCNCCN)CCN
NCGC00090964-04	N(CCNCCN)CCNCCN		Inactive	Oxidative Stress Inhibitor		1	Tetraethylenepentamine	170464940.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	11.52493966&0.0	N(CCNCCN)CCNCCN	N(CCNCCN)CCNCCN
NCGC00166222-04	N(CCNCc1ccccc1)Cc1ccccc1		Inactive	F-box only protein 3 Inhibitor		1	N,N'-Dibenzylethane-1,2-diamine dihydrochloride	170465030.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(CCNCc1ccccc1)Cc1ccccc1.Cl.Cl	N(CCNCc1ccccc1)Cc1ccccc1.Cl.Cl
NCGC00095899-09	N(CCc1c2c([nH]c1)ccc(Cn1ncnc1)c2)(C)C		Inactive	5-HT1B Agonist		1	Rizatriptan Benzoate	405558730.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(CCc1c2c([nH]c1)ccc(Cn1ncnc1)c2)(C)C	N(CCc1c2c([nH]c1)ccc(Cn1ncnc1)c2)(C)C
NCGC00386578-02	N(CCc1c2c([nH]c1)cccc2)c1cc(Nc2ccncc2)ccc1	4.9000001	Active	p53-binding protein Mdm-2 Antagonist	0.0	1	JNJ 26854165 dihydrochloride	363680337.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	3.0	43.8000961289	N(CCc1c2c([nH]c1)cccc2)c1cc(Nc2ccncc2)ccc1	N(CCc1c2c([nH]c1)cccc2)c1cc(Nc2ccncc2)ccc1
NCGC00263171-03	N(CCc1c2c([nH]c1)cccc2)c1ccc(Nc2ccncc2)cc1	5.0500002	Active	MDM2 (hdm2) Inhibitor	0.0	1	Serdemetan	384568641.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	37.3650171134	N(CCc1c2c([nH]c1)cccc2)c1ccc(Nc2ccncc2)cc1	N(CCc1c2c([nH]c1)cccc2)c1ccc(Nc2ccncc2)cc1
NCGC00246113-02	N(CCc1ccccc1)Cc1ccccc1		Inactive			1	NCGC00246113-02	405558428.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(CCc1ccccc1)Cc1ccccc1	N(CCc1ccccc1)Cc1ccccc1
NCGC00093362-05	N(CCc1ncccc1)C		Inactive	Histamine H3 receptor Antagonist		1	Betahistine mesylate	170465694.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)C.N(CCc1ncccc1)C	S(=O)(=O)(O)C.N(CCc1ncccc1)C
NCGC00182981-01	N(CCc1onc(C(CC)c2ccccc2)n1)(CC)CC		Inactive			1	Proxazole citrate	144206776.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(O)(CC(=O)O)CC(=O)O.N(CCc1onc(C(CC)c2ccccc2)n1)(CC)CC	O=C(O)C(O)(CC(=O)O)CC(=O)O.N(CCc1onc(C(CC)c2ccccc2)n1)(CC)CC
NCGC00178737-05	N(C[C@@H](CN1c2c(Sc3c1cccc3)cccc2)C)(C)C	4.9000001	Active	Histamine H1 receptor Antagonist	0.0	1	Trimeprazine tartrate	170465278.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	112.5777832791	O=C(O)[C@@H](O)[C@@H](O)C(=O)O.N(C[C@@H](CN1c2c(Sc3c1cccc3)cccc2)C)(C)C.N(C[C@@H](CN1c2c(Sc3c1cccc3)cccc2)C)(C)C	O=C(O)[C@@H](O)[C@@H](O)C(=O)O.N(C[C@@H](CN1c2c(Sc3c1cccc3)cccc2)C)(C)C.N(C[C@@H](CN1c2c(Sc3c1cccc3)cccc2)C)(C)C
NCGC00371058-01	N(C[C@@H]1OCCC1)Cc1sc2ncnc(NC3CCCCCC3)c2c1		Inactive	Metabotropic glutamate receptor 1 Antagonist		1	YM 230888	363678011.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(C[C@@H]1OCCC1)Cc1sc2ncnc(NC3CCCCCC3)c2c1	N(C[C@@H]1OCCC1)Cc1sc2ncnc(NC3CCCCCC3)c2c1
NCGC00347279-01	N(C[C@H]1OCCC1)c1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1		Inactive	ACK1 Inhibitor		1	AIM-100	174006684.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(C[C@H]1OCCC1)c1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1	N(C[C@H]1OCCC1)c1ncnc2oc(c(-c3ccccc3)c12)-c1ccccc1
NCGC00016343-13	N(Cc1c2c([nH]c1)cccc2)(C)C		Inactive			1	Gramine	376241757.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(Cc1c2c([nH]c1)cccc2)(C)C	N(Cc1c2c([nH]c1)cccc2)(C)C
NCGC00159511-04	N(Cc1c2c(ccc1)cccc2)(Cc1ccc(C(C)(C)C)cc1)C		Inactive	Trichophyton mentagrophytes Inhibitor		1	Butenafine	170465093.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(Cc1c2c(ccc1)cccc2)(Cc1ccc(C(C)(C)C)cc1)C	N(Cc1c2c(ccc1)cccc2)(Cc1ccc(C(C)(C)C)cc1)C
NCGC00273984-04	N(Cc1c2n(CC)c(-c3c(N)non3)nc2cnc1)C1CCNCC1		Inactive	MSK1/2 Inhibitor		1	SB-747651-A	384568706.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(Cc1c2n(CC)c(-c3c(N)non3)nc2cnc1)C1CCNCC1	N(Cc1c2n(CC)c(-c3c(N)non3)nc2cnc1)C1CCNCC1
NCGC00379107-01&NCGC00379107-02	N(Cc1cc2c(n(CC)c3c2cccc3)cc1)C		Inactive			2	PhiKan 083&PhiKan083	363678357.0&363678358.0	2020_NPACT-11_CPE&2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&29.81428572	N(Cc1cc2c(n(CC)c3c2cccc3)cc1)C	N(Cc1cc2c(n(CC)c3c2cccc3)cc1)C
NCGC00262306-10&NCGC00262306-24&NCGC00346976-02	N(Cc1ccc(-n2nncc2)cc1)c1c(C)cnc(-c2c(C(C)C)cccc2)n1		Inactive	USP1/UAF1 Inhibitor&Ubiquitin Carboxyl-terminal Hydrolase Inhibitor		3	ML323&ML-323	384568572.0&434147071.0&384568979.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&-8.1089799479&0.0	N(Cc1ccc(-n2nncc2)cc1)c1c(C)cnc(-c2c(C(C)C)cccc2)n1	N(Cc1ccc(-n2nncc2)cc1)c1c(C)cnc(-c2c(C(C)C)cccc2)n1
NCGC00386931-01	N(Cc1ccc(C(C)C)cc1)c1n(CC)nnn1		Inactive			1	NCGC00386931-01	363680515.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(Cc1ccc(C(C)C)cc1)c1n(CC)nnn1	N(Cc1ccc(C(C)C)cc1)c1n(CC)nnn1
NCGC00090991-02	N(Cc1ccccc1)(C)C		Inactive			1	N,N-Dimethylbenzylamine	144207006.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(Cc1ccccc1)(C)C	N(Cc1ccccc1)(C)C
NCGC00016613-10	N(Cc1ccccc1)(CC1=NCCN1)c1ccccc1		Inactive	Histamine H1 receptor Antagonist		1	Antazoline hydrochloride	170464765.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	N(Cc1ccccc1)(CC1=NCCN1)c1ccccc1.Cl	N(Cc1ccccc1)(CC1=NCCN1)c1ccccc1.Cl
NCGC00168516-02	N(Cc1ccccc1)c1nc(N)nc2[nH]cnc12		Inactive			1	NCGC00168516-02	50113201.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(Cc1ccccc1)c1nc(N)nc2[nH]cnc12	N(Cc1ccccc1)c1nc(N)nc2[nH]cnc12
NCGC00347065-03	N(Cc1ccccc1)c1nc(N2c3c(OCC2)cccc3)nc2c1CCCC2	4.9000001	Active	p97 ATPase Inhibitor	0.0	1	KUC107887N	363677570.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	35.006871904	N(Cc1ccccc1)c1nc(N2c3c(OCC2)cccc3)nc2c1CCCC2	N(Cc1ccccc1)c1nc(N2c3c(OCC2)cccc3)nc2c1CCCC2
NCGC00347066-11	N(Cc1ccccc1)c1nc(NCc2ccccc2)c2c(n1)cccc2		Inactive	p97 ATPase Inhibitor		1	KUC105555N	384568981.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	-8.2244986879&0.0	N(Cc1ccccc1)c1nc(NCc2ccccc2)c2c(n1)cccc2	N(Cc1ccccc1)c1nc(NCc2ccccc2)c2c(n1)cccc2
NCGC00378809-01	N(Cc1n(CCCC)c(-c2ccccc2)nc1-c1ccccc1)(Cc1cc2OCOc2cc1)Cc1cc2OCOc2cc1		Inactive	C5a anaphylatoxin chemotactic receptor Inverse Agonist		1	NDT 9513727	363678212.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(Cc1n(CCCC)c(-c2ccccc2)nc1-c1ccccc1)(Cc1cc2OCOc2cc1)Cc1cc2OCOc2cc1	N(Cc1n(CCCC)c(-c2ccccc2)nc1-c1ccccc1)(Cc1cc2OCOc2cc1)Cc1cc2OCOc2cc1
NCGC00345082-02	N(Cc1nc(-c2ccccc2)sc1)c1nc(NCC(C)C)ccn1		Inactive	lineage-specific differentiation enhancer		1	KHS-101	363677344.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(Cc1nc(-c2ccccc2)sc1)c1nc(NCC(C)C)ccn1	N(Cc1nc(-c2ccccc2)sc1)c1nc(NCC(C)C)ccn1
NCGC00185963-05	N(Cc1nc(C)sc1)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2		Inactive			1	NCGC00185963-05	377020263.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(Cc1nc(C)sc1)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2	N(Cc1nc(C)sc1)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2
NCGC00371045-07	N(Cc1ncccc1)Cc1ccc(CN2CCNCCCNCCNCCC2)cc1		Inactive	Chemokine CXCR4 (SDF-1 Receptor) Antagonist		1	AMD-3465	384569040.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&17.153719692	N(Cc1ncccc1)Cc1ccc(CN2CCNCCCNCCNCCC2)cc1	N(Cc1ncccc1)Cc1ccc(CN2CCNCCCNCCNCCC2)cc1
NCGC00016488-15	N(Cc1occc1)c1ncnc2nc[nH]c12		Inactive	plant hormone		1	Kinetin	384567945.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(Cc1occc1)c1ncnc2nc[nH]c12	N(Cc1occc1)c1ncnc2nc[nH]c12
NCGC00378978-02	N(Cc1onc(C(C)C)c1)c1nc(Nc2n[nH]c(C3CC3)c2)cc(N2CCN(C)CC2)n1		Inactive	IGF-1R Inhibitor		1	XL-228	384569082.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	35.430365472	N(Cc1onc(C(C)C)c1)c1nc(Nc2n[nH]c(C3CC3)c2)cc(N2CCN(C)CC2)n1	N(Cc1onc(C(C)C)c1)c1nc(Nc2n[nH]c(C3CC3)c2)cc(N2CCN(C)CC2)n1
NCGC00185969-01	N(Cc1onc(C)n1)(C)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2		Inactive			1	NCGC00185969-01	85239756.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(Cc1onc(C)n1)(C)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2	N(Cc1onc(C)n1)(C)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2
NCGC00185984-02	N(Cc1sccc1)(C)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2		Inactive			1	NCGC00185984-02	377020332.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(Cc1sccc1)(C)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2	N(Cc1sccc1)(C)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2
NCGC00183847-01	N(Cc1sccc1)(c1ccccc1)C1CCN(C)CC1		Inactive	Histamine H1 receptor Antagonist		1	Thenalidine	144206868.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(Cc1sccc1)(c1ccccc1)C1CCN(C)CC1	N(Cc1sccc1)(c1ccccc1)C1CCN(C)CC1
NCGC00010037-04	N(Cc1sccc1)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2		Inactive			1	NCGC00010037-04	124876875.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(Cc1sccc1)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2	N(Cc1sccc1)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2
NCGC00185982-02	N(Cc1sccn1)(C)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2		Inactive			1	NCGC00185982-02	377020512.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(Cc1sccn1)(C)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2	N(Cc1sccn1)(C)c1ncnc2c1cc(-c1cc3OCOc3cc1)cc2
NCGC00015082-09	N(N)C(=N)N		Inactive			1	AMINOGUANIDINE HYDROCHLORIDE	170466652.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)O.N(N)C(=N)N.N(N)C(=N)N	S(=O)(=O)(O)O.N(N)C(=N)N.N(N)C(=N)N
NCGC00015830-08	N(N)CCc1ccccc1		Inactive	MAO Inhibitor		1	Phenelzine	170465229.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(O)O.N(N)CCc1ccccc1	S(=O)(=O)(O)O.N(N)CCc1ccccc1
NCGC00015501-05&NCGC00015501-09	N(N)c1nncc2c1cccc2		Inactive	Smooth Muscle Relaxant		2	Apresoline	90341825.0&170464806.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&0.0	N(N)c1nncc2c1cccc2	N(N)c1nncc2c1cccc2&N(N)c1nncc2c1cccc2.Cl
NCGC00379132-01	N([C@@H](C)c1ccccc1)c1ncc2onc(-c3cc4OCOc4cc3)c2c1		Inactive	Serine/threonine-protein kinase PLK1 Inhibitor		1	TC-S 7005	363678375.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N([C@@H](C)c1ccccc1)c1ncc2onc(-c3cc4OCOc4cc3)c2c1	N([C@@H](C)c1ccccc1)c1ncc2onc(-c3cc4OCOc4cc3)c2c1
NCGC00024994-06&NCGC00024994-12	N([C@@H](Cc1ccccc1)C)(CC#C)C		Inactive	MAO-B Inhibitor		2	Selegiline hydrochloride	170464993.0&384568038.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&14.814840504	N([C@@H](Cc1ccccc1)C)(CC#C)C.Cl	N([C@@H](Cc1ccccc1)C)(CC#C)C.Cl&N([C@@H](Cc1ccccc1)C)(CC#C)C
NCGC00344505-01	N([C@H](C)c1c2c(ccc1)cccc2)Cc1[nH]c2c(c1)cccc2		Inactive	Calcium-Sensing Receptor (CaSR) Agonist		1	Calindol	174006301.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N([C@H](C)c1c2c(ccc1)cccc2)Cc1[nH]c2c(c1)cccc2	N([C@H](C)c1c2c(ccc1)cccc2)Cc1[nH]c2c(c1)cccc2
NCGC00263149-06	N([C@H](C)c1ccccc1)c1ncnc2[nH]c(-c3ccc(CN4CCN(CC)CC4)cc3)cc12		Inactive	EGFR Inhibitor		1	AEE-788	384568624.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N([C@H](C)c1ccccc1)c1ncnc2[nH]c(-c3ccc(CN4CCN(CC)CC4)cc3)cc12	N([C@H](C)c1ccccc1)c1ncnc2[nH]c(-c3ccc(CN4CCN(CC)CC4)cc3)cc12
NCGC00262376-01	N([C@H]1CNCC1)c1nc(-c2n3c(nc2)C=CC(c2c[nH]nc2)=C3)ccc1		Inactive	Flt3/IRAK Inhibitor		1	NCGC00262376	174006421.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N([C@H]1CNCC1)c1nc(-c2n3c(nc2)C=CC(c2c[nH]nc2)=C3)ccc1	N([C@H]1CNCC1)c1nc(-c2n3c(nc2)C=CC(c2c[nH]nc2)=C3)ccc1
NCGC00480828-04	N([C@H]1[C@H](c2ccccc2)C1)C1CCC(N)CC1		Inactive	Lysine-Specific Histone Demethylase 1A (KDM1A; LSD1) Inhibitor		1	ORY-1001	363681111.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	20.049365308	N([C@H]1[C@H](c2ccccc2)C1)C1CCC(N)CC1	N([C@H]1[C@H](c2ccccc2)C1)C1CCC(N)CC1
MLS000543798-03	N(\Nc1nc(Nc2ccccc2)nc(N2CCOCC2)n1)=C/c1c2c([nH]c1)cccc2	5.1500001	Inactive		0.0	1	MLS000543798-03	406861831.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	5.0	-46.9248905279	N(\Nc1nc(Nc2ccccc2)nc(N2CCOCC2)n1)=C/c1c2c([nH]c1)cccc2	N(\Nc1nc(Nc2ccccc2)nc(N2CCOCC2)n1)=C/c1c2c([nH]c1)cccc2
NCGC00522030-01	N(\Nc1nncc2c1cccc2)=C(\C=C(C)C)/C		Inactive	adrenergic receptor signaling pathway Modulator		1	Budralazine	405558679.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(\Nc1nncc2c1cccc2)=C(\C=C(C)C)/C	N(\Nc1nncc2c1cccc2)=C(\C=C(C)C)/C
NCGC00379217-03	N(c1[nH]nc(C2CC2)c1)c1nc(Nc2cc3[nH]cnc3cc2)ncc1		Inactive	IRE1 Inhibitor		1	APY29	363678425.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	13.0	N(c1[nH]nc(C2CC2)c1)c1nc(Nc2cc3[nH]cnc3cc2)ncc1	N(c1[nH]nc(C2CC2)c1)c1nc(Nc2cc3[nH]cnc3cc2)ncc1
NCGC00016098-11	N(c1c(C)cccc1C)C=1SCCCN=1		Inactive	Sigma opioid receptor Antagonist		1	Xylazine	170466147.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(c1c(C)cccc1C)C=1SCCCN=1	N(c1c(C)cccc1C)C=1SCCCN=1
NCGC00378596-08	N(c1ccc(N2CCOCC2)cc1)C1=NC(c2cc3[nH]ncc3cc2)=Cn2c1ncc2		Inactive	Syk Kinase Inhibitor		1	Entospletinib	384569053.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(c1ccc(N2CCOCC2)cc1)C1=NC(c2cc3[nH]ncc3cc2)=Cn2c1ncc2	N(c1ccc(N2CCOCC2)cc1)C1=NC(c2cc3[nH]ncc3cc2)=Cn2c1ncc2
NCGC00263204-09	N(c1nc(-c2c(C)nc(N)s2)ccn1)c1ccc(N2CCOCC2)cc1		Inactive	Aurora-A/B/C Kinase Inhibitor		1	CYC-116	384568663.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	19.82510578	N(c1nc(-c2c(C)nc(N)s2)ccn1)c1ccc(N2CCOCC2)cc1	N(c1nc(-c2c(C)nc(N)s2)ccn1)c1ccc(N2CCOCC2)cc1
NCGC00263146-04	N(c1nc(-c2cc(N3CCOCC3)ccc2)ccn1)c1ccc(-n2nc(-c3cnc(C)cc3)nc2)cc1		Inactive	JNK 1/2/3 Inhibitor		1	SR-3306	384568621.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		N(c1nc(-c2cc(N3CCOCC3)ccc2)ccn1)c1ccc(-n2nc(-c3cnc(C)cc3)nc2)cc1	N(c1nc(-c2cc(N3CCOCC3)ccc2)ccn1)c1ccc(-n2nc(-c3cnc(C)cc3)nc2)cc1
NCGC00390634-03	N(c1nc(-c2cc3c(C(C)C)n(C)nc3cc2)ccn1)C1CCC(NC2CCOCC2)CC1		Inactive	CDK 7/8/9 Inhibitor		1	LY-2857785	384569203.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	29.5	N(c1nc(-c2cc3c(C(C)C)n(C)nc3cc2)ccn1)C1CCC(NC2CCOCC2)CC1	N(c1nc(-c2cc3c(C(C)C)n(C)nc3cc2)ccn1)C1CCC(NC2CCOCC2)CC1
NCGC00387776-01	N(c1nc(-c2ccccc2)nc2c1cccc2)c1n[nH]c(C)c1		Inactive	Glycogen synthase kinase-3 beta Inhibitor		1	GSK-3 inhibitor XIII	363680663.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(c1nc(-c2ccccc2)nc2c1cccc2)c1n[nH]c(C)c1	N(c1nc(-c2ccccc2)nc2c1cccc2)c1n[nH]c(C)c1
NCGC00263178-03	N(c1nc(/C=C/c2ccccc2)nc(N2CCN(C)CC2)c1)c1n[nH]c(C)c1		Inactive	Aurora-A Inhibitor		1	ENMD-981693	384568647.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(c1nc(/C=C/c2ccccc2)nc(N2CCN(C)CC2)c1)c1n[nH]c(C)c1	N(c1nc(/C=C/c2ccccc2)nc(N2CCN(C)CC2)c1)c1n[nH]c(C)c1
NCGC00384196-02	N(c1nc(Cc2ccccc2)nc2[nH]c3c(c12)ccc(-c1nn(C)nn1)c3)C1CCC(N)CC1		Inactive	Hematopoietic Stem Cell Differentiation Agonist		1	UM 171	363679188.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(c1nc(Cc2ccccc2)nc2[nH]c3c(c12)ccc(-c1nn(C)nn1)c3)C1CCC(N)CC1	N(c1nc(Cc2ccccc2)nc2[nH]c3c(c12)ccc(-c1nn(C)nn1)c3)C1CCC(N)CC1
NCGC00025225-03	N(c1nc(N)c2c(n1)ccc1n(Cc3ccc(C(C)C)cc3)ccc21)C1CC1		Inactive	PAR1 Antagonist		1	SCH-79797	384568059.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		N(c1nc(N)c2c(n1)ccc1n(Cc3ccc(C(C)C)cc3)ccc21)C1CC1	N(c1nc(N)c2c(n1)ccc1n(Cc3ccc(C(C)C)cc3)ccc21)C1CC1
NCGC00386327-03	N(c1nc(NC2CCCCC2)c2nc[nH]c2n1)c1c(C)cc(N2CCOCC2)cc1		Inactive	MPS1 Inhibitor		1	MPI-0479605	363680213.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(c1nc(NC2CCCCC2)c2nc[nH]c2n1)c1c(C)cc(N2CCOCC2)cc1	N(c1nc(NC2CCCCC2)c2nc[nH]c2n1)c1c(C)cc(N2CCOCC2)cc1
NCGC00165880-14	N(c1nc(NC2CCCCC2)c2nc[nH]c2n1)c1ccc(N2CCOCC2)cc1		Inactive	Adenosine A3 Antagonist		1	Reversine	377020303.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(c1nc(NC2CCCCC2)c2nc[nH]c2n1)c1ccc(N2CCOCC2)cc1	N(c1nc(NC2CCCCC2)c2nc[nH]c2n1)c1ccc(N2CCOCC2)cc1
NCGC00386224-06	N(c1ncnc2c1cc1OCCOCCOCCOc1c2)c1cc(C#C)ccc1		Inactive	EGFR Inhibitor		1	Icotinib hydrochloride	377020161.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N(c1ncnc2c1cc1OCCOCCOCCOc1c2)c1cc(C#C)ccc1	N(c1ncnc2c1cc1OCCOCCOCCOc1c2)c1cc(C#C)ccc1
NCGC00386665-06	N(c1nn(c(N)n1)-c1nnc2-c3c(cccc3)CCCc2c1)c1cc2c(cc1)CC[C@H](N1CCCC1)CC2	6.0	Active	AXL Kinase Inhibitor	0.0	1	Bemcentinib	384569144.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.4	73.1288163616	N(c1nn(c(N)n1)-c1nnc2-c3c(cccc3)CCCc2c1)c1cc2c(cc1)CC[C@H](N1CCCC1)CC2	N(c1nn(c(N)n1)-c1nnc2-c3c(cccc3)CCCc2c1)c1cc2c(cc1)CC[C@H](N1CCCC1)CC2
NCGC00386884-01	N(c1sc(-c2ccncc2)nn1)c1c2c(ccc1)cccc2		Inactive			1	SRPIN340	363680480.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(c1sc(-c2ccncc2)nn1)c1c2c(ccc1)cccc2	N(c1sc(-c2ccncc2)nn1)c1c2c(ccc1)cccc2
NCGC00371008-01	N(c1sc2c(n1)-c1c(n[nH]c1)CCC2)c1ncccc1		Inactive	Metabotropic glutamate receptor 4 Positive Allosteric Modulator		1	TC-N 22A	363677990.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N(c1sc2c(n1)-c1c(n[nH]c1)CCC2)c1ncccc1	N(c1sc2c(n1)-c1c(n[nH]c1)CCC2)c1ncccc1
NCGC00378894-01	N(c1sc2c(n1)cccc2)c1ccc(C(C(CC)CC)n2ncnc2)cc1		Inactive	Cytochrome P450 26A1 Inhibitor		1	Talarozole (R enantiomer)	363678261.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	13.0	N(c1sc2c(n1)cccc2)c1ccc(C(C(CC)CC)n2ncnc2)cc1	N(c1sc2c(n1)cccc2)c1ccc(C(C(CC)CC)n2ncnc2)cc1
NCGC00344081-06	N(c1scc(-c2ccncc2)n1)c1cc(C)ccc1	6.0	Active	Renal cell growth inhibition	0.0	1	STF-62247	384568717.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.3	126.8737707259	N(c1scc(-c2ccncc2)n1)c1cc(C)ccc1	N(c1scc(-c2ccncc2)n1)c1cc(C)ccc1
NCGC00249389-22	N1(c2ccc(C3=Cn4ncc(-c5c6c(ncc5)cccc6)c4N=C3)cc2)CCNCC1		Inactive	ALK2 Inhibitor		1	LDN-193189	384568524.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		N1(c2ccc(C3=Cn4ncc(-c5c6c(ncc5)cccc6)c4N=C3)cc2)CCNCC1	N1(c2ccc(C3=Cn4ncc(-c5c6c(ncc5)cccc6)c4N=C3)cc2)CCNCC1
NCGC00386324-08	N1(c2ccc(C3=Cn4ncc(-c5c6c(nccc6)ccc5)c4N=C3)cc2)CCNCC1		Inactive	ALK2 Inhibitor		1	LDN-212854	363680210.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-10.573227672	N1(c2ccc(C3=Cn4ncc(-c5c6c(nccc6)ccc5)c4N=C3)cc2)CCNCC1	N1(c2ccc(C3=Cn4ncc(-c5c6c(nccc6)ccc5)c4N=C3)cc2)CCNCC1
NCGC00408848-01	N1(c2scc(-c3ccccc3)n2)CCOCC1		Inactive	Estrogen receptor alpha Inhibitor		1	VPC-14228	363681064.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	N1(c2scc(-c3ccccc3)n2)CCOCC1	N1(c2scc(-c3ccccc3)n2)CCOCC1
NCGC00094719-08	N12CN3CN(CN(C1)C3)C2		Inactive			1	Methenamine	170465468.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N12CN3CN(CN(C1)C3)C2	N12CN3CN(CN(C1)C3)C2
NCGC00181124-02	N12[C@@H]([C@@H]3CN4[C@H]([C@H](C1)C3)CCCC4)CCCC2		Inactive	sodium ion transport Inhibitor		1	Sparteine	170465740.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N12[C@@H]([C@@H]3CN4[C@H]([C@H](C1)C3)CCCC4)CCCC2	N12[C@@H]([C@@H]3CN4[C@H]([C@H](C1)C3)CCCC4)CCCC2
NCGC00346708-03	N12[C@@H]([C@H]3C=C4[C@@H](NCCC4)[C@@H](C1)C3)CCCC2		Inactive	Mediator Release Inhibitors		1	Aloperine	434147219.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N12[C@@H]([C@H]3C=C4[C@@H](NCCC4)[C@@H](C1)C3)CCCC2	N12[C@@H]([C@H]3C=C4[C@@H](NCCC4)[C@@H](C1)C3)CCCC2
NCGC00094762-08	N1CCNCC1		Inactive			1	Piperazine	405558781.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N1CCNCC1	N1CCNCC1
NCGC00164533-02	N=C(NC(=N)N)NCCCC		Inactive	AMP-activated protein kinase, AMPK Activator		1	Buformin	170465982.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N=C(NC(=N)N)NCCCC	N=C(NC(=N)N)NCCCC
NCGC00016543-13	N=C(NC(=N)N)NCCc1ccccc1		Inactive	antidiabetic drug		1	Phenformin hydrochloride	384567948.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N=C(NC(=N)N)NCCc1ccccc1	N=C(NC(=N)N)NCCc1ccccc1
NCGC00016623-07	N=C(NC(=N)N1CCOCC1)N		Inactive	antiinfluenza drug		1	Moroxydine HCl	434146957.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N=C(NC(=N)N1CCOCC1)N	N=C(NC(=N)N1CCOCC1)N
NCGC00179419-05	N=C(NCC1OC2(OC1)CCCCC2)N		Inactive	Norepinephrine transporter Partial Agonist		1	Guanadrel sulfate	405558962.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N=C(NCC1OC2(OC1)CCCCC2)N	N=C(NCC1OC2(OC1)CCCCC2)N
NCGC00016272-05	N=C(NCCN1CCCCCCC1)N		Inactive			1	Guanethidine sulfate	170464954.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(O)O.S(=O)(=O)(O)O.N=C(NCCN1CCCCCCC1)N	S(=O)(=O)(O)O.S(=O)(=O)(O)O.N=C(NCCN1CCCCCCC1)N
NCGC00090698-06	N=C(Nc1ccccc1)Nc1ccccc1		Inactive			1	1,3-Diphenylguanidine	170465656.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	N=C(Nc1ccccc1)Nc1ccccc1	N=C(Nc1ccccc1)Nc1ccccc1
NCGC00166015-02	N=C1C=CC(=C(c2cc(C)c(N)cc2)c2ccc(N)cc2)C=C1		Inactive			1	C.I. Basic Violet 14	124893209.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	N=C1C=CC(=C(c2cc(C)c(N)cc2)c2ccc(N)cc2)C=C1	N=C1C=CC(=C(c2cc(C)c(N)cc2)c2ccc(N)cc2)C=C1
NCGC00345823-02	NC(C)(C)c1ccc(-c2c(-c3ccccc3)nc3c(n2)cccc3)cc1	4.9000001	Active	AKT Inhibitor	0.0	1	Akt-I-1,2	363677370.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	96.8236584507	NC(C)(C)c1ccc(-c2c(-c3ccccc3)nc3c(n2)cccc3)cc1	NC(C)(C)c1ccc(-c2c(-c3ccccc3)nc3c(n2)cccc3)cc1
NCGC00159491-04&NCGC00159491-08&NCGC00159491-11	NC(C)C12CC3CC(C1)CC(C2)C3		Inactive	M2 Channel Inhibitor		3	Rimantadine	170465164.0&384568182.0&434147008.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	NC(C)C12CC3CC(C1)CC(C2)C3.Cl	NC(C)C12CC3CC(C1)CC(C2)C3.Cl&NC(C)C12CC3CC(C1)CC(C2)C3
NCGC00332100-02	NC(Cc1c2c([nH]c1)cccc2)C		Inactive	Monoamine oxidase A Inhibitor		1	Indopan Acetate	363677316.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	NC(Cc1c2c([nH]c1)cccc2)C	NC(Cc1c2c([nH]c1)cccc2)C
NCGC00262942-01	NC/C(=C(/c1ccccc1)\c1ccccc1)/CC	4.9499998	Active		0.0	1	Etifelmine hydrochloride	170465899.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	2.4	30.310734468	NC/C(=C(/c1ccccc1)\c1ccccc1)/CC.Cl	NC/C(=C(/c1ccccc1)\c1ccccc1)/CC.Cl
NCGC00094819-07	NC1(C)CN(CC(CCCC)CC)CN(CC(CCCC)CC)C1	5.4499998	Active		0.0	1	Hexetidine	170465729.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	90.4443316752	NC1(C)CN(CC(CCCC)CC)CN(CC(CCCC)CC)C1	NC1(C)CN(CC(CCCC)CC)CN(CC(CCCC)CC)C1
NCGC00015705-07&NCGC00015705-13	NC12CC3(C)CC(C)(C1)CC(C2)C3		Inactive	NMDA Antagonist		2	Memantine hydrochloride	170464999.0&384567883.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	NC12CC3(C)CC(C)(C1)CC(C2)C3	NC12CC3(C)CC(C)(C1)CC(C2)C3
NCGC00015036-11&NCGC00015036-23	NC12CC3CC(C1)CC(C2)C3		Inactive	Dopamine Receptor Agonist		2	Amantadine hydrochloride	170464860.0&384567799.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	NC12CC3CC(C1)CC(C2)C3	NC12CC3CC(C1)CC(C2)C3
NCGC00025317-02	NC1=NN=C2Nc3c(N=C12)cccc3		Inactive			1	NSC 693868	377020467.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	NC1=NN=C2Nc3c(N=C12)cccc3	NC1=NN=C2Nc3c(N=C12)cccc3
NCGC00165791-04	NC=1N2c3c(cccc3)Cc3c(cccc3)C2CN=1		Inactive	Histamine H1 receptor Antagonist		1	Epinastine hydrochloride	170465284.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	NC=1N2c3c(cccc3)Cc3c(cccc3)C2CN=1.Cl	NC=1N2c3c(cccc3)Cc3c(cccc3)C2CN=1.Cl
NCGC00386713-03	NCC1CCN(c2nc(-c3cc4c(cc3)cccc4)ccn2)CC1		Inactive	Wnt Signaling Inhibitor		1	WAY-262611	363680411.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	NCC1CCN(c2nc(-c3cc4c(cc3)cccc4)ccn2)CC1	NCC1CCN(c2nc(-c3cc4c(cc3)cccc4)ccn2)CC1
NCGC00015513-11	NCCc1[nH]cnc1		Inactive	Histamine Receptor Agonist		1	Histamine dihydrochloride	170465001.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	NCCc1[nH]cnc1	NCCc1[nH]cnc1
NCGC00015513-20	NCCc1nc[nH]c1		Inactive	Histamine Receptor Agonist		1	Histamine dihydrochloride	384567859.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	NCCc1nc[nH]c1	NCCc1nc[nH]c1
NCGC00370827-02	N[C@H]1CN(c2nc(N)nc3-c4c(cccc4)CCCc23)CC1	5.0500002	Active	Histamine H4 receptor Antagonist	0.0	1	A 943931	363677872.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	3.0	68.2471667519	N[C@H]1CN(c2nc(N)nc3-c4c(cccc4)CCCc23)CC1	N[C@H]1CN(c2nc(N)nc3-c4c(cccc4)CCCc23)CC1
NCGC00015848-05&NCGC00015848-09	N[C@H]1[C@H](c2ccccc2)C1		Inactive	MAO-A/B Inhibitor		2	Tranylcypromine&Tranylcypromine hydrochloride	384567898.0&405558823.0	Annotated/Bioactive Compound Collection&2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	N[C@H]1[C@H](c2ccccc2)C1	N[C@H]1[C@H](c2ccccc2)C1
NCGC00507881-01	Nc1c(-c2n(-c3ccc(C4(N)CCC4)cc3)c3nc(-c4ccccc4)ccc3n2)cccn1		Inactive	AKT Inhibitor		1	Miransertib	384569347.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.59353108	Nc1c(-c2n(-c3ccc(C4(N)CCC4)cc3)c3nc(-c4ccccc4)ccc3n2)cccn1	Nc1c(-c2n(-c3ccc(C4(N)CCC4)cc3)c3nc(-c4ccccc4)ccc3n2)cccn1
NCGC00242225-02	Nc1c(-c2n(C3CC3)c3c(n2)cncc3)non1		Inactive			1	NCGC00242225-02	377020390.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	12.0177332359	Nc1c(-c2n(C3CC3)c3c(n2)cncc3)non1	Nc1c(-c2n(C3CC3)c3c(n2)cncc3)non1
NCGC00242118-02	Nc1c(-c2n(C3CCCCC3)c3c(n2)cncc3)non1		Inactive			1	NCGC00242118-02	377020423.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Nc1c(-c2n(C3CCCCC3)c3c(n2)cncc3)non1	Nc1c(-c2n(C3CCCCC3)c3c(n2)cncc3)non1
NCGC00017020-06	Nc1c(C[n+]2c(C)cccc2)cnc(CCC)n1		Inactive			1	NCGC00017020-06		Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Nc1c(C[n+]2c(C)cccc2)cnc(CCC)n1	Nc1c(C[n+]2c(C)cccc2)cnc(CCC)n1
NCGC00015339-07	Nc1c2c([n+](CCCCCCCCCC[n+]3c(C)cc(N)c4c3cccc4)c(C)c1)cccc2		Inactive	Protein kinase C beta Inhibitor		1	Dequalinium dichloride	225144172.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Nc1c2c([n+](CCCCCCCCCC[n+]3c(C)cc(N)c4c3cccc4)c(C)c1)cccc2	Nc1c2c([n+](CCCCCCCCCC[n+]3c(C)cc(N)c4c3cccc4)c(C)c1)cccc2
NCGC00015054-12&NCGC00015054-20	Nc1c2c(nc3c1CCCC3)cccc2		Inactive	Acetylcholinesterase Inhibitor		2	Tacrine hydrochloride	170465420.0&384567802.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&15.0	Nc1c2c(nc3c1CCCC3)cccc2	Nc1c2c(nc3c1CCCC3)cccc2
NCGC00094857-05&NCGC00094857-06	Nc1c2c(nc3c1cccc3)cccc2		Inactive			2	9-Aminoacridine, monohydrochloride, monohydrate&AMINACRINE	170465046.0&434146993.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		Nc1c2c(nc3c1cccc3)cccc2.Cl.O	Nc1c2c(nc3c1cccc3)cccc2.Cl.O&Nc1c2c(nc3c1cccc3)cccc2
NCGC00178831-03	Nc1cc2[n+](C)c3c(cc2cc1)ccc(N)c3		Inactive	Hypoxia-inducible factor 1 alpha Interacts		1	Acriflavine hydrochloride	170465670.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Nc1cc2[n+](C)c3c(cc2cc1)ccc(N)c3.Nc1cc2nc3c(cc2cc1)ccc(N)c3.[Cl-]	Nc1cc2[n+](C)c3c(cc2cc1)ccc(N)c3.Nc1cc2nc3c(cc2cc1)ccc(N)c3.[Cl-]
NCGC00166245-04	Nc1cc2nc3c(cc2cc1)ccc(N)c3		Inactive	RNA Binding Agent		1	Proflavin hemisulfate	170466523.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(O)O.Nc1cc2nc3c(cc2cc1)ccc(N)c3.Nc1cc2nc3c(cc2cc1)ccc(N)c3	S(=O)(=O)(O)O.Nc1cc2nc3c(cc2cc1)ccc(N)c3.Nc1cc2nc3c(cc2cc1)ccc(N)c3
NCGC00091297-05	Nc1ccccc1		Inactive			1	Anilinium nitrate	170465650.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=[N+](O)[O-].[NH3+]c1ccccc1	O=[N+](O)[O-].[NH3+]c1ccccc1
NCGC00015009-23	Nc1ccncc1		Inactive	Voltage-gated potassium channel subunit Kv1.3 Blocker		1	4-Aminopyridine	405559072.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Nc1ccncc1	Nc1ccncc1
NCGC00183912-01&NCGC00183912-09	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4c3C=CC=C4)cc12		Inactive	ERK1/2 Inhibitor		2	FR-180204	174006438.0&363677100.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	-12.2898779879&0.0	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4c3C=CC=C4)cc12	Nc1n[nH]c2nnc(-c3c(-c4ccccc4)nn4c3C=CC=C4)cc12
NCGC00370852-01	Nc1nc(N2CCNCC2)c2c(n1)C=1[C@H]3[C@@H](OC=1CC2)CCCC3		Inactive			1	A 987306	363677886.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Nc1nc(N2CCNCC2)c2c(n1)C=1[C@H]3[C@@H](OC=1CC2)CCCC3	Nc1nc(N2CCNCC2)c2c(n1)C=1[C@H]3[C@@H](OC=1CC2)CCCC3
NCGC00070736-03&NCGC00070736-17	Nc1nc2c(c3n(CC(C)C)cnc13)cccc2		Inactive	TLR 7 Receptor Antagonist		2	Imiquimod	170464691.0&384568073.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&12.7131630599&0.0&0.0	Nc1nc2c(c3n(CC(C)C)cnc13)cccc2	Nc1nc2c(c3n(CC(C)C)cnc13)cccc2
NCGC00507864-01	Nc1ncc(-c2nc(N3CCOCC3)c3nc4C(C)(C)OCCn4c3n2)cn1		Inactive	PI3K Inhibitor		1	GDC-0084	384569339.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.0895728039	Nc1ncc(-c2nc(N3CCOCC3)c3nc4C(C)(C)OCCn4c3n2)cn1	Nc1ncc(-c2nc(N3CCOCC3)c3nc4C(C)(C)OCCn4c3n2)cn1
NCGC00386370-01	Nc1ncc(-c2nc(N3CCOCC3)nc3n(C(C)C)c(C)nc23)cn1		Inactive	PI3K/mTOR Inhibitor		1	VS-5584	384569129.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Nc1ncc(-c2nc(N3CCOCC3)nc3n(C(C)C)c(C)nc23)cn1	Nc1ncc(-c2nc(N3CCOCC3)nc3n(C(C)C)c(C)nc23)cn1
NCGC00371129-01	Nc1ncc(-c2nc(N3CCOCC3)nc3n(C(C)C)cnc23)cn1		Inactive	Serine/threonine-protein kinase mTOR Inhibitor		1	5-(9-isopropyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine	363678045.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Nc1ncc(-c2nc(N3CCOCC3)nc3n(C(C)C)cnc23)cn1	Nc1ncc(-c2nc(N3CCOCC3)nc3n(C(C)C)cnc23)cn1
NCGC00345447-10	Nc1ncn(C)c-2ncnc1-2		Inactive	PI3K Inhibitor		1	3-Methyladenine	384568734.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Nc1ncn(C)c-2ncnc1-2	Nc1ncn(C)c-2ncnc1-2
NCGC00346839-01	Nc1ncnc2c1cccc2		Inactive	EGFR Inhibitor		1	4-Quinazolinamine	174006584.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Nc1ncnc2c1cccc2	Nc1ncnc2c1cccc2
NCGC00262627-06	Nc1ncnc2n(C(C)(C)C)nc(-c3c4c(ccc3)cccc4)c12		Inactive			1	1-Naphthyl PP1	377020279.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Nc1ncnc2n(C(C)(C)C)nc(-c3c4c(ccc3)cccc4)c12	Nc1ncnc2n(C(C)(C)C)nc(-c3c4c(ccc3)cccc4)c12
NCGC00163376-14	Nc1ncnc2n(C(C)(C)C)nc(-c3ccc(C)cc3)c12		Inactive			1	PP1	377020283.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Nc1ncnc2n(C(C)(C)C)nc(-c3ccc(C)cc3)c12	Nc1ncnc2n(C(C)(C)C)nc(-c3ccc(C)cc3)c12
NCGC00168082-01	Nc1ncnc2n(C(C)(C)C)nc(Cc3c4c(ccc3)cccc4)c12		Inactive			1	1-NM-PP1	174006637.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Nc1ncnc2n(C(C)(C)C)nc(Cc3c4c(ccc3)cccc4)c12	Nc1ncnc2n(C(C)(C)C)nc(Cc3c4c(ccc3)cccc4)c12
NCGC00262632-01	Nc1ncnc2n(C(C)C)nc(Cc3c4c(ccc3)cccc4)c12		Inactive			1	NCGC00262632-01	377020165.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Nc1ncnc2n(C(C)C)nc(Cc3c4c(ccc3)cccc4)c12	Nc1ncnc2n(C(C)C)nc(Cc3c4c(ccc3)cccc4)c12
NCGC00346619-03	Nc1ncnc2n(C3CCCC3)nc(-c3cnc4[nH]ccc4c3)c12		Inactive	PDGFR Inhibitor		1	PP-121	384568861.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Nc1ncnc2n(C3CCCC3)nc(-c3cnc4[nH]ccc4c3)c12	Nc1ncnc2n(C3CCCC3)nc(-c3cnc4[nH]ccc4c3)c12
NCGC00389211-01	Nc1ncnc2n([C@@H]3OCCC3)cnc12		Inactive	Adenylate cyclase Inhibitor		1	SQ 22536	363680739.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Nc1ncnc2n([C@@H]3OCCC3)cnc12	Nc1ncnc2n([C@@H]3OCCC3)cnc12
NCGC00094856-05	Nc1ncnc2nc[nH]c12		Inactive	Xanthine dehydrogenase Inhibitor		1	Adenine	170465950.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Nc1ncnc2nc[nH]c12	Nc1ncnc2nc[nH]c12
NCGC00346654-11	Nc1oc2c(n1)cc(-c1nn(C(C)C)c3ncnc(N)c13)cc2		Inactive	mTORC1/2 Inhibitor		1	INK-128	384568885.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Nc1oc2c(n1)cc(-c1nn(C(C)C)c3ncnc(N)c13)cc2	Nc1oc2c(n1)cc(-c1nn(C(C)C)c3ncnc(N)c13)cc2
NCGC00163160-04	Nc1sc2c(n1)CCN(CC=C)CC2		Inactive	Dopamine D4 receptor Agonist		1	Talipexole	170466015.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Nc1sc2c(n1)CCN(CC=C)CC2	Nc1sc2c(n1)CCN(CC=C)CC2
NCGC00091162-09	Nc1sccn1		Inactive			1	Aminothiazole	434146901.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Nc1sccn1	Nc1sccn1
NCGC00169512-02	O(/C(/[C@H]1[C@H](c2ccccc2)O1)=C/1\C(OC)=CC(=O)O\1)C		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Pothomorphe | Family: Piperaceae | Species: umbellata		1	NCGC00169512-02	363676836.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(/C(/[C@H]1[C@H](c2ccccc2)O1)=C/1\C(OC)=CC(=O)O\1)C	O(/C(/[C@H]1[C@H](c2ccccc2)O1)=C/1\C(OC)=CC(=O)O\1)C
NCGC00385479-01	O(/C=C(\C)/C1[C@@](C=C)(C)C[C@H](O)[C@H]2[C@@H](C)C(=O)O[C@H]12)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385479-01	363679763.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(/C=C(\C)/C1[C@@](C=C)(C)C[C@H](O)[C@H]2[C@@H](C)C(=O)O[C@H]12)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(/C=C(\C)/C1[C@@](C=C)(C)C[C@H](O)[C@H]2[C@@H](C)C(=O)O[C@H]12)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00179584-05	O(/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)/c1nc(N)sc1)C(C(=O)O)(C)C		Inactive	Penicillin-binding protein 4 Inhibitor		1	Ceftazidime	405558776.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)/c1nc(N)sc1)C(C(=O)O)(C)C	O(/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)/c1nc(N)sc1)C(C(=O)O)(C)C
NCGC00402337-02	O(/N=C(\N)/c1cnccc1)CC(O)CN1CCCCC1		Inactive	Insulin Sensitizers		1	BGP-15	384569215.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(/N=C(\N)/c1cnccc1)CC(O)CN1CCCCC1	O(/N=C(\N)/c1cnccc1)CC(O)CN1CCCCC1
NCGC00378829-03	O(/N=C/1\C(C)=CC(=O)C(C(C)C)=C\1)C(=O)c1c(C)cccc1		Inactive			1	Poloxin	377020515.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(/N=C/1\C(C)=CC(=O)C(C(C)C)=C\1)C(=O)c1c(C)cccc1	O(/N=C/1\C(C)=CC(=O)C(C(C)C)=C\1)C(=O)c1c(C)cccc1
NCGC00163732-03	O(/N=C/1\[C@H](C)[C@@H](/C(=C/C(C)C)/C)O[C@]2(O[C@H]3C[C@H](OC(=O)[C@H]4[C@@]/5(O)[C@@H]([C@H](O)C(C)=C4)OC\C\5=C/C=C/[C@H](C)C/C(/C)=C/C3)C2)C\1)C		Inactive			1	Moxidectin	405558680.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.0	O(/N=C/1\[C@H](C)[C@@H](/C(=C/C(C)C)/C)O[C@]2(O[C@H]3C[C@H](OC(=O)[C@H]4[C@@]/5(O)[C@@H]([C@H](O)C(C)=C4)OC\C\5=C/C=C/[C@H](C)C/C(/C)=C/C3)C2)C\1)C	O(/N=C/1\[C@H](C)[C@@H](/C(=C/C(C)C)/C)O[C@]2(O[C@H]3C[C@H](OC(=O)[C@H]4[C@@]/5(O)[C@@H]([C@H](O)C(C)=C4)OC\C\5=C/C=C/[C@H](C)C/C(/C)=C/C3)C2)C\1)C
NCGC00253588-01	O(/N=C/c1c2c(nc3c1CN1C(=O)C4=C([C@@](O)(CC)C(=O)OC4)C=C31)cccc2)C(C)(C)C		Inactive			1	Gimatecan	170465615.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(/N=C/c1c2c(nc3c1CN1C(=O)C4=C([C@@](O)(CC)C(=O)OC4)C=C31)cccc2)C(C)(C)C	O(/N=C/c1c2c(nc3c1CN1C(=O)C4=C([C@@](O)(CC)C(=O)OC4)C=C31)cccc2)C(C)(C)C
NCGC00384274-01	O(/N=C\1/C(=C\2/C(=O)Nc3c/2cccc3)/Nc2c/1cccc2)CCC(O)CO		Inactive			1	Indirubin_E8	377020335.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	14.114285712	O(/N=C\1/C(=C\2/C(=O)Nc3c/2cccc3)/Nc2c/1cccc2)CCC(O)CO	O(/N=C\1/C(=C\2/C(=O)Nc3c/2cccc3)/Nc2c/1cccc2)CCC(O)CO
NCGC00178510-09	O(/N=C\1/[C@H](C)[C@@H](O)[C@@](O)(C)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@H](C)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@](O)(C)C[C@H]/1C)COCCOC		Inactive	Bacterial 70S ribosome Inhibitor		1	Roxithromycin	405558438.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(/N=C\1/[C@H](C)[C@@H](O)[C@@](O)(C)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@H](C)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@](O)(C)C[C@H]/1C)COCCOC	O(/N=C\1/[C@H](C)[C@@H](O)[C@@](O)(C)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@H](C)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@](O)(C)C[C@H]/1C)COCCOC
NCGC00379158-01	O(/N=C\1/c2nc3c(nc2-c2c/1cccc2)cccc3)C(=O)c1occc1		Inactive			1	IQ 3	377020173.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	19.5	O(/N=C\1/c2nc3c(nc2-c2c/1cccc2)cccc3)C(=O)c1occc1	O(/N=C\1/c2nc3c(nc2-c2c/1cccc2)cccc3)C(=O)c1occc1
NCGC00169478-03	O(C(/C=C/C1(O)C(C)(C)CC(O)CC1C)C)C1C(O)C(O)C(O)C(CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Tithonia | Family: Compositae | Species: diversifolia		1	NCGC00169478-03	363676827.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(/C=C/C1(O)C(C)(C)CC(O)CC1C)C)C1C(O)C(O)C(O)C(CO)O1	O(C(/C=C/C1(O)C(C)(C)CC(O)CC1C)C)C1C(O)C(O)C(O)C(CO)O1
NCGC00385830-01	O(C(/C=C/C1(O)C(C)=CC(=O)CC1(CO)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385830-01	363679959.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(/C=C/C1(O)C(C)=CC(=O)CC1(CO)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C(/C=C/C1(O)C(C)=CC(=O)CC1(CO)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00384890-01	O(C(/C=C/C1(O)C(O)(C)CC(O)CC1(C)C)C)C1C(O)C(O)C(O)C(CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Ammi | Family: Apiaceae | Species: visnaga		1	NCGC00384890-01	363679420.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(/C=C/C1(O)C(O)(C)CC(O)CC1(C)C)C)C1C(O)C(O)C(O)C(CO)O1	O(C(/C=C/C1(O)C(O)(C)CC(O)CC1(C)C)C)C1C(O)C(O)C(O)C(CO)O1
NCGC00386009-01	O(C(/C=C/C1(O)C2(C)OCC1(C)CC(=O)C2)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386009-01	363680056.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(/C=C/C1(O)C2(C)OCC1(C)CC(=O)C2)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C(/C=C/C1(O)C2(C)OCC1(C)CC(=O)C2)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385080-02	O(C(/C=C/C1C(C)=CC(=O)CC1(C)C)C)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385080-02	363679522.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(/C=C/C1C(C)=CC(=O)CC1(C)C)C)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C(/C=C/C1C(C)=CC(=O)CC1(C)C)C)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00169491-03	O(C(/C=C/[C@@]1(O)C(C)=CC(=O)CC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Schkuria | Family: Compositae | Species: pinnata		1	NCGC00169491-03	363676830.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(/C=C/[C@@]1(O)C(C)=CC(=O)CC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C(/C=C/[C@@]1(O)C(C)=CC(=O)CC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00380268-01	O(C(/C=C/[C@H]1C(C)=CC(=O)CC1(C)C)CO)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Albizia | Family: Mimosaceae | Species: lebbleck		1	NCGC00380268-01	363678519.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(/C=C/[C@H]1C(C)=CC(=O)CC1(C)C)CO)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C(/C=C/[C@H]1C(C)=CC(=O)CC1(C)C)CO)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00249905-01	O(C(C#C)(CC)C)C(=O)c1c(C(=O)O)cccc1		Inactive			1	Phthalofyne	170466477.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(C(C#C)(CC)C)C(=O)c1c(C(=O)O)cccc1	O(C(C#C)(CC)C)C(=O)c1c(C(=O)O)cccc1
NCGC00384570-01	O(C(C#N)(CC)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Rhodiola | Family: Saxifragaceae | Species: rosea		1	NCGC00384570-01	363679249.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C#N)(CC)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C(C#N)(CC)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00380916-01	O(C(C#N)C(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@](O)(CO)CO2)O1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Detarium | Family: N/A | Species: microcarpum		1	NCGC00380916-01	363678853.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C#N)C(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@](O)(CO)CO2)O1	O(C(C#N)C(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@](O)(CO)CO2)O1
NCGC00381239-01	O(C(C#N)C(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)O1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Detarium | Family: N/A | Species: microcarpum		1	NCGC00381239-01	363679044.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C#N)C(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)O1	O(C(C#N)C(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)O1
NCGC00381068-01	O(C(C#N)c1ccc(O)cc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381068-01	363678955.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C#N)c1ccc(O)cc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C(C#N)c1ccc(O)cc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00168992-02	O(C(C#N)c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	DNA polymerase beta Inhibitor		1	NCGC00168992-02	363676736.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C#N)c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C(C#N)c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00178377-07	O(C(C#N)c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1		Inactive	Nitric oxide synthase, inducible Inhibitor		1	Amygdalin	384568355.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C(C#N)c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1	O(C(C#N)c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1
NCGC00385866-02	O(C(C(C#N)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385866-02	363679977.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C(C#N)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C(C(C#N)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00384988-01	O(C(C(O)[C@@H](C)C1[C@]2(C)[C@](C)(C3[C@@H](OC)C=C4C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O5)CCC4[C@]3(C)CC2)CC1)C=C(C)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384988-01	363679470.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C(O)[C@@H](C)C1[C@]2(C)[C@](C)(C3[C@@H](OC)C=C4C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O5)CCC4[C@]3(C)CC2)CC1)C=C(C)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1	O(C(C(O)[C@@H](C)C1[C@]2(C)[C@](C)(C3[C@@H](OC)C=C4C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O5)CCC4[C@]3(C)CC2)CC1)C=C(C)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1
NCGC00386043-01	O(C(C(O)c1cc(OC)c(O)cc1)C)c1c(OC)cc(CC=C)cc1OC		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Myristica | Family: Myristicaceae | Species: fragrans		1	NCGC00386043-01	363680077.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C(O)c1cc(OC)c(O)cc1)C)c1c(OC)cc(CC=C)cc1OC	O(C(C(O)c1cc(OC)c(O)cc1)C)c1c(OC)cc(CC=C)cc1OC
NCGC00381098-01	O(C(C(Oc1c(OC)cc(/C=C/CO)cc1)CO)c1cc(O)c(OC)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Vitex | Family: Verbenaceae | Species: strikeri		1	NCGC00381098-01	363678968.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C(Oc1c(OC)cc(/C=C/CO)cc1)CO)c1cc(O)c(OC)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C(C(Oc1c(OC)cc(/C=C/CO)cc1)CO)c1cc(O)c(OC)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00344020-02	O(C(C)(C)C)C(=O)N1CCC(OCc2onc(-c3ccncc3)n2)CC1		Inactive	Glucose-dependent insulinotropic receptor Agonist		1	PSN632408	363677321.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C)(C)C)C(=O)N1CCC(OCc2onc(-c3ccncc3)n2)CC1	O(C(C)(C)C)C(=O)N1CCC(OCc2onc(-c3ccncc3)n2)CC1
NCGC00487205-01	O(C(C)(C)C)C(=O)N1[C@H](C(=O)C#CCCCCCCCCCCCCC)COC1(C)C		Inactive			1	SKI 5C	377020514.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C)(C)C)C(=O)N1[C@H](C(=O)C#CCCCCCCCCCCCCC)COC1(C)C	O(C(C)(C)C)C(=O)N1[C@H](C(=O)C#CCCCCCCCCCCCCC)COC1(C)C
NCGC00378712-01	O(C(C)(C)C)C(=O)c1ncn-2c1C(C)(C)Nc1c-2cccc1		Inactive	Serotonin 3a (5-HT3a) receptor Antagonist		1	U 93631	363678165.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C)(C)C)C(=O)c1ncn-2c1C(C)(C)Nc1c-2cccc1	O(C(C)(C)C)C(=O)c1ncn-2c1C(C)(C)Nc1c-2cccc1
NCGC00385391-01	O(C(C)(C)C1CC2C(O)(C)C(O)CC2C(O)(CO)CC1)C1C(O)C(O)C(O)C(CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385391-01	363679718.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C)(C)C1CC2C(O)(C)C(O)CC2C(O)(CO)CC1)C1C(O)C(O)C(O)C(CO)O1	O(C(C)(C)C1CC2C(O)(C)C(O)CC2C(O)(CO)CC1)C1C(O)C(O)C(O)C(CO)O1
NCGC00380554-01	O(C(C)(C)C1CC=C(C)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380554-01	363678647.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C)(C)C1CC=C(C)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)O1	O(C(C)(C)C1CC=C(C)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)O1
NCGC00021147-11	O(C(C)(c1ncccc1)c1ccccc1)CCN(C)C		Inactive	Histamine H1 receptor Antagonist		1	Doxylamine succinate	170465171.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCC(=O)O.O(C(C)(c1ncccc1)c1ccccc1)CCN(C)C	O=C(O)CCC(=O)O.O(C(C)(c1ncccc1)c1ccccc1)CCN(C)C
NCGC00024868-09	O(C(C)C)CCOCc1ccc(OCC(O)CNC(C)C)cc1		Inactive	beta1-Adrenoceptor Antagonists		1	Bisoprolol fumarate	170464815.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)/C=C/C(=O)O.O(C(C)C)CCOCc1ccc(OCC(O)CNC(C)C)cc1.O(C(C)C)CCOCc1ccc(OCC(O)CNC(C)C)cc1	O=C(O)/C=C/C(=O)O.O(C(C)C)CCOCc1ccc(OCC(O)CNC(C)C)cc1.O(C(C)C)CCOCc1ccc(OCC(O)CNC(C)C)cc1
NCGC00385519-01	O(C(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385519-01	363679787.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00507847-01	O(C(C)C)c1c(C#N)cc(-c2onc(-c3c4c([C@@H](NCCO)CC4)ccc3)n2)cc1		Inactive	Lysophospholipid edg8 (S1P5) Receptor Agonist		1	Ozanimod	384569328.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.5	O(C(C)C)c1c(C#N)cc(-c2onc(-c3c4c([C@@H](NCCO)CC4)ccc3)n2)cc1	O(C(C)C)c1c(C#N)cc(-c2onc(-c3c4c([C@@H](NCCO)CC4)ccc3)n2)cc1
NCGC00018139-05&NCGC00018139-07	O(C(C)C)c1cc2OC=C(c3ccccc3)C(=O)c2cc1		Inactive	Treatment of Osteoporosis		2	Ipriflavone	170465997.0&170466811.0	Annotated/Bioactive Compound Collection&2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	12.451882844&0.0&0.0	O(C(C)C)c1cc2OC=C(c3ccccc3)C(=O)c2cc1	O(C(C)C)c1cc2OC=C(c3ccccc3)C(=O)c2cc1
NCGC00483169-01	O(C(C)C)c1ccc(-c2c(CN(CCN)C)c[nH]c2)cc1		Inactive			1	MS023		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C)C)c1ccc(-c2c(CN(CCN)C)c[nH]c2)cc1	O(C(C)C)c1ccc(-c2c(CN(CCN)C)c[nH]c2)cc1
NCGC00371039-08	O(C(C)C)c1ccc(C2=Cn3ncc(-c4c5c(ncc4)cccc5)c3N=C2)cc1		Inactive	Activin receptor type-1 Inhibitor		1	DMH1	363678003.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C)C)c1ccc(C2=Cn3ncc(-c4c5c(ncc4)cccc5)c3N=C2)cc1	O(C(C)C)c1ccc(C2=Cn3ncc(-c4c5c(ncc4)cccc5)c3N=C2)cc1
NCGC00384553-01	O(C(C)C1C2(C)C(O)(C3C(C4(C)C(=CC3)CC(OC3OC(C)C(OC5C(O)C(OC)C(O)C(C)O5)C(OC)C3)CC4)CC2)CC1)C1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384553-01	363679242.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C)C1C2(C)C(O)(C3C(C4(C)C(=CC3)CC(OC3OC(C)C(OC5C(O)C(OC)C(O)C(C)O5)C(OC)C3)CC4)CC2)CC1)C1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1	O(C(C)C1C2(C)C(O)(C3C(C4(C)C(=CC3)CC(OC3OC(C)C(OC5C(O)C(OC)C(O)C(C)O5)C(OC)C3)CC4)CC2)CC1)C1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1
NCGC00384625-01	O(C(C=C)(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@](O)(CO)CO2)O1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384625-01	363679281.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C=C)(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@](O)(CO)CO2)O1	O(C(C=C)(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@](O)(CO)CO2)O1
NCGC00385840-01	O(C(C=C)(CCC=C(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385840-01	363679962.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(C=C)(CCC=C(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C(C=C)(CCC=C(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00384741-01	O(C(CCC1=C(C)C(=O)CCC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384741-01	363679335.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(CCC1=C(C)C(=O)CCC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C(CCC1=C(C)C(=O)CCC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385377-01	O(C(CCC1C(C)=CC(=O)CC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Juniperus | Family: Cupressaceae | Species: communis		1	NCGC00385377-01	363679710.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(CCC1C(C)=CC(=O)CC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C(CCC1C(C)=CC(=O)CC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00380271-01	O(C(CCC1C(C)=CC(=O)CC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380271-01	363678520.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(CCC1C(C)=CC(=O)CC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)O1	O(C(CCC1C(C)=CC(=O)CC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)O1
NCGC00385079-01	O(C(CCC=1C(C)(C)CC(O)CC=1C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385079-01	363679521.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(CCC=1C(C)(C)CC(O)CC=1C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C(CCC=1C(C)(C)CC(O)CC=1C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00169037-02	O(C(CCCCc1ccc(O)cc1)CCc1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Betula | Family: Betulaceae | Species: sp.		1	NCGC00169037-02	363676751.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(CCCCc1ccc(O)cc1)CCc1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C(CCCCc1ccc(O)cc1)CCc1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00347403-02	O(C(CCCCc1ccc(O)cc1)CCc1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Betula | Family: Betulaceae | Species: sp.		1	NCGC00347403-02	363677592.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(CCCCc1ccc(O)cc1)CCc1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1	O(C(CCCCc1ccc(O)cc1)CCc1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1
NCGC00381053-01	O(C(CCCCc1ccc(O)cc1)CCc1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Schima | Family: Ternstroemiaceae | Species: wallichii		1	NCGC00381053-01	363678947.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(CCCCc1ccc(O)cc1)CCc1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)O1	O(C(CCCCc1ccc(O)cc1)CCc1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)O1
NCGC00169076-02	O(C(CCCCc1ccc(O)cc1)CCc1ccc(O)cc1)[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Betula | Family: Betulaceae | Species: sp.		1	NCGC00169076-02	363676762.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(CCCCc1ccc(O)cc1)CCc1ccc(O)cc1)[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1	O(C(CCCCc1ccc(O)cc1)CCc1ccc(O)cc1)[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1
NCGC00347400-02	O(C(CCCCc1ccc(O)cc1)CCc1ccc(O)cc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347400-02	363677591.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(CCCCc1ccc(O)cc1)CCc1ccc(O)cc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C(CCCCc1ccc(O)cc1)CCc1ccc(O)cc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00168965-02	O(C(CCc1ccc(O)cc1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Betula | Family: Betulaceae | Species: sp.		1	NCGC00168965-02	363676730.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(CCc1ccc(O)cc1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1	O(C(CCc1ccc(O)cc1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1
NCGC00380875-01	O(C(CCc1ccc(O)cc1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)C(CO)O2)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Betula | Family: Betulaceae | Species: sp.		1	NCGC00380875-01	363678827.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(CCc1ccc(O)cc1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)C(CO)O2)O1	O(C(CCc1ccc(O)cc1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)C(CO)O2)O1
NCGC00385923-01	O(C(CO)CC=1OC(/C=C/C=C/CC)(C)C(=O)C=1)C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385923-01	363680010.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(CO)CC=1OC(/C=C/C=C/CC)(C)C(=O)C=1)C	O(C(CO)CC=1OC(/C=C/C=C/CC)(C)C(=O)C=1)C
NCGC00015471-08&NCGC00015471-09	O(C(CO)CO)Cn1c2N=C(N)NC(=O)c2nc1		Inactive	DNA Polymerase Inhibitor		2	Ganciclovir	170464961.0&384567853.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O(C(CO)CO)Cn1c2N=C(N)NC(=O)c2nc1	O(C(CO)CO)Cn1c2N=C(N)NC(=O)c2nc1
NCGC00179274-03	O(C(COCc1ccccc1)[C@@H]1[C@H](OCc2ccccc2)[C@@H](O)[C@H](OCC)O1)Cc1ccccc1		Inactive			1	Tribenoside	170465999.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C(COCc1ccccc1)[C@@H]1[C@H](OCc2ccccc2)[C@@H](O)[C@H](OCC)O1)Cc1ccccc1	O(C(COCc1ccccc1)[C@@H]1[C@H](OCc2ccccc2)[C@@H](O)[C@H](OCC)O1)Cc1ccccc1
NCGC00164462-01	O(C(COc1ccc(Oc2ccccc2)cc1)C)c1ncccc1		Inactive	juvenile hormone metabolic process Modulator		1	Pyriproxyfen	26757881.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C(COc1ccc(Oc2ccccc2)cc1)C)c1ncccc1	O(C(COc1ccc(Oc2ccccc2)cc1)C)c1ncccc1
NCGC00385955-01	O(C(Cc1cc(OC)c(OC)cc1)C)c1c(OC)cc(CC=C)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385955-01	363680026.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(Cc1cc(OC)c(OC)cc1)C)c1c(OC)cc(CC=C)cc1	O(C(Cc1cc(OC)c(OC)cc1)C)c1c(OC)cc(CC=C)cc1
NCGC00380936-01	O(C(O)(CC(C)C)C1OC=2C(=O)NC(C)=CC=2O1)C		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380936-01	363678868.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(O)(CC(C)C)C1OC=2C(=O)NC(C)=CC=2O1)C	O(C(O)(CC(C)C)C1OC=2C(=O)NC(C)=CC=2O1)C
NCGC00015771-13	O(C(c1c(C)cccc1)c1ccccc1)CCN(C)C	5.5	Active	Muscarinic Antagonists	0.0	1	Orphenadrine dihydrogen citrate	170464910.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	32.062407504	O=C(O)C(O)(CC(=O)O)CC(=O)O.O(C(c1c(C)cccc1)c1ccccc1)CCN(C)C	O=C(O)C(O)(CC(=O)O)CC(=O)O.O(C(c1c(C)cccc1)c1ccccc1)CCN(C)C
NCGC00016395-06	O(C(c1ccccc1)c1ccccc1)C1CCN(C)CC1		Inactive	Histamine H1 receptor Agonist		1	Diphenylpyraline hydrochloride	170464816.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	24.457883372&20.642335764	O(C(c1ccccc1)c1ccccc1)C1CCN(C)CC1.Cl	O(C(c1ccccc1)c1ccccc1)C1CCN(C)CC1.Cl
NCGC00343938-06	O(C(c1ccccc1)c1ccccc1)C1CCN(CCCc2[nH]nnn2)CC1		Inactive	Hematopoietic prostaglandin D synthase Inhibitor		1	HQL-79	363677318.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C(c1ccccc1)c1ccccc1)C1CCN(CCCc2[nH]nnn2)CC1	O(C(c1ccccc1)c1ccccc1)C1CCN(CCCc2[nH]nnn2)CC1
NCGC00013495-15	O(C(c1ccccc1)c1ccccc1)C1C[C@@H]2N(C)[C@H](C1)CC2	5.007	Active	Dopamine transporter Inhibitor	0.0	1	Benztropine mesylate	405558618.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	64.6658972136	O(C(c1ccccc1)c1ccccc1)C1C[C@@H]2N(C)[C@H](C1)CC2	O(C(c1ccccc1)c1ccccc1)C1C[C@@H]2N(C)[C@H](C1)CC2
NCGC00370962-01	O(C(c1ccccc1)c1ccccc1)CC1CCN(CCCc2ccc(OC)cc2)CC1	5.0	Active	Voltage-gated potassium channel subunit Kv1.4 Inhibitor	0.0	1	UK 78282 hydrochloride	363677959.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	80.1582857184	O(C(c1ccccc1)c1ccccc1)CC1CCN(CCCc2ccc(OC)cc2)CC1	O(C(c1ccccc1)c1ccccc1)CC1CCN(CCCc2ccc(OC)cc2)CC1
NCGC00181913-02	O(C(c1ccccc1)c1ccccc1)CCN(C(C(O)c1ccccc1)C)C	4.9000001	Active	Histamine H1 receptor Antagonist	0.0	1	Difeterol	144206884.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	127.9080902002	O(C(c1ccccc1)c1ccccc1)CCN(C(C(O)c1ccccc1)C)C	O(C(c1ccccc1)c1ccccc1)CCN(C(C(O)c1ccccc1)C)C
NCGC00015335-11	O(C(c1ccccc1)c1ccccc1)CCN(C)C		Inactive	Histamine H1 Receptor Antagonist		1	Diphenhydramine hydrochloride	124879863.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C(c1ccccc1)c1ccccc1)CCN(C)C	O(C(c1ccccc1)c1ccccc1)CCN(C)C
NCGC00381396-01	O(C)C1(CC(C)C)C(=O)NC(O)(Cc2ccccc2)C(=O)N1		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381396-01	363679125.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)C1(CC(C)C)C(=O)NC(O)(Cc2ccccc2)C(=O)N1	O(C)C1(CC(C)C)C(=O)NC(O)(Cc2ccccc2)C(=O)N1
NCGC00522025-01	O(C)C1(O[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)[C@H](C[C@@H]6S[C@@H]6C5)CC4)CC3)CC2)CCCC1		Inactive	Estrogen receptor Antagonist		1	Mepitiostane (Contains ~15% 3a,4a-Epithio isomer)	405558928.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)C1(O[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)[C@H](C[C@@H]6S[C@@H]6C5)CC4)CC3)CC2)CCCC1	O(C)C1(O[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)[C@H](C[C@@H]6S[C@@H]6C5)CC4)CC3)CC2)CCCC1
NCGC00481572-02	O(C)C1(c2c(C)c3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)COC1		Inactive	mTOR Inhibitor		1	GNE-317	377020298.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)C1(c2c(C)c3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)COC1	O(C)C1(c2c(C)c3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)COC1
NCGC00381385-01	O(C)C12OC(=O)C(C)=C1CC1C(=C)C(O)CCC1(C)C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381385-01	363679117.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	12.001430612	O(C)C12OC(=O)C(C)=C1CC1C(=C)C(O)CCC1(C)C2	O(C)C12OC(=O)C(C)=C1CC1C(=C)C(O)CCC1(C)C2
NCGC00385880-01	O(C)C12OC(=O)C(C)=C1CC1C(=C)CCCC1(C)C2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385880-01	363679987.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)C12OC(=O)C(C)=C1CC1C(=C)CCCC1(C)C2	O(C)C12OC(=O)C(C)=C1CC1C(=C)CCCC1(C)C2
NCGC00016487-05	O(C)C1=C(C#N)C(=O)N(C)C=C1		Inactive			1	Ricinine	124882317.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)C1=C(C#N)C(=O)N(C)C=C1	O(C)C1=C(C#N)C(=O)N(C)C=C1
NCGC00091905-05	O(C)C1=CC(=O)O[C@@H](/C=C/c2ccccc2)C1		Inactive	Voltage-gated L-type calcium channel Inhibitor		1	Kavain, DL-	363676553.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)C1=CC(=O)O[C@@H](/C=C/c2ccccc2)C1	O(C)C1=CC(=O)O[C@@H](/C=C/c2ccccc2)C1
NCGC00169002-05	O(C)C1=CC(=O)O[C@@H](CCc2ccccc2)C1		Inactive	<MOA Unknown> | Class: Polyketide/Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169002-05	363676738.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)C1=CC(=O)O[C@@H](CCc2ccccc2)C1	O(C)C1=CC(=O)O[C@@H](CCc2ccccc2)C1
NCGC00380446-01	O(C)C1=CC=2C(=O)N3C(C)C(=O)NC(O)(C(C)C)C3=NC=2OC=C1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380446-01	363678587.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)C1=CC=2C(=O)N3C(C)C(=O)NC(O)(C(C)C)C3=NC=2OC=C1	O(C)C1=CC=2C(=O)N3C(C)C(=O)NC(O)(C(C)C)C3=NC=2OC=C1
NCGC00347503-03	O(C)C1C(O)(CCC2(C)C(C)CCC3(C)C4(C(O)C(O)CC23)OC4)C(O)C(OC)O1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Cornutia | Family: Verbenaceae | Species: pyramidata		1	NCGC00347503-03	363677606.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)C1C(O)(CCC2(C)C(C)CCC3(C)C4(C(O)C(O)CC23)OC4)C(O)C(OC)O1	O(C)C1C(O)(CCC2(C)C(C)CCC3(C)C4(C(O)C(O)CC23)OC4)C(O)C(OC)O1
NCGC00381293-01	O(C)C1C(OC2C(O)C(O)C(O)C(CO)O2)C(C)OC(OC2C(C)OC(OC3C(C)OC(OC4C(C)OC(O[C@@H]5CC=6[C@@](C)(C7[C@H](O)[C@@H](O)[C@]8(C)[C@@H]([C@@H](O)C)CC[C@]8(O)[C@]7(O)CC=6)CC5)CC4OC)CC3OC)CC2OC)C1O		Inactive	<MOA Unknown> | Class: Steroid | Genus: Cionura | Family: Asclepiadaceae | Species: erecta		1	NCGC00381293-01	363679072.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)C1C(OC2C(O)C(O)C(O)C(CO)O2)C(C)OC(OC2C(C)OC(OC3C(C)OC(OC4C(C)OC(O[C@@H]5CC=6[C@@](C)(C7[C@H](O)[C@@H](O)[C@]8(C)[C@@H]([C@@H](O)C)CC[C@]8(O)[C@]7(O)CC=6)CC5)CC4OC)CC3OC)CC2OC)C1O	O(C)C1C(OC2C(O)C(O)C(O)C(CO)O2)C(C)OC(OC2C(C)OC(OC3C(C)OC(OC4C(C)OC(O[C@@H]5CC=6[C@@](C)(C7[C@H](O)[C@@H](O)[C@]8(C)[C@@H]([C@@H](O)C)CC[C@]8(O)[C@]7(O)CC=6)CC5)CC4OC)CC3OC)CC2OC)C1O
NCGC00380325-01	O(C)C1C=C(C)C(O)(CO)C2(C)C1C(C)(C)CCC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380325-01	363678543.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)C1C=C(C)C(O)(CO)C2(C)C1C(C)(C)CCC2	O(C)C1C=C(C)C(O)(CO)C2(C)C1C(C)(C)CCC2
NCGC00385876-01	O(C)C1C=CC23C(O)(OCc4c2cc2OCOc2c4)CN(C)C3C1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385876-01	363679984.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)C1C=CC23C(O)(OCc4c2cc2OCOc2c4)CN(C)C3C1	O(C)C1C=CC23C(O)(OCc4c2cc2OCOc2c4)CN(C)C3C1
NCGC00507869-01	O(C)C1CCC2([C@@]3(N=C(N)C(C)=N3)c3c(ccc(-c4cc(C#CC)cnc4)c3)C2)CC1		Inactive	beta-Secretase Inhibitor		1	LY-3314814	384569343.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(C)C1CCC2([C@@]3(N=C(N)C(C)=N3)c3c(ccc(-c4cc(C#CC)cnc4)c3)C2)CC1	O(C)C1CCC2([C@@]3(N=C(N)C(C)=N3)c3c(ccc(-c4cc(C#CC)cnc4)c3)C2)CC1
NCGC00181009-02	O(C)C1C[N+](C)(C)C/C(=C(/c2sccc2)\c2sccc2)/C1		Inactive	Muscarinic acetylcholine receptor M5 Antagonist		1	Timepidium bromide	170465823.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)C1C[N+](C)(C)C/C(=C(/c2sccc2)\c2sccc2)/C1.[Br-]	O(C)C1C[N+](C)(C)C/C(=C(/c2sccc2)\c2sccc2)/C1.[Br-]
NCGC00482578-01	O(C)C1[C@@H](O)[C@@H](O)C(O)[C@H](O)[C@H]1O		Inactive			1	D-Pinitol		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)C1[C@@H](O)[C@@H](O)C(O)[C@H](O)[C@H]1O	O(C)C1[C@@H](O)[C@@H](O)C(O)[C@H](O)[C@H]1O
NCGC00159429-03&NCGC00159429-14	O(C)C=1C(=O)C(C/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)\C)\C)\C)\C)\C)\C)=C(C)C(=O)C=1OC		Inactive	mitochondrial electron transport		2	Coenzyme Q10&UBIDECARENONE [5mM]	225144226.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O(C)C=1C(=O)C(C/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)\C)\C)\C)\C)\C)\C)=C(C)C(=O)C=1OC	O(C)C=1C(=O)C(C/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)\C)\C)\C)\C)\C)\C)=C(C)C(=O)C=1OC
NCGC00160514-02&NCGC00160514-14	O(C)C=1C(=O)C(CCCCCCCCCCO)=C(C)C(=O)C=1OC		Inactive	Free Radical Scavenger		2	Idebenone	170465611.0&384568196.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O(C)C=1C(=O)C(CCCCCCCCCCO)=C(C)C(=O)C=1OC	O(C)C=1C(=O)C(CCCCCCCCCCO)=C(C)C(=O)C=1OC
NCGC00169621-02	O(C)C=1[C@@H](O)[C@H](/C=C/c2ccccc2)OC(=O)C=1		Inactive	<MOA Unknown> | Class: Polyketide/Shikimate | Genus: Piper | Family: N/A | Species: methysticum		1	NCGC00169621-02	363676850.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)C=1[C@@H](O)[C@H](/C=C/c2ccccc2)OC(=O)C=1	O(C)C=1[C@@H](O)[C@H](/C=C/c2ccccc2)OC(=O)C=1
NCGC00169781-02	O(C)C=1[C@@H](O)[C@H](CCc2ccccc2)OC(=O)C=1		Inactive	<MOA Unknown> | Class: Polyketide/Shikimate | Genus: Piper  | Family: N/A | Species: methysticum		1	NCGC00169781-02	363676885.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)C=1[C@@H](O)[C@H](CCc2ccccc2)OC(=O)C=1	O(C)C=1[C@@H](O)[C@H](CCc2ccccc2)OC(=O)C=1
NCGC00160146-02	O(C)C=1[C@@H](O)[C@H]2c3c(cc4OCOc4c3)CCN3[C@]2(C=1)CCC3		Inactive			1	Cephalotaxlen	434146899.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)C=1[C@@H](O)[C@H]2c3c(cc4OCOc4c3)CCN3[C@]2(C=1)CCC3	O(C)C=1[C@@H](O)[C@H]2c3c(cc4OCOc4c3)CCN3[C@]2(C=1)CCC3
NCGC00380935-01	O(C)N1c2c(C3(C(C=C)(C)C)C41N(C(=O)C(O)=C3)/C(=C\c1[nH]cnc1)/C(=O)N4)cccc2		Inactive	Bacterial enoyl-[acyl-carrier-protein] reductase Inhibitor		1	NCGC00380935-01	363678867.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)N1c2c(C3(C(C=C)(C)C)C41N(C(=O)C(O)=C3)/C(=C\c1[nH]cnc1)/C(=O)N4)cccc2	O(C)N1c2c(C3(C(C=C)(C)C)C41N(C(=O)C(O)=C3)/C(=C\c1[nH]cnc1)/C(=O)N4)cccc2
NCGC00380951-01	O(C)N1c2c(C3(C(C=C)(C)C)C41N(C(=O)C(OC)=C3)C(C(C)C)C(=O)N4)cccc2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380951-01	363678880.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)N1c2c(C3(C(C=C)(C)C)C41N(C(=O)C(OC)=C3)C(C(C)C)C(=O)N4)cccc2	O(C)N1c2c(C3(C(C=C)(C)C)C41N(C(=O)C(OC)=C3)C(C(C)C)C(=O)N4)cccc2
NCGC00168746-02	O(C)[C@@H]1[C@@H](C)OC(OC2[C@@H](C)OC(OC3[C@@H](C)O[C@@H](OC4CC5[C@@](C)(C6C(C7(O)[C@@](C)([C@H](C8=CC(=O)OC8)CC7)C(O)C6)CC5)CC4)C[C@@H]3O)C[C@@H]2O)C[C@@H]1O		Inactive			1	Methyldigoxin	99455400.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)[C@@H]1[C@@H](C)OC(OC2[C@@H](C)OC(OC3[C@@H](C)O[C@@H](OC4CC5[C@@](C)(C6C(C7(O)[C@@](C)([C@H](C8=CC(=O)OC8)CC7)C(O)C6)CC5)CC4)C[C@@H]3O)C[C@@H]2O)C[C@@H]1O	O(C)[C@@H]1[C@@H](C)OC(OC2[C@@H](C)OC(OC3[C@@H](C)O[C@@H](OC4CC5[C@@](C)(C6C(C7(O)[C@@](C)([C@H](C8=CC(=O)OC8)CC7)C(O)C6)CC5)CC4)C[C@@H]3O)C[C@@H]2O)C[C@@H]1O
NCGC00381292-01	O(C)[C@@H]1[C@@H](OC2C(O)C(O)C(OC3C(O)C(O)C(O)C(CO)O3)C(CO)O2)[C@H](C)O[C@@H](O[C@@H]2CC3[C@@](C)(C4C(C5(O)[C@@]6(C(C7(OC6)CC(=O)OC7)CC5)CC4)CC3)CC2)[C@@H]1O		Inactive	<MOA Unknown> | Class: Steroid | Genus: Thevetia | Family: Apocynaceae | Species: plumeriaefolia		1	NCGC00381292-01	363679071.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)[C@@H]1[C@@H](OC2C(O)C(O)C(OC3C(O)C(O)C(O)C(CO)O3)C(CO)O2)[C@H](C)O[C@@H](O[C@@H]2CC3[C@@](C)(C4C(C5(O)[C@@]6(C(C7(OC6)CC(=O)OC7)CC5)CC4)CC3)CC2)[C@@H]1O	O(C)[C@@H]1[C@@H](OC2C(O)C(O)C(OC3C(O)C(O)C(O)C(CO)O3)C(CO)O2)[C@H](C)O[C@@H](O[C@@H]2CC3[C@@](C)(C4C(C5(O)[C@@]6(C(C7(OC6)CC(=O)OC7)CC5)CC4)CC3)CC2)[C@@H]1O
NCGC00094047-10&NCGC00094047-16	O(C)[C@@H]1[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](OC)C2)[C@H](C)O[C@@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H]([C@H](O)C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@H]([C@@H](CC)C)[C@@H](C)CC5)O[C@@H](C4)C/C=C/2\C)OC/3)C1		Inactive	Glutamate-gated Chloride Channel Activator		2	Ivermectin	405558905.0&434147263.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0	0.0&-6.657556704	O(C)[C@@H]1[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](OC)C2)[C@H](C)O[C@@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H]([C@H](O)C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@H]([C@@H](CC)C)[C@@H](C)CC5)O[C@@H](C4)C/C=C/2\C)OC/3)C1	O(C)[C@@H]1[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](OC)C2)[C@H](C)O[C@@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H]([C@H](O)C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@H]([C@@H](CC)C)[C@@H](C)CC5)O[C@@H](C4)C/C=C/2\C)OC/3)C1
NCGC00168290-05	O(C)[C@@H]1[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](OC)C2)[C@H](C)O[C@@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H]([C@H](O)C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@H]([C@H](CC)C)[C@@H](C)C=C5)O[C@@H](C4)C/C=C/2\C)OC/3)C1		Inactive			1	Avermectin B1a	405558426.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	16.561696656	O(C)[C@@H]1[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](OC)C2)[C@H](C)O[C@@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H]([C@H](O)C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@H]([C@H](CC)C)[C@@H](C)C=C5)O[C@@H](C4)C/C=C/2\C)OC/3)C1	O(C)[C@@H]1[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](OC)C2)[C@H](C)O[C@@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H]([C@H](O)C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@H]([C@H](CC)C)[C@@H](C)C=C5)O[C@@H](C4)C/C=C/2\C)OC/3)C1
NCGC00164591-04&NCGC00164591-10	O(C)[C@@H]1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2		Inactive	antimalarial agents		2	Artemether	225144260.0&384568261.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(C)[C@@H]1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2	O(C)[C@@H]1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2
NCGC00162400-09	O(C)[C@@H]1[C@H](NC)C[C@H]2O[C@]1(C)n1c3c4n2c2c(c4c4C(=O)NCc4c3c3c1cccc3)cccc2		Inactive	CDK1/2 Inhibitor		1	Staurosporine	363676610.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)[C@@H]1[C@H](NC)C[C@H]2O[C@]1(C)n1c3c4n2c2c(c4c4C(=O)NCc4c3c3c1cccc3)cccc2	O(C)[C@@H]1[C@H](NC)C[C@H]2O[C@]1(C)n1c3c4n2c2c(c4c4C(=O)NCc4c3c3c1cccc3)cccc2
NCGC00346827-02	O(C)[C@@H]1[C@H](NC)C[C@H]2O[C@]1(C)n1c3c4n2c2c(c4c4C(=O)N[C@@H](O)c4c3c3c1cccc3)cccc2		Inactive	CDK1/2/4/6		1	7-Hydroxystaurosporine	377020326.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O(C)[C@@H]1[C@H](NC)C[C@H]2O[C@]1(C)n1c3c4n2c2c(c4c4C(=O)N[C@@H](O)c4c3c3c1cccc3)cccc2	O(C)[C@@H]1[C@H](NC)C[C@H]2O[C@]1(C)n1c3c4n2c2c(c4c4C(=O)N[C@@H](O)c4c3c3c1cccc3)cccc2
NCGC00386351-01	O(C)[C@@H]1[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C[C@@H]([C@@H](C[C@H]2C[C@@H](OC)[C@@H](n3nnnc3)CC2)C)OC(=O)[C@H]2N(C(=O)C(=O)[C@@]3(O)[C@H](C)CC[C@H](O3)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C1=O)CCCC2		Inactive	smooth muscle cell proliferation Inhibitor		1	Zotarolimus(ABT-578)	363680230.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)[C@@H]1[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C[C@@H]([C@@H](C[C@H]2C[C@@H](OC)[C@@H](n3nnnc3)CC2)C)OC(=O)[C@H]2N(C(=O)C(=O)[C@@]3(O)[C@H](C)CC[C@H](O3)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C1=O)CCCC2	O(C)[C@@H]1[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C[C@@H]([C@@H](C[C@H]2C[C@@H](OC)[C@@H](n3nnnc3)CC2)C)OC(=O)[C@H]2N(C(=O)C(=O)[C@@]3(O)[C@H](C)CC[C@H](O3)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C1=O)CCCC2
NCGC00021305-08&NCGC00021305-19&NCGC00021305-27	O(C)[C@@H]1[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C[C@@H]([C@H](C[C@H]2C[C@@H](OC)[C@H](O)CC2)C)OC(=O)[C@H]2N(C(=O)C(=O)[C@@]3(O)[C@H](C)CC[C@H](O3)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C1=O)CCCC2		Inactive	mTOR Inhibitor		3	Sirolimus	124886756.0&405558660.0&434146972.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O(C)[C@@H]1[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C[C@@H]([C@H](C[C@H]2C[C@@H](OC)[C@H](O)CC2)C)OC(=O)[C@H]2N(C(=O)C(=O)[C@@]3(O)[C@H](C)CC[C@H](O3)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C1=O)CCCC2	O(C)[C@@H]1[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C[C@@H]([C@H](C[C@H]2C[C@@H](OC)[C@H](O)CC2)C)OC(=O)[C@H]2N(C(=O)C(=O)[C@@]3(O)[C@H](C)CC[C@H](O3)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C1=O)CCCC2
NCGC00385794-01	O(C)[C@@H]1[C@H](O)[C@@H](C)O[C@@H](O[C@@H]2C[C@]3(O)[C@@](CO)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385794-01	363679941.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)[C@@H]1[C@H](O)[C@@H](C)O[C@@H](O[C@@H]2C[C@]3(O)[C@@](CO)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C1	O(C)[C@@H]1[C@H](O)[C@@H](C)O[C@@H](O[C@@H]2C[C@]3(O)[C@@](CO)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C1
NCGC00385673-01	O(C)[C@@H]1[C@H](O)[C@@H](O[C@H]2C[C@@H](O)[C@@]3(C)[C@@H](C2)CC[C@H]2[C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CCC32)O[C@H](C)[C@@H]1O		Inactive	<MOA Unknown> | Class: Steroid | Genus: Acocanthera | Family: Apocynaceae | Species: schimperii		1	NCGC00385673-01	363679867.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)[C@@H]1[C@H](O)[C@@H](O[C@H]2C[C@@H](O)[C@@]3(C)[C@@H](C2)CC[C@H]2[C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CCC32)O[C@H](C)[C@@H]1O	O(C)[C@@H]1[C@H](O)[C@@H](O[C@H]2C[C@@H](O)[C@@]3(C)[C@@H](C2)CC[C@H]2[C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CCC32)O[C@H](C)[C@@H]1O
NCGC00261966-01	O(C)[C@@H]1[C@H](O)[C@H](C)O[C@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@@]4(O)[C@H](C(=O)O[C@@H]5C[C@@]6(O[C@@H]([C@@H](C)CC6)C6CCCCC6)O[C@@H](C5)C/C=C/2\C)C=C(C)C[C@H]4OC/3)C1		Inactive			1	NCGC00261966-01	405558496.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	10.6350806439	O(C)[C@@H]1[C@H](O)[C@H](C)O[C@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@@]4(O)[C@H](C(=O)O[C@@H]5C[C@@]6(O[C@@H]([C@@H](C)CC6)C6CCCCC6)O[C@@H](C5)C/C=C/2\C)C=C(C)C[C@H]4OC/3)C1	O(C)[C@@H]1[C@H](O)[C@H](C)O[C@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@@]4(O)[C@H](C(=O)O[C@@H]5C[C@@]6(O[C@@H]([C@@H](C)CC6)C6CCCCC6)O[C@@H](C5)C/C=C/2\C)C=C(C)C[C@H]4OC/3)C1
NCGC00263875-02	O(C)[C@@H]1[C@H](O)[C@H](C)O[C@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H](/C(=N\O)/C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@@H]([C@@H](C)CC5)C5CCCCC5)O[C@@H](C4)C/C=C/2\C)OC/3)C1		Inactive			1	SELAMECTIN	405558820.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)[C@@H]1[C@H](O)[C@H](C)O[C@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H](/C(=N\O)/C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@@H]([C@@H](C)CC5)C5CCCCC5)O[C@@H](C4)C/C=C/2\C)OC/3)C1	O(C)[C@@H]1[C@H](O)[C@H](C)O[C@H](O[C@H]\2[C@@H](C)/C=C/C=C\3/[C@]4(O)[C@@H](/C(=N\O)/C(C)=C[C@H]4C(=O)O[C@@H]4C[C@@]5(O[C@@H]([C@@H](C)CC5)C5CCCCC5)O[C@@H](C4)C/C=C/2\C)OC/3)C1
NCGC00180203-02	O(C)[C@@H]1[C@H]2OC(=O)[C@@]3(c4c(O)c(O)c(C(C)C)cc14)C2C(C)(C)CCC3		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Rosmarinum | Family: Lamiaceae | Species: officinalis		1	NCGC00180203-02	363677004.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)[C@@H]1[C@H]2OC(=O)[C@@]3(c4c(O)c(O)c(C(C)C)cc14)C2C(C)(C)CCC3	O(C)[C@@H]1[C@H]2OC(=O)[C@@]3(c4c(O)c(O)c(C(C)C)cc14)C2C(C)(C)CCC3
NCGC00380984-01	O(C)[C@@H]1[C@]2(O)C(=O)N3C(C(=O)N2[C@]24[C@H](CO)C(C)(C)N2c2c([C@]14O)cccc2)=Cc1c2c([nH]c1C(C)(C)C=C3)cccc2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380984-01	363678903.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)[C@@H]1[C@]2(O)C(=O)N3C(C(=O)N2[C@]24[C@H](CO)C(C)(C)N2c2c([C@]14O)cccc2)=Cc1c2c([nH]c1C(C)(C)C=C3)cccc2	O(C)[C@@H]1[C@]2(O)C(=O)N3C(C(=O)N2[C@]24[C@H](CO)C(C)(C)N2c2c([C@]14O)cccc2)=Cc1c2c([nH]c1C(C)(C)C=C3)cccc2
NCGC00385282-01	O(C)[C@@H]\1/C(/C)=C/CC[C@H](C)[C@@H](C)OC(=O)/C=C/[C@@](O)(C)/C=C/1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385282-01	363679641.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)[C@@H]\1/C(/C)=C/CC[C@H](C)[C@@H](C)OC(=O)/C=C/[C@@](O)(C)/C=C/1	O(C)[C@@H]\1/C(/C)=C/CC[C@H](C)[C@@H](C)OC(=O)/C=C/[C@@](O)(C)/C=C/1
NCGC00162409-08&NCGC00162409-10	O(C)[C@@H]\1[C@@H]([C@H]([C@@H](O)[C@H](C)[C@]2(O)O[C@H](C(C)C)[C@@H](C)[C@H](O)C2)C)OC(=O)/C(/OC)=C\C(\C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C/C(/C)=C\C=C/1		Inactive	Vacuolar H+ ATPase (V-ATPase) Inhibitor		2	Bafilomycin A1&Bafilomycin A1 from Streptomyces griseus	384568225.0&406861845.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O(C)[C@@H]\1[C@@H]([C@H]([C@@H](O)[C@H](C)[C@]2(O)O[C@H](C(C)C)[C@@H](C)[C@H](O)C2)C)OC(=O)/C(/OC)=C\C(\C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C/C(/C)=C\C=C/1	O(C)[C@@H]\1[C@@H]([C@H]([C@@H](O)[C@H](C)[C@]2(O)O[C@H](C(C)C)[C@@H](C)[C@H](O)C2)C)OC(=O)/C(/OC)=C\C(\C)=C/[C@@H](C)[C@@H](O)[C@@H](C)C/C(/C)=C\C=C/1
NCGC00485043-01	O(C)[C@@]1(C)[C@@H](O)[C@H](C)OC(O[C@H]2[C@H](C)[C@@H](OC3[C@H](O)[C@@H](NC)C[C@@H](C)O3)[C@@](O)(C)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@@](O)(C)[C@@H](CC)OC(=O)[C@@H]2C)C1		Inactive			1	CP-64434 hydrate	363681202.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)[C@@]1(C)[C@@H](O)[C@H](C)OC(O[C@H]2[C@H](C)[C@@H](OC3[C@H](O)[C@@H](NC)C[C@@H](C)O3)[C@@](O)(C)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@@](O)(C)[C@@H](CC)OC(=O)[C@@H]2C)C1	O(C)[C@@]1(C)[C@@H](O)[C@H](C)OC(O[C@H]2[C@H](C)[C@@H](OC3[C@H](O)[C@@H](NC)C[C@@H](C)O3)[C@@](O)(C)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@@](O)(C)[C@@H](CC)OC(=O)[C@@H]2C)C1
NCGC00389499-01	O(C)[C@@]1(C)[C@H](OC2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@H](C)C(=O)[C@@H](C)C(=O)OC(CC)[C@@]2(C)OC(=O)N(CCCCn3cc(-c4cnccc4)nc3)[C@H]2[C@H](C)C(=O)[C@H](C)C1		Inactive	Ketolide antibiotic		1	TELITHROMYCIN	405558900.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)[C@@]1(C)[C@H](OC2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@H](C)C(=O)[C@@H](C)C(=O)OC(CC)[C@@]2(C)OC(=O)N(CCCCn3cc(-c4cnccc4)nc3)[C@H]2[C@H](C)C(=O)[C@H](C)C1	O(C)[C@@]1(C)[C@H](OC2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@H](C)C(=O)[C@@H](C)C(=O)OC(CC)[C@@]2(C)OC(=O)N(CCCCn3cc(-c4cnccc4)nc3)[C@H]2[C@H](C)C(=O)[C@H](C)C1
NCGC00347709-02	O(C)[C@@]12[C@H](C)[C@@H](c3cc4OCOc4cc3)O[C@]1(OC)CC(=O)C(CC=C)=C2		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347709-02	363677670.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)[C@@]12[C@H](C)[C@@H](c3cc4OCOc4cc3)O[C@]1(OC)CC(=O)C(CC=C)=C2	O(C)[C@@]12[C@H](C)[C@@H](c3cc4OCOc4cc3)O[C@]1(OC)CC(=O)C(CC=C)=C2
NCGC00169274-03	O(C)[C@H]1C(=O)C(OC)=C2[C@@](CC=C)([C@@H](C)[C@H](c3cc(OC)c4OCOc4c3)O2)C1		Inactive	<MOA Unknown> | Class: lignan | Genus: Nectandra | Family: Lauraceae | Species: sinuata		1	NCGC00169274-03	363676797.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)[C@H]1C(=O)C(OC)=C2[C@@](CC=C)([C@@H](C)[C@H](c3cc(OC)c4OCOc4c3)O2)C1	O(C)[C@H]1C(=O)C(OC)=C2[C@@](CC=C)([C@@H](C)[C@H](c3cc(OC)c4OCOc4c3)O2)C1
NCGC00381186-01	O(C)[C@H]1C(=O)Nc2c([C@]1(O)c1ccc(OC)cc1)c1OC(CCC=C(C)C)(C)C=Cc1cc2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381186-01	363679013.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)[C@H]1C(=O)Nc2c([C@]1(O)c1ccc(OC)cc1)c1OC(CCC=C(C)C)(C)C=Cc1cc2	O(C)[C@H]1C(=O)Nc2c([C@]1(O)c1ccc(OC)cc1)c1OC(CCC=C(C)C)(C)C=Cc1cc2
NCGC00169912-03	O(C)[C@H]1C(=O)Nc2c(c(O)c(CC=C(C)C)cc2)[C@]1(O)c1ccc(OC)cc1		Inactive	<MOA Unknown> | Class: polyketide/shikimi; Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169912-03	363676910.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)[C@H]1C(=O)Nc2c(c(O)c(CC=C(C)C)cc2)[C@]1(O)c1ccc(OC)cc1	O(C)[C@H]1C(=O)Nc2c(c(O)c(CC=C(C)C)cc2)[C@]1(O)c1ccc(OC)cc1
NCGC00510497-01&NCGC00510497-02	O(C)[C@H]1[C@@H](C[C@H](O)CN)O[C@@H]2[C@@H]1CC(=O)C[C@@H]1O[C@@H]3[C@@H]4O[C@@]5(O[C@@H]6[C@H](O[C@H]3CC1)[C@H]4O[C@@H]6C5)CC[C@@H]1O[C@H](C(=C)C1)CC[C@@H]1O[C@@H](C(=C)[C@H](C)C1)C2		Inactive	Tubulin Polymerization Inhibitor		2	Eribulin mesylate	384569459.0&405558688.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(C)[C@H]1[C@@H](C[C@H](O)CN)O[C@@H]2[C@@H]1CC(=O)C[C@@H]1O[C@@H]3[C@@H]4O[C@@]5(O[C@@H]6[C@H](O[C@H]3CC1)[C@H]4O[C@@H]6C5)CC[C@@H]1O[C@H](C(=C)C1)CC[C@@H]1O[C@@H](C(=C)[C@H](C)C1)C2	O(C)[C@H]1[C@@H](C[C@H](O)CN)O[C@@H]2[C@@H]1CC(=O)C[C@@H]1O[C@@H]3[C@@H]4O[C@@]5(O[C@@H]6[C@H](O[C@H]3CC1)[C@H]4O[C@@H]6C5)CC[C@@H]1O[C@H](C(=C)C1)CC[C@@H]1O[C@@H](C(=C)[C@H](C)C1)C2
NCGC00180686-03	O(C)[C@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](C)O[C@H](O[C@H]2C[C@@H](O)[C@@]3(C)[C@@H](C2)CC[C@H]2[C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CCC32)[C@H]1O		Inactive	<MOA Unknown> | Class: Steroid | Genus: Acocanthera | Family: Apocynaceae | Species: schimperii		1	NCGC00180686-03	363677048.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	-13.365800864	O(C)[C@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](C)O[C@H](O[C@H]2C[C@@H](O)[C@@]3(C)[C@@H](C2)CC[C@H]2[C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CCC32)[C@H]1O	O(C)[C@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](C)O[C@H](O[C@H]2C[C@@H](O)[C@@]3(C)[C@@H](C2)CC[C@H]2[C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CCC32)[C@H]1O
NCGC00163470-27&NCGC00163470-28	O(C)[C@H]1[C@H](O)CC[C@@H](/C=C(\C)/[C@@H]2[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(\C)/C[C@H](C)C[C@H](OC)[C@@H]3[C@@H](OC)C[C@@H](C)[C@](O)(C(=O)C(=O)N4[C@H](C(=O)O2)CCCC4)O3)C1		Inactive	mTOR Inhibitor		2	FK-506	405558441.0&384568242.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O(C)[C@H]1[C@H](O)CC[C@@H](/C=C(\C)/[C@@H]2[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(\C)/C[C@H](C)C[C@H](OC)[C@@H]3[C@@H](OC)C[C@@H](C)[C@](O)(C(=O)C(=O)N4[C@H](C(=O)O2)CCCC4)O3)C1	O(C)[C@H]1[C@H](O)CC[C@@H](/C=C(\C)/[C@@H]2[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(\C)/C[C@H](C)C[C@H](OC)[C@@H]3[C@@H](OC)C[C@@H](C)[C@](O)(C(=O)C(=O)N4[C@H](C(=O)O2)CCCC4)O3)C1
NCGC00180641-02	O(C)[C@H]1[C@H](O)[C@H](O[C@@H]2C[C@@H]3[C@@](C)(C4C([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)O[C@@H](C)[C@@H]1O		Inactive	Sodium/potassium-transporting ATPase Inhibitor		1	NCGC00180641-02	363677043.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)[C@H]1[C@H](O)[C@H](O[C@@H]2C[C@@H]3[C@@](C)(C4C([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)O[C@@H](C)[C@@H]1O	O(C)[C@H]1[C@H](O)[C@H](O[C@@H]2C[C@@H]3[C@@](C)(C4C([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)O[C@@H](C)[C@@H]1O
NCGC00380617-01	O(C)[C@H]1[C@H]([C@]2(C)[C@@H](CC=C(C)C)O2)C2(OC2)CC[C@H]1O		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Neosartorya | Family: N/A | Species: N/A		1	NCGC00380617-01	363678674.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)[C@H]1[C@H]([C@]2(C)[C@@H](CC=C(C)C)O2)C2(OC2)CC[C@H]1O	O(C)[C@H]1[C@H]([C@]2(C)[C@@H](CC=C(C)C)O2)C2(OC2)CC[C@H]1O
NCGC00510028-01	O(C)c1[n+](-c2ccccc2)ncc(N)c1		Inactive	Amine oxidase [flavin-containing] B Inhibitor		1	Amezinium methylsulfate	405559018.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1[n+](-c2ccccc2)ncc(N)c1	O(C)c1[n+](-c2ccccc2)ncc(N)c1
NCGC00344588-04&NCGC00344588-08	O(C)c1c(-c2c(C)onc2C)cc2ncc3NC(=O)N([C@H](C)c4ncccc4)c3c2c1		Inactive	Brd4 Inhibitor		2	I-BET151	434147199.0&363677337.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(C)c1c(-c2c(C)onc2C)cc2ncc3NC(=O)N([C@H](C)c4ncccc4)c3c2c1	O(C)c1c(-c2c(C)onc2C)cc2ncc3NC(=O)N([C@H](C)c4ncccc4)c3c2c1
NCGC00386064-01	O(C)c1c(-c2ccc(O)cc2)cc(OC)c2c1oc1c2cc(OC2C(O)C(O)C(CO)O2)c(O)c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386064-01	363680088.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(-c2ccc(O)cc2)cc(OC)c2c1oc1c2cc(OC2C(O)C(O)C(CO)O2)c(O)c1	O(C)c1c(-c2ccc(O)cc2)cc(OC)c2c1oc1c2cc(OC2C(O)C(O)C(CO)O2)c(O)c1
NCGC00378743-01	O(C)c1c(-n2cc(C)nc2)ccc(Nc2sc3c(C(c4ccccc4)CCC3)n2)c1		Inactive	Gamma-secretase Modulator		1	gamma-secretase modulator 1	363678179.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(-n2cc(C)nc2)ccc(Nc2sc3c(C(c4ccccc4)CCC3)n2)c1	O(C)c1c(-n2cc(C)nc2)ccc(Nc2sc3c(C(c4ccccc4)CCC3)n2)c1
NCGC00485035-01	O(C)c1c(/C=C/2\C(=O)Nc3c\2cccc3)c(OC)cc(OC)c1		Inactive			1	IC 261	377020484.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(/C=C/2\C(=O)Nc3c\2cccc3)c(OC)cc(OC)c1	O(C)c1c(/C=C/2\C(=O)Nc3c\2cccc3)c(OC)cc(OC)c1
NCGC00386098-01	O(C)c1c(/C=C/C(O)(C)C)ccc2Oc3c(O)cc(C)cc3COC(=O)c12		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386098-01	363680105.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(/C=C/C(O)(C)C)ccc2Oc3c(O)cc(C)cc3COC(=O)c12	O(C)c1c(/C=C/C(O)(C)C)ccc2Oc3c(O)cc(C)cc3COC(=O)c12
NCGC00387241-01	O(C)c1c(C#N)cc(OC)c(CCNCc2c(O)cccc2)c1		Inactive	Serotonin 2a (5-HT2a) receptor Agonist		1	NBOH-2C-CN hydrochloride	363680588.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(C#N)cc(OC)c(CCNCc2c(O)cccc2)c1	O(C)c1c(C#N)cc(OC)c(CCNCc2c(O)cccc2)c1
NCGC00385823-01	O(C)c1c(C(C)C)c(O)c(O)c2c1C(OC)[C@H]1OC(=O)[C@@]32[C@@H]1C(C)(C)CCC3		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385823-01	363679957.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(C(C)C)c(O)c(O)c2c1C(OC)[C@H]1OC(=O)[C@@]32[C@@H]1C(C)(C)CCC3	O(C)c1c(C(C)C)c(O)c(O)c2c1C(OC)[C@H]1OC(=O)[C@@]32[C@@H]1C(C)(C)CCC3
NCGC00015692-08	O(C)c1c(C(O)C(N)C)cc(OC)cc1		Inactive			1	Methoxamine hydrochloride	225144174.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(C)c1c(C(O)C(N)C)cc(OC)cc1	O(C)c1c(C(O)C(N)C)cc(OC)cc1
NCGC00169730-03	O(C)c1c(C(O)CC(C)C)ccc2Oc3c(O)cc(C)cc3COC(=O)c12		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169730-03	363676878.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(C(O)CC(C)C)ccc2Oc3c(O)cc(C)cc3COC(=O)c12	O(C)c1c(C(O)CC(C)C)ccc2Oc3c(O)cc(C)cc3COC(=O)c12
NCGC00386422-01	O(C)c1c(C2C(C#N)=C(N)Oc3[nH]nc(-c4cc5c(cc4)cccc5)c23)cc(OC)cc1		Inactive	Transcription factor p65 Inhibitor		1	RBC8	363680274.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(C2C(C#N)=C(N)Oc3[nH]nc(-c4cc5c(cc4)cccc5)c23)cc(OC)cc1	O(C)c1c(C2C(C#N)=C(N)Oc3[nH]nc(-c4cc5c(cc4)cccc5)c23)cc(OC)cc1
NCGC00159469-04	O(C)c1c(CC(NC)C)cccc1		Inactive	Adrenergic receptor beta Agonist		1	Methoxyphenamine	170465530.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(C)c1c(CC(NC)C)cccc1	O(C)c1c(CC(NC)C)cccc1
NCGC00385627-01	O(C)c1c(CC=C(C)C)c(OC)cc2OC[C@@H](c3c(O)c(CC=C(C)C)c(O)cc3)Cc12		Inactive	<MOA Unknown> | Class: Flavonoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385627-01	363679846.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(CC=C(C)C)c(OC)cc2OC[C@@H](c3c(O)c(CC=C(C)C)c(O)cc3)Cc12	O(C)c1c(CC=C(C)C)c(OC)cc2OC[C@@H](c3c(O)c(CC=C(C)C)c(O)cc3)Cc12
NCGC00247521-02	O(C)c1c(CC=C(C)C)c(OC)cc2OC[C@@H](c3c(O)cc(O)cc3)Cc12		Inactive	<MOA Unknown> | Class: Flavonoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00247521-02	363677160.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(CC=C(C)C)c(OC)cc2OC[C@@H](c3c(O)cc(O)cc3)Cc12	O(C)c1c(CC=C(C)C)c(OC)cc2OC[C@@H](c3c(O)cc(O)cc3)Cc12
NCGC00385808-01	O(C)c1c(CC=C(C)C)c(OC)cc2oc(-c3c(O)cc(O)cc3)cc12		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385808-01	363679950.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(CC=C(C)C)c(OC)cc2oc(-c3c(O)cc(O)cc3)cc12	O(C)c1c(CC=C(C)C)c(OC)cc2oc(-c3c(O)cc(O)cc3)cc12
NCGC00095694-06	O(C)c1c(CC=C(C)C)c2OC(=O)C=Cc2cc1		Inactive	GABAA Receptor Modulator		1	Ostol	434146888.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(CC=C(C)C)c2OC(=O)C=Cc2cc1	O(C)c1c(CC=C(C)C)c2OC(=O)C=Cc2cc1
NCGC00496840-01	O(C)c1c(CN(C)C)c(OC)cc(C=2c3c(C(=O)N(C)C=2)cncc3)c1		Inactive	Brd7 Inhibitor		1	BI-7273	384569294.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(CN(C)C)c(OC)cc(C=2c3c(C(=O)N(C)C=2)cncc3)c1	O(C)c1c(CN(C)C)c(OC)cc(C=2c3c(C(=O)N(C)C=2)cncc3)c1
NCGC00181097-01	O(C)c1c(CN(C)C)c2OC(c3ccccc3)=C(C)C(=O)c2cc1		Inactive			1	Dimefline hydrochloride	144206266.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(CN(C)C)c2OC(c3ccccc3)=C(C)C(=O)c2cc1.Cl	O(C)c1c(CN(C)C)c2OC(c3ccccc3)=C(C)C(=O)c2cc1.Cl
NCGC00481108-02	O(C)c1c(CN(C)C)cc(OC)c(C=2c3c(C(=O)N(C)C=2)cncc3)c1		Inactive	Brd9 Inhibitor		1	BI-9564	384569253.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(CN(C)C)cc(OC)c(C=2c3c(C(=O)N(C)C=2)cncc3)c1	O(C)c1c(CN(C)C)cc(OC)c(C=2c3c(C(=O)N(C)C=2)cncc3)c1
NCGC00390659-01	O(C)c1c(CNCC[C@]2(c3ncccc3)CC3(OCC2)CCCC3)scc1		Inactive	Mu opioid receptor Agonist		1	TRV130 (hydrochloride)	363680960.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(CNCC[C@]2(c3ncccc3)CC3(OCC2)CCCC3)scc1	O(C)c1c(CNCC[C@]2(c3ncccc3)CC3(OCC2)CCCC3)scc1
NCGC00390625-02	O(C)c1c(CN[C@@H]2[C@H](C(c3ccccc3)c3ccccc3)N3CCC2CC3)cc(C(C)(C)C)cc1	4.9499998	Active	Substance-P receptor Antagonist	0.0	1	Maropitant	405558794.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	109.181356726	O(C)c1c(CN[C@@H]2[C@H](C(c3ccccc3)c3ccccc3)N3CCC2CC3)cc(C(C)(C)C)cc1	O(C)c1c(CN[C@@H]2[C@H](C(c3ccccc3)c3ccccc3)N3CCC2CC3)cc(C(C)(C)C)cc1
NCGC00371069-01	O(C)c1c(CN[C@@H]2[C@H](C(c3ccccc3)c3ccccc3)N3CCC2CC3)cccc1		Inactive	Neurokinin 1 receptor Antagonist		1	CP 96345	363678014.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	30.0666666679	O(C)c1c(CN[C@@H]2[C@H](C(c3ccccc3)c3ccccc3)N3CCC2CC3)cccc1	O(C)c1c(CN[C@@H]2[C@H](C(c3ccccc3)c3ccccc3)N3CCC2CC3)cccc1
NCGC00370844-01	O(C)c1c(CN[C@@H]2[C@H](c3ccccc3)NCCC2)cccc1		Inactive	Neurokinin 1 receptor Antagonist		1	CP 99994 dihydrochloride	363677880.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(CN[C@@H]2[C@H](c3ccccc3)NCCC2)cccc1	O(C)c1c(CN[C@@H]2[C@H](c3ccccc3)NCCC2)cccc1
NCGC00250396-13	O(C)c1c(CO)cc(-c2nc3nc(N4C[C@@H](C)O[C@@H](C)C4)nc(N4CCOCC4)c3cc2)cc1		Inactive	mTORC1/2 Inhibitor		1	KU-0063794	384568545.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(CO)cc(-c2nc3nc(N4C[C@@H](C)O[C@@H](C)C4)nc(N4CCOCC4)c3cc2)cc1	O(C)c1c(CO)cc(-c2nc3nc(N4C[C@@H](C)O[C@@H](C)C4)nc(N4CCOCC4)c3cc2)cc1
NCGC00250405-15	O(C)c1c(CO)cc(-c2nc3nc(N4[C@@H](C)COCC4)nc(N4[C@@H](C)COCC4)c3cc2)cc1		Inactive	mTORC1/2 Inhibitor		1	AZD-8055	384568553.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(CO)cc(-c2nc3nc(N4[C@@H](C)COCC4)nc(N4[C@@H](C)COCC4)c3cc2)cc1	O(C)c1c(CO)cc(-c2nc3nc(N4[C@@H](C)COCC4)nc(N4[C@@H](C)COCC4)c3cc2)cc1
NCGC00015790-18	O(C)c1c(N)c(C=2Oc3c(C(=O)C=2)cccc3)ccc1		Inactive	Mek 2 inibitor		1	PD-098059	384567891.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(N)c(C=2Oc3c(C(=O)C=2)cccc3)ccc1	O(C)c1c(N)c(C=2Oc3c(C(=O)C=2)cccc3)ccc1
NCGC00386579-01	O(C)c1c(N)ccc(N2CCN(C)CC2)c1		Inactive			1	2-Methoxy-4-(4-methylpiperazin-1-yl)aniline dihydrochloride	363680338.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(N)ccc(N2CCN(C)CC2)c1	O(C)c1c(N)ccc(N2CCN(C)CC2)c1
NCGC00016066-14	O(C)c1c(N2CCN(CCCNC=3N(C)C(=O)N(C)C(=O)C=3)CC2)cccc1		Inactive	Adrenergic receptor alpha-1 Antagonist		1	Urapidil hydrochloride	170466013.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(C)c1c(N2CCN(CCCNC=3N(C)C(=O)N(C)C(=O)C=3)CC2)cccc1.Cl	O(C)c1c(N2CCN(CCCNC=3N(C)C(=O)N(C)C(=O)C=3)CC2)cccc1.Cl
NCGC00378986-01	O(C)c1c(N2CCN(CCN(CCC)C3Cc4scnc4CC3)CC2)cccc1		Inactive	Dopamine receptor Binding Agent		1	ST-836 hydrochloride	363678303.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(N2CCN(CCN(CCC)C3Cc4scnc4CC3)CC2)cccc1	O(C)c1c(N2CCN(CCN(CCC)C3Cc4scnc4CC3)CC2)cccc1
NCGC00015126-08	O(C)c1c(N2CCN(CCN3C(=O)CC4(CC3=O)CCCC4)CC2)cccc1		Inactive	Serotonin 1a (5-HT1a) receptor Partial Agonist		1	BMY 7378	363676441.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(N2CCN(CCN3C(=O)CC4(CC3=O)CCCC4)CC2)cccc1	O(C)c1c(N2CCN(CCN3C(=O)CC4(CC3=O)CCCC4)CC2)cccc1
NCGC00390638-01	O(C)c1c(Nc2nc(-c3c4c(n(C)c3)cccc4)ccn2)cc(N)c(N(CCN(C)C)C)c1	4.9000001	Active		0.0	1	Mutated EGFR-IN-1	363680943.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	104.1002911056	O(C)c1c(Nc2nc(-c3c4c(n(C)c3)cccc4)ccn2)cc(N)c(N(CCN(C)C)C)c1	O(C)c1c(Nc2nc(-c3c4c(n(C)c3)cccc4)ccn2)cc(N)c(N(CCN(C)C)C)c1
NCGC00389251-02	O(C)c1c(Nc2nc(-c3c4c(n(C)c3)cncc4)ccn2)ccc(N2CCN(C)CC2)c1	5.0500002	Active	DYRK1B Inhibitor	0.0	1	AZ-191	384569172.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	82.5520898399	O(C)c1c(Nc2nc(-c3c4c(n(C)c3)cncc4)ccn2)ccc(N2CCN(C)CC2)c1	O(C)c1c(Nc2nc(-c3c4c(n(C)c3)cncc4)ccn2)ccc(N2CCN(C)CC2)c1
NCGC00263090-09	O(C)c1c(Nc2nc3N(C(=O)N(C)c3cn2)C2CCCC2)ccc(OC2CCN(C)CC2)c1		Inactive	MPS1 Inhibitor		1	AZ-3146	384568583.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(Nc2nc3N(C(=O)N(C)c3cn2)C2CCCC2)ccc(OC2CCN(C)CC2)c1	O(C)c1c(Nc2nc3N(C(=O)N(C)c3cn2)C2CCCC2)ccc(OC2CCN(C)CC2)c1
NCGC00522579-01	O(C)c1c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)ccc(N2CCN(C)CC2)c1		Inactive	ERK5 Inhibitor		1	XMD17-109 (ERK5-IN-1)	384569528.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)ccc(N2CCN(C)CC2)c1	O(C)c1c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)ccc(N2CCN(C)CC2)c1
NCGC00507875-01	O(C)c1c(Nc2nc3N(C)c4c(C(=O)Nc3cn2)cccc4)ccc(N2CCN(C)CC2)c1	5.0500002	Active	TNK2 Inhibitor	0.0	1	XMD8-87	384569346.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	69.1667055846	O(C)c1c(Nc2nc3N(C)c4c(C(=O)Nc3cn2)cccc4)ccc(N2CCN(C)CC2)c1	O(C)c1c(Nc2nc3N(C)c4c(C(=O)Nc3cn2)cccc4)ccc(N2CCN(C)CC2)c1
NCGC00385233-01	O(C)c1c(O)c(C(COC2C(O)C(O)C(O)C(CO)O2)Cc2cc(OC)c(O)cc2)cc(/C=C/CO)c1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385233-01	363679608.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)c(C(COC2C(O)C(O)C(O)C(CO)O2)Cc2cc(OC)c(O)cc2)cc(/C=C/CO)c1	O(C)c1c(O)c(C(COC2C(O)C(O)C(O)C(CO)O2)Cc2cc(OC)c(O)cc2)cc(/C=C/CO)c1
NCGC00384753-01	O(C)c1c(O)c(C2COc3c(ccc(O)c3)C2)ccc1OC		Inactive	<MOA Unknown> | Class: Flavonoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384753-01	363679338.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)c(C2COc3c(ccc(O)c3)C2)ccc1OC	O(C)c1c(O)c(C2COc3c(ccc(O)c3)C2)ccc1OC
NCGC00380979-01	O(C)c1c(O)c(OC)cc(COC2C(O)C(O)C(O)C(CO)O2)c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Croton | Family: Euphorbiaceae | Species: megalocarpus		1	NCGC00380979-01	363678899.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)c(OC)cc(COC2C(O)C(O)C(O)C(CO)O2)c1	O(C)c1c(O)c(OC)cc(COC2C(O)C(O)C(O)C(CO)O2)c1
NCGC00161927-04	O(C)c1c(O)c(OC)cc([C@@H]2c3c([C@@H](O)C4C2C(=O)OC4)cc2OCOc2c3)c1		Inactive	Antimitotic Agent		1	DMEP	384568217.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(O)c(OC)cc([C@@H]2c3c([C@@H](O)C4C2C(=O)OC4)cc2OCOc2c3)c1	O(C)c1c(O)c(OC)cc([C@@H]2c3c([C@@H](O)C4C2C(=O)OC4)cc2OCOc2c3)c1
NCGC00178065-03	O(C)c1c(O)c(OC)cc([C@H]2[C@H]3C(=O)OCC3C(O[C@H]3[C@H](O)[C@@H](O)C4O[C@H](c5sccc5)OC[C@H]4O3)c3c2cc2OCOc2c3)c1		Inactive	DNA Topoisomerase II Inhibitors		1	TENIPOSIDE	405559077.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0		O(C)c1c(O)c(OC)cc([C@H]2[C@H]3C(=O)OCC3C(O[C@H]3[C@H](O)[C@@H](O)C4O[C@H](c5sccc5)OC[C@H]4O3)c3c2cc2OCOc2c3)c1	O(C)c1c(O)c(OC)cc([C@H]2[C@H]3C(=O)OCC3C(O[C@H]3[C@H](O)[C@@H](O)C4O[C@H](c5sccc5)OC[C@H]4O3)c3c2cc2OCOc2c3)c1
NCGC00482751-01	O(C)c1c(O)c2C(=O)C(OC)=C(c3cc(O)c(OC)cc3)Oc2cc1OC		Inactive			1	Casticin	434147155.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(O)c2C(=O)C(OC)=C(c3cc(O)c(OC)cc3)Oc2cc1OC	O(C)c1c(O)c2C(=O)C(OC)=C(c3cc(O)c(OC)cc3)Oc2cc1OC
NCGC00480772-03	O(C)c1c(O)c2C(=O)C=C(c3ccccc3)Oc2cc1O		Inactive			1	Oroxylin A	376241613.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(O)c2C(=O)C=C(c3ccccc3)Oc2cc1O	O(C)c1c(O)c2C(=O)C=C(c3ccccc3)Oc2cc1O
NCGC00381377-01	O(C)c1c(O)c2C(=O)O[C@H](C)[C@@H](O)c2cc1O		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381377-01	363679112.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)c2C(=O)O[C@H](C)[C@@H](O)c2cc1O	O(C)c1c(O)c2C(=O)O[C@H](C)[C@@H](O)c2cc1O
NCGC00384860-01	O(C)c1c(O)c2OC[C@@H]3[C@@H](Oc4c3ccc(O)c4)c2cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384860-01	363679402.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)c2OC[C@@H]3[C@@H](Oc4c3ccc(O)c4)c2cc1	O(C)c1c(O)c2OC[C@@H]3[C@@H](Oc4c3ccc(O)c4)c2cc1
NCGC00247556-02	O(C)c1c(O)c2Oc3c(OC)cc4c([C@@H](N(C)CC4)Cc4ccc(Oc5c(OC)ccc(c5)C[C@@H]5N(C)CCc(c25)c1)cc4)c3	5.5500002	Active		0.0	1	Fangchinoline	434147067.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	3.0	52.8345269302	O(C)c1c(O)c2Oc3c(OC)cc4c([C@@H](N(C)CC4)Cc4ccc(Oc5c(OC)ccc(c5)C[C@@H]5N(C)CCc(c25)c1)cc4)c3	O(C)c1c(O)c2Oc3c(OC)cc4c([C@@H](N(C)CC4)Cc4ccc(Oc5c(OC)ccc(c5)C[C@@H]5N(C)CCc(c25)c1)cc4)c3
NCGC00178480-03	O(C)c1c(O)c2Oc3ccc(cc3)C[C@@H]3N(C)CCc4c3cc(c(OC)c4)Oc3c(O)ccc(c3)C[C@H]3[N+](C)(C)CCc(c23)c1		Inactive	Small conductance calcium-activated potassium channel protein 2 Blocker		1	(+)-Tubocurarine chloride hydrochloride	170464882.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(C)c1c(O)c2Oc3ccc(cc3)C[C@@H]3N(C)CCc4c3cc(c(OC)c4)Oc3c(O)ccc(c3)C[C@H]3[N+](C)(C)CCc(c23)c1.Cl.[Cl-]	O(C)c1c(O)c2Oc3ccc(cc3)C[C@@H]3N(C)CCc4c3cc(c(OC)c4)Oc3c(O)ccc(c3)C[C@H]3[N+](C)(C)CCc(c23)c1.Cl.[Cl-]
NCGC00346587-16	O(C)c1c(O)c2[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3OC(=O)c2cc1O		Inactive			1	Bergenin monohydrate	434147093.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(C)c1c(O)c2[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3OC(=O)c2cc1O	O(C)c1c(O)c2[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3OC(=O)c2cc1O
NCGC00161641-05	O(C)c1c(O)c2c(cc1)C[C@@H]1N(C)CC[C@]32[C@@H]1C=C(OC)C(=O)C3		Inactive	Antiinflammatory opioid		1	Sinomenine	363676605.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(O)c2c(cc1)C[C@@H]1N(C)CC[C@]32[C@@H]1C=C(OC)C(=O)C3	O(C)c1c(O)c2c(cc1)C[C@@H]1N(C)CC[C@]32[C@@H]1C=C(OC)C(=O)C3
NCGC00385457-01	O(C)c1c(O)c2c3c(C(=O)Nc3cc3c2cccc3)c1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385457-01	363679750.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)c2c3c(C(=O)Nc3cc3c2cccc3)c1	O(C)c1c(O)c2c3c(C(=O)Nc3cc3c2cccc3)c1
NCGC00163540-01	O(C)c1c(O)cc(C=2Oc3c(c(O)cc(O)c3)C(=O)C=2)cc1		Inactive	Lipid Lowering Agents		1	Hesperetin	26756923.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(O)cc(C=2Oc3c(c(O)cc(O)c3)C(=O)C=2)cc1	O(C)c1c(O)cc(C=2Oc3c(c(O)cc(O)c3)C(=O)C=2)cc1
NCGC00380925-01	O(C)c1c(O)cc2C(c3ccc(O)cc3)C(C)C(C)Cc2c1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380925-01	363678859.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	30.468596208	O(C)c1c(O)cc2C(c3ccc(O)cc3)C(C)C(C)Cc2c1	O(C)c1c(O)cc2C(c3ccc(O)cc3)C(C)C(C)Cc2c1
NCGC00380740-01	O(C)c1c(O)cc2C3(C)C(C(C)(C)C(O)CC3)CC(=O)c2c1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380740-01	363678753.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)cc2C3(C)C(C(C)(C)C(O)CC3)CC(=O)c2c1	O(C)c1c(O)cc2C3(C)C(C(C)(C)C(O)CC3)CC(=O)c2c1
NCGC00180342-02	O(C)c1c(O)cc2C3(N(C)CCc2c1)C(=O)c1c2OCOc2ccc1C3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180342-02	363677010.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)cc2C3(N(C)CCc2c1)C(=O)c1c2OCOc2ccc1C3	O(C)c1c(O)cc2C3(N(C)CCc2c1)C(=O)c1c2OCOc2ccc1C3
NCGC00385306-01	O(C)c1c(O)cc2C3(OC)C(N(C)CCc2c1)c1c2OCOc2ccc1C3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385306-01	363679663.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)cc2C3(OC)C(N(C)CCc2c1)c1c2OCOc2ccc1C3	O(C)c1c(O)cc2C3(OC)C(N(C)CCc2c1)c1c2OCOc2ccc1C3
NCGC00385471-01	O(C)c1c(O)cc2C3([N+]([O-])(C)CCc2c1)C(O)c1c2OCOc2ccc1C3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385471-01	363679758.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)cc2C3([N+]([O-])(C)CCc2c1)C(O)c1c2OCOc2ccc1C3	O(C)c1c(O)cc2C3([N+]([O-])(C)CCc2c1)C(O)c1c2OCOc2ccc1C3
NCGC00385959-01	O(C)c1c(O)cc2NC(=O)C3N(C(=O)c2c1)C/C(=C\C)/C3		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385959-01	363680029.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)cc2NC(=O)C3N(C(=O)c2c1)C/C(=C\C)/C3	O(C)c1c(O)cc2NC(=O)C3N(C(=O)c2c1)C/C(=C\C)/C3
NCGC00094082-08	O(C)c1c(O)cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)c1		Inactive	Hypoxia Inducible Factor 1-alpha Inhibitor		1	2-Methoxyestradiol (2-MeOE2)	384568123.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(O)cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)c1	O(C)c1c(O)cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)c1
NCGC00385078-01	O(C)c1c(O)ccc(-c2c(C)c3c(o2)ccc(/C=C/C)c3)c1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385078-01	363679520.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	32.3899859	O(C)c1c(O)ccc(-c2c(C)c3c(o2)ccc(/C=C/C)c3)c1	O(C)c1c(O)ccc(-c2c(C)c3c(o2)ccc(/C=C/C)c3)c1
NCGC00169707-02	O(C)c1c(O)ccc(/C=C/c2cc(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)cc(O)c2)c1		Inactive	<MOA Unknown> | Class: Shikimi / Polyketide | Genus: Picea | Family: Pinaceae | Species: abies		1	NCGC00169707-02	363676871.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)ccc(/C=C/c2cc(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)cc(O)c2)c1	O(C)c1c(O)ccc(/C=C/c2cc(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)cc(O)c2)c1
NCGC00385986-01	O(C)c1c(O)ccc(C(OC2C(O)C(O)C(O)C(CO)O2)C(CO)c2cc(OC)c(O)cc2)c1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385986-01	363680045.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)ccc(C(OC2C(O)C(O)C(O)C(CO)O2)C(CO)c2cc(OC)c(O)cc2)c1	O(C)c1c(O)ccc(C(OC2C(O)C(O)C(O)C(CO)O2)C(CO)c2cc(OC)c(O)cc2)c1
NCGC00163572-01	O(C)c1c(O)ccc(C2=C(O)C(=O)c3c(O)cc(O)cc3O2)c1		Inactive			1	ISORHAMNETINE	26756952.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.910392216	O(C)c1c(O)ccc(C2=C(O)C(=O)c3c(O)cc(O)cc3O2)c1	O(C)c1c(O)ccc(C2=C(O)C(=O)c3c(O)cc(O)cc3O2)c1
NCGC00385293-01	O(C)c1c(O)ccc(C2C(CO)C(CO)Cc3c2cc(O)c(OC)c3)c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Piscidia | Family: Leguminosae | Species: grandiflora		1	NCGC00385293-01	363679652.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)ccc(C2C(CO)C(CO)Cc3c2cc(O)c(OC)c3)c1	O(C)c1c(O)ccc(C2C(CO)C(CO)Cc3c2cc(O)c(OC)c3)c1
NCGC00385401-01	O(C)c1c(O)ccc(C2C(CO)c3c(c(OC)cc(CCCO)c3)O2)c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385401-01	363679723.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)ccc(C2C(CO)c3c(c(OC)cc(CCCO)c3)O2)c1	O(C)c1c(O)ccc(C2C(CO)c3c(c(OC)cc(CCCO)c3)O2)c1
NCGC00091470-05	O(C)c1c(O)ccc(C=CC)c1		Inactive	Tyrosyl-DNA phosphodiesterase 2 Inhibitor		1	Isoeugenol	170465654.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(O)ccc(C=CC)c1	O(C)c1c(O)ccc(C=CC)c1
NCGC00091449-10	O(C)c1c(O)ccc(CC=C)c1		Inactive	reactive oxygen species biosynthetic process Modulator		1	Eugenol	170465464.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(C)c1c(O)ccc(CC=C)c1	O(C)c1c(O)ccc(CC=C)c1
NCGC00169701-03	O(C)c1c(O)ccc(C[C@@H]2[C@@H](Cc3cc(OC)c(O)cc3)COC2=O)c1		Inactive	<MOA Unknown> | Class: Lignan | Genus: N/A | Family: N/A | Species: N/A		1	Matairesinol	363676869.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)ccc(C[C@@H]2[C@@H](Cc3cc(OC)c(O)cc3)COC2=O)c1	O(C)c1c(O)ccc(C[C@@H]2[C@@H](Cc3cc(OC)c(O)cc3)COC2=O)c1
NCGC00346838-01	O(C)c1c(O)ccc(C[C@H]([C@H](CO)Cc2cc(OC)c(O)cc2)CO)c1		Inactive	phenylpropanoid		1	Secoisolariciresinol	174007232.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(O)ccc(C[C@H]([C@H](CO)Cc2cc(OC)c(O)cc2)CO)c1	O(C)c1c(O)ccc(C[C@H]([C@H](CO)Cc2cc(OC)c(O)cc2)CO)c1
NCGC00385544-01	O(C)c1c(O)ccc([C@@H]2[C@@H](C)[C@]3(OC)[C@](OC)(O2)CC(=O)C(CC=C)=C3)c1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385544-01	363679799.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)ccc([C@@H]2[C@@H](C)[C@]3(OC)[C@](OC)(O2)CC(=O)C(CC=C)=C3)c1	O(C)c1c(O)ccc([C@@H]2[C@@H](C)[C@]3(OC)[C@](OC)(O2)CC(=O)C(CC=C)=C3)c1
NCGC00091057-08	O(C)c1c(O)ccc([C@@H]2[C@@H](CO)Oc3c(O2)cc([C@@H]2[C@@H](O)C(=O)c4c(O)cc(O)cc4O2)cc3)c1		Inactive	P-Glycoprotein (MDR-1) Inhibitor		1	Silybin	384568092.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(O)ccc([C@@H]2[C@@H](CO)Oc3c(O2)cc([C@@H]2[C@@H](O)C(=O)c4c(O)cc(O)cc4O2)cc3)c1	O(C)c1c(O)ccc([C@@H]2[C@@H](CO)Oc3c(O2)cc([C@@H]2[C@@H](O)C(=O)c4c(O)cc(O)cc4O2)cc3)c1
NCGC00381434-01	O(C)c1c(O)ccc([C@@H]2[C@H](C)c3c(c(OC)cc(/C=C/C)c3)O2)c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Piper | Family: Piperaceae | Species: capense		1	NCGC00381434-01	363679142.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O)ccc([C@@H]2[C@H](C)c3c(c(OC)cc(/C=C/C)c3)O2)c1	O(C)c1c(O)ccc([C@@H]2[C@H](C)c3c(c(OC)cc(/C=C/C)c3)O2)c1
NCGC00090827-07	O(C)c1c(O)cccc1		Inactive	intestine smooth muscle contraction Inhibitor		1	Guaiacol	225144199.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(O)cccc1	O(C)c1c(O)cccc1
NCGC00016697-04	O(C)c1c(OC)c(CN2CCNCC2)ccc1OC		Inactive	Trifunctional enzyme subunit beta, mitochondrial Inhibitor		1	Trimetazidine dihydrochloride	170465797.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(C)c1c(OC)c(CN2CCNCC2)ccc1OC.Cl.Cl	O(C)c1c(OC)c(CN2CCNCC2)ccc1OC.Cl.Cl
NCGC00095703-06	O(C)c1c(OC)c(OC)c2OC(c3cc(OC)c(OC)cc3)=CC(=O)c2c1OC		Inactive			1	NOBILETIN	434147000.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)c(OC)c2OC(c3cc(OC)c(OC)cc3)=CC(=O)c2c1OC	O(C)c1c(OC)c(OC)c2OC(c3cc(OC)c(OC)cc3)=CC(=O)c2c1OC
NCGC00380288-01	O(C)c1c(OC)c2-c3c(O)ccc(c3)CCC(O)CCCCc(c1O)c2		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Myrica | Family: Myraceae | Species: nagi		1	NCGC00380288-01	363678525.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)c2-c3c(O)ccc(c3)CCC(O)CCCCc(c1O)c2	O(C)c1c(OC)c2-c3c(O)ccc(c3)CCC(O)CCCCc(c1O)c2
NCGC00385775-01	O(C)c1c(OC)c2-c3c(O)ccc(c3)CCC(O)CCCCc(c1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385775-01	363679934.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)c2-c3c(O)ccc(c3)CCC(O)CCCCc(c1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c2	O(C)c1c(OC)c2-c3c(O)ccc(c3)CCC(O)CCCCc(c1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c2
NCGC00163662-01	O(C)c1c(OC)c2-c3c(OC)c(OC)c(OC)cc3C[C@H](C)[C@H](C)Cc2cc1OC		Inactive			1	NCGC00163662-01	26757041.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)c2-c3c(OC)c(OC)c(OC)cc3C[C@H](C)[C@H](C)Cc2cc1OC	O(C)c1c(OC)c2-c3c(OC)c(OC)c(OC)cc3C[C@H](C)[C@H](C)Cc2cc1OC
NCGC00347676-02	O(C)c1c(OC)c2-c3c(OC)c4OCOc4cc3C[C@H](C)[C@](O)(C)Cc2cc1OC		Inactive	MAPK signaling pathway Modulator		1	Schisandrol B	405558731.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)c2-c3c(OC)c4OCOc4cc3C[C@H](C)[C@](O)(C)Cc2cc1OC	O(C)c1c(OC)c2-c3c(OC)c4OCOc4cc3C[C@H](C)[C@](O)(C)Cc2cc1OC
NCGC00180294-02	O(C)c1c(OC)c2C(=O)C=C(c3ccccc3)Oc2cc1OC		Inactive			1	5,6,7-trimethoxyflavone		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)c2C(=O)C=C(c3ccccc3)Oc2cc1OC	O(C)c1c(OC)c2C(=O)C=C(c3ccccc3)Oc2cc1OC
NCGC00163562-01	O(C)c1c(OC)c2Oc3c(OC)cc4c([C@@H](N(C)CC4)Cc4ccc(Oc5c(OC)ccc(c5)C[C@@H]5N(C)CCc(c1OC)c25)cc4)c3		Inactive			1	HERNANDEZINE	26756942.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)c2Oc3c(OC)cc4c([C@@H](N(C)CC4)Cc4ccc(Oc5c(OC)ccc(c5)C[C@@H]5N(C)CCc(c1OC)c25)cc4)c3	O(C)c1c(OC)c2Oc3c(OC)cc4c([C@@H](N(C)CC4)Cc4ccc(Oc5c(OC)ccc(c5)C[C@@H]5N(C)CCc(c1OC)c25)cc4)c3
NCGC00166035-05	O(C)c1c(OC)c2c(cc1OC)CC[C@H](NC)C=1C2=CC=C(OC)C(=O)C=1		Inactive	Tubulin polymerization Inhibitor		1	Demecolcine	384568302.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O(C)c1c(OC)c2c(cc1OC)CC[C@H](NC)C=1C2=CC=C(OC)C(=O)C=1	O(C)c1c(OC)c2c(cc1OC)CC[C@H](NC)C=1C2=CC=C(OC)C(=O)C=1
NCGC00347538-02	O(C)c1c(OC)c2cc(c1O)-c1c(O)ccc(c1)CCC(O)CCCC2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347538-02	363677619.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)c2cc(c1O)-c1c(O)ccc(c1)CCC(O)CCCC2	O(C)c1c(OC)c2cc(c1O)-c1c(O)ccc(c1)CCC(O)CCCC2
NCGC00390660-02	O(C)c1c(OC)cc(-c2c(C)ncc(-c3ccc(N4CCNCC4)cc3)c2)cc1OC	4.9499998	Active	ALK2 Inhibitor	0.0	1	LDN-214117	363680961.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	56.6812014439	O(C)c1c(OC)cc(-c2c(C)ncc(-c3ccc(N4CCNCC4)cc3)c2)cc1OC	O(C)c1c(OC)cc(-c2c(C)ncc(-c3ccc(N4CCNCC4)cc3)c2)cc1OC
NCGC00263098-05	O(C)c1c(OC)cc(/C=C\c2cc(O)c(OC)cc2)cc1OC		Inactive	Tubulin polymerization Inhibitor		1	Combretastatin A-4	384568589.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)cc(/C=C\c2cc(O)c(OC)cc2)cc1OC	O(C)c1c(OC)cc(/C=C\c2cc(O)c(OC)cc2)cc1OC
NCGC00015686-11	O(C)c1c(OC)cc(C(C#N)(C(C)C)CCCN(CCc2cc(OC)c(OC)cc2)C)cc1OC		Inactive	Voltage-gated L-type calcium channel Blocker		1	Gallopamil hydrochloride	170465991.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(C)c1c(OC)cc(C(C#N)(C(C)C)CCCN(CCc2cc(OC)c(OC)cc2)C)cc1OC.Cl	O(C)c1c(OC)cc(C(C#N)(C(C)C)CCCN(CCc2cc(OC)c(OC)cc2)C)cc1OC.Cl
NCGC00167523-03	O(C)c1c(OC)cc(C)c(Cc2c(N)nc(N)nc2)c1		Inactive	Folate biosynthesis Inhibitor		1	Ormetoprim	170465718.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(C)c1c(OC)cc(C)c(Cc2c(N)nc(N)nc2)c1	O(C)c1c(OC)cc(C)c(Cc2c(N)nc(N)nc2)c1
NCGC00182977-01	O(C)c1c(OC)cc(C[C@@H]2NCCc3c2cc(O)c(O)c3)cc1OC		Inactive	Beta-3 adrenergic receptor Agonist		1	Trimethoquinol	144206771.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)cc(C[C@@H]2NCCc3c2cc(O)c(O)c3)cc1OC.Cl	O(C)c1c(OC)cc(C[C@@H]2NCCc3c2cc(O)c(O)c3)cc1OC.Cl
NCGC00378772-01	O(C)c1c(OC)cc(Cc2c(N)nc(N)nc2)c(C(C)C)c1		Inactive	P2X purinoceptor 3 Antagonist		1	RO-3	363678189.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)cc(Cc2c(N)nc(N)nc2)c(C(C)C)c1	O(C)c1c(OC)cc(Cc2c(N)nc(N)nc2)c(C(C)C)c1
NCGC00016055-11&NCGC00016055-16	O(C)c1c(OC)cc(Cc2c(N)nc(N)nc2)cc1OC		Inactive	Bacterial dihydrofolate reductase Inhibitor		2	Trimethoprim	124881736.0&170464633.0	Anti-infectives&Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&0.0	O(C)c1c(OC)cc(Cc2c(N)nc(N)nc2)cc1OC	O(C)c1c(OC)cc(Cc2c(N)nc(N)nc2)cc1OC
NCGC00161419-06	O(C)c1c(OC)cc(NCc2c(C)c3c(N)nc(N)nc3cc2)cc1OC		Inactive	Dihydrofolate Reductase (DHFR) Inhibitor		1	Trimetrexate	384568209.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O(C)c1c(OC)cc(NCc2c(C)c3c(N)nc(N)nc3cc2)cc1OC	O(C)c1c(OC)cc(NCc2c(C)c3c(N)nc(N)nc3cc2)cc1OC
NCGC00380879-01	O(C)c1c(OC)cc([C@@H]2[C@H](C)[C@@H](C)[C@@H](c3cc(OC)c4OCOc4c3)O2)cc1OC		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Saururus | Family: Saururaceae | Species: chinensis		1	NCGC00380879-01	363678831.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	19.8597997079	O(C)c1c(OC)cc([C@@H]2[C@H](C)[C@@H](C)[C@@H](c3cc(OC)c4OCOc4c3)O2)cc1OC	O(C)c1c(OC)cc([C@@H]2[C@H](C)[C@@H](C)[C@@H](c3cc(OC)c4OCOc4c3)O2)cc1OC
NCGC00161923-31	O(C)c1c(OC)cc([C@H]2[C@@H]3C(=O)OC[C@@H]3[C@@H](O)c3c2cc2OCOc2c3)cc1OC		Inactive	IGF-1R Inhibitor		1	Picropodophyllin	384568216.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O(C)c1c(OC)cc([C@H]2[C@@H]3C(=O)OC[C@@H]3[C@@H](O)c3c2cc2OCOc2c3)cc1OC	O(C)c1c(OC)cc([C@H]2[C@@H]3C(=O)OC[C@@H]3[C@@H](O)c3c2cc2OCOc2c3)cc1OC
NCGC00022001-19	O(C)c1c(OC)cc([C@H]2[C@H]3C(=O)OC[C@@H]3[C@@H](O)c3c2cc2OCOc2c3)cc1OC		Inactive	Antimitotic Agent		1	Podofilox	384568009.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O(C)c1c(OC)cc([C@H]2[C@H]3C(=O)OC[C@@H]3[C@@H](O)c3c2cc2OCOc2c3)cc1OC	O(C)c1c(OC)cc([C@H]2[C@H]3C(=O)OC[C@@H]3[C@@H](O)c3c2cc2OCOc2c3)cc1OC
NCGC00379089-04	O(C)c1c(OC)cc-2c(C(=O)N(CCNC)c3c4c(ncc-23)cc2OCOc2c4)c1		Inactive	DNA Topoisomerase I Inhibitor		1	Genz-644282	384569094.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)cc-2c(C(=O)N(CCNC)c3c4c(ncc-23)cc2OCOc2c4)c1	O(C)c1c(OC)cc-2c(C(=O)N(CCNC)c3c4c(ncc-23)cc2OCOc2c4)c1
NCGC00480825-02	O(C)c1c(OC)cc2NC(=O)/C(=C\c3ccc(O)cc3)/c2c1		Inactive			1	RPI-1	377020221.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)cc2NC(=O)/C(=C\c3ccc(O)cc3)/c2c1	O(C)c1c(OC)cc2NC(=O)/C(=C\c3ccc(O)cc3)/c2c1
NCGC00025288-07	O(C)c1c(OC)cc2[C@@H]3C(=O)c4c(O[C@@H]3COc2c1)c1c(OC(C)(C)C=C1)cc4		Inactive	PI3K Inhibitor		1	Deguelin	384568065.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.333486448	O(C)c1c(OC)cc2[C@@H]3C(=O)c4c(O[C@@H]3COc2c1)c1c(OC(C)(C)C=C1)cc4	O(C)c1c(OC)cc2[C@@H]3C(=O)c4c(O[C@@H]3COc2c1)c1c(OC(C)(C)C=C1)cc4
NCGC00017358-15	O(C)c1c(OC)cc2[C@@H]3C(=O)c4c(O[C@@H]3COc2c1)c1c(O[C@@H](C(=C)C)C1)cc4		Inactive	NADH-Ubiquinone Oxidoreductase (Complex I) Inhibitor		1	Rotenone	170466816.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	14.1872224999&0.0&0.0	O(C)c1c(OC)cc2[C@@H]3C(=O)c4c(O[C@@H]3COc2c1)c1c(O[C@@H](C(=C)C)C1)cc4	O(C)c1c(OC)cc2[C@@H]3C(=O)c4c(O[C@@H]3COc2c1)c1c(O[C@@H](C(=C)C)C1)cc4
NCGC00385706-01	O(C)c1c(OC)cc2[C@@H]3[C@H]4[C@]56[N@+]([O-])(CC=C[C@]5(CC(=O)N6c2c1)CC4)CC3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385706-01	363679887.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)cc2[C@@H]3[C@H]4[C@]56[N@+]([O-])(CC=C[C@]5(CC(=O)N6c2c1)CC4)CC3	O(C)c1c(OC)cc2[C@@H]3[C@H]4[C@]56[N@+]([O-])(CC=C[C@]5(CC(=O)N6c2c1)CC4)CC3
NCGC00384995-01	O(C)c1c(OC)cc2[C@H]3[C@@H]4[C@]56N(C(=O)C[C@]5(C=CCN6CC3)CC4)c2c1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384995-01	363679475.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)cc2[C@H]3[C@@H]4[C@]56N(C(=O)C[C@]5(C=CCN6CC3)CC4)c2c1	O(C)c1c(OC)cc2[C@H]3[C@@H]4[C@]56N(C(=O)C[C@]5(C=CCN6CC3)CC4)c2c1
NCGC00183866-01	O(C)c1c(OC)cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2c1		Inactive	Adenylate cyclase Inhibitor		1	Oxypertine hydrochloride	144206763.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2c1.Cl	O(C)c1c(OC)cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2c1.Cl
NCGC00167537-02	O(C)c1c(OC)cc2c(C(=O)C(CC3CCN(Cc4ccccc4)CC3)C2)c1		Inactive	Acetylcholinesterase Inhibitor		1	Donepezil hydrochloride	170464858.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)cc2c(C(=O)C(CC3CCN(Cc4ccccc4)CC3)C2)c1.Cl	O(C)c1c(OC)cc2c(C(=O)C(CC3CCN(Cc4ccccc4)CC3)C2)c1.Cl
NCGC00505021-01	O(C)c1c(OC)cc2c(C(=O)N(CCCN3CCOCC3)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1		Inactive	DNA Topoisomerase I Inhibitor		1	Indotecan hydrochloride (LMP-400)	384569315.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)cc2c(C(=O)N(CCCN3CCOCC3)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1	O(C)c1c(OC)cc2c(C(=O)N(CCCN3CCOCC3)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1
NCGC00505019-01	O(C)c1c(OC)cc2c(C(=O)N(CCCNCCO)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1		Inactive	DNA Topoisomerase I Inhibitor		1	LMP-744	384569313.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)cc2c(C(=O)N(CCCNCCO)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1	O(C)c1c(OC)cc2c(C(=O)N(CCCNCCO)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1
NCGC00505020-01	O(C)c1c(OC)cc2c(C(=O)N(CCCn3cncc3)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1		Inactive	DNA Topoisomerase I Inhibitor		1	Indimitecan hydrochloride (LMP-776)	384569314.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)cc2c(C(=O)N(CCCn3cncc3)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1	O(C)c1c(OC)cc2c(C(=O)N(CCCn3cncc3)C=3c4c(C(=O)C2=3)cc2OCOc2c4)c1
NCGC00263445-02	O(C)c1c(OC)cc2c(N3C(=O)C[C@@H]4OCC=C5[C@H]6[C@@H]4[C@H]3[C@]32[C@@H](N(C5)CC3)C6)c1		Inactive	Vascular endothelial growth factor receptor 2 Inhibitor		1	Brucine-N-oxide	405558773.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)cc2c(N3C(=O)C[C@@H]4OCC=C5[C@H]6[C@@H]4[C@H]3[C@]32[C@@H](N(C5)CC3)C6)c1	O(C)c1c(OC)cc2c(N3C(=O)C[C@@H]4OCC=C5[C@H]6[C@@H]4[C@H]3[C@]32[C@@H](N(C5)CC3)C6)c1
NCGC00181343-03&NCGC00181343-04	O(C)c1c(OC)cc2c([C@@H](CN(CCCN3C(=O)Cc4c(cc(OC)c(OC)c4)CC3)C)C2)c1		Inactive	HCN [I(f)] Blocker		2	Ivabradine hydrochloride	405558672.0&384568396.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(C)c1c(OC)cc2c([C@@H](CN(CCCN3C(=O)Cc4c(cc(OC)c(OC)c4)CC3)C)C2)c1	O(C)c1c(OC)cc2c([C@@H](CN(CCCN3C(=O)Cc4c(cc(OC)c(OC)c4)CC3)C)C2)c1
NCGC00485943-01	O(C)c1c(OC)cc2c([C@@H](CNCCCN3C(=O)Cc4c(cc(OC)c(OC)c4)CC3)C2)c1		Inactive			1	Ivabradine metabolite N-Demethyl Ivabradine (hydrochloride)	363681434.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)cc2c([C@@H](CNCCCN3C(=O)Cc4c(cc(OC)c(OC)c4)CC3)C2)c1	O(C)c1c(OC)cc2c([C@@H](CNCCCN3C(=O)Cc4c(cc(OC)c(OC)c4)CC3)C2)c1
NCGC00024379-17&NCGC00024379-18&NCGC00024379-25&NCGC00024379-29	O(C)c1c(OC)cc2c([C@@H](C[C@@H]3[C@@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)NCC2)c1		Inactive	antiprotozoal agent		4	Emetine dihydrochloride hydrate&Emetine&EMETINE DIHYDROCHLORIDE	434146976.0&384568026.0&434146977.0	Anti-infectives&Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0&4.0&4.0		O(C)c1c(OC)cc2c([C@@H](C[C@@H]3[C@@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)NCC2)c1	O(C)c1c(OC)cc2c([C@@H](C[C@@H]3[C@@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)NCC2)c1
NCGC00092321-03	O(C)c1c(OC)cc2c([C@H]3N(C[C@H](CC(C)C)C(=O)C3)CC2)c1		Inactive	Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor		1	Tetrabenazine Mesylate	405558756.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)cc2c([C@H]3N(C[C@H](CC(C)C)C(=O)C3)CC2)c1	O(C)c1c(OC)cc2c([C@H]3N(C[C@H](CC(C)C)C(=O)C3)CC2)c1
NCGC00180626-04	O(C)c1c(OC)cc2c([C@H]3N(C[C@H](CC)[C@@H](C[C@H]4NCCc5c4cc(OC)c(O)c5)C3)CC2)c1	6.5999999	Inactive		0.0	1	Cephaeline	434147234.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&-1.2	-15.755364812&-56.3099207468	O(C)c1c(OC)cc2c([C@H]3N(C[C@H](CC)[C@@H](C[C@H]4NCCc5c4cc(OC)c(O)c5)C3)CC2)c1	O(C)c1c(OC)cc2c([C@H]3N(C[C@H](CC)[C@@H](C[C@H]4NCCc5c4cc(OC)c(O)c5)C3)CC2)c1
NCGC00160421-03&NCGC00160421-04	O(C)c1c(OC)cc2c(c1)C1N(CC(CC(C)C)C(=O)C1)CC2		Inactive	Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor		2	Tetrabenazine	170464675.0&384568194.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O(C)c1c(OC)cc2c(c1)C1N(CC(CC(C)C)C(=O)C1)CC2	O(C)c1c(OC)cc2c(c1)C1N(CC(CC(C)C)C(=O)C1)CC2
NCGC00408863-01	O(C)c1c(OC)cc2c(c1)C1N(CC(CC(C)C)C(O)(CC)C1)CC2		Inactive	Synaptic vesicular amine transporter Inhibitor		1	Ro 4-1284	363681069.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)cc2c(c1)C1N(CC(CC(C)C)C(O)(CC)C1)CC2	O(C)c1c(OC)cc2c(c1)C1N(CC(CC(C)C)C(O)(CC)C1)CC2
NCGC00385294-01	O(C)c1c(OC)cc2c(c1)C1N(CC(CC)C(CC3=NCCc4c3cc(OC)c(O)c4)C1)CC2		Inactive	Gag-Pol polyprotein Inhibitor		1	NCGC00385294-01	363679653.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)cc2c(c1)C1N(CC(CC)C(CC3=NCCc4c3cc(OC)c(O)c4)C1)CC2	O(C)c1c(OC)cc2c(c1)C1N(CC(CC)C(CC3=NCCc4c3cc(OC)c(O)c4)C1)CC2
NCGC00017376-12	O(C)c1c(OC)cc2c3[C@@H](N(C)CC2)Cc2cc(c(OC)cc2)Oc2ccc(cc2)C[C@@H]2N(C)CCc4c2cc(c(OC)c4)Oc13	5.8000002	Active	Calcium Channel Blocker	0.0	1	Tetrandrine	434146967.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	3.0	46.8669677238	O(C)c1c(OC)cc2c3[C@@H](N(C)CC2)Cc2cc(c(OC)cc2)Oc2ccc(cc2)C[C@@H]2N(C)CCc4c2cc(c(OC)c4)Oc13	O(C)c1c(OC)cc2c3[C@@H](N(C)CC2)Cc2cc(c(OC)cc2)Oc2ccc(cc2)C[C@@H]2N(C)CCc4c2cc(c(OC)c4)Oc13
NCGC00017375-03	O(C)c1c(OC)cc2c3[C@H](N(C)CC2)Cc2cc(c(O)cc2)Oc2ccc(cc2)C[C@@H]2N(C)CCc4c2cc(c(OC)c4)Oc13	5.8499999	Active		0.0	1	Berbamine dihydrochloride	406861834.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	1.2	63.0926461284	O(C)c1c(OC)cc2c3[C@H](N(C)CC2)Cc2cc(c(O)cc2)Oc2ccc(cc2)C[C@@H]2N(C)CCc4c2cc(c(OC)c4)Oc13	O(C)c1c(OC)cc2c3[C@H](N(C)CC2)Cc2cc(c(O)cc2)Oc2ccc(cc2)C[C@@H]2N(C)CCc4c2cc(c(OC)c4)Oc13
NCGC00263444-01	O(C)c1c(OC)cc2c3[C@H]([N+](C)(C)CC2)Cc2cc(c(OC)cc2)Oc2c(OC)cc4c([C@@H]([N+](C)(C)CC4)Cc4ccc(Oc13)cc4)c2		Inactive			1	Metocurine iodide	170465111.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(C)c1c(OC)cc2c3[C@H]([N+](C)(C)CC2)Cc2cc(c(OC)cc2)Oc2c(OC)cc4c([C@@H]([N+](C)(C)CC4)Cc4ccc(Oc13)cc4)c2.[I-].[I-]	O(C)c1c(OC)cc2c3[C@H]([N+](C)(C)CC2)Cc2cc(c(OC)cc2)Oc2c(OC)cc4c([C@@H]([N+](C)(C)CC4)Cc4ccc(Oc13)cc4)c2.[I-].[I-]
NCGC00263017-01	O(C)c1c(OC)cc2nc(-c3ccc(N4CCN(C)CC4)cc3)nc(NCCN3CCOCC3)c2c1	4.9000001	Active	TLR 7, 8 and 9 Antagonist	0.0	1	CPG-52364	137275921.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	63.7639551	O(C)c1c(OC)cc2nc(-c3ccc(N4CCN(C)CC4)cc3)nc(NCCN3CCOCC3)c2c1	O(C)c1c(OC)cc2nc(-c3ccc(N4CCN(C)CC4)cc3)nc(NCCN3CCOCC3)c2c1
NCGC00378708-04	O(C)c1c(OC)cc2nc(C3CC3)nc(N3CCN(c4c(OC)cccc4)CC3)c2c1		Inactive	Neurotensin receptor 1 Agonist		1	ML314	363678162.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	18.482560812	O(C)c1c(OC)cc2nc(C3CC3)nc(N3CCN(c4c(OC)cccc4)CC3)c2c1	O(C)c1c(OC)cc2nc(C3CC3)nc(N3CCN(c4c(OC)cccc4)CC3)c2c1
NCGC00370891-01	O(C)c1c(OC)cc2nc(N3CCC(N4CCCCC4)CC3)nc(NC3CCCCCC3)c2c1	5.5999999	Active	C-C chemokine receptor type 4 Inhibitor	0.0	1	C 021 dihydrochloride	363677913.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	71.8592705376	O(C)c1c(OC)cc2nc(N3CCC(N4CCCCC4)CC3)nc(NC3CCCCCC3)c2c1	O(C)c1c(OC)cc2nc(N3CCC(N4CCCCC4)CC3)nc(NC3CCCCCC3)c2c1
NCGC00185849-01	O(C)c1c(OC)cc2nc(N3CCCCC3)nc(NC3CCN(Cc4ccccc4)CC3)c2c1	5.5	Active		0.0	1	NCGC00185849-01	124896673.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	64.7616583783	O(C)c1c(OC)cc2nc(N3CCCCC3)nc(NC3CCN(Cc4ccccc4)CC3)c2c1	O(C)c1c(OC)cc2nc(N3CCCCC3)nc(NC3CCN(Cc4ccccc4)CC3)c2c1
NCGC00185850-16	O(C)c1c(OC)cc2nc(N3CCN(C)CCC3)nc(NC3CCN(Cc4ccccc4)CC3)c2c1		Inactive	EHMT2 Inhibitor		1	BIX-01294	384568428.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)cc2nc(N3CCN(C)CCC3)nc(NC3CCN(Cc4ccccc4)CC3)c2c1	O(C)c1c(OC)cc2nc(N3CCN(C)CCC3)nc(NC3CCN(Cc4ccccc4)CC3)c2c1
NCGC00263099-07	O(C)c1c(OC)cc2ncnc(-n3c(N)nc(-c4ncccc4)n3)c2c1		Inactive	ATM Kinase Inhibitor		1	CP-466722	384568590.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)cc2ncnc(-n3c(N)nc(-c4ncccc4)n3)c2c1	O(C)c1c(OC)cc2ncnc(-n3c(N)nc(-c4ncccc4)n3)c2c1
NCGC00402348-02	O(C)c1c(OC)cc2ncnc(N3CC(Oc4nc5c(nc4)cccc5)CC3)c2c1	5.0	Active	Phosphodiesterase 10A Inhibitor	0.0	1	PQ-10	363681034.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	43.0563123639	O(C)c1c(OC)cc2ncnc(N3CC(Oc4nc5c(nc4)cccc5)CC3)c2c1	O(C)c1c(OC)cc2ncnc(N3CC(Oc4nc5c(nc4)cccc5)CC3)c2c1
NCGC00163394-01	O(C)c1c(OC)cc2ncnc(Nc3cc(C#C)ccc3)c2c1		Inactive			1	BML-265	26756762.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)cc2ncnc(Nc3cc(C#C)ccc3)c2c1	O(C)c1c(OC)cc2ncnc(Nc3cc(C#C)ccc3)c2c1
NCGC00370851-01	O(C)c1c(OC)cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2c1		Inactive	Tyrosine-protein kinase SRC Inhibitor		1	Src I1	363677885.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2c1	O(C)c1c(OC)cc2ncnc(Nc3ccc(Oc4ccccc4)cc3)c2c1
NCGC00480876-01	O(C)c1c(OC)ccc(-c2c(C)nn3C(NCCN4CCOCC4)=CC(C)=Nc23)c1		Inactive	PI4Kbeta Inhibitor		1	T-00127-HEV1	363681112.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.0	O(C)c1c(OC)ccc(-c2c(C)nn3C(NCCN4CCOCC4)=CC(C)=Nc23)c1	O(C)c1c(OC)ccc(-c2c(C)nn3C(NCCN4CCOCC4)=CC(C)=Nc23)c1
NCGC00253737-01&NCGC00253737-09	O(C)c1c(OC)ccc(/C=C/c2n(C)c3C(=O)N(CC)C(=O)N(CC)c3n2)c1		Inactive	Adenosine A2A Agonist		2	Istradefylline	174007485.0&384568566.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O(C)c1c(OC)ccc(/C=C/c2n(C)c3C(=O)N(CC)C(=O)N(CC)c3n2)c1	O(C)c1c(OC)ccc(/C=C/c2n(C)c3C(=O)N(CC)C(=O)N(CC)c3n2)c1
NCGC00016083-23&NCGC00344584-01	O(C)c1c(OC)ccc(C(C#N)(C(C)C)CCCN(CCc2cc(OC)c(OC)cc2)C)c1		Inactive	Dopamine D2 Receptor (DRD2) Antagonist&Calcium Channel Blocker		2	Verapamil	384567918.0&170464904.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&11.58402444	O(C)c1c(OC)ccc(C(C#N)(C(C)C)CCCN(CCc2cc(OC)c(OC)cc2)C)c1	O(C)c1c(OC)ccc(C(C#N)(C(C)C)CCCN(CCc2cc(OC)c(OC)cc2)C)c1
NCGC00385278-01	O(C)c1c(OC)ccc(C23C(N(C)CC2)=CC(=O)CC3)c1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385278-01	363679638.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)ccc(C23C(N(C)CC2)=CC(=O)CC3)c1	O(C)c1c(OC)ccc(C23C(N(C)CC2)=CC(=O)CC3)c1
NCGC00165912-03	O(C)c1c(OC)ccc(C2=NN=C(C)C(CC)c3c2cc(OC)c(OC)c3)c1		Inactive			1	Tofisopam	405558838.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)ccc(C2=NN=C(C)C(CC)c3c2cc(OC)c(OC)c3)c1	O(C)c1c(OC)ccc(C2=NN=C(C)C(CC)c3c2cc(OC)c(OC)c3)c1
NCGC00386034-01	O(C)c1c(OC)ccc(C2C(C)C(C)C(c3cc(OC)c(O)cc3)O2)c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Myristica | Family: N/A | Species: fragrans		1	NCGC00386034-01	363680072.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)ccc(C2C(C)C(C)C(c3cc(OC)c(O)cc3)O2)c1	O(C)c1c(OC)ccc(C2C(C)C(C)C(c3cc(OC)c(O)cc3)O2)c1
NCGC00169695-02	O(C)c1c(OC)ccc(C2C(COC3C(O)C(O)C(O)C(CO)O3)c3c(c(OC)cc(CCCO)c3)O2)c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169695-02	363676867.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)ccc(C2C(COC3C(O)C(O)C(O)C(CO)O3)c3c(c(OC)cc(CCCO)c3)O2)c1	O(C)c1c(OC)ccc(C2C(COC3C(O)C(O)C(O)C(CO)O3)c3c(c(OC)cc(CCCO)c3)O2)c1
NCGC00169904-02	O(C)c1c(OC)ccc(C2OCC3C(c4cc(OC)c5OCOc5c4)OCC23)c1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169904-02	363676906.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)ccc(C2OCC3C(c4cc(OC)c5OCOc5c4)OCC23)c1	O(C)c1c(OC)ccc(C2OCC3C(c4cc(OC)c5OCOc5c4)OCC23)c1
NCGC00065564-02	O(C)c1c(OC)ccc(C=2Sc3n(c(-c4occc4)nn3)N=2)c1		Inactive			1	ZINC4326719		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	21.3768375801	O(C)c1c(OC)ccc(C=2Sc3n(c(-c4occc4)nn3)N=2)c1	O(C)c1c(OC)ccc(C=2Sc3n(c(-c4occc4)nn3)N=2)c1
NCGC00263226-01	O(C)c1c(OC)ccc(CC2=NN3C([C@H]([C@H](O)C)CCCc4ccccc4)=NC(C)C3C(=O)N2)c1		Inactive	Phosphodiesterase II (PDE2A) Inhibitor		1	BAY-60-7550	137276070.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)ccc(CC2=NN3C([C@H]([C@H](O)C)CCCc4ccccc4)=NC(C)C3C(=O)N2)c1	O(C)c1c(OC)ccc(CC2=NN3C([C@H]([C@H](O)C)CCCc4ccccc4)=NC(C)C3C(=O)N2)c1
NCGC00378775-01	O(C)c1c(OC)ccc(CC2NCCc3c4c([nH]c23)ccc(C)c4)c1	4.9000001	Active	Serotonin 2b (5-HT2b) receptor Antagonist	0.0	1	LY 272015 hydrochloride	363678191.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	44.1523809549	O(C)c1c(OC)ccc(CC2NCCc3c4c([nH]c23)ccc(C)c4)c1	O(C)c1c(OC)ccc(CC2NCCc3c4c([nH]c23)ccc(C)c4)c1
NCGC00263126-04	O(C)c1c(OC)ccc(CCN2CCN(CCCc3ccccc3)CC2)c1		Inactive	sigma1 Receptor Agonist		1	Cutamesine hydrochloride	363677214.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)ccc(CCN2CCN(CCCc3ccccc3)CC2)c1	O(C)c1c(OC)ccc(CCN2CCN(CCCc3ccccc3)CC2)c1
NCGC00346832-02	O(C)c1c(OC)ccc(C[C@@H]([C@@H](Cc2cc(OC)c(OC)cc2)C)C)c1		Inactive	Antimitotic Agent		1	Terameprocol	384568947.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)ccc(C[C@@H]([C@@H](Cc2cc(OC)c(OC)cc2)C)C)c1	O(C)c1c(OC)ccc(C[C@@H]([C@@H](Cc2cc(OC)c(OC)cc2)C)C)c1
NCGC00025291-03	O(C)c1c(OC)ccc(C[C@@H]2[C@@H](Cc3cc(OC)c(O)cc3)C(=O)OC2)c1		Inactive	tumor necrosis factor biosynthetic process Inhibitor		1	Arctigenin	434146980.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)ccc(C[C@@H]2[C@@H](Cc3cc(OC)c(O)cc3)C(=O)OC2)c1	O(C)c1c(OC)ccc(C[C@@H]2[C@@H](Cc3cc(OC)c(O)cc3)C(=O)OC2)c1
NCGC00169522-02	O(C)c1c(OC)ccc(C[C@@H]2[C@@H](Cc3cc(OC)c(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cc3)C(=O)OC2)c1		Inactive	adipose tissue development Inhibitor		1	Arctiin	363676837.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)ccc(C[C@@H]2[C@@H](Cc3cc(OC)c(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cc3)C(=O)OC2)c1	O(C)c1c(OC)ccc(C[C@@H]2[C@@H](Cc3cc(OC)c(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cc3)C(=O)OC2)c1
NCGC00015810-12&NCGC00015810-24&NCGC00015810-26	O(C)c1c(OC)ccc(Cc2nccc3c2cc(OC)c(OC)c3)c1		Inactive	Phosphodiesterase X (PDE10) Inhibitor		3	Papaverine hydrochloride	170465687.0&434146947.0&384567892.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O(C)c1c(OC)ccc(Cc2nccc3c2cc(OC)c(OC)c3)c1.Cl	O(C)c1c(OC)ccc(Cc2nccc3c2cc(OC)c(OC)c3)c1.Cl&O(C)c1c(OC)ccc(Cc2nccc3c2cc(OC)c(OC)c3)c1
NCGC00385732-01	O(C)c1c(OC)ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Hypoestes | Family: Acanthaceae | Species: verticillaris		1	NCGC00385732-01	363679907.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c1	O(C)c1c(OC)ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c1
NCGC00347419-02	O(C)c1c(OC)ccc([C@@H]2OC(=O)c3c(O)cccc3C2)c1		Inactive	<MOA Unknown> | Class: Flavonoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347419-02	363677597.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)ccc([C@@H]2OC(=O)c3c(O)cccc3C2)c1	O(C)c1c(OC)ccc([C@@H]2OC(=O)c3c(O)cccc3C2)c1
NCGC00385092-01	O(C)c1c(OC)ccc([C@@H]2OC[C@@H]3[C@@H](c4cc(OC)c(OC5C(O)C(O)C(O)C(CO)O5)cc4)OC[C@H]23)c1		Inactive	inflammatory response Inhibitor		1	NCGC00385092-01	363679527.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)ccc([C@@H]2OC[C@@H]3[C@@H](c4cc(OC)c(OC5C(O)C(O)C(O)C(CO)O5)cc4)OC[C@H]23)c1	O(C)c1c(OC)ccc([C@@H]2OC[C@@H]3[C@@H](c4cc(OC)c(OC5C(O)C(O)C(O)C(CO)O5)cc4)OC[C@H]23)c1
NCGC00347723-02	O(C)c1c(OC)ccc([C@@H]2[C@@H](C)[C@]3(OC)[C@](OC)(O2)CC(=O)C(CC=C)=C3)c1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347723-02	363677673.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)ccc([C@@H]2[C@@H](C)[C@]3(OC)[C@](OC)(O2)CC(=O)C(CC=C)=C3)c1	O(C)c1c(OC)ccc([C@@H]2[C@@H](C)[C@]3(OC)[C@](OC)(O2)CC(=O)C(CC=C)=C3)c1
NCGC00686699-01	O(C)c1c(OC)ccc([C@@](C#N)(C(C)C)CCCN(CCc2cc(OC)c(OC)cc2)C)c1		Inactive			1	S(-)-Verapamil hydrochloride hydrate	434147192.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC)ccc([C@@](C#N)(C(C)C)CCCN(CCc2cc(OC)c(OC)cc2)C)c1	O(C)c1c(OC)ccc([C@@](C#N)(C(C)C)CCCN(CCc2cc(OC)c(OC)cc2)C)c1
NCGC00168923-03	O(C)c1c(OC)ccc([C@H]2OC[C@@H]3[C@@H](c4cc(OC)c(O[C@H]5[C@H](O)[C@@H](O)C(O)[C@@H](CO)O5)cc4)OC[C@H]23)c1		Inactive	inflammatory response Inhibitor		1	NCGC00168923-03	363676723.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)ccc([C@H]2OC[C@@H]3[C@@H](c4cc(OC)c(O[C@H]5[C@H](O)[C@@H](O)C(O)[C@@H](CO)O5)cc4)OC[C@H]23)c1	O(C)c1c(OC)ccc([C@H]2OC[C@@H]3[C@@H](c4cc(OC)c(O[C@H]5[C@H](O)[C@@H](O)C(O)[C@@H](CO)O5)cc4)OC[C@H]23)c1
NCGC00023230-10&NCGC00023230-28	O(C)c1c(OC)ccc2[C@@H]([C@@H]3N(C)CCc4c3c(OC)c3OCOc3c4)OC(=O)c12		Inactive	Tubulin polymerization inhibitors		2	Noscapine&NOSCAPINE HYDROCHLORIDE	170465539.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&-10.7996781919&0.0	O(C)c1c(OC)ccc2[C@@H]([C@@H]3N(C)CCc4c3c(OC)c3OCOc3c4)OC(=O)c12	O(C)c1c(OC)ccc2[C@@H]([C@@H]3N(C)CCc4c3c(OC)c3OCOc3c4)OC(=O)c12
NCGC00017326-05	O(C)c1c(OC)ccc2[C@H]([C@H]3N(C)CCc4c3cc3OCOc3c4)OC(=O)c12		Inactive	GABA-A receptor; anion channel Antagonist		1	(1S,9R)-beta-Hydrastine	170465706.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(C)c1c(OC)ccc2[C@H]([C@H]3N(C)CCc4c3cc3OCOc3c4)OC(=O)c12	O(C)c1c(OC)ccc2[C@H]([C@H]3N(C)CCc4c3cc3OCOc3c4)OC(=O)c12
NCGC00016333-05	O(C)c1c(OC)ccc2c(OC)c3c(occ3)nc12		Inactive	Acetylcholinesterase Inhibitor		1	Skimmianine	363676481.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)ccc2c(OC)c3c(occ3)nc12	O(C)c1c(OC)ccc2c(OC)c3c(occ3)nc12
NCGC00173359-08	O(C)c1c(OC)ccc2c1CN1C(c3c(cc4OCOc4c3)CC1)C2		Inactive	K+/ATP Signaling Inhibitor		1	Tetrahydroberberine	377020329.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)ccc2c1CN1C(c3c(cc4OCOc4c3)CC1)C2	O(C)c1c(OC)ccc2c1CN1C(c3c(cc4OCOc4c3)CC1)C2
NCGC00073008-02	O(C)c1c(OC)ccc2c1CN1[C@H](c3c(cc(OC)c(OC)c3)CC1)C2		Inactive			1	NCGC00073008-02	124889024.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC)ccc2c1CN1[C@H](c3c(cc(OC)c(OC)c3)CC1)C2	O(C)c1c(OC)ccc2c1CN1[C@H](c3c(cc(OC)c(OC)c3)CC1)C2
NCGC00015225-08	O(C)c1c(OC)ccc2c1c[n+](C)c1c3c(cc4OCOc4c3)ccc21		Inactive	PKC Inhibitor		1	Chelerythrine chloride	384567826.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.7703523641	O(C)c1c(OC)ccc2c1c[n+](C)c1c3c(cc4OCOc4c3)ccc21	O(C)c1c(OC)ccc2c1c[n+](C)c1c3c(cc4OCOc4c3)ccc21
NCGC00016526-07&NCGC00016526-16	O(C)c1c(OC)ccc2c1c[n+]1c(-c3c(cc4OCOc4c3)CC1)c2		Inactive	Protein Tyrosine Phosphatase (PTP) Inhibitor		2	Berberine	170465752.0&384567947.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O(C)c1c(OC)ccc2c1c[n+]1c(-c3c(cc4OCOc4c3)CC1)c2.[Cl-]	O(C)c1c(OC)ccc2c1c[n+]1c(-c3c(cc4OCOc4c3)CC1)c2.[Cl-]&O(C)c1c(OC)ccc2c1c[n+]1c(-c3c(cc4OCOc4c3)CC1)c2
NCGC00384847-01	O(C)c1c(OC2C(O)C(O)C(O)C(CO)O2)ccc(C2C(CO)C(C(O)c3cc(OC)c(O)cc3)CO2)c1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384847-01	363679392.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC2C(O)C(O)C(O)C(CO)O2)ccc(C2C(CO)C(C(O)c3cc(OC)c(O)cc3)CO2)c1	O(C)c1c(OC2C(O)C(O)C(O)C(CO)O2)ccc(C2C(CO)C(C(O)c3cc(OC)c(O)cc3)CO2)c1
NCGC00385145-01	O(C)c1c(OC2C(O)C(O)C(O)C(CO)O2)ccc(C2C(CO)C(Cc3cc(OC)c(O)cc3)CO2)c1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385145-01	363679558.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC2C(O)C(O)C(O)C(CO)O2)ccc(C2C(CO)C(Cc3cc(OC)c(O)cc3)CO2)c1	O(C)c1c(OC2C(O)C(O)C(O)C(CO)O2)ccc(C2C(CO)C(Cc3cc(OC)c(O)cc3)CO2)c1
NCGC00380705-01	O(C)c1c(OC2C(O)C(O)C(O)C(CO)O2)ccc(C2C(CO)C(O)(CO)Cc3c2cc(OC)c(O)c3)c1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380705-01	363678722.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC2C(O)C(O)C(O)C(CO)O2)ccc(C2C(CO)C(O)(CO)Cc3c2cc(OC)c(O)c3)c1	O(C)c1c(OC2C(O)C(O)C(O)C(CO)O2)ccc(C2C(CO)C(O)(CO)Cc3c2cc(OC)c(O)c3)c1
NCGC00169630-02	O(C)c1c(OC2C(O)C(O)C(O)C(CO)O2)ccc(C2OCC3C(c4cc(OC)c(O)cc4)OCC23)c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Lavendula | Family: Lamiaceae | Species: officinalis		1	NCGC00169630-02	363676853.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC2C(O)C(O)C(O)C(CO)O2)ccc(C2OCC3C(c4cc(OC)c(O)cc4)OCC23)c1	O(C)c1c(OC2C(O)C(O)C(O)C(CO)O2)ccc(C2OCC3C(c4cc(OC)c(O)cc4)OCC23)c1
NCGC00015898-15&NCGC00015898-28	O(C)c1c(OC2CCCC2)cc(C2CC(=O)NC2)cc1		Inactive	Phosphodiesterase IIII (PDE4) Inhibitor		2	Rolipram	170465962.0&384567905.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	O(C)c1c(OC2CCCC2)cc(C2CC(=O)NC2)cc1	O(C)c1c(OC2CCCC2)cc(C2CC(=O)NC2)cc1
NCGC00387127-01	O(C)c1c(OC2CCCC2)cc([C@H](Cc2ccncc2)c2ccccc2)cc1		Inactive	Phosphodiesterase 4D Inhibitor		1	CDP 840 hydrochloride	363680545.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(OC2CCCC2)cc([C@H](Cc2ccncc2)c2ccccc2)cc1	O(C)c1c(OC2CCCC2)cc([C@H](Cc2ccncc2)c2ccccc2)cc1
NCGC00016899-11	O(C)c1c(OC2CCCC2)cc([C@H]2CC(=O)NC2)cc1		Inactive	Phosphodiesterase IIII (PDE4) Inhibitor		1	S-(+)-Rolipram	384567966.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(OC2CCCC2)cc([C@H]2CC(=O)NC2)cc1	O(C)c1c(OC2CCCC2)cc([C@H]2CC(=O)NC2)cc1
NCGC00379206-01	O(C)c1c(O[C@@H]2CNCC2)c2c(cc1)CCC2		Inactive	Serotonin 2c (5-HT2c) receptor Agonist		1	Org 37684	363678417.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O[C@@H]2CNCC2)c2c(cc1)CCC2	O(C)c1c(O[C@@H]2CNCC2)c2c(cc1)CCC2
NCGC00384572-01	O(C)c1c(O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@@H](C)O2)ccc(C2C(CO)c3c(c(O)cc(CCCO)c3)O2)c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Juniperus | Family: Cupressaceae | Species: communis		1	NCGC00384572-01	363679250.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@@H](C)O2)ccc(C2C(CO)c3c(c(O)cc(CCCO)c3)O2)c1	O(C)c1c(O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@@H](C)O2)ccc(C2C(CO)c3c(c(O)cc(CCCO)c3)O2)c1
NCGC00168804-02	O(C)c1c(O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@@H](C)O2)ccc(C2C(CO)c3c(c(OC)cc(CCCO)c3)O2)c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Juniperus | Family: Cupressaceae | Species: communis		1	NCGC00168804-02	363676688.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@@H](C)O2)ccc(C2C(CO)c3c(c(OC)cc(CCCO)c3)O2)c1	O(C)c1c(O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@@H](C)O2)ccc(C2C(CO)c3c(c(OC)cc(CCCO)c3)O2)c1
NCGC00168459-04	O(C)c1c(O[C@H]2COCC2)cc(C2=Nn3c(-c4c(OC)ccc(OC)c4)nnc3C=C2)cc1		Inactive	Phosphodiesterase IIII (PDE4) Inhibitor		1	NCGC00168459-01	174006302.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O(C)c1c(O[C@H]2COCC2)cc(C2=Nn3c(-c4c(OC)ccc(OC)c4)nnc3C=C2)cc1	O(C)c1c(O[C@H]2COCC2)cc(C2=Nn3c(-c4c(OC)ccc(OC)c4)nnc3C=C2)cc1
NCGC00385556-01	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(OC)cc(CO)c1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385556-01	363679806.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(OC)cc(CO)c1	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(OC)cc(CO)c1
NCGC00388362-02	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc2OC=C(c3ccc(O)cc3)C(=O)c2c1		Inactive			1	Glycitin		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc2OC=C(c3ccc(O)cc3)C(=O)c2c1	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc2OC=C(c3ccc(O)cc3)C(=O)c2c1
NCGC00385761-01	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(/C=C/C)c1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385761-01	363679928.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(/C=C/C)c1	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(/C=C/C)c1
NCGC00179896-02	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(/C=C/CO)c1		Inactive	Cyclooxygenase-1 Inhibitor		1	NCGC00179896-02	363676984.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(/C=C/CO)c1	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(/C=C/CO)c1
NCGC00380187-01	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(C2C3(O)C(O)(C(c4cc(OC)c(O)cc4)OC3)CO2)c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Valeriana | Family: Valerianaceae | Species: mexicana		1	NCGC00380187-01	363678494.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(C2C3(O)C(O)(C(c4cc(OC)c(O)cc4)OC3)CO2)c1	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(C2C3(O)C(O)(C(c4cc(OC)c(O)cc4)OC3)CO2)c1
NCGC00385694-01	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(CC=C)c1		Inactive	Angiotensin-converting enzyme Inhibitor		1	NCGC00385694-01	363679879.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(CC=C)c1	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(CC=C)c1
NCGC00385227-01	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(CCCO)c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Pinus | Family: Pinaceae | Species: nigra nigra		1	NCGC00385227-01	363679605.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(CCCO)c1	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(CCCO)c1
NCGC00169449-02	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(CCO)c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Fraxinus | Family: Oleaceae | Species: excelsior		1	NCGC00169449-02	363676818.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(CCO)c1	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(CCO)c1
NCGC00385285-01	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(CO)c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Succisa | Family: Dipsacaceae | Species: pratensis		1	NCGC00385285-01	363679644.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(CO)c1	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(CO)c1
NCGC00168940-03	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(C[C@]2(O)[C@H](CO)[C@@H](c3cc(OC)c(O)cc3)OC2)c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: n.b. | Family: N/A | Species: N/A		1	NCGC00168940-03	363676728.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(C[C@]2(O)[C@H](CO)[C@@H](c3cc(OC)c(O)cc3)OC2)c1	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(C[C@]2(O)[C@H](CO)[C@@H](c3cc(OC)c(O)cc3)OC2)c1
NCGC00347812-02	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc([C@@H]2[C@@H](CO)[C@](O)(CO)Cc3c2cc(O)c(OC)c3)c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347812-02	363677694.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc([C@@H]2[C@@H](CO)[C@](O)(CO)Cc3c2cc(O)c(OC)c3)c1	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc([C@@H]2[C@@H](CO)[C@](O)(CO)Cc3c2cc(O)c(OC)c3)c1
NCGC00347731-02	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc([C@H]2OC[C@]3(O)[C@@H](c4cc(OC)c(O)cc4)OC[C@H]23)c1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: Jasminum | Family: N/A | Species: multiflorum		1	NCGC00347731-02	363677675.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc([C@H]2OC[C@]3(O)[C@@H](c4cc(OC)c(O)cc4)OC[C@H]23)c1	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc([C@H]2OC[C@]3(O)[C@@H](c4cc(OC)c(O)cc4)OC[C@H]23)c1
NCGC00385271-01	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc([C@H]2[C@@H](CO)[C@@](O)(Cc3cc(OC)c(O)cc3)CO2)c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Zanthoxylum | Family: Rutaceae | Species: gilletii		1	NCGC00385271-01	363679631.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc([C@H]2[C@@H](CO)[C@@](O)(Cc3cc(OC)c(O)cc3)CO2)c1	O(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc([C@H]2[C@@H](CO)[C@@](O)(Cc3cc(OC)c(O)cc3)CO2)c1
NCGC00381238-01	O(C)c1c(O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)c(C)c(C/C=C(/C/C=C/C(=C/C(C(O)/C(=C/C)/C)C)/C)\C)nc1OC		Inactive	<MOA Unknown> | Class: Polyketide | Genus: - | Family: - | Species: -		1	NCGC00381238-01	363679043.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c(O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)c(C)c(C/C=C(/C/C=C/C(=C/C(C(O)/C(=C/C)/C)C)/C)\C)nc1OC	O(C)c1c(O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)c(C)c(C/C=C(/C/C=C/C(=C/C(C(O)/C(=C/C)/C)C)/C)\C)nc1OC
NCGC00390429-01	O(C)c1c2C(=O)CC(c3ccc(O)cc3)Oc2c(CC=C(C)C)c(O)c1		Inactive			1	Isoxanthohumol	434147201.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c2C(=O)CC(c3ccc(O)cc3)Oc2c(CC=C(C)C)c(O)c1	O(C)c1c2C(=O)CC(c3ccc(O)cc3)Oc2c(CC=C(C)C)c(O)c1
NCGC00385578-01	O(C)c1c2C(=O)OC(C)CCCCCCCc2cc(O)c1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385578-01	363679819.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c2C(=O)OC(C)CCCCCCCc2cc(O)c1	O(C)c1c2C(=O)OC(C)CCCCCCCc2cc(O)c1
NCGC00169582-02	O(C)c1c2C(=O)OC(C)Cc2cc(O)c1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169582-02	363676842.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c2C(=O)OC(C)Cc2cc(O)c1	O(C)c1c2C(=O)OC(C)Cc2cc(O)c1
NCGC00169365-03	O(C)c1c2C(=O)OCc2c(C)c2OC3(C)C(C4(C)C(O)(C(C)(C)OC(=O)CC4)C(O)C3)Cc12		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: ct: Aspergillus | Family: N/A | Species: ct: ustus		1	NCGC00169365-03	363676806.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c2C(=O)OCc2c(C)c2OC3(C)C(C4(C)C(O)(C(C)(C)OC(=O)CC4)C(O)C3)Cc12	O(C)c1c2C(=O)OCc2c(C)c2OC3(C)C(C4(C)C(O)(C(C)(C)OC(=O)CC4)C(O)C3)Cc12
NCGC00384843-01	O(C)c1c2C(=O)OCc2c(C)c2OC3(C)C(C4(C)C(O)CC5(OC)OC(C)(C)C4(C(O)C3)O5)Cc12		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384843-01	363679389.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c2C(=O)OCc2c(C)c2OC3(C)C(C4(C)C(O)CC5(OC)OC(C)(C)C4(C(O)C3)O5)Cc12	O(C)c1c2C(=O)OCc2c(C)c2OC3(C)C(C4(C)C(O)CC5(OC)OC(C)(C)C4(C(O)C3)O5)Cc12
NCGC00347804-02	O(C)c1c2C(=O)OCc2c(C)c2OC3(C)C(C4(C)C5(C(C)(C)OC(O)(O5)CC4)C(O)C3)Cc12		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347804-02	363677692.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c2C(=O)OCc2c(C)c2OC3(C)C(C4(C)C5(C(C)(C)OC(O)(O5)CC4)C(O)C3)Cc12	O(C)c1c2C(=O)OCc2c(C)c2OC3(C)C(C4(C)C5(C(C)(C)OC(O)(O5)CC4)C(O)C3)Cc12
NCGC00381182-01	O(C)c1c2C(=O)OCc2c(C)c2OC3(C)C(C4(C)C5(C(C)(C)OC(OC)(C(O)C4)O5)C(O)C3)Cc12		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381182-01	363679009.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c2C(=O)OCc2c(C)c2OC3(C)C(C4(C)C5(C(C)(C)OC(OC)(C(O)C4)O5)C(O)C3)Cc12	O(C)c1c2C(=O)OCc2c(C)c2OC3(C)C(C4(C)C5(C(C)(C)OC(OC)(C(O)C4)O5)C(O)C3)Cc12
NCGC00380890-01	O(C)c1c2C(=O)OCc2c(C)c2OC3(C)C(C4(C)C5(C(CO)(C)OC(OC)(O5)CC4)C(O)C3)Cc12		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: ct: Aspergillus | Family: N/A | Species: ct: ustus		1	NCGC00380890-01	363678835.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c2C(=O)OCc2c(C)c2OC3(C)C(C4(C)C5(C(CO)(C)OC(OC)(O5)CC4)C(O)C3)Cc12	O(C)c1c2C(=O)OCc2c(C)c2OC3(C)C(C4(C)C5(C(CO)(C)OC(OC)(O5)CC4)C(O)C3)Cc12
NCGC00347535-02	O(C)c1c2C(=O)OCc2c(C)c2O[C@]3(C)[C@@H]([C@]4(C)C(C(O)(C)C)(OC(=O)CC4)CC3)Cc12		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347535-02	363677618.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c2C(=O)OCc2c(C)c2O[C@]3(C)[C@@H]([C@]4(C)C(C(O)(C)C)(OC(=O)CC4)CC3)Cc12	O(C)c1c2C(=O)OCc2c(C)c2O[C@]3(C)[C@@H]([C@]4(C)C(C(O)(C)C)(OC(=O)CC4)CC3)Cc12
NCGC00381185-01	O(C)c1c2C(=O)OCc2c(C)c2O[C@]3(C)[C@@H]([C@]4(C)[C@@]5([C@H](O)C3)C(C)(C)O[C@](OC)(O5)CC4)Cc12		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: ct: Aspergillus | Family: N/A | Species: ct: ustus		1	NCGC00381185-01	363679012.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c2C(=O)OCc2c(C)c2O[C@]3(C)[C@@H]([C@]4(C)[C@@]5([C@H](O)C3)C(C)(C)O[C@](OC)(O5)CC4)Cc12	O(C)c1c2C(=O)OCc2c(C)c2O[C@]3(C)[C@@H]([C@]4(C)[C@@]5([C@H](O)C3)C(C)(C)O[C@](OC)(O5)CC4)Cc12
NCGC00380176-01	O(C)c1c2C(=O)OCc2c(CO)c2OC3(C)C(C4(C)C(O)(C(C)(C)OC(=O)CC4)CC3)Cc12		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380176-01	363678490.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c2C(=O)OCc2c(CO)c2OC3(C)C(C4(C)C(O)(C(C)(C)OC(=O)CC4)CC3)Cc12	O(C)c1c2C(=O)OCc2c(CO)c2OC3(C)C(C4(C)C(O)(C(C)(C)OC(=O)CC4)CC3)Cc12
NCGC00169215-02	O(C)c1c2C(=O)[C@@]3([C@H](C)CC(=O)C=C3OC)Oc2cc(OC)c1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169215-02	363676791.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c2C(=O)[C@@]3([C@H](C)CC(=O)C=C3OC)Oc2cc(OC)c1	O(C)c1c2C(=O)[C@@]3([C@H](C)CC(=O)C=C3OC)Oc2cc(OC)c1
NCGC00385846-01	O(C)c1c2OCOc2cc(-c2cc(O)ccc2)c1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385846-01	363679967.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c2OCOc2cc(-c2cc(O)ccc2)c1	O(C)c1c2OCOc2cc(-c2cc(O)ccc2)c1
NCGC00385072-01	O(C)c1c2OCOc2cc2c1-c1c(OC)c3OCOc3cc1CC(C)C(C)C2		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	Schisandrin C	363679517.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c2OCOc2cc2c1-c1c(OC)c3OCOc3cc1CC(C)C(C)C2	O(C)c1c2OCOc2cc2c1-c1c(OC)c3OCOc3cc1CC(C)C(C)C2
NCGC00016666-06	O(C)c1c2OCOc2cc2c1CN(C)CC2		Inactive	Cytochrome P450 3A4 Inhibitor		1	Hydrocotarnine hydrobromide	170465806.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c2OCOc2cc2c1CN(C)CC2.Br	O(C)c1c2OCOc2cc2c1CN(C)CC2.Br
NCGC00017256-17	O(C)c1c2O[C@@H]3[C@]4(c2c(cc1)CN(C)CC4)C=C[C@H](O)C3		Inactive	Acetylcholinesterase Inhibitors		1	Galanthamine	405558901.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1c2O[C@@H]3[C@]4(c2c(cc1)CN(C)CC4)C=C[C@H](O)C3	O(C)c1c2O[C@@H]3[C@]4(c2c(cc1)CN(C)CC4)C=C[C@H](O)C3
NCGC00161621-03&NCGC00161621-13	O(C)c1c2Oc3c4OCOc4cc4c3[C@@H](N(C)CC4)Cc3ccc(Oc4c(OC)ccc(c4)C[C@H]4N(C)CCc(c4c2)c1)cc3	5.67499995	Active		0.04999969999999987	2	Cepharanthine	170465994.0&406861842.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	83.6376608872&96.0783047704	O(C)c1c2Oc3c4OCOc4cc4c3[C@@H](N(C)CC4)Cc3ccc(Oc4c(OC)ccc(c4)C[C@H]4N(C)CCc(c4c2)c1)cc3	O(C)c1c2Oc3c4OCOc4cc4c3[C@@H](N(C)CC4)Cc3ccc(Oc4c(OC)ccc(c4)C[C@H]4N(C)CCc(c4c2)c1)cc3
NCGC00522011-01	O(C)c1c2[C@@H](C)C=C3C4(N(CC)C(=O)N3Cc2cc(OC)c1)CCN(Cc1cc(C)cc(C)c1)CC4		Inactive	Potent EP4 Receptor Antagonist		1	ER 819762	384569511.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	29.2154811719	O(C)c1c2[C@@H](C)C=C3C4(N(CC)C(=O)N3Cc2cc(OC)c1)CCN(Cc1cc(C)cc(C)c1)CC4	O(C)c1c2[C@@H](C)C=C3C4(N(CC)C(=O)N3Cc2cc(OC)c1)CCN(Cc1cc(C)cc(C)c1)CC4
NCGC00165875-04	O(C)c1c2c(C(CCCN3CCN(C4CCCCC4)CC3)CCC2)ccc1	4.9749999	Active	sigma1/2 Receptor Agonist	0.0	1	PB-28	384568294.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	91.190944837&100.289269056	O(C)c1c2c(C(CCCN3CCN(C4CCCCC4)CC3)CCC2)ccc1	O(C)c1c2c(C(CCCN3CCN(C4CCCCC4)CC3)CCC2)ccc1
NCGC00161703-03	O(C)c1c2c(NN3C(=O)C(C)=CC3=O)nc(-c3sccc3)nc2ccc1		Inactive	IKK beta Inhibitor		1	SPC-839	363676607.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O(C)c1c2c(NN3C(=O)C(C)=CC3=O)nc(-c3sccc3)nc2ccc1	O(C)c1c2c(NN3C(=O)C(C)=CC3=O)nc(-c3sccc3)nc2ccc1
NCGC00254844-01	O(C)c1c2c(OC(=O)C=C2)cc(OC)c1		Inactive			1	5,7-Dimethoxy-2H-chromen-2-one	144211259.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c2c(OC(=O)C=C2)cc(OC)c1	O(C)c1c2c(OC(=O)C=C2)cc(OC)c1
NCGC00378605-01	O(C)c1c2c([C@H](CN(CCc3cc4occc4cc3)C)CCC2)ccc1		Inactive	serotonin uptake Inhibitor		1	A 80426 mesylate	363678119.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	32.4538439719	O(C)c1c2c([C@H](CN(CCc3cc4occc4cc3)C)CCC2)ccc1	O(C)c1c2c([C@H](CN(CCc3cc4occc4cc3)C)CCC2)ccc1
NCGC00485134-01	O(C)c1c2c(c(CNCCc3ccc(OC)cc3)cc1)cccc2	4.9000001	Active	Cyclic AMP-dependent transcription factor ATF-2 Inhibitor	0.0	1	SBI-0087702	363681238.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	102.128085614	O(C)c1c2c(c(CNCCc3ccc(OC)cc3)cc1)cccc2	O(C)c1c2c(c(CNCCc3ccc(OC)cc3)cc1)cccc2
NCGC00385478-01	O(C)c1c2c(nc3c(c2)CN2C(=O)C4=C([C@@](O)(CC)C(=O)OC4)C=C32)ccc1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	9-Methoxycamptothecin	363679762.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c2c(nc3c(c2)CN2C(=O)C4=C([C@@](O)(CC)C(=O)OC4)C=C32)ccc1	O(C)c1c2c(nc3c(c2)CN2C(=O)C4=C([C@@](O)(CC)C(=O)OC4)C=C32)ccc1
NCGC00385071-01	O(C)c1c2c(occ2)nc2C(OC)(CC=C(C)C)C(O)CCc12		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385071-01	363679516.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1c2c(occ2)nc2C(OC)(CC=C(C)C)C(O)CCc12	O(C)c1c2c(occ2)nc2C(OC)(CC=C(C)C)C(O)CCc12
NCGC00347064-04&NCGC00347064-06	O(C)c1c2nc(-n3c(N)nc4c3cccc4)nc(NCc3ccccc3)c2ccc1		Inactive	p97 ATPase Inhibitor		2	KUC107871N	363677569.0&440681594.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O(C)c1c2nc(-n3c(N)nc4c3cccc4)nc(NCc3ccccc3)c2ccc1	O(C)c1c2nc(-n3c(N)nc4c3cccc4)nc(NCc3ccccc3)c2ccc1
NCGC00016418-15&NCGC00016418-23	O(C)c1c2occc2cc2c1OC(=O)C=C2		Inactive	Cytochrome P450 CYP1A2 Inhibitor		2	Methoxsalen	170465041.0&384567939.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O(C)c1c2occc2cc2c1OC(=O)C=C2	O(C)c1c2occc2cc2c1OC(=O)C=C2
NCGC00386697-01	O(C)c1cc(-c2nc(N)nc(NCc3cc4OCOc4cc3)c2)ccc1		Inactive	tubulin complex assembly Inhibitor		1	Wnt agonist 1	363680402.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	23.0	O(C)c1cc(-c2nc(N)nc(NCc3cc4OCOc4cc3)c2)ccc1	O(C)c1cc(-c2nc(N)nc(NCc3cc4OCOc4cc3)c2)ccc1
NCGC00390782-01	O(C)c1cc(C#Cc2ncccc2)cnc1		Inactive	Metabotropic glutamate receptor 5 Antagonist		1	Methoxy-PEPy	363680983.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc(C#Cc2ncccc2)cnc1	O(C)c1cc(C#Cc2ncccc2)cnc1
NCGC00137314-01	O(C)c1cc(C(N2CCN(C)CC2)C2=C(O)n3nc(-c4occc4)nc3S2)ccc1		Inactive			1	NCGC00137314-01	24412697.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc(C(N2CCN(C)CC2)C2=C(O)n3nc(-c4occc4)nc3S2)ccc1	O(C)c1cc(C(N2CCN(C)CC2)C2=C(O)n3nc(-c4occc4)nc3S2)ccc1
NCGC00378738-01	O(C)c1cc(CCc2[nH]c3c(n2)nccc3)ncc1		Inactive	Nitric oxide synthase, inducible Inhibitor		1	BYK 191023 dihydrochloride	363678177.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc(CCc2[nH]c3c(n2)nccc3)ncc1	O(C)c1cc(CCc2[nH]c3c(n2)nccc3)ncc1
NCGC00510503-01	O(C)c1cc(N(CC)Cc2ccc(CCNCC)cc2)c([C@H]2Cc3c(cc(O)cc3)CC2)cc1	5.6500001	Active	Selective Estrogen Receptor Modulators (SERM)	0.0	1	Elacestrant	384569464.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	58.7931797682	O(C)c1cc(N(CC)Cc2ccc(CCNCC)cc2)c([C@H]2Cc3c(cc(O)cc3)CC2)cc1	O(C)c1cc(N(CC)Cc2ccc(CCNCC)cc2)c([C@H]2Cc3c(cc(O)cc3)CC2)cc1
NCGC00178754-06	O(C)c1cc(NC(CCCN)C)c2ncccc2c1		Inactive	antimalarial		1	Primaquine diphosphate	174006623.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	P(=O)(O)(O)O.P(=O)(O)(O)O.O(C)c1cc(NC(CCCN)C)c2ncccc2c1	P(=O)(O)(O)O.P(=O)(O)(O)O.O(C)c1cc(NC(CCCN)C)c2ncccc2c1
NCGC00378630-01	O(C)c1cc(NC2=NC=Nn3c2c(CN2C[C@@H](O)[C@H](N)CC2)cc3)ccc1		Inactive	VEGFR-3 Inhibitor		1	BMS-690514	363678131.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1cc(NC2=NC=Nn3c2c(CN2C[C@@H](O)[C@H](N)CC2)cc3)ccc1	O(C)c1cc(NC2=NC=Nn3c2c(CN2C[C@@H](O)[C@H](N)CC2)cc3)ccc1
NCGC00386990-01	O(C)c1cc(NCCCCCCN(CC)CC)c2nccc(C)c2c1	4.9000001	Active	Leishmania donovani Inhibitor	0.0	1	Sitamaquine tosylate	363680522.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	110.1988952401	O(C)c1cc(NCCCCCCN(CC)CC)c2nccc(C)c2c1	O(C)c1cc(NCCCCCCN(CC)CC)c2nccc(C)c2c1
NCGC00169266-02	O(C)c1cc(O)c(C2COc3c(ccc(O)c3)C2)cc1		Inactive	neutrophil migration Inhibitor		1	NCGC00169266-02	363676796.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc(O)c(C2COc3c(ccc(O)c3)C2)cc1	O(C)c1cc(O)c(C2COc3c(ccc(O)c3)C2)cc1
NCGC00385102-01	O(C)c1cc(O)c(C=2C(Cc3ccc(O)cc3)OC(=O)C=2)cc1		Inactive	<MOA Unknown> | Class: Flavon | Genus: Ononis | Family: Fabaceae | Species: laxiflora		1	NCGC00385102-01	363679534.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc(O)c(C=2C(Cc3ccc(O)cc3)OC(=O)C=2)cc1	O(C)c1cc(O)c(C=2C(Cc3ccc(O)cc3)OC(=O)C=2)cc1
NCGC00095624-03	O(C)c1cc(O)c2C(=O)C(O)=C(c3cc(O)c(O)cc3)Oc2c1		Inactive			1	RHAMNETINE	124891931.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc(O)c2C(=O)C(O)=C(c3cc(O)c(O)cc3)Oc2c1	O(C)c1cc(O)c2C(=O)C(O)=C(c3cc(O)c(O)cc3)Oc2c1
NCGC00169917-02	O(C)c1cc(O)c2C(=O)C3(C(OC)=CC(=O)CC3C)Oc2c1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169917-02	363676913.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc(O)c2C(=O)C3(C(OC)=CC(=O)CC3C)Oc2c1	O(C)c1cc(O)c2C(=O)C3(C(OC)=CC(=O)CC3C)Oc2c1
NCGC00178332-02	O(C)c1cc(O)c2C(=O)C=C(c3ccc(O)cc3)Oc2c1		Inactive			1	Genkwanin	434147049.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1cc(O)c2C(=O)C=C(c3ccc(O)cc3)Oc2c1	O(C)c1cc(O)c2C(=O)C=C(c3ccc(O)cc3)Oc2c1
NCGC00381160-01	O(C)c1cc(O)c2C(=O)OC3(C(C)=CC(=O)C3O)c2c1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381160-01	363679001.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc(O)c2C(=O)OC3(C(C)=CC(=O)C3O)c2c1	O(C)c1cc(O)c2C(=O)OC3(C(C)=CC(=O)C3O)c2c1
NCGC00384948-01	O(C)c1cc(O)c2C(=O)OC3(C)C(c2c1)=CC(O)C(O)C3		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384948-01	363679453.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc(O)c2C(=O)OC3(C)C(c2c1)=CC(O)C(O)C3	O(C)c1cc(O)c2C(=O)OC3(C)C(c2c1)=CC(O)C(O)C3
NCGC00183677-03	O(C)c1cc(O)c2C(=O)O[C@@H](C)C/C=C\C(=O)[C@@H](O)[C@@H](O)CC3OC3c2c1	5.0500002	Active	Mek 1/2 Inhibitor	0.0	1	Hypothemycin	174006434.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	70.8309215263	O(C)c1cc(O)c2C(=O)O[C@@H](C)C/C=C\C(=O)[C@@H](O)[C@@H](O)CC3OC3c2c1	O(C)c1cc(O)c2C(=O)O[C@@H](C)C/C=C\C(=O)[C@@H](O)[C@@H](O)CC3OC3c2c1
NCGC00347789-02	O(C)c1cc(O)c2C(=O)O[C@@H](C)C/C=C\C(=O)[C@@H](O)[C@H](O)CCCc2c1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: Hyalodendron | Family: N/A | Species: sp.		1	NCGC00347789-02	363677688.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc(O)c2C(=O)O[C@@H](C)C/C=C\C(=O)[C@@H](O)[C@H](O)CCCc2c1	O(C)c1cc(O)c2C(=O)O[C@@H](C)C/C=C\C(=O)[C@@H](O)[C@H](O)CCCc2c1
NCGC00380820-01	O(C)c1cc(O)c2C(=O)O[C@@H](C)CCCC(=O)[C@H](O)[C@H](O)C/C=C/c2c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380820-01	363678801.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc(O)c2C(=O)O[C@@H](C)CCCC(=O)[C@H](O)[C@H](O)C/C=C/c2c1	O(C)c1cc(O)c2C(=O)O[C@@H](C)CCCC(=O)[C@H](O)[C@H](O)C/C=C/c2c1
NCGC00179755-02	O(C)c1cc(O)c2C(=O)O[C@]3(C)C(c2c1)=C[C@H](O)[C@@H](O)C3		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Alternaria | Family: N/A | Species: N/A		1	NCGC00179755-02	363676965.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc(O)c2C(=O)O[C@]3(C)C(c2c1)=C[C@H](O)[C@@H](O)C3	O(C)c1cc(O)c2C(=O)O[C@]3(C)C(c2c1)=C[C@H](O)[C@@H](O)C3
NCGC00386030-01	O(C)c1cc(O)cc(/C=C/c2cc(O)ccc2)c1		Inactive	<MOA Unknown> | Class: Shikimi /Polyketide | Genus: Thunia | Family: Orchidaceae | Species: alba		1	NCGC00386030-01	363680070.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc(O)cc(/C=C/c2cc(O)ccc2)c1	O(C)c1cc(O)cc(/C=C/c2cc(O)ccc2)c1
NCGC00385668-01	O(C)c1cc(O)cc(/C=C/c2ccc(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)cc2)c1		Inactive	<MOA Unknown> | Class: Shikimi / Polyketide | Genus: Millettia | Family: Fabaceae | Species: thonningii		1	NCGC00385668-01	363679865.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc(O)cc(/C=C/c2ccc(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)cc2)c1	O(C)c1cc(O)cc(/C=C/c2ccc(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)cc2)c1
NCGC00388121-01	O(C)c1cc(OC)cc(/C=C\c2ccc(O)cc2)c1		Inactive			1	Pterostilbene	377020257.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	15.6527734719	O(C)c1cc(OC)cc(/C=C\c2ccc(O)cc2)c1	O(C)c1cc(OC)cc(/C=C\c2ccc(O)cc2)c1
NCGC00475735-01	O(C)c1cc(OC)cc(N(CCNC(C)C)c2cc3nc(-c4cn(C)nc4)cnc3cc2)c1		Inactive	FGFR 1/2/3/4 Inhibitor		1	Erdafitinib	377020396.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1cc(OC)cc(N(CCNC(C)C)c2cc3nc(-c4cn(C)nc4)cnc3cc2)c1	O(C)c1cc(OC)cc(N(CCNC(C)C)c2cc3nc(-c4cn(C)nc4)cnc3cc2)c1
NCGC00095239-05	O(C)c1cc(OC)cc(OC)c1		Inactive			1	1,3,5-Trimethoxybenzene	170465963.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(C)c1cc(OC)cc(OC)c1	O(C)c1cc(OC)cc(OC)c1
NCGC00380682-01	O(C)c1cc(OC2C(O)C(O)C(O)C(CO)O2)cc(O)c1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Calodendrum | Family: Rutaceae | Species: capense		1	NCGC00380682-01	363678705.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc(OC2C(O)C(O)C(O)C(CO)O2)cc(O)c1	O(C)c1cc(OC2C(O)C(O)C(O)C(CO)O2)cc(O)c1
NCGC00094244-15	O(C)c1cc2/C(=C/c3[nH]cnc3)/C(=O)Nc2cc1		Inactive			1	SU9516	377020259.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	14.209329216	O(C)c1cc2/C(=C/c3[nH]cnc3)/C(=O)Nc2cc1	O(C)c1cc2/C(=C/c3[nH]cnc3)/C(=O)Nc2cc1
NCGC00179370-05	O(C)c1cc2N(C[C@@H](CN(C)C)C)c3c(Sc2cc1)cccc3	4.9000001	Active	Serotonin 2 (5-HT2) receptor Antagonist	0.0	1	Methotrimeprazine maleat salt	405559100.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	102.1767652598	O(C)c1cc2N(C[C@@H](CN(C)C)C)c3c(Sc2cc1)cccc3	O(C)c1cc2N(C[C@@H](CN(C)C)C)c3c(Sc2cc1)cccc3
NCGC00385708-01	O(C)c1cc2N3C(=O)C[C@@]45[C@@]63[N@+]([O-])(CC=C4)CC[C@@H]([C@@H]6CC5)c2cc1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385708-01	363679888.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc2N3C(=O)C[C@@]45[C@@]63[N@+]([O-])(CC=C4)CC[C@@H]([C@@H]6CC5)c2cc1	O(C)c1cc2N3C(=O)C[C@@]45[C@@]63[N@+]([O-])(CC=C4)CC[C@@H]([C@@H]6CC5)c2cc1
NCGC00347650-02	O(C)c1cc2OC[C@@]3(O)[C@H](Oc4c3cc3OCOc3c4)c2cc1		Inactive	<MOA Unknown> | Class: Flavon | Genus: Leucaena | Family: Fabaceae | Species: glauca		1	NCGC00347650-02	363677653.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc2OC[C@@]3(O)[C@H](Oc4c3cc3OCOc3c4)c2cc1	O(C)c1cc2OC[C@@]3(O)[C@H](Oc4c3cc3OCOc3c4)c2cc1
NCGC00487085-02	O(C)c1cc2[C@@]3([C@H](c4cc5[nH]nc(/C=C/c6ccc(CN7C[C@@H](C)O[C@@H](C)C7)cc6)c5cc4)C3)C(=O)Nc2cc1	4.9000001	Active	Polo-like Kinase-4 (Plk-4) Inhibitor	0.0	1	CFI-400945	384569282.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	93.6380660308	O(C)c1cc2[C@@]3([C@H](c4cc5[nH]nc(/C=C/c6ccc(CN7C[C@@H](C)O[C@@H](C)C7)cc6)c5cc4)C3)C(=O)Nc2cc1	O(C)c1cc2[C@@]3([C@H](c4cc5[nH]nc(/C=C/c6ccc(CN7C[C@@H](C)O[C@@H](C)C7)cc6)c5cc4)C3)C(=O)Nc2cc1
NCGC00380742-01	O(C)c1cc2[nH]c3C(C=C(C)C)N4C(=O)C5N(C(=O)C4Cc3c2cc1)CCC5		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380742-01	363678755.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc2[nH]c3C(C=C(C)C)N4C(=O)C5N(C(=O)C4Cc3c2cc1)CCC5	O(C)c1cc2[nH]c3C(C=C(C)C)N4C(=O)C5N(C(=O)C4Cc3c2cc1)CCC5
NCGC00016435-06	O(C)c1cc2[nH]c3c(C)nccc3c2cc1		Inactive			1	HARMINE	124882259.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1cc2[nH]c3c(C)nccc3c2cc1	O(C)c1cc2[nH]c3c(C)nccc3c2cc1
NCGC00095192-05&NCGC00095192-08	O(C)c1cc2c(/C=N/NC(=N)NCCCCC)c[nH]c2cc1		Inactive	5-HT4 Partial Agonist		2	Tegaserod maleate	170466887.0&434146928.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	13.9786708599&0.0	O(C)c1cc2c(/C=N/NC(=N)NCCCCC)c[nH]c2cc1	O(C)c1cc2c(/C=N/NC(=N)NCCCCC)c[nH]c2cc1
NCGC00163505-09	O(C)c1cc2c(C3=C(c4c5c([nH]c4)cccc5)C(=O)NC3=O)cn(CCCN(C)C)c2cc1	4.9000001	Active	PKC Inhibitor	0.0	1	Go-6983	384568244.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	41.1595208399	O(C)c1cc2c(C3=C(c4c5c([nH]c4)cccc5)C(=O)NC3=O)cn(CCCN(C)C)c2cc1	O(C)c1cc2c(C3=C(c4c5c([nH]c4)cccc5)C(=O)NC3=O)cn(CCCN(C)C)c2cc1
NCGC00370860-01	O(C)c1cc2c(CCN(C)C)c(-c3ccccc3)[nH]c2cc1		Inactive	Serotonin 6 (5-HT6) receptor Antagonist		1	BGC 20-761	363677892.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc2c(CCN(C)C)c(-c3ccccc3)[nH]c2cc1	O(C)c1cc2c(CCN(C)C)c(-c3ccccc3)[nH]c2cc1
NCGC00387149-01	O(C)c1cc2c(CCN(C)C)c(CC)[nH]c2cc1		Inactive	Serotonin 6 (5-HT6) receptor Agonist		1	EMDT oxalate	363680550.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc2c(CCN(C)C)c(CC)[nH]c2cc1	O(C)c1cc2c(CCN(C)C)c(CC)[nH]c2cc1
NCGC00017285-06	O(C)c1cc2c(NC(=O)C3=C2OC(C)(C)C=C3)cc1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00017285-06	363676496.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc2c(NC(=O)C3=C2OC(C)(C)C=C3)cc1	O(C)c1cc2c(NC(=O)C3=C2OC(C)(C)C=C3)cc1
NCGC00166281-02	O(C)c1cc2c([C@@H](O)[C@H]3N4C[C@H](C=C)[C@H](C3)CC4)ccnc2cc1		Inactive			1	NCGC00166281-02	124893255.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1cc2c([C@@H](O)[C@H]3N4C[C@H](C=C)[C@H](C3)CC4)ccnc2cc1	O(C)c1cc2c([C@@H](O)[C@H]3N4C[C@H](C=C)[C@H](C3)CC4)ccnc2cc1
NCGC00025091-11	O(C)c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](NCCCCCCN5C(=O)C=CC5=O)CC4)CC3)CC2)cc1		Inactive	Phospholipase C Inhibitor		1	U-73122	384568047.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](NCCCCCCN5C(=O)C=CC5=O)CC4)CC3)CC2)cc1	O(C)c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](NCCCCCCN5C(=O)C=CC5=O)CC4)CC3)CC2)cc1
NCGC00093347-05&NCGC00093347-12	O(C)c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1		Inactive	Estrogen Receptor (ER) Agonist		2	Mestranol	170465357.0&384568112.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	13.8681276919&0.0&0.0	O(C)c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1	O(C)c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1
NCGC00091231-04	O(C)c1cc2c([C@H](O)[C@@H]3N4C[C@H](C=C)C(C3)CC4)ccnc2cc1		Inactive	Antimalarial Agents; Cytochrome P450 Cyp2d6 Inhibitors		1	Quinidine hydrochloride monohydrate	170465031.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.684307924	O(C)c1cc2c([C@H](O)[C@@H]3N4C[C@H](C=C)C(C3)CC4)ccnc2cc1	O(C)c1cc2c([C@H](O)[C@@H]3N4C[C@H](C=C)C(C3)CC4)ccnc2cc1
NCGC00180461-02	O(C)c1cc2c([C@H](O)[C@@H]3N4C[C@H](CC)[C@H](C3)CC4)ccnc2cc1	4.9000001	Active	Sodium channel alpha subunit Inhibitor	0.0	1	Hydroquinidine HCl	405558746.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	97.1899860299	O(C)c1cc2c([C@H](O)[C@@H]3N4C[C@H](CC)[C@H](C3)CC4)ccnc2cc1	O(C)c1cc2c([C@H](O)[C@@H]3N4C[C@H](CC)[C@H](C3)CC4)ccnc2cc1
NCGC00387481-01	O(C)c1cc2c([nH]c3c(-c4c5c(ccc4)cccc5)nccc23)cc1		Inactive	Tumour suppressor p53/oncoprotein Mdm2 Modulator		1	SP 141	363680636.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	21.0	O(C)c1cc2c([nH]c3c(-c4c5c(ccc4)cccc5)nccc23)cc1	O(C)c1cc2c([nH]c3c(-c4c5c(ccc4)cccc5)nccc23)cc1
NCGC00385518-01	O(C)c1cc2n3C(=O)C=Cc4nccc(c34)c2cc1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385518-01	363679786.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1cc2n3C(=O)C=Cc4nccc(c34)c2cc1	O(C)c1cc2n3C(=O)C=Cc4nccc(c34)c2cc1
NCGC00274063-04&NCGC00274063-05	O(C)c1ccc(-c2[nH]c3c(n2)cc(C=2C(C)CC(=O)NN=2)cc3)cc1		Inactive	Phosphodiesterase III (PDE3) Inhibitor		2	Pimobendan	434146882.0&363677311.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(C)c1ccc(-c2[nH]c3c(n2)cc(C=2C(C)CC(=O)NN=2)cc3)cc1	O(C)c1ccc(-c2[nH]c3c(n2)cc(C=2C(C)CC(=O)NN=2)cc3)cc1
NCGC00274063-01	O(C)c1ccc(-c2[nH]c3c(n2)ccc(C=2C(C)CC(=O)NN=2)c3)cc1		Inactive	Phosphodiesterase III (PDE3) Inhibitor		1	Pimobendan	174007050.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1ccc(-c2[nH]c3c(n2)ccc(C=2C(C)CC(=O)NN=2)c3)cc1.Cl	O(C)c1ccc(-c2[nH]c3c(n2)ccc(C=2C(C)CC(=O)NN=2)c3)cc1.Cl
NCGC00263231-01	O(C)c1ccc(-c2c(C)[nH]nc2-c2c(O)cc(O)cc2)cc1		Inactive	Pyruvate Dehydrogenase Kinase 2 Inhibitor		1	PDHK RIKEN	137276075.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-5.7679425799	O(C)c1ccc(-c2c(C)[nH]nc2-c2c(O)cc(O)cc2)cc1	O(C)c1ccc(-c2c(C)[nH]nc2-c2c(O)cc(O)cc2)cc1
NCGC00165096-01	O(C)c1ccc(-c2c(C)nn3c2N=CC=2C(=O)CC(c4ccc(C)cc4)CC3=2)cc1		Inactive			1	NCGC00165096-01	29216850.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1ccc(-c2c(C)nn3c2N=CC=2C(=O)CC(c4ccc(C)cc4)CC3=2)cc1	O(C)c1ccc(-c2c(C)nn3c2N=CC=2C(=O)CC(c4ccc(C)cc4)CC3=2)cc1
NCGC00408885-01	O(C)c1ccc(-c2c(CCCC)c3nccnc3[nH]2)cc1		Inactive	Glycogen synthase kinase-3 beta Inhibitor		1	RP-106	363681073.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1ccc(-c2c(CCCC)c3nccnc3[nH]2)cc1	O(C)c1ccc(-c2c(CCCC)c3nccnc3[nH]2)cc1
NCGC00164996-01	O(C)c1ccc(-c2c3c(nc(-c4cc5NC(=O)COc5cc4)c2)-c2c(OC3)ccc(C)c2)cc1		Inactive			1	NCGC00164996-01	29216750.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1ccc(-c2c3c(nc(-c4cc5NC(=O)COc5cc4)c2)-c2c(OC3)ccc(C)c2)cc1	O(C)c1ccc(-c2c3c(nc(-c4cc5NC(=O)COc5cc4)c2)-c2c(OC3)ccc(C)c2)cc1
NCGC00390402-02	O(C)c1ccc(-c2nc3c(c(C(O)C4NCCCC4)c2)cccc3)cc1	4.9000001	Active	P-Glycoprotein (MDR-1) Inhibitor	0.0	1	NSC-23925	363680887.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	78.0255021856	O(C)c1ccc(-c2nc3c(c(C(O)C4NCCCC4)c2)cccc3)cc1	O(C)c1ccc(-c2nc3c(c(C(O)C4NCCCC4)c2)cccc3)cc1
NCGC00379102-02	O(C)c1ccc(-c2oc(-c3c-4c(C(=O)c5c-4cccc5)ccc3)nc2)cc1		Inactive	microtubule polymerization Inhibitor		1	UA62784	363678352.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1ccc(-c2oc(-c3c-4c(C(=O)c5c-4cccc5)ccc3)nc2)cc1	O(C)c1ccc(-c2oc(-c3c-4c(C(=O)c5c-4cccc5)ccc3)nc2)cc1
NCGC00095109-08	O(C)c1ccc(C(CN(C)C)C2(O)CCCCC2)cc1		Inactive	5-HT Reuptake Inhibitor		1	Venlafaxine	170465123.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(C)c1ccc(C(CN(C)C)C2(O)CCCCC2)cc1	O(C)c1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
NCGC00385130-01	O(C)c1ccc(C(O)C(OC2C(O)C(O)C(O)C(CO)O2)C)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385130-01	363679551.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1ccc(C(O)C(OC2C(O)C(O)C(O)C(CO)O2)C)cc1	O(C)c1ccc(C(O)C(OC2C(O)C(O)C(O)C(CO)O2)C)cc1
NCGC00385893-01	O(C)c1ccc(C(OC2C(O)C(O)C(O)C(CO)O2)C(O)C)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385893-01	363679994.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1ccc(C(OC2C(O)C(O)C(O)C(CO)O2)C(O)C)cc1	O(C)c1ccc(C(OC2C(O)C(O)C(O)C(CO)O2)C(O)C)cc1
NCGC00169065-03	O(C)c1ccc(C2(O)C(O)C(=O)Nc3c2cccc3)cc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169065-03	363676759.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1ccc(C2(O)C(O)C(=O)Nc3c2cccc3)cc1	O(C)c1ccc(C2(O)C(O)C(=O)Nc3c2cccc3)cc1
NCGC00169307-02	O(C)c1ccc(C2(O)C(OC)C(=O)Nc3c2c2OC(CCC=C(C)C)(C)C=Cc2cc3)cc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169307-02	363676800.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1ccc(C2(O)C(OC)C(=O)Nc3c2c2OC(CCC=C(C)C)(C)C=Cc2cc3)cc1	O(C)c1ccc(C2(O)C(OC)C(=O)Nc3c2c2OC(CCC=C(C)C)(C)C=Cc2cc3)cc1
NCGC00381309-01	O(C)c1ccc(C2(O)C(OC)C(=O)Nc3c2cccc3)cc1		Inactive	<MOA Unknown> | Class: polyketide/shikimi; Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381309-01	363679081.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1ccc(C2(O)C(OC)C(=O)Nc3c2cccc3)cc1	O(C)c1ccc(C2(O)C(OC)C(=O)Nc3c2cccc3)cc1
NCGC00345813-03	O(C)c1ccc(C2=C(O)C(=O)c3c(O)cc(O)c(CC=C(C)C)c3O2)cc1	4.9000001	Active	flavone	0.0	1	Icaritin	384568757.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	35.224015528	O(C)c1ccc(C2=C(O)C(=O)c3c(O)cc(O)c(CC=C(C)C)c3O2)cc1	O(C)c1ccc(C2=C(O)C(=O)c3c(O)cc(O)c(CC=C(C)C)c3O2)cc1
NCGC00379085-03	O(C)c1ccc(C2=C(O)C(=O)c3c(O)cc(O)cc3O2)cc1		Inactive			1	Kaempferide	434147113.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1ccc(C2=C(O)C(=O)c3c(O)cc(O)cc3O2)cc1	O(C)c1ccc(C2=C(O)C(=O)c3c(O)cc(O)cc3O2)cc1
NCGC00346592-02	O(C)c1ccc(C2=C(OC3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(OC4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(CC=C(C)C)c3O2)cc1		Inactive	Phosphodiesterase V (PDE5) Inhibitor		1	Icariin	384568852.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1ccc(C2=C(OC3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(OC4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(CC=C(C)C)c3O2)cc1	O(C)c1ccc(C2=C(OC3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(OC4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(CC=C(C)C)c3O2)cc1
NCGC00379236-08	O(C)c1ccc(C2=Cn3ncc(-c4c5c(nccc5)ccc4)c3N=C2)cc1		Inactive	ALK1/2 Inhibitor		1	ML-347	363678438.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1ccc(C2=Cn3ncc(-c4c5c(nccc5)ccc4)c3N=C2)cc1	O(C)c1ccc(C2=Cn3ncc(-c4c5c(nccc5)ccc4)c3N=C2)cc1
NCGC00094969-05	O(C)c1ccc(C2C(=O)c3c(C2=O)cccc3)cc1		Inactive	Vitamin K-dependent gamma-carboxylase Inhibitor		1	Anisindione	170465379.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(C)c1ccc(C2C(=O)c3c(C2=O)cccc3)cc1	O(C)c1ccc(C2C(=O)c3c(C2=O)cccc3)cc1
NCGC00508898-01	O(C)c1ccc(C2C(C#N)=C(N)OC3=C2C(=O)CC(c2c4c(ccc2)cccc4)C3)cc1		Inactive			1	UCPH 101	434147164.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1ccc(C2C(C#N)=C(N)OC3=C2C(=O)CC(c2c4c(ccc2)cccc4)C3)cc1	O(C)c1ccc(C2C(C#N)=C(N)OC3=C2C(=O)CC(c2c4c(ccc2)cccc4)C3)cc1
NCGC00017369-07	O(C)c1ccc(C=2C(=O)c3c(O)cc(O)cc3OC=2)cc1		Inactive	flavanoid		1	Biochanin A	124883152.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1ccc(C=2C(=O)c3c(O)cc(O)cc3OC=2)cc1	O(C)c1ccc(C=2C(=O)c3c(O)cc(O)cc3OC=2)cc1
NCGC00378759-01	O(C)c1ccc(C=2N(C)C(=O)c3c(-c4ccncc4)noc3C=2)cc1		Inactive	Metabotropic glutamate receptor 7 Antagonist		1	MMPIP hydrochloride	363678182.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1ccc(C=2N(C)C(=O)c3c(-c4ccncc4)noc3C=2)cc1	O(C)c1ccc(C=2N(C)C(=O)c3c(-c4ccncc4)noc3C=2)cc1
NCGC00091493-09	O(C)c1ccc(C=CC)cc1		Inactive	TNF signaling pathway Inhibitor		1	Anethole	170465678.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(C)c1ccc(C=CC)cc1	O(C)c1ccc(C=CC)cc1
NCGC00522533-01	O(C)c1ccc(CC(NC[C@H](O)c2c3OCC(=O)Nc3cc(O)c2)(C)C)cc1		Inactive	Beta-2 adrenergic receptor Agonist		1	Olodaterol	405558846.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1ccc(CC(NC[C@H](O)c2c3OCC(=O)Nc3cc(O)c2)(C)C)cc1	O(C)c1ccc(CC(NC[C@H](O)c2c3OCC(=O)Nc3cc(O)c2)(C)C)cc1
NCGC00384826-01	O(C)c1ccc(CC2N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C3N(C)C(=O)C(N(C)C(=O)C(C)NC2=O)Cc2ccc(Oc4c(OC5C(O)C(O)C(O)C(CO)O5)ccc(c4)C3)cc2)cc1		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384826-01	363679380.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1ccc(CC2N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C3N(C)C(=O)C(N(C)C(=O)C(C)NC2=O)Cc2ccc(Oc4c(OC5C(O)C(O)C(O)C(CO)O5)ccc(c4)C3)cc2)cc1	O(C)c1ccc(CC2N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C3N(C)C(=O)C(N(C)C(=O)C(C)NC2=O)Cc2ccc(Oc4c(OC5C(O)C(O)C(O)C(CO)O5)ccc(c4)C3)cc2)cc1
NCGC00186046-02	O(C)c1ccc(CC=2C(=O)N(CCN(CC)CC)c3c(N=2)cccc3)cc1		Inactive	AMPA Antagonist		1	Caroverine	174006990.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1ccc(CC=2C(=O)N(CCN(CC)CC)c3c(N=2)cccc3)cc1	O(C)c1ccc(CC=2C(=O)N(CCN(CC)CC)c3c(N=2)cccc3)cc1
NCGC00015822-15	O(C)c1ccc(CN(CCN(C)C)c2ncccc2)cc1		Inactive	Histamine H1 receptor Antagonist		1	Pyrilamine	170464656.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(C)c1ccc(CN(CCN(C)C)c2ncccc2)cc1	O(C)c1ccc(CN(CCN(C)C)c2ncccc2)cc1
NCGC00178145-03	O(C)c1ccc(CN(CCN(C)C)c2ncccn2)cc1		Inactive			1	Thonzylamine hydrochloride	170465519.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1ccc(CN(CCN(C)C)c2ncccn2)cc1.Cl	O(C)c1ccc(CN(CCN(C)C)c2ncccn2)cc1.Cl
NCGC00016507-05	O(C)c1ccc(CN(CC[N+](CCCCCCCCCCCCCCCC)(C)C)c2ncccn2)cc1		Inactive	osteoclast development Inhibitor		1	Thonzonium bromide	170465335.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1ccc(CN(CC[N+](CCCCCCCCCCCCCCCC)(C)C)c2ncccn2)cc1.[Br-]	O(C)c1ccc(CN(CC[N+](CCCCCCCCCCCCCCCC)(C)C)c2ncccn2)cc1.[Br-]
NCGC00379157-02	O(C)c1ccc(CNCc2c3c(ccc2)cccc3)cc1		Inactive	Inward rectifier potassium channel 2 Inhibitor		1	ML133 HCl	363678391.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1ccc(CNCc2c3c(ccc2)cccc3)cc1	O(C)c1ccc(CNCc2c3c(ccc2)cccc3)cc1
NCGC00379012-01	O(C)c1ccc(CNc2nc(N(CCO)CCO)nc3n(C(C)C)cnc23)cc1		Inactive	CDK1/2 Inhibitor		1	CVT-313	363678315.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.782898728	O(C)c1ccc(CNc2nc(N(CCO)CCO)nc3n(C(C)C)cnc23)cc1	O(C)c1ccc(CNc2nc(N(CCO)CCO)nc3n(C(C)C)cnc23)cc1
NCGC00387248-01	O(C)c1ccc(N(C)c2nc(C)nc3c2cccc3)cc1		Inactive	Tubulin polymerization Inhibitor		1	Azixa	363680593.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1ccc(N(C)c2nc(C)nc3c2cccc3)cc1	O(C)c1ccc(N(C)c2nc(C)nc3c2cccc3)cc1
NCGC00408906-01	O(C)c1ccc(N2C(=O)C=3C(=N2)c2c(NC=3)cccc2)cc1		Inactive	GABA-A receptor; anion channel Antagonist		1	CGS-9895	363681080.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1ccc(N2C(=O)C=3C(=N2)c2c(NC=3)cccc2)cc1	O(C)c1ccc(N2C(=O)C=3C(=N2)c2c(NC=3)cccc2)cc1
NCGC00165770-04	O(C)c1ccc(Nc2nc(NCCO)ccn2)cc1		Inactive	Cardiomyocytes differentiation initiator		1	Cardiogenol	384568280.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1ccc(Nc2nc(NCCO)ccn2)cc1	O(C)c1ccc(Nc2nc(NCCO)ccn2)cc1
NCGC00091390-04	O(C)c1ccc(O)cc1		Inactive	Tyrosinase Substrate		1	4-Methoxyphenol	170464687.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1ccc(O)cc1	O(C)c1ccc(O)cc1
NCGC00385013-01	O(C)c1ccc([C@@H]2OC(=O)c3c(O)cccc3C2)cc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385013-01	363679485.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C)c1ccc([C@@H]2OC(=O)c3c(O)cccc3C2)cc1	O(C)c1ccc([C@@H]2OC(=O)c3c(O)cccc3C2)cc1
NCGC00016737-04	O(C)c1n(-c2nc(OC)cc(C)n2)nc(C)c1		Inactive			1	Epirizole	170465827.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C)c1n(-c2nc(OC)cc(C)n2)nc(C)c1	O(C)c1n(-c2nc(OC)cc(C)n2)nc(C)c1
NCGC00181098-02	O(C)c1nc(N)nc2n(C3C(O)C(O)C(CO)O3)cnc12		Inactive	Purine Antagonist		1	Nelarabine	384568389.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.373963512	O(C)c1nc(N)nc2n(C3C(O)C(O)C(CO)O3)cnc12	O(C)c1nc(N)nc2n(C3C(O)C(O)C(CO)O3)cnc12
NCGC00274059-01	O(C)c1nc(N)nc2n([C@H]3[C@@H](O)[C@H](O)[C@@H](CO)O3)cnc12		Inactive	Antimetabolite		1	Nelarabine	170464759.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(C)c1nc(N)nc2n([C@H]3[C@@H](O)[C@H](O)[C@@H](CO)O3)cnc12	O(C)c1nc(N)nc2n([C@H]3[C@@H](O)[C@H](O)[C@@H](CO)O3)cnc12
NCGC00346659-04	O(C)c1ncc(C=2C(=O)N(C3CCC(OCCO)CC3)c3nc(N)nc(C)c3C=2)cc1		Inactive			1	PF-04691502	384568890.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O(C)c1ncc(C=2C(=O)N(C3CCC(OCCO)CC3)c3nc(N)nc(C)c3C=2)cc1	O(C)c1ncc(C=2C(=O)N(C3CCC(OCCO)CC3)c3nc(N)nc(C)c3C=2)cc1
NCGC00179944-04	O(C/C(=C\CCC(CO)C1C2(C)C(C)(C3C4(C5(C(O)CC(OC6C(O)C(O)C(O)C(CO)O6)C(C)(C)C5CC3)C4)CC2)CC1)/C)C1C(O)C(O)C(O)C(CO)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00179944-04	363676994.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C/C(=C\CCC(CO)C1C2(C)C(C)(C3C4(C5(C(O)CC(OC6C(O)C(O)C(O)C(CO)O6)C(C)(C)C5CC3)C4)CC2)CC1)/C)C1C(O)C(O)C(O)C(CO)O1	O(C/C(=C\CCC(CO)C1C2(C)C(C)(C3C4(C5(C(O)CC(OC6C(O)C(O)C(O)C(CO)O6)C(C)(C)C5CC3)C4)CC2)CC1)/C)C1C(O)C(O)C(O)C(CO)O1
NCGC00381210-01	O(C/C=C(/C(O)(C)C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Hemidesmus | Family: Asclepediaceae | Species: indicus		1	NCGC00381210-01	363679025.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C/C=C(/C(O)(C)C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1	O(C/C=C(/C(O)(C)C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1
NCGC00385504-01	O(C/C=C(/C(O)CC=C(C)C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	Monoamine oxidase B Inhibitor		1	NCGC00385504-01	363679778.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C/C=C(/C(O)CC=C(C)C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C/C=C(/C(O)CC=C(C)C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00381229-01	O(C/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)C1C(O)C(OC2C(O)C(O)C(OC3C(O)C(O)C(OC4C(O)C(O)C(OC5C(O)C(O)C(O)C(C)O5)CO4)C(C)O3)C(C)O2)C(O)C(COC2C(O)C(O)C(OC3C(O)C(O)C(O)CO3)CO2)O1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Thouinidium | Family: Sapindaceae | Species: decandrum		1	NCGC00381229-01	363679037.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)C1C(O)C(OC2C(O)C(O)C(OC3C(O)C(O)C(OC4C(O)C(O)C(OC5C(O)C(O)C(O)C(C)O5)CO4)C(C)O3)C(C)O2)C(O)C(COC2C(O)C(O)C(OC3C(O)C(O)C(O)CO3)CO2)O1	O(C/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)C1C(O)C(OC2C(O)C(O)C(OC3C(O)C(O)C(OC4C(O)C(O)C(OC5C(O)C(O)C(O)C(C)O5)CO4)C(C)O3)C(C)O2)C(O)C(COC2C(O)C(O)C(OC3C(O)C(O)C(O)CO3)CO2)O1
NCGC00386057-01	O(C/C=C(/CCC=C(C)C)\C)CC1C(O)C(O)C(N2C(=O)NC(=O)C=C2)O1	5.0	Active	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00386057-01	363680082.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	3.0	44.8645055224	O(C/C=C(/CCC=C(C)C)\C)CC1C(O)C(O)C(N2C(=O)NC(=O)C=C2)O1	O(C/C=C(/CCC=C(C)C)\C)CC1C(O)C(O)C(N2C(=O)NC(=O)C=C2)O1
NCGC00385690-01	O(C/C=C(/CCC=C(C)C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385690-01	363679876.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C/C=C(/CCC=C(C)C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C/C=C(/CCC=C(C)C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385812-01	O(C/C=C(/CCC=C(C)C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](CO)O2)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385812-01	363679952.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C/C=C(/CCC=C(C)C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](CO)O2)O1	O(C/C=C(/CCC=C(C)C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](CO)O2)O1
NCGC00384602-01	O(C/C=C(/CCC=C(C)C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@](O)(CO)CO2)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384602-01	363679267.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C/C=C(/CCC=C(C)C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@](O)(CO)CO2)O1	O(C/C=C(/CCC=C(C)C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@](O)(CO)CO2)O1
NCGC00385284-01	O(C/C=C(/CC[C@@H]1C(=C)CC[C@@H]2[C@](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)(C)[C@H](O)CC[C@@]12C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385284-01	363679643.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C/C=C(/CC[C@@H]1C(=C)CC[C@@H]2[C@](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)(C)[C@H](O)CC[C@@]12C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C/C=C(/CC[C@@H]1C(=C)CC[C@@H]2[C@](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)(C)[C@H](O)CC[C@@]12C)\C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385685-01	O(C/C=C/c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(OC)c1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385685-01	363679875.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C/C=C/c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(OC)c1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C/C=C/c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(OC)c1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385488-01	O(C/C=C/c1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	tumor necrosis factor production Inhibitor		1	NCGC00385488-01	363679770.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C/C=C/c1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C/C=C/c1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385503-01	O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)O1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385503-01	363679777.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)O1	O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)O1
NCGC00183845-01	O(C/C=C\CNC=1C(=O)C(=O)C=1N)c1nccc(CN2CCCCC2)c1		Inactive	Histamine H2 receptor Binding Agent		1	Pibutidine	144206830.0	Approved Drugs Collection (NPC)&2020_NPACT-1_CPE	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(C/C=C\CNC=1C(=O)C(=O)C=1N)c1nccc(CN2CCCCC2)c1	O(C/C=C\CNC=1C(=O)C(=O)C=1N)c1nccc(CN2CCCCC2)c1
NCGC00385789-01	O(C1C(O)C(O)C(O)C(CO)O1)C1C(C)(C)C2(O)C(O)CC34C(C(=C)C2C1)CCC(C(O)(C)C3)C4		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Kalmia | Family: Ericaceae | Species: latifolia		1	NCGC00385789-01	363679938.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C1C(O)C(O)C(O)C(CO)O1)C1C(C)(C)C2(O)C(O)CC34C(C(=C)C2C1)CCC(C(O)(C)C3)C4	O(C1C(O)C(O)C(O)C(CO)O1)C1C(C)(C)C2(O)C(O)CC34C(C(=C)C2C1)CCC(C(O)(C)C3)C4
NCGC00380684-01	O(C1C(O)C(O)C(O)C(CO)O1)C1C(O)(C)CC=C(C(C)C)C1		Inactive	<MOA Unknown> | Class: Monoterpen | Genus: Thymus | Family: Labiatae | Species: pallidus		1	NCGC00380684-01	363678707.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C1C(O)C(O)C(O)C(CO)O1)C1C(O)(C)CC=C(C(C)C)C1	O(C1C(O)C(O)C(O)C(CO)O1)C1C(O)(C)CC=C(C(C)C)C1
NCGC00384981-01	O(C1C(O)C(O)C(O)CO1)C1C(=C)C(CC/C(=C\CO)/C)C2(C)C(C(C)(C)C(O)CC2)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384981-01	363679467.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C1C(O)C(O)C(O)CO1)C1C(=C)C(CC/C(=C\CO)/C)C2(C)C(C(C)(C)C(O)CC2)C1	O(C1C(O)C(O)C(O)CO1)C1C(=C)C(CC/C(=C\CO)/C)C2(C)C(C(C)(C)C(O)CC2)C1
NCGC00385602-01	O(C1C(O)C(OC2C(O)C(O)C(O)C(CO)O2)C(C)OC1OC1C(CO)(C)C2C(C)(C3C(C)(C4(C)C5(OCC6(C5CC(C)(C)CC6)CC4)C=C3)CC2)CC1)C1C(O)C(O)C(O)C(CO)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Buddleja | Family: Loganiaceae | Species: asiatica		1	NCGC00385602-01	363679831.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C1C(O)C(OC2C(O)C(O)C(O)C(CO)O2)C(C)OC1OC1C(CO)(C)C2C(C)(C3C(C)(C4(C)C5(OCC6(C5CC(C)(C)CC6)CC4)C=C3)CC2)CC1)C1C(O)C(O)C(O)C(CO)O1	O(C1C(O)C(OC2C(O)C(O)C(O)C(CO)O2)C(C)OC1OC1C(CO)(C)C2C(C)(C3C(C)(C4(C)C5(OCC6(C5CC(C)(C)CC6)CC4)C=C3)CC2)CC1)C1C(O)C(O)C(O)C(CO)O1
NCGC00507862-01	O(C=1N=C(NCc2c(-n3nccc3)cccc2)n2ncc(C(C)C)c2N=1)C1CNCCC1		Inactive			1	LDC4297 (LDC044297)	434147163.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C=1N=C(NCc2c(-n3nccc3)cccc2)n2ncc(C(C)C)c2N=1)C1CNCCC1	O(C=1N=C(NCc2c(-n3nccc3)cccc2)n2ncc(C(C)C)c2N=1)C1CNCCC1
NCGC00485383-01	O(CC#C)[C@@H]1C2CCN(C1)CC2		Inactive	Muscarinic acetylcholine receptor M1 Agonist		1	Talsaclidine	363681308.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC#C)[C@@H]1C2CCN(C1)CC2	O(CC#C)[C@@H]1C2CCN(C1)CC2
NCGC00378787-01	O(CC#C)c1cc2C(c3ccc(C(C)C)cc3)=NC(=O)N(C(C)C)c2cc1		Inactive	Calcium sensing receptor Antagonist		1	Calcium-Sensing Receptor Antagonists I	363678200.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	18.0639555559	O(CC#C)c1cc2C(c3ccc(C(C)C)cc3)=NC(=O)N(C(C)C)c2cc1	O(CC#C)c1cc2C(c3ccc(C(C)C)cc3)=NC(=O)N(C(C)C)c2cc1
NCGC00384618-01	O(CC(=C)CCC1=C(C)[C@@H]2[C@]3(C)C([C@H]4C([C@H](O)C3)[C@@]3(C)[C@H](O)C[C@H](O)CC3=CC4)C[C@@H]2O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Steroide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384618-01	363679274.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC(=C)CCC1=C(C)[C@@H]2[C@]3(C)C([C@H]4C([C@H](O)C3)[C@@]3(C)[C@H](O)C[C@H](O)CC3=CC4)C[C@@H]2O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CC(=C)CCC1=C(C)[C@@H]2[C@]3(C)C([C@H]4C([C@H](O)C3)[C@@]3(C)[C@H](O)C[C@H](O)CC3=CC4)C[C@@H]2O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00380237-01	O(CC(=CCCC(O)(C=C)C)C)C1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Monoterpen | Genus: bupleurum | Family: Umbelliferae | Species: fruticosum		1	NCGC00380237-01	363678509.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC(=CCCC(O)(C=C)C)C)C1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CC(=CCCC(O)(C=C)C)C)C1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00015155-11&NCGC00015155-14	O(CC(C)C)CC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1	4.95000005	Active	Calcium Channel Blocker	0.09999990000000025	2	Bepridil	170465240.0&384567817.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	120.1563162583&111.9496352868	O(CC(C)C)CC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1	O(CC(C)C)CC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1
NCGC00370858-01	O(CC(CC)n1nnc2c(Nc3c(C)cc(OC)cc3)nc(C)cc12)C		Inactive	Corticotropin releasing factor receptor 1 Antagonist		1	SN 003	363677890.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC(CC)n1nnc2c(Nc3c(C)cc(OC)cc3)nc(C)cc12)C	O(CC(CC)n1nnc2c(Nc3c(C)cc(OC)cc3)nc(C)cc12)C
NCGC00385395-01	O(CC(CCC1(O)C(C)C2C3(C)C(C4C(C5(C)C(=CC4)CC(O[C@H]4[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](CO)O4)CC5)CC3)CC2O1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385395-01	363679720.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC(CCC1(O)C(C)C2C3(C)C(C4C(C5(C)C(=CC4)CC(O[C@H]4[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](CO)O4)CC5)CC3)CC2O1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CC(CCC1(O)C(C)C2C3(C)C(C4C(C5(C)C(=CC4)CC(O[C@H]4[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](CO)O4)CC5)CC3)CC2O1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385246-01	O(CC(CCC1(O)C(C)C2C3(C)C(C4C(C5(C)C(=CC4)CC(O[C@H]4[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](CO)O4)CC5)CC3)CC2O1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385246-01	363679615.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC(CCC1(O)C(C)C2C3(C)C(C4C(C5(C)C(=CC4)CC(O[C@H]4[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](CO)O4)CC5)CC3)CC2O1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CC(CCC1(O)C(C)C2C3(C)C(C4C(C5(C)C(=CC4)CC(O[C@H]4[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](CO)O4)CC5)CC3)CC2O1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385394-01	O(CC(CCC1(O)C(C)C2C3(C)C(C4C(C5(C)C(CC(O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)CO7)[C@@H](O)[C@H](O)[C@@H](CO)O6)C(O)C5)CC4)CC3)CC2O1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385394-01	363679719.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC(CCC1(O)C(C)C2C3(C)C(C4C(C5(C)C(CC(O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)CO7)[C@@H](O)[C@H](O)[C@@H](CO)O6)C(O)C5)CC4)CC3)CC2O1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CC(CCC1(O)C(C)C2C3(C)C(C4C(C5(C)C(CC(O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)CO7)[C@@H](O)[C@H](O)[C@@H](CO)O6)C(O)C5)CC4)CC3)CC2O1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385201-01	O(CC(CCC1(O)C(C)C2C3(C)C(C4C(C5(C)C(CC(O[C@H]6[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7)[C@@H](O)[C@H](O)[C@@H](CO)O6)C(O)C5)CC4)CC3)CC2O1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385201-01	363679592.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC(CCC1(O)C(C)C2C3(C)C(C4C(C5(C)C(CC(O[C@H]6[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7)[C@@H](O)[C@H](O)[C@@H](CO)O6)C(O)C5)CC4)CC3)CC2O1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CC(CCC1(O)C(C)C2C3(C)C(C4C(C5(C)C(CC(O[C@H]6[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7)[C@@H](O)[C@H](O)[C@@H](CO)O6)C(O)C5)CC4)CC3)CC2O1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385256-01	O(CC(CCC1(O)[C@@H](C)[C@]2(O)[C@]3(C)C(C4C([C@]5(C)C(=CC4)C[C@@H](O[C@H]4[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](CO)O4)CC5)CC3)CC2O1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385256-01	363679621.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC(CCC1(O)[C@@H](C)[C@]2(O)[C@]3(C)C(C4C([C@]5(C)C(=CC4)C[C@@H](O[C@H]4[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](CO)O4)CC5)CC3)CC2O1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CC(CCC1(O)[C@@H](C)[C@]2(O)[C@]3(C)C(C4C([C@]5(C)C(=CC4)C[C@@H](O[C@H]4[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](CO)O4)CC5)CC3)CC2O1)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00261970-01	O(CC(CCCC)CC)c1cc(O)c(-c2nc(-c3c(O)cc(OCC(CCCC)CC)cc3)nc(-c3ccc(OC)cc3)n2)cc1		Inactive			1	BEMOTRIZINOL	225144355.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC(CCCC)CC)c1cc(O)c(-c2nc(-c3c(O)cc(OCC(CCCC)CC)cc3)nc(-c3ccc(OC)cc3)n2)cc1	O(CC(CCCC)CC)c1cc(O)c(-c2nc(-c3c(O)cc(OCC(CCCC)CC)cc3)nc(-c3ccc(OC)cc3)n2)cc1
NCGC00384560-01	O(CC(CO)c1cc(OC)c(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Tannin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384560-01	363679244.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC(CO)c1cc(OC)c(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CC(CO)c1cc(OC)c(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385634-01	O(CC(CO)c1cc2OCOc2cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385634-01	363679850.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC(CO)c1cc2OCOc2cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CC(CO)c1cc2OCOc2cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00015659-14	O(CC(N)C)c1c(C)cccc1C		Inactive			1	Mexiletene hydrochloride	170464740.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC(N)C)c1c(C)cccc1C.Cl	O(CC(N)C)c1c(C)cccc1C.Cl
NCGC00018295-05	O(CC(NC(C(O)c1ccc(O)cc1)C)C)c1ccccc1		Inactive			1	Isoxsuprine hydrochloride	170465968.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(CC(NC(C(O)c1ccc(O)cc1)C)C)c1ccccc1.Cl	O(CC(NC(C(O)c1ccc(O)cc1)C)C)c1ccccc1.Cl
NCGC00380816-01	O(CC(O)(C=C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380816-01	363678797.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC(O)(C=C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CC(O)(C=C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385487-01	O(CC(O)C(O)(C)C)c1c(C)c(OC)c2c(C(=O)NC2)c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385487-01	363679769.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC(O)C(O)(C)C)c1c(C)c(OC)c2c(C(=O)NC2)c1	O(CC(O)C(O)(C)C)c1c(C)c(OC)c2c(C(=O)NC2)c1
NCGC00380733-01	O(CC(O)C(O)(C)C)c1c(C)c(OC)c2c(C(=O)OC2)c1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380733-01	363678746.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC(O)C(O)(C)C)c1c(C)c(OC)c2c(C(=O)OC2)c1	O(CC(O)C(O)(C)C)c1c(C)c(OC)c2c(C(=O)OC2)c1
NCGC00380814-01	O(CC(O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380814-01	363678795.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC(O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CC(O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00164375-03	O(CC(O)C)c1ccccc1		Inactive			1	1-Phenoxy-2-propanol	170465645.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(CC(O)C)c1ccccc1	O(CC(O)C)c1ccccc1
NCGC00538146-01	O(CC(O)CNC(C)(C)C)C=1c2c(C(=O)N(C)C=1)cccc2		Inactive	Adrenergic receptor beta Blocker		1	NCGC00538146-01	405558755.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC(O)CNC(C)(C)C)C=1c2c(C(=O)N(C)C=1)cccc2	O(CC(O)CNC(C)(C)C)C=1c2c(C(=O)N(C)C=1)cccc2
NCGC00532503-01	O(CC(O)CNC(C)(C)C)c1c(C#N)cccc1		Inactive	Beta-2 adrenergic receptor Antagonist		1	BUNITROLOL	405558869.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC(O)CNC(C)(C)C)c1c(C#N)cccc1	O(CC(O)CNC(C)(C)C)c1c(C#N)cccc1
NCGC00179359-04	O(CC(O)CNC(C)(C)C)c1c(C2CCCC2)cccc1		Inactive			1	Penbutolol sulfate	405559025.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	32.097686376	O(CC(O)CNC(C)(C)C)c1c(C2CCCC2)cccc1	O(CC(O)CNC(C)(C)C)c1c(C2CCCC2)cccc1
NCGC00261968-01	O(CC(O)CNC(C)(C)C)c1c(OCC2OCCC2)cccc1		Inactive	Adrenergic receptor beta Antagonist		1	Bufetolol	170465825.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(CC(O)CNC(C)(C)C)c1c(OCC2OCCC2)cccc1	O(CC(O)CNC(C)(C)C)c1c(OCC2OCCC2)cccc1
NCGC00179541-03	O(CC(O)CNC(C)(C)C)c1c2c(NC(=O)CC2)ccc1		Inactive	Adrenergic receptor beta Partial Agonist		1	Carteolol hydrochloride	170465122.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC(O)CNC(C)(C)C)c1c2c(NC(=O)CC2)ccc1.Cl	O(CC(O)CNC(C)(C)C)c1c2c(NC(=O)CC2)ccc1.Cl
NCGC00021623-05	O(CC(O)CNC(C)(C)C)c1c2c(ccc1)C[C@@H](O)[C@@H](O)C2		Inactive	Beta-2 adrenergic receptor Antagonist		1	Nadolol	170464945.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(CC(O)CNC(C)(C)C)c1c2c(ccc1)C[C@@H](O)[C@@H](O)C2	O(CC(O)CNC(C)(C)C)c1c2c(ccc1)C[C@@H](O)[C@@H](O)C2
NCGC00015099-11&NCGC00015099-12	O(CC(O)CNC(C)C)c1c(CC=C)cccc1		Inactive	Beta-adrenergic receptor Antagonist		2	Alprenolol&Alprenolol hydrochloride	170465812.0&440681335.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O(CC(O)CNC(C)C)c1c(CC=C)cccc1	O(CC(O)CNC(C)C)c1c(CC=C)cccc1
NCGC00179342-03	O(CC(O)CNC(C)C)c1c(OCC=C)cccc1		Inactive	Adrenergic receptor beta Antagonist		1	Oxprenolol hydrochloride	170464995.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(CC(O)CNC(C)C)c1c(OCC=C)cccc1.Cl	O(CC(O)CNC(C)C)c1c(OCC=C)cccc1.Cl
NCGC00015786-16	O(CC(O)CNC(C)C)c1c2c([nH]cc2)ccc1		Inactive	Serotonin 1a (5-HT1a) receptor Antagonist		1	Pindolol	170464892.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(CC(O)CNC(C)C)c1c2c([nH]cc2)ccc1	O(CC(O)CNC(C)C)c1c2c([nH]cc2)ccc1
NCGC00015798-15	O(CC(O)CNC(C)C)c1c2c(ccc1)cccc2		Inactive			1	Propranolol HCl	434147191.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC(O)CNC(C)C)c1c2c(ccc1)cccc2	O(CC(O)CNC(C)C)c1c2c(ccc1)cccc2
NCGC00182040-01	O(CC(O)CNCCc1cc(OC)c(OC)cc1)c1cc(C)ccc1		Inactive	Adrenergic receptor beta Antagonist		1	Bevantolol hydrochloride	144206530.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC(O)CNCCc1cc(OC)c(OC)cc1)c1cc(C)ccc1.Cl	O(CC(O)CNCCc1cc(OC)c(OC)cc1)c1cc(C)ccc1.Cl
NCGC00183846-01	O(CC(O)CNCc1cc(OC)c(OC)cc1)c1cc2c(NC(=O)C=C2)cc1		Inactive	Phosphodiesterase 3 Inhibitor		1	Toborinone	144206841.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC(O)CNCc1cc(OC)c(OC)cc1)c1cc2c(NC(=O)C=C2)cc1	O(CC(O)CNCc1cc(OC)c(OC)cc1)c1cc2c(NC(=O)C=C2)cc1
NCGC00095748-04	O(CC(O)CO)CCCCCCCCCCCCCCCCCC		Inactive			1	3-(Octadecyloxy)-1,2-propanediol	170465730.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC(O)CO)CCCCCCCCCCCCCCCCCC	O(CC(O)CO)CCCCCCCCCCCCCCCCCC
NCGC00094908-06	O(CC(O)CO)c1c(C)cccc1		Inactive	Glutamate NMDA receptor Antagonist		1	Mephenesin	170466586.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(CC(O)CO)c1c(C)cccc1	O(CC(O)CO)c1c(C)cccc1
NCGC00094689-06	O(CC(O)CO)c1c(OC)cccc1		Inactive			1	Guaifenesin	170464855.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC(O)CO)c1c(OC)cccc1	O(CC(O)CO)c1c(OC)cccc1
NCGC00387826-01	O(CC(n1c(-c2ccccc2)nc2c1cccc2)C1CCNCC1)c1ccc(-c2n(Cc3ccccc3)c3c(n2)cccc3)cc1		Inactive	Prenyl-Binding Protein (PrBP)/delta Inhibitor		1	Deltarasin	363680682.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC(n1c(-c2ccccc2)nc2c1cccc2)C1CCNCC1)c1ccc(-c2n(Cc3ccccc3)c3c(n2)cccc3)cc1	O(CC(n1c(-c2ccccc2)nc2c1cccc2)C1CCNCC1)c1ccc(-c2n(Cc3ccccc3)c3c(n2)cccc3)cc1
NCGC00249932-01	O(CC)C=1C(=O)N(C)N=CC=1N1CCOCC1		Inactive			1	Emorfazone	170465843.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(CC)C=1C(=O)N(C)N=CC=1N1CCOCC1	O(CC)C=1C(=O)N(C)N=CC=1N1CCOCC1
NCGC00370784-05	O(CC)Cc1n(CC(O)(C)C)c2c(c(N)nc3c2cccc3)n1		Inactive	Toll-Like Receptor 7 (TLR7) Agonist		1	Resiquimod	363677855.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&15.0845049319	O(CC)Cc1n(CC(O)(C)C)c2c(c(N)nc3c2cccc3)n1	O(CC)Cc1n(CC(O)(C)C)c2c(c(N)nc3c2cccc3)n1
NCGC00387261-01	O(CC)c1c(C)cc(C(Nc2ncccc2)c2c(O)c3nc(C)ccc3cc2)cc1		Inactive			1	HLM 006474	363680602.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC)c1c(C)cc(C(Nc2ncccc2)c2c(O)c3nc(C)ccc3cc2)cc1	O(CC)c1c(C)cc(C(Nc2ncccc2)c2c(O)c3nc(C)ccc3cc2)cc1
NCGC00347939-08	O(CC)c1c(N/N=C\2/C(=O)N(c3scc(-c4ccccc4)n3)N=C/2C)cccc1		Inactive	BAX Activator		1	BAM-7	384568991.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	10.9438964279	O(CC)c1c(N/N=C\2/C(=O)N(c3scc(-c4ccccc4)n3)N=C/2C)cccc1	O(CC)c1c(N/N=C\2/C(=O)N(c3scc(-c4ccccc4)n3)N=C/2C)cccc1
NCGC00250385-11	O(CC)c1c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)ccc(N2CCC(O)CC2)c1		Inactive	ERK5/BMK1 Inhibitor		1	XMD8-92	377020424.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-17.02540416	O(CC)c1c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)ccc(N2CCC(O)CC2)c1	O(CC)c1c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)ccc(N2CCC(O)CC2)c1
NCGC00386761-02	O(CC)c1c(Nc2nc3N(C4CCCC4)CCC(=O)N(C)c3cn2)ccc(N2CCC(O)CC2)c1		Inactive	Dual specificity protein kinase TTK Inhibitor		1	Mps1-IN-2	363680438.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC)c1c(Nc2nc3N(C4CCCC4)CCC(=O)N(C)c3cn2)ccc(N2CCC(O)CC2)c1	O(CC)c1c(Nc2nc3N(C4CCCC4)CCC(=O)N(C)c3cn2)ccc(N2CCC(O)CC2)c1
NCGC00370878-01	O(CC)c1c(OCC)ccc(-c2onc(-c3c4c(C(NCCO)CC4)ccc3)n2)c1	5.0999999	Active	Sphingosine 1-phosphate receptor Edg-1  Agonist	0.0	1	CYM 5442 hydrochloride	363677905.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	2.3	113.0312796201	O(CC)c1c(OCC)ccc(-c2onc(-c3c4c(C(NCCO)CC4)ccc3)n2)c1	O(CC)c1c(OCC)ccc(-c2onc(-c3c4c(C(NCCO)CC4)ccc3)n2)c1
NCGC00016557-06	O(CC)c1c(OCC)ccc(Cc2nccc3c2cc(OCC)c(OCC)c3)c1		Inactive	Voltage-gated L-type calcium channel Blocker		1	Ethaverine hydrochloride	170466346.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC)c1c(OCC)ccc(Cc2nccc3c2cc(OCC)c(OCC)c3)c1.Cl	O(CC)c1c(OCC)ccc(Cc2nccc3c2cc(OCC)c(OCC)c3)c1.Cl
NCGC00168251-01	O(CC)c1c2O[C@H]3[C@@H](O)C=C[C@H]4[C@@H]5N(C)CC[C@]34c2c(cc1)C5		Inactive	Opioid receptors; mu/kappa/delta Agonist		1	Ethylmorphine	144206163.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC)c1c2O[C@H]3[C@@H](O)C=C[C@H]4[C@@H]5N(C)CC[C@]34c2c(cc1)C5	O(CC)c1c2O[C@H]3[C@@H](O)C=C[C@H]4[C@@H]5N(C)CC[C@]34c2c(cc1)C5
NCGC00016348-15	O(CC)c1cc2C(C)=CC(C)(C)Nc2cc1		Inactive	Heat shock protein HSP 90-beta Inhibitor		1	Ethoxyquin	405559074.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC)c1cc2C(C)=CC(C)(C)Nc2cc1	O(CC)c1cc2C(C)=CC(C)(C)Nc2cc1
NCGC00096056-02	O(CC)c1cc2c(N)c3c(nc2cc1)cc(N)cc3		Inactive			1	Ethacridine lactate hydrate	170465798.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	-8.2095165519&0.0	O=C(O)C(O)C.O(CC)c1cc2c(N)c3c(nc2cc1)cc(N)cc3.O	O=C(O)C(O)C.O(CC)c1cc2c(N)c3c(nc2cc1)cc(N)cc3.O
NCGC00387760-03	O(CC)c1ccc(/C=C\2/C(=O)N(CCN)C(=O)S/2)cc1		Inactive			1	ERK Inhibitor	377020448.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC)c1ccc(/C=C\2/C(=O)N(CCN)C(=O)S/2)cc1	O(CC)c1ccc(/C=C\2/C(=O)N(CCN)C(=O)S/2)cc1
NCGC00181080-01	O(CC)c1ccc(/N=C(/Nc2ccc(OCC)cc2)\C)cc1		Inactive	Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Inhibitor		1	Phenacaine hydrochloride	144206789.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC)c1ccc(/N=C(/Nc2ccc(OCC)cc2)\C)cc1.Cl	O(CC)c1ccc(/N=C(/Nc2ccc(OCC)cc2)\C)cc1.Cl
NCGC00485083-01	O(CC)c1ccc(Cc2scc(-c3c(C)nc4n3C=CC=C4)n2)cc1		Inactive			1	JK184	363681214.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	12.219428568	O(CC)c1ccc(Cc2scc(-c3c(C)nc4n3C=CC=C4)n2)cc1	O(CC)c1ccc(Cc2scc(-c3c(C)nc4n3C=CC=C4)n2)cc1
NCGC00263211-04	O(CC)c1ccc(Nc2scc(-c3c(C)nc4n3C=CC=C4)n2)cc1		Inactive	Alcohol dehydrogenase 7 Inhibitor		1	JK-184	384568668.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC)c1ccc(Nc2scc(-c3c(C)nc4n3C=CC=C4)n2)cc1	O(CC)c1ccc(Nc2scc(-c3c(C)nc4n3C=CC=C4)n2)cc1
NCGC00387128-01	O(CC)c1n(CC)c2ncnc(N)c2n1		Inactive	Adenosine A2a receptor Antagonist		1	ANR 94	363680546.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC)c1n(CC)c2ncnc(N)c2n1	O(CC)c1n(CC)c2ncnc(N)c2n1
NCGC00381101-01	O(CC/C(=C/CCC(O)(C)C)/C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)O1		Inactive	<MOA Unknown> | Class: Monoterpen | Genus: Detarium | Family: N/A | Species: microcarpum		1	NCGC00381101-01	363678970.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC/C(=C/CCC(O)(C)C)/C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)O1	O(CC/C(=C/CCC(O)(C)C)/C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)O1
NCGC00380275-01	O(CC/C=C\CC)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Fatty acid | Genus: Eucalyptus | Family: Myrtaceae | Species: acmenoides		1	NCGC00380275-01	363678522.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC/C=C\CC)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CC/C=C\CC)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385430-01	O(CC/C=C\CC)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@@H](O)CO2)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385430-01	363679739.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC/C=C\CC)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@@H](O)CO2)O1	O(CC/C=C\CC)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@@H](O)CO2)O1
NCGC00346658-03	O(CC1(C)COC1)c1cc2ncn(-c3nc4c(N5CCC(N)CC5)cccc4cc3)c2cc1		Inactive	PDGFR beta Inhibitor		1	Crenolanib	384568889.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC1(C)COC1)c1cc2ncn(-c3nc4c(N5CCC(N)CC5)cccc4cc3)c2cc1	O(CC1(C)COC1)c1cc2ncn(-c3nc4c(N5CCC(N)CC5)cccc4cc3)c2cc1
NCGC00161599-09&NCGC00161599-13	O(CC1(C)Oc2c(C)c(C)c(O)c(C)c2CC1)c1ccc(CC2C(=O)NC(=O)S2)cc1		Inactive	CCL2 Expression Inhibitor		2	Troglitazone	170465091.0&384568210.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	19.0&18.732162864&29.5	O(CC1(C)Oc2c(C)c(C)c(O)c(C)c2CC1)c1ccc(CC2C(=O)NC(=O)S2)cc1	O(CC1(C)Oc2c(C)c(C)c(O)c(C)c2CC1)c1ccc(CC2C(=O)NC(=O)S2)cc1
NCGC00346881-02	O(CC1(CO)C(=O)C2CCN1CC2)C		Inactive	p53-dependent reactivation of massive apoptosis		1	APR-246	384568958.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC1(CO)C(=O)C2CCN1CC2)C	O(CC1(CO)C(=O)C2CCN1CC2)C
NCGC00385950-01	O(CC1C(C)=CC(=O)CC1(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385950-01	363680023.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC1C(C)=CC(=O)CC1(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CC1C(C)=CC(=O)CC1(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00380670-01	O(CC1C(CCC(O)C)C(C)(C)CC(O)C1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Cassia | Family: Leguminosae | Species: sp.		1	NCGC00380670-01	363678703.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC1C(CCC(O)C)C(C)(C)CC(O)C1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CC1C(CCC(O)C)C(C)(C)CC(O)C1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00380765-01	O(CC1C(O)C(O)C(O)C(OC2C(OC)C(O)C(OC3C(C)OC(OC4CC=5C(C)(C6C(C7(O)C(C)(C(C(O)C)CC7)CC6)CC=5)CC4)CC3OC)OC2C)O1)C1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380765-01	363678770.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC1C(O)C(O)C(O)C(OC2C(OC)C(O)C(OC3C(C)OC(OC4CC=5C(C)(C6C(C7(O)C(C)(C(C(O)C)CC7)CC6)CC=5)CC4)CC3OC)OC2C)O1)C1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1	O(CC1C(O)C(O)C(O)C(OC2C(OC)C(O)C(OC3C(C)OC(OC4CC=5C(C)(C6C(C7(O)C(C)(C(C(O)C)CC7)CC6)CC=5)CC4)CC3OC)OC2C)O1)C1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1
NCGC00384975-01	O(CC1C(O)C(O)C(O)C(OC2C3(C)C(C)(C)C(C(O)C3)C2)O1)C1C(O)C(O)(CO)CO1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384975-01	363679463.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC1C(O)C(O)C(O)C(OC2C3(C)C(C)(C)C(C(O)C3)C2)O1)C1C(O)C(O)(CO)CO1	O(CC1C(O)C(O)C(O)C(OC2C3(C)C(C)(C)C(C(O)C3)C2)O1)C1C(O)C(O)(CO)CO1
NCGC00385425-01	O(CC1C(O)C(O)C(O)C(OC2C3C(C)(C)OC(C)(C2)CC3)O1)C1C(O)C(O)(CO)CO1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385425-01	363679736.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC1C(O)C(O)C(O)C(OC2C3C(C)(C)OC(C)(C2)CC3)O1)C1C(O)C(O)(CO)CO1	O(CC1C(O)C(O)C(O)C(OC2C3C(C)(C)OC(C)(C2)CC3)O1)C1C(O)C(O)(CO)CO1
NCGC00381226-01	O(CC1C(O)C(O)C(O)C(Oc2cc(OC)c(OC)cc2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Croton | Family: Euphorbiaceae | Species: megalocarpus		1	NCGC00381226-01	363679035.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC1C(O)C(O)C(O)C(Oc2cc(OC)c(OC)cc2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O(CC1C(O)C(O)C(O)C(Oc2cc(OC)c(OC)cc2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00380780-01	O(CC1C(O)C(O)C(n2c3N=CNC(=O)c3nc2)O1)C		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380780-01	363678781.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC1C(O)C(O)C(n2c3N=CNC(=O)c3nc2)O1)C	O(CC1C(O)C(O)C(n2c3N=CNC(=O)c3nc2)O1)C
NCGC00380989-01	O(CC1C2(C)c3c(C(=O)C4=C2C(O)CC2(C)C(=O)CCC42)occ3C(=O)O1)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380989-01	363678906.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC1C2(C)c3c(C(=O)C4=C2C(O)CC2(C)C(=O)CCC42)occ3C(=O)O1)C	O(CC1C2(C)c3c(C(=O)C4=C2C(O)CC2(C)C(=O)CCC42)occ3C(=O)O1)C
NCGC00347280-04	O(CC1CC1)c1c(c(O)ccc1)-c1nc(N)c(C#N)c(C2CCNCC2)c1	5.0	Active	IKK beta Inhibitor	0.0	1	IKK-2 Inhibitor VIII	363677574.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.3	97.8607093203	O(CC1CC1)c1c(c(O)ccc1)-c1nc(N)c(C#N)c(C2CCNCC2)c1	O(CC1CC1)c1c(c(O)ccc1)-c1nc(N)c(C#N)c(C2CCNCC2)c1
NCGC00390649-02	O(CC1CC1)c1c(c(O)ccc1)-c1nc2NC(=O)OCc2c([C@H]2CNCCC2)c1	4.9499998	Active	Inhibitor of nuclear factor kappa B kinase beta subunit Inhibitor	0.0	1	Bay-65-1942 hydrochloride	384569206.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	91.286118583	O(CC1CC1)c1c(c(O)ccc1)-c1nc2NC(=O)OCc2c([C@H]2CNCCC2)c1	O(CC1CC1)c1c(c(O)ccc1)-c1nc2NC(=O)OCc2c([C@H]2CNCCC2)c1
NCGC00345793-01	O(CC1CCN(C)CC1)c1cnc(-c2cc(CN3C(=O)C=CC(c4cc(C#N)ccc4)=N3)ccc2)nc1	4.9000001	Active	HGFR Inhibitor	0.0	1	EMD-1214063	174006592.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	108.8480842605	O(CC1CCN(C)CC1)c1cnc(-c2cc(CN3C(=O)C=CC(c4cc(C#N)ccc4)=N3)ccc2)nc1	O(CC1CCN(C)CC1)c1cnc(-c2cc(CN3C(=O)C=CC(c4cc(C#N)ccc4)=N3)ccc2)nc1
NCGC00386746-01	O(CC1CCN(CC2(O)CCOCC2)CC1)c1noc2c1c(O[C@H]1COCC1)ccc2		Inactive	Serotonin 4 (5-HT4) receptor Agonist		1	PF 04995274	363680431.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC1CCN(CC2(O)CCOCC2)CC1)c1noc2c1c(O[C@H]1COCC1)ccc2	O(CC1CCN(CC2(O)CCOCC2)CC1)c1noc2c1c(O[C@H]1COCC1)ccc2
NCGC00095116-05	O(CC1OC(=O)NC1)c1cc(C)cc(C)c1		Inactive			1	Metaxalone	170465241.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&10.142335764	O(CC1OC(=O)NC1)c1cc(C)cc(C)c1	O(CC1OC(=O)NC1)c1cc(C)cc(C)c1
NCGC00384800-01	O(CC=1C2C(C)(C)C(C2)CC=1)C1C(O)C(O)C(O)C(COC2C(O)C(O)(CO)CO2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384800-01	363679363.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC=1C2C(C)(C)C(C2)CC=1)C1C(O)C(O)C(O)C(COC2C(O)C(O)(CO)CO2)O1	O(CC=1C2C(C)(C)C(C2)CC=1)C1C(O)C(O)C(O)C(COC2C(O)C(O)(CO)CO2)O1
NCGC00385505-01	O(CC=1Oc2c(c(OC)c3c(occ3)c2)C(=O)C=1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Ammi | Family: Apiaceae | Species: visnaga		1	NCGC00385505-01	363679779.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC=1Oc2c(c(OC)c3c(occ3)c2)C(=O)C=1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CC=1Oc2c(c(OC)c3c(occ3)c2)C(=O)C=1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385202-01	O(CC=1[C@@H]2[C@H]3OC(=O)[C@H](C)[C@@H]3CCC(C)=C2C(=O)C=1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385202-01	363679593.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC=1[C@@H]2[C@H]3OC(=O)[C@H](C)[C@@H]3CCC(C)=C2C(=O)C=1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CC=1[C@@H]2[C@H]3OC(=O)[C@H](C)[C@@H]3CCC(C)=C2C(=O)C=1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00384889-01	O(CC=1[C@@H]2[C@H]3OC(=O)[C@H](C)[C@@H]3[C@@H](O)CC(C)=C2C(=O)C=1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384889-01	363679419.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC=1[C@@H]2[C@H]3OC(=O)[C@H](C)[C@@H]3[C@@H](O)CC(C)=C2C(=O)C=1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CC=1[C@@H]2[C@H]3OC(=O)[C@H](C)[C@@H]3[C@@H](O)CC(C)=C2C(=O)C=1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00380986-01	O(CC=C(C)C)c1c(C)c(OC)c2C(=O)NC(=O)c2c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380986-01	363678905.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC=C(C)C)c1c(C)c(OC)c2C(=O)NC(=O)c2c1	O(CC=C(C)C)c1c(C)c(OC)c2C(=O)NC(=O)c2c1
NCGC00380840-01	O(CC=C(C)C)c1c(C)c(OC)c2c(C(=O)NC2)c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380840-01	363678808.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC=C(C)C)c1c(C)c(OC)c2c(C(=O)NC2)c1	O(CC=C(C)C)c1c(C)c(OC)c2c(C(=O)NC2)c1
NCGC00381329-01	O(CC=C(C)C)c1c(C)c(OC)c2c(C(=O)OC2)c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381329-01	363679090.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC=C(C)C)c1c(C)c(OC)c2c(C(=O)OC2)c1	O(CC=C(C)C)c1c(C)c(OC)c2c(C(=O)OC2)c1
NCGC00381261-01	O(CC=C(C)C)c1ccc(CCc2cc(OC)c(OC)c(OC)c2)cc1		Inactive	<MOA Unknown> | Class: Shikimi / Polyketide | Genus: Indigofera | Family: Fabaceae | Species: simpliciflora		1	NCGC00381261-01	363679055.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CC=C(C)C)c1ccc(CCc2cc(OC)c(OC)c(OC)c2)cc1	O(CC=C(C)C)c1ccc(CCc2cc(OC)c(OC)c(OC)c2)cc1
NCGC00384694-01	O(CCC(C(O)(C)C)CC)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Hemidesmus | Family: Asclepediaceae | Species: indicus		1	NCGC00384694-01	363679316.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCC(C(O)(C)C)CC)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1	O(CCC(C(O)(C)C)CC)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1
NCGC00381274-01	O(CCC(O)(C(C)C)CO)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: Hemidesmus | Family: Asclepediaceae | Species: indicus		1	NCGC00381274-01	363679059.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCC(O)(C(C)C)CO)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1	O(CCC(O)(C(C)C)CO)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1
NCGC00384713-01	O(CCC)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384713-01	363679323.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCC)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CCC)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00386886-01	O(CCC)c1ccc(-c2nc(OC)c3c(n2)cccc3)cc1		Inactive			1	NCGC00386886-01	363680482.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCC)c1ccc(-c2nc(OC)c3c(n2)cccc3)cc1	O(CCC)c1ccc(-c2nc(OC)c3c(n2)cccc3)cc1
NCGC00483117-01	O(CCC)c1ccc(CCc2n(CCN3CCOCC3)c3c(n2)cc(-c2c(C)onc2C)cc3)cc1		Inactive	CBP/p300 Inhibitor		1	PF-CBP1	363681136.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	15.08360332	O(CCC)c1ccc(CCc2n(CCN3CCOCC3)c3c(n2)cc(-c2c(C)onc2C)cc3)cc1	O(CCC)c1ccc(CCc2n(CCN3CCOCC3)c3c(n2)cc(-c2c(C)onc2C)cc3)cc1
NCGC00482383-01	O(CCC1CCOCC1)C1CC(Oc2ccc(-c3c(CN(CCNC)C)c[nH]n3)cc2)C1		Inactive	PRMT6 Inhibitor		1	EPZ-020411	363681128.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCC1CCOCC1)C1CC(Oc2ccc(-c3c(CN(CCNC)C)c[nH]n3)cc2)C1	O(CCC1CCOCC1)C1CC(Oc2ccc(-c3c(CN(CCNC)C)c[nH]n3)cc2)C1
NCGC00384888-01	O(CCCC(C)C1=C(C)CC2OC(=O)C(=C)C2C1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384888-01	363679418.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCCC(C)C1=C(C)CC2OC(=O)C(=C)C2C1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CCCC(C)C1=C(C)CC2OC(=O)C(=C)C2C1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00386725-07	O(CCCC)c1ccc(CC/C=C\2/C(=O)N(CCN)C(=O)S/2)cc1		Inactive			1	K145 HYDROCHLORIDE	377020203.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCCC)c1ccc(CC/C=C\2/C(=O)N(CCN)C(=O)S/2)cc1	O(CCCC)c1ccc(CC/C=C\2/C(=O)N(CCN)C(=O)S/2)cc1
NCGC00016529-07	O(CCCC)c1ccc(OCCCN2CCOCC2)cc1		Inactive	Sodium channel alpha subunit Antagonist		1	Pramoxine hydrochloride	170465004.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCCC)c1ccc(OCCCN2CCOCC2)cc1.Cl	O(CCCC)c1ccc(OCCCN2CCOCC2)cc1.Cl
NCGC00390283-02&NCGC00390283-03	O(CCCC)c1nc(N)c2NC(=O)CN(Cc3cc(CN4CCCC4)ccc3)c2n1		Inactive	Toll-Like Receptor 7 (TLR7) Agonist		2	Vesatolimod	434147140.0&363680873.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(CCCC)c1nc(N)c2NC(=O)CN(Cc3cc(CN4CCCC4)ccc3)c2n1	O(CCCC)c1nc(N)c2NC(=O)CN(Cc3cc(CN4CCCC4)ccc3)c2n1
NCGC00183007-01	O(CCCCC)c1c(OCC)cc(C2C(=O)NC(=O)S2)cc1		Inactive	Aldose reductase Inhibitor		1	Risarestat	144206824.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCCCC)c1c(OCC)cc(C2C(=O)NC(=O)S2)cc1	O(CCCCC)c1c(OCC)cc(C2C(=O)NC(=O)S2)cc1
NCGC00015938-05	O(CCCCCCNCC(O)c1cc(CO)c(O)cc1)CCCCc1ccccc1		Inactive	Beta-2 adrenergic receptor Agonist		1	Salmeterol xinafoate	170465397.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1c(O)c2c(cc1)cccc2.O(CCCCCCNCC(O)c1cc(CO)c(O)cc1)CCCCc1ccccc1	O=C(O)c1c(O)c2c(cc1)cccc2.O(CCCCCCNCC(O)c1cc(CO)c(O)cc1)CCCCc1ccccc1
NCGC00179034-07&NCGC00179034-15	O(CCCCCOc1ccc(C(=N)N)cc1)c1ccc(C(=N)N)cc1		Inactive	PRL Phosphatase Inhibitor		2	Pentamidine isethionate	170464786.0&384568368.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(O)CCO.S(=O)(=O)(O)CCO.O(CCCCCOc1ccc(C(=N)N)cc1)c1ccc(C(=N)N)cc1	S(=O)(=O)(O)CCO.S(=O)(=O)(O)CCO.O(CCCCCOc1ccc(C(=N)N)cc1)c1ccc(C(=N)N)cc1&O(CCCCCOc1ccc(C(=N)N)cc1)c1ccc(C(=N)N)cc1
NCGC00378574-01	O(CCCCN1CCN(c2c3c(scc3)ccc2)CC1)c1cc2NC(=O)C=Cc2cc1	4.9499998	Active	Dopamine D3 receptor Partial Agonist	0.0	1	Brexpiprazole	405558789.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	66.8058134454	O(CCCCN1CCN(c2c3c(scc3)ccc2)CC1)c1cc2NC(=O)C=Cc2cc1	O(CCCCN1CCN(c2c3c(scc3)ccc2)CC1)c1cc2NC(=O)C=Cc2cc1
NCGC00024778-02	O(CCCCNC)c1c(Cc2ccccc2)cccc1	4.9000001	Active	Monoamine oxidase B Inhibitor	0.0	1	Bifemelane	170465900.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	115.2326794394	O(CCCCNC)c1c(Cc2ccccc2)cccc1	O(CCCCNC)c1c(Cc2ccccc2)cccc1
NCGC00015207-12&NCGC00015207-24	O(CCCCc1n(C2CCCCC2)nnn1)c1cc2c(NC(=O)CC2)cc1		Inactive	Phosphodiesterase III (PDE3) Inhibitor		2	Cilostazol	170465347.0&384567823.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(CCCCc1n(C2CCCCC2)nnn1)c1cc2c(NC(=O)CC2)cc1	O(CCCCc1n(C2CCCCC2)nnn1)c1cc2c(NC(=O)CC2)cc1
NCGC00249914-01	O(CCCN(C)C)C1(Cc2ccccc2)CCCCCC1	4.9000001	Active		0.0	1	Bencyclane	170465760.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	83.9100808879	O(CCCN(C)C)C1(Cc2ccccc2)CCCCCC1	O(CCCN(C)C)C1(Cc2ccccc2)CCCCCC1
NCGC00185956-04	O(CCCN(C)C)c1c(OC)cc2c(NC3CCN(C)CC3)nc(N3CCN(C)CCC3)nc2c1		Inactive	EHMT2 Inhibitor		1	UNC-0224	384568430.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCCN(C)C)c1c(OC)cc2c(NC3CCN(C)CC3)nc(N3CCN(C)CCC3)nc2c1	O(CCCN(C)C)c1c(OC)cc2c(NC3CCN(C)CC3)nc(N3CCN(C)CCC3)nc2c1
NCGC00016397-04	O(CCCN(C)C)c1nn(Cc2ccccc2)c2c1cccc2	4.9000001	Active	prostaglandin production involved in inflammatory response Inhibitor	0.0	1	Benzydamine hydrochloride	170465576.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	84.8030848746	O(CCCN(C)C)c1nn(Cc2ccccc2)c2c1cccc2.Cl	O(CCCN(C)C)c1nn(Cc2ccccc2)c2c1cccc2.Cl
NCGC00370808-01	O(CCCN(CCc1cc(OC)c(OC)cc1)C)c1nc(-c2ccccc2)sn1		Inactive	sodium ion transport Blocker		1	KC 12291 hydrochloride	363677861.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCCN(CCc1cc(OC)c(OC)cc1)C)c1nc(-c2ccccc2)sn1	O(CCCN(CCc1cc(OC)c(OC)cc1)C)c1nc(-c2ccccc2)sn1
NCGC00390643-01	O(CCCN)c1c(c(OC)ccc1)-c1[nH]nc(Nc2ncc(C#N)nc2)c1		Inactive	Chk1 Inhibitor		1	Prexasertib	384569204.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCCN)c1c(c(OC)ccc1)-c1[nH]nc(Nc2ncc(C#N)nc2)c1	O(CCCN)c1c(c(OC)ccc1)-c1[nH]nc(Nc2ncc(C#N)nc2)c1
NCGC00378667-01	O(CCCN)c1c2n(CC)c(-c3c(N)non3)nc2c(C#CCO)nc1		Inactive			1	AKT Kinase Inhibitor	363678142.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCCN)c1c2n(CC)c(-c3c(N)non3)nc2c(C#CCO)nc1	O(CCCN)c1c2n(CC)c(-c3c(N)non3)nc2c(C#CCO)nc1
NCGC00351478-06	O(CCCN1CCCC1)c1c(OC)cc2C3(C(N)=Nc2c1)CCC3		Inactive	G9a/EHMT2; decrease H3K9me2		1	A-366	384569007.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCCN1CCCC1)c1c(OC)cc2C3(C(N)=Nc2c1)CCC3	O(CCCN1CCCC1)c1c(OC)cc2C3(C(N)=Nc2c1)CCC3
NCGC00189220-03&NCGC00189220-12	O(CCCN1CCCC1)c1c(OC)cc2c(NC3CCN(C(C)C)CC3)nc(C3CCCCC3)nc2c1		Inactive	EHMT2 Inhibitor		2	UNC-0638	363677129.0&384568460.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&17.515256592	O(CCCN1CCCC1)c1c(OC)cc2c(NC3CCN(C(C)C)CC3)nc(C3CCCCC3)nc2c1	O(CCCN1CCCC1)c1c(OC)cc2c(NC3CCN(C(C)C)CC3)nc(C3CCCCC3)nc2c1
NCGC00189144-02	O(CCCN1CCCCC1)c1c(OC)cc2c(NC3CCN(C4CCCCC4)CC3)nc(N3CCN(C(C)C)CCC3)nc2c1		Inactive	EHMT2 Inhibitor		1	UNC-0646	384568459.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCCN1CCCCC1)c1c(OC)cc2c(NC3CCN(C4CCCCC4)CC3)nc(N3CCN(C(C)C)CCC3)nc2c1	O(CCCN1CCCCC1)c1c(OC)cc2c(NC3CCN(C4CCCCC4)CC3)nc(N3CCN(C(C)C)CCC3)nc2c1
NCGC00189130-07	O(CCCN1CCCCC1)c1c(OC)cc2c(NC3CCN(CC4CCCCC4)CC3)nc(N3CCN(C(C)C)CCC3)nc2c1	4.8499999	Active	EHMT2 Inhibitor	0.0	1	UNC-0631	384568458.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.4	31.9868476879	O(CCCN1CCCCC1)c1c(OC)cc2c(NC3CCN(CC4CCCCC4)CC3)nc(N3CCN(C(C)C)CCC3)nc2c1	O(CCCN1CCCCC1)c1c(OC)cc2c(NC3CCN(CC4CCCCC4)CC3)nc(N3CCN(C(C)C)CCC3)nc2c1
NCGC00371012-01	O(CCCN1CCCCC1)c1ccc(CN2CCCCC2)cc1	4.9499998	Active	Histamine H3 receptor Antagonist	0.0	1	JNJ 5207852 dihydrochloride	363677992.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	39.1029728544	O(CCCN1CCCCC1)c1ccc(CN2CCCCC2)cc1	O(CCCN1CCCCC1)c1ccc(CN2CCCCC2)cc1
NCGC00408856-01	O(CCCNCC1Oc2c(OC1)cccc2)C		Inactive			1	Quiloflex	363681066.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCCNCC1Oc2c(OC1)cccc2)C	O(CCCNCC1Oc2c(OC1)cccc2)C
NCGC00378832-01	O(CCCO)[C@H]1[C@H](O)C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(O)(C)C)C)CC3)CCC\2)/C[C@H]1O		Inactive			1	Eldecalcitol	405558953.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCCO)[C@H]1[C@H](O)C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(O)(C)C)C)CC3)CCC\2)/C[C@H]1O	O(CCCO)[C@H]1[C@H](O)C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(O)(C)C)C)CC3)CCC\2)/C[C@H]1O
NCGC00522455-01	O(CCCOc1c(OC)cc2C(=O)N3[C@H](C=Nc2c1)CC(=C)C3)c1c(OC)cc2C(=O)N3[C@H](C=Nc2c1)CC(=C)C3		Inactive	DNA-Intercalating Drugs		1	SJG-136	384569517.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCCOc1c(OC)cc2C(=O)N3[C@H](C=Nc2c1)CC(=C)C3)c1c(OC)cc2C(=O)N3[C@H](C=Nc2c1)CC(=C)C3	O(CCCOc1c(OC)cc2C(=O)N3[C@H](C=Nc2c1)CC(=C)C3)c1c(OC)cc2C(=O)N3[C@H](C=Nc2c1)CC(=C)C3
NCGC00183108-01	O(CCCOc1ccc(C(=N)N)cc1)c1ccc(C(=N)N)cc1		Inactive			1	Propamidine	144206602.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(CCCOc1ccc(C(=N)N)cc1)c1ccc(C(=N)N)cc1	O(CCCOc1ccc(C(=N)N)cc1)c1ccc(C(=N)N)cc1
NCGC00385320-01	O(CCCc1cc(OC)c(OC(C(O)c2cc(OC)c(O)cc2)CO)cc1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385320-01	363679673.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCCc1cc(OC)c(OC(C(O)c2cc(OC)c(O)cc2)CO)cc1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O(CCCc1cc(OC)c(OC(C(O)c2cc(OC)c(O)cc2)CO)cc1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00384838-01	O(CCCc1cc(OC)c2OC(c3cc(OC)c(O)cc3)C(CO)c2c1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384838-01	363679386.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCCc1cc(OC)c2OC(c3cc(OC)c(O)cc3)C(CO)c2c1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CCCc1cc(OC)c2OC(c3cc(OC)c(O)cc3)C(CO)c2c1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00021141-05	O(CCN(C)C)c1c(Cc2ccccc2)cccc1		Inactive	Histamine H1 receptor Blocker		1	Phenyltoloxamine citrate	170465477.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	20.952620248	O=C(O)C(O)(CC(=O)O)CC(=O)O.O(CCN(C)C)c1c(Cc2ccccc2)cccc1	O=C(O)C(O)(CC(=O)O)CC(=O)O.O(CCN(C)C)c1c(Cc2ccccc2)cccc1
NCGC00242249-05	O(CCN(C)C)c1ccc(-c2[nH]c(c(-c3ccncc3)n2)-c2cc3c(/C(=N/O)/CC3)cc2)cc1		Inactive	Raf kinase B Inhibitor		1	SB-590885	384568487.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-7.945167676	O(CCN(C)C)c1ccc(-c2[nH]c(c(-c3ccncc3)n2)-c2cc3c(/C(=N/O)/CC3)cc2)cc1	O(CCN(C)C)c1ccc(-c2[nH]c(c(-c3ccncc3)n2)-c2cc3c(/C(=N/O)/CC3)cc2)cc1
NCGC00024928-14&NCGC00024928-23	O(CCN(C)C)c1ccc(/C(=C(/CC)\c2ccccc2)/c2ccccc2)cc1	5.4749999	Active	Selective Estrogen Receptor Modulators (SERM)	0.5500002000000004	2	Tamoxifen	124886964.0&170465425.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	2.3&3.0	109.9917741206&32.9375	O(CCN(C)C)c1ccc(/C(=C(/CC)\c2ccccc2)/c2ccccc2)cc1	O(CCN(C)C)c1ccc(/C(=C(/CC)\c2ccccc2)/c2ccccc2)cc1&O=C(O)C(O)(CC(=O)O)CC(=O)O.O(CCN(C)C)c1ccc(/C(=C(/CC)\c2ccccc2)/c2ccccc2)cc1
NCGC00016618-04	O(CCN(C)C)c1nc(CCCC)cc2c1cccc2	4.9000001	Active	Neuronal acetylcholine receptor; alpha4/beta4 Inhibitor	0.0	1	Dimethisoquin hydrochloride	170465516.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	52.9823529407	O(CCN(C)C)c1nc(CCCC)cc2c1cccc2.Cl	O(CCN(C)C)c1nc(CCCC)cc2c1cccc2.Cl
NCGC00387452-01	O(CCN(C)C)c1ncc(CN2C(=O)Nc3c(N)nc(NCCCC)nc23)cc1		Inactive	Toll-like receptor 7 Agonist		1	DSR 6434	363680617.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCN(C)C)c1ncc(CN2C(=O)Nc3c(N)nc(NCCCC)nc23)cc1	O(CCN(C)C)c1ncc(CN2C(=O)Nc3c(N)nc(NCCCC)nc23)cc1
NCGC00095124-08&NCGC00095124-31	O(CCN(C)c1ncccc1)c1ccc(CC2C(=O)NC(=O)S2)cc1		Inactive	PPARgamma Agonist		2	Rosiglitazone	170465417.0&384568147.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&27.1642066361&19.589432112	O(CCN(C)c1ncccc1)c1ccc(CC2C(=O)NC(=O)S2)cc1	O(CCN(C)c1ncccc1)c1ccc(CC2C(=O)NC(=O)S2)cc1
NCGC00095196-07	O(CCN(CC)CC)c1cc2C(=O)c3c(-c2cc1)ccc(OCCN(CC)CC)c3	4.8249998	Active		0.0	1	TILORONE		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	3.0&2.1	57.5121088082&117.3253002322	O(CCN(CC)CC)c1cc2C(=O)c3c(-c2cc1)ccc(OCCN(CC)CC)c3	O(CCN(CC)CC)c1cc2C(=O)c3c(-c2cc1)ccc(OCCN(CC)CC)c3
NCGC00160485-01	O(CCN(CC)CC)c1cc2sc(N(C)C)nc2cc1		Inactive			1	Diamthazole	144205400.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCN(CC)CC)c1cc2sc(N(C)C)nc2cc1	O(CCN(CC)CC)c1cc2sc(N(C)C)nc2cc1
NCGC00024762-06	O(CCN(CC)CC)c1ccc(Cc2ccccc2)cc1		Inactive	Estrogen Receptor Antagonist		1	Tesmilifene hydrochloride	384568034.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	28.260225664	O(CCN(CC)CC)c1ccc(Cc2ccccc2)cc1	O(CCN(CC)CC)c1ccc(Cc2ccccc2)cc1
NCGC00370679-04	O(CCN1C(=O)COC(COc2c3c([nH]c4c3cccc4)ccc2)C1)c1c(OC)cccc1	5.0	Active		0.0	1	VK-II-36	363677807.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	2.3	104.0935428554	O(CCN1C(=O)COC(COc2c3c([nH]c4c3cccc4)ccc2)C1)c1c(OC)cccc1	O(CCN1C(=O)COC(COc2c3c([nH]c4c3cccc4)ccc2)C1)c1c(OC)cccc1
NCGC00485895-01	O(CCN1CCCC1)c1c(C#Cc2ccccc2)nc2ncccc2n1		Inactive	Protein-glutamine gamma-glutamyltransferase 2 Inhibitor		1	GK921	363681399.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCN1CCCC1)c1c(C#Cc2ccccc2)nc2ncccc2n1	O(CCN1CCCC1)c1c(C#Cc2ccccc2)nc2ncccc2n1
NCGC00381564-09	O(CCN1CCCC1)c1c2cc(Nc3nc(-c4cc(ccc4)COC/C=C/COC2)ccn3)cc1		Inactive			1	Pacritinib		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-21.906121868	O(CCN1CCCC1)c1c2cc(Nc3nc(-c4cc(ccc4)COC/C=C/COC2)ccn3)cc1	O(CCN1CCCC1)c1c2cc(Nc3nc(-c4cc(ccc4)COC/C=C/COC2)ccn3)cc1
NCGC00408918-01	O(CCN1CCCC1)c1ccc(C(=C(CC)c2ccccc2)c2ccc(OCCN3CCCC3)cc2)cc1		Inactive	PERQ amino acid-rich with GYF domain-containing protein 2 Binding Agent		1	Ridaifen-B	363681084.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCN1CCCC1)c1ccc(C(=C(CC)c2ccccc2)c2ccc(OCCN3CCCC3)cc2)cc1	O(CCN1CCCC1)c1ccc(C(=C(CC)c2ccccc2)c2ccc(OCCN3CCCC3)cc2)cc1
NCGC00181100-01	O(CCN1CCCC1)c1ccc([C@H]2[C@H](c3ccccc3)C(C)(C)Oc3c2ccc(OC)c3)cc1		Inactive	Estrogen receptor Partial Agonist		1	Ormeloxifene	144206269.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCN1CCCC1)c1ccc([C@H]2[C@H](c3ccccc3)C(C)(C)Oc3c2ccc(OC)c3)cc1	O(CCN1CCCC1)c1ccc([C@H]2[C@H](c3ccccc3)C(C)(C)Oc3c2ccc(OC)c3)cc1
NCGC00345826-04	O(CCN1CCCCC1)c1cc(-c2n[nH]c3c2cc(-c2n[nH]cn2)cc3)ccc1		Inactive	JNK Inhibitor		1	CC-401	363677373.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCN1CCCCC1)c1cc(-c2n[nH]c3c2cc(-c2n[nH]cn2)cc3)ccc1	O(CCN1CCCCC1)c1cc(-c2n[nH]c3c2cc(-c2n[nH]cn2)cc3)ccc1
NCGC00165869-22	O(CCN1CCCCC1)c1ccc(C2=Cn3ncc(-c4ccncc4)c3N=C2)cc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	Dorsomorphin	384568292.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCN1CCCCC1)c1ccc(C2=Cn3ncc(-c4ccncc4)c3N=C2)cc1	O(CCN1CCCCC1)c1ccc(C2=Cn3ncc(-c4ccncc4)c3N=C2)cc1
NCGC00182995-01	O(CCN1CCCCC1)c1ccc(NC2N(CC)C(=O)c3c2cccc3)cc1		Inactive			1	Etomidoline	144206828.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(CCN1CCCCC1)c1ccc(NC2N(CC)C(=O)c3c2cccc3)cc1	O(CCN1CCCCC1)c1ccc(NC2N(CC)C(=O)c3c2cccc3)cc1
NCGC00510909-01	O(CCN1CCCCC1)c1ccc([C@H]2C(c3ccc(O)cc3)=C(C)c3c(O2)cc(O)cc3)cc1	4.9499998	Active	Selective Estrogen Receptor Modulators (SERM)	0.0	1	Acolbifene	384569493.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	111.5578289191	O(CCN1CCCCC1)c1ccc([C@H]2C(c3ccc(O)cc3)=C(C)c3c(O2)cc(O)cc3)cc1	O(CCN1CCCCC1)c1ccc([C@H]2C(c3ccc(O)cc3)=C(C)c3c(O2)cc(O)cc3)cc1
NCGC00242598-10	O(CCN1CCOCC1)c1cc2nccc(-c3c(-c4ncccc4)nn4c3CCC4)c2cc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	LY-2109761	377020452.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCN1CCOCC1)c1cc2nccc(-c3c(-c4ncccc4)nn4c3CCC4)c2cc1	O(CCN1CCOCC1)c1cc2nccc(-c3c(-c4ncccc4)nn4c3CCC4)c2cc1
NCGC00508900-01	O(CCN1CCOCC1)c1ccc(C2=Cn3ncc(-c4c5c(ncc4)cccc5)c3N=C2)cc1	5.3499999	Active	TGF-bR1 (ALK5) Inhibitor	0.0	1	VU-0364849	384569371.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	82.6981501851	O(CCN1CCOCC1)c1ccc(C2=Cn3ncc(-c4c5c(ncc4)cccc5)c3N=C2)cc1	O(CCN1CCOCC1)c1ccc(C2=Cn3ncc(-c4c5c(ncc4)cccc5)c3N=C2)cc1
NCGC00371119-04	O(CCN1CCOCC1)c1nn(c(C)c1)-c1cc2c(cc1)cccc2		Inactive	Sigma opioid receptor Antagonist		1	S1RA	363678035.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCN1CCOCC1)c1nn(c(C)c1)-c1cc2c(cc1)cccc2	O(CCN1CCOCC1)c1nn(c(C)c1)-c1cc2c(cc1)cccc2
NCGC00510269-04	O(CCN1[C@H](C)C(=O)N(C)CC1)c1ccc(C2CCN(C3=Nn4c(OC)nnc4C=C3)CC2)cc1		Inactive	Brd4 Inhibitor		1	AZD-5153 6-Hydroxy-2-naphthoic acid	384569426.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCN1[C@H](C)C(=O)N(C)CC1)c1ccc(C2CCN(C3=Nn4c(OC)nnc4C=C3)CC2)cc1	O(CCN1[C@H](C)C(=O)N(C)CC1)c1ccc(C2CCN(C3=Nn4c(OC)nnc4C=C3)CC2)cc1
NCGC00346806-06	O(CCNC)c1ccc(/C(=C(\CC)/c2ccccc2)/c2ccc(O)cc2)cc1		Inactive	PKC Inhibitor		1	Endoxifen	384568940.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCNC)c1ccc(/C(=C(\CC)/c2ccccc2)/c2ccc(O)cc2)cc1	O(CCNC)c1ccc(/C(=C(\CC)/c2ccccc2)/c2ccc(O)cc2)cc1
NCGC00388561-04	O(CCNCC(O)CCOc1c2c([nH]c3c2cccc3)ccc1)c1c(OC)cccc1	4.9000001	Active	Adrenergic receptor beta; ADRB1 & ADRB3 Binding Agent	0.0	1	VK-II-86	363680733.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	113.2194857095	O(CCNCC(O)CCOc1c2c([nH]c3c2cccc3)ccc1)c1c(OC)cccc1	O(CCNCC(O)CCOc1c2c([nH]c3c2cccc3)ccc1)c1c(OC)cccc1
NCGC00485926-01	O(CCNCC(O)COc1c2c([nH]c3c2cccc3)ccc1)c1c(OC)cc(O)cc1		Inactive			1	Carvedilol metabolite 4-Hydroxyphenyl Carvedilol	363681421.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCNCC(O)COc1c2c([nH]c3c2cccc3)ccc1)c1c(OC)cc(O)cc1	O(CCNCC(O)COc1c2c([nH]c3c2cccc3)ccc1)c1c(OC)cc(O)cc1
NCGC00167832-06	O(CCNCC(O)COc1c2c([nH]c3c2cccc3)ccc1)c1c(OC)cccc1	4.9000001	Active	beta1-Adrenoceptor Antagonists	0.0	1	Carvedilol tartrate	170465440.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	118.0960122387	O=C(O)C(O)C(O)C(=O)O.O(CCNCC(O)COc1c2c([nH]c3c2cccc3)ccc1)c1c(OC)cccc1	O=C(O)C(O)C(O)C(=O)O.O(CCNCC(O)COc1c2c([nH]c3c2cccc3)ccc1)c1c(OC)cccc1
NCGC00274074-01	O(CCO)CCCCCCCCCCCC		Inactive			1	2-(Dodecyloxy)ethanol	170466587.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCO)CCCCCCCCCCCC	O(CCO)CCCCCCCCCCCC
NCGC00095911-06	O(CCO)CCN1CCN(C2=Nc3c(Sc4c2cccc4)cccc3)CC1		Inactive	Serotonin 2a (5-HT2a) receptor Antagonist		1	Quetiapine	170465146.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(CCO)CCN1CCN(C2=Nc3c(Sc4c2cccc4)cccc3)CC1	O(CCO)CCN1CCN(C2=Nc3c(Sc4c2cccc4)cccc3)CC1
NCGC00167778-02	O(CCO)CCN1CCN(Cc2cc(Oc3ccccc3)ccc2)CC1		Inactive			1	ZK 756326	434147041.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCO)CCN1CCN(Cc2cc(Oc3ccccc3)ccc2)CC1	O(CCO)CCN1CCN(Cc2cc(Oc3ccccc3)ccc2)CC1
NCGC00384193-03	O(CCO)CCNc1c2c(C)n[nH]c2nc2c1cc(OC)cc2		Inactive	MTH1 Inhibitor		1	SCH-51344	384569104.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCO)CCNc1c2c(C)n[nH]c2nc2c1cc(OC)cc2	O(CCO)CCNc1c2c(C)n[nH]c2nc2c1cc(OC)cc2
NCGC00015061-13&NCGC00015061-27&NCGC00015061-29	O(CCO)Cn1c2N=C(N)NC(=O)c2nc1		Inactive	DNA Polymerase Inhibitor		3	Aciclovir&Acyclovir	170464640.0&384567804.0&434146940.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O(CCO)Cn1c2N=C(N)NC(=O)c2nc1	O(CCO)Cn1c2N=C(N)NC(=O)c2nc1
NCGC00167512-03&NCGC00167512-04	O(CCO)[C@H]1[C@H](OC)C[C@H](C[C@@H](C)[C@H]2OC(=O)[C@H]3N(C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@H](OC)/C(/C)=C\C=C/C=C\[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(/C)=C\[C@@H](C)C(=O)C2)CCCC3)CC1		Inactive	mTOR inhibitor		2	Everolimus	384568320.0&405558939.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(CCO)[C@H]1[C@H](OC)C[C@H](C[C@@H](C)[C@H]2OC(=O)[C@H]3N(C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@H](OC)/C(/C)=C\C=C/C=C\[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(/C)=C\[C@@H](C)C(=O)C2)CCCC3)CC1	O(CCO)[C@H]1[C@H](OC)C[C@H](C[C@@H](C)[C@H]2OC(=O)[C@H]3N(C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@H](OC)/C(/C)=C\C=C/C=C\[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(/C)=C\[C@@H](C)C(=O)C2)CCCC3)CC1
NCGC00356073-10&NCGC00356073-13	O(CCO)c1c(C)cc(C2=Nc3c(c(OC)cc(OC)c3)C(=O)N2)cc1C		Inactive	Brd4 Inhibitor		2	RVX-208	384569027.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(CCO)c1c(C)cc(C2=Nc3c(c(OC)cc(OC)c3)C(=O)N2)cc1C	O(CCO)c1c(C)cc(C2=Nc3c(c(OC)cc(OC)c3)C(=O)N2)cc1C
NCGC00090731-08	O(CCO)c1ccccc1		Inactive	Vanilloid receptor Agonist		1	2-Phenoxyethanol	170465671.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCO)c1ccccc1	O(CCO)c1ccccc1
NCGC00389470-01	O(CCOC)CC1OC2C(O)(C)C(CC)OC(=O)C(C)C(OC3OC(C)C(O)C(OC)(C)C3)C(C)C(OC3C(O)C(N(C)C)CC(C)O3)C(O)(C)CC(C)C(C2C)N1		Inactive	Bacterial 70S ribosome Inhibitor		1	Dirithromycin	405558768.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCOC)CC1OC2C(O)(C)C(CC)OC(=O)C(C)C(OC3OC(C)C(O)C(OC)(C)C3)C(C)C(OC3C(O)C(N(C)C)CC(C)O3)C(O)(C)CC(C)C(C2C)N1	O(CCOC)CC1OC2C(O)(C)C(CC)OC(=O)C(C)C(OC3OC(C)C(O)C(OC)(C)C3)C(C)C(OC3C(O)C(N(C)C)CC(C)O3)C(O)(C)CC(C)C(C2C)N1
NCGC00090874-06	O(CCOCCCC)CCOCc1c(CCC)cc2OCOc2c1		Inactive			1	Piperonyl butoxide	170464741.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(CCOCCCC)CCOCc1c(CCC)cc2OCOc2c1	O(CCOCCCC)CCOCc1c(CCC)cc2OCOc2c1
NCGC00163798-06	O(CCOCCO)CCO		Inactive			1	Triethylene glycol	405559002.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCOCCO)CCO	O(CCOCCO)CCO
NCGC00166290-03	O(CCOCCOCCOCCOCCO)CCOCCOCCOCCOCCCCCCCCCCCC		Inactive			1	Polyoxyethylene (9) lauryl ether	170466791.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCOCCOCCOCCOCCO)CCOCCOCCOCCOCCCCCCCCCCCC	O(CCOCCOCCOCCOCCO)CCOCCOCCOCCOCCCCCCCCCCCC
NCGC00509863-01	O(CCOCCOCCOCCO[C@@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC=C)CC3)C4)CC1)CCOCCOCCOC		Inactive	Mu-type opioid receptor Antagonist		1	Naloxegol (oxalate)	405558803.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCOCCOCCOCCO[C@@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC=C)CC3)C4)CC1)CCOCCOCCOC	O(CCOCCOCCOCCO[C@@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC=C)CC3)C4)CC1)CCOCCOCCOC
NCGC00346578-08	O(CCOc1c(OCCO)cc2c(Nc3cc(C#C)ccc3)ncnc2c1)C		Inactive	EGFR Inhibitor		1	OSI-420	384568849.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCOc1c(OCCO)cc2c(Nc3cc(C#C)ccc3)ncnc2c1)C	O(CCOc1c(OCCO)cc2c(Nc3cc(C#C)ccc3)ncnc2c1)C
NCGC00164574-06&NCGC00164574-14&NCGC00164574-25	O(CCOc1c(OCCOC)cc2ncnc(Nc3cc(C#C)ccc3)c2c1)C		Inactive	EGFR Inhibitor		3	Erlotinib	170465434.0&363676637.0&434147028.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O(CCOc1c(OCCOC)cc2ncnc(Nc3cc(C#C)ccc3)c2c1)C	O(CCOc1c(OCCOC)cc2ncnc(Nc3cc(C#C)ccc3)c2c1)C
NCGC00346718-02	O(CCOc1cc2ncn(-c3nc4c(N5CCC(N)CC5)cccc4cc3)c2cc1)C		Inactive	PDGFR beta Inhibitor		1	CP-673451	384568931.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	16.8495145681	O(CCOc1cc2ncn(-c3nc4c(N5CCC(N)CC5)cccc4cc3)c2cc1)C	O(CCOc1cc2ncn(-c3nc4c(N5CCC(N)CC5)cccc4cc3)c2cc1)C
NCGC00016373-08	O(CCOc1ccc(C(CC(C)(C)C)(C)C)cc1)CC[N+](Cc1ccccc1)(C)C		Inactive			1	Benzethonium chloride	170465473.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0		O(CCOc1ccc(C(CC(C)(C)C)(C)C)cc1)CC[N+](Cc1ccccc1)(C)C.[Cl-]	O(CCOc1ccc(C(CC(C)(C)C)(C)C)cc1)CC[N+](Cc1ccccc1)(C)C.[Cl-]
NCGC00378857-02	O(CCOc1ccc(N2CCN(CCn3ncc4-c5n(C(N)=Nc34)nc(-c3occc3)n5)CC2)cc1)C		Inactive	Adenosine A2A Antagonist		1	Preladenant	363678239.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCOc1ccc(N2CCN(CCn3ncc4-c5n(C(N)=Nc34)nc(-c3occc3)n5)CC2)cc1)C	O(CCOc1ccc(N2CCN(CCn3ncc4-c5n(C(N)=Nc34)nc(-c3occc3)n5)CC2)cc1)C
NCGC00253658-01	O(CC[C@H](N(C)C)c1ccccc1)c1c2c(ccc1)cccc2	4.9000001	Active	Serotonin Transporter (SERT) Inhibitor	0.0	1	Dapoxetine	170466555.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	100.8036795534	O(CC[C@H](N(C)C)c1ccccc1)c1c2c(ccc1)cccc2	O(CC[C@H](N(C)C)c1ccccc1)c1c2c(ccc1)cccc2
NCGC00015482-07&NCGC00015482-15	O(CC[N+](CC)(CC)CC)c1c(OCC[N+](CC)(CC)CC)cccc1OCC[N+](CC)(CC)CC		Inactive	Muscarinic M2 Antagonist		2	Gallamine triethiodide	170465398.0&384567857.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O(CC[N+](CC)(CC)CC)c1c(OCC[N+](CC)(CC)CC)cccc1OCC[N+](CC)(CC)CC.[I-].[I-].[I-]	O(CC[N+](CC)(CC)CC)c1c(OCC[N+](CC)(CC)CC)cccc1OCC[N+](CC)(CC)CC.[I-].[I-].[I-]&O(CC[N+](CC)(CC)CC)c1c(OCC[N+](CC)(CC)CC)cccc1OCC[N+](CC)(CC)CC
NCGC00091010-03	O(CC[N+](CCCCCCCCCCCC)(C)C)c1ccccc1		Inactive	HERG Inhibitor		1	Domiphen bromide	170465494.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC[N+](CCCCCCCCCCCC)(C)C)c1ccccc1.[Br-]	O(CC[N+](CCCCCCCCCCCC)(C)C)c1ccccc1.[Br-]
NCGC00181794-01	O(CC[N+](Cc1sccc1)(C)C)c1ccccc1		Inactive	acetylcholine metabolic process Modulator		1	Dimethyl(2-phenoxyethyl)-2-thenylammonium iodide	144207154.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC[N+](Cc1sccc1)(C)C)c1ccccc1.[I-]	O(CC[N+](Cc1sccc1)(C)C)c1ccccc1.[I-]
NCGC00379061-01	O(CC[N+]12CCC(C(O)(c3ccccc3)c3ccccc3)(CC1)CC2)Cc1ccccc1		Inactive	Muscarinic acetylcholine receptor M3 Antagonist		1	Umeclidinium bromide	405558946.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CC[N+]12CCC(C(O)(c3ccccc3)c3ccccc3)(CC1)CC2)Cc1ccccc1	O(CC[N+]12CCC(C(O)(c3ccccc3)c3ccccc3)(CC1)CC2)Cc1ccccc1
NCGC00531790-01	O(CCc1c(C)oc(-c2ccccc2)n1)c1ccc(CC2C(=O)ONC2=O)cc1		Inactive	Peroxisome proliferator-activated receptor gamma Agonist		1	JTT-501	405558852.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCc1c(C)oc(-c2ccccc2)n1)c1ccc(CC2C(=O)ONC2=O)cc1	O(CCc1c(C)oc(-c2ccccc2)n1)c1ccc(CC2C(=O)ONC2=O)cc1
NCGC00378872-01	O(CCc1cc(OC)c(OC)cc1)[C@H]1[C@H](N2C[C@H](O)CC2)CCCC1		Inactive	Voltage-gated potassium channel subunit Kv4.3 Blocker		1	Vernakalant Hydrochloride	363678250.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCc1cc(OC)c(OC)cc1)[C@H]1[C@H](N2C[C@H](O)CC2)CCCC1	O(CCc1cc(OC)c(OC)cc1)[C@H]1[C@H](N2C[C@H](O)CC2)CCCC1
NCGC00185775-01	O(CCc1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	beta-Amyloid (Abeta) Protein Neurotoxicity Inhibitors		1	Salidroside	144207114.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(CCc1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CCc1ccc(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385099-01	O(CCc1ccc(O)cc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385099-01	363679532.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCc1ccc(O)cc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CCc1ccc(O)cc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00384804-01	O(CCc1ccc(OC)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@@H](O)CO2)O1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384804-01	363679365.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	-14.965463224	O(CCc1ccc(OC)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@@H](O)CO2)O1	O(CCc1ccc(OC)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@@H](O)CO2)O1
NCGC00021148-08	O(CCc1ccc(OCC(O)CNC(C)C)cc1)C		Inactive			1	Metoprolol tartrate	170464652.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@H](O)[C@@H](O)C(=O)O.O(CCc1ccc(OCC(O)CNC(C)C)cc1)C.O(CCc1ccc(OCC(O)CNC(C)C)cc1)C	O=C(O)[C@H](O)[C@@H](O)C(=O)O.O(CCc1ccc(OCC(O)CNC(C)C)cc1)C.O(CCc1ccc(OCC(O)CNC(C)C)cc1)C
NCGC00015159-13&NCGC00015159-22	O(CCc1ccc(OCC(O)CNC(C)C)cc1)CC1CC1		Inactive	Beta1-adrenoceptor Antagonists		2	Betaxolol HCl&Betaxolol	405558860.0&384567818.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(CCc1ccc(OCC(O)CNC(C)C)cc1)CC1CC1	O(CCc1ccc(OCC(O)CNC(C)C)cc1)CC1CC1
NCGC00380502-01	O(CCc1ccccc1)C1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)CO2)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Spiraea | Family: Rosaceae | Species: henryi		1	NCGC00380502-01	363678614.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCc1ccccc1)C1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)CO2)O1	O(CCc1ccccc1)C1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)CO2)O1
NCGC00169593-02	O(CCc1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Genista | Family: N/A | Species: umbellata		1	NCGC00169593-02	363676846.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCc1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CCc1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00384577-01	O(CCc1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Gladioulus | Family: Iridaceae | Species: communis		1	NCGC00384577-01	363679255.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCc1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1	O(CCc1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@H](O)[C@@](O)(CO)CO2)O1
NCGC00169796-02	O(CCc1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Gladioulus | Family: Iridaceae | Species: communis		1	NCGC00169796-02	363676888.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCc1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)O1	O(CCc1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)O1
NCGC00384762-01	O(CCc1ccccc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: olea | Family: Oleaceae | Species: europaea		1	NCGC00384762-01	363679342.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCc1ccccc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CCc1ccccc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385096-01	O(CCc1ccccc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385096-01	363679530.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCc1ccccc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CCc1ccccc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385086-01	O(CCc1ccccc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385086-01	363679524.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCc1ccccc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(CCc1ccccc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00387082-01	O(CCc1ccccc1)c1c(OC)ccc(CCN(CCC)CCC)c1		Inactive	Sigma-1 receptor Antagonist		1	NE 100 hydrochloride	363680537.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(CCc1ccccc1)c1c(OC)ccc(CCN(CCC)CCC)c1	O(CCc1ccccc1)c1c(OC)ccc(CCN(CCC)CCC)c1
NCGC00163128-08&NCGC00163128-17	O(CCc1ncc(CC)cc1)c1ccc(CC2C(=O)NC(=O)S2)cc1		Inactive	PPARgamma Agonist		2	Pioglitazone hydrochloride	170465116.0&384568232.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O(CCc1ncc(CC)cc1)c1ccc(CC2C(=O)NC(=O)S2)cc1.Cl	O(CCc1ncc(CC)cc1)c1ccc(CC2C(=O)NC(=O)S2)cc1.Cl&O(CCc1ncc(CC)cc1)c1ccc(CC2C(=O)NC(=O)S2)cc1
NCGC00263093-04&NCGC00263093-14	O(CCc1ncccc1)c1nc(N/N=C/c2cc(C)ccc2)cc(N2CCOCC2)n1	4.9000001	Inactive	PIKFyve Inhibitor	0.0	2	Apilimod&Apilimod mesylate	384568585.0&434146923.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	5.0&5.0	-105.2980753163&-72.1831001384	O(CCc1ncccc1)c1nc(N/N=C/c2cc(C)ccc2)cc(N2CCOCC2)n1	O(CCc1ncccc1)c1nc(N/N=C/c2cc(C)ccc2)cc(N2CCOCC2)n1
NCGC00242514-13	O(CCn1c(C)[n+](Cc2nccnc2)c2C(=O)c3c(C(=O)c12)cccc3)C		Inactive	Survivin Inhibitor		1	Sepantronium bromide	384568506.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O(CCn1c(C)[n+](Cc2nccnc2)c2C(=O)c3c(C(=O)c12)cccc3)C	O(CCn1c(C)[n+](Cc2nccnc2)c2C(=O)c3c(C(=O)c12)cccc3)C
NCGC00181341-02	O(CCn1c(N2CCN(C)CCC2)nc2c1cccc2)CC		Inactive	Histamine H1 receptor Antagonist		1	Emedastine difumarate	170465197.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O.O(CCn1c(N2CCN(C)CCC2)nc2c1cccc2)CC	O=C(O)/C=C/C(=O)O.O=C(O)/C=C/C(=O)O.O(CCn1c(N2CCN(C)CCC2)nc2c1cccc2)CC
NCGC00347278-03	O(C[C@@H](N)Cc1c2c([nH]c1)cccc2)c1cc(-c2cc3c(C)n[nH]c3cc2)cnc1		Inactive	AKT Inhibitor		1	A-443654	384568984.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O(C[C@@H](N)Cc1c2c([nH]c1)cccc2)c1cc(-c2cc3c(C)n[nH]c3cc2)cnc1	O(C[C@@H](N)Cc1c2c([nH]c1)cccc2)c1cc(-c2cc3c(C)n[nH]c3cc2)cnc1
NCGC00263147-03	O(C[C@@H](N)Cc1ccccc1)c1cc(-c2cc3c(C)n[nH]c3cc2)cnc1		Inactive	AKT Inhibitor		1	A-674563	384568622.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O(C[C@@H](N)Cc1ccccc1)c1cc(-c2cc3c(C)n[nH]c3cc2)cnc1	O(C[C@@H](N)Cc1ccccc1)c1cc(-c2cc3c(C)n[nH]c3cc2)cnc1
NCGC00016798-11	O(C[C@@H](O)CNC(C)(C)C)c1c(N2CCOCC2)nsn1		Inactive	Beta-2 adrenergic receptor Antagonist		1	(S)-Timolol	170465062.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(C[C@@H](O)CNC(C)(C)C)c1c(N2CCOCC2)nsn1	O(C[C@@H](O)CNC(C)(C)C)c1c(N2CCOCC2)nsn1
NCGC00016801-05	O(C[C@@H](O)CNC(C)(C)C)c1c2c(C(=O)CCC2)ccc1		Inactive	Beta-2 adrenergic receptor Antagonist		1	Levobunolol hydrochloride	170464743.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O(C[C@@H](O)CNC(C)(C)C)c1c2c(C(=O)CCC2)ccc1.Cl	O(C[C@@H](O)CNC(C)(C)C)c1c2c(C(=O)CCC2)ccc1.Cl
NCGC00378545-01	O(C[C@@H](O)CN[C@@H]1c2c(cccc2)CCC1)c1c(CC)cccc1	4.9000001	Active	Beta-3 adrenergic receptor Agonist	0.0	1	SR 59230A hydrochloride	363678085.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	3.0	90.7161146189	O(C[C@@H](O)CN[C@@H]1c2c(cccc2)CCC1)c1c(CC)cccc1	O(C[C@@H](O)CN[C@@H]1c2c(cccc2)CCC1)c1c(CC)cccc1
NCGC00263181-10	O(C[C@@H]1CNCCC1)c1c2n(CC)c(-c3c(N)non3)nc2c(C#CC(O)(C)C)nc1		Inactive	AKT Inhibitor		1	GSK-690693	384568649.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C[C@@H]1CNCCC1)c1c2n(CC)c(-c3c(N)non3)nc2c(C#CC(O)(C)C)nc1	O(C[C@@H]1CNCCC1)c1c2n(CC)c(-c3c(N)non3)nc2c(C#CC(O)(C)C)nc1
NCGC00380493-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(C)OC=CC2=O)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380493-01	363678608.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(C)OC=CC2=O)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(C)OC=CC2=O)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1
NCGC00160628-03&NCGC00160628-18	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(c3cc(O)c(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	Aldose reductase Inhibitor		2	Rutin trihydrate&RUTOSIDE  (rutin)	170465691.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(c3cc(O)c(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(c3cc(O)c(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00169803-03	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2C(C)OC(O[C@@H]3C[C@@H]4[C@@](C)(C5C6(OC76[C@@](C)(C(C6=CC(=O)OC6)=CC7)CC5)CC4)CC3)CC2OC)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Steroid | Genus: Nerium | Family: Apocynaceae | Species: oleander		1	NCGC00169803-03	363676890.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2C(C)OC(O[C@@H]3C[C@@H]4[C@@](C)(C5C6(OC76[C@@](C)(C(C6=CC(=O)OC6)=CC7)CC5)CC4)CC3)CC2OC)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2C(C)OC(O[C@@H]3C[C@@H]4[C@@](C)(C5C6(OC76[C@@](C)(C(C6=CC(=O)OC6)=CC7)CC5)CC4)CC3)CC2OC)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385224-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2CC(O)(C)C3(C(C)(C)C2)OC(C)CC3)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385224-01	363679602.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2CC(O)(C)C3(C(C)(C)C2)OC(C)CC3)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2CC(O)(C)C3(C(C)(C)C2)OC(C)CC3)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1
NCGC00380538-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCC2C3C(C)(C)C(C3)CC2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380538-01	363678639.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCC2C3C(C)(C)C(C3)CC2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCC2C3C(C)(C)C(C3)CC2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1
NCGC00385590-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCC2C3C(C)(C)C(C3)CC2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385590-01	363679825.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCC2C3C(C)(C)C(C3)CC2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCC2C3C(C)(C)C(C3)CC2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00385822-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCC=2[C@@H]3C(C)(C)[C@@H](C3)CC=2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)CO1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385822-01	363679956.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCC=2[C@@H]3C(C)(C)[C@@H](C3)CC=2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)CO1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCC=2[C@@H]3C(C)(C)[C@@H](C3)CC=2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)CO1
NCGC00384629-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCc2ccccc2)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384629-01	363679282.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCc2ccccc2)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCc2ccccc2)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385106-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCc2ccccc2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385106-01	363679538.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCc2ccccc2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCc2ccccc2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1
NCGC00169814-02	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCc2ccccc2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Terminalia | Family: Combretaceae | Species: avicennoides		1	NCGC00169814-02	363676893.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCc2ccccc2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCc2ccccc2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00384914-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](CO[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)([C@@H](O)C5)CCC(C)(C)C6)=CC4)CC3)CC2)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384914-01	363679435.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](CO[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)([C@@H](O)C5)CCC(C)(C)C6)=CC4)CC3)CC2)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](CO[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)([C@@H](O)C5)CCC(C)(C)C6)=CC4)CC3)CC2)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)O1
NCGC00384687-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@H](O[C@@H]3C(C)(C)[C@H]4[C@@](C)(C5[C@](C)([C@]67[C@@H]([C@H]8[C@](O)(C)CC(C=C(C)C)O[C@@]8(OC6)C7)CC5)CC4)CC3)OC[C@@H]2O)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Rhamnus | Family: Rhamnaceae | Species: lyciodes		1	NCGC00384687-01	363679312.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@H](O[C@@H]3C(C)(C)[C@H]4[C@@](C)(C5[C@](C)([C@]67[C@@H]([C@H]8[C@](O)(C)CC(C=C(C)C)O[C@@]8(OC6)C7)CC5)CC4)CC3)OC[C@@H]2O)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@H](O[C@@H]3C(C)(C)[C@H]4[C@@](C)(C5[C@](C)([C@]67[C@@H]([C@H]8[C@](O)(C)CC(C=C(C)C)O[C@@]8(OC6)C7)CC5)CC4)CC3)OC[C@@H]2O)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00386012-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2C[C@@H](C)[C@H](/C=C/[C@H](O)C)C(C)(C)C2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386012-01	363680059.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2C[C@@H](C)[C@H](/C=C/[C@H](O)C)C(C)(C)C2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2C[C@@H](C)[C@H](/C=C/[C@H](O)C)C(C)(C)C2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1
NCGC00169683-02	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C)OC(OC3CC4C(C)(C5C6(C(=O)C(C)(C(C7=CC(=O)OC7)CC6)CC5)CC4)CC3)C[C@H]2OC)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: steroid | Genus: Nerium | Family: Apocynaceae | Species: oleander		1	NCGC00169683-02	363676862.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C)OC(OC3CC4C(C)(C5C6(C(=O)C(C)(C(C7=CC(=O)OC7)CC6)CC5)CC4)CC3)C[C@H]2OC)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C)OC(OC3CC4C(C)(C5C6(C(=O)C(C)(C(C7=CC(=O)OC7)CC6)CC5)CC4)CC3)C[C@H]2OC)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00380126-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3CC=4[C@@](C)(C5C([C@]6(O)[C@@](C)([C@@H](C7=CC(=O)OC7)CC6)CC5)CC=4)CC3)C[C@@H]2OC)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Beaumontia | Family: Apocynaceae | Species: grandiflora		1	NCGC00380126-01	363678466.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3CC=4[C@@](C)(C5C([C@]6(O)[C@@](C)([C@@H](C7=CC(=O)OC7)CC6)CC5)CC=4)CC3)C[C@@H]2OC)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3CC=4[C@@](C)(C5C([C@]6(O)[C@@](C)([C@@H](C7=CC(=O)OC7)CC6)CC5)CC=4)CC3)C[C@@H]2OC)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00347644-02	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](C=C)[C@H]3C(C(=O)OCC3)=CO2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347644-02	363677649.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](C=C)[C@H]3C(C(=O)OCC3)=CO2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](C=C)[C@H]3C(C(=O)OCC3)=CO2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1
NCGC00169844-02	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](OC)[C@@H](O)[C@@H](O[C@@H]3C[C@@H]4[C@@](C)(C5[C@H]([C@]6(O)[C@@H](C(=C)[C@@H](C7=CC(=O)OC7)CC6)C5)CC4)CC3)O[C@H]2C)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169844-02	363676897.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	13.9822695001	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](OC)[C@@H](O)[C@@H](O[C@@H]3C[C@@H]4[C@@](C)(C5[C@H]([C@]6(O)[C@@H](C(=C)[C@@H](C7=CC(=O)OC7)CC6)C5)CC4)CC3)O[C@H]2C)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](OC)[C@@H](O)[C@@H](O[C@@H]3C[C@@H]4[C@@](C)(C5[C@H]([C@]6(O)[C@@H](C(=C)[C@@H](C7=CC(=O)OC7)CC6)C5)CC4)CC3)O[C@H]2C)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00381214-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(O)cc(CC=C)cc2)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Godmania | Family: Leguminosae | Species: aesculifolia		1	NCGC00381214-01	363679027.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(O)cc(CC=C)cc2)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(O)cc(CC=C)cc2)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385515-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(OC)cc(/C=C/CO)cc2OC)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385515-01	363679783.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(OC)cc(/C=C/CO)cc2OC)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(OC)cc(/C=C/CO)cc2OC)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385088-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c3C(=O)C(O)(Cc4ccc(O)cc4)Oc3cc(O)c2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385088-01	363679525.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c3C(=O)C(O)(Cc4ccc(O)cc4)Oc3cc(O)c2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c3C(=O)C(O)(Cc4ccc(O)cc4)Oc3cc(O)c2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00347532-02	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c3c(OC)cccc3cc3C(=O)OC(C)c23)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347532-02	363677616.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c3c(OC)cccc3cc3C(=O)OC(C)c23)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c3c(OC)cccc3cc3C(=O)OC(C)c23)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00380844-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c3c([nH]c2)cccc3)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Stereospermum | Family: Bignoniaceae | Species: chelonoides		1	NCGC00380844-01	363678810.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c3c([nH]c2)cccc3)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c3c([nH]c2)cccc3)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1
NCGC00380744-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(CC=C(C)C)c(O)cc2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Dodonaea | Family: Sapindaceae | Species: viscosa		1	NCGC00380744-01	363678756.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(CC=C(C)C)c(O)cc2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(CC=C(C)C)c(O)cc2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1
NCGC00344564-05	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	Aryl Hydrocarbon Receptor (AhR) Agonist		1	Diosmin	384568723.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00179501-03&NCGC00179501-09	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C[C@@H](c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	Free Radical Scavenger		2	Aurantiamarin (Methyl Hesperidin)	225144305.0&384568375.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C[C@@H](c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C[C@@H](c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00380365-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(OC)c(O)c(OC)c2)O1)[C@@H]1[C@H](O)[C@@](O)(CO)CO1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380365-01	363678553.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(OC)c(O)c(OC)c2)O1)[C@@H]1[C@H](O)[C@@](O)(CO)CO1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(OC)c(O)c(OC)c2)O1)[C@@H]1[C@H](O)[C@@](O)(CO)CO1
NCGC00169773-02	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2ccc(C=C)cc2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Dicranopteris | Family: Gleicheniaceae | Species: linearis		1	NCGC00169773-02	363676883.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2ccc(C=C)cc2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2ccc(C=C)cc2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00386037-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2ccc(CC=C)cc2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386037-01	363680073.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2ccc(CC=C)cc2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2ccc(CC=C)cc2)O1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00381280-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2ccccc2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381280-01	363679064.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2ccccc2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2ccccc2)O1)[C@H]1[C@H](O)[C@@](O)(CO)CO1
NCGC00386010-01	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](OCc2ccccc2)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386010-01	363680057.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](OCc2ccccc2)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1	O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](OCc2ccccc2)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1
NCGC00532495-01	O(C[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)O[C@H](CO)[C@H]2O)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive			1	Sizofilan	405558842.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)O[C@H](CO)[C@H]2O)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)O[C@H](CO)[C@H]2O)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385658-01	O(C[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@@H]3C[C@@H]4[C@@](C)(C5[C@H](C6[C@@](C)([C@H]7[C@H](C)[C@@]8(O[C@H]7C6)OC[C@@H](C)CC8)CC5)CC4)CC3)O[C@@H]2CO)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1	5.4499998	Active	<MOA Unknown> | Class: Steroid | Genus: Asparagus | Family: Liliaceae | Species: racemosus	0.0	1	NCGC00385658-01	363679861.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	3.0	82.1824665598	O(C[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@@H]3C[C@@H]4[C@@](C)(C5[C@H](C6[C@@](C)([C@H]7[C@H](C)[C@@]8(O[C@H]7C6)OC[C@@H](C)CC8)CC5)CC4)CC3)O[C@@H]2CO)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1	O(C[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@@H]3C[C@@H]4[C@@](C)(C5[C@H](C6[C@@](C)([C@H]7[C@H](C)[C@@]8(O[C@H]7C6)OC[C@@H](C)CC8)CC5)CC4)CC3)O[C@@H]2CO)O1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1
NCGC00380475-01	O(C[C@@H]1[C@H](c2cc(OC)c(O)cc2)Oc2c(OC)cc(CCCO)cc12)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Prasium | Family: N/A | Species: majus		1	NCGC00380475-01	363678601.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@H]1[C@H](c2cc(OC)c(O)cc2)Oc2c(OC)cc(CCCO)cc12)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@@H]1[C@H](c2cc(OC)c(O)cc2)Oc2c(OC)cc(CCCO)cc12)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00348375-01	O(C[C@@H]\1[C@@H](CC)OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H](C)O2)[C@@H](CCN2C[C@H](C)C[C@H](C)C2)C[C@@H](C)C(=O)/C=C/C(/C)=C/1)[C@H]1[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O1		Inactive	Bacterial 70S ribosome Binding Agent		1	TILMICOSIN	405558560.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(C[C@@H]\1[C@@H](CC)OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H](C)O2)[C@@H](CCN2C[C@H](C)C[C@H](C)C2)C[C@@H](C)C(=O)/C=C/C(/C)=C/1)[C@H]1[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O1	O(C[C@@H]\1[C@@H](CC)OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H](C)O2)[C@@H](CCN2C[C@H](C)C[C@H](C)C2)C[C@@H](C)C(=O)/C=C/C(/C)=C/1)[C@H]1[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O1
NCGC00384794-01	O(C[C@@]1(C)OC2([C@@H](C)[C@@H]3[C@]4(C)C([C@H]5C([C@]6(C)C(=CC5)C[C@@H](O[C@H]5[C@H](O[C@H]7[C@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7)[C@@H](CO)O5)CC6)CC4)C[C@@H]3O2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: saponine | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384794-01	363679357.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@]1(C)OC2([C@@H](C)[C@@H]3[C@]4(C)C([C@H]5C([C@]6(C)C(=CC5)C[C@@H](O[C@H]5[C@H](O[C@H]7[C@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7)[C@@H](CO)O5)CC6)CC4)C[C@@H]3O2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@@]1(C)OC2([C@@H](C)[C@@H]3[C@]4(C)C([C@H]5C([C@]6(C)C(=CC5)C[C@@H](O[C@H]5[C@H](O[C@H]7[C@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7)[C@@H](CO)O5)CC6)CC4)C[C@@H]3O2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00381418-01	O(C[C@@]1(C)OC2([C@@H](C)[C@@H]3[C@]4(C)C([C@H]5C([C@]6(C)C(=CC5)C[C@@H](O[C@H]5[C@H](O[C@H]7[C@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](OC8C(O)C(O)C(O)C(CO)O8)[C@H](C)O7)[C@@H](CO)O5)CC6)CC4)C[C@@H]3O2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381418-01	363679134.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@]1(C)OC2([C@@H](C)[C@@H]3[C@]4(C)C([C@H]5C([C@]6(C)C(=CC5)C[C@@H](O[C@H]5[C@H](O[C@H]7[C@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](OC8C(O)C(O)C(O)C(CO)O8)[C@H](C)O7)[C@@H](CO)O5)CC6)CC4)C[C@@H]3O2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@@]1(C)OC2([C@@H](C)[C@@H]3[C@]4(C)C([C@H]5C([C@]6(C)C(=CC5)C[C@@H](O[C@H]5[C@H](O[C@H]7[C@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](OC8C(O)C(O)C(O)C(CO)O8)[C@H](C)O7)[C@@H](CO)O5)CC6)CC4)C[C@@H]3O2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00384584-01	O(C[C@@]1(C)O[C@]2([C@@H](C)[C@@H]3[C@]4(C)[C@H]([C@H]5C([C@]6(C)C(=CC5)C[C@@H](O[C@H]5[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O8)[C@@H](CO)O7)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC6)CC4)C[C@@H]3O2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: saponine | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384584-01	363679260.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@]1(C)O[C@]2([C@@H](C)[C@@H]3[C@]4(C)[C@H]([C@H]5C([C@]6(C)C(=CC5)C[C@@H](O[C@H]5[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O8)[C@@H](CO)O7)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC6)CC4)C[C@@H]3O2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@@]1(C)O[C@]2([C@@H](C)[C@@H]3[C@]4(C)[C@H]([C@H]5C([C@]6(C)C(=CC5)C[C@@H](O[C@H]5[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O8)[C@@H](CO)O7)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC6)CC4)C[C@@H]3O2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00169477-02	O(C[C@@]1(C)[C@@H]2[C@](C)([C@H](CCC=3C(=O)OCC=3)C(=C)CC2)CCC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	lipopolysaccharide-mediated signaling pathway Inhibitor		1	NCGC00169477-02	363676826.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@]1(C)[C@@H]2[C@](C)([C@H](CCC=3C(=O)OCC=3)C(=C)CC2)CCC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@@]1(C)[C@@H]2[C@](C)([C@H](CCC=3C(=O)OCC=3)C(=C)CC2)CCC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385231-01	O(C[C@@]1(C)[C@H](O)CC[C@@]2(C)[C@H](CC/C(=C/CO)/C)C(=C)CC[C@H]12)[C@H]1C(O)[C@@H](O)C(O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385231-01	363679607.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@@]1(C)[C@H](O)CC[C@@]2(C)[C@H](CC/C(=C/CO)/C)C(=C)CC[C@H]12)[C@H]1C(O)[C@@H](O)C(O)[C@@H](CO)O1	O(C[C@@]1(C)[C@H](O)CC[C@@]2(C)[C@H](CC/C(=C/CO)/C)C(=C)CC[C@H]12)[C@H]1C(O)[C@@H](O)C(O)[C@@H](CO)O1
NCGC00015798-11	O(C[C@H](O)CNC(C)C)c1c2c(ccc1)cccc2		Inactive	Adrenergic receptor beta Antagonist		1	Dexpropranolol	170464682.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	11.36662452&18.905993228	O(C[C@H](O)CNC(C)C)c1c2c(ccc1)cccc2	O(C[C@H](O)CNC(C)C)c1c2c(ccc1)cccc2
NCGC00485130-01	O(C[C@H](O)[C@@H](NC(C)C)C)c1c2c(c(C)cc1)CCC2		Inactive	Beta-2 adrenergic receptor Antagonist		1	ICI 118,551 hydrochloride	363681236.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@H](O)[C@@H](NC(C)C)C)c1c2c(c(C)cc1)CCC2	O(C[C@H](O)[C@@H](NC(C)C)C)c1c2c(c(C)cc1)CCC2
NCGC00378710-01	O(C[C@H]1NCC1)c1cc(C#CCCCCO)cnc1		Inactive	Neuronal acetylcholine receptor; alpha4/beta2 Agonist		1	Sazetidine A dihydrochloride	363678164.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@H]1NCC1)c1cc(C#CCCCCO)cnc1	O(C[C@H]1NCC1)c1cc(C#CCCCCO)cnc1
NCGC00387223-01	O(C[C@H]1NCC1)c1cnccc1		Inactive	Neuronal acetylcholine receptor; alpha4/beta2 Agonist		1	A 85380 dihydrochloride	363680578.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@H]1NCC1)c1cnccc1	O(C[C@H]1NCC1)c1cnccc1
NCGC00385417-01	O(C[C@H]1[C@@H](C=C(C)C)C1(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Monoterpen | Genus: chrysanthenum | Family: Compositae | Species: coronarium		1	NCGC00385417-01	363679732.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@H]1[C@@H](C=C(C)C)C1(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@H]1[C@@H](C=C(C)C)C1(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385296-01	O(C[C@H]1[C@H](CO)[C@@H](c2cc(OC)c(O)cc2)c2c(cc(OC)c(O)c2)C1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Bixa | Family: Bixaceae | Species: orellana		1	NCGC00385296-01	363679655.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@H]1[C@H](CO)[C@@H](c2cc(OC)c(O)cc2)c2c(cc(OC)c(O)c2)C1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@H]1[C@H](CO)[C@@H](c2cc(OC)c(O)cc2)c2c(cc(OC)c(O)c2)C1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385287-01	O(C[C@]1(C)[C@H](O)CC[C@@]2(C)[C@H](C/C=C/3\[C@H](O)COC\3=O)C(=C)CC[C@H]12)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Andrographis | Family: Acanthaseae | Species: paniculata		1	NCGC00385287-01	363679646.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(C[C@]1(C)[C@H](O)CC[C@@]2(C)[C@H](C/C=C/3\[C@H](O)COC\3=O)C(=C)CC[C@H]12)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(C[C@]1(C)[C@H](O)CC[C@@]2(C)[C@H](C/C=C/3\[C@H](O)COC\3=O)C(=C)CC[C@H]12)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00371014-01	O(Cc1c2n(CC)c(-c3c(N)non3)nc2c(C#CC(O)(C)C)nc1)[C@@H]1CNCCC1		Inactive			1	GSK 690693	363677994.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(Cc1c2n(CC)c(-c3c(N)non3)nc2c(C#CC(O)(C)C)nc1)[C@@H]1CNCCC1	O(Cc1c2n(CC)c(-c3c(N)non3)nc2c(C#CC(O)(C)C)nc1)[C@@H]1CNCCC1
NCGC00509990-02	O(Cc1ccc(CN2CCOCC2)cc1)c1c2c(C(=O)N([C@@H]3C(=O)NC(=O)CC3)C2)ccc1		Inactive	IL-2 Production Enhancers		1	Iberdomide	384569398.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(Cc1ccc(CN2CCOCC2)cc1)c1c2c(C(=O)N([C@@H]3C(=O)NC(=O)CC3)C2)ccc1	O(Cc1ccc(CN2CCOCC2)cc1)c1c2c(C(=O)N([C@@H]3C(=O)NC(=O)CC3)C2)ccc1
NCGC00379069-03	O(Cc1ccc(CN2CCOCC2)cc1)c1nc(C(C#N)c2sc3c(n2)cccc3)ccn1		Inactive	c-Jun N-terminal kinase 1 Inhibitor		1	AS 602801 (Bentamapimod)	363678338.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(Cc1ccc(CN2CCOCC2)cc1)c1nc(C(C#N)c2sc3c(n2)cccc3)ccn1	O(Cc1ccc(CN2CCOCC2)cc1)c1nc(C(C#N)c2sc3c(n2)cccc3)ccn1
NCGC00242051-10	O(Cc1ccc(OC)cc1)c1c(OC)cc(Cc2c(N)nc(N)nc2)cc1		Inactive	CSF1R (c-FMS) Inhibitor		1	GW-2580	384568482.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(Cc1ccc(OC)cc1)c1c(OC)cc(Cc2c(N)nc(N)nc2)cc1	O(Cc1ccc(OC)cc1)c1c(OC)cc(Cc2c(N)nc(N)nc2)cc1
NCGC00263125-03	O(Cc1ccc(OC)cc1)c1c(OC)cc-2c(OC(=O)c3c-2ccc(C(O)C)c3)c1		Inactive	mTORC1/2 Inhibitor		1	SG-00529	384568608.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(Cc1ccc(OC)cc1)c1c(OC)cc-2c(OC(=O)c3c-2ccc(C(O)C)c3)c1	O(Cc1ccc(OC)cc1)c1c(OC)cc-2c(OC(=O)c3c-2ccc(C(O)C)c3)c1
NCGC00480748-01	O(Cc1ccccc1)C1CCN(CCNC)CC1		Inactive			1	MS049 oxalate salt		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(Cc1ccccc1)C1CCN(CCNC)CC1	O(Cc1ccccc1)C1CCN(CCNC)CC1
NCGC00169955-02	O(Cc1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	response to lipopolysaccharide Inhibitor		1	NCGC00169955-02	363676920.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(Cc1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(Cc1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385728-01	O(Cc1ccccc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Tannin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385728-01	363679903.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(Cc1ccccc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1	O(Cc1ccccc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00384834-01	O(Cc1ccccc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384834-01	363679383.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(Cc1ccccc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](CO)O1	O(Cc1ccccc1)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](CO)O1
NCGC00346461-02	O(Cc1ccccc1)c1cc(-c2c3c(N)ncnc3n(C3CC(CN4CCC4)C3)c2)ccc1		Inactive			1	NVP-AEW541	384568784.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	16.088510172	O(Cc1ccccc1)c1cc(-c2c3c(N)ncnc3n(C3CC(CN4CCC4)C3)c2)ccc1	O(Cc1ccccc1)c1cc(-c2c3c(N)ncnc3n(C3CC(CN4CCC4)C3)c2)ccc1
NCGC00386129-03	O(Cc1ccccc1)c1cc(-c2c3c(N)ncnc3n(C3CC(CN4CCCC4)C3)c2)ccc1	4.9000001	Active	IGF-1R Inhibitor	0.0	1	ADW-742	363680114.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	88.113138156	O(Cc1ccccc1)c1cc(-c2c3c(N)ncnc3n(C3CC(CN4CCCC4)C3)c2)ccc1	O(Cc1ccccc1)c1cc(-c2c3c(N)ncnc3n(C3CC(CN4CCCC4)C3)c2)ccc1
NCGC00370705-03	O(Cc1ccccc1)c1cc2c([nH]c(CNCC#C)c2)cc1		Inactive	Monoamine oxidase B Inhibitor		1	PF9601N	363677813.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(Cc1ccccc1)c1cc2c([nH]c(CNCC#C)c2)cc1	O(Cc1ccccc1)c1cc2c([nH]c(CNCC#C)c2)cc1
NCGC00016360-06&NCGC00016360-07	O(Cc1ccccc1)c1ccc(O)cc1		Inactive	topical medical depigmentation treatment		2	Monobenzone	170464724.0&384567934.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O(Cc1ccccc1)c1ccc(O)cc1	O(Cc1ccccc1)c1ccc(O)cc1
NCGC00015144-05	O(Cc1ccccc1)c1nc(N)nc2[nH]cnc12		Inactive	MGMT Inhibitor		1	O6-Benzylguanine	384567813.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-8.750459488	O(Cc1ccccc1)c1nc(N)nc2[nH]cnc12	O(Cc1ccccc1)c1nc(N)nc2[nH]cnc12
NCGC00378991-02	O(Cc1n(C)c2c(n1)ccc(Oc1cc(C)c(N)c(C)c1)c2)c1ccc(CC2C(=O)NC(=O)S2)cc1		Inactive	PAPRgamma Agonist		1	Efatutazone	384569084.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(Cc1n(C)c2c(n1)ccc(Oc1cc(C)c(N)c(C)c1)c2)c1ccc(CC2C(=O)NC(=O)S2)cc1	O(Cc1n(C)c2c(n1)ccc(Oc1cc(C)c(N)c(C)c1)c2)c1ccc(CC2C(=O)NC(=O)S2)cc1
NCGC00370964-01	O(Cc1n(C)ncn1)c1c(C(C)(C)C)c2n(C(c3noc(C)c3)=NN=C2)n1		Inactive	GABA receptor alpha-5 subunit Inverse Agonist		1	MRK 016	363677961.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(Cc1n(C)ncn1)c1c(C(C)(C)C)c2n(C(c3noc(C)c3)=NN=C2)n1	O(Cc1n(C)ncn1)c1c(C(C)(C)C)c2n(C(c3noc(C)c3)=NN=C2)n1
NCGC00346507-07	O(Cc1n2N=C(c3ccccc3)C=Cc2nn1)c1c2c(ncc1)cc(OC)cc2		Inactive	HGFR Inhibitor		1	AMG-208	363677433.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(Cc1n2N=C(c3ccccc3)C=Cc2nn1)c1c2c(ncc1)cc(OC)cc2	O(Cc1n2N=C(c3ccccc3)C=Cc2nn1)c1c2c(ncc1)cc(OC)cc2
NCGC00378849-03	O(Cc1nc(C2CCN(c3ncc(CC)cn3)CC2)sc1)c1ccc(-n2nnnc2)cc1		Inactive	Glucose-dependent insulinotropic receptor Agonist		1	MBX-2982	363678234.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(Cc1nc(C2CCN(c3ncc(CC)cn3)CC2)sc1)c1ccc(-n2nnnc2)cc1	O(Cc1nc(C2CCN(c3ncc(CC)cn3)CC2)sc1)c1ccc(-n2nnnc2)cc1
NCGC00522052-01	O(Cc1nc(Cn2nnc3c(-c4oc(C)cc4)nc(N)nc23)ccc1)[C@@H]1COCC1		Inactive	Adenosine A2A Antagonist		1	CPI-444	384569512.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.589920232	O(Cc1nc(Cn2nnc3c(-c4oc(C)cc4)nc(N)nc23)ccc1)[C@@H]1COCC1	O(Cc1nc(Cn2nnc3c(-c4oc(C)cc4)nc(N)nc23)ccc1)[C@@H]1COCC1
NCGC00346630-05	O(Cc1nc2c(cc1)cccc2)c1ccc(-c2c(-c3ccncc3)cn(C)n2)cc1	4.9000001	Active	Phosphodiesterase PDE10A Inhibitor	0.0	1	MP-10	363677485.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	85.180584223	O(Cc1nc2c(cc1)cccc2)c1ccc(-c2c(-c3ccncc3)cn(C)n2)cc1	O(Cc1nc2c(cc1)cccc2)c1ccc(-c2c(-c3ccncc3)cn(C)n2)cc1
NCGC00159380-05	O(OC(=O)c1ccccc1)C(=O)c1ccccc1		Inactive			1	Benzoyl peroxide	170464986.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(OC(=O)c1ccccc1)C(=O)c1ccccc1	O(OC(=O)c1ccccc1)C(=O)c1ccccc1
NCGC00384905-01	O([C@@H](/C=C/[C@@]1(O)[C@H](C)CC(=O)CC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Hedera | Family: Hederaceae | Species: helix		1	NCGC00384905-01	363679430.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H](/C=C/[C@@]1(O)[C@H](C)CC(=O)CC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)O1	O([C@@H](/C=C/[C@@]1(O)[C@H](C)CC(=O)CC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)O1
NCGC00384596-01	O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1c2[C@H](C(=O)O)[C@@H](c3cc(O)c(O)cc3)Oc2c(O)cc1		Inactive			1	Lithospermic acid A	434147124.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1c2[C@H](C(=O)O)[C@@H](c3cc(O)c(O)cc3)Oc2c(O)cc1	O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1c2[C@H](C(=O)O)[C@@H](c3cc(O)c(O)cc3)Oc2c(O)cc1
NCGC00385403-01	O([C@@H](C(=O)OC)[C@H]1C(C)(C)C(=O)[C@@H]2C(=O)[C@]1(C)C1C(=C3[C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)C2)C(=O)C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Maerua | Family: Capparaceae | Species: oblongifolia		1	NCGC00385403-01	363679724.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H](C(=O)OC)[C@H]1C(C)(C)C(=O)[C@@H]2C(=O)[C@]1(C)C1C(=C3[C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)C2)C(=O)C	O([C@@H](C(=O)OC)[C@H]1C(C)(C)C(=O)[C@@H]2C(=O)[C@]1(C)C1C(=C3[C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)C2)C(=O)C
NCGC00169779-03	O([C@@H](C)C=1C(=O)O[C@]2([C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C(C(=O)OC)[C@H]3C=C2)C=1)C(=O)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Plumeria | Family: Apocynaceae | Species: rubra		1	NCGC00169779-03	363676884.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H](C)C=1C(=O)O[C@]2([C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C(C(=O)OC)[C@H]3C=C2)C=1)C(=O)/C=C/c1ccc(O)cc1	O([C@@H](C)C=1C(=O)O[C@]2([C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C(C(=O)OC)[C@H]3C=C2)C=1)C(=O)/C=C/c1ccc(O)cc1
NCGC00347741-02	O([C@@H](C)C=1C(=O)O[C@]2([C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C(C(=O)OC)[C@H]3C=C2)C=1)C(=O)/C=C/c1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Artemisia | Family: Compositae | Species: arborescens		1	NCGC00347741-02	363677678.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H](C)C=1C(=O)O[C@]2([C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C(C(=O)OC)[C@H]3C=C2)C=1)C(=O)/C=C/c1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1	O([C@@H](C)C=1C(=O)O[C@]2([C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C(C(=O)OC)[C@H]3C=C2)C=1)C(=O)/C=C/c1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1
NCGC00386005-01	O([C@@H](C)[C@@H]1[C@@]2(C)[C@H](O)[C@@H](O)C3[C@]4(C)C(C[C@@H](OC5OC(C)C(OC6OC(C)C(OC7OC(C)C(OC8C(O)C(OC)C(OC9C(O)C(O)C(O)C(CO)O9)C(C)O8)C(OC)C7)C(OC)C6)C(OC)C5)CC4)CCC3[C@@]2(O)CC1)C(=O)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Steroid | Genus: Dregea | Family: Asclepiadaceae | Species: sp.		1	NCGC00386005-01	363680052.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H](C)[C@@H]1[C@@]2(C)[C@H](O)[C@@H](O)C3[C@]4(C)C(C[C@@H](OC5OC(C)C(OC6OC(C)C(OC7OC(C)C(OC8C(O)C(OC)C(OC9C(O)C(O)C(O)C(CO)O9)C(C)O8)C(OC)C7)C(OC)C6)C(OC)C5)CC4)CCC3[C@@]2(O)CC1)C(=O)/C(=C/C)/C	O([C@@H](C)[C@@H]1[C@@]2(C)[C@H](O)[C@@H](O)C3[C@]4(C)C(C[C@@H](OC5OC(C)C(OC6OC(C)C(OC7OC(C)C(OC8C(O)C(OC)C(OC9C(O)C(O)C(O)C(CO)O9)C(C)O8)C(OC)C7)C(OC)C6)C(OC)C5)CC4)CCC3[C@@]2(O)CC1)C(=O)/C(=C/C)/C
NCGC00379076-01	O([C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)CCC(O)(C)C		Inactive	Vitamin D receptor Agonist		1	Maxacalcitol-D6	405558501.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)CCC(O)(C)C	O([C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)CCC(O)(C)C
NCGC00165856-03	O([C@@H](CCCCCCCCCCC)C[C@H]1[C@H](CCCCCC)C(=O)O1)C(=O)C(NC=O)CC(C)C		Inactive	Fatty acid synthase inhibitor		1	Orlistat	170464663.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&26.9430255441	O([C@@H](CCCCCCCCCCC)C[C@H]1[C@H](CCCCCC)C(=O)O1)C(=O)C(NC=O)CC(C)C	O([C@@H](CCCCCCCCCCC)C[C@H]1[C@H](CCCCCC)C(=O)O1)C(=O)C(NC=O)CC(C)C
NCGC00165856-14&NCGC00165856-15	O([C@@H](CCCCCCCCCCC)C[C@H]1[C@H](CCCCCC)C(=O)O1)C(=O)[C@@H](NC=O)CC(C)C		Inactive			2	ORLISTAT&Orlistat	434147198.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&12.070812368	O([C@@H](CCCCCCCCCCC)C[C@H]1[C@H](CCCCCC)C(=O)O1)C(=O)[C@@H](NC=O)CC(C)C	O([C@@H](CCCCCCCCCCC)C[C@H]1[C@H](CCCCCC)C(=O)O1)C(=O)[C@@H](NC=O)CC(C)C
NCGC00164559-03	O([C@@H](CCNC)c1sccc1)c1c2c(ccc1)cccc2	5.0500002	Active	Serotonin Transporter (SERT) Inhibitor	0.0	1	Duloxetine hydrochloride	170465319.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	79.0561435375	O([C@@H](CCNC)c1sccc1)c1c2c(ccc1)cccc2.Cl	O([C@@H](CCNC)c1sccc1)c1c2c(ccc1)cccc2.Cl
NCGC00385777-01	O([C@@H](CC[C@@]1(O)C(C)=CC(=O)CC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385777-01	363679936.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H](CC[C@@]1(O)C(C)=CC(=O)CC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H](CC[C@@]1(O)C(C)=CC(=O)CC1(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00508876-01	O([C@@H](CN(C)C)C)c1c(C#N)ncc(Nc2ncc(c(OC)c2)-c2cn(C)nc2)n1		Inactive	Chk1 Inhibitor		1	CCT-244747	384569369.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@@H](CN(C)C)C)c1c(C#N)ncc(Nc2ncc(c(OC)c2)-c2cn(C)nc2)n1	O([C@@H](CN(C)C)C)c1c(C#N)ncc(Nc2ncc(c(OC)c2)-c2cn(C)nc2)n1
NCGC00347395-02	O([C@@H](CO[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)[C@]1(C)C=C2[C@H]([C@@]3(C)[C@@H](C(C)(C)[C@@H](O)CC3)CC2)CC1)C(=O)C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Siegesbeckia | Family: Compositae | Species: orientalis		1	NCGC00347395-02	363677588.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H](CO[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)[C@]1(C)C=C2[C@H]([C@@]3(C)[C@@H](C(C)(C)[C@@H](O)CC3)CC2)CC1)C(=O)C	O([C@@H](CO[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)[C@]1(C)C=C2[C@H]([C@@]3(C)[C@@H](C(C)(C)[C@@H](O)CC3)CC2)CC1)C(=O)C
NCGC00263541-01	O([C@@H]([C@@H]1OCCNC1)c1ccccc1)c1c(OCC)cccc1		Inactive			1	Reboxetine mesylate	170465620.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(O)C.O([C@@H]([C@@H]1OCCNC1)c1ccccc1)c1c(OCC)cccc1	S(=O)(=O)(O)C.O([C@@H]([C@@H]1OCCNC1)c1ccccc1)c1c(OCC)cccc1
NCGC00263893-02	O([C@@H]([C@H](O)[C@@H](O)CO)[C@H](O)CO)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1		Inactive	Maltase-glucoamylase Inhibitor		1	Lactitol	170465917.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O([C@@H]([C@H](O)[C@@H](O)CO)[C@H](O)CO)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1	O([C@@H]([C@H](O)[C@@H](O)CO)[C@H](O)CO)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1
NCGC00351592-01	O([C@@H]([C@H](O)c1cc(OC)c(OC)cc1)C)c1c(OC)cc([C@@H]2[C@H](C)[C@@H](C)[C@@H](c3cc(OC)c(O[C@@H]([C@H](O)c4cc(OC)c(OC)cc4)C)cc3)O2)cc1	5.5	Active	HIF-1alpha Inhibitor	0.0	1	Manassantin A	384569012.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.4	36.468301437	O([C@@H]([C@H](O)c1cc(OC)c(OC)cc1)C)c1c(OC)cc([C@@H]2[C@H](C)[C@@H](C)[C@@H](c3cc(OC)c(O[C@@H]([C@H](O)c4cc(OC)c(OC)cc4)C)cc3)O2)cc1	O([C@@H]([C@H](O)c1cc(OC)c(OC)cc1)C)c1c(OC)cc([C@@H]2[C@H](C)[C@@H](C)[C@@H](c3cc(OC)c(O[C@@H]([C@H](O)c4cc(OC)c(OC)cc4)C)cc3)O2)cc1
NCGC00386006-01	O([C@@H]([C@H]1[C@H](CO)[C@@H](c2cc(OC)c(O)cc2)OC1)c1cc(OC)c(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386006-01	363680053.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]([C@H]1[C@H](CO)[C@@H](c2cc(OC)c(O)cc2)OC1)c1cc(OC)c(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H]([C@H]1[C@H](CO)[C@@H](c2cc(OC)c(O)cc2)OC1)c1cc(OC)c(O)cc1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00164575-06	O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]2(C)OC(=O)N(CCCCn3cc(-c4cnccc4)nc3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@]1(OC)C)[C@@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1		Inactive			1	Telithromycin		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]2(C)OC(=O)N(CCCCn3cc(-c4cnccc4)nc3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@]1(OC)C)[C@@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1	O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]2(C)OC(=O)N(CCCCn3cc(-c4cnccc4)nc3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@]1(OC)C)[C@@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1
NCGC00094652-06	O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@@H]1O)[C@@H]1O[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1		Inactive			1	DIGITOXIN	405559111.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@@H]1O)[C@@H]1O[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1	O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@@H]1O)[C@@H]1O[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1
NCGC00090797-12&NCGC00090797-28	O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@@H]1O[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1		Inactive	Steroid		2	Digoxin	405558822.0&384568087.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@@H]1O[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1	O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@@H]1O[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1
NCGC00159441-03	O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](C)O[C@@H](O[C@@H]4C[C@@H]5[C@@](C)([C@@H]6[C@H]([C@]7(O)[C@](C)([C@H](O)C6)[C@@H](C6=CC(=O)OC6)CC7)CC5)CC4)C[C@@H]3O)C[C@@H]2O)C[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	Sodium/potassium-transporting ATPase Inhibitor		1	Deslanoside	170465236.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](C)O[C@@H](O[C@@H]4C[C@@H]5[C@@](C)([C@@H]6[C@H]([C@]7(O)[C@](C)([C@H](O)C6)[C@@H](C6=CC(=O)OC6)CC7)CC5)CC4)C[C@@H]3O)C[C@@H]2O)C[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](C)O[C@@H](O[C@@H]4C[C@@H]5[C@@](C)([C@@H]6[C@H]([C@]7(O)[C@](C)([C@H](O)C6)[C@@H](C6=CC(=O)OC6)CC7)CC5)CC4)C[C@@H]3O)C[C@@H]2O)C[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00386404-01	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@@]2(C)OC(=O)O[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@]1(O)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1		Inactive			1	Erythromycin Cyclocarbonate	363680259.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@@]2(C)OC(=O)O[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@]1(O)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@@]2(C)OC(=O)O[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@]1(O)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1
NCGC00179619-17	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]1(O)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1		Inactive	Bacterial 70S ribosome Binding Agent		1	Erythromycin	384568380.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]1(O)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]1(O)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1
NCGC00178054-06	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]1(OC)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1		Inactive	Macrolide Antibiotic		1	Clarithromycin	405558922.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]1(OC)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1	O([C@@H]1[C@@H](C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]1(OC)C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1
NCGC00385979-01	O([C@@H]1[C@@H](O)CC2[C@]3(C)C(=O)C[C@@]4(C)[C@](C)(C3CC=C2C1(C)C)C[C@@H](O)C4[C@@](O)(C(O)CC=C(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385979-01	363680041.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@@H](O)CC2[C@]3(C)C(=O)C[C@@]4(C)[C@](C)(C3CC=C2C1(C)C)C[C@@H](O)C4[C@@](O)(C(O)CC=C(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@@H](O)CC2[C@]3(C)C(=O)C[C@@]4(C)[C@](C)(C3CC=C2C1(C)C)C[C@@H](O)C4[C@@](O)(C(O)CC=C(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00384498-01	O([C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1O[C@H]1[C@@]2(C)C(=CC[C@H]3C4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OCC(=C)CC6)CCC23)C[C@@H](O)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384498-01	363679215.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	32.0503258559	O([C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1O[C@H]1[C@@]2(C)C(=CC[C@H]3C4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OCC(=C)CC6)CCC23)C[C@@H](O)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O([C@@H]1[C@@H](O)[C@@H](O)CO[C@H]1O[C@H]1[C@@]2(C)C(=CC[C@H]3C4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OCC(=C)CC6)CCC23)C[C@@H](O)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00384710-01	O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1O[C@H]1[C@@]2(C)C(=CCC3C4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OCC(=C)CC6)CCC23)C[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384710-01	363679322.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1O[C@H]1[C@@]2(C)C(=CCC3C4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OCC(=C)CC6)CCC23)C[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@H]1O[C@H]1[C@@]2(C)C(=CCC3C4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OCC(=C)CC6)CCC23)C[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00381008-01	O([C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CO[C@H]1O[C@@H]1[C@](CO)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)[C@]5(OC[C@@]6([C@H](OC7C(O)C(O)C(O)CO7)C4)C5CC(C)(C)CC6)CC3)CC2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Anagallis | Family: Primulaceae | Species: monelli		1	NCGC00381008-01	363678922.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	25.02872188	O([C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CO[C@H]1O[C@@H]1[C@](CO)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)[C@]5(OC[C@@]6([C@H](OC7C(O)C(O)C(O)CO7)C4)C5CC(C)(C)CC6)CC3)CC2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](CO)O1	O([C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CO[C@H]1O[C@@H]1[C@](CO)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)[C@]5(OC[C@@]6([C@H](OC7C(O)C(O)C(O)CO7)C4)C5CC(C)(C)CC6)CC3)CC2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](CO)O1
NCGC00386040-01	O([C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)[C@H](O)[C@@H](CO)O2)CO[C@H]1O[C@@H]1[C@](CO)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)[C@]5(OC[C@@]6([C@H](O)C4)[C@H]5CC(C)(C)CC6)CC3)CC2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	5.4499998	Active	<MOA Unknown> | Class: Saponin | Genus: Anagallis | Family: Primulaceae | Species: monelli	0.0	1	NCGC00386040-01	363680075.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	3.0	88.1643476245	O([C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)[C@H](O)[C@@H](CO)O2)CO[C@H]1O[C@@H]1[C@](CO)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)[C@]5(OC[C@@]6([C@H](O)C4)[C@H]5CC(C)(C)CC6)CC3)CC2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)[C@H](O)[C@@H](CO)O2)CO[C@H]1O[C@@H]1[C@](CO)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)[C@]5(OC[C@@]6([C@H](O)C4)[C@H]5CC(C)(C)CC6)CC3)CC2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385103-01	O([C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)CO[C@H]1O[C@@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)[C@]5(OC[C@@]6([C@H](O)C4)C5C[C@](CO)(C)CC6)CC3)CC2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385103-01	363679535.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)CO[C@H]1O[C@@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)[C@]5(OC[C@@]6([C@H](O)C4)C5C[C@](CO)(C)CC6)CC3)CC2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)CO[C@H]1O[C@@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)[C@]5(OC[C@@]6([C@H](O)C4)C5C[C@](CO)(C)CC6)CC3)CC2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00347408-02	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1CC2C(C)(C3C(C4C(=O)C5OC6(C(C)C5C4(C)CC3)NCC(C)CC6)CC2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347408-02	363677595.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1CC2C(C)(C3C(C4C(=O)C5OC6(C(C)C5C4(C)CC3)NCC(C)CC6)CC2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1CC2C(C)(C3C(C4C(=O)C5OC6(C(C)C5C4(C)CC3)NCC(C)CC6)CC2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00347420-02	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1CC2C(C)(C3C(C4C(C)(C5C(C)C6(OC5C4O)NCC(C)CC6)CC3)CC2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347420-02	363677598.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1CC2C(C)(C3C(C4C(C)(C5C(C)C6(OC5C4O)NCC(C)CC6)CC3)CC2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1CC2C(C)(C3C(C4C(C)(C5C(C)C6(OC5C4O)NCC(C)CC6)CC3)CC2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00381107-01	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1C(C)(C)[C@H]2[C@@](C)(C3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CCC=C(C)C)C)CC4)CC2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	Cathepsin K Inhibitor		1	NCGC00381107-01	363678973.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1C(C)(C)[C@H]2[C@@](C)(C3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CCC=C(C)C)C)CC4)CC2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1C(C)(C)[C@H]2[C@@](C)(C3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CCC=C(C)C)C)CC4)CC2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385114-01	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1C2C(C)(C)[C@@H](O)CC[C@]2(C)C2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H]([C@@](O)(CCC=C(C)C)C)CC3)C1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385114-01	363679543.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1C2C(C)(C)[C@@H](O)CC[C@]2(C)C2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H]([C@@](O)(CCC=C(C)C)C)CC3)C1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1C2C(C)(C)[C@@H](O)CC[C@]2(C)C2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H]([C@@](O)(CCC=C(C)C)C)CC3)C1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1
NCGC00385195-01	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385195-01	363679590.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00381279-01	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)[C@]6(OC[C@@]7(C(=O)C5)[C@H]6CC(C)(C)CC7)CC4)CC3)CC2)OC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Anagallis | Family: N/A | Species: sp.		1	NCGC00381279-01	363679063.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)[C@]6(OC[C@@]7(C(=O)C5)[C@H]6CC(C)(C)CC7)CC4)CC3)CC2)OC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)[C@]6(OC[C@@]7(C(=O)C5)[C@H]6CC(C)(C)CC7)CC4)CC3)CC2)OC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1
NCGC00384601-01	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)C2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](/C(=C\CC=C(C)C)/C)CC3)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384601-01	363679266.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)C2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](/C(=C\CC=C(C)C)/C)CC3)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)C2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](/C(=C\CC=C(C)C)/C)CC3)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00347389-02	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)C2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H]([C@@](O)(CCC=C(C)C)C)CC3)C1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	production of molecular mediator involved in inflammatory response Inhibitor		1	NCGC00347389-02	363677586.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)C2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H]([C@@](O)(CCC=C(C)C)C)CC3)C1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)C2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H]([C@@](O)(CCC=C(C)C)C)CC3)C1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00179611-05	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]1NC(=N)N)[C@H]1[C@H](O[C@H]2[C@@H](NC)[C@H](O)[C@@H](O)[C@H](CO)O2)[C@@](O)(CO)[C@H](C)O1		Inactive	Large-conductance mechanosensitive channel Modulator		1	DIHYDROSTREPTOMYCIN [5mM]	405558590.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]1NC(=N)N)[C@H]1[C@H](O[C@H]2[C@@H](NC)[C@H](O)[C@@H](O)[C@H](CO)O2)[C@@](O)(CO)[C@H](C)O1	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]1NC(=N)N)[C@H]1[C@H](O[C@H]2[C@@H](NC)[C@H](O)[C@@H](O)[C@H](CO)O2)[C@@](O)(CO)[C@H](C)O1
NCGC00384811-01	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](O)CO1)[C@@H]1C(C)(C)C2[C@@]3([C@]4(C([C@@]5(C)[C@@](C)(C6[C@H](C)C[C@@H]7[C@@H](C(O)(C)C)O[C@@]6(C5O)O7)CC4)CC2)C3)CC1		Inactive	inflammatory response to antigenic stimulus Inhibitor		1	NCGC00384811-01	363679369.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](O)CO1)[C@@H]1C(C)(C)C2[C@@]3([C@]4(C([C@@]5(C)[C@@](C)(C6[C@H](C)C[C@@H]7[C@@H](C(O)(C)C)O[C@@]6(C5O)O7)CC4)CC2)C3)CC1	O([C@@H]1[C@@H](O)[C@H](O)[C@@H](O)CO1)[C@@H]1C(C)(C)C2[C@@]3([C@]4(C([C@@]5(C)[C@@](C)(C6[C@H](C)C[C@@H]7[C@@H](C(O)(C)C)O[C@@]6(C5O)O7)CC4)CC2)C3)CC1
NCGC00179265-03	O([C@@H]1[C@@H](O)[C@H](OC2C(N)CC=C(CN)O2)[C@@H](N)C[C@H]1NCC)[C@@H]1[C@H](O)[C@@H](NC)[C@](O)(C)CO1		Inactive	Lysosomal phospholipase A1 Inhibitor		1	Netilmicin sulfate	170465142.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.O([C@@H]1[C@@H](O)[C@H](OC2C(N)CC=C(CN)O2)[C@@H](N)C[C@H]1NCC)[C@@H]1[C@H](O)[C@@H](NC)[C@](O)(C)CO1.O([C@@H]1[C@@H](O)[C@H](OC2C(N)CC=C(CN)O2)[C@@H](N)C[C@H]1NCC)[C@@H]1[C@H](O)[C@@H](NC)[C@](O)(C)CO1	S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.S(=O)(=O)(O)O.O([C@@H]1[C@@H](O)[C@H](OC2C(N)CC=C(CN)O2)[C@@H](N)C[C@H]1NCC)[C@@H]1[C@H](O)[C@@H](NC)[C@](O)(C)CO1.O([C@@H]1[C@@H](O)[C@H](OC2C(N)CC=C(CN)O2)[C@@H](N)C[C@H]1NCC)[C@@H]1[C@H](O)[C@@H](NC)[C@](O)(C)CO1
NCGC00389765-01	O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](N)CC[C@@H](CN)O2)[C@@H](N)C[C@H]1N)[C@@H]1[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O1		Inactive			1	DIBEKACIN	405558422.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](N)CC[C@@H](CN)O2)[C@@H](N)C[C@H]1N)[C@@H]1[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](N)CC[C@@H](CN)O2)[C@@H](N)C[C@H]1N)[C@@H]1[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O1
NCGC00178852-04&NCGC00178852-05	O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](N)C[C@H](O)[C@@H](CN)O2)[C@@H](N)C[C@H]1N)[C@@H]1[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O1		Inactive	30S Ribosomal Protein Inhibitor		2	Tobramycin	384568365.0&225144300.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](N)C[C@H](O)[C@@H](CN)O2)[C@@H](N)C[C@H]1N)[C@@H]1[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](N)C[C@H](O)[C@@H](CN)O2)[C@@H](N)C[C@H]1N)[C@@H]1[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O1
NCGC00483052-01	O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@](CO)(C)C3[C@@](C)([C@@H]4[C@](C)([C@]5(C)C(=C6[C@@](CO)([C@H](O)C5)CCC(C)(C)C6)C=C4)CC3)CC2)O[C@H](C)[C@@H]1O)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive			1	Saikosaponin B2	434147159.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@](CO)(C)C3[C@@](C)([C@@H]4[C@](C)([C@]5(C)C(=C6[C@@](CO)([C@H](O)C5)CCC(C)(C)C6)C=C4)CC3)CC2)O[C@H](C)[C@@H]1O)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@](CO)(C)C3[C@@](C)([C@@H]4[C@](C)([C@]5(C)C(=C6[C@@](CO)([C@H](O)C5)CCC(C)(C)C6)C=C4)CC3)CC2)O[C@H](C)[C@@H]1O)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00179912-02	O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](CO)O[C@H]1OC1CC=2C(C)(C3C(C4C(C)(C5C(C)C6(OC5C4)NCC(C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00179912-02	363676990.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	13.93864598	O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](CO)O[C@H]1OC1CC=2C(C)(C3C(C4C(C)(C5C(C)C6(OC5C4)NCC(C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](CO)O[C@H]1OC1CC=2C(C)(C3C(C4C(C)(C5C(C)C6(OC5C4)NCC(C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00346600-02	O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](CO)O[C@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	peroxiredoxins (PRDX) 1/6		1	Dioscin	384568854.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](CO)O[C@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](CO)O[C@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00169056-02	O([C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@]5(C)[C@@H](O)[C@]6(O)O[C@H](CC=C(C)C)[C@@](O)(C)C6[C@H]5CC4)CC3)CC2)O[C@H](CO)[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Rhamnus | Family: Rhamnaceae | Species: lyciodes		1	NCGC00169056-02	363676755.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@]5(C)[C@@H](O)[C@]6(O)O[C@H](CC=C(C)C)[C@@](O)(C)C6[C@H]5CC4)CC3)CC2)O[C@H](CO)[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@]5(C)[C@@H](O)[C@]6(O)O[C@H](CC=C(C)C)[C@@](O)(C)C6[C@H]5CC4)CC3)CC2)O[C@H](CO)[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00179493-03	O([C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2CC=3[C@@](C)([C@@H]4[C@H]([C@H]5[C@@](C)([C@H]6[C@H](C)[C@@H]7N([C@H]6C5)C[C@@H](C)CC7)CC4)CC=3)CC2)O[C@H](CO)[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	Cholinesterase Inhibitor		1	Solanine alpha	405559114.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2CC=3[C@@](C)([C@@H]4[C@H]([C@H]5[C@@](C)([C@H]6[C@H](C)[C@@H]7N([C@H]6C5)C[C@@H](C)CC7)CC4)CC=3)CC2)O[C@H](CO)[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2CC=3[C@@](C)([C@@H]4[C@H]([C@H]5[C@@](C)([C@H]6[C@H](C)[C@@H]7N([C@H]6C5)C[C@@H](C)CC7)CC4)CC=3)CC2)O[C@H](CO)[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00380455-01	O([C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2[C@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)[C@]6(OC[C@@]7([C@@H](O)C5)[C@H]6CC(C)(C)CC7)C=C4)CC3)CC2)O[C@H](CO)[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Verbascum | Family: Scrophulariaceae | Species: sinaiticum		1	NCGC00380455-01	363678594.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2[C@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)[C@]6(OC[C@@]7([C@@H](O)C5)[C@H]6CC(C)(C)CC7)C=C4)CC3)CC2)O[C@H](CO)[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](CO)O1	O([C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2[C@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)[C@]6(OC[C@@]7([C@@H](O)C5)[C@H]6CC(C)(C)CC7)C=C4)CC3)CC2)O[C@H](CO)[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](CO)O1
NCGC00384707-01	O([C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2[C@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)[C@]6(OC[C@@]7([C@@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O8)C5)[C@H]6CC(C)(C)CC7)C=C4)CC3)CC2)O[C@H](CO)[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Buddleja | Family: Loganiaceae | Species: asiatica		1	NCGC00384707-01	363679320.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2[C@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)[C@]6(OC[C@@]7([C@@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O8)C5)[C@H]6CC(C)(C)CC7)C=C4)CC3)CC2)O[C@H](CO)[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2[C@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)[C@]6(OC[C@@]7([C@@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O8)C5)[C@H]6CC(C)(C)CC7)C=C4)CC3)CC2)O[C@H](CO)[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00380710-01	O([C@@H]1[C@@]2(C)OC(C)(C)[C@@H](C1)CC2)C1C(O)C(O)C(O)C(CO)O1		Inactive	<MOA Unknown> | Class: Monoterpen | Genus: Eucalyptus | Family: Myrtaceae | Species: acmenoides		1	NCGC00380710-01	363678727.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@@]2(C)OC(C)(C)[C@@H](C1)CC2)C1C(O)C(O)C(O)C(CO)O1	O([C@@H]1[C@@]2(C)OC(C)(C)[C@@H](C1)CC2)C1C(O)C(O)C(O)C(CO)O1
NCGC00385704-01	O([C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1CC2[C@@](C)(C3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385704-01	363679885.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1CC2[C@@](C)(C3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1CC2[C@@](C)(C3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC2)CC1)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00380128-01	O([C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@@]2(C)C(=CCC3C4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@@H](C)CC6)CCC23)C[C@H](O)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380128-01	363678467.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@@]2(C)C(=CCC3C4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@@H](C)CC6)CCC23)C[C@H](O)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O([C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@@]2(C)C(=CCC3C4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@@H](C)CC6)CCC23)C[C@H](O)C1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00164248-05	O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	Starch and sucrose metabolism Substrate		1	Sucrose	405559043.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385095-01	O([C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)C[C@@]3(C)[C@H](C2)CCC2C3=CC(=O)[C@]3(C)[C@H]4[C@H](C)[C@@]5(O[C@H]4CC23)OC[C@@H](C)CC5)O[C@@H]1CO)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385095-01	363679529.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)C[C@@]3(C)[C@H](C2)CCC2C3=CC(=O)[C@]3(C)[C@H]4[C@H](C)[C@@]5(O[C@H]4CC23)OC[C@@H](C)CC5)O[C@@H]1CO)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@H](O)[C@@H](CO)O1	O([C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)C[C@@]3(C)[C@H](C2)CCC2C3=CC(=O)[C@]3(C)[C@H]4[C@H](C)[C@@]5(O[C@H]4CC23)OC[C@@H](C)CC5)O[C@@H]1CO)[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@H](O)[C@@H](CO)O1
NCGC00263944-01	O([C@@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O1		Inactive	30S Ribosomal Protein Inhibitor		1	Kanamycin	174006252.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O1	O([C@@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O1
NCGC00263824-02	O([C@@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC[C@@H]([C@H](NC)C)O1		Inactive	Antibiotic		1	GENTAMICIN SULFATE	225144365.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC[C@@H]([C@H](NC)C)O1	O([C@@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC[C@@H]([C@H](NC)C)O1
NCGC00180052-02	O([C@@](C=C)(CCC=C(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@@H](O)CO2)O1		Inactive	<MOA Unknown> | Class: Monoterpen | Genus: Putoria | Family: N/A | Species: calabrica		1	NCGC00180052-02	363677001.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@@](C=C)(CCC=C(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@@H](O)CO2)O1	O([C@@](C=C)(CCC=C(C)C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@@H](O)CO2)O1
NCGC00390639-01	O([C@H](C(=O)O)c1c(C)nc2c(c1-c1c3nccc4c3c(OCC4)cc1)cccc2)C(C)(C)C		Inactive	Human immunodeficiency virus 1 Inhibitor		1	BI 224436	363680944.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H](C(=O)O)c1c(C)nc2c(c1-c1c3nccc4c3c(OCC4)cc1)cccc2)C(C)(C)C	O([C@H](C(=O)O)c1c(C)nc2c(c1-c1c3nccc4c3c(OCC4)cc1)cccc2)C(C)(C)C
NCGC00381231-01	O([C@H](C)C=1C(=O)O[C@]2([C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)O4)OC=C(C(=O)O)[C@H]3C=C2)C=1)C(=O)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Plumeria | Family: N/A | Species: rubra		1	NCGC00381231-01	363679039.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H](C)C=1C(=O)O[C@]2([C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)O4)OC=C(C(=O)O)[C@H]3C=C2)C=1)C(=O)/C=C/c1ccc(O)cc1	O([C@H](C)C=1C(=O)O[C@]2([C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)O4)OC=C(C(=O)O)[C@H]3C=C2)C=1)C(=O)/C=C/c1ccc(O)cc1
NCGC00522632-01	O([C@H](C)[C@@H]1C(=O)C[C@H]2C(=C)[C@H](OC(=O)/C=C(/CC)\C)C[C@@H](C(C)C)[C@H]12)C(=O)C		Inactive	Platelet-Activating Factor Receptor (PAFR) Antagonist		1	Tussilagone	384569533.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H](C)[C@@H]1C(=O)C[C@H]2C(=C)[C@H](OC(=O)/C=C(/CC)\C)C[C@@H](C(C)C)[C@H]12)C(=O)C	O([C@H](C)[C@@H]1C(=O)C[C@H]2C(=C)[C@H](OC(=O)/C=C(/CC)\C)C[C@@H](C(C)C)[C@H]12)C(=O)C
NCGC00378782-02	O([C@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)CCC(O)(CC)CC		Inactive			1	Lexacalcitol	363678196.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)CCC(O)(CC)CC	O([C@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)CCC(O)(CC)CC
NCGC00510489-01	O([C@H](C)c1ccccc1)C(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)onc1C		Inactive	Lysophosphatidic Acid Receptor 1 (LPAR1; EDG2) Antagonist		1	BMS-986020	384569451.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H](C)c1ccccc1)C(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)onc1C	O([C@H](C)c1ccccc1)C(=O)Nc1c(-c2ccc(-c3ccc(C4(C(=O)O)CC4)cc3)cc2)onc1C
NCGC00378906-02	O([C@H](C)c1ccccc1)C(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)onc1C		Inactive	Lysophosphatidic acid receptor Edg-2 Antagonist		1	AM 095 (parent compound)	363678269.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H](C)c1ccccc1)C(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)onc1C	O([C@H](C)c1ccccc1)C(=O)Nc1c(-c2ccc(-c3ccc(CC(=O)O)cc3)cc2)onc1C
NCGC00025345-02	O([C@H](CCNC)c1ccccc1)c1c(C)cccc1		Inactive	Serotonin transporter Inhibitor		1	Atomoxetine hydrochloride	170465067.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H](CCNC)c1ccccc1)c1c(C)cccc1.Cl	O([C@H](CCNC)c1ccccc1)c1c(C)cccc1.Cl
NCGC00485487-01	O([C@H](CN1C(=O)N(C)c2c1c1c(nc2)ccc(-c2cc(C(O)(C)C)cnc2)c1)C)C		Inactive	PI3K Inhibitor		1	LY-3023414	363681356.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.672226248	O([C@H](CN1C(=O)N(C)c2c1c1c(nc2)ccc(-c2cc(C(O)(C)C)cnc2)c1)C)C	O([C@H](CN1C(=O)N(C)c2c1c1c(nc2)ccc(-c2cc(C(O)(C)C)cnc2)c1)C)C
NCGC00164462-05	O([C@H](COc1ccc(Oc2ccccc2)cc1)C)c1ncccc1		Inactive			1	NCGC00164462-05	434147251.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H](COc1ccc(Oc2ccccc2)cc1)C)c1ncccc1	O([C@H](COc1ccc(Oc2ccccc2)cc1)C)c1ncccc1
NCGC00385386-01	O([C@H](C[C@@H](C)[C@H]1C(=O)[C@H](O)[C@]2(C)[C@]1(C)CC[C@]13[C@H]2CCC2C(C)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@@H](O)CO4)CC[C@]12C3)[C@H]1C(C)(C)O1)C(=O)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385386-01	363679713.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H](C[C@@H](C)[C@H]1C(=O)[C@H](O)[C@]2(C)[C@]1(C)CC[C@]13[C@H]2CCC2C(C)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@@H](O)CO4)CC[C@]12C3)[C@H]1C(C)(C)O1)C(=O)C	O([C@H](C[C@@H](C)[C@H]1C(=O)[C@H](O)[C@]2(C)[C@]1(C)CC[C@]13[C@H]2CCC2C(C)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@@H](O)CO4)CC[C@]12C3)[C@H]1C(C)(C)O1)C(=O)C
NCGC00485650-01	O([C@H](C[C@@H](N(C(=O)[C@@H](NC(=O)[C@@H]1N(C)CCCC1)[C@H](CC)C)COC(=O)CC(C)C)C(C)C)c1scc(C(=O)N[C@H](C[C@@H](C(=O)O)C)Cc2ccc(O)cc2)n1)C(=O)C		Inactive	Antimitotic Agent		1	Tubulysin A	363681373.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H](C[C@@H](N(C(=O)[C@@H](NC(=O)[C@@H]1N(C)CCCC1)[C@H](CC)C)COC(=O)CC(C)C)C(C)C)c1scc(C(=O)N[C@H](C[C@@H](C(=O)O)C)Cc2ccc(O)cc2)n1)C(=O)C	O([C@H](C[C@@H](N(C(=O)[C@@H](NC(=O)[C@@H]1N(C)CCCC1)[C@H](CC)C)COC(=O)CC(C)C)C(C)C)c1scc(C(=O)N[C@H](C[C@@H](C(=O)O)C)Cc2ccc(O)cc2)n1)C(=O)C
NCGC00091914-04	O([C@H]([C@@H](OC(=O)/C=C/c1cc(O)c(O)cc1)C(=O)O)C(=O)O)C(=O)/C=C/c1cc(O)c(O)cc1		Inactive			1	Cichoric Acid	434146991.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]([C@@H](OC(=O)/C=C/c1cc(O)c(O)cc1)C(=O)O)C(=O)O)C(=O)/C=C/c1cc(O)c(O)cc1	O([C@H]([C@@H](OC(=O)/C=C/c1cc(O)c(O)cc1)C(=O)O)C(=O)O)C(=O)/C=C/c1cc(O)c(O)cc1
NCGC00178255-02	O([C@H]([C@@H]1N2C[C@H](C=C)[C@H](C1)CC2)c1c2c(ncc1)ccc(OC)c2)C(=O)OCC		Inactive	Ferriprotoporphyrin IX Antagonist		1	QUININE ETHYL CARBONATE	405558844.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.5175643999	O([C@H]([C@@H]1N2C[C@H](C=C)[C@H](C1)CC2)c1c2c(ncc1)ccc(OC)c2)C(=O)OCC	O([C@H]([C@@H]1N2C[C@H](C=C)[C@H](C1)CC2)c1c2c(ncc1)ccc(OC)c2)C(=O)OCC
NCGC00384978-01	O([C@H]([C@H](C)[C@@H]1[C@]2([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC4)CC3)CC1)CC(=O)OC2)C[C@H]1OC(=O)C(C)=C1)C(=O)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384978-01	363679465.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]([C@H](C)[C@@H]1[C@]2([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC4)CC3)CC1)CC(=O)OC2)C[C@H]1OC(=O)C(C)=C1)C(=O)C	O([C@H]([C@H](C)[C@@H]1[C@]2([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC4)CC3)CC1)CC(=O)OC2)C[C@H]1OC(=O)C(C)=C1)C(=O)C
NCGC00181300-01	O([C@H]([C@H](OC(=O)CCC)COC(=O)CCC)[C@@H](OC(=O)CCC)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)C(=O)CCC		Inactive	platelet aggregation Inhibitor		1	Riboflavin tetrabutyrate	144206329.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]([C@H](OC(=O)CCC)COC(=O)CCC)[C@@H](OC(=O)CCC)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)C(=O)CCC	O([C@H]([C@H](OC(=O)CCC)COC(=O)CCC)[C@@H](OC(=O)CCC)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)C(=O)CCC
NCGC00385877-01	O([C@H]1C(=O)OCC1(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385877-01	363679985.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1C(=O)OCC1(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@H]1C(=O)OCC1(C)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00347623-02	O([C@H]1C(O)C(O)C(OC2C(O)C(OC)C(O)C(C)O2)C(CO)O1)[C@H]1C[C@@H](O)[C@]2(C)C3C([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CCC2C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347623-02	363677642.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1C(O)C(O)C(OC2C(O)C(OC)C(O)C(C)O2)C(CO)O1)[C@H]1C[C@@H](O)[C@]2(C)C3C([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CCC2C1	O([C@H]1C(O)C(O)C(OC2C(O)C(OC)C(O)C(C)O2)C(CO)O1)[C@H]1C[C@@H](O)[C@]2(C)C3C([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CCC2C1
NCGC00381095-01	O([C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(=C)C(CC/C(=C\CO)/C)C2(C)C(C(C)(C)C(O)CC2)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381095-01	363678967.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(=C)C(CC/C(=C\CO)/C)C2(C)C(C(C)(C)C(O)CC2)C1	O([C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(=C)C(CC/C(=C\CO)/C)C2(C)C(C(C)(C)C(O)CC2)C1
NCGC00179802-02	O([C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@@H]2C[C@H]3[C@@](CO)(C4[C@H]([C@]5(O)[C@@](C)([C@@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)O[C@@H]1C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Steroid | Genus: Tephrosia | Family: Fabaceae | Species: nana		1	NCGC00179802-02	363676971.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@@H]2C[C@H]3[C@@](CO)(C4[C@H]([C@]5(O)[C@@](C)([C@@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)O[C@@H]1C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@@H]2C[C@H]3[C@@](CO)(C4[C@H]([C@]5(O)[C@@](C)([C@@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)O[C@@H]1C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00263839-02	O([C@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC=C(CN)O1		Inactive	Staphylococcus aureus Inhibitor		1	Pentisomicin	170465779.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC=C(CN)O1	O([C@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC=C(CN)O1
NCGC00347384-02	O([C@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](O[C@@H]3C[C@@H](O)[C@@]4(C)C(=CC[C@H]5C6[C@@](C)([C@H]7[C@H](C)[C@@]8(O[C@H]7C6)OCC(=C)CC8)CCC45)C3)OC[C@@H](O)C2O)O[C@@H](C)[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Steroid | Genus: Ruscus | Family: Liliaceae | Species: aculeatus		1	NCGC00347384-02	363677585.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](O[C@@H]3C[C@@H](O)[C@@]4(C)C(=CC[C@H]5C6[C@@](C)([C@H]7[C@H](C)[C@@]8(O[C@H]7C6)OCC(=C)CC8)CCC45)C3)OC[C@@H](O)C2O)O[C@@H](C)[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](O[C@@H]3C[C@@H](O)[C@@]4(C)C(=CC[C@H]5C6[C@@](C)([C@H]7[C@H](C)[C@@]8(O[C@H]7C6)OCC(=C)CC8)CCC45)C3)OC[C@@H](O)C2O)O[C@@H](C)[C@@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00483049-02	O([C@H]1[C@@](O)(C)C[C@@H](C)N(CCC)C[C@H](C)[C@@H](O)[C@@](O)(C)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)C1C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1		Inactive			1	Gamithromycin	405558723.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@@](O)(C)C[C@@H](C)N(CCC)C[C@H](C)[C@@H](O)[C@@](O)(C)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)C1C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1	O([C@H]1[C@@](O)(C)C[C@@H](C)N(CCC)C[C@H](C)[C@@H](O)[C@@](O)(C)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@](OC)(C)C2)C1C)[C@H]1[C@H](O)[C@@H](N(C)C)C[C@@H](C)O1
NCGC00188433-02	O([C@H]1[C@H](O)[C@@H](NC)C[C@@H](N)[C@@H]1O)[C@@H]1O[C@H](CO)[C@H](O)[C@@H]2OC3([C@H](O)[C@@H](O)[C@@H](O)[C@@H]([C@@H](N)CO)O3)O[C@H]12		Inactive	Ribosome-associated ATPase Inhibitor		1	Hygromycin B	405558855.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@H](O)[C@@H](NC)C[C@@H](N)[C@@H]1O)[C@@H]1O[C@H](CO)[C@H](O)[C@@H]2OC3([C@H](O)[C@@H](O)[C@@H](O)[C@@H]([C@@H](N)CO)O3)O[C@H]12	O([C@H]1[C@H](O)[C@@H](NC)C[C@@H](N)[C@@H]1O)[C@@H]1O[C@H](CO)[C@H](O)[C@@H]2OC3([C@H](O)[C@@H](O)[C@@H](O)[C@@H]([C@@H](N)CO)O3)O[C@H]12
NCGC00160515-01	O([C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](N[C@@H]3[C@H](O)[C@@H](O)[C@H](O)C(CO)=C3)[C@@H](C)O2)[C@@H](CO)O1		Inactive	alpha-Glucosidase Inhibitor		1	Acarbose	29216197.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](N[C@@H]3[C@H](O)[C@@H](O)[C@H](O)C(CO)=C3)[C@@H](C)O2)[C@@H](CO)O1	O([C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](N[C@@H]3[C@H](O)[C@@H](O)[C@H](O)C(CO)=C3)[C@@H](C)O2)[C@@H](CO)O1
NCGC00179906-03	O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1)C1C(C=C)(C)C=C2C(C3(C)C(C(C)(C)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](CO)O4)CC3)CC2)C1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Nephrolepis | Family: Nephrolepidaceae | Species: cordifolia		1	NCGC00179906-03	363676988.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1)C1C(C=C)(C)C=C2C(C3(C)C(C(C)(C)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](CO)O4)CC3)CC2)C1	O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1)C1C(C=C)(C)C=C2C(C3(C)C(C(C)(C)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](CO)O4)CC3)CC2)C1
NCGC00168902-03	O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O		Inactive			1	Hyperoside	434147043.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O	O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O
NCGC00179504-05	O([C@H]1[C@H](O)[C@@H](O)[C@@H]2O[C@H](C)OC[C@H]2O1)[C@H]1[C@@H]2[C@@H]([C@H](c3cc(OC)c(O)c(OC)c3)c3c1cc1OCOc1c3)C(=O)OC2		Inactive	DNA Topoisomerase II Inhibitor		1	Etoposide	225144306.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		O([C@H]1[C@H](O)[C@@H](O)[C@@H]2O[C@H](C)OC[C@H]2O1)[C@H]1[C@@H]2[C@@H]([C@H](c3cc(OC)c(O)c(OC)c3)c3c1cc1OCOc1c3)C(=O)OC2	O([C@H]1[C@H](O)[C@@H](O)[C@@H]2O[C@H](C)OC[C@H]2O1)[C@H]1[C@@H]2[C@@H]([C@H](c3cc(OC)c(O)c(OC)c3)c3c1cc1OCOc1c3)C(=O)OC2
NCGC00346563-03	O([C@H]1[C@H](O)[C@@H](O)[C@@H]2O[C@H](c3sccc3)OC[C@H]2O1)[C@H]1[C@@H]2[C@@H]([C@H](c3cc(OC)c(O)c(OC)c3)c3c1cc1OCOc1c3)C(=O)OC2		Inactive	DNA Topoisomerase II Inhibitor		1	Teniposide	384568841.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O([C@H]1[C@H](O)[C@@H](O)[C@@H]2O[C@H](c3sccc3)OC[C@H]2O1)[C@H]1[C@@H]2[C@@H]([C@H](c3cc(OC)c(O)c(OC)c3)c3c1cc1OCOc1c3)C(=O)OC2	O([C@H]1[C@H](O)[C@@H](O)[C@@H]2O[C@H](c3sccc3)OC[C@H]2O1)[C@H]1[C@@H]2[C@@H]([C@H](c3cc(OC)c(O)c(OC)c3)c3c1cc1OCOc1c3)C(=O)OC2
NCGC00178526-03	O([C@H]1[C@H](O)[C@@H](O)[C@H](N)C[C@@H]1N)[C@H]1[C@H](N)C[C@@H]2O[C@H](O[C@@H]3[C@H](O)[C@@H](O)[C@H](N)[C@@H](CO)O3)[C@@H](NC)[C@@H](O)[C@H]2O1		Inactive			1	APRAMYCIN SULFATE	405559094.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](N)C[C@@H]1N)[C@H]1[C@H](N)C[C@@H]2O[C@H](O[C@@H]3[C@H](O)[C@@H](O)[C@H](N)[C@@H](CO)O3)[C@@H](NC)[C@@H](O)[C@H]2O1	O([C@H]1[C@H](O)[C@@H](O)[C@H](N)C[C@@H]1N)[C@H]1[C@H](N)C[C@@H]2O[C@H](O[C@@H]3[C@H](O)[C@@H](O)[C@H](N)[C@@H](CO)O3)[C@@H](NC)[C@@H](O)[C@H]2O1
NCGC00385214-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1)C1C(C)(C)C2C3(C4(C(C5(C)C(C)(C6C(C)CC7C(C(O)(C)C)OC6(C5O)O7)CC4)=CC2)C3)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385214-01	363679598.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1)C1C(C)(C)C2C3(C4(C(C5(C)C(C)(C6C(C)CC7C(C(O)(C)C)OC6(C5O)O7)CC4)=CC2)C3)CC1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1)C1C(C)(C)C2C3(C4(C(C5(C)C(C)(C6C(C)CC7C(C(O)(C)C)OC6(C5O)O7)CC4)=CC2)C3)CC1
NCGC00380235-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1)C1C2(C)C(=CCC3C4C(C)(C5(O)C(C)C6(OC5C4)OCC(=C)CC6)CCC23)CC(O)C1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380235-01	363678508.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1)C1C2(C)C(=CCC3C4C(C)(C5(O)C(C)C6(OC5C4)OCC(=C)CC6)CCC23)CC(O)C1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1)C1C2(C)C(=CCC3C4C(C)(C5(O)C(C)C6(OC5C4)OCC(=C)CC6)CCC23)CC(O)C1
NCGC00380289-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1)C1C2(C)C(=CCC3C4C(C)(C5(O)C(C)C6(OC5C4)OCC(C)CC6)CCC23)CC(O)C1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380289-01	363678526.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1)C1C2(C)C(=CCC3C4C(C)(C5(O)C(C)C6(OC5C4)OCC(C)CC6)CCC23)CC(O)C1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1)C1C2(C)C(=CCC3C4C(C)(C5(O)C(C)C6(OC5C4)OCC(C)CC6)CCC23)CC(O)C1
NCGC00346608-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1)[C@@H]1C(C)(C)[C@@H]2[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C[C@H]3[C@@]4(C)[C@@](C)([C@H]([C@@H](O)C4)[C@@]4(C)O[C@@H](C(O)(C)C)CC4)CC[C@]43[C@@]2(C4)CC1		Inactive	treatment of degenerative bone diseases		1	Astragaloside A	384568856.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1)[C@@H]1C(C)(C)[C@@H]2[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C[C@H]3[C@@]4(C)[C@@](C)([C@H]([C@@H](O)C4)[C@@]4(C)O[C@@H](C(O)(C)C)CC4)CC[C@]43[C@@]2(C4)CC1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)CO1)[C@@H]1C(C)(C)[C@@H]2[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C[C@H]3[C@@]4(C)[C@@](C)([C@H]([C@@H](O)C4)[C@@]4(C)O[C@@H](C(O)(C)C)CC4)CC[C@]43[C@@]2(C4)CC1
NCGC00389762-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive			1	D-(+)-MALTOSE	405558630.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00160515-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](N[C@@H]3[C@H](O)[C@@H](O)[C@H](O)C(CO)=C3)[C@@H](C)O2)[C@@H](CO)O1		Inactive	alpha-Glucosidase Inhibitor		1	Acarbose	170464784.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](N[C@@H]3[C@H](O)[C@@H](O)[C@H](O)C(CO)=C3)[C@@H](C)O2)[C@@H](CO)O1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO)[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](N[C@@H]3[C@H](O)[C@@H](O)[C@H](O)C(CO)=C3)[C@@H](C)O2)[C@@H](CO)O1
NCGC00385387-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1(C(C)C)CC=C(CO)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385387-01	363679714.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1(C(C)C)CC=C(CO)CC1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1(C(C)C)CC=C(CO)CC1
NCGC00385684-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1=C(C)OC=CC1=O		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385684-01	363679874.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1=C(C)OC=CC1=O	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1=C(C)OC=CC1=O
NCGC00380380-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(C)C(/C=C/C(O)C)C(C)(C)CC1O		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380380-01	363678558.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(C)C(/C=C/C(O)C)C(C)(C)CC1O	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(C)C(/C=C/C(O)C)C(C)(C)CC1O
NCGC00384814-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(C)C(O)(/C=C/C(O)C)C(C)(C)CC1O		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384814-01	363679370.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(C)C(O)(/C=C/C(O)C)C(C)(C)CC1O	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(C)C(O)(/C=C/C(O)C)C(C)(C)CC1O
NCGC00385696-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(O)C(C)C(O)(/C=C/C(O)C)C(C)(C)C1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385696-01	363679881.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(O)C(C)C(O)(/C=C/C(O)C)C(C)(C)C1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(O)C(C)C(O)(/C=C/C(O)C)C(C)(C)C1
NCGC00347646-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1OC=CC2(O)C(O)CC(O)(C)C12		Inactive	bone resorption Inhibitor		1	NCGC00347646-02	363677651.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1OC=CC2(O)C(O)CC(O)(C)C12	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1OC=CC2(O)C(O)CC(O)(C)C12
NCGC00385247-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1/C(/C)=C/[C@H]2OC(=O)[C@H](C)[C@@H]2CC/C(/C)=C/C1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385247-01	363679616.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1/C(/C)=C/[C@H]2OC(=O)[C@H](C)[C@@H]2CC/C(/C)=C/C1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1/C(/C)=C/[C@H]2OC(=O)[C@H](C)[C@@H]2CC/C(/C)=C/C1
NCGC00385793-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(=C)[C@@H]2[C@H]3OC(=O)C(=C)[C@@H]3CC[C@](O)(C)[C@@H]2C1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385793-01	363679940.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(=C)[C@@H]2[C@H]3OC(=O)C(=C)[C@@H]3CC[C@](O)(C)[C@@H]2C1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(=C)[C@@H]2[C@H]3OC(=O)C(=C)[C@@H]3CC[C@](O)(C)[C@@H]2C1
NCGC00385508-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(=O)Nc2c(O1)cc(OC)cc2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Aphelandra | Family: Acanthaceae | Species: deppeana		1	NCGC00385508-01	363679781.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(=O)Nc2c(O1)cc(OC)cc2	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(=O)Nc2c(O1)cc(OC)cc2
NCGC00180709-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)C2[C@](C)([C@H]3[C@@]4(C[C@](O)(C)C(C4)CC3)CC2)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Albizia | Family: N/A | Species: spp		1	NCGC00180709-02	363677052.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)C2[C@](C)([C@H]3[C@@]4(C[C@](O)(C)C(C4)CC3)CC2)CC1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)C2[C@](C)([C@H]3[C@@]4(C[C@](O)(C)C(C4)CC3)CC2)CC1
NCGC00384523-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1CC2[C@@](C)(C3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC2)CC1		Inactive	cardiac muscle contraction Activator		1	NCGC00384523-01	363679229.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1CC2[C@@](C)(C3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC2)CC1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1CC2[C@@](C)(C3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC2)CC1
NCGC00381297-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1CC=2[C@@](C)(C3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC=2)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381297-01	363679074.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	13.11796096	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1CC=2[C@@](C)(C3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC=2)CC1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1CC=2[C@@](C)(C3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC=2)CC1
NCGC00169691-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1OC=C[C@@H]2[C@H]1C(CO)=CC2		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Bellardia | Family: Scrophulariaceae | Species: trixago		1	NCGC00169691-02	363676866.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1OC=C[C@@H]2[C@H]1C(CO)=CC2	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1OC=C[C@@H]2[C@H]1C(CO)=CC2
NCGC00384555-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1OC=C[C@@]2(O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)C=C(C)[C@@H]12		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384555-01	363679243.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1OC=C[C@@]2(O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)C=C(C)[C@@H]12	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1OC=C[C@@]2(O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)C=C(C)[C@@H]12
NCGC00169833-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1OC=C[C@H]2[C@H](O)C=C(CO)[C@@H]12		Inactive	TNF-alpha Inhibitor		1	Aucubin	363676896.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1OC=C[C@H]2[C@H](O)C=C(CO)[C@@H]12	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1OC=C[C@H]2[C@H](O)C=C(CO)[C@@H]12
NCGC00163523-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1OC=C[C@H]2[C@H](O)[C@H]3[C@](CO)(O3)[C@@H]12		Inactive			1	CATALPOL	26756908.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1OC=C[C@H]2[C@H](O)[C@H]3[C@](CO)(O3)[C@@H]12	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1OC=C[C@H]2[C@H](O)[C@H]3[C@](CO)(O3)[C@@H]12
NCGC00169456-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1[C@H](C(O)(C)C)CC[C@]2(CO)[C@@H](O)CC[C@@](O)(C)[C@@H]12		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169456-02	363676820.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1[C@H](C(O)(C)C)CC[C@]2(CO)[C@@H](O)CC[C@@](O)(C)[C@@H]12	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1[C@H](C(O)(C)C)CC[C@]2(CO)[C@@H](O)CC[C@@](O)(C)[C@@H]12
NCGC00485965-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](/C(=C/CC=C(C)C)/C)CC3)C1		Inactive			1	Ginsenoside Rh4	363681448.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](/C(=C/CC=C(C)C)/C)CC3)C1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1[C@H]2C(C)(C)[C@@H](O)CC[C@]2(C)[C@@H]2[C@](C)([C@@]3(C)[C@H]([C@H](O)C2)[C@@H](/C(=C/CC=C(C)C)/C)CC3)C1
NCGC00169762-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1/C(=C/C)/[C@H]2C(C(=O)O[C@H]3[C@H](C)[C@H]([C@H](C(CO)C)C3)COC(=O)C2)=CO1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169762-02	363676881.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1/C(=C/C)/[C@H]2C(C(=O)O[C@H]3[C@H](C)[C@H]([C@H](C(CO)C)C3)COC(=O)C2)=CO1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1/C(=C/C)/[C@H]2C(C(=O)O[C@H]3[C@H](C)[C@H]([C@H](C(CO)C)C3)COC(=O)C2)=CO1
NCGC00347767-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1/C(=C\C)/[C@H]2C(C(=O)OCCc3cc(c(O)cc3)Oc3ccc(cc3)CCOC(=O)C2)=CO1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Fraxinus | Family: Oleaceae | Species: floribunda		1	NCGC00347767-02	363677680.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1/C(=C\C)/[C@H]2C(C(=O)OCCc3cc(c(O)cc3)Oc3ccc(cc3)CCOC(=O)C2)=CO1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1/C(=C\C)/[C@H]2C(C(=O)OCCc3cc(c(O)cc3)Oc3ccc(cc3)CCOC(=O)C2)=CO1
NCGC00385947-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(=O)N(O)c2c(O1)cccc2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385947-01	363680020.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(=O)N(O)c2c(O1)cccc2	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(=O)N(O)c2c(O1)cccc2
NCGC00385507-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(=O)Nc2c(O1)cc(O)cc2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385507-01	363679780.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(=O)Nc2c(O1)cc(O)cc2	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(=O)Nc2c(O1)cc(O)cc2
NCGC00482994-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@]4(C)[C@@H]([C@@H](O)C3)[C@@H]([C@@](O)(CCC=C(C)C)C)CC4)CC2)CC1		Inactive			1	20(S)-Ginsenoside Rh2	434146921.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	15.75952552	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@]4(C)[C@@H]([C@@H](O)C3)[C@@H]([C@@](O)(CCC=C(C)C)C)CC4)CC2)CC1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@]4(C)[C@@H]([C@@H](O)C3)[C@@H]([C@@](O)(CCC=C(C)C)C)CC4)CC2)CC1
NCGC00385999-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C[C@]2(O)[C@@](C)(C3C([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC2)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385999-01	363680049.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C[C@]2(O)[C@@](C)(C3C([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC2)CC1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C[C@]2(O)[C@@](C)(C3C([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC2)CC1
NCGC00180669-03	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@H](C=C)C=2C(C(=O)OCC=2)=CO1		Inactive			1	Gentiopicroside		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@H](C=C)C=2C(C(=O)OCC=2)=CO1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@H](C=C)C=2C(C(=O)OCC=2)=CO1
NCGC00168975-03	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@H](C=C)[C@@]2(O)C(C(=O)OCC2)=CO1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Centaurium | Family: N/A | Species: erythraaea subsp. Erythra		1	Swertiamarine	363676734.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@H](C=C)[C@@]2(O)C(C(=O)OCC2)=CO1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@H](C=C)[C@@]2(O)C(C(=O)OCC2)=CO1
NCGC00169672-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@H](C=C)[C@H]2C(C(=O)N3[C@H](c4nc5c(c(O)c4C3)cccc5)C2)=CO1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169672-02	363676859.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@H](C=C)[C@H]2C(C(=O)N3[C@H](c4nc5c(c(O)c4C3)cccc5)C2)=CO1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@H](C=C)[C@H]2C(C(=O)N3[C@H](c4nc5c(c(O)c4C3)cccc5)C2)=CO1
NCGC00180755-03	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@H](C=C)[C@H]2C(C(=O)OCC2)=CO1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Kurrimoa | Family: Celastraceae | Species: ceylanica		1	Sweroside	363677061.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@H](C=C)[C@H]2C(C(=O)OCC2)=CO1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@H](C=C)[C@H]2C(C(=O)OCC2)=CO1
NCGC00385288-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@](CO)(C)[C@@H]2[C@](C)([C@H](C/C=C/3\[C@H](O)COC\3=O)C(=C)CC2)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385288-01	363679647.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@](CO)(C)[C@@H]2[C@](C)([C@H](C/C=C/3\[C@H](O)COC\3=O)C(=C)CC2)CC1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@](CO)(C)[C@@H]2[C@](C)([C@H](C/C=C/3\[C@H](O)COC\3=O)C(=C)CC2)CC1
NCGC00347641-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@]2(C)C3[C@@H](O)[C@H](O)[C@H](C)[C@@H]4C(=O)O[C@H]([C@H](O)C2[C@@](O)(C)C=C1)[C@]34C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Eurycoma | Family: N/A | Species: longifolia		1	NCGC00347641-02	363677646.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@]2(C)C3[C@@H](O)[C@H](O)[C@H](C)[C@@H]4C(=O)O[C@H]([C@H](O)C2[C@@](O)(C)C=C1)[C@]34C	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1[C@]2(C)C3[C@@H](O)[C@H](O)[C@H](C)[C@@H]4C(=O)O[C@H]([C@H](O)C2[C@@](O)(C)C=C1)[C@]34C
NCGC00380175-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(C(C)C)ccc(C)c1		Inactive	<MOA Unknown> | Class: Monoterpen | Genus: Lippia | Family: N/A | Species: multiflora		1	NCGC00380175-01	363678489.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(C(C)C)ccc(C)c1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(C(C)C)ccc(C)c1
NCGC00380893-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(C(C)C)ccc(CO)c1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380893-01	363678838.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(C(C)C)ccc(CO)c1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(C(C)C)ccc(CO)c1
NCGC00385115-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(C)cc(O)c(C(C)C)c1		Inactive	<MOA Unknown> | Class: Monoterpen | Genus: Senecio | Family: Compositae | Species: fuchsii		1	NCGC00385115-01	363679544.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(C)cc(O)c(C(C)C)c1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(C)cc(O)c(C(C)C)c1
NCGC00385550-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(CC#N)ccc(O)c1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385550-01	363679803.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(CC#N)ccc(O)c1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(CC#N)ccc(O)c1
NCGC00142605-05	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(CO)cccc1		Inactive	Antiinflammatory agent		1	Salicin	384568166.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(CO)cccc1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(CO)cccc1
NCGC00380230-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)c2c(cc1C(C)C)CCC1C(C)(C)C(O)CCC1(O)C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380230-01	363678506.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)c2c(cc1C(C)C)CCC1C(C)(C)C(O)CCC1(O)C2	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)c2c(cc1C(C)C)CCC1C(C)(C)C(O)CCC1(O)C2
NCGC00386029-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)cc(CCO)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: Jasminum | Family: Oleaceae | Species: multiflorum		1	NCGC00386029-01	363680069.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)cc(CCO)cc1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)cc(CCO)cc1
NCGC00482790-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)cc(O)cc1/C=C/c1ccc(O)cc1		Inactive			1	tetrahydroxyl diphenylethylene-2-o-glucoside	434147157.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)cc(O)cc1/C=C/c1ccc(O)cc1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)cc(O)cc1/C=C/c1ccc(O)cc1
NCGC00094874-05	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)cc2OC(=O)C=Cc2c1		Inactive	tumor necrosis factor production Inhibitor		1	Esculin hydrate	225144214.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)cc2OC(=O)C=Cc2c1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)cc2OC(=O)C=Cc2c1
NCGC00169655-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(CC=C)c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Godmania | Family: Leguminosae | Species: aesculifolia		1	NCGC00169655-02	363676856.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(CC=C)c1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc(CC=C)c1
NCGC00168800-03	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c2C(=O)C(O)(Cc3ccc(O)cc3)Oc2cc(O)c1		Inactive	<MOA Unknown> | Class: Flavon | Genus: Erythrina | Family: Papilionaceae | Species: abyssinica		1	NCGC00168800-03	363676686.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	17.3470418479	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c2C(=O)C(O)(Cc3ccc(O)cc3)Oc2cc(O)c1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c2C(=O)C(O)(Cc3ccc(O)cc3)Oc2cc(O)c1
NCGC00169010-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c2c(O)c3C(=O)OCc3cc2ccc1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Rhamnus | Family: Rhamnaceae | Species: prinoides		1	NCGC00169010-02	363676741.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c2c(O)c3C(=O)OCc3cc2ccc1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c2c(O)c3C(=O)OCc3cc2ccc1
NCGC00385147-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c2c(O)cccc2c(O)cc1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385147-01	363679560.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c2c(O)cccc2c(O)cc1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c2c(O)cccc2c(O)cc1
NCGC00163589-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)c2C(=O)C=C(c3cc(O)c(O)cc3)Oc2c1		Inactive			1	LUTEOLIN-7-GLUCOSIDE	434147020.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)c2C(=O)C=C(c3cc(O)c(O)cc3)Oc2c1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)c2C(=O)C=C(c3cc(O)c(O)cc3)Oc2c1
NCGC00384633-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)c2c(O[C@H]([C@H](O)C2)c2ccc(O)cc2)c1		Inactive	<MOA Unknown> | Class: Flavonoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384633-01	363679285.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)c2c(O[C@H]([C@H](O)C2)c2ccc(O)cc2)c1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)c2c(O[C@H]([C@H](O)C2)c2ccc(O)cc2)c1
NCGC00385603-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)cc(-c2oc3c(c2)ccc(O)c3)c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385603-01	363679832.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)cc(-c2oc3c(c2)ccc(O)c3)c1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)cc(-c2oc3c(c2)ccc(O)c3)c1
NCGC00385534-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)cc(-c2oc3c(c2)ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385534-01	363679794.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)cc(-c2oc3c(c2)ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)c1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)cc(-c2oc3c(c2)ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)c1
NCGC00246971-04	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)cc(/C=C/c2ccc(O)cc2)c1		Inactive	V/ICAM1 Expression Inhibitor		1	Polydatin	363677157.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)cc(/C=C/c2ccc(O)cc2)c1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)cc(/C=C/c2ccc(O)cc2)c1
NCGC00384645-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)cc(C)c1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Brucea | Family: Simaroubaceae | Species: javanica		1	NCGC00384645-01	363679292.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)cc(C)c1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc(O)cc(C)c1
NCGC00163532-06	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc2OC=C(c3ccc(O)cc3)C(=O)c2cc1		Inactive	Alcohol Dehydrogenase Inhibitor		1	Daidzin	384568245.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc2OC=C(c3ccc(O)cc3)C(=O)c2cc1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc2OC=C(c3ccc(O)cc3)C(=O)c2cc1
NCGC00169980-03	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc2OC[C@@H]3[C@@H](Oc4c3cc3OCOc3c4)c2cc1		Inactive	<MOA Unknown> | Class: Flavon | Genus: Ononis | Family: Fabaceae | Species: variegata		1	NCGC00169980-03	363676923.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc2OC[C@@H]3[C@@H](Oc4c3cc3OCOc3c4)c2cc1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1cc2OC[C@@H]3[C@@H](Oc4c3cc3OCOc3c4)c2cc1
NCGC00384667-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(/C=C/CO)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384667-01	363679300.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(/C=C/CO)cc1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(/C=C/CO)cc1
NCGC00385190-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(CCC(O)C)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Cistus | Family: Cistaceae | Species: ladanifer		1	NCGC00385190-01	363679587.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(CCC(O)C)cc1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(CCC(O)C)cc1
NCGC00385783-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(CCO)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385783-01	363679937.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(CCO)cc1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(CCO)cc1
NCGC00346601-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(CO)cc1		Inactive	Fibrinogen Inhibitor		1	Gastrodin (Gastrodine)	363677472.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(CO)cc1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(CO)cc1
NCGC00166076-07&NCGC00166076-09	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(O)cc1		Inactive	Free Radical Scavenger		2	Arbutin	170465722.0&434147035.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(O)cc1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(O)cc1
NCGC00385978-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccccc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385978-01	363680040.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccccc1	O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccccc1
NCGC00380465-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](OC2C(C)(C)C3C(C)(C4C(=CC3)CC(C(OC3C(O)C(O)C(O)C(CO)O3)CO)(C)CC4)CC2)O[C@@H]1CO)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380465-01	363678597.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](OC2C(C)(C)C3C(C)(C4C(=CC3)CC(C(OC3C(O)C(O)C(O)C(CO)O3)CO)(C)CC4)CC2)O[C@@H]1CO)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O([C@H]1[C@H](O)[C@@H](O)[C@H](OC2C(C)(C)C3C(C)(C4C(=CC3)CC(C(OC3C(O)C(O)C(O)C(CO)O3)CO)(C)CC4)CC2)O[C@@H]1CO)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00179940-02	O([C@H]1[C@H](O)[C@@H](O)[C@H](OC2C3C(C)(C4C(C5C(C)(C6C(C)C7(C(O)CC(C)CO7)OC6C5)CC4)C2)CCC(O)C3)O[C@@H]1C)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1		Inactive	<MOA Unknown> | Class: Steroid | Genus: Solanum | Family: Solanaceae | Species: torvum		1	NCGC00179940-02	363676993.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](OC2C3C(C)(C4C(C5C(C)(C6C(C)C7(C(O)CC(C)CO7)OC6C5)CC4)C2)CCC(O)C3)O[C@@H]1C)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1	O([C@H]1[C@H](O)[C@@H](O)[C@H](OC2C3C(C)(C4C(C5C(C)(C6C(C)C7(C(O)CC(C)CO7)OC6C5)CC4)C2)CCC(O)C3)O[C@@H]1C)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1
NCGC00384770-01	O([C@H]1[C@H](O)[C@@H](O)[C@H](Oc2c(OC)c(OC)cc(O)c2)O[C@@H]1CO)[C@H]1[C@H](O)[C@@](O)(CO)CO1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384770-01	363679346.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O)[C@H](Oc2c(OC)c(OC)cc(O)c2)O[C@@H]1CO)[C@H]1[C@H](O)[C@@](O)(CO)CO1	O([C@H]1[C@H](O)[C@@H](O)[C@H](Oc2c(OC)c(OC)cc(O)c2)O[C@@H]1CO)[C@H]1[C@H](O)[C@@](O)(CO)CO1
NCGC00179506-05	O([C@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O1		Inactive	30S Ribosomal Protein Inhibitors		1	Kanamycin (sulfate)	405558981.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O1	O([C@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O1
NCGC00183277-01	O([C@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC[C@@H](CNC)O1		Inactive			1	Micronomicin sulfate	144206497.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)O.O([C@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC[C@@H](CNC)O1	S(=O)(=O)(O)O.O([C@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)CC[C@@H](CNC)O1
NCGC00179265-05&NCGC00179265-08	O([C@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@H](NCC)C[C@@H]1N)[C@@H]1[C@H](N)CC=C(CN)O1		Inactive	Lysosomal phospholipase A1 Inhibitor		2	Netilmicin Sulfate	363676940.0&363676941.0	2020_NPACT-10_CPE&2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O([C@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@H](NCC)C[C@@H]1N)[C@@H]1[C@H](N)CC=C(CN)O1	O([C@H]1[C@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@H](NCC)C[C@@H]1N)[C@@H]1[C@H](N)CC=C(CN)O1
NCGC00386383-01	O([C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](O)[C@H](NC)[C@@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H]([C@@H](O)C)O1		Inactive			1	Geneticin (G418 Sulfate)	363680246.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](O)[C@H](NC)[C@@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H]([C@@H](O)C)O1	O([C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](O)[C@H](NC)[C@@](O)(C)CO2)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H]([C@@H](O)C)O1
NCGC00142624-05&NCGC00142624-06	O([C@H]1[C@H](O)[C@@](O)(CO)O[C@@H]1CO)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1		Inactive	Synthetic sugar		2	Lactulose	170464861.0&384568168.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O([C@H]1[C@H](O)[C@@](O)(CO)O[C@@H]1CO)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1	O([C@H]1[C@H](O)[C@@](O)(CO)O[C@@H]1CO)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1
NCGC00016447-01&NCGC00344555-01	O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)[C@@H]1C=C2[C@@](C)([C@@H]3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=COC(=O)C=C5)CC4)CC3)CC2)CC1		Inactive	Cardiac glycoside&Steroid		2	Proscillaridin	144203993.0&170465956.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)[C@@H]1C=C2[C@@](C)([C@@H]3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=COC(=O)C=C5)CC4)CC3)CC2)CC1	O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)[C@@H]1C=C2[C@@](C)([C@@H]3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=COC(=O)C=C5)CC4)CC3)CC2)CC1
NCGC00386008-01	O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)[C@@H]1CC2[C@@](C)(C3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC2)CC1		Inactive	<MOA Unknown> | Class: Steroid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386008-01	363680055.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)[C@@H]1CC2[C@@](C)(C3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC2)CC1	O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)[C@@H]1CC2[C@@](C)(C3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CC2)CC1
NCGC00015769-14&NCGC00015769-32	O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21		Inactive	Sodium/potassium-transporting ATPase subunit alpha-3 Inhibitor		2	Strophantine octahydrate&Ouabain octahydrate	384567888.0&405559108.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0		O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21	O([C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21
NCGC00179612-03	O([C@H]1[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C[C@@H](N)[C@@H]1O)[C@H]1[C@H](O)[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@H](CN)O2)[C@@H](CO)O1		Inactive	30S Ribosomal Protein Inhibitors		1	Neomycin sulfate	225144310.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C[C@@H](N)[C@@H]1O)[C@H]1[C@H](O)[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@H](CN)O2)[C@@H](CO)O1	O([C@H]1[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C[C@@H](N)[C@@H]1O)[C@H]1[C@H](O)[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@H](CN)O2)[C@@H](CO)O1
NCGC00166210-02	O([C@H]1[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](N)C[C@@H](N)[C@@H]1O)[C@H]1[C@H](O)[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@H](CN)O2)[C@@H](CO)O1		Inactive	Bacterial 70S ribosome Inhibitor		1	PAROMOMYCIN SULFATE	405559135.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@H]1[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](N)C[C@@H](N)[C@@H]1O)[C@H]1[C@H](O)[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@H](CN)O2)[C@@H](CO)O1	O([C@H]1[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](N)C[C@@H](N)[C@@H]1O)[C@H]1[C@H](O)[C@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@H](CN)O2)[C@@H](CO)O1
NCGC00178417-03	O([C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C(O)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CN)O1		Inactive	Protein disulfide-isomerase Inhibitor		1	Ribostamycin sulfate	170465814.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)O.O([C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C(O)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CN)O1	S(=O)(=O)(O)O.O([C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C(O)[C@H](N)C[C@@H]1N)[C@@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CN)O1
NCGC00385032-01	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)CC3[C@](C)([C@]2(C)CC1)CCC1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)[C@H](CO)O2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385032-01	363679495.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)CC3[C@](C)([C@]2(C)CC1)CCC1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)[C@H](CO)O2)O1	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)CC3[C@](C)([C@]2(C)CC1)CCC1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)[C@H](CO)O2)O1
NCGC00384586-01	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)CC3[C@](C)([C@]2(C)CC1)C[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	platelet aggregation Inhibitor		1	NCGC00384586-01	363679261.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)CC3[C@](C)([C@]2(C)CC1)C[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)CC3[C@](C)([C@]2(C)CC1)C[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00384801-01	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)CC3[C@](C)([C@]2(C)CC1)C[C@H](O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	NF-kappa B signaling pathway Modulator		1	NCGC00384801-01	363679364.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)CC3[C@](C)([C@]2(C)CC1)C[C@H](O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)CC3[C@](C)([C@]2(C)CC1)C[C@H](O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385113-01	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)CC3[C@](C)([C@]2(C)CC1)C[C@H](O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	toll-like receptor 4 signaling pathway Inhibitor		1	NCGC00385113-01	363679542.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)CC3[C@](C)([C@]2(C)CC1)C[C@H](O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)CC3[C@](C)([C@]2(C)CC1)C[C@H](O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)C1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00482516-02	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](OC2C(OC4C(O)C(O)C(O)C(CO)O4)C(O)C(O)C(CO)O2)CC[C@]31C)C1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)CO2)O1		Inactive			1	Ginsenoside Rb2	434147210.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](OC2C(OC4C(O)C(O)C(O)C(CO)O4)C(O)C(O)C(CO)O2)CC[C@]31C)C1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)CO2)O1	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](OC2C(OC4C(O)C(O)C(O)C(CO)O4)C(O)C(O)C(CO)O2)CC[C@]31C)C1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)CO2)O1
NCGC00386168-01	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)O1		Inactive	Apoptosis Activator		1	Gynostemma Extract	363680131.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)O1	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)O1
NCGC00485983-01	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](CO)O2)O1		Inactive	adipose tissue development Inhibitor		1	Ginsenoside Rc	363681462.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](CO)O2)O1	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](CO)O2)O1
NCGC00347398-04	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1		Inactive			1	Ginsenoside Rb1	434147097.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1	O([C@](CCC=C(C)C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)CC[C@H]1C(C)(C)[C@@H](O[C@H]2[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1
NCGC00263094-05	O(c1c(-c2nc(N)ncc2)cccn1)c1ccc(Nc2nnc(-c3scc(C)c3)c3c2cccc3)cc1	4.9000001	Active	Aurora-A/B/C Kinase Inhibitor	0.0	1	AMG-900	384568586.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	54.603763106	O(c1c(-c2nc(N)ncc2)cccn1)c1ccc(Nc2nnc(-c3scc(C)c3)c3c2cccc3)cc1	O(c1c(-c2nc(N)ncc2)cccn1)c1ccc(Nc2nnc(-c3scc(C)c3)c3c2cccc3)cc1
NCGC00482879-02	O(c1c(C)cc(Nc2ncnc3c2cc(NC=2OCC(C)(C)N=2)cc3)cc1)C1=Cc2n(ncn2)C=C1		Inactive	HER2 Inhibitor		1	Tucatinib	377020215.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(c1c(C)cc(Nc2ncnc3c2cc(NC=2OCC(C)(C)N=2)cc3)cc1)C1=Cc2n(ncn2)C=C1	O(c1c(C)cc(Nc2ncnc3c2cc(NC=2OCC(C)(C)N=2)cc3)cc1)C1=Cc2n(ncn2)C=C1
NCGC00378968-01	O(c1c(CC)n(CCO)nc1CC)c1cc(C#N)cc(C#N)c1		Inactive	Reverse transcriptase Inhibitor		1	Lersivirine	363678296.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(c1c(CC)n(CCO)nc1CC)c1cc(C#N)cc(C#N)c1	O(c1c(CC)n(CCO)nc1CC)c1cc(C#N)cc(C#N)c1
NCGC00485427-01	O(c1c2c(ccc1)cccc2)C1(Oc2c3c(ccc2)cccc3)N=C2[N+](C3CCCCC3)([C-]3CCCCC3)C=NC2=C(N(c2ccc(N3CCOCC3)cc2)c2ccc(N3CCOCC3)cc2)N1		Inactive			1	Purmorphamine	363681333.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	11.1428571401	O(c1c2c(ccc1)cccc2)C1(Oc2c3c(ccc2)cccc3)N=C2[N+](C3CCCCC3)([C-]3CCCCC3)C=NC2=C(N(c2ccc(N3CCOCC3)cc2)c2ccc(N3CCOCC3)cc2)N1	O(c1c2c(ccc1)cccc2)C1(Oc2c3c(ccc2)cccc3)N=C2[N+](C3CCCCC3)([C-]3CCCCC3)C=NC2=C(N(c2ccc(N3CCOCC3)cc2)c2ccc(N3CCOCC3)cc2)N1
NCGC00370768-04	O(c1cc(C)ccc1)C=1C=NC(=O)NC=1		Inactive	Lyn Kinase Activator		1	Tolimidone	363677843.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(c1cc(C)ccc1)C=1C=NC(=O)NC=1	O(c1cc(C)ccc1)C=1C=NC(=O)NC=1
NCGC00380714-01	O(c1cc(O)c2c(OC(c3ccc(O)cc3)C(O)C2)c1)C1C(O)C(O)C(CO)O1		Inactive	<MOA Unknown> | Class: Flavonoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380714-01	363678731.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(c1cc(O)c2c(OC(c3ccc(O)cc3)C(O)C2)c1)C1C(O)C(O)C(CO)O1	O(c1cc(O)c2c(OC(c3ccc(O)cc3)C(O)C2)c1)C1C(O)C(O)C(CO)O1
NCGC00380545-01	O(c1cc(O)cc(/C=C/c2c(O)cc(OC3C(O)C(O)C(O)C(CO)O3)cc2)c1)C1C(O)C(O)C(O)C(CO)O1		Inactive	<MOA Unknown> | Class: Shikimi / Polyketide | Genus: Morus | Family: Moraceae | Species: alba		1	NCGC00380545-01	363678642.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(c1cc(O)cc(/C=C/c2c(O)cc(OC3C(O)C(O)C(O)C(CO)O3)cc2)c1)C1C(O)C(O)C(O)C(CO)O1	O(c1cc(O)cc(/C=C/c2c(O)cc(OC3C(O)C(O)C(O)C(CO)O3)cc2)c1)C1C(O)C(O)C(O)C(CO)O1
NCGC00345792-02&NCGC00345792-04	O(c1cc2c(B(O)OC2)cc1)c1ccc(C#N)cc1		Inactive	Phosphodiesterase IIII (PDE4) Inhibitor		2	AN-2728	363677355.0&405558907.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O(c1cc2c(B(O)OC2)cc1)c1ccc(C#N)cc1	O(c1cc2c(B(O)OC2)cc1)c1ccc(C#N)cc1
NCGC00166146-02	O(c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1)C1CCCC1		Inactive	Estrogen receptor Agonist		1	Quinestrol	170465054.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1)C1CCCC1	O(c1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1)C1CCCC1
NCGC00263041-01	O(c1ccc(-c2c3c(N)ncnc3n(C(C)C)c2)cc1)c1ccccc1		Inactive			1	NCGC00263041-01	377020305.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	17.452870724	O(c1ccc(-c2c3c(N)ncnc3n(C(C)C)c2)cc1)c1ccccc1	O(c1ccc(-c2c3c(N)ncnc3n(C(C)C)c2)cc1)c1ccccc1
NCGC00370980-01	O(c1ccc(-c2c3c(N)ncnc3n(C3CCC(N4CCN(C)CC4)CC3)c2)cc1)c1ccccc1		Inactive	HCK Kinase Inhibitor		1	A-419259	384569038.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(c1ccc(-c2c3c(N)ncnc3n(C3CCC(N4CCN(C)CC4)CC3)c2)cc1)c1ccccc1	O(c1ccc(-c2c3c(N)ncnc3n(C3CCC(N4CCN(C)CC4)CC3)c2)cc1)c1ccccc1
NCGC00015280-06	O(c1ccc(-c2c3c(N)ncnc3n(C3CCCC3)c2)cc1)c1ccccc1		Inactive			1	7-Cyclopentyl-5-(4-phenoxy)phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamine	377020481.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(c1ccc(-c2c3c(N)ncnc3n(C3CCCC3)c2)cc1)c1ccccc1	O(c1ccc(-c2c3c(N)ncnc3n(C3CCCC3)c2)cc1)c1ccccc1
NCGC00378594-02	O(c1ccc(-c2nn([C@H]3CNCCC3)c3ncnc(N)c23)cc1)c1ccccc1	4.9000001	Active		0.0	1	Btk inhibitor 1 (R enantiomer hydrochloride)	363678113.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	58.0819047579	O(c1ccc(-c2nn([C@H]3CNCCC3)c3ncnc(N)c23)cc1)c1ccccc1	O(c1ccc(-c2nn([C@H]3CNCCC3)c3ncnc(N)c23)cc1)c1ccccc1
NCGC00384003-02	O(c1ccc(CN)cc1)c1ccccc1		Inactive			1	4-phenoxybenzylamine		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(c1ccc(CN)cc1)c1ccccc1	O(c1ccc(CN)cc1)c1ccccc1
NCGC00386258-01	O(c1ccc(O)cc1)C1OCCCC1		Inactive			1	Deoxyarbutin	434147127.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(c1ccc(O)cc1)C1OCCCC1	O(c1ccc(O)cc1)C1OCCCC1
NCGC00387448-01	O(c1cnc(Nc2cc(O)ccc2)nc1)c1cc(N(C)C)ccc1		Inactive			1	SEN 1269	363680615.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O(c1cnc(Nc2cc(O)ccc2)nc1)c1cc(N(C)C)ccc1	O(c1cnc(Nc2cc(O)ccc2)nc1)c1cc(N(C)C)ccc1
NCGC00263207-02	O(c1nc(N[C@H](CO)Cc2ccccc2)c2ncn(Cc3ccc(-c4ccccc4)cc3)c2n1)c1cc2c(cc1)CCC2		Inactive	ADP-ribosylation factor GTPase activating protein 1 Inhibitor		1	QS11	384568666.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O(c1nc(N[C@H](CO)Cc2ccccc2)c2ncn(Cc3ccc(-c4ccccc4)cc3)c2n1)c1cc2c(cc1)CCC2	O(c1nc(N[C@H](CO)Cc2ccccc2)c2ncn(Cc3ccc(-c4ccccc4)cc3)c2n1)c1cc2c(cc1)CCC2
NCGC00344053-04	O(c1nc(Nc2ccc(N3CCOCC3)cc2)c2ncn(C3CCCCC3)c2n1)c1c2c(ccc1)cccc2	4.9000001	Active	lineage-specific differentiation enhancer	0.0	1	Purmorphamine	384568716.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	38.39963364	O(c1nc(Nc2ccc(N3CCOCC3)cc2)c2ncn(C3CCCCC3)c2n1)c1c2c(ccc1)cccc2	O(c1nc(Nc2ccc(N3CCOCC3)cc2)c2ncn(C3CCCCC3)c2n1)c1c2c(ccc1)cccc2
NCGC00346638-03	O(c1ncnc2[nH]c(-c3cc(N)ccc3)cc12)c1cc(O)ccc1		Inactive	GSK-3 beta Inhibitor		1	TWS-119	384568872.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O(c1ncnc2[nH]c(-c3cc(N)ccc3)cc12)c1cc(O)ccc1	O(c1ncnc2[nH]c(-c3cc(N)ccc3)cc12)c1cc(O)ccc1
NCGC00481574-01	O/C(=N\Cc1c(O)nc(C)cc1C)/c1c2c(C)cn(C(C)C)c2cc(-c2cnc(N3CCN(C)CC3)cc2)c1	5.0	Active	EZH2 Inhibitor	0.0	1	GSK-503	384569256.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	91.5503375559	O/C(=N\Cc1c(O)nc(C)cc1C)/c1c2c(C)cn(C(C)C)c2cc(-c2cnc(N3CCN(C)CC3)cc2)c1	O/C(=N\Cc1c(O)nc(C)cc1C)/c1c2c(C)cn(C(C)C)c2cc(-c2cnc(N3CCN(C)CC3)cc2)c1
NCGC00319018-01	O/N=C(/[C@H](NCC(CN[C@@H](/C(=N/O)/C)C)(C)C)C)\C		Inactive			1	Exametazime	170465570.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O/N=C(/[C@H](NCC(CN[C@@H](/C(=N/O)/C)C)(C)C)C)\C	O/N=C(/[C@H](NCC(CN[C@@H](/C(=N/O)/C)C)(C)C)C)\C
NCGC00178286-05	O/N=C/c1[n+](C)cccc1		Inactive	Butyrylcholinesterase Activator		1	Pralidoxime chloride	170465059.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O/N=C/c1[n+](C)cccc1.[Cl-]	O/N=C/c1[n+](C)cccc1.[Cl-]
NCGC00485891-01	O/N=C\1/C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC/1		Inactive	Progesterone receptor Agonist		1	Norgestimate metabolite Norelgestromin	363681397.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O/N=C\1/C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC/1	O/N=C\1/C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC/1
NCGC00263179-09	O/N=C\1/c2c(cc(-c3c(-c4ccncc4)nn(CCO)c3)cc2)CC/1		Inactive	Raf kinase B Inhibitor		1	AR-00341677	377020324.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O/N=C\1/c2c(cc(-c3c(-c4ccncc4)nn(CCO)c3)cc2)CC/1	O/N=C\1/c2c(cc(-c3c(-c4ccncc4)nn(CCO)c3)cc2)CC/1
NCGC00487402-01	O/N=C\1/c2nc3c(nc2-c2c/1cccc2)cccc3	5.1999998	Active		0.0	1	IQ-1S	377020497.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	2.4	39.3059723508	O/N=C\1/c2nc3c(nc2-c2c/1cccc2)cccc3	O/N=C\1/c2nc3c(nc2-c2c/1cccc2)cccc3
NCGC00163490-03	O1[C@H]2N3CC[C@@H]1CCCCCC[C@@H]1[C@H]4O[C@H](CCN4CCC1)CCCCCC[C@@H]2CCC3		Inactive			1	Xestospongin C		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O1[C@H]2N3CC[C@@H]1CCCCCC[C@@H]1[C@H]4O[C@H](CCN4CCC1)CCCCCC[C@@H]2CCC3	O1[C@H]2N3CC[C@@H]1CCCCCC[C@@H]1[C@H]4O[C@H](CCN4CCC1)CCCCCC[C@@H]2CCC3
NCGC00480790-01	O1c2c3c(cc-4[n+](c3)CCc3c-4cc4OCOc4c3)ccc2OC1		Inactive			1	Coptisine		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O1c2c3c(cc-4[n+](c3)CCc3c-4cc4OCOc4c3)ccc2OC1	O1c2c3c(cc-4[n+](c3)CCc3c-4cc4OCOc4c3)ccc2OC1
NCGC00380179-01	O=C(/C=C(/C(O)(C)C)\C)C(C)C1C2(C)C(C3=C(C4(C)C(O)(C(C)(C)C(=O)CC4)CC3)CC2)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380179-01	363678491.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C(/C(O)(C)C)\C)C(C)C1C2(C)C(C3=C(C4(C)C(O)(C(C)(C)C(=O)CC4)CC3)CC2)CC1	O=C(/C=C(/C(O)(C)C)\C)C(C)C1C2(C)C(C3=C(C4(C)C(O)(C(C)(C)C(=O)CC4)CC3)CC2)CC1
NCGC00381398-01	O=C(/C=C/C(=C/C(CC)C)/C)C1C(=O)C(O)(C)C(O)CC1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381398-01	363679126.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/C(=C/C(CC)C)/C)C1C(=O)C(O)(C)C(O)CC1	O=C(/C=C/C(=C/C(CC)C)/C)C1C(=O)C(O)(C)C(O)CC1
NCGC00169089-04	O=C(/C=C/C(=C/[C@H](CC)C)/C)Cc1c(C=O)c(O)c(C)c(O)c1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169089-04	363676768.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/C(=C/[C@H](CC)C)/C)Cc1c(C=O)c(O)c(C)c(O)c1	O=C(/C=C/C(=C/[C@H](CC)C)/C)Cc1c(C=O)c(O)c(C)c(O)c1
NCGC00385470-01	O=C(/C=C/C1(O)C(C)(C)CC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC1C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385470-01	363679757.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/C1(O)C(C)(C)CC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC1C)C	O=C(/C=C/C1(O)C(C)(C)CC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC1C)C
NCGC00386113-01	O=C(/C=C/C1(O)C(C)=CC(=O)CC1(C)C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386113-01	363680113.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/C1(O)C(C)=CC(=O)CC1(C)C)C	O=C(/C=C/C1(O)C(C)=CC(=O)CC1(C)C)C
NCGC00384973-01	O=C(/C=C/C1(O)C(O)(C)CC(O)CC1(C)C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384973-01	363679462.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/C1(O)C(O)(C)CC(O)CC1(C)C)C	O=C(/C=C/C1(O)C(O)(C)CC(O)CC1(C)C)C
NCGC00385657-01	O=C(/C=C/C1C(C)(C)CC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC1C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385657-01	363679860.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/C1C(C)(C)CC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC1C)C	O=C(/C=C/C1C(C)(C)CC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC1C)C
NCGC00522633-01	O=C(/C=C/C=1[C@@H](C)C[C@@H]2OC(=O)C(=C)[C@H]2CC=1)C		Inactive	NF-kappaB Activation Inhibitor		1	Xanthatin	384569534.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	31.416160392	O=C(/C=C/C=1[C@@H](C)C[C@@H]2OC(=O)C(=C)[C@H]2CC=1)C	O=C(/C=C/C=1[C@@H](C)C[C@@H]2OC(=O)C(=C)[C@H]2CC=1)C
NCGC00249895-01	O=C(/C=C/C=C/1\C(C)(C)C2CC\1CC2)C		Inactive			1	Bornelone	170465560.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(/C=C/C=C/1\C(C)(C)C2CC\1CC2)C	O=C(/C=C/C=C/1\C(C)(C)C2CC\1CC2)C
NCGC00253590-01	O=C(/C=C/C=C/C(=C/C(O)CCCC)/C)N1C(=O)CCC1		Inactive			1	Variotin	170465957.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&12.3431948761	O=C(/C=C/C=C/C(=C/C(O)CCCC)/C)N1C(=O)CCC1	O=C(/C=C/C=C/C(=C/C(O)CCCC)/C)N1C(=O)CCC1
NCGC00381453-01	O=C(/C=C/C=C/C)C1=C(O)C2(C)[C@]3(O)[C@@]4(C)O[C@]5(O)[C@](C)(C(O)=C(C(=O)/C=C/C=C/C)C2[C@]5(C)O3)C14		Inactive	<MOA Unknown> | Class: polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381453-01	363679149.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/C=C/C)C1=C(O)C2(C)[C@]3(O)[C@@]4(C)O[C@]5(O)[C@](C)(C(O)=C(C(=O)/C=C/C=C/C)C2[C@]5(C)O3)C14	O=C(/C=C/C=C/C)C1=C(O)C2(C)[C@]3(O)[C@@]4(C)O[C@]5(O)[C@](C)(C(O)=C(C(=O)/C=C/C=C/C)C2[C@]5(C)O3)C14
NCGC00380849-01	O=C(/C=C/C=C/C)C1=C(O)[C@@]2(C)[C@]3(O)[C@@]4(C)O[C@]5(O)C(C)(C(O)=C(C(=O)CC/C=C/C)C2[C@]5(C)O3)C14		Inactive	<MOA Unknown> | Class: polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380849-01	363678812.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/C=C/C)C1=C(O)[C@@]2(C)[C@]3(O)[C@@]4(C)O[C@]5(O)C(C)(C(O)=C(C(=O)CC/C=C/C)C2[C@]5(C)O3)C14	O=C(/C=C/C=C/C)C1=C(O)[C@@]2(C)[C@]3(O)[C@@]4(C)O[C@]5(O)C(C)(C(O)=C(C(=O)CC/C=C/C)C2[C@]5(C)O3)C14
NCGC00180620-02	O=C(/C=C/C=C/C)N1[C@H]2N3[C@@H](C4C(C)(C)O4)c4c5c(N(C)[C@@H]6Nc7c(cccc7)[C@]2([C@]56CC3)CC1)ccc4		Inactive	<MOA Unknown> | Class: alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180620-02	363677041.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/C=C/C)N1[C@H]2N3[C@@H](C4C(C)(C)O4)c4c5c(N(C)[C@@H]6Nc7c(cccc7)[C@]2([C@]56CC3)CC1)ccc4	O=C(/C=C/C=C/C)N1[C@H]2N3[C@@H](C4C(C)(C)O4)c4c5c(N(C)[C@@H]6Nc7c(cccc7)[C@]2([C@]56CC3)CC1)ccc4
NCGC00094872-13	O=C(/C=C/C=C/c1cc2OCOc2cc1)N1CCCCC1		Inactive	MAO-A/B Inhibitor		1	Piperine	384568138.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(/C=C/C=C/c1cc2OCOc2cc1)N1CCCCC1	O=C(/C=C/C=C/c1cc2OCOc2cc1)N1CCCCC1
NCGC00371001-05	O=C(/C=C/N1[C@H]2CN(c3ncccc3)[C@@H](C1)C2)c1c(O)cccc1		Inactive	SMARCA2 Inhibitor		1	PFI-3	384569039.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(/C=C/N1[C@H]2CN(c3ncccc3)[C@@H](C1)C2)c1c(O)cccc1	O=C(/C=C/N1[C@H]2CN(c3ncccc3)[C@@H](C1)C2)c1c(O)cccc1
NCGC00485922-01	O=C(/C=C/[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)C1CC1		Inactive	Vitamin D receptor Antagonist		1	MC 1046	363681417.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)C1CC1	O=C(/C=C/[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)C1CC1
NCGC00385733-01	O=C(/C=C/[C@H]1[C@@](O)(C)[C@@H](O)[C@H](O)C2C(C)(C)CCC[C@]12C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385733-01	363679908.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/[C@H]1[C@@](O)(C)[C@@H](O)[C@H](O)C2C(C)(C)CCC[C@]12C)C	O=C(/C=C/[C@H]1[C@@](O)(C)[C@@H](O)[C@H](O)C2C(C)(C)CCC[C@]12C)C
NCGC00482709-01	O=C(/C=C/c1c(OC)cc(O)c(C(C=C)(C)C)c1)c1ccc(O)cc1		Inactive			1	Licochalcone A		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	-11.189625104	O=C(/C=C/c1c(OC)cc(O)c(C(C=C)(C)C)c1)c1ccc(O)cc1	O=C(/C=C/c1c(OC)cc(O)c(C(C=C)(C)C)c1)c1ccc(O)cc1
NCGC00387473-03	O=C(/C=C/c1c(n(C)c2ncccc12)-c1ccccc1)N1Cc2c(cc(OC)c(OC)c2)CC1		Inactive			1	Smad3Inhibitor,SIS3	363680629.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/c1c(n(C)c2ncccc12)-c1ccccc1)N1Cc2c(cc(OC)c(OC)c2)CC1	O=C(/C=C/c1c(n(C)c2ncccc12)-c1ccccc1)N1Cc2c(cc(OC)c(OC)c2)CC1
NCGC00481557-01	O=C(/C=C/c1cc(OC)c(OC)cc1)C1(C(=O)/C=C/c2cc(OC)c(OC)cc2)CCCCC1		Inactive			1	FLLL32	377020253.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/c1cc(OC)c(OC)cc1)C1(C(=O)/C=C/c2cc(OC)c(OC)cc2)CCCCC1	O=C(/C=C/c1cc(OC)c(OC)cc1)C1(C(=O)/C=C/c2cc(OC)c(OC)cc2)CCCCC1
NCGC00090504-14	O=C(/C=C/c1ccc(O)cc1)c1c(O)cc(O)cc1		Inactive	Histone Deacetylase/SIRT1 Activator		1	Isoliquiritigenin	384568078.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(/C=C/c1ccc(O)cc1)c1c(O)cc(O)cc1	O=C(/C=C/c1ccc(O)cc1)c1c(O)cc(O)cc1
NCGC00385460-01	O=C(/C=C/c1ccc(OC)cc1)N1CCCC1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385460-01	363679751.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/c1ccc(OC)cc1)N1CCCC1	O=C(/C=C/c1ccc(OC)cc1)N1CCCC1
NCGC00025228-15	O=C(/C=C/c1ccccc1)c1c(O)c(Cc2c(O)c(C(=O)C)c(O)c(C)c2O)c(O)c2c1OC(C)(C)C=C2		Inactive			1	Rottlerin	384568060.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.949375868	O=C(/C=C/c1ccccc1)c1c(O)c(Cc2c(O)c(C(=O)C)c(O)c(C)c2O)c(O)c2c1OC(C)(C)C=C2	O=C(/C=C/c1ccccc1)c1c(O)c(Cc2c(O)c(C(=O)C)c(O)c(C)c2O)c(O)c2c1OC(C)(C)C=C2
NCGC00242343-01	O=C(/C=C/c1ccccc1)c1c(OC)cc(OC)c2c1OC(C)(C)C=C2		Inactive			1	NCGC00242343-01	109816932.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/c1ccccc1)c1c(OC)cc(OC)c2c1OC(C)(C)C=C2	O=C(/C=C/c1ccccc1)c1c(OC)cc(OC)c2c1OC(C)(C)C=C2
NCGC00487238-01	O=C(/C=C/c1ccccc1)c1sc(C)cc1		Inactive			1	NSC43067	377020172.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/c1ccccc1)c1sc(C)cc1	O=C(/C=C/c1ccccc1)c1sc(C)cc1
NCGC00386709-03	O=C(/C=C/c1cnccc1)c1ccncc1		Inactive			1	3PO	377020174.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/c1cnccc1)c1ccncc1	O=C(/C=C/c1cnccc1)c1ccncc1
NCGC00386328-01	O=C(/C=C/c1nc2c(cc1)cccc2)c1ccncc1		Inactive			1	PFK15		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C/c1nc2c(cc1)cccc2)c1ccncc1	O=C(/C=C/c1nc2c(cc1)cccc2)c1ccncc1
NCGC00402322-02	O=C(/C=C\1/N(CC)c2c(S/1)ccc(O)c2)C		Inactive			1	INDY		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(/C=C\1/N(CC)c2c(S/1)ccc(O)c2)C	O=C(/C=C\1/N(CC)c2c(S/1)ccc(O)c2)C
NCGC00032387-14	O=C(/C=C\1/N(CC)c2c(S/1)ccc(OC)c2)C		Inactive	Clk1, Clk4 Inhibitor		1	TG-003	384568071.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(/C=C\1/N(CC)c2c(S/1)ccc(OC)c2)C	O=C(/C=C\1/N(CC)c2c(S/1)ccc(OC)c2)C
NCGC00378736-01	O=C(/C=C\c1cc(OC)c(OC)c(OC)c1)N1CCN(CC(=O)N2CCCC2)CC1		Inactive	Voltage-gated calcium channel Blocker		1	Cinepazide Maleate	405558463.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(/C=C\c1cc(OC)c(OC)c(OC)c1)N1CCN(CC(=O)N2CCCC2)CC1	O=C(/C=C\c1cc(OC)c(OC)c(OC)c1)N1CCN(CC(=O)N2CCCC2)CC1
NCGC00507865-01	O=C(C#CC)N1C[C@H](N2C(=O)N(c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CC1		Inactive	BTK Inhibitor		1	ONO-4059 (GS-4059)	384569340.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C#CC)N1C[C@H](N2C(=O)N(c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CC1	O=C(C#CC)N1C[C@H](N2C(=O)N(c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CC1
NCGC00479074-01	O=C(C#CC)N1[C@H](c2n3c(c(-c4ccc(C(=O)Nc5ncccc5)cc4)n2)C(N)=NC=C3)CCC1		Inactive	BTK Inhibitor		1	Acalabrutinib	363681103.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C#CC)N1[C@H](c2n3c(c(-c4ccc(C(=O)Nc5ncccc5)cc4)n2)C(N)=NC=C3)CCC1	O=C(C#CC)N1[C@H](c2n3c(c(-c4ccc(C(=O)Nc5ncccc5)cc4)n2)C(N)=NC=C3)CCC1
NCGC00346623-04	O=C(C(=O)c1c-2c(OC)cc[nH]c-2nc1)N1[C@H](C)CN(C(=O)c2ccccc2)CC1		Inactive	HIV Attachment Inhibitor		1	BMS-378806	384568863.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(C(=O)c1c-2c(OC)cc[nH]c-2nc1)N1[C@H](C)CN(C(=O)c2ccccc2)CC1	O=C(C(=O)c1c-2c(OC)cc[nH]c-2nc1)N1[C@H](C)CN(C(=O)c2ccccc2)CC1
NCGC00379018-02	O=C(C(=O)c1c2c(OC)cnc(-n3nc(C)nc3)c2[nH]c1)N1CCN(C(=O)c2ccccc2)CC1		Inactive	Human immunodeficiency virus 1 Inhibitor		1	BMS-626529	363678318.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	22.5969272439	O=C(C(=O)c1c2c(OC)cnc(-n3nc(C)nc3)c2[nH]c1)N1CCN(C(=O)c2ccccc2)CC1	O=C(C(=O)c1c2c(OC)cnc(-n3nc(C)nc3)c2[nH]c1)N1CCN(C(=O)c2ccccc2)CC1
NCGC00496921-02	O=C(C(C)(C)C)N1[C@H](c2ccccc2)CC=N1		Inactive	RIP1 kinase Inhibitor		1	GSK-963	384569298.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C(C)(C)C)N1[C@H](c2ccccc2)CC=N1	O=C(C(C)(C)C)N1[C@H](c2ccccc2)CC=N1
NCGC00016242-05	O=C(C(C)(C)c1cnccc1)c1cnccc1		Inactive	Cytochrome P450 11B1 Inhibitor		1	Metyrapone	170465268.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C(C)(C)c1cnccc1)c1cnccc1	O=C(C(C)(C)c1cnccc1)c1cnccc1
NCGC00015542-07	O=C(C(C)C)c1c(C(C)C)nn2c1C=CC=C2		Inactive	Phosphodiesterase 4A Inhibitor		1	Ibudilast	170466049.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(C(C)C)c1c(C(C)C)nn2c1C=CC=C2	O=C(C(C)C)c1c(C(C)C)nn2c1C=CC=C2
NCGC00249911-01	O=C(C(CCN(C)C)(c1ccccc1)c1ccccc1)CC		Inactive	Mu-type opioid receptor Agonist		1	Normethadone	170465674.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C(CCN(C)C)(c1ccccc1)c1ccccc1)CC	O=C(C(CCN(C)C)(c1ccccc1)c1ccccc1)CC
NCGC00378905-04	O=C(C(CCc1ncccc1)(CCc1ncccc1)C)c1ccccc1		Inactive			1	NSC 42834	377020184.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C(CCc1ncccc1)(CCc1ncccc1)C)c1ccccc1	O=C(C(CCc1ncccc1)(CCc1ncccc1)C)c1ccccc1
NCGC00178060-03	O=C(C(CN1CCCCC1)C)c1ccc(C)cc1		Inactive	Voltage-gated calcium channel Inhibitor		1	Tolperisone hydrochloride	170465769.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(C(CN1CCCCC1)C)c1ccc(C)cc1.Cl	O=C(C(CN1CCCCC1)C)c1ccc(C)cc1.Cl
NCGC00167973-02	O=C(C(CN1CCCCC1)C)c1ccc(CC)cc1		Inactive	skeletal muscle contraction Inhibitor		1	Eperisone hydrochloride	170465796.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C(CN1CCCCC1)C)c1ccc(CC)cc1.Cl	O=C(C(CN1CCCCC1)C)c1ccc(CC)cc1.Cl
NCGC00167445-02	O=C(C(CN1CCN(CC(OCC)c2ccccc2)CC1)C)c1ccccc1		Inactive	Neurokinin 1 receptor Antagonist		1	Eprazinone dihydrochloride	170465851.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C(CN1CCN(CC(OCC)c2ccccc2)CC1)C)c1ccccc1.Cl.Cl	O=C(C(CN1CCN(CC(OCC)c2ccccc2)CC1)C)c1ccccc1.Cl.Cl
NCGC00166322-02	O=C(C(NC(=O)C1NC(=O)CC1)Cc1[nH]cnc1)N1C(C(=O)N)CCC1		Inactive	Thyrotropin-releasing hormone receptor Agonist		1	PROTIRELIN	405558504.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C(NC(=O)C1NC(=O)CC1)Cc1[nH]cnc1)N1C(C(=O)N)CCC1	O=C(C(NC(=O)C1NC(=O)CC1)Cc1[nH]cnc1)N1C(C(=O)N)CCC1
NCGC00168819-02	O=C(C(NC(=O)c1ccc(O)cc1)C(C)C)N1C(C(=O)Nc2c(O)cccc2C(=O)O)CCC1		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00168819-02	363676695.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C(NC(=O)c1ccc(O)cc1)C(C)C)N1C(C(=O)Nc2c(O)cccc2C(=O)O)CCC1	O=C(C(NC(=O)c1ccc(O)cc1)C(C)C)N1C(C(=O)Nc2c(O)cccc2C(=O)O)CCC1
NCGC00380159-01	O=C(C(O)(C)C1C2(C)C(C3C(C4(C)C(O)CC(O)CC4=CC3)C(O)C2)CC1O)C1C(COC2C(O)C(O)C(O)C(CO)O2)(CO)C1		Inactive	<MOA Unknown> | Class: Steroide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380159-01	363678480.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C(O)(C)C1C2(C)C(C3C(C4(C)C(O)CC(O)CC4=CC3)C(O)C2)CC1O)C1C(COC2C(O)C(O)C(O)C(CO)O2)(CO)C1	O=C(C(O)(C)C1C2(C)C(C3C(C4(C)C(O)CC(O)CC4=CC3)C(O)C2)CC1O)C1C(COC2C(O)C(O)C(O)C(CO)O2)(CO)C1
NCGC00386610-01	O=C(C(O)(c1ccccc1)C1CCC1)CCC#CCN(C)C		Inactive	Muscarinic acetylcholine receptor M3 Antagonist		1	MDL 201012	363680354.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C(O)(c1ccccc1)C1CCC1)CCC#CCN(C)C	O=C(C(O)(c1ccccc1)C1CCC1)CCC#CCN(C)C
NCGC00381203-01	O=C(C(O)CO)CCCCCC1C(=O)NC(Cc2ccccc2)C(=O)NC(C(CC)C)C(=O)N2C(C(=O)N1)CCCC2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381203-01	363679019.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C(O)CO)CCCCCC1C(=O)NC(Cc2ccccc2)C(=O)NC(C(CC)C)C(=O)N2C(C(=O)N1)CCCC2	O=C(C(O)CO)CCCCCC1C(=O)NC(Cc2ccccc2)C(=O)NC(C(CC)C)C(=O)N2C(C(=O)N1)CCCC2
NCGC00091396-05	O=C(C(O)c1ccccc1)c1ccccc1		Inactive			1	Benzoin	170465507.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C(O)c1ccccc1)c1ccccc1	O=C(C(O)c1ccccc1)c1ccccc1
NCGC00389790-01	O=C(C(c1ccccc1)c1ccccc1)N1C(C(=O)O)Cc2n(Cc3cc(C)c(N(C)C)cc3)cnc2C1		Inactive	Angiotensin II type 2 (AT-2) receptor Antagonist		1	PD123319	363680853.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C(c1ccccc1)c1ccccc1)N1C(C(=O)O)Cc2n(Cc3cc(C)c(N(C)C)cc3)cnc2C1	O=C(C(c1ccccc1)c1ccccc1)N1C(C(=O)O)Cc2n(Cc3cc(C)c(N(C)C)cc3)cnc2C1
NCGC00378575-03	O=C(C(c1ccccc1)c1ccccc1)N1CCN(CC(O)COc2c3c(nccc3)ccc2)CC1		Inactive	MRP-1 Inhibitor		1	Dofequidar	384569050.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C(c1ccccc1)c1ccccc1)N1CCN(CC(O)COc2c3c(nccc3)ccc2)CC1	O=C(C(c1ccccc1)c1ccccc1)N1CCN(CC(O)COc2c3c(nccc3)ccc2)CC1
MLS002707279-02	O=C(C)C1(C)C2(C)C(C3C=C(C)C=4C(C)(C3CC2)CCC(=O)C=4)CC1		Inactive			1	MLS002707279-02	363676431.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	20.8655536001	O=C(C)C1(C)C2(C)C(C3C=C(C)C=4C(C)(C3CC2)CCC(=O)C=4)CC1	O=C(C)C1(C)C2(C)C(C3C=C(C)C=4C(C)(C3CC2)CCC(=O)C=4)CC1
NCGC00168879-02	O=C(C)C1=C(O)C(C(CC)C)NC1=O		Inactive	<MOA Unknown> | Class: polyketide/AS; Alkaloid | Genus: ct: Alternaria | Family: N/A | Species: N/A		1	NCGC00168879-02	363676711.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)C1=C(O)C(C(CC)C)NC1=O	O=C(C)C1=C(O)C(C(CC)C)NC1=O
NCGC00385554-01	O=C(C)C1C2(C)C(C)(C3=C(C4(C)C(C(C)(C)C(=O)CC4)CC3)CC2)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385554-01	363679805.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)C1C2(C)C(C)(C3=C(C4(C)C(C(C)(C)C(=O)CC4)CC3)CC2)CC1	O=C(C)C1C2(C)C(C)(C3=C(C4(C)C(C(C)(C)C(=O)CC4)CC3)CC2)CC1
NCGC00015785-10	O=C(C)C1C2(C)C(C3C(C4(C)C(=CC(=O)CC4)CC3)CC2)CC1		Inactive	Progestogen hormone		1	Progesterone	384567890.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	20.603648424	O=C(C)C1C2(C)C(C3C(C4(C)C(=CC(=O)CC4)CC3)CC2)CC1	O=C(C)C1C2(C)C(C3C(C4(C)C(=CC(=O)CC4)CC3)CC2)CC1
NCGC00485038-01	O=C(C)C1C2(C)C(C3C(C4(C)C(C[C@@H](O)CC4)CC3)CC2)CC1		Inactive	Gamma-aminobutyric acid receptor subunit gamma-2 Negative Allosteric Modulator		1	5Î²-Pregnan-3Î±-ol-20-one	363681201.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)C1C2(C)C(C3C(C4(C)C(C[C@@H](O)CC4)CC3)CC2)CC1	O=C(C)C1C2(C)C(C3C(C4(C)C(C[C@@H](O)CC4)CC3)CC2)CC1
NCGC00381395-01	O=C(C)C1N(Cc2ccccc2)C(=O)CC1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381395-01	363679124.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)C1N(Cc2ccccc2)C(=O)CC1	O=C(C)C1N(Cc2ccccc2)C(=O)CC1
NCGC00263129-08&NCGC00263129-31	O=C(C)C=1C(=O)N(C2CCCC2)c2nc(Nc3ncc(N4CCNCC4)cc3)ncc2C=1C		Inactive	CDK4/6 Inhibitor		2	Palbociclib	405558929.0&384568610.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&15.875515508	O=C(C)C=1C(=O)N(C2CCCC2)c2nc(Nc3ncc(N4CCNCC4)cc3)ncc2C=1C	O=C(C)C=1C(=O)N(C2CCCC2)c2nc(Nc3ncc(N4CCNCC4)cc3)ncc2C=1C
NCGC00384853-01	O=C(C)C=1C2(C)C(C3C(C4(C)C(CC(O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](CO)O5)CC4)CC3)CC2)CC=1		Inactive	<MOA Unknown> | Class: Steroide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384853-01	363679398.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)C=1C2(C)C(C3C(C4(C)C(CC(O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](CO)O5)CC4)CC3)CC2)CC=1	O=C(C)C=1C2(C)C(C3C(C4(C)C(CC(O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](CO)O5)CC4)CC3)CC2)CC=1
NCGC00380953-01	O=C(C)C=1C2(C)C(C3C(C4(C)C(O)CC(O)CC4=CC3)C(O)C2)CC=1		Inactive	<MOA Unknown> | Class: Steroide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380953-01	363678882.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)C=1C2(C)C(C3C(C4(C)C(O)CC(O)CC4=CC3)C(O)C2)CC=1	O=C(C)C=1C2(C)C(C3C(C4(C)C(O)CC(O)CC4=CC3)C(O)C2)CC=1
NCGC00347814-02	O=C(C)N1C(Cc2ccc(O)cc2)c2c(OC3C(O)C(O)C(O)C(COC4C(O)C(O)(CO)CO4)O3)c(O)ccc2CC1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347814-02	363677696.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)N1C(Cc2ccc(O)cc2)c2c(OC3C(O)C(O)C(O)C(COC4C(O)C(O)(CO)CO4)O3)c(O)ccc2CC1	O=C(C)N1C(Cc2ccc(O)cc2)c2c(OC3C(O)C(O)C(O)C(COC4C(O)C(O)(CO)CO4)O3)c(O)ccc2CC1
NCGC00510264-02	O=C(C)N1CCC(Nc2ncnc(C(=O)NC[C@H](O)CN3Cc4c(cccc4)CC3)c2)CC1		Inactive	PRMT5 Inhibitor		1	GSK-3326595	384569422.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C)N1CCC(Nc2ncnc(C(=O)NC[C@H](O)CN3Cc4c(cccc4)CC3)c2)CC1	O=C(C)N1CCC(Nc2ncnc(C(=O)NC[C@H](O)CN3Cc4c(cccc4)CC3)c2)CC1
NCGC00346955-02	O=C(C)N1CCN(C2CCC(n3nc(-c4cc(OC)c(NC(=O)c5n(C)c6c(c5)cccc6)cc4)c4c(N)ncnc34)CC2)CC1		Inactive	Lck Kinase Inhibitor		1	A-770041	384568976.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C)N1CCN(C2CCC(n3nc(-c4cc(OC)c(NC(=O)c5n(C)c6c(c5)cccc6)cc4)c4c(N)ncnc34)CC2)CC1	O=C(C)N1CCN(C2CCC(n3nc(-c4cc(OC)c(NC(=O)c5n(C)c6c(c5)cccc6)cc4)c4c(N)ncnc34)CC2)CC1
NCGC00378582-01	O=C(C)N1CCN(Cc2ccc([C@@H](Nc3nc(N4[C@@H](C(C)C)COC4=O)ccn3)C)cc2)CC1		Inactive	Isocitrate dehydrogenase [NADP] cytoplasmic Inhibitor		1	Mutant IDH1 inhibitor	363678099.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)N1CCN(Cc2ccc([C@@H](Nc3nc(N4[C@@H](C(C)C)COC4=O)ccn3)C)cc2)CC1	O=C(C)N1CCN(Cc2ccc([C@@H](Nc3nc(N4[C@@H](C(C)C)COC4=O)ccn3)C)cc2)CC1
NCGC00387224-01	O=C(C)N1[C@H](C)Cc2c(C(c3ccc(N)cc3)=N1)cc1OCOc1c2		Inactive	Kainate Receptor Antagonist		1	Ampanel	363680579.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C)N1[C@H](C)Cc2c(C(c3ccc(N)cc3)=N1)cc1OCOc1c2	O=C(C)N1[C@H](C)Cc2c(C(c3ccc(N)cc3)=N1)cc1OCOc1c2
NCGC00169097-03	O=C(C)N1[C@H](C[C@H]2[C@@H](C=C)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C2C(=O)OC)c2c(cc(O)c(O)c2)CC1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Cephaelis | Family: N/A | Species: ipecacuanha		1	NCGC00169097-03	363676772.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)N1[C@H](C[C@H]2[C@@H](C=C)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C2C(=O)OC)c2c(cc(O)c(O)c2)CC1	O=C(C)N1[C@H](C[C@H]2[C@@H](C=C)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C2C(=O)OC)c2c(cc(O)c(O)c2)CC1
NCGC00380403-01	O=C(C)N1c2c(C3(O)C1N1C(=O)C(CC(C)C)NC(=O)C1C3)cccc2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380403-01	363678570.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)N1c2c(C3(O)C1N1C(=O)C(CC(C)C)NC(=O)C1C3)cccc2	O=C(C)N1c2c(C3(O)C1N1C(=O)C(CC(C)C)NC(=O)C1C3)cccc2
NCGC00169052-03	O=C(C)[C@@H]1C(=O)O[C@@]2(C)C(=O)C=C3C([C@@H]12)=COC(/C=C/C(=C/[C@H](CC)C)/C)=C3		Inactive	<MOA Unknown> | Class: polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169052-03	363676753.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)[C@@H]1C(=O)O[C@@]2(C)C(=O)C=C3C([C@@H]12)=COC(/C=C/C(=C/[C@H](CC)C)/C)=C3	O=C(C)[C@@H]1C(=O)O[C@@]2(C)C(=O)C=C3C([C@@H]12)=COC(/C=C/C(=C/[C@H](CC)C)/C)=C3
NCGC00380562-01	O=C(C)[C@@H]1[C@@]2(C)[C@H](O)C(O)C3[C@]4(C)C(=CCC3[C@@]2(O)CC1)C[C@@H](OC1OC(C)C(OC2OC(C)C(OC3C(O)C(O)C(O)C(C)O3)C(OC)C2)C(OC)C1)CC4		Inactive	<MOA Unknown> | Class: Steroid | Genus: Salicornia | Family: Chenopodiaceae | Species: brachiata		1	NCGC00380562-01	363678652.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)[C@@H]1[C@@]2(C)[C@H](O)C(O)C3[C@]4(C)C(=CCC3[C@@]2(O)CC1)C[C@@H](OC1OC(C)C(OC2OC(C)C(OC3C(O)C(O)C(O)C(C)O3)C(OC)C2)C(OC)C1)CC4	O=C(C)[C@@H]1[C@@]2(C)[C@H](O)C(O)C3[C@]4(C)C(=CCC3[C@@]2(O)CC1)C[C@@H](OC1OC(C)C(OC2OC(C)C(OC3C(O)C(O)C(O)C(C)O3)C(OC)C2)C(OC)C1)CC4
NCGC00389959-01	O=C(C)[C@@H]1[C@]2(C)C(C3C([C@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1		Inactive			1	11-alpha-HYDROXYPROGESTERONE	377020240.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)[C@@H]1[C@]2(C)C(C3C([C@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1	O=C(C)[C@@H]1[C@]2(C)C(C3C([C@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1
NCGC00022185-14	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1		Inactive	Progestogen hormone		1	Progesterone	405559122.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	23.2179766079	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1
NCGC00163125-06&NCGC00163125-13	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1		Inactive	Steroid		2	Pregnenolone	170465558.0&384568230.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&13.5	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1
NCGC00179460-03	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)CC2)CC1		Inactive	Glucocorticoid receptor Agonist		1	Medrysone	170465194.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)CC2)CC1	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)CC2)CC1
NCGC00179445-03	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@H]([C@@]4(C)C(=CC(=O)CC4)C=C3)CC2)CC1		Inactive	signaling/transport		1	Dydrogesterone	170465104.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@H]([C@@]4(C)C(=CC(=O)CC4)C=C3)CC2)CC1	O=C(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@H]([C@@]4(C)C(=CC(=O)CC4)C=C3)CC2)CC1
NCGC00390270-02	O=C(C)[C@@]1(N)C[C@H](O[C@@H]2OC[C@@H](O)[C@@H](O)C2)c2c(O)c3C(=O)c4c(C(=O)c3c(O)c2C1)cccc4		Inactive	DNA Topoisomerase II Inhibitor		1	Amrubicin	384569184.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C)[C@@]1(N)C[C@H](O[C@@H]2OC[C@@H](O)[C@@H](O)C2)c2c(O)c3C(=O)c4c(C(=O)c3c(O)c2C1)cccc4	O=C(C)[C@@]1(N)C[C@H](O[C@@H]2OC[C@@H](O)[C@@H](O)C2)c2c(O)c3C(=O)c4c(C(=O)c3c(O)c2C1)cccc4
NCGC00093976-08&NCGC00093976-15	O=C(C)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(C(=O)c3c(O)c2C1)cccc4		Inactive	DNA Topoisomerase II Inhibitor		2	Idarubicin hydrochloride	170464627.0&384568121.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O=C(C)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(C(=O)c3c(O)c2C1)cccc4.Cl	O=C(C)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(C(=O)c3c(O)c2C1)cccc4.Cl&O=C(C)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(C(=O)c3c(O)c2C1)cccc4
NCGC00024246-15&NCGC00024246-16&NCGC00024246-18	O=C(C)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1		Inactive	DNA Topoisomerase II Inhibitor		3	Daunorubicin	170465048.0&384568022.0&434146881.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0		O=C(C)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1	O=C(C)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1
NCGC00169592-02	O=C(C)[C@H]1C2[C@](C(=O)O)(CC1)CC[C@@]1(C)[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)CC4)CC3)CCC21		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Callistemon | Family: Myrtaceae | Species: lanceolatus		1	NCGC00169592-02	363676845.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)[C@H]1C2[C@](C(=O)O)(CC1)CC[C@@]1(C)[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)CC4)CC3)CCC21	O=C(C)[C@H]1C2[C@](C(=O)O)(CC1)CC[C@@]1(C)[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)CC4)CC3)CCC21
NCGC00384849-01	O=C(C)[C@H]1[C@H]2[C@](CO)(OC(=O)C2)CC[C@@H](C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)(C)C)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384849-01	363679394.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)[C@H]1[C@H]2[C@](CO)(OC(=O)C2)CC[C@@H](C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)(C)C)C1	O=C(C)[C@H]1[C@H]2[C@](CO)(OC(=O)C2)CC[C@@H](C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)(C)C)C1
NCGC00510144-01	O=C(C)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1		Inactive			1	Gestonorone	405558510.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1	O=C(C)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1
NCGC00023064-05	O=C(C)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C([C@@H](C)C3)=CC(=O)CC4)CC2)CC1		Inactive			1	Medroxyprogesterone	170466063.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C([C@@H](C)C3)=CC(=O)CC4)CC2)CC1	O=C(C)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C([C@@H](C)C3)=CC(=O)CC4)CC2)CC1
NCGC00380695-01	O=C(C)c1c(C)c2C(=O)CC(O)Cc2cc1O		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380695-01	363678714.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)c1c(C)c2C(=O)CC(O)Cc2cc1O	O=C(C)c1c(C)c2C(=O)CC(O)Cc2cc1O
NCGC00017388-08	O=C(C)c1c(O)c(C)c(O)c2[C@]3(C)C(O)=C(C(=O)C)C(=O)C=C3Oc12		Inactive			1	(+)-Usniacin	434147230.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C)c1c(O)c(C)c(O)c2[C@]3(C)C(O)=C(C(=O)C)C(=O)C=C3Oc12	O=C(C)c1c(O)c(C)c(O)c2[C@]3(C)C(O)=C(C(=O)C)C(=O)C=C3Oc12
NCGC00347404-02	O=C(C)c1c(O)cc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347404-02	363677593.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)c1c(O)cc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1C	O=C(C)c1c(O)cc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1C
NCGC00169534-02	O=C(C)c1c(O)cc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1O		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Juglans | Family: Juglandaceae | Species: regia		1	NCGC00169534-02	363676838.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)c1c(O)cc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1O	O=C(C)c1c(O)cc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1O
NCGC00095249-04	O=C(C)c1c(O)cc2OC(C)(C)C=Cc2c1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: Eupatorium | Family: N/A | Species: ssp.		1	EUPATORIOCHROMENE	363676575.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)c1c(O)cc2OC(C)(C)C=Cc2c1	O=C(C)c1c(O)cc2OC(C)(C)C=Cc2c1
NCGC00381142-01	O=C(C)c1c(O)cc2c3c(OC(O)(C)Cc13)ccc2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381142-01	363678991.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)c1c(O)cc2c3c(OC(O)(C)Cc13)ccc2	O=C(C)c1c(O)cc2c3c(OC(O)(C)Cc13)ccc2
NCGC00385874-01	O=C(C)c1c(OC)c2c(c(OC)c1)OC(C)(C)C=C2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385874-01	363679982.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)c1c(OC)c2c(c(OC)c1)OC(C)(C)C=C2	O=C(C)c1c(OC)c2c(c(OC)c1)OC(C)(C)C=C2
NCGC00385029-01	O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c(O)cccc2cc1C		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Rhamnus | Family: Rhamnaceae | Species: prinoides		1	NCGC00385029-01	363679493.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c(O)cccc2cc1C	O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c(O)cccc2cc1C
NCGC00381092-01	O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)cc1C		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381092-01	363678966.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)cc1C	O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)cc1C
NCGC00381090-01	O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381090-01	363678964.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1C	O=C(C)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1C
NCGC00380366-01	O=C(C)c1cc(O)c(O[C@H]2[C@H](O[C@@]3(CO)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](O)CO2)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Coutarea | Family: Rubiaceae | Species: hexandra		1	NCGC00380366-01	363678554.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)c1cc(O)c(O[C@H]2[C@H](O[C@@]3(CO)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](O)CO2)cc1	O=C(C)c1cc(O)c(O[C@H]2[C@H](O[C@@]3(CO)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](O)CO2)cc1
NCGC00169712-02	O=C(C)c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169712-02	363676872.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1	O=C(C)c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1
NCGC00384614-01	O=C(C)c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)O2)cc1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384614-01	363679272.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	-11.5341841439	O=C(C)c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)O2)cc1	O=C(C)c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)O2)cc1
NCGC00380994-01	O=C(C)c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)O2)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Dictamnus | Family: N/A | Species: dasycarpus		1	NCGC00380994-01	363678910.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)O2)cc1	O=C(C)c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)O2)cc1
NCGC00380688-01	O=C(C)c1cc2C(O)C(C(O)(C)C)Oc2cc1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380688-01	363678710.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)c1cc2C(O)C(C(O)(C)C)Oc2cc1	O=C(C)c1cc2C(O)C(C(O)(C)C)Oc2cc1
NCGC00016634-04	O=C(C)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3	4.9000001	Active		0.0	1	Acetopromazine maleate	170465731.0	2019_NPC-3.2	SARS-CoV-2_CPE_SRI	3.0	105.40061253	O=C(O)/C=C\C(=O)O.O=C(C)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3	O=C(O)/C=C\C(=O)O.O=C(C)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3
NCGC00016642-04	O=C(C)c1cc2N(CCCN3CCC(CCO)CC3)c3c(Sc2cc1)cccc3	4.9000001	Active		0.0	1	Piperacetazine	170465363.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	118.9024985566	O=C(C)c1cc2N(CCCN3CCC(CCO)CC3)c3c(Sc2cc1)cccc3	O=C(C)c1cc2N(CCCN3CCC(CCO)CC3)c3c(Sc2cc1)cccc3
NCGC00181120-02	O=C(C)c1cc2N(CCCN3CCN(CCO)CC3)c3c(Sc2cc1)cccc3		Inactive	Sigma opioid receptor Antagonist		1	Acetophenazine Maleate	405558986.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C)c1cc2N(CCCN3CCN(CCO)CC3)c3c(Sc2cc1)cccc3	O=C(C)c1cc2N(CCCN3CCN(CCO)CC3)c3c(Sc2cc1)cccc3
NCGC00385179-01	O=C(C)c1cc2c(OC(C(CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@H](O)[C@@](O)(CO)CO4)O3)=C)C2)cc1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385179-01	363679580.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)c1cc2c(OC(C(CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@H](O)[C@@](O)(CO)CO4)O3)=C)C2)cc1	O=C(C)c1cc2c(OC(C(CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@H](O)[C@@](O)(CO)CO4)O3)=C)C2)cc1
NCGC00509937-01	O=C(C)c1cc2c(n(CCNC(C)C)c3c2cc(C(=O)C)cc3)cc1		Inactive	NF-kappaB Activation Inhibitor		1	CBL-0137	384569386.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	20.235967668	O=C(C)c1cc2c(n(CCNC(C)C)c3c2cc(C(=O)C)cc3)cc1	O=C(C)c1cc2c(n(CCNC(C)C)c3c2cc(C(=O)C)cc3)cc1
NCGC00247461-02	O=C(C)c1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1		Inactive	triglyceride metabolic process Modulator		1	NCGC00247461-02	363677159.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)c1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1	O=C(C)c1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1
NCGC00380492-01	O=C(C)c1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)O2)cc1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Arthemisia | Family: Compositae | Species: erithmifolia		1	NCGC00380492-01	363678607.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C)c1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)O2)cc1	O=C(C)c1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)O2)cc1
NCGC00390475-03	O=C(C)c1oc2C(=O)c3c(C(=O)c2c1)cccc3		Inactive	STAT-3 Inhibitor		1	Napabucasin	384569185.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	30.582524268	O=C(C)c1oc2C(=O)c3c(C(=O)c2c1)cccc3	O=C(C)c1oc2C(=O)c3c(C(=O)c2c1)cccc3
NCGC00522022-01	O=C(C)c1oc2c(OCC(O)CNC(C)C)cccc2c1		Inactive	Adrenergic receptor beta Antagonist		1	Befunolol	405558805.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C)c1oc2c(OCC(O)CNC(C)C)cccc2c1	O=C(C)c1oc2c(OCC(O)CNC(C)C)cccc2c1
NCGC00385405-01	O=C(C=1C(=O)C(/C=C/C=C/CC)(C)OC=1OC)C1C(O)(C)c2c(O)c(O)c(OC)cc2C(=O)C1C		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385405-01	363679725.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C=1C(=O)C(/C=C/C=C/CC)(C)OC=1OC)C1C(O)(C)c2c(O)c(O)c(OC)cc2C(=O)C1C	O=C(C=1C(=O)C(/C=C/C=C/CC)(C)OC=1OC)C1C(O)(C)c2c(O)c(O)c(OC)cc2C(=O)C1C
NCGC00384969-01	O=C(C=1C(=O)N(C)[C@H](CO)C=1O)[C@]1(C)[C@H](/C=C/C)C=C[C@H]2[C@H]1CC[C@@H](C)C2		Inactive	<MOA Unknown> | Class: alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384969-01	363679460.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C=1C(=O)N(C)[C@H](CO)C=1O)[C@]1(C)[C@H](/C=C/C)C=C[C@H]2[C@H]1CC[C@@H](C)C2	O=C(C=1C(=O)N(C)[C@H](CO)C=1O)[C@]1(C)[C@H](/C=C/C)C=C[C@H]2[C@H]1CC[C@@H](C)C2
NCGC00510501-01	O=C(C=C)N1CCC(C2n3nc(c(C(=O)N)c3NCC2)-c2ccc(Oc3ccccc3)cc2)CC1		Inactive	BTK Inhibitor		1	BGB-3111	384569462.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C=C)N1CCC(C2n3nc(c(C(=O)N)c3NCC2)-c2ccc(Oc3ccccc3)cc2)CC1	O=C(C=C)N1CCC(C2n3nc(c(C(=O)N)c3NCC2)-c2ccc(Oc3ccccc3)cc2)CC1
NCGC00510507-01	O=C(C=C)N1CCC(CNc2c(c(N)ncn2)-c2ccc(Oc3ccccc3)cc2)CC1		Inactive	BTK Inhibitor		1	Evobrutinib	384569468.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C=C)N1CCC(CNc2c(c(N)ncn2)-c2ccc(Oc3ccccc3)cc2)CC1	O=C(C=C)N1CCC(CNc2c(c(N)ncn2)-c2ccc(Oc3ccccc3)cc2)CC1
NCGC00480771-01	O=C(C=C)N1C[C@@H](N2C(=O)N(c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1		Inactive	BTK Inhibitor		1	ONO-4059 analog	384569241.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C=C)N1C[C@@H](N2C(=O)N(c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1	O=C(C=C)N1C[C@@H](N2C(=O)N(c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1
NCGC00507838-01	O=C(C=C)N1C[C@H](Oc2c(CC)nc(C(=O)N)c(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)n2)CC1		Inactive	EGFR (Thr790Met Mutant) Inhibitor		1	Naquotinib mesylate	384569321.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C=C)N1C[C@H](Oc2c(CC)nc(C(=O)N)c(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)n2)CC1	O=C(C=C)N1C[C@H](Oc2c(CC)nc(C(=O)N)c(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)n2)CC1
NCGC00379184-02	O=C(C=C)N1C[C@H](n2nc(-c3cc(C(=O)Nc4cc(C)c(C(C)C)cc4)ccc3)c3c(N)ncnc23)CCC1		Inactive	Tyrosine-protein kinase ITK/TSK  Inhibitor		1	PF 06465469	363678405.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C=C)N1C[C@H](n2nc(-c3cc(C(=O)Nc4cc(C)c(C(C)C)cc4)ccc3)c3c(N)ncnc23)CCC1	O=C(C=C)N1C[C@H](n2nc(-c3cc(C(=O)Nc4cc(C)c(C(C)C)cc4)ccc3)c3c(N)ncnc23)CCC1
NCGC00187912-13&NCGC00187912-17	O=C(C=C)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1		Inactive	BTK Inhibitor		2	Ibrutinib (PCI-32765)	384568446.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(C=C)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1	O=C(C=C)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1
NCGC00501213-01	O=C(C=C)N1[C@@H](C)CC[C@@H](Nc2ncnc3[nH]ccc23)C1		Inactive	Jak3		1	PF-06651600	384569312.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(C=C)N1[C@@H](C)CC[C@@H](Nc2ncnc3[nH]ccc23)C1	O=C(C=C)N1[C@@H](C)CC[C@@H](Nc2ncnc3[nH]ccc23)C1
NCGC00092279-03	O=C(C=C)c1cc2c(cc1)cccc2		Inactive			1	ZM 449829	377020274.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C=C)c1cc2c(cc1)cccc2	O=C(C=C)c1cc2c(cc1)cccc2
NCGC00385291-01	O=C(C=C=C1C(O)(C)CC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC1(C)C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385291-01	363679650.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C=C=C1C(O)(C)CC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC1(C)C)C	O=C(C=C=C1C(O)(C)CC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CC1(C)C)C
NCGC00386033-01	O=C(C=C=C1C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3[C@H](O)[C@@](O)(CO)CO3)O2)(C)CC(O)CC1(C)C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386033-01	363680071.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C=C=C1C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3[C@H](O)[C@@](O)(CO)CO3)O2)(C)CC(O)CC1(C)C)C	O=C(C=C=C1C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]3[C@H](O)[C@@](O)(CO)CO3)O2)(C)CC(O)CC1(C)C)C
NCGC00229511-10&NCGC00229511-21&NCGC00229511-27	O=C(CC#N)N1C[C@H](N(C)c2ncnc3[nH]ccc23)[C@H](C)CC1		Inactive	Jak1/2/3 Inhibitor		3	Tofacitinib	405558458.0&384568461.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	O=C(CC#N)N1C[C@H](N(C)c2ncnc3[nH]ccc23)[C@H](C)CC1	O=C(CC#N)N1C[C@H](N(C)c2ncnc3[nH]ccc23)[C@H](C)CC1
NCGC00095112-05&NCGC00095112-07	O=C(CC(=O)c1ccc(C(C)(C)C)cc1)c1ccc(OC)cc1		Inactive	UVA ray absorber		2	Avobenzone	170464749.0&384568146.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(CC(=O)c1ccc(C(C)(C)C)cc1)c1ccc(OC)cc1	O=C(CC(=O)c1ccc(C(C)(C)C)cc1)c1ccc(OC)cc1
NCGC00380985-01	O=C(CC(C)C)N1C(C(O)c2ccccc2)=CC(=O)C(C(=O)N)=C1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380985-01	363678904.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CC(C)C)N1C(C(O)c2ccccc2)=CC(=O)C(C(=O)N)=C1	O=C(CC(C)C)N1C(C(O)c2ccccc2)=CC(=O)C(C(=O)N)=C1
NCGC00347528-02	O=C(CC(C)C)c1c(O)c2C(CC(C)C)C=3C(=O)C(C)(C)C(=O)C(C)(C)C=3Oc2cc1O		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	Rhodomyrtone A	363677614.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	23.2659574439	O=C(CC(C)C)c1c(O)c2C(CC(C)C)C=3C(=O)C(C)(C)C(=O)C(C)(C)C=3Oc2cc1O	O=C(CC(C)C)c1c(O)c2C(CC(C)C)C=3C(=O)C(C)(C)C(=O)C(C)(C)C=3Oc2cc1O
NCGC00385480-01	O=C(CC(O)/C=C/C)C1=C2C3(C)C4(O)C5(C)OC6(O)C(C)(C(=O)C(=C(/C=C/C=C/C)O2)C3C6(C)O4)C15		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385480-01	363679764.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CC(O)/C=C/C)C1=C2C3(C)C4(O)C5(C)OC6(O)C(C)(C(=O)C(=C(/C=C/C=C/C)O2)C3C6(C)O4)C15	O=C(CC(O)/C=C/C)C1=C2C3(C)C4(O)C5(C)OC6(O)C(C)(C(=O)C(=C(/C=C/C=C/C)O2)C3C6(C)O4)C15
NCGC00381091-01	O=C(CC(OC)CCc1ccc(O)cc1)CCc1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Solanum | Family: Solanaceae | Species: sp.		1	NCGC00381091-01	363678965.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CC(OC)CCc1ccc(O)cc1)CCc1ccc(O)cc1	O=C(CC(OC)CCc1ccc(O)cc1)CCc1ccc(O)cc1
NCGC00094810-08	O=C(CC(c1ccccc1)C=1C(=O)Oc2c(C=1O)cccc2)C		Inactive	Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitor		1	Warfarin sodium	384568136.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(CC(c1ccccc1)C=1C(=O)Oc2c(C=1O)cccc2)C	O=C(CC(c1ccccc1)C=1C(=O)Oc2c(C=1O)cccc2)C
NCGC00094810-04	O=C(CC(c1ccccc1)C=1C(=O)Oc2c(C=1[O-])cccc2)C		Inactive	Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitor		1	Warfarin sodium	170464790.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(CC(c1ccccc1)C=1C(=O)Oc2c(C=1[O-])cccc2)C.[K+]	O=C(CC(c1ccccc1)C=1C(=O)Oc2c(C=1[O-])cccc2)C.[K+]
NCGC00378879-01	O=C(CC(c1ccccc1)c1ccccc1)N1CCN(C(c2ccccc2)c2ccccc2)CC1		Inactive	Voltage-gated N-type calcium channel alpha-1B subunit Blocker		1	NP118809	363678253.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CC(c1ccccc1)c1ccccc1)N1CCN(C(c2ccccc2)c2ccccc2)CC1	O=C(CC(c1ccccc1)c1ccccc1)N1CCN(C(c2ccccc2)c2ccccc2)CC1
NCGC00510508-01	O=C(CC)N1Cc2c(c(C(=O)N[C@@H]3CN(C)CCC3)cc(-c3cc(OC)cc(OC)c3)c2)OCC1		Inactive	CBP/p300 Inhibitor		1	TPOP-146	384569469.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	10.3442252399	O=C(CC)N1Cc2c(c(C(=O)N[C@@H]3CN(C)CCC3)cc(-c3cc(OC)cc(OC)c3)c2)OCC1	O=C(CC)N1Cc2c(c(C(=O)N[C@@H]3CN(C)CCC3)cc(-c3cc(OC)cc(OC)c3)c2)OCC1
NCGC00386755-03	O=C(CC)N1Cc2c(cc(OC)c(O)c2)CC1		Inactive	Cytochrome P450 2C9 Inhibitor		1	PTIQ	363680436.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CC)N1Cc2c(cc(OC)c(O)c2)CC1	O=C(CC)N1Cc2c(cc(OC)c(O)c2)CC1
NCGC00094817-05	O=C(CC)c1c(O)cc(O)cc1O		Inactive	Catechol O-methyltransferase Inhibitor		1	Flopropione	170465817.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(CC)c1c(O)cc(O)cc1O	O=C(CC)c1c(O)cc(O)cc1O
NCGC00015838-06	O=C(CC)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3	4.9000001	Active	Trypanothione reductase Inhibitor	0.0	1	Propionylpromazine hydrochloride	170466841.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	112.7996609618	O=C(CC)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3.Cl	O=C(CC)c1cc2N(CCCN(C)C)c3c(Sc2cc1)cccc3.Cl
NCGC00018097-06	O=C(CC)c1ccc(O)cc1		Inactive	Succinate semialdehyde dehydrogenase Inhibitor		1	Paroxypropione	170465896.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(CC)c1ccc(O)cc1	O=C(CC)c1ccc(O)cc1
NCGC00380637-01	O=C(CC/C=C/C)[C@@H]1[C@@H]([C@]2(C)C(O)=C(C)C(=O)O2)[C@@H]2[C@@](O)(C)C(=O)[C@@]1(C)C(O)=C2C(=O)/C=C/C=C/C		Inactive	<MOA Unknown> | Class: polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380637-01	363678685.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CC/C=C/C)[C@@H]1[C@@H]([C@]2(C)C(O)=C(C)C(=O)O2)[C@@H]2[C@@](O)(C)C(=O)[C@@]1(C)C(O)=C2C(=O)/C=C/C=C/C	O=C(CC/C=C/C)[C@@H]1[C@@H]([C@]2(C)C(O)=C(C)C(=O)O2)[C@@H]2[C@@](O)(C)C(=O)[C@@]1(C)C(O)=C2C(=O)/C=C/C=C/C
NCGC00508867-01	O=C(CC1=NC(=O)C=C(N2CCOCC2)N1)N1C(C)Cc2c1cccc2		Inactive	PI3Kbeta Inhibitor		1	SAR-260301	384569367.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.4235511719	O=C(CC1=NC(=O)C=C(N2CCOCC2)N1)N1C(C)Cc2c1cccc2	O=C(CC1=NC(=O)C=C(N2CCOCC2)N1)N1C(C)Cc2c1cccc2
NCGC00386065-01	O=C(CC1C(C(=O)OC)C2(C(=O)c3c(O)cc(C)cc3O2)C(O)C=C1)C		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386065-01	363680089.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CC1C(C(=O)OC)C2(C(=O)c3c(O)cc(C)cc3O2)C(O)C=C1)C	O=C(CC1C(C(=O)OC)C2(C(=O)c3c(O)cc(C)cc3O2)C(O)C=C1)C
NCGC00380910-01	O=C(CC1CC(=O)NC(=O)C1)c1c(O)c(CO)cc(C)c1		Inactive	<MOA Unknown> | Class: glutarimide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380910-01	363678849.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CC1CC(=O)NC(=O)C1)c1c(O)c(CO)cc(C)c1	O=C(CC1CC(=O)NC(=O)C1)c1c(O)c(CO)cc(C)c1
NCGC00015606-06	O=C(CC1N(C)C(CC(O)c2ccccc2)CCC1)c1ccccc1		Inactive	Synaptic vesicular amine transporter Inhibitor		1	LOBELINE HYDROCHLORIDE	405558910.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(CC1N(C)C(CC(O)c2ccccc2)CCC1)c1ccccc1	O=C(CC1N(C)C(CC(O)c2ccccc2)CCC1)c1ccccc1
NCGC00385308-01	O=C(CC=1C(=O)OCC=1)C1C(=C)CCC2C(CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)(C)C(O)CCC12C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385308-01	363679665.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CC=1C(=O)OCC=1)C1C(=C)CCC2C(CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)(C)C(O)CCC12C	O=C(CC=1C(=O)OCC=1)C1C(=C)CCC2C(CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)(C)C(O)CCC12C
NCGC00381164-01	O=C(CC=1C(=O)OCC=1)C1C(=C)CC[C@@H]2[C@@](CO)(C)C(OC3C(O)C(O)C(O)C(CO)O3)CC[C@@]12C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Andrographis | Family: Acanthaceae | Species: paniculata		1	NCGC00381164-01	363679003.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CC=1C(=O)OCC=1)C1C(=C)CC[C@@H]2[C@@](CO)(C)C(OC3C(O)C(O)C(O)C(CO)O3)CC[C@@]12C	O=C(CC=1C(=O)OCC=1)C1C(=C)CC[C@@H]2[C@@](CO)(C)C(OC3C(O)C(O)C(O)C(CO)O3)CC[C@@]12C
NCGC00180407-02	O=C(CC=1Oc2c(c(O)cc(C)c2C(=O)C=1)C1C(O)C(O)C(O)C(CO)O1)C		Inactive			1	NCGC00180407-02	434147054.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(CC=1Oc2c(c(O)cc(C)c2C(=O)C=1)C1C(O)C(O)C(O)C(CO)O1)C	O=C(CC=1Oc2c(c(O)cc(C)c2C(=O)C=1)C1C(O)C(O)C(O)C(CO)O1)C
NCGC00380213-01	O=C(CCC1=C(C)C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C(O)CC1(C)C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380213-01	363678500.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CCC1=C(C)C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C(O)CC1(C)C)C	O=C(CCC1=C(C)C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C(O)CC1(C)C)C
NCGC00510940-01	O=C(CCC1C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)C		Inactive	Cyclooxygenase Inhibitor		1	Kebuzone	405558634.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(CCC1C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)C	O=C(CCC1C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)C
NCGC00183005-01	O=C(CCC1CCN(Cc2ccccc2)CC1)c1cc2NCCCCc2cc1	4.9499998	Active	Acetylcholinesterase Inhibitor	0.0	1	Zanapezil fumerate	144206802.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	100.7720303677	O=C(O)/C=C/C(=O)O.O=C(CCC1CCN(Cc2ccccc2)CC1)c1cc2NCCCCc2cc1	O=C(O)/C=C/C(=O)O.O=C(CCC1CCN(Cc2ccccc2)CC1)c1cc2NCCCCc2cc1
NCGC00168921-03	O=C(CCC=1C(C)CC2OC(=O)C(=C)C2CC=1)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Xanthium | Family: Compositae | Species: strumarium		1	NCGC00168921-03	363676721.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CCC=1C(C)CC2OC(=O)C(=C)C2CC=1)C	O=C(CCC=1C(C)CC2OC(=O)C(=C)C2CC=1)C
NCGC00386004-01	O=C(CCC=1[C@H](C)C[C@@H]2OC(=O)[C@@]3(C(C(=O)C)=C[C@]4(O)[C@@H](C)C[C@H]5OC(=O)C(=C)[C@H]5CC4C3)[C@@H]2CC=1)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386004-01	363680051.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CCC=1[C@H](C)C[C@@H]2OC(=O)[C@@]3(C(C(=O)C)=C[C@]4(O)[C@@H](C)C[C@H]5OC(=O)C(=C)[C@H]5CC4C3)[C@@H]2CC=1)C	O=C(CCC=1[C@H](C)C[C@@H]2OC(=O)[C@@]3(C(C(=O)C)=C[C@]4(O)[C@@H](C)C[C@H]5OC(=O)C(=C)[C@H]5CC4C3)[C@@H]2CC=1)C
NCGC00182034-01	O=C(CCC=C(CC/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C)C)C		Inactive	Heat shock 70 kDa protein 1 Modulator		1	Teprenone	144206513.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(CCC=C(CC/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C)C)C	O=C(CCC=C(CC/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C)C)C
NCGC00371075-01	O=C(CCCCC1CCCCC1)N1CCC(c2[nH]cnc2)CC1		Inactive	Histamine H3 receptor Antagonist		1	GT 2016	363678019.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CCCCC1CCCCC1)N1CCC(c2[nH]cnc2)CC1	O=C(CCCCC1CCCCC1)N1CCC(c2[nH]cnc2)CC1
NCGC00386060-01	O=C(CCCCCC1C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CC(C)C)C(=O)N2[C@H](C(=O)N1)CCCC2)C1OC1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386060-01	363680085.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CCCCCC1C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CC(C)C)C(=O)N2[C@H](C(=O)N1)CCCC2)C1OC1	O=C(CCCCCC1C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](CC(C)C)C(=O)N2[C@H](C(=O)N1)CCCC2)C1OC1
NCGC00165733-10	O=C(CCCCC[C@H]1C(=O)N[C@@H](Cc2c3c(n(OC)c2)cccc3)C(=O)N[C@@H]([C@H](CC)C)C(=O)N2[C@@H](C(=O)N1)CCCC2)CC		Inactive			1	Apicidin	434147223.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(CCCCC[C@H]1C(=O)N[C@@H](Cc2c3c(n(OC)c2)cccc3)C(=O)N[C@@H]([C@H](CC)C)C(=O)N2[C@@H](C(=O)N1)CCCC2)CC	O=C(CCCCC[C@H]1C(=O)N[C@@H](Cc2c3c(n(OC)c2)cccc3)C(=O)N[C@@H]([C@H](CC)C)C(=O)N2[C@@H](C(=O)N1)CCCC2)CC
NCGC00015801-12&NCGC00015801-17	O=C(CCCCN1C(=O)N(C)c2ncn(C)c2C1=O)C		Inactive	3',5'-cyclic phosphodiesterase Inhibitor		2	Pentoxifylline	170465384.0&363676463.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(CCCCN1C(=O)N(C)c2ncn(C)c2C1=O)C	O=C(CCCCN1C(=O)N(C)c2ncn(C)c2C1=O)C
NCGC00015861-09	O=C(CCCCN1C(=O)N(C)c2ncn(CCC)c2C1=O)C		Inactive	Adenosine receptor Modulator		1	Propentofylline	170465624.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(CCCCN1C(=O)N(C)c2ncn(CCC)c2C1=O)C	O=C(CCCCN1C(=O)N(C)c2ncn(CCC)c2C1=O)C
NCGC00485453-01	O=C(CCCN1CCC(CCCC)CC1)c1c(C)cccc1		Inactive	Muscarinic acetylcholine receptor M1 Agonist		1	AC 42	363681339.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CCCN1CCC(CCCC)CC1)c1c(C)cccc1	O=C(CCCN1CCC(CCCC)CC1)c1c(C)cccc1
NCGC00164603-04	O=C(CCCN1CCC(OC(c2ccccc2)c2ccccc2)CC1)c1ccc(C(C)(C)C)cc1		Inactive	Histamine H1 receptor Antagonist		1	Ebastine	170465995.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	11.87638376&0.0	O=C(CCCN1CCC(OC(c2ccccc2)c2ccccc2)CC1)c1ccc(C(C)(C)C)cc1	O=C(CCCN1CCC(OC(c2ccccc2)c2ccccc2)CC1)c1ccc(C(C)(C)C)cc1
NCGC00016831-09	O=C(CCCN1CCCC1)c1c(OC)cc(OC)cc1OC		Inactive	vasodilator		1	Buflomedil hydrochloride	384567962.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(CCCN1CCCC1)c1c(OC)cc(OC)cc1OC	O=C(CCCN1CCCC1)c1c(OC)cc(OC)cc1OC
NCGC00016107-09	O=C(CCN(C(C)C)Cc1ccccc1)c1cc2c(cc1)cccc2		Inactive	Jak1/3 Inhibitor		1	ZM-39923	363676477.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(CCN(C(C)C)Cc1ccccc1)c1cc2c(cc1)cccc2	O=C(CCN(C(C)C)Cc1ccccc1)c1cc2c(cc1)cccc2
NCGC00384450-03	O=C(CCN1CCC(Cc2ccccc2)CC1)N1Cc2c(SCC1)ccc(OC)c2	5.1999998	Active		0.0	1	JTV519 Hemifumarate	363679204.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	108.7595734726	O=C(CCN1CCC(Cc2ccccc2)CC1)N1Cc2c(SCC1)ccc(OC)c2	O=C(CCN1CCC(Cc2ccccc2)CC1)N1Cc2c(SCC1)ccc(OC)c2
NCGC00016498-08	O=C(CCN1CCCCC1)c1ccc(OCCCC)cc1		Inactive	Sodium channel protein type II alpha subunit Inhibitor		1	Dyclonine hydrochloride	170464776.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&12.402214028	O=C(CCN1CCCCC1)c1ccc(OCCCC)cc1.Cl	O=C(CCN1CCCCC1)c1ccc(OCCCC)cc1.Cl
NCGC00390409-01	O=C(CCNC(=O)c1ccc(C(C)(C)C)cc1)N1CCN(Cc2ccc(OC)cc2)CC1		Inactive			1	Compound112254	363680890.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CCNC(=O)c1ccc(C(C)(C)C)cc1)N1CCN(Cc2ccc(OC)cc2)CC1	O=C(CCNC(=O)c1ccc(C(C)(C)C)cc1)N1CCN(Cc2ccc(OC)cc2)CC1
NCGC00182060-03	O=C(CCN[C@H]([C@H](O)c1ccccc1)C)c1cc(OC)ccc1		Inactive	Adrenergic receptor beta Partial Agonist		1	l-Oxyfedrine hydrochloride	170465929.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(CCN[C@H]([C@H](O)c1ccccc1)C)c1cc(OC)ccc1.Cl	O=C(CCN[C@H]([C@H](O)c1ccccc1)C)c1cc(OC)ccc1.Cl
NCGC00484075-02	O=C(CCO)N1CCC(c2nn(CC)c(-c3nc(c(N)nc3)-c3oc(C(C)(C)C)nn3)n2)CC1		Inactive	PI3Ka/d Inhibitor		1	AZD-8835	384569269.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(CCO)N1CCC(c2nn(CC)c(-c3nc(c(N)nc3)-c3oc(C(C)(C)C)nn3)n2)CC1	O=C(CCO)N1CCC(c2nn(CC)c(-c3nc(c(N)nc3)-c3oc(C(C)(C)C)nn3)n2)CC1
NCGC00380110-01	O=C(CCO)[C@@]1(C)[C@@](O)(C)C=C[C@@H]2[C@@H]1CC[C@H](C)C2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380110-01	363678461.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	13.3297568001	O=C(CCO)[C@@]1(C)[C@@](O)(C)C=C[C@@H]2[C@@H]1CC[C@H](C)C2	O=C(CCO)[C@@]1(C)[C@@](O)(C)C=C[C@@H]2[C@@H]1CC[C@H](C)C2
NCGC00168877-02	O=C(CCO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00168877-02	363676710.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CCO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(O)cc1	O=C(CCO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc(O)cc1
NCGC00385841-01	O=C(CC[C@@H]1[C@]2(C)[C@H]1C[C@@H]1C(=C)C(=O)O[C@@H]1C2)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Carpesium | Family: N/A | Species: abrotanoides		1	NCGC00385841-01	363679963.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CC[C@@H]1[C@]2(C)[C@H]1C[C@@H]1C(=C)C(=O)O[C@@H]1C2)C	O=C(CC[C@@H]1[C@]2(C)[C@H]1C[C@@H]1C(=C)C(=O)O[C@@H]1C2)C
NCGC00110293-01	O=C(CCc1c(C)nc2N(C)C(=O)N(C)C(=O)c2c1C)N1CCN(c2c(C)cc(C)cc2)CC1		Inactive			1	NCGC00110293-01	24384872.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CCc1c(C)nc2N(C)C(=O)N(C)C(=O)c2c1C)N1CCN(c2c(C)cc(C)cc2)CC1	O=C(CCc1c(C)nc2N(C)C(=O)N(C)C(=O)c2c1C)N1CCN(c2c(C)cc(C)cc2)CC1
NCGC00110289-01	O=C(CCc1c(C)nc2N(C)C(=O)N(C)C(=O)c2c1C)N1CCN(c2ccccc2)CC1		Inactive			1	NCGC00110289-01	24384868.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CCc1c(C)nc2N(C)C(=O)N(C)C(=O)c2c1C)N1CCN(c2ccccc2)CC1	O=C(CCc1c(C)nc2N(C)C(=O)N(C)C(=O)c2c1C)N1CCN(c2ccccc2)CC1
NCGC00091109-04	O=C(CCc1cc(O)c(OC)cc1)c1c(O)cc(O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1O		Inactive	synthetic sugar substitute		1	Neohesperidin Dihydrochalcone (Nhdc)	363676550.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CCc1cc(O)c(OC)cc1)c1c(O)cc(O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1O	O=C(CCc1cc(O)c(OC)cc1)c1c(O)cc(O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1O
NCGC00016853-06&NCGC00016853-13	O=C(CCc1cc2c(cc(OC)cc2)cc1)C		Inactive	Cyclooxygenase-2 Inhibitor		2	Nabumetone	170464970.0&434146904.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(CCc1cc2c(cc(OC)cc2)cc1)C	O=C(CCc1cc2c(cc(OC)cc2)cc1)C
NCGC00015840-09	O=C(CCc1ccc(O)cc1)c1c(O)cc(O)cc1O		Inactive	VCAM1 Expression Inhibitor		1	Phloretin	174006856.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(CCc1ccc(O)cc1)c1c(O)cc(O)cc1O	O=C(CCc1ccc(O)cc1)c1c(O)cc(O)cc1O
NCGC00346603-02	O=C(CCc1ccc(O)cc1)c1c(O)cc(O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1O		Inactive			1	Naringin Dihydrochalcone	363677474.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CCc1ccc(O)cc1)c1c(O)cc(O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1O	O=C(CCc1ccc(O)cc1)c1c(O)cc(O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1O
NCGC00142423-05&NCGC00142423-06	O=C(CCc1ccc(O)cc1)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)cc1O		Inactive	SGLT-1/2 Inhibitor		2	Phlorizin	384568163.0&405558498.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(CCc1ccc(O)cc1)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)cc1O	O=C(CCc1ccc(O)cc1)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)cc1O
NCGC00384916-01	O=C(CCc1ccc(O)cc1)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC)cc1O		Inactive	<MOA Unknown> | Class: Flavon | Genus: Kalmia | Family: Ericaceae | Species: latifolia		1	NCGC00384916-01	363679436.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CCc1ccc(O)cc1)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC)cc1O	O=C(CCc1ccc(O)cc1)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC)cc1O
NCGC00385165-01	O=C(CCc1ccc(OC)cc1)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)cc1O		Inactive	<MOA Unknown> | Class: Flavon | Genus: Kalmia | Family: Ericaceae | Species: latifolia		1	NCGC00385165-01	363679575.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CCc1ccc(OC)cc1)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)cc1O	O=C(CCc1ccc(OC)cc1)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)cc1O
NCGC00384745-01	O=C(CCc1ccccc1)c1c(O)c([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(O)c([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c1O		Inactive	<MOA Unknown> | Class: Flavonoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384745-01	363679336.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CCc1ccccc1)c1c(O)c([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(O)c([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c1O	O=C(CCc1ccccc1)c1c(O)c([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(O)c([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c1O
NCGC00385629-01	O=C(CCc1ccccc1)c1c(O)c2c(OC(C(O)(C)C)C2)cc1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385629-01	363679847.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CCc1ccccc1)c1c(O)c2c(OC(C(O)(C)C)C2)cc1	O=C(CCc1ccccc1)c1c(O)c2c(OC(C(O)(C)C)C2)cc1
NCGC00015819-15&NCGC00015819-17	O=C(CCc1ccccc1)c1c(OCC(O)CNCCC)cccc1	4.9000001	Active	Potassium Channel Subfamily K Member 3 (TASK-1; KCNK3) Blocker	0.0	2	Propafenone hydrochloride	170464755.0&384567894.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	97.2111064467&73.8928565939	O=C(CCc1ccccc1)c1c(OCC(O)CNCCC)cccc1	O=C(CCc1ccccc1)c1c(OCC(O)CNCCC)cccc1
NCGC00160484-02	O=C(CCc1ccccc1)c1c(OCCN(CC)CC)cccc1		Inactive	vascular smooth muscle contraction Inhibitor		1	Etafenone	170466000.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	15.659980672&15.564475352	O=C(CCc1ccccc1)c1c(OCCN(CC)CC)cccc1	O=C(CCc1ccccc1)c1c(OCCN(CC)CC)cccc1
NCGC00381286-01	O=C(CN(/C(=C\NC(=O)C)/Cc1cc(OC)c2OCOc2c1)C(=O)C)Cc1ccccc1		Inactive	<MOA Unknown> | Class: AS | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381286-01	363679069.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CN(/C(=C\NC(=O)C)/Cc1cc(OC)c2OCOc2c1)C(=O)C)Cc1ccccc1	O=C(CN(/C(=C\NC(=O)C)/Cc1cc(OC)c2OCOc2c1)C(=O)C)Cc1ccccc1
NCGC00345853-03	O=C(CN(C)C)N1CCC(c2cc(c(NC(=O)c3[nH]cc(C#N)n3)cc2)C2=CCCCC2)CC1	5.0	Active	CSF1R (c-FMS) Inhibitor	0.0	1	JNJ-28312141	384568768.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	99.2720701128	O=C(CN(C)C)N1CCC(c2cc(c(NC(=O)c3[nH]cc(C#N)n3)cc2)C2=CCCCC2)CC1	O=C(CN(C)C)N1CCC(c2cc(c(NC(=O)c3[nH]cc(C#N)n3)cc2)C2=CCCCC2)CC1
NCGC00486936-01	O=C(CN(C)C)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1		Inactive			1	CHMFL-FLT3-122	377020420.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	18.951350624	O=C(CN(C)C)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1	O=C(CN(C)C)N1C[C@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc23)CCC1
NCGC00402238-03	O=C(CN1C(=O)C=CC(C#N)=C1)c1c(C)n(Cc2ccccc2)c(C)c1		Inactive	Sphingosine 1-phosphate receptor Edg-5 Agonist		1	CYM-5520	363680994.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CN1C(=O)C=CC(C#N)=C1)c1c(C)n(Cc2ccccc2)c(C)c1	O=C(CN1C(=O)C=CC(C#N)=C1)c1c(C)n(Cc2ccccc2)c(C)c1
NCGC00485333-01	O=C(CN1C(=O)c2c(N=C1)cccc2)C[C@H]1[C@H](O)CCCN1		Inactive			1	Febrifugine dihydrochloride	363681289.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	-20.4810046399	O=C(CN1C(=O)c2c(N=C1)cccc2)C[C@H]1[C@H](O)CCCN1	O=C(CN1C(=O)c2c(N=C1)cccc2)C[C@H]1[C@H](O)CCCN1
NCGC00015836-12	O=C(CN1CCN(C)CC1)N1c2ncccc2NC(=O)c2c1cccc2		Inactive	Muscarinic acetylcholine receptor M1 Antagonist		1	Pirenzepine	170465793.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(CN1CCN(C)CC1)N1c2ncccc2NC(=O)c2c1cccc2	O=C(CN1CCN(C)CC1)N1c2ncccc2NC(=O)c2c1cccc2
NCGC00350780-09	O=C(CN1C[C@H](C(=O)Nc2cc3c(-c4ccncc4)n[nH]c3cc2)CC1)N1CCN(c2ccc(-c3ncccn3)cc2)CC1		Inactive	ERK1/2 Inhibitor		1	SCH-772984	384569005.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(CN1C[C@H](C(=O)Nc2cc3c(-c4ccncc4)n[nH]c3cc2)CC1)N1CCN(c2ccc(-c3ncccn3)cc2)CC1	O=C(CN1C[C@H](C(=O)Nc2cc3c(-c4ccncc4)n[nH]c3cc2)CC1)N1CCN(c2ccc(-c3ncccn3)cc2)CC1
NCGC00379180-02	O=C(CN1c2c(N3C1=NCC3)cccc2)c1ccc(-c2ccccc2)cc1	4.9000001	Active	Wnt signaling pathway Inhibitor	0.0	1	CCT 031374 hydrobromide	363678402.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	75.9504523879	O=C(CN1c2c(N3C1=NCC3)cccc2)c1ccc(-c2ccccc2)cc1	O=C(CN1c2c(N3C1=NCC3)cccc2)c1ccc(-c2ccccc2)cc1
NCGC00484798-01	O=C(CNC(CNC(=O)C1=Cn2nc(C)cc2N=C1)(C)C)N1[C@H](C#N)CCC1		Inactive	Dipeptidyl peptidase IV Inhibitor		1	Anagliptin	363681178.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(CNC(CNC(=O)C1=Cn2nc(C)cc2N=C1)(C)C)N1[C@H](C#N)CCC1	O=C(CNC(CNC(=O)C1=Cn2nc(C)cc2N=C1)(C)C)N1[C@H](C#N)CCC1
NCGC00386200-01&NCGC00386200-02	O=C(CNC12CC3(O)CC(C1)CC(C3)C2)N1[C@H](C#N)CCC1		Inactive	Dipeptidyl peptidase IV Inhibitor		2	Vildagliptin (LAF-237)&Vildagliptin	363680148.0&405558787.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(CNC12CC3(O)CC(C1)CC(C3)C2)N1[C@H](C#N)CCC1	O=C(CNC12CC3(O)CC(C1)CC(C3)C2)N1[C@H](C#N)CCC1
NCGC00384170-01	O=C(CNCC(CC)C)N1C(COc2cc(C)ccc2)C2C=CSC2CC1	4.9000001	Active	Protein-cysteine N-palmitoyltransferase HHAT Inhibitor	0.0	1	RU-SKI 43	363679174.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	3.0	104.977302184	O=C(CNCC(CC)C)N1C(COc2cc(C)ccc2)C2C=CSC2CC1	O=C(CNCC(CC)C)N1C(COc2cc(C)ccc2)C2C=CSC2CC1
NCGC00379228-03	O=C(CNCC(CC)C)N1C(COc2cc(C)ccc2)c2c(scc2)CC1	4.9000001	Active		0.0	1	RU-SKI 43 (hydrochloride)	363678433.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	106.654933328	O=C(CNCC(CC)C)N1C(COc2cc(C)ccc2)c2c(scc2)CC1	O=C(CNCC(CC)C)N1C(COc2cc(C)ccc2)c2c(scc2)CC1
NCGC00510354-01	O=C(CNCC(CC)C)N1C(c2nc(C)ccc2)c2c(scc2)CC1		Inactive	Protein-Cysteine N-Palmitoyltransferase HHAT Inhibitor		1	RUSKI-201	384569429.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(CNCC(CC)C)N1C(c2nc(C)ccc2)c2c(scc2)CC1	O=C(CNCC(CC)C)N1C(c2nc(C)ccc2)c2c(scc2)CC1
NCGC00384220-02	O=C(CO)N1Cc2c(nc(Nc3nc4n(C5CCC(C)CC5)c5c(c4cn3)ccnc5)cc2)CC1		Inactive	CDK4/6 Inhibitor		1	AMG-925 (FLX925)	384569107.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(CO)N1Cc2c(nc(Nc3nc4n(C5CCC(C)CC5)c5c(c4cn3)ccnc5)cc2)CC1	O=C(CO)N1Cc2c(nc(Nc3nc4n(C5CCC(C)CC5)c5c(c4cn3)ccnc5)cc2)CC1
NCGC00319019-01	O=C(CO)[C@@]1(O)CC(OC2OC(C)C(O)C(N3CC(OC)OCC3)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1		Inactive	DNA Topoisomerase II Inhibitor		1	Nemorubicin	170465590.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(CO)[C@@]1(O)CC(OC2OC(C)C(O)C(N3CC(OC)OCC3)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1	O=C(CO)[C@@]1(O)CC(OC2OC(C)C(O)C(N3CC(OC)OCC3)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1
NCGC00024415-57&NCGC00024415-61	O=C(CO)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1		Inactive	DNA Topoisomerase II Inhibitor		2	Doxorubicin	384568027.0&434146978.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O=C(CO)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1	O=C(CO)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1
NCGC00167982-03&NCGC00167982-04&NCGC00167982-11	O=C(CO)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3OCCCC3)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1		Inactive	DNA Topoisomerase II Inhibitor		3	Pirarubicin	384568344.0&405559004.0&384568345.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		O=C(CO)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3OCCCC3)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1	O=C(CO)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3OCCCC3)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1
NCGC00263918-05&NCGC00263918-08	O=C(CO)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1		Inactive	DNA Topoisomerase II Inhibitor		2	Epirubicin hydrochloride	384568700.0&405559095.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O=C(CO)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1	O=C(CO)[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1
NCGC00485557-01	O=C(CO)[C@]1(O)C2(C)C(C3C(C4(C)C(C(O)C3)=CC(=O)CC4)C(O)C2)CC1		Inactive			1	6Î²-Hydroxycortisol	363681363.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CO)[C@]1(O)C2(C)C(C3C(C4(C)C(C(O)C3)=CC(=O)CC4)C(O)C2)CC1	O=C(CO)[C@]1(O)C2(C)C(C3C(C4(C)C(C(O)C3)=CC(=O)CC4)C(O)C2)CC1
NCGC00090766-07&NCGC00090766-15	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)C=C4)CC3)C(=O)C2)CC1		Inactive	Glucocorticoid steroid		2	Prednisone	170464847.0&384568085.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)C=C4)CC3)C(=O)C2)CC1	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)C=C4)CC3)C(=O)C2)CC1
NCGC00179649-06&NCGC00179649-13	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1		Inactive	Glucocorticoid steroid		2	Prednisolone	170464732.0&384568381.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1
NCGC00022848-17&NCGC00022848-25	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1		Inactive	immunosuppressant		2	Hydrocortisone	170464635.0&384568014.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1
NCGC00022735-06&NCGC00022735-16	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1		Inactive	Glucocorticoid steroid		2	Methylprednisolone	170465051.0&384568013.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1
NCGC00485140-01	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](O)C3)=CC(=O)CC2)CC1		Inactive			1	6Î±-Hydroxycortisol	363681239.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](O)C3)=CC(=O)CC2)CC1	O=C(CO)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](O)C3)=CC(=O)CC2)CC1
NCGC00161834-01	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC(=O)C=C5)CC4)C(O)C3)CC1OC(CCC)O2		Inactive	Glucocorticoid steroid		1	Budesonide	26755470.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC(=O)C=C5)CC4)C(O)C3)CC1OC(CCC)O2	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC(=O)C=C5)CC4)C(O)C3)CC1OC(CCC)O2
NCGC00274065-01&NCGC00274065-06	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C)(C)O2		Inactive	Corticosteroid		2	Desonide	174007408.0&384568711.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C)(C)O2	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C)(C)O2
NCGC00021318-08	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(CCC)O2		Inactive	Glucocorticoid steroid		1	Budesonide	405558701.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(CCC)O2	O=C(CO)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(CCC)O2
NCGC00386873-01	O=C(COC)N1c2c(cc(-c3nc(NC(=O)c4cc(OC)cc(OC)c4)sc3)cc2)CC1		Inactive			1	NCGC00386873-01	363680477.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(COC)N1c2c(cc(-c3nc(NC(=O)c4cc(OC)cc(OC)c4)sc3)cc2)CC1	O=C(COC)N1c2c(cc(-c3nc(NC(=O)c4cc(OC)cc(OC)c4)sc3)cc2)CC1
NCGC00249927-01	O=C(COc1c(OC)cc(CCC)cc1)N1CCN(C(=O)COc2c(OC)cc(CCC)cc2)CC1		Inactive			1	Simetride	170466023.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	5.3896152399&0.0	O=C(COc1c(OC)cc(CCC)cc1)N1CCN(C(=O)COc2c(OC)cc(CCC)cc2)CC1	O=C(COc1c(OC)cc(CCC)cc1)N1CCN(C(=O)COc2c(OC)cc(CCC)cc2)CC1
NCGC00370846-01	O=C(COc1c(OC)cccc1C(C)C)N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1		Inactive	Alpha-1b adrenergic receptor Antagonist		1	Rec 15/2615 dihydrochloride	363677882.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	13.7999999999	O=C(COc1c(OC)cccc1C(C)C)N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1	O=C(COc1c(OC)cccc1C(C)C)N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1
NCGC00370872-07	O=C(COc1c2c(C(=O)NC=C2)ccc1)c1ccccc1		Inactive	Poly [ADP-ribose] polymerase 2 Inhibitor		1	UPF1069	363677900.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(COc1c2c(C(=O)NC=C2)ccc1)c1ccccc1	O=C(COc1c2c(C(=O)NC=C2)ccc1)c1ccccc1
NCGC00402347-02	O=C(COc1cc(C)ccc1)N1CCN(C(=O)c2c(OC)c(OC)ccc2)CC1		Inactive	E3 SUMO-protein ligase CBX4 Modulator		1	MS37452	363681033.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(COc1cc(C)ccc1)N1CCN(C(=O)c2c(OC)c(OC)ccc2)CC1	O=C(COc1cc(C)ccc1)N1CCN(C(=O)c2c(OC)c(OC)ccc2)CC1
NCGC00370895-01	O=C(COc1cc2c(CCN)c[nH]c2cc1)N1CCN(c2ccc(C#N)cc2)CC1		Inactive	Serotonin 1d (5-HT1d) receptor Agonist		1	Donitriptan hydrochloride	363677916.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(COc1cc2c(CCN)c[nH]c2cc1)N1CCN(c2ccc(C#N)cc2)CC1	O=C(COc1cc2c(CCN)c[nH]c2cc1)N1CCN(c2ccc(C#N)cc2)CC1
NCGC00183021-01	O=C(COc1ccc(/C(=N/O)/C)cc1)N1CCCCC1		Inactive	Cyclooxygenase Inhibitor		1	Pifoxime	144206861.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(COc1ccc(/C(=N/O)/C)cc1)N1CCCCC1	O=C(COc1ccc(/C(=N/O)/C)cc1)N1CCCCC1
NCGC00183022-01	O=C(COc1ccc(C(=O)C)cc1)N1CCCCC1		Inactive			1	4'-Piperidinylcarbonylmethoxyacetophenone	144206862.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(COc1ccc(C(=O)C)cc1)N1CCCCC1	O=C(COc1ccc(C(=O)C)cc1)N1CCCCC1
NCGC00378619-01	O=C(COc1ccc(Oc2ccccc2)cc1)Cn1c2c(c(C(=O)C(C)C)c1)cc(C(=O)O)cc2		Inactive	85 kDa calcium-independent phospholipase A2 Inhibitor		1	CAY10650	363678125.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(COc1ccc(Oc2ccccc2)cc1)Cn1c2c(c(C(=O)C(C)C)c1)cc(C(=O)O)cc2	O=C(COc1ccc(Oc2ccccc2)cc1)Cn1c2c(c(C(=O)C(C)C)c1)cc(C(=O)O)cc2
NCGC00381207-01	O=C(C[C@@H]1C(=C)CC[C@@H]2[C@@](CO)(C)[C@H](O)CC[C@@]12C)C=1C(=O)OCC=1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Andrographis | Family: Acanthaceae | Species: paniculata		1	NCGC00381207-01	363679022.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C[C@@H]1C(=C)CC[C@@H]2[C@@](CO)(C)[C@H](O)CC[C@@]12C)C=1C(=O)OCC=1	O=C(C[C@@H]1C(=C)CC[C@@H]2[C@@](CO)(C)[C@H](O)CC[C@@]12C)C=1C(=O)OCC=1
NCGC00386916-01	O=C(C[C@H](c1c(OC)cc(OC)cc1O)c1cc2OCOc2cc1)N1CC(C)CC(C)C1		Inactive			1	NCGC00386916-01	363680503.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(C[C@H](c1c(OC)cc(OC)cc1O)c1cc2OCOc2cc1)N1CC(C)CC(C)C1	O=C(C[C@H](c1c(OC)cc(OC)cc1O)c1cc2OCOc2cc1)N1CC(C)CC(C)C1
NCGC00386575-01	O=C(Cc1c(OC)cccc1)c1c2c(n(CCCCC)c1)cccc2		Inactive	Cannabinoid CB2 receptor Agonist		1	JWH 250	363680336.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Cc1c(OC)cccc1)c1c2c(n(CCCCC)c1)cccc2	O=C(Cc1c(OC)cccc1)c1c2c(n(CCCCC)c1)cccc2
NCGC00370721-04	O=C(Cn1c(NCCCO)nc2c1cc(C)c(C)c2)c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1		Inactive	Protein kinase C beta Inhibitor		1	CID-2858522	363677823.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	18.511179644	O=C(Cn1c(NCCCO)nc2c1cc(C)c(C)c2)c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1	O=C(Cn1c(NCCCO)nc2c1cc(C)c(C)c2)c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1
NCGC00386896-01	O=C(Cn1c2c(c3N=C4SCCN4C(=O)c13)cccc2)N1CCCC1		Inactive			1	NCGC00386896-01	363680489.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Cn1c2c(c3N=C4SCCN4C(=O)c13)cccc2)N1CCCC1	O=C(Cn1c2c(c3N=C4SCCN4C(=O)c13)cccc2)N1CCCC1
NCGC00112665-01	O=C(Cn1ncc2c1-c1c(OC2)cccc1)N1CCN(c2cc(OC)ccc2)CC1		Inactive			1	NCGC00112665-01	24387244.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Cn1ncc2c1-c1c(OC2)cccc1)N1CCN(c2cc(OC)ccc2)CC1	O=C(Cn1ncc2c1-c1c(OC2)cccc1)N1CCN(c2cc(OC)ccc2)CC1
NCGC00112633-01	O=C(Cn1ncc2c1-c1c(OC2)cccc1)N1CCN(c2ccccc2)CC1		Inactive			1	NCGC00112633-01	24387212.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Cn1ncc2c1-c1c(OC2)cccc1)N1CCN(c2ccccc2)CC1	O=C(Cn1ncc2c1-c1c(OC2)cccc1)N1CCN(c2ccccc2)CC1
NCGC00378744-02	O=C(N(C(=O)[C@H]1CN(CC=C)[C@H]2C(c3c4c([nH]cc4C2)ccc3)C1)CCCN(C)C)NCC		Inactive	Serotonin 2b (5-HT2b) receptor Agonist		1	Cabergoline	384569067.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	26.3563464161	O=C(N(C(=O)[C@H]1CN(CC=C)[C@H]2C(c3c4c([nH]cc4C2)ccc3)C1)CCCN(C)C)NCC	O=C(N(C(=O)[C@H]1CN(CC=C)[C@H]2C(c3c4c([nH]cc4C2)ccc3)C1)CCCN(C)C)NCC
NCGC00344544-01	O=C(N(C(=O)[C@H]1CN(CC=C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1)CCCN(C)C)NCC	4.9000001	Active	Serotonin 2b (5-HT2b) receptor Agonist	0.0	1	Cabergoline	170464667.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	102.3549074395	O=C(N(C(=O)[C@H]1CN(CC=C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1)CCCN(C)C)NCC	O=C(N(C(=O)[C@H]1CN(CC=C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1)CCCN(C)C)NCC
NCGC00381111-01	O=C(N(C(C(=O)N)C)C)C(N(C(=O)C1N(C(=O)/C=C/C=C/C(O)C(O)C)CCC1)C)C(C)C		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381111-01	363678975.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(C(C(=O)N)C)C)C(N(C(=O)C1N(C(=O)/C=C/C=C/C(O)C(O)C)CCC1)C)C(C)C	O=C(N(C(C(=O)N)C)C)C(N(C(=O)C1N(C(=O)/C=C/C=C/C(O)C(O)C)CCC1)C)C(C)C
NCGC00386082-01	O=C(N(C(C(=O)N1C(C(=O)O)CCC1)C(C)C)C)C(O)Cc1ccccc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386082-01	363680097.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(C(C(=O)N1C(C(=O)O)CCC1)C(C)C)C)C(O)Cc1ccccc1	O=C(N(C(C(=O)N1C(C(=O)O)CCC1)C(C)C)C)C(O)Cc1ccccc1
NCGC00385036-01	O=C(N(C(C(=O)NC(C(=O)N1C(C(=O)N)CCC1)C)C(C)C)C)/C=C/C=C/C=C/C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385036-01	363679498.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(C(C(=O)NC(C(=O)N1C(C(=O)N)CCC1)C)C(C)C)C)/C=C/C=C/C=C/C	O=C(N(C(C(=O)NC(C(=O)N1C(C(=O)N)CCC1)C)C(C)C)C)/C=C/C=C/C=C/C
NCGC00387461-01	O=C(N(C(C(=O)NCC(=O)OCC)c1sccc1)c1c(OC)cc(OC)cc1)C#C		Inactive	Protein disulfide-isomerase Inhibitor		1	PACMA 31	363680621.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(C(C(=O)NCC(=O)OCC)c1sccc1)c1c(OC)cc(OC)cc1)C#C	O=C(N(C(C(=O)NCC(=O)OCC)c1sccc1)c1c(OC)cc(OC)cc1)C#C
NCGC00386343-01	O=C(N(C(C)C)Cc1onc(-c2cnccc2)n1)COc1ccc(CCC)cc1		Inactive	26S proteosome Inhibitor		1	PI-1840	363680225.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(C(C)C)Cc1onc(-c2cnccc2)n1)COc1ccc(CCC)cc1	O=C(N(C(C)C)Cc1onc(-c2cnccc2)n1)COc1ccc(CCC)cc1
NCGC00249935-01	O=C(N(C)C)CN(C(=O)C)c1ccccc1		Inactive			1	Phenylacetylglycine dimethylamide	170465887.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(C)C)CN(C(=O)C)c1ccccc1	O=C(N(C)C)CN(C(=O)C)c1ccccc1
NCGC00181910-01	O=C(N(C)C)CNC(=O)Cc1ccccc1		Inactive			1	N,N-Dimethyl-2-(2-phenylacetamido)acetamide	144206886.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(C)C)CNC(=O)Cc1ccccc1	O=C(N(C)C)CNC(=O)Cc1ccccc1
NCGC00402255-01	O=C(N(C)C)Nc1c(N(C)C)ccc(-c2ccccc2)c1		Inactive			1	Atglistatin	363681002.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(C)C)Nc1c(N(C)C)ccc(-c2ccccc2)c1	O=C(N(C)C)Nc1c(N(C)C)ccc(-c2ccccc2)c1
NCGC00371133-07	O=C(N(C)C)Nc1cc(-c2ccc(N(C)C)cc2)ccc1		Inactive	Patatin-like phospholipase domain-containing protein 2 Inhibitor		1	Atglistatin	363678049.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(C)C)Nc1cc(-c2ccc(N(C)C)cc2)ccc1	O=C(N(C)C)Nc1cc(-c2ccc(N(C)C)cc2)ccc1
NCGC00346648-05	O=C(N(C)C)Nc1ccc(-c2c(-c3c4c([nH]c(-c5cc(CN(C)C)ccc5)c4)ncc3)cn(CC)n2)cc1		Inactive	Aurora-B/C Inhibitor		1	GSK-1070916A	384568879.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	33.6093613319	O=C(N(C)C)Nc1ccc(-c2c(-c3c4c([nH]c(-c5cc(CN(C)C)ccc5)c4)ncc3)cn(CC)n2)cc1	O=C(N(C)C)Nc1ccc(-c2c(-c3c4c([nH]c(-c5cc(CN(C)C)ccc5)c4)ncc3)cn(CC)n2)cc1
NCGC00390675-01	O=C(N(C)C)c1c(O)c(NC=2C(=O)C(=O)C=2N[C@H](CC)c2oc(C)cc2)ccc1		Inactive			1	SCH 527123	363680968.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(C)C)c1c(O)c(NC=2C(=O)C(=O)C=2N[C@H](CC)c2oc(C)cc2)ccc1	O=C(N(C)C)c1c(O)c(NC=2C(=O)C(=O)C=2N[C@H](CC)c2oc(C)cc2)ccc1
NCGC00379077-01	O=C(N(C)C)c1c(O)c(NC=2C(=O)C(=O)C=2N[C@H](CC)c2occ(C(C)C)c2)ccc1		Inactive			1	SCH 563705	363678343.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(C)C)c1c(O)c(NC=2C(=O)C(=O)C=2N[C@H](CC)c2occ(C(C)C)c2)ccc1	O=C(N(C)C)c1c(O)c(NC=2C(=O)C(=O)C=2N[C@H](CC)c2occ(C(C)C)c2)ccc1
NCGC00346544-09	O=C(N(C)C)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1		Inactive	Mek 5 Inhibitor		1	BIX-02189	384568830.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(C)C)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1	O=C(N(C)C)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1
NCGC00386317-04&NCGC00386317-11	O=C(N(C)C)c1n(C2CCCC2)c2nc(Nc3ncc(N4CCNCC4)cc3)ncc2c1		Inactive	CDK4/6 Inhibitor		2	Ribociclib (LEE011)	384569125.0&405558961.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N(C)C)c1n(C2CCCC2)c2nc(Nc3ncc(N4CCNCC4)cc3)ncc2c1	O=C(N(C)C)c1n(C2CCCC2)c2nc(Nc3ncc(N4CCNCC4)cc3)ncc2c1
NCGC00510683-01	O=C(N(C)C)c1ncc(Oc2c3c(oc(C)c3)cc(C(=O)Nc3ncc(C)nc3)c2)cn1		Inactive	Glucokinase Activator		1	PF-04937319	384569477.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(C)C)c1ncc(Oc2c3c(oc(C)c3)cc(C(=O)Nc3ncc(C)nc3)c2)cn1	O=C(N(C)C)c1ncc(Oc2c3c(oc(C)c3)cc(C(=O)Nc3ncc(C)nc3)c2)cn1
NCGC00371155-01	O=C(N(C)C1(c2ccc(OC)cc2)CCOCC1)c1ccc(NC(=O)c2occc2)cc1		Inactive	Tankyrase-2 Inhibitor		1	JW55	363678068.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(C)C1(c2ccc(OC)cc2)CCOCC1)c1ccc(NC(=O)c2occc2)cc1	O=C(N(C)C1(c2ccc(OC)cc2)CCOCC1)c1ccc(NC(=O)c2occc2)cc1
NCGC00387098-01	O=C(N(C)C1CCCCC1)C=1Sc2n(c3c(n2)ccc(CN(CCOC)C)c3)C=1		Inactive	Metabotropic glutamate receptor 1 Antagonist		1	YM 202074	363680541.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(C)C1CCCCC1)C=1Sc2n(c3c(n2)ccc(CN(CCOC)C)c3)C=1	O=C(N(C)C1CCCCC1)C=1Sc2n(c3c(n2)ccc(CN(CCOC)C)c3)C=1
NCGC00379209-01	O=C(N(C)C1CCN(Cc2ccc(C(=O)N)cc2)CC1)CNc1c(C)c(C)c(N)c(C)c1C		Inactive	Mitogen-activated protein kinase; ERK1/ERK2 Activator		1	SUN 11602	363678419.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(C)C1CCN(Cc2ccc(C(=O)N)cc2)CC1)CNc1c(C)c(C)c(N)c(C)c1C	O=C(N(C)C1CCN(Cc2ccc(C(=O)N)cc2)CC1)CNc1c(C)c(C)c(N)c(C)c1C
NCGC00345083-01	O=C(N(C)C1[C@@H](OC)[C@]2(C)O[C@@H](n3c4c5n2c2c(c5c5C(=O)NC(=O)c5c4c4c3cccc4)cccc2)C1)c1ccccc1		Inactive	lineage-specific differentiation enhancer		1	Stauprimide	174007178.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(C)C1[C@@H](OC)[C@]2(C)O[C@@H](n3c4c5n2c2c(c5c5C(=O)NC(=O)c5c4c4c3cccc4)cccc2)C1)c1ccccc1	O=C(N(C)C1[C@@H](OC)[C@]2(C)O[C@@H](n3c4c5n2c2c(c5c5C(=O)NC(=O)c5c4c4c3cccc4)cccc2)C1)c1ccccc1
NCGC00185750-01	O=C(N(C)[C@@H]1[C@@H](OC)[C@@H](O)[C@H](N)[C@@H](O[C@@H]2[C@H](N)CC[C@@H]([C@@H](N)C)O2)[C@@H]1O)CN		Inactive	Bacterial 70S ribosome Binding Agent		1	Astromicin	144206938.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(C)[C@@H]1[C@@H](OC)[C@@H](O)[C@H](N)[C@@H](O[C@@H]2[C@H](N)CC[C@@H]([C@@H](N)C)O2)[C@@H]1O)CN	O=C(N(C)[C@@H]1[C@@H](OC)[C@@H](O)[C@H](N)[C@@H](O[C@@H]2[C@H](N)CC[C@@H]([C@@H](N)C)O2)[C@@H]1O)CN
NCGC00241102-05&NCGC00241102-08	O=C(N(C)[C@H]1[C@@H](OC)[C@]2(C)O[C@@H](n3c4c5n2c2c(c5c5c(C(=O)NC5)c4c4c3cccc4)cccc2)C1)c1ccccc1		Inactive	PKC/flt3 Inhibitor		2	Midostaurin	434147063.0&384568472.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N(C)[C@H]1[C@@H](OC)[C@]2(C)O[C@@H](n3c4c5n2c2c(c5c5c(C(=O)NC5)c4c4c3cccc4)cccc2)C1)c1ccccc1	O=C(N(C)[C@H]1[C@@H](OC)[C@]2(C)O[C@@H](n3c4c5n2c2c(c5c5c(C(=O)NC5)c4c4c3cccc4)cccc2)C1)c1ccccc1
NCGC00390266-01	O=C(N(C)[C@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CC2)CC3)C4)CC1)/C=C/c1cocc1		Inactive	Kappa opioid receptor Agonist		1	Nalfurafine hydrochloride	405558567.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(C)[C@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CC2)CC3)C4)CC1)/C=C/c1cocc1	O=C(N(C)[C@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CC2)CC3)C4)CC1)/C=C/c1cocc1
NCGC00346880-03	O=C(N(C)c1cc(C=2n3ncc(C(=O)c4sccc4)c3N=CC=2)ccc1)C		Inactive	GABAA Receptor Modulator		1	NBI 34060	363677550.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(C)c1cc(C=2n3ncc(C(=O)c4sccc4)c3N=CC=2)ccc1)C	O=C(N(C)c1cc(C=2n3ncc(C(=O)c4sccc4)c3N=CC=2)ccc1)C
NCGC00263156-12&NCGC00263156-14	O=C(N(C)c1ccc(N/C(/c2ccccc2)=C/2\C(=O)Nc3c\2ccc(C(=O)OC)c3)cc1)CN1CCN(C)CC1		Inactive	VEGFR-1/2/3 Inhibitor		2	Nintedanib	384568630.0&405559117.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N(C)c1ccc(N/C(/c2ccccc2)=C/2\C(=O)Nc3c\2ccc(C(=O)OC)c3)cc1)CN1CCN(C)CC1	O=C(N(C)c1ccc(N/C(/c2ccccc2)=C/2\C(=O)Nc3c\2ccc(C(=O)OC)c3)cc1)CN1CCN(C)CC1
NCGC00402349-02	O=C(N(C)c1ccc(NCc2cc(C(=O)OCC)ccc2)cc1)Nc1ccccc1		Inactive	Sentrin-specific protease 1 Inhibitor		1	GN6958	363681035.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(C)c1ccc(NCc2cc(C(=O)OCC)ccc2)cc1)Nc1ccccc1	O=C(N(C)c1ccc(NCc2cc(C(=O)OCC)ccc2)cc1)Nc1ccccc1
NCGC00025172-03	O=C(N(C)c1ccccc1)C=1C(=O)N(C)c2c(C=1O)cccc2		Inactive	Immunostimulant		1	Roquinimex	384568053.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(C)c1ccccc1)C=1C(=O)N(C)c2c(C=1O)cccc2	O=C(N(C)c1ccccc1)C=1C(=O)N(C)c2c(C=1O)cccc2
NCGC00370707-03	O=C(N(C)c1ccccc1)[C@@H](NC(=O)Cc1c(C)[nH]c2c1cccc2)Cc1ccccc1		Inactive			1	PF74	363677815.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(C)c1ccccc1)[C@@H](NC(=O)Cc1c(C)[nH]c2c1cccc2)Cc1ccccc1	O=C(N(C)c1ccccc1)[C@@H](NC(=O)Cc1c(C)[nH]c2c1cccc2)Cc1ccccc1
NCGC00345798-03	O=C(N(C1CC1)C1CC1)c1n(CC)c2nc(Nc3nn(C)c(C)c3)c3ncn(C)c3c2c1		Inactive	Jak2 Inhibitor		1	BMS-911543	384568747.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(C1CC1)C1CC1)c1n(CC)c2nc(Nc3nn(C)c(C)c3)c3ncn(C)c3c2c1	O=C(N(C1CC1)C1CC1)c1n(CC)c2nc(Nc3nn(C)c(C)c3)c3ncn(C)c3c2c1
NCGC00178778-07	O=C(N(CC)CC)N1CCN(C)CC1		Inactive			1	DIETHYLCARBAMAZINE CITRATE	405559090.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CC)CC)N1CCN(C)CC1	O=C(N(CC)CC)N1CCN(C)CC1
NCGC00179663-03	O=C(N(CC)CC)N[C@@H]1C=C2[C@@H](N(C)C1)Cc1c3c([nH]c1)cccc23		Inactive	Dopamine D5 receptor Agonist		1	(-)-(5S,8R)-Lisuride	170465966.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(N(CC)CC)N[C@@H]1C=C2[C@@H](N(C)C1)Cc1c3c([nH]c1)cccc23	O=C(N(CC)CC)N[C@@H]1C=C2[C@@H](N(C)C1)Cc1c3c([nH]c1)cccc23
NCGC00094476-03	O=C(N(CC)CC)N[C@@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1		Inactive	Serotonin 1a (5-HT1a) receptor Antagonist		1	Terguride	144204835.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CC)CC)N[C@@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1	O=C(N(CC)CC)N[C@@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1
NCGC00344562-01	O=C(N(CC)CC)Nc1cc(C(=O)C)c(OCC(O)CNC(C)(C)C)cc1		Inactive	Beta-2 adrenergic receptor Partial Agonist		1	Celiprolol hydrochloride	170465958.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CC)CC)Nc1cc(C(=O)C)c(OCC(O)CNC(C)(C)C)cc1.Cl	O=C(N(CC)CC)Nc1cc(C(=O)C)c(OCC(O)CNC(C)(C)C)cc1.Cl
NCGC00165825-02	O=C(N(CC)CC)[C@]1([C@@H](CN)C1)c1ccccc1		Inactive	Serotonin transporter Inhibitor		1	Milnacipran hydrochloride	225144261.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CC)CC)[C@]1([C@@H](CN)C1)c1ccccc1	O=C(N(CC)CC)[C@]1([C@@H](CN)C1)c1ccccc1
NCGC00091219-08	O=C(N(CC)CC)c1cc(C)ccc1		Inactive			1	DEET	170466080.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N(CC)CC)c1cc(C)ccc1	O=C(N(CC)CC)c1cc(C)ccc1
NCGC00346641-07	O=C(N(CC)CC)c1ccc(C=2c3c(O)cccc3OC3(C=2)CCNCC3)cc1		Inactive	delta-Opioid Agonist		1	ADL-5859	363677491.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CC)CC)c1ccc(C=2c3c(O)cccc3OC3(C=2)CCNCC3)cc1	O=C(N(CC)CC)c1ccc(C=2c3c(O)cccc3OC3(C=2)CCNCC3)cc1
NCGC00024777-08	O=C(N(CC)CC)c1ccc([C@@H](N2[C@@H](C)CN(CC=C)[C@H](C)C2)c2cc(OC)ccc2)cc1		Inactive	Delta opioid receptor Agonist		1	SNC80	363676532.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(CC)CC)c1ccc([C@@H](N2[C@@H](C)CN(CC=C)[C@H](C)C2)c2cc(OC)ccc2)cc1	O=C(N(CC)CC)c1ccc([C@@H](N2[C@@H](C)CN(CC=C)[C@H](C)C2)c2cc(OC)ccc2)cc1
NCGC00387260-05	O=C(N(CC)Cc1ccccc1)CN1C(=O)N(C)c2c1nc(-c1ccccc1)nc2		Inactive	Translocator protein Agonist		1	AC-5216	363680601.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(CC)Cc1ccccc1)CN1C(=O)N(C)c2c1nc(-c1ccccc1)nc2	O=C(N(CC)Cc1ccccc1)CN1C(=O)N(C)c2c1nc(-c1ccccc1)nc2
NCGC00016065-11	O=C(N(CC)Cc1ccncc1)C(CO)c1ccccc1		Inactive	Muscarinic acetylcholine receptor M3 Antagonist		1	Tropicamide	170464754.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CC)Cc1ccncc1)C(CO)c1ccccc1	O=C(N(CC)Cc1ccncc1)C(CO)c1ccccc1
NCGC00094571-10	O=C(N(CC)c1c(C)cccc1)/C=C/C		Inactive	antipruritic		1	Crotamiton	384568131.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CC)c1c(C)cccc1)/C=C/C	O=C(N(CC)c1c(C)cccc1)/C=C/C
NCGC00094571-08	O=C(N(CC)c1c(C)cccc1)C=CC		Inactive	antipruritic		1	Crotamiton	170464851.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CC)c1c(C)cccc1)C=CC	O=C(N(CC)c1c(C)cccc1)C=CC
NCGC00510699-01	O=C(N(CC)c1c(N2[C@H](C)CNCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1		Inactive	BRPF1 bromodomain Inhibitor		1	GSK9311	384569485.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CC)c1c(N2[C@H](C)CNCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1	O=C(N(CC)c1c(N2[C@H](C)CNCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1
NCGC00390606-01	O=C(N(CC1=NC2=C(C(=O)N1)COCC2)CC1CC1)CN1CCC(C(=O)c2ccc(OC)cc2)CC1		Inactive	Tachykinin NK2 Antagonist		1	TNKS-656	363680925.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N(CC1=NC2=C(C(=O)N1)COCC2)CC1CC1)CN1CCC(C(=O)c2ccc(OC)cc2)CC1	O=C(N(CC1=NC2=C(C(=O)N1)COCC2)CC1CC1)CN1CCC(C(=O)c2ccc(OC)cc2)CC1
NCGC00386497-01	O=C(N(CCC(C)C)Cc1n(Cc2c(C)cccc2)c(C)c(C)n1)c1c(OC)cc(OC)cc1		Inactive	Glucagon-like peptide 1 receptor Antagonist		1	GLP-1 antagonist	363680305.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(CCC(C)C)Cc1n(Cc2c(C)cccc2)c(C)c(C)n1)c1c(OC)cc(OC)cc1	O=C(N(CCC(C)C)Cc1n(Cc2c(C)cccc2)c(C)c(C)n1)c1c(OC)cc(OC)cc1
NCGC00015623-10&NCGC00015623-11	O=C(N(CCC)CCC)C(NC(=O)c1ccccc1)CCC(=O)O		Inactive	Cholecystokinin B receptor Antagonist		2	Proglumide	170465774.0&384567877.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N(CCC)CCC)C(NC(=O)c1ccccc1)CCC(=O)O	O=C(N(CCC)CCC)C(NC(=O)c1ccccc1)CCC(=O)O
NCGC00378853-02	O=C(N(CCCC)CCCC)CN1[C@H]([C@H](C(=O)O)[C@@H](c2cc3OCOc3cc2)C1)c1ccc(OC)cc1		Inactive	Endothelin ETA Receptor Antagonist		1	Atrasentan	384569071.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CCCC)CCCC)CN1[C@H]([C@H](C(=O)O)[C@@H](c2cc3OCOc3cc2)C1)c1ccc(OC)cc1	O=C(N(CCCC)CCCC)CN1[C@H]([C@H](C(=O)O)[C@@H](c2cc3OCOc3cc2)C1)c1ccc(OC)cc1
NCGC00381566-06	O=C(N(CCCC)Cc1ccc(C(=O)NO)cc1)Nc1ccccc1		Inactive			1	Nexturastat A	434147120.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CCCC)Cc1ccc(C(=O)NO)cc1)Nc1ccccc1	O=C(N(CCCC)Cc1ccc(C(=O)NO)cc1)Nc1ccccc1
NCGC00263016-01	O=C(N(CCCCC)CCC12CC3CC(C1)CC(C2)C3)NCCCc1ccncc1		Inactive	TRPV4 Antagonist		1	DE-096	137275920.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CCCCC)CCC12CC3CC(C1)CC(C2)C3)NCCCc1ccncc1	O=C(N(CCCCC)CCC12CC3CC(C1)CC(C2)C3)NCCCc1ccncc1
NCGC00183832-01	O=C(N(CCCc1cnccc1)c1c(C)cccc1C)C(N)C		Inactive	Thromboxane A2 receptor Inhibitor		1	Ro 22-9194	144206801.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CCCc1cnccc1)c1c(C)cccc1C)C(N)C.Cl.Cl	O=C(N(CCCc1cnccc1)c1c(C)cccc1C)C(N)C.Cl.Cl
NCGC00249916-01	O=C(N(CCN(C(=O)N1CCOCC1)CCCC)CCCC)N1CCOCC1		Inactive	skeletal muscle contraction Activator		1	Dimorpholamine	170465773.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(N(CCN(C(=O)N1CCOCC1)CCCC)CCCC)N1CCOCC1	O=C(N(CCN(C(=O)N1CCOCC1)CCCC)CCCC)N1CCOCC1
NCGC00371442-04	O=C(N(CCN(C)C)CC)CNCc1nccc(C(=O)O)c1		Inactive			1	KDM5-C49		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(CCN(C)C)CC)CNCc1nccc(C(=O)O)c1	O=C(N(CCN(C)C)CC)CNCc1nccc(C(=O)O)c1
NCGC00371443-05	O=C(N(CCN(C)C)CC)CNCc1nccc(C(=O)OCC)c1		Inactive	KDM5A/KDM5B Inhibitor		1	KDM5-C70	384569043.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CCN(C)C)CC)CNCc1nccc(C(=O)OCC)c1	O=C(N(CCN(C)C)CC)CNCc1nccc(C(=O)OCC)c1
NCGC00378788-02	O=C(N(CCN(C)C)Cc1ccc(-c2ccc(CNCCc3ccccc3)cc2)cc1)CCC1CCCC1	5.5999999	Active	Serotonin 5a (5-HT5a) receptor Antagonist	0.0	1	SB 699551 dihydrochloride	363678201.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	74.8207332758	O=C(N(CCN(C)C)Cc1ccc(-c2ccc(CNCCc3ccccc3)cc2)cc1)CCC1CCCC1	O=C(N(CCN(C)C)Cc1ccc(-c2ccc(CNCCc3ccccc3)cc2)cc1)CCC1CCCC1
NCGC00370691-03	O=C(N(CCN)Cc1cc(OC)c(OCc2ccccc2)cc1)c1sccc1	5.0	Active	Transient receptor potential cation channel subfamily M member 8 Antagonist	0.0	1	M8-B	363677809.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	3.0	47.1838876958	O=C(N(CCN)Cc1cc(OC)c(OCc2ccccc2)cc1)c1sccc1	O=C(N(CCN)Cc1cc(OC)c(OCc2ccccc2)cc1)c1sccc1
NCGC00386480-01	O=C(N(CCN1CCN(c2c(O)cccc2)CC1)c1ncccc1)C1CCCCC1		Inactive	Serotonin 1a (5-HT1a) receptor Binding Agent		1	desmethyl-WAY 100635 trihydrochloride	363680298.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(CCN1CCN(c2c(O)cccc2)CC1)c1ncccc1)C1CCCCC1	O=C(N(CCN1CCN(c2c(O)cccc2)CC1)c1ncccc1)C1CCCCC1
NCGC00016092-09	O=C(N(CCN1CCN(c2c(OC)cccc2)CC1)c1ncccc1)C1CCCCC1		Inactive	5-HT1A Receptor Antagonist		1	WAY-100635	384567919.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CCN1CCN(c2c(OC)cccc2)CC1)c1ncccc1)C1CCCCC1	O=C(N(CCN1CCN(c2c(OC)cccc2)CC1)c1ncccc1)C1CCCCC1
NCGC00346889-03	O=C(N(CCO)C)C=1C=C(N[C@H]2c3c(C)cccc3OCC2)c2n(cc(C)n2)C=1		Inactive	H+/K+-ATPase Inhibitor		1	PF-03716556	363677553.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CCO)C)C=1C=C(N[C@H]2c3c(C)cccc3OCC2)c2n(cc(C)n2)C=1	O=C(N(CCO)C)C=1C=C(N[C@H]2c3c(C)cccc3OCC2)c2n(cc(C)n2)C=1
NCGC00384200-03	O=C(N(CCO)c1ccccc1)Cc1ccc(C(=O)NO)cc1		Inactive	Histone deacetylase 6 Inhibitor		1	HPOB	434147122.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CCO)c1ccccc1)Cc1ccc(C(=O)NO)cc1	O=C(N(CCO)c1ccccc1)Cc1ccc(C(=O)NO)cc1
NCGC00346685-03	O=C(N(CCOC)CCOC)Cc1c(C(=O)c2cc(OC)c(OCCN3CCOCC3)cc2)c(O)cc(O)c1CC		Inactive	Heat Shock Protein 90 (hsp90) Inhibitor		1	KW-2478	384568909.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CCOC)CCOC)Cc1c(C(=O)c2cc(OC)c(OCCN3CCOCC3)cc2)c(O)cc(O)c1CC	O=C(N(CCOC)CCOC)Cc1c(C(=O)c2cc(OC)c(OCCN3CCOCC3)cc2)c(O)cc(O)c1CC
NCGC00379224-02	O=C(N(CCOC)c1scc(-c2ccccc2)n1)c1cc(OC)c(OC)c(OC)c1		Inactive	Anoctamin-1 Activator		1	Eact	363678430.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(CCOC)c1scc(-c2ccccc2)n1)c1cc(OC)c(OC)c(OC)c1	O=C(N(CCOC)c1scc(-c2ccccc2)n1)c1cc(OC)c(OC)c(OC)c1
NCGC00387092-01	O=C(N(CCc1c(OC)cccc1)[C@H]1CNCC1)c1ccc(CN(CC)CC)cc1		Inactive	cholesterol biosynthetic process Inhibitor		1	PF 429242	434147133.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N(CCc1c(OC)cccc1)[C@H]1CNCC1)c1ccc(CN(CC)CC)cc1	O=C(N(CCc1c(OC)cccc1)[C@H]1CNCC1)c1ccc(CN(CC)CC)cc1
NCGC00485479-01	O=C(N(Cc1c(C)c2c(o1)cccc2)C)/C=C/C1=CNC2=NC(=O)CCC2=C1		Inactive	Bacterial enoyl-[acyl-carrier-protein] reductase Inhibitor		1	AFN-1252	363681348.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(Cc1c(C)c2c(o1)cccc2)C)/C=C/C1=CNC2=NC(=O)CCC2=C1	O=C(N(Cc1c(C)c2c(o1)cccc2)C)/C=C/C1=CNC2=NC(=O)CCC2=C1
NCGC00488703-01	O=C(N(Cc1cc(C2CCN(CCNC)CC2)ncc1)C)c1cc(Oc2ccccc2)ccc1		Inactive			1	NCGC00488703-01	363681474.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(Cc1cc(C2CCN(CCNC)CC2)ncc1)C)c1cc(Oc2ccccc2)ccc1	O=C(N(Cc1cc(C2CCN(CCNC)CC2)ncc1)C)c1cc(Oc2ccccc2)ccc1
NCGC00390361-01	O=C(N(Cc1cc(OC)ccc1)C1CN(Cc2cc3OCOc3cc2)C(C(=O)N2CCNCC2)C1)CC(C)(C)C		Inactive	Smoothened homolog Antagonist		1	CUR-61414	363680880.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(Cc1cc(OC)ccc1)C1CN(Cc2cc3OCOc3cc2)C(C(=O)N2CCNCC2)C1)CC(C)(C)C	O=C(N(Cc1cc(OC)ccc1)C1CN(Cc2cc3OCOc3cc2)C(C(=O)N2CCNCC2)C1)CC(C)(C)C
NCGC00485374-01	O=C(N(Cc1cc(OC)ccc1)[C@@H]1CN(Cc2cc3OCOc3cc2)[C@@H](C(=O)N2CCNCC2)C1)CC(C)(C)C		Inactive	Smoothened homolog Antagonist		1	CUR61414	363681303.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(Cc1cc(OC)ccc1)[C@@H]1CN(Cc2cc3OCOc3cc2)[C@@H](C(=O)N2CCNCC2)C1)CC(C)(C)C	O=C(N(Cc1cc(OC)ccc1)[C@@H]1CN(Cc2cc3OCOc3cc2)[C@@H](C(=O)N2CCNCC2)C1)CC(C)(C)C
NCGC00371091-01	O=C(N(Cc1cc2c(-c3c(cccc3)C2)cc1)C1CCCCCC1)Nc1c(C)cc(C)cc1C		Inactive	Acyl coenzyme A:cholesterol acyltransferase 1 Inhibitor		1	YM 750	363678026.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(Cc1cc2c(-c3c(cccc3)C2)cc1)C1CCCCCC1)Nc1c(C)cc(C)cc1C	O=C(N(Cc1cc2c(-c3c(cccc3)C2)cc1)C1CCCCCC1)Nc1c(C)cc(C)cc1C
NCGC00387773-01	O=C(N(Cc1ccc(N(C)C)cc1)c1ccc(C(C)C)cc1)C1c2c(ccc(OC)c2)CCC1		Inactive	C5a anaphylatoxin chemotactic receptor Antagonist		1	W-54011	363680660.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(Cc1ccc(N(C)C)cc1)c1ccc(C(C)C)cc1)C1c2c(ccc(OC)c2)CCC1	O=C(N(Cc1ccc(N(C)C)cc1)c1ccc(C(C)C)cc1)C1c2c(ccc(OC)c2)CCC1
NCGC00480910-01	O=C(N(Cc1cnccc1)C1CCN(Cc2cc(C#N)ccc2)CC1)Nc1c(-c2ccccc2)cccc1		Inactive			1	BPU-11	377020178.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(Cc1cnccc1)C1CCN(Cc2cc(C#N)ccc2)CC1)Nc1c(-c2ccccc2)cccc1	O=C(N(Cc1cnccc1)C1CCN(Cc2cc(C#N)ccc2)CC1)Nc1c(-c2ccccc2)cccc1
NCGC00386858-01	O=C(N(Cc1cscc1)c1ccc(NC(=O)C2CC2)cc1)Cn1nnc2c1cccc2		Inactive			1	NCGC00386858-01	363680468.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(Cc1cscc1)c1ccc(NC(=O)C2CC2)cc1)Cn1nnc2c1cccc2	O=C(N(Cc1cscc1)c1ccc(NC(=O)C2CC2)cc1)Cn1nnc2c1cccc2
NCGC00386888-01	O=C(N(Cc1sccc1)C1(C(=O)NC2CCCCC2)CCCCC1)c1ncccc1		Inactive			1	NCGC00386888-01	363680484.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(Cc1sccc1)C1(C(=O)NC2CCCCC2)CCCCC1)c1ncccc1	O=C(N(Cc1sccc1)C1(C(=O)NC2CCCCC2)CCCCC1)c1ncccc1
NCGC00159453-05&NCGC00159453-14	O=C(N(O)C(C)c1sc2c(c1)cccc2)N		Inactive	5-Lipoxygenase Inhibitor		2	Zileuton	170465222.0&384568177.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(N(O)C(C)c1sc2c(c1)cccc2)N	O=C(N(O)C(C)c1sc2c(c1)cccc2)N
NCGC00386092-01	O=C(N(O)CCCCCN1C(=O)CCC1=O)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386092-01	363680103.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N(O)CCCCCN1C(=O)CCC1=O)C	O=C(N(O)CCCCCN1C(=O)CCC1=O)C
NCGC00178802-06&NCGC00178802-11	O=C(N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN)CCC(=O)NCCCCCN(O)C(=O)C		Inactive	Iron Chelating Agent		2	Deferoxamine mesylate	170464752.0&384568364.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&13.7651077599	S(=O)(=O)(O)C.O=C(N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN)CCC(=O)NCCCCCN(O)C(=O)C	S(=O)(=O)(O)C.O=C(N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN)CCC(=O)NCCCCCN(O)C(=O)C&O=C(N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN)CCC(=O)NCCCCCN(O)C(=O)C
NCGC00485958-01	O=C(N([C@@H](C)c1[nH]c(-c2ccccc2)cn1)Cc1cc(C(=O)O)c(OC)cc1)[C@@H](N)Cc1c(C)cc(C(=O)N)cc1C		Inactive			1	Eluxadoline	363681443.0	Approved Drugs Collection (NPC)&2020_NPACT-1_CPE	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(N([C@@H](C)c1[nH]c(-c2ccccc2)cn1)Cc1cc(C(=O)O)c(OC)cc1)[C@@H](N)Cc1c(C)cc(C(=O)N)cc1C	O=C(N([C@@H](C)c1[nH]c(-c2ccccc2)cn1)Cc1cc(C(=O)O)c(OC)cc1)[C@@H](N)Cc1c(C)cc(C(=O)N)cc1C
NCGC00386600-02	O=C(N([C@H](/C=C(/C(=O)O)\C)C(C)C)C)[C@@H](NC(=O)[C@@H](NC)C(C)(C)c1ccccc1)C(C)(C)C		Inactive	Tubulin Modulator		1	Taltobulin (trifluoroacetate)	363680351.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N([C@H](/C=C(/C(=O)O)\C)C(C)C)C)[C@@H](NC(=O)[C@@H](NC)C(C)(C)c1ccccc1)C(C)(C)C	O=C(N([C@H](/C=C(/C(=O)O)\C)C(C)C)C)[C@@H](NC(=O)[C@@H](NC)C(C)(C)c1ccccc1)C(C)(C)C
NCGC00485836-01	O=C(N([C@H](C(=O)N[C@@H](C(=O)N)Cc1ccccc1)Cc1ccccc1)C)[C@@H](NC(=O)[C@@H](N(C(=O)[C@@H](NC(=O)C)CCCCN)C)CC(C)C)C(C)C		Inactive	regulation of collagen fibril organization Inhibitor		1	Ac-Lys-(Me)Leu-Val-(Me)Phe-Phe-NH<SUB>2</SUB> trifluoroacetate salt	363681378.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N([C@H](C(=O)N[C@@H](C(=O)N)Cc1ccccc1)Cc1ccccc1)C)[C@@H](NC(=O)[C@@H](N(C(=O)[C@@H](NC(=O)C)CCCCN)C)CC(C)C)C(C)C	O=C(N([C@H](C(=O)N[C@@H](C(=O)N)Cc1ccccc1)Cc1ccccc1)C)[C@@H](NC(=O)[C@@H](N(C(=O)[C@@H](NC(=O)C)CCCCN)C)CC(C)C)C(C)C
NCGC00024789-03	O=C(N([C@H](CN1CCCC1)c1ccccc1)C)Cc1ccccc1		Inactive			1	N-MPPP Hydrochloride		2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N([C@H](CN1CCCC1)c1ccccc1)C)Cc1ccccc1	O=C(N([C@H](CN1CCCC1)c1ccccc1)C)Cc1ccccc1
NCGC00408844-01	O=C(N([C@H](CN1C[C@@H](O)CC1)c1ccccc1)C)C(c1ccccc1)c1ccccc1		Inactive	Mu opioid receptor Agonist		1	Asimadoline HCl	363681063.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N([C@H](CN1C[C@@H](O)CC1)c1ccccc1)C)C(c1ccccc1)c1ccccc1	O=C(N([C@H](CN1C[C@@H](O)CC1)c1ccccc1)C)C(c1ccccc1)c1ccccc1
NCGC00509861-02	O=C(N([C@H]([C@H](OC)CC(=O)N1[C@H]([C@H](OC)[C@H](C(=O)NCCc2ccccc2)C)CCC1)[C@H](CC)C)C)[C@@H](NC(=O)[C@@H](N(C)C)C(C)C)C(C)C		Inactive	microtubule polymerization Inhibitor		1	Auristatin PE	405559023.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N([C@H]([C@H](OC)CC(=O)N1[C@H]([C@H](OC)[C@H](C(=O)NCCc2ccccc2)C)CCC1)[C@H](CC)C)C)[C@@H](NC(=O)[C@@H](N(C)C)C(C)C)C(C)C	O=C(N([C@H]([C@H](OC)CC(=O)N1[C@H]([C@H](OC)[C@H](C(=O)NCCc2ccccc2)C)CCC1)[C@H](CC)C)C)[C@@H](NC(=O)[C@@H](N(C)C)C(C)C)C(C)C
NCGC00485972-01	O=C(N([C@H]([C@H](OC)CC(=O)N1[C@H]([C@H](OC)[C@H](C(=O)N[C@@H](Cc2ccccc2)c2sccn2)C)CCC1)[C@H](CC)C)C)[C@@H](NC(=O)C(N)(C)C)C(C)C		Inactive			1	PF-06380101	363681453.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	8.0	O=C(N([C@H]([C@H](OC)CC(=O)N1[C@H]([C@H](OC)[C@H](C(=O)N[C@@H](Cc2ccccc2)c2sccn2)C)CCC1)[C@H](CC)C)C)[C@@H](NC(=O)C(N)(C)C)C(C)C	O=C(N([C@H]([C@H](OC)CC(=O)N1[C@H]([C@H](OC)[C@H](C(=O)N[C@@H](Cc2ccccc2)c2sccn2)C)CCC1)[C@H](CC)C)C)[C@@H](NC(=O)C(N)(C)C)C(C)C
NCGC00378623-01	O=C(N([C@H]([C@H](OC)CC(=O)N1[C@H]([C@H](OC)[C@H](C(=O)N[C@@H](Cc2ccccc2)c2sccn2)C)CCC1)[C@H](CC)C)C)[C@@H](NC(=O)[C@@H](N(C)C)C(C)C)C(C)C		Inactive	Tubulin polymerization Inhibitor		1	Dolastatin 10	384569059.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N([C@H]([C@H](OC)CC(=O)N1[C@H]([C@H](OC)[C@H](C(=O)N[C@@H](Cc2ccccc2)c2sccn2)C)CCC1)[C@H](CC)C)C)[C@@H](NC(=O)[C@@H](N(C)C)C(C)C)C(C)C	O=C(N([C@H]([C@H](OC)CC(=O)N1[C@H]([C@H](OC)[C@H](C(=O)N[C@@H](Cc2ccccc2)c2sccn2)C)CCC1)[C@H](CC)C)C)[C@@H](NC(=O)[C@@H](N(C)C)C(C)C)C(C)C
NCGC00378591-01	O=C(N(c1c(OC)cc(OC)cc1)c1ncnc(Nc2ccc(N3CCN(C)CC3)cc2)c1)Nc1c(C)cccc1C		Inactive	Serine/threonine-protein kinase SIK3 Inhibitor		1	HG-9-91-01	363678107.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	25.3333333359	O=C(N(c1c(OC)cc(OC)cc1)c1ncnc(Nc2ccc(N3CCN(C)CC3)cc2)c1)Nc1c(C)cccc1C	O=C(N(c1c(OC)cc(OC)cc1)c1ncnc(Nc2ccc(N3CCN(C)CC3)cc2)c1)Nc1c(C)cccc1C
NCGC00371015-01	O=C(N(c1cc2N(C(=O)C)CCc2cc1)C1CCN(CCC2CCCC2)CC1)/C=C/c1cc(C#N)ccc1	4.9000001	Active	Neuropeptide Y receptor type 2 Antagonist	0.0	1	JNJ 5207787	363677995.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	66.739336491	O=C(N(c1cc2N(C(=O)C)CCc2cc1)C1CCN(CCC2CCCC2)CC1)/C=C/c1cc(C#N)ccc1	O=C(N(c1cc2N(C(=O)C)CCc2cc1)C1CCN(CCC2CCCC2)CC1)/C=C/c1cc(C#N)ccc1
NCGC00380339-01	O=C(N)/C(=C/C(=O)C[C@@]12C(=O)O[C@@]3(C)[C@@H]1C[C@@H]2CC3)/C		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380339-01	363678548.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N)/C(=C/C(=O)C[C@@]12C(=O)O[C@@]3(C)[C@@H]1C[C@@H]2CC3)/C	O=C(N)/C(=C/C(=O)C[C@@]12C(=O)O[C@@]3(C)[C@@H]1C[C@@H]2CC3)/C
NCGC00385957-01	O=C(N)/C=C/c1cc(OC)c(OC)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385957-01	363680027.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N)/C=C/c1cc(OC)c(OC)cc1	O=C(N)/C=C/c1cc(OC)c(OC)cc1
NCGC00346491-08	O=C(N)C(=O)c1c(CC)n(Cc2ccccc2)c2c1c(OCC(=O)O)ccc2		Inactive	Secretory Phospholipase A2 (sPLA2) Inhibitor		1	Varespladib	363677425.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)C(=O)c1c(CC)n(Cc2ccccc2)c2c1c(OCC(=O)O)ccc2	O=C(N)C(=O)c1c(CC)n(Cc2ccccc2)c2c1c(OCC(=O)O)ccc2
NCGC00387871-03	O=C(N)C(=O)c1c(CC)n(Cc2ccccc2)c2c1c(OCC(=O)OC)ccc2		Inactive	Phospholipase A2 group IIA Inhibitor		1	Varespladib Methyl	363680713.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N)C(=O)c1c(CC)n(Cc2ccccc2)c2c1c(OCC(=O)OC)ccc2	O=C(N)C(=O)c1c(CC)n(Cc2ccccc2)c2c1c(OCC(=O)OC)ccc2
NCGC00387039-04	O=C(N)C(C)(C)n1ncc(-c2cc3OCCn4c(nc(-c5n(C(C)C)nc(C)n5)c4)-c3cc2)c1		Inactive	PI3Kalpha Inhibitor		1	Taselisib (GDC-0032)	384569150.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.8361201639	O=C(N)C(C)(C)n1ncc(-c2cc3OCCn4c(nc(-c5n(C(C)C)nc(C)n5)c4)-c3cc2)c1	O=C(N)C(C)(C)n1ncc(-c2cc3OCCn4c(nc(-c5n(C(C)C)nc(C)n5)c4)-c3cc2)c1
NCGC00263910-02	O=C(N)C(CC(N(C)C)C)(c1ccccc1)c1ccccc1		Inactive	Muscarinic acetylcholine receptor Antagonist		1	Aminopentamide sulfate	170466283.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(O)O.O=C(N)C(CC(N(C)C)C)(c1ccccc1)c1ccccc1	S(=O)(=O)(O)O.O=C(N)C(CC(N(C)C)C)(c1ccccc1)c1ccccc1
NCGC00186028-02	O=C(N)C(CC)N1C(=O)CCC1		Inactive	N-Type Calcium Channel (Ca(v) 2.2) Blocker		1	Levetiracetam	170464988.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)C(CC)N1C(=O)CCC1	O=C(N)C(CC)N1C(=O)CCC1
NCGC00182080-04	O=C(N)C(CCC)CCC		Inactive			1	Valpromide	434146902.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)C(CCC)CCC	O=C(N)C(CCC)CCC
NCGC00015358-18	O=C(N)C(CCN(C(C)C)C(C)C)(c1ncccc1)c1ccccc1		Inactive	Na channel blocker		1	Disopyramide	174006632.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)C(CCN(C(C)C)C(C)C)(c1ncccc1)c1ccccc1	O=C(N)C(CCN(C(C)C)C(C)C)(c1ncccc1)c1ccccc1
NCGC00016308-06	O=C(N)C(CC[N+](C(C)C)(C(C)C)C)(c1ccccc1)c1ccccc1		Inactive	Muscarinic acetylcholine receptor Antagonist		1	Isopropamide	170465291.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N)C(CC[N+](C(C)C)(C(C)C)C)(c1ccccc1)c1ccccc1	O=C(N)C(CC[N+](C(C)C)(C(C)C)C)(c1ccccc1)c1ccccc1
NCGC00183110-02	O=C(N)C(CCn1c(C)ncc1)(c1ccccc1)c1ccccc1		Inactive	potassium ion transport Inhibitor		1	Imidafenacin	405558861.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)C(CCn1c(C)ncc1)(c1ccccc1)c1ccccc1	O=C(N)C(CCn1c(C)ncc1)(c1ccccc1)c1ccccc1
NCGC00380900-01	O=C(N)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)c1ccccc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380900-01	363678842.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)c1ccccc1	O=C(N)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)c1ccccc1
NCGC00380954-01	O=C(N)C([C@H](O)/C(=C\C=C/C=C/Cc1ocnc1)/C)(C)C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380954-01	363678883.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N)C([C@H](O)/C(=C\C=C/C=C/Cc1ocnc1)/C)(C)C	O=C(N)C([C@H](O)/C(=C\C=C/C=C/Cc1ocnc1)/C)(C)C
NCGC00263922-02	O=C(N)C([C@H]1CN(CCc2cc3c(OCC3)cc2)CC1)(c1ccccc1)c1ccccc1		Inactive	Muscarinic acetylcholine receptor M3 Antagonist		1	Darifenacin hydrobromide	170465079.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(N)C([C@H]1CN(CCc2cc3c(OCC3)cc2)CC1)(c1ccccc1)c1ccccc1.Br	O=C(N)C([C@H]1CN(CCc2cc3c(OCC3)cc2)CC1)(c1ccccc1)c1ccccc1.Br
NCGC00249887-01	O=C(N)C1(CCCNC(C)C)c2c(-c3c1cccc3)cccc2		Inactive	Sodium channel alpha subunit Blocker		1	Indecainide	170465192.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(N)C1(CCCNC(C)C)c2c(-c3c1cccc3)cccc2	O=C(N)C1(CCCNC(C)C)c2c(-c3c1cccc3)cccc2
NCGC00522040-01	O=C(N)C1(N2CCCCC2)CCN(CCCN2c3c(cccc3)CCc3c2cccc3)CC1		Inactive			1	Carpipramine Dihydrochloride	405558850.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)C1(N2CCCCC2)CCN(CCCN2c3c(cccc3)CCc3c2cccc3)CC1	O=C(N)C1(N2CCCCC2)CCN(CCCN2c3c(cccc3)CCc3c2cccc3)CC1
NCGC00510443-01	O=C(N)C1=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4C[C@H]3C[C@H]2CC1=O		Inactive	MMP-9 (Gelatinase B) Inhibitor		1	Incyclinide	384569435.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)C1=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4C[C@H]3C[C@H]2CC1=O	O=C(N)C1=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4C[C@H]3C[C@H]2CC1=O
NCGC00178854-03&NCGC00183044-01	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(N(C)C)c4C[C@H]3C[C@H]2[C@H](N(C)C)C=1O		Inactive	Tetracycline Antibiotic		2	Minocycline hydrochloride&Minocycline	170465049.0&124894250.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(N(C)C)c4C[C@H]3C[C@H]2[C@H](N(C)C)C=1O.Cl	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(N(C)C)c4C[C@H]3C[C@H]2[C@H](N(C)C)C=1O.Cl&O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(N(C)C)c4C[C@H]3C[C@H]2[C@H](N(C)C)C=1O
NCGC00179358-04	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4C(=C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O		Inactive	Tetracycline Antibiotic		1	Methacycline hydrochloride	170465224.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4C(=C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O.Cl	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4C(=C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O.Cl
NCGC00161602-06&NCGC00161602-07&NCGC00161602-13&NCGC00161602-23	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@H](C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O		Inactive	Matrix Metalloproteinase (MMP) Inhibitor		4	Doxycycline&Doxycycline HCl	170465097.0&434146914.0&384568211.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0&0.0	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@H](C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O.Cl	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@H](C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O.Cl&O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@H](C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O
NCGC00017323-08&NCGC00017323-11	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3C[C@H]2[C@H](N(C)C)C=1O		Inactive	30S Ribosomal Protein Inhibitor		2	Tetracycline hydrochloride	170464838.0&384567983.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&9.0804931079	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3C[C@H]2[C@H](N(C)C)C=1O.Cl	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3C[C@H]2[C@H](N(C)C)C=1O.Cl&O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3C[C@H]2[C@H](N(C)C)C=1O
NCGC00091268-11&NCGC00091268-12	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O		Inactive	Tetracycline Antibiotic		2	Oxytetracycline	174007181.0&225144208.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O	O=C(N)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O
NCGC00016645-03	O=C(N)C=1C(=O)[C@]2(O)C(O)=C3C(=O)c4c(O)cccc4C(=C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O		Inactive	Tetracycline Antibiotic		1	Methacycline hydrochloride	124882458.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)C=1C(=O)[C@]2(O)C(O)=C3C(=O)c4c(O)cccc4C(=C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O	O=C(N)C=1C(=O)[C@]2(O)C(O)=C3C(=O)c4c(O)cccc4C(=C)[C@H]3[C@H](O)[C@H]2[C@H](N(C)C)C=1O
NCGC00380424-01	O=C(N)C=1OC2OC(=O)C3C(C=1)C2C=C3		Inactive	<MOA Unknown> | Class: Polyketide | Genus: - | Family: - | Species: -		1	NCGC00380424-01	363678576.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N)C=1OC2OC(=O)C3C(C=1)C2C=C3	O=C(N)C=1OC2OC(=O)C3C(C=1)C2C=C3
NCGC00381005-01	O=C(N)CC1CC(=O)OC(CC(=O)/C(=C/C(=C/C(O)C)/C)/C)C1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381005-01	363678919.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N)CC1CC(=O)OC(CC(=O)/C(=C/C(=C/C(O)C)/C)/C)C1	O=C(N)CC1CC(=O)OC(CC(=O)/C(=C/C(=C/C(O)C)/C)/C)C1
NCGC00166104-04	O=C(N)CCCCC1SSCC1		Inactive	apoptotic process Inhibitor		1	alpha-Lipoic acid amide	170465868.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N)CCCCC1SSCC1	O=C(N)CCCCC1SSCC1
NCGC00346732-02	O=C(N)CC[C@H]1[C@@](CC(=O)N)(C)[C@@]2(C)[NH+]3[Co+]456(O)[NH+]7c8c(N([C@@H]9[C@H](O)[C@@H]([C@@H](CO)O9)OP(=O)([O-])O[C@H](C)CNC(=O)CC[C@]9(C)[C@@H](CC(=O)N)[C@H]2N4C9=C(C)[C-]2[C@@H](CCC(=O)N)C(C)(C)C([NH+]52)=C[C-]2[C@@H](CCC(=O)N)[C@@](CC(=O)N)(C)C(=C(C)[C-]13)[NH+]62)[CH-]7)cc(C)c(C)c8		Inactive	Vitamin		1	Hydroxocobalamin	384568936.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)CC[C@H]1[C@@](CC(=O)N)(C)[C@@]2(C)[NH+]3[Co+]456(O)[NH+]7c8c(N([C@@H]9[C@H](O)[C@@H]([C@@H](CO)O9)OP(=O)([O-])O[C@H](C)CNC(=O)CC[C@]9(C)[C@@H](CC(=O)N)[C@H]2N4C9=C(C)[C-]2[C@@H](CCC(=O)N)C(C)(C)C([NH+]52)=C[C-]2[C@@H](CCC(=O)N)[C@@](CC(=O)N)(C)C(=C(C)[C-]13)[NH+]62)[CH-]7)cc(C)c(C)c8	O=C(N)CC[C@H]1[C@@](CC(=O)N)(C)[C@@]2(C)[NH+]3[Co+]456(O)[NH+]7c8c(N([C@@H]9[C@H](O)[C@@H]([C@@H](CO)O9)OP(=O)([O-])O[C@H](C)CNC(=O)CC[C@]9(C)[C@@H](CC(=O)N)[C@H]2N4C9=C(C)[C-]2[C@@H](CCC(=O)N)C(C)(C)C([NH+]52)=C[C-]2[C@@H](CCC(=O)N)[C@@](CC(=O)N)(C)C(=C(C)[C-]13)[NH+]62)[CH-]7)cc(C)c(C)c8
NCGC00015821-10	O=C(N)CN1C(=O)CCC1		Inactive	Glutamate receptor ionotropic, AMPA 3 Positive Allosteric Modulator		1	Piracetam	170465901.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(N)CN1C(=O)CCC1	O=C(N)CN1C(=O)CCC1
NCGC00185741-02	O=C(N)Cc1c(N)c(C(=O)c2ccccc2)ccc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Nepafenac	170465203.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)Cc1c(N)c(C(=O)c2ccccc2)ccc1	O=C(N)Cc1c(N)c(C(=O)c2ccccc2)ccc1
NCGC00348156-03	O=C(N)Cc1c2c(n(CCCCCCCC)c1)ccc(-c1cc(C)ccc1)c2	5.0	Active		0.0	1	Cysmethynil		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	90.8172024418	O=C(N)Cc1c2c(n(CCCCCCCC)c1)ccc(-c1cc(C)ccc1)c2	O=C(N)Cc1c2c(n(CCCCCCCC)c1)ccc(-c1cc(C)ccc1)c2
NCGC00015007-14	O=C(N)Cc1ccc(OC[C@H](O)CNC(C)C)cc1		Inactive	Beta-2 adrenergic receptor Antagonist		1	R-(+)-Atenolol	170464744.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)Cc1ccc(OC[C@H](O)CNC(C)C)cc1	O=C(N)Cc1ccc(OC[C@H](O)CNC(C)C)cc1
NCGC00065934-05	O=C(N)N1c2c(C(=O)Cc3c1cccc3)cccc2		Inactive	Sodium channel inhibitor		1	Oxcarbazepine	170464811.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N)N1c2c(C(=O)Cc3c1cccc3)cccc2	O=C(N)N1c2c(C(=O)Cc3c1cccc3)cccc2
NCGC00015234-19	O=C(N)N1c2c(cccc2)C=Cc2c1cccc2		Inactive	Sodium channel protein type 5 subunit alpha Blocker		1	Carbamazepine	170464712.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N)N1c2c(cccc2)C=Cc2c1cccc2	O=C(N)N1c2c(cccc2)C=Cc2c1cccc2
NCGC00485669-01	O=C(N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2N(C(=O)[C@@H](N)[C@H](O)C)CCC2)CCC1)[C@H](O)C		Inactive	Glutamate [NMDA] receptor Partial Agonist		1	GLYX-13 trifluoroacetate	363681375.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2N(C(=O)[C@@H](N)[C@H](O)C)CCC2)CCC1)[C@H](O)C	O=C(N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2N(C(=O)[C@@H](N)[C@H](O)C)CCC2)CCC1)[C@H](O)C
NCGC00250393-01	O=C(N)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c3c([nH]c2)cccc3)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](CC(=O)[C@H](N)Cc2ccccc2)CSSC1)C(O)C		Inactive	Somatostatin srif2B (sst4) Agonist		1	CAP-232	137275895.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c3c([nH]c2)cccc3)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](CC(=O)[C@H](N)Cc2ccccc2)CSSC1)C(O)C	O=C(N)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c3c([nH]c2)cccc3)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](CC(=O)[C@H](N)Cc2ccccc2)CSSC1)C(O)C
NCGC00510690-01	O=C(N)[C@@H](Oc1cc2OCCn3c(nc(-c4n(C(C)C)ncn4)c3)-c2cc1)C		Inactive	PI3K alpha Inhibitor		1	GDC-0326	384569480.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)[C@@H](Oc1cc2OCCn3c(nc(-c4n(C(C)C)ncn4)c3)-c2cc1)C	O=C(N)[C@@H](Oc1cc2OCCn3c(nc(-c4n(C(C)C)ncn4)c3)-c2cc1)C
NCGC00160614-01	O=C(N)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1		Inactive			1	Glucuronamide	144205490.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1	O=C(N)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1
NCGC00186028-04	O=C(N)[C@H](CC)N1C(=O)CCC1		Inactive	N-Type Calcium Channel (Ca(v) 2.2) Blocker		1	Levetiracetam	384568436.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)[C@H](CC)N1C(=O)CCC1	O=C(N)[C@H](CC)N1C(=O)CCC1
NCGC00390779-02	O=C(N)[C@H](CC)N1C(=O)C[C@@H](CCC)C1		Inactive	Synaptic vesicle glycoprotein 2A Modulator		1	Brivaracetam	405558777.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)[C@H](CC)N1C(=O)C[C@@H](CCC)C1	O=C(N)[C@H](CC)N1C(=O)C[C@@H](CCC)C1
NCGC00385280-01	O=C(N)[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccccc1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385280-01	363679639.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N)[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccccc1	O=C(N)[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccccc1
NCGC00163492-01	O=C(N)[C@H]1[C@@H](C(=O)CC/C=C/C/C=C/C)O1		Inactive	Fatty Acid Synthase (FAS) Inhibitor		1	Cerulenin	26756878.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.0	O=C(N)[C@H]1[C@@H](C(=O)CC/C=C/C/C=C/C)O1	O=C(N)[C@H]1[C@@H](C(=O)CC/C=C/C/C=C/C)O1
NCGC00091861-07&NCGC00091861-13	O=C(N)c1c(/N=N/N(C)C)nc[nH]1		Inactive	DNA Alkylating Agent		2	Dacarbazine	170464655.0&384568100.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(N)c1c(/N=N/N(C)C)nc[nH]1	O=C(N)c1c(/N=N/N(C)C)nc[nH]1
NCGC00163392-12	O=C(N)c1c(N)cc(-c2cscc2)s1		Inactive			1	SC-514	377020477.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N)c1c(N)cc(-c2cscc2)s1	O=C(N)c1c(N)cc(-c2cscc2)s1
NCGC00165736-04&NCGC00165736-13	O=C(N)c1c(N)n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)cn1		Inactive	AMPK Activator		2	Acadesine	170465608.0&384568276.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N)c1c(N)n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)cn1	O=C(N)c1c(N)n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)cn1
NCGC00370744-02	O=C(N)c1c(N)nc2N(C(=O)N(CC)C(=O)c2c1)C1CC1		Inactive			1	A 484954		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N)c1c(N)nc2N(C(=O)N(CC)C(=O)c2c1)C1CC1	O=C(N)c1c(N)nc2N(C(=O)N(CC)C(=O)c2c1)C1CC1
NCGC00387258-04	O=C(N)c1c(NC(=O)C2CCCCC2)sc(Nc2ccccc2)n1	4.9000001	Active	Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma Inhibitor	0.0	1	UNC3230	363680599.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	51.236	O=C(N)c1c(NC(=O)C2CCCCC2)sc(Nc2ccccc2)n1	O=C(N)c1c(NC(=O)C2CCCCC2)sc(Nc2ccccc2)n1
NCGC00501212-01	O=C(N)c1c(NC2[C@@H]3CC4(O)CC2CC(C4)C3)c2c([nH]cc2)nc1		Inactive	Jak3		1	Peficitinib	384569311.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)c1c(NC2[C@@H]3CC4(O)CC2CC(C4)C3)c2c([nH]cc2)nc1	O=C(N)c1c(NC2[C@@H]3CC4(O)CC2CC(C4)C3)c2c([nH]cc2)nc1
NCGC00346945-06	O=C(N)c1c(NC=2n3c(ncc3)C=C(c3cc(OC)c(OC)cc3)N=2)nccc1		Inactive	Syk Kinase Inhibitor		1	BAY61-3606	363677563.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)c1c(NC=2n3c(ncc3)C=C(c3cc(OC)c(OC)cc3)N=2)nccc1	O=C(N)c1c(NC=2n3c(ncc3)C=C(c3cc(OC)c(OC)cc3)N=2)nccc1
NCGC00351606-08	O=C(N)c1c(Nc2cc(-n3nccn3)ccc2)nc(N[C@H]2[C@@H](N)CCCC2)nc1	5.0500002	Active	Syk Kinase Inhibitor	0.0	1	PRT-062607	384569020.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	69.4335441662	O=C(N)c1c(Nc2cc(-n3nccn3)ccc2)nc(N[C@H]2[C@@H](N)CCCC2)nc1	O=C(N)c1c(Nc2cc(-n3nccn3)ccc2)nc(N[C@H]2[C@@H](N)CCCC2)nc1
NCGC00253909-02	O=C(N)c1c(Nc2cc(C)ccc2)nc(N[C@H]2[C@@H](N)CCCC2)nc1	4.9000001	Active	Syk Kinase Inhibitor	0.0	1	PRT-060318	137275916.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	76.558780021	O=C(N)c1c(Nc2cc(C)ccc2)nc(N[C@H]2[C@@H](N)CCCC2)nc1	O=C(N)c1c(Nc2cc(C)ccc2)nc(N[C@H]2[C@@H](N)CCCC2)nc1
NCGC00481652-04	O=C(N)c1c(Nc2cc(OC)c(N3CCC(N4CCN(C)CC4)CC3)cc2)nc(NC2CCOCC2)c(CC)n1		Inactive			1	Gilteritinib	384569258.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)c1c(Nc2cc(OC)c(N3CCC(N4CCN(C)CC4)CC3)cc2)nc(NC2CCOCC2)c(CC)n1	O=C(N)c1c(Nc2cc(OC)c(N3CCC(N4CCN(C)CC4)CC3)cc2)nc(NC2CCOCC2)c(CC)n1
NCGC00507850-01	O=C(N)c1c(Nc2nc(C)c(C)cc2)cc(N[C@H]2[C@@H](N)CCCC2)nn1		Inactive	Syk Kinase Inhibitor		1	RO-9021	384569330.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	21.27952756	O=C(N)c1c(Nc2nc(C)c(C)cc2)cc(N[C@H]2[C@@H](N)CCCC2)nn1	O=C(N)c1c(Nc2nc(C)c(C)cc2)cc(N[C@H]2[C@@H](N)CCCC2)nn1
NCGC00015595-14	O=C(N)c1c(O)ccc(C(O)CNC(CCc2ccccc2)C)c1		Inactive	Adrenergic receptor Antagonist		1	Labetalol HCl	405558617.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)c1c(O)ccc(C(O)CNC(CCc2ccccc2)C)c1	O=C(N)c1c(O)ccc(C(O)CNC(CCc2ccccc2)C)c1
NCGC00091414-07	O=C(N)c1c(O)cccc1		Inactive			1	Salicylamide	170465496.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(N)c1c(O)cccc1	O=C(N)c1c(O)cccc1
NCGC00094087-05&NCGC00094087-07&NCGC00094087-08	O=C(N)c1c(O)n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)cn1		Inactive	Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor		3	Mizoribine	170466027.0&384568124.0&384568125.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	O=C(N)c1c(O)n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)cn1	O=C(N)c1c(O)n([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)cn1
NCGC00091616-03	O=C(N)c1c(OCC)cccc1		Inactive			1	2-Ethoxybenzamide	170465775.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&7.5839416079	O=C(N)c1c(OCC)cccc1	O=C(N)c1c(OCC)cccc1
NCGC00095049-04	O=C(N)c1c(OCCCCCC)cccc1		Inactive			1	Exalamide	170465990.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(N)c1c(OCCCCCC)cccc1	O=C(N)c1c(OCCCCCC)cccc1
NCGC00481317-01	O=C(N)c1c2c(n(-c3nc(NCc4ccccc4)c4c(n3)CCOC4)c(C)c2)ccc1		Inactive	p97 ATPase Inhibitor		1	CB-5083	363681118.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N)c1c2c(n(-c3nc(NCc4ccccc4)c4c(n3)CCOC4)c(C)c2)ccc1	O=C(N)c1c2c(n(-c3nc(NCc4ccccc4)c4c(n3)CCOC4)c(C)c2)ccc1
NCGC00250404-06&NCGC00250404-15	O=C(N)c1c2nc([C@]3(C)NCCC3)[nH]c2ccc1		Inactive	PARP Inhibitor		2	Veliparib&ABT-888	384568552.0&434147070.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	23.0&0.0	O=C(N)c1c2nc([C@]3(C)NCCC3)[nH]c2ccc1	O=C(N)c1c2nc([C@]3(C)NCCC3)[nH]c2ccc1
NCGC00346435-07&NCGC00346435-13	O=C(N)c1c2nn(-c3ccc([C@H]4CNCCC4)cc3)cc2ccc1	4.9000001	Active	PARP Inhibitor	0.0	2	Niraparib&MK-4827	384568775.0	Anti-infectives&Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0&3.0	83.908583694&79.1640611913&81.2647058816	O=C(N)c1c2nn(-c3ccc([C@H]4CNCCC4)cc3)cc2ccc1	O=C(N)c1c2nn(-c3ccc([C@H]4CNCCC4)cc3)cc2ccc1
NCGC00475742-01	O=C(N)c1cc(CC)c(-n2nc(C(C)C)c3c(-n4cc(-c5cn(C)nc5)nc4)ccnc23)cc1		Inactive	Heat Shock Protein 90 (hsp90) Inhibitor		1	TAS-116	363681099.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	16.539748956	O=C(N)c1cc(CC)c(-n2nc(C(C)C)c3c(-n4cc(-c5cn(C)nc5)nc4)ccnc23)cc1	O=C(N)c1cc(CC)c(-n2nc(C(C)C)c3c(-n4cc(-c5cn(C)nc5)nc4)ccnc23)cc1
NCGC00015034-15&NCGC00015034-21	O=C(N)c1cc(N)ccc1		Inactive	PARP Inhibitor		2	INO-1001	384567798.0&434147202.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N)c1cc(N)ccc1	O=C(N)c1cc(N)ccc1
NCGC00263020-01	O=C(N)c1cc(Nc2nc(-c3c4c(n(C(C)C)c3)cncc4)ccn2)c(C)cc1		Inactive	NFkappaB-inducing kinase Inhibitor		1	NCGC00263020	137275924.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	26.5536942919	O=C(N)c1cc(Nc2nc(-c3c4c(n(C(C)C)c3)cncc4)ccn2)c(C)cc1	O=C(N)c1cc(Nc2nc(-c3c4c(n(C(C)C)c3)cncc4)ccn2)c(C)cc1
NCGC00378959-01	O=C(N)c1cc(Nc2nc(Nc3c(C)ccc(O)c3)ccn2)ccc1		Inactive	Tyrosine-protein kinase TXK Inhibitor		1	Lck inhibitor 2	363678293.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N)c1cc(Nc2nc(Nc3c(C)ccc(O)c3)ccn2)ccc1	O=C(N)c1cc(Nc2nc(Nc3c(C)ccc(O)c3)ccn2)ccc1
NCGC00345856-01	O=C(N)c1cc(c(-c2ccc(C3(N)CCC3)cc2)nc1)-c1ccccc1		Inactive	AKT Inhibitor		1	AZD-26	174006466.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)c1cc(c(-c2ccc(C3(N)CCC3)cc2)nc1)-c1ccccc1	O=C(N)c1cc(c(-c2ccc(C3(N)CCC3)cc2)nc1)-c1ccccc1
NCGC00378801-04	O=C(N)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1		Inactive	Mitogen-activated protein kinase 7 Inhibitor		1	BIX02188	384569070.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1	O=C(N)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1
NCGC00384167-11	O=C(N)c1cc2c(-c3c(-c4nc(C)ccc4)nn4c3CCC4)ccnc2cc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	Galunisertib	384569102.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)c1cc2c(-c3c(-c4nc(C)ccc4)nn4c3CCC4)ccnc2cc1	O=C(N)c1cc2c(-c3c(-c4nc(C)ccc4)nn4c3CCC4)ccnc2cc1
NCGC00389836-01	O=C(N)c1cc2c(NC3C2C[C@H](NC)CC3)cc1		Inactive			1	FROVATRIPTAN SUCCINATE	363680859.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N)c1cc2c(NC3C2C[C@H](NC)CC3)cc1	O=C(N)c1cc2c(NC3C2C[C@H](NC)CC3)cc1
NCGC00408835-01	O=C(N)c1cc2c([nH]c3c2C[C@H](NC)CC3)cc1		Inactive	Serotonin 1d (5-HT1d) receptor Agonist		1	Frovatriptan succinate	405558720.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)c1cc2c([nH]c3c2C[C@H](NC)CC3)cc1	O=C(N)c1cc2c([nH]c3c2C[C@H](NC)CC3)cc1
NCGC00162142-06	O=C(N)c1cc2c([nH]cc2)cc1		Inactive	p38 MAPK Inhibitor		1	SD-169	384568219.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)c1cc2c([nH]cc2)cc1	O=C(N)c1cc2c([nH]cc2)cc1
NCGC00242498-14	O=C(N)c1ccc(-c2[nH]c(c(-c3cc4OCCOc4cc3)n2)-c2ncccc2)cc1		Inactive	Casein Kinase 1 Inhibitor		1	D-4476	384568501.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)c1ccc(-c2[nH]c(c(-c3cc4OCCOc4cc3)n2)-c2ncccc2)cc1	O=C(N)c1ccc(-c2[nH]c(c(-c3cc4OCCOc4cc3)n2)-c2ncccc2)cc1
NCGC00025230-21	O=C(N)c1ccc(-c2[nH]c(c(-c3cc4OCOc4cc3)n2)-c2ncccc2)cc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	SB-431542	377020509.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)c1ccc(-c2[nH]c(c(-c3cc4OCOc4cc3)n2)-c2ncccc2)cc1	O=C(N)c1ccc(-c2[nH]c(c(-c3cc4OCOc4cc3)n2)-c2ncccc2)cc1
NCGC00249351-01	O=C(N)c1ccc(C=2n3ncnc3C(Nc3ccc(N4CCN(CC)CC4)cc3)=CC=2)cc1	5.0999999	Active		0.0	1	NCGC00249351-01	377020500.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	42.7538497793	O=C(N)c1ccc(C=2n3ncnc3C(Nc3ccc(N4CCN(CC)CC4)cc3)=CC=2)cc1	O=C(N)c1ccc(C=2n3ncnc3C(Nc3ccc(N4CCN(CC)CC4)cc3)=CC=2)cc1
NCGC00379193-01	O=C(N)c1ccc(Nc2nc(NC(C)(C)C)c(C#N)c(N)c2)cc1		Inactive	Dual specificity protein kinase TTK Inhibitor		1	TC Mps1 12	363678409.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N)c1ccc(Nc2nc(NC(C)(C)C)c(C#N)c(N)c2)cc1	O=C(N)c1ccc(Nc2nc(NC(C)(C)C)c(C#N)c(N)c2)cc1
NCGC00381426-01	O=C(N)c1ccc(OCC2C(=O)N3C(C(=O)N2)CCC3)cc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381426-01	363679137.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N)c1ccc(OCC2C(=O)N3C(C(=O)N2)CCC3)cc1	O=C(N)c1ccc(OCC2C(=O)N3C(C(=O)N2)CCC3)cc1
NCGC00015142-02	O=C(N)c1ccccc1		Inactive			1	Benzamide	124879383.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N)c1ccccc1	O=C(N)c1ccccc1
NCGC00093354-13	O=C(N)c1cnccc1		Inactive	Vitamin		1	Niacinamide	384568113.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	15.15062762	O=C(N)c1cnccc1	O=C(N)c1cnccc1
MLS003389320-02	O=C(N)c1nc(C2C(O)C(O)C(CO)O2)sc1		Inactive			1	MLS003389320-02	363676432.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N)c1nc(C2C(O)C(O)C(CO)O2)sc1	O=C(N)c1nc(C2C(O)C(O)C(CO)O2)sc1
NCGC00380939-01	O=C(N)c1nc(c(O)c(OC)c1)-c1ncccc1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380939-01	363678871.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N)c1nc(c(O)c(OC)c1)-c1ncccc1	O=C(N)c1nc(c(O)c(OC)c1)-c1ncccc1
NCGC00015833-15&NCGC00015833-18	O=C(N)c1nccnc1		Inactive	Fatty Acid Synthase (FAS) Inhibitor		2	Pyrazinamide	170464703.0&384567896.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(N)c1nccnc1	O=C(N)c1nccnc1
NCGC00167429-04&NCGC00167429-10	O=C(N)c1ncn2C(=O)N(C)N=Nc12		Inactive	DNA Topoisomerase II Inhibitor		2	Temozolomide	170464968.0&384568311.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N)c1ncn2C(=O)N(C)N=Nc12	O=C(N)c1ncn2C(=O)N(C)N=Nc12
NCGC00346555-05&NCGC00346555-08	O=C(N)c1nn(-c2ccc(OC)cc2)c2C(=O)N(c3ccc(N4C(=O)CCCC4)cc3)CCc12		Inactive	Coagulation Factor Xa Inhibitor		2	Apixaban	405558566.0&363677453.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(N)c1nn(-c2ccc(OC)cc2)c2C(=O)N(c3ccc(N4C(=O)CCCC4)cc3)CCc12	O=C(N)c1nn(-c2ccc(OC)cc2)c2C(=O)N(c3ccc(N4C(=O)CCCC4)cc3)CCc12
NCGC00015904-05	O=C(N)c1nn(C2C(O)C(O)C(CO)O2)cn1		Inactive	Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors		1	Ribavirin	440681674.0		DPI_SARS-CoV-2_General	4.0	0.0	O=C(N)c1nn(C2C(O)C(O)C(CO)O2)cn1	O=C(N)c1nn(C2C(O)C(O)C(CO)O2)cn1
NCGC00090726-12&NCGC00090726-15&NCGC00090726-30	O=C(N)c1nn([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)cn1		Inactive	Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor		3	Ribavirin	170464657.0&384568079.0&434146983.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	O=C(N)c1nn([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)cn1	O=C(N)c1nn([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)cn1
NCGC00371130-03	O=C(N)c1oc2c(c1)cc(N1CCN(CCCCc3c4c([nH]c3)ccc(C#N)c4)CC1)cc2	5.0	Active	Sodium-dependent serotonin transporter Inhibitor	0.0	1	Vilazodone Hydrochloride	405558674.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	89.5433268648	O=C(N)c1oc2c(c1)cc(N1CCN(CCCCc3c4c([nH]c3)ccc(C#N)c4)CC1)cc2	O=C(N)c1oc2c(c1)cc(N1CCN(CCCCc3c4c([nH]c3)ccc(C#N)c4)CC1)cc2
NCGC00179246-05	O=C(N/C=C\1/C(=O)N[C@@H]([C@@H]2NC(N)=N[C@@H](O)C2)C(=O)NC[C@H](NC(=O)C[C@@H](N)CCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N/1)N		Inactive	70s Ribosome Inhibitor		1	VIOMYCIN SULFATE	405558719.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N/C=C\1/C(=O)N[C@@H]([C@@H]2NC(N)=N[C@@H](O)C2)C(=O)NC[C@H](NC(=O)C[C@@H](N)CCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N/1)N	O=C(N/C=C\1/C(=O)N[C@@H]([C@@H]2NC(N)=N[C@@H](O)C2)C(=O)NC[C@H](NC(=O)C[C@@H](N)CCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N/1)N
NCGC00167473-02	O=C(N/C=C\1/C(=O)N[C@@H]([C@H]2N=C(N)NCC2)C(=O)NC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CNC(=O)C[C@@H](N)CCCN)C(=O)N/1)N		Inactive			1	Capreomycin IB	174006669.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(N/C=C\1/C(=O)N[C@@H]([C@H]2N=C(N)NCC2)C(=O)NC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CNC(=O)C[C@@H](N)CCCN)C(=O)N/1)N	O=C(N/C=C\1/C(=O)N[C@@H]([C@H]2N=C(N)NCC2)C(=O)NC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CNC(=O)C[C@@H](N)CCCN)C(=O)N/1)N
NCGC00390536-02	O=C(N/N=C(\CO)/[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1)CCCCCN1C(=O)C=CC1=O		Inactive	DNA-Intercalating Drugs		1	Aldoxorubicin hydrochlorid	384569187.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N/N=C(\CO)/[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1)CCCCCN1C(=O)C=CC1=O	O=C(N/N=C(\CO)/[C@@]1(O)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](N)C2)c2c(O)c3C(=O)c4c(OC)cccc4C(=O)c3c(O)c2C1)CCCCCN1C(=O)C=CC1=O
NCGC00167785-11	O=C(N/N=C/c1c(O)c(CC=C)ccc1)CN1CCN(Cc2ccccc2)CC1		Inactive	Procaspase 3 Activator		1	PAC-1	384568336.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	19.76722262	O=C(N/N=C/c1c(O)c(CC=C)ccc1)CN1CCN(Cc2ccccc2)CC1	O=C(N/N=C/c1c(O)c(CC=C)ccc1)CN1CCN(Cc2ccccc2)CC1
NCGC00386289-08	O=C(N/N=C/c1cc(O)c(O)cc1)c1c(O)cc2c(c1)cccc2		Inactive	Dynamin-2 Inhibitor		1	Dynasore	387065823.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N/N=C/c1cc(O)c(O)cc1)c1c(O)cc2c(c1)cccc2	O=C(N/N=C/c1cc(O)c(O)cc1)c1c(O)cc2c(c1)cccc2
NCGC00346879-04	O=C(N/N=C/c1oc(C)cc1)c1c(Oc2ccccc2)cccc1		Inactive	Wnt Signaling Inhibitor		1	PNU-74654	384568957.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N/N=C/c1oc(C)cc1)c1c(Oc2ccccc2)cccc1	O=C(N/N=C/c1oc(C)cc1)c1c(Oc2ccccc2)cccc1
NCGC00344541-01	O=C(N/N=C\1/C(=O)C=C2N(C)CC(O)C2=C/1)N		Inactive			1	Adrenochrome semicarbazone	225144387.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N/N=C\1/C(=O)C=C2N(C)CC(O)C2=C/1)N	O=C(N/N=C\1/C(=O)C=C2N(C)CC(O)C2=C/1)N
NCGC00371070-01	O=C(N/N=C\c1cc(OC)c(OCc2ccccc2)cc1)c1cc2OCOc2cc1		Inactive	fMet-Leu-Phe receptor 1/2 Agonist		1	FPR A14	363678015.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N/N=C\c1cc(OC)c(OCc2ccccc2)cc1)c1cc2OCOc2cc1	O=C(N/N=C\c1cc(OC)c(OCc2ccccc2)cc1)c1cc2OCOc2cc1
NCGC00015116-13&NCGC00015116-20	O=C(N1C(=O)CCC1)c1ccc(OC)cc1		Inactive	AMPA receptor modulator		2	Aniracetam	170465854.0&384567811.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(N1C(=O)CCC1)c1ccc(OC)cc1	O=C(N1C(=O)CCC1)c1ccc(OC)cc1
NCGC00384203-01	O=C(N1C(COc2ccc(OC(C)(C)C)cc2)Cc2c(cccc2)C1)c1c2c(ccc1)cccc2		Inactive	Nuclear receptor subfamily 1 group D member 1 Agonist		1	SR10067	363679194.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N1C(COc2ccc(OC(C)(C)C)cc2)Cc2c(cccc2)C1)c1c2c(ccc1)cccc2	O=C(N1C(COc2ccc(OC(C)(C)C)cc2)Cc2c(cccc2)C1)c1c2c(ccc1)cccc2
NCGC00485075-01	O=C(N1C2C(N(c3nc(N)c4c(n3)cc(OC)c(OC)c4)CC1)CCCC2)c1occc1		Inactive	Alpha-1d adrenergic receptor Antagonist		1	Cyclazosin hydrochloride	363681211.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N1C2C(N(c3nc(N)c4c(n3)cc(OC)c(OC)c4)CC1)CCCC2)c1occc1	O=C(N1C2C(N(c3nc(N)c4c(n3)cc(OC)c(OC)c4)CC1)CCCC2)c1occc1
NCGC00015818-14&NCGC00015818-25	O=C(N1CC(=O)N2C(c3c(cccc3)CC2)C1)C1CCCCC1		Inactive	antiparasitic agent		2	Praziquantel	170464906.0&384567893.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	O=C(N1CC(=O)N2C(c3c(cccc3)CC2)C1)C1CCCCC1	O=C(N1CC(=O)N2C(c3c(cccc3)CC2)C1)C1CCCCC1
NCGC00249902-01	O=C(N1CC(=O)N2C(c3c(cccc3)CCC2)C1)C1CCCCC1		Inactive	calcium ion homeostasis Inhibitor		1	Epsiprantel	170465737.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(N1CC(=O)N2C(c3c(cccc3)CCC2)C1)C1CCCCC1	O=C(N1CC(=O)N2C(c3c(cccc3)CCC2)C1)C1CCCCC1
NCGC00484062-02	O=C(N1CC(C)(C)C1)c1ccc(C=2n3nc(NC(=O)C4CC4)nc3C=CC=2)cc1		Inactive	Jak1 Inhibitor		1	Solcitinib	384569268.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N1CC(C)(C)C1)c1ccc(C=2n3nc(NC(=O)C4CC4)nc3C=CC=2)cc1	O=C(N1CC(C)(C)C1)c1ccc(C=2n3nc(NC(=O)C4CC4)nc3C=CC=2)cc1
NCGC00510705-01	O=C(N1CCC(CC(O)(C)C)CC1)c1[nH]c2c(c1)cc(OC)cc2		Inactive	AKR1C3 Inhibitor		1	ASP-9521	384569488.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N1CCC(CC(O)(C)C)CC1)c1[nH]c2c(c1)cc(OC)cc2	O=C(N1CCC(CC(O)(C)C)CC1)c1[nH]c2c(c1)cc(OC)cc2
NCGC00386924-03	O=C(N1CCC(N2C(=O)OC(c3ccccc3)=N2)CC1)C1(c2ccc(C)cc2)CC1		Inactive	G-protein coupled receptor 55 Antagonist		1	ML191	363680508.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N1CCC(N2C(=O)OC(c3ccccc3)=N2)CC1)C1(c2ccc(C)cc2)CC1	O=C(N1CCC(N2C(=O)OC(c3ccccc3)=N2)CC1)C1(c2ccc(C)cc2)CC1
NCGC00344623-17	O=C(N1CCC(N2CCCC2)CC1)c1c(Nc2ccccc2)cc(C(=O)N2CCC(N3CCCC3)CC2)cc1		Inactive	L3MBTL3 methyllysine (Kme) reader domain Inhibitor		1	UNC-1215	384568726.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	13.324628912	O=C(N1CCC(N2CCCC2)CC1)c1c(Nc2ccccc2)cc(C(=O)N2CCC(N3CCCC3)CC2)cc1	O=C(N1CCC(N2CCCC2)CC1)c1c(Nc2ccccc2)cc(C(=O)N2CCC(N3CCCC3)CC2)cc1
NCGC00167767-12	O=C(N1CCC(N2CCCC2)CC1)c1ccc(Nc2nc(-c3sc4c(c3)cccc4)ccn2)cc1	5.5999999	Active	IKK beta Inhibitor	0.0	1	IKK-16	377020288.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	106.7725284297	O=C(N1CCC(N2CCCC2)CC1)c1ccc(Nc2nc(-c3sc4c(c3)cccc4)ccn2)cc1	O=C(N1CCC(N2CCCC2)CC1)c1ccc(Nc2nc(-c3sc4c(c3)cccc4)ccn2)cc1
NCGC00346807-05	O=C(N1CCC(N2CCN(C)CC2)CC1)c1cc(OC)c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)cc1		Inactive	LRRK2 Inhibitor		1	LRRK2-IN-1	384568941.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N1CCC(N2CCN(C)CC2)CC1)c1cc(OC)c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)cc1	O=C(N1CCC(N2CCN(C)CC2)CC1)c1cc(OC)c(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)cccc4)cc1
NCGC00378965-05	O=C(N1CCC(N2CCN(C)CC2)CC1)c1cc(OCC)c(Nc2nc3N(C4CCCC4)c4c(C(=O)N(C)c3cn2)cccc4)cc1		Inactive	ERK5 Inhibitor		1	XMD17-109	384569078.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-8.6782254359	O=C(N1CCC(N2CCN(C)CC2)CC1)c1cc(OCC)c(Nc2nc3N(C4CCCC4)c4c(C(=O)N(C)c3cn2)cccc4)cc1	O=C(N1CCC(N2CCN(C)CC2)CC1)c1cc(OCC)c(Nc2nc3N(C4CCCC4)c4c(C(=O)N(C)c3cn2)cccc4)cc1
NCGC00402231-02	O=C(N1CCC(c2ccncc2)CC1)c1noc(COc2c(C)cccc2C)c1		Inactive	Sterol 26-hydroxylase, mitochondrial Inhibitor		1	Dafadine-A	363680989.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N1CCC(c2ccncc2)CC1)c1noc(COc2c(C)cccc2C)c1	O=C(N1CCC(c2ccncc2)CC1)c1noc(COc2c(C)cccc2C)c1
NCGC00421916-03	O=C(N1CCC2(CC(=O)c3n(C(C)C)ncc3C2)CC1)c1cc2nc(C)[nH]c2cc1		Inactive	Acetyl-CoA Carboxylase Inhibitor		1	PF-05175157	384569230.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N1CCC2(CC(=O)c3n(C(C)C)ncc3C2)CC1)c1cc2nc(C)[nH]c2cc1	O=C(N1CCC2(CC(=O)c3n(C(C)C)ncc3C2)CC1)c1cc2nc(C)[nH]c2cc1
NCGC00475743-01	O=C(N1CCCC1)c1ccc(-c2cc3N=C(N)CC(C(=O)N(CCC)CCC)=Cc3cc2)cc1		Inactive	Toll-Like Receptor 8 (TLR8) Agonist		1	Motolimod	384569237.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N1CCCC1)c1ccc(-c2cc3N=C(N)CC(C(=O)N(CCC)CCC)=Cc3cc2)cc1	O=C(N1CCCC1)c1ccc(-c2cc3N=C(N)CC(C(=O)N(CCC)CCC)=Cc3cc2)cc1
NCGC00381368-01	O=C(N1CCCCC1)C1C(/C=C/c2cc3OCOc3cc2)O1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381368-01	363679110.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N1CCCCC1)C1C(/C=C/c2cc3OCOc3cc2)O1	O=C(N1CCCCC1)C1C(/C=C/c2cc3OCOc3cc2)O1
NCGC00182992-01	O=C(N1CCCCC1)[C@@H]1NC(=O)CC1		Inactive	GABA-B receptor Antagonist		1	Fasoracetam	144206891.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N1CCCCC1)[C@@H]1NC(=O)CC1	O=C(N1CCCCC1)[C@@H]1NC(=O)CC1
NCGC00371146-01	O=C(N1CCCCC1)c1cc2nccnc2cc1		Inactive	Glutamate receptor ionotropic AMPA Modulator		1	Ampalex	363678060.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N1CCCCC1)c1cc2nccnc2cc1	O=C(N1CCCCC1)c1cc2nccnc2cc1
NCGC00262228-03	O=C(N1CCCCC1)c1cc2ncn(-c3ccc(OC)cc3)c2cc1		Inactive	HPGD Inhibitor		1	NCGC00262228	384568571.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N1CCCCC1)c1cc2ncn(-c3ccc(OC)cc3)c2cc1	O=C(N1CCCCC1)c1cc2ncn(-c3ccc(OC)cc3)c2cc1
NCGC00488967-01	O=C(N1CCN(C)CC1)c1cc2c(cc(CCNc3ncnc4c3cc(C#N)cc4)cc2)cc1		Inactive	CDK 8/19 Inhibitor		1	Senexin-B	363681477.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N1CCN(C)CC1)c1cc2c(cc(CCNc3ncnc4c3cc(C#N)cc4)cc2)cc1	O=C(N1CCN(C)CC1)c1cc2c(cc(CCNc3ncnc4c3cc(C#N)cc4)cc2)cc1
NCGC00522584-01	O=C(N1CCN(C)CC1)c1sc(-c2cc3c(c(C=O)c(O)cc3)cc2)cc1		Inactive	IRE1 Inhibitor		1	MKC-3946	384569530.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N1CCN(C)CC1)c1sc(-c2cc3c(c(C=O)c(O)cc3)cc2)cc1	O=C(N1CCN(C)CC1)c1sc(-c2cc3c(c(C=O)c(O)cc3)cc2)cc1
NCGC00371142-05	O=C(N1CCN(Cc2ccccc2)CC1)c1c(NCCC(C)C)nccc1		Inactive	neurogenesis Activator		1	NSI-189	363678056.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N1CCN(Cc2ccccc2)CC1)c1c(NCCC(C)C)nccc1	O=C(N1CCN(Cc2ccccc2)CC1)c1c(NCCC(C)C)nccc1
NCGC00508883-01	O=C(N1CCN(c2c(C#N)cccn2)CC1)c1cc(CC2=NNC(=O)c3c2cccc3)ccc1		Inactive	PARP Inhibitor		1	AZ-9482	384569370.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N1CCN(c2c(C#N)cccn2)CC1)c1cc(CC2=NNC(=O)c3c2cccc3)ccc1	O=C(N1CCN(c2c(C#N)cccn2)CC1)c1cc(CC2=NNC(=O)c3c2cccc3)ccc1
NCGC00510509-01&NCGC00510509-02	O=C(N1CCN(c2cc3c(NC(=O)CC3)cc2)CC1)c1cc(OC)c(OC)cc1		Inactive	p97 ATPase Inhibitor		2	Vesnarinone	384569470.0&405558927.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(N1CCN(c2cc3c(NC(=O)CC3)cc2)CC1)c1cc(OC)c(OC)cc1	O=C(N1CCN(c2cc3c(NC(=O)CC3)cc2)CC1)c1cc(OC)c(OC)cc1
NCGC00386913-02	O=C(N1CCN(c2ccc(OC)cc2)CC1)c1sc2-c3c(S(=O)(=O)Cc2c1)cccc3		Inactive	Acyl-protein thioesterase 2 Inhibitor		1	ML 349	363680500.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N1CCN(c2ccc(OC)cc2)CC1)c1sc2-c3c(S(=O)(=O)Cc2c1)cccc3	O=C(N1CCN(c2ccc(OC)cc2)CC1)c1sc2-c3c(S(=O)(=O)Cc2c1)cccc3
NCGC00386920-03	O=C(N1CCN(c2nc(C)nc3sc4c(c23)CCCC4)CC1)c1occc1		Inactive	G-protein coupled receptor 55 Antagonist		1	ML192	363680507.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N1CCN(c2nc(C)nc3sc4c(c23)CCCC4)CC1)c1occc1	O=C(N1CCN(c2nc(C)nc3sc4c(c23)CCCC4)CC1)c1occc1
NCGC00016026-10	O=C(N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1)C1OCCC1		Inactive	Alpha1-adrenoceptor Antagonists		1	Terazosin hydrochloride	170465073.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1)C1OCCC1.Cl	O=C(N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1)C1OCCC1.Cl
NCGC00018158-09&NCGC00018158-11	O=C(N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1)C1Oc2c(OC1)cccc2	4.9000001	Active	alpha1-Adrenoceptor Antagonists	0.0	2	Doxazosin mesylate&Doxazosin Mesylate	170465395.0&434146894.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	115.0095588257&109.6921262765	S(=O)(=O)(O)C.O=C(N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1)C1Oc2c(OC1)cccc2	S(=O)(=O)(O)C.O=C(N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1)C1Oc2c(OC1)cccc2&O=C(N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1)C1Oc2c(OC1)cccc2
NCGC00016740-18	O=C(N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1)c1occc1		Inactive	alpha1-Adrenoceptor Antagonists		1	Prazosin	170465415.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0		O=C(N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1)c1occc1	O=C(N1CCN(c2nc(N)c3c(n2)cc(OC)c(OC)c3)CC1)c1occc1
NCGC00346569-03	O=C(N1CCNCC1)c1ccc(/C=C/c2n[nH]c3c2cccc3)cc1		Inactive	Bcr-Abl Inhibitor		1	KW-2449	384568844.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N1CCNCC1)c1ccc(/C=C/c2n[nH]c3c2cccc3)cc1	O=C(N1CCNCC1)c1ccc(/C=C/c2n[nH]c3c2cccc3)cc1
NCGC00371124-02	O=C(N1CCOCC1)[C@H]1CN(C2CCN(C(=O)c3c4c(cc5c3cccc5)cccc4)CC2)CCC1		Inactive	Acetyl-CoA carboxylase 2 Inhibitor		1	CP-640186 (hydrochloride)	363678040.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N1CCOCC1)[C@H]1CN(C2CCN(C(=O)c3c4c(cc5c3cccc5)cccc4)CC2)CCC1	O=C(N1CCOCC1)[C@H]1CN(C2CCN(C(=O)c3c4c(cc5c3cccc5)cccc4)CC2)CCC1
NCGC00509943-03	O=C(N1CCOCC1)c1n2c(nc1)C=CC(c1cc3nc(N)oc3cc1)=C2		Inactive	PI3K alpha Inhibitor		1	Serabelisib	384569391.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N1CCOCC1)c1n2c(nc1)C=CC(c1cc3nc(N)oc3cc1)=C2	O=C(N1CCOCC1)c1n2c(nc1)C=CC(c1cc3nc(N)oc3cc1)=C2
NCGC00485216-01	O=C(N1CSCC1)[C@H]1N(C(=O)[C@H]2[C@H](c3ccccc3)C2)[C@@H]2[C@H](C1)CCCC2		Inactive	Prolyl endopeptidase Inhibitor		1	S 17092	363681255.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N1CSCC1)[C@H]1N(C(=O)[C@H]2[C@H](c3ccccc3)C2)[C@@H]2[C@H](C1)CCCC2	O=C(N1CSCC1)[C@H]1N(C(=O)[C@H]2[C@H](c3ccccc3)C2)[C@@H]2[C@H](C1)CCCC2
NCGC00378896-03&NCGC00378896-04	O=C(N1CSCC1)[C@H]1NC[C@@H](N2CCN(c3n(-c4ccccc4)nc(C)c3)CC2)C1		Inactive	Dipeptidyl peptidase IV Inhibitor		2	Teneligliptin&MP-513   Tenelia   Tenglyn   Teneligliptin hydrobromide hydrate (Prop INNM)	405558594.0&434146898.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N1CSCC1)[C@H]1NC[C@@H](N2CCN(c3n(-c4ccccc4)nc(C)c3)CC2)C1	O=C(N1CSCC1)[C@H]1NC[C@@H](N2CCN(c3n(-c4ccccc4)nc(C)c3)CC2)C1
NCGC00241969-05	O=C(N1C[C@@H](N)CC1)c1c2n(CC)c(-c3c(N)non3)nc2cnc1		Inactive			1	SB 772077B dihydrochloride	377020342.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N1C[C@@H](N)CC1)c1c2n(CC)c(-c3c(N)non3)nc2cnc1	O=C(N1C[C@@H](N)CC1)c1c2n(CC)c(-c3c(N)non3)nc2cnc1
NCGC00482458-01	O=C(N1C[C@@H](NC(=O)C2CC2)CC1)c1[nH]nc(C(C)C)c1		Inactive	Lysine-specific demethylase 5A Inhibitor		1	NCGC00482458-01	363681130.0	Anti-infectives&2020_NPACT-1_CPE	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&0.0	O=C(N1C[C@@H](NC(=O)C2CC2)CC1)c1[nH]nc(C(C)C)c1	O=C(N1C[C@@H](NC(=O)C2CC2)CC1)c1[nH]nc(C(C)C)c1
NCGC00387475-01	O=C(N1C[C@H](CC=2N(c3ccc(-c4cc5c(occ5)cc4)cc3)C(=O)NN=2)CC1)C1CC1		Inactive	Fatty Acid Synthase (FAS) Inhibitor		1	GSK-2194069	384569160.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.0	O=C(N1C[C@H](CC=2N(c3ccc(-c4cc5c(occ5)cc4)cc3)C(=O)NN=2)CC1)C1CC1	O=C(N1C[C@H](CC=2N(c3ccc(-c4cc5c(occ5)cc4)cc3)C(=O)NN=2)CC1)C1CC1
NCGC00371007-05	O=C(N1C[C@H](CO)CCC1)c1ccc(C#Cc2ccc(OC)cc2)cc1		Inactive	Metabotropic glutamate receptor 3 Negative Allosteric Modulator		1	ML289	363677989.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N1C[C@H](CO)CCC1)c1ccc(C#Cc2ccc(OC)cc2)cc1	O=C(N1C[C@H](CO)CCC1)c1ccc(C#Cc2ccc(OC)cc2)cc1
NCGC00263281-01	O=C(N1C[C@H](Cn2c(-c3ccc(-c4cc5c(occ5)cc4)cc3)nc3c2ccnc3)CC1)C1CC1		Inactive	Fatty Acid Synthase (FAS) Inhibitor		1	GSK-1995010	137276089.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N1C[C@H](Cn2c(-c3ccc(-c4cc5c(occ5)cc4)cc3)nc3c2ccnc3)CC1)C1CC1	O=C(N1C[C@H](Cn2c(-c3ccc(-c4cc5c(occ5)cc4)cc3)nc3c2ccnc3)CC1)C1CC1
NCGC00386721-01	O=C(N1C[C@H](N(C)c2ncnc3[nH]ccc23)[C@H](C)CC1)N1CCCC1		Inactive	FGFR 1 Inhibitor		1	PF-956980	363680416.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N1C[C@H](N(C)c2ncnc3[nH]ccc23)[C@H](C)CC1)N1CCCC1	O=C(N1C[C@H](N(C)c2ncnc3[nH]ccc23)[C@H](C)CC1)N1CCCC1
NCGC00480900-01	O=C(N1C[C@H](N)CCC1)c1cc(OC)c2n(C)c(-c3n(CC)c4c(c3)cccc4)nc2c1		Inactive			1	PAD4-IN-1		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N1C[C@H](N)CCC1)c1cc(OC)c2n(C)c(-c3n(CC)c4c(c3)cccc4)nc2c1	O=C(N1C[C@H](N)CCC1)c1cc(OC)c2n(C)c(-c3n(CC)c4c(c3)cccc4)nc2c1
NCGC00480912-02	O=C(N1C[C@H](N)[C@H](O)CC1)c1cc(OC)c2n(C)c(-c3n(CC4CC4)c4c(c3)cccc4)nc2c1		Inactive	PADI4 Inhibitor (Protein-arginine deiminase type-4)		1	GSK-484	363681114.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	26.248368384	O=C(N1C[C@H](N)[C@H](O)CC1)c1cc(OC)c2n(C)c(-c3n(CC4CC4)c4c(c3)cccc4)nc2c1	O=C(N1C[C@H](N)[C@H](O)CC1)c1cc(OC)c2n(C)c(-c3n(CC4CC4)c4c(c3)cccc4)nc2c1
NCGC00482457-02	O=C(N1C[C@H](NC(=O)C2CC2)CC1)c1[nH]nc(C(C)C)c1		Inactive	Lysine-specific demethylase 5A Inhibitor		1	KDM5A-IN-1	363681129.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N1C[C@H](NC(=O)C2CC2)CC1)c1[nH]nc(C(C)C)c1	O=C(N1C[C@H](NC(=O)C2CC2)CC1)c1[nH]nc(C(C)C)c1
NCGC00386772-02	O=C(N1Cc2c(N3CCC(C(=O)CCC)CC3)ncnc2CC1)c1ccc(-c2ccccc2)cc1		Inactive	Potassium channel subfamily K member 9 Antagonist		1	PK-THPP	363680444.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N1Cc2c(N3CCC(C(=O)CCC)CC3)ncnc2CC1)c1ccc(-c2ccccc2)cc1	O=C(N1Cc2c(N3CCC(C(=O)CCC)CC3)ncnc2CC1)c1ccc(-c2ccccc2)cc1
NCGC00346674-02	O=C(N1Cc2c(ccc(CN3CCN(C)CC3)c2)C1)c1c(O)cc(O)c(C(C)C)c1		Inactive	Heat Shock Protein 90 (hsp90) Inhibitor		1	Onalespib	384568900.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	27.5370457439	O=C(N1Cc2c(ccc(CN3CCN(C)CC3)c2)C1)c1c(O)cc(O)c(C(C)C)c1	O=C(N1Cc2c(ccc(CN3CCN(C)CC3)c2)C1)c1c(O)cc(O)c(C(C)C)c1
NCGC00345024-01	O=C(N1Cc2c3n(cc(C4=C(c5n6c(nc5)C=CC=C6)C(=O)NC4=O)c3ccc2)CC1)N1CCOCC1		Inactive	GSK-3 Inhibitor		1	GSK3 Inhibitor	174007010.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N1Cc2c3n(cc(C4=C(c5n6c(nc5)C=CC=C6)C(=O)NC4=O)c3ccc2)CC1)N1CCOCC1	O=C(N1Cc2c3n(cc(C4=C(c5n6c(nc5)C=CC=C6)C(=O)NC4=O)c3ccc2)CC1)N1CCOCC1
NCGC00250392-01	O=C(N1OC[C@@H](O)C1)c1c(Cc2c(C)[nH]nc2C)sc2N(CC(C)C)C(=O)N(C)C(=O)c12		Inactive	MCT1 Inhibitor		1	AR-C155858	137275894.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N1OC[C@@H](O)C1)c1c(Cc2c(C)[nH]nc2C)sc2N(CC(C)C)C(=O)N(C)C(=O)c12	O=C(N1OC[C@@H](O)C1)c1c(Cc2c(C)[nH]nc2C)sc2N(CC(C)C)C(=O)N(C)C(=O)c12
NCGC00386683-01	O=C(NC(=N)N)c1c(n(-c2c3c(nccc3)ccc2)nc1)C1CC1		Inactive	Sodium/hydrogen exchanger 1 Inhibitor		1	Zoniporide hydrochloride	363680395.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC(=N)N)c1c(n(-c2c3c(nccc3)ccc2)nc1)C1CC1	O=C(NC(=N)N)c1c(n(-c2c3c(nccc3)ccc2)nc1)C1CC1
NCGC00510200-01	O=C(NC(=N)Nc1cc(NC(=O)c2ccc(-c3ccccc3)cc2)c(C)cc1)c1cc(OC)c(OC)c(OC)c1	4.9000001	Active	Hedgehog Antagonist	0.0	1	MRT-83	384569415.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	104.9607751853	O=C(NC(=N)Nc1cc(NC(=O)c2ccc(-c3ccccc3)cc2)c(C)cc1)c1cc(OC)c(OC)c(OC)c1	O=C(NC(=N)Nc1cc(NC(=O)c2ccc(-c3ccccc3)cc2)c(C)cc1)c1cc(OC)c(OC)c(OC)c1
NCGC00180997-01	O=C(NC(=O)C(CC)c1ccccc1)N		Inactive			1	Ethylphenylacetylurea	144206203.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC(=O)C(CC)c1ccccc1)N	O=C(NC(=O)C(CC)c1ccccc1)N
NCGC00182986-01	O=C(NC(=O)C(CC)c1ccccc1)NC(=O)C		Inactive			1	Acetylpheneturide	144206817.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC(=O)C(CC)c1ccccc1)NC(=O)C	O=C(NC(=O)C(CC)c1ccccc1)NC(=O)C
NCGC00094754-05	O=C(NC(=O)Cc1ccccc1)N		Inactive	Sodium channel alpha subunit Blocker		1	Phenacemide	170465322.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(NC(=O)Cc1ccccc1)N	O=C(NC(=O)Cc1ccccc1)N
NCGC00096010-07	O=C(NC(C(=O)N)=C)C(NC(=O)c1nc(C2=NC3c4nc(sc4)C4C(C)OC(=O)c5nc6C(O)C(NC(C(CC)C)C(=O)NC(C)C(=O)NC(=C)C(=O)NC(C)C(=O)NC3(c3scc(C(=O)NC(C(O)C)C(=O)N/C(=C/C)/C=7SCC(C(=O)NC(C(O)(C(O)C)C)c8scc(C(=O)N4)n8)N=7)n3)CC2)C=Cc6c(C(O)C)c5)sc1)=C		Inactive			1	Thiostrepton from Streptomyces azureus		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC(C(=O)N)=C)C(NC(=O)c1nc(C2=NC3c4nc(sc4)C4C(C)OC(=O)c5nc6C(O)C(NC(C(CC)C)C(=O)NC(C)C(=O)NC(=C)C(=O)NC(C)C(=O)NC3(c3scc(C(=O)NC(C(O)C)C(=O)N/C(=C/C)/C=7SCC(C(=O)NC(C(O)(C(O)C)C)c8scc(C(=O)N4)n8)N=7)n3)CC2)C=Cc6c(C(O)C)c5)sc1)=C	O=C(NC(C(=O)N)=C)C(NC(=O)c1nc(C2=NC3c4nc(sc4)C4C(C)OC(=O)c5nc6C(O)C(NC(C(CC)C)C(=O)NC(C)C(=O)NC(=C)C(=O)NC(C)C(=O)NC3(c3scc(C(=O)NC(C(O)C)C(=O)N/C(=C/C)/C=7SCC(C(=O)NC(C(O)(C(O)C)C)c8scc(C(=O)N4)n8)N=7)n3)CC2)C=Cc6c(C(O)C)c5)sc1)=C
NCGC00262569-03	O=C(NC(C(=O)N)=C)C(NC(=O)c1nc(C2=N[C@H]3c4nc(sc4)[C@@H]4[C@@H](C)OC(=O)c5nc6[C@@H](O)[C@H](N[C@@H](C(CC)C)C(=O)N[C@@H](C)C(=O)NC(=C)C(=O)N[C@@H](C)C(=O)N[C@]3(c3scc(C(=O)N[C@@H]([C@H](O)C)C(=O)N/C(=C/C)/C=7SC[C@H](C(=O)N[C@@H]([C@@](O)([C@H](O)C)C)c8scc(C(=O)N4)n8)N=7)n3)CC2)C=Cc6c([C@@H](O)C)c5)sc1)=C		Inactive	Toll-like receptor 9 Inhibitor		1	Thiostrepton	405558975.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC(C(=O)N)=C)C(NC(=O)c1nc(C2=N[C@H]3c4nc(sc4)[C@@H]4[C@@H](C)OC(=O)c5nc6[C@@H](O)[C@H](N[C@@H](C(CC)C)C(=O)N[C@@H](C)C(=O)NC(=C)C(=O)N[C@@H](C)C(=O)N[C@]3(c3scc(C(=O)N[C@@H]([C@H](O)C)C(=O)N/C(=C/C)/C=7SC[C@H](C(=O)N[C@@H]([C@@](O)([C@H](O)C)C)c8scc(C(=O)N4)n8)N=7)n3)CC2)C=Cc6c([C@@H](O)C)c5)sc1)=C	O=C(NC(C(=O)N)=C)C(NC(=O)c1nc(C2=N[C@H]3c4nc(sc4)[C@@H]4[C@@H](C)OC(=O)c5nc6[C@@H](O)[C@H](N[C@@H](C(CC)C)C(=O)N[C@@H](C)C(=O)NC(=C)C(=O)N[C@@H](C)C(=O)N[C@]3(c3scc(C(=O)N[C@@H]([C@H](O)C)C(=O)N/C(=C/C)/C=7SC[C@H](C(=O)N[C@@H]([C@@](O)([C@H](O)C)C)c8scc(C(=O)N4)n8)N=7)n3)CC2)C=Cc6c([C@@H](O)C)c5)sc1)=C
NCGC00386919-01	O=C(NC(C(=O)N1C(C(=O)Nc2c3c(nccc3)ccc2)CCC1)C(C)C)C(NC)C		Inactive			1	NCGC00386919-01	363680506.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC(C(=O)N1C(C(=O)Nc2c3c(nccc3)ccc2)CCC1)C(C)C)C(NC)C	O=C(NC(C(=O)N1C(C(=O)Nc2c3c(nccc3)ccc2)CCC1)C(C)C)C(NC)C
NCGC00380777-01	O=C(NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1C(C(=O)NC(C(=O)NC(C(=O)N2C(C(=O)NC(C(=O)NC(CO)Cc3ccccc3)(C)C)CC(O)C2)(CC)C)CCC(=O)N)CC(O)C1)(C)C)(C)C)CC(C)C)C(C)C)(C)C)C(NC(=O)C(NC(=O)C(NC(=O)C)Cc1ccccc1)(C)C)(C)C		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380777-01	363678779.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1C(C(=O)NC(C(=O)NC(C(=O)N2C(C(=O)NC(C(=O)NC(CO)Cc3ccccc3)(C)C)CC(O)C2)(CC)C)CCC(=O)N)CC(O)C1)(C)C)(C)C)CC(C)C)C(C)C)(C)C)C(NC(=O)C(NC(=O)C(NC(=O)C)Cc1ccccc1)(C)C)(C)C	O=C(NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1C(C(=O)NC(C(=O)NC(C(=O)N2C(C(=O)NC(C(=O)NC(CO)Cc3ccccc3)(C)C)CC(O)C2)(CC)C)CCC(=O)N)CC(O)C1)(C)C)(C)C)CC(C)C)C(C)C)(C)C)C(NC(=O)C(NC(=O)C(NC(=O)C)Cc1ccccc1)(C)C)(C)C
NCGC00178768-03	O=C(NC(C(=O)NC1C(=O)NC(CCN)C(=O)NC(Cc2ccccc2)C(=O)NC(CC(C)C)C(=O)NC(CCN)C(=O)NC(CCN)C(=O)NC(C(O)C)C(=O)NCC1)CCN)C(NC(=O)C(NC(=O)CCCCC(CC)C)CCN)C(O)C		Inactive	Peptide Antibiotic		1	POLYMYXIN B SULFATE	405558758.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC(C(=O)NC1C(=O)NC(CCN)C(=O)NC(Cc2ccccc2)C(=O)NC(CC(C)C)C(=O)NC(CCN)C(=O)NC(CCN)C(=O)NC(C(O)C)C(=O)NCC1)CCN)C(NC(=O)C(NC(=O)CCCCC(CC)C)CCN)C(O)C	O=C(NC(C(=O)NC1C(=O)NC(CCN)C(=O)NC(Cc2ccccc2)C(=O)NC(CC(C)C)C(=O)NC(CCN)C(=O)NC(CCN)C(=O)NC(C(O)C)C(=O)NCC1)CCN)C(NC(=O)C(NC(=O)CCCCC(CC)C)CCN)C(O)C
NCGC00389662-01	O=C(NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C(C(=O)NCC(=O)N)CCC1)CCCN=C(N)N)CC(C)C)Cc1ccc(O)cc1)C(NC(=O)C(NC(=O)C(NC(=O)C1NC(=O)CC1)Cc1[nH]cnc1)Cc1c2c([nH]c1)cccc2)CO		Inactive	Putative gonadotropin-releasing hormone II receptor Agonist		1	Luteinizing hormone releasing hormone human acetate salt (LHRH)	405558523.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C(C(=O)NCC(=O)N)CCC1)CCCN=C(N)N)CC(C)C)Cc1ccc(O)cc1)C(NC(=O)C(NC(=O)C(NC(=O)C1NC(=O)CC1)Cc1[nH]cnc1)Cc1c2c([nH]c1)cccc2)CO	O=C(NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C(C(=O)NCC(=O)N)CCC1)CCCN=C(N)N)CC(C)C)Cc1ccc(O)cc1)C(NC(=O)C(NC(=O)C(NC(=O)C1NC(=O)CC1)Cc1[nH]cnc1)Cc1c2c([nH]c1)cccc2)CO
NCGC00386535-01	O=C(NC(C)(C)C)C(CN1CCN(c2c(OC)cccc2)CC1)c1ccccc1		Inactive	Serotonin 1d (5-HT1d) receptor Partial Agonist		1	WAY 100135 dihydrochloride	363680319.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC(C)(C)C)C(CN1CCN(c2c(OC)cccc2)CC1)c1ccccc1	O=C(NC(C)(C)C)C(CN1CCN(c2c(OC)cccc2)CC1)c1ccccc1
NCGC00165863-16	O=C(NC(C)(C)C)Nc1c(-c2cc(OC)cc(OC)c2)cc2c(n1)nc(NCCCCN(CC)CC)nc2	4.8499999	Active	FGFR 1/3 Inhibitor	0.0	1	PD-173074	384568291.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	38.923836384	O=C(NC(C)(C)C)Nc1c(-c2cc(OC)cc(OC)c2)cc2c(n1)nc(NCCCCN(CC)CC)nc2	O=C(NC(C)(C)C)Nc1c(-c2cc(OC)cc(OC)c2)cc2c(n1)nc(NCCCCN(CC)CC)nc2
NCGC00182849-01	O=C(NC(C)(C)C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(C=C(C(=O)O)CC4)=CC3)CC2)CC1		Inactive	3-oxo-5-alpha-steroid 4-dehydrogenase 2 Inhibitor		1	Epristeride	144206545.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC(C)(C)C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(C=C(C(=O)O)CC4)=CC3)CC2)CC1	O=C(NC(C)(C)C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(C=C(C(=O)O)CC4)=CC3)CC2)CC1
NCGC00093560-05&NCGC00093560-13&NCGC00093560-19	O=C(NC(C)(C)C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](NC(=O)C=C4)CC3)CC2)CC1		Inactive	Androgen Receptor Antagonist		3	Finasteride	170464818.0&384568115.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	O=C(NC(C)(C)C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](NC(=O)C=C4)CC3)CC2)CC1	O=C(NC(C)(C)C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](NC(=O)C=C4)CC3)CC2)CC1
NCGC00485347-01	O=C(NC(C)(C)C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](NC(=O)CC4)CC3)CC2)CC1		Inactive	Steroid 5-alpha-reductase 2 Inhibitor		1	3-Oxo-4-aza-5Î±-androstane-17Î²-(N-t-butylcarboxamide)	363681293.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC(C)(C)C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](NC(=O)CC4)CC3)CC2)CC1	O=C(NC(C)(C)C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](NC(=O)CC4)CC3)CC2)CC1
NCGC00386917-01	O=C(NC(C)(C)C)[C@H](N(C(=O)c1occc1)c1ccc(C(C)(C)C)cc1)c1cnccc1		Inactive			1	NCGC00386917-01	363680504.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	15.542285716	O=C(NC(C)(C)C)[C@H](N(C(=O)c1occc1)c1ccc(C(C)(C)C)cc1)c1cnccc1	O=C(NC(C)(C)C)[C@H](N(C(=O)c1occc1)c1ccc(C(C)(C)C)cc1)c1cnccc1
NCGC00378903-01	O=C(NC(C)C)COc1cc(-c2nc(Nc3cc4c([nH]nc4)cc3)c3c(n2)cccc3)ccc1		Inactive	ROCK 2 Inhibitor		1	KD-025	363678268.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC(C)C)COc1cc(-c2nc(Nc3cc4c([nH]nc4)cc3)c3c(n2)cccc3)ccc1	O=C(NC(C)C)COc1cc(-c2nc(Nc3cc4c([nH]nc4)cc3)c3c(n2)cccc3)ccc1
NCGC00016438-04&NCGC00016438-06	O=C(NC(C)C)c1ccc(CNNC)cc1		Inactive	DNA Alkylating Drugs		2	Procarbazine hydrochloride	170465402.0&384567940.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NC(C)C)c1ccc(CNNC)cc1.Cl	O=C(NC(C)C)c1ccc(CNNC)cc1.Cl&O=C(NC(C)C)c1ccc(CNNC)cc1
NCGC00370695-04	O=C(NC(C)C)c1ncc(C#Cc2ccncc2)cc1		Inactive	Metabotropic glutamate receptor 5 Positive Allosteric Modulator		1	LSN2463359	363677811.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC(C)C)c1ncc(C#Cc2ccncc2)cc1	O=C(NC(C)C)c1ncc(C#Cc2ccncc2)cc1
NCGC00182997-01	O=C(NC(C)c1ccccc1)CCCCCCC/C=C\C/C=C\CCCCC		Inactive	Acyl coenzyme A:cholesterol acyltransferase Inhibitor		1	Melinamide	144206837.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(NC(C)c1ccccc1)CCCCCCC/C=C\C/C=C\CCCCC	O=C(NC(C)c1ccccc1)CCCCCCC/C=C\C/C=C\CCCCC
NCGC00263637-05&NCGC00263637-14	O=C(NC(C)c1ccccc1)c1c(/N=C/c2c(O)ccc3c2cccc3)cccc1		Inactive			2	Sirtinol		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(NC(C)c1ccccc1)c1c(/N=C/c2c(O)ccc3c2cccc3)cccc1	O=C(NC(C)c1ccccc1)c1c(/N=C/c2c(O)ccc3c2cccc3)cccc1
NCGC00390412-01	O=C(NC(C)c1sc(-c2sc(Oc3ccc(OC(C)C)cc3)nc2)nc1)C		Inactive	Acetyl-CoA carboxylase 2 Inhibitor		1	ACC2Inhibitor	363680892.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC(C)c1sc(-c2sc(Oc3ccc(OC(C)C)cc3)nc2)nc1)C	O=C(NC(C)c1sc(-c2sc(Oc3ccc(OC(C)C)cc3)nc2)nc1)C
NCGC00263193-02	O=C(NC(C)c1sccn1)Nc1c(OC)cc(Oc2c3c(ncc2)cc(OC)c(OC)c3)cc1		Inactive	CSF1R (c-FMS) Inhibitor		1	KI-20227	384568657.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC(C)c1sccn1)Nc1c(OC)cc(Oc2c3c(ncc2)cc(OC)c(OC)c3)cc1	O=C(NC(C)c1sccn1)Nc1c(OC)cc(Oc2c3c(ncc2)cc(OC)c(OC)c3)cc1
NCGC00388389-01	O=C(NC(C=O)C(O)C(O)[C@H](O)CO)C		Inactive			1	N-acetyl-D-Glucosamine	405558640.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC(C=O)C(O)C(O)[C@H](O)CO)C	O=C(NC(C=O)C(O)C(O)[C@H](O)CO)C
NCGC00380837-01	O=C(NC(CO)CC(O)(C)C)CC(O)CC(=O)Cc1ccccc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380837-01	363678807.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC(CO)CC(O)(C)C)CC(O)CC(=O)Cc1ccccc1	O=C(NC(CO)CC(O)(C)C)CC(O)CC(=O)Cc1ccccc1
NCGC00169629-02	O=C(NC(COC(=O)C)Cc1ccccc1)C(NC(=O)c1ccccc1)Cc1ccccc1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Ruscus | Family: Liliaceae | Species: aculeatus		1	NCGC00169629-02	363676852.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC(COC(=O)C)Cc1ccccc1)C(NC(=O)c1ccccc1)Cc1ccccc1	O=C(NC(COC(=O)C)Cc1ccccc1)C(NC(=O)c1ccccc1)Cc1ccccc1
NCGC00347908-01	O=C(NC(N/C(=N/C#N)/Nc1c2c(ccc1)cccc2)C(C)(C)C)Cc1cc(OC)c(OC)cc1		Inactive	P2X7 Receptor Antagonist		1	A-740003	174006396.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC(N/C(=N/C#N)/Nc1c2c(ccc1)cccc2)C(C)(C)C)Cc1cc(OC)c(OC)cc1	O=C(NC(N/C(=N/C#N)/Nc1c2c(ccc1)cccc2)C(C)(C)C)Cc1cc(OC)c(OC)cc1
NCGC00094763-03	O=C(NC([C@H](O)C)C(=O)N[C@@H](C(=O)N[C@H]1C(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCN)C(=O)N[C@H](CCN)C(=O)NC([C@H](O)C)C(=O)NCC1)CCN)[C@@H](NC(=O)CCCCC(CC)C)CCN		Inactive	Peptide Antibiotic		1	Polymyxin B sulphate	174006989.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC([C@H](O)C)C(=O)N[C@@H](C(=O)N[C@H]1C(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCN)C(=O)N[C@H](CCN)C(=O)NC([C@H](O)C)C(=O)NCC1)CCN)[C@@H](NC(=O)CCCCC(CC)C)CCN	O=C(NC([C@H](O)C)C(=O)N[C@@H](C(=O)N[C@H]1C(=O)N[C@@H](CCN)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCN)C(=O)N[C@H](CCN)C(=O)NC([C@H](O)C)C(=O)NCC1)CCN)[C@@H](NC(=O)CCCCC(CC)C)CCN
NCGC00386207-07	O=C(NC)C1=C(N)N(CC)c2nc(C#C[C@@](O)(COC)C)ccc2C1=O		Inactive			1	SAR131675		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC)C1=C(N)N(CC)c2nc(C#C[C@@](O)(COC)C)ccc2C1=O	O=C(NC)C1=C(N)N(CC)c2nc(C#C[C@@](O)(COC)C)ccc2C1=O
NCGC00263113-03	O=C(NC)N1C(C)Cc2c(C(c3ccc(N)cc3)=N1)cc1OCOc1c2		Inactive	AMPA receptor antagonist		1	GYKI 53655	363677209.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC)N1C(C)Cc2c(C(c3ccc(N)cc3)=N1)cc1OCOc1c2	O=C(NC)N1C(C)Cc2c(C(c3ccc(N)cc3)=N1)cc1OCOc1c2
NCGC00346635-10	O=C(NC)Nc1ccc(-c2nc(N3CC4OC(C3)CC4)c3c(n(C4CCC5(OCCO5)CC4)nc3)n2)cc1		Inactive	mTORC1/2 Inhibitor		1	WYE-125132	377020163.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	35.1650082959	O=C(NC)Nc1ccc(-c2nc(N3CC4OC(C3)CC4)c3c(n(C4CCC5(OCCO5)CC4)nc3)n2)cc1	O=C(NC)Nc1ccc(-c2nc(N3CC4OC(C3)CC4)c3c(n(C4CCC5(OCCO5)CC4)nc3)n2)cc1
NCGC00163450-06	O=C(NC)[C@@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)Cc1c2c([nH]c1)cccc2		Inactive	MMP Inhibitor		1	Ilomastat (GM6001, Galardin)	384568240.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NC)[C@@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)Cc1c2c([nH]c1)cccc2	O=C(NC)[C@@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)Cc1c2c([nH]c1)cccc2
NCGC00370683-05	O=C(NC)[C@@H](NC(=O)[C@@H]([C@@H](N(O)C=O)C)CCCc1ccccc1)C(C)(C)C		Inactive			1	GI254023X	434147099.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC)[C@@H](NC(=O)[C@@H]([C@@H](N(O)C=O)C)CCCc1ccccc1)C(C)(C)C	O=C(NC)[C@@H](NC(=O)[C@@H]([C@@H](N(O)C=O)C)CCCc1ccccc1)C(C)(C)C
NCGC00481603-01	O=C(NC)c1c(C)oc2c1ccc(Oc1ncnc3c1cc(OC)c(OC)c3)c2		Inactive	VEGFR-1/2/3 Inhibitor		1	Fruquintinib	377020212.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC)c1c(C)oc2c1ccc(Oc1ncnc3c1cc(OC)c(OC)c3)c2	O=C(NC)c1c(C)oc2c1ccc(Oc1ncnc3c1cc(OC)c(OC)c3)c2
NCGC00532324-01	O=C(NC)c1c2c(c([C@@H](CNc3ncnc(-c4cnc(C)nc4)c3)C)ccc2)ncc1		Inactive	DNA-PK Inhibitor		1	VX-984	384569538.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC)c1c2c(c([C@@H](CNc3ncnc(-c4cnc(C)nc4)c3)C)ccc2)ncc1	O=C(NC)c1c2c(c([C@@H](CNc3ncnc(-c4cnc(C)nc4)c3)C)ccc2)ncc1
NCGC00378878-02	O=C(NC)c1c2c(cc(Oc3c4c(ncc3)cc(OCC3(N)CC3)c(OC)c4)cc2)ccc1		Inactive	CSF1R (c-FMS) Inhibitor		1	Lucitanib	363678252.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC)c1c2c(cc(Oc3c4c(ncc3)cc(OCC3(N)CC3)c(OC)c4)cc2)ccc1	O=C(NC)c1c2c(cc(Oc3c4c(ncc3)cc(OCC3(N)CC3)c(OC)c4)cc2)ccc1
NCGC00346698-10	O=C(NC)c1cc(-c2nc3nc(N4[C@@H](C)COCC4)nc(N4[C@@H](C)COCC4)c3cc2)ccc1		Inactive	mTORC1/2 Inhibitor		1	Vistusertib	384568918.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC)c1cc(-c2nc3nc(N4[C@@H](C)COCC4)nc(N4[C@@H](C)COCC4)c3cc2)ccc1	O=C(NC)c1cc(-c2nc3nc(N4[C@@H](C)COCC4)nc(N4[C@@H](C)COCC4)c3cc2)ccc1
NCGC00346543-05	O=C(NC)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1	4.9000001	Active	MEK Inhibitor	0.0	1	NCGC00346543	384568829.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	79.0549653568	O=C(NC)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1	O=C(NC)c1cc2NC(=O)/C(=C(\Nc3cc(CN(C)C)ccc3)/c3ccccc3)/c2cc1
NCGC00378553-01	O=C(NC)c1cc2c([C@H](CCN3CCN(c4ccc(C(=O)N)cc4)CC3)OCC2)cc1		Inactive	Serotonin 1d (5-HT1d) receptor Partial Agonist		1	PNU 142633	363678087.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC)c1cc2c([C@H](CCN3CCN(c4ccc(C(=O)N)cc4)CC3)OCC2)cc1	O=C(NC)c1cc2c([C@H](CCN3CCN(c4ccc(C(=O)N)cc4)CC3)OCC2)cc1
NCGC00378655-01	O=C(NC)c1cc2c([C@H](CCN3CCN(c4ccc(OC)cc4)CC3)OCC2)cc1		Inactive	Serotonin 1d (5-HT1d) receptor Agonist		1	PNU 109291	363678138.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC)c1cc2c([C@H](CCN3CCN(c4ccc(OC)cc4)CC3)OCC2)cc1	O=C(NC)c1cc2c([C@H](CCN3CCN(c4ccc(OC)cc4)CC3)OCC2)cc1
NCGC00346631-02	O=C(NC)c1cc2c(cc(C3(O)c4n(cnc4)CC3)cc2)cc1		Inactive	Androgen Biosynthesis Inhibitor		1	Orteronel	363677486.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC)c1cc2c(cc(C3(O)c4n(cnc4)CC3)cc2)cc1	O=C(NC)c1cc2c(cc(C3(O)c4n(cnc4)CC3)cc2)cc1
NCGC00249892-01	O=C(NC)c1cn(-c2nc(N)c3ncn([C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4)c3n2)nc1		Inactive	Adenosine A2a receptor Agonist		1	Lexiscan	170465244.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NC)c1cn(-c2nc(N)c3ncn([C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4)c3n2)nc1	O=C(NC)c1cn(-c2nc(N)c3ncn([C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4)c3n2)nc1
NCGC00386432-02&NCGC00386432-07	O=C(NC)c1nccc(Oc2cc3sc(N[C@H]4[C@H](O)CCCC4)nc3cc2)c1		Inactive	CSF1R (c-FMS) Inhibitor		2	BLZ-945&BLZ945	363680284.0&434147131.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NC)c1nccc(Oc2cc3sc(N[C@H]4[C@H](O)CCCC4)nc3cc2)c1	O=C(NC)c1nccc(Oc2cc3sc(N[C@H]4[C@H](O)CCCC4)nc3cc2)c1
NCGC00346673-02	O=C(NC)c1nn(C)c-2c1C(C)(C)Cc1c-2nc(Nc2ccc(N3CCN(C)CC3)cc2)nc1		Inactive	CDK1/2/4/5 Inhibitor		1	Milciclib	384568899.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC)c1nn(C)c-2c1C(C)(C)Cc1c-2nc(Nc2ccc(N3CCN(C)CC3)cc2)nc1	O=C(NC)c1nn(C)c-2c1C(C)(C)Cc1c-2nc(Nc2ccc(N3CCN(C)CC3)cc2)nc1
NCGC00386087-01	O=C(NC/C=C/C=C(/[C@@H](OC)[C@@H](C)C1[C@@H](O)[C@@H](O)C(/C=C/C=C/C=C(/C(=O)C=2C(=O)NC=CC=2O)\C)O1)\C)[C@@H](CC)[C@]1(O)[C@H](O)[C@H](O)C(C)(C)[C@H](/C=C/C=C/C)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386087-01	363680100.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC/C=C/C=C(/[C@@H](OC)[C@@H](C)C1[C@@H](O)[C@@H](O)C(/C=C/C=C/C=C(/C(=O)C=2C(=O)NC=CC=2O)\C)O1)\C)[C@@H](CC)[C@]1(O)[C@H](O)[C@H](O)C(C)(C)[C@H](/C=C/C=C/C)O1	O=C(NC/C=C/C=C(/[C@@H](OC)[C@@H](C)C1[C@@H](O)[C@@H](O)C(/C=C/C=C/C=C(/C(=O)C=2C(=O)NC=CC=2O)\C)O1)\C)[C@@H](CC)[C@]1(O)[C@H](O)[C@H](O)C(C)(C)[C@H](/C=C/C=C/C)O1
NCGC00384845-01	O=C(NC/C=C/C=C(/[C@@H](OC)[C@@H](C)[C@H]1[C@@H](O)[C@@H](O)[C@@H](/C=C/C=C/C=C(/C(=O)C=2C(=O)N(C)C=CC=2O)\C)O1)\C)[C@@H](CC)[C@]1(O)[C@H](O)[C@H](O)C(C)(C)[C@H](/C=C/C=C/C)O1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384845-01	363679391.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC/C=C/C=C(/[C@@H](OC)[C@@H](C)[C@H]1[C@@H](O)[C@@H](O)[C@@H](/C=C/C=C/C=C(/C(=O)C=2C(=O)N(C)C=CC=2O)\C)O1)\C)[C@@H](CC)[C@]1(O)[C@H](O)[C@H](O)C(C)(C)[C@H](/C=C/C=C/C)O1	O=C(NC/C=C/C=C(/[C@@H](OC)[C@@H](C)[C@H]1[C@@H](O)[C@@H](O)[C@@H](/C=C/C=C/C=C(/C(=O)C=2C(=O)N(C)C=CC=2O)\C)O1)\C)[C@@H](CC)[C@]1(O)[C@H](O)[C@H](O)C(C)(C)[C@H](/C=C/C=C/C)O1
NCGC00263101-07	O=C(NC/C=C/c1cc2c(Nc3cc(C)c(Oc4cnc(C)cc4)cc3)ncnc2cc1)COC		Inactive	HER2 Inhibitor		1	CP-724714	363677202.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC/C=C/c1cc2c(Nc3cc(C)c(Oc4cnc(C)cc4)cc3)ncnc2cc1)COC	O=C(NC/C=C/c1cc2c(Nc3cc(C)c(Oc4cnc(C)cc4)cc3)ncnc2cc1)COC
NCGC00371088-01	O=C(NC1(C(=O)NCC#N)CCCCC1)c1ccc(-c2nc(N3CCN(C)CC3)sc2)cc1		Inactive	Cathepsin K Inhibitor		1	L 006235	363678024.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	15.0	O=C(NC1(C(=O)NCC#N)CCCCC1)c1ccc(-c2nc(N3CCN(C)CC3)sc2)cc1	O=C(NC1(C(=O)NCC#N)CCCCC1)c1ccc(-c2nc(N3CCN(C)CC3)sc2)cc1
NCGC00371151-06	O=C(NC1(C(=O)NCC#N)CCCCC1)c1ccc(N2CCN(CCC)CC2)cc1	5.8000002	Active	Cruzipain (Trypanosoma cruzi) Inhibitor	0.0	1	Balicatib	363678065.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	1.1	81.0802742159	O=C(NC1(C(=O)NCC#N)CCCCC1)c1ccc(N2CCN(CCC)CC2)cc1	O=C(NC1(C(=O)NCC#N)CCCCC1)c1ccc(N2CCN(CCC)CC2)cc1
NCGC00378975-01	O=C(NC1=C(C(=O)O)CCCC1)C(Cc1onc(-c2ncc(O)cc2)n1)(C)C		Inactive	Hydroxycarboxylic acid receptor 2 Agonist		1	MK-6892	363678299.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC1=C(C(=O)O)CCCC1)C(Cc1onc(-c2ncc(O)cc2)n1)(C)C	O=C(NC1=C(C(=O)O)CCCC1)C(Cc1onc(-c2ncc(O)cc2)n1)(C)C
NCGC00379159-05	O=C(NC1=Cc2c(C#N)c3nc4c(nc3n2C=C1)cccc4)c1sccc1		Inactive			1	HI-TOPK-032	377020245.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC1=Cc2c(C#N)c3nc4c(nc3n2C=C1)cccc4)c1sccc1	O=C(NC1=Cc2c(C#N)c3nc4c(nc3n2C=C1)cccc4)c1sccc1
NCGC00183850-01	O=C(NC1=NC(=O)N(C2OC(COC(=O)c3ccccc3)OC2)C=C1)C		Inactive			1	{4-[4-(Acetylamino)-2-oxopyrimidin-1(2H)-yl]-1,3-dioxolan-2-yl}methyl benzoate	144206820.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC1=NC(=O)N(C2OC(COC(=O)c3ccccc3)OC2)C=C1)C	O=C(NC1=NC(=O)N(C2OC(COC(=O)c3ccccc3)OC2)C=C1)C
NCGC00167515-03	O=C(NC1=NC(=O)N([C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=C1)CCCCCCCCCCCCCCCCCCCCC		Inactive	cell growth Inhibitor		1	Enocitabine	405558460.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC1=NC(=O)N([C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=C1)CCCCCCCCCCCCCCCCCCCCC	O=C(NC1=NC(=O)N([C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=C1)CCCCCCCCCCCCCCCCCCCCC
NCGC00485936-01	O=C(NC1=NN=C(CCc2cc(OC)cc(OC)c2)C1)c1ccc(N2C[C@@H](C)N[C@@H](C)C2)cc1		Inactive			1	AZD4547	363681428.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	35.18467708	O=C(NC1=NN=C(CCc2cc(OC)cc(OC)c2)C1)c1ccc(N2C[C@@H](C)N[C@@H](C)C2)cc1	O=C(NC1=NN=C(CCc2cc(OC)cc(OC)c2)C1)c1ccc(N2C[C@@H](C)N[C@@H](C)C2)cc1
NCGC00238454-10	O=C(NC1=Nc2c(OC)c(OC)ccc2C=2N1CCN=2)c1cnccc1		Inactive	PI3K Inhibitor		1	PIK-90	377020194.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC1=Nc2c(OC)c(OC)ccc2C=2N1CCN=2)c1cnccc1	O=C(NC1=Nc2c(OC)c(OC)ccc2C=2N1CCN=2)c1cnccc1
NCGC00346457-02&NCGC00346457-03	O=C(NC1=Nc2c(OC)c(OCCCN3CCOCC3)ccc2C=2N1CCN=2)c1cnc(N)nc1		Inactive	PI3K alpha/delta Inhibitor		2	Copanlisib	405559053.0&384568782.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O=C(NC1=Nc2c(OC)c(OCCCN3CCOCC3)ccc2C=2N1CCN=2)c1cnc(N)nc1	O=C(NC1=Nc2c(OC)c(OCCCN3CCOCC3)ccc2C=2N1CCN=2)c1cnc(N)nc1
NCGC00386536-01	O=C(NC1=Nc2c(cc(OC)c(OC)c2)C=2N1CCN=2)c1cnccc1		Inactive	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Inhibitor		1	PIK 90 analogue	363680320.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC1=Nc2c(cc(OC)c(OC)c2)C=2N1CCN=2)c1cnccc1	O=C(NC1=Nc2c(cc(OC)c(OC)c2)C=2N1CCN=2)c1cnccc1
NCGC00381196-01	O=C(NC1C(=O)N2C(C(=O)NC(C(CC)C)C(=O)NC(C(C)C)C(=O)N3C(C(=O)N(C)C(Cc4ccc(OC)cc4)C(=O)OC1C)CCC3)CCC2)C		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381196-01	363679016.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC1C(=O)N2C(C(=O)NC(C(CC)C)C(=O)NC(C(C)C)C(=O)N3C(C(=O)N(C)C(Cc4ccc(OC)cc4)C(=O)OC1C)CCC3)CCC2)C	O=C(NC1C(=O)N2C(C(=O)NC(C(CC)C)C(=O)NC(C(C)C)C(=O)N3C(C(=O)N(C)C(Cc4ccc(OC)cc4)C(=O)OC1C)CCC3)CCC2)C
NCGC00389455-01	O=C(NC1C(=O)N2C(C(=O)O)C(C)(C)SC12)Cc1ccccc1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	Penicillin G Sodium	405558782.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC1C(=O)N2C(C(=O)[O-])C(C)(C)SC12)Cc1ccccc1	O=C(NC1C(=O)N2C(C(=O)[O-])C(C)(C)SC12)Cc1ccccc1
NCGC00094956-04	O=C(NC1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CSC12)Cc1sccc1		Inactive	Solute carrier family 22 member 7 Inhibitor		1	Cephaloridine	124891818.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CSC12)Cc1sccc1	O=C(NC1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CSC12)Cc1sccc1
NCGC00094854-07	O=C(NC1C(=O)NC(=O)N1)N		Inactive	Allantoinase Substrate		1	Allantoin	170465460.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(NC1C(=O)NC(=O)N1)N	O=C(NC1C(=O)NC(=O)N1)N
NCGC00271789-11	O=C(NC1C(=O)NC(C(C)C)C(=O)N2C(C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC1C)CCC2)c1c2N=C3C(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5C(C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)CCC5)=C(N)C(=O)C(C)=C3Oc2c(C)cc1		Inactive			1	ActinomycinD		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(NC1C(=O)NC(C(C)C)C(=O)N2C(C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC1C)CCC2)c1c2N=C3C(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5C(C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)CCC5)=C(N)C(=O)C(C)=C3Oc2c(C)cc1	O=C(NC1C(=O)NC(C(C)C)C(=O)N2C(C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC1C)CCC2)c1c2N=C3C(C(=O)NC4C(=O)NC(C(C)C)C(=O)N5C(C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)CCC5)=C(N)C(=O)C(C)=C3Oc2c(C)cc1
NCGC00379082-01	O=C(NC1C(=O)NC(C(O)C)C(=O)N2C(C(=O)NC(C(O)C(O)c3ccc(O)cc3)C(=O)NC(C(O)C)C(=O)N3C(C(=O)NC(O)C(O)C1)C(O)C(C)C3)CC(O)C2)c1ccc(-c2ccc(-c3ccc(OCCCCC)cc3)cc2)cc1	5.25	Active		0.0	1	Anidulafungin	405558984.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	87.136923687	O=C(NC1C(=O)NC(C(O)C)C(=O)N2C(C(=O)NC(C(O)C(O)c3ccc(O)cc3)C(=O)NC(C(O)C)C(=O)N3C(C(=O)NC(O)C(O)C1)C(O)C(C)C3)CC(O)C2)c1ccc(-c2ccc(-c3ccc(OCCCCC)cc3)cc2)cc1	O=C(NC1C(=O)NC(C(O)C)C(=O)N2C(C(=O)NC(C(O)C(O)c3ccc(O)cc3)C(=O)NC(C(O)C)C(=O)N3C(C(=O)NC(O)C(O)C1)C(O)C(C)C3)CC(O)C2)c1ccc(-c2ccc(-c3ccc(OCCCCC)cc3)cc2)cc1
NCGC00380296-01	O=C(NC1C(=O)NC(CC(=O)N)C(=O)NC(C(=O)N/C=C\C)C(O)C2(O)C(=O)Nc3c2cccc3-c2c(O)ccc(c2)C1)C(=O)C(CC)C		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380296-01	363678528.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC1C(=O)NC(CC(=O)N)C(=O)NC(C(=O)N/C=C\C)C(O)C2(O)C(=O)Nc3c2cccc3-c2c(O)ccc(c2)C1)C(=O)C(CC)C	O=C(NC1C(=O)NC(CC(=O)N)C(=O)NC(C(=O)N/C=C\C)C(O)C2(O)C(=O)Nc3c2cccc3-c2c(O)ccc(c2)C1)C(=O)C(CC)C
NCGC00379009-01	O=C(NC1C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c3c([nH]c2)cccc3)C(=O)NC(CCCCN)C(=O)NC(C(O)C)C(=O)NC(C(=O)NC(C(O)C)CO)CSSC1)C(N)Cc1ccccc1		Inactive	Growth Hormone Release Inhibitors		1	Octreotide acetate	405558482.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC1C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c3c([nH]c2)cccc3)C(=O)NC(CCCCN)C(=O)NC(C(O)C)C(=O)NC(C(=O)NC(C(O)C)CO)CSSC1)C(N)Cc1ccccc1	O=C(NC1C(=O)NC(Cc2ccccc2)C(=O)NC(Cc2c3c([nH]c2)cccc3)C(=O)NC(CCCCN)C(=O)NC(C(O)C)C(=O)NC(C(=O)NC(C(O)C)CO)CSSC1)C(N)Cc1ccccc1
NCGC00347499-02	O=C(NC1C(O)(C)C(O)C(OC2C3C=C(C)C\4C(C)(C(=O)C=5C(=O)OC6(C=5O)C(C)(C=C(C(=O)O)C(C)C6)/C=C(\C)/CC/C=C/4\C)C3C(C)CC2)OC1C)c1c(O)cc(OC)cc1C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347499-02	363677604.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC1C(O)(C)C(O)C(OC2C3C=C(C)C\4C(C)(C(=O)C=5C(=O)OC6(C=5O)C(C)(C=C(C(=O)O)C(C)C6)/C=C(\C)/CC/C=C/4\C)C3C(C)CC2)OC1C)c1c(O)cc(OC)cc1C	O=C(NC1C(O)(C)C(O)C(OC2C3C=C(C)C\4C(C)(C(=O)C=5C(=O)OC6(C=5O)C(C)(C=C(C(=O)O)C(C)C6)/C=C(\C)/CC/C=C/4\C)C3C(C)CC2)OC1C)c1c(O)cc(OC)cc1C
NCGC00386093-01	O=C(NC1C(O)C(O)/C(/C)=C\C(C)C/C=C/C2C(O)C(C)=C(C)C3C(Cc4c5c([nH]c4)cccc5)NC(=O)C23C(=O)C1)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386093-01	363680104.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC1C(O)C(O)/C(/C)=C\C(C)C/C=C/C2C(O)C(C)=C(C)C3C(Cc4c5c([nH]c4)cccc5)NC(=O)C23C(=O)C1)C	O=C(NC1C(O)C(O)/C(/C)=C\C(C)C/C=C/C2C(O)C(C)=C(C)C3C(Cc4c5c([nH]c4)cccc5)NC(=O)C23C(=O)C1)C
NCGC00380124-01	O=C(NC1C(O)C(O)C(CO)OC1OC(C)(C)C1OC2C(C)(C=C(C3C4(C)C(C5(C)C(C(O)C4)OC(C(O)(C)C)CC5)CC3)CC2)CC1)C		Inactive	<MOA Unknown> | Class: triterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380124-01	363678465.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC1C(O)C(O)C(CO)OC1OC(C)(C)C1OC2C(C)(C=C(C3C4(C)C(C5(C)C(C(O)C4)OC(C(O)(C)C)CC5)CC3)CC2)CC1)C	O=C(NC1C(O)C(O)C(CO)OC1OC(C)(C)C1OC2C(C)(C=C(C3C4(C)C(C5(C)C(C(O)C4)OC(C(O)(C)C)CC5)CC3)CC2)CC1)C
NCGC00347780-02	O=C(NC1C(O)C(O)C(CO)OC1OC1C(C)(C)C2C(C)(C3C(C)(C4(C)C(C5C(C(=O)O)(C(O)C4)CCC(C)(C)C5)=CC3)CC2)CC1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347780-02	363677686.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC1C(O)C(O)C(CO)OC1OC1C(C)(C)C2C(C)(C3C(C)(C4(C)C(C5C(C(=O)O)(C(O)C4)CCC(C)(C)C5)=CC3)CC2)CC1)C	O=C(NC1C(O)C(O)C(CO)OC1OC1C(C)(C)C2C(C)(C3C(C)(C4(C)C(C5C(C(=O)O)(C(O)C4)CCC(C)(C)C5)=CC3)CC2)CC1)C
NCGC00380734-01	O=C(NC1C(O)C(O)C(COC)OC1OC(C)(C)C1OC2C(C)(C=C(C3C4(C)C(C5(C)C(C(O)C4)OC(C(O)(C)C)CC5)CC3)CC2)CC1)C		Inactive	<MOA Unknown> | Class: triterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380734-01	363678747.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC1C(O)C(O)C(COC)OC1OC(C)(C)C1OC2C(C)(C=C(C3C4(C)C(C5(C)C(C(O)C4)OC(C(O)(C)C)CC5)CC3)CC2)CC1)C	O=C(NC1C(O)C(O)C(COC)OC1OC(C)(C)C1OC2C(C)(C=C(C3C4(C)C(C5(C)C(C(O)C4)OC(C(O)(C)C)CC5)CC3)CC2)CC1)C
NCGC00180267-02	O=C(NC1C(O)C(O)C(COC)OC1OC(C)(C)C1OC2C(C)(C=C(C3C4(C)C(C5(C)C(C(O)C4)OC(C(OC4C(NC(=O)C)C(O)C(O)C(CO)O4)(C)C)CC5)CC3)CC2)CC1)C		Inactive	<MOA Unknown> | Class: triterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180267-02	363677006.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC1C(O)C(O)C(COC)OC1OC(C)(C)C1OC2C(C)(C=C(C3C4(C)C(C5(C)C(C(O)C4)OC(C(OC4C(NC(=O)C)C(O)C(O)C(CO)O4)(C)C)CC5)CC3)CC2)CC1)C	O=C(NC1C(O)C(O)C(COC)OC1OC(C)(C)C1OC2C(C)(C=C(C3C4(C)C(C5(C)C(C(O)C4)OC(C(OC4C(NC(=O)C)C(O)C(O)C(CO)O4)(C)C)CC5)CC3)CC2)CC1)C
NCGC00510518-01	O=C(NC1CC1)c1c(C)cc(-c2c3n(C(NCC4CC(O)(C)C4)=CC(Oc4cnccc4)=N3)nc2)cc1		Inactive	MPS1 Inhibitor		1	CFI-402257	384569471.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC1CC1)c1c(C)cc(-c2c3n(C(NCC4CC(O)(C)C4)=CC(Oc4cnccc4)=N3)nc2)cc1	O=C(NC1CC1)c1c(C)cc(-c2c3n(C(NCC4CC(O)(C)C4)=CC(Oc4cnccc4)=N3)nc2)cc1
NCGC00346966-01	O=C(NC1CC1)c1cc(-c2cc3[nH]nc(NC(=O)C4CC4)c3cc2)ccc1		Inactive	Receptor-interacting serine/threonine-protein kinase 1 (RIPK1)		1	HMSL10088	174006754.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC1CC1)c1cc(-c2cc3[nH]nc(NC(=O)C4CC4)c3cc2)ccc1	O=C(NC1CC1)c1cc(-c2cc3[nH]nc(NC(=O)C4CC4)c3cc2)ccc1
NCGC00386261-01	O=C(NC1CC2N(c3ncc(C(=O)C4CC4)cc3)C(C1)CC2)c1c(C)cc(C(=O)N)c(N[C@@H](CC)C)c1	6.5999999	Active	Heat Shock Protein 90 (Hsp90) Inhibitor	0.0	1	XL-888	363680173.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	1.4	41.8301442439	O=C(NC1CC2N(c3ncc(C(=O)C4CC4)cc3)C(C1)CC2)c1c(C)cc(C(=O)N)c(N[C@@H](CC)C)c1	O=C(NC1CC2N(c3ncc(C(=O)C4CC4)cc3)C(C1)CC2)c1c(C)cc(C(=O)N)c(N[C@@H](CC)C)c1
NCGC00371036-02	O=C(NC1CCC(CCN2Cc3c(cc(C#N)cc3)CC2)CC1)c1c2c(ncc1)cccc2		Inactive	Dopamine D3 receptor Antagonist		1	SB 277011A	363678001.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC1CCC(CCN2Cc3c(cc(C#N)cc3)CC2)CC1)c1c2c(ncc1)cccc2	O=C(NC1CCC(CCN2Cc3c(cc(C#N)cc3)CC2)CC1)c1c2c(ncc1)cccc2
NCGC00263087-10	O=C(NC1CCC(N2CCN(CC3CC3)CC2)CC1)c1cc(OC)c(Nc2nc3N(C(C)C)[C@H](CC)C(=O)N(C)c3cn2)cc1		Inactive	Polo-like Kinase-1 (Plk-1) Inhibitor		1	Volasertib	384568581.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(NC1CCC(N2CCN(CC3CC3)CC2)CC1)c1cc(OC)c(Nc2nc3N(C(C)C)[C@H](CC)C(=O)N(C)c3cn2)cc1	O=C(NC1CCC(N2CCN(CC3CC3)CC2)CC1)c1cc(OC)c(Nc2nc3N(C(C)C)[C@H](CC)C(=O)N(C)c3cn2)cc1
NCGC00386933-01	O=C(NC1CCC1)Cc1ccc(-c2ccccc2)cc1		Inactive			1	NCGC00386933-01	363680517.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC1CCC1)Cc1ccc(-c2ccccc2)cc1	O=C(NC1CCC1)Cc1ccc(-c2ccccc2)cc1
NCGC00386840-01	O=C(NC1CCCC1)[C@H](N(C(=O)Cn1nc(-c2cc3OCOc3cc2)nn1)C1CCCCC1)C		Inactive			1	NCGC00386840-01	363680460.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC1CCCC1)[C@H](N(C(=O)Cn1nc(-c2cc3OCOc3cc2)nn1)C1CCCCC1)C	O=C(NC1CCCC1)[C@H](N(C(=O)Cn1nc(-c2cc3OCOc3cc2)nn1)C1CCCCC1)C
NCGC00346836-09	O=C(NC1CCCCC1)[C@@H]1CN([C@H](C)CC1)c1nc(NC)nc(-c2cc3[nH]nc(N)c3cc2)c1		Inactive	Phosphoinositide Dependent Kinase Inhibitor		1	GSK-2334470	384568948.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.3599971599	O=C(NC1CCCCC1)[C@@H]1CN([C@H](C)CC1)c1nc(NC)nc(-c2cc3[nH]nc(N)c3cc2)c1	O=C(NC1CCCCC1)[C@@H]1CN([C@H](C)CC1)c1nc(NC)nc(-c2cc3[nH]nc(N)c3cc2)c1
NCGC00253438-12	O=C(NC1CCN(C)CC1)c1cc(OC)c(Nc2nc3N([C@H](CC)C(=O)N(C)c3cn2)C2CCCC2)cc1		Inactive	Polo-like Kinase-1 (Plk-1) Inhibitor		1	BI-2536	384568561.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(NC1CCN(C)CC1)c1cc(OC)c(Nc2nc3N([C@H](CC)C(=O)N(C)c3cn2)C2CCCC2)cc1	O=C(NC1CCN(C)CC1)c1cc(OC)c(Nc2nc3N([C@H](CC)C(=O)N(C)c3cn2)C2CCCC2)cc1
NCGC00165810-02	O=C(NC1CCN(CCc2c3c([nH]c2)cccc3)CC1)c1ccccc1		Inactive	Alpha-1d adrenergic receptor Antagonist		1	Indoramin hydrochloride	170466233.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	13.30594184	O=C(NC1CCN(CCc2c3c([nH]c2)cccc3)CC1)c1ccccc1.Cl	O=C(NC1CCN(CCc2c3c([nH]c2)cccc3)CC1)c1ccccc1.Cl
NCGC00370758-10	O=C(NC1CCN(Cc2ccccc2)CC1)COc1ccc(C(=O)c2ccccc2)cc1		Inactive	Adiponectin receptor protein 2 Agonist		1	AdipoRon	363677838.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC1CCN(Cc2ccccc2)CC1)COc1ccc(C(=O)c2ccccc2)cc1	O=C(NC1CCN(Cc2ccccc2)CC1)COc1ccc(C(=O)c2ccccc2)cc1
NCGC00346679-10	O=C(NC1CCOCC1)c1ccc(-c2nccc(-c3c(-c4ncccc4)n[nH]c3)c2)cc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	GW-788388	363677513.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC1CCOCC1)c1ccc(-c2nccc(-c3c(-c4ncccc4)n[nH]c3)c2)cc1	O=C(NC1CCOCC1)c1ccc(-c2nccc(-c3c(-c4ncccc4)n[nH]c3)c2)cc1
NCGC00183029-02	O=C(NC1CNCCC1)c1cc(OC)c(OC)c(OC)c1		Inactive	reactive oxygen species biosynthetic process Inhibitor		1	Troxipide	170465889.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NC1CNCCC1)c1cc(OC)c(OC)c(OC)c1	O=C(NC1CNCCC1)c1cc(OC)c(OC)c(OC)c1
NCGC00183873-03&NCGC00183873-05	O=C(NC1C[C@@H]2N(C)[C@@H](C1)CCC2)c1nn(C)c2c1cccc2		Inactive			2	Granisetron·HCl&Granisetron hydrochloride		Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NC1C[C@@H]2N(C)[C@@H](C1)CCC2)c1nn(C)c2c1cccc2	O=C(NC1C[C@@H]2N(C)[C@@H](C1)CCC2)c1nn(C)c2c1cccc2
NCGC00183011-01	O=C(NC1C[C@@H]2N(C)[C@H](C1)CC2)N1C(=O)Nc2c1cccc2		Inactive	Serotonin 3 (5-HT3) receptor Antagonist		1	Itasetron	144206831.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&0.0	O=C(NC1C[C@@H]2N(C)[C@H](C1)CC2)N1C(=O)Nc2c1cccc2	O=C(NC1C[C@@H]2N(C)[C@H](C1)CC2)N1C(=O)Nc2c1cccc2
NCGC00408801-01	O=C(NC1C[C@H]2N(c3ncc(C(=O)C4CC4)cc3)C(C1)CC2)c1c(C)cc(C(=O)N)c(N[C@@H](CC)C)c1	6.1999998	Active	Heat Shock Protein 90 (Hsp90) Inhibitor	0.0	1	XL-888	363681051.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	1.4	59.9378593564	O=C(NC1C[C@H]2N(c3ncc(C(=O)C4CC4)cc3)C(C1)CC2)c1c(C)cc(C(=O)N)c(N[C@@H](CC)C)c1	O=C(NC1C[C@H]2N(c3ncc(C(=O)C4CC4)cc3)C(C1)CC2)c1c(C)cc(C(=O)N)c(N[C@@H](CC)C)c1
NCGC00370732-02	O=C(NC=1C(=O)N(N(C)C=1C)c1ccccc1)C1ON=C(c2c(C)nn(CC)c2)C1		Inactive			1	ISPA-28	363677829.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC=1C(=O)N(N(C)C=1C)c1ccccc1)C1ON=C(c2c(C)nn(CC)c2)C1	O=C(NC=1C(=O)N(N(C)C=1C)c1ccccc1)C1ON=C(c2c(C)nn(CC)c2)C1
NCGC00016605-08	O=C(NC=1C(=O)N(N(C)C=1C)c1ccccc1)c1cnccc1		Inactive			1	Nifenazone	170466050.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NC=1C(=O)N(N(C)C=1C)c1ccccc1)c1cnccc1	O=C(NC=1C(=O)N(N(C)C=1C)c1ccccc1)c1cnccc1
NCGC00370837-01	O=C(NC=1SC(C)(N(C(=O)C)N=1)c1ccccc1)C		Inactive	Kinesin-like protein 1 Inhibitor		1	K 858	363677876.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC=1SC(C)(N(C(=O)C)N=1)c1ccccc1)C	O=C(NC=1SC(C)(N(C(=O)C)N=1)c1ccccc1)C
NCGC00387803-01	O=C(NCC(=O)N)C(NC(=O)C1N(C(=O)C2NC(=O)C(CC(=O)N)NC(=O)C(C(O)C)NC(=O)C(C(CC)C)NC(=O)C(Cc3ccc(OCC)cc3)NC(=O)CCSSC2)CCC1)CCCN		Inactive	Oxytocin receptor Antagonist		1	Atosiban	405558677.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC(=O)N)C(NC(=O)C1N(C(=O)C2NC(=O)C(CC(=O)N)NC(=O)C(C(O)C)NC(=O)C(C(CC)C)NC(=O)C(Cc3ccc(OCC)cc3)NC(=O)CCSSC2)CCC1)CCCN	O=C(NCC(=O)N)C(NC(=O)C1N(C(=O)C2NC(=O)C(CC(=O)N)NC(=O)C(C(O)C)NC(=O)C(C(CC)C)NC(=O)C(Cc3ccc(OCC)cc3)NC(=O)CCSSC2)CCC1)CCCN
NCGC00379053-02	O=C(NCC(=O)N)C(NC(=O)C1N(C(=O)C2NC(=O)C(CC(=O)N)NC(=O)C(CCC(=O)N)NC(=O)C(Cc3ccccc3)NC(=O)C(Cc3ccc(O)cc3)NC(=O)CCSSC2)CCC1)CCCNC(=N)N		Inactive	Vasopressin receptor Agonist		1	Desmopressin (Acetate)	405558564.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC(=O)N)C(NC(=O)C1N(C(=O)C2NC(=O)C(CC(=O)N)NC(=O)C(CCC(=O)N)NC(=O)C(Cc3ccccc3)NC(=O)C(Cc3ccc(O)cc3)NC(=O)CCSSC2)CCC1)CCCNC(=N)N	O=C(NCC(=O)N)C(NC(=O)C1N(C(=O)C2NC(=O)C(CC(=O)N)NC(=O)C(CCC(=O)N)NC(=O)C(Cc3ccccc3)NC(=O)C(Cc3ccc(O)cc3)NC(=O)CCSSC2)CCC1)CCCNC(=N)N
NCGC00390811-01	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)C([C@H](CC)C)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CC(C)C		Inactive	Oxytocin receptor Agonist		1	Oxytocin	405558950.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)C([C@H](CC)C)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CC(C)C	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)C([C@H](CC)C)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CC(C)C
NCGC00181743-02	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCCN		Inactive	Vasopressin receptor Agonist		1	Lypressin	144206977.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCCN	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCCN
NCGC00509864-02	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCN		Inactive			1	ORNIPRESSIN	405558494.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCN	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCN
NCGC00185754-01	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC2)CCC1)CCCCN		Inactive	Vasopressin V1a Receptor Partial Agonist		1	Terlipressin	144206925.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC2)CCC1)CCCCN	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC2)CCC1)CCCCN
NCGC00182033-01	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCCN		Inactive	Vasopressin V1a receptor Agonist		1	Felypressin	144206485.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCCN	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H](N)CSSC2)CCC1)CCCCN
NCGC00183107-01	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@H](Cc3ccc(O)cc3)N(C)C(=O)CCCSC2)CCC1)CC(C)C		Inactive			1	NCGC00183107-01	124894307.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@H](Cc3ccc(O)cc3)N(C)C(=O)CCCSC2)CCC1)CC(C)C	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@H](Cc3ccc(O)cc3)N(C)C(=O)CCCSC2)CCC1)CC(C)C
NCGC00485451-02	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@H](Cc3ccc(OC)cc3)NC(=O)CCCSC2)CCC1)CC(C)C		Inactive			1	Carbetocin	363681337.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@H](Cc3ccc(OC)cc3)NC(=O)CCCSC2)CCC1)CC(C)C	O=C(NCC(=O)N)[C@@H](NC(=O)[C@H]1N(C(=O)[C@H]2NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@H](Cc3ccc(OC)cc3)NC(=O)CCCSC2)CCC1)CC(C)C
NCGC00384204-04	O=C(NCC(=O)N1CCCC1)Nc1cc2c(cncc2)cc1		Inactive	PRMT3 Inhibitor		1	SGC-707	363679195.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC(=O)N1CCCC1)Nc1cc2c(cncc2)cc1	O=C(NCC(=O)N1CCCC1)Nc1cc2c(cncc2)cc1
NCGC00387457-01	O=C(NCC(=O)N1CCCCC1)Nc1cc2snnc2cc1		Inactive			1	UNC 2327		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCC(=O)N1CCCCC1)Nc1cc2snnc2cc1	O=C(NCC(=O)N1CCCCC1)Nc1cc2snnc2cc1
NCGC00378640-02&NCGC00378640-03	O=C(NCC(=O)O)[C@H](CN1C[C@H](C)[C@](C)(c2cc(O)ccc2)CC1)Cc1ccccc1		Inactive	mu-Opioid Antagonist		2	Alvimopan	363678135.0&405558558.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NCC(=O)O)[C@H](CN1C[C@H](C)[C@](C)(c2cc(O)ccc2)CC1)Cc1ccccc1	O=C(NCC(=O)O)[C@H](CN1C[C@H](C)[C@](C)(c2cc(O)ccc2)CC1)Cc1ccccc1
NCGC00186464-03&NCGC00186464-04	O=C(NCC(C(=O)N)(C)C)[C@H](C(C)C)C[C@H](O)[C@@H](N)C[C@@H](C(C)C)Cc1cc(OCCCOC)c(OC)cc1		Inactive	Renin Inhibitor		2	Aliskiren hemifumarate	170465199.0&384568441.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(NCC(C(=O)N)(C)C)[C@H](C(C)C)C[C@H](O)[C@@H](N)C[C@@H](C(C)C)Cc1cc(OCCCOC)c(OC)cc1.Cl	O=C(NCC(C(=O)N)(C)C)[C@H](C(C)C)C[C@H](O)[C@@H](N)C[C@@H](C(C)C)Cc1cc(OCCCOC)c(OC)cc1.Cl&O=C(NCC(C(=O)N)(C)C)[C@H](C(C)C)C[C@H](O)[C@@H](N)C[C@@H](C(C)C)Cc1cc(OCCCOC)c(OC)cc1
NCGC00511392-01	O=C(NCC(C)(C)n1nc(-c2ccc(C)cc2)c2c(N)ncnc12)c1ccncc1		Inactive	RIP2 kinase Inhibitor		1	WEHI-345	384569503.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC(C)(C)n1nc(-c2ccc(C)cc2)c2c(N)ncnc12)c1ccncc1	O=C(NCC(C)(C)n1nc(-c2ccc(C)cc2)c2c(N)ncnc12)c1ccncc1
NCGC00347573-02	O=C(NCC(C)C)/C=C/CCCCc1cc2OCOc2cc1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347573-02	363677628.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCC(C)C)/C=C/CCCCc1cc2OCOc2cc1	O=C(NCC(C)C)/C=C/CCCCc1cc2OCOc2cc1
NCGC00253572-01	O=C(NCC(CC)(CC)c1cc(OC)ccc1)CCCO		Inactive			1	Embutramide	170465662.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC(CC)(CC)c1cc(OC)ccc1)CCCO	O=C(NCC(CC)(CC)c1cc(OC)ccc1)CCCO
NCGC00178238-05	O=C(NCC(O)c1c(OC)ccc(OC)c1)CN		Inactive	Alpha-1b adrenergic receptor Agonist		1	Midodrine hydrochloride	170464672.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC(O)c1c(OC)ccc(OC)c1)CN.Cl	O=C(NCC(O)c1c(OC)ccc(OC)c1)CN.Cl
NCGC00485416-01	O=C(NCC(c1ccccc1)c1ccccc1)[C@@H](NC(=O)[C@H]1N(C(=O)CCC(=O)c2ccccc2)Cc2c(cccc2)C1)CCCCN		Inactive	C-X-C chemokine receptor type 3 Agonist		1	VUF10661	363681328.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	18.5278486881	O=C(NCC(c1ccccc1)c1ccccc1)[C@@H](NC(=O)[C@H]1N(C(=O)CCC(=O)c2ccccc2)Cc2c(cccc2)C1)CCCCN	O=C(NCC(c1ccccc1)c1ccccc1)[C@@H](NC(=O)[C@H]1N(C(=O)CCC(=O)c2ccccc2)Cc2c(cccc2)C1)CCCCN
NCGC00481575-01	O=C(NCC)C#Cc1cc2NC(=O)/C(=C(\Nc3ccc(CN(C)C)cc3)/c3ccccc3)/c2cc1		Inactive	Aurora Kinase Inhibitor		1	BI-847325	363681124.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC)C#Cc1cc2NC(=O)/C(=C(\Nc3ccc(CN(C)C)cc3)/c3ccccc3)/c2cc1	O=C(NCC)C#Cc1cc2NC(=O)/C(=C(\Nc3ccc(CN(C)C)cc3)/c3ccccc3)/c2cc1
NCGC00346520-02	O=C(NCC)CCC/C=C\C[C@@H]1[C@@H](/C=C/C(O)CCc2ccccc2)[C@@H](O)C[C@@H]1O		Inactive	prostaglandin		1	Bimatoprost	363677439.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC)CCC/C=C\C[C@@H]1[C@@H](/C=C/C(O)CCc2ccccc2)[C@@H](O)C[C@@H]1O	O=C(NCC)CCC/C=C\C[C@@H]1[C@@H](/C=C/C(O)CCc2ccccc2)[C@@H](O)C[C@@H]1O
NCGC00181745-03	O=C(NCC)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O		Inactive	prostaglandin		1	Bimatoprost	405558553.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O	O=C(NCC)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
NCGC00346574-04	O=C(NCC)Nc1c(OC)cc(-c2nc(N[C@@H](CCC)c3cnccc3)c(C)cn2)cc1		Inactive	Tubulin depolymerization Inhibitor		1	Lexibulin hydrochloride	384568847.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(NCC)Nc1c(OC)cc(-c2nc(N[C@@H](CCC)c3cnccc3)c(C)cn2)cc1	O=C(NCC)Nc1c(OC)cc(-c2nc(N[C@@H](CCC)c3cnccc3)c(C)cn2)cc1
NCGC00346465-06	O=C(NCC)Nc1ccc(-c2nc(N3[C@@H](C)COCC3)c3c(n2)CN(C2COC2)CC3)cc1		Inactive	Pim-3 Kinase Inhibitor, mTOR		1	GDC-0349	384568786.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC)Nc1ccc(-c2nc(N3[C@@H](C)COCC3)c3c(n2)CN(C2COC2)CC3)cc1	O=C(NCC)Nc1ccc(-c2nc(N3[C@@H](C)COCC3)c3c(n2)CN(C2COC2)CC3)cc1
NCGC00372509-03	O=C(NCC)Nc1sc(-c2nc(-c3nccnc3)nc(-c3c(C)cc(OC)cc3C)c2)cn1		Inactive	LIMK1/LIMK2 Inhibitor		1	BMS-4	363678075.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC)Nc1sc(-c2nc(-c3nccnc3)nc(-c3c(C)cc(OC)cc3C)c2)cn1	O=C(NCC)Nc1sc(-c2nc(-c3nccnc3)nc(-c3c(C)cc(OC)cc3C)c2)cn1
NCGC00247878-08	O=C(NCC)c1c(c(-c2c(O)cc(O)c(C(C)C)c2)on1)-c1ccc(CN2CCOCC2)cc1	6.5	Active	Heat Shock Protein 90 (hsp90) Inhibitor	0.0	1	NVP-AUY922	384568519.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	1.4	41.645736205	O=C(NCC)c1c(c(-c2c(O)cc(O)c(C(C)C)c2)on1)-c1ccc(CN2CCOCC2)cc1	O=C(NCC)c1c(c(-c2c(O)cc(O)c(C(C)C)c2)on1)-c1ccc(CN2CCOCC2)cc1
NCGC00379203-01	O=C(NCC1(N(C)C)CCCC1)c1cc(OC)c(OCc2ccccc2)c(OC)c1		Inactive	Glycine transporter 2 Inhibitor		1	Org 25543 hydrochloride	363678415.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCC1(N(C)C)CCCC1)c1cc(OC)c(OCc2ccccc2)c(OC)c1	O=C(NCC1(N(C)C)CCCC1)c1cc(OC)c(OCc2ccccc2)c(OC)c1
NCGC00384304-02	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c(C)c(N(CC)C2CCC(N(CCOC)C)CC2)cc(C#CCN2CCOCC2)c1		Inactive	Histone-lysine N-methyltransferase EZH2 Inhibitor		1	EPZ011989	384569110.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c(C)c(N(CC)C2CCC(N(CCOC)C)CC2)cc(C#CCN2CCOCC2)c1	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c(C)c(N(CC)C2CCC(N(CCOC)C)CC2)cc(C#CCN2CCOCC2)c1
NCGC00381562-02	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c(C)c(N(CC)C2CCOCC2)cc(-c2ccc(CN3CCOCC3)cc2)c1		Inactive	EZH2 Inhibitor		1	Tazemetostat	384569100.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c(C)c(N(CC)C2CCOCC2)cc(-c2ccc(CN3CCOCC3)cc2)c1	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c(C)c(N(CC)C2CCOCC2)cc(-c2ccc(CN3CCOCC3)cc2)c1
NCGC00480919-01	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(C)cn(C(C)C)c2cc(-c2cnc(N3CCN(C)CC3)cc2)c1	4.9000001	Active		0.0	1	GSK-503?EZH2 inhibitor	384569251.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	114.8964516004	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(C)cn(C(C)C)c2cc(-c2cnc(N3CCN(C)CC3)cc2)c1	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(C)cn(C(C)C)c2cc(-c2cnc(N3CCN(C)CC3)cc2)c1
NCGC00347286-15	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(C)cn([C@H](CC)C)c2cc(-c2cnc(N3CCNCC3)cc2)c1		Inactive	EZH2 Inhibitor		1	GSK-126	384568986.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-14.6553659599	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(C)cn([C@H](CC)C)c2cc(-c2cnc(N3CCNCC3)cc2)c1	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(C)cn([C@H](CC)C)c2cc(-c2cnc(N3CCNCC3)cc2)c1
NCGC00351604-03	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(n(C3CCCC3)nc2)cc(-c2ccc(CN3CCOCC3)cc2)c1		Inactive	EZH2 Inhibitor		1	EPZ-005687	384569019.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(n(C3CCCC3)nc2)cc(-c2ccc(CN3CCOCC3)cc2)c1	O=C(NCC=1C(=O)NC(C)=CC=1C)c1c2c(n(C3CCCC3)nc2)cc(-c2ccc(CN3CCOCC3)cc2)c1
NCGC00351480-16	O=C(NCC=1C(=O)NC(C)=CC=1CCC)c1c2c(n(C(C)C)nc2)cc(-c2cc(N3CCN(C)CC3)ncc2)c1	4.9000001	Active	EZH2 Inhibitor	0.0	1	GSK-343	384569008.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	97.7137210766	O=C(NCC=1C(=O)NC(C)=CC=1CCC)c1c2c(n(C(C)C)nc2)cc(-c2cc(N3CCN(C)CC3)ncc2)c1	O=C(NCC=1C(=O)NC(C)=CC=1CCC)c1c2c(n(C(C)C)nc2)cc(-c2cc(N3CCN(C)CC3)ncc2)c1
NCGC00351477-05	O=C(NCC=1C(=O)NC(C)=CC=1CCC)c1c2c(n(C(C)C)nc2)cc(-c2cnc(N3CCN(C(C)C)CC3)cc2)c1		Inactive	EZH1 Inhibitor		1	UNC-1999	384569006.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	13.5811373039	O=C(NCC=1C(=O)NC(C)=CC=1CCC)c1c2c(n(C(C)C)nc2)cc(-c2cnc(N3CCN(C(C)C)CC3)cc2)c1	O=C(NCC=1C(=O)NC(C)=CC=1CCC)c1c2c(n(C(C)C)nc2)cc(-c2cnc(N3CCN(C(C)C)CC3)cc2)c1
NCGC00390645-03	O=C(NCC=1C(=O)NC(C)=CC=1OC)c1c(C)n([C@H](C)C2CCOCC2)c2c1cccc2		Inactive	EZH2 Inhibitor		1	CPI-360	384569205.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCC=1C(=O)NC(C)=CC=1OC)c1c(C)n([C@H](C)C2CCOCC2)c2c1cccc2	O=C(NCC=1C(=O)NC(C)=CC=1OC)c1c(C)n([C@H](C)C2CCOCC2)c2c1cccc2
NCGC00183031-08	O=C(NCCC(=O)O)[C@H](O)C(CO)(C)C		Inactive			1	D-Pantothenic acid		Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NCCC(=O)O)[C@H](O)C(CO)(C)C	O=C(NCCC(=O)O)[C@H](O)C(CO)(C)C
NCGC00023595-03	O=C(NCCC(C)C)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)O)O1)CC(C)C		Inactive			1	Loxistatin Acid (E-64C)	363676526.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	18.2609633399	O=C(NCCC(C)C)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)O)O1)CC(C)C	O=C(NCCC(C)C)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)O)O1)CC(C)C
NCGC00167328-03	O=C(NCCC(C)C)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)OCC)O1)CC(C)C	5.3000002	Active	Calpain Inhibitor	0.0	1	Aloxistatin	363676654.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&2.2	57.5391355313&48.5863801616	O=C(NCCC(C)C)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)OCC)O1)CC(C)C	O=C(NCCC(C)C)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)OCC)O1)CC(C)C
NCGC00507842-01	O=C(NCCC)c1c(C)c2C(Nc3c(C)ccc(C(=O)NC4CC4)c3)=NC=Nn2c1		Inactive	p38 MAPK Inhibitor		1	BMS-582949	384569324.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCCC)c1c(C)c2C(Nc3c(C)ccc(C(=O)NC4CC4)c3)=NC=Nn2c1	O=C(NCCC)c1c(C)c2C(Nc3c(C)ccc(C(=O)NC4CC4)c3)=NC=Nn2c1
NCGC00167476-02	O=C(NCCCC(=O)O)C(O)C(CO)(C)C		Inactive			1	Calcium hopantenate	50112729.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCCCC(=O)[O-])C(O)C(CO)(C)C	O=C(NCCCC(=O)[O-])C(O)C(CO)(C)C
NCGC00385854-01	O=C(NCCCC(NC(=O)Cc1ccccc1)C(=O)O)N		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385854-01	363679970.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCCC(NC(=O)Cc1ccccc1)C(=O)O)N	O=C(NCCCC(NC(=O)Cc1ccccc1)C(=O)O)N
NCGC00182868-16	O=C(NCCCCC1CCN(C(=O)c2ccccc2)CC1)/C=C/c1cnccc1		Inactive	NAMPT Inhibitor		1	Daporinad	384568412.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCCCCC1CCN(C(=O)c2ccccc2)CC1)/C=C/c1cnccc1	O=C(NCCCCC1CCN(C(=O)c2ccccc2)CC1)/C=C/c1cnccc1
NCGC00402267-03	O=C(NCCCCN1CCN(c2c(OC)cccc2)CC1)c1ccc(-c2ncsc2)cc1		Inactive	Dopamine D3 receptor Partial Agonist		1	OS-3-106	363681007.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCCCN1CCN(c2c(OC)cccc2)CC1)c1ccc(-c2ncsc2)cc1	O=C(NCCCCN1CCN(c2c(OC)cccc2)CC1)c1ccc(-c2ncsc2)cc1
NCGC00167801-02	O=C(NCCCCN1CCOCC1)c1oc2c(c1)cccc2		Inactive	MMP13 Inhibitor		1	CL-82198	384568338.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCCCCN1CCOCC1)c1oc2c(c1)cccc2	O=C(NCCCCN1CCOCC1)c1oc2c(c1)cccc2
NCGC00163544-09	O=C(NCCCCNC(=N)N)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)O)O1)CC(C)C		Inactive			1	E-64	434147018.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.3461538479	O=C(NCCCCNC(=N)N)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)O)O1)CC(C)C	O=C(NCCCCNC(=N)N)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)O)O1)CC(C)C
NCGC00183869-01	O=C(NCCCCNCCCN)C(O)NC(=O)CCCCCCNC(=N)N		Inactive	Heat shock protein HSP90 Binding Agent		1	Gusperimus trihydrochloride	144206777.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCCCCNCCCN)C(O)NC(=O)CCCCCCNC(=N)N.Cl.Cl.Cl	O=C(NCCCCNCCCN)C(O)NC(=O)CCCCCCNC(=N)N.Cl.Cl.Cl
NCGC00402299-03	O=C(NCCCCn1c2c(c3C(=O)NCCc13)cccc2)C		Inactive	Bromodomain-containing protein 1 Inhibitor		1	Olinone	363681020.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCCCn1c2c(c3C(=O)NCCc13)cccc2)C	O=C(NCCCCn1c2c(c3C(=O)NCCc13)cccc2)C
NCGC00356803-11	O=C(NCCCN(C(C)C)C[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3cc2)O1)Nc1ccc(C(C)(C)C)cc1		Inactive	DOT1L Inhibitor		1	EPZ004777	384569032.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCCCN(C(C)C)C[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3cc2)O1)Nc1ccc(C(C)(C)C)cc1	O=C(NCCCN(C(C)C)C[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3cc2)O1)Nc1ccc(C(C)(C)C)cc1
NCGC00183808-01&NCGC00183808-18	O=C(NCCCN(C)C)c1ccc(-c2cc(O)c3ncccc3c2)cc1	5.0	Active	JMJ Inhibitor	0.1999998000000005	2	ML324	85736407.0&434147059.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	61.3739917899&43.9694041752	O=C(NCCCN(C)C)c1ccc(-c2cc(O)c3ncccc3c2)cc1	O=C(NCCCN(C)C)c1ccc(-c2cc(O)c3ncccc3c2)cc1
NCGC00095152-09	O=C(NCCCN(C)c1nc(N)c2c(n1)cc(OC)c(OC)c2)C1OCCC1		Inactive	alpha1-Adrenoceptor Antagonists		1	Alfuzosin hydrochloride	170465022.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NCCCN(C)c1nc(N)c2c(n1)cc(OC)c(OC)c2)C1OCCC1.Cl	O=C(NCCCN(C)c1nc(N)c2c(n1)cc(OC)c(OC)c2)C1OCCC1.Cl
NCGC00485144-01	O=C(NCCCN1CCC(c2cc(OC)ccc2)CC1)Nc1cc(C2C(C(=O)OC)=C(C)NC(C)=C2C(=O)OC)ccc1		Inactive	Neuropeptide Y receptor type 1 Antagonist		1	BMS-193885	363681243.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCCN1CCC(c2cc(OC)ccc2)CC1)Nc1cc(C2C(C(=O)OC)=C(C)NC(C)=C2C(=O)OC)ccc1	O=C(NCCCN1CCC(c2cc(OC)ccc2)CC1)Nc1cc(C2C(C(=O)OC)=C(C)NC(C)=C2C(=O)OC)ccc1
NCGC00387110-02	O=C(NCCCN1CCC2(OCc3c2cccc3)CC1)[C@@H]1N(Cc2ccccc2)CCC1		Inactive	Nociceptin receptor Antagonist		1	BAN ORL 24	363680543.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	16.3577766799	O=C(NCCCN1CCC2(OCc3c2cccc3)CC1)[C@@H]1N(Cc2ccccc2)CCC1	O=C(NCCCN1CCC2(OCc3c2cccc3)CC1)[C@@H]1N(Cc2ccccc2)CCC1
NCGC00356417-05	O=C(NCCCN1CCCC1)c1cc(C#N)cc(-c2c(N3CCN(CCn4c5c(c(C)c4)cccc5)CC3)cccc2)c1	4.9499998	Active	SMYD2 Inhibitor	0.0	1	LLY-507	384569030.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	136.4506697474	O=C(NCCCN1CCCC1)c1cc(C#N)cc(-c2c(N3CCN(CCn4c5c(c(C)c4)cccc5)CC3)cccc2)c1	O=C(NCCCN1CCCC1)c1cc(C#N)cc(-c2c(N3CCN(CCn4c5c(c(C)c4)cccc5)CC3)cccc2)c1
NCGC00379218-04	O=C(NCCCN1CCN(c2ccc(OC)cc2)CC1)CN1C(=O)c2n(-c3c(C)ccnc13)ccc2		Inactive	Kappa opioid receptor Antagonist		1	ML190	363678426.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCCN1CCN(c2ccc(OC)cc2)CC1)CN1C(=O)c2n(-c3c(C)ccnc13)ccc2	O=C(NCCCN1CCN(c2ccc(OC)cc2)CC1)CN1C(=O)c2n(-c3c(C)ccnc13)ccc2
NCGC00370816-01	O=C(NCCCN1CCOCC1)c1c2n(C(c3ccccc3)=CC(c3ccccc3)=N2)nc1		Inactive	P-glycoprotein 1 Inhibitor		1	Reversan	363677867.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCCN1CCOCC1)c1c2n(C(c3ccccc3)=CC(c3ccccc3)=N2)nc1	O=C(NCCCN1CCOCC1)c1c2n(C(c3ccccc3)=CC(c3ccccc3)=N2)nc1
NCGC00522516-01	O=C(NCCCN=[N+]=[N-])CCCOc1c(C(C)(C)C)cc(-c2[nH]c3c(n2)ccc(N2CCN(C)CC2)c3)cc1C(C)(C)C		Inactive	microRNA-96 Inhibitor		1	MIR96-IN-1	384569523.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCCCN=[N+]=[N-])CCCOc1c(C(C)(C)C)cc(-c2[nH]c3c(n2)ccc(N2CCN(C)CC2)c3)cc1C(C)(C)C	O=C(NCCCN=[N+]=[N-])CCCOc1c(C(C)(C)C)cc(-c2[nH]c3c(n2)ccc(N2CCN(C)CC2)c3)cc1C(C)(C)C
NCGC00016027-04	O=C(NCCCNC(=O)/C(/C#N)=C/c1cc(O)c(O)cc1)/C(/C#N)=C/c1cc(O)c(O)cc1		Inactive			1	Tyrphostin AG 537	90341804.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCCNC(=O)/C(/C#N)=C/c1cc(O)c(O)cc1)/C(/C#N)=C/c1cc(O)c(O)cc1	O=C(NCCCNC(=O)/C(/C#N)=C/c1cc(O)c(O)cc1)/C(/C#N)=C/c1cc(O)c(O)cc1
NCGC00386818-01	O=C(NCCCNC(=O)c1noc(-c2ccccc2)c1)c1c(O)nccc1		Inactive	CDH1 Expression Enhancers		1	ML327	363680447.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCCCNC(=O)c1noc(-c2ccccc2)c1)c1c(O)nccc1	O=C(NCCCNC(=O)c1noc(-c2ccccc2)c1)c1c(O)nccc1
NCGC00378780-02	O=C(NCCCNc1c(C2CC2)cnc(Nc2cc(CN3CCOCC3)ccc2)n1)C1CCC1		Inactive	ULK1 Inhibitor		1	MRT-67307	363678194.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCCCNc1c(C2CC2)cnc(Nc2cc(CN3CCOCC3)ccc2)n1)C1CCC1	O=C(NCCCNc1c(C2CC2)cnc(Nc2cc(CN3CCOCC3)ccc2)n1)C1CCC1
NCGC00506821-05	O=C(NCCCNc1c(C2CC2)cnc(Nc2cc3c(cc2)CN(C)CC3)n1)C1CCC1		Inactive			1	NCGC00506821-05		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCCNc1c(C2CC2)cnc(Nc2cc3c(cc2)CN(C)CC3)n1)C1CCC1	O=C(NCCCNc1c(C2CC2)cnc(Nc2cc3c(cc2)CN(C)CC3)n1)C1CCC1
NCGC00486904-01	O=C(NCCCNc1c(C2CC2)cnc(Nc2ccc(N3CCOCC3)cc2)n1)C1CCC1		Inactive	IKK-epsilon Inhibitor		1	MRT-68601 hydrochloride	377020217.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NCCCNc1c(C2CC2)cnc(Nc2ccc(N3CCOCC3)cc2)n1)C1CCC1	O=C(NCCCNc1c(C2CC2)cnc(Nc2ccc(N3CCOCC3)cc2)n1)C1CCC1
NCGC00186658-01	O=C(NCCCO)[C@H](O)C(CO)(C)C		Inactive			1	Dexpanthenol	170464647.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(NCCCO)[C@H](O)C(CO)(C)C	O=C(NCCCO)[C@H](O)C(CO)(C)C
NCGC00386907-01	O=C(NCCCOC)c1ccc(CN2C(=O)N(Cc3ccc(C(C)C)cc3)c3c(C2=O)cccc3)cc1		Inactive			1	NCGC00386907-01	363680495.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCCOC)c1ccc(CN2C(=O)N(Cc3ccc(C(C)C)cc3)c3c(C2=O)cccc3)cc1	O=C(NCCCOC)c1ccc(CN2C(=O)N(Cc3ccc(C(C)C)cc3)c3c(C2=O)cccc3)cc1
NCGC00167499-02	O=C(NCCCOc1cc(CN2CCCCC2)ccc1)COC(=O)C		Inactive			1	Roxatidine acetate hydrochloride	170465941.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NCCCOc1cc(CN2CCCCC2)ccc1)COC(=O)C.Cl	O=C(NCCCOc1cc(CN2CCCCC2)ccc1)COC(=O)C.Cl
NCGC00182982-01	O=C(NCCCOc1cc(CN2CCCCC2)ccc1)NCC		Inactive	Histamine H2 receptor Antagonist		1	Dalcotidine	144206834.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&8.058394164	O=C(NCCCOc1cc(CN2CCCCC2)ccc1)NCC	O=C(NCCCOc1cc(CN2CCCCC2)ccc1)NCC
NCGC00370961-01	O=C(NCCCOc1ccc(C(=O)N2CCC(N3C(=O)CCc4c3cccc4)CC2)cc1)C		Inactive	Vasopressin V1a receptor Antagonist		1	OPC 21268	363677958.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCCOc1ccc(C(=O)N2CCC(N3C(=O)CCc4c3cccc4)CC2)cc1)C	O=C(NCCCOc1ccc(C(=O)N2CCC(N3C(=O)CCc4c3cccc4)CC2)cc1)C
NCGC00016028-08	O=C(NCCCc1ccccc1)/C(/C#N)=C/c1cc(O)c(O)cc1		Inactive			1	Tyrphostin AG 555	90341437.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.6674157359	O=C(NCCCc1ccccc1)/C(/C#N)=C/c1cc(O)c(O)cc1	O=C(NCCCc1ccccc1)/C(/C#N)=C/c1cc(O)c(O)cc1
NCGC00386690-01	O=C(NCCCn1cncc1)c1noc(-c2occc2)c1		Inactive	Wnt signaling pathway Agonist		1	SKL 2001	363680397.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCCn1cncc1)c1noc(-c2occc2)c1	O=C(NCCCn1cncc1)c1noc(-c2occc2)c1
NCGC00346668-04	O=C(NCCN(C(C)C)C(C)C)CN1C(=O)CCC1		Inactive	neuroprotective drug		1	Pramiracetam	363677504.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCN(C(C)C)C(C)C)CN1C(=O)CCC1	O=C(NCCN(C(C)C)C(C)C)CN1C(=O)CCC1
NCGC00386424-05	O=C(NCCN(C)C)C=1C2=Nc3c(C(=O)N2C=CC=1)cc1c(c3)cccc1		Inactive			1	BMH-21	377020286.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCN(C)C)C=1C2=Nc3c(C(=O)N2C=CC=1)cc1c(c3)cccc1	O=C(NCCN(C)C)C=1C2=Nc3c(C(=O)N2C=CC=1)cc1c(c3)cccc1
NCGC00386757-02	O=C(NCCN(C)C)COc1c2cccc1Cc1c(OCC(=O)NCCN(C)C)c(ccc1)Cc1c(OCC(=O)NCCN(C)C)c(ccc1)Cc1c(OCC(=O)NCCN(C)C)c(ccc1)C2		Inactive	Allosteric Inhibitor of galectin-1		1	OTX-008	384569145.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCCN(C)C)COc1c2cccc1Cc1c(OCC(=O)NCCN(C)C)c(ccc1)Cc1c(OCC(=O)NCCN(C)C)c(ccc1)Cc1c(OCC(=O)NCCN(C)C)c(ccc1)C2	O=C(NCCN(C)C)COc1c2cccc1Cc1c(OCC(=O)NCCN(C)C)c(ccc1)Cc1c(OCC(=O)NCCN(C)C)c(ccc1)Cc1c(OCC(=O)NCCN(C)C)c(ccc1)C2
NCGC00510483-02	O=C(NCCN(CC)CC)c1c(C)c(/C=C\2/C(=O)Nc3c/2cc(-c2nc(-c4ccccc4)sc2)cc3)[nH]c1C		Inactive	PDGFR alpha Inhibitor		1	Amcasertib	384569446.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCCN(CC)CC)c1c(C)c(/C=C\2/C(=O)Nc3c/2cc(-c2nc(-c4ccccc4)sc2)cc3)[nH]c1C	O=C(NCCN(CC)CC)c1c(C)c(/C=C\2/C(=O)Nc3c/2cc(-c2nc(-c4ccccc4)sc2)cc3)[nH]c1C
NCGC00016338-10	O=C(NCCN(CC)CC)c1c2c(nc(OCCCC)c1)cccc2	4.9000001	Active	Sodium channel protein type X alpha subunit Blocker	0.0	1	Dibucaine	170464829.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	124.4693306303	O=C(NCCN(CC)CC)c1c2c(nc(OCCCC)c1)cccc2	O=C(NCCN(CC)CC)c1c2c(nc(OCCCC)c1)cccc2
NCGC00345840-03	O=C(NCCN(CC)CC)c1cc2nc(c(-c3ccccc3)nc2cc1)-c1ccc(CN2CCC(N3C(=O)Nc4c3cccc4)CC2)cc1		Inactive	AKT Inhibitor		1	Merck-22-6	384568763.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(NCCN(CC)CC)c1cc2nc(c(-c3ccccc3)nc2cc1)-c1ccc(CN2CCC(N3C(=O)Nc4c3cccc4)CC2)cc1	O=C(NCCN(CC)CC)c1cc2nc(c(-c3ccccc3)nc2cc1)-c1ccc(CN2CCC(N3C(=O)Nc4c3cccc4)CC2)cc1
NCGC00015859-14	O=C(NCCN(CC)CC)c1ccc(N)cc1		Inactive	Sodium channel alpha subunit Blocker		1	Procainamide	170464952.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(NCCN(CC)CC)c1ccc(N)cc1	O=C(NCCN(CC)CC)c1ccc(N)cc1
NCGC00380223-01	O=C(NCCN1C(C(O)c2ccccc2)=CC(=O)C(C(=O)O)=C1)CC(C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380223-01	363678503.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCN1C(C(O)c2ccccc2)=CC(=O)C(C(=O)O)=C1)CC(C)C	O=C(NCCN1C(C(O)c2ccccc2)=CC(=O)C(C(=O)O)=C1)CC(C)C
NCGC00408890-01	O=C(NCCN1CCC(O)(Cc2ccccc2)CC1)Nc1c2c(nc(C)c1)cccc2		Inactive	Urotensin II receptor Antagonist		1	Palosuran	363681075.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCN1CCC(O)(Cc2ccccc2)CC1)Nc1c2c(nc(C)c1)cccc2	O=C(NCCN1CCC(O)(Cc2ccccc2)CC1)Nc1c2c(nc(C)c1)cccc2
NCGC00386898-01	O=C(NCCN1CCC(n2c(O)nc3c2cccc3)CC1)c1cc2c(cc1)cccc2		Inactive			1	NCGC00386898-01	363680490.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	12.166666668	O=C(NCCN1CCC(n2c(O)nc3c2cccc3)CC1)c1cc2c(cc1)cccc2	O=C(NCCN1CCC(n2c(O)nc3c2cccc3)CC1)c1cc2c(cc1)cccc2
NCGC00402291-01	O=C(NCCN1CCOCC1)C(N)C(CC)C		Inactive	Low affinity neurotrophin receptor p75NTR Binding Agent		1	LM11A-31 Dihydrochloride	363681015.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCN1CCOCC1)C(N)C(CC)C	O=C(NCCN1CCOCC1)C(N)C(CC)C
NCGC00386513-01	O=C(NCCNC(=O)c1nc(NCC(c2ccccc2)c2ccccc2)c2ncn([C@@H]3[C@H](O)[C@H](O)[C@@H](C(=O)NCC)O3)c2n1)NC1CCN(c2ncccc2)CC1		Inactive	Adenosine A2a receptor Agonist		1	UK 432097	363680312.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCNC(=O)c1nc(NCC(c2ccccc2)c2ccccc2)c2ncn([C@@H]3[C@H](O)[C@H](O)[C@@H](C(=O)NCC)O3)c2n1)NC1CCN(c2ncccc2)CC1	O=C(NCCNC(=O)c1nc(NCC(c2ccccc2)c2ccccc2)c2ncn([C@@H]3[C@H](O)[C@H](O)[C@@H](C(=O)NCC)O3)c2n1)NC1CCN(c2ncccc2)CC1
NCGC00482810-01	O=C(NCCNCc1c(OC)nc(OCc2c(C)c(-c3ccccc3)ccc2)cc1)C	5.5	Active	Inhibitor of PD-l/PD-Ll	0.0	1	BMS-202	384569261.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	43.0829284351	O=C(NCCNCc1c(OC)nc(OCc2c(C)c(-c3ccccc3)ccc2)cc1)C	O=C(NCCNCc1c(OC)nc(OCc2c(C)c(-c3ccccc3)ccc2)cc1)C
NCGC00386637-01	O=C(NCCNc1c(C#N)cc2c(C)cc(C)cc2n1)c1cc(OC)ccc1		Inactive	Cystic fibrosis transmembrane conductance regulator Modulator		1	CoPo 22	363680366.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCNc1c(C#N)cc2c(C)cc(C)cc2n1)c1cc(OC)ccc1	O=C(NCCNc1c(C#N)cc2c(C)cc(C)cc2n1)c1cc(OC)ccc1
NCGC00015793-12	O=C(NCCO)CCCCCCCCCCCCCCC		Inactive			1	Palmitoylethanolamide	434146946.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCCO)CCCCCCCCCCCCCCC	O=C(NCCO)CCCCCCCCCCCCCCC
NCGC00387179-04	O=C(NCCO)c1cc(C(=O)NCCO)cc(C(=O)NCCO)c1		Inactive			1	LM22A-4	377020343.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCO)c1cc(C(=O)NCCO)cc(C(=O)NCCO)c1	O=C(NCCO)c1cc(C(=O)NCCO)cc(C(=O)NCCO)c1
NCGC00411883-01	O=C(NCCOC)Nc1cc2nc(c(-c3sccc3)nc2cc1)-c1sccc1	5.1500001	Active		0.0	1	NCGC00411883-01		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	2.1	113.7176581733	O=C(NCCOC)Nc1cc2nc(c(-c3sccc3)nc2cc1)-c1sccc1	O=C(NCCOC)Nc1cc2nc(c(-c3sccc3)nc2cc1)-c1sccc1
NCGC00346486-03	O=C(NCCOc1ccc(C(=O)NO)cc1)c1c(CN(C)C)c2c(o1)cccc2		Inactive	HDAC Inhibitor		1	Abexinostat	384568795.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NCCOc1ccc(C(=O)NO)cc1)c1c(CN(C)C)c2c(o1)cccc2	O=C(NCCOc1ccc(C(=O)NO)cc1)c1c(CN(C)C)c2c(o1)cccc2
NCGC00386630-01	O=C(NCCOc1ccccc1)c1c(-c2cc(OC)c(OC)c(OC)c2)nc(N[C@H](CO)Cc2ccccc2)cc1		Inactive	Calcium sensing receptor Antagonist		1	CaSR antagonist 18c	363680362.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCOc1ccccc1)c1c(-c2cc(OC)c(OC)c(OC)c2)nc(N[C@H](CO)Cc2ccccc2)cc1	O=C(NCCOc1ccccc1)c1c(-c2cc(OC)c(OC)c(OC)c2)nc(N[C@H](CO)Cc2ccccc2)cc1
NCGC00095187-08&NCGC00095187-09	O=C(NCC[C@H]1c2c3c(OCC3)ccc2CC1)CC		Inactive			2	RAMELTEON&Ramelteon		Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NCC[C@H]1c2c3c(OCC3)ccc2CC1)CC	O=C(NCC[C@H]1c2c3c(OCC3)ccc2CC1)CC
NCGC00386319-04	O=C(NCCc1c(C)[nH]c2c1cccc2)c1sccc1		Inactive	Arp2/3 complex inhibitor		1	CK-636	363680208.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCc1c(C)[nH]c2c1cccc2)c1sccc1	O=C(NCCc1c(C)[nH]c2c1cccc2)c1sccc1
NCGC00015039-07	O=C(NCCc1c2c([nH]c1)ccc(O)c2)C		Inactive			1	N-Acetyl-5-hydroxytryptamine	90341149.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCc1c2c([nH]c1)ccc(O)c2)C	O=C(NCCc1c2c([nH]c1)ccc(O)c2)C
NCGC00487351-01	O=C(NCCc1c2c([nH]c1)ccc(O)c2)c1c(O)c2c(cc1)cccc2		Inactive			1	MS-1020	377020237.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCc1c2c([nH]c1)ccc(O)c2)c1c(O)c2c(cc1)cccc2	O=C(NCCc1c2c([nH]c1)ccc(O)c2)c1c(O)c2c(cc1)cccc2
NCGC00015680-18&NCGC00015680-33	O=C(NCCc1c2c([nH]c1)ccc(OC)c2)C		Inactive	NOS2 Expression Inhibitor		2	Melatonin	170465589.0&384567881.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&-7.460176992&0.0	O=C(NCCc1c2c([nH]c1)ccc(OC)c2)C	O=C(NCCc1c2c([nH]c1)ccc(OC)c2)C
NCGC00015088-09	O=C(NCCc1c2c([nH]c1)cccc2)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	N-ACETYLTRYPTAMINE	363676439.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCc1c2c([nH]c1)cccc2)C	O=C(NCCc1c2c([nH]c1)cccc2)C
NCGC00253646-01&NCGC00253646-08	O=C(NCCc1c2c(ccc(OC)c2)ccc1)C		Inactive	5-HT2C Antagonist		2	Agomelatine	174006904.0&384568565.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(NCCc1c2c(ccc(OC)c2)ccc1)C	O=C(NCCc1c2c(ccc(OC)c2)ccc1)C
NCGC00380781-01	O=C(NCCc1ccc(O)cc1)C(NC(=O)C)CCC(=O)O		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380781-01	363678782.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCc1ccc(O)cc1)C(NC(=O)C)CCC(=O)O	O=C(NCCc1ccc(O)cc1)C(NC(=O)C)CCC(=O)O
NCGC00429125-01	O=C(NCCc1ccccc1)C1(N2CCN(CC)CC2)Cc2c(cccc2)C1		Inactive			1	NCGC00429125-01	375874932.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCCc1ccccc1)C1(N2CCN(CC)CC2)Cc2c(cccc2)C1	O=C(NCCc1ccccc1)C1(N2CCN(CC)CC2)Cc2c(cccc2)C1
NCGC00263906-02	O=C(NCN1CCCC1)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)C3C[C@H]2[C@H](N(C)C)C=1O		Inactive			1	Rolitetracycline	170465919.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NCN1CCCC1)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)C3C[C@H]2[C@H](N(C)C)C=1O	O=C(NCN1CCCC1)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)C3C[C@H]2[C@H](N(C)C)C=1O
NCGC00179313-05	O=C(NCNC(=O)NC1N(CO)C(=O)NC1=O)NC1N(CO)C(=O)NC1=O		Inactive	T-lymphocyte activation antigen CD86 Activator		1	Imidazolidinyl urea	405559029.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCNC(=O)NC1N(CO)C(=O)NC1=O)NC1N(CO)C(=O)NC1=O	O=C(NCNC(=O)NC1N(CO)C(=O)NC1=O)NC1N(CO)C(=O)NC1=O
NCGC00386836-01	O=C(NC[C@@H]1N(CC)CCC1)c1cc2NC(=O)c3c(c(C)ccc3)Sc2cc1		Inactive			1	NCGC00386836-01	363680456.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC[C@@H]1N(CC)CCC1)c1cc2NC(=O)c3c(c(C)ccc3)Sc2cc1	O=C(NC[C@@H]1N(CC)CCC1)c1cc2NC(=O)c3c(c(C)ccc3)Sc2cc1
NCGC00483168-02	O=C(NC[C@H](O)CN1Cc2c(cccc2)CC1)c1cc(NC2CCC2)ncc1		Inactive	PRMT5 Inhibitor		1	EPZ-015866	384569264.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC[C@H](O)CN1Cc2c(cccc2)CC1)c1cc(NC2CCC2)ncc1	O=C(NC[C@H](O)CN1Cc2c(cccc2)CC1)c1cc(NC2CCC2)ncc1
NCGC00386436-01	O=C(NC[C@H](O)CN1Cc2c(cccc2)CC1)c1ncnc(NC2COC2)c1		Inactive	PRMT5 Inhibitor		1	EPZ-015666	384569141.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC[C@H](O)CN1Cc2c(cccc2)CC1)c1ncnc(NC2COC2)c1	O=C(NC[C@H](O)CN1Cc2c(cccc2)CC1)c1ncnc(NC2COC2)c1
NCGC00378625-01	O=C(NC[C@H]1C[C@@H](CN)CCC1)[C@H](NC(=O)N1CCC2(c3c(cccc3)C=C2)CC1)Cc1c2c([nH]c1)cccc2		Inactive	Somatostatin receptor type 2 Agonist		1	(1R,1 S,3 R/1R,1 R,3 S)-L-054,264	363678129.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NC[C@H]1C[C@@H](CN)CCC1)[C@H](NC(=O)N1CCC2(c3c(cccc3)C=C2)CC1)Cc1c2c([nH]c1)cccc2	O=C(NC[C@H]1C[C@@H](CN)CCC1)[C@H](NC(=O)N1CCC2(c3c(cccc3)C=C2)CC1)Cc1c2c([nH]c1)cccc2
NCGC00522560-01	O=C(NC[C@H]1[C@H](c2c3c(OCC3)ccc2)C1)CC		Inactive	Melatonin receptor type 1B Agonist		1	Tasimelteon	405558964.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NC[C@H]1[C@H](c2c3c(OCC3)ccc2)C1)CC	O=C(NC[C@H]1[C@H](c2c3c(OCC3)ccc2)C1)CC
NCGC00386732-01	O=C(NCc1c(-c2c(C(=O)NCCc3cnccc3)cccc2)cccc1)Cc1ccc(OC)cc1		Inactive	Voltage-gated potassium channel subunit Kv1.5 Blocker		1	AVE 0118 hydrochloride	363680422.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCc1c(-c2c(C(=O)NCCc3cnccc3)cccc2)cccc1)Cc1ccc(OC)cc1	O=C(NCc1c(-c2c(C(=O)NCCc3cnccc3)cccc2)cccc1)Cc1ccc(OC)cc1
NCGC00370993-01	O=C(NCc1c(C)cc(C(=O)N2c3c(Nc4n(C)ncc4C2)cccc3)cc1)N1CCN(Cc2cc(O)cc(O)c2)CC1		Inactive			1	WAY 267464 dihydrochloride	363677981.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCc1c(C)cc(C(=O)N2c3c(Nc4n(C)ncc4C2)cccc3)cc1)N1CCN(Cc2cc(O)cc(O)c2)CC1	O=C(NCc1c(C)cc(C(=O)N2c3c(Nc4n(C)ncc4C2)cccc3)cc1)N1CCN(Cc2cc(O)cc(O)c2)CC1
NCGC00386702-01	O=C(NCc1c(C)cc(C(=O)N2c3c(cccc3)CCCC2)cc1)N1[C@H](C(=O)N(C)C)CCC1		Inactive	Vasopressin V2 receptor Agonist		1	Fedovapagon	363680405.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCc1c(C)cc(C(=O)N2c3c(cccc3)CCCC2)cc1)N1[C@H](C(=O)N(C)C)CCC1	O=C(NCc1c(C)cc(C(=O)N2c3c(cccc3)CCCC2)cc1)N1[C@H](C(=O)N(C)C)CCC1
NCGC00387243-01	O=C(NCc1c(C)oc2c1cccc2)NCc1sccc1		Inactive	Nuclear receptor subfamily 1 group I member 3 Inverse Agonist		1	S 07662	363680590.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCc1c(C)oc2c1cccc2)NCc1sccc1	O=C(NCc1c(C)oc2c1cccc2)NCc1sccc1
NCGC00510160-03	O=C(NCc1cc(C)c(Oc2cc(C)cc(C)c2)cc1)[C@@H](N)C		Inactive	CoActivator Associated Arginine Methyltransferase 1 (CARM1; PRMT4) Inhibitor		1	SGC-2085	384569410.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	25.8049656039	O=C(NCc1cc(C)c(Oc2cc(C)cc(C)c2)cc1)[C@@H](N)C	O=C(NCc1cc(C)c(Oc2cc(C)cc(C)c2)cc1)[C@@H](N)C
NCGC00371153-09	O=C(NCc1cc(O)ccc1)Nc1scc(-c2ccncc2)n1		Inactive	ROCK1/ROCK2 Inhibitor		1	RKI-1447	363678067.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCc1cc(O)ccc1)Nc1scc(-c2ccncc2)n1	O=C(NCc1cc(O)ccc1)Nc1scc(-c2ccncc2)n1
NCGC00017337-17&NCGC00017337-22	O=C(NCc1cc(OC)c(O)cc1)CCCC/C=C/C(C)C		Inactive			2	(E)-Capsaicin&Capsaicin	405559082.0&384567985.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NCc1cc(OC)c(O)cc1)CCCC/C=C/C(C)C	O=C(NCc1cc(OC)c(O)cc1)CCCC/C=C/C(C)C
NCGC00016441-03	O=C(NCc1cc(OC)c(O)cc1)CCCC/C=C\C(C)C		Inactive			1	(Z)-Capsaicin	124882263.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCc1cc(OC)c(O)cc1)CCCC/C=C\C(C)C	O=C(NCc1cc(OC)c(O)cc1)CCCC/C=C\C(C)C
NCGC00016089-06	O=C(NCc1cc(OC)c(O)cc1)CCCCCCCC		Inactive	Vanilloid receptor Agonist		1	Nonivamide	170466476.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(NCc1cc(OC)c(O)cc1)CCCCCCCC	O=C(NCc1cc(OC)c(O)cc1)CCCCCCCC
NCGC00371147-01	O=C(NCc1cc(OC)ccc1)Nc1scc(-c2ccncc2)n1		Inactive	Rho-associated protein kinase 2 Inhibitor		1	1-(3-methoxybenzyl)-3-(4-(pyridin-4-yl)thiazol-2-yl)urea	363678061.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	15.2638824121	O=C(NCc1cc(OC)ccc1)Nc1scc(-c2ccncc2)n1	O=C(NCc1cc(OC)ccc1)Nc1scc(-c2ccncc2)n1
NCGC00370764-01	O=C(NCc1cc2c(n(-c3c(OC)cccc3)nc2)cc1)C(CCC)CCC		Inactive	Smoothened homolog Antagonist		1	M 25	363677840.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCc1cc2c(n(-c3c(OC)cccc3)nc2)cc1)C(CCC)CCC	O=C(NCc1cc2c(n(-c3c(OC)cccc3)nc2)cc1)C(CCC)CCC
NCGC00370898-03	O=C(NCc1ccc(OC)cc1)c1c(N)c2c(C)cc(C)nc2s1		Inactive	Muscarinic acetylcholine receptor M4 Positive Allosteric Modulator		1	VU0152100	363677918.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCc1ccc(OC)cc1)c1c(N)c2c(C)cc(C)nc2s1	O=C(NCc1ccc(OC)cc1)c1c(N)c2c(C)cc(C)nc2s1
NCGC00016509-06&NCGC00016509-08	O=C(NCc1ccc(OCCN(C)C)cc1)c1cc(OC)c(OC)c(OC)c1		Inactive	Dopamine D2 receptor Antagonist		2	Trimethobenzamide hydrochloride&TRIMETHOBENZAMIDE HYDROCHLORIDE	170465132.0&434146956.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	13.094816692&0.0&0.0	O=C(NCc1ccc(OCCN(C)C)cc1)c1cc(OC)c(OC)c(OC)c1.Cl	O=C(NCc1ccc(OCCN(C)C)cc1)c1cc(OC)c(OC)c(OC)c1.Cl&O=C(NCc1ccc(OCCN(C)C)cc1)c1cc(OC)c(OC)c(OC)c1
NCGC00167529-02	O=C(NCc1ccc(OCCN(C)C)cc1)c1cc(OC)c(OC)cc1		Inactive	Acetylcholinesterase Inhibitor		1	Itopride hydrochloride	170465974.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCc1ccc(OCCN(C)C)cc1)c1cc(OC)c(OC)cc1.Cl	O=C(NCc1ccc(OCCN(C)C)cc1)c1cc(OC)c(OC)cc1.Cl
NCGC00016014-09	O=C(NCc1ccccc1)/C(/C#N)=C/c1cc(O)c(O)cc1		Inactive	STAT-3 Inhibitor		1	Tyrphostin B42	124881627.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCc1ccccc1)/C(/C#N)=C/c1cc(O)c(O)cc1	O=C(NCc1ccccc1)/C(/C#N)=C/c1cc(O)c(O)cc1
NCGC00346644-04	O=C(NCc1ccccc1)Cc1ncc(-c2ccc(OCCN3CCOCC3)cc2)cc1		Inactive	Src Kinase Inhibitor		1	KX-01	384568876.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(NCc1ccccc1)Cc1ncc(-c2ccc(OCCN3CCOCC3)cc2)cc1	O=C(NCc1ccccc1)Cc1ncc(-c2ccc(OCCN3CCOCC3)cc2)cc1
NCGC00263116-09	O=C(NCc1ccccc1)N1[C@@H]2N([C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3c4c(ccc3)cccc4)C2)C(=O)CC1		Inactive	Wnt Signaling Inhibitor		1	ICG-001	384568600.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(NCc1ccccc1)N1[C@@H]2N([C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3c4c(ccc3)cccc4)C2)C(=O)CC1	O=C(NCc1ccccc1)N1[C@@H]2N([C@@H](Cc3ccc(O)cc3)C(=O)N(Cc3c4c(ccc3)cccc4)C2)C(=O)CC1
NCGC00345807-02	O=C(NCc1ccccc1)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)NCCc2ccc(O)cc2)O1)Cc1ccccc1	6.5	Active	Cathepsin L Inhibitor	0.0	1	CAA-0225	384568753.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	1.1	102.6036396486	O=C(NCc1ccccc1)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)NCCc2ccc(O)cc2)O1)Cc1ccccc1	O=C(NCc1ccccc1)[C@@H](NC(=O)[C@@H]1[C@@H](C(=O)NCCc2ccc(O)cc2)O1)Cc1ccccc1
NCGC00253740-06	O=C(NCc1ccccc1)[C@H](NC(=O)C)COC		Inactive	NMDA Glycine-Site Antagonist		1	Lacosamide	384568567.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCc1ccccc1)[C@H](NC(=O)C)COC	O=C(NCc1ccccc1)[C@H](NC(=O)C)COC
NCGC00187983-01	O=C(NCc1ccccc1)c1nc(Nc2ncncc2)sc1		Inactive	ROCK Inhibitor		1	Thiazovivin	174006432.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCc1ccccc1)c1nc(Nc2ncncc2)sc1	O=C(NCc1ccccc1)c1nc(Nc2ncncc2)sc1
NCGC00387851-04	O=C(NCc1nc(OC)c(OC)cc1)c1c(-c2sccn2)cnc(-c2cc(C)cnc2)c1		Inactive	Orexin receptor 2 Antagonist		1	MK-3697	363680700.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCc1nc(OC)c(OC)cc1)c1c(-c2sccn2)cnc(-c2cc(C)cnc2)c1	O=C(NCc1nc(OC)c(OC)cc1)c1c(-c2sccn2)cnc(-c2cc(C)cnc2)c1
NCGC00346627-08	O=C(NCc1ncc(C)nc1)C=1C(=O)c2c(nc(N3CCN(C)CCC3)cc2)N2c3c(SC=12)cccc3		Inactive	RNA Polymerase Inhibitor		1	CX-5461	363677484.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NCc1ncc(C)nc1)C=1C(=O)c2c(nc(N3CCN(C)CCC3)cc2)N2c3c(SC=12)cccc3	O=C(NCc1ncc(C)nc1)C=1C(=O)c2c(nc(N3CCN(C)CCC3)cc2)N2c3c(SC=12)cccc3
NCGC00387474-01	O=C(NCc1ncccc1)Nc1oc(-c2occc2)nn1		Inactive	Nuclear factor erythroid 2-related factor 2 Activator		1	NK 252	363680630.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCc1ncccc1)Nc1oc(-c2occc2)nn1	O=C(NCc1ncccc1)Nc1oc(-c2occc2)nn1
NCGC00386863-01	O=C(NCc1onc(C(C)C)c1)c1cc(OC2CCN(C)CC2)c(OC)cc1		Inactive			1	ML 352 hydrochloride	363680472.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NCc1onc(C(C)C)c1)c1cc(OC2CCN(C)CC2)c(OC)cc1	O=C(NCc1onc(C(C)C)c1)c1cc(OC2CCN(C)CC2)c(OC)cc1
NCGC00016244-15&NCGC00016244-21	O=C(NN)c1ccncc1		Inactive	Cytochrome P450 CYP1A2 Inhibitor		2	Isoniazid	170466877.0&384567924.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NN)c1ccncc1	O=C(NN)c1ccncc1
NCGC00390804-01	O=C(NNC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2NC(=O)CC2)Cc2[nH]cnc2)Cc2c3c([nH]c2)cccc3)CO)Cc2ccc(O)cc2)COC(C)(C)C)CC(C)C)CCCNC(=N)N)CCC1)N		Inactive	LNCaP Inhibitor		1	Goserelin (acetate)	405558960.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NNC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2NC(=O)CC2)Cc2[nH]cnc2)Cc2c3c([nH]c2)cccc3)CO)Cc2ccc(O)cc2)COC(C)(C)C)CC(C)C)CCCNC(=N)N)CCC1)N	O=C(NNC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]2NC(=O)CC2)Cc2[nH]cnc2)Cc2c3c([nH]c2)cccc3)CO)Cc2ccc(O)cc2)COC(C)(C)C)CC(C)C)CCCNC(=N)N)CCC1)N
NCGC00015163-09	O=C(NNCc1c(O)c(O)c(O)cc1)C(N)CO		Inactive	DOPA decarboxylase Inhibitor		1	Benserazide	170465804.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NNCc1c(O)c(O)c(O)cc1)C(N)CO.Cl	O=C(NNCc1c(O)c(O)c(O)cc1)C(N)CO.Cl
NCGC00016267-06	O=C(NNCc1ccccc1)c1noc(C)c1		Inactive	Monoamine oxidase Inhibitor		1	Isocarboxazid	405558734.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NNCc1ccccc1)c1noc(C)c1	O=C(NNCc1ccccc1)c1noc(C)c1
NCGC00371137-09	O=C(NNc1ccccc1)c1ccncc1		Inactive	SCD1 Inhibitor		1	PluriSln 1	384569042.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NNc1ccccc1)c1ccncc1	O=C(NNc1ccccc1)c1ccncc1
NCGC00162453-19	O=C(NO)/C=C/C(=C/[C@H](C(=O)c1ccc(N(C)C)cc1)C)/C		Inactive	HDAC Inhibitor		1	Trichostatin A	384568228.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NO)/C=C/C(=C/[C@H](C(=O)c1ccc(N(C)C)cc1)C)/C	O=C(NO)/C=C/C(=C/[C@H](C(=O)c1ccc(N(C)C)cc1)C)/C
NCGC00263136-04&NCGC00263136-07	O=C(NO)/C=C/c1cc2nc(CCCC)n(CCN(CC)CC)c2cc1		Inactive	HDAC Inhibitor		2	Pracinostat	363677222.0&384568614.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NO)/C=C/c1cc2nc(CCCC)n(CCN(CC)CC)c2cc1	O=C(NO)/C=C/c1cc2nc(CCCC)n(CCN(CC)CC)c2cc1
NCGC00532294-01	O=C(NO)/C=C/c1ccc(CN(CC23CC4CC(C2)CC(C3)C4)C)cc1		Inactive	HDAC Inhibitor		1	Martinostat	384569537.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NO)/C=C/c1ccc(CN(CC23CC4CC(C2)CC(C3)C4)C)cc1	O=C(NO)/C=C/c1ccc(CN(CC23CC4CC(C2)CC(C3)C4)C)cc1
NCGC00345539-05&NCGC00345539-10	O=C(NO)/C=C/c1ccc(CN(CCO)CCc2c3c([nH]c2)cccc3)cc1		Inactive	HDAC Inhibitor		2	Dacinostat	434147084.0&384568737.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NO)/C=C/c1ccc(CN(CCO)CCc2c3c([nH]c2)cccc3)cc1	O=C(NO)/C=C/c1ccc(CN(CCO)CCc2c3c([nH]c2)cccc3)cc1
NCGC00263117-05&NCGC00263117-14&NCGC00263117-22	O=C(NO)/C=C/c1ccc(CNCCc2c(C)[nH]c3c2cccc3)cc1		Inactive	HDAC Inhibitor		3	Panobinostat	405558944.0&384568601.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(NO)/C=C/c1ccc(CNCCc2c(C)[nH]c3c2cccc3)cc1	O=C(NO)/C=C/c1ccc(CNCCc2c(C)[nH]c3c2cccc3)cc1
NCGC00263649-02	O=C(NO)C=Cc1n(C)cc(C(=O)Cc2ccccc2)c1		Inactive			1	APHA Compound 8		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NO)C=Cc1n(C)cc(C(=O)Cc2ccccc2)c1	O=C(NO)C=Cc1n(C)cc(C(=O)Cc2ccccc2)c1
NCGC00510505-01	O=C(NO)CCCCCCC(=O)N/N=C/c1ccc(N(c2ccccc2)c2ccccc2)cc1		Inactive	HDAC Inhibitor		1	WT-161	384569466.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NO)CCCCCCC(=O)N/N=C/c1ccc(N(c2ccccc2)c2ccccc2)cc1	O=C(NO)CCCCCCC(=O)N/N=C/c1ccc(N(c2ccccc2)c2ccccc2)cc1
NCGC00168085-05&NCGC00168085-15&NCGC00168085-26	O=C(NO)CCCCCCC(=O)Nc1ccccc1		Inactive	HDAC Inhibitor		3	Vorinostat (SAHA)	170465180.0&384568346.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(NO)CCCCCCC(=O)Nc1ccccc1	O=C(NO)CCCCCCC(=O)Nc1ccccc1
NCGC00346891-02	O=C(NO)CCCCCCC(=O)Nc1cnccc1		Inactive	HDAC Inhibitor		1	Pyroxamide	384568964.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NO)CCCCCCC(=O)Nc1cnccc1	O=C(NO)CCCCCCC(=O)Nc1cnccc1
NCGC00343505-01	O=C(NO)CCCCCCC(=O)Nc1scc(-c2cc(N)ccc2)n1		Inactive	signaling/transport		1	Wr-301801	174006607.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NO)CCCCCCC(=O)Nc1scc(-c2cc(N)ccc2)n1	O=C(NO)CCCCCCC(=O)Nc1scc(-c2cc(N)ccc2)n1
NCGC00181165-01	O=C(NO)CCCCCCCCC		Inactive			1	Sodium decanehydroxamate	144206782.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[O-])CCCCCCCCC.[Na+]	O=C(N[O-])CCCCCCCCC.[Na+]
NCGC00263617-13	O=C(NO)CCCCCCNC(=O)c1ccc(N(C)C)cc1		Inactive	HDAC Inhibitor		1	M-344	384568694.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NO)CCCCCCNC(=O)c1ccc(N(C)C)cc1	O=C(NO)CCCCCCNC(=O)c1ccc(N(C)C)cc1
NCGC00345802-01&NCGC00345802-09	O=C(NO)CCCCCCNC(=O)c1cnc(N(c2ccccc2)c2ccccc2)nc1		Inactive	HDAC Inhibitor		2	ACY-1215	174006356.0&384568750.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NO)CCCCCCNC(=O)c1cnc(N(c2ccccc2)c2ccccc2)nc1	O=C(NO)CCCCCCNC(=O)c1cnc(N(c2ccccc2)c2ccccc2)nc1
NCGC00263177-04	O=C(NO)CCCCCCOc1c(OC)cc2ncnc(Nc3cc(C#C)ccc3)c2c1		Inactive	EGFR Inhibitor		1	CUDC-101	384568646.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NO)CCCCCCOc1c(OC)cc2ncnc(Nc3cc(C#C)ccc3)c2c1	O=C(NO)CCCCCCOc1c(OC)cc2ncnc(Nc3cc(C#C)ccc3)c2c1
NCGC00159564-05	O=C(NO)CCCCCN1C(=O)c2c3c(ccc2)cccc3C1=O		Inactive			1	Scriptaid	434147009.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NO)CCCCCN1C(=O)c2c3c(ccc2)cccc3C1=O	O=C(NO)CCCCCN1C(=O)c2c3c(ccc2)cccc3C1=O
NCGC00263610-05	O=C(NO)CCCCCNC(=O)c1ccc(N(C)C)cc1		Inactive			1	CAY10398		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NO)CCCCCNC(=O)c1ccc(N(C)C)cc1	O=C(NO)CCCCCNC(=O)c1ccc(N(C)C)cc1
NCGC00379210-02	O=C(NO)CCCCCONC(=O)c1cc(C)cc(C)c1		Inactive	Histone deacetylase 6 Inhibitor		1	LMK235	434146880.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NO)CCCCCONC(=O)c1cc(C)cc(C)c1	O=C(NO)CCCCCONC(=O)c1cc(C)cc(C)c1
NCGC00016611-10&NCGC00016611-11	O=C(NO)Cc1ccc(OCCCC)cc1		Inactive	non-steroidal antiinflammatory		2	Bufexamac	170465813.0&384567953.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&-13.7555886759	O=C(NO)Cc1ccc(OCCCC)cc1	O=C(NO)Cc1ccc(OCCCC)cc1
NCGC00015520-11&NCGC00015520-13	O=C(NO)N		Inactive	Ribonucleoside-Diphosphate Reductase Inhibitor		2	Hydroxyurea	170465025.0&384567861.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	O=C(NO)N	O=C(NO)N
NCGC00378859-02	O=C(NO)[C@@H](NC(=O)c1ccc(C#Cc2ccc(CN3CCOCC3)cc2)cc1)[C@H](O)C		Inactive	UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase Inhibitor		1	CHIR 090	363678241.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(NO)[C@@H](NC(=O)c1ccc(C#Cc2ccc(CN3CCOCC3)cc2)cc1)[C@H](O)C	O=C(NO)[C@@H](NC(=O)c1ccc(C#Cc2ccc(CN3CCOCC3)cc2)cc1)[C@H](O)C
NCGC00371093-04	O=C(NO)[C@@H](O)[C@H](C(=O)N[C@H](C(=O)NC)C(C)(C)C)CC(C)C		Inactive	Matrix Metalloproteinase Inhibitor		1	Marimastat	384569041.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NO)[C@@H](O)[C@H](C(=O)N[C@H](C(=O)NC)C(C)(C)C)CC(C)C	O=C(NO)[C@@H](O)[C@H](C(=O)N[C@H](C(=O)NC)C(C)(C)C)CC(C)C
NCGC00378675-01	O=C(NO)[C@H](C[C@H](NC(=O)c1ccc(Oc2ccccc2)cc1)COCOCC)C		Inactive	Matrix Metalloproteinase (MMP) Inhibitor		1	ONO-4817	384569062.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NO)[C@H](C[C@H](NC(=O)c1ccc(Oc2ccccc2)cc1)COCOCC)C	O=C(NO)[C@H](C[C@H](NC(=O)c1ccc(Oc2ccccc2)cc1)COCOCC)C
NCGC00408830-04	O=C(NO)c1cc(C(=O)NCCc2ccccc2)ccc1		Inactive			1	BRD73954	434147150.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NO)c1cc(C(=O)NCCc2ccccc2)ccc1	O=C(NO)c1cc(C(=O)NCCc2ccccc2)ccc1
NCGC00601806-01	O=C(NO)c1cc(NCc2ccccc2)c(C)cc1		Inactive			1	TH34	434147179.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NO)c1cc(NCc2ccccc2)c(C)cc1	O=C(NO)c1cc(NCc2ccccc2)c(C)cc1
NCGC00345492-06	O=C(NO)c1cc2n(Cc3ccc(OC)cc3)ccc2cc1		Inactive	HDAC Inhibitor		1	PCI-34051	384568736.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	20.0937589479&0.0	O=C(NO)c1cc2n(Cc3ccc(OC)cc3)ccc2cc1	O=C(NO)c1cc2n(Cc3ccc(OC)cc3)ccc2cc1
NCGC00499576-01	O=C(NO)c1ccc(C2=Nc3c(Oc4c2cccc4)cccc3)cc1		Inactive	HDAC Inhibitor		1	HDACi-01	384569308.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NO)c1ccc(C2=Nc3c(Oc4c2cccc4)cccc3)cc1	O=C(NO)c1ccc(C2=Nc3c(Oc4c2cccc4)cccc3)cc1
NCGC00263606-06	O=C(NO)c1ccc(Cn2c3c(c4c2CCN(C)C4)cccc3)cc1		Inactive	HDAC Inhibitor		1	Tubastatin A	384568693.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NO)c1ccc(Cn2c3c(c4c2CCN(C)C4)cccc3)cc1	O=C(NO)c1ccc(Cn2c3c(c4c2CCN(C)C4)cccc3)cc1
NCGC00345786-03	O=C(NO)c1ccc(Cn2c3c(c4c2CN(C)CC4)cccc3)cc1		Inactive	HDAC Inhibitor		1	Compound 7	384568741.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(NO)c1ccc(Cn2c3c(c4c2CN(C)CC4)cccc3)cc1	O=C(NO)c1ccc(Cn2c3c(c4c2CN(C)CC4)cccc3)cc1
NCGC00346692-03&NCGC00346692-04	O=C(NO)c1cnc(N(Cc2sc3c(N4CCOCC4)nc(-c4cnc(OC)cc4)nc3c2)C)nc1		Inactive	PI3K Inhibitor		2	CUDC-907	384568914.0&434146886.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NO)c1cnc(N(Cc2sc3c(N4CCOCC4)nc(-c4cnc(OC)cc4)nc3c2)C)nc1	O=C(NO)c1cnc(N(Cc2sc3c(N4CCOCC4)nc(-c4cnc(OC)cc4)nc3c2)C)nc1
NCGC00346487-03&NCGC00346487-05	O=C(NO)c1cnc(N2CCC(CNCc3c4c(n(C)c3)cccc4)CC2)nc1		Inactive	HDAC Inhibitor		2	Quisinostat	384568796.0&385842041.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NO)c1cnc(N2CCC(CNCc3c4c(n(C)c3)cccc4)CC2)nc1	O=C(NO)c1cnc(N2CCC(CNCc3c4c(n(C)c3)cccc4)CC2)nc1
NCGC00511370-01&NCGC00511370-02	O=C(NO)c1cnc(NC2(c3ccccc3)CC2)nc1		Inactive	HDAC Inhibitor		2	ACY-738	384569499.0&434147169.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(NO)c1cnc(NC2(c3ccccc3)CC2)nc1	O=C(NO)c1cnc(NC2(c3ccccc3)CC2)nc1
NCGC00386419-01	O=C(N[C@@H](C(=O)N)Cc1ccccc1)[C@H](NC(=O)[C@H](NC(=O)C)Cc1ccc(O)cc1)CCCNC(=N)N		Inactive	Dual specificity mitogen-activated protein kinase kinase 7 Binding Agent		1	DTP3	363680272.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@@H](C(=O)N)Cc1ccccc1)[C@H](NC(=O)[C@H](NC(=O)C)Cc1ccc(O)cc1)CCCNC(=N)N	O=C(N[C@@H](C(=O)N)Cc1ccccc1)[C@H](NC(=O)[C@H](NC(=O)C)Cc1ccc(O)cc1)CCCNC(=N)N
NCGC00370792-04	O=C(N[C@@H](C(=O)N1CCC(C(=O)CCC)(c2ccccc2)CC1)Cc1ccc(OC)cc1)[C@@H](N)Cc1n(C)cnc1		Inactive	Melanocortin receptor 1 Agonist		1	BMS-470539 2 HCl	363677858.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@@H](C(=O)N1CCC(C(=O)CCC)(c2ccccc2)CC1)Cc1ccc(OC)cc1)[C@@H](N)Cc1n(C)cnc1	O=C(N[C@@H](C(=O)N1CCC(C(=O)CCC)(c2ccccc2)CC1)Cc1ccc(OC)cc1)[C@@H](N)Cc1n(C)cnc1
NCGC00378854-02	O=C(N[C@@H](C(=O)N1C[C@](C(=O)N(N(C)C)C)(Cc2ccccc2)CCC1)Cc1c2c([nH]c1)cccc2)C(N)(C)C		Inactive	GHS Receptor Agonist		1	Anamorelin	384569072.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H](C(=O)N1C[C@](C(=O)N(N(C)C)C)(Cc2ccccc2)CCC1)Cc1c2c([nH]c1)cccc2)C(N)(C)C	O=C(N[C@@H](C(=O)N1C[C@](C(=O)N(N(C)C)C)(Cc2ccccc2)CCC1)Cc1c2c([nH]c1)cccc2)C(N)(C)C
NCGC00181352-01	O=C(N[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1ccc(O)cc1)[C@H](N)CC(=O)NC		Inactive			1	Aspoxicillin	144206363.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1ccc(O)cc1)[C@H](N)CC(=O)NC	O=C(N[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1ccc(O)cc1)[C@H](N)CC(=O)NC
NCGC00183364-03	O=C(N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1[C@@H](C(=O)NCC)CCC1)CCCNC(=N)N)CC(C)C)CC(C)C)Cc1ccc(O)cc1)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)Cc1nc[nH]c1)Cc1c2c([nH]c1)cccc2)CO		Inactive			1	Leuprolide (Acetate)		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1[C@@H](C(=O)NCC)CCC1)CCCNC(=N)N)CC(C)C)CC(C)C)Cc1ccc(O)cc1)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)Cc1nc[nH]c1)Cc1c2c([nH]c1)cccc2)CO	O=C(N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1[C@@H](C(=O)NCC)CCC1)CCCNC(=N)N)CC(C)C)CC(C)C)Cc1ccc(O)cc1)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)Cc1nc[nH]c1)Cc1c2c([nH]c1)cccc2)CO
NCGC00378631-01	O=C(N[C@@H](C(C)(C)C)C(=O)N1[C@H](C(=O)NC(C(=O)C(=O)N)CC2CCC2)[C@H]2C(C)(C)[C@H]2C1)NC(C)(C)C		Inactive	Hepatitis C virus serine protease, NS3/NS4A Inhibitor		1	Boceprevir	405558552.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N[C@@H](C(C)(C)C)C(=O)N1[C@H](C(=O)NC(C(=O)C(=O)N)CC2CCC2)[C@H]2C(C)(C)[C@H]2C1)NC(C)(C)C	O=C(N[C@@H](C(C)(C)C)C(=O)N1[C@H](C(=O)NC(C(=O)C(=O)N)CC2CCC2)[C@H]2C(C)(C)[C@H]2C1)NC(C)(C)C
NCGC00346545-03&NCGC00346545-08	O=C(N[C@@H](C(C)(C)C)C(=O)N1[C@H](C(=O)N[C@H](C(=O)C(=O)NC2CC2)CCC)[C@@H]2[C@H](C1)CCC2)[C@@H](NC(=O)c1nccnc1)C1CCCCC1		Inactive	HCV NS3 NS4A Protease Inhibitor		2	Telaprevir (VX-950)	405558725.0&384568831.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(N[C@@H](C(C)(C)C)C(=O)N1[C@H](C(=O)N[C@H](C(=O)C(=O)NC2CC2)CCC)[C@@H]2[C@H](C1)CCC2)[C@@H](NC(=O)c1nccnc1)C1CCCCC1	O=C(N[C@@H](C(C)(C)C)C(=O)N1[C@H](C(=O)N[C@H](C(=O)C(=O)NC2CC2)CCC)[C@@H]2[C@H](C1)CCC2)[C@@H](NC(=O)c1nccnc1)C1CCCCC1
NCGC00378654-01	O=C(N[C@@H](C(C)C)CN1C[C@H](C)[C@](C)(c2cc(O)ccc2)CC1)[C@@H]1NCc2c(ccc(O)c2)C1		Inactive	Kappa opioid receptor Antagonist		1	JDTic dihydrochloride	363678137.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@@H](C(C)C)CN1C[C@H](C)[C@](C)(c2cc(O)ccc2)CC1)[C@@H]1NCc2c(ccc(O)c2)C1	O=C(N[C@@H](C(C)C)CN1C[C@H](C)[C@](C)(c2cc(O)ccc2)CC1)[C@@H]1NCc2c(ccc(O)c2)C1
NCGC00346433-06&NCGC00346433-07	O=C(N[C@@H](C(CC)CC)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N)C		Inactive	Influenza Infection Inhibitor		2	Peramivir	434147086.0&405558732.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N[C@@H](C(CC)CC)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N)C	O=C(N[C@@H](C(CC)CC)[C@@H]1[C@H](O)[C@@H](C(=O)O)C[C@H]1NC(=N)N)C
NCGC00509939-01	O=C(N[C@@H](C)C=1N(c2ccccc2)C(=O)c2c(C#Cc3cn(C)nc3)cccc2C=1)c1c(N)nn2c1N=CC=C2		Inactive	PI3Kgamma Inhibitor		1	IPI-549	384569388.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H](C)C=1N(c2ccccc2)C(=O)c2c(C#Cc3cn(C)nc3)cccc2C=1)c1c(N)nn2c1N=CC=C2	O=C(N[C@@H](C)C=1N(c2ccccc2)C(=O)c2c(C#Cc3cn(C)nc3)cccc2C=1)c1c(N)nn2c1N=CC=C2
NCGC00510708-01	O=C(N[C@@H](C)c1ccc(-c2nc(CCC3CCCC3)on2)cc1)[C@@H]1[C@@H](O)CCN1		Inactive	Sphingosine Kinase 1 (SphK1) Inhibitor		1	NCGC00510708	384569489.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H](C)c1ccc(-c2nc(CCC3CCCC3)on2)cc1)[C@@H]1[C@@H](O)CCN1	O=C(N[C@@H](C)c1ccc(-c2nc(CCC3CCCC3)on2)cc1)[C@@H]1[C@@H](O)CCN1
NCGC00379250-01	O=C(N[C@@H](C)c1ccccc1)CCC1=Nc2c(C(=O)N1)cccc2		Inactive	Poly [ADP-ribose] polymerase 3 Inhibitor		1	ME 0328	434147116.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	9.10337798	O=C(N[C@@H](C)c1ccccc1)CCC1=Nc2c(C(=O)N1)cccc2	O=C(N[C@@H](C)c1ccccc1)CCC1=Nc2c(C(=O)N1)cccc2
NCGC00345816-01	O=C(N[C@@H](C)c1ccccc1)[C@@H](NC(=O)[C@@H](CC(=O)O)CC(C)C)Cc1c2c([nH]c1)cccc2		Inactive	MMP Inhibitor		1	GM-1489	174007112.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H](C)c1ccccc1)[C@@H](NC(=O)[C@@H](CC(=O)O)CC(C)C)Cc1c2c([nH]c1)cccc2	O=C(N[C@@H](C)c1ccccc1)[C@@H](NC(=O)[C@@H](CC(=O)O)CC(C)C)Cc1c2c([nH]c1)cccc2
NCGC00423987-01	O=C(N[C@@H](C1CC(O)C1)C1CCNCC1)CCc1onc(O)c1		Inactive			1	NCGC00423987-01	375883579.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@@H](C1CC(O)C1)C1CCNCC1)CCc1onc(O)c1	O=C(N[C@@H](C1CC(O)C1)C1CCNCC1)CCc1onc(O)c1
NCGC00423714-01	O=C(N[C@@H](C1CC(O)C1)C1CCNCC1)c1cc2N(C)C(=O)Oc2cc1		Inactive			1	NCGC00423714-01	375882965.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@@H](C1CC(O)C1)C1CCNCC1)c1cc2N(C)C(=O)Oc2cc1	O=C(N[C@@H](C1CC(O)C1)C1CCNCC1)c1cc2N(C)C(=O)Oc2cc1
NCGC00346469-03&NCGC00346469-08	O=C(N[C@@H](CC(C)C)B(O)O)[C@@H](NC(=O)c1nc(-c2ccccc2)ccc1)[C@H](O)C		Inactive	Proteasome Inhibitor		2	Delanzomib	384568788.0&434146883.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O=C(N[C@@H](CC(C)C)B(O)O)[C@@H](NC(=O)c1nc(-c2ccccc2)ccc1)[C@H](O)C	O=C(N[C@@H](CC(C)C)B(O)O)[C@@H](NC(=O)c1nc(-c2ccccc2)ccc1)[C@H](O)C
NCGC00242506-06&NCGC00242506-13	O=C(N[C@@H](CC(C)C)B(O)O)[C@@H](NC(=O)c1nccnc1)Cc1ccccc1		Inactive	Proteasome Inhibitor		2	Bortezomib	405558982.0&384568504.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		O=C(N[C@@H](CC(C)C)B(O)O)[C@@H](NC(=O)c1nccnc1)Cc1ccccc1	O=C(N[C@@H](CC(C)C)B(O)O)[C@@H](NC(=O)c1nccnc1)Cc1ccccc1
NCGC00016978-04&NCGC00016978-13	O=C(N[C@@H](CC(C)C)c1c(N2CCCCC2)cccc1)Cc1cc(OCC)c(C(=O)O)cc1		Inactive	Insulin Secretagogues		2	Repaglinide	225144184.0&384567971.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	21.625158032&0.0&0.0	O=C(N[C@@H](CC(C)C)c1c(N2CCCCC2)cccc1)Cc1cc(OCC)c(C(=O)O)cc1	O=C(N[C@@H](CC(C)C)c1c(N2CCCCC2)cccc1)Cc1cc(OCC)c(C(=O)O)cc1
NCGC00370774-02	O=C(N[C@@H](CC)c1ccccc1)c1c(O)c(-c2ccccc2)nc2c1cccc2		Inactive			1	Talnetant	363677847.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@@H](CC)c1ccccc1)c1c(O)c(-c2ccccc2)nc2c1cccc2	O=C(N[C@@H](CC)c1ccccc1)c1c(O)c(-c2ccccc2)nc2c1cccc2
NCGC00263107-03	O=C(N[C@@H]([C@@H](CC)C)C(=O)N1CCC2(c3c(cccc3)CC2)CC1)[C@@H](NC(=O)c1oncc1)CC1CCCCC1		Inactive	PAR2 Antagonist		1	GB-83	384568594.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]([C@@H](CC)C)C(=O)N1CCC2(c3c(cccc3)CC2)CC1)[C@@H](NC(=O)c1oncc1)CC1CCCCC1	O=C(N[C@@H]([C@@H](CC)C)C(=O)N1CCC2(c3c(cccc3)CC2)CC1)[C@@H](NC(=O)c1oncc1)CC1CCCCC1
NCGC00389337-01	O=C(N[C@@H]([C@H](CC)C)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(=O)[C@]1(C)OC1)CC(C)C)[C@@H](N(C(=O)C)C)[C@H](CC)C		Inactive			1	Epoxomicin	434147137.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]([C@H](CC)C)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(=O)[C@]1(C)OC1)CC(C)C)[C@@H](N(C(=O)C)C)[C@H](CC)C	O=C(N[C@@H]([C@H](CC)C)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(=O)[C@]1(C)OC1)CC(C)C)[C@@H](N(C(=O)C)C)[C@H](CC)C
NCGC00599627-01	O=C(N[C@@H]([C@H](O)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(=O)N)Cc1ccc(O)cc1)CC(=O)N)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](N)C)CO)[C@H](O)C)[C@H](O)C		Inactive			1	Adaptavir   D-Ala1-peptide T-NH2   DAPTA   RAP-101  	434146906.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]([C@H](O)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(=O)N)Cc1ccc(O)cc1)CC(=O)N)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](N)C)CO)[C@H](O)C)[C@H](O)C	O=C(N[C@@H]([C@H](O)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)C(=O)N)Cc1ccc(O)cc1)CC(=O)N)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](N)C)CO)[C@H](O)C)[C@H](O)C
NCGC00509905-01	O=C(N[C@@H]([C@H](O)c1cc2OCCOc2cc1)CN1CCCC1)CCCCCCC	4.9000001	Active	Ceramide glucosyltransferase Antagonist	0.0	1	Eliglustat (Tartrate)	405558462.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	41.2511389728	O=C(N[C@@H]([C@H](O)c1cc2OCCOc2cc1)CN1CCCC1)CCCCCCC	O=C(N[C@@H]([C@H](O)c1cc2OCCOc2cc1)CN1CCCC1)CCCCCCC
NCGC00485925-01	O=C(N[C@@H]([C@H](O)c1cc2OCCOc2cc1)CN1CCCC1)CCCCCCCC	4.9000001	Active	Ceramide glucosyltransferase Inhibitor	0.0	1	Genz-123346 (free base)	363681420.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	3.0	95.6249101119	O=C(N[C@@H]([C@H](O)c1cc2OCCOc2cc1)CN1CCCC1)CCCCCCCC	O=C(N[C@@H]([C@H](O)c1cc2OCCOc2cc1)CN1CCCC1)CCCCCCCC
NCGC00161370-01	O=C(N[C@@H]([C@H](O)c1ccccc1)CN1CCOCC1)CCCCCCCCCCCCCCC		Inactive			1	DL-PPMP	26754974.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@@H]([C@H](O)c1ccccc1)CN1CCOCC1)CCCCCCCCCCCCCCC	O=C(N[C@@H]([C@H](O)c1ccccc1)CN1CCOCC1)CCCCCCCCCCCCCCC
NCGC00510527-02	O=C(N[C@@H]1C(=O)N(C)c2c(OC1)cccc2)c1[nH]nc(Cc2ccccc2)n1		Inactive	RIP1 kinase Inhibitor		1	GSK-2982772	384569474.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N(C)c2c(OC1)cccc2)c1[nH]nc(Cc2ccccc2)n1	O=C(N[C@@H]1C(=O)N(C)c2c(OC1)cccc2)c1[nH]nc(Cc2ccccc2)n1
NCGC00499427-02	O=C(N[C@@H]1C(=O)N(C)c2c(OC1)cccc2)c1noc(Cc2ccccc2)c1		Inactive	RIP1 kinase Inhibitor		1	GSK-481	384569306.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N(C)c2c(OC1)cccc2)c1noc(Cc2ccccc2)c1	O=C(N[C@@H]1C(=O)N(C)c2c(OC1)cccc2)c1noc(Cc2ccccc2)c1
NCGC00159513-03	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(/C=C/C)CS[C@H]12)[C@H](N)c1ccc(O)cc1		Inactive	Cephalosporin antibiotic		1	Cefprozil	225144231.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(/C=C/C)CS[C@H]12)[C@H](N)c1ccc(O)cc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(/C=C/C)CS[C@H]12)[C@H](N)c1ccc(O)cc1
NCGC00263951-01	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@@H]12)[C@H](N)C1=CCC=CC1		Inactive	Cephalosporin antibiotic		1	CEPHRADINE	405558705.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@@H]12)[C@H](N)C1=CCC=CC1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@@H]12)[C@H](N)C1=CCC=CC1
NCGC00179556-03	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@H]12)[C@H](N)c1ccc(O)cc1		Inactive	Solute carrier family 15 member 2 Substrate		1	Cefadroxil	170464658.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@H]12)[C@H](N)c1ccc(O)cc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@H]12)[C@H](N)c1ccc(O)cc1
NCGC00159522-05	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@H]12)[C@H](N)c1ccccc1		Inactive	Cephalosporin antibiotic		1	Cephalexin	170464982.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@H]12)[C@H](N)c1ccccc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C)CS[C@H]12)[C@H](N)c1ccccc1
NCGC00178499-08	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C=C)CS[C@H]12)/C(=N\O)/c1nc(N)sc1		Inactive	Cephalosporin antibiotic		1	Cefdinir	405559056.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C=C)CS[C@H]12)/C(=N\O)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C=C)CS[C@H]12)/C(=N\O)/c1nc(N)sc1
NCGC00179521-03	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C=C)CS[C@H]12)/C(=N\OCC(=O)O)/c1nc(N)sc1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	Cefixime	405559067.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C=C)CS[C@H]12)/C(=N\OCC(=O)O)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C=C)CS[C@H]12)/C(=N\OCC(=O)O)/c1nc(N)sc1
NCGC00379079-03	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(CN3N(CCO)C(=N)C=C3)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1		Inactive	Antibiotic		1	Cefoselis (sulfate)	405558638.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(CN3N(CCO)C(=N)C=C3)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(CN3N(CCO)C(=N)C=C3)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1
NCGC00093358-08	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	Cefotaxime sodium salt	405558920.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(=O)C)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(=O)C)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1
NCGC00510891-01	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)CC#N		Inactive			1	Cefacetrile	405558954.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)CC#N	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)CC#N
NCGC00023699-09	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)Cc1sccc1		Inactive	Solute carrier family 22 member 7 Inhibitor		1	Cephalothin	170465101.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)Cc1sccc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)Cc1sccc1
NCGC00521078-02	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)[C@H](N)c1ccccc1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	Cephaloglycin	405558643.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)[C@H](N)c1ccccc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)[C@H](N)c1ccccc1
NCGC00532497-01	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1		Inactive			1	CEFPODOXIME	405559088.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(COC)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1
NCGC00183016-01	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(Cn3nc(C)nn3)CS[C@H]12)/C(=N/OC)/c1nc(N)sc1		Inactive			1	Cefteram	144206853.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(Cn3nc(C)nn3)CS[C@H]12)/C(=N/OC)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(Cn3nc(C)nn3)CS[C@H]12)/C(=N/OC)/c1nc(N)sc1
NCGC00185745-01	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(OC)CS[C@H]12)[C@H](N)C1=CCC=CC1		Inactive			1	Cefroxadine	144206693.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(OC)CS[C@H]12)[C@H](N)C1=CCC=CC1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(OC)CS[C@H]12)[C@H](N)C1=CCC=CC1
NCGC00178501-04	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)/C(=C\CC(=O)O)/c1nc(N)sc1		Inactive	Peptidoglycan synthase FtsI Inhibitor		1	CEFTIBUTEN	405558519.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)/C(=C\CC(=O)O)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)/C(=C\CC(=O)O)/c1nc(N)sc1
NCGC00167460-03	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=CCS[C@H]12)/C(=N/OC)/c1nc(N)sc1		Inactive	Bacterial Penicillin-binding Protein Inhibitor		1	Ceftizoxim·Na	405558486.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=CCS[C@H]12)/C(=N/OC)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=CCS[C@H]12)/C(=N/OC)/c1nc(N)sc1
NCGC00178554-03	O=C(N[C@@H]1C(=O)N2C(C(=O)O)C(C)(C)S[C@H]12)[C@H](NC(=O)N1C(=O)NCC1)c1ccccc1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	AZLOCILLIN SODIUM	405558664.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])C(C)(C)S[C@H]12)[C@H](NC(=O)N1C(=O)NCC1)c1ccccc1	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])C(C)(C)S[C@H]12)[C@H](NC(=O)N1C(=O)NCC1)c1ccccc1
NCGC00017147-02	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[N+]3(C)CCCC3)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	CEFEPIME HYDROCHLORIDE	405559036.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C[N+]3(C)CCCC3)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1	O=C(N[C@@H]1C(=O)N2C(C(=O)O)=C(C[N+]3(C)CCCC3)CS[C@H]12)/C(=N\OC)/c1nc(N)sc1
NCGC00181750-01	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3c4n(N=CC=C4)cc3)CS[C@H]12)/C(=N/OC)/c1nc(N)sn1		Inactive	Bacterial penicillin-binding protein Binding Agent		1	Cefozopran hydrochloride	144206474.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3c4n(N=CC=C4)cc3)CS[C@H]12)/C(=N/OC)/c1nc(N)sn1.Cl	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3c4n(N=CC=C4)cc3)CS[C@H]12)/C(=N/OC)/c1nc(N)sn1.Cl
NCGC00179310-03	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccc(C(=O)N)cc3)CS[C@H]12)Cc1sccc1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	Cefalonium	170466431.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccc(C(=O)N)cc3)CS[C@H]12)Cc1sccc1	O=C(N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccc(C(=O)N)cc3)CS[C@H]12)Cc1sccc1
NCGC00016797-11&NCGC00016797-15	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@@H]12)[C@@H](N)c1ccc(O)cc1		Inactive	beta-lactam antibiotic		2	Amoxicillin sodium	405558548.0&384567960.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@@H]12)[C@@H](N)c1ccc(O)cc1	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@@H]12)[C@@H](N)c1ccc(O)cc1
NCGC00179009-06	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)C(Oc1ccccc1)C		Inactive	Bacterial penicillin-binding protein Inhibitor		1	Phenethicillin potassium salt	405558484.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)C(Oc1ccccc1)C	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)C(Oc1ccccc1)C
NCGC00160673-01	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)C(Oc1ccccc1)CC		Inactive			1	Propicillin	144205529.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)C(Oc1ccccc1)CC	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)C(Oc1ccccc1)CC
NCGC00164005-06	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)COc1ccccc1		Inactive			1	PENICILLIN V POTASSIUM	405558690.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)COc1ccccc1	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)COc1ccccc1
NCGC00023282-21	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1		Inactive			1	AMPICILLIN SODIUM	405558724.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1
NCGC00253577-01	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCC3=C(C)OC(=O)O3)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1		Inactive			1	Lenampicillin hydrochloride	170465777.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCC3=C(C)OC(=O)O3)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1.Cl	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCC3=C(C)OC(=O)O3)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1.Cl
NCGC00179290-03	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)C(C)(C)C)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1		Inactive			1	Pivampicillin	170466065.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)C(C)(C)C)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)C(C)(C)C)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1
NCGC00188437-01	O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)[C@H]3C(C)(C)S(=O)(=O)[C@H]4N3C(=O)C4)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1		Inactive	Staphylococcus Aureus Inhibitor		1	Sultamicillin tosylate	144206543.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)c1ccc(C)cc1.O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)[C@H]3C(C)(C)S(=O)(=O)[C@H]4N3C(=O)C4)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1	S(=O)(=O)(O)c1ccc(C)cc1.O=C(N[C@@H]1C(=O)N2[C@@H](C(=O)OCOC(=O)[C@H]3C(C)(C)S(=O)(=O)[C@H]4N3C(=O)C4)C(C)(C)S[C@H]12)[C@H](N)c1ccccc1
NCGC00346675-02	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)NC(c3ccccc3)c3ccccc3)CC[C@@H]2CCN(C(=O)CC(C)C)C1)[C@@H](NC)C		Inactive	IAP Inhibitor		1	AT-406	384568901.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)NC(c3ccccc3)c3ccccc3)CC[C@@H]2CCN(C(=O)CC(C)C)C1)[C@@H](NC)C	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)NC(c3ccccc3)c3ccccc3)CC[C@@H]2CCN(C(=O)CC(C)C)C1)[C@@H](NC)C
NCGC00263236-02	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)N[C@H](c3nnn(CCCCc4ccc(CCCCn5nnc([C@@H](NC(=O)[C@H]6N7C(=O)[C@@H](NC(=O)[C@@H](NC)C)CCCC[C@H]7CC6)c6ccccc6)c5)cc4)c3)c3ccccc3)CC[C@@H]2CCCC1)[C@@H](NC)C		Inactive	IAP Inhibitor		1	SM-164	384568680.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)N[C@H](c3nnn(CCCCc4ccc(CCCCn5nnc([C@@H](NC(=O)[C@H]6N7C(=O)[C@@H](NC(=O)[C@@H](NC)C)CCCC[C@H]7CC6)c6ccccc6)c5)cc4)c3)c3ccccc3)CC[C@@H]2CCCC1)[C@@H](NC)C	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)N[C@H](c3nnn(CCCCc4ccc(CCCCn5nnc([C@@H](NC(=O)[C@H]6N7C(=O)[C@@H](NC(=O)[C@@H](NC)C)CCCC[C@H]7CC6)c6ccccc6)c5)cc4)c3)c3ccccc3)CC[C@@H]2CCCC1)[C@@H](NC)C
NCGC00263949-02	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)O)C(C)(C)S[C@H]12)[C@H](NC(=O)N1C(=O)C(=O)N(CC)CC1)c1ccccc1		Inactive	Penicillin-binding protein 2B Binding Agent		1	Piperacillin sodium salt	170465380.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)[O-])C(C)(C)S[C@H]12)[C@H](NC(=O)N1C(=O)C(=O)N(CC)CC1)c1ccccc1.[Na+]	O=C(N[C@@H]1C(=O)N2[C@H](C(=O)[O-])C(C)(C)S[C@H]12)[C@H](NC(=O)N1C(=O)C(=O)N(CC)CC1)c1ccccc1.[Na+]
NCGC00390548-02	O=C(N[C@@H]1C(=O)N[C@@H](Cc2[nH]cnc2)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N)CSSC1)C		Inactive	N-Cadherin Antagonist		1	Exherin	384569190.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N[C@@H](Cc2[nH]cnc2)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N)CSSC1)C	O=C(N[C@@H]1C(=O)N[C@@H](Cc2[nH]cnc2)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N)CSSC1)C
NCGC00181796-03	O=C(N[C@@H]1C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2c3c([nH]c2)cccc3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)CO)CSSC1)[C@H](N)Cc1ccccc1		Inactive	Growth Hormone Release Inhibitor		1	Octreotide	384568403.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2c3c([nH]c2)cccc3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)CO)CSSC1)[C@H](N)Cc1ccccc1	O=C(N[C@@H]1C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2c3c([nH]c2)cccc3)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(=O)N[C@@H]([C@H](O)C)CO)CSSC1)[C@H](N)Cc1ccccc1
NCGC00379034-03	O=C(N[C@@H]1C(=O)N[C@@H]([C@H](O)C)C(=O)N2[C@H](C(=O)N[C@@H]([C@@H](O)[C@H](O)c3ccc(O)cc3)C(=O)N[C@@H]([C@H](O)CCN)C(=O)N3[C@@H]([C@@H](O)CC3)C(=O)N[C@H](NCCN)[C@H](O)C1)C[C@@H](O)C2)CCCCCCCCC(CC(CC)C)C		Inactive			1	Caspofungin Acetate		Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1C(=O)N[C@@H]([C@H](O)C)C(=O)N2[C@H](C(=O)N[C@@H]([C@@H](O)[C@H](O)c3ccc(O)cc3)C(=O)N[C@@H]([C@H](O)CCN)C(=O)N3[C@@H]([C@@H](O)CC3)C(=O)N[C@H](NCCN)[C@H](O)C1)C[C@@H](O)C2)CCCCCCCCC(CC(CC)C)C	O=C(N[C@@H]1C(=O)N[C@@H]([C@H](O)C)C(=O)N2[C@H](C(=O)N[C@@H]([C@@H](O)[C@H](O)c3ccc(O)cc3)C(=O)N[C@@H]([C@H](O)CCN)C(=O)N3[C@@H]([C@@H](O)CC3)C(=O)N[C@H](NCCN)[C@H](O)C1)C[C@@H](O)C2)CCCCCCCCC(CC(CC)C)C
NCGC00094594-13&NCGC00094594-17	O=C(N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@H](CC)C)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](Cc2[nH]cnc2)C(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)NCCCC1)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)C1N=C(C(N)C(CC)C)SC1)CC(C)C)CCC(=O)O)[C@H](CC)C		Inactive			2	Bacitracin&Bacitracin (Zinc)	405558650.0&384568133.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@H](CC)C)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](Cc2[nH]cnc2)C(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)NCCCC1)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)C1N=C(C(N)C(CC)C)SC1)CC(C)C)CCC(=O)O)[C@H](CC)C	O=C(N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@H](CC)C)C(=O)N[C@H](Cc2ccccc2)C(=O)N[C@@H](Cc2[nH]cnc2)C(=O)N[C@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)NCCCC1)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)C1N=C(C(N)C(CC)C)SC1)CC(C)C)CCC(=O)O)[C@H](CC)C
NCGC00025125-18&NCGC00025125-23	O=C(N[C@@H]1C=2C(c3c(OC)c(OC)c(OC)cc3CC1)=CC=C(OC)C(=O)C=2)C		Inactive	Tubulin polymerization Inhibitor		2	Colchicine	170465011.0&384568052.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(N[C@@H]1C=2C(c3c(OC)c(OC)c(OC)cc3CC1)=CC=C(OC)C(=O)C=2)C	O=C(N[C@@H]1C=2C(c3c(OC)c(OC)c(OC)cc3CC1)=CC=C(OC)C(=O)C=2)C
NCGC00263228-01	O=C(N[C@@H]1C[C@@H](C(=O)N(C)c2ccc(-c3oc4c(n3)cccc4)cc2)CC1)CC		Inactive	Fatty Acid Synthase (FAS) Inhibitor		1	FASN BI	137276072.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	23.0	O=C(N[C@@H]1C[C@@H](C(=O)N(C)c2ccc(-c3oc4c(n3)cccc4)cc2)CC1)CC	O=C(N[C@@H]1C[C@@H](C(=O)N(C)c2ccc(-c3oc4c(n3)cccc4)cc2)CC1)CC
NCGC00386554-01	O=C(N[C@@H]1C[C@@H]2N(C)[C@H](CC1)CC2)c1nn(C)c2c1cccc2		Inactive			1	Granisetron hydrochloride	363680324.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@@H]1C[C@@H]2N(C)[C@H](CC1)CC2)c1nn(C)c2c1cccc2	O=C(N[C@@H]1C[C@@H]2N(C)[C@H](CC1)CC2)c1nn(C)c2c1cccc2
NCGC00485370-01	O=C(N[C@@H]1N=C(c2ccccc2)c2c(N(C)C1)cccc2)Nc1cc(C)ccc1		Inactive			1	L-365260	363681300.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@@H]1N=C(c2ccccc2)c2c(N(C)C1)cccc2)Nc1cc(C)ccc1	O=C(N[C@@H]1N=C(c2ccccc2)c2c(N(C)C1)cccc2)Nc1cc(C)ccc1
NCGC00386414-01	O=C(N[C@@H]1[C@@H](C(=O)O)O[C@H](N2C(=O)N=C(N)C=C2)C=C1)C[C@@H](N)CCN(C(=N)N)C		Inactive	Escherichia coli Inhibitor		1	Blasticidin S HCl	363680267.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	16.5	O=C(N[C@@H]1[C@@H](C(=O)O)O[C@H](N2C(=O)N=C(N)C=C2)C=C1)C[C@@H](N)CCN(C(=N)N)C	O=C(N[C@@H]1[C@@H](C(=O)O)O[C@H](N2C(=O)N=C(N)C=C2)C=C1)C[C@@H](N)CCN(C(=N)N)C
NCGC00384912-01	O=C(N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1C(C)(C)[C@H]2[C@@](C)(C3[C@](C)([C@@]4(C)C([C@H]5[C@@](C(=O)O)([C@H](O)C4)CCC(C)(C)C5)=CC3)CC2)CC1)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384912-01	363679434.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1C(C)(C)[C@H]2[C@@](C)(C3[C@](C)([C@@]4(C)C([C@H]5[C@@](C(=O)O)([C@H](O)C4)CCC(C)(C)C5)=CC3)CC2)CC1)C	O=C(N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1C(C)(C)[C@H]2[C@@](C)(C3[C@](C)([C@@]4(C)C([C@H]5[C@@](C(=O)O)([C@H](O)C4)CCC(C)(C)C5)=CC3)CC2)CC1)C
NCGC00380541-01	O=C(N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC2C(O)C(OC3C(O)C(O)C(O)C(C)O3)C(O)C(C)O2)O[C@H]1O[C@@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)C([C@H]5[C@@](C(=O)OC6C(O)C(O)C(O)CO6)(CC4)CCC(C)(C)C5)=CC3)CC2)CC1)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: Acacia | Family: Fabaceae | Species: catechu		1	NCGC00380541-01	363678640.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC2C(O)C(OC3C(O)C(O)C(O)C(C)O3)C(O)C(C)O2)O[C@H]1O[C@@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)C([C@H]5[C@@](C(=O)OC6C(O)C(O)C(O)CO6)(CC4)CCC(C)(C)C5)=CC3)CC2)CC1)C	O=C(N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC2C(O)C(OC3C(O)C(O)C(O)C(C)O3)C(O)C(C)O2)O[C@H]1O[C@@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)C([C@H]5[C@@](C(=O)OC6C(O)C(O)C(O)CO6)(CC4)CCC(C)(C)C5)=CC3)CC2)CC1)C
NCGC00384703-01	O=C(N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)[C@@H](O)CO2)O[C@H]1O[C@@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)C(C5[C@@](C(=O)O)([C@H](O)C4)CCC(C)(C)C5)=CC3)CC2)CC1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384703-01	363679317.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)[C@@H](O)CO2)O[C@H]1O[C@@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)C(C5[C@@](C(=O)O)([C@H](O)C4)CCC(C)(C)C5)=CC3)CC2)CC1)C	O=C(N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)[C@@H](O)CO2)O[C@H]1O[C@@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)C(C5[C@@](C(=O)O)([C@H](O)C4)CCC(C)(C)C5)=CC3)CC2)CC1)C
NCGC00381285-01	O=C(N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)[C@@H](O)CO2)O[C@H]1O[C@@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)C(C5[C@@](C(=O)O)([C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)C4)CCC(C)(C)C5)=CC3)CC2)CC1)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381285-01	363679068.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)[C@@H](O)CO2)O[C@H]1O[C@@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)C(C5[C@@](C(=O)O)([C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)C4)CCC(C)(C)C5)=CC3)CC2)CC1)C	O=C(N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)[C@@H](O)CO2)O[C@H]1O[C@@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)C(C5[C@@](C(=O)O)([C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)C4)CCC(C)(C)C5)=CC3)CC2)CC1)C
NCGC00386018-01	O=C(N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)[C@@H](O)[C@@H](C)O2)O[C@H]1O[C@@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)C(C5[C@@](C(=O)O)(C(O)C4)CCC(C)(C)C5)=CC3)CC2)CC1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386018-01	363680062.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)[C@@H](O)[C@@H](C)O2)O[C@H]1O[C@@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)C(C5[C@@](C(=O)O)(C(O)C4)CCC(C)(C)C5)=CC3)CC2)CC1)C	O=C(N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)[C@@H](O)[C@@H](C)O2)O[C@H]1O[C@@H]1C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)C(C5[C@@](C(=O)O)(C(O)C4)CCC(C)(C)C5)=CC3)CC2)CC1)C
NCGC00485979-01	O=C(N[C@@H]1[C@H](C)O[C@@H](O[C@@H]2[C@H](C)O[C@@H](O[C@@H]\3[C@H](C)/C=C/C=C\4/[C@@]5(O)[C@H]([C@H](O)C(C)=C[C@H]5C(=O)O[C@@H]5CC6(O[C@@H]([C@@H](CC)C)[C@H](C)C=C6)O[C@H](C5)C/C=C/3\C)OC/4)C[C@@H]2OC)C[C@@H]1OC)C		Inactive			1	Eprinomectin	363681458.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	27.332690824	O=C(N[C@@H]1[C@H](C)O[C@@H](O[C@@H]2[C@H](C)O[C@@H](O[C@@H]\3[C@H](C)/C=C/C=C\4/[C@@]5(O)[C@H]([C@H](O)C(C)=C[C@H]5C(=O)O[C@@H]5CC6(O[C@@H]([C@@H](CC)C)[C@H](C)C=C6)O[C@H](C5)C/C=C/3\C)OC/4)C[C@@H]2OC)C[C@@H]1OC)C	O=C(N[C@@H]1[C@H](C)O[C@@H](O[C@@H]2[C@H](C)O[C@@H](O[C@@H]\3[C@H](C)/C=C/C=C\4/[C@@]5(O)[C@H]([C@H](O)C(C)=C[C@H]5C(=O)O[C@@H]5CC6(O[C@@H]([C@@H](CC)C)[C@H](C)C=C6)O[C@H](C5)C/C=C/3\C)OC/4)C[C@@H]2OC)C[C@@H]1OC)C
NCGC00159460-01&NCGC00159460-04	O=C(N[C@@H]1[C@H](O)Cc2c1cccc2)[C@@H](C[C@H](O)CN1[C@H](C(=O)NC(C)(C)C)CN(Cc2cnccc2)CC1)Cc1ccccc1		Inactive	HIV Protease Inhibitors		2	INDINAVIR SULFATE&Indinavir sulfate	363676591.0&170465228.0	Anti-infectives&2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(N[C@@H]1[C@H](O)Cc2c1cccc2)[C@@H](C[C@H](O)CN1[C@H](C(=O)NC(C)(C)C)CN(Cc2cnccc2)CC1)Cc1ccccc1	O=C(N[C@@H]1[C@H](O)Cc2c1cccc2)[C@@H](C[C@H](O)CN1[C@H](C(=O)NC(C)(C)C)CN(Cc2cnccc2)CC1)Cc1ccccc1&S(=O)(=O)(O)O.O=C(N[C@@H]1[C@H](O)Cc2c1cccc2)[C@@H](C[C@H](O)CN1[C@H](C(=O)NC(C)(C)C)CN(Cc2cnccc2)CC1)Cc1ccccc1
NCGC00384474-01	O=C(N[C@@H]1[C@H](OCC)OC(=O)C1)[C@H]1N2C(=O)[C@@H](NC(=O)c3nccc4c3cccc4)CCC(=O)N2CCC1		Inactive	Caspase-1 Inhibitor		1	Pralnacasan	384569111.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@H]1[C@H](OCC)OC(=O)C1)[C@H]1N2C(=O)[C@@H](NC(=O)c3nccc4c3cccc4)CCC(=O)N2CCC1	O=C(N[C@@H]1[C@H](OCC)OC(=O)C1)[C@H]1N2C(=O)[C@@H](NC(=O)c3nccc4c3cccc4)CCC(=O)N2CCC1
NCGC00017074-02	O=C(N[C@@]1(C(C)C)C(=O)N2[C@@H](C(C)C)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1		Inactive	Adrenergic receptor alpha Blocker		1	Hydergine	144206902.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)C.O=C(N[C@@]1(C(C)C)C(=O)N2[C@@H](C(C)C)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1	S(=O)(=O)(O)C.O=C(N[C@@]1(C(C)C)C(=O)N2[C@@H](C(C)C)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1
NCGC00183332-01	O=C(N[C@@]1(C(C)C)C(=O)N2[C@@H](CC(C)C)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1		Inactive	D(1A) dopamine receptor Partial Agonist		1	Dihydroergocriptine	144206629.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.508248236	O=C(N[C@@]1(C(C)C)C(=O)N2[C@@H](CC(C)C)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1	O=C(N[C@@]1(C(C)C)C(=O)N2[C@@H](CC(C)C)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@H]1CN(C)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1
NCGC00356592-02	O=C(N[C@@]1(C)C(=O)N2[C@@H](Cc3ccccc3)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23		Inactive			1	Ergotamine tartrate	405559037.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@@]1(C)C(=O)N2[C@@H](Cc3ccccc3)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23	O=C(N[C@@]1(C)C(=O)N2[C@@H](Cc3ccccc3)C(=O)N3[C@H]([C@]2(O)O1)CCC3)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23
NCGC00507840-01	O=C(N[C@H](C(=O)N)CCCCN)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CCCCN)Cc1c2c([nH]c1)cccc2)Cc1c2c([nH]c1)cccc2)CCCCN)CCCCN)Cc1c2c([nH]c1)cccc2)C(c1ccccc1)c1ccccc1		Inactive	Microenvironment modifier		1	LTX-315	384569322.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@H](C(=O)N)CCCCN)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CCCCN)Cc1c2c([nH]c1)cccc2)Cc1c2c([nH]c1)cccc2)CCCCN)CCCCN)Cc1c2c([nH]c1)cccc2)C(c1ccccc1)c1ccccc1	O=C(N[C@H](C(=O)N)CCCCN)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CCCCN)Cc1c2c([nH]c1)cccc2)Cc1c2c([nH]c1)cccc2)CCCCN)CCCCN)Cc1c2c([nH]c1)cccc2)C(c1ccccc1)c1ccccc1
NCGC00485847-01	O=C(N[C@H](C(=O)N)Cc1ccccc1)[C@@H](NC(=O)C12CC3CC(C1)CC(C2)C3)CCCNC(=N)N		Inactive	Neuropeptide FF receptor 2 Antagonist		1	RF9 trifluoroacetate salt	363681380.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@H](C(=O)N)Cc1ccccc1)[C@@H](NC(=O)C12CC3CC(C1)CC(C2)C3)CCCNC(=N)N	O=C(N[C@H](C(=O)N)Cc1ccccc1)[C@@H](NC(=O)C12CC3CC(C1)CC(C2)C3)CCCNC(=N)N
NCGC00485629-01	O=C(N[C@H](C(=O)N)Cc1ccccc1)[C@@H](NC(=O)CNC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](N)C)Cc2ccc(O)cc2)CCC1)CCCCN		Inactive	Proteinase activated receptor 4 Agonist		1	Ala-Tyr-Pro-Gly-Lys-Phe-NH<SUB>2</SUB> trifluoroacetate salt	363681370.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@H](C(=O)N)Cc1ccccc1)[C@@H](NC(=O)CNC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](N)C)Cc2ccc(O)cc2)CCC1)CCCCN	O=C(N[C@H](C(=O)N)Cc1ccccc1)[C@@H](NC(=O)CNC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](N)C)Cc2ccc(O)cc2)CCC1)CCCCN
NCGC00482904-01	O=C(N[C@H](C(=O)N1C[C@]2(Cc3ccccc3)C(=O)N(C)N=C2CC1)COCc1ccccc1)C(N)(C)C		Inactive	Ghrelin receptor Agonist		1	Capromorelin	405558917.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@H](C(=O)N1C[C@]2(Cc3ccccc3)C(=O)N(C)N=C2CC1)COCc1ccccc1)C(N)(C)C	O=C(N[C@H](C(=O)N1C[C@]2(Cc3ccccc3)C(=O)N(C)N=C2CC1)COCc1ccccc1)C(N)(C)C
NCGC00390575-03	O=C(N[C@H](C(=O)N1[C@H](C(=O)Nc2c(-c3ccccc3)nc(-c3occn3)s2)CCC1)C1CCCCC1)[C@@H](NC)C		Inactive	IAP Inhibitor		1	CUDC-427	384569195.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@H](C(=O)N1[C@H](C(=O)Nc2c(-c3ccccc3)nc(-c3occn3)s2)CCC1)C1CCCCC1)[C@@H](NC)C	O=C(N[C@H](C(=O)N1[C@H](C(=O)Nc2c(-c3ccccc3)nc(-c3occn3)s2)CCC1)C1CCCCC1)[C@@H](NC)C
NCGC00386277-03	O=C(N[C@H](C(=O)N1[C@H](C(=O)Nc2c(-c3ccccc3)nns2)CCC1)C1CCCCC1)[C@@H](NC)C		Inactive	IAP Inhibitor		1	GDC-0152	384569120.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@H](C(=O)N1[C@H](C(=O)Nc2c(-c3ccccc3)nns2)CCC1)C1CCCCC1)[C@@H](NC)C	O=C(N[C@H](C(=O)N1[C@H](C(=O)Nc2c(-c3ccccc3)nns2)CCC1)C1CCCCC1)[C@@H](NC)C
NCGC00385349-01	O=C(N[C@H](C(=O)NC(C(=O)N[C@H](C(=O)NC(C(=O)N1[C@H](C(=O)N[C@H](C(=O)NC(C(=O)N2[C@H](C(=O)NC(C(=O)C3N[C@H](C(=O)N[C@H](C(=O)NCC(=O)O)Cc4ccccc4)CC3)(CC)C)CC(O)C2)(C)C)CCC(=O)N)CCC1)(C)C)CC(C)C)(C)C)C(O)C)[C@@H](NC(=O)C(NC(=O)[C@@H](NC(=O)C(NC(=O)[C@@H](NC(=O)C)Cc1c2c([nH]c1)cccc2)(CC)C)CCC(=O)N)(C)C)[C@@H](CC)C		Inactive	<MOA Unknown> | Class: peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385349-01	363679693.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@H](C(=O)NC(C(=O)N[C@H](C(=O)NC(C(=O)N1[C@H](C(=O)N[C@H](C(=O)NC(C(=O)N2[C@H](C(=O)NC(C(=O)C3N[C@H](C(=O)N[C@H](C(=O)NCC(=O)O)Cc4ccccc4)CC3)(CC)C)CC(O)C2)(C)C)CCC(=O)N)CCC1)(C)C)CC(C)C)(C)C)C(O)C)[C@@H](NC(=O)C(NC(=O)[C@@H](NC(=O)C(NC(=O)[C@@H](NC(=O)C)Cc1c2c([nH]c1)cccc2)(CC)C)CCC(=O)N)(C)C)[C@@H](CC)C	O=C(N[C@H](C(=O)NC(C(=O)N[C@H](C(=O)NC(C(=O)N1[C@H](C(=O)N[C@H](C(=O)NC(C(=O)N2[C@H](C(=O)NC(C(=O)C3N[C@H](C(=O)N[C@H](C(=O)NCC(=O)O)Cc4ccccc4)CC3)(CC)C)CC(O)C2)(C)C)CCC(=O)N)CCC1)(C)C)CC(C)C)(C)C)C(O)C)[C@@H](NC(=O)C(NC(=O)[C@@H](NC(=O)C(NC(=O)[C@@H](NC(=O)C)Cc1c2c([nH]c1)cccc2)(CC)C)CCC(=O)N)(C)C)[C@@H](CC)C
NCGC00347242-02	O=C(N[C@H](C(=O)NC(C)(C)C)Cc1ccc(OCc2ccccc2)cc1)[C@@H](N(Cc1ccc(C(C)(C)C)cc1)C)CC(C)C		Inactive	Voltage-gated N-type calcium channel alpha-1B subunit Blocker		1	PD 173212	363677571.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@H](C(=O)NC(C)(C)C)Cc1ccc(OCc2ccccc2)cc1)[C@@H](N(Cc1ccc(C(C)(C)C)cc1)C)CC(C)C	O=C(N[C@H](C(=O)NC(C)(C)C)Cc1ccc(OCc2ccccc2)cc1)[C@@H](N(Cc1ccc(C(C)(C)C)cc1)C)CC(C)C
NCGC00485671-01	O=C(N[C@H](C(=O)NCCN)C)[C@@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)C(C)(C)C		Inactive	ADAM17 Inhibitor		1	TAPI-2 acetate salt	363681376.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@H](C(=O)NCCN)C)[C@@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)C(C)(C)C	O=C(N[C@H](C(=O)NCCN)C)[C@@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)C(C)(C)C
NCGC00485944-01	O=C(N[C@H](C(=O)NCCN)C)[C@@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)Cc1cc2c(cc1)cccc2		Inactive	ADAM17 Inhibitor		1	TAPI-1	363681435.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@H](C(=O)NCCN)C)[C@@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)Cc1cc2c(cc1)cccc2	O=C(N[C@H](C(=O)NCCN)C)[C@@H](NC(=O)[C@@H](CC(=O)NO)CC(C)C)Cc1cc2c(cc1)cccc2
NCGC00167301-02	O=C(N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1[C@H](C(=O)NCC(=O)N)CCC1)CCCNC(=N)N)CC(C)C)Cc1c2c([nH]c1)cccc2)Cc1ccc(O)cc1)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)Cc1[nH]cnc1)Cc1c2c([nH]c1)cccc2)CO		Inactive	Gonadotropin-releasing hormone receptor Agonist		1	Triptorelin	405558815.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1[C@H](C(=O)NCC(=O)N)CCC1)CCCNC(=N)N)CC(C)C)Cc1c2c([nH]c1)cccc2)Cc1ccc(O)cc1)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)Cc1[nH]cnc1)Cc1c2c([nH]c1)cccc2)CO	O=C(N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1[C@H](C(=O)NCC(=O)N)CCC1)CCCNC(=N)N)CC(C)C)Cc1c2c([nH]c1)cccc2)Cc1ccc(O)cc1)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)Cc1[nH]cnc1)Cc1c2c([nH]c1)cccc2)CO
NCGC00485985-01	O=C(N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1[C@H](C(=O)NCC)CCC1)CCCNC(=N)N)CC(C)C)C)Cc1ccc(O)cc1)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)Cc1[nH]cnc1)Cc1c2c([nH]c1)cccc2)CO		Inactive	Progonadoliberin-1 Agonist		1	Alarelin (Acetate)	363681464.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1[C@H](C(=O)NCC)CCC1)CCCNC(=N)N)CC(C)C)C)Cc1ccc(O)cc1)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)Cc1[nH]cnc1)Cc1c2c([nH]c1)cccc2)CO	O=C(N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1[C@H](C(=O)NCC)CCC1)CCCNC(=N)N)CC(C)C)C)Cc1ccc(O)cc1)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)Cc1[nH]cnc1)Cc1c2c([nH]c1)cccc2)CO
NCGC00346556-03&NCGC00346556-07	O=C(N[C@H](C(=O)N[C@@H]1C(=O)N(C)CCc2c1cccc2)C)[C@@H](O)C(C)C		Inactive	g-Secretase Inhibitor		2	Semagacestat	384568839.0&434147218.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N[C@H](C(=O)N[C@@H]1C(=O)N(C)CCc2c1cccc2)C)[C@@H](O)C(C)C	O=C(N[C@H](C(=O)N[C@@H]1C(=O)N(C)CCc2c1cccc2)C)[C@@H](O)C(C)C
NCGC00263280-01	O=C(N[C@H](C(=O)N[C@@]1(C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc2c3c([nH]c2)cccc3)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(=O)N)CCC(=O)N)(C)CCC/C=C\CCCCCC1)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCNC(=O)C)CCC(=O)N)CO)CCC(=O)N)CCC(=O)N)[C@@H](O)C		Inactive	HDM2/HDMX Inhibitor		1	Ac-SAH-p53-8	137276088.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@H](C(=O)N[C@@]1(C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc2c3c([nH]c2)cccc3)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(=O)N)CCC(=O)N)(C)CCC/C=C\CCCCCC1)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCNC(=O)C)CCC(=O)N)CO)CCC(=O)N)CCC(=O)N)[C@@H](O)C	O=C(N[C@H](C(=O)N[C@@]1(C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc2c3c([nH]c2)cccc3)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(=O)N)CCC(=O)N)(C)CCC/C=C\CCCCCC1)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCNC(=O)C)CCC(=O)N)CO)CCC(=O)N)CCC(=O)N)[C@@H](O)C
NCGC00249613-08&NCGC00249613-10&NCGC00249613-11	O=C(N[C@H](C(=O)N[C@H](C(=O)[C@]1(C)OC1)CC(C)C)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)CN1CCOCC1)CCc1ccccc1)CC(C)C		Inactive	Proteasome Inhibitor		3	Carfilzomib	434147069.0&384568530.0&405558759.0	Anti-infectives&Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		O=C(N[C@H](C(=O)N[C@H](C(=O)[C@]1(C)OC1)CC(C)C)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)CN1CCOCC1)CCc1ccccc1)CC(C)C	O=C(N[C@H](C(=O)N[C@H](C(=O)[C@]1(C)OC1)CC(C)C)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)CN1CCOCC1)CCc1ccccc1)CC(C)C
NCGC00161662-08	O=C(N[C@H](C(=O)N[C@H](C=O)CCCC)CC(C)C)[C@@H](NC(=O)C)CC(C)C	5.9499998	Active		0.0	1	Calpain Inhibitor I, ALLN	406861843.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	1.3	97.9947689664	O=C(N[C@H](C(=O)N[C@H](C=O)CCCC)CC(C)C)[C@@H](NC(=O)C)CC(C)C	O=C(N[C@H](C(=O)N[C@H](C=O)CCCC)CC(C)C)[C@@H](NC(=O)C)CC(C)C
NCGC00163460-03	O=C(N[C@H](C(=O)N[C@H](C=O)CCCNC(=N)N)CC(C)C)[C@@H](NC(=O)C)CC(C)C		Inactive			1	Leupeptin, Microbial	434147016.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	32.5134554879	O=C(N[C@H](C(=O)N[C@H](C=O)CCCNC(=N)N)CC(C)C)[C@@H](NC(=O)C)CC(C)C	O=C(N[C@H](C(=O)N[C@H](C=O)CCCNC(=N)N)CC(C)C)[C@@H](NC(=O)C)CC(C)C
NCGC00161670-08	O=C(N[C@H](C(=O)N[C@H]([C@@H](O)CC(=O)N[C@H](C(=O)N[C@H]([C@@H](O)CC(=O)O)CC(C)C)C)CC(C)C)C(C)C)[C@@H](NC(=O)CC(C)C)C(C)C		Inactive	Aspartyl Protease Inhibitor		1	Pepstatin	384568214.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N[C@H](C(=O)N[C@H]([C@@H](O)CC(=O)N[C@H](C(=O)N[C@H]([C@@H](O)CC(=O)O)CC(C)C)C)CC(C)C)C(C)C)[C@@H](NC(=O)CC(C)C)C(C)C	O=C(N[C@H](C(=O)N[C@H]([C@@H](O)CC(=O)N[C@H](C(=O)N[C@H]([C@@H](O)CC(=O)O)CC(C)C)C)CC(C)C)C(C)C)[C@@H](NC(=O)CC(C)C)C(C)C
NCGC00346517-07&NCGC00346517-10	O=C(N[C@H](C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)c2c(N)cccc2)NC(=O)[C@H]([C@H](CC(=O)O)C)NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)CC(=O)O)[C@H](NC(=O)[C@@H](NC(=O)CCCCCCCCC)Cc1c2c([nH]c1)cccc2)CC(=O)N		Inactive	Lipopeptide Antibiotic		2	Daptomycin	405558903.0&384568815.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(N[C@H](C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)c2c(N)cccc2)NC(=O)[C@H]([C@H](CC(=O)O)C)NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)CC(=O)O)[C@H](NC(=O)[C@@H](NC(=O)CCCCCCCCC)Cc1c2c([nH]c1)cccc2)CC(=O)N	O=C(N[C@H](C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)c2c(N)cccc2)NC(=O)[C@H]([C@H](CC(=O)O)C)NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)CC(=O)O)[C@H](NC(=O)[C@@H](NC(=O)CCCCCCCCC)Cc1c2c([nH]c1)cccc2)CC(=O)N
NCGC00485360-01	O=C(N[C@H](C(=O)Nc1cc2OC(=O)C=C(C)c2cc1)CC(=O)O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)CC(=O)O)CCC(=O)O)C(C)C		Inactive	Caspase-8 Substrate		1	N-Acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin	363681298.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@H](C(=O)Nc1cc2OC(=O)C=C(C)c2cc1)CC(=O)O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)CC(=O)O)CCC(=O)O)C(C)C	O=C(N[C@H](C(=O)Nc1cc2OC(=O)C=C(C)c2cc1)CC(=O)O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)CC(=O)O)CCC(=O)O)C(C)C
NCGC00378964-01	O=C(N[C@H](C(=O)[C@]1(C)OC1)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)CN1CCOCC1)C)Cc1ccc(OC)cc1		Inactive			1	ONX-0914		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@H](C(=O)[C@]1(C)OC1)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)CN1CCOCC1)C)Cc1ccc(OC)cc1	O=C(N[C@H](C(=O)[C@]1(C)OC1)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)CN1CCOCC1)C)Cc1ccc(OC)cc1
NCGC00345799-06	O=C(N[C@H](C(=O)[C@]1(C)OC1)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)c1sc(C)nc1)COC)COC		Inactive	Proteasome Inhibitor		1	Oprozomib	384568748.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O=C(N[C@H](C(=O)[C@]1(C)OC1)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)c1sc(C)nc1)COC)COC	O=C(N[C@H](C(=O)[C@]1(C)OC1)Cc1ccccc1)[C@@H](NC(=O)[C@@H](NC(=O)c1sc(C)nc1)COC)COC
NCGC00389341-01	O=C(N[C@H](C(=O)[C@]1(CO)OC1)CC(C)C)[C@@H](NC(=O)CCCCC(C)C)CO		Inactive	26S proteosome Inhibitor		1	Dihydroeponemycin	363680773.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@H](C(=O)[C@]1(CO)OC1)CC(C)C)[C@@H](NC(=O)CCCCC(C)C)CO	O=C(N[C@H](C(=O)[C@]1(CO)OC1)CC(C)C)[C@@H](NC(=O)CCCCC(C)C)CO
NCGC00188640-01	O=C(N[C@H](C)c1c2c(ccc1)cccc2)c1c(C)ccc(N)c1		Inactive			1	GRL0617	124899261.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@H](C)c1c2c(ccc1)cccc2)c1c(C)ccc(N)c1	O=C(N[C@H](C)c1c2c(ccc1)cccc2)c1c(C)ccc(N)c1
NCGC00345452-02	O=C(N[C@H](C=O)CC(=O)O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)CC(=O)O)CCC(=O)O)C(C)C		Inactive			1	Ac-DEVD-CHO	434147083.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@H](C=O)CC(=O)O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)CC(=O)O)CCC(=O)O)C(C)C	O=C(N[C@H](C=O)CC(=O)O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)CC(=O)O)CCC(=O)O)C(C)C
NCGC00378760-01	O=C(N[C@H](CCC)c1cc2OCOc2cc1)N1[C@@H](Oc2ccc(C(=O)N3CCN(C)CC3)cc2)C(CC)(CC)C1=O	4.9000001	Active	Leukocyte elastase Inhibitor	0.0	1	DMP 777	363678183.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	3.0	120.1992984342	O=C(N[C@H](CCC)c1cc2OCOc2cc1)N1[C@@H](Oc2ccc(C(=O)N3CCN(C)CC3)cc2)C(CC)(CC)C1=O	O=C(N[C@H](CCC)c1cc2OCOc2cc1)N1[C@@H](Oc2ccc(C(=O)N3CCN(C)CC3)cc2)C(CC)(CC)C1=O
NCGC00345784-11	O=C(N[C@H](CN(C)C)c1ccccc1)N1C(C)(C)c2[nH]nc(Nc3nc(C)nc4c3scc4)c2C1		Inactive	p21-Activated Kinase 4 (PAK4) Inhibitor		1	PF-3758309	384568740.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@H](CN(C)C)c1ccccc1)N1C(C)(C)c2[nH]nc(Nc3nc(C)nc4c3scc4)c2C1	O=C(N[C@H](CN(C)C)c1ccccc1)N1C(C)(C)c2[nH]nc(Nc3nc(C)nc4c3scc4)c2C1
NCGC00017253-03	O=C(N[C@H](CO)C)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23		Inactive	Serotonin (5-HT) receptor Partial Agonist		1	Ergobasine	124882896.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@H](CO)C)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23	O=C(N[C@H](CO)C)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23
NCGC00017258-08	O=C(N[C@H](CO)CC)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23		Inactive	Serotonin 2b (5-HT2b) receptor Partial Agonist		1	Methergine	170465383.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(N[C@H](CO)CC)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23	O=C(N[C@H](CO)CC)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c([nH]c1)cccc23
NCGC00024027-09	O=C(N[C@H](CO)CC)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c(n(C)c1)cccc23		Inactive	Serotonin 7 (5-HT7) receptor Antagonist		1	Methysergide	170464684.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&8.479371316	O=C(N[C@H](CO)CC)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c(n(C)c1)cccc23	O=C(N[C@H](CO)CC)[C@@H]1C=C2[C@H](N(C)C1)Cc1c3c(n(C)c1)cccc23
NCGC00164576-04	O=C(N[C@H](C[C@H](O)[C@@H](NC(=O)COc1c(C)cccc1C)Cc1ccccc1)Cc1ccccc1)[C@H](C(C)C)N1C(=O)NCCC1	4.9000001	Active	HIV Protease Inhibitors	0.0	1	Lopinavir	170464773.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	66.5594527409	O=C(N[C@H](C[C@H](O)[C@@H](NC(=O)COc1c(C)cccc1C)Cc1ccccc1)Cc1ccccc1)[C@H](C(C)C)N1C(=O)NCCC1	O=C(N[C@H](C[C@H](O)[C@@H](NC(=O)COc1c(C)cccc1C)Cc1ccccc1)Cc1ccccc1)[C@H](C(C)C)N1C(=O)NCCC1
NCGC00378583-01	O=C(N[C@H]([C@@H](O)[C@@H](O)C1CC1)CC1CCCCC1)[C@H](NC(=O)c1[nH]c2c(n1)cccc2)Cc1ncsc1		Inactive	P2X purinoceptor 1 Antagonist		1	Ro 0437626	363678100.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@H]([C@@H](O)[C@@H](O)C1CC1)CC1CCCCC1)[C@H](NC(=O)c1[nH]c2c(n1)cccc2)Cc1ncsc1	O=C(N[C@H]([C@@H](O)[C@@H](O)C1CC1)CC1CCCCC1)[C@H](NC(=O)c1[nH]c2c(n1)cccc2)Cc1ncsc1
NCGC00091469-04&NCGC00091469-15	O=C(N[C@H]([C@H](O)CN1[C@H](C(=O)NC(C)(C)C)C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1)[C@@H](NC(=O)c1nc2c(cc1)cccc2)CC(=O)N		Inactive	protease inhibitor		2	Saquinavir&Saquinavir Mesylate	225144210.0&434146988.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&27.4674157321	O=C(N[C@H]([C@H](O)CN1[C@H](C(=O)NC(C)(C)C)C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1)[C@@H](NC(=O)c1nc2c(cc1)cccc2)CC(=O)N	O=C(N[C@H]([C@H](O)CN1[C@H](C(=O)NC(C)(C)C)C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1)[C@@H](NC(=O)c1nc2c(cc1)cccc2)CC(=O)N
NCGC00371056-01	O=C(N[C@H]1C(=O)N(C)c2c(C(c3ccccc3)=N1)cccc2)Nc1cc(C)ccc1		Inactive	Cholecystokinin B receptor Antagonist		1	L-365,260	363678010.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@H]1C(=O)N(C)c2c(C(c3ccccc3)=N1)cccc2)Nc1cc(C)ccc1	O=C(N[C@H]1C(=O)N(C)c2c(C(c3ccccc3)=N1)cccc2)Nc1cc(C)ccc1
NCGC00485486-02	O=C(N[C@H]1C(=O)N(CC(=O)C(C)(C)C)c2c(N(C3CCCCC3)C1)cccc2)Nc1cc(C(=O)O)ccc1		Inactive	CCK2 (CCKB/Gastrin) Receptor Antagonist		1	Nastorazepide	384569277.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@H]1C(=O)N(CC(=O)C(C)(C)C)c2c(N(C3CCCCC3)C1)cccc2)Nc1cc(C(=O)O)ccc1	O=C(N[C@H]1C(=O)N(CC(=O)C(C)(C)C)c2c(N(C3CCCCC3)C1)cccc2)Nc1cc(C(=O)O)ccc1
NCGC00378600-02	O=C(N[C@H]1C[C@@H](N(C)CC1)c1[nH]c2c(n1)cccc2)Nc1ccc(C#N)cc1		Inactive	Hedgehog Antagonist		1	Glasdegib	363678116.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@H]1C[C@@H](N(C)CC1)c1[nH]c2c(n1)cccc2)Nc1ccc(C#N)cc1	O=C(N[C@H]1C[C@@H](N(C)CC1)c1[nH]c2c(n1)cccc2)Nc1ccc(C#N)cc1
NCGC00402230-01	O=C(N[C@H]1C[C@@H](c2ccccc2)c2c(cccc2)C1)CC		Inactive	Melatonin receptor 1B Antagonist		1	4P-PDOT	363680988.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@H]1C[C@@H](c2ccccc2)c2c(cccc2)C1)CC	O=C(N[C@H]1C[C@@H](c2ccccc2)c2c(cccc2)C1)CC
NCGC00271789-02	O=C(N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]2N(C(=O)[C@@H](C(C)C)NC1=O)CCC2)c1c2N=C3C(C(=O)N[C@H]4[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]5N(C(=O)[C@@H](C(C)C)NC4=O)CCC5)=C(N)C(=O)C(C)=C3Oc2c(C)cc1		Inactive	DNA-Directed RNA Polymerase Inhibitor		1	Actinomycin D	170464668.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0		O=C(N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]2N(C(=O)[C@@H](C(C)C)NC1=O)CCC2)c1c2N=C3C(C(=O)N[C@H]4[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]5N(C(=O)[C@@H](C(C)C)NC4=O)CCC5)=C(N)C(=O)C(C)=C3Oc2c(C)cc1	O=C(N[C@H]1[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]2N(C(=O)[C@@H](C(C)C)NC1=O)CCC2)c1c2N=C3C(C(=O)N[C@H]4[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]5N(C(=O)[C@@H](C(C)C)NC4=O)CCC5)=C(N)C(=O)C(C)=C3Oc2c(C)cc1
NCGC00179500-07&NCGC00179500-14	O=C(N[C@H]1[C@@H](O)[C@H](n2c3ncnc(N(C)C)c3nc2)O[C@@H]1CO)[C@@H](N)Cc1ccc(OC)cc1		Inactive	translation Inhibitor		2	Puromycin 2HCl&Puromycin dihydrochloride	363676946.0&440681604.0	2020_NPACT-1_CPE&2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(N[C@H]1[C@@H](O)[C@H](n2c3ncnc(N(C)C)c3nc2)O[C@@H]1CO)[C@@H](N)Cc1ccc(OC)cc1	O=C(N[C@H]1[C@@H](O)[C@H](n2c3ncnc(N(C)C)c3nc2)O[C@@H]1CO)[C@@H](N)Cc1ccc(OC)cc1
NCGC00475765-01	O=C(N[C@H]1[C@H](C)N(C(=O)C)c2c(N(Cc3c(C)ccc4c3cccc4)C1=O)ccc(C#N)c2)[C@@H](NC)C		Inactive	IAP Inhibitor		1	Compound 36	384569238.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@H]1[C@H](C)N(C(=O)C)c2c(N(Cc3c(C)ccc4c3cccc4)C1=O)ccc(C#N)c2)[C@@H](NC)C	O=C(N[C@H]1[C@H](C)N(C(=O)C)c2c(N(Cc3c(C)ccc4c3cccc4)C1=O)ccc(C#N)c2)[C@@H](NC)C
NCGC00095191-12&NCGC00095191-14&NCGC00095191-16	O=C(N[C@H]1[C@H](OC(CC)CC)C=C(C(=O)OCC)C[C@@H]1N)C		Inactive	Neuraminidase (sialidase) Inhibitors		3	Oseltamivir Phosphate&Oseltamivir (phosphate)&Oseltamivir phosphate	405558461.0&434146999.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(N[C@H]1[C@H](OC(CC)CC)C=C(C(=O)OCC)C[C@@H]1N)C	O=C(N[C@H]1[C@H](OC(CC)CC)C=C(C(=O)OCC)C[C@@H]1N)C
NCGC00093350-05	O=C(N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C1)[C@@H](O)CCN		Inactive	30S ribosomal protein S12 Inhibitor		1	Amikacin	174006656.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C1)[C@@H](O)CCN	O=C(N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](N)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C1)[C@@H](O)CCN
NCGC00390238-01	O=C(N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@@H](O)[C@H](OC2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C1)[C@@H](O)CN		Inactive	30S Ribosomal Protein Inhibitors		1	Isepamicin	405558465.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@@H](O)[C@H](OC2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C1)[C@@H](O)CN	O=C(N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@@H](O)[C@H](OC2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C1)[C@@H](O)CN
NCGC00164587-01	O=C(N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C1)C(O)CN		Inactive	30S Ribosomal Protein Inhibitors		1	Isepamicin sulfate	144205766.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)O.O=C(N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C1)C(O)CN	S(=O)(=O)(O)O.O=C(N[C@H]1[C@H](O[C@@H]2[C@H](O)[C@@H](NC)[C@](O)(C)CO2)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@@H](N)C1)C(O)CN
NCGC00164561-02&NCGC00164561-11	O=C(N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1NC(=N)N)C		Inactive	Neuraminidase (Sialidase) Inhibitors		2	Zanamivir	170464662.0&434147025.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1NC(=N)N)C	O=C(N[C@H]1[C@H]([C@H](O)[C@H](O)CO)OC(C(=O)O)=C[C@@H]1NC(=N)N)C
NCGC00386568-01	O=C(N[C@H]1c2c(cc(C(C)(C)C)cc2)CC1)Nc1c2c([nH]nc2)ccc1		Inactive	Vanilloid receptor Antagonist		1	ABT 102	363680331.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(N[C@H]1c2c(cc(C(C)(C)C)cc2)CC1)Nc1c2c([nH]nc2)ccc1	O=C(N[C@H]1c2c(cc(C(C)(C)C)cc2)CC1)Nc1c2c([nH]nc2)ccc1
NCGC00386335-01	O=C(Nc1[nH]c2c(n1)ccc(C(=O)c1ccccc1)c2)c1nc(C2CCN(c3ncnc4c3scc4)CC2)sc1		Inactive	Nuclear factor NF-kappa-B complex Inhibitor		1	SC75741	363680219.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1[nH]c2c(n1)ccc(C(=O)c1ccccc1)c2)c1nc(C2CCN(c3ncnc4c3scc4)CC2)sc1	O=C(Nc1[nH]c2c(n1)ccc(C(=O)c1ccccc1)c2)c1nc(C2CCN(c3ncnc4c3scc4)CC2)sc1
NCGC00346493-03	O=C(Nc1c(-c2[nH]c3c(n2)cc(CN2CCOCC2)cc3)n[nH]c1)NC1CC1		Inactive	Aurora-A/B Inhibitor		1	AT-9283	384568800.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(Nc1c(-c2[nH]c3c(n2)cc(CN2CCOCC2)cc3)n[nH]c1)NC1CC1	O=C(Nc1c(-c2[nH]c3c(n2)cc(CN2CCOCC2)cc3)n[nH]c1)NC1CC1
NCGC00387156-01	O=C(Nc1c(-c2c(-c3cc(C)ccc3)nc(CC)s2)cccn1)c1ccccc1		Inactive	Wnt signaling pathway Inhibitor		1	TAK 715	363680552.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	18.099999996	O=C(Nc1c(-c2c(-c3cc(C)ccc3)nc(CC)s2)cccn1)c1ccccc1	O=C(Nc1c(-c2c(-c3cc(C)ccc3)nc(CC)s2)cccn1)c1ccccc1
NCGC00186090-01	O=C(Nc1c(-c2ccc(N3CCN(C)CC3)cc2)c2c(s1)CNCC2)C		Inactive			1	NCGC00186090-01	104224141.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c(-c2ccc(N3CCN(C)CC3)cc2)c2c(s1)CNCC2)C	O=C(Nc1c(-c2ccc(N3CCN(C)CC3)cc2)c2c(s1)CNCC2)C
NCGC00351778-01	O=C(Nc1c(-c2nc3SC=C(CN4CCNCC4)n3c2)cccc1)c1nc2c(cc1)cccc2		Inactive			1	SRT1720	363677785.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c(-c2nc3SC=C(CN4CCNCC4)n3c2)cccc1)c1nc2c(cc1)cccc2	O=C(Nc1c(-c2nc3SC=C(CN4CCNCC4)n3c2)cccc1)c1nc2c(cc1)cccc2
NCGC00182052-15	O=C(Nc1c(-c2nc3SC=C(CN4CCNCC4)n3c2)cccc1)c1nc2c(nc1)cccc2		Inactive	Histone Deacetylase/SIRT1 Activator		1	SRT-1720	384568407.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(-c2nc3SC=C(CN4CCNCC4)n3c2)cccc1)c1nc2c(nc1)cccc2	O=C(Nc1c(-c2nc3SC=C(CN4CCNCC4)n3c2)cccc1)c1nc2c(nc1)cccc2
NCGC00379071-02	O=C(Nc1c(-c2nc3SC=C(CN4CCOCC4)n3c2)cccc1)c1c(C)nc(-c2cnccc2)s1		Inactive	SIRT1 Activator		1	SRT-2104	384569093.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(-c2nc3SC=C(CN4CCOCC4)n3c2)cccc1)c1c(C)nc(-c2cnccc2)s1	O=C(Nc1c(-c2nc3SC=C(CN4CCOCC4)n3c2)cccc1)c1c(C)nc(-c2cnccc2)s1
NCGC00508871-01	O=C(Nc1c(-c2nn(-c3ccc(CCN4Cc5c(cc(OC)c(OC)c5)CC4)cc3)nn2)cc(OC)c(OC)c1)C=1Oc2c(C(=O)C=1)cccc2		Inactive	P-Glycoprotein (MDR-1) Inhibitor		1	HM-30181	384569368.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(-c2nn(-c3ccc(CCN4Cc5c(cc(OC)c(OC)c5)CC4)cc3)nn2)cc(OC)c(OC)c1)C=1Oc2c(C(=O)C=1)cccc2	O=C(Nc1c(-c2nn(-c3ccc(CCN4Cc5c(cc(OC)c(OC)c5)CC4)cc3)nn2)cc(OC)c(OC)c1)C=1Oc2c(C(=O)C=1)cccc2
NCGC00185090-08	O=C(Nc1c(-c2sc3c(n2)cccc3)c2c(s1)CNC2)C		Inactive	APE1 inhibitor		1	NCGC00185090-04	363677102.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c(-c2sc3c(n2)cccc3)c2c(s1)CNC2)C	O=C(Nc1c(-c2sc3c(n2)cccc3)c2c(s1)CNC2)C
NCGC00483118-01	O=C(Nc1c(-c2sc3ncc(CN4CCCC4)cc3n2)cccc1)c1c(CCCOC)sc(-c2ccccc2)n1		Inactive	SIRT1 Activator		1	SRT-3025	363681137.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.192718664	O=C(Nc1c(-c2sc3ncc(CN4CCCC4)cc3n2)cccc1)c1c(CCCOC)sc(-c2ccccc2)n1	O=C(Nc1c(-c2sc3ncc(CN4CCCC4)cc3n2)cccc1)c1c(CCCOC)sc(-c2ccccc2)n1
NCGC00340210-02	O=C(Nc1c(C#N)c2c(s1)CC(C(CC)(C)C)CC2)C(CC)CC		Inactive	Glucagon receptor Antagonist		1	Glucagon receptor antagonist I	363677317.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	31.0	O=C(Nc1c(C#N)c2c(s1)CC(C(CC)(C)C)CC2)C(CC)CC	O=C(Nc1c(C#N)c2c(s1)CC(C(CC)(C)C)CC2)C(CC)CC
NCGC00242227-11	O=C(Nc1c(C#N)c2c(s1)CCCC2)c1c2c(ccc1)cccc2		Inactive	JNK 2/3 Inhibitor		1	TCS-JNK-5a	377020378.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(C#N)c2c(s1)CCCC2)c1c2c(ccc1)cccc2	O=C(Nc1c(C#N)c2c(s1)CCCC2)c1c2c(ccc1)cccc2
NCGC00167787-03	O=C(Nc1c(C(=O)N)c2c(s1)CCCC2)c1cc(OC)c(OC)cc1		Inactive			1	TCS 359		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c(C(=O)N)c2c(s1)CCCC2)c1cc(OC)c(OC)cc1	O=C(Nc1c(C(=O)N)c2c(s1)CCCC2)c1cc(OC)c(OC)cc1
NCGC00481403-01	O=C(Nc1c(C(=O)N)cc(-c2c(O[C@@H]3CNCC3)cc(-c3c(C)onc3C)cc2)s1)N		Inactive	IKK beta Inhibitor		1	AZD-3264	377020458.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(C(=O)N)cc(-c2c(O[C@@H]3CNCC3)cc(-c3c(C)onc3C)cc2)s1)N	O=C(Nc1c(C(=O)N)cc(-c2c(O[C@@H]3CNCC3)cc(-c3c(C)onc3C)cc2)s1)N
NCGC00380775-01	O=C(Nc1c(C(=O)N)cccc1)C(NC(=O)CC(=O)O)C		Inactive	<MOA Unknown> | Class: peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380775-01	363678777.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c(C(=O)N)cccc1)C(NC(=O)CC(=O)O)C	O=C(Nc1c(C(=O)N)cccc1)C(NC(=O)CC(=O)O)C
NCGC00476193-01	O=C(Nc1c(C(=O)N)nn(C2CCOCC2)c1)c1nc(-c2cc(C)ncc2)oc1		Inactive			1	AS 2444697	377020427.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c(C(=O)N)nn(C2CCOCC2)c1)c1nc(-c2cc(C)ncc2)oc1	O=C(Nc1c(C(=O)N)nn(C2CCOCC2)c1)c1nc(-c2cc(C)ncc2)oc1
NCGC00274038-02	O=C(Nc1c(C(=O)N)sc(-c2ccc(CN3CCOCC3)cc2)c1)N		Inactive	TGF-bR1 (ALK5) Inhibitor		1	AZ-TAK1 Inhibitor	384568708.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(C(=O)N)sc(-c2ccc(CN3CCOCC3)cc2)c1)N	O=C(Nc1c(C(=O)N)sc(-c2ccc(CN3CCOCC3)cc2)c1)N
NCGC00263196-01	O=C(Nc1c(C(=O)O)cc(C(C)(C)C)s1)Nc1cc2c([nH]nc2)cc1		Inactive	p70 ribosomal S6 kinase (S6K1) Inhibitor		1	S6K-18	137276040.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(C(=O)O)cc(C(C)(C)C)s1)Nc1cc2c([nH]nc2)cc1	O=C(Nc1c(C(=O)O)cc(C(C)(C)C)s1)Nc1cc2c([nH]nc2)cc1
NCGC00242492-04	O=C(Nc1c(C(=O)O)cccc1)/C=C(\C)/c1cc2c(cc1)cccc2		Inactive	Telomerase Inhibitor		1	BIBR-1532	384568498.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(C(=O)O)cccc1)/C=C(\C)/c1cc2c(cc1)cccc2	O=C(Nc1c(C(=O)O)cccc1)/C=C(\C)/c1cc2c(cc1)cccc2
NCGC00018185-20&NCGC00018185-23	O=C(Nc1c(C(=O)O)cccc1)/C=C/c1cc(OC)c(OC)cc1		Inactive	TNF-alpha Production Inhibitor		2	Tranilast	363676503.0&405558891.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Nc1c(C(=O)O)cccc1)/C=C/c1cc(OC)c(OC)cc1	O=C(Nc1c(C(=O)O)cccc1)/C=C/c1cc(OC)c(OC)cc1
NCGC00249930-01	O=C(Nc1c(C(=O)OC)cccc1C)CN(CC)CC		Inactive			1	Tolycaine	170465945.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(C(=O)OC)cccc1C)CN(CC)CC	O=C(Nc1c(C(=O)OC)cccc1C)CN(CC)CC
NCGC00179248-03	O=C(Nc1c(C(=O)OC)scc1C)C(NCCC)C		Inactive	Sodium channel alpha subunit Blocker		1	Articaine hydrochloride	170464825.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(Nc1c(C(=O)OC)scc1C)C(NCCC)C.Cl	O=C(Nc1c(C(=O)OC)scc1C)C(NCCC)C.Cl
NCGC00346602-01	O=C(Nc1c(C(=O)O[C@]23[C@@H]4[C@]5([C@@H](OC)CC2)[C@H](N(CC)C3)[C@@H]([C@]2(O)[C@@]3(O)[C@@H](OC)[C@@H]([C@@H](OC)C2)C[C@@H]53)C4)cccc1)C		Inactive	Antiinflammatory alkaloid		1	Lappaconitine	174006325.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(C(=O)O[C@]23[C@@H]4[C@]5([C@@H](OC)CC2)[C@H](N(CC)C3)[C@@H]([C@]2(O)[C@@]3(O)[C@@H](OC)[C@@H]([C@@H](OC)C2)C[C@@H]53)C4)cccc1)C	O=C(Nc1c(C(=O)O[C@]23[C@@H]4[C@]5([C@@H](OC)CC2)[C@H](N(CC)C3)[C@@H]([C@]2(O)[C@@]3(O)[C@@H](OC)[C@@H]([C@@H](OC)C2)C[C@@H]53)C4)cccc1)C
NCGC00242480-02&NCGC00242480-03	O=C(Nc1c(C(C)(C)C)cc(C(C)(C)C)c(O)c1)C=1C(=O)c2c(NC=1)cccc2		Inactive	CFTR Channel Activator		2	Ivacaftor	384568492.0&405559089.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	24.673056364&0.0	O=C(Nc1c(C(C)(C)C)cc(C(C)(C)C)c(O)c1)C=1C(=O)c2c(NC=1)cccc2	O=C(Nc1c(C(C)(C)C)cc(C(C)(C)C)c(O)c1)C=1C(=O)c2c(NC=1)cccc2
NCGC00345857-05	O=C(Nc1c(C)c(C=2N=C(Nc3ccc(C(=O)N4CCOCC4)cc3)C(=O)N(C)C=2)ccc1)c1ccc(C(C)(C)C)cc1		Inactive	BTK Inhibitor		1	CGI-1746	384568771.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(C)c(C=2N=C(Nc3ccc(C(=O)N4CCOCC4)cc3)C(=O)N(C)C=2)ccc1)c1ccc(C(C)(C)C)cc1	O=C(Nc1c(C)c(C=2N=C(Nc3ccc(C(=O)N4CCOCC4)cc3)C(=O)N(C)C=2)ccc1)c1ccc(C(C)(C)C)cc1
NCGC00390563-02	O=C(Nc1c(C)c(C=2N=C(Nc3ccc(C4N(C)CCN(C)C4=O)cc3)C(=O)N(C)C=2)ccc1)c1sc2c(c1)CCCC2		Inactive	BTK Inhibitor		1	GDC-0834 racemate	384569193.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(C)c(C=2N=C(Nc3ccc(C4N(C)CCN(C)C4=O)cc3)C(=O)N(C)C=2)ccc1)c1sc2c(c1)CCCC2	O=C(Nc1c(C)c(C=2N=C(Nc3ccc(C4N(C)CCN(C)C4=O)cc3)C(=O)N(C)C=2)ccc1)c1sc2c(c1)CCCC2
NCGC00370914-01	O=C(Nc1c(C)c2c(n(C(C)C)c3c2cccc3)cc1)N1CCOCC1		Inactive	Neuropeptide Y receptor type 5 Antagonist		1	NPY 5RA972	363677930.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c(C)c2c(n(C(C)C)c3c2cccc3)cc1)N1CCOCC1	O=C(Nc1c(C)c2c(n(C(C)C)c3c2cccc3)cc1)N1CCOCC1
NCGC00102010-01	O=C(Nc1c(C)cc(-c2oc3c(n2)nccc3)cc1)COc1ccc(C(C)(C)C)cc1		Inactive			1	NCGC00102010-01	24275708.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c(C)cc(-c2oc3c(n2)nccc3)cc1)COc1ccc(C(C)(C)C)cc1	O=C(Nc1c(C)cc(-c2oc3c(n2)nccc3)cc1)COc1ccc(C(C)(C)C)cc1
NCGC00379212-01	O=C(Nc1c(C)ccc(-c2[nH]ccn2)c1)c1ccc(OCc2ncccc2)cc1		Inactive	Smoothened homolog Antagonist		1	AZ 12080282 dihydrochloride	363678421.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c(C)ccc(-c2[nH]ccn2)c1)c1ccc(OCc2ncccc2)cc1	O=C(Nc1c(C)ccc(-c2[nH]ccn2)c1)c1ccc(OCc2ncccc2)cc1
NCGC00386301-06	O=C(Nc1c(C)ccc(CNC)c1)c1ccc(Nc2nc(-c3ccccc3)c3c(n2)cccc3)cc1		Inactive	Smo Inhibitor		1	BMS-833923	363680195.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(C)ccc(CNC)c1)c1ccc(Nc2nc(-c3ccccc3)c3c(n2)cccc3)cc1	O=C(Nc1c(C)ccc(CNC)c1)c1ccc(Nc2nc(-c3ccccc3)c3c(n2)cccc3)cc1
NCGC00510701-01	O=C(Nc1c(C)ccc(NC(=O)c2cc3OCCOc3cc2)c1)c1cc2c(nc(OCCN3CCCC3)cc2)cc1		Inactive	Heat Shock Factor Protein 1 (HSF1) Inhibitor		1	CCT251236	384569486.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.860203652	O=C(Nc1c(C)ccc(NC(=O)c2cc3OCCOc3cc2)c1)c1cc2c(nc(OCCN3CCCC3)cc2)cc1	O=C(Nc1c(C)ccc(NC(=O)c2cc3OCCOc3cc2)c1)c1cc2c(nc(OCCN3CCCC3)cc2)cc1
NCGC00485933-01	O=C(Nc1c(C)ccc(OC2=Nn3c(nc(NC(=O)C4CC4)c3)C=C2)c1)c1n(C)nc(C)c1		Inactive	PDGFR Inhibitor		1	TAK-593	363681426.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(C)ccc(OC2=Nn3c(nc(NC(=O)C4CC4)c3)C=C2)c1)c1n(C)nc(C)c1	O=C(Nc1c(C)ccc(OC2=Nn3c(nc(NC(=O)C4CC4)c3)C=C2)c1)c1n(C)nc(C)c1
NCGC00015860-06	O=C(Nc1c(C)cccc1)C(NCCC)C		Inactive	reactive oxygen species biosynthetic process Inhibitor		1	Prilocaine hydrochloride	170464697.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(Nc1c(C)cccc1)C(NCCC)C.Cl	O=C(Nc1c(C)cccc1)C(NCCC)C.Cl
NCGC00370940-01	O=C(Nc1c(C)cccc1)Nc1ccc(CC(=O)N2[C@H](C(=O)N3CCC(CC(=O)O)CC3)COCC2)cc1		Inactive	Integrin alpha-4/beta-1 Antagonist		1	TCS 2314	363677946.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c(C)cccc1)Nc1ccc(CC(=O)N2[C@H](C(=O)N3CCC(CC(=O)O)CC3)COCC2)cc1	O=C(Nc1c(C)cccc1)Nc1ccc(CC(=O)N2[C@H](C(=O)N3CCC(CC(=O)O)CC3)COCC2)cc1
NCGC00386592-01	O=C(Nc1c(C)cccc1)Nc1ccc(CN2C(=O)N([C@H](C(=O)N[C@@H](CC(=O)O)c3ccccc3)CC(C)C)C(=O)C2(C)C)cc1		Inactive	Integrin alpha-4/beta-1 Antagonist		1	HMR 1031	363680347.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c(C)cccc1)Nc1ccc(CN2C(=O)N([C@H](C(=O)N[C@@H](CC(=O)O)c3ccccc3)CC(C)C)C(=O)C2(C)C)cc1	O=C(Nc1c(C)cccc1)Nc1ccc(CN2C(=O)N([C@H](C(=O)N[C@@H](CC(=O)O)c3ccccc3)CC(C)C)C(=O)C2(C)C)cc1
NCGC00183654-01	O=C(Nc1c(C)cccc1C)C(N(CCC)CC)CC		Inactive	Sodium channel protein type II alpha subunit Blocker		1	Etidocaine	144206521.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(C)cccc1C)C(N(CCC)CC)CC	O=C(Nc1c(C)cccc1C)C(N(CCC)CC)CC
NCGC00162129-06	O=C(Nc1c(C)cccc1C)C(N)C		Inactive	Sodium channel alpha subunit Inhibitor		1	Tocainide hydrochloride	170465114.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(C)cccc1C)C(N)C.Cl	O=C(Nc1c(C)cccc1C)C(N)C.Cl
NCGC00018284-06	O=C(Nc1c(C)cccc1C)C1N(C)CCCC1		Inactive	Sodium channel protein type X alpha subunit Inhibitor		1	MEPIVACAINE HYDROCHLORIDE	405559140.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Nc1c(C)cccc1C)C1N(C)CCCC1	O=C(Nc1c(C)cccc1C)C1N(C)CCCC1
NCGC00167454-02	O=C(Nc1c(C)cccc1C)CC12N(CCC1)CCC2		Inactive	Sodium channel alpha subunit Blocker		1	Pilsicainide	170465988.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(C)cccc1C)CC12N(CCC1)CCC2	O=C(Nc1c(C)cccc1C)CC12N(CCC1)CCC2
NCGC00015611-18	O=C(Nc1c(C)cccc1C)CN(CC)CC		Inactive	Sodium channel protein type IX alpha subunit Blocker		1	Lidocaine	170464729.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Nc1c(C)cccc1C)CN(CC)CC	O=C(Nc1c(C)cccc1C)CN(CC)CC
NCGC00186006-10	O=C(Nc1c(C)cccc1C)CN1C(=O)CCC1		Inactive	GABAergic Transmission Enhancer		1	Nefiracetam	384568434.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-12.376902972	O=C(Nc1c(C)cccc1C)CN1C(=O)CCC1	O=C(Nc1c(C)cccc1C)CN1C(=O)CCC1
NCGC00015897-08&NCGC00015897-20	O=C(Nc1c(C)cccc1C)CN1CCN(CC(O)COc2c(OC)cccc2)CC1		Inactive	Sodium channel Inhibitor		2	Ranolazine	170465435.0&384567904.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	O=C(Nc1c(C)cccc1C)CN1CCN(CC(O)COc2c(OC)cccc2)CC1	O=C(Nc1c(C)cccc1C)CN1CCN(CC(O)COc2c(OC)cccc2)CC1
NCGC00017043-03&NCGC00091886-04	O=C(Nc1c(C)cccc1C)C[N+](CC)(CC)Cc1ccccc1		Inactive	Taste receptor type 2 member 8 Agonist&Glycolysis / Gluconeogenesis Inhibitor		2	Denatonium benzoate	405558882.0&170464678.0	Approved Drugs Collection (NPC)&Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&0.0	O=C(Nc1c(C)cccc1C)C[N+](CC)(CC)Cc1ccccc1	O=C(Nc1c(C)cccc1C)C[N+](CC)(CC)Cc1ccccc1&O=C(Nc1c(C)cccc1C)C[N+](CC)(CC)Cc1ccccc1.O=C([O-])c1ccccc1
NCGC00164597-02	O=C(Nc1c(C)cccc1C)[C@H]1N(CCC)CCCC1		Inactive	Voltage-gated potassium channel subunit Kv1.5 Inhibitor		1	Ropivacaine hydrochloride	170465120.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(C)cccc1C)[C@H]1N(CCC)CCCC1.Cl	O=C(Nc1c(C)cccc1C)[C@H]1N(CCC)CCCC1.Cl
NCGC00178579-04	O=C(Nc1c(C)cccc1C)[C@H]1N(CCCC)CCCC1		Inactive	Sodium channel protein type IV alpha subunit Blocker		1	Levobupivacaine hydrochloride	170465452.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(C)cccc1C)[C@H]1N(CCCC)CCCC1.Cl	O=C(Nc1c(C)cccc1C)[C@H]1N(CCCC)CCCC1.Cl
NCGC00346526-03	O=C(Nc1c(CC)cccc1CC)N1Cc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2C1		Inactive	Aurora-A/B/c Inhibitor		1	PHA-680632	384568820.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Nc1c(CC)cccc1CC)N1Cc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2C1	O=C(Nc1c(CC)cccc1CC)N1Cc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2C1
NCGC00185765-02	O=C(Nc1c(CCC2N(C)CCCC2)cccc1)c1ccc(OC)cc1		Inactive	Sodium channel protein type V alpha subunit Inhibitor		1	Encainide hydrochloride	405558508.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(CCC2N(C)CCCC2)cccc1)c1ccc(OC)cc1	O=C(Nc1c(CCC2N(C)CCCC2)cccc1)c1ccc(OC)cc1
NCGC00387805-01	O=C(Nc1c(N(CCN(C)C)C)cc(OC)c(Nc2nc(-c3c4c([nH]c3)cccc4)ccn2)c1)C=C		Inactive	Epidermal growth factor receptor Inhibitor		1	AZ5104	363680673.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	13.6226245959	O=C(Nc1c(N(CCN(C)C)C)cc(OC)c(Nc2nc(-c3c4c([nH]c3)cccc4)ccn2)c1)C=C	O=C(Nc1c(N(CCN(C)C)C)cc(OC)c(Nc2nc(-c3c4c([nH]c3)cccc4)ccn2)c1)C=C
NCGC00378622-03&NCGC00378622-10	O=C(Nc1c(N(CCN(C)C)C)cc(OC)c(Nc2nc(-c3c4c(n(C)c3)cccc4)ccn2)c1)C=C		Inactive	EGFR (Thr790Met Mutant) Inhibitor		2	Osimertinib mesylate	405558589.0&363678127.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&33.4379985439	O=C(Nc1c(N(CCN(C)C)C)cc(OC)c(Nc2nc(-c3c4c(n(C)c3)cccc4)ccn2)c1)C=C	O=C(Nc1c(N(CCN(C)C)C)cc(OC)c(Nc2nc(-c3c4c(n(C)c3)cccc4)ccn2)c1)C=C
NCGC00263618-04	O=C(Nc1c(N)cccc1)CCCCCCC(=O)Nc1ccccc1		Inactive			1	CAY10433		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c(N)cccc1)CCCCCCC(=O)Nc1ccccc1	O=C(Nc1c(N)cccc1)CCCCCCC(=O)Nc1ccccc1
NCGC00381565-04	O=C(Nc1c(N)cccc1)CCCCCNC(=O)c1ccc(C)cc1		Inactive	Histone deacetylase 3 Inhibitor		1	RG2833	434147119.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(N)cccc1)CCCCCNC(=O)c1ccc(C)cc1	O=C(Nc1c(N)cccc1)CCCCCNC(=O)c1ccc(C)cc1
NCGC00263182-04	O=C(Nc1c(N)cccc1)c1ccc(CNc2nc(-c3cnccc3)ccn2)cc1		Inactive	HDAC Inhibitor		1	Mocetinostat	384568650.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Nc1c(N)cccc1)c1ccc(CNc2nc(-c3cnccc3)ccn2)cc1	O=C(Nc1c(N)cccc1)c1ccc(CNc2nc(-c3cnccc3)ccn2)cc1
NCGC00402247-01	O=C(Nc1c(N)cccc1)c1nccnc1		Inactive			1	BG45	434147148.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(N)cccc1)c1nccnc1	O=C(Nc1c(N)cccc1)c1nccnc1
NCGC00348107-03	O=C(Nc1c(N2CCC(C)CC2)cc(N2CCN(C)CC2)cc1)c1[nH]cc(C#N)c1		Inactive	CSF1R (c-FMS) Inhibitor		1	c-FMS Inhibitor	363677735.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(N2CCC(C)CC2)cc(N2CCN(C)CC2)cc1)c1[nH]cc(C#N)c1	O=C(Nc1c(N2CCC(C)CC2)cc(N2CCN(C)CC2)cc1)c1[nH]cc(C#N)c1
NCGC00476204-01	O=C(Nc1c(N2CCCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1	5.0	Active	BRPF1 bromodomain Inhibitor	0.0	1	PFI-4	363681102.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	39.276150628	O=C(Nc1c(N2CCCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1	O=C(Nc1c(N2CCCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1
NCGC00386929-02	O=C(Nc1c(N2CCCC2)cccc1)[C@@H](CC)c1ccccc1		Inactive			1	ML252	363680513.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c(N2CCCC2)cccc1)[C@@H](CC)c1ccccc1	O=C(Nc1c(N2CCCC2)cccc1)[C@@H](CC)c1ccccc1
NCGC00107508-04	O=C(Nc1c(N2CCCCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1		Inactive	BRPF1 bromodomain Inhibitor		1	GSK-5959	384568161.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(N2CCCCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1	O=C(Nc1c(N2CCCCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1
NCGC00509915-01	O=C(Nc1c(N2[C@H](C)CNCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1		Inactive	BRPF1 bromodomain Inhibitor		1	GSK-6853	384569381.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	24.9581993559	O=C(Nc1c(N2[C@H](C)CNCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1	O=C(Nc1c(N2[C@H](C)CNCC2)cc2N(C)C(=O)N(C)c2c1)c1c(OC)cccc1
NCGC00183095-07	O=C(Nc1c(O)c2C(=O)C3=C(O)[C@@]4(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]4C[C@@H]3Cc2c(N(C)C)c1)CNC(C)(C)C		Inactive	glycylcycline antibiotics		1	Tigecycline	384568415.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Nc1c(O)c2C(=O)C3=C(O)[C@@]4(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]4C[C@@H]3Cc2c(N(C)C)c1)CNC(C)(C)C	O=C(Nc1c(O)c2C(=O)C3=C(O)[C@@]4(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]4C[C@@H]3Cc2c(N(C)C)c1)CNC(C)(C)C
NCGC00183095-01	O=C(Nc1c(O)c2C(=O)C3=C(O)[C@]4(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]4C[C@@H]3Cc2c(N(C)C)c1)CNC(C)(C)C		Inactive	glycylcycline antibiotics		1	Tigecycline	124894296.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(O)c2C(=O)C3=C(O)[C@]4(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]4C[C@@H]3Cc2c(N(C)C)c1)CNC(C)(C)C	O=C(Nc1c(O)c2C(=O)C3=C(O)[C@]4(O)C(=O)C(C(=O)N)=C(O)[C@@H](N(C)C)[C@@H]4C[C@@H]3Cc2c(N(C)C)c1)CNC(C)(C)C
NCGC00379050-01	O=C(Nc1c(OC)cc(N2CCOCC2)cc1)c1nc(-c2cnccc2)sc1		Inactive	Interleukin-1 receptor-associated kinase 4 Inhibitor		1	IRAK inhibitor 6	363678328.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c(OC)cc(N2CCOCC2)cc1)c1nc(-c2cnccc2)sc1	O=C(Nc1c(OC)cc(N2CCOCC2)cc1)c1nc(-c2cnccc2)sc1
NCGC00378704-01	O=C(Nc1c(OC)cc(OC)cc1OC)c1oc(Cc2c(C)cc3C(C)(C)CCC(C)(C)c3c2)cc1	4.9499998	Active	Gonadotropin-releasing hormone receptor Antagonist	0.0	1	AG 045572	363678158.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	3.0	37.6006304849	O=C(Nc1c(OC)cc(OC)cc1OC)c1oc(Cc2c(C)cc3C(C)(C)CCC(C)(C)c3c2)cc1	O=C(Nc1c(OC)cc(OC)cc1OC)c1oc(Cc2c(C)cc3C(C)(C)CCC(C)(C)c3c2)cc1
NCGC00346937-01	O=C(Nc1c(OC)ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)c1)[C@H](N)CO		Inactive	Tubulin polymerization Inhibitor		1	Ombrabulin	174007341.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(OC)ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)c1)[C@H](N)CO	O=C(Nc1c(OC)ccc(/C=C\c2cc(OC)c(OC)c(OC)c2)c1)[C@H](N)CO
NCGC00485052-01	O=C(Nc1c(OC)cccc1)Nc1cc2c(cc1)cccc2		Inactive	Scavenger receptor class B member 1 Modulator		1	BLT-4	363681208.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	27.0776263919	O=C(Nc1c(OC)cccc1)Nc1cc2c(cc1)cccc2	O=C(Nc1c(OC)cccc1)Nc1cc2c(cc1)cccc2
NCGC00345833-01	O=C(Nc1c(OCCN(C)C)cc(-c2c[nH]nc2)cc1)C1Oc2c(OC1)cccc2		Inactive	ROCK II Inhibitor		1	SR-3677	174006422.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c(OCCN(C)C)cc(-c2c[nH]nc2)cc1)C1Oc2c(OC1)cccc2	O=C(Nc1c(OCCN(C)C)cc(-c2c[nH]nc2)cc1)C1Oc2c(OC1)cccc2
NCGC00370771-01	O=C(Nc1c2c(C(=O)NC2)ccc1)CN1CCN(C(=O)[C@H]2[C@H](O)[C@H](O)[C@@H](n3c4ncnc(N)c4nc3)O2)CC1		Inactive	Poly [ADP-ribose] polymerase-1 Inhibitor		1	EB 47	363677844.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	12.5	O=C(Nc1c2c(C(=O)NC2)ccc1)CN1CCN(C(=O)[C@H]2[C@H](O)[C@H](O)[C@@H](n3c4ncnc(N)c4nc3)O2)CC1	O=C(Nc1c2c(C(=O)NC2)ccc1)CN1CCN(C(=O)[C@H]2[C@H](O)[C@H](O)[C@@H](n3c4ncnc(N)c4nc3)O2)CC1
NCGC00378715-01	O=C(Nc1c2c(C)c(C)oc2nc2c1CCCC2)CN1C(=O)CCC1		Inactive	High affinity choline transporter 1 Binding Agent		1	Coluracetam	363678167.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c2c(C)c(C)oc2nc2c1CCCC2)CN1C(=O)CCC1	O=C(Nc1c2c(C)c(C)oc2nc2c1CCCC2)CN1C(=O)CCC1
NCGC00378633-01	O=C(Nc1c2c([nH]c1)ncc(-c1ccc(C#N)cc1)c2)c1cnccc1		Inactive	Serine/threonine-protein kinase Chk1  Inhibitor		1	LKB1(AAK1 dual inhibitor)	363678133.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c2c([nH]c1)ncc(-c1ccc(C#N)cc1)c2)c1cnccc1	O=C(Nc1c2c([nH]c1)ncc(-c1ccc(C#N)cc1)c2)c1cnccc1
NCGC00346944-02	O=C(Nc1c2c([nH]cc2)ncc1)c1ccc([C@H](N)C)cc1		Inactive	ROCK Inhibitor		1	Y-39983	363677562.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c2c([nH]cc2)ncc1)c1ccc([C@H](N)C)cc1	O=C(Nc1c2c([nH]cc2)ncc1)c1ccc([C@H](N)C)cc1
NCGC00250387-06	O=C(Nc1c2c(c(-c3c4OC(N5CCOCC5)=CC(=O)c4ccc3)cc1)sc1c2cccc1)CN1CCN(CC)CC1		Inactive	DNA-PK Inhibitor		1	KU-0060648	384568540.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1c2c(c(-c3c4OC(N5CCOCC5)=CC(=O)c4ccc3)cc1)sc1c2cccc1)CN1CCN(CC)CC1	O=C(Nc1c2c(c(-c3c4OC(N5CCOCC5)=CC(=O)c4ccc3)cc1)sc1c2cccc1)CN1CCN(CC)CC1
NCGC00347905-02	O=C(Nc1c2c(nc(NCCNCCO)cc2)ccc1)CC12CC3CC(C1)CC(C2)C3		Inactive	P2X7 Receptor Antagonist		1	AZ-10606120	363677717.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.5837563399	O=C(Nc1c2c(nc(NCCNCCO)cc2)ccc1)CC12CC3CC(C1)CC(C2)C3	O=C(Nc1c2c(nc(NCCNCCO)cc2)ccc1)CC12CC3CC(C1)CC(C2)C3
NCGC00484999-01	O=C(Nc1c2ncccc2ccc1)c1ccc(N2C(=O)[C@H]3[C@@H](C2=O)C2C=CC3C2)cc1		Inactive	Tankyrase-2 Inhibitor		1	IWR-1	363681181.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c2ncccc2ccc1)c1ccc(N2C(=O)[C@H]3[C@@H](C2=O)C2C=CC3C2)cc1	O=C(Nc1c2ncccc2ccc1)c1ccc(N2C(=O)[C@H]3[C@@H](C2=O)C2C=CC3C2)cc1
NCGC00386244-01	O=C(Nc1c2ncccc2ccc1)c1ccc(N2C(=O)[C@]3(C)[C@H](C2=O)[C@@H]2C=C[C@H]3C2)cc1		Inactive			1	IWR-1-endo	363680166.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c2ncccc2ccc1)c1ccc(N2C(=O)[C@]3(C)[C@H](C2=O)[C@@H]2C=C[C@H]3C2)cc1	O=C(Nc1c2ncccc2ccc1)c1ccc(N2C(=O)[C@]3(C)[C@H](C2=O)[C@@H]2C=C[C@H]3C2)cc1
NCGC00390547-02	O=C(Nc1c[n+](C)c2c(c1)cccc2)c1nc(C(=O)Nc2c[n+](C)c3c(c2)cccc3)ccc1		Inactive			1	360A (iodide)	377020275.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1c[n+](C)c2c(c1)cccc2)c1nc(C(=O)Nc2c[n+](C)c3c(c2)cccc3)ccc1	O=C(Nc1c[n+](C)c2c(c1)cccc2)c1nc(C(=O)Nc2c[n+](C)c3c(c2)cccc3)ccc1
NCGC00018215-06	O=C(Nc1cc(C(=O)C)c(OCC(O)CNC(C)C)cc1)CCC		Inactive	Beta-1 adrenergic receptor Antagonist		1	Acebutolol hydrochloride	170465309.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1cc(C(=O)C)c(OCC(O)CNC(C)C)cc1)CCC.Cl	O=C(Nc1cc(C(=O)C)c(OCC(O)CNC(C)C)cc1)CCC.Cl
NCGC00188641-04	O=C(Nc1cc(C(=O)N[C@H](C)c2c3c(ccc2)cccc3)c(C)cc1)C		Inactive			1	PLpro inhibitor	434147061.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1cc(C(=O)N[C@H](C)c2c3c(ccc2)cccc3)c(C)cc1)C	O=C(Nc1cc(C(=O)N[C@H](C)c2c3c(ccc2)cccc3)c(C)cc1)C
NCGC00490649-01	O=C(Nc1cc(C(OCCN2CCCCC2)c2sc3c(C(=O)O)ccnc3c2)ccc1)/C=C/CN(C)C		Inactive			1	NCGC00490649-01	434147162.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0	0.0&0.0	O=C(Nc1cc(C(OCCN2CCCCC2)c2sc3c(C(=O)O)ccnc3c2)ccc1)/C=C/CN(C)C	O=C(Nc1cc(C(OCCN2CCCCC2)c2sc3c(C(=O)O)ccnc3c2)ccc1)/C=C/CN(C)C
NCGC00370711-04	O=C(Nc1cc(C)ccc1)CN1CCC(c2ncccc2)CC1		Inactive	Dopamine D4 receptor Agonist		1	A-412997 Dihydrochloride	363677818.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1cc(C)ccc1)CN1CCC(c2ncccc2)CC1	O=C(Nc1cc(C)ccc1)CN1CCC(c2ncccc2)CC1
NCGC00371098-01	O=C(Nc1cc(C)ccc1)NC1C(=O)N(CC(=O)c2c(C)cccc2)c2c(C(c3ccccc3)=N1)cccc2		Inactive	Cholecystokinin B receptor Antagonist		1	YM 022	363678030.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1cc(C)ccc1)NC1C(=O)N(CC(=O)c2c(C)cccc2)c2c(C(c3ccccc3)=N1)cccc2	O=C(Nc1cc(C)ccc1)NC1C(=O)N(CC(=O)c2c(C)cccc2)c2c(C(c3ccccc3)=N1)cccc2
NCGC00174046-02	O=C(Nc1cc(C2=NCCN2)ccc1)Nc1cc(C2=NCCN2)ccc1		Inactive	Adenosine deaminase Inhibitor		1	Imidocarb dipropionate	170466330.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1cc(C2=NCCN2)ccc1)Nc1cc(C2=NCCN2)ccc1.O=C(O)CC.O=C(O)CC	O=C(Nc1cc(C2=NCCN2)ccc1)Nc1cc(C2=NCCN2)ccc1.O=C(O)CC.O=C(O)CC
NCGC00249904-01	O=C(Nc1cc(C2N=C3SCCN3C2)ccc1)C(C)C		Inactive	Nicotinic acetylcholine receptor alpha subunit Agonist		1	Butamisole	170466389.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Nc1cc(C2N=C3SCCN3C2)ccc1)C(C)C	O=C(Nc1cc(C2N=C3SCCN3C2)ccc1)C(C)C
NCGC00274171-10	O=C(Nc1cc(C=2SC=3N(C(=O)C=C(N4CCNCC4)N=3)N=2)cnc1)CN		Inactive	Integrin alphaIIbbeta3 (Fibrinogen gpIIb/IIIa) Antagonist		1	RUC-4	384568713.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1cc(C=2SC=3N(C(=O)C=C(N4CCNCC4)N=3)N=2)cnc1)CN	O=C(Nc1cc(C=2SC=3N(C(=O)C=C(N4CCNCC4)N=3)N=2)cnc1)CN
NCGC00386479-01	O=C(Nc1cc(N2CCN(C)CC2)c(O)cc1)c1ccc(-c2c(C)cc(-c3oc(C)nn3)cc2)cc1	4.9000001	Active	5-hydroxytryptamine receptor 1D Antagonist	0.0	1	GMC 2-113	363680297.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	136.4417714318	O=C(Nc1cc(N2CCN(C)CC2)c(O)cc1)c1ccc(-c2c(C)cc(-c3oc(C)nn3)cc2)cc1	O=C(Nc1cc(N2CCN(C)CC2)c(O)cc1)c1ccc(-c2c(C)cc(-c3oc(C)nn3)cc2)cc1
NCGC00379144-01	O=C(Nc1cc(N2CCN(C)CC2)c(OC)cc1)N1c2c(c3c(cc2)cccc3)CC1		Inactive	Serotonin 2c (5-HT2c) receptor Inverse Agonist		1	S 32212 hydrochloride	363678383.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1cc(N2CCN(C)CC2)c(OC)cc1)N1c2c(c3c(cc2)cccc3)CC1	O=C(Nc1cc(N2CCN(C)CC2)c(OC)cc1)N1c2c(c3c(cc2)cccc3)CC1
NCGC00386477-01	O=C(Nc1cc(N2CCN(C)CC2)c(OC)cc1)c1ccc(-c2c(C)cc(-c3oc(C)nn3)cc2)cc1	4.9000001	Active	5-hydroxytryptamine receptor 1D Antagonist	0.0	1	GMC 2-29	363680295.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	118.9976571397	O=C(Nc1cc(N2CCN(C)CC2)c(OC)cc1)c1ccc(-c2c(C)cc(-c3oc(C)nn3)cc2)cc1	O=C(Nc1cc(N2CCN(C)CC2)c(OC)cc1)c1ccc(-c2c(C)cc(-c3oc(C)nn3)cc2)cc1
NCGC00386945-01	O=C(Nc1cc(N2CCN(C)CC2)c(OC)cc1)c1ccc(-c2c(C)cc(C(=N)N)cc2)cc1		Inactive			1	NCGC00386945-01	363680519.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1cc(N2CCN(C)CC2)c(OC)cc1)c1ccc(-c2c(C)cc(C(=N)N)cc2)cc1	O=C(Nc1cc(N2CCN(C)CC2)c(OC)cc1)c1ccc(-c2c(C)cc(C(=N)N)cc2)cc1
NCGC00386478-01	O=C(Nc1cc(N2CCN(C)CC2)c(OC)cc1)c1ccc(-c2c(C)cc(C(=O)N)cc2)cc1		Inactive	5-hydroxytryptamine receptor 1D Antagonist		1	GMC 3-15	363680296.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1cc(N2CCN(C)CC2)c(OC)cc1)c1ccc(-c2c(C)cc(C(=O)N)cc2)cc1	O=C(Nc1cc(N2CCN(C)CC2)c(OC)cc1)c1ccc(-c2c(C)cc(C(=O)N)cc2)cc1
NCGC00386909-03	O=C(Nc1cc(NC(=O)c2cc(C)ccc2)ccc1)c1c(OC)cccc1		Inactive	Potassium channel subfamily K member 3 Inhibitor		1	ML365	363680497.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	32.099999996	O=C(Nc1cc(NC(=O)c2cc(C)ccc2)ccc1)c1c(OC)cccc1	O=C(Nc1cc(NC(=O)c2cc(C)ccc2)ccc1)c1c(OC)cccc1
NCGC00025109-13	O=C(Nc1cc(NC(=O)c2ccc(O)cc2)c(C)cc1)c1cc(N(C)C)ccc1		Inactive	Raf Kinase Inhibitor		1	ZM-336372	384568051.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1cc(NC(=O)c2ccc(O)cc2)c(C)cc1)c1cc(N(C)C)ccc1	O=C(Nc1cc(NC(=O)c2ccc(O)cc2)c(C)cc1)c1cc(N(C)C)ccc1
NCGC00253869-01	O=C(Nc1cc(Nc2c(C)cnc(Nc3ccccc3)n2)ccc1)C=C		Inactive			1	NCGC00253869-01	377020397.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1cc(Nc2c(C)cnc(Nc3ccccc3)n2)ccc1)C=C	O=C(Nc1cc(Nc2c(C)cnc(Nc3ccccc3)n2)ccc1)C=C
NCGC00250380-10	O=C(Nc1cc(Nc2cc3C(=O)N(C)C=Nc3cc2)c(C)cc1)c1cc(C(C#N)(C)C)ccc1		Inactive	Raf kinase B/C Inhibitor		1	AZ-628	377020384.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	13.7129760279	O=C(Nc1cc(Nc2cc3C(=O)N(C)C=Nc3cc2)c(C)cc1)c1cc(C(C#N)(C)C)ccc1	O=C(Nc1cc(Nc2cc3C(=O)N(C)C=Nc3cc2)c(C)cc1)c1cc(C(C#N)(C)C)ccc1
NCGC00159456-06&NCGC00159456-11&NCGC00159456-30	O=C(Nc1cc(Nc2nc(-c3cnccc3)ccn2)c(C)cc1)c1ccc(CN2CCN(C)CC2)cc1	5.083333333333333	Active	Bcr-Abl Inhibitor	0.25	3	Imatinib	124892208.0&170465393.0&384568179.0	Anti-infectives&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0&3.0	92.0991085737&100.0691578298&117.5107086602	O=C(Nc1cc(Nc2nc(-c3cnccc3)ccn2)c(C)cc1)c1ccc(CN2CCN(C)CC2)cc1	O=C(Nc1cc(Nc2nc(-c3cnccc3)ccn2)c(C)cc1)c1ccc(CN2CCN(C)CC2)cc1&S(=O)(=O)(O)C.O=C(Nc1cc(Nc2nc(-c3cnccc3)ccn2)c(C)cc1)c1ccc(CN2CCN(C)CC2)cc1
NCGC00485941-02	O=C(Nc1cc(Nc2nc(-c3cnccc3)ccn2)c(C)cc1)c1ccc(CN2CCNCC2)cc1		Inactive	LRRK2 Inhibitor		1	CGP-74588 (N-Desmethyl imatinib)	384569278.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1cc(Nc2nc(-c3cnccc3)ccn2)c(C)cc1)c1ccc(CN2CCNCC2)cc1	O=C(Nc1cc(Nc2nc(-c3cnccc3)ccn2)c(C)cc1)c1ccc(CN2CCNCC2)cc1
NCGC00160624-04	O=C(Nc1cc(OCC)c(C(=O)OC)cc1)C		Inactive	folic acid biosynthetic process Modulator		1	Ethopabate	170466827.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(Nc1cc(OCC)c(C(=O)OC)cc1)C	O=C(Nc1cc(OCC)c(C(=O)OC)cc1)C
NCGC00498432-01	O=C(Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3c2scc3)ccc1)C=C		Inactive	Jak3 Inhibitor		1	Olmutinib	384569299.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3c2scc3)ccc1)C=C	O=C(Nc1cc(Oc2nc(Nc3ccc(N4CCN(C)CC4)cc3)nc3c2scc3)ccc1)C=C
NCGC00370866-10	O=C(Nc1cc-2c(NC(=O)c3c-2cccc3)cc1)CN(C)C		Inactive	Poly [ADP-ribose] polymerase-1 Inhibitor		1	PJ34 Hydrochloride	363677895.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	15.5	O=C(Nc1cc-2c(NC(=O)c3c-2cccc3)cc1)CN(C)C	O=C(Nc1cc-2c(NC(=O)c3c-2cccc3)cc1)CN(C)C
NCGC00263205-02	O=C(Nc1cc2NCC(C)(C)c2cc1)c1c(NCc2ccncc2)nccc1		Inactive	VEGFR-1,2,3 Inhibitor		1	Motesanib	384568664.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	13.5	O=C(Nc1cc2NCC(C)(C)c2cc1)c1c(NCc2ccncc2)nccc1	O=C(Nc1cc2NCC(C)(C)c2cc1)c1c(NCc2ccncc2)nccc1
NCGC00181765-03	O=C(Nc1cc2OC(c3[nH]nnn3)=CC(=O)c2cc1)c1ccc(OCCCCc2ccccc2)cc1		Inactive	Leukotriene CysLT1/2 (LTD4) Antagonist		1	Pranlukast hydrate	384568399.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Nc1cc2OC(c3[nH]nnn3)=CC(=O)c2cc1)c1ccc(OCCCCc2ccccc2)cc1	O=C(Nc1cc2OC(c3[nH]nnn3)=CC(=O)c2cc1)c1ccc(OCCCCc2ccccc2)cc1
NCGC00263132-03	O=C(Nc1cc2[nH]c(-c3cn(C)nc3)c3c2c(C(=O)NN=C3)c1)[C@H](N)C1CCCCC1		Inactive	Chk1 Inhibitor		1	PF-477736	384568612.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(Nc1cc2[nH]c(-c3cn(C)nc3)c3c2c(C(=O)NN=C3)c1)[C@H](N)C1CCCCC1	O=C(Nc1cc2[nH]c(-c3cn(C)nc3)c3c2c(C(=O)NN=C3)c1)[C@H](N)C1CCCCC1
NCGC00124306-01	O=C(Nc1cc2c(C)cc(Nc3ccc(OC)cc3)nc2cc1)c1cc(OC)cc(OC)c1		Inactive			1	NCGC00124306-01	24399689.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	13.0	O=C(Nc1cc2c(C)cc(Nc3ccc(OC)cc3)nc2cc1)c1cc(OC)cc(OC)c1	O=C(Nc1cc2c(C)cc(Nc3ccc(OC)cc3)nc2cc1)c1cc(OC)cc(OC)c1
NCGC00161418-13	O=C(Nc1cc2c(N)cc(C)nc2cc1)c1c(COc2ccc(CC)cc2)cccc1		Inactive	ORL1 (OP4, NOP) Antagonist		1	JTC-801	384568208.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(Nc1cc2c(N)cc(C)nc2cc1)c1c(COc2ccc(CC)cc2)cccc1	O=C(Nc1cc2c(N)cc(C)nc2cc1)c1c(COc2ccc(CC)cc2)cccc1
NCGC00229735-09	O=C(Nc1cc2c(Sc3c(C=4OC(N5CCOCC5)=CC(=O)C=4)cccc3C2)cc1)CN1C[C@@H](C)O[C@@H](C)C1		Inactive	ATM Kinase Inhibitor		1	KU-60019	384568464.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.0	O=C(Nc1cc2c(Sc3c(C=4OC(N5CCOCC5)=CC(=O)C=4)cccc3C2)cc1)CN1C[C@@H](C)O[C@@H](C)C1	O=C(Nc1cc2c(Sc3c(C=4OC(N5CCOCC5)=CC(=O)C=4)cccc3C2)cc1)CN1C[C@@H](C)O[C@@H](C)C1
NCGC00485034-01	O=C(Nc1cc2c([nH]nc2)cc1)C1CCC1		Inactive	Rho-associated protein kinase 1  Inhibitor		1	Rhodblock 6	363681199.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1cc2c([nH]nc2)cc1)C1CCC1	O=C(Nc1cc2c([nH]nc2)cc1)C1CCC1
NCGC00507845-01	O=C(Nc1cc2c(cncc2)cc1)[C@H](CN)c1ccc(COC(=O)c2c(C)cc(C)cc2)cc1		Inactive	ROCK Inhibitor		1	Netarsudil	384569326.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Nc1cc2c(cncc2)cc1)[C@H](CN)c1ccc(COC(=O)c2c(C)cc(C)cc2)cc1	O=C(Nc1cc2c(cncc2)cc1)[C@H](CN)c1ccc(COC(=O)c2c(C)cc(C)cc2)cc1
NCGC00390715-04	O=C(Nc1cc2c3c(C(=O)N(CCN(C)C)C(=O)c3ccc2)c1)N		Inactive	Chemokine Receptor Antagonist		1	UNBS-5162	384569208.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1cc2c3c(C(=O)N(CCN(C)C)C(=O)c3ccc2)c1)N	O=C(Nc1cc2c3c(C(=O)N(CCN(C)C)C(=O)c3ccc2)c1)N
NCGC00487231-01	O=C(Nc1cc2nc3c(c(Nc4ccc(N(C)C)cc4)c2cc1)ccc(NC(=O)CCN1CCCC1)c3)CCN1CCCC1		Inactive			1	BRACO19 trihydrochloride	377020453.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1cc2nc3c(c(Nc4ccc(N(C)C)cc4)c2cc1)ccc(NC(=O)CCN1CCCC1)c3)CCN1CCCC1	O=C(Nc1cc2nc3c(c(Nc4ccc(N(C)C)cc4)c2cc1)ccc(NC(=O)CCN1CCCC1)c3)CCN1CCCC1
NCGC00386826-01	O=C(Nc1ccc(-c2c3nc[nH]c3ncc2)cc1)Nc1ccc(-c2ccc(C#N)cc2)cc1		Inactive			1	NCGC00386826-01	363680451.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccc(-c2c3nc[nH]c3ncc2)cc1)Nc1ccc(-c2ccc(C#N)cc2)cc1	O=C(Nc1ccc(-c2c3nc[nH]c3ncc2)cc1)Nc1ccc(-c2ccc(C#N)cc2)cc1
NCGC00346522-06	O=C(Nc1ccc(-c2ccc(C(=O)[C@H]3[C@H](C(=O)O)CCC3)cc2)cc1)Nc1ccccc1		Inactive	Diacylglycerol Acyltransferase Type 1 (DGAT-1) Inhibitor		1	A-922500	384568817.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1ccc(-c2ccc(C(=O)[C@H]3[C@H](C(=O)O)CCC3)cc2)cc1)Nc1ccccc1	O=C(Nc1ccc(-c2ccc(C(=O)[C@H]3[C@H](C(=O)O)CCC3)cc2)cc1)Nc1ccccc1
NCGC00379128-01	O=C(Nc1ccc(-c2cnccc2)cc1)CCCCN1CCOCC1		Inactive	Neuronal acetylcholine receptor subunit alpha-7 Agonist		1	SEN 12333	363678374.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccc(-c2cnccc2)cc1)CCCCN1CCOCC1	O=C(Nc1ccc(-c2cnccc2)cc1)CCCCN1CCOCC1
NCGC00263085-12	O=C(Nc1ccc(-c2cnccc2)cc1)Cc1ccc(-c2cc(C)ncc2)cc1		Inactive	Wnt Signaling Inhibitor		1	Wnt-C59	384568580.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	21.5	O=C(Nc1ccc(-c2cnccc2)cc1)Cc1ccc(-c2cc(C)ncc2)cc1	O=C(Nc1ccc(-c2cnccc2)cc1)Cc1ccc(-c2cc(C)ncc2)cc1
NCGC00387788-02	O=C(Nc1ccc(-c2nc(N3CCOCC3)c3c(n(C4CCN(C(=O)OC)CC4)nc3)n2)cc1)NC1CC1		Inactive	Serine/threonine-protein kinase mTOR Inhibitor		1	mTORInhibitor,WYE-23	363680668.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccc(-c2nc(N3CCOCC3)c3c(n(C4CCN(C(=O)OC)CC4)nc3)n2)cc1)NC1CC1	O=C(Nc1ccc(-c2nc(N3CCOCC3)c3c(n(C4CCN(C(=O)OC)CC4)nc3)n2)cc1)NC1CC1
NCGC00538163-01	O=C(Nc1ccc(-c2nocn2)cc1)CN(C(=O)C1CCS(=O)(=O)CC1)c1c(C)cccc1C		Inactive			1	Amenamevir	434147178.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1ccc(-c2nocn2)cc1)CN(C(=O)C1CCS(=O)(=O)CC1)c1c(C)cccc1C	O=C(Nc1ccc(-c2nocn2)cc1)CN(C(=O)C1CCS(=O)(=O)CC1)c1c(C)cccc1C
NCGC00487389-01	O=C(Nc1ccc(/C(=N/NC(=N)N)/C)cc1)Nc1ccc(/C(=N/NC(=N)N)/C)cc1		Inactive			1	NSC109555	377020182.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccc(/C(=N/NC(=N)N)/C)cc1)Nc1ccc(/C(=N/NC(=N)N)/C)cc1	O=C(Nc1ccc(/C(=N/NC(=N)N)/C)cc1)Nc1ccc(/C(=N/NC(=N)N)/C)cc1
NCGC00386925-01	O=C(Nc1ccc(C(=O)C)cc1)CNC(=O)c1c2c(nc(-c3cc(OC)c(OC)c(OC)c3)c1)ccc(OC)c2		Inactive			1	NCGC00386925-01	363680509.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccc(C(=O)C)cc1)CNC(=O)c1c2c(nc(-c3cc(OC)c(OC)c(OC)c3)c1)ccc(OC)c2	O=C(Nc1ccc(C(=O)C)cc1)CNC(=O)c1c2c(nc(-c3cc(OC)c(OC)c(OC)c3)c1)ccc(OC)c2
NCGC00370777-04&NCGC00370777-10	O=C(Nc1ccc(C(=O)N2CCC(N(C)C)CC2)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1		Inactive	PI3K alpha Inhibitor		2	Gedatolisib	363677849.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Nc1ccc(C(=O)N2CCC(N(C)C)CC2)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1	O=C(Nc1ccc(C(=O)N2CCC(N(C)C)CC2)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1
NCGC00346649-04	O=C(Nc1ccc(C(=O)N2CCN(C)CC2)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3nnn(CC)c3n2)cc1		Inactive	PI3K Inhibitor		1	PKI-402	384568880.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(Nc1ccc(C(=O)N2CCN(C)CC2)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3nnn(CC)c3n2)cc1	O=C(Nc1ccc(C(=O)N2CCN(C)CC2)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3nnn(CC)c3n2)cc1
NCGC00345881-04&NCGC00345881-05	O=C(Nc1ccc(C(=O)N2c3c(-c4[nH]c(C)nc4CC2)cccc3)cc1)c1c(-c2ccccc2)cccc1		Inactive	Vasopressin (AVP) V1a/V2 Antagonist		2	Conivaptan hydrochloride	405559087.0&363677399.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&12.609432572	O=C(Nc1ccc(C(=O)N2c3c(-c4[nH]c(C)nc4CC2)cccc3)cc1)c1c(-c2ccccc2)cccc1	O=C(Nc1ccc(C(=O)N2c3c(-c4[nH]c(C)nc4CC2)cccc3)cc1)c1c(-c2ccccc2)cccc1
NCGC00262931-02	O=C(Nc1ccc(C(=O)N2c3c(C(N(C)C)CCC2)cccc3)cc1)c1c(C)cccc1		Inactive	Vasopressin V2 receptor Antagonist		1	Mozavaptan	363677192.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccc(C(=O)N2c3c(C(N(C)C)CCC2)cccc3)cc1)c1c(C)cccc1	O=C(Nc1ccc(C(=O)N2c3c(C(N(C)C)CCC2)cccc3)cc1)c1c(C)cccc1
NCGC00241114-02	O=C(Nc1ccc(C(=O)NC(C)(C)C)cc1)C		Inactive	p38 MAPK Inhibitor		1	CPI-1189	384568479.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1ccc(C(=O)NC(C)(C)C)cc1)C	O=C(Nc1ccc(C(=O)NC(C)(C)C)cc1)C
NCGC00379145-08	O=C(Nc1ccc(C(=O)NCC2(c3ccc(OC)cc3)CCOCC2)cc1)c1occc1		Inactive			1	JW55	363678384.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccc(C(=O)NCC2(c3ccc(OC)cc3)CCOCC2)cc1)c1occc1	O=C(Nc1ccc(C(=O)NCC2(c3ccc(OC)cc3)CCOCC2)cc1)c1occc1
NCGC00263153-07&NCGC00263153-10	O=C(Nc1ccc(C(=O)NO)cc1)[C@@H](C(C)C)c1ccccc1		Inactive	HDAC Inhibitor		2	AR-42&AR-42(HDAC-42)	384568627.0&434147262.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Nc1ccc(C(=O)NO)cc1)[C@@H](C(C)C)c1ccccc1	O=C(Nc1ccc(C(=O)NO)cc1)[C@@H](C(C)C)c1ccccc1
NCGC00263639-13&NCGC00263639-15	O=C(Nc1ccc(C(=O)Nc2c(N)cccc2)cc1)C		Inactive	HDAC Inhibitor		2	Tacedinaline	384568696.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Nc1ccc(C(=O)Nc2c(N)cccc2)cc1)C	O=C(Nc1ccc(C(=O)Nc2c(N)cccc2)cc1)C
NCGC00090820-03	O=C(Nc1ccc(C(=O)O)cc1)C		Inactive	immune response Modulator		1	4-Acetamidobenzoic acid	170466207.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Nc1ccc(C(=O)O)cc1)C	O=C(Nc1ccc(C(=O)O)cc1)C
NCGC00164607-01	O=C(Nc1ccc(C(=O)O)cc1)[C@@H](NC(=O)c1ccccc1)Cc1ccc(O)cc1		Inactive			1	Bentiromide sodium	144205782.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1ccc(C(=O)[O-])cc1)[C@@H](NC(=O)c1ccccc1)Cc1ccc(O)cc1.[Na+]	O=C(Nc1ccc(C(=O)[O-])cc1)[C@@H](NC(=O)c1ccccc1)Cc1ccc(O)cc1.[Na+]
NCGC00181909-01	O=C(Nc1ccc(C(=O)OCC)cc1)CN1CCCCC1		Inactive			1	Sulcaine	144206885.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(Nc1ccc(C(=O)OCC)cc1)CN1CCCCC1	O=C(Nc1ccc(C(=O)OCC)cc1)CN1CCCCC1
NCGC00370751-02	O=C(Nc1ccc(C(C)C)cc1)C(N(C(=O)Cc1c2c([nH]c1)cccc2)C)c1ccccc1	4.9000001	Active	Cystic fibrosis transmembrane conductance regulator Activator	0.0	1	PG-01	363677835.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	3.0	85.3637489638	O=C(Nc1ccc(C(C)C)cc1)C(N(C(=O)Cc1c2c([nH]c1)cccc2)C)c1ccccc1	O=C(Nc1ccc(C(C)C)cc1)C(N(C(=O)Cc1c2c([nH]c1)cccc2)C)c1ccccc1
NCGC00378740-04	O=C(Nc1ccc(C(C)C)cc1)Cn1c2C(=O)N(C)C(=O)N(C)c2nc1		Inactive	Transient receptor potential cation channel subfamily A member 1 Antagonist		1	HC-030031	363678178.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccc(C(C)C)cc1)Cn1c2C(=O)N(C)C(=O)N(C)c2nc1	O=C(Nc1ccc(C(C)C)cc1)Cn1c2C(=O)N(C)C(=O)N(C)c2nc1
NCGC00285960-02	O=C(Nc1ccc(C(CC)C)cc1)Cn1c2C(=O)N(C)C(=O)N(C)c2nc1		Inactive	Transient receptor potential cation channel subfamily A member 1 Antagonist		1	TCS 5861528	363677315.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccc(C(CC)C)cc1)Cn1c2C(=O)N(C)C(=O)N(C)c2nc1	O=C(Nc1ccc(C(CC)C)cc1)Cn1c2C(=O)N(C)C(=O)N(C)c2nc1
NCGC00386395-01	O=C(Nc1ccc(C)cc1)C(=O)NC1CC(C)(C)NC(C)(C)C1		Inactive	Envelope glycoprotein gp160 Binding Agent		1	YYA-021	363680252.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	-5.969957076	O=C(Nc1ccc(C)cc1)C(=O)NC1CC(C)(C)NC(C)(C)C1	O=C(Nc1ccc(C)cc1)C(=O)NC1CC(C)(C)NC(C)(C)C1
NCGC00379092-01	O=C(Nc1ccc(C)cc1)N1CCN(c2nc(N)nc3sc(-c4cnccc4)nc23)CC1	4.9499998	Active	Phosphatidylinositol 4-kinase beta Inhibitor	0.0	1	PI4KIII beta inhibitor 3	363678348.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	2.4	39.2632486	O=C(Nc1ccc(C)cc1)N1CCN(c2nc(N)nc3sc(-c4cnccc4)nc23)CC1	O=C(Nc1ccc(C)cc1)N1CCN(c2nc(N)nc3sc(-c4cnccc4)nc23)CC1
NCGC00263225-01	O=C(Nc1ccc(C)cc1)N[C@@]1(CC(=O)Nc2ccc(C)cc2)C(=O)N(CC(OCC)OCC)c2c1cccc2	4.9000001	Active	gastrin/CCKB receptor Antagonist	0.0	1	AG-041R	137276069.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	49.81418304	O=C(Nc1ccc(C)cc1)N[C@@]1(CC(=O)Nc2ccc(C)cc2)C(=O)N(CC(OCC)OCC)c2c1cccc2	O=C(Nc1ccc(C)cc1)N[C@@]1(CC(=O)Nc2ccc(C)cc2)C(=O)N(CC(OCC)OCC)c2c1cccc2
NCGC00249393-08	O=C(Nc1ccc(C2(C#N)CCCC2)cc1)c1c(NCc2ccncc2)nccc1		Inactive	VEGFR-2 Inhibitor		1	Apatinib	377020310.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1ccc(C2(C#N)CCCC2)cc1)c1c(NCc2ccncc2)nccc1	O=C(Nc1ccc(C2(C#N)CCCC2)cc1)c1c(NCc2ccncc2)nccc1
NCGC00165782-07	O=C(Nc1ccc(C2=NCCN2)cc1)/C=C/c1ccc(/C=C/C(=O)Nc2ccc(C3=NCCN3)cc2)cc1		Inactive	Neutral Sphingomyelinase (N-SMase) Inhibitor		1	GW-4869	384568282.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1ccc(C2=NCCN2)cc1)/C=C/c1ccc(/C=C/C(=O)Nc2ccc(C3=NCCN3)cc2)cc1	O=C(Nc1ccc(C2=NCCN2)cc1)/C=C/c1ccc(/C=C/C(=O)Nc2ccc(C3=NCCN3)cc2)cc1
NCGC00346448-03	O=C(Nc1ccc(CCN2Cc3c(cc(OC)c(OC)c3)CC2)cc1)c1c(NC(=O)c2cnc3c(c2)cccc3)cc(OC)c(OC)c1		Inactive	P-Glycoprotein (MDR-1) Inhibitor		1	Tariquidar	384568779.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1ccc(CCN2Cc3c(cc(OC)c(OC)c3)CC2)cc1)c1c(NC(=O)c2cnc3c(c2)cccc3)cc(OC)c(OC)c1	O=C(Nc1ccc(CCN2Cc3c(cc(OC)c(OC)c3)CC2)cc1)c1c(NC(=O)c2cnc3c(c2)cccc3)cc(OC)c(OC)c1
NCGC00263219-03	O=C(Nc1ccc(CCN2Cc3c(cc(OC)c(OC)c3)CC2)cc1)c1c2Nc3c(OC)cccc3C(=O)c2ccc1		Inactive	P-Glycoprotein (MDR-1) Inhibitor		1	Elacridar	384568673.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Nc1ccc(CCN2Cc3c(cc(OC)c(OC)c3)CC2)cc1)c1c2Nc3c(OC)cccc3C(=O)c2ccc1	O=C(Nc1ccc(CCN2Cc3c(cc(OC)c(OC)c3)CC2)cc1)c1c2Nc3c(OC)cccc3C(=O)c2ccc1
NCGC00386239-01	O=C(Nc1ccc(CCNC[C@H](O)c2ccccc2)cc1)Cc1nc(N)sc1		Inactive	Beta-3 adrenergic receptor Agonist		1	Mirabegron	405558549.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1ccc(CCNC[C@H](O)c2ccccc2)cc1)Cc1nc(N)sc1	O=C(Nc1ccc(CCNC[C@H](O)c2ccccc2)cc1)Cc1nc(N)sc1
NCGC00386750-04	O=C(Nc1ccc(CCNN)cc1)CCCc1ccccc1		Inactive			1	Bizine Dihydrochloride		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccc(CCNN)cc1)CCCc1ccccc1	O=C(Nc1ccc(CCNN)cc1)CCCc1ccccc1
NCGC00386865-03	O=C(Nc1ccc(CN2CCC(C(=O)OCC)(CCc3ccccc3)CC2)cc1)C		Inactive	Opioid receptors; mu & delta Agonist		1	ML335	363680473.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccc(CN2CCC(C(=O)OCC)(CCc3ccccc3)CC2)cc1)C	O=C(Nc1ccc(CN2CCC(C(=O)OCC)(CCc3ccccc3)CC2)cc1)C
NCGC00487399-01	O=C(Nc1ccc(C[N+](C)(C)C2CCOCC2)cc1)C1=Cc2c(ccc(-c3ccc(C)cc3)c2)CCC1		Inactive			1	TAK-779	434147161.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1ccc(C[N+](C)(C)C2CCOCC2)cc1)C1=Cc2c(ccc(-c3ccc(C)cc3)c2)CCC1	O=C(Nc1ccc(C[N+](C)(C)C2CCOCC2)cc1)C1=Cc2c(ccc(-c3ccc(C)cc3)c2)CCC1
NCGC00387231-01	O=C(Nc1ccc(N2CCC(C(=O)N3CCOCC3)CC2)cc1)c1cnc(Oc2ccccc2)nc1		Inactive	Hematopoietic prostaglandin D synthase Inhibitor		1	TFC 007	363680585.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccc(N2CCC(C(=O)N3CCOCC3)CC2)cc1)c1cnc(Oc2ccccc2)nc1	O=C(Nc1ccc(N2CCC(C(=O)N3CCOCC3)CC2)cc1)c1cnc(Oc2ccccc2)nc1
NCGC00487129-01	O=C(Nc1ccc(Nc2ncnc3c2cc(OC)c(OC)c3)cc1)c1ccccc1		Inactive			1	N-[4-[(6,7-Dimethoxy-4-quinazolinyl)amino]phenyl]benzamide hydrochloride	377020464.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccc(Nc2ncnc3c2cc(OC)c(OC)c3)cc1)c1ccccc1	O=C(Nc1ccc(Nc2ncnc3c2cc(OC)c(OC)c3)cc1)c1ccccc1
NCGC00159574-16	O=C(Nc1ccc(Nc2ncnc3c2cc(OC)c(OCCCN2CCOCC2)c3)cc1)c1ccccc1	4.9499998	Active	Aurora-A/B Inhibitor	0.0	1	ZM-447439	384568190.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	79.3053209575	O=C(Nc1ccc(Nc2ncnc3c2cc(OC)c(OCCCN2CCOCC2)c3)cc1)c1ccccc1	O=C(Nc1ccc(Nc2ncnc3c2cc(OC)c(OCCCN2CCOCC2)c3)cc1)c1ccccc1
NCGC00090752-04	O=C(Nc1ccc(O)cc1)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C		Inactive	RARbeta/gamma Agonist		1	Fenretinide	26752780.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-11.053855208	O=C(Nc1ccc(O)cc1)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C	O=C(Nc1ccc(O)cc1)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C
NCGC00016361-20&NCGC00016361-21	O=C(Nc1ccc(O)cc1)C		Inactive	Cyclooxygenase-3 Inhibitor		2	Acetaminophen	405558740.0&384567935.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Nc1ccc(O)cc1)C	O=C(Nc1ccc(O)cc1)C
NCGC00160580-02	O=C(Nc1ccc(O)cc1)c1c(O)cccc1		Inactive	Ribonucleoside-diphosphate reductase M2 chain Inhibitor		1	2-Hydroxy-N-(4-hydroxyphenyl)-benzamide	405558623.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Nc1ccc(O)cc1)c1c(O)cccc1	O=C(Nc1ccc(O)cc1)c1c(O)cccc1
NCGC00241097-06	O=C(Nc1ccc(OC(C)C)cc1)N1CCN(c2ncnc3c2cc(OC)c(OCCCN2CCCCC2)c3)CC1		Inactive	KIT Inhibitor		1	Tandutinib	384568469.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1ccc(OC(C)C)cc1)N1CCN(c2ncnc3c2cc(OC)c(OCCCN2CCCCC2)c3)CC1	O=C(Nc1ccc(OC(C)C)cc1)N1CCN(c2ncnc3c2cc(OC)c(OCCCN2CCCCC2)c3)CC1
NCGC00485175-01	O=C(Nc1ccc(OC)cc1)C1[C@H](C(C)C)CC[C@@H](C)C1		Inactive	Transient receptor potential cation channel subfamily M member 8 Agonist		1	WS-12	363681248.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccc(OC)cc1)C1[C@H](C(C)C)CC[C@@H](C)C1	O=C(Nc1ccc(OC)cc1)C1[C@H](C(C)C)CC[C@@H](C)C1
NCGC00378820-01	O=C(Nc1ccc(OC)cc1)NC=1n2nc(-c3occc3)nc2-c2c(nn(CCC)c2)N=1		Inactive	Adenosine receptors; A2a & A3 Antagonist		1	MRE 3008F20	363678219.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccc(OC)cc1)NC=1n2nc(-c3occc3)nc2-c2c(nn(CCC)c2)N=1	O=C(Nc1ccc(OC)cc1)NC=1n2nc(-c3occc3)nc2-c2c(nn(CCC)c2)N=1
NCGC00016281-11	O=C(Nc1ccc(OCC)cc1)C		Inactive	Prostaglandin G/H synthase 1 Inhibitor		1	Phenacetin	170465554.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(Nc1ccc(OCC)cc1)C	O=C(Nc1ccc(OCC)cc1)C
NCGC00166139-03	O=C(Nc1ccc(OCC)cc1)CC(O)C		Inactive			1	3-Hydroxy-4-butyrophenetidide	170465885.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1ccc(OCC)cc1)CC(O)C	O=C(Nc1ccc(OCC)cc1)CC(O)C
NCGC00091326-06	O=C(Nc1ccccc1)C		Inactive			1	Acetanilide	170465493.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(Nc1ccccc1)C	O=C(Nc1ccccc1)C
NCGC00370873-01	O=C(Nc1ccccc1)N1CCC(Cc2cnc3c(c2)cccc3)CC1		Inactive	Anandamide amidohydrolase Inhibitor		1	PF 750	363677901.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccccc1)N1CCC(Cc2cnc3c(c2)cccc3)CC1	O=C(Nc1ccccc1)N1CCC(Cc2cnc3c(c2)cccc3)CC1
NCGC00388308-02	O=C(Nc1ccccc1)N1CCN(Cc2nc3c(cc2)cccc3)CC1		Inactive	Anandamide amidohydrolase Inhibitor		1	FAAHInhibitor,PF-622	363680726.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccccc1)N1CCN(Cc2nc3c(cc2)cccc3)CC1	O=C(Nc1ccccc1)N1CCN(Cc2nc3c(cc2)cccc3)CC1
NCGC00378802-04	O=C(Nc1ccccc1)N1CCN(c2snc(-c3ccccc3)n2)CC1		Inactive	Fatty-acid amide hydrolase 2 Inhibitor		1	JNJ-1661010	363678206.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ccccc1)N1CCN(c2snc(-c3ccccc3)n2)CC1	O=C(Nc1ccccc1)N1CCN(c2snc(-c3ccccc3)n2)CC1
NCGC00076924-03	O=C(Nc1ccccc1)c1c(O)cccc1		Inactive			1	Salicylanilide	434146981.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1ccccc1)c1c(O)cccc1	O=C(Nc1ccccc1)c1c(O)cccc1
NCGC00387446-03	O=C(Nc1ccccc1)c1ccc(Nc2nnc(-c3ccc(O)cc3)c3c2cccc3)cc1	5.0	Active	Fatty-acid amide hydrolase 1 Inhibitor	0.0	1	ARN272	363680613.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	3.0	49.1488463007	O=C(Nc1ccccc1)c1ccc(Nc2nnc(-c3ccc(O)cc3)c3c2cccc3)cc1	O=C(Nc1ccccc1)c1ccc(Nc2nnc(-c3ccc(O)cc3)c3c2cccc3)cc1
NCGC00092276-11	O=C(Nc1ccncc1)C1CCC([C@H](N)C)CC1		Inactive			1	NCGC00092276-11	384568101.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1ccncc1)C1CCC([C@H](N)C)CC1	O=C(Nc1ccncc1)C1CCC([C@H](N)C)CC1
NCGC00379247-02	O=C(Nc1cn(-c2cc(C(=O)Nc3cc(OC)c(OC)c(OC)c3)ccc2)nc1)Nc1cc(C)ccc1		Inactive	c-Jun N-terminal kinase 3 Inhibitor		1	SR 3576	363678446.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1cn(-c2cc(C(=O)Nc3cc(OC)c(OC)c(OC)c3)ccc2)nc1)Nc1cc(C)ccc1	O=C(Nc1cn(-c2cc(C(=O)Nc3cc(OC)c(OC)c(OC)c3)ccc2)nc1)Nc1cc(C)ccc1
NCGC00015917-09	O=C(Nc1cnccc1)N1c2c(cc3n(C)ccc3c2)CC1		Inactive	5-HT2B Receptor Antagonist		1	SB-206553	384567906.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1cnccc1)N1c2c(cc3n(C)ccc3c2)CC1	O=C(Nc1cnccc1)N1c2c(cc3n(C)ccc3c2)CC1
NCGC00387034-01	O=C(Nc1n(-c2ccc(C)cc2)nc(C(C)(C)C)c1)Nc1[nH]nc(COc2cnccc2)c1		Inactive	Protein tyrosine kinase 2 beta Inhibitor		1	PF4618433	363680528.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1n(-c2ccc(C)cc2)nc(C(C)(C)C)c1)Nc1[nH]nc(COc2cnccc2)c1	O=C(Nc1n(-c2ccc(C)cc2)nc(C(C)(C)C)c1)Nc1[nH]nc(COc2cnccc2)c1
NCGC00241104-09	O=C(Nc1n(-c2ccc(C)cc2)nc(C(C)(C)C)c1)Nc1c2c(c(OCCN3CCOCC3)cc1)cccc2		Inactive	p38 MAPK Inhibitor		1	Doramapimod	384568474.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1n(-c2ccc(C)cc2)nc(C(C)(C)C)c1)Nc1c2c(c(OCCN3CCOCC3)cc1)cccc2	O=C(Nc1n(-c2ccc(C)cc2)nc(C(C)(C)C)c1)Nc1c2c(c(OCCN3CCOCC3)cc1)cccc2
NCGC00370800-01	O=C(Nc1n(-c2ccccc2)nc(-c2ccccc2)c1)c1cc(C#N)ccc1		Inactive	Metabotropic glutamate receptor 5 Positive Allosteric Modulator		1	CDPPB	363677859.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1n(-c2ccccc2)nc(-c2ccccc2)c1)c1cc(C#N)ccc1	O=C(Nc1n(-c2ccccc2)nc(-c2ccccc2)c1)c1cc(C#N)ccc1
NCGC00386889-01	O=C(Nc1n(-c2ccccc2)ncc1C)COCc1ccccc1		Inactive			1	NCGC00386889-01	363680485.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1n(-c2ccccc2)ncc1C)COCc1ccccc1	O=C(Nc1n(-c2ccccc2)ncc1C)COCc1ccccc1
NCGC00379091-01	O=C(Nc1n(CCCN(C)C)c2c(n1)cccc2)c1cc2n3[C@H](C)CCNC(=O)c3cc2cc1		Inactive	p70 ribosomal S6 kinase (S6K1) Inhibitor		1	BIX-02565	363678347.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1n(CCCN(C)C)c2c(n1)cccc2)c1cc2n3[C@H](C)CCNC(=O)c3cc2cc1	O=C(Nc1n(CCCN(C)C)c2c(n1)cccc2)c1cc2n3[C@H](C)CCNC(=O)c3cc2cc1
NCGC00387447-01	O=C(Nc1n(CCc2ccccc2)c2c(n1)cccc2)c1ccccc1		Inactive	Neuropeptide Y receptor type 5 Antagonist		1	GW 438014A	363680614.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1n(CCc2ccccc2)c2c(n1)cccc2)c1ccccc1	O=C(Nc1n(CCc2ccccc2)c2c(n1)cccc2)c1ccccc1
NCGC00346713-05	O=C(Nc1n[nH]c(CCc2cc(OC)cc(OC)c2)c1)c1ccc(N2C[C@@H](C)N[C@@H](C)C2)cc1	4.9000001	Active	FGFR 3 Inhibitor	0.0	1	AZD-4547	363677532.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	49.435441853	O=C(Nc1n[nH]c(CCc2cc(OC)cc(OC)c2)c1)c1ccc(N2C[C@@H](C)N[C@@H](C)C2)cc1	O=C(Nc1n[nH]c(CCc2cc(OC)cc(OC)c2)c1)c1ccc(N2C[C@@H](C)N[C@@H](C)C2)cc1
NCGC00263168-03	O=C(Nc1n[nH]c2C(C)(C)N(C(=O)C3CCN(C)CC3)Cc12)CC(C)C		Inactive	CDK Inhibitor		1	PHA-793887	384568638.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1n[nH]c2C(C)(C)N(C(=O)C3CCN(C)CC3)Cc12)CC(C)C	O=C(Nc1n[nH]c2C(C)(C)N(C(=O)C3CCN(C)CC3)Cc12)CC(C)C
NCGC00379120-01	O=C(Nc1nc(-n2c(C)cc(C)n2)nc(-c2nc(N3CCC(OC)CC3)ccc2)c1)C		Inactive	Adenosine A2a receptor Antagonist		1	TC-G 1004	363678368.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	16.5666666679	O=C(Nc1nc(-n2c(C)cc(C)n2)nc(-c2nc(N3CCC(OC)CC3)ccc2)c1)C	O=C(Nc1nc(-n2c(C)cc(C)n2)nc(-c2nc(N3CCC(OC)CC3)ccc2)c1)C
NCGC00387087-01	O=C(Nc1nc(OCC)c(C#N)c(N)c1)Cc1c(OC)ccc(OC)c1		Inactive	c-Jun N-terminal kinase 3 Inhibitor		1	TCS JNK 6o	363680538.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1nc(OCC)c(C#N)c(N)c1)Cc1c(OC)ccc(OC)c1	O=C(Nc1nc(OCC)c(C#N)c(N)c1)Cc1c(OC)ccc(OC)c1
NCGC00357427-09	O=C(Nc1nc2c(c(OCCN)c1)cccc2)c1nc(C(=O)Nc2nc3c(c(OCCN)c2)cccc3)cc(OCCN)c1		Inactive	G-quadraplex binding ligand		1	Pyridostatin	384569034.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1nc2c(c(OCCN)c1)cccc2)c1nc(C(=O)Nc2nc3c(c(OCCN)c2)cccc3)cc(OCCN)c1	O=C(Nc1nc2c(c(OCCN)c1)cccc2)c1nc(C(=O)Nc2nc3c(c(OCCN)c2)cccc3)cc(OCCN)c1
NCGC00347950-07	O=C(Nc1ncc(-c2nccnc2)cc1)Cc1cc(C)c(-c2cc(C)ncc2)nc1		Inactive	Wnt Signaling Inhibitor		1	LGK-974	363677730.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1ncc(-c2nccnc2)cc1)Cc1cc(C)c(-c2cc(C)ncc2)nc1	O=C(Nc1ncc(-c2nccnc2)cc1)Cc1cc(C)c(-c2cc(C)ncc2)nc1
NCGC00509947-01	O=C(Nc1ncc(C#N)c(NCCOC)c1)N1c2nc(C=O)c(CN3C(=O)CN(C)CC3)cc2CCC1		Inactive	FGFR4 Inhibitor		1	NVP-FGF-401	384569394.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1ncc(C#N)c(NCCOC)c1)N1c2nc(C=O)c(CN3C(=O)CN(C)CC3)cc2CCC1	O=C(Nc1ncc(C#N)c(NCCOC)c1)N1c2nc(C=O)c(CN3C(=O)CN(C)CC3)cc2CCC1
NCGC00346670-03	O=C(Nc1ncc(Oc2c3c(ncc2)cc(OC)cc3)cc1)C=1C(=O)N(N(CC(O)(C)C)C=1C)c1ccccc1		Inactive	HGFR Inhibitor		1	AMG-458	384568896.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1ncc(Oc2c3c(ncc2)cc(OC)cc3)cc1)C=1C(=O)N(N(CC(O)(C)C)C=1C)c1ccccc1	O=C(Nc1ncc(Oc2c3c(ncc2)cc(OC)cc3)cc1)C=1C(=O)N(N(CC(O)(C)C)C=1C)c1ccccc1
NCGC00347953-05	O=C(Nc1ncc2[nH]ccc2c1)c1ccccc1		Inactive	Oct4 Activator		1	OAC1	363677731.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ncc2[nH]ccc2c1)c1ccccc1	O=C(Nc1ncc2[nH]ccc2c1)c1ccccc1
NCGC00345834-05	O=C(Nc1nccc(-c2c(-c3cc(C)ccc3)nc(CC)s2)c1)c1ccccc1	4.9000001	Active	p38 MAPK Inhibitor	0.0	1	TAK-715	363677378.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	61.29271679	O=C(Nc1nccc(-c2c(-c3cc(C)ccc3)nc(CC)s2)c1)c1ccccc1	O=C(Nc1nccc(-c2c(-c3cc(C)ccc3)nc(CC)s2)c1)c1ccccc1
NCGC00402241-03	O=C(Nc1nccc(C)c1)C(C)c1cc(C(=O)c2ccccc2)ccc1		Inactive			1	Piketoprofen	363680997.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1nccc(C)c1)C(C)c1cc(C(=O)c2ccccc2)ccc1	O=C(Nc1nccc(C)c1)C(C)c1cc(C(=O)c2ccccc2)ccc1
NCGC00015823-17&NCGC00015823-23	O=C(Nc1ncccc1)C=1N(C)S(=O)(=O)c2c(C=1O)cccc2		Inactive	Cyclooxygenase Inhibitor		2	Piroxicam	170464817.0&384567895.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(Nc1ncccc1)C=1N(C)S(=O)(=O)c2c(C=1O)cccc2	O=C(Nc1ncccc1)C=1N(C)S(=O)(=O)c2c(C=1O)cccc2
NCGC00016889-06&NCGC00016889-15	O=C(Nc1ncccc1)C=1N(C)S(=O)(=O)c2c(C=1O)scc2		Inactive	non-steroidal antiinflammatory		2	Tenoxicam	170465677.0&384567965.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Nc1ncccc1)C=1N(C)S(=O)(=O)c2c(C=1O)scc2	O=C(Nc1ncccc1)C=1N(C)S(=O)(=O)c2c(C=1O)scc2
NCGC00386871-03	O=C(Nc1ncnc(N2CCC(C)CC2)c1)c1ccccc1		Inactive	Zinc finger protein GLI1 Inhibitor		1	ML340	363680476.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1ncnc(N2CCC(C)CC2)c1)c1ccccc1	O=C(Nc1ncnc(N2CCC(C)CC2)c1)c1ccccc1
NCGC00386908-01	O=C(Nc1nn(C)c2nc3c(cc12)ccc(OC)c3)c1occc1		Inactive			1	NCGC00386908-01	363680496.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1nn(C)c2nc3c(cc12)ccc(OC)c3)c1occc1	O=C(Nc1nn(C)c2nc3c(cc12)ccc(OC)c3)c1occc1
NCGC00345855-06	O=C(Nc1nn2C(c3ccc(CN4CCS(=O)(=O)CC4)cc3)=CC=Cc2n1)C1CC1		Inactive	Jak1/2 Inhibitor		1	Filgotinib	384568770.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1nn2C(c3ccc(CN4CCS(=O)(=O)CC4)cc3)=CC=Cc2n1)C1CC1	O=C(Nc1nn2C(c3ccc(CN4CCS(=O)(=O)CC4)cc3)=CC=Cc2n1)C1CC1
NCGC00386400-04	O=C(Nc1nn2C(c3ccc(OCc4cnc(C#N)cc4)cc3)=CC=Cc2n1)C1CC1		Inactive			1	GLPG0634	363680256.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1nn2C(c3ccc(OCc4cnc(C#N)cc4)cc3)=CC=Cc2n1)C1CC1	O=C(Nc1nn2C(c3ccc(OCc4cnc(C#N)cc4)cc3)=CC=Cc2n1)C1CC1
NCGC00481318-01	O=C(Nc1nnc(-c2ccccc2)cc1)Cn1c2C(=O)N(C)C(=O)N(C)c2nc1		Inactive			1	NCGC00481318-01		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	15.5	O=C(Nc1nnc(-c2ccccc2)cc1)Cn1c2C(=O)N(C)C(=O)N(C)c2nc1	O=C(Nc1nnc(-c2ccccc2)cc1)Cn1c2C(=O)N(C)C(=O)N(C)c2nc1
NCGC00242493-09	O=C(Nc1noc(C(C)(C)C)c1)Nc1ccc(-c2nc3Sc4c(-n3c2)ccc(OCCN2CCOCC2)c4)cc1	5.5999999	Active	Flt3 Inhibitor	0.0	1	Quizartinib	384568499.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	1.2	43.8881420671	O=C(Nc1noc(C(C)(C)C)c1)Nc1ccc(-c2nc3Sc4c(-n3c2)ccc(OCCN2CCOCC2)c4)cc1	O=C(Nc1noc(C(C)(C)C)c1)Nc1ccc(-c2nc3Sc4c(-n3c2)ccc(OCCN2CCOCC2)c4)cc1
NCGC00390764-01	O=C(Nc1noc2c1cccc2)c1ccc(C)cc1		Inactive	Inositol-trisphosphate 3-kinase A Inhibitor		1	BAMB-4	363680981.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1noc2c1cccc2)c1ccc(C)cc1	O=C(Nc1noc2c1cccc2)c1ccc(C)cc1
NCGC00386825-01	O=C(Nc1oc(-c2cc3OCCOc3cc2)nn1)C1CCCCC1		Inactive			1	NCGC00386825-01	363680450.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1oc(-c2cc3OCCOc3cc2)nn1)C1CCCCC1	O=C(Nc1oc(-c2cc3OCCOc3cc2)nn1)C1CCCCC1
NCGC00345805-01	O=C(Nc1oc(-c2occc2)nn1)c1c2c(nc(-c3ccccc3)c1)cccc2		Inactive	STAT-3 Inhibitor		1	STX-0119	174006676.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	29.319688408	O=C(Nc1oc(-c2occc2)nn1)c1c2c(nc(-c3ccccc3)c1)cccc2	O=C(Nc1oc(-c2occc2)nn1)c1c2c(nc(-c3ccccc3)c1)cccc2
NCGC00247866-05	O=C(Nc1sc(-c2ccncc2)nn1)Nc1cc(C#N)c(-c2c[nH]nc2)cc1		Inactive	BLM Inhibitor		1	NCGC00247866	384568517.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1sc(-c2ccncc2)nn1)Nc1cc(C#N)c(-c2c[nH]nc2)cc1	O=C(Nc1sc(-c2ccncc2)nn1)Nc1cc(C#N)c(-c2c[nH]nc2)cc1
NCGC00390650-01	O=C(Nc1sc(C(=O)OCC)c(C)n1)[C@H](C(C)C)N1C(=O)Nc2c(C1=O)cccc2		Inactive	Kinesin-like protein KIF15 Inhibitor		1	Kif15-IN-1	363680954.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1sc(C(=O)OCC)c(C)n1)[C@H](C(C)C)N1C(=O)Nc2c(C1=O)cccc2	O=C(Nc1sc(C(=O)OCC)c(C)n1)[C@H](C(C)C)N1C(=O)Nc2c(C1=O)cccc2
NCGC00263191-02	O=C(Nc1sc(C(C)C)cn1)[C@@H](C)c1ccc(NC(=O)C)cc1		Inactive	CDK2 Inhibitor		1	PHA-690509	363677255.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(Nc1sc(C(C)C)cn1)[C@@H](C)c1ccc(NC(=O)C)cc1	O=C(Nc1sc(C(C)C)cn1)[C@@H](C)c1ccc(NC(=O)C)cc1
NCGC00018248-18&NCGC00018248-24&NCGC00018248-25&NCGC00018248-26	O=C(Nc1sc(C)cn1)C=1N(C)S(=O)(=O)c2c(C=1O)cccc2		Inactive	Cyclooxygenase-1/2 Inhibitor&Neuropharmacol 39: 1653 (2000)		4	Meloxicam&NCGC00018248-24&MELOXICAM SODIUM	384567999.0&434146969.0&405558534.0	Annotated/Bioactive Compound Collection&Anti-infectives&Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0&0.0	O=C(Nc1sc(C)cn1)C=1N(C)S(=O)(=O)c2c(C=1O)cccc2	O=C(Nc1sc(C)cn1)C=1N(C)S(=O)(=O)c2c(C=1O)cccc2
NCGC00601824-01	O=C(Nc1sc(NC2CCN(c3sc(NC(=O)Cc4ccccc4)nn3)CC2)nn1)Cc1ccccc1		Inactive			1	UPGL00004	434147181.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1sc(NC2CCN(c3sc(NC(=O)Cc4ccccc4)nn3)CC2)nn1)Cc1ccccc1	O=C(Nc1sc(NC2CCN(c3sc(NC(=O)Cc4ccccc4)nn3)CC2)nn1)Cc1ccccc1
NCGC00346624-10	O=C(Nc1sc(c(C)n1)-c1nc(C(C)(C)C)sc1)N1[C@H](C(=O)N)CCC1		Inactive	PI3Kalpha Inhibitor		1	A-66	384568864.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1sc(c(C)n1)-c1nc(C(C)(C)C)sc1)N1[C@H](C(=O)N)CCC1	O=C(Nc1sc(c(C)n1)-c1nc(C(C)(C)C)sc1)N1[C@H](C(=O)N)CCC1
NCGC00282602-03	O=C(Nc1sc(c(C)n1)-c1nc(Nc2c(OC)cccc2)sc1)C	5.0999999	Active		0.0	1	JNJ0966	406861850.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	2.4	61.4635409123	O=C(Nc1sc(c(C)n1)-c1nc(Nc2c(OC)cccc2)sc1)C	O=C(Nc1sc(c(C)n1)-c1nc(Nc2c(OC)cccc2)sc1)C
NCGC00390641-01	O=C(Nc1sc(c(C)n1)-c1oc(C)nn1)[C@H](C(C)C)N1C(=O)Nc2c(C1=O)cccc2		Inactive	Kinesin-like protein KIF15 Inhibitor		1	Kif15-IN-2	363680946.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1sc(c(C)n1)-c1oc(C)nn1)[C@H](C(C)C)N1C(=O)Nc2c(C1=O)cccc2	O=C(Nc1sc(c(C)n1)-c1oc(C)nn1)[C@H](C(C)C)N1C(=O)Nc2c(C1=O)cccc2
NCGC00386837-01	O=C(Nc1sc2c(C)ccc(OC)c2n1)c1ccncc1		Inactive			1	NCGC00386837-01	363680457.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1sc2c(C)ccc(OC)c2n1)c1ccncc1	O=C(Nc1sc2c(C)ccc(OC)c2n1)c1ccncc1
NCGC00378653-02	O=C(Nc1sc2c(N3CCOCC3)ccc(OC)c2n1)N1CCC(O)(C)CC1		Inactive	Adenosine A2a receptor Antagonist		1	Tozadenant	363678136.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1sc2c(N3CCOCC3)ccc(OC)c2n1)N1CCC(O)(C)CC1	O=C(Nc1sc2c(N3CCOCC3)ccc(OC)c2n1)N1CCC(O)(C)CC1
NCGC00263217-05	O=C(Nc1sc2c(n1)ccc(NC(=O)C1C3CC4CC1CC(C3)C4)c2)c1ccccc1		Inactive	Ceramide kinase Inhibitor		1	NVP-231	384568671.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(Nc1sc2c(n1)ccc(NC(=O)C1C3CC4CC1CC(C3)C4)c2)c1ccccc1	O=C(Nc1sc2c(n1)ccc(NC(=O)C1C3CC4CC1CC(C3)C4)c2)c1ccccc1
NCGC00386342-01	O=C(Nc1scc(-c2c(C)cc(C)cc2C)n1)c1ccccc1		Inactive	Kinetochore protein NDC80 homolog Inhibitor		1	INH6	363680224.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Nc1scc(-c2c(C)cc(C)cc2C)n1)c1ccccc1	O=C(Nc1scc(-c2c(C)cc(C)cc2C)n1)c1ccccc1
NCGC00386426-01	O=C(Nc1scc(-c2c(C)cc(Oc3ccc(OC)cc3)cc2C)n1)c1ccncc1		Inactive	Kinetochore protein NDC80 homolog Inhibitor		1	TAI-1	363680278.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	13.5	O=C(Nc1scc(-c2c(C)cc(Oc3ccc(OC)cc3)cc2C)n1)c1ccncc1	O=C(Nc1scc(-c2c(C)cc(Oc3ccc(OC)cc3)cc2C)n1)c1ccncc1
NCGC00506872-01	O=C(Nc1scc(C(=O)NCCN(C(C)C)C(C)C)n1)c1c(O)cc(OC)c(OC)c1		Inactive	Acetylcholinesterase Inhibitor		1	Acotiamide hydrochlorid	405558502.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Nc1scc(C(=O)NCCN(C(C)C)C(C)C)n1)c1c(O)cc(OC)c(OC)c1	O=C(Nc1scc(C(=O)NCCN(C(C)C)C(C)C)n1)c1c(O)cc(OC)c(OC)c1
NCGC00385481-01	O=C(O)/C(/C(O)CO)=C/C[C@@H]1C(=C)CC[C@@H]2[C@@](CO)(C)C(O)CC[C@@]12C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Andrographis | Family: Acanthaceae | Species: paniculata		1	NCGC00385481-01	363679765.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(/C(O)CO)=C/C[C@@H]1C(=C)CC[C@@H]2[C@@](CO)(C)C(O)CC[C@@]12C	O=C(O)/C(/C(O)CO)=C/C[C@@H]1C(=C)CC[C@@H]2[C@@](CO)(C)C(O)CC[C@@]12C
NCGC00169132-02	O=C(O)/C(/CCC=C(C)C)=C/1\[C@@H](OC(=O)C)C[C@]2(C)[C@@]3(C)C(=O)[C@@H](OC(=O)C)[C@H]4[C@H](C)C(=O)C=C[C@]4(C)[C@@H]3CC[C@@H]\12		Inactive	Trypanosoma brucei brucei Inhibitor		1	helvolic acid	363676776.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(/CCC=C(C)C)=C/1\[C@@H](OC(=O)C)C[C@]2(C)[C@@]3(C)C(=O)[C@@H](OC(=O)C)[C@H]4[C@H](C)C(=O)C=C[C@]4(C)[C@@H]3CC[C@@H]\12	O=C(O)/C(/CCC=C(C)C)=C/1\[C@@H](OC(=O)C)C[C@]2(C)[C@@]3(C)C(=O)[C@@H](OC(=O)C)[C@H]4[C@H](C)C(=O)C=C[C@]4(C)[C@@H]3CC[C@@H]\12
NCGC00017030-10	O=C(O)/C(/CCC=C(C)C)=C\1/[C@@H](OC(=O)C)CC2(C)[C@]3(C)[C@@H]([C@H](O)C[C@@H]/12)[C@]1(C)[C@H]([C@H](C)[C@H](O)CC1)CC3		Inactive			1	Fusidic Acid (sodium salt)	405558530.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])/C(/CCC=C(C)C)=C\1/[C@@H](OC(=O)C)CC2(C)[C@]3(C)[C@@H]([C@H](O)C[C@@H]/12)[C@]1(C)[C@H]([C@H](C)[C@H](O)CC1)CC3	O=C([O-])/C(/CCC=C(C)C)=C\1/[C@@H](OC(=O)C)CC2(C)[C@]3(C)[C@@H]([C@H](O)C[C@@H]/12)[C@]1(C)[C@H]([C@H](C)[C@H](O)CC1)CC3
NCGC00380815-01	O=C(O)/C(/CCC=C(C)C)=C\1/[C@@H](OC(=O)C)C[C@]2(C)[C@@]3(C)C(=O)[C@@H](O)[C@H]4[C@H](C)C(=O)C=C[C@]4(C)[C@@H]3CC[C@@H]/12		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Aspergillus | Family: N/A | Species: fumigatus		1	NCGC00380815-01	363678796.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(/CCC=C(C)C)=C\1/[C@@H](OC(=O)C)C[C@]2(C)[C@@]3(C)C(=O)[C@@H](O)[C@H]4[C@H](C)C(=O)C=C[C@]4(C)[C@@H]3CC[C@@H]/12	O=C(O)/C(/CCC=C(C)C)=C\1/[C@@H](OC(=O)C)C[C@]2(C)[C@@]3(C)C(=O)[C@@H](O)[C@H]4[C@H](C)C(=O)C=C[C@]4(C)[C@@H]3CC[C@@H]/12
NCGC00390769-01	O=C(O)/C(/O)=C/C(=O)c1cc(CN=[N+]=[N-])ccc1		Inactive			1	HIV-1 integrase inhibitor	434147147.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)/C(/O)=C/C(=O)c1cc(CN=[N+]=[N-])ccc1	O=C(O)/C(/O)=C/C(=O)c1cc(CN=[N+]=[N-])ccc1
NCGC00384895-01	O=C(O)/C(=C/C(=O)O)/C=C/[C@@H]1C(=C)CC[C@@H]2[C@@](CO)(C)C(O)CC[C@@]12C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Andrographis | Family: Acanthaseae | Species: paniculata		1	NCGC00384895-01	363679423.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/C(=O)O)/C=C/[C@@H]1C(=C)CC[C@@H]2[C@@](CO)(C)C(O)CC[C@@]12C	O=C(O)/C(=C/C(=O)O)/C=C/[C@@H]1C(=C)CC[C@@H]2[C@@](CO)(C)C(O)CC[C@@]12C
NCGC00013082-04	O=C(O)/C(=C/C(=O)O)/CC(=O)O		Inactive	Cytoplasmic aconitate hydratase Substrate		1	trans-Aconitic acid	170466847.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&13.255474452	O=C(O)/C(=C/C(=O)O)/CC(=O)O	O=C(O)/C(=C/C(=O)O)/CC(=O)O
NCGC00384793-01	O=C(O)/C(=C/C(O)C/C(=C/CC/C(=C/CCC(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)(C=C)C)/C)/C)/C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384793-01	363679356.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/C(O)C/C(=C/CC/C(=C/CCC(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)(C=C)C)/C)/C)/C	O=C(O)/C(=C/C(O)C/C(=C/CC/C(=C/CCC(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)(C=C)C)/C)/C)/C
NCGC00648718-02	O=C(O)/C(=C/C)/C		Inactive			1	Tiglic acid		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/C)/C	O=C(O)/C(=C/C)/C
NCGC00385428-01	O=C(O)/C(=C/C1C23C(C)(O2)CCC3C(C)CC1)/C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385428-01	363679737.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/C1C23C(C)(O2)CCC3C(C)CC1)/C	O=C(O)/C(=C/C1C23C(C)(O2)CCC3C(C)CC1)/C
NCGC00385750-01	O=C(O)/C(=C/C=C/C(C)C1C2(C)C(C)(C3C4(C5(C(C(C)(C)C(=O)CC5)CC3)C4)CC2)CC1)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385750-01	363679921.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/C=C/C(C)C1C2(C)C(C)(C3C4(C5(C(C(C)(C)C(=O)CC5)CC3)C4)CC2)CC1)/C	O=C(O)/C(=C/C=C/C(C)C1C2(C)C(C)(C3C4(C5(C(C(C)(C)C(=O)CC5)CC3)C4)CC2)CC1)/C
NCGC00385362-01	O=C(O)/C(=C/CC/C(=C/CC/C(=C/CC[C@@]1(C)Oc2c(C)cc(O)cc2CC1)/C)/C)/C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: Clusia | Family: Guttiferae | Species: guatemalensis		1	garcinoic acid 	363679702.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/CC/C(=C/CC/C(=C/CC[C@@]1(C)Oc2c(C)cc(O)cc2CC1)/C)/C)/C	O=C(O)/C(=C/CC/C(=C/CC/C(=C/CC[C@@]1(C)Oc2c(C)cc(O)cc2CC1)/C)/C)/C
NCGC00169874-02	O=C(O)/C(=C/CCC(=C)C1(O)CC=C(C)CC1)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169874-02	363676902.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/CCC(=C)C1(O)CC=C(C)CC1)/C	O=C(O)/C(=C/CCC(=C)C1(O)CC=C(C)CC1)/C
NCGC00384736-01	O=C(O)/C(=C/CCC(C(=O)O)C1C2(C)C(C)(C3=C(C4(C)C(C(C)(C)C(=O)CC4)CC3)CC2)CC1)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Pistacia | Family: N/A | Species: spp.		1	NCGC00384736-01	363679332.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	6.760532148	O=C(O)/C(=C/CCC(C(=O)O)C1C2(C)C(C)(C3=C(C4(C)C(C(C)(C)C(=O)CC4)CC3)CC2)CC1)/C	O=C(O)/C(=C/CCC(C(=O)O)C1C2(C)C(C)(C3=C(C4(C)C(C(C)(C)C(=O)CC4)CC3)CC2)CC1)/C
NCGC00179866-03	O=C(O)/C(=C/CCC(C)C1C2(C)C(C)(C(O)C1)C1C3(C4(C(C(C)(C)C(OC5C(O)C(O)C(O)CO5)CC4)CC1)C3)CC2O)/C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Spondianthus | Family: Anacardiaceae | Species: preussii		1	NCGC00179866-03	363676980.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/CCC(C)C1C2(C)C(C)(C(O)C1)C1C3(C4(C(C(C)(C)C(OC5C(O)C(O)C(O)CO5)CC4)CC1)C3)CC2O)/C	O=C(O)/C(=C/CCC(C)C1C2(C)C(C)(C(O)C1)C1C3(C4(C(C(C)(C)C(OC5C(O)C(O)C(O)CO5)CC4)CC1)C3)CC2O)/C
NCGC00380995-01	O=C(O)/C(=C/CCC(O)(C)c1ccc(C)cc1)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380995-01	363678911.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/CCC(O)(C)c1ccc(C)cc1)/C	O=C(O)/C(=C/CCC(O)(C)c1ccc(C)cc1)/C
NCGC00169905-02	O=C(O)/C(=C/CCC1(C)C(O)(C)C2CC1CC2)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169905-02	363676907.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	24.965517244	O=C(O)/C(=C/CCC1(C)C(O)(C)C2CC1CC2)/C	O=C(O)/C(=C/CCC1(C)C(O)(C)C2CC1CC2)/C
NCGC00169782-02	O=C(O)/C(=C/CCC1(C)C2(C)C3C2CC1C3)/C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Artocarpus | Family: Urticaceae | Species: intergrifolia		1	NCGC00169782-02	363676886.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/CCC1(C)C2(C)C3C2CC1C3)/C	O=C(O)/C(=C/CCC1(C)C2(C)C3C2CC1C3)/C
NCGC00381046-01	O=C(O)/C(=C/CC[C@@H](C)[C@@H]1[C@]2(C)[C@@](C)(C(O)C1)C1[C@]3([C@@]4([C@H](C(C)(C)[C@@H](OC5C(OC6C(O)C(O)C(O)C(CO)O6)C(O)C(O)CO5)CC4)CC1)C3)CC2O)/C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Spondianthus | Family: Anacardiaceae | Species: preussii		1	NCGC00381046-01	363678942.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/CC[C@@H](C)[C@@H]1[C@]2(C)[C@@](C)(C(O)C1)C1[C@]3([C@@]4([C@H](C(C)(C)[C@@H](OC5C(OC6C(O)C(O)C(O)C(CO)O6)C(O)C(O)CO5)CC4)CC1)C3)CC2O)/C	O=C(O)/C(=C/CC[C@@H](C)[C@@H]1[C@]2(C)[C@@](C)(C(O)C1)C1[C@]3([C@@]4([C@H](C(C)(C)[C@@H](OC5C(OC6C(O)C(O)C(O)C(CO)O6)C(O)C(O)CO5)CC4)CC1)C3)CC2O)/C
NCGC00380845-01	O=C(O)/C(=C/CC[C@@H](C)[C@@H]1[C@]2(C)[C@](C)(C3[C@]4([C@@]5([C@H](C(C)(C)[C@@H](OC6C(O)C(O)C(OC7C(O)C(O)C(O)CO7)C(COC(=O)C)O6)CC5)CC3)C4)CC2O)CC1O)/C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Ananas | Family: Bromeliaceae | Species: sativus		1	NCGC00380845-01	363678811.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/CC[C@@H](C)[C@@H]1[C@]2(C)[C@](C)(C3[C@]4([C@@]5([C@H](C(C)(C)[C@@H](OC6C(O)C(O)C(OC7C(O)C(O)C(O)CO7)C(COC(=O)C)O6)CC5)CC3)C4)CC2O)CC1O)/C	O=C(O)/C(=C/CC[C@@H](C)[C@@H]1[C@]2(C)[C@](C)(C3[C@]4([C@@]5([C@H](C(C)(C)[C@@H](OC6C(O)C(O)C(OC7C(O)C(O)C(O)CO7)C(COC(=O)C)O6)CC5)CC3)C4)CC2O)CC1O)/C
NCGC00169801-02	O=C(O)/C(=C/CC[C@H](CO)[C@H]1[C@@]2(C)[C@@](C)(C3=C([C@]4(C)C(C(C)(C)C(=O)CC4)CC3)CC2)CC1)/C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Echinops | Family: Compositae | Species: sp.		1	NCGC00169801-02	363676889.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/CC[C@H](CO)[C@H]1[C@@]2(C)[C@@](C)(C3=C([C@]4(C)C(C(C)(C)C(=O)CC4)CC3)CC2)CC1)/C	O=C(O)/C(=C/CC[C@H](CO)[C@H]1[C@@]2(C)[C@@](C)(C3=C([C@]4(C)C(C(C)(C)C(=O)CC4)CC3)CC2)CC1)/C
NCGC00385332-01	O=C(O)/C(=C/CC[C@](O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)CO1)(C=C)C)/C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385332-01	363679683.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/CC[C@](O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)CO1)(C=C)C)/C	O=C(O)/C(=C/CC[C@](O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)CO1)(C=C)C)/C
NCGC00380929-01	O=C(O)/C(=C/[C@@H]1[C@@H](C(C)C)CCC(CO)=C1)/CO		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380929-01	363678861.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/[C@@H]1[C@@H](C(C)C)CCC(CO)=C1)/CO	O=C(O)/C(=C/[C@@H]1[C@@H](C(C)C)CCC(CO)=C1)/CO
NCGC00381338-01	O=C(O)/C(=C/[C@@H]1[C@@H](C(C)C)CC[C@]2(O)[C@H]1C(=O)OC2)/CO		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381338-01	363679099.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/[C@@H]1[C@@H](C(C)C)CC[C@]2(O)[C@H]1C(=O)OC2)/CO	O=C(O)/C(=C/[C@@H]1[C@@H](C(C)C)CC[C@]2(O)[C@H]1C(=O)OC2)/CO
NCGC00091907-03	O=C(O)/C(=C/[C@H]1C2=C(C)C[C@@H](O)[C@@H]2[C@H](C)CC1)/C		Inactive	GABA-A receptor; benzodiazepine site Positive Allosteric Modulator		1	Hydroxyvalerenic Acid	363676554.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/[C@H]1C2=C(C)C[C@@H](O)[C@@H]2[C@H](C)CC1)/C	O=C(O)/C(=C/[C@H]1C2=C(C)C[C@@H](O)[C@@H]2[C@H](C)CC1)/C
NCGC00091920-03	O=C(O)/C(=C/[C@H]1C2=C(C)C[C@@H](OC(=O)C)[C@@H]2[C@H](C)CC1)/C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: VALERIANA | Family: N/A | Species: OFFICINALIS		1	Acetoxyvalerenic Acid	363676555.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C(=C/[C@H]1C2=C(C)C[C@@H](OC(=O)C)[C@@H]2[C@H](C)CC1)/C	O=C(O)/C(=C/[C@H]1C2=C(C)C[C@@H](OC(=O)C)[C@@H]2[C@H](C)CC1)/C
NCGC00164557-06&NCGC00164557-11	O=C(O)/C(=C/c1n(Cc2ccc(C(=O)O)cc2)c(CCCC)nc1)/Cc1sccc1		Inactive	urate transport Inhibitor		2	Eprosartan (mesylate)&Eprosartan mesylate	363676634.0&405558474.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)/C(=C/c1n(Cc2ccc(C(=O)O)cc2)c(CCCC)nc1)/Cc1sccc1	O=C(O)/C(=C/c1n(Cc2ccc(C(=O)O)cc2)c(CCCC)nc1)/Cc1sccc1
NCGC00095237-14	O=C(O)/C(=C\CC12C(=O)C3C=C4C(=O)c5c(O)c6c(c(CC=C(C)C)c5OC14C(C(C)(C)O2)C3)OC(CCC=C(C)C)(C)C=C6)/C		Inactive			1	Gambogic acid		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	-14.3703803199	O=C(O)/C(=C\CC12C(=O)C3C=C4C(=O)c5c(O)c6c(c(CC=C(C)C)c5OC14C(C(C)(C)O2)C3)OC(CCC=C(C)C)(C)C=C6)/C	O=C(O)/C(=C\CC12C(=O)C3C=C4C(=O)c5c(O)c6c(c(CC=C(C)C)c5OC14C(C(C)(C)O2)C3)OC(CCC=C(C)C)(C)C=C6)/C
NCGC00249913-01	O=C(O)/C(=N\NC(=O)c1ccncc1)/C		Inactive	Isocitrate lyase Inhibitor		1	Isoniazid pyruvate	170465758.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)/C(=N\NC(=O)c1ccncc1)/C	O=C(O)/C(=N\NC(=O)c1ccncc1)/C
NCGC00385723-01	O=C(O)/C/1=C\CC/C(/C)=C/C2OC(=O)C(=C)C2CC/C(/C)=C/CC\1		Inactive	<MOA Unknown> | Class: diterpene | Genus: Anisochilus | Family: Lamiaceae | Species: carnosus		1	NCGC00385723-01	363679898.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C/1=C\CC/C(/C)=C/C2OC(=O)C(=C)C2CC/C(/C)=C/CC\1	O=C(O)/C/1=C\CC/C(/C)=C/C2OC(=O)C(=C)C2CC/C(/C)=C/CC\1
NCGC00385725-01	O=C(O)/C/1=C\CC/C(/C)=C/CC(C)(C)/C=C/C\1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Lychnophora | Family: N/A | Species: columnaris		1	NCGC00385725-01	363679900.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C/1=C\CC/C(/C)=C/CC(C)(C)/C=C/C\1	O=C(O)/C/1=C\CC/C(/C)=C/CC(C)(C)/C=C/C\1
NCGC00380943-01	O=C(O)/C/1=C\CC/C(/C)=C/[C@H]2OC(=O)[C@@H](C)[C@@H]2CC\1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Taraxacum | Family: Asteraceae | Species: officinalis		1	NCGC00380943-01	363678875.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C/1=C\CC/C(/C)=C/[C@H]2OC(=O)[C@@H](C)[C@@H]2CC\1	O=C(O)/C/1=C\CC/C(/C)=C/[C@H]2OC(=O)[C@@H](C)[C@@H]2CC\1
NCGC00385814-01	O=C(O)/C=C(/C=C/C1(O)C(C)=CC(=O)CC1(CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C)\C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385814-01	363679954.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C=C(/C=C/C1(O)C(C)=CC(=O)CC1(CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C)\C	O=C(O)/C=C(/C=C/C1(O)C(C)=CC(=O)CC1(CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C)\C
NCGC00017280-37	O=C(O)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C		Inactive	Retinoid RORbeta Ligand		1	Tretinoin	384567982.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	9.508368204	O=C(O)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C	O=C(O)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C
NCGC00163127-04&NCGC00163127-08	O=C(O)/C=C(/C=C/C=C(/C=C/c1c(C)c(C)c(OC)cc1C)\C)\C		Inactive	retinoid		2	Acitretin	225144249.0&384568231.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&29.6660623681	O=C(O)/C=C(/C=C/C=C(/C=C/c1c(C)c(C)c(OC)cc1C)\C)\C	O=C(O)/C=C(/C=C/C=C(/C=C/c1c(C)c(C)c(OC)cc1C)\C)\C
NCGC00522288-01	O=C(O)/C=C(/C=C/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C		Inactive			1	PERETINOIN	434147171.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)/C=C(/C=C/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C	O=C(O)/C=C(/C=C/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C
NCGC00386776-01	O=C(O)/C=C(/C=C/[C@H]1[C@@](C)(c2cc3C(C)(C)CCC(C)(C)c3cc2)C1)\C	5.0500002	Active	RXR Agonist	0.0	1	AGN-194204	384569146.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	64.1812472851	O=C(O)/C=C(/C=C/[C@H]1[C@@](C)(c2cc3C(C)(C)CCC(C)(C)c3cc2)C1)\C	O=C(O)/C=C(/C=C/[C@H]1[C@@](C)(c2cc3C(C)(C)CCC(C)(C)c3cc2)C1)\C
NCGC00385724-01	O=C(O)/C=C(/CCC1=C(C)C(=O)CC2C(C)(C)CCC[C@]12C)\C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385724-01	363679899.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C=C(/CCC1=C(C)C(=O)CC2C(C)(C)CCC[C@]12C)\C	O=C(O)/C=C(/CCC1=C(C)C(=O)CC2C(C)(C)CCC[C@]12C)\C
NCGC00381257-01	O=C(O)/C=C(/CCC1C(=C)CCC2C(C(=O)O)(C)CC(O)CC12C)\C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381257-01	363679054.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C=C(/CCC1C(=C)CCC2C(C(=O)O)(C)CC(O)CC12C)\C	O=C(O)/C=C(/CCC1C(=C)CCC2C(C(=O)O)(C)CC(O)CC12C)\C
NCGC00384643-01	O=C(O)/C=C(/CC[C@H]1C(=C)CCC2C(C)(C)CCC[C@]12C)\C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Albizia | Family: Fabaceae | Species: coriaria***		1	NCGC00384643-01	363679291.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C=C(/CC[C@H]1C(=C)CCC2C(C)(C)CCC[C@]12C)\C	O=C(O)/C=C(/CC[C@H]1C(=C)CCC2C(C)(C)CCC[C@]12C)\C
NCGC00384928-01	O=C(O)/C=C(/COC(=O)C)\CC[C@@H]1C(C)=CC(=O)[C@@H]2C(C)(C)CCC[C@@]12C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Acritopappus | Family: N/A | Species: sp. Nov. 3		1	NCGC00384928-01	363679444.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C=C(/COC(=O)C)\CC[C@@H]1C(C)=CC(=O)[C@@H]2C(C)(C)CCC[C@@]12C	O=C(O)/C=C(/COC(=O)C)\CC[C@@H]1C(C)=CC(=O)[C@@H]2C(C)(C)CCC[C@@]12C
NCGC00380576-01	O=C(O)/C=C(/COC(=O)C)\CC[C@@H]1C(C=O)=CC[C@@H]2C(C)(C)CCC[C@@]12C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Acritopappus | Family: N/A | Species: sp. Nov. 3		1	NCGC00380576-01	363678658.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C=C(/COC(=O)C)\CC[C@@H]1C(C=O)=CC[C@@H]2C(C)(C)CCC[C@@]12C	O=C(O)/C=C(/COC(=O)C)\CC[C@@H]1C(C=O)=CC[C@@H]2C(C)(C)CCC[C@@]12C
NCGC00385177-01	O=C(O)/C=C(/COC(=O)C)\CC[C@@H]1C(CO)=CC[C@@H]2C(C)(C)CCC[C@@]12C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Acritopappus | Family: N/A | Species: sp. Nov. 3		1	NCGC00385177-01	363679579.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C=C(/COC(=O)C)\CC[C@@H]1C(CO)=CC[C@@H]2C(C)(C)CCC[C@@]12C	O=C(O)/C=C(/COC(=O)C)\CC[C@@H]1C(CO)=CC[C@@H]2C(C)(C)CCC[C@@]12C
NCGC00094358-05&NCGC00094358-38	O=C(O)/C=C(\C=C\C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)/C		Inactive	Retinoid RAR Agonist		2	Isotretinoin	26753641.0&384568128.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)/C=C(\C=C\C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)/C	O=C(O)/C=C(\C=C\C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)/C
NCGC00385412-01	O=C(O)/C=C(\C=C\[C@@]1(O)[C@]2(C)OC[C@@]1(C)C[C@@H](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C2)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Mangifera | Family: Anacardiaceae | Species: indica		1	NCGC00385412-01	363679729.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C=C(\C=C\[C@@]1(O)[C@]2(C)OC[C@@]1(C)C[C@@H](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C2)/C	O=C(O)/C=C(\C=C\[C@@]1(O)[C@]2(C)OC[C@@]1(C)C[C@@H](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C2)/C
NCGC00380250-01	O=C(O)/C=C/C(=O)N[C@]1(C)C(=O)O[C@]2(C)C(O)=C(C)C(=O)/C(=C(/O)\C=C\C=C\C)/[C@H]12		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380250-01	363678514.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C=C/C(=O)N[C@]1(C)C(=O)O[C@]2(C)C(O)=C(C)C(=O)/C(=C(/O)\C=C\C=C\C)/[C@H]12	O=C(O)/C=C/C(=O)N[C@]1(C)C(=O)O[C@]2(C)C(O)=C(C)C(=O)/C(=C(/O)\C=C\C=C\C)/[C@H]12
NCGC00380716-01	O=C(O)/C=C/C1C(O)(C)C(O)C(OC(=O)C)C2C(C)(C)CCCC12C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380716-01	363678733.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C=C/C1C(O)(C)C(O)C(OC(=O)C)C2C(C)(C)CCCC12C	O=C(O)/C=C/C1C(O)(C)C(O)C(OC(=O)C)C2C(C)(C)CCCC12C
NCGC00091737-05	O=C(O)/C=C/C=C/C		Inactive			1	Sorbic acid	405559109.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&-6.9135835439	O=C(O)/C=C/C=C/C	O=C(O)/C=C/C=C/C
NCGC00380736-01	O=C(O)/C=C/C=C/[C@@H]1[C@H](/C(=C/C)/C)C(C)=C[C@H]2[C@@H](O)CC[C@H](C)[C@@H]12		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380736-01	363678749.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C=C/C=C/[C@@H]1[C@H](/C(=C/C)/C)C(C)=C[C@H]2[C@@H](O)CC[C@H](C)[C@@H]12	O=C(O)/C=C/C=C/[C@@H]1[C@H](/C(=C/C)/C)C(C)=C[C@H]2[C@@H](O)CC[C@H](C)[C@@H]12
NCGC00253601-01	O=C(O)/C=C/CCCCCCCC		Inactive			1	Calcium undecylenate	170465553.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])/C=C/CCCCCCCC.O=C([O-])/C=C/CCCCCCCC.[Ca+2]	O=C([O-])/C=C/CCCCCCCC.O=C([O-])/C=C/CCCCCCCC.[Ca+2]
NCGC00344134-02	O=C(O)/C=C/CCCC[C@@H]1[C@@H](/C=C/[C@@H](O)C[C@H](CCCC)C)[C@H](O)CC1=O		Inactive			1	Limaprost	405559048.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)/C=C/CCCC[C@@H]1[C@@H](/C=C/[C@@H](O)C[C@H](CCCC)C)[C@H](O)CC1=O	O=C(O)/C=C/CCCC[C@@H]1[C@@H](/C=C/[C@@H](O)C[C@H](CCCC)C)[C@H](O)CC1=O
NCGC00384718-01	O=C(O)/C=C/c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c(occ2)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Psoralea | Family: Leguminosae | Species: corylifolia		1	NCGC00384718-01	363679325.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C=C/c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c(occ2)cc1	O=C(O)/C=C/c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c(occ2)cc1
NCGC00380533-01	O=C(O)/C=C/c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc2OCOc2c1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380533-01	363678635.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C=C/c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc2OCOc2c1	O=C(O)/C=C/c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc2OCOc2c1
NCGC00385149-01	O=C(O)/C=C/c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)c3cc(OC)c(OC)c(OC)c3)O2)cccc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385149-01	363679562.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C=C/c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)c3cc(OC)c(OC)c(OC)c3)O2)cccc1	O=C(O)/C=C/c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)c3cc(OC)c(OC)c(OC)c3)O2)cccc1
NCGC00247490-02	O=C(O)/C=C/c1cc(O)c(OC)cc1		Inactive			1	3-Hydroxy-4-methoxycinnamic acid	434147066.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)/C=C/c1cc(O)c(OC)cc1	O=C(O)/C=C/c1cc(O)c(OC)cc1
NCGC00095522-06	O=C(O)/C=C/c1cc(OC)c(OC)cc1		Inactive			1	DIMETHYLCAFFEIC ACID	434147226.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)/C=C/c1cc(OC)c(OC)cc1	O=C(O)/C=C/c1cc(OC)c(OC)cc1
NCGC00380654-01	O=C(O)/C=C/c1cc(OC)c(O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380654-01	363678693.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	-11.643219448	O=C(O)/C=C/c1cc(OC)c(O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1	O=C(O)/C=C/c1cc(OC)c(O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1
NCGC00385117-01	O=C(O)/C=C/c1cc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(O)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Dicranopteris | Family: Gleicheniaceae | Species: linearis		1	NCGC00385117-01	363679545.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C=C/c1cc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(O)cc1	O=C(O)/C=C/c1cc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(O)cc1
NCGC00370868-01	O=C(O)/C=C/c1cc(c(O)cc1)-c1c(OCCCCC)cc2C(C)(C)CCC(C)(C)c2c1	5.0	Active	Retinoid X receptor beta Antagonist	0.0	1	UVI 3003	363677897.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	3.0	40.6721532607	O=C(O)/C=C/c1cc(c(O)cc1)-c1c(OCCCCC)cc2C(C)(C)CCC(C)(C)c2c1	O=C(O)/C=C/c1cc(c(O)cc1)-c1c(OCCCCC)cc2C(C)(C)CCC(C)(C)c2c1
NCGC00485908-01	O=C(O)/C=C/c1ccc(-c2cc(c(O)cc2)C23CC4CC(C2)CC(C3)C4)cc1	4.9499998	Active	apoptotic process Activator	0.0	1	Adarotene	363681407.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	3.0	58.0364039311	O=C(O)/C=C/c1ccc(-c2cc(c(O)cc2)C23CC4CC(C2)CC(C3)C4)cc1	O=C(O)/C=C/c1ccc(-c2cc(c(O)cc2)C23CC4CC(C2)CC(C3)C4)cc1
NCGC00025195-06&NCGC00025195-09	O=C(O)/C=C/c1ccc(Cn2cncc2)cc1		Inactive	Thromboxane Synthase Inhibitor		2	Ozagrel hydrochloride	170466054.0&384568055.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)/C=C/c1ccc(Cn2cncc2)cc1.Cl	O=C(O)/C=C/c1ccc(Cn2cncc2)cc1.Cl&O=C(O)/C=C/c1ccc(Cn2cncc2)cc1
NCGC00159448-05	O=C(O)/C=C/c1ccc(OC)cc1		Inactive			1	4-Methoxycinnamic acid	225144227.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)/C=C/c1ccc(OC)cc1	O=C(O)/C=C/c1ccc(OC)cc1
NCGC00169406-02	O=C(O)/C=C/c1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Plumeria | Family: Apocynaceae | Species: rubra		1	NCGC00169406-02	363676813.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C=C/c1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1	O=C(O)/C=C/c1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1
NCGC00165979-06	O=C(O)/C=C/c1ccccc1		Inactive			1	CINNAMIC ACID	405558448.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)/C=C/c1ccccc1	O=C(O)/C=C/c1ccccc1
NCGC00182053-03	O=C(O)/C=C/c1nc(/C(=C/CN2CCCC2)/c2ccc(C)cc2)ccc1		Inactive	Histamine H1 receptor Antagonist		1	Acrivastine	405558933.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)/C=C/c1nc(/C(=C/CN2CCCC2)/c2ccc(C)cc2)ccc1	O=C(O)/C=C/c1nc(/C(=C/CN2CCCC2)/c2ccc(C)cc2)ccc1
NCGC00090970-03	O=C(O)/C=C\C(=O)O		Inactive	NADP-dependent malic enzyme, mitochondrial Inhibitor		1	Maleic acid	170465983.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)/C=C\C(=O)O	O=C(O)/C=C\C(=O)O
NCGC00384792-01	O=C(O)/C=C\c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384792-01	363679355.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)/C=C\c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC)cc1	O=C(O)/C=C\c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC)cc1
NCGC00385267-01	O=C(O)C(=C)C1C(O)CC(C)C2C(=C(C)C(=O)C2)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385267-01	363679627.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)C1C(O)CC(C)C2C(=C(C)C(=O)C2)C1	O=C(O)C(=C)C1C(O)CC(C)C2C(=C(C)C(=O)C2)C1
NCGC00384956-01	O=C(O)C(=C)C1CC(O)C2(C)C(C(=C)CCC2)C1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384956-01	363679457.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)C1CC(O)C2(C)C(C(=C)CCC2)C1	O=C(O)C(=C)C1CC(O)C2(C)C(C(=C)CCC2)C1
NCGC00381105-01	O=C(O)C(=C)C1CC(O)C2(C)C(C(O)(C)CCC2)C1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Borreria | Family: N/A | Species: verticillata		1	NCGC00381105-01	363678972.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)C1CC(O)C2(C)C(C(O)(C)CCC2)C1	O=C(O)C(=C)C1CC(O)C2(C)C(C(O)(C)CCC2)C1
NCGC00347724-02	O=C(O)C(=C)C1CC(OC(=O)CC(CC)C)C2(C)C(C(=C)CCC2)C1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Borreria | Family: N/A | Species: verticillata		1	NCGC00347724-02	363677674.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)C1CC(OC(=O)CC(CC)C)C2(C)C(C(=C)CCC2)C1	O=C(O)C(=C)C1CC(OC(=O)CC(CC)C)C2(C)C(C(=C)CCC2)C1
NCGC00385873-01	O=C(O)C(=C)C1CC2(C)OC(=O)CCC2C(C)CC1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385873-01	363679981.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)C1CC2(C)OC(=O)CCC2C(C)CC1	O=C(O)C(=C)C1CC2(C)OC(=O)CCC2C(C)CC1
NCGC00385464-01	O=C(O)C(=C)C1CC2C(=C)C(O)CCC2(C)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385464-01	363679754.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)C1CC2C(=C)C(O)CCC2(C)CC1	O=C(O)C(=C)C1CC2C(=C)C(O)CCC2(C)CC1
NCGC00385647-01	O=C(O)C(=C)C1CC2C(O)(C)C(O)CCC2(C)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385647-01	363679855.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)C1CC2C(O)(C)C(O)CCC2(C)CC1	O=C(O)C(=C)C1CC2C(O)(C)C(O)CCC2(C)CC1
NCGC00179704-04	O=C(O)C(=C)C1CC2C(O)(C)CCCC2(C)CC1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Dittrichia | Family: Compositae | Species: viscosa		1	NCGC00179704-04	363676955.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)C1CC2C(O)(C)CCCC2(C)CC1	O=C(O)C(=C)C1CC2C(O)(C)CCCC2(C)CC1
NCGC00169093-02	O=C(O)C(=C)C1[C@@H](O)CC2(C)C(=C(C)CCC2)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Artemisia | Family: N/A | Species: pectinata		1	NCGC00169093-02	363676769.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)C1[C@@H](O)CC2(C)C(=C(C)CCC2)C1	O=C(O)C(=C)C1[C@@H](O)CC2(C)C(=C(C)CCC2)C1
NCGC00385455-01	O=C(O)C(=C)CCO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385455-01	363679749.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)CCO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O=C(O)C(=C)CCO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00385912-01	O=C(O)C(=C)[C@@H]1CC=C(CCC(=O)C)[C@@H](C)CC1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Xanthium | Family: Compositae | Species: pungens		1	NCGC00385912-01	363680003.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)[C@@H]1CC=C(CCC(=O)C)[C@@H](C)CC1	O=C(O)C(=C)[C@@H]1CC=C(CCC(=O)C)[C@@H](C)CC1
NCGC00385910-01	O=C(O)C(=C)[C@@H]1[C@H]2O[C@]3([C@@H](C)C2)[C@@](C)(C(=O)CC3)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385910-01	363680001.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)[C@@H]1[C@H]2O[C@]3([C@@H](C)C2)[C@@](C)(C(=O)CC3)C1	O=C(O)C(=C)[C@@H]1[C@H]2O[C@]3([C@@H](C)C2)[C@@](C)(C(=O)CC3)C1
NCGC00385301-01	O=C(O)C(=C)[C@@H]1[C@H]2O[C@]3([C@@H](C)C2)[C@@](C)([C@@H](O)CC3)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385301-01	363679659.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)[C@@H]1[C@H]2O[C@]3([C@@H](C)C2)[C@@](C)([C@@H](O)CC3)C1	O=C(O)C(=C)[C@@H]1[C@H]2O[C@]3([C@@H](C)C2)[C@@](C)([C@@H](O)CC3)C1
NCGC00180717-02	O=C(O)C(=C)[C@@]1(O)C[C@H]2C(=C)CCC[C@]2(C)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Cassia | Family: N/A | Species: longifolia		1	NCGC00180717-02	363677053.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)[C@@]1(O)C[C@H]2C(=C)CCC[C@]2(C)CC1	O=C(O)C(=C)[C@@]1(O)C[C@H]2C(=C)CCC[C@]2(C)CC1
NCGC00180565-02	O=C(O)C(=C)[C@H]1CC2=C(C)C(=O)C[C@H]2[C@@H](C)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180565-02	363677036.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)[C@H]1CC2=C(C)C(=O)C[C@H]2[C@@H](C)CC1	O=C(O)C(=C)[C@H]1CC2=C(C)C(=O)C[C@H]2[C@@H](C)CC1
NCGC00180293-02	O=C(O)C(=C)[C@H]1CC2C(=C)[C@H](O)CC[C@]2(C)CC1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Pulicaria | Family: Compositae | Species: dysenterica		1	NCGC00180293-02	363677008.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)[C@H]1CC2C(=C)[C@H](O)CC[C@]2(C)CC1	O=C(O)C(=C)[C@H]1CC2C(=C)[C@H](O)CC[C@]2(C)CC1
NCGC00169889-02	O=C(O)C(=C)[C@H]1C[C@H]2[C@@](O)(C)CCC[C@]2(C)CC1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Pulicaria | Family: Compositae | Species: dysenterica		1	NCGC00169889-02	363676904.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)[C@H]1C[C@H]2[C@@](O)(C)CCC[C@]2(C)CC1	O=C(O)C(=C)[C@H]1C[C@H]2[C@@](O)(C)CCC[C@]2(C)CC1
NCGC00180350-02	O=C(O)C(=C)[C@H]1C[C@]2(C(=O)C)[C@@H](O)CC[C@]2(C)CC1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Pulicaria | Family: Compositae | Species: dysenterica		1	NCGC00180350-02	363677012.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)[C@H]1C[C@]2(C(=O)C)[C@@H](O)CC[C@]2(C)CC1	O=C(O)C(=C)[C@H]1C[C@]2(C(=O)C)[C@@H](O)CC[C@]2(C)CC1
NCGC00169769-02	O=C(O)C(=C)[C@H]1C[C@]2(C)[C@@H](C)CCCC2=CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169769-02	363676882.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)[C@H]1C[C@]2(C)[C@@H](C)CCCC2=CC1	O=C(O)C(=C)[C@H]1C[C@]2(C)[C@@H](C)CCCC2=CC1
NCGC00384653-01	O=C(O)C(=C)[C@H]1[C@H](O)[C@H]2C(=C)CCC[C@]2(C)CC1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Laggera | Family: Compositae | Species: pterodonta		1	NCGC00384653-01	363679293.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=C)[C@H]1[C@H](O)[C@H]2C(=C)CCC[C@]2(C)CC1	O=C(O)C(=C)[C@H]1[C@H](O)[C@H]2C(=C)CCC[C@]2(C)CC1
NCGC00347876-02	O=C(O)C(=O)/C(=C/C[C@H]1C(=C)CCC2C(C)(C)CCC[C@]12C)/CO		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347876-02	363677714.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(=O)/C(=C/C[C@H]1C(=C)CCC2C(C)(C)CCC[C@]12C)/CO	O=C(O)C(=O)/C(=C/C[C@H]1C(=C)CCC2C(C)(C)CCC[C@]12C)/CO
NCGC00166276-06	O=C(O)C(=O)C[C@H](O)[C@@H](NC(=O)C)[C@@H](O)[C@H](O)[C@H](O)CO		Inactive			1	N-ACETYLNEURAMIC ACID	434147038.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(=O)C[C@H](O)[C@@H](NC(=O)C)[C@@H](O)[C@H](O)[C@H](O)CO	O=C(O)C(=O)C[C@H](O)[C@@H](NC(=O)C)[C@@H](O)[C@H](O)[C@H](O)CO
NCGC00188429-03	O=C(O)C(=O)Nc1cc(-c2[nH]nnn2)ccc1		Inactive	Mediator Release Inhibitor		1	Acitazanolast	384568449.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(=O)Nc1cc(-c2[nH]nnn2)ccc1	O=C(O)C(=O)Nc1cc(-c2[nH]nnn2)ccc1
NCGC00188429-02	O=C(O)C(=O)Nc1cc(-c2n[nH]nn2)ccc1		Inactive	Mediator Release Inhibitor		1	Acitazanolast	170466060.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(=O)Nc1cc(-c2n[nH]nn2)ccc1	O=C(O)C(=O)Nc1cc(-c2n[nH]nn2)ccc1
NCGC00249898-01	O=C(O)C(=O)c1cc(C)c(C)cc1		Inactive			1	Sodium 3, 4-dimethylphenyl-glyoxylate	170465549.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])C(=O)c1cc(C)c(C)cc1.[Na+]	O=C([O-])C(=O)c1cc(C)c(C)cc1.[Na+]
NCGC00022579-05	O=C(O)C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1ccccc1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	Carbenicillin disodium	170465106.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C([O-])C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)c1ccccc1.[Na+].[Na+]	O=C([O-])C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)c1ccccc1.[Na+].[Na+]
NCGC00388518-02	O=C(O)C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1cscc1		Inactive			1	Ticarcillin sodium	405559121.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)c1cscc1	O=C(O)C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)c1cscc1
NCGC00381253-01	O=C(O)C(C(CC)C)N1C(=O)c2c(C(=O)O)c(OC)c(C)c(OCC=C(C)C)c2C1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381253-01	363679052.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(C(CC)C)N1C(=O)c2c(C(=O)O)c(OC)c(C)c(OCC=C(C)C)c2C1	O=C(O)C(C(CC)C)N1C(=O)c2c(C(=O)O)c(OC)c(C)c(OCC=C(C)C)c2C1
NCGC00347719-02	O=C(O)C(C)(C)C=1C(CC(=O)O)C2(C)C(=O)CC3(C)C(C)(C2CC=1)CC(O)C3C(O)(C(=O)/C=C/C(OC(=O)C)(C)C)C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Lagenaria | Family: Cucurbitaceae | Species: siceraria		1	NCGC00347719-02	363677672.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(C)(C)C=1C(CC(=O)O)C2(C)C(=O)CC3(C)C(C)(C2CC=1)CC(O)C3C(O)(C(=O)/C=C/C(OC(=O)C)(C)C)C	O=C(O)C(C)(C)C=1C(CC(=O)O)C2(C)C(=O)CC3(C)C(C)(C2CC=1)CC(O)C3C(O)(C(=O)/C=C/C(OC(=O)C)(C)C)C
NCGC00015453-08	O=C(O)C(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1		Inactive	Histamine H1 receptor Antagonist		1	Fexofenadine hydrochloride	170464669.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1.Cl	O=C(O)C(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1.Cl
NCGC00262907-01	O=C(O)C(C)(C)c1ccc(CCN2CCC(c3n(CCOCC)c4c(n3)cccc4)CC2)cc1		Inactive			1	Bilastine	170466329.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(C)(C)c1ccc(CCN2CCC(c3n(CCOCC)c4c(n3)cccc4)CC2)cc1	O=C(O)C(C)(C)c1ccc(CCN2CCC(c3n(CCOCC)c4c(n3)cccc4)CC2)cc1
NCGC00385238-01	O=C(O)C(C)C1C2(C)C(C)(C3C(=O)C=C4C(C)(C)C(=O)CCC4C3(C)CC2)CC1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385238-01	363679612.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(C)C1C2(C)C(C)(C3C(=O)C=C4C(C)(C)C(=O)CCC4C3(C)CC2)CC1	O=C(O)C(C)C1C2(C)C(C)(C3C(=O)C=C4C(C)(C)C(=O)CCC4C3(C)CC2)CC1
NCGC00385586-01	O=C(O)C(C)C1OC(C(C(O)CC)C)CC1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385586-01	363679822.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(C)C1OC(C(C(O)CC)C)CC1	O=C(O)C(C)C1OC(C(C(O)CC)C)CC1
NCGC00183658-01	O=C(O)C(C)c1c2c(c(C3CCCCC3)cc1)cccc2		Inactive	Prostaglandin G/H synthase 2 Inhibitor		1	Quadrisol	144207184.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(C)c1c2c(c(C3CCCCC3)cc1)cccc2	O=C(O)C(C)c1c2c(c(C3CCCCC3)cc1)cccc2
NCGC00015578-12&NCGC00015578-18	O=C(O)C(C)c1cc(C(=O)c2ccccc2)ccc1		Inactive	non-steroidal antiinflammatory		2	Ketoprofen	170465449.0&384567866.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)C(C)c1cc(C(=O)c2ccccc2)ccc1	O=C(O)C(C)c1cc(C(=O)c2ccccc2)ccc1
NCGC00167980-02	O=C(O)C(C)c1cc2c(Oc3ncccc3C2)cc1		Inactive	prostaglandin biosynthetic process Inhibitor		1	Pranoprofen	170465811.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(C)c1cc2c(Oc3ncccc3C2)cc1	O=C(O)C(C)c1cc2c(Oc3ncccc3C2)cc1
NCGC00183878-01&NCGC00263585-01	O=C(O)C(C)c1cc2c(Sc3c(C(=O)C2)cccc3)cc1		Inactive	Cyclooxygenase Inhibitor		2	Zaltoprofen	124894594.0&170465838.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)C(C)c1cc2c(Sc3c(C(=O)C2)cccc3)cc1	O=C(O)C(C)c1cc2c(Sc3c(C(=O)C2)cccc3)cc1
NCGC00183010-01	O=C(O)C(C)c1ccc(/C=C\2/C(=O)CCCC/2)cc1		Inactive	Prostaglandin G/H synthase 2 Inhibitor		1	Pelubiprofen	144206823.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)C(C)c1ccc(/C=C\2/C(=O)CCCC/2)cc1	O=C(O)C(C)c1ccc(/C=C\2/C(=O)CCCC/2)cc1
NCGC00094916-06&NCGC00094916-09	O=C(O)C(C)c1ccc(C(=O)c2sccc2)cc1		Inactive	Prostaglandin G/H synthase 2 Inhibitor		2	Suprofen&.	170465412.0&434146900.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)C(C)c1ccc(C(=O)c2sccc2)cc1	O=C(O)C(C)c1ccc(C(=O)c2sccc2)cc1
NCGC00015529-15&NCGC00015529-22	O=C(O)C(C)c1ccc(CC(C)C)cc1		Inactive	Cyclooxygenase-1/2 Inhibitor		2	Ibuprofen lysine	170464979.0&384567862.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	O=C(O)C(C)c1ccc(CC(C)C)cc1	O=C(O)C(C)c1ccc(CC(C)C)cc1
NCGC00015594-09	O=C(O)C(C)c1ccc(CC2C(=O)CCC2)cc1		Inactive			1	LOXOPROFEN SODIUM		2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)C(C)c1ccc(CC2C(=O)CCC2)cc1	O=C(O)C(C)c1ccc(CC2C(=O)CCC2)cc1
NCGC00522017-01	O=C(O)C(C)c1ccc(NCC(=C)C)cc1		Inactive	Cyclooxygenase-2 Inhibitor		1	rac Alminoprofen	405558807.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(C)c1ccc(NCC(=C)C)cc1	O=C(O)C(C)c1ccc(NCC(=C)C)cc1
NCGC00179573-03	O=C(O)C(C)c1sc(C(=O)c2ccccc2)cc1		Inactive	Cyclooxygenase Inhibitor		1	Tiaprofenic acid	170465577.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)C(C)c1sc(C(=O)c2ccccc2)cc1	O=C(O)C(C)c1sc(C(=O)c2ccccc2)cc1
NCGC00390568-02	O=C(O)C(CC(=O)O[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@@H]3[C@](C)([C@@]4(C)[C@@H]([C@H]5[C@H](C(=C)C)CC[C@]5(C(=O)O)CC4)CC3)CC2)CC1)(C)C		Inactive	Gag-Pol polyprotein Inhibitor		1	Bevirimat	434147142.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	19.6707865159	O=C(O)C(CC(=O)O[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@@H]3[C@](C)([C@@]4(C)[C@@H]([C@H]5[C@H](C(=C)C)CC[C@]5(C(=O)O)CC4)CC3)CC2)CC1)(C)C	O=C(O)C(CC(=O)O[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@@H]3[C@](C)([C@@]4(C)[C@@H]([C@H]5[C@H](C(=C)C)CC[C@]5(C(=O)O)CC4)CC3)CC2)CC1)(C)C
NCGC00095055-08&NCGC00095055-12&NCGC00095055-13	O=C(O)C(CC)C1OC(C(C(O)C(C(=O)C(CC)C2C(C)CC(C)C3(O[C@]4(C(O)C=C3)O[C@@](C)(C3OC(C)[C@](O)(CC)CC3)CC4)O2)C)C)C(C)CC1		Inactive	Anticoccidial/Antibacterial		3	Salinomycin&SALINOMYCIN, SODIUM	434147206.0&384568142.0	Anti-infectives&Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		O=C([O-])C(CC)C1OC(C(C(O)C(C(=O)C(CC)C2C(C)CC(C)C3(O[C@]4(C(O)C=C3)O[C@@](C)(C3OC(C)[C@](O)(CC)CC3)CC4)O2)C)C)C(C)CC1	O=C([O-])C(CC)C1OC(C(C(O)C(C(=O)C(CC)C2C(C)CC(C)C3(O[C@]4(C(O)C=C3)O[C@@](C)(C3OC(C)[C@](O)(CC)CC3)CC4)O2)C)C)C(C)CC1
NCGC00380811-02	O=C(O)C(CC1(O)c2c(N3C(=O)C(C)(C)N(O)C13)cccc2)N1C(=O)c2c(N=C1)cccc2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380811-02	363678793.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(CC1(O)c2c(N3C(=O)C(C)(C)N(O)C13)cccc2)N1C(=O)c2c(N=C1)cccc2	O=C(O)C(CC1(O)c2c(N3C(=O)C(C)(C)N(O)C13)cccc2)N1C(=O)c2c(N=C1)cccc2
NCGC00380812-02	O=C(O)C(CC1(O)c2c(N3C(=O)C(C)(C)NC13)cccc2)N1C(=O)c2c(N=C1)cccc2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380812-02	363678794.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(CC1(O)c2c(N3C(=O)C(C)(C)NC13)cccc2)N1C(=O)c2c(N=C1)cccc2	O=C(O)C(CC1(O)c2c(N3C(=O)C(C)(C)NC13)cccc2)N1C(=O)c2c(N=C1)cccc2
NCGC00380598-01	O=C(O)C(CC1C(=O)N2C(C(=O)NC(C(CC)C)C(=O)N(C)C(C(C)C)C(=O)N(C)C(C)C(=O)NCCC(=O)O1)CCC2)C		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380598-01	363678666.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(CC1C(=O)N2C(C(=O)NC(C(CC)C)C(=O)N(C)C(C(C)C)C(=O)N(C)C(C)C(=O)NCCC(=O)O1)CCC2)C	O=C(O)C(CC1C(=O)N2C(C(=O)NC(C(CC)C)C(=O)N(C)C(C(C)C)C(=O)N(C)C(C)C(=O)NCCC(=O)O1)CCC2)C
NCGC00381332-01	O=C(O)C(CCC(=O)N)N1C(=O)c2c(c3OC4(C5(C)C(C(C)(C)C(O)CC5)CCC4C)Cc3c(O)c2)C1		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381332-01	363679093.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(CCC(=O)N)N1C(=O)c2c(c3OC4(C5(C)C(C(C)(C)C(O)CC5)CCC4C)Cc3c(O)c2)C1	O=C(O)C(CCC(=O)N)N1C(=O)c2c(c3OC4(C5(C)C(C(C)(C)C(O)CC5)CCC4C)Cc3c(O)c2)C1
NCGC00381051-01	O=C(O)C(CCC(=O)O)N1C(=O)c2c(c(O)c(OC/C=C(/CC/C=C(\CCC=C(C)C)/C)\C)c(OC)c2)C1		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: Aspergillus ? | Family: N/A | Species: N/A		1	NCGC00381051-01	363678946.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(CCC(=O)O)N1C(=O)c2c(c(O)c(OC/C=C(/CC/C=C(\CCC=C(C)C)/C)\C)c(OC)c2)C1	O=C(O)C(CCC(=O)O)N1C(=O)c2c(c(O)c(OC/C=C(/CC/C=C(\CCC=C(C)C)/C)\C)c(OC)c2)C1
NCGC00169069-02	O=C(O)C(CCC(=O)O)N1C(=O)c2c(c3OC(CC/C=C(/CCC=C(C)C)\C)(C)C(O)Cc3c(O)c2)C1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169069-02	363676760.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(CCC(=O)O)N1C(=O)c2c(c3OC(CC/C=C(/CCC=C(C)C)\C)(C)C(O)Cc3c(O)c2)C1	O=C(O)C(CCC(=O)O)N1C(=O)c2c(c3OC(CC/C=C(/CCC=C(C)C)\C)(C)C(O)Cc3c(O)c2)C1
NCGC00381038-01	O=C(O)C(CCC(=O)O)N1C(=O)c2c(c3OC4C(O)(C)CCC5C(CCC=C(C)C)(C)Oc(c3C45)c2)C1		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381038-01	363678937.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(CCC(=O)O)N1C(=O)c2c(c3OC4C(O)(C)CCC5C(CCC=C(C)C)(C)Oc(c3C45)c2)C1	O=C(O)C(CCC(=O)O)N1C(=O)c2c(c3OC4C(O)(C)CCC5C(CCC=C(C)C)(C)Oc(c3C45)c2)C1
NCGC00091149-21&NCGC00091149-26	O=C(O)C(CCC)CCC		Inactive			2	VALPROATE SODIUM&Valproic acid sodium salt (Sodium valproate)	434147193.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	O=C(O)C(CCC)CCC	O=C(O)C(CCC)CCC
NCGC00380395-01	O=C(O)C(CCCNC(=N)N)N1C(=O)c2c(c3OC4(C5(C)C(C(C)(C)C(O)CC5)CCC4C)Cc3c(O)c2)C1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380395-01	363678565.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(CCCNC(=N)N)N1C(=O)c2c(c3OC4(C5(C)C(C(C)(C)C(O)CC5)CCC4C)Cc3c(O)c2)C1	O=C(O)C(CCCNC(=N)N)N1C(=O)c2c(c3OC4(C5(C)C(C(C)(C)C(O)CC5)CCC4C)Cc3c(O)c2)C1
NCGC00016794-13&NCGC00016794-14	O=C(O)C(CCCOc1c(C)ccc(C)c1)(C)C		Inactive	PPARalpha Agonist		2	Gemfibrozil	170464998.0&174007259.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&-9.331858412&0.0	O=C(O)C(CCCOc1c(C)ccc(C)c1)(C)C	O=C(O)C(CCCOc1c(C)ccc(C)c1)(C)C
NCGC00380501-01	O=C(O)C(CO)C1C(COC2C(O)C(O)C(O)C(CO)O2)=C(C)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380501-01	363678613.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(CO)C1C(COC2C(O)C(O)C(O)C(CO)O2)=C(C)CC1	O=C(O)C(CO)C1C(COC2C(O)C(O)C(O)C(CO)O2)=C(C)CC1
NCGC00386074-01	O=C(O)C(N(C(=O)c1ccccc1)C)Cc1c(OC)cccc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386074-01	363680092.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(N(C(=O)c1ccccc1)C)Cc1c(OC)cccc1	O=C(O)C(N(C(=O)c1ccccc1)C)Cc1c(OC)cccc1
NCGC00420882-01	O=C(O)C(N)(CC1c2c(Oc3c1cccc3)cccc2)C1C(C(=O)O)C1		Inactive	mgluR3 Receptor Antagonist;Signal Transduction Modulators;mgluR2 Receptor Antagonist		1	LY-341495	384569225.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(N)(CC1c2c(Oc3c1cccc3)cccc2)C1C(C(=O)O)C1	O=C(O)C(N)(CC1c2c(Oc3c1cccc3)cccc2)C1C(C(=O)O)C1
NCGC00274084-01	O=C(O)C(N)C(CC)C		Inactive			1	DL-Isoleucine	170465505.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)C(N)C(CC)C	O=C(O)C(N)C(CC)C
NCGC00183365-02	O=C(O)C(N)CCCN		Inactive	G-protein coupled receptor family C group 6 member A Agonist		1	ORNITHINE HYDROCHLORIDE	405558661.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(N)CCCN	O=C(O)C(N)CCCN
NCGC00390443-01	O=C(O)C(NC(=O)C(N)Cc1c2c([nH]c1)cccc2)CCC(=O)O		Inactive	Peroxisome proliferator-activated receptor gamma Antagonist		1	PPAR?Antagonist,G3335	363680895.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(NC(=O)C(N)Cc1c2c([nH]c1)cccc2)CCC(=O)O	O=C(O)C(NC(=O)C(N)Cc1c2c([nH]c1)cccc2)CCC(=O)O
NCGC00169728-02	O=C(O)C(NC(=O)C(NC(=O)C)Cc1ccccc1)C(C)C		Inactive	<MOA Unknown> | Class: peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169728-02	363676877.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(NC(=O)C(NC(=O)C)Cc1ccccc1)C(C)C	O=C(O)C(NC(=O)C(NC(=O)C)Cc1ccccc1)C(C)C
NCGC00344533-01	O=C(O)C(NC(=O)C)CCC(=O)N		Inactive			1	Nalpha-Acetyl-L-glutamine	170465810.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(NC(=O)C)CCC(=O)N	O=C(O)C(NC(=O)C)CCC(=O)N
NCGC00381382-01	O=C(O)C(NC(=O)C)Cc1c2C(=O)C=CC=Cc2[nH]c1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381382-01	363679116.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(NC(=O)C)Cc1c2C(=O)C=CC=Cc2[nH]c1	O=C(O)C(NC(=O)C)Cc1c2C(=O)C=CC=Cc2[nH]c1
NCGC00384987-01	O=C(O)C(NC(=O)C)Cc1ccc(OC)cc1		Inactive	<MOA Unknown> | Class: Amino acid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384987-01	363679469.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(NC(=O)C)Cc1ccc(OC)cc1	O=C(O)C(NC(=O)C)Cc1ccc(OC)cc1
NCGC00042134-05	O=C(O)C(NC(=O)C)Cc1ccccc1		Inactive	Dopamine receptor Agonist		1	Afalanine	363676544.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	13.1286031039	O=C(O)C(NC(=O)C)Cc1ccccc1	O=C(O)C(NC(=O)C)Cc1ccccc1
NCGC00389655-01	O=C(O)C(NC(=O)C1N(C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)CC(=O)O)CCCN=C(N)N)C(C)C)Cc2ccc(O)cc2)C(CC)C)Cc2[nH]cnc2)CCC1)Cc1ccccc1		Inactive			1	Angiotensin II	405558595.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(NC(=O)C1N(C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)CC(=O)O)CCCN=C(N)N)C(C)C)Cc2ccc(O)cc2)C(CC)C)Cc2[nH]cnc2)CCC1)Cc1ccccc1	O=C(O)C(NC(=O)C1N(C(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(N)CC(=O)O)CCCN=C(N)N)C(C)C)Cc2ccc(O)cc2)C(CC)C)Cc2[nH]cnc2)CCC1)Cc1ccccc1
NCGC00381359-01	O=C(O)C(NC(=O)C1NCCC1)Cc1ccccc1		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381359-01	363679105.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(NC(=O)C1NCCC1)Cc1ccccc1	O=C(O)C(NC(=O)C1NCCC1)Cc1ccccc1
NCGC00384850-01	O=C(O)C(NC(=O)CC(NC(=O)C(NC(=O)C(NC(=O)c1[nH]ccc1)CC)CO)c1ccccc1)CC		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384850-01	363679395.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(NC(=O)CC(NC(=O)C(NC(=O)C(NC(=O)c1[nH]ccc1)CC)CO)c1ccccc1)CC	O=C(O)C(NC(=O)CC(NC(=O)C(NC(=O)C(NC(=O)c1[nH]ccc1)CC)CO)c1ccccc1)CC
NCGC00384567-01	O=C(O)C(NC(=O)c1c(N)cccc1)C		Inactive	<MOA Unknown> | Class: peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384567-01	363679246.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(NC(=O)c1c(N)cccc1)C	O=C(O)C(NC(=O)c1c(N)cccc1)C
NCGC00169908-02	O=C(O)C(NC(=O)c1c(O)cc(OC(=O)c2c(O[C@H]3[C@H](OC(=O)C)[C@@H](O)[C@H](O)[C@@H](CO)O3)cc(OC(=O)c3c(OC)cc(OC)cc3C)cc2C)cc1C)C		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169908-02	363676909.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(NC(=O)c1c(O)cc(OC(=O)c2c(O[C@H]3[C@H](OC(=O)C)[C@@H](O)[C@H](O)[C@@H](CO)O3)cc(OC(=O)c3c(OC)cc(OC)cc3C)cc2C)cc1C)C	O=C(O)C(NC(=O)c1c(O)cc(OC(=O)c2c(O[C@H]3[C@H](OC(=O)C)[C@@H](O)[C@H](O)[C@@H](CO)O3)cc(OC(=O)c3c(OC)cc(OC)cc3C)cc2C)cc1C)C
NCGC00015038-11	O=C(O)C(NC(=O)c1ccc(NCc2nc3c(N)nc(N)nc3nc2)cc1)CCC(=O)O		Inactive	Dihydrofolate Reductase (DHFR) Inhibitor		1	Aminopterin	384567800.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(NC(=O)c1ccc(NCc2nc3c(N)nc(N)nc3nc2)cc1)CCC(=O)O	O=C(O)C(NC(=O)c1ccc(NCc2nc3c(N)nc(N)nc3nc2)cc1)CCC(=O)O
NCGC00179305-04	O=C(O)C(NCNC(=O)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3C[C@H]2[C@H](N(C)C)C=1O)CCCCN		Inactive			1	Lymecycline	405558898.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(NCNC(=O)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3C[C@H]2[C@H](N(C)C)C=1O)CCCCN	O=C(O)C(NCNC(=O)C=1C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@](O)(C)[C@H]3C[C@H]2[C@H](N(C)C)C=1O)CCCCN
NCGC00015185-06	O=C(O)C(NN)(Cc1cc(O)c(O)cc1)C		Inactive	Aromatic-L-amino-acid decarboxylase Inhibitor		1	Carbidopa	384567819.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-6.299554052	O=C(O)C(NN)(Cc1cc(O)c(O)cc1)C	O=C(O)C(NN)(Cc1cc(O)c(O)cc1)C
NCGC00167547-02	O=C(O)C(O)(C(C(=O)O)CCCCCCCCCCCCCCCC)CC(=O)O		Inactive			1	Agaric acid	170465652.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(O)(C(C(=O)O)CCCCCCCCCCCCCCCC)CC(=O)O	O=C(O)C(O)(C(C(=O)O)CCCCCCCCCCCCCCCC)CC(=O)O
NCGC00380940-01	O=C(O)C(O)(C)C1C2C(C)(C3C(C)(C4(C)C(C5(C)C(C(COC6C(O)C(O)C(O)C(CO)O6)(C)C(O)CC5)CC4)CC3)CC2)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380940-01	363678872.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(O)(C)C1C2C(C)(C3C(C)(C4(C)C(C5(C)C(C(COC6C(O)C(O)C(O)C(CO)O6)(C)C(O)CC5)CC4)CC3)CC2)CC1	O=C(O)C(O)(C)C1C2C(C)(C3C(C)(C4(C)C(C5(C)C(C(COC6C(O)C(O)C(O)C(CO)O6)(C)C(O)CC5)CC4)CC3)CC2)CC1
NCGC00164253-04	O=C(O)C(O)(CC(=O)O)CC(=O)O		Inactive			1	LITHIUM CITRATE	405558476.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])C(O)(CC(=O)[O-])CC(=O)[O-]	O=C([O-])C(O)(CC(=O)[O-])CC(=O)[O-]
NCGC00381200-01	O=C(O)C(O)(CC1(C)OC(=O)C=C(C)C1)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381200-01	363679018.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(O)(CC1(C)OC(=O)C=C(C)C1)C	O=C(O)C(O)(CC1(C)OC(=O)C=C(C)C1)C
NCGC00380693-01	O=C(O)C(O)(CC1C(O)=C(C(=O)C2C(/C(=C/C)/C)C=CC3C2C(C)CC(C)C3)C(=O)N1)C		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380693-01	363678712.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(O)(CC1C(O)=C(C(=O)C2C(/C(=C/C)/C)C=CC3C2C(C)CC(C)C3)C(=O)N1)C	O=C(O)C(O)(CC1C(O)=C(C(=O)C2C(/C(=C/C)/C)C=CC3C2C(C)CC(C)C3)C(=O)N1)C
NCGC00381429-01	O=C(O)C(O)C(C)c1c2c([nH]c1)cccc2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381429-01	363679140.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(O)C(C)c1c2c([nH]c1)cccc2	O=C(O)C(O)C(C)c1c2c([nH]c1)cccc2
NCGC00347131-03	O=C(O)C(O)C(O)C(=O)O		Inactive			1	D(-)-Tartaric acid	405558948.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(O)C(O)C(=O)O	O=C(O)C(O)C(O)C(=O)O
NCGC00043225-04	O=C(O)C(O)CC(=O)O		Inactive			1	Disodium 2-hydroxybutanedioate	170465632.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C([O-])C(O)CC(=O)[O-].[Na+].[Na+]	O=C([O-])C(O)CC(=O)[O-].[Na+].[Na+]
NCGC00346605-03	O=C(O)C(O)Cc1cc(O)c(O)cc1		Inactive	Pregnane X Receptor (PXR) Regulator		1	Sodium Danshensu	384568855.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])C(O)Cc1cc(O)c(O)cc1	O=C([O-])C(O)Cc1cc(O)c(O)cc1
NCGC00264001-02	O=C(O)C(O)[C@H](O)[C@H](O)[C@H](O)[C@H](O)CO		Inactive			1	CALCIUM GLUCEPTATE	405558708.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])C(O)[C@H](O)[C@H](O)[C@H](O)[C@H](O)CO	O=C([O-])C(O)[C@H](O)[C@H](O)[C@H](O)[C@H](O)CO
NCGC00390668-02	O=C(O)C(OC(C)(C)C)c1c(C)nc2c(c1-c1cc3c(OCCC3)cc1)cccc2		Inactive			1	(±)-BI-D	434147144.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(OC(C)(C)C)c1c(C)nc2c(c1-c1cc3c(OCCC3)cc1)cccc2	O=C(O)C(OC(C)(C)C)c1c(C)nc2c(c1-c1cc3c(OCCC3)cc1)cccc2
NCGC00346710-03	O=C(O)C(OCc1nn(Cc2ccccc2)c2c1cccc2)(C)C		Inactive	non-steroidal antiinflammatory		1	Bindarit	363677530.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(OCc1nn(Cc2ccccc2)c2c1cccc2)(C)C	O=C(O)C(OCc1nn(Cc2ccccc2)c2c1cccc2)(C)C
NCGC00384819-01	O=C(O)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C=C/c2cc(OC)c3OC(c4cc(OC)c(O)cc4)C(CO)c3c2)O1)(C)C		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384819-01	363679375.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C=C/c2cc(OC)c3OC(c4cc(OC)c(O)cc4)C(CO)c3c2)O1)(C)C	O=C(O)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C=C/c2cc(OC)c3OC(c4cc(OC)c(O)cc4)C(CO)c3c2)O1)(C)C
NCGC00384999-01	O=C(O)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C=C/c2ccc(O)cc2)O1)=Cc1ccccc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384999-01	363679477.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C=C/c2ccc(O)cc2)O1)=Cc1ccccc1	O=C(O)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C=C/c2ccc(O)cc2)O1)=Cc1ccccc1
NCGC00385424-01	O=C(O)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)c2cc(OC)c(O)c(OC)c2)O1)(C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385424-01	363679735.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)c2cc(OC)c(O)c(OC)c2)O1)(C)C	O=C(O)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)c2cc(OC)c(O)c(OC)c2)O1)(C)C
NCGC00384887-01	O=C(O)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)c1ccccc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384887-01	363679417.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)c1ccccc1	O=C(O)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)c1ccccc1
NCGC00485114-01	O=C(O)C(Oc1cc([C@H]2CN(C(=O)Cc3ccc(C(C)C)cc3)CCC2)ccc1)(C)C		Inactive	Peroxisome proliferator-activated receptor alpha Agonist		1	CP-775146	363681227.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C([O-])C(Oc1cc([C@H]2CN(C(=O)Cc3ccc(C(C)C)cc3)CCC2)ccc1)(C)C	O=C([O-])C(Oc1cc([C@H]2CN(C(=O)Cc3ccc(C(C)C)cc3)CCC2)ccc1)(C)C
NCGC00167453-02&NCGC00167453-04	O=C(O)C(Oc1ccc(C2(c3ccc(OC(C(=O)O)(CC)C)cc3)CCCCC2)cc1)(CC)C		Inactive	treatment of lipoprotein diseases		2	Clinofibrate	174007296.0&384568314.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)C(Oc1ccc(C2(c3ccc(OC(C(=O)O)(CC)C)cc3)CCCCC2)cc1)(CC)C	O=C(O)C(Oc1ccc(C2(c3ccc(OC(C(=O)O)(CC)C)cc3)CCCCC2)cc1)(CC)C
NCGC00390260-01	O=C(O)C(Oc1ccc(CC(=O)Nc2cc(C)cc(C)c2)cc1)(C)C		Inactive	Chemosensitizer		1	Efaproxiral	363680869.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(Oc1ccc(CC(=O)Nc2cc(C)cc(C)c2)cc1)(C)C	O=C(O)C(Oc1ccc(CC(=O)Nc2cc(C)cc(C)c2)cc1)(C)C
NCGC00385958-01	O=C(O)C1(C(O)(CC)C)CC(=O)OC1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385958-01	363680028.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C(O)(CC)C)CC(=O)OC1	O=C(O)C1(C(O)(CC)C)CC(=O)OC1
NCGC00384933-01	O=C(O)C1(C)C(O)CCC2(C)C1CCC1(C)C3(C(=O)O)C(C4C(C(=O)O)(CC3)CCC4C(=C)C)CCC21		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384933-01	363679446.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C(O)CCC2(C)C1CCC1(C)C3(C(=O)O)C(C4C(C(=O)O)(CC3)CCC4C(=C)C)CCC21	O=C(O)C1(C)C(O)CCC2(C)C1CCC1(C)C3(C(=O)O)C(C4C(C(=O)O)(CC3)CCC4C(=C)C)CCC21
NCGC00385334-01	O=C(O)C1(C)C(O)CCC2(C)C3C(C)(C4(C)C(C5C(C)(CC4)CCC(C)C5C)=CC3)CCC12		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385334-01	363679685.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C(O)CCC2(C)C3C(C)(C4(C)C(C5C(C)(CC4)CCC(C)C5C)=CC3)CCC12	O=C(O)C1(C)C(O)CCC2(C)C3C(C)(C4(C)C(C5C(C)(CC4)CCC(C)C5C)=CC3)CCC12
NCGC00347586-02	O=C(O)C1(C)C(O)CCC2(C)C3C(C)(C4(C)C(C5C(O)(C)C(C)CCC5(C(=O)O)CC4)=CC3)CCC12		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347586-02	363677631.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C(O)CCC2(C)C3C(C)(C4(C)C(C5C(O)(C)C(C)CCC5(C(=O)O)CC4)=CC3)CCC12	O=C(O)C1(C)C(O)CCC2(C)C3C(C)(C4(C)C(C5C(O)(C)C(C)CCC5(C(=O)O)CC4)=CC3)CCC12
NCGC00380721-01	O=C(O)C1(C)C2C(C)(C(=O)C3(C(O)CC(C=C)(C)C3)CC2)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380721-01	363678737.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(C(=O)C3(C(O)CC(C=C)(C)C3)CC2)CCC1	O=C(O)C1(C)C2C(C)(C(=O)C3(C(O)CC(C=C)(C)C3)CC2)CCC1
NCGC00385346-01	O=C(O)C1(C)C2C(C)(C(CC/C(=C\CO)/C)C(=C)CC2)CCC1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Juniperus | Family: Coniferea | Species: indica		1	NCGC00385346-01	363679691.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(C(CC/C(=C\CO)/C)C(=C)CC2)CCC1	O=C(O)C1(C)C2C(C)(C(CC/C(=C\CO)/C)C(=C)CC2)CCC1
NCGC00347803-02	O=C(O)C1(C)C2C(C)(C(CC/C(=C\CO)/CO)C(=C)CC2)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347803-02	363677691.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(C(CC/C(=C\CO)/CO)C(=C)CC2)CCC1	O=C(O)C1(C)C2C(C)(C(CC/C(=C\CO)/CO)C(=C)CC2)CCC1
NCGC00169206-02	O=C(O)C1(C)C2C(C)(C(CC34C(O)C(O)C(=C)C(O)C3O4)C(C)=CC2)CCC1		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169206-02	363676789.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(C(CC34C(O)C(O)C(=C)C(O)C3O4)C(C)=CC2)CCC1	O=C(O)C1(C)C2C(C)(C(CC34C(O)C(O)C(=C)C(O)C3O4)C(C)=CC2)CCC1
NCGC00385344-01	O=C(O)C1(C)C2C(C)(C(CCC=3C(=O)OCC=3)C(=C)CC2)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385344-01	363679689.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(C(CCC=3C(=O)OCC=3)C(=C)CC2)CCC1	O=C(O)C1(C)C2C(C)(C(CCC=3C(=O)OCC=3)C(=C)CC2)CCC1
NCGC00380931-01	O=C(O)C1(C)C2C(C)(C34OC3(C(O)C2)CC(CCOC2C(O)C(O)C(O)C(CO)O2)(C)CC4)CCC1		Inactive	<MOA Unknown> | Class: diterpene | Genus: Geniculosporium | Family: N/A | Species: sp.		1	NCGC00380931-01	363678863.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(C34OC3(C(O)C2)CC(CCOC2C(O)C(O)C(O)C(CO)O2)(C)CC4)CCC1	O=C(O)C1(C)C2C(C)(C34OC3(C(O)C2)CC(CCOC2C(O)C(O)C(O)C(CO)O2)(C)CC4)CCC1
NCGC00380535-01	O=C(O)C1(C)C2C(C)(C3=CC(=O)C(C=C)(C)CC3CC2)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380535-01	363678637.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(C3=CC(=O)C(C=C)(C)CC3CC2)CCC1	O=C(O)C1(C)C2C(C)(C3=CC(=O)C(C=C)(C)CC3CC2)CCC1
NCGC00385046-01	O=C(O)C1(C)C2C(C)(C3=CCC(C=C)(C)CC3CC2)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385046-01	363679503.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(C3=CCC(C=C)(C)CC3CC2)CCC1	O=C(O)C1(C)C2C(C)(C3=CCC(C=C)(C)CC3CC2)CCC1
NCGC00380522-01	O=C(O)C1(C)C2C(C)(C3C(C(=O)C2)=CC(O)(C(C)C)CC3)CCC1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Pinus | Family: Pinaceae | Species: nigra nigra		1	NCGC00380522-01	363678629.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(C3C(C(=O)C2)=CC(O)(C(C)C)CC3)CCC1	O=C(O)C1(C)C2C(C)(C3C(C(=O)C2)=CC(O)(C(C)C)CC3)CCC1
NCGC00380636-01	O=C(O)C1(C)C2C(C)(C3C(C(=O)C2)=CC(OO)(C(C)C)CC3)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380636-01	363678684.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(C3C(C(=O)C2)=CC(OO)(C(C)C)CC3)CCC1	O=C(O)C1(C)C2C(C)(C3C(C(=O)C2)=CC(OO)(C(C)C)CC3)CCC1
NCGC00385643-01	O=C(O)C1(C)C2C(C)(C3C(C(O)C2)=CC(C=C)(C)CC3)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385643-01	363679853.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(C3C(C(O)C2)=CC(C=C)(C)CC3)CCC1	O=C(O)C1(C)C2C(C)(C3C(C(O)C2)=CC(C=C)(C)CC3)CCC1
NCGC00347612-02	O=C(O)C1(C)C2C(C)(C3C4(C5C(CO)(O5)C(C4)CC3)CC2)CCC1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347612-02	363677640.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(C3C4(C5C(CO)(O5)C(C4)CC3)CC2)CCC1	O=C(O)C1(C)C2C(C)(C3C4(C5C(CO)(O5)C(C4)CC3)CC2)CCC1
NCGC00347546-02	O=C(O)C1(C)C2C(C)(C3C4(CC(=O)C(C4)CC3)CC2)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347546-02	363677621.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(C3C4(CC(=O)C(C4)CC3)CC2)CCC1	O=C(O)C1(C)C2C(C)(C3C4(CC(=O)C(C4)CC3)CC2)CCC1
NCGC00384568-01	O=C(O)C1(C)C2C(C)(C3C4(CC(C(=O)O)C(C4)CC3)CC2)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384568-01	363679247.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	-15.1775969359	O=C(O)C1(C)C2C(C)(C3C4(CC(C(=O)O)C(C4)CC3)CC2)CCC1	O=C(O)C1(C)C2C(C)(C3C4(CC(C(=O)O)C(C4)CC3)CC2)CCC1
NCGC00169784-02	O=C(O)C1(C)C2C(C)(C3C4(CC(O)(CO)C(C4)CC3)CC2)CCC1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Aspilia | Family: Compositae | Species: mossambicensis		1	NCGC00169784-02	363676887.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(C3C4(CC(O)(CO)C(C4)CC3)CC2)CCC1	O=C(O)C1(C)C2C(C)(C3C4(CC(O)(CO)C(C4)CC3)CC2)CCC1
NCGC00385609-01	O=C(O)C1(C)C2C(C)(C3C4(CC5(C)C(C5C3)C4)CC2)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385609-01	363679837.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(C3C4(CC5(C)C(C5C3)C4)CC2)CCC1	O=C(O)C1(C)C2C(C)(C3C4(CC5(C)C(C5C3)C4)CC2)CCC1
NCGC00381358-01	O=C(O)C1(C)C2C(C)(C=3C4(CC(CO)C(C4)CC=3)CC2)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381358-01	363679104.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(C=3C4(CC(CO)C(C4)CC=3)CC2)CCC1	O=C(O)C1(C)C2C(C)(C=3C4(CC(CO)C(C4)CC=3)CC2)CCC1
NCGC00347651-02	O=C(O)C1(C)C2C(C)(c3c(C(=O)C2)cc(C(C)C)cc3)CCC1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Picea | Family: Pinaceae | Species: abies		1	NCGC00347651-02	363677654.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(c3c(C(=O)C2)cc(C(C)C)cc3)CCC1	O=C(O)C1(C)C2C(C)(c3c(C(=O)C2)cc(C(C)C)cc3)CCC1
NCGC00380719-01	O=C(O)C1(C)C2C(C)(c3c(C(O)C2)cc(C(C)C)cc3)CCC1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Picea | Family: Pinaceae | Species: abies		1	NCGC00380719-01	363678736.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(c3c(C(O)C2)cc(C(C)C)cc3)CCC1	O=C(O)C1(C)C2C(C)(c3c(C(O)C2)cc(C(C)C)cc3)CCC1
NCGC00380525-01	O=C(O)C1(C)C2C(C)(c3c(C(O)C2)cc(C(O)(C)C)cc3)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380525-01	363678630.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(C)C2C(C)(c3c(C(O)C2)cc(C(O)(C)C)cc3)CCC1	O=C(O)C1(C)C2C(C)(c3c(C(O)C2)cc(C(O)(C)C)cc3)CCC1
NCGC00380437-01	O=C(O)C1(O)C(C(=O)O)=CC(=O)C2C(C)(C)CCCC12C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380437-01	363678583.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(O)C(C(=O)O)=CC(=O)C2C(C)(C)CCCC12C	O=C(O)C1(O)C(C(=O)O)=CC(=O)C2C(C)(C)CCCC12C
NCGC00381448-01	O=C(O)C1(O)C(CO)=CC(O)C2C(C)(C)CCCC12C		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381448-01	363679147.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(O)C(CO)=CC(O)C2C(C)(C)CCCC12C	O=C(O)C1(O)C(CO)=CC(O)C2C(C)(C)CCCC12C
NCGC00180760-02	O=C(O)C1(O)C2OCC3(C(/C(=C(/CO)\C)/CC3)CC1)C2		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: Fusarium | Family: N/A | Species: N/A		1	NCGC00180760-02	363677062.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(O)C2OCC3(C(/C(=C(/CO)\C)/CC3)CC1)C2	O=C(O)C1(O)C2OCC3(C(/C(=C(/CO)\C)/CC3)CC1)C2
NCGC00170013-03	O=C(O)C1(O)C2OCC3(C(C(C(O)(C)C)=CC3)CC1)C2		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: Penicillium ? | Family: N/A | Species: N/A		1	NCGC00170013-03	363676927.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1(O)C2OCC3(C(C(C(O)(C)C)=CC3)CC1)C2	O=C(O)C1(O)C2OCC3(C(C(C(O)(C)C)=CC3)CC1)C2
NCGC00169053-03	O=C(O)C12C(C(C(=C)C)CC1)C1C(C)(C3(C)C(C4(C)C(C=O)C(O)C(C)(C)C4CC3)CC1)CC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Zizyphus | Family: Rhamnaceae | Species: xyloyrus		1	NCGC00169053-03	363676754.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C12C(C(C(=C)C)CC1)C1C(C)(C3(C)C(C4(C)C(C=O)C(O)C(C)(C)C4CC3)CC1)CC2	O=C(O)C12C(C(C(=C)C)CC1)C1C(C)(C3(C)C(C4(C)C(C=O)C(O)C(C)(C)C4CC3)CC1)CC2
NCGC00385826-01	O=C(O)C12C(C(O)(C)C(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(CO)(C)C(O)CC4)CC3)CC=1)CC2		Inactive	Staphylococcus aureus Inhibitor		1	NCGC00385826-01	363679958.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C12C(C(O)(C)C(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(CO)(C)C(O)CC4)CC3)CC=1)CC2	O=C(O)C12C(C(O)(C)C(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(CO)(C)C(O)CC4)CC3)CC=1)CC2
NCGC00180871-02	O=C(O)C12C(C(O)(C)C(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(CO)(C)[C@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Cordia | Family: Boraginaceae | Species: vignei		1	NCGC00180871-02	363677078.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C12C(C(O)(C)C(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(CO)(C)[C@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O)C12C(C(O)(C)C(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(CO)(C)[C@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00380146-01	O=C(O)C12C(C3(C)C4C(C)(C(=O)OC4O)CCC3)CCC(C(=C)C1)C2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380146-01	363678473.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C12C(C3(C)C4C(C)(C(=O)OC4O)CCC3)CCC(C(=C)C1)C2	O=C(O)C12C(C3(C)C4C(C)(C(=O)OC4O)CCC3)CCC(C(=C)C1)C2
NCGC00381217-01	O=C(O)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(OC7C(O)C(OC8C(O)C(OC9C(O)C(O)C(O)C(COC%10C(O)C(O)C(O)C(CO)O%10)O9)C(O)C(CO)O8)C(O)C(CO)O7)C(O)C(CO)O6)CC5)CC4)CC=3)CC1)CC(C)(C)C(O)C2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381217-01	363679030.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(OC7C(O)C(OC8C(O)C(OC9C(O)C(O)C(O)C(COC%10C(O)C(O)C(O)C(CO)O%10)O9)C(O)C(CO)O8)C(O)C(CO)O7)C(O)C(CO)O6)CC5)CC4)CC=3)CC1)CC(C)(C)C(O)C2	O=C(O)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(OC7C(O)C(OC8C(O)C(OC9C(O)C(O)C(O)C(COC%10C(O)C(O)C(O)C(CO)O%10)O9)C(O)C(CO)O8)C(O)C(CO)O7)C(O)C(CO)O6)CC5)CC4)CC=3)CC1)CC(C)(C)C(O)C2
NCGC00385553-01	O=C(O)C12C(C=3C(C)(C4(C)C(C5(C)C(C(CO)(C)C(O)CC5)C(O)C4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385553-01	363679804.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C12C(C=3C(C)(C4(C)C(C5(C)C(C(CO)(C)C(O)CC5)C(O)C4)CC=3)CC1)CC(C)(C)CC2	O=C(O)C12C(C=3C(C)(C4(C)C(C5(C)C(C(CO)(C)C(O)CC5)C(O)C4)CC=3)CC1)CC(C)(C)CC2
NCGC00384739-01	O=C(O)C12C(O)CC3(C)C4(C)C(C5(C)C(C(C)(C)C(OC6C(OC7C(OC8C(O)C(O)(CO)CO8)C(O)C(O)C(CO)O7)C(O)C(O)C(CO)O6)CC5)CC4)CC=C3C1CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384739-01	363679333.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C12C(O)CC3(C)C4(C)C(C5(C)C(C(C)(C)C(OC6C(OC7C(OC8C(O)C(O)(CO)CO8)C(O)C(O)C(CO)O7)C(O)C(O)C(CO)O6)CC5)CC4)CC=C3C1CC(C)(C)CC2	O=C(O)C12C(O)CC3(C)C4(C)C(C5(C)C(C(C)(C)C(OC6C(OC7C(OC8C(O)C(O)(CO)CO8)C(O)C(O)C(CO)O7)C(O)C(O)C(CO)O6)CC5)CC4)CC=C3C1CC(C)(C)CC2
NCGC00380217-01	O=C(O)C12C3(O)C(C(=O)CC1C(C)(C)CCC2)=CC(C=C)(C)CC3		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380217-01	363678501.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C12C3(O)C(C(=O)CC1C(C)(C)CCC2)=CC(C=C)(C)CC3	O=C(O)C12C3(O)C(C(=O)CC1C(C)(C)CCC2)=CC(C=C)(C)CC3
NCGC00346598-02	O=C(O)C1=CC(O)C(O)[C@H](O)C1		Inactive	plant biochemical intermediate		1	Shikimic acid	384568853.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C1=CC(O)C(O)[C@H](O)C1	O=C(O)C1=CC(O)C(O)[C@H](O)C1
NCGC00385483-01	O=C(O)C1=CC2(O)C3(C(C)CCC13)CC(C)(C)C2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385483-01	363679766.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1=CC2(O)C3(C(C)CCC13)CC(C)(C)C2	O=C(O)C1=CC2(O)C3(C(C)CCC13)CC(C)(C)C2
NCGC00381256-01	O=C(O)C1=CC2C(O)C(C)(C)CC32C(C)CCC13	5.5	Active	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00381256-01	363679053.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	3.0	47.919852768	O=C(O)C1=CC2C(O)C(C)(C)CC32C(C)CCC13	O=C(O)C1=CC2C(O)C(C)(C)CC32C(C)CCC13
NCGC00381403-01	O=C(O)C1=CC2C3(C(C)CCC13)CC(C)(C)C2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381403-01	363679127.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1=CC2C3(C(C)CCC13)CC(C)(C)C2	O=C(O)C1=CC2C3(C(C)CCC13)CC(C)(C)C2
NCGC00381328-01	O=C(O)C1=CC2C3(C(O)(CO)C(=O)OCC13)CC(C)(C)C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381328-01	363679089.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1=CC2C3(C(O)(CO)C(=O)OCC13)CC(C)(C)C2	O=C(O)C1=CC2C3(C(O)(CO)C(=O)OCC13)CC(C)(C)C2
NCGC00385027-01	O=C(O)C1=CCCC(=C)C2C(C(C)(C)C2)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385027-01	363679491.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1=CCCC(=C)C2C(C(C)(C)C2)CC1	O=C(O)C1=CCCC(=C)C2C(C(C)(C)C2)CC1
NCGC00169586-03	O=C(O)C1=COC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2C(C)CCC12		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Parentucellia | Family: Scrophulariaceae | Species: viscosa		1	NCGC00169586-03	363676844.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1=COC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2C(C)CCC12	O=C(O)C1=COC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2C(C)CCC12
NCGC00165772-06	O=C(O)C1C(=C)C(=O)OC1CCCCCCCC		Inactive	Fatty Acid Synthase (FAS) Inhibitor		1	C75	384568281.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C1C(=C)C(=O)OC1CCCCCCCC	O=C(O)C1C(=C)C(=O)OC1CCCCCCCC
NCGC00384815-01	O=C(O)C1C(C(=O)O)C(c2c(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)cc(OC)cc2)C1c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384815-01	363679371.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C(C(=O)O)C(c2c(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)cc(OC)cc2)C1c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC)cc1	O=C(O)C1C(C(=O)O)C(c2c(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)cc(OC)cc2)C1c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC)cc1
NCGC00485285-01	O=C(O)C1C(O)C(O)C(O)C(OC2C(O)C3(C)C(C4C(c5c(cc(O)cc5)CC4)CC3)C2)O1		Inactive			1	Estriol 16Î±-(Î²-D-glucuronide) sodium salt	363681277.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C(O)C(O)C(O)C(OC2C(O)C3(C)C(C4C(c5c(cc(O)cc5)CC4)CC3)C2)O1	O=C(O)C1C(O)C(O)C(O)C(OC2C(O)C3(C)C(C4C(c5c(cc(O)cc5)CC4)CC3)C2)O1
NCGC00485351-01	O=C(O)C1C(O)C(O)C(O)C(OC2C3(C)C(C4C(c5c(cc(O)cc5)CC4)CC3)CC2)O1		Inactive	Canalicular multispecific organic anion transporter 1 Binding Agent		1	Î²-Estradiol 17-(Î²-D-glucuronide) sodium salt	363681295.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C(O)C(O)C(O)C(OC2C3(C)C(C4C(c5c(cc(O)cc5)CC4)CC3)CC2)O1	O=C(O)C1C(O)C(O)C(O)C(OC2C3(C)C(C4C(c5c(cc(O)cc5)CC4)CC3)CC2)O1
NCGC00485278-01	O=C(O)C1C(O)C(O)C(O)C(OC2CC3C(C)(C4C(C5C(C)(C(C(O)C)CC5)CC4)CC3)CC2)O1		Inactive			1	5Î²-Pregnane-3Î±,20Î±-diol glucuronide	363681276.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C(O)C(O)C(O)C(OC2CC3C(C)(C4C(C5C(C)(C(C(O)C)CC5)CC4)CC3)CC2)O1	O=C(O)C1C(O)C(O)C(O)C(OC2CC3C(C)(C4C(C5C(C)(C(C(O)C)CC5)CC4)CC3)CC2)O1
NCGC00485349-01	O=C(O)C1C(O)C(O)C(O)C(Oc2cc3c(cc2)C2C(C4C(C)(C(O)CC4)CC2)CC3)O1		Inactive	Canalicular multispecific organic anion transporter 1 Substrate		1	Î²-Estradiol 3-(Î²-D-glucuronide) sodium salt	363681294.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C(O)C(O)C(O)C(Oc2cc3c(cc2)C2C(C4C(C)(C(O)CC4)CC2)CC3)O1	O=C(O)C1C(O)C(O)C(O)C(Oc2cc3c(cc2)C2C(C4C(C)(C(O)CC4)CC2)CC3)O1
NCGC00385736-01	O=C(O)C1C(O)C(O)C(OC2C(O)C(O)C(O)C(C(=O)O)O2)C(OC2C(C)(C)C3C(C=O)(C4C(C)(C5(C)C(C6C(C)(C(O)CC(CO)(C)C6)CC5)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385736-01	363679911.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C(O)C(O)C(OC2C(O)C(O)C(O)C(C(=O)O)O2)C(OC2C(C)(C)C3C(C=O)(C4C(C)(C5(C)C(C6C(C)(C(O)CC(CO)(C)C6)CC5)=CC4)CC3)CC2)O1	O=C(O)C1C(O)C(O)C(OC2C(O)C(O)C(O)C(C(=O)O)O2)C(OC2C(C)(C)C3C(C=O)(C4C(C)(C5(C)C(C6C(C)(C(O)CC(CO)(C)C6)CC5)=CC4)CC3)CC2)O1
NCGC00380513-01	O=C(O)C1C(O)C(O)C(OC2C(OC3C(O)C(O)C(O)C(C)O3)C(O)C(O)CO2)C(O[C@@H]2C(C)(C)C3[C@@](C)(C4C(=O)C=C5[C@](C)([C@]4(C)CC3)CC[C@@]3(C)C(O)CC(C)(C)CC53)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Ononis | Family: Fabaceae | Species: spinosa		1	NCGC00380513-01	363678623.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C(O)C(O)C(OC2C(OC3C(O)C(O)C(O)C(C)O3)C(O)C(O)CO2)C(O[C@@H]2C(C)(C)C3[C@@](C)(C4C(=O)C=C5[C@](C)([C@]4(C)CC3)CC[C@@]3(C)C(O)CC(C)(C)CC53)CC2)O1	O=C(O)C1C(O)C(O)C(OC2C(OC3C(O)C(O)C(O)C(C)O3)C(O)C(O)CO2)C(O[C@@H]2C(C)(C)C3[C@@](C)(C4C(=O)C=C5[C@](C)([C@]4(C)CC3)CC[C@@]3(C)C(O)CC(C)(C)CC53)CC2)O1
NCGC00381086-01	O=C(O)C1C(O)C(O)C(OC2C(OC3C(O)C(O)C(O)C(C)O3)C(O)C(O)CO2)C(O[C@@H]2C(C)(C)C3[C@@](C)(C4C(=O)CC=5[C@](C)([C@]4(C)CC3)CC[C@@]3(C)C(O)CC(C)(C)CC=53)CC2)O1		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Ononis | Family: Fabaceae | Species: spinosa		1	NCGC00381086-01	363678961.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C(O)C(O)C(OC2C(OC3C(O)C(O)C(O)C(C)O3)C(O)C(O)CO2)C(O[C@@H]2C(C)(C)C3[C@@](C)(C4C(=O)CC=5[C@](C)([C@]4(C)CC3)CC[C@@]3(C)C(O)CC(C)(C)CC=53)CC2)O1	O=C(O)C1C(O)C(O)C(OC2C(OC3C(O)C(O)C(O)C(C)O3)C(O)C(O)CO2)C(O[C@@H]2C(C)(C)C3[C@@](C)(C4C(=O)CC=5[C@](C)([C@]4(C)CC3)CC[C@@]3(C)C(O)CC(C)(C)CC=53)CC2)O1
NCGC00169641-02	O=C(O)C1C(O)C(O)C(OC2C(OC3C(O)C(O)C(O)C(C)O3)C(O)C(O)CO2)C(O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@](C)(C(O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Ononis | Family: Fabaceae | Species: spinosa		1	NCGC00169641-02	363676854.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C(O)C(O)C(OC2C(OC3C(O)C(O)C(O)C(C)O3)C(O)C(O)CO2)C(O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@](C)(C(O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1	O=C(O)C1C(O)C(O)C(OC2C(OC3C(O)C(O)C(O)C(C)O3)C(O)C(O)CO2)C(O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@](C)(C(O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1
NCGC00381177-01	O=C(O)C1C(O)C(O)C(OC2C(OC3C(O)C(O)C(O)C(CO)O3)C(O)C(O)C(CO)O2)C(OC2C(CO)(C)C3C(C)(C4C(C)(C5(C)C(C6C(C)(C(OC7C(O)C(OC8C(O)C(O)C(O)C(CO)O8)C(O)CO7)C(O)C(C)(C)C6)CC5)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381177-01	363679007.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C(O)C(O)C(OC2C(OC3C(O)C(O)C(O)C(CO)O3)C(O)C(O)C(CO)O2)C(OC2C(CO)(C)C3C(C)(C4C(C)(C5(C)C(C6C(C)(C(OC7C(O)C(OC8C(O)C(O)C(O)C(CO)O8)C(O)CO7)C(O)C(C)(C)C6)CC5)=CC4)CC3)CC2)O1	O=C(O)C1C(O)C(O)C(OC2C(OC3C(O)C(O)C(O)C(CO)O3)C(O)C(O)C(CO)O2)C(OC2C(CO)(C)C3C(C)(C4C(C)(C5(C)C(C6C(C)(C(OC7C(O)C(OC8C(O)C(O)C(O)C(CO)O8)C(O)CO7)C(O)C(C)(C)C6)CC5)=CC4)CC3)CC2)O1
NCGC00380873-01	O=C(O)C1C(O)C(OC2C(O)C(O)C(O)C(C)O2)C(OC2C(O)C(O)C(O)CO2)C(OC2C(C)(C)C3C(C)(C4C(C)(C5(C)C(=C6C(C)(C(O)CC(C)(C)C6)CC5)C=C4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Ononis | Family: Fabaceae | Species: spinosa		1	NCGC00380873-01	363678826.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	10.6309012919	O=C(O)C1C(O)C(OC2C(O)C(O)C(O)C(C)O2)C(OC2C(O)C(O)C(O)CO2)C(OC2C(C)(C)C3C(C)(C4C(C)(C5(C)C(=C6C(C)(C(O)CC(C)(C)C6)CC5)C=C4)CC3)CC2)O1	O=C(O)C1C(O)C(OC2C(O)C(O)C(O)C(C)O2)C(OC2C(O)C(O)C(O)CO2)C(OC2C(C)(C)C3C(C)(C4C(C)(C5(C)C(=C6C(C)(C(O)CC(C)(C)C6)CC5)C=C4)CC3)CC2)O1
NCGC00384691-01	O=C(O)C1C(O)C(OC2C(O)C(O)C(OC3C(O)C(O)C(O)CO3)C(C)O2)C(O)C(OC2C(C)(C)C3C(C)(C4C(C)(C5(C)C(C6C(C)(C(O)CC(COC7C(O)C(O)C(O)C(CO)O7)(C)C6)CC5)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Ormocarpum | Family: Papilionaceae | Species: kirkii		1	NCGC00384691-01	363679314.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C(O)C(OC2C(O)C(O)C(OC3C(O)C(O)C(O)CO3)C(C)O2)C(O)C(OC2C(C)(C)C3C(C)(C4C(C)(C5(C)C(C6C(C)(C(O)CC(COC7C(O)C(O)C(O)C(CO)O7)(C)C6)CC5)=CC4)CC3)CC2)O1	O=C(O)C1C(O)C(OC2C(O)C(O)C(OC3C(O)C(O)C(O)CO3)C(C)O2)C(O)C(OC2C(C)(C)C3C(C)(C4C(C)(C5(C)C(C6C(C)(C(O)CC(COC7C(O)C(O)C(O)C(CO)O7)(C)C6)CC5)=CC4)CC3)CC2)O1
NCGC00263831-02	O=C(O)C1C(O)C[C@]2(O)OC1CC(OC1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@H](C)[C@H](C)OC(=O)CC(O)CC(O)CC(O)CCC(O)C(O)C2		Inactive	Antifungal Agent		1	NYSTATIN	405558644.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C1C(O)C[C@]2(O)OC1CC(OC1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@H](C)[C@H](C)OC(=O)CC(O)CC(O)CC(O)CCC(O)C(O)C2	O=C(O)C1C(O)C[C@]2(O)OC1CC(OC1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@H](C)[C@H](C)OC(=O)CC(O)CC(O)CC(O)CCC(O)C(O)C2
NCGC00385432-01	O=C(O)C1C(c2cc(OC)c(O)c(OC)c2)c2c(c(O)c3OCOc3c2)CC1CO		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385432-01	363679740.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C(c2cc(OC)c(O)c(OC)c2)c2c(c(O)c3OCOc3c2)CC1CO	O=C(O)C1C(c2cc(OC)c(O)c(OC)c2)c2c(c(O)c3OCOc3c2)CC1CO
NCGC00380991-01	O=C(O)C1C2(C(CC)=C(C)C(=O)C(C)C2)C(=O)CC1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380991-01	363678907.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C2(C(CC)=C(C)C(=O)C(C)C2)C(=O)CC1	O=C(O)C1C2(C(CC)=C(C)C(=O)C(C)C2)C(=O)CC1
NCGC00380930-01	O=C(O)C1C2(O)C(CO)(C)CC(C)(C)C2CCC1C		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: ct Botrytis sp. | Family: N/A | Species: N/A		1	NCGC00380930-01	363678862.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C2(O)C(CO)(C)CC(C)(C)C2CCC1C	O=C(O)C1C2(O)C(CO)(C)CC(C)(C)C2CCC1C
NCGC00381369-01	O=C(O)C1C23C(C)C(=O)CC2C(C(C)(C)C3)C(O)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381369-01	363679111.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C23C(C)C(=O)CC2C(C(C)(C)C3)C(O)C1	O=C(O)C1C23C(C)C(=O)CC2C(C(C)(C)C3)C(O)C1
NCGC00380321-01	O=C(O)C1C23C(C)C(=O)CC2C(C(CO)(C)C3)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380321-01	363678541.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C23C(C)C(=O)CC2C(C(CO)(C)C3)CC1	O=C(O)C1C23C(C)C(=O)CC2C(C(CO)(C)C3)CC1
NCGC00385929-01	O=C(O)C1C23C(C45C(O)C(O)C(O)C(C)(C(=O)O4)C15)CCC(C(=C)C2)C3		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385929-01	363680014.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C23C(C45C(O)C(O)C(O)C(C)(C(=O)O4)C15)CCC(C(=C)C2)C3	O=C(O)C1C23C(C45C(O)C(O)C(O)C(C)(C(=O)O4)C15)CCC(C(=C)C2)C3
NCGC00380821-02	O=C(O)C1C23C(C45C(O)CC(O)C(C)(C(=O)O4)C15)CCC(C(=C)C2)C3		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380821-02	363678802.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C23C(C45C(O)CC(O)C(C)(C(=O)O4)C15)CCC(C(=C)C2)C3	O=C(O)C1C23C(C45C(O)CC(O)C(C)(C(=O)O4)C15)CCC(C(=C)C2)C3
NCGC00385927-01	O=C(O)C1C23C(C45C(O)CCC(C)(C(=O)O4)C15)CCC(C(=C)C2)C3		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385927-01	363680012.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C23C(C45C(O)CCC(C)(C(=O)O4)C15)CCC(C(=C)C2)C3	O=C(O)C1C23C(C45C(O)CCC(C)(C(=O)O4)C15)CCC(C(=C)C2)C3
NCGC00384640-01	O=C(O)C1C23C(C=4C1C1(C)C(=O)OC(C1O)C=4)CCC(O)(C(=C)C2)C3		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384640-01	363679289.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C23C(C=4C1C1(C)C(=O)OC(C1O)C=4)CCC(O)(C(=C)C2)C3	O=C(O)C1C23C(C=4C1C1(C)C(=O)OC(C1O)C=4)CCC(O)(C(=C)C2)C3
NCGC00381049-01	O=C(O)C1C=CC2NC(=O)C(=C)OC2C1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381049-01	363678945.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1C=CC2NC(=O)C(=C)OC2C1	O=C(O)C1C=CC2NC(=O)C(=C)OC2C1
NCGC00167520-05&NCGC00167520-06	O=C(O)C1CCC(C#N)(c2cc(OC3CCCC3)c(OC)cc2)CC1		Inactive	Phosphodiesterase IIII (PDE4) Inhibitor		2	Cilomilast	384568323.0&405558432.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)C1CCC(C#N)(c2cc(OC3CCCC3)c(OC)cc2)CC1	O=C(O)C1CCC(C#N)(c2cc(OC3CCCC3)c(OC)cc2)CC1
NCGC00016569-09&NCGC00016569-10	O=C(O)C1CCC(CN)CC1		Inactive	Tissue-type Plasminogen Activator Inhibitor (tpa) Inhibitor		2	TRANEXAMIC ACID&Tranexamic Acid	225144181.0&384567950.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)C1CCC(CN)CC1	O=C(O)C1CCC(CN)CC1
NCGC00386179-04	O=C(O)C1CCC(c2n3N=CN=C(N)c3c(-c3[nH]c4c(OC)cccc4c3)n2)CC1		Inactive	mTORC1/2 Inhibitor		1	OSI-027	363680137.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C1CCC(c2n3N=CN=C(N)c3c(-c3[nH]c4c(OC)cccc4c3)n2)CC1	O=C(O)C1CCC(c2n3N=CN=C(N)c3c(-c3[nH]c4c(OC)cccc4c3)n2)CC1
NCGC00386619-01	O=C(O)C1CCN(c2nc(Nc3nccc(C)c3)c3n(CCOCC)nc(CC)c3n2)CC1		Inactive			1	PDE5 inhibitor 42	363680360.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1CCN(c2nc(Nc3nccc(C)c3)c3n(CCOCC)nc(CC)c3n2)CC1	O=C(O)C1CCN(c2nc(Nc3nccc(C)c3)c3n(CCOCC)nc(CC)c3n2)CC1
NCGC00015977-06	O=C(O)C1CN(CCC=C(c2ccccc2)c2ccccc2)CCC1		Inactive	GAT-1 Inhibitor		1	SKF-89976A	384567912.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C1CN(CCC=C(c2ccccc2)c2ccccc2)CCC1	O=C(O)C1CN(CCC=C(c2ccccc2)c2ccccc2)CCC1
NCGC00379155-01	O=C(O)C1CN(Cc2sc(-c3nc(-c4ccc(Oc5ccccc5)cc4)on3)c(CC)c2)C1		Inactive	Sphingosine 1-phosphate receptor Edg-8 Agonist		1	CS 2100	363678389.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1CN(Cc2sc(-c3nc(-c4ccc(Oc5ccccc5)cc4)on3)c(CC)c2)C1	O=C(O)C1CN(Cc2sc(-c3nc(-c4ccc(Oc5ccccc5)cc4)on3)c(CC)c2)C1
NCGC00385982-01	O=C(O)C1N2C(=O)C3=COC(OC4C(O)C(O)C(O)C(CO)O4)C(C=C)C3CC2c2[nH]c3c(c2C1)cccc3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385982-01	363680043.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C1N2C(=O)C3=COC(OC4C(O)C(O)C(O)C(CO)O4)C(C=C)C3CC2c2[nH]c3c(c2C1)cccc3	O=C(O)C1N2C(=O)C3=COC(OC4C(O)C(O)C(O)C(CO)O4)C(C=C)C3CC2c2[nH]c3c(c2C1)cccc3
NCGC00263467-03	O=C(O)C1NC(=O)CC1		Inactive			1	2-Pyrrolidone-5-carboxylic acid	225144361.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C1NC(=O)CC1	O=C(O)C1NC(=O)CC1
NCGC00532517-01	O=C(O)C=1C(=O)c2c(N(C3CC3)C=1)c(C)c(-c1cc(C)c(NC)nc1)cc2		Inactive	Topoisomerase IV Inhibitor		1	OZENOXACIN	405558514.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C=1C(=O)c2c(N(C3CC3)C=1)c(C)c(-c1cc(C)c(NC)nc1)cc2	O=C(O)C=1C(=O)c2c(N(C3CC3)C=1)c(C)c(-c1cc(C)c(NC)nc1)cc2
NCGC00018181-12	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(C)cc2		Inactive	Quinoline Antibiotic		1	Nalidixic acid	170465215.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(C)cc2	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(C)cc2
NCGC00016743-08	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(N1CCCC1)nc2		Inactive			1	Piromidic acid	170466042.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(N1CCCC1)nc2	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(N1CCCC1)nc2
NCGC00016866-11	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(N1CCNCC1)nc2		Inactive			1	Pipemidic acid	170465767.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(N1CCNCC1)nc2	O=C(O)C=1C(=O)c2c(N(CC)C=1)nc(N1CCNCC1)nc2
NCGC00015277-17	O=C(O)C=1C(=O)c2c(N(CC)N=1)cc1OCOc1c2		Inactive	Topoisomerase IV Inhibitor		1	Cinoxacin	170465414.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)C=1C(=O)c2c(N(CC)N=1)cc1OCOc1c2	O=C(O)C=1C(=O)c2c(N(CC)N=1)cc1OCOc1c2
NCGC00379063-03&NCGC00379063-04&NCGC00379063-05	O=C(O)C=1C(=O)c2c(N(c3sccn3)C=1)nc(N1C[C@H](OC)[C@@H](NC)C1)cc2		Inactive	DNA Topoisomerase II Inhibitor		3	Vosaroxin&Voreloxin Hydrochloride&Voreloxin	384569091.0	Annotated/Bioactive Compound Collection&2020_NPACT-11_CPE	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)C=1C(=O)c2c(N(c3sccn3)C=1)nc(N1C[C@H](OC)[C@@H](NC)C1)cc2	O=C(O)C=1C(=O)c2c(N(c3sccn3)C=1)nc(N1C[C@H](OC)[C@@H](NC)C1)cc2
NCGC00388402-01	O=C(O)C=1C(=O)c2c(NC=1)c1c(cc2)cccc1		Inactive			1	NSC 210902	377020387.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C=1C(=O)c2c(NC=1)c1c(cc2)cccc1	O=C(O)C=1C(=O)c2c(NC=1)c1c(cc2)cccc1
NCGC00384989-01	O=C(O)C=1C(CCC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C)C(C)(C)CC(=O)C=1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384989-01	363679471.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C=1C(CCC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C)C(C)(C)CC(=O)C=1	O=C(O)C=1C(CCC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C)C(C)(C)CC(=O)C=1
NCGC00381404-01	O=C(O)C=1C(O)CC2C(C)(C)CCCC2(C)C=1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381404-01	363679128.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C=1C(O)CC2C(C)(C)CCCC2(C)C=1	O=C(O)C=1C(O)CC2C(C)(C)CCCC2(C)C=1
NCGC00380942-01	O=C(O)C=1C2(C)C(C(C)(C)CCC2)CC=1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380942-01	363678874.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C=1C2(C)C(C(C)(C)CCC2)CC=1	O=C(O)C=1C2(C)C(C(C)(C)CCC2)CC=1
NCGC00385270-01	O=C(O)C=1C2(C)C(O)CC(C)C(CCc3cocc3)(C)C2CCC=1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Caryopteris | Family: Verbenaceae | Species: odorata		1	NCGC00385270-01	363679630.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C=1C2(C)C(O)CC(C)C(CCc3cocc3)(C)C2CCC=1	O=C(O)C=1C2(C)C(O)CC(C)C(CCc3cocc3)(C)C2CCC=1
NCGC00385272-01	O=C(O)C=1C2(CO)C(C(CCc3cocc3)(C)C(C)CC2)CCC=1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385272-01	363679632.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C=1C2(CO)C(C(CCc3cocc3)(C)C(C)CC2)CCC=1	O=C(O)C=1C2(CO)C(C(CCc3cocc3)(C)C(C)CC2)CCC=1
NCGC00182073-03	O=C(O)C=1N(CC)c2c(CCC)c3OC(C(=O)O)=CC(=O)c3cc2C(=O)C=1		Inactive	mast cell degranulation Inhibitor		1	Nedocromil	170464978.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C=1N(CC)c2c(CCC)c3OC(C(=O)O)=CC(=O)c3cc2C(=O)C=1	O=C(O)C=1N(CC)c2c(CCC)c3OC(C(=O)O)=CC(=O)c3cc2C(=O)C=1
NCGC00188943-09	O=C(O)C=1NC(=O)NC(=O)C=1		Inactive	metabolite		1	Orotic acid	384568454.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C=1NC(=O)NC(=O)C=1	O=C(O)C=1NC(=O)NC(=O)C=1
NCGC00381327-01	O=C(O)C=1OC=2OC3(C)C(C4(C)C(C(C)(C)C(O)CC4)CC3)CC=2C(=O)C=1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381327-01	363679088.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C=1OC=2OC3(C)C(C4(C)C(C(C)(C)C(O)CC4)CC3)CC=2C(=O)C=1	O=C(O)C=1OC=2OC3(C)C(C4(C)C(C(C)(C)C(O)CC4)CC3)CC=2C(=O)C=1
NCGC00022858-08&NCGC00022858-10	O=C(O)C=1Oc2c(c(OCC(O)COc3c4C(=O)C=C(C(=O)O)Oc4ccc3)ccc2)C(=O)C=1		Inactive	Mediator Release Inhibitor		2	Sodium cromoglycate	170464887.0&384568015.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&-14.739502328	O=C([O-])C=1Oc2c(c(OCC(O)COc3c4C(=O)C=C(C(=O)[O-])Oc4ccc3)ccc2)C(=O)C=1.[Na+].[Na+]	O=C([O-])C=1Oc2c(c(OCC(O)COc3c4C(=O)C=C(C(=O)[O-])Oc4ccc3)ccc2)C(=O)C=1.[Na+].[Na+]&O=C([O-])C=1Oc2c(c(OCC(O)COc3c4C(=O)C=C(C(=O)[O-])Oc4ccc3)ccc2)C(=O)C=1
NCGC00178007-02	O=C(O)C=1[C@@H]2[C@@H]([C@@H](C)[C@@H](O)C2)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Rauvolfia | Family: Apocynaceae | Species: caffra		1	Loganic acid	363676928.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C=1[C@@H]2[C@@H]([C@@H](C)[C@@H](O)C2)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1	O=C(O)C=1[C@@H]2[C@@H]([C@@H](C)[C@@H](O)C2)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1
NCGC00385161-01	O=C(O)C=1[C@@H]2[C@@H]3[C@@H](O[C@H]4C(CC)C(=O)OC34C=C2)OC=1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Plumeria | Family: Apocynaceae | Species: rubra		1	NCGC00385161-01	363679572.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C=1[C@@H]2[C@@H]3[C@@H](O[C@H]4C(CC)C(=O)OC34C=C2)OC=1	O=C(O)C=1[C@@H]2[C@@H]3[C@@H](O[C@H]4C(CC)C(=O)OC34C=C2)OC=1
NCGC00385605-01	O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)C(C)OC(=O)C2		Inactive	<MOA Unknown> | Class: Iridoid | Genus: olea | Family: Oleaceae | Species: europaea		1	NCGC00385605-01	363679833.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)C(C)OC(=O)C2	O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)C(C)OC(=O)C2
NCGC00346663-04	O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)C(CO)=CC2		Inactive	radioprotectant		1	Geniposidic acid	384568893.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)C(CO)=CC2	O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)C(CO)=CC2
NCGC00347506-02	O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@](O)(C)CC2		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Vitex | Family: Verbenaceae | Species: agenus		1	NCGC00347506-02	363677608.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@](O)(C)CC2	O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@](O)(C)CC2
NCGC00380353-01	O=C(O)C=1[C@H]2C3([C@@](O)(CO)C(=O)OC2)[C@@H]([C@H](C)C(C)=C3)C=1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380353-01	363678551.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C=1[C@H]2C3([C@@](O)(CO)C(=O)OC2)[C@@H]([C@H](C)C(C)=C3)C=1	O=C(O)C=1[C@H]2C3([C@@](O)(CO)C(=O)OC2)[C@@H]([C@H](C)C(C)=C3)C=1
NCGC00385967-01	O=C(O)C=1[C@H]2[C@]3(C(=C)C(=O)OC2)C(C=1)CC(C)(C)C3		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385967-01	363680033.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C=1[C@H]2[C@]3(C(=C)C(=O)OC2)C(C=1)CC(C)(C)C3	O=C(O)C=1[C@H]2[C@]3(C(=C)C(=O)OC2)C(C=1)CC(C)(C)C3
NCGC00380393-01	O=C(O)C=1[C@H]2[C@]3([C@H](C)C(=O)OC2)[C@H](C=1)CC(C)(C)C3		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380393-01	363678564.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C=1[C@H]2[C@]3([C@H](C)C(=O)OC2)[C@H](C=1)CC(C)(C)C3	O=C(O)C=1[C@H]2[C@]3([C@H](C)C(=O)OC2)[C@H](C=1)CC(C)(C)C3
NCGC00385407-01	O=C(O)CC(=O)NC(C)C1=Nc2c(C(=O)N1)cccc2		Inactive	<MOA Unknown> | Class: alkaloid | Genus: Penicillium ? | Family: N/A | Species: N/A		1	NCGC00385407-01	363679726.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC(=O)NC(C)C1=Nc2c(C(=O)N1)cccc2	O=C(O)CC(=O)NC(C)C1=Nc2c(C(=O)N1)cccc2
NCGC00074767-04	O=C(O)CC(=O)c1c2OC(C)(C)C=Cc2c(OC)cc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Juniperus | Family: Cupressaceae | Species: communis		1	URSINOIC ACID	363676545.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC(=O)c1c2OC(C)(C)C=Cc2c(OC)cc1	O=C(O)CC(=O)c1c2OC(C)(C)C=Cc2c(OC)cc1
NCGC00385316-01	O=C(O)CC(CCC1=C(C)C(=O)CC2C(C)(C)CCC[C@]12C)C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Cistus | Family: Cistaceae | Species: ladanifer		1	NCGC00385316-01	363679672.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC(CCC1=C(C)C(=O)CC2C(C)(C)CCC[C@]12C)C	O=C(O)CC(CCC1=C(C)C(=O)CC2C(C)(C)CCC[C@]12C)C
NCGC00385462-01	O=C(O)CC(CCC1=C(C)C(=O)[C@@H](OC(=O)C)C2C(C)(C)CCC[C@]12C)C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Cistus | Family: Cistaceae | Species: ladanifer		1	NCGC00385462-01	363679752.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC(CCC1=C(C)C(=O)[C@@H](OC(=O)C)C2C(C)(C)CCC[C@]12C)C	O=C(O)CC(CCC1=C(C)C(=O)[C@@H](OC(=O)C)C2C(C)(C)CCC[C@]12C)C
NCGC00380894-01	O=C(O)CC(CCC1=C(C)C(O)C(OC(=O)C)C2C(C)(C)CCCC12C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380894-01	363678839.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC(CCC1=C(C)C(O)C(OC(=O)C)C2C(C)(C)CCCC12C)C	O=C(O)CC(CCC1=C(C)C(O)C(OC(=O)C)C2C(C)(C)CCCC12C)C
NCGC00385898-01	O=C(O)CC(CCC1C(=C)CCC2C(C(=O)O)(C)CCCC12C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385898-01	363679997.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC(CCC1C(=C)CCC2C(C(=O)O)(C)CCCC12C)C	O=C(O)CC(CCC1C(=C)CCC2C(C(=O)O)(C)CCCC12C)C
NCGC00347842-02	O=C(O)CC(CCC1C(=C)CCC2C(C(=O)OC)(C)CCCC12C)C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Pinus | Family: Pinaceae | Species: nigra nigra		1	NCGC00347842-02	363677706.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC(CCC1C(=C)CCC2C(C(=O)OC)(C)CCCC12C)C	O=C(O)CC(CCC1C(=C)CCC2C(C(=O)OC)(C)CCCC12C)C
NCGC00385429-01	O=C(O)CC(CCC1C(=C)CCC2C(C)(C)CC(O)CC12C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385429-01	363679738.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC(CCC1C(=C)CCC2C(C)(C)CC(O)CC12C)C	O=C(O)CC(CCC1C(=C)CCC2C(C)(C)CC(O)CC12C)C
NCGC00384884-01	O=C(O)CC(CCC1C(=C)CCC2C(COC(=O)C)(C)CCCC12C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384884-01	363679414.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC(CCC1C(=C)CCC2C(COC(=O)C)(C)CCCC12C)C	O=C(O)CC(CCC1C(=C)CCC2C(COC(=O)C)(C)CCCC12C)C
NCGC00381082-01	O=C(O)CC(Nc1ccc(C=O)cc1)/C=C/C=C/C		Inactive	<MOA Unknown> | Class: polyketide | Genus: N/A | Family: N/A | Species: N/A		1	Obscurolic acid A	363678959.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC(Nc1ccc(C=O)cc1)/C=C/C=C/C	O=C(O)CC(Nc1ccc(C=O)cc1)/C=C/C=C/C
NCGC00169704-02	O=C(O)CC(OC1C(O)C(O)C(O)C(CO)O1)CCc1ccccc1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Amaranthus | Family: Amaranthaceae | Species: flexus		1	NCGC00169704-02	363676870.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC(OC1C(O)C(O)C(O)C(CO)O1)CCc1ccccc1	O=C(O)CC(OC1C(O)C(O)C(O)C(CO)O1)CCc1ccccc1
NCGC00380628-01	O=C(O)CC/C(=C/CC/C(=C/Cc1c(OC)c(C)c2c(c1O)C(=O)OC2)/C)/C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380628-01	363678681.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC/C(=C/CC/C(=C/Cc1c(OC)c(C)c2c(c1O)C(=O)OC2)/C)/C	O=C(O)CC/C(=C/CC/C(=C/Cc1c(OC)c(C)c2c(c1O)C(=O)OC2)/C)/C
NCGC00161345-07	O=C(O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC		Inactive	Voltage-gated L-type calcium channel Modulator		1	DOCONEXENT	405558420.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC	O=C(O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC
NCGC00025325-03	O=C(O)CC/C=C\CC[C@@H]1[C@@H](N2CCCCC2)[C@@H](O)C[C@@H]1OCc1ccc(-c2ccccc2)cc1		Inactive	Prostanoid TP Antagonist		1	Vapiprost hydrochloride	174006925.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)CC/C=C\CC[C@@H]1[C@@H](N2CCCCC2)[C@@H](O)C[C@@H]1OCc1ccc(-c2ccccc2)cc1	O=C(O)CC/C=C\CC[C@@H]1[C@@H](N2CCCCC2)[C@@H](O)C[C@@H]1OCc1ccc(-c2ccccc2)cc1
NCGC00381353-01	O=C(O)CC1(C)C(C)CCC2(C=O)C(CO)=CCCC12		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381353-01	363679103.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC1(C)C(C)CCC2(C=O)C(CO)=CCCC12	O=C(O)CC1(C)C(C)CCC2(C=O)C(CO)=CCCC12
NCGC00385541-01	O=C(O)CC1(C)OC2(C(COC(=O)C)=CCC3C(C)(C)CCCC23C)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Grindelia | Family: N/A | Species: spp		1	NCGC00385541-01	363679797.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC1(C)OC2(C(COC(=O)C)=CCC3C(C)(C)CCCC23C)CC1	O=C(O)CC1(C)OC2(C(COC(=O)C)=CCC3C(C)(C)CCCC23C)CC1
NCGC00015399-16&NCGC00015399-27	O=C(O)CC1(CC)OCCc2c3c(c(CC)ccc3)[nH]c12		Inactive	Cyclooxygenase-2 Inhibitor		2	Etodolac	170464915.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)CC1(CC)OCCc2c3c(c(CC)ccc3)[nH]c12	O=C(O)CC1(CC)OCCc2c3c(c(CC)ccc3)[nH]c12
NCGC00015466-09&NCGC00015466-11	O=C(O)CC1(CN)CCCCC1		Inactive	Calcium Channels (Voltage-Gated) alpha2/delta-1 Subunit Ligands		2	Gabapentin	90340599.0&170464715.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)CC1(CN)CCCCC1	O=C(O)CC1(CN)CCCCC1
NCGC00385842-01	O=C(O)CC1(O)C(=O)Nc2c1cccc2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385842-01	363679964.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC1(O)C(=O)Nc2c1cccc2	O=C(O)CC1(O)C(=O)Nc2c1cccc2
NCGC00378846-01	O=C(O)CC12CCC(c3ccc(C=4C(C)(C)Oc5ncnc(N)c5N=4)cc3)(CC1)CC2		Inactive	Diacylglycerol O-acyltransferase 1 Inhibitor		1	DGAT-1 inhibitor 2	363678232.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC12CCC(c3ccc(C=4C(C)(C)Oc5ncnc(N)c5N=4)cc3)(CC1)CC2	O=C(O)CC12CCC(c3ccc(C=4C(C)(C)Oc5ncnc(N)c5N=4)cc3)(CC1)CC2
NCGC00385275-01	O=C(O)CC1C(C(=O)OC)=COC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C1C=C		Inactive	<MOA Unknown> | Class: Iridoid | Genus: olea | Family: Oleaceae | Species: europaea		1	NCGC00385275-01	363679635.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC1C(C(=O)OC)=COC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C1C=C	O=C(O)CC1C(C(=O)OC)=COC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C1C=C
NCGC00380210-01	O=C(O)CC1C(C/C=C\CC)C(OC2C(O)C(O)C(O)C(CO)O2)CC1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380210-01	363678499.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC1C(C/C=C\CC)C(OC2C(O)C(O)C(O)C(CO)O2)CC1	O=C(O)CC1C(C/C=C\CC)C(OC2C(O)C(O)C(O)C(CO)O2)CC1
NCGC00381155-01	O=C(O)CC1C(c2c(O)c(OC)c(-c3ccc(O)cc3)cc2OC)=CC(=O)O1		Inactive	<MOA Unknown> | Class: shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381155-01	363678998.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC1C(c2c(O)c(OC)c(-c3ccc(O)cc3)cc2OC)=CC(=O)O1	O=C(O)CC1C(c2c(O)c(OC)c(-c3ccc(O)cc3)cc2OC)=CC(=O)O1
NCGC00378858-01	O=C(O)CC1CCC(c2ccc(-c3c(C)nc(C)c(C(=O)N)n3)cc2)CC1		Inactive	Diacylglycerol O-acyltransferase 1 Inhibitor		1	AZD7687	363678240.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC1CCC(c2ccc(-c3c(C)nc(C)c(C(=O)N)n3)cc2)CC1	O=C(O)CC1CCC(c2ccc(-c3c(C)nc(C)c(C(=O)N)n3)cc2)CC1
NCGC00378678-01	O=C(O)CC1CCC(c2ccc(C=3C(C)(C)Oc4ncnc(N)c4N=3)cc2)CC1		Inactive	Diacylglycerol O-acyltransferase 1 Inhibitor		1	T863	363678146.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC1CCC(c2ccc(C=3C(C)(C)Oc4ncnc(N)c4N=3)cc2)CC1	O=C(O)CC1CCC(c2ccc(C=3C(C)(C)Oc4ncnc(N)c4N=3)cc2)CC1
NCGC00356837-03	O=C(O)CC1CCC(c2ccc(N3C(=O)c4c(N)ncnc4OCC3)cc2)CC1		Inactive	Diacylglycerol Acyltransferase Type 1 (DGAT-1) Inhibitor		1	PF-04620110	384569033.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CC1CCC(c2ccc(N3C(=O)c4c(N)ncnc4OCC3)cc2)CC1	O=C(O)CC1CCC(c2ccc(N3C(=O)c4c(N)ncnc4OCC3)cc2)CC1
NCGC00186000-02	O=C(O)CC1ON=C(c2ccccc2)C1		Inactive	p38MAPK cascade Inhibitor		1	VGX-1027	363677106.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC1ON=C(c2ccccc2)C1	O=C(O)CC1ON=C(c2ccccc2)C1
NCGC00249052-02	O=C(O)CCC(=O)C		Inactive			1	Calcium levulinate	170465651.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C([O-])CCC(=O)C.O=C([O-])CCC(=O)C.[Ca+2].O.O	O=C([O-])CCC(=O)C.O=C([O-])CCC(=O)C.[Ca+2].O.O
NCGC00178086-03&NCGC00178086-06	O=C(O)CCC(=O)CN		Inactive	DNA Inhibitor		2	Aminolevulinic acid hydrochloride&AMINOLEVULINIC ACID HYDROCHLORIDE	170464700.0&434147046.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)CCC(=O)CN.Cl	O=C(O)CCC(=O)CN.Cl&O=C(O)CCC(=O)CN
NCGC00091281-10	O=C(O)CCC(=O)NN(C)C		Inactive	KDM2/7 Histone Demethylases Inhibitor		1	Daminozide	384568095.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCC(=O)NN(C)C	O=C(O)CCC(=O)NN(C)C
NCGC00159372-04	O=C(O)CCC(=O)O		Inactive			1	Butanedioic acid	170465738.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCC(=O)O	O=C(O)CCC(=O)O
NCGC00167448-02	O=C(O)CCC(=O)c1c(OCC)cc(OCC)c(OCC)c1		Inactive	Catechol O-methyltransferase Inhibitor		1	Trepibutone	170465772.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCC(=O)c1c(OCC)cc(OCC)c(OCC)c1	O=C(O)CCC(=O)c1c(OCC)cc(OCC)c(OCC)c1
NCGC00016834-07	O=C(O)CCC(=O)c1ccc(-c2ccccc2)cc1		Inactive	Prostaglandin G/H synthase 2 Inhibitor		1	Fenbufen	170465799.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&6.291970808	O=C(O)CCC(=O)c1ccc(-c2ccccc2)cc1	O=C(O)CCC(=O)c1ccc(-c2ccccc2)cc1
NCGC00016087-11	O=C(O)CCC(N)C=C		Inactive	Gamma-amino-N-butyrate transaminase Inhibitor		1	Vigabatrin	225144175.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCC(N)C=C	O=C(O)CCC(N)C=C
NCGC00380933-01	O=C(O)CCC(OC(=O)C)CCCCC1=C(CC=CCC)C(=O)CC1		Inactive	<MOA Unknown> | Class: Fatty acid | Genus: Vicoa | Family: Compositae | Species: indica		1	NCGC00380933-01	363678865.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCC(OC(=O)C)CCCCC1=C(CC=CCC)C(=O)CC1	O=C(O)CCC(OC(=O)C)CCCCC1=C(CC=CCC)C(=O)CC1
NCGC00167427-02	O=C(O)CCC/C=C/1\O[C@@H]2[C@@H]([C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C2)C\1		Inactive	Prostanoid IP receptor Agonist		1	Epoprostenol sodium	124893308.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])CCC/C=C/1\O[C@@H]2[C@@H]([C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C2)C\1	O=C([O-])CCC/C=C/1\O[C@@H]2[C@@H]([C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C2)C\1
NCGC00344182-03	O=C(O)CCC/C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]1O		Inactive	Prostanoid FP receptor Agonist		1	5-trans Prostaglandin F2?	405558427.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCC/C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]1O	O=C(O)CCC/C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]1O
NCGC00181784-01	O=C(O)CCC/C=C\1/C[C@@H]2C(/C=C/[C@@H](O)C(CC#CC)C)[C@H](O)C[C@@H]2C/1		Inactive	Prostanoid IP receptor Agonist		1	Iloprost	144207135.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCC/C=C\1/C[C@@H]2C(/C=C/[C@@H](O)C(CC#CC)C)[C@H](O)C[C@@H]2C/1	O=C(O)CCC/C=C\1/C[C@@H]2C(/C=C/[C@@H](O)C(CC#CC)C)[C@H](O)C[C@@H]2C/1
NCGC00161344-07	O=C(O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC		Inactive	lipoprotein oxidation Inhibitor		1	Eicosapentaenoic Acid	405558471.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC	O=C(O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC
NCGC00161290-05	O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)C(CCCC)(C)C)[C@H](O)CC1=O		Inactive	prostaglandin		1	16,16-dimethyl PGE2	174006821.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)C(CCCC)(C)C)[C@H](O)CC1=O	O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)C(CCCC)(C)C)[C@H](O)CC1=O
NCGC00092361-06	O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)CC1=O		Inactive	prostaglandin		1	Prostaglandin E2	174006772.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)CC1=O	O=C(O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)CC1=O
NCGC00386590-01	O=C(O)CCC/C=C\C[C@@H]1[C@@H](NC(=O)c2c3c(sc2)ccc(O)c3)[C@H]2C(C)(C)[C@@H](C1)C2		Inactive	Prostanoid DP receptor Antagonist		1	S 5751	363680345.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCC/C=C\C[C@@H]1[C@@H](NC(=O)c2c3c(sc2)ccc(O)c3)[C@H]2C(C)(C)[C@@H](C1)C2	O=C(O)CCC/C=C\C[C@@H]1[C@@H](NC(=O)c2c3c(sc2)ccc(O)c3)[C@H]2C(C)(C)[C@@H](C1)C2
NCGC00384937-01	O=C(O)CCC1(C)C(=O)C=CC23C(O)C4(C)OC(C12)CC4C3		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384937-01	363679448.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCC1(C)C(=O)C=CC23C(O)C4(C)OC(C12)CC4C3	O=C(O)CCC1(C)C(=O)C=CC23C(O)C4(C)OC(C12)CC4C3
NCGC00380429-01	O=C(O)CCC1(C)C(=O)C=CC23C1C1OC(C)(C(C2)C1)C3		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380429-01	363678579.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCC1(C)C(=O)C=CC23C1C1OC(C)(C(C2)C1)C3	O=C(O)CCC1(C)C(=O)C=CC23C1C1OC(C)(C(C2)C1)C3
NCGC00169028-02	O=C(O)CCC1(C)C(C(O)(C)C)C(O)CC2(C)Oc3c(C)c4c(c(OC)c3CC12)C(=O)OC4		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169028-02	363676746.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCC1(C)C(C(O)(C)C)C(O)CC2(C)Oc3c(C)c4c(c(OC)c3CC12)C(=O)OC4	O=C(O)CCC1(C)C(C(O)(C)C)C(O)CC2(C)Oc3c(C)c4c(c(OC)c3CC12)C(=O)OC4
NCGC00380957-01	O=C(O)CCC1(C)C(C(O)(C)C)CCC2(C)C3(C(=O)OC)C(=O)C(O)(C)C(=O)C3(C)C(=C)CC12		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380957-01	363678885.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCC1(C)C(C(O)(C)C)CCC2(C)C3(C(=O)OC)C(=O)C(O)(C)C(=O)C3(C)C(=C)CC12	O=C(O)CCC1(C)C(C(O)(C)C)CCC2(C)C3(C(=O)OC)C(=O)C(O)(C)C(=O)C3(C)C(=C)CC12
NCGC00381066-01	O=C(O)CCC1(C)C(C(O)(C)C)CCC2(C)C3C(C)(C(=O)C(C(=O)OC)(C)OC3=O)C(=C)CC12		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381066-01	363678954.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCC1(C)C(C(O)(C)C)CCC2(C)C3C(C)(C(=O)C(C(=O)OC)(C)OC3=O)C(=C)CC12	O=C(O)CCC1(C)C(C(O)(C)C)CCC2(C)C3C(C)(C(=O)C(C(=O)OC)(C)OC3=O)C(=C)CC12
NCGC00185003-01	O=C(O)CCC1=C(C)C=2N=C1C=C1C(CCC(=O)O)=C(C)C(=N1)C=[cH0]1c(C=C)c(C)[cH0]([nH]1)=Cc1c(C=C)c(C)c([nH]1)C=2		Inactive			1	NCGC00185003-01	124896579.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])CCC1=C(C)C=2N=C1C=C1C(CCC(=O)[O-])=C(C)C(=N1)C=[cH0]1c(C=C)c(C)[cH0]([nH]1)=Cc1c(C=C)c(C)c([nH]1)C=2	O=C([O-])CCC1=C(C)C=2N=C1C=C1C(CCC(=O)[O-])=C(C)C(=N1)C=[cH0]1c(C=C)c(C)[cH0]([nH]1)=Cc1c(C=C)c(C)c([nH]1)C=2
NCGC00385295-01	O=C(O)CCC1C(=O)N(C)C(Cc2ccc(OC)cc2)C(=O)NC(C)C(=O)N(C)C2C(=O)N(C)C(C(=O)NC(C)C(=O)N1)Cc1cc(c(OC3C(O)C(O)C(O)C(CO)O3)cc1)Oc1ccc(cc1)C2		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385295-01	363679654.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCC1C(=O)N(C)C(Cc2ccc(OC)cc2)C(=O)NC(C)C(=O)N(C)C2C(=O)N(C)C(C(=O)NC(C)C(=O)N1)Cc1cc(c(OC3C(O)C(O)C(O)C(CO)O3)cc1)Oc1ccc(cc1)C2	O=C(O)CCC1C(=O)N(C)C(Cc2ccc(OC)cc2)C(=O)NC(C)C(=O)N(C)C2C(=O)N(C)C(C(=O)NC(C)C(=O)N1)Cc1cc(c(OC3C(O)C(O)C(O)C(CO)O3)cc1)Oc1ccc(cc1)C2
NCGC00381022-01	O=C(O)CCC1[C@@H](C)CC[C@H]2C(=C)C(=O)O[C@H]2C1(O)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Ambrosia | Family: Compositae | Species: cumanensis		1	NCGC00381022-01	363678929.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCC1[C@@H](C)CC[C@H]2C(=C)C(=O)O[C@H]2C1(O)C	O=C(O)CCC1[C@@H](C)CC[C@H]2C(=C)C(=O)O[C@H]2C1(O)C
NCGC00384515-01	O=C(O)CCC=1[C@](O)(C)[C@@H]2OC(=O)C(=C)[C@@H]2CCC=1C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Ambrosia | Family: Compositae | Species: cumanensis		1	NCGC00384515-01	363679226.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCC=1[C@](O)(C)[C@@H]2OC(=O)C(=C)[C@@H]2CCC=1C	O=C(O)CCC=1[C@](O)(C)[C@@H]2OC(=O)C(=C)[C@@H]2CCC=1C
NCGC00183281-03	O=C(O)CCCC		Inactive			1	Valeric acid	405558533.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCCC	O=C(O)CCCC
NCGC00160469-01	O=C(O)CCCC/C=C\C/C=C\C/C=C\CCCCC		Inactive	prostanoid metabolic process Interacts		1	Gamolenic acid	144205388.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCCC/C=C\C/C=C\C/C=C\CCCCC	O=C(O)CCCC/C=C\C/C=C\C/C=C\CCCCC
NCGC00091345-04	O=C(O)CCCCC(=O)O		Inactive			1	Hexanedioic acid	170465352.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)CCCCC(=O)O	O=C(O)CCCCC(=O)O
NCGC00016032-11&NCGC00016032-14	O=C(O)CCCCC1SSCC1		Inactive			2	alpha-Lipoic acid&THIOCTIC ACID	170465713.0&434146951.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)CCCCC1SSCC1	O=C(O)CCCCC1SSCC1
NCGC00345022-04	O=C(O)CCCCCC(=O)NN=C1CCCC1		Inactive	lineage-specific differentiation enhancer		1	IDE-2	384568730.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCCCCC(=O)NN=C1CCCC1	O=C(O)CCCCCC(=O)NN=C1CCCC1
NCGC00181296-02&NCGC00181296-08	O=C(O)CCCCCC(c1ccccc1)C=1C(=O)C(C)=C(C)C(=O)C=1C		Inactive	Prostanoid TP Agonist		2	Seratrodast	170465940.0&384568395.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)CCCCCC(c1ccccc1)C=1C(=O)C(C)=C(C)C(=O)C=1C	O=C(O)CCCCCC(c1ccccc1)C=1C(=O)C(C)=C(C)C(=O)C=1C
NCGC00090957-05	O=C(O)CCCCCCC		Inactive	Solute carrier family 22 member 8 Substrate		1	Octanoic acid	405558921.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)CCCCCCC	O=C(O)CCCCCCC
NCGC00344326-02	O=C(O)CCCCCCC/C=C/C/C=C/CCCCC		Inactive	Streptococcus mutans Inhibitor		1	9(E),12(E)-Octadecadienoic acid	405558983.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCCCCCC/C=C/C/C=C/CCCCC	O=C(O)CCCCCCC/C=C/C/C=C/CCCCC
NCGC00344330-02	O=C(O)CCCCCCC/C=C/CCCCCCCC		Inactive	SiHa Inhibitor		1	Elaidic Acid	405558971.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCCCCCC/C=C/CCCCCCCC	O=C(O)CCCCCCC/C=C/CCCCCCCC
NCGC00091058-11	O=C(O)CCCCCCC/C=C\C/C=C\C/C=C\CC		Inactive	Fatty acid desaturase 2 Substrate		1	Linolenic acid	225144205.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCCCCCC/C=C\C/C=C\C/C=C\CC	O=C(O)CCCCCCC/C=C\C/C=C\C/C=C\CC
NCGC00248225-03	O=C(O)CCCCCCC/C=C\CCCCCC		Inactive	Gap junction Modulator		1	9(Z)-Hexadecenoic acid	405558987.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCCCCCC/C=C\CCCCCC	O=C(O)CCCCCCC/C=C\CCCCCC
NCGC00161336-01	O=C(O)CCCCCCC/C=C\C[C@H](O)CCCCCC		Inactive	Prostanoid EP3 receptor Binding Agent		1	Potassium ricinoleate	26754911.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCCCCCC/C=C\C[C@H](O)CCCCCC	O=C(O)CCCCCCC/C=C\C[C@H](O)CCCCCC
NCGC00476141-01	O=C(O)CCCCCCC1[C@@H](/C=C/C(O)CCCCC)[C@@H](O)CC1=O		Inactive	Prostanoid EP1 receptor Agonist		1	11?-Prostaglandin E1	405558649.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCCCCCC1[C@@H](/C=C/C(O)CCCCC)[C@@H](O)CC1=O	O=C(O)CCCCCCC1[C@@H](/C=C/C(O)CCCCC)[C@@H](O)CC1=O
NCGC00014993-12	O=C(O)CCCCCCCC(=O)O		Inactive	reactive oxygen species biosynthetic process Inhibitor		1	Nonanedioic acid	170465358.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)CCCCCCCC(=O)O	O=C(O)CCCCCCCC(=O)O
NCGC00381246-01	O=C(O)CCCCCCCC1(OC(=O)C)C(C/C=C\CC)C(=O)C=C1		Inactive	<MOA Unknown> | Class: Fatty acid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381246-01	363679049.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCCCCCCC1(OC(=O)C)C(C/C=C\CC)C(=O)C=C1	O=C(O)CCCCCCCC1(OC(=O)C)C(C/C=C\CC)C(=O)C=C1
NCGC00386022-01	O=C(O)CCCCCCCC1=C(C/C=C/CC)C(=O)CC1		Inactive	<MOA Unknown> | Class: Fatty acid | Genus: Vicoa | Family: Compositae | Species: indica		1	NCGC00386022-01	363680065.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCCCCCCC1=C(C/C=C/CC)C(=O)CC1	O=C(O)CCCCCCCC1=C(C/C=C/CC)C(=O)CC1
NCGC00387080-02	O=C(O)CCCCCCCC1C(CC2C(CCCCC)C2)C1		Inactive			1	DCP-LA	377020504.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	12.0	O=C(O)CCCCCCCC1C(CC2C(CCCCC)C2)C1	O=C(O)CCCCCCCC1C(CC2C(CCCCC)C2)C1
NCGC00091320-05	O=C(O)CCCCCCCCC		Inactive	Peroxisome proliferator-activated receptor gamma Modulator		1	Decanoic acid	225144209.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)CCCCCCCCC	O=C(O)CCCCCCCCC
NCGC00164361-03	O=C(O)CCCCCCCCC(=O)O		Inactive			1	Decanedioic acid	434147023.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCCCCCCCC(=O)O	O=C(O)CCCCCCCCC(=O)O
NCGC00159425-09	O=C(O)CCCCCCCCC=C		Inactive	Fatty Acid Biosynthesis Inhibitor		1	ZINC UNDECYLENATE	405559144.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)CCCCCCCCC=C	O=C(O)CCCCCCCCC=C
NCGC00091596-05	O=C(O)CCCCCCCCCCCCCCCCC		Inactive			1	Octadecanoic acid	170465630.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)CCCCCCCCCCCCCCCCC	O=C(O)CCCCCCCCCCCCCCCCC
NCGC00386020-01	O=C(O)CCCCCCC[C@@H]1[C@@H](C/C=C\CC)C(=O)C=C1		Inactive	<MOA Unknown> | Class: Fatty acid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386020-01	363680064.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCCCCCC[C@@H]1[C@@H](C/C=C\CC)C(=O)C=C1	O=C(O)CCCCCCC[C@@H]1[C@@H](C/C=C\CC)C(=O)C=C1
NCGC00183843-01	O=C(O)CCCCCCNC1c2c(cccc2)CCc2c1cccc2		Inactive	Dopamine transporter Inhibitor		1	Amineptine	144206864.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCCCCCNC1c2c(cccc2)CCc2c1cccc2	O=C(O)CCCCCCNC1c2c(cccc2)CCc2c1cccc2
NCGC00485149-01	O=C(O)CCCCCC[C@@H]1N(CC[C@@H](O)C2CCCCC2)C(=O)NC1=O		Inactive	Prostanoid DP receptor Agonist		1	BW 245C	363681244.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCCCCC[C@@H]1N(CC[C@@H](O)C2CCCCC2)C(=O)NC1=O	O=C(O)CCCCCC[C@@H]1N(CC[C@@H](O)C2CCCCC2)C(=O)NC1=O
NCGC00016535-12&NCGC00016535-19	O=C(O)CCCCCC[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)CC1=O		Inactive			2	Alprostadil&Prostaglandin E1		Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)CCCCCC[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)CC1=O	O=C(O)CCCCCC[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)CC1=O
NCGC00015092-10&NCGC00015092-11	O=C(O)CCCCCN		Inactive	PAI Inhibitor		2	Aminocaproic acid	170465057.0&384567807.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)CCCCCN	O=C(O)CCCCCN
NCGC00485182-01	O=C(O)CCCCCN1C(C)=C(C(=O)OCc2ccccc2)C(c2ccc(-c3ccccc3)cc2)NC1=O		Inactive	Chaperone protein DnaK Inhibitor		1	116-9e	363681250.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCCCCN1C(C)=C(C(=O)OCc2ccccc2)C(c2ccc(-c3ccccc3)cc2)NC1=O	O=C(O)CCCCCN1C(C)=C(C(=O)OCc2ccccc2)C(c2ccc(-c3ccccc3)cc2)NC1=O
NCGC00378941-04	O=C(O)CCCCN(CCc1c(OCc2ccc(CCc3ccccc3)cc2)cccc1)Cc1ccc(C(=O)O)cc1		Inactive	Soluble Guanylate Cyclase (sGC) Activator		1	Cinaciguat	384569076.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCCCN(CCc1c(OCc2ccc(CCc3ccccc3)cc2)cccc1)Cc1ccc(C(=O)O)cc1	O=C(O)CCCCN(CCc1c(OCc2ccc(CCc3ccccc3)cc2)cccc1)Cc1ccc(C(=O)O)cc1
NCGC00346835-01	O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=N)N[C@H]12		Inactive	NOS-2 Inhibitor		1	2-Iminobiotin	174007481.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=N)N[C@H]12	O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=N)N[C@H]12
NCGC00179580-04	O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12		Inactive			1	Biotin	170464763.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12	O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12
NCGC00015043-10	O=C(O)CCCN		Inactive	GABA-A receptor; anion channel Activator		1	GABA	225144171.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)CCCN	O=C(O)CCCN
NCGC00380619-01	O=C(O)CCCN1C(=O)c2c(c3O[C@@]4([C@H](C)CCC5C(C)(C)[C@H](O)[C@H](O)C[C@]45C)Cc3c(O)c2)C1		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380619-01	363678676.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCCN1C(=O)c2c(c3O[C@@]4([C@H](C)CCC5C(C)(C)[C@H](O)[C@H](O)C[C@]45C)Cc3c(O)c2)C1	O=C(O)CCCN1C(=O)c2c(c3O[C@@]4([C@H](C)CCC5C(C)(C)[C@H](O)[C@H](O)C[C@]45C)Cc3c(O)c2)C1
NCGC00183097-01	O=C(O)CCCc1c2O[C@@H]3[C@@H]([C@@H](/C=C/[C@@H](O)C(CC#CC)C)[C@H](O)C3)c2ccc1		Inactive	Thyroid hormone receptor Antagonist		1	Beraprost sodium	144206467.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])CCCc1c2O[C@@H]3[C@@H]([C@@H](/C=C/[C@@H](O)C(CC#CC)C)[C@H](O)C3)c2ccc1.[Na+]	O=C([O-])CCCc1c2O[C@@H]3[C@@H]([C@@H](/C=C/[C@@H](O)C(CC#CC)C)[C@H](O)C3)c2ccc1.[Na+]
NCGC00164296-05	O=C(O)CCCc1c2c([nH]c1)cccc2		Inactive	plant hormone		1	3-indolebutyric acid	363676628.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCCc1c2c([nH]c1)cccc2	O=C(O)CCCc1c2c([nH]c1)cccc2
NCGC00018113-07&NCGC00018113-18	O=C(O)CCCc1ccccc1		Inactive	Glutamine Binding Agent		2	Sodium 4-phenylbutyrate&Sodium Phenylbutyrate	170465108.0&434146968.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C([O-])CCCc1ccccc1.[Na+]	O=C([O-])CCCc1ccccc1.[Na+]&O=C(O)CCCc1ccccc1
NCGC00346575-02	O=C(O)CCN(C(=O)c1cc2nc(CNc3ccc(C(=N)N)cc3)n(C)c2cc1)c1ncccc1		Inactive	Thrombin Inhibitor		1	Dabigatran	384568848.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCN(C(=O)c1cc2nc(CNc3ccc(C(=N)N)cc3)n(C)c2cc1)c1ncccc1	O=C(O)CCN(C(=O)c1cc2nc(CNc3ccc(C(=N)N)cc3)n(C)c2cc1)c1ncccc1
NCGC00378779-01	O=C(O)CCN(CCCOc1ccc(Cc2ccccc2)cc1)C		Inactive	Leukotriene A-4 hydrolase Inhibitor		1	SC 57461A	363678193.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCN(CCCOc1ccc(Cc2ccccc2)cc1)C	O=C(O)CCN(CCCOc1ccc(Cc2ccccc2)cc1)C
NCGC00373154-02	O=C(O)CCN(O)C(=O)CCCCCCCCC1CC1		Inactive			1	TC-E 5002		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCN(O)C(=O)CCCCCCCCC1CC1	O=C(O)CCN(O)C(=O)CCCCCCCCC1CC1
NCGC00164634-02&NCGC00164634-07	O=C(O)CCNC(=O)c1ccc(/N=N/c2cc(C(=O)O)c(O)cc2)cc1		Inactive	agents for IBS and constipation		2	Balsalazide disodium	170465305.0&384568272.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&10.4503904479	O=C(O)CCNC(=O)c1ccc(/N=N/c2cc(C(=O)O)c(O)cc2)cc1	O=C(O)CCNC(=O)c1ccc(/N=N/c2cc(C(=O)O)c(O)cc2)cc1
NCGC00018241-07	O=C(O)CCNC(=O)c1ccccc1		Inactive	Solute carrier family 22 member 8 Inhibitor		1	Betamipron	170466040.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCNC(=O)c1ccccc1	O=C(O)CCNC(=O)c1ccccc1
NCGC00371010-02	O=C(O)CCNC1c2c(c(-c3nc(-c4cc(C#N)c(OC(C)C)cc4)on3)ccc2)CC1		Inactive	Sphingosine 1-phosphate receptor Edg-1  Agonist		1	RP 001 hydrochloride	363677991.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCNC1c2c(c(-c3nc(-c4cc(C#N)c(OC(C)C)cc4)on3)ccc2)CC1	O=C(O)CCNC1c2c(c(-c3nc(-c4cc(C#N)c(OC(C)C)cc4)on3)ccc2)CC1
NCGC00351549-05	O=C(O)CCNc1nc(-c2cnccc2)nc(N2CCc3c(cccc3)CC2)c1		Inactive	Inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A		1	GSK-J2	384569011.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCNc1nc(-c2cnccc2)nc(N2CCc3c(cccc3)CC2)c1	O=C(O)CCNc1nc(-c2cnccc2)nc(N2CCc3c(cccc3)CC2)c1
NCGC00420877-01	O=C(O)CCNc1nc(-c2ncccc2)nc(N2CCN(C(=O)C(C#N)=C(C)C)CCC2)c1		Inactive			1	NCGC00420877-01		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCNc1nc(-c2ncccc2)nc(N2CCN(C(=O)C(C#N)=C(C)C)CCC2)c1	O=C(O)CCNc1nc(-c2ncccc2)nc(N2CCN(C(=O)C(C#N)=C(C)C)CCC2)c1
NCGC00347943-09	O=C(O)CCNc1nc(-c2ncccc2)nc(N2CCc3c(cccc3)CC2)c1		Inactive	H3K27 Histone Demethylases UTX and JMJD3 Inhibitor		1	GSK-J1	363677724.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCNc1nc(-c2ncccc2)nc(N2CCc3c(cccc3)CC2)c1	O=C(O)CCNc1nc(-c2ncccc2)nc(N2CCc3c(cccc3)CC2)c1
NCGC00024025-05	O=C(O)CC[C@@H](C)[C@@H]1[C@@]2(C)C(=O)C[C@@H]3[C@]4(C)[C@H](CC(=O)[C@H]3[C@@H]2CC1)CC(=O)CC4		Inactive	bile acid secretion Inhibitor		1	Dehydrocholic acid	170465502.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)CC[C@@H](C)[C@@H]1[C@@]2(C)C(=O)C[C@@H]3[C@]4(C)[C@H](CC(=O)[C@H]3[C@@H]2CC1)CC(=O)CC4	O=C(O)CC[C@@H](C)[C@@H]1[C@@]2(C)C(=O)C[C@@H]3[C@]4(C)[C@H](CC(=O)[C@H]3[C@@H]2CC1)CC(=O)CC4
NCGC00091038-04	O=C(O)CC[C@@H](C)[C@@H]1[C@@]2(C)[C@@H](O)C[C@@H]3[C@]4(C)[C@@H](C[C@H](O)CC4)CC[C@H]3[C@@H]2CC1		Inactive			1	Sodium deoxycholate monohydrate	225144203.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C([O-])CC[C@@H](C)[C@@H]1[C@@]2(C)[C@@H](O)C[C@@H]3[C@]4(C)[C@@H](C[C@H](O)CC4)CC[C@H]3[C@@H]2CC1	O=C([O-])CC[C@@H](C)[C@@H]1[C@@]2(C)[C@@H](O)C[C@@H]3[C@]4(C)[C@@H](C[C@H](O)CC4)CC[C@H]3[C@@H]2CC1
NCGC00142384-03	O=C(O)CC[C@@H](C)[C@@H]1[C@@]2(C)[C@@H](O)C[C@@H]3[C@]4(C)[C@H](C[C@@H](O)[C@H]3[C@@H]2CC1)C[C@H](O)CC4		Inactive	Bile acid receptor FXR Agonist		1	Cholic Acid	405559065.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)CC[C@@H](C)[C@@H]1[C@@]2(C)[C@@H](O)C[C@@H]3[C@]4(C)[C@H](C[C@@H](O)[C@H]3[C@@H]2CC1)C[C@H](O)CC4	O=C(O)CC[C@@H](C)[C@@H]1[C@@]2(C)[C@@H](O)C[C@@H]3[C@]4(C)[C@H](C[C@@H](O)[C@H]3[C@@H]2CC1)C[C@H](O)CC4
NCGC00264052-02	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)C(C3C([C@]4(C)[C@H]([C@@H](O)C3)C[C@H](O)CC4)CC2)CC1		Inactive	Glucocorticoid steroid		1	Hyodeoxycholic acid	384568702.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.7822691719	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)C(C3C([C@]4(C)[C@H]([C@@H](O)C3)C[C@H](O)CC4)CC2)CC1	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)C(C3C([C@]4(C)[C@H]([C@@H](O)C3)C[C@H](O)CC4)CC2)CC1
NCGC00179363-03&NCGC00179363-05	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@@H](O)C[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1		Inactive	Steroid		2	Ursodiol	225144303.0&384568372.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@@H](O)C[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@@H](O)C[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1
NCGC00142400-07	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@H](O)C[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1		Inactive	Farnesoid X Receptor Agonist		1	Chenodeoxycholic acid	384568162.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@H](O)C[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@H](O)C[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1
NCGC00480885-01	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@H](O)[C@H](CC)[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1		Inactive	Bile acid receptor FXR Agonist		1	INT-747 (Obeticholic acid)	405558423.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@H](O)[C@H](CC)[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1	O=C(O)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@@H]3[C@H](O)[C@H](CC)[C@H]4[C@@](C)([C@H]3CC2)CC[C@@H](O)C4)CC1
NCGC00380320-01	O=C(O)CC[C@@]1(C)C(C(O)(C)C)C(O)C[C@]2(C)Oc3c(C)c4c(c(OC)c3C[C@H]12)C(=O)OC4		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: ct: Aspergillus | Family: N/A | Species: N/A		1	NCGC00380320-01	363678540.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CC[C@@]1(C)C(C(O)(C)C)C(O)C[C@]2(C)Oc3c(C)c4c(c(OC)c3C[C@H]12)C(=O)OC4	O=C(O)CC[C@@]1(C)C(C(O)(C)C)C(O)C[C@]2(C)Oc3c(C)c4c(c(OC)c3C[C@H]12)C(=O)OC4
NCGC00179626-05	O=C(O)CC[C@@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)C=C3)CC2)CC1		Inactive	Mineralocorticoid Receptor Antagonist		1	NCGC00179626-05	405558909.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])CC[C@@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)C=C3)CC2)CC1	O=C([O-])CC[C@@]1(O)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)C=C3)CC2)CC1
NCGC00013414-04	O=C(O)CCc1[nH]c2c(n1)cccc2		Inactive			1	Procodazole	170466381.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCc1[nH]c2c(n1)cccc2	O=C(O)CCc1[nH]c2c(n1)cccc2
NCGC00346878-04	O=C(O)CCc1c(/C=C/2\C(=O)Nc3c\2cccc3)[nH]cc1C		Inactive	FGFR 1/3 Inhibitor		1	SU-5402	384568956.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCc1c(/C=C/2\C(=O)Nc3c\2cccc3)[nH]cc1C	O=C(O)CCc1c(/C=C/2\C(=O)Nc3c\2cccc3)[nH]cc1C
NCGC00370874-01	O=C(O)CCc1c(C)c(/C=C/2\C(=O)Nc3c\2ccc(-c2ccccc2)c3)[nH]c1C		Inactive	Platelet-derived growth factor receptor beta Inhibitor		1	SU 16f	363677902.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCc1c(C)c(/C=C/2\C(=O)Nc3c\2ccc(-c2ccccc2)c3)[nH]c1C	O=C(O)CCc1c(C)c(/C=C/2\C(=O)Nc3c\2ccc(-c2ccccc2)c3)[nH]c1C
NCGC00241113-04	O=C(O)CCc1c(C)c(/C=C/2\C(=O)Nc3c\2cccc3)[nH]c1C		Inactive	VEGFR-2 Inhibitor		1	Orantinib	384568478.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCc1c(C)c(/C=C/2\C(=O)Nc3c\2cccc3)[nH]c1C	O=C(O)CCc1c(C)c(/C=C/2\C(=O)Nc3c\2cccc3)[nH]c1C
NCGC00381349-01	O=C(O)CCc1c(CC(=O)O)c(C(=O)C)[nH]c1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381349-01	363679101.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCc1c(CC(=O)O)c(C(=O)C)[nH]c1	O=C(O)CCc1c(CC(=O)O)c(C(=O)C)[nH]c1
NCGC00380817-01	O=C(O)CCc1c(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380817-01	363678798.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCc1c(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc1	O=C(O)CCc1c(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc1
NCGC00380819-01	O=C(O)CCc1c(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380819-01	363678800.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCc1c(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc1	O=C(O)CCc1c(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)ccc1
NCGC00381184-01	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(O)ccc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381184-01	363679011.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(O)ccc1	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(O)ccc1
NCGC00384499-01	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(OC)c2occc2c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: crithmum | Family: Umbelliferae | Species: maritimum		1	NCGC00384499-01	363679216.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(OC)c2occc2c1	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(OC)c2occc2c1
NCGC00168932-02	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c(occ2)cc1OC		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Ferulago | Family: Umbelliferae | Species: thyrsiflora		1	NCGC00168932-02	363676727.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c(occ2)cc1OC	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c(occ2)cc1OC
NCGC00180868-02	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Herniaria | Family: Caryophyllaceae | Species: glabra		1	NCGC00180868-02	363677077.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC)cc1	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC)cc1
NCGC00169648-02	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc2occc2c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Cachrys | Family: N/A | Species: libanotis		1	NCGC00169648-02	363676855.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc2occc2c1	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc2occc2c1
NCGC00380757-01	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@](O)(CO)CO3)O2)cc2occc2c1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380757-01	363678763.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@](O)(CO)CO3)O2)cc2occc2c1	O=C(O)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@](O)(CO)CO3)O2)cc2occc2c1
NCGC00344089-02	O=C(O)CCc1ccc(C#Cc2c(C)cccc2)cc1		Inactive	G-protein coupled receptor 120 Agonist		1	TUG 424	363677326.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCc1ccc(C#Cc2c(C)cccc2)cc1	O=C(O)CCc1ccc(C#Cc2c(C)cccc2)cc1
NCGC00024976-06	O=C(O)CCc1ccc(CCNc2nc(N)c3ncn([C@H]4[C@H](O)[C@H](O)[C@@H](C(=O)NCC)O4)c3n2)cc1		Inactive	Adenosine A2A Agonist		1	CGS-21680	363676534.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCc1ccc(CCNc2nc(N)c3ncn([C@H]4[C@H](O)[C@H](O)[C@@H](C(=O)NCC)O4)c3n2)cc1	O=C(O)CCc1ccc(CCNc2nc(N)c3ncn([C@H]4[C@H](O)[C@H](O)[C@@H](C(=O)NCC)O4)c3n2)cc1
NCGC00167811-13	O=C(O)CCc1ccc(NCc2cc(Oc3ccccc3)ccc2)cc1		Inactive	Free Fatty Acid Receptor 1 Agonist		1	GW-9508	363676671.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	22.0	O=C(O)CCc1ccc(NCc2cc(Oc3ccccc3)ccc2)cc1	O=C(O)CCc1ccc(NCc2cc(Oc3ccccc3)ccc2)cc1
NCGC00382803-03	O=C(O)CCc1ccc(O)cc1		Inactive			1	Desaminotyrosine	434147121.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCc1ccc(O)cc1	O=C(O)CCc1ccc(O)cc1
NCGC00164584-03	O=C(O)CCc1ccc(OC(=O)C2CCC(CN)CC2)cc1		Inactive	Prostaglandin Synthesis and Regulation Modulator		1	Cetraxate hydrochloride	170465783.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)CCc1ccc(OC(=O)C2CCC(CN)CC2)cc1.Cl	O=C(O)CCc1ccc(OC(=O)C2CCC(CN)CC2)cc1.Cl
NCGC00378558-04	O=C(O)CCc1n(c(-c2ccc(-n3cncc3)cc2)cc1)-c1c(C)cc(C(=O)N)cc1		Inactive			1	N6022	363678090.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCc1n(c(-c2ccc(-n3cncc3)cc2)cc1)-c1c(C)cc(C(=O)N)cc1	O=C(O)CCc1n(c(-c2ccc(-n3cncc3)cc2)cc1)-c1c(C)cc(C(=O)N)cc1
NCGC00385560-01	O=C(O)CCc1nccc2c1[nH]c1c2cccc1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385560-01	363679808.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CCc1nccc2c1[nH]c1c2cccc1	O=C(O)CCc1nccc2c1[nH]c1c2cccc1
NCGC00014711-14	O=C(O)CCc1oc(c(-c2ccccc2)n1)-c1ccccc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Oxaprozin	170464987.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)CCc1oc(c(-c2ccccc2)n1)-c1ccccc1	O=C(O)CCc1oc(c(-c2ccccc2)n1)-c1ccccc1
NCGC00532505-01	O=C(O)CN(C)C		Inactive	Glutamate [NMDA] receptor Agonist		1	N,N-DIMETHYLGLYCINE HYDROCHLORIDE	405558468.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CN(C)C	O=C(O)CN(C)C
NCGC00016902-04	O=C(O)CN(CC(=O)O)CC(=O)Nc1c(CC)cccc1CC		Inactive			1	Etifenin	170466635.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)CN(CC(=O)O)CC(=O)Nc1c(CC)cccc1CC	O=C(O)CN(CC(=O)O)CC(=O)Nc1c(CC)cccc1CC
NCGC00015360-08	O=C(O)CN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC(=O)O		Inactive	Radioactive metals Chelating Agent		1	Pentetic acid	170465150.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&11.56321112	O=C(O)CN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC(=O)O	O=C(O)CN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC(=O)O
NCGC00181349-02	O=C(O)CN(CC(=O)O)c1c(C#N)c(CC(=O)O)c(C(=O)O)s1		Inactive			1	Strontium Ranelate	225144325.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C([O-])CN(CC(=O)[O-])c1c(C#N)c(CC(=O)[O-])c(C(=O)[O-])s1	O=C([O-])CN(CC(=O)[O-])c1c(C#N)c(CC(=O)[O-])c(C(=O)[O-])s1
NCGC00370805-01	O=C(O)CN(CCOc1c(C(C)(C)C)cc(-c2cc3OCOc3cc2)cc1)C		Inactive	GlyT-1 Inhibitor		1	LY-2365109 hydrochloride	384569036.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CN(CCOc1c(C(C)(C)C)cc(-c2cc3OCOc3cc2)cc1)C	O=C(O)CN(CCOc1c(C(C)(C)C)cc(-c2cc3OCOc3cc2)cc1)C
NCGC00263114-01	O=C(O)CN(C[C@H]1[C@@H](c2ccccc2)c2c(cc(OC)cc2)CC1)C		Inactive	Glycine Transporter 1 (GlyT-1) Inhibitor		1	SCH-900435	137275958.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CN(C[C@H]1[C@@H](c2ccccc2)c2c(cc(OC)cc2)CC1)C	O=C(O)CN(C[C@H]1[C@@H](c2ccccc2)c2c(cc(OC)cc2)CC1)C
NCGC00166207-01	O=C(O)CN1c2c(C(=O)c3c1cccc3)cccc2		Inactive	Interferon Inducers		1	Cridanimod	144205901.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CN1c2c(C(=O)c3c1cccc3)cccc2	O=C(O)CN1c2c(C(=O)c3c1cccc3)cccc2
NCGC00496910-01	O=C(O)CNC(=O)C1C(=O)N(C(=O)N(C1=O)C1CCCCC1)C1CCCCC1		Inactive	HIF Prolyl Hydroxylase Inhibitor		1	Daprodustat	384569297.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CNC(=O)C1C(=O)N(C(=O)N(C1=O)C1CCCCC1)C1CCCCC1	O=C(O)CNC(=O)C1C(=O)N(C(=O)N(C1=O)C1CCCCC1)C1CCCCC1
NCGC00344625-13	O=C(O)CNC(=O)C=1C(=O)N(Cc2ccccc2)c2c(C=1O)cccc2		Inactive	HIF Prolyl Hydroxylase Inhibitor		1	IOX2	363677341.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	9.407751164	O=C(O)CNC(=O)C=1C(=O)N(Cc2ccccc2)c2c(C=1O)cccc2	O=C(O)CNC(=O)C=1C(=O)N(Cc2ccccc2)c2c(C=1O)cccc2
NCGC00346527-03	O=C(O)CNC(=O)c1c(O)c2c(c(C)n1)cc(Oc1ccccc1)cc2		Inactive	HIF Prolyl Hydroxylase Inhibitor		1	Roxadustat	384568821.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CNC(=O)c1c(O)c2c(c(C)n1)cc(Oc1ccccc1)cc2	O=C(O)CNC(=O)c1c(O)c2c(c(C)n1)cc(Oc1ccccc1)cc2
NCGC00016279-05	O=C(O)CNC(=O)c1ccc(N)cc1		Inactive			1	Aminohippuric acid	170465155.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)CNC(=O)c1ccc(N)cc1	O=C(O)CNC(=O)c1ccc(N)cc1
NCGC00159486-06	O=C(O)CNC(=O)c1ccccc1		Inactive	Solute carrier family 22 member 8 Inhibitor		1	Hippuric acid	170464791.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)CNC(=O)c1ccccc1	O=C(O)CNC(=O)c1ccccc1
NCGC00274269-01	O=C(O)CNCCNCCNCCCCCCCCCCCC		Inactive			1	NCGC00274269-01	225144370.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	11.920668064&14.23357664	O=C(O)CNCCNCCNCCCCCCCCCCCC	O=C(O)CNCCNCCNCCCCCCCCCCCC
NCGC00485029-01	O=C(O)CO/N=C\1/C=C2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)CC/1		Inactive			1	Testosterone 3-(O-carboxymethyl)oxime	363681197.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CO/N=C\1/C=C2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)CC/1	O=C(O)CO/N=C\1/C=C2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)CC/1
NCGC00485143-01	O=C(O)CO/N=C\1/C=C2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)CO)CC[C@H]4[C@@H]3CC2)CC/1		Inactive			1	Hydrocortisone 3-(O-carboxymethyl)oxime	363681242.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)CO/N=C\1/C=C2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)CO)CC[C@H]4[C@@H]3CC2)CC/1	O=C(O)CO/N=C\1/C=C2[C@@](C)([C@H]3[C@@H](O)C[C@]4(C)[C@@](O)(C(=O)CO)CC[C@H]4[C@@H]3CC2)CC/1
NCGC00476132-02	O=C(O)COCCCCN(C(C)C)c1nc(c(-c2ccccc2)nc1)-c1ccccc1		Inactive			1	MRE-269 (ACT-333679)		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)COCCCCN(C(C)C)c1nc(c(-c2ccccc2)nc1)-c1ccccc1	O=C(O)COCCCCN(C(C)C)c1nc(c(-c2ccccc2)nc1)-c1ccccc1
NCGC00159481-03	O=C(O)COc1c(C(=O)/C=C/c2ccc(OC/C=C(\C)/C)cc2)ccc(OC/C=C(\C)/C)c1	4.9000001	Active	Prostaglandin Synthesis and Regulation Modulator	0.0	1	Sofalcone	170466017.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	60.4152667985	O=C(O)COc1c(C(=O)/C=C/c2ccc(OC/C=C(\C)/C)cc2)ccc(OC/C=C(\C)/C)c1	O=C(O)COc1c(C(=O)/C=C/c2ccc(OC/C=C(\C)/C)cc2)ccc(OC/C=C(\C)/C)c1
NCGC00319020-01	O=C(O)COc1c2c(ccc1)C[C@H]1[C@H](CC[C@H](O)CCCCC)[C@@H](O)C[C@H]1C2		Inactive	Prostanoid IP receptor Agonist		1	NCGC00319020-01	225144374.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)COc1c2c(ccc1)C[C@H]1[C@H](CC[C@H](O)CCCCC)[C@@H](O)C[C@H]1C2	O=C(O)COc1c2c(ccc1)C[C@H]1[C@H](CC[C@H](O)CCCCC)[C@@H](O)C[C@H]1C2
NCGC00387254-02	O=C(O)COc1cc(-c2c(-n3c(CC)c(c(-c4ccccc4)n3)-c3ccccc3)cccc2)ccc1		Inactive	Fatty acid-binding protein, brain Inhibitor		1	FABP4 inhibitor 	363680595.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)COc1cc(-c2c(-n3c(CC)c(c(-c4ccccc4)n3)-c3ccccc3)cccc2)ccc1	O=C(O)COc1cc(-c2c(-n3c(CC)c(c(-c4ccccc4)n3)-c3ccccc3)cccc2)ccc1
NCGC00370927-01	O=C(O)COc1ccc(-c2[nH]c3C(=O)N(CCC)C(=O)N(CCC)c3n2)cc1		Inactive	Adenosine A2b receptor Antagonist		1	XCC	363677939.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)COc1ccc(-c2[nH]c3C(=O)N(CCC)C(=O)N(CCC)c3n2)cc1	O=C(O)COc1ccc(-c2[nH]c3C(=O)N(CCC)C(=O)N(CCC)c3n2)cc1
NCGC00015599-10	O=C(O)COc1ccc(OCCCOc2c(CCC)c(O)c(C(=O)C)cc2)cc1	5.0500002	Active	PPARdelta Agonist	0.0	1	L-165041	384567870.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	41.8835247956	O=C(O)COc1ccc(OCCCOc2c(CCC)c(O)c(C(=O)C)cc2)cc1	O=C(O)COc1ccc(OCCCOc2c(CCC)c(O)c(C(=O)C)cc2)cc1
NCGC00091151-04	O=C(O)COc1ccccc1		Inactive	cell proliferation Activator		1	Phenoxyacetic acid	170465537.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)COc1ccccc1	O=C(O)COc1ccccc1
NCGC00263571-01	O=C(O)COc1nn(Cc2ccccc2)c2c1cccc2		Inactive	Xanthine dehydrogenase/oxidase Inhibitor		1	Bendazac sodium	170465952.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])COc1nn(Cc2ccccc2)c2c1cccc2.[Na+]	O=C([O-])COc1nn(Cc2ccccc2)c2c1cccc2.[Na+]
NCGC00095186-11	O=C(O)C[C@@H](CN)CC(C)C		Inactive			1	Pregabalin		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C[C@@H](CN)CC(C)C	O=C(O)C[C@@H](CN)CC(C)C
NCGC00386512-01	O=C(O)C[C@@H](NC(=O)c1scc(-c2ccc(-c3ccncc3)cc2)c1)c1ccccc1		Inactive	Matrix metalloproteinase 12 Inhibitor		1	PF 00356231	363680311.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C[C@@H](NC(=O)c1scc(-c2ccc(-c3ccncc3)cc2)c1)c1ccccc1	O=C(O)C[C@@H](NC(=O)c1scc(-c2ccc(-c3ccncc3)cc2)c1)c1ccccc1
NCGC00507844-01	O=C(O)C[C@@H]1C(=O)N2[C@H](C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](Cc3c4c([nH]c3)cccc4)C(=O)N1)CCC2		Inactive	Endothelin ETA Receptor Antagonist		1	BQ-123	384569325.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C[C@@H]1C(=O)N2[C@H](C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](Cc3c4c([nH]c3)cccc4)C(=O)N1)CCC2	O=C(O)C[C@@H]1C(=O)N2[C@H](C(=O)N[C@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](Cc3c4c([nH]c3)cccc4)C(=O)N1)CCC2
NCGC00024504-09	O=C(O)C[C@@H]1[C@@H](C(=O)O)NC[C@@H]1C(=C)C		Inactive	Glutamate receptor ionotropic kainate 5 Agonist		1	Kainic acid	170465818.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)C[C@@H]1[C@@H](C(=O)O)NC[C@@H]1C(=C)C	O=C(O)C[C@@H]1[C@@H](C(=O)O)NC[C@@H]1C(=C)C
NCGC00385243-01	O=C(O)C[C@@H]1[C@@H](C/C=C\CCO)C(=O)CC1		Inactive	<MOA Unknown> | Class: Fatty acid | Genus: Thymus | Family: Labiatae | Species: pallidus		1	NCGC00385243-01	363679614.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C[C@@H]1[C@@H](C/C=C\CCO)C(=O)CC1	O=C(O)C[C@@H]1[C@@H](C/C=C\CCO)C(=O)CC1
NCGC00380878-01	O=C(O)C[C@@H]1[C@@H](C/C=C\CCOC2C(O)C(O)C(O)C(CO)O2)C(=O)CC1		Inactive	<MOA Unknown> | Class: Fatty acid | Genus: Lavendula | Family: Lamiaceae | Species: officinalis		1	NCGC00380878-01	363678830.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C[C@@H]1[C@@H](C/C=C\CCOC2C(O)C(O)C(O)C(CO)O2)C(=O)CC1	O=C(O)C[C@@H]1[C@@H](C/C=C\CCOC2C(O)C(O)C(O)C(CO)O2)C(=O)CC1
NCGC00378586-01	O=C(O)C[C@H](C#CC)c1ccc(OCc2sc(CN3CCC4(c5c(cccc5)C=C4)CC3)cc2)cc1		Inactive	Free fatty acid receptor 1 Agonist		1	GPR40 Activator 1	363678103.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	11.8758749439	O=C(O)C[C@H](C#CC)c1ccc(OCc2sc(CN3CCC4(c5c(cccc5)C=C4)CC3)cc2)cc1	O=C(O)C[C@H](C#CC)c1ccc(OCc2sc(CN3CCC4(c5c(cccc5)C=C4)CC3)cc2)cc1
NCGC00180720-03	O=C(O)C[C@H](CC[C@H]1C(C)=CC(=O)C2C(C)(C)CCC[C@]12C)C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Cistus | Family: Cistaceae | Species: ladanifer		1	NCGC00180720-03	363677054.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C[C@H](CC[C@H]1C(C)=CC(=O)C2C(C)(C)CCC[C@]12C)C	O=C(O)C[C@H](CC[C@H]1C(C)=CC(=O)C2C(C)(C)CCC[C@]12C)C
NCGC00180676-03	O=C(O)C[C@H](CC[C@H]1[C@@](O)(C)CCC2C(C)(C)CCC[C@]12C)C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Cistus | Family: Cistaceae | Species: ladanifer		1	NCGC00180676-03	363677046.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C[C@H](CC[C@H]1[C@@](O)(C)CCC2C(C)(C)CCC[C@]12C)C	O=C(O)C[C@H](CC[C@H]1[C@@](O)(C)CCC2C(C)(C)CCC[C@]12C)C
NCGC00483929-01	O=C(O)C[C@H](c1cc(OC)c2n(C)nnc2c1)c1cc(CN2S(=O)(=O)c3c(O[C@H](C)C2)cccc3)c(C)cc1		Inactive	NRF2:KEAP1 Inhibitor		1	KI-696	363681148.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C[C@H](c1cc(OC)c2n(C)nnc2c1)c1cc(CN2S(=O)(=O)c3c(O[C@H](C)C2)cccc3)c(C)cc1	O=C(O)C[C@H](c1cc(OC)c2n(C)nnc2c1)c1cc(CN2S(=O)(=O)c3c(O[C@H](C)C2)cccc3)c(C)cc1
NCGC00384663-01	O=C(O)C[C@H]1/C(=C/C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Fraxinus | Family: Oleaceae | Species: excelsior		1	NCGC00384663-01	363679298.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C[C@H]1/C(=C/C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC	O=C(O)C[C@H]1/C(=C/C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC
NCGC00167505-03	O=C(O)C[C@H]1C(=O)N[C@@H](Cc2c3c([nH]c2)cccc3)C(=O)N2[C@H](C(=O)N[C@H](C(=O)N)CSSCCC(=O)N[C@@H](CCCCNC(=N)N)C(=O)NCC(=O)N1)CCC2		Inactive	Integrin alpha-IIb/beta-3 Inhibitor		1	Eptifibatide	405558574.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C[C@H]1C(=O)N[C@@H](Cc2c3c([nH]c2)cccc3)C(=O)N2[C@H](C(=O)N[C@H](C(=O)N)CSSCCC(=O)N[C@@H](CCCCNC(=N)N)C(=O)NCC(=O)N1)CCC2	O=C(O)C[C@H]1C(=O)N[C@@H](Cc2c3c([nH]c2)cccc3)C(=O)N2[C@H](C(=O)N[C@H](C(=O)N)CSSCCC(=O)N[C@@H](CCCCNC(=N)N)C(=O)NCC(=O)N1)CCC2
NCGC00390264-01	O=C(O)C[C@H]1C(=O)N[C@H](Cc2ccccc2)C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N1		Inactive	Integrin alphavbeta3 (Vitronectin) Antagonist		1	Cilengitide	384569183.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C[C@H]1C(=O)N[C@H](Cc2ccccc2)C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N1	O=C(O)C[C@H]1C(=O)N[C@H](Cc2ccccc2)C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N1
NCGC00386242-02	O=C(O)C[C@H]1C(=O)N[C@H](Cc2ccccc2)C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N1		Inactive	Integrin alpha-V/beta-5 Antagonist		1	Cilengitide	405558444.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C[C@H]1C(=O)N[C@H](Cc2ccccc2)C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N1	O=C(O)C[C@H]1C(=O)N[C@H](Cc2ccccc2)C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N1
NCGC00510003-01	O=C(O)C[C@H]1OB(O)[C@@H](NC(=O)Cc2sccc2)CC1		Inactive			1	Vaborbactam	405559093.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C[C@H]1OB(O)[C@@H](NC(=O)Cc2sccc2)CC1	O=C(O)C[C@H]1OB(O)[C@@H](NC(=O)Cc2sccc2)CC1
NCGC00380454-01	O=C(O)C[C@H]1[C@@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Lonicera | Family: Caprifoliaceae | Species: etrusca		1	NCGC00380454-01	363678593.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C[C@H]1[C@@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC	O=C(O)C[C@H]1[C@@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC
NCGC00169595-03	O=C(O)C[C@]1(C)O[C@@]2(C(C)=CCC3C(C)(C)CCC[C@]23C)CC1		Inactive	WiDr Inhibitor		1	NCGC00169595-03	363676847.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)C[C@]1(C)O[C@@]2(C(C)=CCC3C(C)(C)CCC[C@]23C)CC1	O=C(O)C[C@]1(C)O[C@@]2(C(C)=CCC3C(C)(C)CCC[C@]23C)CC1
NCGC00485429-01	O=C(O)Cc1c(-c2c3c(nc4c2CC(C(=O)NN)CC4)cccc3)cc(N/C=C/2\C(=O)Oc3c(C\2=O)ccc(N(CC)CC)c3)cc1		Inactive	Butyrylcholinesterase Inhibitor		1	PE 154	363681334.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	18.432571432	O=C(O)Cc1c(-c2c3c(nc4c2CC(C(=O)NN)CC4)cccc3)cc(N/C=C/2\C(=O)Oc3c(C\2=O)ccc(N(CC)CC)c3)cc1	O=C(O)Cc1c(-c2c3c(nc4c2CC(C(=O)NN)CC4)cccc3)cc(N/C=C/2\C(=O)Oc3c(C\2=O)ccc(N(CC)CC)c3)cc1
NCGC00184993-03	O=C(O)Cc1c(N)c(C(=O)c2ccccc2)ccc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Amfenac Sodium	225144335.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C([O-])Cc1c(N)c(C(=O)c2ccccc2)ccc1	O=C([O-])Cc1c(N)c(C(=O)c2ccccc2)ccc1
NCGC00167563-01	O=C(O)Cc1c(c(-c2ccc(OC)cc2)no1)-c1ccc(OC)cc1		Inactive	Cyclooxygenase-1 Inhibitor		1	Mofezolac	144206111.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)Cc1c(c(-c2ccc(OC)cc2)no1)-c1ccc(OC)cc1	O=C(O)Cc1c(c(-c2ccc(OC)cc2)no1)-c1ccc(OC)cc1
NCGC00165783-03&NCGC00165783-04	O=C(O)Cc1c2Oc3c(C)c(C)ccc3C(=O)c2ccc1		Inactive	Interferon Inducer		2	Vadimezan	384568283.0&434147030.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)Cc1c2Oc3c(C)c(C)ccc3C(=O)c2ccc1	O=C(O)Cc1c2Oc3c(C)c(C)ccc3C(=O)c2ccc1
NCGC00090987-05	O=C(O)Cc1c2c(ccc1)cccc2		Inactive	Fusarium oxysporum Inhibitor		1	1-Naphthaleneacetic acid	170466030.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)Cc1c2c(ccc1)cccc2	O=C(O)Cc1c2c(ccc1)cccc2
NCGC00380387-01	O=C(O)Cc1c2c(n(C3C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)C(O)C(O)CO3)c1)cccc2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380387-01	363678562.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)Cc1c2c(n(C3C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)C(O)C(O)CO3)c1)cccc2	O=C(O)Cc1c2c(n(C3C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)C(O)C(O)CO3)c1)cccc2
NCGC00385010-01	O=C(O)Cc1c2c(n([C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O3)c1)cccc2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385010-01	363679482.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)Cc1c2c(n([C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O3)c1)cccc2	O=C(O)Cc1c2c(n([C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O)[C@@H](CO)O3)c1)cccc2
NCGC00385011-01	O=C(O)Cc1c2c(n([C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)CO3)c1)cccc2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385011-01	363679483.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)Cc1c2c(n([C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)CO3)c1)cccc2	O=C(O)Cc1c2c(n([C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)CO3)c1)cccc2
NCGC00183833-01	O=C(O)Cc1cc(-c2c(O[C@@H]3[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)ccc(CCCCCCc3cc(c(O[C@@H]4[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cc3)-c3cc(CC(=O)O)ccc3)c2)ccc1		Inactive	Selectin E Inhibitor		1	Bimosiamose	144206811.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)Cc1cc(-c2c(O[C@@H]3[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)ccc(CCCCCCc3cc(c(O[C@@H]4[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cc3)-c3cc(CC(=O)O)ccc3)c2)ccc1	O=C(O)Cc1cc(-c2c(O[C@@H]3[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)ccc(CCCCCCc3cc(c(O[C@@H]4[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cc3)-c3cc(CC(=O)O)ccc3)c2)ccc1
NCGC00263532-01&NCGC00263532-10	O=C(O)Cc1cc2/C(=C\CCN(C)C)/c3c(cccc3)COc2cc1		Inactive	Mediator Release Inhibitor		2	Olopatadine hydrochloride	170465181.0&384568685.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)Cc1cc2/C(=C\CCN(C)C)/c3c(cccc3)COc2cc1.Cl	O=C(O)Cc1cc2/C(=C\CCN(C)C)/c3c(cccc3)COc2cc1.Cl&O=C(O)Cc1cc2/C(=C\CCN(C)C)/c3c(cccc3)COc2cc1
NCGC00160451-02	O=C(O)Cc1ccc(CC(C)C)cc1		Inactive			1	Ibufenac	170465922.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)Cc1ccc(CC(C)C)cc1	O=C(O)Cc1ccc(CC(C)C)cc1
NCGC00160450-03	O=C(O)Cc1ccc(NC(=O)C)cc1		Inactive			1	4-Acetylaminophenylacetic acid	170465954.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)Cc1ccc(NC(=O)C)cc1	O=C(O)Cc1ccc(NC(=O)C)cc1
NCGC00385797-01	O=C(O)Cc1ccc(OCC(O)C(=C)C)cc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385797-01	363679943.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)Cc1ccc(OCC(O)C(=C)C)cc1	O=C(O)Cc1ccc(OCC(O)C(=C)C)cc1
NCGC00159477-05	O=C(O)Cc1ccccc1		Inactive			1	Phenylacetic acid	170465102.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	6.427530816&0.0	O=C(O)Cc1ccccc1	O=C(O)Cc1ccccc1
NCGC00447128-01	O=C(O)Cc1cnc(-c2ccc(C(C)N3CCCCC3)cc2)cc1		Inactive			1	NCGC00447128-01	375883306.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)Cc1cnc(-c2ccc(C(C)N3CCCCC3)cc2)cc1	O=C(O)Cc1cnc(-c2ccc(C(C)N3CCCCC3)cc2)cc1
NCGC00178815-03	O=C(O)Cc1n(C)c(C(=O)c2ccc(C)cc2)cc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Tolmetin sodium dihydrate	170465216.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C([O-])Cc1n(C)c(C(=O)c2ccc(C)cc2)cc1.[Na+].O.O	O=C([O-])Cc1n(C)c(C(=O)c2ccc(C)cc2)cc1.[Na+].O.O
NCGC00386759-01	O=C(O)Cn1nc(-c2ccc(CN(CCCCOc3ccc(CN4CCCC4)cc3)CCc3ccccc3)cc2)nn1		Inactive	Histone acetyltransferase KAT5 Inhibitor		1	TH 1834	363680437.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)Cn1nc(-c2ccc(CN(CCCCOc3ccc(CN4CCCC4)cc3)CCc3ccccc3)cc2)nn1	O=C(O)Cn1nc(-c2ccc(CN(CCCCOc3ccc(CN4CCCC4)cc3)CCc3ccccc3)cc2)nn1
NCGC00094887-05	O=C(O)[C@@H](C)c1cc(Oc2ccccc2)ccc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Fenoprofen calcium salt dihydrate	170465299.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])[C@@H](C)c1cc(Oc2ccccc2)ccc1.O=C([O-])[C@@H](C)c1cc(Oc2ccccc2)ccc1.[Ca+2].O.O	O=C([O-])[C@@H](C)c1cc(Oc2ccccc2)ccc1.O=C([O-])[C@@H](C)c1cc(Oc2ccccc2)ccc1.[Ca+2].O.O
NCGC00016759-04&NCGC00016759-08&NCGC00016759-38	O=C(O)[C@@H](C)c1cc2c(cc(OC)cc2)cc1		Inactive	Cyclooxygenase-1/2 Inhibitor		3	Naproxen sodium	170465301.0&384567957.0&434146959.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	O=C([O-])[C@@H](C)c1cc2c(cc(OC)cc2)cc1.[Na+]	O=C([O-])[C@@H](C)c1cc2c(cc(OC)cc2)cc1.[Na+]&O=C(O)[C@@H](C)c1cc2c(cc(OC)cc2)cc1
NCGC00183861-01	O=C(O)[C@@H](CCCCCC)CCC		Inactive	S100 beta biosynthetic process Inhibitor		1	(2R)-2-Propyloctanoic acid	144206875.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@@H](CCCCCC)CCC	O=C(O)[C@@H](CCCCCC)CCC
NCGC00178027-08&NCGC00178027-11	O=C(O)[C@@H](N(C(=O)CCCC)Cc1ccc(-c2c(-c3n[nH]nn3)cccc2)cc1)C(C)C		Inactive	Neprilysin Inhibitor		2	VALSARTAN&Valsartan	405559028.0&434147045.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@@H](N(C(=O)CCCC)Cc1ccc(-c2c(-c3n[nH]nn3)cccc2)cc1)C(C)C	O=C(O)[C@@H](N(C(=O)CCCC)Cc1ccc(-c2c(-c3n[nH]nn3)cccc2)cc1)C(C)C
NCGC00344520-01	O=C(O)[C@@H](N)C(C)C		Inactive	tryptophan transport Inhibitor		1	L-Valine	225144376.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H](N)C(C)C	O=C(O)[C@@H](N)C(C)C
NCGC00024499-06	O=C(O)[C@@H](N)CC(=O)O		Inactive	Isoaspartyl peptidase/L-asparaginase Interacts		1	D-Aspartic acid	225144192.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)[C@@H](N)CC(=O)O	O=C(O)[C@@H](N)CC(=O)O
NCGC00166296-02	O=C(O)[C@@H](N)CCCCN		Inactive	Serotonin 4 (5-HT4) receptor Antagonist		1	L-(+)-Lysine monohydrochloride	225144279.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)[C@@H](N)CCCCN	O=C(O)[C@@H](N)CCCCN
NCGC00024715-05	O=C(O)[C@@H](N)CCCNC(=N)N		Inactive			1	L-Arginine	170465748.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)[C@@H](N)CCCNC(=N)N	O=C(O)[C@@H](N)CCCNC(=N)N
NCGC00378702-01	O=C(O)[C@@H](N)CN1C(=O)N(Cc2c(C(=O)O)sc(-c3ccccc3)c2)C(=O)C(C)=C1		Inactive	Glutamate receptor ionotropic kainate 1 Antagonist		1	ACET	363678156.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H](N)CN1C(=O)N(Cc2c(C(=O)O)sc(-c3ccccc3)c2)C(=O)C(C)=C1	O=C(O)[C@@H](N)CN1C(=O)N(Cc2c(C(=O)O)sc(-c3ccccc3)c2)C(=O)C(C)=C1
NCGC00370889-01	O=C(O)[C@@H](N)CN1C(=O)N(Cc2c(C(=O)O)scc2)C(=O)C(C)=C1		Inactive	Glutamate receptor ionotropic kainate 3 Antagonist		1	UBP 310	363677911.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H](N)CN1C(=O)N(Cc2c(C(=O)O)scc2)C(=O)C(C)=C1	O=C(O)[C@@H](N)CN1C(=O)N(Cc2c(C(=O)O)scc2)C(=O)C(C)=C1
NCGC00179528-04	O=C(O)[C@@H](N)CN1C=C(O)C(=O)C=C1		Inactive	Tyrosinase Inhibitor		1	L-Mimosine	363676947.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H](N)CN1C=C(O)C(=O)C=C1	O=C(O)[C@@H](N)CN1C=C(O)C(=O)C=C1
NCGC00601952-15	O=C(O)[C@@H](N)Cc1c2c([nH]c1)ccc(O)c2		Inactive			1	5-Hydroxy-L-tryptophan		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H](N)Cc1c2c([nH]c1)ccc(O)c2	O=C(O)[C@@H](N)Cc1c2c([nH]c1)ccc(O)c2
NCGC00016270-09&NCGC00016270-13	O=C(O)[C@@H](N)Cc1cc(O)c(O)cc1		Inactive	Dopamine Precursors		2	Levodopa	225144176.0&384567928.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)[C@@H](N)Cc1cc(O)c(O)cc1	O=C(O)[C@@H](N)Cc1cc(O)c(O)cc1
NCGC00344531-01	O=C(O)[C@@H](N)[C@@H](O)c1cc(O)c(O)cc1		Inactive	Adrenergic receptor Agonist		1	Droxidopa	170465890.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H](N)[C@@H](O)c1cc(O)c(O)cc1	O=C(O)[C@@H](N)[C@@H](O)c1cc(O)c(O)cc1
NCGC00164520-02	O=C(O)[C@@H](N)[C@H](O)C		Inactive			1	L-Threonine	170465476.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@@H](N)[C@H](O)C	O=C(O)[C@@H](N)[C@H](O)C
NCGC00385093-01	O=C(O)[C@@H](NC(=O)/C=C/c1ccc(O)cc1)Cc1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385093-01	363679528.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H](NC(=O)/C=C/c1ccc(O)cc1)Cc1ccc(O)cc1	O=C(O)[C@@H](NC(=O)/C=C/c1ccc(O)cc1)Cc1ccc(O)cc1
NCGC00385225-01	O=C(O)[C@@H](NC(=O)/C=C\c1ccc(O)cc1)Cc1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385225-01	363679603.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H](NC(=O)/C=C\c1ccc(O)cc1)Cc1ccc(O)cc1	O=C(O)[C@@H](NC(=O)/C=C\c1ccc(O)cc1)Cc1ccc(O)cc1
NCGC00159393-03	O=C(O)[C@@H](NC(=O)C)Cc1ccc(O)cc1		Inactive			1	N-Acetyl-L-tyrosine	170465742.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)[C@@H](NC(=O)C)Cc1ccc(O)cc1	O=C(O)[C@@H](NC(=O)C)Cc1ccc(O)cc1
NCGC00507698-01	O=C(O)[C@@H](NC(=O)CC1=C2[C@@H](CCC(=O)O)[C@H](C)C(=N2)C=[cH0]2c(C)c(C=C)[cH0]([nH]2)=Cc2c(C)c(CC)c([nH]2)C=C2C(C)=C(C(=O)O)C1=N2)CC(=O)O		Inactive			1	Talaporfin sodium	405558614.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H](NC(=O)CC1=C2[C@@H](CCC(=O)O)[C@H](C)C(=N2)C=[cH0]2c(C)c(C=C)[cH0]([nH]2)=Cc2c(C)c(CC)c([nH]2)C=C2C(C)=C(C(=O)O)C1=N2)CC(=O)O	O=C(O)[C@@H](NC(=O)CC1=C2[C@@H](CCC(=O)O)[C@H](C)C(=N2)C=[cH0]2c(C)c(C=C)[cH0]([nH]2)=Cc2c(C)c(CC)c([nH]2)C=C2C(C)=C(C(=O)O)C1=N2)CC(=O)O
NCGC00521952-01	O=C(O)[C@@H](NC(=O)CC[C@@H](NC(=O)[C@@H](NC(=O)[C@H](O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(=O)C)C)C)C(=O)N)CCCCNC(=O)CCCCCCCCCCCCCCCCC		Inactive	TNF-alpha Activator		1	ROMURTIDE	405558571.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H](NC(=O)CC[C@@H](NC(=O)[C@@H](NC(=O)[C@H](O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(=O)C)C)C)C(=O)N)CCCCNC(=O)CCCCCCCCCCCCCCCCC	O=C(O)[C@@H](NC(=O)CC[C@@H](NC(=O)[C@@H](NC(=O)[C@H](O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(=O)C)C)C)C(=O)N)CCCCNC(=O)CCCCCCCCCCCCCCCCC
NCGC00499351-01	O=C(O)[C@@H](NC(=O)N1[C@@H](Cc2ccccc2)C(=O)N(Cc2c(C)nc[nH]2)CC1)CC(C)C		Inactive	Geranyl Geranyl Transferase Inhibitor		1	GGTI-2418	384569305.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H](NC(=O)N1[C@@H](Cc2ccccc2)C(=O)N(Cc2c(C)nc[nH]2)CC1)CC(C)C	O=C(O)[C@@H](NC(=O)N1[C@@H](Cc2ccccc2)C(=O)N(Cc2c(C)nc[nH]2)CC1)CC(C)C
NCGC00522278-01&NCGC00522278-02	O=C(O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)Cc1c2c([nH]c1)cccc2		Inactive	VEGF Inhibitor		2	Oglufanide	384569514.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)Cc1c2c([nH]c1)cccc2	O=C(O)[C@@H](NC(=O)[C@@H](N)CCC(=O)O)Cc1c2c([nH]c1)cccc2
NCGC00485853-01	O=C(O)[C@@H](NC(=O)[C@@H](NC(=O)C(NC(=O)[C@@H](N)Cc1ccc(O)cc1)(C)C)Cc1[nH]c2c(c1)cccc2)Cc1ccccc1		Inactive	amyloid fibril formation Inhibitor		1	Aib-1 trifluoroacetate salt	363681381.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H](NC(=O)[C@@H](NC(=O)C(NC(=O)[C@@H](N)Cc1ccc(O)cc1)(C)C)Cc1[nH]c2c(c1)cccc2)Cc1ccccc1	O=C(O)[C@@H](NC(=O)[C@@H](NC(=O)C(NC(=O)[C@@H](N)Cc1ccc(O)cc1)(C)C)Cc1[nH]c2c(c1)cccc2)Cc1ccccc1
NCGC00485994-01	O=C(O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]2N(C(=O)[C@@H](NC(=O)[C@H]3N(C(=O)[C@@H](N)Cc4ccccc4)CCC3)CCCNC(=N)N)CCC2)CC(=O)N)CC(=O)O)Cc2ccccc2)CCC(=O)O)CCC(=O)O)[C@H](CC)C)CCC1)CCC(=O)O)CCC(=O)O)Cc1ccc(O)cc1)CC(C)C		Inactive			1	Bivalirudin (Trifluoroacetate)	405558931.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]2N(C(=O)[C@@H](NC(=O)[C@H]3N(C(=O)[C@@H](N)Cc4ccccc4)CCC3)CCCNC(=N)N)CCC2)CC(=O)N)CC(=O)O)Cc2ccccc2)CCC(=O)O)CCC(=O)O)[C@H](CC)C)CCC1)CCC(=O)O)CCC(=O)O)Cc1ccc(O)cc1)CC(C)C	O=C(O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]2N(C(=O)[C@@H](NC(=O)[C@H]3N(C(=O)[C@@H](N)Cc4ccccc4)CCC3)CCCNC(=N)N)CCC2)CC(=O)N)CC(=O)O)Cc2ccccc2)CCC(=O)O)CCC(=O)O)[C@H](CC)C)CCC1)CCC(=O)O)CCC(=O)O)Cc1ccc(O)cc1)CC(C)C
NCGC00346895-01	O=C(O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](O)[C@H](N)CC(C)C)C(C)C)C(C)C)CC(=O)O		Inactive	cytosolic leucine aminopeptidase Inhibitor		1	Amastatin	174007115.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](O)[C@H](N)CC(C)C)C(C)C)C(C)C)CC(=O)O	O=C(O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](O)[C@H](N)CC(C)C)C(C)C)C(C)C)CC(=O)O
NCGC00025323-08&NCGC00025323-13	O=C(O)[C@@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)CC(C)C		Inactive	Leukotriene A4 Hydrolase Inhibitor		2	Ubenimex	405558831.0&384568067.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)CC(C)C	O=C(O)[C@@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)CC(C)C
NCGC00167590-02	O=C(O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)Cc2ccc(O)cc2)[C@H](CC)C)Cc2nc[nH]c2)CCC1)Cc1ccccc1		Inactive			1	Angiotensin IV trifluoroacetate salt	363676668.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)Cc2ccc(O)cc2)[C@H](CC)C)Cc2nc[nH]c2)CCC1)Cc1ccccc1	O=C(O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)Cc2ccc(O)cc2)[C@H](CC)C)Cc2nc[nH]c2)CCC1)Cc1ccccc1
NCGC00390805-02	O=C(O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H]2N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H]3N(C(=O)[C@H]4N(C(=O)[C@@H](NC(=O)[C@H](N)CCCNC(=N)N)CCCNC(=N)N)CCC4)C[C@H](O)C3)Cc3sccc3)CO)Cc3c(cccc3)C2)[C@@H]2[C@H](C1)CCCC2)CCCNC(=N)N		Inactive	Bradykinin B2 receptor Antagonist		1	Icatibant	405558587.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H]2N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H]3N(C(=O)[C@H]4N(C(=O)[C@@H](NC(=O)[C@H](N)CCCNC(=N)N)CCCNC(=N)N)CCC4)C[C@H](O)C3)Cc3sccc3)CO)Cc3c(cccc3)C2)[C@@H]2[C@H](C1)CCCC2)CCCNC(=N)N	O=C(O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H]2N(C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H]3N(C(=O)[C@H]4N(C(=O)[C@@H](NC(=O)[C@H](N)CCCNC(=N)N)CCCNC(=N)N)CCC4)C[C@H](O)C3)Cc3sccc3)CO)Cc3c(cccc3)C2)[C@@H]2[C@H](C1)CCCC2)CCCNC(=N)N
NCGC00389841-01	O=C(O)[C@@H](NC(=O)[C@H]1NC(=O)CNC(=O)[C@H]([C@H](O)C)NC(=O)[C@H]2NC(=O)[C@H](C)NC(=O)[C@H]3N(C(=O)[C@H](CC(=O)N)NC(=O)[C@H]4NC(=O)[C@@H](NC(=O)[C@H](Cc5ccc(O)cc5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CSSC4)CSSC2)CSSC1)CCC3)Cc1ccc(O)cc1		Inactive	Heat-stable enterotoxin receptor Agonist		1	LINACLOTIDE (1 mg/ml)	405558997.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H](NC(=O)[C@H]1NC(=O)CNC(=O)[C@H]([C@H](O)C)NC(=O)[C@H]2NC(=O)[C@H](C)NC(=O)[C@H]3N(C(=O)[C@H](CC(=O)N)NC(=O)[C@H]4NC(=O)[C@@H](NC(=O)[C@H](Cc5ccc(O)cc5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CSSC4)CSSC2)CSSC1)CCC3)Cc1ccc(O)cc1	O=C(O)[C@@H](NC(=O)[C@H]1NC(=O)CNC(=O)[C@H]([C@H](O)C)NC(=O)[C@H]2NC(=O)[C@H](C)NC(=O)[C@H]3N(C(=O)[C@H](CC(=O)N)NC(=O)[C@H]4NC(=O)[C@@H](NC(=O)[C@H](Cc5ccc(O)cc5)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CSSC4)CSSC2)CSSC1)CCC3)Cc1ccc(O)cc1
NCGC00242596-02&NCGC00242596-05	O=C(O)[C@@H](NC(=O)c1ccc(C(CC#C)Cc2nc3c(N)nc(N)nc3nc2)cc1)CCC(=O)O		Inactive			2	Pralatrexate&Pralatrexate 		Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O=C(O)[C@@H](NC(=O)c1ccc(C(CC#C)Cc2nc3c(N)nc(N)nc3nc2)cc1)CCC(=O)O	O=C(O)[C@@H](NC(=O)c1ccc(C(CC#C)Cc2nc3c(N)nc(N)nc3nc2)cc1)CCC(=O)O
NCGC00166414-05&NCGC00166414-11	O=C(O)[C@@H](NC(=O)c1ccc(CCc2c3C(=O)N=C(N)Nc3[nH]c2)cc1)CCC(=O)O		Inactive	Thymidylate synthase Inhibitor		2	Pemetrexed&Pemetrexed Disodium heptahydrate	384568308.0&405558550.0	Anti-infectives&Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)[C@@H](NC(=O)c1ccc(CCc2c3C(=O)N=C(N)Nc3[nH]c2)cc1)CCC(=O)O	O=C(O)[C@@H](NC(=O)c1ccc(CCc2c3C(=O)N=C(N)Nc3[nH]c2)cc1)CCC(=O)O
NCGC00025060-15&NCGC00025060-22	O=C(O)[C@@H](NC(=O)c1ccc(N(Cc2nc3c(N)nc(N)nc3nc2)C)cc1)CCC(=O)O		Inactive	Dihydrofolate Reductase (DHFR) Inhibitor		2	Methotrexate	170464688.0&384568045.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O=C(O)[C@@H](NC(=O)c1ccc(N(Cc2nc3c(N)nc(N)nc3nc2)C)cc1)CCC(=O)O	O=C(O)[C@@H](NC(=O)c1ccc(N(Cc2nc3c(N)nc(N)nc3nc2)C)cc1)CCC(=O)O
NCGC00510946-01	O=C(O)[C@@H](NC(=O)c1ccc(N2CN3C=4C(=O)N=C(N)NC=4NCC3C2)cc1)CCC(=O)O		Inactive	Antimetabolite		1	Modufolin	384569495.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H](NC(=O)c1ccc(N2CN3C=4C(=O)N=C(N)NC=4NCC3C2)cc1)CCC(=O)O	O=C(O)[C@@H](NC(=O)c1ccc(N2CN3C=4C(=O)N=C(N)NC=4NCC3C2)cc1)CCC(=O)O
NCGC00178756-05	O=C(O)[C@@H](NC(=O)c1ccc(NCC2N(C=O)C=3C(=O)N=C(N)NC=3NC2)cc1)CCC(=O)O		Inactive	Antineoplastic Enhancing Agents		1	LEUCOVORIN CALCIUM	225144299.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])[C@@H](NC(=O)c1ccc(NCC2N(C=O)C=3C(=O)N=C(N)NC=3NC2)cc1)CCC(=O)[O-]	O=C([O-])[C@@H](NC(=O)c1ccc(NCC2N(C=O)C=3C(=O)N=C(N)NC=3NC2)cc1)CCC(=O)[O-]
NCGC00378841-01	O=C(O)[C@@H](NC(=O)c1ccc(NC[C@@H]2N(C)C=3C(=O)NC(N)=NC=3NC2)cc1)CCC(=O)O		Inactive			1	Levomefolate calcium	405558655.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H](NC(=O)c1ccc(NC[C@@H]2N(C)C=3C(=O)NC(N)=NC=3NC2)cc1)CCC(=O)O	O=C(O)[C@@H](NC(=O)c1ccc(NC[C@@H]2N(C)C=3C(=O)NC(N)=NC=3NC2)cc1)CCC(=O)O
NCGC00185071-01	O=C(O)[C@@H](NC(=O)c1ccc(NC[C@H]2N(C=O)C=3C(=O)N=C(N)NC=3NC2)cc1)CCC(=O)O		Inactive	Antineoplastic Enhancing Agents		1	Calcium folinate	124896608.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])[C@@H](NC(=O)c1ccc(NC[C@H]2N(C=O)C=3C(=O)N=C(N)NC=3NC2)cc1)CCC(=O)[O-]	O=C([O-])[C@@H](NC(=O)c1ccc(NC[C@H]2N(C=O)C=3C(=O)N=C(N)NC=3NC2)cc1)CCC(=O)[O-]
NCGC00016265-08	O=C(O)[C@@H](NC(=O)c1ccc(NCc2nc3C(=O)N=C(N)Nc3nc2)cc1)CCC(=O)O		Inactive	folic acid-containing compound metabolic process Substrate		1	Folic acid	170464833.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)[C@@H](NC(=O)c1ccc(NCc2nc3C(=O)N=C(N)Nc3nc2)cc1)CCC(=O)O	O=C(O)[C@@H](NC(=O)c1ccc(NCc2nc3C(=O)N=C(N)Nc3nc2)cc1)CCC(=O)O
NCGC00229704-02	O=C(O)[C@@H](NC(=O)c1sc(N(Cc2cc3C(=O)N=C(C)Nc3cc2)C)cc1)CCC(=O)O		Inactive	thymidylate synthase Inhibitor		1	Raltitrexed	384568463.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H](NC(=O)c1sc(N(Cc2cc3C(=O)N=C(C)Nc3cc2)C)cc1)CCC(=O)O	O=C(O)[C@@H](NC(=O)c1sc(N(Cc2cc3C(=O)N=C(C)Nc3cc2)C)cc1)CCC(=O)O
NCGC00229704-01	O=C(O)[C@@H](NC(=O)c1sc(N(Cc2cc3C(=O)NC(C)=Nc3cc2)C)cc1)CCC(=O)O		Inactive	thymidylate synthase Inhibitor		1	Raltitrexed	124939249.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H](NC(=O)c1sc(N(Cc2cc3C(=O)NC(C)=Nc3cc2)C)cc1)CCC(=O)O	O=C(O)[C@@H](NC(=O)c1sc(N(Cc2cc3C(=O)NC(C)=Nc3cc2)C)cc1)CCC(=O)O
NCGC00179623-04&NCGC00179623-07	O=C(O)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)CCCCN)CCc1ccccc1		Inactive	Angiotensin-converting enzyme Inhibitor		2	Lisinopril dihydrate&Lisinopril	170464907.0&434147052.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)CCCCN)CCc1ccccc1.O.O	O=C(O)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)CCCCN)CCc1ccccc1.O.O&O=C(O)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)CCCCN)CCc1ccccc1
NCGC00389603-01	O=C(O)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@H]2[C@@H]1CCCC2)C)CCC		Inactive	Angiotensin-converting enzyme Inhibitor		1	PERINDOPRILAT	363680816.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@H]2[C@@H]1CCCC2)C)CCC	O=C(O)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@H]2[C@@H]1CCCC2)C)CCC
NCGC00025251-08&NCGC00025251-09	O=C(O)[C@@H](Nc1c(C(=O)c2ccccc2)cccc1)Cc1ccc(OCCN(C)c2ncccc2)cc1		Inactive	PAPRgamma Agonist		2	GW-1929	384568063.0&384568064.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@@H](Nc1c(C(=O)c2ccccc2)cccc1)Cc1ccc(OCCN(C)c2ncccc2)cc1	O=C(O)[C@@H](Nc1c(C(=O)c2ccccc2)cccc1)Cc1ccc(OCCN(C)c2ncccc2)cc1
NCGC00378922-01	O=C(O)[C@@H](OC)Cc1c2sccc2c(OCCc2c(C)oc(-c3ccccc3)n2)cc1		Inactive	Peroxisome proliferator-activated receptor gamma Agonist		1	Aleglitazar	363678280.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H](OC)Cc1c2sccc2c(OCCc2c(C)oc(-c3ccccc3)n2)cc1	O=C(O)[C@@H](OC)Cc1c2sccc2c(OCCc2c(C)oc(-c3ccccc3)n2)cc1
NCGC00402292-03	O=C(O)[C@@H](Oc1ccc(-c2ccccc2)cc1)Cc1ccccc1		Inactive	Peroxisome proliferator-activated receptor gamma Partial Agonist		1	LT175	363681016.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H](Oc1ccc(-c2ccccc2)cc1)Cc1ccccc1	O=C(O)[C@@H](Oc1ccc(-c2ccccc2)cc1)Cc1ccccc1
NCGC00160662-02&NCGC00346730-07	O=C(O)[C@@H](Oc1nc(C)cc(C)n1)C(OC)(c1ccccc1)c1ccccc1		Inactive	Endothelin ETA Receptor Antagonist		2	Ambrisentan	170465143.0&384568935.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)[C@@H](Oc1nc(C)cc(C)n1)C(OC)(c1ccccc1)c1ccccc1	O=C(O)[C@@H](Oc1nc(C)cc(C)n1)C(OC)(c1ccccc1)c1ccccc1
NCGC00250411-03	O=C(O)[C@@H](c1ccc(OCc2nc3c(cc2)cccc3)cc1)C1CCCC1		Inactive	5-lipoxygenase-activating (FLAP) Inhibitor		1	Veliflapon	384568559.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H](c1ccc(OCc2nc3c(cc2)cccc3)cc1)C1CCCC1	O=C(O)[C@@H](c1ccc(OCc2nc3c(cc2)cccc3)cc1)C1CCCC1
NCGC00390789-01	O=C(O)[C@@H]1NCc2c(cccc2)C1		Inactive			1	(R)-1,2,3,4-Tetrahydro-3-isoquinolinecarboxylic acid	363680984.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1NCc2c(cccc2)C1	O=C(O)[C@@H]1NCc2c(cccc2)C1
NCGC00485267-01	O=C(O)[C@@H]1[C@@H](CCC)OC(=O)C1=C		Inactive	Histone acetyltransferase KAT2A Inhibitor		1	MB-3	363681273.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](CCC)OC(=O)C1=C	O=C(O)[C@@H]1[C@@H](CCC)OC(=O)C1=C
NCGC00090808-04&NCGC00090808-05	O=C(O)[C@@H]1[C@@H](O)C[C@]2(O)O[C@H]1C[C@@H](O[C@H]1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C2		Inactive	Macrolide Antibiotic		2	Amphotericin B	405558702.0&384568088.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)[C@@H]1[C@@H](O)C[C@]2(O)O[C@H]1C[C@@H](O[C@H]1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C2	O=C(O)[C@@H]1[C@@H](O)C[C@]2(O)O[C@H]1C[C@@H](O[C@H]1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C2
NCGC00183039-03	O=C(O)[C@@H]1[C@@H](O)C[C@]2(O)O[C@H]1C[C@@H](O[C@H]1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C2		Inactive	Antifungal Agent		1	Nystatin	384568414.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)C[C@]2(O)O[C@H]1C[C@@H](O[C@H]1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C2	O=C(O)[C@@H]1[C@@H](O)C[C@]2(O)O[C@H]1C[C@@H](O[C@H]1[C@@H](O)[C@@H](N)[C@H](O)[C@@H](C)O1)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C2
NCGC00496851-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1		Inactive			1	NCGC00496851-01	405559033.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1
NCGC00380754-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2C(C(=O)O)(C)C3C(C)(C4C(C)(C5(C)C(C6C(C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O%10)[C@@](O)(CO)CO9)[C@@H](O)[C@H](C)O8)[C@@H](O)[C@H](O)[C@@H](C)O7)(C(O)CC(C)(C)C6)CC5)=CC4)CC3)CC2O)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380754-01	363678762.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2C(C(=O)O)(C)C3C(C)(C4C(C)(C5(C)C(C6C(C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O%10)[C@@](O)(CO)CO9)[C@@H](O)[C@H](C)O8)[C@@H](O)[C@H](O)[C@@H](C)O7)(C(O)CC(C)(C)C6)CC5)=CC4)CC3)CC2O)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2C(C(=O)O)(C)C3C(C)(C4C(C)(C5(C)C(C6C(C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O%10)[C@@](O)(CO)CO9)[C@@H](O)[C@H](C)O8)[C@@H](O)[C@H](O)[C@@H](C)O7)(C(O)CC(C)(C)C6)CC5)=CC4)CC3)CC2O)O1
NCGC00384897-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCC(O)COC(=O)c2ccccc2)O1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: limoniumu | Family: Plumbaginaceae | Species: mucronatum		1	NCGC00384897-01	363679424.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCC(O)COC(=O)c2ccccc2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCC(O)COC(=O)c2ccccc2)O1
NCGC00384528-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	regulation of sperm motility Inhibitor		1	NCGC00384528-01	363679232.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00180494-03	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Saponaria | Family: Caryophyllaceae | Species: album		1	NCGC00180494-03	363677029.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00347541-02	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(CO)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347541-02	363677620.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(CO)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(CO)(C)C6)=CC4)CC3)CC2)O1
NCGC00380273-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CC[C@@](C(=O)OC)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Bocconia | Family: N/A | Species: arborea		1	NCGC00380273-01	363678521.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CC[C@@](C(=O)OC)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CC[C@@](C(=O)OC)(C)C6)=CC4)CC3)CC2)O1
NCGC00180563-02	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O8)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Sesbania | Family: Fabaceae | Species: pachycarpa		1	NCGC00180563-02	363677035.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	11.8474820199	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O8)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O8)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00381031-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Withania | Family: Solanaceae | Species: adpressa		1	NCGC00381031-01	363678934.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00385565-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)C[C@]3(C)C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(=C)C6)=CC4)CCC3[C@]2(C=O)C)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385565-01	363679812.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)C[C@]3(C)C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(=C)C6)=CC4)CCC3[C@]2(C=O)C)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)C[C@]3(C)C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(=C)C6)=CC4)CCC3[C@]2(C=O)C)O1
NCGC00169139-03	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Zanha | Family: Burseraceae | Species: golungensis		1	NCGC00169139-03	363676778.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00385376-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](O)C[C@@]3(C)C([C@H](O)C[C@@]4(C)[C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O[C@@H]%10[C@H](O)[C@@](O)(CO)CO%10)[C@H](O)CO9)[C@H](C)O8)[C@@H](O)[C@H](CO)O7)([C@H](O)C5)CCC(C)(C)C6)=CCC34)[C@@]2(CO)C)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Bridelia | Family: Euphorbiaceae | Species: aubrevillei		1	NCGC00385376-01	363679709.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	28.5	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](O)C[C@@]3(C)C([C@H](O)C[C@@]4(C)[C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O[C@@H]%10[C@H](O)[C@@](O)(CO)CO%10)[C@H](O)CO9)[C@H](C)O8)[C@@H](O)[C@H](CO)O7)([C@H](O)C5)CCC(C)(C)C6)=CCC34)[C@@]2(CO)C)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](O)C[C@@]3(C)C([C@H](O)C[C@@]4(C)[C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O[C@@H]%10[C@H](O)[C@@](O)(CO)CO%10)[C@H](O)CO9)[C@H](C)O8)[C@@H](O)[C@H](CO)O7)([C@H](O)C5)CCC(C)(C)C6)=CCC34)[C@@]2(CO)C)O1
NCGC00384879-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](O)C[C@@]3(C)C([C@H](O)C[C@@]4(C)[C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O[C@H]%10[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O%10)[C@H](O)CO9)[C@H](C)O8)[C@@H](O)[C@@H](O)CO7)(CC5)CCC(C)(C)C6)=CCC34)[C@@]2(CO)C)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384879-01	363679411.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](O)C[C@@]3(C)C([C@H](O)C[C@@]4(C)[C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O[C@H]%10[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O%10)[C@H](O)CO9)[C@H](C)O8)[C@@H](O)[C@@H](O)CO7)(CC5)CCC(C)(C)C6)=CCC34)[C@@]2(CO)C)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](O)C[C@@]3(C)C([C@H](O)C[C@@]4(C)[C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O[C@H]%10[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O%10)[C@H](O)CO9)[C@H](C)O8)[C@@H](O)[C@@H](O)CO7)(CC5)CCC(C)(C)C6)=CCC34)[C@@]2(CO)C)O1
NCGC00384877-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](O)C[C@@]3(C)C([C@H](O)C[C@@]4(C)[C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O[C@H]%10[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O%10)[C@H](O)CO9)[C@H](C)O8)[C@@H](O)[C@H](CO)O7)([C@H](O)C5)CCC(C)(C)C6)=CCC34)[C@@]2(CO)C)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384877-01	363679409.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](O)C[C@@]3(C)C([C@H](O)C[C@@]4(C)[C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O[C@H]%10[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O%10)[C@H](O)CO9)[C@H](C)O8)[C@@H](O)[C@H](CO)O7)([C@H](O)C5)CCC(C)(C)C6)=CCC34)[C@@]2(CO)C)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](O)C[C@@]3(C)C([C@H](O)C[C@@]4(C)[C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O[C@H]%10[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O%10)[C@H](O)CO9)[C@H](C)O8)[C@@H](O)[C@H](CO)O7)([C@H](O)C5)CCC(C)(C)C6)=CCC34)[C@@]2(CO)C)O1
NCGC00168926-02	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](O)C[C@]3(C)C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O)CO9)[C@H](C)O8)[C@@H](O)[C@@H](O)CO7)(CC5)CCC(C)(C)C6)=CC4)CCC3[C@@]2(C(=O)O)C)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Medicago | Family: Leguminosae | Species: sativa		1	NCGC00168926-02	363676724.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](O)C[C@]3(C)C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O)CO9)[C@H](C)O8)[C@@H](O)[C@@H](O)CO7)(CC5)CCC(C)(C)C6)=CC4)CCC3[C@@]2(C(=O)O)C)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](O)C[C@]3(C)C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O)CO9)[C@H](C)O8)[C@@H](O)[C@@H](O)CO7)(CC5)CCC(C)(C)C6)=CC4)CCC3[C@@]2(C(=O)O)C)O1
NCGC00168815-02	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](O)C[C@]3(C)C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CCC3[C@@]2(CO)C)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Saponaria | Family: Caryophyllaceae | Species: album		1	NCGC00168815-02	363676694.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](O)C[C@]3(C)C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CCC3[C@@]2(CO)C)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](O)C[C@]3(C)C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CCC3[C@@]2(CO)C)O1
NCGC00485340-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@]3(C)[C@H]([C@H]4[C@@H](c5c(cc(O)cc5)CC4)CC3)C2)O1		Inactive			1	Estriol 16Î±-(Î²-D-glucuronide)	363681291.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@]3(C)[C@H]([C@H]4[C@@H](c5c(cc(O)cc5)CC4)CC3)C2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@]3(C)[C@H]([C@H]4[C@@H](c5c(cc(O)cc5)CC4)CC3)C2)O1
NCGC00480778-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(O)c(O)c3C(=O)C=C(c4ccc(O)cc4)Oc3c2)O1		Inactive			1	Scutellarin	434147152.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(O)c(O)c3C(=O)C=C(c4ccc(O)cc4)Oc3c2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(O)c(O)c3C(=O)C=C(c4ccc(O)cc4)Oc3c2)O1
NCGC00386028-03	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(O)c(O)c3C(=O)C=C(c4ccccc4)Oc3c2)O1		Inactive	prolyl endopeptidase inhibitor		1	BAICALIN	434147126.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(O)c(O)c3C(=O)C=C(c4ccccc4)Oc3c2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(O)c(O)c3C(=O)C=C(c4ccccc4)Oc3c2)O1
NCGC00485332-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc3c([C@@H]4[C@H]([C@H]5[C@@](C)(C(=O)CC5)CC4)CC3)cc2)O1		Inactive	UDP-glucuronosyltransferase 1-9 Substrate		1	Estrone 3-(Î²-D-glucuronide) sodium salt	363681288.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C([O-])[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc3c([C@@H]4[C@H]([C@H]5[C@@](C)(C(=O)CC5)CC4)CC3)cc2)O1	O=C([O-])[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc3c([C@@H]4[C@H]([C@H]5[C@@](C)(C(=O)CC5)CC4)CC3)cc2)O1
NCGC00385529-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](OC2C(O)C(O)C(O)C(CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Sesbania | Family: N/A | Species: sesban		1	NCGC00385529-01	363679793.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](OC2C(O)C(O)C(O)C(CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](OC2C(O)C(O)C(O)C(CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00381003-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](OC2C(O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(O)C(O)C(CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@](C)(C(O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Rothia | Family: Fabaceae | Species: sp.		1	NCGC00381003-01	363678917.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](OC2C(O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(O)C(O)C(CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@](C)(C(O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](OC2C(O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(O)C(O)C(CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@](C)(C(O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1
NCGC00384681-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O[C@H]7[C@H](O)[C@@H](OC8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)CO7)[C@H](O)C(C)(C)C6)CC5)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: saponine | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384681-01	363679306.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O[C@H]7[C@H](O)[C@@H](OC8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)CO7)[C@H](O)C(C)(C)C6)CC5)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O[C@H]7[C@H](O)[C@@H](OC8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)CO7)[C@H](O)C(C)(C)C6)CC5)=CC4)CC3)CC2)O1
NCGC00385159-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@](C=O)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O[C@H]%10[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O%10)[C@H](O)CO9)[C@H](C)O8)[C@@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O8)[C@@H](C)O7)([C@H](O)C5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385159-01	363679570.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@](C=O)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O[C@H]%10[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O%10)[C@H](O)CO9)[C@H](C)O8)[C@@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O8)[C@@H](C)O7)([C@H](O)C5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@](C=O)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@@H](O[C@H]%10[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O%10)[C@H](O)CO9)[C@H](C)O8)[C@@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O8)[C@@H](C)O7)([C@H](O)C5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00183128-02&NCGC00183128-03&NCGC00183128-07	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O2)[C@@H](O[C@@H]2C(C)(C)[C@H]3[C@@](C)([C@H]4C(=O)C=C5[C@](C)([C@]4(C)CC3)CC[C@]3(C)[C@H]5C[C@](C(=O)O)(C)CC3)CC2)O1		Inactive			3	Glycyrrhizic acid&Ammonium Glycyrrhizinate	384568417.0	Anti-infectives&Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&19.0&0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O2)[C@@H](O[C@@H]2C(C)(C)[C@H]3[C@@](C)([C@H]4C(=O)C=C5[C@](C)([C@]4(C)CC3)CC[C@]3(C)[C@H]5C[C@](C(=O)O)(C)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O2)[C@@H](O[C@@H]2C(C)(C)[C@H]3[C@@](C)([C@H]4C(=O)C=C5[C@](C)([C@]4(C)CC3)CC[C@]3(C)[C@H]5C[C@](C(=O)O)(C)CC3)CC2)O1
NCGC00380557-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@H](O)CO2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380557-01	363678648.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@H](O)CO2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@H](O)CO2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00384873-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O9)[C@H](C)O8)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384873-01	363679407.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O9)[C@H](C)O8)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O[C@H]9[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O9)[C@H](C)O8)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00168953-02	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@@H](O)CO2)[C@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: saponine | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00168953-02	363676729.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@@H](O)CO2)[C@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@@H](O)CO2)[C@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1
NCGC00385557-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)(C(=O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385557-01	363679807.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)(C(=O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)(C(=O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1
NCGC00385739-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O)CC(C(=O)O)(C)C6)CC5)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385739-01	363679914.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O)CC(C(=O)O)(C)C6)CC5)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O)CC(C(=O)O)(C)C6)CC5)=CC4)CC3)CC2)O1
NCGC00380668-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: saponine | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380668-01	363678702.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1
NCGC00385973-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)CO2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C=O)(C4[C@](C)([C@@]5(C)C(C6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385973-01	363680037.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)CO2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C=O)(C4[C@](C)([C@@]5(C)C(C6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)CO2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C=O)(C4[C@](C)([C@@]5(C)C(C6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1
NCGC00381308-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)CO2)[C@H](O[C@@H]2C(C)(C)C3[C@@](CO)(C4[C@](C)([C@@]5(C)C(C6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381308-01	363679080.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)CO2)[C@H](O[C@@H]2C(C)(C)C3[C@@](CO)(C4[C@](C)([C@@]5(C)C(C6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)CO2)[C@H](O[C@@H]2C(C)(C)C3[C@@](CO)(C4[C@](C)([C@@]5(C)C(C6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1
NCGC00385211-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O)[C@@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Calendula | Family: N/A | Species: officinalis		1	NCGC00385211-01	363679596.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O)[C@@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O)[C@@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00347399-02	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	inflammatory response Inhibitor		1	NCGC00347399-02	363677590.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00385230-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385230-01	363679606.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00385374-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@](C=O)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](OC8C(O)C(O)C(O)C(C)O8)[C@@H](OC8C(O)C(O)C(OC9C(O)C(O)C(O)CO9)C(C)O8)[C@@H](C)O7)([C@H](O)C5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Saponaria | Family: Caryophyllaceae | Species: officinalis		1	NCGC00385374-01	363679708.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@](C=O)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](OC8C(O)C(O)C(O)C(C)O8)[C@@H](OC8C(O)C(O)C(OC9C(O)C(O)C(O)CO9)C(C)O8)[C@@H](C)O7)([C@H](O)C5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@](C=O)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](OC8C(O)C(O)C(O)C(C)O8)[C@@H](OC8C(O)C(O)C(OC9C(O)C(O)C(O)CO9)C(C)O8)[C@@H](C)O7)([C@H](O)C5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00385141-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@](C=O)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](OC8C(O)C(O)C(O)C(CO)O8)[C@@H](O)[C@@H](OC8C(O)C(O)C(OC9C(O)C(O)C(O)CO9)C(C)O8)[C@@H](C)O7)([C@H](O)C5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Saponaria | Family: Caryophyllaceae | Species: officinalis		1	NCGC00385141-01	363679555.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@](C=O)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](OC8C(O)C(O)C(O)C(CO)O8)[C@@H](O)[C@@H](OC8C(O)C(O)C(OC9C(O)C(O)C(O)CO9)C(C)O8)[C@@H](C)O7)([C@H](O)C5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2[C@](C=O)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](OC8C(O)C(O)C(O)C(CO)O8)[C@@H](O)[C@@H](OC8C(O)C(O)C(OC9C(O)C(O)C(O)CO9)C(C)O8)[C@@H](C)O7)([C@H](O)C5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00384686-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: sciadodendron | Family: Araliaceae | Species: excelsum		1	NCGC00384686-01	363679311.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00385193-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Myrciaria | Family: Myrtaceae | Species: floribunda		1	NCGC00385193-01	363679589.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00384610-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Myrciaria | Family: Myrtaceae | Species: floribunda		1	NCGC00384610-01	363679270.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00384492-01	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)[C@]6(OC[C@@]7([C@H](O)C5)C6CC(C)(C)CC7)CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: Primula | Family: Primulaceae | Species: veris		1	NCGC00384492-01	363679209.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)[C@]6(OC[C@@]7([C@H](O)C5)C6CC(C)(C)CC7)CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)[C@]6(OC[C@@]7([C@H](O)C5)C6CC(C)(C)CC7)CC4)CC3)CC2)O1
NCGC00179805-02	O=C(O)[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@](C(=O)O)(CCC(C)(C)C6O)CC5)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00179805-02	363676973.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@](C(=O)O)(CCC(C)(C)C6O)CC5)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@](C(=O)O)(CCC(C)(C)C6O)CC5)=CC4)CC3)CC2)O1
NCGC00180793-02	O=C(O)[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O[C@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)([C@H](O)C5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180793-02	363677065.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O[C@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)([C@H](O)C5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O)[C@H](O[C@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)([C@H](O)C5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00168826-02	O=C(O)[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00168826-02	363676696.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00168832-02	O=C(O)[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00168832-02	363676697.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C(C6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00385153-01	O=C(O)[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385153-01	363679566.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00179899-02	O=C(O)[C@@H]1[C@@]23[C@@H](C(=C)C(C)(C)[C@@H](C2)CC3)CC1		Inactive	Mycobacterium tuberculosis H37Rv Inhibitor		1	NCGC00179899-02	363676986.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@@]23[C@@H](C(=C)C(C)(C)[C@@H](C2)CC3)CC1	O=C(O)[C@@H]1[C@@]23[C@@H](C(=C)C(C)(C)[C@@H](C2)CC3)CC1
NCGC00408796-01	O=C(O)[C@@H]1[C@H](C(=O)N2CCN(C)CC2)[C@H]2O[C@@H]1CC2		Inactive	Protein Phosphatase 2A (PP-2A) Inhibitor		1	EMPM	384569220.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H]1[C@H](C(=O)N2CCN(C)CC2)[C@H]2O[C@@H]1CC2	O=C(O)[C@@H]1[C@H](C(=O)N2CCN(C)CC2)[C@H]2O[C@@H]1CC2
NCGC00386934-01	O=C(O)[C@@H]1[C@H](C(=O)N2[C@H](CN3C(=O)c4c(C3=O)cccc4)c3c(cccc3)CC2)CCCC1		Inactive			1	NCGC00386934-01	363680518.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@H](C(=O)N2[C@H](CN3C(=O)c4c(C3=O)cccc4)c3c(cccc3)CC2)CCCC1	O=C(O)[C@@H]1[C@H](C(=O)N2[C@H](CN3C(=O)c4c(C3=O)cccc4)c3c(cccc3)CC2)CCCC1
NCGC00016686-07	O=C(O)[C@@H]1[C@H](O)C[C@]2(O)O[C@H]1C[C@H](O[C@H]1[C@H](O)[C@H](N)[C@H](O)[C@H](C)O1)/C=C\C=C/C=C\C=C/C[C@H](C)OC(=O)/C=C\[C@H]1O[C@@H]1C[C@H](O)C2		Inactive	Antifungal Agent		1	Natamycin	363676490.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H]1[C@H](O)C[C@]2(O)O[C@H]1C[C@H](O[C@H]1[C@H](O)[C@H](N)[C@H](O)[C@H](C)O1)/C=C\C=C/C=C\C=C/C[C@H](C)OC(=O)/C=C\[C@H]1O[C@@H]1C[C@H](O)C2	O=C(O)[C@@H]1[C@H](O)C[C@]2(O)O[C@H]1C[C@H](O[C@H]1[C@H](O)[C@H](N)[C@H](O)[C@H](C)O1)/C=C\C=C/C=C\C=C/C[C@H](C)OC(=O)/C=C\[C@H]1O[C@@H]1C[C@H](O)C2
NCGC00016686-13	O=C(O)[C@@H]1[C@H](O)C[C@]2(O)O[C@H]1C[C@H](O[C@H]1[C@H](O)[C@H](N)[C@H](O)[C@H](C)O1)C=CC=CC=CC=CC[C@H](C)OC(=O)C=C[C@H]1O[C@@H]1C[C@H](O)C2		Inactive	Anti-fungal		1	Pimaricin	405558570.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@H]1[C@H](O)C[C@]2(O)O[C@H]1C[C@H](O[C@H]1[C@H](O)[C@H](N)[C@H](O)[C@H](C)O1)C=CC=CC=CC=CC[C@H](C)OC(=O)C=C[C@H]1O[C@@H]1C[C@H](O)C2	O=C(O)[C@@H]1[C@H](O)C[C@]2(O)O[C@H]1C[C@H](O[C@H]1[C@H](O)[C@H](N)[C@H](O)[C@H](C)O1)C=CC=CC=CC=CC[C@H](C)OC(=O)C=C[C@H]1O[C@@H]1C[C@H](O)C2
NCGC00385971-01	O=C(O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385971-01	363680036.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1
NCGC00380498-01	O=C(O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](C(=O)O)O[C@H]2O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380498-01	363678610.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	12.486696228	O=C(O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](C(=O)O)O[C@H]2O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](C(=O)O)O[C@H]2O[C@@H]2C(C)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1
NCGC00380763-01	O=C(O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](C(=O)O)O[C@H]2O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380763-01	363678768.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	11.0959360399	O=C(O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](C(=O)O)O[C@H]2O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1	O=C(O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](C(=O)O)O[C@H]2O[C@@H]2[C@@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@](C)([C@H](O)CC(C)(C)C6)CC5)=CC4)CC3)CC2)O1
NCGC00169180-03	O=C(O)[C@@H]1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)OC)[C@H]2CC1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Forsythia | Family: Oleaceae | Species: europaea		1	NCGC00169180-03	363676786.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)OC)[C@H]2CC1	O=C(O)[C@@H]1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)OC)[C@H]2CC1
NCGC00485401-01	O=C(O)[C@@H]1[C@H]2[C@](N)(C(=O)O)CC[C@@H]12		Inactive	Metabotropic glutamate receptor 3 Agonist		1	LY-354740 hydrate	363681314.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@H]1[C@H]2[C@](N)(C(=O)O)CC[C@@H]12	O=C(O)[C@@H]1[C@H]2[C@](N)(C(=O)O)CC[C@@H]12
NCGC00024667-14&NCGC00024667-19	O=C(O)[C@@](N)(Cc1cc(O)c(O)cc1)C		Inactive	DOPA decarboxylase Inhibitor		2	Methyldopa	170464643.0&384568031.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)[C@@](N)(Cc1cc(O)c(O)cc1)C.O=C(O)[C@@](N)(Cc1cc(O)c(O)cc1)C.O.O.O	O=C(O)[C@@](N)(Cc1cc(O)c(O)cc1)C.O=C(O)[C@@](N)(Cc1cc(O)c(O)cc1)C.O.O.O&O=C(O)[C@@](N)(Cc1cc(O)c(O)cc1)C
NCGC00015701-06	O=C(O)[C@@](N)(Cc1ccc(O)cc1)C		Inactive	Tyrosine 3-hydroxylase Inhibitor		1	Metyrosine	170465112.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)[C@@](N)(Cc1ccc(O)cc1)C	O=C(O)[C@@](N)(Cc1ccc(O)cc1)C
NCGC00024596-08	O=C(O)[C@@](NN)(Cc1cc(O)c(O)cc1)C		Inactive	decarboxylase inhibitor		1	Carbidopa	225144194.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@@](NN)(Cc1cc(O)c(O)cc1)C	O=C(O)[C@@](NN)(Cc1cc(O)c(O)cc1)C
NCGC00380725-01	O=C(O)[C@@]1(C)C2=C(O)C(=O)C=3[C@@](O)(C(=O)C[C@](C=C)(C)C=3)[C@@]32[C@@H](C3)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380725-01	363678739.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]1(C)C2=C(O)C(=O)C=3[C@@](O)(C(=O)C[C@](C=C)(C)C=3)[C@@]32[C@@H](C3)CC1	O=C(O)[C@@]1(C)C2=C(O)C(=O)C=3[C@@](O)(C(=O)C[C@](C=C)(C)C=3)[C@@]32[C@@H](C3)CC1
NCGC00180857-02	O=C(O)[C@@]1(C)C2C(C)(C3C(=C[C@](C=C)(C)CC3)CC2)CCC1		Inactive	Calcium-activated potassium channel subunit alpha-1 Opener		1	NCGC00180857-02	363677075.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]1(C)C2C(C)(C3C(=C[C@](C=C)(C)CC3)CC2)CCC1	O=C(O)[C@@]1(C)C2C(C)(C3C(=C[C@](C=C)(C)CC3)CC2)CCC1
NCGC00168472-03	O=C(O)[C@@]1(C)C2[C@@](C)(C3C(=CC2)C[C@](C=C)(C)CC3)CCC1		Inactive	GABA-A receptor; benzodiazepine site Positive Allosteric Modulator		1	NCGC00168472-03	363676680.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]1(C)C2[C@@](C)(C3C(=CC2)C[C@](C=C)(C)CC3)CCC1	O=C(O)[C@@]1(C)C2[C@@](C)(C3C(=CC2)C[C@](C=C)(C)CC3)CCC1
NCGC00386059-01	O=C(O)[C@@]1(C)C2[C@@](C)(C3C(C=C(C(C)C)C(=O)C3)=CC2)CCC1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386059-01	363680084.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]1(C)C2[C@@](C)(C3C(C=C(C(C)C)C(=O)C3)=CC2)CCC1	O=C(O)[C@@]1(C)C2[C@@](C)(C3C(C=C(C(C)C)C(=O)C3)=CC2)CCC1
NCGC00386056-01	O=C(O)[C@@]1(C)C2[C@@](C)(C3C(C=C(C(C)C)C(O)C3)=CC2)CCC1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386056-01	363680081.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]1(C)C2[C@@](C)(C3C(C=C(C(C)C)C(O)C3)=CC2)CCC1	O=C(O)[C@@]1(C)C2[C@@](C)(C3C(C=C(C(C)C)C(O)C3)=CC2)CCC1
NCGC00169806-03	O=C(O)[C@@]1(C)C2[C@@](C)([C@@H](CCC(O)(C=C)C)C(=C)CC2)CCC1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169806-03	363676892.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]1(C)C2[C@@](C)([C@@H](CCC(O)(C=C)C)C(=C)CC2)CCC1	O=C(O)[C@@]1(C)C2[C@@](C)([C@@H](CCC(O)(C=C)C)C(=C)CC2)CCC1
NCGC00169419-02	O=C(O)[C@@]1(C)C2[C@@](C)(c3c(cc(C(C)C)cc3)CC2)CCC1		Inactive	TGF-beta signaling pathway Modulator		1	Dihydroabietic acid	363676814.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]1(C)C2[C@@](C)(c3c(cc(C(C)C)cc3)CC2)CCC1	O=C(O)[C@@]1(C)C2[C@@](C)(c3c(cc(C(C)C)cc3)CC2)CCC1
NCGC00169565-02	O=C(O)[C@@]1(C)C2[C@](C)(C3C4(CC(=C)C(C4)CC3)CC2)CCC1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Elaeoselinum | Family: Apiaceae | Species: foetidum		1	NCGC00169565-02	363676840.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]1(C)C2[C@](C)(C3C4(CC(=C)C(C4)CC3)CC2)CCC1	O=C(O)[C@@]1(C)C2[C@](C)(C3C4(CC(=C)C(C4)CC3)CC2)CCC1
NCGC00485408-01	O=C(O)[C@@]1(C)C[C@@H]2[C@@](C)(CC[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)CC5)CC4)CC=C23)CC1		Inactive			1	HENA	363681321.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]1(C)C[C@@H]2[C@@](C)(CC[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)CC5)CC4)CC=C23)CC1	O=C(O)[C@@]1(C)C[C@@H]2[C@@](C)(CC[C@@]3(C)[C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)CC5)CC4)CC=C23)CC1
NCGC00178913-11	O=C(O)[C@@]1(C)C[C@H]2[C@@]3(C)[C@@](C)(C=4[C@](C)(C=5C(C(C)=C(O)C(=O)C=5)=CC=4)CC3)CC[C@@]2(C)CC1		Inactive	Heat Shock Protein 90 (hsp90) Inhibitor		1	Tripterin	384568367.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(O)[C@@]1(C)C[C@H]2[C@@]3(C)[C@@](C)(C=4[C@](C)(C=5C(C(C)=C(O)C(=O)C=5)=CC=4)CC3)CC[C@@]2(C)CC1	O=C(O)[C@@]1(C)C[C@H]2[C@@]3(C)[C@@](C)(C=4[C@](C)(C=5C(C(C)=C(O)C(=O)C=5)=CC=4)CC3)CC[C@@]2(C)CC1
NCGC00180745-02	O=C(O)[C@@]1(C)C[C@H]2[C@@]3(C)[C@@](C)(C=4[C@](C)(c5c(C(=O)C=4)cc(O)c(O)c5)CC3)CC[C@@]2(C)CC1		Inactive	<MOA Unknown> | Class: nortriterpene | Genus: Kokoona | Family: Celastraceae | Species: zeylanica		1	NCGC00180745-02	363677059.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	10.0576496719	O=C(O)[C@@]1(C)C[C@H]2[C@@]3(C)[C@@](C)(C=4[C@](C)(c5c(C(=O)C=4)cc(O)c(O)c5)CC3)CC[C@@]2(C)CC1	O=C(O)[C@@]1(C)C[C@H]2[C@@]3(C)[C@@](C)(C=4[C@](C)(c5c(C(=O)C=4)cc(O)c(O)c5)CC3)CC[C@@]2(C)CC1
NCGC00180415-03	O=C(O)[C@@]1(C)[C@@H](O)CC[C@]2(C)C3[C@](C)([C@@]4(C)C(C5[C@@](O)(C)[C@H](C)CC[C@]5(C(=O)O)CC4)=CC3)CCC12		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Myricarubra | Family: Myricaceae | Species: N/A		1	NCGC00180415-03	363677020.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]1(C)[C@@H](O)CC[C@]2(C)C3[C@](C)([C@@]4(C)C(C5[C@@](O)(C)[C@H](C)CC[C@]5(C(=O)O)CC4)=CC3)CCC12	O=C(O)[C@@]1(C)[C@@H](O)CC[C@]2(C)C3[C@](C)([C@@]4(C)C(C5[C@@](O)(C)[C@H](C)CC[C@]5(C(=O)O)CC4)=CC3)CCC12
NCGC00180680-03	O=C(O)[C@@]1(C)[C@@H]2[C@](C)(C=3[C@@]4(CC(=C)[C@H](C4)CC=3)CC2)CCC1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Aspilia | Family: Compositae | Species: mossambicensis		1	NCGC00180680-03	363677047.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	27.6269294759	O=C(O)[C@@]1(C)[C@@H]2[C@](C)(C=3[C@@]4(CC(=C)[C@H](C4)CC=3)CC2)CCC1	O=C(O)[C@@]1(C)[C@@H]2[C@](C)(C=3[C@@]4(CC(=C)[C@H](C4)CC=3)CC2)CCC1
NCGC00380240-01	O=C(O)[C@@]1(C)[C@@H]2[C@](C)(C=3[C@@]4(CC(O)(CO)[C@H](C4)CC=3)CC2)CCC1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380240-01	363678511.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]1(C)[C@@H]2[C@](C)(C=3[C@@]4(CC(O)(CO)[C@H](C4)CC=3)CC2)CCC1	O=C(O)[C@@]1(C)[C@@H]2[C@](C)(C=3[C@@]4(CC(O)(CO)[C@H](C4)CC=3)CC2)CCC1
NCGC00169469-03	O=C(O)[C@@]1(C)[C@@H]2[C@](C)([C@H](CCC(CCO)C)C(=C)CC2)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169469-03	363676823.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]1(C)[C@@H]2[C@](C)([C@H](CCC(CCO)C)C(=C)CC2)CCC1	O=C(O)[C@@]1(C)[C@@H]2[C@](C)([C@H](CCC(CCO)C)C(=C)CC2)CCC1
NCGC00485884-01	O=C(O)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@]4(CC(=O)[C@](C)(C4)CC3)CC2)CCC1		Inactive	DNA topoisomerase II Inhibitor		1	Isosteviol	363681393.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@]4(CC(=O)[C@](C)(C4)CC3)CC2)CCC1	O=C(O)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@]4(CC(=O)[C@](C)(C4)CC3)CC2)CCC1
NCGC00380971-01	O=C(O)[C@@]1(C)[C@H](C[C@H](O)CC)C(C)=C[C@H]2[C@@H]1CCCC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380971-01	363678894.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]1(C)[C@H](C[C@H](O)CC)C(C)=C[C@H]2[C@@H]1CCCC2	O=C(O)[C@@]1(C)[C@H](C[C@H](O)CC)C(C)=C[C@H]2[C@@H]1CCCC2
NCGC00347583-02	O=C(O)[C@@]1(C)[C@H]2[C@@](C)(c3c(C(=O)C2)cc(C(O)(C)C)cc3)CCC1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Pinus | Family: Pinaceae | Species: nigra nigra		1	NCGC00347583-02	363677630.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]1(C)[C@H]2[C@@](C)(c3c(C(=O)C2)cc(C(O)(C)C)cc3)CCC1	O=C(O)[C@@]1(C)[C@H]2[C@@](C)(c3c(C(=O)C2)cc(C(O)(C)C)cc3)CCC1
NCGC00385372-01	O=C(O)[C@@]1(C)[C@H]2[C@@](C)(c3c(C(O)C2)cc(C(O)(C)C)cc3)CCC1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Pinus | Family: Pinaceae | Species: nigra nigra		1	NCGC00385372-01	363679706.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]1(C)[C@H]2[C@@](C)(c3c(C(O)C2)cc(C(O)(C)C)cc3)CCC1	O=C(O)[C@@]1(C)[C@H]2[C@@](C)(c3c(C(O)C2)cc(C(O)(C)C)cc3)CCC1
NCGC00347643-02	O=C(O)[C@@]12C([C@@H](C(=C)C)CC1)C1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)C(=O)CC4)CC3)CC1)CC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347643-02	363677648.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]12C([C@@H](C(=C)C)CC1)C1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)C(=O)CC4)CC3)CC1)CC2	O=C(O)[C@@]12C([C@@H](C(=C)C)CC1)C1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)C(=O)CC4)CC3)CC1)CC2
NCGC00385328-01	O=C(O)[C@@]12C([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@@]4(C)[C@@H](O)[C@@H](O)[C@H](O)C(C)(C)C4CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Butyrospermum | Family: N/A | Species: parkii		1	NCGC00385328-01	363679680.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]12C([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@@]4(C)[C@@H](O)[C@@H](O)[C@H](O)C(C)(C)C4CC3)CC=1)CC2	O=C(O)[C@@]12C([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@@]4(C)[C@@H](O)[C@@H](O)[C@H](O)C(C)(C)C4CC3)CC=1)CC2
NCGC00169714-02	O=C(O)[C@@]12C([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Rubus | Family: Rosaceae | Species: idaeus		1	NCGC00169714-02	363676873.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]12C([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O)[C@@]12C([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00386041-01	O=C(O)[C@@]12C([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Rubus | Family: Rosaceae | Species: idaeus		1	NCGC00386041-01	363680076.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]12C([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O)[C@@]12C([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00169506-02	O=C(O)[C@@]12C([C@H](C(=C)C)CC1)C1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)[C@H](O)C4)CC3)CC1)CC2		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Quercus | Family: Fagaceae | Species: cerris		1	NCGC00169506-02	363676833.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]12C([C@H](C(=C)C)CC1)C1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)[C@H](O)C4)CC3)CC1)CC2	O=C(O)[C@@]12C([C@H](C(=C)C)CC1)C1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)[C@H](O)C4)CC3)CC1)CC2
NCGC00179701-03	O=C(O)[C@@]12C([C@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)C(=O)CC4)C(O)C3)CC1)CC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00179701-03	363676953.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]12C([C@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)C(=O)CC4)C(O)C3)CC1)CC2	O=C(O)[C@@]12C([C@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)C(=O)CC4)C(O)C3)CC1)CC2
NCGC00180693-03	O=C(O)[C@@]12C([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(CO)(CO)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Achras | Family: Sapotaceae | Species: sapota		1	NCGC00180693-03	363677049.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]12C([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(CO)(CO)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O)[C@@]12C([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(CO)(CO)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00384631-01	O=C(O)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive	Insulin signaling pathway Modulator		1	NCGC00384631-01	363679284.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00017223-05	O=C(O)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC=1)CC2		Inactive	STAT-3 Inhibitor		1	Ursolic acid	384567976.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC=1)CC2	O=C(O)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC=1)CC2
NCGC00346584-02	O=C(O)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive	Nitric Oxide Production Inhibitor		1	Asiatic acid	363677465.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00385258-01	O=C(O)[C@@]12[C@@H]([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)CC4)C(O)C3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Ternstroenia | Family: Theaceae | Species: tepezapote		1	NCGC00385258-01	363679623.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]12[C@@H]([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)CC4)C(O)C3)CC=1)CC2	O=C(O)[C@@]12[C@@H]([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)CC4)C(O)C3)CC=1)CC2
NCGC00347357-02	O=C(O)[C@@]12[C@@H]([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Terminalia | Family: Combretaceae | Species: chebula		1	NCGC00347357-02	363677576.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]12[C@@H]([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O)[C@@]12[C@@H]([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00169620-03	O=C(O)[C@@]12[C@@H]([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Lawsonia | Family: Lythraceae | Species: inermis		1	NCGC00169620-03	363676849.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]12[C@@H]([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O)[C@@]12[C@@H]([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00180746-02	O=C(O)[C@@]12[C@@H]([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Maerua | Family: Capparidaceae | Species: angolensis		1	NCGC00180746-02	363677060.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]12[C@@H]([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O)[C@@]12[C@@H]([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00385731-01	O=C(O)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)CO8)[C@@H](O)[C@@H](O)CO7)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385731-01	363679906.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)CO8)[C@@H](O)[C@@H](O)CO7)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	O=C(O)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)CO8)[C@@H](O)[C@@H](O)CO7)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2
NCGC00384795-01	O=C(O)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)CO8)[C@@H](O)[C@@H](O)CO7)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384795-01	363679358.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)CO8)[C@@H](O)[C@@H](O)CO7)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	O=C(O)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)CO8)[C@@H](O)[C@@H](O)CO7)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2
NCGC00163409-07	O=C(O)[C@@]12[C@H]([C@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC1)CC2		Inactive	Caspase 3/8 Activator		1	Betulinic acid	384568234.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@@]12[C@H]([C@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC1)CC2	O=C(O)[C@@]12[C@H]([C@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC1)CC2
NCGC00169945-03	O=C(O)[C@@]12c3c(O)c(OC)c(C(C)C)cc3CCC1C(C)(C)CCC2		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Salvia | Family: Labiatae | Species: pomivera		1	NCGC00169945-03	363676919.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@@]12c3c(O)c(OC)c(C(C)C)cc3CCC1C(C)(C)CCC2	O=C(O)[C@@]12c3c(O)c(OC)c(C(C)C)cc3CCC1C(C)(C)CCC2
NCGC00347572-02	O=C(O)[C@H](CCC(=O)O)N1C(=O)c2c(c3O[C@@]4([C@H](C)CCC5C(C)(C)[C@@H](OC(=O)C)CC[C@]45C)Cc3c(O)c2)C1		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347572-02	363677627.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@H](CCC(=O)O)N1C(=O)c2c(c3O[C@@]4([C@H](C)CCC5C(C)(C)[C@@H](OC(=O)C)CC[C@]45C)Cc3c(O)c2)C1	O=C(O)[C@H](CCC(=O)O)N1C(=O)c2c(c3O[C@@]4([C@H](C)CCC5C(C)(C)[C@@H](OC(=O)C)CC[C@]45C)Cc3c(O)c2)C1
NCGC00381001-01	O=C(O)[C@H](CCC(=O)O)N1C(=O)c2c(c3O[C@@]4([C@H](C)CCC5C(C)(C)[C@H](OC(=O)C)[C@H](OC(=O)C)C[C@]45C)Cc3c(O)c2)C1		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381001-01	363678915.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@H](CCC(=O)O)N1C(=O)c2c(c3O[C@@]4([C@H](C)CCC5C(C)(C)[C@H](OC(=O)C)[C@H](OC(=O)C)C[C@]45C)Cc3c(O)c2)C1	O=C(O)[C@H](CCC(=O)O)N1C(=O)c2c(c3O[C@@]4([C@H](C)CCC5C(C)(C)[C@H](OC(=O)C)[C@H](OC(=O)C)C[C@]45C)Cc3c(O)c2)C1
NCGC00346524-02	O=C(O)[C@H](C[C@H](C(=O)/C(=C/[C@H](C)[C@@H]1[C@H](C)[C@@H](O)C[C@]2(O1)O[C@](C)([C@@H]1O[C@]3([C@H](C)[C@@H](OC4O[C@H](C)[C@@H](OC)CC4)C1)[C@@H](C)C[C@H]([C@@H]1[C@@H](C)C[C@@H](C)[C@](O)(CO)O1)O3)CC2)/C)C)C		Inactive	Polyether Antibiotic		1	Nanchangmycin	384568818.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-44.1981813379	O=C([O-])[C@H](C[C@H](C(=O)/C(=C/[C@H](C)[C@@H]1[C@H](C)[C@@H](O)C[C@]2(O1)O[C@](C)([C@@H]1O[C@]3([C@H](C)[C@@H](OC4O[C@H](C)[C@@H](OC)CC4)C1)[C@@H](C)C[C@H]([C@@H]1[C@@H](C)C[C@@H](C)[C@](O)(CO)O1)O3)CC2)/C)C)C	O=C([O-])[C@H](C[C@H](C(=O)/C(=C/[C@H](C)[C@@H]1[C@H](C)[C@@H](O)C[C@]2(O1)O[C@](C)([C@@H]1O[C@]3([C@H](C)[C@@H](OC4O[C@H](C)[C@@H](OC)CC4)C1)[C@@H](C)C[C@H]([C@@H]1[C@@H](C)C[C@@H](C)[C@](O)(CO)O1)O3)CC2)/C)C)C
NCGC00014891-14	O=C(O)[C@H](Cc1c2c([nH]c1)cccc2)N1C(=O)c2c(C1=O)cccc2		Inactive	DNA Methyltransferase (DNMT) Inhibitor		1	RG-108	384567795.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@H](Cc1c2c([nH]c1)cccc2)N1C(=O)c2c(C1=O)cccc2	O=C(O)[C@H](Cc1c2c([nH]c1)cccc2)N1C(=O)c2c(C1=O)cccc2
NCGC00024494-02	O=C(O)[C@H](N)C		Inactive	Alanine aminotransferase 1 Substrate		1	D-Alanine	170465038.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@H](N)C	O=C(O)[C@H](N)C
NCGC00013565-03	O=C(O)[C@H](N)CC(C)C		Inactive	Mammalian target of Rapamycin (mTORC1) Activator		1	D-Leucine	170465492.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@H](N)CC(C)C	O=C(O)[C@H](N)CC(C)C
NCGC00093936-08	O=C(O)[C@H](N)CCC(=O)N		Inactive	Protein-glutamine gamma-glutamyltransferase Substrate		1	D-Glutamine	170465304.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@H](N)CCC(=O)N	O=C(O)[C@H](N)CCC(=O)N
NCGC00024501-04	O=C(O)[C@H](N)CCC(=O)O		Inactive	Metabotropic glutamate receptor 1 Agonist		1	D-Glutamic acid	225144193.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@H](N)CCC(=O)O	O=C(O)[C@H](N)CCC(=O)O
NCGC00094363-07	O=C(O)[C@H](N)CO		Inactive	Serine palmitoyltransferase 1 Substrate		1	D-SERINE	405558559.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@H](N)CO	O=C(O)[C@H](N)CO
NCGC00094437-05	O=C(O)[C@H](N)Cc1c2c([nH]c1)cccc2		Inactive	Tryptophan metabolism Substrate		1	d-Tryptophan	170465485.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)[C@H](N)Cc1c2c([nH]c1)cccc2	O=C(O)[C@H](N)Cc1c2c([nH]c1)cccc2
NCGC00346842-04	O=C(O)[C@H](N)Cc1c2c(n(C)c1)cccc2		Inactive	IDO Inhibitor		1	Indoximod	384568951.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@H](N)Cc1c2c(n(C)c1)cccc2	O=C(O)[C@H](N)Cc1c2c(n(C)c1)cccc2
NCGC00163338-03	O=C(O)[C@H](N)Cc1ccccc1		Inactive			1	D-Phenylalanine	405558712.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@H](N)Cc1ccccc1	O=C(O)[C@H](N)Cc1ccccc1
NCGC00142611-02	O=C(O)[C@H](N)Cc1nc[nH]c1		Inactive	Histidine decarboxylase Substrate		1	D-HISTIDINE	26754413.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@H](N)Cc1nc[nH]c1	O=C(O)[C@H](N)Cc1nc[nH]c1
NCGC00095121-16&NCGC00271534-03	O=C(O)[C@H](NC(=O)C1CCC(C(C)C)CC1)Cc1ccccc1		Inactive	Insulin Secretagogues		2	NATEGLINIDE&Nateglinide	174006849.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@H](NC(=O)C1CCC(C(C)C)CC1)Cc1ccccc1	O=C(O)[C@H](NC(=O)C1CCC(C(C)C)CC1)Cc1ccccc1
NCGC00164593-02	O=C(O)[C@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C)CCc1ccccc1		Inactive			1	Enalapril acid	170464938.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C)CCc1ccccc1	O=C(O)[C@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C)CCc1ccccc1
NCGC00344532-01	O=C(O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)O		Inactive			1	Mucic acid	170464883.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)O	O=C(O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)O
NCGC00164076-03	O=C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO		Inactive			1	SODIUM GLUCONATE	405559091.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO	O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
NCGC00179532-03	O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)[C@H](O)CO		Inactive	Matrix Metalloproteinase (MMP) Inhibitor		1	Lactobionic acid	170466730.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)[C@H](O)CO	O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)[C@H](O)CO
NCGC00166022-02	O=C(O)[C@H](O)c1ccccc1		Inactive			1	D-(-)-Mandelic acid	170465573.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@H](O)c1ccccc1	O=C(O)[C@H](O)c1ccccc1
NCGC00510484-01	O=C(O)[C@H](Oc1cc(CN(CCCOc2ccc(OC)cc2)c2oc3c(n2)cccc3)ccc1)CC		Inactive	PPARalpha Agonist		1	Pemafibrate	384569447.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@H](Oc1cc(CN(CCCOc2ccc(OC)cc2)c2oc3c(n2)cccc3)ccc1)CC	O=C(O)[C@H](Oc1cc(CN(CCCOc2ccc(OC)cc2)c2oc3c(n2)cccc3)ccc1)CC
NCGC00163469-03	O=C(O)[C@H]([C@H](OC)[C@H](C)[C@@H]1[C@H](C)[C@@H](O)CC2(O1)O[C@](C)([C@@H]1O[C@](CC)([C@H]3[C@@H](C)C[C@H]([C@@H]4[C@@H](C)C[C@@H](C)[C@](O)(CO)O4)O3)CC1)CC2)C		Inactive			1	Monensin sodium salt	405558704.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(O)[C@H]([C@H](OC)[C@H](C)[C@@H]1[C@H](C)[C@@H](O)CC2(O1)O[C@](C)([C@@H]1O[C@](CC)([C@H]3[C@@H](C)C[C@H]([C@@H]4[C@@H](C)C[C@@H](C)[C@](O)(CO)O4)O3)CC1)CC2)C	O=C(O)[C@H]([C@H](OC)[C@H](C)[C@@H]1[C@H](C)[C@@H](O)CC2(O1)O[C@](C)([C@@H]1O[C@](CC)([C@H]3[C@@H](C)C[C@H]([C@@H]4[C@@H](C)C[C@@H](C)[C@](O)(CO)O4)O3)CC1)CC2)C
NCGC00180892-03	O=C(O)[C@H]1/C(=C/CO)/O[C@H]2N1C(=O)C2		Inactive			1	CLAVULANATE LITHIUM	225144312.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])[C@H]1/C(=C/CO)/O[C@H]2N1C(=O)C2	O=C([O-])[C@H]1/C(=C/CO)/O[C@H]2N1C(=O)C2
NCGC00159336-03	O=C(O)[C@H]1C(C)(C)S(=O)(=O)[C@H]2N1C(=O)C2		Inactive	beta-Lactamase Inhibitor		1	Sulbactam	170465248.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)[C@H]1C(C)(C)S(=O)(=O)[C@H]2N1C(=O)C2	O=C(O)[C@H]1C(C)(C)S(=O)(=O)[C@H]2N1C(=O)C2
NCGC00263825-02	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@@H](N3C(=O)[C@@H](c4ccccc4)NC3(C)C)C(=O)N12		Inactive	Bacterial penicillin-binding protein Inhibitor		1	HETACILLIN POTASSIUM	405558828.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])[C@H]1C(C)(C)S[C@@H]2[C@@H](N3C(=O)[C@@H](c4ccccc4)NC3(C)C)C(=O)N12	O=C([O-])[C@H]1C(C)(C)S[C@@H]2[C@@H](N3C(=O)[C@@H](c4ccccc4)NC3(C)C)C(=O)N12
NCGC00164583-02	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](/N=C/N3CCCCCC3)C(=O)N12		Inactive			1	Amdinocillin	170465354.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](/N=C/N3CCCCCC3)C(=O)N12	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](/N=C/N3CCCCCC3)C(=O)N12
NCGC00263560-01	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](N)C(=O)N12		Inactive			1	6-Aminopenicillanic acid	225144362.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](N)C(=O)N12	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](N)C(=O)N12
NCGC00022787-04	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(C)onc3-c3ccccc3)C(=O)N12		Inactive	beta-lactam antibiotic		1	Oxacillin sodium	405558799.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(C)onc3-c3ccccc3)C(=O)N12	O=C([O-])[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(C)onc3-c3ccccc3)C(=O)N12
NCGC00178877-03	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(OC)cccc3OC)C(=O)N12		Inactive	peptidoglycan biosynthetic process Inhibitor		1	Methicillin sodium hydrate	170465152.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(OC)cccc3OC)C(=O)N12.[Na+].O	O=C([O-])[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(OC)cccc3OC)C(=O)N12.[Na+].O
NCGC00273482-01	O=C(O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(OCC)ccc4c3cccc4)C(=O)N12		Inactive			1	Nafcillin sodium monohydrate	170465253.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(OCC)ccc4c3cccc4)C(=O)N12.[Na+].O	O=C([O-])[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)c3c(OCC)ccc4c3cccc4)C(=O)N12.[Na+].O
NCGC00386159-01	O=C(O)[C@H]1C2[C@@H]([C@@H](C)[C@H](C)C1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC=1)CC2		Inactive			1	Ursolic Acid	363680127.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@H]1C2[C@@H]([C@@H](C)[C@H](C)C1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC=1)CC2	O=C(O)[C@H]1C2[C@@H]([C@@H](C)[C@H](C)C1)C=1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC=1)CC2
NCGC00346594-02	O=C(O)[C@H]1C2[C@H](C=3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)CC5)CC4)CC=3)CC2)CC(C)(C)C1		Inactive	Secretory Phospholipase A2 (sPLA2) Inhibitor		1	Oleanolic acid	363677469.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@H]1C2[C@H](C=3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)CC5)CC4)CC=3)CC2)CC(C)(C)C1	O=C(O)[C@H]1C2[C@H](C=3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)CC5)CC4)CC=3)CC2)CC(C)(C)C1
NCGC00164626-02	O=C(O)[C@H]1CN(CC/C=C(\c2c(C)ccs2)/c2c(C)ccs2)CCC1		Inactive	GAT-1 Inhibitor		1	Tiagabine hydrochloride	170465153.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@H]1CN(CC/C=C(\c2c(C)ccs2)/c2c(C)ccs2)CCC1.Cl	O=C(O)[C@H]1CN(CC/C=C(\c2c(C)ccs2)/c2c(C)ccs2)CCC1.Cl
NCGC00164626-07	O=C(O)[C@H]1CN(CCC=C(c2c(C)ccs2)c2c(C)ccs2)CCC1		Inactive	GAT-1 Inhibitor		1	Tiagabine hydrochloride	384568269.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@H]1CN(CCC=C(c2c(C)ccs2)c2c(C)ccs2)CCC1	O=C(O)[C@H]1CN(CCC=C(c2c(C)ccs2)c2c(C)ccs2)CCC1
NCGC00160516-03	O=C(O)[C@H]1N(C(=O)[C@H]2NC(=O)CC2)CSC1		Inactive	natural killer cell mediated cytotoxicity Activator		1	Pidotimod	363676602.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@H]1N(C(=O)[C@H]2NC(=O)CC2)CSC1	O=C(O)[C@H]1N(C(=O)[C@H]2NC(=O)CC2)CSC1
NCGC00507856-01	O=C(O)[C@H]1N(Cc2c(OC)cc(OCc3c(C)c(-c4ccccc4)ccc3)cc2OC)CCCC1		Inactive	PD-1 /PD-L1 interaction Inhibitor		1	PD-1/PD-L1 Inhibitor 1	384569334.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@H]1N(Cc2c(OC)cc(OCc3c(C)c(-c4ccccc4)ccc3)cc2OC)CCCC1	O=C(O)[C@H]1N(Cc2c(OC)cc(OCc3c(C)c(-c4ccccc4)ccc3)cc2OC)CCCC1
NCGC00014017-03	O=C(O)[C@H]1NCCC1		Inactive			1	L-Proline	225144170.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@H]1NCCC1	O=C(O)[C@H]1NCCC1
NCGC00378884-01	O=C(O)[C@H]1NC[C@H]2[C@@H](C1)C[C@@H](CCc1n[nH]nn1)CC2		Inactive	Glutamate receptor ionotropic kainate Antagonist		1	Tezampanel	363678257.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@H]1NC[C@H]2[C@@H](C1)C[C@@H](CCc1n[nH]nn1)CC2	O=C(O)[C@H]1NC[C@H]2[C@@H](C1)C[C@@H](CCc1n[nH]nn1)CC2
NCGC00179705-03	O=C(O)[C@H]1N[C@@H](C[C@H]2[C@@H](C=C)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C2C(=O)OC)c2[nH]c3c(c2C1)cccc3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Acacia | Family: Mimosaceae | Species: ataxacantha		1	NCGC00179705-03	363676956.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@H]1N[C@@H](C[C@H]2[C@@H](C=C)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C2C(=O)OC)c2[nH]c3c(c2C1)cccc3	O=C(O)[C@H]1N[C@@H](C[C@H]2[C@@H](C=C)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C2C(=O)OC)c2[nH]c3c(c2C1)cccc3
NCGC00168248-02	O=C(O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@H]2N(C)[C@@H]1CC2		Inactive			1	Benzoylecgonine	144206406.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@H]2N(C)[C@@H]1CC2	O=C(O)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@H]2N(C)[C@@H]1CC2
NCGC00346612-06	O=C(O)[C@H]1[C@@H]2S(=O)(=O)C[C@@](N)(C(=O)O)[C@H]12		Inactive	mgluR2/3 Agonist		1	LY-2140023	384568858.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@H]1[C@@H]2S(=O)(=O)C[C@@](N)(C(=O)O)[C@H]12	O=C(O)[C@H]1[C@@H]2S(=O)(=O)C[C@@](N)(C(=O)O)[C@H]12
NCGC00385928-01	O=C(O)[C@H]1[C@@H]2[C@@](C(=O)O)(C)CCC[C@@]2(C)[C@H]2[C@]31CC(=C)[C@@H](C3)CC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385928-01	363680013.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@H]1[C@@H]2[C@@](C(=O)O)(C)CCC[C@@]2(C)[C@H]2[C@]31CC(=C)[C@@H](C3)CC2	O=C(O)[C@H]1[C@@H]2[C@@](C(=O)O)(C)CCC[C@@]2(C)[C@H]2[C@]31CC(=C)[C@@H](C3)CC2
NCGC00380833-01	O=C(O)[C@H]1[C@@H]2[C@@](C(=O)O)(C)[C@@H](O)CC[C@@]2(C)[C@H]2[C@]31CC(=C)[C@@H](C3)CC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380833-01	363678805.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@H]1[C@@H]2[C@@](C(=O)O)(C)[C@@H](O)CC[C@@]2(C)[C@H]2[C@]31CC(=C)[C@@H](C3)CC2	O=C(O)[C@H]1[C@@H]2[C@@](C(=O)O)(C)[C@@H](O)CC[C@@]2(C)[C@H]2[C@]31CC(=C)[C@@H](C3)CC2
NCGC00380795-01	O=C(O)[C@H]1[C@@H]2[C@@]3(C)[C@@H](O)C=C[C@@]2(OC3=O)[C@H]2[C@]31CC(=C)[C@@H](C3)CC2		Inactive	<MOA Unknown> | Class: diterpene | Genus: - | Family: - | Species: -		1	NCGC00380795-01	363678785.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@H]1[C@@H]2[C@@]3(C)[C@@H](O)C=C[C@@]2(OC3=O)[C@H]2[C@]31CC(=C)[C@@H](C3)CC2	O=C(O)[C@H]1[C@@H]2[C@@]3(C)[C@@H](O)C=C[C@@]2(OC3=O)[C@H]2[C@]31CC(=C)[C@@H](C3)CC2
NCGC00091033-09	O=C(O)[C@H]1[C@@H]2[C@@]3(C)[C@@H](O)C=C[C@@]2(OC3=O)[C@H]2[C@]31CC(=C)[C@@](O)(C3)CC2		Inactive	steroid biosynthetic process Activator		1	Gibberellic acid	363676549.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@H]1[C@@H]2[C@@]3(C)[C@@H](O)C=C[C@@]2(OC3=O)[C@H]2[C@]31CC(=C)[C@@](O)(C3)CC2	O=C(O)[C@H]1[C@@H]2[C@@]3(C)[C@@H](O)C=C[C@@]2(OC3=O)[C@H]2[C@]31CC(=C)[C@@](O)(C3)CC2
NCGC00380836-01	O=C(O)[C@H]1[C@@H]2[C@@]3(C)[C@@H](O)C=C[C@@]2(OC3=O)[C@H]2[C@]31CC(=C)[C@H]([C@@H](O)C2)C3		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380836-01	363678806.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@H]1[C@@H]2[C@@]3(C)[C@@H](O)C=C[C@@]2(OC3=O)[C@H]2[C@]31CC(=C)[C@H]([C@@H](O)C2)C3	O=C(O)[C@H]1[C@@H]2[C@@]3(C)[C@@H](O)C=C[C@@]2(OC3=O)[C@H]2[C@]31CC(=C)[C@H]([C@@H](O)C2)C3
NCGC00380182-01	O=C(O)[C@H]1[C@@H]2[C@@]3(C)[C@@H](O)CC[C@@]2(OC3=O)[C@H]2[C@]31CC(=C)[C@@H](C3)CC2		Inactive	<MOA Unknown> | Class: diterpene | Genus: - | Family: - | Species: -		1	NCGC00380182-01	363678493.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@H]1[C@@H]2[C@@]3(C)[C@@H](O)CC[C@@]2(OC3=O)[C@H]2[C@]31CC(=C)[C@@H](C3)CC2	O=C(O)[C@H]1[C@@H]2[C@@]3(C)[C@@H](O)CC[C@@]2(OC3=O)[C@H]2[C@]31CC(=C)[C@@H](C3)CC2
NCGC00384481-01	O=C(O)[C@H]1[C@@H]2[C@@]3(C)[C@@H](O)[C@H](OC3=O)C=C2[C@H]2[C@]31CC(=C)[C@@H](C3)CC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384481-01	363679206.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@H]1[C@@H]2[C@@]3(C)[C@@H](O)[C@H](OC3=O)C=C2[C@H]2[C@]31CC(=C)[C@@H](C3)CC2	O=C(O)[C@H]1[C@@H]2[C@@]3(C)[C@@H](O)[C@H](OC3=O)C=C2[C@H]2[C@]31CC(=C)[C@@H](C3)CC2
NCGC00180814-02	O=C(O)[C@H]1[C@@](CCc2cocc2)(C)[C@@H]2[C@](C)(C(C)=CCC2)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180814-02	363677068.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@H]1[C@@](CCc2cocc2)(C)[C@@H]2[C@](C)(C(C)=CCC2)CC1	O=C(O)[C@H]1[C@@](CCc2cocc2)(C)[C@@H]2[C@](C)(C(C)=CCC2)CC1
NCGC00159340-05	O=C(O)[C@H]1[C@@](Cn2nncc2)(C)S(=O)(=O)[C@H]2N1C(=O)C2		Inactive	Bacterial beta-lactamase TEM Inhibitor		1	Tazobactam sodium	170465148.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])[C@H]1[C@@](Cn2nncc2)(C)S(=O)(=O)[C@H]2N1C(=O)C2.[Na+]	O=C([O-])[C@H]1[C@@](Cn2nncc2)(C)S(=O)(=O)[C@H]2N1C(=O)C2.[Na+]
NCGC00380804-01	O=C(O)[C@H]1[C@H](O)/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](C)OC(=O)[C@H](C)[C@@H](O)C[C@@H](O)C[C@@H](O)CCC[C@@H](O)C[C@H]1O		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380804-01	363678790.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@H]1[C@H](O)/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](C)OC(=O)[C@H](C)[C@@H](O)C[C@@H](O)C[C@@H](O)CCC[C@@H](O)C[C@H]1O	O=C(O)[C@H]1[C@H](O)/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](C)OC(=O)[C@H](C)[C@@H](O)C[C@@H](O)C[C@@H](O)CCC[C@@H](O)C[C@H]1O
NCGC00168838-03	O=C(O)[C@H]1[C@H](O)C(C)(C)C2[C@@]1(C)C1[C@](C)([C@@]3(C)C(C4[C@H](C(=C)C)CC[C@]4(C(=O)O)CC3)CC1)CC2		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Zizyphus | Family: Rhamnaceae | Species: xyloyrus		1	NCGC00168838-03	363676699.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	-9.735632188	O=C(O)[C@H]1[C@H](O)C(C)(C)C2[C@@]1(C)C1[C@](C)([C@@]3(C)C(C4[C@H](C(=C)C)CC[C@]4(C(=O)O)CC3)CC1)CC2	O=C(O)[C@H]1[C@H](O)C(C)(C)C2[C@@]1(C)C1[C@](C)([C@@]3(C)C(C4[C@H](C(=C)C)CC[C@]4(C(=O)O)CC3)CC1)CC2
NCGC00180485-03	O=C(O)[C@H]1[C@H]2C[C@]3([C@H]([C@@]4(C)[C@@H]([C@@](C(=O)OC)(C)CCC4)CC3)CC2)C1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Annona | Family: Annonaceae | Species: holosericea		1	NCGC00180485-03	363677027.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@H]1[C@H]2C[C@]3([C@H]([C@@]4(C)[C@@H]([C@@](C(=O)OC)(C)CCC4)CC3)CC2)C1	O=C(O)[C@H]1[C@H]2C[C@]3([C@H]([C@@]4(C)[C@@H]([C@@](C(=O)OC)(C)CCC4)CC3)CC2)C1
NCGC00185990-04	O=C(O)[C@H]1c2n(c(C(=O)c3ccccc3)cc2)CC1		Inactive	non-steroidal antiinflammatory		1	Ketorolac	170464659.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@H]1c2n(c(C(=O)c3ccccc3)cc2)CC1.OCC(N)(CO)CO	O=C(O)[C@H]1c2n(c(C(=O)c3ccccc3)cc2)CC1.OCC(N)(CO)CO
NCGC00380707-01	O=C(O)[C@]1(C)C2[C@@H](O)[C@@H](O)C34C([C@@]2(C)CCC1)CCC(C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)(CO)C3)C4		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380707-01	363678724.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]1(C)C2[C@@H](O)[C@@H](O)C34C([C@@]2(C)CCC1)CCC(C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)(CO)C3)C4	O=C(O)[C@]1(C)C2[C@@H](O)[C@@H](O)C34C([C@@]2(C)CCC1)CCC(C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)(CO)C3)C4
NCGC00169678-02	O=C(O)[C@]1(C)C2[C@@](C)(C3C4(C=C(CO)C(C4)CC3)CC2)CCC1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Elaeoselinum | Family: Umbelliferae | Species: asclepium		1	NCGC00169678-02	363676860.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]1(C)C2[C@@](C)(C3C4(C=C(CO)C(C4)CC3)CC2)CCC1	O=C(O)[C@]1(C)C2[C@@](C)(C3C4(C=C(CO)C(C4)CC3)CC2)CCC1
NCGC00380536-01	O=C(O)[C@]1(C)C2[C@@](C)(C3C4(CC(CO)C(C4)CC3)CC2)CCC1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Annona | Family: Annonaceae | Species: holosericea		1	NCGC00380536-01	363678638.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]1(C)C2[C@@](C)(C3C4(CC(CO)C(C4)CC3)CC2)CCC1	O=C(O)[C@]1(C)C2[C@@](C)(C3C4(CC(CO)C(C4)CC3)CC2)CCC1
NCGC00385974-01	O=C(O)[C@]1(C)C2[C@@](C)([C@@H](CC/C(=C\CO)/C)[C@@](O)(C)CC2)CCC1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Maba | Family: Ebenaceae | Species: buxifolia		1	NCGC00385974-01	363680038.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]1(C)C2[C@@](C)([C@@H](CC/C(=C\CO)/C)[C@@](O)(C)CC2)CCC1	O=C(O)[C@]1(C)C2[C@@](C)([C@@H](CC/C(=C\CO)/C)[C@@](O)(C)CC2)CCC1
NCGC00385611-01	O=C(O)[C@]1(C)C2[C@@](C)(c3c(C(=O)C2)cc(C(C)C)cc3)CCC1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Pinus | Family: Pinaceae | Species: nigra nigra		1	NCGC00385611-01	363679838.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]1(C)C2[C@@](C)(c3c(C(=O)C2)cc(C(C)C)cc3)CCC1	O=C(O)[C@]1(C)C2[C@@](C)(c3c(C(=O)C2)cc(C(C)C)cc3)CCC1
NCGC00385373-01	O=C(O)[C@]1(C)C2[C@@](C)(c3c([C@H](O)C2)cc(C(C)C)cc3)CCC1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Pinus | Family: Pinaceae | Species: nigra nigra		1	NCGC00385373-01	363679707.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]1(C)C2[C@@](C)(c3c([C@H](O)C2)cc(C(C)C)cc3)CCC1	O=C(O)[C@]1(C)C2[C@@](C)(c3c([C@H](O)C2)cc(C(C)C)cc3)CCC1
NCGC00347501-02	O=C(O)[C@]1(C)C2[C@](C)([C@H](CCc3cocc3)C(=C)CC2)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Polyalthia  | Family: N/A | Species: fragrans		1	NCGC00347501-02	363677605.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]1(C)C2[C@](C)([C@H](CCc3cocc3)C(=C)CC2)CCC1	O=C(O)[C@]1(C)C2[C@](C)([C@H](CCc3cocc3)C(=C)CC2)CCC1
NCGC00017244-10&NCGC00017244-16	O=C(O)[C@]1(C)C[C@@H]2[C@@](C)(CC[C@@]3(C)[C@@]4(C)[C@H](C(=O)C=C23)[C@]2(C)[C@H](C(C)(C)[C@@H](O)CC2)CC4)CC1		Inactive	15-hydroxyprostaglandin dehydrogenase Inhibitor		2	Enoxolone&ENOXOLONE	384567978.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&15.6096002199	O=C(O)[C@]1(C)C[C@@H]2[C@@](C)(CC[C@@]3(C)[C@@]4(C)[C@H](C(=O)C=C23)[C@]2(C)[C@H](C(C)(C)[C@@H](O)CC2)CC4)CC1	O=C(O)[C@]1(C)C[C@@H]2[C@@](C)(CC[C@@]3(C)[C@@]4(C)[C@H](C(=O)C=C23)[C@]2(C)[C@H](C(C)(C)[C@@H](O)CC2)CC4)CC1
NCGC00484082-01	O=C(O)[C@]1(C)N=C(c2c(O)cc(OCCOCCOC)cc2)SC1		Inactive			1	SP-420	363681173.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]1(C)N=C(c2c(O)cc(OCCOCCOC)cc2)SC1	O=C(O)[C@]1(C)N=C(c2c(O)cc(OCCOCCOC)cc2)SC1
NCGC00347421-02	O=C(O)[C@]1(C)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)CC[C@]2(C)C3[C@](C)([C@@]4(C)C([C@H]5[C@@](C(=O)O)([C@H](O)C4)CCC(C)(C)C5)=CC3)CCC12		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347421-02	363677599.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]1(C)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)CC[C@]2(C)C3[C@](C)([C@@]4(C)C([C@H]5[C@@](C(=O)O)([C@H](O)C4)CCC(C)(C)C5)=CC3)CCC12	O=C(O)[C@]1(C)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)CO2)CC[C@]2(C)C3[C@](C)([C@@]4(C)C([C@H]5[C@@](C(=O)O)([C@H](O)C4)CCC(C)(C)C5)=CC3)CCC12
NCGC00380333-01	O=C(O)[C@]1(C)[C@H]2[C@@](C)(C3C(=CC(C=C)(C)CC3)CC2)CCC1		Inactive	Calcium-activated potassium channel subunit alpha-1 Opener		1	NCGC00380333-01	363678544.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]1(C)[C@H]2[C@@](C)(C3C(=CC(C=C)(C)CC3)CC2)CCC1	O=C(O)[C@]1(C)[C@H]2[C@@](C)(C3C(=CC(C=C)(C)CC3)CC2)CCC1
NCGC00168805-03	O=C(O)[C@]1(CCc2cocc2)[C@H](C)CC[C@@]2(C)C(C)=CCC[C@H]12		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00168805-03	363676689.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]1(CCc2cocc2)[C@H](C)CC[C@@]2(C)C(C)=CCC[C@H]12	O=C(O)[C@]1(CCc2cocc2)[C@H](C)CC[C@@]2(C)C(C)=CCC[C@H]12
NCGC00169916-02	O=C(O)[C@]1(O)[C@@H]2OC[C@]3(C(C(=C(C)C)CC3)CC1)C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Fusarium | Family: N/A | Species: N/A		1	NCGC00169916-02	363676912.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	-14.73032904	O=C(O)[C@]1(O)[C@@H]2OC[C@]3(C(C(=C(C)C)CC3)CC1)C2	O=C(O)[C@]1(O)[C@@H]2OC[C@]3(C(C(=C(C)C)CC3)CC1)C2
NCGC00179743-02	O=C(O)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Ochrosia | Family: Apocynaceae | Species: borbonica		1	NCGC00179743-02	363676963.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00385632-01	O=C(O)[C@]12C(C=O)=C[C@H]3[C@@H]([C@@]1(C)C2)CC(C)(C)C3		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: Lactarius | Family: Basidiomycetaceae | Species: vellereus		1	NCGC00385632-01	363679848.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12C(C=O)=C[C@H]3[C@@H]([C@@]1(C)C2)CC(C)(C)C3	O=C(O)[C@]12C(C=O)=C[C@H]3[C@@H]([C@@]1(C)C2)CC(C)(C)C3
NCGC00380418-01	O=C(O)[C@]12C(O)CC(CO)(C)CC1C13C([C@@]4(C)C([C@@]5(C)[C@@H](O)[C@@H](O)[C@H](O)C(CO)(C)C5CC4)C=C1)(C3)CC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Cordia | Family: Boraginaceae | Species: vignei		1	NCGC00380418-01	363678574.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12C(O)CC(CO)(C)CC1C13C([C@@]4(C)C([C@@]5(C)[C@@H](O)[C@@H](O)[C@H](O)C(CO)(C)C5CC4)C=C1)(C3)CC2	O=C(O)[C@]12C(O)CC(CO)(C)CC1C13C([C@@]4(C)C([C@@]5(C)[C@@H](O)[C@@H](O)[C@H](O)C(CO)(C)C5CC4)C=C1)(C3)CC2
NCGC00347703-02	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)C(=O)CC4)CC3)CC[C@@H]1C1[C@H](C(=C)C)CC[C@]1(C(=O)O)CC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347703-02	363677667.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)C(=O)CC4)CC3)CC[C@@H]1C1[C@H](C(=C)C)CC[C@]1(C(=O)O)CC2	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)C(=O)CC4)CC3)CC[C@@H]1C1[C@H](C(=C)C)CC[C@]1(C(=O)O)CC2
NCGC00347611-02	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)CC4)CC3)CC[C@@H]1C1[C@@](C(=O)O)(CC2)CCC1C(=C)C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Aralia | Family: Araliaceae | Species: armata		1	NCGC00347611-02	363677639.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)CC4)CC3)CC[C@@H]1C1[C@@](C(=O)O)(CC2)CCC1C(=C)C	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)CC4)CC3)CC[C@@H]1C1[C@@](C(=O)O)(CC2)CCC1C(=C)C
NCGC00179804-02	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](OC5C(O)C(OC6C(O)C(O)C(O)C(CO)O6)C(O)C(C)O5)CC4)CC3)CC=C1C1[C@@](C(=O)O)(CC2)CCC(C)C1C		Inactive	<MOA Unknown> | Class: Saponin | Genus: n.b. | Family: N/A | Species: N/A		1	NCGC00179804-02	363676972.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](OC5C(O)C(OC6C(O)C(O)C(O)C(CO)O6)C(O)C(C)O5)CC4)CC3)CC=C1C1[C@@](C(=O)O)(CC2)CCC(C)C1C	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](OC5C(O)C(OC6C(O)C(O)C(O)C(CO)O6)C(O)C(C)O5)CC4)CC3)CC=C1C1[C@@](C(=O)O)(CC2)CCC(C)C1C
NCGC00380924-01	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](OC5C(O)C(OC6C(O)C(O)C(OC7C(O)C(O)C(O)C(C)O7)C(C)O6)C(O)C(CO)O5)CC4)CC3)CC=C1C1[C@@H](C)[C@H](C)CC[C@]1(C(=O)O)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380924-01	363678858.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](OC5C(O)C(OC6C(O)C(O)C(OC7C(O)C(O)C(O)C(C)O7)C(C)O6)C(O)C(CO)O5)CC4)CC3)CC=C1C1[C@@H](C)[C@H](C)CC[C@]1(C(=O)O)CC2	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](OC5C(O)C(OC6C(O)C(O)C(OC7C(O)C(O)C(O)C(C)O7)C(C)O6)C(O)C(CO)O5)CC4)CC3)CC=C1C1[C@@H](C)[C@H](C)CC[C@]1(C(=O)O)CC2
NCGC00169560-02	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](C)O5)CC4)CC3)CC=C1C1[C@@](C(=O)O)(CC2)CCC(C)(C)C1		Inactive	<MOA Unknown> | Class: Saponin | Genus: n.b. | Family: N/A | Species: N/A		1	NCGC00169560-02	363676839.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](C)O5)CC4)CC3)CC=C1C1[C@@](C(=O)O)(CC2)CCC(C)(C)C1	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](C)O5)CC4)CC3)CC=C1C1[C@@](C(=O)O)(CC2)CCC(C)(C)C1
NCGC00347606-02	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](C)O5)CC4)CC3)CC=C1[C@@H]1[C@@H](C)[C@H](C)CC[C@]1(C(=O)O)CC2		Inactive	Phosphodiesterase 1 Inhibitor		1	NCGC00347606-02	363677637.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](C)O5)CC4)CC3)CC=C1[C@@H]1[C@@H](C)[C@H](C)CC[C@]1(C(=O)O)CC2	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](C)O5)CC4)CC3)CC=C1[C@@H]1[C@@H](C)[C@H](C)CC[C@]1(C(=O)O)CC2
NCGC00168872-03	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC4)CC3)CC=C1C1[C@@](C(=O)O)(CC2)CCC(C)C1C		Inactive	<MOA Unknown> | Class: Saponin | Genus: n.b. | Family: N/A | Species: N/A		1	NCGC00168872-03	363676709.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC4)CC3)CC=C1C1[C@@](C(=O)O)(CC2)CCC(C)C1C	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC4)CC3)CC=C1C1[C@@](C(=O)O)(CC2)CCC(C)C1C
NCGC00169815-02	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O5)CC4)CC3)CC=C1[C@@H]1[C@@H](C)[C@H](C)CC[C@]1(C(=O)O)CC2		Inactive	Phosphodiesterase 1 Inhibitor		1	NCGC00169815-02	363676894.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O5)CC4)CC3)CC=C1[C@@H]1[C@@H](C)[C@H](C)CC[C@]1(C(=O)O)CC2	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O5)CC4)CC3)CC=C1[C@@H]1[C@@H](C)[C@H](C)CC[C@]1(C(=O)O)CC2
NCGC00179909-03	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@H](O)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](C)O5)CC4)CC3)CC=C1C1[C@@H](C)[C@H](C)CC[C@]1(C(=O)O)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Acacia | Family: Mimosaceae | Species: ataxacantha		1	NCGC00179909-03	363676989.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@H](O)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](C)O5)CC4)CC3)CC=C1C1[C@@H](C)[C@H](C)CC[C@]1(C(=O)O)CC2	O=C(O)[C@]12[C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@H](O)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](C)O5)CC4)CC3)CC=C1C1[C@@H](C)[C@H](C)CC[C@]1(C(=O)O)CC2
NCGC00384495-01	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@@]5(C)C(=O)C[C@H](O)[C@](CO)(C)C5CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384495-01	363679212.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@@]5(C)C(=O)C[C@H](O)[C@](CO)(C)C5CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@@]5(C)C(=O)C[C@H](O)[C@](CO)(C)C5CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00347737-02	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)C(O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Brassaiopsis | Family: Araliaceae | Species: hainla		1	NCGC00347737-02	363677676.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)C(O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)C(O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00384893-01	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@@H](O)CO6)[C@@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384893-01	363679421.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@@H](O)CO6)[C@@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@@H](O)CO6)[C@@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00385302-01	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O)[C@@H](CO)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385302-01	363679660.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O)[C@@H](CO)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O)[C@@H](CO)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00347379-02	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)CO8)[C@@H](O)[C@H](C)O7)[C@@H](O)[C@@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Aesculus | Family: Hippocastanaceae | Species: sp.		1	NCGC00347379-02	363677584.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)CO8)[C@@H](O)[C@H](C)O7)[C@@H](O)[C@@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)CO8)[C@@H](O)[C@H](C)O7)[C@@H](O)[C@@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00169988-02	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O)[C@H](O)C5)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Maerua | Family: Capparidaceae | Species: angolensis		1	NCGC00169988-02	363676924.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O)[C@H](O)C5)CC=3)CC1)CC(C)(C)CC2	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O)[C@H](O)C5)CC=3)CC1)CC(C)(C)CC2
NCGC00384894-01	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)C5)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384894-01	363679422.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)C5)CC=3)CC1)CC(C)(C)CC2	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)C5)CC=3)CC1)CC(C)(C)CC2
NCGC00017222-10	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive			1	OLEANOIC ACID	434146963.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00390255-01	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)[C@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	Glycogen Phosphorylase Inhibitor		1	Maslinic acid	384569181.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)[C@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O)[C@]12[C@H](C=3[C@](C)([C@@]4(C)[C@@H]([C@]5(C)[C@H](C(C)(C)[C@@H](O)[C@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00095150-08&NCGC00095150-16	O=C(O)c1c(-c2ccc(Cn3c(CCC)nc4c(C)cc(-c5n(C)c6c(n5)cccc6)cc34)cc2)cccc1		Inactive	Angiotensin AT1 Antagonist		2	Telmisartan	170464873.0&384568151.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	O=C(O)c1c(-c2ccc(Cn3c(CCC)nc4c(C)cc(-c5n(C)c6c(n5)cccc6)cc34)cc2)cccc1	O=C(O)c1c(-c2ccc(Cn3c(CCC)nc4c(C)cc(-c5n(C)c6c(n5)cccc6)cc34)cc2)cccc1
NCGC00263694-01	O=C(O)c1c(C(=O)Nc2ccc(-c3ccccc3)cc2)cccc1		Inactive	chondrocyte differentiation initiator		1	Kartogenin	174007246.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1c(C(=O)Nc2ccc(-c3ccccc3)cc2)cccc1	O=C(O)c1c(C(=O)Nc2ccc(-c3ccccc3)cc2)cccc1
NCGC00091015-01	O=C(O)c1c(C(c2ccc(O)cc2)c2ccc(O)cc2)cccc1		Inactive			1	Phenolphthalin	17389504.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1c(C(c2ccc(O)cc2)c2ccc(O)cc2)cccc1	O=C(O)c1c(C(c2ccc(O)cc2)c2ccc(O)cc2)cccc1
NCGC00384944-01	O=C(O)c1c(C)c(C)c2OC3C(O)C(O)C(O)C(C(O)C(O)C4C(O)C(O)C(O)C(Oc1c2)O4)O3		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384944-01	363679451.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c(C)c(C)c2OC3C(O)C(O)C(O)C(C(O)C(O)C4C(O)C(O)C(O)C(Oc1c2)O4)O3	O=C(O)c1c(C)c(C)c2OC3C(O)C(O)C(O)C(C(O)C(O)C4C(O)C(O)C(O)C(Oc1c2)O4)O3
NCGC00247988-03	O=C(O)c1c(C)c2C(=O)c3c(O)c([C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(O)c(O)c3C(=O)c2cc1O		Inactive	Solute carrier organic anion transporter family member 1B1 Inhibitor		1	Cochineal	170466801.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1c(C)c2C(=O)c3c(O)c([C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(O)c(O)c3C(=O)c2cc1O	O=C(O)c1c(C)c2C(=O)c3c(O)c([C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(O)c(O)c3C(=O)c2cc1O
NCGC00182059-03&NCGC00182059-11	O=C(O)c1c(C)nc(-c2cc(C#N)c(OCC(C)C)cc2)s1		Inactive	Xanthine Oxidase Inhibitor		2	Febuxostat	170465220.0&384568409.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)c1c(C)nc(-c2cc(C#N)c(OCC(C)C)cc2)s1	O=C(O)c1c(C)nc(-c2cc(C#N)c(OCC(C)C)cc2)s1
NCGC00250410-11	O=C(O)c1c(C2CCCC2)cc(-c2c3c([nH]c2)ncc(-c2ccccc2)c3)cc1	5.0250001	Active	SGK1 Inhibitor	0.0	1	GSK-650394	384568558.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	51.6044640138&44.0333239052	O=C(O)c1c(C2CCCC2)cc(-c2c3c([nH]c2)ncc(-c2ccccc2)c3)cc1	O=C(O)c1c(C2CCCC2)cc(-c2c3c([nH]c2)ncc(-c2ccccc2)c3)cc1
NCGC00379003-05	O=C(O)c1c(CCCOc2ccc(CN)cc2)sc(-c2cc3/C(=N/Nc4sc5c(n4)cccc5)/CCCc3cc2)n1		Inactive	Bcl-xl Inhibitor		1	WEHI-539	384569085.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1c(CCCOc2ccc(CN)cc2)sc(-c2cc3/C(=N/Nc4sc5c(n4)cccc5)/CCCc3cc2)n1	O=C(O)c1c(CCCOc2ccc(CN)cc2)sc(-c2cc3/C(=N/Nc4sc5c(n4)cccc5)/CCCc3cc2)n1
NCGC00380367-01	O=C(O)c1c(CCc2ccccc2)cc(OC)c2c1OC(C(O)(C)C)C2		Inactive	<MOA Unknown> | Class: Shikimi / Polyketide | Genus: Glycyrrhiza | Family: N/A | Species: foetida		1	NCGC00380367-01	363678555.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c(CCc2ccccc2)cc(OC)c2c1OC(C(O)(C)C)C2	O=C(O)c1c(CCc2ccccc2)cc(OC)c2c1OC(C(O)(C)C)C2
NCGC00346532-01&NCGC00346532-04	O=C(O)c1c(N(C(=O)C2CCC(C)CC2)C2CCC(O)CC2)cc(C#CC(C)(C)C)s1		Inactive			2	VX-222	174007365.0&434147088.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)c1c(N(C(=O)C2CCC(C)CC2)C2CCC(O)CC2)cc(C#CC(C)(C)C)s1	O=C(O)c1c(N(C(=O)C2CCC(C)CC2)C2CCC(O)CC2)cc(C#CC(C)(C)C)s1
NCGC00346467-01	O=C(O)c1c(N(C(=O)C2CCC(C)CC2)C2CCC(OC)CC2)cc(C2=CCCCC2)s1		Inactive			1	VCH-916 	174007403.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])c1c(N(C(=O)C2CCC(C)CC2)C2CCC(OC)CC2)cc(C2=CCCCC2)s1	O=C([O-])c1c(N(C(=O)C2CCC(C)CC2)C2CCC(OC)CC2)cc(C2=CCCCC2)s1
NCGC00386724-03&NCGC00386724-06	O=C(O)c1c(N)ccc(C(=O)c2c(C)c(OC)c3n2C=CC=C3)c1		Inactive			2	SSR128129E	363680419.0	2020_NPACT-1_CPE&2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C([O-])c1c(N)ccc(C(=O)c2c(C)c(OC)c3n2C=CC=C3)c1	O=C([O-])c1c(N)ccc(C(=O)c2c(C)c(OC)c3n2C=CC=C3)c1
NCGC00167472-03&NCGC00167472-10	O=C(O)c1c(N)nc2Oc3c(C(=O)c2c1)cc(C(C)C)cc3		Inactive	Mediator Release Inhibitor		2	Amlexanox	170465365.0&384568317.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)c1c(N)nc2Oc3c(C(=O)c2c1)cc(C(C)C)cc3	O=C(O)c1c(N)nc2Oc3c(C(=O)c2c1)cc(C(C)C)cc3
NCGC00025064-17	O=C(O)c1c(NC)ccc2oc(C[C@@H]3[C@H](C)CC[C@]4([C@H](C)C[C@@H](C)[C@@H]([C@@H](C(=O)c5[nH]ccc5)C)O4)O3)nc12		Inactive			1	A23187, free acid		2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0		O=C(O)c1c(NC)ccc2oc(C[C@@H]3[C@H](C)CC[C@]4([C@H](C)C[C@@H](C)[C@@H]([C@@H](C(=O)c5[nH]ccc5)C)O4)O3)nc12	O=C(O)c1c(NC)ccc2oc(C[C@@H]3[C@H](C)CC[C@]4([C@H](C)C[C@@H](C)[C@@H]([C@@H](C(=O)c5[nH]ccc5)C)O4)O3)nc12
NCGC00263154-08	O=C(O)c1c(N[C@H](C)C=2C3=NC(N4CCOCC4)=CC(=O)N3C=C(C)C=2)cccc1		Inactive	PI3Kb/d Inhibitor		1	AZD-6482	384568628.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1c(N[C@H](C)C=2C3=NC(N4CCOCC4)=CC(=O)N3C=C(C)C=2)cccc1	O=C(O)c1c(N[C@H](C)C=2C3=NC(N4CCOCC4)=CC(=O)N3C=C(C)C=2)cccc1
NCGC00016278-10	O=C(O)c1c(Nc2c(C)c(C)ccc2)cccc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Mefenamic acid	170464813.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)c1c(Nc2c(C)c(C)ccc2)cccc1	O=C(O)c1c(Nc2c(C)c(C)ccc2)cccc1
NCGC00384275-01	O=C(O)c1c(Nc2c3c(n(C)c2)nccc3)cncc1		Inactive			1	NCGC00384275-01	363679201.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c(Nc2c3c(n(C)c2)nccc3)cncc1	O=C(O)c1c(Nc2c3c(n(C)c2)nccc3)cncc1
NCGC00385333-01	O=C(O)c1c(O)c(CC=C(C)C)c(OC)cc1/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385333-01	363679684.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c(O)c(CC=C(C)C)c(OC)cc1/C=C/c1ccccc1	O=C(O)c1c(O)c(CC=C(C)C)c(OC)cc1/C=C/c1ccccc1
NCGC00169025-02	O=C(O)c1c(O)c(CC=C(C)C)ccc1Oc1c(O)cc(C)cc1CO		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169025-02	363676745.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c(O)c(CC=C(C)C)ccc1Oc1c(O)cc(C)cc1CO	O=C(O)c1c(O)c(CC=C(C)C)ccc1Oc1c(O)cc(C)cc1CO
NCGC00385569-01	O=C(O)c1c(O)c(COC)c2OC(=O)c3c(C)cc(O)c(CO)c3Oc2c1C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385569-01	363679814.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c(O)c(COC)c2OC(=O)c3c(C)cc(O)c(CO)c3Oc2c1C	O=C(O)c1c(O)c(COC)c2OC(=O)c3c(C)cc(O)c(CO)c3Oc2c1C
NCGC00013369-07&NCGC00263960-01	O=C(O)c1c(O)c(Cc2c(O)c(C(=O)O)cc3c2cccc3)c2c(c1)cccc2		Inactive	antiparasitic agent		2	Pamoic acid disodium salt&OXANTEL PAMOATE	405558714.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)c1c(O)c(Cc2c(O)c(C(=O)O)cc3c2cccc3)c2c(c1)cccc2	O=C(O)c1c(O)c(Cc2c(O)c(C(=O)O)cc3c2cccc3)c2c(c1)cccc2&O=C(O)c1c(O)c(Cc2c(O)c(C(=O)O)cc3c2cccc3)c2c(c1)cccc2.Oc1cc(/C=C/C=2N(C)CCCN=2)ccc1
NCGC00384984-01	O=C(O)c1c(O)c2c(c(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)O3)c1)cccc2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384984-01	363679468.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c(O)c2c(c(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)O3)c1)cccc2	O=C(O)c1c(O)c2c(c(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)O3)c1)cccc2
NCGC00380968-01	O=C(O)c1c(O)cc(OC)cc1CCc1ccccc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380968-01	363678892.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c(O)cc(OC)cc1CCc1ccccc1	O=C(O)c1c(O)cc(OC)cc1CCc1ccccc1
NCGC00380115-01	O=C(O)c1c(O)cc(Oc2cc(O)cc(C)c2)cc1C		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380115-01	363678462.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c(O)cc(Oc2cc(O)cc(C)c2)cc1C	O=C(O)c1c(O)cc(Oc2cc(O)cc(C)c2)cc1C
NCGC00181008-02	O=C(O)c1c(O)ccc(/N=N/c2cc(C(=O)O)c(O)cc2)c1		Inactive	Cyclooxygenase Inhibitor		1	Olsalazine sodium	225144315.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])c1c(O)ccc(/N=N/c2cc(C(=O)[O-])c(O)cc2)c1	O=C([O-])c1c(O)ccc(/N=N/c2cc(C(=O)[O-])c(O)cc2)c1
NCGC00402304-03	O=C(O)c1c(O)ccc(N(C(=O)c2ccc(Oc3ccccc3)cc2)Cc2ccc(C3CCCCC3)cc2)c1		Inactive	Signal transducer and activator of transcription 3 Inhibitor		1	S3I-1757	363681022.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c(O)ccc(N(C(=O)c2ccc(Oc3ccccc3)cc2)Cc2ccc(C3CCCCC3)cc2)c1	O=C(O)c1c(O)ccc(N(C(=O)c2ccc(Oc3ccccc3)cc2)Cc2ccc(C3CCCCC3)cc2)c1
NCGC00016344-07	O=C(O)c1c(O)ccc(N)c1		Inactive	reactive oxygen species biosynthetic process Inhibitor		1	5-Aminosalicylic acid	170464840.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)c1c(O)ccc(N)c1	O=C(O)c1c(O)ccc(N)c1
NCGC00384900-01	O=C(O)c1c(O)ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384900-01	363679426.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c(O)ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c1	O=C(O)c1c(O)ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c1
NCGC00159447-01	O=C(O)c1c(O)cccc1		Inactive			1	Sodium Salicylate	434146937.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1c(O)cccc1	O=C(O)c1c(O)cccc1
NCGC00169660-02	O=C(O)c1c(O)cccc1CCCCCCC/C=C\C/C=C\CC=C		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Anacardium | Family: Anacardiaceae | Species: occidentale		1	NCGC00169660-02	363676857.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c(O)cccc1CCCCCCC/C=C\C/C=C\CC=C	O=C(O)c1c(O)cccc1CCCCCCC/C=C\C/C=C\CC=C
NCGC00263625-09	O=C(O)c1c(O)cccc1CCCCCCCCCCCCCCC	5.6500001	Active		0.0	1	AnacardicAcid	434147227.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	1.1	108.4163033951	O=C(O)c1c(O)cccc1CCCCCCCCCCCCCCC	O=C(O)c1c(O)cccc1CCCCCCCCCCCCCCC
NCGC00263121-03	O=C(O)c1c(O)cccc1CCc1ccc(CCCCCCC)cc1	4.9000001	Active	Histone acetyltransferase Inhibitor	0.0	1	MG-149	384568605.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	75.192057977	O=C(O)c1c(O)cccc1CCc1ccc(CCCCCCC)cc1	O=C(O)c1c(O)cccc1CCc1ccc(CCCCCCC)cc1
NCGC00387761-01	O=C(O)c1c(O)nnc(-c2c(-c3ccccc3)nn3c2C=CC=C3)c1		Inactive			1	2,3-Dihydro-3-oxo-6-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)-4-pyridazinecarboxylic acid	363680652.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c(O)nnc(-c2c(-c3ccccc3)nn3c2C=CC=C3)c1	O=C(O)c1c(O)nnc(-c2c(-c3ccccc3)nn3c2C=CC=C3)c1
NCGC00385595-01	O=C(O)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c(O)cccc2c(O)c1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385595-01	363679827.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c(O)cccc2c(O)c1	O=C(O)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c(O)cccc2c(O)c1
NCGC00241036-03	O=C(O)c1c2c(c(O)cc1)ncc(N1CCOCC1)c2		Inactive	JMJ Inhibitor		1	NCGC00241036	384568468.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1c2c(c(O)cc1)ncc(N1CCOCC1)c2	O=C(O)c1c2c(c(O)cc1)ncc(N1CCOCC1)c2
NCGC00183784-18	O=C(O)c1c2c(c(O)cc1)nccc2		Inactive	Lysine-Specific Demethylase 4A (KDM4A; JMJD2A) Inhibitor		1	IOX-1	384568420.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1c2c(c(O)cc1)nccc2	O=C(O)c1c2c(c(O)cc1)nccc2
NCGC00388035-03	O=C(O)c1c2c(n(CCOc3c(C)ccc(C)c3)c1)cccc2		Inactive	Ras-related protein Rab-7a Activator		1	ML098	363680721.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c2c(n(CCOc3c(C)ccc(C)c3)c1)cccc2	O=C(O)c1c2c(n(CCOc3c(C)ccc(C)c3)c1)cccc2
NCGC00018221-13	O=C(O)c1c2c(nc(-c3ccccc3)c1)cccc2		Inactive	Proto-oncogene c-Fos Activator		1	Cinchophen	363676506.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c2c(nc(-c3ccccc3)c1)cccc2	O=C(O)c1c2c(nc(-c3ccccc3)c1)cccc2
NCGC00025213-06	O=C(O)c1c2c3c(C(=O)n4c5c(nc4-c3cc1)cccc5)ccc2		Inactive			1	STO-609-acetic acid	377020529.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c2c3c(C(=O)n4c5c(nc4-c3cc1)cccc5)ccc2	O=C(O)c1c2c3c(C(=O)n4c5c(nc4-c3cc1)cccc5)ccc2
NCGC00167474-06	O=C(O)c1c2n(Cc3ccc(-c4c(-c5[nH]nnn5)cccc4)cc3)c(OCC)nc2ccc1		Inactive	Type-1 angiotensin II receptor Antagonist		1	Candesartan	363676659.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1c2n(Cc3ccc(-c4c(-c5[nH]nnn5)cccc4)cc3)c(OCC)nc2ccc1	O=C(O)c1c2n(Cc3ccc(-c4c(-c5[nH]nnn5)cccc4)cc3)c(OCC)nc2ccc1
NCGC00386206-03&NCGC00386206-04	O=C(O)c1c2n(Cc3ccc(-c4c(C5=NC(=O)ON5)cccc4)cc3)c(OCC)nc2ccc1		Inactive	Type-1 angiotensin II receptor Antagonist		2	Azilsartan (TAK-536)&Azilsartan	405558540.0&363680151.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)c1c2n(Cc3ccc(-c4c(C5=NC(=O)ON5)cccc4)cc3)c(OCC)nc2ccc1	O=C(O)c1c2n(Cc3ccc(-c4c(C5=NC(=O)ON5)cccc4)cc3)c(OCC)nc2ccc1
NCGC00485470-01	O=C(O)c1c2sc(-c3n(CCN4CCCCC4)c4c(n3)cccc4)cc2ncc1		Inactive			1	NCGC00485470-01	363681340.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1c2sc(-c3n(CCN4CCCCC4)c4c(n3)cccc4)cc2ncc1	O=C(O)c1c2sc(-c3n(CCN4CCCCC4)c4c(n3)cccc4)cc2ncc1
NCGC00488726-01	O=C(O)c1c2sc(C(OCCN3CCCCC3)c3cc(N)ccc3)cc2ncc1		Inactive			1	NCGC00488726-01	434147211.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1c2sc(C(OCCN3CCCCC3)c3cc(N)ccc3)cc2ncc1	O=C(O)c1c2sc(C(OCCN3CCCCC3)c3cc(N)ccc3)cc2ncc1
NCGC00347753-02	O=C(O)c1cc(C(=O)CCC2C(O)C(O)C(n3c4ncnc(O)c4nc3)O2)ccc1		Inactive	<MOA Unknown> | Class: nucleoside | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347753-02	363677679.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1cc(C(=O)CCC2C(O)C(O)C(n3c4ncnc(O)c4nc3)O2)ccc1	O=C(O)c1cc(C(=O)CCC2C(O)C(O)C(n3c4ncnc(O)c4nc3)O2)ccc1
NCGC00091125-07	O=C(O)c1cc(O)c(O)c(O)c1		Inactive	intrinsic apoptotic signaling pathway in response to oxidative stress Inhibitor		1	Gallic acid	170465633.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&-8.175977648	O=C(O)c1cc(O)c(O)c(O)c1	O=C(O)c1cc(O)c(O)c(O)c1
NCGC00380738-02	O=C(O)c1cc(O)c(OC2C(O)C(O)C(O)C(COC(=O)C3=CCC(C(O)(C)C)CC3)O2)c(O)c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380738-02	363678751.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1cc(O)c(OC2C(O)C(O)C(O)C(COC(=O)C3=CCC(C(O)(C)C)CC3)O2)c(O)c1	O=C(O)c1cc(O)c(OC2C(O)C(O)C(O)C(COC(=O)C3=CCC(C(O)(C)C)CC3)O2)c(O)c1
NCGC00018199-09	O=C(O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1		Inactive	component of rhubarb		1	Rhein	384567996.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1	O=C(O)c1cc(O)c2C(=O)c3c(O)cccc3C(=O)c2c1
NCGC00095095-04	O=C(O)c1cc(O)c2C(=O)c3c(O[C@H]4C(O)C(O)C(O)C(CO)O4)cccc3[C@@H]([C@H]3c4c(c(O)cc(C(=O)O)c4)C(=O)c4c(O[C@H]5C(O)C(O)C(O)C(CO)O5)cccc34)c2c1		Inactive	Helv Chim Acta 33: 313 (1950)		1	SENNOSIDE A	434147215.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1cc(O)c2C(=O)c3c(O[C@H]4C(O)C(O)C(O)C(CO)O4)cccc3[C@@H]([C@H]3c4c(c(O)cc(C(=O)O)c4)C(=O)c4c(O[C@H]5C(O)C(O)C(O)C(CO)O5)cccc34)c2c1	O=C(O)c1cc(O)c2C(=O)c3c(O[C@H]4C(O)C(O)C(O)C(CO)O4)cccc3[C@@H]([C@H]3c4c(c(O)cc(C(=O)O)c4)C(=O)c4c(O[C@H]5C(O)C(O)C(O)C(CO)O5)cccc34)c2c1
NCGC00385183-01	O=C(O)c1cc(O)c2C(=O)c3c(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cccc3[C@@H]([C@H]3c4c(c(O)cc(C(=O)O)c4)C(=O)c4c(O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)cccc34)c2c1		Inactive	Potassium-transporting ATPase Inhibitor		1	NCGC00385183-01	405559009.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1cc(O)c2C(=O)c3c(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cccc3[C@@H]([C@H]3c4c(c(O)cc(C(=O)O)c4)C(=O)c4c(O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)cccc34)c2c1	O=C(O)c1cc(O)c2C(=O)c3c(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cccc3[C@@H]([C@H]3c4c(c(O)cc(C(=O)O)c4)C(=O)c4c(O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)cccc34)c2c1
NCGC00381048-01	O=C(O)c1cc(O)c2C(c3c(O)c(C/C=C(/CCC=C(C)C)\C)ccc3O)OC(=O)c2c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381048-01	363678944.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1cc(O)c2C(c3c(O)c(C/C=C(/CCC=C(C)C)\C)ccc3O)OC(=O)c2c1	O=C(O)c1cc(O)c2C(c3c(O)c(C/C=C(/CCC=C(C)C)\C)ccc3O)OC(=O)c2c1
NCGC00166280-02	O=C(O)c1cc(O)c2O[Bi](O)Oc2c1		Inactive			1	Bismuth(III) gallate basic hydrate	225144278.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1cc(O)c2O[Bi](O)Oc2c1	O=C(O)c1cc(O)c2O[Bi](O)Oc2c1
NCGC00385868-01	O=C(O)c1cc(OC)c(OC2C(O)C(O)C(O)C(CO)O2)cc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385868-01	363679978.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1cc(OC)c(OC2C(O)C(O)C(O)C(CO)O2)cc1	O=C(O)c1cc(OC)c(OC2C(O)C(O)C(O)C(CO)O2)cc1
NCGC00380505-01	O=C(O)c1cc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)C3=CCC(C(O)(C)C)CC3)O2)c(O)c(O)c1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380505-01	363678616.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1cc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)C3=CCC(C(O)(C)C)CC3)O2)c(O)c(O)c1	O=C(O)c1cc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)C3=CCC(C(O)(C)C)CC3)O2)c(O)c(O)c1
NCGC00485077-01	O=C(O)c1cc2C(=O)N(C=3C(=O)N(N(C)C=3C)c3ccccc3)C(=O)c2cc1		Inactive	14-3-3 protein sigma Binding Agent		1	BV02	363681212.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1cc2C(=O)N(C=3C(=O)N(N(C)C=3C)c3ccccc3)C(=O)c2cc1	O=C(O)c1cc2C(=O)N(C=3C(=O)N(N(C)C=3C)c3ccccc3)C(=O)c2cc1
NCGC00092284-04	O=C(O)c1cc2c(cc(-c3cc(c(O)cc3)C34CC5CC(C3)CC(C4)C5)cc2)cc1		Inactive	RARgamma Agonist		1	AHPN	384568102.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(O)c1cc2c(cc(-c3cc(c(O)cc3)C34CC5CC(C3)CC(C4)C5)cc2)cc1	O=C(O)c1cc2c(cc(-c3cc(c(O)cc3)C34CC5CC(C3)CC(C4)C5)cc2)cc1
NCGC00164617-04&NCGC00164617-14	O=C(O)c1cc2c(cc(-c3cc(c(OC)cc3)C34CC5CC(C3)CC(C4)C5)cc2)cc1		Inactive	topical retinoid		2	Adapalene	170464674.0&384568266.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)c1cc2c(cc(-c3cc(c(OC)cc3)C34CC5CC(C3)CC(C4)C5)cc2)cc1	O=C(O)c1cc2c(cc(-c3cc(c(OC)cc3)C34CC5CC(C3)CC(C4)C5)cc2)cc1
NCGC00370963-01	O=C(O)c1ccc(-c2[nH]c(-c3nc4c(C(C)C)cccc4c(-c4ccccc4)c3)cc2)cc1	4.9499998	Active	Retinoic acid receptor alpha Antagonist	0.0	1	ER 50891	363677960.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	94.7641773537	O=C(O)c1ccc(-c2[nH]c(-c3nc4c(C(C)C)cccc4c(-c4ccccc4)c3)cc2)cc1	O=C(O)c1ccc(-c2[nH]c(-c3nc4c(C(C)C)cccc4c(-c4ccccc4)c3)cc2)cc1
NCGC00370788-02	O=C(O)c1ccc(-c2cc(COc3c(C)c(C)c4C(=O)C(C5CCCC5)Cc4c3)ccc2)cc1	4.9000001	Active	Metabotropic glutamate receptor 2 Positive Allosteric Modulator	0.0	1	Biphenyl-indanone A	363677856.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	49.1250101859	O=C(O)c1ccc(-c2cc(COc3c(C)c(C)c4C(=O)C(C5CCCC5)Cc4c3)ccc2)cc1	O=C(O)c1ccc(-c2cc(COc3c(C)c(C)c4C(=O)C(C5CCCC5)Cc4c3)ccc2)cc1
NCGC00181754-07	O=C(O)c1ccc(-n2c(-c3c(O)cccc3)nc(-c3c(O)cccc3)n2)cc1		Inactive	Iron Chelator		1	Deferasirox	384568398.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	28.534634412	O=C(O)c1ccc(-n2c(-c3c(O)cccc3)nc(-c3c(O)cccc3)n2)cc1	O=C(O)c1ccc(-n2c(-c3c(O)cccc3)nc(-c3c(O)cccc3)n2)cc1
NCGC00354780-01	O=C(O)c1ccc(-n2nc(/C=C/c3cc(OC)c(O)cc3)c(/C=C/c3cc(OC)c(O)cc3)c2)cc1		Inactive			1	NCGC00354780-01		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C([O-])c1ccc(-n2nc(/C=C/c3cc(OC)c(O)cc3)c(/C=C/c3cc(OC)c(O)cc3)c2)cc1	O=C([O-])c1ccc(-n2nc(/C=C/c3cc(OC)c(O)cc3)c(/C=C/c3cc(OC)c(O)cc3)c2)cc1
NCGC00485412-01	O=C(O)c1ccc(/C=C(\C)/c2c(OCCCCCCC)cc3S(=O)(=O)CCC(C)(C)c3c2)cc1		Inactive	Retinoic acid receptor gamma Antagonist		1	Ro 41-5253	363681325.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1ccc(/C=C(\C)/c2c(OCCCCCCC)cc3S(=O)(=O)CCC(C)(C)c3c2)cc1	O=C(O)c1ccc(/C=C(\C)/c2c(OCCCCCCC)cc3S(=O)(=O)CCC(C)(C)c3c2)cc1
NCGC00387103-01	O=C(O)c1ccc(/C=C/c2cc3C(C#Cc4ccccc4)=CCC(C)(C)c3cc2)cc1		Inactive	Retinoic acid receptor gamma Inverse Agonist		1	BMS 493	363680542.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1ccc(/C=C/c2cc3C(C#Cc4ccccc4)=CCC(C)(C)c3cc2)cc1	O=C(O)c1ccc(/C=C/c2cc3C(C#Cc4ccccc4)=CCC(C)(C)c3cc2)cc1
NCGC00181016-19	O=C(O)c1ccc(C(=C)c2c(C)cc3C(C)(C)CCC(C)(C)c3c2)cc1	4.9000001	Active	Retinoid RXR Agonist	0.0	1	Bexarotene	384568387.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	53.8005024241	O=C(O)c1ccc(C(=C)c2c(C)cc3C(C)(C)CCC(C)(C)c3c2)cc1	O=C(O)c1ccc(C(=C)c2c(C)cc3C(C)(C)CCC(C)(C)c3c2)cc1
NCGC00181111-02&NCGC00181111-05	O=C(O)c1ccc(C(=O)Nc2cc3C(C)(C)CCC(C)(C)c3cc2)cc1		Inactive	Retinoid RAR Agonist		2	Tamibarotene	170465883.0&384568390.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)c1ccc(C(=O)Nc2cc3C(C)(C)CCC(C)(C)c3cc2)cc1	O=C(O)c1ccc(C(=O)Nc2cc3C(C)(C)CCC(C)(C)c3cc2)cc1
NCGC00370884-01	O=C(O)c1ccc(C2(c3cc4C(C)(C)CCC(C)(C)c4cc3)OCCO2)cc1		Inactive	Retinoid X receptor beta Agonist		1	SR 11237	363677910.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1ccc(C2(c3cc4C(C)(C)CCC(C)(C)c4cc3)OCCO2)cc1	O=C(O)c1ccc(C2(c3cc4C(C)(C)CCC(C)(C)c4cc3)OCCO2)cc1
NCGC00370944-01	O=C(O)c1ccc(C2=Nc3c(Sc4c2cc2C(C)(C)CCC(C)(C)c2c4)cccc3)cc1		Inactive	Retinoid X receptor gamma Agonist		1	HX 630	363677949.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	28.5	O=C(O)c1ccc(C2=Nc3c(Sc4c2cc2C(C)(C)CCC(C)(C)c2c4)cccc3)cc1	O=C(O)c1ccc(C2=Nc3c(Sc4c2cc2C(C)(C)CCC(C)(C)c2c4)cccc3)cc1
NCGC00166226-02	O=C(O)c1ccc(CCC)cc1		Inactive			1	4-Propylbenzoic acid	225144274.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1ccc(CCC)cc1	O=C(O)c1ccc(CCC)cc1
NCGC00387878-04	O=C(O)c1ccc(CN2CCC(CN[C@H]3[C@H](c4ccccc4)C3)CC2)cc1		Inactive	Lysine-Specific Histone Demethylase 1A (KDM1A; LSD1) Inhibitor		1	GSK-2879552	384569167.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1ccc(CN2CCC(CN[C@H]3[C@H](c4ccccc4)C3)CC2)cc1	O=C(O)c1ccc(CN2CCC(CN[C@H]3[C@H](c4ccccc4)C3)CC2)cc1
NCGC00488702-01	O=C(O)c1ccc(COCC2=CSC3N=C(C(=O)NCc4cc(OC)ccc4)NC(=O)C23)cc1		Inactive			1	NCGC00488702-01	363681473.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1ccc(COCC2=CSC3N=C(C(=O)NCc4cc(OC)ccc4)NC(=O)C23)cc1	O=C(O)c1ccc(COCC2=CSC3N=C(C(=O)NCc4cc(OC)ccc4)NC(=O)C23)cc1
NCGC00091051-04	O=C(O)c1ccc(N)cc1		Inactive	Carbonic anhydrase II Inhibitor		1	4-Aminobenzoic acid	170466660.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)c1ccc(N)cc1	O=C(O)c1ccc(N)cc1
NCGC00370863-01	O=C(O)c1ccc(NC(=O)c2cc3C(C)(C)C(=O)C(C)(C)c3cc2)cc1		Inactive	Retinoic acid receptor alpha Agonist		1	BMS 753	363677893.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1ccc(NC(=O)c2cc3C(C)(C)C(=O)C(C)(C)c3cc2)cc1	O=C(O)c1ccc(NC(=O)c2cc3C(C)(C)C(=O)C(C)(C)c3cc2)cc1
NCGC00370906-01	O=C(O)c1ccc(NC(=O)c2cc3C(c4cnc5c(c4)cccc5)=CCC(C)(C)c3cc2)cc1		Inactive	Retinoic acid receptor alpha Neutral Antagonist		1	BMS 195614	363677925.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1ccc(NC(=O)c2cc3C(c4cnc5c(c4)cccc5)=CCC(C)(C)c3cc2)cc1	O=C(O)c1ccc(NC(=O)c2cc3C(c4cnc5c(c4)cccc5)=CCC(C)(C)c3cc2)cc1
NCGC00380603-02	O=C(O)c1ccc(NC2C(/C=C/C(O)C)OC(=O)C2)cc1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380603-02	363678668.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1ccc(NC2C(/C=C/C(O)C)OC(=O)C2)cc1	O=C(O)c1ccc(NC2C(/C=C/C(O)C)OC(=O)C2)cc1
NCGC00381099-01	O=C(O)c1ccc(NC2C(C(O)/C=C/C)OC(=O)C2)cc1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381099-01	363678969.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1ccc(NC2C(C(O)/C=C/C)OC(=O)C2)cc1	O=C(O)c1ccc(NC2C(C(O)/C=C/C)OC(=O)C2)cc1
NCGC00385891-01	O=C(O)c1ccc(OC2C(O)C(O)C(O)C(CO)O2)cc1		Inactive	<MOA Unknown> | Class: Tannin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385891-01	363679993.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1ccc(OC2C(O)C(O)C(O)C(CO)O2)cc1	O=C(O)c1ccc(OC2C(O)C(O)C(O)C(CO)O2)cc1
NCGC00166266-03	O=C(O)c1ccc(OCCCOc2ccc(C(=O)O)cc2)cc1		Inactive			1	1,3-Bis(4-carboxyphenoxy)propane	170466646.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1ccc(OCCCOc2ccc(C(=O)O)cc2)cc1	O=C(O)c1ccc(OCCCOc2ccc(C(=O)O)cc2)cc1
NCGC00263135-02	O=C(O)c1cn(-c2cc(C#N)c(OCC(C)(C)C)cc2)nc1		Inactive	Xanthine Oxidase Inhibitor		1	Piraxostat	384568613.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1cn(-c2cc(C#N)c(OCC(C)(C)C)cc2)nc1	O=C(O)c1cn(-c2cc(C#N)c(OCC(C)(C)C)cc2)nc1
NCGC00242489-02	O=C(O)c1cnc(C2(c3c(C)cc4C(C)(C)CCC(C)(C)c4c3)CC2)cc1		Inactive	RXR Agonist		1	LG-100268	363677145.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1cnc(C2(c3c(C)cc4C(C)(C)CCC(C)(C)c4c3)CC2)cc1	O=C(O)c1cnc(C2(c3c(C)cc4C(C)(C)CCC(C)(C)c4c3)CC2)cc1
NCGC00370994-02	O=C(O)c1cnc(N(C)c2c(OCCCCCC)cc3C(C)(C)CCC(C)(C)c3c2)nc1		Inactive	Retinoid X receptor alpha Antagonist		1	PA 452	363677982.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1cnc(N(C)c2c(OCCCCCC)cc3C(C)(C)CCC(C)(C)c3c2)nc1	O=C(O)c1cnc(N(C)c2c(OCCCCCC)cc3C(C)(C)CCC(C)(C)c3c2)nc1
NCGC00387236-02	O=C(O)c1cnc(NC(=O)c2cc(O[C@H](COC)C)cc(O[C@H](Cc3ccccc3)C)c2)cc1		Inactive			1	GKA50	377020439.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1cnc(NC(=O)c2cc(O[C@H](COC)C)cc(O[C@H](Cc3ccccc3)C)c2)cc1	O=C(O)c1cnc(NC(=O)c2cc(O[C@H](COC)C)cc(O[C@H](Cc3ccccc3)C)c2)cc1
NCGC00016268-08&NCGC00016268-21	O=C(O)c1cnccc1		Inactive	Nicotinic acid		2	Niacin	170465044.0&384567927.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)c1cnccc1	O=C(O)c1cnccc1
NCGC00246968-04&NCGC00246968-07	O=C(O)c1n(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c(CCC)nc1C(O)(C)C		Inactive	Angiotensin AT1 Antagonist		2	Olmesartan	405558442.0&384568514.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O)c1n(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c(CCC)nc1C(O)(C)C	O=C(O)c1n(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c(CCC)nc1C(O)(C)C
NCGC00379170-01	O=C(O)c1n[nH]c2[C@H]3[C@H](C3)Cc12		Inactive	Hydroxycarboxylic acid receptor 2 Agonist		1	MK 1903	363678395.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1n[nH]c2[C@H]3[C@H](C3)Cc12	O=C(O)c1n[nH]c2[C@H]3[C@H](C3)Cc12
NCGC00188943-03	O=C(O)c1nc(O)nc(O)c1		Inactive	metabolite		1	Orotic acid	170465761.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)c1nc(O)nc(O)c1	O=C(O)c1nc(O)nc(O)c1
NCGC00166236-02&NCGC00166236-04	O=C(O)c1nc(O)nc(O)n1		Inactive	Orotate Phosphoribosyltransferase Inhibitor		2	Oteracil potassium&Oxonic acid potassium salt	405559107.0&434147037.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	O=C([O-])c1nc(O)nc(O)n1	O=C([O-])c1nc(O)nc(O)n1
NCGC00167452-03	O=C(O)c1nc2C(=O)C=C3Oc4c(N=C3c2c(O)c1)cccc4		Inactive	maintenance of lens transparency Activator		1	Pirenoxine Sodium	225144286.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])c1nc2C(=O)C=C3Oc4c(N=C3c2c(O)c1)cccc4	O=C([O-])c1nc2C(=O)C=C3Oc4c(N=C3c2c(O)c1)cccc4
NCGC00160519-13	O=C(O)c1ncc(C)[n+]([O-])c1		Inactive	Niacin deravitive		1	Acipimox	384568197.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)c1ncc(C)[n+]([O-])c1	O=C(O)c1ncc(C)[n+]([O-])c1
NCGC00165993-02	O=C(O)c1ncccc1		Inactive			1	Picolinic acid	170466822.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)c1ncccc1	O=C(O)c1ncccc1
NCGC00386708-02	O=C(O)c1nn2C(=O)c3c(N(C)c2c1)ccc(NC(=O)c1ccccc1)c3		Inactive	Beta-nerve growth factor Modulator		1	PD 90780	363680409.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O)c1nn2C(=O)c3c(N(C)c2c1)ccc(NC(=O)c1ccccc1)c3	O=C(O)c1nn2C(=O)c3c(N(C)c2c1)ccc(NC(=O)c1ccccc1)c3
NCGC00384778-01	O=C(OC(/C(=C/COC(=O)C)/C)CC1C(=C)C(OC(=O)C)C(=O)C2C(C)(C)C(O)CCC12C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384778-01	363679349.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC(/C(=C/COC(=O)C)/C)CC1C(=C)C(OC(=O)C)C(=O)C2C(C)(C)C(O)CCC12C)C	O=C(OC(/C(=C/COC(=O)C)/C)CC1C(=C)C(OC(=O)C)C(=O)C2C(C)(C)C(O)CCC12C)C
NCGC00380512-01	O=C(OC(/C(=C/COC(=O)C)/C)CC1C(=C)C(OC(=O)C)C(=O)C2C(C)(C)C(OC(=O)C)CCC12C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380512-01	363678622.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC(/C(=C/COC(=O)C)/C)CC1C(=C)C(OC(=O)C)C(=O)C2C(C)(C)C(OC(=O)C)CCC12C)C	O=C(OC(/C(=C/COC(=O)C)/C)CC1C(=C)C(OC(=O)C)C(=O)C2C(C)(C)C(OC(=O)C)CCC12C)C
NCGC00385564-01	O=C(OC(/C(=C/COC(=O)C)/C)CC1C(C)=C(OC(=O)C)C(=O)C2C(C)(C)C(O)CCC12C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385564-01	363679811.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC(/C(=C/COC(=O)C)/C)CC1C(C)=C(OC(=O)C)C(=O)C2C(C)(C)C(O)CCC12C)C	O=C(OC(/C(=C/COC(=O)C)/C)CC1C(C)=C(OC(=O)C)C(=O)C2C(C)(C)C(O)CCC12C)C
NCGC00263529-01	O=C(OC(C)(C)C)/C=C/c1c(C2C(C(=O)OCC)=C(C)NC(C)=C2C(=O)OCC)cccc1		Inactive	Ca channel blocker - DHP class		1	Lacidipine	170465580.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC(C)(C)C)/C=C/c1c(C2C(C(=O)OCC)=C(C)NC(C)=C2C(=O)OCC)cccc1	O=C(OC(C)(C)C)/C=C/c1c(C2C(C(=O)OCC)=C(C)NC(C)=C2C(=O)OCC)cccc1
NCGC00347910-01	O=C(OC(C)(C)C)NCCCCCCNc1nc(NCCO)nc2n(C(C)C)cnc12		Inactive	CaMK-II Inhibitor		1	CK-59	174006383.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC(C)(C)C)NCCCCCCNc1nc(NCCO)nc2n(C(C)C)cnc12	O=C(OC(C)(C)C)NCCCCCCNc1nc(NCCO)nc2n(C(C)C)cnc12
NCGC00181306-04	O=C(OC(C)(C)C)N[C@H]([C@@H](O)C(=O)O[C@@H]1C(C)=C2[C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)c1ccccc1		Inactive	Tubulin depolymerization Inhibitor		1	Docetaxel	170464919.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O=C(OC(C)(C)C)N[C@H]([C@@H](O)C(=O)O[C@@H]1C(C)=C2[C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)c1ccccc1	O=C(OC(C)(C)C)N[C@H]([C@@H](O)C(=O)O[C@@H]1C(C)=C2[C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)c1ccccc1
NCGC00346704-03&NCGC00346704-07	O=C(OC(C)(C)C)N[C@H]([C@@H](O)C(=O)O[C@@H]1C(C)=C2[C@@H](OC)C(=O)[C@]3(C)[C@@H](OC)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)c1ccccc1		Inactive	Tubulin depolymerization Inhibitor		2	Cabazitaxel	405558547.0&384568923.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O=C(OC(C)(C)C)N[C@H]([C@@H](O)C(=O)O[C@@H]1C(C)=C2[C@@H](OC)C(=O)[C@]3(C)[C@@H](OC)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)c1ccccc1	O=C(OC(C)(C)C)N[C@H]([C@@H](O)C(=O)O[C@@H]1C(C)=C2[C@@H](OC)C(=O)[C@]3(C)[C@@H](OC)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)c1ccccc1
NCGC00485838-01	O=C(OC(C)(C)C)N[C@H]([C@H](O)CN(C(=O)N[C@H](C(=O)N[C@H](C(=O)OC)C(C)C)CC(C)C)Cc1ccccc1)Cc1ccccc1		Inactive	Gamma-secretase Inhibitor		1	III-31-C	363681379.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC(C)(C)C)N[C@H]([C@H](O)CN(C(=O)N[C@H](C(=O)N[C@H](C(=O)OC)C(C)C)CC(C)C)Cc1ccccc1)Cc1ccccc1	O=C(OC(C)(C)C)N[C@H]([C@H](O)CN(C(=O)N[C@H](C(=O)N[C@H](C(=O)OC)C(C)C)CC(C)C)Cc1ccccc1)Cc1ccccc1
NCGC00165962-02	O=C(OC(C)(C)C)N[C@H]([C@H](O)C[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(C)C)Cc1ccccc1)Cc1ccccc1		Inactive			1	L-685458	434147034.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC(C)(C)C)N[C@H]([C@H](O)C[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(C)C)Cc1ccccc1)Cc1ccccc1	O=C(OC(C)(C)C)N[C@H]([C@H](O)C[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(C)C)Cc1ccccc1)Cc1ccccc1
NCGC00250390-07&NCGC00250390-10	O=C(OC(C)(C)C)Nc1ccc(-c2onc(C(=O)NCCCCCCC(=O)NO)c2)cc1		Inactive	HDAC Inhibitor		2	ISOX	434146930.0&384568543.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC(C)(C)C)Nc1ccc(-c2onc(C(=O)NCCCCCCC(=O)NO)c2)cc1	O=C(OC(C)(C)C)Nc1ccc(-c2onc(C(=O)NCCCCCCC(=O)NO)c2)cc1
NCGC00164588-02&NCGC00164588-06	O=C(OC(C)C)C(C(=O)OC(C)C)=C1SC=CS1		Inactive	Liver Protein Metabolism		2	Malotilate	170465879.0&384568259.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(OC(C)C)C(C(=O)OC(C)C)=C1SC=CS1	O=C(OC(C)C)C(C(=O)OC(C)C)=C1SC=CS1
NCGC00025341-06	O=C(OC(C)C)C1=C(C)NC(C)=C(C(=O)OC)C1c1c2nonc2ccc1		Inactive	Calcium Channel Blocker		1	Isradipine	170465070.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC(C)C)C1=C(C)NC(C)=C(C(=O)OC)C1c1c2nonc2ccc1	O=C(OC(C)C)C1=C(C)NC(C)=C(C(=O)OC)C1c1c2nonc2ccc1
NCGC00183877-01	O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](CCC(=O)CCCCCCC)[C@H](O)C[C@@H]1O		Inactive	Prostanoid FP receptor Agonist		1	Unoprostone isopropyl ester	144207178.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](CCC(=O)CCCCCCC)[C@H](O)C[C@@H]1O	O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](CCC(=O)CCCCCCC)[C@H](O)C[C@@H]1O
NCGC00246969-06	O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O		Inactive	Prostanoid FP receptor Agonist		1	Latanoprost	405558599.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O	O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
NCGC00164071-03	O=C(OC(C)C)CCCCCCCCCCCCC		Inactive			1	Isopropyl tetradecanoic acid	170465683.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OC(C)C)CCCCCCCCCCCCC	O=C(OC(C)C)CCCCCCCCCCCCC
NCGC00164128-02	O=C(OC(C)C)CCCCCCCCCCCCCCC		Inactive	N-acylsphingosine-amidohydrolase Inhibitor		1	Hexadecanoic acid, 1-methylethyl ester	170465544.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC(C)C)CCCCCCCCCCCCCCC	O=C(OC(C)C)CCCCCCCCCCCCCCC
NCGC00181110-02	O=C(OC(C)C)Nc1cc2nc(-c3ncsc3)[nH]c2cc1		Inactive	glucose transport Inhibitor		1	Cambendazole	124893647.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC(C)C)Nc1cc2nc(-c3ncsc3)[nH]c2cc1	O=C(OC(C)C)Nc1cc2nc(-c3ncsc3)[nH]c2cc1
NCGC00262943-01	O=C(OC(C)c1ccc(C)cc1)C1(C)C(C)(C)C(C(=O)O)CC1		Inactive			1	Tocanfil	170466061.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC(C)c1ccc(C)cc1)C1(C)C(C)(C)C(C(=O)O)CC1.OCCNCCO	O=C(OC(C)c1ccc(C)cc1)C1(C)C(C)(C)C(C(=O)O)CC1.OCCNCCO
NCGC00261973-01	O=C(OC(CC(=O)NCC(CCCC)CC)C)CCC(=O)O		Inactive			1	Butoctamide semisuccinate	170466034.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC(CC(=O)NCC(CCCC)CC)C)CCC(=O)O	O=C(OC(CC(=O)NCC(CCCC)CC)C)CCC(=O)O
NCGC00381424-01	O=C(OC(CC(C)C)c1c(OC)c(C(=O)O)c(Oc2c(O)cc(C)cc2/C=C/C(=O)C)cc1)C		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381424-01	363679136.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC(CC(C)C)c1c(OC)c(C(=O)O)c(Oc2c(O)cc(C)cc2/C=C/C(=O)C)cc1)C	O=C(OC(CC(C)C)c1c(OC)c(C(=O)O)c(Oc2c(O)cc(C)cc2/C=C/C(=O)C)cc1)C
NCGC00169902-02	O=C(OC(CC(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C)C)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169902-02	363676905.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC(CC(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C)C)/C=C/c1ccc(O)cc1	O=C(OC(CC(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C)C)/C=C/c1ccc(O)cc1
NCGC00386045-01	O=C(OC(CC)c1cc(OC)c(OC)cc1)/C(=C\C)/COC(=O)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Shikimi | Genus: bupleurum | Family: Umbelliferae | Species: fruticosum		1	NCGC00386045-01	363680078.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC(CC)c1cc(OC)c(OC)cc1)/C(=C\C)/COC(=O)/C(=C/C)/C	O=C(OC(CC)c1cc(OC)c(OC)cc1)/C(=C\C)/COC(=O)/C(=C/C)/C
NCGC00380964-01	O=C(OC(CC12C(=O)N3C(C(=O)N1CCC2)CCC3)C)N		Inactive	<MOA Unknown> | Class: Amino acid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380964-01	363678889.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC(CC12C(=O)N3C(C(=O)N1CCC2)CCC3)C)N	O=C(OC(CC12C(=O)N3C(C(=O)N1CCC2)CCC3)C)N
NCGC00179382-03	O=C(OC(CNC1CCCCC1)C)c1ccccc1		Inactive	Sodium channel alpha subunit Blocker		1	Hexylcaine hydrochloride	170465088.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC(CNC1CCCCC1)C)c1ccccc1.Cl	O=C(OC(CNC1CCCCC1)C)c1ccccc1.Cl
NCGC00091612-09	O=C(OC(COC(=O)C)COC(=O)C)C		Inactive			1	Triacetin	170465543.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC(COC(=O)C)COC(=O)C)C	O=C(OC(COC(=O)C)COC(=O)C)C
NCGC00091285-03	O=C(OC(COC(=O)CCCCCCC)COC(=O)CCCCCCC)CCCCCCC		Inactive			1	Tricaprylin	170465841.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC(COC(=O)CCCCCCC)COC(=O)CCCCCCC)CCCCCCC	O=C(OC(COC(=O)CCCCCCC)COC(=O)CCCCCCC)CCCCCCC
NCGC00166142-04&NCGC00166142-07	O=C(OC(COC(=O)Nc1ccccc1)CN1CCCCC1)Nc1ccccc1		Inactive	sodium ion transmembrane transport Inhibitor		2	Diperodon hydrochloride&Diperodon HCl	170465536.0&434147233.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	12.2580942401&20.721542228	O=C(OC(COC(=O)Nc1ccccc1)CN1CCCCC1)Nc1ccccc1.Cl	O=C(OC(COC(=O)Nc1ccccc1)CN1CCCCC1)Nc1ccccc1.Cl&O=C(OC(COC(=O)Nc1ccccc1)CN1CCCCC1)Nc1ccccc1
NCGC00183841-01	O=C(OC(COCCC(C)C)CN1CCOCC1)c1cc(OC)c(OC)c(OC)c1		Inactive			1	Amoproxan	144206871.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC(COCCC(C)C)CN1CCOCC1)c1cc(OC)c(OC)c(OC)c1	O=C(OC(COCCC(C)C)CN1CCOCC1)c1cc(OC)c(OC)c(OC)c1
NCGC00167489-03	O=C(OC(COc1c(CCc2cc(OC)ccc2)cccc1)CN(C)C)CCC(=O)O	4.9000001	Active	5HT(2A) and 5HT(2B) inhibitor	0.0	1	Sarpogrelate hydrochloride	174006666.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	69.2793202346	O=C(OC(COc1c(CCc2cc(OC)ccc2)cccc1)CN(C)C)CCC(=O)O.Cl	O=C(OC(COc1c(CCc2cc(OC)ccc2)cccc1)CN(C)C)CCC(=O)O.Cl
NCGC00262961-01	O=C(OC(COc1c2C(=O)C=C(C(=O)OCC)Oc2ccc1)COc1c2C(=O)C=C(C(=O)OCC)Oc2ccc1)[C@@H](N)CCCCN		Inactive	mast cell activation Inhibitor		1	Cromoglicate lisetil	170465975.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OC(COc1c2C(=O)C=C(C(=O)OCC)Oc2ccc1)COc1c2C(=O)C=C(C(=O)OCC)Oc2ccc1)[C@@H](N)CCCCN	O=C(OC(COc1c2C(=O)C=C(C(=O)OCC)Oc2ccc1)COc1c2C(=O)C=C(C(=O)OCC)Oc2ccc1)[C@@H](N)CCCCN
NCGC00015045-09	O=C(OC(C[N+](C)(C)C)C)C		Inactive	Muscarinic acetylcholine receptor M2 Binding Agent		1	Methacholine chloride	170464971.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OC(C[N+](C)(C)C)C)C.[Cl-]	O=C(OC(C[N+](C)(C)C)C)C.[Cl-]
NCGC00015245-10&NCGC00015245-12	O=C(OC(C[N+](C)(C)C)C)N		Inactive	Muscarinic receptor Agonist		2	Bethanechol chloride	170464912.0&384567831.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(OC(C[N+](C)(C)C)C)N.[Cl-]	O=C(OC(C[N+](C)(C)C)C)N.[Cl-]&O=C(OC(C[N+](C)(C)C)C)N
NCGC00532500-01	O=C(OC(OC(=O)C(C)C)C)NCC1(CC(=O)O)CCCCC1		Inactive			1	GABAPENTIN ENACARBIL	405559030.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC(OC(=O)C(C)C)C)NCC1(CC(=O)O)CCCCC1	O=C(OC(OC(=O)C(C)C)C)NCC1(CC(=O)O)CCCCC1
NCGC00164598-03	O=C(OC(OC(=O)C1=C(COC)CS[C@@H]2[C@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)C(=O)N12)C)OC(C)C		Inactive			1	CEFPODOXIME PROXETIL	405558543.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC(OC(=O)C1=C(COC)CS[C@@H]2[C@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)C(=O)N12)C)OC(C)C	O=C(OC(OC(=O)C1=C(COC)CS[C@@H]2[C@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)C(=O)N12)C)OC(C)C
NCGC00179582-03	O=C(OC(OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N12)C)OCC		Inactive			1	Bacampicillin hydrochloride	170465170.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC(OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N12)C)OCC.Cl	O=C(OC(OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N12)C)OCC.Cl
NCGC00095123-10	O=C(OC(OC(=O)c1c2n(Cc3ccc(-c4c(-c5[nH]nnn5)cccc4)cc3)c(OCC)nc2ccc1)C)OC1CCCCC1		Inactive			1	Candesartan cilexetil (Atacand)	405558788.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC(OC(=O)c1c2n(Cc3ccc(-c4c(-c5[nH]nnn5)cccc4)cc3)c(OCC)nc2ccc1)C)OC1CCCCC1	O=C(OC(OC(=O)c1c2n(Cc3ccc(-c4c(-c5[nH]nnn5)cccc4)cc3)c(OCC)nc2ccc1)C)OC1CCCCC1
NCGC00164605-02	O=C(OC(OC1=C(C(=O)Nc2ncccc2)N(C)S(=O)(=O)c2c1cccc2)C)OCC		Inactive	Cyclooxygenase Inhibitor		1	Ampiroxicam	170466020.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC(OC1=C(C(=O)Nc2ncccc2)N(C)S(=O)(=O)c2c1cccc2)C)OCC	O=C(OC(OC1=C(C(=O)Nc2ncccc2)N(C)S(=O)(=O)c2c1cccc2)C)OCC
NCGC00380314-01	O=C(OC)/C(/C=C(/C=C/C=C/C=C(/C(=O)C12C(=O)NC(O)(CCO)C1O2)\C)\C)=C\C		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380314-01	363678537.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)/C(/C=C(/C=C/C=C/C=C(/C(=O)C12C(=O)NC(O)(CCO)C1O2)\C)\C)=C\C	O=C(OC)/C(/C=C(/C=C/C=C/C=C(/C(=O)C12C(=O)NC(O)(CCO)C1O2)\C)\C)=C\C
NCGC00385802-01	O=C(OC)/C(/CO)=C\1/C[C@H]2C(=C)CCC[C@]2(C)CC/1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Cassinia | Family: N/A | Species: longifolia		1	NCGC00385802-01	363679947.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)/C(/CO)=C\1/C[C@H]2C(=C)CCC[C@]2(C)CC/1	O=C(OC)/C(/CO)=C\1/C[C@H]2C(=C)CCC[C@]2(C)CC/1
NCGC00380661-01	O=C(OC)/C(=C/CCC(OC1C(O)C(O)C(O)C(COC(=O)CC(O)(CC(=O)O)C)O1)(C=C)C)/C		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380661-01	363678697.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)/C(=C/CCC(OC1C(O)C(O)C(O)C(COC(=O)CC(O)(CC(=O)O)C)O1)(C=C)C)/C	O=C(OC)/C(=C/CCC(OC1C(O)C(O)C(O)C(COC(=O)CC(O)(CC(=O)O)C)O1)(C=C)C)/C
NCGC00380660-01	O=C(OC)/C(=C/CCC(OC1C(O)C(O)C(OC2C(O)C(O)C(O)C(CO)O2)C(COC(=O)CC(O)(CC(=O)O)C)O1)(C=C)C)/C		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380660-01	363678696.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)/C(=C/CCC(OC1C(O)C(O)C(OC2C(O)C(O)C(O)C(CO)O2)C(COC(=O)CC(O)(CC(=O)O)C)O1)(C=C)C)/C	O=C(OC)/C(=C/CCC(OC1C(O)C(O)C(OC2C(O)C(O)C(O)C(CO)O2)C(COC(=O)CC(O)(CC(=O)O)C)O1)(C=C)C)/C
NCGC00531792-01	O=C(OC)/C(=C/[C@H]1[C@H](C(=O)O[C@H]2C(C)=C(C/C=C/C=C)C(=O)C2)C1(C)C)/C		Inactive	Plasmodium falciparum Inhibitor		1	PYRETHRIN II	405559034.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)/C(=C/[C@H]1[C@H](C(=O)O[C@H]2C(C)=C(C/C=C/C=C)C(=O)C2)C1(C)C)/C	O=C(OC)/C(=C/[C@H]1[C@H](C(=O)O[C@H]2C(C)=C(C/C=C/C=C)C(=O)C2)C1(C)C)/C
NCGC00179890-03	O=C(OC)/C(=C\OC)/C1C(CC)CN2C(C3(C(=O)Nc4c3c(O)ccc4)CC2)C1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00179890-03	363676983.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)/C(=C\OC)/C1C(CC)CN2C(C3(C(=O)Nc4c3c(O)ccc4)CC2)C1	O=C(OC)/C(=C\OC)/C1C(CC)CN2C(C3(C(=O)Nc4c3c(O)ccc4)CC2)C1
NCGC00168922-02	O=C(OC)/C=C(/CC[C@H]1C(=C)CCC2[C@](C(=O)O)(C)CCC[C@]12C)\C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Juniperus | Family: Cupressaceae | Species: cf. oxycedrus		1	NCGC00168922-02	363676722.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)/C=C(/CC[C@H]1C(=C)CCC2[C@](C(=O)O)(C)CCC[C@]12C)\C	O=C(OC)/C=C(/CC[C@H]1C(=C)CCC2[C@](C(=O)O)(C)CCC[C@]12C)\C
NCGC00180855-02	O=C(OC)/C=C(\COC(=O)C)/CC[C@@H]1C(=C)CC[C@@H]2C(C)(C)CCC[C@@]12C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180855-02	363677074.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)/C=C(\COC(=O)C)/CC[C@@H]1C(=C)CC[C@@H]2C(C)(C)CCC[C@@]12C	O=C(OC)/C=C(\COC(=O)C)/CC[C@@H]1C(=C)CC[C@@H]2C(C)(C)CCC[C@@]12C
NCGC00346639-03	O=C(OC)/C=C/C(=O)OC		Inactive	NFkappaB-inducing kinase Inhibitor		1	Dimethyl fumarate	384568873.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)/C=C/C(=O)OC	O=C(OC)/C=C/C(=O)OC
NCGC00384820-01	O=C(OC)/C=C/C12C(C(C)(C)OC1)C(O)C(OC(=O)C)C1(C)C34C(C)(C(c5cocc5)OC(=O)C3O4)CCC21		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384820-01	363679376.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)/C=C/C12C(C(C)(C)OC1)C(O)C(OC(=O)C)C1(C)C34C(C)(C(c5cocc5)OC(=O)C3O4)CCC21	O=C(OC)/C=C/C12C(C(C)(C)OC1)C(O)C(OC(=O)C)C1(C)C34C(C)(C(c5cocc5)OC(=O)C3O4)CCC21
NCGC00380152-01	O=C(OC)/C=C/C=C/C(=O)OC1C2C(C)(C)CCCC2(C)C2(O)C(=O)OCC2=C1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380152-01	363678476.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)/C=C/C=C/C(=O)OC1C2C(C)(C)CCCC2(C)C2(O)C(=O)OCC2=C1	O=C(OC)/C=C/C=C/C(=O)OC1C2C(C)(C)CCCC2(C)C2(O)C(=O)OCC2=C1
NCGC00248247-02	O=C(OC)/C=C\C(=O)OC		Inactive	NFkappaB-inducing kinase Inhibitor		1	Dimethyl maleate	170466784.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)/C=C\C(=O)OC	O=C(OC)/C=C\C(=O)OC
NCGC00380515-01	O=C(OC)C(=C)C1C(O)C(C(CO)=C)C(C=C)(C)CC1O		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380515-01	363678624.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C(=C)C1C(O)C(C(CO)=C)C(C=C)(C)CC1O	O=C(OC)C(=C)C1C(O)C(C(CO)=C)C(C=C)(C)CC1O
NCGC00380482-01	O=C(OC)C(=C)C1C(O)C2C(=O)CCC(O)C2(C)CC1O		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380482-01	363678605.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C(=C)C1C(O)C2C(=O)CCC(O)C2(C)CC1O	O=C(OC)C(=C)C1C(O)C2C(=O)CCC(O)C2(C)CC1O
NCGC00384994-01	O=C(OC)C(=C)C1C(O)C2C(C)(C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)CC(=O)C2C)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384994-01	363679474.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C(=C)C1C(O)C2C(C)(C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)CC(=O)C2C)CC1	O=C(OC)C(=C)C1C(O)C2C(C)(C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)CC(=O)C2C)CC1
NCGC00385639-01	O=C(OC)C(=C)C1C(O)C2C(O)(CO)CCC(=O)C2(C)CC1O		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385639-01	363679851.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C(=C)C1C(O)C2C(O)(CO)CCC(=O)C2(C)CC1O	O=C(OC)C(=C)C1C(O)C2C(O)(CO)CCC(=O)C2(C)CC1O
NCGC00168854-02	O=C(OC)C(=C)[C@@]12[C@@H](OC(=O)C(CO)CN3C(C(=O)O)CCC3)C[C@]3(C)[C@](O)(/C(=C\C)/C(=O)O3)CC[C@](C)(O1)CC2=O		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00168854-02	363676705.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C(=C)[C@@]12[C@@H](OC(=O)C(CO)CN3C(C(=O)O)CCC3)C[C@]3(C)[C@](O)(/C(=C\C)/C(=O)O3)CC[C@](C)(O1)CC2=O	O=C(OC)C(=C)[C@@]12[C@@H](OC(=O)C(CO)CN3C(C(=O)O)CCC3)C[C@]3(C)[C@](O)(/C(=C\C)/C(=O)O3)CC[C@](C)(O1)CC2=O
NCGC00380444-01	O=C(OC)C(=C)[C@H]1C[C@]2(C)[C@@H](C)C(=O)C=CC2=CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380444-01	363678586.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C(=C)[C@H]1C[C@]2(C)[C@@H](C)C(=O)C=CC2=CC1	O=C(OC)C(=C)[C@H]1C[C@]2(C)[C@@H](C)C(=O)C=CC2=CC1
NCGC00168850-03	O=C(OC)C(=C)[C@H]1[C@H](O)[C@H]2C(=C)C(=O)OC[C@@]2(C=C)C[C@@H]1O		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Vernonia | Family: Compositae | Species: lasiopus		1	NCGC00168850-03	363676703.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C(=C)[C@H]1[C@H](O)[C@H]2C(=C)C(=O)OC[C@@]2(C=C)C[C@@H]1O	O=C(OC)C(=C)[C@H]1[C@H](O)[C@H]2C(=C)C(=O)OC[C@@]2(C=C)C[C@@H]1O
NCGC00370904-01	O=C(OC)C(C(=O)OC)Cc1ccc(OCCN2C(=O)Sc3c2ccc(C(=O)c2ccccc2)c3)cc1		Inactive	Peroxisome proliferator-activated receptor gamma Agonist		1	S26948	363677923.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C(C(=O)OC)Cc1ccc(OCCN2C(=O)Sc3c2ccc(C(=O)c2ccccc2)c3)cc1	O=C(OC)C(C(=O)OC)Cc1ccc(OCCN2C(=O)Sc3c2ccc(C(=O)c2ccccc2)c3)cc1
NCGC00380172-01	O=C(OC)C(C)C1C(O)C2C(O)(C)C=CC(=O)C2(C)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Artemisia | Family: N/A | Species: absinthium		1	NCGC00380172-01	363678487.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C(C)C1C(O)C2C(O)(C)C=CC(=O)C2(C)CC1	O=C(OC)C(C)C1C(O)C2C(O)(C)C=CC(=O)C2(C)CC1
NCGC00380980-02	O=C(OC)C(CC1(O)c2c(N3C(=O)C(C)(C)N(O)C13)cccc2)N1C(=O)c2c(N=C1)cccc2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380980-02	363678900.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C(CC1(O)c2c(N3C(=O)C(C)(C)N(O)C13)cccc2)N1C(=O)c2c(N=C1)cccc2	O=C(OC)C(CC1(O)c2c(N3C(=O)C(C)(C)N(O)C13)cccc2)N1C(=O)c2c(N=C1)cccc2
NCGC00381141-01	O=C(OC)C(CC1(O)c2c(N3C(=O)C(CC(C)C)NC13)cccc2)N1C(=O)c2c(N=C1)cccc2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381141-01	363678990.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C(CC1(O)c2c(N3C(=O)C(CC(C)C)NC13)cccc2)N1C(=O)c2c(N=C1)cccc2	O=C(OC)C(CC1(O)c2c(N3C(=O)C(CC(C)C)NC13)cccc2)N1C(=O)c2c(N=C1)cccc2
NCGC00169436-02	O=C(OC)C(NC(=O)c1ccccc1)Cc1ccccc1		Inactive	<MOA Unknown> | Class: Amino acid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169436-02	363676817.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C(NC(=O)c1ccccc1)Cc1ccccc1	O=C(OC)C(NC(=O)c1ccccc1)Cc1ccccc1
NCGC00384635-01	O=C(OC)C(O)[C@H]1C(C)(C)C(=O)C[C@H]2[C@]1(C)[C@@H]1C(=C)[C@@]3([C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)O2		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Crinum | Family: Amaryllidaceae | Species: jagus		1	NCGC00384635-01	363679287.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C(O)[C@H]1C(C)(C)C(=O)C[C@H]2[C@]1(C)[C@@H]1C(=C)[C@@]3([C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)O2	O=C(OC)C(O)[C@H]1C(C)(C)C(=O)C[C@H]2[C@]1(C)[C@@H]1C(=C)[C@@]3([C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)O2
NCGC00380905-01	O=C(OC)C(OC(=O)C)[C@H]1C(C)(C)C(=O)C[C@H]2[C@]1(C)[C@@H]1C(=C)[C@@]3([C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)O2		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Maerua | Family: Capparaceae | Species: oblongifolia		1	NCGC00380905-01	363678845.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C(OC(=O)C)[C@H]1C(C)(C)C(=O)C[C@H]2[C@]1(C)[C@@H]1C(=C)[C@@]3([C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)O2	O=C(OC)C(OC(=O)C)[C@H]1C(C)(C)C(=O)C[C@H]2[C@]1(C)[C@@H]1C(=C)[C@@]3([C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)O2
NCGC00248587-03	O=C(OC)C(c1ccccc1)C1NCCCC1		Inactive			1	METHYLPHENIDATE HYDROCHLORIDE	405558857.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)C(c1ccccc1)C1NCCCC1	O=C(OC)C(c1ccccc1)C1NCCCC1
NCGC00385347-01	O=C(OC)C1(C)C2C(C)(C(CCC=3C(=O)OCC=3)C(=C)CC2)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385347-01	363679692.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C1(C)C2C(C)(C(CCC=3C(=O)OCC=3)C(=C)CC2)CCC1	O=C(OC)C1(C)C2C(C)(C(CCC=3C(=O)OCC=3)C(=C)CC2)CCC1
NCGC00385292-01	O=C(OC)C1(C)C2C(C)(c3c(C(O)C2O)cc(C(C)C)cc3)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385292-01	363679651.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C1(C)C2C(C)(c3c(C(O)C2O)cc(C(C)C)cc3)CCC1	O=C(OC)C1(C)C2C(C)(c3c(C(O)C2O)cc(C(C)C)cc3)CCC1
NCGC00384782-01	O=C(OC)C1(C)CC2C(C(=O)O)(CCC3(C)C4(C)C(C5(C)C(C(CO)(C)C(OC6C(O)C(O)C(O)CO6)C(O)C5)CC4)CC=C23)CC1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384782-01	363679350.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C1(C)CC2C(C(=O)O)(CCC3(C)C4(C)C(C5(C)C(C(CO)(C)C(OC6C(O)C(O)C(O)CO6)C(O)C5)CC4)CC=C23)CC1	O=C(OC)C1(C)CC2C(C(=O)O)(CCC3(C)C4(C)C(C5(C)C(C(CO)(C)C(OC6C(O)C(O)C(O)CO6)C(O)C5)CC4)CC=C23)CC1
NCGC00347391-02	O=C(OC)C1(CO)[C@@H]2/C(=C\C)/CN3C(C4=Nc5c(cc(OC)cc5)[C@@]14CC3)C2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Vinca | Family: N/A | Species: sp.		1	NCGC00347391-02	363677587.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C1(CO)[C@@H]2/C(=C\C)/CN3C(C4=Nc5c(cc(OC)cc5)[C@@]14CC3)C2	O=C(OC)C1(CO)[C@@H]2/C(=C\C)/CN3C(C4=Nc5c(cc(OC)cc5)[C@@]14CC3)C2
NCGC00169454-03	O=C(OC)C1(Cc2ccc(O)cc2)C(c2ccc(O)cc2)=C(OC)C(=O)O1		Inactive	<MOA Unknown> | Class: shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169454-03	363676819.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C1(Cc2ccc(O)cc2)C(c2ccc(O)cc2)=C(OC)C(=O)O1	O=C(OC)C1(Cc2ccc(O)cc2)C(c2ccc(O)cc2)=C(OC)C(=O)O1
NCGC00381152-01	O=C(OC)C12C(=O)C(O)(C)C(=O)C(C)(C1=C)CC1C3(C)C=CC(=O)OC(C)(C)C3CCC21C		Inactive	<MOA Unknown> | Class: sesterterpene | Genus: Aspergillus ? | Family: N/A | Species: N/A		1	NCGC00381152-01	363678996.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C12C(=O)C(O)(C)C(=O)C(C)(C1=C)CC1C3(C)C=CC(=O)OC(C)(C)C3CCC21C	O=C(OC)C12C(=O)C(O)(C)C(=O)C(C)(C1=C)CC1C3(C)C=CC(=O)OC(C)(C)C3CCC21C
NCGC00380728-01	O=C(OC)C12C(=O)C(O)(C)C(=O)C1(C)C(C)=CC1C2(C)CCC2C(C)(C)C3OC(=O)C12CC3		Inactive	<MOA Unknown> | Class: sesterterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380728-01	363678742.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C12C(=O)C(O)(C)C(=O)C1(C)C(C)=CC1C2(C)CCC2C(C)(C)C3OC(=O)C12CC3	O=C(OC)C12C(=O)C(O)(C)C(=O)C1(C)C(C)=CC1C2(C)CCC2C(C)(C)C3OC(=O)C12CC3
NCGC00380147-01	O=C(OC)C12C(=O)C(O)(C)C(=O)C1(C)C(C)=CC1C2(C)CCC2C(CO)(C)C3OC(=O)C12CC3		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380147-01	363678474.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C12C(=O)C(O)(C)C(=O)C1(C)C(C)=CC1C2(C)CCC2C(CO)(C)C3OC(=O)C12CC3	O=C(OC)C12C(=O)C(O)(C)C(=O)C1(C)C(C)=CC1C2(C)CCC2C(CO)(C)C3OC(=O)C12CC3
NCGC00380204-01	O=C(OC)C12C(O)=C(C)C(=O)C1(C)C(C)=CC1C2(C)CCC2C(C)(C)C(O)CCC12CO		Inactive	<MOA Unknown> | Class: sesterterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380204-01	363678497.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C12C(O)=C(C)C(=O)C1(C)C(C)=CC1C2(C)CCC2C(C)(C)C(O)CCC12CO	O=C(OC)C12C(O)=C(C)C(=O)C1(C)C(C)=CC1C2(C)CCC2C(C)(C)C(O)CCC12CO
NCGC00347680-02	O=C(OC)C12C(O)=C(C)C(=O)C1(C)C(C)=CC1C2(C)CCC2C(C)(C)C3OC(=O)C12CC3		Inactive	<MOA Unknown> | Class: sesterterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347680-02	363677664.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C12C(O)=C(C)C(=O)C1(C)C(C)=CC1C2(C)CCC2C(C)(C)C3OC(=O)C12CC3	O=C(OC)C12C(O)=C(C)C(=O)C1(C)C(C)=CC1C2(C)CCC2C(C)(C)C3OC(=O)C12CC3
NCGC00347772-02	O=C(OC)C12[C@@](C)(C(=O)OC(C)C1=O)C(=C)CC1[C@@]2(C)C(=O)C(O)=C2C(C)(C)C(=O)C=C[C@]12C		Inactive	<MOA Unknown> | Class: sesterterpene | Genus: Aspergillus | Family: N/A | Species: N/A		1	NCGC00347772-02	363677683.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	22.829496404	O=C(OC)C12[C@@](C)(C(=O)OC(C)C1=O)C(=C)CC1[C@@]2(C)C(=O)C(O)=C2C(C)(C)C(=O)C=C[C@]12C	O=C(OC)C12[C@@](C)(C(=O)OC(C)C1=O)C(=C)CC1[C@@]2(C)C(=O)C(O)=C2C(C)(C)C(=O)C=C[C@]12C
NCGC00385157-01	O=C(OC)C12c3[nH]c4c(c3CCN3C1C(CC)CC(C2)C3)cccc4		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385157-01	363679568.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C12c3[nH]c4c(c3CCN3C1C(CC)CC(C2)C3)cccc4	O=C(OC)C12c3[nH]c4c(c3CCN3C1C(CC)CC(C2)C3)cccc4
NCGC00385864-01	O=C(OC)C1=C(c2[nH]ccc2)c2c(C(=O)N1)cccc2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385864-01	363679975.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C1=C(c2[nH]ccc2)c2c(C(=O)N1)cccc2	O=C(OC)C1=C(c2[nH]ccc2)c2c(C(=O)N1)cccc2
NCGC00385305-01	O=C(OC)C1=C2Nc3c(cccc3)C32C2C(C(O)C)(C1)CCCN2CC3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Vinca | Family: N/A | Species: sp.		1	NCGC00385305-01	363679662.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C1=C2Nc3c(cccc3)C32C2C(C(O)C)(C1)CCCN2CC3	O=C(OC)C1=C2Nc3c(cccc3)C32C2C(C(O)C)(C1)CCCN2CC3
NCGC00169059-03	O=C(OC)C1=COC(C)C2C1CC1C3(C(=O)Nc4c3cccc4)CCN1C2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Uncaria | Family: N/A | Species: tomentosa		1	NCGC00169059-03	363676757.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C1=COC(C)C2C1CC1C3(C(=O)Nc4c3cccc4)CCN1C2	O=C(OC)C1=COC(C)C2C1CC1C3(C(=O)Nc4c3cccc4)CCN1C2
NCGC00169504-02	O=C(OC)C1=COC(OC2C(O)C(O)C(O)C(CO)O2)C2C(O)(CO)C=CC12		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Cynometra | Family: Fabaceae | Species: megalophylla		1	NCGC00169504-02	363676832.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C1=COC(OC2C(O)C(O)C(O)C(CO)O2)C2C(O)(CO)C=CC12	O=C(OC)C1=COC(OC2C(O)C(O)C(O)C(CO)O2)C2C(O)(CO)C=CC12
NCGC00384786-01	O=C(OC)C1=COC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2C(C)C(=O)CC12		Inactive	<MOA Unknown> | Class: Iridoide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384786-01	363679352.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C1=COC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2C(C)C(=O)CC12	O=C(OC)C1=COC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2C(C)C(=O)CC12
NCGC00485125-01	O=C(OC)C1=CO[C@@H](O)C2C(CO)=CCC12		Inactive	Mitochondrial uncoupling protein 2 Inhibitor		1	Genipin	363681233.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C1=CO[C@@H](O)C2C(CO)=CCC12	O=C(OC)C1=CO[C@@H](O)C2C(CO)=CCC12
NCGC00385262-01	O=C(OC)C1=CO[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2[C@H](C)CC(=O)C12		Inactive	Hepatitis C virus Inhibitor		1	NCGC00385262-01	363679624.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C1=CO[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2[C@H](C)CC(=O)C12	O=C(OC)C1=CO[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2[C@H](C)CC(=O)C12
NCGC00381156-01	O=C(OC)C1C(O)(C)OC2(C)C(=O)C=C3C(C12)=COC(/C=C/C(=C/C(CC)C)/C)=C3		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381156-01	363678999.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C1C(O)(C)OC2(C)C(=O)C=C3C(C12)=COC(/C=C/C(=C/C(CC)C)/C)=C3	O=C(OC)C1C(O)(C)OC2(C)C(=O)C=C3C(C12)=COC(/C=C/C(=C/C(CC)C)/C)=C3
NCGC00380712-01	O=C(OC)C1C(c2ccc(O)cc2)C(C(=O)O)C1c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380712-01	363678729.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C1C(c2ccc(O)cc2)C(C(=O)O)C1c1ccc(O)cc1	O=C(OC)C1C(c2ccc(O)cc2)C(C(=O)O)C1c1ccc(O)cc1
NCGC00380708-03	O=C(OC)C1C(c2ccc(O)cc2)C(C(=O)OC)C1c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380708-03	363678725.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C1C(c2ccc(O)cc2)C(C(=O)OC)C1c1ccc(O)cc1	O=C(OC)C1C(c2ccc(O)cc2)C(C(=O)OC)C1c1ccc(O)cc1
NCGC00385474-01	O=C(OC)C1C2[N+]([O-])(C)C/C(=C/C)/C1CC(=O)c1[nH]c3c(c1C2)cccc3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385474-01	363679760.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C1C2[N+]([O-])(C)C/C(=C/C)/C1CC(=O)c1[nH]c3c(c1C2)cccc3	O=C(OC)C1C2[N+]([O-])(C)C/C(=C/C)/C1CC(=O)c1[nH]c3c(c1C2)cccc3
NCGC00181762-01	O=C(OC)C=1C(=O)c2c(NC=1)cc(OCc1ccccc1)c(CCCC)c2		Inactive	Eimeria tenella Inhibitor		1	Nequinate	144206498.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)C=1C(=O)c2c(NC=1)cc(OCc1ccccc1)c(CCCC)c2	O=C(OC)C=1C(=O)c2c(NC=1)cc(OCc1ccccc1)c(CCCC)c2
NCGC00385509-01	O=C(OC)C=1C(CC2OC(CCc3ccc(O)cc3)CC(=O)C2)C(C=C)C(OC2C(O)C(O)C(O)C(CO)O2)OC=1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Hydrangea | Family: Rosaceae | Species: macrophylla		1	NCGC00385509-01	363679782.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1C(CC2OC(CCc3ccc(O)cc3)CC(=O)C2)C(C=C)C(OC2C(O)C(O)C(O)C(CO)O2)OC=1	O=C(OC)C=1C(CC2OC(CCc3ccc(O)cc3)CC(=O)C2)C(C=C)C(OC2C(O)C(O)C(O)C(CO)O2)OC=1
NCGC00385526-01	O=C(OC)C=1C(Cc2nccc3c2[nH]c2c3cccc2)C(C=C)C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Pauridiantha | Family: Rubiaceae | Species: paucinervis		1	NCGC00385526-01	363679790.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1C(Cc2nccc3c2[nH]c2c3cccc2)C(C=C)C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1	O=C(OC)C=1C(Cc2nccc3c2[nH]c2c3cccc2)C(C=C)C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1
NCGC00385299-01	O=C(OC)C=1C2(O)C(=O)CC(C)C2C(OC2C(O)C(O)C(O)C(CO)O2)OC=1		Inactive	<MOA Unknown> | Class: Iridoide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385299-01	363679658.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1C2(O)C(=O)CC(C)C2C(OC2C(O)C(O)C(O)C(CO)O2)OC=1	O=C(OC)C=1C2(O)C(=O)CC(C)C2C(OC2C(O)C(O)C(O)C(CO)O2)OC=1
NCGC00384715-01	O=C(OC)C=1[C@@H](/C(/C=O)=C\C[C@H]2[C@@H](C=C)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C2C(=O)OC)[C@@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384715-01	363679324.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1[C@@H](/C(/C=O)=C\C[C@H]2[C@@H](C=C)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C2C(=O)OC)[C@@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1	O=C(OC)C=1[C@@H](/C(/C=O)=C\C[C@H]2[C@@H](C=C)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C2C(=O)OC)[C@@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1
NCGC00384550-01	O=C(OC)C=1[C@@H](CC=O)[C@@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384550-01	363679240.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1[C@@H](CC=O)[C@@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1	O=C(OC)C=1[C@@H](CC=O)[C@@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1
NCGC00384878-01	O=C(OC)C=1[C@@H](CCO)[C@@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1		Inactive	<MOA Unknown> | Class: Iridoide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384878-01	363679410.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1[C@@H](CCO)[C@@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1	O=C(OC)C=1[C@@H](CCO)[C@@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1
NCGC00178124-03	O=C(OC)C=1[C@@H]2[C@@H]([C@@H](C)[C@@H](O)C2)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1		Inactive			1	LOGANIN	434147047.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)C=1[C@@H]2[C@@H]([C@@H](C)[C@@H](O)C2)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1	O=C(OC)C=1[C@@H]2[C@@H]([C@@H](C)[C@@H](O)C2)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1
NCGC00385878-01	O=C(OC)C=1[C@@H]2[C@@H]3[C@@H](O[C@H]4[C@H](CC)C(=O)O[C@@]34C=C2)OC=1		Inactive	<MOA Unknown> | Class: Iridoide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385878-01	363679986.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1[C@@H]2[C@@H]3[C@@H](O[C@H]4[C@H](CC)C(=O)O[C@@]34C=C2)OC=1	O=C(OC)C=1[C@@H]2[C@@H]3[C@@H](O[C@H]4[C@H](CC)C(=O)O[C@@]34C=C2)OC=1
NCGC00186010-03	O=C(OC)C=1[C@@H]2[C@H]([C@H](O)OC=1)C(CO)=CC2		Inactive	Free Radical Scavenger		1	Genipin	363677108.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1[C@@H]2[C@H]([C@H](O)OC=1)C(CO)=CC2	O=C(OC)C=1[C@@H]2[C@H]([C@H](O)OC=1)C(CO)=CC2
NCGC00346662-06	O=C(OC)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)C(CO)=CC2		Inactive	P2Y purinoceptor 14 Inhibitor		1	Geniposide	434147094.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)C(CO)=CC2	O=C(OC)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)C(CO)=CC2
NCGC00385752-02	O=C(OC)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@H](C)OC(OC)C2		Inactive	<MOA Unknown> | Class: Iridoide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385752-02	363679923.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@H](C)OC(OC)C2	O=C(OC)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@H](C)OC(OC)C2
NCGC00347624-02	O=C(OC)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@]1(OC(=O)C([C@@H](O)C)=C1)C=C2		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Plumeria | Family: Apocynaceae | Species: rubra		1	NCGC00347624-02	363677643.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@]1(OC(=O)C([C@@H](O)C)=C1)C=C2	O=C(OC)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@]1(OC(=O)C([C@@H](O)C)=C1)C=C2
NCGC00347524-02	O=C(OC)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)O3)OC=1)C(CO)=CC2		Inactive	Acetylcholinesterase Inhibitor		1	NCGC00347524-02	363677612.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)O3)OC=1)C(CO)=CC2	O=C(OC)C=1[C@@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)O3)OC=1)C(CO)=CC2
NCGC00385619-01	O=C(OC)C=1[C@@]2(O)C(=O)CC(C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Syringa | Family: Oleaceae | Species: vulgaris		1	NCGC00385619-01	363679842.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1[C@@]2(O)C(=O)CC(C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1	O=C(OC)C=1[C@@]2(O)C(=O)CC(C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1
NCGC00380737-01	O=C(OC)C=1[C@H]2C(O)[C@H](O)[C@H](C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380737-01	363678750.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1[C@H]2C(O)[C@H](O)[C@H](C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1	O=C(OC)C=1[C@H]2C(O)[C@H](O)[C@H](C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1
NCGC00385345-01	O=C(OC)C=1[C@H]2C(O)[C@H](O)[C@H](CO)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385345-01	363679690.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1[C@H]2C(O)[C@H](O)[C@H](CO)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1	O=C(OC)C=1[C@H]2C(O)[C@H](O)[C@H](CO)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1
NCGC00169057-02	O=C(OC)C=1[C@H]2[C@H](O)C[C@@](O)(C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Parentucellia | Family: Scrophulariaceae | Species: viscosa		1	NCGC00169057-02	363676756.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1[C@H]2[C@H](O)C[C@@](O)(C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1	O=C(OC)C=1[C@H]2[C@H](O)C[C@@](O)(C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1
NCGC00385998-01	O=C(OC)C=1[C@H]2[C@H](O)[C@H](O)[C@@](O)(C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1		Inactive	<MOA Unknown> | Class: Iridoide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385998-01	363680048.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1[C@H]2[C@H](O)[C@H](O)[C@@](O)(C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1	O=C(OC)C=1[C@H]2[C@H](O)[C@H](O)[C@@](O)(C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1
NCGC00385516-01	O=C(OC)C=1[C@]2(O)[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)C(CO)=CC2		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Thevetia | Family: Apocynaceae | Species: plumeriaefolia		1	NCGC00385516-01	363679784.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1[C@]2(O)[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)C(CO)=CC2	O=C(OC)C=1[C@]2(O)[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)C(CO)=CC2
NCGC00169696-02	O=C(OC)C=1[C@]2(O)[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@](O)(C)[C@@H](O)C2		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Ocimum | Family: Lamiaceae | Species: gratissimum		1	NCGC00169696-02	363676868.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C=1[C@]2(O)[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@](O)(C)[C@@H](O)C2	O=C(OC)C=1[C@]2(O)[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@](O)(C)[C@@H](O)C2
NCGC00384932-01	O=C(OC)CC(O)C1C(O)C(O)C(c2ccccc2)O1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384932-01	363679445.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)CC(O)C1C(O)C(O)C(c2ccccc2)O1	O=C(OC)CC(O)C1C(O)C(O)C(c2ccccc2)O1
NCGC00381137-01	O=C(OC)CC(O)CC(O)/C=C/c1c(C)ccc2c1C(O)CC(C)C2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381137-01	363678988.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)CC(O)CC(O)/C=C/c1c(C)ccc2c1C(O)CC(C)C2	O=C(OC)CC(O)CC(O)/C=C/c1c(C)ccc2c1C(O)CC(C)C2
NCGC00380751-01	O=C(OC)CC(O)CC(O)/C=C/c1c(C)ccc2c1C(OC(=O)C)CC(C)C2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380751-01	363678759.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	10.58689356	O=C(OC)CC(O)CC(O)/C=C/c1c(C)ccc2c1C(OC(=O)C)CC(C)C2	O=C(OC)CC(O)CC(O)/C=C/c1c(C)ccc2c1C(OC(=O)C)CC(C)C2
NCGC00385588-01	O=C(OC)CC1(O)C(=O)Nc2c1cccc2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385588-01	363679823.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)CC1(O)C(=O)Nc2c1cccc2	O=C(OC)CC1(O)C(=O)Nc2c1cccc2
NCGC00478993-01	O=C(OC)CC1C(C/C=C\CC)C(=O)CC1		Inactive			1	NCGC00478993-01	377020256.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)CC1C(C/C=C\CC)C(=O)CC1	O=C(OC)CC1C(C/C=C\CC)C(=O)CC1
NCGC00381427-01	O=C(OC)CC1OC(C)C2(C(=O)c3c(O)cccc3C2(O)C(=O)OC)C1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381427-01	363679138.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)CC1OC(C)C2(C(=O)c3c(O)cccc3C2(O)C(=O)OC)C1	O=C(OC)CC1OC(C)C2(C(=O)c3c(O)cccc3C2(O)C(=O)OC)C1
NCGC00381362-01	O=C(OC)CC1OC(C)C2=C(O)c3c(O)cccc3C(=O)C32OC13		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381362-01	363679107.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	17.615879832	O=C(OC)CC1OC(C)C2=C(O)c3c(O)cccc3C(=O)C32OC13	O=C(OC)CC1OC(C)C2=C(O)c3c(O)cccc3C(=O)C32OC13
NCGC00379103-02	O=C(OC)CC1ON=C(c2ccc(O)cc2)C1		Inactive	Macrophage migration inhibitory factor Inhibitor		1	MIF antagonist	363678353.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)CC1ON=C(c2ccc(O)cc2)C1	O=C(OC)CC1ON=C(c2ccc(O)cc2)C1
NCGC00018251-05	O=C(OC)CCC(=O)CN		Inactive	Porphyrin and chlorophyll metabolism Modulator		1	Methyl delta-aminolevulinate hydrochloride	225144187.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC)CCC(=O)CN	O=C(OC)CCC(=O)CN
NCGC00380402-01	O=C(OC)CCC1(C)C(C(O)(C)C)C(O)CC2(C)Oc3c(C)c4c(c(OC)c3CC12)C(=O)OC4		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380402-01	363678569.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)CCC1(C)C(C(O)(C)C)C(O)CC2(C)Oc3c(C)c4c(c(OC)c3CC12)C(=O)OC4	O=C(OC)CCC1(C)C(C(O)(C)C)C(O)CC2(C)Oc3c(C)c4c(c(OC)c3CC12)C(=O)OC4
NCGC00162445-05	O=C(OC)CCCCCC[C@@H]1[C@@H](/C=C/CC(O)(CCCC)C)[C@H](O)CC1=O		Inactive	Prostanoid EP3 receptor Agonist		1	Misoprostol	225144248.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)CCCCCC[C@@H]1[C@@H](/C=C/CC(O)(CCCC)C)[C@H](O)CC1=O	O=C(OC)CCCCCC[C@@H]1[C@@H](/C=C/CC(O)(CCCC)C)[C@H](O)CC1=O
NCGC00181355-02	O=C(OC)CCC[N+](C)(C)C		Inactive	Muscarinic acetylcholine receptor Agonist		1	Carpronium chloride	225144327.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)CCC[N+](C)(C)C	O=C(OC)CCC[N+](C)(C)C
NCGC00485026-01	O=C(OC)CC[C@@H](C)C1C2(C)[C@@H](O)CC3C4(C)C(C[C@H](OC(=O)C)CC4)CCC3C2CC1	4.9000001	Active		0.0	1	5Î²-Cholanic acid-3Î±,12Î±-diol 3-acetate methyl ester	363681194.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	3.0	71.2800593646	O=C(OC)CC[C@@H](C)C1C2(C)[C@@H](O)CC3C4(C)C(C[C@H](OC(=O)C)CC4)CCC3C2CC1	O=C(OC)CC[C@@H](C)C1C2(C)[C@@H](O)CC3C4(C)C(C[C@H](OC(=O)C)CC4)CCC3C2CC1
NCGC00485011-01	O=C(OC)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@H](C(=O)C3)C[C@H](OC(=O)C)CC4)CC2)CC1		Inactive			1	5Î±-Cholanic acid-3Î±-ol-6-one 3-acetate methyl ester	363681186.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@H](C(=O)C3)C[C@H](OC(=O)C)CC4)CC2)CC1	O=C(OC)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@H](C(=O)C3)C[C@H](OC(=O)C)CC4)CC2)CC1
NCGC00346712-02&NCGC00346712-07	O=C(OC)CCc1c(C)[cH0]=2[nH][cH0]1=CC=1C(CCC(=O)O)=C(C)C(N=1)=Cc1c(C=C)c(C)c([nH]1)C=C1N=C([C@]3(C)[C@H](C(=O)OC)C(C(=O)OC)=CC=C13)C=2		Inactive	photosensitizer		2	Verteporfin	440681570.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(OC)CCc1c(C)[cH0]=2[nH][cH0]1=CC=1C(CCC(=O)O)=C(C)C(N=1)=Cc1c(C=C)c(C)c([nH]1)C=C1N=C([C@]3(C)[C@H](C(=O)OC)C(C(=O)OC)=CC=C13)C=2	O=C(OC)CCc1c(C)[cH0]=2[nH][cH0]1=CC=1C(CCC(=O)O)=C(C)C(N=1)=Cc1c(C=C)c(C)c([nH]1)C=C1N=C([C@]3(C)[C@H](C(=O)OC)C(C(=O)OC)=CC=C13)C=2
NCGC00385419-01	O=C(OC)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(OC)c2occc2c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: ferula | Family: Apiaceae | Species: communis		1	NCGC00385419-01	363679733.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(OC)c2occc2c1	O=C(OC)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(OC)c2occc2c1
NCGC00185766-04	O=C(OC)CCc1ccc(OCC(O)CNC(C)C)cc1		Inactive	sodium ion transport Inhibitor		1	Esmolol hydrochloride	170465277.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)CCc1ccc(OCC(O)CNC(C)C)cc1.Cl	O=C(OC)CCc1ccc(OCC(O)CNC(C)C)cc1.Cl
NCGC00180557-02	O=C(OC)C[C@H]1/C(=C/C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Jasminum | Family: Oleaceae | Species: sambac		1	NCGC00180557-02	363677034.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C[C@H]1/C(=C/C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC	O=C(OC)C[C@H]1/C(=C/C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC
NCGC00384921-01	O=C(OC)C[C@H]1C(C)(C)C(=O)C[C@H]2[C@]1(C)[C@@H]1C(=C)[C@@]3([C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)O2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384921-01	363679441.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C[C@H]1C(C)(C)C(=O)C[C@H]2[C@]1(C)[C@@H]1C(=C)[C@@]3([C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)O2	O=C(OC)C[C@H]1C(C)(C)C(=O)C[C@H]2[C@]1(C)[C@@H]1C(=C)[C@@]3([C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)O2
NCGC00385726-01	O=C(OC)C[C@H]1C(C)(C)[C@H](OC(=O)C)C2C(=O)[C@]1(C)C1C(=C3[C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)C2		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Crinum | Family: Amaryllidaceae | Species: jagus		1	NCGC00385726-01	363679901.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C[C@H]1C(C)(C)[C@H](OC(=O)C)C2C(=O)[C@]1(C)C1C(=C3[C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)C2	O=C(OC)C[C@H]1C(C)(C)[C@H](OC(=O)C)C2C(=O)[C@]1(C)C1C(=C3[C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)C2
NCGC00384964-01	O=C(OC)C[C@H]1C(C)(C)[C@H](OC(=O)c2ccccc2)C2C(=O)[C@]1(C)C1C(=C3[C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384964-01	363679458.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C[C@H]1C(C)(C)[C@H](OC(=O)c2ccccc2)C2C(=O)[C@]1(C)C1C(=C3[C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)C2	O=C(OC)C[C@H]1C(C)(C)[C@H](OC(=O)c2ccccc2)C2C(=O)[C@]1(C)C1C(=C3[C@](C)([C@H](c4cocc4)OC(=O)C3)CC1)C2
NCGC00180053-03	O=C(OC)C[C@H]1[C@@]2(C)[C@@H]([C@H](O)C3[C@]1(C)C(=O)C=C[C@]3(C(=O)OC)C)O[C@H]1C2=C(C)[C@H](c2cocc2)C1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180053-03	363677002.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C[C@H]1[C@@]2(C)[C@@H]([C@H](O)C3[C@]1(C)C(=O)C=C[C@]3(C(=O)OC)C)O[C@H]1C2=C(C)[C@H](c2cocc2)C1	O=C(OC)C[C@H]1[C@@]2(C)[C@@H]([C@H](O)C3[C@]1(C)C(=O)C=C[C@]3(C(=O)OC)C)O[C@H]1C2=C(C)[C@H](c2cocc2)C1
NCGC00169906-03	O=C(OC)C[C@H]1[C@@]2(C)[C@@H]([C@H](OC(=O)C)C3[C@]1(C)C(=O)C=C[C@]3(C(=O)OC)C)O[C@H]1C2=C(C)[C@H](c2cocc2)C1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Azadirachta | Family: Meliaceae | Species: indica		1	NCGC00169906-03	363676908.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)C[C@H]1[C@@]2(C)[C@@H]([C@H](OC(=O)C)C3[C@]1(C)C(=O)C=C[C@]3(C(=O)OC)C)O[C@H]1C2=C(C)[C@H](c2cocc2)C1	O=C(OC)C[C@H]1[C@@]2(C)[C@@H]([C@H](OC(=O)C)C3[C@]1(C)C(=O)C=C[C@]3(C(=O)OC)C)O[C@H]1C2=C(C)[C@H](c2cocc2)C1
NCGC00386859-01	O=C(OC)Cn1nc(-c2cc(OC)ccc2)c2c1cccc2		Inactive			1	NCGC00386859-01	363680469.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)Cn1nc(-c2cc(OC)ccc2)c2c1cccc2	O=C(OC)Cn1nc(-c2cc(OC)ccc2)c2c1cccc2
NCGC00504899-01	O=C(OC)N(Cc1cc(N2CCN(C(c3ccccc3)c3ccccc3)CC2)ccc1)C		Inactive			1	NCGC00504899-01	375798063.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)N(Cc1cc(N2CCN(C(c3ccccc3)c3ccccc3)CC2)ccc1)C	O=C(OC)N(Cc1cc(N2CCN(C(c3ccccc3)c3ccccc3)CC2)ccc1)C
NCGC00095156-06	O=C(OC)N/N=C/C=1N([O-])c2c([N+](=O)C=1)cccc2		Inactive			1	Carbadox	170466261.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)N/N=C/c1[n+]([O-])c2c([n+]([O-])c1)cccc2	O=C(OC)N/N=C/c1[n+]([O-])c2c([n+]([O-])c1)cccc2
NCGC00498399-01	O=C(OC)N1[C@H](C(=O)N2CCN(c3ccccc3)CC2)[C@@H](C(=O)NO)CC2(C1)CC2		Inactive	ADAM10 Inhibitor		1	Aderbasib	363681480.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)N1[C@H](C(=O)N2CCN(c3ccccc3)CC2)[C@@H](C(=O)NO)CC2(C1)CC2	O=C(OC)N1[C@H](C(=O)N2CCN(c3ccccc3)CC2)[C@@H](C(=O)NO)CC2(C1)CC2
NCGC00522503-01&NCGC00522503-02	O=C(OC)N[C@H](C(=O)N1[C@@H](C)CC[C@H]1c1[nH]c2c(n1)ccc1c2cc2OCc3c(-c2c1)ccc(-c1[nH]c([C@H]2N(C(=O)[C@H](NC(=O)OC)c4ccccc4)C[C@@H](COC)C2)nc1)c3)C(C)C		Inactive	Nonstructural protein 5A Inhibitor		2	Velpatasvir&VELPATASVIR	405558874.0&434147174.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC)N[C@H](C(=O)N1[C@@H](C)CC[C@H]1c1[nH]c2c(n1)ccc1c2cc2OCc3c(-c2c1)ccc(-c1[nH]c([C@H]2N(C(=O)[C@H](NC(=O)OC)c4ccccc4)C[C@@H](COC)C2)nc1)c3)C(C)C	O=C(OC)N[C@H](C(=O)N1[C@@H](C)CC[C@H]1c1[nH]c2c(n1)ccc1c2cc2OCc3c(-c2c1)ccc(-c1[nH]c([C@H]2N(C(=O)[C@H](NC(=O)OC)c4ccccc4)C[C@@H](COC)C2)nc1)c3)C(C)C
NCGC00510316-01&NCGC00510316-02	O=C(OC)N[C@H](C(=O)N1[C@H](C(=O)Nc2ccc([C@H]3N([C@H](c4ccc(NC(=O)[C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC5)cc4)CC3)c3ccc(C(C)(C)C)cc3)cc2)CCC1)C(C)C		Inactive			2	ombitasvir&Ombitasvir	434147243.0&405559012.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC)N[C@H](C(=O)N1[C@H](C(=O)Nc2ccc([C@H]3N([C@H](c4ccc(NC(=O)[C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC5)cc4)CC3)c3ccc(C(C)(C)C)cc3)cc2)CCC1)C(C)C	O=C(OC)N[C@H](C(=O)N1[C@H](C(=O)Nc2ccc([C@H]3N([C@H](c4ccc(NC(=O)[C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC5)cc4)CC3)c3ccc(C(C)(C)C)cc3)cc2)CCC1)C(C)C
NCGC00510317-02	O=C(OC)N[C@H](C(=O)N1[C@H](c2[nH]c(-c3cc4c(n5[C@H](c6ccccc6)Oc6c(-c5c4)ccc(-c4[nH]c([C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC5)nc4)c6)cc3)cn2)CCC1)C(C)C		Inactive	Nonstructural protein 5A Inhibitor		1	Elbasvir	405558499.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC)N[C@H](C(=O)N1[C@H](c2[nH]c(-c3cc4c(n5[C@H](c6ccccc6)Oc6c(-c5c4)ccc(-c4[nH]c([C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC5)nc4)c6)cc3)cn2)CCC1)C(C)C	O=C(OC)N[C@H](C(=O)N1[C@H](c2[nH]c(-c3cc4c(n5[C@H](c6ccccc6)Oc6c(-c5c4)ccc(-c4[nH]c([C@H]5N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC5)nc4)c6)cc3)cn2)CCC1)C(C)C
NCGC00346533-07&NCGC00346533-09&NCGC00346533-13	O=C(OC)N[C@H](C(=O)N1[C@H](c2[nH]c(-c3ccc(-c4ccc(-c5[nH]c([C@H]6N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC6)nc5)cc4)cc3)cn2)CCC1)C(C)C		Inactive	HCV NS5A Inhibitor		3	Daclatasvir dihydrochloride	434147089.0&405558621.0&384568823.0	Anti-infectives&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(OC)N[C@H](C(=O)N1[C@H](c2[nH]c(-c3ccc(-c4ccc(-c5[nH]c([C@H]6N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC6)nc5)cc4)cc3)cn2)CCC1)C(C)C	O=C(OC)N[C@H](C(=O)N1[C@H](c2[nH]c(-c3ccc(-c4ccc(-c5[nH]c([C@H]6N(C(=O)[C@@H](NC(=O)OC)C(C)C)CCC6)nc5)cc4)cc3)cn2)CCC1)C(C)C
NCGC00182552-02&NCGC00182552-14	O=C(OC)N[C@H](C(=O)NN(C[C@H](O)[C@@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)Cc1ccccc1)Cc1ccc(-c2ncccc2)cc1)C(C)(C)C		Inactive	HIV Protease Inhibitors&Human immunodeficiency virus type 1 protease Inhibitor		2	Atazanavir	170465290.0&434147058.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(OC)N[C@H](C(=O)NN(C[C@H](O)[C@@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)Cc1ccccc1)Cc1ccc(-c2ncccc2)cc1)C(C)(C)C	O=C(OC)N[C@H](C(=O)NN(C[C@H](O)[C@@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)Cc1ccccc1)Cc1ccc(-c2ncccc2)cc1)C(C)(C)C
NCGC00016806-13&NCGC00016806-17	O=C(OC)Nc1[nH]c2c(n1)cc(C(=O)c1ccccc1)cc2		Inactive	Tubulin depolymerization Inhibitor		2	Mebendazole	170464914.0&384567961.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		O=C(OC)Nc1[nH]c2c(n1)cc(C(=O)c1ccccc1)cc2	O=C(OC)Nc1[nH]c2c(n1)cc(C(=O)c1ccccc1)cc2
NCGC00015647-31	O=C(OC)Nc1[nH]c2c(n1)cc(C(=O)c1sccc1)cc2		Inactive	Tubulin Polymerization Inhibitor		1	Nocodazole	384567878.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(OC)Nc1[nH]c2c(n1)cc(C(=O)c1sccc1)cc2	O=C(OC)Nc1[nH]c2c(n1)cc(C(=O)c1sccc1)cc2
NCGC00016706-10	O=C(OC)Nc1[nH]c2c(n1)cc(CCCC)cc2		Inactive	Tubulin depolymerization Inhibitor		1	Parbendazole	384567956.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(OC)Nc1[nH]c2c(n1)cc(CCCC)cc2	O=C(OC)Nc1[nH]c2c(n1)cc(CCCC)cc2
NCGC00018238-09&NCGC00018238-11	O=C(OC)Nc1[nH]c2c(n1)cc(OCCC)cc2		Inactive	DNA Polymerase Inhibitor		2	Oxibendazole	170465661.0&384567998.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		O=C(OC)Nc1[nH]c2c(n1)cc(OCCC)cc2	O=C(OC)Nc1[nH]c2c(n1)cc(OCCC)cc2
NCGC00242484-09	O=C(OC)Nc1ccc(-c2nc(N3CCOCC3)c3c(n(C4CCN(C(=O)OC)CC4)nc3)n2)cc1		Inactive	mTORC1/2 Inhibitor		1	WYE-354	377020241.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.35355648	O=C(OC)Nc1ccc(-c2nc(N3CCOCC3)c3c(n(C4CCN(C(=O)OC)CC4)nc3)n2)cc1	O=C(OC)Nc1ccc(-c2nc(N3CCOCC3)c3c(n(C4CCN(C(=O)OC)CC4)nc3)n2)cc1
NCGC00346636-03	O=C(OC)Nc1ccc(-c2nc(N3CCOCC3)c3c(n(C4CCN(Cc5cnccc5)CC4)nc3)n2)cc1		Inactive	mTOR Inhibitor		1	WYE-687	363677489.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)Nc1ccc(-c2nc(N3CCOCC3)c3c(n(C4CCN(Cc5cnccc5)CC4)nc3)n2)cc1	O=C(OC)Nc1ccc(-c2nc(N3CCOCC3)c3c(n(C4CCN(Cc5cnccc5)CC4)nc3)n2)cc1
NCGC00160481-02	O=C(OC)Nc1sc2c(n1)ccc(OCCC)c2		Inactive	microtubule polymerization Inhibitor		1	Tioxidazole	124892286.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)Nc1sc2c(n1)ccc(OCCC)c2	O=C(OC)Nc1sc2c(n1)ccc(OCCC)c2
NCGC00091104-10	O=C(OC)[C@@H](NC(=O)[C@@H](N)CC(=O)O)Cc1ccccc1		Inactive	Synthetic sugar substitute		1	Aspartame	384568093.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)[C@@H](NC(=O)[C@@H](N)CC(=O)O)Cc1ccccc1	O=C(OC)[C@@H](NC(=O)[C@@H](N)CC(=O)O)Cc1ccccc1
NCGC00507885-01	O=C(OC)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1ccc(C(C)(C)C)cc1)Cc1ccccc1)C)CC(C)C)CCCCN(CC)CC)CO		Inactive	Peptidic Inhibitor of CDYL/CBX4/CBX7		1	UNC-3866	384569350.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1ccc(C(C)(C)C)cc1)Cc1ccccc1)C)CC(C)C)CCCCN(CC)CC)CO	O=C(OC)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1ccc(C(C)(C)C)cc1)Cc1ccccc1)C)CC(C)C)CCCCN(CC)CC)CO
NCGC00386670-01	O=C(OC)[C@@H](NC(=O)[C@H]1N(C(=O)CCCCC)CCC1)Cc1ccc(O)cc1		Inactive	glutamate homeostasis Modulator		1	Dilept	363680386.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)[C@@H](NC(=O)[C@H]1N(C(=O)CCCCC)CCC1)Cc1ccc(O)cc1	O=C(OC)[C@@H](NC(=O)[C@H]1N(C(=O)CCCCC)CCC1)Cc1ccc(O)cc1
NCGC00378870-01	O=C(OC)[C@@H](NCC12CC3CC(C1)CC(C2)C3)CC1N=CN=C1		Inactive	Matrix protein 2 Blocker		1	M2 ion channel blocker	363678248.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)[C@@H](NCC12CC3CC(C1)CC(C2)C3)CC1N=CN=C1	O=C(OC)[C@@H](NCC12CC3CC(C1)CC(C2)C3)CC1N=CN=C1
NCGC00380700-01	O=C(OC)[C@@H](O)[C@@H]1[C@]2(C)C3(O)[C@@H](C(=O)[C@@H](O)[C@]1(C)C3)[C@]13O[C@]41[C@](C)([C@H](c1cocc1)OC(=O)C4)CCC23		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Khaya | Family: Meliaceae | Species: ivorensis		1	NCGC00380700-01	363678717.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)[C@@H](O)[C@@H]1[C@]2(C)C3(O)[C@@H](C(=O)[C@@H](O)[C@]1(C)C3)[C@]13O[C@]41[C@](C)([C@H](c1cocc1)OC(=O)C4)CCC23	O=C(OC)[C@@H](O)[C@@H]1[C@]2(C)C3(O)[C@@H](C(=O)[C@@H](O)[C@]1(C)C3)[C@]13O[C@]41[C@](C)([C@H](c1cocc1)OC(=O)C4)CCC23
NCGC00378763-01	O=C(OC)[C@@H]([C@H](NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1)C)Cc1cc(C(=N)N)ccc1		Inactive	Coagulation factor X Inhibitor		1	Otamixaban	363678185.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)[C@@H]([C@H](NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1)C)Cc1cc(C(=N)N)ccc1	O=C(OC)[C@@H]([C@H](NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1)C)Cc1cc(C(=N)N)ccc1
NCGC00091250-12	O=C(OC)[C@@H]1[C@@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3	4.9499998	Active	Alkaloid anitpsychotic	0.0	1	Reserpine	170465405.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	106.4287387469	O=C(OC)[C@@H]1[C@@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3	O=C(OC)[C@@H]1[C@@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3
NCGC00168786-02	O=C(OC)[C@@H]1[C@@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cccc3	4.9000001	Active	Synaptic vesicular amine transporter Inhibitor	0.0	1	Deserpidine	144206653.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	75.2486985513	O=C(OC)[C@@H]1[C@@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cccc3	O=C(OC)[C@@H]1[C@@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cccc3
NCGC00385920-01	O=C(OC)[C@@H]1[C@@H]2/C(=C\C)/CN3[C@H](C4=Nc5c(cccc5)[C@@]14CC3)C2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	(+)-strictamine	363680007.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)[C@@H]1[C@@H]2/C(=C\C)/CN3[C@H](C4=Nc5c(cccc5)[C@@]14CC3)C2	O=C(OC)[C@@H]1[C@@H]2/C(=C\C)/CN3[C@H](C4=Nc5c(cccc5)[C@@]14CC3)C2
NCGC00169009-02	O=C(OC)[C@@]1(C)C(=O)[C@@]2(C)C(=C)C[C@@]3(O)[C@@](C)(C(=O)C(O)=C4C(C)(C)C(=O)CC[C@]34C)[C@@H]2C(=O)O1		Inactive	<MOA Unknown> | Class: sesterterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169009-02	363676740.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)[C@@]1(C)C(=O)[C@@]2(C)C(=C)C[C@@]3(O)[C@@](C)(C(=O)C(O)=C4C(C)(C)C(=O)CC[C@]34C)[C@@H]2C(=O)O1	O=C(OC)[C@@]1(C)C(=O)[C@@]2(C)C(=C)C[C@@]3(O)[C@@](C)(C(=O)C(O)=C4C(C)(C)C(=O)CC[C@]34C)[C@@H]2C(=O)O1
NCGC00179741-03	O=C(OC)[C@@]1(C)C2[C@](C)(C3[C@@]4(CC(=C)[C@@H](C4)CC3)CC2)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Helianthus  | Family: N/A | Species: annuus		1	NCGC00179741-03	363676961.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)[C@@]1(C)C2[C@](C)(C3[C@@]4(CC(=C)[C@@H](C4)CC3)CC2)CCC1	O=C(OC)[C@@]1(C)C2[C@](C)(C3[C@@]4(CC(=C)[C@@H](C4)CC3)CC2)CCC1
NCGC00178090-03	O=C(OC)[C@@]1(C)C[C@H]2[C@@]3(C)[C@@](C)(C=4[C@](C)(C=5C(C(C)=C(O)C(=O)C=5)=CC=4)CC3)CC[C@@]2(C)CC1	5.9499998	Inactive		0.0	1	Pristimerin	406861848.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	5.0	-75.5924983828	O=C(OC)[C@@]1(C)C[C@H]2[C@@]3(C)[C@@](C)(C=4[C@](C)(C=5C(C(C)=C(O)C(=O)C=5)=CC=4)CC3)CC[C@@]2(C)CC1	O=C(OC)[C@@]1(C)C[C@H]2[C@@]3(C)[C@@](C)(C=4[C@](C)(C=5C(C(C)=C(O)C(=O)C=5)=CC=4)CC3)CC[C@@]2(C)CC1
NCGC00380426-01	O=C(OC)[C@@]1(C)[C@@H]2[C@](C)(C(=O)CC[C@H]3C(=O)C=C(C3O)CC2)CCC1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Elaeoselinum | Family: Apiaceae | Species: foetidum		1	NCGC00380426-01	363678577.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)[C@@]1(C)[C@@H]2[C@](C)(C(=O)CC[C@H]3C(=O)C=C(C3O)CC2)CCC1	O=C(OC)[C@@]1(C)[C@@H]2[C@](C)(C(=O)CC[C@H]3C(=O)C=C(C3O)CC2)CCC1
NCGC00179273-03	O=C(OC)[C@@]1(C)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@@H]1[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21		Inactive	Glucocorticoid receptor Agonist		1	Rimexolone	170464695.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)[C@@]1(C)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@@H]1[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21	O=C(OC)[C@@]1(C)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@@H]1[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21
NCGC00169858-03	O=C(OC)[C@@]1(Cc2cc(CC=C(C)C)c(O)cc2)C(c2ccc(O)cc2)=C(O)C(=O)O1		Inactive	<MOA Unknown> | Class: shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169858-03	363676901.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)[C@@]1(Cc2cc(CC=C(C)C)c(O)cc2)C(c2ccc(O)cc2)=C(O)C(=O)O1	O=C(OC)[C@@]1(Cc2cc(CC=C(C)C)c(O)cc2)C(c2ccc(O)cc2)=C(O)C(=O)O1
NCGC00371106-01	O=C(OC)[C@@]1([C@H](CN2CCC(O)(c3ccccc3)CC2)C1)c1ccc(C)cc1		Inactive	Sigma-1 receptor Agonist		1	(±)-PPCC oxalate	363678033.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)[C@@]1([C@H](CN2CCC(O)(c3ccccc3)CC2)C1)c1ccc(C)cc1	O=C(OC)[C@@]1([C@H](CN2CCC(O)(c3ccccc3)CC2)C1)c1ccc(C)cc1
NCGC00185772-01	O=C(OC)[C@@]1(c2c(OC)cc3N(C)[C@H]4[C@@](O)(C(=O)N)[C@H](O)[C@@]5(CC)[C@@H]6N(CC=C5)CC[C@]46c3c2)c2[nH]c3c(c2CC[N@@]2C[C@](O)(CC)C[C@H](C1)C2)cccc3		Inactive	Tubulin polymerization inhibitor		1	Vindesine sulfate salt	124896659.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0		S(=O)(=O)(O)O.O=C(OC)[C@@]1(c2c(OC)cc3N(C)[C@H]4[C@@](O)(C(=O)N)[C@H](O)[C@@]5(CC)[C@@H]6N(CC=C5)CC[C@]46c3c2)c2[nH]c3c(c2CC[N@@]2C[C@](O)(CC)C[C@H](C1)C2)cccc3	S(=O)(=O)(O)O.O=C(OC)[C@@]1(c2c(OC)cc3N(C)[C@H]4[C@@](O)(C(=O)N)[C@H](O)[C@@]5(CC)[C@@H]6N(CC=C5)CC[C@]46c3c2)c2[nH]c3c(c2CC[N@@]2C[C@](O)(CC)C[C@H](C1)C2)cccc3
NCGC00385182-01	O=C(OC)[C@@]12[C@H]3C(CC)=CC(C1)C[N@]3CCc1c3c([nH]c21)cccc3		Inactive	Vanilloid receptor Partial Agonist		1	NCGC00385182-01	363679582.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)[C@@]12[C@H]3C(CC)=CC(C1)C[N@]3CCc1c3c([nH]c21)cccc3	O=C(OC)[C@@]12[C@H]3C(CC)=CC(C1)C[N@]3CCc1c3c([nH]c21)cccc3
NCGC00380281-01	O=C(OC)[C@@]12c3c(O)c(O)c(C(C)C)cc3CCC1C(C)(C)CCC2		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Rosmarinus | Family: N/A | Species: officinalis		1	NCGC00380281-01	363678523.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	11.2604316519	O=C(OC)[C@@]12c3c(O)c(O)c(C(C)C)cc3CCC1C(C)(C)CCC2	O=C(OC)[C@@]12c3c(O)c(O)c(C(C)C)cc3CCC1C(C)(C)CCC2
NCGC00347533-02	O=C(OC)[C@H](O)[C@H]1C(C)(C)[C@H](OC(=O)C(C)C)[C@@]2(O)C(=O)[C@]1(C)C1[C@@]3(O[C@H]23)C2[C@](C)([C@H](c3cocc3)OC(=O)C2)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347533-02	363677617.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)[C@H](O)[C@H]1C(C)(C)[C@H](OC(=O)C(C)C)[C@@]2(O)C(=O)[C@]1(C)C1[C@@]3(O[C@H]23)C2[C@](C)([C@H](c3cocc3)OC(=O)C2)CC1	O=C(OC)[C@H](O)[C@H]1C(C)(C)[C@H](OC(=O)C(C)C)[C@@]2(O)C(=O)[C@]1(C)C1[C@@]3(O[C@H]23)C2[C@](C)([C@H](c3cocc3)OC(=O)C2)CC1
NCGC00347396-02	O=C(OC)[C@H](O)[C@H]1C(C)(C)[C@H](OC(=O)C)[C@@]2(O)C(=O)[C@]1(C)C1[C@@]3(O[C@H]23)C2[C@](C)([C@H](c3cocc3)OC(=O)C2)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347396-02	363677589.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)[C@H](O)[C@H]1C(C)(C)[C@H](OC(=O)C)[C@@]2(O)C(=O)[C@]1(C)C1[C@@]3(O[C@H]23)C2[C@](C)([C@H](c3cocc3)OC(=O)C2)CC1	O=C(OC)[C@H](O)[C@H]1C(C)(C)[C@H](OC(=O)C)[C@@]2(O)C(=O)[C@]1(C)C1[C@@]3(O[C@H]23)C2[C@](C)([C@H](c3cocc3)OC(=O)C2)CC1
NCGC00347608-02	O=C(OC)[C@H](O)[C@H]1C(C)(C)[C@H](OC(=O)CC)[C@@]2(O)C(=O)[C@]1(C)C1[C@@]3(O[C@H]23)C2[C@](C)([C@H](c3cocc3)OC(=O)C2)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347608-02	363677638.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)[C@H](O)[C@H]1C(C)(C)[C@H](OC(=O)CC)[C@@]2(O)C(=O)[C@]1(C)C1[C@@]3(O[C@H]23)C2[C@](C)([C@H](c3cocc3)OC(=O)C2)CC1	O=C(OC)[C@H](O)[C@H]1C(C)(C)[C@H](OC(=O)CC)[C@@]2(O)C(=O)[C@]1(C)C1[C@@]3(O[C@H]23)C2[C@](C)([C@H](c3cocc3)OC(=O)C2)CC1
NCGC00384661-01	O=C(OC)[C@H]1[C@@H](O)C(O)[C@@H]2C(C(=O)OC)=CO[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H]12		Inactive	<MOA Unknown> | Class: Iridoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384661-01	363679297.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)[C@H]1[C@@H](O)C(O)[C@@H]2C(C(=O)OC)=CO[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H]12	O=C(OC)[C@H]1[C@@H](O)C(O)[C@@H]2C(C(=O)OC)=CO[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H]12
NCGC00025018-10&NCGC00025018-11	O=C(OC)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c3c([nH]c12)cccc3		Inactive	alpha2-Adrenoceptor Antagonist		2	Yohimbine	170465467.0&363676536.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(OC)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c3c([nH]c12)cccc3	O=C(OC)[C@H]1[C@@H](O)CC[C@@H]2[C@@H]1C[C@@H]1N(C2)CCc2c3c([nH]c12)cccc3
NCGC00379062-01	O=C(OC)[C@H]1[C@@H](O)[C@]2(O)[C@@]([C@@H]1c1ccccc1)(c1ccc(OC)cc1)Oc1c2c(OC)cc(O[C@H]2[C@H](OC)OC[C@H]([C@@H](O)CO)O2)c1		Inactive			1	Episilvestrol	384569090.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)[C@H]1[C@@H](O)[C@]2(O)[C@@]([C@@H]1c1ccccc1)(c1ccc(OC)cc1)Oc1c2c(OC)cc(O[C@H]2[C@H](OC)OC[C@H]([C@@H](O)CO)O2)c1	O=C(OC)[C@H]1[C@@H](O)[C@]2(O)[C@@]([C@@H]1c1ccccc1)(c1ccc(OC)cc1)Oc1c2c(OC)cc(O[C@H]2[C@H](OC)OC[C@H]([C@@H](O)CO)O2)c1
NCGC00379005-02	O=C(OC)[C@H]1[C@@H](O)[C@]2(O)[C@@]([C@@H]1c1ccccc1)(c1ccc(OC)cc1)Oc1c2c(OC)cc(O[C@H]2[C@H](OC)OC[C@H]([C@H](O)CO)O2)c1		Inactive			1	Silvestrol	434146908.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	32.3146067439	O=C(OC)[C@H]1[C@@H](O)[C@]2(O)[C@@]([C@@H]1c1ccccc1)(c1ccc(OC)cc1)Oc1c2c(OC)cc(O[C@H]2[C@H](OC)OC[C@H]([C@H](O)CO)O2)c1	O=C(OC)[C@H]1[C@@H](O)[C@]2(O)[C@@]([C@@H]1c1ccccc1)(c1ccc(OC)cc1)Oc1c2c(OC)cc(O[C@H]2[C@H](OC)OC[C@H]([C@H](O)CO)O2)c1
NCGC00159467-03	O=C(OC)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@H]2N(C)[C@@H]1CC2		Inactive	Serotonin transporter Inhibitor		1	(-)-Cocaine hydrochloride	144206436.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@H]2N(C)[C@@H]1CC2.Cl	O=C(OC)[C@H]1[C@@H](OC(=O)c2ccccc2)C[C@H]2N(C)[C@@H]1CC2.Cl
NCGC00167503-02	O=C(OC)[C@H]1[C@@](O)(CC)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@@H](O[C@@H]4O[C@@H](C)C(=O)CC4)[C@@H](O)C3)[C@@H](N(C)C)C2)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc12		Inactive	DNA Topoisomerase II Inhibitor		1	Aclarubicin	174007366.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC)[C@H]1[C@@](O)(CC)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@@H](O[C@@H]4O[C@@H](C)C(=O)CC4)[C@@H](O)C3)[C@@H](N(C)C)C2)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc12	O=C(OC)[C@H]1[C@@](O)(CC)C[C@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@@H](O[C@@H]4O[C@@H](C)C(=O)CC4)[C@@H](O)C3)[C@@H](N(C)C)C2)c2c(O)c3C(=O)c4c(O)cccc4C(=O)c3cc12
NCGC00159559-03&NCGC00159559-10	O=C(OC)[C@H]1[C@H]2[C@H]3[C@@](C)([C@@]4(OC(=O)CC4)CC3)C[C@H]3O[C@@]23[C@]2(C)C(=CC(=O)CC2)C1		Inactive	Mineralocorticoid Receptor (MR) Antagonist		2	Eplerenone	170465283.0&384568188.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC)[C@H]1[C@H]2[C@H]3[C@@](C)([C@@]4(OC(=O)CC4)CC3)C[C@H]3O[C@@]23[C@]2(C)C(=CC(=O)CC2)C1	O=C(OC)[C@H]1[C@H]2[C@H]3[C@@](C)([C@@]4(OC(=O)CC4)CC3)C[C@H]3O[C@@]23[C@]2(C)C(=CC(=O)CC2)C1
NCGC00168799-03	O=C(OC)[C@]1(O)[C@@]2(C)[C@@H]([C@]3(C)[C@@H](C(=O)O[C@H](c4cocc4)C3)CC2)CC=C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00168799-03	363676685.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)[C@]1(O)[C@@]2(C)[C@@H]([C@]3(C)[C@@H](C(=O)O[C@H](c4cocc4)C3)CC2)CC=C1	O=C(OC)[C@]1(O)[C@@]2(C)[C@@H]([C@]3(C)[C@@H](C(=O)O[C@H](c4cocc4)C3)CC2)CC=C1
NCGC00185772-02	O=C(OC)[C@]1(c2c(OC)cc3N(C)C4[C@@](O)(C(=O)N)[C@H](O)[C@@]5(CC)[C@@H]6N(CC=C5)CC[C@@]46c3c2)c2[nH]c3c(c2CCN2C[C@@](O)(CC)CC(C1)C2)cccc3		Inactive	Tubulin polymerization inhibitor		1	Vindesine sulfate salt	439785997.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0		O=C(OC)[C@]1(c2c(OC)cc3N(C)C4[C@@](O)(C(=O)N)[C@H](O)[C@@]5(CC)[C@@H]6N(CC=C5)CC[C@@]46c3c2)c2[nH]c3c(c2CCN2C[C@@](O)(CC)CC(C1)C2)cccc3	O=C(OC)[C@]1(c2c(OC)cc3N(C)C4[C@@](O)(C(=O)N)[C@H](O)[C@@]5(CC)[C@@H]6N(CC=C5)CC[C@@]46c3c2)c2[nH]c3c(c2CCN2C[C@@](O)(CC)CC(C1)C2)cccc3
NCGC00381012-01	O=C(OC)[C@]12[C@@](C)(C(=O)OC(C)C1=O)C(=C)CC1[C@@]2(C)C(=O)C(O)=C2C(C)(C)C(=O)CC(O)[C@]12C		Inactive	<MOA Unknown> | Class: sesterterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381012-01	363678924.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)[C@]12[C@@](C)(C(=O)OC(C)C1=O)C(=C)CC1[C@@]2(C)C(=O)C(O)=C2C(C)(C)C(=O)CC(O)[C@]12C	O=C(OC)[C@]12[C@@](C)(C(=O)OC(C)C1=O)C(=C)CC1[C@@]2(C)C(=O)C(O)=C2C(C)(C)C(=O)CC(O)[C@]12C
NCGC00186460-03&NCGC00186460-07	O=C(OC)[C@]12[C@H]([C@H]3C(=O)C=C4[C@]5(C)[C@H](C(C)(C)C(=O)C(C#N)=C5)CC[C@@]4(C)[C@]3(C)CC1)CC(C)(C)CC2		Inactive	NF-kappaB signaling Inhibitor		2	Bardoxolone methyl	384568440.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O=C(OC)[C@]12[C@H]([C@H]3C(=O)C=C4[C@]5(C)[C@H](C(C)(C)C(=O)C(C#N)=C5)CC[C@@]4(C)[C@]3(C)CC1)CC(C)(C)CC2	O=C(OC)[C@]12[C@H]([C@H]3C(=O)C=C4[C@]5(C)[C@H](C(C)(C)C(=O)C(C#N)=C5)CC[C@@]4(C)[C@]3(C)CC1)CC(C)(C)CC2
NCGC00599701-01	O=C(OC)c1c(-c2c(C(=O)OC)cc(OC)c3OCOc23)c2OCOc2c(OC)c1		Inactive			1	BDD   BFD   DDB   alpha-DDB   Bifendate Biphenyldimethyldicarboxylate		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)c1c(-c2c(C(=O)OC)cc(OC)c3OCOc23)c2OCOc2c(OC)c1	O=C(OC)c1c(-c2c(C(=O)OC)cc(OC)c3OCOc23)c2OCOc2c(OC)c1
NCGC00408803-01	O=C(OC)c1c(-c2c(CO)cc(OC)c3OCOc23)c2OCOc2c(OC)c1		Inactive			1	Bicyclol	434147149.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)c1c(-c2c(CO)cc(OC)c3OCOc23)c2OCOc2c(OC)c1	O=C(OC)c1c(-c2c(CO)cc(OC)c3OCOc23)c2OCOc2c(OC)c1
NCGC00380975-01	O=C(OC)c1c(C(=O)c2c(O)c3c(OC4(C)C(O)CCC3O4)cc2OC)c(OC)cc(OC)c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380975-01	363678897.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)c1c(C(=O)c2c(O)c3c(OC4(C)C(O)CCC3O4)cc2OC)c(OC)cc(OC)c1	O=C(OC)c1c(C(=O)c2c(O)c3c(OC4(C)C(O)CCC3O4)cc2OC)c(OC)cc(OC)c1
NCGC00380783-01	O=C(OC)c1c(C(=O)c2c(O)c3c(OC4(C)OC3CCC4)cc2OC)c(OC)cc(OC)c1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380783-01	363678783.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)c1c(C(=O)c2c(O)c3c(OC4(C)OC3CCC4)cc2OC)c(OC)cc(OC)c1	O=C(OC)c1c(C(=O)c2c(O)c3c(OC4(C)OC3CCC4)cc2OC)c(OC)cc(OC)c1
NCGC00380876-01	O=C(OC)c1c(CC=C(C)C)c(OC2C(O)C(O)C(O)C(CO)O2)c2c(c1OC1C(O)C(O)C(O)C(CO)O1)cccc2		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Rubia | Family: Rubiaceae | Species: tinctoria		1	NCGC00380876-01	363678828.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)c1c(CC=C(C)C)c(OC2C(O)C(O)C(O)C(CO)O2)c2c(c1OC1C(O)C(O)C(O)C(CO)O1)cccc2	O=C(OC)c1c(CC=C(C)C)c(OC2C(O)C(O)C(O)C(CO)O2)c2c(c1OC1C(O)C(O)C(O)C(CO)O1)cccc2
NCGC00381073-01	O=C(OC)c1c(O)c([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(O)cc1CC/C=C\C=C/CCC		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381073-01	363678957.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)c1c(O)c([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(O)cc1CC/C=C\C=C/CCC	O=C(OC)c1c(O)c([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(O)cc1CC/C=C\C=C/CCC
NCGC00091106-05	O=C(OC)c1c(O)cccc1		Inactive			1	Methyl salicylate	225144206.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)c1c(O)cccc1	O=C(OC)c1c(O)cccc1
NCGC00381176-01	O=C(OC)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC(=O)c2c(OC)cc(OC)cc2C)cc1C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381176-01	363679006.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC(=O)c2c(OC)cc(OC)cc2C)cc1C	O=C(OC)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC(=O)c2c(OC)cc(OC)cc2C)cc1C
NCGC00385068-02	O=C(OC)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)O2)cc(OC)cc1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Primula | Family: Primulaceae | Species: veris		1	NCGC00385068-02	363679515.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)O2)cc(OC)cc1	O=C(OC)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)O2)cc(OC)cc1
NCGC00180731-02	O=C(OC)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)O2)cccc1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Primula | Family: Primulaceae | Species: veris		1	NCGC00180731-02	363677056.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)O2)cccc1	O=C(OC)c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)O2)cccc1
NCGC00380578-01	O=C(OC)c1c(O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380578-01	363678659.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)c1c(O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1	O=C(OC)c1c(O[C@H]2[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1
NCGC00160392-03	O=C(OC)c1c2nc3c(O)cc(O)c(C=O)c3nc2c(O)cc1		Inactive			1	LOMOFUGIN	124892264.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)c1c2nc3c(O)cc(O)c(C=O)c3nc2c(O)cc1	O=C(OC)c1c2nc3c(O)cc(O)c(C=O)c3nc2c(O)cc1
NCGC00485967-01	O=C(OC)c1cc(C(=O)N2CCN(C(=O)c3ccc(C(=N)N)cc3)CC2)cc(CN2CCN(C(=N)N)CC2)c1		Inactive	Lysine-specific histone demethylase 1A Inhibitor		1	CBB1007 (trihydrochloride)	363681450.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)c1cc(C(=O)N2CCN(C(=O)c3ccc(C(=N)N)cc3)CC2)cc(CN2CCN(C(=N)N)CC2)c1	O=C(OC)c1cc(C(=O)N2CCN(C(=O)c3ccc(C(=N)N)cc3)CC2)cc(CN2CCN(C(=N)N)CC2)c1
NCGC00247606-02	O=C(OC)c1cc(O)c(O)c(O)c1		Inactive			1	Methyl gallate	434147068.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)c1cc(O)c(O)c(O)c1	O=C(OC)c1cc(O)c(O)c(O)c1
NCGC00385007-02	O=C(OC)c1cc(OC)c(OC(C(O)c2cc(OC)c(O)cc2)CO)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385007-02	363679481.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)c1cc(OC)c(OC(C(O)c2cc(OC)c(O)cc2)CO)cc1	O=C(OC)c1cc(OC)c(OC(C(O)c2cc(OC)c(O)cc2)CO)cc1
NCGC00385741-01	O=C(OC)c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385741-01	363679915.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1	O=C(OC)c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1
NCGC00384861-01	O=C(OC)c1cc(OC)c(O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)c(OC)c1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384861-01	363679403.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)c1cc(OC)c(O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)c(OC)c1	O=C(OC)c1cc(OC)c(O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)c(OC)c1
NCGC00389579-02	O=C(OC)c1cc2[nH]c3ncnc(NCCCN4CCCCC4)c3c2cc1		Inactive	Hematopoietic Stem Cell Differentiation Agonist		1	UM729	363680806.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC)c1cc2[nH]c3ncnc(NCCCN4CCCCC4)c3c2cc1	O=C(OC)c1cc2[nH]c3ncnc(NCCCN4CCCCC4)c3c2cc1
NCGC00159376-04	O=C(OC)c1ccc(O)cc1		Inactive	canonical glycolysis Inhibitor		1	Methylparaben	170465480.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC)c1ccc(O)cc1	O=C(OC)c1ccc(O)cc1
NCGC00159479-05	O=C(OC)c1cnccc1		Inactive			1	Methyl nicotinate	170465506.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC)c1cnccc1	O=C(OC)c1cnccc1
NCGC00073457-04	O=C(OC)c1n(C(C)c2ccccc2)cnc1		Inactive	Cytochrome P450 2A5 Inhibitor		1	Metomidate hydrochloride	170466159.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC)c1n(C(C)c2ccccc2)cnc1.Cl	O=C(OC)c1n(C(C)c2ccccc2)cnc1.Cl
NCGC00385440-01	O=C(OC/C(/C(=O)O[C@H]1[C@H]2C(=C)C(=O)O[C@H]2/C=C(/C)\[C@@H](OC(=O)C)C/C=C(\C)/C1)=C\C)/C(=C/C)/CO		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Liatris  | Family: N/A | Species: cylindracea		1	NCGC00385440-01	363679741.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC/C(/C(=O)O[C@H]1[C@H]2C(=C)C(=O)O[C@H]2/C=C(/C)\[C@@H](OC(=O)C)C/C=C(\C)/C1)=C\C)/C(=C/C)/CO	O=C(OC/C(/C(=O)O[C@H]1[C@H]2C(=C)C(=O)O[C@H]2/C=C(/C)\[C@@H](OC(=O)C)C/C=C(\C)/C1)=C\C)/C(=C/C)/CO
NCGC00347515-02	O=C(OC/C(=C\CCC(O)(C=C)C)/C)C(C)C1OC(C=C)(C)CC1		Inactive	<MOA Unknown> | Class: Monoterpen | Genus: Polygonatum | Family: Liliaceae | Species: kingianum		1	NCGC00347515-02	363677610.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC/C(=C\CCC(O)(C=C)C)/C)C(C)C1OC(C=C)(C)CC1	O=C(OC/C(=C\CCC(O)(C=C)C)/C)C(C)C1OC(C=C)(C)CC1
NCGC00384504-01	O=C(OC/C/1=C\[C@H]2OC(=O)C(=C)[C@@H]2CC/C(/CO)=C/CC\1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384504-01	363679218.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC/C/1=C\[C@H]2OC(=O)C(=C)[C@@H]2CC/C(/CO)=C/CC\1)C	O=C(OC/C/1=C\[C@H]2OC(=O)C(=C)[C@@H]2CC/C(/CO)=C/CC\1)C
NCGC00095056-04	O=C(OC/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C)CCCCCCCCCCCCCCC		Inactive			1	Retinyl palmitate	225144218.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OC/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C)CCCCCCCCCCCCCCC	O=C(OC/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C)CCCCCCCCCCCCCCC
NCGC00182546-02	O=C(OC/C=C(/CC/C=C(\C)/C)\C)CC/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C		Inactive	positive regulation of mucus secretion Interacts		1	Gefarnate	170465908.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC/C=C(/CC/C=C(\C)/C)\C)CC/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C	O=C(OC/C=C(/CC/C=C(\C)/C)\C)CC/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C
NCGC00384582-01	O=C(OC/C=C(\CCC1C(=C)C(OC2C(O)C(O)C(O)C(CO)O2)CC2C(C)(C)C(O)CCC12C)/C)CC(=O)O		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384582-01	363679258.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC/C=C(\CCC1C(=C)C(OC2C(O)C(O)C(O)C(CO)O2)CC2C(C)(C)C(O)CCC12C)/C)CC(=O)O	O=C(OC/C=C(\CCC1C(=C)C(OC2C(O)C(O)C(O)C(CO)O2)CC2C(C)(C)C(O)CCC12C)/C)CC(=O)O
NCGC00386046-01	O=C(OC/C=C/c1ccc(OC)cc1)/C(=C\C)/COC(=O)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Shikimi | Genus: bupleurum | Family: Umbelliferae | Species: fruticosum		1	NCGC00386046-01	363680079.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC/C=C/c1ccc(OC)cc1)/C(=C\C)/COC(=O)/C(=C/C)/C	O=C(OC/C=C/c1ccc(OC)cc1)/C(=C\C)/COC(=O)/C(=C/C)/C
NCGC00384709-01	O=C(OC/C=C\1/C(CC(=O)OCCc2ccc(O)cc2)C(C(=O)OC)=COC/1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384709-01	363679321.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC/C=C\1/C(CC(=O)OCCc2ccc(O)cc2)C(C(=O)OC)=COC/1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C/c1ccccc1	O=C(OC/C=C\1/C(CC(=O)OCCc2ccc(O)cc2)C(C(=O)OC)=COC/1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C/c1ccccc1
NCGC00385015-01	O=C(OC/C=C\1/[C@H](CC(=O)OC)C(C(=O)O)=CO[C@H]/1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C/c1cc(OC)c(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385015-01	363679486.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC/C=C\1/[C@H](CC(=O)OC)C(C(=O)O)=CO[C@H]/1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C/c1cc(OC)c(O)cc1	O=C(OC/C=C\1/[C@H](CC(=O)OC)C(C(=O)O)=CO[C@H]/1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C/c1cc(OC)c(O)cc1
NCGC00380467-01	O=C(OC/C=C\1/[C@H](CC(=O)OC)C(C(=O)O)=CO[C@H]/1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C\c1ccccc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380467-01	363678598.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC/C=C\1/[C@H](CC(=O)OC)C(C(=O)O)=CO[C@H]/1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C\c1ccccc1	O=C(OC/C=C\1/[C@H](CC(=O)OC)C(C(=O)O)=CO[C@H]/1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C\c1ccccc1
NCGC00381437-01	O=C(OC1(C)C(=O)C2=C(C=C(/C=C/C)OC2)CC1O)c1c(OC)cc(O)cc1C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381437-01	363679143.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1(C)C(=O)C2=C(C=C(/C=C/C)OC2)CC1O)c1c(OC)cc(O)cc1C	O=C(OC1(C)C(=O)C2=C(C=C(/C=C/C)OC2)CC1O)c1c(OC)cc(O)cc1C
NCGC00380627-01	O=C(OC1(C)C(=O)C2=C(C=C(CCC)OC2)CC1O)c1c(O)cc(OC)cc1C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380627-01	363678680.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1(C)C(=O)C2=C(C=C(CCC)OC2)CC1O)c1c(O)cc(OC)cc1C	O=C(OC1(C)C(=O)C2=C(C=C(CCC)OC2)CC1O)c1c(O)cc(OC)cc1C
NCGC00380886-01	O=C(OC1(C)C2C(OC3C(O)C(O)C(O)C(CO)O3)OC=C(C(=O)O)C2CC1)/C(=C/CCC(CCO)C)/C		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Vitex | Family: Verbenaceae | Species: negundo		1	NCGC00380886-01	363678833.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1(C)C2C(OC3C(O)C(O)C(O)C(CO)O3)OC=C(C(=O)O)C2CC1)/C(=C/CCC(CCO)C)/C	O=C(OC1(C)C2C(OC3C(O)C(O)C(O)C(CO)O3)OC=C(C(=O)O)C2CC1)/C(=C/CCC(CCO)C)/C
NCGC00381419-01	O=C(OC1(CC(C(=O)OC)N2C(=O)c3c(N=C2)cccc3)c2c(N3C(=O)C(C)(C)N(O)C13)cccc2)C(C)C		Inactive	<MOA Unknown> | Class: alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381419-01	363679135.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1(CC(C(=O)OC)N2C(=O)c3c(N=C2)cccc3)c2c(N3C(=O)C(C)(C)N(O)C13)cccc2)C(C)C	O=C(OC1(CC(C(=O)OC)N2C(=O)c3c(N=C2)cccc3)c2c(N3C(=O)C(C)(C)N(O)C13)cccc2)C(C)C
NCGC00380913-01	O=C(OC1(CCCCC2OC(=O)CC2)C(C/C=C\CC)C(=O)C=C1)C		Inactive	<MOA Unknown> | Class: Fatty acid | Genus: Vitex | Family: Verbenaceae | Species: strikeri		1	NCGC00380913-01	363678850.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1(CCCCC2OC(=O)CC2)C(C/C=C\CC)C(=O)C=C1)C	O=C(OC1(CCCCC2OC(=O)CC2)C(C/C=C\CC)C(=O)C=C1)C
NCGC00387832-02	O=C(OC1/C(/C)=C/C(C)C(O)C(OC)CC(C)CC=2C(=O)C(NC(=O)/C(/C)=C/C=C/C1OC)=CC(=O)C=2NCC=C)N		Inactive	Heat Shock Protein 90 (hsp90) Inhibitor		1	17-AAG (KOS953)	384569164.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1/C(/C)=C/C(C)C(O)C(OC)CC(C)CC=2C(=O)C(NC(=O)/C(/C)=C/C=C/C1OC)=CC(=O)C=2NCC=C)N	O=C(OC1/C(/C)=C/C(C)C(O)C(OC)CC(C)CC=2C(=O)C(NC(=O)/C(/C)=C/C=C/C1OC)=CC(=O)C=2NCC=C)N
NCGC00380976-01	O=C(OC1/C(/C)=C/C(C)C(O)C(OC)CC(C)Cc2cc(O)cc(NC(=O)/C(/C)=C/CCC1OC)c2)N		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380976-01	363678898.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1/C(/C)=C/C(C)C(O)C(OC)CC(C)Cc2cc(O)cc(NC(=O)/C(/C)=C/CCC1OC)c2)N	O=C(OC1/C(/C)=C/C(C)C(O)C(OC)CC(C)Cc2cc(O)cc(NC(=O)/C(/C)=C/CCC1OC)c2)N
NCGC00381208-01	O=C(OC1/C(/C)=C\C(=O)/C=C(\C)/C[C@H](O)[C@H]2C(=C)C(=O)O[C@H]12)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Vicoa | Family: Compositae | Species: indica		1	NCGC00381208-01	363679023.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1/C(/C)=C\C(=O)/C=C(\C)/C[C@H](O)[C@H]2C(=C)C(=O)O[C@H]12)/C(=C\C)/C	O=C(OC1/C(/C)=C\C(=O)/C=C(\C)/C[C@H](O)[C@H]2C(=C)C(=O)O[C@H]12)/C(=C\C)/C
NCGC00385813-01	O=C(OC1/C(=C/CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)/C(C(=O)O)=C(C)C1)/C=C/c1cc(OC)c(O)cc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385813-01	363679953.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1/C(=C/CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)/C(C(=O)O)=C(C)C1)/C=C/c1cc(OC)c(O)cc1	O=C(OC1/C(=C/CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)/C(C(=O)O)=C(C)C1)/C=C/c1cc(OC)c(O)cc1
NCGC00385076-01	O=C(OC1/C(=C/CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)/C(C(=O)O)=C(C)C1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385076-01	363679519.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1/C(=C/CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)/C(C(=O)O)=C(C)C1)/C=C/c1ccc(O)cc1	O=C(OC1/C(=C/CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)/C(C(=O)O)=C(C)C1)/C=C/c1ccc(O)cc1
NCGC00385572-01	O=C(OC1/C(=C/CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)/C(C(=O)O)=C(C)C1)/C=C\c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385572-01	363679815.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1/C(=C/CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)/C(C(=O)O)=C(C)C1)/C=C\c1ccc(O)cc1	O=C(OC1/C(=C/CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)/C(C(=O)O)=C(C)C1)/C=C\c1ccc(O)cc1
NCGC00381206-01	O=C(OC1/C(=C\C[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@@]23C)/C(=O)OC1)/C(/C(O)C[C@@H]1C(=C)CC[C@@H]2[C@@](CO)(C)[C@H](O)CC[C@@]12C)=C/CO		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Andrographis | Family: Acanthaceae | Species: paniculata		1	NCGC00381206-01	363679021.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1/C(=C\C[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@@]23C)/C(=O)OC1)/C(/C(O)C[C@@H]1C(=C)CC[C@@H]2[C@@](CO)(C)[C@H](O)CC[C@@]12C)=C/CO	O=C(OC1/C(=C\C[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@@]23C)/C(=O)OC1)/C(/C(O)C[C@@H]1C(=C)CC[C@@H]2[C@@](CO)(C)[C@H](O)CC[C@@]12C)=C/CO
NCGC00380865-01	O=C(OC12C(=O)/C(/C)=C/C3C(C)(C)C3CC/C(/COC3C(O)C(O)C(O)C(CO)O3)=C\C1C(O)C(C)C2)C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Euphorbia | Family: Euphorbiaceae | Species: guyoniana		1	NCGC00380865-01	363678821.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC12C(=O)/C(/C)=C/C3C(C)(C)C3CC/C(/COC3C(O)C(O)C(O)C(CO)O3)=C\C1C(O)C(C)C2)C	O=C(OC12C(=O)/C(/C)=C/C3C(C)(C)C3CC/C(/COC3C(O)C(O)C(O)C(CO)O3)=C\C1C(O)C(C)C2)C
NCGC00385653-01	O=C(OC12C(=O)C(C)/C=C/C(C)(C)C(=O)CC(OC(=O)c3ccccc3)/C(/C)=C\C1C(OC(=O)c1ccccc1)C(C)C2)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385653-01	363679858.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	17.0	O=C(OC12C(=O)C(C)/C=C/C(C)(C)C(=O)CC(OC(=O)c3ccccc3)/C(/C)=C\C1C(OC(=O)c1ccccc1)C(C)C2)C	O=C(OC12C(=O)C(C)/C=C/C(C)(C)C(=O)CC(OC(=O)c3ccccc3)/C(/C)=C\C1C(OC(=O)c1ccccc1)C(C)C2)C
NCGC00381019-01	O=C(OC12C(=O)C(C)/C=C/C(C)(C)C(OC(=O)C)C(=O)/C=C(\C)/C(OC(=O)C)C1C(OC(=O)c1ccccc1)C(C)C2)C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Euphorbia | Family: Euphorbiaceae | Species: sp.		1	NCGC00381019-01	363678927.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC12C(=O)C(C)/C=C/C(C)(C)C(OC(=O)C)C(=O)/C=C(\C)/C(OC(=O)C)C1C(OC(=O)c1ccccc1)C(C)C2)C	O=C(OC12C(=O)C(C)/C=C/C(C)(C)C(OC(=O)C)C(=O)/C=C(\C)/C(OC(=O)C)C1C(OC(=O)c1ccccc1)C(C)C2)C
NCGC00385123-01	O=C(OC12C(C)(C)C1C1C(O)(C(C)C2O)C2C=C(C)C(=O)C2CC(CO)=C1)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385123-01	363679549.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC12C(C)(C)C1C1C(O)(C(C)C2O)C2C=C(C)C(=O)C2CC(CO)=C1)C	O=C(OC12C(C)(C)C1C1C(O)(C(C)C2O)C2C=C(C)C(=O)C2CC(CO)=C1)C
NCGC00385607-01	O=C(OC12C(C)(C)C1C1C(O)(C(C)C2OC(=O)C(C)C)C2C(O)(C(=O)C(C)=C2)CC(CO)=C1)C(CC)CC		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385607-01	363679835.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	12.0	O=C(OC12C(C)(C)C1C1C(O)(C(C)C2OC(=O)C(C)C)C2C(O)(C(=O)C(C)=C2)CC(CO)=C1)C(CC)CC	O=C(OC12C(C)(C)C1C1C(O)(C(C)C2OC(=O)C(C)C)C2C(O)(C(=O)C(C)=C2)CC(CO)=C1)C(CC)CC
NCGC00380715-01	O=C(OC12C(C)(C)C1C1C(O)(C(C)C2OC(=O)C)C2C(O)(C(=O)C(C)=C2)CC(CO)=C1)C(CC)C	5.4499998	Active	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00380715-01	363678732.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	2.2	70.325686752	O=C(OC12C(C)(C)C1C1C(O)(C(C)C2OC(=O)C)C2C(O)(C(=O)C(C)=C2)CC(CO)=C1)C(CC)C	O=C(OC12C(C)(C)C1C1C(O)(C(C)C2OC(=O)C)C2C(O)(C(=O)C(C)=C2)CC(CO)=C1)C(CC)C
NCGC00385757-01	O=C(OC12C(OC(=O)C)C(C)/C=C/C(C)(C)C(OC(=O)C)C(OC(=O)C)C(O)/C(/C)=C\C1C(OC(=O)c1ccccc1)C(C)C2)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385757-01	363679927.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC12C(OC(=O)C)C(C)/C=C/C(C)(C)C(OC(=O)C)C(OC(=O)C)C(O)/C(/C)=C\C1C(OC(=O)c1ccccc1)C(C)C2)C	O=C(OC12C(OC(=O)C)C(C)/C=C/C(C)(C)C(OC(=O)C)C(OC(=O)C)C(O)/C(/C)=C\C1C(OC(=O)c1ccccc1)C(C)C2)C
NCGC00380095-01	O=C(OC1C(=C)C(=O)CC2C(C)(O2)CC2OC(=O)C(=C)C2C1O)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Vicoa | Family: Compositae | Species: indica		1	NCGC00380095-01	363678459.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(=C)C(=O)CC2C(C)(O2)CC2OC(=O)C(=C)C2C1O)/C(=C\C)/C	O=C(OC1C(=C)C(=O)CC2C(C)(O2)CC2OC(=O)C(=C)C2C1O)/C(=C\C)/C
NCGC00384851-01	O=C(OC1C(=C)C2C(C)(CC1)CCC(C(O)(C)C)C2)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384851-01	363679396.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	9.3514412441	O=C(OC1C(=C)C2C(C)(CC1)CCC(C(O)(C)C)C2)C	O=C(OC1C(=C)C2C(C)(CC1)CCC(C(O)(C)C)C2)C
NCGC00384840-01	O=C(OC1C(=C)C2C(C)(CC3(O)OC(=O)C(C)=C3C2)CC1)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384840-01	363679387.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(=C)C2C(C)(CC3(O)OC(=O)C(C)=C3C2)CC1)C	O=C(OC1C(=C)C2C(C)(CC3(O)OC(=O)C(C)=C3C2)CC1)C
NCGC00385918-01	O=C(OC1C(=C)C2C(C)(CC3(OC)OC(=O)C(C)=C3C2)CC1)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385918-01	363680005.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(=C)C2C(C)(CC3(OC)OC(=O)C(C)=C3C2)CC1)C	O=C(OC1C(=C)C2C(C)(CC3(OC)OC(=O)C(C)=C3C2)CC1)C
NCGC00385219-01	O=C(OC1C(=C)C2C3OC(=O)C(=C)C3CCC(=C)C2C1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385219-01	363679599.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(=C)C2C3OC(=O)C(=C)C3CCC(=C)C2C1)C	O=C(OC1C(=C)C2C3OC(=O)C(=C)C3CCC(=C)C2C1)C
NCGC00381057-01	O=C(OC1C(=C)CC(=O)C2C(C)(O2)CC2OC(=O)C(=C)C2C1O)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: N/A | Genus: Vicoa | Family: Compositae | Species: indica		1	NCGC00381057-01	363678949.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(=C)CC(=O)C2C(C)(O2)CC2OC(=O)C(=C)C2C1O)/C(=C\C)/C	O=C(OC1C(=C)CC(=O)C2C(C)(O2)CC2OC(=O)C(=C)C2C1O)/C(=C\C)/C
NCGC00381205-01	O=C(OC1C(=C)[C@@H]2C(OC(=O)C)[C@@]31C([C@@]1(C)C([C@@](C(=O)O)(C)CCC1)CC3)CC2)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Elaeoselinum | Family: Apiaceae | Species: foetidum		1	NCGC00381205-01	363679020.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(=C)[C@@H]2C(OC(=O)C)[C@@]31C([C@@]1(C)C([C@@](C(=O)O)(C)CCC1)CC3)CC2)/C(=C\C)/C	O=C(OC1C(=C)[C@@H]2C(OC(=O)C)[C@@]31C([C@@]1(C)C([C@@](C(=O)O)(C)CCC1)CC3)CC2)/C(=C\C)/C
NCGC00385676-01	O=C(OC1C(=C)[C@@H]2C[C@@]31[C@](O)([C@@]1(C)C([C@@](C(=O)O)(C)CCC1)CC3)CC2)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385676-01	363679869.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(=C)[C@@H]2C[C@@]31[C@](O)([C@@]1(C)C([C@@](C(=O)O)(C)CCC1)CC3)CC2)C	O=C(OC1C(=C)[C@@H]2C[C@@]31[C@](O)([C@@]1(C)C([C@@](C(=O)O)(C)CCC1)CC3)CC2)C
NCGC00381331-01	O=C(OC1C(=O)C(CO)=CC(O)C1C(C)C)CC(CC)C	4.9000001	Active	<MOA Unknown> | Class: Monoterpen | Genus: Borreria | Family: N/A | Species: verticillata	0.0	1	NCGC00381331-01	363679092.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	3.0	42.8562143221	O=C(OC1C(=O)C(CO)=CC(O)C1C(C)C)CC(CC)C	O=C(OC1C(=O)C(CO)=CC(O)C1C(C)C)CC(CC)C
NCGC00380593-01	O=C(OC1C(=O)OC(CCC)C(O)C(O)/C=C/CC1)/C=C/C=C/C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: Phoma | Family: N/A | Species: sp.		1	NCGC00380593-01	363678664.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(=O)OC(CCC)C(O)C(O)/C=C/CC1)/C=C/C=C/C	O=C(OC1C(=O)OC(CCC)C(O)C(O)/C=C/CC1)/C=C/C=C/C
NCGC00274274-01	O=C(OC1C(C(=O)N(CC)CC)CN2C(c3c(cc(OC)c(OC)c3)CC2)C1)C		Inactive	Dopamine D2 receptor Modulator		1	Benzquinamide	170465138.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC1C(C(=O)N(CC)CC)CN2C(c3c(cc(OC)c(OC)c3)CC2)C1)C	O=C(OC1C(C(=O)N(CC)CC)CN2C(c3c(cc(OC)c(OC)c3)CC2)C1)C
NCGC00385700-01	O=C(OC1C(C(=O)O)(C)C2C(C)(C3C(C)(C4(C)C(C5C(C)(CC4)CCC(C)(C)C5)=CC3)CC2)CC1)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385700-01	363679883.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C(=O)O)(C)C2C(C)(C3C(C)(C4(C)C(C5C(C)(CC4)CCC(C)(C)C5)=CC3)CC2)CC1)C	O=C(OC1C(C(=O)O)(C)C2C(C)(C3C(C)(C4(C)C(C5C(C)(CC4)CCC(C)(C)C5)=CC3)CC2)CC1)C
NCGC00380793-01	O=C(OC1C(C(=O)O)(C)C2C(C)(C3C(C)(C4(C)C(C5C(C)(CC4)CCC(C)C5C)=CC3)CC2)CC1)C		Inactive	Inhibitor of nuclear factor kappa B kinase beta subunit Inhibitor		1	NCGC00380793-01	363678784.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C(=O)O)(C)C2C(C)(C3C(C)(C4(C)C(C5C(C)(CC4)CCC(C)C5C)=CC3)CC2)CC1)C	O=C(OC1C(C(=O)O)(C)C2C(C)(C3C(C)(C4(C)C(C5C(C)(CC4)CCC(C)C5C)=CC3)CC2)CC1)C
NCGC00381245-01	O=C(OC1C(C(C(=O)O)=C)C(O)C(C(CO)=C)C(C=C)(C)C1)/C(=C\COC(=O)C)/C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381245-01	363679048.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C(C(=O)O)=C)C(O)C(C(CO)=C)C(C=C)(C)C1)/C(=C\COC(=O)C)/C	O=C(OC1C(C(C(=O)O)=C)C(O)C(C(CO)=C)C(C=C)(C)C1)/C(=C\COC(=O)C)/C
NCGC00385107-01	O=C(OC1C(C(C(=O)OC)=C)C(O)C(C(CO)=C)C(C=C)(C)C1)C(C(O)COC(=O)C)=C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385107-01	363679539.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C(C(=O)OC)=C)C(O)C(C(CO)=C)C(C=C)(C)C1)C(C(O)COC(=O)C)=C	O=C(OC1C(C(C(=O)OC)=C)C(O)C(C(CO)=C)C(C=C)(C)C1)C(C(O)COC(=O)C)=C
NCGC00381316-01	O=C(OC1C(C(C)C)C(O)C2C(C)(O2)CCC2C(C)(O2)C1)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Echinacea | Family: Asteraceae | Species: angustifolia		1	NCGC00381316-01	363679083.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C(C)C)C(O)C2C(C)(O2)CCC2C(C)(O2)C1)/C=C/c1ccccc1	O=C(OC1C(C(C)C)C(O)C2C(C)(O2)CCC2C(C)(O2)C1)/C=C/c1ccccc1
NCGC00159361-06	O=C(OC1C(C(C)C)CCC(C)C1)c1c(N)cccc1		Inactive			1	Menthyl Anthranilate	405559000.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	21.76007326	O=C(OC1C(C(C)C)CCC(C)C1)c1c(N)cccc1	O=C(OC1C(C(C)C)CCC(C)C1)c1c(N)cccc1
NCGC00181042-02	O=C(OC1C(C(C)C)CCC(C)C1)c1c(O)cccc1		Inactive			1	Menthyl salicylate	225144318.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OC1C(C(C)C)CCC(C)C1)c1c(O)cccc1	O=C(OC1C(C(C)C)CCC(C)C1)c1c(O)cccc1
NCGC00380759-01	O=C(OC1C(C(CCCOC(=O)C)C)=C(C)CC2OC(=O)C(=C)C12)CC(CC)C	5.4499998	Active	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00380759-01	363678764.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	3.0	44.0983354419	O=C(OC1C(C(CCCOC(=O)C)C)=C(C)CC2OC(=O)C(=C)C12)CC(CC)C	O=C(OC1C(C(CCCOC(=O)C)C)=C(C)CC2OC(=O)C(=C)C12)CC(CC)C
NCGC00381230-01	O=C(OC1C(C)(C)C(C(OC(=O)C)C(=O)OC)C2(C)C(=O)C1(O)CC1=C3C(C)(C(c4cocc4)OC(=O)C3)CCC21)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Walsura | Family: Meliaceae | Species: trijuga		1	NCGC00381230-01	363679038.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C)(C)C(C(OC(=O)C)C(=O)OC)C2(C)C(=O)C1(O)CC1=C3C(C)(C(c4cocc4)OC(=O)C3)CCC21)/C(=C/C)/C	O=C(OC1C(C)(C)C(C(OC(=O)C)C(=O)OC)C2(C)C(=O)C1(O)CC1=C3C(C)(C(c4cocc4)OC(=O)C3)CCC21)/C(=C/C)/C
NCGC00381063-01	O=C(OC1C(C)(C)C2C(C)(C(=O)C1)C1C(C)(OC=3OC(C)CC(=O)C=3C1)CC2)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381063-01	363678953.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C)(C)C2C(C)(C(=O)C1)C1C(C)(OC=3OC(C)CC(=O)C=3C1)CC2)C	O=C(OC1C(C)(C)C2C(C)(C(=O)C1)C1C(C)(OC=3OC(C)CC(=O)C=3C1)CC2)C
NCGC00381443-01	O=C(OC1C(C)(C)C2C(C)(C(O)C1)C1C(C)(C(OC(=O)C)C2)C23C(C)(C(c4cocc4)C(=O)C2O3)CC1)C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: trichilia | Family: Meliaceae | Species: americana		1	NCGC00381443-01	363679146.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C)(C)C2C(C)(C(O)C1)C1C(C)(C(OC(=O)C)C2)C23C(C)(C(c4cocc4)C(=O)C2O3)CC1)C	O=C(OC1C(C)(C)C2C(C)(C(O)C1)C1C(C)(C(OC(=O)C)C2)C23C(C)(C(c4cocc4)C(=O)C2O3)CC1)C
NCGC00380762-01	O=C(OC1C(C)(C)C2C(C)(C3(C(C)CC2)Oc2c(C=O)c(CO)cc(O)c2C3)CC1O)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380762-01	363678767.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C)(C)C2C(C)(C3(C(C)CC2)Oc2c(C=O)c(CO)cc(O)c2C3)CC1O)C	O=C(OC1C(C)(C)C2C(C)(C3(C(C)CC2)Oc2c(C=O)c(CO)cc(O)c2C3)CC1O)C
NCGC00385693-01	O=C(OC1C(C)(C)C2C(C)(C3C(C)(C4(C)C(C(OC(=O)C)C3)C(C3(C)OC(=O)CC3)CC4)CC2)CC1)CC(=O)O		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385693-01	363679878.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C)(C)C2C(C)(C3C(C)(C4(C)C(C(OC(=O)C)C3)C(C3(C)OC(=O)CC3)CC4)CC2)CC1)CC(=O)O	O=C(OC1C(C)(C)C2C(C)(C3C(C)(C4(C)C(C(OC(=O)C)C3)C(C3(C)OC(=O)CC3)CC4)CC2)CC1)CC(=O)O
NCGC00380769-01	O=C(OC1C(C)(C)C2C(C)(C3C(C)(C4(C)C(C5C(C(=O)O)(CC4)CCC(C)C5C)=CC3)CC2)CC1)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380769-01	363678772.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C)(C)C2C(C)(C3C(C)(C4(C)C(C5C(C(=O)O)(CC4)CCC(C)C5C)=CC3)CC2)CC1)/C=C/c1ccccc1	O=C(OC1C(C)(C)C2C(C)(C3C(C)(C4(C)C(C5C(C(=O)O)(CC4)CCC(C)C5C)=CC3)CC2)CC1)/C=C/c1ccccc1
NCGC00179932-02	O=C(OC1C(C)(C)C2C(C)(C3C(C)(C4(C)C(C5C(C(=O)OC)(CC4)CCC(C)C5C)=CC3)CC2)CC1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Prunella | Family: N/A | Species: vulgaris		1	NCGC00179932-02	363676991.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C)(C)C2C(C)(C3C(C)(C4(C)C(C5C(C(=O)OC)(CC4)CCC(C)C5C)=CC3)CC2)CC1)C	O=C(OC1C(C)(C)C2C(C)(C3C(C)(C4(C)C(C5C(C(=O)OC)(CC4)CCC(C)C5C)=CC3)CC2)CC1)C
NCGC00380920-01	O=C(OC1C(C)(C)C2C(C)(C3C(C)(C4(C)C(C5C(O)(C)C6(CO[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)OC(=O)C5(C(O)C4)CC6)=CC3)CC2)CC1O)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380920-01	363678856.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C)(C)C2C(C)(C3C(C)(C4(C)C(C5C(O)(C)C6(CO[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)OC(=O)C5(C(O)C4)CC6)=CC3)CC2)CC1O)C	O=C(OC1C(C)(C)C2C(C)(C3C(C)(C4(C)C(C5C(O)(C)C6(CO[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)OC(=O)C5(C(O)C4)CC6)=CC3)CC2)CC1O)C
NCGC00384939-01	O=C(OC1C(C)(C)C2C(C=O)(C3C(C)(C4(C(=O)OC)C(=O)C(O)(C)C(=O)C4(C)C(C)=C3)CC2)CC1)C		Inactive	<MOA Unknown> | Class: sesterterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384939-01	363679449.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C)(C)C2C(C=O)(C3C(C)(C4(C(=O)OC)C(=O)C(O)(C)C(=O)C4(C)C(C)=C3)CC2)CC1)C	O=C(OC1C(C)(C)C2C(C=O)(C3C(C)(C4(C(=O)OC)C(=O)C(O)(C)C(=O)C4(C)C(C)=C3)CC2)CC1)C
NCGC00385730-01	O=C(OC1C(C)(C)CC2C(C(=O)O)(C1)CCC1(C)C3(C)C(C4(C)C(C(C)(C)C(OC5C(OC6C(OC7C(O)C(O)C(O)CO7)C(O)C(O)C(CO)O6)C(OC6C(O)C(O)C(O)CO6)C(O)C(COC6C(O)C(O)C(O)CO6)O5)CC4)CC3)CC=C21)/C(=C/CCC(O)(C=C)C)/C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385730-01	363679905.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C)(C)CC2C(C(=O)O)(C1)CCC1(C)C3(C)C(C4(C)C(C(C)(C)C(OC5C(OC6C(OC7C(O)C(O)C(O)CO7)C(O)C(O)C(CO)O6)C(OC6C(O)C(O)C(O)CO6)C(O)C(COC6C(O)C(O)C(O)CO6)O5)CC4)CC3)CC=C21)/C(=C/CCC(O)(C=C)C)/C	O=C(OC1C(C)(C)CC2C(C(=O)O)(C1)CCC1(C)C3(C)C(C4(C)C(C(C)(C)C(OC5C(OC6C(OC7C(O)C(O)C(O)CO7)C(O)C(O)C(CO)O6)C(OC6C(O)C(O)C(O)CO6)C(O)C(COC6C(O)C(O)C(O)CO6)O5)CC4)CC3)CC=C21)/C(=C/CCC(O)(C=C)C)/C
NCGC00384533-01	O=C(OC1C(C)(C)CC2C3(C1OC(=O)C)C(O)OC12C(C)(C2(C)C(C4(C)C(C(C)(C)C(OC5C(OC6C(O)C(O)C(O)C(CO)O6)C(OC6C(OC7C(OC8C(O)C(O)C(O)CO8)C(O)C(O)C(C)O7)C(O)C(O)C(CO)O6)C(O)C(C(=O)O)O5)CC4)CC2)CC1)CC3OC(=O)C)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384533-01	363679235.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C)(C)CC2C3(C1OC(=O)C)C(O)OC12C(C)(C2(C)C(C4(C)C(C(C)(C)C(OC5C(OC6C(O)C(O)C(O)C(CO)O6)C(OC6C(OC7C(OC8C(O)C(O)C(O)CO8)C(O)C(O)C(C)O7)C(O)C(O)C(CO)O6)C(O)C(C(=O)O)O5)CC4)CC2)CC1)CC3OC(=O)C)/C(=C\C)/C	O=C(OC1C(C)(C)CC2C3(C1OC(=O)C)C(O)OC12C(C)(C2(C)C(C4(C)C(C(C)(C)C(OC5C(OC6C(O)C(O)C(O)C(CO)O6)C(OC6C(OC7C(OC8C(O)C(O)C(O)CO8)C(O)C(O)C(C)O7)C(O)C(O)C(CO)O6)C(O)C(C(=O)O)O5)CC4)CC2)CC1)CC3OC(=O)C)/C(=C\C)/C
NCGC00163953-03	O=C(OC1C(C)=C(CC=C)C(=O)C1)C1C(C)(C)C1/C=C(\C)/C		Inactive	Testis-specific androgen-binding protein Binding Agent		1	Allethrin	144214035.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1C(C)=C(CC=C)C(=O)C1)C1C(C)(C)C1/C=C(\C)/C	O=C(OC1C(C)=C(CC=C)C(=O)C1)C1C(C)(C)C1/C=C(\C)/C
NCGC00380563-01	O=C(OC1C(C)=C2C(=O)C=C(C)C2C(O)C2C(=C)C(=O)OC12)C=C(C)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Vicoa | Family: Compositae | Species: indica		1	NCGC00380563-01	363678653.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C)=C2C(=O)C=C(C)C2C(O)C2C(=C)C(=O)OC12)C=C(C)C	O=C(OC1C(C)=C2C(=O)C=C(C)C2C(O)C2C(=C)C(=O)OC12)C=C(C)C
NCGC00385751-01	O=C(OC1C(C)C2C(OC3C(O)C(O)C(O)C(CO)O3)OC=C(C(=O)OC)C2C1)C(O)CC(=O)O		Inactive	<MOA Unknown> | Class: Iridoide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385751-01	363679922.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C)C2C(OC3C(O)C(O)C(O)C(CO)O3)OC=C(C(=O)OC)C2C1)C(O)CC(=O)O	O=C(OC1C(C)C2C(OC3C(O)C(O)C(O)C(CO)O3)OC=C(C(=O)OC)C2C1)C(O)CC(=O)O
NCGC00385745-01	O=C(OC1C(C2(C)C(O)(C3C(C4(C)C(CC(OC5OC(C)C(OC6C(O)C(O)C(O)C(CO)O6)C(OC)C5)CC4)CC3)CC2)C1)C1=CC(=O)OC1)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385745-01	363679919.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C2(C)C(O)(C3C(C4(C)C(CC(OC5OC(C)C(OC6C(O)C(O)C(O)C(CO)O6)C(OC)C5)CC4)CC3)CC2)C1)C1=CC(=O)OC1)C	O=C(OC1C(C2(C)C(O)(C3C(C4(C)C(CC(OC5OC(C)C(OC6C(O)C(O)C(O)C(CO)O6)C(OC)C5)CC4)CC3)CC2)C1)C1=CC(=O)OC1)C
NCGC00347853-02	O=C(OC1C(C=C)(C)CC=2C(C3(C)C(C(C(=O)O)(C)CCC3)CC=2)C1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347853-02	363677712.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(C=C)(C)CC=2C(C3(C)C(C(C(=O)O)(C)CCC3)CC=2)C1)C	O=C(OC1C(C=C)(C)CC=2C(C3(C)C(C(C(=O)O)(C)CCC3)CC=2)C1)C
NCGC00385411-01	O=C(OC1C(O)(C(=O)OC)C2(C(=O)OC)C(C3(C(=O)OC(c4cocc4)C3)C(C)=CC2)CC1)C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Croton | Family: Euphorbiaceae | Species: megalocarpus		1	NCGC00385411-01	363679728.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)(C(=O)OC)C2(C(=O)OC)C(C3(C(=O)OC(c4cocc4)C3)C(C)=CC2)CC1)C	O=C(OC1C(O)(C(=O)OC)C2(C(=O)OC)C(C3(C(=O)OC(c4cocc4)C3)C(C)=CC2)CC1)C
NCGC00380358-01	O=C(OC1C(O)(C)C(=O)C2=C(C=C(/C=C/C)OC2)C1)c1c(O)cc(OC)cc1C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380358-01	363678552.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)(C)C(=O)C2=C(C=C(/C=C/C)OC2)C1)c1c(O)cc(OC)cc1C	O=C(OC1C(O)(C)C(=O)C2=C(C=C(/C=C/C)OC2)C1)c1c(O)cc(OC)cc1C
NCGC00380131-01	O=C(OC1C(O)(C)C(=O)C2=C(C=C(CCC)OC2)C1)c1c(O)cc(OC)cc1C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380131-01	363678469.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)(C)C(=O)C2=C(C=C(CCC)OC2)C1)c1c(O)cc(OC)cc1C	O=C(OC1C(O)(C)C(=O)C2=C(C=C(CCC)OC2)C1)c1c(O)cc(OC)cc1C
NCGC00385714-01	O=C(OC1C(O)(C)C(=O)C=C2C=C(/C=C/C(=C/C(CC)C)/C)OCC12)C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385714-01	363679892.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)(C)C(=O)C=C2C=C(/C=C/C(=C/C(CC)C)/C)OCC12)C	O=C(OC1C(O)(C)C(=O)C=C2C=C(/C=C/C(=C/C(CC)C)/C)OCC12)C
NCGC00381326-01	O=C(OC1C(O)(C)C(=O)C=C2C=C(/C=C/C)OCC12)c1c(O)cc(O)cc1C		Inactive	<MOA Unknown> | Class: polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381326-01	363679087.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)(C)C(=O)C=C2C=C(/C=C/C)OCC12)c1c(O)cc(O)cc1C	O=C(OC1C(O)(C)C(=O)C=C2C=C(/C=C/C)OCC12)c1c(O)cc(O)cc1C
NCGC00384732-01	O=C(OC1C(O)(C)C2C3(OC1C(C(=C)C)C)OCC1(C4(C)C(C5(C)C(C(C)(C)C(OC6C(OC7C(O)C(O)C(CO)O7)C(OC7C(O)C(OC8C(O)C(O)C(O)CO8)C(O)C(CO)O7)C(O)CO6)CC5)CC4)CCC21)C3)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384732-01	363679331.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)(C)C2C3(OC1C(C(=C)C)C)OCC1(C4(C)C(C5(C)C(C(C)(C)C(OC6C(OC7C(O)C(O)C(CO)O7)C(OC7C(O)C(OC8C(O)C(O)C(O)CO8)C(O)C(CO)O7)C(O)CO6)CC5)CC4)CCC21)C3)C	O=C(OC1C(O)(C)C2C3(OC1C(C(=C)C)C)OCC1(C4(C)C(C5(C)C(C(C)(C)C(OC6C(OC7C(O)C(O)C(CO)O7)C(OC7C(O)C(OC8C(O)C(O)C(O)CO8)C(O)C(CO)O7)C(O)CO6)CC5)CC4)CCC21)C3)C
NCGC00181116-02	O=C(OC1C(O)(C)CC(OC2C(N(C)C)C(O)C(O[C@@H]3[C@@H](OC)[C@H](OC(=O)C)CC(=O)O[C@H](C)C[C@@H]4OC4/C=C\C(=O)[C@H](C)C[C@@H]3CC=O)OC2C)OC1C)CC(C)C		Inactive	Bacterial 70S ribosome Inhibitor		1	Carbomycin A	124893648.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1C(O)(C)CC(OC2C(N(C)C)C(O)C(O[C@@H]3[C@@H](OC)[C@H](OC(=O)C)CC(=O)O[C@H](C)C[C@@H]4OC4/C=C\C(=O)[C@H](C)C[C@@H]3CC=O)OC2C)OC1C)CC(C)C	O=C(OC1C(O)(C)CC(OC2C(N(C)C)C(O)C(O[C@@H]3[C@@H](OC)[C@H](OC(=O)C)CC(=O)O[C@H](C)C[C@@H]4OC4/C=C\C(=O)[C@H](C)C[C@@H]3CC=O)OC2C)OC1C)CC(C)C
NCGC00384788-01	O=C(OC1C(O)/C(/C=O)=C/CC/C(/CO)=C/C2OC(=O)C(=C)C12)C(CC)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384788-01	363679353.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)/C(/C=O)=C/CC/C(/CO)=C/C2OC(=O)C(=C)C12)C(CC)C	O=C(OC1C(O)/C(/C=O)=C/CC/C(/CO)=C/C2OC(=O)C(=C)C12)C(CC)C
NCGC00380497-01	O=C(OC1C(O)C(=C)C(CC/C(=C\CO)/C)C2(C)C1C(C(=O)O)(C)CCC2)c1ccccc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380497-01	363678609.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(=C)C(CC/C(=C\CO)/C)C2(C)C1C(C(=O)O)(C)CCC2)c1ccccc1	O=C(OC1C(O)C(=C)C(CC/C(=C\CO)/C)C2(C)C1C(C(=O)O)(C)CCC2)c1ccccc1
NCGC00380652-01	O=C(OC1C(O)C(C)(C)C2C(C)(C3(C(C)CC2)Oc2c(C=O)c(CO)cc(O)c2C3)C1)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380652-01	363678691.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(C)(C)C2C(C)(C3(C(C)CC2)Oc2c(C=O)c(CO)cc(O)c2C3)C1)C	O=C(OC1C(O)C(C)(C)C2C(C)(C3(C(C)CC2)Oc2c(C=O)c(CO)cc(O)c2C3)C1)C
NCGC00381002-01	O=C(OC1C(O)C(C)(C)C2C(C)(C3(C(C)CC2)Oc2c(c(O)cc4C(=O)NCc24)C3)C1)C		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381002-01	363678916.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(C)(C)C2C(C)(C3(C(C)CC2)Oc2c(c(O)cc4C(=O)NCc24)C3)C1)C	O=C(OC1C(O)C(C)(C)C2C(C)(C3(C(C)CC2)Oc2c(c(O)cc4C(=O)NCc24)C3)C1)C
NCGC00521080-01	O=C(OC1C(O)C(C)OC(OC2C(C)OC(OC3C(C)OC(OC4CC5C(C)(C6C(C7(O)C(C)(C(C8=CC(=O)OC8)CC7)CC6)CC5)CC4)CC3O)CC2O)C1)C		Inactive	Sodium/potassium-transporting ATPase Inhibitor		1	Digitoxin 3'''-Acetate	405558469.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1C(O)C(C)OC(OC2C(C)OC(OC3C(C)OC(OC4CC5C(C)(C6C(C7(O)C(C)(C(C8=CC(=O)OC8)CC7)CC6)CC5)CC4)CC3O)CC2O)C1)C	O=C(OC1C(O)C(C)OC(OC2C(C)OC(OC3C(C)OC(OC4CC5C(C)(C6C(C7(O)C(C)(C(C8=CC(=O)OC8)CC7)CC6)CC5)CC4)CC3O)CC2O)C1)C
NCGC00347850-02	O=C(OC1C(O)C(O)C(C)OC1OC(C)(C)C1CC2C(=C)CCCC2(C)CC1)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347850-02	363677711.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(C)OC1OC(C)(C)C1CC2C(=C)CCCC2(C)CC1)/C(=C\C)/C	O=C(OC1C(O)C(O)C(C)OC1OC(C)(C)C1CC2C(=C)CCCC2(C)CC1)/C(=C\C)/C
NCGC00385264-02	O=C(OC1C(O)C(O)C(C)OC1OC1(C)C2C(C(C)CC2)C2C(C)(C)C2CC1)/C=C(/CC)\C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385264-02	363679625.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(C)OC1OC1(C)C2C(C(C)CC2)C2C(C)(C)C2CC1)/C=C(/CC)\C	O=C(OC1C(O)C(O)C(C)OC1OC1(C)C2C(C(C)CC2)C2C(C)(C)C2CC1)/C=C(/CC)\C
NCGC00380519-01	O=C(OC1C(O)C(O)C(CO)OC1OC1OC=C(C(=O)O)C2C(O)CC(O)(C)C12)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380519-01	363678627.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(CO)OC1OC1OC=C(C(=O)O)C2C(O)CC(O)(C)C12)/C=C/c1ccc(O)cc1	O=C(OC1C(O)C(O)C(CO)OC1OC1OC=C(C(=O)O)C2C(O)CC(O)(C)C12)/C=C/c1ccc(O)cc1
NCGC00380918-01	O=C(OC1C(O)C(O)C(CO)OC1OC1OC=C(C(=O)O)C2C1C(=C)C(O)C2)/C=C\c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380918-01	363678854.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(CO)OC1OC1OC=C(C(=O)O)C2C1C(=C)C(O)C2)/C=C\c1ccc(O)cc1	O=C(OC1C(O)C(O)C(CO)OC1OC1OC=C(C(=O)O)C2C1C(=C)C(O)C2)/C=C\c1ccc(O)cc1
NCGC00384796-01	O=C(OC1C(O)C(O)C(CO)OC1OC1OC=C(C(=O)O)C2C1C(O)(C)CC2)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384796-01	363679359.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(CO)OC1OC1OC=C(C(=O)O)C2C1C(O)(C)CC2)/C=C/c1ccc(O)cc1	O=C(OC1C(O)C(O)C(CO)OC1OC1OC=C(C(=O)O)C2C1C(O)(C)CC2)/C=C/c1ccc(O)cc1
NCGC00380896-01	O=C(OC1C(O)C(O)C(CO)OC1OCC1=COC(OC(=O)CC(C)C)C2C(O)(COC(=O)C)CCC12)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380896-01	363678841.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(CO)OC1OCC1=COC(OC(=O)CC(C)C)C2C(O)(COC(=O)C)CCC12)/C=C/c1ccc(O)cc1	O=C(OC1C(O)C(O)C(CO)OC1OCC1=COC(OC(=O)CC(C)C)C2C(O)(COC(=O)C)CCC12)/C=C/c1ccc(O)cc1
NCGC00380456-01	O=C(OC1C(O)C(O)C(O)C(CO)O1)C1(C)C(O)CC(O)C23C4(C(C5(C)C(C)(C(C6(C)OC(C(O)(C)C)CC6)CC5)CC4)CCC12)C3		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Cassia | Family: Leguminosae | Species: floribunda		1	NCGC00380456-01	363678595.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(CO)O1)C1(C)C(O)CC(O)C23C4(C(C5(C)C(C)(C(C6(C)OC(C(O)(C)C)CC6)CC5)CC4)CCC12)C3	O=C(OC1C(O)C(O)C(O)C(CO)O1)C1(C)C(O)CC(O)C23C4(C(C5(C)C(C)(C(C6(C)OC(C(O)(C)C)CC6)CC5)CC4)CCC12)C3
NCGC00169467-03	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C(C)C(C)CC1)C=1C(C(=O)O)(C3(C)C(C4(C)C(C(C)(C)C(OC5C(O)C(O)C(O)C(C)O5)CC4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Agelaea | Family: Connaraceae | Species: obliqua		1	NCGC00169467-03	363676822.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C(C)C(C)CC1)C=1C(C(=O)O)(C3(C)C(C4(C)C(C(C)(C)C(OC5C(O)C(O)C(O)C(C)O5)CC4)CC3)CC=1)CC2	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C(C)C(C)CC1)C=1C(C(=O)O)(C3(C)C(C4(C)C(C(C)(C)C(OC5C(O)C(O)C(O)C(C)O5)CC4)CC3)CC=1)CC2
NCGC00169718-03	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C(O)(C)C(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(C(=O)O)(C)C(O)C(O)C4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Lavendula | Family: Lamiaceae | Species: officinalis		1	NCGC00169718-03	363676875.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C(O)(C)C(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(C(=O)O)(C)C(O)C(O)C4)CC3)CC=1)CC2	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C(O)(C)C(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(C(=O)O)(C)C(O)C(O)C4)CC3)CC=1)CC2
NCGC00385137-01	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C(O)(C)C(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(CO)(C)C(O)CC4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385137-01	363679554.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C(O)(C)C(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(CO)(C)C(O)CC4)CC3)CC=1)CC2	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C(O)(C)C(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(CO)(C)C(O)CC4)CC3)CC=1)CC2
NCGC00385859-01	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C(O)C(C)(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(C(=O)O)(C)C(O)CC4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385859-01	363679971.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C(O)C(C)(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(C(=O)O)(C)C(O)CC4)CC3)CC=1)CC2	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C(O)C(C)(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(C(=O)O)(C)C(O)CC4)CC3)CC=1)CC2
NCGC00169820-03	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C=3C(C(=O)O)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(O)C(O)C(C)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169820-03	363676895.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C=3C(C(=O)O)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(O)C(O)C(C)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C=3C(C(=O)O)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(O)C(O)C(C)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00384763-01	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(OC7C(O)C(O)C(O)C(CO)O7)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Calendula | Family: N/A | Species: officinalis		1	NCGC00384763-01	363679343.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(OC7C(O)C(O)C(O)C(CO)O7)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(OC7C(O)C(O)C(O)C(CO)O7)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00385212-01	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(OC7C(O)C(O)C(O)CO7)C(OC7C(O)C(O)C(O)C(C)O7)C(CO)O6)CC5)CC4)CC=3)CC1)CC(=C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385212-01	363679597.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(OC7C(O)C(O)C(O)CO7)C(OC7C(O)C(O)C(O)C(C)O7)C(CO)O6)CC5)CC4)CC=3)CC1)CC(=C)CC2	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(OC7C(O)C(O)C(O)CO7)C(OC7C(O)C(O)C(O)C(C)O7)C(CO)O6)CC5)CC4)CC=3)CC1)CC(=C)CC2
NCGC00384727-01	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(CO)(C)C(OC6C(O)C(O)C(O)C(COC7C(O)C(O)C(O)C(C)O7)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384727-01	363679328.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(CO)(C)C(OC6C(O)C(O)C(O)C(COC7C(O)C(O)C(O)C(C)O7)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(OC1C(O)C(O)C(O)C(CO)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(CO)(C)C(OC6C(O)C(O)C(O)C(COC7C(O)C(O)C(O)C(C)O7)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00347376-02	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@@]12C([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](C(=O)O)(C)[C@@H](O)CC4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Myricarubra | Family: Myricaceae | Species: N/A		1	NCGC00347376-02	363677581.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@@]12C([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](C(=O)O)(C)[C@@H](O)CC4)CC3)CC=1)CC2	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@@]12C([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](C(=O)O)(C)[C@@H](O)CC4)CC3)CC=1)CC2
NCGC00384539-01	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C(=O)O)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@H](O)[C@@H](OC6C(O)C(O)C(O)C(CO)O6)[C@H](C)O5)CC4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Sarcocephalus | Family: Rubiaceae | Species: cordatus		1	NCGC00384539-01	363679237.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C(=O)O)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@H](O)[C@@H](OC6C(O)C(O)C(O)C(CO)O6)[C@H](C)O5)CC4)CC3)CC=1)CC2	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C(=O)O)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@H](O)[C@@H](OC6C(O)C(O)C(O)C(CO)O6)[C@H](C)O5)CC4)CC3)CC=1)CC2
NCGC00385168-01	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	inflammatory response Inhibitor		1	NCGC00385168-01	363679576.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00381223-01	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(O)CO6)CC5)CC4)CC=3)CC1)CC(C(=O)O)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Schefflera | Family: Araliaceae | Species: venulosa		1	NCGC00381223-01	363679033.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(O)CO6)CC5)CC4)CC=3)CC1)CC(C(=O)O)(C)CC2	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(O)CO6)CC5)CC4)CC=3)CC1)CC(C(=O)O)(C)CC2
NCGC00180255-02	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(O)C(O)C(C(=O)O)O6)[C@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Canthium | Family: Rubiaceae | Species: sp.		1	NCGC00180255-02	363677005.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(O)C(O)C(C(=O)O)O6)[C@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(O)C(O)C(C(=O)O)O6)[C@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00179850-02	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(CO)(CO)[C@@H](OC6C(O)C(O)C(O)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00179850-02	363676977.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(CO)(CO)[C@@H](OC6C(O)C(O)C(O)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(OC1C(O)C(O)C(O)C(CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(CO)(CO)[C@@H](OC6C(O)C(O)C(O)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00380500-01	O=C(OC1C(O)C(O)C(O)C(CO)O1)c1cc2c(OC(C(=C)C)C2)cc1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380500-01	363678612.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(CO)O1)c1cc2c(OC(C(=C)C)C2)cc1	O=C(OC1C(O)C(O)C(O)C(CO)O1)c1cc2c(OC(C(=C)C)C2)cc1
NCGC00380730-01	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1)C12C(C(O)(C)C(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(C(=O)O)(C)C(O)CC4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380730-01	363678744.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1)C12C(C(O)(C)C(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(C(=O)O)(C)C(O)CC4)CC3)CC=1)CC2	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1)C12C(C(O)(C)C(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(C(=O)O)(C)C(O)CC4)CC3)CC=1)CC2
NCGC00380907-01	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1)C12C(C(O)C(C)(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(C(=O)O)(C)C(O)CC4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380907-01	363678847.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1)C12C(C(O)C(C)(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(C(=O)O)(C)C(O)CC4)CC3)CC=1)CC2	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1)C12C(C(O)C(C)(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(C(=O)O)(C)C(O)CC4)CC3)CC=1)CC2
NCGC00169251-02	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1)C12C(C(O)C(C)(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(C)(C)C(OC5C(O)C(O)C(O)CO5)CC4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Succisa | Family: Dipsacaceae | Species: pratensis		1	NCGC00169251-02	363676794.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	12.0124209081	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1)C12C(C(O)C(C)(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(C)(C)C(OC5C(O)C(O)C(O)CO5)CC4)CC3)CC=1)CC2	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1)C12C(C(O)C(C)(C)CC1)C=1C(C)(C3(C)C(C4(C)C(C(C)(C)C(OC5C(O)C(O)C(O)CO5)CC4)CC3)CC=1)CC2
NCGC00380484-01	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1)C=1C(C)(C)CCCC=1C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380484-01	363678606.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1)C=1C(C)(C)CCCC=1C	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(O)C(CO)O2)O1)C=1C(C)(C)CCCC=1C
NCGC00380772-01	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(OC3C(O)C(O)C(O)C(C)O3)C(CO)O2)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380772-01	363678774.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(OC3C(O)C(O)C(O)C(C)O3)C(CO)O2)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(OC3C(O)C(O)C(O)C(C)O3)C(CO)O2)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00380902-01	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(OC3C(O)C(O)C(OC4C(O)C(O)C(O)C(CO)O4)C(C)O3)C(CO)O2)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(CO)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380902-01	363678844.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(OC3C(O)C(O)C(OC4C(O)C(O)C(O)C(CO)O4)C(C)O3)C(CO)O2)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(CO)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(OC3C(O)C(O)C(OC4C(O)C(O)C(O)C(CO)O4)C(C)O3)C(CO)O2)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(CO)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00347510-02	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(CO)O2)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@](C(=O)O)(C)[C@H](O)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Acanthopanax | Family: Araliaceae | Species: aculeatum		1	NCGC00347510-02	363677609.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(CO)O2)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@](C(=O)O)(C)[C@H](O)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(OC1C(O)C(O)C(O)C(COC2C(O)C(O)C(O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(CO)O2)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@](C(=O)O)(C)[C@H](O)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00385737-01	O=C(OC1C(O)C(O)C(O)CO1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(O)C(O)C(COC7C(O)C(O)C(O)CO7)O6)C(O)C5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385737-01	363679912.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O)CO1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(O)C(O)C(COC7C(O)C(O)C(O)CO7)O6)C(O)C5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(OC1C(O)C(O)C(O)CO1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(O)C(O)C(COC7C(O)C(O)C(O)CO7)O6)C(O)C5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00381234-01	O=C(OC1C(O)C(O)C(OC2C(O)C(O)C(O)C(C)O2)C(COC2C(O)C(O)C(O)C(CO)O2)O1)C12C(C(C(=C)C)CC1)C1C(C(=O)O)(C3(C)C(C4(C)C(C(C)(C)C(=O)CC4)CC3)CC1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381234-01	363679041.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(OC2C(O)C(O)C(O)C(C)O2)C(COC2C(O)C(O)C(O)C(CO)O2)O1)C12C(C(C(=C)C)CC1)C1C(C(=O)O)(C3(C)C(C4(C)C(C(C)(C)C(=O)CC4)CC3)CC1)CC2	O=C(OC1C(O)C(O)C(OC2C(O)C(O)C(O)C(C)O2)C(COC2C(O)C(O)C(O)C(CO)O2)O1)C12C(C(C(=C)C)CC1)C1C(C(=O)O)(C3(C)C(C4(C)C(C(C)(C)C(=O)CC4)CC3)CC1)CC2
NCGC00381283-01	O=C(OC1C(O)C(O)C(OC2C(O)C(O)C(O)C(COC3C(O)C(O)C(O)CO3)O2)C(CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(O)C(OC7C(O)C(O)C(OC8C(O)C(O)C(O)CO8)CO7)C(C)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381283-01	363679066.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(OC2C(O)C(O)C(O)C(COC3C(O)C(O)C(O)CO3)O2)C(CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(O)C(OC7C(O)C(O)C(OC8C(O)C(O)C(O)CO8)CO7)C(C)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(OC1C(O)C(O)C(OC2C(O)C(O)C(O)C(COC3C(O)C(O)C(O)CO3)O2)C(CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(O)C(OC7C(O)C(O)C(OC8C(O)C(O)C(O)CO8)CO7)C(C)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00381225-01	O=C(OC1C(O)C(O)C(OC2C(O)C(O)C(O)C(O)C2O)OC1CO)c1c(OC)cc(O)cc1C		Inactive	<MOA Unknown> | Class: Sugar | Genus: Phoma | Family: N/A | Species: sp.		1	NCGC00381225-01	363679034.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(OC2C(O)C(O)C(O)C(O)C2O)OC1CO)c1c(OC)cc(O)cc1C	O=C(OC1C(O)C(O)C(OC2C(O)C(O)C(O)C(O)C2O)OC1CO)c1c(OC)cc(O)cc1C
NCGC00381337-01	O=C(OC1C(O)C(O)C(OC2C(O)C(O)C(OC3C(O)C(O)C(O)CO3)CO2)C(CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(O)C(OC7C(O)C(OC8C(O)C(O)C(O)C(CO)O8)C(O)C(CO)O7)C(C)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381337-01	363679098.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(OC2C(O)C(O)C(OC3C(O)C(O)C(O)CO3)CO2)C(CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(O)C(OC7C(O)C(OC8C(O)C(O)C(O)C(CO)O8)C(O)C(CO)O7)C(C)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(OC1C(O)C(O)C(OC2C(O)C(O)C(OC3C(O)C(O)C(O)CO3)CO2)C(CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(O)C(OC7C(O)C(OC8C(O)C(O)C(O)C(CO)O8)C(O)C(CO)O7)C(C)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00347591-02	O=C(OC1C(O)C(O)C(OC2C3C=C(C)C\4C(C)(C(=O)C=5C(=O)OC6(C=5O)C(C)(C=C(C(=O)O)C(C)C6)/C=C(\C)/CC/C=C/4\C)C3C(C)CC2)OC1C)c1c(OC)cc(OC)cc1C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347591-02	363677634.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(OC2C3C=C(C)C\4C(C)(C(=O)C=5C(=O)OC6(C=5O)C(C)(C=C(C(=O)O)C(C)C6)/C=C(\C)/CC/C=C/4\C)C3C(C)CC2)OC1C)c1c(OC)cc(OC)cc1C	O=C(OC1C(O)C(O)C(OC2C3C=C(C)C\4C(C)(C(=O)C=5C(=O)OC6(C=5O)C(C)(C=C(C(=O)O)C(C)C6)/C=C(\C)/CC/C=C/4\C)C3C(C)CC2)OC1C)c1c(OC)cc(OC)cc1C
NCGC00384829-01	O=C(OC1C(O)C(O)C(O[C@@H]2[C@@H](O)[C@@H](OC3C(O)C(O)C(OC4C(O)C(O)C(O)CO4)C(C)O3)[C@@H](C)O[C@H]2OC(=O)[C@@]23[C@H](O)C[C@@]4(C)[C@@]5(C)C([C@]6(C)C([C@@](C=O)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)CO8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC=C4[C@@H]2CC(C)(C)CC3)OC1CO)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: Saponaria | Family: Caryophyllaceae | Species: officinalis		1	NCGC00384829-01	363679381.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C(O[C@@H]2[C@@H](O)[C@@H](OC3C(O)C(O)C(OC4C(O)C(O)C(O)CO4)C(C)O3)[C@@H](C)O[C@H]2OC(=O)[C@@]23[C@H](O)C[C@@]4(C)[C@@]5(C)C([C@]6(C)C([C@@](C=O)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)CO8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC=C4[C@@H]2CC(C)(C)CC3)OC1CO)C	O=C(OC1C(O)C(O)C(O[C@@H]2[C@@H](O)[C@@H](OC3C(O)C(O)C(OC4C(O)C(O)C(O)CO4)C(C)O3)[C@@H](C)O[C@H]2OC(=O)[C@@]23[C@H](O)C[C@@]4(C)[C@@]5(C)C([C@]6(C)C([C@@](C=O)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)CO8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC=C4[C@@H]2CC(C)(C)CC3)OC1CO)C
NCGC00385030-01	O=C(OC1C(O)C(O)C2OC1OC(C(=O)OCc1ccc(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)cc1)(CC(C)C)CC(=O)OC(C(=O)O)CC(=O)OC2)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385030-01	363679494.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)C2OC1OC(C(=O)OCc1ccc(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)cc1)(CC(C)C)CC(=O)OC(C(=O)O)CC(=O)OC2)/C=C/c1ccc(O)cc1	O=C(OC1C(O)C(O)C2OC1OC(C(=O)OCc1ccc(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)cc1)(CC(C)C)CC(=O)OC(C(=O)O)CC(=O)OC2)/C=C/c1ccc(O)cc1
NCGC00381240-02	O=C(OC1C(O)C(O)CC(O)(C(=O)O)C1)/C=C/c1cc(OC)c2OC(c3cc(OC)c(O)cc3)C(CO)c2c1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381240-02	363679045.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(O)CC(O)(C(=O)O)C1)/C=C/c1cc(OC)c2OC(c3cc(OC)c(O)cc3)C(CO)c2c1	O=C(OC1C(O)C(O)CC(O)(C(=O)O)C1)/C=C/c1cc(OC)c2OC(c3cc(OC)c(O)cc3)C(CO)c2c1
NCGC00381294-01	O=C(OC1C(O)C(OC(=O)C)C(COC(=O)C)OC1OC1C(O)C(O)C(OC2C(O)C(O)C(OC3C(O)C(O)COC3OC3C(O)C(O)C(OC4C(C)(C)C5C(C)(C6C(C)(C7(C)C(C8C(C(=O)OC9C(OC%10C(O)C(O)C(OC%11C(O)C(O)(CO)CO%11)CO%10)C(O)C(O)C(CO)O9)(C(O)C7)CCC(C)(C)C8)=CC6)CC5)CC4)OC3CO)OC2)OC1)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Eutada | Family: Mimosaceae | Species: africana		1	NCGC00381294-01	363679073.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	12.5116588919	O=C(OC1C(O)C(OC(=O)C)C(COC(=O)C)OC1OC1C(O)C(O)C(OC2C(O)C(O)C(OC3C(O)C(O)COC3OC3C(O)C(O)C(OC4C(C)(C)C5C(C)(C6C(C)(C7(C)C(C8C(C(=O)OC9C(OC%10C(O)C(O)C(OC%11C(O)C(O)(CO)CO%11)CO%10)C(O)C(O)C(CO)O9)(C(O)C7)CCC(C)(C)C8)=CC6)CC5)CC4)OC3CO)OC2)OC1)/C=C/c1ccccc1	O=C(OC1C(O)C(OC(=O)C)C(COC(=O)C)OC1OC1C(O)C(O)C(OC2C(O)C(O)C(OC3C(O)C(O)COC3OC3C(O)C(O)C(OC4C(C)(C)C5C(C)(C6C(C)(C7(C)C(C8C(C(=O)OC9C(OC%10C(O)C(O)C(OC%11C(O)C(O)(CO)CO%11)CO%10)C(O)C(O)C(CO)O9)(C(O)C7)CCC(C)(C)C8)=CC6)CC5)CC4)OC3CO)OC2)OC1)/C=C/c1ccccc1
NCGC00384543-01	O=C(OC1C(O)C(OC(=O)C23C(O)CC4(C)C5(C)C(C6(C)C(C(C)(C)C(OC7C(O)C(O)C(OC8C(O)C(OC9C(O)C(O)C(O)CO9)C(O)C(CO)O8)C(CO)O7)CC6)CC5)CC=C4C2CC(C)(C)CC3)OCC1OC1C(O)C(OC2C(O)C(OC3C(O)C(O)C(O)C(C)O3)C(O)CO2)C(OC2C(O)C(O)C(O)C(CO)O2)CO1)/C(=C\CCC(O)(C=C)C)/C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384543-01	363679239.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(OC(=O)C23C(O)CC4(C)C5(C)C(C6(C)C(C(C)(C)C(OC7C(O)C(O)C(OC8C(O)C(OC9C(O)C(O)C(O)CO9)C(O)C(CO)O8)C(CO)O7)CC6)CC5)CC=C4C2CC(C)(C)CC3)OCC1OC1C(O)C(OC2C(O)C(OC3C(O)C(O)C(O)C(C)O3)C(O)CO2)C(OC2C(O)C(O)C(O)C(CO)O2)CO1)/C(=C\CCC(O)(C=C)C)/C	O=C(OC1C(O)C(OC(=O)C23C(O)CC4(C)C5(C)C(C6(C)C(C(C)(C)C(OC7C(O)C(O)C(OC8C(O)C(OC9C(O)C(O)C(O)CO9)C(O)C(CO)O8)C(CO)O7)CC6)CC5)CC=C4C2CC(C)(C)CC3)OCC1OC1C(O)C(OC2C(O)C(OC3C(O)C(O)C(O)C(C)O3)C(O)CO2)C(OC2C(O)C(O)C(O)C(CO)O2)CO1)/C(=C\CCC(O)(C=C)C)/C
NCGC00380438-01	O=C(OC1C(O)C(OC23C(=O)C=C(C)C2C(OC2C(O)C(O)C(O)C(CO)O2)OC=C3)OC(C)C1O)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Iridoide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380438-01	363678584.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C(OC23C(=O)C=C(C)C2C(OC2C(O)C(O)C(O)C(CO)O2)OC=C3)OC(C)C1O)/C=C/c1ccccc1	O=C(OC1C(O)C(OC23C(=O)C=C(C)C2C(OC2C(O)C(O)C(O)C(CO)O2)OC=C3)OC(C)C1O)/C=C/c1ccccc1
NCGC00380993-01	O=C(OC1C(O)C2C(C(=O)O)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C1C)c1ccccc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380993-01	363678909.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C2C(C(=O)O)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C1C)c1ccccc1	O=C(OC1C(O)C2C(C(=O)O)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C1C)c1ccccc1
NCGC00385626-01	O=C(OC1C(O)C2C(C(=O)OC)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C1C)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385626-01	363679845.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C2C(C(=O)OC)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C1C)/C=C/c1ccc(O)cc1	O=C(OC1C(O)C2C(C(=O)OC)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C1C)/C=C/c1ccc(O)cc1
NCGC00347836-02	O=C(OC1C(O)C2C(C)C=3C(O)(OC(=O)C=3)CC2C2(C)C1C(CO)(C)CCC2)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347836-02	363677703.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C2C(C)C=3C(O)(OC(=O)C=3)CC2C2(C)C1C(CO)(C)CCC2)C	O=C(OC1C(O)C2C(C)C=3C(O)(OC(=O)C=3)CC2C2(C)C1C(CO)(C)CCC2)C
NCGC00380517-01	O=C(OC1C(O)C2C(C)C=3C(OC)(OC(=O)C=3)CC2C2(C)C1C(C)(C)C(OC(=O)C)CC2)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380517-01	363678625.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)C2C(C)C=3C(OC)(OC(=O)C=3)CC2C2(C)C1C(C)(C)C(OC(=O)C)CC2)C	O=C(OC1C(O)C2C(C)C=3C(OC)(OC(=O)C=3)CC2C2(C)C1C(C)(C)C(OC(=O)C)CC2)C
NCGC00388216-01	O=C(OC1C(O)C2C(O)C(O1)COC(=O)c1c(c(O)c(O)c(O)c1)-c1c(O)c(O)c(O)cc1C(=O)O2)c1cc(O)c(O)c(O)c1		Inactive			1	Corilagin	434146919.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1C(O)C2C(O)C(O1)COC(=O)c1c(c(O)c(O)c(O)c1)-c1c(O)c(O)c(O)cc1C(=O)O2)c1cc(O)c(O)c(O)c1	O=C(OC1C(O)C2C(O)C(O1)COC(=O)c1c(c(O)c(O)c(O)c1)-c1c(O)c(O)c(O)cc1C(=O)O2)c1cc(O)c(O)c(O)c1
NCGC00384908-01	O=C(OC1C(O)CC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2C1C1(C)C(C(=O)OC(c3cocc3)C1)CC2)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Tinospora | Family: Menispermaceae | Species: cordifolia		1	NCGC00384908-01	363679433.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)CC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2C1C1(C)C(C(=O)OC(c3cocc3)C1)CC2)C	O=C(OC1C(O)CC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2C1C1(C)C(C(=O)OC(c3cocc3)C1)CC2)C
NCGC00385651-01	O=C(OC1C(O)c2c(C3(C)C(O)CCC(C(=O)OC)(C)C13)cc(O)c(C(C)C)c2)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385651-01	363679857.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)c2c(C3(C)C(O)CCC(C(=O)OC)(C)C13)cc(O)c(C(C)C)c2)C	O=C(OC1C(O)c2c(C3(C)C(O)CCC(C(=O)OC)(C)C13)cc(O)c(C(C)C)c2)C
NCGC00380382-01	O=C(OC1C(O)c2c(c(O)cc(C(C)C)c2)C2(C)C(=O)CCC(C(=O)OC)(C)C12)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380382-01	363678560.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)c2c(c(O)cc(C(C)C)c2)C2(C)C(=O)CCC(C(=O)OC)(C)C12)C	O=C(OC1C(O)c2c(c(O)cc(C(C)C)c2)C2(C)C(=O)CCC(C(=O)OC)(C)C12)C
NCGC00380999-01	O=C(OC1C(O)c2c(c(O)cc(C(C)C)c2)C2(C)C(O)CCC(C(=O)OC)(C)C12)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380999-01	363678913.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O)c2c(c(O)cc(C(C)C)c2)C2(C)C(O)CCC(C(=O)OC)(C)C12)C	O=C(OC1C(O)c2c(c(O)cc(C(C)C)c2)C2(C)C(O)CCC(C(=O)OC)(C)C12)C
NCGC00384534-01	O=C(OC1C(OC(=O)C)/C(/C=O)=C\CC/C(/CO)=C/C2OC(=O)C(=C)C12)C(=C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384534-01	363679236.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(OC(=O)C)/C(/C=O)=C\CC/C(/CO)=C/C2OC(=O)C(=C)C12)C(=C)C	O=C(OC1C(OC(=O)C)/C(/C=O)=C\CC/C(/CO)=C/C2OC(=O)C(=C)C12)C(=C)C
NCGC00346893-01	O=C(OC1C(OC(=O)C)C(C)OC(OC2=C(c3ccc(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)C1O)C		Inactive	RSK Inhibitor		1	SL-0101-1	174007040.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1C(OC(=O)C)C(C)OC(OC2=C(c3ccc(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)C1O)C	O=C(OC1C(OC(=O)C)C(C)OC(OC2=C(c3ccc(O)cc3)Oc3c(c(O)cc(O)c3)C2=O)C1O)C
NCGC00381108-01	O=C(OC1C(OC(=O)C)C(c2ccccc2)CCC1c1ccccc1)C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381108-01	363678974.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(OC(=O)C)C(c2ccccc2)CCC1c1ccccc1)C	O=C(OC1C(OC(=O)C)C(c2ccccc2)CCC1c1ccccc1)C
NCGC00169855-03	O=C(OC1C(OC(=O)c2c(OC)cc(O)cc2C)C(CO)OC1N1C(=O)NC(=O)C=C1)C		Inactive	<MOA Unknown> | Class: nucleoside | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169855-03	363676900.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(OC(=O)c2c(OC)cc(O)cc2C)C(CO)OC1N1C(=O)NC(=O)C=C1)C	O=C(OC1C(OC(=O)c2c(OC)cc(O)cc2C)C(CO)OC1N1C(=O)NC(=O)C=C1)C
NCGC00380349-01	O=C(OC1C(OC(=O)c2ccccc2)C2C(C(=O)O)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C1C)C		Inactive	<MOA Unknown> | Class: Iridoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380349-01	363678550.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(OC(=O)c2ccccc2)C2C(C(=O)O)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C1C)C	O=C(OC1C(OC(=O)c2ccccc2)C2C(C(=O)O)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C1C)C
NCGC00381304-01	O=C(OC1C(OC(=O)c2ccccc2)C2C(C(=O)OC)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C1C)C		Inactive	<MOA Unknown> | Class: Iridoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381304-01	363679077.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(OC(=O)c2ccccc2)C2C(C(=O)OC)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C1C)C	O=C(OC1C(OC(=O)c2ccccc2)C2C(C(=O)OC)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C1C)C
NCGC00381263-01	O=C(OC1C(OC(=O)c2ccccc2)C2C(C)(C(OC(=O)C)CCC2(C)C)C23C1CC(=O)C(C)(C2)CC3)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381263-01	363679057.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(OC(=O)c2ccccc2)C2C(C)(C(OC(=O)C)CCC2(C)C)C23C1CC(=O)C(C)(C2)CC3)C	O=C(OC1C(OC(=O)c2ccccc2)C2C(C)(C(OC(=O)C)CCC2(C)C)C23C1CC(=O)C(C)(C2)CC3)C
NCGC00385762-01	O=C(OC1C(OC(=O)c2ccccc2)C2C(C)(C)CC(=O)CC2(C)C23C1CC(O)C(C)(C2)CC3)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385762-01	363679929.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(OC(=O)c2ccccc2)C2C(C)(C)CC(=O)CC2(C)C23C1CC(O)C(C)(C2)CC3)C	O=C(OC1C(OC(=O)c2ccccc2)C2C(C)(C)CC(=O)CC2(C)C23C1CC(O)C(C)(C2)CC3)C
NCGC00381262-01	O=C(OC1C(OC(=O)c2ccccc2)C2C(C)(C)CCC(C)=C2C23C1CC(=O)C(C)(C2)CC3)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381262-01	363679056.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	13.909090904	O=C(OC1C(OC(=O)c2ccccc2)C2C(C)(C)CCC(C)=C2C23C1CC(=O)C(C)(C2)CC3)C	O=C(OC1C(OC(=O)c2ccccc2)C2C(C)(C)CCC(C)=C2C23C1CC(=O)C(C)(C2)CC3)C
NCGC00532507-01	O=C(OC1C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C1OC(=O)c1cnccc1)c1cnccc1		Inactive			1	INOSITOL NIACINATE	405558892.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C1OC(=O)c1cnccc1)c1cnccc1	O=C(OC1C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C(OC(=O)c2cnccc2)C1OC(=O)c1cnccc1)c1cnccc1
NCGC00385463-01	O=C(OC1C(OC)/C(/C=O)=C/CC/C(/C)=C/C2OC(=O)C(=C)C12)C(CC)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385463-01	363679753.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(OC)/C(/C=O)=C/CC/C(/C)=C/C2OC(=O)C(=C)C12)C(CC)C	O=C(OC1C(OC)/C(/C=O)=C/CC/C(/C)=C/C2OC(=O)C(=C)C12)C(CC)C
NCGC00385109-01	O=C(OC1C(OC)/C(/C=O)=C/CC/C(/CO)=C/C2OC(=O)C(=C)C12)C(CC)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385109-01	363679540.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(OC)/C(/C=O)=C/CC/C(/CO)=C/C2OC(=O)C(=C)C12)C(CC)C	O=C(OC1C(OC)/C(/C=O)=C/CC/C(/CO)=C/C2OC(=O)C(=C)C12)C(CC)C
NCGC00015888-06	O=C(OC1C(OC)C(C(=O)OC)C2C(C1)CN1C(c3[nH]c4c(c3CC1)ccc(OC)c4)C2)c1cc(OC)c(OC)c(OC)c1	5.0	Active	Alkaloid antipsychotic	0.0	1	Reserpine	384567902.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	95.8151936596	O=C(OC1C(OC)C(C(=O)OC)C2C(C1)CN1C(c3[nH]c4c(c3CC1)ccc(OC)c4)C2)c1cc(OC)c(OC)c(OC)c1	O=C(OC1C(OC)C(C(=O)OC)C2C(C1)CN1C(c3[nH]c4c(c3CC1)ccc(OC)c4)C2)c1cc(OC)c(OC)c(OC)c1
NCGC00384728-01	O=C(OC1C(OC)C(O)C(OC2C(C)OC(OC3CC=4C(C)(C5C(C6(O)C(C)(C(C(OC7C(O)C(O)C(O)C(COC8C(O)C(O)C(O)C(CO)O8)O7)C)CC6)CC5)CC=4)CC3)CC2OC)OC1C)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384728-01	363679329.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(OC)C(O)C(OC2C(C)OC(OC3CC=4C(C)(C5C(C6(O)C(C)(C(C(OC7C(O)C(O)C(O)C(COC8C(O)C(O)C(O)C(CO)O8)O7)C)CC6)CC5)CC=4)CC3)CC2OC)OC1C)/C(=C/C)/C	O=C(OC1C(OC)C(O)C(OC2C(C)OC(OC3CC=4C(C)(C5C(C6(O)C(C)(C(C(OC7C(O)C(O)C(O)C(COC8C(O)C(O)C(O)C(CO)O8)O7)C)CC6)CC5)CC=4)CC3)CC2OC)OC1C)/C(=C/C)/C
NCGC00380157-01	O=C(OC1C(OC)C=2C(=O)OCC=2C2(C)C1C(CO)(C)CCC2)c1ccccc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380157-01	363678479.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	16.1223021599	O=C(OC1C(OC)C=2C(=O)OCC=2C2(C)C1C(CO)(C)CCC2)c1ccccc1	O=C(OC1C(OC)C=2C(=O)OCC=2C2(C)C1C(CO)(C)CCC2)c1ccccc1
NCGC00380639-01	O=C(OC1C(OC2C(O)C(O)C(O)C(CO)O2)C(C)(C)C2C(C)(C=3C(C4(C)C(C)(C5C(C)(C(C(C)C)C(O)C5O)CC4)CC=3)CC2)C1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380639-01	363678686.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	-13.292484444	O=C(OC1C(OC2C(O)C(O)C(O)C(CO)O2)C(C)(C)C2C(C)(C=3C(C4(C)C(C)(C5C(C)(C(C(C)C)C(O)C5O)CC4)CC=3)CC2)C1)C	O=C(OC1C(OC2C(O)C(O)C(O)C(CO)O2)C(C)(C)C2C(C)(C=3C(C4(C)C(C)(C5C(C)(C(C(C)C)C(O)C5O)CC4)CC=3)CC2)C1)C
NCGC00385699-01	O=C(OC1C(OC2C(O)C(O)C(OC3C(O)C(O)C(O)C(C)O3)C(C)O2)C(O)C(O)C(CO)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(CO)(C)C(OC6C(OC7C(O)C(OC8C(O)C(O)C(O)C(C)O8)C(O)C(CO)O7)C(O)C(O)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385699-01	363679882.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(OC2C(O)C(O)C(OC3C(O)C(O)C(O)C(C)O3)C(C)O2)C(O)C(O)C(CO)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(CO)(C)C(OC6C(OC7C(O)C(OC8C(O)C(O)C(O)C(C)O8)C(O)C(CO)O7)C(O)C(O)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(OC1C(OC2C(O)C(O)C(OC3C(O)C(O)C(O)C(C)O3)C(C)O2)C(O)C(O)C(CO)O1)C12C(C=3C(C)(C4(C)C(C5(C)C(C(CO)(C)C(OC6C(OC7C(O)C(OC8C(O)C(O)C(O)C(C)O8)C(O)C(CO)O7)C(O)C(O)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00381102-01	O=C(OC1C(OC2C(O)C(O)C(OC3C(O)C(O)C(O)CO3)C(C)O2)C(O)C(CO)O1)[C@@]12C(O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(O)C(O)C(C(=O)O)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Stachys | Family: Labiatae | Species: glutinosa		1	NCGC00381102-01	363678971.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(OC2C(O)C(O)C(OC3C(O)C(O)C(O)CO3)C(C)O2)C(O)C(CO)O1)[C@@]12C(O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(O)C(O)C(C(=O)O)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	O=C(OC1C(OC2C(O)C(O)C(OC3C(O)C(O)C(O)CO3)C(C)O2)C(O)C(CO)O1)[C@@]12C(O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(O)C(O)C(C(=O)O)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2
NCGC00381335-01	O=C(OC1C(OC2C(O)C(O)C(OC3C(O)C(OC4C(O)C(O)C(O)CO4)C(O)CO3)CO2)C(OC(=O)C23C(O)C(O)C4(C)C5(C)C(C6(C)C(C(C)(C)C(OC7C(O)C(O)C(O)C(COC8C(OC9C(O)C(O)C(O)C(COC(=O)C)O9)C(O)C(OC(=O)C)CO8)O7)CC6)CC5)CC=C4C2CC(C)(C)CC3)OC(CO)C1O)/C(=C/CCC(O)(C=C)C)/C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381335-01	363679096.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(OC2C(O)C(O)C(OC3C(O)C(OC4C(O)C(O)C(O)CO4)C(O)CO3)CO2)C(OC(=O)C23C(O)C(O)C4(C)C5(C)C(C6(C)C(C(C)(C)C(OC7C(O)C(O)C(O)C(COC8C(OC9C(O)C(O)C(O)C(COC(=O)C)O9)C(O)C(OC(=O)C)CO8)O7)CC6)CC5)CC=C4C2CC(C)(C)CC3)OC(CO)C1O)/C(=C/CCC(O)(C=C)C)/C	O=C(OC1C(OC2C(O)C(O)C(OC3C(O)C(OC4C(O)C(O)C(O)CO4)C(O)CO3)CO2)C(OC(=O)C23C(O)C(O)C4(C)C5(C)C(C6(C)C(C(C)(C)C(OC7C(O)C(O)C(O)C(COC8C(OC9C(O)C(O)C(O)C(COC(=O)C)O9)C(O)C(OC(=O)C)CO8)O7)CC6)CC5)CC=C4C2CC(C)(C)CC3)OC(CO)C1O)/C(=C/CCC(O)(C=C)C)/C
NCGC00384705-01	O=C(OC1C(OC2C(O)C(O)C(OC3C(O)C(OC4C(O)C(O)C(O)CO4)C(O)CO3)CO2)C(OC(=O)C23C(O)C(O)C4(C)C5(C)C(C6(C)C(C(C)(C)C(OC7C(OC8C(O)C(O)C(O)CO8)C(O)C(O)C(COC8C(OC9C(OC(=O)C)C(O)C(O)C(COC(=O)C)O9)C(O)C(OC(=O)C)CO8)O7)CC6)CC5)CC=C4C2CC(C)(C)CC3)OC(CO)C1O)/C(=C/CCC(O)(C=C)C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384705-01	363679318.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	15.0	O=C(OC1C(OC2C(O)C(O)C(OC3C(O)C(OC4C(O)C(O)C(O)CO4)C(O)CO3)CO2)C(OC(=O)C23C(O)C(O)C4(C)C5(C)C(C6(C)C(C(C)(C)C(OC7C(OC8C(O)C(O)C(O)CO8)C(O)C(O)C(COC8C(OC9C(OC(=O)C)C(O)C(O)C(COC(=O)C)O9)C(O)C(OC(=O)C)CO8)O7)CC6)CC5)CC=C4C2CC(C)(C)CC3)OC(CO)C1O)/C(=C/CCC(O)(C=C)C)/C	O=C(OC1C(OC2C(O)C(O)C(OC3C(O)C(OC4C(O)C(O)C(O)CO4)C(O)CO3)CO2)C(OC(=O)C23C(O)C(O)C4(C)C5(C)C(C6(C)C(C(C)(C)C(OC7C(OC8C(O)C(O)C(O)CO8)C(O)C(O)C(COC8C(OC9C(OC(=O)C)C(O)C(O)C(COC(=O)C)O9)C(O)C(OC(=O)C)CO8)O7)CC6)CC5)CC=C4C2CC(C)(C)CC3)OC(CO)C1O)/C(=C/CCC(O)(C=C)C)/C
NCGC00381020-01	O=C(OC1C(OC2C(O)C(OC3C(O)C(O)(CO)CO3)C(OC3C(O)C(O)C(OC4C(O)C(O)C(O)CO4)CO3)CO2)C(O)C(O)C(CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](OC4C(O)C(O)C(O)C(C)O4)[C@@H](O)C5)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Afrosersalisia | Family: Sapotaceae | Species: cerasifera		1	NCGC00381020-01	363678928.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(OC2C(O)C(OC3C(O)C(O)(CO)CO3)C(OC3C(O)C(O)C(OC4C(O)C(O)C(O)CO4)CO3)CO2)C(O)C(O)C(CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](OC4C(O)C(O)C(O)C(C)O4)[C@@H](O)C5)CC=3)CC1)CC(C)(C)CC2	O=C(OC1C(OC2C(O)C(OC3C(O)C(O)(CO)CO3)C(OC3C(O)C(O)C(OC4C(O)C(O)C(O)CO4)CO3)CO2)C(O)C(O)C(CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](OC4C(O)C(O)C(O)C(C)O4)[C@@H](O)C5)CC=3)CC1)CC(C)(C)CC2
NCGC00385323-01	O=C(OC1C(O[C@H]2[C@H](O)[C@H](O)[C@@H](OC3C(O)C(OC4C(O)C(O)C(O)C(C)O4)C(O)CO3)[C@H](C)O2)C(O)C(O)CO1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](OC4C(O)C(O)C(O)C(CO)O4)[C@@H](O)C5)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Afrosersalisia | Family: Sapotaceae | Species: cerasifera		1	NCGC00385323-01	363679676.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C(O[C@H]2[C@H](O)[C@H](O)[C@@H](OC3C(O)C(OC4C(O)C(O)C(O)C(C)O4)C(O)CO3)[C@H](C)O2)C(O)C(O)CO1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](OC4C(O)C(O)C(O)C(CO)O4)[C@@H](O)C5)CC=3)CC1)CC(C)(C)CC2	O=C(OC1C(O[C@H]2[C@H](O)[C@H](O)[C@@H](OC3C(O)C(OC4C(O)C(O)C(O)C(C)O4)C(O)CO3)[C@H](C)O2)C(O)C(O)CO1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](OC4C(O)C(O)C(O)C(CO)O4)[C@@H](O)C5)CC=3)CC1)CC(C)(C)CC2
NCGC00381118-01	O=C(OC1C2(C(C(=C)C)CCC2C)CC(O)C2(C)OC12)C(N)CCC(=O)O		Inactive	<MOA Unknown> | Class: terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381118-01	363678977.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C(C(=C)C)CCC2C)CC(O)C2(C)OC12)C(N)CCC(=O)O	O=C(OC1C2(C(C(=C)C)CCC2C)CC(O)C2(C)OC12)C(N)CCC(=O)O
NCGC00347785-02	O=C(OC1C2(C)C(C(=C)CC1)CC1=C(C)C(=O)OC1(O)C2)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Smyrnium | Family: Umbelliferae | Species: olusatrum		1	NCGC00347785-02	363677687.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(C(=C)CC1)CC1=C(C)C(=O)OC1(O)C2)C	O=C(OC1C2(C)C(C(=C)CC1)CC1=C(C)C(=O)OC1(O)C2)C
NCGC00381393-01	O=C(OC1C2(C)C(C(=C)CC1)CC1=C(C)C(=O)OC1C2)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Smyrnium | Family: Umbelliferae | Species: olusatrum		1	NCGC00381393-01	363679123.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(C(=C)CC1)CC1=C(C)C(=O)OC1C2)C	O=C(OC1C2(C)C(C(=C)CC1)CC1=C(C)C(=O)OC1C2)C
NCGC00385735-01	O=C(OC1C2(C)C(C(=O)C)CCC32OC23C(C3(C)C(CC(OC4OC(C)C(OC5C(O)C(OC)C(O)C(C)O5)C(OC)C4)CC3)CC2)C1OC(=O)/C(=C/C)/C)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Steroide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385735-01	363679910.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(C(=O)C)CCC32OC23C(C3(C)C(CC(OC4OC(C)C(OC5C(O)C(OC)C(O)C(C)O5)C(OC)C4)CC3)CC2)C1OC(=O)/C(=C/C)/C)/C(=C/C)/C	O=C(OC1C2(C)C(C(=O)C)CCC32OC23C(C3(C)C(CC(OC4OC(C)C(OC5C(O)C(OC)C(O)C(C)O5)C(OC)C4)CC3)CC2)C1OC(=O)/C(=C/C)/C)/C(=C/C)/C
NCGC00347740-02	O=C(OC1C2(C)C(C(C)(C)C(O)C1)CC(OC(=O)C)C1(C)C34C(C)(C(c5cocc5)C(=O)C3O4)CCC21)C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: trichilia | Family: Meliaceae | Species: americana		1	NCGC00347740-02	363677677.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(C(C)(C)C(O)C1)CC(OC(=O)C)C1(C)C34C(C)(C(c5cocc5)C(=O)C3O4)CCC21)C	O=C(OC1C2(C)C(C(C)(C)C(O)C1)CC(OC(=O)C)C1(C)C34C(C)(C(c5cocc5)C(=O)C3O4)CCC21)C
NCGC00380319-01	O=C(OC1C2(C)C(C(C)(C)CC1)CC=C1C(=O)OCC21)C(NC(=O)C)C(C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380319-01	363678539.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(C(C)(C)CC1)CC=C1C(=O)OCC21)C(NC(=O)C)C(C)C	O=C(OC1C2(C)C(C(C)(C)CC1)CC=C1C(=O)OCC21)C(NC(=O)C)C(C)C
NCGC00385655-01	O=C(OC1C2(C)C(C(C)=CC1O)CC1C(=C)C(=O)OC1C2)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385655-01	363679859.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(C(C)=CC1O)CC1C(=C)C(=O)OC1C2)C	O=C(OC1C2(C)C(C(C)=CC1O)CC1C(=C)C(=O)OC1C2)C
NCGC00380527-01	O=C(OC1C2(C)C(C(O)(C(C)C)C1)C(OC(=O)c1ccc(O)cc1)C=C(C)C(=O)C2)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380527-01	363678632.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(C(O)(C(C)C)C1)C(OC(=O)c1ccc(O)cc1)C=C(C)C(=O)C2)C	O=C(OC1C2(C)C(C(O)(C(C)C)C1)C(OC(=O)c1ccc(O)cc1)C=C(C)C(=O)C2)C
NCGC00381251-01	O=C(OC1C2(C)C(C(O)(C(C)C)CC2)C(OC(=O)c2ccc(O)cc2)CC(C)=C1)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381251-01	363679050.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(C(O)(C(C)C)CC2)C(OC(=O)c2ccc(O)cc2)CC(C)=C1)/C(=C/C)/C	O=C(OC1C2(C)C(C(O)(C(C)C)CC2)C(OC(=O)c2ccc(O)cc2)CC(C)=C1)/C(=C/C)/C
NCGC00168841-03	O=C(OC1C2(C)C(C)(C)C(C1)CC2)/C=C/c1cc(OC)c(O)cc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Conocephalum  | Family: N/A | Species: conicum		1	NCGC00168841-03	363676700.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(C)(C)C(C1)CC2)/C=C/c1cc(OC)c(O)cc1	O=C(OC1C2(C)C(C)(C)C(C1)CC2)/C=C/c1cc(OC)c(O)cc1
NCGC00159354-06	O=C(OC1C2(C)C(C)(C)C(C1)CC2)C		Inactive			1	BORNYL ACETATE	405559120.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1C2(C)C(C)(C)C(C1)CC2)C	O=C(OC1C2(C)C(C)(C)C(C1)CC2)C
NCGC00380776-01	O=C(OC1C2(C)C(C)(C)C(C1)CC2)C(O)(CC(=O)O)CC(=O)O		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380776-01	363678778.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(C)(C)C(C1)CC2)C(O)(CC(=O)O)CC(=O)O	O=C(OC1C2(C)C(C)(C)C(C1)CC2)C(O)(CC(=O)O)CC(=O)O
NCGC00386085-01	O=C(OC1C2(C)C(C)OC32C=2OC4(C)C(C5(C)C(OC(=O)C)CC(C(O)(C)C)OC5CC4)C(O)C=2C(=O)C=C3C1C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386085-01	363680099.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(C)OC32C=2OC4(C)C(C5(C)C(OC(=O)C)CC(C(O)(C)C)OC5CC4)C(O)C=2C(=O)C=C3C1C)C	O=C(OC1C2(C)C(C)OC32C=2OC4(C)C(C5(C)C(OC(=O)C)CC(C(O)(C)C)OC5CC4)C(O)C=2C(=O)C=C3C1C)C
NCGC00380263-01	O=C(OC1C2(C)C(C3(OC3)C3OC13)C1OC(=O)C(C)C1CC2)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Ammodaucus | Family: Umbelliferae | Species: leucotrichus		1	NCGC00380263-01	363678517.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(C3(OC3)C3OC13)C1OC(=O)C(C)C1CC2)/C(=C\C)/C	O=C(OC1C2(C)C(C3(OC3)C3OC13)C1OC(=O)C(C)C1CC2)/C(=C\C)/C
NCGC00385549-01	O=C(OC1C2(C)C(C=3C(C)(C4(C)C(C(=O)C=3)C3(C)C(C(C)(C)C(OC5C(OC6C(O)C(O)C(O)C(C(=O)O)O6)C(O)C(O)C(C(=O)O)O5)CC3)CC4)CC2)CC(C(=O)O)(C)C1)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385549-01	363679802.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(C=3C(C)(C4(C)C(C(=O)C=3)C3(C)C(C(C)(C)C(OC5C(OC6C(O)C(O)C(O)C(C(=O)O)O6)C(O)C(O)C(C(=O)O)O5)CC3)CC4)CC2)CC(C(=O)O)(C)C1)C	O=C(OC1C2(C)C(C=3C(C)(C4(C)C(C(=O)C=3)C3(C)C(C(C)(C)C(OC5C(OC6C(O)C(O)C(O)C(C(=O)O)O6)C(O)C(O)C(C(=O)O)O5)CC3)CC4)CC2)CC(C(=O)O)(C)C1)C
NCGC00385453-01	O=C(OC1C2(C)C(O)(C3C(C4(C)C(=CC3)CC(OC3OC(C)C(OC5OC(C)C(OC6C(O)C(OC)C(OC7C(O)C(O)C(O)C(CO)O7)C(C)O6)C(OC)C5)C(OC)C3)CC4)C1)CCC2C(=O)C)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385453-01	363679747.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(O)(C3C(C4(C)C(=CC3)CC(OC3OC(C)C(OC5OC(C)C(OC6C(O)C(OC)C(OC7C(O)C(O)C(O)C(CO)O7)C(C)O6)C(OC)C5)C(OC)C3)CC4)C1)CCC2C(=O)C)/C(=C/C)/C	O=C(OC1C2(C)C(O)(C3C(C4(C)C(=CC3)CC(OC3OC(C)C(OC5OC(C)C(OC6C(O)C(OC)C(OC7C(O)C(O)C(O)C(CO)O7)C(C)O6)C(OC)C5)C(OC)C3)CC4)C1)CCC2C(=O)C)/C(=C/C)/C
NCGC00385063-01	O=C(OC1C2(C)C(O)(C3C(C4(C)C(=CC3)CC(OC3OC(C)C(OC5OC(C)C(OC6C(O)C(OC)C(OC7C(O)C(O)C(O)C(CO)O7)C(C)O6)C(OC)C5)C(OC)C3)CC4)C1OC(=O)C)CCC2C(O)C)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Steroid | Genus: Condurango | Family: N/A | Species: N/A		1	NCGC00385063-01	363679514.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(O)(C3C(C4(C)C(=CC3)CC(OC3OC(C)C(OC5OC(C)C(OC6C(O)C(OC)C(OC7C(O)C(O)C(O)C(CO)O7)C(C)O6)C(OC)C5)C(OC)C3)CC4)C1OC(=O)C)CCC2C(O)C)/C=C/c1ccccc1	O=C(OC1C2(C)C(O)(C3C(C4(C)C(=CC3)CC(OC3OC(C)C(OC5OC(C)C(OC6C(O)C(OC)C(OC7C(O)C(O)C(O)C(CO)O7)C(C)O6)C(OC)C5)C(OC)C3)CC4)C1OC(=O)C)CCC2C(O)C)/C=C/c1ccccc1
NCGC00384852-02	O=C(OC1C2(C)C(O)(C3C(C4(C)C(=CC3)CC(OC3OC(C)C(OC5OC(C)C(OC6OC(C)C(OC7OC(C)C(O)C(OC)C7)C(OC)C6)C(OC)C5)C(OC)C3)CC4)C1)CCC2C(=O)C)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384852-02	363679397.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(O)(C3C(C4(C)C(=CC3)CC(OC3OC(C)C(OC5OC(C)C(OC6OC(C)C(OC7OC(C)C(O)C(OC)C7)C(OC)C6)C(OC)C5)C(OC)C3)CC4)C1)CCC2C(=O)C)/C(=C/C)/C	O=C(OC1C2(C)C(O)(C3C(C4(C)C(=CC3)CC(OC3OC(C)C(OC5OC(C)C(OC6OC(C)C(OC7OC(C)C(O)C(OC)C7)C(OC)C6)C(OC)C5)C(OC)C3)CC4)C1)CCC2C(=O)C)/C(=C/C)/C
NCGC00381127-01	O=C(OC1C2(C)C(O)(C3C(C4(C)C(=CC3)CC(OC3OC(C)C(OC5OC(C)C(OC6OC(C)C(OC7OC(C)C(OC8OC(C)C(OC9C(O)C(O)C(O)C(CO)O9)C(OC)C8)C(OC)C7)C(OC)C6)C(OC)C5)C(OC)C3)CC4)C1)CCC2C(=O)C)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381127-01	363678982.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(O)(C3C(C4(C)C(=CC3)CC(OC3OC(C)C(OC5OC(C)C(OC6OC(C)C(OC7OC(C)C(OC8OC(C)C(OC9C(O)C(O)C(O)C(CO)O9)C(OC)C8)C(OC)C7)C(OC)C6)C(OC)C5)C(OC)C3)CC4)C1)CCC2C(=O)C)/C(=C/C)/C	O=C(OC1C2(C)C(O)(C3C(C4(C)C(=CC3)CC(OC3OC(C)C(OC5OC(C)C(OC6OC(C)C(OC7OC(C)C(OC8OC(C)C(OC9C(O)C(O)C(O)C(CO)O9)C(OC)C8)C(OC)C7)C(OC)C6)C(OC)C5)C(OC)C3)CC4)C1)CCC2C(=O)C)/C(=C/C)/C
NCGC00347665-02	O=C(OC1C2(C)C(O)OC3OCC45C(O)CC2C3(C(O)C1)C4C(=O)C(O)C1(C)C(O)(c2cocc2)CC2OC512)C(CC)C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: trichilia | Family: Meliaceae | Species: americana		1	NCGC00347665-02	363677661.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C(O)OC3OCC45C(O)CC2C3(C(O)C1)C4C(=O)C(O)C1(C)C(O)(c2cocc2)CC2OC512)C(CC)C	O=C(OC1C2(C)C(O)OC3OCC45C(O)CC2C3(C(O)C1)C4C(=O)C(O)C1(C)C(O)(c2cocc2)CC2OC512)C(CC)C
NCGC00381227-01	O=C(OC1C2(C)C(O)OC3OCC45C(O)CC2C3(C(O)C1)C4C(=O)CC1(C)C(c2cocc2)CC2OC512)C(CC)C	5.4000001	Active	<MOA Unknown> | Class: Triterpen | Genus: trichilia | Family: Meliaceae | Species: americana	0.0	1	NCGC00381227-01	363679036.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	2.2	92.7552193991	O=C(OC1C2(C)C(O)OC3OCC45C(O)CC2C3(C(O)C1)C4C(=O)CC1(C)C(c2cocc2)CC2OC512)C(CC)C	O=C(OC1C2(C)C(O)OC3OCC45C(O)CC2C3(C(O)C1)C4C(=O)CC1(C)C(c2cocc2)CC2OC512)C(CC)C
NCGC00381084-01	O=C(OC1C2(C)C3(C(=C)C4(C(C)(C)OC(=O)CC4)C1)C(OC(=O)C)C1(C)C(=O)C42C(=O)OC(C)C4(C(=O)O1)O3)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381084-01	363678960.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C3(C(=C)C4(C(C)(C)OC(=O)CC4)C1)C(OC(=O)C)C1(C)C(=O)C42C(=O)OC(C)C4(C(=O)O1)O3)/C(=C/C)/C	O=C(OC1C2(C)C3(C(=C)C4(C(C)(C)OC(=O)CC4)C1)C(OC(=O)C)C1(C)C(=O)C42C(=O)OC(C)C4(C(=O)O1)O3)/C(=C/C)/C
NCGC00385799-01	O=C(OC1C2(C)C3(C(C)(C)OC(OC)(O3)C1)C(O)CC1(C)Oc3c(C)c4c(c(OC)c3CC21)C(=O)OC4)C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385799-01	363679945.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C3(C(C)(C)OC(OC)(O3)C1)C(O)CC1(C)Oc3c(C)c4c(c(OC)c3CC21)C(=O)OC4)C	O=C(OC1C2(C)C3(C(C)(C)OC(OC)(O3)C1)C(O)CC1(C)Oc3c(C)c4c(c(OC)c3CC21)C(=O)OC4)C
NCGC00381056-01	O=C(OC1C2(C)C3(O)C(C(=O)OC3)=CCC2C(C)(C)CC1)C(NC(=O)C)C(C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381056-01	363678948.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C3(O)C(C(=O)OC3)=CCC2C(C)(C)CC1)C(NC(=O)C)C(C)C	O=C(OC1C2(C)C3(O)C(C(=O)OC3)=CCC2C(C)(C)CC1)C(NC(=O)C)C(C)C
NCGC00380573-01	O=C(OC1C2(C)C34C(C)(C(OC(=O)C(C)C)CC2C2(C)C(OC(=O)C)CC(=O)OC(C)(C)C2C1)C(c1cocc1)CC3O4)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: trichilia | Family: Meliaceae | Species: americana		1	NCGC00380573-01	363678655.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C34C(C)(C(OC(=O)C(C)C)CC2C2(C)C(OC(=O)C)CC(=O)OC(C)(C)C2C1)C(c1cocc1)CC3O4)/C(=C/C)/C	O=C(OC1C2(C)C34C(C)(C(OC(=O)C(C)C)CC2C2(C)C(OC(=O)C)CC(=O)OC(C)(C)C2C1)C(c1cocc1)CC3O4)/C(=C/C)/C
NCGC00380222-01	O=C(OC1C2(C)C3=C(C(=O)CC2C2(C)C=CC(=O)C(C)(C)C2C1)C(C=1C(=O)OC(O)C=1)CC3)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380222-01	363678502.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C3=C(C(=O)CC2C2(C)C=CC(=O)C(C)(C)C2C1)C(C=1C(=O)OC(O)C=1)CC3)C	O=C(OC1C2(C)C3=C(C(=O)CC2C2(C)C=CC(=O)C(C)(C)C2C1)C(C=1C(=O)OC(O)C=1)CC3)C
NCGC00380597-01	O=C(OC1C2(C)C3C(C)(C(=O)C(C(=O)OC)(C)OC3=O)C(=C)CC2C2(C)C(O)CC(=O)C(C)(C)C2C1O)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380597-01	363678665.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C3C(C)(C(=O)C(C(=O)OC)(C)OC3=O)C(=C)CC2C2(C)C(O)CC(=O)C(C)(C)C2C1O)C	O=C(OC1C2(C)C3C(C)(C(=O)C(C(=O)OC)(C)OC3=O)C(=C)CC2C2(C)C(O)CC(=O)C(C)(C)C2C1O)C
NCGC00347662-02	O=C(OC1C2(C)C3C(C)(C(=O)C(C(=O)OC)(C)OC3=O)C(=C)CC2C2(C)C(O)CC(=O)C(C)(C)C2C1OC(=O)C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347662-02	363677660.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C3C(C)(C(=O)C(C(=O)OC)(C)OC3=O)C(=C)CC2C2(C)C(O)CC(=O)C(C)(C)C2C1OC(=O)C)C	O=C(OC1C2(C)C3C(C)(C(=O)C(C(=O)OC)(C)OC3=O)C(=C)CC2C2(C)C(O)CC(=O)C(C)(C)C2C1OC(=O)C)C
NCGC00380238-01	O=C(OC1C2(C)C3C(C)(C(=O)C(C)OC3=O)C(=C)CC2C2(C)C(OC(=O)C)CC(=O)OC(C)(C)C2C1O)C		Inactive	<MOA Unknown> | Class: sesterterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380238-01	363678510.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C3C(C)(C(=O)C(C)OC3=O)C(=C)CC2C2(C)C(OC(=O)C)CC(=O)OC(C)(C)C2C1O)C	O=C(OC1C2(C)C3C(C)(C(=O)C(C)OC3=O)C(=C)CC2C2(C)C(OC(=O)C)CC(=O)OC(C)(C)C2C1O)C
NCGC00380642-01	O=C(OC1C2(C)C3C(C)(C(=O)C(C)OC3=O)C(=C)CC2C2(C)C=CC(=O)OC(C)(C)C2C1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380642-01	363678687.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(C)C3C(C)(C(=O)C(C)OC3=O)C(=C)CC2C2(C)C=CC(=O)OC(C)(C)C2C1)C	O=C(OC1C2(C)C3C(C)(C(=O)C(C)OC3=O)C(=C)CC2C2(C)C=CC(=O)OC(C)(C)C2C1)C
NCGC00386019-01	O=C(OC1C2(CO)C(O)C(O)C3(C)C4(C)C(C5(C)C(C(C)(C)C(O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O9)[C@@H](O)[C@@H](O)CO8)[C@@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3C2CC(C)(C)C1)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386019-01	363680063.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(CO)C(O)C(O)C3(C)C4(C)C(C5(C)C(C(C)(C)C(O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O9)[C@@H](O)[C@@H](O)CO8)[C@@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3C2CC(C)(C)C1)/C(=C\C)/C	O=C(OC1C2(CO)C(O)C(O)C3(C)C4(C)C(C5(C)C(C(C)(C)C(O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O9)[C@@H](O)[C@@H](O)CO8)[C@@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3C2CC(C)(C)C1)/C(=C\C)/C
NCGC00381026-01	O=C(OC1C2(CO)C(OC(=O)C)C(OC(=O)/C=C/C=C/C=C/CCC)C3(C)C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(O)C(OC7C(O)C(OC8C(OC9C(O)C(O)C(O)C(CO)O9)C(O)C(O)C(CO)O8)C(O)C(C(=O)O)O7)C(C)O6)CC5)CC4)CC=C3C2CC(C)(C)C1)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Saponin | Genus: Ternstroenia | Family: Theaceae | Species: tepezapote		1	NCGC00381026-01	363678933.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(CO)C(OC(=O)C)C(OC(=O)/C=C/C=C/C=C/CCC)C3(C)C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(O)C(OC7C(O)C(OC8C(OC9C(O)C(O)C(O)C(CO)O9)C(O)C(O)C(CO)O8)C(O)C(C(=O)O)O7)C(C)O6)CC5)CC4)CC=C3C2CC(C)(C)C1)/C(=C\C)/C	O=C(OC1C2(CO)C(OC(=O)C)C(OC(=O)/C=C/C=C/C=C/CCC)C3(C)C4(C)C(C5(C)C(C(C)(C)C(OC6C(O)C(O)C(OC7C(O)C(OC8C(OC9C(O)C(O)C(O)C(CO)O9)C(O)C(O)C(CO)O8)C(O)C(C(=O)O)O7)C(C)O6)CC5)CC4)CC=C3C2CC(C)(C)C1)/C(=C\C)/C
NCGC00381209-01	O=C(OC1C2(O)C(C(=O)O)(C)C(O)CCC2(C)C2C(C1OC(=O)c1ccccc1)C(C)C=1C(O)(OC(=O)C=1)C2)c1ccccc1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Caralluma | Family: Asclepiadaceae | Species: adscendens		1	NCGC00381209-01	363679024.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(O)C(C(=O)O)(C)C(O)CCC2(C)C2C(C1OC(=O)c1ccccc1)C(C)C=1C(O)(OC(=O)C=1)C2)c1ccccc1	O=C(OC1C2(O)C(C(=O)O)(C)C(O)CCC2(C)C2C(C1OC(=O)c1ccccc1)C(C)C=1C(O)(OC(=O)C=1)C2)c1ccccc1
NCGC00169148-03	O=C(OC1C2(O)C(C(CO)=C1)C(OC1C(O)C(O)C(O)C(CO)O1)OC=C2)c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Tabebuia | Family: Bignoniaceae | Species: impetiginosa		1	NCGC00169148-03	363676781.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(O)C(C(CO)=C1)C(OC1C(O)C(O)C(O)C(CO)O1)OC=C2)c1ccc(O)cc1	O=C(OC1C2(O)C(C(CO)=C1)C(OC1C(O)C(O)C(O)C(CO)O1)OC=C2)c1ccc(O)cc1
NCGC00380718-01	O=C(OC1C2(OC(=O)C(C)C)C(C)(C)C2C2C(O)(C1C)C1C(O)(C(=O)C(C)=C1)CC(CO)=C2)/C(=C/C)/C	5.3499999	Active	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00380718-01	363678735.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	2.4	54.4339101888	O=C(OC1C2(OC(=O)C(C)C)C(C)(C)C2C2C(O)(C1C)C1C(O)(C(=O)C(C)=C1)CC(CO)=C2)/C(=C/C)/C	O=C(OC1C2(OC(=O)C(C)C)C(C)(C)C2C2C(O)(C1C)C1C(O)(C(=O)C(C)=C1)CC(CO)=C2)/C(=C/C)/C
NCGC00384808-01	O=C(OC1C2(OC(=O)C(C)C)C(C)(C)C2C2C(O)(C1C)C1C(O)(C(=O)C(C)=C1)CC(CO)=C2)C(CC)C	6.5500002	Active	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00384808-01	363679368.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	1.4	64.3062201	O=C(OC1C2(OC(=O)C(C)C)C(C)(C)C2C2C(O)(C1C)C1C(O)(C(=O)C(C)=C1)CC(CO)=C2)C(CC)C	O=C(OC1C2(OC(=O)C(C)C)C(C)(C)C2C2C(O)(C1C)C1C(O)(C(=O)C(C)=C1)CC(CO)=C2)C(CC)C
NCGC00385645-01	O=C(OC1C2(OC(=O)C)C(C)(C)C2C2C(O)(C1C)C1C(O)(C(=O)C(C)=C1)CC(CO)=C2)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385645-01	363679854.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2(OC(=O)C)C(C)(C)C2C2C(O)(C1C)C1C(O)(C(=O)C(C)=C1)CC(CO)=C2)/C(=C/C)/C	O=C(OC1C2(OC(=O)C)C(C)(C)C2C2C(O)(C1C)C1C(O)(C(=O)C(C)=C1)CC(CO)=C2)/C(=C/C)/C
NCGC00380717-01	O=C(OC1C2(OC(=O)C)C(C)(C)C2C2C(O)(C1C)C1C=C(C)C(=O)C1CC(CO)=C2)/C(=C/C)/C	5.9000001	Active	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00380717-01	363678734.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	3.0	96.4619181952	O=C(OC1C2(OC(=O)C)C(C)(C)C2C2C(O)(C1C)C1C=C(C)C(=O)C1CC(CO)=C2)/C(=C/C)/C	O=C(OC1C2(OC(=O)C)C(C)(C)C2C2C(O)(C1C)C1C=C(C)C(=O)C1CC(CO)=C2)/C(=C/C)/C
NCGC00385776-01	O=C(OC1C2=C(COC(=O)C)C(=O)O[C@@H]2[C@@H]2[C@](C)(O2)/C=C\[C@H]2[C@](COC(=O)C)(O2)C1)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Vemonia | Family: Compositae | Species: colorata		1	NCGC00385776-01	363679935.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2=C(COC(=O)C)C(=O)O[C@@H]2[C@@H]2[C@](C)(O2)/C=C\[C@H]2[C@](COC(=O)C)(O2)C1)/C(=C/C)/C	O=C(OC1C2=C(COC(=O)C)C(=O)O[C@@H]2[C@@H]2[C@](C)(O2)/C=C\[C@H]2[C@](COC(=O)C)(O2)C1)/C(=C/C)/C
NCGC00385946-01	O=C(OC1C2C(=C)C(=O)OC2/C=C(\C)/CC/C=C(\C)/C1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385946-01	363680019.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2C(=C)C(=O)OC2/C=C(\C)/CC/C=C(\C)/C1)C	O=C(OC1C2C(=C)C(=O)OC2/C=C(\C)/CC/C=C(\C)/C1)C
NCGC00385818-01	O=C(OC1C2C(=C)C(=O)OC2/C=C(\CO)/CC/C=C(\C=O)/C1)CC(C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385818-01	363679955.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2C(=C)C(=O)OC2/C=C(\CO)/CC/C=C(\C=O)/C1)CC(C)C	O=C(OC1C2C(=C)C(=O)OC2/C=C(\CO)/CC/C=C(\C=O)/C1)CC(C)C
NCGC00347587-02	O=C(OC1C2C(=C)C(=O)OC2/C=C(\CO)/CCCC(CO)C1)C(=C)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Siegesbeckia | Family: Compositae | Species: orientalis		1	NCGC00347587-02	363677632.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2C(=C)C(=O)OC2/C=C(\CO)/CCCC(CO)C1)C(=C)C	O=C(OC1C2C(=C)C(=O)OC2/C=C(\CO)/CCCC(CO)C1)C(=C)C
NCGC00384580-01	O=C(OC1C2C(=C)C(=O)OC2/C=C(\COC(=O)C)/CC/C=C(\C=O)/C1)C(CC)C	5.4499998	Active	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00384580-01	363679256.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	3.0	42.969150226	O=C(OC1C2C(=C)C(=O)OC2/C=C(\COC(=O)C)/CC/C=C(\C=O)/C1)C(CC)C	O=C(OC1C2C(=C)C(=O)OC2/C=C(\COC(=O)C)/CC/C=C(\C=O)/C1)C(CC)C
NCGC00384581-01	O=C(OC1C2C(=C)C(=O)OC2/C=C(\COC(=O)C)/CC/C=C(\C=O)/C1)CC(C)C	5.4499998	Active	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00384581-01	363679257.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	3.0	35.535215113	O=C(OC1C2C(=C)C(=O)OC2/C=C(\COC(=O)C)/CC/C=C(\C=O)/C1)CC(C)C	O=C(OC1C2C(=C)C(=O)OC2/C=C(\COC(=O)C)/CC/C=C(\C=O)/C1)CC(C)C
NCGC00384790-01	O=C(OC1C2C(=C)C(=O)OC2/C=C(\COO)/CC/C=C(\COC(=O)C)/C1)C(CC)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384790-01	363679354.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2C(=C)C(=O)OC2/C=C(\COO)/CC/C=C(\COC(=O)C)/C1)C(CC)C	O=C(OC1C2C(=C)C(=O)OC2/C=C(\COO)/CC/C=C(\COC(=O)C)/C1)C(CC)C
NCGC00384503-01	O=C(OC1C2C(=C)C(=O)OC2C=C(C)C=2OC(C)(C(=O)C=2)C1)/C(=C/COC(=O)C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Bejaranoa  | Family: N/A | Species: semistriata		1	NCGC00384503-01	363679217.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2C(=C)C(=O)OC2C=C(C)C=2OC(C)(C(=O)C=2)C1)/C(=C/COC(=O)C)/C	O=C(OC1C2C(=C)C(=O)OC2C=C(C)C=2OC(C)(C(=O)C=2)C1)/C(=C/COC(=O)C)/C
NCGC00381113-01	O=C(OC1C2C(=C)C(=O)OC2CC(=C)C=2OC(C)(C(=O)C=2)C1)C(=C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381113-01	363678976.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	33.148801132	O=C(OC1C2C(=C)C(=O)OC2CC(=C)C=2OC(C)(C(=O)C=2)C1)C(=C)C	O=C(OC1C2C(=C)C(=O)OC2CC(=C)C=2OC(C)(C(=O)C=2)C1)C(=C)C
NCGC00347826-02	O=C(OC1C2C(C)(C)CCCC2(C)C2(C(C)C1)OC1(C(O)OC(=O)C1)CC2)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347826-02	363677698.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2C(C)(C)CCCC2(C)C2(C(C)C1)OC1(C(O)OC(=O)C1)CC2)C	O=C(OC1C2C(C)(C)CCCC2(C)C2(C(C)C1)OC1(C(O)OC(=O)C1)CC2)C
NCGC00381315-01	O=C(OC1C2C(C)(C)CCCC2(C)C2(O)C(=O)OCC2=C1)/C=C/C=C/C(=O)C(O)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381315-01	363679082.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2C(C)(C)CCCC2(C)C2(O)C(=O)OCC2=C1)/C=C/C=C/C(=O)C(O)C	O=C(OC1C2C(C)(C)CCCC2(C)C2(O)C(=O)OCC2=C1)/C=C/C=C/C(=O)C(O)C
NCGC00380085-01	O=C(OC1C2C(C)(C)CCCC2(C)C2(O)C(=O)OCC2=C1)/C=C/C=C/C=O		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380085-01	363678455.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2C(C)(C)CCCC2(C)C2(O)C(=O)OCC2=C1)/C=C/C=C/C=O	O=C(OC1C2C(C)(C)CCCC2(C)C2(O)C(=O)OCC2=C1)/C=C/C=C/C=O
NCGC00381170-01	O=C(OC1C2C(C)(C)CCCC2(C)C2(O)C(=O)OCC2=C1)/C=C/C=C/CC(O)C		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381170-01	363679005.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2C(C)(C)CCCC2(C)C2(O)C(=O)OCC2=C1)/C=C/C=C/CC(O)C	O=C(OC1C2C(C)(C)CCCC2(C)C2(O)C(=O)OCC2=C1)/C=C/C=C/CC(O)C
NCGC00385472-01	O=C(OC1C2C(C)(C3(C)C(C4C(C)(CC(OC(=O)C(C(O)C)C)C(C)C4C)CC3)=C1)CC(OC(=O)C)C1C(C)(C)C(O)C(=O)CC21C)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385472-01	363679759.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2C(C)(C3(C)C(C4C(C)(CC(OC(=O)C(C(O)C)C)C(C)C4C)CC3)=C1)CC(OC(=O)C)C1C(C)(C)C(O)C(=O)CC21C)/C(=C\C)/C	O=C(OC1C2C(C)(C3(C)C(C4C(C)(CC(OC(=O)C(C(O)C)C)C(C)C4C)CC3)=C1)CC(OC(=O)C)C1C(C)(C)C(O)C(=O)CC21C)/C(=C\C)/C
NCGC00384823-01	O=C(OC1C2C(C)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C(CO)C1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384823-01	363679378.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2C(C)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C(CO)C1)/C=C/c1ccc(O)cc1	O=C(OC1C2C(C)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C(CO)C1)/C=C/c1ccc(O)cc1
NCGC00347774-02	O=C(OC1C2C(C3(C)C(C(=O)OC(c4cocc4)C3)CC2)C(OC(=O)C)C(OC(=O)C)C1)/C=C/c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Tinospora | Family: Menispermaceae | Species: cordifolia		1	NCGC00347774-02	363677684.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2C(C3(C)C(C(=O)OC(c4cocc4)C3)CC2)C(OC(=O)C)C(OC(=O)C)C1)/C=C/c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1	O=C(OC1C2C(C3(C)C(C(=O)OC(c4cocc4)C3)CC2)C(OC(=O)C)C(OC(=O)C)C1)/C=C/c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1
NCGC00169298-03	O=C(OC1C2C(CCC(O)CC(O)CC(=O)O)C(C)C=CC2=CC(C)C1)C(CC)C		Inactive	HMG-CoA reductase Inhibitor		1	NCGC00169298-03	363676799.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2C(CCC(O)CC(O)CC(=O)O)C(C)C=CC2=CC(C)C1)C(CC)C	O=C(OC1C2C(CCC(O)CC(O)CC(=O)O)C(C)C=CC2=CC(C)C1)C(CC)C
NCGC00380390-01	O=C(OC1C2C(CO)(C)CCCC2(C)C2(O)C(C(=O)OC2)=C1)c1ccccc1		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380390-01	363678563.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2C(CO)(C)CCCC2(C)C2(O)C(C(=O)OC2)=C1)c1ccccc1	O=C(OC1C2C(CO)(C)CCCC2(C)C2(O)C(C(=O)OC2)=C1)c1ccccc1
NCGC00347841-02	O=C(OC1C2C(CO)(C)CCCC2(C)C2(O)C(C(=O)OC2)C1)c1ccccc1		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347841-02	363677705.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2C(CO)(C)CCCC2(C)C2(O)C(C(=O)OC2)C1)c1ccccc1	O=C(OC1C2C(CO)(C)CCCC2(C)C2(O)C(C(=O)OC2)C1)c1ccccc1
NCGC00380852-01	O=C(OC1C2C(CO)(O2)C2C(OC3C(O)C(O)C(O)C(CO)O3)OC=CC12)c1cc(OC)c(OC)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Tabebuia | Family: Bignoniaceae | Species: impetiginosa		1	NCGC00380852-01	363678814.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2C(CO)(O2)C2C(OC3C(O)C(O)C(O)C(CO)O3)OC=CC12)c1cc(OC)c(OC)cc1	O=C(OC1C2C(CO)(O2)C2C(OC3C(O)C(O)C(O)C(CO)O3)OC=CC12)c1cc(OC)c(OC)cc1
NCGC00385585-01	O=C(OC1C2C(COC)C(=O)OC2CC(=C)C=2OC(C)(C(=O)C=2)C1)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385585-01	363679821.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	22.206896552	O=C(OC1C2C(COC)C(=O)OC2CC(=C)C=2OC(C)(C(=O)C=2)C1)/C(=C\C)/C	O=C(OC1C2C(COC)C(=O)OC2CC(=C)C=2OC(C)(C(=O)C=2)C1)/C(=C\C)/C
NCGC00380534-01	O=C(OC1C2C(COC)C(=O)OC2CC(=C)C=2OC(C)(C(=O)C=2)C1)C(=C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380534-01	363678636.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2C(COC)C(=O)OC2CC(=C)C=2OC(C)(C(=O)C=2)C1)C(=C)C	O=C(OC1C2C(COC)C(=O)OC2CC(=C)C=2OC(C)(C(=O)C=2)C1)C(=C)C
NCGC00346874-02	O=C(OC1C2CC3CC1CC(C2)C3)N[C@@](C(=O)NC[C@H](NC(=O)CCC(=O)O)c1ccccc1)(Cc1c2c([nH]c1)cccc2)C		Inactive	CCK2 (CCKB/Gastrin) Antagonist		1	PD-134308	384568952.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	9.885176188	O=C(OC1C2CC3CC1CC(C2)C3)N[C@@](C(=O)NC[C@H](NC(=O)CCC(=O)O)c1ccccc1)(Cc1c2c([nH]c1)cccc2)C	O=C(OC1C2CC3CC1CC(C2)C3)N[C@@](C(=O)NC[C@H](NC(=O)CCC(=O)O)c1ccccc1)(Cc1c2c([nH]c1)cccc2)C
NCGC00485298-01	O=C(OC1C2CCN(C1)CC2)C(O)(c1ccccc1)c1ccccc1		Inactive	Muscarinic acetylcholine receptor M2 Antagonist		1	(Â±)-Quinuclidinyl benzilate	363681281.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C2CCN(C1)CC2)C(O)(c1ccccc1)c1ccccc1	O=C(OC1C2CCN(C1)CC2)C(O)(c1ccccc1)c1ccccc1
NCGC00018171-06	O=C(OC1C2CC[N+](C)(C1)CC2)C(O)(c1ccccc1)c1ccccc1		Inactive			1	Clidinium bromide	170464768.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OC1C2CC[N+](C)(C1)CC2)C(O)(c1ccccc1)c1ccccc1.[Br-]	O=C(OC1C2CC[N+](C)(C1)CC2)C(O)(c1ccccc1)c1ccccc1.[Br-]
NCGC00168848-03	O=C(OC1C=2[C@@](C)(C3C(O)([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)C1)CC[C@H](O[C@H]1[C@H](O)[C@@H](OC)[C@@H](O)[C@@H](C)O1)C=2)C		Inactive	<MOA Unknown> | Class: Steroid | Genus: Acocanthera | Family: Apocynaceae | Species: schimperii		1	NCGC00168848-03	363676702.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C=2[C@@](C)(C3C(O)([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)C1)CC[C@H](O[C@H]1[C@H](O)[C@@H](OC)[C@@H](O)[C@@H](C)O1)C=2)C	O=C(OC1C=2[C@@](C)(C3C(O)([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)C1)CC[C@H](O[C@H]1[C@H](O)[C@@H](OC)[C@@H](O)[C@@H](C)O1)C=2)C
NCGC00380526-01	O=C(OC1C=C(C(=O)O)C2(CO)C(C(CCc3cocc3)(C)C(C)CC2)C1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380526-01	363678631.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C=C(C(=O)O)C2(CO)C(C(CCc3cocc3)(C)C(C)CC2)C1)C	O=C(OC1C=C(C(=O)O)C2(CO)C(C(CCc3cocc3)(C)C(C)CC2)C1)C
NCGC00380082-01	O=C(OC1C=C(C=O)C(O)(C(=O)O)C2(C)C1C(C)(C)CCC2)/C=C/C=C/C=C/C		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380082-01	363678453.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C=C(C=O)C(O)(C(=O)O)C2(C)C1C(C)(C)CCC2)/C=C/C=C/C=C/C	O=C(OC1C=C(C=O)C(O)(C(=O)O)C2(C)C1C(C)(C)CCC2)/C=C/C=C/C=C/C
NCGC00380149-01	O=C(OC1C=C(CO)C2C(OC3C(O)C(O)C(O)C(CO)O3)OC=CC12)c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Tabebuia | Family: Bignoniaceae | Species: impetiginosa		1	NCGC00380149-01	363678475.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C=C(CO)C2C(OC3C(O)C(O)C(O)C(CO)O3)OC=CC12)c1ccc(O)cc1	O=C(OC1C=C(CO)C2C(OC3C(O)C(O)C(O)C(CO)O3)OC=CC12)c1ccc(O)cc1
NCGC00159506-06	O=C(OC1CC(C)(C)CC(C)C1)C(O)c1ccccc1		Inactive	Voltage-gated calcium channel Blocker		1	Cyclandelate	405558545.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1CC(C)(C)CC(C)C1)C(O)c1ccccc1	O=C(OC1CC(C)(C)CC(C)C1)C(O)c1ccccc1
NCGC00091888-09	O=C(OC1CC(C)(C)CC(C)C1)c1c(O)cccc1		Inactive			1	3,3,5-Trimethylcyclohexyl salicylate	170465478.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC1CC(C)(C)CC(C)C1)c1c(O)cccc1	O=C(OC1CC(C)(C)CC(C)C1)c1c(O)cccc1
NCGC00381432-01	O=C(OC1CC(O)CC(O)C(C)C(O)/C(/C)=C/CCC(C)C(C(C/C(=C\CCCCCNC(=N)NC)/C)C)OC(=O)C(C)C(O)/C=C/C(C)C(O)CC(O)C(C)C(O)CCC(C)C(O)CC2(O)C(O)C(O)CC(O2)C1)CC(=O)O		Inactive	<MOA Unknown> | Class: macrolide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381432-01	363679141.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1CC(O)CC(O)C(C)C(O)/C(/C)=C/CCC(C)C(C(C/C(=C\CCCCCNC(=N)NC)/C)C)OC(=O)C(C)C(O)/C=C/C(C)C(O)CC(O)C(C)C(O)CCC(C)C(O)CC2(O)C(O)C(O)CC(O2)C1)CC(=O)O	O=C(OC1CC(O)CC(O)C(C)C(O)/C(/C)=C/CCC(C)C(C(C/C(=C\CCCCCNC(=N)NC)/C)C)OC(=O)C(C)C(O)/C=C/C(C)C(O)CC(O)C(C)C(O)CCC(C)C(O)CC2(O)C(O)C(O)CC(O2)C1)CC(=O)O
NCGC00015026-16	O=C(OC1CC2N(C)C(C1)CC2)C(CO)c1ccccc1		Inactive			1	Atropine (sulfate monohydrate)	384567797.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1CC2N(C)C(C1)CC2)C(CO)c1ccccc1	O=C(OC1CC2N(C)C(C1)CC2)C(CO)c1ccccc1
NCGC00485452-01	O=C(OC1CC2N(C)C(C1)CC2)C(COC)c1ccccc1		Inactive			1	Atropine methyl nitrate	363681338.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1CC2N(C)C(C1)CC2)C(COC)c1ccccc1	O=C(OC1CC2N(C)C(C1)CC2)C(COC)c1ccccc1
NCGC00402270-03	O=C(OC1CC2N(C)C(C1)CC2)N1C(=O)Nc2c(cccc2)C1		Inactive	Muscarinic acetylcholine receptor M4 Antagonist		1	DAU5884 hydrochloride	363681009.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1CC2N(C)C(C1)CC2)N1C(=O)Nc2c(cccc2)C1	O=C(OC1CC2N(C)C(C1)CC2)N1C(=O)Nc2c(cccc2)C1
NCGC00261971-01	O=C(OC1CC2N(C)C(C1)CCC2(C)C)C(O)(c1sccc1)c1sccc1		Inactive			1	Mazaticol	170466055.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	14.7697511961&0.0	O=C(OC1CC2N(C)C(C1)CCC2(C)C)C(O)(c1sccc1)c1sccc1	O=C(OC1CC2N(C)C(C1)CCC2(C)C)C(O)(c1sccc1)c1sccc1
NCGC00013724-04&NCGC00013724-07	O=C(OC1CC2[N+](C)(C)C(C3OC23)C1)[C@H](CO)c1ccccc1		Inactive			2	Methscopolamine (bromide)&(-)-Scopolamine methyl bromide		Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC1CC2[N+](C)(C)C(C3OC23)C1)[C@H](CO)c1ccccc1	O=C(OC1CC2[N+](C)(C)C(C3OC23)C1)[C@H](CO)c1ccccc1
NCGC00522037-01	O=C(OC1CC2[N+](CC)(C)C([C@@H]3O[C@H]23)C1)[C@H](CO)c1ccccc1		Inactive	Muscarinic acetylcholine receptor Antagonist		1	Oxitropium Bromide	405558419.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1CC2[N+](CC)(C)C([C@@H]3O[C@H]23)C1)[C@H](CO)c1ccccc1	O=C(OC1CC2[N+](CC)(C)C([C@@H]3O[C@H]23)C1)[C@H](CO)c1ccccc1
NCGC00522020-01	O=C(OC1CC2[N+](Cc3ccc(OCCCC)cc3)(C)C(C1)CC2)[C@H](CO)c1ccccc1		Inactive	Muscarinic acetylcholine receptor Antagonist		1	Butropium Bromide	405558868.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1CC2[N+](Cc3ccc(OCCCC)cc3)(C)C(C1)CC2)[C@H](CO)c1ccccc1	O=C(OC1CC2[N+](Cc3ccc(OCCCC)cc3)(C)C(C1)CC2)[C@H](CO)c1ccccc1
NCGC00389390-01	O=C(OC1CC=2C(C)(C3C(C4C(C)(C(c5cnccc5)=CC4)CC3)CC=2)CC1)C		Inactive	Cytochrome P450 17A1 Inhibitor		1	Abiraterone acetate	405558467.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	20.658307208	O=C(OC1CC=2C(C)(C3C(C4C(C)(C(c5cnccc5)=CC4)CC3)CC=2)CC1)C	O=C(OC1CC=2C(C)(C3C(C4C(C)(C(c5cnccc5)=CC4)CC3)CC=2)CC1)C
NCGC00263175-02	O=C(OC1CCCC1)[C@@H](NC(=O)[C@@H]([C@H](O)C(=O)NO)CC(C)C)c1ccccc1		Inactive	Aminopeptidase N Inhibitor		1	Tosedostat	384568645.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1CCCC1)[C@@H](NC(=O)[C@@H]([C@H](O)C(=O)NO)CC(C)C)c1ccccc1	O=C(OC1CCCC1)[C@@H](NC(=O)[C@@H]([C@H](O)C(=O)NO)CC(C)C)c1ccccc1
NCGC00181103-02	O=C(OC1CCN(C)CC1)C(OCCC)(c1ccccc1)c1ccccc1	4.9000001	Active	Muscarinic acetylcholine receptor Blocker	0.0	1	Propiverine hydrochloride	170466036.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	67.2471548775	O=C(OC1CCN(C)CC1)C(OCCC)(c1ccccc1)c1ccccc1.Cl	O=C(OC1CCN(C)CC1)C(OCCC)(c1ccccc1)c1ccccc1.Cl
NCGC00387169-01	O=C(OC1CCN(c2nncc3c2cc(OC)c(OC)c3)CC1)NCC		Inactive	cAMP metabolic process Modulator		1	Carbazeran citrate	363680555.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1CCN(c2nncc3c2cc(OC)c(OC)c3)CC1)NCC	O=C(OC1CCN(c2nncc3c2cc(OC)c(OC)c3)CC1)NCC
NCGC00178395-04	O=C(OC1CN(CC)CCC1)C(c1ccccc1)c1ccccc1		Inactive			1	Piperidolate hydrochloride	170465927.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OC1CN(CC)CCC1)C(c1ccccc1)c1ccccc1.Cl	O=C(OC1CN(CC)CCC1)C(c1ccccc1)c1ccccc1.Cl
NCGC00178783-03	O=C(OC1C[C@@H]2N(C)C(C1)CC2)[C@H](CO)c1ccccc1		Inactive	M1 Muscarinic acetylcholine receptor Antagonists		1	HYOSCYAMINE	405558529.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1C[C@@H]2N(C)C(C1)CC2)[C@H](CO)c1ccccc1	O=C(OC1C[C@@H]2N(C)C(C1)CC2)[C@H](CO)c1ccccc1
NCGC00024357-07	O=C(OC1C[C@@H]2N(C)[C@@H]([C@H]3O[C@@H]23)C1)[C@H](CO)c1ccccc1		Inactive	Muscarinic Antagonists		1	Scopolamine hydrobromide	170464830.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC1C[C@@H]2N(C)[C@@H]([C@H]3O[C@@H]23)C1)[C@H](CO)c1ccccc1.Br	O=C(OC1C[C@@H]2N(C)[C@@H]([C@H]3O[C@@H]23)C1)[C@H](CO)c1ccccc1.Br
NCGC00179630-03	O=C(OC1C[C@@H]2N(C)[C@H](C1)CC2)C(O)c1ccccc1		Inactive	Muscarinic acetylcholine receptor Antagonist		1	Homatropine hydrobromide	170465642.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1C[C@@H]2N(C)[C@H](C1)CC2)C(O)c1ccccc1.Br	O=C(OC1C[C@@H]2N(C)[C@H](C1)CC2)C(O)c1ccccc1.Br
NCGC00024434-05	O=C(OC1C[C@@H]2N(C)[C@H](C1)CC2)C1c2c(N=C1)cccc2		Inactive			1	Tropisetron HCl	363676528.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1C[C@@H]2N(C)[C@H](C1)CC2)C1c2c(N=C1)cccc2	O=C(OC1C[C@@H]2N(C)[C@H](C1)CC2)C1c2c(N=C1)cccc2
NCGC00161414-03	O=C(OC1C[C@@H]2N(C)[C@H](C1)CC2)c1c2c([nH]c1)cccc2		Inactive	5-HT3 Antagonists		1	Tropisetron	170466432.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1C[C@@H]2N(C)[C@H](C1)CC2)c1c2c([nH]c1)cccc2	O=C(OC1C[C@@H]2N(C)[C@H](C1)CC2)c1c2c([nH]c1)cccc2
NCGC00181048-02	O=C(OC1C[C@@H]2N3[C@H](C1)CC(C(=O)C3)C2)c1c2c([nH]c1)cccc2		Inactive	Serotonin 3a (5-HT3a) receptor Antagonist		1	Dolasetron mesylate hydrate	225144319.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1C[C@@H]2N3[C@H](C1)CC(C(=O)C3)C2)c1c2c([nH]c1)cccc2	O=C(OC1C[C@@H]2N3[C@H](C1)CC(C(=O)C3)C2)c1c2c([nH]c1)cccc2
NCGC00022819-04	O=C(OC1C[C@@H]2[N+](C(C)C)(C)[C@H](C1)CC2)C(CO)c1ccccc1		Inactive	Muscarinic Antagonists		1	Ipratropium bromide	405559003.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OC1C[C@@H]2[N+](C(C)C)(C)[C@H](C1)CC2)C(CO)c1ccccc1	O=C(OC1C[C@@H]2[N+](C(C)C)(C)[C@H](C1)CC2)C(CO)c1ccccc1
NCGC00379039-02	O=C(OC1C[C@@H]2[N+](C)(C)[C@@H]([C@H]3O[C@H]23)C1)C(O)(c1sccc1)c1sccc1		Inactive	Muscarinic M3 Antagonists		1	Tiotropium (Bromide)	405559060.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1C[C@@H]2[N+](C)(C)[C@@H]([C@H]3O[C@H]23)C1)C(O)(c1sccc1)c1sccc1	O=C(OC1C[C@@H]2[N+](C)(C)[C@@H]([C@H]3O[C@H]23)C1)C(O)(c1sccc1)c1sccc1
NCGC00021394-04	O=C(OC1C[C@@H]2[N+](C)(C)[C@H](C1)CC2)C(CCC)CCC		Inactive	Muscarinic acetylcholine receptor M3 Antagonist		1	Anisotropine methylbromide	144207024.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC1C[C@@H]2[N+](C)(C)[C@H](C1)CC2)C(CCC)CCC.[Br-]	O=C(OC1C[C@@H]2[N+](C)(C)[C@H](C1)CC2)C(CCC)CCC.[Br-]
NCGC00015080-08	O=C(OC1C[C@@H]2[N+](C)(C)[C@H](C1)CC2)C(CO)c1ccccc1		Inactive	Muscarinic acetylcholine receptor Antagonist		1	Methylatropine nitrate	170465893.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=[N+]([O-])[O-].O=C(OC1C[C@@H]2[N+](C)(C)[C@H](C1)CC2)C(CO)c1ccccc1	O=[N+]([O-])[O-].O=C(OC1C[C@@H]2[N+](C)(C)[C@H](C1)CC2)C(CO)c1ccccc1
NCGC00186628-01&NCGC00186628-02	O=C(OC1C[C@@H]2[N+](CCCC)(C)[C@@H]([C@H]3O[C@@H]23)C1)[C@H](CO)c1ccccc1		Inactive	Muscarinic acetylcholine receptor Antagonist		2	Butylscopolamine bromide	124897815.0&170465685.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC1C[C@@H]2[N+](CCCC)(C)[C@@H]([C@H]3O[C@@H]23)C1)[C@H](CO)c1ccccc1	O=C(OC1C[C@@H]2[N+](CCCC)(C)[C@@H]([C@H]3O[C@@H]23)C1)[C@H](CO)c1ccccc1&O=C(OC1C[C@@H]2[N+](CCCC)(C)[C@@H]([C@H]3O[C@@H]23)C1)[C@H](CO)c1ccccc1.[Br-]
NCGC00484907-01	O=C(OC1C[C@@H]2[N+]([O-])(C)[C@H]([C@@H]3O[C@H]23)C1)C(CO)c1ccccc1		Inactive	Acetylcholinesterase Inhibitor		1	(-)-Scopolamine N-oxide	405559073.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1C[C@@H]2[N+]([O-])(C)[C@H]([C@@H]3O[C@H]23)C1)C(CO)c1ccccc1	O=C(OC1C[C@@H]2[N+]([O-])(C)[C@H]([C@@H]3O[C@H]23)C1)C(CO)c1ccccc1
NCGC00167438-02	O=C(OC1C[C@@H]2[N+]3([C@H](C1)CC2)CCCC3)C(O)(c1ccccc1)c1ccccc1		Inactive	Muscarinic Antagonists		1	Trospium chloride	174006890.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC1C[C@@H]2[N+]3([C@H](C1)CC2)CCCC3)C(O)(c1ccccc1)c1ccccc1.[Cl-]	O=C(OC1C[C@@H]2[N+]3([C@H](C1)CC2)CCCC3)C(O)(c1ccccc1)c1ccccc1.[Cl-]
NCGC00178803-03	O=C(OC1C[C@H]2[N+](C)(C)C(C1)CC2)C(O)c1ccccc1		Inactive			1	HOMATROPINE METHYLBROMIDE	405558716.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1C[C@H]2[N+](C)(C)C(C1)CC2)C(O)c1ccccc1	O=C(OC1C[C@H]2[N+](C)(C)C(C1)CC2)C(O)c1ccccc1
NCGC00179456-04	O=C(OC1C[N+](C)(C)CC1)C(O)(c1ccccc1)C1CCCC1		Inactive			1	Glycopyrrolate bromide	170465427.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1C[N+](C)(C)CC1)C(O)(c1ccccc1)C1CCCC1.[Br-]	O=C(OC1C[N+](C)(C)CC1)C(O)(c1ccccc1)C1CCCC1.[Br-]
NCGC00178896-05	O=C(OC1C[N+](C)(C)CCC1)C(O)(c1ccccc1)c1ccccc1		Inactive	Muscarinic acetylcholine receptor M3 Antagonist		1	Mepenzolate bromide	170465214.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1C[N+](C)(C)CCC1)C(O)(c1ccccc1)c1ccccc1.[Br-]	O=C(OC1C[N+](C)(C)CCC1)C(O)(c1ccccc1)c1ccccc1.[Br-]
NCGC00347879-02	O=C(OC1OC=C(CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2C1C(O)(CO)C(O)C2)CC(C)C		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Centranthus | Family: N/A | Species: ruber		1	NCGC00347879-02	363677716.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1OC=C(CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2C1C(O)(CO)C(O)C2)CC(C)C	O=C(OC1OC=C(CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2C1C(O)(CO)C(O)C2)CC(C)C
NCGC00380653-01	O=C(OC1[C@@H](O)C(C)(C)[C@H]2[C@@](C)([C@@]3([C@H](C)CC2)Oc2c(c(O)cc4C(=O)NCc24)C3)C1)C		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380653-01	363678692.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1[C@@H](O)C(C)(C)[C@H]2[C@@](C)([C@@]3([C@H](C)CC2)Oc2c(c(O)cc4C(=O)NCc24)C3)C1)C	O=C(OC1[C@@H](O)C(C)(C)[C@H]2[C@@](C)([C@@]3([C@H](C)CC2)Oc2c(c(O)cc4C(=O)NCc24)C3)C1)C
NCGC00380518-01	O=C(OC1[C@@H](OC(=O)C)/C(/CO)=C/CC/C(/CO)=C/[C@H]2OC(=O)C(=C)C12)C(CC)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380518-01	363678626.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1[C@@H](OC(=O)C)/C(/CO)=C/CC/C(/CO)=C/[C@H]2OC(=O)C(=C)C12)C(CC)C	O=C(OC1[C@@H](OC(=O)C)/C(/CO)=C/CC/C(/CO)=C/[C@H]2OC(=O)C(=C)C12)C(CC)C
NCGC00380477-01	O=C(OC1[C@@](O)(C(C)C)C2[C@@H](OC(=O)c3ccc(O)cc3)C=C(C)CC(O)[C@@]2(C)C1)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Ferula | Family: Umbelliferae | Species: communis		1	NCGC00380477-01	363678602.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1[C@@](O)(C(C)C)C2[C@@H](OC(=O)c3ccc(O)cc3)C=C(C)CC(O)[C@@]2(C)C1)C	O=C(OC1[C@@](O)(C(C)C)C2[C@@H](OC(=O)c3ccc(O)cc3)C=C(C)CC(O)[C@@]2(C)C1)C
NCGC00381252-01	O=C(OC1[C@H](C(C)C)[C@]2(C)C(C1=O)C1OCC=3[C@@H](O)CC[C@](C)(C1=3)CC2)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381252-01	363679051.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1[C@H](C(C)C)[C@]2(C)C(C1=O)C1OCC=3[C@@H](O)CC[C@](C)(C1=3)CC2)C	O=C(OC1[C@H](C(C)C)[C@]2(C)C(C1=O)C1OCC=3[C@@H](O)CC[C@](C)(C1=3)CC2)C
NCGC00380877-01	O=C(OC1[C@H](O)CC(O)(C(=O)O)C[C@H]1O)/C=C/c1cc(OC)c(O)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Ammi | Family: Apiaceae | Species: visnaga		1	NCGC00380877-01	363678829.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1[C@H](O)CC(O)(C(=O)O)C[C@H]1O)/C=C/c1cc(OC)c(O)cc1	O=C(OC1[C@H](O)CC(O)(C(=O)O)C[C@H]1O)/C=C/c1cc(OC)c(O)cc1
NCGC00380946-01	O=C(OC1[C@H](O)CC(O)(C(=O)O)C[C@H]1O)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Tithonia | Family: Compositae | Species: diversifolia		1	NCGC00380946-01	363678877.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1[C@H](O)CC(O)(C(=O)O)C[C@H]1O)/C=C/c1ccc(O)cc1	O=C(OC1[C@H](O)CC(O)(C(=O)O)C[C@H]1O)/C=C/c1ccc(O)cc1
NCGC00094932-04&NCGC00094932-06	O=C(OC1[C@H](O[C@@H]2C(O)C(O)C(O)C(CO)O2)[C@@H](C)O[C@@H](O[C@H]2C(C)O[C@@H](O[C@H]3C(C)O[C@H](OC4CC5[C@](C)(C6C([C@@]7(O)[C@@](C)(C(O)C6)C(C6=CC(=O)OC6)CC7)CC5)CC4)CC3O)CC2O)C1)C		Inactive			2	NCGC00094932-04&LANATOSIDE C	405558692.0&434146995.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC1[C@H](O[C@@H]2C(O)C(O)C(O)C(CO)O2)[C@@H](C)O[C@@H](O[C@H]2C(C)O[C@@H](O[C@H]3C(C)O[C@H](OC4CC5[C@](C)(C6C([C@@]7(O)[C@@](C)(C(O)C6)C(C6=CC(=O)OC6)CC7)CC5)CC4)CC3O)CC2O)C1)C	O=C(OC1[C@H](O[C@@H]2C(O)C(O)C(O)C(CO)O2)[C@@H](C)O[C@@H](O[C@H]2C(C)O[C@@H](O[C@H]3C(C)O[C@H](OC4CC5[C@](C)(C6C([C@@]7(O)[C@@](C)(C(O)C6)C(C6=CC(=O)OC6)CC7)CC5)CC4)CC3O)CC2O)C1)C
NCGC00380086-01	O=C(OC1[C@H]2C(C)(C)CCC[C@]2(C)[C@@]2(O)C(=O)OC(O)C2=C1)/C=C/C=C/C=C/C		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380086-01	363678456.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1[C@H]2C(C)(C)CCC[C@]2(C)[C@@]2(O)C(=O)OC(O)C2=C1)/C=C/C=C/C=C/C	O=C(OC1[C@H]2C(C)(C)CCC[C@]2(C)[C@@]2(O)C(=O)OC(O)C2=C1)/C=C/C=C/C=C/C
NCGC00385965-01	O=C(OC1[C@]2(C)C(=O)C=C[C@H]2[C@H](C)C[C@H]2OC(=O)C(=C)[C@@H]12)C(=C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385965-01	363680032.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC1[C@]2(C)C(=O)C=C[C@H]2[C@H](C)C[C@H]2OC(=O)C(=C)[C@@H]12)C(=C)C	O=C(OC1[C@]2(C)C(=O)C=C[C@H]2[C@H](C)C[C@H]2OC(=O)C(=C)[C@@H]12)C(=C)C
NCGC00159403-03	O=C(OC1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCC		Inactive			1	Nandrolone decanoate	26754490.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCC	O=C(OC1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCC
NCGC00015767-10	O=C(OCC#CCN(CC)CC)C(O)(c1ccccc1)C1CCCCC1	5.4499998	Active	Muscarinic Antagonists	0.0	1	Oxybutynin chloride	405559139.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	2.4	31.4237288079	O=C(OCC#CCN(CC)CC)C(O)(c1ccccc1)C1CCCCC1	O=C(OCC#CCN(CC)CC)C(O)(c1ccccc1)C1CCCCC1
NCGC00381157-01	O=C(OCC(=C)C12C(=O)C=C3C(C)(C(C)CC(O)C3O)C1O2)C(O)C(O)CN		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381157-01	363679000.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC(=C)C12C(=O)C=C3C(C)(C(C)CC(O)C3O)C1O2)C(O)C(O)CN	O=C(OCC(=C)C12C(=O)C=C3C(C)(C(C)CC(O)C3O)C1O2)C(O)C(O)CN
NCGC00168887-02	O=C(OCC(=C)C1C(OC(=O)C(C)C)c2c(O1)cc(C(=O)C)cc2)C(C)C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: Brickellia | Family: N/A | Species: spp		1	NCGC00168887-02	363676713.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC(=C)C1C(OC(=O)C(C)C)c2c(O1)cc(C(=O)C)cc2)C(C)C	O=C(OCC(=C)C1C(OC(=O)C(C)C)c2c(O1)cc(C(=O)C)cc2)C(C)C
NCGC00386003-01	O=C(OCC(=C)C1Oc2c(cc(C(=O)C)cc2)C1)CC(C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386003-01	363680050.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC(=C)C1Oc2c(cc(C(=O)C)cc2)C1)CC(C)C	O=C(OCC(=C)C1Oc2c(cc(C(=O)C)cc2)C1)CC(C)C
NCGC00181915-01	O=C(OCC(=O)N(C)C)C(C)c1cc2c(Oc3nc(C)ccc3C2)cc1		Inactive			1	Mepranoprofen arbamel	144206887.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCC(=O)N(C)C)C(C)c1cc2c(Oc3nc(C)ccc3C2)cc1	O=C(OCC(=O)N(C)C)C(C)c1cc2c(Oc3nc(C)ccc3C2)cc1
NCGC00167526-02&NCGC00167526-06	O=C(OCC(=O)N(C)C)Cc1ccc(OC(=O)c2ccc(NC(=N)N)cc2)cc1		Inactive	Serine Protease Inhibitor		2	Camostat	170465784.0&384568326.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	S(=O)(=O)(O)C.O=C(OCC(=O)N(C)C)Cc1ccc(OC(=O)c2ccc(NC(=N)N)cc2)cc1	S(=O)(=O)(O)C.O=C(OCC(=O)N(C)C)Cc1ccc(OC(=O)c2ccc(NC(=N)N)cc2)cc1&O=C(OCC(=O)N(C)C)Cc1ccc(OC(=O)c2ccc(NC(=N)N)cc2)cc1
NCGC00379204-01	O=C(OCC(=O)NC)NCCC1CCN(c2nc(C)ccc2)CC1		Inactive	Anandamide amidohydrolase Inhibitor		1	SA 47	363678416.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC(=O)NC)NCCC1CCN(c2nc(C)ccc2)CC1	O=C(OCC(=O)NC)NCCC1CCN(c2nc(C)ccc2)CC1
NCGC00022043-06	O=C(OCC(=O)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)C		Inactive	Mineralocorticoid receptor Agonist		1	Deoxycorticosterone acetate	170465334.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	15.3735524881&0.0	O=C(OCC(=O)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)C	O=C(OCC(=O)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)C
NCGC00160511-01	O=C(OCC(=O)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)C(C)(C)C		Inactive			1	Desoxycorticosterone Pivalate	29216193.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(=O)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)C(C)(C)C	O=C(OCC(=O)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)C(C)(C)C
NCGC00242504-01	O=C(OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@@H]1[C@]3(C)C(C(C)=C[C@@H]21)=Cc1n(-c2ccccc2)ncc1C3)C	4.9000001	Active	Glucocorticoid Receptor (GR) Agonist	0.0	1	Cortivazol	137275858.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.4	31.0	O=C(OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@@H]1[C@]3(C)C(C(C)=C[C@@H]21)=Cc1n(-c2ccccc2)ncc1C3)C	O=C(OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@@H]1[C@]3(C)C(C(C)=C[C@@H]21)=Cc1n(-c2ccccc2)ncc1C3)C
NCGC00263897-02	O=C(OCC(=O)[C@]1(O)[C@]2(C)C(C3C([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CCC(=O)O		Inactive			1	PREDNISOLONE HEMISUCCINATE	405559061.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(=O)[C@]1(O)[C@]2(C)C(C3C([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CCC(=O)O	O=C(OCC(=O)[C@]1(O)[C@]2(C)C(C3C([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CCC(=O)O
NCGC00021277-04	O=C(OCC(=O)[C@]1(O)[C@]2(C)C(C3C([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)C		Inactive			1	Hydrocortisone acetate	170466796.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(=O)[C@]1(O)[C@]2(C)C(C3C([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)C	O=C(OCC(=O)[C@]1(O)[C@]2(C)C(C3C([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)C
NCGC00021191-09&NCGC00021191-15	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H](C(=O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)C		Inactive	Glucocorticoid steroid		2	Cortisone acetate	170464685.0&384568005.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H](C(=O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)C	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H](C(=O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)C
NCGC00261967-01	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C		Inactive	Glucocorticoid and meneralocorticoid receptor agonists/antagonists Agonist		1	Prednisolone farnesylate	170466045.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)/C=C(/CC/C=C(/CC/C=C(\C)/C)\C)\C
NCGC00021925-03&NCGC00021925-05	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)C		Inactive	Glucocorticoid steroid		2	Prednisolone acetate	170464632.0&363676517.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)C	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)C
NCGC00249886-01	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CC(C)(C)C		Inactive			1	Prednisolone tebutate	170465430.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CC(C)(C)C	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CC(C)(C)C
NCGC00022248-04	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC(=O)O		Inactive			1	Hydrocortisone 21-hemisuccinate sodium salt	170465053.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC(=O)[O-].[Na+]	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC(=O)[O-].[Na+]
NCGC00249883-01	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CN(CC)CC		Inactive	Glucocorticoid receptor Agonist		1	Hydrocortamate	170465314.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CN(CC)CC	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CN(CC)CC
NCGC00159503-02	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)C		Inactive			1	Methylprednisolone acetate	144205275.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)C	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)C
NCGC00185763-03	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)CCC(=O)O		Inactive			1	6?-Methylprednisolone 21-hemisuccinate	405558627.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)CCC(=O)O	O=C(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)CCC(=O)O
NCGC00485028-01	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O)CC5)CC3)C[C@H]1O2)C		Inactive			1	16,17-Epoxy-21-acetoxypregnenolone	363681196.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O)CC5)CC3)C[C@H]1O2)C	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O)CC5)CC3)C[C@H]1O2)C
NCGC00263521-01&NCGC00263521-07	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C)=N2)C		Inactive	Corticosteroid		2	Deflazacort	170466610.0&384568684.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C)=N2)C	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C)=N2)C
NCGC00386545-01	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C1CCCCC1)O2)C(C)C		Inactive	Glucocorticoid receptor Agonist		1	Ciclesonide	405558718.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C1CCCCC1)O2)C(C)C	O=C(OCC(=O)[C@]12[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)C[C@H]1OC(C1CCCCC1)O2)C(C)C
NCGC00249890-01	O=C(OCC(C(CC)C)(COC(=O)N)C)N		Inactive			1	Mebutamate	170465233.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(C(CC)C)(COC(=O)N)C)N	O=C(OCC(C(CC)C)(COC(=O)N)C)N
NCGC00015954-04	O=C(OCC(C)C)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O		Inactive	DNA topoisomerase II Inhibitor		1	Sobuzoxane	90341303.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(C)C)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O	O=C(OCC(C)C)OCN1C(=O)CN(CCN2CC(=O)N(COC(=O)OCC(C)C)C(=O)C2)CC1=O
NCGC00160682-02	O=C(OCC(C)C)c1ccc(N)cc1		Inactive			1	Isocaine	170466550.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(C)C)c1ccc(N)cc1	O=C(OCC(C)C)c1ccc(N)cc1
NCGC00091585-03&NCGC00091585-05	O=C(OCC(CCCC)CC)/C(/C#N)=C(/c1ccccc1)\c1ccccc1		Inactive	photosensitizer		2	Octocrylene	29215118.0&170464719.0	Annotated/Bioactive Compound Collection&2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(OCC(CCCC)CC)/C(/C#N)=C(/c1ccccc1)\c1ccccc1	O=C(OCC(CCCC)CC)/C(/C#N)=C(/c1ccccc1)\c1ccccc1
NCGC00160623-04	O=C(OCC(CCCC)CC)C=Cc1ccc(OC)cc1		Inactive			1	Octinoxate	170464894.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(CCCC)CC)C=Cc1ccc(OC)cc1	O=C(OCC(CCCC)CC)C=Cc1ccc(OC)cc1
NCGC00159324-04	O=C(OCC(CCCC)CC)c1c(O)cccc1		Inactive			1	2-Ethylhexyl salicylate	170465498.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(CCCC)CC)c1c(O)cccc1	O=C(OCC(CCCC)CC)c1c(O)cccc1
NCGC00090764-04	O=C(OCC(CCCC)CC)c1ccc(N(C)C)cc1		Inactive			1	2-Ethylhexyl 4-(dimethylamino)benzoate	170465499.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCC(CCCC)CC)c1ccc(N(C)C)cc1	O=C(OCC(CCCC)CC)c1ccc(N(C)C)cc1
NCGC00183599-01	O=C(OCC(CCCC)CC)c1ccc(Nc2nc(Nc3ccc(C(=O)OCC(CCCC)CC)cc3)nc(Nc3ccc(C(=O)OCC(CCCC)CC)cc3)n2)cc1		Inactive			1	NCGC00183599-01	124894454.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(CCCC)CC)c1ccc(Nc2nc(Nc3ccc(C(=O)OCC(CCCC)CC)cc3)nc(Nc3ccc(C(=O)OCC(CCCC)CC)cc3)n2)cc1	O=C(OCC(CCCC)CC)c1ccc(Nc2nc(Nc3ccc(C(=O)OCC(CCCC)CC)cc3)nc(Nc3ccc(C(=O)OCC(CCCC)CC)cc3)n2)cc1
NCGC00381411-01	O=C(OCC(CO)C1C(COC(=O)CC2C(C(=O)OC)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C=C)C(C)C(O)C1)CC1/C(=C/C)/C(OC2C(O)C(O)C(O)C(CO)O2)OC=C1C(=O)O		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381411-01	363679131.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC(CO)C1C(COC(=O)CC2C(C(=O)OC)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C=C)C(C)C(O)C1)CC1/C(=C/C)/C(OC2C(O)C(O)C(O)C(CO)O2)OC=C1C(=O)O	O=C(OCC(CO)C1C(COC(=O)CC2C(C(=O)OC)=COC(OC3C(O)C(O)C(O)C(CO)O3)C2C=C)C(C)C(O)C1)CC1/C(=C/C)/C(OC2C(O)C(O)C(O)C(CO)O2)OC=C1C(=O)O
NCGC00095133-06&NCGC00095133-09	O=C(OCC(COC(=O)C)CCn1c2nc(N)ncc2nc1)C		Inactive	antiviral		2	Famciclovir	170464774.0&384568149.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	O=C(OCC(COC(=O)C)CCn1c2nc(N)ncc2nc1)C	O=C(OCC(COC(=O)C)CCn1c2nc(N)ncc2nc1)C
NCGC00015429-14&NCGC00015429-18	O=C(OCC(COC(=O)N)c1ccccc1)N		Inactive	GABA(A) Receptor Modulators		2	Felbamate	170465178.0&384567842.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCC(COC(=O)N)c1ccccc1)N	O=C(OCC(COC(=O)N)c1ccccc1)N
NCGC00538142-01	O=C(OCC(COC(=O)c1cnccc1)(COC(=O)c1cnccc1)CCCCCC)c1cnccc1		Inactive	vasoconstriction Inhibitor		1	NCGC00538142-01	405558454.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(COC(=O)c1cnccc1)(COC(=O)c1cnccc1)CCCCCC)c1cnccc1	O=C(OCC(COC(=O)c1cnccc1)(COC(=O)c1cnccc1)CCCCCC)c1cnccc1
NCGC00185747-02	O=C(OCC(COC(=O)c1cnccc1)(COC(=O)c1cnccc1)COC(=O)c1cnccc1)c1cnccc1		Inactive	Hydroxycarboxylic acid receptor 2 Agonist		1	Niceritrol	170465789.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(COC(=O)c1cnccc1)(COC(=O)c1cnccc1)COC(=O)c1cnccc1)c1cnccc1	O=C(OCC(COC(=O)c1cnccc1)(COC(=O)c1cnccc1)COC(=O)c1cnccc1)c1cnccc1
NCGC00018269-05	O=C(OCC(N(C)C)(CC)c1ccccc1)c1cc(OC)c(OC)c(OC)c1		Inactive			1	Trimebutine maleate	170465734.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O)/C=C\C(=O)O.O=C(OCC(N(C)C)(CC)c1ccccc1)c1cc(OC)c(OC)c(OC)c1	O=C(O)/C=C\C(=O)O.O=C(OCC(N(C)C)(CC)c1ccccc1)c1cc(OC)c(OC)c(OC)c1
NCGC00016551-04	O=C(OCC(NCCC)(C)C)c1ccccc1		Inactive	Sodium channel alpha subunits; brain (Types I, II, III) Inhibitor		1	Meprylcaine hydrochloride	170466009.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCC(NCCC)(C)C)c1ccccc1.Cl	O=C(OCC(NCCC)(C)C)c1ccccc1.Cl
NCGC00159505-03	O=C(OCC(O)C)CCCCCCCCCCCCCCCCC		Inactive			1	Octadecanoic acid, monoester with 1,2-propanediol	29215477.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(O)C)CCCCCCCCCCCCCCCCC	O=C(OCC(O)C)CCCCCCCCCCCCCCCCC
NCGC00161605-02	O=C(OCC(O)C1C(O)=C(O)C(=O)O1)CCCCCCCCCCCCCCC		Inactive			1	L-Ascorbyl 6-palmitate	405558500.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(O)C1C(O)=C(O)C(=O)O1)CCCCCCCCCCCCCCC	O=C(OCC(O)C1C(O)=C(O)C(=O)O1)CCCCCCCCCCCCCCC
NCGC00381119-01	O=C(OCC(O)CO)C(C)C1OC(CC(=O)C)CC1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381119-01	363678978.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC(O)CO)C(C)C1OC(CC(=O)C)CC1	O=C(OCC(O)CO)C(C)C1OC(CC(=O)C)CC1
NCGC00166144-03	O=C(OCC(O)CO)CCCCCCC		Inactive			1	2,3-Dihydroxypropyl octanoate	170465212.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(O)CO)CCCCCCC	O=C(OCC(O)CO)CCCCCCC
NCGC00164528-04	O=C(OCC(O)CO)CCCCCCCCCCC		Inactive	Toxic shock syndrome toxin-1 Inhibitor		1	GLYCERYL LAURATE	225144258.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCC(O)CO)CCCCCCCCCCC	O=C(OCC(O)CO)CCCCCCCCCCC
NCGC00164529-04	O=C(OCC(O)CO)CCCCCCCCCCCCCCCCC		Inactive	Phospholipase A2 group IIA Inhibitor		1	1-Stearoyl-rac-glycerol	170465522.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCC(O)CO)CCCCCCCCCCCCCCCCC	O=C(OCC(O)CO)CCCCCCCCCCCCCCCCC
NCGC00249900-01	O=C(OCC(O)CO)c1c(N)cccc1		Inactive			1	Glyceryl 1-(2-aminobenzoate)	170465551.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(O)CO)c1c(N)cccc1	O=C(OCC(O)CO)c1c(N)cccc1
NCGC00380867-01	O=C(OCC(O)COC1C(O)C(O)C(O)C(CO)O1)CCCCCCC/C=C\C/C=C\C/C=C\CC		Inactive	<MOA Unknown> | Class: Fatty acid | Genus: Tithonia | Family: Compositae | Species: diversifolia		1	NCGC00380867-01	363678822.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC(O)COC1C(O)C(O)C(O)C(CO)O1)CCCCCCC/C=C\C/C=C\C/C=C\CC	O=C(OCC(O)COC1C(O)C(O)C(O)C(CO)O1)CCCCCCC/C=C\C/C=C\C/C=C\CC
NCGC00018257-08&NCGC00018257-16	O=C(OCC(O)COc1c(OC)cccc1)N		Inactive	Muscle relaxant		2	Methocarbamol	170464808.0&434146970.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(OCC(O)COc1c(OC)cccc1)N	O=C(OCC(O)COc1c(OC)cccc1)N
NCGC00386253-01	O=C(OCC(OCN1C=NC2C(=O)NC(N)=NC12)CO)[C@@H](N)C(C)C		Inactive	Human herpesvirus 5 DNA polymerase Inhibitor		1	Valganciclovir HCl	363680169.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(OCN1C=NC2C(=O)NC(N)=NC12)CO)[C@@H](N)C(C)C	O=C(OCC(OCN1C=NC2C(=O)NC(N)=NC12)CO)[C@@H](N)C(C)C
NCGC00389459-01	O=C(OCC(OCn1c2NC(N)=NC(=O)c2nc1)CO)C(N)C(C)C		Inactive	DNA Polymerase Inhibitor		1	Cymeval	377020277.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(OCn1c2NC(N)=NC(=O)c2nc1)CO)C(N)C(C)C	O=C(OCC(OCn1c2NC(N)=NC(=O)c2nc1)CO)C(N)C(C)C
NCGC00387997-02	O=C(OCC(OCn1c2NC(N)=NC(=O)c2nc1)CO)[C@@H](N)C(C)C		Inactive	Viral Dna Polymerase Inhibitor		1	Valganciclovir·HCl	405558800.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC(OCn1c2NC(N)=NC(=O)c2nc1)CO)[C@@H](N)C(C)C	O=C(OCC(OCn1c2NC(N)=NC(=O)c2nc1)CO)[C@@H](N)C(C)C
NCGC00167500-02	O=C(OCC)/C=C(/C=C/C=C(/C=Cc1c(C)c(C)c(OC)cc1C)\C)\C		Inactive	Retinoic acid receptor alpha Agonist		1	Etretinate	170465372.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCC)/C=C(/C=C/C=C(/C=Cc1c(C)c(C)c(OC)cc1C)\C)\C	O=C(OCC)/C=C(/C=C/C=C(/C=Cc1c(C)c(C)c(OC)cc1C)\C)\C
NCGC00248275-02	O=C(OCC)/C=C(/C=C/C[C@H](CCCC(C)C)C)\C		Inactive			1	S-Hydroprene	225144342.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)/C=C(/C=C/C[C@H](CCCC(C)C)C)\C	O=C(OCC)/C=C(/C=C/C[C@H](CCCC(C)C)C)\C
NCGC00249928-01	O=C(OCC)/C=C\C=C/C=C\C=C/C=C\CCCCCCCCC		Inactive			1	Eicosapentaenoic acid ethyl ester	170466007.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCC)/C=C\C=C/C=C\C=C/C=C\CCCCCCCCC	O=C(OCC)/C=C\C=C/C=C\C=C/C=C\CCCCCCCCC
NCGC00081778-05	O=C(OCC)C(Oc1c2c(C(=O)N(CC(=O)Nc3cc4OCCOc4cc3)C=C2)ccc1)C		Inactive	SF1 (NR5A1) Receptor Antagonist		1	SID-7969543	384568076.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)C(Oc1c2c(C(=O)N(CC(=O)Nc3cc4OCCOc4cc3)C=C2)ccc1)C	O=C(OCC)C(Oc1c2c(C(=O)N(CC(=O)Nc3cc4OCCOc4cc3)C=C2)ccc1)C
NCGC00183870-01	O=C(OCC)C1(c2ccccc2)CCN(C)CCC1		Inactive	Opioid receptors; mu/kappa/delta Modulator		1	Ethoheptazine hydrochloride	144206778.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)C1(c2ccccc2)CCN(C)CCC1.Cl	O=C(OCC)C1(c2ccccc2)CCN(C)CCC1.Cl
NCGC00253613-01	O=C(OCC)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1		Inactive			1	Anileridine	170465266.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1	O=C(OCC)C1(c2ccccc2)CCN(CCc2ccc(N)cc2)CC1
NCGC00347947-04	O=C(OCC)C1=C(C)NC2=C(C(=O)CC(C)(C)C2)C1c1ccc(-c2ccccc2)cc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	ITD-1	384568994.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(OCC)C1=C(C)NC2=C(C(=O)CC(C)(C)C2)C1c1ccc(-c2ccccc2)cc1	O=C(OCC)C1=C(C)NC2=C(C(=O)CC(C)(C)C2)C1c1ccc(-c2ccccc2)cc1
NCGC00024631-03	O=C(OCC)C1=C(O)C(=O)N(Cc2ccccc2)C1		Inactive	Aldose Reductase Inhibitor		1	EBPC	384568030.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)C1=C(O)C(=O)N(Cc2ccccc2)C1	O=C(OCC)C1=C(O)C(=O)N(Cc2ccccc2)C1
NCGC00386645-03	O=C(OCC)C=1C(=O)Nc2c3c(C(=O)c4c(cccc4)C=13)ccc2		Inactive			1	NQDI-1	377020313.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC)C=1C(=O)Nc2c3c(C(=O)c4c(cccc4)C=13)ccc2	O=C(OCC)C=1C(=O)Nc2c3c(C(=O)c4c(cccc4)C=13)ccc2
NCGC00379249-01	O=C(OCC)C=1C(=O)Oc2c(ccc(O)c2)C=1		Inactive			1	YZ9	377020229.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC)C=1C(=O)Oc2c(ccc(O)c2)C=1	O=C(OCC)C=1C(=O)Oc2c(ccc(O)c2)C=1
NCGC00018204-13	O=C(OCC)C=1n2c3c(c4c2[C@@H]2[C@](CC)(C=1)CCCN2CC4)cccc3		Inactive	Na channel blocker, also PDE1, IKK inhibitor		1	Vinpocetine	170465859.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	8.239685664&0.0	O=C(OCC)C=1n2c3c(c4c2[C@@H]2[C@](CC)(C=1)CCCN2CC4)cccc3	O=C(OCC)C=1n2c3c(c4c2[C@@H]2[C@](CC)(C=1)CCCN2CC4)cccc3
NCGC00021382-07	O=C(OCC)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](OC)(C)C3)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]2(O)C)O[C@H](C)C[C@@H]1N(C)C		Inactive	Bacterial 70S ribosome Binding Agent		1	ERYTHROMYCIN ETHYLSUCCINATE	405558563.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](OC)(C)C3)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]2(O)C)O[C@H](C)C[C@@H]1N(C)C	O=C(OCC)CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](OC)(C)C3)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]2(O)C)O[C@H](C)C[C@@H]1N(C)C
NCGC00181039-02	O=C(OCC)CCCCCCC/C=C\C/C=C\CCCCC		Inactive	regulation of prostaglandin secretion Inhibitor		1	Ethyl linoleate	170466006.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)CCCCCCC/C=C\C/C=C\CCCCC	O=C(OCC)CCCCCCC/C=C\C/C=C\CCCCC
NCGC00378882-01	O=C(OCC)CCN(C(=O)c1cc2nc(CNc3ccc(C(=N)N)cc3)n(C)c2cc1)c1ncccc1		Inactive	Quinone reductase 2 Inhibitor		1	Dabigatran ethyl ester	363678255.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC)CCN(C(=O)c1cc2nc(CNc3ccc(C(=N)N)cc3)n(C)c2cc1)c1ncccc1	O=C(OCC)CCN(C(=O)c1cc2nc(CNc3ccc(C(=N)N)cc3)n(C)c2cc1)c1ncccc1
NCGC00344626-12	O=C(OCC)CCNc1nc(-c2ncccc2)nc(N2CCc3c(cccc3)CC2)c1		Inactive	Lysine-Specific Demethylase 6A (UTX) Inhibitor		1	GSK-J4	384568727.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	18.4733061	O=C(OCC)CCNc1nc(-c2ncccc2)nc(N2CCc3c(cccc3)CC2)c1	O=C(OCC)CCNc1nc(-c2ncccc2)nc(N2CCc3c(cccc3)CC2)c1
NCGC00378939-05	O=C(OCC)CNC(=O)[C@H]1N(C(=O)Cc2ccccc2)CCC1		Inactive	glutamate receptor signaling pathway Modulator		1	Noopept	363678288.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC)CNC(=O)[C@H]1N(C(=O)Cc2ccccc2)CCC1	O=C(OCC)CNC(=O)[C@H]1N(C(=O)Cc2ccccc2)CCC1
NCGC00345818-01	O=C(OCC)CN[C@@H](C(=O)N1[C@H](C(=O)N(C)c2ccc(/C(=N/O)/N)cc2)CC1)C1CCCCC1		Inactive	Thrombin Inhibitor		1	Ximelagatran	174006826.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)CN[C@@H](C(=O)N1[C@H](C(=O)N(C)c2ccc(/C(=N/O)/N)cc2)CC1)C1CCCCC1	O=C(OCC)CN[C@@H](C(=O)N1[C@H](C(=O)N(C)c2ccc(/C(=N/O)/N)cc2)CC1)C1CCCCC1
NCGC00183598-02	O=C(OCC)CN[C@@H](C(=O)N1[C@H](C(=O)NCc2ccc(/C(=N/O)/N)cc2)CC1)C1CCCCC1		Inactive	Thrombin Inhibitor		1	Ximelagatran	405559049.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)CN[C@@H](C(=O)N1[C@H](C(=O)NCc2ccc(/C(=N/O)/N)cc2)CC1)C1CCCCC1	O=C(OCC)CN[C@@H](C(=O)N1[C@H](C(=O)NCc2ccc(/C(=N/O)/N)cc2)CC1)C1CCCCC1
NCGC00182973-01	O=C(OCC)COc1cc2OC(=O)C(CCN(CC)CC)=C(C)c2cc1		Inactive	Platelet Aggregation (Plug Formation) Inhibitor		1	Chromonar hydrochloride	144206761.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)COc1cc2OC(=O)C(CCN(CC)CC)=C(C)c2cc1.Cl	O=C(OCC)COc1cc2OC(=O)C(CCN(CC)CC)=C(C)c2cc1.Cl
NCGC00182622-03	O=C(OCC)COc1cc2OC(c3ccccc3)=CC(=O)c2cc1		Inactive			1	EFLOXATE	405558472.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)COc1cc2OC(c3ccccc3)=CC(=O)c2cc1	O=C(OCC)COc1cc2OC(c3ccccc3)=CC(=O)c2cc1
NCGC00160454-01	O=C(OCC)Cc1ccc(-c2ccccc2)cc1		Inactive			1	Felbinac ethyl	144205377.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)Cc1ccc(-c2ccccc2)cc1	O=C(OCC)Cc1ccc(-c2ccccc2)cc1
NCGC00182996-01	O=C(OCC)Cn1c(-c2sc(c(-c3ccc(OC)cc3)n2)-c2ccc(OC)cc2)ccc1		Inactive	platelet aggregation Inhibitor		1	Pamicogrel	144206832.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	24.211693548	O=C(OCC)Cn1c(-c2sc(c(-c3ccc(OC)cc3)n2)-c2ccc(OC)cc2)ccc1	O=C(OCC)Cn1c(-c2sc(c(-c3ccc(OC)cc3)n2)-c2ccc(OC)cc2)ccc1
NCGC00402271-03	O=C(OCC)N1CCC(N2C[C@H](NC(=O)c3c(C)cccc3)CCC2)CC1		Inactive	Muscarinic acetylcholine receptor M1 Agonist		1	VU0364572 TFA salt	363681010.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC)N1CCC(N2C[C@H](NC(=O)c3c(C)cccc3)CCC2)CC1	O=C(OCC)N1CCC(N2C[C@H](NC(=O)c3c(C)cccc3)CCC2)CC1
NCGC00386615-02	O=C(OCC)N1CCC(NCCNC(=O)c2c(C)cccc2)CC1		Inactive	Muscarinic acetylcholine receptor M1 Positive Allosteric Modulator		1	VU 0357017 hydrochloride	363680356.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC)N1CCC(NCCNC(=O)c2c(C)cccc2)CC1	O=C(OCC)N1CCC(NCCNC(=O)c2c(C)cccc2)CC1
NCGC00402313-04	O=C(OCC)N1CCN(C(=O)CN2C(=O)c3c(C)cc(C)nc3S2)CC1		Inactive			1	YMU1	377020432.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC)N1CCN(C(=O)CN2C(=O)c3c(C)cc(C)nc3S2)CC1	O=C(OCC)N1CCN(C(=O)CN2C(=O)c3c(C)cc(C)nc3S2)CC1
NCGC00386359-03	O=C(OCC)NCCCC(=O)NCCc1ccccc1		Inactive			1	Santacruzamate A (CAY10683)	434147130.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)NCCCC(=O)NCCc1ccccc1	O=C(OCC)NCCCC(=O)NCCc1ccccc1
NCGC00182063-03	O=C(OCC)NNc1nnc(N(CC(O)C)CC)cc1		Inactive			1	Cadralazine	170466021.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)NNc1nnc(N(CC(O)C)CC)cc1	O=C(OCC)NNc1nnc(N(CC(O)C)CC)cc1
NCGC00016640-06	O=C(OCC)NNc1nncc2c1cccc2		Inactive	histone acetylation Inhibitor		1	Todralazine hydrochloride	170465782.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCC)NNc1nncc2c1cccc2.Cl	O=C(OCC)NNc1nncc2c1cccc2.Cl
NCGC00263896-03	O=C(OCC)Nc1[nH]c2c(n1)cccc2		Inactive			1	LOBENDAZOLE	363677299.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC)Nc1[nH]c2c(n1)cccc2	O=C(OCC)Nc1[nH]c2c(n1)cccc2
NCGC00370773-01	O=C(OCC)Nc1c(N)cc(NCc2c(C)cc(C)cc2C)cc1		Inactive			1	AA 29504	363677846.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC)Nc1c(N)cc(NCc2c(C)cc(C)cc2C)cc1	O=C(OCC)Nc1c(N)cc(NCc2c(C)cc(C)cc2C)cc1
NCGC00016809-07	O=C(OCC)Nc1cc2N(C(=O)CCN3CCOCC3)c3c(Sc2cc1)cccc3		Inactive	class 1c antiarrhythmic, Na(v)1.5 channel blocker		1	Moricizine hydrochloride	174006664.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)Nc1cc2N(C(=O)CCN3CCOCC3)c3c(Sc2cc1)cccc3.Cl	O=C(OCC)Nc1cc2N(C(=O)CCN3CCOCC3)c3c(Sc2cc1)cccc3.Cl
NCGC00179357-05	O=C(OCC)O[C@@]1(C(=O)COC(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1		Inactive	Glucocorticoid Receptor Agonist		1	PREDNICARBATE	405558774.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)O[C@@]1(C(=O)COC(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1	O=C(OCC)O[C@@]1(C(=O)COC(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1
NCGC00179590-04	O=C(OCC)Oc1c(OC)cc(C(=O)O[C@H]2[C@H](OC)[C@@H](C(=O)OC)[C@@H]3[C@H](C2)CN2[C@@H](c4[nH]c5c(c4CC2)ccc(OC)c5)C3)cc1OC		Inactive			1	Syrosingopine	405558663.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	30.078063792	O=C(OCC)Oc1c(OC)cc(C(=O)O[C@H]2[C@H](OC)[C@@H](C(=O)OC)[C@@H]3[C@H](C2)CN2[C@@H](c4[nH]c5c(c4CC2)ccc(OC)c5)C3)cc1OC	O=C(OCC)Oc1c(OC)cc(C(=O)O[C@H]2[C@H](OC)[C@@H](C(=O)OC)[C@@H]3[C@H](C2)CN2[C@@H](c4[nH]c5c(c4CC2)ccc(OC)c5)C3)cc1OC
NCGC00387800-02	O=C(OCC)[C@@H](C[C@H](NC(=O)CCC(=O)O)Cc1ccc(-c2ccccc2)cc1)C		Inactive			1	AHU-377	405558830.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)[C@@H](C[C@H](NC(=O)CCC(=O)O)Cc1ccc(-c2ccccc2)cc1)C	O=C(OCC)[C@@H](C[C@H](NC(=O)CCC(=O)O)Cc1ccc(-c2ccccc2)cc1)C
NCGC00181345-01&NCGC00263583-01	O=C(OCC)[C@@H](N[C@@H]1C(=O)N(CC(=O)O)C[C@@H](c2sccc2)SC1)CCc1ccccc1		Inactive	Angiotensin-I Converting Enzyme Inhibitor		2	Temocapril hydrochloride	50125938.0&170465944.0	Annotated/Bioactive Compound Collection&2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&-15.00152772&0.0	O=C(OCC)[C@@H](N[C@@H]1C(=O)N(CC(=O)O)C[C@@H](c2sccc2)SC1)CCc1ccccc1.Cl	O=C(OCC)[C@@H](N[C@@H]1C(=O)N(CC(=O)O)C[C@@H](c2sccc2)SC1)CCc1ccccc1.Cl
NCGC00182039-02	O=C(OCC)[C@@H](N[C@@H]1C(=O)N2[C@H](C(=O)O)CCCN2CCC1)CCc1ccccc1		Inactive	Angiotensin-converting enzyme Inhibitor		1	Cilazapril	225144330.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)[C@@H](N[C@@H]1C(=O)N2[C@H](C(=O)O)CCCN2CCC1)CCc1ccccc1	O=C(OCC)[C@@H](N[C@@H]1C(=O)N2[C@H](C(=O)O)CCCN2CCC1)CCc1ccccc1
NCGC00181755-01	O=C(OCC)[C@@H](N[C@H](C(=O)N(CC(=O)O)C1Cc2c(cccc2)C1)C)CCc1ccccc1		Inactive			1	Delapril hydrochloride	144206480.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)[C@@H](N[C@H](C(=O)N(CC(=O)O)C1Cc2c(cccc2)C1)C)CCc1ccccc1.Cl	O=C(OCC)[C@@H](N[C@H](C(=O)N(CC(=O)O)C1Cc2c(cccc2)C1)C)CCc1ccccc1.Cl
NCGC00021569-09&NCGC00021569-20	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C)CCc1ccccc1		Inactive	Angiotensin-I Converting Enzyme Inhibitor		2	Enalapril maleate	170464969.0&384568008.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C)CCc1ccccc1	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C)CCc1ccccc1
NCGC00181342-02	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CN(C)C1=O)C)CCc1ccccc1		Inactive			1	Imidapril hydrochloride	170466024.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CN(C)C1=O)C)CCc1ccccc1.Cl	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)CN(C)C1=O)C)CCc1ccccc1.Cl
NCGC00182079-09	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@@H]2[C@@H]1CCCC2)C)CCc1ccccc1		Inactive			1	TRANDOLAPRIL		Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@@H]2[C@@H]1CCCC2)C)CCc1ccccc1	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@@H]2[C@@H]1CCCC2)C)CCc1ccccc1
NCGC00178127-02&NCGC00178127-11	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@H]2[C@@H]1CCC2)C)CCc1ccccc1		Inactive	Angiotensin-I Converting Enzyme Inhibitor		2	Ramipril	170464731.0&384568353.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@H]2[C@@H]1CCC2)C)CCc1ccccc1	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@H]2[C@@H]1CCC2)C)CCc1ccccc1
NCGC00159509-02&NCGC00274070-01	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@H]2[C@@H]1CCCC2)C)CCC		Inactive	Angiotensin-I Converting Enzyme Inhibitor		2	Perindopril	29215484.0&170464836.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@H]2[C@@H]1CCCC2)C)CCC	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)C[C@H]2[C@@H]1CCCC2)C)CCC
NCGC00263546-01&NCGC00263546-03	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)Cc2c(cc(OC)c(OC)c2)C1)C)CCc1ccccc1		Inactive	Angiotensin-converting enzyme Inhibitor		2	Moexipril hydrochloride&Moexipril HCl	170465131.0&434147075.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)Cc2c(cc(OC)c(OC)c2)C1)C)CCc1ccccc1.Cl	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)Cc2c(cc(OC)c(OC)c2)C1)C)CCc1ccccc1.Cl&O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)Cc2c(cc(OC)c(OC)c2)C1)C)CCc1ccccc1
NCGC00167962-06	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)Cc2c(cccc2)C1)C)CCc1ccccc1		Inactive	Angiotensin-converting enzyme Inhibitor		1	Quinapril hydrochloride	170465312.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)Cc2c(cccc2)C1)C)CCc1ccccc1.Cl	O=C(OCC)[C@@H](N[C@H](C(=O)N1[C@H](C(=O)O)Cc2c(cccc2)C1)C)CCc1ccccc1.Cl
NCGC00386661-01	O=C(OCC)[C@H](CCc1ccccc1)CC1(C(=O)N[C@@H]2C(=O)N(CC(=O)O)c3c(cccc3)CC2)CCCC1		Inactive	Neprilysin Inhibitor		1	Daglutril	363680379.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC)[C@H](CCc1ccccc1)CC1(C(=O)N[C@@H]2C(=O)N(CC(=O)O)c3c(cccc3)CC2)CCCC1	O=C(OCC)[C@H](CCc1ccccc1)CC1(C(=O)N[C@@H]2C(=O)N(CC(=O)O)c3c(cccc3)CC2)CCCC1
NCGC00015661-12	O=C(OCC)[N-]c1on[n+](N2CCOCC2)c1		Inactive			1	Molsidomine	170465872.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCC)[N-]c1on[n+](N2CCOCC2)c1	O=C(OCC)[N-]c1on[n+](N2CCOCC2)c1
NCGC00090974-06	O=C(OCC)c1c(C(=O)OCC)cccc1		Inactive	Androgen receptor Antagonist		1	Diethyl phthalate	225144200.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCC)c1c(C(=O)OCC)cccc1	O=C(OCC)c1c(C(=O)OCC)cccc1
NCGC00160670-08	O=C(OCC)c1c(C)n(C)c2c1cc(O)cc2		Inactive	antiinfluenza drug		1	Mecarbinate	384568202.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCC)c1c(C)n(C)c2c1cc(O)cc2	O=C(OCC)c1c(C)n(C)c2c1cc(O)cc2
NCGC00159451-06	O=C(OCC)c1c(N)sc2c1CCN(Cc1ccccc1)C2		Inactive	lipid oxidation Inhibitor		1	Tinoridine	170465864.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCC)c1c(N)sc2c1CCN(Cc1ccccc1)C2	O=C(OCC)c1c(N)sc2c1CCN(Cc1ccccc1)C2
NCGC00167562-01	O=C(OCC)c1c(O)c2c(nc1)cc(OCC(C)C)c(OCC(C)C)c2		Inactive			1	Buquinolate	144206110.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)c1c(O)c2c(nc1)cc(OCC(C)C)c(OCC(C)C)c2	O=C(OCC)c1c(O)c2c(nc1)cc(OCC(C)C)c(OCC(C)C)c2
NCGC00181109-03	O=C(OCC)c1c(O)c2c(nc1)cc(OCC)c(OCCCCCCCCCC)c2		Inactive	Antiprotozoal agent		1	Decoquinate	170466244.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)c1c(O)c2c(nc1)cc(OCC)c(OCCCCCCCCCC)c2	O=C(OCC)c1c(O)c2c(nc1)cc(OCC)c(OCCCCCCCCCC)c2
NCGC00181161-03	O=C(OCC)c1c(O)cccc1		Inactive			1	Ethyl salicylate	170466844.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC)c1c(O)cccc1	O=C(OCC)c1c(O)cccc1
NCGC00370951-06	O=C(OCC)c1cc(N)c(NC2CCCCC2)cc1		Inactive			1	Ferrostatin-1	363677952.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC)c1cc(N)c(NC2CCCCC2)cc1	O=C(OCC)c1cc(N)c(NC2CCCCC2)cc1
NCGC00166020-03	O=C(OCC)c1cc(N)ccc1		Inactive	Sodium channel alpha subunit Blocker		1	Ethyl 3-aminobenzoate methanesulfonic acid salt	170465717.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(O)C.O=C(OCC)c1cc(N)ccc1	S(=O)(=O)(O)C.O=C(OCC)c1cc(N)ccc1
NCGC00386753-04	O=C(OCC)c1ccc(N(C)c2nc(-c3ccccc3)sc2)cc1		Inactive	neurogenesis Activator		1	Neuropathiazol	363680434.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC)c1ccc(N(C)c2nc(-c3ccccc3)sc2)cc1	O=C(OCC)c1ccc(N(C)c2nc(-c3ccccc3)sc2)cc1
NCGC00016352-07	O=C(OCC)c1ccc(N)cc1		Inactive	Sodium channel protein type 10 subunit alpha Blocker		1	Benzocaine	170465463.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCC)c1ccc(N)cc1	O=C(OCC)c1ccc(N)cc1
NCGC00160654-06	O=C(OCC)c1ccc(O)cc1		Inactive			1	Ethylparaben	170465715.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCC)c1ccc(O)cc1	O=C(OCC)c1ccc(O)cc1
NCGC00378843-02	O=C(OCC)c1ccc(OCCC2CCN(c3nnc(C)cc3)CC2)cc1		Inactive	viral genome replication Inhibitor		1	Pirodavir	363678231.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC)c1ccc(OCCC2CCN(c3nnc(C)cc3)CC2)cc1	O=C(OCC)c1ccc(OCCC2CCN(c3nnc(C)cc3)CC2)cc1
NCGC00183836-01	O=C(OCC)c1ccc(OCCN2[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C2)cc1		Inactive	Maltase-glucoamylase Inhibitor		1	Emiglitate	144206827.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCC)c1ccc(OCCN2[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C2)cc1	O=C(OCC)c1ccc(OCCN2[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C2)cc1
NCGC00167525-02&NCGC00167525-11	O=C(OCC)c1cnc(C#Cc2cc3C(C)(C)CCSc3cc2)cc1		Inactive	Retinoid RAR Agonist		2	Tazarotene	170464671.0&384568325.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&19.5&13.5	O=C(OCC)c1cnc(C#Cc2cc3C(C)(C)CCSc3cc2)cc1	O=C(OCC)c1cnc(C#Cc2cc3C(C)(C)CCSc3cc2)cc1
NCGC00025176-02	O=C(OCC)c1n(C(C)c2ccccc2)cnc1		Inactive	GABAA Receptor Modulator		1	Etomidate	170465117.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&8.485401464	O=C(OCC)c1n(C(C)c2ccccc2)cnc1	O=C(OCC)c1n(C(C)c2ccccc2)cnc1
NCGC00016799-08	O=C(OCC1(CCCC)C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)CCC(=O)O		Inactive	Prostaglandin G/H synthase 2 Inhibitor		1	Suxibuzone	170465972.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCC1(CCCC)C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)CCC(=O)O	O=C(OCC1(CCCC)C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)CCC(=O)O
NCGC00182074-03	O=C(OCC1(COC(=O)c2cnccc2)C(O)C(COC(=O)c2cnccc2)(COC(=O)c2cnccc2)CCC1)c1cnccc1		Inactive	Cholesterol biosynthesis Modulator		1	Nicomolol	170465790.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC1(COC(=O)c2cnccc2)C(O)C(COC(=O)c2cnccc2)(COC(=O)c2cnccc2)CCC1)c1cnccc1	O=C(OCC1(COC(=O)c2cnccc2)C(O)C(COC(=O)c2cnccc2)(COC(=O)c2cnccc2)CCC1)c1cnccc1
NCGC00385053-01	O=C(OCC1(O)C(=O)OC2C3C(=C)C(O)CC3C(=C)CCC12)C	5.0	Active	<MOA Unknown> | Class: Sesquiterpen | Genus: Ferula | Family: Umbelliferae | Species: communis	0.0	1	NCGC00385053-01	363679508.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	3.0	37.52025816	O=C(OCC1(O)C(=O)OC2C3C(=C)C(O)CC3C(=C)CCC12)C	O=C(OCC1(O)C(=O)OC2C3C(=C)C(O)CC3C(=C)CCC12)C
NCGC00380932-01	O=C(OCC1(O)C2C(=O)OCC(C(=O)O)=CC2C(C(C)C)CC1)/C(=C/C1C(C(C)C)CCC(CO)=C1)/CO		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: Gliocladium | Family: N/A | Species: N/A		1	NCGC00380932-01	363678864.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1(O)C2C(=O)OCC(C(=O)O)=CC2C(C(C)C)CC1)/C(=C/C1C(C(C)C)CCC(CO)=C1)/CO	O=C(OCC1(O)C2C(=O)OCC(C(=O)O)=CC2C(C(C)C)CC1)/C(=C/C1C(C(C)C)CCC(CO)=C1)/CO
NCGC00380915-01	O=C(OCC1(OC2C(OC3C(O)C(O)(CO)CO3)C(OC3C(O)C(O)C(OC4C(O)C(O)C(O)C(C)O4)C(C)O3)C(OC(=O)/C=C/c3ccc(O)cc3)C(CO)O2)C(O)C(O)C(CO)O1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: quillaja | Family: Rosaceae | Species: saponaria		1	NCGC00380915-01	363678852.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	-16.28897508	O=C(OCC1(OC2C(OC3C(O)C(O)(CO)CO3)C(OC3C(O)C(O)C(OC4C(O)C(O)C(O)C(C)O4)C(C)O3)C(OC(=O)/C=C/c3ccc(O)cc3)C(CO)O2)C(O)C(O)C(CO)O1)/C=C/c1ccc(O)cc1	O=C(OCC1(OC2C(OC3C(O)C(O)(CO)CO3)C(OC3C(O)C(O)C(OC4C(O)C(O)C(O)C(C)O4)C(C)O3)C(OC(=O)/C=C/c3ccc(O)cc3)C(CO)O2)C(O)C(O)C(CO)O1)/C=C/c1ccc(O)cc1
NCGC00169578-03	O=C(OCC1(c2c(OC(=O)C(C)C)cc(C)cc2)OC1)C(C)C		Inactive	<MOA Unknown> | Class: Monoterpen | Genus: Ranunculus | Family: Ranunculaceae | Species: sp.		1	NCGC00169578-03	363676841.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1(c2c(OC(=O)C(C)C)cc(C)cc2)OC1)C(C)C	O=C(OCC1(c2c(OC(=O)C(C)C)cc(C)cc2)OC1)C(C)C
NCGC00384685-01	O=C(OCC12C(O)C(OC(=O)c3ccccc3)C=CC1O2)c1ccccc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Uvaria | Family: Annonaceae | Species: leptocladon		1	NCGC00384685-01	363679310.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC12C(O)C(OC(=O)c3ccccc3)C=CC1O2)c1ccccc1	O=C(OCC12C(O)C(OC(=O)c3ccccc3)C=CC1O2)c1ccccc1
NCGC00179570-03	O=C(OCC1=C(C(=O)O)N2C(=O)[C@@H](N)[C@H]2SC1)C		Inactive	Cephalosporin intermediate		1	7-Aminocephalosporanic acid	363676948.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1=C(C(=O)O)N2C(=O)[C@@H](N)[C@H]2SC1)C	O=C(OCC1=C(C(=O)O)N2C(=O)[C@@H](N)[C@H]2SC1)C
NCGC00093351-06	O=C(OCC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)Cc3sccc3)[C@H]2SC1)N		Inactive	Penicillin-binding protein 2B Inhibitor		1	Cefoxitin	170465105.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)Cc3sccc3)[C@H]2SC1)N	O=C(OCC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)Cc3sccc3)[C@H]2SC1)N
NCGC00185751-06	O=C(OCC1=C(C(=O)OC(OC(=O)C)C)N2C(=O)[C@@H](NC(=O)/C(=N/OC)/c3occc3)[C@H]2SC1)N		Inactive			1	Cefuroxime Axetil	405558449.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC1=C(C(=O)OC(OC(=O)C)C)N2C(=O)[C@@H](NC(=O)/C(=N/OC)/c3occc3)[C@H]2SC1)N	O=C(OCC1=C(C(=O)OC(OC(=O)C)C)N2C(=O)[C@@H](NC(=O)/C(=N/OC)/c3occc3)[C@H]2SC1)N
NCGC00183096-01	O=C(OCC1=C(C(=O)OCOC(=O)C(C)(C)C)N2C(=O)[C@@H](NC(=O)/C(=C\CC)/c3nc(N)sc3)[C@H]2SC1)N		Inactive	Penicillin-binding protein Inhibitor		1	Cefcapene pivoxil hydrochloride	144206464.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC1=C(C(=O)OCOC(=O)C(C)(C)C)N2C(=O)[C@@H](NC(=O)/C(=C\CC)/c3nc(N)sc3)[C@H]2SC1)N.Cl	O=C(OCC1=C(C(=O)OCOC(=O)C(C)(C)C)N2C(=O)[C@@H](NC(=O)/C(=C\CC)/c3nc(N)sc3)[C@H]2SC1)N.Cl
NCGC00385056-01	O=C(OCC1=C(C(CCCOC(=O)C)C)[C@@H](OC(=O)C)C2C(=C)C(=O)OC2C1)C(C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Inula | Family: N/A | Species: japonica		1	NCGC00385056-01	363679511.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1=C(C(CCCOC(=O)C)C)[C@@H](OC(=O)C)C2C(=C)C(=O)OC2C1)C(C)C	O=C(OCC1=C(C(CCCOC(=O)C)C)[C@@H](OC(=O)C)C2C(=C)C(=O)OC2C1)C(C)C
NCGC00390559-05	O=C(OCC1=C(C)OC(=O)O1)c1c2n(Cc3ccc(-c4c(C5=NOC(=O)N5)cccc4)cc3)c(OCC)nc2ccc1		Inactive	Type-1 angiotensin II receptor Antagonist		1	Azilsartan Medoxomil	405558503.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC1=C(C)OC(=O)O1)c1c2n(Cc3ccc(-c4c(C5=NC(=O)O[N-]5)cccc4)cc3)c(OCC)nc2ccc1	O=C(OCC1=C(C)OC(=O)O1)c1c2n(Cc3ccc(-c4c(C5=NC(=O)O[N-]5)cccc4)cc3)c(OCC)nc2ccc1
NCGC00095136-09	O=C(OCC1=C(C)OC(=O)O1)c1n(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c(CCC)nc1C(O)(C)C		Inactive			1	Olmesartan medoxomil	405558542.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC1=C(C)OC(=O)O1)c1n(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c(CCC)nc1C(O)(C)C	O=C(OCC1=C(C)OC(=O)O1)c1n(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c(CCC)nc1C(O)(C)C
NCGC00169681-03	O=C(OCC1=CC(O)C2C1[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)OC=C2)c1ccccc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Parentucellia | Family: Scrophulariaceae | Species: viscosa		1	NCGC00169681-03	363676861.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1=CC(O)C2C1[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)OC=C2)c1ccccc1	O=C(OCC1=CC(O)C2C1[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)OC=C2)c1ccccc1
NCGC00386754-01	O=C(OCC1=CC[C@@H](C(=C)C)CC1)NC(=O)c1ncn2C(=O)N(C)N=Nc12		Inactive	DNA Blocker		1	NEO 212	363680435.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1=CC[C@@H](C(=C)C)CC1)NC(=O)c1ncn2C(=O)N(C)N=Nc12	O=C(OCC1=CC[C@@H](C(=C)C)CC1)NC(=O)c1ncn2C(=O)N(C)N=Nc12
NCGC00385012-01	O=C(OCC1=CO[C@@H](OC(=O)CC(C)C)C2[C@]3([C@@H](OC(=O)C)CC12)OC3)CC(C)C		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Valeriana | Family: N/A | Species: mexicana		1	NCGC00385012-01	363679484.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1=CO[C@@H](OC(=O)CC(C)C)C2[C@]3([C@@H](OC(=O)C)CC12)OC3)CC(C)C	O=C(OCC1=CO[C@@H](OC(=O)CC(C)C)C2[C@]3([C@@H](OC(=O)C)CC12)OC3)CC(C)C
NCGC00380511-01	O=C(OCC1C(O)C(O)C(O)C(OC(CCC2C(C)=CC(=O)CC2(C)C)C)O1)c1cc(O)c(O)c(O)c1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380511-01	363678621.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1C(O)C(O)C(O)C(OC(CCC2C(C)=CC(=O)CC2(C)C)C)O1)c1cc(O)c(O)c(O)c1	O=C(OCC1C(O)C(O)C(O)C(OC(CCC2C(C)=CC(=O)CC2(C)C)C)O1)c1cc(O)c(O)c(O)c1
NCGC00385105-01	O=C(OCC1C(O)C(O)C(O)C(OC2(CO)C(O)C(O)C(CO)O2)O1)/C=C/c1cc(OC)c(O)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Saponaria | Family: Caryophyllaceae | Species: album		1	NCGC00385105-01	363679537.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1C(O)C(O)C(O)C(OC2(CO)C(O)C(O)C(CO)O2)O1)/C=C/c1cc(OC)c(O)cc1	O=C(OCC1C(O)C(O)C(O)C(OC2(CO)C(O)C(O)C(CO)O2)O1)/C=C/c1cc(OC)c(O)cc1
NCGC00385495-01	O=C(OCC1C(O)C(O)C(O)C(OC2(CO)C(O)C3OC(=O)C4C(c5ccc(O)cc5)c5c(OC)c(O)c(OC)cc5C=C4C(=O)OCC3O2)O1)/C=C/c1ccc(OC2C(O)C(O)C(O)C(C)O2)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Tournefortia | Family: Boraginaceae | Species: volubilis		1	NCGC00385495-01	363679774.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1C(O)C(O)C(O)C(OC2(CO)C(O)C3OC(=O)C4C(c5ccc(O)cc5)c5c(OC)c(O)c(OC)cc5C=C4C(=O)OCC3O2)O1)/C=C/c1ccc(OC2C(O)C(O)C(O)C(C)O2)cc1	O=C(OCC1C(O)C(O)C(O)C(OC2(CO)C(O)C3OC(=O)C4C(c5ccc(O)cc5)c5c(OC)c(O)c(OC)cc5C=C4C(=O)OCC3O2)O1)/C=C/c1ccc(OC2C(O)C(O)C(O)C(C)O2)cc1
NCGC00381133-01	O=C(OCC1C(O)C(O)C(O)C(OC2C(O)C(O)C(O)C(CO)O2)O1)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381133-01	363678986.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1C(O)C(O)C(O)C(OC2C(O)C(O)C(O)C(CO)O2)O1)/C(=C/C)/C	O=C(OCC1C(O)C(O)C(O)C(OC2C(O)C(O)C(O)C(CO)O2)O1)/C(=C/C)/C
NCGC00380379-01	O=C(OCC1C(O)C(O)C(O)C(OCC2(C)C3C(C)(C(CCC=4C(=O)OCC=4)C(=C)CC3)CCC2)O1)CC(=O)O		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380379-01	363678557.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1C(O)C(O)C(O)C(OCC2(C)C3C(C)(C(CCC=4C(=O)OCC=4)C(=C)CC3)CCC2)O1)CC(=O)O	O=C(OCC1C(O)C(O)C(O)C(OCC2(C)C3C(C)(C(CCC=4C(=O)OCC=4)C(=C)CC3)CCC2)O1)CC(=O)O
NCGC00381132-01	O=C(OCC1C(O)C(O)C(O)C(OCC2C(O)C(O)C(O)C(OC3(CO)C(O)C(O)C(CO)O3)O2)O1)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381132-01	363678985.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1C(O)C(O)C(O)C(OCC2C(O)C(O)C(O)C(OC3(CO)C(O)C(O)C(CO)O3)O2)O1)/C(=C/C)/C	O=C(OCC1C(O)C(O)C(O)C(OCC2C(O)C(O)C(O)C(OC3(CO)C(O)C(O)C(CO)O3)O2)O1)/C(=C/C)/C
NCGC00381276-01	O=C(OCC1C(O)C(O)C(OC(=O)C(=C)CCO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CO1)C(=C)CCO		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381276-01	363679060.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1C(O)C(O)C(OC(=O)C(=C)CCO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CO1)C(=C)CCO	O=C(OCC1C(O)C(O)C(OC(=O)C(=C)CCO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)CO1)C(=C)CCO
NCGC00381043-01	O=C(OCC1C(O)C(O)C(OC2C(O)C(O)C(O)C(CO)O2)C(O)O1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Cuscuta | Family: Convolvulaceae | Species: reflexa		1	NCGC00381043-01	363678940.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1C(O)C(O)C(OC2C(O)C(O)C(O)C(CO)O2)C(O)O1)/C=C/c1ccc(O)cc1	O=C(OCC1C(O)C(O)C(OC2C(O)C(O)C(O)C(CO)O2)C(O)O1)/C=C/c1ccc(O)cc1
NCGC00386039-01	O=C(OCC1C(O)C(O)C2C(C(=O)OC)=COC(OC3C(O)C(O)C(O)C(CO)O3)C12)/C=C/c1cc(O)c(O)cc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386039-01	363680074.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1C(O)C(O)C2C(C(=O)OC)=COC(OC3C(O)C(O)C(O)C(CO)O3)C12)/C=C/c1cc(O)c(O)cc1	O=C(OCC1C(O)C(O)C2C(C(=O)OC)=COC(OC3C(O)C(O)C(O)C(CO)O3)C12)/C=C/c1cc(O)c(O)cc1
NCGC00380434-01	O=C(OCC1C(O)C(O)C2C(C(=O)OC)=COC(OC3C(O)C(O)C(O)C(CO)O3)C12)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380434-01	363678581.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1C(O)C(O)C2C(C(=O)OC)=COC(OC3C(O)C(O)C(O)C(CO)O3)C12)/C=C/c1ccc(O)cc1	O=C(OCC1C(O)C(O)C2C(C(=O)OC)=COC(OC3C(O)C(O)C(O)C(CO)O3)C12)/C=C/c1ccc(O)cc1
NCGC00381284-01	O=C(OCC1C(O)C(OC2C(O)C(OC3C(O)C(OC4C(O)C(O)C(O)C(COC5C(O)C(O)C(O)C(CO)O5)O4)C(O)C(CO)O3)C(O)C(CO)O2)C(O)C(OC2C(C)(C)C3C(C)(C4C(C)(C5(C)C(C6C(C(=O)O)(CC(O)C(C)(C)C6)CC5)=CC4)CC3)CC2)O1)/C(=C/CCC(O)(C=C)C)/C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381284-01	363679067.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1C(O)C(OC2C(O)C(OC3C(O)C(OC4C(O)C(O)C(O)C(COC5C(O)C(O)C(O)C(CO)O5)O4)C(O)C(CO)O3)C(O)C(CO)O2)C(O)C(OC2C(C)(C)C3C(C)(C4C(C)(C5(C)C(C6C(C(=O)O)(CC(O)C(C)(C)C6)CC5)=CC4)CC3)CC2)O1)/C(=C/CCC(O)(C=C)C)/C	O=C(OCC1C(O)C(OC2C(O)C(OC3C(O)C(OC4C(O)C(O)C(O)C(COC5C(O)C(O)C(O)C(CO)O5)O4)C(O)C(CO)O3)C(O)C(CO)O2)C(O)C(OC2C(C)(C)C3C(C)(C4C(C)(C5(C)C(C6C(C(=O)O)(CC(O)C(C)(C)C6)CC5)=CC4)CC3)CC2)O1)/C(=C/CCC(O)(C=C)C)/C
NCGC00385186-01	O=C(OCC1C(OC2C(O)C(OC(=O)/C(=C/C)/C)C(OC(=O)/C(=C/C)/C)C(CO)O2)C(O)C(O)C(OC2C(O)C(O)C(OC3C(O)C(OC(=O)/C(=C/C)/C)C(OC(=O)/C(=C/C)/C)C(CO)O3)C(COC(=O)/C(=C/C)/C)O2)O1)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: oligoglycoside | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385186-01	363679585.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1C(OC2C(O)C(OC(=O)/C(=C/C)/C)C(OC(=O)/C(=C/C)/C)C(CO)O2)C(O)C(O)C(OC2C(O)C(O)C(OC3C(O)C(OC(=O)/C(=C/C)/C)C(OC(=O)/C(=C/C)/C)C(CO)O3)C(COC(=O)/C(=C/C)/C)O2)O1)/C(=C/C)/C	O=C(OCC1C(OC2C(O)C(OC(=O)/C(=C/C)/C)C(OC(=O)/C(=C/C)/C)C(CO)O2)C(O)C(O)C(OC2C(O)C(O)C(OC3C(O)C(OC(=O)/C(=C/C)/C)C(OC(=O)/C(=C/C)/C)C(CO)O3)C(COC(=O)/C(=C/C)/C)O2)O1)/C(=C/C)/C
NCGC00380575-01	O=C(OCC1C(OC2C(O)C(OC3C(O)C(O)C(O)CO3)C(O)C(C)O2)C(O)C(O)C(O[C@@H]2[C@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: Heteranthera | Family: Pontederiaceae | Species: callaefolia		1	NCGC00380575-01	363678657.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1C(OC2C(O)C(OC3C(O)C(O)C(O)CO3)C(O)C(C)O2)C(O)C(O)C(O[C@@H]2[C@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1)C	O=C(OCC1C(OC2C(O)C(OC3C(O)C(O)C(O)CO3)C(O)C(C)O2)C(O)C(O)C(O[C@@H]2[C@](CO)(C)C3[C@@](C)(C4[C@](C)([C@@]5(C)C([C@H]6[C@@](C(=O)O)(CC5)CCC(C)(C)C6)=CC4)CC3)CC2)O1)C
NCGC00246835-02	O=C(OCC1C2(OC)N(C=3C(=O)C(C)=C(N)C(=O)C1=3)CC1N(C)C21)N		Inactive	DNA-Damaging Drugs		1	Porfiromycin	384568512.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC1C2(OC)N(C=3C(=O)C(C)=C(N)C(=O)C1=3)CC1N(C)C21)N	O=C(OCC1C2(OC)N(C=3C(=O)C(C)=C(N)C(=O)C1=3)CC1N(C)C21)N
NCGC00371042-02	O=C(OCC1CCN(C(OC(C)(C)C)=O)CC1)Nc1c(OC)cccc1		Inactive	Small conductance calcium-activated potassium channel protein 1 Activator		1	GW542573X	363678005.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC1CCN(C(OC(C)(C)C)=O)CC1)Nc1c(OC)cccc1	O=C(OCC1CCN(C(OC(C)(C)C)=O)CC1)Nc1c(OC)cccc1
NCGC00167423-01	O=C(OCC1[N+](C)(C)CCCC1)C(O)(c1ccccc1)c1ccccc1		Inactive	Muscarinic acetylcholine receptor Antagonist		1	Bevonium metilsulfate	144205980.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(OC)[O-].O=C(OCC1[N+](C)(C)CCCC1)C(O)(c1ccccc1)c1ccccc1	S(=O)(=O)(OC)[O-].O=C(OCC1[N+](C)(C)CCCC1)C(O)(c1ccccc1)c1ccccc1
NCGC00385679-01	O=C(OCC=1C2C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)C2CC=1)c1cc(OC)c(O)cc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385679-01	363679871.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC=1C2C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)C2CC=1)c1cc(OC)c(O)cc1	O=C(OCC=1C2C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)C2CC=1)c1cc(OC)c(O)cc1
NCGC00018210-05	O=C(OCC=1N(C)CCCN=1)C(O)(c1ccccc1)C1CCCCC1		Inactive	Muscarinic acetylcholine receptor M4 Binding Agent		1	Oxyphencyclimine hydrochloride	170465276.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCC=1N(C)CCCN=1)C(O)(c1ccccc1)C1CCCCC1.Cl	O=C(OCC=1N(C)CCCN=1)C(O)(c1ccccc1)C1CCCCC1.Cl
NCGC00169007-03	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)[C@H]2CC=1)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Salvia | Family: Labiatae | Species: sp.		1	NCGC00169007-03	363676739.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)[C@H]2CC=1)/C=C/c1ccccc1	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)[C@H]2CC=1)/C=C/c1ccccc1
NCGC00180458-02	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)[C@H]2[C@@H](O)C=1)C		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Rubia | Family: Rubiaceae | Species: tinctoria		1	NCGC00180458-02	363677026.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)[C@H]2[C@@H](O)C=1)C	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)[C@H]2[C@@H](O)C=1)C
NCGC00380265-01	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)OC)[C@H]2[C@@H](O)C=1)C		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Antiaris | Family: Urticaceae | Species: africana***		1	NCGC00380265-01	363678518.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)OC)[C@H]2[C@@H](O)C=1)C	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)OC)[C@H]2[C@@H](O)C=1)C
NCGC00385615-01	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C3C(=O)OC([C@@H]23)C=1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Cruciata | Family: Rubiaceae | Species: glabra		1	NCGC00385615-01	363679839.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C3C(=O)OC([C@@H]23)C=1)/C=C/c1ccc(O)cc1	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C3C(=O)OC([C@@H]23)C=1)/C=C/c1ccc(O)cc1
NCGC00380739-01	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C3C(=O)O[C@H]([C@@H]23)C=1)C		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Rubia | Family: Rubiaceae | Species: tinctoria		1	Asperuloside	363678752.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C3C(=O)O[C@H]([C@@H]23)C=1)C	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C3C(=O)O[C@H]([C@@H]23)C=1)C
NCGC00384573-01	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@H]2[C@H](O)C=1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Vitex | Family: Verbenaceae | Species: agenus		1	NCGC00384573-01	363679251.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@H]2[C@H](O)C=1)/C=C/c1ccc(O)cc1	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@H]2[C@H](O)C=1)/C=C/c1ccc(O)cc1
NCGC00168851-03	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@H]2[C@H](O)C=1)c1ccc(O)cc1		Inactive	leukotriene B4 biosynthetic process Inhibitor		1	NCGC00168851-03	363676704.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@H]2[C@H](O)C=1)c1ccc(O)cc1	O=C(OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@H]2[C@H](O)C=1)c1ccc(O)cc1
NCGC00159435-03	O=C(OCCC(C)C)/C=C/c1ccc(OC)cc1		Inactive			1	Amiloxate	29215377.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCCC(C)C)/C=C/c1ccc(OC)cc1	O=C(OCCC(C)C)/C=C/c1ccc(OC)cc1
NCGC00164526-02	O=C(OCCC(C)C)C(NCCN(CC)CC)c1ccccc1		Inactive	Muscarinic acetylcholine receptor Antagonist		1	Camylofin	170465936.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&18.7000763679	O=C(OCCC(C)C)C(NCCN(CC)CC)c1ccccc1	O=C(OCCC(C)C)C(NCCN(CC)CC)c1ccccc1
NCGC00385540-01	O=C(OCCC(CCC1C(=C)CCC2C(C)(C)C(O)CCC12C)C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385540-01	363679796.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCC(CCC1C(=C)CCC2C(C)(C)C(O)CCC12C)C)C	O=C(OCCC(CCC1C(=C)CCC2C(C)(C)C(O)CCC12C)C)C
NCGC00380550-01	O=C(OCCC(CCC1C(=C)CCC2C(C)(C)C(O)CCC12C)C)CCC(=O)O		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380550-01	363678645.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCC(CCC1C(=C)CCC2C(C)(C)C(O)CCC12C)C)CCC(=O)O	O=C(OCCC(CCC1C(=C)CCC2C(C)(C)C(O)CCC12C)C)CCC(=O)O
NCGC00380552-01	O=C(OCCC(CCC1C(=C)CCC2C(C)(C)CC(=O)CC12C)C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380552-01	363678646.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCC(CCC1C(=C)CCC2C(C)(C)CC(=O)CC12C)C)C	O=C(OCCC(CCC1C(=C)CCC2C(C)(C)CC(=O)CC12C)C)C
NCGC00380160-01	O=C(OCCC(CCC1C(=C)CCC2C(C)(C)CC(O)CC12C)C)CCC(=O)O		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380160-01	363678481.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCC(CCC1C(=C)CCC2C(C)(C)CC(O)CC12C)C)CCC(=O)O	O=C(OCCC(CCC1C(=C)CCC2C(C)(C)CC(O)CC12C)C)CCC(=O)O
NCGC00380376-01	O=C(OCCC(CCC1C(O)(C)CCC2C(C)(C)CCCC12C)C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380376-01	363678556.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCC(CCC1C(O)(C)CCC2C(C)(C)CCCC12C)C)C	O=C(OCCC(CCC1C(O)(C)CCC2C(C)(C)CCCC12C)C)C
NCGC00183027-01	O=C(OCCC)Cc1cc(OC)c(OCC(=O)N(CC)CC)cc1		Inactive	GABA-A receptor; agonist GABA site Positive Allosteric Modulator		1	Propanidid	144206858.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	10.603428568	O=C(OCCC)Cc1cc(OC)c(OCC(=O)N(CC)CC)cc1	O=C(OCCC)Cc1cc(OC)c(OCC(=O)N(CC)CC)cc1
NCGC00387212-05	O=C(OCCC)c1ccc(NC(=O)C=2C(=O)N(CCCCCC)c3c(C=2O)cccc3)cc1		Inactive	Smoothened homolog Agonist		1	GSA-10	363680571.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCC)c1ccc(NC(=O)C=2C(=O)N(CCCCCC)c3c(C=2O)cccc3)cc1	O=C(OCCC)c1ccc(NC(=O)C=2C(=O)N(CCCCCC)c3c(C=2O)cccc3)cc1
NCGC00090965-07	O=C(OCCC)c1ccc(O)cc1		Inactive			1	Propyl-4-hydroxybenzoate	405559148.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCCC)c1ccc(O)cc1	O=C(OCCC)c1ccc(O)cc1
NCGC00159383-04	O=C(OCCC)c1ccccc1		Inactive			1	Propyl benzoate	170465563.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCCC)c1ccccc1	O=C(OCCC)c1ccccc1
NCGC00183655-01	O=C(OCCCC)C(=O)Nc1cc(-c2n[nH]nn2)ccc1		Inactive	histamine secretion by mast cell Inhibitor		1	Tazanolast	144206520.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCCCC)C(=O)Nc1cc(-c2n[nH]nn2)ccc1	O=C(OCCCC)C(=O)Nc1cc(-c2n[nH]nn2)ccc1
NCGC00370922-01	O=C(OCCCC)NC(=O)C1c2c(Oc3c1cccc3)cccc2		Inactive	Metabotropic glutamate receptor 5 Positive Allosteric Modulator		1	Ro 67-4853	363677936.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCCC)NC(=O)C1c2c(Oc3c1cccc3)cccc2	O=C(OCCCC)NC(=O)C1c2c(Oc3c1cccc3)cccc2
NCGC00481621-01	O=C(OCCCC)c1c2sc(C(OCCN3CCCCC3)c3c(C)cccc3)cc2ncc1	4.9000001	Active		0.0	1	NCGC00481621-01		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	3.0	105.172838472	O=C(OCCCC)c1c2sc(C(OCCN3CCCCC3)c3c(C)cccc3)cc2ncc1	O=C(OCCCC)c1c2sc(C(OCCN3CCCCC3)c3c(C)cccc3)cc2ncc1
NCGC00016353-08	O=C(OCCCC)c1ccc(N)cc1		Inactive			1	Butyl 4-aminobenzoate	170465735.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCCCC)c1ccc(N)cc1	O=C(OCCCC)c1ccc(N)cc1
NCGC00016354-11	O=C(OCCCC)c1ccc(O)cc1		Inactive			1	Butylparaben	170465688.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCCCC)c1ccc(O)cc1	O=C(OCCCC)c1ccc(O)cc1
NCGC00262929-01&NCGC00262929-03	O=C(OCCCCCC)/N=C(/N)\c1ccc(NCc2n(C)c3c(n2)cc(C(=O)N(CCC(=O)OCC)c2ncccc2)cc3)cc1		Inactive	Thrombin Inhibitor		2	BIBR-1048	170466107.0&384568578.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&-11.0014903121	O=C(OCCCCCC)/N=C(/N)\c1ccc(NCc2n(C)c3c(n2)cc(C(=O)N(CCC(=O)OCC)c2ncccc2)cc3)cc1	O=C(OCCCCCC)/N=C(/N)\c1ccc(NCc2n(C)c3c(n2)cc(C(=O)N(CCC(=O)OCC)c2ncccc2)cc3)cc1
NCGC00164126-01	O=C(OCCCCCCCC)c1cc(O)c(O)c(O)c1		Inactive			1	Octyl gallate	26757543.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	31.4741573041	O=C(OCCCCCCCC)c1cc(O)c(O)c(O)c1	O=C(OCCCCCCCC)c1cc(O)c(O)c(O)c1
NCGC00164554-06	O=C(OCCCCCCCCC(=O)O)/C=C(/C[C@H]1[C@H](O)[C@H](O)[C@@H](C[C@H]2[C@H]([C@H]([C@@H](O)C)C)O2)CO1)\C		Inactive			1	Mupirocin	405558980.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCCCCCCCCC(=O)O)/C=C(/C[C@H]1[C@H](O)[C@H](O)[C@@H](C[C@H]2[C@H]([C@H]([C@@H](O)C)C)O2)CO1)\C	O=C(OCCCCCCCCC(=O)O)/C=C(/C[C@H]1[C@H](O)[C@H](O)[C@@H](C[C@H]2[C@H]([C@H]([C@@H](O)C)C)O2)CO1)\C
NCGC00262598-02&NCGC00262598-03	O=C(OCCCCCOC(=O)CC[N+]1(C)C(Cc2cc(OC)c(OC)cc2)c2c(cc(OC)c(OC)c2)CC1)CC[N+]1(C)C(Cc2cc(OC)c(OC)cc2)c2c(cc(OC)c(OC)c2)CC1		Inactive			2	Atracurium besylate	225144360.0&384568573.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCCCCCOC(=O)CC[N+]1(C)C(Cc2cc(OC)c(OC)cc2)c2c(cc(OC)c(OC)c2)CC1)CC[N+]1(C)C(Cc2cc(OC)c(OC)cc2)c2c(cc(OC)c(OC)c2)CC1	O=C(OCCCCCOC(=O)CC[N+]1(C)C(Cc2cc(OC)c(OC)cc2)c2c(cc(OC)c(OC)c2)CC1)CC[N+]1(C)C(Cc2cc(OC)c(OC)cc2)c2c(cc(OC)c(OC)c2)CC1
NCGC00018277-06	O=C(OCCCCN(C(Cc1ccc(OC)cc1)C)CC)c1cc(OC)c(OC)cc1		Inactive			1	Mebeverine hydrochloride	170466168.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCCCCN(C(Cc1ccc(OC)cc1)C)CC)c1cc(OC)c(OC)cc1.Cl	O=C(OCCCCN(C(Cc1ccc(OC)cc1)C)CC)c1cc(OC)c(OC)cc1.Cl
NCGC00016411-10	O=C(OCCCN(CCCC)CCCC)c1ccc(N)cc1		Inactive			1	Butacaine	170465459.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCCCN(CCCC)CCCC)c1ccc(N)cc1	O=C(OCCCN(CCCC)CCCC)c1ccc(N)cc1
NCGC00253585-01	O=C(OCCCN1C(C)CCCC1)c1ccc(OC2CCCCC2)cc1	4.9000001	Active		0.0	1	Cyclomethycaine	170465528.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	114.6904388916	O=C(OCCCN1C(C)CCCC1)c1ccc(OC2CCCCC2)cc1	O=C(OCCCN1C(C)CCCC1)c1ccc(OC2CCCCC2)cc1
NCGC00167552-01	O=C(OCCCN1C(C)CCCC1)c1ccccc1		Inactive	Nicotinic acetylcholine receptor  Blocker		1	Piperocaine hydrochloride	144206100.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCCCN1C(C)CCCC1)c1ccccc1.Cl	O=C(OCCCN1C(C)CCCC1)c1ccccc1.Cl
NCGC00016747-07	O=C(OCCCN1CCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CCC1)c1cc(OC)c(OC)c(OC)c1		Inactive	Equilibrative nucleoside transporter 2 Inhibitor		1	Dilazep	170465831.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	29.4563843199	O=C(OCCCN1CCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CCC1)c1cc(OC)c(OC)c(OC)c1	O=C(OCCCN1CCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CCC1)c1cc(OC)c(OC)c(OC)c1
NCGC00385881-01	O=C(OCCC[C@H](C)C=1[C@@H](O)[C@@H]2C(=C)C(=O)O[C@@H]2CC=1C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	1-O-Acetylbritannilactone	363679988.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCC[C@H](C)C=1[C@@H](O)[C@@H]2C(=C)C(=O)O[C@@H]2CC=1C)C	O=C(OCCC[C@H](C)C=1[C@@H](O)[C@@H]2C(=C)C(=O)O[C@@H]2CC=1C)C
NCGC00167469-02	O=C(OCCC[N+]1(C)[C@H](Cc2cc(OC)c(OC)c(OC)c2)c2c(cc(OC)c(OC)c2)CC1)CC/C=C/CCC(=O)OCCC[N+]1(C)[C@H](Cc2cc(OC)c(OC)c(OC)c2)c2c(cc(OC)c(OC)c2)CC1		Inactive			1	NCGC00167469-02	405558707.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCCC[N+]1(C)[C@H](Cc2cc(OC)c(OC)c(OC)c2)c2c(cc(OC)c(OC)c2)CC1)CC/C=C/CCC(=O)OCCC[N+]1(C)[C@H](Cc2cc(OC)c(OC)c(OC)c2)c2c(cc(OC)c(OC)c2)CC1	O=C(OCCC[N+]1(C)[C@H](Cc2cc(OC)c(OC)c(OC)c2)c2c(cc(OC)c(OC)c2)CC1)CC/C=C/CCC(=O)OCCC[N+]1(C)[C@H](Cc2cc(OC)c(OC)c(OC)c2)c2c(cc(OC)c(OC)c2)CC1
NCGC00164589-02	O=C(OCCCc1ccccc1)N		Inactive			1	Phenprobamate	170465902.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCCCc1ccccc1)N	O=C(OCCCc1ccccc1)N
NCGC00018213-06	O=C(OCCN(C)C)C(c1ccccc1)C1(O)CCCC1		Inactive	Muscarinic acetylcholine receptor Antagonist		1	Cyclopentolate hydrochloride	170464720.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCCN(C)C)C(c1ccccc1)C1(O)CCCC1.Cl	O=C(OCCN(C)C)C(c1ccccc1)C1(O)CCCC1.Cl
NCGC00016049-07	O=C(OCCN(C)C)c1ccc(NCCCC)cc1		Inactive	Sodium channel alpha subunit Blocker		1	Tetracaine hydrochloride	170465190.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCCN(C)C)c1ccc(NCCCC)cc1.Cl	O=C(OCCN(C)C)c1ccc(NCCCC)cc1.Cl
NCGC00178213-05	O=C(OCCN(CC)CC)C(Cc1c2c(ccc1)cccc2)CC1OCCC1	4.9000001	Active	Serotonin 2 (5-HT2) receptor Antagonist	0.0	1	Nafronyl oxalate	170465616.0	2019_NPC-2.2	SARS-CoV-2_CPE_SRI	3.0	55.8658320879	O=C(O)C(=O)O.O=C(OCCN(CC)CC)C(Cc1c2c(ccc1)cccc2)CC1OCCC1	O=C(O)C(=O)O.O=C(OCCN(CC)CC)C(Cc1c2c(ccc1)cccc2)CC1OCCC1
NCGC00181082-01	O=C(OCCN(CC)CC)C(O)(c1ccccc1)c1ccccc1		Inactive	Muscarinic acetylcholine receptor M4 Antagonist		1	Benzactyzine methobromide	144206254.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	BrC.O=C(OCCN(CC)CC)C(O)(c1ccccc1)c1ccccc1	BrC.O=C(OCCN(CC)CC)C(O)(c1ccccc1)c1ccccc1
NCGC00015368-11	O=C(OCCN(CC)CC)C1(C2CCCCC2)CCCCC1	4.9499998	Active	Muscarinic acetylcholine receptor M3 Antagonist	0.0	1	Dicyclomine	170464896.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	34.07459678	O=C(OCCN(CC)CC)C1(C2CCCCC2)CCCCC1	O=C(OCCN(CC)CC)C1(C2CCCCC2)CCCCC1
NCGC00167426-03	O=C(OCCN(CC)CC)C1(c2ccccc2)CCCC1		Inactive			1	Caramiphen edisylate	170465518.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)CCS(=O)(=O)O.O=C(OCCN(CC)CC)C1(c2ccccc2)CCCC1.O=C(OCCN(CC)CC)C1(c2ccccc2)CCCC1	S(=O)(=O)(O)CCS(=O)(=O)O.O=C(OCCN(CC)CC)C1(c2ccccc2)CCCC1.O=C(OCCN(CC)CC)C1(c2ccccc2)CCCC1
NCGC00016505-06	O=C(OCCN(CC)CC)c1c(OCCC)cc(N)cc1		Inactive			1	PROPOXYCAINE HYDROCHLORIDE	405558691.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCCN(CC)CC)c1c(OCCC)cc(N)cc1	O=C(OCCN(CC)CC)c1c(OCCC)cc(N)cc1
NCGC00016991-05&NCGC00016991-07	O=C(OCCN(CC)CC)c1cc(N)c(OCCC)cc1		Inactive	Sodium Channel Inhibitor		2	Proparacaine	170465400.0&384567972.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCCN(CC)CC)c1cc(N)c(OCCC)cc1.Cl	O=C(OCCN(CC)CC)c1cc(N)c(OCCC)cc1.Cl&O=C(OCCN(CC)CC)c1cc(N)c(OCCC)cc1
NCGC00016667-04	O=C(OCCN(CC)CC)c1cc(OCCCC)c(N)cc1		Inactive	Sodium channel alpha subunit Blocker		1	Benoxinate hydrochloride	170464771.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCCN(CC)CC)c1cc(OCCCC)c(N)cc1.Cl	O=C(OCCN(CC)CC)c1cc(OCCCC)c(N)cc1.Cl
NCGC00183003-01	O=C(OCCN(CC)CC)c1ccc(NCCCC)cc1		Inactive			1	Depolipon	144206803.0	Approved Drugs Collection (NPC)&2020_NPACT-1_CPE	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCC[NH+](CC)CC)c1ccc(NCCCC)cc1.[Cl-]	O=C(OCC[NH+](CC)CC)c1ccc(NCCCC)cc1.[Cl-]
NCGC00159450-04	O=C(OCCN(CC)CC)c1ccc(OCC)cc1		Inactive			1	Parethoxycaine	170465538.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	-8.2122905039&0.0	O=C(OCCN(CC)CC)c1ccc(OCC)cc1	O=C(OCCN(CC)CC)c1ccc(OCC)cc1
NCGC00167584-01	O=C(OCCN(CC)CC)c1cnccc1		Inactive	cell growth Inhibitor		1	Nicametate citrate	144206129.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(O)(CC(=O)O)CC(=O)O.O=C(OCCN(CC)CC)c1cnccc1	O=C(O)C(O)(CC(=O)O)CC(=O)O.O=C(OCCN(CC)CC)c1cnccc1
NCGC00538148-01	O=C(OCCN(CCO)CCO)c1c(O)cccc1		Inactive			1	NCGC00538148-01	405558798.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCCN(CCO)CCO)c1c(O)cccc1	O=C(OCCN(CCO)CCO)c1c(O)cccc1
NCGC00249909-01	O=C(OCCN1C(C)C(c2ccccc2)OCC1)C(CC)c1ccccc1		Inactive	Monoamine transporters; Norepinephrine & dopamine Agonist		1	Fenbutrazate	170465618.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCCN1C(C)C(c2ccccc2)OCC1)C(CC)c1ccccc1	O=C(OCCN1C(C)C(c2ccccc2)OCC1)C(CC)c1ccccc1
NCGC00181083-01	O=C(OCCN1CCCCC1)C(O)(c1ccccc1)c1ccccc1		Inactive			1	Piperilate hydrochloride	144206255.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCCN1CCCCC1)C(O)(c1ccccc1)c1ccccc1.Cl	O=C(OCCN1CCCCC1)C(O)(c1ccccc1)c1ccccc1.Cl
NCGC00016636-05	O=C(OCCN1CCCCC1)c1c2OC(c3ccccc3)=C(C)C(=O)c2ccc1		Inactive	Muscarinic acetylcholine receptors; M1 & M2 Antagonist		1	Flavoxate hydrochloride	170466285.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCCN1CCCCC1)c1c2OC(c3ccccc3)=C(C)C(=O)c2ccc1.Cl	O=C(OCCN1CCCCC1)c1c2OC(c3ccccc3)=C(C)C(=O)c2ccc1.Cl
NCGC00159459-03&NCGC00159459-04&NCGC00159459-08	O=C(OCCN1CCOCC1)CC/C(=C/Cc1c(OC)c(C)c2c(c1O)C(=O)OC2)/C		Inactive	Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitor		3	Mycophenolate mofetil	29215410.0&170464859.0&384568181.0	Anti-infectives&2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0		O=C(OCCN1CCOCC1)CC/C(=C/Cc1c(OC)c(C)c2c(c1O)C(=O)OC2)/C	O=C(OCCN1CCOCC1)CC/C(=C/Cc1c(OC)c(C)c2c(c1O)C(=O)OC2)/C
NCGC00183103-01	O=C(OCCO)CCC(=O)Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C		Inactive			1	Tocophersolan	144206517.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	21.712367096	O=C(OCCO)CCC(=O)Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C	O=C(OCCO)CCC(=O)Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C
NCGC00188435-01	O=C(OCCO)CCCCCCCCCCCCCCCCC		Inactive			1	2-Hydroxyethyl octadecanoate	144206587.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCCO)CCCCCCCCCCCCCCCCC	O=C(OCCO)CCCCCCCCCCCCCCCCC
NCGC00159379-04	O=C(OCCO)c1c(O)cccc1		Inactive			1	BETA-HYDROXYETHYL SALICYLATE	225144223.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCCO)c1c(O)cccc1	O=C(OCCO)c1c(O)cccc1
NCGC00346826-01	O=C(OCCOC)C1=C(C)NC2=C(C(=O)CC(c3c(OC)cccc3)C2)C1c1cc(O)ccc1		Inactive	Smoothened (Smo) Receptor Antagonist		1	HPI-1	174006691.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCCOC)C1=C(C)NC2=C(C(=O)CC(c3c(OC)cccc3)C2)C1c1cc(O)ccc1	O=C(OCCOC)C1=C(C)NC2=C(C(=O)CC(c3c(OC)cccc3)C2)C1c1cc(O)ccc1
NCGC00249899-01	O=C(OCCOCC)C=Cc1ccc(OC)cc1		Inactive			1	Cinoxate	170465555.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCCOCC)C=Cc1ccc(OC)cc1	O=C(OCCOCC)C=Cc1ccc(OC)cc1
NCGC00249906-01	O=C(OCCOCCCC)c1cnccc1		Inactive	positive regulation of vasodilation Activator		1	Nicoboxil	170465989.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	12.9063582239&15.0108958799	O=C(OCCOCCCC)c1cnccc1	O=C(OCCOCCCC)c1cnccc1
NCGC00389219-01	O=C(OCCOCCN(CC)CC)C(CC)(CC)c1ccccc1		Inactive			1	Oxeladin Citrate	405558942.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	23.163009408	O=C(OCCOCCN(CC)CC)C(CC)(CC)c1ccccc1	O=C(OCCOCCN(CC)CC)C(CC)(CC)c1ccccc1
NCGC00024595-08	O=C(OCCOCCN(CC)CC)C1(c2ccccc2)CCCC1	4.8499999	Active	Sigma-1 receptor Agonist	0.0	1	Carbetapentane	170465562.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	2.4	30.10800224	O=C(OCCOCCN(CC)CC)C1(c2ccccc2)CCCC1	O=C(OCCOCCN(CC)CC)C1(c2ccccc2)CCCC1
NCGC00016362-05	O=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)c1ccc(NCCCC)cc1		Inactive	Slowly adapting pulmonary stretch receptor Inhibitor		1	Benzonatate	170465391.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)c1ccc(NCCCC)cc1	O=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)c1ccc(NCCCC)cc1
NCGC00178638-02&NCGC00178638-13	O=C(OCCOCn1c2N=C(N)NC(=O)c2nc1)[C@@H](N)C(C)C		Inactive	DNA Polymerase Inhibitor		2	Valaciclovir	170465373.0&384568359.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(OCCOCn1c2N=C(N)NC(=O)c2nc1)[C@@H](N)C(C)C.Cl	O=C(OCCOCn1c2N=C(N)NC(=O)c2nc1)[C@@H](N)C(C)C.Cl&O=C(OCCOCn1c2N=C(N)NC(=O)c2nc1)[C@@H](N)C(C)C
NCGC00380868-01	O=C(OCC[C@H]1[C@@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC)c1cc(O)c(O)c(O)c1		Inactive	<MOA Unknown> | Class: iridoid | Genus: Cornus | Family: Cornaceae | Species: mas		1	NCGC00380868-01	363678823.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC[C@H]1[C@@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC)c1cc(O)c(O)c(O)c1	O=C(OCC[C@H]1[C@@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC)c1cc(O)c(O)c(O)c1
NCGC00380934-01	O=C(OCC[C@H]1[C@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)O)/C=C/c1cc(O)c(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Kurrimoa | Family: Celastraceae | Species: ceylanica		1	NCGC00380934-01	363678866.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCC[C@H]1[C@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)O)/C=C/c1cc(O)c(O)cc1	O=C(OCC[C@H]1[C@H](C=C)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)O)/C=C/c1cc(O)c(O)cc1
NCGC00015854-10	O=C(OCC[N+](C(C)C)(C(C)C)C)C1c2c(Oc3c1cccc3)cccc2		Inactive	Muscarinic acetylcholine receptor M4 Antagonist		1	Propantheline bromide	170464881.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC[N+](C(C)C)(C(C)C)C)C1c2c(Oc3c1cccc3)cccc2.[Br-]	O=C(OCC[N+](C(C)C)(C(C)C)C)C1c2c(Oc3c1cccc3)cccc2.[Br-]
NCGC00018123-07	O=C(OCC[N+](C)(C)C)C		Inactive	Acetylcholinesterase Substrate		1	Acetylcholine chloride	170464783.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&7.841542572	O=C(OCC[N+](C)(C)C)C.[Cl-]	O=C(OCC[N+](C)(C)C)C.[Cl-]
NCGC00015971-05	O=C(OCC[N+](C)(C)C)CCC(=O)OCC[N+](C)(C)C		Inactive	Muscle-type nicotinic acetylcholine receptor Agonist		1	Succinylcholine chloride	170464625.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC[N+](C)(C)C)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-]	O=C(OCC[N+](C)(C)C)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-]
NCGC00015237-07	O=C(OCC[N+](C)(C)C)N		Inactive	Acetylcholinesterase Substrate		1	Carbachol	170464972.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCC[N+](C)(C)C)N.[Cl-]	O=C(OCC[N+](C)(C)C)N.[Cl-]
NCGC00185757-01	O=C(OCC[N+](CC)(CC)C)C(C(CC)C)c1ccccc1		Inactive	Muscarinic acetylcholine receptor M3 Antagonist		1	Diethylmethyl(2-3-methyl-2-phenylvaleryloxy)-ethyl)ammonium bromide	144207102.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC[N+](CC)(CC)C)C(C(CC)C)c1ccccc1.[Br-]	O=C(OCC[N+](CC)(CC)C)C(C(CC)C)c1ccccc1.[Br-]
NCGC00018256-06	O=C(OCC[N+](CC)(CC)C)C(O)(c1ccccc1)C1CCCCC1		Inactive	Muscarinic acetylcholine receptor Antagonist		1	Oxyphenonium bromide	170465282.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCC[N+](CC)(CC)C)C(O)(c1ccccc1)C1CCCCC1.[Br-]	O=C(OCC[N+](CC)(CC)C)C(O)(c1ccccc1)C1CCCCC1.[Br-]
NCGC00016239-04	O=C(OCC[N+](CC)(CC)C)C1c2c(Oc3c1cccc3)cccc2		Inactive	Histamine H2 receptor Antagonist		1	Methantheline bromide	170465350.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC[N+](CC)(CC)C)C1c2c(Oc3c1cccc3)cccc2.[Br-]	O=C(OCC[N+](CC)(CC)C)C1c2c(Oc3c1cccc3)cccc2.[Br-]
NCGC00183852-01	O=C(OCC[N+](CC)(CC)CC)C(C1CCCC1)C1CCCC1		Inactive	Muscarinic acetylcholine receptor Antagonist		1	Diponium bromide	144206825.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC[N+](CC)(CC)CC)C(C1CCCC1)C1CCCC1.[Br-]	O=C(OCC[N+](CC)(CC)CC)C(C1CCCC1)C1CCCC1.[Br-]
NCGC00167509-02	O=C(OCC[N+]1(CC)CCCCC1)C(O)(c1ccccc1)c1ccccc1		Inactive	Muscarinic acetylcholine receptor Antagonist		1	Pipethanate ethylbromide	170465967.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCC[N+]1(CC)CCCCC1)C(O)(c1ccccc1)c1ccccc1.[Br-]	O=C(OCC[N+]1(CC)CCCCC1)C(O)(c1ccccc1)c1ccccc1.[Br-]
NCGC00380698-01	O=C(OCCc1cc(O)c(O)cc1)C=1[C@@]2(O)C(=O)CC(C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Syringa | Family: Oleaceae | Species: vulgaris		1	NCGC00380698-01	363678716.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCc1cc(O)c(O)cc1)C=1[C@@]2(O)C(=O)CC(C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1	O=C(OCCc1cc(O)c(O)cc1)C=1[C@@]2(O)C(=O)CC(C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1
NCGC00384520-01	O=C(OCCc1cc(O)c(O)cc1)C[C@H]1/C(=C/CO)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)O		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Jasminum | Family: Oleaceae | Species: multiflorum		1	NCGC00384520-01	363679227.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCc1cc(O)c(O)cc1)C[C@H]1/C(=C/CO)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)O	O=C(OCCc1cc(O)c(O)cc1)C[C@H]1/C(=C/CO)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)O
NCGC00169074-02&NCGC00169074-03	O=C(OCCc1cc(O)c(O)cc1)C[C@H]1/C(=C\C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Ononis | Family: Fabaceae | Species: spinosa		2	Oleuropein	363676761.0	2020_NPACT-4_CPE&2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OCCc1cc(O)c(O)cc1)C[C@H]1/C(=C\C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC	O=C(OCCc1cc(O)c(O)cc1)C[C@H]1/C(=C\C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC
NCGC00381305-01	O=C(OCCc1ccc(O)cc1)C1=COC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2C(C)C(O)C(O)C12		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381305-01	363679078.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCc1ccc(O)cc1)C1=COC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2C(C)C(O)C(O)C12	O=C(OCCc1ccc(O)cc1)C1=COC(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C2C(C)C(O)C(O)C12
NCGC00381009-01	O=C(OCCc1ccc(O)cc1)C=1[C@@]2(O)C(=O)CC(C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Syringa | Family: Oleaceae | Species: vulgaris		1	NCGC00381009-01	363678923.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCc1ccc(O)cc1)C=1[C@@]2(O)C(=O)CC(C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1	O=C(OCCc1ccc(O)cc1)C=1[C@@]2(O)C(=O)CC(C)[C@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=1
NCGC00381243-01	O=C(OCCc1ccc(O)cc1)CC1/C(=C/COC(=O)c2cc(OC)c(OC3C(O)C(O)C(O)C(CO)O3)cc2)/C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381243-01	363679047.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCc1ccc(O)cc1)CC1/C(=C/COC(=O)c2cc(OC)c(OC3C(O)C(O)C(O)C(CO)O3)cc2)/C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC	O=C(OCCc1ccc(O)cc1)CC1/C(=C/COC(=O)c2cc(OC)c(OC3C(O)C(O)C(O)C(CO)O3)cc2)/C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC
NCGC00381323-01	O=C(OCCc1ccc(O)cc1)C[C@H]1/C(=C/C)/[C@H](OC2C(O)C(O)C(O)C(COC3C(O)C(O)C(O)C(CO)O3)O2)OC=C1C(=O)OC		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Pistacia | Family: Anacardiaceae | Species: sp.		1	NCGC00381323-01	363679086.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCc1ccc(O)cc1)C[C@H]1/C(=C/C)/[C@H](OC2C(O)C(O)C(O)C(COC3C(O)C(O)C(O)C(CO)O3)O2)OC=C1C(=O)OC	O=C(OCCc1ccc(O)cc1)C[C@H]1/C(=C/C)/[C@H](OC2C(O)C(O)C(O)C(COC3C(O)C(O)C(O)C(CO)O3)O2)OC=C1C(=O)OC
NCGC00169850-02	O=C(OCCc1ccc(O)cc1)C[C@H]1/C(=C/C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)O		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169850-02	363676899.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCc1ccc(O)cc1)C[C@H]1/C(=C/C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)O	O=C(OCCc1ccc(O)cc1)C[C@H]1/C(=C/C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)O
NCGC00386017-01	O=C(OCCc1ccc(O)cc1)C[C@H]1/C(=C/C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OCCc1ccc(O)cc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386017-01	363680061.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCc1ccc(O)cc1)C[C@H]1/C(=C/C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OCCc1ccc(O)cc1	O=C(OCCc1ccc(O)cc1)C[C@H]1/C(=C/C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OCCc1ccc(O)cc1
NCGC00385019-01	O=C(OCCc1ccc(O)cc1)C[C@H]1/C(=C/CO)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)O		Inactive	<MOA Unknown> | Class: Iridoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385019-01	363679488.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCc1ccc(O)cc1)C[C@H]1/C(=C/CO)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)O	O=C(OCCc1ccc(O)cc1)C[C@H]1/C(=C/CO)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)O
NCGC00169934-02	O=C(OCCc1ccc(O)cc1)C[C@H]1/C(=C/CO)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Fraxinus | Family: Oleaceae | Species: excelsior		1	NCGC00169934-02	363676918.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCc1ccc(O)cc1)C[C@H]1/C(=C/CO)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC	O=C(OCCc1ccc(O)cc1)C[C@H]1/C(=C/CO)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC
NCGC00169398-02	O=C(OCCc1ccc(OC(=O)C[C@H]2/C(=C\C)/[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C2C(=O)OC)cc1)C[C@H]1/C(=C\C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169398-02	363676811.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCCc1ccc(OC(=O)C[C@H]2/C(=C\C)/[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C2C(=O)OC)cc1)C[C@H]1/C(=C\C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC	O=C(OCCc1ccc(OC(=O)C[C@H]2/C(=C\C)/[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C2C(=O)OC)cc1)C[C@H]1/C(=C\C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC
NCGC00095175-08	O=C(OCOC(=O)C1=C(/C=C\c2c(C)ncs2)CS[C@@H]2[C@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)C(=O)N12)C(C)(C)C		Inactive	Cephalosporin Antibiotic		1	Cefditoren (Pivoxil)	405558969.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCOC(=O)C1=C(/C=C\c2c(C)ncs2)CS[C@@H]2[C@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)C(=O)N12)C(C)(C)C	O=C(OCOC(=O)C1=C(/C=C\c2c(C)ncs2)CS[C@@H]2[C@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)C(=O)N12)C(C)(C)C
NCGC00181788-01	O=C(OCOC(=O)C1=C(C)CS[C@@H]2[C@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)C(=O)N12)C(C)(C)C		Inactive			1	Cefetamet pivoxil HCl	144206472.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCOC(=O)C1=C(C)CS[C@@H]2[C@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)C(=O)N12)C(C)(C)C.Cl	O=C(OCOC(=O)C1=C(C)CS[C@@H]2[C@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)C(=O)N12)C(C)(C)C.Cl
NCGC00179344-04	O=C(OCOC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](/N=C/N3CCCCCC3)C(=O)N12)C(C)(C)C		Inactive			1	Pivmecillinam	405558689.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCOC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](/N=C/N3CCCCCC3)C(=O)N12)C(C)(C)C	O=C(OCOC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](/N=C/N3CCCCCC3)C(=O)N12)C(C)(C)C
NCGC00181308-01	O=C(OC[C@@H](O)[C@@H]1[C@H](O)[C@@H](O)CO1)CCCCCCCCCCCCCCC		Inactive			1	Sorbitan monohexadecanoate	144206336.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC[C@@H](O)[C@@H]1[C@H](O)[C@@H](O)CO1)CCCCCCCCCCCCCCC	O=C(OC[C@@H](O)[C@@H]1[C@H](O)[C@@H](O)CO1)CCCCCCCCCCCCCCC
NCGC00385562-01	O=C(OC[C@@H]1C(O)[C@H](O)C(O)[C@H](O[C@@H]2OC=C(C(=O)O)[C@@H]3[C@H]2[C@](O)(C)CC3)O1)/C(=C/CCC(CCO)C)/C		Inactive	<MOA Unknown> | Class: Iridoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385562-01	363679809.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1C(O)[C@H](O)C(O)[C@H](O[C@@H]2OC=C(C(=O)O)[C@@H]3[C@H]2[C@](O)(C)CC3)O1)/C(=C/CCC(CCO)C)/C	O=C(OC[C@@H]1C(O)[C@H](O)C(O)[C@H](O[C@@H]2OC=C(C(=O)O)[C@@H]3[C@H]2[C@](O)(C)CC3)O1)/C(=C/CCC(CCO)C)/C
NCGC00380753-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)C(C)C		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380753-01	363678761.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)C(C)C	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)C(C)C
NCGC00380648-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)C(CC)C		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380648-01	363678689.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)C(CC)C	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)C(CC)C
NCGC00380161-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)Cc1ccccc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380161-01	363678482.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)Cc1ccccc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)Cc1ccccc1
NCGC00385221-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C=C/c1cc(OC)c(O)c(OC)c1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385221-01	363679600.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C=C/c1cc(OC)c(O)c(OC)c1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C=C/c1cc(OC)c(O)c(OC)c1
NCGC00385222-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385222-01	363679601.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)c1ccc(O)cc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)c1ccc(O)cc1
NCGC00384971-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)c1ccccc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384971-01	363679461.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)c1ccccc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)c1ccccc1
NCGC00380580-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](O)[C@H](OC(=O)C)[C@@H](CO)O2)O1)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380580-01	363678661.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](O)[C@H](OC(=O)C)[C@@H](CO)O2)O1)/C=C/c1ccccc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](O)[C@H](OC(=O)C)[C@@H](CO)O2)O1)/C=C/c1ccccc1
NCGC00385695-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@]2(CO)[C@H](O)[C@@H](O)[C@H](CO)O2)O1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385695-01	363679880.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@]2(CO)[C@H](O)[C@@H](O)[C@H](CO)O2)O1)/C=C/c1ccc(O)cc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@]2(CO)[C@H](O)[C@@H](O)[C@H](CO)O2)O1)/C=C/c1ccc(O)cc1
NCGC00384750-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@]2(CO)[C@H](O)[C@@H](O)[C@H](CO)O2)O1)c1cc(OC)c(O)cc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384750-01	363679337.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@]2(CO)[C@H](O)[C@@H](O)[C@H](CO)O2)O1)c1cc(OC)c(O)cc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@]2(CO)[C@H](O)[C@@H](O)[C@H](CO)O2)O1)c1cc(OC)c(O)cc1
NCGC00385169-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC(=O)/C=C/c2ccccc2)O1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Eucalyptus | Family: Myrtaceae | Species: camaldulensis		1	NCGC00385169-01	363679577.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC(=O)/C=C/c2ccccc2)O1)/C=C/c1ccc(O)cc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC(=O)/C=C/c2ccccc2)O1)/C=C/c1ccc(O)cc1
NCGC00380741-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC(=O)/C=C/c2ccccc2)O1)C(C(O)CO)=C		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Spiraea | Family: Rosaceae | Species: chamaedryfolia		1	NCGC00380741-01	363678754.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC(=O)/C=C/c2ccccc2)O1)C(C(O)CO)=C	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC(=O)/C=C/c2ccccc2)O1)C(C(O)CO)=C
NCGC00385101-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC(=O)C2=CCC(C(O)(C)C)CC2)O1)C1=CCC(C(O)(C)C)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385101-01	363679533.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC(=O)C2=CCC(C(O)(C)C)CC2)O1)C1=CCC(C(O)(C)C)CC1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC(=O)C2=CCC(C(O)(C)C)CC2)O1)C1=CCC(C(O)(C)C)CC1
NCGC00380690-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)O1)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Eucalyptus | Family: Myrtaceae | Species: acmenoides		1	NCGC00380690-01	363678711.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)O1)/C=C/c1ccccc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)O1)/C=C/c1ccccc1
NCGC00381023-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC(C=C)(CC/C=C(/C(=O)O[C@H]2[C@H](O)[C@@H](O)[C@H](OC(C=C)(CC/C=C(/C(=O)O)\C)C)O[C@@H]2CO)\C)C)O1)/C(=C/CCC(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)(C=C)C)/C		Inactive	<MOA Unknown> | Class: Monoterpen | Genus: Acacia | Family: Mimosaceae | Species: cyclops		1	NCGC00381023-01	363678930.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC(C=C)(CC/C=C(/C(=O)O[C@H]2[C@H](O)[C@@H](O)[C@H](OC(C=C)(CC/C=C(/C(=O)O)\C)C)O[C@@H]2CO)\C)C)O1)/C(=C/CCC(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)(C=C)C)/C	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC(C=C)(CC/C=C(/C(=O)O[C@H]2[C@H](O)[C@@H](O)[C@H](OC(C=C)(CC/C=C(/C(=O)O)\C)C)O[C@@H]2CO)\C)C)O1)/C(=C/CCC(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)(C=C)C)/C
NCGC00385033-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC/C=C/2\C(C(=O)O)=C(C)CC\2O)O1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385033-01	363679496.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC/C=C/2\C(C(=O)O)=C(C)CC\2O)O1)/C=C/c1ccc(O)cc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC/C=C/2\C(C(=O)O)=C(C)CC\2O)O1)/C=C/c1ccc(O)cc1
NCGC00380468-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2(O)/C(=C\C(O)(C)C)/C(=O)C(C)(C)C(=O)C2(C)C)O1)c1cc(O)c(O)c(O)c1		Inactive	<MOA Unknown> | Class: Shikimi / Polyketide | Genus: Callistemon | Family: Myrtaceae | Species: lanceolatus		1	NCGC00380468-01	363678599.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2(O)/C(=C\C(O)(C)C)/C(=O)C(C)(C)C(=O)C2(C)C)O1)c1cc(O)c(O)c(O)c1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2(O)/C(=C\C(O)(C)C)/C(=O)C(C)(C)C(=O)C2(C)C)O1)c1cc(O)c(O)c(O)c1
NCGC00384576-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(C)OC=CC2=O)O1)CC(O)(CC(=O)O)C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: Ononis | Family: Fabaceae | Species: variegata		1	NCGC00384576-01	363679254.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(C)OC=CC2=O)O1)CC(O)(CC(=O)O)C	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2=C(C)OC=CC2=O)O1)CC(O)(CC(=O)O)C
NCGC00380506-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2C(O)CCCC2)O1)/C=C/c1cc(O)c(O)cc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380506-01	363678617.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2C(O)CCCC2)O1)/C=C/c1cc(O)c(O)cc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2C(O)CCCC2)O1)/C=C/c1cc(O)c(O)cc1
NCGC00380895-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2CC(C)(C)C(C(=O)O)=C(C)C2)O1)/C=C/c1cc(OC)c(O)c(OC)c1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380895-01	363678840.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2CC(C)(C)C(C(=O)O)=C(C)C2)O1)/C=C/c1cc(OC)c(O)c(OC)c1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2CC(C)(C)C(C(=O)O)=C(C)C2)O1)/C=C/c1cc(OC)c(O)c(OC)c1
NCGC00385037-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2OC=C(C(=O)O)C3C(O)CC(O)(C)C23)O1)/C=C/c1cc(OC)c(O)c(OC)c1		Inactive	<MOA Unknown> | Class: Iridoide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385037-01	363679499.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	15.354767184	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2OC=C(C(=O)O)C3C(O)CC(O)(C)C23)O1)/C=C/c1cc(OC)c(O)c(OC)c1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2OC=C(C(=O)O)C3C(O)CC(O)(C)C23)O1)/C=C/c1cc(OC)c(O)c(OC)c1
NCGC00380173-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2OC=C(C(=O)O)C3C2C(=C)C(O)C3)O1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Scutellaria | Family: Labiatae | Species: sieberi		1	NCGC00380173-01	363678488.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2OC=C(C(=O)O)C3C2C(=C)C(O)C3)O1)/C=C/c1ccc(O)cc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2OC=C(C(=O)O)C3C2C(=C)C(O)C3)O1)/C=C/c1ccc(O)cc1
NCGC00384772-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2OC=C(C(=O)O)C3C2C(=C)C(O)C3)O1)c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384772-01	363679347.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2OC=C(C(=O)O)C3C2C(=C)C(O)C3)O1)c1ccc(O)cc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2OC=C(C(=O)O)C3C2C(=C)C(O)C3)O1)c1ccc(O)cc1
NCGC00380892-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2OC=C(C(=O)OC)C3C2C(CO)=CC3)O1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380892-01	363678837.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2OC=C(C(=O)OC)C3C2C(CO)=CC3)O1)/C=C/c1ccc(O)cc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC2OC=C(C(=O)OC)C3C2C(CO)=CC3)O1)/C=C/c1ccc(O)cc1
NCGC00169476-02	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCC(C)C2(O)CC(=O)OC2)O1)/C=C/c1cc(O)c(O)cc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169476-02	363676825.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCC(C)C2(O)CC(=O)OC2)O1)/C=C/c1cc(O)c(O)cc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCC(C)C2(O)CC(=O)OC2)O1)/C=C/c1cc(O)c(O)cc1
NCGC00381336-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCCC(C(=O)OC2C(O)C(O)C(COC(=O)C(=C)CCO)OC2)=C)O1)C(=C)CCO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381336-01	363679097.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCCC(C(=O)OC2C(O)C(O)C(COC(=O)C(=C)CCO)OC2)=C)O1)C(=C)CCO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCCC(C(=O)OC2C(O)C(O)C(COC(=O)C(=C)CCO)OC2)=C)O1)C(=C)CCO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00380381-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCCc2ccc(O)cc2)O1)CC1C(=O)Nc2c1cccc2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380381-01	363678559.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCCc2ccc(O)cc2)O1)CC1C(=O)Nc2c1cccc2	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCCc2ccc(O)cc2)O1)CC1C(=O)Nc2c1cccc2
NCGC00347702-02	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCCc2ccc(O)cc2)O1)C[C@H]1/C(=C/C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Piper | Family: Piperaceae | Species: sp.		1	NCGC00347702-02	363677666.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCCc2ccc(O)cc2)O1)C[C@H]1/C(=C/C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OCCc2ccc(O)cc2)O1)C[C@H]1/C(=C/C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC
NCGC00386112-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC[C@@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC3OC=C(C(=O)OC)C4C3C(CO)=CC4)O2)O1)/C=C\c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386112-01	363680112.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC[C@@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC3OC=C(C(=O)OC)C4C3C(CO)=CC4)O2)O1)/C=C\c1ccc(O)cc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC[C@@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC3OC=C(C(=O)OC)C4C3C(CO)=CC4)O2)O1)/C=C\c1ccc(O)cc1
NCGC00385576-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC[C@@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]3OC=C(C(=O)OC)[C@@H]4[C@H]3C(CO)=CC4)O2)O1)/C=C/c1cc(OC)c(O)c(OC)c1		Inactive	<MOA Unknown> | Class: Iridoide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385576-01	363679817.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC[C@@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]3OC=C(C(=O)OC)[C@@H]4[C@H]3C(CO)=CC4)O2)O1)/C=C/c1cc(OC)c(O)c(OC)c1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC[C@@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]3OC=C(C(=O)OC)[C@@H]4[C@H]3C(CO)=CC4)O2)O1)/C=C/c1cc(OC)c(O)c(OC)c1
NCGC00347599-02	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC[C@@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]3OC=C(C(=O)OC)[C@@H]4[C@H]3C(CO)=CC4)O2)O1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347599-02	363677635.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC[C@@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]3OC=C(C(=O)OC)[C@@H]4[C@H]3C(CO)=CC4)O2)O1)/C=C/c1ccc(O)cc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC[C@@H]2[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]3OC=C(C(=O)OC)[C@@H]4[C@H]3C(CO)=CC4)O2)O1)/C=C/c1ccc(O)cc1
NCGC00385466-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2OC=C(C(=O)O)[C@@H]3[C@H]2C(=C)[C@@H](O)C3)O1)/C=C/c1cc(OC)c(O)c(OC)c1		Inactive	<MOA Unknown> | Class: Iridoide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385466-01	363679755.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2OC=C(C(=O)O)[C@@H]3[C@H]2C(=C)[C@@H](O)C3)O1)/C=C/c1cc(OC)c(O)c(OC)c1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2OC=C(C(=O)O)[C@@H]3[C@H]2C(=C)[C@@H](O)C3)O1)/C=C/c1cc(OC)c(O)c(OC)c1
NCGC00169485-03	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2OC=C(C(=O)O)[C@@H]3[C@H]2[C@](O)(C)CC3)O1)/C=C/c1cc(O)c(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Vitex | Family: Verbenaceae | Species: agenus		1	NCGC00169485-03	363676829.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2OC=C(C(=O)O)[C@@H]3[C@H]2[C@](O)(C)CC3)O1)/C=C/c1cc(O)c(O)cc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2OC=C(C(=O)O)[C@@H]3[C@H]2[C@](O)(C)CC3)O1)/C=C/c1cc(O)c(O)cc1
NCGC00169258-03	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2OC=C(C(=O)O)[C@@H]3[C@H]2[C@](O)(C)CC3)O1)c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Vitex | Family: Verbenaceae | Species: agenus		1	NCGC00169258-03	363676795.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2OC=C(C(=O)O)[C@@H]3[C@H]2[C@](O)(C)CC3)O1)c1ccc(O)cc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2OC=C(C(=O)O)[C@@H]3[C@H]2[C@](O)(C)CC3)O1)c1ccc(O)cc1
NCGC00384993-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2OC=C(C(=O)OC)[C@@H]3[C@H]2C(CO)=CC3)O1)/C=C/c1cc(OC)c(O)c(OC)c1		Inactive	<MOA Unknown> | Class: Iridoide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384993-01	363679473.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2OC=C(C(=O)OC)[C@@H]3[C@H]2C(CO)=CC3)O1)/C=C/c1cc(OC)c(O)c(OC)c1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H]2OC=C(C(=O)OC)[C@@H]3[C@H]2C(CO)=CC3)O1)/C=C/c1cc(OC)c(O)c(OC)c1
NCGC00169346-02	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)C=C(C(=O)OC)C2)O1)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Cytisus | Family: Fabaceae | Species: tribracteolatus		1	NCGC00169346-02	363676803.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)C=C(C(=O)OC)C2)O1)/C=C/c1ccccc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)C=C(C(=O)OC)C2)O1)/C=C/c1ccccc1
NCGC00380749-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@]23[C@]4(COC(=O)c5ccccc5)[C@H]5O[C@@]2(C)C[C@](O)(O5)[C@@H]4C3)O1)c1ccccc1		Inactive	<MOA Unknown> | Class: Monoterpen | Genus: Paeonia | Family: Paeoniaceae | Species: lactiflora		1	NCGC00380749-01	363678757.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@]23[C@]4(COC(=O)c5ccccc5)[C@H]5O[C@@]2(C)C[C@](O)(O5)[C@@H]4C3)O1)c1ccccc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@]23[C@]4(COC(=O)c5ccccc5)[C@H]5O[C@@]2(C)C[C@](O)(O5)[C@@H]4C3)O1)c1ccccc1
NCGC00380228-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(C(C)C)cc(O)c(C)c2)O1)CC(=O)O		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380228-01	363678504.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(C(C)C)cc(O)c(C)c2)O1)CC(=O)O	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(C(C)C)cc(O)c(C)c2)O1)CC(=O)O
NCGC00380842-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(CCC(=O)O)cc(c(OC)c2)C2C(O)C(O)(C)C(=O)O2)O1)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC)c(C2C(O)C(O)(C)C(=O)O2)c1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380842-01	363678809.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(CCC(=O)O)cc(c(OC)c2)C2C(O)C(O)(C)C(=O)O2)O1)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC)c(C2C(O)C(O)(C)C(=O)O2)c1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(CCC(=O)O)cc(c(OC)c2)C2C(O)C(O)(C)C(=O)O2)O1)CCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(OC)c(C2C(O)C(O)(C)C(=O)O2)c1
NCGC00385097-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(CO)cc(O)cc2)O1)c1ccccc1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385097-01	363679531.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(CO)cc(O)cc2)O1)c1ccccc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(CO)cc(O)cc2)O1)c1ccccc1
NCGC00385104-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(CO)cccc2)O1)c1ccccc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385104-01	363679536.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(CO)cccc2)O1)c1ccccc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(CO)cccc2)O1)c1ccccc1
NCGC00384818-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(COC(=O)C3(O)C(O)CCC=C3)cccc2)O1)c1ccccc1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384818-01	363679374.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(COC(=O)C3(O)C(O)CCC=C3)cccc2)O1)c1ccccc1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2c(COC(=O)C3(O)C(O)CCC=C3)cccc2)O1)c1ccccc1
NCGC00169928-02	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc3OC[C@@H]4[C@@H](Oc5c4cc4OCOc4c5)c3cc2)O1)CC(=O)O		Inactive	<MOA Unknown> | Class: Flavon | Genus: Ononis | Family: Fabaceae | Species: spinosa		1	NCGC00169928-02	363676915.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc3OC[C@@H]4[C@@H](Oc5c4cc4OCOc4c5)c3cc2)O1)CC(=O)O	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc3OC[C@@H]4[C@@H](Oc5c4cc4OCOc4c5)c3cc2)O1)CC(=O)O
NCGC00385351-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2ccc(O)cc2)O1)/C=C/C1(O)C=CC(=O)C=C1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: Grevillea | Family: N/A | Species: robusta		1	NCGC00385351-01	363679695.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2ccc(O)cc2)O1)/C=C/C1(O)C=CC(=O)C=C1	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2ccc(O)cc2)O1)/C=C/C1(O)C=CC(=O)C=C1
NCGC00381438-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381438-01	363679144.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C(=C/C)/C	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C(=C/C)/C
NCGC00385709-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](OC(=O)/C(=C/C)/C)[C@@H](CO)O2)O1)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385709-01	363679889.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](OC(=O)/C(=C/C)/C)[C@@H](CO)O2)O1)/C(=C/C)/C	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](OC(=O)/C(=C/C)/C)[C@@H](CO)O2)O1)/C(=C/C)/C
NCGC00381148-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O2)[C@@H](O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381148-01	363678995.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O2)[C@@H](O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C(=C/C)/C	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O2)[C@@H](O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C(=C/C)/C
NCGC00381333-01	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](OC(=O)/C(=C/C)/C)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O3)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O2)O1)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: olgoglycoside | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381333-01	363679094.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](OC(=O)/C(=C/C)/C)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O3)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O2)O1)/C(=C/C)/C	O=C(OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](OC(=O)/C(=C/C)/C)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O3)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O2)O1)/C(=C/C)/C
NCGC00381334-01	O=C(OC[C@@H]1[C@@H](O)[C@H](OC(=O)/C(=C/C)/C)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O[C@@H]2O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O3)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O2)O1)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: oligoglycoside | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381334-01	363679095.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](OC(=O)/C(=C/C)/C)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O[C@@H]2O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O3)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O2)O1)/C(=C/C)/C	O=C(OC[C@@H]1[C@@H](O)[C@H](OC(=O)/C(=C/C)/C)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O[C@@H]2O[C@@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O3)[C@@H](O)[C@H](O)[C@@H](COC(=O)/C(=C/C)/C)O2)O1)/C(=C/C)/C
NCGC00380914-01	O=C(OC[C@@H]1[C@@H](O)[C@H](OC(=O)/C=C/c2cc(OC)c(O)cc2)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)(CO)O1)/C=C/c1cc(OC)c(O)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Cymbopogon | Family: Gramineae | Species: citratus		1	NCGC00380914-01	363678851.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](OC(=O)/C=C/c2cc(OC)c(O)cc2)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)(CO)O1)/C=C/c1cc(OC)c(O)cc1	O=C(OC[C@@H]1[C@@H](O)[C@H](OC(=O)/C=C/c2cc(OC)c(O)cc2)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)(CO)O1)/C=C/c1cc(OC)c(O)cc1
NCGC00385500-01	O=C(OC[C@@H]1[C@@H](O)[C@H](OC(=O)CC(C)C)[C@@](O[C@@H]2[C@H](OC(=O)CC(C)C)[C@@H](O)[C@H](O)[C@@H](CO)O2)(COC(=O)CC(C)C)O1)CC(C)C		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385500-01	363679776.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](OC(=O)CC(C)C)[C@@](O[C@@H]2[C@H](OC(=O)CC(C)C)[C@@H](O)[C@H](O)[C@@H](CO)O2)(COC(=O)CC(C)C)O1)CC(C)C	O=C(OC[C@@H]1[C@@H](O)[C@H](OC(=O)CC(C)C)[C@@](O[C@@H]2[C@H](OC(=O)CC(C)C)[C@@H](O)[C@H](O)[C@@H](CO)O2)(COC(=O)CC(C)C)O1)CC(C)C
NCGC00179867-02	O=C(OC[C@@H]1[C@@H](O)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@@H](O)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)O1)c1cc(O)c(O)c(O)c1		Inactive			1	NCGC00179867-02	405559098.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC[C@@H]1[C@@H](O)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@@H](O)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)O1)c1cc(O)c(O)c(O)c1	O=C(OC[C@@H]1[C@@H](O)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@@H](O)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)O1)c1cc(O)c(O)c(O)c1
NCGC00263622-03	O=C(OC[C@@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](N2C(=O)N=C(N)N=C2)O1)C		Inactive			1	2 ,3 ,5 -triacetyl-5-Azacytidine		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](N2C(=O)N=C(N)N=C2)O1)C	O=C(OC[C@@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](N2C(=O)N=C(N)N=C2)O1)C
NCGC00160615-03	O=C(OC[C@@H]1[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@@H](OC(=O)C)[C@@H](O[C@@]2(COC(=O)C)[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@@H](COC(=O)C)O2)O1)C		Inactive			1	Sucrose octaacetate	170465525.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OC[C@@H]1[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@@H](OC(=O)C)[C@@H](O[C@@]2(COC(=O)C)[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@@H](COC(=O)C)O2)O1)C	O=C(OC[C@@H]1[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@@H](OC(=O)C)[C@@H](O[C@@]2(COC(=O)C)[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@@H](COC(=O)C)O2)O1)C
NCGC00385146-01	O=C(OC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](OC(=O)CC(C)C)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)(COC(=O)CC(C)C)O1)CC(C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385146-01	363679559.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](OC(=O)CC(C)C)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)(COC(=O)CC(C)C)O1)CC(C)C	O=C(OC[C@@H]1[C@@H](OC(=O)CC(C)C)[C@H](OC(=O)CC(C)C)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)(COC(=O)CC(C)C)O1)CC(C)C
NCGC00186054-01	O=C(OC[C@@H]1[C@@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)O1)c1cc(OC(=O)c2cc(O)c(O)c(O)c2)c(O)c(O)c1		Inactive	Beta-secretase 1 Inhibitor		1	Tannic acid	124896727.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.1920374679	O=C(OC[C@@H]1[C@@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)O1)c1cc(OC(=O)c2cc(O)c(O)c(O)c2)c(O)c(O)c1	O=C(OC[C@@H]1[C@@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)[C@H](OC(=O)c2cc(OC(=O)c3cc(O)c(O)c(O)c3)c(O)c(O)c2)O1)c1cc(OC(=O)c2cc(O)c(O)c(O)c2)c(O)c(O)c1
NCGC00385160-01	O=C(OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)OC2)O1)c1ccccc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385160-01	363679571.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)OC2)O1)c1ccccc1	O=C(OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)OC2)O1)c1ccccc1
NCGC00384583-01	O=C(OC[C@@]1(C)C2[C@H](OC(=O)C)[C@H](O)[C@H]3[C@@H](C)C=4[C@](OC)(OC(=O)C=4)CC3[C@@]2(C)CCC1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384583-01	363679259.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@]1(C)C2[C@H](OC(=O)C)[C@H](O)[C@H]3[C@@H](C)C=4[C@](OC)(OC(=O)C=4)CC3[C@@]2(C)CCC1)C	O=C(OC[C@@]1(C)C2[C@H](OC(=O)C)[C@H](O)[C@H]3[C@@H](C)C=4[C@](OC)(OC(=O)C=4)CC3[C@@]2(C)CCC1)C
NCGC00180820-03	O=C(OC[C@@]1(C)C2[C@](C)(C3C4(C=C[C@](C)(C4)CC3)CC2)CCC1)CCC(=O)OC		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Fabiana | Family: N/A | Species: densa var.ramulosa		1	NCGC00180820-03	363677070.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@]1(C)C2[C@](C)(C3C4(C=C[C@](C)(C4)CC3)CC2)CCC1)CCC(=O)OC	O=C(OC[C@@]1(C)C2[C@](C)(C3C4(C=C[C@](C)(C4)CC3)CC2)CCC1)CCC(=O)OC
NCGC00384680-01	O=C(OC[C@@]1(C)[C@H]2[C@@H](C(=C)CCC=C(CO)C(=O)C2)C1)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Pulicaria | Family: Compositae | Species: odora		1	NCGC00384680-01	363679305.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@]1(C)[C@H]2[C@@H](C(=C)CCC=C(CO)C(=O)C2)C1)C	O=C(OC[C@@]1(C)[C@H]2[C@@H](C(=C)CCC=C(CO)C(=O)C2)C1)C
NCGC00169156-03	O=C(OC[C@@]12C(=O)C[C@@H](C)[C@@]3(C(=O)O[C@H](c4cocc4)C3)[C@H]1CC[C@H](OC(=O)C)[C@]12OC1)C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Teucrium | Family: N/A | Species: lusitanicum		1	NCGC00169156-03	363676784.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@]12C(=O)C[C@@H](C)[C@@]3(C(=O)O[C@H](c4cocc4)C3)[C@H]1CC[C@H](OC(=O)C)[C@]12OC1)C	O=C(OC[C@@]12C(=O)C[C@@H](C)[C@@]3(C(=O)O[C@H](c4cocc4)C3)[C@H]1CC[C@H](OC(=O)C)[C@]12OC1)C
NCGC00380853-01	O=C(OC[C@@]12C(=O)C[C@@H](C)[C@@]3([C@H](OC(=O)C)O[C@H](c4cocc4)C3)[C@H]1CCC[C@]12OC1)C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Teucrium | Family: Labiatae | Species: capitatum		1	NCGC00380853-01	363678815.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@]12C(=O)C[C@@H](C)[C@@]3([C@H](OC(=O)C)O[C@H](c4cocc4)C3)[C@H]1CCC[C@]12OC1)C	O=C(OC[C@@]12C(=O)C[C@@H](C)[C@@]3([C@H](OC(=O)C)O[C@H](c4cocc4)C3)[C@H]1CCC[C@]12OC1)C
NCGC00347625-02	O=C(OC[C@@]12[C@@H](OC(=O)C)C[C@@H](C)[C@](C)([C@H]3O[C@@H]4OC=C[C@@H]4C3)[C@H]1CCC[C@]12OC1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347625-02	363677644.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@]12[C@@H](OC(=O)C)C[C@@H](C)[C@](C)([C@H]3O[C@@H]4OC=C[C@@H]4C3)[C@H]1CCC[C@]12OC1)C	O=C(OC[C@@]12[C@@H](OC(=O)C)C[C@@H](C)[C@](C)([C@H]3O[C@@H]4OC=C[C@@H]4C3)[C@H]1CCC[C@]12OC1)C
NCGC00385597-01	O=C(OC[C@@]12[C@@H](OC(=O)C)[C@@H](O)[C@H]3[C@@](O)(C)[C@]41[C@H](O)[C@@H](C(=O)[C@H]2OC(=O)C)[C@@](C)(O4)COC(=O)c1c([C@@H](C)[C@H](C)C(=O)O3)nccc1)C		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385597-01	363679829.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@]12[C@@H](OC(=O)C)[C@@H](O)[C@H]3[C@@](O)(C)[C@]41[C@H](O)[C@@H](C(=O)[C@H]2OC(=O)C)[C@@](C)(O4)COC(=O)c1c([C@@H](C)[C@H](C)C(=O)O3)nccc1)C	O=C(OC[C@@]12[C@@H](OC(=O)C)[C@@H](O)[C@H]3[C@@](O)(C)[C@]41[C@H](O)[C@@H](C(=O)[C@H]2OC(=O)C)[C@@](C)(O4)COC(=O)c1c([C@@H](C)[C@H](C)C(=O)O3)nccc1)C
NCGC00385297-01	O=C(OC[C@@]12[C@@H](OC(=O)C)[C@@H](O)[C@H]3[C@@](O)(C)[C@]41[C@H](OC(=O)C)[C@@H](C(=O)[C@H]2OC(=O)C)[C@@](C)(O4)COC(=O)c1c([C@@H](C)[C@H](C)C(=O)O3)nccc1)C		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385297-01	363679656.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@]12[C@@H](OC(=O)C)[C@@H](O)[C@H]3[C@@](O)(C)[C@]41[C@H](OC(=O)C)[C@@H](C(=O)[C@H]2OC(=O)C)[C@@](C)(O4)COC(=O)c1c([C@@H](C)[C@H](C)C(=O)O3)nccc1)C	O=C(OC[C@@]12[C@@H](OC(=O)C)[C@@H](O)[C@H]3[C@@](O)(C)[C@]41[C@H](OC(=O)C)[C@@H](C(=O)[C@H]2OC(=O)C)[C@@](C)(O4)COC(=O)c1c([C@@H](C)[C@H](C)C(=O)O3)nccc1)C
NCGC00385298-01	O=C(OC[C@@]12[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H]3[C@@](O)(C)[C@]41[C@H](O)[C@@H](C(=O)[C@H]2OC(=O)C)[C@@](C)(O4)COC(=O)c1c([C@@H](C)[C@H](C)C(=O)O3)nccc1)C		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385298-01	363679657.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@]12[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H]3[C@@](O)(C)[C@]41[C@H](O)[C@@H](C(=O)[C@H]2OC(=O)C)[C@@](C)(O4)COC(=O)c1c([C@@H](C)[C@H](C)C(=O)O3)nccc1)C	O=C(OC[C@@]12[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H]3[C@@](O)(C)[C@]41[C@H](O)[C@@H](C(=O)[C@H]2OC(=O)C)[C@@](C)(O4)COC(=O)c1c([C@@H](C)[C@H](C)C(=O)O3)nccc1)C
NCGC00380549-01	O=C(OC[C@@]12[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H]3[C@@](O)(C)[C@]41[C@H](OC(=O)C)[C@@H](C(=O)[C@H]2OC(=O)C)[C@@](C)(O4)COC(=O)c1c([C@@H](C)[C@H](C)C(=O)O3)nccc1)C		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380549-01	363678644.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@]12[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H]3[C@@](O)(C)[C@]41[C@H](OC(=O)C)[C@@H](C(=O)[C@H]2OC(=O)C)[C@@](C)(O4)COC(=O)c1c([C@@H](C)[C@H](C)C(=O)O3)nccc1)C	O=C(OC[C@@]12[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H]3[C@@](O)(C)[C@]41[C@H](OC(=O)C)[C@@H](C(=O)[C@H]2OC(=O)C)[C@@](C)(O4)COC(=O)c1c([C@@H](C)[C@H](C)C(=O)O3)nccc1)C
NCGC00384623-01	O=C(OC[C@@]12[C@@H](OC(=O)c3cocc3)[C@@H](OC(=O)c3cocc3)C[C@@](O)(C)[C@]31[C@H](OC(=O)C)[C@H](C(C)(C)O3)C[C@@H]2OC(=O)c1cocc1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384623-01	363679279.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@]12[C@@H](OC(=O)c3cocc3)[C@@H](OC(=O)c3cocc3)C[C@@](O)(C)[C@]31[C@H](OC(=O)C)[C@H](C(C)(C)O3)C[C@@H]2OC(=O)c1cocc1)C	O=C(OC[C@@]12[C@@H](OC(=O)c3cocc3)[C@@H](OC(=O)c3cocc3)C[C@@](O)(C)[C@]31[C@H](OC(=O)C)[C@H](C(C)(C)O3)C[C@@H]2OC(=O)c1cocc1)C
NCGC00169326-03	O=C(OC[C@@]12[C@@]3(C)[C@H](OC(=O)C)[C@@H](O)[C@H]([C@@]43OC4)O[C@@H]1C=C(C)[C@@H](O)C2)C		Inactive	<MOA Unknown> | Class: trichothecene | Genus: ct Fusarium | Family: N/A | Species: N/A		1	NCGC00169326-03	363676801.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	-31.6020966319	O=C(OC[C@@]12[C@@]3(C)[C@H](OC(=O)C)[C@@H](O)[C@H]([C@@]43OC4)O[C@@H]1C=C(C)[C@@H](O)C2)C	O=C(OC[C@@]12[C@@]3(C)[C@H](OC(=O)C)[C@@H](O)[C@H]([C@@]43OC4)O[C@@H]1C=C(C)[C@@H](O)C2)C
NCGC00180527-03	O=C(OC[C@@]12[C@@]3(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@]4(C)O[C@H]1O[C@](O)([C@@H]2C3)C4)c1ccccc1		Inactive	neuromuscular blocker		1	NCGC00180527-03	363677032.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@]12[C@@]3(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@]4(C)O[C@H]1O[C@](O)([C@@H]2C3)C4)c1ccccc1	O=C(OC[C@@]12[C@@]3(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@]4(C)O[C@H]1O[C@](O)([C@@H]2C3)C4)c1ccccc1
NCGC00384925-01	O=C(OC[C@@]12[C@H](O)C[C@@H](C)[C@@]3(C(=O)O[C@H](c4cocc4)C3)[C@H]1C[C@H](O)C[C@]12OC1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384925-01	363679443.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@@]12[C@H](O)C[C@@H](C)[C@@]3(C(=O)O[C@H](c4cocc4)C3)[C@H]1C[C@H](O)C[C@]12OC1)C	O=C(OC[C@@]12[C@H](O)C[C@@H](C)[C@@]3(C(=O)O[C@H](c4cocc4)C3)[C@H]1C[C@H](O)C[C@]12OC1)C
NCGC00181140-02	O=C(OC[C@H](OC)C=1C(=O)C(N2CC2)=C(C)C(=O)C=1N1CC1)N		Inactive	cell growth Inhibitor		1	Carboquone	124893654.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC[C@H](OC)C=1C(=O)C(N2CC2)=C(C)C(=O)C=1N1CC1)N	O=C(OC[C@H](OC)C=1C(=O)C(N2CC2)=C(C)C(=O)C=1N1CC1)N
NCGC00183020-01	O=C(OC[C@H](OC)COC(=O)N1CCC(OC(=O)NCCCCCCCCCCCCCCCCCC)CC1)N(C(=O)c1c(OC)cccc1)Cc1[n+](CC)cccc1		Inactive	Platelet activating factor receptor Antagonist		1	Minopafant	144206826.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(OC[C@H](OC)COC(=O)N1CCC(OC(=O)NCCCCCCCCCCCCCCCCCC)CC1)N(C(=O)c1c(OC)cccc1)Cc1[n+](CC)cccc1.[Cl-]	O=C(OC[C@H](OC)COC(=O)N1CCC(OC(=O)NCCCCCCCCCCCCCCCCCC)CC1)N(C(=O)c1c(OC)cccc1)Cc1[n+](CC)cccc1.[Cl-]
NCGC00182709-03	O=C(OC[C@H]1OC(C)(C)OC1)CCc1ccc(OC[C@@H](O)CNCCNC(=O)N2CCOCC2)cc1		Inactive	Beta-1 adrenergic receptor Antagonist		1	Landiolol hydrochloride	170465910.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC[C@H]1OC(C)(C)OC1)CCc1ccc(OC[C@@H](O)CNCCNC(=O)N2CCOCC2)cc1.Cl	O=C(OC[C@H]1OC(C)(C)OC1)CCc1ccc(OC[C@@H](O)CNCCNC(=O)N2CCOCC2)cc1.Cl
NCGC00174736-02	O=C(OC[C@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](N2C(=O)NC(=O)C=C2)O1)C		Inactive	Pyrimidine Antagonist		1	Uridine triacetate	174006168.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OC[C@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](N2C(=O)NC(=O)C=C2)O1)C	O=C(OC[C@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](N2C(=O)NC(=O)C=C2)O1)C
NCGC00163468-05&NCGC00163468-12	O=C(OC[C@H]1[C@]2(OC)N(C=3C(=O)C(C)=C(N)C(=O)C1=3)C[C@@H]1N[C@H]21)N		Inactive	DNA Alkylating Agent		2	Mitomycin C	170464814.0&384568241.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		O=C(OC[C@H]1[C@]2(OC)N(C=3C(=O)C(C)=C(N)C(=O)C1=3)C[C@@H]1N[C@H]21)N	O=C(OC[C@H]1[C@]2(OC)N(C=3C(=O)C(C)=C(N)C(=O)C1=3)C[C@@H]1N[C@H]21)N
NCGC00378751-01	O=C(OC[C@]1(N=[N+]=[N-])[C@@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](N2C(=O)N=C(N)C=C2)O1)C(C)C		Inactive			1	Balapiravir	377020534.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OC[C@]1(N=[N+]=[N-])[C@@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](N2C(=O)N=C(N)C=C2)O1)C(C)C	O=C(OC[C@]1(N=[N+]=[N-])[C@@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](N2C(=O)N=C(N)C=C2)O1)C(C)C
NCGC00384724-01	O=C(OC[C@]1(O)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2c(OC)cc(C(=O)O)cc2)OC1)c1cc(OC)c(O)cc1		Inactive	<MOA Unknown> | Class: Tannin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384724-01	363679327.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@]1(O)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2c(OC)cc(C(=O)O)cc2)OC1)c1cc(OC)c(O)cc1	O=C(OC[C@]1(O)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2c(OC)cc(C(=O)O)cc2)OC1)c1cc(OC)c(O)cc1
NCGC00385181-01	O=C(OC[C@]1(O)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2ccc(O)cc2)OC1)c1cc(OC)c(O)c(OC)c1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385181-01	363679581.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@]1(O)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2ccc(O)cc2)OC1)c1cc(OC)c(O)c(OC)c1	O=C(OC[C@]1(O)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2ccc(O)cc2)OC1)c1cc(OC)c(O)c(OC)c1
NCGC00347878-02	O=C(OC[C@]1(O)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2ccc(O)cc2)OC1)c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Myrsine | Family: Myrsinaceae | Species: capitellata		1	NCGC00347878-02	363677715.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@]1(O)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2ccc(O)cc2)OC1)c1ccc(O)cc1	O=C(OC[C@]1(O)[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]2Oc2ccc(O)cc2)OC1)c1ccc(O)cc1
NCGC00384613-01	O=C(OC[C@]1(O)[C@H]2C[C@]3([C@H]([C@@]4(C)[C@@H]([C@@](C(=O)O)(C)CCC4)CC3)CC2)C1)CC(C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384613-01	363679271.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@]1(O)[C@H]2C[C@]3([C@H]([C@@]4(C)[C@@H]([C@@](C(=O)O)(C)CCC4)CC3)CC2)C1)CC(C)C	O=C(OC[C@]1(O)[C@H]2C[C@]3([C@H]([C@@]4(C)[C@@H]([C@@](C(=O)O)(C)CCC4)CC3)CC2)C1)CC(C)C
NCGC00385286-01	O=C(OC[C@]1(O)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)[C@H]2C=C1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385286-01	363679645.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@]1(O)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)[C@H]2C=C1)/C=C/c1ccc(O)cc1	O=C(OC[C@]1(O)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)[C@H]2C=C1)/C=C/c1ccc(O)cc1
NCGC00169374-02	O=C(OC[C@]12C(=O)O[C@]3(C)[C@@]1(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C[C@H]2[C@H](O)C3)c1ccccc1		Inactive	<MOA Unknown> | Class: Monoterpen | Genus: Paeonia | Family: Paeoniaceae | Species: lactiflora		1	Albiflorin	363676809.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@]12C(=O)O[C@]3(C)[C@@]1(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C[C@H]2[C@H](O)C3)c1ccccc1	O=C(OC[C@]12C(=O)O[C@]3(C)[C@@]1(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C[C@H]2[C@H](O)C3)c1ccccc1
NCGC00169336-02	O=C(OC[C@]12O[C@H]1[C@@H](O)[C@H]1[C@@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Scutellaria | Family: Labiatae | Species: sieberi		1	NCGC00169336-02	363676802.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@]12O[C@H]1[C@@H](O)[C@H]1[C@@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1)/C=C/c1ccc(O)cc1	O=C(OC[C@]12O[C@H]1[C@@H](O)[C@H]1[C@@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1)/C=C/c1ccc(O)cc1
NCGC00168968-03	O=C(OC[C@]12O[C@H]1[C@@H](O)[C@H]1[C@@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Scutellaria | Family: Labiatae | Species: sieberi		1	NCGC00168968-03	363676731.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@]12O[C@H]1[C@@H](O)[C@H]1[C@@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1)/C=C/c1ccccc1	O=C(OC[C@]12O[C@H]1[C@@H](O)[C@H]1[C@@H]2[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1)/C=C/c1ccccc1
NCGC00384493-01	O=C(OC[C@]12[C@@H](O)[C@H](OC(=O)C)C(C)(C)C[C@H]1C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](CO)(C)[C@@H](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](C(=O)O)O5)CC4)CC3)CC=1)C[C@H]2O)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384493-01	363679210.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@]12[C@@H](O)[C@H](OC(=O)C)C(C)(C)C[C@H]1C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](CO)(C)[C@@H](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](C(=O)O)O5)CC4)CC3)CC=1)C[C@H]2O)C	O=C(OC[C@]12[C@@H](O)[C@H](OC(=O)C)C(C)(C)C[C@H]1C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](CO)(C)[C@@H](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](C(=O)O)O5)CC4)CC3)CC=1)C[C@H]2O)C
NCGC00385148-01	O=C(OC[C@]12[C@H](OC(=O)C)[C@H](OC(=O)c3ccccc3)[C@@H]3[C@@H](OC(=O)C)[C@@]1([C@H](C)C[C@H](OC(=O)C)[C@@H]2OC(=O)c1ccccc1)OC3(C)C)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Euonymus | Family: Celastraceae | Species: latifolius		1	NCGC00385148-01	363679561.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@]12[C@H](OC(=O)C)[C@H](OC(=O)c3ccccc3)[C@@H]3[C@@H](OC(=O)C)[C@@]1([C@H](C)C[C@H](OC(=O)C)[C@@H]2OC(=O)c1ccccc1)OC3(C)C)C	O=C(OC[C@]12[C@H](OC(=O)C)[C@H](OC(=O)c3ccccc3)[C@@H]3[C@@H](OC(=O)C)[C@@]1([C@H](C)C[C@H](OC(=O)C)[C@@H]2OC(=O)c1ccccc1)OC3(C)C)C
NCGC00385150-01	O=C(OC[C@]12[C@H](OC(=O)C)[C@H](OC(=O)c3ccccc3)[C@@H]3[C@@H](OC(=O)C)[C@@]1([C@H](C)C[C@H](OC(=O)c1ccccc1)[C@@H]2OC(=O)c1ccccc1)OC3(C)C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385150-01	363679563.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@]12[C@H](OC(=O)C)[C@H](OC(=O)c3ccccc3)[C@@H]3[C@@H](OC(=O)C)[C@@]1([C@H](C)C[C@H](OC(=O)c1ccccc1)[C@@H]2OC(=O)c1ccccc1)OC3(C)C)C	O=C(OC[C@]12[C@H](OC(=O)C)[C@H](OC(=O)c3ccccc3)[C@@H]3[C@@H](OC(=O)C)[C@@]1([C@H](C)C[C@H](OC(=O)c1ccccc1)[C@@H]2OC(=O)c1ccccc1)OC3(C)C)C
NCGC00485258-01	O=C(OC[C@]12[C@H]3[C@H](OC)[C@]4(O)[C@]5(O)[C@H]6[C@@H](OC)[C@@H]([C@@H](OC)C5)C[C@H]6[C@@]3([C@@H](OC)CC1)[C@@H]4N(CC)C2)c1c(N2C(=O)[C@@H](C)CC2=O)cccc1		Inactive	Neuronal acetylcholine receptor subunit alpha-7 Antagonist		1	Methyllycaconitine citrate salt	363681269.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC[C@]12[C@H]3[C@H](OC)[C@]4(O)[C@]5(O)[C@H]6[C@@H](OC)[C@@H]([C@@H](OC)C5)C[C@H]6[C@@]3([C@@H](OC)CC1)[C@@H]4N(CC)C2)c1c(N2C(=O)[C@@H](C)CC2=O)cccc1	O=C(OC[C@]12[C@H]3[C@H](OC)[C@]4(O)[C@]5(O)[C@H]6[C@@H](OC)[C@@H]([C@@H](OC)C5)C[C@H]6[C@@]3([C@@H](OC)CC1)[C@@H]4N(CC)C2)c1c(N2C(=O)[C@@H](C)CC2=O)cccc1
NCGC00380409-01	O=C(OC\1C(C)OC(=O)CCC(OC(=O)C)C(O)/C=C/1)/C=C/C		Inactive	<MOA Unknown> | Class: macrolide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380409-01	363678572.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC\1C(C)OC(=O)CCC(OC(=O)C)C(O)/C=C/1)/C=C/C	O=C(OC\1C(C)OC(=O)CCC(OC(=O)C)C(O)/C=C/1)/C=C/C
NCGC00385329-01	O=C(OC\1C(O)(C)/C=C/C(=O)/C(/CO)=C\CC(CCC=C(C)C)(C)/C=C/1)C=C(C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385329-01	363679681.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OC\1C(O)(C)/C=C/C(=O)/C(/CO)=C\CC(CCC=C(C)C)(C)/C=C/1)C=C(C)C	O=C(OC\1C(O)(C)/C=C/C(=O)/C(/CO)=C\CC(CCC=C(C)C)(C)/C=C/1)C=C(C)C
NCGC00381076-01	O=C(OCc1c(NC(=O)CCC(=O)O)cccc1)C(O)(C(O)C)CC		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Justicia | Family: Acanthaceae | Species: schimperiana		1	NCGC00381076-01	363678958.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1c(NC(=O)CCC(=O)O)cccc1)C(O)(C(O)C)CC	O=C(OCc1c(NC(=O)CCC(=O)O)cccc1)C(O)(C(O)C)CC
NCGC00347677-02	O=C(OCc1c(NC(=O)CCC(N)C(=O)O)cccc1)C(O)([C@@H](O)C)[C@@H](O)C		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Justicia | Family: Acanthaceae | Species: schimperiana		1	NCGC00347677-02	363677663.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1c(NC(=O)CCC(N)C(=O)O)cccc1)C(O)([C@@H](O)C)[C@@H](O)C	O=C(OCc1c(NC(=O)CCC(N)C(=O)O)cccc1)C(O)([C@@H](O)C)[C@@H](O)C
NCGC00381016-01	O=C(OCc1c(OC2C(OC(=O)C3C=CCC3)C(O)C(O)C(COC(=O)C3C=CCC3)O2)ccc(O)c1)C1(O)C(OC(=O)C2C=CCC2)C(=O)CCC1O		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Flacourtia | Family: Flacourtiaceae | Species: indica		1	NCGC00381016-01	363678925.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1c(OC2C(OC(=O)C3C=CCC3)C(O)C(O)C(COC(=O)C3C=CCC3)O2)ccc(O)c1)C1(O)C(OC(=O)C2C=CCC2)C(=O)CCC1O	O=C(OCc1c(OC2C(OC(=O)C3C=CCC3)C(O)C(O)C(COC(=O)C3C=CCC3)O2)ccc(O)c1)C1(O)C(OC(=O)C2C=CCC2)C(=O)CCC1O
NCGC00179726-03	O=C(OCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(O)ccc1)C1(O)C(=O)C=CC2C1C1C(=O)C(O)(C(=O)OCc3c(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(O)ccc3)C2C=C1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Trimeria | Family: Flacourtiaceae | Species: grandiflora		1	NCGC00179726-03	363676959.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(O)ccc1)C1(O)C(=O)C=CC2C1C1C(=O)C(O)(C(=O)OCc3c(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(O)ccc3)C2C=C1	O=C(OCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(O)ccc1)C1(O)C(=O)C=CC2C1C1C(=O)C(O)(C(=O)OCc3c(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(O)ccc3)C2C=C1
NCGC00380503-01	O=C(OCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1)/C=C/c1cc(O)c(O)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Populus | Family: Salicaceae | Species: nigra		1	NCGC00380503-01	363678615.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1)/C=C/c1cc(O)c(O)cc1	O=C(OCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1)/C=C/c1cc(O)c(O)cc1
NCGC00380452-01	O=C(OCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1)C1(O)C(=O)CCC=C1		Inactive	NF-kappa B signaling pathway Inhibitor		1	NCGC00380452-01	363678591.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1)C1(O)C(=O)CCC=C1	O=C(OCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1)C1(O)C(=O)CCC=C1
NCGC00381006-01	O=C(OCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1)C1(O)C(O)CCC=C1		Inactive	<MOA Unknown> | Class: presalycinate | Genus: Salix | Family: Salicaceae | Species: appendiculata		1	NCGC00381006-01	363678920.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1)C1(O)C(O)CCC=C1	O=C(OCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1)C1(O)C(O)CCC=C1
NCGC00169372-02	O=C(OCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1)c1c(OC)c(OC2C(O)C(O)C(O)C(CO)O2)ccc1O		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Solidago | Family: Asteraceae | Species: gigantea		1	NCGC00169372-02	363676808.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1)c1c(OC)c(OC2C(O)C(O)C(O)C(CO)O2)ccc1O	O=C(OCc1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cccc1)c1c(OC)c(OC2C(O)C(O)C(O)C(CO)O2)ccc1O
NCGC00262957-01	O=C(OCc1cc(OC(=O)[C@H]2C(C)(C)S[C@@H]3[C@H](NC(=O)Cc4ccccc4)C(=O)N23)ccc1)C(C)C		Inactive			1	Tobicillin	170466044.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCc1cc(OC(=O)[C@H]2C(C)(C)S[C@@H]3[C@H](NC(=O)Cc4ccccc4)C(=O)N23)ccc1)C(C)C	O=C(OCc1cc(OC(=O)[C@H]2C(C)(C)S[C@@H]3[C@H](NC(=O)Cc4ccccc4)C(=O)N23)ccc1)C(C)C
NCGC00385593-01	O=C(OCc1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)C(O)C(O)(CC)C		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385593-01	363679826.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)C(O)C(O)(CC)C	O=C(OCc1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)C(O)C(O)(CC)C
NCGC00094561-06	O=C(OCc1cc(Oc2ccccc2)ccc1)C1C(C)(C)C1/C=C(\C)/C		Inactive			1	Phenothrin	170465585.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCc1cc(Oc2ccccc2)ccc1)C1C(C)(C)C1/C=C(\C)/C	O=C(OCc1cc(Oc2ccccc2)ccc1)C1C(C)(C)C1/C=C(\C)/C
NCGC00346743-03	O=C(OCc1cc2c(cc(CN(CC)CC)cc2)cc1)Nc1ccc(C(=O)NO)cc1		Inactive	HDAC Inhibitor		1	Givinostat hydrochloride	384568939.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCc1cc2c(cc(CN(CC)CC)cc2)cc1)Nc1ccc(C(=O)NO)cc1	O=C(OCc1cc2c(cc(CN(CC)CC)cc2)cc1)Nc1ccc(C(=O)NO)cc1
NCGC00485261-01	O=C(OCc1ccc(CNCCCCN(O)C(=O)/C=C/C(=O)OC)cc1)Nc1c2c(ccc1)cccc2		Inactive	Lysine-specific demethylase 4E Inhibitor		1	Methylstat	363681270.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	18.1388125399	O=C(OCc1ccc(CNCCCCN(O)C(=O)/C=C/C(=O)OC)cc1)Nc1c2c(ccc1)cccc2	O=C(OCc1ccc(CNCCCCN(O)C(=O)/C=C/C(=O)OC)cc1)Nc1c2c(ccc1)cccc2
NCGC00380919-01	O=C(OCc1ccc(OC2C(O)C(O)C(O)C(CO)O2)cc1)C(OC1C(O)C(O)C(O)C(CO)O1)C(OC(=O)/C=C/c1cc(OC)c(O)cc1)(C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380919-01	363678855.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1ccc(OC2C(O)C(O)C(O)C(CO)O2)cc1)C(OC1C(O)C(O)C(O)C(CO)O1)C(OC(=O)/C=C/c1cc(OC)c(O)cc1)(C)C	O=C(OCc1ccc(OC2C(O)C(O)C(O)C(CO)O2)cc1)C(OC1C(O)C(O)C(O)C(CO)O1)C(OC(=O)/C=C/c1cc(OC)c(O)cc1)(C)C
NCGC00381128-01	O=C(OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)C(O)C(O)(C)C		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Ecballium | Family: N/A | Species: elaterium		1	NCGC00381128-01	363678983.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)C(O)C(O)(C)C	O=C(OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)C(O)C(O)(C)C
NCGC00380542-01	O=C(OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)C(O)C(O)(CC)C		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Ecballium | Family: N/A | Species: elaterium		1	NCGC00380542-01	363678641.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)C(O)C(O)(CC)C	O=C(OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)C(O)C(O)(CC)C
NCGC00380579-01	O=C(OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)C(OC(=O)/C=C\c1ccc(O)cc1)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)(C)C		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Ecballium | Family: N/A | Species: elaterium		1	NCGC00380579-01	363678660.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)C(OC(=O)/C=C\c1ccc(O)cc1)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)(C)C	O=C(OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)C(OC(=O)/C=C\c1ccc(O)cc1)C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)(C)C
NCGC00380170-01	O=C(OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)CC(O)(CC(=O)O)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380170-01	363678485.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)CC(O)(CC(=O)O)C	O=C(OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)CC(O)(CC(=O)O)C
NCGC00380171-01	O=C(OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)CC(O)(CC(=O)OC)C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380171-01	363678486.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)CC(O)(CC(=O)OC)C	O=C(OCc1ccc(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc1)CC(O)(CC(=O)OC)C
NCGC00166124-03	O=C(OCc1ccccc1)C=Cc1ccccc1		Inactive			1	Benzyl cinnamate	170465584.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCc1ccccc1)C=Cc1ccccc1	O=C(OCc1ccccc1)C=Cc1ccccc1
NCGC00485154-01	O=C(OCc1ccccc1)NC(C(=O)NC(C(=O)NC(C(=O)Nc1cc2c(cc1)cccc2)CCC(=O)O)CC(C)C)CC(C)C		Inactive			1	Z-Leu-Leu-Glu Î²-naphthylamide	363681246.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1ccccc1)NC(C(=O)NC(C(=O)NC(C(=O)Nc1cc2c(cc1)cccc2)CCC(=O)O)CC(C)C)CC(C)C	O=C(OCc1ccccc1)NC(C(=O)NC(C(=O)NC(C(=O)Nc1cc2c(cc1)cccc2)CCC(=O)O)CC(C)C)CC(C)C
NCGC00386602-01	O=C(OCc1ccccc1)NCc1c(-c2c(C(=O)NCCc3ncccc3)cccc2)cccc1		Inactive	Voltage-gated potassium channel subunit Kv1.5 Blocker		1	S 9947	363680352.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1ccccc1)NCc1c(-c2c(C(=O)NCCc3ncccc3)cccc2)cccc1	O=C(OCc1ccccc1)NCc1c(-c2c(C(=O)NCCc3ncccc3)cccc2)cccc1
NCGC00345806-02	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)C=O)CC(C)C)Cc1ccccc1	5.0	Active	Cathepsin S Inhibitor	0.0	1	Cathepsin S Inhibitor	384568752.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.1	121.9980153899	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)C=O)CC(C)C)Cc1ccccc1	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)C=O)CC(C)C)Cc1ccccc1
NCGC00485335-01	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)Nc1cc2OC(=O)C=C(C)c2cc1)CCC(=O)O)CC(C)C)CC(C)C		Inactive			1	Z-Leu-Leu-Glu-7-amido-4-methylcoumarin	363681290.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)Nc1cc2OC(=O)C=C(C)c2cc1)CCC(=O)O)CC(C)C)CC(C)C	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)Nc1cc2OC(=O)C=C(C)c2cc1)CCC(=O)O)CC(C)C)CC(C)C
NCGC00161679-02&NCGC00161679-13	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C=O)CC(C)C)CC(C)C)CC(C)C	6.4000001	Inactive	Proteasome Inhibitor	0.0	2	MG-132	26755342.0&434147013.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	5.0&4.0	-68.764867708&0.0	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C=O)CC(C)C)CC(C)C)CC(C)C	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C=O)CC(C)C)CC(C)C)CC(C)C
NCGC00345815-02	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C=O)CCC)CC(C)C)CC(C)C		Inactive	Proteasome Inhibitor		1	MG-115	384568758.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C=O)CCC)CC(C)C)CC(C)C	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C=O)CCC)CC(C)C)CC(C)C
NCGC00163432-03&NCGC00163432-05	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C=O)CCCC)CC(C)C	6.2249999	Active	Proteasome Inhibitor	0.5500002000000004	2	Calpeptin	384568239.0&406861847.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	1.1&1.3	91.612702075&110.3452484768	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C=O)CCCC)CC(C)C	O=C(OCc1ccccc1)N[C@H](C(=O)N[C@H](C=O)CCCC)CC(C)C
NCGC00164155-02	O=C(OCc1ccccc1)c1ccc(O)cc1		Inactive	Estrogen receptor alpha Agonist		1	Benzylparaben	170465711.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCc1ccccc1)c1ccc(O)cc1	O=C(OCc1ccccc1)c1ccc(O)cc1
NCGC00094981-07	O=C(OCc1ccccc1)c1ccccc1		Inactive			1	Benzyl benzoate	170465382.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCc1ccccc1)c1ccccc1	O=C(OCc1ccccc1)c1ccccc1
NCGC00166105-04	O=C(OCc1ccccc1)c1cnccc1		Inactive			1	BENZYL NICOTINATE	225144269.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	18.22158408&0.0	O=C(OCc1ccccc1)c1cnccc1	O=C(OCc1ccccc1)c1cnccc1
NCGC00165833-10&NCGC00165833-11	O=C(OCc1cnccc1)NCc1ccc(C(=O)Nc2c(N)cccc2)cc1		Inactive	HDAC Inhibitor		2	Entinostat	384568288.0&434147031.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCc1cnccc1)NCc1ccc(C(=O)Nc2c(N)cccc2)cc1	O=C(OCc1cnccc1)NCc1ccc(C(=O)Nc2c(N)cccc2)cc1
NCGC00074022-02	O=C(OCc1nc(COC(=O)NC)ccc1)NC		Inactive	Bradykinin B2 receptor Antagonist		1	Pyricarbate	144204540.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(OCc1nc(COC(=O)NC)ccc1)NC	O=C(OCc1nc(COC(=O)NC)ccc1)NC
NCGC00249924-01	O=C(OCc1ncccc1)C(C)c1ccc(CC(C)C)cc1		Inactive			1	Ibuprofen piconol	170465895.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(OCc1ncccc1)C(C)c1ccc(CC(C)C)cc1	O=C(OCc1ncccc1)C(C)c1ccc(CC(C)C)cc1
NCGC00386235-04&NCGC00386235-06	O=C(OCc1scnc1)N[C@H](CC[C@@H](NC(=O)[C@@H](NC(=O)N(Cc1nc(C(C)C)sc1)C)CCN1CCOCC1)Cc1ccccc1)Cc1ccccc1		Inactive	Cytochrome P450 3A Inhibitor		2	Cobicistat	405558682.0&434146931.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	13.174870824&32.741912288	O=C(OCc1scnc1)N[C@H](CC[C@@H](NC(=O)[C@@H](NC(=O)N(Cc1nc(C(C)C)sc1)C)CCN1CCOCC1)Cc1ccccc1)Cc1ccccc1	O=C(OCc1scnc1)N[C@H](CC[C@@H](NC(=O)[C@@H](NC(=O)N(Cc1nc(C(C)C)sc1)C)CCN1CCOCC1)Cc1ccccc1)Cc1ccccc1
NCGC00159462-04&NCGC00159462-20	O=C(OCc1scnc1)N[C@H]([C@@H](O)C[C@@H](NC(=O)[C@@H](NC(=O)N(Cc1nc(C(C)C)sc1)C)C(C)C)Cc1ccccc1)Cc1ccccc1		Inactive	HIV Protease Inhibitors		2	Ritonavir	170464891.0&434147007.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0&4.0	0.0&0.0&0.0	O=C(OCc1scnc1)N[C@H]([C@@H](O)C[C@@H](NC(=O)[C@@H](NC(=O)N(Cc1nc(C(C)C)sc1)C)C(C)C)Cc1ccccc1)Cc1ccccc1	O=C(OCc1scnc1)N[C@H]([C@@H](O)C[C@@H](NC(=O)[C@@H](NC(=O)N(Cc1nc(C(C)C)sc1)C)C(C)C)Cc1ccccc1)Cc1ccccc1
NCGC00162413-14	O=C(O[C@@H]/1[C@@H](OC)/C=C\C=C(\C)/C(=O)NC=2C(=O)C(=C(OC)C(=O)C=2)C[C@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C\1/C)N		Inactive	Heat Shock Protein 90 (hsp90) Inhibitor		1	Geldanamycin	384568226.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]/1[C@@H](OC)/C=C\C=C(\C)/C(=O)NC=2C(=O)C(=C(OC)C(=O)C=2)C[C@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C\1/C)N	O=C(O[C@@H]/1[C@@H](OC)/C=C\C=C(\C)/C(=O)NC=2C(=O)C(=C(OC)C(=O)C=2)C[C@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C\1/C)N
NCGC00346438-02&NCGC00346438-03	O=C(O[C@@H]/1[C@@H](OC)/C=C\C=C(\C)/C(=O)Nc2c(O)c(c(NCC=C)c(O)c2)C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C\1/C)N		Inactive	Heat shock protein HSP90 Inhibitor		2	Retaspimycin Hydrochloride&Retaspimycin (Hydrochloride)	384568777.0&405558694.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	21.8190169999&7.623393312	O=C(O[C@@H]/1[C@@H](OC)/C=C\C=C(\C)/C(=O)Nc2c(O)c(c(NCC=C)c(O)c2)C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C\1/C)N	O=C(O[C@@H]/1[C@@H](OC)/C=C\C=C(\C)/C(=O)Nc2c(O)c(c(NCC=C)c(O)c2)C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C\1/C)N
NCGC00381047-01	O=C(O[C@@H]/1[C@@H](OC)[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\CO)/CC/C=C\1/C=O)C(=C)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Siegesbeckia | Family: Compositae | Species: orientalis		1	NCGC00381047-01	363678943.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]/1[C@@H](OC)[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\CO)/CC/C=C\1/C=O)C(=C)C	O=C(O[C@@H]/1[C@@H](OC)[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\CO)/CC/C=C\1/C=O)C(=C)C
NCGC00385543-01	O=C(O[C@@H]1C(=C)C2CC31C([C@@]1(C)C([C@@](C(=O)O)(C)CCC1)CC3)CC2)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Aspilia | Family: N/A | Species: sp.		1	NCGC00385543-01	363679798.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1C(=C)C2CC31C([C@@]1(C)C([C@@](C(=O)O)(C)CCC1)CC3)CC2)/C(=C\C)/C	O=C(O[C@@H]1C(=C)C2CC31C([C@@]1(C)C([C@@](C(=O)O)(C)CCC1)CC3)CC2)/C(=C\C)/C
NCGC00347704-02	O=C(O[C@@H]1C(C)(C)[C@@H]2[C@@](C)([C@@H](OC(=O)C)C1)[C@H]1[C@@]3(O[C@@H]3C3=C(C)C(=O)O[C@@H]3C1)CC2)C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Suregada | Family: Euphorbiaceae | Species: Zanzibarica		1	NCGC00347704-02	363677668.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1C(C)(C)[C@@H]2[C@@](C)([C@@H](OC(=O)C)C1)[C@H]1[C@@]3(O[C@@H]3C3=C(C)C(=O)O[C@@H]3C1)CC2)C	O=C(O[C@@H]1C(C)(C)[C@@H]2[C@@](C)([C@@H](OC(=O)C)C1)[C@H]1[C@@]3(O[C@@H]3C3=C(C)C(=O)O[C@@H]3C1)CC2)C
NCGC00169584-03	O=C(O[C@@H]1C(C)(C)[C@@H]2[C@](C=O)([C@H]3[C@@](C)([C@@]4(C(=O)OC)[C@](C)(C(=O)C(C)C4=O)C(C)=C3)CC2)CC1)C		Inactive	<MOA Unknown> | Class: sesterterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169584-03	363676843.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1C(C)(C)[C@@H]2[C@](C=O)([C@H]3[C@@](C)([C@@]4(C(=O)OC)[C@](C)(C(=O)C(C)C4=O)C(C)=C3)CC2)CC1)C	O=C(O[C@@H]1C(C)(C)[C@@H]2[C@](C=O)([C@H]3[C@@](C)([C@@]4(C(=O)OC)[C@](C)(C(=O)C(C)C4=O)C(C)=C3)CC2)CC1)C
NCGC00179431-03	O=C(O[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3C(=O)C=C4[C@](C)([C@]3(C)CC2)CC[C@]2(C)[C@H]4C[C@](C(=O)O)(C)CC2)CC1)CCC(=O)O		Inactive	gap junction assembly Inhibitor		1	Carbenoxolone sodium	170465951.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3C(=O)C=C4[C@](C)([C@]3(C)CC2)CC[C@]2(C)[C@H]4C[C@](C(=O)[O-])(C)CC2)CC1)CCC(=O)[O-].[Na+].[Na+]	O=C(O[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3C(=O)C=C4[C@](C)([C@]3(C)CC2)CC[C@]2(C)[C@H]4C[C@](C(=O)[O-])(C)CC2)CC1)CCC(=O)[O-].[Na+].[Na+]
NCGC00181756-01	O=C(O[C@@H]1C(C)(C)[C@H]2[C@@]3([C@]4([C@H]([C@@]5(C)[C@@](C)([C@@H]([C@@H](CC/C=C(\C)/C)C)CC5)CC4)CC2)C3)CC1)/C=C/c1cc(OC)c(O)cc1		Inactive	lipid oxidation Inhibitor		1	gamma-Oryzanol	144206489.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1C(C)(C)[C@H]2[C@@]3([C@]4([C@H]([C@@]5(C)[C@@](C)([C@@H]([C@@H](CC/C=C(\C)/C)C)CC5)CC4)CC2)C3)CC1)/C=C/c1cc(OC)c(O)cc1	O=C(O[C@@H]1C(C)(C)[C@H]2[C@@]3([C@]4([C@H]([C@@]5(C)[C@@](C)([C@@H]([C@@H](CC/C=C(\C)/C)C)CC5)CC4)CC2)C3)CC1)/C=C/c1cc(OC)c(O)cc1
NCGC00522039-01	O=C(O[C@@H]1C(C)=C(C/C=C\C=C)C(=O)C1)[C@H]1[C@H](C=C(C)C)C1(C)C		Inactive	Trypanosoma brucei rhodesiense Inhibitor		1	Pyrethrin 1	405558749.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1C(C)=C(C/C=C\C=C)C(=O)C1)[C@H]1[C@H](C=C(C)C)C1(C)C	O=C(O[C@@H]1C(C)=C(C/C=C\C=C)C(=O)C1)[C@H]1[C@H](C=C(C)C)C1(C)C
NCGC00024995-15&NCGC00024995-43	O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)(C3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1		Inactive	Tubulin depolymerization Inhibitor&Tubulin Depolymerization Inhibitor		2	Paclitaxel	384568039.0&405558867.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)(C3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1	O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)(C3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1
NCGC00346661-05	O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@H](O)[C@@H](NC(=O)/C(=C/C)/C)c1ccccc1		Inactive	Tubulin depolymerization Inhibitor		1	Cephalomannine	384568892.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@H](O)[C@@H](NC(=O)/C(=C/C)/C)c1ccccc1	O=C(O[C@@H]1C(C)=C2[C@@H](OC(=O)C)C(=O)[C@]3(C)[C@@H](O)C[C@@H]4[C@](OC(=O)C)([C@H]3[C@H](OC(=O)c3ccccc3)[C@@](O)(C2(C)C)C1)CO4)[C@H](O)[C@@H](NC(=O)/C(=C/C)/C)c1ccccc1
NCGC00169033-03	O=C(O[C@@H]1C(C)=C2[C@@H]3[C@@](O)([C@H](OC(=O)CCC)C[C@](OC(=O)C)(C)C2C1)[C@](O)(C)C(=O)O3)/C(=C/C)/C	5.4499998	Active	<MOA Unknown> | Class: Sesquiterpen | Genus: Thapsia | Family: Umbelliferae | Species: garganica	0.0	1	NCGC00169033-03	363676750.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	3.0	94.3032372548	O=C(O[C@@H]1C(C)=C2[C@@H]3[C@@](O)([C@H](OC(=O)CCC)C[C@](OC(=O)C)(C)C2C1)[C@](O)(C)C(=O)O3)/C(=C/C)/C	O=C(O[C@@H]1C(C)=C2[C@@H]3[C@@](O)([C@H](OC(=O)CCC)C[C@](OC(=O)C)(C)C2C1)[C@](O)(C)C(=O)O3)/C(=C/C)/C
NCGC00380750-01	O=C(O[C@@H]1C(C)=C[C@@H]2[C@@](COC(=O)C)([C@@]3(C)[C@H](O)[C@@H](O)[C@H]([C@@]43OC4)O2)C1)CC(C)C	6.0999999	Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00380750-01	363678758.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	5.0	-68.231791788	O=C(O[C@@H]1C(C)=C[C@@H]2[C@@](COC(=O)C)([C@@]3(C)[C@H](O)[C@@H](O)[C@H]([C@@]43OC4)O2)C1)CC(C)C	O=C(O[C@@H]1C(C)=C[C@@H]2[C@@](COC(=O)C)([C@@]3(C)[C@H](O)[C@@H](O)[C@H]([C@@]43OC4)O2)C1)CC(C)C
NCGC00380615-01	O=C(O[C@@H]1C(C)=C[C@@H]2[C@@](COC(=O)C)([C@@]3(C)[C@H](OC(=O)C)[C@@H](O)[C@H]([C@]43OC4)O2)C1)CC(C)C	6.0999999	Inactive	<MOA Unknown> | Class: trichothecene | Genus: ct Fusarium | Family: N/A | Species: N/A	0.0	1	NCGC00380615-01	363678672.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	5.0	-33.973509936	O=C(O[C@@H]1C(C)=C[C@@H]2[C@@](COC(=O)C)([C@@]3(C)[C@H](OC(=O)C)[C@@H](O)[C@H]([C@]43OC4)O2)C1)CC(C)C	O=C(O[C@@H]1C(C)=C[C@@H]2[C@@](COC(=O)C)([C@@]3(C)[C@H](OC(=O)C)[C@@H](O)[C@H]([C@]43OC4)O2)C1)CC(C)C
NCGC00385882-01	O=C(O[C@@H]1C([C@H](CCCO)C)=C(C)C[C@H]2OC(=O)C(=C)[C@@H]12)C(C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385882-01	363679989.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	15.517497812	O=C(O[C@@H]1C([C@H](CCCO)C)=C(C)C[C@H]2OC(=O)C(=C)[C@@H]12)C(C)C	O=C(O[C@@H]1C([C@H](CCCO)C)=C(C)C[C@H]2OC(=O)C(=C)[C@@H]12)C(C)C
NCGC00253579-01	O=C(O[C@@H]1C2(C)C(C3C(C4C(=C[C@@H](OC(=O)CC)CC4)CC3)CC2)CC1)CC		Inactive	Androgen Receptor Agonist		1	Bolandiol dipropionate	170465909.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O[C@@H]1C2(C)C(C3C(C4C(=C[C@@H](OC(=O)CC)CC4)CC3)CC2)CC1)CC	O=C(O[C@@H]1C2(C)C(C3C(C4C(=C[C@@H](OC(=O)CC)CC4)CC3)CC2)CC1)CC
NCGC00380561-01	O=C(O[C@@H]1C2=C(COC)C(=O)OC2=CC2(C)OC(O)([C@@](O)(C)C1)CC2)C(=C)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Vernonia | Family: Compositae | Species: patens		1	NCGC00380561-01	363678651.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1C2=C(COC)C(=O)OC2=CC2(C)OC(O)([C@@](O)(C)C1)CC2)C(=C)C	O=C(O[C@@H]1C2=C(COC)C(=O)OC2=CC2(C)OC(O)([C@@](O)(C)C1)CC2)C(=C)C
NCGC00380701-01	O=C(O[C@@H]1C2=C(COC)C(=O)O[C@]32[C@@H](OC(=O)C)[C@@](O)(C)CC[C@]3(O)[C@@](OC(=O)C)(C)C1)C(=C)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Vernonia | Family: Compositae | Species: patens		1	NCGC00380701-01	363678718.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1C2=C(COC)C(=O)O[C@]32[C@@H](OC(=O)C)[C@@](O)(C)CC[C@]3(O)[C@@](OC(=O)C)(C)C1)C(=C)C	O=C(O[C@@H]1C2=C(COC)C(=O)O[C@]32[C@@H](OC(=O)C)[C@@](O)(C)CC[C@]3(O)[C@@](OC(=O)C)(C)C1)C(=C)C
NCGC00485382-01	O=C(O[C@@H]1C2CCN(C1)CC2)C		Inactive	Muscarinic acetylcholine receptor M4 Agonist		1	Aceclidine hydrochloride	363681307.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1C2CCN(C1)CC2)C	O=C(O[C@@H]1C2CCN(C1)CC2)C
NCGC00263936-02	O=C(O[C@@H]1C2CCN(C1)CC2)C1[C@@H](c2ccccc2)c2c(cccc2)CN1		Inactive			1	SOLIFENACIN SUCCINATE	363677304.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1C2CCN(C1)CC2)C1[C@@H](c2ccccc2)c2c(cccc2)CN1	O=C(O[C@@H]1C2CCN(C1)CC2)C1[C@@H](c2ccccc2)c2c(cccc2)CN1
NCGC00168778-06	O=C(O[C@@H]1C2CCN(C1)CC2)N1[C@@H](c2ccccc2)c2c(cccc2)CC1		Inactive	Muscarinic acetylcholine receptor M5 Antagonist		1	Solifenacin (hydrochloride)	405558475.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1C2CCN(C1)CC2)N1[C@@H](c2ccccc2)c2c(cccc2)CC1	O=C(O[C@@H]1C2CCN(C1)CC2)N1[C@@H](c2ccccc2)c2c(cccc2)CC1
NCGC00386257-02	O=C(O[C@@H]1C2CC[N+](CCCOc3ccccc3)(C1)CC2)C(O)(c1sccc1)c1sccc1		Inactive	Muscarinic acetylcholine receptor M3 Antagonist		1	Aclidinium (Bromide)	405559015.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1C2CC[N+](CCCOc3ccccc3)(C1)CC2)C(O)(c1sccc1)c1sccc1	O=C(O[C@@H]1C2CC[N+](CCCOc3ccccc3)(C1)CC2)C(O)(c1sccc1)c1sccc1
NCGC00387792-03	O=C(O[C@@H]1C=2[C@]3(C)[C@H](COC)OC(=O)/C(=C\N(CC=C)CC=C)/C3=C(O)C(=O)C=2[C@@H]2[C@@](C)(C(=O)CC2)C1)C		Inactive			1	PX-866	384569161.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1C=2[C@]3(C)[C@H](COC)OC(=O)/C(=C\N(CC=C)CC=C)/C3=C(O)C(=O)C=2[C@@H]2[C@@](C)(C(=O)CC2)C1)C	O=C(O[C@@H]1C=2[C@]3(C)[C@H](COC)OC(=O)/C(=C\N(CC=C)CC=C)/C3=C(O)C(=O)C=2[C@@H]2[C@@](C)(C(=O)CC2)C1)C
NCGC00387794-01	O=C(O[C@@H]1C=2[C@]3(C)[C@H](COC)OC(=O)/C(=C\N(CCCN(C)C)C)/C3=C(O)C(=O)C=2[C@@H]2[C@@](C)([C@@H](O)CC2)C1)C	6.5500002	Active		0.0	1	PX-13-17OH 	377020486.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	2.4	80.3174927086	O=C(O[C@@H]1C=2[C@]3(C)[C@H](COC)OC(=O)/C(=C\N(CCCN(C)C)C)/C3=C(O)C(=O)C=2[C@@H]2[C@@](C)([C@@H](O)CC2)C1)C	O=C(O[C@@H]1C=2[C@]3(C)[C@H](COC)OC(=O)/C(=C\N(CCCN(C)C)C)/C3=C(O)C(=O)C=2[C@@H]2[C@@](C)([C@@H](O)CC2)C1)C
NCGC00380962-01	O=C(O[C@@H]1C=C(CO)C(O)(C(=O)OC)[C@]2(C)C1C(C)(C)CCC2)/C=C/C=C/C=C/C		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380962-01	363678887.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1C=C(CO)C(O)(C(=O)OC)[C@]2(C)C1C(C)(C)CCC2)/C=C/C=C/C=C/C	O=C(O[C@@H]1C=C(CO)C(O)(C(=O)OC)[C@]2(C)C1C(C)(C)CCC2)/C=C/C=C/C=C/C
NCGC00166138-04	O=C(O[C@@H]1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@](OC(=O)C)(C#C)CC4)CC3)CC2)CC1)C		Inactive	Progesterone receptor Agonist		1	Ethynodiol diacetate	170464933.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@](OC(=O)C)(C#C)CC4)CC3)CC2)CC1)C	O=C(O[C@@H]1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@](OC(=O)C)(C#C)CC4)CC3)CC2)CC1)C
NCGC00166271-02	O=C(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](C(=O)C)CC4)CC3)CC=2)CC1)C		Inactive			1	Pregnenolone acetate	405558657.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](C(=O)C)CC4)CC3)CC=2)CC1)C	O=C(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](C(=O)C)CC4)CC3)CC=2)CC1)C
NCGC00485229-01	O=C(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC=2)CC1)NCCN(C)C	4.9000001	Active		0.0	1	Cholesteryl 3Î²-N-(diÂ­methylÂ­aminoÂ­ethyl)Â­carbamate hydrochloride	363681264.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	74.1953896879	O=C(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC=2)CC1)NCCN(C)C	O=C(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC=2)CC1)NCCN(C)C
NCGC00378589-01	O=C(O[C@@H]1COCC1)NCc1cc(NC(=O)Nc2cc(OC)c(-c3ocnc3)cc2)ccc1	4.9000001	Active	Inosine-5'-monophosphate dehydrogenase 2 Inhibitor	0.0	1	Merimepodib	363678106.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	3.0	72.2779169889	O=C(O[C@@H]1COCC1)NCc1cc(NC(=O)Nc2cc(OC)c(-c3ocnc3)cc2)ccc1	O=C(O[C@@H]1COCC1)NCc1cc(NC(=O)Nc2cc(OC)c(-c3ocnc3)cc2)ccc1
NCGC00485098-01	O=C(O[C@@H]1C[C@H]2N(C)[C@H](C[C@@H]2O)C1)[C@H](CO)c1ccccc1		Inactive	TNF-alpha Inhibitor		1	(+/-)-Anisodamine	363681221.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1C[C@H]2N(C)[C@H](C[C@@H]2O)C1)[C@H](CO)c1ccccc1	O=C(O[C@@H]1C[C@H]2N(C)[C@H](C[C@@H]2O)C1)[C@H](CO)c1ccccc1
NCGC00385671-01	O=C(O[C@@H]1OC=C(CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H]2[C@H]1[C@@](O)(COC(=O)C)[C@@H](O)C2)CC(C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385671-01	363679866.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1OC=C(CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H]2[C@H]1[C@@](O)(COC(=O)C)[C@@H](O)C2)CC(C)C	O=C(O[C@@H]1OC=C(CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H]2[C@H]1[C@@](O)(COC(=O)C)[C@@H](O)C2)CC(C)C
NCGC00384998-01	O=C(O[C@@H]1OC=C(CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H]2[C@H]1[C@](O)(CO)[C@@H]1O[C@@H]21)CC(C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384998-01	363679476.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1OC=C(CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H]2[C@H]1[C@](O)(CO)[C@@H]1O[C@@H]21)CC(C)C	O=C(O[C@@H]1OC=C(CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H]2[C@H]1[C@](O)(CO)[C@@H]1O[C@@H]21)CC(C)C
NCGC00384617-01	O=C(O[C@@H]1OC=C(CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)O2)[C@@H]2[C@H]1[C@H](CO)[C@@H](O)C2)CC(C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384617-01	363679273.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1OC=C(CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)O2)[C@@H]2[C@H]1[C@H](CO)[C@@H](O)C2)CC(C)C	O=C(O[C@@H]1OC=C(CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)O2)[C@@H]2[C@H]1[C@H](CO)[C@@H](O)C2)CC(C)C
NCGC00168813-03	O=C(O[C@@H]1[C@@H](C(C(=O)OC)=C)[C@H](O)C2C(=C)C(=O)OC[C@@]2(C=C)C1)C(CO)=C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Vernonia | Family: Compositae | Species: lasiopus		1	NCGC00168813-03	363676693.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](C(C(=O)OC)=C)[C@H](O)C2C(=C)C(=O)OC[C@@]2(C=C)C1)C(CO)=C	O=C(O[C@@H]1[C@@H](C(C(=O)OC)=C)[C@H](O)C2C(=C)C(=O)OC[C@@]2(C=C)C1)C(CO)=C
NCGC00169078-03	O=C(O[C@@H]1[C@@H](C(C)C)[C@@H](OC(=O)/C(=C\C)/C)C=C(CO)C1=O)/C(=C/CO)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Sphaeranthus  | Family: N/A | Species: confertifolius		1	NCGC00169078-03	363676763.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](C(C)C)[C@@H](OC(=O)/C(=C\C)/C)C=C(CO)C1=O)/C(=C/CO)/C	O=C(O[C@@H]1[C@@H](C(C)C)[C@@H](OC(=O)/C(=C\C)/C)C=C(CO)C1=O)/C(=C/CO)/C
NCGC00507775-01	O=C(O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(=O)C)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@@]1(OC(=O)C)C)CC		Inactive	Ribosome Inhibitor		1	Midecamycin Acetate	405558744.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(=O)C)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@@]1(OC(=O)C)C)CC	O=C(O[C@@H]1[C@@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(=O)C)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@@]1(OC(=O)C)C)CC
NCGC00384598-01	O=C(O[C@@H]1[C@@H](C)[C@@]2(O)[C@H](C3C(C)(C)[C@]13OC(=O)C(CC)C)C=C(CO)C[C@]1(O)C(=O)C(C)=CC21)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384598-01	363679265.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](C)[C@@]2(O)[C@H](C3C(C)(C)[C@]13OC(=O)C(CC)C)C=C(CO)C[C@]1(O)C(=O)C(C)=CC21)/C(=C/C)/C	O=C(O[C@@H]1[C@@H](C)[C@@]2(O)[C@H](C3C(C)(C)[C@]13OC(=O)C(CC)C)C=C(CO)C[C@]1(O)C(=O)C(C)=CC21)/C(=C/C)/C
NCGC00385608-01	O=C(O[C@@H]1[C@@H](C)[C@]2(O)[C@H]3[C@@H](C(=O)C(C)=C3)CC(CO)=C[C@H]2C2C(C)(C)[C@]12OC(=O)C(CC)C)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385608-01	363679836.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	29.5	O=C(O[C@@H]1[C@@H](C)[C@]2(O)[C@H]3[C@@H](C(=O)C(C)=C3)CC(CO)=C[C@H]2C2C(C)(C)[C@]12OC(=O)C(CC)C)/C(=C/C)/C	O=C(O[C@@H]1[C@@H](C)[C@]2(O)[C@H]3[C@@H](C(=O)C(C)=C3)CC(CO)=C[C@H]2C2C(C)(C)[C@]12OC(=O)C(CC)C)/C(=C/C)/C
NCGC00017338-03	O=C(O[C@@H]1[C@@H](CCCCCC)C(=O)O[C@H](C)[C@H](NC(=O)c2c(O)c(NC=O)ccc2)C(=O)O[C@H]1C)CC(C)C		Inactive	Antifungal Agent		1	Antimycin A	124883057.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O=C(O[C@@H]1[C@@H](CCCCCC)C(=O)O[C@H](C)[C@H](NC(=O)c2c(O)c(NC=O)ccc2)C(=O)O[C@H]1C)CC(C)C	O=C(O[C@@H]1[C@@H](CCCCCC)C(=O)O[C@H](C)[C@H](NC(=O)c2c(O)c(NC=O)ccc2)C(=O)O[C@H]1C)CC(C)C
NCGC00380470-01	O=C(O[C@@H]1[C@@H](O)/C(/C=O)=C\CC/C(/CO)=C/[C@H]2OC(=O)C(=C)[C@H]12)C(=C)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Siegesbeckia | Family: Compositae | Species: orientalis		1	NCGC00380470-01	363678600.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)/C(/C=O)=C\CC/C(/CO)=C/[C@H]2OC(=O)C(=C)[C@H]12)C(=C)C	O=C(O[C@@H]1[C@@H](O)/C(/C=O)=C\CC/C(/CO)=C/[C@H]2OC(=O)C(=C)[C@H]12)C(=C)C
NCGC00169930-02	O=C(O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Scrophularia | Family: Scrophulariaceae | Species: nodosa		1	NCGC00169930-02	363676916.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1ccc(O)cc1	O=C(O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1ccc(O)cc1
NCGC00180417-03	O=C(O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1ccc(OC)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Buddleia | Family: Loganiaceae | Species: officinalis		1	NCGC00180417-03	363677021.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1ccc(OC)cc1	O=C(O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1ccc(OC)cc1
NCGC00179753-02	O=C(O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]3[C@H]([C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C3)C(CO)=C2)O[C@H]1C)/C=C/c1cc(O)c(OC)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Buddleia | Family: Loganiaceae | Species: officinalis		1	NCGC00179753-02	363676964.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]3[C@H]([C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C3)C(CO)=C2)O[C@H]1C)/C=C/c1cc(O)c(OC)cc1	O=C(O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]3[C@H]([C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C3)C(CO)=C2)O[C@H]1C)/C=C/c1cc(O)c(OC)cc1
NCGC00380162-01	O=C(O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H](CO)[C@H]1O)C(C)C		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380162-01	363678483.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H](CO)[C@H]1O)C(C)C	O=C(O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H](CO)[C@H]1O)C(C)C
NCGC00380647-01	O=C(O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H](CO)[C@H]1O)C(CC)C		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380647-01	363678688.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H](CO)[C@H]1O)C(CC)C	O=C(O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H](CO)[C@H]1O)C(CC)C
NCGC00380752-01	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C(CC)C		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380752-01	363678760.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C(CC)C	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C(CC)C
NCGC00384977-01	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1C(O)CCCC1)/C=C/c1cc(O)c(O)cc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384977-01	363679464.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1C(O)CCCC1)/C=C/c1cc(O)c(O)cc1	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1C(O)CCCC1)/C=C/c1cc(O)c(O)cc1
NCGC00384773-01	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1C(O)CCCC1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384773-01	363679348.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1C(O)CCCC1)/C=C/c1ccc(O)cc1	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1C(O)CCCC1)/C=C/c1ccc(O)cc1
NCGC00385720-01	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1OC=C(C(=O)O)C2C1C(O)(C)CC2)/C(=C/CC/C(=C/CO)/C)/C		Inactive	<MOA Unknown> | Class: Iridoide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385720-01	363679896.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1OC=C(C(=O)O)C2C1C(O)(C)CC2)/C(=C/CC/C(=C/CO)/C)/C	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1OC=C(C(=O)O)C2C1C(O)(C)CC2)/C(=C/CC/C(=C/CO)/C)/C
NCGC00381278-01	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1CC(C(=O)O)(C(=O)O)C2[C@](C)([C@H]3[C@@]4([C@@H](O)C(=C)[C@@H](C4)CC3)CC2)C1)CC(C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381278-01	363679062.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1CC(C(=O)O)(C(=O)O)C2[C@](C)([C@H]3[C@@]4([C@@H](O)C(=C)[C@@H](C4)CC3)CC2)C1)CC(C)C	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1CC(C(=O)O)(C(=O)O)C2[C@](C)([C@H]3[C@@]4([C@@H](O)C(=C)[C@@H](C4)CC3)CC2)C1)CC(C)C
NCGC00385477-01	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1OC=C(C(=O)O)[C@@H]2[C@H]1C(=C)C(O)C2)c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Vitex | Family: Verbenaceae | Species: negundo		1	NCGC00385477-01	363679761.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1OC=C(C(=O)O)[C@@H]2[C@H]1C(=C)C(O)C2)c1ccc(O)cc1	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1OC=C(C(=O)O)[C@@H]2[C@H]1C(=C)C(O)C2)c1ccc(O)cc1
NCGC00169503-02	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@H](O)C=C(C(=O)OC)C1)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Cytisus | Family: Fabaceae | Species: tribracteolatus		1	NCGC00169503-02	363676831.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@H](O)C=C(C(=O)OC)C1)/C=C/c1ccccc1	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@H](O)C=C(C(=O)OC)C1)/C=C/c1ccccc1
NCGC00380234-01	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c(CO)cc(O)cc1)c1ccccc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380234-01	363678507.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c(CO)cc(O)cc1)c1ccccc1	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c(CO)cc(O)cc1)c1ccccc1
NCGC00168868-02	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c(COC(=O)C2(O)C(=O)CCC=C2)cccc1)C		Inactive	<MOA Unknown> | Class: presalicinate | Genus: Cytisus | Family: Leguminosae | Species: scoparius		1	NCGC00168868-02	363676708.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c(COC(=O)C2(O)C(=O)CCC=C2)cccc1)C	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c(COC(=O)C2(O)C(=O)CCC=C2)cccc1)C
NCGC00381000-01	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)C)O[C@@H]1O[C@@]1(COC(=O)CC(C)C)[C@@H](O)[C@H](OC(=O)C)[C@@H](COC(=O)C(C)C)O1)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Sugar | Genus: echinops | Family: Compositae | Species: spinosus		1	NCGC00381000-01	363678914.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)C)O[C@@H]1O[C@@]1(COC(=O)CC(C)C)[C@@H](O)[C@H](OC(=O)C)[C@@H](COC(=O)C(C)C)O1)/C(=C/C)/C	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)C)O[C@@H]1O[C@@]1(COC(=O)CC(C)C)[C@@H](O)[C@H](OC(=O)C)[C@@H](COC(=O)C(C)C)O1)/C(=C/C)/C
NCGC00380106-01	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)C)O[C@@H]1O[C@@]1(COC(=O)CC(C)C)[C@@H](O)[C@H](OC(=O)C)[C@@H](COC(=O)C(CC)C)O1)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Sugar | Genus: echinops | Family: Compositae | Species: spinosus		1	NCGC00380106-01	363678460.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)C)O[C@@H]1O[C@@]1(COC(=O)CC(C)C)[C@@H](O)[C@H](OC(=O)C)[C@@H](COC(=O)C(CC)C)O1)/C(=C/C)/C	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)C)O[C@@H]1O[C@@]1(COC(=O)CC(C)C)[C@@H](O)[C@H](OC(=O)C)[C@@H](COC(=O)C(CC)C)O1)/C(=C/C)/C
NCGC00385663-01	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]1OC(=O)/C=C/c1cc(OC)c(O)c(OC)c1)/C=C/c1cc(OC)c(O)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385663-01	363679863.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]1OC(=O)/C=C/c1cc(OC)c(O)c(OC)c1)/C=C/c1cc(OC)c(O)cc1	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]1OC(=O)/C=C/c1cc(OC)c(O)c(OC)c1)/C=C/c1cc(OC)c(O)cc1
NCGC00510887-02	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CC[N@@]2C1)CCC		Inactive			1	Celgosivir (hydrochloride)	434147168.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	29.071531272	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CC[N@@]2C1)CCC	O=C(O[C@@H]1[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CC[N@@]2C1)CCC
NCGC00485977-01	O=C(O[C@@H]1[C@@H](O)[C@H](OC(=O)C)CO[C@H]1O[C@@H]1C(C)(C)[C@@H]2[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C[C@H]3[C@@]4(C)[C@@](C)([C@H]([C@@H](O)C4)[C@]4(C)O[C@H](C(O)(C)C)CC4)CC[C@]43[C@@]2(C4)CC1)C		Inactive			1	Isoastragaloside I	363681457.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](OC(=O)C)CO[C@H]1O[C@@H]1C(C)(C)[C@@H]2[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C[C@H]3[C@@]4(C)[C@@](C)([C@H]([C@@H](O)C4)[C@]4(C)O[C@H](C(O)(C)C)CC4)CC[C@]43[C@@]2(C4)CC1)C	O=C(O[C@@H]1[C@@H](O)[C@H](OC(=O)C)CO[C@H]1O[C@@H]1C(C)(C)[C@@H]2[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C[C@H]3[C@@]4(C)[C@@](C)([C@H]([C@@H](O)C4)[C@]4(C)O[C@H](C(O)(C)C)CC4)CC[C@]43[C@@]2(C4)CC1)C
NCGC00380507-01	O=C(O[C@@H]1[C@@H](O)[C@H](OC2C(O)CCCC2)O[C@H](CO)[C@H]1O)/C=C/c1cc(O)c(O)cc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380507-01	363678618.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](OC2C(O)CCCC2)O[C@H](CO)[C@H]1O)/C=C/c1cc(O)c(O)cc1	O=C(O[C@@H]1[C@@H](O)[C@H](OC2C(O)CCCC2)O[C@H](CO)[C@H]1O)/C=C/c1cc(O)c(O)cc1
NCGC00385717-01	O=C(O[C@@H]1[C@@H](O)[C@H](OC2OC=C(C(=O)O)C3C2C(O)(C)CC3)O[C@H](CO)[C@H]1O)/C(=C/CCC(CCO)C)/C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385717-01	363679893.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](OC2OC=C(C(=O)O)C3C2C(O)(C)CC3)O[C@H](CO)[C@H]1O)/C(=C/CCC(CCO)C)/C	O=C(O[C@@H]1[C@@H](O)[C@H](OC2OC=C(C(=O)O)C3C2C(O)(C)CC3)O[C@H](CO)[C@H]1O)/C(=C/CCC(CCO)C)/C
NCGC00384817-01	O=C(O[C@@H]1[C@@H](O)[C@H](OCCc2ccccc2)O[C@H](CO)[C@H]1O)CC(O)(CC(=O)O)C		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384817-01	363679373.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](OCCc2ccccc2)O[C@H](CO)[C@H]1O)CC(O)(CC(=O)O)C	O=C(O[C@@H]1[C@@H](O)[C@H](OCCc2ccccc2)O[C@H](CO)[C@H]1O)CC(O)(CC(=O)O)C
NCGC00485976-01	O=C(O[C@@H]1[C@@H](O)[C@H](O[C@@H]2C(C)(C)[C@@H]3[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)C[C@H]4[C@@]5(C)[C@@](C)([C@H]([C@@H](O)C5)[C@]5(C)O[C@H](C(O)(C)C)CC5)CC[C@]54[C@@]3(C5)CC2)OC[C@H]1O)C		Inactive			1	Isoastragaloside II	363681456.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](O[C@@H]2C(C)(C)[C@@H]3[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)C[C@H]4[C@@]5(C)[C@@](C)([C@H]([C@@H](O)C5)[C@]5(C)O[C@H](C(O)(C)C)CC5)CC[C@]54[C@@]3(C5)CC2)OC[C@H]1O)C	O=C(O[C@@H]1[C@@H](O)[C@H](O[C@@H]2C(C)(C)[C@@H]3[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)C[C@H]4[C@@]5(C)[C@@](C)([C@H]([C@@H](O)C5)[C@]5(C)O[C@H](C(O)(C)C)CC5)CC[C@]54[C@@]3(C5)CC2)OC[C@H]1O)C
NCGC00380687-01	O=C(O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](O)CO[C@H]3O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3O[C@@H]3[C@](CO)(C)C4[C@@](C)(C5[C@](C)([C@@]6(C)C([C@H]7[C@@](C(=O)O)(CC6)CCC(C)(C)C7)=CC5)CC4)CC3)O[C@H]2C)OC[C@H]1O)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: Gilbertiodendron | Family: Fabaceae | Species: limba		1	NCGC00380687-01	363678709.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](O)CO[C@H]3O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3O[C@@H]3[C@](CO)(C)C4[C@@](C)(C5[C@](C)([C@@]6(C)C([C@H]7[C@@](C(=O)O)(CC6)CCC(C)(C)C7)=CC5)CC4)CC3)O[C@H]2C)OC[C@H]1O)C	O=C(O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](O)[C@@H](O)[C@H](O[C@@H]3[C@@H](O)[C@H](O)CO[C@H]3O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3O[C@@H]3[C@](CO)(C)C4[C@@](C)(C5[C@](C)([C@@]6(C)C([C@H]7[C@@](C(=O)O)(CC6)CCC(C)(C)C7)=CC5)CC4)CC3)O[C@H]2C)OC[C@H]1O)C
NCGC00385017-01	O=C(O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](C=C)[C@@]3(O)C(C(=O)OCC3)=CO2)O[C@H](CO)[C@H]1O)/C=C/c1cc(OC)c(O)cc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Swertia | Family: Gentianaceae | Species: chirata		1	NCGC00385017-01	363679487.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](C=C)[C@@]3(O)C(C(=O)OCC3)=CO2)O[C@H](CO)[C@H]1O)/C=C/c1cc(OC)c(O)cc1	O=C(O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](C=C)[C@@]3(O)C(C(=O)OCC3)=CO2)O[C@H](CO)[C@H]1O)/C=C/c1cc(OC)c(O)cc1
NCGC00385226-01	O=C(O[C@@H]1[C@@H](O)[C@]2(O)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H](OC2)C[C@@H]13)c1ccccc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385226-01	363679604.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)[C@]2(O)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H](OC2)C[C@@H]13)c1ccccc1	O=C(O[C@@H]1[C@@H](O)[C@]2(O)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H](OC2)C[C@@H]13)c1ccccc1
NCGC00385132-01	O=C(O[C@@H]1[C@@H](O)c2c(c(O)cc(C(C)C)c2)[C@]2(C)C1[C@](C(=O)OC)(C)C(=O)C=C2)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385132-01	363679553.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O)c2c(c(O)cc(C(C)C)c2)[C@]2(C)C1[C@](C(=O)OC)(C)C(=O)C=C2)C	O=C(O[C@@H]1[C@@H](O)c2c(c(O)cc(C(C)C)c2)[C@]2(C)C1[C@](C(=O)OC)(C)C(=O)C=C2)C
NCGC00380574-01	O=C(O[C@@H]1[C@@H](OC(=O)/C=C/c2ccc(O)cc2)[C@H](C)O[C@@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)[C@@H]1O)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Scrophularia | Family: Scrophulariaceae | Species: nodosa		1	NCGC00380574-01	363678656.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](OC(=O)/C=C/c2ccc(O)cc2)[C@H](C)O[C@@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)[C@@H]1O)/C=C/c1ccc(O)cc1	O=C(O[C@@H]1[C@@H](OC(=O)/C=C/c2ccc(O)cc2)[C@H](C)O[C@@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)[C@@H]1O)/C=C/c1ccc(O)cc1
NCGC00169479-03	O=C(O[C@@H]1[C@@H](OC(=O)C(=C)C)[C@H]2C(=C)C(=O)O[C@@H]2C[C@@H](C)[C@@H]2O[C@@H]2C(=O)[C@@]1(O)C)C(=C)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Calea | Family: Compositae | Species: urticifolia		1	NCGC00169479-03	363676828.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	30.41802068	O=C(O[C@@H]1[C@@H](OC(=O)C(=C)C)[C@H]2C(=C)C(=O)O[C@@H]2C[C@@H](C)[C@@H]2O[C@@H]2C(=O)[C@@]1(O)C)C(=C)C	O=C(O[C@@H]1[C@@H](OC(=O)C(=C)C)[C@H]2C(=C)C(=O)O[C@@H]2C[C@@H](C)[C@@H]2O[C@@H]2C(=O)[C@@]1(O)C)C(=C)C
NCGC00380711-01	O=C(O[C@@H]1[C@@H](OC(=O)C)C(=C)[C@H](OC(=O)C)[C@H]2[C@@H](OC(=O)C)C(C)C[C@]2(OC(=O)C)C(=O)[C@H](C)/C=C/C(C)(C)C1=O)C(C)C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Euphorbia | Family: Euphorbiaceae | Species: paralias		1	NCGC00380711-01	363678728.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](OC(=O)C)C(=C)[C@H](OC(=O)C)[C@H]2[C@@H](OC(=O)C)C(C)C[C@]2(OC(=O)C)C(=O)[C@H](C)/C=C/C(C)(C)C1=O)C(C)C	O=C(O[C@@H]1[C@@H](OC(=O)C)C(=C)[C@H](OC(=O)C)[C@H]2[C@@H](OC(=O)C)C(C)C[C@]2(OC(=O)C)C(=O)[C@H](C)/C=C/C(C)(C)C1=O)C(C)C
NCGC00380508-01	O=C(O[C@@H]1[C@@H](OC(=O)C)C(=C)[C@H](OC(=O)C)[C@H]2[C@@H](OC(=O)C)[C@@](OC(=O)C)(C)C[C@]2(OC(=O)C)C(=O)[C@H](C)/C=C/C(C)(C)C1=O)C(C)C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Euphorbia | Family: Euphorbiaceae | Species: paralias		1	NCGC00380508-01	363678619.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](OC(=O)C)C(=C)[C@H](OC(=O)C)[C@H]2[C@@H](OC(=O)C)[C@@](OC(=O)C)(C)C[C@]2(OC(=O)C)C(=O)[C@H](C)/C=C/C(C)(C)C1=O)C(C)C	O=C(O[C@@H]1[C@@H](OC(=O)C)C(=C)[C@H](OC(=O)C)[C@H]2[C@@H](OC(=O)C)[C@@](OC(=O)C)(C)C[C@]2(OC(=O)C)C(=O)[C@H](C)/C=C/C(C)(C)C1=O)C(C)C
NCGC00380509-01	O=C(O[C@@H]1[C@@H](OC(=O)C)C(=C)[C@H](OC(=O)C)[C@H]2[C@@H](OC(=O)C)[C@@](OC(=O)C)(C)C[C@]2(OC(=O)C)C(=O)[C@H](C)/C=C/C(C)(C)C1=O)C(CC)C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Euphorbia | Family: Euphorbiaceae | Species: paralias		1	NCGC00380509-01	363678620.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](OC(=O)C)C(=C)[C@H](OC(=O)C)[C@H]2[C@@H](OC(=O)C)[C@@](OC(=O)C)(C)C[C@]2(OC(=O)C)C(=O)[C@H](C)/C=C/C(C)(C)C1=O)C(CC)C	O=C(O[C@@H]1[C@@H](OC(=O)C)C(=C)[C@H](OC(=O)C)[C@H]2[C@@H](OC(=O)C)[C@@](OC(=O)C)(C)C[C@]2(OC(=O)C)C(=O)[C@H](C)/C=C/C(C)(C)C1=O)C(CC)C
NCGC00386011-01	O=C(O[C@@H]1[C@@H](OC(=O)C)C(=O)C(C)(C)/C=C/[C@@H](C)[C@H](OC(=O)C)[C@]2(O)[C@H]([C@@H](OC(=O)c3ccccc3)[C@@H](C)C2)[C@@H](OC(=O)C)C1=C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386011-01	363680058.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](OC(=O)C)C(=O)C(C)(C)/C=C/[C@@H](C)[C@H](OC(=O)C)[C@]2(O)[C@H]([C@@H](OC(=O)c3ccccc3)[C@@H](C)C2)[C@@H](OC(=O)C)C1=C)C	O=C(O[C@@H]1[C@@H](OC(=O)C)C(=O)C(C)(C)/C=C/[C@@H](C)[C@H](OC(=O)C)[C@]2(O)[C@H]([C@@H](OC(=O)c3ccccc3)[C@@H](C)C2)[C@@H](OC(=O)C)C1=C)C
NCGC00381211-01	O=C(O[C@@H]1[C@@H](OC(=O)C)C2[C@]3(C)C(C[C@@H](OC4OC(C)C(OC5OC(C)C(OC6OC(C)C(OC7C(O)C(OC)C(OC8C(O)C(O)C(O)C(CO)O8)C(C)O7)C(OC)C6)C(OC)C5)C(OC)C4)CC3)CCC2[C@]2(O)[C@@]1(C)C(C(=O)C)CC2)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Dregea | Family: Asclepiadaceae | Species: sp.		1	NCGC00381211-01	363679026.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](OC(=O)C)C2[C@]3(C)C(C[C@@H](OC4OC(C)C(OC5OC(C)C(OC6OC(C)C(OC7C(O)C(OC)C(OC8C(O)C(O)C(O)C(CO)O8)C(C)O7)C(OC)C6)C(OC)C5)C(OC)C4)CC3)CCC2[C@]2(O)[C@@]1(C)C(C(=O)C)CC2)/C=C/c1ccccc1	O=C(O[C@@H]1[C@@H](OC(=O)C)C2[C@]3(C)C(C[C@@H](OC4OC(C)C(OC5OC(C)C(OC6OC(C)C(OC7C(O)C(OC)C(OC8C(O)C(O)C(O)C(CO)O8)C(C)O7)C(OC)C6)C(OC)C5)C(OC)C4)CC3)CCC2[C@]2(O)[C@@]1(C)C(C(=O)C)CC2)/C=C/c1ccccc1
NCGC00385207-01	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@@H]4[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Buddleia | Family: Loginaceae | Species: polystachya		1	NCGC00385207-01	363679595.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@@H]4[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1ccccc1	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@@H]4[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1ccccc1
NCGC00384952-01	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1cc(O)c(OC)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Scrophularia | Family: Scrophulariaceae | Species: lyrata		1	NCGC00384952-01	363679454.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1cc(O)c(OC)cc1	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1cc(O)c(OC)cc1
NCGC00169403-02	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1ccc(OC)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Scrophularia | Family: Scrophulariaceae | Species: lyrata		1	NCGC00169403-02	363676812.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1ccc(OC)cc1	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1ccc(OC)cc1
NCGC00169152-03	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Salvia | Family: Labiatae | Species: sp.		1	NCGC00169152-03	363676782.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1ccccc1	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@H]1C)/C=C/c1ccccc1
NCGC00169210-02	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@](O)(C)C(=O)/C=C\[C@H](C)C[C@H]2OC(=O)C(=C)[C@H]12)C(=C)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Calea | Family: Compositae | Species: urticifolia		1	NCGC00169210-02	363676790.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@](O)(C)C(=O)/C=C\[C@H](C)C[C@H]2OC(=O)C(=C)[C@H]12)C(=C)C	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@](O)(C)C(=O)/C=C\[C@H](C)C[C@H]2OC(=O)C(=C)[C@H]12)C(=C)C
NCGC00169288-03	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@](O)(C)C(=O)[C@H]2O[C@H]2[C@H](C)C[C@H]2OC(=O)C(=C)[C@H]12)C(=C)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Calea | Family: Compositae | Species: urticifolia		1	NCGC00169288-03	363676798.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	13.502158272	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@](O)(C)C(=O)[C@H]2O[C@H]2[C@H](C)C[C@H]2OC(=O)C(=C)[C@H]12)C(=C)C	O=C(O[C@@H]1[C@@H](OC(=O)C)[C@](O)(C)C(=O)[C@H]2O[C@H]2[C@H](C)C[C@H]2OC(=O)C(=C)[C@H]12)C(=C)C
NCGC00016060-14	O=C(O[C@@H]1[C@@H](OC(=O)CCCCCCC)[C@@H]2[C@](OC(=O)C)(C)C[C@H](OC(=O)CCC)[C@]3(O)[C@@](O)(C)C(=O)O[C@H]3C2=C1C)/C(=C\C)/C		Inactive	SERCA inhibitor		1	Thapsigargin	384567917.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(O[C@@H]1[C@@H](OC(=O)CCCCCCC)[C@@H]2[C@](OC(=O)C)(C)C[C@H](OC(=O)CCC)[C@]3(O)[C@@](O)(C)C(=O)O[C@H]3C2=C1C)/C(=C\C)/C	O=C(O[C@@H]1[C@@H](OC(=O)CCCCCCC)[C@@H]2[C@](OC(=O)C)(C)C[C@H](OC(=O)CCC)[C@]3(O)[C@@](O)(C)C(=O)O[C@H]3C2=C1C)/C(=C\C)/C
NCGC00380453-01	O=C(O[C@@H]1[C@@H](OC(=O)c2ccccc2)[C@]2(C)[C@@H](C(=O)C)CC[C@]2(O)[C@@]2(O)C1[C@]1(C)C(=CC2)C[C@@H](OC2OC(C)C(OC3OC(C)C(OC4OC(C)C(OC5C(O)C(OC)C(OC6C(O)C(O)C(O)C(CO)O6)C(C)O5)C(OC)C4)C(OC)C3)C(OC)C2)CC1)C		Inactive	<MOA Unknown> | Class: Steroid | Genus: Cionura | Family: Asclepiadaceae | Species: erecta		1	NCGC00380453-01	363678592.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](OC(=O)c2ccccc2)[C@]2(C)[C@@H](C(=O)C)CC[C@]2(O)[C@@]2(O)C1[C@]1(C)C(=CC2)C[C@@H](OC2OC(C)C(OC3OC(C)C(OC4OC(C)C(OC5C(O)C(OC)C(OC6C(O)C(O)C(O)C(CO)O6)C(C)O5)C(OC)C4)C(OC)C3)C(OC)C2)CC1)C	O=C(O[C@@H]1[C@@H](OC(=O)c2ccccc2)[C@]2(C)[C@@H](C(=O)C)CC[C@]2(O)[C@@]2(O)C1[C@]1(C)C(=CC2)C[C@@H](OC2OC(C)C(OC3OC(C)C(OC4OC(C)C(OC5C(O)C(OC)C(OC6C(O)C(O)C(O)C(CO)O6)C(C)O5)C(OC)C4)C(OC)C3)C(OC)C2)CC1)C
NCGC00381455-01	O=C(O[C@@H]1[C@@H](OC)/C(/C=O)=C\CC/C(/C)=C/[C@H]2OC(=O)C(=C)[C@H]12)C(C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Acanthospermum  | Family: N/A | Species: glabratum		1	NCGC00381455-01	363679150.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](OC)/C(/C=O)=C\CC/C(/C)=C/[C@H]2OC(=O)C(=C)[C@H]12)C(C)C	O=C(O[C@@H]1[C@@H](OC)/C(/C=O)=C\CC/C(/C)=C/[C@H]2OC(=O)C(=C)[C@H]12)C(C)C
NCGC00386081-01	O=C(O[C@@H]1[C@@H](OC)C2=C(C(=O)N(C(C(=O)O)C)C2)[C@]2(C)[C@@H]1C(C)(C)CCC2)/C=C/C=C/C=C/C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386081-01	363680096.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](OC)C2=C(C(=O)N(C(C(=O)O)C)C2)[C@]2(C)[C@@H]1C(C)(C)CCC2)/C=C/C=C/C=C/C	O=C(O[C@@H]1[C@@H](OC)C2=C(C(=O)N(C(C(=O)O)C)C2)[C@]2(C)[C@@H]1C(C)(C)CCC2)/C=C/C=C/C=C/C
NCGC00381147-01	O=C(O[C@@H]1[C@@H](OC)C2=C(C(=O)N(C(C(=O)O)CCC(=O)O)C2)[C@]2(C)[C@@H]1C(C)(C)CCC2)/C=C/C=C/C=C/C		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381147-01	363678994.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](OC)C2=C(C(=O)N(C(C(=O)O)CCC(=O)O)C2)[C@]2(C)[C@@H]1C(C)(C)CCC2)/C=C/C=C/C=C/C	O=C(O[C@@H]1[C@@H](OC)C2=C(C(=O)N(C(C(=O)O)CCC(=O)O)C2)[C@]2(C)[C@@H]1C(C)(C)CCC2)/C=C/C=C/C=C/C
NCGC00384619-01	O=C(O[C@@H]1[C@@H](OC2C(O)C(O)C(O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@H](O)CO3)C(C)O2)[C@H](OC(=O)[C@]23C(C=4[C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]8[C@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O)CO9)[C@@H](O)[C@@H](O)CO8)O7)CC6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@H](CO)[C@H]1O)/C(=C/CCC(O)(C=C)C)/C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384619-01	363679275.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](OC2C(O)C(O)C(O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@H](O)CO3)C(C)O2)[C@H](OC(=O)[C@]23C(C=4[C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]8[C@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O)CO9)[C@@H](O)[C@@H](O)CO8)O7)CC6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@H](CO)[C@H]1O)/C(=C/CCC(O)(C=C)C)/C	O=C(O[C@@H]1[C@@H](OC2C(O)C(O)C(O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@H](O)CO3)C(C)O2)[C@H](OC(=O)[C@]23C(C=4[C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]8[C@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O)CO9)[C@@H](O)[C@@H](O)CO8)O7)CC6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@H](CO)[C@H]1O)/C(=C/CCC(O)(C=C)C)/C
NCGC00347668-02	O=C(O[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)C3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=CC23)O[C@H]1C)/C=C/c1ccc(OC)cc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Buddleja | Family: Loganiaceae | Species: asiatica		1	NCGC00347668-02	363677662.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)C3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=CC23)O[C@H]1C)/C=C/c1ccc(OC)cc1	O=C(O[C@@H]1[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)C3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=CC23)O[C@H]1C)/C=C/c1ccc(OC)cc1
NCGC00384706-01	O=C(O[C@@H]1[C@@H]([C@@H](C(=C)C)C)O[C@]23OC[C@@]4([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](CO)O8)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)CO7)CC6)CC5)CCC4C2[C@]1(O)C)C3)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384706-01	363679319.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H]([C@@H](C(=C)C)C)O[C@]23OC[C@@]4([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](CO)O8)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)CO7)CC6)CC5)CCC4C2[C@]1(O)C)C3)C	O=C(O[C@@H]1[C@@H]([C@@H](C(=C)C)C)O[C@]23OC[C@@]4([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](CO)O8)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)CO7)CC6)CC5)CCC4C2[C@]1(O)C)C3)C
NCGC00385189-01	O=C(O[C@@H]1[C@@H]([C@]2(C)C(O)(C3C([C@]4(C)C(C[C@@H](O[C@@H]5O[C@H](C)[C@H](O[C@@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)O6)[C@H](OC)C5)CC4)CC3)CC2)C1)C1=CC(=O)OC1)C		Inactive	<MOA Unknown> | Class: Steroid | Genus: Nerium | Family: Apocynaceae | Species: oleander		1	NCGC00385189-01	363679586.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H]([C@]2(C)C(O)(C3C([C@]4(C)C(C[C@@H](O[C@@H]5O[C@H](C)[C@H](O[C@@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)O6)[C@H](OC)C5)CC4)CC3)CC2)C1)C1=CC(=O)OC1)C	O=C(O[C@@H]1[C@@H]([C@]2(C)C(O)(C3C([C@]4(C)C(C[C@@H](O[C@@H]5O[C@H](C)[C@H](O[C@@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)O6)[C@H](OC)C5)CC4)CC3)CC2)C1)C1=CC(=O)OC1)C
NCGC00385413-01	O=C(O[C@@H]1[C@@H]([C@]2(C)[C@@](O)(C3C([C@]4(C)[C@@H](C[C@@H](OC5OC(C)C(O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)C(OC)C5)CC4)CC3)CC2)C1)C1=CC(=O)OC1)C		Inactive	<MOA Unknown> | Class: Steroid | Genus: Nerium | Family: Apocynaceae | Species: oleander		1	NCGC00385413-01	363679730.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H]([C@]2(C)[C@@](O)(C3C([C@]4(C)[C@@H](C[C@@H](OC5OC(C)C(O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)C(OC)C5)CC4)CC3)CC2)C1)C1=CC(=O)OC1)C	O=C(O[C@@H]1[C@@H]([C@]2(C)[C@@](O)(C3C([C@]4(C)[C@@H](C[C@@H](OC5OC(C)C(O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)C(OC)C5)CC4)CC3)CC2)C1)C1=CC(=O)OC1)C
NCGC00264069-01	O=C(O[C@@H]1[C@@H]([C@]2(C)[C@@](O)(C3C([C@]4(C)[C@@H](C[C@@H](O[C@@H]5OC(C)[C@@H](O)[C@H](OC)C5)CC4)CC3)CC2)C1)C1=CC(=O)OC1)C		Inactive	Sodium/potassium-transporting ATPase Blocker		1	OLEANDRIN		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0	0.0&0.0	O=C(O[C@@H]1[C@@H]([C@]2(C)[C@@](O)(C3C([C@]4(C)[C@@H](C[C@@H](O[C@@H]5OC(C)[C@@H](O)[C@H](OC)C5)CC4)CC3)CC2)C1)C1=CC(=O)OC1)C	O=C(O[C@@H]1[C@@H]([C@]2(C)[C@@](O)(C3C([C@]4(C)[C@@H](C[C@@H](O[C@@H]5OC(C)[C@@H](O)[C@H](OC)C5)CC4)CC3)CC2)C1)C1=CC(=O)OC1)C
NCGC00385622-01	O=C(O[C@@H]1[C@@H]2[C@@H](C)C(=O)O[C@H]2[C@@H]2C(C)=CC[C@@H]2[C@](O)(C)C1)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Ammodaucus | Family: Umbelliferae | Species: leucotrichus		1	NCGC00385622-01	363679843.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H]2[C@@H](C)C(=O)O[C@H]2[C@@H]2C(C)=CC[C@@H]2[C@](O)(C)C1)/C(=C/C)/C	O=C(O[C@@H]1[C@@H]2[C@@H](C)C(=O)O[C@H]2[C@@H]2C(C)=CC[C@@H]2[C@](O)(C)C1)/C(=C/C)/C
NCGC00169628-03	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@@H](C)C=CC2=CCC1)C(CC)C		Inactive	HMG-CoA reductase Inhibitor		1	NCGC00169628-03	363676851.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@@H](C)C=CC2=CCC1)C(CC)C	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@@H](C)C=CC2=CCC1)C(CC)C
NCGC00188962-02	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@@H](C)C=CC2=C[C@@H](O)C1)[C@H](CC)C		Inactive	HMG-CoA Reductase Inhibitor		1	Pravastatin sodium	174007284.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@@H](C)C=CC2=C[C@@H](O)C1)[C@H](CC)C	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@@H](C)C=CC2=C[C@@H](O)C1)[C@H](CC)C
NCGC00025202-12	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@H]3OC(=O)C[C@H](O)C3)[C@@H](C)C=CC2=CCC1)[C@H](CC)C		Inactive	HMG-CoA Reductase Inhibitor		1	Mevastatin	384568056.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	19.8355391839	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@H]3OC(=O)C[C@H](O)C3)[C@@H](C)C=CC2=CCC1)[C@H](CC)C	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@H]3OC(=O)C[C@H](O)C3)[C@@H](C)C=CC2=CCC1)[C@H](CC)C
NCGC00017324-07&NCGC00017324-15	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@H]3OC(=O)C[C@H](O)C3)[C@@H](C)C=CC2=C[C@H](C)C1)C(CC)(C)C		Inactive	HMG-CoA Reductase Inhibitor		2	Simvastatin	170464984.0&384567984.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	14.915520628&0.0&0.0	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@H]3OC(=O)C[C@H](O)C3)[C@@H](C)C=CC2=C[C@H](C)C1)C(CC)(C)C	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@H]3OC(=O)C[C@H](O)C3)[C@@H](C)C=CC2=C[C@H](C)C1)C(CC)(C)C
NCGC00023509-13&NCGC00023509-18	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@H]3OC(=O)C[C@H](O)C3)[C@@H](C)C=CC2=C[C@H](C)C1)[C@H](CC)C		Inactive	HMG-CoA Reductase Inhibitor		2	Lovastatin	170464913.0&384568018.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	12.133909292&19.6204379519&0.0	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@H]3OC(=O)C[C@H](O)C3)[C@@H](C)C=CC2=C[C@H](C)C1)[C@H](CC)C	O=C(O[C@@H]1[C@@H]2[C@@H](CC[C@H]3OC(=O)C[C@H](O)C3)[C@@H](C)C=CC2=C[C@H](C)C1)[C@H](CC)C
NCGC00168796-02	O=C(O[C@@H]1[C@@H]2[C@@](O)(C)C[C@]31[C@H]([C@](O)(C)[C@H]1[C@](O)([C@H](O)C3)C(C)(C)[C@@H](O)C1)CC2)C		Inactive	sodium ion transport Activator		1	NCGC00168796-02	363676684.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@H]2[C@@](O)(C)C[C@]31[C@H]([C@](O)(C)[C@H]1[C@](O)([C@H](O)C3)C(C)(C)[C@@H](O)C1)CC2)C	O=C(O[C@@H]1[C@@H]2[C@@](O)(C)C[C@]31[C@H]([C@](O)(C)[C@H]1[C@](O)([C@H](O)C3)C(C)(C)[C@@H](O)C1)CC2)C
NCGC00385269-01	O=C(O[C@@H]1[C@@](O)(C)[C@@H]2[C@@](O)(C(C(=O)OC)=COC2O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C1)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Ocimum | Family: Lamiaceae | Species: gratissimum		1	NCGC00385269-01	363679629.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@](O)(C)[C@@H]2[C@@](O)(C(C(=O)OC)=COC2O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C1)/C=C/c1ccccc1	O=C(O[C@@H]1[C@@](O)(C)[C@@H]2[C@@](O)(C(C(=O)OC)=COC2O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C1)/C=C/c1ccccc1
NCGC00179785-03	O=C(O[C@@H]1[C@@](O)(C)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)OC)[C@@]2(O)C1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Ocimum | Family: Lamiaceae | Species: gratissimum		1	NCGC00179785-03	363676970.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@](O)(C)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)OC)[C@@]2(O)C1)/C=C/c1ccc(O)cc1	O=C(O[C@@H]1[C@@](O)(C)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)OC)[C@@]2(O)C1)/C=C/c1ccc(O)cc1
NCGC00347303-01	O=C(O[C@@H]1[C@@]2(C(C)C)O[C@](C)([C@H](OC(=O)CO)C2)[C@H]2[C@H]1[C@H](C)CC2)/C=C/c1ccccc1		Inactive	PKC Activator		1	Englerin A	174006484.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@@]2(C(C)C)O[C@](C)([C@H](OC(=O)CO)C2)[C@H]2[C@H]1[C@H](C)CC2)/C=C/c1ccccc1	O=C(O[C@@H]1[C@@]2(C(C)C)O[C@](C)([C@H](OC(=O)CO)C2)[C@H]2[C@H]1[C@H](C)CC2)/C=C/c1ccccc1
NCGC00380909-01	O=C(O[C@@H]1[C@@]2(C)C(C(C)(C)[C@H](O)C1)C[C@@H](OC(=O)C)[C@@]1(C)C=3[C@](C)(C(C(CO)CC(O)C4C(C)(C)O4)CC=3)CCC21)C		Inactive	<MOA Unknown> | Class: triterpene | Genus: Chukrasia | Family: Meliaceae | Species: tabularis		1	NCGC00380909-01	363678848.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@]2(C)C(C(C)(C)[C@H](O)C1)C[C@@H](OC(=O)C)[C@@]1(C)C=3[C@](C)(C(C(CO)CC(O)C4C(C)(C)O4)CC=3)CCC21)C	O=C(O[C@@H]1[C@@]2(C)C(C(C)(C)[C@H](O)C1)C[C@@H](OC(=O)C)[C@@]1(C)C=3[C@](C)(C(C(CO)CC(O)C4C(C)(C)O4)CC=3)CCC21)C
NCGC00385546-01	O=C(O[C@@H]1[C@@]2(C)C(C(C)(C)[C@H](O)C1)C[C@@H](OC(=O)C)[C@@]1(C)[C@]34[C@](C)([C@H](c5cocc5)OC(=O)[C@H]3O4)CCC21)C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: trichilia | Family: Meliaceae | Species: americana		1	NCGC00385546-01	363679800.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@]2(C)C(C(C)(C)[C@H](O)C1)C[C@@H](OC(=O)C)[C@@]1(C)[C@]34[C@](C)([C@H](c5cocc5)OC(=O)[C@H]3O4)CCC21)C	O=C(O[C@@H]1[C@@]2(C)C(C(C)(C)[C@H](O)C1)C[C@@H](OC(=O)C)[C@@]1(C)[C@]34[C@](C)([C@H](c5cocc5)OC(=O)[C@H]3O4)CCC21)C
NCGC00381060-01	O=C(O[C@@H]1[C@@]2(C)C([C@@H](OC(=O)c3ccc(O)cc3)C[C@@]3(C)O[C@H]3C2)[C@](O)(C(C)C)C1)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Ferula | Family: Umbelliferae | Species: communis		1	NCGC00381060-01	363678950.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@]2(C)C([C@@H](OC(=O)c3ccc(O)cc3)C[C@@]3(C)O[C@H]3C2)[C@](O)(C(C)C)C1)C	O=C(O[C@@H]1[C@@]2(C)C([C@@H](OC(=O)c3ccc(O)cc3)C[C@@]3(C)O[C@H]3C2)[C@](O)(C(C)C)C1)C
NCGC00347654-02	O=C(O[C@@H]1[C@@]2(C)[C@@H]([C@@H](OC(=O)c3ccc(O)cc3)CC(C)=CC2)[C@](O)(C(C)C)C1)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Ferula | Family: Umbelliferae | Species: communis		1	NCGC00347654-02	363677657.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@]2(C)[C@@H]([C@@H](OC(=O)c3ccc(O)cc3)CC(C)=CC2)[C@](O)(C(C)C)C1)C	O=C(O[C@@H]1[C@@]2(C)[C@@H]([C@@H](OC(=O)c3ccc(O)cc3)CC(C)=CC2)[C@](O)(C(C)C)C1)C
NCGC00385575-01	O=C(O[C@@H]1[C@@]2(C)[C@@H]([C@@H](OC(=O)c3ccc(OC)cc3)CC(C)=CC2)[C@](O)(C(C)C)C1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385575-01	363679816.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@]2(C)[C@@H]([C@@H](OC(=O)c3ccc(OC)cc3)CC(C)=CC2)[C@](O)(C(C)C)C1)C	O=C(O[C@@H]1[C@@]2(C)[C@@H]([C@@H](OC(=O)c3ccc(OC)cc3)CC(C)=CC2)[C@](O)(C(C)C)C1)C
NCGC00180281-02	O=C(O[C@@H]1[C@@]2(C)[C@H](C(C)(C)CC1)CCC=1C(=O)OCC2=1)[C@H](NC(=O)C)C(C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180281-02	363677007.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@]2(C)[C@H](C(C)(C)CC1)CCC=1C(=O)OCC2=1)[C@H](NC(=O)C)C(C)C	O=C(O[C@@H]1[C@@]2(C)[C@H](C(C)(C)CC1)CCC=1C(=O)OCC2=1)[C@H](NC(=O)C)C(C)C
NCGC00385268-01	O=C(O[C@@H]1[C@@]2(C)[C@H](c3cocc3)C[C@H]3O[C@@]23[C@]2(C)[C@H](O)CC3[C@@]4(C)[C@@H](O)OC[C@@]3([C@@H](O)C[C@H]4OC(=O)C)C2C1=O)C	5.5500002	Active	<MOA Unknown> | Class: Triterpen | Genus: Melia | Family: Meliaceae | Species: azedarach	0.0	1	NCGC00385268-01	363679628.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	2.2	87.1808643502	O=C(O[C@@H]1[C@@]2(C)[C@H](c3cocc3)C[C@H]3O[C@@]23[C@]2(C)[C@H](O)CC3[C@@]4(C)[C@@H](O)OC[C@@]3([C@@H](O)C[C@H]4OC(=O)C)C2C1=O)C	O=C(O[C@@H]1[C@@]2(C)[C@H](c3cocc3)C[C@H]3O[C@@]23[C@]2(C)[C@H](O)CC3[C@@]4(C)[C@@H](O)OC[C@@]3([C@@H](O)C[C@H]4OC(=O)C)C2C1=O)C
NCGC00345812-02&NCGC00345812-03	O=C(O[C@@H]1[C@@]2(O)[C@H](O)C(CO)=CC3C(=O)C2([C@H](C)C[C@H]2C(C)(C)[C@@H]32)C=C1C)/C(=C\C)/C		Inactive	PKC Activator		2	Ingenol mebutate	405558836.0&384568756.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	-10.749710988&-24.5	O=C(O[C@@H]1[C@@]2(O)[C@H](O)C(CO)=CC3C(=O)C2([C@H](C)C[C@H]2C(C)(C)[C@@H]32)C=C1C)/C(=C\C)/C	O=C(O[C@@H]1[C@@]2(O)[C@H](O)C(CO)=CC3C(=O)C2([C@H](C)C[C@H]2C(C)(C)[C@@H]32)C=C1C)/C(=C\C)/C
NCGC00385357-01	O=C(O[C@@H]1[C@@]23[C@H](O)C[C@@]4(C)[C@@]5(C)C([C@]6(C)C([C@@](CO)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O)CO9)[C@@H](O)[C@H](O)[C@@H](CO)O8)CO7)CC6)CC5)CC[C@]4(OC2)C3CC(C)(C)C1)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: Anagallis | Family: Primulaceae | Species: monelli		1	NCGC00385357-01	363679697.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@@]23[C@H](O)C[C@@]4(C)[C@@]5(C)C([C@]6(C)C([C@@](CO)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O)CO9)[C@@H](O)[C@H](O)[C@@H](CO)O8)CO7)CC6)CC5)CC[C@]4(OC2)C3CC(C)(C)C1)C	O=C(O[C@@H]1[C@@]23[C@H](O)C[C@@]4(C)[C@@]5(C)C([C@]6(C)C([C@@](CO)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O)CO9)[C@@H](O)[C@H](O)[C@@H](CO)O8)CO7)CC6)CC5)CC[C@]4(OC2)C3CC(C)(C)C1)C
NCGC00385312-01	O=C(O[C@@H]1[C@@]23[C@H](O)C[C@@]4(C)[C@@]5(C)C([C@]6(C)C([C@@](CO)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O[C@H]%10[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O%10)CO9)[C@@H](O)[C@H](O)[C@@H](CO)O8)CO7)CC6)CC5)CC[C@]4(OC2)C3CC(C)(C)C1)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: Anagallis | Family: Primulaceae | Species: monelli		1	NCGC00385312-01	363679669.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	27.077200576	O=C(O[C@@H]1[C@@]23[C@H](O)C[C@@]4(C)[C@@]5(C)C([C@]6(C)C([C@@](CO)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O[C@H]%10[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O%10)CO9)[C@@H](O)[C@H](O)[C@@H](CO)O8)CO7)CC6)CC5)CC[C@]4(OC2)C3CC(C)(C)C1)C	O=C(O[C@@H]1[C@@]23[C@H](O)C[C@@]4(C)[C@@]5(C)C([C@]6(C)C([C@@](CO)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O[C@H]%10[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O%10)CO9)[C@@H](O)[C@H](O)[C@@H](CO)O8)CO7)CC6)CC5)CC[C@]4(OC2)C3CC(C)(C)C1)C
NCGC00380589-01	O=C(O[C@@H]1[C@H](/C=C/[C@@H](O)[C@@H](O)C)OC(=O)C=C1)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380589-01	363678663.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](/C=C/[C@@H](O)[C@@H](O)C)OC(=O)C=C1)/C(=C/C)/C	O=C(O[C@@H]1[C@H](/C=C/[C@@H](O)[C@@H](O)C)OC(=O)C=C1)/C(=C/C)/C
NCGC00384506-01	O=C(O[C@@H]1[C@H](/C=C/[C@H](O)[C@H](O)C)OC(=O)C=C1)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384506-01	363679220.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](/C=C/[C@H](O)[C@H](O)C)OC(=O)C=C1)/C(=C/C)/C	O=C(O[C@@H]1[C@H](/C=C/[C@H](O)[C@H](O)C)OC(=O)C=C1)/C(=C/C)/C
NCGC00180769-03	O=C(O[C@@H]1[C@H](C(C)C)[C@@H](OC(=O)C)C(=O)C(CO)=C1)/C(=C/C)/C	5.1500001	Active	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00180769-03	363677063.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	3.0	92.2615169096	O=C(O[C@@H]1[C@H](C(C)C)[C@@H](OC(=O)C)C(=O)C(CO)=C1)/C(=C/C)/C	O=C(O[C@@H]1[C@H](C(C)C)[C@@H](OC(=O)C)C(=O)C(CO)=C1)/C(=C/C)/C
NCGC00385754-01	O=C(O[C@@H]1[C@H](C)C[C@@]23O[C@@]12[C@H]1C(=C)CCc2occ(C)c2[C@@H]1[C@]1(C)O[C@H]31)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385754-01	363679925.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](C)C[C@@]23O[C@@]12[C@H]1C(=C)CCc2occ(C)c2[C@@H]1[C@]1(C)O[C@H]31)C	O=C(O[C@@H]1[C@H](C)C[C@@]23O[C@@]12[C@H]1C(=C)CCc2occ(C)c2[C@@H]1[C@]1(C)O[C@H]31)C
NCGC00380800-01	O=C(O[C@@H]1[C@H](C)[C@@H](O)/C(/C)=C\CCc2cc(O)cc(NC(=O)C[C@@H](OC)/C=C/C=C/C=C/C1)c2)[C@H](NC(=O)C1CCCCC1)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380800-01	363678788.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](C)[C@@H](O)/C(/C)=C\CCc2cc(O)cc(NC(=O)C[C@@H](OC)/C=C/C=C/C=C/C1)c2)[C@H](NC(=O)C1CCCCC1)C	O=C(O[C@@H]1[C@H](C)[C@@H](O)/C(/C)=C\CCc2cc(O)cc(NC(=O)C[C@@H](OC)/C=C/C=C/C=C/C1)c2)[C@H](NC(=O)C1CCCCC1)C
NCGC00016981-05	O=C(O[C@@H]1[C@H](C)[C@H](C)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](OC(=O)C)[C@H](OC)C2)[C@H](C)[C@H](O[C@H]2[C@H](OC(=O)C)[C@H](N(C)C)C[C@H](C)O2)[C@H](C)C[C@]2(C(=O)[C@@H]1C)OC2)C		Inactive	70S ribosome Inhibitor		1	Troleandomycin	405558894.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@H](C)[C@H](C)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](OC(=O)C)[C@H](OC)C2)[C@H](C)[C@H](O[C@H]2[C@H](OC(=O)C)[C@H](N(C)C)C[C@H](C)O2)[C@H](C)C[C@]2(C(=O)[C@@H]1C)OC2)C	O=C(O[C@@H]1[C@H](C)[C@H](C)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](OC(=O)C)[C@H](OC)C2)[C@H](C)[C@H](O[C@H]2[C@H](OC(=O)C)[C@H](N(C)C)C[C@H](C)O2)[C@H](C)C[C@]2(C(=O)[C@@H]1C)OC2)C
NCGC00169154-02	O=C(O[C@@H]1[C@H](C)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)[C@H]2C1)/C=C/c1cc(OC)c(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Salvia | Family: Labiatae | Species: sp.		1	NCGC00169154-02	363676783.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](C)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)[C@H]2C1)/C=C/c1cc(OC)c(O)cc1	O=C(O[C@@H]1[C@H](C)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)[C@H]2C1)/C=C/c1cc(OC)c(O)cc1
NCGC00169684-02	O=C(O[C@@H]1[C@H](C)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)[C@H]2C1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Vitex | Family: Verbenaceae | Species: agenus		1	NCGC00169684-02	363676863.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](C)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)[C@H]2C1)/C=C/c1ccc(O)cc1	O=C(O[C@@H]1[C@H](C)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C(C(=O)O)[C@H]2C1)/C=C/c1ccc(O)cc1
NCGC00380891-01	O=C(O[C@@H]1[C@H](C)[C@]2(C)C(=CC(=O)[C@](O)(C(C=O)=C)C2)C=C1)/C=C/C=C/[C@@H](CC)C		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380891-01	363678836.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](C)[C@]2(C)C(=CC(=O)[C@](O)(C(C=O)=C)C2)C=C1)/C=C/C=C/[C@@H](CC)C	O=C(O[C@@H]1[C@H](C)[C@]2(C)C(=CC(=O)[C@](O)(C(C=O)=C)C2)C=C1)/C=C/C=C/[C@@H](CC)C
NCGC00485932-01	O=C(O[C@@H]1[C@H](C2=COC(=O)C=C2)[C@]2(C)[C@@](O)([C@H]3[C@@H]([C@]4(C)[C@@H](C[C@@H](O)CC4)CC3)CC2)C1)C		Inactive	PC-3 Inhibitor		1	Bufotalin	363681425.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](C2=COC(=O)C=C2)[C@]2(C)[C@@](O)([C@H]3[C@@H]([C@]4(C)[C@@H](C[C@@H](O)CC4)CC3)CC2)C1)C	O=C(O[C@@H]1[C@H](C2=COC(=O)C=C2)[C@]2(C)[C@@](O)([C@H]3[C@@H]([C@]4(C)[C@@H](C[C@@H](O)CC4)CC3)CC2)C1)C
NCGC00168883-03	O=C(O[C@@H]1[C@H](O)C(C)=C2C(=O)[C@@H]3[C@@](C)(O3)C2[C@H]2OC(=O)C(=C)[C@H]12)/C(=C/C)/COC(=O)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Lasiolena | Family: N/A | Species: santosii		1	NCGC00168883-03	363676712.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](O)C(C)=C2C(=O)[C@@H]3[C@@](C)(O3)C2[C@H]2OC(=O)C(=C)[C@H]12)/C(=C/C)/COC(=O)C	O=C(O[C@@H]1[C@H](O)C(C)=C2C(=O)[C@@H]3[C@@](C)(O3)C2[C@H]2OC(=O)C(=C)[C@H]12)/C(=C/C)/COC(=O)C
NCGC00347504-02	O=C(O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1)c1c(OC)cc(O)cc1C		Inactive	<MOA Unknown> | Class: nucleoside | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347504-02	363677607.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1)c1c(OC)cc(O)cc1C	O=C(O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1)c1c(OC)cc(O)cc1C
NCGC00347832-02	O=C(O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1)c1c(OC)cc(OC)cc1C		Inactive	<MOA Unknown> | Class: nucleoside | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347832-02	363677701.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1)c1c(OC)cc(OC)cc1C	O=C(O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1)c1c(OC)cc(OC)cc1C
NCGC00169079-02	O=C(O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1cc(O)c(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Scrophularia | Family: Scrophulariaceae | Species: frutescens		1	NCGC00169079-02	363676764.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1cc(O)c(O)cc1	O=C(O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1cc(O)c(O)cc1
NCGC00180408-03	O=C(O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Verbascum | Family: Scrophulariaceae | Species: giganteum		1	NCGC00180408-03	363677018.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccc(O)cc1	O=C(O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccc(O)cc1
NCGC00169017-02	O=C(O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Bussea | Family: Fabaceae | Species: occidentalis		1	NCGC00169017-02	363676744.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccccc1	O=C(O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccccc1
NCGC00380436-01	O=C(O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@]12C(=O)C=C(C)[C@H]1[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)OC=C2)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380436-01	363678582.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@]12C(=O)C=C(C)[C@H]1[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)OC=C2)/C=C/c1ccccc1	O=C(O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@]12C(=O)C=C(C)[C@H]1[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)OC=C2)/C=C/c1ccccc1
NCGC00263874-02	O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](C)[C@H](C)[C@H](CC)OC2OC(C(NC(=O)c2c(C)c(N)nc(C(NCC(N)C(=O)N)CC(=O)N)n2)C(=O)NC(C(O)C(C(=O)NC(C(=O)NCCc2scc(-c3scc(C(=O)NCCCCNC(=N)N)n3)n2)C(O)C)C)C)c2nc[nH]c2)O[C@H](CO)[C@H]1O)N		Inactive			1	BLEOMYCIN (bleomycin B2 shown)	405559102.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](C)[C@H](C)[C@H](CC)OC2OC(C(NC(=O)c2c(C)c(N)nc(C(NCC(N)C(=O)N)CC(=O)N)n2)C(=O)NC(C(O)C(C(=O)NC(C(=O)NCCc2scc(-c3scc(C(=O)NCCCCNC(=N)N)n3)n2)C(O)C)C)C)c2nc[nH]c2)O[C@H](CO)[C@H]1O)N	O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](C)[C@H](C)[C@H](CC)OC2OC(C(NC(=O)c2c(C)c(N)nc(C(NCC(N)C(=O)N)CC(=O)N)n2)C(=O)NC(C(O)C(C(=O)NC(C(=O)NCCc2scc(-c3scc(C(=O)NCCCCNC(=N)N)n3)n2)C(O)C)C)C)c2nc[nH]c2)O[C@H](CO)[C@H]1O)N
NCGC00182036-01	O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](O)[C@H](O)[C@H](CO)O[C@H]2OC(C(NC(=O)c2c(C)c(N)nc(C(NCC(N)C(=O)N)CC(=O)N)n2)C(=O)NC(C(O)C(C(=O)NC(C(=O)NCCc2scc(-c3scc(C(=O)NCCCN[C@@H](C)c4ccccc4)n3)n2)C(O)C)C)C)c2[nH]cnc2)O[C@H](CO)[C@H]1O)N		Inactive			1	Peplomycin sulfate	144206501.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)O.O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](O)[C@H](O)[C@H](CO)O[C@H]2OC(C(NC(=O)c2c(C)c(N)nc(C(NCC(N)C(=O)N)CC(=O)N)n2)C(=O)NC(C(O)C(C(=O)NC(C(=O)NCCc2scc(-c3scc(C(=O)NCCCN[C@@H](C)c4ccccc4)n3)n2)C(O)C)C)C)c2[nH]cnc2)O[C@H](CO)[C@H]1O)N	S(=O)(=O)(O)O.O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@@H](O)[C@H](O)[C@H](CO)O[C@H]2OC(C(NC(=O)c2c(C)c(N)nc(C(NCC(N)C(=O)N)CC(=O)N)n2)C(=O)NC(C(O)C(C(=O)NC(C(=O)NCCc2scc(-c3scc(C(=O)NCCCN[C@@H](C)c4ccccc4)n3)n2)C(O)C)C)C)c2[nH]cnc2)O[C@H](CO)[C@H]1O)N
NCGC00385692-01	O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](OC2C3(C)C(=CCC4C5C(C)(C6C(C)C7(OC6C5)OCC(=C)CC7)CCC34)CC(O)C2)OC1)C(O)C(CC)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385692-01	363679877.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](OC2C3(C)C(=CCC4C5C(C)(C6C(C)C7(OC6C5)OCC(=C)CC7)CCC34)CC(O)C2)OC1)C(O)C(CC)C	O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](OC2C3(C)C(=CCC4C5C(C)(C6C(C)C7(OC6C5)OCC(=C)CC7)CCC34)CC(O)C2)OC1)C(O)C(CC)C
NCGC00385144-01	O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@H](O)CO3)[C@H](C)O2)[C@H](OC(=O)[C@]23[C@H](C=4[C@](C)([C@@]5(C)C([C@]6(C)C([C@@](C=O)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)CO8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@@H]1C)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385144-01	363679557.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@H](O)CO3)[C@H](C)O2)[C@H](OC(=O)[C@]23[C@H](C=4[C@](C)([C@@]5(C)C([C@]6(C)C([C@@](C=O)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)CO8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@@H]1C)C	O=C(O[C@@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@H](O)CO3)[C@H](C)O2)[C@H](OC(=O)[C@]23[C@H](C=4[C@](C)([C@@]5(C)C([C@]6(C)C([C@@](C=O)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)CO8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@@H]1C)C
NCGC00180681-03	O=C(O[C@@H]1[C@H](OC(=O)/C=C/c2cc(O)c(O)cc2)C[C@@](O)(C(=O)O)C[C@H]1O)/C=C/c1cc(O)c(O)cc1		Inactive			1	Isochlorogenic acid C	434147056.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@H](OC(=O)/C=C/c2cc(O)c(O)cc2)C[C@@](O)(C(=O)O)C[C@H]1O)/C=C/c1cc(O)c(O)cc1	O=C(O[C@@H]1[C@H](OC(=O)/C=C/c2cc(O)c(O)cc2)C[C@@](O)(C(=O)O)C[C@H]1O)/C=C/c1cc(O)c(O)cc1
NCGC00168908-03	O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccc(OC)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Verbascum | Family: Scrophulariaceae | Species: giganteum		1	NCGC00168908-03	363676719.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccc(OC)cc1	O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccc(OC)cc1
NCGC00169849-02	O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: verbascum | Family: Scrophulariaceae | Species: virgatum		1	NCGC00169849-02	363676898.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccccc1	O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccccc1
NCGC00380334-01	O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](OC(=O)C)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Scrophularia | Family: Scrophulariaceae | Species: frutescens		1	NCGC00380334-01	363678545.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](OC(=O)C)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccc(O)cc1	O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](OC(=O)C)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccc(O)cc1
NCGC00169427-03	O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Scrophularia | Family: Scrophulariaceae | Species: frutescens		1	NCGC00169427-03	363676816.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccccc1	O=C(O[C@@H]1[C@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](C)O[C@H]1O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccccc1
NCGC00380770-01	O=C(O[C@@H]1[C@H](OC(=O)c2c(OC)cc(O)cc2C)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1)C		Inactive	<MOA Unknown> | Class: nucleoside | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380770-01	363678773.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](OC(=O)c2c(OC)cc(O)cc2C)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1)C	O=C(O[C@@H]1[C@H](OC(=O)c2c(OC)cc(O)cc2C)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1)C
NCGC00180737-03	O=C(O[C@@H]1[C@H](OC(=O)c2c(OC)cc(OC)cc2C)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1)C		Inactive	<MOA Unknown> | Class: nucleoside | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180737-03	363677057.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](OC(=O)c2c(OC)cc(OC)cc2C)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1)C	O=C(O[C@@H]1[C@H](OC(=O)c2c(OC)cc(OC)cc2C)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1)C
NCGC00385326-01	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@H](C)O2)[C@H](OC(=O)[C@@]23[C@H](O)C[C@@]4(C)[C@@]5(C)C([C@]6(C)C([C@@](C=O)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC=C4[C@@H]2CC(C)(C)CC3)O[C@@H]1C)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385326-01	363679679.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@H](C)O2)[C@H](OC(=O)[C@@]23[C@H](O)C[C@@]4(C)[C@@]5(C)C([C@]6(C)C([C@@](C=O)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC=C4[C@@H]2CC(C)(C)CC3)O[C@@H]1C)C	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@H](C)O2)[C@H](OC(=O)[C@@]23[C@H](O)C[C@@]4(C)[C@@]5(C)C([C@]6(C)C([C@@](C=O)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC=C4[C@@H]2CC(C)(C)CC3)O[C@@H]1C)C
NCGC00384886-01	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@H](C)O2)[C@H](OC(=O)[C@]23[C@H](C=4[C@](C)([C@@]5(C)C([C@]6(C)C([C@@](C=O)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@@H]1C)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384886-01	363679416.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	22.566955368	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@H](C)O2)[C@H](OC(=O)[C@]23[C@H](C=4[C@](C)([C@@]5(C)C([C@]6(C)C([C@@](C=O)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@@H]1C)C	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@H](C)O2)[C@H](OC(=O)[C@]23[C@H](C=4[C@](C)([C@@]5(C)C([C@]6(C)C([C@@](C=O)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@@H]1C)C
NCGC00385678-01	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](C)O[C@H]1Oc1c(OC)c2nc3occc3c(OC)c2cc1)C		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385678-01	363679870.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](C)O[C@H]1Oc1c(OC)c2nc3occc3c(OC)c2cc1)C	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](C)O[C@H]1Oc1c(OC)c2nc3occc3c(OC)c2cc1)C
NCGC00384859-01	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](C)O2)[C@H](OC(=O)C23C(O)CC(C)(C)CC2C=2C(C)(C4(C)C(C5(C)C(C(C(=O)O)(C)C(O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O6)C(O)C5)CC4)CC=2)CC3)O[C@@H]1C)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384859-01	363679401.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](C)O2)[C@H](OC(=O)C23C(O)CC(C)(C)CC2C=2C(C)(C4(C)C(C5(C)C(C(C(=O)O)(C)C(O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O6)C(O)C5)CC4)CC=2)CC3)O[C@@H]1C)C	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](C)O2)[C@H](OC(=O)C23C(O)CC(C)(C)CC2C=2C(C)(C4(C)C(C5(C)C(C(C(=O)O)(C)C(O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O6)C(O)C5)CC4)CC=2)CC3)O[C@@H]1C)C
NCGC00385151-01	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](C)O2)[C@H](OC(=O)[C@]23[C@H](C=4[C@](C)([C@@]5(C)C([C@]6(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O7)[C@@H](O)C6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@@H]1C)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385151-01	363679564.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](C)O2)[C@H](OC(=O)[C@]23[C@H](C=4[C@](C)([C@@]5(C)C([C@]6(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O7)[C@@H](O)C6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@@H]1C)C	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](C)O2)[C@H](OC(=O)[C@]23[C@H](C=4[C@](C)([C@@]5(C)C([C@]6(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O7)[C@@H](O)C6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@@H]1C)C
NCGC00384624-01	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](OC(=O)[C@]23[C@H](C=4[C@](C)([C@@]5(C)C([C@]6(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O7)[C@@H](O)C6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@@H]1C)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384624-01	363679280.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](OC(=O)[C@]23[C@H](C=4[C@](C)([C@@]5(C)C([C@]6(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O7)[C@@H](O)C6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@@H]1C)C	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](OC(=O)[C@]23[C@H](C=4[C@](C)([C@@]5(C)C([C@]6(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O7)[C@@H](O)C6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@@H]1C)C
NCGC00385152-01	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](C)O2)[C@H](OC(=O)[C@]23[C@H](C=4[C@](C)([C@@]5(C)C([C@]6(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O7)[C@@H](O)C6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@@H]1C)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385152-01	363679565.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](C)O2)[C@H](OC(=O)[C@]23[C@H](C=4[C@](C)([C@@]5(C)C([C@]6(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O7)[C@@H](O)C6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@@H]1C)C	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@](O)(CO)CO2)[C@@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](C)O2)[C@H](OC(=O)[C@]23[C@H](C=4[C@](C)([C@@]5(C)C([C@]6(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O7)[C@@H](O)C6)CC5)CC=4)CC2)CC(C)(C)CC3)O[C@@H]1C)C
NCGC00384689-01	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)CO7)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Medicago | Family: Fabaceae | Species: marina		1	NCGC00384689-01	363679313.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)CO7)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)CO7)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00024309-17&NCGC00024309-20	O=C(O[C@@H]1[C@H](c2ccc(OC)cc2)Sc2c(N(CCN(C)C)C1=O)cccc2)C		Inactive	Ca2+ channel blocker, similar pharmacology to verapamil		2	(+)-Diltiazem&Diltiazem hydrochloride	170464699.0&384568024.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(O[C@@H]1[C@H](c2ccc(OC)cc2)Sc2c(N(CCN(C)C)C1=O)cccc2)C	O=C(O[C@@H]1[C@H](c2ccc(OC)cc2)Sc2c(N(CCN(C)C)C1=O)cccc2)C
NCGC00384522-02	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\C)/CC2OC(=O)C(=C2)C1)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384522-02	363679228.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\C)/CC2OC(=O)C(=C2)C1)/C(=C\C)/C	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\C)/CC2OC(=O)C(=C2)C1)/C(=C\C)/C
NCGC00384526-01	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\C)/CC2OC(=O)C(=C2)C1)C(=C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384526-01	363679231.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\C)/CC2OC(=O)C(=C2)C1)C(=C)C	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\C)/CC2OC(=O)C(=C2)C1)C(=C)C
NCGC00385206-01	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\CO)/CC/C=C(\C)/C1)C(C(O)CO)=C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Centaurea | Family: Compositae | Species: pumilio		1	NCGC00385206-01	363679594.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\CO)/CC/C=C(\C)/C1)C(C(O)CO)=C	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\CO)/CC/C=C(\C)/C1)C(C(O)CO)=C
NCGC00380889-01	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\CO)/CC/C=C(\C)/C1)C(CO)=C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Centaurea | Family: Compositae | Species: melitensis		1	NCGC00380889-01	363678834.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\CO)/CC/C=C(\C)/C1)C(CO)=C	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\CO)/CC/C=C(\C)/C1)C(CO)=C
NCGC00386023-01	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C/2\CO[C@@H](O)[C@@]3(O[C@@H]3CC\2)C1)C(CO)=C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386023-01	363680066.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	17.3022747199	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C/2\CO[C@@H](O)[C@@]3(O[C@@H]3CC\2)C1)C(CO)=C	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C/2\CO[C@@H](O)[C@@]3(O[C@@H]3CC\2)C1)C(CO)=C
NCGC00380558-01	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2C=C(C)C(O)CC(=O)[C@@](O)(C)C1)C(=C)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Bejaranoa | Family: Asteraceae | Species: semistriata		1	NCGC00380558-01	363678649.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2C=C(C)C(O)CC(=O)[C@@](O)(C)C1)C(=C)C	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2C=C(C)C(O)CC(=O)[C@@](O)(C)C1)C(=C)C
NCGC00180381-03	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2[C@H](O)C(=C)[C@@H]2O[C@@H]2[C@@H]2[C@@](C)(O2)C1)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180381-03	363677015.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2[C@H](O)C(=C)[C@@H]2O[C@@H]2[C@@H]2[C@@](C)(O2)C1)/C(=C\C)/C	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2[C@H](O)C(=C)[C@@H]2O[C@@H]2[C@@H]2[C@@](C)(O2)C1)/C(=C\C)/C
NCGC00168845-02	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2[C@H]2C(=C)[C@@H](O)C[C@H]2C(=C)C1)C(CO)=C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Centaurea | Family: Compositae | Species: salmantica		1	NCGC00168845-02	363676701.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2[C@H]2C(=C)[C@@H](O)C[C@H]2C(=C)C1)C(CO)=C	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2[C@H]2C(=C)[C@@H](O)C[C@H]2C(=C)C1)C(CO)=C
NCGC00169369-02	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2[C@H]2C(=O)CC[C@@H](O)[C@]2(C)C1)C(CO)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Onopordum | Family: Compositae | Species: tauricum		1	NCGC00169369-02	363676807.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2[C@H]2C(=O)CC[C@@H](O)[C@]2(C)C1)C(CO)C	O=C(O[C@@H]1[C@H]2C(=C)C(=O)O[C@@H]2[C@H]2C(=O)CC[C@@H](O)[C@]2(C)C1)C(CO)C
NCGC00385494-01	O=C(O[C@@H]1[C@H]2C(C)(C)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)CC[C@@]32[C@]2([C@H]([C@@]4(C)[C@@](C)([C@H]([C@@H](O)C4)C4(C)OC(C(O)(C)C)CC4)CC2)C1)C3)C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Astrogalus | Family: Fabaceae | Species: asterias		1	NCGC00385494-01	363679773.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2C(C)(C)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)CC[C@@]32[C@]2([C@H]([C@@]4(C)[C@@](C)([C@H]([C@@H](O)C4)C4(C)OC(C(O)(C)C)CC4)CC2)C1)C3)C	O=C(O[C@@H]1[C@H]2C(C)(C)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)CC[C@@]32[C@]2([C@H]([C@@]4(C)[C@@](C)([C@H]([C@@H](O)C4)C4(C)OC(C(O)(C)C)CC4)CC2)C1)C3)C
NCGC00385396-01	O=C(O[C@@H]1[C@H]2[C@@H](C)C(=O)O[C@@H]2C2C(CO)=CC(=O)C2=C(C)C1)Cc1ccc(O)cc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385396-01	363679721.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2[C@@H](C)C(=O)O[C@@H]2C2C(CO)=CC(=O)C2=C(C)C1)Cc1ccc(O)cc1	O=C(O[C@@H]1[C@H]2[C@@H](C)C(=O)O[C@@H]2C2C(CO)=CC(=O)C2=C(C)C1)Cc1ccc(O)cc1
NCGC00386007-01	O=C(O[C@@H]1[C@H]2[C@@H](OC(=O)C)[C@@H]3C(=C)[C@@H](OC(=O)C)CC[C@@]3(C)[C@@H](OC(=O)C)[C@H](OC(=O)C)C(C2(C)C)=C(C)C1)C(CC)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386007-01	363680054.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2[C@@H](OC(=O)C)[C@@H]3C(=C)[C@@H](OC(=O)C)CC[C@@]3(C)[C@@H](OC(=O)C)[C@H](OC(=O)C)C(C2(C)C)=C(C)C1)C(CC)C	O=C(O[C@@H]1[C@H]2[C@@H](OC(=O)C)[C@@H]3C(=C)[C@@H](OC(=O)C)CC[C@@]3(C)[C@@H](OC(=O)C)[C@H](OC(=O)C)C(C2(C)C)=C(C)C1)C(CC)C
NCGC00385618-01	O=C(O[C@@H]1[C@H]2[C@@H](OC)C[C@]3(OC(=O)C)[C@@H]4[C@H](OC)C5[C@]6(COC)CN(CC)[C@H]4[C@]5([C@@H](O)CC6)C(C13)C2)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385618-01	363679841.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2[C@@H](OC)C[C@]3(OC(=O)C)[C@@H]4[C@H](OC)C5[C@]6(COC)CN(CC)[C@H]4[C@]5([C@@H](O)CC6)C(C13)C2)C	O=C(O[C@@H]1[C@H]2[C@@H](OC)C[C@]3(OC(=O)C)[C@@H]4[C@H](OC)C5[C@]6(COC)CN(CC)[C@H]4[C@]5([C@@H](O)CC6)C(C13)C2)C
NCGC00385664-01	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1cc(O)c(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385664-01	363679864.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1cc(O)c(O)cc1	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1cc(O)c(O)cc1
NCGC00180624-03	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1cc(O)c(OC)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Picrorhiza | Family: Scrophulariaceae | Species: kurroa		1	NCGC00180624-03	363677042.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1cc(O)c(OC)cc1	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1cc(O)c(OC)cc1
NCGC00180405-03	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1cc(OC)c(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Picrorhiza | Family: Scrophulariaceae | Species: kurroa		1	NCGC00180405-03	363677017.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1cc(OC)c(O)cc1	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1cc(OC)c(O)cc1
NCGC00347822-02	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Veronica | Family: Scrophulariaceae | Species: anagallis-aquatica		1	NCGC00347822-02	363677697.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccc(O)cc1	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)/C=C/c1ccc(O)cc1
NCGC00347847-02	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)c1cc(O)c(O)cc1		Inactive	<MOA Unknown> | Class: Iridoide | Genus: Veronica | Family: Scrophulariaceae | Species: anagallis-aquatica		1	NCGC00347847-02	363677709.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)c1cc(O)c(O)cc1	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)c1cc(O)c(O)cc1
NCGC00180420-04	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)c1cc(OC)c(O)cc1		Inactive			1	Picroside 2	434147055.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)c1cc(OC)c(O)cc1	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)c1cc(OC)c(O)cc1
NCGC00347848-02	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)c1ccc(O)cc1		Inactive	Peroxisome proliferator-activated receptor alpha Agonist		1	NCGC00347848-02	363677710.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)c1ccc(O)cc1	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)c1ccc(O)cc1
NCGC00385339-01	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)c1ccccc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Veronica | Family: Scrophulariaceae | Species: anagallis-aquatica		1	NCGC00385339-01	363679687.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)c1ccccc1	O=C(O[C@@H]1[C@H]2[C@](CO)(O2)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@H]12)c1ccccc1
NCGC00384641-01	O=C(O[C@@H]1[C@H]2[C@](O)(C(C)C)CC[C@]2(C)[C@H](OC(=O)C)[C@@H]2[C@@](C)(O2)C1)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384641-01	363679290.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@H]2[C@](O)(C(C)C)CC[C@]2(C)[C@H](OC(=O)C)[C@@H]2[C@@](C)(O2)C1)/C(=C\C)/C	O=C(O[C@@H]1[C@H]2[C@](O)(C(C)C)CC[C@]2(C)[C@H](OC(=O)C)[C@@H]2[C@@](C)(O2)C1)/C(=C\C)/C
NCGC00381237-01	O=C(O[C@@H]1[C@](O)(C(=O)/C=C/C)[C@@H](C)C(=O)C[C@H]2C(=C)C(=O)O[C@@H]12)C(CC)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Ajania | Family: N/A | Species: spp		1	NCGC00381237-01	363679042.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@](O)(C(=O)/C=C/C)[C@@H](C)C(=O)C[C@H]2C(=C)C(=O)O[C@@H]12)C(CC)C	O=C(O[C@@H]1[C@](O)(C(=O)/C=C/C)[C@@H](C)C(=O)C[C@H]2C(=C)C(=O)O[C@@H]12)C(CC)C
NCGC00180697-02	O=C(O[C@@H]1[C@](O)(C)CC[C@@H](C(=C)C)C1)c1ccccc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Ferula | Family: N/A | Species: spp		1	NCGC00180697-02	363677050.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@](O)(C)CC[C@@H](C(=C)C)C1)c1ccccc1	O=C(O[C@@H]1[C@](O)(C)CC[C@@H](C(=C)C)C1)c1ccccc1
NCGC00385048-01	O=C(O[C@@H]1[C@]2(C)C(=O)C=C[C@H]2[C@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]12)/C(=C\C)/C	5.1999998	Active	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00385048-01	363679504.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	3.0	90.5343878632	O=C(O[C@@H]1[C@]2(C)C(=O)C=C[C@H]2[C@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]12)/C(=C\C)/C	O=C(O[C@@H]1[C@]2(C)C(=O)C=C[C@H]2[C@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]12)/C(=C\C)/C
NCGC00347858-02	O=C(O[C@@H]1[C@]2(C)C(=O)C=C[C@H]2[C@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]12)C(=C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347858-02	363677713.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@]2(C)C(=O)C=C[C@H]2[C@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]12)C(=C)C	O=C(O[C@@H]1[C@]2(C)C(=O)C=C[C@H]2[C@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]12)C(=C)C
NCGC00347562-02	O=C(O[C@@H]1[C@]2(C)C(=O)C=C[C@H]2[C@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]12)C(C)C	5.1500001	Active	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00347562-02	363677623.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	3.0	85.0550050033	O=C(O[C@@H]1[C@]2(C)C(=O)C=C[C@H]2[C@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]12)C(C)C	O=C(O[C@@H]1[C@]2(C)C(=O)C=C[C@H]2[C@H](C)C[C@H]2OC(=O)[C@@H](C)[C@@H]12)C(C)C
NCGC00180409-03	O=C(O[C@@H]1[C@]2(C)C([C@@H](OC(=O)c3ccc(O)cc3)CC(C)=C1)[C@](O)(C(C)C)CC2)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Ferula | Family: Umbelliferae | Species: communis		1	NCGC00180409-03	363677019.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@]2(C)C([C@@H](OC(=O)c3ccc(O)cc3)CC(C)=C1)[C@](O)(C(C)C)CC2)/C(=C\C)/C	O=C(O[C@@H]1[C@]2(C)C([C@@H](OC(=O)c3ccc(O)cc3)CC(C)=C1)[C@](O)(C(C)C)CC2)/C(=C\C)/C
NCGC00180730-03	O=C(O[C@@H]1[C@]2(C)C3(O)C(C(=O)OC3)=CC[C@H]2C(C)(C)CC1)C(NC(=O)C)C(C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180730-03	363677055.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@]2(C)C3(O)C(C(=O)OC3)=CC[C@H]2C(C)(C)CC1)C(NC(=O)C)C(C)C	O=C(O[C@@H]1[C@]2(C)C3(O)C(C(=O)OC3)=CC[C@H]2C(C)(C)CC1)C(NC(=O)C)C(C)C
NCGC00485121-01	O=C(O[C@@H]1[C@]2(C)[C@@H](C(=O)C)CC[C@H]2[C@H]2[C@@H]([C@]3(C)[C@@H](C[C@H](OC(=O)C)CC3)CC2)C1)C		Inactive			1	3Î±,12Î±-Dihydroxy-5Î²-pregnan-20-one 3,12-diacetate	363681231.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	11.261714284	O=C(O[C@@H]1[C@]2(C)[C@@H](C(=O)C)CC[C@H]2[C@H]2[C@@H]([C@]3(C)[C@@H](C[C@H](OC(=O)C)CC3)CC2)C1)C	O=C(O[C@@H]1[C@]2(C)[C@@H](C(=O)C)CC[C@H]2[C@H]2[C@@H]([C@]3(C)[C@@H](C[C@H](OC(=O)C)CC3)CC2)C1)C
NCGC00380134-01	O=C(O[C@@H]1[C@]2(C)[C@@H](OC(=O)c3cocc3)CCC(O)(C)[C@@]32OC(C)(C)[C@H](C1)C3)c1cocc1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Maytenus | Family: Celastraceae | Species: undata		1	NCGC00380134-01	363678470.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@@H](OC(=O)c3cocc3)CCC(O)(C)[C@@]32OC(C)(C)[C@H](C1)C3)c1cocc1	O=C(O[C@@H]1[C@]2(C)[C@@H](OC(=O)c3cocc3)CCC(O)(C)[C@@]32OC(C)(C)[C@H](C1)C3)c1cocc1
NCGC00167439-03	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3C(=C4C(=CC(=O)CC4)CC3)C=C2)CC1)C		Inactive	Progesterone receptor Binding Agent		1	Trenbolone (acetate)	405558864.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3C(=C4C(=CC(=O)CC4)CC3)C=C2)CC1)C	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3C(=C4C(=CC(=O)CC4)CC3)C=C2)CC1)C
NCGC00181156-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=C(O)C(=O)CC4)CC3)CC2)CC1)CCC1CCCC1		Inactive	Androgen Receptor Agonist		1	Oxabolone cipioncate	144206313.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=C(O)C(=O)CC4)CC3)CC2)CC1)CCC1CCCC1	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=C(O)C(=O)CC4)CC3)CC2)CC1)CCC1CCCC1
NCGC00249920-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCC1CCCCC1		Inactive	Androgen Receptor Agonist		1	Nandrolone cyclohexylpropionate	170465905.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCC1CCCCC1	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCC1CCCCC1
NCGC00159356-02&NCGC00274069-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCc1ccccc1		Inactive	Steroid hormone		2	Nandrolone phenylpropionate&Nandrolone phenpropionate	29215274.0&170465193.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCc1ccccc1	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCc1ccccc1
NCGC00249919-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCc1occc1		Inactive			1	Nandrolone furylpropionate	170465918.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&-12.766194736	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCc1occc1	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)CCc1occc1
NCGC00484057-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@]4(C)C(C)=CC(=O)C[C@@H]4CC3)CC2)CC1)C		Inactive			1	Methenolone (acetate)	363681150.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@]4(C)C(C)=CC(=O)C[C@@H]4CC3)CC2)CC1)C	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@]4(C)C(C)=CC(=O)C[C@@H]4CC3)CC2)CC1)C
NCGC00167979-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@]4(C)C(C)=CC(=O)C[C@@H]4CC3)CC2)CC1)CCCCCC		Inactive			1	Methenolone enanthate	144206153.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@]4(C)C(C)=CC(=O)C[C@@H]4CC3)CC2)CC1)CCCCCC	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@@]4(C)C(C)=CC(=O)C[C@@H]4CC3)CC2)CC1)CCCCCC
NCGC00378669-02	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)C=C4)CC3)CC2)CC1)CCCCCCCCC=C		Inactive			1	Boldenone Undecylenate	405558970.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)C=C4)CC3)CC2)CC1)CCCCCCCCC=C	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)C=C4)CC3)CC2)CC1)CCCCCCCCC=C
NCGC00179602-03	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CC		Inactive	Androgen Receptor Agonist		1	Testosterone propionate	170464835.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CC	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CC
NCGC00181019-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCC(C)C		Inactive			1	Testosterone isocaproate	144206222.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCC(C)C	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCC(C)C
NCGC00346736-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCC1CCCC1		Inactive	Androgen Receptor Activator		1	Testosterone cypionate	174007287.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCC1CCCC1	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCC1CCCC1
NCGC00160513-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCC		Inactive	Androgen Receptor Agonist		1	Testosterone decanoate	144205416.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCC	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCC
NCGC00484056-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCCC		Inactive			1	Testosterone (undecanoate)	405558851.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCCC	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCCCCCCCCC
NCGC00160504-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCc1ccccc1		Inactive			1	Testosterone 17-phenylpropionate	144206667.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCc1ccccc1	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCc1ccccc1
NCGC00507798-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](CC(=O)[C@H](C)C4)CC3)CC2)CC1)CC		Inactive	Androgen Receptor Agonist		1	Drostanolone propionate	405559055.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](CC(=O)[C@H](C)C4)CC3)CC2)CC1)CC	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](CC(=O)[C@H](C)C4)CC3)CC2)CC1)CC
NCGC00166134-02	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCC1CCCC1		Inactive	Androgen Receptor Antagonist		1	Estradiol cypionate	170464789.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCC1CCCC1	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCC1CCCC1
NCGC00018166-02	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCCC		Inactive			1	Estradiol valerate	405558513.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCCC	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCCC
NCGC00188442-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCCCCC		Inactive			1	Estradiol enanthate	144206583.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCCCCC	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1)CCCCCC
NCGC00344540-01	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(OC(=O)CC)cc4)CC3)CC2)CC1)CC		Inactive			1	17-BETA-ESTRADIOL 3,17-DIPROPIONATE	225144386.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(OC(=O)CC)cc4)CC3)CC2)CC1)CC	O=C(O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(OC(=O)CC)cc4)CC3)CC2)CC1)CC
NCGC00385281-01	O=C(O[C@@H]1[C@]2(C)[C@](C)([C@H](OC(=O)C)[C@H]3[C@@H](OC(=O)c4ccccc4)[C@@H](C)C[C@]13O)C[C@@]1(OC(=O)C)C(=O)C(C)(C)C[C@@H]21)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385281-01	363679640.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@]2(C)[C@](C)([C@H](OC(=O)C)[C@H]3[C@@H](OC(=O)c4ccccc4)[C@@H](C)C[C@]13O)C[C@@]1(OC(=O)C)C(=O)C(C)(C)C[C@@H]21)C	O=C(O[C@@H]1[C@]2(C)[C@](C)([C@H](OC(=O)C)[C@H]3[C@@H](OC(=O)c4ccccc4)[C@@H](C)C[C@]13O)C[C@@]1(OC(=O)C)C(=O)C(C)(C)C[C@@H]21)C
NCGC00385378-01	O=C(O[C@@H]1[C@]2(O)O[C@H]3[C@H](O[C@@H]2O[C@H](C)C1)CC1[C@@](C=O)(C2[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC2)CC1)C3)C		Inactive	<MOA Unknown> | Class: Steroid | Genus: Asclepias | Family: Asclepiadaceae | Species: curassavica		1	NCGC00385378-01	363679711.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@]2(O)O[C@H]3[C@H](O[C@@H]2O[C@H](C)C1)CC1[C@@](C=O)(C2[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC2)CC1)C3)C	O=C(O[C@@H]1[C@]2(O)O[C@H]3[C@H](O[C@@H]2O[C@H](C)C1)CC1[C@@](C=O)(C2[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC2)CC1)C3)C
NCGC00381041-01	O=C(O[C@@H]1[C@]23[C@@H](O)O[C@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O)CO9)[C@@H](O)[C@H](O)[C@@H](CO)O8)CO7)CC6)CC5)CC4)C[C@H]2O)C3CC(C)(C)C1)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: anagallis | Family: Primulaceae | Species: monelli		1	NCGC00381041-01	363678939.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@]23[C@@H](O)O[C@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O)CO9)[C@@H](O)[C@H](O)[C@@H](CO)O8)CO7)CC6)CC5)CC4)C[C@H]2O)C3CC(C)(C)C1)C	O=C(O[C@@H]1[C@]23[C@@H](O)O[C@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O)[C@@H](O)[C@H](O)CO9)[C@@H](O)[C@H](O)[C@@H](CO)O8)CO7)CC6)CC5)CC4)C[C@H]2O)C3CC(C)(C)C1)C
NCGC00385970-01	O=C(O[C@@H]1[C@]23[C@H](O)O[C@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@](O)(CO)CO%10)[C@H](O)[C@@H](O)[C@H](C)O9)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC4)C[C@H]2O)C3CC(C)(C)C1)/C=C/CCC		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385970-01	363680035.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@]23[C@H](O)O[C@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@](O)(CO)CO%10)[C@H](O)[C@@H](O)[C@H](C)O9)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC4)C[C@H]2O)C3CC(C)(C)C1)/C=C/CCC	O=C(O[C@@H]1[C@]23[C@H](O)O[C@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@](O)(CO)CO%10)[C@H](O)[C@@H](O)[C@H](C)O9)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC4)C[C@H]2O)C3CC(C)(C)C1)/C=C/CCC
NCGC00381045-01	O=C(O[C@@H]1[C@]23[C@H](O)O[C@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@](O)(CO)CO%10)[C@H](O)[C@@H](O)[C@H](C)O9)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC4)C[C@H]2OC(=O)C)C3CC(C)(C)C1)/C=C/CCC		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381045-01	363678941.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]1[C@]23[C@H](O)O[C@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@](O)(CO)CO%10)[C@H](O)[C@@H](O)[C@H](C)O9)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC4)C[C@H]2OC(=O)C)C3CC(C)(C)C1)/C=C/CCC	O=C(O[C@@H]1[C@]23[C@H](O)O[C@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@](O)(CO)CO%10)[C@H](O)[C@@H](O)[C@H](C)O9)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC4)C[C@H]2OC(=O)C)C3CC(C)(C)C1)/C=C/CCC
NCGC00165752-04	O=C(O[C@@H]1c2c(N(C(=O)N)c3c(cccc3)C1)cccc2)C		Inactive	Sodium channel alpha subunit Antagonist		1	Eslicarbazepine (acetate)	405558796.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]1c2c(N(C(=O)N)c3c(cccc3)C1)cccc2)C	O=C(O[C@@H]1c2c(N(C(=O)N)c3c(cccc3)C1)cccc2)C
NCGC00163424-11	O=C(O[C@@H]\1[C@@H](OC)/C=C\C=C(/C)\C(=O)NC=2C(=O)C(=C(NCC=C)C(=O)C=2)C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C/1\C)N		Inactive	Heat Shock Protein 90 (hsp90) Inhibitor		1	Tanespimycin	384568237.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@H]\1[C@@H](OC)/C=C\C=C(/C)\C(=O)NC=2C(=O)C(=C(NCC=C)C(=O)C=2)C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C/1\C)N	O=C(O[C@@H]\1[C@@H](OC)/C=C\C=C(/C)\C(=O)NC=2C(=O)C(=C(NCC=C)C(=O)C=2)C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C/1\C)N
NCGC00347424-03	O=C(O[C@@H]\1[C@@](O)(C)CC[C@@H](O)CC(=O)O[C@H](/C(=C/C=C/[C@H](C[C@@H]2[C@@H]([C@@H]([C@@H](O)CC)C)O2)C)/C)[C@@H](C)/C=C/1)C		Inactive			1	Pladienolide B	363677601.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@H]\1[C@@](O)(C)CC[C@@H](O)CC(=O)O[C@H](/C(=C/C=C/[C@H](C[C@@H]2[C@@H]([C@@H]([C@@H](O)CC)C)O2)C)/C)[C@@H](C)/C=C/1)C	O=C(O[C@@H]\1[C@@](O)(C)CC[C@@H](O)CC(=O)O[C@H](/C(=C/C=C/[C@H](C[C@@H]2[C@@H]([C@@H]([C@@H](O)CC)C)O2)C)/C)[C@@H](C)/C=C/1)C
NCGC00017048-03	O=C(O[C@@]([C@H](CN(C)C)C)(Cc1ccccc1)c1ccccc1)CC		Inactive	Kappa Opioid Receptor Antagonist		1	Levopropoxyphene napsylate	405558477.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)c1cc2c(cc1)cccc2.O=C(O[C@@]([C@H](CN(C)C)C)(Cc1ccccc1)c1ccccc1)CC	S(=O)(=O)(O)c1cc2c(cc1)cccc2.O=C(O[C@@]([C@H](CN(C)C)C)(Cc1ccccc1)c1ccccc1)CC
NCGC00378913-02	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3C([C@@H](c4ccc(N(C)C)cc4)C2)=C2C(=CC(=O)CC2)CC3)CC1)C		Inactive	Progesterone receptor Modulator		1	Ulipristal	363678273.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3C([C@@H](c4ccc(N(C)C)cc4)C2)=C2C(=CC(=O)CC2)CC3)CC1)C	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3C([C@@H](c4ccc(N(C)C)cc4)C2)=C2C(=CC(=O)CC2)CC3)CC1)C
NCGC00179247-04	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(C(C)=C3)=CC(=O)CC4)CC2)CC1)C		Inactive	Androgen Receptor Antagonist		1	Nomegestrol acetate	405558605.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(C(C)=C3)=CC(=O)CC4)CC2)CC1)C	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(C(C)=C3)=CC(=O)CC4)CC2)CC1)C
NCGC00021268-04	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCCCC	5.0999999	Active		0.0	1	Hydroxyprogesterone caproate	170465210.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	56.3946527502	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCCCC	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CCCCC
NCGC00024196-05&NCGC00024196-12	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(C(C)=C3)=CC(=O)CC4)CC2)CC1)C		Inactive	Progesterone Receptor Antagonist		2	Megestrol acetate	170465406.0&384568021.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&10.570428508	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(C(C)=C3)=CC(=O)CC4)CC2)CC1)C	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(C(C)=C3)=CC(=O)CC4)CC2)CC1)C
NCGC00022037-07&NCGC00263480-01	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C([C@@H](C)C3)=CC(=O)CC4)CC2)CC1)C		Inactive	Progesterone Receptor Agonist		2	Medroxyprogesterone acetate	363676518.0&170464622.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	12.6178582079&0.0	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C([C@@H](C)C3)=CC(=O)CC4)CC2)CC1)C	O=C(O[C@@]1(C(=O)C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C([C@@H](C)C3)=CC(=O)CC4)CC2)CC1)C
NCGC00262960-01	O=C(O[C@@]1(C(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC		Inactive	Glucocorticoid receptor Agonist		1	Resocortol butyrate	170466824.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@]1(C(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC	O=C(O[C@@]1(C(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC
NCGC00346468-03	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CC		Inactive	Androgen Receptor Antagonist		1	17 alpha-propionate	384568787.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CC	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1)CC
NCGC00274077-01	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC		Inactive			1	Hydrocortisone 17-butyrate	170465456.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC
NCGC00024016-03	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCCC		Inactive			1	Hydrocortisone valerate	170464775.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCCC	O=C(O[C@@]1(C(=O)CO)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCCC
NCGC00532510-01	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CCCC		Inactive			1	PREDNISOLONE VALERATE ACETATE	405558610.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CCCC	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)CCCC
NCGC00532512-01	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CC		Inactive			1	HYDROCORTISONE ACEPONATE	405558972.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CC	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CC
NCGC00510142-01	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)CC		Inactive			1	Methylprednisolone aceponate	405558524.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)CC	O=C(O[C@@]1(C(=O)COC(=O)C)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C([C@@H](C)C3)=CC(=O)C=C2)CC1)CC
NCGC00183276-01	O=C(O[C@@]1(C(=O)COC(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC		Inactive			1	Hydrocortisone buteprate	144206491.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@@]1(C(=O)COC(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC	O=C(O[C@@]1(C(=O)COC(=O)CC)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)CCC
NCGC00380166-01	O=C(O[C@@]12[C@@H](c3cc(OC)c(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cc3)OC[C@@H]1[C@@H](c1cc(OC)c(O)cc1)OC2)C		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Jasminum | Family: Oleaceae | Species: sambac		1	NCGC00380166-01	363678484.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@@]12[C@@H](c3cc(OC)c(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cc3)OC[C@@H]1[C@@H](c1cc(OC)c(O)cc1)OC2)C	O=C(O[C@@]12[C@@H](c3cc(OC)c(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)cc3)OC[C@@H]1[C@@H](c1cc(OC)c(O)cc1)OC2)C
NCGC00385192-01	O=C(O[C@H]1/C(/C)=C/C2[C@@H](OC(=O)c3ccccc3)[C@H](C)C[C@]2(O)C(=O)/C(/C)=C/C2C(C)(C)C2C1)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385192-01	363679588.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	13.5	O=C(O[C@H]1/C(/C)=C/C2[C@@H](OC(=O)c3ccccc3)[C@H](C)C[C@]2(O)C(=O)/C(/C)=C/C2C(C)(C)C2C1)C	O=C(O[C@H]1/C(/C)=C/C2[C@@H](OC(=O)c3ccccc3)[C@H](C)C[C@]2(O)C(=O)/C(/C)=C/C2C(C)(C)C2C1)C
NCGC00385054-01	O=C(O[C@H]1C(=C)CC[C@@H]2C(C)(C)[C@@H]2/C=C(\C)/C(=O)[C@]2(OC(=O)C)[C@@H]1[C@@H](OC(=O)c1ccccc1)[C@@H](C)C2)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385054-01	363679509.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1C(=C)CC[C@@H]2C(C)(C)[C@@H]2/C=C(\C)/C(=O)[C@]2(OC(=O)C)[C@@H]1[C@@H](OC(=O)c1ccccc1)[C@@H](C)C2)C	O=C(O[C@H]1C(=C)CC[C@@H]2C(C)(C)[C@@H]2/C=C(\C)/C(=O)[C@]2(OC(=O)C)[C@@H]1[C@@H](OC(=O)c1ccccc1)[C@@H](C)C2)C
NCGC00380860-01	O=C(O[C@H]1C(=C)[C@@H]2C[C@@]31C([C@@]1(C)C([C@@](C(=O)O)(C)CCC1)CC3)CC2)C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Elaeoselinum | Family: Apiaceae | Species: foetidum		1	NCGC00380860-01	363678819.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1C(=C)[C@@H]2C[C@@]31C([C@@]1(C)C([C@@](C(=O)O)(C)CCC1)CC3)CC2)C	O=C(O[C@H]1C(=C)[C@@H]2C[C@@]31C([C@@]1(C)C([C@@](C(=O)O)(C)CCC1)CC3)CC2)C
NCGC00169732-02	O=C(O[C@H]1C(=C)[C@@H]2C[C@@]31[C@](O)([C@@]1(C)[C@@H]([C@@](C(=O)O)(C)CCC1)CC3)CC2)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Aspilia | Family: Compositae | Species: mossambicensis		1	NCGC00169732-02	363676879.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1C(=C)[C@@H]2C[C@@]31[C@](O)([C@@]1(C)[C@@H]([C@@](C(=O)O)(C)CCC1)CC3)CC2)/C(=C\C)/C	O=C(O[C@H]1C(=C)[C@@H]2C[C@@]31[C@](O)([C@@]1(C)[C@@H]([C@@](C(=O)O)(C)CCC1)CC3)CC2)/C(=C\C)/C
NCGC00378324-03	O=C(O[C@H]1C(=O)O[C@H]2[C@@]34[C@@H]1[C@@](C(=O)OC)([C@@H](O)[C@H](O)[C@@H]3[C@]1(C)[C@H](C(C)=C(O)C(=O)C1)C2)OC4)/C=C(/C(C)C)\C	6.0999999	Inactive	MYC Expression Inhibitor;Apoptosis Inducers	0.0	1	Bruceantin	384569047.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	5.0	-94.6600189574	O=C(O[C@H]1C(=O)O[C@H]2[C@@]34[C@@H]1[C@@](C(=O)OC)([C@@H](O)[C@H](O)[C@@H]3[C@]1(C)[C@H](C(C)=C(O)C(=O)C1)C2)OC4)/C=C(/C(C)C)\C	O=C(O[C@H]1C(=O)O[C@H]2[C@@]34[C@@H]1[C@@](C(=O)OC)([C@@H](O)[C@H](O)[C@@H]3[C@]1(C)[C@H](C(C)=C(O)C(=O)C1)C2)OC4)/C=C(/C(C)C)\C
NCGC00183831-01	O=C(O[C@H]1C(=O)O[C@H]2[C@H](OC(=O)C)C(=O)O[C@@H]12)C		Inactive			1	Aceglatone	144206883.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1C(=O)O[C@H]2[C@H](OC(=O)C)C(=O)O[C@@H]12)C	O=C(O[C@H]1C(=O)O[C@H]2[C@H](OC(=O)C)C(=O)O[C@@H]12)C
NCGC00384655-01	O=C(O[C@H]1C(=O)[C@]2(C)C(O)C[C@@H]3[C@](OC(=O)C)([C@H]2[C@H](OC(=O)c2ccccc2)[C@@]2(O)C(C)(C)C1=C(C)[C@@H](O)C2)CO3)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384655-01	363679294.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1C(=O)[C@]2(C)C(O)C[C@@H]3[C@](OC(=O)C)([C@H]2[C@H](OC(=O)c2ccccc2)[C@@]2(O)C(C)(C)C1=C(C)[C@@H](O)C2)CO3)C	O=C(O[C@H]1C(=O)[C@]2(C)C(O)C[C@@H]3[C@](OC(=O)C)([C@H]2[C@H](OC(=O)c2ccccc2)[C@@]2(O)C(C)(C)C1=C(C)[C@@H](O)C2)CO3)C
NCGC00384505-01	O=C(O[C@H]1C(C)(C)C2C3C(=O)C=C(C)C2C3(C)[C@H](OC(=O)CC(C)C)C1)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384505-01	363679219.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1C(C)(C)C2C3C(=O)C=C(C)C2C3(C)[C@H](OC(=O)CC(C)C)C1)/C(=C\C)/C	O=C(O[C@H]1C(C)(C)C2C3C(=O)C=C(C)C2C3(C)[C@H](OC(=O)CC(C)C)C1)/C(=C\C)/C
NCGC00385486-01	O=C(O[C@H]1C(C)(C)C2C3C(=O)C=C(C)C2[C@@]3(C)[C@H](OC(=O)/C(=C\C)/C)C1)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Stevia | Family: N/A | Species: polycephala		1	NCGC00385486-01	363679768.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1C(C)(C)C2C3C(=O)C=C(C)C2[C@@]3(C)[C@H](OC(=O)/C(=C\C)/C)C1)/C(=C\C)/C	O=C(O[C@H]1C(C)(C)C2C3C(=O)C=C(C)C2[C@@]3(C)[C@H](OC(=O)/C(=C\C)/C)C1)/C(=C\C)/C
NCGC00380726-01	O=C(O[C@H]1C(C)(C)C2[C@@](C)(C3([C@H](C)CC2)Oc2c(c(O)cc4C(=O)NCc24)C3)CC1O)C		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380726-01	363678740.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1C(C)(C)C2[C@@](C)(C3([C@H](C)CC2)Oc2c(c(O)cc4C(=O)NCc24)C3)CC1O)C	O=C(O[C@H]1C(C)(C)C2[C@@](C)(C3([C@H](C)CC2)Oc2c(c(O)cc4C(=O)NCc24)C3)CC1O)C
NCGC00381452-01	O=C(O[C@H]1C(C)(C)C2[C@H]3OC(=O)[C@]2(C2[C@](C)([C@@]4(C(=O)OC)C(O)=C(C)C(=O)[C@@]4(C)C(C)=C2)C3)CC1)C		Inactive	<MOA Unknown> | Class: sesterterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381452-01	363679148.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1C(C)(C)C2[C@H]3OC(=O)[C@]2(C2[C@](C)([C@@]4(C(=O)OC)C(O)=C(C)C(=O)[C@@]4(C)C(C)=C2)C3)CC1)C	O=C(O[C@H]1C(C)(C)C2[C@H]3OC(=O)[C@]2(C2[C@](C)([C@@]4(C(=O)OC)C(O)=C(C)C(=O)[C@@]4(C)C(C)=C2)C3)CC1)C
NCGC00380242-01	O=C(O[C@H]1C(C)(C)C2[C@](C)([C@@H](OC(=O)C)C1)C1[C@@](C)([C@H](O)C2)[C@]23[C@](C)([C@H](C=4C(O)OC(=O)C=4)C[C@H]2O3)CC1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Trichilia | Family: Meliaceae | Species: cf. oerstediana		1	NCGC00380242-01	363678512.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1C(C)(C)C2[C@](C)([C@@H](OC(=O)C)C1)C1[C@@](C)([C@H](O)C2)[C@]23[C@](C)([C@H](C=4C(O)OC(=O)C=4)C[C@H]2O3)CC1)C	O=C(O[C@H]1C(C)(C)C2[C@](C)([C@@H](OC(=O)C)C1)C1[C@@](C)([C@H](O)C2)[C@]23[C@](C)([C@H](C=4C(O)OC(=O)C=4)C[C@H]2O3)CC1)C
NCGC00385727-01	O=C(O[C@H]1C(C)(C)[C@H](CC(=O)OC)[C@]2(C)C(=O)C1CC1=C3[C@](C)([C@H](c4cocc4)OC(=O)C3)CCC21)C(C)C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Crinum | Family: Amaryllidaceae | Species: jagus		1	NCGC00385727-01	363679902.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1C(C)(C)[C@H](CC(=O)OC)[C@]2(C)C(=O)C1CC1=C3[C@](C)([C@H](c4cocc4)OC(=O)C3)CCC21)C(C)C	O=C(O[C@H]1C(C)(C)[C@H](CC(=O)OC)[C@]2(C)C(=O)C1CC1=C3[C@](C)([C@H](c4cocc4)OC(=O)C3)CCC21)C(C)C
NCGC00380937-01	O=C(O[C@H]1C(C)(C)[C@H](CC(=O)OC)[C@]2(C)C(=O)[C@@]1(O)[C@H]1O[C@@]31C1[C@](C)([C@H](c4cocc4)OC(=O)C1)CCC23)C(C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380937-01	363678869.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1C(C)(C)[C@H](CC(=O)OC)[C@]2(C)C(=O)[C@@]1(O)[C@H]1O[C@@]31C1[C@](C)([C@H](c4cocc4)OC(=O)C1)CCC23)C(C)C	O=C(O[C@H]1C(C)(C)[C@H](CC(=O)OC)[C@]2(C)C(=O)[C@@]1(O)[C@H]1O[C@@]31C1[C@](C)([C@H](c4cocc4)OC(=O)C1)CCC23)C(C)C
NCGC00390251-01	O=C(O[C@H]1C(O)[C@H](OC(=O)/C=C/c2cc(O)c(O)cc2)CC(O)(C(=O)O)C1)/C=C/c1cc(O)c(O)cc1		Inactive			1	Isochlorogenic acid A	434147139.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1C(O)[C@H](OC(=O)/C=C/c2cc(O)c(O)cc2)CC(O)(C(=O)O)C1)/C=C/c1cc(O)c(O)cc1	O=C(O[C@H]1C(O)[C@H](OC(=O)/C=C/c2cc(O)c(O)cc2)CC(O)(C(=O)O)C1)/C=C/c1cc(O)c(O)cc1
NCGC00385198-01	O=C(O[C@H]1C([C@@H](CCCO)C)=C(C)C[C@@H]2OC(=O)[C@@]3([C@@H]4[C@@H](OC(=O)C)[C@@]5([C@H](C)C[C@H]6OC(=O)C(=C)[C@@H]6CC5=C4C)C3)[C@H]12)C(CC)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385198-01	363679591.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1C([C@@H](CCCO)C)=C(C)C[C@@H]2OC(=O)[C@@]3([C@@H]4[C@@H](OC(=O)C)[C@@]5([C@H](C)C[C@H]6OC(=O)C(=C)[C@@H]6CC5=C4C)C3)[C@H]12)C(CC)C	O=C(O[C@H]1C([C@@H](CCCO)C)=C(C)C[C@@H]2OC(=O)[C@@]3([C@@H]4[C@@H](OC(=O)C)[C@@]5([C@H](C)C[C@H]6OC(=O)C(=C)[C@@H]6CC5=C4C)C3)[C@H]12)C(CC)C
NCGC00178357-03	O=C(O[C@H]1C(n2c3ncnc(NC(=O)CCC)c3nc2)O[C@H]2[C@H]1OP(=O)(O)OC2)CCC		Inactive			1	BUCLADESINE	405558832.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1C(n2c3ncnc(NC(=O)CCC)c3nc2)O[C@H]2[C@H]1OP(=O)(O)OC2)CCC	O=C(O[C@H]1C(n2c3ncnc(NC(=O)CCC)c3nc2)O[C@H]2[C@H]1OP(=O)(O)OC2)CCC
NCGC00385467-01	O=C(O[C@H]1C2(OC(=O)C)[C@H](OC(=O)C)C(C)([C@@H](OC(=O)C)[C@]3(O)[C@@H]1[C@@H](OC(=O)c1ccccc1)[C@@H](C)C3)[C@@H]1[C@H](C(=O)C(C)(C)C1)C2)COC(=O)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385467-01	363679756.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1C2(OC(=O)C)[C@H](OC(=O)C)C(C)([C@@H](OC(=O)C)[C@]3(O)[C@@H]1[C@@H](OC(=O)c1ccccc1)[C@@H](C)C3)[C@@H]1[C@H](C(=O)C(C)(C)C1)C2)COC(=O)C	O=C(O[C@H]1C2(OC(=O)C)[C@H](OC(=O)C)C(C)([C@@H](OC(=O)C)[C@]3(O)[C@@H]1[C@@H](OC(=O)c1ccccc1)[C@@H](C)C3)[C@@H]1[C@H](C(=O)C(C)(C)C1)C2)COC(=O)C
NCGC00179819-03	O=C(O[C@H]1C2C(=C)C(=O)O[C@@H]2[C@H]2[C@H](C)C(=O)C[C@H]2C(=C)C1)/C(=C/CO)/COC(=O)/C(=C/CO)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Centaurea | Family: N/A | Species: spp		1	NCGC00179819-03	363676975.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1C2C(=C)C(=O)O[C@@H]2[C@H]2[C@H](C)C(=O)C[C@H]2C(=C)C1)/C(=C/CO)/COC(=O)/C(=C/CO)/C	O=C(O[C@H]1C2C(=C)C(=O)O[C@@H]2[C@H]2[C@H](C)C(=O)C[C@H]2C(=C)C1)/C(=C/CO)/COC(=O)/C(=C/CO)/C
NCGC00169111-03	O=C(O[C@H]1C2C(C)(C)CCC[C@]2(C)[C@@](O)(CCC2=CC(=O)OC2)[C@H](C)C1)C		Inactive	K562 Inhibitor		1	NCGC00169111-03	363676775.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1C2C(C)(C)CCC[C@]2(C)[C@@](O)(CCC2=CC(=O)OC2)[C@H](C)C1)C	O=C(O[C@H]1C2C(C)(C)CCC[C@]2(C)[C@@](O)(CCC2=CC(=O)OC2)[C@H](C)C1)C
NCGC00380384-01	O=C(O[C@H]1C2C(C)(C)CCC[C@]2(C)[C@@]2(O)C(=O)OCC2=C1)/C=C/C=C/C(=O)O		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380384-01	363678561.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1C2C(C)(C)CCC[C@]2(C)[C@@]2(O)C(=O)OCC2=C1)/C=C/C=C/C(=O)O	O=C(O[C@H]1C2C(C)(C)CCC[C@]2(C)[C@@]2(O)C(=O)OCC2=C1)/C=C/C=C/C(=O)O
NCGC00169179-04	O=C(O[C@H]1C2C(C)(C)CCC[C@]2(C)[C@@]2(O)C(=O)OCC2=C1)/C=C/C=C/C(O)C(O)C		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: Aspergillus ? | Family: N/A | Species: N/A		1	NCGC00169179-04	363676785.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1C2C(C)(C)CCC[C@]2(C)[C@@]2(O)C(=O)OCC2=C1)/C=C/C=C/C(O)C(O)C	O=C(O[C@H]1C2C(C)(C)CCC[C@]2(C)[C@@]2(O)C(=O)OCC2=C1)/C=C/C=C/C(O)C(O)C
NCGC00016094-10	O=C(O[C@H]1C=2[C@@]3(C)[C@@H](COC)OC(=O)c4c3c(C(=O)C=2C2[C@@](C)(C(=O)CC2)C1)oc4)C		Inactive	PI3K Inhibitor		1	17_-hydroxy Wortmannin	384567920.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1C=2[C@@]3(C)[C@@H](COC)OC(=O)c4c3c(C(=O)C=2C2[C@@](C)(C(=O)CC2)C1)oc4)C	O=C(O[C@H]1C=2[C@@]3(C)[C@@H](COC)OC(=O)c4c3c(C(=O)C=2C2[C@@](C)(C(=O)CC2)C1)oc4)C
NCGC00345783-02	O=C(O[C@H]1C=2[C@@]3(C)[C@@H](COC)OC(=O)c4c3c(C(=O)C=2[C@H]2[C@@](C)([C@@H](O)CC2)C1)oc4)C		Inactive	PI3K Inhibitor		1	17-hydroxy Wortmannin	384568739.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1C=2[C@@]3(C)[C@@H](COC)OC(=O)c4c3c(C(=O)C=2[C@H]2[C@@](C)([C@@H](O)CC2)C1)oc4)C	O=C(O[C@H]1C=2[C@@]3(C)[C@@H](COC)OC(=O)c4c3c(C(=O)C=2[C@H]2[C@@](C)([C@@H](O)CC2)C1)oc4)C
NCGC00182606-01	O=C(O[C@H]1CC(C)(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=CC=2C(C)(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC=2C)\C)\C)/C)/C)=C(C)C1)CCCCCCCCCCCCCCC		Inactive			1	Physalien	144206657.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1CC(C)(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=CC=2C(C)(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC=2C)\C)\C)/C)/C)=C(C)C1)CCCCCCCCCCCCCCC	O=C(O[C@H]1CC(C)(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=CC=2C(C)(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC=2C)\C)\C)/C)/C)=C(C)C1)CCCCCCCCCCCCCCC
NCGC00378682-03	O=C(O[C@H]1CN2C(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(OCc4ccccc4)cc3)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc3c4c([nH]c3)cccc4)NC(=O)[C@H](c3ccccc3)NC(=O)[C@@H]2C1)NCCN		Inactive	Somatostatin receptor 5 Agonist		1	Pasireotide (ditrifluoroacetate)	405558784.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1CN2C(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(OCc4ccccc4)cc3)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc3c4c([nH]c3)cccc4)NC(=O)[C@H](c3ccccc3)NC(=O)[C@@H]2C1)NCCN	O=C(O[C@H]1CN2C(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](Cc3ccc(OCc4ccccc4)cc3)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc3c4c([nH]c3)cccc4)NC(=O)[C@H](c3ccccc3)NC(=O)[C@@H]2C1)NCCN
NCGC00385049-01	O=C(O[C@H]1[C@@H](C(C)C)[C@@H](O)[C@@H]2[C@@](C)(O2)CC/C=C(\C)/C1)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Echinacea | Family: Asteraceae | Species: angustifolia		1	NCGC00385049-01	363679505.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](C(C)C)[C@@H](O)[C@@H]2[C@@](C)(O2)CC/C=C(\C)/C1)/C=C/c1ccccc1	O=C(O[C@H]1[C@@H](C(C)C)[C@@H](O)[C@@H]2[C@@](C)(O2)CC/C=C(\C)/C1)/C=C/c1ccccc1
NCGC00386061-01	O=C(O[C@H]1[C@@H](C(O)(C)C)O[C@@H]2C([C@@]3(O)[C@@](C)([C@]4(C)[C@H](Cc5c6c([nH]c45)cccc6)CC3)CC2)=C1)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386061-01	363680086.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](C(O)(C)C)O[C@@H]2C([C@@]3(O)[C@@](C)([C@]4(C)[C@H](Cc5c6c([nH]c45)cccc6)CC3)CC2)=C1)C	O=C(O[C@H]1[C@@H](C(O)(C)C)O[C@@H]2C([C@@]3(O)[C@@](C)([C@]4(C)[C@H](Cc5c6c([nH]c45)cccc6)CC3)CC2)=C1)C
NCGC00384679-01	O=C(O[C@H]1[C@@H](C)/C=C/C(C)(C)[C@H](OC(=O)C)C[C@@H](OC(=O)C)/C(/C)=C/[C@H]2[C@@H](OC(=O)c3ccccc3)[C@@H](C)C[C@]12O)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384679-01	363679304.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](C)/C=C/C(C)(C)[C@H](OC(=O)C)C[C@@H](OC(=O)C)/C(/C)=C/[C@H]2[C@@H](OC(=O)c3ccccc3)[C@@H](C)C[C@]12O)C	O=C(O[C@H]1[C@@H](C)/C=C/C(C)(C)[C@H](OC(=O)C)C[C@@H](OC(=O)C)/C(/C)=C/[C@H]2[C@@H](OC(=O)c3ccccc3)[C@@H](C)C[C@]12O)C
NCGC00385055-01	O=C(O[C@H]1[C@@H](C)C[C@]2(OC(=O)C)C(=O)/C(/C)=C/[C@H]3C(C)(C)[C@H]3CCC(=C)[C@H](OC(=O)C)[C@@H]12)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385055-01	363679510.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](C)C[C@]2(OC(=O)C)C(=O)/C(/C)=C/[C@H]3C(C)(C)[C@H]3CCC(=C)[C@H](OC(=O)C)[C@@H]12)C	O=C(O[C@H]1[C@@H](C)C[C@]2(OC(=O)C)C(=O)/C(/C)=C/[C@H]3C(C)(C)[C@H]3CCC(=C)[C@H](OC(=O)C)[C@@H]12)C
NCGC00161626-04	O=C(O[C@H]1[C@@H](C)C[C@]2(OC(=O)C)C(=O)/C(/C)=C/[C@H]3C(C)(C)[C@H]3CC[C@@]3([C@@H](OC(=O)C)[C@@H]12)OC3)Cc1ccccc1		Inactive			1	Euphobiasteroid	434147012.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@@H](C)C[C@]2(OC(=O)C)C(=O)/C(/C)=C/[C@H]3C(C)(C)[C@H]3CC[C@@]3([C@@H](OC(=O)C)[C@@H]12)OC3)Cc1ccccc1	O=C(O[C@H]1[C@@H](C)C[C@]2(OC(=O)C)C(=O)/C(/C)=C/[C@H]3C(C)(C)[C@H]3CC[C@@]3([C@@H](OC(=O)C)[C@@H]12)OC3)Cc1ccccc1
NCGC00380458-01	O=C(O[C@H]1[C@@H](C)C[C@]2(OC(=O)C)C(=O)[C@]3(C)[C@](C)([C@H](OC(=O)C)[C@@H]12)C(=O)[C@H]1[C@@H](OC(=O)C)C(C)(C)C[C@@H]31)CCC		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380458-01	363678596.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](C)C[C@]2(OC(=O)C)C(=O)[C@]3(C)[C@](C)([C@H](OC(=O)C)[C@@H]12)C(=O)[C@H]1[C@@H](OC(=O)C)C(C)(C)C[C@@H]31)CCC	O=C(O[C@H]1[C@@H](C)C[C@]2(OC(=O)C)C(=O)[C@]3(C)[C@](C)([C@H](OC(=O)C)[C@@H]12)C(=O)[C@H]1[C@@H](OC(=O)C)C(C)(C)C[C@@H]31)CCC
NCGC00385361-01	O=C(O[C@H]1[C@@H](C)OC(=O)c2c(O)cc3O[C@@]4(C)[C@@H](O)C[C@H]5C(C)(C)C(=O)C=C[C@]5(C)[C@@H]4Cc3c12)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385361-01	363679701.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](C)OC(=O)c2c(O)cc3O[C@@]4(C)[C@@H](O)C[C@H]5C(C)(C)C(=O)C=C[C@]5(C)[C@@H]4Cc3c12)C	O=C(O[C@H]1[C@@H](C)OC(=O)c2c(O)cc3O[C@@]4(C)[C@@H](O)C[C@H]5C(C)(C)C(=O)C=C[C@]5(C)[C@@H]4Cc3c12)C
NCGC00182708-01	O=C(O[C@H]1[C@@H](N2CC[N+](C)(C)CC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CC[N+](C)(C)CC4)C3)CC[C@@H]21)C		Inactive	Muscle-type nicotinic acetylcholine receptor Antagonist		1	Pipecuronium bromide	144206565.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@@H](N2CC[N+](C)(C)CC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CC[N+](C)(C)CC4)C3)CC[C@@H]21)C.[Br-].[Br-]	O=C(O[C@H]1[C@@H](N2CC[N+](C)(C)CC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CC[N+](C)(C)CC4)C3)CC[C@@H]21)C.[Br-].[Br-]
NCGC00381330-01	O=C(O[C@H]1[C@@H](O)[C@@H](N2C(=O)NC(=O)C=C2)O[C@@H]1CO)c1c(OC)cc(O)cc1C		Inactive	<MOA Unknown> | Class: nucleoside | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381330-01	363679091.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](O)[C@@H](N2C(=O)NC(=O)C=C2)O[C@@H]1CO)c1c(OC)cc(O)cc1C	O=C(O[C@H]1[C@@H](O)[C@@H](N2C(=O)NC(=O)C=C2)O[C@@H]1CO)c1c(OC)cc(O)cc1C
NCGC00381289-01	O=C(O[C@H]1[C@@H](O)[C@@H]2C(C(=O)OC)=CO[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H]2[C@H]1C)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381289-01	363679070.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](O)[C@@H]2C(C(=O)OC)=CO[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H]2[C@H]1C)/C=C/c1ccccc1	O=C(O[C@H]1[C@@H](O)[C@@H]2C(C(=O)OC)=CO[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H]2[C@H]1C)/C=C/c1ccccc1
NCGC00024996-10	O=C(O[C@H]1[C@@H](O)[C@@H]2[C@](C)([C@@H](O)CCC2(C)C)[C@]2(O)[C@]1(C)O[C@](C=C)(C)CC2=O)C		Inactive			1	Forskolin		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](O)[C@@H]2[C@](C)([C@@H](O)CCC2(C)C)[C@]2(O)[C@]1(C)O[C@](C=C)(C)CC2=O)C	O=C(O[C@H]1[C@@H](O)[C@@H]2[C@](C)([C@@H](O)CCC2(C)C)[C@]2(O)[C@]1(C)O[C@](C=C)(C)CC2=O)C
NCGC00347813-02	O=C(O[C@H]1[C@@H](O)[C@H](N2C(=O)NC(=O)C=C2)O[C@@H]1CO)c1c(OC)cc(OC)cc1C		Inactive	<MOA Unknown> | Class: nucleoside | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347813-02	363677695.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](O)[C@H](N2C(=O)NC(=O)C=C2)O[C@@H]1CO)c1c(OC)cc(OC)cc1C	O=C(O[C@H]1[C@@H](O)[C@H](N2C(=O)NC(=O)C=C2)O[C@@H]1CO)c1c(OC)cc(OC)cc1C
NCGC00169121-02	O=C(O[C@H]1[C@@H](O)[C@H](O)C[C@](O)(C(=O)O)C1)/C=C/c1cc(O)c(O)cc1		Inactive			1	Neochlorogenic acid	434147044.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@@H](O)[C@H](O)C[C@](O)(C(=O)O)C1)/C=C/c1cc(O)c(O)cc1	O=C(O[C@H]1[C@@H](O)[C@H](O)C[C@](O)(C(=O)O)C1)/C=C/c1cc(O)c(O)cc1
NCGC00168971-02	O=C(O[C@H]1[C@@H](O)[C@H](O)C[C@](O)(C(=O)O)C1)/C=C/c1cc(OC)c(O)cc1		Inactive	Influenza A virus (H5N1) Inhibitor		1	NCGC00168971-02	363676732.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](O)[C@H](O)C[C@](O)(C(=O)O)C1)/C=C/c1cc(OC)c(O)cc1	O=C(O[C@H]1[C@@H](O)[C@H](O)C[C@](O)(C(=O)O)C1)/C=C/c1cc(OC)c(O)cc1
NCGC00384821-01	O=C(O[C@H]1[C@@H](O)[C@H](O)C[C@](O)(C(=O)O)C1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Zanthoxylum | Family: Rutaceae | Species: usambarense		1	NCGC00384821-01	363679377.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](O)[C@H](O)C[C@](O)(C(=O)O)C1)/C=C/c1ccc(O)cc1	O=C(O[C@H]1[C@@H](O)[C@H](O)C[C@](O)(C(=O)O)C1)/C=C/c1ccc(O)cc1
NCGC00384692-01	O=C(O[C@H]1[C@@H](O)[C@H](OC2C3C(CO)(O3)C3C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=CC23)O[C@@H](C)[C@@H]1O)/C=C/c1cc(OC)c(OC)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384692-01	363679315.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](O)[C@H](OC2C3C(CO)(O3)C3C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=CC23)O[C@@H](C)[C@@H]1O)/C=C/c1cc(OC)c(OC)cc1	O=C(O[C@H]1[C@@H](O)[C@H](OC2C3C(CO)(O3)C3C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=CC23)O[C@@H](C)[C@@H]1O)/C=C/c1cc(OC)c(OC)cc1
NCGC00168892-03	O=C(O[C@H]1[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@@H](C)[C@@H]1O)/C=C/c1cc(O)c(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Scrophularia | Family: Scrophulariaceae | Species: frutescens		1	NCGC00168892-03	363676715.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@@H](C)[C@@H]1O)/C=C/c1cc(O)c(O)cc1	O=C(O[C@H]1[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@@H](C)[C@@H]1O)/C=C/c1cc(O)c(O)cc1
NCGC00169094-03	O=C(O[C@H]1[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@@H](C)[C@@H]1O)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Salvia | Family: Labiatae | Species: sp.		1	NCGC00169094-03	363676770.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@@H](C)[C@@H]1O)/C=C/c1ccccc1	O=C(O[C@H]1[C@@H](O)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@@H](C)[C@@H]1O)/C=C/c1ccccc1
NCGC00178810-03	O=C(O[C@H]1[C@@H](O)[C@H](Oc2c(C)c3OC(=O)C(NC(=O)c4cc(C/C=C(\C)/C)c(O)cc4)C(=O)c3cc2)OC(C)(C)[C@@H]1OC)N		Inactive	Heat Shock Protein 90 (hsp90) Inhibitor		1	Novobiocin sodium	170465360.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@@H](O)[C@H](Oc2c(C)c3OC(=O)C(NC(=O)c4cc(C/C=C(\C)/C)c(O)cc4)=C([O-])c3cc2)OC(C)(C)[C@@H]1OC)N.[Na+]	O=C(O[C@H]1[C@@H](O)[C@H](Oc2c(C)c3OC(=O)C(NC(=O)c4cc(C/C=C(\C)/C)c(O)cc4)=C([O-])c3cc2)OC(C)(C)[C@@H]1OC)N.[Na+]
NCGC00161630-03	O=C(O[C@H]1[C@@H](O)[C@H](Oc2c(C)c3OC(=O)C(NC(=O)c4cc(CC=C(C)C)c(O)cc4)C(=O)c3cc2)OC(C)(C)[C@@H]1OC)N		Inactive	Heat Shock Protein 90 (hsp90) Inhibitor		1	Novobiocin sodium	384568212.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@@H](O)[C@H](Oc2c(C)c3OC(=O)C(NC(=O)c4cc(CC=C(C)C)c([O-])cc4)=C(O)c3cc2)OC(C)(C)[C@@H]1OC)N	O=C(O[C@H]1[C@@H](O)[C@H](Oc2c(C)c3OC(=O)C(NC(=O)c4cc(CC=C(C)C)c([O-])cc4)=C(O)c3cc2)OC(C)(C)[C@@H]1OC)N
NCGC00485529-01	O=C(O[C@H]1[C@@H](O)[C@H]2C(C)(C)CCC[C@]2(C)C2[C@]1(C)O[C@](C=C)(C)CC2=O)C		Inactive	Voltage-gated calcium channel Blocker		1	1,9-Dideoxyforskolin from Coleus forskohlii	363681362.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](O)[C@H]2C(C)(C)CCC[C@]2(C)C2[C@]1(C)O[C@](C=C)(C)CC2=O)C	O=C(O[C@H]1[C@@H](O)[C@H]2C(C)(C)CCC[C@]2(C)C2[C@]1(C)O[C@](C=C)(C)CC2=O)C
NCGC00381135-01	O=C(O[C@H]1[C@@H](OC(=O)C(CC)C)C[C@@](O)(C)[C@]23[C@H](OC(=O)C)[C@H](C(C)(C)O2)C[C@H](OC(=O)c2ccccc2)[C@]13COC(=O)C)C(CC)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381135-01	363678987.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](OC(=O)C(CC)C)C[C@@](O)(C)[C@]23[C@H](OC(=O)C)[C@H](C(C)(C)O2)C[C@H](OC(=O)c2ccccc2)[C@]13COC(=O)C)C(CC)C	O=C(O[C@H]1[C@@H](OC(=O)C(CC)C)C[C@@](O)(C)[C@]23[C@H](OC(=O)C)[C@H](C(C)(C)O2)C[C@H](OC(=O)c2ccccc2)[C@]13COC(=O)C)C(CC)C
NCGC00384923-01	O=C(O[C@H]1[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)CO[C@H]2O[C@H]2[C@@]3(C)C(=CCC4C5[C@@](C)([C@@H]6[C@H](C)[C@@]7([C@@H](O)[C@@H](OC8C(O)C(O)C(O)C(C)O8)C(=C)CO7)O[C@H]6C5)CCC34)C[C@@H](O)C2)O[C@@H](C)[C@@H]1OC(=O)C)C		Inactive	<MOA Unknown> | Class: Steroid | Genus: Euphorbia | Family: Euphorbiaceae | Species: depauperata		1	NCGC00384923-01	363679442.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)CO[C@H]2O[C@H]2[C@@]3(C)C(=CCC4C5[C@@](C)([C@@H]6[C@H](C)[C@@]7([C@@H](O)[C@@H](OC8C(O)C(O)C(O)C(C)O8)C(=C)CO7)O[C@H]6C5)CCC34)C[C@@H](O)C2)O[C@@H](C)[C@@H]1OC(=O)C)C	O=C(O[C@H]1[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@@H](O)CO[C@H]2O[C@H]2[C@@]3(C)C(=CCC4C5[C@@](C)([C@@H]6[C@H](C)[C@@]7([C@@H](O)[C@@H](OC8C(O)C(O)C(O)C(C)O8)C(=C)CO7)O[C@H]6C5)CCC34)C[C@@H](O)C2)O[C@@H](C)[C@@H]1OC(=O)C)C
NCGC00169107-02	O=C(O[C@H]1[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@@H]4[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O4)OC=C[C@@H]23)O[C@@H](C)[C@@H]1O)/C=C/c1ccc(OC)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Buddleia | Family: Loginaceae | Species: polystachya		1	NCGC00169107-02	363676774.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@@H]4[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O4)OC=C[C@@H]23)O[C@@H](C)[C@@H]1O)/C=C/c1ccc(OC)cc1	O=C(O[C@H]1[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@@H]4[C@@H](O)[C@H](O)[C@@H](O)[C@H](CO)O4)OC=C[C@@H]23)O[C@@H](C)[C@@H]1O)/C=C/c1ccc(OC)cc1
NCGC00384953-01	O=C(O[C@H]1[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@@H](C)[C@@H]1OC(=O)/C=C/c1ccccc1)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384953-01	363679455.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@@H](C)[C@@H]1OC(=O)/C=C/c1ccccc1)/C=C/c1ccccc1	O=C(O[C@H]1[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@@H](C)[C@@H]1OC(=O)/C=C/c1ccccc1)/C=C/c1ccccc1
NCGC00179976-03	O=C(O[C@H]1[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@@H](C)[C@@H]1OC(=O)C)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Scrophularia | Family: Scrophulariaceae | Species: nodosa		1	NCGC00179976-03	363676998.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@@H](C)[C@@H]1OC(=O)C)/C=C/c1ccccc1	O=C(O[C@H]1[C@@H](OC(=O)C)[C@H](O[C@@H]2[C@H]3[C@](CO)(O3)[C@H]3[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)OC=C[C@@H]23)O[C@@H](C)[C@@H]1OC(=O)C)/C=C/c1ccccc1
NCGC00384622-01	O=C(O[C@H]1[C@@H](OC(=O)c2cocc2)C[C@@](O)(C)[C@]23[C@H](OC(=O)C)[C@H](C(C)(C)O2)C[C@H](OC(=O)c2cocc2)[C@]13COC(=O)C)C(CC)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384622-01	363679278.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H](OC(=O)c2cocc2)C[C@@](O)(C)[C@]23[C@H](OC(=O)C)[C@H](C(C)(C)O2)C[C@H](OC(=O)c2cocc2)[C@]13COC(=O)C)C(CC)C	O=C(O[C@H]1[C@@H](OC(=O)c2cocc2)C[C@@](O)(C)[C@]23[C@H](OC(=O)C)[C@H](C(C)(C)O2)C[C@H](OC(=O)c2cocc2)[C@]13COC(=O)C)C(CC)C
NCGC00163699-07&NCGC00163699-10	O=C(O[C@H]1[C@@H](OC)[C@H]([C@]2(C)[C@@H](CC=C(C)C)O2)[C@]2(OC2)CC1)/C=C/C=C/C=C/C=C/C(=O)O		Inactive	Methionine Aminopeptidase 2 Inhibitor		2	Fumagillin	405559052.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0&4.0	0.0&9.3447669319&0.0	O=C(O[C@H]1[C@@H](OC)[C@H]([C@]2(C)[C@@H](CC=C(C)C)O2)[C@]2(OC2)CC1)/C=C/C=C/C=C/C=C/C(=O)O	O=C(O[C@H]1[C@@H](OC)[C@H]([C@]2(C)[C@@H](CC=C(C)C)O2)[C@]2(OC2)CC1)/C=C/C=C/C=C/C=C/C(=O)O
NCGC00167467-03	O=C(O[C@H]1[C@@H]([N+]2(C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CCCCC4)C3)CC[C@@H]21)C		Inactive	Steroid non-depolarizing neuromuscular Blocker		1	Vecuronium bromide	170465295.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O[C@H]1[C@@H]([N+]2(C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CCCCC4)C3)CC[C@@H]21)C.[Br-]	O=C(O[C@H]1[C@@H]([N+]2(C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CCCCC4)C3)CC[C@@H]21)C.[Br-]
NCGC00023037-06&NCGC00023037-08	O=C(O[C@H]1[C@@H]([N+]2(C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H]([N+]4(C)CCCCC4)C3)CC[C@@H]21)C		Inactive	Steroid non-depolarizing Blocker		2	Pancuronium bromide	124886818.0&225144191.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O[C@H]1[C@@H]([N+]2(C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H]([N+]4(C)CCCCC4)C3)CC[C@@H]21)C	O=C(O[C@H]1[C@@H]([N+]2(C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H]([N+]4(C)CCCCC4)C3)CC[C@@H]21)C
NCGC00167433-05&NCGC00167433-06	O=C(O[C@H]1[C@@H]([N+]2(CC=C)CCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](O)[C@@H](N4CCOCC4)C3)CC[C@@H]21)C		Inactive	Steroid non-depolarizing neuromuscular Blocker		2	Rocuronium bromide	405558883.0&384568312.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O[C@H]1[C@@H]([N+]2(CC=C)CCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](O)[C@@H](N4CCOCC4)C3)CC[C@@H]21)C	O=C(O[C@H]1[C@@H]([N+]2(CC=C)CCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](O)[C@@H](N4CCOCC4)C3)CC[C@@H]21)C
NCGC00183839-01	O=C(O[C@H]1[C@@H]([N+]2(CC=C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CCCCC4)C3)CC[C@@H]21)CC		Inactive	Muscarinic acetylcholine receptor M5 Negative Allosteric Modulator		1	Rapacuronium bromide	144206855.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@@H]([N+]2(CC=C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CCCCC4)C3)CC[C@@H]21)CC.[Br-]	O=C(O[C@H]1[C@@H]([N+]2(CC=C)CCCCC2)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)[C@H](C[C@H](OC(=O)C)[C@@H](N4CCCCC4)C3)CC[C@@H]21)CC.[Br-]
NCGC00164319-07	O=C(O[C@H]1[C@@H](c2cc(O)c(O)c(O)c2)Oc2c(c(O)cc(O)c2)C1)c1cc(O)c(O)c(O)c1		Inactive			1	EPIGALLOCATECHIN-3-MONOGALLATE	434147022.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@@H](c2cc(O)c(O)c(O)c2)Oc2c(c(O)cc(O)c2)C1)c1cc(O)c(O)c(O)c1	O=C(O[C@H]1[C@@H](c2cc(O)c(O)c(O)c2)Oc2c(c(O)cc(O)c2)C1)c1cc(O)c(O)c(O)c1
NCGC00179135-02	O=C(O[C@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1)c1cc(O)c(O)c(O)c1		Inactive			1	EPICATECHIN MONOGALLATE		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1)c1cc(O)c(O)c(O)c1	O=C(O[C@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1)c1cc(O)c(O)c(O)c1
NCGC00385310-01	O=C(O[C@H]1[C@@H]2C(C(=O)OC)=COC(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H]2[C@](O)(C)C1)CCc1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Solenostemon | Family: Labiateae | Species: graniticola		1	NCGC00385310-01	363679667.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@H]2C(C(=O)OC)=COC(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H]2[C@](O)(C)C1)CCc1ccc(O)cc1	O=C(O[C@H]1[C@@H]2C(C(=O)OC)=COC(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@@H]2[C@](O)(C)C1)CCc1ccc(O)cc1
NCGC00385335-01	O=C(O[C@H]1[C@@](C(=O)O)(C)C2[C@@](C)(C3[C@H](O)C=C4[C@](C)([C@]3(C)CC2)CC[C@]2(C)[C@@H]4[C@@H](C)[C@H](C)CC2)CC1)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385335-01	363679686.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@](C(=O)O)(C)C2[C@@](C)(C3[C@H](O)C=C4[C@](C)([C@]3(C)CC2)CC[C@]2(C)[C@@H]4[C@@H](C)[C@H](C)CC2)CC1)C	O=C(O[C@H]1[C@@](C(=O)O)(C)C2[C@@](C)(C3[C@H](O)C=C4[C@](C)([C@]3(C)CC2)CC[C@]2(C)[C@@H]4[C@@H](C)[C@H](C)CC2)CC1)C
NCGC00384943-01	O=C(O[C@H]1[C@@](COC(=O)c2[nH]c(C)cc2)(CO[C@@H]2O[C@@H](C)[C@H](OC)CC2)[C@@H]2[C@](C)([C@H]3[C@](C)([C@H](C4=C(O)C(=O)OC4O)C(C)=CC3)CC2)CC1)C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384943-01	363679450.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@](COC(=O)c2[nH]c(C)cc2)(CO[C@@H]2O[C@@H](C)[C@H](OC)CC2)[C@@H]2[C@](C)([C@H]3[C@](C)([C@H](C4=C(O)C(=O)OC4O)C(C)=CC3)CC2)CC1)C	O=C(O[C@H]1[C@@](COC(=O)c2[nH]c(C)cc2)(CO[C@@H]2O[C@@H](C)[C@H](OC)CC2)[C@@H]2[C@](C)([C@H]3[C@](C)([C@H](C4=C(O)C(=O)OC4O)C(C)=CC3)CC2)CC1)C
NCGC00384673-01	O=C(O[C@H]1[C@@]2(C)C=3[C@](C)([C@@H](c4cocc4)C(=O)C=3)CCC2[C@@]2(C)C=CC(=O)C(C)(C)C2C1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384673-01	363679301.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@]2(C)C=3[C@](C)([C@@H](c4cocc4)C(=O)C=3)CCC2[C@@]2(C)C=CC(=O)C(C)(C)C2C1)C	O=C(O[C@H]1[C@@]2(C)C=3[C@](C)([C@@H](c4cocc4)C(=O)C=3)CCC2[C@@]2(C)C=CC(=O)C(C)(C)C2C1)C
NCGC00385718-01	O=C(O[C@H]1[C@@]2(C)C=3[C@](C)([C@H](C=4C(=O)OC(OC)C=4)CC=3)CCC2[C@@]2(C)C=CC(=O)C(C)(C)C2C1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385718-01	363679894.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@]2(C)C=3[C@](C)([C@H](C=4C(=O)OC(OC)C=4)CC=3)CCC2[C@@]2(C)C=CC(=O)C(C)(C)C2C1)C	O=C(O[C@H]1[C@@]2(C)C=3[C@](C)([C@H](C=4C(=O)OC(OC)C=4)CC=3)CCC2[C@@]2(C)C=CC(=O)C(C)(C)C2C1)C
NCGC00179162-03	O=C(O[C@H]1[C@@]2(C)C=3[C@](C)([C@H](c4cocc4)OC(=O)C=3)CCC2[C@@]2(C)C=CC(=O)C(C)(C)C2C1)C	4.9000001	Active		0.0	1	DEOXYGEDUNIN	377020271.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	3.0	70.4956703151	O=C(O[C@H]1[C@@]2(C)C=3[C@](C)([C@H](c4cocc4)OC(=O)C=3)CCC2[C@@]2(C)C=CC(=O)C(C)(C)C2C1)C	O=C(O[C@H]1[C@@]2(C)C=3[C@](C)([C@H](c4cocc4)OC(=O)C=3)CCC2[C@@]2(C)C=CC(=O)C(C)(C)C2C1)C
NCGC00485970-01	O=C(O[C@H]1[C@@]2(C)[C@@](C)([C@@H](O)C34O[C@H](C(O)(C)C)[C@H](O3)C[C@@H](C)[C@H]24)[C@H]2[C@]3([C@@]4([C@H](C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@@H](O)CO5)CC4)CC2)C3)C1)C		Inactive			1	Cimiracemoside D	363681451.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@]2(C)[C@@](C)([C@@H](O)C34O[C@H](C(O)(C)C)[C@H](O3)C[C@@H](C)[C@H]24)[C@H]2[C@]3([C@@]4([C@H](C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@@H](O)CO5)CC4)CC2)C3)C1)C	O=C(O[C@H]1[C@@]2(C)[C@@](C)([C@@H](O)C34O[C@H](C(O)(C)C)[C@H](O3)C[C@@H](C)[C@H]24)[C@H]2[C@]3([C@@]4([C@H](C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@@H](O)CO5)CC4)CC2)C3)C1)C
NCGC00385389-01	O=C(O[C@H]1[C@@]2(C)[C@](C)([C@H]3[C@]4([C@@]5([C@H](C(C)(C)[C@@H](OC6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC3)C4)C1)CC1OC3(OCC4(C)OC34)C[C@@H](C)C21)C		Inactive	angiogenesis Inhibitor		1	NCGC00385389-01	363679716.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@]2(C)[C@](C)([C@H]3[C@]4([C@@]5([C@H](C(C)(C)[C@@H](OC6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC3)C4)C1)CC1OC3(OCC4(C)OC34)C[C@@H](C)C21)C	O=C(O[C@H]1[C@@]2(C)[C@](C)([C@H]3[C@]4([C@@]5([C@H](C(C)(C)[C@@H](OC6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC3)C4)C1)CC1OC3(OCC4(C)OC34)C[C@@H](C)C21)C
NCGC00179126-03	O=C(O[C@H]1[C@@]2(C)[C@]34[C@](C)([C@H](c5cocc5)OC(=O)[C@H]3O4)CCC2[C@@]2(C)C=CC(=O)C(C)(C)C2C1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Azadirachta | Family: N/A | Species: indica		1	GEDUNIN	363676939.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	10.4198640759	O=C(O[C@H]1[C@@]2(C)[C@]34[C@](C)([C@H](c5cocc5)OC(=O)[C@H]3O4)CCC2[C@@]2(C)C=CC(=O)C(C)(C)C2C1)C	O=C(O[C@H]1[C@@]2(C)[C@]34[C@](C)([C@H](c5cocc5)OC(=O)[C@H]3O4)CCC2[C@@]2(C)C=CC(=O)C(C)(C)C2C1)C
NCGC00485963-01	O=C(O[C@H]1[C@@]2(O)[C@@H](OC)[C@H](O)[C@]3(O)[C@@H]4[C@H](OC)[C@@H]5[C@@]6(COC)[C@H](O)C[C@H](OC)[C@]5([C@@H]4N(CC)C6)[C@@H]([C@H]13)C2)c1ccccc1		Inactive			1	Benzoylaconine	363681446.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@]2(O)[C@@H](OC)[C@H](O)[C@]3(O)[C@@H]4[C@H](OC)[C@@H]5[C@@]6(COC)[C@H](O)C[C@H](OC)[C@]5([C@@H]4N(CC)C6)[C@@H]([C@H]13)C2)c1ccccc1	O=C(O[C@H]1[C@@]2(O)[C@@H](OC)[C@H](O)[C@]3(O)[C@@H]4[C@H](OC)[C@@H]5[C@@]6(COC)[C@H](O)C[C@H](OC)[C@]5([C@@H]4N(CC)C6)[C@@H]([C@H]13)C2)c1ccccc1
NCGC00180843-03	O=C(O[C@H]1[C@@]2(O)[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C2)[C@@]2(C)O[C@@H]12)/C(=C/CC[C@](O)(C=C)C)/C		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Kickxia | Family: Apocynaceae | Species: lanigera		1	NCGC00180843-03	363677072.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@]2(O)[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C2)[C@@]2(C)O[C@@H]12)/C(=C/CC[C@](O)(C=C)C)/C	O=C(O[C@H]1[C@@]2(O)[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C2)[C@@]2(C)O[C@@H]12)/C(=C/CC[C@](O)(C=C)C)/C
NCGC00385538-01	O=C(O[C@H]1[C@@]2(OC(=O)C)[C@H](OC(=O)C)[C@@](C)([C@@H](OC(=O)C)[C@]3(O)[C@@H]1[C@@H](OC(=O)c1ccccc1)[C@@H](C)C3)[C@@H]1[C@H](C(=O)C(C)(C)C1)C2)CO		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385538-01	363679795.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@]2(OC(=O)C)[C@H](OC(=O)C)[C@@](C)([C@@H](OC(=O)C)[C@]3(O)[C@@H]1[C@@H](OC(=O)c1ccccc1)[C@@H](C)C3)[C@@H]1[C@H](C(=O)C(C)(C)C1)C2)CO	O=C(O[C@H]1[C@@]2(OC(=O)C)[C@H](OC(=O)C)[C@@](C)([C@@H](OC(=O)C)[C@]3(O)[C@@H]1[C@@H](OC(=O)c1ccccc1)[C@@H](C)C3)[C@@H]1[C@H](C(=O)C(C)(C)C1)C2)CO
NCGC00380620-01	O=C(O[C@H]1[C@@]2([C@H](OC(=O)C)CC[C@H](C)O2)OC=C2C(=O)[C@](OC(=O)C)(C)C(=O)C(O)=C12)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380620-01	363678677.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@]2([C@H](OC(=O)C)CC[C@H](C)O2)OC=C2C(=O)[C@](OC(=O)C)(C)C(=O)C(O)=C12)C	O=C(O[C@H]1[C@@]2([C@H](OC(=O)C)CC[C@H](C)O2)OC=C2C(=O)[C@](OC(=O)C)(C)C(=O)C(O)=C12)C
NCGC00381303-01	O=C(O[C@H]1[C@@]23C([C@@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](OC8C(O)C(O)C(O)C(CO)O8)[C@@H](OC8[C@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@](O)(CO)CO%10)[C@H](O)[C@@H](O)[C@H](C)O9)C(O)C(O)C(CO)O8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC4)C1)OC2)CC(C)(C)CC3)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381303-01	363679076.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@@]23C([C@@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](OC8C(O)C(O)C(O)C(CO)O8)[C@@H](OC8[C@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@](O)(CO)CO%10)[C@H](O)[C@@H](O)[C@H](C)O9)C(O)C(O)C(CO)O8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC4)C1)OC2)CC(C)(C)CC3)C	O=C(O[C@H]1[C@@]23C([C@@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](OC8C(O)C(O)C(O)C(CO)O8)[C@@H](OC8[C@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@](O)(CO)CO%10)[C@H](O)[C@@H](O)[C@H](C)O9)C(O)C(O)C(CO)O8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC4)C1)OC2)CC(C)(C)CC3)C
NCGC00384509-01	O=C(O[C@H]1[C@H](C)CN(C)[C@H]2[C@H]1c1c3c([nH]c(C(C=C)(C)C)c3C2)ccc1)C		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384509-01	363679221.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](C)CN(C)[C@H]2[C@H]1c1c3c([nH]c(C(C=C)(C)C)c3C2)ccc1)C	O=C(O[C@H]1[C@H](C)CN(C)[C@H]2[C@H]1c1c3c([nH]c(C(C=C)(C)C)c3C2)ccc1)C
NCGC00262543-01	O=C(O[C@H]1[C@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)C(O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@@H](O)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@]1(O)C)CC		Inactive	Ribosome Inhibitor		1	Midecamycin	405558985.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)C(O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@@H](O)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@]1(O)C)CC	O=C(O[C@H]1[C@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)C(O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)C/C=C/C=C/[C@@H](O)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@]1(O)C)CC
NCGC00510884-01	O=C(O[C@H]1[C@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]3[C@@H](C)[C@H](OC(=O)C)CC(=O)O[C@H](CC)[C@@H](CO[C@H]4[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O4)/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@]1(O)C)CC(C)C		Inactive	Bacterial 70S ribosome Inhibitor		1	Tylvalosin	405558459.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]3[C@@H](C)[C@H](OC(=O)C)CC(=O)O[C@H](CC)[C@@H](CO[C@H]4[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O4)/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@]1(O)C)CC(C)C	O=C(O[C@H]1[C@H](C)O[C@@H](O[C@H]2[C@H](N(C)C)[C@@H](O)[C@H](O[C@@H]3[C@@H](C)[C@H](OC(=O)C)CC(=O)O[C@H](CC)[C@@H](CO[C@H]4[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O4)/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]3CC=O)O[C@@H]2C)C[C@]1(O)C)CC(C)C
NCGC00380952-01	O=C(O[C@H]1[C@H](C)[C@@H](O)[C@@H]2[C@H]3[C@@H]4[C@H]5C(=O)O[C@H]6[C@@H](C)[C@@]5(O)O[C@@](C)([C@@H]4C[C@@H]3C(C(=O)O)=C[C@H]12)CC6)C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380952-01	363678881.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](C)[C@@H](O)[C@@H]2[C@H]3[C@@H]4[C@H]5C(=O)O[C@H]6[C@@H](C)[C@@]5(O)O[C@@](C)([C@@H]4C[C@@H]3C(C(=O)O)=C[C@H]12)CC6)C	O=C(O[C@H]1[C@H](C)[C@@H](O)[C@@H]2[C@H]3[C@@H]4[C@H]5C(=O)O[C@H]6[C@@H](C)[C@@]5(O)O[C@@](C)([C@@H]4C[C@@H]3C(C(=O)O)=C[C@H]12)CC6)C
NCGC00022678-08	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(/C=N/N3CCN(C)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C		Inactive	DNA-Directed RNA Polymerase Inhibitor		1	Rifampicin	384568012.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(/C=N/N3CCN(C)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(/C=N/N3CCN(C)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C
NCGC00167431-03	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(/C=N\N3CCN(C4CCCC4)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C		Inactive	DNA-Directed RNA Polymerase Inhibitor		1	Rifapentine	124893311.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.6844316721	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(/C=N\N3CCN(C4CCCC4)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(/C=N\N3CCN(C4CCCC4)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C
NCGC00271415-05	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(O)c3c(O)c(C)c4O[C@@](C)(C(=O)c4c3c3nc4n(c23)C=CC(C)=C4)O/C=C/[C@H](OC)[C@H]1C)C		Inactive	Pregnane X Receptor (PXR) Agonist		1	Rifaximin	384568704.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(O)c3c(O)c(C)c4O[C@@](C)(C(=O)c4c3c3nc4n(c23)C=CC(C)=C4)O/C=C/[C@H](OC)[C@H]1C)C	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(/C)\C(=O)Nc2c(O)c3c(O)c(C)c4O[C@@](C)(C(=O)c4c3c3nc4n(c23)C=CC(C)=C4)O/C=C/[C@H](OC)[C@H]1C)C
NCGC00022678-23	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(C)C(=O)Nc2c(/C=N/N3CCN(C)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C		Inactive			1	Rifampicin		Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(C)C(=O)Nc2c(/C=N/N3CCN(C)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(C)C(=O)Nc2c(/C=N/N3CCN(C)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C
NCGC00090762-05&NCGC00090762-11	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(\C)/C(=O)NC=2C(=O)c3c(O)c(C)c4O[C@@](C)(C(=O)c4c3C3=NC4(NC=23)CCN(CC(C)C)CC4)O/C=C/[C@H](OC)[C@H]1C)C		Inactive	Cytochrome P450 3a4 Substrate		2	Rifabutin	384568084.0&405558775.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(\C)/C(=O)NC=2C(=O)c3c(O)c(C)c4O[C@@](C)(C(=O)c4c3C3=NC4(NC=23)CCN(CC(C)C)CC4)O/C=C/[C@H](OC)[C@H]1C)C	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(\C)/C(=O)NC=2C(=O)c3c(O)c(C)c4O[C@@](C)(C(=O)c4c3C3=NC4(NC=23)CCN(CC(C)C)CC4)O/C=C/[C@H](OC)[C@H]1C)C
NCGC00386298-01	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(\C)/C(=O)Nc2c(/C=N/N3CCN(C4CCCC4)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C		Inactive	DNA-Directed RNA Polymerase Inhibitor		1	Rifapentine	405559051.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(\C)/C(=O)Nc2c(/C=N/N3CCN(C4CCCC4)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(\C)/C(=O)Nc2c(/C=N/N3CCN(C4CCCC4)CC3)c(O)c3c(c(O)c(C)c4O[C@@](C)(C(=O)c34)O/C=C/[C@H](OC)[C@H]1C)c2O)C
NCGC00387269-01	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(\C)/C(=O)Nc2c(O)c3c(O)c(C)c4O[C@@](C)(C(=O)c4c3c3nc4n(c23)C=CC(C)=C4)O/C=C\[C@H](OC)[C@H]1C)C		Inactive	Pregnane X Receptor (PXR) Agonist		1	Rifaximin	405558998.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(\C)/C(=O)Nc2c(O)c3c(O)c(C)c4O[C@@](C)(C(=O)c4c3c3nc4n(c23)C=CC(C)=C4)O/C=C\[C@H](OC)[C@H]1C)C	O=C(O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(\C)/C(=O)Nc2c(O)c3c(O)c(C)c4O[C@@](C)(C(=O)c4c3c3nc4n(c23)C=CC(C)=C4)O/C=C\[C@H](OC)[C@H]1C)C
NCGC00164600-03&NCGC00164600-10&NCGC00164600-15	O=C(O[C@H]1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2)CCC(=O)O		Inactive	Antimalarial Agents		3	Artesunate&ARTESUNATE	174006961.0&405558902.0&434147029.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&13.5&0.0	O=C(O[C@H]1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2)CCC(=O)O	O=C(O[C@H]1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2)CCC(=O)O
NCGC00380305-01	O=C(O[C@H]1[C@H](C)[C@]2(C)C(=CC(=O)C(=C(C)C)C2)CC1)/C(=C/CO)/C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380305-01	363678531.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](C)[C@]2(C)C(=CC(=O)C(=C(C)C)C2)CC1)/C(=C/CO)/C	O=C(O[C@H]1[C@H](C)[C@]2(C)C(=CC(=O)C(=C(C)C)C2)CC1)/C(=C/CO)/C
NCGC00522306-02	O=C(O[C@H]1[C@H](CC(C)C)CN2[C@@H](c3c(cc(OC)c(OC)c3)CC2)C1)[C@@H](N)C(C)C		Inactive			1	Valbenazine	405558870.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	28.453629028	O=C(O[C@H]1[C@H](CC(C)C)CN2[C@@H](c3c(cc(OC)c(OC)c3)CC2)C1)[C@@H](N)C(C)C	O=C(O[C@H]1[C@H](CC(C)C)CN2[C@@H](c3c(cc(OC)c(OC)c3)CC2)C1)[C@@H](N)C(C)C
NCGC00385744-01	O=C(O[C@H]1[C@H](O)C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)C(C5[C@@](C(=O)O)(CC4)CCC(C)(C)C5)=CC3)CC2)C1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385744-01	363679918.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)C(C5[C@@](C(=O)O)(CC4)CCC(C)(C)C5)=CC3)CC2)C1)C	O=C(O[C@H]1[C@H](O)C(C)(C)C2[C@@](C)(C3[C@](C)([C@@]4(C)C(C5[C@@](C(=O)O)(CC4)CCC(C)(C)C5)=CC3)CC2)C1)C
NCGC00385742-01	O=C(O[C@H]1[C@H](O)C[C@]2(C)C3[C@](C)([C@@]4(C)C(C5[C@@](C(=O)O)(CC4)CCC(C)(C)C5)=CC3)CCC2C1(C)C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385742-01	363679916.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)C[C@]2(C)C3[C@](C)([C@@]4(C)C(C5[C@@](C(=O)O)(CC4)CCC(C)(C)C5)=CC3)CCC2C1(C)C)C	O=C(O[C@H]1[C@H](O)C[C@]2(C)C3[C@](C)([C@@]4(C)C(C5[C@@](C(=O)O)(CC4)CCC(C)(C)C5)=CC3)CCC2C1(C)C)C
NCGC00385121-01	O=C(O[C@H]1[C@H](O)C[C@]2(C)C3[C@](C)([C@@]4(C)C([C@@H]5[C@@](O)(C)[C@H](C)CC[C@]5(C(=O)O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC4)=CC3)CCC2[C@]1(C(=O)O)CO)[C@]1(C)[C@@H](O)[C@H](O)C[C@]2(C)C3[C@](C)([C@@]4(C)C([C@@H]5[C@@](O)(C)[C@H](C)CC[C@]5(C(=O)O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC4)=CC3)CCC12		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385121-01	363679547.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)C[C@]2(C)C3[C@](C)([C@@]4(C)C([C@@H]5[C@@](O)(C)[C@H](C)CC[C@]5(C(=O)O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC4)=CC3)CCC2[C@]1(C(=O)O)CO)[C@]1(C)[C@@H](O)[C@H](O)C[C@]2(C)C3[C@](C)([C@@]4(C)C([C@@H]5[C@@](O)(C)[C@H](C)CC[C@]5(C(=O)O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC4)=CC3)CCC12	O=C(O[C@H]1[C@H](O)C[C@]2(C)C3[C@](C)([C@@]4(C)C([C@@H]5[C@@](O)(C)[C@H](C)CC[C@]5(C(=O)O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC4)=CC3)CCC2[C@]1(C(=O)O)CO)[C@]1(C)[C@@H](O)[C@H](O)C[C@]2(C)C3[C@](C)([C@@]4(C)C([C@@H]5[C@@](O)(C)[C@H](C)CC[C@]5(C(=O)O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC4)=CC3)CCC12
NCGC00386109-01	O=C(O[C@H]1[C@H](O)[C@@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@H]3[C@H]4[C@@H]([C@@]5(C)C(=O)OC=6C(=O)O[C@@]7(C=6O)[C@H](C=C(C(=O)O)[C@@H](C)C7)/C=C/CCCC[C@H]5C=C4)CCC3)C[C@H]2O)C1)c1c(OC)cccc1C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386109-01	363680109.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@H]3[C@H]4[C@@H]([C@@]5(C)C(=O)OC=6C(=O)O[C@@]7(C=6O)[C@H](C=C(C(=O)O)[C@@H](C)C7)/C=C/CCCC[C@H]5C=C4)CCC3)C[C@H]2O)C1)c1c(OC)cccc1C	O=C(O[C@H]1[C@H](O)[C@@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@H]3[C@H]4[C@@H]([C@@]5(C)C(=O)OC=6C(=O)O[C@@]7(C=6O)[C@H](C=C(C(=O)O)[C@@H](C)C7)/C=C/CCCC[C@H]5C=C4)CCC3)C[C@H]2O)C1)c1c(OC)cccc1C
NCGC00385084-01	O=C(O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)CO)/C=C/c1cc(OC)c(O)c(OC)c1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385084-01	363679523.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)CO)/C=C/c1cc(OC)c(O)c(OC)c1	O=C(O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)CO)/C=C/c1cc(OC)c(O)c(OC)c1
NCGC00384564-01	O=C(O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)CO)/C=C/c1cc(OC)c(O)cc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384564-01	363679245.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)CO)/C=C/c1cc(OC)c(O)cc1	O=C(O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)CO)/C=C/c1cc(OC)c(O)cc1
NCGC00347659-02	O=C(O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)c2ccc(O)cc2)O1)CO)/C=C/c1cc(OC)c(OC)c(OC)c1		Inactive	NF-kappa B signaling pathway Inhibitor		1	NCGC00347659-02	363677658.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)c2ccc(O)cc2)O1)CO)/C=C/c1cc(OC)c(OC)c(OC)c1	O=C(O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)c2ccc(O)cc2)O1)CO)/C=C/c1cc(OC)c(OC)c(OC)c1
NCGC00385441-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C(=C/CC/C(=C/CO)/C)/C		Inactive	<MOA Unknown> | Class: Monoterpen | Genus: Rytigynia | Family: Rubiaceae | Species: acuminatissima		1	NCGC00385441-01	363679742.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C(=C/CC/C(=C/CO)/C)/C	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C(=C/CC/C(=C/CO)/C)/C
NCGC00385283-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C/1=C\CC/C(/C)=C/[C@H]2OC(=O)C(=C)[C@@H]2CC\1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Taraxacum | Family: Asteraceae | Species: officinalis		1	NCGC00385283-01	363679642.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C/1=C\CC/C(/C)=C/[C@H]2OC(=O)C(=C)[C@@H]2CC\1	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C/1=C\CC/C(/C)=C/[C@H]2OC(=O)C(=C)[C@@H]2CC\1
NCGC00380499-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C(/C=C/[C@@]1(O)[C@@]2(C)OC[C@@]1(C)C[C@H](O)C2)\C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Andira | Family: Leguminosae | Species: inermis		1	NCGC00380499-01	363678611.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C(/C=C/[C@@]1(O)[C@@]2(C)OC[C@@]1(C)C[C@H](O)C2)\C	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C(/C=C/[C@@]1(O)[C@@]2(C)OC[C@@]1(C)C[C@H](O)C2)\C
NCGC00385000-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C/c1c(O)cccc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Jasminum | Family: Oleaceae | Species: fruticans		1	NCGC00385000-01	363679478.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C/c1c(O)cccc1	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C/c1c(O)cccc1
NCGC00385766-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C/c1cc(OC)c(O)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Acacia | Family: Fabaceae | Species: nilotica		1	NCGC00385766-01	363679931.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C/c1cc(OC)c(O)cc1	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)/C=C/c1cc(OC)c(O)cc1
NCGC00169081-02	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C[C@H]1/C(=C\C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Fraxinus | Family: Oleaceae | Species: excelsior		1	NCGC00169081-02	363676766.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C[C@H]1/C(=C\C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)C[C@H]1/C(=C\C)/[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)OC=C1C(=O)OC
NCGC00385360-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C(C(O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](C(=O)O)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Rubus | Family: Rosaceae | Species: fruticosus		1	NCGC00385360-01	363679700.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C(C(O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](C(=O)O)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C(C(O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](C(=O)O)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00169096-02	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Rubus | Family: Rosaceae | Species: fruticosus		1	NCGC00169096-02	363676771.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00169922-02	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Terminalia | Family: Combretiaceae | Species: chebula		1	NCGC00169922-02	363676914.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00347771-02	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(CO)(CO)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Achras | Family: Sapotaceae | Species: sapota		1	NCGC00347771-02	363677682.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(CO)(CO)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C(C(CO)(CO)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00179844-02	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Lawsonia | Family: Lythraceae | Species: inermis		1	NCGC00179844-02	363676976.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00169662-02	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@H](O)C3)[C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC=1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Lawsonia | Family: Lythraceae | Species: inermis		1	NCGC00169662-02	363676858.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@H](O)C3)[C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC=1)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12C([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@H](O)C3)[C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC=1)CC2
NCGC00179703-03	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C(=O)O)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Acacia | Family: Mimosaceae | Species: ataxacantha		1	NCGC00179703-03	363676954.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C(=O)O)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC4)CC3)CC=1)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C(=O)O)([C@@]3(C)C([C@]4(C)C(C(C)(C)[C@@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)CC4)CC3)CC=1)CC2
NCGC00179727-03	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@@H]([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](C(=O)O)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Rubus | Family: Rosaceae | Species: idaeus		1	NCGC00179727-03	363676960.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@@H]([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](C(=O)O)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@@H]([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](C(=O)O)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00380479-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@@H]([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@H](O)C3)C(C)(C)[C@@H](O)[C@H](O)C4)CC=1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Utricularia | Family: Lentibularieae | Species: gibba		1	NCGC00380479-01	363678603.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@@H]([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@H](O)C3)C(C)(C)[C@@H](O)[C@H](O)C4)CC=1)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@@H]([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@H](O)C3)C(C)(C)[C@@H](O)[C@H](O)C4)CC=1)CC2
NCGC00385385-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@@H]([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](C=O)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385385-01	363679712.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@@H]([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](C=O)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@@H]([C@H](O)C(C)(C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](C=O)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00384587-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384587-01	363679262.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2
NCGC00384885-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]1(C)[C@H](O)CC[C@]2(C)C3[C@](C)([C@@]4(C)C([C@H]5[C@@](C(=O)O[C@H]6[C@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@H](O)[C@@H](CO[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)[C@H](O)[C@@H](CO)O7)O6)(CC4)CCC(C)(C)C5)=CC3)CCC12		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384885-01	363679415.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]1(C)[C@H](O)CC[C@]2(C)C3[C@](C)([C@@]4(C)C([C@H]5[C@@](C(=O)O[C@H]6[C@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@H](O)[C@@H](CO[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)[C@H](O)[C@@H](CO)O7)O6)(CC4)CCC(C)(C)C5)=CC3)CCC12	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]1(C)[C@H](O)CC[C@]2(C)C3[C@](C)([C@@]4(C)C([C@H]5[C@@](C(=O)O[C@H]6[C@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@H](O)[C@@H](CO[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O8)[C@@H](O)[C@H](O)[C@@H](CO)O7)O6)(CC4)CCC(C)(C)C5)=CC3)CCC12
NCGC00384496-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Galium | Family: Rubiaceae | Species: tricornutum		1	NCGC00384496-01	363679213.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(C(=O)O)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00180591-02	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Maerua | Family: Capparidaceae | Species: angolensis		1	NCGC00180591-02	363677040.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00347377-02	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)[C@@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Saponaria | Family: Caryophyllaceae | Species: album		1	NCGC00347377-02	363677582.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)[C@@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)[C@@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00381089-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)[C@@H](O)C5)CC4)CC=3)CC1)CC(C=O)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Saponaria | Family: Caryophyllaceae | Species: album		1	NCGC00381089-01	363678963.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)[C@@H](O)C5)CC4)CC=3)CC1)CC(C=O)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)[C@@H](O)C5)CC4)CC=3)CC1)CC(C=O)(C)CC2
NCGC00380181-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)[C@@H](O)C5)CC4)CC=3)CC1)CC(CO)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Saponaria | Family: Caryophyllaceae | Species: album		1	NCGC00380181-01	363678492.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)[C@@H](O)C5)CC4)CC=3)CC1)CC(CO)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)[C@@H](O)C5)CC4)CC=3)CC1)CC(CO)(C)CC2
NCGC00180568-03	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O)[C@H](O)C5)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Chrysobalanus | Family: Chrysobalanaceae | Species: icaco		1	NCGC00180568-03	363677038.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O)[C@H](O)C5)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O)[C@H](O)C5)CC=3)CC1)CC(C)(C)CC2
NCGC00384682-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@@H]6[C@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@H](O)[C@@H](CO)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Calendula | Family: Compositae | Species: suffruticosa		1	NCGC00384682-01	363679307.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@@H]6[C@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@H](O)[C@@H](CO)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@@H]6[C@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@H](O)[C@@H](CO)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00168985-02	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Gouania | Family: Rhamnaceae | Species: leptostachya		1	NCGC00168985-02	363676735.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00381017-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](C)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Cussonia | Family: Araliaceae | Species: spicata		1	NCGC00381017-01	363678926.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](C)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](C)O6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00385051-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)cc(O)cc1/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Shikimi / Polyketide | Genus: Agonis | Family: Myrtaceae | Species: flexuosa		1	NCGC00385051-01	363679507.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)cc(O)cc1/C=C/c1ccccc1	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1c(O)cc(O)cc1/C=C/c1ccccc1
NCGC00385680-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccccc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385680-01	363679872.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccccc1	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccccc1
NCGC00380938-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC2C(O)C(O)C(O)CO2)O1)C=1C(C)(C)CCCC=1C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380938-01	363678870.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC2C(O)C(O)C(O)CO2)O1)C=1C(C)(C)CCCC=1C	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC2C(O)C(O)C(O)CO2)O1)C=1C(C)(C)CCCC=1C
NCGC00160471-02	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)\C)\C)/C)/C		Inactive	Tyrosinase Inhibitor		1	Crocin?	405558579.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)\C)\C)/C)/C	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)\C)\C)/C)/C
NCGC00384868-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C(=O)O[C@H]1[C@H](OC(=O)/C=C/c2cc(O)c(O)cc2)[C@H](O)C[C@@](O)(C(=O)O)C1)\C)\C)/C)/C		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384868-01	363679405.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C(=O)O[C@H]1[C@H](OC(=O)/C=C/c2cc(O)c(O)cc2)[C@H](O)C[C@@](O)(C(=O)O)C1)\C)\C)/C)/C	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C(=O)O[C@H]1[C@H](OC(=O)/C=C/c2cc(O)c(O)cc2)[C@H](O)C[C@@](O)(C(=O)O)C1)\C)\C)/C)/C
NCGC00347683-02	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](C(=O)O)(C)[C@@H](O)CC4)CC3)CC=1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Phyllamthus | Family: Euphoribiaceae | Species: urinaria		1	NCGC00347683-02	363677665.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](C(=O)O)(C)[C@@H](O)CC4)CC3)CC=1)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@](O)(C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)C([C@]4(C)C([C@](C(=O)O)(C)[C@@H](O)CC4)CC3)CC=1)CC2
NCGC00381125-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12C(C(C)C(C)=CC1)C1[C@](C)([C@@]3(C)C([C@]4(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC1)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Centella | Family: Apiaceae | Species: asiatica		1	NCGC00381125-01	363678981.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12C(C(C)C(C)=CC1)C1[C@](C)([C@@]3(C)C([C@]4(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC1)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12C(C(C)C(C)=CC1)C1[C@](C)([C@@]3(C)C([C@]4(C)C([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC1)CC2
NCGC00385158-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7)[C@@H](O)[C@@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	Interleukin-1 receptor-associated kinase 1  Inhibitor		1	NCGC00385158-01	363679569.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7)[C@@H](O)[C@@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@]12C(C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7)[C@@H](O)[C@@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00385248-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385248-01	363679617.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00385122-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O)[C@H](O)C5)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Centella | Family: Apiaceae | Species: asiatica		1	NCGC00385122-01	363679548.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O)[C@H](O)C5)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O)[C@H](O)C5)CC=3)CC1)CC(C)(C)CC2
NCGC00384677-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](N[C@@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]4[C@H](O)[C@@H](O)[C@H](O[C@@H]5[C@H](O)[C@@H](O)[C@H](O[C@@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](CO)O5)[C@@H](CO)O4)C(CO)=C3)[C@@H](C)O2)[C@@H](CO)O1)CC(C)C		Inactive	<MOA Unknown> | Class: oligoglycoside | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384677-01	363679303.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](N[C@@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]4[C@H](O)[C@@H](O)[C@H](O[C@@H]5[C@H](O)[C@@H](O)[C@H](O[C@@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](CO)O5)[C@@H](CO)O4)C(CO)=C3)[C@@H](C)O2)[C@@H](CO)O1)CC(C)C	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@H](O)[C@@H](O)[C@H](N[C@@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]4[C@H](O)[C@@H](O)[C@H](O[C@@H]5[C@H](O)[C@@H](O)[C@H](O[C@@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](CO)O5)[C@@H](CO)O4)C(CO)=C3)[C@@H](C)O2)[C@@H](CO)O1)CC(C)C
NCGC00385746-01	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O8)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385746-01	363679920.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O8)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](CO)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O8)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00384797-01	O=C(O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384797-01	363679360.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2
NCGC00385641-01	O=C(O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385641-01	363679852.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00385527-01	O=C(O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O3)O2)O1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385527-01	363679791.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O3)O2)O1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]3[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O3)O2)O1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2
NCGC00384798-01	O=C(O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](CO[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384798-01	363679361.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](CO[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@H](O)[C@@H](CO[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O3)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)CO6)CC5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00347375-02	O=C(O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)C12C(C(C(=C)C)CC1)C1C(C(=O)O)(C3(C)C(C4(C)C(C(C)(C)C(O)CC4)CC3)CC1)CC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347375-02	363677580.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)C12C(C(C(=C)C)CC1)C1C(C(=O)O)(C3(C)C(C4(C)C(C(C)(C)C(O)CC4)CC3)CC1)CC2	O=C(O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)O1)C12C(C(C(=C)C)CC1)C1C(C(=O)O)(C3(C)C(C4(C)C(C(C)(C)C(O)CC4)CC3)CC1)CC2
NCGC00381233-01	O=C(O[C@H]1[C@H](O)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)(CO)O[C@@H]1CO)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381233-01	363679040.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)(CO)O[C@@H]1CO)/C=C/c1ccccc1	O=C(O[C@H]1[C@H](O)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)(CO)O[C@@H]1CO)/C=C/c1ccccc1
NCGC00381281-01	O=C(O[C@H]1[C@H](O)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)C)O2)(CO)O[C@@H]1CO)/C=C/c1ccccc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381281-01	363679065.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)C)O2)(CO)O[C@@H]1CO)/C=C/c1ccccc1	O=C(O[C@H]1[C@H](O)[C@@](O[C@@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](COC(=O)C)O2)(CO)O[C@@H]1CO)/C=C/c1ccccc1
NCGC00385499-01	O=C(O[C@H]1[C@H](O)[C@H](O)C[C@@](O)(C(=O)O)C1)/C=C/c1cc(OC)c(O)cc1		Inactive	Influenza A virus (H5N1) Inhibitor		1	NCGC00385499-01	363679775.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@H](O)C[C@@](O)(C(=O)O)C1)/C=C/c1cc(OC)c(O)cc1	O=C(O[C@H]1[C@H](O)[C@H](O)C[C@@](O)(C(=O)O)C1)/C=C/c1cc(OC)c(O)cc1
NCGC00169030-02	O=C(O[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)Cc1ccccc1		Inactive	<MOA Unknown> | Class: shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169030-02	363676748.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)Cc1ccccc1	O=C(O[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)Cc1ccccc1
NCGC00016724-04	O=C(O[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@H](O)[C@H](C)O3)[C@H](CO)O2)O1)[C@@]12[C@@H]([C@H](C)[C@H](C)CC1)C=1[C@](C)([C@]3(C)[C@H]([C@]4(C)[C@H]([C@](CO)(C)[C@H](O)[C@H](O)C4)CC3)CC=1)CC2		Inactive			1	NCGC00016724-04		2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@H](O)[C@H](C)O3)[C@H](CO)O2)O1)[C@@]12[C@@H]([C@H](C)[C@H](C)CC1)C=1[C@](C)([C@]3(C)[C@H]([C@]4(C)[C@H]([C@](CO)(C)[C@H](O)[C@H](O)C4)CC3)CC=1)CC2	O=C(O[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@H](O)[C@H](C)O3)[C@H](CO)O2)O1)[C@@]12[C@@H]([C@H](C)[C@H](C)CC1)C=1[C@](C)([C@]3(C)[C@H]([C@]4(C)[C@H]([C@](CO)(C)[C@H](O)[C@H](O)C4)CC3)CC=1)CC2
NCGC00380702-01	O=C(O[C@H]1[C@H](O)[C@H]2C(=C)C(=O)O[C@@H]2[C@H]2C(C)=CC(=O)C2=C1C)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Vicoa | Family: Compositae | Species: indica		1	NCGC00380702-01	363678719.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@H]2C(=C)C(=O)O[C@@H]2[C@H]2C(C)=CC(=O)C2=C1C)/C(=C\C)/C	O=C(O[C@H]1[C@H](O)[C@H]2C(=C)C(=O)O[C@@H]2[C@H]2C(C)=CC(=O)C2=C1C)/C(=C\C)/C
NCGC00385520-01	O=C(O[C@H]1[C@H](O)[C@](O)(C)[C@H](/C=C/C(=O)C)[C@]2(C)C1C(C)(C)CCC2)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385520-01	363679788.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@](O)(C)[C@H](/C=C/C(=O)C)[C@]2(C)C1C(C)(C)CCC2)C	O=C(O[C@H]1[C@H](O)[C@](O)(C)[C@H](/C=C/C(=O)C)[C@]2(C)C1C(C)(C)CCC2)C
NCGC00385705-01	O=C(O[C@H]1[C@H](O)[C@]2(COC(=O)C)[C@@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3C2CC1(C)C)C(CC)C		Inactive	glucose import Inhibitor		1	NCGC00385705-01	363679886.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@]2(COC(=O)C)[C@@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3C2CC1(C)C)C(CC)C	O=C(O[C@H]1[C@H](O)[C@]2(COC(=O)C)[C@@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3C2CC1(C)C)C(CC)C
NCGC00384494-01	O=C(O[C@H]1[C@H](O)[C@]2(COC(=O)C)[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@](CO)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384494-01	363679211.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O)[C@]2(COC(=O)C)[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@](CO)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C	O=C(O[C@H]1[C@H](O)[C@]2(COC(=O)C)[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@](CO)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C
NCGC00381025-01	O=C(O[C@H]1[C@H](OC(=O)/C(=C/CCC(O)(C=C)C)/C)[C@@H](CO)O[C@@H](OC(C=C)(CC/C=C(/C(=O)O)\C)C)[C@@H]1O)/C(=C/CCC(O)(C=C)C)/C		Inactive	<MOA Unknown> | Class: Monoterpen | Genus: Acacia | Family: Mimosaceae | Species: cyclops		1	NCGC00381025-01	363678932.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](OC(=O)/C(=C/CCC(O)(C=C)C)/C)[C@@H](CO)O[C@@H](OC(C=C)(CC/C=C(/C(=O)O)\C)C)[C@@H]1O)/C(=C/CCC(O)(C=C)C)/C	O=C(O[C@H]1[C@H](OC(=O)/C(=C/CCC(O)(C=C)C)/C)[C@@H](CO)O[C@@H](OC(C=C)(CC/C=C(/C(=O)O)\C)C)[C@@H]1O)/C(=C/CCC(O)(C=C)C)/C
NCGC00381024-01	O=C(O[C@H]1[C@H](OC(=O)/C(=C/CCC(O)(C=C)C)/C)[C@@H](CO)O[C@@H](OC(C=C)(CC/C=C(/C(=O)O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)\C)C)[C@@H]1O)/C(=C/CCC(O)(C=C)C)/C		Inactive	<MOA Unknown> | Class: Monoterpen | Genus: Acacia | Family: Mimosaceae | Species: cyclops		1	NCGC00381024-01	363678931.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](OC(=O)/C(=C/CCC(O)(C=C)C)/C)[C@@H](CO)O[C@@H](OC(C=C)(CC/C=C(/C(=O)O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)\C)C)[C@@H]1O)/C(=C/CCC(O)(C=C)C)/C	O=C(O[C@H]1[C@H](OC(=O)/C(=C/CCC(O)(C=C)C)/C)[C@@H](CO)O[C@@H](OC(C=C)(CC/C=C(/C(=O)O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)\C)C)[C@@H]1O)/C(=C/CCC(O)(C=C)C)/C
NCGC00385343-01	O=C(O[C@H]1[C@H](OC(=O)/C(=C\C)/C)[C@]23[C@H](O)O[C@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@H](O)[C@H](O)CO%10)[C@H](O)[C@@H](O)[C@H](C)O9)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC4)C[C@H]2O)C3CC1(C)C)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385343-01	363679688.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](OC(=O)/C(=C\C)/C)[C@]23[C@H](O)O[C@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@H](O)[C@H](O)CO%10)[C@H](O)[C@@H](O)[C@H](C)O9)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC4)C[C@H]2O)C3CC1(C)C)/C(=C\C)/C	O=C(O[C@H]1[C@H](OC(=O)/C(=C\C)/C)[C@]23[C@H](O)O[C@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@H](O)[C@H](O)CO%10)[C@H](O)[C@@H](O)[C@H](C)O9)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC4)C[C@H]2O)C3CC1(C)C)/C(=C\C)/C
NCGC00385980-01	O=C(O[C@H]1[C@H](OC(=O)/C=C/c2ccccc2)[C@]23[C@H](O)O[C@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@](O)(CO)CO%10)[C@H](O)[C@@H](O)[C@H](C)O9)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC4)C[C@H]2OC(=O)C)C3CC1(C)C)/C=C/c1cc(O)c(O)cc1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385980-01	363680042.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](OC(=O)/C=C/c2ccccc2)[C@]23[C@H](O)O[C@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@](O)(CO)CO%10)[C@H](O)[C@@H](O)[C@H](C)O9)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC4)C[C@H]2OC(=O)C)C3CC1(C)C)/C=C/c1cc(O)c(O)cc1	O=C(O[C@H]1[C@H](OC(=O)/C=C/c2ccccc2)[C@]23[C@H](O)O[C@]4([C@](C)([C@@]5(C)C([C@]6(C)C(C(C)(C)[C@@H](O[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@@H](O[C@H]8[C@H](O[C@H]9[C@H](O[C@H]%10[C@H](O)[C@@](O)(CO)CO%10)[C@H](O)[C@@H](O)[C@H](C)O9)[C@@H](O)[C@@H](O)[C@@H](CO)O8)[C@H](O)[C@@H](C(=O)O)O7)CC6)CC5)CC4)C[C@H]2OC(=O)C)C3CC1(C)C)/C=C/c1cc(O)c(O)cc1
NCGC00249922-01	O=C(O[C@H]1[C@H](OC(=O)C)CC2C1(C)CCC1c3c(cc(OC(=O)c4ccccc4)cc3)CCC21)C		Inactive			1	Estriol benzoate diacetate	170465998.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@H](OC(=O)C)CC2C1(C)CCC1c3c(cc(OC(=O)c4ccccc4)cc3)CCC21)C	O=C(O[C@H]1[C@H](OC(=O)C)CC2C1(C)CCC1c3c(cc(OC(=O)c4ccccc4)cc3)CCC21)C
NCGC00380906-01	O=C(O[C@H]1[C@H](OC(=O)C)C[C@@H]2[C@](C)([C@H](C)C[C@H](OC(=O)C)[C@@]2(COC(=O)C)[C@@]21OC2)[C@H]1O[C@@H]2OC=C[C@@H]2C1)C(OC(=O)C)(CC)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380906-01	363678846.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](OC(=O)C)C[C@@H]2[C@](C)([C@H](C)C[C@H](OC(=O)C)[C@@]2(COC(=O)C)[C@@]21OC2)[C@H]1O[C@@H]2OC=C[C@@H]2C1)C(OC(=O)C)(CC)C	O=C(O[C@H]1[C@H](OC(=O)C)C[C@@H]2[C@](C)([C@H](C)C[C@H](OC(=O)C)[C@@]2(COC(=O)C)[C@@]21OC2)[C@H]1O[C@@H]2OC=C[C@@H]2C1)C(OC(=O)C)(CC)C
NCGC00380581-01	O=C(O[C@H]1[C@H](OC(=O)C)[C@@]2(C)[C@]3(OC3)CCC[C@@H]2[C@]2(C)[C@@]1(C)OC1(CC(=O)OC1)CC2)C(C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380581-01	363678662.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](OC(=O)C)[C@@]2(C)[C@]3(OC3)CCC[C@@H]2[C@]2(C)[C@@]1(C)OC1(CC(=O)OC1)CC2)C(C)C	O=C(O[C@H]1[C@H](OC(=O)C)[C@@]2(C)[C@]3(OC3)CCC[C@@H]2[C@]2(C)[C@@]1(C)OC1(CC(=O)OC1)CC2)C(C)C
NCGC00381072-01	O=C(O[C@H]1[C@H](OC(=O)C)[C@]2(CO)[C@H](O)[C@H](O)[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O[C@H]7[C@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)CO8)[C@@H](O)CO7)[C@H](O)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Saponin | Genus: Pittosporum | Family: Pittosporaceae | Species: viridifolium		1	NCGC00381072-01	363678956.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](OC(=O)C)[C@]2(CO)[C@H](O)[C@H](O)[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O[C@H]7[C@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)CO8)[C@@H](O)CO7)[C@H](O)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C	O=C(O[C@H]1[C@H](OC(=O)C)[C@]2(CO)[C@H](O)[C@H](O)[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O[C@H]7[C@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)CO8)[C@@H](O)CO7)[C@H](O)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)/C(=C/C)/C
NCGC00380121-01	O=C(O[C@H]1[C@H](OC(=O)C)[C@]2(CO)[C@H](O)[C@H](O)[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O[C@H]7[C@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)CO8)[C@@H](O)CO7)[C@H](O)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)C(OC(=O)C)(CC)C		Inactive	<MOA Unknown> | Class: Saponin | Genus: Pittosporum | Family: Pittosporaceae | Species: viridifolium		1	NCGC00380121-01	363678464.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	15.5186313561	O=C(O[C@H]1[C@H](OC(=O)C)[C@]2(CO)[C@H](O)[C@H](O)[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O[C@H]7[C@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)CO8)[C@@H](O)CO7)[C@H](O)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)C(OC(=O)C)(CC)C	O=C(O[C@H]1[C@H](OC(=O)C)[C@]2(CO)[C@H](O)[C@H](O)[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](O[C@H]7[C@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@@H](O)CO8)[C@@H](O)CO7)[C@H](O)[C@@H](C(=O)O)O6)CC5)CC4)CC=C3[C@@H]2CC1(C)C)C(OC(=O)C)(CC)C
NCGC00249918-01	O=C(O[C@H]1[C@H](OC(=O)CC)C[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(OC(=O)CC)c2)CC		Inactive			1	Estriol tripropionate	170465876.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O[C@H]1[C@H](OC(=O)CC)C[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(OC(=O)CC)c2)CC	O=C(O[C@H]1[C@H](OC(=O)CC)C[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(OC(=O)CC)c2)CC
NCGC00167518-09&NCGC00167518-12	O=C(O[C@H]1[C@H](OC)C[C@H](C[C@@H](C)[C@H]2OC(=O)[C@H]3N(C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C2)CCCC3)CC1)C(CO)(CO)C		Inactive	mTOR Inhibitor		2	Temsirolimus	405559026.0&384568322.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O[C@H]1[C@H](OC)C[C@H](C[C@@H](C)[C@H]2OC(=O)[C@H]3N(C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C2)CCCC3)CC1)C(CO)(CO)C	O=C(O[C@H]1[C@H](OC)C[C@H](C[C@@H](C)[C@H]2OC(=O)[C@H]3N(C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C2)CCCC3)CC1)C(CO)(CO)C
NCGC00253604-01	O=C(O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@@H]2[C@H](C1)CN1[C@@H](c3[nH]c4c(c3CC1)ccc(OC)c4)C2)/C=C/c1cc(OC)c(O)cc1	4.9000001	Active	smooth muscle contraction Inhibitor	0.0	1	Rescimetol	170465875.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	95.9391538807	O=C(O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@@H]2[C@H](C1)CN1[C@@H](c3[nH]c4c(c3CC1)ccc(OC)c4)C2)/C=C/c1cc(OC)c(O)cc1	O=C(O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@@H]2[C@H](C1)CN1[C@@H](c3[nH]c4c(c3CC1)ccc(OC)c4)C2)/C=C/c1cc(OC)c(O)cc1
NCGC00179585-04	O=C(O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@@H]2[C@H](C1)CN1[C@@H](c3[nH]c4c(c3CC1)ccc(OC)c4)C2)/C=C/c1cc(OC)c(OC)c(OC)c1		Inactive	Serotonergic synapse Inhibitor		1	Rescinnamin	363676949.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@@H]2[C@H](C1)CN1[C@@H](c3[nH]c4c(c3CC1)ccc(OC)c4)C2)/C=C/c1cc(OC)c(OC)c(OC)c1	O=C(O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@@H]2[C@H](C1)CN1[C@@H](c3[nH]c4c(c3CC1)ccc(OC)c4)C2)/C=C/c1cc(OC)c(OC)c(OC)c1
NCGC00185767-01	O=C(O[C@H]1[C@H](OC)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2O[C@H](C)[C@@H](N(C)C)CC2)C=CC=CC[C@@H](C)OC(=O)C1)C	4.9000001	Active	Bacterial 70S ribosome Binding Agent	0.0	1	Spiramycin II	144207139.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	107.996831121	O=C(O[C@H]1[C@H](OC)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2O[C@H](C)[C@@H](N(C)C)CC2)C=CC=CC[C@@H](C)OC(=O)C1)C	O=C(O[C@H]1[C@H](OC)[C@@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2O[C@H](C)[C@@H](N(C)C)CC2)C=CC=CC[C@@H](C)OC(=O)C1)C
NCGC00179619-06	O=C(O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](OC)(C)C3)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]2(O)C)O[C@H](C)C[C@@H]1N(C)C)CC		Inactive	NF-kappaB Activation Inhibitor		1	Erythromycin propionate	170465433.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](OC)(C)C3)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]2(O)C)O[C@H](C)C[C@@H]1N(C)C)CC	O=C(O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](OC)(C)C3)[C@@H](C)C(=O)O[C@H](CC)[C@](O)(C)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@]2(O)C)O[C@H](C)C[C@@H]1N(C)C)CC
NCGC00385128-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)CO7)[C@@H](CO)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385128-01	363679550.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)CO7)[C@@H](CO)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O[C@H]7[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O7)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)CO7)[C@@H](CO)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2
NCGC00385738-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385738-01	363679913.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@@](C(=O)O)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)C5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00385331-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](OC/C=C(/CCC=C(C)C)\C)O[C@@H]1CO)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385331-01	363679682.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](OC/C=C(/CCC=C(C)C)\C)O[C@@H]1CO)/C=C/c1ccc(O)cc1	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](OC/C=C(/CCC=C(C)C)\C)O[C@@H]1CO)/C=C/c1ccc(O)cc1
NCGC00378687-03	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](OCCc2cc(O)c(O)cc2)O[C@@H]1CO)/C=C/c1cc(O)c(O)cc1		Inactive			1	Verbascoside	434147241.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](OCCc2cc(O)c(O)cc2)O[C@@H]1CO)/C=C/c1cc(O)c(O)cc1	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](OCCc2cc(O)c(O)cc2)O[C@@H]1CO)/C=C/c1cc(O)c(O)cc1
NCGC00381215-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](OCCc2cc(OC)c(OC)cc2)O[C@@H]1CO[C@@H]1[C@H](O)[C@@](O)(CO)CO1)/C=C/c1cc(O)c(O)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381215-01	363679028.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](OCCc2cc(OC)c(OC)cc2)O[C@@H]1CO[C@@H]1[C@H](O)[C@@](O)(CO)CO1)/C=C/c1cc(O)c(O)cc1	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O)[C@H](OCCc2cc(OC)c(OC)cc2)O[C@@H]1CO[C@@H]1[C@H](O)[C@@](O)(CO)CO1)/C=C/c1cc(O)c(O)cc1
NCGC00385806-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)[C@@H](C)O1)C12C(C=3C(CO)(C4(C)C(C5(C)C(C(C(=O)O)(C)C(O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)C(O)C5)CC4)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385806-01	363679949.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)[C@@H](C)O1)C12C(C=3C(CO)(C4(C)C(C5(C)C(C(C(=O)O)(C)C(O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)C(O)C5)CC4)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)[C@@H](C)O1)C12C(C=3C(CO)(C4(C)C(C5(C)C(C(C(=O)O)(C)C(O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)C(O)C5)CC4)CC=3)CC1)CC(C)(C)CC2
NCGC00385729-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@@H]4[C@@H](O)[C@@H](O)[C@H](O)[C@@H](C)O4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@H](O)[C@H](O)C5)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385729-01	363679904.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@@H]4[C@@H](O)[C@@H](O)[C@H](O)[C@@H](C)O4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@H](O)[C@H](O)C5)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@@H]4[C@@H](O)[C@@H](O)[C@H](O)[C@@H](C)O4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@H](O)[C@H](O)C5)CC=3)CC1)CC(C)(C)CC2
NCGC00385252-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)C5)CC=C3[C@@H]1CC(C)(C)CC2	5.6999998	Active	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00385252-01	363679618.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	3.0	81.6825763742	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)C5)CC=C3[C@@H]1CC(C)(C)CC2	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)C5)CC=C3[C@@H]1CC(C)(C)CC2
NCGC00384864-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O)[C@@H](O)[C@@H](O)CO7)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	5.6999998	Active	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00384864-01	363679404.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	3.0	96.17019568	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O)[C@@H](O)[C@@H](O)CO7)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O)[C@@H](O)[C@@H](O)CO7)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2
NCGC00385171-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O[C@@H]6[C@H](O)[C@@](O)(CO)CO6)[C@@H](CO)O4)[C@@H](O)C5)CC=C3[C@@H]1CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Madhuca | Family: Sapotacea | Species: butyracea		1	NCGC00385171-01	363679578.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O[C@@H]6[C@H](O)[C@@](O)(CO)CO6)[C@@H](CO)O4)[C@@H](O)C5)CC=C3[C@@H]1CC(C)(C)CC2	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O[C@@H]6[C@H](O)[C@@](O)(CO)CO6)[C@@H](CO)O4)[C@@H](O)C5)CC=C3[C@@H]1CC(C)(C)CC2
NCGC00385415-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](CO)O4)[C@@H](O)C5)CC=C3[C@@H]1CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Madhuca | Family: Sapotacea | Species: butyracea		1	NCGC00385415-01	363679731.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](CO)O4)[C@@H](O)C5)CC=C3[C@@H]1CC(C)(C)CC2	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](CO)O4)[C@@H](O)C5)CC=C3[C@@H]1CC(C)(C)CC2
NCGC00380921-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@](C(=O)O)(CO)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)C5)CC4)CC=C3[C@@H]1CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380921-01	363678857.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	18.1289592719	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@](C(=O)O)(CO)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)C5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@](C(=O)O)(CO)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O)C5)CC4)CC=C3[C@@H]1CC(C)(C)CC2
NCGC00384880-02	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)C5)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384880-02	363679412.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)C5)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@@H](O)C5)CC=3)CC1)CC(C)(C)CC2
NCGC00385241-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)[C@@H](C)O1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)C5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	5.6999998	Active	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00385241-01	363679613.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	3.0	109.6897258415	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)[C@@H](C)O1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)C5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)[C@@H](C)O1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C([C@@](CO)(C)[C@@H](O[C@H]6[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)C5)CC4)CC=C3[C@@H]1CC(C)(C)CC2
NCGC00381088-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@H](C)O2)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](OC(=O)/C=C/c3ccc(O)cc3)[C@H](O)[C@@H](CO)O2)O[C@@H]1CO)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381088-01	363678962.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@H](C)O2)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](OC(=O)/C=C/c3ccc(O)cc3)[C@H](O)[C@@H](CO)O2)O[C@@H]1CO)/C=C/c1ccc(O)cc1	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@H](C)O2)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](OC(=O)/C=C/c3ccc(O)cc3)[C@H](O)[C@@H](CO)O2)O[C@@H]1CO)/C=C/c1ccc(O)cc1
NCGC00384979-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](C)O3)[C@H](C)O2)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](OC(=O)/C=C/c3ccc(O)cc3)[C@H](O)[C@@H](CO)O2)O[C@@H]1CO)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384979-01	363679466.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](C)O3)[C@H](C)O2)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](OC(=O)/C=C/c3ccc(O)cc3)[C@H](O)[C@@H](CO)O2)O[C@@H]1CO)/C=C/c1ccc(O)cc1	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@](O)(CO)CO4)[C@H](C)O3)[C@H](C)O2)[C@@H](O)[C@@H](O[C@@]2(CO)[C@@H](OC(=O)/C=C/c3ccc(O)cc3)[C@H](O)[C@@H](CO)O2)O[C@@H]1CO)/C=C/c1ccc(O)cc1
NCGC00385322-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@@H]4[C@@H](O)[C@@H](O)[C@H](O)[C@@H](C)O4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@H](O)C5)CC=3)CC1)CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385322-01	363679675.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	22.371908544	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@@H]4[C@@H](O)[C@@H](O)[C@H](O)[C@@H](C)O4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@H](O)C5)CC=3)CC1)CC(C)(C)CC2	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@@H]4[C@@H](O)[C@@H](O)[C@H](O)[C@@H](C)O4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@@H](O)CO1)[C@]12[C@H](C=3[C@](C)([C@@]4(C)C([C@]5(C)C([C@H](O)C4)[C@@](CO)(C)[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@H](O)C5)CC=3)CC1)CC(C)(C)CC2
NCGC00385743-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O)[C@@H](O)[C@@H](O)CO7)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	5.6999998	Active	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00385743-01	363679917.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	3.0	103.7221466071	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O)[C@@H](O)[C@@H](O)CO7)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O)[C@@H](O)[C@@H](O)CO7)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2
NCGC00385321-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O)[C@@H](O)[C@@H](O)CO7)O6)[C@@H](O)C5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	5.6999998	Active	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00385321-01	363679674.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	3.0	91.9899296477	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O)[C@@H](O)[C@@H](O)CO7)O6)[C@@H](O)C5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O)[C@@H](O)[C@@H](O)CO7)O6)[C@@H](O)C5)CC4)CC=C3[C@@H]1CC(C)(C)CC2
NCGC00385156-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@@H](O)CO3)[C@H](C)O2)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O)[C@@H](O)[C@@H](O)CO7)O6)[C@@H](O)C5)CC4)CC=C3[C@@H]1CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385156-01	363679567.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@@H](O)CO3)[C@H](C)O2)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O)[C@@H](O)[C@@H](O)CO7)O6)[C@@H](O)C5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O[C@H]3[C@H](O)[C@@](O)(CO)CO3)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@@H](O)CO3)[C@H](C)O2)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](O)CO1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O)[C@@H](O)[C@@H](O)CO7)O6)[C@@H](O)C5)CC4)CC=C3[C@@H]1CC(C)(C)CC2
NCGC00384530-01	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)CO8)[C@@H](O)[C@@H](O)CO7)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2		Inactive	<MOA Unknown> | Class: Saponin | Genus: Gleditsia | Family: N/A | Species: triacanthos		1	NCGC00384530-01	363679233.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)CO8)[C@@H](O)[C@@H](O)CO7)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2	O=C(O[C@H]1[C@H](O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)CO4)[C@H](O)CO3)[C@H](C)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]12[C@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]7[C@H](O[C@H]8[C@H](O)[C@@H](O)[C@H](O)CO8)[C@@H](O)[C@@H](O)CO7)O6)CC5)CC4)CC=C3[C@@H]1CC(C)(C)CC2
NCGC00385050-01	O=C(O[C@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(/C)\[C@@H](OC(=O)C)C/C=C(\C)/C1)/C(=C/CO)/CO		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Schkuria | Family: Compositae | Species: pinnata		1	NCGC00385050-01	363679506.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(/C)\[C@@H](OC(=O)C)C/C=C(\C)/C1)/C(=C/CO)/CO	O=C(O[C@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(/C)\[C@@H](OC(=O)C)C/C=C(\C)/C1)/C(=C/CO)/CO
NCGC00380850-01	O=C(O[C@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\C)/C(=O)/C=C/[C@@](O)(C)C1)C(C)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Tithonia | Family: Compositae | Species: diversifolia		1	NCGC00380850-01	363678813.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\C)/C(=O)/C=C/[C@@](O)(C)C1)C(C)C	O=C(O[C@H]1[C@H]2C(=C)C(=O)O[C@@H]2/C=C(\C)/C(=O)/C=C/[C@@](O)(C)C1)C(C)C
NCGC00380727-01	O=C(O[C@H]1[C@H]2C(C)(C)CCC[C@]2(C)C(O)(C(=O)O)C(CO)=C1)/C=C/C=C/C=C/C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380727-01	363678741.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H]2C(C)(C)CCC[C@]2(C)C(O)(C(=O)O)C(CO)=C1)/C=C/C=C/C=C/C	O=C(O[C@H]1[C@H]2C(C)(C)CCC[C@]2(C)C(O)(C(=O)O)C(CO)=C1)/C=C/C=C/C=C/C
NCGC00384946-01	O=C(O[C@H]1[C@H]2C(C)(C)CCC[C@]2(C)[C@@](O)(CO)C(C(=O)O)=C1)/C=C/C=C/C(O)C(O)C		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: Aspergillus ? | Family: N/A | Species: N/A		1	NCGC00384946-01	363679452.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H]2C(C)(C)CCC[C@]2(C)[C@@](O)(CO)C(C(=O)O)=C1)/C=C/C=C/C(O)C(O)C	O=C(O[C@H]1[C@H]2C(C)(C)CCC[C@]2(C)[C@@](O)(CO)C(C(=O)O)=C1)/C=C/C=C/C(O)C(O)C
NCGC00380885-01	O=C(O[C@H]1[C@H]2C(C)(C)CCC[C@]2(C)[C@@](O)(CO)C(CO)=C1)/C=C/C=C/C=C/C		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: Aspergillus | Family: N/A | Species: cf niger ct ustus		1	NCGC00380885-01	363678832.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H]2C(C)(C)CCC[C@]2(C)[C@@](O)(CO)C(CO)=C1)/C=C/C=C/C=C/C	O=C(O[C@H]1[C@H]2C(C)(C)CCC[C@]2(C)[C@@](O)(CO)C(CO)=C1)/C=C/C=C/C=C/C
NCGC00380963-01	O=C(O[C@H]1[C@H]2C(C)(C)CCC[C@]2(C)[C@@]2(O)C(=O)OCC2=C1)/C=C/C=C/C		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380963-01	363678888.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H]2C(C)(C)CCC[C@]2(C)[C@@]2(O)C(=O)OCC2=C1)/C=C/C=C/C	O=C(O[C@H]1[C@H]2C(C)(C)CCC[C@]2(C)[C@@]2(O)C(=O)OCC2=C1)/C=C/C=C/C
NCGC00169507-03	O=C(O[C@H]1[C@H]2C(C)(C)CCC[C@]2(C)[C@@]2(O)C(=O)OCC2=C1)/C=C/C=C/C=C/C		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: Aspergillus | Family: N/A | Species: cf niger ct ustus		1	NCGC00169507-03	363676834.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@H]2C(C)(C)CCC[C@]2(C)[C@@]2(O)C(=O)OCC2=C1)/C=C/C=C/C=C/C	O=C(O[C@H]1[C@H]2C(C)(C)CCC[C@]2(C)[C@@]2(O)C(=O)OCC2=C1)/C=C/C=C/C=C/C
NCGC00169459-03	O=C(O[C@H]1[C@](C=C)(C)CCC=2[C@@]3(C)[C@@H](OC(=O)C)CC[C@](C(=O)OC)(C)C3C[C@@H](OC(=O)C)C1=2)C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Lycopus | Family: Lamiaceae | Species: europaeus		1	NCGC00169459-03	363676821.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@](C=C)(C)CCC=2[C@@]3(C)[C@@H](OC(=O)C)CC[C@](C(=O)OC)(C)C3C[C@@H](OC(=O)C)C1=2)C	O=C(O[C@H]1[C@](C=C)(C)CCC=2[C@@]3(C)[C@@H](OC(=O)C)CC[C@](C(=O)OC)(C)C3C[C@@H](OC(=O)C)C1=2)C
NCGC00263548-23	O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C		Inactive	Tubulin polymerization inhibitor		1	VINBLASTINE SULFATE	384568687.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C	O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C
NCGC00344583-01	O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CC[N@]4C[C@](O)(CC)C[C@@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C		Inactive	Tubulin Inhibitor		1	Vinblastine sulfate	170464976.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0		S(=O)(=O)(O)O.O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CC[N@]4C[C@](O)(CC)C[C@@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C	S(=O)(=O)(O)O.O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CC[N@]4C[C@](O)(CC)C[C@@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C
NCGC00165966-05&NCGC00165966-06	O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CN4CC(CC)=C[C@@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C		Inactive			2	Vinorelbine (ditartrate)&Vinorelbine tartrate 	384568301.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CN4CC(CC)=C[C@@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C	O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CN4CC(CC)=C[C@@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C
NCGC00163700-12&NCGC00163700-14	O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C=O)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C		Inactive	Tubulin polymerization Inhibitor		2	Vincristine sulfate	404904683.0&384568248.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C=O)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C	O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C=O)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@@H]2[C@@]1(CC)C=CCN2CC3)C
NCGC00380599-01	O=C(O[C@H]1[C@](O)(C)C(=O)C2=C(C=C(/C=C/C)OC2)C1)c1c(C)c(O)c(OC)cc1O		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380599-01	363678667.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@](O)(C)C(=O)C2=C(C=C(/C=C/C)OC2)C1)c1c(C)c(O)c(OC)cc1O	O=C(O[C@H]1[C@](O)(C)C(=O)C2=C(C=C(/C=C/C)OC2)C1)c1c(C)c(O)c(OC)cc1O
NCGC00381004-01	O=C(O[C@H]1[C@](O)(C)C2[C@@](C)(CC(=O)C(=C(C)C)C2)CC1)C1(C)C(C)O1		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: Pluchea | Family: Compositae | Species: odorata		1	NCGC00381004-01	363678918.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@](O)(C)C2[C@@](C)(CC(=O)C(=C(C)C)C2)CC1)C1(C)C(C)O1	O=C(O[C@H]1[C@](O)(C)C2[C@@](C)(CC(=O)C(=C(C)C)C2)CC1)C1(C)C(C)O1
NCGC00247515-02	O=C(O[C@H]1[C@](O)(C)[C@@H](C)Cc2c(c(OC)c3OCOc3c2)-c2c(OC)c(OC)c(OC)cc12)/C(=C\C)/C		Inactive			1	Schisantherin B		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@](O)(C)[C@@H](C)Cc2c(c(OC)c3OCOc3c2)-c2c(OC)c(OC)c(OC)cc12)/C(=C\C)/C	O=C(O[C@H]1[C@](O)(C)[C@@H](C)Cc2c(c(OC)c3OCOc3c2)-c2c(OC)c(OC)c(OC)cc12)/C(=C\C)/C
NCGC00347519-02	O=C(O[C@H]1[C@](OC(=O)C)(C)[C@H]2[C@@](C)(CC(=O)C(=C(C)C)C2)CC1)C(O)(C(OC(=O)C)C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347519-02	363677611.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@](OC(=O)C)(C)[C@H]2[C@@](C)(CC(=O)C(=C(C)C)C2)CC1)C(O)(C(OC(=O)C)C)C	O=C(O[C@H]1[C@](OC(=O)C)(C)[C@H]2[C@@](C)(CC(=O)C(=C(C)C)C2)CC1)C(O)(C(OC(=O)C)C)C
NCGC00347358-02	O=C(O[C@H]1[C@]2(C)C3C([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CCC2C[C@@H](O[C@H]2C(O)C(O)C(OC3C(O)C(OC)C(O)C(C)O3)C(CO)O2)C1)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347358-02	363677577.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@]2(C)C3C([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CCC2C[C@@H](O[C@H]2C(O)C(O)C(OC3C(O)C(OC)C(O)C(C)O3)C(CO)O2)C1)C	O=C(O[C@H]1[C@]2(C)C3C([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CCC2C[C@@H](O[C@H]2C(O)C(O)C(OC3C(O)C(OC)C(O)C(C)O3)C(CO)O2)C1)C
NCGC00385143-01	O=C(O[C@H]1[C@]2(C)[C@@H](C(=O)C)CC[C@]2(O)[C@H]2C([C@]3(C)C(=CC2)C[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@@H]4O[C@H](C)[C@@H](O[C@@H]5O[C@H](C)[C@@H](O[C@@H]6O[C@H](C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@H](OC)C6)[C@@H](OC)C5)[C@@H](OC)C4)[C@@H](OC)C2)CC3)C1)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385143-01	363679556.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@]2(C)[C@@H](C(=O)C)CC[C@]2(O)[C@H]2C([C@]3(C)C(=CC2)C[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@@H]4O[C@H](C)[C@@H](O[C@@H]5O[C@H](C)[C@@H](O[C@@H]6O[C@H](C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@H](OC)C6)[C@@H](OC)C5)[C@@H](OC)C4)[C@@H](OC)C2)CC3)C1)/C(=C/C)/C	O=C(O[C@H]1[C@]2(C)[C@@H](C(=O)C)CC[C@]2(O)[C@H]2C([C@]3(C)C(=CC2)C[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@@H]4O[C@H](C)[C@@H](O[C@@H]5O[C@H](C)[C@@H](O[C@@H]6O[C@H](C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@H](OC)C6)[C@@H](OC)C5)[C@@H](OC)C4)[C@@H](OC)C2)CC3)C1)/C(=C/C)/C
NCGC00384620-01	O=C(O[C@H]1[C@]2(C)[C@@H](C(=O)C)CC[C@]2(O)[C@H]2C([C@]3(C)C(=CC2)C[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@@H]4O[C@H](C)[C@@H](O[C@H]5[C@H](O)[C@@H](OC)[C@H](O[C@@H]6O[C@H](C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](OC)C6)[C@@H](C)O5)[C@@H](OC)C4)[C@@H](OC)C2)CC3)C1)/C(=C/C)/C		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384620-01	363679276.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	14.060975612	O=C(O[C@H]1[C@]2(C)[C@@H](C(=O)C)CC[C@]2(O)[C@H]2C([C@]3(C)C(=CC2)C[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@@H]4O[C@H](C)[C@@H](O[C@H]5[C@H](O)[C@@H](OC)[C@H](O[C@@H]6O[C@H](C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](OC)C6)[C@@H](C)O5)[C@@H](OC)C4)[C@@H](OC)C2)CC3)C1)/C(=C/C)/C	O=C(O[C@H]1[C@]2(C)[C@@H](C(=O)C)CC[C@]2(O)[C@H]2C([C@]3(C)C(=CC2)C[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@@H]4O[C@H](C)[C@@H](O[C@H]5[C@H](O)[C@@H](OC)[C@H](O[C@@H]6O[C@H](C)[C@@H](O[C@H]7[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O7)[C@@H](OC)C6)[C@@H](C)O5)[C@@H](OC)C4)[C@@H](OC)C2)CC3)C1)/C(=C/C)/C
NCGC00180744-03	O=C(O[C@H]1[C@]2(C)[C@@H](C)CC[C@H](OC(=O)C)[C@H]2C(=O)c2occ(C)c12)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Senecio | Family: N/A | Species: spp		1	NCGC00180744-03	363677058.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@]2(C)[C@@H](C)CC[C@H](OC(=O)C)[C@H]2C(=O)c2occ(C)c12)C	O=C(O[C@H]1[C@]2(C)[C@@H](C)CC[C@H](OC(=O)C)[C@H]2C(=O)c2occ(C)c12)C
NCGC00180495-02	O=C(O[C@H]1[C@]2(C)[C@@H](C)CC[C@H]3O[C@@]23C(=O)c2occ(C)c12)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Euryops  | Family: N/A | Species: spp.		1	NCGC00180495-02	363677030.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@]2(C)[C@@H](C)CC[C@H]3O[C@@]23C(=O)c2occ(C)c12)C	O=C(O[C@H]1[C@]2(C)[C@@H](C)CC[C@H]3O[C@@]23C(=O)c2occ(C)c12)C
NCGC00347604-02	O=C(O[C@H]1[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(O)CO6)CC5)CC4)CC=C3C2CC(C)(C)C1)c1ccccc1		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347604-02	363677636.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(O)CO6)CC5)CC4)CC=C3C2CC(C)(C)C1)c1ccccc1	O=C(O[C@H]1[C@]2(CO)[C@@H](O)C[C@@]3(C)[C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(O)CO6)CC5)CC4)CC=C3C2CC(C)(C)C1)c1ccccc1
NCGC00485961-01	O=C(O[C@H]1[C@]2(O)[C@@H](OC)[C@H](O)[C@@]3(O)[C@@H]1[C@@H](C14C(OC)C[C@@H](O)[C@]5(COC)[C@H]1[C@@H](OC)C3C4N(C)C5)C2)c1ccccc1		Inactive	Cytochrome P450 3A5 Substrate		1	Benzoylmesaconine	363681445.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@]2(O)[C@@H](OC)[C@H](O)[C@@]3(O)[C@@H]1[C@@H](C14C(OC)C[C@@H](O)[C@]5(COC)[C@H]1[C@@H](OC)C3C4N(C)C5)C2)c1ccccc1	O=C(O[C@H]1[C@]2(O)[C@@H](OC)[C@H](O)[C@@]3(O)[C@@H]1[C@@H](C14C(OC)C[C@@H](O)[C@]5(COC)[C@H]1[C@@H](OC)C3C4N(C)C5)C2)c1ccccc1
NCGC00384842-01	O=C(O[C@H]1[C@]23C(C)(C)O[C@](OC)(O2)CC[C@]3(C)[C@@H]2[C@@](C)(Oc3c(C)c4c(c(OC)c3C2)C(=O)OC4)C1)C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384842-01	363679388.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@H]1[C@]23C(C)(C)O[C@](OC)(O2)CC[C@]3(C)[C@@H]2[C@@](C)(Oc3c(C)c4c(c(OC)c3C2)C(=O)OC4)C1)C	O=C(O[C@H]1[C@]23C(C)(C)O[C@](OC)(O2)CC[C@]3(C)[C@@H]2[C@@](C)(Oc3c(C)c4c(c(OC)c3C2)C(=O)OC4)C1)C
NCGC00163440-02	O=C(O[C@H]\1[C@@]23C(=O)N[C@@H](Cc4ccccc4)[C@@H]2[C@H](C)C(=C)[C@@H](O)[C@@H]3/C=C/C[C@H](C)C(=O)[C@](O)(C)/C=C/1)C		Inactive	actin polymerization or depolymerization Inhibitor		1	CYTOCHALASIN D	26756823.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	15.5	O=C(O[C@H]\1[C@@]23C(=O)N[C@@H](Cc4ccccc4)[C@@H]2[C@H](C)C(=C)[C@@H](O)[C@@H]3/C=C/C[C@H](C)C(=O)[C@](O)(C)/C=C/1)C	O=C(O[C@H]\1[C@@]23C(=O)N[C@@H](Cc4ccccc4)[C@@H]2[C@H](C)C(=C)[C@@H](O)[C@@H]3/C=C/C[C@H](C)C(=O)[C@](O)(C)/C=C/1)C
NCGC00380290-01	O=C(O[C@H]\1[C@H](O)[C@H]2C(=C)C(=O)O[C@@H]2C/C(/C)=C\C(=O)/C=C/1\C)/C(=C\C)/C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Vicoa | Family: Compositae | Species: indica		1	NCGC00380290-01	363678527.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	15.0449982041	O=C(O[C@H]\1[C@H](O)[C@H]2C(=C)C(=O)O[C@@H]2C/C(/C)=C\C(=O)/C=C/1\C)/C(=C\C)/C	O=C(O[C@H]\1[C@H](O)[C@H]2C(=C)C(=O)O[C@@H]2C/C(/C)=C\C(=O)/C=C/1\C)/C(=C\C)/C
NCGC00183366-07	O=C(O[C@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)C		Inactive	Progesterone Receptor Agonist		1	NORETHINDRONE ACETATE	405558906.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)C	O=C(O[C@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CC(=O)CC4)CC3)CC2)CC1)C
NCGC00344561-01	O=C(O[C@]1(C#C)[C@]2(CC)[C@H]([C@H]3[C@@H]([C@@H]4C(=C/C(=N/O)/CC4)CC3)CC2)CC1)C		Inactive	Progesterone receptor Agonist		1	Norgestimate	170464733.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(O[C@]1(C#C)[C@]2(CC)[C@H]([C@H]3[C@@H]([C@@H]4C(=C/C(=N/O)/CC4)CC3)CC2)CC1)C	O=C(O[C@]1(C#C)[C@]2(CC)[C@H]([C@H]3[C@@H]([C@@H]4C(=C/C(=N/O)/CC4)CC3)CC2)CC1)C
NCGC00166298-02	O=C(O[C@]1(C(=O)C)C(=C)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)C(C(C)=C[C@@H]21)=CC(=O)CC3)C		Inactive			1	Melengestrol acetate	170465702.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(O[C@]1(C(=O)C)C(=C)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)C(C(C)=C[C@@H]21)=CC(=O)CC3)C	O=C(O[C@]1(C(=O)C)C(=C)C[C@@H]2[C@]1(C)CC[C@@H]1[C@]3(C)C(C(C)=C[C@@H]21)=CC(=O)CC3)C
NCGC00385034-01	O=C(O[C@]1(C)C2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@]2(O)[C@@H](O)C1)/C=C/c1ccccc1		Inactive	Nitric oxide synthase, inducible Inhibitor		1	NCGC00385034-01	363679497.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@]1(C)C2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@]2(O)[C@@H](O)C1)/C=C/c1ccccc1	O=C(O[C@]1(C)C2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@]2(O)[C@@H](O)C1)/C=C/c1ccccc1
NCGC00385277-01	O=C(O[C@]1(C)C2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@]2(O)[C@H](O)C1)/C=C/c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: iridoid | Genus: Harpagophytum | Family: Pedaliaceae | Species: procumbens		1	NCGC00385277-01	363679637.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@]1(C)C2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@]2(O)[C@H](O)C1)/C=C/c1ccc(O)cc1	O=C(O[C@]1(C)C2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@]2(O)[C@H](O)C1)/C=C/c1ccc(O)cc1
NCGC00380676-01	O=C(O[C@]1(C)C2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@]2(O)[C@H](O)C1)/C=C\c1ccc(O)cc1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380676-01	363678704.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@]1(C)C2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@]2(O)[C@H](O)C1)/C=C\c1ccc(O)cc1	O=C(O[C@]1(C)C2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@]2(O)[C@H](O)C1)/C=C\c1ccc(O)cc1
NCGC00180384-03	O=C(O[C@]1(C)[C@H](OC(=O)C2(C)C(C)O2)CC[C@@]2(C)[C@H]1CC(=C(C)C)C(=O)C2)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Laggera | Family: Compositae | Species: pterodonta		1	NCGC00180384-03	363677016.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@]1(C)[C@H](OC(=O)C2(C)C(C)O2)CC[C@@]2(C)[C@H]1CC(=C(C)C)C(=O)C2)C	O=C(O[C@]1(C)[C@H](OC(=O)C2(C)C(C)O2)CC[C@@]2(C)[C@H]1CC(=C(C)C)C(=O)C2)C
NCGC00482789-01	O=C(O[C@]1(C)[C@H]2[C@H](OC3C(O)C(O)C(O)C(CO)O3)OC=C[C@@]2(O)[C@H](O)C1)C		Inactive			1	8-O-Acetylharpagide	434147156.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@]1(C)[C@H]2[C@H](OC3C(O)C(O)C(O)C(CO)O3)OC=C[C@@]2(O)[C@H](O)C1)C	O=C(O[C@]1(C)[C@H]2[C@H](OC3C(O)C(O)C(O)C(CO)O3)OC=C[C@@]2(O)[C@H](O)C1)C
NCGC00179325-04	O=C(O[C@]1(C)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@]2(O)[C@H](O)C1)/C=C/c1ccccc1		Inactive	Nitric oxide synthase, inducible Inhibitor		1	Harpagoside	363676942.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(O[C@]1(C)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@]2(O)[C@H](O)C1)/C=C/c1ccccc1	O=C(O[C@]1(C)[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C[C@@]2(O)[C@H](O)C1)/C=C/c1ccccc1
NCGC00017360-04	O=C(O[C@]12[C@@H](O)[C@H](OC)[C@]3(O)[C@H](OC(=O)c4ccccc4)C1C([C@]14[C@@H](OC)C[C@@H](O)[C@]5(COC)C1[C@@H](OC)C2[C@H]4N(CC)C5)C3)C		Inactive			1	Aconitine	405558809.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@]12[C@@H](O)[C@H](OC)[C@]3(O)[C@H](OC(=O)c4ccccc4)C1C([C@]14[C@@H](OC)C[C@@H](O)[C@]5(COC)C1[C@@H](OC)C2[C@H]4N(CC)C5)C3)C	O=C(O[C@]12[C@@H](O)[C@H](OC)[C@]3(O)[C@H](OC(=O)c4ccccc4)C1C([C@]14[C@@H](OC)C[C@@H](O)[C@]5(COC)C1[C@@H](OC)C2[C@H]4N(CC)C5)C3)C
NCGC00346660-03	O=C(O[C@]12[C@H]3[C@H](OC(=O)c4ccccc4)[C@@]4(O)C(C)(C)C([C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@H]1OC2)=C(C)[C@@H](O)C4)C		Inactive	antineoplastic intermediate		1	10-Deacetylbaccatin	384568891.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O[C@]12[C@H]3[C@H](OC(=O)c4ccccc4)[C@@]4(O)C(C)(C)C([C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@H]1OC2)=C(C)[C@@H](O)C4)C	O=C(O[C@]12[C@H]3[C@H](OC(=O)c4ccccc4)[C@@]4(O)C(C)(C)C([C@@H](O)C(=O)[C@]3(C)[C@@H](O)C[C@H]1OC2)=C(C)[C@@H](O)C4)C
NCGC00015067-14&NCGC00015067-22&NCGC00015067-24	O=C(Oc1c(C(=O)O)cccc1)C		Inactive	HMG-CoA Reductase Inhibitor		3	Aspirin	170465039.0&384567805.0&434146911.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C(Oc1c(C(=O)O)cccc1)C	O=C(Oc1c(C(=O)O)cccc1)C
NCGC00096014-03	O=C(Oc1c(C(=O)O)cccc1)c1c(O)cccc1		Inactive	prostaglandin biosynthetic process Inhibitor		1	Salsalate	170465545.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(Oc1c(C(=O)O)cccc1)c1c(O)cccc1	O=C(Oc1c(C(=O)O)cccc1)c1c(O)cccc1
NCGC00167468-02	O=C(Oc1c(C(=O)Oc2ccc(NC(=O)C)cc2)cccc1)C		Inactive	prostaglandin biosynthetic process Inhibitor		1	Benorylate	170466237.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(Oc1c(C(=O)Oc2ccc(NC(=O)C)cc2)cccc1)C	O=C(Oc1c(C(=O)Oc2ccc(NC(=O)C)cc2)cccc1)C
NCGC00387165-01	O=C(Oc1c(C(C)C)cccc1)NCCc1cc2c(cc1)cccc2		Inactive	Neutral cholesterol ester hydrolase 1 Inhibitor		1	JW 480	363680554.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Oc1c(C(C)C)cccc1)NCCc1cc2c(cc1)cccc2	O=C(Oc1c(C(C)C)cccc1)NCCc1cc2c(cc1)cccc2
NCGC00159498-03	O=C(Oc1c(C)c(C)c(OCC(O)CNC(C)C)cc1C)C		Inactive	Beta-2 adrenergic receptor Antagonist		1	Metipranolol	29215466.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1c(C)c(C)c(OCC(O)CNC(C)C)cc1C)C	O=C(Oc1c(C)c(C)c(OCC(O)CNC(C)C)cc1C)C
NCGC00181354-02	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C		Inactive	Retinoic acid receptor gamma Agonist		1	Tocoretinate	225144326.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C
NCGC00095255-08	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)C		Inactive			1	dl-alpha-Tocopheryl acetate	170465444.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)C	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)C
NCGC00167561-03	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)CCC(=O)O		Inactive			1	D-alpha-Tocopherol succinate	225144294.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	13.808483292	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)CCC(=O)O	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)CCC(=O)O
NCGC00164499-03	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)c1cnccc1		Inactive	platelet aggregation Inhibitor		1	DL-alpha Tocopheryl nicotinate	170465780.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)c1cnccc1	O=C(Oc1c(C)c(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1C)c1cnccc1
NCGC00181159-03	O=C(Oc1c(C)c2OCOc2c2[C@H]3N4[C@@H](O)[C@H]5N(C)[C@@H]([C@@H]4[C@H](SC[C@@]4(C(=O)OC3)NCCc3c4cc(OC)c(O)c3)c12)c1c(O)c(OC)c(C)cc1C5)C		Inactive	DNA-Damaging Drug		1	Trabectedin	384568393.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&10.73254536	O=C(Oc1c(C)c2OCOc2c2[C@H]3N4[C@@H](O)[C@H]5N(C)[C@@H]([C@@H]4[C@H](SC[C@@]4(C(=O)OC3)NCCc3c4cc(OC)c(O)c3)c12)c1c(O)c(OC)c(C)cc1C5)C	O=C(Oc1c(C)c2OCOc2c2[C@H]3N4[C@@H](O)[C@H]5N(C)[C@@H]([C@@H]4[C@H](SC[C@@]4(C(=O)OC3)NCCc3c4cc(OC)c(O)c3)c12)c1c(O)c(OC)c(C)cc1C5)C
NCGC00510477-01	O=C(Oc1c(C)c2OCOc2c2[C@H]3N4[C@@H](O)[C@H]5N(C)[C@@H]([C@@H]4[C@H](SC[C@@]4(C(=O)OC3)NCCc3c6c([nH]c43)ccc(OC)c6)c12)c1c(O)c(OC)c(C)cc1C5)C		Inactive	RNA Polymerase Inhibitor		1	Lurbinectedin	384569440.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1c(C)c2OCOc2c2[C@H]3N4[C@@H](O)[C@H]5N(C)[C@@H]([C@@H]4[C@H](SC[C@@]4(C(=O)OC3)NCCc3c6c([nH]c43)ccc(OC)c6)c12)c1c(O)c(OC)c(C)cc1C5)C	O=C(Oc1c(C)c2OCOc2c2[C@H]3N4[C@@H](O)[C@H]5N(C)[C@@H]([C@@H]4[C@H](SC[C@@]4(C(=O)OC3)NCCc3c6c([nH]c43)ccc(OC)c6)c12)c1c(O)c(OC)c(C)cc1C5)C
NCGC00160567-01	O=C(Oc1c(C)cc(OC(=O)C)c2c1cccc2)C		Inactive			1	Acetomenaphthone	144205458.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1c(C)cc(OC(=O)C)c2c1cccc2)C	O=C(Oc1c(C)cc(OC(=O)C)c2c1cccc2)C
NCGC00015678-10	O=C(Oc1c(C)cc(OCCN(C)C)c(C(C)C)c1)C		Inactive	Adrenergic receptor alpha-1 Antagonist		1	Moxisylyte hydrochloride	170465759.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1c(C)cc(OCCN(C)C)c(C(C)C)c1)C.Cl	O=C(Oc1c(C)cc(OCCN(C)C)c(C(C)C)c1)C.Cl
NCGC00346959-11	O=C(Oc1c(C)cccc1C)N(c1c(OC)cc(OC)cc1)c1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1		Inactive	Lck Kinase Inhibitor		1	HMSL10038	384568977.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	10.14866886	O=C(Oc1c(C)cccc1C)N(c1c(OC)cc(OC)cc1)c1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1	O=C(Oc1c(C)cccc1C)N(c1c(OC)cc(OC)cc1)c1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1
NCGC00385548-01	O=C(Oc1c(C2(COC(=O)C(C)C)OC2)ccc(C)c1)C(CC)C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385548-01	363679801.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Oc1c(C2(COC(=O)C(C)C)OC2)ccc(C)c1)C(CC)C	O=C(Oc1c(C2(COC(=O)C(C)C)OC2)ccc(C)c1)C(CC)C
NCGC00179499-05	O=C(Oc1c(OC(=O)C(C)(C)C)ccc(C(O)CNC)c1)C(C)(C)C		Inactive	Beta-2 adrenergic receptor Agonist		1	Dipivefrin hydrochloride	405559013.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1c(OC(=O)C(C)(C)C)ccc(C(O)CNC)c1)C(C)(C)C	O=C(Oc1c(OC(=O)C(C)(C)C)ccc(C(O)CNC)c1)C(C)(C)C
NCGC00253593-01	O=C(Oc1c(OC(=O)c2ccc(C)cc2)ccc(C(O)CNC(C)(C)C)c1)c1ccc(C)cc1		Inactive	Beta-2 adrenergic receptor Agonist		1	Bitolterol	170465239.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	20.86662452&25.4504193359	O=C(Oc1c(OC(=O)c2ccc(C)cc2)ccc(C(O)CNC(C)(C)C)c1)c1ccc(C)cc1	O=C(Oc1c(OC(=O)c2ccc(C)cc2)ccc(C(O)CNC(C)(C)C)c1)c1ccc(C)cc1
NCGC00164512-02	O=C(Oc1c(OC)cccc1)Oc1c(OC)cccc1		Inactive			1	Guaiacol carbonate	170465684.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(Oc1c(OC)cccc1)Oc1c(OC)cccc1	O=C(Oc1c(OC)cccc1)Oc1c(OC)cccc1
NCGC00346540-03	O=C(Oc1c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)cc(CO)cc1)C(C)C		Inactive	Muscarinic Antagonists		1	FESOTERODINE FUMARATE	405558955.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)cc(CO)cc1)C(C)C	O=C(Oc1c([C@H](CCN(C(C)C)C(C)C)c2ccccc2)cc(CO)cc1)C(C)C
NCGC00090680-06	O=C(Oc1c2c(ccc1)cccc2)NC		Inactive	Acetylcholinesterase Inhibitor		1	Carbaryl	170465695.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1c2c(ccc1)cccc2)NC	O=C(Oc1c2c(ccc1)cccc2)NC
NCGC00390698-01	O=C(Oc1c2ncccc2ccc1)c1c2c(n(CCCCC)c1)cccc2		Inactive	Cannabinoid CB2 receptor Agonist		1	PB-22	363680971.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Oc1c2ncccc2ccc1)c1c2c(n(CCCCC)c1)cccc2	O=C(Oc1c2ncccc2ccc1)c1c2c(n(CCCCC)c1)cccc2
NCGC00159478-04	O=C(Oc1c2ncccc2ccc1)c1ccccc1		Inactive			1	Benzoxiquine	170465534.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Oc1c2ncccc2ccc1)c1ccccc1	O=C(Oc1c2ncccc2ccc1)c1ccccc1
NCGC00015862-07	O=C(Oc1c[n+](C)ccc1)N(C)C		Inactive	Acetylcholinesterase Inhibitor		1	Pyridostigmine bromide	170464878.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1c[n+](C)ccc1)N(C)C.[Br-]	O=C(Oc1c[n+](C)ccc1)N(C)C.[Br-]
NCGC00510033-02	O=C(Oc1c[n+](C)ccc1)N(CCCCCCN(C(=O)Oc1c[n+](C)ccc1)C)C		Inactive	Acetylcholinesterase Inhibitor		1	Distigmine Bromide	405558528.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1c[n+](C)ccc1)N(CCCCCCN(C(=O)Oc1c[n+](C)ccc1)C)C	O=C(Oc1c[n+](C)ccc1)N(CCCCCCN(C(=O)Oc1c[n+](C)ccc1)C)C
NCGC00165915-05	O=C(Oc1cc(-c2cc(C(=O)N)ccc2)ccc1)NC1CCCCC1		Inactive	Fatty Acid Amide Hydrolase (FAAH) Inhibitor		1	KDS-4103	384568299.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1cc(-c2cc(C(=O)N)ccc2)ccc1)NC1CCCCC1	O=C(Oc1cc(-c2cc(C(=O)N)ccc2)ccc1)NC1CCCCC1
NCGC00159365-04	O=C(Oc1cc(C)ccc1)C		Inactive			1	m-Cresyl acetate	170466849.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1cc(C)ccc1)C	O=C(Oc1cc(C)ccc1)C
NCGC00484080-01&NCGC00484080-02	O=C(Oc1cc(NC(=O)C2(CN)CCN(c3ncnc4[nH]cc(C)c34)CC2)ccc1)N(C)C		Inactive	LIMK1/LIMK2 Inhibitor		2	LX-7101	363681171.0&384569271.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Oc1cc(NC(=O)C2(CN)CCN(c3ncnc4[nH]cc(C)c34)CC2)ccc1)N(C)C	O=C(Oc1cc(NC(=O)C2(CN)CCN(c3ncnc4[nH]cc(C)c34)CC2)ccc1)N(C)C
NCGC00351473-01	O=C(Oc1cc(O)cc(-c2cc(C(=O)N)ccc2)c1)NC1CCCCC1		Inactive			1	NCGC00351473-01	363677747.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Oc1cc(O)cc(-c2cc(C(=O)N)ccc2)c1)NC1CCCCC1	O=C(Oc1cc(O)cc(-c2cc(C(=O)N)ccc2)c1)NC1CCCCC1
NCGC00095054-05	O=C(Oc1cc(O)ccc1)C		Inactive			1	Resorcinol monoacetate	170465513.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1cc(O)ccc1)C	O=C(Oc1cc(O)ccc1)C
NCGC00179546-05	O=C(Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1)N(C)C		Inactive	Butyrylcholinesterase Inhibitor		1	Bambuterol hydrochloride	170466370.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1)N(C)C.Cl	O=C(Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1)N(C)C.Cl
NCGC00167531-02	O=C(Oc1cc([C@@H](N(C)C)C)ccc1)N(CC)C		Inactive	Acetylcholinesterase Inhibitors		1	Rivastigmine tartrate	170464721.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(Oc1cc([C@@H](N(C)C)C)ccc1)N(CC)C.O=C(O)[C@@H](O)[C@H](O)C(=O)O	O=C(Oc1cc([C@@H](N(C)C)C)ccc1)N(CC)C.O=C(O)[C@@H](O)[C@H](O)C(=O)O
NCGC00015730-11	O=C(Oc1cc([N+](C)(C)C)ccc1)N(C)C		Inactive	Acetylcholinesterase Inhibitor		1	Neostigmine bromide	170465765.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(Oc1cc([N+](C)(C)C)ccc1)N(C)C.[Br-]	O=C(Oc1cc([N+](C)(C)C)ccc1)N(C)C.[Br-]
NCGC00179526-05	O=C(Oc1cc([N+](C)(C)C)ccc1)N(CCCCCCCCCCN(C(=O)Oc1cc([N+](C)(C)C)ccc1)C)C		Inactive	Acetylcholinesterase Inhibitor		1	Demecarium bromide	405558429.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1cc([N+](C)(C)C)ccc1)N(CCCCCCCCCCN(C(=O)Oc1cc([N+](C)(C)C)ccc1)C)C	O=C(Oc1cc([N+](C)(C)C)ccc1)N(CCCCCCCCCCN(C(=O)Oc1cc([N+](C)(C)C)ccc1)C)C
NCGC00351474-02	O=C(Oc1cc(c(O)cc1)-c1cc(C(=O)N)ccc1)NC1CCCCC1		Inactive			1	URB937	363677748.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Oc1cc(c(O)cc1)-c1cc(C(=O)N)ccc1)NC1CCCCC1	O=C(Oc1cc(c(O)cc1)-c1cc(C(=O)N)ccc1)NC1CCCCC1
NCGC00402328-02	O=C(Oc1cc2N(CC)/C(=C/C(=O)C)/Sc2cc1)C		Inactive			1	TG007	377020425.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Oc1cc2N(CC)/C(=C/C(=O)C)/Sc2cc1)C	O=C(Oc1cc2N(CC)/C(=C/C(=O)C)/Sc2cc1)C
NCGC00093889-12	O=C(Oc1cc2[C@@]3(C)[C@@H](N(C)c2cc1)N(C)CC3)NC		Inactive			1	Physostigmine	170465757.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1cc2[C@@]3(C)[C@@H](N(C)c2cc1)N(C)CC3)NC	O=C(Oc1cc2[C@@]3(C)[C@@H](N(C)c2cc1)N(C)CC3)NC
NCGC00178697-07	O=C(Oc1cc2c(CC)c3c(nc2cc1)C=1N(C(=O)C2=C([C@@](O)(CC)C(=O)OC2)C=1)C3)N1CCC(N2CCCCC2)CC1		Inactive	DNA Topoisomerase I Inhibitor		1	Irinotecan	384568360.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(Oc1cc2c(CC)c3c(nc2cc1)C=1N(C(=O)C2=C([C@@](O)(CC)C(=O)OC2)C=1)C3)N1CCC(N2CCCCC2)CC1	O=C(Oc1cc2c(CC)c3c(nc2cc1)C=1N(C(=O)C2=C([C@@](O)(CC)C(=O)OC2)C=1)C3)N1CCC(N2CCCCC2)CC1
NCGC00249885-01	O=C(Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)C		Inactive			1	Estradiol acetate	170465258.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&11.981509156	O=C(Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)C	O=C(Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)C
NCGC00021274-04	O=C(Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)c1ccccc1		Inactive			1	ESTRADIOL BENZOATE	405559069.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	15.14170938&0.0	O=C(Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)c1ccccc1	O=C(Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)CC4)CC3)CC2)cc1)c1ccccc1
NCGC00389778-03	O=C(Oc1cc2c(cc(C(=N)N)cc2)cc1)c1ccc(N=C(N)N)cc1		Inactive	Tryptase Inhibitors		1	NafamostatMesylate			DPI_SARS-CoV-2_General	4.0	0.0	O=C(Oc1cc2c(cc(C(=N)N)cc2)cc1)c1ccc(N=C(N)N)cc1	O=C(Oc1cc2c(cc(C(=N)N)cc2)cc1)c1ccc(N=C(N)N)cc1
NCGC00160398-05&NCGC00160398-09&NCGC00160398-13	O=C(Oc1cc2c(cc(C(=N)N)cc2)cc1)c1ccc(NC(=N)N)cc1		Inactive	Tryptase Inhibitor		3	Nafamostat mesilate&NafamostatMesylate	170465855.0&384568193.0&434147011.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0&0.0	S(=O)(=O)(O)C.O=C(Oc1cc2c(cc(C(=N)N)cc2)cc1)c1ccc(NC(=N)N)cc1	S(=O)(=O)(O)C.O=C(Oc1cc2c(cc(C(=N)N)cc2)cc1)c1ccc(NC(=N)N)cc1&O=C(Oc1cc2c(cc(C(=N)N)cc2)cc1)c1ccc(NC(=N)N)cc1
NCGC00181917-01	O=C(Oc1cc2c(cc1)CCC2)C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1ccccc1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	Carbenicillin indanyl	144206652.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1cc2c(cc1)CCC2)C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1ccccc1	O=C(Oc1cc2c(cc1)CCC2)C(C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12)c1ccccc1
NCGC00370867-02	O=C(Oc1ccc(-c2ccc(C(=O)N)cc2)cc1)N(Cc1cc(-c2ccncc2)ccc1)C		Inactive	Monoacylglycerol lipase ABHD6 Inhibitor		1	WWL 70	363677896.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Oc1ccc(-c2ccc(C(=O)N)cc2)cc1)N(Cc1cc(-c2ccncc2)ccc1)C	O=C(Oc1ccc(-c2ccc(C(=O)N)cc2)cc1)N(Cc1cc(-c2ccncc2)ccc1)C
NCGC00384183-06	O=C(Oc1ccc(-c2ccc(C(=O)OCC)cc2)cc1)N(Cc1cc(-c2ccncc2)ccc1)C		Inactive	Liver carboxylesterase 1 Inhibitor		1	WWL113	363679178.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(Oc1ccc(-c2ccc(C(=O)OCC)cc2)cc1)N(Cc1cc(-c2ccncc2)ccc1)C	O=C(Oc1ccc(-c2ccc(C(=O)OCC)cc2)cc1)N(Cc1cc(-c2ccncc2)ccc1)C
NCGC00025297-04&NCGC00025297-06&NCGC00025297-10	O=C(Oc1ccc(C(=O)OCC)cc1)CCCCCNC(=N)N		Inactive	NF-kappaB Activation Inhibitor		3	Gabexate mesilate	170465830.0&384568066.0&434147254.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(O)C.O=C(Oc1ccc(C(=O)OCC)cc1)CCCCCNC(=N)N	S(=O)(=O)(O)C.O=C(Oc1ccc(C(=O)OCC)cc1)CCCCCNC(=N)N&O=C(Oc1ccc(C(=O)OCC)cc1)CCCCCNC(=N)N
NCGC00165767-04	O=C(Oc1ccc(C(c2ccc(OC(=O)C)cc2)=C2CCCCC2)cc1)C		Inactive	Estrogen receptor beta Antagonist		1	Cyclofenil	170465970.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1ccc(C(c2ccc(OC(=O)C)cc2)=C2CCCCC2)cc1)C	O=C(Oc1ccc(C(c2ccc(OC(=O)C)cc2)=C2CCCCC2)cc1)C
NCGC00016522-10	O=C(Oc1ccc(C(c2ncccc2)c2ccc(OC(=O)C)cc2)cc1)C		Inactive			1	Bisacodyl	170464843.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1ccc(C(c2ncccc2)c2ccc(OC(=O)C)cc2)cc1)C	O=C(Oc1ccc(C(c2ncccc2)c2ccc(OC(=O)C)cc2)cc1)C
NCGC00182998-01	O=C(Oc1ccc(C2(c3ccc(OC(=O)C)cc3)C(=O)Nc3c(O2)cccc3)cc1)C		Inactive			1	Bisoxatin acetate	144206872.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(Oc1ccc(C2(c3ccc(OC(=O)C)cc3)C(=O)Nc3c(O2)cccc3)cc1)C	O=C(Oc1ccc(C2(c3ccc(OC(=O)C)cc3)C(=O)Nc3c(O2)cccc3)cc1)C
NCGC00095933-04	O=C(Oc1ccccc1)c1c(O)cc(N)cc1		Inactive			1	Phenyl 4-aminosalicylate	170465273.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(Oc1ccccc1)c1c(O)cc(N)cc1	O=C(Oc1ccccc1)c1c(O)cc(N)cc1
NCGC00090887-04	O=C(Oc1ccccc1)c1c(O)cccc1		Inactive	Estrogen receptor alpha Agonist		1	Phenyl salicylate	170465501.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(Oc1ccccc1)c1c(O)cccc1	O=C(Oc1ccccc1)c1c(O)cccc1
NCGC00386928-01	O=C(Oc1ncc(-c2ccccc2)cc1)N1CCN(c2c3c(nc(C)c2)cccc3)CC1	5.0	Active		0.0	1	NCGC00386928-01	363680512.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	85.9017563135	O=C(Oc1ncc(-c2ccccc2)cc1)N1CCN(c2c3c(nc(C)c2)cccc3)CC1	O=C(Oc1ncc(-c2ccccc2)cc1)N1CCN(c2c3c(nc(C)c2)cccc3)CC1
NCGC00346894-04	O=C([C@@H](C/C=C/C)C)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O		Inactive	P-Glycoprotein (MDR-1; ABCB1) Inhibitor		1	Valspodar	384568965.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([C@@H](C/C=C/C)C)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O	O=C([C@@H](C/C=C/C)C)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O
NCGC00242597-01&NCGC00242597-02&NCGC00242597-10	O=C([C@@H](N)C12CC3(O)CC(C1)CC(C3)C2)N1[C@H](C#N)C[C@H]2[C@@H]1C2		Inactive	DPP-IV Inhibitor		3	Saxagliptin	124950715.0&363677150.0&434147064.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C([C@@H](N)C12CC3(O)CC(C1)CC(C3)C2)N1[C@H](C#N)C[C@H]2[C@@H]1C2	O=C([C@@H](N)C12CC3(O)CC(C1)CC(C3)C2)N1[C@H](C#N)C[C@H]2[C@@H]1C2
NCGC00378542-02	O=C([C@@H](N)CC)N1[C@H](C(=O)NCCCC)Cc2c1cccc2		Inactive	Tripeptidyl-peptidase 2 Inhibitor		1	Butabindide oxalate	363678084.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C([C@@H](N)CC)N1[C@H](C(=O)NCCCC)Cc2c1cccc2	O=C([C@@H](N)CC)N1[C@H](C(=O)NCCCC)Cc2c1cccc2
NCGC00387470-01	O=C([C@@H](N)[C@@H](CC)C)N1Cc2c(cccc2)C1		Inactive			1	TC-E 5007	363680626.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C([C@@H](N)[C@@H](CC)C)N1Cc2c(cccc2)C1	O=C([C@@H](N)[C@@H](CC)C)N1Cc2c(cccc2)C1
NCGC00181033-02	O=C([C@@H](NC(=O)[C@@H]1NC(=O)N(C)C(=O)C1)Cc1[nH]cnc1)N1[C@H](C(=O)N)CCC1		Inactive	Thyrotropin-Releasing Hormone (TRH) Analogs		1	Taltirelin	174006814.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([C@@H](NC(=O)[C@@H]1NC(=O)N(C)C(=O)C1)Cc1[nH]cnc1)N1[C@H](C(=O)N)CCC1	O=C([C@@H](NC(=O)[C@@H]1NC(=O)N(C)C(=O)C1)Cc1[nH]cnc1)N1[C@H](C(=O)N)CCC1
NCGC00163431-06	O=C([C@@H](NC(=O)[C@@H]1[C@@H](C(=O)NCCC)O1)C(CC)C)N1[C@H](C(=O)OC)CCC1		Inactive	Cathepsin B Inhibitor		1	CA-074 Me	384568238.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	23.792012596&22.6038882121	O=C([C@@H](NC(=O)[C@@H]1[C@@H](C(=O)NCCC)O1)C(CC)C)N1[C@H](C(=O)OC)CCC1	O=C([C@@H](NC(=O)[C@@H]1[C@@H](C(=O)NCCC)O1)C(CC)C)N1[C@H](C(=O)OC)CCC1
NCGC00381723-02	O=C([C@@H](NC(=O)[C@H]1NC(=O)N(C)C(=O)C1)Cc1nc[nH]c1)N1[C@H](C(=O)N)CCC1		Inactive	Thyrotropin-Releasing Hormone (TRH) Analogs		1	Taltirelin	405558765.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([C@@H](NC(=O)[C@H]1NC(=O)N(C)C(=O)C1)Cc1nc[nH]c1)N1[C@H](C(=O)N)CCC1	O=C([C@@H](NC(=O)[C@H]1NC(=O)N(C)C(=O)C1)Cc1nc[nH]c1)N1[C@H](C(=O)N)CCC1
NCGC00370876-01	O=C([C@@H](NCc1ccncc1)C(C)(C)C)N1Cc2c(cc(OC)c(OC)c2)CC1		Inactive	Orexin receptor 2 Antagonist		1	TCS OX2 29	363677904.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C([C@@H](NCc1ccncc1)C(C)(C)C)N1Cc2c(cc(OC)c(OC)c2)CC1	O=C([C@@H](NCc1ccncc1)C(C)(C)C)N1Cc2c(cc(OC)c(OC)c2)CC1
NCGC00387037-01	O=C([C@@H](O)C)N1CCC(N2C(=O)N(C)c3c2c2nc(-c4cnc(C)cc4)ccc2nc3)CC1		Inactive	mTOR Inhibitor		1	PF-04979064	363680530.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	28.9991708159	O=C([C@@H](O)C)N1CCC(N2C(=O)N(C)c3c2c2nc(-c4cnc(C)cc4)ccc2nc3)CC1	O=C([C@@H](O)C)N1CCC(N2C(=O)N(C)c3c2c2nc(-c4cnc(C)cc4)ccc2nc3)CC1
NCGC00263109-15	O=C([C@@H](O)C)N1CCN(Cc2c(C)c3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1		Inactive	mTOR Inhibitor		1	GDC-0980	384568596.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([C@@H](O)C)N1CCN(Cc2c(C)c3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1	O=C([C@@H](O)C)N1CCN(Cc2c(C)c3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1
NCGC00186637-01	O=C([C@@H](O)[C@@H](O)C)[C@H](OC)[C@H]1[C@H](OC2O[C@H](C)[C@@H](O)[C@H](OC3O[C@@H](C)[C@H](O)[C@@H](OC4O[C@@H](C)[C@H](OC(=O)C)[C@](O)(C)C4)C3)C2)C(=O)c2c(O)c3c(O)c(C)c(OC4O[C@@H](C)[C@@H](OC(=O)C)[C@@H](OC5O[C@@H](C)[C@@H](OC)[C@@H](O)C5)C4)cc3cc2C1		Inactive			1	Chromomycin A<SUB>3</SUB> from Streptomyces griseus	124897824.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([C@@H](O)[C@@H](O)C)[C@H](OC)[C@H]1[C@H](OC2O[C@H](C)[C@@H](O)[C@H](OC3O[C@@H](C)[C@H](O)[C@@H](OC4O[C@@H](C)[C@H](OC(=O)C)[C@](O)(C)C4)C3)C2)C(=O)c2c(O)c3c(O)c(C)c(OC4O[C@@H](C)[C@@H](OC(=O)C)[C@@H](OC5O[C@@H](C)[C@@H](OC)[C@@H](O)C5)C4)cc3cc2C1	O=C([C@@H](O)[C@@H](O)C)[C@H](OC)[C@H]1[C@H](OC2O[C@H](C)[C@@H](O)[C@H](OC3O[C@@H](C)[C@H](O)[C@@H](OC4O[C@@H](C)[C@H](OC(=O)C)[C@](O)(C)C4)C3)C2)C(=O)c2c(O)c3c(O)c(C)c(OC4O[C@@H](C)[C@@H](OC(=O)C)[C@@H](OC5O[C@@H](C)[C@@H](OC)[C@@H](O)C5)C4)cc3cc2C1
NCGC00181319-01	O=C([C@@H](O)[C@H](O)C)[C@@H](OC)C1[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](O[C@@H]4O[C@H](C)[C@@H](O)[C@](O)(C)C4)C3)C2)C(=O)c2c(O)c3c(O)c(C)c(O[C@@H]4O[C@H](C)[C@H](O)[C@H](O[C@@H]5O[C@H](C)[C@@H](O)[C@H](O)C5)C4)cc3cc2C1		Inactive	DNA Antagonist		1	Plicamycin	144206340.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([C@@H](O)[C@H](O)C)[C@@H](OC)C1[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](O[C@@H]4O[C@H](C)[C@@H](O)[C@](O)(C)C4)C3)C2)C(=O)c2c(O)c3c(O)c(C)c(O[C@@H]4O[C@H](C)[C@H](O)[C@H](O[C@@H]5O[C@H](C)[C@@H](O)[C@H](O)C5)C4)cc3cc2C1	O=C([C@@H](O)[C@H](O)C)[C@@H](OC)C1[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](O[C@@H]4O[C@H](C)[C@@H](O)[C@](O)(C)C4)C3)C2)C(=O)c2c(O)c3c(O)c(C)c(O[C@@H]4O[C@H](C)[C@H](O)[C@H](O[C@@H]5O[C@H](C)[C@@H](O)[C@H](O)C5)C4)cc3cc2C1
NCGC00344523-01	O=C([C@@H](O)[C@H](O)[C@@H](O)CO)CO		Inactive			1	L-(-)-Sorbose	170465548.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([C@@H](O)[C@H](O)[C@@H](O)CO)CO	O=C([C@@H](O)[C@H](O)[C@@H](O)CO)CO
NCGC00386418-01	O=C([C@@H](O)[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)[C@H](O)CO)CO		Inactive			1	Lactulose	363680271.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C([C@@H](O)[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)[C@H](O)CO)CO	O=C([C@@H](O)[C@H](O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)[C@H](O)CO)CO
NCGC00386484-01	O=C([C@@](CCN1CCN(c2c(OC)cccc2)CC1)(C)c1ccccc1)C1CCCCC1	5.0	Active	Serotonin 2b (5-HT2b) receptor Modulator	0.0	1	(R)-(-)-LY 426965 dihydrochloride	363680300.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	84.8757605359	O=C([C@@](CCN1CCN(c2c(OC)cccc2)CC1)(C)c1ccccc1)C1CCCCC1	O=C([C@@](CCN1CCN(c2c(OC)cccc2)CC1)(C)c1ccccc1)C1CCCCC1
NCGC00385384-01	O=C([C@@](O)(C)C1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@]1(C)C2CC=C2C(C)(C)[C@H](O)[C@@H](O)CC12)CCC(OC(=O)C)(C)C		Inactive			1	NCGC00385384-01	434147125.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([C@@](O)(C)C1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@]1(C)C2CC=C2C(C)(C)[C@H](O)[C@@H](O)CC12)CCC(OC(=O)C)(C)C	O=C([C@@](O)(C)C1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@]1(C)C2CC=C2C(C)(C)[C@H](O)[C@@H](O)CC12)CCC(OC(=O)C)(C)C
NCGC00385062-01	O=C([C@@](O)(C)C1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@]1(C)[C@H]2CC=C2C(C)(C)C(=O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C[C@@H]12)/C=C/C(OC(=O)C)(C)C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Lagenaria | Family: Cucurbitaceae | Species: siceraria		1	NCGC00385062-01	363679513.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C([C@@](O)(C)C1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@]1(C)[C@H]2CC=C2C(C)(C)C(=O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C[C@@H]12)/C=C/C(OC(=O)C)(C)C	O=C([C@@](O)(C)C1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@]1(C)[C@H]2CC=C2C(C)(C)C(=O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C[C@@H]12)/C=C/C(OC(=O)C)(C)C
NCGC00179767-02	O=C([C@@](O)(C)[C@@H]1[C@]2(C)[C@](C)([C@H]3[C@@](C)(C(=O)C2)[C@H]2C(C(C)(C)C(=O)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=C2)=CC3)CC1O)/C=C/C(OC(=O)C)(C)C		Inactive	lipid metabolic process Modulator		1	NCGC00179767-02	363676967.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([C@@](O)(C)[C@@H]1[C@]2(C)[C@](C)([C@H]3[C@@](C)(C(=O)C2)[C@H]2C(C(C)(C)C(=O)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=C2)=CC3)CC1O)/C=C/C(OC(=O)C)(C)C	O=C([C@@](O)(C)[C@@H]1[C@]2(C)[C@](C)([C@H]3[C@@](C)(C(=O)C2)[C@H]2C(C(C)(C)C(=O)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=C2)=CC3)CC1O)/C=C/C(OC(=O)C)(C)C
NCGC00384825-01	O=C([C@@](O)(C)[C@@H]1[C@]2(C)[C@](O)(C3=CC(=O)[C@H]4[C@@](C)(C3CC2)C[C@H](O)[C@H](O)C4)CC1)C[C@H]1[C@H](C)C(=O)O[C@@H]1C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384825-01	363679379.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C([C@@](O)(C)[C@@H]1[C@]2(C)[C@](O)(C3=CC(=O)[C@H]4[C@@](C)(C3CC2)C[C@H](O)[C@H](O)C4)CC1)C[C@H]1[C@H](C)C(=O)O[C@@H]1C	O=C([C@@](O)(C)[C@@H]1[C@]2(C)[C@](O)(C3=CC(=O)[C@H]4[C@@](C)(C3CC2)C[C@H](O)[C@H](O)C4)CC1)C[C@H]1[C@H](C)C(=O)O[C@@H]1C
NCGC00014911-03	O=C([C@@](O)(C)[C@H]1[C@H](O)C[C@@]2(C)[C@@]1(C)CC(=O)[C@@]1(C)[C@H]3C(C(C)(C)C(=O)C(O)=C3)=CC[C@@H]21)/C=C\C(O)(C)C		Inactive	STAT-3 Inhibitor		1	Cucurbitacin I	384567796.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C([C@@](O)(C)[C@H]1[C@H](O)C[C@@]2(C)[C@@]1(C)CC(=O)[C@@]1(C)[C@H]3C(C(C)(C)C(=O)C(O)=C3)=CC[C@@H]21)/C=C\C(O)(C)C	O=C([C@@](O)(C)[C@H]1[C@H](O)C[C@@]2(C)[C@@]1(C)CC(=O)[C@@]1(C)[C@H]3C(C(C)(C)C(=O)C(O)=C3)=CC[C@@H]21)/C=C\C(O)(C)C
NCGC00179885-03	O=C([C@@](O)(C)[C@H]1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@@]1(C)[C@H]3C(C(C)(C)C(=O)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=C3)=CC[C@@H]21)/C=C/C(O)(C)C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Ecballium | Family: N/A | Species: elaterium		1	NCGC00179885-03	363676982.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C([C@@](O)(C)[C@H]1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@@]1(C)[C@H]3C(C(C)(C)C(=O)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=C3)=CC[C@@H]21)/C=C/C(O)(C)C	O=C([C@@](O)(C)[C@H]1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@@]1(C)[C@H]3C(C(C)(C)C(=O)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)=C3)=CC[C@@H]21)/C=C/C(O)(C)C
NCGC00385253-01	O=C([C@@](O)(C)[C@H]1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@]1(C)[C@H]2CC=C2C(C)(C)C(=O)[C@@H](O)C[C@@H]12)/C=C/C(O)(C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Begonia | Family: Begoniaceae | Species: keniensis		1	NCGC00385253-01	363679619.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C([C@@](O)(C)[C@H]1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@]1(C)[C@H]2CC=C2C(C)(C)C(=O)[C@@H](O)C[C@@H]12)/C=C/C(O)(C)C	O=C([C@@](O)(C)[C@H]1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@]1(C)[C@H]2CC=C2C(C)(C)C(=O)[C@@H](O)C[C@@H]12)/C=C/C(O)(C)C
NCGC00385061-01	O=C([C@@](O)(C)[C@H]1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@]1(C)[C@H]2CC=C2C(C)(C)C(=O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C[C@@H]12)/C=C/C(O)(C)C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Ecballium | Family: N/A | Species: elaterium		1	NCGC00385061-01	363679512.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C([C@@](O)(C)[C@H]1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@]1(C)[C@H]2CC=C2C(C)(C)C(=O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C[C@@H]12)/C=C/C(O)(C)C	O=C([C@@](O)(C)[C@H]1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@]1(C)[C@H]2CC=C2C(C)(C)C(=O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C[C@@H]12)/C=C/C(O)(C)C
NCGC00386015-01	O=C([C@@](OC(=O)C)(C)[C@H]1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@@]1(C)[C@H]3C(C(C)(C)C(=O)C(O)=C3)=CC[C@@H]21)/C=C/C(O)(C)C		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Iberis | Family: N/A | Species: contracta		1	NCGC00386015-01	363680060.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C([C@@](OC(=O)C)(C)[C@H]1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@@]1(C)[C@H]3C(C(C)(C)C(=O)C(O)=C3)=CC[C@@H]21)/C=C/C(O)(C)C	O=C([C@@](OC(=O)C)(C)[C@H]1[C@H](O)C[C@]2(C)[C@]1(C)CC(=O)[C@@]1(C)[C@H]3C(C(C)(C)C(=O)C(O)=C3)=CC[C@@H]21)/C=C/C(O)(C)C
NCGC00263203-06	O=C([C@H](OC)c1ccccc1)N1Cc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2C1		Inactive	Aurora-A/B/C Kinase Inhibitor		1	Danusertib	384568662.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([C@H](OC)c1ccccc1)N1Cc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2C1	O=C([C@H](OC)c1ccccc1)N1Cc2c(NC(=O)c3ccc(N4CCN(C)CC4)cc3)n[nH]c2C1
NCGC00162440-05	O=C([C@H]([C@H](O)[C@H](C/C(=C/C(=O)O)/C)C)C)[C@@H](/C=C(/C=C/C[C@H](/C=C(\C=C\[C@H]1[C@@H](C)C=CC(=O)O1)/CC)C)\C)C		Inactive	Nuclear export Inhibitor		1	Leptomycin B	384568227.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.924686188	O=C([C@H]([C@H](O)[C@H](C/C(=C/C(=O)O)/C)C)C)[C@@H](/C=C(/C=C/C[C@H](/C=C(\C=C\[C@H]1[C@@H](C)C=CC(=O)O1)/CC)C)\C)C	O=C([C@H]([C@H](O)[C@H](C/C(=C/C(=O)O)/C)C)C)[C@@H](/C=C(/C=C/C[C@H](/C=C(\C=C\[C@H]1[C@@H](C)C=CC(=O)O1)/CC)C)\C)C
NCGC00167437-02	O=C([C@H]1Cc2nc[nH]c2CC1)c1c2c(n(C)c1)cccc2		Inactive	Serotonin 3a (5-HT3a) receptor Antagonist		1	Ramosetron hydrochloride	170465928.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([C@H]1Cc2nc[nH]c2CC1)c1c2c(n(C)c1)cccc2.Cl	O=C([C@H]1Cc2nc[nH]c2CC1)c1c2c(n(C)c1)cccc2.Cl
NCGC00178874-03	O=C([O-])CC(O)C[N+](C)(C)C		Inactive	Mitochondrial carnitine/acylcarnitine carrier protein Substrate		1	DL-Carnitine HCl	405558577.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CC(O)C[N+](C)(C)C	O=C(O)CC(O)C[N+](C)(C)C
NCGC00162463-03	O=C([O-])CC[C@H](C[C@@H](C[C@@H](C(=O)CC(=O)[C@@H](C[C@@H](C/C=C/[C@H]([C@@H](O)[C@H]([C@@H](O)C[C@H]1O[C@](C)([C@@H]2O[C@@]([C@H](O)C)(C)CC2)CC1)C)C)C)C)C)C)C	5.4000001	Active	Potassium channel subfamily K member 2 Inhibitor	0.0	1	Ionomycin(Calciumsalt)	363676613.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	58.348926376	O=C([C@H](C[C@H](C[C@@H](CCC(=O)[O-])C)C)C)/C=C(\[O-])/[C@@H](C[C@@H](C/C=C/[C@H]([C@@H](O)[C@H]([C@@H](O)C[C@H]1O[C@](C)([C@@H]2O[C@@]([C@H](O)C)(C)CC2)CC1)C)C)C)C	O=C([C@H](C[C@H](C[C@@H](CCC(=O)[O-])C)C)C)/C=C(\[O-])/[C@@H](C[C@@H](C/C=C/[C@H]([C@@H](O)[C@H]([C@@H](O)C[C@H]1O[C@](C)([C@@H]2O[C@@]([C@H](O)C)(C)CC2)CC1)C)C)C)C
NCGC00015150-04&NCGC00015150-07	O=C([O-])C[N+](C)(C)C		Inactive	Nitric Oxide (NO) Donors		2	Betaine	174007375.0&384567816.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&10.427031976	O=C(O)C[N+](C)(C)C.[Cl-]	O=C(O)C[N+](C)(C)C.[Cl-]&O=C(O)C[N+](C)(C)C
NCGC00095649-07	O=C([O-])c1c[n+](C)ccc1		Inactive			1	Trigonelline hydrochloride	434146929.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C([O-])c1c[n+](C)ccc1	O=C([O-])c1c[n+](C)ccc1
NCGC00263233-01	O=C(c1[nH]c2c(c3c(cc2)cccc3)c1)c1ccc(N)cc1	4.5	Active	Inducible phosphofructokinase-2 Inhibitor	0.0	1	IPFK2	137276077.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	86.713372591	O=C(c1[nH]c2c(c3c(cc2)cccc3)c1)c1ccc(N)cc1	O=C(c1[nH]c2c(c3c(cc2)cccc3)c1)c1ccc(N)cc1
NCGC00160396-04	O=C(c1c(C)n(CCN2CCOCC2)c2c1cccc2)c1ccc(OC)cc1		Inactive	COX Inhibitor and cannabinoid (CB) agonist		1	Pravadoline	170466117.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(c1c(C)n(CCN2CCOCC2)c2c1cccc2)c1ccc(OC)cc1	O=C(c1c(C)n(CCN2CCOCC2)c2c1cccc2)c1ccc(OC)cc1
NCGC00480730-01	O=C(c1c(N)c(c(C)cc1)-c1cc2c(nc(C)cc2)cc1)C=1C(=O)N(N(C)C=1c1ccccc1)c1ccccc1		Inactive	PERK Inhibitor		1	AMG PERK 44	377020519.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(c1c(N)c(c(C)cc1)-c1cc2c(nc(C)cc2)cc1)C=1C(=O)N(N(C)C=1c1ccccc1)c1ccccc1	O=C(c1c(N)c(c(C)cc1)-c1cc2c(nc(C)cc2)cc1)C=1C(=O)N(N(C)C=1c1ccccc1)c1ccccc1
NCGC00386433-04	O=C(c1c(N)n(-c2cc3[nH]c(C)nc3cc2)nc1)c1[nH]c2c(c1)cccc2	4.9499998	Active	FGFR 1/2/3 Inhibitor	0.0	1	CH-5183284	384569140.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	85.1716603591	O=C(c1c(N)n(-c2cc3[nH]c(C)nc3cc2)nc1)c1[nH]c2c(c1)cccc2	O=C(c1c(N)n(-c2cc3[nH]c(C)nc3cc2)nc1)c1[nH]c2c(c1)cccc2
NCGC00347642-03	O=C(c1c(O)c2c(OC3(C)C4C2C(C)(C)C4CC3)cc1O)c1ccccc1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Hypericum | Family: Guttiferae | Species: hookerianum		1	NCGC00347642-03	363677647.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	32.323845072	O=C(c1c(O)c2c(OC3(C)C4C2C(C)(C)C4CC3)cc1O)c1ccccc1	O=C(c1c(O)c2c(OC3(C)C4C2C(C)(C)C4CC3)cc1O)c1ccccc1
NCGC00016393-07	O=C(c1c(O)cc(OC)cc1)c1c(O)cccc1		Inactive			1	2,2'-Dihydroxy-4-methoxybenzophenone	170465540.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(c1c(O)cc(OC)cc1)c1c(O)cccc1	O=C(c1c(O)cc(OC)cc1)c1c(O)cccc1
NCGC00016394-10	O=C(c1c(O)cc(OC)cc1)c1ccccc1		Inactive			1	2-Hydroxy-4-methoxybenzophenone	170465010.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(c1c(O)cc(OC)cc1)c1ccccc1	O=C(c1c(O)cc(OC)cc1)c1ccccc1
NCGC00380087-01	O=C(c1c(O)cc2OC3(C)CC4c2c1OC(C)(C)C4CC3)c1ccccc1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Hypericum | Family: Guttiferae | Species: hookerianum		1	NCGC00380087-01	363678457.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	19.6158798321	O=C(c1c(O)cc2OC3(C)CC4c2c1OC(C)(C)C4CC3)c1ccccc1	O=C(c1c(O)cc2OC3(C)CC4c2c1OC(C)(C)C4CC3)c1ccccc1
NCGC00384934-01	O=C(c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)cc1O)c1ccccc1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Borreria | Family: N/A | Species: verticillata		1	NCGC00384934-01	363679447.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)cc1O)c1ccccc1	O=C(c1c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)cc(O)cc1O)c1ccccc1
NCGC00485948-01	O=C(c1c2c(ccc1)cccc2)C=1c2c3N([C@H](CN4CCOCC4)COc3ccc2)CC=1		Inactive	Cannabinoid CB2 receptor Agonist		1	WIN 55,212-2 (Mesylate)	363681436.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(c1c2c(ccc1)cccc2)C=1c2c3N([C@H](CN4CCOCC4)COc3ccc2)CC=1	O=C(c1c2c(ccc1)cccc2)C=1c2c3N([C@H](CN4CCOCC4)COc3ccc2)CC=1
NCGC00378993-02	O=C(c1c2c(n(CCCC)c1)cccc2)c1c2c(ccc1)cccc2		Inactive	Cannabinoid CB1 receptor Neutral Antagonist		1	JWH 073	363678305.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(c1c2c(n(CCCC)c1)cccc2)c1c2c(ccc1)cccc2	O=C(c1c2c(n(CCCC)c1)cccc2)c1c2c(ccc1)cccc2
NCGC00390224-01	O=C(c1c2c(n(CCCCC)c1)cccc2)C1C(C)(C)C1(C)C		Inactive	Cannabinoid CB2 receptor Agonist		1	UR-144	363680865.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(c1c2c(n(CCCCC)c1)cccc2)C1C(C)(C)C1(C)C	O=C(c1c2c(n(CCCCC)c1)cccc2)C1C(C)(C)C1(C)C
NCGC00386566-01	O=C(c1c2c(n(CCCCC)c1)cccc2)c1c2c(ccc1)cccc2		Inactive	Cannabinoid CB2 receptor Agonist		1	JWH 018	363680329.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(c1c2c(n(CCCCC)c1)cccc2)c1c2c(ccc1)cccc2	O=C(c1c2c(n(CCCCC)c1)cccc2)c1c2c(ccc1)cccc2
NCGC00386885-01	O=C(c1cc(OC(C)C)ccc1)C1CN(Cc2c(C)n(CCC)nc2)CCC1		Inactive			1	NCGC00386885-01	363680481.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(c1cc(OC(C)C)ccc1)C1CN(Cc2c(C)n(CCC)nc2)CCC1	O=C(c1cc(OC(C)C)ccc1)C1CN(Cc2c(C)n(CCC)nc2)CCC1
NCGC00092375-02	O=C(c1cc2c(nc3OCCCc3c2)cc1)C1CCC(OC)CC1		Inactive	mgluR1 Antagonist		1	JNJ-16259685	174006314.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(c1cc2c(nc3OCCCc3c2)cc1)C1CCC(OC)CC1	O=C(c1cc2c(nc3OCCCc3c2)cc1)C1CCC(OC)CC1
NCGC00387530-01	O=C(c1ccc(N2C(=O)c3c4C(C)(C)Oc5c(O)c(OC)ccc5-c4ccc3C2=O)cc1)c1ccccc1		Inactive			1	Ampkinone	377020408.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(c1ccc(N2C(=O)c3c4C(C)(C)Oc5c(O)c(OC)ccc5-c4ccc3C2=O)cc1)c1ccccc1	O=C(c1ccc(N2C(=O)c3c4C(C)(C)Oc5c(O)c(OC)ccc5-c4ccc3C2=O)cc1)c1ccccc1
NCGC00380982-01	O=C(c1ccccc1)C1(OC)C(O)C2(C(=O)C(C)=C(C(O)C(O)/C=C/CC)O2)C(=O)N1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380982-01	363678902.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(c1ccccc1)C1(OC)C(O)C2(C(=O)C(C)=C(C(O)C(O)/C=C/CC)O2)C(=O)N1	O=C(c1ccccc1)C1(OC)C(O)C2(C(=O)C(C)=C(C(O)C(O)/C=C/CC)O2)C(=O)N1
NCGC00381039-01	O=C(c1ccccc1)C1(OC)C(O)C2(C(=O)C(C)=C(C(O)C(O)/C=C\CC)O2)C(=O)N1		Inactive	<MOA Unknown> | Class: polyketide/AS | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381039-01	363678938.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(c1ccccc1)C1(OC)C(O)C2(C(=O)C(C)=C(C(O)C(O)/C=C\CC)O2)C(=O)N1	O=C(c1ccccc1)C1(OC)C(O)C2(C(=O)C(C)=C(C(O)C(O)/C=C\CC)O2)C(=O)N1
NCGC00381007-01	O=C(c1ccccc1)[C@@]1(O)[C@H](O)[C@]2(C(=O)C(C)=C([C@@H](O)[C@@H](O)/C=C\CC)O2)C(=O)N1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381007-01	363678921.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(c1ccccc1)[C@@]1(O)[C@H](O)[C@]2(C(=O)C(C)=C([C@@H](O)[C@@H](O)/C=C\CC)O2)C(=O)N1	O=C(c1ccccc1)[C@@]1(O)[C@H](O)[C@]2(C(=O)C(C)=C([C@@H](O)[C@@H](O)/C=C\CC)O2)C(=O)N1
NCGC00380089-01	O=C(c1ccccc1)[C@@]1(OC)[C@H](O)[C@]2(C(=O)C(C)=C([C@@H](O)[C@@H](O)/C=C\CC)O2)C(=O)N1		Inactive	<MOA Unknown> | Class: polyketide/AS; Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380089-01	363678458.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(c1ccccc1)[C@@]1(OC)[C@H](O)[C@]2(C(=O)C(C)=C([C@@H](O)[C@@H](O)/C=C\CC)O2)C(=O)N1	O=C(c1ccccc1)[C@@]1(OC)[C@H](O)[C@]2(C(=O)C(C)=C([C@@H](O)[C@@H](O)/C=C\CC)O2)C(=O)N1
NCGC00090787-08	O=C(c1ccccc1)c1ccccc1		Inactive			1	Benzophenone	170465649.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C(c1ccccc1)c1ccccc1	O=C(c1ccccc1)c1ccccc1
NCGC00185990-14	O=C(c1n2c(C(C(=O)O)CC2)cc1)c1ccccc1		Inactive	non-steroidal antiinflammatory		1	Ketorolac	384568431.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(c1n2c(C(C(=O)O)CC2)cc1)c1ccccc1	O=C(c1n2c(C(C(=O)O)CC2)cc1)c1ccccc1
NCGC00499248-01	O=C(c1nc2c(-c3ccc(-c4cn(C)nc4)cc3)cnc(N)c2cc1)C1CC(OC)C1		Inactive	CDK 8/19 Inhibitor		1	CDK8i-51	384569304.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	16.814720812	O=C(c1nc2c(-c3ccc(-c4cn(C)nc4)cc3)cnc(N)c2cc1)C1CC(OC)C1	O=C(c1nc2c(-c3ccc(-c4cn(C)nc4)cc3)cnc(N)c2cc1)C1CC(OC)C1
NCGC00370957-01	O=C(c1ncccc1)c1c2n(C(c3ccncc3)=CC=N2)nc1		Inactive	GABA-A receptor; benzodiazepine site Positive Allosteric Modulator		1	Ocinaplon	363677955.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(c1ncccc1)c1c2n(C(c3ccncc3)=CC=N2)nc1	O=C(c1ncccc1)c1c2n(C(c3ccncc3)=CC=N2)nc1
NCGC00390792-01	O=C(n1cncc1)c1c(C)occ1		Inactive	reverse transcription Blocker		1	5S rRNA modificator	363680985.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(n1cncc1)c1c(C)occ1	O=C(n1cncc1)c1c(C)occ1
NCGC00511348-01	O=C(n1nc(C(O)(c2ccccc2)c2ccccc2)cn1)N1C(CC)CCCC1		Inactive	ABHD11 Inhibitor		1	ML226	384569496.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(n1nc(C(O)(c2ccccc2)c2ccccc2)cn1)N1C(CC)CCCC1	O=C(n1nc(C(O)(c2ccccc2)c2ccccc2)cn1)N1C(CC)CCCC1
NCGC00370714-02	O=C(n1nc(C(O)(c2ccccc2)c2ccccc2)cn1)N1CCC(C(C)(C)C)CC1	5.0	Active	Acyl-protein thioesterase 2 Inhibitor	0.0	1	ML211	363677821.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	44.6929256407	O=C(n1nc(C(O)(c2ccccc2)c2ccccc2)cn1)N1CCC(C(C)(C)C)CC1	O=C(n1nc(C(O)(c2ccccc2)c2ccccc2)cn1)N1CCC(C(C)(C)C)CC1
NCGC00386849-01	O=C(n1nnc(-c2ccc(-c3c(OC)cccc3)cc2)c1)N1C(Cc2ccccc2)CCCC1		Inactive			1	NCGC00386849-01	363680465.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	23.5	O=C(n1nnc(-c2ccc(-c3c(OC)cccc3)cc2)c1)N1C(Cc2ccccc2)CCCC1	O=C(n1nnc(-c2ccc(-c3c(OC)cccc3)cc2)c1)N1C(Cc2ccccc2)CCCC1
NCGC00386845-01	O=C(n1nnc(-c2ccc(-c3cc(C(=O)O)ccc3)cc2)c1)N1C(Cc2ccccc2)CCCC1		Inactive			1	NCGC00386845-01	363680462.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(n1nnc(-c2ccc(-c3cc(C(=O)O)ccc3)cc2)c1)N1C(Cc2ccccc2)CCCC1	O=C(n1nnc(-c2ccc(-c3cc(C(=O)O)ccc3)cc2)c1)N1C(Cc2ccccc2)CCCC1
NCGC00386847-02	O=C(n1nnc(-c2ccc(-c3ccc(OC)cc3)cc2)c1)N1C(c2ccccc2)CCCC1		Inactive	Monoacylglycerol lipase ABHD6 Inhibitor		1	ML295	363680463.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C(n1nnc(-c2ccc(-c3ccc(OC)cc3)cc2)c1)N1C(c2ccccc2)CCCC1	O=C(n1nnc(-c2ccc(-c3ccc(OC)cc3)cc2)c1)N1C(c2ccccc2)CCCC1
NCGC00380340-01	O=C/1OC(C)CC(O)/C=C/C(O)/C=C\1		Inactive	<MOA Unknown> | Class: macrolide | Genus: n.b. | Family: N/A | Species: N/A		1	NCGC00380340-01	363678549.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C/1OC(C)CC(O)/C=C/C(O)/C=C\1	O=C/1OC(C)CC(O)/C=C/C(O)/C=C\1
NCGC00385803-01	O=C/C/1=C/CC/C(/CO)=C/[C@H]2OC(=O)C(=C)[C@@H]2[C@@H](O)C\1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Urospermum  | Family: N/A | Species: dalechampii		1	NCGC00385803-01	363679948.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C/C/1=C/CC/C(/CO)=C/[C@H]2OC(=O)C(=C)[C@@H]2[C@@H](O)C\1	O=C/C/1=C/CC/C(/CO)=C/[C@H]2OC(=O)C(=C)[C@@H]2[C@@H](O)C\1
NCGC00385517-01	O=C/C/1=C/CC/C(/CO)=C/[C@H]2OC(=O)C(=C)[C@@H]2[C@H](O)C\1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385517-01	363679785.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C/C/1=C/CC/C(/CO)=C/[C@H]2OC(=O)C(=C)[C@@H]2[C@H](O)C\1	O=C/C/1=C/CC/C(/CO)=C/[C@H]2OC(=O)C(=C)[C@@H]2[C@H](O)C\1
NCGC00385983-01	O=C/C=C/c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(OC)c1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Phillyrea | Family: N/A | Species: latifolia		1	NCGC00385983-01	363680044.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C/C=C/c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(OC)c1	O=C/C=C/c1cc(OC)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c(OC)c1
NCGC00091512-04	O=C/C=C/c1ccccc1		Inactive	Peroxisome proliferator-activated receptor gamma Agonist		1	(2E)-3-Phenylprop-2-enal	144204695.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C/C=C/c1ccccc1	O=C/C=C/c1ccccc1
NCGC00381138-01	O=C1/C(/C)=C/C(C)C(=O)/C=C/C(O)(C)C(CC)OC(=O)C(C)CC1C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381138-01	363678989.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1/C(/C)=C/C(C)C(=O)/C=C/C(O)(C)C(CC)OC(=O)C(C)CC1C	O=C1/C(/C)=C/C(C)C(=O)/C=C/C(O)(C)C(CC)OC(=O)C(C)CC1C
NCGC00385388-01	O=C1/C(/C)=C/CCC(C)CCO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](O2)CO[C@@H]2OC[C@H](O)[C@H](O)[C@H]2O1		Inactive	<MOA Unknown> | Class: Sugar | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385388-01	363679715.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1/C(/C)=C/CCC(C)CCO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](O2)CO[C@@H]2OC[C@H](O)[C@H](O)[C@H]2O1	O=C1/C(/C)=C/CCC(C)CCO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](O2)CO[C@@H]2OC[C@H](O)[C@H](O)[C@H]2O1
NCGC00385390-01	O=C1/C(/C)=C/CC[C@H](C)CCO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](O2)CO[C@H]2[C@H](O)[C@@](O)(CO1)CO2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385390-01	363679717.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1/C(/C)=C/CC[C@H](C)CCO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](O2)CO[C@H]2[C@H](O)[C@@](O)(CO1)CO2	O=C1/C(/C)=C/CC[C@H](C)CCO[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](O2)CO[C@H]2[C@H](O)[C@@](O)(CO1)CO2
NCGC00347645-02	O=C1/C(/C)=C/[C@@H](C)C[C@@H](C)[C@@H](Cc2ocnc2)OC(=O)/C(/C)=C/[C@@H](C)C[C@@H](C)[C@@H](Cc2ocnc2)O1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: - | Family: - | Species: -		1	NCGC00347645-02	363677650.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1/C(/C)=C/[C@@H](C)C[C@@H](C)[C@@H](Cc2ocnc2)OC(=O)/C(/C)=C/[C@@H](C)C[C@@H](C)[C@@H](Cc2ocnc2)O1	O=C1/C(/C)=C/[C@@H](C)C[C@@H](C)[C@@H](Cc2ocnc2)OC(=O)/C(/C)=C/[C@@H](C)C[C@@H](C)[C@@H](Cc2ocnc2)O1
NCGC00179302-06	O=C1/C(=C/2\C(=O)c3c(N\2)cccc3)/c2c(N1)cccc2		Inactive	CDK1/2/4/5 Inhibitor		1	Indirubin	384568370.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1/C(=C/2\C(=O)c3c(N\2)cccc3)/c2c(N1)cccc2	O=C1/C(=C/2\C(=O)c3c(N\2)cccc3)/c2c(N1)cccc2
NCGC00482702-01	O=C1/C(=C/CC2C(=C)CCC3C(CO)(C)C(O)CCC23C)/C=CO1		Inactive			1	Dehydroandrographolide	434146936.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1/C(=C/CC2C(=C)CCC3C(CO)(C)C(O)CCC23C)/C=CO1	O=C1/C(=C/CC2C(=C)CCC3C(CO)(C)C(O)CCC23C)/C=CO1
NCGC00095597-05	O=C1/C(=C/CC2C(=C)CCC3[C@@](CO)(C)C(O)CC[C@]23C)/C(O)CO1	4.9499998	Active	TNF-alpha Production Inhibitor	0.0	1	Andrographolide	384568158.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	62.1380824706	O=C1/C(=C/CC2C(=C)CCC3[C@@](CO)(C)C(O)CC[C@]23C)/C(O)CO1	O=C1/C(=C/CC2C(=C)CCC3[C@@](CO)(C)C(O)CC[C@]23C)/C(O)CO1
NCGC00179817-06	O=C1/C(=C/C[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@@]23C)/[C@H](O)CO1	4.8499999	Active	TNF-alpha Production Inhibitor	0.0	1	Andrographolide	384568383.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	34.0	O=C1/C(=C/C[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@@]23C)/[C@H](O)CO1	O=C1/C(=C/C[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@@]23C)/[C@H](O)CO1
NCGC00263169-06	O=C1/C(=C/c2c(C(C)(C)C)[nH]cn2)/NC(=O)/C(=C/c2ccccc2)/N1		Inactive	Tubulin polymerization Inhibitor		1	Plinabulin	384568639.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1/C(=C/c2c(C(C)(C)C)[nH]cn2)/NC(=O)/C(=C/c2ccccc2)/N1	O=C1/C(=C/c2c(C(C)(C)C)[nH]cn2)/NC(=O)/C(=C/c2ccccc2)/N1
NCGC00387042-02	O=C1/C(=C/c2c(N3CC(N)CCC3)c(-c3ccccc3)ccc2)/SC(=O)N1		Inactive	Pim-1/2/3 kinase Inhibitor		1	AZD-1208	384569151.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	13.3716461159	O=C1/C(=C/c2c(N3CC(N)CCC3)c(-c3ccccc3)ccc2)/SC(=O)N1	O=C1/C(=C/c2c(N3CC(N)CCC3)c(-c3ccccc3)ccc2)/SC(=O)N1
NCGC00390455-01	O=C1/C(=C/c2cc3OCOc3cc2)/N=C(Nc2ccccc2)N1		Inactive			1	LeucettineL41	377020228.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1/C(=C/c2cc3OCOc3cc2)/N=C(Nc2ccccc2)N1	O=C1/C(=C/c2cc3OCOc3cc2)/N=C(Nc2ccccc2)N1
NCGC00388183-01	O=C1/C(=C/c2cc3OCOc3cc2)/SC(=O)N1		Inactive			1	AS-041164	377020243.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1/C(=C/c2cc3OCOc3cc2)/SC(=O)N1	O=C1/C(=C/c2cc3OCOc3cc2)/SC(=O)N1
NCGC00346509-08	O=C1/C(=C/c2cc3c(-c4ccncc4)ccnc3cc2)/SC(=O)N1		Inactive	PI3Kalpha Inhibitor		1	GSK-615	384568811.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C1/C(=C/c2cc3c(-c4ccncc4)ccnc3cc2)/SC(=O)N1	O=C1/C(=C/c2cc3c(-c4ccncc4)ccnc3cc2)/SC(=O)N1
NCGC00186030-12	O=C1/C(=C/c2cc3nccnc3cc2)/SC(=O)N1		Inactive	PI3K gamma Inhibitor		1	AS-605240	384568437.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1/C(=C/c2cc3nccnc3cc2)/SC(=O)N1	O=C1/C(=C/c2cc3nccnc3cc2)/SC(=O)N1
NCGC00387161-01	O=C1/C(=C/c2cnccc2)/N=C(/C=C/c2ccccc2)O1		Inactive			1	TC-DAPK 6	377020533.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1/C(=C/c2cnccc2)/N=C(/C=C/c2ccccc2)O1	O=C1/C(=C/c2cnccc2)/N=C(/C=C/c2ccccc2)O1
NCGC00163355-05	O=C1/C(=C\2/C(=O)c3c(N/2)cccc3)/Nc2c1cccc2		Inactive			1	Indigo	170465746.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1/C(=C\2/C(=O)c3c(N/2)cccc3)/Nc2c1cccc2	O=C1/C(=C\2/C(=O)c3c(N/2)cccc3)/Nc2c1cccc2
NCGC00094381-09	O=C1/C(=C\c2c(C)cc(C)[nH]2)/c2c(N1)cccc2		Inactive	Flt3 Inhibitor		1	Semaxanib	384568130.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1/C(=C\c2c(C)cc(C)[nH]2)/c2c(N1)cccc2	O=C1/C(=C\c2c(C)cc(C)[nH]2)/c2c(N1)cccc2
NCGC00242501-03	O=C1/C(=C\c2c(C)n(c(C)c2)-c2ccccc2)/Sc2n1c1c(n2)cccc1		Inactive	Triple Functional Domain Protein (TRIO) Inhibitor		1	ITX3	377020171.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1/C(=C\c2c(C)n(c(C)c2)-c2ccccc2)/Sc2n1c1c(n2)cccc1	O=C1/C(=C\c2c(C)n(c(C)c2)-c2ccccc2)/Sc2n1c1c(n2)cccc1
NCGC00390470-01	O=C1/C(=C\c2c(O)ccc(O)c2)/c2c(N1)cccc2		Inactive			1	TripolinA	377020506.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1/C(=C\c2c(O)ccc(O)c2)/c2c(N1)cccc2	O=C1/C(=C\c2c(O)ccc(O)c2)/c2c(N1)cccc2
NCGC00161398-06	O=C1/C(=C\c2c3c(n(C)c2)cccc3)/c2ncccc2N1		Inactive	Trk A Inhibitor		1	GW-441756	384568205.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1/C(=C\c2c3c(n(C)c2)cccc3)/c2ncccc2N1	O=C1/C(=C\c2c3c(n(C)c2)cccc3)/c2ncccc2N1
NCGC00390296-02	O=C1/C(=C\c2cc3c(nccc3)cc2)/SC(NCc2sccc2)=N1		Inactive			1	RO-3306	377020246.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1/C(=C\c2cc3c(nccc3)cc2)/SC(NCc2sccc2)=N1	O=C1/C(=C\c2cc3c(nccc3)cc2)/SC(NCc2sccc2)=N1
NCGC00167419-03	O=C1/C(=C\c2ccc(C)cc2)/C2C(C)(C)C1(C)CC2		Inactive			1	ENZACAMENE	405559131.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1/C(=C\c2ccc(C)cc2)/C2C(C)(C)C1(C)CC2	O=C1/C(=C\c2ccc(C)cc2)/C2C(C)(C)C1(C)CC2
NCGC00025170-13	O=C1/C(=C\c2ccc(N(C)C)cc2)/c2c(N1)cccc2		Inactive			1	SU 4312		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1/C(=C\c2ccc(N(C)C)cc2)/c2c(N1)cccc2	O=C1/C(=C\c2ccc(N(C)C)cc2)/c2c(N1)cccc2
NCGC00532513-01	O=C1/C(=N\NC(=N)N)/C=C2C(O)CN(C)C2=C1		Inactive			1	ADRENOCHROME MONOAMINOGUANIDINE MESILATE ANHYDROUS	405558436.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1/C(=N\NC(=N)N)/C=C2C(O)CN(C)C2=C1	O=C1/C(=N\NC(=N)N)/C=C2C(O)CN(C)C2=C1
NCGC00163645-02	O=C1C(/C=C/[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@@]23C)=CCO1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Andrographis | Family: Acanthaceae | Species: paniculata		1	ANDROGRAPHOLIDE, DEHYDRO-	363676625.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(/C=C/[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@@]23C)=CCO1	O=C1C(/C=C/[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@@]23C)=CCO1
NCGC00482596-01	O=C1C(=C(C)C)C/C=C(\C)/CC/C=C(\C)/C1		Inactive			1	Germacrone	434146933.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(=C(C)C)C/C=C(\C)/CC/C=C(\C)/C1	O=C1C(=C(C)C)C/C=C(\C)/CC/C=C(\C)/C1
NCGC00385849-01	O=C1C(=C(C)C)CC2C(O)(C)CCC2(O)C(C)=C1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385849-01	363679969.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C(C)C)CC2C(O)(C)CCC2(O)C(C)=C1	O=C1C(=C(C)C)CC2C(O)(C)CCC2(O)C(C)=C1
NCGC00385860-01	O=C1C(=C(C)C)CC2C(O)(C)CCC2C(C)=C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385860-01	363679972.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C(C)C)CC2C(O)(C)CCC2C(C)=C1	O=C1C(=C(C)C)CC2C(O)(C)CCC2C(C)=C1
NCGC00385577-02	O=C1C(=C(C)C)CC2C(O)(C)CCC2C(O)(C)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385577-02	363679818.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C(C)C)CC2C(O)(C)CCC2C(O)(C)C1	O=C1C(=C(C)C)CC2C(O)(C)CCC2C(O)(C)C1
NCGC00381379-01	O=C1C(=C(C)C)C[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381379-01	363679114.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C(C)C)C[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1	O=C1C(=C(C)C)C[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1
NCGC00385872-01	O=C1C(=C)C2C(O)/C=C(\C)/CCC(O)C(=C)CC2O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385872-01	363679980.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)C2C(O)/C=C(\C)/CCC(O)C(=C)CC2O1	O=C1C(=C)C2C(O)/C=C(\C)/CCC(O)C(=C)CC2O1
NCGC00385885-01	O=C1C(=C)C2C(O)C(C(CCCO)C)=C(C)CC2O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385885-01	363679990.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)C2C(O)C(C(CCCO)C)=C(C)CC2O1	O=C1C(=C)C2C(O)C(C(CCCO)C)=C(C)CC2O1
NCGC00385039-01	O=C1C(=C)C2C(O)C/C(/CO)=C/CC/C(/C)=C/C2O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385039-01	363679501.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)C2C(O)C/C(/CO)=C/CC/C(/C)=C/C2O1	O=C1C(=C)C2C(O)C/C(/CO)=C/CC/C(/C)=C/C2O1
NCGC00168996-02	O=C1C(=C)C2C(O)CC(C)C3C(=C(C)C(=O)C3)C2O1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Tithonia | Family: Compositae | Species: sp.		1	NCGC00168996-02	363676737.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)C2C(O)CC(C)C3C(=C(C)C(=O)C3)C2O1	O=C1C(=C)C2C(O)CC(C)C3C(=C(C)C(=O)C3)C2O1
NCGC00167740-02	O=C1C(=C)C2C(O1)/C=C(/C)\CC/C=C(/C)\CC2		Inactive	Telomerase Inhibitor		1	Costunolide	384568332.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	13.474895392	O=C1C(=C)C2C(O1)/C=C(/C)\CC/C=C(/C)\CC2	O=C1C(=C)C2C(O1)/C=C(/C)\CC/C=C(/C)\CC2
NCGC00381319-01	O=C1C(=C)C2C(O1)/C=C(\C)/CC1OC(=O)C(=C1)CC/C=C(\C)/CC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Crotolaria | Family: Leguminosae | Species: incana		1	NCGC00381319-01	363679084.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	14.050325856	O=C1C(=C)C2C(O1)/C=C(\C)/CC1OC(=O)C(=C1)CC/C=C(\C)/CC2	O=C1C(=C)C2C(O1)/C=C(\C)/CC1OC(=O)C(=C1)CC/C=C(\C)/CC2
NCGC00385837-01	O=C1C(=C)C2C(O1)C1C(=C)CCC(O)C1(C)CC2		Inactive	nitric oxide production involved in inflammatory response Inhibitor		1	NCGC00385837-01	363679960.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)C2C(O1)C1C(=C)CCC(O)C1(C)CC2	O=C1C(=C)C2C(O1)C1C(=C)CCC(O)C1(C)CC2
NCGC00385274-01	O=C1C(=C)C2C(O1)C1C(C)=CCC(O)C1(C)CC2		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Conyza | Family: Asteraceae | Species: sp.		1	NCGC00385274-01	363679634.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)C2C(O1)C1C(C)=CCC(O)C1(C)CC2	O=C1C(=C)C2C(O1)C1C(C)=CCC(O)C1(C)CC2
NCGC00179809-02	O=C1C(=C)C2C(O1)CC(C)C(CCC(O)C)=CC2		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Dittrichia | Family: Compositae | Species: viscosa		1	NCGC00179809-02	363676974.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)C2C(O1)CC(C)C(CCC(O)C)=CC2	O=C1C(=C)C2C(O1)CC(C)C(CCC(O)C)=CC2
NCGC00385038-01	O=C1C(=C)C2C(O1)CC1(C)C(O)C(=O)C=C(C)C1C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385038-01	363679500.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)C2C(O1)CC1(C)C(O)C(=O)C=C(C)C1C2	O=C1C(=C)C2C(O1)CC1(C)C(O)C(=O)C=C(C)C1C2
NCGC00385616-01	O=C1C(=C)C2[C@@H](O1)CC(=C)[C@@H]1[C@H]([C@@](O)(C)CC1)C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385616-01	363679840.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	-11.5229884999	O=C1C(=C)C2[C@@H](O1)CC(=C)[C@@H]1[C@H]([C@@](O)(C)CC1)C2	O=C1C(=C)C2[C@@H](O1)CC(=C)[C@@H]1[C@H]([C@@](O)(C)CC1)C2
NCGC00179975-02	O=C1C(=C)C2[C@@H]([C@@]3(O)C(C)=CC(=O)C3=C(C)CC2)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Artemisia | Family: N/A | Species: sp.		1	NCGC00179975-02	363676997.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)C2[C@@H]([C@@]3(O)C(C)=CC(=O)C3=C(C)CC2)O1	O=C1C(=C)C2[C@@H]([C@@]3(O)C(C)=CC(=O)C3=C(C)CC2)O1
NCGC00385163-01	O=C1C(=C)[C@@H](C/C=C(/CC2OC(=O)C(C)C2)\C)CO1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Anthemis | Family: Compositae | Species: tigrensis		1	NCGC00385163-01	363679574.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)[C@@H](C/C=C(/CC2OC(=O)C(C)C2)\C)CO1	O=C1C(=C)[C@@H](C/C=C(/CC2OC(=O)C(C)C2)\C)CO1
NCGC00169143-02	O=C1C(=C)[C@@H]2[C@@H](O)C[C@](C=C)(C)[C@H](C(CO)=C)[C@H]2O1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Centaurea | Family: Compositae | Species: pumilio		1	NCGC00169143-02	363676779.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)[C@@H]2[C@@H](O)C[C@](C=C)(C)[C@H](C(CO)=C)[C@H]2O1	O=C1C(=C)[C@@H]2[C@@H](O)C[C@](C=C)(C)[C@H](C(CO)=C)[C@H]2O1
NCGC00180818-02	O=C1C(=C)[C@@H]2[C@@H](O1)C[C@@H](C)[C@H]1[C@@](C)(C(=O)CC1)C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180818-02	363677069.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	24.3798413439	O=C1C(=C)[C@@H]2[C@@H](O1)C[C@@H](C)[C@H]1[C@@](C)(C(=O)CC1)C2	O=C1C(=C)[C@@H]2[C@@H](O1)C[C@@H](C)[C@H]1[C@@](C)(C(=O)CC1)C2
NCGC00169726-02	O=C1C(=C)[C@@H]2[C@H](O)CC(=C)[C@H]3[C@H](C(=C)[C@@H](O)C3)[C@H]2O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169726-02	363676876.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)[C@@H]2[C@H](O)CC(=C)[C@H]3[C@H](C(=C)[C@@H](O)C3)[C@H]2O1	O=C1C(=C)[C@@H]2[C@H](O)CC(=C)[C@H]3[C@H](C(=C)[C@@H](O)C3)[C@H]2O1
NCGC00180848-02	O=C1C(=C)[C@@H]2[C@H](O)C[C@]3(C)[C@@H](O)CC=C(C)[C@H]3[C@@H]2O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Pegolettia | Family: N/A | Species: senegalensis		1	NCGC00180848-02	363677073.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	21.0	O=C1C(=C)[C@@H]2[C@H](O)C[C@]3(C)[C@@H](O)CC=C(C)[C@H]3[C@@H]2O1	O=C1C(=C)[C@@H]2[C@H](O)C[C@]3(C)[C@@H](O)CC=C(C)[C@H]3[C@@H]2O1
NCGC00169991-02	O=C1C(=C)[C@@H]2[C@H](O1)C[C@@]1(C)[C@H](O)CCC(=C)C1C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Iva | Family: N/A | Species: sp.		1	NCGC00169991-02	363676925.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)[C@@H]2[C@H](O1)C[C@@]1(C)[C@H](O)CCC(=C)C1C2	O=C1C(=C)[C@@H]2[C@H](O1)C[C@@]1(C)[C@H](O)CCC(=C)C1C2
NCGC00385909-01	O=C1C(=C)[C@@H]2[C@H](O1)C[C@H](C)C=1[C@@](C)([C@@H](O)C(=O)C=1)C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385909-01	363680000.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)[C@@H]2[C@H](O1)C[C@H](C)C=1[C@@](C)([C@@H](O)C(=O)C=1)C2	O=C1C(=C)[C@@H]2[C@H](O1)C[C@H](C)C=1[C@@](C)([C@@H](O)C(=O)C=1)C2
NCGC00169080-02	O=C1C(=C)[C@@H]2[C@H](O1)C[C@H](C)[C@H]1C(=C(C)C(=O)C1)C2	4.9499998	Active	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00169080-02	363676765.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	3.0	53.0779816548	O=C1C(=C)[C@@H]2[C@H](O1)C[C@H](C)[C@H]1C(=C(C)C(=O)C1)C2	O=C1C(=C)[C@@H]2[C@H](O1)C[C@H](C)[C@H]1C(=C(C)C(=O)C1)C2
NCGC00385324-01	O=C1C(=C)[C@@H]2[C@H](O1)C[C@H](C)[C@H]1[C@@](C)([C@@H](O)C(=O)C1)C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385324-01	363679677.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)[C@@H]2[C@H](O1)C[C@H](C)[C@H]1[C@@](C)([C@@H](O)C(=O)C1)C2	O=C1C(=C)[C@@H]2[C@H](O1)C[C@H](C)[C@H]1[C@@](C)([C@@H](O)C(=O)C1)C2
NCGC00178225-05	O=C1C(=C)[C@@H]2[C@H](O1)C[C@]1(C)C([C@@H](C)CCC1)=C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	HELENINE	363676931.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)[C@@H]2[C@H](O1)C[C@]1(C)C([C@@H](C)CCC1)=C2	O=C1C(=C)[C@@H]2[C@H](O1)C[C@]1(C)C([C@@H](C)CCC1)=C2
NCGC00179964-02	O=C1C(=C)[C@@H]2[C@H](O1)C[C@]1(C)C([C@@H](C)C[C@H](O)C1)=C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Inula | Family: N/A | Species: sp.		1	NCGC00179964-02	363676996.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	15.0602836919	O=C1C(=C)[C@@H]2[C@H](O1)C[C@]1(C)C([C@@H](C)C[C@H](O)C1)=C2	O=C1C(=C)[C@@H]2[C@H](O1)C[C@]1(C)C([C@@H](C)C[C@H](O)C1)=C2
NCGC00385020-01	O=C1C(=C)[C@@H]2[C@H](O1)C[C@]1(C)[C@@H](CCC(O)C)[C@@H]1C2		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Dittrichia | Family: Compositae | Species: viscosa		1	NCGC00385020-01	363679489.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)[C@@H]2[C@H](O1)C[C@]1(C)[C@@H](CCC(O)C)[C@@H]1C2	O=C1C(=C)[C@@H]2[C@H](O1)C[C@]1(C)[C@@H](CCC(O)C)[C@@H]1C2
NCGC00384720-01	O=C1C(=C)[C@@H]2[C@H](O1)C[C@]1(C)[C@](O)(C(=C)CCC1)C2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384720-01	363679326.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	14.5909090919	O=C1C(=C)[C@@H]2[C@H](O1)C[C@]1(C)[C@](O)(C(=C)CCC1)C2	O=C1C(=C)[C@@H]2[C@H](O1)C[C@]1(C)[C@](O)(C(=C)CCC1)C2
NCGC00346595-02	O=C1C(=C)[C@H]2[C@@H](O)[C@]31[C@@]1(O)[C@@H](O)[C@@H]4C(C)(C)CC[C@H](O)[C@]4(C3CC2)CO1	4.9000001	Active	Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activator	0.0	1	Oridonin	363677470.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	119.7536695986	O=C1C(=C)[C@H]2[C@@H](O)[C@]31[C@@]1(O)[C@@H](O)[C@@H]4C(C)(C)CC[C@H](O)[C@]4(C3CC2)CO1	O=C1C(=C)[C@H]2[C@@H](O)[C@]31[C@@]1(O)[C@@H](O)[C@@H]4C(C)(C)CC[C@H](O)[C@]4(C3CC2)CO1
NCGC00168931-02	O=C1C(=C)[C@H]2[C@@H](O1)C=1[C@@](C)(C(=O)C2)CCCC=1C	5.0	Active	<MOA Unknown> | Class: Terpenoid | Genus: Artemisia | Family: N/A | Species: tournefortiana	0.0	1	NCGC00168931-02	363676726.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	3.0	57.2010495839	O=C1C(=C)[C@H]2[C@@H](O1)C=1[C@@](C)(C(=O)C2)CCCC=1C	O=C1C(=C)[C@H]2[C@@H](O1)C=1[C@@](C)(C(=O)C2)CCCC=1C
NCGC00380135-02	O=C1C(=C)[C@H]2[C@H](C(O)(C)[C@@]3([C@@H](C)CC2)OC(=O)CC3)O1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Ambrosia | Family: Compositae | Species: cumanensis		1	NCGC00380135-02	363678471.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)[C@H]2[C@H](C(O)(C)[C@@]3([C@@H](C)CC2)OC(=O)CC3)O1	O=C1C(=C)[C@H]2[C@H](C(O)(C)[C@@]3([C@@H](C)CC2)OC(=O)CC3)O1
NCGC00385273-01	O=C1C(=C)[C@H]2[C@H](O1)[C@H]1C(=C)CC[C@@H](O)[C@]1(C)CC2		Inactive	nitric oxide production involved in inflammatory response Inhibitor		1	NCGC00385273-01	363679633.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)[C@H]2[C@H](O1)[C@H]1C(=C)CC[C@@H](O)[C@]1(C)CC2	O=C1C(=C)[C@H]2[C@H](O1)[C@H]1C(=C)CC[C@@H](O)[C@]1(C)CC2
NCGC00385838-01	O=C1C(=C)[C@H]2[C@H](O1)[C@H]1C(=C)CC[C@H]1C(=C)CC2		Inactive	Thioredoxin reductase 1 Inhibitor		1	Dehydrocostus Lactone	363679961.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)[C@H]2[C@H](O1)[C@H]1C(=C)CC[C@H]1C(=C)CC2	O=C1C(=C)[C@H]2[C@H](O1)[C@H]1C(=C)CC[C@H]1C(=C)CC2
NCGC00485131-01	O=C1C(=C)[C@H]2[C@H](O1)[C@H]1C(C)=CC(=O)C1=C(C)CC2		Inactive	regulation of mast cell degranulation Modulator		1	Dehydroleucodine	363681237.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)[C@H]2[C@H](O1)[C@H]1C(C)=CC(=O)C1=C(C)CC2	O=C1C(=C)[C@H]2[C@H](O1)[C@H]1C(C)=CC(=O)C1=C(C)CC2
NCGC00390770-02	O=C1C(=C)[C@H]2[C@H](O1)[C@H]1C(C)=CC[C@@]31[C@@](C)(O3)CC2		Inactive	Farnesyltransferase Inhibitor		1	Arglabin	384569212.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	18.443784472	O=C1C(=C)[C@H]2[C@H](O1)[C@H]1C(C)=CC[C@@]31[C@@](C)(O3)CC2	O=C1C(=C)[C@H]2[C@H](O1)[C@H]1C(C)=CC[C@@]31[C@@](C)(O3)CC2
NCGC00385924-01	O=C1C(=C)[C@H]2[C@H]([C@]3(C)OC(=O)CCC3=C(C)CC2)O1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Ambrosia | Family: Compositae | Species: cumanensis		1	NCGC00385924-01	363680011.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=C)[C@H]2[C@H]([C@]3(C)OC(=O)CCC3=C(C)CC2)O1	O=C1C(=C)[C@H]2[C@H]([C@]3(C)OC(=O)CCC3=C(C)CC2)O1
NCGC00015598-16	O=C1C(=O)C2=C(OC(C)(C)CC2)c2c1cccc2		Inactive	Tryptophan 2,3-Dioxygenase (TDO) Inhibitor		1	beta-Lapachone	384567869.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(=O)C2=C(OC(C)(C)CC2)c2c1cccc2	O=C1C(=O)C2=C(OC(C)(C)CC2)c2c1cccc2
NCGC00163650-04	O=C1C(=O)C=2[C@@H](C)COC=2c2c1c1c(C(C)(C)CCC1)cc2		Inactive	STAT-3 Inhibitor		1	Cryptotanshinone	384568247.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(=O)C=2[C@@H](C)COC=2c2c1c1c(C(C)(C)CCC1)cc2	O=C1C(=O)C=2[C@@H](C)COC=2c2c1c1c(C(C)(C)CCC1)cc2
NCGC00163651-06	O=C1C(=O)C=2[C@@H](C)COC=2c2c1c1c(c(C)ccc1)cc2		Inactive			1	DIHYDROTANSHINONE I	434147021.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(=O)C=2[C@@H](C)COC=2c2c1c1c(c(C)ccc1)cc2	O=C1C(=O)C=2[C@@H](C)COC=2c2c1c1c(c(C)ccc1)cc2
NCGC00167798-05&NCGC00167798-06	O=C1C(=O)O[Pt]2(O1)NC1C(N2)CCCC1		Inactive	DNA Alkylating Agent		2	Oxaliplatin	405558440.0&384568337.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1C(=O)O[Pt]2(O1)NC1C(N2)CCCC1	O=C1C(=O)O[Pt]2(O1)NC1C(N2)CCCC1
NCGC00095709-02&NCGC00095709-08	O=C1C(=O)c2c(-c3occ(C)c13)ccc1C(C)(C)CCCc21		Inactive	TNF-alpha Production Inhibitor		2	Tanshinone IIA	50107688.0&363676577.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1C(=O)c2c(-c3occ(C)c13)ccc1C(C)(C)CCCc21	O=C1C(=O)c2c(-c3occ(C)c13)ccc1C(C)(C)CCCc21
NCGC00247624-03	O=C1C(=O)c2c3c(c(C)ccc3)ccc2-c2occ(C)c12		Inactive	TNF-alpha Production Inhibitors		1	Tanshinone I	363677161.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(=O)c2c3c(c(C)ccc3)ccc2-c2occ(C)c12	O=C1C(=O)c2c3c(c(C)ccc3)ccc2-c2occ(C)c12
NCGC00250373-04	O=C1C(C#N)=C(O)c2c(-c3ccc(-c4c(O)cccc4)cc3)csc2N1		Inactive	AMPK Activator		1	A-769662	384568535.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(C#N)=C(O)c2c(-c3ccc(-c4c(O)cccc4)cc3)csc2N1	O=C1C(C#N)=C(O)c2c(-c3ccc(-c4c(O)cccc4)cc3)csc2N1
NCGC00162385-04	O=C1C(C#N)=CC(=C(C)N1)C1=Cn2c(ncc2)C=C1		Inactive	Phosphodiesterase III (PDE3) Inhibitor		1	Olprinone	170465898.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1C(C#N)=CC(=C(C)N1)C1=Cn2c(ncc2)C=C1.Cl	O=C1C(C#N)=CC(=C(C)N1)C1=Cn2c(ncc2)C=C1.Cl
NCGC00015675-11&NCGC00015675-22	O=C1C(C#N)=CC(c2ccncc2)=C(C)N1		Inactive	Phosphodiesterase III (PDE3) Inhibitor		2	Milrinone	170465221.0&384567880.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1C(C#N)=CC(c2ccncc2)=C(C)N1	O=C1C(C#N)=CC(c2ccncc2)=C(C)N1
NCGC00378812-01	O=C1C(C#N)C(=O)c2c(-c3ccc(-c4c(O)cccc4)cc3)csc2N1		Inactive			1	A-769662	363678214.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C#N)C(=O)c2c(-c3ccc(-c4c(O)cccc4)cc3)csc2N1	O=C1C(C#N)C(=O)c2c(-c3ccc(-c4c(O)cccc4)cc3)csc2N1
NCGC00180357-02	O=C1C(C(=C)C)=C[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180357-02	363677014.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C(=C)C)=C[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1	O=C1C(C(=C)C)=C[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1
NCGC00380448-01	O=C1C(C(=C)C)CC2(CO)C(C)C(O)CCC2=C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380448-01	363678588.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C(=C)C)CC2(CO)C(C)C(O)CCC2=C1	O=C1C(C(=C)C)CC2(CO)C(C)C(O)CCC2=C1
NCGC00381622-01	O=C1C(C(C)C)=C(C)Nc2c(C#N)cnn12		Inactive			1	NCGC00381622-01		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C(C)C)=C(C)Nc2c(C#N)cnn12	O=C1C(C(C)C)=C(C)Nc2c(C#N)cnn12
NCGC00486892-01	O=C1C(C(C)C)=C(c2ccccc2)Nc2c(C#N)cnn12		Inactive	Lysine-Specific Demethylase 5B (KDM5B; JARID1B) Inhibitor		1	CPI-455	384569280.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(C(C)C)=C(c2ccccc2)Nc2c(C#N)cnn12	O=C1C(C(C)C)=C(c2ccccc2)Nc2c(C#N)cnn12
NCGC00178250-05	O=C1C(C(C)C)=CC(=O)C(C)=C1		Inactive			1	Thymoquinone	377020330.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C(C)C)=CC(=O)C(C)=C1	O=C1C(C(C)C)=CC(=O)C(C)=C1
NCGC00380992-01	O=C1C(C(C)C)C2C=C(C)C(OC3C(O)C(O)C(O)C(CO)O3)CC2C(C)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380992-01	363678908.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C(C)C)C2C=C(C)C(OC3C(O)C(O)C(O)C(CO)O3)CC2C(C)C1	O=C1C(C(C)C)C2C=C(C)C(OC3C(O)C(O)C(O)C(CO)O3)CC2C(C)C1
NCGC00384906-01	O=C1C(C(C)C)N2C(=O)C3=C(OC=CC=C3)N=C2/C(=C/C(C)C)/N1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384906-01	363679431.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C(C)C)N2C(=O)C3=C(OC=CC=C3)N=C2/C(=C/C(C)C)/N1	O=C1C(C(C)C)N2C(=O)C3=C(OC=CC=C3)N=C2/C(=C/C(C)C)/N1
NCGC00385185-01	O=C1C(C(C)C)N2C(=O)c3c(N=C2/C(=C/C(C)C)/N1)cccc3		Inactive	<MOA Unknown> | Class: alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385185-01	363679584.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C(C)C)N2C(=O)c3c(N=C2/C(=C/C(C)C)/N1)cccc3	O=C1C(C(C)C)N2C(=O)c3c(N=C2/C(=C/C(C)C)/N1)cccc3
NCGC00380832-01	O=C1C(C(C)C)N2C(=O)c3c(c(O)ccc3)N=C2C(=CC(C)C)N1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380832-01	363678804.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C(C)C)N2C(=O)c3c(c(O)ccc3)N=C2C(=CC(C)C)N1	O=C1C(C(C)C)N2C(=O)c3c(c(O)ccc3)N=C2C(=CC(C)C)N1
NCGC00180427-03	O=C1C(C(C)C)NC(=O)C(C)NC(=O)CCCNC(=O)C(Cc2c3c([nH]c2)cccc3)NC(=O)C(C)NC(=O)C(C(C)C)NC(=O)C(C(C)c2ccccc2)N1		Inactive	<MOA Unknown> | Class: peptide | Genus: Aspergillus | Family: N/A | Species: N/A		1	NCGC00180427-03	363677024.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C(C)C)NC(=O)C(C)NC(=O)CCCNC(=O)C(Cc2c3c([nH]c2)cccc3)NC(=O)C(C)NC(=O)C(C(C)C)NC(=O)C(C(C)c2ccccc2)N1	O=C1C(C(C)C)NC(=O)C(C)NC(=O)CCCNC(=O)C(Cc2c3c([nH]c2)cccc3)NC(=O)C(C)NC(=O)C(C(C)C)NC(=O)C(C(C)c2ccccc2)N1
NCGC00347837-02	O=C1C(C(C)C)NC(=O)C(C)NC(=O)CCCNC(=O)C(Cc2c3c([nH]c2)cccc3)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(C(C)c2ccccc2)N1		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347837-02	363677704.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C(C)C)NC(=O)C(C)NC(=O)CCCNC(=O)C(Cc2c3c([nH]c2)cccc3)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(C(C)c2ccccc2)N1	O=C1C(C(C)C)NC(=O)C(C)NC(=O)CCCNC(=O)C(Cc2c3c([nH]c2)cccc3)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(C(C)c2ccccc2)N1
NCGC00385798-01	O=C1C(C(C)C)NC(=O)C(Cc2c3c([nH]c2)cccc3)NC(=O)C(C)NC(=O)CNC(=O)C(C(C)C)NC(=O)C2N1CCC2		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385798-01	363679944.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C(C)C)NC(=O)C(Cc2c3c([nH]c2)cccc3)NC(=O)C(C)NC(=O)CNC(=O)C(C(C)C)NC(=O)C2N1CCC2	O=C1C(C(C)C)NC(=O)C(Cc2c3c([nH]c2)cccc3)NC(=O)C(C)NC(=O)CNC(=O)C(C(C)C)NC(=O)C2N1CCC2
NCGC00381364-02	O=C1C(C(C)C)NC(=O)C2N1CCC2		Inactive	<MOA Unknown> | Class: Amino acid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381364-02	363679108.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C(C)C)NC(=O)C2N1CCC2	O=C1C(C(C)C)NC(=O)C2N1CCC2
NCGC00380613-01	O=C1C(C(C)C)NC(=O)CNC(=O)C(C(O)c2cc(CC=C(C)C)c(O)cc2)NC(=O)CNC(=O)C(Cc2c3c([nH]c2)cccc3)NC(=O)C2N(C(=O)CN1)CCC2		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380613-01	363678670.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C(C)C)NC(=O)CNC(=O)C(C(O)c2cc(CC=C(C)C)c(O)cc2)NC(=O)CNC(=O)C(Cc2c3c([nH]c2)cccc3)NC(=O)C2N(C(=O)CN1)CCC2	O=C1C(C(C)C)NC(=O)CNC(=O)C(C(O)c2cc(CC=C(C)C)c(O)cc2)NC(=O)CNC(=O)C(Cc2c3c([nH]c2)cccc3)NC(=O)C2N(C(=O)CN1)CCC2
NCGC00381417-01	O=C1C(C(C)C)NC(=O)c2c(NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(C)NC(=O)C(C(O)C)NC(=O)C(C(CC)C)NC(=O)C3N1CCC3)cccc2		Inactive	<MOA Unknown> | Class: peptide | Genus: Penicillium | Family: N/A | Species: raistrickii		1	NCGC00381417-01	363679133.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C(C)C)NC(=O)c2c(NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(C)NC(=O)C(C(O)C)NC(=O)C(C(CC)C)NC(=O)C3N1CCC3)cccc2	O=C1C(C(C)C)NC(=O)c2c(NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(C)NC(=O)C(C(O)C)NC(=O)C(C(CC)C)NC(=O)C3N1CCC3)cccc2
NCGC00253567-01	O=C1C(C(CC)C)(CC=C)C(=O)NC(=O)N1		Inactive	GABA-A receptor; anion channel Positive Allosteric Modulator		1	Talbutal	170465408.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(C(CC)C)(CC=C)C(=O)NC(=O)N1	O=C1C(C(CC)C)(CC=C)C(=O)NC(=O)N1
NCGC00346442-02	O=C1C(C(CC)c2ccccc2)=C(O)c2c(O1)cccc2		Inactive	Cytochrome P450 3A4 Substrate		1	Phenprocoumon	405558576.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(C(CC)c2ccccc2)=C(O)c2c(O1)cccc2	O=C1C(C(CC)c2ccccc2)=C(O)c2c(O1)cccc2
NCGC00380778-01	O=C1C(C(O)C)NC(=O)C2N1CCC2		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380778-01	363678780.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C(O)C)NC(=O)C2N1CCC2	O=C1C(C(O)C)NC(=O)C2N1CCC2
NCGC00169363-02	O=C1C(C(O)C[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@@]23C)=CCO1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Andrographis | Family: Acanthaceae | Species: paniculata		1	NCGC00169363-02	363676805.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C(O)C[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@@]23C)=CCO1	O=C1C(C(O)C[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)[C@H](O)CC[C@@]23C)=CCO1
NCGC00380960-01	O=C1C(C)(C)C2C(C)(C3C(C)(C4(C)C(O)(C5(O)C(C)CC(C(O)C(O)(C)C)OC5C4)CC3)CC2)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380960-01	363678886.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)(C)C2C(C)(C3C(C)(C4(C)C(O)(C5(O)C(C)CC(C(O)C(O)(C)C)OC5C4)CC3)CC2)CC1	O=C1C(C)(C)C2C(C)(C3C(C)(C4(C)C(O)(C5(O)C(C)CC(C(O)C(O)(C)C)OC5C4)CC3)CC2)CC1
NCGC00380528-01	O=C1C(C)(C)C2C(C)(C3C(C4(C)C(C)(C(C(O)(C/C=C/C(O)(C)C)C)C(O)C4)CC3)CC2)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380528-01	363678633.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)(C)C2C(C)(C3C(C4(C)C(C)(C(C(O)(C/C=C/C(O)(C)C)C)C(O)C4)CC3)CC2)CC1	O=C1C(C)(C)C2C(C)(C3C(C4(C)C(C)(C(C(O)(C/C=C/C(O)(C)C)C)C(O)C4)CC3)CC2)CC1
NCGC00384870-01	O=C1C(C)(C)C2[C@@](C)([C@@H]3[C@@H](O)CC=4[C@@](C)([C@@]3(C)CC2)C[C@@H]2O[C@H]([C@@H](O)C(O)(C)C)C[C@@H](C)C=42)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384870-01	363679406.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)(C)C2[C@@](C)([C@@H]3[C@@H](O)CC=4[C@@](C)([C@@]3(C)CC2)C[C@@H]2O[C@H]([C@@H](O)C(O)(C)C)C[C@@H](C)C=42)CC1	O=C1C(C)(C)C2[C@@](C)([C@@H]3[C@@H](O)CC=4[C@@](C)([C@@]3(C)CC2)C[C@@H]2O[C@H]([C@@H](O)C(O)(C)C)C[C@@H](C)C=42)CC1
NCGC00381190-01	O=C1C(C)(C)NC2C(O)(CC3C(=O)NC(O)(C(C)C)C=4N3C(=O)c3c(N=4)cccc3)c3c(N12)cccc3		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381190-01	363679015.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)(C)NC2C(O)(CC3C(=O)NC(O)(C(C)C)C=4N3C(=O)c3c(N=4)cccc3)c3c(N12)cccc3	O=C1C(C)(C)NC2C(O)(CC3C(=O)NC(O)(C(C)C)C=4N3C(=O)c3c(N=4)cccc3)c3c(N12)cccc3
NCGC00347410-03	O=C1C(C)=C(C)CC(C(C)C2C3(C)C(C4C(C5(C)C(O)CC(OC6C(O)C(O)C(O)C(COC7C(O)C(O)C(O)C(CO)O7)O6)CC5=CC4)CC3)CC2)O1		Inactive	superoxide metabolic process Modulator		1	withanoside V	363677596.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C(C)CC(C(C)C2C3(C)C(C4C(C5(C)C(O)CC(OC6C(O)C(O)C(O)C(COC7C(O)C(O)C(O)C(CO)O7)O6)CC5=CC4)CC3)CC2)O1	O=C1C(C)=C(C)CC(C(C)C2C3(C)C(C4C(C5(C)C(O)CC(OC6C(O)C(O)C(O)C(COC7C(O)C(O)C(O)C(CO)O7)O6)CC5=CC4)CC3)CC2)O1
NCGC00347778-02	O=C1C(C)=C(C)CC(C(C)C2C3(C)C(C4C5OC5C5(O)C(C)(C(O)CC(OC6C(O)C(O)C(O)C(CO)O6)C5)C4CC3)CC2O)O1		Inactive	<MOA Unknown> | Class: Steroid | Genus: Mandragora | Family: Solanaceae | Species: autumnalis		1	NCGC00347778-02	363677685.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C(C)CC(C(C)C2C3(C)C(C4C5OC5C5(O)C(C)(C(O)CC(OC6C(O)C(O)C(O)C(CO)O6)C5)C4CC3)CC2O)O1	O=C1C(C)=C(C)CC(C(C)C2C3(C)C(C4C5OC5C5(O)C(C)(C(O)CC(OC6C(O)C(O)C(O)C(CO)O6)C5)C4CC3)CC2O)O1
NCGC00385675-01	O=C1C(C)=C(C)CC(C(C)C2C3(C)C(C4C5OC5C5(O)C(C)(C(O)CC(OC6C(O)C(O)C(OC7C(O)C(O)C(O)C(C)O7)C(CO)O6)C5)C4CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Steroid | Genus: Mandragora | Family: Solanaceae | Species: autumnalis		1	NCGC00385675-01	363679868.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C(C)CC(C(C)C2C3(C)C(C4C5OC5C5(O)C(C)(C(O)CC(OC6C(O)C(O)C(OC7C(O)C(O)C(O)C(C)O7)C(CO)O6)C5)C4CC3)CC2)O1	O=C1C(C)=C(C)CC(C(C)C2C3(C)C(C4C5OC5C5(O)C(C)(C(O)CC(OC6C(O)C(O)C(OC7C(O)C(O)C(O)C(C)O7)C(CO)O6)C5)C4CC3)CC2)O1
NCGC00381320-01	O=C1C(C)=C(C)CC(C(C)C2C3(C)C(C4C5OC5C5(O)C(C)(C(O)CC(OC6C(O)C(O)C(OC7C(O)C(O)C(O)C(C)O7)C(CO)O6)C5)C4CC3)CC2O)O1		Inactive	<MOA Unknown> | Class: Steroid | Genus: Mandragora | Family: Solanaceae | Species: autumnalis		1	NCGC00381320-01	363679085.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C(C)CC(C(C)C2C3(C)C(C4C5OC5C5(O)C(C)(C(O)CC(OC6C(O)C(O)C(OC7C(O)C(O)C(O)C(C)O7)C(CO)O6)C5)C4CC3)CC2O)O1	O=C1C(C)=C(C)CC(C(C)C2C3(C)C(C4C5OC5C5(O)C(C)(C(O)CC(OC6C(O)C(O)C(OC7C(O)C(O)C(O)C(C)O7)C(CO)O6)C5)C4CC3)CC2O)O1
NCGC00384907-01	O=C1C(C)=C(C)CC(C(O)(C)C2C3(C)C(C4C(C5(C)C(O)CC(OC6C(O)C(O)C(O)C(COC7C(O)C(O)C(O)C(CO)O7)O6)CC5=CC4)CC3)CC2)O1		Inactive	neuron projection development Activator		1	NCGC00384907-01	363679432.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C(C)CC(C(O)(C)C2C3(C)C(C4C(C5(C)C(O)CC(OC6C(O)C(O)C(O)C(COC7C(O)C(O)C(O)C(CO)O7)O6)CC5=CC4)CC3)CC2)O1	O=C1C(C)=C(C)CC(C(O)(C)C2C3(C)C(C4C(C5(C)C(O)CC(OC6C(O)C(O)C(O)C(COC7C(O)C(O)C(O)C(CO)O7)O6)CC5=CC4)CC3)CC2)O1
NCGC00179900-02	O=C1C(C)=C(CO)CC(C(C)C2C3(C)C(C4C(C5(C)C(O)CC(OC6C(O)C(O)C(O)C(COC7C(O)C(O)C(O)C(CO)O7)O6)CC5=CC4)CC3)CC2)O1		Inactive	<MOA Unknown> | Class: Steroid | Genus: Withania | Family: Solanaceae | Species: somnifera		1	NCGC00179900-02	363676987.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C(CO)CC(C(C)C2C3(C)C(C4C(C5(C)C(O)CC(OC6C(O)C(O)C(O)C(COC7C(O)C(O)C(O)C(CO)O7)O6)CC5=CC4)CC3)CC2)O1	O=C1C(C)=C(CO)CC(C(C)C2C3(C)C(C4C(C5(C)C(O)CC(OC6C(O)C(O)C(O)C(COC7C(O)C(O)C(O)C(CO)O7)O6)CC5=CC4)CC3)CC2)O1
NCGC00384740-01	O=C1C(C)=C2C(C(C)CC(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C(O)(C(O)(C)C)C2)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384740-01	363679334.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C2C(C(C)CC(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C(O)(C(O)(C)C)C2)C1	O=C1C(C)=C2C(C(C)CC(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C(O)(C(O)(C)C)C2)C1
NCGC00380567-01	O=C1C(C)=C2C(C(O)C3[C@@](C)([C@@H](C)CCC3)C2)O1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Petasites | Family: Compositae | Species: officinalis		1	NCGC00380567-01	363678654.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C2C(C(O)C3[C@@](C)([C@@H](C)CCC3)C2)O1	O=C1C(C)=C2C(C(O)C3[C@@](C)([C@@H](C)CCC3)C2)O1
NCGC00380624-01	O=C1C(C)=C2C(C)(CC1)CCC(CO)C(CO)=C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380624-01	363678678.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C2C(C)(CC1)CCC(CO)C(CO)=C2	O=C1C(C)=C2C(C)(CC1)CCC(CO)C(CO)=C2
NCGC00380735-01	O=C1C(C)=C2C(O)(C(O)C3[C@@](C)([C@@H](C)CCC3)C2)O1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Petasites | Family: Compositae | Species: officinalis		1	NCGC00380735-01	363678748.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C2C(O)(C(O)C3[C@@](C)([C@@H](C)CCC3)C2)O1	O=C1C(C)=C2C(O)(C(O)C3[C@@](C)([C@@H](C)CCC3)C2)O1
NCGC00381360-01	O=C1C(C)=C2C(O)(O1)C/C(/C)=C/CCC(C)C(=O)C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381360-01	363679106.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C2C(O)(O1)C/C(/C)=C/CCC(C)C(=O)C2	O=C1C(C)=C2C(O)(O1)C/C(/C)=C/CCC(C)C(=O)C2
NCGC00390775-03	O=C1C(C)=C2C(O1)=C[C@]1(C)[C@H](C(=C)CCC1)C2		Inactive	TNF-alpha Production Inhibitor		1	Atractylenolide I	384569213.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(C)=C2C(O1)=C[C@]1(C)[C@H](C(=C)CCC1)C2	O=C1C(C)=C2C(O1)=C[C@]1(C)[C@H](C(=C)CCC1)C2
NCGC00385953-01	O=C1C(C)=C2C(O1)C/C(/C)=C/CCC(C)C(=O)C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385953-01	363680025.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C2C(O1)C/C(/C)=C/CCC(C)C(=O)C2	O=C1C(C)=C2C(O1)C/C(/C)=C/CCC(C)C(=O)C2
NCGC00385649-01	O=C1C(C)=C2C(O1)CC(O)(C)C1C(C(O)(C)CC1)C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385649-01	363679856.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C2C(O1)CC(O)(C)C1C(C(O)(C)CC1)C2	O=C1C(C)=C2C(O1)CC(O)(C)C1C(C(O)(C)CC1)C2
NCGC00381407-02	O=C1C(C)=C2C(O1)CC1(C)OC1CCC1(C)OC1C2		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Smyrnium | Family: Umbelliferae | Species: olusatrum		1	NCGC00381407-02	363679129.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C2C(O1)CC1(C)OC1CCC1(C)OC1C2	O=C1C(C)=C2C(O1)CC1(C)OC1CCC1(C)OC1C2
NCGC00385304-01	O=C1C(C)=C2[C@@](O)(O1)C[C@]1(C)[C@H](C(=C)CCC1)C2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	Atractylenolide III	363679661.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C2[C@@](O)(O1)C[C@]1(C)[C@H](C(=C)CCC1)C2	O=C1C(C)=C2[C@@](O)(O1)C[C@]1(C)[C@H](C(=C)CCC1)C2
NCGC00169029-02	O=C1C(C)=C2[C@](O)(O1)C[C@H]1[C@@](C)([C@@H](C)CCC1)C2		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Petasites | Family: Asteraceae | Species: hybridus		1	NCGC00169029-02	363676747.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C2[C@](O)(O1)C[C@H]1[C@@](C)([C@@H](C)CCC1)C2	O=C1C(C)=C2[C@](O)(O1)C[C@H]1[C@@](C)([C@@H](C)CCC1)C2
NCGC00385028-01	O=C1C(C)=C2[C@](O)(O1)C[C@]1(C)OC1CC[C@]1(C)O[C@@H]1C2		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Smyrnium | Family: Umbelliferae | Species: olusatrum		1	NCGC00385028-01	363679492.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C2[C@](O)(O1)C[C@]1(C)OC1CC[C@]1(C)O[C@@H]1C2	O=C1C(C)=C2[C@](O)(O1)C[C@]1(C)OC1CC[C@]1(C)O[C@@H]1C2
NCGC00016258-06	O=C1C(C)=CC(=O)c2c1cccc2		Inactive	CDC25 Phosphatase Inhibitor		1	Menadione	170464997.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		O=C1C(C)=CC(=O)c2c1cccc2	O=C1C(C)=CC(=O)c2c1cccc2
NCGC00385596-01	O=C1C(C)=CCC(/C(=C/CCC(O)(C=C)C)/C)O1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385596-01	363679828.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=CCC(/C(=C/CCC(O)(C=C)C)/C)O1	O=C1C(C)=CCC(/C(=C/CCC(O)(C=C)C)/C)O1
NCGC00385911-01	O=C1C(C)=C[C@@H]2[C@H](C(C)C)[C@@H](O)C[C@@H](C)[C@@H]2C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385911-01	363680002.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)=C[C@@H]2[C@H](C(C)C)[C@@H](O)C[C@@H](C)[C@@H]2C1	O=C1C(C)=C[C@@H]2[C@H](C(C)C)[C@@H](O)C[C@@H](C)[C@@H]2C1
NCGC00246799-02	O=C1C(C)C(C)Oc2c1c(O)c1c(O)cc(O)c(-c3c(O)cc(O)c4c(O)c5C(=O)C(C)C(C)Oc5cc34)c1c2		Inactive			1	NCGC00246799-02	377020446.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)C(C)Oc2c1c(O)c1c(O)cc(O)c(-c3c(O)cc(O)c4c(O)c5C(=O)C(C)C(C)Oc5cc34)c1c2	O=C1C(C)C(C)Oc2c1c(O)c1c(O)cc(O)c(-c3c(O)cc(O)c4c(O)c5C(=O)C(C)C(C)Oc5cc34)c1c2
NCGC00385949-01	O=C1C(C)C2(O)C(O1)C1=C(C)C(=O)CCC1(C)CC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385949-01	363680022.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)C2(O)C(O1)C1=C(C)C(=O)CCC1(C)CC2	O=C1C(C)C2(O)C(O1)C1=C(C)C(=O)CCC1(C)CC2
NCGC00384597-02	O=C1C(C)C2(O)C(O1)C1=C(C)C(O)CCC1(C)CC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384597-02	363679264.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)C2(O)C(O1)C1=C(C)C(O)CCC1(C)CC2	O=C1C(C)C2(O)C(O1)C1=C(C)C(O)CCC1(C)CC2
NCGC00385921-01	O=C1C(C)C2(O)C(O1)C1=C(C)CCCC1(C)CC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385921-01	363680008.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)C2(O)C(O1)C1=C(C)CCCC1(C)CC2	O=C1C(C)C2(O)C(O1)C1=C(C)CCCC1(C)CC2
NCGC00169016-02	O=C1C(C)C2C(O1)C1C(C)=CCC(O)C1(C)CC2		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Conyza | Family: Asteraceae | Species: sp.		1	NCGC00169016-02	363676743.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)C2C(O1)C1C(C)=CCC(O)C1(C)CC2	O=C1C(C)C2C(O1)C1C(C)=CCC(O)C1(C)CC2
NCGC00385755-01	O=C1C(C)CC(O)C2(C(C)C3C4(C)C(C(O)C3O2)C2C(C3(C)C(CC(OC5C(OC6C(O)C(O)C(O)C(C)O6)C(O)C(O)C(CO)O5)CC3)CC2)CC4)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Solanum | Family: N/A | Species: dulcamara		1	NCGC00385755-01	363679926.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)CC(O)C2(C(C)C3C4(C)C(C(O)C3O2)C2C(C3(C)C(CC(OC5C(OC6C(O)C(O)C(O)C(C)O6)C(O)C(O)C(CO)O5)CC3)CC2)CC4)O1	O=C1C(C)CC(O)C2(C(C)C3C4(C)C(C(O)C3O2)C2C(C3(C)C(CC(OC5C(OC6C(O)C(O)C(O)C(C)O6)C(O)C(O)C(CO)O5)CC3)CC2)CC4)O1
NCGC00380154-02	O=C1C(C)NC2C3(OC4N(C)C(=O)C(N5C(=O)c6c(N=C45)cccc6)C3)c3c(N12)cccc3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380154-02	363678477.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(C)NC2C3(OC4N(C)C(=O)C(N5C(=O)c6c(N=C45)cccc6)C3)c3c(N12)cccc3	O=C1C(C)NC2C3(OC4N(C)C(=O)C(N5C(=O)c6c(N=C45)cccc6)C3)c3c(N12)cccc3
NCGC00181325-03	O=C1C(C/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)=C(C)C(=O)c2c1cccc2		Inactive	bone resorption Inhibitor		1	Menaquinone	405558876.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(C/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)=C(C)C(=O)c2c1cccc2	O=C1C(C/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)=C(C)C(=O)c2c1cccc2
NCGC00159423-03	O=C1C(C/C=C(/CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)\C)=C(C)C(=O)c2c1cccc2		Inactive	Vitamin K epoxide reductase complex subunit 1 Substrate		1	Phytonadione	170464798.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(C/C=C(/CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)\C)=C(C)C(=O)c2c1cccc2	O=C1C(C/C=C(/CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)\C)=C(C)C(=O)c2c1cccc2
NCGC00380254-01	O=C1C(CC(C)C)NC(=O)C2N1C1C(O)(c3c(N1)cccc3)C2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380254-01	363678515.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(CC(C)C)NC(=O)C2N1C1C(O)(c3c(N1)cccc3)C2	O=C1C(CC(C)C)NC(=O)C2N1C1C(O)(c3c(N1)cccc3)C2
NCGC00386076-01	O=C1C(CC(C)C)OC(=O)CCCNC(=O)C(CC(C)C)NC(=O)C(C)N1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386076-01	363680093.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(CC(C)C)OC(=O)CCCNC(=O)C(CC(C)C)NC(=O)C(C)N1	O=C1C(CC(C)C)OC(=O)CCCNC(=O)C(CC(C)C)NC(=O)C(C)N1
NCGC00015418-09&NCGC00015418-11	O=C1C(CC)(C)CC(=O)N1		Inactive	T-Type Calcium Channel Blocker		2	Ethosuximide	170464802.0&384567840.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1C(CC)(C)CC(=O)N1	O=C1C(CC)(C)CC(=O)N1
NCGC00015110-09&NCGC00015110-20	O=C1C(CC)(c2ccc(N)cc2)CCC(=O)N1		Inactive	Aromatase Inhibitor		2	Aminoglutethimide	170465259.0&384567810.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&11.905857744	O=C1C(CC)(c2ccc(N)cc2)CCC(=O)N1	O=C1C(CC)(c2ccc(N)cc2)CCC(=O)N1
NCGC00015834-19&NCGC00015834-27	O=C1C(CC)(c2ccccc2)C(=O)NCN1		Inactive	Anticonvulsant agent		2	Primidone	170464846.0&384567897.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1C(CC)(c2ccccc2)C(=O)NCN1	O=C1C(CC)(c2ccccc2)C(=O)NCN1
NCGC00510440-01&NCGC00510440-02	O=C1C(CC)=C(c2c(C)cccc2)Nc2c(C#N)cnn12		Inactive	Selective Inhibitor of KDM5 demethylases (H3K4 specific)		2	CPI-4203	384569432.0&384569433.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1C(CC)=C(c2c(C)cccc2)Nc2c(C#N)cnn12	O=C1C(CC)=C(c2c(C)cccc2)Nc2c(C#N)cnn12
NCGC00381183-01	O=C1C(CC2(C(C=C)(C)C)C(=O)Nc3c2cc2c(OC(C)(C)C=C2)c3)NC(=O)C2N1CCC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381183-01	363679010.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(CC2(C(C=C)(C)C)C(=O)Nc3c2cc2c(OC(C)(C)C=C2)c3)NC(=O)C2N1CCC2	O=C1C(CC2(C(C=C)(C)C)C(=O)Nc3c2cc2c(OC(C)(C)C=C2)c3)NC(=O)C2N1CCC2
NCGC00016296-07	O=C1C(CC=2C(=O)Oc3c(C=2O)cccc3)=C(O)c2c(O1)cccc2		Inactive	Vitamin k epoxide reductase complex subunit 1 isoform 1 Inhibitor		1	Dicumarol	170465275.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1C(CC=2C(=O)Oc3c(C=2O)cccc3)=C(O)c2c(O1)cccc2	O=C1C(CC=2C(=O)Oc3c(C=2O)cccc3)=C(O)c2c(O1)cccc2
NCGC00179297-04	O=C1C(CCC)C(=O)N2N1C(N(C)C)=Nc1c2cc(C)cc1		Inactive	interleukin-1 alpha production Inhibitor		1	Azapropazone	405558878.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(CCC)C(=O)N2N1C(N(C)C)=Nc1c2cc(C)cc1	O=C1C(CCC)C(=O)N2N1C(N(C)C)=Nc1c2cc(C)cc1
NCGC00179869-02	O=C1C(CCC2(C)C(C)CCC3(C)C4(C(O)C(O)CC23)OC4)=CC(O)O1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Cornutia | Family: Verbenaceae | Species: pyramidata		1	NCGC00179869-02	363676981.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(CCC2(C)C(C)CCC3(C)C4(C(O)C(O)CC23)OC4)=CC(O)O1	O=C1C(CCC2(C)C(C)CCC3(C)C4(C(O)C(O)CC23)OC4)=CC(O)O1
NCGC00384992-01	O=C1C(CCC2(C)C(C)CCC34C(C(=O)OC3)=CC(O)CC24)=CC(O)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384992-01	363679472.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(CCC2(C)C(C)CCC34C(C(=O)OC3)=CC(O)CC24)=CC(O)O1	O=C1C(CCC2(C)C(C)CCC34C(C(=O)OC3)=CC(O)CC24)=CC(O)O1
NCGC00017248-18	O=C1C(CCCCCCCCCCC)=C(O)C(=O)C=C1O		Inactive	IAP Inhibitor		1	Embelin	384567980.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(CCCCCCCCCCC)=C(O)C(=O)C=C1O	O=C1C(CCCCCCCCCCC)=C(O)C(=O)C=C1O
NCGC00385234-01	O=C1C(CC[C@@H]2C(=C)CCC3[C@@](CO)(C)CCC[C@@]23C)=CCO1		Inactive	p38MAPK cascade Inhibitor		1	NCGC00385234-01	363679609.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(CC[C@@H]2C(=C)CCC3[C@@](CO)(C)CCC[C@@]23C)=CCO1	O=C1C(CC[C@@H]2C(=C)CCC3[C@@](CO)(C)CCC[C@@]23C)=CCO1
NCGC00168865-02	O=C1C(CC[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)C(O)CC[C@@]23C)=CCO1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00168865-02	363676707.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(CC[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)C(O)CC[C@@]23C)=CCO1	O=C1C(CC[C@@H]2C(=C)CC[C@@H]3[C@@](CO)(C)C(O)CC[C@@]23C)=CCO1
NCGC00162218-05	O=C1C(CN2CCOCC2)CCc2[nH]c(C)c(CC)c12		Inactive	Serotonin 7 (5-HT7) receptor Antagonist		1	Molindone hydrochloride	170465047.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(CN2CCOCC2)CCc2[nH]c(C)c(CC)c12.Cl	O=C1C(CN2CCOCC2)CCc2[nH]c(C)c(CC)c12.Cl
NCGC00385875-01	O=C1C(CO)=CCCC(=C)[C@@H]2[C@H](C(C)(C)C2)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385875-01	363679983.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(CO)=CCCC(=C)[C@@H]2[C@H](C(C)(C)C2)C1	O=C1C(CO)=CCCC(=C)[C@@H]2[C@H](C(C)(C)C2)C1
NCGC00385408-01	O=C1C(Cc2[nH]cnc2)NC(=O)C(Cc2c3c([nH]c2)cccc3)N1		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385408-01	363679727.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(Cc2[nH]cnc2)NC(=O)C(Cc2c3c([nH]c2)cccc3)N1	O=C1C(Cc2[nH]cnc2)NC(=O)C(Cc2c3c([nH]c2)cccc3)N1
NCGC00380807-01	O=C1C(Cc2c(C(C=C)(C)C)[nH]c3c2cc2c(OC(C)(C)C=C2)c3)NC(=O)C2N1CCC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380807-01	363678792.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(Cc2c(C(C=C)(C)C)[nH]c3c2cc2c(OC(C)(C)C=C2)c3)NC(=O)C2N1CCC2	O=C1C(Cc2c(C(C=C)(C)C)[nH]c3c2cc2c(OC(C)(C)C=C2)c3)NC(=O)C2N1CCC2
NCGC00347570-02	O=C1C(Cc2c(C(C=C)(C)C)[nH]c3c2cc2c(OC(C)(C)C=C2)c3)NC(=O)C=2N1CCC=2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347570-02	363677625.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(Cc2c(C(C=C)(C)C)[nH]c3c2cc2c(OC(C)(C)C=C2)c3)NC(=O)C=2N1CCC=2	O=C1C(Cc2c(C(C=C)(C)C)[nH]c3c2cc2c(OC(C)(C)C=C2)c3)NC(=O)C=2N1CCC=2
NCGC00384831-01	O=C1C(Cc2c3c([nH]c2)cccc3)N2C(=O)c3c(N=C2CN1)cccc3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384831-01	363679382.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(Cc2c3c([nH]c2)cccc3)N2C(=O)c3c(N=C2CN1)cccc3	O=C1C(Cc2c3c([nH]c2)cccc3)N2C(=O)c3c(N=C2CN1)cccc3
NCGC00380229-01	O=C1C(Cc2c3c([nH]c2)cccc3)NC(=O)C(C)N1		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380229-01	363678505.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(Cc2c3c([nH]c2)cccc3)NC(=O)C(C)N1	O=C1C(Cc2c3c([nH]c2)cccc3)NC(=O)C(C)N1
NCGC00384902-01	O=C1C(Cc2c3c([nH]c2)cccc3)NC(=O)C(Cc2c3c([nH]c2)cccc3)N1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384902-01	363679428.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(Cc2c3c([nH]c2)cccc3)NC(=O)C(Cc2c3c([nH]c2)cccc3)N1	O=C1C(Cc2c3c([nH]c2)cccc3)NC(=O)C(Cc2c3c([nH]c2)cccc3)N1
NCGC00347713-02	O=C1C(Cc2c3c([nH]c2)cccc3)NC(=O)CNC(=O)C(C(O)c2ccc(O)cc2)NC(=O)CNC(=O)C(C(C)C)NC(=O)CNC(=O)C2N1CCC2		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347713-02	363677671.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(Cc2c3c([nH]c2)cccc3)NC(=O)CNC(=O)C(C(O)c2ccc(O)cc2)NC(=O)CNC(=O)C(C(C)C)NC(=O)CNC(=O)C2N1CCC2	O=C1C(Cc2c3c([nH]c2)cccc3)NC(=O)CNC(=O)C(C(O)c2ccc(O)cc2)NC(=O)CNC(=O)C(C(C)C)NC(=O)CNC(=O)C2N1CCC2
NCGC00384484-01	O=C1C(Cc2c3c([nH]c2)cccc3)NC(=O)CNC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(C(C)C)NC(=O)CNC(=O)C2N1CCC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384484-01	363679208.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(Cc2c3c([nH]c2)cccc3)NC(=O)CNC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(C(C)C)NC(=O)CNC(=O)C2N1CCC2	O=C1C(Cc2c3c([nH]c2)cccc3)NC(=O)CNC(=O)C(Cc2ccc(O)cc2)NC(=O)CNC(=O)C(C(C)C)NC(=O)CNC(=O)C2N1CCC2
NCGC00384639-01	O=C1C(Cc2ccc(O)cc2)NC(=O)C2N1CCC2		Inactive	<MOA Unknown> | Class: Amino acid | Genus: - | Family: - | Species: -		1	NCGC00384639-01	363679288.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(Cc2ccc(O)cc2)NC(=O)C2N1CCC2	O=C1C(Cc2ccc(O)cc2)NC(=O)C2N1CCC2
NCGC00381179-01	O=C1C(Cc2ccccc2)=C(O)C(c2ccc(O)cc2)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381179-01	363679008.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(Cc2ccccc2)=C(O)C(c2ccc(O)cc2)O1	O=C1C(Cc2ccccc2)=C(O)C(c2ccc(O)cc2)O1
NCGC00380870-01	O=C1C(Cc2ccccc2)=C(c2ccccc2)CO1		Inactive	<MOA Unknown> | Class: polyketide/shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380870-01	363678824.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(Cc2ccccc2)=C(c2ccccc2)CO1	O=C1C(Cc2ccccc2)=C(c2ccccc2)CO1
NCGC00180043-02	O=C1C(Cc2ccccc2)N(C)C(=O)c2c(N1)cccc2		Inactive	<MOA Unknown> | Class: alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180043-02	363677000.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(Cc2ccccc2)N(C)C(=O)c2c(N1)cccc2	O=C1C(Cc2ccccc2)N(C)C(=O)c2c(N1)cccc2
NCGC00347844-02	O=C1C(Cc2ccccc2)NC(=O)C(CC2(N)C(N)Nc3c2cccc3)NC(=O)C(Cc2ccccc2)N1		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347844-02	363677707.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(Cc2ccccc2)NC(=O)C(CC2(N)C(N)Nc3c2cccc3)NC(=O)C(Cc2ccccc2)N1	O=C1C(Cc2ccccc2)NC(=O)C(CC2(N)C(N)Nc3c2cccc3)NC(=O)C(Cc2ccccc2)N1
NCGC00380633-02	O=C1C(Cc2ccccc2)NC(=O)C2N1CCC2		Inactive	<MOA Unknown> | Class: Amino acid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380633-02	363678683.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(Cc2ccccc2)NC(=O)C2N1CCC2	O=C1C(Cc2ccccc2)NC(=O)C2N1CCC2
NCGC00169194-02	O=C1C(Cc2ccccc2)NC2C(O)(CC3C(=O)NC(C(C)C)C(=O)N3)c3c(N12)cccc3		Inactive	<MOA Unknown> | Class: alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169194-02	363676788.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(Cc2ccccc2)NC2C(O)(CC3C(=O)NC(C(C)C)C(=O)N3)c3c(N12)cccc3	O=C1C(Cc2ccccc2)NC2C(O)(CC3C(=O)NC(C(C)C)C(=O)N3)c3c(N12)cccc3
NCGC00180346-02	O=C1C(Cc2nc[nH]c2)NC(=O)C2N1C1C(C(C=C)(C)C)(c3c(N1)cccc3)C2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180346-02	363677011.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(Cc2nc[nH]c2)NC(=O)C2N1C1C(C(C=C)(C)C)(c3c(N1)cccc3)C2	O=C1C(Cc2nc[nH]c2)NC(=O)C2N1C1C(C(C=C)(C)C)(c3c(N1)cccc3)C2
NCGC00179341-04	O=C1C(Cn2c(C)ncc2)CCc2n(C)c3c(c12)cccc3		Inactive	5-HT3 Antagonists		1	Ondansetron	170464701.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(Cn2c(C)ncc2)CCc2n(C)c3c(c12)cccc3	O=C1C(Cn2c(C)ncc2)CCc2n(C)c3c(c12)cccc3
NCGC00016896-06	O=C1C(N)=CC(c2ccncc2)=CN1		Inactive	platelet aggregation Inhibitor		1	Amrinone	170465367.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(N)=CC(c2ccncc2)=CN1	O=C1C(N)=CC(c2ccncc2)=CN1
NCGC00015989-17&NCGC00015989-22	O=C1C(N2C(=O)c3c(C2=O)cccc3)CCC(=O)N1		Inactive	TNF-alpha Production Inhibitor		2	Thalidomide	170465323.0&384567913.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	O=C1C(N2C(=O)c3c(C2=O)cccc3)CCC(=O)N1	O=C1C(N2C(=O)c3c(C2=O)cccc3)CCC(=O)N1
NCGC00346551-03&NCGC00346551-05	O=C1C(N2C(=O)c3c(N)cccc3C2=O)CCC(=O)N1		Inactive	TNF-alpha Production Inhibitor		2	Pomalidomide	405559099.0&384568836.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1C(N2C(=O)c3c(N)cccc3C2=O)CCC(=O)N1	O=C1C(N2C(=O)c3c(N)cccc3C2=O)CCC(=O)N1
NCGC00381187-01	O=C1C(N2C(=O)c3c(N=C2)cccc3)C[C@]2(O1)[C@H]1N(O)C(C)(C)C(=O)N1c1c2cccc1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381187-01	363679014.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(N2C(=O)c3c(N=C2)cccc3)C[C@]2(O1)[C@H]1N(O)C(C)(C)C(=O)N1c1c2cccc1	O=C1C(N2C(=O)c3c(N=C2)cccc3)C[C@]2(O1)[C@H]1N(O)C(C)(C)C(=O)N1c1c2cccc1
NCGC00167491-04	O=C1C(N2C(=O)c3c(c(N)ccc3)C2)CCC(=O)N1		Inactive	TNF-alpha Production Inhibitor		1	Lenalidomide	170465201.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C1C(N2C(=O)c3c(c(N)ccc3)C2)CCC(=O)N1	O=C1C(N2C(=O)c3c(c(N)ccc3)C2)CCC(=O)N1
NCGC00509909-01	O=C1C(N2C(C)=Nc3c(c(N)ccc3)C2=O)CCC(=O)N1		Inactive	TNF-alpha Production Inhibitor		1	Avadomide	384569376.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(N2C(C)=Nc3c(c(N)ccc3)C2=O)CCC(=O)N1	O=C1C(N2C(C)=Nc3c(c(N)ccc3)C2=O)CCC(=O)N1
NCGC00510878-01	O=C1C(N2CC2)=CC(=O)c2n(C)c(/C=C/CO)c(CO)c12		Inactive	DNA Alkylating Drugs		1	Apaziquone	384569492.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(N2CC2)=CC(=O)c2n(C)c(/C=C/CO)c(CO)c12	O=C1C(N2CC2)=CC(=O)c2n(C)c(/C=C/CO)c(CO)c12
NCGC00179264-03	O=C1C(NCC)(c2sccc2)CCCC1		Inactive	Glutamate [NMDA] receptor subunit epsilon 2 Antagonist		1	Tiletamine Hydrochloride	405558786.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(NCC)(c2sccc2)CCCC1	O=C1C(NCC)(c2sccc2)CCCC1
NCGC00177846-03	O=C1C(NCCc2ccccc2)=C2c3c(C(=O)c4c2cccc4)cccc3N1		Inactive			1	BRD7389	377020463.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(NCCc2ccccc2)=C2c3c(C(=O)c4c2cccc4)cccc3N1	O=C1C(NCCc2ccccc2)=C2c3c(C(=O)c4c2cccc4)cccc3N1
NCGC00167794-02	O=C1C(Nc2ccc(C)cc2)=CC(=O)c2sc(C)nc12		Inactive			1	Ryuvidine		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(Nc2ccc(C)cc2)=CC(=O)c2sc(C)nc12	O=C1C(Nc2ccc(C)cc2)=CC(=O)c2sc(C)nc12
NCGC00492296-02&NCGC00492296-03	O=C1C(Nc2ncnc(N)c2)=CC(C)=C2C(=O)NC3(N12)CCCCC3		Inactive	MNK1/2 Inhibitor		2	eFT508	384569287.0&434146922.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1C(Nc2ncnc(N)c2)=CC(C)=C2C(=O)NC3(N12)CCCCC3	O=C1C(Nc2ncnc(N)c2)=CC(C)=C2C(=O)NC3(N12)CCCCC3
NCGC00347407-02	O=C1C(O)(C)C(O)(C)C(C)C(=O)OCC=2C3N(CC=2)CCC3O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347407-02	363677594.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(O)(C)C(O)(C)C(C)C(=O)OCC=2C3N(CC=2)CCC3O1	O=C1C(O)(C)C(O)(C)C(C)C(=O)OCC=2C3N(CC=2)CCC3O1
NCGC00385937-01	O=C1C(O)(C)C(O)(C)C(C)C(=O)OCC=2C3[N+]([O-])(CC=2)CCC3O1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385937-01	363680017.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(O)(C)C(O)(C)C(C)C(=O)OCC=2C3[N+]([O-])(CC=2)CCC3O1	O=C1C(O)(C)C(O)(C)C(C)C(=O)OCC=2C3[N+]([O-])(CC=2)CCC3O1
NCGC00380966-01	O=C1C(O)(C)C(O)C2C(=C1C)C=C(C)OC2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380966-01	363678891.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(O)(C)C(O)C2C(=C1C)C=C(C)OC2	O=C1C(O)(C)C(O)C2C(=C1C)C=C(C)OC2
NCGC00169236-03	O=C1C(O)(C)C(O)C=2C(C=C(/C=C/C(=C/C(CCO)C)/C)OC=2)=C1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: - | Family: - | Species: -		1	NCGC00169236-03	363676792.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(O)(C)C(O)C=2C(C=C(/C=C/C(=C/C(CCO)C)/C)OC=2)=C1	O=C1C(O)(C)C(O)C=2C(C=C(/C=C/C(=C/C(CCO)C)/C)OC=2)=C1
NCGC00384848-01	O=C1C(O)(C)C2C(C(O)(CO)CCC(C(OC3C(O)C(O)C(O)C(CO)O3)(C)C)C2)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384848-01	363679393.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(O)(C)C2C(C(O)(CO)CCC(C(OC3C(O)C(O)C(O)C(CO)O3)(C)C)C2)C1	O=C1C(O)(C)C2C(C(O)(CO)CCC(C(OC3C(O)C(O)C(O)C(CO)O3)(C)C)C2)C1
NCGC00380973-01	O=C1C(O)(C)OC(=O)C2(C3(C)C(C(C)=CC4C3CCCC4)CC(CC)O2)O1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380973-01	363678896.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(O)(C)OC(=O)C2(C3(C)C(C(C)=CC4C3CCCC4)CC(CC)O2)O1	O=C1C(O)(C)OC(=O)C2(C3(C)C(C(C)=CC4C3CCCC4)CC(CC)O2)O1
NCGC00385254-01	O=C1C(O)(CCC(C)C)C(O)C(C)(C)C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C1(C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385254-01	363679620.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(O)(CCC(C)C)C(O)C(C)(C)C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C1(C)C	O=C1C(O)(CCC(C)C)C(O)C(C)(C)C(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)C1(C)C
NCGC00090548-04&NCGC00090548-05	O=C1C(O)=C(C)N(C)C=C1		Inactive	Iron Chelating Agent		2	Deferiprone	405558541.0&434147239.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1C(O)=C(C)N(C)C=C1	O=C1C(O)=C(C)N(C)C=C1
NCGC00094931-06	O=C1C(O)=C(CC=C(C)C)C(=O)c2c1cccc2		Inactive			1	Lapachol	434146994.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(O)=C(CC=C(C)C)C(=O)c2c1cccc2	O=C1C(O)=C(CC=C(C)C)C(=O)c2c1cccc2
NCGC00091517-06	O=C1C(O)=C(O)[C@@H]([C@@H](O)CO)O1		Inactive			1	L-Ascorbic acid	170464728.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C1C(O)=C(O)[C@@H]([C@@H](O)CO)O1	O=C1C(O)=C(O)[C@@H]([C@@H](O)CO)O1
NCGC00381199-01	O=C1C(O)=C([C@@H](CO)C)[C@@H]2[C@]1(C)C/C=C(\C)/CC/C=C(\C)/CC[C@H](O)/C(/C)=C/C2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381199-01	363679017.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(O)=C([C@@H](CO)C)[C@@H]2[C@]1(C)C/C=C(\C)/CC/C=C(\C)/CC[C@H](O)/C(/C)=C/C2	O=C1C(O)=C([C@@H](CO)C)[C@@H]2[C@]1(C)C/C=C(\C)/CC/C=C(\C)/CC[C@H](O)/C(/C)=C/C2
NCGC00015672-15	O=C1C(O)=C(c2c(O)cc(O)cc2)Oc2c1c(O)cc(O)c2		Inactive	Cytochrome P450 CYP1A2 Inhibitor		1	Morin hydrate	384567879.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(O)=C(c2c(O)cc(O)cc2)Oc2c1c(O)cc(O)c2	O=C1C(O)=C(c2c(O)cc(O)cc2)Oc2c1c(O)cc(O)c2
NCGC00015697-01	O=C1C(O)=C(c2cc(O)c(O)c(O)c2)Oc2c1c(O)cc(O)c2		Inactive	Cytochrome P450 CYP1A2 Inhibitor		1	Myricetin	11111487.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(O)=C(c2cc(O)c(O)c(O)c2)Oc2c1c(O)cc(O)c2	O=C1C(O)=C(c2cc(O)c(O)c(O)c2)Oc2c1c(O)cc(O)c2
NCGC00015870-26&NCGC00015870-27	O=C1C(O)=C(c2cc(O)c(O)cc2)Oc2c1c(O)cc(O)c2		Inactive	Flavone		2	Quercetin	384567899.0&170466817.0	Annotated/Bioactive Compound Collection&2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1C(O)=C(c2cc(O)c(O)cc2)Oc2c1c(O)cc(O)c2	O=C1C(O)=C(c2cc(O)c(O)cc2)Oc2c1c(O)cc(O)c2&O=C1C(O)=C(c2cc(O)c(O)cc2)Oc2c1c(O)cc(O)c2.O.O
NCGC00017344-11	O=C1C(O)=C(c2cc(O)c(O)cc2)Oc2c1ccc(O)c2		Inactive	Histone Deacetylase/SIRT1 Activator		1	Fisetin	384567986.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(O)=C(c2cc(O)c(O)cc2)Oc2c1ccc(O)c2	O=C1C(O)=C(c2cc(O)c(O)cc2)Oc2c1ccc(O)c2
NCGC00016480-10&NCGC00016480-20	O=C1C(O)=C(c2ccc(O)cc2)Oc2c1c(O)cc(O)c2		Inactive	flavanoid		2	Kaempferol	384567944.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1C(O)=C(c2ccc(O)cc2)Oc2c1c(O)cc(O)c2	O=C1C(O)=C(c2ccc(O)cc2)Oc2c1c(O)cc(O)c2
NCGC00096023-03	O=C1C(O)=C(c2ccc(O)cc2)Oc2c1cccc2		Inactive			1	3,4 -DIHYDROXYFLAVONE	434147002.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	-11.993025284	O=C1C(O)=C(c2ccc(O)cc2)Oc2c1cccc2	O=C1C(O)=C(c2ccc(O)cc2)Oc2c1cccc2
NCGC00180812-03	O=C1C(O)=C2C(C)(C)O[C@@H]3[C@@]2(C2[C@]1(C)[C@]14[C@](C)([C@H](c5cocc5)OC(=O)[C@H]1O4)CC2)COC(=O)C3		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Fagaropsis | Family: Rutaceae | Species: angolensis		1	NCGC00180812-03	363677067.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(O)=C2C(C)(C)O[C@@H]3[C@@]2(C2[C@]1(C)[C@]14[C@](C)([C@H](c5cocc5)OC(=O)[C@H]1O4)CC2)COC(=O)C3	O=C1C(O)=C2C(C)(C)O[C@@H]3[C@@]2(C2[C@]1(C)[C@]14[C@](C)([C@H](c5cocc5)OC(=O)[C@H]1O4)CC2)COC(=O)C3
NCGC00164380-01	O=C1C(O)=C2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC2)CC1		Inactive	Aromatase Inhibitor		1	Formestane	26757799.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(O)=C2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC2)CC1	O=C1C(O)=C2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC2)CC1
NCGC00094565-03	O=C1C(O)=CC(C(C)C)=CC=C1		Inactive			1	Hinokitiol	26753708.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(O)=CC(C(C)C)=CC=C1	O=C1C(O)=CC(C(C)C)=CC=C1
NCGC00017325-06&NCGC00017325-10	O=C1C(O)=COC(CO)=C1		Inactive	Tyrosinase Inhibitor		2	Kojic acid&KOJIC ACID	170466814.0&434146964.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	-6.064245812&0.0&0.0	O=C1C(O)=COC(CO)=C1	O=C1C(O)=COC(CO)=C1
NCGC00381143-01	O=C1C(O)C(O)(c2ccccc2)c2c(N1)cccc2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381143-01	363678992.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(O)C(O)(c2ccccc2)c2c(N1)cccc2	O=C1C(O)C(O)(c2ccccc2)c2c(N1)cccc2
NCGC00381277-01	O=C1C(O)C(O)CC(/C=C/C=C/CCC)C1CO		Inactive	<MOA Unknown> | Class: polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381277-01	363679061.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(O)C(O)CC(/C=C/C=C/CCC)C1CO	O=C1C(O)C(O)CC(/C=C/C=C/CCC)C1CO
NCGC00380449-01	O=C1C(O)C2=C(C)C(O)CCC2(C)C(c2cocc2)O1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Dictamnus | Family: N/A | Species: dasycarpus		1	NCGC00380449-01	363678589.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(O)C2=C(C)C(O)CCC2(C)C(c2cocc2)O1	O=C1C(O)C2=C(C)C(O)CCC2(C)C(c2cocc2)O1
NCGC00380405-01	O=C1C(O)CC(=O)C23C(=O)NC(CC(C)C)C2C(C)C(C)=CC3/C=C(\C)/CCC1O		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380405-01	363678571.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(O)CC(=O)C23C(=O)NC(CC(C)C)C2C(C)C(C)=CC3/C=C(\C)/CCC1O	O=C1C(O)CC(=O)C23C(=O)NC(CC(C)C)C2C(C)C(C)=CC3/C=C(\C)/CCC1O
NCGC00380084-01	O=C1C(O)CCC=2OC3(C)C(C(C(CC/C=C(/CO)\C)C)=CC3)CC1=2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380084-01	363678454.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(O)CCC=2OC3(C)C(C(C(CC/C=C(/CO)\C)C)=CC3)CC1=2	O=C1C(O)CCC=2OC3(C)C(C(C(CC/C=C(/CO)\C)C)=CC3)CC1=2
NCGC00385977-01	O=C1C(OC)C(O)(C2(C)C(CC=C(C)C)O2)C2(OC2)CC1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385977-01	363680039.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(OC)C(O)(C2(C)C(CC=C(C)C)O2)C2(OC2)CC1	O=C1C(OC)C(O)(C2(C)C(CC=C(C)C)O2)C2(OC2)CC1
NCGC00163489-03&NCGC00163489-05	O=C1C([C@H](O)CC=C(C)C)=CC(=O)c2c(O)ccc(O)c12		Inactive	Drugs Acting on Chemokine Receptors		2	Shikonin	384568243.0&434147017.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1C([C@H](O)CC=C(C)C)=CC(=O)c2c(O)ccc(O)c12	O=C1C([C@H](O)CC=C(C)C)=CC(=O)c2c(O)ccc(O)c12
NCGC00181135-02	O=C1C([C@H](O)CCCCC)[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)CC(O)C(O)C(O)C(C)=CC=CC=CC=CC=C[C@@H](O)C(C)O1		Inactive			1	Pentamycin	144206785.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C([C@H](O)CCCCC)[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)CC(O)C(O)C(O)C(C)=CC=CC=CC=CC=C[C@@H](O)C(C)O1	O=C1C([C@H](O)CCCCC)[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)CC(O)C(O)C(O)C(C)=CC=CC=CC=CC=C[C@@H](O)C(C)O1
NCGC00167434-02	O=C1C(c2[nH]nnn2)=CN=C2C(C)=CC=CN12		Inactive			1	Pemirolast potassium	170465431.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(c2nnn[n-]2)=CN=C2C(C)=CC=CN12.[K+]	O=C1C(c2nnn[n-]2)=CN=C2C(C)=CC=CN12.[K+]
NCGC00262009-03	O=C1C(c2c3c([nH]c2)cccc3)=C(c2c3c([nH]c2)cccc3)C(=O)N1		Inactive	CDK4 Inhibitor		1	Bisindolylmaleimide	377020269.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(c2c3c([nH]c2)cccc3)=C(c2c3c([nH]c2)cccc3)C(=O)N1	O=C1C(c2c3c([nH]c2)cccc3)=C(c2c3c([nH]c2)cccc3)C(=O)N1
NCGC00262036-03	O=C1C(c2c3c(n(CCCN)c2)cccc3)=C(c2c3c(n(C)c2)cccc3)C(=O)N1		Inactive			1	Bisindolylmaleimide VIII (acetate)		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	13.247753332	O=C1C(c2c3c(n(CCCN)c2)cccc3)=C(c2c3c(n(C)c2)cccc3)C(=O)N1	O=C1C(c2c3c(n(CCCN)c2)cccc3)=C(c2c3c(n(C)c2)cccc3)C(=O)N1
NCGC00262061-03	O=C1C(c2c3c(n4c2CC(CN)CC4)cccc3)=C(c2c3c(n(C)c2)cccc3)C(=O)N1		Inactive	PKC Inhibitor		1	Ro-31-8425	384568570.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(c2c3c(n4c2CC(CN)CC4)cccc3)=C(c2c3c(n(C)c2)cccc3)C(=O)N1	O=C1C(c2c3c(n4c2CC(CN)CC4)cccc3)=C(c2c3c(n(C)c2)cccc3)C(=O)N1
NCGC00408892-01	O=C1C(c2ccc(O)cc2)(c2ccc(O)cc2)c2c(c(C)ccc2)N1	6.0	Active	Estrogen receptor alpha Modulator	0.0	1	BHPI	363681076.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	1.4	36.6461671168	O=C1C(c2ccc(O)cc2)(c2ccc(O)cc2)c2c(c(C)ccc2)N1	O=C1C(c2ccc(O)cc2)(c2ccc(O)cc2)c2c(c(C)ccc2)N1
NCGC00096060-07	O=C1C(c2ccc(O)cc2)=COc2c([C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)c(O)ccc12		Inactive			1	Puerarin	384568159.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(c2ccc(O)cc2)=COc2c([C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)c(O)ccc12	O=C1C(c2ccc(O)cc2)=COc2c([C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)c(O)ccc12
NCGC00015479-19&NCGC00015479-22	O=C1C(c2ccc(O)cc2)=COc2c1c(O)cc(O)c2		Inactive	DNA Topoisomerase II Inhibitor		2	Genistein	170466848.0&384567855.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1C(c2ccc(O)cc2)=COc2c1c(O)cc(O)c2	O=C1C(c2ccc(O)cc2)=COc2c1c(O)cc(O)c2
NCGC00015365-22	O=C1C(c2ccc(O)cc2)=COc2c1ccc(O)c2		Inactive	Estrogen Receptor (ER) beta Agonist		1	Daidzein	384567838.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(c2ccc(O)cc2)=COc2c1ccc(O)c2	O=C1C(c2ccc(O)cc2)=COc2c1ccc(O)c2
NCGC00021139-11	O=C1C(c2ccccc2)(c2ccccc2)NC(=O)N1		Inactive			1	5,5-Diphenylhydantoin	170464785.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1C(c2ccccc2)(c2ccccc2)NC(=O)N1	O=C1C(c2ccccc2)(c2ccccc2)NC(=O)N1
NCGC00166113-04	O=C1C(c2ccccc2)=C1c1ccccc1		Inactive	immune system process Activator		1	Diphenylcyclopropenone	170465593.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1C(c2ccccc2)=C1c1ccccc1	O=C1C(c2ccccc2)=C1c1ccccc1
NCGC00016329-07	O=C1C(c2ccccc2)C(=O)c2c1cccc2		Inactive	Vitamin k epoxide reductase complex subunit 1 isoform 1 Inhibitor		1	Phenindione	170465130.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1C(c2ccccc2)C(=O)c2c1cccc2	O=C1C(c2ccccc2)C(=O)c2c1cccc2
NCGC00238621-08	O=C1C(c2nc(N3CCN(C)CC3)nc3c2cccc3)=C(c2c3c([nH]c2)cccc3)C(=O)N1		Inactive	Protein kinase C theta Inhibitor		1	Sotrastaurin	384568467.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C(c2nc(N3CCN(C)CC3)nc3c2cccc3)=C(c2c3c([nH]c2)cccc3)C(=O)N1	O=C1C(c2nc(N3CCN(C)CC3)nc3c2cccc3)=C(c2c3c([nH]c2)cccc3)C(=O)N1
NCGC00371002-02	O=C1C(c2sc3c(n2)cccc3)=COc2c(CN3CCCCC3)c(O)c(CC)cc12		Inactive	S-phase kinase-associated protein 2 Inhibitor		1	SKP2-C25	363677987.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C(c2sc3c(n2)cccc3)=COc2c(CN3CCCCC3)c(O)c(CC)cc12	O=C1C(c2sc3c(n2)cccc3)=COc2c(CN3CCCCC3)c(O)c(CC)cc12
NCGC00015223-21	O=C1C2(C(=O)O[Pt-4]([NH3+])([NH-])O1)CCC2		Inactive			1	Carboplatin		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C2(C(=O)O[Pt-4]([NH3+])([NH-])O1)CCC2	O=C1C2(C(=O)O[Pt-4]([NH3+])([NH-])O1)CCC2
NCGC00380520-01	O=C1C2(C(C)CC3C4(CO)C(O)(CO3)CCC(O)C24)CC(c2cocc2)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380520-01	363678628.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(C(C)CC3C4(CO)C(O)(CO3)CCC(O)C24)CC(c2cocc2)O1	O=C1C2(C(C)CC3C4(CO)C(O)(CO3)CCC(O)C24)CC(c2cocc2)O1
NCGC00347378-02	O=C1C2(C(C)CCC3(O)C(C)=CC(=O)CC23)CC(c2cocc2)O1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Croton | Family: Euphorbiaceae | Species: reflexifolius		1	NCGC00347378-02	363677583.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(C(C)CCC3(O)C(C)=CC(=O)CC23)CC(c2cocc2)O1	O=C1C2(C(C)CCC3(O)C(C)=CC(=O)CC23)CC(c2cocc2)O1
NCGC00384760-01	O=C1C2(C(CO)=C)OC2C2(C)C(C)CC(O)C(O)C2=C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384760-01	363679341.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(C(CO)=C)OC2C2(C)C(C)CC(O)C(O)C2=C1	O=C1C2(C(CO)=C)OC2C2(C)C(C)CC(O)C(O)C2=C1
NCGC00090730-05	O=C1C2(C)C(C)(C)C(C1)CC2		Inactive			1	Camphor	434146984.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C2(C)C(C)(C)C(C1)CC2	O=C1C2(C)C(C)(C)C(C1)CC2
NCGC00380663-01	O=C1C2(C)C3C(C(=O)C(C)OC3O1)C1(C)C(=O)C=C3C(C)(C)OC(=O)C=C3C3(OC3)C1C2		Inactive	<MOA Unknown> | Class: sesterterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380663-01	363678699.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(C)C3C(C(=O)C(C)OC3O1)C1(C)C(=O)C=C3C(C)(C)OC(=O)C=C3C3(OC3)C1C2	O=C1C2(C)C3C(C(=O)C(C)OC3O1)C1(C)C(=O)C=C3C(C)(C)OC(=O)C=C3C3(OC3)C1C2
NCGC00381216-01	O=C1C2(C)C3C(C(=O)C(C)OC3O1)C1(C)C(=O)CC=3C(C)(C)OC(=O)CC=3C(CO)=C1C2		Inactive	<MOA Unknown> | Class: sesterterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381216-01	363679029.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(C)C3C(C(=O)C(C)OC3O1)C1(C)C(=O)CC=3C(C)(C)OC(=O)CC=3C(CO)=C1C2	O=C1C2(C)C3C(C(=O)C(C)OC3O1)C1(C)C(=O)CC=3C(C)(C)OC(=O)CC=3C(CO)=C1C2
NCGC00380683-01	O=C1C2(C)C3C(C)(C4(C(C)CC3O1)OC1(C(O)C(OC)OC1O)CC4)CCC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380683-01	363678706.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(C)C3C(C)(C4(C(C)CC3O1)OC1(C(O)C(OC)OC1O)CC4)CCC2	O=C1C2(C)C3C(C)(C4(C(C)CC3O1)OC1(C(O)C(OC)OC1O)CC4)CCC2
NCGC00386089-01	O=C1C2(C)C3C(C)(OC=4OC(C)CC(=O)C=4C3)CCC2C(C)(C)C2OC12		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386089-01	363680101.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(C)C3C(C)(OC=4OC(C)CC(=O)C=4C3)CCC2C(C)(C)C2OC12	O=C1C2(C)C3C(C)(OC=4OC(C)CC(=O)C=4C3)CCC2C(C)(C)C2OC12
NCGC00386063-01	O=C1C2(C)C3C(C)(OC=4OC(C)CC(=O)C=4C3)CCC2C(C)(C)C=C1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386063-01	363680087.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(C)C3C(C)(OC=4OC(C)CC(=O)C=4C3)CCC2C(C)(C)C=C1	O=C1C2(C)C3C(C)(OC=4OC(C)CC(=O)C=4C3)CCC2C(C)(C)C=C1
NCGC00385941-01	O=C1C2(C)OC2C(O)C(C2C(C(O)(C)C)O2)=C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385941-01	363680018.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(C)OC2C(O)C(C2C(C(O)(C)C)O2)=C1	O=C1C2(C)OC2C(O)C(C2C(C(O)(C)C)O2)=C1
NCGC00384966-01	O=C1C2(CO)C(C)(C3C(C1O)CC(CO)(C)C3)C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384966-01	363679459.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(CO)C(C)(C3C(C1O)CC(CO)(C)C3)C2	O=C1C2(CO)C(C)(C3C(C1O)CC(CO)(C)C3)C2
NCGC00380442-01	O=C1C2(O)C(C)OC(=O)C32C(=C)C1(C)CC1C(O)(C)C=2C(C(C)(C)OC(=O)C=2)=CCC31C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380442-01	363678585.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(O)C(C)OC(=O)C32C(=C)C1(C)CC1C(O)(C)C=2C(C(C)(C)OC(=O)C=2)=CCC31C	O=C1C2(O)C(C)OC(=O)C32C(=C)C1(C)CC1C(O)(C)C=2C(C(C)(C)OC(=O)C=2)=CCC31C
NCGC00347648-02	O=C1C2(O)C(C)OC(=O)C32C(=C)C1(C)CC1C2(C)OC(C31C)C1OC31C(C)(C)OC(=O)C=C23		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347648-02	363677652.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(O)C(C)OC(=O)C32C(=C)C1(C)CC1C2(C)OC(C31C)C1OC31C(C)(C)OC(=O)C=C23	O=C1C2(O)C(C)OC(=O)C32C(=C)C1(C)CC1C2(C)OC(C31C)C1OC31C(C)(C)OC(=O)C=C23
NCGC00380529-01	O=C1C2(O)C(CO)(C)C(C)(C=3C(C(C)CC=3)C2)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380529-01	363678634.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(O)C(CO)(C)C(C)(C=3C(C(C)CC=3)C2)C1	O=C1C2(O)C(CO)(C)C(C)(C=3C(C(C)CC=3)C2)C1
NCGC00380950-01	O=C1C2(O)C(O)(C(O)c3c(O)cccc13)CCC1=C2C(=O)CC(C)C1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380950-01	363678879.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(O)C(O)(C(O)c3c(O)cccc13)CCC1=C2C(=O)CC(C)C1	O=C1C2(O)C(O)(C(O)c3c(O)cccc13)CCC1=C2C(=O)CC(C)C1
NCGC00381242-01	O=C1C2(O)C(O)CC(/C=C/C=C/CCC)C2CO1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381242-01	363679046.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(O)C(O)CC(/C=C/C=C/CCC)C2CO1	O=C1C2(O)C(O)CC(/C=C/C=C/CCC)C2CO1
NCGC00179768-02	O=C1C2(O)C3(C(O)CC4(O)C2C(=O)CC(C)C4)OC3c2c(O)cccc12		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00179768-02	363676968.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(O)C3(C(O)CC4(O)C2C(=O)CC(C)C4)OC3c2c(O)cccc12	O=C1C2(O)C3(C(O)CC4(O)C2C(=O)CC(C)C4)OC3c2c(O)cccc12
NCGC00381392-01	O=C1C2(O)C3(C)C(C(C)(C)C(=O)CC3)C(O)C=C2CO1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381392-01	363679122.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(O)C3(C)C(C(C)(C)C(=O)CC3)C(O)C=C2CO1	O=C1C2(O)C3(C)C(C(C)(C)C(=O)CC3)C(O)C=C2CO1
NCGC00380650-01	O=C1C2(O)C3(C)C(C(C)(C)C(O)CC3)C(O)C=C2CO1		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: Aspergillus ? | Family: N/A | Species: N/A		1	NCGC00380650-01	363678690.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(O)C3(C)C(C(C)(C)C(O)CC3)C(O)C=C2CO1	O=C1C2(O)C3(C)C(C(C)(C)C(O)CC3)C(O)C=C2CO1
NCGC00380949-01	O=C1C2(O)C3(C)C(O)(C=CC2=C2C4(C(C(C)C(C(O)C(C(C)C)C)C4)CC2)C1)CC(O)CC3		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380949-01	363678878.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2(O)C3(C)C(O)(C=CC2=C2C4(C(C(C)C(C(O)C(C(C)C)C)C4)CC2)C1)CC(O)CC3	O=C1C2(O)C3(C)C(O)(C=CC2=C2C4(C(C(C)C(C(O)C(C(C)C)C)C4)CC2)C1)CC(O)CC3
NCGC00384807-01	O=C1C23C(C4(C)C(C(C)(C)CCC4)C1)CCC(C(O)(CO)C2)C3		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384807-01	363679367.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	10.34477826	O=C1C23C(C4(C)C(C(C)(C)CCC4)C1)CCC(C(O)(CO)C2)C3	O=C1C23C(C4(C)C(C(C)(C)CCC4)C1)CCC(C(O)(CO)C2)C3
NCGC00380997-01	O=C1C2=C(C)[C@]3([C@H](C)[C@@H]4NC[C@@H](C)C[C@H]4O3)CC[C@H]2[C@H]2C1[C@]1(C)C(=CC2)C[C@@H](O)CC1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Veratrum | Family: Liliaceae | Species: album		1	NCGC00380997-01	363678912.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2=C(C)[C@]3([C@H](C)[C@@H]4NC[C@@H](C)C[C@H]4O3)CC[C@H]2[C@H]2C1[C@]1(C)C(=CC2)C[C@@H](O)CC1	O=C1C2=C(C)[C@]3([C@H](C)[C@@H]4NC[C@@H](C)C[C@H]4O3)CC[C@H]2[C@H]2C1[C@]1(C)C(=CC2)C[C@@H](O)CC1
NCGC00180775-03	O=C1C2C(CO)(CO)CCCC2(C)C2C3(C1)CC(=C)C(C3)CC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180775-03	363677064.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2C(CO)(CO)CCCC2(C)C2C3(C1)CC(=C)C(C3)CC2	O=C1C2C(CO)(CO)CCCC2(C)C2C3(C1)CC(=C)C(C3)CC2
NCGC00385237-01	O=C1C2C3(C)C(C)(C(C(C(O)/C=C/C(O)(C)C)C)CC3)CCC2(C)C2C(C(C)(C)C(O)CC2)=C1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385237-01	363679611.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C2C3(C)C(C)(C(C(C(O)/C=C/C(O)(C)C)C)CC3)CCC2(C)C2C(C(C)(C)C(O)CC2)=C1	O=C1C2C3(C)C(C)(C(C(C(O)/C=C/C(O)(C)C)C)CC3)CCC2(C)C2C(C(C)(C)C(O)CC2)=C1
NCGC00380144-01	O=C1C=2C(=C)C(C)(C(C)C(O)C=2)CC/C(/C)=C/CCC2(C)OC12		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380144-01	363678472.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C=2C(=C)C(C)(C(C)C(O)C=2)CC/C(/C)=C/CCC2(C)OC12	O=C1C=2C(=C)C(C)(C(C)C(O)C=2)CC/C(/C)=C/CCC2(C)OC12
NCGC00187642-04	O=C1C=2C3(N=C(Nc4oc5c(n4)cccc5)NC=2CCC1)CCCC3		Inactive			1	NCGC00187642-04	163827029.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C=2C3(N=C(Nc4oc5c(n4)cccc5)NC=2CCC1)CCCC3	O=C1C=2C3(N=C(Nc4oc5c(n4)cccc5)NC=2CCC1)CCCC3
NCGC00188574-01	O=C1C=2C3(N=C(Nc4oc5c(n4)cccc5)NC=2CCC1)CCSCC3		Inactive			1	NCGC00188574-01	87550839.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C=2C3(N=C(Nc4oc5c(n4)cccc5)NC=2CCC1)CCSCC3	O=C1C=2C3(N=C(Nc4oc5c(n4)cccc5)NC=2CCC1)CCSCC3
NCGC00385774-01	O=C1C=C(C)C(/C=C/C(OC2C(O)C(O)C(O)C(COC3C(O)C(O)C(O)CO3)O2)C)C(C)(C)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Sapindus | Family: Sapindaceae | Species: mukorossi		1	NCGC00385774-01	363679933.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C=C(C)C(/C=C/C(OC2C(O)C(O)C(O)C(COC3C(O)C(O)C(O)CO3)O2)C)C(C)(C)C1	O=C1C=C(C)C(/C=C/C(OC2C(O)C(O)C(O)C(COC3C(O)C(O)C(O)CO3)O2)C)C(C)(C)C1
NCGC00381439-01	O=C1C=C(C)C(CO)C2(C)C1C(C)(C)CC(O)C2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381439-01	363679145.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C=C(C)C(CO)C2(C)C1C(C)(C)CC(O)C2	O=C1C=C(C)C(CO)C2(C)C1C(C)(C)CC(O)C2
NCGC00385600-01	O=C1C=C(C)C(O)(CCC(O)C)C(C)(C)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385600-01	363679830.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C=C(C)C(O)(CCC(O)C)C(C)(C)C1	O=C1C=C(C)C(O)(CCC(O)C)C(C)(C)C1
NCGC00385906-01	O=C1C=C(C)C2(C3(C)C1C(C)(C)CCC3)OC1(CC(=O)OC1)CC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385906-01	363679998.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C=C(C)C2(C3(C)C1C(C)(C)CCC3)OC1(CC(=O)OC1)CC2	O=C1C=C(C)C2(C3(C)C1C(C)(C)CCC3)OC1(CC(=O)OC1)CC2
NCGC00385006-01	O=C1C=C(C)[C@@H]2C1C(CO)=CC[C@H]1[C@@H]([C@H](/C=C\C=C(C)C)C)CC[C@]1(C)C2		Inactive	<MOA Unknown> | Class: sesterterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385006-01	363679480.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C=C(C)[C@@H]2C1C(CO)=CC[C@H]1[C@@H]([C@H](/C=C\C=C(C)C)C)CC[C@]1(C)C2	O=C1C=C(C)[C@@H]2C1C(CO)=CC[C@H]1[C@@H]([C@H](/C=C\C=C(C)C)C)CC[C@]1(C)C2
NCGC00381144-01	O=C1C=C(C)[C@H](CO)[C@]2(C)C1C(C)(C)CCC2		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381144-01	363678993.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C=C(C)[C@H](CO)[C@]2(C)C1C(C)(C)CCC2	O=C1C=C(C)[C@H](CO)[C@]2(C)C1C(C)(C)CCC2
NCGC00263190-11	O=C1C=C(N2CCOCC2)OC(c2c3Sc4c(Sc3ccc2)cccc4)=C1	5.0	Active	ATM Kinase Inhibitor	0.0	1	KU-0064	384568655.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.4	90.5469878849	O=C1C=C(N2CCOCC2)OC(c2c3Sc4c(Sc3ccc2)cccc4)=C1	O=C1C=C(N2CCOCC2)OC(c2c3Sc4c(Sc3ccc2)cccc4)=C1
MLS002703591-02	O=C1C=C2C(=C3C=CC4(C)C(O)(C#C)CCC4C3CC2)CC1		Inactive			1	MLS002703591-02	363676430.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C=C2C(=C3C=CC4(C)C(O)(C#C)CCC4C3CC2)CC1	O=C1C=C2C(=C3C=CC4(C)C(O)(C#C)CCC4C3CC2)CC1
NCGC00025179-12&NCGC00025179-20	O=C1C=C2C(=C3[C@@H](c4ccc(N(C)C)cc4)C[C@]4(C)[C@](O)(C#CC)CC[C@H]4[C@@H]3CC2)CC1		Inactive	Progesterone Receptor Antagonist		2	Mifepristone	170465151.0&384568054.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	31.069873996&22.4033877081&28.724437848	O=C1C=C2C(=C3[C@@H](c4ccc(N(C)C)cc4)C[C@]4(C)[C@](O)(C#CC)CC[C@H]4[C@@H]3CC2)CC1	O=C1C=C2C(=C3[C@@H](c4ccc(N(C)C)cc4)C[C@]4(C)[C@](O)(C#CC)CC[C@H]4[C@@H]3CC2)CC1
NCGC00346502-04&NCGC00346502-06	O=C1C=C2C(=C3[C@H]([C@H]4[C@@](C)([C@](O)(CC#N)CC4)CC3)CC2)CC1		Inactive	Synthetic progesterone		2	Dienogest	405558629.0&384568807.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1C=C2C(=C3[C@H]([C@H]4[C@@](C)([C@](O)(CC#N)CC4)CC3)CC2)CC1	O=C1C=C2C(=C3[C@H]([C@H]4[C@@](C)([C@](O)(CC#N)CC4)CC3)CC2)CC1
NCGC00166309-02	O=C1C=C2C(=C3[C@H]([C@H]4[C@@](C)([C@](O)(CC=C)CC4)C=C3)CC2)CC1		Inactive			1	Altrenogest	170465646.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C=C2C(=C3[C@H]([C@H]4[C@@](C)([C@](O)(CC=C)CC4)C=C3)CC2)CC1	O=C1C=C2C(=C3[C@H]([C@H]4[C@@](C)([C@](O)(CC=C)CC4)C=C3)CC2)CC1
NCGC00167457-02	O=C1C=C2C(=C3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)C=C3)CC2)CC1		Inactive	Progesterone receptor Agonist		1	Gestrinone	170466364.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C=C2C(=C3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)C=C3)CC2)CC1	O=C1C=C2C(=C3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)C=C3)CC2)CC1
NCGC00095023-08	O=C1C=C2C(C)(C3C(C4C(C)(C(O)(C#C)CC4)CC3)CC2)CC1		Inactive	Progestogen hormone		1	Ethisterone	384568141.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C=C2C(C)(C3C(C4C(C)(C(O)(C#C)CC4)CC3)CC2)CC1	O=C1C=C2C(C)(C3C(C4C(C)(C(O)(C#C)CC4)CC3)CC2)CC1
MLS002694957-02	O=C1C=C2C(C3C(C4C(CC)(C(O)(CC)CC4)CC3)CC2)CC1		Inactive			1	MLS002694957-02	363676428.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C=C2C(C3C(C4C(CC)(C(O)(CC)CC4)CC3)CC2)CC1	O=C1C=C2C(C3C(C4C(CC)(C(O)(CC)CC4)CC3)CC2)CC1
NCGC00344378-02	O=C1C=C2C([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC1		Inactive	Progestogen hormone		1	Norgestrel	405558518.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C=C2C([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC1	O=C1C=C2C([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC1
NCGC00274271-01	O=C1C=C2[C@@H](C)C[C@H]3[C@H]4[C@@](C)([C@](O)(C#CC)CC4)CC[C@@H]3[C@@]2(C)CC1		Inactive			1	Dimethisteron	170465914.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C=C2[C@@H](C)C[C@H]3[C@H]4[C@@](C)([C@](O)(C#CC)CC4)CC[C@@H]3[C@@]2(C)CC1	O=C1C=C2[C@@H](C)C[C@H]3[C@H]4[C@@](C)([C@](O)(C#CC)CC4)CC[C@@H]3[C@@]2(C)CC1
NCGC00253603-01	O=C1C=C2[C@@H]([C@@H]3[C@@H]([C@H](C)C2)[C@H]2[C@@](C)([C@](O)(C)CC2)CC3)CC1		Inactive	Progesterone receptor Agonist		1	Mibolerone	170466095.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C=C2[C@@H]([C@@H]3[C@@H]([C@H](C)C2)[C@H]2[C@@](C)([C@](O)(C)CC2)CC3)CC1	O=C1C=C2[C@@H]([C@@H]3[C@@H]([C@H](C)C2)[C@H]2[C@@](C)([C@](O)(C)CC2)CC3)CC1
NCGC00183854-01	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)[C@@H](CC)C4)CC3)CC2)CC1		Inactive			1	Oxendolone	144206842.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)[C@@H](CC)C4)CC3)CC2)CC1	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](O)[C@@H](CC)C4)CC3)CC2)CC1
NCGC00179669-04	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)CC1		Inactive			1	Norethindrone	170464683.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)CC1	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)CC1
NCGC00263565-01&NCGC00263565-06	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)C=C4)CC3)CC2)CC1		Inactive	Progestogen hormone		2	Gestodene	170466131.0&384568689.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)C=C4)CC3)CC2)CC1	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)C=C4)CC3)CC2)CC1
NCGC00159349-15	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC1		Inactive	Progestogen hormone		1	Levonorgestrel	384568171.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC1	O=C1C=C2[C@@H]([C@@H]3[C@H]([C@H]4[C@@](CC)([C@](O)(C#C)CC4)CC3)CC2)CC1
NCGC00168777-04	O=C1C=C2[C@@H]([C@H]3C(=C)C[C@]4(CC)[C@](O)(C#C)CC[C@H]4[C@@H]3CC2)CC1		Inactive	contraceptive		1	Etonogestrel	405558738.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C=C2[C@@H]([C@H]3C(=C)C[C@]4(CC)[C@](O)(C#C)CC[C@H]4[C@@H]3CC2)CC1	O=C1C=C2[C@@H]([C@H]3C(=C)C[C@]4(CC)[C@](O)(C#C)CC[C@H]4[C@@H]3CC2)CC1
NCGC00485419-01	O=C1C=C2[C@@](C)([C@@H]3[C@@H]([C@H](O)C2)[C@H]2[C@@](C)([C@@H](O)CC2)CC3)CC1		Inactive			1	7?-Hydroxytestosterone	363681329.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C=C2[C@@](C)([C@@H]3[C@@H]([C@H](O)C2)[C@H]2[C@@](C)([C@@H](O)CC2)CC3)CC1	O=C1C=C2[C@@](C)([C@@H]3[C@@H]([C@H](O)C2)[C@H]2[C@@](C)([C@@H](O)CC2)CC3)CC1
NCGC00271596-03&NCGC00271596-15	O=C1C=C2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC2=C)C=C1		Inactive	Aromatase Inhibitor		2	Exemestane	170464628.0&384568705.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1C=C2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC2=C)C=C1	O=C1C=C2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC2=C)C=C1
NCGC00256230-01	O=C1C=C2[C@](C)([C@H](C)C1)C[C@H](C(=C)C)CC2		Inactive			1	Nootkatone	144212702.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1C=C2[C@](C)([C@H](C)C1)C[C@H](C(=C)C)CC2	O=C1C=C2[C@](C)([C@H](C)C1)C[C@H](C(=C)C)CC2
NCGC00385896-01	O=C1CC(C)(C)C2C(C)(C(CCC(CCO)C)C(=C)CC2)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385896-01	363679995.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1CC(C)(C)C2C(C)(C(CCC(CCO)C)C(=C)CC2)C1	O=C1CC(C)(C)C2C(C)(C(CCC(CCO)C)C(=C)CC2)C1
NCGC00168836-03	O=C1CC(CO)(CO)C2C(C)(C3C4(CC5(C)C(C5C3)C4)CC2O)C1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Psiadia | Family: Compositae | Species: punctulata		1	NCGC00168836-03	363676698.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1CC(CO)(CO)C2C(C)(C3C4(CC5(C)C(C5C3)C4)CC2O)C1	O=C1CC(CO)(CO)C2C(C)(C3C4(CC5(C)C(C5C3)C4)CC2O)C1
NCGC00094740-05	O=C1CC2=C(C3C(C4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)CC1		Inactive	Progesterone receptor Agonist		1	NORETHYNODREL	405558843.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1CC2=C(C3C(C4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)CC1	O=C1CC2=C(C3C(C4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)CC1
NCGC00164632-02&NCGC00164632-07	O=C1CC2=C([C@@H]3[C@@H]([C@H](C)C2)[C@H]2[C@@](C)([C@](O)(C#C)CC2)CC3)CC1		Inactive	Steryl-sulfatase  Inhibitor		2	Tibolone&TIBOLONE	170465874.0&384568271.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&7.640156184	O=C1CC2=C([C@@H]3[C@@H]([C@H](C)C2)[C@H]2[C@@](C)([C@](O)(C#C)CC2)CC3)CC1	O=C1CC2=C([C@@H]3[C@@H]([C@H](C)C2)[C@H]2[C@@](C)([C@](O)(C#C)CC2)CC3)CC1
NCGC00167559-01	O=C1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C=CC4)CC3)CC2)CC1		Inactive			1	Androstenone	144206107.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C=CC4)CC3)CC2)CC1	O=C1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C=CC4)CC3)CC2)CC1
NCGC00181911-01	O=C1N(C(=O)NC(=O)C1CCCC)C1CCCCC1		Inactive	Cytochrome P450 2C9 Inhibitor		1	Bucolome	144206890.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&0.0	O=C1N(C(=O)NC(=O)C1CCCC)C1CCCCC1	O=C1N(C(=O)NC(=O)C1CCCC)C1CCCCC1
NCGC00510355-01	O=C1N(C(C)C)C(=O)C=C(N[C@@H](C)c2ccccc2)N1		Inactive	Drugs Targeting Myosin		1	Mavacamten	384569430.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(C(C)C)C(=O)C=C(N[C@@H](C)c2ccccc2)N1	O=C1N(C(C)C)C(=O)C=C(N[C@@H](C)c2ccccc2)N1
NCGC00378555-02	O=C1N(C(CC)CC)c2nc(C#C)cnc2N1		Inactive	Troponin I, fast skeletal muscle Activator		1	Tirasemtiv	363678089.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(C(CC)CC)c2nc(C#C)cnc2N1	O=C1N(C(CC)CC)c2nc(C#C)cnc2N1
NCGC00384901-01	O=C1N(C)/C(=C\c2ccccc2)/C=2N(C(=O)c3c(N=2)cccc3)c2c1cccc2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384901-01	363679427.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(C)/C(=C\c2ccccc2)/C=2N(C(=O)c3c(N=2)cccc3)c2c1cccc2	O=C1N(C)/C(=C\c2ccccc2)/C=2N(C(=O)c3c(N=2)cccc3)c2c1cccc2
NCGC00014873-05	O=C1N(C)C(=O)C2=C(NCCCN(C)C)c3c(N(C)C2=N1)cccc3		Inactive	MDM2 (hdm2) Inhibitor		1	HLI-373989	384567794.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(C)C(=O)C2=C(NCCCN(C)C)c3c(N(C)C2=N1)cccc3	O=C1N(C)C(=O)C2=C(NCCCN(C)C)c3c(N(C)C2=N1)cccc3
NCGC00189077-01	O=C1N(C)C(=O)CC1(C)c1ccccc1		Inactive	Voltage-gated T-type calcium channel Inhibitor		1	Methsuximide	144207162.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	10.744525552&0.0	O=C1N(C)C(=O)CC1(C)c1ccccc1	O=C1N(C)C(=O)CC1(C)c1ccccc1
NCGC00179333-03	O=C1N(C)C(=O)CC1c1ccccc1		Inactive			1	Phensuximide	170465315.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(C)C(=O)CC1c1ccccc1	O=C1N(C)C(=O)CC1c1ccccc1
NCGC00181148-01	O=C1N(C)C(=O)NC(=O)C1(CC)CC		Inactive	GABA-A receptor; anion channel Binding Agent		1	Metharbital	144206305.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(C)C(=O)NC(=O)C1(CC)CC	O=C1N(C)C(=O)NC(=O)C1(CC)CC
NCGC00165924-04	O=C1N(C)C(=O)N[C@@]1(CC)c1ccccc1		Inactive	Sodium channel protein type V alpha subunit Inhibitor		1	(S)-Mephenytoin	170465368.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(C)C(=O)N[C@@]1(CC)c1ccccc1	O=C1N(C)C(=O)N[C@@]1(CC)c1ccccc1
NCGC00016383-05	O=C1N(C)C(=O)OC1(C)C		Inactive	Voltage-gated T-type calcium channel Blocker		1	Trimethadione	225144178.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(C)C(=O)OC1(C)C	O=C1N(C)C(=O)OC1(C)C
NCGC00183600-04	O=C1N(C)C(=O)OC1(CC)C		Inactive	Voltage-gated T-type calcium channel Blocker		1	PARAMETHADIONE	405558625.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(C)C(=O)OC1(CC)C	O=C1N(C)C(=O)OC1(CC)C
NCGC00018117-32	O=C1N(C)C(=O)c2[nH]cnc2N1C		Inactive	Adenosine Receptor Antagonist		1	Theophyllamine	384567991.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(C)C(=O)c2[nH]cnc2N1C	O=C1N(C)C(=O)c2[nH]cnc2N1C
NCGC00015208-19&NCGC00015208-25	O=C1N(C)C(=O)c2n(C)cnc2N1C		Inactive	Chitinase Inhibitor		2	Caffeine	170464929.0&384567824.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)C(O)(CC(=O)O)CC(=O)O.O=C1N(C)C(=O)c2n(C)cnc2N1C	O=C(O)C(O)(CC(=O)O)CC(=O)O.O=C1N(C)C(=O)c2n(C)cnc2N1C&O=C1N(C)C(=O)c2n(C)cnc2N1C
NCGC00018121-07	O=C1N(C)C(=O)c2n(CC(O)C)cnc2N1C		Inactive	3',5'-cyclic phosphodiesterase Inhibitor		1	Proxyphylline	170465953.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C1N(C)C(=O)c2n(CC(O)C)cnc2N1C	O=C1N(C)C(=O)c2n(CC(O)C)cnc2N1C
NCGC00018099-09&NCGC00018099-17	O=C1N(C)C(=O)c2n(CC(O)CO)cnc2N1C		Inactive	Xanthine Derivative		2	Dyphylline	170465316.0&384567989.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1N(C)C(=O)c2n(CC(O)CO)cnc2N1C	O=C1N(C)C(=O)c2n(CC(O)CO)cnc2N1C
NCGC00159330-04	O=C1N(C)C(=O)c2n(CC3OCCO3)cnc2N1C		Inactive	Adenosine A1 Antagonist		1	Doxofylline	363676585.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(C)C(=O)c2n(CC3OCCO3)cnc2N1C	O=C1N(C)C(=O)c2n(CC3OCCO3)cnc2N1C
NCGC00402265-03	O=C1N(C)C(=O)c2n(Cc3ccc(C(C)(C)C)cc3)cnc2N1C		Inactive	Sulfonylurea receptor 1, Kir6.2 Activator		1	VU0071063	363681006.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(C)C(=O)c2n(Cc3ccc(C(C)(C)C)cc3)cnc2N1C	O=C1N(C)C(=O)c2n(Cc3ccc(C(C)(C)C)cc3)cnc2N1C
NCGC00018117-17	O=C1N(C)C(=O)c2nc[nH]c2N1C		Inactive	Adenosine Receptor Antagonist		1	Theophyllamine	170466874.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1N(C)C(=O)c2nc[nH]c2N1C	O=C1N(C)C(=O)c2nc[nH]c2N1C
NCGC00347652-02	O=C1N(C)C(C(C)C)C(=O)NC(Cc2ccccc2)C(=O)NCCC(=O)N2C(C(=O)OC(CC(C)C)C(=O)N(C)C1C(C)C)CCC2		Inactive	<MOA Unknown> | Class: depsipeptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347652-02	363677655.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(C)C(C(C)C)C(=O)NC(Cc2ccccc2)C(=O)NCCC(=O)N2C(C(=O)OC(CC(C)C)C(=O)N(C)C1C(C)C)CCC2	O=C1N(C)C(C(C)C)C(=O)NC(Cc2ccccc2)C(=O)NCCC(=O)N2C(C(=O)OC(CC(C)C)C(=O)N(C)C1C(C)C)CCC2
NCGC00093704-19&NCGC00093704-43	O=C1N(C)C(C(O)C(C/C=C/C)C)C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C1C(C)C		Inactive	immunosuppressant		2	Cyclosporine A&Cyclosporin A	384568118.0&434147249.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1N(C)C(C(O)C(C/C=C/C)C)C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C1C(C)C	O=C1N(C)C(C(O)C(C/C=C/C)C)C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C1C(C)C
NCGC00169957-03	O=C1N(C)C(C)C(=O)NCCC(=O)OC(CC(C)C)C(=O)N2C(C(=O)NC(C(CC)C)C(=O)N(C)C1C(C)C)CCC2		Inactive	Vacuolar H(+)-ATPase Inhibitor		1	NCGC00169957-03	363676921.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	14.106478296	O=C1N(C)C(C)C(=O)NCCC(=O)OC(CC(C)C)C(=O)N2C(C(=O)NC(C(CC)C)C(=O)N(C)C1C(C)C)CCC2	O=C1N(C)C(C)C(=O)NCCC(=O)OC(CC(C)C)C(=O)N2C(C(=O)NC(C(CC)C)C(=O)N(C)C1C(C)C)CCC2
NCGC00381061-01	O=C1N(C)C(C)C(=O)NCCC(=O)OC(CC(O)CO)C(=O)N2C(C(=O)NC(C(CC)C)C(=O)N(C)C1C(C)C)C(C)CC2		Inactive	<MOA Unknown> | Class: Peptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381061-01	363678951.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(C)C(C)C(=O)NCCC(=O)OC(CC(O)CO)C(=O)N2C(C(=O)NC(C(CC)C)C(=O)N(C)C1C(C)C)C(C)CC2	O=C1N(C)C(C)C(=O)NCCC(=O)OC(CC(O)CO)C(=O)N2C(C(=O)NC(C(CC)C)C(=O)N(C)C1C(C)C)C(C)CC2
NCGC00381220-02	O=C1N(C)C(C)C(=O)NCCC(=O)OC(CC(O)CO)C(=O)N2C(C(=O)NC(C(CC)C)C(=O)N(C)C1C(C)C)CCC2		Inactive	<MOA Unknown> | Class: depsipeptide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381220-02	363679031.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(C)C(C)C(=O)NCCC(=O)OC(CC(O)CO)C(=O)N2C(C(=O)NC(C(CC)C)C(=O)N(C)C1C(C)C)CCC2	O=C1N(C)C(C)C(=O)NCCC(=O)OC(CC(O)CO)C(=O)N2C(C(=O)NC(C(CC)C)C(=O)N(C)C1C(C)C)CCC2
NCGC00370979-01	O=C1N(C)C(NC[C@@H](N)Cc2ccccc2)=NC(c2ccncc2)=C1c1cc2c(cc1)cccc2	4.9000001	Active	p38 MAPK Inhibitor	0.0	1	AMG-548	363677973.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	115.3413792452	O=C1N(C)C(NC[C@@H](N)Cc2ccccc2)=NC(c2ccncc2)=C1c1cc2c(cc1)cccc2	O=C1N(C)C(NC[C@@H](N)Cc2ccccc2)=NC(c2ccncc2)=C1c1cc2c(cc1)cccc2
NCGC00159430-04	O=C1N(C)C(O)=NC(=O)C1(C)C1=CCCCC1		Inactive	GABA-A receptor; benzodiazepine site Activator		1	Hexobarbital	170465860.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(C)C(O)=NC(=O)C1(C)C1=CCCCC1	O=C1N(C)C(O)=NC(=O)C1(C)C1=CCCCC1
NCGC00510506-01	O=C1N(C)C=C(c2c(CO)c(N3C(=O)c4n(c5c(c4)CC(C)(C)C5)CC3)ncc2)C=C1Nc1ncc(N2[C@@H](C)CN(C3COC3)CC2)cc1		Inactive	BTK Inhibitor		1	RG-7845 (GDC-0853)	384569467.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(C)C=C(c2c(CO)c(N3C(=O)c4n(c5c(c4)CC(C)(C)C5)CC3)ncc2)C=C1Nc1ncc(N2[C@@H](C)CN(C3COC3)CC2)cc1	O=C1N(C)C=C(c2c(CO)c(N3C(=O)c4n(c5c(c4)CC(C)(C)C5)CC3)ncc2)C=C1Nc1ncc(N2[C@@H](C)CN(C3COC3)CC2)cc1
NCGC00263909-02&NCGC00263909-08	O=C1N(C)CC(=O)N2[C@H](c3cc4OCOc4cc3)c3[nH]c4c(c3C[C@H]12)cccc4		Inactive	Phosphodiesterase V (PDE5) inhibitor&Phosphodiesterase 6 Inhibitor		2	Tadalafil	170464819.0&384568699.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1N(C)CC(=O)N2[C@H](c3cc4OCOc4cc3)c3[nH]c4c(c3C[C@H]12)cccc4	O=C1N(C)CC(=O)N2[C@H](c3cc4OCOc4cc3)c3[nH]c4c(c3C[C@H]12)cccc4
NCGC00386077-01	O=C1N(C)[C@@H](C(C)C)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)O[C@H](CC(C)C)C(=O)N(C)[C@@H]([C@@H](CC)C)C(=O)O[C@@H]1C(C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386077-01	363680094.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(C)[C@@H](C(C)C)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)O[C@H](CC(C)C)C(=O)N(C)[C@@H]([C@@H](CC)C)C(=O)O[C@@H]1C(C)C	O=C1N(C)[C@@H](C(C)C)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)O[C@H](CC(C)C)C(=O)N(C)[C@@H]([C@@H](CC)C)C(=O)O[C@@H]1C(C)C
NCGC00507682-01	O=C1N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](Cc2ccc(N3CCOCC3)cc2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@@H]1Cc1ccc(N2CCOCC2)cc1	5.1500001	Active	synaptic transmission Modulator	0.0	1	Emodepside	405558968.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	2.2	67.7479259279	O=C1N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](Cc2ccc(N3CCOCC3)cc2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@@H]1Cc1ccc(N2CCOCC2)cc1	O=C1N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](Cc2ccc(N3CCOCC3)cc2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@@H]1Cc1ccc(N2CCOCC2)cc1
NCGC00380798-01	O=C1N(C)[C@@H](Cc2ccccc2)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H](Cc2ccccc2)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H](Cc2ccccc2)C(=O)O[C@@H]1C(C)C		Inactive	Tyrosine-protein kinase SRC Inhibitor		1	NCGC00380798-01	363678787.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(C)[C@@H](Cc2ccccc2)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H](Cc2ccccc2)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H](Cc2ccccc2)C(=O)O[C@@H]1C(C)C	O=C1N(C)[C@@H](Cc2ccccc2)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H](Cc2ccccc2)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H](Cc2ccccc2)C(=O)O[C@@H]1C(C)C
NCGC00347566-02	O=C1N(C)[C@@H]([C@@H](CC)C)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]1C(C)C		Inactive	MAPK signaling pathway Inhibitor		1	NCGC00347566-02	363677624.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(C)[C@@H]([C@@H](CC)C)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]1C(C)C	O=C1N(C)[C@@H]([C@@H](CC)C)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]1C(C)C
NCGC00386078-01	O=C1N(C)[C@@H]([C@H](CC)C)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](CC)C)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](CC)C)C(=O)O[C@@H]1C(C)C		Inactive	Acetyl-CoA acetyltransferase, mitochondrial Inhibitor		1	NCGC00386078-01	363680095.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(C)[C@@H]([C@H](CC)C)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](CC)C)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](CC)C)C(=O)O[C@@H]1C(C)C	O=C1N(C)[C@@H]([C@H](CC)C)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](CC)C)C(=O)O[C@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](CC)C)C(=O)O[C@@H]1C(C)C
NCGC00093704-12	O=C1N(C)[C@@H]([C@H](O)[C@@H](C/C=C/C)C)C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@H]1C(C)C		Inactive	immunosuppressant		1	Cyclosporine A	170466812.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(C)[C@@H]([C@H](O)[C@@H](C/C=C/C)C)C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@H]1C(C)C	O=C1N(C)[C@@H]([C@H](O)[C@@H](C/C=C/C)C)C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@H]1C(C)C
NCGC00180312-03	O=C1N(C)[C@@]2([C@H](c3ccccc3)O2)C=2N(C(=O)c3c(N=2)cccc3)c2c1cccc2		Inactive	<MOA Unknown> | Class: alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180312-03	363677009.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(C)[C@@]2([C@H](c3ccccc3)O2)C=2N(C(=O)c3c(N=2)cccc3)c2c1cccc2	O=C1N(C)[C@@]2([C@H](c3ccccc3)O2)C=2N(C(=O)c3c(N=2)cccc3)c2c1cccc2
NCGC00507976-02	O=C1N(C)[C@]23[C@H](C(C)(C)[C@@]4(c5c(NC4)c4OC=CC(C)(C)Oc4cc5)C2)C[C@]21[C@@](O)(C)CCN2C3		Inactive			1	Derquantel	405558509.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(C)[C@]23[C@H](C(C)(C)[C@@]4(c5c(NC4)c4OC=CC(C)(C)Oc4cc5)C2)C[C@]21[C@@](O)(C)CCN2C3	O=C1N(C)[C@]23[C@H](C(C)(C)[C@@]4(c5c(NC4)c4OC=CC(C)(C)Oc4cc5)C2)C[C@]21[C@@](O)(C)CCN2C3
NCGC00389591-02	O=C1N(C)c2c(C)nc(Nc3cn(C4CCNCC4)nc3)nc2N(C)c2c1cc1c(c2)cccc1	4.9000001	Active	NUAK family SNF1-like kinase 1 Inhibitor	0.0	1	HTH-01-015	363680812.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	96.4544	O=C1N(C)c2c(C)nc(Nc3cn(C4CCNCC4)nc3)nc2N(C)c2c1cc1c(c2)cccc1	O=C1N(C)c2c(C)nc(Nc3cn(C4CCNCC4)nc3)nc2N(C)c2c1cc1c(c2)cccc1
NCGC00486943-01	O=C1N(C)c2c(N1C)cc(N1C(=O)c3c4c(c(CCCO)cc3)cccc4C1=O)c(C)c2		Inactive			1	BAY-299	363681469.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(C)c2c(N1C)cc(N1C(=O)c3c4c(c(CCCO)cc3)cccc4C1=O)c(C)c2	O=C1N(C)c2c(N1C)cc(N1C(=O)c3c4c(c(CCCO)cc3)cccc4C1=O)c(C)c2
NCGC00187481-08	O=C1N(C)c2c(N1c1ccc(C(C#N)(C)C)cc1)c1c(nc2)ccc(-c2cnc3c(c2)cccc3)c1		Inactive	mTOR Inhibitor		1	BEZ-235	384568444.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C1N(C)c2c(N1c1ccc(C(C#N)(C)C)cc1)c1c(nc2)ccc(-c2cnc3c(c2)cccc3)c1	O=C1N(C)c2c(N1c1ccc(C(C#N)(C)C)cc1)c1c(nc2)ccc(-c2cnc3c(c2)cccc3)c1
NCGC00016023-18&NCGC00016023-19	O=C1N(C)c2ncn(C)c2C(=O)N1		Inactive	Phosphodiesterase Inhibitor		2	Theobromine	170465487.0&384567916.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1N(C)c2ncn(C)c2C(=O)N1	O=C1N(C)c2ncn(C)c2C(=O)N1
NCGC00496836-02	O=C1N(C2CCC(OC)CC2)c2nc(-c3cnc(C(O)(C)C)cc3)cnc2NC1		Inactive	mTOR Inhibitor		1	CC-223	384569292.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(C2CCC(OC)CC2)c2nc(-c3cnc(C(O)(C)C)cc3)cnc2NC1	O=C1N(C2CCC(OC)CC2)c2nc(-c3cnc(C(O)(C)C)cc3)cnc2NC1
NCGC00496839-01	O=C1N(C2CCCC2)c2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2C=C1C#N		Inactive	RET Inhibitor		1	ON-123300	384569293.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	30.218454588	O=C1N(C2CCCC2)c2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2C=C1C#N	O=C1N(C2CCCC2)c2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc2C=C1C#N
NCGC00390669-01	O=C1N(C2CCN(C3CCN(Cc4c(C)cccc4)CC3)CC2)c2c(N1)cccc2		Inactive	Muscarinic acetylcholine receptor M1 Agonist		1	TBPB	363680964.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(C2CCN(C3CCN(Cc4c(C)cccc4)CC3)CC2)c2c(N1)cccc2	O=C1N(C2CCN(C3CCN(Cc4c(C)cccc4)CC3)CC2)c2c(N1)cccc2
NCGC00159544-04	O=C1N(C2CCN(CC3(C)OCc4c(-n5c3ccc5)cccc4)CC2)c2c(N1)cccc2	4.9000001	Active	Calmodulin Antagonist	0.0	1	Zaldaride maleate	384568186.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	118.2117133868	O=C1N(C2CCN(CC3(C)OCc4c(-n5c3ccc5)cccc4)CC2)c2c(N1)cccc2	O=C1N(C2CCN(CC3(C)OCc4c(-n5c3ccc5)cccc4)CC2)c2c(N1)cccc2
NCGC00165727-10	O=C1N(C2CCN(Cc3ccc(-c4c(-c5ccccc5)nc5c(n4)cc4nc[nH]c4c5)cc3)CC2)c2c(N1)cccc2		Inactive	AKT Inhibitor		1	AKT Inhibitor VIII	377020224.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(C2CCN(Cc3ccc(-c4c(-c5ccccc5)nc5c(n4)cc4nc[nH]c4c5)cc3)CC2)c2c(N1)cccc2	O=C1N(C2CCN(Cc3ccc(-c4c(-c5ccccc5)nc5c(n4)cc4nc[nH]c4c5)cc3)CC2)c2c(N1)cccc2
NCGC00183848-01	O=C1N(C2O[C@@H](CO)OC2)C=CC(N)=N1		Inactive	DNA Polymerase Inhibitor		1	Troxacitabine	124894563.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1N(C2O[C@@H](CO)OC2)C=CC(N)=N1	O=C1N(C2O[C@@H](CO)OC2)C=CC(N)=N1
NCGC00015415-05	O=C1N(CC)C(=O)C=C1		Inactive			1	N-Ethylmaleimide	434146943.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(CC)C(=O)C=C1	O=C1N(CC)C(=O)C=C1
NCGC00179401-03	O=C1N(CC)C(=O)NC1c1ccccc1		Inactive	Sodium channel protein type V alpha subunit Inhibitor		1	Ethotoin	225144304.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(CC)C(=O)NC1c1ccccc1	O=C1N(CC)C(=O)NC1c1ccccc1
NCGC00522580-01	O=C1N(CC)C2=NC(c3c(C)nc(-c4[nH]cnn4)cc3)=CNC2=NC1		Inactive	DNA-PK Inhibitor		1	CC-115	384569529.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(CC)C2=NC(c3c(C)nc(-c4[nH]cnn4)cc3)=CNC2=NC1	O=C1N(CC)C2=NC(c3c(C)nc(-c4[nH]cnn4)cc3)=CNC2=NC1
NCGC00167459-02	O=C1N(CC)CC(CCN2CCOCC2)C1(c1ccccc1)c1ccccc1		Inactive	Potassium channel subfamily K member 9 Inhibitor		1	Doxapram hydrochloride	170465313.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(CC)CC(CCN2CCOCC2)C1(c1ccccc1)c1ccccc1.Cl	O=C1N(CC)CC(CCN2CCOCC2)C1(c1ccccc1)c1ccccc1.Cl
NCGC00160611-03	O=C1N(CC)CCC1		Inactive			1	1-Ethyl-2-pyrrolidinone	170465488.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C1N(CC)CCC1	O=C1N(CC)CCC1
NCGC00379112-01	O=C1N(CC)c2c(N1[C@@H]1CN(c3nc(-c4oc5c(c4)cccc5)ccn3)CCC1)cccc2		Inactive	Anandamide amidohydrolase Inhibitor		1	TC-F 2	363678362.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	24.133333328	O=C1N(CC)c2c(N1[C@@H]1CN(c3nc(-c4oc5c(c4)cccc5)ccn3)CCC1)cccc2	O=C1N(CC)c2c(N1[C@@H]1CN(c3nc(-c4oc5c(c4)cccc5)ccn3)CCC1)cccc2
NCGC00344513-02	O=C1N(CC)c2c(N1[C@H]1[C@H](CO)CN(CC3CCCCCCC3)CC1)cccc2		Inactive	ORL1 (OP4, NOP) Antagonist		1	J113397	363677334.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(CC)c2c(N1[C@H]1[C@H](CO)CN(CC3CCCCCCC3)CC1)cccc2	O=C1N(CC)c2c(N1[C@H]1[C@H](CO)CN(CC3CCCCCCC3)CC1)cccc2
NCGC00387875-03	O=C1N(CC)c2nc(N)nc(C)c2C=C1c1[nH]ncc1		Inactive	mTORC1/2 Inhibitor		1	Voxtalisib	363680715.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(CC)c2nc(N)nc(C)c2C=C1c1[nH]ncc1	O=C1N(CC)c2nc(N)nc(C)c2C=C1c1[nH]ncc1
NCGC00370981-01	O=C1N(CC2NCCCC2)CCN1c1ccccc1		Inactive	D(2) dopamine receptor Partial Agonist		1	GSK 789472 hydrochloride	363677975.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(CC2NCCCC2)CCN1c1ccccc1	O=C1N(CC2NCCCC2)CCN1c1ccccc1
NCGC00263183-02	O=C1N(CC=C)N(c2nc(C(O)(C)C)ccc2)c2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc12		Inactive	Wee1 Kinase Inhibitor		1	MK-1775	384568651.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C1N(CC=C)N(c2nc(C(O)(C)C)ccc2)c2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc12	O=C1N(CC=C)N(c2nc(C(O)(C)C)ccc2)c2nc(Nc3ccc(N4CCN(C)CC4)cc3)ncc12
NCGC00263139-03	O=C1N(CCC)C(=O)c2[nH]c(C34C5C[C@H](C3)CC(C4)C5)nc2N1CCC		Inactive	Adenosine A1 Antagonist		1	Rolofylline	384568617.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(CCC)C(=O)c2[nH]c(C34C5C[C@H](C3)CC(C4)C5)nc2N1CCC	O=C1N(CCC)C(=O)c2[nH]c(C34C5C[C@H](C3)CC(C4)C5)nc2N1CCC
NCGC00408912-01	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)CC(C)(C)C1		Inactive	5-hydroxytryptamine receptor 1A Agonist		1	Gepirone Hydrochloride	363681081.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)CC(C)(C)C1	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)CC(C)(C)C1
NCGC00015162-10	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)CC2(C1)CCCC2		Inactive	Serotonin 1a (5-HT1a) receptor Partial Agonist		1	Buspirone	170464909.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)CC2(C1)CCCC2	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)CC2(C1)CCCC2
NCGC00386676-01	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)CC2([C@@H]1O)CCCC2		Inactive	Serotonin 1a (5-HT1a) receptor Partial Agonist		1	(S)-6-Hydroxybuspirone hydrochloride	363680389.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)CC2([C@@H]1O)CCCC2	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)CC2([C@@H]1O)CCCC2
NCGC00182990-01	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)[C@@H]2[C@H]1[C@@H]1C[C@H]2CC1		Inactive	Serotonin 1a (5-HT1a) receptor Partial Agonist		1	Tandospirone	144206869.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)[C@@H]2[C@H]1[C@@H]1C[C@H]2CC1	O=C1N(CCCCN2CCN(c3ncccn3)CC2)C(=O)[C@@H]2[C@H]1[C@@H]1C[C@H]2CC1
NCGC00370712-03	O=C1N(CCCN2CCC(CCCC)CC2)c2c(cccc2)CC1		Inactive	Muscarinic acetylcholine receptor M5 Antagonist		1	77-LH-28-1 Oxalate	363677819.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(CCCN2CCC(CCCC)CC2)c2c(cccc2)CC1	O=C1N(CCCN2CCC(CCCC)CC2)c2c(cccc2)CC1
NCGC00262941-01	O=C1N(CCCN2CCCCCC2)[C@H](CC(C)C)[C@H](c2ccccc2)O1		Inactive	Glutamate [NMDA] receptor Antagonist		1	Ipenoxazone hydrochloride	170465754.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	18.100727472	O=C1N(CCCN2CCCCCC2)[C@H](CC(C)C)[C@H](c2ccccc2)O1.Cl	O=C1N(CCCN2CCCCCC2)[C@H](CC(C)C)[C@H](c2ccccc2)O1.Cl
NCGC00015774-06	O=C1N(CCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)c2c(N1)cccc2	4.9000001	Active	Histamine H1 receptor Antagonist	0.0	1	Oxatomide	170466059.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	91.7079333799	O=C1N(CCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)c2c(N1)cccc2	O=C1N(CCCN2CCN(C(c3ccccc3)c3ccccc3)CC2)c2c(N1)cccc2
NCGC00346513-02	O=C1N(CCN(C)C)C(=O)c2c3c(cc(N)cc13)ccc2		Inactive	DNA Topoisomerase II Inhibitor		1	Amonafide	384568813.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(CCN(C)C)C(=O)c2c3c(cc(N)cc13)ccc2	O=C1N(CCN(C)C)C(=O)c2c3c(cc(N)cc13)ccc2
NCGC00160395-04	O=C1N(CCN(C)C)c2c(N(C)c3c1cccc3)cccc2		Inactive	Monoamine transporter Inhibitor		1	Dibenzepin hydrochloride	170466001.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(CCN(C)C)c2c(N(C)c3c1cccc3)cccc2.Cl	O=C1N(CCN(C)C)c2c(N(C)c3c1cccc3)cccc2.Cl
NCGC00510704-01	O=C1N(CCN2CCOCC2)C(C)(C)c2sc(-c3nc(Nc4n(C)ncc4)ncc3)cc12		Inactive	ERK1/2 Inhibitor		1	LY-3214996	384569487.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(CCN2CCOCC2)C(C)(C)c2sc(-c3nc(Nc4n(C)ncc4)ncc3)cc12	O=C1N(CCN2CCOCC2)C(C)(C)c2sc(-c3nc(Nc4n(C)ncc4)ncc3)cc12
NCGC00381123-01	O=C1N(CCO)Cc2c3O[C@@]4([C@H](C)CCC5C(C)(C)[C@H](O)CC[C@]45C)Cc3c(O)cc12		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381123-01	363678980.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(CCO)Cc2c3O[C@@]4([C@H](C)CCC5C(C)(C)[C@H](O)CC[C@]45C)Cc3c(O)cc12	O=C1N(CCO)Cc2c3O[C@@]4([C@H](C)CCC5C(C)(C)[C@H](O)CC[C@]45C)Cc3c(O)cc12
NCGC00167480-02	O=C1N(CO)C(=O)CC1		Inactive			1	N-Hydroxymethylsuccinimide	225144289.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(CO)C(=O)CC1	O=C1N(CO)C(=O)CC1
NCGC00386382-03	O=C1N(C[C@H]2[C@H](CN3CCN(c4nsc5c4cccc5)CC3)CCCC2)C(=O)[C@@H]2[C@H]1[C@@H]1C[C@H]2CC1		Inactive			1	Lurasidone (Hydrochloride)	405558555.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	16.3844432719	O=C1N(C[C@H]2[C@H](CN3CCN(c4nsc5c4cccc5)CC3)CCCC2)C(=O)[C@@H]2[C@H]1[C@@H]1C[C@H]2CC1	O=C1N(C[C@H]2[C@H](CN3CCN(c4nsc5c4cccc5)CC3)CCCC2)C(=O)[C@@H]2[C@H]1[C@@H]1C[C@H]2CC1
NCGC00386215-04&NCGC00386215-05	O=C1N(Cc2c(C#N)cccc2)C(N2C[C@H](N)CCC2)=CC(=O)N1C		Inactive			2	ALOGLIPTIN BENZOATE&Alogliptin (SYR-322)	434147242.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1N(Cc2c(C#N)cccc2)C(N2C[C@H](N)CCC2)=CC(=O)N1C	O=C1N(Cc2c(C#N)cccc2)C(N2C[C@H](N)CCC2)=CC(=O)N1C
NCGC00386747-06	O=C1N(Cc2c(C)cccc2)C2=NCCN2C2=C1CN(Cc1ccccc1)CC2		Inactive	ERK Inhibitor		1	TIC-10	363680432.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(Cc2c(C)cccc2)C2=NCCN2C2=C1CN(Cc1ccccc1)CC2	O=C1N(Cc2c(C)cccc2)C2=NCCN2C2=C1CN(Cc1ccccc1)CC2
NCGC00167528-02	O=C1N(Cc2c(C)nc[nH]2)CCc2n(C)c3c(c12)cccc3		Inactive	Serotonin 3a (5-HT3a) receptor Antagonist		1	Alosetron hydrochloride	170465416.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(Cc2c(C)nc[nH]2)CCc2n(C)c3c(c12)cccc3.Cl	O=C1N(Cc2c(C)nc[nH]2)CCc2n(C)c3c(c12)cccc3.Cl
NCGC00095122-14	O=C1N(Cc2ccc(-c3c(-c4[nH]nnn4)cccc3)cc2)C(CCCC)=NC21CCCC2		Inactive			1	Irbesartan	434146996.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(Cc2ccc(-c3c(-c4[nH]nnn4)cccc3)cc2)C(CCCC)=NC21CCCC2	O=C1N(Cc2ccc(-c3c(-c4[nH]nnn4)cccc3)cc2)C(CCCC)=NC21CCCC2
NCGC00095122-05	O=C1N(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)C(CCCC)=NC21CCCC2		Inactive			1	Irbesartan	170464670.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C1N(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)C(CCCC)=NC21CCCC2	O=C1N(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)C(CCCC)=NC21CCCC2
NCGC00390218-01	O=C1N(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c2nc(C)nc(C)c2CC1		Inactive	Type-1 angiotensin II receptor Antagonist		1	Tasosartan	363680862.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c2nc(C)nc(C)c2CC1	O=C1N(Cc2ccc(-c3c(-c4n[nH]nn4)cccc3)cc2)c2nc(C)nc(C)c2CC1
NCGC00386380-02	O=C1N(Cc2ccccc2)C(=O)SN1c1c2c(ccc1)cccc2		Inactive	GSK-3 Inhibitor		1	Tideglusib	384569130.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(Cc2ccccc2)C(=O)SN1c1c2c(ccc1)cccc2	O=C1N(Cc2ccccc2)C(=O)SN1c1c2c(ccc1)cccc2
NCGC00346655-02&NCGC00346655-06	O=C1N(Cc2nc(C)c3c(n2)cccc3)C(=O)c2n(CC#CC)c(N3C[C@H](N)CCC3)nc2N1C		Inactive	DPP-IV Inhibitor		2	Linagliptin	405558934.0&384568886.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1N(Cc2nc(C)c3c(n2)cccc3)C(=O)c2n(CC#CC)c(N3C[C@H](N)CCC3)nc2N1C	O=C1N(Cc2nc(C)c3c(n2)cccc3)C(=O)c2n(CC#CC)c(N3C[C@H](N)CCC3)nc2N1C
NCGC00053301-03	O=C1N(Cc2occc2)C(CC)=Nc2c3c(sc12)nc1c(c3)COC(C)(C)C1		Inactive			1	NCGC00053301-03		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(Cc2occc2)C(CC)=Nc2c3c(sc12)nc1c(c3)COC(C)(C)C1	O=C1N(Cc2occc2)C(CC)=Nc2c3c(sc12)nc1c(c3)COC(C)(C)C1
NCGC00164612-02	O=C1N(N(C)C(C)=C1C(C)C)c1ccccc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Propyphenazone	170465821.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C1N(N(C)C(C)=C1C(C)C)c1ccccc1	O=C1N(N(C)C(C)=C1C(C)C)c1ccccc1
NCGC00016257-10	O=C1N(N(C)C(C)=C1N(C)C)c1ccccc1		Inactive			1	4-Dimethylaminoantipyrine	170465863.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C1N(N(C)C(C)=C1N(C)C)c1ccccc1	O=C1N(N(C)C(C)=C1N(C)C)c1ccccc1
NCGC00164582-02	O=C1N(N(c2ccccc2)C(=O)C1C/C=C(\C)/C)c1ccccc1		Inactive			1	Feprazone	170465969.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1N(N(c2ccccc2)C(=O)C1C/C=C(\C)/C)c1ccccc1	O=C1N(N(c2ccccc2)C(=O)C1C/C=C(\C)/C)c1ccccc1
NCGC00094748-07	O=C1N(N(c2ccccc2)C(=O)C1CCCC)c1ccc(O)cc1		Inactive			1	Oxyphenbutazone	170465310.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0		O=C1N(N(c2ccccc2)C(=O)C1CCCC)c1ccc(O)cc1	O=C1N(N(c2ccccc2)C(=O)C1CCCC)c1ccc(O)cc1
NCGC00371083-02	O=C1N(N2CCCCCC2)C=Nc2c3c(N(C)C)ccnc3sc12		Inactive	Metabotropic glutamate receptor 1 Antagonist		1	A 841720	363678022.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(N2CCCCCC2)C=Nc2c3c(N(C)C)ccnc3sc12	O=C1N(N2CCCCCC2)C=Nc2c3c(N(C)C)ccnc3sc12
NCGC00384844-01	O=C1N(O)CCOCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CC1		Inactive	<MOA Unknown> | Class: siderophor | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384844-01	363679390.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(O)CCOCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CC1	O=C1N(O)CCOCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CC1
NCGC00485082-01	O=C1N(O)c2c(cccc2)C[C@@H]1N		Inactive	Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial Inhibitor		1	PF-04859989 hydrochloride	363681213.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(O)c2c(cccc2)C[C@@H]1N	O=C1N(O)c2c(cccc2)C[C@@H]1N
NCGC00023212-14&NCGC00023212-30	O=C1N([C@@H]2O[C@H](CO)C=C2)C=C(C)C(=O)N1		Inactive	Reverse Transcriptase Inhibitor		2	Stavudine&Stavudine (d4T)	170464820.0&434146973.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1N([C@@H]2O[C@H](CO)C=C2)C=C(C)C(=O)N1	O=C1N([C@@H]2O[C@H](CO)C=C2)C=C(C)C(=O)N1
NCGC00090705-15&NCGC00090705-24	O=C1N([C@@H]2O[C@H](CO)CC2)C=CC(N)=N1		Inactive	Reverse Transcriptase Inhibitor		2	2',3'-Dideoxycytidine&Zalcitabine	170465128.0&434146982.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1N([C@@H]2O[C@H](CO)CC2)C=CC(N)=N1	O=C1N([C@@H]2O[C@H](CO)CC2)C=CC(N)=N1
NCGC00023945-12&NCGC00023945-24	O=C1N([C@@H]2O[C@H](CO)[C@@H](N=[N+]=[N-])C2)C=C(C)C(=O)N1		Inactive	Reverse Transcriptase Inhibitor		2	3'-Azido-3'-deoxythymidine&Zidovudine	170464737.0&434146975.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1N([C@@H]2O[C@H](CO)[C@@H](N=[N+]=[N-])C2)C=C(C)C(=O)N1	O=C1N([C@@H]2O[C@H](CO)[C@@H](N=[N+]=[N-])C2)C=C(C)C(=O)N1
NCGC00388290-01	O=C1N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=C(C)C(N)=N1		Inactive			1	5-Methyl-2 -deoxycytidine	377020295.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=C(C)C(N)=N1	O=C1N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=C(C)C(N)=N1
NCGC00166088-02&NCGC00166088-10	O=C1N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=NC(N)=N1		Inactive	DNA Methyltransferase (DNMT) Inhibitor		2	Decitabine	170465126.0&384568303.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=NC(N)=N1	O=C1N([C@@H]2O[C@H](CO)[C@@H](O)C2)C=NC(N)=N1
NCGC00166415-03	O=C1N([C@H]2C3CCN(C2)CC3)C[C@@H]2c3c1cccc3CCC2		Inactive	Serotonin 3a (5-HT3a) receptor Antagonist		1	Palonosetron hydrochloride	170465300.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N([C@H]2C3CCN(C2)CC3)C[C@@H]2c3c1cccc3CCC2.Cl	O=C1N([C@H]2C3CCN(C2)CC3)C[C@@H]2c3c1cccc3CCC2.Cl
NCGC00159341-17&NCGC00159341-18&NCGC00159341-20	O=C1N([C@H]2O[C@@H](CO)SC2)C=CC(N)=N1		Inactive	Reverse Transcriptase Inhibitor		3	Lamivudine&LAMIVUDINE	384568170.0&405558739.0&434147004.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1N([C@H]2O[C@@H](CO)SC2)C=CC(N)=N1	O=C1N([C@H]2O[C@@H](CO)SC2)C=CC(N)=N1
NCGC00346560-03&NCGC00346560-06&NCGC00346560-12	O=C1N([C@H]2O[C@@H](CO)[C@H](O)C2)C=C(C)C(=O)N1		Inactive	DNA Polymerase Inhibitor		3	Telbivudine&telbivudine	384568840.0&405558940.0&434147091.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1N([C@H]2O[C@@H](CO)[C@H](O)C2)C=C(C)C(=O)N1	O=C1N([C@H]2O[C@@H](CO)[C@H](O)C2)C=C(C)C(=O)N1
NCGC00093356-10	O=C1N([C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=CC(N)=N1		Inactive	DNA Polymerase Inhibitor		1	Cytarabine	384568114.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N([C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=CC(N)=N1	O=C1N([C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)C=CC(N)=N1
NCGC00485878-01	O=C1N([C@H]2[C@@H](O)[C@H](O)[C@@](N=[N+]=[N-])(CO)O2)C=CC(=O)N1		Inactive	NS5B Inhibitor		1	Nucleoside-Analog-2	363681388.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N([C@H]2[C@@H](O)[C@H](O)[C@@](N=[N+]=[N-])(CO)O2)C=CC(=O)N1	O=C1N([C@H]2[C@@H](O)[C@H](O)[C@@](N=[N+]=[N-])(CO)O2)C=CC(=O)N1
NCGC00378981-01	O=C1N([C@H]2[C@@H](O)[C@H](O)[C@@](N=[N+]=[N-])(CO)O2)C=CC(N)=N1		Inactive			1	RO-9187	434147109.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	-9.6556233679	O=C1N([C@H]2[C@@H](O)[C@H](O)[C@@](N=[N+]=[N-])(CO)O2)C=CC(N)=N1	O=C1N([C@H]2[C@@H](O)[C@H](O)[C@@](N=[N+]=[N-])(CO)O2)C=CC(N)=N1
NCGC00484060-01	O=C1N([C@H]2[C@@](O)(C)[C@H](O)[C@@H](CO)O2)C=CC(N)=N1		Inactive	Picornaviridae Inhibitor		1	NM107	363681153.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N([C@H]2[C@@](O)(C)[C@H](O)[C@@H](CO)O2)C=CC(N)=N1	O=C1N([C@H]2[C@@](O)(C)[C@H](O)[C@@H](CO)O2)C=CC(N)=N1
NCGC00017312-04	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=CC(=O)N1		Inactive	Anti-anxiety drug		1	Uridine	363676497.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=CC(=O)N1	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=CC(=O)N1
NCGC00142483-07&NCGC00142483-09	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=CC(N)=N1		Inactive	Cytidine Deaminase Inhibitor&Dna Polymerase Inhibitors; Nucleoside		2	Cytidine&CYTIDINE	384568164.0&405558808.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=CC(N)=N1	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=CC(N)=N1
NCGC00159549-16	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=CC=N1		Inactive	Cytidine Deaminase Inhibitor		1	Zebularine	384568187.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=CC=N1	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=CC=N1
NCGC00090851-10&NCGC00090851-14&NCGC00090851-17	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=NC(N)=N1		Inactive	DNA Methyltransferase (DNMT) Inhibitor		3	5-Azacitidine	170465076.0&434146912.0&384568089.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0		O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=NC(N)=N1	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)C=NC(N)=N1
NCGC00345810-01	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)CCC(O)N1		Inactive	Cytidine Deaminase Inhibitor		1	Tetrahydrouridine	174007307.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	13.3178686319	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)CCC(O)N1	O=C1N([C@H]2[C@H](O)[C@H](O)[C@@H](CO)O2)CCC(O)N1
NCGC00168114-09	O=C1N(c2c(C)cccc2)C(Cn2c3ncnc(N)c3nc2)=Nc2c1c(C)ccc2		Inactive	PI3K Inhibitor		1	IC-87114	363676679.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(c2c(C)cccc2)C(Cn2c3ncnc(N)c3nc2)=Nc2c1c(C)ccc2	O=C1N(c2c(C)cccc2)C(Cn2c3ncnc(N)c3nc2)=Nc2c1c(C)ccc2
NCGC00346614-07	O=C1N(c2c(C)cccc2)C(Cn2nc(-c3cc(O)ccc3)c3c(N)ncnc23)=Nc2c1c(C)ccc2		Inactive	PI3K Inhibitor		1	PIK-294	363677477.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(c2c(C)cccc2)C(Cn2nc(-c3cc(O)ccc3)c3c(N)ncnc23)=Nc2c1c(C)ccc2	O=C1N(c2c(C)cccc2)C(Cn2nc(-c3cc(O)ccc3)c3c(N)ncnc23)=Nc2c1c(C)ccc2
NCGC00346579-03	O=C1N(c2c(C)cccc2)C(Cn2ncc3c(N)ncnc23)=Nc2c1c(C)ccc2		Inactive	PI3K Inhibitor		1	PIK-293	363677461.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(c2c(C)cccc2)C(Cn2ncc3c(N)ncnc23)=Nc2c1c(C)ccc2	O=C1N(c2c(C)cccc2)C(Cn2ncc3c(N)ncnc23)=Nc2c1c(C)ccc2
NCGC00346678-15	O=C1N(c2cc3c(n(C)cc3)cc2)C(c2c(O)cc(O)c(C(C)C)c2)=NN1		Inactive	Heat Shock Protein 90 (hsp90) Inhibitor		1	Ganetespib (STA-9090)	384568904.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-31.2559808639	O=C1N(c2cc3c(n(C)cc3)cc2)C(c2c(O)cc(O)c(C(C)C)c2)=NN1	O=C1N(c2cc3c(n(C)cc3)cc2)C(c2c(O)cc(O)c(C(C)C)c2)=NN1
NCGC00345843-02	O=C1N(c2ccc(-c3occn3)cc2)C=CC(C)=C1c1cc2c(nc(N)nc2)cc1		Inactive	KIT Inhibitor		1	AMG-25	363677386.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(c2ccc(-c3occn3)cc2)C=CC(C)=C1c1cc2c(nc(N)nc2)cc1	O=C1N(c2ccc(-c3occn3)cc2)C=CC(C)=C1c1cc2c(nc(N)nc2)cc1
NCGC00386292-05	O=C1N(c2ccc(C(C#N)(C)C)cc2)c2c3c(ncc2CO1)ccc(-c1cnc2c(c1)cccc2)c3		Inactive	Serine/threonine-protein kinase mTOR Inhibitor		1	ETP46464	363680191.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	13.333333328	O=C1N(c2ccc(C(C#N)(C)C)cc2)c2c3c(ncc2CO1)ccc(-c1cnc2c(c1)cccc2)c3	O=C1N(c2ccc(C(C#N)(C)C)cc2)c2c3c(ncc2CO1)ccc(-c1cnc2c(c1)cccc2)c3
NCGC00370733-05	O=C1N(c2ccccc2)C(c2sc(C)cc2)Nc2c1cccc2		Inactive			1	Retro-2	434147100.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(c2ccccc2)C(c2sc(C)cc2)Nc2c1cccc2	O=C1N(c2ccccc2)C(c2sc(C)cc2)Nc2c1cccc2
NCGC00015806-06	O=C1N(c2ccccc2)C=C(C)C=C1		Inactive			1	Pirfenidone	170465606.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(c2ccccc2)C=C(C)C=C1	O=C1N(c2ccccc2)C=C(C)C=C1
NCGC00378863-02	O=C1N(c2ccccc2)C=C(c2ncccc2)C=C1c1c(C#N)cccc1		Inactive	Glutamate receptor ionotropic AMPA Antagonist		1	Perampanel	363678243.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(c2ccccc2)C=C(c2ncccc2)C=C1c1c(C#N)cccc1	O=C1N(c2ccccc2)C=C(c2ncccc2)C=C1c1c(C#N)cccc1
NCGC00018218-10&NCGC00018218-13	O=C1N(c2ccccc2)N=C(C)C1		Inactive	Free Radical Scavenger		2	Edaravone	170465935.0&384567997.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1N(c2ccccc2)N=C(C)C1	O=C1N(c2ccccc2)N=C(C)C1
NCGC00263596-03	O=C1N(c2ccccc2)N=C(Nc2n[nH]c(C)c2)c2c1cccc2		Inactive			1	Phthalazinone pyrazole	377020445.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N(c2ccccc2)N=C(Nc2n[nH]c(C)c2)c2c1cccc2	O=C1N(c2ccccc2)N=C(Nc2n[nH]c(C)c2)c2c1cccc2
NCGC00015412-21	O=C1N(c2ccccc2)[Se]c2c1cccc2	4.9000001	Active		0.0	1	Ebselen	406861832.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	3.0	70.781230047	O=C1N(c2ccccc2)[Se]c2c1cccc2	O=C1N(c2ccccc2)[Se]c2c1cccc2
NCGC00015590-08	O=C1N(c2ccccc2)c2c(C1(Cc1ccncc1)Cc1ccncc1)cccc2		Inactive	K(ATP) Channel Blocker		1	Linopirdine	384567868.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(c2ccccc2)c2c(C1(Cc1ccncc1)Cc1ccncc1)cccc2	O=C1N(c2ccccc2)c2c(C1(Cc1ccncc1)Cc1ccncc1)cccc2
NCGC00388364-06	O=C1N(c2ncnc(N3CCOCC3)c2)NC=C1n1nncc1		Inactive	HIF Prolyl Hydroxylase Inhibitor		1	Molidustat	384569169.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N(c2ncnc(N3CCOCC3)c2)NC=C1n1nncc1	O=C1N(c2ncnc(N3CCOCC3)c2)NC=C1n1nncc1
NCGC00378805-02	O=C1N2C(=NC(N3CCOCC3)=C1)c1c(cccc1)C=C2		Inactive	Serine/threonine-protein kinase mTOR Inhibitor		1	Compound401	363678209.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N2C(=NC(N3CCOCC3)=C1)c1c(cccc1)C=C2	O=C1N2C(=NC(N3CCOCC3)=C1)c1c(cccc1)C=C2
NCGC00186465-06	O=C1N2C(=NN1)c1c(nc(c(-c3ccccc3)c1)-c1ccc(C3(N)CCC3)cc1)C=C2		Inactive	AKT Inhibitor		1	MK-2206	384568442.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C1N2C(=NN1)c1c(nc(c(-c3ccccc3)c1)-c1ccc(C3(N)CCC3)cc1)C=C2	O=C1N2C(=NN1)c1c(nc(c(-c3ccccc3)c1)-c1ccc(C3(N)CCC3)cc1)C=C2
NCGC00015892-08	O=C1N2C(=Nc3c1cccc3)c1[nH]c3c(c1CC2)cccc3		Inactive	Cyclooxygenase-2 Inhibitor		1	Rutaecarpine	363676469.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N2C(=Nc3c1cccc3)c1[nH]c3c(c1CC2)cccc3	O=C1N2C(=Nc3c1cccc3)c1[nH]c3c(c1CC2)cccc3
NCGC00389454-01	O=C1N2C(C(=N)N1)C2		Inactive	Ribonucleoside-Diphosphate Reductase Inhibitors		1	IMEXON	405558490.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N2C(C(=N)N1)C2	O=C1N2C(C(=N)N1)C2
NCGC00380729-01	O=C1N2C(C(=O)N3[C@H]1C[C@]1(C(=O)c4c(N1)cccc4)C(C)(C)C=C3)=CCC2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380729-01	363678743.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N2C(C(=O)N3[C@H]1C[C@]1(C(=O)c4c(N1)cccc4)C(C)(C)C=C3)=CCC2	O=C1N2C(C(=O)N3[C@H]1C[C@]1(C(=O)c4c(N1)cccc4)C(C)(C)C=C3)=CCC2
NCGC00346495-14	O=C1N2C(C(C(Nc3ccccc3)C)=CC(C)=C2)=NC(N2CCOCC2)=C1		Inactive	PI3Kbeta Inhibitor		1	TGX-221	384568801.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N2C(C(C(Nc3ccccc3)C)=CC(C)=C2)=NC(N2CCOCC2)=C1	O=C1N2C(C(C(Nc3ccccc3)C)=CC(C)=C2)=NC(N2CCOCC2)=C1
NCGC00169472-02	O=C1N2C(C(O)CC2)=Nc2c1cccc2		Inactive	nitric oxide biosynthetic process Inhibitor		1	NCGC00169472-02	363676824.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N2C(C(O)CC2)=Nc2c1cccc2	O=C1N2C(C(O)CC2)=Nc2c1cccc2
NCGC00385422-01	O=C1N2C(N(C)c3c1cccc3)C1Nc3c(cccc3)C1CC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385422-01	363679734.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N2C(N(C)c3c1cccc3)C1Nc3c(cccc3)C1CC2	O=C1N2C(N(C)c3c1cccc3)C1Nc3c(cccc3)C1CC2
NCGC00163553-03	O=C1N2C(N(C)c3c1cccc3)c1[nH]c3c(c1CC2)cccc3		Inactive	Dietary supplement & part of traditional chinese medicines; alkaloid known to have several pharmacological effects including anti-tumor activity; inducer of apoptosis		1	Evodiamine	363676623.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N2C(N(C)c3c1cccc3)c1[nH]c3c(c1CC2)cccc3	O=C1N2C(N(C)c3c1cccc3)c1[nH]c3c(c1CC2)cccc3
NCGC00014802-05	O=C1N2C(N(Cc3c(C)cccc3)C3=C1CN(Cc1ccccc1)CC3)=NCC2		Inactive	Serine/threonine-protein kinase AKT Inhibitor		1	TIC10	363676436.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N2C(N(Cc3c(C)cccc3)C3=C1CN(Cc1ccccc1)CC3)=NCC2	O=C1N2C(N(Cc3c(C)cccc3)C3=C1CN(Cc1ccccc1)CC3)=NCC2
NCGC00408837-01	O=C1N2C(N(Cc3c(C)cccc3)CC2)=NC2=C1CN(Cc1ccccc1)CC2		Inactive			1	Linear TIC10	363681061.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N2C(N(Cc3c(C)cccc3)CC2)=NC2=C1CN(Cc1ccccc1)CC2	O=C1N2C(N(Cc3c(C)cccc3)CC2)=NC2=C1CN(Cc1ccccc1)CC2
NCGC00016463-08	O=C1N2C([C@H]3CNC[C@@H](C2)C3)=CC=C1		Inactive	Nicotinic alpha3beta4 Partial Agonist		1	Cytisine	384567942.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N2C([C@H]3CNC[C@@H](C2)C3)=CC=C1	O=C1N2C([C@H]3CNC[C@@H](C2)C3)=CC=C1
NCGC00179722-03	O=C1N2C(c3[nH]c4c(c3CC2)cccc4)CC2[C@@H](C=C)C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C12		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00179722-03	363676958.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N2C(c3[nH]c4c(c3CC2)cccc4)CC2[C@@H](C=C)C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C12	O=C1N2C(c3[nH]c4c(c3CC2)cccc4)CC2[C@@H](C=C)C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C12
NCGC00386055-01	O=C1N2C3(C(=O)NC41C(C(C)(C)C1=[N+]([O-])c5c(C1(O)C4)ccc1OC(C)(C)C=Cc51)C3)CCC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386055-01	363680080.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	-11.7118525399	O=C1N2C3(C(=O)NC41C(C(C)(C)C1=[N+]([O-])c5c(C1(O)C4)ccc1OC(C)(C)C=Cc51)C3)CCC2	O=C1N2C3(C(=O)NC41C(C(C)(C)C1=[N+]([O-])c5c(C1(O)C4)ccc1OC(C)(C)C=Cc51)C3)CCC2
NCGC00380427-01	O=C1N2C3(C(C=C)(C)C)C(O)(c4c(N3)c3OC(C)(C)C=Cc3cc4)CC2C(=O)N2C1CCC2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380427-01	363678578.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N2C3(C(C=C)(C)C)C(O)(c4c(N3)c3OC(C)(C)C=Cc3cc4)CC2C(=O)N2C1CCC2	O=C1N2C3(C(C=C)(C)C)C(O)(c4c(N3)c3OC(C)(C)C=Cc3cc4)CC2C(=O)N2C1CCC2
NCGC00179759-02	O=C1N2C3=Nc4c(C(=O)NC3CCC2=Nc2c1cccc2)cccc4		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00179759-02	363676966.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N2C3=Nc4c(C(=O)NC3CCC2=Nc2c1cccc2)cccc4	O=C1N2C3=Nc4c(C(=O)NC3CCC2=Nc2c1cccc2)cccc4
NCGC00381062-01	O=C1N2C3C(C(C=C)(C)C)(c4c(N3)cccc4)CC2C(=O)N2C3C(C(C=C)(C)C)(c4c(N3)cccc4)CC12		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381062-01	363678952.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N2C3C(C(C=C)(C)C)(c4c(N3)cccc4)CC2C(=O)N2C3C(C(C=C)(C)C)(c4c(N3)cccc4)CC12	O=C1N2C3C(C(C=C)(C)C)(c4c(N3)cccc4)CC2C(=O)N2C3C(C(C=C)(C)C)(c4c(N3)cccc4)CC12
NCGC00160217-03	O=C1N2[C@@H]([C@@H]3[C@H]4N(CCC3)CCC[C@H]4C2)CC=C1		Inactive	HERG Inhibitor		1	Sophocarpine	363676600.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1N2[C@@H]([C@@H]3[C@H]4N(CCC3)CCC[C@H]4C2)CC=C1	O=C1N2[C@@H]([C@@H]3[C@H]4N(CCC3)CCC[C@H]4C2)CC=C1
NCGC00160338-03	O=C1N2[C@@H]([C@H]3[C@@H]4[N@+]([O-])(CCC3)CCC[C@@H]4C2)CCC1		Inactive			1	Oxymatrine	434147010.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&18.279490344	O=C1N2[C@@H]([C@H]3[C@@H]4[N@+]([O-])(CCC3)CCC[C@@H]4C2)CCC1	O=C1N2[C@@H]([C@H]3[C@@H]4[N@+]([O-])(CCC3)CCC[C@@H]4C2)CCC1
NCGC00180002-03	O=C1N2[C@@H](c3[nH]c4c(c3CC2)cccc4)C[C@H]2[C@@H](C=C)C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C12		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Stictocardia | Family: Convolvulaceae | Species: tiliifolia		1	NCGC00180002-03	363676999.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N2[C@@H](c3[nH]c4c(c3CC2)cccc4)C[C@H]2[C@@H](C=C)C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C12	O=C1N2[C@@H](c3[nH]c4c(c3CC2)cccc4)C[C@H]2[C@@H](C=C)C(O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C12
NCGC00386070-01	O=C1N2[C@@]3(C(=O)N[C@]41[C@H](C(C)(C)C=1[C@](O)(c5c(N=1)c1c(OC(C)(C)C=C1)cc5)C4)C3)CCC2		Inactive	<MOA Unknown> | Class: alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386070-01	363680090.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N2[C@@]3(C(=O)N[C@]41[C@H](C(C)(C)C=1[C@](O)(c5c(N=1)c1c(OC(C)(C)C=C1)cc5)C4)C3)CCC2	O=C1N2[C@@]3(C(=O)N[C@]41[C@H](C(C)(C)C=1[C@](O)(c5c(N=1)c1c(OC(C)(C)C=C1)cc5)C4)C3)CCC2
NCGC00186632-01	O=C1N2[C@H]3[C@@H]4[C@@H](OCC=C5[C@@H]4C[C@@H]4[N@@](C5)CC[C@]34c3c2cccc3)C1		Inactive	Glycine receptor subunit alpha-1 Antagonist		1	Strychnine	124897819.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N2[C@H]3[C@@H]4[C@@H](OCC=C5[C@@H]4C[C@@H]4[N@@](C5)CC[C@]34c3c2cccc3)C1	O=C1N2[C@H]3[C@@H]4[C@@H](OCC=C5[C@@H]4C[C@@H]4[N@@](C5)CC[C@]34c3c2cccc3)C1
NCGC00346440-02	O=C1N2c3c(N1)cccc3C[C@@H](NC)C2		Inactive	Dopamine D2 Agonist		1	Sumanirole maleate	384568778.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N2c3c(N1)cccc3C[C@@H](NC)C2	O=C1N2c3c(N1)cccc3C[C@@H](NC)C2
NCGC00180355-02	O=C1N2c3c(O)cccc3C(=O)Nc3c(cccc3)C2=Nc2c1cccc2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180355-02	363677013.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N2c3c(O)cccc3C(=O)Nc3c(cccc3)C2=Nc2c1cccc2	O=C1N2c3c(O)cccc3C(=O)Nc3c(cccc3)C2=Nc2c1cccc2
NCGC00346470-02	O=C1N2c3c([C@@H](O)[C@H](NC(C)C)CC2)cccc3N1		Inactive	beta1-Adrenoceptor Antagonists		1	Zilpaterol·HCl	405558976.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N2c3c([C@@H](O)[C@H](NC(C)C)CC2)cccc3N1	O=C1N2c3c([C@@H](O)[C@H](NC(C)C)CC2)cccc3N1
NCGC00385307-01	O=C1N2c3c(cc4OCOc4c3)C3[C@@]42C2N(CC=C[C@@]2(C1)CC4)CC3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385307-01	363679664.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N2c3c(cc4OCOc4c3)C3[C@@]42C2N(CC=C[C@@]2(C1)CC4)CC3	O=C1N2c3c(cc4OCOc4c3)C3[C@@]42C2N(CC=C[C@@]2(C1)CC4)CC3
NCGC00181304-01	O=C1N=C(N)C2N1C2		Inactive	Ribonucleoside-Diphosphate Reductase Inhibitor		1	Imexon	50125901.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N=C(N)C2N1C2	O=C1N=C(N)C2N1C2
NCGC00263533-01	O=C1N=C(N)Nc2n(CCC(CO)CO)cnc12		Inactive	Human herpesvirus 1 DNA polymerase Inhibitor		1	Penciclovir	170464955.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1N=C(N)Nc2n(CCC(CO)CO)cnc12	O=C1N=C(N)Nc2n(CCC(CO)CO)cnc12
NCGC00387147-01	O=C1N=C(c2ncccc2)Sc2c1cccc2		Inactive	Macrophage migration inhibitory factor Binding Agent		1	BTZO 1	363680549.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N=C(c2ncccc2)Sc2c1cccc2	O=C1N=C(c2ncccc2)Sc2c1cccc2
NCGC00017291-12&NCGC00017291-17	O=C1N=C2N(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c3c(N=C2C(=O)N1)cc(C)c(C)c3		Inactive			2	RIBOFLAVIN&Riboflavin		Annotated/Bioactive Compound Collection&2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1N=C2N(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c3c(N=C2C(=O)N1)cc(C)c(C)c3	O=C1N=C2N(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c3c(N=C2C(=O)N1)cc(C)c(C)c3
NCGC00274079-01	O=C1N=C2NC(=O)NC(=O)C2N1		Inactive			1	Sodium urate	170465686.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1NC(=O)C=2NC(=O)[N-]C=2N1.[Na+]	O=C1NC(=O)C=2NC(=O)[N-]C=2N1.[Na+]
NCGC00651741-01	O=C1N=C2O[C@H]3[C@H](O)[C@@H](CO)O[C@H]3N2C=C1		Inactive			1	2,2 -Cyclouridine	434147182.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	-11.244635192	O=C1N=C2O[C@H]3[C@H](O)[C@@H](CO)O[C@H]3N2C=C1	O=C1N=C2O[C@H]3[C@H](O)[C@@H](CO)O[C@H]3N2C=C1
NCGC00485876-01	O=C1N=C2O[C@H]3[C@H](O)[C@@](N=[N+]=[N-])(CO)O[C@H]3N2C=C1		Inactive			1	Nucleoside-Analog-1		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N=C2O[C@H]3[C@H](O)[C@@](N=[N+]=[N-])(CO)O[C@H]3N2C=C1	O=C1N=C2O[C@H]3[C@H](O)[C@@](N=[N+]=[N-])(CO)O[C@H]3N2C=C1
NCGC00263119-07	O=C1NC(=O)C=2c3c4c(n(c3)CCO[C@H](CN(C)C)CCn3c5c(c(c3)C1=2)cccc5)cccc4		Inactive	PKC Inhibitor		1	Ruboxistaurin mesylate	384568603.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1NC(=O)C=2c3c4c(n(c3)CCO[C@H](CN(C)C)CCn3c5c(c(c3)C1=2)cccc5)cccc4	O=C1NC(=O)C=2c3c4c(n(c3)CCO[C@H](CN(C)C)CCn3c5c(c(c3)C1=2)cccc5)cccc4
NCGC00181030-02	O=C1NC(=O)C=CN1		Inactive	Dihydropyrimidine dehydrogenase Substrate		1	Uracil	170465915.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1NC(=O)C=CN1	O=C1NC(=O)C=CN1
NCGC00016288-06	O=C1NC(=O)CC(CC)(C)C1		Inactive	GABA-A receptor; anion channel Antagonist		1	Bemegride	405559005.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1NC(=O)CC(CC)(C)C1	O=C1NC(=O)CC(CC)(C)C1
NCGC00346949-01	O=C1NC(=O)CN(C(C(C)N2CC(=O)NC(=O)C2)C)C1		Inactive	DNA Topoisomerase II Inhibitor		1	ICRF-193	174007427.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1NC(=O)CN(C(C(C)N2CC(=O)NC(=O)C2)C)C1	O=C1NC(=O)CN(C(C(C)N2CC(=O)NC(=O)C2)C)C1
NCGC00263544-01&NCGC00263544-04	O=C1NC(=O)CN([C@H](CN2CC(=O)NC(=O)C2)C)C1		Inactive	DNA Topoisomerase II Inhibitor		2	Dexrazoxane hydrochloride	170464709.0&384568686.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&13.171586712&0.0	O=C1NC(=O)CN([C@H](CN2CC(=O)NC(=O)C2)C)C1	O=C1NC(=O)CN([C@H](CN2CC(=O)NC(=O)C2)C)C1
NCGC00093700-05	O=C1NC(=O)c2c1cc(Nc1ccccc1)c(Nc1ccccc1)c2	5.0	Active	Protein kinase C beta type Inhibitor	0.0	1	DAPH	90341268.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	78.2409910647	O=C1NC(=O)c2c1cc(Nc1ccccc1)c(Nc1ccccc1)c2	O=C1NC(=O)c2c1cc(Nc1ccccc1)c(Nc1ccccc1)c2
NCGC00159573-02	O=C1NC(=O)c2c3c([nH]c4c3cccc4)c3[nH]c4c(c3c12)cccc4		Inactive			1	Arcyriaflavin A	377020468.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(=O)c2c3c([nH]c4c3cccc4)c3[nH]c4c(c3c12)cccc4	O=C1NC(=O)c2c3c([nH]c4c3cccc4)c3[nH]c4c(c3c12)cccc4
NCGC00167774-02	O=C1NC(=O)c2c3c4n(c5c3cccc5)C3OC(n5c4c(c4c5cccc4)c12)CC3		Inactive			1	SB 218078	377020392.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(=O)c2c3c4n(c5c3cccc5)C3OC(n5c4c(c4c5cccc4)c12)CC3	O=C1NC(=O)c2c3c4n(c5c3cccc5)C3OC(n5c4c(c4c5cccc4)c12)CC3
NCGC00380297-01	O=C1NC(C)=CC=2OC(C(O)CC(C)C)OC1=2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380297-01	363678529.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(C)=CC=2OC(C(O)CC(C)C)OC1=2	O=C1NC(C)=CC=2OC(C(O)CC(C)C)OC1=2
NCGC00025146-05	O=C1NC(C)=Nc2c(O)cccc12		Inactive			1	NU-1025	434146979.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	10.5	O=C1NC(C)=Nc2c(O)cccc12	O=C1NC(C)=Nc2c(O)cccc12
NCGC00381428-01	O=C1NC(CC(C)C)C2C(C)=C(C)C(OO)C\3C12C(=O)CC(OC)C(O)C(O)CC/C(/C)=C/3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381428-01	363679139.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(CC(C)C)C2C(C)=C(C)C(OO)C\3C12C(=O)CC(OC)C(O)C(O)CC/C(/C)=C/3	O=C1NC(CC(C)C)C2C(C)=C(C)C(OO)C\3C12C(=O)CC(OC)C(O)C(O)CC/C(/C)=C/3
NCGC00381121-01	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3(O)C12OC(=O)/C=C/C(O)C(O)C(O)(C)/C=C/3		Inactive	<MOA Unknown> | Class: polyketide/AS; Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381121-01	363678979.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3(O)C12OC(=O)/C=C/C(O)C(O)C(O)(C)/C=C/3	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3(O)C12OC(=O)/C=C/C(O)C(O)C(O)(C)/C=C/3
NCGC00380155-01	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3(O)C12OC(=O)/C=C/C(O)CC(O)(C)/C=C/3		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380155-01	363678478.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3(O)C12OC(=O)/C=C/C(O)CC(O)(C)/C=C/3	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3(O)C12OC(=O)/C=C/C(O)CC(O)(C)/C=C/3
NCGC00380732-01	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)/C=C/C(O)C(O)CC/C(/C)=C/3		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380732-01	363678745.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	13.969064752	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)/C=C/C(O)C(O)CC/C(/C)=C/3	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)/C=C/C(O)C(O)CC/C(/C)=C/3
NCGC00347828-02	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CC(O)C(O)C(O)CC/C(/C)=C/3		Inactive	<MOA Unknown> | Class: polyketide/AS; Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347828-02	363677700.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CC(O)C(O)C(O)CC/C(/C)=C/3	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CC(O)C(O)C(O)CC/C(/C)=C/3
NCGC00347575-02	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CC(OC)C(O)C(O)CC/C(/C)=C/3		Inactive	<MOA Unknown> | Class: polyketide/AS; Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347575-02	363677629.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CC(OC)C(O)C(O)CC/C(/C)=C/3	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CC(OC)C(O)C(O)CC/C(/C)=C/3
NCGC00380188-01	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CC(OC)C(O)CC/C(/C)=C/3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380188-01	363678495.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CC(OC)C(O)CC/C(/C)=C/3	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CC(OC)C(O)CC/C(/C)=C/3
NCGC00380607-01	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CC(OC)C(O)CCC/C(/C)=C/3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380607-01	363678669.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CC(OC)C(O)CCC/C(/C)=C/3	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CC(OC)C(O)CCC/C(/C)=C/3
NCGC00380397-01	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CC(OC)CCCC/C(/C)=C/3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380397-01	363678567.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CC(OC)CCCC/C(/C)=C/3	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CC(OC)CCCC/C(/C)=C/3
NCGC00380117-01	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CCC1OC(C)(C)OC1CC/C(/C)=C/3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380117-01	363678463.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CCC1OC(C)(C)OC1CC/C(/C)=C/3	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12C(=O)CCC1OC(C)(C)OC1CC/C(/C)=C/3
NCGC00380311-01	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12OC(=O)/C=C/C(O)C(O)CC/C(/C)=C/3		Inactive	<MOA Unknown> | Class: polyketide/AS; Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380311-01	363678535.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12OC(=O)/C=C/C(O)C(O)CC/C(/C)=C/3	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12OC(=O)/C=C/C(O)C(O)CC/C(/C)=C/3
NCGC00347526-02	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12OC(=O)/C=C/C(O)CCC/C(/C)=C/3		Inactive	<MOA Unknown> | Class: polyketide/AS; Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347526-02	363677613.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12OC(=O)/C=C/C(O)CCC/C(/C)=C/3	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12OC(=O)/C=C/C(O)CCC/C(/C)=C/3
NCGC00380312-01	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12OC(=O)/C=C/CC(O)CC/C(/C)=C/3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380312-01	363678536.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12OC(=O)/C=C/CC(O)CC/C(/C)=C/3	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12OC(=O)/C=C/CC(O)CC/C(/C)=C/3
NCGC00381131-01	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12OC(=O)CC1OC(C)(C)OC1C(O)CC/C(/C)=C/3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381131-01	363678984.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12OC(=O)CC1OC(C)(C)OC1C(O)CC/C(/C)=C/3	O=C1NC(CC(C)C)C2C(C)C(C)=CC\3C12OC(=O)CC1OC(C)(C)OC1C(O)CC/C(/C)=C/3
NCGC00370901-01	O=C1NC(CCN2CCN(c3cc(C)c(C)cc3)CC2)c2c1cccc2		Inactive	Dopamine D4 receptor Antagonist		1	PD 168568 dihydrochloride	363677921.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(CCN2CCN(c3cc(C)c(C)cc3)CC2)c2c1cccc2	O=C1NC(CCN2CCN(c3cc(C)c(C)cc3)CC2)c2c1cccc2
NCGC00347846-02	O=C1NC(Cc2c3c([nH]c2)cccc3)C2C(C)C3(C)OC3C\3C12C(=O)CC(OC)C(O)CC(C)C/C=C/3		Inactive	<MOA Unknown> | Class: polyketide/AS | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347846-02	363677708.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(Cc2c3c([nH]c2)cccc3)C2C(C)C3(C)OC3C\3C12C(=O)CC(OC)C(O)CC(C)C/C=C/3	O=C1NC(Cc2c3c([nH]c2)cccc3)C2C(C)C3(C)OC3C\3C12C(=O)CC(OC)C(O)CC(C)C/C=C/3
NCGC00485328-01	O=C1NC(N)=NC=2NC[C@H]([C@@H](O)[C@@H](O)C)NC1=2		Inactive	Phenylalanine-4-hydroxylase Substrate		1	(6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride	363681287.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1NC(N)=NC=2NC[C@H]([C@@H](O)[C@@H](O)C)NC1=2	O=C1NC(N)=NC=2NC[C@H]([C@@H](O)[C@@H](O)C)NC1=2
NCGC00263533-12	O=C1NC(N)=Nc2n(CCC(CO)CO)cnc12		Inactive			1	Penciclovir	434147074.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1NC(N)=Nc2n(CCC(CO)CO)cnc12	O=C1NC(N)=Nc2n(CCC(CO)CO)cnc12
NCGC00164563-04&NCGC00164563-06&NCGC00164563-12	O=C1NC(N)=Nc2n([C@@H]3C(=C)[C@H](CO)[C@@H](O)C3)cnc12		Inactive	DNA Polymerase Inhibitors		3	Entecavir (monohydrate)&Entecavir	405558991.0&434147235.0&384568253.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1NC(N)=Nc2n([C@@H]3C(=C)[C@H](CO)[C@@H](O)C3)cnc12	O=C1NC(N)=Nc2n([C@@H]3C(=C)[C@H](CO)[C@@H](O)C3)cnc12
NCGC00485409-01	O=C1NC(N)=Nc2n([C@H]3[C@@](O)(C)[C@H](O)[C@@H](CO)O3)cnc12		Inactive	Hepatitis C virus NS5B RNA-dependent RNA polymerase Inhibitor		1	2?-C-Methylguanosine	363681322.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(N)=Nc2n([C@H]3[C@@](O)(C)[C@H](O)[C@@H](CO)O3)cnc12	O=C1NC(N)=Nc2n([C@H]3[C@@](O)(C)[C@H](O)[C@@H](CO)O3)cnc12
NCGC00142496-02	O=C1NC(N)=Nc2n([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)cnc12		Inactive	apoptotic process Inhibitor		1	Guanosine	363676580.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(N)=Nc2n([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)cnc12	O=C1NC(N)=Nc2n([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)cnc12
NCGC00485380-01	O=C1NC(NCC)=Nc2n([C@@H]3O[C@H](CO)[C@@H](O)C3)cnc12		Inactive	DNA topoisomerase I Modulator		1	N2-Ethyl-2â€²-deoxyguanosine	363681306.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC(NCC)=Nc2n([C@@H]3O[C@H](CO)[C@@H](O)C3)cnc12	O=C1NC(NCC)=Nc2n([C@@H]3O[C@H](CO)[C@@H](O)C3)cnc12
NCGC00521943-01	O=C1NC([C@H]2N3CCC(C2)CC3)=Nc2c1sc(-c1c(C)n[nH]c1)c2		Inactive	CDK 7 Inhibitor		1	TAK-931	384569508.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	30.8221757279	O=C1NC([C@H]2N3CCC(C2)CC3)=Nc2c1sc(-c1c(C)n[nH]c1)c2	O=C1NC([C@H]2N3CCC(C2)CC3)=Nc2c1sc(-c1c(C)n[nH]c1)c2
NCGC00378834-01	O=C1NC([C@H]2[C@H](C)CN(Cc3ccccc3)C2)=Nc2n(C3CCOCC3)ncc12		Inactive	Phosphodiesterase 9A Inhibitor		1	PDE-9 inhibitor	363678226.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC([C@H]2[C@H](C)CN(Cc3ccccc3)C2)=Nc2n(C3CCOCC3)ncc12	O=C1NC([C@H]2[C@H](C)CN(Cc3ccccc3)C2)=Nc2n(C3CCOCC3)ncc12
NCGC00379008-02	O=C1NC([C@H]2[C@H](C)CN(Cc3ncccn3)C2)=Nc2n(C3CCOCC3)ncc12		Inactive	Phosphodiesterase 9A Inhibitor		1	PF 04447943	363678313.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC([C@H]2[C@H](C)CN(Cc3ncccn3)C2)=Nc2n(C3CCOCC3)ncc12	O=C1NC([C@H]2[C@H](C)CN(Cc3ncccn3)C2)=Nc2n(C3CCOCC3)ncc12
NCGC00263655-01	O=C1NC2=C([C@]3(N)/C(=C\C)/[C@@H](C=C(C)C3)C2)C=C1		Inactive	Acetylcholinesterase Inhibitors		1	Huperzine A	170466837.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C1NC2=C([C@]3(N)/C(=C\C)/[C@@H](C=C(C)C3)C2)C=C1	O=C1NC2=C([C@]3(N)/C(=C\C)/[C@@H](C=C(C)C3)C2)C=C1
NCGC00485883-01	O=C1NC=Nc2c([C@H]3[C@H](O)[C@H](O)[C@@H](CO)N3)c[nH]c12		Inactive	Purine nucleoside phosphorylase Inhibitor		1	Forodesine (hydrochloride)	363681392.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1NC=Nc2c([C@H]3[C@H](O)[C@H](O)[C@@H](CO)N3)c[nH]c12	O=C1NC=Nc2c([C@H]3[C@H](O)[C@H](O)[C@@H](CO)N3)c[nH]c12
NCGC00380761-01	O=C1NC=Nc2n(C3C(O)C(OC)C(CO)O3)cnc12		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380761-01	363678766.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NC=Nc2n(C3C(O)C(OC)C(CO)O3)cnc12	O=C1NC=Nc2n(C3C(O)C(OC)C(CO)O3)cnc12
NCGC00090691-03&NCGC00090691-14	O=C1NC=Nc2n([C@@H]3O[C@H](CO)CC3)cnc12		Inactive	Reverse Transcriptase Inhibitor&Human immunodeficiency virus type 1 reverse transcriptase Inhibitor		2	2',3'-Dideoxyinosine&Didanosine	174006954.0&434146910.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&-7.929835652&0.0	O=C1NC=Nc2n([C@@H]3O[C@H](CO)CC3)cnc12	O=C1NC=Nc2n([C@@H]3O[C@H](CO)CC3)cnc12
NCGC00095787-05	O=C1NC=Nc2n([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)cnc12		Inactive			1	(-)-Inosine	405559132.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1NC=Nc2n([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)cnc12	O=C1NC=Nc2n([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)cnc12
NCGC00043555-10	O=C1NCCCc2c3c(oc12)ccc(O)c3		Inactive			1	CID755673	377020255.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NCCCc2c3c(oc12)ccc(O)c3	O=C1NCCCc2c3c(oc12)ccc(O)c3
NCGC00241412-01	O=C1NCCSc2c3c(sc12)ccc(O)c3		Inactive			1	kb NB 142-70	124950449.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NCCSc2c3c(sc12)ccc(O)c3	O=C1NCCSc2c3c(sc12)ccc(O)c3
NCGC00346723-07	O=C1NCCc2[nH]c(-c3ccncc3)cc12		Inactive	CDC 7 Inhibitor		1	PHA-767491A	384568934.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C1NCCc2[nH]c(-c3ccncc3)cc12	O=C1NCCc2[nH]c(-c3ccncc3)cc12
NCGC00168108-05&NCGC00168108-06	O=C1NCCn2c(-c3ccc(CN(C)C)cc3)nc3c2c1ccc3		Inactive	PARP Inhibitor		2	AG-14361	363676676.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&15.5	O=C1NCCn2c(-c3ccc(CN(C)C)cc3)nc3c2c1ccc3	O=C1NCCn2c(-c3ccc(CN(C)C)cc3)nc3c2c1ccc3
NCGC00169011-03	O=C1NCc2c3O[C@@]4([C@H](C)CCC5C(C)(C)[C@H](O)CC[C@]45C)Cc3c(O)cc12		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169011-03	363676742.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NCc2c3O[C@@]4([C@H](C)CCC5C(C)(C)[C@H](O)CC[C@]45C)Cc3c(O)cc12	O=C1NCc2c3O[C@@]4([C@H](C)CCC5C(C)(C)[C@H](O)CC[C@]45C)Cc3c(O)cc12
NCGC00347551-02	O=C1NCc2c3O[C@@]4([C@H](C)CC[C@H]5C(C)(C)[C@H](O)[C@H](O)C[C@]45C)Cc3c(O)cc12		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347551-02	363677622.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1NCc2c3O[C@@]4([C@H](C)CC[C@H]5C(C)(C)[C@H](O)[C@H](O)C[C@]45C)Cc3c(O)cc12	O=C1NCc2c3O[C@@]4([C@H](C)CC[C@H]5C(C)(C)[C@H](O)[C@H](O)C[C@]45C)Cc3c(O)cc12
NCGC00163451-04	O=C1NCc2c3c(n(CCC#N)c4c3cccc4)c3n(C)c4c(c3c12)cccc4		Inactive	PKC Inhibitor		1	Go-6976	363676620.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C1NCc2c3c(n(CCC#N)c4c3cccc4)c3n(C)c4c(c3c12)cccc4	O=C1NCc2c3c(n(CCC#N)c4c3cccc4)c3n(C)c4c(c3c12)cccc4
NCGC00244256-04	O=C1NCc2c3c4n([C@@]5(C)[C@@](O)(CO)C[C@H](O5)n5c4c(c4c5cccc4)c12)c1c3cccc1		Inactive	Jak/Tyk/Flt Inhibitor		1	Lestaurtinib	377020319.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C1NCc2c3c4n([C@@]5(C)[C@@](O)(CO)C[C@H](O5)n5c4c(c4c5cccc4)c12)c1c3cccc1	O=C1NCc2c3c4n([C@@]5(C)[C@@](O)(CO)C[C@H](O5)n5c4c(c4c5cccc4)c12)c1c3cccc1
NCGC00263564-04	O=C1NN=C([C@H](C)C1)c1ccc(NN=C(C#N)C#N)cc1		Inactive	K(ATP) Channel Activator		1	Levosimendan	384568688.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1NN=C([C@H](C)C1)c1ccc(NN=C(C#N)C#N)cc1	O=C1NN=C([C@H](C)C1)c1ccc(NN=C(C#N)C#N)cc1
NCGC00380304-01	O=C1N[C@@H](CC(C)C)[C@@H]2[C@H](C)C(C)=CC\3[C@]12C(=O)[C@H]1O[C@H]1[C@H](O)[C@H](O)CC/C(/C)=C/3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380304-01	363678530.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N[C@@H](CC(C)C)[C@@H]2[C@H](C)C(C)=CC\3[C@]12C(=O)[C@H]1O[C@H]1[C@H](O)[C@H](O)CC/C(/C)=C/3	O=C1N[C@@H](CC(C)C)[C@@H]2[C@H](C)C(C)=CC\3[C@]12C(=O)[C@H]1O[C@H]1[C@H](O)[C@H](O)CC/C(/C)=C/3
NCGC00386058-01	O=C1N[C@@H](CC(C)C)[C@@H]2[C@H](C)C(C)=C[C@@H]3[C@H]4[C@H]5[C@H](O)CC[C@](C)(O5)[C@H]4CC(=O)[C@@]123		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386058-01	363680083.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N[C@@H](CC(C)C)[C@@H]2[C@H](C)C(C)=C[C@@H]3[C@H]4[C@H]5[C@H](O)CC[C@](C)(O5)[C@H]4CC(=O)[C@@]123	O=C1N[C@@H](CC(C)C)[C@@H]2[C@H](C)C(C)=C[C@@H]3[C@H]4[C@H]5[C@H](O)CC[C@](C)(O5)[C@H]4CC(=O)[C@@]123
NCGC00380709-01	O=C1N[C@@H](Cc2c3c([nH]c2)cccc3)[C@@H]2[C@H](C)C(=C)[C@@H](O)[C@H]\3[C@]12C(=O)/C=C/C(=O)[C@H](O)/C(/C)=C\[C@@H](C)C/C=C/3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380709-01	363678726.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N[C@@H](Cc2c3c([nH]c2)cccc3)[C@@H]2[C@H](C)C(=C)[C@@H](O)[C@H]\3[C@]12C(=O)/C=C/C(=O)[C@H](O)/C(/C)=C\[C@@H](C)C/C=C/3	O=C1N[C@@H](Cc2c3c([nH]c2)cccc3)[C@@H]2[C@H](C)C(=C)[C@@H](O)[C@H]\3[C@]12C(=O)/C=C/C(=O)[C@H](O)/C(/C)=C\[C@@H](C)C/C=C/3
NCGC00385184-01	O=C1N[C@@H](Cc2c3c([nH]c2)cccc3)[C@@H]2[C@H](C)[C@@]3(C)O[C@H]3[C@H]\3[C@]12C(=O)/C=C/C(=O)[C@H](O)/C(/C)=C/[C@@H](C)C/C=C/3		Inactive	<MOA Unknown> | Class: polyketide/AS; Alkaloid | Genus: cf Acremonium (Ct: Chaetomium) | Family: N/A | Species: N/A		1	NCGC00385184-01	363679583.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N[C@@H](Cc2c3c([nH]c2)cccc3)[C@@H]2[C@H](C)[C@@]3(C)O[C@H]3[C@H]\3[C@]12C(=O)/C=C/C(=O)[C@H](O)/C(/C)=C/[C@@H](C)C/C=C/3	O=C1N[C@@H](Cc2c3c([nH]c2)cccc3)[C@@H]2[C@H](C)[C@@]3(C)O[C@H]3[C@H]\3[C@]12C(=O)/C=C/C(=O)[C@H](O)/C(/C)=C/[C@@H](C)C/C=C/3
NCGC00384659-01	O=C1N[C@@H](Cc2ccccc2)CN2[C@H]1CCCC2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384659-01	363679296.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1N[C@@H](Cc2ccccc2)CN2[C@H]1CCCC2	O=C1N[C@@H](Cc2ccccc2)CN2[C@H]1CCCC2
NCGC00388356-01	O=C1N[C@@H](Cc2ccccc2)[C@@H]2[C@H](C)C(=C)[C@@H](O)[C@H]\3[C@]12OC(=O)/C=C/C(=O)CCC[C@@H](C)C/C=C/3		Inactive			1	Cytochalasin A	363680727.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	16.471428572	O=C1N[C@@H](Cc2ccccc2)[C@@H]2[C@H](C)C(=C)[C@@H](O)[C@H]\3[C@]12OC(=O)/C=C/C(=O)CCC[C@@H](C)C/C=C/3	O=C1N[C@@H](Cc2ccccc2)[C@@H]2[C@H](C)C(=C)[C@@H](O)[C@H]\3[C@]12OC(=O)/C=C/C(=O)CCC[C@@H](C)C/C=C/3
NCGC00351595-02	O=C1N[C@H](C)CNc2c3c(sc12)ccc1nc(-c2cnc(C)cc2)ccc31		Inactive	MAPKAP-K2 (MK2) Inhibitor		1	PF-3644022	363677763.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1N[C@H](C)CNc2c3c(sc12)ccc1nc(-c2cnc(C)cc2)ccc31	O=C1N[C@H](C)CNc2c3c(sc12)ccc1nc(-c2cnc(C)cc2)ccc31
NCGC00484799-01	O=C1Nc2c(C)cc(O)c(-c3ccc([C@H](CN(C)C)C)cc3)c2-c2c1scc2		Inactive	PDZ-binding kinase Inhibitor		1	OTS964	363681179.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1Nc2c(C)cc(O)c(-c3ccc([C@H](CN(C)C)C)cc3)c2-c2c1scc2	O=C1Nc2c(C)cc(O)c(-c3ccc([C@H](CN(C)C)C)cc3)c2-c2c1scc2
NCGC00507851-01	O=C1Nc2c(C)cc(O)c(-c3ccc([C@H](CN)C)cc3)c2-c2c1scc2		Inactive	PBK Inhibitor		1	OTS-514	384569331.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-8.979004668	O=C1Nc2c(C)cc(O)c(-c3ccc([C@H](CN)C)cc3)c2-c2c1scc2	O=C1Nc2c(C)cc(O)c(-c3ccc([C@H](CN)C)cc3)c2-c2c1scc2
NCGC00065890-14	O=C1Nc2c(C)ccnc2N(C2CC2)c2ncccc12		Inactive	Reverse Transcriptase Inhibitor		1	Nevirapine	405558819.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1Nc2c(C)ccnc2N(C2CC2)c2ncccc12	O=C1Nc2c(C)ccnc2N(C2CC2)c2ncccc12
NCGC00378727-01	O=C1Nc2c(N1)ccc(C#CCN1CCC(Cc3ccccc3)CC1)c2		Inactive	Glutamate NMDA receptor; GRIN1/GRIN2B Antagonist		1	TCS 46b	363678173.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1Nc2c(N1)ccc(C#CCN1CCC(Cc3ccccc3)CC1)c2	O=C1Nc2c(N1)ccc(C#CCN1CCC(Cc3ccccc3)CC1)c2
NCGC00389282-01	O=C1Nc2c(O)ccc(C(O)CNC3Cc4c(cc(CC)c(CC)c4)C3)c2C=C1		Inactive	Beta-2 adrenergic receptor Agonist		1	Indacaterol Maleate	363680761.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1Nc2c(O)ccc(C(O)CNC3Cc4c(cc(CC)c(CC)c4)C3)c2C=C1	O=C1Nc2c(O)ccc(C(O)CNC3Cc4c(cc(CC)c(CC)c4)C3)c2C=C1
NCGC00386216-07	O=C1Nc2c(O)ccc([C@@H](O)CNC3Cc4c(cc(CC)c(CC)c4)C3)c2C=C1		Inactive			1	Indacaterol (maleate)	405559054.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1Nc2c(O)ccc([C@@H](O)CNC3Cc4c(cc(CC)c(CC)c4)C3)c2C=C1	O=C1Nc2c(O)ccc([C@@H](O)CNC3Cc4c(cc(CC)c(CC)c4)C3)c2C=C1
NCGC00018291-03&NCGC00024999-04	O=C1Nc2c(O)ccc([C@@H](O)[C@@H](NC(C)C)CC)c2C=C1		Inactive	beta2-Adrenoceptor Agonists&beta2-Adrenoceptor Agonist		2	Procaterol&Procaterol hydrochloride	170465820.0&384568040.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1Nc2c(O)ccc([C@@H](O)[C@@H](NC(C)C)CC)c2C=C1	O=C1Nc2c(O)ccc([C@@H](O)[C@@H](NC(C)C)CC)c2C=C1
NCGC00507868-01	O=C1Nc2c(c(-c3cc4c(-c5cn(C)nc5)nn(C)c4cc3)ccc2)N[C@H](C)C1		Inactive	CBP/p300 Inhibitor		1	CPI-637	384569342.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1Nc2c(c(-c3cc4c(-c5cn(C)nc5)nn(C)c4cc3)ccc2)N[C@H](C)C1	O=C1Nc2c(c(-c3cc4c(-c5cn(C)nc5)nn(C)c4cc3)ccc2)N[C@H](C)C1
NCGC00484808-01	O=C1Nc2c(c(-c3cn(C(C)(C)C)nc3)ccc2)N[C@H](C)C1		Inactive	CBP/p300 Inhibitor		1	CPI-703	384569273.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1Nc2c(c(-c3cn(C(C)(C)C)nc3)ccc2)N[C@H](C)C1	O=C1Nc2c(c(-c3cn(C(C)(C)C)nc3)ccc2)N[C@H](C)C1
NCGC00485861-01	O=C1Nc2c(c(-c3cn(CCCC#C)nc3)ccc2)N[C@@H](C)C1		Inactive			1	NCGC00485861-01	363681384.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1Nc2c(c(-c3cn(CCCC#C)nc3)ccc2)N[C@@H](C)C1	O=C1Nc2c(c(-c3cn(CCCC#C)nc3)ccc2)N[C@@H](C)C1
NCGC00485860-01	O=C1Nc2c(c(-c3cn(CCCC#C)nc3)ccc2)N[C@H](C)C1		Inactive			1	NCGC00485860-01	363681383.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1Nc2c(c(-c3cn(CCCC#C)nc3)ccc2)N[C@H](C)C1	O=C1Nc2c(c(-c3cn(CCCC#C)nc3)ccc2)N[C@H](C)C1
NCGC00015893-06	O=C1Nc2c(c(CCN(CCC)CCC)ccc2)C1		Inactive	Dopamine D3 receptor Partial Agonist		1	Ropinirole	170465139.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1Nc2c(c(CCN(CCC)CCC)ccc2)C1	O=C1Nc2c(c(CCN(CCC)CCC)ccc2)C1
NCGC00382195-02	O=C1Nc2c(cccc2)C1		Inactive			1	Oxindole		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1Nc2c(cccc2)C1	O=C1Nc2c(cccc2)C1
NCGC00169049-03	O=C1O/C(=C\CCC)/C2=C1C(O)C(O)CC2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: Ligustrum | Family: Oleaceae | Species: wallichii		1	NCGC00169049-03	363676752.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1O/C(=C\CCC)/C2=C1C(O)C(O)CC2	O=C1O/C(=C\CCC)/C2=C1C(O)C(O)CC2
NCGC00385988-01	O=C1OC(=O)C=2C(C3(C)C(C(C)(C)CCC3)CC=2)=C2C3(C)C(C(C)(C)CCC3)CC=C12		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385988-01	363680046.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(=O)C=2C(C3(C)C(C(C)(C)CCC3)CC=2)=C2C3(C)C(C(C)(C)CCC3)CC=C12	O=C1OC(=O)C=2C(C3(C)C(C(C)(C)CCC3)CC=2)=C2C3(C)C(C(C)(C)CCC3)CC=C12
NCGC00380965-01	O=C1OC(=O)C=2C(O)(C3=C1C(C)(C)CCC3)CCC(C=C)(C)C=2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380965-01	363678890.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(=O)C=2C(O)(C3=C1C(C)(C)CCC3)CCC(C=C)(C)C=2	O=C1OC(=O)C=2C(O)(C3=C1C(C)(C)CCC3)CCC(C=C)(C)C=2
NCGC00485197-01	O=C1OC(C)=CC=2O[C@@H]3C(=CC1=2)CC[C@H]([C@@H](Cn1c-2ncnc-2c(N)nc1)C)C3		Inactive			1	Aminopurinyl pyranobenzopyranone  monohydrate	363681253.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(C)=CC=2O[C@@H]3C(=CC1=2)CC[C@H]([C@@H](Cn1c-2ncnc-2c(N)nc1)C)C3	O=C1OC(C)=CC=2O[C@@H]3C(=CC1=2)CC[C@H]([C@@H](Cn1c-2ncnc-2c(N)nc1)C)C3
NCGC00347808-02	O=C1OC(C)C/C=C/C(O)C(O)CC/C=C/c2c1c(O)cc(O)c2		Inactive	<MOA Unknown> | Class: Macrolide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347808-02	363677693.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(C)C/C=C/C(O)C(O)CC/C=C/c2c1c(O)cc(O)c2	O=C1OC(C)C/C=C/C(O)C(O)CC/C=C/c2c1c(O)cc(O)c2
NCGC00381387-02	O=C1OC(C)CCC(=O)CC(O)C(O)C1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381387-02	363679118.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(C)CCC(=O)CC(O)C(O)C1	O=C1OC(C)CCC(=O)CC(O)C(O)C1
NCGC00381162-01	O=C1OC(C)CCC(=O)CC(OC)C(O)C1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381162-01	363679002.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(C)CCC(=O)CC(OC)C(O)C1	O=C1OC(C)CCC(=O)CC(OC)C(O)C1
NCGC00384480-02	O=C1OC(C)CCCC(O)CC(=O)Cc2c1c(O)cc(O)c2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384480-02	363679205.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(C)CCCC(O)CC(=O)Cc2c1c(O)cc(O)c2	O=C1OC(C)CCCC(O)CC(=O)Cc2c1c(O)cc(O)c2
NCGC00384588-01	O=C1OC(C)CCCC(O)CC(=O)c2c(O)cc(O)cc2C1		Inactive	<MOA Unknown> | Class: macrolide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384588-01	363679263.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	19.809312636	O=C1OC(C)CCCC(O)CC(=O)c2c(O)cc(O)cc2C1	O=C1OC(C)CCCC(O)CC(=O)c2c(O)cc(O)cc2C1
NCGC00384542-01	O=C1OC(C)CCCC(O)CCC/C=C/c2c1c(O)cc(O)c2		Inactive	RAW264.7 Inhibitor		1	NCGC00384542-01	363679238.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	12.012942292	O=C1OC(C)CCCC(O)CCC/C=C/c2c1c(O)cc(O)c2	O=C1OC(C)CCCC(O)CCC/C=C/c2c1c(O)cc(O)c2
NCGC00184708-02	O=C1OC(C)CCCC(O)CCCCCc2c1c(O)cc(O)c2		Inactive	smooth muscle contraction Inhibitor		1	NCGC00184708-02	124896555.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1OC(C)CCCC(O)CCCCCc2c1c(O)cc(O)c2	O=C1OC(C)CCCC(O)CCCCCc2c1c(O)cc(O)c2
NCGC00384664-01	O=C1OC(C)CCCC(OC)CC(=O)c2c(O)cc(O)cc2C1		Inactive	<MOA Unknown> | Class: macrolide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384664-01	363679299.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(C)CCCC(OC)CC(=O)c2c(O)cc(O)cc2C1	O=C1OC(C)CCCC(OC)CC(=O)c2c(O)cc(O)cc2C1
NCGC00179952-02	O=C1OC(C)CCCCCC(=O)c2c(O)cc(O)cc2C1		Inactive	Jak-STAT signaling pathway Inhibitor		1	NCGC00179952-02	363676995.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(C)CCCCCC(=O)c2c(O)cc(O)cc2C1	O=C1OC(C)CCCCCC(=O)c2c(O)cc(O)cc2C1
NCGC00385579-01	O=C1OC(C)CCCCCCCc2c1c(O)cc(O)c2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385579-01	363679820.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(C)CCCCCCCc2c1c(O)cc(O)c2	O=C1OC(C)CCCCCCCc2c1c(O)cc(O)c2
NCGC00015169-03	O=C1OC(C2N(C)CCc3c2cc2OCOc2c3)c2c1c1OCOc1cc2		Inactive	GABA-A receptor; anion channel Antagonist		1	(+)-Bicuculline	363676442.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(C2N(C)CCc3c2cc2OCOc2c3)c2c1c1OCOc1cc2	O=C1OC(C2N(C)CCc3c2cc2OCOc2c3)c2c1c1OCOc1cc2
NCGC00381271-01	O=C1OC(CC/C=C/C)Cc2c1c(O)c(CCCC)c(O)c2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381271-01	363679058.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	27.924839704	O=C1OC(CC/C=C/C)Cc2c1c(O)c(CCCC)c(O)c2	O=C1OC(CC/C=C/C)Cc2c1c(O)c(CCCC)c(O)c2
NCGC00385795-01	O=C1OC(CCC2C(C)C=CC3C2CCCC3)CC(O)C1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385795-01	363679942.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(CCC2C(C)C=CC3C2CCCC3)CC(O)C1	O=C1OC(CCC2C(C)C=CC3C2CCCC3)CC(O)C1
NCGC00380928-01	O=C1OC(O)(C)C=2OC(/C=C/C)C(O)C(O)C1=2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380928-01	363678860.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(O)(C)C=2OC(/C=C/C)C(O)C(O)C1=2	O=C1OC(O)(C)C=2OC(/C=C/C)C(O)C(O)C1=2
NCGC00179711-03	O=C1OC(O)C(CCC2(C)C(C)CCC3(C)C4(C(O)C(O)CC23)OC4)=C1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Cornutia | Family: Verbenaceae | Species: pyramidata		1	NCGC00179711-03	363676957.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(O)C(CCC2(C)C(C)CCC3(C)C4(C(O)C(O)CC23)OC4)=C1	O=C1OC(O)C(CCC2(C)C(C)CCC3(C)C4(C(O)C(O)CC23)OC4)=C1
NCGC00380941-01	O=C1OC(O)C2(O)C3(C)C(C(C)(C)CCC3)CC=C12		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380941-01	363678873.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(O)C2(O)C3(C)C(C(C)(C)CCC3)CC=C12	O=C1OC(O)C2(O)C3(C)C(C(C)(C)CCC3)CC=C12
NCGC00385865-01	O=C1OC(O)C=2C(O)C3C(=C(C)CC1=2)CC(C)(C)C3		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385865-01	363679976.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(O)C=2C(O)C3C(=C(C)CC1=2)CC(C)(C)C3	O=C1OC(O)C=2C(O)C3C(=C(C)CC1=2)CC(C)(C)C3
NCGC00385445-01	O=C1OC(O)C=2C(O)C3C(C(O)(C)CC1=2)CC(C)(C)C3		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385445-01	363679744.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(O)C=2C(O)C3C(C(O)(C)CC1=2)CC(C)(C)C3	O=C1OC(O)C=2C(O)C3C(C(O)(C)CC1=2)CC(C)(C)C3
NCGC00384569-01	O=C1OC(O)C=2C3(C)C(C(C)(C)CCC3)CC(O)C1=2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384569-01	363679248.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(O)C=2C3(C)C(C(C)(C)CCC3)CC(O)C1=2	O=C1OC(O)C=2C3(C)C(C(C)(C)CCC3)CC(O)C1=2
NCGC00381408-02	O=C1OC(OC)C=2C3(C)C(C(C)(C)CCC3)CC(O)C1=2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381408-02	363679130.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(OC)C=2C3(C)C(C(C)(C)CCC3)CC(O)C1=2	O=C1OC(OC)C=2C3(C)C(C(C)(C)CCC3)CC(O)C1=2
NCGC00018200-12	O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2c1cccc2		Inactive	store-operated calcium entry Blocker		1	Phenolphthalein	170465559.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2c1cccc2	O=C1OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2c1cccc2
NCGC00385719-01	O=C1OC(c2cocc2)C2(C)C3(C4(C)C(=O)CC(C(O)(C)C)C5(C4CC2)COC(=O)CC5)OC13		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385719-01	363679895.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(c2cocc2)C2(C)C3(C4(C)C(=O)CC(C(O)(C)C)C5(C4CC2)COC(=O)CC5)OC13	O=C1OC(c2cocc2)C2(C)C3(C4(C)C(=O)CC(C(O)(C)C)C5(C4CC2)COC(=O)CC5)OC13
NCGC00380560-01	O=C1OC(c2cocc2)C2(C)C3(C4(C)C(=O)CC5C(C)(C)OC(=O)CC(O)C5(C)C4C(O)C2)OC13		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Canarium | Family: Burseraceae | Species: album		1	NCGC00380560-01	363678650.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(c2cocc2)C2(C)C3(C4(C)C(=O)CC5C(C)(C)OC(=O)CC(O)C5(C)C4C(O)C2)OC13	O=C1OC(c2cocc2)C2(C)C3(C4(C)C(=O)CC5C(C)(C)OC(=O)CC(O)C5(C)C4C(O)C2)OC13
NCGC00380451-01	O=C1OC(c2cocc2)CC2(C)C1CCC1(C)C(O)(C)C(O)CCC21		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Croton | Family: Euphorbiaceae | Species: megalocarpus		1	NCGC00380451-01	363678590.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC(c2cocc2)CC2(C)C1CCC1(C)C(O)(C)C(O)CCC21	O=C1OC(c2cocc2)CC2(C)C1CCC1(C)C(O)(C)C(O)CCC21
NCGC00384532-01	O=C1OC/C(=C\2/C3(C)C(O)(C4C(C5(C)C(=CC4)CC(OC4C(O)C(OC6C(O)C(O)C(O)C(CO)O6)C(O)C(CO)O4)CC5)CC3)CC/2)/C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384532-01	363679234.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC/C(=C\2/C3(C)C(O)(C4C(C5(C)C(=CC4)CC(OC4C(O)C(OC6C(O)C(O)C(O)C(CO)O6)C(O)C(CO)O4)CC5)CC3)CC/2)/C1	O=C1OC/C(=C\2/C3(C)C(O)(C4C(C5(C)C(=CC4)CC(OC4C(O)C(OC6C(O)C(O)C(O)C(CO)O6)C(O)C(CO)O4)CC5)CC3)CC/2)/C1
NCGC00380546-01	O=C1OC/C(=C\2/C3(C)C(O)(C4C(C5(C)C(CC(OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(CO)O6)CC5)CC4)CC3)CC/2)/C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380546-01	363678643.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC/C(=C\2/C3(C)C(O)(C4C(C5(C)C(CC(OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(CO)O6)CC5)CC4)CC3)CC/2)/C1	O=C1OC/C(=C\2/C3(C)C(O)(C4C(C5(C)C(CC(OC6C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(CO)O6)CC5)CC4)CC3)CC/2)/C1
NCGC00384525-01	O=C1OC/C(=C\2/C3(C)C(O)(C4C(C5(C)C(CC(OC6C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(O)C(CO)O6)CC5)CC4)CC3)CC/2)/C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384525-01	363679230.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	13.492822968	O=C1OC/C(=C\2/C3(C)C(O)(C4C(C5(C)C(CC(OC6C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(O)C(CO)O6)CC5)CC4)CC3)CC/2)/C1	O=C1OC/C(=C\2/C3(C)C(O)(C4C(C5(C)C(CC(OC6C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(O)C(CO)O6)CC5)CC4)CC3)CC/2)/C1
NCGC00381034-01	O=C1OC2(C)C(c3c1c(O)cc(O)c3)=CC(O)C(O)C2		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381034-01	363678936.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC2(C)C(c3c1c(O)cc(O)c3)=CC(O)C(O)C2	O=C1OC2(C)C(c3c1c(O)cc(O)c3)=CC(O)C(O)C2
NCGC00381378-01	O=C1OC2(O)C(C(C)C3C(C4(C)C(O)CCC(C)(C)C4CC3)C2)=C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381378-01	363679113.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC2(O)C(C(C)C3C(C4(C)C(O)CCC(C)(C)C4CC3)C2)=C1	O=C1OC2(O)C(C(C)C3C(C4(C)C(O)CCC(C)(C)C4CC3)C2)=C1
NCGC00347834-02	O=C1OC2(O)C(C(C)C3C(O)CC4C(CO)(C)CCCC4(C)C3C2)=C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347834-02	363677702.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC2(O)C(C(C)C3C(O)CC4C(CO)(C)CCCC4(C)C3C2)=C1	O=C1OC2(O)C(C(C)C3C(O)CC4C(CO)(C)CCCC4(C)C3C2)=C1
NCGC00161643-05	O=C1OC2(c3c1cccc3)c1c(Oc3c2ccc(O)c3)cc(O)cc1		Inactive			1	Fluorescein sodium	170464991.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1OC2(c3c1cccc3)c1c(Oc3c2ccc([O-])c3)cc([O-])cc1.[Na+].[Na+]	O=C1OC2(c3c1cccc3)c1c(Oc3c2ccc([O-])c3)cc([O-])cc1.[Na+].[Na+]
NCGC00380862-01	O=C1OC2C(C)(C)/C=C\C(=O)/C(/C)=C/CCC1=C2		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Naupilus | Family: Compositae | Species: aquaticus		1	NCGC00380862-01	363678820.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	24.11059294	O=C1OC2C(C)(C)/C=C\C(=O)/C(/C)=C/CCC1=C2	O=C1OC2C(C)(C)/C=C\C(=O)/C(/C)=C/CCC1=C2
NCGC00169804-02	O=C1OC2C(C)(C)/C=C\C(=O)/C(/C)=C\CCC1=C2	4.9000001	Active	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00169804-02	363676891.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	3.0	59.5639334849	O=C1OC2C(C)(C)/C=C\C(=O)/C(/C)=C\CCC1=C2	O=C1OC2C(C)(C)/C=C\C(=O)/C(/C)=C\CCC1=C2
NCGC00385442-01	O=C1OC2C(O)C(c3ccccc3)OC2C=C1		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385442-01	363679743.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC2C(O)C(c3ccccc3)OC2C=C1	O=C1OC2C(O)C(c3ccccc3)OC2C=C1
NCGC00485987-01	O=C1OC2OCC(O)C(O)C2OC2C(O)C(OC3C(O)C(O)C(O)CO3)C(C(C)O2)OC(=O)CC(O)(C)CC(=O)OC2C(O)C(O)C(OC3C(O)C(O)C(CO)OC3OC3C(CO)(C)C4C(C)(C5C(C)(C6(C)C(C7C1(C(O)C6)CCC(C)(C)C7)=CC5)CC4)CC3O)OC2	5.3000002	Active		0.0	1	Tubeimoside II	363681466.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	59.3666300799	O=C1OC2OCC(O)C(O)C2OC2C(O)C(OC3C(O)C(O)C(O)CO3)C(C(C)O2)OC(=O)CC(O)(C)CC(=O)OC2C(O)C(O)C(OC3C(O)C(O)C(CO)OC3OC3C(CO)(C)C4C(C)(C5C(C)(C6(C)C(C7C1(C(O)C6)CCC(C)(C)C7)=CC5)CC4)CC3O)OC2	O=C1OC2OCC(O)C(O)C2OC2C(O)C(OC3C(O)C(O)C(O)CO3)C(C(C)O2)OC(=O)CC(O)(C)CC(=O)OC2C(O)C(O)C(OC3C(O)C(O)C(CO)OC3OC3C(CO)(C)C4C(C)(C5C(C)(C6(C)C(C7C1(C(O)C6)CCC(C)(C)C7)=CC5)CC4)CC3O)OC2
NCGC00485919-01	O=C1OC=C([C@@H]2[C@]3(C)[C@@](O)([C@H]4[C@@H]([C@]5(C)[C@@](O)(C[C@@H](O)CC5)CC4)CC3)CC2)C=C1		Inactive			1	Telocinobufagin	363681415.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC=C([C@@H]2[C@]3(C)[C@@](O)([C@H]4[C@@H]([C@]5(C)[C@@](O)(C[C@@H](O)CC5)CC4)CC3)CC2)C=C1	O=C1OC=C([C@@H]2[C@]3(C)[C@@](O)([C@H]4[C@@H]([C@]5(C)[C@@](O)(C[C@@H](O)CC5)CC4)CC3)CC2)C=C1
NCGC00485918-01	O=C1OC=C([C@@H]2[C@]3(C)[C@@](O)([C@H]4[C@H]([C@H](O)C3)[C@]3(C)[C@@H](C[C@@H](O)CC3)CC4)CC2)C=C1		Inactive	Vascular endothelial growth factor receptor 2 Inhibitor		1	Gamabufotalin	363681414.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC=C([C@@H]2[C@]3(C)[C@@](O)([C@H]4[C@H]([C@H](O)C3)[C@]3(C)[C@@H](C[C@@H](O)CC3)CC4)CC2)C=C1	O=C1OC=C([C@@H]2[C@]3(C)[C@@](O)([C@H]4[C@H]([C@H](O)C3)[C@]3(C)[C@@H](C[C@@H](O)CC3)CC4)CC2)C=C1
NCGC00181021-02	O=C1OC=C([C@@H]2[C@]3(C)[C@@]4(O[C@@H]4C2)C2C([C@]4(C)[C@@H](C[C@@H](O)CC4)CC2)CC3)C=C1		Inactive	Sodium/potassium-transporting ATPase Inhibitor		1	Bufogenin	124893634.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	21.0329153561	O=C1OC=C([C@@H]2[C@]3(C)[C@@]4(O[C@@H]4C2)C2C([C@]4(C)[C@@H](C[C@@H](O)CC4)CC2)CC3)C=C1	O=C1OC=C([C@@H]2[C@]3(C)[C@@]4(O[C@@H]4C2)C2C([C@]4(C)[C@@H](C[C@@H](O)CC4)CC2)CC3)C=C1
NCGC00168912-02	O=C1OCC(C2[C@]3(C)C(O)(C4C([C@]5(C)C(C[C@@H](OC6OC(C)C(OC7C(O)C(O)C(O)C(COC8C(O)C(O)C(O)C(CO)O8)O7)C(OC)C6)CC5)CC4)CC3)CC2)=C1		Inactive	<MOA Unknown> | Class: Steroid | Genus: Nerium | Family: Apocynaceae | Species: oleander		1	NCGC00168912-02	363676720.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OCC(C2[C@]3(C)C(O)(C4C([C@]5(C)C(C[C@@H](OC6OC(C)C(OC7C(O)C(O)C(O)C(COC8C(O)C(O)C(O)C(CO)O8)O7)C(OC)C6)CC5)CC4)CC3)CC2)=C1	O=C1OCC(C2[C@]3(C)C(O)(C4C([C@]5(C)C(C[C@@H](OC6OC(C)C(OC7C(O)C(O)C(O)C(COC8C(O)C(O)C(O)C(CO)O8)O7)C(OC)C6)CC5)CC4)CC3)CC2)=C1
NCGC00385359-01	O=C1OCC([C@@H]2[C@]3(C)[C@@](O)(C4C([C@]5(C)C(C[C@@H](OC6OC(C)C(O)C(OC)C6)CC5)CC4)CC3)CC2)=C1		Inactive	<MOA Unknown> | Class: Steroid | Genus: Nerium | Family: Apocynaceae | Species: oleander		1	NCGC00385359-01	363679699.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OCC([C@@H]2[C@]3(C)[C@@](O)(C4C([C@]5(C)C(C[C@@H](OC6OC(C)C(O)C(OC)C6)CC5)CC4)CC3)CC2)=C1	O=C1OCC([C@@H]2[C@]3(C)[C@@](O)(C4C([C@]5(C)C(C[C@@H](OC6OC(C)C(O)C(OC)C6)CC5)CC4)CC3)CC2)=C1
NCGC00347770-02	O=C1OCC([C@@H]2[C@]3(C)[C@@](O)([C@H]4C([C@]5(C)C(=CC4)C[C@@H](O)CC5)CC3)CC2)=C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347770-02	363677681.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OCC([C@@H]2[C@]3(C)[C@@](O)([C@H]4C([C@]5(C)C(=CC4)C[C@@H](O)CC5)CC3)CC2)=C1	O=C1OCC([C@@H]2[C@]3(C)[C@@](O)([C@H]4C([C@]5(C)C(=CC4)C[C@@H](O)CC5)CC3)CC2)=C1
NCGC00347423-03	O=C1OCC([C@@H]2[C@]3(C)[C@@](O)([C@H]4C([C@]5(C)[C@H](C[C@@H](OC6C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(O)C(CO)O6)CC5)CC4)CC3)CC2)=C1		Inactive	Sodium/potassium-transporting ATPase Inhibitor		1	NCGC00347423-03	363677600.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OCC([C@@H]2[C@]3(C)[C@@](O)([C@H]4C([C@]5(C)[C@H](C[C@@H](OC6C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(O)C(CO)O6)CC5)CC4)CC3)CC2)=C1	O=C1OCC([C@@H]2[C@]3(C)[C@@](O)([C@H]4C([C@]5(C)[C@H](C[C@@H](OC6C(OC7C(O)C(O)C(O)C(CO)O7)C(O)C(O)C(CO)O6)CC5)CC4)CC3)CC2)=C1
NCGC00384854-01	O=C1OCC([C@@H]2[C@]3(C)[C@@](O)([C@H]4[C@@H]([C@]5(C)[C@H](C[C@@H](O)CC5)CC4)CC3)CC2)=C1		Inactive	Sodium/potassium-transporting ATPase Inhibitor		1	NCGC00384854-01	363679399.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OCC([C@@H]2[C@]3(C)[C@@](O)([C@H]4[C@@H]([C@]5(C)[C@H](C[C@@H](O)CC5)CC4)CC3)CC2)=C1	O=C1OCC([C@@H]2[C@]3(C)[C@@](O)([C@H]4[C@@H]([C@]5(C)[C@H](C[C@@H](O)CC5)CC4)CC3)CC2)=C1
NCGC00380855-01	O=C1OCC2(OC3(O)C4(C)C2CCC23C(C3(C)C(CC(OC5C(O)C(OC)C(OC6C(O)C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(CO)O6)C(C)O5)CC3)CC2)CC4)C1		Inactive	<MOA Unknown> | Class: steroid | Genus: Thevetia | Family: Apocynaceae | Species: plumeriaefolia		1	NCGC00380855-01	363678816.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OCC2(OC3(O)C4(C)C2CCC23C(C3(C)C(CC(OC5C(O)C(OC)C(OC6C(O)C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(CO)O6)C(C)O5)CC3)CC2)CC4)C1	O=C1OCC2(OC3(O)C4(C)C2CCC23C(C3(C)C(CC(OC5C(O)C(OC)C(OC6C(O)C(O)C(OC7C(O)C(O)C(O)C(CO)O7)C(CO)O6)C(C)O5)CC3)CC2)CC4)C1
NCGC00385871-01	O=C1OCC23C(O)C4C(C(O)(C)C12C3)CC(C)(C)C4		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385871-01	363679979.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OCC23C(O)C4C(C(O)(C)C12C3)CC(C)(C)C4	O=C1OCC23C(O)C4C(C(O)(C)C12C3)CC(C)(C)C4
NCGC00380686-01	O=C1OCC23C1=CC(O)CC2C(CCC=1C(O)OC(=O)C=1)(C)C(C)CC3		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380686-01	363678708.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OCC23C1=CC(O)CC2C(CCC=1C(O)OC(=O)C=1)(C)C(C)CC3	O=C1OCC23C1=CC(O)CC2C(CCC=1C(O)OC(=O)C=1)(C)C(C)CC3
NCGC00385290-01	O=C1OCC23C1=CC(O)CC2C(CCc1cocc1)(C)C(C)CC3		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385290-01	363679649.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OCC23C1=CC(O)CC2C(CCc1cocc1)(C)C(C)CC3	O=C1OCC23C1=CC(O)CC2C(CCc1cocc1)(C)C(C)CC3
NCGC00385633-01	O=C1OCC2C3(C)C(C(CO)(C)CCC3)C(O)C=C12		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385633-01	363679849.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OCC2C3(C)C(C(CO)(C)CCC3)C(O)C=C12	O=C1OCC2C3(C)C(C(CO)(C)CCC3)C(O)C=C12
NCGC00385131-01	O=C1OCC=2C(O)C3C(C(O)(C)CC1=2)CC(C)(C)C3		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385131-01	363679552.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OCC=2C(O)C3C(C(O)(C)CC1=2)CC(C)(C)C3	O=C1OCC=2C(O)C3C(C(O)(C)CC1=2)CC(C)(C)C3
NCGC00384816-01	O=C1OCC=2C(O)C3C(C(O)(C)CC1=2)CC(CO)(C)C3		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384816-01	363679372.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OCC=2C(O)C3C(C(O)(C)CC1=2)CC(CO)(C)C3	O=C1OCC=2C(O)C3C(C(O)(C)CC1=2)CC(CO)(C)C3
NCGC00163411-06	O=C1OCC=2[C@H]3[C@@](C)([C@]45O[C@H]4[C@H]4[C@@](C(C)C)([C@@H](O)[C@]65O[C@H]6C3)O4)CCC1=2		Inactive	Inhibition of RNA polymerase II mediated transcription		1	Triptolide	384568235.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C1OCC=2[C@H]3[C@@](C)([C@]45O[C@H]4[C@H]4[C@@](C(C)C)([C@@H](O)[C@]65O[C@H]6C3)O4)CCC1=2	O=C1OCC=2[C@H]3[C@@](C)([C@]45O[C@H]4[C@H]4[C@@](C(C)C)([C@@H](O)[C@]65O[C@H]6C3)O4)CCC1=2
NCGC00263884-02	O=C1OC[C@H](Cc2cc3c(CCN(C)C)c[nH]c3cc2)N1		Inactive	5-HT1B Agonist		1	Zolmitriptan	170464875.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1OC[C@H](Cc2cc3c(CCN(C)C)c[nH]c3cc2)N1	O=C1OC[C@H](Cc2cc3c(CCN(C)C)c[nH]c3cc2)N1
NCGC00385922-01	O=C1OC[C@H]2C(=O)C[C@@H]3[C@@H]4C(C)(C)CC23[C@H]1CC4		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385922-01	363680009.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1OC[C@H]2C(=O)C[C@@H]3[C@@H]4C(C)(C)CC23[C@H]1CC4	O=C1OC[C@H]2C(=O)C[C@@H]3[C@@H]4C(C)(C)CC23[C@H]1CC4
NCGC00344549-05	O=C1OC[C@]2(C)[C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C)CC4)CC3)CC[C@H]2C1		Inactive	Synthetic Steroid		1	Oxandrolone	384568721.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1OC[C@]2(C)[C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C)CC4)CC3)CC[C@H]2C1	O=C1OC[C@]2(C)[C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C)CC4)CC3)CC[C@H]2C1
NCGC00166299-03	O=C1O[Bi](O)Oc2c1cccc2		Inactive			1	BISMUTH SUBSALICYLATE	225144280.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1O[Bi](O)Oc2c1cccc2	O=C1O[Bi](O)Oc2c1cccc2
NCGC00090809-11	O=C1O[C@@H](C)CCCC(=O)CCC/C=C/c2c1c(O)cc(O)c2		Inactive			1	NCGC00090809-11		2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1O[C@@H](C)CCCC(=O)CCC/C=C/c2c1c(O)cc(O)c2	O=C1O[C@@H](C)CCCC(=O)CCC/C=C/c2c1c(O)cc(O)c2
NCGC00485224-01	O=C1O[C@@H](C)CCC[C@H](O)CCC/C=C/c2c1c(O)cc(O)c2		Inactive	RAW264.7 Inhibitor		1	Î±-Zearalenol	363681262.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1O[C@@H](C)CCC[C@H](O)CCC/C=C/c2c1c(O)cc(O)c2	O=C1O[C@@H](C)CCC[C@H](O)CCC/C=C/c2c1c(O)cc(O)c2
NCGC00017385-06	O=C1O[C@@H]([C@H]2N(C)CCc3c2cc2OCOc2c3)c2c1c1OCOc1cc2		Inactive	GABA-A receptor; anion channel Antagonist		1	(+)-Bicuculline	363676500.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1O[C@@H]([C@H]2N(C)CCc3c2cc2OCOc2c3)c2c1c1OCOc1cc2	O=C1O[C@@H]([C@H]2N(C)CCc3c2cc2OCOc2c3)c2c1c1OCOc1cc2
NCGC00385492-01&NCGC00385492-02	O=C1O[C@@H](c2cocc2)[C@@]2(C)C1=C(C)CCC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		2	Fraxinellone	363679771.0&363679772.0	2020_NPACT-8_CPE&2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C1O[C@@H](c2cocc2)[C@@]2(C)C1=C(C)CCC2	O=C1O[C@@H](c2cocc2)[C@@]2(C)C1=C(C)CCC2
NCGC00178483-14	O=C1O[C@@H](c2cocc2)[C@@]2(C)[C@]3([C@]4(C)C(=O)C[C@H]5C(C)(C)O[C@@H]6[C@@]5([C@H]4CC2)COC(=O)C6)O[C@H]13		Inactive			1	Limonin	434147188.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1O[C@@H](c2cocc2)[C@@]2(C)[C@]3([C@]4(C)C(=O)C[C@H]5C(C)(C)O[C@@H]6[C@@]5([C@H]4CC2)COC(=O)C6)O[C@H]13	O=C1O[C@@H](c2cocc2)[C@@]2(C)[C@]3([C@]4(C)C(=O)C[C@H]5C(C)(C)O[C@@H]6[C@@]5([C@H]4CC2)COC(=O)C6)O[C@H]13
NCGC00485986-01	O=C1O[C@@H]2OCC(O)[C@@H](O)[C@H]2OC2C(O)C(OC3C(O)C(O)C(O)CO3)C(C(C)O2)OC(=O)CC(O)(C)CC(=O)O[C@@H]2[C@@H](O)[C@@H](O)[C@H](OC3C(O)C(O)C(CO)OC3OC3C(CO)(C)C4C(C)(C5C(C)(C6(C)C(C7C1(CC6)CCC(C)(C)C7)=CC5)CC4)CC3O)OC2		Inactive	Wnt signaling pathway Inhibitor		1	Tubeimoside I	363681465.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1O[C@@H]2OCC(O)[C@@H](O)[C@H]2OC2C(O)C(OC3C(O)C(O)C(O)CO3)C(C(C)O2)OC(=O)CC(O)(C)CC(=O)O[C@@H]2[C@@H](O)[C@@H](O)[C@H](OC3C(O)C(O)C(CO)OC3OC3C(CO)(C)C4C(C)(C5C(C)(C6(C)C(C7C1(CC6)CCC(C)(C)C7)=CC5)CC4)CC3O)OC2	O=C1O[C@@H]2OCC(O)[C@@H](O)[C@H]2OC2C(O)C(OC3C(O)C(O)C(O)CO3)C(C(C)O2)OC(=O)CC(O)(C)CC(=O)O[C@@H]2[C@@H](O)[C@@H](O)[C@H](OC3C(O)C(O)C(CO)OC3OC3C(CO)(C)C4C(C)(C5C(C)(C6(C)C(C7C1(CC6)CCC(C)(C)C7)=CC5)CC4)CC3O)OC2
NCGC00485142-01	O=C1O[C@@H]2[C@@H](C(=C)C)[C@@H]1[C@@]1(O)[C@@]3(C)[C@@H]2OC(=O)[C@@]23O[C@@H]2C1		Inactive	Glycine receptor subunit alpha-2 Blocker		1	Picrotoxinin	363681241.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1O[C@@H]2[C@@H](C(=C)C)[C@@H]1[C@@]1(O)[C@@]3(C)[C@@H]2OC(=O)[C@@]23O[C@@H]2C1	O=C1O[C@@H]2[C@@H](C(=C)C)[C@@H]1[C@@]1(O)[C@@]3(C)[C@@H]2OC(=O)[C@@]23O[C@@H]2C1
NCGC00482625-01	O=C1O[C@@H]2[C@@H](C(C)C)[C@H]1[C@H]1[C@@]3(C)[C@@H]2N(C)C[C@H]3CC1		Inactive			1	Dendrobine		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1O[C@@H]2[C@@H](C(C)C)[C@H]1[C@H]1[C@@]3(C)[C@@H]2N(C)C[C@H]3CC1	O=C1O[C@@H]2[C@@H](C(C)C)[C@H]1[C@H]1[C@@]3(C)[C@@H]2N(C)C[C@H]3CC1
NCGC00017246-10	O=C1O[C@@H]2[C@@H](C(O)(C)C)[C@H]1[C@@]1(O)[C@@]3(C)[C@@H]2OC(=O)[C@@]23O[C@@H]2C1		Inactive			1	PICROTIN		Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1O[C@@H]2[C@@H](C(O)(C)C)[C@H]1[C@@]1(O)[C@@]3(C)[C@@H]2OC(=O)[C@@]23O[C@@H]2C1	O=C1O[C@@H]2[C@@H](C(O)(C)C)[C@H]1[C@@]1(O)[C@@]3(C)[C@@H]2OC(=O)[C@@]23O[C@@H]2C1
NCGC00384575-01	O=C1O[C@@H]2[C@H](O)C3[C@](C)([C@H](O)[C@@H](O)CC3=C)C3[C@@H](O)[C@H](O)[C@H](C)C1[C@]23C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384575-01	363679253.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1O[C@@H]2[C@H](O)C3[C@](C)([C@H](O)[C@@H](O)CC3=C)C3[C@@H](O)[C@H](O)[C@H](C)C1[C@]23C	O=C1O[C@@H]2[C@H](O)C3[C@](C)([C@H](O)[C@@H](O)CC3=C)C3[C@@H](O)[C@H](O)[C@H](C)C1[C@]23C
NCGC00385365-01	O=C1O[C@@]2(C)C(C(C)(C)C[C@H](O)C2)=C1		Inactive	Estrogen receptor beta Modulator		1	NCGC00385365-01	363679703.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1O[C@@]2(C)C(C(C)(C)C[C@H](O)C2)=C1	O=C1O[C@@]2(C)C(C(C)(C)C[C@H](O)C2)=C1
NCGC00163620-03	O=C1O[C@@]2(C)[C@@H]([C@]3(C)[C@H](C(C)(C)CCC3)CC2)C1		Inactive	sesquiterpene natural product		1	Sclareolide	363676624.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1O[C@@]2(C)[C@@H]([C@]3(C)[C@H](C(C)(C)CCC3)CC2)C1	O=C1O[C@@]2(C)[C@@H]([C@]3(C)[C@H](C(C)(C)CCC3)CC2)C1
NCGC00164590-02&NCGC00164590-08	O=C1O[C@@]2([C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C([C@H]6[C@@H]4C6)=CC(=O)CC5)CC3)[C@H]3[C@@H]2C3)CC1		Inactive	Synthetic progesterone		2	Drospirenone	170464870.0&384568260.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1O[C@@]2([C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C([C@H]6[C@@H]4C6)=CC(=O)CC5)CC3)[C@H]3[C@@H]2C3)CC1	O=C1O[C@@]2([C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C([C@H]6[C@@H]4C6)=CC(=O)CC5)CC3)[C@H]3[C@@H]2C3)CC1
NCGC00380944-01	O=C1O[C@@]23[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O)CC5)CC4)C=C2)CC[C@]21C3[C@@H](C)[C@H](C)CC2		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Eucalyptus | Family: Myrtaceae | Species: acmenoides		1	NCGC00380944-01	363678876.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1O[C@@]23[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O)CC5)CC4)C=C2)CC[C@]21C3[C@@H](C)[C@H](C)CC2	O=C1O[C@@]23[C@](C)([C@@]4(C)C([C@]5(C)C(C(C)(C)[C@@H](O)CC5)CC4)C=C2)CC[C@]21C3[C@@H](C)[C@H](C)CC2
NCGC00380632-01	O=C1O[C@H](C)C[C@H](O)/C=C/[C@H](O)[C@@H](O)C1		Inactive	<MOA Unknown> | Class: macrolide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380632-01	363678682.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1O[C@H](C)C[C@H](O)/C=C/[C@H](O)[C@@H](O)C1	O=C1O[C@H](C)C[C@H](O)/C=C/[C@H](O)[C@@H](O)C1
NCGC00179938-02	O=C1O[C@H](C)[C@@]23C(=O)O[C@]4(C)[C@@H](O)[C@]5(C(=C)[C@@]6(C(C)(C)OC(=O)C=C6)CC[C@]5(C)[C@]12C4=C)O3		Inactive	<MOA Unknown> | Class: sesterterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00179938-02	363676992.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1O[C@H](C)[C@@]23C(=O)O[C@]4(C)[C@@H](O)[C@]5(C(=C)[C@@]6(C(C)(C)OC(=O)C=C6)CC[C@]5(C)[C@]12C4=C)O3	O=C1O[C@H](C)[C@@]23C(=O)O[C@]4(C)[C@@H](O)[C@]5(C(=C)[C@@]6(C(C)(C)OC(=O)C=C6)CC[C@]5(C)[C@]12C4=C)O3
NCGC00380859-01	O=C1O[C@H]2[C@H](O)C3C(C)(C)CCC[C@@]13c1c(O)c(O)c(C(C)C)cc21		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Rosmarinus | Family: N/A | Species: officinalis		1	NCGC00380859-01	363678818.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1O[C@H]2[C@H](O)C3C(C)(C)CCC[C@@]13c1c(O)c(O)c(C(C)C)cc21	O=C1O[C@H]2[C@H](O)C3C(C)(C)CCC[C@@]13c1c(O)c(O)c(C(C)C)cc21
NCGC00385309-01	O=C1O[C@H]2c3c(C)coc3C/C(/C)=C/CCC1=C2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385309-01	363679666.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1O[C@H]2c3c(C)coc3C/C(/C)=C/CCC1=C2	O=C1O[C@H]2c3c(C)coc3C/C(/C)=C/CCC1=C2
NCGC00181152-02&NCGC00181152-04	O=C1O[Pt+2]O[CH-]1		Inactive			2	Nedaplatin		Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1O[Pt+2]O[CH-]1	O=C1O[Pt+2]O[CH-]1
NCGC00016345-08&NCGC00016345-14	O=C1Oc2c(C(C)=C1)ccc(O)c2		Inactive	MAO-A Inhibitor		2	4-Methylumbelliferone	170465819.0&384567933.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1Oc2c(C(C)=C1)ccc(O)c2	O=C1Oc2c(C(C)=C1)ccc(O)c2
NCGC00016643-09&NCGC00016643-13	O=C1Oc2c(C)c3oc(C)cc3cc2C(C)=C1		Inactive	phototherapy treatment of skin disorders		2	Trioxsalen	170465339.0&384567955.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1Oc2c(C)c3oc(C)cc3cc2C(C)=C1	O=C1Oc2c(C)c3oc(C)cc3cc2C(C)=C1
NCGC00386569-01	O=C1Oc2c(N3CCN(Cc4ccc(-c5ccccc5)cc4)CC3)cccc2N1		Inactive			1	Bifeprunox mesylate	363680332.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1Oc2c(N3CCN(Cc4ccc(-c5ccccc5)cc4)CC3)cccc2N1	O=C1Oc2c(N3CCN(Cc4ccc(-c5ccccc5)cc4)CC3)cccc2N1
NCGC00017245-10&NCGC00017245-15	O=C1Oc2c(O)c(O)cc3C(=O)Oc4c(O)c(O)cc1c4-c23		Inactive	Aldose Reductase Inhibitor		2	Ellagic acid	170466649.0&384567979.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1Oc2c(O)c(O)cc3C(=O)Oc4c(O)c(O)cc1c4-c23	O=C1Oc2c(O)c(O)cc3C(=O)Oc4c(O)c(O)cc1c4-c23
NCGC00522008-01	O=C1Oc2c(c(O)ccc2C2=C1CNCC2)C1OCCCO1		Inactive	IRE1 Inhibitor		1	BI09	384569510.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.2426778279	O=C1Oc2c(c(O)ccc2C2=C1CNCC2)C1OCCCO1	O=C1Oc2c(c(O)ccc2C2=C1CNCC2)C1OCCCO1
NCGC00025208-05	O=C1Oc2c(c3c(cc2)cccc3)CC1		Inactive			1	Splitomicin	434146909.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1Oc2c(c3c(cc2)cccc3)CC1	O=C1Oc2c(c3c(cc2)cccc3)CC1
NCGC00017351-07	O=C1Oc2c(cc3c(occ3)c2)C=C1		Inactive			1	Psoralen	434147185.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1Oc2c(cc3c(occ3)c2)C=C1	O=C1Oc2c(cc3c(occ3)c2)C=C1
NCGC00091502-11&NCGC00091502-16	O=C1Oc2c(cccc2)C=C1		Inactive	Vitamin k epoxide reductase complex subunit 1 isoform 1 Inhibitor		2	Coumarin&COUMARIN	170465665.0&434146989.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1Oc2c(cccc2)C=C1	O=C1Oc2c(cccc2)C=C1
NCGC00091491-03	O=C1Oc2c(cccc2)CC1		Inactive			1	Hydrocoumarin		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1Oc2c(cccc2)CC1	O=C1Oc2c(cccc2)CC1
NCGC00388372-01	O=C1Oc2c3c(occ3)ccc2C=C1		Inactive			1	Angelicin	434147136.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1Oc2c3c(occ3)ccc2C=C1	O=C1Oc2c3c(occ3)ccc2C=C1
NCGC00095003-07	O=C1Sc2c(O1)cc(O)cc2		Inactive	Carbonic Anhydrase Type I Inhibitor		1	Tioxolone	384568140.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1Sc2c(O1)cc(O)cc2	O=C1Sc2c(O1)cc(O)cc2
NCGC00522019-01	O=C1[C@-](Cc2[nH]cnc2)N2C(=O)CCN[Zn+2]2O1		Inactive			1	Polaprezinc	405559035.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1[C@-](Cc2[nH]cnc2)N2C(=O)CCN[Zn+2]2O1	O=C1[C@-](Cc2[nH]cnc2)N2C(=O)CCN[Zn+2]2O1
NCGC00025342-07	O=C1[C@@H](C(O)(C)C)O[C@@H]2C([C@@]3(O)[C@@](C)([C@]4(C)[C@H](Cc5c6c([nH]c45)cccc6)CC3)CC2)=C1		Inactive	Sarcoplasmic/endoplasmic reticulum calcium ATPase 1  Inhibitor		1	PAXILLINE	363676542.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@H](C(O)(C)C)O[C@@H]2C([C@@]3(O)[C@@](C)([C@]4(C)[C@H](Cc5c6c([nH]c45)cccc6)CC3)CC2)=C1	O=C1[C@@H](C(O)(C)C)O[C@@H]2C([C@@]3(O)[C@@](C)([C@]4(C)[C@H](Cc5c6c([nH]c45)cccc6)CC3)CC2)=C1
NCGC00480752-01	O=C1[C@@H](C(O)CO)OC(=O)C1=O		Inactive			1	L-Dehydroascorbic acid	377020356.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@H](C(O)CO)OC(=O)C1=O	O=C1[C@@H](C(O)CO)OC(=O)C1=O
NCGC00380287-01	O=C1[C@@H](C)C/C=C/[C@H]2[C@H]3[C@@](C)([C@@H](C)[C@H]4[C@H](Cc5ccccc5)NC(=O)[C@@]24OC(=O)O/C=C/[C@]1(O)C)O3		Inactive	<MOA Unknown> | Class: polyketide/AS | Genus: N/A | Family: N/A | Species: N/A		1	Cytochalasin E from Aspergillus clavatus	363678524.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	16.6319290439	O=C1[C@@H](C)C/C=C/[C@H]2[C@H]3[C@@](C)([C@@H](C)[C@H]4[C@H](Cc5ccccc5)NC(=O)[C@@]24OC(=O)O/C=C/[C@]1(O)C)O3	O=C1[C@@H](C)C/C=C/[C@H]2[C@H]3[C@@](C)([C@@H](C)[C@H]4[C@H](Cc5ccccc5)NC(=O)[C@@]24OC(=O)O/C=C/[C@]1(O)C)O3
NCGC00346666-01	O=C1[C@@H](C)[C@@]2(O)[C@@H](O1)CC13[C@@H]4OC(=O)[C@]21O[C@@H]1OC(=O)[C@H](O)C31[C@H](C(C)(C)C)C4		Inactive	GABA(A) Receptor Antagonist		1	Ginkgolide A	174006218.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1[C@@H](C)[C@@]2(O)[C@@H](O1)CC13[C@@H]4OC(=O)[C@]21O[C@@H]1OC(=O)[C@H](O)C31[C@H](C(C)(C)C)C4	O=C1[C@@H](C)[C@@]2(O)[C@@H](O1)CC13[C@@H]4OC(=O)[C@]21O[C@@H]1OC(=O)[C@H](O)C31[C@H](C(C)(C)C)C4
NCGC00385448-01	O=C1[C@@H](C)[C@@]2(O)[C@H]([C@H](O)[C@]34[C@H]5[C@H](O)[C@@H](C(C)(C)C)[C@]63[C@H](O)C(=O)O[C@H]6O[C@]24C(=O)O5)O1		Inactive	Platelet activating factor receptor Antagonist		1	NCGC00385448-01	363679745.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@H](C)[C@@]2(O)[C@H]([C@H](O)[C@]34[C@H]5[C@H](O)[C@@H](C(C)(C)C)[C@]63[C@H](O)C(=O)O[C@H]6O[C@]24C(=O)O5)O1	O=C1[C@@H](C)[C@@]2(O)[C@H]([C@H](O)[C@]34[C@H]5[C@H](O)[C@@H](C(C)(C)C)[C@]63[C@H](O)C(=O)O[C@H]6O[C@]24C(=O)O5)O1
NCGC00169685-02	O=C1[C@@H](C)[C@H](C[C@@H](O)[C@@](O)(C)[C@@H]2[C@]3(C)[C@](O)(C4=CC(=O)[C@H]5[C@@](C)(C4CC3)C[C@H](O)[C@H](O)C5)CC2)[C@@H](C)O1		Inactive	<MOA Unknown> | Class: Steroid | Genus: Teucrium | Family: Labiatea | Species: sp.		1	NCGC00169685-02	363676864.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@H](C)[C@H](C[C@@H](O)[C@@](O)(C)[C@@H]2[C@]3(C)[C@](O)(C4=CC(=O)[C@H]5[C@@](C)(C4CC3)C[C@H](O)[C@H](O)C5)CC2)[C@@H](C)O1	O=C1[C@@H](C)[C@H](C[C@@H](O)[C@@](O)(C)[C@@H]2[C@]3(C)[C@](O)(C4=CC(=O)[C@H]5[C@@](C)(C4CC3)C[C@H](O)[C@H](O)C5)CC2)[C@@H](C)O1
NCGC00384836-01	O=C1[C@@H](C)[C@H]2O[C@@H](C[C@@H](CC)OC(=O)[C@H](C)[C@@H]3O[C@H](C[C@H](C)OC(=O)[C@@H](C)[C@H]4O[C@@H](C[C@@H](CC)OC(=O)[C@H](C)[C@@H]5O[C@H](C[C@H](CC)O1)CC5)CC4)CC3)CC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384836-01	363679384.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	19.890070916	O=C1[C@@H](C)[C@H]2O[C@@H](C[C@@H](CC)OC(=O)[C@H](C)[C@@H]3O[C@H](C[C@H](C)OC(=O)[C@@H](C)[C@H]4O[C@@H](C[C@@H](CC)OC(=O)[C@H](C)[C@@H]5O[C@H](C[C@H](CC)O1)CC5)CC4)CC3)CC2	O=C1[C@@H](C)[C@H]2O[C@@H](C[C@@H](CC)OC(=O)[C@H](C)[C@@H]3O[C@H](C[C@H](C)OC(=O)[C@@H](C)[C@H]4O[C@@H](C[C@@H](CC)OC(=O)[C@H](C)[C@@H]5O[C@H](C[C@H](CC)O1)CC5)CC4)CC3)CC2
NCGC00263447-01	O=C1[C@@H](C)[C@H]2[C@H](O1)C1=C(C)C(=O)C=C[C@]1(C)CC2		Inactive			1	alpha-Santonin	170465728.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C1[C@@H](C)[C@H]2[C@H](O1)C1=C(C)C(=O)C=C[C@]1(C)CC2	O=C1[C@@H](C)[C@H]2[C@H](O1)C1=C(C)C(=O)C=C[C@]1(C)CC2
NCGC00247310-03	O=C1[C@@H](C)[C@H]2[C@H](O1)[C@H]1[C@@](O)(C)C=CC(=O)[C@]1(C)CC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Artemisia | Family: N/A | Species: absinthium		1	NCGC00247310-03	363677158.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@H](C)[C@H]2[C@H](O1)[C@H]1[C@@](O)(C)C=CC(=O)[C@]1(C)CC2	O=C1[C@@H](C)[C@H]2[C@H](O1)[C@H]1[C@@](O)(C)C=CC(=O)[C@]1(C)CC2
NCGC00385311-01	O=C1[C@@H](C)[C@H]2[C@H](O1)[C@H]1[C@](O)(C)C=CC(=O)[C@]1(C)CC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Artemisia | Family: N/A | Species: absinthium		1	NCGC00385311-01	363679668.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@H](C)[C@H]2[C@H](O1)[C@H]1[C@](O)(C)C=CC(=O)[C@]1(C)CC2	O=C1[C@@H](C)[C@H]2[C@H](O1)[C@H]1[C@](O)(C)C=CC(=O)[C@]1(C)CC2
NCGC00384783-01	O=C1[C@@H](C)[C@H]2[C@H]([C@H](CC)[C@@H]3[C@H]4N(C(=O)C[C@H]24)CCCC3)O1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384783-01	363679351.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@H](C)[C@H]2[C@H]([C@H](CC)[C@@H]3[C@H]4N(C(=O)C[C@H]24)CCCC3)O1	O=C1[C@@H](C)[C@H]2[C@H]([C@H](CC)[C@@H]3[C@H]4N(C(=O)C[C@H]24)CCCC3)O1
NCGC00023339-16	O=C1[C@@H](CC)[C@@H](Cc2n(C)cnc2)CO1		Inactive	Muscarinic acetylcholine receptor M3 Agonist		1	Pilocarpine	170464845.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C1[C@@H](CC)[C@@H](Cc2n(C)cnc2)CO1	O=C1[C@@H](CC)[C@@H](Cc2n(C)cnc2)CO1
NCGC00249415-01	O=C1[C@@H](Cc2c(C)nc[nH]2)CCc2c(C)c3c(n12)cccc3		Inactive	5-hydroxytryptamine receptor 4 Antagonist		1	Fabesetron	144206751.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1[C@@H](Cc2c(C)nc[nH]2)CCc2c(C)c3c(n12)cccc3	O=C1[C@@H](Cc2c(C)nc[nH]2)CCc2c(C)c3c(n12)cccc3
NCGC00093674-07	O=C1[C@@H](N)CON1		Inactive			1	CYCLOSERINE (L)	434146992.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1[C@@H](N)CON1	O=C1[C@@H](N)CON1
NCGC00167491-06&NCGC00167491-14	O=C1[C@@H](N2C(=O)c3c(c(N)ccc3)C2)CCC(=O)N1		Inactive	TNF-alpha Production Inhibitor		2	Lenalidomide	434147237.0&384568318.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1[C@@H](N2C(=O)c3c(c(N)ccc3)C2)CCC(=O)N1	O=C1[C@@H](N2C(=O)c3c(c(N)ccc3)C2)CCC(=O)N1
NCGC00164524-02	O=C1[C@@H](O)[C@H]2OC(O)[C@H](O)[C@H]2O1		Inactive			1	D-Glucuronolactone	50111689.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1[C@@H](O)[C@H]2OC(O)[C@H](O)[C@H]2O1	O=C1[C@@H](O)[C@H]2OC(O)[C@H](O)[C@H]2O1
NCGC00385451-01	O=C1[C@@H](O)[C@]23[C@](O)(C(C)(C)C)C[C@@H]4OC(=O)C[C@]24C(=O)O[C@@H]3O1		Inactive	GABA(A) Receptor Antagonists		1	NCGC00385451-01	363679746.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@H](O)[C@]23[C@](O)(C(C)(C)C)C[C@@H]4OC(=O)C[C@]24C(=O)O[C@@H]3O1	O=C1[C@@H](O)[C@]23[C@](O)(C(C)(C)C)C[C@@H]4OC(=O)C[C@]24C(=O)O[C@@H]3O1
NCGC00384799-01	O=C1[C@@H](c2cocc2)OC[C@@]21[C@H](C)CC[C@@H]1C(C)=CC(=O)C[C@H]21		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384799-01	363679362.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@H](c2cocc2)OC[C@@]21[C@H](C)CC[C@@H]1C(C)=CC(=O)C[C@H]21	O=C1[C@@H](c2cocc2)OC[C@@]21[C@H](C)CC[C@@H]1C(C)=CC(=O)C[C@H]21
NCGC00024427-05&NCGC00024427-09	O=C1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CC2)CC3)C4)CC1		Inactive	mu-Opioid Antagonist		2	Naltrexone hydrochloride	170465207.0&384568028.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CC2)CC3)C4)CC1	O=C1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CC2)CC3)C4)CC1
NCGC00024674-14	O=C1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC=C)CC3)C4)CC1		Inactive			1	NCGC00024674-14		Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC=C)CC3)C4)CC1	O=C1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC=C)CC3)C4)CC1
NCGC00378877-01	O=C1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H]([N+](CC2CC2)(C)CC3)C4)CC1		Inactive			1	Methylnaltrexone Bromide	405558536.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H]([N+](CC2CC2)(C)CC3)C4)CC1	O=C1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H]([N+](CC2CC2)(C)CC3)C4)CC1
NCGC00485025-01	O=C1[C@@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)C1)CC[C@H](O)C2		Inactive			1	6-Ketocholestanol	363681193.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)C1)CC[C@H](O)C2	O=C1[C@@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)C1)CC[C@H](O)C2
NCGC00169138-03	O=C1[C@@H]2[C@@](O)([C@@H](O)c3c(O)cccc13)C(O)C(O)C1=C2C(=O)C[C@H](C)C1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169138-03	363676777.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@H]2[C@@](O)([C@@H](O)c3c(O)cccc13)C(O)C(O)C1=C2C(=O)C[C@H](C)C1	O=C1[C@@H]2[C@@](O)([C@@H](O)c3c(O)cccc13)C(O)C(O)C1=C2C(=O)C[C@H](C)C1
NCGC00384621-01	O=C1[C@@](O)(C(=C)C)C[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384621-01	363679277.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@](O)(C(=C)C)C[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1	O=C1[C@@](O)(C(=C)C)C[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1
NCGC00380309-01	O=C1[C@@](O)(C)[C@H](O)C=2C(=C1C)C=C(C)OC=2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380309-01	363678533.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@](O)(C)[C@H](O)C=2C(=C1C)C=C(C)OC=2	O=C1[C@@](O)(C)[C@H](O)C=2C(=C1C)C=C(C)OC=2
NCGC00378635-03	O=C1[C@@]2(C(C)C)O[C@H]2[C@@H]2O[C@]32[C@]2(C)[C@H](C4=C(C(=O)OC4)CC2)C[C@@H]2O[C@]132		Inactive	Immunosuppressants		1	Triptonide	384569060.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.68746564	O=C1[C@@]2(C(C)C)O[C@H]2[C@@H]2O[C@]32[C@]2(C)[C@H](C4=C(C(=O)OC4)CC2)C[C@@H]2O[C@]132	O=C1[C@@]2(C(C)C)O[C@H]2[C@@H]2O[C@]32[C@]2(C)[C@H](C4=C(C(=O)OC4)CC2)C[C@@H]2O[C@]132
NCGC00385045-01	O=C1[C@@]2(C(C)CC3(O)OC(=O)C4=C3C2CCC4)C[C@@H](c2cocc2)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385045-01	363679502.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@]2(C(C)CC3(O)OC(=O)C4=C3C2CCC4)C[C@@H](c2cocc2)O1	O=C1[C@@]2(C(C)CC3(O)OC(=O)C4=C3C2CCC4)C[C@@H](c2cocc2)O1
NCGC00090730-03	O=C1[C@@]2(C)C(C)(C)[C@@H](C1)CC2		Inactive			1	D-Camphor	170465497.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1[C@@]2(C)C(C)(C)[C@@H](C1)CC2	O=C1[C@@]2(C)C(C)(C)[C@@H](C1)CC2
NCGC00168809-03	O=C1[C@@]2(C)[C@@H](C3=CC(=O)OC3)CC[C@@]31C([C@]1(C)[C@@H](C[C@@H](OC4OC(C)C(OC5C(O)C(O)C(O)C(COC6C(O)C(O)C(O)C(CO)O6)O5)C(OC)C4)CC1)CC3)CC2		Inactive	<MOA Unknown> | Class: Steroid | Genus: Nerium | Family: Apocynaceae | Species: oleander		1	NCGC00168809-03	363676691.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@]2(C)[C@@H](C3=CC(=O)OC3)CC[C@@]31C([C@]1(C)[C@@H](C[C@@H](OC4OC(C)C(OC5C(O)C(O)C(O)C(COC6C(O)C(O)C(O)C(CO)O6)O5)C(OC)C4)CC1)CC3)CC2	O=C1[C@@]2(C)[C@@H](C3=CC(=O)OC3)CC[C@@]31C([C@]1(C)[C@@H](C[C@@H](OC4OC(C)C(OC5C(O)C(O)C(O)C(COC6C(O)C(O)C(O)C(CO)O6)O5)C(OC)C4)CC1)CC3)CC2
NCGC00380828-01	O=C1[C@@]2(C)[C@@H]3[C@@](C)([C@H]4[C@]5([C@@H](O)[C@@H]3O1)CC(=C)[C@@H](C5)CC4)CCC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380828-01	363678803.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@]2(C)[C@@H]3[C@@](C)([C@H]4[C@]5([C@@H](O)[C@@H]3O1)CC(=C)[C@@H](C5)CC4)CCC2	O=C1[C@@]2(C)[C@@H]3[C@@](C)([C@H]4[C@]5([C@@H](O)[C@@H]3O1)CC(=C)[C@@H](C5)CC4)CCC2
NCGC00380801-01	O=C1[C@@]2(CO)[C@@H]3[C@](C)([C@H]4[C@]5([C@@H](O)[C@@H]3O1)CC(=C)[C@@H](C5)CC4)CCC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380801-01	363678789.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@]2(CO)[C@@H]3[C@](C)([C@H]4[C@]5([C@@H](O)[C@@H]3O1)CC(=C)[C@@H](C5)CC4)CCC2	O=C1[C@@]2(CO)[C@@H]3[C@](C)([C@H]4[C@]5([C@@H](O)[C@@H]3O1)CC(=C)[C@@H](C5)CC4)CCC2
NCGC00092288-05	O=C1[C@@]2(O)C(N(c3ccccc3)CC2)=Nc2c1cc(C)cc2		Inactive	myosin II ATPase Inhibitor		1	(-)-Blebbistatin	363676556.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1[C@@]2(O)C(N(c3ccccc3)CC2)=Nc2c1cc(C)cc2	O=C1[C@@]2(O)C(N(c3ccccc3)CC2)=Nc2c1cc(C)cc2
NCGC00380697-01	O=C1[C@@]2([C@H](C)CC3OC(=O)C=4C(O)CCC2C3=4)C[C@@H](c2cocc2)O1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Teucrium | Family: Labiatae | Species: divaricatum		1	NCGC00380697-01	363678715.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@]2([C@H](C)CC3OC(=O)C=4C(O)CCC2C3=4)C[C@@H](c2cocc2)O1	O=C1[C@@]2([C@H](C)CC3OC(=O)C=4C(O)CCC2C3=4)C[C@@H](c2cocc2)O1
NCGC00180662-03	O=C1[C@@]2([C@H](C)CC[C@]3(C)C4(C)C(=O)O[C@]23CC4)C[C@H](c2cocc2)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Chiliotrichium | Family: N/A | Species: rosmarinifolium		1	NCGC00180662-03	363677045.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@]2([C@H](C)CC[C@]3(C)C4(C)C(=O)O[C@]23CC4)C[C@H](c2cocc2)O1	O=C1[C@@]2([C@H](C)CC[C@]3(C)C4(C)C(=O)O[C@]23CC4)C[C@H](c2cocc2)O1
NCGC00380706-01	O=C1[C@@]2([C@H](C)C[C@@H](O)[C@@]3(CO)C(CO)=CCC[C@H]23)C[C@@H](c2cocc2)O1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Teucrium | Family: Labiatae | Species: capitatum		1	NCGC00380706-01	363678723.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@]2([C@H](C)C[C@@H](O)[C@@]3(CO)C(CO)=CCC[C@H]23)C[C@@H](c2cocc2)O1	O=C1[C@@]2([C@H](C)C[C@@H](O)[C@@]3(CO)C(CO)=CCC[C@H]23)C[C@@H](c2cocc2)O1
NCGC00384904-01	O=C1[C@@]2([C@H](C)C[C@@H](O)[C@]34[C@H]([C@H](O)OC3)CCC[C@H]24)C[C@@H](c2cocc2)O1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Teucrium | Family: Labiatae | Species: capitatum		1	NCGC00384904-01	363679429.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@]2([C@H](C)C[C@@H](O)[C@]34[C@H]([C@H](O)OC3)CCC[C@H]24)C[C@@H](c2cocc2)O1	O=C1[C@@]2([C@H](C)C[C@@H](O)[C@]34[C@H]([C@H](O)OC3)CCC[C@H]24)C[C@@H](c2cocc2)O1
NCGC00169747-02	O=C1[C@@]2([C@H](C)C[C@@H](O)[C@]34[C@](CO)(OC3)CCC[C@H]24)C[C@@H](c2cocc2)O1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Teucrium | Family: Labiatae | Species: divaricatum		1	NCGC00169747-02	363676880.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@]2([C@H](C)C[C@@H](O)[C@]34[C@](CO)(OC3)CCC[C@H]24)C[C@@H](c2cocc2)O1	O=C1[C@@]2([C@H](C)C[C@@H](O)[C@]34[C@](CO)(OC3)CCC[C@H]24)C[C@@H](c2cocc2)O1
NCGC00385276-01	O=C1[C@@]2([C@H](C)C[C@@H](O)[C@]34[C@](CO)(OC3)C[C@@H](O)CC24)CC(c2cocc2)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385276-01	363679636.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@]2([C@H](C)C[C@@H](O)[C@]34[C@](CO)(OC3)C[C@@H](O)CC24)CC(c2cocc2)O1	O=C1[C@@]2([C@H](C)C[C@@H](O)[C@]34[C@](CO)(OC3)C[C@@H](O)CC24)CC(c2cocc2)O1
NCGC00385790-01	O=C1[C@@]2([C@H](C)[C@H](O)[C@@H]3OC(=O)C4=C3[C@@H]2CCC4)C[C@@H](c2cocc2)O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385790-01	363679939.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@@]2([C@H](C)[C@H](O)[C@@H]3OC(=O)C4=C3[C@@H]2CCC4)C[C@@H](c2cocc2)O1	O=C1[C@@]2([C@H](C)[C@H](O)[C@@H]3OC(=O)C4=C3[C@@H]2CCC4)C[C@@H](c2cocc2)O1
NCGC00095606-02	O=C1[C@H](C(C)C)CC[C@@H](C)C1		Inactive	TNF-alpha Inhibitor		1	(2S,5R)-5-Methyl-2-(propan-2-yl)cyclohexanone	170465578.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1[C@H](C(C)C)CC[C@@H](C)C1	O=C1[C@H](C(C)C)CC[C@@H](C)C1
NCGC00345085-02	O=C1[C@H](C(C)C)N(C)c2c3c([nH]cc3C[C@@H](CO)N1)ccc2	5.6500001	Active	lineage-specific differentiation enhancer	0.0	1	(-)-Indolactam V	384568733.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.3	97.5883132208	O=C1[C@H](C(C)C)N(C)c2c3c([nH]cc3C[C@@H](CO)N1)ccc2	O=C1[C@H](C(C)C)N(C)c2c3c([nH]cc3C[C@@H](CO)N1)ccc2
NCGC00263220-07	O=C1[C@H](C(C)C)NC(=O)/C(=C/C)/NC(=O)[C@@H]2NC(=O)[C@@H](C(C)C)NC(=O)C[C@H](O1)/C=C\CCSSC2		Inactive	HDAC Inhibitor		1	Romidepsin	384568674.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1[C@H](C(C)C)NC(=O)/C(=C/C)/NC(=O)[C@@H]2NC(=O)[C@@H](C(C)C)NC(=O)C[C@H](O1)/C=C\CCSSC2	O=C1[C@H](C(C)C)NC(=O)/C(=C/C)/NC(=O)[C@@H]2NC(=O)[C@@H](C(C)C)NC(=O)C[C@H](O1)/C=C\CCSSC2
NCGC00384552-01	O=C1[C@H](C)C2(O)[C@H]([C@H](O)[C@@]34[C@@]52C(=O)OC3[C@H](O)[C@@H](C(C)(C)C)C24[C@@H](O)C(=O)O[C@H]2O5)O1		Inactive	Platelet activating factor receptor Antagonist		1	NCGC00384552-01	363679241.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H](C)C2(O)[C@H]([C@H](O)[C@@]34[C@@]52C(=O)OC3[C@H](O)[C@@H](C(C)(C)C)C24[C@@H](O)C(=O)O[C@H]2O5)O1	O=C1[C@H](C)C2(O)[C@H]([C@H](O)[C@@]34[C@@]52C(=O)OC3[C@H](O)[C@@H](C(C)(C)C)C24[C@@H](O)C(=O)O[C@H]2O5)O1
NCGC00169614-02	O=C1[C@H](C)N2[C@]3(C)NC(=O)[C@H](N4C(=O)c5c(N=C34)cccc5)C[C@@]3(O)[C@@H]2N1c1c3cccc1		Inactive	<MOA Unknown> | Class: alkaloid | Genus: ct: Aspergillus | Family: N/A | Species: ct: fumigatus		1	NCGC00169614-02	363676848.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H](C)N2[C@]3(C)NC(=O)[C@H](N4C(=O)c5c(N=C34)cccc5)C[C@@]3(O)[C@@H]2N1c1c3cccc1	O=C1[C@H](C)N2[C@]3(C)NC(=O)[C@H](N4C(=O)c5c(N=C34)cccc5)C[C@@]3(O)[C@@H]2N1c1c3cccc1
NCGC00380614-01	O=C1[C@H](C)N[C@@H]2[C@](O)(C[C@@H]3C(=O)N[C@@H](C)C=4N3C(=O)c3c(N=4)cccc3)c3c(N12)cccc3		Inactive	<MOA Unknown> | Class: N/A | Genus: Aspergillus | Family: N/A | Species: fumigatus		1	NCGC00380614-01	363678671.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H](C)N[C@@H]2[C@](O)(C[C@@H]3C(=O)N[C@@H](C)C=4N3C(=O)c3c(N=4)cccc3)c3c(N12)cccc3	O=C1[C@H](C)N[C@@H]2[C@](O)(C[C@@H]3C(=O)N[C@@H](C)C=4N3C(=O)c3c(N=4)cccc3)c3c(N12)cccc3
NCGC00379024-02	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C\C[C@@H](/C(=C/c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C		Inactive	Tubulin depolymerization Inhibitor		1	Epothilone D	384569087.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	13.947425668	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C\C[C@@H](/C(=C/c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C\C[C@@H](/C(=C/c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C
NCGC00378665-02&NCGC00378665-03	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C/c2nc(C)sc2)/C)NC(=O)C[C@H](O)C1(C)C		Inactive	Microtubule-Stabilizing Agents		2	Ixabepilone	405558443.0&384569061.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C/c2nc(C)sc2)/C)NC(=O)C[C@H](O)C1(C)C	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C/c2nc(C)sc2)/C)NC(=O)C[C@H](O)C1(C)C
NCGC00181131-04&NCGC00181131-08	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C/c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C		Inactive	Tubulin depolymerization Inhibitor		2	Epothilone B	405558592.0&384568392.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C/c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C/c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C
NCGC00346505-02	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C/c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C		Inactive	Tubulin depolymerization Inhibitor		1	Epothilone A	363677432.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C/c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C	O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C/c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C
NCGC00384511-01	O=C1[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@@H]2[C@@H](C)[C@]3(C(=O)C[C@@H](C)[C@@H](C[C@@H](O)C)O3)O[C@@H]([C@@H]2C)CC[C@H](CC)/C=C/C=C/C[C@H](C)C(O)[C@@](O)(C)C(=O)[C@H](C)C(O)[C@@H]1C		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384511-01	363679222.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@@H]2[C@@H](C)[C@]3(C(=O)C[C@@H](C)[C@@H](C[C@@H](O)C)O3)O[C@@H]([C@@H]2C)CC[C@H](CC)/C=C/C=C/C[C@H](C)C(O)[C@@](O)(C)C(=O)[C@H](C)C(O)[C@@H]1C	O=C1[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@@H]2[C@@H](C)[C@]3(C(=O)C[C@@H](C)[C@@H](C[C@@H](O)C)O3)O[C@@H]([C@@H]2C)CC[C@H](CC)/C=C/C=C/C[C@H](C)C(O)[C@@](O)(C)C(=O)[C@H](C)C(O)[C@@H]1C
NCGC00380724-01	O=C1[C@H](C)[C@@H](OC2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@H](C)C[C@@H](C)C(=O)/C=C/[C@@](O)(C)[C@@H](CC)OC(=O)[C@@H]1C		Inactive	Streptococcus pyogenes Inhibitor		1	NCGC00380724-01	363678738.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H](C)[C@@H](OC2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@H](C)C[C@@H](C)C(=O)/C=C/[C@@](O)(C)[C@@H](CC)OC(=O)[C@@H]1C	O=C1[C@H](C)[C@@H](OC2[C@H](O)[C@@H](N(C)C)C[C@@H](C)O2)[C@@H](C)C[C@@H](C)C(=O)/C=C/[C@@](O)(C)[C@@H](CC)OC(=O)[C@@H]1C
NCGC00384729-01	O=C1[C@H](C)[C@@H]2O[C@H](C[C@H](C)OC(=O)[C@@H](C)[C@H]3O[C@@H](C[C@@H](CC)OC(=O)[C@H](C)[C@@H]4O[C@H](C[C@H](C)OC(=O)[C@@H](C)[C@H]5O[C@@H](C[C@@H](CC)O1)CC5)CC4)CC3)CC2		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384729-01	363679330.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	25.9592274679	O=C1[C@H](C)[C@@H]2O[C@H](C[C@H](C)OC(=O)[C@@H](C)[C@H]3O[C@@H](C[C@@H](CC)OC(=O)[C@H](C)[C@@H]4O[C@H](C[C@H](C)OC(=O)[C@@H](C)[C@H]5O[C@@H](C[C@@H](CC)O1)CC5)CC4)CC3)CC2	O=C1[C@H](C)[C@@H]2O[C@H](C[C@H](C)OC(=O)[C@@H](C)[C@H]3O[C@@H](C[C@@H](CC)OC(=O)[C@H](C)[C@@H]4O[C@H](C[C@H](C)OC(=O)[C@@H](C)[C@H]5O[C@@H](C[C@@H](CC)O1)CC5)CC4)CC3)CC2
NCGC00385887-01	O=C1[C@H](C)[C@@H]2[C@@H](O)CC(C)=C3C(=O)C=C(CO)[C@@H]3[C@H]2O1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385887-01	363679991.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H](C)[C@@H]2[C@@H](O)CC(C)=C3C(=O)C=C(CO)[C@@H]3[C@H]2O1	O=C1[C@H](C)[C@@H]2[C@@H](O)CC(C)=C3C(=O)C=C(CO)[C@@H]3[C@H]2O1
NCGC00161634-09	O=C1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2		Inactive	antimalarial agents		1	Artemisinin	384568213.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2	O=C1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2
NCGC00380972-01	O=C1[C@H](CC(C)C)NC(=O)[C@H]2N1[C@@H]1N3[C@@]4(C)[C@@H]([C@]5(C)C(C(C)(C)CCC5)CC4)C[C@@]1(c1c3cccc1)C2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380972-01	363678895.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H](CC(C)C)NC(=O)[C@H]2N1[C@@H]1N3[C@@]4(C)[C@@H]([C@]5(C)C(C(C)(C)CCC5)CC4)C[C@@]1(c1c3cccc1)C2	O=C1[C@H](CC(C)C)NC(=O)[C@H]2N1[C@@H]1N3[C@@]4(C)[C@@H]([C@]5(C)C(C(C)(C)CCC5)CC4)C[C@@]1(c1c3cccc1)C2
NCGC00381032-01	O=C1[C@H](CCCCCCCCC#C/C=C/CCC=C)[C@@H](O)[C@@H](C)O1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: Sapranthus | Family: Annonaceae | Species: nicaraguensis		1	NCGC00381032-01	363678935.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H](CCCCCCCCC#C/C=C/CCC=C)[C@@H](O)[C@@H](C)O1	O=C1[C@H](CCCCCCCCC#C/C=C/CCC=C)[C@@H](O)[C@@H](C)O1
NCGC00386111-01	O=C1[C@H](Cc2c(C(C=C)(C)C)[nH]c3c(CC=C(C)C)cc(CC=C(C)C)cc23)NC(=O)[C@H](C)N1		Inactive	Protein-tyrosine phosphatase 1B Inhibitor		1	NCGC00386111-01	363680111.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H](Cc2c(C(C=C)(C)C)[nH]c3c(CC=C(C)C)cc(CC=C(C)C)cc23)NC(=O)[C@H](C)N1	O=C1[C@H](Cc2c(C(C=C)(C)C)[nH]c3c(CC=C(C)C)cc(CC=C(C)C)cc23)NC(=O)[C@H](C)N1
NCGC00386110-01	O=C1[C@H](Cc2c(C(C=C)(C)C)[nH]c3c2cccc3)NC(=O)[C@H](C)N1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386110-01	363680110.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H](Cc2c(C(C=C)(C)C)[nH]c3c2cccc3)NC(=O)[C@H](C)N1	O=C1[C@H](Cc2c(C(C=C)(C)C)[nH]c3c2cccc3)NC(=O)[C@H](C)N1
NCGC00385485-01	O=C1[C@H](Cc2c(C(C=C)(C)C)[nH]c3c2cccc3)NC(=O)[C@H](Cc2c3c([nH]c2)cccc3)N1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385485-01	363679767.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H](Cc2c(C(C=C)(C)C)[nH]c3c2cccc3)NC(=O)[C@H](Cc2c3c([nH]c2)cccc3)N1	O=C1[C@H](Cc2c(C(C=C)(C)C)[nH]c3c2cccc3)NC(=O)[C@H](Cc2c3c([nH]c2)cccc3)N1
NCGC00016306-08&NCGC00016306-09	O=C1[C@H](N)CON1		Inactive	NMDA Glycine-Site Receptor Partial Agonist		2	D-Cycloserine	170465249.0&384567930.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1[C@H](N)CON1	O=C1[C@H](N)CON1
NCGC00344522-01	O=C1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1		Inactive	Calcium Chelating Agent		1	Gluconolactone	170465327.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1	O=C1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
NCGC00016024-05	O=C1[C@H](O)[C@@H](c2cc(O)c(O)cc2)Oc2c1c(O)cc(O)c2		Inactive			1	(±)-Taxifolin	90341784.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1[C@H](O)[C@@H](c2cc(O)c(O)cc2)Oc2c1c(O)cc(O)c2	O=C1[C@H](O)[C@@H](c2cc(O)c(O)cc2)Oc2c1c(O)cc(O)c2
NCGC00384766-01	O=C1[C@H](O)[C@@H]2[C@](C)([C@H](O)C(=O)C=C2C)C2[C@@H](O)[C@H]3[C@H](C)[C@H](C(=O)O3)[C@]12C	5.0	Active	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00384766-01	363679345.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	3.0	45.7109744544	O=C1[C@H](O)[C@@H]2[C@](C)([C@H](O)C(=O)C=C2C)C2[C@@H](O)[C@H]3[C@H](C)[C@H](C(=O)O3)[C@]12C	O=C1[C@H](O)[C@@H]2[C@](C)([C@H](O)C(=O)C=C2C)C2[C@@H](O)[C@H]3[C@H](C)[C@H](C(=O)O3)[C@]12C
NCGC00347491-02	O=C1[C@H](O)[C@@]2(O)C(=C)[C@@H](O)[C@]3(O)OC[C@@]42[C@H](O1)CC1[C@](C)([C@H](O)C(=O)C=C1C)C34		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347491-02	363677602.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H](O)[C@@]2(O)C(=C)[C@@H](O)[C@]3(O)OC[C@@]42[C@H](O1)CC1[C@](C)([C@H](O)C(=O)C=C1C)C34	O=C1[C@H](O)[C@@]2(O)C(=C)[C@@H](O)[C@]3(O)OC[C@@]42[C@H](O1)CC1[C@](C)([C@H](O)C(=O)C=C1C)C34
NCGC00347530-02	O=C1[C@H](O)[C@@]2(O)[C@@H](C)[C@@H](O)[C@H](O)C3[C@@]2(C)[C@H](O1)CC=1[C@]3(C)[C@H](O)[C@@H](O)CC=1C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347530-02	363677615.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H](O)[C@@]2(O)[C@@H](C)[C@@H](O)[C@H](O)C3[C@@]2(C)[C@H](O1)CC=1[C@]3(C)[C@H](O)[C@@H](O)CC=1C	O=C1[C@H](O)[C@@]2(O)[C@@H](C)[C@@H](O)[C@H](O)C3[C@@]2(C)[C@H](O1)CC=1[C@]3(C)[C@H](O)[C@@H](O)CC=1C
NCGC00384765-01	O=C1[C@H](O)[C@]2(O)[C@]3(C)[C@H](O1)CC1[C@](C)([C@H](O)[C@@H](O)CC1(O)C)C3[C@H](O)[C@H](O)C2C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384765-01	363679344.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H](O)[C@]2(O)[C@]3(C)[C@H](O1)CC1[C@](C)([C@H](O)[C@@H](O)CC1(O)C)C3[C@H](O)[C@H](O)C2C	O=C1[C@H](O)[C@]2(O)[C@]3(C)[C@H](O1)CC1[C@](C)([C@H](O)[C@@H](O)CC1(O)C)C3[C@H](O)[C@H](O)C2C
NCGC00025245-05	O=C1[C@H](O)[C@]23[C@H](C(C)(C)C)C[C@H]4OC(=O)[C@@]5([C@@]6(O)[C@H](C)C(=O)OC6[C@H](O)[C@@]245)O[C@@H]3O1		Inactive	GABA(A) Receptor Antagonist		1	Ginkgolide B	384568062.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1[C@H](O)[C@]23[C@H](C(C)(C)C)C[C@H]4OC(=O)[C@@]5([C@@]6(O)[C@H](C)C(=O)OC6[C@H](O)[C@@]245)O[C@@H]3O1	O=C1[C@H](O)[C@]23[C@H](C(C)(C)C)C[C@H]4OC(=O)[C@@]5([C@@]6(O)[C@H](C)C(=O)OC6[C@H](O)[C@@]245)O[C@@H]3O1
NCGC00346686-10	O=C1[C@H]([C@H](c2c3c4n(c2)CCCc4ccc3)C(=O)N1)c1c2c([nH]c1)cccc2		Inactive	HGFR Inhibitor		1	Tivantinib	384568910.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C1[C@H]([C@H](c2c3c4n(c2)CCCc4ccc3)C(=O)N1)c1c2c([nH]c1)cccc2	O=C1[C@H]([C@H](c2c3c4n(c2)CCCc4ccc3)C(=O)N1)c1c2c([nH]c1)cccc2
NCGC00180707-03	O=C1[C@H]2C(C)(C)CCC[C@]2(C)[C@@H](CC[C@@](O)(C=C)C)C(C)=C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Vitex | Family: N/A | Species: spp		1	NCGC00180707-03	363677051.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H]2C(C)(C)CCC[C@]2(C)[C@@H](CC[C@@](O)(C=C)C)C(C)=C1	O=C1[C@H]2C(C)(C)CCC[C@]2(C)[C@@H](CC[C@@](O)(C=C)C)C(C)=C1
NCGC00180650-02	O=C1[C@H]2C(C)(C)CCC[C@]2(C)[C@@](O)(CO)C(C)=C1		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: Aspergillus | Family: N/A | Species: cf niger		1	NCGC00180650-02	363677044.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H]2C(C)(C)CCC[C@]2(C)[C@@](O)(CO)C(C)=C1	O=C1[C@H]2C(C)(C)CCC[C@]2(C)[C@@](O)(CO)C(C)=C1
NCGC00385289-01	O=C1[C@H]2OC(=O)[C@]3([C@@H]2C(C)(C)CCC3)c2c(O)c(O)c(C(C)C)cc12		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385289-01	363679648.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H]2OC(=O)[C@]3([C@@H]2C(C)(C)CCC3)c2c(O)c(O)c(C(C)C)cc12	O=C1[C@H]2OC(=O)[C@]3([C@@H]2C(C)(C)CCC3)c2c(O)c(O)c(C(C)C)cc12
NCGC00385915-01	O=C1[C@H]2[C@@](C)(O2)CC/C=C(\C)/Cc2occ(C)c12		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385915-01	363680004.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H]2[C@@](C)(O2)CC/C=C(\C)/Cc2occ(C)c12	O=C1[C@H]2[C@@](C)(O2)CC/C=C(\C)/Cc2occ(C)c12
NCGC00163547-01	O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)(C([C@@H]([C@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2		Inactive	Steroid prohormone		1	Ecdysone	26756928.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)(C([C@@H]([C@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2	O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)(C([C@@H]([C@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2
NCGC00390385-01	O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@@H]([C@@](O)([C@H](O)CCC(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2		Inactive	Ecdysone receptor Activator		1	PonasteroneA	363680885.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@@H]([C@@](O)([C@H](O)CCC(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2	O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@@H]([C@@](O)([C@H](O)CCC(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2
NCGC00346709-02	O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@@H]([C@@](O)([C@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2		Inactive	reduces expression of cPEPCK		1	20-hydroxyecdysone	384568926.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@@H]([C@@](O)([C@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2	O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@@H]([C@@](O)([C@H](O)CCC(O)(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2
NCGC00169882-02	O=C1[C@H]2[C@H]([C@@H](O)C=C1)CC(=O)OC(C)CCCC2	4.9499998	Active	<MOA Unknown> | Class: macrolide | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00169882-02	363676903.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	3.0	55.3552175057	O=C1[C@H]2[C@H]([C@@H](O)C=C1)CC(=O)OC(C)CCCC2	O=C1[C@H]2[C@H]([C@@H](O)C=C1)CC(=O)OC(C)CCCC2
NCGC00380626-01	O=C1[C@](O)(C)C[C@@H](O)C(/C=C/C(O)(C)C)=C1		Inactive	<MOA Unknown> | Class: polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380626-01	363678679.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@](O)(C)C[C@@H](O)C(/C=C/C(O)(C)C)=C1	O=C1[C@](O)(C)C[C@@H](O)C(/C=C/C(O)(C)C)=C1
NCGC00167831-05	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(c(CC)c4C3)cc(O)cc5)=C2)CO1		Inactive	DNA Topoisomerase I Inhibitor		1	SN-38	363676672.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(c(CC)c4C3)cc(O)cc5)=C2)CO1	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(c(CC)c4C3)cc(O)cc5)=C2)CO1
NCGC00506803-01	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(c(CCNC(C)C)c4C3)cccc5)=C2)CO1		Inactive	DNA Topoisomerase I Inhibitor		1	Belotecan	384569319.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(c(CCNC(C)C)c4C3)cccc5)=C2)CO1	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(c(CCNC(C)C)c4C3)cccc5)=C2)CO1
NCGC00014925-06	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(c(CN(C)C)c(O)cc5)cc4C3)=C2)CO1		Inactive	DNA Topoisomerase I Inhibitor		1	Topotecan hydrochloride	170465137.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(c(CN(C)C)c(O)cc5)cc4C3)=C2)CO1.Cl	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(c(CN(C)C)c(O)cc5)cc4C3)=C2)CO1.Cl
NCGC00095986-04	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(cc(O)cc5)cc4C3)=C2)CO1		Inactive	DNA Topoisomerase I Inhibitor		1	10-hydroxycamptothecin	363676578.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(cc(O)cc5)cc4C3)=C2)CO1	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(cc(O)cc5)cc4C3)=C2)CO1
NCGC00016994-20	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(cc4C3)cccc5)=C2)CO1		Inactive	DNA Topoisomerase I Inhibitor		1	Camptothecin	384567973.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(cc4C3)cccc5)=C2)CO1	O=C1[C@](O)(CC)C2=C(C(=O)N3C(c4nc5c(cc4C3)cccc5)=C2)CO1
NCGC00380805-01	O=C1[C@]2(C(C)(C)C3[C@@]4(N(C)C(=O)[C@]5([C@@H](C)CCN5C4)C3)C2)c2c(N1)c1OC=CC(C)(C)Oc1cc2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380805-01	363678791.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@]2(C(C)(C)C3[C@@]4(N(C)C(=O)[C@]5([C@@H](C)CCN5C4)C3)C2)c2c(N1)c1OC=CC(C)(C)Oc1cc2	O=C1[C@]2(C(C)(C)C3[C@@]4(N(C)C(=O)[C@]5([C@@H](C)CCN5C4)C3)C2)c2c(N1)c1OC=CC(C)(C)Oc1cc2
NCGC00347802-02	O=C1[C@]2(C(C)(C)C3[C@@]4(N(C)C(=O)[C@]5([C@@](O)(C)CCN5C4)C3)C2)c2c(N1)c1OC=CC(C)(C)Oc1cc2		Inactive	<MOA Unknown> | Class: alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	paraherquamide A	363677690.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@]2(C(C)(C)C3[C@@]4(N(C)C(=O)[C@]5([C@@](O)(C)CCN5C4)C3)C2)c2c(N1)c1OC=CC(C)(C)Oc1cc2	O=C1[C@]2(C(C)(C)C3[C@@]4(N(C)C(=O)[C@]5([C@@](O)(C)CCN5C4)C3)C2)c2c(N1)c1OC=CC(C)(C)Oc1cc2
NCGC00485432-01	O=C1[C@]2(C(C)C)[C@H](C(C)=C1)C2	4.9000001	Active	Transient receptor potential cation channel subfamily M member 8 Agonist	0.0	1	(-)-Umbellulone	363681336.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	3.0	41.8235990399	O=C1[C@]2(C(C)C)[C@H](C(C)=C1)C2	O=C1[C@]2(C(C)C)[C@H](C(C)=C1)C2
NCGC00380396-01	O=C1[C@]2(C(CO)=C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1	5.1999998	Active	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00380396-01	363678566.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	2.2	43.4616840083	O=C1[C@]2(C(CO)=C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1	O=C1[C@]2(C(CO)=C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1
NCGC00018176-05	O=C1[C@]2(C)C(C3C(c4c(cc(O)cc4)CC3)CC2)CC1		Inactive	Steroid hormone		1	Estrone	384567995.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1[C@]2(C)C(C3C(c4c(cc(O)cc4)CC3)CC2)CC1	O=C1[C@]2(C)C(C3C(c4c(cc(O)cc4)CC3)CC2)CC1
NCGC00169423-02	O=C1[C@]2(C)C3[C@](C)([C@@](O)(CCC=4C(O)OC(=O)C=4)[C@H](C)C[C@H]3O1)CCC2		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Mentha | Family: Lamiaceae | Species: longifolia		1	NCGC00169423-02	363676815.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@]2(C)C3[C@](C)([C@@](O)(CCC=4C(O)OC(=O)C=4)[C@H](C)C[C@H]3O1)CCC2	O=C1[C@]2(C)C3[C@](C)([C@@](O)(CCC=4C(O)OC(=O)C=4)[C@H](C)C[C@H]3O1)CCC2
NCGC00023902-09	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1		Inactive	Cytochrome P450 19A1 Substrate		1	4-Androstene-3,17-dione	170465907.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1
NCGC00093802-06&NCGC00093802-09	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1		Inactive	Steroid hormone		2	Dehydroepiandrosterone	170465614.0&363676565.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1
NCGC00485031-01	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@H](C[C@H](O)CC4)CC3)CC2)CC1		Inactive	Glucose-6-phosphate 1-dehydrogenase Inhibitor		1	Etiocholan-3Î±-ol-17-one	363681198.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@H](C[C@H](O)CC4)CC3)CC2)CC1	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@H](C[C@H](O)CC4)CC3)CC2)CC1
NCGC00142619-04	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](C[C@@H](O)CC4)CC3)CC2)CC1		Inactive	Glucose-6-phosphate 1-dehydrogenase Inhibitor		1	Epiandrosterone	363676583.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](C[C@@H](O)CC4)CC3)CC2)CC1	O=C1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](C[C@@H](O)CC4)CC3)CC2)CC1
NCGC00485311-01	O=C1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(c(O)c(O)cc4)CC3)CC2)CC1		Inactive	Estrogen receptor Partial Agonist		1	4-Hydroxyestrone	363681284.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(c(O)c(O)cc4)CC3)CC2)CC1	O=C1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(c(O)c(O)cc4)CC3)CC2)CC1
NCGC00023643-15	O=C1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1		Inactive	Steroid hormone		1	Estrone	170465020.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1	O=C1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1
NCGC00485120-01	O=C1[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1		Inactive			1	4-Androsten-11Î²-ol-3,17-dione	363681230.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1	O=C1[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1
NCGC00347571-02	O=C1[C@]2(C)[C@H]3[C@H](C)[C@@]4(O[C@H]3CC2C2C([C@]3(C)[C@H](C[C@@H](O)CC3)CC2)=C1)OC[C@@H](C)CC4		Inactive	<MOA Unknown> | Class: Steroide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347571-02	363677626.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@]2(C)[C@H]3[C@H](C)[C@@]4(O[C@H]3CC2C2C([C@]3(C)[C@H](C[C@@H](O)CC3)CC2)=C1)OC[C@@H](C)CC4	O=C1[C@]2(C)[C@H]3[C@H](C)[C@@]4(O[C@H]3CC2C2C([C@]3(C)[C@H](C[C@@H](O)CC3)CC2)=C1)OC[C@@H](C)CC4
NCGC00384756-01	O=C1[C@]2(C)[C@H]3[C@H](C)[C@@]4(O[C@H]3CC2C2C([C@]3(C)[C@H](C[C@@H](O)CC3)CC2)C1)OC[C@@H](C)CC4		Inactive	<MOA Unknown> | Class: Steroide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384756-01	363679339.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@]2(C)[C@H]3[C@H](C)[C@@]4(O[C@H]3CC2C2C([C@]3(C)[C@H](C[C@@H](O)CC3)CC2)C1)OC[C@@H](C)CC4	O=C1[C@]2(C)[C@H]3[C@H](C)[C@@]4(O[C@H]3CC2C2C([C@]3(C)[C@H](C[C@@H](O)CC3)CC2)C1)OC[C@@H](C)CC4
NCGC00384758-01	O=C1[C@]2(C)[C@H]3[C@H](C)[C@@]4(O[C@H]3CC2C2C([C@]3(C)[C@H](C[C@@H](O)[C@H](O)C3)CC2)=C1)OC[C@@H](C)CC4		Inactive	<MOA Unknown> | Class: Steroid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384758-01	363679340.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@]2(C)[C@H]3[C@H](C)[C@@]4(O[C@H]3CC2C2C([C@]3(C)[C@H](C[C@@H](O)[C@H](O)C3)CC2)=C1)OC[C@@H](C)CC4	O=C1[C@]2(C)[C@H]3[C@H](C)[C@@]4(O[C@H]3CC2C2C([C@]3(C)[C@H](C[C@@H](O)[C@H](O)C3)CC2)=C1)OC[C@@H](C)CC4
NCGC00025212-08	O=C1[C@]2(C)[C@](C)(C(=O)O1)C1OC2CC1		Inactive	PP-1 Inhibitors;PP-2A Inhibitors		1	Cantharidin	170465704.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C1[C@]2(C)[C@](C)(C(=O)O1)C1OC2CC1	O=C1[C@]2(C)[C@](C)(C(=O)O1)C1OC2CC1
NCGC00025212-26	O=C1[C@]2(C)[C@](C)(C(=O)O1)[C@@H]1O[C@H]2CC1		Inactive			1	Cantharidin	384568057.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C1[C@]2(C)[C@](C)(C(=O)O1)[C@@H]1O[C@H]2CC1	O=C1[C@]2(C)[C@](C)(C(=O)O1)[C@@H]1O[C@H]2CC1
NCGC00169088-03	O=C1[C@]2(N(C)C(=O)c3c(N1)cccc3)[C@@H](c1cc(O)ccc1)O2		Inactive	Protein-tyrosine phosphatase 1B Inhibitor		1	NCGC00169088-03	363676767.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@]2(N(C)C(=O)c3c(N1)cccc3)[C@@H](c1cc(O)ccc1)O2	O=C1[C@]2(N(C)C(=O)c3c(N1)cccc3)[C@@H](c1cc(O)ccc1)O2
NCGC00169192-02	O=C1[C@]2(N(C)C(=O)c3c(N1)cccc3)[C@@H](c1ccccc1)O2		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Fusarium | Family: N/A | Species: N/A		1	NCGC00169192-02	363676787.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@]2(N(C)C(=O)c3c(N1)cccc3)[C@@H](c1ccccc1)O2	O=C1[C@]2(N(C)C(=O)c3c(N1)cccc3)[C@@H](c1ccccc1)O2
NCGC00017354-07	O=C1[C@]2(O)O[C@@H]3[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@H]3O[C@@H]2O[C@H](C)C1		Inactive	Antibiotic		1	Spectinomycin dihydrochloride	170465149.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1[C@]2(O)O[C@@H]3[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@H]3O[C@@H]2O[C@H](C)C1.Cl.Cl	O=C1[C@]2(O)O[C@@H]3[C@@H](NC)[C@@H](O)[C@@H](NC)[C@H](O)[C@H]3O[C@@H]2O[C@H](C)C1.Cl.Cl
NCGC00180418-02	O=C1[C@]2(O)[C@@]3(C)[C@H]([C@@]4(C)C(C(=O)O[C@H](c5cocc5)C4)CC3)[C@H](O1)C=C2		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Euphorbia | Family: Euphorbiaceae | Species: depauperata		1	NCGC00180418-02	363677022.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@]2(O)[C@@]3(C)[C@H]([C@@]4(C)C(C(=O)O[C@H](c5cocc5)C4)CC3)[C@H](O1)C=C2	O=C1[C@]2(O)[C@@]3(C)[C@H]([C@@]4(C)C(C(=O)O[C@H](c5cocc5)C4)CC3)[C@H](O1)C=C2
NCGC00180567-02	O=C1[C@]2(O)[C@]3(C)[C@@H]([C@H](O)C=C2CO1)C(C)(C)CCC3		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180567-02	363677037.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@]2(O)[C@]3(C)[C@@H]([C@H](O)C=C2CO1)C(C)(C)CCC3	O=C1[C@]2(O)[C@]3(C)[C@@H]([C@H](O)C=C2CO1)C(C)(C)CCC3
NCGC00168858-02	O=C1[C@]2(O)[C@]3(C)[C@@H]([C@H](O)C=C2CO1)C(C)(C)C[C@H](O)C3		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00168858-02	363676706.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1[C@]2(O)[C@]3(C)[C@@H]([C@H](O)C=C2CO1)C(C)(C)C[C@H](O)C3	O=C1[C@]2(O)[C@]3(C)[C@@H]([C@H](O)C=C2CO1)C(C)(C)C[C@H](O)C3
NCGC00346951-01	O=C1c2[n+](-c3c1cccc3)ccc1c2[nH]c2c1cccc2		Inactive	CDK4/6 Inhibitor		1	Fascaplysin	174007091.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C1c2[n+](-c3c1cccc3)ccc1c2[nH]c2c1cccc2	O=C1c2[n+](-c3c1cccc3)ccc1c2[nH]c2c1cccc2
NCGC00263222-02	O=C1c2c(C(=O)C=3OC(C)(C)[C@@H](O)[C@@H](NCc4ccccc4)C1=3)cccc2		Inactive	IDO Inhibitor		1	CAY-10581	384568676.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1c2c(C(=O)C=3OC(C)(C)[C@@H](O)[C@@H](NCc4ccccc4)C1=3)cccc2	O=C1c2c(C(=O)C=3OC(C)(C)[C@@H](O)[C@@H](NCc4ccccc4)C1=3)cccc2
NCGC00094960-06&NCGC00094960-07	O=C1c2c(C(=O)c3c1cccc3)cccc2		Inactive	Beta amyloid A4 protein Binding Agent		2	Anthraquinone&ANTHRAQUINONE	170466833.0&434146876.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1c2c(C(=O)c3c1cccc3)cccc2	O=C1c2c(C(=O)c3c1cccc3)cccc2
NCGC00385992-01	O=C1c2c(N(C)C(CCCCC/C=C\CCCC)=C1)cccc2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385992-01	363680047.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1c2c(N(C)C(CCCCC/C=C\CCCC)=C1)cccc2	O=C1c2c(N(C)C(CCCCC/C=C\CCCC)=C1)cccc2
NCGC00016622-11	O=C1c2c(NCCN(CC)CC)ccc(CO)c2Sc2c1cccc2	5.125	Active		0.0	1	Hycanthone	434146889.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	3.0&1.2	49.4339701761&73.9495987434	O=C1c2c(NCCN(CC)CC)ccc(CO)c2Sc2c1cccc2	O=C1c2c(NCCN(CC)CC)ccc(CO)c2Sc2c1cccc2
NCGC00487207-01	O=C1c2c(NCCN(CC)CC)ccc3ncn(c23)-c2c1cc(O)cc2		Inactive			1	Symadex	377020156.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1c2c(NCCN(CC)CC)ccc3ncn(c23)-c2c1cc(O)cc2	O=C1c2c(NCCN(CC)CC)ccc3ncn(c23)-c2c1cc(O)cc2
NCGC00274280-01	O=C1c2c(NCCN)ccc(NCCN)c2C(=O)c2c1cncc2		Inactive	DNA Modulator		1	Pixantronemaleate	225144373.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1c2c(NCCN)ccc(NCCN)c2C(=O)c2c1cncc2	O=C1c2c(NCCN)ccc(NCCN)c2C(=O)c2c1cncc2
NCGC00482644-02	O=C1c2c(O)c(O)c(O)cc2OC(c2ccc(O)cc2)=C1		Inactive			1	Scutellarein	434147154.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1c2c(O)c(O)c(O)cc2OC(c2ccc(O)cc2)=C1	O=C1c2c(O)c(O)c(O)cc2OC(c2ccc(O)cc2)=C1
NCGC00017236-16	O=C1c2c(O)c(O)c(O)cc2OC(c2ccccc2)=C1		Inactive	Cyp2C9 Inhibitor		1	Baicalein	384567977.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	14.5528089839&0.0	O=C1c2c(O)c(O)c(O)cc2OC(c2ccccc2)=C1	O=C1c2c(O)c(O)c(O)cc2OC(c2ccccc2)=C1
NCGC00095227-06	O=C1c2c(O)c(O)ccc2C(=O)c2c1cccc2		Inactive	Calcium Binding Agent		1	Alizarin	170465641.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1c2c(O)c(O)ccc2C(=O)c2c1cccc2	O=C1c2c(O)c(O)ccc2C(=O)c2c1cccc2
NCGC00163618-01	O=C1c2c(O)c(c(OC3C(O)C(O)C(O)C(CO)O3)cc2OC(c2ccc(O)cc2)=C1)C1C(O)C(O)C(O)C(CO)O1		Inactive			1	SAPONARIN	26756999.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1c2c(O)c(c(OC3C(O)C(O)C(O)C(CO)O3)cc2OC(c2ccc(O)cc2)=C1)C1C(O)C(O)C(O)C(CO)O1	O=C1c2c(O)c(c(OC3C(O)C(O)C(O)C(CO)O3)cc2OC(c2ccc(O)cc2)=C1)C1C(O)C(O)C(O)C(CO)O1
NCGC00091823-01&NCGC00091823-09	O=C1c2c(O)cc(C)cc2C(=O)c2c1c(O)ccc2		Inactive	VEGFR-1/2 Inhibitor		2	Chrysophanol	17389107.0&384568098.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1c2c(O)cc(C)cc2C(=O)c2c1c(O)ccc2	O=C1c2c(O)cc(C)cc2C(=O)c2c1c(O)ccc2
NCGC00163510-01	O=C1c2c(O)cc(CO)cc2C(=O)c2c1c(O)ccc2		Inactive	Caspase 3 Activator		1	Aloe-emodin	26756894.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1c2c(O)cc(CO)cc2C(=O)c2c1c(O)ccc2	O=C1c2c(O)cc(CO)cc2C(=O)c2c1c(O)ccc2
NCGC00183867-02&NCGC00183867-06	O=C1c2c(O)cc(CO)cc2[C@@H]([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c1c(O)ccc2		Inactive			2	Aloin&ALOIN	434147060.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1c2c(O)cc(CO)cc2[C@@H]([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c1c(O)ccc2	O=C1c2c(O)cc(CO)cc2[C@@H]([C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c2c1c(O)ccc2
NCGC00247542-02	O=C1c2c(O)cc(O)c(-c3c(O)ccc(C=4Oc5c(c(O)cc(O)c5)C(=O)C=4)c3)c2OC(c2ccc(O)cc2)=C1		Inactive			1	Amentoflavone	434147240.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1c2c(O)cc(O)c(-c3c(O)ccc(C=4Oc5c(c(O)cc(O)c5)C(=O)C=4)c3)c2OC(c2ccc(O)cc2)=C1	O=C1c2c(O)cc(O)c(-c3c(O)ccc(C=4Oc5c(c(O)cc(O)c5)C(=O)C=4)c3)c2OC(c2ccc(O)cc2)=C1
NCGC00482848-01	O=C1c2c(O)cc(O)c([C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)c2OC(c2cc(O)c(O)cc2)=C1		Inactive			1	Orientin	434147158.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1c2c(O)cc(O)c([C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)c2OC(c2cc(O)c(O)cc2)=C1	O=C1c2c(O)cc(O)c([C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)c2OC(c2cc(O)c(O)cc2)=C1
NCGC00015420-15	O=C1c2c(O)cc(O)cc2C(=O)c2c1c(O)cc(C)c2		Inactive	Casein Kinase 2 Inhibitor		1	Emodin	384567841.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.645684444	O=C1c2c(O)cc(O)cc2C(=O)c2c1c(O)cc(C)c2	O=C1c2c(O)cc(O)cc2C(=O)c2c1c(O)cc(C)c2
NCGC00169062-04	O=C1c2c(O)cc(O)cc2CC(=O)OC(C)CCCC2OC12		Inactive	<MOA Unknown> | Class: macrolide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169062-04	363676758.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1c2c(O)cc(O)cc2CC(=O)OC(C)CCCC2OC12	O=C1c2c(O)cc(O)cc2CC(=O)OC(C)CCCC2OC12
NCGC00016467-10	O=C1c2c(O)cc(O)cc2OC(c2cc(O)c(O)cc2)=C1		Inactive	alpha-Glucosidase Inhibitor		1	Digitoflavone	384567943.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1c2c(O)cc(O)cc2OC(c2cc(O)c(O)cc2)=C1	O=C1c2c(O)cc(O)cc2OC(c2cc(O)c(O)cc2)=C1
NCGC00015049-24	O=C1c2c(O)cc(O)cc2OC(c2ccc(O)cc2)=C1		Inactive	NMDA Receptor Antagonist		1	Apigenin	384567801.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1c2c(O)cc(O)cc2OC(c2ccc(O)cc2)=C1	O=C1c2c(O)cc(O)cc2OC(c2ccc(O)cc2)=C1
NCGC00016456-20	O=C1c2c(O)cc(O)cc2OC(c2ccccc2)=C1		Inactive	Antiinflammatory Drug		1	Chrysine	384567941.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1c2c(O)cc(O)cc2OC(c2ccccc2)=C1	O=C1c2c(O)cc(O)cc2OC(c2ccccc2)=C1
NCGC00016457-02	O=C1c2c(O)cc(O)cc2O[C@H](c2ccc(O)cc2)C1		Inactive	Estrogen Receptor (ER) beta Agonist		1	Naringenin	124882284.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1c2c(O)cc(O)cc2O[C@H](c2ccc(O)cc2)C1	O=C1c2c(O)cc(O)cc2O[C@H](c2ccc(O)cc2)C1
NCGC00015693-09&NCGC00015693-13&NCGC00015693-19	O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c12		Inactive	DNA Topoisomerase II Inhibitor		3	Mitoxantrone	170465183.0&434146945.0&384567882.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0		O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c12.Cl.Cl	O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c12.Cl.Cl&O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c12
NCGC00346890-02	O=C1c2c(O)ccc(O)c2C(=O)c2c(NCC[N+]([O-])(C)C)ccc(NCC[N+]([O-])(C)C)c12		Inactive	DNA Topoisomerase II Inhibitor		1	Banoxantrone	384568963.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1c2c(O)ccc(O)c2C(=O)c2c(NCC[N+]([O-])(C)C)ccc(NCC[N+]([O-])(C)C)c12	O=C1c2c(O)ccc(O)c2C(=O)c2c(NCC[N+]([O-])(C)C)ccc(NCC[N+]([O-])(C)C)c12
NCGC00091367-05&NCGC00091367-08	O=C1c2c(O)cccc2C(=O)c2c1c(O)ccc2		Inactive	DNA topoisomerase II alpha Inhibitor		2	Danthron&DANTHRON	170465532.0&434146873.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=C1c2c(O)cccc2C(=O)c2c1c(O)ccc2	O=C1c2c(O)cccc2C(=O)c2c1c(O)ccc2
NCGC00091330-07	O=C1c2c(O)cccc2Cc2c1c(O)ccc2		Inactive			1	Anthralin	170466655.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1c2c(O)cccc2Cc2c1c(O)ccc2	O=C1c2c(O)cccc2Cc2c1c(O)ccc2
NCGC00165840-04	O=C1c2c(OC(N3CCOCC3)=C1)c1c(cc2)cccc1		Inactive			1	NU7026		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1c2c(OC(N3CCOCC3)=C1)c1c(cc2)cccc1	O=C1c2c(OC(N3CCOCC3)=C1)c1c(cc2)cccc1
NCGC00387229-03	O=C1c2c(OC(c3ccc(C(C)C)cc3)=C1)cccc2		Inactive	Tankyrase-2 Inhibitor		1	MN-64	363680583.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1c2c(OC(c3ccc(C(C)C)cc3)=C1)cccc2	O=C1c2c(OC(c3ccc(C(C)C)cc3)=C1)cccc2
NCGC00179903-03	O=C1c2c(OC(c3ccccc3)=C1)ccc(O)c2		Inactive			1	6-HYDROXYFLAVONE	377020312.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1c2c(OC(c3ccccc3)=C1)ccc(O)c2	O=C1c2c(OC(c3ccccc3)=C1)ccc(O)c2
NCGC00095802-05	O=C1c2c(OC(c3ccccc3)C1)cccc2		Inactive			1	Flavanone	434147212.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1c2c(OC(c3ccccc3)C1)cccc2	O=C1c2c(OC(c3ccccc3)C1)cccc2
NCGC00370972-01	O=C1c2c(O[C@H](c3ccc(O)cc3)C1)cc(O)cc2		Inactive	Estrogen receptor beta Agonist		1	Liquiritigenin	363677967.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1c2c(O[C@H](c3ccc(O)cc3)C1)cc(O)cc2	O=C1c2c(O[C@H](c3ccc(O)cc3)C1)cc(O)cc2
NCGC00371020-01	O=C1c2c(Oc3c1cccc3)ccc(N1CC3C(CN(C)C3)C1)c2		Inactive	Neuronal acetylcholine receptor protein alpha-7 subunit Agonist		1	A 844606	363677997.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	26.5	O=C1c2c(Oc3c1cccc3)ccc(N1CC3C(CN(C)C3)C1)c2	O=C1c2c(Oc3c1cccc3)ccc(N1CC3C(CN(C)C3)C1)c2
NCGC00385771-01	O=C1c2c([C@]3(C)C([C@@](CO)(C)CCC3)C1)ccc(C(O)(C)C)c2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385771-01	363679932.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1c2c([C@]3(C)C([C@@](CO)(C)CCC3)C1)ccc(C(O)(C)C)c2	O=C1c2c([C@]3(C)C([C@@](CO)(C)CCC3)C1)ccc(C(O)(C)C)c2
NCGC00378735-01	O=C1c2c(c(-c3ccc(N)cc3)ccc2)OC(N2CCOCC2)=C1		Inactive	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Inhibitor		1	PI 828	363678176.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1c2c(c(-c3ccc(N)cc3)ccc2)OC(N2CCOCC2)=C1	O=C1c2c(c(-c3ccc(N)cc3)ccc2)OC(N2CCOCC2)=C1
NCGC00015622-10	O=C1c2c(c(-c3ccccc3)ccc2)OC(N2CCOCC2)=C1		Inactive	PI3K Inhibitor		1	LY-294002	384567876.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1c2c(c(-c3ccccc3)ccc2)OC(N2CCOCC2)=C1	O=C1c2c(c(-c3ccccc3)ccc2)OC(N2CCOCC2)=C1
NCGC00017190-01	O=C1c2c(c(O)c(O)cc2)OC(c2cc(O)ccc2)=C1		Inactive			1	NCGC00017190-01	11113107.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1c2c(c(O)c(O)cc2)OC(c2cc(O)ccc2)=C1	O=C1c2c(c(O)c(O)cc2)OC(c2cc(O)ccc2)=C1
NCGC00169103-03	O=C1c2c(c(O)ccc2)C(O)C2(O)C1C=1C(=O)CC(C)CC=1C1OC21		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169103-03	363676773.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1c2c(c(O)ccc2)C(O)C2(O)C1C=1C(=O)CC(C)CC=1C1OC21	O=C1c2c(c(O)ccc2)C(O)C2(O)C1C=1C(=O)CC(C)CC=1C1OC21
NCGC00385257-01	O=C1c2c(cc3OCOc3c2)CCN(C)Cc2c(cc3OCOc3c2)C1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385257-01	363679622.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1c2c(cc3OCOc3c2)CCN(C)Cc2c(cc3OCOc3c2)C1	O=C1c2c(cc3OCOc3c2)CCN(C)Cc2c(cc3OCOc3c2)C1
NCGC00346688-03&NCGC00346688-04	O=C1c2c3c([nH]c2C(C)(C)c2c1cc(CC)c(N1CCC(N4CCOCC4)CC1)c2)cc(C#N)cc3		Inactive	ALK Inhibitor		2	Alectinib (CH5424802)	405559044.0&363677517.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C1c2c3c([nH]c2C(C)(C)c2c1cc(CC)c(N1CCC(N4CCOCC4)CC1)c2)cc(C#N)cc3	O=C1c2c3c([nH]c2C(C)(C)c2c1cc(CC)c(N1CCC(N4CCOCC4)CC1)c2)cc(C#N)cc3
NCGC00015958-18	O=C1c2c3c([nH]nc3-c3c1cccc3)ccc2		Inactive	SAPK1 (JNK) Inhibitor		1	SP-600125	384567910.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1c2c3c([nH]nc3-c3c1cccc3)ccc2	O=C1c2c3c([nH]nc3-c3c1cccc3)ccc2
NCGC00370838-01	O=C1c2c3n(c(N4CCC(c5c(C)nc[nH]5)CC4)nc3ccc2)CC1		Inactive	Poly [ADP-ribose] polymerase-1 Inhibitor		1	BYK 49187	363677877.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1c2c3n(c(N4CCC(c5c(C)nc[nH]5)CC4)nc3ccc2)CC1	O=C1c2c3n(c(N4CCC(c5c(C)nc[nH]5)CC4)nc3ccc2)CC1
NCGC00510502-02	O=C1c2scc(-c3cc4OCCOc4cc3)c2OC(N2CCOCC2)=C1		Inactive	PI3K beta Inhibitor		1	SF-2523	384569463.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1c2scc(-c3cc4OCCOc4cc3)c2OC(N2CCOCC2)=C1	O=C1c2scc(-c3cc4OCCOc4cc3)c2OC(N2CCOCC2)=C1
NCGC00015580-13	O=C1c2sccc2/C(=C\2/CCN(C)CC/2)/c2c(cccc2)C1		Inactive	Histamine H1 Receptor Antagonist		1	Ketotifen	170465378.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C1c2sccc2/C(=C\2/CCN(C)CC/2)/c2c(cccc2)C1	O=C1c2sccc2/C(=C\2/CCN(C)CC/2)/c2c(cccc2)C1
NCGC00015580-22	O=C1c2sccc2C(=C2CCN(C)CC2)c2c(cccc2)C1		Inactive	Histamine H1 Receptor Antagonist		1	Ketotifen	384567867.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C1c2sccc2C(=C2CCN(C)CC2)c2c(cccc2)C1	O=C1c2sccc2C(=C2CCN(C)CC2)c2c(cccc2)C1
NCGC00262533-03	O=C1n2c3c(c4c2[C@@H]2[C@](CC)(C1)CCCN2CC4)cccc3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: Vinca  | Family: N/A | Species: minor		1	Eburnamonine (-)	363677188.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C1n2c3c(c4c2[C@@H]2[C@](CC)(C1)CCCN2CC4)cccc3	O=C1n2c3c(c4c2[C@@H]2[C@](CC)(C1)CCCN2CC4)cccc3
NCGC00381390-01	O=CC1(C)C2C(C)(C3C4(CC(CO)C(C4)CC3)CC2)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381390-01	363679120.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=CC1(C)C2C(C)(C3C4(CC(CO)C(C4)CC3)CC2)CCC1	O=CC1(C)C2C(C)(C3C4(CC(CO)C(C4)CC3)CC2)CCC1
NCGC00485220-01	O=CC12C(O)(CC(O)CC1)CCC1C3(O)C(C)(C(C4=CC(=O)OC4)CC3)CCC21		Inactive			1	Strophanthidin	363681259.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=CC12C(O)(CC(O)CC1)CCC1C3(O)C(C)(C(C4=CC(=O)OC4)CC3)CCC21	O=CC12C(O)(CC(O)CC1)CCC1C3(O)C(C)(C(C4=CC(=O)OC4)CC3)CCC21
NCGC00380658-01	O=CC12C3C(C4(O)C(C)(C(C5=CC(=O)OC5)C(O)C4)CC3)CCC1CC(O[C@H]1[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H](C)O1)CC2		Inactive	<MOA Unknown> | Class: Steroide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380658-01	363678695.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=CC12C3C(C4(O)C(C)(C(C5=CC(=O)OC5)C(O)C4)CC3)CCC1CC(O[C@H]1[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H](C)O1)CC2	O=CC12C3C(C4(O)C(C)(C(C5=CC(=O)OC5)C(O)C4)CC3)CCC1CC(O[C@H]1[C@H](O)[C@H](O)[C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)[C@H](C)O1)CC2
NCGC00384920-01	O=CC12C3C(C4(O)C(C)(C(C5=CC(=O)OC5)CC4)CC3)CCC1CC(OC1C(O)C(OC)C(OC3C(O)C(O)C(O)C(CO)O3)C(C)O1)CC2		Inactive	<MOA Unknown> | Class: Steroid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384920-01	363679440.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=CC12C3C(C4(O)C(C)(C(C5=CC(=O)OC5)CC4)CC3)CCC1CC(OC1C(O)C(OC)C(OC3C(O)C(O)C(O)C(CO)O3)C(C)O1)CC2	O=CC12C3C(C4(O)C(C)(C(C5=CC(=O)OC5)CC4)CC3)CCC1CC(OC1C(O)C(OC)C(OC3C(O)C(O)C(O)C(CO)O3)C(C)O1)CC2
NCGC00384876-01	O=CC12C3C(C4(O)C(C)(C(C5=CC(=O)OC5)CC4)CC3)CCC1CC(OC1OC(C)C(O)C(OC)C1)CC2		Inactive	<MOA Unknown> | Class: Steroide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384876-01	363679408.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=CC12C3C(C4(O)C(C)(C(C5=CC(=O)OC5)CC4)CC3)CCC1CC(OC1OC(C)C(O)C(OC)C1)CC2	O=CC12C3C(C4(O)C(C)(C(C5=CC(=O)OC5)CC4)CC3)CCC1CC(OC1OC(C)C(O)C(OC)C1)CC2
NCGC00385325-01	O=CC12C3C(C4(O)C(C)(C(C5=CC(=O)OC5)CC4)CC3)CCC1CC(OC1OC(C)C(OC3C(O)C(O)C(O)C(CO)O3)C(OC)C1)CC2		Inactive	<MOA Unknown> | Class: Steroide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385325-01	363679678.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=CC12C3C(C4(O)C(C)(C(C5=CC(=O)OC5)CC4)CC3)CCC1CC(OC1OC(C)C(OC3C(O)C(O)C(O)C(CO)O3)C(OC)C1)CC2	O=CC12C3C(C4(O)C(C)(C(C5=CC(=O)OC5)CC4)CC3)CCC1CC(OC1OC(C)C(OC3C(O)C(O)C(O)C(CO)O3)C(OC)C1)CC2
NCGC00385809-01	O=CC1C2C(C)(C(O)CC1)CC(O)C1C(=C)C(=O)OC21		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385809-01	363679951.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=CC1C2C(C)(C(O)CC1)CC(O)C1C(=C)C(=O)OC21	O=CC1C2C(C)(C(O)CC1)CC(O)C1C(=C)C(=O)OC21
NCGC00181031-03	O=CCC(CCCC(O)(C)C)C		Inactive	Transient receptor potential cation channel subfamily M member 8 Agonist		1	Hydroxycitronellal	225144317.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=CCC(CCCC(O)(C)C)C	O=CCC(CCCC(O)(C)C)C
NCGC00091110-01&NCGC00091110-02	O=CCCCC=O		Inactive			2	Glutaraldehyde	144204634.0&124890454.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=CCCCC=O	O=CCCCC=O
NCGC00274270-01	O=CC[C@@H]1C(OC2C(O)C(N(C)C)C(OC3OC(C)C(O)C(O)(C)C3)CO2)C(OC)[C@H](O)CC(=O)O[C@H](C)C/C=C/C=C/C(O)[C@H](C)C1		Inactive			1	NCGC00274270-01	405559068.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=CC[C@@H]1C(OC2C(O)C(N(C)C)C(OC3OC(C)C(O)C(O)(C)C3)CO2)C(OC)[C@H](O)CC(=O)O[C@H](C)C/C=C/C=C/C(O)[C@H](C)C1	O=CC[C@@H]1C(OC2C(O)C(N(C)C)C(OC3OC(C)C(O)C(O)(C)C3)CO2)C(OC)[C@H](O)CC(=O)O[C@H](C)C/C=C/C=C/C(O)[C@H](C)C1
NCGC00263872-02	O=CC[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](OC)[C@H](O)CC(=O)O[C@@H](C)C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](N(C)C)CC2)[C@H](C)C1		Inactive	Bacterial 70S ribosome Binding Agent		1	SPIRAMYCIN	405558421.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=CC[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](OC)[C@H](O)CC(=O)O[C@@H](C)C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](N(C)C)CC2)[C@H](C)C1	O=CC[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](OC)[C@H](O)CC(=O)O[C@@H](C)C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](N(C)C)CC2)[C@H](C)C1
NCGC00263955-02	O=CC[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](C)[C@H](O)CC(=O)O[C@H](CC)[C@@H](CO[C@H]2[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O2)/C=C(\C)/C=C/C(=O)[C@H](C)C1		Inactive			1	TYLOSIN TARTRATE	405559071.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=CC[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](C)[C@H](O)CC(=O)O[C@H](CC)[C@@H](CO[C@H]2[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O2)/C=C(\C)/C=C/C(=O)[C@H](C)C1	O=CC[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@](O)(C)C3)[C@@H](C)O2)[C@@H](C)[C@H](O)CC(=O)O[C@H](CC)[C@@H](CO[C@H]2[C@H](OC)[C@H](OC)[C@H](O)[C@@H](C)O2)/C=C(\C)/C=C/C(=O)[C@H](C)C1
NCGC00262939-01	O=CN(/C(/C)=C/1\SC(=O)OCC\1)Cc1c(N)nc(C)nc1		Inactive			1	Cycotiamine	170465848.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=CN(/C(/C)=C/1\SC(=O)OCC\1)Cc1c(N)nc(C)nc1	O=CN(/C(/C)=C/1\SC(=O)OCC\1)Cc1c(N)nc(C)nc1
NCGC00025167-02	O=CNc1c(O)ccc([C@H](O)CN[C@H](Cc2ccc(OC)cc2)C)c1		Inactive	Voltage-Gated K(V) 7 (KCNQ) Channel Activator		1	Formoterol hemifumarate	405558911.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=CNc1c(O)ccc([C@H](O)CN[C@H](Cc2ccc(OC)cc2)C)c1	O=CNc1c(O)ccc([C@H](O)CN[C@H](Cc2ccc(OC)cc2)C)c1
NCGC00179862-03	O=C[C@@]1(C)C2[C@@](C)([C@@H](CC/C(=C/CO)/C)C(=C)CC2)CCC1		Inactive	<MOA Unknown> | Class: diterpene | Genus: Juniperus | Family: Cupressaceae | Species: communis		1	NCGC00179862-03	363676979.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C[C@@]1(C)C2[C@@](C)([C@@H](CC/C(=C/CO)/C)C(=C)CC2)CCC1	O=C[C@@]1(C)C2[C@@](C)([C@@H](CC/C(=C/CO)/C)C(=C)CC2)CCC1
NCGC00384918-01	O=C[C@@]12C3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CCC1C[C@H]1O[C@H]3[C@](O)([C@H](O)C[C@@H](C)O3)O[C@@H]1C2		Inactive	negative regulation of Wnt signaling pathway Inhibitor		1	NCGC00384918-01	363679438.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C[C@@]12C3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CCC1C[C@H]1O[C@H]3[C@](O)([C@H](O)C[C@@H](C)O3)O[C@@H]1C2	O=C[C@@]12C3[C@H]([C@]4(O)[C@@](C)([C@@H](C5=CC(=O)OC5)CC4)CC3)CCC1C[C@H]1O[C@H]3[C@](O)([C@H](O)C[C@@H](C)O3)O[C@@H]1C2
NCGC00385528-01	O=C[C@@]12C3[C@H]([C@]4(O)[C@@](C)([C@@](O)(C5=CC(=O)OC5)CC4)CC3)CCC1C[C@H]1OC3[C@](O)([C@H](O)C[C@@H](C)O3)O[C@@H]1C2		Inactive	<MOA Unknown> | Class: Steroid | Genus: Tephrosia | Family: Fabaceae | Species: nana		1	NCGC00385528-01	363679792.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	8.444145544	O=C[C@@]12C3[C@H]([C@]4(O)[C@@](C)([C@@](O)(C5=CC(=O)OC5)CC4)CC3)CCC1C[C@H]1OC3[C@](O)([C@H](O)C[C@@H](C)O3)O[C@@H]1C2	O=C[C@@]12C3[C@H]([C@]4(O)[C@@](C)([C@@](O)(C5=CC(=O)OC5)CC4)CC3)CCC1C[C@H]1OC3[C@](O)([C@H](O)C[C@@H](C)O3)O[C@@H]1C2
NCGC00384881-02	O=C[C@@]12[C@@H](C[C@@H](OC3OC(C)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)[C@@H](CO)O4)C(OC)C3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)CCC21		Inactive	<MOA Unknown> | Class: Saponin | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384881-02	363679413.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C[C@@]12[C@@H](C[C@@H](OC3OC(C)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)[C@@H](CO)O4)C(OC)C3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)CCC21	O=C[C@@]12[C@@H](C[C@@H](OC3OC(C)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)[C@@H](CO)O4)C(OC)C3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)CCC21
NCGC00384656-01	O=C[C@@]12[C@@H](C[C@@H](O[C@H]3[C@@H](O)[C@H](OC)[C@@H](O)[C@H](C)O3)CC1)CCC1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)CCC21		Inactive	NCI-H460 Inhibitor		1	NCGC00384656-01	363679295.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C[C@@]12[C@@H](C[C@@H](O[C@H]3[C@@H](O)[C@H](OC)[C@@H](O)[C@H](C)O3)CC1)CCC1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)CCC21	O=C[C@@]12[C@@H](C[C@@H](O[C@H]3[C@@H](O)[C@H](OC)[C@@H](O)[C@H](C)O3)CC1)CCC1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)CCC21
NCGC00385023-01	O=C[C@@]12[C@@H]([C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C=C3C(C)(C)[C@@H](O)CCC13)[C@@]1(C)[C@@](C)([C@@H]([C@@H](C/C=C/C(O)(C)C)C)CC1)CC2		Inactive	<MOA Unknown> | Class: Triterpen | Genus: Momordica | Family: Cucurbitaceae | Species: balsamina		1	NCGC00385023-01	363679490.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C[C@@]12[C@@H]([C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C=C3C(C)(C)[C@@H](O)CCC13)[C@@]1(C)[C@@](C)([C@@H]([C@@H](C/C=C/C(O)(C)C)C)CC1)CC2	O=C[C@@]12[C@@H]([C@@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)C=C3C(C)(C)[C@@H](O)CCC13)[C@@]1(C)[C@@](C)([C@@H]([C@@H](C/C=C/C(O)(C)C)C)CC1)CC2
NCGC00384630-01	O=C[C@@]12[C@@](O)(C[C@@H](OC3OC(C)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)C(OC)C3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)CCC21		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Castilla | Family: Moraceae | Species: elastica		1	NCGC00384630-01	363679283.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C[C@@]12[C@@](O)(C[C@@H](OC3OC(C)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)C(OC)C3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)CCC21	O=C[C@@]12[C@@](O)(C[C@@H](OC3OC(C)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)C(OC)C3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)CCC21
NCGC00169509-02	O=C[C@@]12[C@@](O)(C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@H](OC)C3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)CC[C@H]21		Inactive	Sodium/potassium-transporting ATPase Inhibitor		1	NCGC00169509-02	363676835.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C[C@@]12[C@@](O)(C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@H](OC)C3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)CC[C@H]21	O=C[C@@]12[C@@](O)(C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@H](OC)C3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)CC[C@H]21
NCGC00384917-01	O=C[C@@]12[C@@](O)(C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](O)C3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)CCC21		Inactive	A549 Inhibitor		1	NCGC00384917-01	363679437.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C[C@@]12[C@@](O)(C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](O)C3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)CCC21	O=C[C@@]12[C@@](O)(C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](O)C3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)CCC21
NCGC00384513-01	O=C[C@@]12[C@H](C[C@@H](O[C@@H]3[C@H](O)[C@@H](OC)[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)O4)[C@H](C)O3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)CCC21		Inactive	Sodium/potassium-transporting ATPase Inhibitor		1	NCGC00384513-01	363679224.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C[C@@]12[C@H](C[C@@H](O[C@@H]3[C@H](O)[C@@H](OC)[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)O4)[C@H](C)O3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)CCC21	O=C[C@@]12[C@H](C[C@@H](O[C@@H]3[C@H](O)[C@@H](OC)[C@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)O4)[C@H](C)O3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@@H](C4=CC(=O)OC4)CC3)CCC21
NCGC00168904-03	O=C[C@]1(C)C2[C@@](C)([C@@H](CC/C(=C/CO)/C)C(=C)CC2)CCC1		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Juniperus | Family: Cupressaceae | Species: communis		1	NCGC00168904-03	363676718.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C[C@]1(C)C2[C@@](C)([C@@H](CC/C(=C/CO)/C)C(=C)CC2)CCC1	O=C[C@]1(C)C2[C@@](C)([C@@H](CC/C(=C/CO)/C)C(=C)CC2)CCC1
NCGC00159339-04&NCGC00159339-10	O=C[C@]1(O)[C@@H](O[C@H]2[C@@H](NC)[C@H](O)[C@@H](O)[C@H](CO)O2)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]2NC(=N)N)O[C@H]1C		Inactive	30S Ribosomal Protein Inhibitors&30s Ribosomal Protein Inhibitors		2	Streptomycin (sulfate)&Streptomycin sulfate	384568169.0&405558717.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C[C@]1(O)[C@@H](O[C@H]2[C@@H](NC)[C@H](O)[C@@H](O)[C@H](CO)O2)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]2NC(=N)N)O[C@H]1C	O=C[C@]1(O)[C@@H](O[C@H]2[C@@H](NC)[C@H](O)[C@@H](O)[C@H](CO)O2)[C@H](O[C@@H]2[C@@H](O)[C@H](O)[C@@H](NC(=N)N)[C@H](O)[C@H]2NC(=N)N)O[C@H]1C
NCGC00385962-01	O=C\1OC(C)C/C=C/C=C\CCCCC(O)C/C=C/1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385962-01	363680031.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C\1OC(C)C/C=C/C=C\CCCCC(O)C/C=C/1	O=C\1OC(C)C/C=C/C=C\CCCCC(O)C/C=C/1
NCGC00380618-01	O=C\1OC[C@@]23[C@]4(C)[C@@]5(OC5)[C@H](O[C@@H]2C=C(C)CC3)C[C@H]4OC(=O)/C=C\C=C\C(=O)OCC/C(/C)=C/1		Inactive	<MOA Unknown> | Class: trichothecene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380618-01	363678675.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=C\1OC[C@@]23[C@]4(C)[C@@]5(OC5)[C@H](O[C@@H]2C=C(C)CC3)C[C@H]4OC(=O)/C=C\C=C\C(=O)OCC/C(/C)=C/1	O=C\1OC[C@@]23[C@]4(C)[C@@]5(OC5)[C@H](O[C@@H]2C=C(C)CC3)C[C@H]4OC(=O)/C=C\C=C\C(=O)OCC/C(/C)=C/1
NCGC00017254-05&NCGC00017254-11	O=C\1O[C@@H](C)CCC/C=C/C2[C@H]([C@H](O)/C=C/1)C[C@@H](O)C2		Inactive	Golgi-Specific Brefeldin A-Resistance Guanine Nucleotide Exchange Factor 1 (GBF1) Inhibitor		2	Cyanein	384567981.0&404904668.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		O=C\1O[C@@H](C)CCC/C=C/C2[C@H]([C@H](O)/C=C/1)C[C@@H](O)C2	O=C\1O[C@@H](C)CCC/C=C/C2[C@H]([C@H](O)/C=C/1)C[C@@H](O)C2
NCGC00483033-01	O=C\1[C@H](C)C[C@H](CCN2CCCCC2)[C@H](OC2C(O)C(N(C)C)C(O)C(C)O2)[C@@H](C)[C@H](O)CC(=O)O[C@H](CC)[C@@H](CN2CCCCC2)/C=C(\C)/C=C/1		Inactive	Bacterial 70S ribosome Inhibitor		1	Tildipirosin	405559127.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C\1[C@H](C)C[C@H](CCN2CCCCC2)[C@H](OC2C(O)C(N(C)C)C(O)C(C)O2)[C@@H](C)[C@H](O)CC(=O)O[C@H](CC)[C@@H](CN2CCCCC2)/C=C(\C)/C=C/1	O=C\1[C@H](C)C[C@H](CCN2CCCCC2)[C@H](OC2C(O)C(N(C)C)C(O)C(C)O2)[C@@H](C)[C@H](O)CC(=O)O[C@H](CC)[C@@H](CN2CCCCC2)/C=C(\C)/C=C/1
NCGC00380665-01	O=C\1c2c(O)cc(O)cc2CC(=O)OC(C)CCC/C=C/1	5.5500002	Active	<MOA Unknown> | Class: macrolide | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00380665-01	363678700.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	1.2	42.6896911829	O=C\1c2c(O)cc(O)cc2CC(=O)OC(C)CCC/C=C/1	O=C\1c2c(O)cc(O)cc2CC(=O)OC(C)CCC/C=C/1
NCGC00166206-04	O=Cc1c(C=O)cccc1		Inactive			1	1,2-Benzenedicarboxaldehyde	170466016.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=Cc1c(C=O)cccc1	O=Cc1c(C=O)cccc1
NCGC00347495-02	O=Cc1c(CO)cc(O)c2c1OC1(C3(C)C(C(C)(C)C(O)C(O)C3)CCC1C)C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347495-02	363677603.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=Cc1c(CO)cc(O)c2c1OC1(C3(C)C(C(C)(C)C(O)C(O)C3)CCC1C)C2	O=Cc1c(CO)cc(O)c2c1OC1(C3(C)C(C(C)(C)C(O)C(O)C3)CCC1C)C2
NCGC00385563-01	O=Cc1c(O)c(C=O)c(O)c(C(CC(C)C)C2C3(C)C(C(O)(C)CC2)CC(C(O)(C)C)CC3)c1O		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385563-01	363679810.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=Cc1c(O)c(C=O)c(O)c(C(CC(C)C)C2C3(C)C(C(O)(C)CC2)CC(C(O)(C)C)CC3)c1O	O=Cc1c(O)c(C=O)c(O)c(C(CC(C)C)C2C3(C)C(C(O)(C)CC2)CC(C(O)(C)C)CC3)c1O
NCGC00380764-01	O=Cc1c(O)c(CC2(C)C(C)CCC3C(C)(C)C(O)CC=C23)c(O)cc1CO		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380764-01	363678769.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=Cc1c(O)c(CC2(C)C(C)CCC3C(C)(C)C(O)CC=C23)c(O)cc1CO	O=Cc1c(O)c(CC2(C)C(C)CCC3C(C)(C)C(O)CC=C23)c(O)cc1CO
NCGC00386103-01	O=Cc1c(O)c(CC=C(C)C)cc2oc(/C=C/C=C/C)cc12		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386103-01	363680106.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=Cc1c(O)c(CC=C(C)C)cc2oc(/C=C/C=C/C)cc12	O=Cc1c(O)c(CC=C(C)C)cc2oc(/C=C/C=C/C)cc12
NCGC00386105-01	O=Cc1c(O)c(CC=C(C)C)cc2oc(/C=C/CCC)cc12		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386105-01	363680107.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=Cc1c(O)c(CC=C(C)C)cc2oc(/C=C/CCC)cc12	O=Cc1c(O)c(CC=C(C)C)cc2oc(/C=C/CCC)cc12
NCGC00016423-15	O=Cc1c(O)c(O)c(C(C)C)c2c1c(O)c(-c1c(O)c3c(C=O)c(O)c(O)c(C(C)C)c3cc1C)c(C)c2		Inactive	Bcl-xl Inhibitor		1	(-)-Gossypol	170466800.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=Cc1c(O)c(O)c(C(C)C)c2c1c(O)c(-c1c(O)c3c(C=O)c(O)c(O)c(C(C)C)c3cc1C)c(C)c2	O=Cc1c(O)c(O)c(C(C)C)c2c1c(O)c(-c1c(O)c3c(C=O)c(O)c(O)c(C(C)C)c3cc1C)c(C)c2
NCGC00379137-01	O=Cc1c(O)ccc2C(C)=CC(=O)Oc12		Inactive	Serine/threonine-protein kinase/endoribonuclease IRE1 Inhibitor		1	4?8C	363678379.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=Cc1c(O)ccc2C(C)=CC(=O)Oc12	O=Cc1c(O)ccc2C(C)=CC(=O)Oc12
NCGC00522012-01	O=N/C(/C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(/C=C\3/C(=O)N([C@H]4CN(C(=O)OCC5=C(C)OC(=O)O5)CC4)CC/3)CS[C@H]12)=C\1/N=C(N)SN/1		Inactive			1	CEFTOBIPROLE MEDOCARIL SODIUM	405558834.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=N/C(/C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(/C=C\3/C(=O)N([C@H]4CN(C(=O)OCC5=C(C)OC(=O)O5)CC4)CC/3)CS[C@H]12)=C\1/N=C(N)SN/1	O=N/C(/C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(/C=C\3/C(=O)N([C@H]4CN(C(=O)OCC5=C(C)OC(=O)O5)CC4)CC/3)CS[C@H]12)=C\1/N=C(N)SN/1
NCGC00178500-07&NCGC00178500-19	O=NN(C(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O)C		Inactive	DNA Alkylating Agent		2	Streptozotocin&Streptozocin	170464827.0&384568356.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=NN(C(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O)C	O=NN(C(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O)C
NCGC00163363-01	O=NN1C(c2cnccc2)CCC1		Inactive			1	N'-NITROSONORNICOTINE	26756720.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=NN1C(c2cnccc2)CCC1	O=NN1C(c2cnccc2)CCC1
NCGC00091066-01	O=NOCCC(C)C		Inactive	vasodilation Activator		1	3-Methylbutyl nitrite	144204625.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=NOCCC(C)C	O=NOCCC(C)C
NCGC00165844-06	O=Nc1c(OCC2CCCCC2)nc(N)nc1N		Inactive			1	NU-6027	384568289.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.5	O=Nc1c(OCC2CCCCC2)nc(N)nc1N	O=Nc1c(OCC2CCCCC2)nc(N)nc1N
NCGC00485353-01	O=P1(O)OC2C(O)C(n3c4NC(N)=NC(=O)c4nc3)OC2CO1		Inactive	cGMP-dependent protein kinase 2 Activator		1	Guanosine 3â€²,5â€²-cyclic monophosphate	363681296.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=P1(O)OC2C(O)C(n3c4NC(N)=NC(=O)c4nc3)OC2CO1	O=P1(O)OC2C(O)C(n3c4NC(N)=NC(=O)c4nc3)OC2CO1
NCGC00093588-04	O=P1(O)O[C@H]2[C@@H](O)[C@H](n3c4ncnc(N)c4nc3)O[C@@H]2CO1		Inactive	cAMP-dependent protein kinase type II-alpha regulatory subunit Activator		1	cAMP	170466839.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=P1(O)O[C@H]2[C@@H](O)[C@H](n3c4ncnc(N)c4nc3)O[C@@H]2CO1	O=P1(O)O[C@H]2[C@@H](O)[C@H](n3c4ncnc(N)c4nc3)O[C@@H]2CO1
NCGC00485306-01	O=P1([O-])O[C@H]2[C@@H](O)[C@H](n3c4N=C(N)NC(=O)c4nc3)O[C@@H]2CO1		Inactive	cGMP-dependent protein kinase 2 Activator		1	Guanosine 3â€²,5â€²-cyclic monophosphate sodium salt	363681283.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=P1([O-])O[C@H]2[C@@H](O)[C@H](n3c4N=C(N)NC(=O)c4nc3)O[C@@H]2CO1	O=P1([O-])O[C@H]2[C@@H](O)[C@H](n3c4N=C(N)NC(=O)c4nc3)O[C@@H]2CO1
NCGC00390346-01	O=S1(=O)CCN(Cc2cc(NCC3CCOCC3)c3[nH]c(-c4ccccc4)cc3c2)CC1		Inactive	calcium ion transport Inhibitor		1	NecrosisInhibitor,Necrox-5	363680877.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=S1(=O)CCN(Cc2cc(NCC3CCOCC3)c3[nH]c(-c4ccccc4)cc3c2)CC1	O=S1(=O)CCN(Cc2cc(NCC3CCOCC3)c3[nH]c(-c4ccccc4)cc3c2)CC1
NCGC00167751-05	O=S1(=O)N(COC=2N=C3C(OCCN4CCCCC4)=CC=CN3C(=O)C=2)C(=O)c2c(C(C)C)cc(OC)cc12	5.0500002	Active	Leukocyte Elastase Inhibitor	0.0	1	SSR-69071	384568334.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	44.7065913437	O=S1(=O)N(COC=2N=C3C(OCCN4CCCCC4)=CC=CN3C(=O)C=2)C(=O)c2c(C(C)C)cc(OC)cc12	O=S1(=O)N(COC=2N=C3C(OCCN4CCCCC4)=CC=CN3C(=O)C=2)C(=O)c2c(C(C)C)cc(OC)cc12
NCGC00378679-01	O=S1(=O)N(Cc2cc3c(CCN(C)C)c[nH]c3cc2)CCN1C		Inactive	Serotonin 1d (5-HT1d) receptor Agonist		1	L-703,664 succinate	363678147.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=S1(=O)N(Cc2cc3c(CCN(C)C)c[nH]c3cc2)CCN1C	O=S1(=O)N(Cc2cc3c(CCN(C)C)c[nH]c3cc2)CCN1C
NCGC00138287-01	O=S1(=O)N(c2c(CC)cccc2)C(=O)N(CC=2N=C3N(C(=O)C=2)C=CC=C3)c2c1cccc2		Inactive			1	NCGC00138287-01	24413670.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=S1(=O)N(c2c(CC)cccc2)C(=O)N(CC=2N=C3N(C(=O)C=2)C=CC=C3)c2c1cccc2	O=S1(=O)N(c2c(CC)cccc2)C(=O)N(CC=2N=C3N(C(=O)C=2)C=CC=C3)c2c1cccc2
NCGC00138251-01	O=S1(=O)N(c2cc(C)ccc2)C(=O)N(Cc2ccc(C(C)(C)C)cc2)c2c1cccc2		Inactive			1	NCGC00138251-01	24413634.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=S1(=O)N(c2cc(C)ccc2)C(=O)N(Cc2ccc(C(C)(C)C)cc2)c2c1cccc2	O=S1(=O)N(c2cc(C)ccc2)C(=O)N(Cc2ccc(C(C)(C)C)cc2)c2c1cccc2
NCGC00094918-07	O=S1(=O)NC(=O)c2c1cccc2		Inactive	Taste receptor type 1 member 3 Binding Agent		1	Saccharin	170465766.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=S1(=O)NC(=O)c2c1cccc2	O=S1(=O)NC(=O)c2c1cccc2
NCGC00388398-01	O=S1(=O)NCN(CN2CNS(=O)(=O)CC2)CC1		Inactive			1	Taurolidine		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=S1(=O)NCN(CN2CNS(=O)(=O)CC2)CC1	O=S1(=O)NCN(CN2CNS(=O)(=O)CC2)CC1
NCGC00013109-03	O=S1(=O)OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2c1cccc2		Inactive	amyloid fibril formation Inhibitor		1	Phenol red	170465805.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=S1(=O)OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2c1cccc2	O=S1(=O)OC(c2ccc(O)cc2)(c2ccc(O)cc2)c2c1cccc2
NCGC00159388-05	O=[N+](OCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])[O-]		Inactive	Soluble guanylate cyclase Activator		1	Pentaerythritol tetranitrate	225144224.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+](OCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])[O-]	O=[N+](OCC(CO[N+](=O)[O-])(CO[N+](=O)[O-])CO[N+](=O)[O-])[O-]
NCGC00182985-01	O=[N+](OCCN(CCO[N+](=O)[O-])CCO[N+](=O)[O-])[O-]		Inactive	Soluble guanylate cyclase Activator		1	Trolnitrate	144206882.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+](OCCN(CCO[N+](=O)[O-])CCO[N+](=O)[O-])[O-]	O=[N+](OCCN(CCO[N+](=O)[O-])CCO[N+](=O)[O-])[O-]
NCGC00025357-04&NCGC00025357-13	O=[N+](OCCNC(=O)c1cnccc1)[O-]		Inactive	K(ATP) Channel Activator		2	Nicorandil	170465582.0&384568070.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=[N+](OCCNC(=O)c1cnccc1)[O-]	O=[N+](OCCNC(=O)c1cnccc1)[O-]
NCGC00167981-03	O=[N+](O[C@H]1[C@H]2OC[C@H](O)[C@H]2OC1)[O-]		Inactive			1	Isosorbide mononitrate	405559096.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+](O[C@H]1[C@H]2OC[C@H](O)[C@H]2OC1)[O-]	O=[N+](O[C@H]1[C@H]2OC[C@H](O)[C@H]2OC1)[O-]
NCGC00178830-05	O=[N+](O[C@H]1[C@H]2OC[C@H](O[N+](=O)[O-])[C@H]2OC1)[O-]		Inactive			1	Isosorbide dinitrate	170464980.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+](O[C@H]1[C@H]2OC[C@H](O[N+](=O)[O-])[C@H]2OC1)[O-]	O=[N+](O[C@H]1[C@H]2OC[C@H](O[N+](=O)[O-])[C@H]2OC1)[O-]
NCGC00024717-10	O=[N+]([O-])NC(=N)NCCC[C@H](N)C(=O)OC		Inactive	Nitric Oxide Synthase Inhibitor		1	L-NAME	384568032.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-12.584864392	O=[N+]([O-])NC(=N)NCCC[C@H](N)C(=O)OC	O=[N+]([O-])NC(=N)NCCC[C@H](N)C(=O)OC
NCGC00344620-03	O=[N+]([O-])c1c(-c2oc(/C=C\3/C(=O)N(c4ccc(C(=O)O)cc4)N=C/3C)cc2)cc(C)c(C)c1		Inactive	Histone N-Acetyltransferase (HAT) Inhibitor		1	C-646	384568724.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1c(-c2oc(/C=C\3/C(=O)N(c4ccc(C(=O)O)cc4)N=C/3C)cc2)cc(C)c(C)c1	O=[N+]([O-])c1c(-c2oc(/C=C\3/C(=O)N(c4ccc(C(=O)O)cc4)N=C/3C)cc2)cc(C)c(C)c1
NCGC00094985-05	O=[N+]([O-])c1c(C)c(C(=O)N)cc([N+](=O)[O-])c1		Inactive			1	Zoalene	170465727.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1c(C)c(C(=O)N)cc([N+](=O)[O-])c1	O=[N+]([O-])c1c(C)c(C(=O)N)cc([N+](=O)[O-])c1
NCGC00347945-09	O=[N+]([O-])c1c(C)n(-c2ccc(OC)cc2)c2c1ccc(O)c2		Inactive	DYRK Inhibitor		1	ID-8	384568993.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1c(C)n(-c2ccc(OC)cc2)c2c1ccc(O)c2	O=[N+]([O-])c1c(C)n(-c2ccc(OC)cc2)c2c1ccc(O)c2
NCGC00015748-17	O=[N+]([O-])c1c(C2C(C(=O)OC)=C(C)NC(C)=C2C(=O)OC)cccc1		Inactive	Voltage-gated L-type calcium channel alpha-1C subunit Inhibitor		1	Nifedipine	170465006.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=[N+]([O-])c1c(C2C(C(=O)OC)=C(C)NC(C)=C2C(=O)OC)cccc1	O=[N+]([O-])c1c(C2C(C(=O)OC)=C(C)NC(C)=C2C(=O)OC)cccc1
NCGC00182054-03	O=[N+]([O-])c1c(C2C(C(=O)OCC(=O)C)=C(C)NC(C)=C2C(=O)OC)cccc1		Inactive	Voltage-gated calcium channel Antagonist		1	Aranidipine	170465977.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1c(C2C(C(=O)OCC(=O)C)=C(C)NC(C)=C2C(=O)OC)cccc1	O=[N+]([O-])c1c(C2C(C(=O)OCC(=O)C)=C(C)NC(C)=C2C(=O)OC)cccc1
NCGC00164633-02	O=[N+]([O-])c1c(C2C(C(=O)OCC(C)C)=C(C)NC(C)=C2C(=O)OC)cccc1		Inactive	Ca2+ channel blocker (dihydropyridine)		1	Nisoldipine	170465320.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	32.5	O=[N+]([O-])c1c(C2C(C(=O)OCC(C)C)=C(C)NC(C)=C2C(=O)OC)cccc1	O=[N+]([O-])c1c(C2C(C(=O)OCC(C)C)=C(C)NC(C)=C2C(=O)OC)cccc1
NCGC00370978-02	O=[N+]([O-])c1c(Nc2cc3c(C[C@@H]4N(C)CCC4)c[nH]c3cc2)nccc1		Inactive	Serotonin 1d (5-HT1d) receptor Agonist		1	CP 135807	363677972.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1c(Nc2cc3c(C[C@@H]4N(C)CCC4)c[nH]c3cc2)nccc1	O=[N+]([O-])c1c(Nc2cc3c(C[C@@H]4N(C)CCC4)c[nH]c3cc2)nccc1
NCGC00387499-01	O=[N+]([O-])c1c(Nc2cc3c([nH]nc3)cc2)nc(NC)cc1		Inactive	Heat shock factor protein 1 Inhibitor		1	KRIBB11	363680646.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1c(Nc2cc3c([nH]nc3)cc2)nc(NC)cc1	O=[N+]([O-])c1c(Nc2cc3c([nH]nc3)cc2)nc(NC)cc1
NCGC00164555-03&NCGC00164555-10	O=[N+]([O-])c1c(O)c(O)cc(/C=C(/C(=O)N(CC)CC)\C#N)c1		Inactive	NCI-H1299 Inhibitor		2	Entacapone	170464850.0&434147024.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O=[N+]([O-])c1c(O)c(O)cc(/C=C(/C(=O)N(CC)CC)\C#N)c1	O=[N+]([O-])c1c(O)c(O)cc(/C=C(/C(=O)N(CC)CC)\C#N)c1
NCGC00165815-06	O=[N+]([O-])c1c(O/N=[N+](\[O-])/N2CCN(C(=O)OCC)CC2)ccc([N+](=O)[O-])c1		Inactive	Nitric Oxide (NO) Donors		1	NSC-724771	384568286.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1c(O/N=[N+](\[O-])/N2CCN(C(=O)OCC)CC2)ccc([N+](=O)[O-])c1	O=[N+]([O-])c1c(O/N=[N+](\[O-])/N2CCN(C(=O)OCC)CC2)ccc([N+](=O)[O-])c1
NCGC00510691-01	O=[N+]([O-])c1c(OCC2OC(=O)C(Cc3ccccc3)C2)cccc1		Inactive	Inhibitor of autophagy		1	3-BDO	384569481.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1c(OCC2OC(=O)C(Cc3ccccc3)C2)cccc1	O=[N+]([O-])c1c(OCC2OC(=O)C(Cc3ccccc3)C2)cccc1
NCGC00485151-01	O=[N+]([O-])c1c2N(C(=O)CC[C@H](N)C(=O)O)CCc2cc(CC(=O)OC)c1		Inactive			1	Glutamate, Caged hydrate	363681245.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1c2N(C(=O)CC[C@H](N)C(=O)O)CCc2cc(CC(=O)OC)c1	O=[N+]([O-])c1c2N(C(=O)CC[C@H](N)C(=O)O)CCc2cc(CC(=O)OC)c1
NCGC00249897-01	O=[N+]([O-])c1c2[Hg]Oc2c(C)cc1		Inactive			1	Nitromersol	170465514.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0		O=[N+]([O-])c1c2[Hg]Oc2c(C)cc1	O=[N+]([O-])c1c2[Hg]Oc2c(C)cc1
NCGC00185073-03	O=[N+]([O-])c1c2[nH]c(C(=O)O)cc2ccc1		Inactive	DNA-(apurinic or apyrimidinic site) lyase Inhibitor		1	CRT0044876	363677101.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1c2[nH]c(C(=O)O)cc2ccc1	O=[N+]([O-])c1c2[nH]c(C(=O)O)cc2ccc1
NCGC00160664-04	O=[N+]([O-])c1c2c(c(O)cc1)nccc2	4.9000001	Active	Methionine Aminopeptidase-2 (MetAP2) Inhibitor	0.0	1	Nitroxoline	384568201.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	39.2797366609	O=[N+]([O-])c1c2c(c(O)cc1)nccc2	O=[N+]([O-])c1c2c(c(O)cc1)nccc2
NCGC00167969-02	O=[N+]([O-])c1c2c(nc3c(c2)CN2C(=O)C4=C([C@@](O)(CC)C(=O)OC4)C=C32)ccc1		Inactive			1	Rubitecan	124893436.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1c2c(nc3c(c2)CN2C(=O)C4=C([C@@](O)(CC)C(=O)OC4)C=C32)ccc1	O=[N+]([O-])c1c2c(nc3c(c2)CN2C(=O)C4=C([C@@](O)(CC)C(=O)OC4)C=C32)ccc1
NCGC00246958-03	O=[N+]([O-])c1c2no[n+]([O-])c2c(N2CCN(C)CC2)cc1		Inactive	MDM4 (MDMX) Inhibitor		1	NSC-207895	363677155.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1c2no[n+]([O-])c2c(N2CCN(C)CC2)cc1	O=[N+]([O-])c1c2no[n+]([O-])c2c(N2CCN(C)CC2)cc1
NCGC00346825-02	O=[N+]([O-])c1c2nonc2c(Nc2c(-c3ccccc3)cccc2)cc1		Inactive	MYC Expression Inhibitor		1	10074-G5	384568944.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	28.0	O=[N+]([O-])c1c2nonc2c(Nc2c(-c3ccccc3)cccc2)cc1	O=[N+]([O-])c1c2nonc2c(Nc2c(-c3ccccc3)cccc2)cc1
NCGC00185998-01	O=[N+]([O-])c1c2sc(C(=O)N)[n+]([O-])c2cc(C#N)c1		Inactive			1	BTO-1	90341624.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1c2sc(C(=O)N)[n+]([O-])c2cc(C#N)c1	O=[N+]([O-])c1c2sc(C(=O)N)[n+]([O-])c2cc(C#N)c1
NCGC00347904-03	O=[N+]([O-])c1cc(-c2ccc(OCC(CCc3ccncc3)N3C(=O)SCC3=O)cc2)ccc1	4.9000001	Active	P2X7 Receptor Antagonist	0.0	1	AZ-11645373	384568988.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	47.6892572128	O=[N+]([O-])c1cc(-c2ccc(OCC(CCc3ccncc3)N3C(=O)SCC3=O)cc2)ccc1	O=[N+]([O-])c1cc(-c2ccc(OCC(CCc3ccncc3)N3C(=O)SCC3=O)cc2)ccc1
NCGC00105475-01	O=[N+]([O-])c1cc(-c2nc(C=3C(=O)N(c4c(N)cccc4)C4=C(C(=O)CC(c5ccc(OC)cc5)C4)C=3)sc2)ccc1		Inactive			1	NCGC00105475-01	24268820.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1cc(-c2nc(C=3C(=O)N(c4c(N)cccc4)C4=C(C(=O)CC(c5ccc(OC)cc5)C4)C=3)sc2)ccc1	O=[N+]([O-])c1cc(-c2nc(C=3C(=O)N(c4c(N)cccc4)C4=C(C(=O)CC(c5ccc(OC)cc5)C4)C=3)sc2)ccc1
NCGC00387777-01	O=[N+]([O-])c1cc(-n2c(C)c(C(=O)OCC)c(C)n2)ccc1		Inactive	cAMP-specific 3',5'-cyclic phosphodiesterase 4D Inhibitor		1	Phosphodiesterase 4 inhibitor	363680664.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1cc(-n2c(C)c(C(=O)OCC)c(C)n2)ccc1	O=[N+]([O-])c1cc(-n2c(C)c(C(=O)OCC)c(C)n2)ccc1
NCGC00241411-01	O=[N+]([O-])c1cc(C(=O)Nc2n(CCCO)c3c(n2)cc(OC(=O)C(C)(C)C)cc3)ccc1		Inactive	IRAK Inhibitor		1	NCGC00241411	137275845.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1cc(C(=O)Nc2n(CCCO)c3c(n2)cc(OC(=O)C(C)(C)C)cc3)ccc1	O=[N+]([O-])c1cc(C(=O)Nc2n(CCCO)c3c(n2)cc(OC(=O)C(C)(C)C)cc3)ccc1
NCGC00186035-08	O=[N+]([O-])c1cc(C(=O)Nc2n(CCN3CCOCC3)c3c(n2)cccc3)ccc1		Inactive	IRAK Inhibitor		1	IRAK-1-4 Inhibitor I	384568438.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1cc(C(=O)Nc2n(CCN3CCOCC3)c3c(n2)cccc3)ccc1	O=[N+]([O-])c1cc(C(=O)Nc2n(CCN3CCOCC3)c3c(n2)cccc3)ccc1
NCGC00402240-03	O=[N+]([O-])c1cc(C(=O)O)c(Nc2cc(OC)c3c(c2)cccc3)cc1		Inactive	Anoctamin-1 Blocker		1	MONNA	363680996.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1cc(C(=O)O)c(Nc2cc(OC)c3c(c2)cccc3)cc1	O=[N+]([O-])c1cc(C(=O)O)c(Nc2cc(OC)c3c(c2)cccc3)cc1
NCGC00015714-16	O=[N+]([O-])c1cc(C2C(C(=O)OC(C)C)=C(C)NC(C)=C2C(=O)OCCOC)ccc1		Inactive	Voltage-gated L-type calcium channel Antagonist		1	Nimodipine	170466561.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=[N+]([O-])c1cc(C2C(C(=O)OC(C)C)=C(C)NC(C)=C2C(=O)OCCOC)ccc1	O=[N+]([O-])c1cc(C2C(C(=O)OC(C)C)=C(C)NC(C)=C2C(=O)OCCOC)ccc1
NCGC00167435-07	O=[N+]([O-])c1cc(C2C(C(=O)OC)=C(C#N)NC(C)=C2C(=O)OC(C)C)ccc1		Inactive	Voltage-gated L-type calcium channel alpha-1C subunit Blocker		1	Nilvadipine	405558817.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1cc(C2C(C(=O)OC)=C(C#N)NC(C)=C2C(=O)OC(C)C)ccc1	O=[N+]([O-])c1cc(C2C(C(=O)OC)=C(C#N)NC(C)=C2C(=O)OC(C)C)ccc1
NCGC00162150-04	O=[N+]([O-])c1cc(C2C(C(=O)OC/C=C/c3ccccc3)=C(C)NC(C)=C2C(=O)OCCOC)ccc1	4.9499998	Active	Voltage-gated N-type calcium channel alpha-1B subunit Inhibitor	0.0	1	Cilnidipine	170465867.0	2019_NPC-2.2	SARS-CoV-2_CPE_SRI	3.0	57.6285621437	O=[N+]([O-])c1cc(C2C(C(=O)OC/C=C/c3ccccc3)=C(C)NC(C)=C2C(=O)OCCOC)ccc1	O=[N+]([O-])c1cc(C2C(C(=O)OC/C=C/c3ccccc3)=C(C)NC(C)=C2C(=O)OCCOC)ccc1
NCGC00167436-02	O=[N+]([O-])c1cc(C2C(C(=O)OC3CN(C(c4ccccc4)c4ccccc4)C3)=C(N)NC(C)=C2C(=O)OC(C)C)ccc1		Inactive	Ca channel blocker - DHP class		1	Azelnidipine	174006618.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	28.663750504&0.0	O=[N+]([O-])c1cc(C2C(C(=O)OC3CN(C(c4ccccc4)c4ccccc4)C3)=C(N)NC(C)=C2C(=O)OC(C)C)ccc1	O=[N+]([O-])c1cc(C2C(C(=O)OC3CN(C(c4ccccc4)c4ccccc4)C3)=C(N)NC(C)=C2C(=O)OC(C)C)ccc1
NCGC00015713-13	O=[N+]([O-])c1cc(C2C(C(=O)OCC)=C(C)NC(C)=C2C(=O)OC)ccc1		Inactive	Intermediate conductance calcium-activated potassium channel protein 4 Inhibitor		1	Nitrendipine	170465897.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&6.9138984399	O=[N+]([O-])c1cc(C2C(C(=O)OCC)=C(C)NC(C)=C2C(=O)OC)ccc1	O=[N+]([O-])c1cc(C2C(C(=O)OCC)=C(C)NC(C)=C2C(=O)OC)ccc1
NCGC00163135-04	O=[N+]([O-])c1cc(C2C(C(=O)OCCCN3CCC(c4ccccc4)(c4ccccc4)CC3)=C(C)NC(C)=C2C(=O)OC)ccc1		Inactive	L-type Ca2+ channel Blocker		1	Niguldipine	124892401.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	27.6129524961	O=[N+]([O-])c1cc(C2C(C(=O)OCCCN3CCC(c4ccccc4)(c4ccccc4)CC3)=C(C)NC(C)=C2C(=O)OC)ccc1	O=[N+]([O-])c1cc(C2C(C(=O)OCCCN3CCC(c4ccccc4)(c4ccccc4)CC3)=C(C)NC(C)=C2C(=O)OC)ccc1
NCGC00015747-09	O=[N+]([O-])c1cc(C2C(C(=O)OCCN(Cc3ccccc3)C)=C(C)NC(C)=C2C(=O)OC)ccc1	5.0	Active	Ca channel blocker - DHP class	0.0	1	Nicardipine	170465173.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	63.5876565971	O=[N+]([O-])c1cc(C2C(C(=O)OCCN(Cc3ccccc3)C)=C(C)NC(C)=C2C(=O)OC)ccc1	O=[N+]([O-])c1cc(C2C(C(=O)OCCN(Cc3ccccc3)C)=C(C)NC(C)=C2C(=O)OC)ccc1
NCGC00182046-04	O=[N+]([O-])c1cc(C2C(C(=O)OCCN(Cc3ccccc3)c3ccccc3)=C(C)NC(C)=C2P2(=O)OCC(C)(C)CO2)ccc1		Inactive			1	Efonidipine hydrochloride monoethanolate		Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1cc(C2C(C(=O)OCCN(Cc3ccccc3)c3ccccc3)=C(C)NC(C)=C2P2(=O)OCC(C)(C)CO2)ccc1	O=[N+]([O-])c1cc(C2C(C(=O)OCCN(Cc3ccccc3)c3ccccc3)=C(C)NC(C)=C2P2(=O)OCC(C)(C)CO2)ccc1
NCGC00167493-04	O=[N+]([O-])c1cc(C2C(C(=O)OCCN3CCN(C(c4ccccc4)c4ccccc4)CC3)=C(C)NC(C)=C2C(=O)OC)ccc1	5.0250001	Active	Calcium Channel Blocker	0.0	1	Manidipine	174006297.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	33.5776539119&60.8800897361	O=[N+]([O-])c1cc(C2C(C(=O)OCCN3CCN(C(c4ccccc4)c4ccccc4)CC3)=C(C)NC(C)=C2C(=O)OC)ccc1.Cl.Cl	O=[N+]([O-])c1cc(C2C(C(=O)OCCN3CCN(C(c4ccccc4)c4ccccc4)CC3)=C(C)NC(C)=C2C(=O)OC)ccc1.Cl.Cl
NCGC00253607-01	O=[N+]([O-])c1cc(C2C(C(=O)OCCc3ccc(N4CCN(C(c5ccccc5)c5ccccc5)CC4)cc3)=C(C)NC(C)=C2C(=O)OC)ccc1		Inactive	calcium ion transmembrane transport Blocker		1	Watanidipine	170465844.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=[N+]([O-])c1cc(C2C(C(=O)OCCc3ccc(N4CCN(C(c5ccccc5)c5ccccc5)CC4)cc3)=C(C)NC(C)=C2C(=O)OC)ccc1	O=[N+]([O-])c1cc(C2C(C(=O)OCCc3ccc(N4CCN(C(c5ccccc5)c5ccccc5)CC4)cc3)=C(C)NC(C)=C2C(=O)OC)ccc1
NCGC00167492-03	O=[N+]([O-])c1cc(C2C(C(OC(CN(CCC(c3ccccc3)c3ccccc3)C)(C)C)=O)=C(C)NC(C)=C2C(=O)OC)ccc1	4.9499998	Active	Voltage-gated L-type calcium channel Blocker	0.0	1	Lercanidipine hydrochloride	170465587.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	41.3252148971	O=[N+]([O-])c1cc(C2C(C(OC(CN(CCC(c3ccccc3)c3ccccc3)C)(C)C)=O)=C(C)NC(C)=C2C(=O)OC)ccc1.Cl	O=[N+]([O-])c1cc(C2C(C(OC(CN(CCC(c3ccccc3)c3ccccc3)C)(C)C)=O)=C(C)NC(C)=C2C(=O)OC)ccc1.Cl
NCGC00015571-07	O=[N+]([O-])c1cc(C=2NC(=O)N(c3c(O)cccc3)CC=2)ccc1		Inactive	Transient receptor potential cation channel subfamily M member 8 Agonist		1	ICILIN	363676457.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1cc(C=2NC(=O)N(c3c(O)cccc3)CC=2)ccc1	O=[N+]([O-])c1cc(C=2NC(=O)N(c3c(O)cccc3)CC=2)ccc1
NCGC00262625-01	O=[N+]([O-])c1cc(Cc2nn(C(C)(C)C)c3ncnc(N)c23)ccc1		Inactive			1	NCGC00262625-01	377020518.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1cc(Cc2nn(C(C)(C)C)c3ncnc(N)c23)ccc1	O=[N+]([O-])c1cc(Cc2nn(C(C)(C)C)c3ncnc(N)c23)ccc1
NCGC00370829-01	O=[N+]([O-])c1cc(N2C(=O)N(Cc3ccncc3)C(=O)c3c2nccc3)ccc1		Inactive	Phosphodiesterase 4D Inhibitor		1	RS 25344 hydrochloride	363677873.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1cc(N2C(=O)N(Cc3ccncc3)C(=O)c3c2nccc3)ccc1	O=[N+]([O-])c1cc(N2C(=O)N(Cc3ccncc3)C(=O)c3c2nccc3)ccc1
NCGC00185768-03	O=[N+]([O-])c1cc([C@@H]2C(C(=O)OC)=C(C)NC(C)=C2C(=O)O[C@H]2CN(Cc3ccccc3)CCC2)ccc1	4.9000001	Active		0.0	1	Benidipine HCl	363677104.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	75.6607076799	O=[N+]([O-])c1cc([C@@H]2C(C(=O)OC)=C(C)NC(C)=C2C(=O)O[C@H]2CN(Cc3ccccc3)CCC2)ccc1	O=[N+]([O-])c1cc([C@@H]2C(C(=O)OC)=C(C)NC(C)=C2C(=O)O[C@H]2CN(Cc3ccccc3)CCC2)ccc1
NCGC00094736-05	O=[N+]([O-])c1cc([N+](=O)[O-])cc(C(=O)N)c1		Inactive	Eimeria tenella Inhibitor		1	Nitromide	170466818.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=[N+]([O-])c1cc([N+](=O)[O-])cc(C(=O)N)c1	O=[N+]([O-])c1cc([N+](=O)[O-])cc(C(=O)N)c1
NCGC00091351-01	O=[N+]([O-])c1cc([N+](=O)[O-])ccc1		Inactive			1	m-Dinitrobenzene	17388932.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1cc([N+](=O)[O-])ccc1	O=[N+]([O-])c1cc([N+](=O)[O-])ccc1
NCGC00370965-01	O=[N+]([O-])c1cc2c(C(=O)C(=O)N[C@H](C)c3ccccc3)c[nH]c2cc1		Inactive	GABA-A receptor; alpha-1/beta-2/gamma-2 Partial Agonist		1	TCS 1205	363677962.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1cc2c(C(=O)C(=O)N[C@H](C)c3ccccc3)c[nH]c2cc1	O=[N+]([O-])c1cc2c(C(=O)C(=O)N[C@H](C)c3ccccc3)c[nH]c2cc1
NCGC00390459-02	O=[N+]([O-])c1cc2c([nH]c3-c4c(NC(=O)Cc23)cccc4)cc1		Inactive			1	Alsterpaullone		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	15.73119288	O=[N+]([O-])c1cc2c([nH]c3-c4c(NC(=O)Cc23)cccc4)cc1	O=[N+]([O-])c1cc2c([nH]c3-c4c(NC(=O)Cc23)cccc4)cc1
NCGC00386828-02	O=[N+]([O-])c1cc2c(c(CO)n(C)c2cc1)-c1ccccc1		Inactive			1	ML 354	363680453.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1cc2c(c(CO)n(C)c2cc1)-c1ccccc1	O=[N+]([O-])c1cc2c(c(CO)n(C)c2cc1)-c1ccccc1
NCGC00381605-01	O=[N+]([O-])c1cc2n(C)cc(C3=C(c4c5c(n(C)c4)cccc5)C(=O)NC3=O)c2cc1		Inactive	PKC Inhibitor		1	MKC-1	384569101.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1cc2n(C)cc(C3=C(c4c5c(n(C)c4)cccc5)C(=O)NC3=O)c2cc1	O=[N+]([O-])c1cc2n(C)cc(C3=C(c4c5c(n(C)c4)cccc5)C(=O)NC3=O)c2cc1
NCGC00402245-03	O=[N+]([O-])c1cc2sc(NC(=O)C3CCCCC3)nc2cc1		Inactive	Voltage-gated L-type calcium channel Modulator		1	HUP30	363680998.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1cc2sc(NC(=O)C3CCCCC3)nc2cc1	O=[N+]([O-])c1cc2sc(NC(=O)C3CCCCC3)nc2cc1
NCGC00370928-02	O=[N+]([O-])c1ccc(-c2oc(/C=C\3/C(=O)N(c4ccc(C(=O)O)cc4)C(c4ccccc4)=C/3)cc2)cc1		Inactive	Eukaryotic translation initation factor Inhibitor		1	4E1RCat	363677940.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1ccc(-c2oc(/C=C\3/C(=O)N(c4ccc(C(=O)O)cc4)C(c4ccccc4)=C/3)cc2)cc1	O=[N+]([O-])c1ccc(-c2oc(/C=C\3/C(=O)N(c4ccc(C(=O)O)cc4)C(c4ccccc4)=C/3)cc2)cc1
NCGC00024622-05	O=[N+]([O-])c1ccc(-c2oc(/C=N/N3C(=O)NC(=O)C3)cc2)cc1		Inactive	Ryanodine receptor 1 Antagonist		1	Dantrolene sodium	170464793.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&20.979371316	O=[N+]([O-])c1ccc(-c2oc(/C=N/N3C(=O)[N-]C(=O)C3)cc2)cc1.[Na+]	O=[N+]([O-])c1ccc(-c2oc(/C=N/N3C(=O)[N-]C(=O)C3)cc2)cc1.[Na+]
NCGC00384206-05	O=[N+]([O-])c1ccc(/C=C\2/C(=O)/C(=C/c3ccc([N+](=O)[O-])cc3)/CN(C(=O)C=C)C/2)cc1		Inactive			1	b-AP15	434147123.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1ccc(/C=C\2/C(=O)/C(=C/c3ccc([N+](=O)[O-])cc3)/CN(C(=O)C=C)C/2)cc1	O=[N+]([O-])c1ccc(/C=C\2/C(=O)/C(=C/c3ccc([N+](=O)[O-])cc3)/CN(C(=O)C=C)C/2)cc1
NCGC00487312-01	O=[N+]([O-])c1ccc(C#CC(=O)OC)cc1		Inactive			1	NPP	377020309.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1ccc(C#CC(=O)OC)cc1	O=[N+]([O-])c1ccc(C#CC(=O)OC)cc1
NCGC00388142-01	O=[N+]([O-])c1ccc(C(=O)CN2C(=N)SC3=C2CCCC3)cc1		Inactive			1	p-nitro-Pifithrin-?		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1ccc(C(=O)CN2C(=N)SC3=C2CCCC3)cc1	O=[N+]([O-])c1ccc(C(=O)CN2C(=N)SC3=C2CCCC3)cc1
NCGC00379100-01	O=[N+]([O-])c1ccc(C(=O)Nc2c(C(=O)Nc3ccc(CCO)cc3)cccc2)cc1		Inactive	ATP-binding cassette sub-family G member 2 Inhibitor		1	KS 176	363678350.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1ccc(C(=O)Nc2c(C(=O)Nc3ccc(CCO)cc3)cccc2)cc1	O=[N+]([O-])c1ccc(C(=O)Nc2c(C(=O)Nc3ccc(CCO)cc3)cccc2)cc1
NCGC00370929-02	O=[N+]([O-])c1ccc(C(=O)Nc2n(-c3ccccc3)nc(-c3ccccc3)c2)cc1		Inactive	Metabotropic glutamate receptor 5 Positive Allosteric Modulator		1	VU 29	363677941.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1ccc(C(=O)Nc2n(-c3ccccc3)nc(-c3ccccc3)c2)cc1	O=[N+]([O-])c1ccc(C(=O)Nc2n(-c3ccccc3)nc(-c3ccccc3)c2)cc1
NCGC00388157-02	O=[N+]([O-])c1ccc(C(=O)OCc2nc(Nc3ccccc3)nc(N)n2)cc1		Inactive	Ubiquitin-conjugating enzyme E2 B Inhibitor		1	TZ9	363680724.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1ccc(C(=O)OCc2nc(Nc3ccccc3)nc(N)n2)cc1	O=[N+]([O-])c1ccc(C(=O)OCc2nc(Nc3ccccc3)nc(N)n2)cc1
NCGC00179658-04	O=[N+]([O-])c1ccc(C(CC(=O)C)C=2C(=O)Oc3c(C=2O)cccc3)cc1		Inactive	Vitamin k epoxide reductase complex subunit 1 isoform 1 Inhibitor		1	Acenocoumarol	170465636.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1ccc(C(CC(=O)C)C=2C(=O)Oc3c(C=2O)cccc3)cc1	O=[N+]([O-])c1ccc(C(CC(=O)C)C=2C(=O)Oc3c(C=2O)cccc3)cc1
NCGC00378797-01	O=[N+]([O-])c1ccc(C2=NN(c3ccccc3)C(=O)C2)cc1		Inactive	Prion protein Inhibitor		1	TCS PrP Inhibitor 13	363678204.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1ccc(C2=NN(c3ccccc3)C(=O)C2)cc1	O=[N+]([O-])c1ccc(C2=NN(c3ccccc3)C(=O)C2)cc1
NCGC00370923-11	O=[N+]([O-])c1ccc(C2C(C(=O)OC3CCCCC3)=C(C)NC3=C2C(=O)CC(C)(C)C3)cc1		Inactive	Notch signaling pathway Inhibitor		1	FLI-06	363677937.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1ccc(C2C(C(=O)OC3CCCCC3)=C(C)NC3=C2C(=O)CC(C)(C)C3)cc1	O=[N+]([O-])c1ccc(C2C(C(=O)OC3CCCCC3)=C(C)NC3=C2C(=O)CC(C)(C)C3)cc1
NCGC00164637-02	O=[N+]([O-])c1ccc(CCCN(CCO)CCNC=2N(C)C(=O)N(C)C(=O)C=2)cc1		Inactive	K(ATP) Channel Blocker		1	Nifekalant	170465960.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1ccc(CCCN(CCO)CCNC=2N(C)C(=O)N(C)C(=O)C=2)cc1.Cl	O=[N+]([O-])c1ccc(CCCN(CCO)CCNC=2N(C)C(=O)N(C)C(=O)C=2)cc1.Cl
NCGC00370865-01	O=[N+]([O-])c1ccc(C[C@H](NC(=O)c2c3c(ccc2)cccc3)C(=O)OC)cc1		Inactive	C-C chemokine receptor type 3 Antagonist		1	SB 328437	363677894.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1ccc(C[C@H](NC(=O)c2c3c(ccc2)cccc3)C(=O)OC)cc1	O=[N+]([O-])c1ccc(C[C@H](NC(=O)c2c3c(ccc2)cccc3)C(=O)OC)cc1
NCGC00378666-01	O=[N+]([O-])c1ccc(NC(=O)N[C@](C(=O)NCC2(c3ncc(OC)cc3)CCCCC2)(Cc2c3c([nH]c2)cccc3)C)cc1		Inactive	Neuromedin B receptor Antagonist		1	PD 176252	363678141.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	16.088735524	O=[N+]([O-])c1ccc(NC(=O)N[C@](C(=O)NCC2(c3ncc(OC)cc3)CCCCC2)(Cc2c3c([nH]c2)cccc3)C)cc1	O=[N+]([O-])c1ccc(NC(=O)N[C@](C(=O)NCC2(c3ncc(OC)cc3)CCCCC2)(Cc2c3c([nH]c2)cccc3)C)cc1
NCGC00166218-02	O=[N+]([O-])c1ccc(NC(=O)Nc2ccc([N+](=O)[O-])cc2)cc1		Inactive			1	4,4'-Dinitrodiphenylurea	170465744.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=[N+]([O-])c1ccc(NC(=O)Nc2ccc([N+](=O)[O-])cc2)cc1	O=[N+]([O-])c1ccc(NC(=O)Nc2ccc([N+](=O)[O-])cc2)cc1
NCGC00387460-02	O=[N+]([O-])c1ccc(NN2C(C(O)CCCCCCCCCC)C=CC3C(=O)N(c4ccccc4)C(=O)C23)cc1		Inactive			1	A12B4C3	377020385.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1ccc(NN2C(C(O)CCCCCCCCCC)C=CC3C(=O)N(c4ccccc4)C(=O)C23)cc1	O=[N+]([O-])c1ccc(NN2C(C(O)CCCCCCCCCC)C=CC3C(=O)N(c4ccccc4)C(=O)C23)cc1
NCGC00370729-08	O=[N+]([O-])c1ccc(Nc2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1	5.0500002	Active		0.0	1	MHY1485		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	3.0	70.1136644423	O=[N+]([O-])c1ccc(Nc2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1	O=[N+]([O-])c1ccc(Nc2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1
NCGC00263237-09	O=[N+]([O-])c1ccc(OC(=O)N2CCC(C(O)(c3cc4OCOc4cc3)c3cc4OCOc4cc3)CC2)cc1		Inactive	Monoacylglycerol lipase (MAGL) Inhibitor		1	JZL-184	384568681.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=[N+]([O-])c1ccc(OC(=O)N2CCC(C(O)(c3cc4OCOc4cc3)c3cc4OCOc4cc3)CC2)cc1	O=[N+]([O-])c1ccc(OC(=O)N2CCC(C(O)(c3cc4OCOc4cc3)c3cc4OCOc4cc3)CC2)cc1
NCGC00346837-02	O=[N+]([O-])c1ccc(OC(=O)N2CCN(Cc3cc(Oc4ccccc4)ccc3)CC2)cc1		Inactive	Monoacylglycerol lipase (MAGL) Inhibitor		1	JZL-195	363677547.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1ccc(OC(=O)N2CCN(Cc3cc(Oc4ccccc4)ccc3)CC2)cc1	O=[N+]([O-])c1ccc(OC(=O)N2CCN(Cc3cc(Oc4ccccc4)ccc3)CC2)cc1
NCGC00386326-01	O=[N+]([O-])c1ccc(Oc2c(c(O)cc(O)c2)-c2onc(C(=O)NC3CCN(C)CC3)c2)cc1		Inactive	Heat shock protein HSP 90-alpha Inhibitor		1	NMS-E973	363680212.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1ccc(Oc2c(c(O)cc(O)c2)-c2onc(C(=O)NC3CCN(C)CC3)c2)cc1	O=[N+]([O-])c1ccc(Oc2c(c(O)cc(O)c2)-c2onc(C(=O)NC3CCN(C)CC3)c2)cc1
NCGC00347955-03	O=[N+]([O-])c1ccc([C@@H](NC(=O)c2cc3c(C)c(C)n(Cc4ccc(-c5c(C(=O)O)cccc5)cc4)c3cc2)C)cc1		Inactive	PPARgamma Modulator		1	SR-1664	384568999.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1ccc([C@@H](NC(=O)c2cc3c(C)c(C)n(Cc4ccc(-c5c(C(=O)O)cccc5)cc4)c3cc2)C)cc1	O=[N+]([O-])c1ccc([C@@H](NC(=O)c2cc3c(C)c(C)n(Cc4ccc(-c5c(C(=O)O)cccc5)cc4)c3cc2)C)cc1
NCGC00263224-03	O=[N+]([O-])c1ccc([C@@H](O)[C@H](NC(=O)CCCCCCCCCCCCC)CO)cc1		Inactive	Ceramidase Inhibitor		1	D-NMAPPD	384568678.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1ccc([C@@H](O)[C@H](NC(=O)CCCCCCCCCCCCC)CO)cc1	O=[N+]([O-])c1ccc([C@@H](O)[C@H](NC(=O)CCCCCCCCCCCCC)CO)cc1
NCGC00091398-01	O=[N+]([O-])c1ccccc1		Inactive	Glutathione reductase Inhibitor		1	Nitrobenzene	17389793.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1ccccc1	O=[N+]([O-])c1ccccc1
NCGC00485395-01	O=[N+]([O-])c1cnc(Oc2cc3c(OC(c4ccccc4)CC3)cc2)cc1		Inactive	Sodium/calcium exchanger 1 Inhibitor		1	ORM-10103	363681309.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1cnc(Oc2cc3c(OC(c4ccccc4)CC3)cc2)cc1	O=[N+]([O-])c1cnc(Oc2cc3c(OC(c4ccccc4)CC3)cc2)cc1
NCGC00166238-02	O=[N+]([O-])c1n(CC(=O)NCc2ccccc2)ccn1		Inactive	Pyruvate:ferredoxin oxidoreductase Substrate		1	Benznidazole	170466539.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1n(CC(=O)NCc2ccccc2)ccn1	O=[N+]([O-])c1n(CC(=O)NCc2ccccc2)ccn1
NCGC00095158-04&NCGC00095158-08	O=[N+]([O-])c1n(CC(O)C)c(C)nc1		Inactive	antiprotozoal agent		2	Secnidazole	170466630.0&405559097.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=[N+]([O-])c1n(CC(O)C)c(C)nc1	O=[N+]([O-])c1n(CC(O)C)c(C)nc1
NCGC00485480-01	O=[N+]([O-])c1n(CC(O)CN2CCOCC2)c(C)nc1		Inactive	UDP-glucuronosyltransferase 1-9 Substrate		1	Morinidazole	363681349.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1n(CC(O)CN2CCOCC2)c(C)nc1	O=[N+]([O-])c1n(CC(O)CN2CCOCC2)c(C)nc1
NCGC00261977-03	O=[N+]([O-])c1n(CCN2CCOCC2)cnc1		Inactive	Radiosensitizers		1	Nimorazole	384568569.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1n(CCN2CCOCC2)cnc1	O=[N+]([O-])c1n(CCN2CCOCC2)cnc1
NCGC00016446-17	O=[N+]([O-])c1n(CCO)c(C)nc1		Inactive	Antibiotic		1	Metronidazole	405558937.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1n(CCO)c(C)nc1	O=[N+]([O-])c1n(CCO)c(C)nc1
NCGC00160502-01	O=[N+]([O-])c1n(CCOC(=O)c2ccccc2)c(C)nc1		Inactive			1	NCGC00160502-01	29216184.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1n(CCOC(=O)c2ccccc2)c(C)nc1	O=[N+]([O-])c1n(CCOC(=O)c2ccccc2)c(C)nc1
NCGC00183013-01	O=[N+]([O-])c1n(CO[C@H]([C@H](O)CO)CO)ccn1		Inactive	Apoptosis Modulator		1	Doranidazole	144206845.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1n(CO[C@H]([C@H](O)CO)CO)ccn1	O=[N+]([O-])c1n(CO[C@H]([C@H](O)CO)CO)ccn1
NCGC00485477-01	O=[N+]([O-])c1n(C[C@H](O)CN2CCOCC2)c(C)nc1		Inactive	UDP-glucuronosyltransferase 1-9 Substrate		1	Morinidazole (R enantiomer)	363681346.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O=[N+]([O-])c1n(C[C@H](O)CN2CCOCC2)c(C)nc1	O=[N+]([O-])c1n(C[C@H](O)CN2CCOCC2)c(C)nc1
NCGC00183106-01	O=[N+]([O-])c1oc(/C=C/c2nc(CO)ccc2)cc1		Inactive	Aeromonas salmonicida Inhibitor		1	NCGC00183106-01	124894306.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1oc(/C=C/c2nc(CO)ccc2)cc1	O=[N+]([O-])c1oc(/C=C/c2nc(CO)ccc2)cc1
NCGC00091505-07	O=[N+]([O-])c1oc(/C=N/N2C(=O)NC(=O)C2)cc1		Inactive	Probable pyruvate-flavodoxin oxidoreductase Substrate		1	Nitrofurantoin	170464739.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=[N+]([O-])c1oc(/C=N/N2C(=O)NC(=O)C2)cc1	O=[N+]([O-])c1oc(/C=N/N2C(=O)NC(=O)C2)cc1
NCGC00095304-05	O=[N+]([O-])c1oc(/C=N/N2C(=O)OCC2)cc1		Inactive	DNA Crosslinking Agent		1	Furazolidone	170464641.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=[N+]([O-])c1oc(/C=N/N2C(=O)OCC2)cc1	O=[N+]([O-])c1oc(/C=N/N2C(=O)OCC2)cc1
NCGC00090686-11	O=[N+]([O-])c1oc(/C=N/NC(=O)N)cc1		Inactive	Antibiotic		1	Nitrofurazone	170464946.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1oc(/C=N/NC(=O)N)cc1	O=[N+]([O-])c1oc(/C=N/NC(=O)N)cc1
NCGC00164507-02	O=[N+]([O-])c1oc(CN=O)cc1		Inactive			1	Nifuroxime	124893124.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=[N+]([O-])c1oc(CN=O)cc1	O=[N+]([O-])c1oc(CN=O)cc1
NCGC00371125-09	O=[N+]([O-])c1sc(NC(=O)NCc2ccc(OC)cc2)nc1	4.9000001	Active	GSK-3 alpha Inhibitor	0.0	1	AR-A014418	363678041.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	72.811843721	O=[N+]([O-])c1sc(NC(=O)NCc2ccc(OC)cc2)nc1	O=[N+]([O-])c1sc(NC(=O)NCc2ccc(OC)cc2)nc1
NCGC00388427-02	O=[N+]([O-])c1sc(NC(=O)c2c(O)cccc2)nc1	5.5	Active	Trichomonas vaginalis Inhibitor	0.0	1	Tizoxanide	434146885.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	1.4	39.30635415	O=[N+]([O-])c1sc(NC(=O)c2c(O)cccc2)nc1	O=[N+]([O-])c1sc(NC(=O)c2c(O)cccc2)nc1
NCGC00090774-05&NCGC00090774-12	O=[N+]([O-])c1sc(NC(=O)c2c(OC(=O)C)cccc2)nc1	5.17499995	Active	antiprotozoal agent	0.45000030000000013	2	Nitazoxanide	170465090.0&384568086.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General&SARS-CoV-2 cytopathic effect (CPE)	3.0&2.2&1.1&3.0	60.3321271339&53.1627864329&84.1239327444&98.3779904283	O=[N+]([O-])c1sc(NC(=O)c2c(OC(=O)C)cccc2)nc1	O=[N+]([O-])c1sc(NC(=O)c2c(OC(=O)C)cccc2)nc1
NCGC00390788-02	O=[N+]1N=C(N)N([O-])c2c1cccc2		Inactive	DNA-Damaging Drugs		1	Tirapazamine	384569214.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[O-][n+]1c(N)n[n+]([O-])c2c1cccc2	[O-][n+]1c(N)n[n+]([O-])c2c1cccc2
NCGC00385897-01	OC(/C=C/C1(O)C2(C)OCC1(C)CC(O)C2)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385897-01	363679996.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC(/C=C/C1(O)C2(C)OCC1(C)CC(O)C2)C	OC(/C=C/C1(O)C2(C)OCC1(C)CC(O)C2)C
NCGC00242511-03&NCGC00242511-04	OC(/C=C/C=C/[C@@H](C)[C@@H]1C2(C)[C@H](/C(=C/C=C\3/C(=C)[C@@H](O)C[C@H](O)C/3)/CCC2)CC1)(CC)CC		Inactive	Vitamin D Analog		2	Seocalcitol	384568505.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OC(/C=C/C=C/[C@@H](C)[C@@H]1C2(C)[C@H](/C(=C/C=C\3/C(=C)[C@@H](O)C[C@H](O)C/3)/CCC2)CC1)(CC)CC	OC(/C=C/C=C/[C@@H](C)[C@@H]1C2(C)[C@H](/C(=C/C=C\3/C(=C)[C@@H](O)C[C@H](O)C/3)/CCC2)CC1)(CC)CC
NCGC00381348-01	OC(/C=C/CC(C)C1CC(O)C(O)(C)CC1)(C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381348-01	363679100.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC(/C=C/CC(C)C1CC(O)C(O)(C)CC1)(C)C	OC(/C=C/CC(C)C1CC(O)C(O)(C)CC1)(C)C
NCGC00486863-01	OC(=N)Nc1cc2/C(=C(\C)/c3[nH]ccc3)/C(O)=Nc2cc1		Inactive			1	BX517(PDK1 inhibitor2)	377020201.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC(=N)Nc1cc2/C(=C(\C)/c3[nH]ccc3)/C(O)=Nc2cc1	OC(=N)Nc1cc2/C(=C(\C)/c3[nH]ccc3)/C(O)=Nc2cc1
NCGC00386026-01	OC(C(=C)CCC1C(O)(C)CCC2C(C)(C)C(O)CCC12C)CO		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386026-01	363680067.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC(C(=C)CCC1C(O)(C)CCC2C(C)(C)C(O)CCC12C)CO	OC(C(=C)CCC1C(O)(C)CCC2C(C)(C)C(O)CCC12C)CO
NCGC00185769-02	OC(C(C)(C)C)C=Cc1cc2OCOc2cc1		Inactive	Gaba Synthesis, Release, Reuptake And Degradation Modulator		1	Stiripentol	405558693.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(C(C)(C)C)C=Cc1cc2OCOc2cc1	OC(C(C)(C)C)C=Cc1cc2OCOc2cc1
NCGC00024643-10	OC(C(C)N1CCC(Cc2ccccc2)CC1)c1ccc(O)cc1		Inactive	Kir3.1/Kir3.4 Inhibitor		1	Ifenprodil	170465791.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&-13.008537748	OC(C(C)N1CCC(Cc2ccccc2)CC1)c1ccc(O)cc1	OC(C(C)N1CCC(Cc2ccccc2)CC1)c1ccc(O)cc1
NCGC00091575-03	OC(C(CO)CC)CCC		Inactive			1	2-Ethyl-1,3-hexanediol	170465521.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OC(C(CO)CC)CCC	OC(C(CO)CC)CCC
NCGC00249896-01	OC(C(N(C/C=C/c1ccccc1)C)C)c1ccccc1		Inactive			1	Cinnamedrine	170465535.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	11.448905108&0.0	OC(C(N(C/C=C/c1ccccc1)C)C)c1ccccc1	OC(C(N(C/C=C/c1ccccc1)C)C)c1ccccc1
NCGC00510907-01	OC(C(N(CC)C)C)c1ccccc1		Inactive	Beta-2 adrenergic receptor Agonist		1	Etafedrine hydrochloride	405558912.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(C(N(CC)C)C)c1ccccc1	OC(C(N(CC)C)C)c1ccccc1
NCGC00018239-11	OC(C(NC(C)C)CC)c1cc(O)c(O)cc1		Inactive			1	ISOETHARINE MESYLATE	405558425.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(C(NC(C)C)CC)c1cc(O)c(O)cc1	OC(C(NC(C)C)CC)c1cc(O)c(O)cc1
NCGC00015716-09	OC(C(NC(CCc1ccccc1)C)C)c1ccc(O)cc1		Inactive	Glutamate NMDA receptor; Grin1/Grin2c Antagonist		1	Nylidrin	170465637.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(C(NC(CCc1ccccc1)C)C)c1ccc(O)cc1	OC(C(NC(CCc1ccccc1)C)C)c1ccc(O)cc1
NCGC00015408-05	OC(C(NC)C)c1ccccc1		Inactive	Norepinephrine Transporter Inhibitor		1	RACEPHEDRINE HYDROCHLORIDE	405558670.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(C(NC)C)c1ccccc1	OC(C(NC)C)c1ccccc1
NCGC00015887-06	OC(C(NCCc1ccc(O)cc1)C)c1ccc(O)cc1		Inactive	beta2-Adrenoceptor Agonist		1	Ritodrine hydrochloride	384567901.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(C(NCCc1ccc(O)cc1)C)c1ccc(O)cc1	OC(C(NCCc1ccc(O)cc1)C)c1ccc(O)cc1
NCGC00384806-01	OC(C(O)CC1C(O)(C)C(O)C(O)C2C(C)(C)CCCC12C)(C=C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384806-01	363679366.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC(C(O)CC1C(O)(C)C(O)C(O)C2C(C)(C)CCCC12C)(C=C)C	OC(C(O)CC1C(O)(C)C(O)C(O)C2C(C)(C)CCCC12C)(C=C)C
NCGC00347588-02	OC(C(O)c1cc2c(C)c(-c3cc4OCOc4cc3)oc2cc1)C		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347588-02	363677633.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC(C(O)c1cc2c(C)c(-c3cc4OCOc4cc3)oc2cc1)C	OC(C(O)c1cc2c(C)c(-c3cc4OCOc4cc3)oc2cc1)C
NCGC00385400-01	OC(C(c1c2c([nH]c1)cccc2)c1c2c([nH]c1)cccc2)CO		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385400-01	363679722.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC(C(c1c2c([nH]c1)cccc2)c1c2c([nH]c1)cccc2)CO	OC(C(c1c2c([nH]c1)cccc2)c1c2c([nH]c1)cccc2)CO
NCGC00347660-02	OC(C)(C)C1C2C(C)(CC(O)C(=C)CCC(O)C(=C)CC2)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347660-02	363677659.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC(C)(C)C1C2C(C)(CC(O)C(=C)CCC(O)C(=C)CC2)CC1	OC(C)(C)C1C2C(C)(CC(O)C(=C)CCC(O)C(=C)CC2)CC1
NCGC00385861-01	OC(C)(C)C1C2C3C(C)(C4(CO)C(C3O)C24)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385861-01	363679973.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC(C)(C)C1C2C3C(C)(C4(CO)C(C3O)C24)CC1	OC(C)(C)C1C2C3C(C)(C4(CO)C(C3O)C24)CC1
NCGC00385844-01	OC(C)(C)C1CC2C(O)(C)CCCC2(C)CC1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Sphaeranthus | Family: Compositae | Species: suaveolens		1	NCGC00385844-01	363679965.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC(C)(C)C1CC2C(O)(C)CCCC2(C)CC1	OC(C)(C)C1CC2C(O)(C)CCCC2(C)CC1
NCGC00164431-01	OC(C)(C)C1CC=C(C)CC1		Inactive	Acetylcholinesterase Inhibitor		1	Terpineol	144205671.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(C)(C)C1CC=C(C)CC1	OC(C)(C)C1CC=C(C)CC1
NCGC00159414-01	OC(C)(C)C1CCC(O)(C)CC1		Inactive			1	p-Menthane-1,8-diol monohydrate	225144225.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(C)(C)C1CCC(O)(C)CC1	OC(C)(C)C1CCC(O)(C)CC1
NCGC00521941-01	OC(C)(C)c1cc2n([C@H](c3ccccc3)C3CCOCC3)c3c(ncc(-c4n(C)nnc4C)c3)c2cc1		Inactive	Brd4 Inhibitor		1	BMS-986158	384569506.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(C)(C)c1cc2n([C@H](c3ccccc3)C3CCOCC3)c3c(ncc(-c4n(C)nnc4C)c3)c2cc1	OC(C)(C)c1cc2n([C@H](c3ccccc3)C3CCOCC3)c3c(ncc(-c4n(C)nnc4C)c3)c2cc1
NCGC00386556-01	OC(C)(C)c1cc2ncn(-c3cc(-c4c(C#N)cccc4)ccc3)c2cc1		Inactive	GABA-A receptor; anion channel Positive Allosteric Modulator		1	NS 11394	363680326.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC(C)(C)c1cc2ncn(-c3cc(-c4c(C#N)cccc4)ccc3)c2cc1	OC(C)(C)c1cc2ncn(-c3cc(-c4c(C#N)cccc4)ccc3)c2cc1
NCGC00345837-03	OC(C)(C)c1sc2c(N3CCOCC3)nc(-c3c(C)nc(N)nc3)nc2c1		Inactive	PI3K Inhibitor		1	GNE-490	384568761.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(C)(C)c1sc2c(N3CCOCC3)nc(-c3c(C)nc(N)nc3)nc2c1	OC(C)(C)c1sc2c(N3CCOCC3)nc(-c3c(C)nc(N)nc3)nc2c1
NCGC00345838-04	OC(C)(C)c1sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc2c1		Inactive	PI3K Inhibitor		1	GNE-493	363677381.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(C)(C)c1sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc2c1	OC(C)(C)c1sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc2c1
NCGC00344509-02	OC(C)(c1sc2c(n1)cccc2)c1c(C)cc(C)cc1		Inactive	Calcium-Sensing Receptor (CaSR) Agonist		1	AC-265347	384568719.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(C)(c1sc2c(n1)cccc2)c1c(C)cc(C)cc1	OC(C)(c1sc2c(n1)cccc2)c1c(C)cc(C)cc1
NCGC00160543-01	OC(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@H](C[C@@H](O)CC4)CC3)CC2)CC1		Inactive	G-protein coupled bile acid receptor 1 Agonist		1	Pregnandiol	144205439.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@H](C[C@@H](O)CC4)CC3)CC2)CC1	OC(C)[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@H](C[C@@H](O)CC4)CC3)CC2)CC1
NCGC00385734-01	OC(C=C)(C)C1OC2(C)C(O)C(O)C3C(C)(C)CCCC3(C)C2C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385734-01	363679909.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC(C=C)(C)C1OC2(C)C(O)C(O)C3C(C)(C)CCCC3(C)C2C1	OC(C=C)(C)C1OC2(C)C(O)C(O)C3C(C)(C)CCCC3(C)C2C1
NCGC00165972-02	OC(CC)c1ccccc1		Inactive	Glycolysis / Gluconeogenesis Activator		1	1-Phenyl-1-propanol	405559080.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(CC)c1ccccc1	OC(CC)c1ccccc1
NCGC00386274-04	OC(CC1n2c(-c3c1cccc3)cnc2)C1CCCCC1		Inactive	Indoleamine 2,3-dioxygenase 1 Inhibitor		1	NLG919	363680179.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC(CC1n2c(-c3c1cccc3)cnc2)C1CCCCC1	OC(CC1n2c(-c3c1cccc3)cnc2)C1CCCCC1
NCGC00387136-01	OC(CCCC(Nc1c(C#N)c(C)cc(Nc2n[nH]c(C)c2)n1)C)(C)C		Inactive			1	TC-A 2317 hydrochloride	377020394.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC(CCCC(Nc1c(C#N)c(C)cc(Nc2n[nH]c(C)c2)n1)C)(C)C	OC(CCCC(Nc1c(C#N)c(C)cc(Nc2n[nH]c(C)c2)n1)C)(C)C
NCGC00344546-01	OC(CCCC)c1ccccc1		Inactive			1	Fenipentol	225144389.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(CCCC)c1ccccc1	OC(CCCC)c1ccccc1
NCGC00016624-05	OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1		Inactive	Muscarinic acetylcholine receptor M5 Antagonist		1	Diphenidol	170465280.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1	OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1
NCGC00249926-01	OC(CCCN1[C@@H](C)CCC[C@H]1C)(c1ncccc1)c1ccccc1		Inactive			1	Pirmenol	170466004.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OC(CCCN1[C@@H](C)CCC[C@H]1C)(c1ncccc1)c1ccccc1	OC(CCCN1[C@@H](C)CCC[C@H]1C)(c1ncccc1)c1ccccc1
NCGC00161326-08	OC(CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)CC[C@H](O)C\3)/CCC2)CC1)(C)C		Inactive			1	Calcifediol (monohydrate)	405559040.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)CC[C@H](O)C\3)/CCC2)CC1)(C)C	OC(CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)CC[C@H](O)C\3)/CCC2)CC1)(C)C
NCGC00161327-01&NCGC00161327-10&NCGC00161327-11	OC(CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)(C)C		Inactive	Vitamin D Analog		3	Calcitriol	26754891.0&384568203.0&384568204.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	OC(CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)(C)C	OC(CCC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1)(C)C
NCGC00018186-07	OC(CCN1CCCC1)(c1ccccc1)C1CCCCC1		Inactive	Muscarinic acetylcholine receptor M4 Antagonist		1	Procyclidine hydrochloride	170464805.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	28.0	OC(CCN1CCCC1)(c1ccccc1)C1CCCCC1.Cl	OC(CCN1CCCC1)(c1ccccc1)C1CCCCC1.Cl
NCGC00182965-05&NCGC00182965-11	OC(CCN1CCCCC1)(c1ccccc1)C1C2C=CC(C1)C2		Inactive	Anticholinergic		2	Biperiden	170465324.0&384568413.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	24.474921624&12.144382608	OC(CCN1CCCCC1)(c1ccccc1)C1C2C=CC(C1)C2.Cl	OC(CCN1CCCCC1)(c1ccccc1)C1C2C=CC(C1)C2.Cl&OC(CCN1CCCCC1)(c1ccccc1)C1C2C=CC(C1)C2
NCGC00521081-01	OC(CCN1CCCCC1)(c1ccccc1)C1CCCC1		Inactive			1	Cycrimine Hydrochloride	405558993.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(CCN1CCCCC1)(c1ccccc1)C1CCCC1	OC(CCN1CCCCC1)(c1ccccc1)C1CCCC1
NCGC00016003-10	OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1	4.9499998	Active	Muscarinic acetylcholine receptor M5 Antagonist	0.0	1	Trihexyphenidyl hydrochloride	170464756.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	68.5409749375	OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1.Cl	OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1.Cl
NCGC00013289-09	OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1		Inactive	Muscarinic acetylcholine receptor Antagonist		1	Pridinol	170465865.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1	OC(CCN1CCCCC1)(c1ccccc1)c1ccccc1
NCGC00179360-05	OC(CC[N+](CC)(CC)CC)(c1ccccc1)C1CCCCC1		Inactive	Muscarinic acetylcholine receptor M3 Antagonist		1	Tridihexethyl chloride	405558856.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(CC[N+](CC)(CC)CC)(c1ccccc1)C1CCCCC1	OC(CC[N+](CC)(CC)CC)(c1ccccc1)C1CCCCC1
NCGC00167553-02	OC(CN)c1cc(O)ccc1		Inactive	Adrenergic receptor alpha-1 Agonist		1	Norphenylephrine hydrochloride	225144293.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(CN)c1cc(O)ccc1	OC(CN)c1cc(O)ccc1
NCGC00015760-12	OC(CN)c1ccc(O)cc1		Inactive	Dopamine transporter Binding Agent		1	Octopamine	170465959.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OC(CN)c1ccc(O)cc1	OC(CN)c1ccc(O)cc1
NCGC00183838-01	OC(CN1CCCCC1)c1noc(-c2ccccc2)c1		Inactive			1	Perisoxal citrate	144206844.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)C(O)(CC(=O)O)CC(=O)O.OC(CN1CCCCC1)c1noc(-c2ccccc2)c1	O=C(O)C(O)(CC(=O)O)CC(=O)O.OC(CN1CCCCC1)c1noc(-c2ccccc2)c1
NCGC00182972-01	OC(CN1CC[N+](C)(C)CC1)(c1ccccc1)C1CCCCC1		Inactive	Muscarinic acetylcholine receptor M5 Antagonist		1	Hexocyclium	144206775.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(OC)[O-].OC(CN1CC[N+](C)(C)CC1)(c1ccccc1)C1CCCCC1	S(=O)(=O)(OC)[O-].OC(CN1CC[N+](C)(C)CC1)(c1ccccc1)C1CCCCC1
NCGC00015955-16&NCGC00015955-22	OC(CNC(C)(C)C)c1cc(CO)c(O)cc1		Inactive	beta2-Adrenoceptor Agonist		2	Salbutamol sulfate	170465034.0&384567909.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	OC(CNC(C)(C)C)c1cc(CO)c(O)cc1	OC(CNC(C)(C)C)c1cc(CO)c(O)cc1
NCGC00016010-09	OC(CNC(C)(C)C)c1cc(O)cc(O)c1		Inactive	cAMP biosynthetic process Partial Agonist		1	Terbutaline hemisulfate	170464990.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)O.OC(CNC(C)(C)C)c1cc(O)cc(O)c1.OC(CNC(C)(C)C)c1cc(O)cc(O)c1	S(=O)(=O)(O)O.OC(CNC(C)(C)C)c1cc(O)cc(O)c1.OC(CNC(C)(C)C)c1cc(O)cc(O)c1
NCGC00014810-01	OC(CNC(C)(C)C)c1nc(CO)c(O)cc1		Inactive	Beta-2 adrenergic receptor Agonist		1	Pirbuterol hydrochloride	144203612.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(CNC(C)(C)C)c1nc(CO)c(O)cc1.Cl	OC(CNC(C)(C)C)c1nc(CO)c(O)cc1.Cl
NCGC00015558-14&NCGC00015558-16	OC(CNC(C)C)c1cc(O)c(O)cc1		Inactive	beta-Adrenoceptor Agonist		2	Isoprenaline hydrochloride	170464679.0&384567864.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	OC(CNC(C)C)c1cc(O)c(O)cc1	OC(CNC(C)C)c1cc(O)c(O)cc1
NCGC00164602-03	OC(CNC(CCc1ccc(O)cc1)C)c1ccc(O)cc1		Inactive	Beta-2 adrenergic receptor Agonist		1	RACTOPAMINE HYDROCHLORIDE	405558703.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(CNC(CCc1ccc(O)cc1)C)c1ccc(O)cc1	OC(CNC(CCc1ccc(O)cc1)C)c1ccc(O)cc1
NCGC00274276-01	OC(CNC(Cc1cc2OCOc2cc1)C)c1cc(O)c(O)cc1		Inactive	Beta-2 adrenergic receptor Agonist		1	NCGC00274276-01	225144372.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(CNC(Cc1cc2OCOc2cc1)C)c1cc(O)c(O)cc1	OC(CNC(Cc1cc2OCOc2cc1)C)c1cc(O)c(O)cc1
NCGC00015430-06	OC(CNC(Cc1ccc(O)cc1)C)c1cc(O)cc(O)c1		Inactive			1	Fenoterol hydrobromide	170465657.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	OC(CNC(Cc1ccc(O)cc1)C)c1cc(O)cc(O)c1.Br	OC(CNC(Cc1ccc(O)cc1)C)c1cc(O)cc(O)c1.Br
NCGC00015924-24	OC(CNC)c1ccc(O)cc1		Inactive	alpha1-Adrenoceptor Agonist		1	Synephrine	384567908.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(CNC)c1ccc(O)cc1	OC(CNC)c1ccc(O)cc1
NCGC00390678-03	OC(CNCC(CC(CN)CC)CC)CNCC(CC(CN)CC)C		Inactive			1	Sevelamer Hydrochloride (Technical Grade)		Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(CNCC(CC(CN)CC)CC)CNCC(CC(CN)CC)C	OC(CNCC(CC(CN)CC)CC)CNCC(CC(CN)CC)C
NCGC00179276-04	OC(CNCC)c1cc(O)ccc1		Inactive			1	Etilefrine hydrochloride	225144301.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(CNCC)c1cc(O)ccc1	OC(CNCC)c1cc(O)ccc1
NCGC00160423-02	OC(CNCCCC)c1ccc(O)cc1		Inactive			1	Bamethan	225144236.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(CNCCCC)c1ccc(O)cc1	OC(CNCCCC)c1ccc(O)cc1
NCGC00167522-02	OC(CNCCCCCCNCC(O)c1cc(O)c(O)cc1)c1cc(O)c(O)cc1		Inactive	Beta-2 adrenergic receptor Agonist		1	Hexoprenaline sulfate	170465755.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(O)O.OC(CNCCCCCCNCC(O)c1cc(O)c(O)cc1)c1cc(O)c(O)cc1	S(=O)(=O)(O)O.OC(CNCCCCCCNCC(O)c1cc(O)c(O)cc1)c1cc(O)c(O)cc1
NCGC00507892-01	OC(CNc1nc(CC2CC2)c(-c2nc(Nc3ccncc3)ncc2)cn1)(C)C	5.9499998	Active	VPS34 Inhibitor	0.0	1	VPS34 Inhibitor 1 (Compound 19, PIK-III analogue)	384569355.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	1.3	88.3627613143	OC(CNc1nc(CC2CC2)c(-c2nc(Nc3ccncc3)ncc2)cn1)(C)C	OC(CNc1nc(CC2CC2)c(-c2nc(Nc3ccncc3)ncc2)cn1)(C)C
NCGC00018230-10	OC(CO)CN1CCN(c2ccccc2)CC1		Inactive			1	Dropropizine	363676507.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC(CO)CN1CCN(c2ccccc2)CC1	OC(CO)CN1CCN(c2ccccc2)CC1
NCGC00387769-02	OC(Cn1c(CNCC)nc2c(N)nc3c(c12)cccc3)(C)C		Inactive	Toll-Like Receptor 7 (TLR7) Agonist		1	Gardiquimod	363680656.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	13.4484272159&0.0	OC(Cn1c(CNCC)nc2c(N)nc3c(c12)cccc3)(C)C	OC(Cn1c(CNCC)nc2c(N)nc3c(c12)cccc3)(C)C
NCGC00483210-07	OC(Cn1ncc(-c2nc(N3[C@@H](c4ccccc4)COCC3)c3c(n2)ccc(-c2c(C)onc2C)c3)c1)(C)C		Inactive			1	NCGC00483210-07		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC(Cn1ncc(-c2nc(N3[C@@H](c4ccccc4)COCC3)c3c(n2)ccc(-c2c(C)onc2C)c3)c1)(C)C	OC(Cn1ncc(-c2nc(N3[C@@H](c4ccccc4)COCC3)c3c(n2)ccc(-c2c(C)onc2C)c3)c1)(C)C
NCGC00379044-01&NCGC00379044-02	OC([C@H](/C=C/[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)/CCC2)CC1)C)(C)C		Inactive	Vitamin D Receptor (VDR) Agonist		2	Paricalcitol-D6 (ABT-358)	405559020.0&384569089.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OC([C@H](/C=C/[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)/CCC2)CC1)C)(C)C	OC([C@H](/C=C/[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)/CCC2)CC1)C)(C)C
NCGC00016064-12	OC(c1ccccc1)(c1ccccc1)C1CCN(CCCC(O)c2ccc(C(C)(C)C)cc2)CC1		Inactive			1	Terfenadine	170465598.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	12.908990164&0.0	OC(c1ccccc1)(c1ccccc1)C1CCN(CCCC(O)c2ccc(C(C)(C)C)cc2)CC1	OC(c1ccccc1)(c1ccccc1)C1CCN(CCCC(O)c2ccc(C(C)(C)C)cc2)CC1
NCGC00180860-02	OC/C(=C\CO)/CC[C@@H]1C(CO)=CCC2C(C)(C)CCC[C@@]12C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180860-02	363677076.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC/C(=C\CO)/CC[C@@H]1C(CO)=CCC2C(C)(C)CCC[C@@]12C	OC/C(=C\CO)/CC[C@@H]1C(CO)=CCC2C(C)(C)CCC[C@@]12C
NCGC00017343-11	OC/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C		Inactive	Retinol dehydrogenase 12 Substrate		1	RETINOL	405558473.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C	OC/C=C(/C=C/C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)\C
NCGC00095707-04	OC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)\C)\C)\C)\C)\C		Inactive	tobacco isoprenoid alcohol		1	SOLANESOL	434147207.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)\C)\C)\C)\C)\C	OC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)\C)\C)\C)\C)\C)\C
NCGC00013095-10	OC/C=C(/CC/C=C(\C)/C)\C		Inactive	Trichomonas vaginalis Inhibitor		1	Geraniol	170465692.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	OC/C=C(/CC/C=C(\C)/C)\C	OC/C=C(/CC/C=C(\C)/C)\C
NCGC00385919-01	OC/C=C(\CCC1C(=C)CCC2C(C)(C)CCCC12C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385919-01	363680006.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC/C=C(\CCC1C(=C)CCC2C(C)(C)CCCC12C)/C	OC/C=C(\CCC1C(=C)CCC2C(C)(C)CCCC12C)/C
NCGC00381351-01	OC/C=C(\CCC1C2(C)C(C(C)(C)CCC2)CCC1C)/C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381351-01	363679102.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC/C=C(\CCC1C2(C)C(C(C)(C)CCC2)CCC1C)/C	OC/C=C(\CCC1C2(C)C(C(C)(C)CCC2)CCC1C)/C
NCGC00168806-03	OC/C=C(\CC[C@@H]1[C@](O)(C)CCC2C(C)(C)CCC[C@@]12C)/C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Dodonaea | Family: Sapindaceae | Species: viscosa		1	NCGC00168806-03	363676690.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC/C=C(\CC[C@@H]1[C@](O)(C)CCC2C(C)(C)CCC[C@@]12C)/C	OC/C=C(\CC[C@@H]1[C@](O)(C)CCC2C(C)(C)CCC[C@@]12C)/C
NCGC00347368-02	OC/C=C(\CC[C@@H]1[C@](O)(C)CC[C@@H]2C(C)(C)C[C@@H](O)C[C@@]12C)/C		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Dodonaea | Family: Sapindaceae | Species: viscosa		1	NCGC00347368-02	363677578.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC/C=C(\CC[C@@H]1[C@](O)(C)CC[C@@H]2C(C)(C)C[C@@H](O)C[C@@]12C)/C	OC/C=C(\CC[C@@H]1[C@](O)(C)CC[C@@H]2C(C)(C)C[C@@H](O)C[C@@]12C)/C
NCGC00385368-01	OC/C=C/C=C/[C@@H]1Oc2c(O)cc(O)cc2C1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385368-01	363679704.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC/C=C/C=C/[C@@H]1Oc2c(O)cc(O)cc2C1	OC/C=C/C=C/[C@@H]1Oc2c(O)cc(O)cc2C1
NCGC00166097-02	OC/C=C/c1ccccc1		Inactive	prostaglandin secretion Inhibitor		1	Cinnamyl alcohol	225144268.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC/C=C/c1ccccc1	OC/C=C/c1ccccc1
NCGC00179245-04	OC/C=C\1/[C@H]2C3=CN4c5c(cccc5)[C@]56[C@H]7[N@+](CC=C)(C/C(=C\CO)/[C@@H](C(=CN8c9c(cccc9)[C@]9([C@@H]([N@+](CC=C)(C/1)CC9)C2)C38)C45)C7)CC6		Inactive			1	Alcuronium chloride	405558585.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC/C=C\1/[C@H]2C3=CN4c5c(cccc5)[C@]56[C@H]7[N@+](CC=C)(C/C(=C\CO)/[C@@H](C(=CN8c9c(cccc9)[C@]9([C@@H]([N@+](CC=C)(C/1)CC9)C2)C38)C45)C7)CC6	OC/C=C\1/[C@H]2C3=CN4c5c(cccc5)[C@]56[C@H]7[N@+](CC=C)(C/C(=C\CO)/[C@@H](C(=CN8c9c(cccc9)[C@]9([C@@H]([N@+](CC=C)(C/1)CC9)C2)C38)C45)C7)CC6
MLS002608514-02	OC1(C)C2(C)C(C3C(C4(C)C(=Cc5n[nH]cc5C4)CC3)CC2)CC1		Inactive			1	MLS002608514-02	363676426.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	27.5939404801	OC1(C)C2(C)C(C3C(C4(C)C(=Cc5n[nH]cc5C4)CC3)CC2)CC1	OC1(C)C2(C)C(C3C(C4(C)C(=Cc5n[nH]cc5C4)CC3)CC2)CC1
NCGC00385890-01	OC1(C)C2C(C(O)c3c(coc3)C1)CC(C)(C)C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385890-01	363679992.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC1(C)C2C(C(O)c3c(coc3)C1)CC(C)(C)C2	OC1(C)C2C(C(O)c3c(coc3)C1)CC(C)(C)C2
NCGC00385606-01	OC1(C)C2C3C(C)(C)C3CCC(O)(C)C2CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385606-01	363679834.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC1(C)C2C3C(C)(C)C3CCC(O)(C)C2CC1	OC1(C)C2C3C(C)(C)C3CCC(O)(C)C2CC1
NCGC00250375-10	OC1(C)CC(c2n3c(c(-c4cc5nc(-c6ccccc6)ccc5cc4)n2)C(N)=NC=C3)C1		Inactive	IGF-1R Inhibitor		1	Linsitinib	384568536.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC1(C)CC(c2n3c(c(-c4cc5nc(-c6ccccc6)ccc5cc4)n2)C(N)=NC=C3)C1	OC1(C)CC(c2n3c(c(-c4cc5nc(-c6ccccc6)ccc5cc4)n2)C(N)=NC=C3)C1
NCGC00408954-01	OC1=C(C(C)C)C(c2cn(C(C)(C)C)nc2)=Nc2c(C#N)cnn12		Inactive			1	NCGC00408954-01		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC1=C(C(C)C)C(c2cn(C(C)(C)C)nc2)=Nc2c(C#N)cnn12	OC1=C(C(C)C)C(c2cn(C(C)(C)C)nc2)=Nc2c(C#N)cnn12
NCGC00137486-01	OC1=C(C(N2CCC(O)CC2)c2ccccc2)Sc2n1nc(-c1occc1)n2		Inactive			1	NCGC00137486-01	24412869.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC1=C(C(N2CCC(O)CC2)c2ccccc2)Sc2n1nc(-c1occc1)n2	OC1=C(C(N2CCC(O)CC2)c2ccccc2)Sc2n1nc(-c1occc1)n2
NCGC00137274-01	OC1=C(C(N2CCCC2)c2ccc(C)cc2)Sc2n1nc(-c1occc1)n2		Inactive			1	NCGC00137274-01	24412657.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC1=C(C(N2CCCC2)c2ccc(C)cc2)Sc2n1nc(-c1occc1)n2	OC1=C(C(N2CCCC2)c2ccc(C)cc2)Sc2n1nc(-c1occc1)n2
NCGC00137284-01	OC1=C(C(N2CCN(CC)CC2)c2ccc(C)cc2)Sc2n1nc(-c1occc1)n2		Inactive			1	NCGC00137284-01	24412667.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC1=C(C(N2CCN(CC)CC2)c2ccc(C)cc2)Sc2n1nc(-c1occc1)n2	OC1=C(C(N2CCN(CC)CC2)c2ccc(C)cc2)Sc2n1nc(-c1occc1)n2
NCGC00137282-01	OC1=C(C(N2CCOCC2)c2ccc(C)cc2)Sc2n1nc(-c1occc1)n2		Inactive			1	NCGC00137282-01	24412665.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC1=C(C(N2CCOCC2)c2ccc(C)cc2)Sc2n1nc(-c1occc1)n2	OC1=C(C(N2CCOCC2)c2ccc(C)cc2)Sc2n1nc(-c1occc1)n2
NCGC00137456-01	OC1=C(C(N2CCOCC2)c2ccccc2)Sc2n1nc(-c1occc1)n2		Inactive			1	NCGC00137456-01	24412839.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC1=C(C(N2CCOCC2)c2ccccc2)Sc2n1nc(-c1occc1)n2	OC1=C(C(N2CCOCC2)c2ccccc2)Sc2n1nc(-c1occc1)n2
NCGC00159409-08	OC1C(O)C(O)C(O)C(O)C1O		Inactive			1	myo-Inositol		Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC1C(O)C(O)C(O)C(O)C1O	OC1C(O)C(O)C(O)C(O)C1O
NCGC00385948-01	OC1C(O)CC2N3Cc4c(cc5OCOc5c4)C(C2=C1)C3	5.5	Active	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A	0.0	1	NCGC00385948-01	363680021.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	2.2	44.9070389219	OC1C(O)CC2N3Cc4c(cc5OCOc5c4)C(C2=C1)C3	OC1C(O)CC2N3Cc4c(cc5OCOc5c4)C(C2=C1)C3
NCGC00380310-01	OC1C2(C(C)C(O)CC2C(=C)C)CC(O)C2(C)OC12		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380310-01	363678534.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	14.9611973439	OC1C2(C(C)C(O)CC2C(=C)C)CC(O)C2(C)OC12	OC1C2(C(C)C(O)CC2C(=C)C)CC(O)C2(C)OC12
NCGC00385764-01	OC1C2(C)C(=C3C(C)(C4(C)C(C5(C)C(C(C)(C)C(O)CC5)CC4)C=C3)CC2)CC(C)(C)C1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385764-01	363679930.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC1C2(C)C(=C3C(C)(C4(C)C(C5(C)C(C(C)(C)C(O)CC5)CC4)C=C3)CC2)CC(C)(C)C1	OC1C2(C)C(=C3C(C)(C4(C)C(C5(C)C(C(C)(C)C(O)CC5)CC4)C=C3)CC2)CC(C)(C)C1
NCGC00263517-03	OC1C2(C)C(C)(C)C(C1)CC2		Inactive			1	BORNEOL	405558915.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC1C2(C)C(C)(C)C(C1)CC2	OC1C2(C)C(C)(C)C(C1)CC2
NCGC00385952-01	OC1C2(C)C(CCC=C(C)C)(C)C(C1)CC2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385952-01	363680024.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC1C2(C)C(CCC=C(C)C)(C)C(C1)CC2	OC1C2(C)C(CCC=C(C)C)(C)C(C1)CC2
NCGC00482960-01	OC1C=C(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C=2C(C)(C)CC(O)CC=2C)\C)\C)/C)/C)C(C)(C)C1		Inactive			1	Xanthophyll	405558848.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC1C=C(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C=2C(C)(C)CC(O)CC=2C)\C)\C)/C)/C)C(C)(C)C1	OC1C=C(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C=2C(C)(C)CC(O)CC=2C)\C)\C)/C)/C)C(C)(C)C1
NCGC00095486-03	OC1CC=2C(C)(C3C(=CC=2)C2C(C)(C(C(/C=C/C(C(C)C)C)C)CC2)CC3)CC1		Inactive	Sterol (fungal cell wall)		1	Ergosterol	174007452.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC1CC=2C(C)(C3C(=CC=2)C2C(C)(C(C(/C=C/C(C(C)C)C)C)CC2)CC3)CC1	OC1CC=2C(C)(C3C(=CC=2)C2C(C)(C(C(/C=C/C(C(C)C)C)C)CC2)CC3)CC1
NCGC00160163-01	OC1CC=2C(C)(C3C(C4C(C)(C5[C@H](C)[C@@]6(OC5C4)OC[C@H](C)CC6)CC3)CC=2)CC1		Inactive	Cyclooxygenase up-regulator		1	Diosgenin	50109897.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC1CC=2C(C)(C3C(C4C(C)(C5[C@H](C)[C@@]6(OC5C4)OC[C@H](C)CC6)CC3)CC=2)CC1	OC1CC=2C(C)(C3C(C4C(C)(C5[C@H](C)[C@@]6(OC5C4)OC[C@H](C)CC6)CC3)CC=2)CC1
NCGC00247785-11	OC1CCC(N2C(=N)c3c(c(n(Cc4ccccc4)c3N=C2)-c2ccccc2)-c2ccccc2)CC1	4.9000001	Active	Perinuclear compartment (PNC) assembly Inhibitor	0.0	1	Metarrestin (KUC109088N)	384568516.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.4	35.470521888	OC1CCC(N2C(=N)c3c(c(n(Cc4ccccc4)c3N=C2)-c2ccccc2)-c2ccccc2)CC1	OC1CCC(N2C(=N)c3c(c(n(Cc4ccccc4)c3N=C2)-c2ccccc2)-c2ccccc2)CC1
NCGC00408831-01	OC1CCC(Nc2c(-c3ncc(CN4CCOCC4)cc3)ccc(NCCCC)c2)CC1		Inactive			1	UNC2250	363681060.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC1CCC(Nc2c(-c3ncc(CN4CCOCC4)cc3)ccc(NCCCC)c2)CC1	OC1CCC(Nc2c(-c3ncc(CN4CCOCC4)cc3)ccc(NCCCC)c2)CC1
NCGC00386394-01	OC1CCC(Nc2c(-c3ncc(CN4CCOCC4)cc3)cnc(NCCCC)n2)CC1		Inactive	Tyrosine-protein kinase Mer Inhibitor		1	UNC2250	384569131.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC1CCC(Nc2c(-c3ncc(CN4CCOCC4)cc3)cnc(NCCCC)n2)CC1	OC1CCC(Nc2c(-c3ncc(CN4CCOCC4)cc3)cnc(NCCCC)n2)CC1
NCGC00370841-01	OC1CCC(Nc2nc(-c3ccccc3)nc3[nH]ccc23)CC1		Inactive	Adenosine A1 receptor Antagonist		1	SLV 320	363677878.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC1CCC(Nc2nc(-c3ccccc3)nc3[nH]ccc23)CC1	OC1CCC(Nc2nc(-c3ccccc3)nc3[nH]ccc23)CC1
NCGC00346952-01	OC1CCC(Nc2nc(Nc3cc4c(n(Cc5ccccc5)cc4)cc3)nc(NCC)c2)CC1		Inactive	CDK4/6 Inhibitor		1	Cdk4/6 Inhibitor IV	174006970.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC1CCC(Nc2nc(Nc3cc4c(n(Cc5ccccc5)cc4)cc3)nc(NCC)c2)CC1	OC1CCC(Nc2nc(Nc3cc4c(n(Cc5ccccc5)cc4)cc3)nc(NCC)c2)CC1
NCGC00510682-01	OC1CCC(Nc2nc(Nc3sc4c(n3)ccc(CC)c4)cc(Cc3ccccc3)n2)CC1		Inactive	ITK Inhibitor		1	GSK-2250665A	384569476.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC1CCC(Nc2nc(Nc3sc4c(n3)ccc(CC)c4)cc(Cc3ccccc3)n2)CC1	OC1CCC(Nc2nc(Nc3sc4c(n3)ccc(CC)c4)cc(Cc3ccccc3)n2)CC1
NCGC00095086-04	OC1CCN(CCCN2c3c(Sc4c2cccc4)ccc(C#N)c3)CC1	5.0	Active	Dopamine D2 receptor Antagonist	0.0	1	PERICIAZINE	405558569.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	63.8079322836	OC1CCN(CCCN2c3c(Sc4c2cccc4)ccc(C#N)c3)CC1	OC1CCN(CCCN2c3c(Sc4c2cccc4)ccc(C#N)c3)CC1
NCGC00386195-06	OC1C[C@@H]2N(C)[C@@H]([C@H]3O[C@@H]23)C1		Inactive			1	Scopine		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC1C[C@@H]2N(C)[C@@H]([C@H]3O[C@@H]23)C1	OC1C[C@@H]2N(C)[C@@H]([C@H]3O[C@@H]23)C1
NCGC00385848-01	OC1n2c3c(c4c2C2C(CC)(C1)CCCN2CC4)cccc3		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385848-01	363679968.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC1n2c3c(c4c2C2C(CC)(C1)CCCN2CC4)cccc3	OC1n2c3c(c4c2C2C(CC)(C1)CCCN2CC4)cccc3
NCGC00385701-01	OCC(C)C1C=2C(C)(CC3C(CO)CC(O)C3C(O)(C)CC=2)CC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385701-01	363679884.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCC(C)C1C=2C(C)(CC3C(CO)CC(O)C3C(O)(C)CC=2)CC1	OCC(C)C1C=2C(C)(CC3C(CO)CC(O)C3C(O)(C)CC=2)CC1
NCGC00166213-02	OCC(CCCCCCCCCC)CCCCCCCC		Inactive			1	2-Octyl-1-dodecanol	170465533.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OCC(CCCCCCCCCC)CCCCCCCC	OCC(CCCCCCCCCC)CCCCCCCC
NCGC00188399-06&NCGC00188399-16	OCC(N)(CO)CCc1ccc(CCCCCCCC)cc1		Inactive	Sphingosine Kinase 1 (SphK1) Inhibitor		2	Fingolimod hydrochloride	405558994.0&377020258.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		OCC(N)(CO)CCc1ccc(CCCCCCCC)cc1	OCC(N)(CO)CCc1ccc(CCCCCCCC)cc1
NCGC00159412-04	OCC(N)(CO)CO		Inactive	calcium ion transport Inhibitor		1	Tromethamine	170464686.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	OCC(N)(CO)CO	OCC(N)(CO)CO
NCGC00164595-02	OCC(N[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@](O)(CO)C1)CO		Inactive			1	Voglibose	170465993.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OCC(N[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@](O)(CO)C1)CO	OCC(N[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@](O)(CO)C1)CO
NCGC00347632-02	OCC1(C)C2C(C)(C(CC34C(O)C(O)C(=C)C(O)C3O4)C(C)=CC2)CCC1		Inactive	<MOA Unknown> | Class: sesquiterpene(shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347632-02	363677645.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCC1(C)C2C(C)(C(CC34C(O)C(O)C(=C)C(O)C3O4)C(C)=CC2)CCC1	OCC1(C)C2C(C)(C(CC34C(O)C(O)C(=C)C(O)C3O4)C(C)=CC2)CCC1
NCGC00169715-02	OCC1(C)C2C(C)(c3c(C(O)C2)cc(C(C)C)cc3)CCC1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169715-02	363676874.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCC1(C)C2C(C)(c3c(C(O)C2)cc(C(C)C)cc3)CCC1	OCC1(C)C2C(C)(c3c(C(O)C2)cc(C(C)C)cc3)CCC1
NCGC00381166-01	OCC1(C)C2C(CO)(C(CO)C(C)=CC2)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381166-01	363679004.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCC1(C)C2C(CO)(C(CO)C(C)=CC2)CCC1	OCC1(C)C2C(CO)(C(CO)C(C)=CC2)CCC1
NCGC00380130-01	OCC1(O)C(CO)=CC(O)C2C(C)(C)CCCC12C		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380130-01	363678468.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCC1(O)C(CO)=CC(O)C2C(C)(C)CCCC12C	OCC1(O)C(CO)=CC(O)C2C(C)(C)CCCC12C
NCGC00385969-01	OCC12C(O)C3C(C4(C)C1(O2)CC4)CC(C)(C)C3		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385969-01	363680034.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCC12C(O)C3C(C4(C)C1(O2)CC4)CC(C)(C)C3	OCC12C(O)C3C(C4(C)C1(O2)CC4)CC(C)(C)C3
NCGC00386072-01	OCC1=C(C)C(O)C(O)C2C(C)(C)CCCC12C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386072-01	363680091.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCC1=C(C)C(O)C(O)C2C(C)(C)CCCC12C	OCC1=C(C)C(O)C(O)C2C(C)(C)CCCC12C
NCGC00476094-01	OCC1=CCC2C(C)(C)Oc3c(c(O)cc(C(CCCCCC)(C)C)c3)[C@H]2C1	5.0	Active	NMDA Receptor Antagonist	0.0	1	Dexanabinol	384569239.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.4	74.3890755706	OCC1=CCC2C(C)(C)Oc3c(c(O)cc(C(CCCCCC)(C)C)c3)[C@H]2C1	OCC1=CCC2C(C)(C)Oc3c(c(O)cc(C(CCCCCC)(C)C)c3)[C@H]2C1
NCGC00169963-02	OCC1C2(C)C3C(C(C)(C)CCC2)C1CC3		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Juniperus | Family: N/A | Species: spp		1	NCGC00169963-02	363676922.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCC1C2(C)C3C(C(C)(C)CCC2)C1CC3	OCC1C2(C)C3C(C(C)(C)CCC2)C1CC3
NCGC00384837-01	OCC1C2CC3(C(C4(C)C(C(O)(C)CCC4)CC3)CC2)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384837-01	363679385.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCC1C2CC3(C(C4(C)C(C(O)(C)CCC4)CC3)CC2)C1	OCC1C2CC3(C(C4(C)C(C(O)(C)CCC4)CC3)CC2)C1
NCGC00381456-01	OCC=1C(CO)C2(C)C(C(C)(C)CCC2)CC=1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381456-01	363679151.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCC=1C(CO)C2(C)C(C(C)(C)CCC2)CC=1	OCC=1C(CO)C2(C)C(C(C)(C)CCC2)CC=1
NCGC00347620-02	OCC=1C(O)C2C(CC3C(C)=CCC4C(C)(C)CCCC34C)(C(O)C=1)O2		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347620-02	363677641.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCC=1C(O)C2C(CC3C(C)=CCC4C(C)(C)CCCC34C)(C(O)C=1)O2	OCC=1C(O)C2C(CC3C(C)=CCC4C(C)(C)CCCC34C)(C(O)C=1)O2
NCGC00169248-02	OCC=1C(O)C2C(CC3C(C)=CCC4C(CO)(C)CCCC34C)(C(O)C=1)O2		Inactive	<MOA Unknown> | Class: sesquiterpene/shikimi | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169248-02	363676793.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCC=1C(O)C2C(CC3C(C)=CCC4C(CO)(C)CCCC34C)(C(O)C=1)O2	OCC=1C(O)C2C(CC3C(C)=CCC4C(CO)(C)CCCC34C)(C(O)C=1)O2
NCGC00263603-10	OCC=1[C@@H](O)[C@@H](O)[C@H](n2c3c(c(N)ncc3)nc2)C=1		Inactive	EZH2 Inhibitor		1	3-Deazaneplanocin A	384568692.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	27.5	OCC=1[C@@H](O)[C@@H](O)[C@H](n2c3c(c(N)ncc3)nc2)C=1	OCC=1[C@@H](O)[C@@H](O)[C@H](n2c3c(c(N)ncc3)nc2)C=1
NCGC00385659-01	OCCC(CCC1C(=C)CCC2C(C)(C)C(O)CCC12C)C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385659-01	363679862.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCCC(CCC1C(=C)CCC2C(C)(C)C(O)CCC12C)C	OCCC(CCC1C(=C)CCC2C(C)(C)C(O)CCC12C)C
NCGC00385110-01	OCCC(CCC1[C@@](O)(C)CCC2C(C)(C)CCCC12C)C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385110-01	363679541.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCCC(CCC1[C@@](O)(C)CCC2C(C)(C)CCCC12C)C	OCCC(CCC1[C@@](O)(C)CCC2C(C)(C)CCCC12C)C
NCGC00381391-01	OCCC1(O)C(C)(C)CC(O)CC1C		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381391-01	363679121.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCCC1(O)C(C)(C)CC(O)CC1C	OCCC1(O)C(C)(C)CC(O)CC1C
NCGC00159368-05	OCCCCCCCCCCCCCCCC		Inactive	Fatty aldehyde dehydrogenase Substrate		1	1-Hexadecanol	170465348.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OCCCCCCCCCCCCCCCC	OCCCCCCCCCCCCCCCC
NCGC00159369-04	OCCCCCCCCCCCCCCCCCC		Inactive			1	1-Octadecanol	170465526.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OCCCCCCCCCCCCCCCCCC	OCCCCCCCCCCCCCCCCCC
NCGC00159370-04&NCGC00159370-10	OCCCCCCCCCCCCCCCCCCCCCC		Inactive	Anti-Herpes Simplex Virus Drug		2	Docosanol	124892111.0&384568173.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	OCCCCCCCCCCCCCCCCCCCCCC	OCCCCCCCCCCCCCCCCCCCCCC
NCGC00274075-01	OCCCCCCCCCCCCCCCCCCCCCCCCCCCC		Inactive	PI3K-Akt signaling pathway Activator		1	1-Octacosanol	405558919.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	OCCCCCCCCCCCCCCCCCCCCCCCCCCCC	OCCCCCCCCCCCCCCCCCCCCCCCCCCCC
NCGC00485185-01	OCCCCCNCCn1c2ncnc(N)c2nc1		Inactive			1	NB001	363681251.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCCCCCNCCn1c2ncnc(N)c2nc1	OCCCCCNCCn1c2ncnc(N)c2nc1
NCGC00181149-01	OCCCNc1ccccc1		Inactive			1	3-Anilinopropan-1-ol	144206306.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OCCCNc1ccccc1	OCCCNc1ccccc1
NCGC00165739-02	OCCCNc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		Inactive			1	Bohemine	377020359.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCCCNc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1	OCCCNc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1
NCGC00379057-02	OCCCc1c(NCc2cc3n(Cc4c(O)ccc(C)n4)c(NCCCN4CCOCC4)nc3cc2)cc(C)cc1	4.9000001	Active	Respiratory syncytial virus Inhibitor	0.0	1	TMC353121	434146905.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	3.0	52.2540178059	OCCCc1c(NCc2cc3n(Cc4c(O)ccc(C)n4)c(NCCCN4CCOCC4)nc3cc2)cc(C)cc1	OCCCc1c(NCc2cc3n(Cc4c(O)ccc(C)n4)c(NCCCN4CCOCC4)nc3cc2)cc(C)cc1
NCGC00159411-02	OCCN(CCO)CCO		Inactive			1	Triethanolamine	144206717.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OCCN(CCO)CCO	OCCN(CCO)CCO
NCGC00015385-18&NCGC00015385-22	OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1		Inactive	Phosphodiesterase PDE3 Inhibitor		2	Dipyridamole	170464694.0&384567839.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1	OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
NCGC00162068-04&NCGC00162068-06	OCCN1CCN(CCCN2c3c(cccc3)C=Cc3c2cccc3)CC1		Inactive	Serotonin 2 (5-HT2) receptor Antagonist		2	Opipramol dihydrochloride	144206704.0&170465942.0	Anti-infectives&Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&0.0	OCCN1CCN(CCCN2c3c(cccc3)C=Cc3c2cccc3)CC1.Cl.Cl	OCCN1CCN(CCCN2c3c(cccc3)C=Cc3c2cccc3)CC1.Cl.Cl
NCGC00270540-02&NCGC00270540-05	OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1		Inactive	alpha-Glucosidase Inhibitor		2	Miglitol	170465326.0&384568703.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1	OCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C1
NCGC00347941-04	OCCNC1c2[nH]c3c(c2CCC1)cc(-c1ccccc1)cc3		Inactive	Cdc42 Inhibitor		1	CASIN	363677723.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OCCNC1c2[nH]c3c(c2CCC1)cc(-c1ccccc1)cc3	OCCNC1c2[nH]c3c(c2CCC1)cc(-c1ccccc1)cc3
NCGC00015763-09	OCCNc1nc(NCc2ccccc2)c2ncn(C)c2n1		Inactive	Mitogen-activated protein kinase 1 Inhibitor		1	Olomoucine	90340618.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OCCNc1nc(NCc2ccccc2)c2ncn(C)c2n1	OCCNc1nc(NCc2ccccc2)c2ncn(C)c2n1
NCGC00346656-03	OCC[C@H]1N(C2=Nc3c(CC)cnn3C(NCc3c[n+]([O-])ccc3)=C2)CCCC1		Inactive	CDK1/2/5/9 Inhibitor		1	Dinaciclib (SCH727965)	384568887.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		OCC[C@H]1N(C2=Nc3c(CC)cnn3C(NCc3c[n+]([O-])ccc3)=C2)CCCC1	OCC[C@H]1N(C2=Nc3c(CC)cnn3C(NCc3c[n+]([O-])ccc3)=C2)CCCC1
NCGC00015219-07	OCC[N+](C)(C)C		Inactive			1	Choline Chloride	405558926.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OCC[N+](C)(C)C	OCC[N+](C)(C)C
NCGC00017013-05&NCGC00017013-06	OCCc1c(C)[n+](Cc2c(N)nc(C)nc2)cs1		Inactive			2	Thiamine hydrochloride&Thiamine chloride	434146961.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OCCc1c(C)[n+](Cc2c(N)nc(C)nc2)cs1	OCCc1c(C)[n+](Cc2c(N)nc(C)nc2)cs1
NCGC00166215-04&NCGC00166215-05	OCCc1ccccc1		Inactive			2	PHENYLETHYL ALCOHOL&2-Phenylethanol	434147036.0&170466787.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OCCc1ccccc1	OCCc1ccccc1
NCGC00263161-11	OCCn1ncc(-c2nc3n(Cc4cc5c(nccc5)cc4)nnc3nc2)c1		Inactive	HGFR Inhibitor		1	PF-04217903	363677237.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OCCn1ncc(-c2nc3n(Cc4cc5c(nccc5)cc4)nnc3nc2)c1	OCCn1ncc(-c2nc3n(Cc4cc5c(nccc5)cc4)nnc3nc2)c1
NCGC00178864-03&NCGC00178864-04	OC[C@@H](NCCN[C@H](CO)CC)CC		Inactive			2	Ethambutol dihydrochloride&Ethambutol HCl	174006619.0&434146907.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OC[C@@H](NCCN[C@H](CO)CC)CC.Cl.Cl	OC[C@@H](NCCN[C@H](CO)CC)CC.Cl.Cl&OC[C@@H](NCCN[C@H](CO)CC)CC
NCGC00164560-05&NCGC00164560-17	OC[C@@H]1C=C[C@H](n2c3nc(N)nc(NC4CC4)c3nc2)C1		Inactive			2	ABACAVIR SULFATE&Abacavir hemisulfate	405559145.0&434147259.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OC[C@@H]1C=C[C@H](n2c3nc(N)nc(NC4CC4)c3nc2)C1	OC[C@@H]1C=C[C@H](n2c3nc(N)nc(NC4CC4)c3nc2)C1
NCGC00092314-15	OC[C@@H]1[C@@H](O)C(O)[C@H](n2c3ncnc4N(C)N=C(N)c(c34)c2)O1		Inactive			1	Triciribine	434146913.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC[C@@H]1[C@@H](O)C(O)[C@H](n2c3ncnc4N(C)N=C(N)c(c34)c2)O1	OC[C@@H]1[C@@H](O)C(O)[C@H](n2c3ncnc4N(C)N=C(N)c(c34)c2)O1
NCGC00182045-03	OC[C@@H]1[C@@H](O)C[C@H](n2c3N=CNC[C@@H](O)c3nc2)O1		Inactive	Adenosine Deaminase Inhibitor		1	Pentostatin	384568404.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC[C@@H]1[C@@H](O)C[C@H](n2c3N=CNC[C@@H](O)c3nc2)O1	OC[C@@H]1[C@@H](O)C[C@H](n2c3N=CNC[C@@H](O)c3nc2)O1
NCGC00388420-02	OC[C@@H]1[C@@H](O)C[C@H](n2c3NC=NC[C@@H](O)c3nc2)O1		Inactive	Adenosine Deaminase Inhibitor		1	Pentostatin	363680730.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC[C@@H]1[C@@H](O)C[C@H](n2c3NC=NC[C@@H](O)c3nc2)O1	OC[C@@H]1[C@@H](O)C[C@H](n2c3NC=NC[C@@H](O)c3nc2)O1
NCGC00485882-01	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](c2c3ncnc(N)c3[nH]c2)N1		Inactive			1	BCX 4430	363681391.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0	0.0&0.0	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](c2c3ncnc(N)c3[nH]c2)N1	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](c2c3ncnc(N)c3[nH]c2)N1
NCGC00485421-01	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c(N)nc3c(N)ncnc23)O1		Inactive	Generic Transcription Pathway Inhibitor		1	8-Aminoadenosine	363681331.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	17.823413408	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c(N)nc3c(N)ncnc23)O1	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c(N)nc3c(N)ncnc23)O1
NCGC00093846-07	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3c(c(N)ncc3)nc2)O1		Inactive			1	3-Deazaadenosine	434147222.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3c(c(N)ncc3)nc2)O1	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3c(c(N)ncc3)nc2)O1
NCGC00163638-01	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3cc2)O1		Inactive			1	TUBERCIDIN	26757019.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	-14.6551874439	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3cc2)O1	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3cc2)O1
NCGC00023673-10&NCGC00023673-18	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1		Inactive	Adenosine Receptor Agonist		2	Adenosine	405558447.0&384568019.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1
NCGC00162241-09	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(NC)c3nc2)O1		Inactive	DNA oxidative demethylase ALKBH1 Substrate		1	N6-Methyladenosine	434146915.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(NC)c3nc2)O1	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(NC)c3nc2)O1
NCGC00253650-01	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(NC/C=C(\C)/C)c3nc2)O1		Inactive			1	Riboprine	170466472.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(NC/C=C(\C)/C)c3nc2)O1	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(NC/C=C(\C)/C)c3nc2)O1
NCGC00484059-01	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(NCc4ccc(O)cc4)c3nc2)O1		Inactive	Equilibrative nucleoside transporter 1 Inhibitor		1	N6-(4-Hydroxybenzyl)adenosine	363681152.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(NCc4ccc(O)cc4)c3nc2)O1	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(NCc4ccc(O)cc4)c3nc2)O1
NCGC00092314-06	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc4N(C)N=C(N)c(c34)c2)O1		Inactive	AKT Inhibitor		1	Triciribine	363676559.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc4N(C)N=C(N)c(c34)c2)O1	OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc4N(C)N=C(N)c(c34)c2)O1
NCGC00686670-01	OC[C@@H]1[C@@H](O)[C@@H](O)[C@](C#N)(c2n3N=CN=C(N)c3cc2)O1	5.7249999	Active		0.0	1	GS-441524		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	1.1&1.1	96.3904172384&117.1794425091	OC[C@@H]1[C@@H](O)[C@@H](O)[C@](C#N)(c2n3N=CN=C(N)c3cc2)O1	OC[C@@H]1[C@@H](O)[C@@H](O)[C@](C#N)(c2n3N=CN=C(N)c3cc2)O1
NCGC00159322-05&NCGC00159322-14&NCGC00159322-18	OC[C@@H]1[C@@H](O)[C@@H]2OC3=NC(=N)C=CN3[C@@H]2O1		Inactive	antiviral		3	Cyclocytidine&ANCITABINE HYDROCHLORIDE&Cyclocytidine HCl	434146924.0	Anti-infectives&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	OC[C@@H]1[C@@H](O)[C@@H]2OC3=NC(=N)C=CN3[C@@H]2O1	OC[C@@H]1[C@@H](O)[C@@H]2OC3=NC(=N)C=CN3[C@@H]2O1
NCGC00178826-03	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](N)C(O)O1		Inactive	Solute carrier organic anion transporter family member 1B3 Inhibitor		1	Glucosamine hydrochloride	170466505.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](N)C(O)O1.Cl	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](N)C(O)O1.Cl
NCGC00160621-05&NCGC00160621-08	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)O1		Inactive			2	DEXTROSE&Dextrose		Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)O1	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)O1
NCGC00485920-01	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@]2(O1)OCc1c2cc(Cc2ccc(CC)cc2)cc1		Inactive	Sodium/glucose cotransporter 2 Inhibitor		1	Tofogliflozin (hydrate)	363681416.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@]2(O1)OCc1c2cc(Cc2ccc(CC)cc2)cc1	OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@]2(O1)OCc1c2cc(Cc2ccc(CC)cc2)cc1
NCGC00015383-07	OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)CN1		Inactive			1	NCGC00015383-07		Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)CN1	OC[C@@H]1[C@@H](O)[C@H](O)[C@H](O)CN1
NCGC00178869-11	OC[C@@H]1[C@@H](O)[C@H](O)[C@H](n2c3ncnc(N)c3nc2)O1		Inactive	Adenosine Receptor Agonist; Anti-Herpes Simplex Virus Drug		1	Vidarabine	384568366.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	OC[C@@H]1[C@@H](O)[C@H](O)[C@H](n2c3ncnc(N)c3nc2)O1	OC[C@@H]1[C@@H](O)[C@H](O)[C@H](n2c3ncnc(N)c3nc2)O1
NCGC00686698-01	OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)CN1		Inactive			1	Migalastat	434147250.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)CN1	OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)CN1
NCGC00387257-01	OC[C@@H]1[C@H](O)[C@H](O)[C@H](n2c3ncnc(N)c3c(C#N)c2)O1		Inactive	Serine/threonine-protein kinase/endoribonuclease IRE1 Inhibitor		1	Toyocamycin	363680598.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC[C@@H]1[C@H](O)[C@H](O)[C@H](n2c3ncnc(N)c3c(C#N)c2)O1	OC[C@@H]1[C@H](O)[C@H](O)[C@H](n2c3ncnc(N)c3c(C#N)c2)O1
NCGC00179780-02	OC[C@@]1(C)C2[C@](C)(C3[C@]4(C=C[C@](C)(C4)CC3)CC2)CCC1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00179780-02	363676969.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC[C@@]1(C)C2[C@](C)(C3[C@]4(C=C[C@](C)(C4)CC3)CC2)CCC1	OC[C@@]1(C)C2[C@](C)(C3[C@]4(C=C[C@](C)(C4)CC3)CC2)CCC1
NCGC00169994-02	OC[C@@]1(O)C(C)=C[C@H](O)[C@H]2C(C)(C)CCC[C@]12C		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169994-02	363676926.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC[C@@]1(O)C(C)=C[C@H](O)[C@H]2C(C)(C)CCC[C@]12C	OC[C@@]1(O)C(C)=C[C@H](O)[C@H]2C(C)(C)CCC[C@]12C
NCGC00180556-02	OC[C@@]1(O)C(CO)=C[C@@H](O)[C@H]2C(C)(C)CCC[C@]12C		Inactive	<MOA Unknown> | Class: sesquiterpene | Genus: Aspergillus | Family: N/A | Species: cf niger		1	NCGC00180556-02	363677033.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC[C@@]1(O)C(CO)=C[C@@H](O)[C@H]2C(C)(C)CCC[C@]12C	OC[C@@]1(O)C(CO)=C[C@@H](O)[C@H]2C(C)(C)CCC[C@]12C
NCGC00381381-01	OC[C@@]12[C@@]3(C)[C@H](O)[C@@H](O)[C@H]([C@@]43OC4)O[C@@H]1C=C(C)[C@@H](O)C2		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381381-01	363679115.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	28.0116588919	OC[C@@]12[C@@]3(C)[C@H](O)[C@@H](O)[C@H]([C@@]43OC4)O[C@@H]1C=C(C)[C@@H](O)C2	OC[C@@]12[C@@]3(C)[C@H](O)[C@@H](O)[C@H]([C@@]43OC4)O[C@@H]1C=C(C)[C@@H](O)C2
NCGC00168803-04	OC[C@@]12[C@H]([C@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC1)CC2		Inactive	SK-BR-3 Inhibitor		1	Betulin	363676687.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC[C@@]12[C@H]([C@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC1)CC2	OC[C@@]12[C@H]([C@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC1)CC2
NCGC00370890-01	OC[C@H](Nc1nc(NCc2ccc(-c3ncccc3)cc2)c2ncn(C(C)C)c2n1)CC		Inactive			1	(R)-CR8	363677912.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC[C@H](Nc1nc(NCc2ccc(-c3ncccc3)cc2)c2ncn(C(C)C)c2n1)CC	OC[C@H](Nc1nc(NCc2ccc(-c3ncccc3)cc2)c2ncn(C(C)C)c2n1)CC
NCGC00094374-12	OC[C@H](Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1)CC		Inactive	CDK Inhibitor		1	Seliciclib	384568129.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC[C@H](Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1)CC	OC[C@H](Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1)CC
NCGC00485485-01	OC[C@H](Nc1nc(NCc2ccccc2)c2ncn(CCC)c2n1)CC		Inactive	Cyclin-dependent kinase 2/cyclin A Inhibitor		1	Ca2+ channel agonist 1	363681354.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC[C@H](Nc1nc(NCc2ccccc2)c2ncn(CCC)c2n1)CC	OC[C@H](Nc1nc(NCc2ccccc2)c2ncn(CCC)c2n1)CC
NCGC00390421-03	OC[C@H](Nc1nc(NCc2sc(C)cc2)c2ncn(CCC)c2n1)CC		Inactive			1	GV-58	377020434.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC[C@H](Nc1nc(NCc2sc(C)cc2)c2ncn(CCC)c2n1)CC	OC[C@H](Nc1nc(NCc2sc(C)cc2)c2ncn(CCC)c2n1)CC
NCGC00370879-01	OC[C@H](Nc1nc(Nc2cc(-c3ncccc3)ccc2)c2ncn(C(C)C)c2n1)CC		Inactive			1	(R)-DRF053 dihydrochloride	363677906.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC[C@H](Nc1nc(Nc2cc(-c3ncccc3)ccc2)c2ncn(C(C)C)c2n1)CC	OC[C@H](Nc1nc(Nc2cc(-c3ncccc3)ccc2)c2ncn(C(C)C)c2n1)CC
NCGC00024452-04	OC[C@H]1N(CCCC)C[C@H](O)[C@@H](O)[C@@H]1O		Inactive	Maltase-glucoamylase Inhibitor		1	Miglustat	170464950.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC[C@H]1N(CCCC)C[C@H](O)[C@@H](O)[C@@H]1O	OC[C@H]1N(CCCC)C[C@H](O)[C@@H](O)[C@@H]1O
NCGC00090791-01	OC[C@H]1O[C@@H](n2c3ncnc(N)c3nc2)CC1		Inactive			1	2'	17389408.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC[C@H]1O[C@@H](n2c3ncnc(N)c3nc2)CC1	OC[C@H]1O[C@@H](n2c3ncnc(N)c3nc2)CC1
NCGC00092360-02	OC[C@H]1O[C@@H](n2c3ncnc(N)c3nc2)[C@H](O)C1		Inactive	Purine Antagonist		1	Cordycepin	384568106.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OC[C@H]1O[C@@H](n2c3ncnc(N)c3nc2)[C@H](O)C1	OC[C@H]1O[C@@H](n2c3ncnc(N)c3nc2)[C@H](O)C1
NCGC00485105-01	OC[C@H]1[C@H](O)O[C@H]2N3C(O[C@@H]12)=NC(=N)C=C3		Inactive			1	Ancitabine hydrochloride	363681224.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC[C@H]1[C@H](O)O[C@H]2N3C(O[C@@H]12)=NC(=N)C=C3	OC[C@H]1[C@H](O)O[C@H]2N3C(O[C@@H]12)=NC(=N)C=C3
NCGC00385845-01	OC[C@]1(C)C2[C@@](C)(C3=C(COC3)CC2)CCC1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385845-01	363679966.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC[C@]1(C)C2[C@@](C)(C3=C(COC3)CC2)CCC1	OC[C@]1(C)C2[C@@](C)(C3=C(COC3)CC2)CCC1
NCGC00023142-06	OC[C@]1(C)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@H]1[C@@]32C[C@H]([C@@](O)(CO)CC3)C1		Inactive	Leishmania sp. Inhibitor		1	APHIDICOLIN	363676522.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	OC[C@]1(C)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@H]1[C@@]32C[C@H]([C@@](O)(CO)CC3)C1	OC[C@]1(C)[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@H]1[C@@]32C[C@H]([C@@](O)(CO)CC3)C1
NCGC00016261-08	OCc1c(O)c(C)ncc1CO		Inactive	Oxidative Stress Inhibitor		1	Pyridoxine	170464634.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	OCc1c(O)c(C)ncc1CO	OCc1c(O)c(C)ncc1CO
NCGC00094779-05	OCc1c(O)cccc1		Inactive			1	Salicyl alcohol	170465547.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&9.8753340919	OCc1c(O)cccc1	OCc1c(O)cccc1
NCGC00091865-02	OCc1ccccc1		Inactive			1	Benzyl alcohol	124891475.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OCc1ccccc1	OCc1ccccc1
NCGC00016103-16	OCc1oc(-c2nn(Cc3ccccc3)c3c2cccc3)cc1		Inactive	HIF-1alpha Inhibitor		1	Lificiguat	384567922.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OCc1oc(-c2nn(Cc3ccccc3)c3c2cccc3)cc1	OCc1oc(-c2nn(Cc3ccccc3)c3c2cccc3)cc1
NCGC00159570-14	OCc1sc(-c2oc(-c3sc(CO)cc3)cc2)cc1		Inactive	MDM2 (hdm2) Inhibitor		1	RITA	384568189.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	OCc1sc(-c2oc(-c3sc(CO)cc3)cc2)cc1	OCc1sc(-c2oc(-c3sc(CO)cc3)cc2)cc1
NCGC00248196-04	ON1C(C)(C)CC(O)CC1(C)C		Inactive	Free Radical Scavenger		1	Tempol	384568523.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	ON1C(C)(C)CC(O)CC1(C)C	ON1C(C)(C)CC(O)CC1(C)C
NCGC00378796-01	O[C@@H](C(C)C)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1		Inactive	Vitamin D receptor Agonist		1	Tacalcitol	405558914.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H](C(C)C)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1	O[C@@H](C(C)C)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1
NCGC00485929-01	O[C@@H](C(O)(C)C)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1		Inactive	Vitamin D3 receptor Binding Agent		1	Calcitetrol	363681423.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O[C@@H](C(O)(C)C)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1	O[C@@H](C(O)(C)C)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)[C@@H](O)C[C@H](O)C\3)/CCC2)CC1
NCGC00348363-01	O[C@@H](C(O)[C@H](O)CO)CO		Inactive	sugar alcohol		1	ARABITOL(D)	405558824.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H](C(O)[C@H](O)CO)CO	O[C@@H](C(O)[C@H](O)CO)CO
NCGC00408804-01	O[C@@H](CCN1C[C@H](C)[C@](C)(c2cc(O)ccc2)CC1)C1CCCCC1		Inactive	Mu opioid receptor Antagonist		1	LY-255582	363681052.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O[C@@H](CCN1C[C@H](C)[C@](C)(c2cc(O)ccc2)CC1)C1CCCCC1	O[C@@H](CCN1C[C@H](C)[C@](C)(c2cc(O)ccc2)CC1)C1CCCCC1
NCGC00159406-12&NCGC00159406-15	O[C@@H](CN)c1cc(O)c(O)cc1		Inactive	alpha/beta-adrenoceptor Agonist		2	Noradrenaline bitartrate monohydrate	170465227.0&384568174.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O.O[C@@H](CN)c1cc(O)c(O)cc1	O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O.O[C@@H](CN)c1cc(O)c(O)cc1&O[C@@H](CN)c1cc(O)c(O)cc1
NCGC00142615-08&NCGC00142615-10	O[C@@H](CNC)c1cc(O)c(O)cc1		Inactive	alpha/beta-adrenoceptor Agonist		2	Epinephrine	170464973.0&384568167.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	O[C@@H](CNC)c1cc(O)c(O)cc1	O[C@@H](CNC)c1cc(O)c(O)cc1
NCGC00024257-08&NCGC00024257-10	O[C@@H](CNC)c1cc(O)ccc1		Inactive	alpha1-Adrenoceptor Agonist		2	Phenylephrine hydrochloride	170465356.0&384568023.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O[C@@H](CNC)c1cc(O)ccc1.Cl	O[C@@H](CNC)c1cc(O)ccc1.Cl&O[C@@H](CNC)c1cc(O)ccc1
NCGC00178692-04	O[C@@H]([C@@H](N(C)C)C)c1ccccc1		Inactive	Beta-1 adrenergic receptor Agonist		1	N-METHYL (-)EPHEDRINE [1R,2S]	405558430.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]([C@@H](N(C)C)C)c1ccccc1	O[C@@H]([C@@H](N(C)C)C)c1ccccc1
NCGC00161359-01	O[C@@H]([C@@H](N(C)C)CO)/C=C/CCCCCCCCCCCCC		Inactive			1	N,N-DIMETHYLSPHINGOSINE	26754955.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O[C@@H]([C@@H](N(C)C)CO)/C=C/CCCCCCCCCCCCC	O[C@@H]([C@@H](N(C)C)CO)/C=C/CCCCCCCCCCCCC
NCGC00016542-06	O[C@@H]([C@@H](N)C)c1cc(O)c(O)cc1		Inactive	Adrenergic receptor alpha-2 Agonist		1	Levonordefrin	170464794.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O[C@@H]([C@@H](N)C)c1cc(O)c(O)cc1	O[C@@H]([C@@H](N)C)c1cc(O)c(O)cc1
NCGC00178024-05	O[C@@H]([C@@H](N)C)c1cc(O)ccc1		Inactive	Adrenergic receptor alpha-1 Agonist		1	Metaraminol bitartrate	170465256.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O=C(O)[C@@H](O)[C@@H](O)C(=O)O.O[C@@H]([C@@H](N)C)c1cc(O)ccc1	O=C(O)[C@@H](O)[C@@H](O)C(=O)O.O[C@@H]([C@@H](N)C)c1cc(O)ccc1
NCGC00345852-03	O[C@@H]([C@@H](NC1=Nc2c(C(C)C)cnn2C(NCc2ccccc2)=C1)CO)CO		Inactive	CDK1/2/5/9 Inhibitor		1	BS-194	384568767.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		O[C@@H]([C@@H](NC1=Nc2c(C(C)C)cnn2C(NCc2ccccc2)=C1)CO)CO	O[C@@H]([C@@H](NC1=Nc2c(C(C)C)cnn2C(NCc2ccccc2)=C1)CO)CO
NCGC00179566-03	O[C@@H]([C@@H](NCCc1ccc(O)cc1)C)c1ccc(O)cc1		Inactive	beta2-Adrenoceptor Agonists		1	Ritodrine hydrochloride	225144308.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]([C@@H](NCCc1ccc(O)cc1)C)c1ccc(O)cc1	O[C@@H]([C@@H](NCCc1ccc(O)cc1)C)c1ccc(O)cc1
NCGC00384684-01	O[C@@H]([C@@H](O)C)/C=C/c1c(CO)c(O)ccc1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Sordaria | Family: N/A | Species: sp.		1	NCGC00384684-01	363679309.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O[C@@H]([C@@H](O)C)/C=C/c1c(CO)c(O)ccc1	O[C@@H]([C@@H](O)C)/C=C/c1c(CO)c(O)ccc1
NCGC00166072-02	O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](O)CO		Inactive	osmotic diuretic agent		1	D-Galactitol	170465564.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](O)CO	O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](O)CO
NCGC00166125-02	O[C@@H]([C@H](O)[C@@H](O)CNC)[C@H](O)CO		Inactive	amino sugar		1	Meglumine	170465359.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O[C@@H]([C@H](O)[C@@H](O)CNC)[C@H](O)CO	O[C@@H]([C@H](O)[C@@H](O)CNC)[C@H](O)CO
NCGC00164246-18	O[C@@H]([C@H](O)[C@H](O)CO)[C@H](O)CO		Inactive			1	D-Sorbitol		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]([C@H](O)[C@H](O)CO)[C@H](O)CO	O[C@@H]([C@H](O)[C@H](O)CO)[C@H](O)CO
NCGC00262526-04	O[C@@H]([C@H]1[N@@]2C[C@H](C=C)[C@H](C1)CC2)c1c2c(ncc1)cccc2		Inactive	Alkaloid; P-Glycoprotein (MDR-1) Inhibitor		1	CINCHONIDINE	405558875.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]([C@H]1[N@@]2C[C@H](C=C)[C@H](C1)CC2)c1c2c(ncc1)cccc2	O[C@@H]([C@H]1[N@@]2C[C@H](C=C)[C@H](C1)CC2)c1c2c(ncc1)cccc2
NCGC00182058-01	O[C@@H]1/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/C(C(C)C)C)C)CC3)CCC/2)/CC(=C)[C@@H](O)C1		Inactive			1	Doxercalciferol	405558580.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/C(C(C)C)C)C)CC3)CCC/2)/CC(=C)[C@@H](O)C1	O[C@@H]1/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/C(C(C)C)C)C)CC3)CCC/2)/CC(=C)[C@@H](O)C1
NCGC00182058-03	O[C@@H]1C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC\2)/C[C@@H](O)C1		Inactive	Vitamin D Analog		1	Doxercalciferol	124893779.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.192688288	O[C@@H]1C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC\2)/C[C@@H](O)C1	O[C@@H]1C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC\2)/C[C@@H](O)C1
NCGC00379045-01	O[C@@H]1C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC3)CCC\2)/C[C@@H](O)C1		Inactive	Increase blood calcium level via a variety of mechanisms		1	Alfacalcidol-D6	405558455.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC3)CCC\2)/C[C@@H](O)C1	O[C@@H]1C(=C)/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC3)CCC\2)/C[C@@H](O)C1
NCGC00385313-01	O[C@@H]1C(=C)[C@H](O)CCC(=C)[C@H](O)C[C@H](C(=C)C)C1		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Achillea | Family: Compositae | Species: ageratum		1	NCGC00385313-01	363679670.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O[C@@H]1C(=C)[C@H](O)CCC(=C)[C@H](O)C[C@H](C(=C)C)C1	O[C@@H]1C(=C)[C@H](O)CCC(=C)[C@H](O)C[C@H](C(=C)C)C1
NCGC00168853-03	O[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@@H]3[C@](C)([C@@]4(C)[C@@H]([C@H]5[C@H](C(=C)C)CC[C@]5(C)CC4)CC3)CC2)CC1		Inactive	Steroid		1	Lupeol	174006790.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@@H]3[C@](C)([C@@]4(C)[C@@H]([C@H]5[C@H](C(=C)C)CC[C@]5(C)CC4)CC3)CC2)CC1	O[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@@H]3[C@](C)([C@@]4(C)[C@@H]([C@H]5[C@H](C(=C)C)CC[C@]5(C)CC4)CC3)CC2)CC1
NCGC00166307-05	O[C@@H]1C/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC/2)/C(=C)CC1		Inactive	Vitamin D receptor Agonist		1	ERGOCALCIFEROL	405559070.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1C/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC/2)/C(=C)CC1	O[C@@H]1C/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC/2)/C(=C)CC1
NCGC00159331-07	O[C@@H]1C/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC3)CCC/2)/C(=C)CC1		Inactive	Vitamin D receptor Binding Agent		1	CHOLECALCIFEROL	405558699.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O[C@@H]1C/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC3)CCC/2)/C(=C)CC1	O[C@@H]1C/C(=C/C=C\2/[C@H]3[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC3)CCC/2)/C(=C)CC1
NCGC00166147-02	O[C@@H]1C/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC\2)/[C@@H](C)CC1		Inactive	Vitamin D receptor Agonist		1	Dihydrotachysterol	144205894.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1C/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC\2)/[C@@H](C)CC1	O[C@@H]1C/C(=C\C=C/2\[C@H]3[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC3)CCC\2)/[C@@H](C)CC1
NCGC00346711-02	O[C@@H]1CC=2[C@@](C)(C3C(C4[C@@](C)(C(n5c6c(nc5)cccc6)=CC4)CC3)CC=2)CC1		Inactive	Selective Androgen Receptor Modulators (SARM)		1	Galeterone	363677531.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1CC=2[C@@](C)(C3C(C4[C@@](C)(C(n5c6c(nc5)cccc6)=CC4)CC3)CC=2)CC1	O[C@@H]1CC=2[C@@](C)(C3C(C4[C@@](C)(C(n5c6c(nc5)cccc6)=CC4)CC3)CC=2)CC1
NCGC00485372-01	O[C@@H]1CC=2[C@@](C)(C=3C([C@H]4[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC4)CC=3)=CC=2)CC1		Inactive			1	Ergosta-5,7,9(11),22-tetraen-3Î²-ol	363681301.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O[C@@H]1CC=2[C@@](C)(C=3C([C@H]4[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC4)CC=3)=CC=2)CC1	O[C@@H]1CC=2[C@@](C)(C=3C([C@H]4[C@@](C)([C@@H]([C@@H](/C=C/[C@@H](C(C)C)C)C)CC4)CC=3)=CC=2)CC1
NCGC00163474-07	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4C(=C(C)[C@]5([C@H](C)[C@@H]6NC[C@@H](C)C[C@H]6O5)CC4)C3)CC=2)CC1		Inactive	Smo Receptor Antagonist		1	Cyclopamine	363676621.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	26.5059569321	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4C(=C(C)[C@]5([C@H](C)[C@@H]6NC[C@@H](C)C[C@H]6O5)CC4)C3)CC=2)CC1	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4C(=C(C)[C@]5([C@H](C)[C@@H]6NC[C@@H](C)C[C@H]6O5)CC4)C3)CC=2)CC1
NCGC00263148-07	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(c5cnccc5)=CC4)CC3)CC=2)CC1		Inactive	Androgen Biosynthesis Inhibitor		1	Abiraterone	384568623.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(c5cnccc5)=CC4)CC3)CC=2)CC1	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(c5cnccc5)=CC4)CC3)CC=2)CC1
NCGC00142599-02	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](/C=C/[C@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1		Inactive	Steroid hormone		1	Stigmasterol	174007475.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](/C=C/[C@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](/C=C/[C@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1
NCGC00159351-05	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC=2)CC1		Inactive	Transient receptor potential cation channel subfamily V member 1 Inhibitor		1	Cholesterol	225144221.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC=2)CC1	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC=2)CC1
NCGC00142598-07	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1		Inactive	Cholesterol lowering drug		1	beta-Sitosterol	384568165.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1	O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1
NCGC00344535-01	O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC2)CC1		Inactive	Sterol regulatory element-binding protein cleavage-activating protein Binding Agent		1	5alpha-Cholestan-3beta-ol	225144382.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC2)CC1	O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H]([C@@H](CCCC(C)C)C)CC4)CC3)CC2)CC1
NCGC00248905-02	O[C@@H]1[C@@H](C(C)C)CC[C@H](C)C1		Inactive	Transient receptor potential cation channel subfamily A member 1 Antagonist		1	(1S,2R,5S)-(+)-Menthol	225144344.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1[C@@H](C(C)C)CC[C@H](C)C1	O[C@@H]1[C@@H](C(C)C)CC[C@H](C)C1
NCGC00485002-01	O[C@@H]1[C@@H](C)O[C@@H](n2c3ncnc(N)c3nc2)C1		Inactive			1	2â€²,5â€²-Dideoxyadenosine	363681183.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O[C@@H]1[C@@H](C)O[C@@H](n2c3ncnc(N)c3nc2)C1	O[C@@H]1[C@@H](C)O[C@@H](n2c3ncnc(N)c3nc2)C1
NCGC00262549-02	O[C@@H]1[C@@H](CC)C2C3[C@@H](O)[C@]45[C@@H](N(C)c6c4cccc6)[C@@H](N1[C@@H]3C5)C2		Inactive	Voltage-gated potassium channel subunit Kv4.3 Inhibitor		1	Ajmaline	405559078.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1[C@@H](CC)C2C3[C@@H](O)[C@]45[C@@H](N(C)c6c4cccc6)[C@@H](N1[C@@H]3C5)C2	O[C@@H]1[C@@H](CC)C2C3[C@@H](O)[C@]45[C@@H](N(C)c6c4cccc6)[C@@H](N1[C@@H]3C5)C2
NCGC00160355-01	O[C@@H]1[C@@H](O)[C@@H](O)CO[C@@H]1O		Inactive			1	NCGC00160355-01	29216036.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1[C@@H](O)[C@@H](O)CO[C@@H]1O	O[C@@H]1[C@@H](O)[C@@H](O)CO[C@@H]1O
NCGC00017331-07	O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1		Inactive	superoxide anion generation Inhibitor		1	CIANIDANOL	434146965.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1	O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1
NCGC00179652-04	O[C@@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CCC2)CC3)C4)CC1		Inactive	Kappa opioid receptor Partial Agonist		1	Nalbuphine hydrochloride	405558847.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CCC2)CC3)C4)CC1	O[C@@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC2CCC2)CC3)C4)CC1
NCGC00485892-01	O[C@@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC=C)CC3)C4)CC1		Inactive	Mu opioid receptor Antagonist		1	6-Alpha Naloxol	363681398.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O[C@@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC=C)CC3)C4)CC1	O[C@@H]1[C@@H]2Oc3c(O)ccc4c3[C@@]32[C@](O)([C@H](N(CC=C)CC3)C4)CC1
NCGC00167959-12	O[C@@H]1[C@H]2[C@H](N(C)Cc3c4OCOc4ccc23)c2c(cc3OCOc3c2)C1		Inactive	microtubule polymerization Inhibitor		1	(+)-Chelidonine	434147231.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1[C@H]2[C@H](N(C)Cc3c4OCOc4ccc23)c2c(cc3OCOc3c2)C1	O[C@@H]1[C@H]2[C@H](N(C)Cc3c4OCOc4ccc23)c2c(cc3OCOc3c2)C1
NCGC00179861-02	O[C@@H]1[C@H]2[C@](O)(C(C)C)CC[C@]2(C)CC=C(C)C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: Ferula  | Family: N/A | Species: jaeschkeana		1	NCGC00179861-02	363676978.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O[C@@H]1[C@H]2[C@](O)(C(C)C)CC[C@]2(C)CC=C(C)C1	O[C@@H]1[C@H]2[C@](O)(C(C)C)CC[C@]2(C)CC=C(C)C1
NCGC00380796-01	O[C@@H]1[C@](CCC=C(C)C)(C)[C@H]2[C@@](C)([C@H](Cc3c4c([nH]c3)cccc4)C(=C)CC2)CC1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380796-01	363678786.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	13.513758152	O[C@@H]1[C@](CCC=C(C)C)(C)[C@H]2[C@@](C)([C@H](Cc3c4c([nH]c3)cccc4)C(=C)CC2)CC1	O[C@@H]1[C@](CCC=C(C)C)(C)[C@H]2[C@@](C)([C@H](Cc3c4c([nH]c3)cccc4)C(=C)CC2)CC1
NCGC00274061-01&NCGC00274061-07	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@]5(O[C@@H]5C(O)=C(C#N)C4)CC3)CC2)CC1		Inactive	Estrogen Receptor (ER) beta Modulators		2	Trilostane	174007161.0&384568709.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@]5(O[C@@H]5C(O)=C(C#N)C4)CC3)CC2)CC1	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@@]5(O[C@@H]5C(O)=C(C#N)C4)CC3)CC2)CC1
NCGC00344556-01	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](C[C@@H]5S[C@@H]5C4)CC3)CC2)CC1		Inactive			1	Epitiostanol	225144391.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](C[C@@H]5S[C@@H]5C4)CC3)CC2)CC1	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](C[C@@H]5S[C@@H]5C4)CC3)CC2)CC1
NCGC00091544-18&NCGC00091544-23	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1		Inactive	Estrogen Receptor (ER) Agonist		2	Estradiol	405558561.0&384568097.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&13.780450548&0.0	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1	O[C@@H]1[C@]2(C)[C@H]([C@H]3[C@@H](c4c(cc(O)cc4)CC3)CC2)CC1
NCGC00385625-01	O[C@@H]1[C@]2(O)[C@]3([C@@](C)([C@@H]4[C@H]1CC(C)(C)C4)C3)C(O)OC2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385625-01	363679844.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O[C@@H]1[C@]2(O)[C@]3([C@@](C)([C@@H]4[C@H]1CC(C)(C)C4)C3)C(O)OC2	O[C@@H]1[C@]2(O)[C@]3([C@@](C)([C@@H]4[C@H]1CC(C)(C)C4)C3)C(O)OC2
NCGC00179676-03	O[C@@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1	4.9000001	Active		0.0	1	Lynestrenol	170465984.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	2.4	32.426640924	O[C@@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1	O[C@@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1
NCGC00482601-01	O[C@@]12C(C)(C)[C@H]3C[C@@H]([C@@H](C)CC1)[C@]2(C)CC3		Inactive			1	Patchouli alcohol	434147186.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@@]12C(C)(C)[C@H]3C[C@@H]([C@@H](C)CC1)[C@]2(C)CC3	O[C@@]12C(C)(C)[C@H]3C[C@@H]([C@@H](C)CC1)[C@]2(C)CC3
NCGC00181006-02	O[C@H](C(NC)C)c1ccc(O)cc1		Inactive			1	1-(4-Hydroxyphenyl)-2-methyl-2-methylaminoethanol hydrochloride	225144314.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@H](C(NC)C)c1ccc(O)cc1	O[C@H](C(NC)C)c1ccc(O)cc1
NCGC00379027-01	O[C@H](C(O)(C)C)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)CC[C@H](O)C\3)/CCC2)CC1		Inactive	Vitamin D3 receptor Agonist		1	(24S)-24,25-Dihydroxyvitamin D3	405558665.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@H](C(O)(C)C)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)CC[C@H](O)C\3)/CCC2)CC1	O[C@H](C(O)(C)C)CC[C@@H](C)[C@@H]1[C@]2(C)[C@H](/C(=C/C=C/3\C(=C)CC[C@H](O)C\3)/CCC2)CC1
NCGC00262542-10	O[C@H]([C@@H]1[N@@]2C[C@H](C=C)[C@H](C1)CC2)c1c2c(ncc1)cccc2		Inactive			1	NCGC00262542-10		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	15.736138692	O[C@H]([C@@H]1[N@@]2C[C@H](C=C)[C@H](C1)CC2)c1c2c(ncc1)cccc2	O[C@H]([C@@H]1[N@@]2C[C@H](C=C)[C@H](C1)CC2)c1c2c(ncc1)cccc2
NCGC00386543-02	O[C@H]([C@H](C)N1CCC(O)(c2ccccc2)CC1)c1ccc(O)cc1		Inactive	Glutamate [NMDA] receptor subunit epsilon 2 Antagonist		1	CP 101606	363680322.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O[C@H]([C@H](C)N1CCC(O)(c2ccccc2)CC1)c1ccc(O)cc1	O[C@H]([C@H](C)N1CCC(O)(c2ccccc2)CC1)c1ccc(O)cc1
NCGC00274057-01	O[C@H]([C@H](N)C)c1ccccc1		Inactive	Adrenergic receptor alpha-1 Agonist		1	Phenylpropanolamine hydrochloride	170465627.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@H]([C@H](N)C)c1ccccc1.Cl	O[C@H]([C@H](N)C)c1ccccc1.Cl
NCGC00387119-01	O[C@H]([C@H](NC)CO)/C=C/c1ccc(CCCCC)cc1	5.6999998	Active		0.0	1	SK1-I	377020333.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	3.0	32.8165714319	O[C@H]([C@H](NC)CO)/C=C/c1ccc(CCCCC)cc1	O[C@H]([C@H](NC)CO)/C=C/c1ccc(CCCCC)cc1
NCGC00181020-01	O[C@H]1CC(C)(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=CC=2C(C)(C)C[C@H](O)CC=2C)\C)\C)/C)/C)=C(C)C1		Inactive	osteoclast development Inhibitor		1	Zeaxanthin	144206223.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@H]1CC(C)(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=CC=2C(C)(C)C[C@H](O)CC=2C)\C)\C)/C)/C)=C(C)C1	O[C@H]1CC(C)(C)C(/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=CC=2C(C)(C)C[C@H](O)CC=2C)\C)\C)/C)/C)=C(C)C1
NCGC00351597-01&NCGC00351597-13	O[C@H]1[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O[C@@H]1CN(C(C)C)C1CC(CCc2[nH]c3c(n2)cc(C(C)(C)C)cc3)C1		Inactive	DOT1L Inhibitor		2	EPZ-5676	387059832.0&384569015.0	2020_NPACT-2_CPE&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O[C@H]1[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O[C@@H]1CN(C(C)C)C1CC(CCc2[nH]c3c(n2)cc(C(C)(C)C)cc3)C1	O[C@H]1[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O[C@@H]1CN(C(C)C)C1CC(CCc2[nH]c3c(n2)cc(C(C)(C)C)cc3)C1
NCGC00017331-08	O[C@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1		Inactive	superoxide anion generation Inhibitor		1	(-)-Epicatechin	170465932.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O[C@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1	O[C@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1
NCGC00381388-01	O[C@H]1[C@H](/C=C/C=C)OC[C@@H]1/C=C/C=C/C		Inactive	Hemagglutinin Inhibitor		1	NCGC00381388-01	363679119.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O[C@H]1[C@H](/C=C/C=C)OC[C@@H]1/C=C/C=C/C	O[C@H]1[C@H](/C=C/C=C)OC[C@@H]1/C=C/C=C/C
NCGC00346590-02	O[C@H]1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2		Inactive	antimalarial agents		1	Artenimol	363677468.0	Annotated/Bioactive Compound Collection&2020_NPACT-1_CPE	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O[C@H]1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2	O[C@H]1[C@H](C)[C@H]2[C@@]34OO[C@@](C)(O[C@H]3O1)CC[C@H]4[C@H](C)CC2
NCGC00380338-01	O[C@H]1[C@H](O)CC2[C@](CCc3cocc3)(C)[C@H](C)CC[C@@]2(C)[C@@]21OC2		Inactive	<MOA Unknown> | Class: Diterpen | Genus: Cornutia | Family: Verbenaceae | Species: pyramidata		1	NCGC00380338-01	363678547.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O[C@H]1[C@H](O)CC2[C@](CCc3cocc3)(C)[C@H](C)CC[C@@]2(C)[C@@]21OC2	O[C@H]1[C@H](O)CC2[C@](CCc3cocc3)(C)[C@H](C)CC[C@@]2(C)[C@@]21OC2
NCGC00166111-06&NCGC00274080-01	O[C@H]1[C@H](O)C[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(O)c2		Inactive	Estrogen Receptor (ER) Agonist		2	Estriol	384568304.0&170465807.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	O[C@H]1[C@H](O)C[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(O)c2	O[C@H]1[C@H](O)C[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CCc2c1ccc(O)c2
NCGC00180429-03	O[C@H]1[C@H](O)[C@@H]2[C@@](O)(C)[C@H]3N(C[C@@H](C)CC3)C[C@H]2[C@H]2[C@]1(O)[C@@H]1[C@H](O)C[C@@H]3C4(O)[C@@H](O)CC[C@]3(C)[C@@]1(O4)C2		Inactive	SW1990 Inhibitor		1	NCGC00180429-03	363677025.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O[C@H]1[C@H](O)[C@@H]2[C@@](O)(C)[C@H]3N(C[C@@H](C)CC3)C[C@H]2[C@H]2[C@]1(O)[C@@H]1[C@H](O)C[C@@H]3C4(O)[C@@H](O)CC[C@]3(C)[C@@]1(O4)C2	O[C@H]1[C@H](O)[C@@H]2[C@@](O)(C)[C@H]3N(C[C@@H](C)CC3)C[C@H]2[C@H]2[C@]1(O)[C@@H]1[C@H](O)C[C@@H]3C4(O)[C@@H](O)CC[C@]3(C)[C@@]1(O4)C2
NCGC00345819-01	O[C@H]1[C@H](O)[C@]2(C)[C@@H]([C@H]1O)[C@H]1[C@@H](c3c(cc(O)cc3)CC1)CC2		Inactive	Selective Estrogen Receptor Modulators (SERM)		1	Estetrol	174007301.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@H]1[C@H](O)[C@]2(C)[C@@H]([C@H]1O)[C@H]1[C@@H](c3c(cc(O)cc3)CC1)CC2	O[C@H]1[C@H](O)[C@]2(C)[C@@H]([C@H]1O)[C@H]1[C@@H](c3c(cc(O)cc3)CC1)CC2
NCGC00346606-02	O[C@H]1[C@H]([C@@H](NC)C)[C@]2(C)[C@](C)([C@H]3[C@]4([C@@]5([C@H](C(C)(C)[C@@H](NC)CC5)CC3)C4)CC2)C1	5.5	Active	acute myocardial ischemia drug	0.0	1	Cyclovirobuxin D	363677475.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	68.5806321736	O[C@H]1[C@H]([C@@H](NC)C)[C@]2(C)[C@](C)([C@H]3[C@]4([C@@]5([C@H](C(C)(C)[C@@H](NC)CC5)CC3)C4)CC2)C1	O[C@H]1[C@H]([C@@H](NC)C)[C@]2(C)[C@](C)([C@H]3[C@]4([C@@]5([C@H](C(C)(C)[C@@H](NC)CC5)CC3)C4)CC2)C1
NCGC00160508-03	O[C@H]1[C@H]2OC[C@H](O)[C@H]2OC1		Inactive			1	Isosorbide	170465187.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O[C@H]1[C@H]2OC[C@H](O)[C@H]2OC1	O[C@H]1[C@H]2OC[C@H](O)[C@H]2OC1
NCGC00169914-02	O[C@H]1[C@]2(C(=C)C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00169914-02	363676911.0	2020_NPACT-5_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O[C@H]1[C@]2(C(=C)C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1	O[C@H]1[C@]2(C(=C)C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1
NCGC00017226-06&NCGC00017226-08	O[C@](C=C)(CC[C@H]1[C@@](O)(C)CC[C@H]2C(C)(C)CCC[C@]12C)C		Inactive			2	NCGC00017226-06&Sclareol		2020_NPACT-10_CPE&2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O[C@](C=C)(CC[C@H]1[C@@](O)(C)CC[C@H]2C(C)(C)CCC[C@]12C)C	O[C@](C=C)(CC[C@H]1[C@@](O)(C)CC[C@H]2C(C)(C)CCC[C@]12C)C
NCGC00179665-04	O[C@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=Cc5oncc5C4)CC3)CC2)CC1	4.9000001	Active	Androgen Receptor Agonist	0.0	1	Danazol	170464884.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	41.1379158191	O[C@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=Cc5oncc5C4)CC3)CC2)CC1	O[C@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=Cc5oncc5C4)CC3)CC2)CC1
NCGC00485262-01	O[C@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](CC5=Nc6n(c7c(n6)cccc7)C=C5C4)CC3)CC2)CC1	5.0999999	Active		0.0	1	WIN 51708 hydrate	363681271.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	49.2621608909	O[C@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](CC5=Nc6n(c7c(n6)cccc7)C=C5C4)CC3)CC2)CC1	O[C@]1(C#C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](CC5=Nc6n(c7c(n6)cccc7)C=C5C4)CC3)CC2)CC1
NCGC00167449-02	O[C@]1(C#C)[C@]2(CC)[C@H]([C@H]3[C@H](C(=C)C2)[C@@H]2C(=CCCC2)CC3)CC1	4.9499998	Active	Progesterone receptor Agonist	0.0	1	Desogestrel	225144285.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	54.8713285822	O[C@]1(C#C)[C@]2(CC)[C@H]([C@H]3[C@H](C(=C)C2)[C@@H]2C(=CCCC2)CC3)CC1	O[C@]1(C#C)[C@]2(CC)[C@H]([C@H]3[C@H](C(=C)C2)[C@@H]2C(=CCCC2)CC3)CC1
NCGC00385862-01	O[C@]1(C)C2C=C(C(C)C)CC[C@](O)(C)C2CC1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385862-01	363679974.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	O[C@]1(C)C2C=C(C(C)C)CC[C@](O)(C)C2CC1	O[C@]1(C)C2C=C(C(C)C)CC[C@](O)(C)C2CC1
NCGC00344550-03	O[C@]1(C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](Cc5[nH]ncc5C4)CC3)CC2)CC1		Inactive	Synthetic Steroid		1	Stanozolol	384568722.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@]1(C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](Cc5[nH]ncc5C4)CC3)CC2)CC1	O[C@]1(C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](Cc5[nH]ncc5C4)CC3)CC2)CC1
NCGC00181290-01	O[C@]1(C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](Cc5nonc5C4)CC3)CC2)CC1		Inactive			1	Furazabol	144206325.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@]1(C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](Cc5nonc5C4)CC3)CC2)CC1	O[C@]1(C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)[C@H](Cc5nonc5C4)CC3)CC2)CC1
NCGC00167514-02	O[C@]1(CC)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1		Inactive	Androgen Receptor Agonist		1	Ethylestrenol	170465211.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.3441084481	O[C@]1(CC)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1	O[C@]1(CC)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1
NCGC00159497-02	O[C@]1(CC=C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1		Inactive	Progesterone receptor Agonist		1	Allylestrenol	144205271.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@]1(CC=C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1	O[C@]1(CC=C)[C@]2(C)[C@H]([C@H]3[C@@H]([C@@H]4C(=CCCC4)CC3)CC2)CC1
NCGC00346607-02	O[C@]12[C@H](C(C)C)C[C@@]3([C@@H](C)CC[C@H]3C(=C)C1)O2		Inactive	mitochondrial modulator		1	Curcumol	363677476.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O[C@]12[C@H](C(C)C)C[C@@]3([C@@H](C)CC[C@H]3C(=C)C1)O2	O[C@]12[C@H](C(C)C)C[C@@]3([C@@H](C)CC[C@H]3C(=C)C1)O2
NCGC00346954-01	Oc1c(-c2ccc(-c3n[nH]c(Nc4cc(CNC5CC5)ccc4)c3)cc2)ccc(O)c1		Inactive	Chk1 Inhibitor		1	TCS-2312	174007019.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Oc1c(-c2ccc(-c3n[nH]c(Nc4cc(CNC5CC5)ccc4)c3)cc2)ccc(O)c1	Oc1c(-c2ccc(-c3n[nH]c(Nc4cc(CNC5CC5)ccc4)c3)cc2)ccc(O)c1
NCGC00091595-07	Oc1c(-c2ccccc2)cccc1		Inactive			1	Sodium 2-phenylphenate tetrahydrate	170465724.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	[O-]c1c(-c2ccccc2)cccc1.[Na+].O.O.O.O	[O-]c1c(-c2ccccc2)cccc1.[Na+].O.O.O.O
NCGC00387217-01	Oc1c(-c2nc(NC[C@H](N)CC)ccn2)cc(-c2cn(C)nc2)cc1		Inactive			1	CRT 0066101	363680575.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	-17.4457130559	Oc1c(-c2nc(NC[C@H](N)CC)ccn2)cc(-c2cn(C)nc2)cc1	Oc1c(-c2nc(NC[C@H](N)CC)ccn2)cc(-c2cn(C)nc2)cc1
NCGC00169713-02	Oc1c(/C=C/c2cc(O)cc(O)c2)ccc(O)c1		Inactive			1	Oxyresveratrol	434147255.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1c(/C=C/c2cc(O)cc(O)c2)ccc(O)c1	Oc1c(/C=C/c2cc(O)cc(O)c2)ccc(O)c1
NCGC00166289-02	Oc1c(/C=C/c2ccc(C(=N)N)cc2)ccc(C(=N)N)c1		Inactive			1	Hydroxystilbamidine bis(methanesulfonate)	124893257.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1c(/C=C/c2ccc(C(=N)N)cc2)ccc(C(=N)N)c1	Oc1c(/C=C/c2ccc(C(=N)N)cc2)ccc(C(=N)N)c1
NCGC00166079-02	Oc1c(/N=N/c2c(C)cc(/N=N/c3c(C)cccc3)cc2)c2c(cc1)cccc2		Inactive			1	C.I. Solvent Red 24	170465710.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1c(/N=N/c2c(C)cc(/N=N/c3c(C)cccc3)cc2)c2c(cc1)cccc2	Oc1c(/N=N/c2c(C)cc(/N=N/c3c(C)cccc3)cc2)c2c(cc1)cccc2
NCGC00015992-01	Oc1c(C(C)(C)C)cc(C=C(C#N)C#N)cc1C(C)(C)C		Inactive			1	Tyrphostin A9	11111849.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	24.5	Oc1c(C(C)(C)C)cc(C=C(C#N)C#N)cc1C(C)(C)C	Oc1c(C(C)(C)C)cc(C=C(C#N)C#N)cc1C(C)(C)C
NCGC00385162-01	Oc1c(C(C)C)c2c([C@]3(C)[C@H](C(C)(C)CCC3)CC2)cc1		Inactive	Staphylococcus aureus Inhibitor		1	NCGC00385162-01	363679573.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	27.7058162919	Oc1c(C(C)C)c2c([C@]3(C)[C@H](C(C)(C)CCC3)CC2)cc1	Oc1c(C(C)C)c2c([C@]3(C)[C@H](C(C)(C)CCC3)CC2)cc1
NCGC00159373-04	Oc1c(C(C)C)ccc(C)c1		Inactive	Aldose reductase Inhibitor		1	Thymol	170465504.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Oc1c(C(C)C)ccc(C)c1	Oc1c(C(C)C)ccc(C)c1
NCGC00015389-07&NCGC00015389-14	Oc1c(C(C)C)cccc1C(C)C		Inactive	TRPV1 (Vanilloid VR1 Receptor) Agonist		2	Propofol	124879993.0&170464994.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&0.0	Oc1c(C(C)C)cccc1C(C)C	Oc1c(C(C)C)cccc1C(C)C
NCGC00015766-13&NCGC00015766-16	Oc1c(C)c(CC2=NCCN2)c(C)cc1C(C)(C)C		Inactive	alpha2A(2D)-Adrenoceptor Agonist		2	Oxymetazoline hydrochloride	170464916.0&363676461.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Oc1c(C)c(CC2=NCCN2)c(C)cc1C(C)(C)C	Oc1c(C)c(CC2=NCCN2)c(C)cc1C(C)(C)C
NCGC00380856-01	Oc1c(C)c(O)cc2c1COC1(O)C2OCCC1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380856-01	363678817.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1c(C)c(O)cc2c1COC1(O)C2OCCC1	Oc1c(C)c(O)cc2c1COC1(O)C2OCCC1
NCGC00253592-01	Oc1c(C)cc(O)c2c1cccc2		Inactive	regulation of blood coagulation Activator		1	Menadiol	170465455.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Oc1c(C)cc(O)c2c1cccc2	Oc1c(C)cc(O)c2c1cccc2
NCGC00091534-02	Oc1c(C)cccc1		Inactive			1	o-Cresol	26753043.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1c(C)cccc1	Oc1c(C)cccc1
NCGC00347653-02	Oc1c(C2COc3c4c(OC(C(=C)C)C4)ccc3C2)ccc(O)c1		Inactive	<MOA Unknown> | Class: Flavonoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347653-02	363677656.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1c(C2COc3c4c(OC(C(=C)C)C4)ccc3C2)ccc(O)c1	Oc1c(C2COc3c4c(OC(C(=C)C)C4)ccc3C2)ccc(O)c1
NCGC00381221-01	Oc1c(CC=C(C)C)c(C)c2c3c(O)cc(C)cc3oc2c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381221-01	363679032.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1c(CC=C(C)C)c(C)c2c3c(O)cc(C)cc3oc2c1	Oc1c(CC=C(C)C)c(C)c2c3c(O)cc(C)cc3oc2c1
NCGC00347827-02	Oc1c(CC=C(C)C)cc2[C@@H]3Oc4c([C@@H]3COc2c1)ccc(O)c4		Inactive	<MOA Unknown> | Class: Shikimate | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00347827-02	363677699.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1c(CC=C(C)C)cc2[C@@H]3Oc4c([C@@H]3COc2c1)ccc(O)c4	Oc1c(CC=C(C)C)cc2[C@@H]3Oc4c([C@@H]3COc2c1)ccc(O)c4
NCGC00163567-08	Oc1c(CC=C)cc(-c2c(O)ccc(CC=C)c2)cc1		Inactive	NF-kappaB Activation Modulator		1	Honokiol	434147019.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1c(CC=C)cc(-c2c(O)ccc(CC=C)c2)cc1	Oc1c(CC=C)cc(-c2c(O)ccc(CC=C)c2)cc1
NCGC00599698-01	Oc1c(CCCC)ccc(O)c1		Inactive			1	4-Butylresorcinol Rucinol	434147253.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1c(CCCC)ccc(O)c1	Oc1c(CCCC)ccc(O)c1
NCGC00180998-01	Oc1c(CCCCC)ccc(C)c1		Inactive			1	Amylmetacresol	144206204.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1c(CCCCC)ccc(C)c1	Oc1c(CCCCC)ccc(C)c1
NCGC00091208-09&NCGC00091208-11	Oc1c(CCCCCC)ccc(O)c1		Inactive	Tyrosinase Inhibitor		2	4-Hexylresorcinol&HEXYLRESORCINOL	170465471.0&434146986.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Oc1c(CCCCCC)ccc(O)c1	Oc1c(CCCCCC)ccc(O)c1
NCGC00387166-03	Oc1c(CN(CC)CC)cc(/C(=C(\CC)/c2cc(CN(CC)CC)c(O)cc2)/CC)cc1	5.0	Active		0.0	1	NSC 33994	377020198.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	103.0130375341	Oc1c(CN(CC)CC)cc(/C(=C(\CC)/c2cc(CN(CC)CC)c(O)cc2)/CC)cc1	Oc1c(CN(CC)CC)cc(/C(=C(\CC)/c2cc(CN(CC)CC)c(O)cc2)/CC)cc1
NCGC00167544-02	Oc1c(Cc2c(O)c(-n3nc4c(n3)cccc4)cc(C(CC(C)(C)C)(C)C)c2)cc(C(CC(C)(C)C)(C)C)cc1-n1nc2c(n1)cccc2		Inactive			1	2,2'-Methylenebis[6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol]	225144291.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1c(Cc2c(O)c(-n3nc4c(n3)cccc4)cc(C(CC(C)(C)C)(C)C)c2)cc(C(CC(C)(C)C)(C)C)cc1-n1nc2c(n1)cccc2	Oc1c(Cc2c(O)c(-n3nc4c(n3)cccc4)cc(C(CC(C)(C)C)(C)C)c2)cc(C(CC(C)(C)C)(C)C)cc1-n1nc2c(n1)cccc2
NCGC00408795-01	Oc1c(O)cc2c(C(Cc3ccc(O)cc3)NCC2)c1		Inactive	Beta-2 adrenergic receptor Agonist		1	Higenamine hydrochloride	363681050.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1c(O)cc2c(C(Cc3ccc(O)cc3)NCC2)c1	Oc1c(O)cc2c(C(Cc3ccc(O)cc3)NCC2)c1
NCGC00095462-04	Oc1c(O)cc2c(c1)C1C(O)(COc3c1ccc(O)c3)C2		Inactive			1	BRAZILIN	377020402.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	18.685732376	Oc1c(O)cc2c(c1)C1C(O)(COc3c1ccc(O)c3)C2	Oc1c(O)cc2c(c1)C1C(O)(COc3c1ccc(O)c3)C2
NCGC00094226-13	Oc1c(O)ccc(/C=C/c2cc(O)cc(O)c2)c1		Inactive	Syk Kinase Inhibitor		1	Piceatannol	384568127.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1c(O)ccc(/C=C/c2cc(O)cc(O)c2)c1	Oc1c(O)ccc(/C=C/c2cc(O)cc(O)c2)c1
NCGC00347063-02	Oc1c(O)ccc(C2CCN(c3c4c(ncc3)cccc4)CC2)c1		Inactive	M18 Aspartyl Aminopeptidase Inhibitor		1	KUC110948N	384568980.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	25.3495145681	Oc1c(O)ccc(C2CCN(c3c4c(ncc3)cccc4)CC2)c1	Oc1c(O)ccc(C2CCN(c3c4c(ncc3)cccc4)CC2)c1
NCGC00015741-13	Oc1c(O)ccc(CC(C(Cc2cc(O)c(O)cc2)C)C)c1		Inactive	5-Lipoxygenase Inhibitor		1	4,4 -(2,3-Dimethyltetramethylene)dipyrocatechol	405558741.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1c(O)ccc(CC(C(Cc2cc(O)c(O)cc2)C)C)c1	Oc1c(O)ccc(CC(C(Cc2cc(O)c(O)cc2)C)C)c1
NCGC00015519-11&NCGC00015519-15	Oc1c(O)ccc(CCN)c1		Inactive	Neurotransmitter		2	Dopamine hydrochloride	170464942.0&384567860.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Oc1c(O)ccc(CCN)c1	Oc1c(O)ccc(CCN)c1
NCGC00015321-11	Oc1c(O)ccc(CCNC(CCc2ccc(O)cc2)C)c1		Inactive	beta1-Adrenoceptor Antagonists		1	Dobutamine	170465050.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1c(O)ccc(CCNC(CCc2ccc(O)cc2)C)c1	Oc1c(O)ccc(CCNC(CCc2ccc(O)cc2)C)c1
NCGC00184998-02	Oc1c(O)ccc(CCNCCCCCCNCCc2ccccc2)c1		Inactive	D(2) dopamine receptor Agonist		1	Dopexamine	170466408.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1c(O)ccc(CCNCCCCCCNCCc2ccccc2)c1	Oc1c(O)ccc(CCNCCCCCCNCCc2ccccc2)c1
NCGC00094201-03	Oc1c(O)ccc(C[C@@H]([C@@H](Cc2cc(O)c(O)cc2)C)C)c1		Inactive	5-Lipoxygenase Inhibitor		1	Masoprocol	124891671.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1c(O)ccc(C[C@@H]([C@@H](Cc2cc(O)c(O)cc2)C)C)c1	Oc1c(O)ccc(C[C@@H]([C@@H](Cc2cc(O)c(O)cc2)C)C)c1
NCGC00183049-01	Oc1c(O)ccc2[C@@H](c3cc(O)c(O)cc3)CNCc12		Inactive			1	Zelandopam	144206852.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Oc1c(O)ccc2[C@@H](c3cc(O)c(O)cc3)CNCc12.Cl	Oc1c(O)ccc2[C@@H](c3cc(O)c(O)cc3)CNCc12.Cl
NCGC00025349-05	Oc1c(O)ccc2c1-c1c3[C@H](N(C)CCc3ccc1)C2		Inactive	D2-like dopamine receptor Agonist		1	Apomorphine	170465297.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1c(O)ccc2c1-c1c3[C@H](N(C)CCc3ccc1)C2	Oc1c(O)ccc2c1-c1c3[C@H](N(C)CCc3ccc1)C2
NCGC00095460-08	Oc1c(O)ccc2c1OCC1(O)C2c2c(cc(O)c(O)c2)C1		Inactive	Iron Chelator		1	Hematoxylin	384568157.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1c(O)ccc2c1OCC1(O)C2c2c(cc(O)c(O)c2)C1	Oc1c(O)ccc2c1OCC1(O)C2c2c(cc(O)c(O)c2)C1
NCGC00021666-04	Oc1c2O[C@H]3C(=C)CC[C@@]4(O)[C@@H]5N(CC6CC6)CC[C@]34c2c(cc1)C5		Inactive	Kappa opioid receptor Partial Agonist		1	Nalmefene	170465281.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1c2O[C@H]3C(=C)CC[C@@]4(O)[C@@H]5N(CC6CC6)CC[C@]34c2c(cc1)C5	Oc1c2O[C@H]3C(=C)CC[C@@]4(O)[C@@H]5N(CC6CC6)CC[C@]34c2c(cc1)C5
NCGC00181099-01	Oc1c2[C@@H]3OCC45[C@@H]3[C@@](C)(Oc2cc(C)c1)CC[C@H]4C(C)(C)CCC5	4.9000001	Active		0.0	1	Siccanin	144206268.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	58.1163425019	Oc1c2[C@@H]3OCC45[C@@H]3[C@@](C)(Oc2cc(C)c1)CC[C@H]4C(C)(C)CCC5	Oc1c2[C@@H]3OCC45[C@@H]3[C@@](C)(Oc2cc(C)c1)CC[C@H]4C(C)(C)CCC5
NCGC00181774-02	Oc1c2c(O)cc(C)cc2cc2c1c(O)ccc2		Inactive			1	Chrysarobin	170465659.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	29.920432224&11.154415396	Oc1c2c(O)cc(C)cc2cc2c1c(O)ccc2	Oc1c2c(O)cc(C)cc2cc2c1c(O)ccc2
NCGC00386090-01	Oc1c2c(OC3(C4(C)C(C(C)(C)C(O)CC4)CCC3C)C2)c2C(=N)NCc2c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386090-01	363680102.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1c2c(OC3(C4(C)C(C(C)(C)C(O)CC4)CCC3C)C2)c2C(=N)NCc2c1	Oc1c2c(OC3(C4(C)C(C(C)(C)C(O)CC4)CCC3C)C2)c2C(=N)NCc2c1
NCGC00386084-01	Oc1c2c(OC3(C4(C)C(C(C)(C)C(O)CC4)CCC3C)C2)c2c(C(=N)NC2)c1		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00386084-01	363680098.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1c2c(OC3(C4(C)C(C(C)(C)C(O)CC4)CCC3C)C2)c2c(C(=N)NC2)c1	Oc1c2c(OC3(C4(C)C(C(C)(C)C(O)CC4)CCC3C)C2)c2c(C(=N)NC2)c1
NCGC00485881-01	Oc1c2c(c(C(CCNC)c3sccc3)cc1)cccc2	4.9000001	Active		0.0	1	Duloxetine metabolite Para-Naphthol Duloxetine	363681390.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	47.0769640942	Oc1c2c(c(C(CCNC)c3sccc3)cc1)cccc2	Oc1c2c(c(C(CCNC)c3sccc3)cc1)cccc2
NCGC00386465-01	Oc1c2c(ccc1)CC(N(CCC)CCc1cscc1)CC2		Inactive	Dopamine D2 receptor Agonist		1	N 0734 hydrochloride	363680294.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1c2c(ccc1)CC(N(CCC)CCc1cscc1)CC2	Oc1c2c(ccc1)CC(N(CCC)CCc1cscc1)CC2
NCGC00168748-02	Oc1c2c(ccc1)C[C@@H](N(CCC)CCc1sccc1)CC2		Inactive	Dopamine D4 receptor Agonist		1	Rotigotine	170465204.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1c2c(ccc1)C[C@@H](N(CCC)CCc1sccc1)CC2	Oc1c2c(ccc1)C[C@@H](N(CCC)CCc1sccc1)CC2
NCGC00090708-11&NCGC00159447-07	Oc1c2ncccc2ccc1		Inactive	Trichophyton interdigitale Inhibitor&Trichophyton Interdigitale Inhibitor		2	OXYQUINOLINE HEMISULFATE&8-Quinolinol Salicylic acid (1:1)	405558695.0&170465482.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Oc1c2ncccc2ccc1	Oc1c2ncccc2ccc1&O=C(O)c1c(O)cccc1.Oc1c2ncccc2ccc1
NCGC00346508-12	Oc1cc(-c2c(-c3cc(O)ccc3)nc3nc(N)nc(N)c3n2)ccc1		Inactive	PI3K Inhibitor		1	TG-100115	384568810.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1cc(-c2c(-c3cc(O)ccc3)nc3nc(N)nc(N)c3n2)ccc1	Oc1cc(-c2c(-c3cc(O)ccc3)nc3nc(N)nc(N)c3n2)ccc1
NCGC00356072-01	Oc1cc(-c2ccc([C@H]3[C@@H](N)C3)cc2)ccc1		Inactive	Lysine-specific histone demethylase 1 Inhibitor		1		363677795.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1cc(-c2ccc([C@H]3[C@@H](N)C3)cc2)ccc1	Oc1cc(-c2ccc([C@H]3[C@@H](N)C3)cc2)ccc1
NCGC00187906-15	Oc1cc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)ccc1		Inactive	PI3Kalpha, beta, gamma Inhibitor		1	PI-103	377020302.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Oc1cc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)ccc1	Oc1cc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)ccc1
NCGC00344069-03	Oc1cc(-c2nc(N3CCOCC3)c3sccc3n2)ccc1		Inactive			1	PI3-Kinase ? Inhibitor 2	377020407.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	29.914285712	Oc1cc(-c2nc(N3CCOCC3)c3sccc3n2)ccc1	Oc1cc(-c2nc(N3CCOCC3)c3sccc3n2)ccc1
NCGC00386209-03	Oc1cc(-c2nc3c(N)nc(N)nc3nc2)ccc1		Inactive			1	TG100713	377020252.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1cc(-c2nc3c(N)nc(N)nc3nc2)ccc1	Oc1cc(-c2nc3c(N)nc(N)nc3nc2)ccc1
NCGC00532496-01	Oc1cc(C)c(C(C)(C)C)cc1	5.5999999	Active		0.0	1	P-T-BUTYL-M-CRESOL	405558633.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	40.7418265899	Oc1cc(C)c(C(C)(C)C)cc1	Oc1cc(C)c(C(C)(C)C)cc1
NCGC00253541-03	Oc1cc(C)c2O[C@@](CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)(C)CCc2c1		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	.delta.-Tocotrienol	363677185.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1cc(C)c2O[C@@](CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)(C)CCc2c1	Oc1cc(C)c2O[C@@](CC/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)(C)CCc2c1
NCGC00160622-04	Oc1cc(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1		Inactive			1	D-delta-Tocopherol	144206758.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Oc1cc(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1	Oc1cc(C)c2O[C@@](CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)(C)CCc2c1
NCGC00510073-01	Oc1cc(C)c2[C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)CCC4)CC3)Cc2c1		Inactive	SHIP-1 Activator		1	AQX-MN-100	384569407.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1cc(C)c2[C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)CCC4)CC3)Cc2c1	Oc1cc(C)c2[C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)CCC4)CC3)Cc2c1
NCGC00159366-02	Oc1cc(C)ccc1		Inactive			1	m-Cresol	29215286.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1cc(C)ccc1	Oc1cc(C)ccc1
NCGC00179295-03	Oc1cc(C2(CC)CN(C)CCCC2)ccc1		Inactive	Mu opioid receptor Partial Agonist		1	Meptazinol hydrochloride	170466363.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Oc1cc(C2(CC)CN(C)CCCC2)ccc1.Cl	Oc1cc(C2(CC)CN(C)CCCC2)ccc1.Cl
NCGC00183015-01	Oc1cc(C2=C3N=C(C(c4cc(O)ccc4)=C4N=C(C(c5cc(O)ccc5)=C5N=C(C(c6cc(O)ccc6)=C6N=C2C=C6)C=C5)CC4)C=C3)ccc1		Inactive	cell proliferation Inhibitor		1	Temoporfin	144206848.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Oc1cc(C2=C3N=C(C(c4cc(O)ccc4)=C4N=C(C(c5cc(O)ccc5)=C5N=C(C(c6cc(O)ccc6)=C6N=C2C=C6)C=C5)CC4)C=C3)ccc1	Oc1cc(C2=C3N=C(C(c4cc(O)ccc4)=C4N=C(C(c5cc(O)ccc5)=C5N=C(C(c6cc(O)ccc6)=C6N=C2C=C6)C=C5)CC4)C=C3)ccc1
NCGC00016311-19&NCGC00016311-32	Oc1cc(N(CC2=NCCN2)c2ccc(C)cc2)ccc1		Inactive	alpha-Adrenoceptor Antagonist		2	Phentolamine mesilate	170464866.0&384567931.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Oc1cc(N(CC2=NCCN2)c2ccc(C)cc2)ccc1	Oc1cc(N(CC2=NCCN2)c2ccc(C)cc2)ccc1
NCGC00486911-01	Oc1cc(Nc2c3c([nH]c4c3cccc4)ncc2)ccc1		Inactive			1	Tilfrinib	377020520.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1cc(Nc2c3c([nH]c4c3cccc4)ncc2)ccc1	Oc1cc(Nc2c3c([nH]c4c3cccc4)ncc2)ccc1
NCGC00486912-01	Oc1cc(Nc2c3sc(-c4cc(CN5CCOCC5)ccc4)cc3ncc2)ccc1		Inactive			1	LCB 03-0110 dihydrochloride	377020409.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1cc(Nc2c3sc(-c4cc(CN5CCOCC5)ccc4)cc3ncc2)ccc1	Oc1cc(Nc2c3sc(-c4cc(CN5CCOCC5)ccc4)cc3ncc2)ccc1
NCGC00134287-01	Oc1cc(Nc2ncnc3sc4c(c23)CCCC4)ccc1		Inactive			1	NCGC00134287-01	24409670.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1cc(Nc2ncnc3sc4c(c23)CCCC4)ccc1	Oc1cc(Nc2ncnc3sc4c(c23)CCCC4)ccc1
NCGC00017352-22&NCGC00017352-31	Oc1cc(O)cc(/C=C/c2ccc(O)cc2)c1		Inactive	Cyclooxygenase-2 Inhibitor		2	Resveratrol	384567987.0&434146966.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Oc1cc(O)cc(/C=C/c2ccc(O)cc2)c1	Oc1cc(O)cc(/C=C/c2ccc(O)cc2)c1
NCGC00168928-02	Oc1cc(O)cc(CCCCCCC/C=C\C/C=C\CC=C)c1		Inactive	<MOA Unknown> | Class: aromatic polyketide | Genus: Anacardium | Family: Anacardiaceae | Species: occidentale		1	NCGC00168928-02	363676725.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1cc(O)cc(CCCCCCC/C=C\C/C=C\CC=C)c1	Oc1cc(O)cc(CCCCCCC/C=C\C/C=C\CC=C)c1
NCGC00166270-02	Oc1cc(O)cc(O)c1		Inactive	Voltage-gated calcium channel Inhibitor		1	1,3,5-Trihydroxybenzene dihydrate	225144277.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1cc(O)cc(O)c1	Oc1cc(O)cc(O)c1
NCGC00091501-06	Oc1cc(O)ccc1		Inactive	leukotriene B4 biosynthetic process Inhibitor		1	Resorcinol	170465462.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1cc(O)ccc1	Oc1cc(O)ccc1
NCGC00015409-11	Oc1cc([N+](CC)(C)C)ccc1		Inactive	Butyrylcholinesterase Inhibitor		1	Edrophonium chloride	170464801.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1cc([N+](CC)(C)C)ccc1.[Cl-]	Oc1cc([N+](CC)(C)C)ccc1.[Cl-]
NCGC00386503-01	Oc1cc2C(N3CCN(C)CC3)=Nc3c(Nc2cc1)cccc3		Inactive	Muscarinic acetylcholine receptor M1 Antagonist		1	GMC 1-165	363680309.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1cc2C(N3CCN(C)CC3)=Nc3c(Nc2cc1)cccc3	Oc1cc2C(N3CCN(C)CC3)=Nc3c(Nc2cc1)cccc3
NCGC00346822-02	Oc1cc2OCC(c3ccc(O)cc3)=Cc2cc1		Inactive	Sphingosine Kinase 1 (SphK1) Inhibitor		1	Idronoxil	377020351.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.5460250999	Oc1cc2OCC(c3ccc(O)cc3)=Cc2cc1	Oc1cc2OCC(c3ccc(O)cc3)=Cc2cc1
NCGC00386208-01	Oc1cc2OC[C@H](c3ccc(O)cc3)Cc2cc1		Inactive	PC-3 Inhibitor		1	Equol	363680152.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1cc2OC[C@H](c3ccc(O)cc3)Cc2cc1	Oc1cc2OC[C@H](c3ccc(O)cc3)Cc2cc1
NCGC00025072-08	Oc1cc2[C@H]3OCCN(CCC)[C@@H]3COc2cc1		Inactive	Dopamine D2/D3 Agonist		1	PD-128907	384568046.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1cc2[C@H]3OCCN(CCC)[C@@H]3COc2cc1	Oc1cc2[C@H]3OCCN(CCC)[C@@H]3COc2cc1
NCGC00346557-02	Oc1cc2[C@H]3[C@@H]([C@H](c4ccc(O)cc4)Oc2cc1)CCC3		Inactive	Estrogen Receptor (ER) beta Agonist		1	Erteberel	363677454.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1cc2[C@H]3[C@@H]([C@H](c4ccc(O)cc4)Oc2cc1)CCC3	Oc1cc2[C@H]3[C@@H]([C@H](c4ccc(O)cc4)Oc2cc1)CCC3
NCGC00024985-08	Oc1cc2[C@]3(C)[C@@H](C)C(N(CC=C)CC3)Cc2cc1		Inactive			1	(+)-N-Allylnormetazocine hydrochloride		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1cc2[C@]3(C)[C@@H](C)C(N(CC=C)CC3)Cc2cc1	Oc1cc2[C@]3(C)[C@@H](C)C(N(CC=C)CC3)Cc2cc1
NCGC00274273-01	Oc1cc2[C@]3(C)[C@@H](N)[C@H](Cc2cc1)CCCCC3		Inactive	Mu opioid receptor Partial Agonist		1	NCGC00274273-01	225144371.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1cc2[C@]3(C)[C@@H](N)[C@H](Cc2cc1)CCCCC3	Oc1cc2[C@]3(C)[C@@H](N)[C@H](Cc2cc1)CCCCC3
NCGC00247716-01	Oc1cc2[C@]3(C)[C@H](C)[C@@H](N(C/C=C(\C)/C)CC3)Cc2cc1		Inactive			1	(+)-Pentazocine succinate	144206429.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	O=C(O)CCC(=O)O.Oc1cc2[C@]3(C)[C@H](C)[C@@H](N(C/C=C(\C)/C)CC3)Cc2cc1	O=C(O)CCC(=O)O.Oc1cc2[C@]3(C)[C@H](C)[C@@H](N(C/C=C(\C)/C)CC3)Cc2cc1
NCGC00091533-10&NCGC00091533-17	Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1		Inactive	Estrogen Receptor (ER) Agonist		2	Ethinylestradiol	170464983.0&384568096.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&10.861177628	Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1	Oc1cc2c([C@@H]3[C@H]([C@H]4[C@@](C)([C@](O)(C#C)CC4)CC3)CC2)cc1
NCGC00188346-18	Oc1cc2c([nH]c(-c3nn(C(C)C)c4ncnc(N)c34)c2)cc1		Inactive			1	PP242		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		Oc1cc2c([nH]c(-c3nn(C(C)C)c4ncnc(N)c34)c2)cc1	Oc1cc2c([nH]c(-c3nn(C(C)C)c4ncnc(N)c34)c2)cc1
NCGC00485085-01	Oc1cc2c(cc1)C[C@H]1N(CC3CCC3)CCC32[C@H]1CCCC3		Inactive	Delta opioid receptor Binding Agent		1	Butorphan S(+)-mandelate	363681216.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1cc2c(cc1)C[C@H]1N(CC3CCC3)CCC32[C@H]1CCCC3	Oc1cc2c(cc1)C[C@H]1N(CC3CCC3)CCC32[C@H]1CCCC3
NCGC00162247-06	Oc1cc2c(cc1)C[C@H]1N(CC=C)CC[C@@]32[C@H]1CCCC3		Inactive	Mu-type opioid receptor Antagonist		1	Levallorphan	170465778.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1cc2c(cc1)C[C@H]1N(CC=C)CC[C@@]32[C@H]1CCCC3	Oc1cc2c(cc1)C[C@H]1N(CC=C)CC[C@@]32[C@H]1CCCC3
NCGC00408881-01	Oc1cc2nccc(-c3c(-c4ncccc4)nn4c3CCC4)c2cc1		Inactive	TGF-beta receptor type-1 Inhibitor		1	TGF-B-recpotor inhibitor	363681071.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1cc2nccc(-c3c(-c4ncccc4)nn4c3CCC4)c2cc1	Oc1cc2nccc(-c3c(-c4ncccc4)nn4c3CCC4)c2cc1
NCGC00387215-01	Oc1ccc(-c2[nH]c3ncnc(N[C@H](C)c4ccccc4)c3c2)cc1		Inactive	EGFR Inhibitor		1	PKI-166	384569154.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1ccc(-c2[nH]c3ncnc(N[C@H](C)c4ccccc4)c3c2)cc1	Oc1ccc(-c2[nH]c3ncnc(N[C@H](C)c4ccccc4)c3c2)cc1
NCGC00379004-01	Oc1ccc(-c2n3N=C(NCc4occc4)C=Cc3nc2)cc1		Inactive	Interleukin-1 receptor-associated kinase 4 Inhibitor		1	IRAK inhibitor 2	363678312.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1ccc(-c2n3N=C(NCc4occc4)C=Cc3nc2)cc1	Oc1ccc(-c2n3N=C(NCc4occc4)C=Cc3nc2)cc1
NCGC00018153-10	Oc1ccc(/C(/C(=C/C)/c2ccc(O)cc2)=C\C)cc1		Inactive	Estrogen Receptor (ER) Agonist		1	Dienestrol	170465362.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1ccc(/C(/C(=C/C)/c2ccc(O)cc2)=C\C)cc1	Oc1ccc(/C(/C(=C/C)/c2ccc(O)cc2)=C\C)cc1
NCGC00090749-19	Oc1ccc(/C(=C(\CC)/c2ccc(O)cc2)/CC)cc1	4.9000001	Active	Estrogen Receptor (ER) Agonist	0.0	1	Diethylstilbestrol	384568080.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	46.8327064936	Oc1ccc(/C(=C(\CC)/c2ccc(O)cc2)/CC)cc1	Oc1ccc(/C(=C(\CC)/c2ccc(O)cc2)/CC)cc1
NCGC00390469-01	Oc1ccc(/C=C/C(C=C)(CCC=C(C)C)C)cc1		Inactive			1	Bakuchiol	377020466.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1ccc(/C=C/C(C=C)(CCC=C(C)C)C)cc1	Oc1ccc(/C=C/C(C=C)(CCC=C(C)C)C)cc1
NCGC00388443-01	Oc1ccc(/N=N\c2c(N)[nH]nc2N)cc1		Inactive			1	CAY10574	377020282.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1ccc(/N=N\c2c(N)[nH]nc2N)cc1	Oc1ccc(/N=N\c2c(N)[nH]nc2N)cc1
NCGC00090749-12	Oc1ccc(C(=C(CC)c2ccc(O)cc2)CC)cc1	5.3499999	Active	Estrogen Receptor (ER) Agonist	0.0	1	Diethylstilbestrol	170464803.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	38.3206455469	Oc1ccc(C(=C(CC)c2ccc(O)cc2)CC)cc1	Oc1ccc(C(=C(CC)c2ccc(O)cc2)CC)cc1
NCGC00094818-13	Oc1ccc(C(C(CC)c2ccc(O)cc2)CC)cc1		Inactive	17-betahydroxysteroid dehydrogenase Inhibitor		1	Hexestrol	384568137.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1ccc(C(C(CC)c2ccc(O)cc2)CC)cc1	Oc1ccc(C(C(CC)c2ccc(O)cc2)CC)cc1
NCGC00159377-04	Oc1ccc(C(C)(C)C)cc1		Inactive	UDP-glucuronosyltransferase 1-6 Substrate		1	4-tert-Butylphenol	170465689.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Oc1ccc(C(C)(C)C)cc1	Oc1ccc(C(C)(C)C)cc1
NCGC00164127-07	Oc1ccc(C(CC(C)(C)C)(C)C)cc1	4.9499998	Active		0.0	1	4-(1,1,3,3-Tetramethylbutyl)phenol	170465157.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	43.419940352	Oc1ccc(C(CC(C)(C)C)(C)C)cc1	Oc1ccc(C(CC(C)(C)C)(C)C)cc1
NCGC00345883-07	Oc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1		Inactive	Serotonin transporter Inhibitor		1	DESVENLAFAXINE SUCCINATE	405558880.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1	Oc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
NCGC00091519-09	Oc1ccc(C)cc1		Inactive			1	p-Cresol	170465495.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1ccc(C)cc1	Oc1ccc(C)cc1
NCGC00178433-02	Oc1ccc(CC(N)C)cc1		Inactive	Adrenergic receptor Agonist		1	HYDROXYAMPHETAMINE HYDROBROMIDE	405558631.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1ccc(CC(N)C)cc1	Oc1ccc(CC(N)C)cc1
NCGC00386744-01	Oc1ccc(CCCn2ncc3-c4n(C(N)=Nc23)nc(-c2occc2)n4)cc1		Inactive	Adenosine A3 receptor Antagonist		1	Desmethyl SCH 442416	363680429.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1ccc(CCCn2ncc3-c4n(C(N)=Nc23)nc(-c2occc2)n4)cc1	Oc1ccc(CCCn2ncc3-c4n(C(N)=Nc23)nc(-c2occc2)n4)cc1
NCGC00263553-13	Oc1ccc(CCNc2nc(-c3c4c(sc3)cccc4)nc3n(C(C)C)cnc23)cc1		Inactive	Aryl Hydrocarbon Receptor (AhR) Antagonist		1	StemRegenin 1	363677284.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	15.251459364	Oc1ccc(CCNc2nc(-c3c4c(sc3)cccc4)nc3n(C(C)C)cnc23)cc1	Oc1ccc(CCNc2nc(-c3c4c(sc3)cccc4)nc3n(C(C)C)cnc23)cc1
NCGC00015523-13	Oc1ccc(O)cc1		Inactive			1	Hydroquinone	170464661.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	Oc1ccc(O)cc1	Oc1ccc(O)cc1
NCGC00385801-01	Oc1ccc([C@@H](/C=C\c2ccc(O)cc2)C=C)cc1		Inactive	<MOA Unknown> | Class: Flavon | Genus: Lactuca | Family: Compositae | Species: capensis		1	NCGC00385801-01	363679946.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	Oc1ccc([C@@H](/C=C\c2ccc(O)cc2)C=C)cc1	Oc1ccc([C@@H](/C=C\c2ccc(O)cc2)C=C)cc1
NCGC00094818-09	Oc1ccc([C@H]([C@@H](CC)c2ccc(O)cc2)CC)cc1		Inactive	17-betahydroxysteroid dehydrogenase Inhibitor		1	Hexestrol	170466031.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Oc1ccc([C@H]([C@@H](CC)c2ccc(O)cc2)CC)cc1	Oc1ccc([C@H]([C@@H](CC)c2ccc(O)cc2)CC)cc1
NCGC00380704-01	Oc1ccc([C@H]2[C@H](C)c3c(O2)ccc(/C=C/C)c3)cc1		Inactive	<MOA Unknown> | Class: Shikimi | Genus: Krameria | Family: Krameriaceae | Species: triandra		1	NCGC00380704-01	363678721.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	13.780911064	Oc1ccc([C@H]2[C@H](C)c3c(O2)ccc(/C=C/C)c3)cc1	Oc1ccc([C@H]2[C@H](C)c3c(O2)ccc(/C=C/C)c3)cc1
NCGC00091454-07	Oc1ccccc1		Inactive			1	Phenol	170465486.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1ccccc1	Oc1ccccc1
NCGC00015094-18&NCGC00015094-22	Oc1ncnc2[nH]ncc12		Inactive			2	Allopurinol	405558932.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	-11.008756172&0.0	Oc1ncnc2[nH]ncc12	Oc1ncnc2[nH]ncc12
NCGC00092327-05	Oc1ncnc2c1cccc2		Inactive			1	4-HQN	434146935.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Oc1ncnc2c1cccc2	Oc1ncnc2c1cccc2
NCGC00379135-01	On1c(c(C2CCNCC2)cn1)-c1cc(-c2ccccc2)ccc1		Inactive	GABA-A receptor; anion channel Antagonist		1	PHP 501 trifluoroacetate	363678377.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	On1c(c(C2CCNCC2)cn1)-c1cc(-c2ccccc2)ccc1	On1c(c(C2CCNCC2)cn1)-c1cc(-c2ccccc2)ccc1
NCGC00159352-06&NCGC00159352-14	P(=O)(O)(O)C(P(=O)(O)O)(O)C		Inactive	ATP Inhibitor		2	Etidronate&ETIDRONATE DISODIUM	434147005.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	P(=O)(O)(O)C(P(=O)(O)O)(O)C	P(=O)(O)(O)C(P(=O)(O)O)(O)C
NCGC00165862-02	P(=O)(O)(O)C(P(=O)(O)O)(O)CCN		Inactive	Farnesyl diphosphate synthase Inhibitor		1	Pamidronic acid	170464689.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	P(=O)(O)(O)C(P(=O)(O)O)(O)CCN	P(=O)(O)(O)C(P(=O)(O)O)(O)CCN
NCGC00183829-01	P(=O)(O)(O)C(P(=O)(O)O)(O)Cc1n2c(nc1)C=CC=C2		Inactive	Geranylgeranyl pyrophosphate synthetase Inhibitor		1	Minodronic acid	144206806.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	P(=O)(O)(O)C(P(=O)(O)O)(O)Cc1n2c(nc1)C=CC=C2	P(=O)(O)(O)C(P(=O)(O)O)(O)Cc1n2c(nc1)C=CC=C2
NCGC00159521-09&NCGC00159521-16	P(=O)(O)(O)C(P(=O)(O)O)(O)Cn1cncc1		Inactive	Farnesyl Pyrophosphate Synthase Inhibitor		2	Zoledronic acid monohydrate	405558779.0&384568184.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	P(=O)(O)(O)C(P(=O)(O)O)(O)Cn1cncc1	P(=O)(O)(O)C(P(=O)(O)O)(O)Cn1cncc1
NCGC00024728-02	P(=O)(O)(O)C(P(=O)(O)O)(Oc1ccc(O)cc1)C		Inactive	inositol monophophatase Inhibitor		1	L-690330	384568033.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(O)(O)C(P(=O)(O)O)(Oc1ccc(O)cc1)C	P(=O)(O)(O)C(P(=O)(O)O)(Oc1ccc(O)cc1)C
NCGC00165719-15&NCGC00165719-16	P(=O)(O)(O)C(P(=O)(O)[O-])(O)CCCN		Inactive	Geranylgeranyl pyrophosphate synthetase Inhibitor		2	ALENDRONATE SODIUM&Alendronate (Fosamax)	405559128.0&384568274.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	P(=O)(O)(O)C(P(=O)(O)[O-])(O)CCCN	P(=O)(O)(O)C(P(=O)(O)[O-])(O)CCCN
NCGC00186037-02&NCGC00186037-10	P(=O)(O)(O)C(P(=O)(O)[O-])(O)CCN(CCCCC)C		Inactive	Treatment of Osteoporosis		2	Ibandronate sodium hydrate	225144338.0&384568439.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	P(=O)(O)(O)C(P(=O)(O)[O-])(O)CCN(CCCCC)C	P(=O)(O)(O)C(P(=O)(O)[O-])(O)CCN(CCCCC)C
NCGC00274056-12	P(=O)(O)(O)C(P(=O)(O)[O-])(O)Cc1cnccc1		Inactive			1	Risedronate sodium	434147079.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	P(=O)(O)(O)C(P(=O)(O)[O-])(O)Cc1cnccc1	P(=O)(O)(O)C(P(=O)(O)[O-])(O)Cc1cnccc1
NCGC00370857-01	P(=O)(O)(O)CCCOc1cc2c(CC(=O)N)c(CC)n(Cc3ccccc3)c2cc1		Inactive	Phospholipase A2 group V Inhibitor		1	LY 311727	363677889.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	P(=O)(O)(O)CCCOc1cc2c(CC(=O)N)c(CC)n(Cc3ccccc3)c2cc1	P(=O)(O)(O)CCCOc1cc2c(CC(=O)N)c(CC)n(Cc3ccccc3)c2cc1
NCGC00487176-01	P(=O)(O)(O)CCN1C=2C(=O)C(=O)C=2NCCC1		Inactive			1	EAA-090	405558601.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(O)(O)CCN1C=2C(=O)C(=O)C=2NCCC1	P(=O)(O)(O)CCN1C=2C(=O)C(=O)C=2NCCC1
NCGC00485653-01	P(=O)(O)(O)CC[C@@H](N)C(=O)Nc1cc(CCCCCC)ccc1		Inactive	Sphingosine 1-phosphate receptor Edg-1  Antagonist		1	W146 hydrate	363681374.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	P(=O)(O)(O)CC[C@@H](N)C(=O)Nc1cc(CCCCCC)ccc1	P(=O)(O)(O)CC[C@@H](N)C(=O)Nc1cc(CCCCCC)ccc1
NCGC00160539-02	P(=O)(O)(O)COCCn1c2ncnc(N)c2nc1		Inactive	DNA polymerase/reverse transcriptase Inhibitor		1	Adefovir	225144241.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(O)(O)COCCn1c2ncnc(N)c2nc1	P(=O)(O)(O)COCCn1c2ncnc(N)c2nc1
NCGC00167535-16	P(=O)(O)(O)CO[C@@H](Cn1c2ncnc(N)c2nc1)C		Inactive	Reverse Transcriptase Inhibitor		1	Tenofovir	434147040.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(O)(O)CO[C@@H](Cn1c2ncnc(N)c2nc1)C	P(=O)(O)(O)CO[C@@H](Cn1c2ncnc(N)c2nc1)C
NCGC00184994-02&NCGC00184994-11	P(=O)(O)(O)CO[C@H](CO)CN1C(=O)N=C(N)C=C1		Inactive	DNA Polymerase Inhibitor		2	Cidofovir	225144336.0&384568422.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	P(=O)(O)(O)CO[C@H](CO)CN1C(=O)N=C(N)C=C1	P(=O)(O)(O)CO[C@H](CO)CN1C(=O)N=C(N)C=C1
NCGC00037856-01	P(=O)(O)(O)CP(=O)(O)O		Inactive			1	Medronic acid	144204525.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(O)(O)CP(=O)(O)O	P(=O)(O)(O)CP(=O)(O)O
NCGC00390240-01	P(=O)(O)(O)N1C(=O)N=C(CN2[C@H]([C@@H](O[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)OCC2)c2ccc(F)cc2)N1		Inactive	Neurokinin 1 receptor Antagonist		1	MK-0517 (Fosaprepitant)	363680867.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	P(=O)(O)(O)N1C(=O)N=C(CN2[C@H]([C@@H](O[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)OCC2)c2ccc(F)cc2)N1	P(=O)(O)(O)N1C(=O)N=C(CN2[C@H]([C@@H](O[C@H](C)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)OCC2)c2ccc(F)cc2)N1
NCGC00165862-04	P(=O)(O)([O-])C(P(=O)(O)[O-])(O)CCN		Inactive	Farnesyl diphosphate synthase Inhibitor		1	Pamidronate Disodium	434147033.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(O)([O-])C(P(=O)(O)[O-])(O)CCN	P(=O)(O)([O-])C(P(=O)(O)[O-])(O)CCN
NCGC00274056-01	P(=O)(O)([O-])C(P(=O)(O)[O-])(O)Cc1cnccc1		Inactive	Farnesyl diphosphate synthase Inhibitor		1	Risedronate sodium	170464992.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	P(=O)(O)([O-])C(P(=O)(O)[O-])(O)Cc1cnccc1.[Na+].[Na+]	P(=O)(O)([O-])C(P(=O)(O)[O-])(O)Cc1cnccc1.[Na+].[Na+]
NCGC00166037-04	P(=O)(OC(CO)CO)([O-])[O-]		Inactive			1	beta-Glycerol phosphate disodium salt pentahydrate	405558431.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OC(CO)CO)([O-])[O-]	P(=O)(OC(CO)CO)([O-])[O-]
NCGC00182029-01	P(=O)(OC(Cn1ncnc1)(Cn1ncnc1)c1c(F)cc(F)cc1)(O)O		Inactive	Cytochrome P450 51 Inhibitor		1	Fosfluconazole	144206487.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OC(Cn1ncnc1)(Cn1ncnc1)c1c(F)cc(F)cc1)(O)O	P(=O)(OC(Cn1ncnc1)(Cn1ncnc1)c1c(F)cc(F)cc1)(O)O
NCGC00483012-01	P(=O)(OC1C(OP(=O)(O)O)C(OP(=O)(O)O)C(OP(=O)(O)O)C(OP(=O)(O)O)C1OP(=O)(O)O)(O)O		Inactive	lipid oxidation Inhibitor		1	Phytic acid	405558945.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OC1C(OP(=O)(O)O)C(OP(=O)(O)O)C(OP(=O)(O)O)C(OP(=O)(O)O)C1OP(=O)(O)O)(O)O	P(=O)(OC1C(OP(=O)(O)O)C(OP(=O)(O)O)C(OP(=O)(O)O)C(OP(=O)(O)O)C1OP(=O)(O)O)(O)O
NCGC00021226-04	P(=O)(OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21)([O-])[O-]		Inactive	Glucocorticoid receptor Agonist		1	Dexamethasone 21-phosphate disodium salt	225144188.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	P(=O)(OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21)([O-])[O-]	P(=O)(OCC(=O)[C@@]1(O)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C(=CC(=O)C=C3)CC[C@@H]21)([O-])[O-]
NCGC00388369-01	P(=O)(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)([O-])[O-]		Inactive	Glucocorticoid receptor Agonist		1	Prednisolone Phosphate (sodium salt)	405558865.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)([O-])[O-]	P(=O)(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)C=C2)CC3)CC1)([O-])[O-]
NCGC00167464-02	P(=O)(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)([O-])[O-]		Inactive			1	Hydrocortisone Sodium Phosphate	225144288.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)([O-])[O-]	P(=O)(OCC(=O)[C@]1(O)[C@]2(C)[C@H]([C@H]3[C@H]([C@@H](O)C2)[C@]2(C)C(=CC(=O)CC2)CC3)CC1)([O-])[O-]
NCGC00181029-01	P(=O)(OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC)(OCC[N+](C)(C)C)[O-]		Inactive	Apolipoprotein A-I Binding Agent		1	1,2-Ditetradecanoyl-rac-glycerol-3-phosphocholine	144206232.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC)(OCC[N+](C)(C)C)[O-]	P(=O)(OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC)(OCC[N+](C)(C)C)[O-]
NCGC00485276-01	P(=O)(OCC)(OCC)Oc1cc2OC(=O)C=C(C)c2cc1		Inactive			1	Diethylumbelliferyl phosphate	363681274.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	P(=O)(OCC)(OCC)Oc1cc2OC(=O)C=C(C)c2cc1	P(=O)(OCC)(OCC)Oc1cc2OC(=O)C=C(C)c2cc1
NCGC00183017-01	P(=O)(OCC)(Oc1ccc([N+](=O)[O-])cc1)CC		Inactive			1	Ethyl 4-nitrophenyl ethylphosphonate	144206877.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	P(=O)(OCC)(Oc1ccc([N+](=O)[O-])cc1)CC	P(=O)(OCC)(Oc1ccc([N+](=O)[O-])cc1)CC
NCGC00346503-01	P(=O)(OCCCCCCCCCCCCCCCCCC)(OC1CC[N+](C)(C)CC1)[O-]		Inactive	PI3K kinase Activator		1	Perifosine	174006514.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OCCCCCCCCCCCCCCCCCC)(OC1CC[N+](C)(C)CC1)[O-]	P(=O)(OCCCCCCCCCCCCCCCCCC)(OC1CC[N+](C)(C)CC1)[O-]
NCGC00379339-01	P(=O)(OCCCOCCCCCCCCCCCCCCCC)(O)COC(CO)CN1C(=O)N=C(N)C=C1		Inactive	DNA polymerase Inhibitor		1	Brincidofovir	377020268.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OCCCOCCCCCCCCCCCCCCCC)(O)COC(CO)CN1C(=O)N=C(N)C=C1	P(=O)(OCCCOCCCCCCCCCCCCCCCC)(O)COC(CO)CN1C(=O)N=C(N)C=C1
NCGC00686671-01	P(=O)(OCCCOCCCCCCCCCCCCCCCC)(O)CO[C@H](CO)CN1C(=O)N=C(N)C=C1		Inactive			1	Brincidofovir	434147183.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0	0.0&0.0	P(=O)(OCCCOCCCCCCCCCCCCCCCC)(O)CO[C@H](CO)CN1C(=O)N=C(N)C=C1	P(=O)(OCCCOCCCCCCCCCCCCCCCC)(O)CO[C@H](CO)CN1C(=O)N=C(N)C=C1
NCGC00378734-08	P(=O)(OCCN(CCCOc1cc2ncnc(Nc3n[nH]c(CC(=O)Nc4cc(F)ccc4)c3)c2cc1)CC)(O)O		Inactive			1	AZD1152	384569066.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OCCN(CCCOc1cc2ncnc(Nc3n[nH]c(CC(=O)Nc4cc(F)ccc4)c3)c2cc1)CC)(O)O	P(=O)(OCCN(CCCOc1cc2ncnc(Nc3n[nH]c(CC(=O)Nc4cc(F)ccc4)c3)c2cc1)CC)(O)O
NCGC00095169-05&NCGC00095169-07	P(=O)(OCC[N+](C)(C)C)(OCCCCCCCCCCCCCCCC)[O-]		Inactive			2	Miltefosine	170465622.0&434146998.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	P(=O)(OCC[N+](C)(C)C)(OCCCCCCCCCCCCCCCC)[O-]	P(=O)(OCC[N+](C)(C)C)(OCCCCCCCCCCCCCCCC)[O-]
NCGC00386373-08	P(=O)(OCN1C(=O)C(C)(C)Oc2c1nc(Nc1c(F)cnc(Nc3cc(OC)c(OC)c(OC)c3)n1)cc2)([O-])[O-]		Inactive			1	R788 (Fostamatinib)		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OCN1C(=O)C(C)(C)Oc2c1nc(Nc1c(F)cnc(Nc3cc(OC)c(OC)c(OC)c3)n1)cc2)([O-])[O-]	P(=O)(OCN1C(=O)C(C)(C)Oc2c1nc(Nc1c(F)cnc(Nc3cc(OC)c(OC)c(OC)c3)n1)cc2)([O-])[O-]
NCGC00249894-01	P(=O)(OCN1C(=O)C(c2ccccc2)(c2ccccc2)NC1=O)(O)O		Inactive	Sodium channel protein type VIII alpha subunit Inhibitor		1	Fosphenytoin	170465016.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	P(=O)(OCN1C(=O)C(c2ccccc2)(c2ccccc2)NC1=O)(O)O	P(=O)(OCN1C(=O)C(c2ccccc2)(c2ccccc2)NC1=O)(O)O
NCGC00164624-02&NCGC00164624-11	P(=O)(OCOC(=O)C(C)(C)C)(OCOC(=O)C(C)(C)C)COCCn1c2ncnc(N)c2nc1		Inactive	DNA Polymerase Inhibitor		2	Adefovir dipivoxil	170464742.0&377020406.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	P(=O)(OCOC(=O)C(C)(C)C)(OCOC(=O)C(C)(C)C)COCCn1c2ncnc(N)c2nc1	P(=O)(OCOC(=O)C(C)(C)C)(OCOC(=O)C(C)(C)C)COCCn1c2ncnc(N)c2nc1
NCGC00183876-03	P(=O)(OCOC(=O)OC(C)C)(OCOC(=O)OC(C)C)CO[C@@H](Cn1c2ncnc(N)c2nc1)C		Inactive	Reverse Transcriptase Inhibitor		1	Tenofovir disoproxil fumarate	170465338.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OCOC(=O)OC(C)C)(OCOC(=O)OC(C)C)CO[C@@H](Cn1c2ncnc(N)c2nc1)C.O=C(O)C=CC(=O)O	P(=O)(OCOC(=O)OC(C)C)(OCOC(=O)OC(C)C)CO[C@@H](Cn1c2ncnc(N)c2nc1)C.O=C(O)C=CC(=O)O
NCGC00482851-02	P(=O)(OC[C@@H]1OC(=O)N(c2cc(F)c(-c3cnc(-c4nn(C)nn4)cc3)cc2)C1)(O)O		Inactive	Bacterial 70S ribosome Antagonist		1	Tedizolid (phosphate)	363681131.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	P(=O)(OC[C@@H]1OC(=O)N(c2cc(F)c(-c3cnc(-c4nn(C)nn4)cc3)cc2)C1)(O)O	P(=O)(OC[C@@H]1OC(=O)N(c2cc(F)c(-c3cnc(-c4nn(C)nn4)cc3)cc2)C1)(O)O
NCGC00346450-01	P(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc4N(C)N=C(N)c(c34)c2)O1)(O)O		Inactive	AKT Inhibitor		1	Triciribine phosphate	174006450.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc4N(C)N=C(N)c(c34)c2)O1)(O)O	P(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc4N(C)N=C(N)c(c34)c2)O1)(O)O
NCGC00182047-04&NCGC00182047-14	P(=O)(OC[C@@H]1[C@@H](O)[C@H](O)[C@H](n2c3nc(F)nc(N)c3nc2)O1)(O)O		Inactive	Purine Antagonist		2	Fludarabine phosphate&FludarabinePhosphate	384568405.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	P(=O)(OC[C@@H]1[C@@H](O)[C@H](O)[C@H](n2c3nc(F)nc(N)c3nc2)O1)(O)O	P(=O)(OC[C@@H]1[C@@H](O)[C@H](O)[C@H](n2c3nc(F)nc(N)c3nc2)O1)(O)O
NCGC00389431-01	P(=O)(OC[C@H](O)[C@H](O)[C@H](O)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)(O)[O-]		Inactive	NADH oxidation Oxidative Enzyme		1	RIBOFLAVIN 5-PHOSPHATE SODIUM	405558646.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OC[C@H](O)[C@H](O)[C@H](O)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)(O)[O-]	P(=O)(OC[C@H](O)[C@H](O)[C@H](O)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)(O)[O-]
NCGC00013364-03	P(=O)(OCc1c(C)c(O)c(C)nc1)(O)O		Inactive			1	Vitamin B6	405558556.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OCc1c(C)c(O)c(C)nc1)(O)O	P(=O)(OCc1c(C)c(O)c(C)nc1)(O)O
NCGC00166300-02	P(=O)(OCc1c(C=O)c(O)c(C)nc1)(O)O		Inactive	P2X purinoceptor 2 Antagonist		1	Pyridoxal phosphate hydrate	170466028.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	P(=O)(OCc1c(C=O)c(O)c(C)nc1)(O)O.O	P(=O)(OCc1c(C=O)c(O)c(C)nc1)(O)O.O
NCGC00181045-01	P(=O)(OCc1c(CN)c(O)c(C)nc1)(O)O		Inactive			1	Pyridoxamine phosphate	144206246.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OCc1c(CN)c(O)c(C)nc1)(O)O	P(=O)(OCc1c(CN)c(O)c(C)nc1)(O)O
NCGC00510187-01	P(=O)(OCn1c2c(-n3nc(C)nc3)ncc(OC)c2c(C(=O)C(=O)N2CCN(C(=O)c3ccccc3)CC2)c1)(O)O		Inactive			1	BMS-663068	434147197.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OCn1c2c(-n3nc(C)nc3)ncc(OC)c2c(C(=O)C(=O)N2CCN(C(=O)c3ccccc3)CC2)c1)(O)O	P(=O)(OCn1c2c(-n3nc(C)nc3)ncc(OC)c2c(C(=O)C(=O)N2CCN(C(=O)c3ccccc3)CC2)c1)(O)O
NCGC00013687-03	P(=O)(OP(=O)(O)O)(O)O		Inactive			1	Pyrophosphoric acid	405559136.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	P(=O)(OP(=O)(O)O)(O)O	P(=O)(OP(=O)(O)O)(O)O
NCGC00160617-03	P(=O)(OP(=O)(O)O)(OCCc1c(C)[n+](Cc2c(N)nc(C)nc2)cs1)O		Inactive			1	Thiamine pyrophosphate	405559130.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OP(=O)(O)O)(OCCc1c(C)[n+](Cc2c(N)nc(C)nc2)cs1)O	P(=O)(OP(=O)(O)O)(OCCc1c(C)[n+](Cc2c(N)nc(C)nc2)cs1)O
NCGC00178032-03	P(=O)(OP(=O)(OCC[N+](C)(C)C)[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)C(N2C(=O)N=C(N)C=C2)O1)O		Inactive			1	CITICOLINE	405558452.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OP(=O)(OCC[N+](C)(C)C)[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)C(N2C(=O)N=C(N)C=C2)O1)O	P(=O)(OP(=O)(OCC[N+](C)(C)C)[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)C(N2C(=O)N=C(N)C=C2)O1)O
NCGC00178839-08	P(=O)(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H]([n+]2cc(C(=O)N)ccc2)O1)[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)O		Inactive			1	NAD+	405558451.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H]([n+]2cc(C(=O)N)ccc2)O1)[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)O	P(=O)(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H]([n+]2cc(C(=O)N)ccc2)O1)[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)O
NCGC00344578-01	P(=O)(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)[O-])(OC[C@@H](O)[C@@H](O)[C@@H](O)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)[O-]		Inactive	oxidative phosphorylation Modulator		1	Flavin adenine dinucleotide disodium salt hydrate	225144395.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)[O-])(OC[C@@H](O)[C@@H](O)[C@@H](O)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)[O-].[Na+].[Na+].O	P(=O)(OP(=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)[O-])(OC[C@@H](O)[C@@H](O)[C@@H](O)CN1c2c(N=C3C(=O)NC(=O)N=C13)cc(C)c(C)c2)[O-].[Na+].[Na+].O
NCGC00186629-04	P(=O)(OP(=O)(OP(=O)(O)[O-])[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)O		Inactive			1	ATP (disodium salt)	405558525.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(OP(=O)(OP(=O)(O)[O-])[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)O	P(=O)(OP(=O)(OP(=O)(O)[O-])[O-])(OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)O
NCGC00167432-05	P(=O)(O[C@H](OC(=O)CC)C(C)C)(CC(=O)N1[C@H](C(=O)O)C[C@@H](C2CCCCC2)C1)CCCCc1ccccc1		Inactive	Angiotensin-converting enzyme Inhibitor		1	Fosinopril·Na	405558492.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(O[C@H](OC(=O)CC)C(C)C)(CC(=O)N1[C@H](C(=O)[O-])C[C@@H](C2CCCCC2)C1)CCCCc1ccccc1	P(=O)(O[C@H](OC(=O)CC)C(C)C)(CC(=O)N1[C@H](C(=O)[O-])C[C@@H](C2CCCCC2)C1)CCCCc1ccccc1
NCGC00346481-02	P(=O)(O[C@H]1[C@H](OC)C[C@H](C[C@@H](C)[C@H]2OC(=O)[C@H]3N(C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C2)CCCC3)CC1)(C)C		Inactive	mTOR Inhibitor		1	Ridaforolimus	363677418.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(O[C@H]1[C@H](OC)C[C@H](C[C@@H](C)[C@H]2OC(=O)[C@H]3N(C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C2)CCCC3)CC1)(C)C	P(=O)(O[C@H]1[C@H](OC)C[C@H](C[C@@H](C)[C@H]2OC(=O)[C@H]3N(C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@H](OC)/C(/C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(/C)=C/[C@@H](C)C(=O)C2)CCCC3)CC1)(C)C
NCGC00185753-04	P(=O)(Oc1c(OC)cc([C@H]2[C@H]3C(=O)OC[C@@H]3[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)c3c2cc2OCOc2c3)cc1OC)(O)O		Inactive			1	Etoposide  Phosphate	405558896.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(Oc1c(OC)cc([C@H]2[C@H]3C(=O)OC[C@@H]3[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)c3c2cc2OCOc2c3)cc1OC)(O)O	P(=O)(Oc1c(OC)cc([C@H]2[C@H]3C(=O)OC[C@@H]3[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)c3c2cc2OCOc2c3)cc1OC)(O)O
NCGC00181335-02	P(=O)(Oc1ccc(/C(=C(\CC)/c2ccc(OP(=O)(O)O)cc2)/CC)cc1)(O)O		Inactive	estrogen-related receptor gamma Inverse Agonist		1	Fosfestrol tetrasodium	225144324.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)(Oc1ccc(/C(=C(\CC)/c2ccc(OP(=O)(O)O)cc2)/CC)cc1)(O)O	P(=O)(Oc1ccc(/C(=C(\CC)/c2ccc(OP(=O)(O)O)cc2)/CC)cc1)(O)O
NCGC00178317-03&NCGC00178317-04	P(=O)([O-])([O-])C(=O)O		Inactive	Human immunodeficiency virus type 1 reverse transcriptase Inhibitor		2	Foscarnet trisodium&Foscarnet Sodium	170465060.0&434147048.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	P(=O)([O-])([O-])C(=O)[O-].[Na+].[Na+].[Na+]	P(=O)([O-])([O-])C(=O)[O-].[Na+].[Na+].[Na+]&P(=O)([O-])([O-])C(=O)[O-]
NCGC00348378-01	P(=O)([O-])([O-])[C@@H]1[C@H](C)O1		Inactive	UDP-N-acetylglucosamine 1-carboxyvinyltransferase Inhibitor		1	FOSFOMYCIN	405559146.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(=O)([O-])([O-])[C@@H]1[C@H](C)O1	P(=O)([O-])([O-])[C@@H]1[C@H](C)O1
NCGC00168783-01	P(F)(=O)(OC(C)C)OC(C)C		Inactive	Acetylcholinesterase Inhibitor		1	Diisopropyl fluorophosphate	144206196.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	P(F)(=O)(OC(C)C)OC(C)C	P(F)(=O)(OC(C)C)OC(C)C
NCGC00025029-03	S(/C(/N)=C(\C#N)/C(/C#N)=C(/Sc1c(N)cccc1)\N)c1c(N)cccc1		Inactive	Mek 1/2 inhibitor		1	U-0126	26752096.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(/C(/N)=C(\C#N)/C(/C#N)=C(/Sc1c(N)cccc1)\N)c1c(N)cccc1	S(/C(/N)=C(\C#N)/C(/C#N)=C(/Sc1c(N)cccc1)\N)c1c(N)cccc1
NCGC00092290-11	S(/C(/N)=C(\C#N)/c1c(C(F)(F)F)cccc1)c1ccc(N)cc1		Inactive	Mek 1/2 Inhibitor		1	SL-327	384568103.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(/C(/N)=C(\C#N)/c1c(C(F)(F)F)cccc1)c1ccc(N)cc1	S(/C(/N)=C(\C#N)/c1c(C(F)(F)F)cccc1)c1ccc(N)cc1
NCGC00379165-02	S(/C(=N/C1CCCCC1)/NC1CCCCC1)CC=1N2C(SC=1)=NC(C)(C)C2	5.4000001	Active		0.0	1	IT1t dihydrochloride	434147114.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	2.3	85.819713651	S(/C(=N/C1CCCCC1)/NC1CCCCC1)CC=1N2C(SC=1)=NC(C)(C)C2	S(/C(=N/C1CCCCC1)/NC1CCCCC1)CC=1N2C(SC=1)=NC(C)(C)C2
NCGC00249929-01	S(/C=C(/n1cncc1)\c1c(OCCCCC)cccc1)C		Inactive	ergosterol biosynthetic process Inhibitor		1	Neticonazole	170466035.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(/C=C(/n1cncc1)\c1c(OCCCCC)cccc1)C	S(/C=C(/n1cncc1)\c1c(OCCCCC)cccc1)C
NCGC00384919-01	S(/C=C/C(=O)O[C@H]1[C@H](C)[C@]2(C)C(=CC(=O)C(=C(C)C)C2)CC1)C		Inactive	<MOA Unknown> | Class: Sesquiterpen | Genus: Petasites | Family: Compositae | Species: officinalis		1	NCGC00384919-01	363679439.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(/C=C/C(=O)O[C@H]1[C@H](C)[C@]2(C)C(=CC(=O)C(=C(C)C)C2)CC1)C	S(/C=C/C(=O)O[C@H]1[C@H](C)[C@]2(C)C(=CC(=O)C(=C(C)C)C2)CC1)C
NCGC00015148-12	S(=O)(=N)(CCC(N)C(=O)O)CCCC		Inactive	Glutamate-Cysteine Ligase (gamma-Glutamylcysteine Synthetase) Inhibitor		1	Buthionine sulphoximine	384567814.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=N)(CCC(N)C(=O)O)CCCC	S(=O)(=N)(CCC(N)C(=O)O)CCCC
NCGC00475726-01	S(=O)(=N)(Cc1cc(Nc2nc(-c3c(OC)cc(F)cc3)ncn2)ccc1)C		Inactive	CDK 9 Inhibitor		1	Atuveciclib	377020349.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	26.719482116	S(=O)(=N)(Cc1cc(Nc2nc(-c3c(OC)cc(F)cc3)ncn2)ccc1)C	S(=O)(=N)(Cc1cc(Nc2nc(-c3c(OC)cc(F)cc3)ncn2)ccc1)C
NCGC00372956-01	S(=O)(=N)(c1ccc(Nc2nc(O[C@@H]([C@H](O)C)C)c(C(F)(F)F)cn2)cc1)C1CC1		Inactive	Jak2/3 Inhibitor		1	Roniciclib	384569045.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=N)(c1ccc(Nc2nc(O[C@@H]([C@H](O)C)C)c(C(F)(F)F)cn2)cc1)C1CC1	S(=O)(=N)(c1ccc(Nc2nc(O[C@@H]([C@H](O)C)C)c(C(F)(F)F)cn2)cc1)C1CC1
NCGC00025272-09	S(=O)(=O)(/C=C/C#N)c1ccc(C)cc1		Inactive			1	Bay 11-7821(BAY 11-7082)		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(/C=C/C#N)c1ccc(C)cc1	S(=O)(=O)(/C=C/C#N)c1ccc(C)cc1
NCGC00386141-07	S(=O)(=O)(/C=C/c1c(OC)cc(OC)cc1OC)Cc1cc(NCC(=O)O)c(OC)cc1		Inactive	Tubulin depolymerization Inhibitor		1	Rigosertib (ON-01910)	384569112.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(/C=C/c1c(OC)cc(OC)cc1OC)Cc1cc(NCC(=O)[O-])c(OC)cc1	S(=O)(=O)(/C=C/c1c(OC)cc(OC)cc1OC)Cc1cc(NCC(=O)[O-])c(OC)cc1
NCGC00510493-01	S(=O)(=O)(/C=C/c1c(OC)cc(OC)cc1OC)Cc1cc(OP(=O)(O)O)c(OC)cc1		Inactive	Polo-like Kinase-1 (Plk-1) Inhibitor		1	Briciclib	384569455.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(/C=C/c1c(OC)cc(OC)cc1OC)Cc1cc(OP(=O)(O)O)c(OC)cc1	S(=O)(=O)(/C=C/c1c(OC)cc(OC)cc1OC)Cc1cc(OP(=O)(O)O)c(OC)cc1
NCGC00021202-03	S(=O)(=O)(/N=C(/N)\CCSCc1nc(/N=C(\N)/N)sc1)N		Inactive	Histamine H2 Receptor Antagonists		1	Famotidine	170464877.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(/N=C(/N)\CCSCc1nc(/N=C(\N)/N)sc1)N	S(=O)(=O)(/N=C(/N)\CCSCc1nc(/N=C(\N)/N)sc1)N
NCGC00601698-01	S(=O)(=O)(/N=C(\O)/[C@]1(/N=C(\O)/[C@H]2N3C(=O)[C@H](C(C)(C)C)/N=C(\O)/O[C@H]4[C@H](OC/C=C/C(F)(F)c5nc6c(nc5O[C@H](C2)C3)cccc6)CCC4)[C@H](C(F)F)C1)C1(C)CC1		Inactive			1	Glecaprevir		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0	0.0&0.0	S(=O)(=O)(/N=C(\O)/[C@]1(/N=C(\O)/[C@H]2N3C(=O)[C@H](C(C)(C)C)/N=C(\O)/O[C@H]4[C@H](OC/C=C/C(F)(F)c5nc6c(nc5O[C@H](C2)C3)cccc6)CCC4)[C@H](C(F)F)C1)C1(C)CC1	S(=O)(=O)(/N=C(\O)/[C@]1(/N=C(\O)/[C@H]2N3C(=O)[C@H](C(C)(C)C)/N=C(\O)/O[C@H]4[C@H](OC/C=C/C(F)(F)c5nc6c(nc5O[C@H](C2)C3)cccc6)CCC4)[C@H](C(F)F)C1)C1(C)CC1
NCGC00263141-05	S(=O)(=O)(/N=C/c1c(O)ccc2c1cccc2)c1sccc1		Inactive	Serine/Threonine Kinase/Endoribonuclease IRE1 Inhibitor		1	STF-083010	377020222.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(/N=C/c1c(O)ccc2c1cccc2)c1sccc1	S(=O)(=O)(/N=C/c1c(O)ccc2c1cccc2)c1sccc1
NCGC00378650-01	S(=O)(=O)(C(C)(C)C)CC1(NC(=O)N[C@@H](C(C)(C)C)C(=O)N2[C@H](C(=O)N[C@H](C(=O)C(=O)NC3CC3)CCCC)[C@H]3C(C)(C)[C@H]3C2)CCCCC1		Inactive			1	Narlaprevir	434147190.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C(C)(C)C)CC1(NC(=O)N[C@@H](C(C)(C)C)C(=O)N2[C@H](C(=O)N[C@H](C(=O)C(=O)NC3CC3)CCCC)[C@H]3C(C)(C)[C@H]3C2)CCCCC1	S(=O)(=O)(C(C)(C)C)CC1(NC(=O)N[C@@H](C(C)(C)C)C(=O)N2[C@H](C(=O)N[C@H](C(=O)C(=O)NC3CC3)CCCC)[C@H]3C(C)(C)[C@H]3C2)CCCCC1
NCGC00507848-01	S(=O)(=O)(C(C)(C)C)c1cc2c(Nc3n[nH]c4c3cc(F)cc4)ccnc2cc1		Inactive	RIP2 kinase Inhibitor		1	GSK-583	384569329.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	16.484204132	S(=O)(=O)(C(C)(C)C)c1cc2c(Nc3n[nH]c4c3cc(F)cc4)ccnc2cc1	S(=O)(=O)(C(C)(C)C)c1cc2c(Nc3n[nH]c4c3cc(F)cc4)ccnc2cc1
NCGC00387463-02	S(=O)(=O)(C(C)C)c1c(Nc2c3c([nH]cc3)nc(Nc3c(OC)cc(N4CCC(O)CC4)cc3)c2)cccc1		Inactive	MPS1 Inhibitor		1	MPS1-IN-1	384569159.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C(C)C)c1c(Nc2c3c([nH]cc3)nc(Nc3c(OC)cc(N4CCC(O)CC4)cc3)c2)cccc1	S(=O)(=O)(C(C)C)c1c(Nc2c3c([nH]cc3)nc(Nc3c(OC)cc(N4CCC(O)CC4)cc3)c2)cccc1
NCGC00345791-06	S(=O)(=O)(C(C)C)c1c(Nc2nc(Nc3c(OC)cc(N4CCC(N5CCN(C)CC5)CC4)cc3)ncn2)cccc1		Inactive	ALK Inhibitor		1	ASP-3026	384568744.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C(C)C)c1c(Nc2nc(Nc3c(OC)cc(N4CCC(N5CCN(C)CC5)CC4)cc3)ncn2)cccc1	S(=O)(=O)(C(C)C)c1c(Nc2nc(Nc3c(OC)cc(N4CCC(N5CCN(C)CC5)CC4)cc3)ncn2)cccc1
NCGC00402294-03	S(=O)(=O)(C(C)C)c1c(Nc2nc(Nc3c(OC)cc(N4CCC(O)CC4)cc3)nc3[nH]cnc23)cccc1		Inactive	Dual specificity protein kinase TTK Inhibitor		1	Mps1-IN-3	363681017.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(C(C)C)c1c(Nc2nc(Nc3c(OC)cc(N4CCC(O)CC4)cc3)nc3[nH]cnc23)cccc1	S(=O)(=O)(C(C)C)c1c(Nc2nc(Nc3c(OC)cc(N4CCC(O)CC4)cc3)nc3[nH]cnc23)cccc1
NCGC00390417-03	S(=O)(=O)(C(C)C)c1cc2c(Nc3cc4ncsc4cc3)ccnc2cc1		Inactive	RIP3 kinase Inhibitor		1	GSK-872	363680893.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C(C)C)c1cc2c(Nc3cc4ncsc4cc3)ccnc2cc1	S(=O)(=O)(C(C)C)c1cc2c(Nc3cc4ncsc4cc3)ccnc2cc1
NCGC00386313-08	S(=O)(=O)(C(C)C)c1ccc(-c2nc(c(N)nc2)-c2onc(-c3ccc(CNC)cc3)c2)cc1	5.6500001	Active	ATR Kinase Inhibitor	0.0	1	Berzosertib	384569124.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	1.4	77.7935735568	S(=O)(=O)(C(C)C)c1ccc(-c2nc(c(N)nc2)-c2onc(-c3ccc(CNC)cc3)c2)cc1	S(=O)(=O)(C(C)C)c1ccc(-c2nc(c(N)nc2)-c2onc(-c3ccc(CNC)cc3)c2)cc1
NCGC00370766-02	S(=O)(=O)(C(F)(F)F)c1ccc(NC(=O)C2=CCN(c3c(C(F)(F)F)cccn3)CC2)cc1		Inactive	Vanilloid receptor Antagonist		1	A 784168	363677841.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	19.824324324	S(=O)(=O)(C(F)(F)F)c1ccc(NC(=O)C2=CCN(c3c(C(F)(F)F)cccn3)CC2)cc1	S(=O)(=O)(C(F)(F)F)c1ccc(NC(=O)C2=CCN(c3c(C(F)(F)F)cccn3)CC2)cc1
NCGC00182044-02	S(=O)(=O)(C(F)(F)F)c1ccc(Oc2c(C)cc(N3C(=O)N(C)C(=O)NC3=O)cc2)cc1		Inactive			1	Toltrazuril (sulfone)	405558806.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C(F)(F)F)c1ccc(Oc2c(C)cc(N3C(=O)N(C)C(=O)NC3=O)cc2)cc1	S(=O)(=O)(C(F)(F)F)c1ccc(Oc2c(C)cc(N3C(=O)N(C)C(=O)NC3=O)cc2)cc1
NCGC00167470-05	S(=O)(=O)(C)N1C(=O)N(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)CC1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	Mezlocillin Sodium	405558684.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)N1C(=O)N(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)CC1	S(=O)(=O)(C)N1C(=O)N(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)CC1
NCGC00390674-01	S(=O)(=O)(C)N1C(=O)[C@@H](C(C)C)[C@@H]2N(C(=O)/C=C/CN3CCCCC3)CC[C@@H]12		Inactive	U-937 Inhibitor		1	GW311616	363680967.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(C)N1C(=O)[C@@H](C(C)C)[C@@H]2N(C(=O)/C=C/CN3CCCCC3)CC[C@@H]12	S(=O)(=O)(C)N1C(=O)[C@@H](C(C)C)[C@@H]2N(C(=O)/C=C/CN3CCCCC3)CC[C@@H]12
NCGC00346632-02	S(=O)(=O)(C)N1CCC(Nc2nc(N)c(C(=O)c3c(F)c(F)ccc3OC)cn2)CC1		Inactive	CDK1/2/4 Inhibitor		1	R-547	384568868.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	16.5	S(=O)(=O)(C)N1CCC(Nc2nc(N)c(C(=O)c3c(F)c(F)ccc3OC)cn2)CC1	S(=O)(=O)(C)N1CCC(Nc2nc(N)c(C(=O)c3c(F)c(F)ccc3OC)cn2)CC1
NCGC00507966-01	S(=O)(=O)(C)N1CCN(C(C)c2cc(c(Nc3cc(F)c(OC)nc3)nc2)-c2nc(N)nc(C)n2)CC1		Inactive	PI3K alpha Inhibitor		1	AMG-511	384569359.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)N1CCN(C(C)c2cc(c(Nc3cc(F)c(OC)nc3)nc2)-c2nc(N)nc(C)n2)CC1	S(=O)(=O)(C)N1CCN(C(C)c2cc(c(Nc3cc(F)c(OC)nc3)nc2)-c2nc(N)nc(C)n2)CC1
NCGC00345851-06	S(=O)(=O)(C)N1CCN(Cc2c(C)c3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1		Inactive	PI3K Inhibitor		1	GNE-477	384568766.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)N1CCN(Cc2c(C)c3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1	S(=O)(=O)(C)N1CCN(Cc2c(C)c3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1
NCGC00187482-21	S(=O)(=O)(C)N1CCN(Cc2sc3c(N4CCOCC4)nc(-c4c5c([nH]nc5)ccc4)nc3c2)CC1		Inactive	PI3K Inhibitor		1	Pictilisib	384568445.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		S(=O)(=O)(C)N1CCN(Cc2sc3c(N4CCOCC4)nc(-c4c5c([nH]nc5)ccc4)nc3c2)CC1	S(=O)(=O)(C)N1CCN(Cc2sc3c(N4CCOCC4)nc(-c4c5c([nH]nc5)ccc4)nc3c2)CC1
NCGC00402368-01	S(=O)(=O)(C)N1CCN([C@@H](C)c2cc(c(Nc3cc(F)c(OC)nc3)nc2)-c2nc(N)nc(C)n2)CC1		Inactive	PI3Kalpha Inhibitor		1	AMG-511	384569217.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)N1CCN([C@@H](C)c2cc(c(Nc3cc(F)c(OC)nc3)nc2)-c2nc(N)nc(C)n2)CC1	S(=O)(=O)(C)N1CCN([C@@H](C)c2cc(c(Nc3cc(F)c(OC)nc3)nc2)-c2nc(N)nc(C)n2)CC1
NCGC00263115-03	S(=O)(=O)(C)N1c2c(C3(C1)CCN(C(=O)[C@H](NC(=O)C(N)(C)C)COCc1ccccc1)CC3)cccc2		Inactive	Growth Hormone Secretagogue		1	Ibutamoren mesilate	384568599.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)N1c2c(C3(C1)CCN(C(=O)[C@H](NC(=O)C(N)(C)C)COCc1ccccc1)CC3)cccc2	S(=O)(=O)(C)N1c2c(C3(C1)CCN(C(=O)[C@H](NC(=O)C(N)(C)C)COCc1ccccc1)CC3)cccc2
NCGC00346650-02	S(=O)(=O)(C)N1c2nc(N3CCOCC3)nc(-c3cnc(N)nc3)c2CC1		Inactive	PI3Kalpha, beta, gamma Inhibitor		1	CH-5132799	384568881.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)N1c2nc(N3CCOCC3)nc(-c3cnc(N)nc3)c2CC1	S(=O)(=O)(C)N1c2nc(N3CCOCC3)nc(-c3cnc(N)nc3)c2CC1
NCGC00356119-03	S(=O)(=O)(C)c1c(-c2c3n(c(C(=O)C)c2)C=CC(OCCC)=C3)cccc1		Inactive	BAZ2B Inhibitor		1	GSK-2801	384569028.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)c1c(-c2c3n(c(C(=O)C)c2)C=CC(OCCC)=C3)cccc1	S(=O)(=O)(C)c1c(-c2c3n(c(C(=O)C)c2)C=CC(OCCC)=C3)cccc1
NCGC00242056-04	S(=O)(=O)(C)c1c(COc2c(C#N)sc(-n3c4c(nc3)cc(OC)c(OC)c4)c2)cccc1		Inactive	IKK-epsilon Inhibitor		1	IKK-3 Inhibitor IX	384568484.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)c1c(COc2c(C#N)sc(-n3c4c(nc3)cc(OC)c(OC)c4)c2)cccc1	S(=O)(=O)(C)c1c(COc2c(C#N)sc(-n3c4c(nc3)cc(OC)c(OC)c4)c2)cccc1
NCGC00351483-01	S(=O)(=O)(C)c1c(F)c(C)c(C(=O)N2Cc3c(OCC2)ccc(-c2cnc(N)cc2)c3)cc1		Inactive	mTORC1/2 Inhibitor		1	XL-388	384569010.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)c1c(F)c(C)c(C(=O)N2Cc3c(OCC2)ccc(-c2cnc(N)cc2)c3)cc1	S(=O)(=O)(C)c1c(F)c(C)c(C(=O)N2Cc3c(OCC2)ccc(-c2cnc(N)cc2)c3)cc1
NCGC00402285-03	S(=O)(=O)(C)c1c(N2CCN(C3=NC4=C(C(=O)N3)CSCC4)CC2)cccc1		Inactive	Tankyrase-2 Inhibitor		1	G244-LM	363681013.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(C)c1c(N2CCN(C3=NC4=C(C(=O)N3)CSCC4)CC2)cccc1	S(=O)(=O)(C)c1c(N2CCN(C3=NC4=C(C(=O)N3)CSCC4)CC2)cccc1
NCGC00387306-01	S(=O)(=O)(C)c1c2[C@H](O)C(F)(F)Cc2c(Oc2cc(F)cc(C#N)c2)cc1		Inactive	HIF-2alpha Inhibitor		1	PT-2385	384569157.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)c1c2[C@H](O)C(F)(F)Cc2c(Oc2cc(F)cc(C#N)c2)cc1	S(=O)(=O)(C)c1c2[C@H](O)C(F)(F)Cc2c(Oc2cc(F)cc(C#N)c2)cc1
NCGC00182390-05	S(=O)(=O)(C)c1cc(-c2c3c(Sc4n(C)nnn4)ncnc3sc2)ccc1	4.9499998	Active		0.0	1	NCGC00182390-05	406861849.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	3.0&2.2	69.9342313999&100.3955998983	S(=O)(=O)(C)c1cc(-c2c3c(Sc4n(C)nnn4)ncnc3sc2)ccc1	S(=O)(=O)(C)c1cc(-c2c3c(Sc4n(C)nnn4)ncnc3sc2)ccc1
NCGC00386672-01	S(=O)(=O)(C)c1cc(-c2ccc(-c3c(C)nc4c(C(F)(F)F)cccc4n3)cc2)ccc1		Inactive	LXR-beta Partial Agonist		1	WYE 672	363680387.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(C)c1cc(-c2ccc(-c3c(C)nc4c(C(F)(F)F)cccc4n3)cc2)ccc1	S(=O)(=O)(C)c1cc(-c2ccc(-c3c(C)nc4c(C(F)(F)F)cccc4n3)cc2)ccc1
NCGC00379029-01	S(=O)(=O)(C)c1cc(C(=O)N2CCN(c3c(F)cc(C(F)(F)F)cn3)CC2)c(O[C@H](C(F)(F)F)C)cc1		Inactive	Glycine transporter 1 Inhibitor		1	Bitopertin	363678321.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(C)c1cc(C(=O)N2CCN(c3c(F)cc(C(F)(F)F)cn3)CC2)c(O[C@H](C(F)(F)F)C)cc1	S(=O)(=O)(C)c1cc(C(=O)N2CCN(c3c(F)cc(C(F)(F)F)cn3)CC2)c(O[C@H](C(F)(F)F)C)cc1
NCGC00015996-10	S(=O)(=O)(C)c1cc(C(=O)NCCN(CC)CC)c(OC)cc1		Inactive	Dopamine D3 receptor Antagonist		1	Tiapride hydrochloride	170465877.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(C)c1cc(C(=O)NCCN(CC)CC)c(OC)cc1.Cl	S(=O)(=O)(C)c1cc(C(=O)NCCN(CC)CC)c(OC)cc1.Cl
NCGC00386586-01	S(=O)(=O)(C)c1cc(C2CCN(CCC)CC2)ccc1		Inactive	Dopamine D2 receptor Antagonist		1	ACR 16 hydrochloride	363680342.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(C)c1cc(C2CCN(CCC)CC2)ccc1	S(=O)(=O)(C)c1cc(C2CCN(CCC)CC2)ccc1
NCGC00263133-09	S(=O)(=O)(C)c1cc(CNc2c(C(F)(F)F)cnc(Nc3cc4c(NC(=O)CC4)cc3)n2)ccc1		Inactive	Focal Adhesion Kinase (FAK) Inhibitor		1	PF-573228	363677220.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)c1cc(CNc2c(C(F)(F)F)cnc(Nc3cc4c(NC(=O)CC4)cc3)n2)ccc1	S(=O)(=O)(C)c1cc(CNc2c(C(F)(F)F)cnc(Nc3cc4c(NC(=O)CC4)cc3)n2)ccc1
NCGC00386765-03	S(=O)(=O)(C)c1cc(F)c(-n2ncc3c(OC4CCN(C(=O)OC(C)C)CC4)ncnc23)cc1		Inactive	Glucose-dependent insulinotropic receptor Agonist		1	APD668	363680440.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(C)c1cc(F)c(-n2ncc3c(OC4CCN(C(=O)OC(C)C)CC4)ncnc23)cc1	S(=O)(=O)(C)c1cc(F)c(-n2ncc3c(OC4CCN(C(=O)OC(C)C)CC4)ncnc23)cc1
NCGC00386584-02	S(=O)(=O)(C)c1cc(F)c(Nc2c([N+](=O)[O-])c(N3CCC(c4onc(C(C)C)n4)CC3)ncn2)cc1		Inactive	Glucose-dependent insulinotropic receptor Agonist		1	AR 231453	363680340.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(C)c1cc(F)c(Nc2c([N+](=O)[O-])c(N3CCC(c4onc(C(C)C)n4)CC3)ncn2)cc1	S(=O)(=O)(C)c1cc(F)c(Nc2c([N+](=O)[O-])c(N3CCC(c4onc(C(C)C)n4)CC3)ncn2)cc1
NCGC00488781-01	S(=O)(=O)(C)c1cc(OC)c(Nc2nn3c(n2)C=CC(c2ccc(NC(=O)[C@H](C)c4ccc(F)cc4)cc2)=C3)cc1		Inactive	MPS1 Inhibitor		1	BAY-1161909	363681475.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)c1cc(OC)c(Nc2nn3c(n2)C=CC(c2ccc(NC(=O)[C@H](C)c4ccc(F)cc4)cc2)=C3)cc1	S(=O)(=O)(C)c1cc(OC)c(Nc2nn3c(n2)C=CC(c2ccc(NC(=O)[C@H](C)c4ccc(F)cc4)cc2)=C3)cc1
NCGC00510185-01	S(=O)(=O)(C)c1cc(S(=O)(=O)c2sc(CN)cc2)cc(-c2ccccc2)c1		Inactive			1	CCT365623	434146927.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)c1cc(S(=O)(=O)c2sc(CN)cc2)cc(-c2ccccc2)c1	S(=O)(=O)(C)c1cc(S(=O)(=O)c2sc(CN)cc2)cc(-c2ccccc2)c1
NCGC00378664-01	S(=O)(=O)(C)c1cc([C@H]2CN(CCC)CCC2)ccc1		Inactive	Serotonin 2a (5-HT2a) receptor Modulator		1	OSU 6162 hydrochloride	363678140.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(C)c1cc([C@H]2CN(CCC)CCC2)ccc1	S(=O)(=O)(C)c1cc([C@H]2CN(CCC)CCC2)ccc1
NCGC00386669-01	S(=O)(=O)(C)c1ccc(-c2c(-c3ccc(OCC)cc3)nn3N=CC=Cc23)cc1		Inactive	Cyclooxygenase-2 Inhibitor		1	GW 406381	363680385.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(C)c1ccc(-c2c(-c3ccc(OCC)cc3)nn3N=CC=Cc23)cc1	S(=O)(=O)(C)c1ccc(-c2c(-c3ccc(OCC)cc3)nn3N=CC=Cc23)cc1
NCGC00371131-03&NCGC00371131-09	S(=O)(=O)(C)c1ccc(-c2c(C)cc(OCc3n(c(SC4CCCC4)nn3)-c3cnccc3)cc2)cc1		Inactive	p97 ATPase Inhibitor		2	NMS-873	434147189.0&363678047.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(C)c1ccc(-c2c(C)cc(OCc3n(c(SC4CCCC4)nn3)-c3cnccc3)cc2)cc1	S(=O)(=O)(C)c1ccc(-c2c(C)cc(OCc3n(c(SC4CCCC4)nn3)-c3cnccc3)cc2)cc1
NCGC00346637-05	S(=O)(=O)(C)c1ccc(-c2ccc([C@H](N[C@H](C(=O)NC3(C#N)CC3)CC(F)(C)C)C(F)(F)F)cc2)cc1		Inactive	Cathepsin K Inhibitor		1	Odanacatib	384568871.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(C)c1ccc(-c2ccc([C@H](N[C@H](C(=O)NC3(C#N)CC3)CC(F)(C)C)C(F)(F)F)cc2)cc1	S(=O)(=O)(C)c1ccc(-c2ccc([C@H](N[C@H](C(=O)NC3(C#N)CC3)CC(F)(C)C)C(F)(F)F)cc2)cc1
NCGC00346444-07	S(=O)(=O)(C)c1ccc(-c2nc(C(=O)Nc3ccccc3)c(N)nc2)cc1		Inactive	ATR Kinase Inhibitor		1	VE-821	363677406.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.5	S(=O)(=O)(C)c1ccc(-c2nc(C(=O)Nc3ccccc3)c(N)nc2)cc1	S(=O)(=O)(C)c1ccc(-c2nc(C(=O)Nc3ccccc3)c(N)nc2)cc1
NCGC00346568-05	S(=O)(=O)(C)c1ccc(-c2ncc(OCC3CCN(c4onc(C(C)C)n4)CC3)cc2)cc1		Inactive	Glucose-Dependent Insulinotropic Receptor (GDIR, GPR119) Agonist		1	GSK-1292263A	363677455.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)c1ccc(-c2ncc(OCC3CCN(c4onc(C(C)C)n4)CC3)cc2)cc1	S(=O)(=O)(C)c1ccc(-c2ncc(OCC3CCN(c4onc(C(C)C)n4)CC3)cc2)cc1
NCGC00371062-01	S(=O)(=O)(C)c1ccc(-n2c(-c3ccc(F)cc3)cc(C(F)(F)F)n2)cc1		Inactive	Prostaglandin G/H synthase 2 Inhibitor		1	SC 58125	363678013.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(C)c1ccc(-n2c(-c3ccc(F)cc3)cc(C(F)(F)F)n2)cc1	S(=O)(=O)(C)c1ccc(-n2c(-c3ccc(F)cc3)cc(C(F)(F)F)n2)cc1
NCGC00485124-01	S(=O)(=O)(C)c1ccc(/C=C/2\C(C)=C(CC(=O)O)c3c\2ccc(F)c3)cc1		Inactive	Phosphodiesterase 5A Inhibitor		1	Sulindac sulfone	363681232.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(C)c1ccc(/C=C/2\C(C)=C(CC(=O)O)c3c\2ccc(F)c3)cc1	S(=O)(=O)(C)c1ccc(/C=C/2\C(C)=C(CC(=O)O)c3c\2ccc(F)c3)cc1
NCGC00386499-01	S(=O)(=O)(C)c1ccc(C(C(=O)OC)CC2CCCC2)cc1		Inactive			1	Methyl-3-cyclopentyl-2-(4-methylsulfonylphenyl)propionate	363680306.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(C)c1ccc(C(C(=O)OC)CC2CCCC2)cc1	S(=O)(=O)(C)c1ccc(C(C(=O)OC)CC2CCCC2)cc1
NCGC00389572-01	S(=O)(=O)(C)c1ccc(C2=C(OCC3CC3)C(=O)OC2(C)C)cc1		Inactive	Cyclooxygenase-2 Inhibitor		1	FIROCOXIB	405558697.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)c1ccc(C2=C(OCC3CC3)C(=O)OC2(C)C)cc1	S(=O)(=O)(C)c1ccc(C2=C(OCC3CC3)C(=O)OC2(C)C)cc1
NCGC00095118-08&NCGC00095118-17	S(=O)(=O)(C)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1		Inactive	Cyclooxygenase-2 Inhibitor		2	Rofecoxib	363676573.0&405558837.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(C)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1	S(=O)(=O)(C)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1
NCGC00507938-02	S(=O)(=O)(C)c1ccc(C=2c3n(C(NCc4occc4)=NC=2)cnn3)cc1		Inactive	Polycomb protein EED (PRC2/EED-EZH2 non-catalytic subunit) Inhibitor		1	EED-226	384569357.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)c1ccc(C=2c3n(C(NCc4occc4)=NC=2)cnn3)cc1	S(=O)(=O)(C)c1ccc(C=2c3n(C(NCc4occc4)=NC=2)cnn3)cc1
NCGC00378564-01	S(=O)(=O)(C)c1ccc([C@H](C(=O)Nc2sccn2)CC2CCCC2)cc1		Inactive	Glucokinase Activator		1	Ro-28-1675	384569049.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)c1ccc([C@H](C(=O)Nc2sccn2)CC2CCCC2)cc1	S(=O)(=O)(C)c1ccc([C@H](C(=O)Nc2sccn2)CC2CCCC2)cc1
NCGC00378593-02&NCGC00378593-08	S(=O)(=O)(C)c1cnc(CNC(=O)C=2C(=O)N(c3cc(C(F)(F)F)ccc3)C(C)=C(c3n(C)ncc3)C=2)cc1		Inactive	Leukocyte elastase Inhibitor		2	AZD9668&Alvelestat (AZD9668£©	384569052.0&434147106.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(C)c1cnc(CNC(=O)C=2C(=O)N(c3cc(C(F)(F)F)ccc3)C(C)=C(c3n(C)ncc3)C=2)cc1	S(=O)(=O)(C)c1cnc(CNC(=O)C=2C(=O)N(c3cc(C(F)(F)F)ccc3)C(C)=C(c3n(C)ncc3)C=2)cc1
NCGC00480770-01	S(=O)(=O)(C)n1nc2c(c1)CN([C@@H]1C[C@H](N)[C@@H](c3c(F)ccc(F)c3)OC1)C2		Inactive	Dipeptidyl peptidase IV Inhibitor		1	MK-3102	405558938.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C)n1nc2c(c1)CN([C@@H]1C[C@H](N)[C@@H](c3c(F)ccc(F)c3)OC1)C2	S(=O)(=O)(C)n1nc2c(c1)CN([C@@H]1C[C@H](N)[C@@H](c3c(F)ccc(F)c3)OC1)C2
NCGC00475744-02	S(=O)(=O)(C1(c2nc(-c3ccc(NC(=S)NCCO)cc3)nc(N3[C@@H](C)COCC3)c2)CC1)C1CC1		Inactive	mTORC1/2 Inhibitor		1	AZD-3147	377020261.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(C1(c2nc(-c3ccc(NC(=S)NCCO)cc3)nc(N3[C@@H](C)COCC3)c2)CC1)C1CC1	S(=O)(=O)(C1(c2nc(-c3ccc(NC(=S)NCCO)cc3)nc(N3[C@@H](C)COCC3)c2)CC1)C1CC1
NCGC00420874-01	S(=O)(=O)(C=C)N1CCN(c2nc(-c3ncccc3)nc(NCCC(=O)O)c2)CCC1		Inactive			1	NCGC00420874-01		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(C=C)N1CCN(c2nc(-c3ncccc3)nc(NCCC(=O)O)c2)CCC1	S(=O)(=O)(C=C)N1CCN(c2nc(-c3ncccc3)nc(NCCC(=O)O)c2)CCC1
NCGC00115775-02	S(=O)(=O)(CC(C)C)c1c(S(=O)(=O)c2ccccc2)nc(-c2ccc(F)cc2)o1		Inactive			1	NCGC00115775-02	434147003.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	-8.79468178	S(=O)(=O)(CC(C)C)c1c(S(=O)(=O)c2ccccc2)nc(-c2ccc(F)cc2)o1	S(=O)(=O)(CC(C)C)c1c(S(=O)(=O)c2ccccc2)nc(-c2ccc(F)cc2)o1
NCGC00389674-01	S(=O)(=O)(CC(N1C(=O)c2c(NC(=O)C)cccc2C1=O)c1cc(OCC)c(OC)cc1)C		Inactive	Phosphodiesterase 4 Inhibitor		1	Apremilast (CC-10004)	405558478.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(CC(N1C(=O)c2c(NC(=O)C)cccc2C1=O)c1cc(OCC)c(OC)cc1)C	S(=O)(=O)(CC(N1C(=O)c2c(NC(=O)C)cccc2C1=O)c1cc(OCC)c(OC)cc1)C
NCGC00345839-10&NCGC00345839-16	S(=O)(=O)(CC)N1CC(CC#N)(n2ncc(-c3ncnc4[nH]ccc34)c2)C1		Inactive	Jak2 Inhibitor		2	Baricitinib	384568762.0&434147208.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(CC)N1CC(CC#N)(n2ncc(-c3ncnc4[nH]ccc34)c2)C1	S(=O)(=O)(CC)N1CC(CC#N)(n2ncc(-c3ncnc4[nH]ccc34)c2)C1
NCGC00390588-01	S(=O)(=O)(CC)N1CCC(C(C)n2c(C)c(C(=O)NCC=3C(=O)NC(C)=CC=3OC)c3c2cccc3)CC1		Inactive			1	CPI-169 racemate	384569199.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(CC)N1CCC(C(C)n2c(C)c(C(=O)NCC=3C(=O)NC(C)=CC=3OC)c3c2cccc3)CC1	S(=O)(=O)(CC)N1CCC(C(C)n2c(C)c(C(=O)NCC=3C(=O)NC(C)=CC=3OC)c3c2cccc3)CC1
NCGC00481546-01	S(=O)(=O)(CC)N1CCC([C@@H](C)n2c(C)c(/C(/O)=N/Cc3c(O)nc(C)cc3OC)c3c2cccc3)CC1		Inactive	EZH2 Inhibitor		1	CPI-169 racemate	384569255.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(CC)N1CCC([C@@H](C)n2c(C)c(/C(/O)=N/Cc3c(O)nc(C)cc3OC)c3c2cccc3)CC1	S(=O)(=O)(CC)N1CCC([C@@H](C)n2c(C)c(/C(/O)=N/Cc3c(O)nc(C)cc3OC)c3c2cccc3)CC1
NCGC00386415-05	S(=O)(=O)(CC)N1CCN(c2ccc(Nc3nc(NC4CC4)c(C(=O)N)cn3)cc2)CC1		Inactive	TYK2 Inhibitor		1	Cerdulatinib	384569133.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(CC)N1CCN(c2ccc(Nc3nc(NC4CC4)c(C(=O)N)cn3)cc2)CC1	S(=O)(=O)(CC)N1CCN(c2ccc(Nc3nc(NC4CC4)c(C(=O)N)cn3)cc2)CC1
NCGC00092310-06&NCGC00092310-14	S(=O)(=O)(CC)c1c(N)cc(OC)c(C(=O)NCC2N(CC)CCC2)c1		Inactive	Dopamine D2/D3 Antagonist		2	Amisulpride	170466480.0&384568104.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(CC)c1c(N)cc(OC)c(C(=O)NCC2N(CC)CCC2)c1	S(=O)(=O)(CC)c1c(N)cc(OC)c(C(=O)NCC2N(CC)CCC2)c1
NCGC00346645-06	S(=O)(=O)(CC)c1cc(-c2c3c(c(C)c(C(=O)NC4CCN(C)CC4)c2)[nH]c2ncc(C)cc32)ccc1		Inactive	Aurora-A/B Inhibitor		1	TAK-901	384568877.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(CC)c1cc(-c2c3c(c(C)c(C(=O)NC4CCN(C)CC4)c2)[nH]c2ncc(C)cc32)ccc1	S(=O)(=O)(CC)c1cc(-c2c3c(c(C)c(C(=O)NC4CCN(C)CC4)c2)[nH]c2ncc(C)cc32)ccc1
NCGC00184999-01	S(=O)(=O)(CC)c1cc(C(=O)NCC2N(CC)CCC2)c(OC)cc1		Inactive	Dopamine D3 receptor Antagonist		1	Sultopride hydrochloride	144207174.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(CC)c1cc(C(=O)NCC2N(CC)CCC2)c(OC)cc1.Cl	S(=O)(=O)(CC)c1cc(C(=O)NCC2N(CC)CCC2)c(OC)cc1.Cl
NCGC00508865-03	S(=O)(=O)(CC)c1cc2nc(-c3cc4c(cc3)cccc4)oc2cc1		Inactive	enhances expression of utrophin		1	Ezutromid	384569366.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	10.0	S(=O)(=O)(CC)c1cc2nc(-c3cc4c(cc3)cccc4)oc2cc1	S(=O)(=O)(CC)c1cc2nc(-c3cc4c(cc3)cccc4)oc2cc1
NCGC00346932-04	S(=O)(=O)(CC1SC1)c1ccc(Oc2ccccc2)cc1		Inactive	MMP2/9 Inhibitor		1	SB-3CT	384568968.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(CC1SC1)c1ccc(Oc2ccccc2)cc1	S(=O)(=O)(CC1SC1)c1ccc(Oc2ccccc2)cc1
NCGC00481107-02	S(=O)(=O)(CCC)c1nc(NC2CC2)cc(-c2cc3c(n(C4CC(C)(C)NC(C)(C)C4)cc3)cc2)n1		Inactive	CECR2 Inhibitor		1	NVS-CECR2-1	384569252.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-20.961935756	S(=O)(=O)(CCC)c1nc(NC2CC2)cc(-c2cc3c(n(C4CC(C)(C)NC(C)(C)C4)cc3)cc2)n1	S(=O)(=O)(CCC)c1nc(NC2CC2)cc(-c2cc3c(n(C4CC(C)(C)NC(C)(C)C4)cc3)cc2)n1
NCGC00346669-05	S(=O)(=O)(CCCOc1cc(C)c(c(C)c1)-c1cc(COc2cc3OC[C@@H](CC(=O)O)c3cc2)ccc1)C		Inactive	Insulin Secretagogues		1	TAK-875	384568895.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	12.2047828519	S(=O)(=O)(CCCOc1cc(C)c(c(C)c1)-c1cc(COc2cc3OC[C@@H](CC(=O)O)c3cc2)ccc1)C	S(=O)(=O)(CCCOc1cc(C)c(c(C)c1)-c1cc(COc2cc3OC[C@@H](CC(=O)O)c3cc2)ccc1)C
NCGC00485952-01	S(=O)(=O)(CCCOc1cc(C)c(c(C)c1)-c1cc(COc2ccc(C=3[SH0](=O)NC(=O)C=3)cc2)ccc1)C		Inactive	Free fatty acid receptor 1 Agonist		1	GPR40 Activator 2	363681439.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(CCCOc1cc(C)c(c(C)c1)-c1cc(COc2ccc(C=3[SH0](=O)NC(=O)C=3)cc2)ccc1)C	S(=O)(=O)(CCCOc1cc(C)c(c(C)c1)-c1cc(COc2ccc(C=3[SH0](=O)NC(=O)C=3)cc2)ccc1)C
NCGC00508820-02	S(=O)(=O)(CCN(CC)CC)[C@H]1[C@@H]2C(=O)O[C@H](C(C)C)[C@H](C)/C=C/C(=O)NC/C=C/C(/C)=C/[C@@H](O)CC(=O)Cc3occ(C(=O)N2CC1)n3		Inactive	Bacterial 70S ribosome Inhibitor		1	Dalfopristin	405559042.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(CCN(CC)CC)[C@H]1[C@@H]2C(=O)O[C@H](C(C)C)[C@H](C)/C=C/C(=O)NC/C=C/C(/C)=C/[C@@H](O)CC(=O)Cc3occ(C(=O)N2CC1)n3	S(=O)(=O)(CCN(CC)CC)[C@H]1[C@@H]2C(=O)O[C@H](C(C)C)[C@H](C)/C=C/C(=O)NC/C=C/C(/C)=C/[C@@H](O)CC(=O)Cc3occ(C(=O)N2CC1)n3
NCGC00346672-02	S(=O)(=O)(CCNCc1oc(-c2cc3c(Nc4cc(C)c(OC5=Cc6n(ncn6)C=C5)cc4)ncnc3cc2)cc1)C		Inactive	HER2 Inhibitor		1	ARRY-380	384568898.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(CCNCc1oc(-c2cc3c(Nc4cc(C)c(OC5=Cc6n(ncn6)C=C5)cc4)ncnc3cc2)cc1)C	S(=O)(=O)(CCNCc1oc(-c2cc3c(Nc4cc(C)c(OC5=Cc6n(ncn6)C=C5)cc4)ncnc3cc2)cc1)C
NCGC00015602-06	S(=O)(=O)(CC[C@H](N)C(=O)NC1[C@@]2(CS(=O)(=O)N3CCN(c4c(C)cccc4)CC3)C(C)(C)C(C1)CC2)C		Inactive			1	L-368,899		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(CC[C@H](N)C(=O)NC1[C@@]2(CS(=O)(=O)N3CCN(c4c(C)cccc4)CC3)C(C)(C)C(C1)CC2)C	S(=O)(=O)(CC[C@H](N)C(=O)NC1[C@@]2(CS(=O)(=O)N3CCN(c4c(C)cccc4)CC3)C(C)(C)C(C1)CC2)C
NCGC00263929-02	S(=O)(=O)(CCc1cc2[nH]cc(C[C@@H]3N(C)CCC3)c2cc1)c1ccccc1		Inactive			1	ELETRIPTAN HYDROBROMIDE	363677302.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(CCc1cc2[nH]cc(C[C@@H]3N(C)CCC3)c2cc1)c1ccccc1	S(=O)(=O)(CCc1cc2[nH]cc(C[C@@H]3N(C)CCC3)c2cc1)c1ccccc1
NCGC00181130-02	S(=O)(=O)(CCc1cc2c(C[C@@H]3N(C)CCC3)c[nH]c2cc1)c1ccccc1		Inactive	5-hydroxytryptamine receptor 1F Agonist		1	Eletriptan	170465317.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(CCc1cc2c(C[C@@H]3N(C)CCC3)c[nH]c2cc1)c1ccccc1	S(=O)(=O)(CCc1cc2c(C[C@@H]3N(C)CCC3)c[nH]c2cc1)c1ccccc1
NCGC00016741-09	S(=O)(=O)(CCn1c(C)ncc1[N+](=O)[O-])CC		Inactive			1	Tinidazole	170465196.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(CCn1c(C)ncc1[N+](=O)[O-])CC	S(=O)(=O)(CCn1c(C)ncc1[N+](=O)[O-])CC
NCGC00485951-02	S(=O)(=O)(C[C@H](N[C@H](C(F)(F)F)c1ccc(F)cc1)C(=O)N[C@H](C(=O)C(=O)NC1CC1)CC)CC1CC1	7.0	Active	Cathepsin S Inhibitor	0.0	1	VBY-825	384569279.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	1.3	105.4931425094	S(=O)(=O)(C[C@H](N[C@H](C(F)(F)F)c1ccc(F)cc1)C(=O)N[C@H](C(=O)C(=O)NC1CC1)CC)CC1CC1	S(=O)(=O)(C[C@H](N[C@H](C(F)(F)F)c1ccc(F)cc1)C(=O)N[C@H](C(=O)C(=O)NC1CC1)CC)CC1CC1
NCGC00167487-12&NCGC00167487-15	S(=O)(=O)(C[C@](O)(C(=O)Nc1cc(C(F)(F)F)c(C#N)cc1)C)c1ccc(F)cc1		Inactive	Androgen Receptor Antagonist		2	Bicalutamide&BICALUTAMIDE	405558511.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(C[C@](O)(C(=O)Nc1cc(C(F)(F)F)c(C#N)cc1)C)c1ccc(F)cc1	S(=O)(=O)(C[C@](O)(C(=O)Nc1cc(C(F)(F)F)c(C#N)cc1)C)c1ccc(F)cc1
NCGC00485902-01	S(=O)(=O)(Cc1c(C)c(OC)c(C)cn1)c1[nH]c2c(n1)cc(OC)cc2		Inactive	Cytochrome P450 2C19 Inhibitor		1	Omeprazole metabolite Omeprazole sulfone	363681404.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Cc1c(C)c(OC)c(C)cn1)c1[nH]c2c(n1)cc(OC)cc2	S(=O)(=O)(Cc1c(C)c(OC)c(C)cn1)c1[nH]c2c(n1)cc(OC)cc2
NCGC00351609-09	S(=O)(=O)(Cc1c(C)oc(-c2ccc(C(=O)NCc3cnccc3)cc2)n1)c1ccc(C)cc1		Inactive	Solute Carrier Family 2, Facilitated Glucose Transporter Member 1 (GLUT-1; SLC2A1) Inhibitor		1	STF-118804	363677780.0	Annotated/Bioactive Compound Collection&2020_NPACT-1_CPE	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(Cc1c(C)oc(-c2ccc(C(=O)NCc3cnccc3)cc2)n1)c1ccc(C)cc1	S(=O)(=O)(Cc1c(C)oc(-c2ccc(C(=O)NCc3cnccc3)cc2)n1)c1ccc(C)cc1
NCGC00346972-08	S(=O)(=O)(Cc1cc(OCc2ccc(CN3[C@@H](CO)CCC3)cc2)cc(C)c1)c1ccccc1		Inactive	Sphingosine Kinase 1 (SphK1) Inhibitor		1	PF-543	384568978.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	19.7803347239	S(=O)(=O)(Cc1cc(OCc2ccc(CN3[C@@H](CO)CCC3)cc2)cc(C)c1)c1ccccc1	S(=O)(=O)(Cc1cc(OCc2ccc(CN3[C@@H](CO)CCC3)cc2)cc(C)c1)c1ccccc1
NCGC00095135-05&NCGC00095135-12	S(=O)(=O)(Cc1cc2c(CCN(C)C)c[nH]c2cc1)N1CCCC1		Inactive	5-HT1B Agonist		2	Almotriptan	170465288.0&384568150.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(Cc1cc2c(CCN(C)C)c[nH]c2cc1)N1CCCC1	S(=O)(=O)(Cc1cc2c(CCN(C)C)c[nH]c2cc1)N1CCCC1
NCGC00346535-02	S(=O)(=O)(N(C(=O)C)c1c(/C=C/c2cc[n+]([O-])cc2)cccc1)c1ccc(OC)cc1		Inactive	Polo-like Kinase-1 (Plk-1) Inhibitor		1	IVX-214	384568825.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N(C(=O)C)c1c(/C=C/c2cc[n+]([O-])cc2)cccc1)c1ccc(OC)cc1	S(=O)(=O)(N(C(=O)C)c1c(/C=C/c2cc[n+]([O-])cc2)cccc1)c1ccc(OC)cc1
NCGC00249884-01	S(=O)(=O)(N(C(=O)C)c1c(C)c(C)no1)c1ccc(N)cc1		Inactive	Bacterial dihydropteroate synthase Inhibitor		1	Sulfisoxazole acetal	170465159.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(N(C(=O)C)c1c(C)c(C)no1)c1ccc(N)cc1	S(=O)(=O)(N(C(=O)C)c1c(C)c(C)no1)c1ccc(N)cc1
NCGC00387725-02	S(=O)(=O)(N(C)C)N1CCN(c2ccc(OCc3n(C)nc(C)c3-c3c4n(CCN5CCOCC5)c(C(=O)O)c(CCCOc5c6c(ccc5)cccc6)c4ccc3)cc2)CC1		Inactive	Mcl-1 Inhibitor		1	A-1210477	363680650.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N(C)C)N1CCN(c2ccc(OCc3n(C)nc(C)c3-c3c4n(CCN5CCOCC5)c(C(=O)O)c(CCCOc5c6c(ccc5)cccc6)c4ccc3)cc2)CC1	S(=O)(=O)(N(C)C)N1CCN(c2ccc(OCc3n(C)nc(C)c3-c3c4n(CCN5CCOCC5)c(C(=O)O)c(CCCOc5c6c(ccc5)cccc6)c4ccc3)cc2)CC1
NCGC00483024-01	S(=O)(=O)(N(C)C)NC(=O)c1cc2n3c(c(C4CCCCC4)c2cc1)-c1c([C@H]2[C@@](C(=O)N4[C@H]5CN(C)C[C@@H]4CC5)(C3)C2)cc(OC)cc1		Inactive			1	BMS-791325 hydrochloride	377020421.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	9.4022471961	S(=O)(=O)(N(C)C)NC(=O)c1cc2n3c(c(C4CCCCC4)c2cc1)-c1c([C@H]2[C@@](C(=O)N4[C@H]5CN(C)C[C@@H]4CC5)(C3)C2)cc(OC)cc1	S(=O)(=O)(N(C)C)NC(=O)c1cc2n3c(c(C4CCCCC4)c2cc1)-c1c([C@H]2[C@@](C(=O)N4[C@H]5CN(C)C[C@@H]4CC5)(C3)C2)cc(OC)cc1
NCGC00370722-02	S(=O)(=O)(N(C)C)c1cc(C(=O)N2CCN(c3c(C)c(C)ccc3)CC2)c(N2CCCC2)cc1		Inactive			1	ML184	363677824.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N(C)C)c1cc(C(=O)N2CCN(c3c(C)c(C)ccc3)CC2)c(N2CCCC2)cc1	S(=O)(=O)(N(C)C)c1cc(C(=O)N2CCN(c3c(C)c(C)ccc3)CC2)c(N2CCCC2)cc1
NCGC00351072-01	S(=O)(=O)(N(C)C)c1cc(C(=O)Nc2sc(C)cn2)c(N2CCCC2)cc1	5.9000001	Active		0.0	1	ML414	406861855.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	1.3	82.0604625711	S(=O)(=O)(N(C)C)c1cc(C(=O)Nc2sc(C)cn2)c(N2CCCC2)cc1	S(=O)(=O)(N(C)C)c1cc(C(=O)Nc2sc(C)cn2)c(N2CCCC2)cc1
NCGC00015998-06	S(=O)(=O)(N(C)C)c1cc2/C(=C/CCN3CCN(C)CC3)/c3c(Sc2cc1)cccc3	4.9000001	Active	dopamine secretion Inhibitor	0.0	1	THIOTHIXENE	405558925.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	101.11960043	S(=O)(=O)(N(C)C)c1cc2/C(=C/CCN3CCN(C)CC3)/c3c(Sc2cc1)cccc3	S(=O)(=O)(N(C)C)c1cc2/C(=C/CCN3CCN(C)CC3)/c3c(Sc2cc1)cccc3
NCGC00015981-12	S(=O)(=O)(N(C)C)c1cc2/C(=C/c3[nH]c4c(c3)CCCC4)/C(=O)Nc2cc1		Inactive			1	SU6656		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N(C)C)c1cc2/C(=C/c3[nH]c4c(c3)CCCC4)/C(=O)Nc2cc1	S(=O)(=O)(N(C)C)c1cc2/C(=C/c3[nH]c4c(c3)CCCC4)/C(=O)Nc2cc1
NCGC00249414-01	S(=O)(=O)(N(C)C)c1cc2N(CC(N(C)C)C)c3c(Sc2cc1)cccc3	4.5500002	Active	Serotonin (5-HT) receptor Antagonist	0.0	1	Fonazine	144206752.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	103.7806715257	S(=O)(=O)(N(C)C)c1cc2N(CC(N(C)C)C)c3c(Sc2cc1)cccc3	S(=O)(=O)(N(C)C)c1cc2N(CC(N(C)C)C)c3c(Sc2cc1)cccc3
NCGC00182048-01	S(=O)(=O)(N(C)C)c1cc2N(CCCN3CCC(CCOC(=O)CCCCCCCCCCCCCCC)CC3)c3c(Sc2cc1)cccc3		Inactive	Dopamine D2 receptor Antagonist		1	Pipothiazine palmitate	144206970.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N(C)C)c1cc2N(CCCN3CCC(CCOC(=O)CCCCCCCCCCCCCCC)CC3)c3c(Sc2cc1)cccc3	S(=O)(=O)(N(C)C)c1cc2N(CCCN3CCC(CCOC(=O)CCCCCCCCCCCCCCC)CC3)c3c(Sc2cc1)cccc3
NCGC00179625-03	S(=O)(=O)(N(C)C)c1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3	4.9499998	Active	Serotonin 2a (5-HT2a) receptor Antagonist	0.0	1	Thioproperazine dimethanesulfonate	170465871.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	95.6807001815	S(=O)(=O)(O)C.S(=O)(=O)(O)C.S(=O)(=O)(N(C)C)c1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3	S(=O)(=O)(O)C.S(=O)(=O)(O)C.S(=O)(=O)(N(C)C)c1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3
NCGC00379167-01	S(=O)(=O)(N(C)C)c1ccc(NC(=S)N2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1	4.9499998	Active	Neuropeptide Y receptor type 2 Antagonist	0.0	1	CYM 9484	363678394.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	59.1965714271	S(=O)(=O)(N(C)C)c1ccc(NC(=S)N2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1	S(=O)(=O)(N(C)C)c1ccc(NC(=S)N2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
NCGC00160631-02	S(=O)(=O)(N(C)C)c1ccc(OP(=S)(OC)OC)cc1		Inactive	Trichostrongylus axei Inhibitor		1	Famphur	170466840.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(N(C)C)c1ccc(OP(=S)(OC)OC)cc1	S(=O)(=O)(N(C)C)c1ccc(OP(=S)(OC)OC)cc1
NCGC00344391-03&NCGC00344391-06	S(=O)(=O)(N(C)C1Cc2c3c(n(CC(=O)O)c2CC1)cccc3)c1ccc(F)cc1		Inactive	prostaglandin D2 CRTH2 inhibitor&G protein-coupled receptor 44 Antagonist		2	TM30089	363677332.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&12.0	S(=O)(=O)(N(C)C1Cc2c3c(n(CC(=O)O)c2CC1)cccc3)c1ccc(F)cc1	S(=O)(=O)(N(C)C1Cc2c3c(n(CC(=O)O)c2CC1)cccc3)c1ccc(F)cc1
NCGC00387222-01	S(=O)(=O)(N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2c1cc(OCCCC(F)(F)F)cc2)C		Inactive	Voltage-gated potassium channel beta subunit Mink Blocker		1	HMR 1556	363680577.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2c1cc(OCCCC(F)(F)F)cc2)C	S(=O)(=O)(N(C)[C@@H]1[C@@H](O)C(C)(C)Oc2c1cc(OCCCC(F)(F)F)cc2)C
NCGC00370948-06	S(=O)(=O)(N(C)c1c(CNc2c(C(F)(F)F)cnc(Nc3cc4c(NC(=O)C4)cc3)n2)cccc1)C		Inactive	Protein tyrosine kinase 2 beta Inhibitor		1	PF-431396	363677950.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	15.1999999959	S(=O)(=O)(N(C)c1c(CNc2c(C(F)(F)F)cnc(Nc3cc4c(NC(=O)C4)cc3)n2)cccc1)C	S(=O)(=O)(N(C)c1c(CNc2c(C(F)(F)F)cnc(Nc3cc4c(NC(=O)C4)cc3)n2)cccc1)C
NCGC00242495-18	S(=O)(=O)(N(C)c1c(CNc2c(C(F)(F)F)cnc(Nc3cc4c(NC(=O)C4)cc3)n2)cccn1)C		Inactive			1	PF-562271	377020400.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N(C)c1c(CNc2c(C(F)(F)F)cnc(Nc3cc4c(NC(=O)C4)cc3)n2)cccn1)C	S(=O)(=O)(N(C)c1c(CNc2c(C(F)(F)F)cnc(Nc3cc4c(NC(=O)C4)cc3)n2)cccn1)C
NCGC00386425-01	S(=O)(=O)(N(C)c1c(CNc2c(C(F)(F)F)cnc(Nc3ccc(C(=O)NC)cc3)n2)nccn1)C		Inactive	Focal Adhesion Kinase (FAK) Inhibitor		1	Defactinib	384569137.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N(C)c1c(CNc2c(C(F)(F)F)cnc(Nc3ccc(C(=O)NC)cc3)n2)nccn1)C	S(=O)(=O)(N(C)c1c(CNc2c(C(F)(F)F)cnc(Nc3ccc(C(=O)NC)cc3)n2)nccn1)C
NCGC00386495-01	S(=O)(=O)(N(C)c1cc(C(=O)N[C@H]([C@H](O)CNC2CC2)Cc2ccccc2)cc(C(=O)N[C@H](C)c2ccccc2)c1)C		Inactive	Beta-secretase 1 Inhibitor		1	BACE-1 Inhibitor	363680304.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N(C)c1cc(C(=O)N[C@H]([C@H](O)CNC2CC2)Cc2ccccc2)cc(C(=O)N[C@H](C)c2ccccc2)c1)C	S(=O)(=O)(N(C)c1cc(C(=O)N[C@H]([C@H](O)CNC2CC2)Cc2ccccc2)cc(C(=O)N[C@H](C)c2ccccc2)c1)C
NCGC00387187-01	S(=O)(=O)(N(C)c1ccc(NC(=O)Nc2ccccc2)cc1)c1cn(-c2ccc(F)cc2)nc1		Inactive	Integrin alpha2/beta1 Binding Agent		1	BTT 3033	363680562.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N(C)c1ccc(NC(=O)Nc2ccccc2)cc1)c1cn(-c2ccc(F)cc2)nc1	S(=O)(=O)(N(C)c1ccc(NC(=O)Nc2ccccc2)cc1)c1cn(-c2ccc(F)cc2)nc1
NCGC00095143-05&NCGC00095143-07	S(=O)(=O)(N(C)c1nc(C(C)C)c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)n1)C		Inactive			2	Rosuvastatin Calcium&Rosuvastatin calcium (Crestor)	434147258.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(N(C)c1nc(C(C)C)c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)n1)C	S(=O)(=O)(N(C)c1nc(C(C)C)c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)n1)C
NCGC00386678-02	S(=O)(=O)(N(CC(=O)N(CC)Cc1cnccc1)c1cnc(OC)cc1)c1c(C)cccc1		Inactive	Orexin receptor 2 Antagonist		1	EMPA	363680391.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N(CC(=O)N(CC)Cc1cnccc1)c1cnc(OC)cc1)c1c(C)cccc1	S(=O)(=O)(N(CC(=O)N(CC)Cc1cnccc1)c1cnc(OC)cc1)c1c(C)cccc1
NCGC00345808-01	S(=O)(=O)(N(CC(=O)N(Cc1ccc(C2CCCCC2)cc1)c1cc(O)c(C(=O)O)cc1)C)c1c(F)c(F)c(F)c(F)c1F		Inactive	STAT-3 Inhibitor		1	BP-1-102	174006728.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N(CC(=O)N(Cc1ccc(C2CCCCC2)cc1)c1cc(O)c(C(=O)O)cc1)C)c1c(F)c(F)c(F)c(F)c1F	S(=O)(=O)(N(CC(=O)N(Cc1ccc(C2CCCCC2)cc1)c1cc(O)c(C(=O)O)cc1)C)c1c(F)c(F)c(F)c(F)c1F
NCGC00386350-01	S(=O)(=O)(N(CC(=O)N(Cc1ccc(C2CCCCC2)cc1)c1ccc(C(=O)O)cc1)C)c1c(F)c(F)c(F)c(F)c1F		Inactive	Signal transducer and activator of transcription 3 Inhibitor		1	SH-4-54	363680229.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N(CC(=O)N(Cc1ccc(C2CCCCC2)cc1)c1ccc(C(=O)O)cc1)C)c1c(F)c(F)c(F)c(F)c1F	S(=O)(=O)(N(CC(=O)N(Cc1ccc(C2CCCCC2)cc1)c1ccc(C(=O)O)cc1)C)c1c(F)c(F)c(F)c(F)c1F
NCGC00508861-01	S(=O)(=O)(N(CC(C)C)c1ccc(CC)cc1)c1cc(CO)c(OCC2CCOCC2)cc1	4.9000001	Active	ROR-gamma Inverse Agonist	0.0	1	GSK-2981278	384569365.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	58.824219273	S(=O)(=O)(N(CC(C)C)c1ccc(CC)cc1)c1cc(CO)c(OCC2CCOCC2)cc1	S(=O)(=O)(N(CC(C)C)c1ccc(CC)cc1)c1cc(CO)c(OCC2CCOCC2)cc1
NCGC00159555-06	S(=O)(=O)(N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1ccccc1		Inactive	Nuclear receptor subfamily 1 group I member 3 Inverse Agonist		1	T0901317	363676596.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1ccccc1	S(=O)(=O)(N(CC(F)(F)F)c1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1ccccc1
NCGC00079434-04	S(=O)(=O)(N(CC(O)Cn1c2c(c3c1cccc3)cccc2)Cc1occc1)C		Inactive	Cryptochrome Activator		1	KL001	384568075.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	16.5	S(=O)(=O)(N(CC(O)Cn1c2c(c3c1cccc3)cccc2)Cc1occc1)C	S(=O)(=O)(N(CC(O)Cn1c2c(c3c1cccc3)cccc2)Cc1occc1)C
NCGC00507860-01	S(=O)(=O)(N(CC)C)Nc1c(F)c(C(=O)c2c3c([nH]c2)ncc(-c2cnc(C4CC4)nc2)c3)c(F)cc1		Inactive	Raf kinase B Inhibitor		1	PLX-7904	384569336.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	29.5	S(=O)(=O)(N(CC)C)Nc1c(F)c(C(=O)c2c3c([nH]c2)ncc(-c2cnc(C4CC4)nc2)c3)c(F)cc1	S(=O)(=O)(N(CC)C)Nc1c(F)c(C(=O)c2c3c([nH]c2)ncc(-c2cnc(C4CC4)nc2)c3)c(F)cc1
NCGC00522534-01	S(=O)(=O)(N(CC)CC)N[C@@H]1CN(CCC)[C@H]2[C@H](C1)Cc1c(O)cccc1C2		Inactive			1	Quinagolide (hydrochloride)	405558466.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N(CC)CC)N[C@@H]1CN(CCC)[C@H]2[C@H](C1)Cc1c(O)cccc1C2	S(=O)(=O)(N(CC)CC)N[C@@H]1CN(CCC)[C@H]2[C@H](C1)Cc1c(O)cccc1C2
NCGC00408822-01	S(=O)(=O)(N(CC)CC)c1cc(NC(=O)c2c(CC)c(C(=O)C)c(C)[nH]2)c(O)cc1		Inactive			1	XD14		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N(CC)CC)c1cc(NC(=O)c2c(CC)c(C(=O)C)c(C)[nH]2)c(O)cc1	S(=O)(=O)(N(CC)CC)c1cc(NC(=O)c2c(CC)c(C(=O)C)c(C)[nH]2)c(O)cc1
NCGC00016251-13&NCGC00016251-17	S(=O)(=O)(N(CCC)CCC)c1ccc(C(=O)O)cc1		Inactive	Solute carrier family 22 member 8 Inhibitor		2	Probenecid	170464839.0&434146952.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(N(CCC)CCC)c1ccc(C(=O)O)cc1	S(=O)(=O)(N(CCC)CCC)c1ccc(C(=O)O)cc1
NCGC00346463-01	S(=O)(=O)(N(CCO)c1c(C2CC2)cc2c(C(=O)NC)c(-c3ccc(F)cc3)oc2c1)C		Inactive	RNA-Directed RNA Polymerase Inhibitor		1	Nesbuvir	174007343.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(N(CCO)c1c(C2CC2)cc2c(C(=O)NC)c(-c3ccc(F)cc3)oc2c1)C	S(=O)(=O)(N(CCO)c1c(C2CC2)cc2c(C(=O)NC)c(-c3ccc(F)cc3)oc2c1)C
NCGC00159461-07&NCGC00159461-08	S(=O)(=O)(N(C[C@@H](O)[C@@H](NC(=O)O[C@@H]1COCC1)Cc1ccccc1)CC(C)C)c1ccc(N)cc1		Inactive	HIV Protease Inhibitors		2	Amprenavir	405558958.0&434147006.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(N(C[C@@H](O)[C@@H](NC(=O)O[C@@H]1COCC1)Cc1ccccc1)CC(C)C)c1ccc(N)cc1	S(=O)(=O)(N(C[C@@H](O)[C@@H](NC(=O)O[C@@H]1COCC1)Cc1ccccc1)CC(C)C)c1ccc(N)cc1
NCGC00388284-07&NCGC00388284-12	S(=O)(=O)(N(C[C@@H](O)[C@@H](NC(=O)O[C@@H]1[C@H]2[C@@H](OC1)OCC2)Cc1ccccc1)CC(C)C)c1ccc(N)cc1		Inactive	Hiv Protease Inhibitors		2	Darunavir (Ethanolate)&Darunavir	405558659.0&434147220.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(N(C[C@@H](O)[C@@H](NC(=O)O[C@@H]1[C@H]2[C@@H](OC1)OCC2)Cc1ccccc1)CC(C)C)c1ccc(N)cc1	S(=O)(=O)(N(C[C@@H](O)[C@@H](NC(=O)O[C@@H]1[C@H]2[C@@H](OC1)OCC2)Cc1ccccc1)CC(C)C)c1ccc(N)cc1
NCGC00522434-01	S(=O)(=O)(N(C[C@@H](O)[C@@H](NC(=O)[C@@H](NC(=O)CNCc1cc(F)ccc1)C(C)(C)C)Cc1ccccc1)CC(C)C)c1cc(N)ccc1		Inactive			1	DPC-681	434147172.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	-13.87977528	S(=O)(=O)(N(C[C@@H](O)[C@@H](NC(=O)[C@@H](NC(=O)CNCc1cc(F)ccc1)C(C)(C)C)Cc1ccccc1)CC(C)C)c1cc(N)ccc1	S(=O)(=O)(N(C[C@@H](O)[C@@H](NC(=O)[C@@H](NC(=O)CNCc1cc(F)ccc1)C(C)(C)C)Cc1ccccc1)CC(C)C)c1cc(N)ccc1
NCGC00168771-03&NCGC00168771-04	S(=O)(=O)(N(C[C@@H](OP(=O)([O-])[O-])[C@@H](NC(=O)O[C@H]1COCC1)Cc1ccccc1)CC(C)C)c1ccc(N)cc1		Inactive			2	Fosamprenavir (Calcium Salt)&Fosamprenavir Calcium Salt	434147204.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(N(C[C@@H](OP(=O)([O-])[O-])[C@@H](NC(=O)O[C@H]1COCC1)Cc1ccccc1)CC(C)C)c1ccc(N)cc1	S(=O)(=O)(N(C[C@@H](OP(=O)([O-])[O-])[C@@H](NC(=O)O[C@H]1COCC1)Cc1ccccc1)CC(C)C)c1ccc(N)cc1
NCGC00386685-01	S(=O)(=O)(N(C[C@H](O)CN1C2CC(NC(=O)C=3C(=O)N(C(C)C)c4c(cccc4)C=3)CC1CC2)C)C		Inactive	5-hydroxytryptamine receptor 4 Agonist		1	TD 5108	363680396.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N(C[C@H](O)CN1C2CC(NC(=O)C=3C(=O)N(C(C)C)c4c(cccc4)C=3)CC1CC2)C)C	S(=O)(=O)(N(C[C@H](O)CN1C2CC(NC(=O)C=3C(=O)N(C(C)C)c4c(cccc4)C=3)CC1CC2)C)C
NCGC00346695-02	S(=O)(=O)(N(C[C@H]1OCCOC1)C)Nc1cc2C(=O)c3c(ncc(-c4cn(C)nc4)c3)C=Cc2cc1		Inactive	VEGFR-1 (Flt-1) Inhibitors		1	MK-2461	363677522.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N(C[C@H]1OCCOC1)C)Nc1cc2C(=O)c3c(ncc(-c4cn(C)nc4)c3)C=Cc2cc1	S(=O)(=O)(N(C[C@H]1OCCOC1)C)Nc1cc2C(=O)c3c(ncc(-c4cn(C)nc4)c3)C=Cc2cc1
NCGC00504898-01	S(=O)(=O)(N(Cc1cc(N2CCN(C(c3ccccc3)c3ccccc3)CC2)ccc1)C)C		Inactive			1	NCGC00504898-01		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N(Cc1cc(N2CCN(C(c3ccccc3)c3ccccc3)CC2)ccc1)C)C	S(=O)(=O)(N(Cc1cc(N2CCN(C(c3ccccc3)c3ccccc3)CC2)ccc1)C)C
NCGC00370754-01	S(=O)(=O)(N(Cc1cnccc1)c1cc(-c2ccc(C#N)cc2)ccc1)CC		Inactive			1	CBiPES hydrochloride	363677836.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N(Cc1cnccc1)c1cc(-c2ccc(C#N)cc2)ccc1)CC	S(=O)(=O)(N(Cc1cnccc1)c1cc(-c2ccc(C#N)cc2)ccc1)CC
NCGC00378807-01	S(=O)(=O)(N(Cc1cnccc1)c1ccc(Oc2c(OC)cccc2)cc1)CC(F)(F)F		Inactive	Metabotropic glutamate receptor 2 Positive Allosteric Modulator		1	LY 487379 hydrochloride	363678211.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N(Cc1cnccc1)c1ccc(Oc2c(OC)cccc2)cc1)CC(F)(F)F	S(=O)(=O)(N(Cc1cnccc1)c1ccc(Oc2c(OC)cccc2)cc1)CC(F)(F)F
NCGC00386762-01	S(=O)(=O)(N(Cc1oc(C(F)(F)F)cc1)Cc1ccc(-c2cc(S(=O)(=O)C)ccc2)cc1)c1c(C)cc(C)cc1C		Inactive	Oxysterols receptor LXR-beta Inverse Agonist		1	GSK 2033	363680439.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N(Cc1oc(C(F)(F)F)cc1)Cc1ccc(-c2cc(S(=O)(=O)C)ccc2)cc1)c1c(C)cc(C)cc1C	S(=O)(=O)(N(Cc1oc(C(F)(F)F)cc1)Cc1ccc(-c2cc(S(=O)(=O)C)ccc2)cc1)c1c(C)cc(C)cc1C
NCGC00162358-05	S(=O)(=O)(N)C#Cc1ccccc1		Inactive			1	Pifithrin-¦Ì		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N)C#Cc1ccccc1	S(=O)(=O)(N)C#Cc1ccccc1
NCGC00016508-03&NCGC00016508-04	S(=O)(=O)(N)C=1S/C(=N/C(=O)C)/N(C)N=1		Inactive	Carbonic anhydrase XII Inhibitor		2	Methazolamide	434146955.0&405558554.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(N)C=1S/C(=N/C(=O)C)/N(C)N=1	S(=O)(=O)(N)C=1S/C(=N/C(=O)C)/N(C)N=1
NCGC00159319-04	S(=O)(=O)(N)Cc1noc2c1cccc2		Inactive	Na channel blocker, T-type Ca channel blocker		1	Zonisamide	174006630.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(N)Cc1noc2c1cccc2	S(=O)(=O)(N)Cc1noc2c1cccc2
NCGC00183012-01	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NC(CCCCC)NS(=O)(=O)c2c1		Inactive	Thiazide-sensitive sodium-chloride cotransporter Inhibitor		1	Penflutizide	144206843.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NC(CCCCC)NS(=O)(=O)c2c1	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NC(CCCCC)NS(=O)(=O)c2c1
NCGC00018194-08	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NC(Cc3ccccc3)NS(=O)(=O)c2c1		Inactive	Thiazide-sensitive sodium-chloride cotransporter Inhibitor		1	Bendroflumethiazide	170465156.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NC(Cc3ccccc3)NS(=O)(=O)c2c1	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NC(Cc3ccccc3)NS(=O)(=O)c2c1
NCGC00016401-09	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NCNS(=O)(=O)c2c1		Inactive	Thiazide-sensitive sodium-chloride cotransporter Inhibitor		1	Hydroflumethiazide	170465082.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NCNS(=O)(=O)c2c1	S(=O)(=O)(N)c1c(C(F)(F)F)cc2NCNS(=O)(=O)c2c1
NCGC00016561-05	S(=O)(=O)(N)c1c(C)cc2c(S(=O)(=O)CCC2)c1		Inactive	Translocator protein Inhibitor		1	Meticrane	170465801.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N)c1c(C)cc2c(S(=O)(=O)CCC2)c1	S(=O)(=O)(N)c1c(C)cc2c(S(=O)(=O)CCC2)c1
NCGC00378984-02	S(=O)(=O)(N)c1c(C)nc(N(C(=O)Cc2ccc(-c3ncccc3)cc2)C)s1		Inactive			1	Pritelivir (BAY 57-1293)	434147110.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N)c1c(C)nc(N(C(=O)Cc2ccc(-c3ncccc3)cc2)C)s1	S(=O)(=O)(N)c1c(C)nc(N(C(=O)Cc2ccc(-c3ncccc3)cc2)C)s1
NCGC00249925-01	S(=O)(=O)(N)c1c(F)cc(-c2c(C3CCCCC3)nc(C)o2)cc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Tilmacoxib	170466033.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(N)c1c(F)cc(-c2c(C3CCCCC3)nc(C)o2)cc1	S(=O)(=O)(N)c1c(F)cc(-c2c(C3CCCCC3)nc(C)o2)cc1
NCGC00167442-03	S(=O)(=O)(N)c1c(OC)ccc(C[C@H](NCCOc2c(OCC)cccc2)C)c1		Inactive	alpha1-Adrenoceptor Antagonists		1	Tamsulosin hydrochloride	170464826.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N)c1c(OC)ccc(C[C@H](NCCOc2c(OCC)cccc2)C)c1.Cl	S(=O)(=O)(N)c1c(OC)ccc(C[C@H](NCCOc2c(OCC)cccc2)C)c1.Cl
NCGC00016878-04	S(=O)(=O)(N)c1c(Oc2ccccc2)c(N2CCCC2)cc(C(=O)O)c1		Inactive	Cystic fibrosis transmembrane conductance regulator Antagonist		1	Piretanide	170465869.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(N)c1c(Oc2ccccc2)c(N2CCCC2)cc(C(=O)O)c1	S(=O)(=O)(N)c1c(Oc2ccccc2)c(N2CCCC2)cc(C(=O)O)c1
NCGC00015149-16&NCGC00015149-25	S(=O)(=O)(N)c1c(Oc2ccccc2)c(NCCCC)cc(C(=O)O)c1		Inactive	Loop Diuretics		2	Bumetanide	170464735.0&384567815.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(N)c1c(Oc2ccccc2)c(NCCCC)cc(C(=O)O)c1	S(=O)(=O)(N)c1c(Oc2ccccc2)c(NCCCC)cc(C(=O)O)c1
NCGC00345811-02	S(=O)(=O)(N)c1c2C(=O)c3c(c(O)ccc3)C(=O)c2ccc1		Inactive	STAT-3 Inhibitor		1	LLL-12	384568755.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		S(=O)(=O)(N)c1c2C(=O)c3c(c(O)ccc3)C(=O)c2ccc1	S(=O)(=O)(N)c1c2C(=O)c3c(c(O)ccc3)C(=O)c2ccc1
NCGC00015966-10	S(=O)(=O)(N)c1cc(C(=O)NC[C@H]2N(CC)CCC2)c(OC)cc1		Inactive	Dopamine D2 Antagonist		1	Levosulpiride	170465834.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N)c1cc(C(=O)NC[C@H]2N(CC)CCC2)c(OC)cc1	S(=O)(=O)(N)c1cc(C(=O)NC[C@H]2N(CC)CCC2)c(OC)cc1
NCGC00242167-02	S(=O)(=O)(N)c1cc(N/C=C/2\C(=O)Nc3c\2cccc3)ccc1		Inactive			1	NCGC00242167-02	377020516.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N)c1cc(N/C=C/2\C(=O)Nc3c\2cccc3)ccc1	S(=O)(=O)(N)c1cc(N/C=C/2\C(=O)Nc3c\2cccc3)ccc1
NCGC00242042-02	S(=O)(=O)(N)c1cc(Nc2nc(N(C)c3ccc(NC(=O)Nc4ccc(OC(F)(F)F)cc4)cc3)ccn2)ccc1		Inactive			1	GW806742X	377020316.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N)c1cc(Nc2nc(N(C)c3ccc(NC(=O)Nc4ccc(OC(F)(F)F)cc4)cc3)ccn2)ccc1	S(=O)(=O)(N)c1cc(Nc2nc(N(C)c3ccc(NC(=O)Nc4ccc(OC(F)(F)F)cc4)cc3)ccn2)ccc1
NCGC00402377-02	S(=O)(=O)(N)c1cc(c(O)cc1)-c1c(O)c(-c2[nH]c3c(n2)cc(C(=N)N)cc3)cc(CC(=O)N[C@H](C(=O)O)CC(=O)O)c1		Inactive	Coagulation Factor VIIa Inhibitor		1	PCI-27483	384569219.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N)c1cc(c(O)cc1)-c1c(O)c(-c2[nH]c3c(n2)cc(C(=N)N)cc3)cc(CC(=O)N[C@H](C(=O)O)CC(=O)O)c1	S(=O)(=O)(N)c1cc(c(O)cc1)-c1c(O)c(-c2[nH]c3c(n2)cc(C(=N)N)cc3)cc(CC(=O)N[C@H](C(=O)O)CC(=O)O)c1
NCGC00095129-06&NCGC00095129-15	S(=O)(=O)(N)c1ccc(-c2c(C)onc2-c2ccccc2)cc1		Inactive	Cyclooxygenase-2 Inhibitor		2	Valdecoxib	170465163.0&384568148.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(N)c1ccc(-c2c(C)onc2-c2ccccc2)cc1	S(=O)(=O)(N)c1ccc(-c2c(C)onc2-c2ccccc2)cc1
NCGC00485044-01	S(=O)(=O)(N)c1ccc(-n2c(-c3c(C)ccc(C)c3)cc(C(F)(F)F)n2)cc1	4.9000001	Active	Wnt signaling pathway Inhibitor	0.0	1	2,5-Dimethyl-celecoxib	363681203.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	3.0	52.7946934689	S(=O)(=O)(N)c1ccc(-n2c(-c3c(C)ccc(C)c3)cc(C(F)(F)F)n2)cc1	S(=O)(=O)(N)c1ccc(-n2c(-c3c(C)ccc(C)c3)cc(C(F)(F)F)n2)cc1
NCGC00095312-04	S(=O)(=O)(N)c1ccc(-n2c(-c3cc(F)c(OC)cc3)cc(C(F)F)n2)cc1		Inactive	Prostaglandin G/H synthase 2 Inhibitor		1	Deracoxib	170465679.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(N)c1ccc(-n2c(-c3cc(F)c(OC)cc3)cc(C(F)F)n2)cc1	S(=O)(=O)(N)c1ccc(-n2c(-c3cc(F)c(OC)cc3)cc(C(F)F)n2)cc1
NCGC00091455-09&NCGC00091455-13	S(=O)(=O)(N)c1ccc(-n2c(-c3ccc(C)cc3)cc(C(F)(F)F)n2)cc1	4.95000005	Active	Cyclooxygenase-2 Inhibitor	0.09999990000000025	2	Celecoxib	170464693.0&363676552.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	3.0&3.0	71.4170672538&71.2283964703	S(=O)(=O)(N)c1ccc(-n2c(-c3ccc(C)cc3)cc(C(F)(F)F)n2)cc1	S(=O)(=O)(N)c1ccc(-n2c(-c3ccc(C)cc3)cc(C(F)(F)F)n2)cc1
NCGC00510931-01	S(=O)(=O)(N)c1ccc(-n2c(-c3ccc(F)cc3)cc(C(F)(F)F)n2)cc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Mavacoxib	405558811.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N)c1ccc(-n2c(-c3ccc(F)cc3)cc(C(F)(F)F)n2)cc1	S(=O)(=O)(N)c1ccc(-n2c(-c3ccc(F)cc3)cc(C(F)(F)F)n2)cc1
NCGC00016403-06&NCGC00016403-11	S(=O)(=O)(N)c1ccc(CN)cc1		Inactive	Carbonic anhydrase II Inhibitor		2	Mafenide hydrochloride&Mafenide (Acetate)	170465055.0&434147229.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(N)c1ccc(CN)cc1.Cl	S(=O)(=O)(N)c1ccc(CN)cc1.Cl&S(=O)(=O)(N)c1ccc(CN)cc1
NCGC00379067-01	S(=O)(=O)(N)c1ccc(CNC2=Nn3c(-c4cc(OC)c(OC)cc4)cnc3C=C2)cc1		Inactive	Interleukin-1 receptor-associated kinase 4 Inhibitor		1	IRAK inhibitor 3	363678336.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N)c1ccc(CNC2=Nn3c(-c4cc(OC)c(OC)cc4)cnc3C=C2)cc1	S(=O)(=O)(N)c1ccc(CNC2=Nn3c(-c4cc(OC)c(OC)cc4)cnc3C=C2)cc1
NCGC00372530-03	S(=O)(=O)(N)c1ccc(Cc2c(CC3CC3)n(-c3scc(C(=O)O)n3)nc2-c2cc(-c3ccccc3)ccc2)cc1		Inactive	LDHA Inhibitor		1	NCGC00372530	384569044.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N)c1ccc(Cc2c(CC3CC3)n(-c3scc(C(=O)O)n3)nc2-c2cc(-c3ccccc3)ccc2)cc1	S(=O)(=O)(N)c1ccc(Cc2c(CC3CC3)n(-c3scc(C(=O)O)n3)nc2-c2cc(-c3ccccc3)ccc2)cc1
NCGC00016285-05&NCGC00016285-09	S(=O)(=O)(N)c1ccc(N)cc1		Inactive	Carbonic Anhydrase Type I/II/IX Inhibitor		2	Sulfanilamide	170464653.0&384567929.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(N)c1ccc(N)cc1	S(=O)(=O)(N)c1ccc(N)cc1
NCGC00263209-09	S(=O)(=O)(N)c1ccc(N2C(c3ccc(OC)cc3)CC(c3ccccc3)=N2)cc1	4.9499998	Active	Cdc42 GTPase Inhibitor	0.0	1	ML-141	363677266.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	92.2371916726	S(=O)(=O)(N)c1ccc(N2C(c3ccc(OC)cc3)CC(c3ccccc3)=N2)cc1	S(=O)(=O)(N)c1ccc(N2C(c3ccc(OC)cc3)CC(c3ccccc3)=N2)cc1
NCGC00388162-02	S(=O)(=O)(N)c1ccc(N2C(c3ccccc3)CC(c3ccccc3)=N2)cc1		Inactive	Cell division control protein 42 homolog Inhibitor		1	MLS-573151	363680725.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	21.48923746	S(=O)(=O)(N)c1ccc(N2C(c3ccccc3)CC(c3ccccc3)=N2)cc1	S(=O)(=O)(N)c1ccc(N2C(c3ccccc3)CC(c3ccccc3)=N2)cc1
NCGC00370775-02	S(=O)(=O)(N)c1ccc(N2CCN(CC[C@@H]3OCCc4c3cccc4)CC2)cc1		Inactive	Dopamine D4 receptor Antagonist		1	Sonepiprazole hydrochloride	363677848.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N)c1ccc(N2CCN(CC[C@@H]3OCCc4c3cccc4)CC2)cc1	S(=O)(=O)(N)c1ccc(N2CCN(CC[C@@H]3OCCc4c3cccc4)CC2)cc1
NCGC00249907-01	S(=O)(=O)(N)c1ccc(N2S(=O)(=O)CCCC2)cc1		Inactive	Carbonic anhydrase XII Inhibitor		1	Sulthiame	170465788.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&-10.643025344	S(=O)(=O)(N)c1ccc(N2S(=O)(=O)CCCC2)cc1	S(=O)(=O)(N)c1ccc(N2S(=O)(=O)CCCC2)cc1
NCGC00379154-03	S(=O)(=O)(N)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1		Inactive	Carbonic anhydrase XII Inhibitor		1	U-104	363678388.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1	S(=O)(=O)(N)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1
NCGC00509913-01	S(=O)(=O)(N)c1ccc(NC(=S)N2CCN(C/C=C/c3ccccc3)CC2)cc1		Inactive	Antagonist of the beta-Catenin/TCF4 interaction		1	LF3	384569379.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N)c1ccc(NC(=S)N2CCN(C/C=C/c3ccccc3)CC2)cc1	S(=O)(=O)(N)c1ccc(NC(=S)N2CCN(C/C=C/c3ccccc3)CC2)cc1
NCGC00347067-04	S(=O)(=O)(N)c1ccc(NC=2C(=O)c3c(C(=O)C=2)cccc3)cc1		Inactive	microphthalmia-associated transcription factor (MITF) Inhibitor		1	KUC111774N	384568982.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N)c1ccc(NC=2C(=O)c3c(C(=O)C=2)cccc3)cc1	S(=O)(=O)(N)c1ccc(NC=2C(=O)c3c(C(=O)C=2)cccc3)cc1
NCGC00387780-01	S(=O)(=O)(N)c1ccc(Nc2n(C(=S)Nc3c(F)cccc3F)nc(N)n2)cc1		Inactive	Cyclin-dependent kinase 2/cyclin A Inhibitor		1	Cdk1/2 inhibitor III	363680665.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	16.159734668	S(=O)(=O)(N)c1ccc(Nc2n(C(=S)Nc3c(F)cccc3F)nc(N)n2)cc1	S(=O)(=O)(N)c1ccc(Nc2n(C(=S)Nc3c(F)cccc3F)nc(N)n2)cc1
NCGC00346950-03	S(=O)(=O)(N)c1ccc(Nc2nc(OCC3CCCCC3)c3[nH]cnc3n2)cc1		Inactive	CDK1/2 Inhibitor		1	NU-6102	363677566.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N)c1ccc(Nc2nc(OCC3CCCCC3)c3[nH]cnc3n2)cc1	S(=O)(=O)(N)c1ccc(Nc2nc(OCC3CCCCC3)c3[nH]cnc3n2)cc1
NCGC00499183-01	S(=O)(=O)(N)c1ccc(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)scc4)cc1		Inactive	MST1/2		1	XMU-MP-1	363681481.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N)c1ccc(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)scc4)cc1	S(=O)(=O)(N)c1ccc(Nc2nc3N(C)c4c(C(=O)N(C)c3cn2)scc4)cc1
NCGC00263151-07	S(=O)(=O)(N)c1ccc(Nc2nn(C(=O)c3c(F)cccc3F)c(N)n2)cc1	4.9000001	Active	Aurora Kinase Inhibitor	0.0	1	JNJ-7706621	384568625.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	37.7163964209	S(=O)(=O)(N)c1ccc(Nc2nn(C(=O)c3c(F)cccc3F)c(N)n2)cc1	S(=O)(=O)(N)c1ccc(Nc2nn(C(=O)c3c(F)cccc3F)c(N)n2)cc1
NCGC00182551-01	S(=O)(=O)(N)c1ccc(OP(=S)(OC)OC)cc1		Inactive	Acetylcholinesterase and butyrylcholinesterase (AChE and BChE) Inhibitor		1	Cythioate	144206631.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N)c1ccc(OP(=S)(OC)OC)cc1	S(=O)(=O)(N)c1ccc(OP(=S)(OC)OC)cc1
NCGC00015074-14&NCGC00015074-17	S(=O)(=O)(N)c1sc(NC(=O)C)nn1		Inactive	Carbonic anhydrase XII Inhibitor		2	Acetazolamide&ACETAZOLAMIDE	170464692.0&434146941.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(N)c1sc(NC(=O)C)nn1	S(=O)(=O)(N)c1sc(NC(=O)C)nn1
NCGC00179542-03&NCGC00179542-09	S(=O)(=O)(N)c1sc2S(=O)(=O)N(CCCOC)C[C@H](NCC)c2c1		Inactive	Carbonic anhydrase II Inhibitor		2	Brinzolamide	170464926.0&434146887.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(N)c1sc2S(=O)(=O)N(CCCOC)C[C@H](NCC)c2c1	S(=O)(=O)(N)c1sc2S(=O)(=O)N(CCCOC)C[C@H](NCC)c2c1
NCGC00179244-03&NCGC00179244-11	S(=O)(=O)(N)c1sc2S(=O)(=O)[C@@H](C)C[C@H](NCC)c2c1		Inactive	Carbonic Anhydrase Type II Inhibitor		2	Dorzolamide hydrochloride	170465119.0&384568369.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	S(=O)(=O)(N)c1sc2S(=O)(=O)[C@@H](C)C[C@H](NCC)c2c1.Cl	S(=O)(=O)(N)c1sc2S(=O)(=O)[C@@H](C)C[C@H](NCC)c2c1.Cl&S(=O)(=O)(N)c1sc2S(=O)(=O)[C@@H](C)C[C@H](NCC)c2c1
NCGC00018249-05	S(=O)(=O)(N)c1sc2c(n1)ccc(OCC)c2		Inactive	Carbonic anhydrase Inhibitor		1	Ethoxzolamide	170465083.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(N)c1sc2c(n1)ccc(OCC)c2	S(=O)(=O)(N)c1sc2c(n1)ccc(OCC)c2
NCGC00390447-01	S(=O)(=O)(N1C(C)CCCC1)c1ccc(N2C(=O)CCC2)cc1		Inactive	Aldo-keto-reductase family 1 member C3 Inhibitor		1	AKR1C3InhibitorII	363680896.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1C(C)CCCC1)c1ccc(N2C(=O)CCC2)cc1	S(=O)(=O)(N1C(C)CCCC1)c1ccc(N2C(=O)CCC2)cc1
NCGC00485940-01	S(=O)(=O)(N1CCC2(OCC(=O)N(C3CC3)C2)CC1)c1ccc(-c2cc3ncccc3cc2)cc1	5.0	Active	Fatty acid synthase  Inhibitor	0.0	1	FAS-IN-1	363681431.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	2.4	68.5036597902	S(=O)(=O)(N1CCC2(OCC(=O)N(C3CC3)C2)CC1)c1ccc(-c2cc3ncccc3cc2)cc1	S(=O)(=O)(N1CCC2(OCC(=O)N(C3CC3)C2)CC1)c1ccc(-c2cc3ncccc3cc2)cc1
NCGC00485089-01	S(=O)(=O)(N1CCCC1)c1c(-c2ccc(CNCC(C)C)cc2)cccc1		Inactive	Kappa opioid receptor Antagonist		1	PF-04455242 hydrochloride	363681218.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1CCCC1)c1c(-c2ccc(CNCC(C)C)cc2)cccc1	S(=O)(=O)(N1CCCC1)c1c(-c2ccc(CNCC(C)C)cc2)cccc1
NCGC00344077-02	S(=O)(=O)(N1CCCCC1)c1oc(C)c(NC(=O)Nc2ccccc2)c1		Inactive	Endothelial lipase Inhibitor		1	GSK 264220A	363677324.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1CCCCC1)c1oc(C)c(NC(=O)Nc2ccccc2)c1	S(=O)(=O)(N1CCCCC1)c1oc(C)c(NC(=O)Nc2ccccc2)c1
NCGC00386869-01	S(=O)(=O)(N1CCCCCC1)c1c2c(c(OCC)cc1)cccc2		Inactive			1	NCGC00386869-01	363680475.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1CCCCCC1)c1c2c(c(OCC)cc1)cccc2	S(=O)(=O)(N1CCCCCC1)c1c2c(c(OCC)cc1)cccc2
NCGC00386739-01	S(=O)(=O)(N1CCCCCC1)c1cc(C(=O)Nc2cc([N+](=O)[O-])ccc2)ccc1		Inactive	NAD-dependent deacetylase sirtuin 2 Inhibitor		1	AK 1	363680427.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1CCCCCC1)c1cc(C(=O)Nc2cc([N+](=O)[O-])ccc2)ccc1	S(=O)(=O)(N1CCCCCC1)c1cc(C(=O)Nc2cc([N+](=O)[O-])ccc2)ccc1
NCGC00095099-05&NCGC00095099-11	S(=O)(=O)(N1CCN(C)CC1)c1cc(c(OCC)cc1)C1=Nc2c(CCC)nn(C)c2C(=O)N1		Inactive	Phosphodiesterase V (PDE5) Inhibitor		2	Sildenafil citrate	170465285.0&384568144.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(N1CCN(C)CC1)c1cc(c(OCC)cc1)C1=Nc2c(CCC)nn(C)c2C(=O)N1.O=C(O)C(O)(CC(=O)O)CC(=O)O	S(=O)(=O)(N1CCN(C)CC1)c1cc(c(OCC)cc1)C1=Nc2c(CCC)nn(C)c2C(=O)N1.O=C(O)C(O)(CC(=O)O)CC(=O)O&S(=O)(=O)(N1CCN(C)CC1)c1cc(c(OCC)cc1)C1=Nc2c(CCC)nn(C)c2C(=O)N1
NCGC00167533-02&NCGC00167533-04	S(=O)(=O)(N1CCN(CC)CC1)c1cc(c(OCC)cc1)C1=NC(=O)c2c(C)nc(CCC)n2N1		Inactive	Phosphodiesterase V (PDE5) Inhibitor		2	Vardenafil	170465607.0&384568328.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(N1CCN(CC)CC1)c1cc(c(OCC)cc1)C1=NC(=O)c2c(C)nc(CCC)n2N1.O=C(O)C(O)(CC(=O)O)CC(=O)O	S(=O)(=O)(N1CCN(CC)CC1)c1cc(c(OCC)cc1)C1=NC(=O)c2c(C)nc(CCC)n2N1.O=C(O)C(O)(CC(=O)O)CC(=O)O&S(=O)(=O)(N1CCN(CC)CC1)c1cc(c(OCC)cc1)C1=NC(=O)c2c(C)nc(CCC)n2N1
NCGC00386722-01	S(=O)(=O)(N1CCN(CC)CC1)c1cc(c(OCC)nc1)C1=Nc2c(CC)n(CCOC)nc2C(=O)N1		Inactive	Cytochrome P450 3A4 Substrate		1	Gisadenafil besylate	363680417.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1CCN(CC)CC1)c1cc(c(OCC)nc1)C1=Nc2c(CC)n(CCOC)nc2C(=O)N1	S(=O)(=O)(N1CCN(CC)CC1)c1cc(c(OCC)nc1)C1=Nc2c(CC)n(CCOC)nc2C(=O)N1
NCGC00378703-02	S(=O)(=O)(N1CCN(CCO)CC1)c1cc(c(OCCC)cc1)C1=Nc2c(CCC)cn(CC)c2C(=O)N1		Inactive	Phosphodiesterase 5A Inhibitor		1	Mirodenafil (dihydrochloride)	363678157.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1CCN(CCO)CC1)c1cc(c(OCCC)cc1)C1=Nc2c(CCC)cn(CC)c2C(=O)N1	S(=O)(=O)(N1CCN(CCO)CC1)c1cc(c(OCCC)cc1)C1=Nc2c(CCC)cn(CC)c2C(=O)N1
NCGC00185916-05	S(=O)(=O)(N1CCN(S(=O)(=O)c2cc3OCCOc3cc2)CCC1)c1cc(N)ccc1		Inactive	PKM2 Activator		1	DASA-58	384568429.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N1CCN(S(=O)(=O)c2cc3OCCOc3cc2)CCC1)c1cc(N)ccc1	S(=O)(=O)(N1CCN(S(=O)(=O)c2cc3OCCOc3cc2)CCC1)c1cc(N)ccc1
NCGC00386862-01	S(=O)(=O)(N1CCN(c2c(C)cc(C)cc2)CC1)N1CCCCC1		Inactive			1	NCGC00386862-01	363680471.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1CCN(c2c(C)cc(C)cc2)CC1)N1CCCCC1	S(=O)(=O)(N1CCN(c2c(C)cc(C)cc2)CC1)N1CCCCC1
NCGC00390704-02	S(=O)(=O)(N1CCNCCC1)c1c2c(C(=O)NC=C2)ccc1		Inactive			1	Hydroxyfasudil (hydrochloride)	377020365.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1CCNCCC1)c1c2c(C(=O)NC=C2)ccc1	S(=O)(=O)(N1CCNCCC1)c1c2c(C(=O)NC=C2)ccc1
NCGC00018100-08&NCGC00018100-16	S(=O)(=O)(N1CCNCCC1)c1c2c(cncc2)ccc1		Inactive	ROCK Inhibitor		2	Fasudil hydrochloride	170466011.0&384567990.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	S(=O)(=O)(N1CCNCCC1)c1c2c(cncc2)ccc1.Cl	S(=O)(=O)(N1CCNCCC1)c1c2c(cncc2)ccc1.Cl&S(=O)(=O)(N1CCNCCC1)c1c2c(cncc2)ccc1
NCGC00167805-03	S(=O)(=O)(N1CCOCC1)c1cc2c(nc(C)c3C(=O)N(CCOC(=O)C)C(=O)c23)cc1		Inactive	Caspase 3 Inhibitor		1	Ivachtin	384568340.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N1CCOCC1)c1cc2c(nc(C)c3C(=O)N(CCOC(=O)C)C(=O)c23)cc1	S(=O)(=O)(N1CCOCC1)c1cc2c(nc(C)c3C(=O)N(CCOC(=O)C)C(=O)c23)cc1
NCGC00390451-01	S(=O)(=O)(N1Cc2c(cccc2)CC1)c1cc(C(=O)O)ccc1		Inactive	Aldo-keto-reductase family 1 member C3 Inhibitor		1	AKR1C3InhibitorI	363680897.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1Cc2c(cccc2)CC1)c1cc(C(=O)O)ccc1	S(=O)(=O)(N1Cc2c(cccc2)CC1)c1cc(C(=O)O)ccc1
NCGC00263092-02	S(=O)(=O)(N1[C@@H](C(=O)NO)C(C)(C)SCC1)c1ccc(OCC#CCO)cc1		Inactive	TNF-alpha-Converting Enzyme Inhibitor		1	Apratastat	384568584.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N1[C@@H](C(=O)NO)C(C)(C)SCC1)c1ccc(OCC#CCO)cc1	S(=O)(=O)(N1[C@@H](C(=O)NO)C(C)(C)SCC1)c1ccc(OCC#CCO)cc1
NCGC00485069-01	S(=O)(=O)(N1[C@@H](C(=O)NO)C(C)(C)SCC1)c1ccc(Oc2ccncc2)cc1		Inactive	Matrix metalloproteinase-2 Inhibitor		1	Prinomastat hydrochloride	363681209.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1[C@@H](C(=O)NO)C(C)(C)SCC1)c1ccc(Oc2ccncc2)cc1	S(=O)(=O)(N1[C@@H](C(=O)NO)C(C)(C)SCC1)c1ccc(Oc2ccncc2)cc1
NCGC00379200-06	S(=O)(=O)(N1[C@@H](C(=O)Nc2scc(-c3ccc(OC)cc3)n2)CCCC1)c1ccc(C)cc1	4.9499998	Active	Voltage-gated potassium channel subunit Kv7.1 Activator	0.0	1	ML277	363678412.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	57.8985442046	S(=O)(=O)(N1[C@@H](C(=O)Nc2scc(-c3ccc(OC)cc3)n2)CCCC1)c1ccc(C)cc1	S(=O)(=O)(N1[C@@H](C(=O)Nc2scc(-c3ccc(OC)cc3)n2)CCCC1)c1ccc(C)cc1
NCGC00346802-02	S(=O)(=O)(N1[C@@H](C)CN(C(=O)CN)CCC1)c1c2c(C)cncc2ccc1		Inactive	ROCK II Inhibitor		1	Glycyl-H-1152	363677541.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N1[C@@H](C)CN(C(=O)CN)CCC1)c1c2c(C)cncc2ccc1	S(=O)(=O)(N1[C@@H](C)CN(C(=O)CN)CCC1)c1c2c(C)cncc2ccc1
NCGC00378616-03	S(=O)(=O)(N1[C@@H](C)CNCCC1)c1c2c(C)cncc2ccc1		Inactive			1	(S)-H-1152 (hydrochloride)	377020416.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1[C@@H](C)CNCCC1)c1c2c(C)cncc2ccc1	S(=O)(=O)(N1[C@@H](C)CNCCC1)c1c2c(C)cncc2ccc1
NCGC00496843-01&NCGC00496843-02	S(=O)(=O)(N1[C@@H](C)CNCCC1)c1c2c(F)cncc2ccc1		Inactive	ROCK1/ROCK2 Inhibitor		2	Ripasudil	405558535.0&384569296.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(N1[C@@H](C)CNCCC1)c1c2c(F)cncc2ccc1	S(=O)(=O)(N1[C@@H](C)CNCCC1)c1c2c(F)cncc2ccc1
NCGC00386485-01	S(=O)(=O)(N1[C@@H](CCN2CCC(C)CC2)CCC1)c1cc(C)ccc1		Inactive	Serotonin 7 (5-HT7) receptor Antagonist		1	SB 258741 hydrochloride	363680301.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1[C@@H](CCN2CCC(C)CC2)CCC1)c1cc(C)ccc1	S(=O)(=O)(N1[C@@H](CCN2CCC(C)CC2)CCC1)c1cc(C)ccc1
NCGC00402365-02	S(=O)(=O)(N1[C@@H](c2ccc(C(C)(C)C)cc2)C(C(=O)O)=CC[C@H]1c1ccc(C)cc1)c1ccc(C)cc1		Inactive	Platelet-activating factor acetylhydrolase IB gamma subunit Inhibitor		1	PAFAH1b2/3-IN-P11	363681043.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	12.9999999959	S(=O)(=O)(N1[C@@H](c2ccc(C(C)(C)C)cc2)C(C(=O)O)=CC[C@H]1c1ccc(C)cc1)c1ccc(C)cc1	S(=O)(=O)(N1[C@@H](c2ccc(C(C)(C)C)cc2)C(C(=O)O)=CC[C@H]1c1ccc(C)cc1)c1ccc(C)cc1
NCGC00386890-01	S(=O)(=O)(N1[C@H](C(=O)Nc2c(C)ccc(C)c2)CCC1)c1c2ncccc2ccc1		Inactive			1	NCGC00386890-01	363680486.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1[C@H](C(=O)Nc2c(C)ccc(C)c2)CCC1)c1c2ncccc2ccc1	S(=O)(=O)(N1[C@H](C(=O)Nc2c(C)ccc(C)c2)CCC1)c1c2ncccc2ccc1
NCGC00387479-01	S(=O)(=O)(N1[C@H](C(=O)Nc2cc(C)cc(C)c2)CCC1)c1ccc(OC)cc1		Inactive	Orexin receptor 2 Inhibitor		1	ACT 462206	363680635.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1[C@H](C(=O)Nc2cc(C)cc(C)c2)CCC1)c1ccc(OC)cc1	S(=O)(=O)(N1[C@H](C(=O)Nc2cc(C)cc(C)c2)CCC1)c1ccc(OC)cc1
NCGC00485490-01	S(=O)(=O)(N1[C@H](COc2cnccc2)CCC1)c1cc2C(=O)C(=O)N(Cc3ccc(OC)cc3)c2cc1		Inactive	Caspase-3 Inhibitor		1	NSCI	363681358.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1[C@H](COc2cnccc2)CCC1)c1cc2C(=O)C(=O)N(Cc3ccc(OC)cc3)c2cc1	S(=O)(=O)(N1[C@H](COc2cnccc2)CCC1)c1cc2C(=O)C(=O)N(Cc3ccc(OC)cc3)c2cc1
NCGC00509886-03	S(=O)(=O)(N1[C@H](Cc2ccccc2)CN(Cc2[nH]cnc2)c2c(cc(C#N)cc2)C1)c1sccc1		Inactive	Farnesyltransferase (geranylgeranyl pyrophosphate synthase) Inhibitor		1	BMS-214662	384569374.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	30.633374436	S(=O)(=O)(N1[C@H](Cc2ccccc2)CN(Cc2[nH]cnc2)c2c(cc(C#N)cc2)C1)c1sccc1	S(=O)(=O)(N1[C@H](Cc2ccccc2)CN(Cc2[nH]cnc2)c2c(cc(C#N)cc2)C1)c1sccc1
NCGC00370915-01	S(=O)(=O)(N1[C@H](c2ccc(F)cc2)CCC1)c1ccc(C)cc1		Inactive	Metabotropic glutamate receptor 1 Positive Allosteric Modulator		1	Ro 67-7476	363677931.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1[C@H](c2ccc(F)cc2)CCC1)c1ccc(C)cc1	S(=O)(=O)(N1[C@H](c2ccc(F)cc2)CCC1)c1ccc(C)cc1
NCGC00510350-01	S(=O)(=O)(N1c2c(-c3ccncc3)cccc2CC1)c1ccc(OC)cc1		Inactive	Tubulin polymerization Inhibitor		1	MPT-0B098	384569428.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.692225444	S(=O)(=O)(N1c2c(-c3ccncc3)cccc2CC1)c1ccc(OC)cc1	S(=O)(=O)(N1c2c(-c3ccncc3)cccc2CC1)c1ccc(OC)cc1
NCGC00370990-01	S(=O)(=O)(N1c2c(c(N3CCNCC3)ccc2)OCC1)c1c(F)cccc1		Inactive	Serotonin 6 (5-HT6) receptor Antagonist		1	R 1485 dihydrochloride	363677980.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N1c2c(c(N3CCNCC3)ccc2)OCC1)c1c(F)cccc1	S(=O)(=O)(N1c2c(c(N3CCNCC3)ccc2)OCC1)c1c(F)cccc1
NCGC00249938-01	S(=O)(=O)(N=C1N=CC=CN1)c1cc(OCCOC)ccc1		Inactive			1	Glymidine sodium	170465939.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)([O-])(=Nc1ncccn1)c1cc(OCCOC)ccc1.[Na+]	S(=O)([O-])(=Nc1ncccn1)c1cc(OCCOC)ccc1.[Na+]
NCGC00183137-01	S(=O)(=O)(N=C1N=CC=CN1)c1ccc(N)cc1		Inactive			1	Sulfadiazine silver	144207020.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)([O-])(=Nc1ncccn1)c1ccc(N)cc1.[Ag+]	S(=O)([O-])(=Nc1ncccn1)c1ccc(N)cc1.[Ag+]
NCGC00018234-07	S(=O)(=O)(NC(=N)N)c1ccc(N)cc1		Inactive			1	Sulfaguanidine	170465708.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC(=N)N)c1ccc(N)cc1	S(=O)(=O)(NC(=N)N)c1ccc(N)cc1
NCGC00018242-07	S(=O)(=O)(NC(=O)C)c1ccc(N)cc1		Inactive	Bacterial dihydropteroate synthase Inhibitor		1	Sulfacetamide	170464944.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC(=O)C)c1ccc(N)cc1	S(=O)(=O)(NC(=O)C)c1ccc(N)cc1
NCGC00390624-01	S(=O)(=O)(NC(=O)C1CCN(c2c(C#N)cc(C(=O)OCC)c(C)n2)CC1)Cc1ccccc1		Inactive	P2Y purinoceptor 12 Antagonist		1	AZD1283	363680934.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(NC(=O)C1CCN(c2c(C#N)cc(C(=O)OCC)c(C)n2)CC1)Cc1ccccc1	S(=O)(=O)(NC(=O)C1CCN(c2c(C#N)cc(C(=O)OCC)c(C)n2)CC1)Cc1ccccc1
NCGC00181773-05	S(=O)(=O)(NC(=O)CC)c1ccc(-c2c(C)onc2-c2ccccc2)cc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Parecoxib	405558622.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC(=O)CC)c1ccc(-c2c(C)onc2-c2ccccc2)cc1	S(=O)(=O)(NC(=O)CC)c1ccc(-c2c(C)onc2-c2ccccc2)cc1
NCGC00370833-02	S(=O)(=O)(NC(=O)COCCCCN(C(C)C)c1nc(c(-c2ccccc2)nc1)-c1ccccc1)C		Inactive	platelet aggregation Inhibitor		1	NS-304	405558607.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC(=O)COCCCCN(C(C)C)c1nc(c(-c2ccccc2)nc1)-c1ccccc1)C	S(=O)(=O)(NC(=O)COCCCCN(C(C)C)c1nc(c(-c2ccccc2)nc1)-c1ccccc1)C
NCGC00344041-02	S(=O)(=O)(NC(=O)Cc1ccc(N2C(=O)c3c(OCC)c4c(c(OCC)c3C2)cccc4)cc1)c1ccccc1		Inactive	Thromboxane A2 receptor Antagonist		1	GW 627368	363677322.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(NC(=O)Cc1ccc(N2C(=O)c3c(OCC)c4c(c(OCC)c3C2)cccc4)cc1)c1ccccc1	S(=O)(=O)(NC(=O)Cc1ccc(N2C(=O)c3c(OCC)c4c(c(OCC)c3C2)cccc4)cc1)c1ccccc1
NCGC00016879-06	S(=O)(=O)(NC(=O)NC(C)C)c1c(Nc2cc(C)ccc2)ccnc1		Inactive	Loop Diuretics		1	Torsemide	170465279.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(NC(=O)NC(C)C)c1c(Nc2cc(C)ccc2)ccnc1	S(=O)(=O)(NC(=O)NC(C)C)c1c(Nc2cc(C)ccc2)ccnc1
NCGC00016960-07	S(=O)(=O)(NC(=O)NC1CCC(C)CC1)c1ccc(CCNC(=O)N2C(=O)C(CC)=C(C)C2)cc1		Inactive	K(ATP) Channel Blocker		1	Glimepiride	170464966.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(NC(=O)NC1CCC(C)CC1)c1ccc(CCNC(=O)N2C(=O)C(CC)=C(C)C2)cc1	S(=O)(=O)(NC(=O)NC1CCC(C)CC1)c1ccc(CCNC(=O)N2C(=O)C(CC)=C(C)C2)cc1
NCGC00015014-11	S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(C(=O)C)cc1		Inactive	Sulfonylurea receptor 1, Kir6.2 Inhibitor		1	Acetohexamide	170465411.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(C(=O)C)cc1	S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(C(=O)C)cc1
NCGC00016819-05	S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(CCN2C(=O)C(C)(C)c3c(C2=O)cc(OC)cc3)cc1		Inactive	Cytochrome P450 3A4 Substrate		1	Gliquidone	170465581.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(CCN2C(=O)C(C)(C)c3c(C2=O)cc(OC)cc3)cc1	S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(CCN2C(=O)C(C)(C)c3c(C2=O)cc(OC)cc3)cc1
NCGC00015462-14&NCGC00015462-22	S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(CCNC(=O)c2ncc(C)nc2)cc1		Inactive	K(ATP) Channel Blocker		2	Glipizide	170465089.0&384567852.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(CCNC(=O)c2ncc(C)nc2)cc1	S(=O)(=O)(NC(=O)NC1CCCCC1)c1ccc(CCNC(=O)c2ncc(C)nc2)cc1
NCGC00015999-19	S(=O)(=O)(NC(=O)NCCCC)c1ccc(C)cc1		Inactive	Sulfonylurea receptor 1, Kir6.2 Inhibitor		1	Tolbutamide	170465238.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC(=O)NCCCC)c1ccc(C)cc1	S(=O)(=O)(NC(=O)NCCCC)c1ccc(C)cc1
NCGC00095107-09&NCGC00095107-18	S(=O)(=O)(NC(=O)NN1CC2C(C1)CCC2)c1ccc(C)cc1		Inactive	K(ATP) Channel Blocker		2	Gliclazide	170465698.0&384568145.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(NC(=O)NN1CC2C(C1)CCC2)c1ccc(C)cc1	S(=O)(=O)(NC(=O)NN1CC2C(C1)CCC2)c1ccc(C)cc1
NCGC00016009-19	S(=O)(=O)(NC(=O)NN1CCCCCC1)c1ccc(C)cc1		Inactive	ATP-sensitive inward rectifier potassium channel 1 Inhibitor		1	Tolazamide	170465136.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(NC(=O)NN1CCCCCC1)c1ccc(C)cc1	S(=O)(=O)(NC(=O)NN1CCCCCC1)c1ccc(C)cc1
NCGC00248064-08	S(=O)(=O)(NC(=O)Nc1c2c(cc3c1CCC3)CCC2)c1occ(C(O)(C)C)c1		Inactive	IL-1 Production Enhancers		1	CP-456773	384568522.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC(=O)Nc1c2c(cc3c1CCC3)CCC2)c1occ(C(O)(C)C)c1	S(=O)(=O)(NC(=O)Nc1c2c(cc3c1CCC3)CCC2)c1occ(C(O)(C)C)c1
NCGC00386668-01	S(=O)(=O)(NC(=O)OCCCC)c1c(-c2ccc(Cn3cncc3)cc2)cc(CC(C)C)s1		Inactive	Angiotensin AT2 Receptor Agonist		1	M-024	363680384.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC(=O)OCCCC)c1c(-c2ccc(Cn3cncc3)cc2)cc(CC(C)C)s1	S(=O)(=O)(NC(=O)OCCCC)c1c(-c2ccc(Cn3cncc3)cc2)cc(CC(C)C)s1
NCGC00378873-04	S(=O)(=O)(NC(=O)[C@H](C)c1ccc(CC(C)C)cc1)C		Inactive	Chemokine CXCR1/CXCR2 (IL-8 Receptor) Receptor Antagonist		1	Reparixin	384569073.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC(=O)[C@H](C)c1ccc(CC(C)C)cc1)C	S(=O)(=O)(NC(=O)[C@H](C)c1ccc(CC(C)C)cc1)C
NCGC00485973-01	S(=O)(=O)(NC(=O)[C@]1(NC(=O)[C@H]2N3C(=O)[C@H](C(C)(C)C)NC(=O)OCC(C)(C)CCCCc4c5c(ccc4)CN(C(=O)O[C@H](C2)C3)C5)[C@H](CC)C1)C1CC1		Inactive	Hepatitis C virus serine protease, NS3/NS4A Inhibitor		1	Vaniprevir	363681454.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(NC(=O)[C@]1(NC(=O)[C@H]2N3C(=O)[C@H](C(C)(C)C)NC(=O)OCC(C)(C)CCCCc4c5c(ccc4)CN(C(=O)O[C@H](C2)C3)C5)[C@H](CC)C1)C1CC1	S(=O)(=O)(NC(=O)[C@]1(NC(=O)[C@H]2N3C(=O)[C@H](C(C)(C)C)NC(=O)OCC(C)(C)CCCCc4c5c(ccc4)CN(C(=O)O[C@H](C2)C3)C5)[C@H](CC)C1)C1CC1
NCGC00378916-02	S(=O)(=O)(NC(=O)[C@]1(NC(=O)[C@H]2N3C(=O)[C@H](C(C)(C)C)NC(=O)O[C@H]4[C@@H](C4)CCCCCc4nc5c(nc4O[C@H](C2)C3)cc(OC)cc5)[C@H](C=C)C1)C1CC1		Inactive			1	MK-5172	405558457.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&15.4353507519	S(=O)(=O)(NC(=O)[C@]1(NC(=O)[C@H]2N3C(=O)[C@H](C(C)(C)C)NC(=O)O[C@H]4[C@@H](C4)CCCCCc4nc5c(nc4O[C@H](C2)C3)cc(OC)cc5)[C@H](C=C)C1)C1CC1	S(=O)(=O)(NC(=O)[C@]1(NC(=O)[C@H]2N3C(=O)[C@H](C(C)(C)C)NC(=O)O[C@H]4[C@@H](C4)CCCCCc4nc5c(nc4O[C@H](C2)C3)cc(OC)cc5)[C@H](C=C)C1)C1CC1
NCGC00378657-01	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3C(C(=O)N(C)CCCC/C=C\[C@@H]1C2)C[C@H](Oc1c2c(c(C)c(OC)cc2)nc(-c2scc(C(C)C)n2)c1)C3)C1CC1		Inactive			1	Simeprevir	405558913.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0&4.0	0.0&0.0&14.3532385839	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3C(C(=O)N(C)CCCC/C=C\[C@@H]1C2)C[C@H](Oc1c2c(c(C)c(OC)cc2)nc(-c2scc(C(C)C)n2)c1)C3)C1CC1	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3C(C(=O)N(C)CCCC/C=C\[C@@H]1C2)C[C@H](Oc1c2c(c(C)c(OC)cc2)nc(-c2scc(C(C)C)n2)c1)C3)C1CC1
NCGC00346498-01&NCGC00346498-06	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3N(C(=O)[C@@H](NC(=O)OC(C)(C)C)CCCCC/C=C\[C@@H]1C2)C[C@H](OC(=O)N1Cc2c(F)cccc2C1)C3)C1CC1		Inactive	HCV Protease Inhibitor		2	Danoprevir	174007476.0&434147087.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3N(C(=O)[C@@H](NC(=O)OC(C)(C)C)CCCCC/C=C\[C@@H]1C2)C[C@H](OC(=O)N1Cc2c(F)cccc2C1)C3)C1CC1	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3N(C(=O)[C@@H](NC(=O)OC(C)(C)C)CCCCC/C=C\[C@@H]1C2)C[C@H](OC(=O)N1Cc2c(F)cccc2C1)C3)C1CC1
NCGC00509859-02	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3N(C(=O)[C@@H](NC(=O)c4ncc(C)nc4)CCCCC/C=C\[C@@H]1C2)C[C@H](Oc1nc2c(c4c1cccc4)cccc2)C3)C1CC1		Inactive			1	Paritaprevir	434147165.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3N(C(=O)[C@@H](NC(=O)c4ncc(C)nc4)CCCCC/C=C\[C@@H]1C2)C[C@H](Oc1nc2c(c4c1cccc4)cccc2)C3)C1CC1	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3N(C(=O)[C@@H](NC(=O)c4ncc(C)nc4)CCCCC/C=C\[C@@H]1C2)C[C@H](Oc1nc2c(c4c1cccc4)cccc2)C3)C1CC1
NCGC00509859-03	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3N(C(=O)[C@@H](NC(=O)c4ncc(C)nc4)CCCCCC=C[C@@H]1C2)C[C@H](Oc1nc2c(c4c1cccc4)cccc2)C3)C1CC1		Inactive			1	ABT-450		Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3N(C(=O)[C@@H](NC(=O)c4ncc(C)nc4)CCCCCC=C[C@@H]1C2)C[C@H](Oc1nc2c(c4c1cccc4)cccc2)C3)C1CC1	S(=O)(=O)(NC(=O)[C@]12NC(=O)[C@H]3N(C(=O)[C@@H](NC(=O)c4ncc(C)nc4)CCCCCC=C[C@@H]1C2)C[C@H](Oc1nc2c(c4c1cccc4)cccc2)C3)C1CC1
NCGC00164547-06&NCGC00164547-18	S(=O)(=O)(NC(=O)c1cc(OC)c(Cc2c3c(n(C)c2)ccc(NC(=O)OC2CCCC2)c3)cc1)c1c(C)cccc1		Inactive	Leukotriene CysLT1 (LTD4) Antagonist		2	Zafirlukast	174007053.0&384568250.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(NC(=O)c1cc(OC)c(Cc2c3c(n(C)c2)ccc(NC(=O)OC2CCCC2)c3)cc1)c1c(C)cccc1	S(=O)(=O)(NC(=O)c1cc(OC)c(Cc2c3c(n(C)c2)ccc(NC(=O)OC2CCCC2)c3)cc1)c1c(C)cccc1
NCGC00016385-08	S(=O)(=O)(NC(=O)c1ccccc1)c1ccc(N)cc1		Inactive			1	Sulfabenzamide	170465133.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(NC(=O)c1ccccc1)c1ccc(N)cc1	S(=O)(=O)(NC(=O)c1ccccc1)c1ccc(N)cc1
NCGC00181137-01	S(=O)(=O)(NC(=S)N)c1ccc(N)cc1		Inactive			1	Sulfathiourea	144206297.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC(=S)N)c1ccc(N)cc1	S(=O)(=O)(NC(=S)N)c1ccc(N)cc1
NCGC00345845-02	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3cc(CN4CCOCC4)ccc3)n2)ccc1		Inactive	Jak2 Inhibitor		1	TG-89	363677388.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3cc(CN4CCOCC4)ccc3)n2)ccc1	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3cc(CN4CCOCC4)ccc3)n2)ccc1
NCGC00345846-01	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(CN4CCOCC4)cc3)n2)ccc1		Inactive	Jak2 Inhibitor		1	TG-46	174006734.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(CN4CCOCC4)cc3)n2)ccc1	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(CN4CCOCC4)cc3)n2)ccc1
NCGC00262608-11	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(N4CCN(C)CC4)cc3)n2)ccc1		Inactive	Jak2 Inhibitor		1	TG-101209	377020442.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(N4CCN(C)CC4)cc3)n2)ccc1	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(N4CCN(C)CC4)cc3)n2)ccc1
NCGC00244252-03	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(OCCN4CCCC4)cc3)n2)ccc1		Inactive	Jak2 Inhibitor		1	TG-101348	384568507.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(OCCN4CCCC4)cc3)n2)ccc1	S(=O)(=O)(NC(C)(C)C)c1cc(Nc2c(C)cnc(Nc3ccc(OCCN4CCCC4)cc3)n2)ccc1
NCGC00390707-01	S(=O)(=O)(NC)CC1CCC(N(C)c2ncnc3[nH]ccc23)CC1		Inactive	Tyrosine-protein kinase JAK3 Inhibitor		1	Oclacitinib	405559019.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC)CC1CCC(N(C)c2ncnc3[nH]ccc23)CC1	S(=O)(=O)(NC)CC1CCC(N(C)c2ncnc3[nH]ccc23)CC1
NCGC00181786-02	S(=O)(=O)(NC)CCc1cc2c(C3CCN(C)CC3)c[nH]c2cc1		Inactive	5-HT1B Agonist		1	Naratriptan hydrochloride	170465423.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC)CCc1cc2c(C3CCN(C)CC3)c[nH]c2cc1.Cl	S(=O)(=O)(NC)CCc1cc2c(C3CCN(C)CC3)c[nH]c2cc1.Cl
NCGC00095838-04	S(=O)(=O)(NC)Cc1cc2c(CCN(C)C)c[nH]c2cc1		Inactive	5-HT1B Agonist		1	Sumatriptan	170465377.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	-6.9245810079&0.0	S(=O)(=O)(NC)Cc1cc2c(CCN(C)C)c[nH]c2cc1	S(=O)(=O)(NC)Cc1cc2c(CCN(C)C)c[nH]c2cc1
NCGC00509904-02	S(=O)(=O)(NC)Nc1c(F)c(CC=2C(=O)Oc3c(C=2C)ccc(Oc2ncccn2)c3)ccn1		Inactive	Raf kinase B/C Inhibitor		1	RO-5126766	384569375.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC)Nc1c(F)c(CC=2C(=O)Oc3c(C=2C)ccc(Oc2ncccn2)c3)ccn1	S(=O)(=O)(NC)Nc1c(F)c(CC=2C(=O)Oc3c(C=2C)ccc(Oc2ncccn2)c3)ccn1
NCGC00344481-01	S(=O)(=O)(NC)c1cc2/C(=C/c3c(CCCN4CCN(C)CC4)c4c([nH]3)CCCC4)/C(=O)Nc2cc1		Inactive	Yes1 Kinase Inhibitor		1	PRP01-012	377020180.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC)c1cc2/C(=C/c3c(CCCN4CCN(C)CC4)c4c([nH]3)CCCC4)/C(=O)Nc2cc1	S(=O)(=O)(NC)c1cc2/C(=C/c3c(CCCN4CCN(C)CC4)c4c([nH]3)CCCC4)/C(=O)Nc2cc1
NCGC00253598-01	S(=O)(=O)(NC1=NC(=O)N(CC)C=C1)c1ccc(N)cc1		Inactive	Dihydropteroate synthetase Inhibitor		1	Sulfacytine	170465286.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(NC1=NC(=O)N(CC)C=C1)c1ccc(N)cc1	S(=O)(=O)(NC1=NC(=O)N(CC)C=C1)c1ccc(N)cc1
NCGC00355875-04	S(=O)(=O)(NC1CC1)c1c(Nc2cc(Oc3cc(F)cc(F)c3)cc(C(=O)O)c2)c2c(nc1)cc(-c1c(OC)nc(OC)nc1)cc2		Inactive	LDHA Inhibitor		1	GSK-2837808A	384569024.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC1CC1)c1c(Nc2cc(Oc3cc(F)cc(F)c3)cc(C(=O)O)c2)c2c(nc1)cc(-c1c(OC)nc(OC)nc1)cc2	S(=O)(=O)(NC1CC1)c1c(Nc2cc(Oc3cc(F)cc(F)c3)cc(C(=O)O)c2)c2c(nc1)cc(-c1c(OC)nc(OC)nc1)cc2
NCGC00347935-08	S(=O)(=O)(NC1CC1)c1cc(NC(=O)Nc2cc(C(F)(F)F)ccc2)c(-c2cscc2)cc1		Inactive	Mutant IDH2 Inhibitor		1	AGI-6780	363677721.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC1CC1)c1cc(NC(=O)Nc2cc(C(F)(F)F)ccc2)c(-c2cscc2)cc1	S(=O)(=O)(NC1CC1)c1cc(NC(=O)Nc2cc(C(F)(F)F)ccc2)c(-c2cscc2)cc1
NCGC00378893-04	S(=O)(=O)(NC1CCNCC1)c1c(C(F)(F)F)ccc(S(=O)(=O)c2ccccc2)c1		Inactive	Secreted frizzled-related protein 1 Inhibitor		1	WAY 316606 hydrochloride	363678260.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(NC1CCNCC1)c1c(C(F)(F)F)ccc(S(=O)(=O)c2ccccc2)c1	S(=O)(=O)(NC1CCNCC1)c1c(C(F)(F)F)ccc(S(=O)(=O)c2ccccc2)c1
NCGC00386927-01	S(=O)(=O)(NCC(=O)Nc1c(C)ccc(C)c1)c1cc2OC(=O)Nc2cc1		Inactive			1	NCGC00386927-01	363680511.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(NCC(=O)Nc1c(C)ccc(C)c1)c1cc2OC(=O)Nc2cc1	S(=O)(=O)(NCC(=O)Nc1c(C)ccc(C)c1)c1cc2OC(=O)Nc2cc1
NCGC00370739-04	S(=O)(=O)(NCC(C)c1ccc(-c2ccc(C#N)cc2)cc1)C(C)C		Inactive	Glutamate receptor ionotropic AMPA Positive Allosteric Modulator		1	LY404187	363677830.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(NCC(C)c1ccc(-c2ccc(C#N)cc2)cc1)C(C)C	S(=O)(=O)(NCC(C)c1ccc(-c2ccc(C#N)cc2)cc1)C(C)C
NCGC00370759-04	S(=O)(=O)(NCC1CC1)c1ccc(Nc2nc(N3c4c(cc(O)cc4)CCC3)ccn2)cc1	5.5	Active	BMP Signalling and Regulation Inhibitor	0.0	1	Pyrintegrin	363677839.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	2.3	86.7397511077	S(=O)(=O)(NCC1CC1)c1ccc(Nc2nc(N3c4c(cc(O)cc4)CCC3)ccn2)cc1	S(=O)(=O)(NCC1CC1)c1ccc(Nc2nc(N3c4c(cc(O)cc4)CCC3)ccn2)cc1
NCGC00390381-01	S(=O)(=O)(NCC1CCC(C(=O)NCCCc2ccccc2)CC1)c1c2nsnc2ccc1		Inactive	Hedgehog Signaling Pathway Inhibitor		1	SmoAntagonist,SA10	363680884.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(NCC1CCC(C(=O)NCCCc2ccccc2)CC1)c1c2nsnc2ccc1	S(=O)(=O)(NCC1CCC(C(=O)NCCCc2ccccc2)CC1)c1c2nsnc2ccc1
NCGC00371082-01	S(=O)(=O)(NCC1CCC(CNc2nc(N)c3c(n2)cccc3)CC1)c1c2c(ccc1)cccc2		Inactive	Neuropeptide Y receptor type 5 Antagonist		1	CGP 71683 hydrochloride	363678021.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(NCC1CCC(CNc2nc(N)c3c(n2)cccc3)CC1)c1c2c(ccc1)cccc2	S(=O)(=O)(NCC1CCC(CNc2nc(N)c3c(n2)cccc3)CC1)c1c2c(ccc1)cccc2
NCGC00370875-01	S(=O)(=O)(NCC1CCC(Nc2sc3c(n2)-c2c(SCC3)cccc2)CC1)C	4.9000001	Active	Neuropeptide Y receptor type 5 Antagonist	0.0	1	LU AA33810	363677903.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	66.5914285739	S(=O)(=O)(NCC1CCC(Nc2sc3c(n2)-c2c(SCC3)cccc2)CC1)C	S(=O)(=O)(NCC1CCC(Nc2sc3c(n2)-c2c(SCC3)cccc2)CC1)C
NCGC00485405-01	S(=O)(=O)(NCC1ON=C(c2cc(F)c(N3C[C@@H](NC(=O)C)CC3)cc2)C1)C(C)C		Inactive	Glutamate receptor ionotropic, AMPA Positive Allosteric Modulator		1	PF-04725379	363681318.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(NCC1ON=C(c2cc(F)c(N3C[C@@H](NC(=O)C)CC3)cc2)C1)C(C)C	S(=O)(=O)(NCC1ON=C(c2cc(F)c(N3C[C@@H](NC(=O)C)CC3)cc2)C1)C(C)C
NCGC00510476-01	S(=O)(=O)(NCCN(C)C)Cc1cc(Nc2nc(Oc3cc4c([nH]c(C)c4)cc3)ccn2)ccc1	4.9000001	Active	VEGFR-2 Inhibitor	0.0	1	Sulfatinib	384569439.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	69.6344037379	S(=O)(=O)(NCCN(C)C)Cc1cc(Nc2nc(Oc3cc4c([nH]c(C)c4)cc3)ccn2)ccc1	S(=O)(=O)(NCCN(C)C)Cc1cc(Nc2nc(Oc3cc4c([nH]c(C)c4)cc3)ccn2)ccc1
NCGC00510482-01	S(=O)(=O)(NC[C@@]1(N(C(=O)C(C)(C)C)N=C(NC(=O)C(C)(C)C)S1)c1ccccc1)CCNCC		Inactive	Kinesin-Like Spindle Protein KIF11 (KSP, Eg5) Inhibitor		1	Litronesib	384569445.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NC[C@@]1(N(C(=O)C(C)(C)C)N=C(NC(=O)C(C)(C)C)S1)c1ccccc1)CCNCC	S(=O)(=O)(NC[C@@]1(N(C(=O)C(C)(C)C)N=C(NC(=O)C(C)(C)C)S1)c1ccccc1)CCNCC
NCGC00390642-01	S(=O)(=O)(NC[C@H](C)c1ccc(-c2ccc(CCNS(=O)(=O)C)cc2)cc1)C(C)C		Inactive	Glutamate receptor ionotropic AMPA Positive Allosteric Modulator		1	LY451395	363680947.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(NC[C@H](C)c1ccc(-c2ccc(CCNS(=O)(=O)C)cc2)cc1)C(C)C	S(=O)(=O)(NC[C@H](C)c1ccc(-c2ccc(CCNS(=O)(=O)C)cc2)cc1)C(C)C
NCGC00370740-02	S(=O)(=O)(NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1)C(C)C		Inactive	Glutamate receptor ionotropic AMPA Positive Allosteric Modulator		1	LY450108	363677831.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1)C(C)C	S(=O)(=O)(NC[C@H](C)c1ccc(NC(=O)c2cc(F)cc(F)c2)cc1)C(C)C
NCGC00167510-02&NCGC00167510-09	S(=O)(=O)(NC[C@H]1NC[C@@H](SC=2[C@H](C)[C@@H]3[C@@H]([C@H](O)C)C(=O)N3C=2C(=O)O)C1)N		Inactive	Carbapenem Antibiotic		2	Doripenem&Doripenem Hydrate	170465085.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(NC[C@H]1NC[C@@H](SC=2[C@H](C)[C@@H]3[C@@H]([C@H](O)C)C(=O)N3C=2C(=O)O)C1)N	S(=O)(=O)(NC[C@H]1NC[C@@H](SC=2[C@H](C)[C@@H]3[C@@H]([C@H](O)C)C(=O)N3C=2C(=O)O)C1)N
NCGC00485396-01	S(=O)(=O)(NC[C@H]1ON=C(c2cc(F)c(N3CCCC3)cc2)C1)C(C)C		Inactive	Glutamate receptor ionotropic, AMPA Positive Allosteric Modulator		1	PF-04701475	363681310.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(NC[C@H]1ON=C(c2cc(F)c(N3CCCC3)cc2)C1)C(C)C	S(=O)(=O)(NC[C@H]1ON=C(c2cc(F)c(N3CCCC3)cc2)C1)C(C)C
NCGC00386887-01	S(=O)(=O)(NCc1ccc(C(=O)NCCN(C(C)C)Cc2ccccc2)cc1)c1ccc(C)cc1		Inactive			1	NCGC00386887-01	363680483.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(NCc1ccc(C(=O)NCCN(C(C)C)Cc2ccccc2)cc1)c1ccc(C)cc1	S(=O)(=O)(NCc1ccc(C(=O)NCCN(C(C)C)Cc2ccccc2)cc1)c1ccc(C)cc1
NCGC00379139-02	S(=O)(=O)(NCc1ccc(C(=O)Nc2cnccc2)cc1)c1ccc(C(C)(C)C)cc1		Inactive	Nicotinamide phosphoribosyltransferase Inhibitor		1	STF 31	363678381.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(NCc1ccc(C(=O)Nc2cnccc2)cc1)c1ccc(C(C)(C)C)cc1	S(=O)(=O)(NCc1ccc(C(=O)Nc2cnccc2)cc1)c1ccc(C(C)(C)C)cc1
NCGC00378567-02	S(=O)(=O)(NCc1ncccc1)Cc1cc2C(=O)c3c(ncc(-c4cn(C)nc4)c3)C=Cc2cc1		Inactive	HGFR Inhibitor		1	MK-8033	363678092.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(NCc1ncccc1)Cc1cc2C(=O)c3c(ncc(-c4cn(C)nc4)c3)C=Cc2cc1	S(=O)(=O)(NCc1ncccc1)Cc1cc2C(=O)c3c(ncc(-c4cn(C)nc4)c3)C=Cc2cc1
NCGC00351479-01	S(=O)(=O)(N[C@@H](C(=O)N1CCCC1)Cc1cc(C(F)(F)F)ccc1)c1cc(F)c2c(c1)CCNC2		Inactive	Potent and selective SETD7 Inhibitor. Inhibits YAP nuclear translocation and function following activation of the Hippo signaling pathway in MCF7 cells.		1	(R)-PFI-2	363677753.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N[C@@H](C(=O)N1CCCC1)Cc1cc(C(F)(F)F)ccc1)c1cc(F)c2c(c1)CCNC2	S(=O)(=O)(N[C@@H](C(=O)N1CCCC1)Cc1cc(C(F)(F)F)ccc1)c1cc(F)c2c(c1)CCNC2
NCGC00387210-01	S(=O)(=O)(N[C@@H]1[C@@H](c2ccc(-c3sc(C#N)cc3)cc2)COCC1)C(C)C		Inactive	Glutamate receptor ionotropic AMPA Positive Allosteric Modulator		1	PF 4778574	363680569.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(N[C@@H]1[C@@H](c2ccc(-c3sc(C#N)cc3)cc2)COCC1)C(C)C	S(=O)(=O)(N[C@@H]1[C@@H](c2ccc(-c3sc(C#N)cc3)cc2)COCC1)C(C)C
NCGC00166413-09	S(=O)(=O)(N[C@H](C(=O)N1[C@@H](C(=O)O)C[C@H](C)CC1)CCCNC(=N)N)c1c2NCC(C)Cc2ccc1		Inactive	Thrombin Inhibitor		1	Argatroban	384568307.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N[C@H](C(=O)N1[C@@H](C(=O)O)C[C@H](C)CC1)CCCNC(=N)N)c1c2NCC(C)Cc2ccc1	S(=O)(=O)(N[C@H](C(=O)N1[C@@H](C(=O)O)C[C@H](C)CC1)CCCNC(=N)N)c1c2NCC(C)Cc2ccc1
NCGC00166413-02	S(=O)(=O)(N[C@H](C(=O)N1[C@@H](C(=O)O)C[C@H](C)CC1)CCCNC(=N)N)c1c2NC[C@H](C)Cc2ccc1		Inactive	Thrombin Inhibitor		1	Argatroban	170464871.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(N[C@H](C(=O)N1[C@@H](C(=O)O)C[C@H](C)CC1)CCCNC(=N)N)c1c2NC[C@H](C)Cc2ccc1	S(=O)(=O)(N[C@H](C(=O)N1[C@@H](C(=O)O)C[C@H](C)CC1)CCCNC(=N)N)c1c2NC[C@H](C)Cc2ccc1
NCGC00509997-02	S(=O)(=O)(N[C@H](C(=O)O)CNc1c(C)c(N2CCC(c3nc4NCCCc4cc3)CC2)nc(C)n1)c1ccc(OC)cc1		Inactive	Integrin Receptor Antagonist		1	GLPG-0187	384569404.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N[C@H](C(=O)O)CNc1c(C)c(N2CCC(c3nc4NCCCc4cc3)CC2)nc(C)n1)c1ccc(OC)cc1	S(=O)(=O)(N[C@H](C(=O)O)CNc1c(C)c(N2CCC(c3nc4NCCCc4cc3)CC2)nc(C)n1)c1ccc(OC)cc1
NCGC00263584-01	S(=O)(=O)(N[C@H](C(=O)O)Cc1ccc(OCCCCC2CCNCC2)cc1)CCCC		Inactive	Integrin alpha-IIb/beta-3 Antagonist		1	Tirofiban hydrochloride monohydrate	170465092.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(N[C@H](C(=O)O)Cc1ccc(OCCCCC2CCNCC2)cc1)CCCC.Cl.O	S(=O)(=O)(N[C@H](C(=O)O)Cc1ccc(OCCCCC2CCNCC2)cc1)CCCC.Cl.O
NCGC00346615-02	S(=O)(=O)(N[C@H](C(=O)OC)CCCNC(=N)N)c1ccc(C)cc1		Inactive	Anaphase Promoting Complex (APC) Inhibitor		1	TAME	384568859.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(N[C@H](C(=O)OC)CCCNC(=N)N)c1ccc(C)cc1	S(=O)(=O)(N[C@H](C(=O)OC)CCCNC(=N)N)c1ccc(C)cc1
NCGC00402282-02	S(=O)(=O)(N[C@H]1CN(Cc2ccc(OC(C)C)cc2)CC1)c1c(C)ccc(F)c1		Inactive	DNA gyrase Inhibitor		1	(R)-Gyramide A Hydrochloride	363681012.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	15.982560812	S(=O)(=O)(N[C@H]1CN(Cc2ccc(OC(C)C)cc2)CC1)c1c(C)ccc(F)c1	S(=O)(=O)(N[C@H]1CN(Cc2ccc(OC(C)C)cc2)CC1)c1c(C)ccc(F)c1
NCGC00475734-01	S(=O)(=O)(N[C@H]1C[C@@H]2[C@@](C)([C@@H]3[C@H]([C@H]4C(=C(C)C[C@]5([C@H](C)[C@@H]6NC[C@@H](C)C[C@H]6O5)CC4)C3)CC2)CC1)C	5.5	Active	Hedgehog Antagonist	0.0	1	Patidegib	384569234.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	44.981814176	S(=O)(=O)(N[C@H]1C[C@@H]2[C@@](C)([C@@H]3[C@H]([C@H]4C(=C(C)C[C@]5([C@H](C)[C@@H]6NC[C@@H](C)C[C@H]6O5)CC4)C3)CC2)CC1)C	S(=O)(=O)(N[C@H]1C[C@@H]2[C@@](C)([C@@H]3[C@H]([C@H]4C(=C(C)C[C@]5([C@H](C)[C@@H]6NC[C@@H](C)C[C@H]6O5)CC4)C3)CC2)CC1)C
NCGC00167519-02&NCGC00167519-07	S(=O)(=O)(N[C@H]1Cc2c3c(n(CCC(=O)O)c2CC1)cccc3)c1ccc(F)cc1		Inactive	prostaglandin D2 CRTH2 Inhibitor		2	Ramatroban	170465980.0&363676664.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(N[C@H]1Cc2c3c(n(CCC(=O)O)c2CC1)cccc3)c1ccc(F)cc1	S(=O)(=O)(N[C@H]1Cc2c3c(n(CCC(=O)O)c2CC1)cccc3)c1ccc(F)cc1
NCGC00263570-01&NCGC00263570-02&NCGC00263570-06	S(=O)(=O)(Nc1c(C(=O)NCC(=O)O)cccc1)c1ccc(OC(=O)C(C)(C)C)cc1		Inactive	Neutrophil Elastase Inhibitor		3	Sivelestat sodium hydrate&Sivelestat sodium salt&Sivelestat sodium salt hydrate	170465996.0&434146918.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	S(=O)(=O)(Nc1c(C(=O)NCC(=O)[O-])cccc1)c1ccc(OC(=O)C(C)(C)C)cc1.[Na+].O.O.O.O	S(=O)(=O)(Nc1c(C(=O)NCC(=O)[O-])cccc1)c1ccc(OC(=O)C(C)(C)C)cc1.[Na+].O.O.O.O&S(=O)(=O)(Nc1c(C(=O)NCC(=O)O)cccc1)c1ccc(OC(=O)C(C)(C)C)cc1
NCGC00387214-02	S(=O)(=O)(Nc1c(C(=O)N[C@H](C(=O)O)CCCNC(=N)N)scc1)c1c2nsnc2ccc1		Inactive	Neuropilin-1 Antagonist		1	EG00229	363680573.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1c(C(=O)N[C@H](C(=O)O)CCCNC(=N)N)scc1)c1c2nsnc2ccc1	S(=O)(=O)(Nc1c(C(=O)N[C@H](C(=O)O)CCCNC(=N)N)scc1)c1c2nsnc2ccc1
NCGC00262995-02	S(=O)(=O)(Nc1c(C(=O)Nc2scc(-c3ccccc3)n2)ccc(C(F)(F)F)c1)c1ccc(C)cc1		Inactive	Ubiquitin C-terminal Hydrolase 2 (USP2) Inhibitor		1	ML-364	384568579.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	14.5	S(=O)(=O)(Nc1c(C(=O)Nc2scc(-c3ccccc3)n2)ccc(C(F)(F)F)c1)c1ccc(C)cc1	S(=O)(=O)(Nc1c(C(=O)Nc2scc(-c3ccccc3)n2)ccc(C(F)(F)F)c1)c1ccc(C)cc1
NCGC00016384-15	S(=O)(=O)(Nc1c(C)c(C)no1)c1ccc(N)cc1		Inactive	Antibiotic		1	Sulfisoxazole	170464636.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1c(C)c(C)no1)c1ccc(N)cc1	S(=O)(=O)(Nc1c(C)c(C)no1)c1ccc(N)cc1
NCGC00370745-03	S(=O)(=O)(Nc1c(C)c(C)no1)c1ccc(NC(=O)c2c3c(c(C)cc(C)c3)nc(-c3ncccc3)c2)cc1		Inactive	G-protein coupled receptor 55 Antagonist		1	ML193	363677832.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1c(C)c(C)no1)c1ccc(NC(=O)c2c3c(c(C)cc(C)c3)nc(-c3ncccc3)c2)cc1	S(=O)(=O)(Nc1c(C)c(C)no1)c1ccc(NC(=O)c2c3c(c(C)cc(C)c3)nc(-c3ncccc3)c2)cc1
NCGC00387253-02	S(=O)(=O)(Nc1c(C)cc(C)cc1C)c1ccc(OC)cc1		Inactive	Free fatty acid receptor 4 Agonist		1	GSK137647A	363680594.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1c(C)cc(C)cc1C)c1ccc(OC)cc1	S(=O)(=O)(Nc1c(C)cc(C)cc1C)c1ccc(OC)cc1
NCGC00522513-01	S(=O)(=O)(Nc1c(C)ccc(-c2cc(C#N)sc2)c1)c1ccc(OC)cc1		Inactive	HIF-1alpha Inhibitor		1	EL-102	384569522.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1c(C)ccc(-c2cc(C#N)sc2)c1)c1ccc(OC)cc1	S(=O)(=O)(Nc1c(C)ccc(-c2cc(C#N)sc2)c1)c1ccc(OC)cc1
NCGC00390693-06	S(=O)(=O)(Nc1c(C)ccc(-c2sc(C#N)cc2)c1)c1ccc(C)cc1		Inactive	Tubulin polymerization Inhibitor		1	ELR-510444	384569207.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1c(C)ccc(-c2sc(C#N)cc2)c1)c1ccc(C)cc1	S(=O)(=O)(Nc1c(C)ccc(-c2sc(C#N)cc2)c1)c1ccc(C)cc1
NCGC00485111-01	S(=O)(=O)(Nc1c(C)ccc(C)c1)c1c(C)ccc(C(=O)Nc2c(-c3ccccc3)cccc2)c1		Inactive			1	SF-22	363681226.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	24.3571428519	S(=O)(=O)(Nc1c(C)ccc(C)c1)c1c(C)ccc(C(=O)Nc2c(-c3ccccc3)cccc2)c1	S(=O)(=O)(Nc1c(C)ccc(C)c1)c1c(C)ccc(C(=O)Nc2c(-c3ccccc3)cccc2)c1
NCGC00346946-02&NCGC00346946-03	S(=O)(=O)(Nc1c(C)ccc(Nc2ncnc(-c3cc(N4C(=O)c5c(C4=O)cccc5)ccc3)c2)c1)C		Inactive	CDK 9 Inhibitor		2	CDK9 Inhibitor	363677564.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1c(C)ccc(Nc2ncnc(-c3cc(N4C(=O)c5c(C4=O)cccc5)ccc3)c2)c1)C	S(=O)(=O)(Nc1c(C)ccc(Nc2ncnc(-c3cc(N4C(=O)c5c(C4=O)cccc5)ccc3)c2)c1)C
NCGC00483921-01	S(=O)(=O)(Nc1c(F)c(C(=O)c2c3c([nH]c2)ncc(-c2cnc(C4CC4)nc2)c3)c(F)cc1)N1C[C@H](F)CC1		Inactive	Raf kinase B Inhibitor		1	PLX-8394	363681140.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1c(F)c(C(=O)c2c3c([nH]c2)ncc(-c2cnc(C4CC4)nc2)c3)c(F)cc1)N1C[C@H](F)CC1	S(=O)(=O)(Nc1c(F)c(C(=O)c2c3c([nH]c2)ncc(-c2cnc(C4CC4)nc2)c3)c(F)cc1)N1C[C@H](F)CC1
NCGC00378825-01	S(=O)(=O)(Nc1c(F)c(C(=O)c2c3c([nH]c2)ncc(-c2cnccc2)c3)c(F)cc1)C(C)C		Inactive	Serine/threonine-protein kinase B-raf Inhibitor		1	BRAF inhibitor	363678223.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1c(F)c(C(=O)c2c3c([nH]c2)ncc(-c2cnccc2)c3)c(F)cc1)C(C)C	S(=O)(=O)(Nc1c(F)c(C(=O)c2c3c([nH]c2)ncc(-c2cnccc2)c3)c(F)cc1)C(C)C
NCGC00402354-01	S(=O)(=O)(Nc1c(F)cc(CNC(=S)NCc2ccc(C(C)(C)C)cc2)cc1)C		Inactive	Vanilloid receptor Antagonist		1	JYL1421	363681038.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1c(F)cc(CNC(=S)NCc2ccc(C(C)(C)C)cc2)cc1)C	S(=O)(=O)(Nc1c(F)cc(CNC(=S)NCc2ccc(C(C)(C)C)cc2)cc1)C
NCGC00402264-02	S(=O)(=O)(Nc1c(N2CCCCC2)cccc1)c1sc(C)cc1		Inactive	Mucolipin-1 Activator		1	MK6-83	363681005.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1c(N2CCCCC2)cccc1)c1sc(C)cc1	S(=O)(=O)(Nc1c(N2CCCCC2)cccc1)c1sc(C)cc1
NCGC00386618-01	S(=O)(=O)(Nc1c(Nc2cc(OC)cc(OC)c2)nc2c(n1)cccc2)c1cc(NC(=O)c2cc(OC)c(C)cc2)ccc1		Inactive	Serine/threonine-protein kinase mTOR Inhibitor		1	XL PI3K/mTOR inhibitor	363680359.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1c(Nc2cc(OC)cc(OC)c2)nc2c(n1)cccc2)c1cc(NC(=O)c2cc(OC)c(C)cc2)ccc1	S(=O)(=O)(Nc1c(Nc2cc(OC)cc(OC)c2)nc2c(n1)cccc2)c1cc(NC(=O)c2cc(OC)c(C)cc2)ccc1
NCGC00387032-01	S(=O)(=O)(Nc1c(Nc2cc(OC)cc(OC)c2)nc2c(n1)cccc2)c1ccc(NC(=O)c2cc(C)c(OC)cc2)cc1		Inactive			1	XL765	363680527.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1c(Nc2cc(OC)cc(OC)c2)nc2c(n1)cccc2)c1ccc(NC(=O)c2cc(C)c(OC)cc2)cc1	S(=O)(=O)(Nc1c(Nc2cc(OC)cc(OC)c2)nc2c(n1)cccc2)c1ccc(NC(=O)c2cc(C)c(OC)cc2)cc1
NCGC00346541-04	S(=O)(=O)(Nc1c(Nc2cc(OC)cc(OC)c2)nc2c(n1)cccc2)c1ccc(NC(=O)c2cc(OC)c(C)cc2)cc1	4.9499998	Active	mTORC1/2 Inhibitor	0.0	1	XL-765	384568827.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	78.5754075258	S(=O)(=O)(Nc1c(Nc2cc(OC)cc(OC)c2)nc2c(n1)cccc2)c1ccc(NC(=O)c2cc(OC)c(C)cc2)cc1	S(=O)(=O)(Nc1c(Nc2cc(OC)cc(OC)c2)nc2c(n1)cccc2)c1ccc(NC(=O)c2cc(OC)c(C)cc2)cc1
NCGC00346492-03	S(=O)(=O)(Nc1c(Nc2cc3nsnc3cc2)nc2c(n1)cccc2)c1ccc(C)cc1		Inactive	PI3K Inhibitor		1	XL-147	384568799.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1c(Nc2cc3nsnc3cc2)nc2c(n1)cccc2)c1ccc(C)cc1	S(=O)(=O)(Nc1c(Nc2cc3nsnc3cc2)nc2c(n1)cccc2)c1ccc(C)cc1
NCGC00346494-06	S(=O)(=O)(Nc1c(Nc2ccc(O)cc2)nccc1)c1ccc(OC)cc1		Inactive	Tubulin polymerization Inhibitor		1	E-7010	363677427.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1c(Nc2ccc(O)cc2)nccc1)c1ccc(OC)cc1	S(=O)(=O)(Nc1c(Nc2ccc(O)cc2)nccc1)c1ccc(OC)cc1
NCGC00371097-01	S(=O)(=O)(Nc1c(O)ccc(C(O)CNC(Cc2ccccc2)(C)C)c1)C		Inactive	Beta-3 adrenergic receptor Agonist		1	Zinterol hydrochloride	363678029.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1c(O)ccc(C(O)CNC(Cc2ccccc2)(C)C)c1)C	S(=O)(=O)(Nc1c(O)ccc(C(O)CNC(Cc2ccccc2)(C)C)c1)C
NCGC00016612-05&NCGC00016612-13&NCGC00016612-14	S(=O)(=O)(Nc1c(OC)c(OC)ncn1)c1ccc(N)cc1		Inactive	Dihydropteroate Synthase (DHPS) Inhibitor		3	Sulfadoxine	170464751.0&384567954.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	S(=O)(=O)(Nc1c(OC)c(OC)ncn1)c1ccc(N)cc1	S(=O)(=O)(Nc1c(OC)c(OC)ncn1)c1ccc(N)cc1
NCGC00370882-01	S(=O)(=O)(Nc1c(OC)cc(Nc2ccccc2)cc1)c1c(C(=O)OC)scc1		Inactive	Peroxisome proliferator-activated receptor delta Inverse Agonist		1	GSK 0660	363677908.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1c(OC)cc(Nc2ccccc2)cc1)c1c(C(=O)OC)scc1	S(=O)(=O)(Nc1c(OC)cc(Nc2ccccc2)cc1)c1c(C(=O)OC)scc1
NCGC00242479-03	S(=O)(=O)(Nc1c(OC)nc(C)cn1)c1c(-c2ccc(-c3ocnn3)cc2)nccc1		Inactive	Endothelin ETA Receptor Antagonist		1	Zibotentan	363677141.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1c(OC)nc(C)cn1)c1c(-c2ccc(-c3ocnn3)cc2)nccc1	S(=O)(=O)(Nc1c(OC)nc(C)cn1)c1c(-c2ccc(-c3ocnn3)cc2)nccc1
NCGC00250408-02	S(=O)(=O)(Nc1c(OC)ncc(-c2cc3c(-c4cnncc4)ccnc3cc2)c1)c1c(F)cc(F)cc1		Inactive	PI3Kalpha/beta/delta/gamma Inhibitor		1	GSK-2126458	384568556.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.0	S(=O)(=O)(Nc1c(OC)ncc(-c2cc3c(-c4cnncc4)ccnc3cc2)c1)c1c(F)cc(F)cc1	S(=O)(=O)(Nc1c(OC)ncc(-c2cc3c(-c4cnncc4)ccnc3cc2)c1)c1c(F)cc(F)cc1
NCGC00160482-02	S(=O)(=O)(Nc1c(OC)nccn1)c1ccc(N)cc1		Inactive	Bacterial dihydropteroate synthase Inhibitor		1	Sulfalene	170465930.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1c(OC)nccn1)c1ccc(N)cc1	S(=O)(=O)(Nc1c(OC)nccn1)c1ccc(N)cc1
NCGC00379058-01	S(=O)(=O)(Nc1c(Oc2c(OC)cccc2)c(OC)nc(-c2ccncc2)n1)c1ncc(C)cc1		Inactive	Endothelin receptor ET-A Antagonist		1	Avosentan	363678332.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1c(Oc2c(OC)cccc2)c(OC)nc(-c2ccncc2)n1)c1ncc(C)cc1	S(=O)(=O)(Nc1c(Oc2c(OC)cccc2)c(OC)nc(-c2ccncc2)n1)c1ncc(C)cc1
NCGC00167440-02	S(=O)(=O)(Nc1c(Oc2c(OC)cccc2)c(OCCO)nc(-c2ncccn2)n1)c1ccc(C(C)(C)C)cc1		Inactive	Endothelin receptor, ET-A/ET-B Antagonist		1	Bosentan	170465245.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1c(Oc2c(OC)cccc2)c(OCCO)nc(-c2ncccn2)n1)c1ccc(C(C)(C)C)cc1	S(=O)(=O)(Nc1c(Oc2c(OC)cccc2)c(OCCO)nc(-c2ncccn2)n1)c1ccc(C(C)(C)C)cc1
NCGC00015725-15&NCGC00015725-27	S(=O)(=O)(Nc1c(Oc2ccccc2)cc([N+](=O)[O-])cc1)C		Inactive	Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitor		2	Nimesulide	170465612.0&384567885.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(Nc1c(Oc2ccccc2)cc([N+](=O)[O-])cc1)C	S(=O)(=O)(Nc1c(Oc2ccccc2)cc([N+](=O)[O-])cc1)C
NCGC00181783-03&NCGC00181783-05	S(=O)(=O)(Nc1c(Oc2ccccc2)cc2C(=O)C(NC=O)=COc2c1)C		Inactive	NF-kappaB (NFKB) Activation Inhibitor		2	Iguratimod	405558470.0&384568402.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1c(Oc2ccccc2)cc2C(=O)C(NC=O)=COc2c1)C	S(=O)(=O)(Nc1c(Oc2ccccc2)cc2C(=O)C(NC=O)=COc2c1)C
NCGC00475733-01	S(=O)(=O)(Nc1c2[nH]cc(C#N)c2c(C)cc1)c1cc(C#N)ccc1	4.8499999	Active	Integrin Receptor Antagonist	0.0	1	E-7820	384569233.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	31.0	S(=O)(=O)(Nc1c2[nH]cc(C#N)c2c(C)cc1)c1cc(C#N)ccc1	S(=O)(=O)(Nc1c2[nH]cc(C#N)c2c(C)cc1)c1cc(C#N)ccc1
NCGC00507962-02	S(=O)(=O)(Nc1c2c(-c3cc4N(C)CCc4cc3)cn(C(C)C)c2ncc1)c1nn(C)cc1		Inactive	NADPH Oxidase 2 Inhibitor		1	GSK2795039	384569358.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1c2c(-c3cc4N(C)CCc4cc3)cn(C(C)C)c2ncc1)c1nn(C)cc1	S(=O)(=O)(Nc1c2c(-c3cc4N(C)CCc4cc3)cn(C(C)C)c2ncc1)c1nn(C)cc1
NCGC00262829-02	S(=O)(=O)(Nc1c2c(c(O)c(-c3c(O)ccc4c3cccc4)c1)cccc2)c1ccc(OC)cc1		Inactive	STAT3 Expression Inhibitor		1	C-188-9	174006692.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1c2c(c(O)c(-c3c(O)ccc4c3cccc4)c1)cccc2)c1ccc(OC)cc1	S(=O)(=O)(Nc1c2c(c(O)c(-c3c(O)ccc4c3cccc4)c1)cccc2)c1ccc(OC)cc1
NCGC00165855-05	S(=O)(=O)(Nc1cc(C#C/C=C/C(=O)NO)ccc1)c1ccccc1		Inactive	Histone Deacetylase (HDAC) Inhibitor		1	Oxamflatin	384568290.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1cc(C#C/C=C/C(=O)NO)ccc1)c1ccccc1	S(=O)(=O)(Nc1cc(C#C/C=C/C(=O)NO)ccc1)c1ccccc1
NCGC00371053-01	S(=O)(=O)(Nc1cc(C(F)(F)F)c(-c2cc3c(n(-c4ccc(F)cc4)nc3)cc2)cc1)Cc1ccccc1	4.9000001	Active	Glucocorticoid receptor Agonist	0.0	1	GSK 9027	363678009.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	111.620723824	S(=O)(=O)(Nc1cc(C(F)(F)F)c(-c2cc3c(n(-c4ccc(F)cc4)nc3)cc2)cc1)Cc1ccccc1	S(=O)(=O)(Nc1cc(C(F)(F)F)c(-c2cc3c(n(-c4ccc(F)cc4)nc3)cc2)cc1)Cc1ccccc1
NCGC00188796-01	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1c(NC(CO)C)cc2NC(=O)CCc2c1		Inactive			1	NCGC00188796-01	99431224.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1c(NC(CO)C)cc2NC(=O)CCc2c1	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1c(NC(CO)C)cc2NC(=O)CCc2c1
NCGC00188790-01	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1c(NCCO)cc2NC(=O)CCc2c1		Inactive			1	NCGC00188790-01	99431218.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1c(NCCO)cc2NC(=O)CCc2c1	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1c(NCCO)cc2NC(=O)CCc2c1
NCGC00188897-01	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1c(N[C@@H](CO)C)cc2NC(=O)CCc2c1		Inactive			1	NCGC00188897-01	99431233.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1c(N[C@@H](CO)C)cc2NC(=O)CCc2c1	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1c(N[C@@H](CO)C)cc2NC(=O)CCc2c1
NCGC00188898-01	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1c(N[C@H](CO)C)cc2NC(=O)CCc2c1		Inactive			1	NCGC00188898-01	99431234.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1c(N[C@H](CO)C)cc2NC(=O)CCc2c1	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1c(N[C@H](CO)C)cc2NC(=O)CCc2c1
NCGC00185939-01	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1cc2c(NC(=O)CC2)cc1		Inactive			1	NCGC00185939-01	85176568.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1cc2c(NC(=O)CC2)cc1	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1cc2c(NC(=O)CC2)cc1
NCGC00507890-02	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1cc2c(NC(c3ccc(C(=O)O)cc3)C3C2C=CC3)cc1		Inactive	MDM2 (hdm2) Inhibitor		1	MX-69	384569354.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	13.216582448	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1cc2c(NC(c3ccc(C(=O)O)cc3)C3C2C=CC3)cc1	S(=O)(=O)(Nc1cc(C)c(C)cc1)c1cc2c(NC(c3ccc(C(=O)O)cc3)C3C2C=CC3)cc1
NCGC00386329-06	S(=O)(=O)(Nc1cc(C2=Cn3c(C(=O)OCC)cnc3C=C2)cnc1)c1ccccc1		Inactive			1	NCGC00386329-06		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	28.5	S(=O)(=O)(Nc1cc(C2=Cn3c(C(=O)OCC)cnc3C=C2)cnc1)c1ccccc1	S(=O)(=O)(Nc1cc(C2=Cn3c(C(=O)OCC)cnc3C=C2)cnc1)c1ccccc1
NCGC00093644-07&NCGC00093644-09	S(=O)(=O)(Nc1cc(OC)c(Nc2c3c(nc4c2cccc4)cccc3)cc1)C		Inactive	DNA Topoisomerase II Inhibitor		2	Amsacrine	404904675.0&384568116.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		S(=O)(=O)(Nc1cc(OC)c(Nc2c3c(nc4c2cccc4)cccc3)cc1)C	S(=O)(=O)(Nc1cc(OC)c(Nc2c3c(nc4c2cccc4)cccc3)cc1)C
NCGC00379087-02	S(=O)(=O)(Nc1cc([C@@H](CC)C=2C(=O)O[C@](CCC)(CCc3ccccc3)CC=2O)ccc1)c1ncc(C(F)(F)F)cc1		Inactive			1	Tipranavir	405558770.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	17.0&0.0	S(=O)(=O)(Nc1cc([C@@H](CC)C=2C(=O)O[C@](CCC)(CCc3ccccc3)CC=2O)ccc1)c1ncc(C(F)(F)F)cc1	S(=O)(=O)(Nc1cc([C@@H](CC)C=2C(=O)O[C@](CCC)(CCc3ccccc3)CC=2O)ccc1)c1ncc(C(F)(F)F)cc1
NCGC00507889-01	S(=O)(=O)(Nc1cc(c(Oc2c(F)cc(F)cc2)cc1)C=1c2c(C(=O)N(C)C=1)[nH]cc2)CC		Inactive	Brd4 Inhibitor		1	Mivebresib (ABBV-075)	384569353.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1cc(c(Oc2c(F)cc(F)cc2)cc1)C=1c2c(C(=O)N(C)C=1)[nH]cc2)CC	S(=O)(=O)(Nc1cc(c(Oc2c(F)cc(F)cc2)cc1)C=1c2c(C(=O)N(C)C=1)[nH]cc2)CC
NCGC00188863-02&NCGC00188863-06	S(=O)(=O)(Nc1cc2c(C(=O)c3ccc(OCCCN(CCCC)CCCC)cc3)c(CCCC)oc2cc1)C		Inactive	alpha,beta-Adrenoceptor Antagonist		2	Dronedarone hydrochloride	170465064.0&384568452.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	20.725705328&0.0	S(=O)(=O)(Nc1cc2c(C(=O)c3ccc(OCCCN(CCCC)CCCC)cc3)c(CCCC)oc2cc1)C	S(=O)(=O)(Nc1cc2c(C(=O)c3ccc(OCCCN(CCCC)CCCC)cc3)c(CCCC)oc2cc1)C
NCGC00344624-17	S(=O)(=O)(Nc1cc2c(NC(=O)N(C)C2)cc1)c1c(OC)cccc1		Inactive	Bromodomain-containing protein 4 Inhibitor		1	PFI-1		2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1cc2c(NC(=O)N(C)C2)cc1)c1c(OC)cccc1	S(=O)(=O)(Nc1cc2c(NC(=O)N(C)C2)cc1)c1c(OC)cccc1
NCGC00168776-03&NCGC00168776-10	S(=O)(=O)(Nc1cc2c([nH]c(C(=O)N3CCN(c4c(NC(C)C)cccn4)CC3)c2)cc1)C		Inactive	Human immunodeficiency virus type 1 reverse transcriptase Inhibitor		2	Delavirdine&Delavirdine (mesylate)	170464664.0&434147213.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1cc2c([nH]c(C(=O)N3CCN(c4c(NC(C)C)cccn4)CC3)c2)cc1)C	S(=O)(=O)(Nc1cc2c([nH]c(C(=O)N3CCN(c4c(NC(C)C)cccn4)CC3)c2)cc1)C
NCGC00378604-04	S(=O)(=O)(Nc1cc2c(cc(-c3c(OC)c(C(C)(C)C)cc(N4C(=O)NC(=O)C=C4)c3)cc2)cc1)C	5.0	Active		0.0	1	ABT-333	377020340.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	3.0	99.6747646481	S(=O)(=O)(Nc1cc2c(cc(-c3c(OC)c(C(C)(C)C)cc(N4C(=O)NC(=O)C=C4)c3)cc2)cc1)C	S(=O)(=O)(Nc1cc2c(cc(-c3c(OC)c(C(C)(C)C)cc(N4C(=O)NC(=O)C=C4)c3)cc2)cc1)C
NCGC00508859-01	S(=O)(=O)(Nc1cc2c(cc1)CN(C(=O)COc1cnccc1)CC2)CC(O)(C)C		Inactive	NAMPT Inhibitor		1	NAMPT-IN-1	384569364.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1cc2c(cc1)CN(C(=O)COc1cnccc1)CC2)CC(O)(C)C	S(=O)(=O)(Nc1cc2c(cc1)CN(C(=O)COc1cnccc1)CC2)CC(O)(C)C
NCGC00388394-02	S(=O)(=O)(Nc1ccc(-n2cncc2)cc1)c1ccc(C(C)(C)C)cc1		Inactive			1	ISCK03	377020513.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1ccc(-n2cncc2)cc1)c1ccc(C(C)(C)C)cc1	S(=O)(=O)(Nc1ccc(-n2cncc2)cc1)c1ccc(C(C)(C)C)cc1
NCGC00386704-01	S(=O)(=O)(Nc1ccc(C(=O)N2CCN(CC3CC3)CC2)cc1)c1c2ncccc2ccc1		Inactive	Phase II PKR Activator, for pyruvate kinase deficiency; however, could be useful for oncology as well.		1	Mitapivat	363680407.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1ccc(C(=O)N2CCN(CC3CC3)CC2)cc1)c1c2ncccc2ccc1	S(=O)(=O)(Nc1ccc(C(=O)N2CCN(CC3CC3)CC2)cc1)c1c2ncccc2ccc1
NCGC00378899-03	S(=O)(=O)(Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1sccc1		Inactive	Nuclear receptor ROR-alpha Inverse Agonist		1	SR 3335	363678265.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1sccc1	S(=O)(=O)(Nc1ccc(C(O)(C(F)(F)F)C(F)(F)F)cc1)c1sccc1
NCGC00181771-02&NCGC00181771-06	S(=O)(=O)(Nc1ccc(C(O)CCCN(CCCCCCC)CC)cc1)C		Inactive	K(ATP) Channel Blocker		2	Ibutilide fumarate	405558709.0&384568401.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1ccc(C(O)CCCN(CCCCCCC)CC)cc1)C	S(=O)(=O)(Nc1ccc(C(O)CCCN(CCCCCCC)CC)cc1)C
NCGC00015919-14&NCGC00015919-17	S(=O)(=O)(Nc1ccc(C(O)CNC(C)C)cc1)C		Inactive	beta-Adrenoceptor Antagonist		2	Sotalol	405558886.0&384567907.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1ccc(C(O)CNC(C)C)cc1)C	S(=O)(=O)(Nc1ccc(C(O)CNC(C)C)cc1)C
NCGC00263234-01	S(=O)(=O)(Nc1ccc(CCCC)cc1)c1cc(C(=O)N2CCN(c3c(C)c(C)ccc3)CC2)c(C)cc1		Inactive	IDH1 Inhibitor		1	IDH-001	137276078.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.1536930559	S(=O)(=O)(Nc1ccc(CCCC)cc1)c1cc(C(=O)N2CCN(c3c(C)c(C)ccc3)CC2)c(C)cc1	S(=O)(=O)(Nc1ccc(CCCC)cc1)c1cc(C(=O)N2CCN(c3c(C)c(C)ccc3)CC2)c(C)cc1
NCGC00387268-04	S(=O)(=O)(Nc1ccc(CCCC)cc1)c1ccc(F)cc1		Inactive	Free fatty acid receptor 1 Antagonist		1	DC260126	363680605.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1ccc(CCCC)cc1)c1ccc(F)cc1	S(=O)(=O)(Nc1ccc(CCCC)cc1)c1ccc(F)cc1
NCGC00370893-01	S(=O)(=O)(Nc1ccc(CCNCCC)cc1)c1ccc(OC(F)(F)F)cc1		Inactive	D(3) dopamine receptor Antagonist		1	PNU 177864 hydrochloride	363677914.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1ccc(CCNCCC)cc1)c1ccc(OC(F)(F)F)cc1	S(=O)(=O)(Nc1ccc(CCNCCC)cc1)c1ccc(OC(F)(F)F)cc1
NCGC00378717-01	S(=O)(=O)(Nc1ccc(CCNC[C@H](O)COc2cc(CNC(=O)C)ccc2)cc1)c1ccccc1		Inactive	Beta-3 adrenergic receptor Antagonist		1	L-748,337	363678169.0	2020_NPACT-8_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1ccc(CCNC[C@H](O)COc2cc(CNC(=O)C)ccc2)cc1)c1ccccc1	S(=O)(=O)(Nc1ccc(CCNC[C@H](O)COc2cc(CNC(=O)C)ccc2)cc1)c1ccccc1
NCGC00538156-01	S(=O)(=O)(Nc1ccc(NC(=O)C(CO)(C)C)cc1)c1c2c(c(N(C)C)ccc2)ccc1		Inactive			1	NCGC00538156-01		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1ccc(NC(=O)C(CO)(C)C)cc1)c1c2c(c(N(C)C)ccc2)ccc1	S(=O)(=O)(Nc1ccc(NC(=O)C(CO)(C)C)cc1)c1c2c(c(N(C)C)ccc2)ccc1
NCGC00522552-01	S(=O)(=O)(Nc1ccc(O)cc1)c1c(OC)ccc(-c2c(C)nc(NC(=O)C(C)(C)C)s2)c1		Inactive			1	PI4KIIIbeta-IN-10	434147175.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	21.5	S(=O)(=O)(Nc1ccc(O)cc1)c1c(OC)ccc(-c2c(C)nc(NC(=O)C(C)(C)C)s2)c1	S(=O)(=O)(Nc1ccc(O)cc1)c1c(OC)ccc(-c2c(C)nc(NC(=O)C(C)(C)C)s2)c1
NCGC00164549-02&NCGC00164549-12	S(=O)(=O)(Nc1ccc(OCCN(CCc2ccc(NS(=O)(=O)C)cc2)C)cc1)C		Inactive	K(V)11.1 (erg1) Channel Blocker		2	Dofetilide	170465418.0&384568251.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1ccc(OCCN(CCc2ccc(NS(=O)(=O)C)cc2)C)cc1)C	S(=O)(=O)(Nc1ccc(OCCN(CCc2ccc(NS(=O)(=O)C)cc2)C)cc1)C
NCGC00095045-05	S(=O)(=O)(Nc1ccc([N+](=O)[O-])cc1)c1ccc(NC(=O)C)cc1		Inactive	Eimeria tenella Inhibitor		1	Sulfanitran	170466141.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1ccc([N+](=O)[O-])cc1)c1ccc(NC(=O)C)cc1	S(=O)(=O)(Nc1ccc([N+](=O)[O-])cc1)c1ccc(NC(=O)C)cc1
NCGC00263155-04&NCGC00263155-09	S(=O)(=O)(Nc1ccccc1)c1cc(/C=C/C(=O)NO)ccc1		Inactive	HDAC Inhibitor		2	Belinostat	384568629.0&404904701.0	Anti-infectives&Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(Nc1ccccc1)c1cc(/C=C/C(=O)NO)ccc1	S(=O)(=O)(Nc1ccccc1)c1cc(/C=C/C(=O)NO)ccc1
NCGC00378390-01	S(=O)(=O)(Nc1ccccc1)c1ccc(C(=O)N(Cc2ccccc2)C)cc1		Inactive	LIMK Inhibitor		1	Compound 2	384569048.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1ccccc1)c1ccc(C(=O)N(Cc2ccccc2)C)cc1	S(=O)(=O)(Nc1ccccc1)c1ccc(C(=O)N(Cc2ccccc2)C)cc1
NCGC00015925-12	S(=O)(=O)(Nc1n(-c2ccccc2)ncc1)c1ccc(N)cc1		Inactive	Antibiotic		1	Sulfaphenazole	170465185.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1n(-c2ccccc2)ncc1)c1ccc(N)cc1	S(=O)(=O)(Nc1n(-c2ccccc2)ncc1)c1ccc(N)cc1
NCGC00018243-09	S(=O)(=O)(Nc1nc(C)cc(C)n1)c1ccc(N)cc1		Inactive	Bacterial dihydropteroate synthase Inhibitor		1	Sulfamethazine	170464893.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1nc(C)cc(C)n1)c1ccc(N)cc1	S(=O)(=O)(Nc1nc(C)cc(C)n1)c1ccc(N)cc1
NCGC00016386-06	S(=O)(=O)(Nc1nc(C)ccn1)c1ccc(N)cc1		Inactive	Bacterial dihydropteroate synthase Inhibitor		1	Sulfamerazine	170464738.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1nc(C)ccn1)c1ccc(N)cc1	S(=O)(=O)(Nc1nc(C)ccn1)c1ccc(N)cc1
NCGC00263229-03	S(=O)(=O)(Nc1nc(C)ccn1)c1ccc(NC(=O)Nc2ccc(S(=O)(=O)Nc3nc(C)ccn3)cc2)cc1		Inactive	Fatty Acid Synthase (FAS) Inhibitor		1	GSK-837149A	363677274.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-13.3583802479	S(=O)(=O)(Nc1nc(C)ccn1)c1ccc(NC(=O)Nc2ccc(S(=O)(=O)Nc3nc(C)ccn3)cc2)cc1	S(=O)(=O)(Nc1nc(C)ccn1)c1ccc(NC(=O)Nc2ccc(S(=O)(=O)Nc3nc(C)ccn3)cc2)cc1
NCGC00164492-02	S(=O)(=O)(Nc1nc(C)nc(C)c1)c1ccc(N)cc1		Inactive			1	Sulfisomidine	170465986.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1nc(C)nc(C)c1)c1ccc(N)cc1	S(=O)(=O)(Nc1nc(C)nc(C)c1)c1ccc(N)cc1
NCGC00183014-01	S(=O)(=O)(Nc1nc(C)nc(OC)c1)c1ccc(N)cc1		Inactive	Bacterial dihydrofolate reductase Inhibitor		1	Sulfamethomidine	144206847.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1nc(C)nc(OC)c1)c1ccc(N)cc1	S(=O)(=O)(Nc1nc(C)nc(OC)c1)c1ccc(N)cc1
NCGC00370811-01	S(=O)(=O)(Nc1nc(N)ccc1)c1ccc(-c2ccc(C#N)cc2)cc1		Inactive	11-beta-hydroxysteroid dehydrogenase 1 Inhibitor		1	PF 915275	363677862.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1nc(N)ccc1)c1ccc(-c2ccc(C#N)cc2)cc1	S(=O)(=O)(Nc1nc(N)ccc1)c1ccc(-c2ccc(C#N)cc2)cc1
NCGC00016375-09	S(=O)(=O)(Nc1nc(OC)nc(OC)c1)c1ccc(N)cc1		Inactive	Antibiotic		1	Sulfadimethoxine	170465690.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1nc(OC)nc(OC)c1)c1ccc(N)cc1	S(=O)(=O)(Nc1nc(OC)nc(OC)c1)c1ccc(N)cc1
NCGC00379081-01	S(=O)(=O)(Nc1nc(SCc2c(F)c(F)ccc2)nc(N[C@@H]([C@@H](O)CO)C)c1)N1CCC1		Inactive	Interleukin-8 receptor B Interacts		1	SRT3109	363678344.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1nc(SCc2c(F)c(F)ccc2)nc(N[C@@H]([C@@H](O)CO)C)c1)N1CCC1	S(=O)(=O)(Nc1nc(SCc2c(F)c(F)ccc2)nc(N[C@@H]([C@@H](O)CO)C)c1)N1CCC1
NCGC00178376-05	S(=O)(=O)(Nc1nc2c(nc1)cccc2)c1ccc(N)cc1		Inactive			1	Sulfaquinoxaline	170465653.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1nc2c(nc1)cccc2)c1ccc(N)cc1	S(=O)(=O)(Nc1nc2c(nc1)cccc2)c1ccc(N)cc1
NCGC00387131-01	S(=O)(=O)(Nc1ncc(C(=O)CSC(=O)C)cc1)c1ccc(OCCCN(C)C)cc1		Inactive	Histone deacetylase Inhibitor		1	KD 5170	363680547.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1ncc(C(=O)CSC(=O)C)cc1)c1ccc(OCCCN(C)C)cc1	S(=O)(=O)(Nc1ncc(C(=O)CSC(=O)C)cc1)c1ccc(OCCCN(C)C)cc1
NCGC00016530-07	S(=O)(=O)(Nc1ncc(OC)cn1)c1ccc(N)cc1		Inactive	Antibiotic		1	Sulfameter	170465428.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1ncc(OC)cn1)c1ccc(N)cc1	S(=O)(=O)(Nc1ncc(OC)cn1)c1ccc(N)cc1
NCGC00090903-01&NCGC00090903-11	S(=O)(=O)(Nc1ncccc1)c1ccc(/N=N/c2cc(C(=O)O)c(O)cc2)cc1		Inactive	NFKB Activation Inhibitor		2	Sulfasalazine	144204588.0&170464716.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(Nc1ncccc1)c1ccc(/N=N/c2cc(C(=O)O)c(O)cc2)cc1	S(=O)(=O)(Nc1ncccc1)c1ccc(/N=N/c2cc(C(=O)O)c(O)cc2)cc1
NCGC00016408-09	S(=O)(=O)(Nc1ncccc1)c1ccc(N)cc1		Inactive	Antibiotic		1	Sulfapyridine	170464707.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1ncccc1)c1ccc(N)cc1	S(=O)(=O)(Nc1ncccc1)c1ccc(N)cc1
NCGC00016305-11	S(=O)(=O)(Nc1ncccn1)c1ccc(N)cc1		Inactive	Antibiotic		1	Silver sulfadiazine	405559001.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1ncccn1)c1ccc(N)cc1	S(=O)(=O)(Nc1ncccn1)c1ccc(N)cc1
NCGC00016572-12	S(=O)(=O)(Nc1ncnc(OC)c1)c1ccc(N)cc1		Inactive			1	Sulfamonomethoxine	170465768.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1ncnc(OC)c1)c1ccc(N)cc1	S(=O)(=O)(Nc1ncnc(OC)c1)c1ccc(N)cc1
NCGC00016324-09	S(=O)(=O)(Nc1nnc(OC)cc1)c1ccc(N)cc1		Inactive			1	Sulfamethoxypyridazine	170466374.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1nnc(OC)cc1)c1ccc(N)cc1	S(=O)(=O)(Nc1nnc(OC)cc1)c1ccc(N)cc1
NCGC00181916-01	S(=O)(=O)(Nc1nnc(OCC)cc1)c1ccc(N)cc1		Inactive			1	Sulfaethoxypyridazine	144206640.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1nnc(OCC)cc1)c1ccc(N)cc1	S(=O)(=O)(Nc1nnc(OCC)cc1)c1ccc(N)cc1
NCGC00016533-24	S(=O)(=O)(Nc1noc(C)c1)c1ccc(N)cc1		Inactive			1	NCGC00016533-24		Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1noc(C)c1)c1ccc(N)cc1	S(=O)(=O)(Nc1noc(C)c1)c1ccc(N)cc1
NCGC00183871-04	S(=O)(=O)(Nc1noc(C)c1)c1ccc(NC(=O)C)cc1		Inactive			1	N-Acetyl sulfamethoxazole	170466005.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1noc(C)c1)c1ccc(NC(=O)C)cc1	S(=O)(=O)(Nc1noc(C)c1)c1ccc(NC(=O)C)cc1
NCGC00182991-01	S(=O)(=O)(Nc1sc(C(C)(C)C)nn1)c1ccccc1		Inactive	insulin secretion Activator		1	Glybuzole	144206873.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1sc(C(C)(C)C)nn1)c1ccccc1	S(=O)(=O)(Nc1sc(C(C)(C)C)nn1)c1ccccc1
NCGC00016407-08&NCGC00016407-16	S(=O)(=O)(Nc1sc(C)nn1)c1ccc(N)cc1		Inactive	Antibacterial		2	Sulfamethizole	170465369.0&384567937.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(Nc1sc(C)nn1)c1ccc(N)cc1	S(=O)(=O)(Nc1sc(C)nn1)c1ccc(N)cc1
NCGC00351476-01	S(=O)(=O)(Nc1sc(CC)nn1)c1ccc(NC(=S)NC(=O)/C=C/c2ccc(F)cc2)cc1		Inactive			1	TG6-129	363677750.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1sc(CC)nn1)c1ccc(NC(=S)NC(=O)/C=C/c2ccc(F)cc2)cc1	S(=O)(=O)(Nc1sc(CC)nn1)c1ccc(NC(=S)NC(=O)/C=C/c2ccc(F)cc2)cc1
NCGC00263773-18	S(=O)(=O)(Nc1sc2c(n1)cccc2)c1ccc(NCc2c(O)c(OC)ccc2)cc1		Inactive	Arachidonate 12-lipoxygenase Inhibitor		1	ML355	363677296.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1sc2c(n1)cccc2)c1ccc(NCc2c(O)c(OC)ccc2)cc1	S(=O)(=O)(Nc1sc2c(n1)cccc2)c1ccc(NCc2c(O)c(OC)ccc2)cc1
NCGC00370730-07	S(=O)(=O)(Nc1scc(-c2cc([N+](=O)[O-])ccc2)n1)c1cc(OC)c(OC)cc1		Inactive	Kynurenine 3-monooxygenase Inhibitor		1	Ro 61-8048	363677828.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1scc(-c2cc([N+](=O)[O-])ccc2)n1)c1cc(OC)c(OC)cc1	S(=O)(=O)(Nc1scc(-c2cc([N+](=O)[O-])ccc2)n1)c1cc(OC)c(OC)cc1
NCGC00485173-01	S(=O)(=O)(Nc1sccn1)c1cc(C#N)c(Oc2c(-c3n(C)ncc3)cccc2)cc1		Inactive			1	PF-04856264	363681247.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1sccn1)c1cc(C#N)c(Oc2c(-c3n(C)ncc3)cccc2)cc1	S(=O)(=O)(Nc1sccn1)c1cc(C#N)c(Oc2c(-c3n(C)ncc3)cccc2)cc1
NCGC00016309-06	S(=O)(=O)(Nc1sccn1)c1ccc(N)cc1		Inactive	Escherichia coli Inhibitor		1	Sulfathiazole	170465454.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Nc1sccn1)c1ccc(N)cc1	S(=O)(=O)(Nc1sccn1)c1ccc(N)cc1
NCGC00379252-02	S(=O)(=O)(Nc1sccn1)c1ccc(NC(=O)C(c2ccccc2)c2ccccc2)cc1		Inactive	Sodium channel protein type 3 subunit alpha Blocker		1	ICA-121431	363678449.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1sccn1)c1ccc(NC(=O)C(c2ccccc2)c2ccccc2)cc1	S(=O)(=O)(Nc1sccn1)c1ccc(NC(=O)C(c2ccccc2)c2ccccc2)cc1
NCGC00016367-08	S(=O)(=O)(Nc1sccn1)c1ccc(NC(=O)CCC(=O)O)cc1		Inactive			1	Succinylsulfathiazole	170465721.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(Nc1sccn1)c1ccc(NC(=O)CCC(=O)O)cc1	S(=O)(=O)(Nc1sccn1)c1ccc(NC(=O)CCC(=O)O)cc1
NCGC00343893-01	S(=O)(=O)(Nc1sccn1)c1ccc(NC(=O)c2c3c(nc(-c4ccccc4)c2)cccc3)cc1		Inactive			1	NCGC00343893-01	161004115.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Nc1sccn1)c1ccc(NC(=O)c2c3c(nc(-c4ccccc4)c2)cccc3)cc1	S(=O)(=O)(Nc1sccn1)c1ccc(NC(=O)c2c3c(nc(-c4ccccc4)c2)cccc3)cc1
NCGC00346547-03	S(=O)(=O)(Nc1scnn1)c1ccc(CCCCCCCCCCCC)cc1	4.9000001	Active	Phosphoinositide Dependent Kinase Inhibitor	0.0	1	PHT-427	384568833.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	126.5393372726	S(=O)(=O)(Nc1scnn1)c1ccc(CCCCCCCCCCCC)cc1	S(=O)(=O)(Nc1scnn1)c1ccc(CCCCCCCCCCCC)cc1
NCGC00380481-01	S(=O)(=O)(O)C12OC3[C@@]4(COC(=O)c5ccccc5)[C@@](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)([C@@](C)(O3)C1)C[C@@H]24		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380481-01	363678604.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(O)C12OC3[C@@]4(COC(=O)c5ccccc5)[C@@](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)([C@@](C)(O3)C1)C[C@@H]24	S(=O)(=O)(O)C12OC3[C@@]4(COC(=O)c5ccccc5)[C@@](O[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)([C@@](C)(O3)C1)C[C@@H]24
NCGC00380901-01	S(=O)(=O)(O)CC1C(=O)OC2C1C(OC(=O)Cc1ccc(O)cc1)CC(C)=C1C(=O)C=C(CO)C21		Inactive	<MOA Unknown> | Class: Terpenoid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380901-01	363678843.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(O)CC1C(=O)OC2C1C(OC(=O)Cc1ccc(O)cc1)CC(C)=C1C(=O)C=C(CO)C21	S(=O)(=O)(O)CC1C(=O)OC2C1C(OC(=O)Cc1ccc(O)cc1)CC(C)=C1C(=O)C=C(CO)C21
NCGC00015997-10&NCGC00015997-12	S(=O)(=O)(O)CCN		Inactive	Antioxidant		2	Taurine	170465726.0&384567914.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)(O)CCN	S(=O)(=O)(O)CCN
NCGC00016936-04	S(=O)(=O)(O)N1[C@@H](C)[C@H](NC(=O)/C(=N/OC(C(=O)O)(C)C)/c2nc(N)sc2)C1=O		Inactive	beta-lactam antibiotic		1	Aztreonam	170465110.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(O)N1[C@@H](C)[C@H](NC(=O)/C(=N/OC(C(=O)O)(C)C)/c2nc(N)sc2)C1=O	S(=O)(=O)(O)N1[C@@H](C)[C@H](NC(=O)/C(=N/OC(C(=O)O)(C)C)/c2nc(N)sc2)C1=O
NCGC00181160-01	S(=O)(=O)(O)c1c(C(C)C)cc2c([C@]3(C)[C@H]([C@@](C(=O)O)(C)CCC3)CC2)c1		Inactive	Urease subunit alpha Inhibitor		1	Ecabet	144206316.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)c1c(C(C)C)cc2c([C@]3(C)[C@H]([C@@](C(=O)O)(C)CCC3)CC2)c1	S(=O)(=O)(O)c1c(C(C)C)cc2c([C@]3(C)[C@H]([C@@](C(=O)O)(C)CCC3)CC2)c1
NCGC00017041-05	S(=O)(=O)(O)c1c(O)ccc(O)c1		Inactive			1	Dobesilate Calcium		Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)c1c(O)ccc(O)c1	S(=O)(=O)(O)c1c(O)ccc(O)c1
NCGC00159404-04	S(=O)(=O)(O)c1c(OC)cc(O)c(C(=O)c2ccccc2)c1		Inactive			1	Sulisobenzone	170465489.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)c1c(OC)cc(O)c(C(=O)c2ccccc2)c1	S(=O)(=O)(O)c1c(OC)cc(O)c(C(=O)c2ccccc2)c1
NCGC00013917-09	S(=O)(=O)(O)c1c2c(c(O)c(/N=N/c3cc4c(cc(S(=O)(=O)O)cc4)cc3)c1)nccc2		Inactive	Protein Tyrosine Phosphatase SHP-2 (PTP2C) Inhibitor		1	NSC-87877	363676433.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)c1c2c(c(O)c(/N=N/c3cc4c(cc(S(=O)(=O)O)cc4)cc3)c1)nccc2	S(=O)(=O)(O)c1c2c(c(O)c(/N=N/c3cc4c(cc(S(=O)(=O)O)cc4)cc3)c1)nccc2
NCGC00166262-03	S(=O)(=O)(O)c1cc2nc(-c3ccccc3)[nH]c2cc1		Inactive			1	Ensulizole	170465490.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)c1cc2nc(-c3ccccc3)[nH]c2cc1	S(=O)(=O)(O)c1cc2nc(-c3ccccc3)[nH]c2cc1
NCGC00248146-03	S(=O)(=O)(O)c1ccc(C)cc1		Inactive			1	4-Methylbenzenesulfonic acid	405558963.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)c1ccc(C)cc1	S(=O)(=O)(O)c1ccc(C)cc1
NCGC00164534-02	S(=O)(=O)(O)c1ccc(O)cc1		Inactive			1	4-Phenolsulfonic acid	170465916.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(O)c1ccc(O)cc1	S(=O)(=O)(O)c1ccc(O)cc1
NCGC00091687-01	S(=O)(=O)(O)c1ccccc1		Inactive			1	Benzene sulfonic acid	17389167.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)c1ccccc1	S(=O)(=O)(O)c1ccccc1
NCGC00166301-04	S(=O)(=O)(OC(CC(C)C)CCC(CCCC)CC)[O-]		Inactive	Vitamin K-dependent protein S Inhibitor		1	SODIUM TETRADECYL SULFATE	405558515.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(OC(CC(C)C)CCC(CCCC)CC)[O-]	S(=O)(=O)(OC(CC(C)C)CCC(CCCC)CC)[O-]
NCGC00386449-03	S(=O)(=O)(OC)N[C@@H]1[C@@H](O)[C@@H](O)[C@H](NC=2n3nc(-c4cc(SC(F)(F)F)ccc4)cc3N=CC=2)C1		Inactive	Ubiquitin-Activating Enzyme E1 Inhibitor		1	MLN-7243	384569142.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(OC)N[C@@H]1[C@@H](O)[C@@H](O)[C@H](NC=2n3nc(-c4cc(SC(F)(F)F)ccc4)cc3N=CC=2)C1	S(=O)(=O)(OC)N[C@@H]1[C@@H](O)[C@@H](O)[C@H](NC=2n3nc(-c4cc(SC(F)(F)F)ccc4)cc3N=CC=2)C1
NCGC00385358-01	S(=O)(=O)(OC1C(C)C2C(/C=C/C=C/C(=O)O)C(/C(=C/C)/C)C(C)=CC2CC1)O		Inactive	<MOA Unknown> | Class: polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00385358-01	363679698.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(OC1C(C)C2C(/C=C/C=C/C(=O)O)C(/C(=C/C)/C)C(C)=CC2CC1)O	S(=O)(=O)(OC1C(C)C2C(/C=C/C=C/C(=O)O)C(/C(=C/C)/C)C(C)=CC2CC1)O
NCGC00262641-04	S(=O)(=O)(OCC(=O)Nc1cc(O)c(C(=O)O)cc1)c1ccc(C)cc1		Inactive	STAT-3 Inhibitor		1	S31-201	384568576.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(OCC(=O)Nc1cc(O)c(C(=O)O)cc1)c1ccc(C)cc1	S(=O)(=O)(OCC(=O)Nc1cc(O)c(C(=O)O)cc1)c1ccc(C)cc1
NCGC00181153-01	S(=O)(=O)(OCC(O)C(O)COS(=O)(=O)C)C		Inactive	cell growth Inhibitor		1	Treosulfan	144206310.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(OCC(O)C(O)COS(=O)(=O)C)C	S(=O)(=O)(OCC(O)C(O)COS(=O)(=O)C)C
NCGC00274082-01	S(=O)(=O)(OCCCCCCCCCCCC)[O-]		Inactive			1	Sodium dodecyl sulfate	170465474.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(OCCCCCCCCCCCC)[O-].[Na+]	S(=O)(=O)(OCCCCCCCCCCCC)[O-].[Na+]
NCGC00090905-12&NCGC00090905-16	S(=O)(=O)(OCCCCOS(=O)(=O)C)C		Inactive	DNA Alkylating Agent		2	Busulfan	170465232.0&384568090.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(OCCCCOS(=O)(=O)C)C	S(=O)(=O)(OCCCCOS(=O)(=O)C)C
NCGC00182974-01	S(=O)(=O)(OCCCNCCCOS(=O)(=O)C)C		Inactive			1	Improsulfan tosylate	144206762.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(OCCCNCCCOS(=O)(=O)C)C.S(=O)(=O)(O)c1ccc(C)cc1	S(=O)(=O)(OCCCNCCCOS(=O)(=O)C)C.S(=O)(=O)(O)c1ccc(C)cc1
NCGC00345794-11	S(=O)(=O)(OC[C@H]1[C@@H](O)C[C@H](n2c3ncnc(N[C@@H]4c5c(cccc5)CC4)c3cc2)C1)N		Inactive	NEDD8-Activating Enzyme (NAE) Inhibitor		1	MLN-4924	384568745.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	30.5&18.5	S(=O)(=O)(OC[C@H]1[C@@H](O)C[C@H](n2c3ncnc(N[C@@H]4c5c(cccc5)CC4)c3cc2)C1)N	S(=O)(=O)(OC[C@H]1[C@@H](O)C[C@H](n2c3ncnc(N[C@@H]4c5c(cccc5)CC4)c3cc2)C1)N
NCGC00178714-04&NCGC00178714-18	S(=O)(=O)(OC[C@]12OC(C)(C)O[C@H]1[C@@H]1OC(C)(C)O[C@@H]1CO2)N		Inactive	Na channel blocker		2	Topiramate	170464746.0&434147050.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(OC[C@]12OC(C)(C)O[C@H]1[C@@H]1OC(C)(C)O[C@@H]1CO2)N	S(=O)(=O)(OC[C@]12OC(C)(C)O[C@H]1[C@@H]1OC(C)(C)O[C@@H]1CO2)N
NCGC00390740-02&NCGC00390740-04	S(=O)(=O)(ON1C(=O)N2[C@H](C(=O)N)CC[C@@H]1C2)[O-]		Inactive			2	Avibactam (sodium)&Avibactam sodium	434147145.0&405559079.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(ON1C(=O)N2[C@H](C(=O)N)CC[C@@H]1C2)[O-]	S(=O)(=O)(ON1C(=O)N2[C@H](C(=O)N)CC[C@@H]1C2)[O-]
NCGC00354779-07	S(=O)(=O)(ON=C1C=C(C)C(=O)C(C)=C1)c1ccc(OC)cc1		Inactive			1	L002		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	16.356104992	S(=O)(=O)(ON=C1C=C(C)C(=O)C(C)=C1)c1ccc(OC)cc1	S(=O)(=O)(ON=C1C=C(C)C(=O)C(C)=C1)c1ccc(OC)cc1
NCGC00162137-02	S(=O)(=O)(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC=2)CC1)[O-]		Inactive	Estrogen receptor alpha Partial Agonist		1	Dehydroepiandrosterone Sulfate (sodium salt)	405558967.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC=2)CC1)[O-]	S(=O)(=O)(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)(C(=O)CC4)CC3)CC=2)CC1)[O-]
NCGC00485084-01	S(=O)(=O)(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](C(=O)C)CC4)CC3)CC=2)CC1)O		Inactive	Glutamate [NMDA] receptor Positive Allosteric Modulator		1	Pregnenolone sulfate sodium salt	363681215.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](C(=O)C)CC4)CC3)CC=2)CC1)O	S(=O)(=O)(O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@@H](C(=O)C)CC4)CC3)CC=2)CC1)O
NCGC00346572-02	S(=O)(=O)(Oc1c(C(C)C)cccc1C(C)C)NC(=O)Cc1c(C(C)C)cc(C(C)C)cc1C(C)C		Inactive	Cyp2C9 Inhibitor		1	Avasimibe	363677457.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Oc1c(C(C)C)cccc1C(C)C)NC(=O)Cc1c(C(C)C)cc(C(C)C)cc1C(C)C	S(=O)(=O)(Oc1c(C(C)C)cccc1C(C)C)NC(=O)Cc1c(C(C)C)cc(C(C)C)cc1C(C)C
NCGC00378997-07	S(=O)(=O)(Oc1c(O)ccc([C@H](O)[C@@H](O)C2C(=O)NC([C@H](O)CC(=O)N)C(=O)N3C([C@@H](O)[C@@H](C)C3)C(=O)N[C@H](O)[C@H](O)C[C@H](NC(=O)c3ccc(-c4noc(-c5ccc(OCCCCC)cc5)c4)cc3)C(=O)NC([C@H](O)C)C(=O)N3C(C(=O)N2)C[C@@H](O)C3)c1)O		Inactive			1	Micafunginsodium	405558539.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Oc1c(O)ccc([C@H](O)[C@@H](O)C2C(=O)NC([C@H](O)CC(=O)N)C(=O)N3C([C@@H](O)[C@@H](C)C3)C(=O)N[C@H](O)[C@H](O)C[C@H](NC(=O)c3ccc(-c4noc(-c5ccc(OCCCCC)cc5)c4)cc3)C(=O)NC([C@H](O)C)C(=O)N3C(C(=O)N2)C[C@@H](O)C3)c1)O	S(=O)(=O)(Oc1c(O)ccc([C@H](O)[C@@H](O)C2C(=O)NC([C@H](O)CC(=O)N)C(=O)N3C([C@@H](O)[C@@H](C)C3)C(=O)N[C@H](O)[C@H](O)C[C@H](NC(=O)c3ccc(-c4noc(-c5ccc(OCCCCC)cc5)c4)cc3)C(=O)NC([C@H](O)C)C(=O)N3C(C(=O)N2)C[C@@H](O)C3)c1)O
NCGC00380433-01	S(=O)(=O)(Oc1cc(O)c2C(=O)OC(C)CCCC(O)CCC/C=C/c2c1)O		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380433-01	363678580.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	16.38026608	S(=O)(=O)(Oc1cc(O)c2C(=O)OC(C)CCCC(O)CCC/C=C/c2c1)O	S(=O)(=O)(Oc1cc(O)c2C(=O)OC(C)CCCC(O)CCC/C=C/c2c1)O
NCGC00386502-01	S(=O)(=O)(Oc1cc2C(N3CCN(C)CC3)=Nc3c(Nc2cc1)cccc3)C(F)(F)F		Inactive	5-hydroxytryptamine receptor 2C Inhibitor		1	GMC 1-169	363680308.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(Oc1cc2C(N3CCN(C)CC3)=Nc3c(Nc2cc1)cccc3)C(F)(F)F	S(=O)(=O)(Oc1cc2C(N3CCN(C)CC3)=Nc3c(Nc2cc1)cccc3)C(F)(F)F
NCGC00480830-01	S(=O)(=O)(Oc1cc2OC(=O)C3=C(c2cc1)CCCCC3)N		Inactive	Carbonic Anhydrase Type II Inhibitor; Steryl-Sulfatase (STS) Inhibitor		1	Irosustat (STX-64)	384569248.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Oc1cc2OC(=O)C3=C(c2cc1)CCCCC3)N	S(=O)(=O)(Oc1cc2OC(=O)C3=C(c2cc1)CCCCC3)N
NCGC00370905-02	S(=O)(=O)(Oc1cc2c(C3CCN(C)CC3)cn(C)c2cc1)c1c(F)cccc1F	5.0500002	Active	Serotonin 6 (5-HT6) receptor Antagonist	0.0	1	SGS 518	363677924.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	3.0	109.4233675072	S(=O)(=O)(Oc1cc2c(C3CCN(C)CC3)cn(C)c2cc1)c1c(F)cccc1F	S(=O)(=O)(Oc1cc2c(C3CCN(C)CC3)cn(C)c2cc1)c1c(F)cccc1F
NCGC00016682-06	S(=O)(=O)(Oc1cc2c([C@@H]3[C@H]([C@@H]4[C@](C)(C(=O)CC4)CC3)CC2)cc1)O		Inactive			1	ESTROPIPATE		Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Oc1cc2c([C@@H]3[C@H]([C@@H]4[C@](C)(C(=O)CC4)CC3)CC2)cc1)O	S(=O)(=O)(Oc1cc2c([C@@H]3[C@H]([C@@H]4[C@](C)(C(=O)CC4)CC3)CC2)cc1)O
NCGC00182711-02	S(=O)(=O)(Oc1ccc(C(c2[nH+]cccc2)c2ccc(OS(=O)(=O)[O-])cc2)cc1)[O-]		Inactive			1	Picosulfate sodium	225144334.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(Oc1ccc(C(c2ncccc2)c2ccc(OS(=O)(=O)[O-])cc2)cc1)[O-]	S(=O)(=O)(Oc1ccc(C(c2ncccc2)c2ccc(OS(=O)(=O)[O-])cc2)cc1)[O-]
NCGC00182082-03	S(=O)(=O)(Oc1ccc(CCOc2ccc(C[C@@H](OCC)C(=O)O)cc2)cc1)C		Inactive			1	Tesaglitazar	170466025.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(Oc1ccc(CCOc2ccc(C[C@@H](OCC)C(=O)O)cc2)cc1)C	S(=O)(=O)(Oc1ccc(CCOc2ccc(C[C@@H](OCC)C(=O)O)cc2)cc1)C
NCGC00162398-11	S(=O)(=O)(Oc1ccc(C[C@H](N(S(=O)(=O)c2c3c(cncc3)ccc2)C)C(=O)N2CCN(c3ccccc3)CC2)cc1)c1c2c(cncc2)ccc1		Inactive			1	NCGC00162398-11		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	22.0	S(=O)(=O)(Oc1ccc(C[C@H](N(S(=O)(=O)c2c3c(cncc3)ccc2)C)C(=O)N2CCN(c3ccccc3)CC2)cc1)c1c2c(cncc2)ccc1	S(=O)(=O)(Oc1ccc(C[C@H](N(S(=O)(=O)c2c3c(cncc3)ccc2)C)C(=O)N2CCN(c3ccccc3)CC2)cc1)c1c2c(cncc2)ccc1
NCGC00183363-01	S(=O)(=O)(Oc1ccc(C[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc2ccccc2)CC(=O)O)CCSC)Cc2c3c([nH]c2)cccc3)CCSC)cc1)O		Inactive	Cholecystokinin A receptor Agonist		1	Sincalide	144207030.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(Oc1ccc(C[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc2ccccc2)CC(=O)O)CCSC)Cc2c3c([nH]c2)cccc3)CCSC)cc1)O	S(=O)(=O)(Oc1ccc(C[C@H](NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc2ccccc2)CC(=O)O)CCSC)Cc2c3c([nH]c2)cccc3)CCSC)cc1)O
NCGC00386992-01	S(=O)(=O)([C@@](C(=O)NO)(CCN1C(=O)C=C(c2c(F)cc(OC)cc2)C=C1)C)C		Inactive	UDP-3-O-acyl-N-acetylglucosamine deacetylase Inhibitor		1	PF 05081090	363680523.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)([C@@](C(=O)NO)(CCN1C(=O)C=C(c2c(F)cc(OC)cc2)C=C1)C)C	S(=O)(=O)([C@@](C(=O)NO)(CCN1C(=O)C=C(c2c(F)cc(OC)cc2)C=C1)C)C
NCGC00164140-07&NCGC00164140-08	S(=O)(=O)([O-])C(C(=O)OCC(CCCC)CC)CC(=O)OCC(CCCC)CC		Inactive			2	Dioctyl sulfosuccinate sodium salt&DOCUSATE SODIUM	225144252.0&434146916.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)([O-])C(C(=O)OCC(CCCC)CC)CC(=O)OCC(CCCC)CC	S(=O)(=O)([O-])C(C(=O)OCC(CCCC)CC)CC(=O)OCC(CCCC)CC
NCGC00274268-01	S(=O)(=O)([O-])C(C(=O)[O-])CC(=O)OCCNC(=O)CCCCCCC/C=C/CCCCCCCC		Inactive			1	NCGC00274268-01	225144369.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])C(C(=O)[O-])CC(=O)OCCNC(=O)CCCCCCC/C=C/CCCCCCCC	S(=O)(=O)([O-])C(C(=O)[O-])CC(=O)OCCNC(=O)CCCCCCC/C=C/CCCCCCCC
NCGC00160478-02	S(=O)(=O)([O-])C1(C)C(=O)c2c(C(=O)C1)cccc2		Inactive	NQO1 protein Substrate		1	Menadione sodium bisulfite	225144239.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])C1(C)C(=O)c2c(C(=O)C1)cccc2	S(=O)(=O)([O-])C1(C)C(=O)c2c(C(=O)C1)cccc2
NCGC00167565-02&NCGC00167565-06	S(=O)(=O)([O-])C1N(C)C=2C(=C/C(=N/NC(=O)N)/C(=O)C=2)C1		Inactive	Hemostatics		2	Carbazochrome sodium sulfonate	384568329.0&405558754.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)([O-])C1N(C)C=2C(=C/C(=N/NC(=O)N)/C(=O)C=2)C1	S(=O)(=O)([O-])C1N(C)C=2C(=C/C(=N/NC(=O)N)/C(=O)C=2)C1
NCGC00532506-01	S(=O)(=O)([O-])CC(=O)OCCCCCCCCCCCC		Inactive			1	SODIUM LAURYL SULFOACETATE	405559116.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])CC(=O)OCCCCCCCCCCCC	S(=O)(=O)([O-])CC(=O)OCCCCCCCCCCCC
NCGC00166409-02	S(=O)(=O)([O-])CC(S)CS		Inactive			1	Sodium 2,3-dimercaptopropanesulfonate monohydrate	225144282.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])CC(S)CS	S(=O)(=O)([O-])CC(S)CS
NCGC00348365-01	S(=O)(=O)([O-])CCCC[N+]1=C(/C=C/C=C/C=C/C=C\2/N(CCCCS(=O)(=O)[O-])c3c(C/2(C)C)c2c(cc3)cccc2)C(C)(C)c2c3c(ccc12)cccc3		Inactive			1	INDOCYANINE GREEN	405558700.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])CCCC[N+]1=C(/C=C/C=C/C=C/C=C\2/N(CCCCS(=O)(=O)[O-])c3c(C/2(C)C)c2c(cc3)cccc2)C(C)(C)c2c3c(ccc12)cccc3	S(=O)(=O)([O-])CCCC[N+]1=C(/C=C/C=C/C=C/C=C\2/N(CCCCS(=O)(=O)[O-])c3c(C/2(C)C)c2c(cc3)cccc2)C(C)(C)c2c3c(ccc12)cccc3
NCGC00167462-03&NCGC00167462-06	S(=O)(=O)([O-])CCCNC(=O)C		Inactive			2	Acamprosate Calcium&ACAMPROSATE CALCIUM	225144287.0&384568315.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&12.9060150359	S(=O)(=O)([O-])CCCNC(=O)C	S(=O)(=O)([O-])CCCNC(=O)C
NCGC00344538-01	S(=O)(=O)([O-])CCCS(=O)(=O)[O-]		Inactive			1	1,3-Propanedisulfonic acid disodium salt	225144385.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])CCCS(=O)(=O)[O-]	S(=O)(=O)([O-])CCCS(=O)(=O)[O-]
NCGC00178318-04&NCGC00178318-05	S(=O)(=O)([O-])CCS		Inactive	Antineoplastic Enhancing Agents		2	Sodium 2-mercaptoethanesulfonate&Mesna	170464862.0&384568354.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(=O)(=O)([O-])CCS.[Na+]	S(=O)(=O)([O-])CCS.[Na+]&S(=O)(=O)([O-])CCS
NCGC00346482-01	S(=O)(=O)([O-])CCSSCCS(=O)(=O)[O-]		Inactive	chemoprotective agent		1	Mesna disulfide	174006230.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O[Na])CCSSCCS(=O)(=O)O[Na]	S(=O)(=O)(O[Na])CCSSCCS(=O)(=O)O[Na]
NCGC00178220-05	S(=O)(=O)([O-])CN(C)C=1C(=O)N(N(C)C=1C)c1ccccc1		Inactive	Prostaglandin G/H synthase 1 Inhibitor		1	Dipyrone	170465672.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])CN(C)C=1C(=O)N(N(C)C=1C)c1ccccc1.[Na+]	S(=O)(=O)([O-])CN(C)C=1C(=O)N(N(C)C=1C)c1ccccc1.[Na+]
NCGC00181167-01	S(=O)(=O)([O-])CNNC(=O)c1ccncc1		Inactive			1	Isoniazid sodium methanesulfonate	144206321.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])CNNC(=O)c1ccncc1.[Na+]	S(=O)(=O)([O-])CNNC(=O)c1ccncc1.[Na+]
NCGC00389552-01	S(=O)(=O)([O-])Cn1c(SCC2=C(C(=O)[O-])N3C(=O)[C@H](NC(=O)[C@H](O)c4ccccc4)[C@H]3SC2)nnn1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	CEFONICID SODIUM	405558752.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])Cn1c(SCC2=C(C(=O)[O-])N3C(=O)[C@H](NC(=O)[C@H](O)c4ccccc4)[C@H]3SC2)nnn1	S(=O)(=O)([O-])Cn1c(SCC2=C(C(=O)[O-])N3C(=O)[C@H](NC(=O)[C@H](O)c4ccccc4)[C@H]3SC2)nnn1
NCGC00162106-17	S(=O)(=O)([O-])[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccc(C(=O)N)cc3)CS[C@H]12)c1ccccc1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	Cefsulodin Sodium Salt	405559010.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccc(C(=O)N)cc3)CS[C@H]12)c1ccccc1	S(=O)(=O)([O-])[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccc(C(=O)N)cc3)CS[C@H]12)c1ccccc1
NCGC00182030-01	S(=O)(=O)([O-])[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)c1ccccc1		Inactive			1	Sulbenicillin disodium	144206509.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)c1ccccc1.[Na+].[Na+]	S(=O)(=O)([O-])[C@@H](C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)[O-])C(C)(C)S[C@H]12)c1ccccc1.[Na+].[Na+]
NCGC00253597-01	S(=O)(=O)([O-])c1c(/C(/c2ccc(N(CC)CC)cc2)=C\2/C=C/C(=[N+](/CC)\CC)/C=C/2)cc(S(=O)(=O)[O-])cc1		Inactive			1	Isosulfan blue	170464639.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)([O-])c1c(/C(/c2ccc(N(CC)CC)cc2)=C\2/C=C/C(=[N+](/CC)\CC)/C=C/2)cc(S(=O)(=O)[O-])cc1.[Na+]	S(=O)(=O)([O-])c1c(/C(/c2ccc(N(CC)CC)cc2)=C\2/C=C/C(=[N+](/CC)\CC)/C=C/2)cc(S(=O)(=O)[O-])cc1.[Na+]
NCGC00181334-04	S(=O)(=O)([O-])c1c(C(C)(C)C)ccc2c1ccc(C(C)(C)C)c2		Inactive			1	DIBUNATE SODIUM	225144323.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])c1c(C(C)(C)C)ccc2c1ccc(C(C)(C)C)c2	S(=O)(=O)([O-])c1c(C(C)(C)C)ccc2c1ccc(C(C)(C)C)c2
NCGC00024822-03	S(=O)(=O)([O-])c1c(N)c2c(O)c(/N=N/c3c(C)cc(-c4cc(C)c(/N=N/c5c(O)c6c(N)c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c6cc5)cc4)cc3)ccc2c(S(=O)(=O)[O-])c1		Inactive	Serum albumin Binding Agent		1	EVANS BLUE	405559142.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)([O-])c1c(N)c2c(O)c(/N=N/c3c(C)cc(-c4cc(C)c(/N=N/c5c(O)c6c(N)c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c6cc5)cc4)cc3)ccc2c(S(=O)(=O)[O-])c1	S(=O)(=O)([O-])c1c(N)c2c(O)c(/N=N/c3c(C)cc(-c4cc(C)c(/N=N/c5c(O)c6c(N)c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])c6cc5)cc4)cc3)ccc2c(S(=O)(=O)[O-])c1
NCGC00344528-01	S(=O)(=O)([O-])c1c(N=Nc2c(C)cc(-c3cc(C)c(N=Nc4c(O)c5c(N)cc(S(=O)(=O)[O-])cc5cc4S(=O)(=O)[O-])cc3)cc2)c(O)c2c(N)cc(S(=O)(=O)[O-])cc2c1		Inactive			1	TRYPAN BLUE	225144379.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)([O-])c1c(N=Nc2c(C)cc(-c3cc(C)c(N=Nc4c(O)c5c(N)cc(S(=O)(=O)[O-])cc5cc4S(=O)(=O)[O-])cc3)cc2)c(O)c2c(N)cc(S(=O)(=O)[O-])cc2c1	S(=O)(=O)([O-])c1c(N=Nc2c(C)cc(-c3cc(C)c(N=Nc4c(O)c5c(N)cc(S(=O)(=O)[O-])cc5cc4S(=O)(=O)[O-])cc3)cc2)c(O)c2c(N)cc(S(=O)(=O)[O-])cc2c1
NCGC00166248-03	S(=O)(=O)([O-])c1c(O)c(C(c2ccc(N(C)C)cc2)=C2C=CC(=[N+](C)C)C=C2)c2c(c1)cc(S(=O)(=O)[O-])cc2		Inactive			1	Green S	405559150.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])c1c(O)c(C(c2ccc(N(C)C)cc2)=C2C=CC(=[N+](C)C)C=C2)c2c(c1)cc(S(=O)(=O)[O-])cc2	S(=O)(=O)([O-])c1c(O)c(C(c2ccc(N(C)C)cc2)=C2C=CC(=[N+](C)C)C=C2)c2c(c1)cc(S(=O)(=O)[O-])cc2
NCGC00187598-03	S(=O)(=O)([O-])c1c(O)c(N=Nc2c3c(c(S(=O)(=O)[O-])cc2)cccc3)c2c(c1)cc(S(=O)(=O)[O-])cc2		Inactive			1	Amaranth	405558767.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])c1c(O)c(N=Nc2c3c(c(S(=O)(=O)[O-])cc2)cccc3)c2c(c1)cc(S(=O)(=O)[O-])cc2	S(=O)(=O)([O-])c1c(O)c(N=Nc2c3c(c(S(=O)(=O)[O-])cc2)cccc3)c2c(c1)cc(S(=O)(=O)[O-])cc2
NCGC00183019-01	S(=O)(=O)([O-])c1c2-c(c(CC)c1)cccc(C(C)C)c2		Inactive	thromboxane A2 signaling pathway Antagonist		1	Egualen sodium	144206815.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)([O-])c1c2-c(c(CC)c1)cccc(C(C)C)c2.[Na+]	S(=O)(=O)([O-])c1c2-c(c(CC)c1)cccc(C(C)C)c2.[Na+]
NCGC00025177-18	S(=O)(=O)([O-])c1c2c(NC(=O)c3cc(NC(=O)c4cc(NC(=O)Nc5cc(C(=O)Nc6c(C)ccc(C(=O)Nc7c8c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])cc8c(S(=O)(=O)[O-])cc7)c6)ccc5)ccc4)c(C)cc3)ccc(S(=O)(=O)[O-])c2cc(S(=O)(=O)[O-])c1		Inactive			1	SURAMIN		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])c1c2c(NC(=O)c3cc(NC(=O)c4cc(NC(=O)Nc5cc(C(=O)Nc6c(C)ccc(C(=O)Nc7c8c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])cc8c(S(=O)(=O)[O-])cc7)c6)ccc5)ccc4)c(C)cc3)ccc(S(=O)(=O)[O-])c2cc(S(=O)(=O)[O-])c1	S(=O)(=O)([O-])c1c2c(NC(=O)c3cc(NC(=O)c4cc(NC(=O)Nc5cc(C(=O)Nc6c(C)ccc(C(=O)Nc7c8c(S(=O)(=O)[O-])cc(S(=O)(=O)[O-])cc8c(S(=O)(=O)[O-])cc7)c6)ccc5)ccc4)c(C)cc3)ccc(S(=O)(=O)[O-])c2cc(S(=O)(=O)[O-])c1
NCGC00167502-01	S(=O)(=O)([O-])c1cc(C(=O)OCC(=O)C2(O)C3(C)C(C4C(F)(C5(C)C(=CC(=O)C=C5)CC4)C(O)C3)CC2C)ccc1		Inactive			1	NCGC00167502-01	50112755.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])c1cc(C(=O)OCC(=O)C2(O)C3(C)C(C4C(F)(C5(C)C(=CC(=O)C=C5)CC4)C(O)C3)CC2C)ccc1	S(=O)(=O)([O-])c1cc(C(=O)OCC(=O)C2(O)C3(C)C(C4C(F)(C5(C)C(=CC(=O)C=C5)CC4)C(O)C3)CC2C)ccc1
NCGC00522027-01	S(=O)(=O)([O-])c1cc(C(=O)OCC(=O)[C@]2(O)[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)CC2)ccc1		Inactive			1	Predocol	405558881.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])c1cc(C(=O)OCC(=O)[C@]2(O)[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)CC2)ccc1	S(=O)(=O)([O-])c1cc(C(=O)OCC(=O)[C@]2(O)[C@]3(C)[C@H]([C@H]4[C@H]([C@@H](O)C3)[C@]3(C)C(=CC(=O)C=C3)CC4)CC2)ccc1
NCGC00090714-01	S(=O)(=O)([O-])c1cc(C)c(C)cc1		Inactive			1	Sodium xylenesulfonate	144204551.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])c1cc(C)c(C)cc1.[Na+]	S(=O)(=O)([O-])c1cc(C)c(C)cc1.[Na+]
NCGC00344534-01	S(=O)(=O)([O-])c1cc2C(=O)/C(=C\3/C(=O)c4c(N/3)ccc(S(=O)(=O)[O-])c4)/Nc2cc1		Inactive			1	Indigo carmine	225144381.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)([O-])c1cc2C(=O)/C(=C\3/C(=O)c4c(N/3)ccc(S(=O)(=O)[O-])c4)/Nc2cc1	S(=O)(=O)([O-])c1cc2C(=O)/C(=C\3/C(=O)c4c(N/3)ccc(S(=O)(=O)[O-])c4)/Nc2cc1
NCGC00485226-01	S(=O)(=O)([O-])c1ccc(Nc2ncnc3n([C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4)cnc23)cc1		Inactive	Adenosine A3 receptor Agonist		1	N<SUP>6</SUP>-p-Sulfophenyladenosine sodium salt	363681263.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)([O-])c1ccc(Nc2ncnc3n([C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4)cnc23)cc1	S(=O)(=O)([O-])c1ccc(Nc2ncnc3n([C@H]4[C@H](O)[C@H](O)[C@@H](CO)O4)cnc23)cc1
NCGC00351779-01	S(=O)(=O)(c1c(N)n(-c2ccc(F)cc2)c2nc3c(nc12)cccc3)c1ccccc1		Inactive	NAD-dependent deacetylase sirtuin 1 Activator		1	SIRT1 Activator II	363677786.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(c1c(N)n(-c2ccc(F)cc2)c2nc3c(nc12)cccc3)c1ccccc1	S(=O)(=O)(c1c(N)n(-c2ccc(F)cc2)c2nc3c(nc12)cccc3)c1ccccc1
NCGC00370934-02	S(=O)(=O)(c1c2c(n(CCN(C)C)c1)nccc2)c1cc(F)ccc1		Inactive	Serotonin 2c (5-HT2c) receptor Antagonist		1	WAY 208466 dihydrochloride	363677944.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(c1c2c(n(CCN(C)C)c1)nccc2)c1cc(F)ccc1	S(=O)(=O)(c1c2c(n(CCN(C)C)c1)nccc2)c1cc(F)ccc1
NCGC00356746-04	S(=O)(=O)(c1cc(C(F)(F)F)ccc1)c1ccc(CNC(=O)c2cnc3[nH]ncc3c2)cc1		Inactive	NAMPT Inhibitor		1	GNE-618	384569031.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(c1cc(C(F)(F)F)ccc1)c1ccc(CNC(=O)c2cnc3[nH]ncc3c2)cc1	S(=O)(=O)(c1cc(C(F)(F)F)ccc1)c1ccc(CNC(=O)c2cnc3[nH]ncc3c2)cc1
NCGC00346620-06	S(=O)(=O)(c1cc(C)c2ncc(C(=O)N)c(Nc3cc(OC)ccc3)c2c1)c1cc(C(=O)N(C)C)ccc1		Inactive	Phosphodiesterase IIII (PDE4) Inhibitor		1	GSK-256066	363677481.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(c1cc(C)c2ncc(C(=O)N)c(Nc3cc(OC)ccc3)c2c1)c1cc(C(=O)N(C)C)ccc1	S(=O)(=O)(c1cc(C)c2ncc(C(=O)N)c(Nc3cc(OC)ccc3)c2c1)c1cc(C(=O)N(C)C)ccc1
NCGC00378624-01	S(=O)(=O)(c1cc(F)cc(F)c1)c1ccc(CNC(=O)C2=Cn3c(ncc3)C=C2)cc1		Inactive	Nicotinamide phosphoribosyltransferase Inhibitor		1	GNE-617 hydrochloride	363678128.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(c1cc(F)cc(F)c1)c1ccc(CNC(=O)C2=Cn3c(ncc3)C=C2)cc1	S(=O)(=O)(c1cc(F)cc(F)c1)c1ccc(CNC(=O)C2=Cn3c(ncc3)C=C2)cc1
NCGC00016322-13	S(=O)(=O)(c1ccc(N)cc1)c1ccc(N)cc1		Inactive	Bacterial dihydropteroate synthase Inhibitor		1	Dapsone	170464895.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(=O)(=O)(c1ccc(N)cc1)c1ccc(N)cc1	S(=O)(=O)(c1ccc(N)cc1)c1ccc(N)cc1
NCGC00387451-01	S(=O)(=O)(c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1)C1(C(=O)NO)CCN(CCOC)CC1		Inactive	Matrix metalloproteinase-9 Inhibitor		1	SD 2590 hydrochloride	363680616.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1)C1(C(=O)NO)CCN(CCOC)CC1	S(=O)(=O)(c1ccc(Oc2ccc(OC(F)(F)F)cc2)cc1)C1(C(=O)NO)CCN(CCOC)CC1
NCGC00346628-05	S(=O)(=O)(c1ccc([C@]2(C(=O)Nc3sc(SCCN4CCCC4)cn3)[C@H](C3CCCCC3)C2)cc1)C1CC1		Inactive	Glucokinase Activator		1	LY-2608204	384568867.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(c1ccc([C@]2(C(=O)Nc3sc(SCCN4CCCC4)cn3)[C@H](C3CCCCC3)C2)cc1)C1CC1	S(=O)(=O)(c1ccc([C@]2(C(=O)Nc3sc(SCCN4CCCC4)cn3)[C@H](C3CCCCC3)C2)cc1)C1CC1
NCGC00386220-04	S(=O)(=O)(c1cnc2c(N3CCNCC3)cccc2c1)c1ccccc1		Inactive	Serotonin 6 (5-HT6) receptor Antagonist		1	SB-742457	363680156.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(c1cnc2c(N3CCNCC3)cccc2c1)c1ccccc1	S(=O)(=O)(c1cnc2c(N3CCNCC3)cccc2c1)c1ccccc1
NCGC00025379-01	S(=O)(=O)(c1n(C)c2c(c1C(C)C)cccc2)c1ccc(OCCCN(CCc2cc(OC)c(OC)cc2)C)cc1		Inactive	Ca2+ channel Antagonist		1	SR 33805	11114298.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(c1n(C)c2c(c1C(C)C)cccc2)c1ccc(OCCCN(CCc2cc(OC)c(OC)cc2)C)cc1	S(=O)(=O)(c1n(C)c2c(c1C(C)C)cccc2)c1ccc(OCCCN(CCc2cc(OC)c(OC)cc2)C)cc1
NCGC00379215-03	S(=O)(=O)(c1oc([N+](=O)[O-])cc1)c1ccc(C)cc1		Inactive	Ubiquitin-conjugating enzyme E2 N Inhibitor		1	NSC697923	363678423.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(c1oc([N+](=O)[O-])cc1)c1ccc(C)cc1	S(=O)(=O)(c1oc([N+](=O)[O-])cc1)c1ccc(C)cc1
NCGC00386236-02	S(=O)(=O)(n1c(-c2c(F)cccc2)cc(CNC)c1)c1cnccc1		Inactive	Potassium-transporting ATPase Blocker		1	TAK 438	405558685.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(n1c(-c2c(F)cccc2)cc(CNC)c1)c1cnccc1	S(=O)(=O)(n1c(-c2c(F)cccc2)cc(CNC)c1)c1cnccc1
NCGC00350414-04	S(=O)(=O)(n1c(C)cc(C)c1)c1c(C)cc(C)cc1C		Inactive	Rap guanine nucleotide exchange factor 4 Inhibitor		1	HJC0350	363677741.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(n1c(C)cc(C)c1)c1c(C)cc(C)cc1C	S(=O)(=O)(n1c(C)cc(C)c1)c1c(C)cc(C)cc1C
MLS000114252-02	S(=O)(=O)(n1c(C)nc2c1cccc2)c1ccc(OCC)cc1		Inactive			1	MLS000114252-02	363676425.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(n1c(C)nc2c1cccc2)c1ccc(OCC)cc1	S(=O)(=O)(n1c(C)nc2c1cccc2)c1ccc(OCC)cc1
MLS000107414-02	S(=O)(=O)(n1c(C)nc2c1cccc2)c1ccc(OCCCC)cc1		Inactive			1	MLS000107414-02	363676423.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(n1c(C)nc2c1cccc2)c1ccc(OCCCC)cc1	S(=O)(=O)(n1c(C)nc2c1cccc2)c1ccc(OCCCC)cc1
NCGC00371046-02	S(=O)(=O)(n1c2c(c(CCN(C)C)c1)cc(OC)cc2)c1ccccc1	4.9000001	Active	Serotonin 7 (5-HT7) receptor Antagonist	0.0	1	MS 245 oxalate	363678006.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	83.2295238109	S(=O)(=O)(n1c2c(c(CCN(C)C)c1)cc(OC)cc2)c1ccccc1	S(=O)(=O)(n1c2c(c(CCN(C)C)c1)cc(OC)cc2)c1ccccc1
NCGC00370815-01	S(=O)(=O)(n1c2c(cc1)ccc(N1CC3N(CC1)CCC3)c2)c1c2c(ccc1)cccc2	4.9000001	Active	Serotonin 6 (5-HT6) receptor Antagonist	0.0	1	NPS ALX Compound 4a dihydrochloride	363677866.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	3.0	100.1310234429	S(=O)(=O)(n1c2c(cc1)ccc(N1CC3N(CC1)CCC3)c2)c1c2c(ccc1)cccc2	S(=O)(=O)(n1c2c(cc1)ccc(N1CC3N(CC1)CCC3)c2)c1c2c(ccc1)cccc2
MLS000109973-02	S(=O)(=O)(n1c2c(nc1)cc(C)c(C)c2)c1ccc(OC)cc1		Inactive			1	MLS000109973-02	363676424.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(n1c2c(nc1)cc(C)c(C)c2)c1ccc(OC)cc1	S(=O)(=O)(n1c2c(nc1)cc(C)c(C)c2)c1ccc(OC)cc1
MLS000107042-02	S(=O)(=O)(n1c2c(nc1)cccc2)c1c(C)ccc(C)c1		Inactive			1	MLS000107042-02	363676422.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(n1c2c(nc1)cccc2)c1c(C)ccc(C)c1	S(=O)(=O)(n1c2c(nc1)cccc2)c1c(C)ccc(C)c1
MLS000033224-02	S(=O)(=O)(n1c2c(nc1)cccc2)c1ccc(S(=O)(=O)N2CCCCCC2)cc1		Inactive			1	MLS000033224-02	363676420.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(=O)(=O)(n1c2c(nc1)cccc2)c1ccc(S(=O)(=O)N2CCCCCC2)cc1	S(=O)(=O)(n1c2c(nc1)cccc2)c1ccc(S(=O)(=O)N2CCCCCC2)cc1
NCGC00381559-05&NCGC00381559-06	S(=O)(=O)(n1cc(/C=C/C(=O)NO)cc1)c1ccc(CN(C)C)cc1		Inactive	HDAC Inhibitor		2	Resminostat	434147117.0&384569099.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(n1cc(/C=C/C(=O)NO)cc1)c1ccc(CN(C)C)cc1	S(=O)(=O)(n1cc(/C=C/C(=O)NO)cc1)c1ccc(CN(C)C)cc1
NCGC00384199-05	S(=O)(=O)(n1cc(/C=C/C(=O)Nc2c(N)cccc2)cc1)c1ccc(-c2cn(C)nc2)cc1		Inactive	HDAC Inhibitor		1	4SC-202	384569106.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(=O)(=O)(n1cc(/C=C/C(=O)Nc2c(N)cccc2)cc1)c1ccc(-c2cn(C)nc2)cc1	S(=O)(=O)(n1cc(/C=C/C(=O)Nc2c(N)cccc2)cc1)c1ccc(-c2cn(C)nc2)cc1
NCGC00181773-01	S(=O)([O-])(=NC(=O)CC)c1ccc(-c2c(C)onc2-c2ccccc2)cc1		Inactive	Cyclooxygenase-2 Inhibitor		1	Parecoxib sodium	144206591.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)([O-])(=NC(=O)CC)c1ccc(-c2c(C)onc2-c2ccccc2)cc1.[Na+]	S(=O)([O-])(=NC(=O)CC)c1ccc(-c2c(C)onc2-c2ccccc2)cc1.[Na+]
NCGC00249901-01	S(C#N)CC(=O)O		Inactive			1	Thiocyanoacetic acid sodium salt	170465517.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(C#N)CC(=O)[O-].[Na+]	S(C#N)CC(=O)[O-].[Na+]
NCGC00013037-01	S(C#N)CC(=O)O[C@H]1[C@@]2(C)C(C)(C)[C@@H](C1)CC2		Inactive			1	Thanite	144203555.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C#N)CC(=O)O[C@H]1[C@@]2(C)C(C)(C)[C@@H](C1)CC2	S(C#N)CC(=O)O[C@H]1[C@@]2(C)C(C)(C)[C@@H](C1)CC2
NCGC00371134-02	S(C#N)c1c(N)nc(N)c(SC#N)c1		Inactive	Ubiquitin carboxyl-terminal hydrolase isozyme L3 Inhibitor		1	PR-619	434147102.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	20.3078651719	S(C#N)c1c(N)nc(N)c(SC#N)c1	S(C#N)c1c(N)nc(N)c(SC#N)c1
NCGC00016764-04	S(C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCOP(=O)(O)O)C(=O)c1ccccc1		Inactive			1	Benfotiamine	170465987.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCOP(=O)(O)O)C(=O)c1ccccc1	S(C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCOP(=O)(O)O)C(=O)c1ccccc1
NCGC00165871-04	S(C(=O)C(C)C)CCCCCCC(=O)Nc1scc(-c2ccccc2)n1		Inactive			1	NCH 51		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(C(=O)C(C)C)CCCCCCC(=O)Nc1scc(-c2ccccc2)n1	S(C(=O)C(C)C)CCCCCCC(=O)Nc1scc(-c2ccccc2)n1
NCGC00386198-07	S(C(=O)C(C)C)c1c(NC(=O)C2(CC(CC)CC)CCCCC2)cccc1		Inactive	Cholesteryl ester transfer protein Modulator		1	Dalcetrapib	384569114.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C(=O)C(C)C)c1c(NC(=O)C2(CC(CC)CC)CCCCC2)cccc1	S(C(=O)C(C)C)c1c(NC(=O)C2(CC(CC)CC)CCCCC2)cccc1
NCGC00179511-08	S(C(=O)C)CC(C(=O)NCC(=O)OCc1ccccc1)Cc1ccccc1		Inactive	Neprilysin (Enkephalinase, Neutral Endopeptidase, NEP) Inhibitor		1	Racecadotril	384568376.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C(=O)C)CC(C(=O)NCC(=O)OCc1ccccc1)Cc1ccccc1	S(C(=O)C)CC(C(=O)NCC(=O)OCc1ccccc1)Cc1ccccc1
NCGC00182987-01	S(C(=O)C)CC(C(=O)O)CC(=O)c1ccc(C)cc1		Inactive	cytokine production involved in inflammatory response Inhibitor		1	Esonarimod	144206833.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(C(=O)C)CC(C(=O)O)CC(=O)c1ccc(C)cc1	S(C(=O)C)CC(C(=O)O)CC(=O)c1ccc(C)cc1
NCGC00182037-01	S(C(=O)C)C[C@H](C(=O)N1[C@H](C(=O)N[C@H](C(=O)O)Cc2ccccc2)CCC1)C		Inactive	Angiotensin-I Converting Enzyme Inhibitor		1	Alacepril	124893756.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(C(=O)C)C[C@H](C(=O)N1[C@H](C(=O)N[C@H](C(=O)O)Cc2ccccc2)CCC1)C	S(C(=O)C)C[C@H](C(=O)N1[C@H](C(=O)N[C@H](C(=O)O)Cc2ccccc2)CCC1)C
NCGC00015948-10	S(C(=O)C)[C@H]1[C@H]2[C@H]3[C@@](C)([C@@]4(OC(=O)CC4)CC3)CC[C@@H]2[C@]2(C)C(=CC(=O)CC2)C1		Inactive			1	Spironolactone		Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C(=O)C)[C@H]1[C@H]2[C@H]3[C@@](C)([C@@]4(OC(=O)CC4)CC3)CC[C@@H]2[C@]2(C)C(=CC(=O)CC2)C1	S(C(=O)C)[C@H]1[C@H]2[C@H]3[C@@](C)([C@@]4(OC(=O)CC4)CC3)CC[C@@H]2[C@]2(C)C(=CC(=O)CC2)C1
NCGC00183026-01	S(C(=O)OCC)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)OCC		Inactive			1	Dicethiamine hydrochloride	144206821.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(C(=O)OCC)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)OCC.Cl	S(C(=O)OCC)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)OCC.Cl
NCGC00168973-03	S(C(=O)OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C3C(=O)O[C@H]([C@@H]23)C=1)C		Inactive	<MOA Unknown> | Class: Iridoid | Genus: Putoria | Family: N/A | Species: calabrica		1	NCGC00168973-03	363676733.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(C(=O)OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C3C(=O)O[C@H]([C@@H]23)C=1)C	S(C(=O)OCC=1[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=C3C(=O)O[C@H]([C@@H]23)C=1)C
NCGC00179308-04	S(C(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)CC21)=CC(=O)C=C3)CF		Inactive	Corticosteroid		1	Fluticasone propionate	170464975.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(C(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)CC21)=CC(=O)C=C3)CF	S(C(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)CC21)=CC(=O)C=C3)CF
NCGC00179308-13	S(C(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)C[C@@H]21)=CC(=O)C=C3)CF		Inactive	Corticosteroid		1	Fluticasone propionate	384568371.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)C[C@@H]21)=CC(=O)C=C3)CF	S(C(=O)[C@@]1(OC(=O)CC)[C@H](C)C[C@@H]2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)C[C@@H]21)=CC(=O)C=C3)CF
NCGC00386509-01	S(C(=O)[C@@]1(OC(=O)c2occc2)[C@H](C)CC2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)CC21)=CC(=O)C=C3)CF		Inactive	Glucocorticoid Receptor (GR) Agonist		1	Fluticasone furoate	384569143.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&19.84422524	S(C(=O)[C@@]1(OC(=O)c2occc2)[C@H](C)CC2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)CC21)=CC(=O)C=C3)CF	S(C(=O)[C@@]1(OC(=O)c2occc2)[C@H](C)CC2[C@]1(C)C[C@H](O)[C@]1(F)[C@]3(C)C([C@@H](F)CC21)=CC(=O)C=C3)CF
NCGC00182993-01	S(C(=O)c1ccccc1)CC(=O)NCC(=O)NCC(=O)NCC(=O)O		Inactive			1	Betiatide	144206816.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(C(=O)c1ccccc1)CC(=O)NCC(=O)NCC(=O)NCC(=O)O	S(C(=O)c1ccccc1)CC(=O)NCC(=O)NCC(=O)NCC(=O)O
NCGC00167455-02	S(C(=O)c1ccccc1)C[C@@H](C(=O)N1[C@H](C(=O)O)C[C@H](Sc2ccccc2)C1)C		Inactive			1	Zofenopril	170465605.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C(=O)c1ccccc1)C[C@@H](C(=O)N1[C@H](C(=O)O)C[C@H](Sc2ccccc2)C1)C	S(C(=O)c1ccccc1)C[C@@H](C(=O)N1[C@H](C(=O)O)C[C@H](Sc2ccccc2)C1)C
NCGC00167543-05	S(C(=O)c1occc1)CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)[C@H]2SC1		Inactive	Cephalosporin antibiotic		1	CEFTIOFUR HYDROCHLORIDE	405558783.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C(=O)c1occc1)CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)[C@H]2SC1	S(C(=O)c1occc1)CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N/OC)/c3nc(N)sc3)[C@H]2SC1
NCGC00378562-01	S(C(C(=O)N1c2c(Sc3c1cccc3)cccc2)CC)c1nnc2c([nH]c3c2cccc3)n1		Inactive			1	Inauhzin		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(C(C(=O)N1c2c(Sc3c1cccc3)cccc2)CC)c1nnc2c([nH]c3c2cccc3)n1	S(C(C(=O)N1c2c(Sc3c1cccc3)cccc2)CC)c1nnc2c([nH]c3c2cccc3)n1
NCGC00015480-17	S(C(C(=O)O)(C)C)c1ccc(CCN(C(=O)NC2CCCCC2)CCCCC2CCCCC2)cc1		Inactive	PPARalpha Agonist		1	GW-7647	384567856.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-8.4716840479	S(C(C(=O)O)(C)C)c1ccc(CCN(C(=O)NC2CCCCC2)CCCCC2CCCCC2)cc1	S(C(C(=O)O)(C)C)c1ccc(CCN(C(=O)NC2CCCCC2)CCCCC2CCCCC2)cc1
NCGC00484071-01&NCGC00485966-01	S(C(C)(C)C)c1c(CC(C(=O)O)(C)C)n(Cc2ccc(-c3cnc(OCC)cc3)cc2)c2c1cc(OCc1ncc(C)cc1)cc2		Inactive	5-lipoxygenase activating protein Inhibitor		2	GSK2190915 (sodium salt)&GSK2190915	363681163.0&363681449.0	2020_NPACT-1_CPE&2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(C(C)(C)C)c1c(CC(C(=O)[O-])(C)C)n(Cc2ccc(-c3cnc(OCC)cc3)cc2)c2c1cc(OCc1ncc(C)cc1)cc2	S(C(C)(C)C)c1c(CC(C(=O)[O-])(C)C)n(Cc2ccc(-c3cnc(OCC)cc3)cc2)c2c1cc(OCc1ncc(C)cc1)cc2&S(C(C)(C)C)c1c(CC(C(=O)O)(C)C)n(Cc2ccc(-c3cnc(OCC)cc3)cc2)c2c1cc(OCc1ncc(C)cc1)cc2
NCGC00379075-01	S(C(C)(C)C)c1c(CC(C(=O)O)(C)C)n(Cc2ccc(-c3ncc(OC)cn3)cc2)c2c1cc(OC[C@H]1N(C(=O)C)c3c(cccc3)C1)cc2		Inactive	leukotriene biosynthetic process Inhibitor		1	AM679	363678342.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(C(C)(C)C)c1c(CC(C(=O)O)(C)C)n(Cc2ccc(-c3ncc(OC)cn3)cc2)c2c1cc(OC[C@H]1N(C(=O)C)c3c(cccc3)C1)cc2	S(C(C)(C)C)c1c(CC(C(=O)O)(C)C)n(Cc2ccc(-c3ncc(OC)cn3)cc2)c2c1cc(OC[C@H]1N(C(=O)C)c3c(cccc3)C1)cc2
NCGC00344764-12	S(C(CCSCc1ccccc1)CCCCC(=O)O)Cc1ccccc1		Inactive	altered energy metabolism-directed agent		1	CPI-613	384568729.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	8.94452502	S(C(CCSCc1ccccc1)CCCCC(=O)O)Cc1ccccc1	S(C(CCSCc1ccccc1)CCCCC(=O)O)Cc1ccccc1
NCGC00522551-01	S(C(F)(F)F)c1ccc(C(=O)N[C@@](C#N)(COc2c(C(F)(F)F)ccc(C#N)c2)C)cc1		Inactive			1	Monepantel	405558479.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	18.1633064519	S(C(F)(F)F)c1ccc(C(=O)N[C@@](C#N)(COc2c(C(F)(F)F)ccc(C#N)c2)C)cc1	S(C(F)(F)F)c1ccc(C(=O)N[C@@](C#N)(COc2c(C(F)(F)F)ccc(C#N)c2)C)cc1
NCGC00263905-04	S(C(F)(F)F)c1ccc(Oc2c(C)cc(N3C(=O)N(C)C(=O)NC3=O)cc2)cc1		Inactive			1	TOLTRAZURIL	405558935.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C(F)(F)F)c1ccc(Oc2c(C)cc(N3C(=O)N(C)C(=O)NC3=O)cc2)cc1	S(C(F)(F)F)c1ccc(Oc2c(C)cc(N3C(=O)N(C)C(=O)NC3=O)cc2)cc1
NCGC00182999-01	S(C(F)F)CC(=O)N[C@@]1(OC)C(=O)N2C(C(=O)O)=C(CSc3n(CCO)nnn3)CO[C@@H]12		Inactive	Streptococcus pneumoniae Inhibitor		1	Flomoxef	144206879.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(C(F)F)CC(=O)N[C@@]1(OC)C(=O)N2C(C(=O)O)=C(CSc3n(CCO)nnn3)CO[C@@H]12	S(C(F)F)CC(=O)N[C@@]1(OC)C(=O)N2C(C(=O)O)=C(CSc3n(CCO)nnn3)CO[C@@H]12
NCGC00016777-08&NCGC00016777-10	S(C(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)(C)C)c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1		Inactive	Serine Protease Hepsin Inhibitor		2	Probucol	170464772.0&384567958.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	S(C(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)(C)C)c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1	S(C(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)(C)C)c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1
NCGC00159541-03	S(C(c1ccccc1)(c1ccccc1)c1ccccc1)C[C@@H](N)C(=O)O		Inactive	Mitotic Kinesin Eg5 Inhibitor		1	S-Trityl-L-cysteine	384568185.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C(c1ccccc1)(c1ccccc1)c1ccccc1)C[C@@H](N)C(=O)O	S(C(c1ccccc1)(c1ccccc1)c1ccccc1)C[C@@H](N)C(=O)O
NCGC00485411-01	S(C)C=1C(=O)C=C2[C@@H](NC(=O)C)CCc3c(c(OC)c(OC)c(OC)c3)C2=CC=1		Inactive	Tubulin Inhibitor		1	Thiocolchicine	363681324.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(C)C=1C(=O)C=C2[C@@H](NC(=O)C)CCc3c(c(OC)c(OC)c(OC)c3)C2=CC=1	S(C)C=1C(=O)C=C2[C@@H](NC(=O)C)CCc3c(c(OC)c(OC)c(OC)c3)C2=CC=1
NCGC00159326-03	S(C)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H]([C@H](NC(=O)[C@H]2N(C)C[C@H](CCC)C2)[C@H](O)C)O1		Inactive	Antibiotic		1	Lincomycin hydrochloride	170465252.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H]([C@H](NC(=O)[C@H]2N(C)C[C@H](CCC)C2)[C@H](O)C)O1.Cl	S(C)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H]([C@H](NC(=O)[C@H]2N(C)C[C@H](CCC)C2)[C@H](O)C)O1.Cl
NCGC00380667-01	S(C)[C@@]1(CO)N(C)C(=O)[C@@]2(SC)N(C1=O)[C@@H]1[C@@H](O)C=CC=C1C2		Inactive	<MOA Unknown> | Class: AS | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380667-01	363678701.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(C)[C@@]1(CO)N(C)C(=O)[C@@]2(SC)N(C1=O)[C@@H]1[C@@H](O)C=CC=C1C2	S(C)[C@@]1(CO)N(C)C(=O)[C@@]2(SC)N(C1=O)[C@@H]1[C@@H](O)C=CC=C1C2
NCGC00163548-03	S(C)[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@@H](NC(=O)c3nc4c(nc3)cccc4)COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc3c(nc1)cccc3)COC(=O)[C@@H](C(C)C)N(C)C2=O		Inactive	Antineoplastic Antibiotics		1	Echinomycin	384568246.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		S(C)[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@@H](NC(=O)c3nc4c(nc3)cccc4)COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc3c(nc1)cccc3)COC(=O)[C@@H](C(C)C)N(C)C2=O	S(C)[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@@H](NC(=O)c3nc4c(nc3)cccc4)COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc3c(nc1)cccc3)COC(=O)[C@@H](C(C)C)N(C)C2=O
NCGC00167816-03	S(C)c1cc(OC)c(C(=O)N2CCC(Cc3ccccc3)CC2)cc1		Inactive	p38 MAPK Inhibitor		1	JX-401	384568341.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C)c1cc(OC)c(C(=O)N2CCC(Cc3ccccc3)CC2)cc1	S(C)c1cc(OC)c(C(=O)N2CCC(Cc3ccccc3)CC2)cc1
NCGC00016059-13	S(C)c1cc2N(CCC3N(C)CCCC3)c3c(Sc2cc1)cccc3		Inactive	Serotonin 2c (5-HT2c) receptor Antagonist		1	Thioridazine	170465080.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(C)c1cc2N(CCC3N(C)CCCC3)c3c(Sc2cc1)cccc3	S(C)c1cc2N(CCC3N(C)CCCC3)c3c(Sc2cc1)cccc3
NCGC00510491-01	S(C)c1ccc(C(=O)/C=C/c2cc(C)c(OC(C(=O)O)(C)C)c(C)c2)cc1	4.5	Active	PPARalpha Agonist	0.0	1	Elafibranor	384569453.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	111.5737185279	S(C)c1ccc(C(=O)/C=C/c2cc(C)c(OC(C(=O)O)(C)C)c(C)c2)cc1	S(C)c1ccc(C(=O)/C=C/c2cc(C)c(OC(C(=O)O)(C)C)c(C)c2)cc1
NCGC00015400-05	S(C)c1ccc(C(=O)C2=C(C)NC(=O)N2)cc1		Inactive	Phosphodiesterase 3 Inhibitor		1	Enoximone	170466419.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(C)c1ccc(C(=O)C2=C(C)NC(=O)N2)cc1	S(C)c1ccc(C(=O)C2=C(C)NC(=O)N2)cc1
NCGC00378781-01	S(C)c1ccc(C(=O)N[C@H]2[C@@H](NC(=O)CNC(=O)c3c(NC(=O)NC(C)C)ccc(C(F)(F)F)c3)CCCC2)cc1		Inactive	C-C chemokine receptor type 2 Antagonist		1	BMS CCR2 22	363678195.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(C)c1ccc(C(=O)N[C@H]2[C@@H](NC(=O)CNC(=O)c3c(NC(=O)NC(C)C)ccc(C(F)(F)F)c3)CCCC2)cc1	S(C)c1ccc(C(=O)N[C@H]2[C@@H](NC(=O)CNC(=O)c3c(NC(=O)NC(C)C)ccc(C(F)(F)F)c3)CCCC2)cc1
NCGC00480721-01	S(C)c1nc(Oc2ccc(-c3[nH]c(Nc4cc(C(F)(F)F)ccc4)nn3)cc2)cc(N)n1		Inactive			1	KG 5	377020289.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(C)c1nc(Oc2ccc(-c3[nH]c(Nc4cc(C(F)(F)F)ccc4)nn3)cc2)cc(N)n1	S(C)c1nc(Oc2ccc(-c3[nH]c(Nc4cc(C(F)(F)F)ccc4)nn3)cc2)cc(N)n1
NCGC00015448-06	S(C/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)c1c(C(=O)O)cccc1		Inactive	mTOR Inhibitor		1	Salirasib	384567849.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)c1c(C(=O)O)cccc1	S(C/C=C(/CC/C=C(/CCC=C(C)C)\C)\C)c1c(C(=O)O)cccc1
NCGC00348157-02	S(C/C=C(/CCn1nnc(CCc2ccc(-c3ccccc3)cc2)c1)\C)CCC(=O)OC		Inactive			1	NCGC00348157-02		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(C/C=C(/CCn1nnc(CCc2ccc(-c3ccccc3)cc2)c1)\C)CCC(=O)OC	S(C/C=C(/CCn1nnc(CCc2ccc(-c3ccccc3)cc2)c1)\C)CCC(=O)OC
NCGC00346570-04	S(C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)OCOC(=O)C(C)(C)C)C1CN(C=2SCCN=2)C1		Inactive	Carbapenem Antibiotic		1	Tebipenem pivoxil	405558791.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)OCOC(=O)C(C)(C)C)C1CN(C=2SCCN=2)C1	S(C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)OCOC(=O)C(C)(C)C)C1CN(C=2SCCN=2)C1
NCGC00164551-05	S(C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)[O-])C1C[n+]2n(cnc2)C1		Inactive			1	Biapenem	405558526.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)[O-])C1C[n+]2n(cnc2)C1	S(C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)[O-])C1C[n+]2n(cnc2)C1
NCGC00023016-07	S(CC#N)CC(=O)N[C@]1(OC)C(=O)N2C(C(=O)O)=C(CSc3n(C)nnn3)CS[C@H]12		Inactive	Bacterial penicillin-binding protein Inhibitor		1	Cefmetazole sodium	170465052.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC#N)CC(=O)N[C@]1(OC)C(=O)N2C(C(=O)[O-])=C(CSc3n(C)nnn3)CS[C@H]12.[Na+]	S(CC#N)CC(=O)N[C@]1(OC)C(=O)N2C(C(=O)[O-])=C(CSc3n(C)nnn3)CS[C@H]12.[Na+]
NCGC00387186-01	S(CC(=O)N(c1scc(C)n1)C1CC1)c1nnc(-c2ccccc2)cc1		Inactive	Solute carrier family 12 member 5 Inhibitor		1	VU 0463271	363680561.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC(=O)N(c1scc(C)n1)C1CC1)c1nnc(-c2ccccc2)cc1	S(CC(=O)N(c1scc(C)n1)C1CC1)c1nnc(-c2ccccc2)cc1
NCGC00370975-03	S(CC(=O)N1[C@H](C(=O)Nc2c(-c3ccccc3)cccc2)CCC1)c1n(C)c2c(n1)cccc2		Inactive			1	TCS 1102	363677969.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC(=O)N1[C@H](C(=O)Nc2c(-c3ccccc3)cccc2)CCC1)c1n(C)c2c(n1)cccc2	S(CC(=O)N1[C@H](C(=O)Nc2c(-c3ccccc3)cccc2)CCC1)c1n(C)c2c(n1)cccc2
NCGC00386905-01	S(CC(=O)NCCN1CCNCC1)c1nn2C(C)=C(Cc3ccc(C)cc3)C(C)=Nc2n1		Inactive			1	NCGC00386905-01	363680493.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC(=O)NCCN1CCNCC1)c1nn2C(C)=C(Cc3ccc(C)cc3)C(C)=Nc2n1	S(CC(=O)NCCN1CCNCC1)c1nn2C(C)=C(Cc3ccc(C)cc3)C(C)=Nc2n1
NCGC00408921-01	S(CC(=O)NCCc1ccccc1)Cc1c(C)oc(-c2ccc(CC)cc2)n1		Inactive	Catenin beta-1 Binding Agent		1	iCRT3	363681086.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC(=O)NCCc1ccccc1)Cc1c(C)oc(-c2ccc(CC)cc2)n1	S(CC(=O)NCCc1ccccc1)Cc1c(C)oc(-c2ccc(CC)cc2)n1
NCGC00162116-04	S(CC(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(=O)C)CS[C@H]12)c1ccncc1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	Cephapirin sodium	170465306.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(CC(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(=O)C)CS[C@H]12)c1ccncc1.[Na+]	S(CC(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(COC(=O)C)CS[C@H]12)c1ccncc1.[Na+]
NCGC00101581-01	S(CC(=O)Nc1cc(C)c(C)cc1)c1nc(-c2c(OC)cccc2)[nH]n1		Inactive			1	NCGC00101581-01	24275279.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC(=O)Nc1cc(C)c(C)cc1)c1nc(-c2c(OC)cccc2)[nH]n1	S(CC(=O)Nc1cc(C)c(C)cc1)c1nc(-c2c(OC)cccc2)[nH]n1
NCGC00386903-01	S(CC(=O)Nc1cc2c(cc1)CCC2)C=1N(c2ccccc2)C(=O)c2c(N=1)cccc2	4.9000001	Active		0.0	1	NCGC00386903-01	363680492.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	3.0	51.323408038	S(CC(=O)Nc1cc2c(cc1)CCC2)C=1N(c2ccccc2)C(=O)c2c(N=1)cccc2	S(CC(=O)Nc1cc2c(cc1)CCC2)C=1N(c2ccccc2)C(=O)c2c(N=1)cccc2
NCGC00168109-05	S(CC(=O)Nc1ccc(-n2c(-c3cc4OCOc4cc3)nc(OC)n2)cc1)c1ccccc1		Inactive	GEF Inhibitor		1	Secin H3	363676677.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC(=O)Nc1ccc(-n2c(-c3cc4OCOc4cc3)nc(OC)n2)cc1)c1ccccc1	S(CC(=O)Nc1ccc(-n2c(-c3cc4OCOc4cc3)nc(OC)n2)cc1)c1ccccc1
NCGC00379245-06	S(CC(=O)Nc1ncc(-c2ccccc2)cc1)C=1N(c2ccccc2)C(=O)C=2SCCC=2N=1		Inactive	Probable protein-cysteine N-palmitoyltransferase porcupine Inhibitor		1	IWP-L6	363678444.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC(=O)Nc1ncc(-c2ccccc2)cc1)C=1N(c2ccccc2)C(=O)C=2SCCC=2N=1	S(CC(=O)Nc1ncc(-c2ccccc2)cc1)C=1N(c2ccccc2)C(=O)C=2SCCC=2N=1
NCGC00387496-01	S(CC(=O)Nc1sc(Cc2c3c(ccc2)cccc3)cn1)c1nc(C)cc(C)n1		Inactive	NAD-dependent deacetylase sirtuin 2 Inhibitor		1	SirReal 2	363680645.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC(=O)Nc1sc(Cc2c3c(ccc2)cccc3)cn1)c1nc(C)cc(C)n1	S(CC(=O)Nc1sc(Cc2c3c(ccc2)cccc3)cn1)c1nc(C)cc(C)n1
NCGC00047353-02	S(CC(=O)Nc1sc2c(n1)ccc(C)c2)C=1N(C)C(=O)C=2SC(C)CC=2N=1		Inactive			1	IWP 12		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC(=O)Nc1sc2c(n1)ccc(C)c2)C=1N(C)C(=O)C=2SC(C)CC=2N=1	S(CC(=O)Nc1sc2c(n1)ccc(C)c2)C=1N(C)C(=O)C=2SC(C)CC=2N=1
NCGC00387247-04	S(CC(=O)Nc1sc2c(n1)ccc(C)c2)C=1N(c2c(OC)cccc2)C(=O)C=2SCCC=2N=1		Inactive	Wnt signaling pathway Inhibitor		1	IWP-4	363680592.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC(=O)Nc1sc2c(n1)ccc(C)c2)C=1N(c2c(OC)cccc2)C(=O)C=2SCCC=2N=1	S(CC(=O)Nc1sc2c(n1)ccc(C)c2)C=1N(c2c(OC)cccc2)C(=O)C=2SCCC=2N=1
NCGC00387416-03	S(CC(=O)Nc1sc2c(n1)ccc(C)c2)C=1N(c2ccc(F)cc2)C(=O)C=2SCCC=2N=1		Inactive	Wnt signaling pathway Inhibitor		1	IWP-3	363680611.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC(=O)Nc1sc2c(n1)ccc(C)c2)C=1N(c2ccc(F)cc2)C(=O)C=2SCCC=2N=1	S(CC(=O)Nc1sc2c(n1)ccc(C)c2)C=1N(c2ccc(F)cc2)C(=O)C=2SCCC=2N=1
NCGC00347948-15	S(CC(=O)Nc1sc2c(n1)ccc(C)c2)C=1N(c2ccccc2)C(=O)C=2SCCC=2N=1		Inactive	Wnt Signaling Inhibitor		1	IWP-2	384568995.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC(=O)Nc1sc2c(n1)ccc(C)c2)C=1N(c2ccccc2)C(=O)C=2SCCC=2N=1	S(CC(=O)Nc1sc2c(n1)ccc(C)c2)C=1N(c2ccccc2)C(=O)C=2SCCC=2N=1
NCGC00185774-02&NCGC00185774-06	S(CC(=O)O)CC(=O)NC1C(=O)SCC1		Inactive	Mucolytic Agent		2	Erdosteine	170465586.0&384568426.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S(CC(=O)O)CC(=O)NC1C(=O)SCC1	S(CC(=O)O)CC(=O)NC1C(=O)SCC1
NCGC00263559-01	S(CC(=O)O)CC(N)C(=O)O		Inactive	regulation of mucus secretion Modulator		1	Carbocysteine	170465800.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(CC(=O)O)CC(N)C(=O)O	S(CC(=O)O)CC(N)C(=O)O
NCGC00408920-01	S(CC(=O)OCC)C=1N(CCCN2CCCC2)C(=O)c2sc3c(c2N=1)cccc3	4.9000001	Active	Aldehyde dehydrogenase 1A1 Inhibitor	0.0	1	CM037	363681085.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	3.0	33.0	S(CC(=O)OCC)C=1N(CCCN2CCCC2)C(=O)c2sc3c(c2N=1)cccc3	S(CC(=O)OCC)C=1N(CCCN2CCCC2)C(=O)c2sc3c(c2N=1)cccc3
NCGC00379007-02	S(CC(=O)O[C@H]1C2(C)[C@H](C)CCC3([C@@H](C)[C@H](O)[C@@](C=C)(C)C1)[C@H]2C(=O)CC3)C1C[C@@H]2N(C)[C@H](C1)CC2	4.9000001	Active	70S ribosome Inhibitor	0.0	1	Retapamulin	405558888.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	51.8537105158	S(CC(=O)O[C@H]1C2(C)[C@H](C)CCC3([C@@H](C)[C@H](O)[C@@](C=C)(C)C1)[C@H]2C(=O)CC3)C1C[C@@H]2N(C)[C@H](C1)CC2	S(CC(=O)O[C@H]1C2(C)[C@H](C)CCC3([C@@H](C)[C@H](O)[C@@](C=C)(C)C1)[C@H]2C(=O)CC3)C1C[C@@H]2N(C)[C@H](C1)CC2
NCGC00167542-01	S(CC(=O)O[C@H]1[C@]2(C)C(C)CC[C@]3([C@@H](C)[C@H](O)[C@@](C=C)(C)C1)[C@H]2C(=O)CC3)CCN(CC)CC		Inactive	Bacterial 70S ribosome Inhibitor		1	Tiamulin	144206092.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	18.8020565519	S(CC(=O)O[C@H]1[C@]2(C)C(C)CC[C@]3([C@@H](C)[C@H](O)[C@@](C=C)(C)C1)[C@H]2C(=O)CC3)CCN(CC)CC	S(CC(=O)O[C@H]1[C@]2(C)C(C)CC[C@]3([C@@H](C)[C@H](O)[C@@](C=C)(C)C1)[C@H]2C(=O)CC3)CCN(CC)CC
NCGC00408889-01	S(CC(=O)c1sccc1)C=1N(CC(=C)C)C(=O)c2c(sc3c2CCCC3)N=1		Inactive	Phosphodiesterase 4D Antagonist		1	Eggmanone	363681074.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC(=O)c1sccc1)C=1N(CC(=C)C)C(=O)c2c(sc3c2CCCC3)N=1	S(CC(=O)c1sccc1)C=1N(CC(=C)C)C(=O)c2c(sc3c2CCCC3)N=1
NCGC00380713-01	S(CC(N)C(=O)O)C1C(O)(C)/C=C/C(OC)/C(/C)=C/CCC(C)C(C)OC(=O)C1		Inactive	<MOA Unknown> | Class: Alkaloid | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380713-01	363678730.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC(N)C(=O)O)C1C(O)(C)/C=C/C(OC)/C(/C)=C/CCC(C)C(C)OC(=O)C1	S(CC(N)C(=O)O)C1C(O)(C)/C=C/C(OC)/C(/C)=C/CCC(C)C(C)OC(=O)C1
NCGC00380315-02	S(CC(O)C(=O)O)C1CC(=O)CCC(C)OC(=O)CC1		Inactive	<MOA Unknown> | Class: macrolide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380315-02	363678538.0	2020_NPACT-7_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC(O)C(=O)O)C1CC(=O)CCC(C)OC(=O)CC1	S(CC(O)C(=O)O)C1CC(=O)CCC(C)OC(=O)CC1
NCGC00380419-01	S(CC(O)C(=O)O)C1CC(=O)c2c(O)cc(O)cc2CC(=O)OC(C)CCC1		Inactive	<MOA Unknown> | Class: macrolide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00380419-01	363678575.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC(O)C(=O)O)C1CC(=O)c2c(O)cc(O)cc2CC(=O)OC(C)CCC1	S(CC(O)C(=O)O)C1CC(=O)c2c(O)cc(O)cc2CC(=O)OC(C)CCC1
NCGC00181107-01	S(CC(O)CNC(C)(C)C)c1scc(-c2sc(C(=O)N)cc2)n1		Inactive	Adrenergic receptor beta Antagonist		1	Arotinolol hydrochloride	144206274.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC(O)CNC(C)(C)C)c1scc(-c2sc(C(=O)N)cc2)n1.Cl	S(CC(O)CNC(C)(C)C)c1scc(-c2sc(C(=O)N)cc2)n1.Cl
NCGC00381367-01	S(CC(OC(=O)C)C(=O)O)C1CC(=O)CCC(C)OC(=O)CC1		Inactive	<MOA Unknown> | Class: Polyketide | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00381367-01	363679109.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC(OC(=O)C)C(=O)O)C1CC(=O)CCC(C)OC(=O)CC1	S(CC(OC(=O)C)C(=O)O)C1CC(=O)CCC(C)OC(=O)CC1
NCGC00017115-04&NCGC00262537-04	S(CC)c1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3		Inactive	Dopamine receptor Antagonist		2	Thiethylperazine Malate&Thiethylperazine dimalate 	405558764.0	Anti-infectives&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	34.754177664&12.252159696	S(CC)c1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3	S(CC)c1cc2N(CCCN3CCN(C)CC3)c3c(Sc2cc1)cccc3
NCGC00373220-03	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)c1n(C)nnn1		Inactive			1	CEFMENOXIME HYDROCHLORIDE	405558647.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)c1n(C)nnn1	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)c1n(C)nnn1
NCGC00181012-01	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)c1snnc1		Inactive	Peptidoglycan biosynthesis Inhibitor		1	Cefuzonam hydrochloride	144206215.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)c1snnc1.Cl	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)c1snnc1.Cl
NCGC00179514-05	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3c(CN)cccc3)[C@H]2SC1)c1n(CC(=O)O)nnn1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	Ceforanide	405558924.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3c(CN)cccc3)[C@H]2SC1)c1n(CC(=O)O)nnn1	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3c(CN)cccc3)[C@H]2SC1)c1n(CC(=O)O)nnn1
NCGC00179594-03	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3nc(N)sc3)[C@H]2SC1)c1n(CCN(C)C)nnn1		Inactive	Escherichia coli Inhibitor		1	Cefotiam hydrochloride	170465103.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3nc(N)sc3)[C@H]2SC1)c1n(CCN(C)C)nnn1.Cl	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cc3nc(N)sc3)[C@H]2SC1)c1n(CCN(C)C)nnn1.Cl
NCGC00022653-09	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cn3nnnc3)[C@H]2SC1)c1sc(C)nn1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	Cefazolin	170465254.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cn3nnnc3)[C@H]2SC1)c1sc(C)nn1	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cn3nnnc3)[C@H]2SC1)c1sc(C)nn1
NCGC00182064-02	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)Cn3nnnc3)[C@H]2SC1)c1scnn1		Inactive	Peptidoglycan biosynthesis Inhibitor		1	Ceftezole sodium	144206691.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)Cn3nnnc3)[C@H]2SC1)c1scnn1.[Na+]	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)Cn3nnnc3)[C@H]2SC1)c1scnn1.[Na+]
NCGC00185755-03	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1)c1nn[nH]c1		Inactive			1	Cefatrizine		Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1)c1nn[nH]c1	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1)c1nn[nH]c1
NCGC00179599-03&NCGC00179599-13	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](NC(=O)N3C(=O)C(=O)N(CC)CC3)c3ccc(O)cc3)[C@H]2SC1)c1n(C)nnn1		Inactive	Cephalosporin antibiotic&Bacterial penicillin-binding protein Inhibitor		2	Cefoperazone sodium&Cefoperazone (sodium salt)	170465235.0&384568379.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)[C@H](NC(=O)N3C(=O)C(=O)N(CC)CC3)c3ccc(O)cc3)[C@H]2SC1)c1n(C)nnn1.[Na+]	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)[C@H](NC(=O)N3C(=O)C(=O)N(CC)CC3)c3ccc(O)cc3)[C@H]2SC1)c1n(C)nnn1.[Na+]&S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](NC(=O)N3C(=O)C(=O)N(CC)CC3)c3ccc(O)cc3)[C@H]2SC1)c1n(C)nnn1
NCGC00167444-04	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](NC(=O)c3c(O)cc(C)nc3)c3ccc(O)cc3)[C@H]2SC1)c1n(C)nnn1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	Cefpiramide (sodium)	405558753.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](NC(=O)c3c(O)cc(C)nc3)c3ccc(O)cc3)[C@H]2SC1)c1n(C)nnn1	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](NC(=O)c3c(O)cc(C)nc3)c3ccc(O)cc3)[C@H]2SC1)c1n(C)nnn1
NCGC00344529-02	S(CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](OC=O)c3ccccc3)[C@H]2SC1)c1n(C)nnn1		Inactive	Bacterial Penicillin-binding Protein Inhibitor		1	Cefamandole (nafate)	405558584.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)[C@H](OC=O)c3ccccc3)[C@H]2SC1)c1n(C)nnn1	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)[C@H](OC=O)c3ccccc3)[C@H]2SC1)c1n(C)nnn1
NCGC00178851-03	S(CC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)C(C(=O)O)c3ccc(O)cc3)[C@H]2OC1)c1n(C)nnn1		Inactive	Bacterial penicillin-binding protein Inhibitor		1	Moxalactam disodium	170465353.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC1=C(C(=O)[O-])N2C(=O)[C@@](OC)(NC(=O)C(C(=O)[O-])c3ccc(O)cc3)[C@H]2OC1)c1n(C)nnn1.[Na+].[Na+]	S(CC1=C(C(=O)[O-])N2C(=O)[C@@](OC)(NC(=O)C(C(=O)[O-])c3ccc(O)cc3)[C@H]2OC1)c1n(C)nnn1.[Na+].[Na+]
NCGC00016914-06	S(CC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)C3SC(=C(C(=O)O)C(=O)N)S3)[C@H]2SC1)c1n(C)nnn1		Inactive	Bacterial Penicillin-binding Protein Inhibitor		1	CEFOTETAN	405559123.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)C3SC(=C(C(=O)O)C(=O)N)S3)[C@H]2SC1)c1n(C)nnn1	S(CC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)C3SC(=C(C(=O)O)C(=O)N)S3)[C@H]2SC1)c1n(C)nnn1
NCGC00507774-01	S(CC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)[C@H](NC(=O)N3C(=O)C(=O)N(CC)CC3)[C@@H](O)C)[C@H]2SC1)c1n(C)nnn1		Inactive	Peptidoglycan biosynthesis Inhibitor		1	Cefbuperazone 	405558959.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)[C@H](NC(=O)N3C(=O)C(=O)N(CC)CC3)[C@@H](O)C)[C@H]2SC1)c1n(C)nnn1	S(CC1=C(C(=O)O)N2C(=O)[C@@](OC)(NC(=O)[C@H](NC(=O)N3C(=O)C(=O)N(CC)CC3)[C@@H](O)C)[C@H]2SC1)c1n(C)nnn1
NCGC00263855-02	S(CC1=C(C(=O)O)N2C(=O)[C@H](NC(=O)C(O)c3ccccc3)C2SC1)c1n(C)nnn1		Inactive			1	CEFAMANDOLE SODIUM	405558952.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC1=C(C(=O)[O-])N2C(=O)[C@H](NC(=O)C(O)c3ccccc3)C2SC1)c1n(C)nnn1	S(CC1=C(C(=O)[O-])N2C(=O)[C@H](NC(=O)C(O)c3ccccc3)C2SC1)c1n(C)nnn1
NCGC00483046-01	S(CC1=C(C(=O)OC(OC(=O)OC2CCCCC2)C)N2C(=O)[C@@H](NC(=O)Cc3nc(N)sc3)[C@H]2SC1)c1n(CCN(C)C)nnn1		Inactive			1	SCE 2174	405559041.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC1=C(C(=O)OC(OC(=O)OC2CCCCC2)C)N2C(=O)[C@@H](NC(=O)Cc3nc(N)sc3)[C@H]2SC1)c1n(CCN(C)C)nnn1	S(CC1=C(C(=O)OC(OC(=O)OC2CCCCC2)C)N2C(=O)[C@@H](NC(=O)Cc3nc(N)sc3)[C@H]2SC1)c1n(CCN(C)C)nnn1
NCGC00263961-02	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)C=1N(C)N=C(O)C(=O)N=1		Inactive	Solute carrier family 22 member 8 Inhibitor		1	Ceftriaxone disodium trihydrate	170465387.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)C=1N(C)N=C([O-])C(=O)N=1.[Na+].[Na+].O.O.O	S(CC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)/C(=N\OC)/c3nc(N)sc3)[C@H]2SC1)C=1N(C)N=C([O-])C(=O)N=1.[Na+].[Na+].O.O.O
NCGC00180491-02	S(CC1C(O)C(O)C(n2c3N=CNC(=O)c3nc2)O1)C		Inactive	<MOA Unknown> | Class: nucleoside | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00180491-02	363677028.0	2020_NPACT-4_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC1C(O)C(O)C(n2c3N=CNC(=O)c3nc2)O1)C	S(CC1C(O)C(O)C(n2c3N=CNC(=O)c3nc2)O1)C
NCGC00263645-02	S(CC1C(O)C(O)C(n2c3ncnc(N)c3nc2)O1)C		Inactive	Spermine synthase Inhibitor		1	5 -Deoxy-5 -(methylthio)adenosine	363677294.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC1C(O)C(O)C(n2c3ncnc(N)c3nc2)O1)C	S(CC1C(O)C(O)C(n2c3ncnc(N)c3nc2)O1)C
NCGC00506889-01	S(CCC(=O)O)C[C@H]1O[C@H]2[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)O)O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)O)O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)O)O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)O)O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)O)O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)O)O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)O)O1)O2		Inactive			1	Sugammadex	405558538.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CCC(=O)[O-])C[C@H]1O[C@H]2[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O2	S(CCC(=O)[O-])C[C@H]1O[C@H]2[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O[C@@H]1[C@H](O)[C@@H](O)[C@@H]([C@@H](CSCCC(=O)[O-])O1)O2
NCGC00016876-12	S(CCC)c1cc2nc(NC(=O)OC)[nH]c2cc1		Inactive	Tubulin Inhibitor		1	Albendazole	170464897.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CCC)c1cc2nc(NC(=O)OC)[nH]c2cc1	S(CCC)c1cc2nc(NC(=O)OC)[nH]c2cc1
NCGC00379052-01	S(CCC)c1nc(N[C@H]2[C@H](c3cc(F)c(F)cc3)C2)c2nnn([C@H]3[C@H](O)[C@H](O)[C@@H](OCCO)C3)c2n1		Inactive	Purinergic receptor P2Y12 Antagonist		1	Ticagrelor	405558613.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CCC)c1nc(N[C@H]2[C@H](c3cc(F)c(F)cc3)C2)c2nnn([C@H]3[C@H](O)[C@H](O)[C@@H](OCCO)C3)c2n1	S(CCC)c1nc(N[C@H]2[C@H](c3cc(F)c(F)cc3)C2)c2nnn([C@H]3[C@H](O)[C@H](O)[C@@H](OCCO)C3)c2n1
NCGC00263612-03	S(CCCCCCC(=O)NO)c1cc2c(cc1)cccc2		Inactive			1	HNHA		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CCCCCCC(=O)NO)c1cc2c(cc1)cccc2	S(CCCCCCC(=O)NO)c1cc2c(cc1)cccc2
NCGC00188866-01	S(CCCCCOC=1C(=O)C=C(CN2CCOCC2)OC=1)c1c2c(ncc1)cc(C(F)(F)F)cc2		Inactive	Rac1 Inhibitor		1	NCGC00188866	137275837.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CCCCCOC=1C(=O)C=C(CN2CCOCC2)OC=1)c1c2c(ncc1)cc(C(F)(F)F)cc2	S(CCCCCOC=1C(=O)C=C(CN2CCOCC2)OC=1)c1c2c(ncc1)cc(C(F)(F)F)cc2
NCGC00402289-04	S(CCCN)c1c2c(nc3c1cc(OC)cc3)ccc(OC)c2	4.9000001	Active		0.0	1	LDN-192960 DIHYDROCHLORIDE	377020181.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	40.6313940768	S(CCCN)c1c2c(nc3c1cc(OC)cc3)ccc(OC)c2	S(CCCN)c1c2c(nc3c1cc(OC)cc3)ccc(OC)c2
NCGC00379214-02	S(CCCN1C(=O)c2c3c(ccc2)cccc3C1=O)c1n(c(-c2ccncc2)nn1)-c1ccc(OC)cc1		Inactive	Tachykinin NK1 Antagonist		1	WIKI4	363678422.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CCCN1C(=O)c2c3c(ccc2)cccc3C1=O)c1n(c(-c2ccncc2)nn1)-c1ccc(OC)cc1	S(CCCN1C(=O)c2c3c(ccc2)cccc3C1=O)c1n(c(-c2ccncc2)nn1)-c1ccc(OC)cc1
NCGC00485648-01	S(CCCN1CCN(Cc2c(OC)c(OC)c(OC)cc2)CC1)c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1	5.4499998	Active	Oxidative Stress Inhibitor	0.0	1	S-15176 difumarate salt	363681372.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	3.0	80.998870943	S(CCCN1CCN(Cc2c(OC)c(OC)c(OC)cc2)CC1)c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1	S(CCCN1CCN(Cc2c(OC)c(OC)c(OC)cc2)CC1)c1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1
NCGC00015876-11	S(CCN/C(/NC)=C/[N+](=O)[O-])Cc1oc(CN(C)C)cc1		Inactive	Histamine H2 receptor Antagonist		1	Ranitidine	170465134.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(CCN/C(/NC)=C/[N+](=O)[O-])Cc1oc(CN(C)C)cc1	S(CCN/C(/NC)=C/[N+](=O)[O-])Cc1oc(CN(C)C)cc1
NCGC00091439-07	S(CCN/C(=N/C#N)/NC)Cc1c(C)[nH]cn1		Inactive	Multidrug and toxin extrusion protein 1 Inhibitor		1	Cimetidine	170464651.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(CCN/C(=N/C#N)/NC)Cc1c(C)[nH]cn1	S(CCN/C(=N/C#N)/NC)Cc1c(C)[nH]cn1
NCGC00390703-02	S(CCN1CCOCC1)c1[nH]c2c(n1)cc(OCC)cc2		Inactive	Sigma opioid receptor Agonist		1	CM 346(Obenoxazine)	363680973.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CCN1CCOCC1)c1[nH]c2c(n1)cc(OCC)cc2	S(CCN1CCOCC1)c1[nH]c2c(n1)cc(OCC)cc2
NCGC00016934-06	S(CCNC(NC)=C[N+](=O)[O-])Cc1nc(CN(C)C)sc1		Inactive	Histamine H2 receptor Antagonist		1	Nizatidine	170464780.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(CCNC(NC)=C[N+](=O)[O-])Cc1nc(CN(C)C)sc1	S(CCNC(NC)=C[N+](=O)[O-])Cc1nc(CN(C)C)sc1
NCGC00167958-05	S(CCNC=N)C1=C(C(=O)O)N2C(=O)[C@H]([C@H](O)C)[C@H]2C1		Inactive	Penicillin-binding protein 2 Inhibitor		1	Imipenem	170464934.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(CCNC=N)C1=C(C(=O)O)N2C(=O)[C@H]([C@H](O)C)[C@H]2C1	S(CCNC=N)C1=C(C(=O)O)N2C(=O)[C@H]([C@H](O)C)[C@H]2C1
NCGC00159387-03	S(CCOCCO)CCCCCCCCCCCC		Inactive			1	Laureth 10s	170465561.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(CCOCCO)CCCCCCCCCCCC	S(CCOCCO)CCCCCCCCCCCC
NCGC00163683-02	S(CC[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)Cc1ccccc1)C(=O)O)C		Inactive	Opioid growth factor		1	Metenkephalin	174006806.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)Cc1ccccc1)C(=O)O)C	S(CC[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccc(O)cc1)Cc1ccccc1)C(=O)O)C
NCGC00160620-02	S(CC[C@H](N)C(=O)O)C		Inactive	S-adenosylmethionine synthetase (MAT 1 and MAT 2) Substrate		1	L-Methionine	225144244.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(CC[C@H](N)C(=O)O)C	S(CC[C@H](N)C(=O)O)C
NCGC00249931-01	S(CC[C@H](NC(=O)C)C(=O)NCCc1cc(OC(=O)OCC)c(OC(=O)OCC)cc1)C		Inactive	Dopamine D1 receptor Agonist		1	Docarpamine	170465850.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(CC[C@H](NC(=O)C)C(=O)NCCc1cc(OC(=O)OCC)c(OC(=O)OCC)cc1)C	S(CC[C@H](NC(=O)C)C(=O)NCCc1cc(OC(=O)OCC)c(OC(=O)OCC)cc1)C
NCGC00485326-01	S(CC[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@H]3N(C(=O)[C@@H](N)CC(=O)O)CCC3)CCC2)CC(=O)O)CCC1)CC(=O)O)CCCNC(=N)N)Cc1ccccc1)Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N)CCSC)C		Inactive			1	Hylambatin	363681286.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@H]3N(C(=O)[C@@H](N)CC(=O)O)CCC3)CCC2)CC(=O)O)CCC1)CC(=O)O)CCCNC(=N)N)Cc1ccccc1)Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N)CCSC)C	S(CC[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(C(=O)[C@@H](NC(=O)[C@H]2N(C(=O)[C@H]3N(C(=O)[C@@H](N)CC(=O)O)CCC3)CCC2)CC(=O)O)CCC1)CC(=O)O)CCCNC(=N)N)Cc1ccccc1)Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N)CCSC)C
NCGC00183362-01	S(CC[C@H](NC(=O)[C@@H](NC(=O)CCNC(=O)OC(C)(C)C)Cc1c2c([nH]c1)cccc2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(=O)O)C		Inactive	CCK2 receptor Agonist		1	Pentagastrin	124894389.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC[C@H](NC(=O)[C@@H](NC(=O)CCNC(=O)OC(C)(C)C)Cc1c2c([nH]c1)cccc2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(=O)O)C	S(CC[C@H](NC(=O)[C@@H](NC(=O)CCNC(=O)OC(C)(C)C)Cc1c2c([nH]c1)cccc2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(=O)O)C
NCGC00182027-01	S(CC[C@H](NC(=O)[C@@H](NC(=O)OC(CC)(C)C)Cc1c2c([nH]c1)cccc2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(=O)O)C		Inactive	Cholecystokinin receptor Agonist		1	Amogastrin	144206458.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC[C@H](NC(=O)[C@@H](NC(=O)OC(CC)(C)C)Cc1c2c([nH]c1)cccc2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(=O)O)C	S(CC[C@H](NC(=O)[C@@H](NC(=O)OC(CC)(C)C)Cc1c2c([nH]c1)cccc2)C(=O)N[C@H](C(=O)N[C@H](C(=O)N)Cc1ccccc1)CC(=O)O)C
NCGC00485583-01	S(CC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)CCC(=O)O)CO)C(=O)N[C@H](C=O)CC(=O)O)C		Inactive	Caspase-8 Inhibitor		1	N-Acetyl-Glu-Ser-Met-Asp-al	363681365.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(CC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)CCC(=O)O)CO)C(=O)N[C@H](C=O)CC(=O)O)C	S(CC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)C)CCC(=O)O)CO)C(=O)N[C@H](C=O)CC(=O)O)C
NCGC00165961-04	S(CC[C@H](NC(=O)c1c(-c2ccccc2)cc(NC[C@@H](N)CS)cc1)C(=O)OC)C		Inactive			1	FTI-277 hydrochloride	434147194.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(CC[C@H](NC(=O)c1c(-c2ccccc2)cc(NC[C@@H](N)CS)cc1)C(=O)OC)C	S(CC[C@H](NC(=O)c1c(-c2ccccc2)cc(NC[C@@H](N)CS)cc1)C(=O)OC)C
NCGC00420698-02	S(CCc1sc(NC(=O)Cc2ccccc2)nn1)CCc1sc(NC(=O)Cc2ccccc2)nn1		Inactive	Glutaminase Inhibitor		1	BPTES	384569223.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(CCc1sc(NC(=O)Cc2ccccc2)nn1)CCc1sc(NC(=O)Cc2ccccc2)nn1	S(CCc1sc(NC(=O)Cc2ccccc2)nn1)CCc1sc(NC(=O)Cc2ccccc2)nn1
NCGC00181749-01	S(C[C@@H](N)C(=O)O)CC(=O)N[C@]1(OC)C(=O)N2C(C(=O)O)=C(CSc3n(C)nnn3)CS[C@H]12		Inactive	Peptidoglycan biosynthesis Inhibitor		1	Cefminox sodium	144206473.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C[C@@H](N)C(=O)[O-])CC(=O)N[C@]1(OC)C(=O)N2C(C(=O)O)=C(CSc3n(C)nnn3)CS[C@H]12.[Na+]	S(C[C@@H](N)C(=O)[O-])CC(=O)N[C@]1(OC)C(=O)N2C(C(=O)O)=C(CSc3n(C)nnn3)CS[C@H]12.[Na+]
NCGC00484844-01	S(C[C@@H](N)C(=O)O)CCCC/C=C(\NC(=O)[C@H]1C(C)(C)C1)/C(=O)O		Inactive	Renal dipeptidase  Inhibitor		1	Cilastatin	405559021.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C[C@@H](N)C(=O)O)CCCC/C=C(\NC(=O)[C@H]1C(C)(C)C1)/C(=O)O	S(C[C@@H](N)C(=O)O)CCCC/C=C(\NC(=O)[C@H]1C(C)(C)C1)/C(=O)O
NCGC00346877-07	S(C[C@@H]([C@H](C(=O)N[C@H](C(=O)NC)Cc1ccccc1)CC(C)C)C(=O)NO)c1sccc1		Inactive	Matrix Metalloproteinase Inhibitor		1	Batimastat	384568955.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(C[C@@H]([C@H](C(=O)N[C@H](C(=O)NC)Cc1ccccc1)CC(C)C)C(=O)NO)c1sccc1	S(C[C@@H]([C@H](C(=O)N[C@H](C(=O)NC)Cc1ccccc1)CC(C)C)C(=O)NO)c1sccc1
NCGC00346840-06	S(C[C@@H]1O[C@H](c2ccc(NC(=O)CCCCCCC(=O)NO)cc2)O[C@H](c2ccc(CO)cc2)C1)c1oc(c(-c2ccccc2)n1)-c1ccccc1		Inactive	HDAC Inhibitor		1	Tubacin	384568949.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C[C@@H]1O[C@H](c2ccc(NC(=O)CCCCCCC(=O)NO)cc2)O[C@H](c2ccc(CO)cc2)C1)c1oc(c(-c2ccccc2)n1)-c1ccccc1	S(C[C@@H]1O[C@H](c2ccc(NC(=O)CCCCCCC(=O)NO)cc2)O[C@H](c2ccc(CO)cc2)C1)c1oc(c(-c2ccccc2)n1)-c1ccccc1
NCGC00510528-01	S(C[C@@H]1[C@@H](O)CN(Cc2c3ncnc(N)c3[nH]c2)C1)C		Inactive	Inhibitor of MTAP		1	MT-DADMe-ImmA	384569475.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C[C@@H]1[C@@H](O)CN(Cc2c3ncnc(N)c3[nH]c2)C1)C	S(C[C@@H]1[C@@H](O)CN(Cc2c3ncnc(N)c3[nH]c2)C1)C
NCGC00164556-02	S(C[C@H](N)C(=O)O)CCCO		Inactive	Mucin-5AC Inhibitor		1	Fudosteine	170465764.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(C[C@H](N)C(=O)O)CCCO	S(C[C@H](N)C(=O)O)CCCO
NCGC00263221-03	S(C[C@H](NC(=O)CC[C@H](N)C(=O)OCC)C(=O)N[C@@H](C(=O)OCC)c1ccccc1)Cc1ccccc1		Inactive	Glutathione-s-transferase P1 (GSTP1) Inhibitor		1	Ezatiostat	384568675.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(C[C@H](NC(=O)CC[C@H](N)C(=O)OCC)C(=O)N[C@@H](C(=O)OCC)c1ccccc1)Cc1ccccc1	S(C[C@H](NC(=O)CC[C@H](N)C(=O)OCC)C(=O)N[C@@H](C(=O)OCC)c1ccccc1)Cc1ccccc1
NCGC00090782-06&NCGC00090782-17	S(C[C@H](NC(=O)c1c(C)c(O)ccc1)[C@H](O)CN1[C@H](C(=O)NC(C)(C)C)C[C@H]2[C@@H](C1)CCCC2)c1ccccc1	5.7166667	Active	HIV Protease Inhibitors	0.16666700000000034	2	Nelfinavir mesylate&Nelfinavir Mesylate	170465351.0&406861837.0	2019_NPC-2.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	3.0&3.0&3.0&1.1	86.0006346274&148.695203974&103.9014972875&94.5772937247	S(=O)(=O)(O)C.S(C[C@H](NC(=O)c1c(C)c(O)ccc1)[C@H](O)CN1[C@H](C(=O)NC(C)(C)C)C[C@H]2[C@@H](C1)CCCC2)c1ccccc1	S(=O)(=O)(O)C.S(C[C@H](NC(=O)c1c(C)c(O)ccc1)[C@H](O)CN1[C@H](C(=O)NC(C)(C)C)C[C@H]2[C@@H](C1)CCCC2)c1ccccc1&S(C[C@H](NC(=O)c1c(C)c(O)ccc1)[C@H](O)CN1[C@H](C(=O)NC(C)(C)C)C[C@H]2[C@@H](C1)CCCC2)c1ccccc1
NCGC00017366-08	S(C[C@H]1CN(CCC)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1)C		Inactive	Dopamine D3 receptor Agonist		1	Pergolide methanesulfonate	170465250.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(=O)(=O)(O)C.S(C[C@H]1CN(CCC)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1)C	S(=O)(=O)(O)C.S(C[C@H]1CN(CCC)[C@H]2[C@@H](c3c4c([nH]cc4C2)ccc3)C1)C
NCGC00092344-05	S(Cc1c(C)nc(-c2cc(F)c(C(F)(F)F)cc2)s1)c1cc(C)c(OCC(=O)O)cc1		Inactive	PPARgamma Agonist		1	GW-0742	174007302.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(Cc1c(C)nc(-c2cc(F)c(C(F)(F)F)cc2)s1)c1cc(C)c(OCC(=O)O)cc1	S(Cc1c(C)nc(-c2cc(F)c(C(F)(F)F)cc2)s1)c1cc(C)c(OCC(=O)O)cc1
NCGC00241455-04	S(Cc1c(C)nc(-c2ccc(C(F)(F)F)cc2)s1)c1cc(C)c(OCC(=O)O)cc1		Inactive	PPARdelta Agonist		1	GW-501516	384568480.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	15.499392468	S(Cc1c(C)nc(-c2ccc(C(F)(F)F)cc2)s1)c1cc(C)c(OCC(=O)O)cc1	S(Cc1c(C)nc(-c2ccc(C(F)(F)F)cc2)s1)c1cc(C)c(OCC(=O)O)cc1
NCGC00025214-06	S(Cc1c(O)c(OC)cc(/C=C(\C#N)/C(=O)N)c1)c1sc2c(n1)cccc2		Inactive			1	Tyrphostin AG 825	377020159.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(Cc1c(O)c(OC)cc(/C=C(\C#N)/C(=O)N)c1)c1sc2c(n1)cccc2	S(Cc1c(O)c(OC)cc(/C=C(\C#N)/C(=O)N)c1)c1sc2c(n1)cccc2
NCGC00386337-05	S(Cc1ccc(F)cc1)C=1N(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)C2=C(C(=O)N=1)CCC2	5.5999999	Active	LDL-associated phospholipase A2 Inhibitor	0.0	1	Darapladib	363680220.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	3.0	69.7384617822	S(Cc1ccc(F)cc1)C=1N(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)C2=C(C(=O)N=1)CCC2	S(Cc1ccc(F)cc1)C=1N(CC(=O)N(CCN(CC)CC)Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)C2=C(C(=O)N=1)CCC2
NCGC00263167-10	S(Cc1oc(C(C)(C)C)cn1)c1sc(NC(=O)C2CCNCC2)nc1		Inactive	CDK 2/7/9 Inhibitor		1	SNS-032	384568637.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		S(Cc1oc(C(C)(C)C)cn1)c1sc(NC(=O)C2CCNCC2)nc1	S(Cc1oc(C(C)(C)C)cn1)c1sc(NC(=O)C2CCNCC2)nc1
NCGC00346705-02	S(F)(=O)(=O)Cc1ccccc1		Inactive	Serine Protease Inhibitor		1	PMSF	384568924.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(F)(=O)(=O)Cc1ccccc1	S(F)(=O)(=O)Cc1ccccc1
NCGC00015097-03	S(F)(=O)(=O)c1ccc(CCN)cc1		Inactive			1	4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride	90340895.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(F)(=O)(=O)c1ccc(CCN)cc1	S(F)(=O)(=O)c1ccc(CCN)cc1
NCGC00042523-03	S(N1CCOCC1)c1sc2c(n1)cccc2		Inactive			1	N-Oxydiethylenebenzothiazole-2-sulfenamide	170465568.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(N1CCOCC1)c1sc2c(n1)cccc2	S(N1CCOCC1)c1sc2c(n1)cccc2
NCGC00159502-03	S(NC1CCCCC1)c1sc2c(n1)cccc2		Inactive	Aryl hydrocarbon receptor Agonist		1	N-Cyclohexyl-2-benzothiazolesulfenamide	29215472.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(NC1CCCCC1)c1sc2c(n1)cccc2	S(NC1CCCCC1)c1sc2c(n1)cccc2
NCGC00015073-05	S(P(=O)(O)O)CCNCCCN		Inactive	Alkaline phosphatase placental-like Substrate		1	Amifostine	170465179.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(P(=O)(O)O)CCNCCCN	S(P(=O)(O)O)CCNCCCN
NCGC00522018-01	S(P(=O)(OCC)OCC)CC[N+](C)(C)C		Inactive	Cholinesterases; ACHE & BCHE Inhibitor		1	Echothiophate Iodide	405559038.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(P(=O)(OCC)OCC)CC[N+](C)(C)C	S(P(=O)(OCC)OCC)CC[N+](C)(C)C
NCGC00167456-02	S(S/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)C(C)C)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)C(C)C		Inactive			1	Bisibutiamine	170466019.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(S/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)C(C)C)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)C(C)C	S(S/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)C(C)C)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)C(C)C
NCGC00183879-01	S(S/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)c1ccccc1)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)c1ccccc1		Inactive			1	Bisbentiamine	144206468.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(S/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)c1ccccc1)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)c1ccccc1	S(S/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)c1ccccc1)/C(=C(\N(C=O)Cc1c(N)nc(C)nc1)/C)/CCOC(=O)c1ccccc1
NCGC00181294-01	S(SC(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO)C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO		Inactive	HIV Infection Inhibitor		1	Thiamine disulfide	144206326.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(SC(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO)C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO	S(SC(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO)C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO
NCGC00091563-12	S(SC(=S)N(C)C)C(=S)N(C)C		Inactive			1	Thiram	170465664.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0		S(SC(=S)N(C)C)C(=S)N(C)C	S(SC(=S)N(C)C)C(=S)N(C)C
NCGC00181776-02	S(SC(=S)N1CCCCC1)C(=S)N1CCCCC1		Inactive			1	Dicyclopentamethylenethiuram disulfide	170465709.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0		S(SC(=S)N1CCCCC1)C(=S)N1CCCCC1	S(SC(=S)N1CCCCC1)C(=S)N1CCCCC1
NCGC00179291-04	S(SCC1OCCC1)/C(=C(/N(C=O)Cc1c(N)nc(C)nc1)\C)/CCO		Inactive			1	Fursultiamine Hydrochloride	405558735.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(SCC1OCCC1)/C(=C(/N(C=O)Cc1c(N)nc(C)nc1)\C)/CCO	S(SCC1OCCC1)/C(=C(/N(C=O)Cc1c(N)nc(C)nc1)\C)/CCO
NCGC00319022-01	S(SCCC(SC(=O)C)CCCCC(=O)OC)/C(=C(/N(C=O)Cc1c(N)nc(C)nc1)\C)/CCO		Inactive			1	Octotiamine	170465976.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(SCCC(SC(=O)C)CCCCC(=O)OC)/C(=C(/N(C=O)Cc1c(N)nc(C)nc1)\C)/CCO	S(SCCC(SC(=O)C)CCCCC(=O)OC)/C(=C(/N(C=O)Cc1c(N)nc(C)nc1)\C)/CCO
NCGC00167447-02	S(SCCC)C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO		Inactive	Apoptosis Activator		1	Prosultiamine	170465884.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(SCCC)C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO	S(SCCC)C(=C(N(C=O)Cc1c(N)nc(C)nc1)C)CCO
NCGC00181028-02	S(SCCNC(=O)CCNC(=O)[C@H](O)C(CO)(C)C)CCNC(=O)CCNC(=O)[C@H](O)C(CO)(C)C		Inactive	HMG-CoA reductase Inhibitor		1	D-Pantethine	225144316.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(SCCNC(=O)CCNC(=O)[C@H](O)C(CO)(C)C)CCNC(=O)CCNC(=O)[C@H](O)C(CO)(C)C	S(SCCNC(=O)CCNC(=O)[C@H](O)C(CO)(C)C)CCNC(=O)CCNC(=O)[C@H](O)C(CO)(C)C
NCGC00166006-02	S(SC[C@H](N)C(=O)O)C[C@H](N)C(=O)O		Inactive	Cystine/glutamate transporter Substrate		1	L-Cystine	170465457.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(SC[C@H](N)C(=O)O)C[C@H](N)C(=O)O	S(SC[C@H](N)C(=O)O)C[C@H](N)C(=O)O
NCGC00344537-01	S(SC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O		Inactive	Glutathione reductase Substrate		1	L-Glutathione oxidized disodium salt	225144384.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(SC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)[O-])C[C@H](NC(=O)CC[C@H](N)C(=O)[O-])C(=O)NCC(=O)O	S(SC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)[O-])C[C@H](NC(=O)CC[C@H](N)C(=O)[O-])C(=O)NCC(=O)O
NCGC00166140-02	S(SCc1c(CO)c(O)c(C)nc1)Cc1c(CO)c(O)c(C)nc1		Inactive	acetylcholine biosynthetic process Activator		1	Pyrithioxin dihydrochloride	170465839.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(SCc1c(CO)c(O)c(C)nc1)Cc1c(CO)c(O)c(C)nc1.Cl.Cl	S(SCc1c(CO)c(O)c(C)nc1)Cc1c(CO)c(O)c(C)nc1.Cl.Cl
NCGC00164493-02	S(Sc1[n+]([O-])cccc1)c1[n+]([O-])cccc1	5.3499999	Active		0.0	1	Dipyrithione	170465699.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	2.4	33.4636135479	S(Sc1[n+]([O-])cccc1)c1[n+]([O-])cccc1	S(Sc1[n+]([O-])cccc1)c1[n+]([O-])cccc1
NCGC00346876-03	S(Sc1[nH]ccn1)C(CC)C		Inactive	Thioredoxin Reductase Inhibitor		1	PX-12	384568954.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(Sc1[nH]ccn1)C(CC)C	S(Sc1[nH]ccn1)C(CC)C
NCGC00186047-02	S(Sc1c(O)ccc2c1cccc2)c1c(O)ccc2c1cccc2		Inactive	p21-Activated Kinase 1 (PAK1) Inhibitor		1	IPA-3	174006753.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(Sc1c(O)ccc2c1cccc2)c1c(O)ccc2c1cccc2	S(Sc1c(O)ccc2c1cccc2)c1c(O)ccc2c1cccc2
NCGC00091238-03	S(Sc1sc2c(n1)cccc2)c1sc2c(n1)cccc2		Inactive			1	2,2'-Dithiobisbenzothiazole	170465723.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(Sc1sc2c(n1)cccc2)c1sc2c(n1)cccc2	S(Sc1sc2c(n1)cccc2)c1sc2c(n1)cccc2
NCGC00386735-01	S([C@@H](C)c1ccccc1)c1nc(N[C@@H](CO)CC(C)C)c2sc(N)nc2n1		Inactive	Chemokine CX3CR1 Receptor Antagonist		1	AZD-8797	363680425.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S([C@@H](C)c1ccccc1)c1nc(N[C@@H](CO)CC(C)C)c2sc(N)nc2n1	S([C@@H](C)c1ccccc1)c1nc(N[C@@H](CO)CC(C)C)c2sc(N)nc2n1
NCGC00253670-01	S([C@H]1C[C@@H](C(=O)N(C)C)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)O		Inactive	Carbapenem Antibiotic		1	Meropenem	170466350.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&9.169530356	S([C@H]1C[C@@H](C(=O)N(C)C)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)O	S([C@H]1C[C@@H](C(=O)N(C)C)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)O
NCGC00179259-06	S([C@H]1C[C@@H](C(=O)N(C)C)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)[N@]2C=1C(=O)O		Inactive			1	Meropenem	405558497.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S([C@H]1C[C@@H](C(=O)N(C)C)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)[N@]2C=1C(=O)O	S([C@H]1C[C@@H](C(=O)N(C)C)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)[N@]2C=1C(=O)O
NCGC00387409-02	S([C@H]1C[C@@H](C(=O)Nc2cc(C(=O)O)ccc2)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)O		Inactive	Peptidoglycan synthase FtsI Inhibitor		1	Ertapenem	405558624.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S([C@H]1C[C@@H](C(=O)Nc2cc(C(=O)O)ccc2)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)O	S([C@H]1C[C@@H](C(=O)Nc2cc(C(=O)O)ccc2)NC1)C=1[C@H](C)[C@@H]2[C@@H]([C@H](O)C)C(=O)N2C=1C(=O)O
NCGC00510504-01	S([C@H]1[C@H](O)[C@@H](n2nnc(-c3cc(F)ccc3)c2)[C@@H](O)[C@@H](CO)O1)[C@H]1[C@H](O)[C@@H](n2nnc(-c3cc(F)ccc3)c2)[C@@H](O)[C@@H](CO)O1		Inactive	Galectin 3 Inhibitor		1	TD-139	384569465.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S([C@H]1[C@H](O)[C@@H](n2nnc(-c3cc(F)ccc3)c2)[C@@H](O)[C@@H](CO)O1)[C@H]1[C@H](O)[C@@H](n2nnc(-c3cc(F)ccc3)c2)[C@@H](O)[C@@H](CO)O1	S([C@H]1[C@H](O)[C@@H](n2nnc(-c3cc(F)ccc3)c2)[C@@H](O)[C@@H](CO)O1)[C@H]1[C@H](O)[C@@H](n2nnc(-c3cc(F)ccc3)c2)[C@@H](O)[C@@H](CO)O1
NCGC00241108-15	S(c1c(C(=O)NC)cccc1)c1cc2[nH]nc(/C=C/c3ncccc3)c2cc1		Inactive	VEGFR-1/2/3 Inhibitor		1	Axitinib	384568476.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(c1c(C(=O)NC)cccc1)c1cc2[nH]nc(/C=C/c3ncccc3)c2cc1	S(c1c(C(=O)NC)cccc1)c1cc2[nH]nc(/C=C/c3ncccc3)c2cc1
NCGC00241108-04	S(c1c(C(=O)NC)cccc1)c1cc2n[nH]c(/C=C/c3ncccc3)c2cc1		Inactive	VEGFR-1/2/3 Inhibitor		1	Axitinib	170466656.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(c1c(C(=O)NC)cccc1)c1cc2n[nH]c(/C=C/c3ncccc3)c2cc1	S(c1c(C(=O)NC)cccc1)c1cc2n[nH]c(/C=C/c3ncccc3)c2cc1
NCGC00387264-01	S(c1c(C(=O)NCC2(N3CCN(c4ccccc4)CC3)CCOCC2)cccn1)c1ccccc1		Inactive	P2X purinoceptor 7 Antagonist		1	JNJ 47965567	363680603.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(c1c(C(=O)NCC2(N3CCN(c4ccccc4)CC3)CCOCC2)cccn1)c1ccccc1	S(c1c(C(=O)NCC2(N3CCN(c4ccccc4)CC3)CCOCC2)cccn1)c1ccccc1
NCGC00386237-01&NCGC00386237-08	S(c1c(C)cc(C)cc1)c1c(N2CCNCC2)cccc1		Inactive	5-HT1D Receptor Antagonist		2	Brintellix	384569118.0&405558626.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(c1c(C)cc(C)cc1)c1c(N2CCNCC2)cccc1	S(c1c(C)cc(C)cc1)c1c(N2CCNCC2)cccc1
NCGC00229512-05	S(c1c(C)cc(OC)c(C(=O)N2CCN(C(=O)C)CC2)c1)c1sc(NC(=O)c2ccc(CNC(C(C)(C)C)C)cc2)nc1	4.9000001	Active	ITK Inhibitor	0.0	1	BMS-509744	384568462.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	47.0743317318	S(c1c(C)cc(OC)c(C(=O)N2CCN(C(=O)C)CC2)c1)c1sc(NC(=O)c2ccc(CNC(C(C)(C)C)C)cc2)nc1	S(c1c(C)cc(OC)c(C(=O)N2CCN(C(=O)C)CC2)c1)c1sc(NC(=O)c2ccc(CNC(C(C)(C)C)C)cc2)nc1
NCGC00346941-01	S(c1c(C)cc(OC)c(C(=O)N2CCN(C(=O)C)CC2)c1)c1sc(NC(=O)c2ccc(CNC(C(C)C)C)cc2)nc1		Inactive	ITK Inhibitor		1	ITK Inhibitor	174006381.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(c1c(C)cc(OC)c(C(=O)N2CCN(C(=O)C)CC2)c1)c1sc(NC(=O)c2ccc(CNC(C(C)C)C)cc2)nc1	S(c1c(C)cc(OC)c(C(=O)N2CCN(C(=O)C)CC2)c1)c1sc(NC(=O)c2ccc(CNC(C(C)C)C)cc2)nc1
NCGC00181023-03	S(c1c(C)ccc2nc(N)nc(O)c12)c1ccncc1		Inactive			1	NOLATREXED HCL	405558825.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S(c1c(C)ccc2nc(N)nc(O)c12)c1ccncc1	S(c1c(C)ccc2nc(N)nc(O)c12)c1ccncc1
NCGC00476185-01	S(c1c([N+](=O)[O-])cc(/C=C/2\C(=O)NC(=S)S\2)cc1)c1c(C)cccc1		Inactive			1	AM-TS23	377020507.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	26.11428572	S(c1c([N+](=O)[O-])cc(/C=C/2\C(=O)NC(=S)S\2)cc1)c1c(C)cccc1	S(c1c([N+](=O)[O-])cc(/C=C/2\C(=O)NC(=S)S\2)cc1)c1c(C)cccc1
NCGC00263556-10	S(c1c([N+](=O)[O-])cc(C(=O)C)s1)c1c(F)cc(F)cc1		Inactive			1	P 22077	434147076.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	17.192667148	S(c1c([N+](=O)[O-])cc(C(=O)C)s1)c1c(F)cc(F)cc1	S(c1c([N+](=O)[O-])cc(C(=O)C)s1)c1c(F)cc(F)cc1
NCGC00167761-04	S(c1c2c(sc(C(=O)N)c2)cnc1)c1ccc(C)cc1		Inactive	Selectin E Inhibitor		1	A-205804	363676669.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(c1c2c(sc(C(=O)N)c2)cnc1)c1ccc(C)cc1	S(c1c2c(sc(C(=O)N)c2)cnc1)c1ccc(C)cc1
NCGC00181307-01	S(c1cc(NC(=O)COC)c(/N=C(\NC(=O)OC)/NC(=O)OC)cc1)c1ccccc1		Inactive			1	Febantel	144206335.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(c1cc(NC(=O)COC)c(/N=C(\NC(=O)OC)/NC(=O)OC)cc1)c1ccccc1	S(c1cc(NC(=O)COC)c(/N=C(\NC(=O)OC)/NC(=O)OC)cc1)c1ccccc1
NCGC00016855-10&NCGC00016855-19	S(c1cc2nc(NC(=O)OC)[nH]c2cc1)c1ccccc1		Inactive	antiparasitic agent		2	Fenbendazole	170465647.0&384567963.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(c1cc2nc(NC(=O)OC)[nH]c2cc1)c1ccccc1	S(c1cc2nc(NC(=O)OC)[nH]c2cc1)c1ccccc1
NCGC00378762-01	S(c1ccc([N+](=O)[O-])cc1)c1ccc(NC(=O)Nc2c(C(C)C)cccc2C(C)C)cc1		Inactive	Acyl coenzyme A:cholesterol acyltransferase 2 Inhibitor		1	VULM 1457	363678184.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(c1ccc([N+](=O)[O-])cc1)c1ccc(NC(=O)Nc2c(C(C)C)cccc2C(C)C)cc1	S(c1ccc([N+](=O)[O-])cc1)c1ccc(NC(=O)Nc2c(C(C)C)cccc2C(C)C)cc1
NCGC00015060-18&NCGC00015060-28	S(c1n(C)cnc1[N+](=O)[O-])c1ncnc2nc[nH]c12		Inactive	Purine Antagonist		2	Azathioprine	170464989.0&384567803.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S(c1n(C)cnc1[N+](=O)[O-])c1ncnc2nc[nH]c12	S(c1n(C)cnc1[N+](=O)[O-])c1ncnc2nc[nH]c12
NCGC00263145-02	S(c1n(c(O)nn1)-c1cc2OCCOc2cc1)c1sc([N+](=O)[O-])cn1		Inactive	SAPK1 (JNK) Inhibitor		1	BI-78D3	384568620.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		S(c1n(c(O)nn1)-c1cc2OCCOc2cc1)c1sc([N+](=O)[O-])cn1	S(c1n(c(O)nn1)-c1cc2OCCOc2cc1)c1sc([N+](=O)[O-])cn1
NCGC00263163-11	S(c1n2N=C(c3cn(C)nc3)C=Cc2nn1)c1cc2c(nccc2)cc1		Inactive	HGFR Inhibitor		1	SGX-523	384568634.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(c1n2N=C(c3cn(C)nc3)C=Cc2nn1)c1cc2c(nccc2)cc1	S(c1n2N=C(c3cn(C)nc3)C=Cc2nn1)c1cc2c(nccc2)cc1
NCGC00378960-01	S(c1n2N=C(c3cn(C)nc3)C=Cc2nn1)c1cc2c(nn(C)c2)cc1		Inactive			1	c-Met inhibitor 1	363678294.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S(c1n2N=C(c3cn(C)nc3)C=Cc2nn1)c1cc2c(nn(C)c2)cc1	S(c1n2N=C(c3cn(C)nc3)C=Cc2nn1)c1cc2c(nn(C)c2)cc1
NCGC00168110-05	S(c1nc(Nc2[nH]nc(C)c2)cc(N2CCN(C)CC2)n1)c1ccc(NC(=O)C2CC2)cc1		Inactive	Aurora-A/B/C Kinase Inhibitor		1	Tozasertib	363676678.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		S(c1nc(Nc2[nH]nc(C)c2)cc(N2CCN(C)CC2)n1)c1ccc(NC(=O)C2CC2)cc1	S(c1nc(Nc2[nH]nc(C)c2)cc(N2CCN(C)CC2)n1)c1ccc(NC(=O)C2CC2)cc1
NCGC00378568-07	S(c1sc(C)nn1)c1ncnc2c1cc(OC)c(OC)c2	4.9000001	Active		0.0	1	SKLB1002	377020287.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	3.0	77.2976483958	S(c1sc(C)nn1)c1ncnc2c1cc(OC)c(OC)c2	S(c1sc(C)nn1)c1ncnc2c1cc(OC)c(OC)c2
NCGC00480922-01	S(c1sc(NC(=O)Nc2ccc(C)cc2)nn1)c1ncnc2c1ccc(OCCCN1CCOCC1)c2		Inactive	Flt3 Inhibitor		1	SKLB4771	377020364.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(c1sc(NC(=O)Nc2ccc(C)cc2)nn1)c1ncnc2c1ccc(OCCCN1CCOCC1)c2	S(c1sc(NC(=O)Nc2ccc(C)cc2)nn1)c1ncnc2c1ccc(OCCCN1CCOCC1)c2
NCGC00483038-01	S(c1scc(-c2cc[n+](C)cc2)n1)C1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OCC)/c3nc(NP(=O)(O)O)sn3)[C@H]2SC1		Inactive			1	TAK-599	405558609.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S(c1scc(-c2cc[n+](C)cc2)n1)C1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OCC)/c3nc(NP(=O)(O)O)sn3)[C@H]2SC1	S(c1scc(-c2cc[n+](C)cc2)n1)C1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OCC)/c3nc(NP(=O)(O)O)sn3)[C@H]2SC1
NCGC00346833-03	S/C(/C(=O)O)=C\c1c2c([nH]c1)ccc(F)c2		Inactive			1	PD-151746	434147096.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S/C(/C(=O)O)=C\c1c2c([nH]c1)ccc(F)c2	S/C(/C(=O)O)=C\c1c2c([nH]c1)ccc(F)c2
NCGC00091146-08	S1c2c(Nc3c1cccc3)cccc2		Inactive	Trichostrongylus colubriformis Inhibitor		1	Phenothiazine	170466563.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S1c2c(Nc3c1cccc3)cccc2	S1c2c(Nc3c1cccc3)cccc2
NCGC00390600-01	S=C(N(C)C)CC=1C(=O)N(Cc2ccc(-c3c(-c4[nH]nnn4)cccc3)cc2)C(CCCC)=NC=1C		Inactive	Angiotensin II receptor Antagonist		1	Fimasartan	363680921.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S=C(N(C)C)CC=1C(=O)N(Cc2ccc(-c3c(-c4[nH]nnn4)cccc3)cc2)C(CCCC)=NC=1C	S=C(N(C)C)CC=1C(=O)N(Cc2ccc(-c3c(-c4[nH]nnn4)cccc3)cc2)C(CCCC)=NC=1C
NCGC00183862-01	S=C(N(CC(=O)O)C)c1c2c(c(C(F)(F)F)c(OC)cc2)ccc1		Inactive	Aldose Reductase Inhibitor		1	Tolrestat	144206867.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S=C(N(CC(=O)O)C)c1c2c(c(C(F)(F)F)c(OC)cc2)ccc1	S=C(N(CC(=O)O)C)c1c2c(c(C(F)(F)F)c(OC)cc2)ccc1
NCGC00183656-11	S=C(N(NC(=O)CC(=O)NN(C(=S)c1ccccc1)C)C)c1ccccc1		Inactive	Copper Chelator		1	Elesclomol (STA-4783)	363677096.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-11.8005648001	S=C(N(NC(=O)CC(=O)NN(C(=S)c1ccccc1)C)C)c1ccccc1	S=C(N(NC(=O)CC(=O)NN(C(=S)c1ccccc1)C)C)c1ccccc1
NCGC00094466-03	S=C(N)C(C#N)=Cc1cc(O)c(O)cc1		Inactive			1	Tyrphostin 47	90341238.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S=C(N)C(C#N)=Cc1cc(O)c(O)cc1	S=C(N)C(C#N)=Cc1cc(O)c(O)cc1
NCGC00016497-09&NCGC00016497-13	S=C(N)c1cc(CC)ncc1		Inactive	Cell Wall Biosynthesis Inhibitor		2	Ethionamide	170465169.0&384567946.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S=C(N)c1cc(CC)ncc1	S=C(N)c1cc(CC)ncc1
NCGC00095164-04&NCGC00095164-06	S=C(N)c1cc(CCC)ncc1		Inactive	tuberculosis treatment		2	Protionamide	170465795.0&384568153.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S=C(N)c1cc(CCC)ncc1	S=C(N)c1cc(CCC)ncc1
NCGC00386745-04	S=C(N)c1ccc(OC(=O)C(C)c2cc3c(cc(OC)cc3)cc2)cc1		Inactive	Cyclooxygenase-2 Inhibitor		1	ATB-346	363680430.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S=C(N)c1ccc(OC(=O)C(C)c2cc3c(cc(OC)cc3)cc2)cc1	S=C(N)c1ccc(OC(=O)C(C)c2cc3c(cc(OC)cc3)cc2)cc1
NCGC00386321-01	S=C(N/N=C/c1c(N)cccn1)N		Inactive	Ribonucleoside-Diphosphate Reductase Inhibitor		1	Triapine	384569126.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S=C(N/N=C/c1c(N)cccn1)N	S=C(N/N=C/c1c(N)cccn1)N
NCGC00483925-02	S=C(NC(=O)Cc1ccc(F)cc1)Nc1cc(F)c(Oc2c3sc(-c4ncc(CNCCOC)cc4)cc3ncc2)cc1	5.8499999	Active	VEGFR-1/2/3 Inhibitor	0.0	1	Glesatinib	384569266.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.4	43.7776267959	S=C(NC(=O)Cc1ccc(F)cc1)Nc1cc(F)c(Oc2c3sc(-c4ncc(CNCCOC)cc4)cc3ncc2)cc1	S=C(NC(=O)Cc1ccc(F)cc1)Nc1cc(F)c(Oc2c3sc(-c4ncc(CNCCOC)cc4)cc3ncc2)cc1
NCGC00346510-06	S=C(NC(=O)Cc1ccccc1)Nc1cc(F)c(Oc2c3sc(-c4ncn(C)c4)cc3ncc2)cc1	5.4499998	Active	HGFR Inhibitor	0.0	1	MGCD-265	384568812.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	2.4	49.548154428	S=C(NC(=O)Cc1ccccc1)Nc1cc(F)c(Oc2c3sc(-c4ncn(C)c4)cc3ncc2)cc1	S=C(NC(=O)Cc1ccccc1)Nc1cc(F)c(Oc2c3sc(-c4ncn(C)c4)cc3ncc2)cc1
NCGC00386664-02	S=C(NC(=O)c1cc(OC)c(OC)c(OC)c1)Nc1cc(NC(=O)c2ccccc2)ccc1		Inactive	Smoothened homolog Antagonist		1	MRT 10	363680381.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S=C(NC(=O)c1cc(OC)c(OC)c(OC)c1)Nc1cc(NC(=O)c2ccccc2)ccc1	S=C(NC(=O)c1cc(OC)c(OC)c(OC)c1)Nc1cc(NC(=O)c2ccccc2)ccc1
NCGC00181351-13	S=C(NC(=O)c1ccc(C(C)(C)C)cc1)Nc1ccc(NC(=O)C)cc1		Inactive	Cellular tumor antigen p53 Activator		1	Tenovin-1		2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S=C(NC(=O)c1ccc(C(C)(C)C)cc1)Nc1ccc(NC(=O)C)cc1	S=C(NC(=O)c1ccc(C(C)(C)C)cc1)Nc1ccc(NC(=O)C)cc1
NCGC00347068-02	S=C(NC(=O)c1ccccc1)Nc1c(C(=O)O)c2c(s1)COC(C)(C)C2		Inactive	Rab7 GTPase Inhibitor		1	KUC103669N	384568983.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S=C(NC(=O)c1ccccc1)Nc1c(C(=O)O)c2c(s1)COC(C)(C)C2	S=C(NC(=O)c1ccccc1)Nc1c(C(=O)O)c2c(s1)COC(C)(C)C2
NCGC00015988-11	S=C(NC1CCCCC1)N1CCC(c2nc[nH]c2)CC1		Inactive			1	Thioperamide maleate salt	363676470.0	2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S=C(NC1CCCCC1)N1CCC(c2nc[nH]c2)CC1	S=C(NC1CCCCC1)N1CCC(c2nc[nH]c2)CC1
NCGC00091400-02	S=C(NCC=C)N		Inactive			1	Allylthiourea	170465680.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S=C(NCC=C)N	S=C(NCC=C)N
NCGC00263158-07	S=C(NCc1cc2OCOc2cc1)N1CCN(c2ncnc3c2oc2c3cccc2)CC1	4.9499998	Active	PDGFR alpha Inhibitor	0.0	1	Amuvatinib	363677235.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	61.0831718751	S=C(NCc1cc2OCOc2cc1)N1CCN(c2ncnc3c2oc2c3cccc2)CC1	S=C(NCc1cc2OCOc2cc1)N1CCN(c2ncnc3c2oc2c3cccc2)CC1
NCGC00538144-01	S=C(Nc1cc(C(F)(F)F)ccc1)N1C(C)CCCC1C		Inactive	Taenia pisiformis Inhibitor		1	NCGC00538144-01	405558557.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	19.8054120199	S=C(Nc1cc(C(F)(F)F)ccc1)N1C(C)CCCC1C	S=C(Nc1cc(C(F)(F)F)ccc1)N1C(C)CCCC1C
NCGC00370968-01	S=C(Nc1ccc(OCC)cc1)N1CCC(C(O)(c2ccccc2)c2ccccc2)CC1		Inactive	Neuropeptide Y receptor type 2 Antagonist		1	SF 11	363677964.0	2020_NPACT-10_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S=C(Nc1ccc(OCC)cc1)N1CCC(C(O)(c2ccccc2)c2ccccc2)CC1	S=C(Nc1ccc(OCC)cc1)N1CCC(C(O)(c2ccccc2)c2ccccc2)CC1
NCGC00165721-16	S=C(Nc1ccccc1)n1nc(c(-c2c3c(ncc2)cccc3)c1)-c1nc(C)ccc1		Inactive	TGF-bR1 (ALK5) Inhibitor		1	A-83-01	377020368.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S=C(Nc1ccccc1)n1nc(c(-c2c3c(ncc2)cccc3)c1)-c1nc(C)ccc1	S=C(Nc1ccccc1)n1nc(c(-c2c3c(ncc2)cccc3)c1)-c1nc(C)ccc1
NCGC00532504-01	S=C(OC)NCCn1c(C)ncc1[N+](=O)[O-]		Inactive	Trichomonas Inhibitor		1	CARNIDAZOLE	405558531.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S=C(OC)NCCn1c(C)ncc1[N+](=O)[O-]	S=C(OC)NCCn1c(C)ncc1[N+](=O)[O-]
NCGC00249934-01	S=C(Oc1cc2c(cc1)C1CC2CC1)N(C)c1cc(C)ccc1		Inactive			1	Tolciclate	170465866.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	13.894892676	S=C(Oc1cc2c(cc1)C1CC2CC1)N(C)c1cc(C)ccc1	S=C(Oc1cc2c(cc1)C1CC2CC1)N(C)c1cc(C)ccc1
NCGC00182984-01	S=C(Oc1cc2c(cc1)CCC2)N(C)c1cc(C)ccc1		Inactive			1	Tolindate	144206849.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S=C(Oc1cc2c(cc1)CCC2)N(C)c1cc(C)ccc1	S=C(Oc1cc2c(cc1)CCC2)N(C)c1cc(C)ccc1
NCGC00164601-02	S=C(Oc1cc2c(cc1)CCCC2)N(C)c1nc(OC)ccc1		Inactive	Fungal Squalene Monooxygenase Inhibitor		1	Liranaftate	170466057.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	16.534381136&0.0	S=C(Oc1cc2c(cc1)CCCC2)N(C)c1nc(OC)ccc1	S=C(Oc1cc2c(cc1)CCCC2)N(C)c1nc(OC)ccc1
NCGC00016610-07&NCGC00016610-12	S=C(Oc1cc2c(cc1)cccc2)N(C)c1cc(C)ccc1		Inactive	Fungal Squalene Monooxygenase Inhibitor		2	Tolnaftate	170465508.0&384567952.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S=C(Oc1cc2c(cc1)cccc2)N(C)c1cc(C)ccc1	S=C(Oc1cc2c(cc1)cccc2)N(C)c1cc(C)ccc1
NCGC00166328-02	S=C(S)N(CC)CC		Inactive			1	Ammonium diethyldithiocarbamate	434146879.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	32.1966292119	S=C(S)N(CC)CC	S=C(S)N(CC)CC
NCGC00188440-01	S=C(S)N(CCCC)CCCC		Inactive			1	Zinc dibutyldithiocarbamate	144206589.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S=C([S-])N(CCCC)CCCC.S=C([S-])N(CCCC)CCCC.[Zn+2]	S=C([S-])N(CCCC)CCCC.S=C([S-])N(CCCC)CCCC.[Zn+2]
NCGC00390751-02	S=C(S)O[C@@H]1[C@H]2[C@H]3[C@@H]([C@@H](C1)C2)CCC3		Inactive			1	SPK-601	434147146.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[K]SC(=S)O[C@@H]1[C@H]2[C@H]3[C@@H]([C@@H](C1)C2)CCC3	[K]SC(=S)O[C@@H]1[C@H]2[C@H]3[C@@H]([C@@H](C1)C2)CCC3
NCGC00159424-04	S=C(SC(=S)N(C)C)N(C)C		Inactive			1	Tetramethylthiuram monosulfide	170465567.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S=C(SC(=S)N(C)C)N(C)C	S=C(SC(=S)N(C)C)N(C)C
NCGC00387263-04&NCGC00387263-05	S=C1C(C)=C(c2nccnc2)SS1		Inactive	Nuclear Factor Erythroid 2-Related Factor 2 (NFE2-Related Factor 2; NFE2L2; NRF2) Activator		2	Oltipraz	384569156.0&434147134.0	Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S=C1C(C)=C(c2nccnc2)SS1	S=C1C(C)=C(c2nccnc2)SS1
NCGC00387209-01	S=C1C(C2c3c(cc(C)cc3)C=Cc3c2ccc(C)c3)=CN(Cc2oc(C(=O)Nc3[nH]nnn3)cc2)C(=O)N1		Inactive	Purinergic receptor P2Y2 Antagonist		1	AR-C 118925XX	363680568.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S=C1C(C2c3c(cc(C)cc3)C=Cc3c2ccc(C)c3)=CN(Cc2oc(C(=O)Nc3[nH]nnn3)cc2)C(=O)N1	S=C1C(C2c3c(cc(C)cc3)C=Cc3c2ccc(C)c3)=CN(Cc2oc(C(=O)Nc3[nH]nnn3)cc2)C(=O)N1
NCGC00182983-01	S=C1N(/N=C/c2ccc(C)cc2)C(c2ccccc2)=CS1		Inactive			1	Fezatione	144206829.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S=C1N(/N=C/c2ccc(C)cc2)C(c2ccccc2)=CS1	S=C1N(/N=C/c2ccc(C)cc2)C(c2ccccc2)=CS1
NCGC00016760-08	S=C1N(C(=O)OCC)C=CN1C		Inactive			1	Carbimazole	170465583.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	S=C1N(C(=O)OCC)C=CN1C	S=C1N(C(=O)OCC)C=CN1C
NCGC00092372-12	S=C1N(C)C(=O)C(Cc2c3c([nH]c2)cccc3)N1		Inactive	RIP1 Kinase Inhibitor		1	Necrostatin-1	384568108.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S=C1N(C)C(=O)C(Cc2c3c([nH]c2)cccc3)N1	S=C1N(C)C(=O)C(Cc2c3c([nH]c2)cccc3)N1
NCGC00384899-01	S=C1N(C)C(=O)C=2N(C1=O)[C@@H]1[C@@H](OC(=O)c3cc(Oc4c(O)ccc(C=O)c4)c(OC)cc3)C=COC=C1C=2		Inactive	<MOA Unknown> | Class: N/A | Genus: N/A | Family: N/A | Species: N/A		1	NCGC00384899-01	363679425.0	2020_NPACT-6_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S=C1N(C)C(=O)C=2N(C1=O)[C@@H]1[C@@H](OC(=O)c3cc(Oc4c(O)ccc(C=O)c4)c(OC)cc3)C=COC=C1C=2	S=C1N(C)C(=O)C=2N(C1=O)[C@@H]1[C@@H](OC(=O)c3cc(Oc4c(O)ccc(C=O)c4)c(OC)cc3)C=COC=C1C=2
NCGC00094721-07	S=C1N(C)C=CN1		Inactive	Thyroid peroxidase Inhibitor		1	Methimazole	170464856.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&13.3029197079	S=C1N(C)C=CN1	S=C1N(C)C=CN1
NCGC00387301-01	S=C1N(C2CCN(CCCC(=O)c3ccc(F)cc3)CC2)c2c(N1)cccc2	5.0	Active	serotonin receptor signaling pathway Modulator	0.0	1	Timiperone	405558737.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	48.9294117632	S=C1N(C2CCN(CCCC(=O)c3ccc(F)cc3)CC2)c2c(N1)cccc2	S=C1N(C2CCN(CCCC(=O)c3ccc(F)cc3)CC2)c2c(N1)cccc2
NCGC00164613-04&NCGC00164613-08	S=C1N(CC(=O)O)C(=O)/C(=C/C(=C/c2ccccc2)/C)/S1		Inactive	Aldose Reductase Inhibitor		2	Epalrestat	384568264.0&405558568.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S=C1N(CC(=O)O)C(=O)/C(=C/C(=C/c2ccccc2)/C)/S1	S=C1N(CC(=O)O)C(=O)/C(=C/C(=C/c2ccccc2)/C)/S1
NCGC00508823-01	S=C1N(Cc2ccc(-c3nn[nH]c3)cc2)C(C)(C)C(=O)N1c1cc(C(F)(F)F)c(C#N)cc1	5.0500002	Active		0.0	1	BG-15a	384569360.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	41.0739029991	S=C1N(Cc2ccc(-c3nn[nH]c3)cc2)C(C)(C)C(=O)N1c1cc(C(F)(F)F)c(C#N)cc1	S=C1N(Cc2ccc(-c3nn[nH]c3)cc2)C(C)(C)C(=O)N1c1cc(C(F)(F)F)c(C#N)cc1
NCGC00160606-01	S=C1N(Cc2ccccc2)CN(Cc2ccccc2)CS1		Inactive			1	Sulbentine	144205485.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	11.488416984	S=C1N(Cc2ccccc2)CN(Cc2ccccc2)CS1	S=C1N(Cc2ccccc2)CN(Cc2ccccc2)CS1
NCGC00387465-01	S=C1N([C@@H](CC)c2cc(F)c(F)cc2)C(C(=O)OC)=C(c2oncc2)N1		Inactive			1	JNJ 27141491	363680624.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S=C1N([C@@H](CC)c2cc(F)c(F)cc2)C(C(=O)OC)=C(c2oncc2)N1	S=C1N([C@@H](CC)c2cc(F)c(F)cc2)C(C(=O)OC)=C(c2oncc2)N1
NCGC00346651-08	S=C1N([C@@H]2Cc3c(c(F)cc(F)c3)CC2)C(CN)=CN1		Inactive	Dopamine beta-monooxygenase Inhibitor		1	Nepicastat hydrochloride	384568882.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S=C1N([C@@H]2Cc3c(c(F)cc(F)c3)CC2)C(CN)=CN1	S=C1N([C@@H]2Cc3c(c(F)cc(F)c3)CC2)C(CN)=CN1
NCGC00390632-01	S=C1N(c2cc(C(F)(F)F)c(C#N)cc2)C(=O)C(C)(C)N1c1cc(F)c(C(=O)N)cc1		Inactive	Androgen Receptor Antagonist		1	N-desmethyl Enzalutamide	363680939.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S=C1N(c2cc(C(F)(F)F)c(C#N)cc2)C(=O)C(C)(C)N1c1cc(F)c(C(=O)N)cc1	S=C1N(c2cc(C(F)(F)F)c(C#N)cc2)C(=O)C(C)(C)N1c1cc(F)c(C(=O)N)cc1
NCGC00263120-06	S=C1N(c2cc(C(F)(F)F)c(C#N)cc2)C(=O)C(C)(C)N1c1cc(F)c(C(=O)NC)cc1		Inactive	Androgen Receptor Antagonist		1	Enzalutamide	384568604.0	Approved Drugs Collection (NPC)&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	S=C1N(c2cc(C(F)(F)F)c(C#N)cc2)C(=O)C(C)(C)N1c1cc(F)c(C(=O)NC)cc1	S=C1N(c2cc(C(F)(F)F)c(C#N)cc2)C(=O)C(C)(C)N1c1cc(F)c(C(=O)NC)cc1
NCGC00263137-03	S=C1N(c2cc(C(F)(F)F)c(C#N)cc2)C(=O)C2(N1c1cc(F)c(C(=O)NC)cc1)CCC2		Inactive	Androgen Receptor Antagonist		1	RD-162	384568615.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S=C1N(c2cc(C(F)(F)F)c(C#N)cc2)C(=O)C2(N1c1cc(F)c(C(=O)NC)cc1)CCC2	S=C1N(c2cc(C(F)(F)F)c(C#N)cc2)C(=O)C2(N1c1cc(F)c(C(=O)NC)cc1)CCC2
NCGC00346725-06	S=C1N(c2cc(C(F)(F)F)c(C#N)nc2)C(=O)C2(N1c1cc(F)c(C(=O)NC)cc1)CCC2		Inactive	Androgen Receptor Antagonist		1	Apalutamide	363677538.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S=C1N(c2cc(C(F)(F)F)c(C#N)nc2)C(=O)C2(N1c1cc(F)c(C(=O)NC)cc1)CCC2	S=C1N(c2cc(C(F)(F)F)c(C#N)nc2)C(=O)C2(N1c1cc(F)c(C(=O)NC)cc1)CCC2
NCGC00379251-01	S=C1N(c2cc(C(F)(F)F)ccc2)C(=O)c2c(N1)cc(C(=O)NCc1ccccc1)cc2		Inactive	L-threonine 3-dehydrogenase, mitochondrial Inhibitor		1	Qc 1	363678448.0	2020_NPACT-12_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S=C1N(c2cc(C(F)(F)F)ccc2)C(=O)c2c(N1)cc(C(=O)NCc1ccccc1)cc2	S=C1N(c2cc(C(F)(F)F)ccc2)C(=O)c2c(N1)cc(C(=O)NCc1ccccc1)cc2
NCGC00016229-14&NCGC00016229-20	S=C1NC(=O)C=C(CCC)N1		Inactive	Antithyroid Drugs		2	Propylthiouracil	170464965.0&384567923.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	11.99427262&0.0&0.0	S=C1NC(=O)C=C(CCC)N1	S=C1NC(=O)C=C(CCC)N1
NCGC00025103-05	S=C1NC(C)=C(C(=O)OCC)C(c2cc(O)ccc2)N1		Inactive	Kinesin-Like Spindle Protein Inhibitor		1	Monastrol	384568050.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0		S=C1NC(C)=C(C(=O)OCC)C(c2cc(O)ccc2)N1	S=C1NC(C)=C(C(=O)OCC)C(c2cc(O)ccc2)N1
NCGC00387255-02	S=C1NC(c2cc(O)ccc2)C=2C(=O)CC(C)(C)CC=2N1		Inactive	Kinesin-like protein 1 Inhibitor		1	Dimethylenastron	363680596.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S=C1NC(c2cc(O)ccc2)C=2C(=O)CC(C)(C)CC=2N1	S=C1NC(c2cc(O)ccc2)C=2C(=O)CC(C)(C)CC=2N1
NCGC00387766-01	S=C1NC(c2cc(O)ccc2)c2c(F)cccc2N1		Inactive	Kinesin-like protein 1 Inhibitor		1	VS-83	363680654.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S=C1NC(c2cc(O)ccc2)c2c(F)cccc2N1	S=C1NC(c2cc(O)ccc2)c2c(F)cccc2N1
NCGC00091641-12&NCGC00091641-16	S=C1NC=Nc2nc[nH]c12		Inactive			2	MERCAPTOPURINE&6-Mercaptopurine	434146990.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0		S=C1NC=Nc2nc[nH]c12	S=C1NC=Nc2nc[nH]c12
NCGC00482529-01	S=C1O[C@H](C=C)CN1		Inactive			1	Epigoitrin		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S=C1O[C@H](C=C)CN1	S=C1O[C@H](C=C)CN1
NCGC00185994-09	S=C1S/C(=C/c2ccc(CC)cc2)/C(=O)N1	4.9000001	Active	MYC Expression Inhibitor	0.0	1	10058-F4	384568432.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	70.6897509689	S=C1S/C(=C/c2ccc(CC)cc2)/C(=O)N1	S=C1S/C(=C/c2ccc(CC)cc2)/C(=O)N1
NCGC00167471-02	S=C1SSC(c2ccc(OC)cc2)=C1		Inactive			1	Anethole trithione	170465669.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S=C1SSC(c2ccc(OC)cc2)=C1	S=C1SSC(c2ccc(OC)cc2)=C1
NCGC00487217-01	S=C1SSC2=C1CCC2		Inactive			1	CPDT	377020389.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S=C1SSC2=C1CCC2	S=C1SSC2=C1CCC2
NCGC00485321-01	S=C=Nc1c2[nH]c3[C@@H]4Oc5c(O)ccc6c5[C@@]54[C@](O)([C@H](N(CC4CC4)CC5)C6)Cc3c2ccc1	4.9000001	Active	Delta opioid receptor Antagonist	0.0	1	Naltrindole isothiocyanate hydrochloride	363681285.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	3.0	129.8951488971	S=C=Nc1c2[nH]c3[C@@H]4Oc5c(O)ccc6c5[C@@]54[C@](O)([C@H](N(CC4CC4)CC5)C6)Cc3c2ccc1	S=C=Nc1c2[nH]c3[C@@H]4Oc5c(O)ccc6c5[C@@]54[C@](O)([C@H](N(CC4CC4)CC5)C6)Cc3c2ccc1
NCGC00182049-02	S=C=Nc1ccc(Oc2ccc([N+](=O)[O-])cc2)cc1		Inactive	ATP biosynthetic process Inhibitor		1	Nitroscanate	225144331.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S=C=Nc1ccc(Oc2ccc([N+](=O)[O-])cc2)cc1	S=C=Nc1ccc(Oc2ccc([N+](=O)[O-])cc2)cc1
NCGC00095042-08&NCGC00095042-09	S=P(N1CC1)(N1CC1)N1CC1		Inactive	Cytochrome P450 Oxidase Inhibitor		2	ThioTEPA	174006555.0&225144216.0	Annotated/Bioactive Compound Collection&2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	S=P(N1CC1)(N1CC1)N1CC1	S=P(N1CC1)(N1CC1)N1CC1
NCGC00091635-09	S=P(OC)(OC)Oc1cc(C)c(SC)cc1		Inactive	Acetylcholinesterase Inhibitor		1	Fenthion	170466807.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S=P(OC)(OC)Oc1cc(C)c(SC)cc1	S=P(OC)(OC)Oc1cc(C)c(SC)cc1
NCGC00091902-11	S=P(SC(C(=O)OCC)CC(=O)OCC)(OC)OC		Inactive	Acetylcholinesterase Inhibitor		1	Malathion	170465311.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S=P(SC(C(=O)OCC)CC(=O)OCC)(OC)OC	S=P(SC(C(=O)OCC)CC(=O)OCC)(OC)OC
NCGC00080392-05	S=P(SCN1C(=O)c2c(C1=O)cccc2)(OC)OC		Inactive	Acetylcholinesterase Inhibitor		1	Phosmet	170466810.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	S=P(SCN1C(=O)c2c(C1=O)cccc2)(OC)OC	S=P(SCN1C(=O)c2c(C1=O)cccc2)(OC)OC
NCGC00159422-04&NCGC00159422-10	SC(C(=O)NCC(=O)O)C		Inactive	Copper Chelator		2	Tiopronin	170465217.0&384568176.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	SC(C(=O)NCC(=O)O)C	SC(C(=O)NCC(=O)O)C
NCGC00183271-01	SC(C(=O)N[C@H](C(=O)O)CS)(C)C		Inactive			1	Bucillamine	144206469.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	SC(C(=O)N[C@H](C(=O)O)CS)(C)C	SC(C(=O)N[C@H](C(=O)O)CS)(C)C
NCGC00024359-10	SC([C@@H](N)C(=O)O)(C)C		Inactive	Copper Chelator		1	Penicillamine	384568025.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	SC([C@@H](N)C(=O)O)(C)C	SC([C@@H](N)C(=O)O)(C)C
NCGC00014602-05	SC([C@H](N)C(=O)O)(C)C		Inactive	Copper Chelator		1	L-Penicillamine	405558637.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	SC([C@H](N)C(=O)O)(C)C	SC([C@H](N)C(=O)O)(C)C
NCGC00248803-03	SCC(N)C(=O)O		Inactive			1	DL-Cysteine	170464842.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	SCC(N)C(=O)O	SCC(N)C(=O)O
NCGC00167479-01	SCC(NCCNC(C(=O)OCC)CS)C(=O)OCC		Inactive			1	Bicisate dihydrochloride	144206036.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	SCC(NCCNC(C(=O)OCC)CS)C(=O)OCC.Cl.Cl	SCC(NCCNC(C(=O)OCC)CS)C(=O)OCC.Cl.Cl
NCGC00015691-06	SCCN		Inactive	Protein-glutamine gamma-glutamyltransferase 2 Inhibitor		1	Cysteamine hydrochloride	170466795.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	SCCN.Cl	SCCN.Cl
NCGC00023654-13&NCGC00023654-26	SC[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C		Inactive	Angiotensin-converting enzyme Inhibitor		2	Captopril	170464644.0&434146974.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	SC[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C	SC[C@H](C(=O)N1[C@H](C(=O)O)CCC1)C
NCGC00166005-02	SC[C@H](N)C(=O)OC		Inactive			1	L-Cysteine methyl ester hydrochloride	225144264.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	SC[C@H](N)C(=O)OC	SC[C@H](N)C(=O)OC
NCGC00166061-02	SC[C@H](N)C(=O)OCC		Inactive			1	L-Cysteine ethyl ester hydrochloride	225144266.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	SC[C@H](N)C(=O)OCC	SC[C@H](N)C(=O)OCC
NCGC00022304-21&NCGC00022304-23	SC[C@H](NC(=O)C)C(=O)O		Inactive			2	ACETYLCYSTEINE	434147246.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0	SC[C@H](NC(=O)C)C(=O)O	SC[C@H](NC(=O)C)C(=O)O
NCGC00264046-02	SC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O		Inactive	Glutathione reductase, mitochondrial Substrate		1	Glutathione	170465600.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	SC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O	SC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O
NCGC00390546-03	SC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(C(=O)C)CCC1)Cc1nc[nH]c1)CO)C(=O)N[C@H](C(=O)N)CC(=O)N		Inactive	Integrin alphavbeta3 (Vitronectin) Antagonist		1	ATN-161	384569189.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	SC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(C(=O)C)CCC1)Cc1nc[nH]c1)CO)C(=O)N[C@H](C(=O)N)CC(=O)N	SC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(C(=O)C)CCC1)Cc1nc[nH]c1)CO)C(=O)N[C@H](C(=O)N)CC(=O)N
NCGC00264003-02	S[C@@H]([C@H](S)C(=O)O)C(=O)O		Inactive	Lead Chelating Agent		1	(2R,3R)-2,3-Dimercaptosuccinic acid	170465255.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S[C@@H]([C@H](S)C(=O)O)C(=O)O	S[C@@H]([C@H](S)C(=O)O)C(=O)O
NCGC00509984-01	S[C@H](C(=O)N[C@@H]1C(=O)N2[C@H](C(=O)O)CCC[C@@H]2SCC1)Cc1ccccc1		Inactive	Neprilysin Inhibitor		1	Omapatrilat	405559059.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S[C@H](C(=O)N[C@@H]1C(=O)N2[C@H](C(=O)O)CCC[C@@H]2SCC1)Cc1ccccc1	S[C@H](C(=O)N[C@@H]1C(=O)N2[C@H](C(=O)O)CCC[C@@H]2SCC1)Cc1ccccc1
NCGC00013216-05	S[C@H](CS)CO		Inactive			1	2,3-Dimercapto-1-propanol		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	S[C@H](CS)CO	S[C@H](CS)CO
NCGC00485585-01	S[P@]1(=O)O[C@H]2[C@@H](O)[C@H](n3c4ncnc(N)c4nc3)O[C@@H]2CO1		Inactive	cAMP-dependent protein kinase (PKA) Activator		1	Sp-Adenosine 3â€²,5â€²-cyclic monophosphorothioate triethylammonium salt hydrate	363681366.0	2020_NPACT-9_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	S[P@]1(=O)O[C@H]2[C@@H](O)[C@H](n3c4ncnc(N)c4nc3)O[C@@H]2CO1	S[P@]1(=O)O[C@H]2[C@@H](O)[C@H](n3c4ncnc(N)c4nc3)O[C@@H]2CO1
NCGC00018107-05	Sc1c(C(=O)O)cccc1		Inactive	prostaglandin biosynthetic process Inhibitor		1	2-Thiosalicylic acid	170465571.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	Sc1c(C(=O)O)cccc1	Sc1c(C(=O)O)cccc1
NCGC00096122-05	Sc1ncnc2n([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)cnc12		Inactive	Serine/threonine-protein kinase N1 Inhibitor		1	Thioinosine	170465903.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		Sc1ncnc2n([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)cnc12	Sc1ncnc2n([C@H]3[C@H](O)[C@H](O)[C@@H](CO)O3)cnc12
NCGC00091643-10	Sc1sc2c(n1)cccc2		Inactive	Thyroid peroxidase Inhibitor		1	2-Mercaptobenzothiazole	405558936.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	Sc1sc2c(n1)cccc2	Sc1sc2c(n1)cccc2
NCGC00166059-02	[Al](OC(=O)C)(OC(=O)C)O		Inactive			1	Aluminum acetate, basic	405558445.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[Al](OC(=O)C)(OC(=O)C)O	[Al](OC(=O)C)(OC(=O)C)O
NCGC00160596-03	[Al](OC(=O)CCCCCCCCCCCCCCCCC)(O)O		Inactive			1	Aluminum monostearate	225144243.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	[Al](OC(=O)CCCCCCCCCCCCCCCCC)(O)O	[Al](OC(=O)CCCCCCCCCCCCCCCCC)(O)O
NCGC00253586-01	[Al](OC1=NC(NC(=O)N)C(=O)N1)(O)O		Inactive			1	Isalon	170465491.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	[Al](OC1=NC(NC(=O)N)C(=O)N1)(O)O	[Al](OC1=NC(NC(=O)N)C(=O)N1)(O)O
NCGC00094558-09	[As](=O)(O)(C)C		Inactive			1	CACODYLIC ACID	405558943.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[As](=O)(O)(C)C	[As](=O)(O)(C)C
NCGC00094812-05	[As](=O)(O)(O)c1cc(NC(=O)C)c(O)cc1		Inactive			1	Acetarsol	170466503.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	[As](=O)(O)(O)c1cc(NC(=O)C)c(O)cc1	[As](=O)(O)(O)c1cc(NC(=O)C)c(O)cc1
NCGC00016372-07	[As](=O)(O)(O)c1cc([N+](=O)[O-])c(O)cc1		Inactive			1	4-Hydroxy-3-nitrophenylarsonic acid	170465666.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[As](=O)(O)(O)c1cc([N+](=O)[O-])c(O)cc1	[As](=O)(O)(O)c1cc([N+](=O)[O-])c(O)cc1
NCGC00093366-05	[As](=O)(O)(O)c1ccc(N)cc1		Inactive	Apoptosis Activator		1	(4-Aminophenyl)arsonic acid	170465635.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[As](=O)(O)(O)c1ccc(N)cc1	[As](=O)(O)(O)c1ccc(N)cc1
NCGC00016374-05	[As](=O)(O)(O)c1ccc(NC(=O)N)cc1		Inactive			1	Carbarsone	170466507.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[As](=O)(O)(O)c1ccc(NC(=O)N)cc1	[As](=O)(O)(O)c1ccc(NC(=O)N)cc1
NCGC00181154-03	[As](=O)(O)(O)c1ccc([N+](=O)[O-])cc1		Inactive			1	Nitarsone	170465716.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	[As](=O)(O)(O)c1ccc([N+](=O)[O-])cc1	[As](=O)(O)(O)c1ccc([N+](=O)[O-])cc1
NCGC00261972-01	[As](SCCN)(SCCN)c1ccc(Nc2nc(N)nc(N)n2)cc1		Inactive			1	NCGC00261972-01	225144356.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[As](SCCN)(SCCN)c1ccc(Nc2nc(N)nc(N)n2)cc1	[As](SCCN)(SCCN)c1ccc(Nc2nc(N)nc(N)n2)cc1
NCGC00356590-01	[As]12O[As](O1)O2		Inactive			1	Arsenic trioxide 	405558620.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[As]12O[As](O1)O2	[As]12O[As](O1)O2
NCGC00160391-09&NCGC00160391-11&NCGC00160391-12	[Au-](S[C@H]1[C@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@@H](COC(=O)C)O1)[P+](CC)(CC)CC		Inactive	Thioredoxin Reductase Inhibitor		3	Auranofin	405558686.0&384568191.0&434146878.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0		[Au-](S[C@H]1[C@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@@H](COC(=O)C)O1)[P+](CC)(CC)CC	[Au-](S[C@H]1[C@H](OC(=O)C)[C@@H](OC(=O)C)[C@H](OC(=O)C)[C@@H](COC(=O)C)O1)[P+](CC)(CC)CC
NCGC00506887-01	[Au]SC(C(=O)O)CC(=O)O		Inactive	Prostaglandin E synthase Inhibitor		1	Sodium aurothiomalate(I)	405558583.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[Au]SC(C(=O)[O-])CC(=O)O	[Au]SC(C(=O)[O-])CC(=O)O
NCGC00182975-01	[Bi-]([OH2+])O[As](=O)(O)c1ccc(NC(=O)CO)cc1		Inactive			1	Amoebicon	144206766.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[Bi-]([OH2+])O[As](=O)(O)c1ccc(NC(=O)CO)cc1	[Bi-]([OH2+])O[As](=O)(O)c1ccc(NC(=O)CO)cc1
NCGC00475727-01	[C@@H](C)(n1nnc2ncc(-c3cn(C)nc3)nc12)C1=Cn2c(ncc2)C=C1		Inactive	HGFR Inhibitor		1	Savolitinib	363681098.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[C@@H](C)(n1nnc2ncc(-c3cn(C)nc3)nc12)C1=Cn2c(ncc2)C=C1	[C@@H](C)(n1nnc2ncc(-c3cn(C)nc3)nc12)C1=Cn2c(ncc2)C=C1
NCGC00162225-04&NCGC00162225-11	[C@@H]1(c2ccccc2)N=C2SCCN2C1		Inactive	Nicotinic Receptor Agonist		2	L-tetramisol	434147014.0&384568220.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	[C@@H]1(c2ccccc2)N=C2SCCN2C1	[C@@H]1(c2ccccc2)N=C2SCCN2C1
NCGC00371080-02	[C@H](C)(c1c(C)c(C)ccc1)c1[nH]cnc1		Inactive	Adrenergic receptor alpha-2 Agonist		1	Dexmedetomidine	405558766.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[C@H](C)(c1c(C)c(C)ccc1)c1[nH]cnc1	[C@H](C)(c1c(C)c(C)ccc1)c1[nH]cnc1
NCGC00408882-01	[C@H]1([C@@H]2NCCCC2)OC(c2ccccc2)(c2ccccc2)OC1		Inactive			1	Levoxadrol	363681072.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	[C@H]1([C@@H]2NCCCC2)OC(c2ccccc2)(c2ccccc2)OC1	[C@H]1([C@@H]2NCCCC2)OC(c2ccccc2)(c2ccccc2)OC1
NCGC00167578-04	[Ca](OC(=O)[C@H](CC(=O)N1C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1)OC(=O)[C@H](CC(=O)N1C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1		Inactive	Insulin Secretagogues		1	Mitiglinide calcium	384568330.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[Ca](OC(=O)[C@H](CC(=O)N1C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1)OC(=O)[C@H](CC(=O)N1C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1	[Ca](OC(=O)[C@H](CC(=O)N1C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1)OC(=O)[C@H](CC(=O)N1C[C@H]2[C@@H](C1)CCCC2)Cc1ccccc1
NCGC00249888-01	[Co+](C#N)N1[C@]2(C)[C@](CC(=O)N)(C)[C@H](CCC(=O)N)C1=C(C)C=1[C@](CC(=O)N)(C)[C@H](CCC(=O)N)C(N=1)=CC=1C(C)(C)[C@H](CCC(=O)N)C(=C(C)C=3[C@@](CCC(=O)NC[C@H](OP(=O)(O[C@H]4[C@@H](O)[C@@H](n5c6c(nc5)cc(C)c(C)c6)O[C@@H]4CO)[O-])C)(C)[C@@H](CC(=O)N)[C@H]2N=3)N=1		Inactive			1	Vitamin B12	170464872.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[Co+](C#N)N1[C@]2(C)[C@](CC(=O)N)(C)[C@H](CCC(=O)N)C1=C(C)C=1[C@](CC(=O)N)(C)[C@H](CCC(=O)N)C(N=1)=CC=1C(C)(C)[C@H](CCC(=O)N)C(=C(C)C=3[C@@](CCC(=O)NC[C@H](OP(=O)(O[C@H]4[C@@H](O)[C@@H](n5c6c(nc5)cc(C)c(C)c6)O[C@@H]4CO)[O-])C)(C)[C@@H](CC(=O)N)[C@H]2N=3)N=1	[Co+](C#N)N1[C@]2(C)[C@](CC(=O)N)(C)[C@H](CCC(=O)N)C1=C(C)C=1[C@](CC(=O)N)(C)[C@H](CCC(=O)N)C(N=1)=CC=1C(C)(C)[C@H](CCC(=O)N)C(=C(C)C=3[C@@](CCC(=O)NC[C@H](OP(=O)(O[C@H]4[C@@H](O)[C@@H](n5c6c(nc5)cc(C)c(C)c6)O[C@@H]4CO)[O-])C)(C)[C@@H](CC(=O)N)[C@H]2N=3)N=1
NCGC00249888-03	[Co](C#N)[n+]1c2c(n(C3C(O)C(OP(=O)(OC(CNC(=O)CCC\4(C)C(CC(=O)N)C=5C6(C)C(CC(=O)N)(C)C(CCC(=O)N)C(/C(/C)=C/7\C(CC(=O)N)(C)C(CCC(=O)N)C(=N\7)/C=C\7/C(C)(C)C(CCC(=O)N)C(/C(/C)=C/4\N=5)=N/7)=N6)C)[O-])C(CO)O3)c1)cc(C)c(C)c2		Inactive			1	Vitamin B12	384568534.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	-13.677161456	[Co](C#N)[n+]1c2c(n(C3C(O)C(OP(=O)(OC(CNC(=O)CCC\4(C)C(CC(=O)N)C=5C6(C)C(CC(=O)N)(C)C(CCC(=O)N)C(/C(/C)=C/7\C(CC(=O)N)(C)C(CCC(=O)N)C(=N\7)/C=C\7/C(C)(C)C(CCC(=O)N)C(/C(/C)=C/4\N=5)=N/7)=N6)C)[O-])C(CO)O3)c1)cc(C)c(C)c2	[Co](C#N)[n+]1c2c(n(C3C(O)C(OP(=O)(OC(CNC(=O)CCC\4(C)C(CC(=O)N)C=5C6(C)C(CC(=O)N)(C)C(CCC(=O)N)C(/C(/C)=C/7\C(CC(=O)N)(C)C(CCC(=O)N)C(=N\7)/C=C\7/C(C)(C)C(CCC(=O)N)C(/C(/C)=C/4\N=5)=N/7)=N6)C)[O-])C(CO)O3)c1)cc(C)c(C)c2
NCGC00166055-04	[Fe-2](N=O)(C#N)(C#N)(C#N)(C#N)C#N		Inactive			1	SODIUM NITROPRUSSIDE	405558446.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[Fe-2](N=O)(C#N)(C#N)(C#N)(C#N)C#N	[Fe-2](N=O)(C#N)(C#N)(C#N)(C#N)C#N
NCGC00161826-02	[Hg+]c1ccccc1		Inactive	platelet aggregation Inhibitor		1	Phenylmercuric borate	124892360.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	4.0	22.7433501079	[Hg+]c1ccccc1	[Hg+]c1ccccc1
NCGC00181320-01	[Hg](O)CC(OC)CNC(=O)c1c(OCC(=O)O)cccc1		Inactive			1	Mersalyl acid	144206341.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[Hg](O)CC(OC)CNC(=O)c1c(OCC(=O)O)cccc1	[Hg](O)CC(OC)CNC(=O)c1c(OCC(=O)O)cccc1
NCGC00262588-02	[Hg](O)c1c(O)c(Br)cc2C3(OC(=O)c4c3cccc4)c3c(Oc12)cc(O)c(Br)c3		Inactive			1	Merbromin	225144359.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[Hg](O)c1c([O-])c(Br)cc2C3(OC(=O)c4c3cccc4)c3c(Oc12)cc([O-])c(Br)c3.[Na+].[Na+].O.O.O	[Hg](O)c1c([O-])c(Br)cc2C3(OC(=O)c4c3cccc4)c3c(Oc12)cc([O-])c(Br)c3.[Na+].[Na+].O.O.O
NCGC00091050-09	[Hg](OC(=O)C)c1ccccc1		Inactive			1	Phenylmercuric acetate	170465524.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		[Hg](OC(=O)C)c1ccccc1	[Hg](OC(=O)C)c1ccccc1
NCGC00166257-03	[Mn](O[Mn-][OH2+])O[Mn-][OH2+]		Inactive			1	NCGC00166257-03	50111747.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[Mn](O[Mn-][OH2+])O[Mn-][OH2+]	[Mn](O[Mn-][OH2+])O[Mn-][OH2+]
NCGC00161827-01	[Mo-2]([OH2+])([OH2+])(O)O		Inactive	Xanthine dehydrogenase Binding Agent		1	NCGC00161827-01	26755462.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[Mo-2]([OH2+])([OH2+])([O-])[O-]	[Mo-2]([OH2+])([OH2+])([O-])[O-]
NCGC00521082-01	[N+](C)(C)(C)C1CCC(CC2CCC([N+](C)(C)C)CC2)CC1		Inactive			1	Mebezonium Iodide	405558841.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[N+](C)(C)(C)C1CCC(CC2CCC([N+](C)(C)C)CC2)CC1	[N+](C)(C)(C)C1CCC(CC2CCC([N+](C)(C)C)CC2)CC1
NCGC00091112-09&NCGC00091112-15	[N+](C)(C)=C1C=CC(=C(c2ccc(N(C)C)cc2)c2ccc(N(C)C)cc2)C=C1		Inactive	TNFR1 (p55/CD120a) Modulator		2	Methylrosaniline chloride	170464787.0&384568094.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&-13.451494156	[N+](C)(C)=C1C=CC(=C(c2ccc(N(C)C)cc2)c2ccc(N(C)C)cc2)C=C1.[Cl-]	[N+](C)(C)=C1C=CC(=C(c2ccc(N(C)C)cc2)c2ccc(N(C)C)cc2)C=C1.[Cl-]&[N+](C)(C)=C1C=CC(=C(c2ccc(N(C)C)cc2)c2ccc(N(C)C)cc2)C=C1
NCGC00178214-04	[N+](CCCCCCCCCCCCC)(Cc1ccccc1)(C)C		Inactive			1	BENZALKONIUM CHLORIDE	405559118.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[N+](CCCCCCCCCCCCC)(Cc1ccccc1)(C)C	[N+](CCCCCCCCCCCCC)(Cc1ccccc1)(C)C
NCGC00164283-07	[N+](CCCCCCCCCCCCCCCC)(C)(C)C		Inactive	Cell membrane Interacts		1	Hexadecyltrimethylammonium bromide	170465714.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	-7.092178768&0.0	[N+](CCCCCCCCCCCCCCCC)(C)(C)C.[Br-]	[N+](CCCCCCCCCCCCCCCC)(C)(C)C.[Br-]
NCGC00344524-01	[N+](CCCCCCCCCCCCCCCC)(Cc1ccccc1)(C)C		Inactive			1	Benzylhexadecyldimethylammonium chloride	170465465.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[N+](CCCCCCCCCCCCCCCC)(Cc1ccccc1)(C)C.[Cl-]	[N+](CCCCCCCCCCCCCCCC)(Cc1ccccc1)(C)C.[Cl-]
NCGC00015323-11	[N+](CCCCCCCCCC[N+](C)(C)C)(C)(C)C		Inactive	Muscle-type nicotinic acetylcholine receptor Partial Agonist		1	Decamethonium bromide	170465349.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[N+](CCCCCCCCCC[N+](C)(C)C)(C)(C)C.[Br-].[Br-]	[N+](CCCCCCCCCC[N+](C)(C)C)(C)(C)C.[Br-].[Br-]
NCGC00015496-08	[N+](CCCCCC[N+](C)(C)C)(C)(C)C		Inactive			1	N,N,N,N',N',N'-Hexamethylhexane-1,6-diaminium	170465837.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	[N+](CCCCCC[N+](C)(C)C)(C)(C)C	[N+](CCCCCC[N+](C)(C)C)(C)(C)C
NCGC00182971-01	[N+](CCCCCC[N+](C)(C)C1c2c(-c3c1cccc3)cccc2)(C)(C)C1c2c(-c3c1cccc3)cccc2		Inactive	Cholinesterase Inhibitor		1	Hexafluorenium dibromide	144206765.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[N+](CCCCCC[N+](C)(C)C1c2c(-c3c1cccc3)cccc2)(C)(C)C1c2c(-c3c1cccc3)cccc2.[Br-].[Br-]	[N+](CCCCCC[N+](C)(C)C1c2c(-c3c1cccc3)cccc2)(C)(C)C1c2c(-c3c1cccc3)cccc2.[Br-].[Br-]
NCGC00013058-02	[N+](\C)(/C)=C\1/C=C/C(=C(/c2ccc(N(C)C)cc2)\c2ccccc2)/C=C/1		Inactive			1	Malachite green oxalate	170465712.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0		O=C(O)C(=O)O.O=C(O)C(=O)[O-].O=C(O)C(=O)[O-].[N+](\C)(/C)=C\1/C=C/C(=C(/c2ccc(N(C)C)cc2)\c2ccccc2)/C=C/1.[N+](\C)(/C)=C\1/C=C/C(=C(/c2ccc(N(C)C)cc2)\c2ccccc2)/C=C/1	O=C(O)C(=O)O.O=C(O)C(=O)[O-].O=C(O)C(=O)[O-].[N+](\C)(/C)=C\1/C=C/C(=C(/c2ccc(N(C)C)cc2)\c2ccccc2)/C=C/1.[N+](\C)(/C)=C\1/C=C/C(=C(/c2ccc(N(C)C)cc2)\c2ccccc2)/C=C/1
NCGC00015831-06	[NH+](CCC(c1ncccc1)c1ccccc1)(C)C		Inactive	Histamine H1 receptor Antagonist		1	Pheniramine maleate	170464902.0	Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	O=C([O-])/C=C\C(=O)[O-].[NH+](CCC(c1[nH+]cccc1)c1ccccc1)(C)C	O=C([O-])/C=C\C(=O)[O-].[NH+](CCC(c1[nH+]cccc1)c1ccccc1)(C)C
NCGC00015673-13&NCGC00015673-19	[O-][n+]1c(N)nc(N2CCCCC2)cc1N		Inactive	K(ATP) Channel Activator		2	Minoxidil	170464704.0	Approved Drugs Collection (NPC)&2019_NPC-3.2&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	[O-][n+]1c(N)nc(N2CCCCC2)cc1N	[O-][n+]1c(N)nc(N2CCCCC2)cc1N
NCGC00686694-01	[P@@](=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@](C#N)(c2n3N=CN=C(N)c3cc2)O1)(Oc1ccccc1)N[C@H](C(=O)OCC(CC)CC)C	5.0749998	Active	RNA-dependent RNA polymerase inhibitor	0.0	1	Remdesivir	406861862.0	Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	3.0&1.1	133.0922101341&115.827272724	[P@@](=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@](C#N)(c2n3N=CN=C(N)c3cc2)O1)(Oc1ccccc1)N[C@H](C(=O)OCC(CC)CC)C	[P@@](=O)(OC[C@@H]1[C@@H](O)[C@@H](O)[C@](C#N)(c2n3N=CN=C(N)c3cc2)O1)(Oc1ccccc1)N[C@H](C(=O)OCC(CC)CC)C
NCGC00346462-07	[P@@](=O)(OC[C@@H]1[C@@H](O)[C@](F)(C)[C@H](N2C(=O)NC(=O)C=C2)O1)(Oc1ccccc1)N[C@H](C(=O)OC(C)C)C		Inactive	RNA-Directed RNA Polymerase Inhibitor		1	Sofosbuvir	384568785.0	Anti-infectives&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&DPI_SARS-CoV-2_General	4.0&4.0&4.0	0.0&0.0&0.0	[P@@](=O)(OC[C@@H]1[C@@H](O)[C@](F)(C)[C@H](N2C(=O)NC(=O)C=C2)O1)(Oc1ccccc1)N[C@H](C(=O)OC(C)C)C	[P@@](=O)(OC[C@@H]1[C@@H](O)[C@](F)(C)[C@H](N2C(=O)NC(=O)C=C2)O1)(Oc1ccccc1)N[C@H](C(=O)OC(C)C)C
NCGC00390564-03&NCGC00390564-04	[P@@](=O)(Oc1ccccc1)(N[C@H](C(=O)OC(C)C)C)CO[C@@H](Cn1c2ncnc(N)c2nc1)C		Inactive			2	GS-7340&GS7340	405558816.0&434147141.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	[P@@](=O)(Oc1ccccc1)(N[C@H](C(=O)OC(C)C)C)CO[C@@H](Cn1c2ncnc(N)c2nc1)C	[P@@](=O)(Oc1ccccc1)(N[C@H](C(=O)OC(C)C)C)CO[C@@H](Cn1c2ncnc(N)c2nc1)C
NCGC00378598-01	[P@](=O)(OC[C@@H]1[C@@H](O)[C@](F)(C)[C@H](N2C(=O)NC(=O)C=C2)O1)(Oc1ccccc1)N[C@H](C(=O)OC(C)C)C		Inactive	RNA-Directed RNA Polymerase Inhibitor		1	PSI-7976	405558839.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[P@](=O)(OC[C@@H]1[C@@H](O)[C@](F)(C)[C@H](N2C(=O)NC(=O)C=C2)O1)(Oc1ccccc1)N[C@H](C(=O)OC(C)C)C	[P@](=O)(OC[C@@H]1[C@@H](O)[C@](F)(C)[C@H](N2C(=O)NC(=O)C=C2)O1)(Oc1ccccc1)N[C@H](C(=O)OC(C)C)C
NCGC00178241-13	[Pt-2](Cl)(Cl)([NH3+])[NH3+]		Inactive			1	Cisplatin		Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[Pt-2](Cl)(Cl)([NH3+])[NH3+]	[Pt-2](Cl)(Cl)([NH3+])[NH3+]
NCGC00346930-01	[Pt](Cl)(Cl)(N)N1C(C)=CCC=C1		Inactive	DNA Alkylating Agent		1	Picoplatin	174007462.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[Pt](Cl)(Cl)(N)[NH+]1C(C)=CC=C[CH-]1	[Pt](Cl)(Cl)(N)[NH+]1C(C)=CC=C[CH-]1
NCGC00181000-02&NCGC00181000-08	[S+](CCC(=O)Nc1ccc(OCC(O)COCC)cc1)(C)C		Inactive	Mediator Release Inhibitor		2	Suplatast tosylate	170465881.0&384568385.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	-5.6106194719&0.0&0.0	[S+](CCC(=O)Nc1ccc(OCC(O)COCC)cc1)(C)C.S(=O)(=O)([O-])c1ccc(C)cc1	[S+](CCC(=O)Nc1ccc(OCC(O)COCC)cc1)(C)C.S(=O)(=O)([O-])c1ccc(C)cc1&[S+](CCC(=O)Nc1ccc(OCC(O)COCC)cc1)(C)C
NCGC00167557-01	[S+](CCC(N)C(=O)O)(C)C		Inactive	ERK1 and ERK2 cascade Activator		1	DL-Methionine methylsulfonium chloride	144206105.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[S+](CCC(N)C(=O)O)(C)C.[Cl-]	[S+](CCC(N)C(=O)O)(C)C.[Cl-]
NCGC00346501-04&NCGC00346501-07	[S+](CCCNC(=O)c1nc(-c2nc(CCNC(=O)[C@H](NC(=O)[C@@H]([C@@H](O)[C@@H](NC(=O)[C@@H](NC(=O)c3c(C)c(N)nc([C@@H](NC[C@@H](N)C(=O)N)CC(=O)N)n3)C(O[C@@H]3[C@H](O[C@@H]4[C@@H](O)[C@@H](OC(=O)N)[C@H](O)[C@@H](CO)O4)[C@H](O)[C@@H](O)[C@@H](CO)O3)c3nc[nH]c3)C)C)[C@H](O)C)sc2)sc1)(C)C		Inactive	glycopeptide antibiotic		2	Bleomycin sulfate	384568806.0&405558521.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0		[S+](CCCNC(=O)c1nc(-c2nc(CCNC(=O)[C@H](NC(=O)[C@@H]([C@@H](O)[C@@H](NC(=O)[C@@H](NC(=O)c3c(C)c(N)nc([C@@H](NC[C@@H](N)C(=O)N)CC(=O)N)n3)C(O[C@@H]3[C@H](O[C@@H]4[C@@H](O)[C@@H](OC(=O)N)[C@H](O)[C@@H](CO)O4)[C@H](O)[C@@H](O)[C@@H](CO)O3)c3nc[nH]c3)C)C)[C@H](O)C)sc2)sc1)(C)C	[S+](CCCNC(=O)c1nc(-c2nc(CCNC(=O)[C@H](NC(=O)[C@@H]([C@@H](O)[C@@H](NC(=O)[C@@H](NC(=O)c3c(C)c(N)nc([C@@H](NC[C@@H](N)C(=O)N)CC(=O)N)n3)C(O[C@@H]3[C@H](O[C@@H]4[C@@H](O)[C@@H](OC(=O)N)[C@H](O)[C@@H](CO)O4)[C@H](O)[C@@H](O)[C@@H](CO)O3)c3nc[nH]c3)C)C)[C@H](O)C)sc2)sc1)(C)C
NCGC00167546-03	[S+](CC[C@H](N)C(=O)O)(C[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)C		Inactive	S-adenosylmethionine synthase isoform type-2 Binding Agent		1	S-(5 -Adenosyl)-L-methionine p-toluenesulfonate salt	225144292.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	[S+](CC[C@H](N)C(=O)O)(C[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)C	[S+](CC[C@H](N)C(=O)O)(C[C@@H]1[C@@H](O)[C@@H](O)[C@H](n2c3ncnc(N)c3nc2)O1)C
NCGC00386267-03	[S@@H0](=O)(Cc1c(C)c(OCC(F)(F)F)ccn1)c1[nH]c2c(n1)cccc2		Inactive	H+/K+-ATPase Inhibitor		1	(R)-Lansoprazole	405558696.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[S@@H0](=O)(Cc1c(C)c(OCC(F)(F)F)ccn1)c1[nH]c2c(n1)cccc2	[S@@H0](=O)(Cc1c(C)c(OCC(F)(F)F)ccn1)c1[nH]c2c(n1)cccc2
NCGC00685392-02	[S@H0](=O)(Cc1n(CCC)cnc1)c1ccc(NC(=O)C2=Cc3c(N(CC(C)C)CCC2)ccc(-c2ccc(OCCOCCCC)cc2)c3)cc1	5.0500002	Active		0.0	1	Cenicriviroc Mesylate		Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)	3.0	68.3349725215	[S@H0](=O)(Cc1n(CCC)cnc1)c1ccc(NC(=O)C2=Cc3c(N(CC(C)C)CCC2)ccc(-c2ccc(OCCOCCCC)cc2)c3)cc1	[S@H0](=O)(Cc1n(CCC)cnc1)c1ccc(NC(=O)C2=Cc3c(N(CC(C)C)CCC2)ccc(-c2ccc(OCCOCCCC)cc2)c3)cc1
NCGC00387711-02	[S@](=O)(=N)(C)C1(c2nc(-c3c4c([nH]cc4)ncc3)nc(N3[C@H](C)COCC3)c2)CC1		Inactive	ATR Kinase Inhibitor		1	AZD-6738	363680649.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[S@](=O)(=N)(C)C1(c2nc(-c3c4c([nH]cc4)ncc3)nc(N3[C@H](C)COCC3)c2)CC1	[S@](=O)(=N)(C)C1(c2nc(-c3c4c([nH]cc4)ncc3)nc(N3[C@H](C)COCC3)c2)CC1
NCGC00183849-01	[SH0](=O)(C)C=1C(=O)c2c(N(C)C=1)cc(F)cc2		Inactive	Phosphodiesterase 3 Inhibitor		1	Flosequinan	144206866.0	2020_NPACT-1_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	[SH0](=O)(C)C=1C(=O)c2c(N(C)C=1)cc(F)cc2	[SH0](=O)(C)C=1C(=O)c2c(N(C)C=1)cc(F)cc2
NCGC00163157-05	[SH0](=O)(C)c1cc2N(CCC3N(C)CCCC3)c3c(Sc2cc1)cccc3	4.9000001	Active	D(2) dopamine receptor Antagonist	0.0	1	Mesoridazine	170465272.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	3.0	106.2332919843	[SH0](=O)(C)c1cc2N(CCC3N(C)CCCC3)c3c(Sc2cc1)cccc3	[SH0](=O)(C)c1cc2N(CCC3N(C)CCCC3)c3c(Sc2cc1)cccc3
NCGC00025035-05	[SH0](=O)(C)c1ccc(-c2[nH]c(c(-c3ccc(F)cc3)n2)-c2ccncc2)cc1		Inactive	p38 MAPK Inhibitor		1	SB-203580	124886984.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	31.060747664	[SH0](=O)(C)c1ccc(-c2[nH]c(c(-c3ccc(F)cc3)n2)-c2ccncc2)cc1	[SH0](=O)(C)c1ccc(-c2[nH]c(c(-c3ccc(F)cc3)n2)-c2ccncc2)cc1
NCGC00346554-01	[SH0](=O)(C)c1ccc(-c2[nH]c(c(-c3ccncc3)n2)-c2cc3c(cc(OC)cc3)cc2)cc1		Inactive	Tie-2 kinase Inhibitor		1	Tie-2 kinase Inhibitor	174006708.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[SH0](=O)(C)c1ccc(-c2[nH]c(c(-c3ccncc3)n2)-c2cc3c(cc(OC)cc3)cc2)cc1	[SH0](=O)(C)c1ccc(-c2[nH]c(c(-c3ccncc3)n2)-c2cc3c(cc(OC)cc3)cc2)cc1
NCGC00015970-10&NCGC00015970-11	[SH0](=O)(C)c1ccc(/C=C\2/C(C)=C(CC(=O)O)c3c/2ccc(F)c3)cc1		Inactive	ABCC1 Expression Enhancer		2	Sulindac	174007228.0&170464648.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&0.0	[SH0](=O)(C)c1ccc(/C=C\2/C(C)=C(CC(=O)O)c3c/2ccc(F)c3)cc1	[SH0](=O)(C)c1ccc(/C=C\2/C(C)=C(CC(=O)O)c3c/2ccc(F)c3)cc1
NCGC00186528-19	[SH0](=O)(C)c1sc2c(n(C)c3C(=O)N(Cc4cc(N)ccc4)N=Cc23)c1		Inactive	PKM2 Activator		1	TEPP-46	384568443.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[SH0](=O)(C)c1sc2c(n(C)c3C(=O)N(Cc4cc(N)ccc4)N=Cc23)c1	[SH0](=O)(C)c1sc2c(n(C)c3C(=O)N(Cc4cc(N)ccc4)N=Cc23)c1
NCGC00386918-02	[SH0](=O)(C)c1sc2c(n(C)c3C(=O)N(Cc4cc(OC)ccc4)N=Cc23)c1		Inactive	Pyruvate kinase isozymes M1/M2 Activator		1	ML 202	363680505.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	[SH0](=O)(C)c1sc2c(n(C)c3C(=O)N(Cc4cc(OC)ccc4)N=Cc23)c1	[SH0](=O)(C)c1sc2c(n(C)c3C(=O)N(Cc4cc(OC)ccc4)N=Cc23)c1
NCGC00263530-01	[SH0](=O)(CC(=O)NC/C=C\COc1nccc(CN2CCCCC2)c1)Cc1occc1		Inactive	Histamine H2 Receptor Antagonists		1	Lafutidine	170465978.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	[SH0](=O)(CC(=O)NC/C=C\COc1nccc(CN2CCCCC2)c1)Cc1occc1	[SH0](=O)(CC(=O)NC/C=C\COc1nccc(CN2CCCCC2)c1)Cc1occc1
NCGC00379201-03	[SH0](=O)(CC)c1nc(C(F)(F)F)cc(-c2cc(OCc3ccccc3)ccc2)n1		Inactive			1	BETP	363678413.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	[SH0](=O)(CC)c1nc(C(F)(F)F)cc(-c2cc(OCc3ccccc3)ccc2)n1	[SH0](=O)(CC)c1nc(C(F)(F)F)cc(-c2cc(OCc3ccccc3)ccc2)n1
NCGC00025092-02	[SH0](=O)(CC1(OC)CCN(CCc2c3c([nH]c2)ccc(F)c3)CC1)c1ccccc1		Inactive	Tachykinin NK2 Antagonist		1	GR-159897	174007484.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[SH0](=O)(CC1(OC)CCN(CCc2c3c([nH]c2)ccc(F)c3)CC1)c1ccccc1	[SH0](=O)(CC1(OC)CCN(CCc2c3c([nH]c2)ccc(F)c3)CC1)c1ccccc1
NCGC00253760-02	[SH0](=O)(CCC)c1cc2nc(NC(=O)OC)[nH]c2cc1		Inactive	antiparasitic agent		1	Albendazole oxide	174006227.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[SH0](=O)(CCC)c1cc2nc(NC(=O)OC)[nH]c2cc1	[SH0](=O)(CCC)c1cc2nc(NC(=O)OC)[nH]c2cc1
NCGC00016255-10	[SH0](=O)(CCC1C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)c1ccccc1		Inactive	Canalicular Multispecific Organic Anion Transporter 1 Modulator		1	SULFINPYRAZONE	170464677.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[SH0](=O)(CCC1C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)c1ccccc1	[SH0](=O)(CCC1C(=O)N(N(c2ccccc2)C1=O)c1ccccc1)c1ccccc1
NCGC00164789-04&NCGC00164789-05	[SH0](=O)(CCCC(F)(F)C(F)(F)F)CCCCCCCCC[C@H]1[C@H]2[C@H]3[C@@](C)([C@@H](O)CC3)CC[C@@H]2c2c(cc(O)cc2)C1		Inactive	Estrogen Receptor Antagonist		2	Fulvestrant	170464917.0&174007328.0	Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	[SH0](=O)(CCCC(F)(F)C(F)(F)F)CCCCCCCCC[C@H]1[C@H]2[C@H]3[C@@](C)([C@@H](O)CC3)CC[C@@H]2c2c(cc(O)cc2)C1	[SH0](=O)(CCCC(F)(F)C(F)(F)F)CCCCCCCCC[C@H]1[C@H]2[C@H]3[C@@](C)([C@@H](O)CC3)CC[C@@H]2c2c(cc(O)cc2)C1
NCGC00016925-11&NCGC00016925-21&NCGC00386177-01	[SH0](=O)(Cc1c(C)c(OC)c(C)cn1)c1[nH]c2c(n1)cc(OC)cc2		Inactive	ABCC3 Expression Enhancer		3	Omeprazole&Esomeprazole Sodium	170465443.0&384567968.0&363680135.0	Approved Drugs Collection (NPC)&2019_NPC-2.2&Anti-infectives&Annotated/Bioactive Compound Collection&Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0&4.0&4.0	0.0&0.0&0.0&0.0&0.0	[SH0](=O)(Cc1c(C)c(OC)c(C)cn1)c1[nH]c2c(n1)cc(OC)cc2	[SH0](=O)(Cc1c(C)c(OC)c(C)cn1)c1[nH]c2c(n1)cc(OC)cc2&[SH0](=O)(Cc1c(C)c(OC)c(C)cn1)c1nc2c([n-]1)ccc(OC)c2.[SH0](=O)(Cc1c(C)c(OC)c(C)cn1)c1nc2c([n-]1)ccc(OC)c2
NCGC00167521-07	[SH0](=O)(Cc1c(C)c(OC)c(C)cn1)c1[nH]c2c(n1)nc(OC)cc2		Inactive	Potassium-transporting ATPase Inhibitor		1	Tenatoprazole	384568324.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[SH0](=O)(Cc1c(C)c(OC)c(C)cn1)c1[nH]c2c(n1)nc(OC)cc2	[SH0](=O)(Cc1c(C)c(OC)c(C)cn1)c1[nH]c2c(n1)nc(OC)cc2
NCGC00167521-02	[SH0](=O)(Cc1c(C)c(OC)c(C)cn1)c1nc-2[nH]c(OC)ccc-2n1		Inactive	Potassium-transporting ATPase Inhibitor		1	Tenatoprazole	170465931.0	2019_NPC-2.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	[SH0](=O)(Cc1c(C)c(OC)c(C)cn1)c1nc-2[nH]c(OC)ccc-2n1	[SH0](=O)(Cc1c(C)c(OC)c(C)cn1)c1nc-2[nH]c(OC)ccc-2n1
NCGC00015615-15	[SH0](=O)(Cc1c(C)c(OCC(F)(F)F)ccn1)c1[nH]c2c(n1)cccc2		Inactive	H+/K+-ATPase Inhibitor		1	Lansoprazole	170464649.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[SH0](=O)(Cc1c(C)c(OCC(F)(F)F)ccn1)c1[nH]c2c(n1)cccc2	[SH0](=O)(Cc1c(C)c(OCC(F)(F)F)ccn1)c1[nH]c2c(n1)cccc2
NCGC00159518-02&NCGC00159518-05	[SH0](=O)(Cc1c(C)c(OCCCOC)ccn1)c1[nH]c2c(n1)cccc2		Inactive	H+/K+-ATPase Inhibitor		2	Rabeprazole	144205289.0&170464736.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&0.0	[SH0](=O)(Cc1c(C)c(OCCCOC)ccn1)c1nc2c([n-]1)cccc2.[Na+]	[SH0](=O)(Cc1c(C)c(OCCCOC)ccn1)c1nc2c([n-]1)cccc2.[Na+]
NCGC00095188-04&NCGC00095188-05	[SH0](=O)(Cc1c(OC)c(OC)ccn1)c1[nH]c2c(n1)cc(OC(F)F)cc2		Inactive	H+/K+-ATPase Inhibitor		2	Pantoprazole	174007264.0&170466337.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0&4.0	0.0&0.0&0.0	[SH0](=O)(Cc1c(OC)c(OC)ccn1)c1[nH]c2c(n1)cc(OC(F)F)cc2	[SH0](=O)(Cc1c(OC)c(OC)ccn1)c1[nH]c2c(n1)cc(OC(F)F)cc2
NCGC00185770-01	[SH0](=O)(OC[C@@H]1[C@@H](O[SH0](=O)[O-])[C@H](O[SH0](=O)[O-])[C@@H](O[SH0](=O)[O-])[C@@H](O[C@@]2(CO[SH0](=O)[O-])[C@@H](O[SH0](=O)[O-])[C@H](O[SH0](=O)[O-])[C@@H](CO[SH0](=O)[O-])O2)O1)[O-]		Inactive			1	Sucrose octasulfate, sodium salt	144207173.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	[SH0](=O)(OC[C@@H]1[C@@H](O[SH0](=O)[O-])[C@H](O[SH0](=O)[O-])[C@@H](O[SH0](=O)[O-])[C@@H](O[C@@]2(CO[SH0](=O)[O-])[C@@H](O[SH0](=O)[O-])[C@H](O[SH0](=O)[O-])[C@@H](CO[SH0](=O)[O-])O2)O1)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]	[SH0](=O)(OC[C@@H]1[C@@H](O[SH0](=O)[O-])[C@H](O[SH0](=O)[O-])[C@@H](O[SH0](=O)[O-])[C@@H](O[C@@]2(CO[SH0](=O)[O-])[C@@H](O[SH0](=O)[O-])[C@H](O[SH0](=O)[O-])[C@@H](CO[SH0](=O)[O-])O2)O1)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
NCGC00183864-01	[SH0](=O)([O-])CNc1ccc(S(=O)(=O)c2ccc(NC[SH0](=O)[O-])cc2)cc1		Inactive	Dihydropteroate synthase 1 Inhibitor		1	Adesulfone sodium	144206768.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[SH0](=O)([O-])CNc1ccc(S(=O)(=O)c2ccc(NC[SH0](=O)[O-])cc2)cc1.[Na+].[Na+]	[SH0](=O)([O-])CNc1ccc(S(=O)(=O)c2ccc(NC[SH0](=O)[O-])cc2)cc1.[Na+].[Na+]
NCGC00253591-01	[SH0](=O)(c1[nH]c2c(n1)cccc2)C1c2nccc(OC)c2CCCC1		Inactive			1	Nepaprazole	170465906.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[SH0](=O)(c1[nH]c2c(n1)cccc2)C1c2nccc(OC)c2CCCC1	[SH0](=O)(c1[nH]c2c(n1)cccc2)C1c2nccc(OC)c2CCCC1
NCGC00095157-04&NCGC00095157-05	[SH0](=O)(c1cc2nc(NC(=O)OC)[nH]c2cc1)c1ccccc1		Inactive	antiparasitic agent		2	Oxfendazole	144206994.0&170466223.0	Annotated/Bioactive Compound Collection&Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	[SH0](=O)(c1cc2nc(NC(=O)OC)[nH]c2cc1)c1ccccc1	[SH0](=O)(c1cc2nc(NC(=O)OC)[nH]c2cc1)c1ccccc1
NCGC00159438-03	[Se](CCC(N)C(=O)O)C		Inactive	dietary supplement		1	L-selenomethionine	26754506.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[Se](CCC(N)C(=O)O)C	[Se](CCC(N)C(=O)O)C
NCGC00181044-04	[Se](CC[C@H](N)C(=O)O)C		Inactive	dietary supplement		1	Selenomethionine	405558757.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[Se](CC[C@H](N)C(=O)O)C	[Se](CC[C@H](N)C(=O)O)C
NCGC00164100-01	[Si](O[Si](C)(C)C)(O[Si](C)(C)C)(C)C		Inactive			1	Trisiloxane, octamethyl-	26757517.0	Approved Drugs Collection (NPC)&Anti-infectives	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	[Si](O[Si](C)(C)C)(O[Si](C)(C)C)(C)C	[Si](O[Si](C)(C)C)(O[Si](C)(C)C)(C)C
NCGC00532508-01	[Si](O[Si](C)(C)C)(O[Si](C)(C)C)(CC(Cc1c(O)c(-n2nc3c(n2)cccc3)cc(C)c1)C)C		Inactive			1	DROMETRIZOLE TRISILOXANE	405558978.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[Si](O[Si](C)(C)C)(O[Si](C)(C)C)(CC(Cc1c(O)c(-n2nc3c(n2)cccc3)cc(C)c1)C)C	[Si](O[Si](C)(C)C)(O[Si](C)(C)C)(CC(Cc1c(O)c(-n2nc3c(n2)cccc3)cc(C)c1)C)C
NCGC00166115-02	[Sn](OC(=O)CCCCCCCCCCC)(OC(=O)CCCCCCCCCCC)(CCCC)CCCC		Inactive			1	Dibutyltin dilaurate	170466843.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[Sn](OC(=O)CCCCCCCCCCC)(OC(=O)CCCCCCCCCCC)(CCCC)CCCC	[Sn](OC(=O)CCCCCCCCCCC)(OC(=O)CCCCCCCCCCC)(CCCC)CCCC
NCGC00183121-01	[Zn](Sc1[n+]([O-])cccc1)Sc1[n+]([O-])cccc1		Inactive			1	Zinc pyrithione	144206950.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	[Zn](Sc1[n+]([O-])cccc1)Sc1[n+]([O-])cccc1	[Zn](Sc1[n+]([O-])cccc1)Sc1[n+]([O-])cccc1
NCGC00167539-03	[nH]1c2c(cc1)cccc2		Inactive	Tryptophan synthase beta chain Substrate		1	Indole	170465733.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	[nH]1c2c(cc1)cccc2	[nH]1c2c(cc1)cccc2
NCGC00159539-02	c1(-c2ccccc2)n[nH]c2c1oc1c2cccc1		Inactive			1	GTP 14564	377020267.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	c1(-c2ccccc2)n[nH]c2c1oc1c2cccc1	c1(-c2ccccc2)n[nH]c2c1oc1c2cccc1
NCGC00263122-02	c1(-c2n[nH]c3c2CCC3)n[nH]nn1		Inactive	Nicotinic Acid Receptor Partial Agonist		1	MK-0354	363677213.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	c1(-c2n[nH]c3c2CCC3)n[nH]nn1	c1(-c2n[nH]c3c2CCC3)n[nH]nn1
NCGC00016410-13&NCGC00016410-25	c1(-c2ncsc2)[nH]c2c(n1)cccc2		Inactive	Methionine Aminopeptidase-1 (MetAP1) Inhibitor		2	Thiabendazole	170464939.0&384567938.0	2019_NPC-3.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	c1(-c2ncsc2)[nH]c2c(n1)cccc2	c1(-c2ncsc2)[nH]c2c(n1)cccc2
NCGC00162222-04	c1(C2(c3ccccc3)C(C3=NCCN3)C2)ccccc1		Inactive	Voltage-sensitive sodium channel Blocker		1	Cibenzoline succinate	405558949.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	c1(C2(c3ccccc3)C(C3=NCCN3)C2)ccccc1	c1(C2(c3ccccc3)C(C3=NCCN3)C2)ccccc1
NCGC00015620-17	c1(C2N=C3SCCN3C2)ccccc1		Inactive			1	NCGC00015620-17		Approved Drugs Collection (NPC)&2019_NPC-3.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	c1(C2N=C3SCCN3C2)ccccc1	c1(C2N=C3SCCN3C2)ccccc1
NCGC00484897-01	c1(C2OC[C@@H]3C(c4cc5OCOc5cc4)OC[C@H]23)cc2OCOc2cc1		Inactive			1	(-)-Asarinin	377020399.0	2020_NPACT-3_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	c1(C2OC[C@@H]3C(c4cc5OCOc5cc4)OC[C@H]23)cc2OCOc2cc1	c1(C2OC[C@@H]3C(c4cc5OCOc5cc4)OC[C@H]23)cc2OCOc2cc1
NCGC00387126-01	c1(C=2c3c(scc3)CCC=2)[nH]cnc1		Inactive	Alpha-2A adrenergic receptor Agonist		1	RWJ 52353	363680544.0	2020_NPACT-11_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	c1(C=2c3c(scc3)CCC=2)[nH]cnc1	c1(C=2c3c(scc3)CCC=2)[nH]cnc1
NCGC00167839-10	c1(c(-c2c3c(ncc2)cccc3)c[nH]n1)-c1ncccc1		Inactive			1	LY-364947		2020_NPACT-2_CPE	SARS-CoV-2_CPE_SRI	4.0	0.0	c1(c(-c2c3c(ncc2)cccc3)c[nH]n1)-c1ncccc1	c1(c(-c2c3c(ncc2)cccc3)c[nH]n1)-c1ncccc1
NCGC00063561-03	c1(c(-c2ccccc2)nc[nH]1)-c1ccccc1		Inactive			1	4,5-Diphenylimidazole	170465946.0	Approved Drugs Collection (NPC)&2019_NPC-2.2	SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2_CPE_SRI	4.0&4.0	0.0&0.0	c1(c(-c2ccccc2)nc[nH]1)-c1ccccc1	c1(c(-c2ccccc2)nc[nH]1)-c1ccccc1
NCGC00013822-04	c1(c(c(-c2ccncc2)sc1-c1ccncc1)-c1ccncc1)-c1ccncc1	5.0500002	Active	Hedgehog Antagonist	0.0	1	NSC-75503	384567789.0	Annotated/Bioactive Compound Collection	SARS-CoV-2 cytopathic effect (CPE)	3.0	46.1238481339	c1(c(c(-c2ccncc2)sc1-c1ccncc1)-c1ccncc1)-c1ccncc1	c1(c(c(-c2ccncc2)sc1-c1ccncc1)-c1ccncc1)-c1ccncc1
NCGC00090793-05	c12c(cccc1)cccc2		Inactive	Metabolism of xenobiotics by cytochrome P450 Substrate		1	NAPHTHALENE, ZONE REFINED	225144198.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	c12c(cccc1)cccc2	c12c(cccc1)cccc2
NCGC00247735-02&NCGC00247735-03	n1c2c(ncc1)cc1c(c2)C2CNCC1C2		Inactive	Nicotinic alpha3beta4 Agonist		2	Varenicline tartrate	174007164.0&363677162.0	2019_NPC-2.2&Approved Drugs Collection (NPC)&Annotated/Bioactive Compound Collection	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0&4.0	0.0&0.0&0.0	Cl.n1c2c(ncc1)cc1c(c2)C2CNCC1C2	Cl.n1c2c(ncc1)cc1c(c2)C2CNCC1C2&n1c2c(ncc1)cc1c(c2)C2CNCC1C2
NCGC00094646-04	s1c2c(c3c1cccc3)cccc2		Inactive	Cytochrome P450 2C9 Inhibitor		1	Dibenzothiophene	170465511.0	2019_NPC-3.2&Approved Drugs Collection (NPC)	SARS-CoV-2_CPE_SRI&SARS-CoV-2 cytopathic effect (CPE)	4.0&4.0	0.0&0.0	s1c2c(c3c1cccc3)cccc2	s1c2c(c3c1cccc3)cccc2
NCGC00091399-01	s1c2c(nc1)cccc2		Inactive			1	Benzothiazole	17389158.0	Approved Drugs Collection (NPC)	SARS-CoV-2 cytopathic effect (CPE)	4.0	0.0	s1c2c(nc1)cccc2	s1c2c(nc1)cccc2
